##########################################################################################
# OVERVIEW                                                                               #
#                                                                                        #
#     ADAM is an abbreviation database generated from the 2006                           #
#     baseline of MEDLINE. It covers frequently used abbreviations                       #
#     and their definitions (or long-forms), including both                              #
#     acronyms and non-acronym abbreviations.                                            #
#                                                                                        #
# DESCRIPTION                                                                            #
#                                                                                        #
#     ADAM includes 59,405 distinct abbrevaition/long-form pairs. For                    #
#     each record, there are 5 columns deliminated by Tab:                               #
# 	    Column 1: Preferred abbreviation (the most commonly used)                    #
# 	    Column 2: Variants of the abbreviation                                       #
# 	    Column 3: Long-form and variants (for each variant, the count                #
# 	              and its score are given)                                           #
# 	    Column 4: Score (the likelihood of the long-form being a phrase)             #
#            Column 5: Count (the number of times the abbreivation/long-form             #
# 	              pair has been defined)                                             #
# Reference                                                                              #
#                                                                                        #
#     Wei Zhou, Vetle I. Torvik and Neil R. Smalheiser. ADAM: Another Database           #
#     of Abbreviations in MEDLINE. The manuscript has been submitted for publication.    #
#                                                                                        #
# Copyright                                                                              #
#                                                                                        #
#     University of Illinois at Chicago, 2006.                                           #
#                                                                                        #
# License                                                                                #
#                                                                                        #
#     GNU General Public License                                                         #
#                                                                                        #
# Acknowledgements                                                                       #
#                                                                                        #
#     This Human Brain Project/Neuroinformatics research                                 #
#     is funded jointly by the National Library of Medicine                              #
#     and the National Institute of Mental Health.                                       #
##########################################################################################
$Can	$Can:18	Canadian dollars:18:0.8365	0.8365	18
(*)NO	(*)NO:23	Nitric oxide:23:0.8715	0.8715	23
(*)OH	(*)OH:15	hydroxyl radical:15:0.6386	0.6386	15
(+)-MCPG	(+)-MCPG:10	(+)-alpha-methyl-4-carboxyphenylglycine:10:0.9000	0.9000	10
(.)NO	(.)NO:7|(.-)NO:2	nitric oxide:9:0.6794	0.6794	9
(.)OH	(.)OH:9|(.-)OH:2	hydroxyl radical:11:0.7357	0.7357	11
(1)H	(1)H:20	proton:20:0.7037	0.7037	20
(1)H-MRSI	(1)H-MRSI:10	Proton magnetic resonance spectroscopic imaging:10:0.5856	0.5856	10
(1)H-MRS	(1)H-MRS:55|(1)HMRS:1	proton magnetic resonance spectroscopy:56:0.8254	0.8254	56
(1)H-NMR	(1)H-NMR:8|(1)HNMR:1	nuclear magnetic resonance:9:0.4587	0.4587	9
(1)O(2)	(1)O(2):52	Singlet oxygen:52:0.8134	0.8134	52
(1)O2	(1)O2:18	singlet oxygen:18:0.6381	0.6381	18
(131)I	(131)I:15	radioiodine:15:0.2500	0.2500	15
(2)H	(2)H:13	deuterium:13:0.9231	0.9231	13
(31)P-MRS	(31)P-MRS:15|(31)PMRS:1	magnetic resonance spectroscopy:16:0.5171	0.5171	16
(90)Y	(90)Y:10	yttrium-90:10:0.5625	0.5625	10
(99m)Tc	(99m)Tc:18|(99m)TC:1	technetium-99m:19:0.4500	0.4500	19
*NO	*NO:77	nitric oxide:77:0.9612	0.9612	77
*NO2	*NO2:9	nitrogen dioxide:9:0.6794	0.6794	9
*O2-	*O2-:11	superoxide anion:11:0.7357	0.7357	11
*OH	*OH:10	hydroxyl:10:0.0405	0.0405	10
*OH	*OH:193|-*OH:3	hydroxyl radical:124:0.8791|hydroxyl radicals:72:0.8773	0.8791	196
+Gz	+Gz:29|+gz:2|+GZ:2	acceleration:33:0.3556	0.3556	33
+dP/dt	+dP/dt:18|+dp/dt:3	contractility:21:0.1835	0.1835	21
+dP/dt	+dP/dt:6|+dp/dt:1	left ventricular pressure:7:0.5926	0.5926	7
+dP/dt	+dP/dt:6	rate of left ventricular pressure development:6:0.3728	0.3728	6
+ve	+ve:12	positive:12:0.3793	0.3793	12
.NO	.NO:165	nitric oxide:165:0.9817	0.9817	165
.NO	.NO:8	nitric oxide radical:8:0.6411	0.6411	8
.NO2	.NO2:9	nitrogen dioxide:9:0.6794	0.6794	9
.O2-	.O2-:10	radicals:10:0.1111	0.1111	10
.O2-	.O2-:28	superoxide:28:0.3333	0.3333	28
.O2-	.O2-:26	superoxide anion:26:0.8251	0.8251	26
.O2-	.O2-:9	superoxide radical:9:0.4587	0.4587	9
.OH	.OH:48	hydroxyl:48:0.0839	0.0839	48
.OH	.OH:456	hydroxyl radical:308:0.8800|hydroxyl radicals:148:0.8694	0.8800	456
1,1,1-TCE	1,1,1-TCE:17	1,1,1-trichloroethane:17:0.9412	0.9412	17
1,1-DCE	1,1-DCE:27	1,1-dichloroethylene:27:0.7027	0.7027	27
1,2-DAG	1,2-DAG:16	1,2-diacylglycerol:16:0.8824	0.8824	16
1,2-DCA	1,2-DCA:9	1,2-dichloroethane:9:0.6667	0.6667	9
1,2-DCB	1,2-DCB:16	1,2-dichlorobenzene:16:0.9375	0.9375	16
1,2-DCE	1,2-DCE:12	1,2-dichloroethane:12:0.7857	0.7857	12
1,2-DG	1,2-DG:12	1,2-diacylglycerol:12:0.7857	0.7857	12
1,2-DMH	1,2-DMH:11	1,2-dimethylhydrazine:11:0.5263	0.5263	11
1,2-GDN	1,2-GDN:9	glyceryl-1,2-dinitrate:9:0.3478	0.3478	9
1,2-PD	1,2-PD:9	1,2-propanediol:9:0.8889	0.8889	9
1,25D3	1,25D3:28|1,25-D3:26	1,25-dihydroxyvitamin D3:54:0.4730	0.4730	54
1,25D	1,25D:11|1,25-D:10	1,25-dihydroxyvitamin D:21:0.6040	0.6040	21
1,25D	1,25D:7|1,25-D:4	1,25-Dihydroxyvitamin D3:11:0.2154	0.2154	11
1,3-DNB	1,3-DNB:16	1,3-Dinitrobenzene:16:0.9375	0.9375	16
1,3-DNP	1,3-DNP:9	1,3-Dinitropyrene:9:0.8889	0.8889	9
1,3-D	1,3-D:28|1,3-d:1	1,3-dichloropropene:29:0.8750	0.8750	29
1,3-PD	1,3-PD:12	1,3-Propanediol:12:0.8462	0.8462	12
1,3-DMU	1,3-DMU:15|1,3DMU:4	1,3-dimethyluric acid:19:0.6537	0.6537	19
1,4,5-IP3	1,4,5-IP3:31	inositol 1,4,5-trisphosphate:31:0.9043	0.9043	31
1,4-BD	1,4-BD:13	1,4-butanediol:13:0.8571	0.8571	13
1,4-DHP	1,4-DHP:14	1,4-dihydropyridine:14:0.5909	0.5909	14
1,4-DCB	1,4-DCB:11	1,4-dichlorobenzene:11:0.8333	0.8333	11
1,5-AG	1,5-AG:10|1,5AG:3	1,5-anhydro-D-glucitol:13:0.2857	0.2857	13
1,5-AG	1,5-AG:14|1,5AG:11	1,5-anhydroglucitol:25:0.5714	0.5714	25
1,6-DNP	1,6-DNP:26|1,6DNP:1	1,6-Dinitropyrene:27:0.8966	0.8966	27
1,8-DNP	1,8-DNP:24|1,8DNP:1	1,8-dinitropyrene:25:0.9600	0.9600	25
1-ABT	1-ABT:9	1-aminobenzotriazole:9:0.8000	0.8000	9
1-EBIO	1-EBIO:24	1-ethyl-2-benzimidazolinone:24:0.8214	0.8214	24
1-MCP	1-MCP:21	1-methylcyclopropene:21:0.9091	0.9091	21
1-NOP	1-NOP:10	1-nitrosopyrene:10:0.9000	0.9000	10
1-HP	1-HP:10	1-hydroxypyrene:10:0.5000	0.5000	10
1/T1	1/T1:12	relaxation rates:12:0.7571	0.7571	12
10-EdAM	10-EdAM:5|10EdAM:1|10-EDAM:1|10EDAM:1	10-ethyl-10-deaza-aminopterin:8:0.2500	0.2500	8
10-EdAM	10-EdAM:7|10-EDAM:6|10EDAM:1	10-ethyl-10-deazaaminopterin:14:0.4062	0.4062	14
11-DOC	11-DOC:9	11-Deoxycortisol:9:0.7273	0.7273	9
11-OCS	11-OCS:11	11-oxycorticosteroids:11:0.7692	0.7692	11
11-OHCS	11-OHCS:18	11-hydroxycorticosteroids:18:0.4722	0.4722	18
11-HSD	11-HSD:28|11HSD:8	11 beta-hydroxysteroid dehydrogenase:36:0.9174	0.9174	36
11C	11C:9	carbon-11:9:0.1818	0.1818	9
11p	11p:6	short arm of chromosome 11:6:0.5290	0.5290	6
12-HEPE	12-HEPE:8	12-hydroxyeicosapentaenoic acid:8:0.5006	0.5006	8
12-LOX	12-LOX:27	12-lipoxygenase:27:0.8387	0.8387	27
12/15-LO	12/15-LO:13	12/15-lipoxygenase:13:0.7500	0.7500	13
12-HETE	12-HETE:183|12HETE:2|12-Hete:1	12-hydroxyeicosatetraenoic acid:186:0.4932	0.4932	186
12-LO	12-LO:40|12LO:1	12-lipoxygenase:41:0.9524	0.9524	41
12S	12S:4	mitochondrial small subunit:4:0.1618	0.1618	4
13-OXO	13-OXO:8	13-oxooctadecadienoic acid:8:0.5006	0.5006	8
131I	131I:10	radio-iodine:10:0.0254	0.0254	10
131I	131I:70|131-I:6	radioactive iodine:76:0.8254	0.8254	76
131I	131I:95|131-I:4	radioiodine:99:0.2768	0.2768	99
1321N1	1321N1:15	Human astrocytoma cells:15:0.8045	0.8045	15
13-APA	13-APA:13|13APA:1	13-Azaprostanoic acid:14:0.5589	0.5589	14
13C-NMR	13C-NMR:21	nuclear magnetic resonance:21:0.6400	0.6400	21
13cRA	13cRA:26|13-cRA:25|13-CRA:18|13CRA:4|13-c-RA:1	13-cis-retinoic acid:59:0.6766|13-cis retinoic acid:15:0.7096	0.7096	74
13C-UBT	13C-UBT:57|13CUBT:2	13C-urea breath test:59:0.6656	0.6656	59
13C	13C:11	carbon-13:11:0.1205	0.1205	11
13C	13C:13	Indole-3-carbinol:13:0.1446	0.1446	13
13-HODE	13-HODE:81|13-hode:1	13-hydroxyoctadecadienoic acid:82:0.5730	0.5730	82
1400W	1400W:14	N-(3-(Aminomethyl)benzyl)acetamidine:14:0.2500	0.2500	14
14C	14C:8	labeled with radioactive carbon:8:0.5006	0.5006	8
14C	14C:10	Radiocarbon:10:0.0570	0.0570	10
15-ADON	15-ADON:10	15-acetyldeoxynivalenol:10:0.6000	0.6000	10
15-LO-1	15-LO-1:9	15-lipoxygenase-1:9:0.8000	0.8000	9
15-LOX	15-LOX:15	15-lipoxygenase:15:0.8235	0.8235	15
15-LOX-1	15-LOX-1:11	15-lipoxygenase-1:11:0.8333	0.8333	11
15-LO	15-LO:47|15LO:2	15-Lipoxygenase:49:0.8889	0.8889	49
15N'	15N':28	15N excess:28:0.8941	0.8941	28
15N'	15N':10	atom-% 15N-excess:10:0.2643	0.2643	10
15-PGDH	15-PGDH:34|15PGDH:1	15-hydroxyprostaglandin dehydrogenase:35:0.5771	0.5771	35
16PF	16PF:13	Sixteen Personality Factor Questionnaire:13:0.4849	0.4849	13
17-ODYA	17-ODYA:31	17-octadecynoic acid:31:0.7718	0.7718	31
17-AAG	17-AAG:28|17AAG:15	17-allylamino-17-demethoxygeldanamycin:30:0.3537|17-(Allylamino)-17-demethoxygeldanamycin:13:0.1463	0.3537	43
17-HP	17-HP:16	17-hydroxyprogesterone:16:0.7143	0.7143	16
17HSDs	17HSDs:9	17beta-Hydroxysteroid dehydrogenases:9:0.3945	0.3945	9
17HSD	17HSD:15|17-HSD:13	17 beta-Hydroxysteroid dehydrogenase:28:0.8941	0.8941	28
17HSD	17HSD:12|17-HSD:3	17beta-hydroxysteroid dehydrogenase:15:0.1777	0.1777	15
17-KSR	17-KSR:9|17KSR:1	17-Ketosteroid reductase:10:0.7103	0.7103	10
17-KS	17-KS:38|17KS:2	17-ketosteroids:40:0.6000	0.6000	40
17-KS	17-KS:11|17KS:1	urinary 17-ketosteroid:12:0.2868	0.2868	12
17-OHCS	17-OHCS:44|17-OH-CS:3|17OHCS:1|17OH-CS:1	17-hydroxycorticosteroids:49:0.4486	0.4486	49
17-OHCS	17-OHCS:8	urinary 17-hydroxycorticosteroid:8:0.1125	0.1125	8
17-OHP	17-OHP:83|17OHP:22|17-OH-P:3|17OH-P:2	17 alpha-hydroxyprogesterone:110:0.9728	0.9728	110
17-OHP	17-OHP:225|17OHP:49|17-OH-P:17|17OH-P:5	17-HYDROXYPROGESTERONE:289:0.5422|17 hydroxyprogesterone:7:0.1329	0.5422	296
17-OHP	17-OHP:11|17-OH-P:10|17OHP:2|17OH-P:1	17-OH-progesterone:24:0.0432	0.0432	24
17-OHP	17-OHP:21|17OHP:11	17alpha-hydroxyprogesterone:32:0.0582	0.0582	32
17-OH	17-OH:10	17-hydroxylase:10:0.3750	0.3750	10
18-MC	18-MC:15	18-methoxycoronaridine:15:0.9333	0.9333	15
18FDG	18FDG:17	fluorodeoxyglucose:17:0.1019	0.1019	17
18F-FDG	18F-FDG:31	18F-fluorodeoxyglucose:31:0.2479	0.2479	31
18F-FDG	18F-FDG:9	fluorine-18 fluorodeoxyglucose:9:0.3069	0.3069	9
18-OH-B	18-OH-B:41|18-OHB:36|18OH-B:5|18OHB:4	18-hydroxycorticosterone:86:0.8416	0.8416	86
18-OH-F	18-OH-F:6|18-OHF:6|18OHF:1	18-hydroxycortisol:13:0.9231	0.9231	13
18S	18S:38	small subunit:23:0.7955|small-subunit:15:0.1818	0.7955	38
19-NA	19-NA:12	19-norandrosterone:12:0.7857	0.7857	12
19F	19F:10	Fluorine-19:10:0.3103	0.3103	10
19F-NMR	19F-NMR:9	magnetic resonance:9:0.6794	0.6794	9
1A29	1A29:7|1A-29:3	monoclonal antibody:10:0.4363	0.4363	10
1-AP	1-AP:10	1-aminopyrene:10:0.6000	0.6000	10
1BnTIQ	1BnTIQ:11|1-BnTIQ:1	1-Benzyl-1,2,3,4-tetrahydroisoquinoline:12:0.9167	0.9167	12
1-CBF	1-CBF:13|1CBF:8	Local cerebral blood flow:21:0.8594	0.8594	21
1CTP	1CTP:10	telopeptide of type 1 collagen:10:0.7103	0.7103	10
1D-IEF	1D-IEF:18	one-dimensional isoelectric focusing:18:0.7539	0.7539	18
1DI	1DI:12	first dorsal interosseous:12:0.7571	0.7571	12
1H-MRSI	1H-MRSI:36	proton magnetic resonance spectroscopic imaging:36:0.7433	0.7433	36
1H-MRS	1H-MRS:159|1HMRS:10	proton magnetic resonance spectroscopy:169:0.8961	0.8961	169
1K,1C	1K,1C:1	one-kidney one-clip:1:0.8045	0.8045	1
1K1C	1K1C:8|1K-1C:1	hypertension:9:0.0741	0.0741	9
1K1C	1K1C:5|1K-1C:3	hypertensive rats:8:0.4102	0.4102	8
1K1C	1K1C:4|1K-1C:2	one-kidney one-clip:4:0.8941|one-kidney one clip:2:0.7834	0.8941	6
1LV	1-LV:5|1LV:5	one-lung ventilation:10:0.7103	0.7103	10
1MU	1MU:13|1-MU:12	1-methyluric acid:25:0.8186	0.8186	25
1-MX	1-MX:9	metabolism of infused 1-methylxanthine:9:0.5470	0.5470	9
1MeTIQ	1MeTIQ:11|1-MeTIQ:6	1-methyl-1,2,3,4-tetrahydroisoquinoline:17:0.8000	0.8000	17
1-NP	1-NP:108|1NP:3	1-nitropyrene:111:0.7586	0.7586	111
1-NN	1-NN:10	1-Nitronaphthalene:10:0.6429	0.6429	10
1O(2)	1O(2):14	singlet oxygen:14:0.5589	0.5589	14
1O2*	1O2*:5	singlet molecular oxygen:5:0.4422	0.4422	5
1O2	1O2:50	singlet molecular oxygen:50:0.9082	0.9082	50
1O2	1O2:258|1o2:1	singlet oxygen:259:0.7757	0.7757	259
1-OHP	1-OHP:69|1-OH-P:3|1OHP:3	1-hydroxypyrene:75:0.8222	0.8222	75
1-PP	1-PP:10|1PP:1	metabolite 1-(2-pyrimidinyl)-piperazine:11:0.3548	0.3548	11
1q	1q:9	long arm of chromosome 1:9:0.6794	0.6794	9
1RM	1RM:49|1-RM:1	1 repetition maximum:50:0.4084	0.4084	50
1RM	1RM:31|1-RM:13	one repetition maximum:44:0.3566	0.3566	44
1-RM	1-RM:9|1RM:6	strength:15:0.0686	0.0686	15
1X	1X:23|1-X:2	1-methylxanthine:25:0.1491	0.1491	25
1A	1A:9	first-order:9:0.0085	0.0085	9
1C	1C:9	round spermatids:9:0.5470	0.5470	9
1D	1D:6	one dimension:6:0.1838	0.1838	6
1D	1D:202|1-D:104|1-d:2	one-dimensional:300:0.5547|one dimensional:8:0.5006	0.5547	308
1H	1H:112|1-H:1	Proton:113:0.3889	0.3889	113
1-MA	1-MA:10	hormone 1-methyladenine:10:0.4480	0.4480	10
1-N	1-N:7|1N:2	1-naphthol:9:0.1356	0.1356	9
1p	1p:24	short arm of chromosome 1:24:0.8768	0.8768	24
1U	1U:6|1-U:2	1-methyluric acid:8:0.5006	0.5006	8
2',5'-OAS	2',5'-OAS:15	2',5'-oligoadenylate synthetase:15:0.8045	0.8045	15
2'5'AS	2'5'AS:5|2'5'-AS:2|2'-5'AS:1|2'5'As:1	synthetase:9:0.8889	0.8889	9
2'-dCF	2'-dCF:9|2'-DCF:6|2'dCF:1|2'DCF:1	2'-deoxycoformycin:17:0.8000	0.8000	17
2,3-BPG	2,3-BPG:16	2,3-bisphosphoglycerate:16:0.5769	0.5769	16
2,3-DHB	2,3-DHB:11	2,3-dihydroxybenzoic acid:11:0.7357	0.7357	11
2,3-DHBA	2,3-DHBA:55	2,3-dihydroxybenzoic acid:55:0.8225	0.8225	55
2,3-DPG	2,3-DPG:11	2,3-bisphosphoglycerate:11:0.0274	0.0274	11
2,3-DPG	2,3-DPG:291|2,3DPG:6	2,3-Diphosphoglycerate:297:0.8110	0.8110	297
2,3-DPG	2,3-DPG:8	2,3-diphosphoglycerate concentration:8:0.5006	0.5006	8
2,3-DPG	2,3-DPG:14|2,3DPG:1	2,3-diphosphoglyceric acid:15:0.6386	0.6386	15
2,4,5-TCP	2,4,5-TCP:13	2,4,5-trichlorophenol:13:0.9231	0.9231	13
2,4,6-TCP	2,4,6-TCP:35	2,4,6-trichlorophenol:35:0.9714	0.9714	35
2,4-DAT	2,4-DAT:16	2,4-diaminotoluene:16:0.9333	0.9333	16
2,4-DNT	2,4-DNT:44	2,4-dinitrotoluene:44:0.9149	0.9149	44
2,4-DCP	2,4-DCP:64|2,4DCP:1	2,4-dichlorophenol:65:0.9143	0.9143	65
2,4-DNP	2,4-DNP:53	2,4-dinitrophenol:53:0.8966	0.8966	53
2,4-D	2,4-D:39|2,4-d:2	2,4-dichlorophenoxyacetate:41:0.0636	0.0636	41
2,4-D	2,4-D:462|2,4D:4|2,4-d:3	2,4-dichlorophenoxyacetic acid:469:0.8360	0.8360	469
2,5-DHB	2,5-DHB:11	2,5-dihydroxybenzoic acid:11:0.7357	0.7357	11
2,5-DHBA	2,5-DHBA:16	2,5-dihydroxybenzoic acid:16:0.6748	0.6748	16
2,5-HD	2,5-HD:122|2,5HD:6	2,5-hexanedione:128:0.9071	0.9071	128
2-5AS	2-5AS:34	synthetase:34:0.7857	0.7857	34
2-B4O	2-B4O:11	2-Buten-4-olide:11:0.9091	0.9091	11
2-EHA	2-EHA:16	2-ethylhexanoic acid:16:0.7261	0.7261	16
2-FAA	2-FAA:40	N-2-fluorenylacetamide:40:0.8667	0.8667	40
2-HBP	2-HBP:12	2-hydroxybiphenyl:12:0.8462	0.8462	12
2-HEMA	2-HEMA:16	2-hydroxyethyl methacrylate:16:0.7261	0.7261	16
2-MAA	2-MAA:14	2-methoxyacetic acid:14:0.7909	0.7909	14
2-NDHSA	2-NDHSA:11	N-(3,5-dichlorophenyl)-2-hydroxysuccinamic acid:11:0.6182	0.6182	11
2-NOF	2-NOF:10	2-nitrosofluorene:10:0.9000	0.9000	10
2-OADC	2-OADC:10	dehydrogenase complex:10:0.7103	0.7103	10
2-OH-DMI	2-OH-DMI:12	2-hydroxydesipramine:12:0.6111	0.6111	12
2.4G2	2.4G2:7	monoclonal antibody:7:0.2902	0.2902	7
20-HETE	20-HETE:128	20-hydroxyeicosatetraenoic acid:128:0.7462	0.7462	128
20-MC	20-MC:10	20-methylcholanthrene:10:0.8182	0.8182	10
201Tl	201Tl:11	thallium-201 chloride:11:0.3495	0.3495	11
20-Hz	20-Hz:10	Pdi at low-frequency:10:0.6182	0.6182	10
21-DF	21-DF:9|21DF:1	21-deoxycortisol:10:0.8182	0.8182	10
21-OHD	21-OHD:49|21OHD:13	21-hydroxylase deficiency:62:0.8612	0.8612	62
21-OH	21-OH:73|21OH:10	21-hydroxylase:83:0.8200	0.8200	83
24EE	24EE:15|24-EE:5	energy expenditure:20:0.8525	0.8525	20
25(OH)D3	25(OH)D3:13|25-(OH)D3:8|25-(OH)-D3:1	25-hydroxycholecalciferol:22:0.2800	0.2800	22
25(OH)D3	25(OH)D3:33|25-(OH)D3:5	25-hydroxyvitamin D3:38:0.6322	0.6322	38
25(OH)D	25(OH)D:61|25-(OH)D:6	25-hydroxyvitamin D:67:0.7400	0.7400	67
254-S	254-S:12	nedaplatin:12:0.2895	0.2895	12
25-HCC	25-HCC:24|25HCC:1	25-hydroxycholecalciferol:25:0.8000	0.8000	25
25-HC	25-HC:7|25HC:3	25-hydroxycholesterol:10:0.8182	0.8182	10
25-OHC	25-OHC:18|25OHC:8|25-OH-C:1	25-hydroxycholesterol:27:0.8966	0.8966	27
25OHD2	25OHD2:5|25-OH-D2:4|25-OHD2:3	25-hydroxyvitamin D2:12:0.7571	0.7571	12
25-OHD3	25-OHD3:24|25OHD3:13|25-OH-D3:12|25-OH-D-3:1	25-hydroxycholecalciferol:50:0.2279	0.2279	50
25OHD3	25OHD3:45|25-OH-D3:42|25-OHD3:24|25-ohd3:1|25OH-D3:1	25-hydroxyvitamin D3:113:0.7386	0.7386	113
25-OHD	25-OHD:9|25OHD:3|25-OH-D:2	25-hydroxycholecalciferol:14:0.0270	0.0270	14
25-OHD	25-OHD:175|25OHD:121|25-OH-D:59|25OH-D:2	25-hydroxyvitamin D:357:0.8104	0.8104	357
25-OHD	25-OHD:3|25OHD:2|25-OH-D:1	25-hydroxyvitamin D3:6:0.1838	0.1838	6
25-OH	25-OH:16|25OH:1	25-hydroxycholesterol:17:0.7619	0.7619	17
2-5A	2-5A:11	2',5'-linked oligoadenylates:11:0.3495	0.3495	11
2-5A	2-5A:119	2',5'-oligoadenylate:90:0.4564|2',5'-oligoadenylates:10:0.0462|2'-5'-oligoadenylate:10:0.0462|2'-5' oligoadenylate:9:0.1945	0.4564	119
2-AAF	2-AAF:262|2AAF:27	2-acetylaminofluorene:289:0.8623	0.8623	289
2AA	2AA:34|2-AA:33	2-aminoanthracene:67:0.8571	0.8571	67
2ADNT	2-ADNT:5|2ADNT:5	2-amino-4,6-dinitrotoluene:10:0.6000	0.6000	10
2AFC	2AFC:23|2-AFC:8	two-alternative forced-choice:31:0.8003	0.8003	31
2-AF	2-AF:101|2AF:21	2-aminofluorene:122:0.7961	0.7961	122
2-AG	2-AG:29	2-arachidonoyl-glycerol:15:0.0828|2-arachidonoyl glycerol:14:0.5589	0.5589	29
2-AG	2-AG:87|2AG:1	2-arachidonoylglycerol:88:0.5148	0.5148	88
2-AG	2-AG:31	2-arachidonylglycerol:31:0.1775	0.1775	31
2-APB	2-APB:47|2APB:5	2-Aminoethoxydiphenyl borate:52:0.6826	0.6826	52
2-APB	2-APB:8	2-aminoethyl diphenylborate:8:0.5006	0.5006	8
2-APH	2-APH:11|2APH:2	2-amino-7-phosphonoheptanoic acid:13:0.4444	0.4444	13
2APV	2-APV:2|2APV:2	antagonist 2-amino-5-phosphonovalerate:4:0.1838	0.1838	4
2-AP	2-AP:18	2-(allylthio)pyrazine:18:0.1062	0.1062	18
2-AP	2-AP:57|2AP:46|2-Ap:1	2-aminopurine:104:0.6438	0.6438	104
2BA	2BA:6|2-BA:4	2-bromoacrolein:10:0.7500	0.7500	10
2-BP	2-BP:15|2BP:4	2-Bromopropane:19:0.7826	0.7826	19
2-CADO	2-CADO:35|2CADO:4|2-C-Ado:1	2-chloroadenosine:40:0.9070	0.9070	40
2C-B	2C-B:12	4-bromo-2,5-dimethoxyphenethylamine:12:0.4348	0.4348	12
2-CLA	2-CLA:9|2ClA:2|2-ClA:2|2CLA:1	2-chloroadenosine:14:0.6190	0.6190	14
2-CP	2-CP:27|2CP:2	2-chlorophenol:29:0.4828	0.4828	29
2-CP	2-CP:15|2CP:2	2-chloroprocaine:17:0.2759	0.2759	17
2-CA	2-CA:26|2CA:19	2-chloroadenosine:45:0.7458	0.7458	45
2-CdA	2-CdA:18|2CdA:11|2-Cda:1	2-chloro-2'-deoxyadenosine:30:0.0942	0.0942	30
2-CdA	2-CdA:142|2-CDA:40|2CdA:14|2CDA:1|2-cda:1	2-chlorodeoxyadenosine:198:0.6396	0.6396	198
2-CdA	2-CdA:45|2CdA:5|2-CDA:2|2CDA:1	cladribine:53:0.1656	0.1656	53
2-ClAdo	2-ClAdo:6|2-Cl-Ado:2|2ClAdo:2|2-cl-Ado:1|2Clado:1	2-chloroadenosine:12:0.5789	0.5789	12
2DE	2DE:14|2-DE:6	two-dimensional:20:0.0186	0.0186	20
2DE	2DE:9|2-DE:1	two-dimensional echocardiograms:10:0.7103	0.7103	10
2DE	2DE:16|2-DE:6	Two-dimensional echocardiographic:22:0.6531	0.6531	22
2DE	2DE:137|2-DE:29|2dE:2|2D-E:2|2-D-E:1	two-dimensional echocardiography:171:0.7856	0.7856	171
2-DE	2-DE:314|2DE:49|2D-E:1	two-dimensional electrophoresis:364:0.4623	0.4623	364
2-DE	2-DE:243|2DE:31|2D-E:1	two-dimensional gel electrophoresis:275:0.7757	0.7757	275
2DFT	2DFT:10|2D-FT:2	two-dimensional Fourier transform:12:0.4557	0.4557	12
2DGE	2DGE:16|2-DGE:15|2D-GE:5	Two-dimensional gel electrophoresis:36:0.6953	0.6953	36
2-DG	2-DG:9|2DG:2	[14C]2-deoxy-D-glucose:11:0.0073	0.0073	11
2-DG	2-DG:90|2DG:30	[14C]2-deoxyglucose:75:0.0542|14C-2-deoxyglucose:26:0.0183|[14C]-2-deoxyglucose:19:0.0132	0.0542	120
2-DG	2-DG:6|2DG:4	2-[14C]deoxyglucose:10:0.0066	0.0066	10
2-DG	2-DG:332|2DG:197|2dG:7|2-dG:4|2-dg:2|2-Dg:1|2-D-G:1	2-deoxy-d-glucose:544:0.3968	0.3968	544
2DG	2DG:9|2-DG:6|2dG:2	2-deoxy-glucose:11:0.0073|2-deoxy glucose:6:0.1838	0.1838	17
2-DG	2-DG:292|2DG:157|2-dg:3|2-dG:2|2dG:2|2dg:1	2-deoxyglucose:457:0.3338	0.3338	457
2DG	2DG:7|2-DG:4|2dG:1	[3H]2-deoxy-D-glucose:12:0.0081	0.0081	12
2-DG	2-DG:6|2DG:3	[3H]2-deoxyglucose:9:0.0059	0.0059	9
2-DOG	2-DOG:33|2DOG:9|2-dOG:1	2-deoxy-D-glucose:43:0.3529	0.3529	43
2-DOG	2-DOG:43|2DOG:5	2-deoxyglucose:48:0.3950	0.3950	48
2D-PAGE	2D-PAGE:30|2DPAGE:1	Two-dimensional gel electrophoresis:31:0.1151	0.1151	31
2D-PAGE	2D-PAGE:124|2-D-PAGE:1	two-dimensional polyacrylamide gel electrophoresis:125:0.8319	0.8319	125
2D-echo	2D-echo:9|2D-Echo:6|2D-ECHO:2	two-dimensional echocardiography:17:0.6211	0.6211	17
2-EE	2-EE:8|2EE:1	2-ethoxyethanol:9:0.7273	0.7273	9
2-EH	2-EH:19|2EH:2	2-ethylhexanol:21:0.7692	0.7692	21
2EN	2EN:8|2-EN:2	2-Ethynylnaphthalene:10:0.6000	0.6000	10
2H-NMR	2H-NMR:19	deuterium nuclear magnetic resonance:19:0.7173	0.7173	19
2H2(18)O	2H2(18)O:7	doubly labeled water:7:0.5926	0.5926	7
2H2O	2H2O:13	deuterium oxide:13:0.7753	0.7753	13
2H2O	2H2O:7	heavy water:7:0.1850	0.1850	7
2H3	2H3:8	rat basophilic leukemia:8:0.6411	0.6411	8
2HPT	2HPT:32|2-HPT:2	secondary hyperparathyroidism:34:0.8644	0.8644	34
2IFC	2IFC:6|2-IFC:1	two-interval forced-choice:7:0.5856	0.5856	7
2IT	2IT:9|2-IT:8|2-It:1	2-iminothiolane:18:0.7391	0.7391	18
2K1C	2K1C:1	2-kidney 1-clip:1:0.6460	0.6460	1
2K1C	2K1C:9	hypertension:9:0.0329	0.0329	9
2K1C	2K1C:11|2K-1C:5	hypertensive rats:16:0.6024	0.6024	16
2K1C	2K1C:10|2K-1C:4	two-kidney one-clip:11:0.9100|two-kidney one clip:3:0.7149	0.9100	14
2ME2	2ME2:17|2-ME2:5|2-mE2:1	2-methoxyestradiol:23:0.9565	0.9565	23
2-ME	2-ME:219|2ME:37|2-Me:18|2-me:1	2-mercaptoethanol:275:0.6773	0.6773	275
2ME	2ME:4|2-ME:1	industrial solvent 2-methoxyethanol:5:0.5856	0.5856	5
2-ME	2-ME:5|2ME:3	metabolite 2-methoxyestradiol:8:0.0961	0.0961	8
2-MPG	2-MPG:14	2-mercaptopropionylglycine:14:0.5909	0.5909	14
2-MeOE1	2-MeOE1:7|2MeOE1:2|2-meoE1:1	2-methoxyestrone:10:0.7500	0.7500	10
2-MeOE2	2-MeOE2:13|2-MeO-E2:4|2MeOE2:2|2-meOE2:1|2-meoE2:1	2-methoxyestradiol:21:0.6667	0.6667	21
2-MeOE2	2-MeOE2:7|2MeOE2:2	2-methoxyoestradiol:9:0.2667	0.2667	9
2-NA	2-NA:20|2NA:2	2-naphthylamine:22:0.5833	0.5833	22
2-NF	2-NF:25|2NF:3	2-nitrofluorene:28:0.8182	0.8182	28
2-NP	2-NP:40|2NP:6	2-nitropropane:46:0.7895	0.7895	46
2NT	2NT:9|2-NT:3	2-Nitrotoluene:12:0.8462	0.8462	12
2n	2n:5|2N:1	Chromosome number:6:0.1838	0.1838	6
2-OG	2-OG:15|2OG:8	2-oxoglutarate:23:0.9167	0.9167	23
2-OHE1	2-OHE1:45|2OHE1:7|2OH-E1:2|2-OH-E1:1	2-hydroxyestrone:55:0.7534	0.7534	55
2-OHE2	2-OHE2:32|2-OH-E2:19|2OHE2:4|2OH-E2:2	2-hydroxyestradiol:57:0.6477	0.6477	57
2-OHE2	2-OHE2:6|2OHE2:3	2-hydroxyoestradiol:9:0.0909	0.0909	9
2-PAM	2-PAM:8	2-pyridine aldoxime methiodide:8:0.6411	0.6411	8
2-PAM	2-PAM:4	2-pyridine aldoxime methochloride:4:0.0918	0.0918	4
2-PAM	2-PAM:27|2PAM:1	pralidoxime:28:0.2673	0.2673	28
2-PAM	2-PAM:8	pralidoxime chloride:8:0.2327	0.2327	8
2-PAM	2-PAM:5	pyridine-2-aldoxime methochloride:5:0.0612	0.0612	5
2PD	2PD:11|2-PD:5|2pd:2	two-point discrimination:18:0.6903	0.6903	18
2-PEA	2-PEA:12|2PEA:2	2-Pyridylethylamine:14:0.6190	0.6190	14
2PN	2PN:8	two pronuclear:8:0.4102	0.4102	8
2PN	2PN:5|2-PN:1	two pronuclei:6:0.2243	0.2243	6
2-TEA	2-TEA:8|2TEA:2	2-thiazolylethylamine:10:0.9000	0.9000	10
2VO	2VO:3|2-VO:1|2-vo:1	carotid artery occlusion:5:0.4422	0.4422	5
2VO	2VO:1	permanent bilateral occlusion of common carotid arteries:1:0.2818	0.2818	1
2VO	2VO:6	permanent occlusion of bilateral common carotid arteries:6:0.7357	0.7357	6
2cDI	2cDI:26|2CDI:1	2c deviation index:27:0.8312	0.8312	27
2C	2C:25|2c:15	diploid:40:0.1512	0.1512	40
2C	2C:5	diploid cells:5:0.1132	0.1132	5
2DG6P	2-DG-6-P:4|2DG6P:4|2dG6P:2|2-DG6P:1	2-deoxyglucose-6-phosphate:11:0.3333	0.3333	11
2-dGlc	2-dGlc:9|2dGlc:6|2dglc:1	2-deoxy-D-glucose:16:0.5357	0.5357	16
2-D	2-D:109|2D:95	2-dimensional:204:0.0601	0.0601	204
2D	2D:5|2-D:4	gel electrophoresis:9:0.5470	0.5470	9
2D	2D:14	two dimensions:14:0.6911	0.6911	14
2D	2D:1651|2-D:1174|2-d:3|2d:2	two-dimensional:2736:0.8102|two dimensional:94:0.8670	0.8670	2830
2H	2H:33	deuterium:33:0.1362	0.1362	33
2K	2K:9	two-kidney:9:0.2000	0.2000	9
3'-Me-DAB	3'-Me-DAB:68|3'-MeDAB:27|3'MeDAB:7|3'-ME-DAB:1|3'Me-DAB:1	3'-methyl-4-dimethylaminoazobenzene:104:0.6753	0.6753	104
3'-T1	3'-T1:8|3'T1:1	3'-monoiodothyronine:9:0.6667	0.6667	9
3'-UTR	3'-UTR:230|3'UTR:163|3'utr:1	3'-untranslated region:244:0.5344|3' untranslated region:144:0.8947|3' untranslated regions:6:0.2243	0.8947	394
3'UT	3'UT:8|3'ut:1	3' untranslated:9:0.6794	0.6794	9
3,3'-T2	3,3'-T2:36|3,3'T2:4	3,3'-diiodothyronine:40:0.6964	0.6964	40
3,4-DAP	3,4-DAP:74	3,4-diaminopyridine:74:0.9605	0.9605	74
3,4-DCA	3,4-DCA:18	3,4-Dichloroaniline:18:0.8500	0.8500	18
3,4-DHBA	3,4-DHBA:13	3,4-dihydroxybenzoic acid:13:0.7753	0.7753	13
3,5-T2	3,5-T2:18	3,5-diiodothyronine:18:0.5862	0.5862	18
3-AcDON	3-AcDON:11	3-acetyldeoxynivalenol:11:0.7692	0.7692	11
3-BHA	3-BHA:9	3-Tert-butyl-4-hydroxyanisole:9:0.6667	0.6667	9
3-MCPD	3-MCPD:10	3-monochloropropane-1,2-diol:10:0.3333	0.3333	10
31P-MRS	31P-MRS:112|31PMRS:2|31p-MRS:1	magnetic resonance spectroscopy:115:0.7550	0.7550	115
31P-NMR	31P-NMR:18	31P-nuclear magnetic resonance:18:0.1090	0.1090	18
31P-NMR	31P-NMR:58|31PNMR:2	nuclear magnetic resonance:60:0.5702	0.5702	60
31P	31P:67|31p:2	phosphorus:69:0.4564	0.4564	69
31P	31P:51|31p:1	Phosphorus-31:45:0.3020|Phosphorus 31:7:0.3524	0.3524	52
32Pi	32Pi:5|32PI:1	radioactive inorganic phosphate:6:0.3728	0.3728	6
32P	32P:15	chromic phosphate:15:0.3614	0.3614	15
32P	32P:48|32-P:2|32p:1	radioactive phosphorus:51:0.8316	0.8316	51
32P	32P:11	radiophosphorus:11:0.0549	0.0549	11
3-ABA	3-ABA:30|3ABA:4	3-aminobenzamide:34:0.7674	0.7674	34
3-AB	3-AB:97|3AB:86|3-ab:1	3-aminobenzamide:184:0.9059	0.9059	184
3-APS	3-APS:9|3APS:2	3-aminopropane sulphonic acid:11:0.4728	0.4728	11
3-AP	3-AP:52|3AP:15	3-Acetylpyridine:67:0.6442	0.6442	67
3-AP	3-AP:8|3-Ap:2	3-aminopyridine:10:0.0865	0.0865	10
3-AT	3-AT:13|3AT:6	3-amino-1,2,4-triazole:19:0.3830	0.3830	19
3-AT	3-AT:11|3AT:6	3-aminotriazole:17:0.3404	0.3404	17
3-CB	3-CB:11|3CB:6	3-chlorobenzoate:17:0.6400	0.6400	17
3-CLT	3-CLT:8|3CLT:4	Lissajous' trajectory:12:0.5664	0.5664	12
3-CLT	3-CLT:4|3CLT:3	Three-channel Lissajous' trajectories:7:0.5926	0.5926	7
3CLpro	3CLpro:8	3C-like proteinase:8:0.4102	0.4102	8
3-CPs	3-CPs:27|3CPs:2|3-CPS:1	3-carbethoxypsoralen:30:0.9062	0.9062	30
3-CP	3-CP:7|3CP:2	3-chlorophenol:9:0.2051	0.2051	9
3CBA	3CBA:6|3-CBA:4|3-Cba:3|3-cba:1|3Cba:1	3-chlorobenzoate:15:0.7368	0.7368	15
3D(pol)	3D(pol):6	Poliovirus RNA-dependent RNA polymerase:6:0.2827	0.2827	6
3D-QSAR	3D-QSAR:74	three-dimensional quantitative structure-activity relationship:74:0.7954	0.7954	74
3D-SSP	3D-SSP:18	three-dimensional stereotactic surface projections:9:0.4587|three-dimensional stereotactic surface projection:9:0.4587	0.4587	18
3DAC	3DAC:8|3-DAC:2|3D-AC:1	three-dimensional anisotropy contrast:11:0.4728	0.4728	11
3D-CRT	3D-CRT:39|3DCRT:26|3-DCRT:3	three-dimensional conformal radiation therapy:68:0.6274	0.6274	68
3D-CRT	3D-CRT:69|3DCRT:25|3-D-CRT:1|3-DCRT:1	three-dimensional conformal radiotherapy:96:0.6967	0.6967	96
3D-CTA	3D-CTA:26|3DCTA:5|3-D-CT-A:1	three-dimensional CT angiography:32:0.5576	0.5576	32
3D-CT	3D-CT:20|3DCT:9|3-D-CT:2|3-DCT:2	Three-dimensional Computed Tomography:33:0.5306	0.5306	33
3D-CT	3D-CT:9|3DCT:2|3-DCT:1	three-dimensional CT:12:0.3524	0.3524	12
3DE	3DE:41|3-DE:8	echocardiography:49:0.7619	0.7619	49
3DFT	3DFT:12	Fourier transformation:12:0.7571	0.7571	12
3DFT	3DFT:21|3-DFT:3	three-dimensional Fourier transform:24:0.7151	0.7151	24
3-DG	3-DG:56|3DG:14	3-deoxyglucosone:70:0.8625	0.8625	70
3D-MRI	3D-MRI:12|3DMRI:1	magnetic resonance imaging:13:0.7753	0.7753	13
3DRA	3DRA:5|3D-RA:2	Three-dimensional rotational angiography:7:0.3524	0.3524	7
3DR	3DR:8|3D-R:1	three-dimensional reconstruction:9:0.3945	0.3945	9
3DUS	3DUS:14|3D-US:3|3-DUS:1|3-D-US:1	three-dimensional ultrasound:19:0.6537	0.6537	19
3DUS	3DUS:7|3D-US:2	ultrasonography:9:0.2162	0.2162	9
3Dpol	3Dpol:12	RNA-dependent RNA polymerase:12:0.5664	0.5664	12
3H-5-HT	3H-5-HT:20	3H-5-hydroxytryptamine:20:0.4419	0.4419	20
3H-ACh	3H-ACh:17	3H-acetylcholine:17:0.6400	0.6400	17
3H-DHA	3H-DHA:36	3H-dihydroalprenolol:36:0.6863	0.6863	36
3H-DHM	3H-DHM:10	3H-dihydromorphine:10:0.9000	0.9000	10
3H-NA	3H-NA:44	3H-noradrenaline:44:0.5972	0.5972	44
3H-NMS	3H-NMS:14	3H-N-methylscopolamine:14:0.5200	0.5200	14
3H-flu	3H-flu:8|3H-FLU:1	3H-flunitrazepam:9:0.7273	0.7273	9
3H2O	3H2O:29	Tritiated water:29:0.7581	0.7581	29
3HAO	3HAO:8|3-HAO:3	3-hydroxyanthranilic acid oxygenase:11:0.7357	0.7357	11
3HB	3HB:32|3-HB:17	3-hydroxybutyrate:49:0.5581	0.5581	49
3HB	3HB:4|3-HB:1	3-hydroxybutyric acid:5:0.0902	0.0902	5
3H-DA	3H-DA:25	3H-dopamine:25:0.6000	0.6000	25
3HHx	3HHx:11	3-hydroxyhexanoate:11:0.7143	0.7143	11
3-HK	3-HK:25|3HK:12	3-hydroxykynurenine:37:0.8372	0.8372	37
3H-NE	3H-NE:25	3H-norepinephrine:25:0.4444	0.4444	25
3H-NE	3H-NE:9	tritiated norepinephrine:9:0.2757	0.2757	9
3-HPA	3-HPA:8	3-hydroxypicolinic acid:8:0.3463	0.3463	8
3H-QNB	3H-QNB:30	3H-quinuclidinyl benzilate:30:0.4630	0.4630	30
3H-QNB	3H-QNB:8	3H-quinuclidinyl benzylate:8:0.2327	0.2327	8
3H-TdR	3H-TdR:112|3HTdR:43|3H-Tdr:12|3HTdr:9|3-H-TdR:2|3H-TDR:2|3-H-TDR:1|3HTDR:1|3H-tdR:1	tritiated thymidine:183:0.8061	0.8061	183
3H-T	3H-T:22|3HT:6	3H-thymidine:28:0.3750	0.3750	28
3HT	3HT:9|3H-T:4|3-H-T:1	tritiated thymidine:14:0.7909	0.7909	14
3LL	3LL:19|3ll:1	Lewis lung:20:0.7766	0.7766	20
3LL	3LL:179|3-LL:1	Lewis lung carcinoma:180:0.9272	0.9272	180
3LL	3LL:6	Lewis Lung carcinoma cells:6:0.5290	0.5290	6
3MA	3MA:11|3-MA:8	3-methyladenine:19:0.7826	0.7826	19
3-MCA	3-MCA:19|3MCA:3	3-methylcholanthrene:22:0.9545	0.9545	22
3-MC	3-MC:300|3MC:123|3-Mc:2	3-methylcholanthrene:425:0.9197	0.9197	425
3-MeH	3-MeH:10|3-MEH:1|3MEH:1	3-methylhistidine:12:0.7857	0.7857	12
3MH	3MH:55|3-MH:40	3-methylhistidine:95:0.8468	0.8468	95
3MI	3MI:63|3-MI:22|3-Mi:1	3-methylindole:86:0.8673	0.8673	86
3-MP	3-MP:13|3MP:5	3-mercaptopropionic acid:18:0.5228	0.5228	18
3MS	3MS:13	Modified Mini-Mental State:13:0.7753	0.7753	13
3MS	3MS:9|3-MS:1	Modified Mini-Mental State Exam:10:0.7103	0.7103	10
3MS	3MS:20	Modified Mini-Mental State Examination:20:0.8525	0.8525	20
3-MT	3-MT:147|3MT:13	3-methoxytyramine:160:0.8933	0.8933	160
3-MX	3-MX:20|3MX:6	3-methylxanthine:26:0.8621	0.8621	26
3MeA	3MeA:13|3-MeA:7|3-meA:3	3-methyladenine:23:0.8462	0.8462	23
3-Mehis	3-Mehis:7|3-MeHis:7|3-MeHIS:1|3MeHis:1	3-methylhistidine:16:0.7895	0.7895	16
3-NBA	3-NBA:15	3-nitrobenzanthrone:15:0.8235	0.8235	15
3-NPA	3-NPA:70|3NPA:5	3-nitropropionic acid:75:0.9159	0.9159	75
3-NP	3-NP:19|3NP:8	mitochondrial toxin 3-nitropropionic acid:27:0.9126	0.9126	27
3-NT	3-NT:47|3NT:10	3-nitrotyrosine:57:0.8235	0.8235	57
3-OHBA	3-OHBA:9|3OHBA:1	3-hydroxybutyrate:10:0.5625	0.5625	10
3-OHB	3-OHB:22|3OHB:4	3-hydroxybutyrate:26:0.5581	0.5581	26
3OHKyn	3OHKyn:7|3-OH-KYN:1|3-OH-Kyn:1|3-OHKyn:1	3-hydroxykynurenine:10:0.6923	0.6923	10
3-OMD	3-OMD:50|3OMD:12|3-O-MD:4	3-O-methyldopa:66:0.7927	0.7927	66
3-OMG	3-OMG:26|3-O-MG:12|3OMG:6|3-o-MG:1|3-omG:1	3-O-methyl-D-glucose:46:0.2629	0.2629	46
3-OMG	3-OMG:6|3-O-MG:5|3OMG:3|3-O-M-G:1	3-O-methyl glucose:15:0.4951	0.4951	15
3-O-MG	3-O-MG:23|3-OMG:22|3OMG:7	3-O-methylglucose:52:0.2914	0.2914	52
3-PBA	3-PBA:9|3PBA:8	3-phenoxybenzoic acid:17:0.5760	0.5760	17
3-PGA	3-PGA:16|3PGA:4	3-phosphoglycerate:20:0.5278	0.5278	20
3-PGA	3-PGA:5|3PGA:3	3-phosphoglyceric acid:8:0.5006	0.5006	8
3PGDH	3PGDH:8|3-PGDH:5	3-phosphoglycerate dehydrogenase:13:0.7753	0.7753	13
3-PG	3-PG:12|3PG:6	3-phosphoglycerate:18:0.7083	0.7083	18
3-PPP	3-PPP:16	3-(3-hydroxyphenyl)-N-n-propylpiperidine:16:0.2727	0.2727	16
3SR	3SR:11	self-sustained sequence replication:11:0.7103	0.7103	11
3T3	3T3:5	fibroblast cell line:5:0.1973	0.1973	5
3TC	3TC:19	2',3'-dideoxy-3'-thiacytidine:19:0.0492	0.0492	19
3TC	3TC:252|3-TC:1	lamivudine:253:0.6858	0.6858	253
3V	3V:38|3v:1	third ventricle:39:0.6077	0.6077	39
3D	3D:227|3-d:173|3-D:1	3-dimensional:401:0.0670	0.0670	401
3D	3D:29|3-D:10	three dimensions:39:0.7143	0.7143	39
3D	3D:3528|3-D:1660|3-d:4|3d:4	three-dimensional:4993:0.8363|three dimensional:203:0.8913	0.8913	5196
3D	3D:10|3-D:4	three-dimensionally:14:0.0022	0.0022	14
3D	3D:8|3-D:5	tridimensional:13:0.0020	0.0020	13
3H	3H:18|3-H:1	tritiated:19:0.0519	0.0519	19
3H	3H:28	Tritium:28:0.0778	0.0778	28
3-MG	3-MG:14|3MG:11	3-O-methyl-D-glucose:25:0.3529	0.3529	25
3-MG	3-MG:16|3MG:2	3-O-methylglucose:18:0.2500	0.2500	18
3N	3N:8|3n:7	triploid:15:0.3889	0.3889	15
3p	3p:31	short arm of chromosome 3:31:0.9043	0.9043	31
4-ASA	4-ASA:11	4-aminosalicylic acid:11:0.5355	0.5355	11
4-CIN	4-CIN:9	alpha-cyano-4-hydroxycinnamate:9:0.6154	0.6154	9
4-dione	4-dione:6|4-DIONE:3	androstenedione:9:0.6154	0.6154	9
4-MTA	4-MTA:15	4-methylthioamphetamine:15:0.8750	0.8750	15
4-POBN	4-POBN:13	alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone:13:0.2400	0.2400	13
4-S-CAP	4-S-CAP:19	4-S-cysteaminylphenol:19:0.9474	0.9474	19
4.1R	4.1R:10	protein 4.1:10:0.4363	0.4363	10
40K	40K:10	body potassium:10:0.2873	0.2873	10
42K	42K:10	potassium:10:0.3333	0.3333	10
4AAF	4AAF:8|4-AAF:8	4-acetylaminofluorene:16:0.8333	0.8333	16
4-ABP	4-ABP:53|4ABP:6	4-aminobiphenyl:59:0.8923	0.8923	59
4ADNT	4ADNT:9|4-ADNT:5	4-amino-2,6-dinitrotoluene:14:0.8667	0.8667	14
4-APP	4-APP:10|4APP:1	4-aminopyrazolo[3,4-d]pyrimidine:11:0.2128	0.2128	11
4-AP	4-AP:5	1 mM-4-aminopyridine:5:0.0902	0.0902	5
4-AP	4-AP:11	4-Aminophenol:11:0.0094	0.0094	11
4-AP	4-AP:923|4AP:77|4-Ap:1	4-aminopyridine:1001:0.9390	0.9390	1001
4-CA	4-CA:6|4CA:3	4-chloroaniline:9:0.6667	0.6667	9
4-CBA	4-CBA:9|4CBA:1	4-chlorobenzoate:10:0.5294	0.5294	10
4-CB	4-CB:10|4CB:4	4-chlorobiphenyl:14:0.4333	0.4333	14
4CMB	4CMB:21	4-chloromethylbiphenyl:21:0.9048	0.9048	21
4CPG	4CPG:9|4-CPG:3	(S)-4-carboxyphenylglycine:12:0.4231	0.4231	12
4-CP	4-CP:31|4CP:6|4-cp:4	4-chlorophenol:41:0.7407	0.7407	41
4-CmC	4-CmC:17|4CmC:4|4-cmc:2|4-CMC:1	4-chloro-m-cresol:24:0.9200	0.9200	24
4C	4C:12|4c:1	primary spermatocytes:13:0.7753	0.7753	13
4-DAMP	4-DAMP:22	4-diphenylacetoxy-N-methylpiperidine:22:0.1141	0.1141	22
4-DAMP	4-DAMP:50|4DAMP:2	4-diphenylacetoxy-N-methylpiperidine methiodide:52:0.4564	0.4564	52
4-DAMP	4-DAMP:11	4-diphenylacetoxy-N-methylpiperidine methobromide:11:0.2582	0.2582	11
4-DMDR	4-DMDR:10|4-dmDR:1	4-demethoxydaunorubicin:11:0.8333	0.8333	11
4E-BP1	4E-BP1:7|4EBP1:1	binding protein-1:8:0.1196	0.1196	8
4E-BP1	4E-BP1:8	eIF4E-binding protein:8:0.1004	0.1004	8
4E-BP1	4E-BP1:6	eukaryotic initiation factor 4E-binding protein-1:6:0.5290	0.5290	6
4F2hc	4F2hc:14|4F2HC:3	4F2 heavy chain:17:0.6748	0.6748	17
4G/5G	4G/5G:10	insertion/deletion:10:0.2195	0.2195	10
4G/5G	4G/5G:9	polymorphism:9:0.1951	0.1951	9
4-HAQO	4-HAQO:15|4HAQO:13	4-hydroxyaminoquinoline 1-oxide:28:0.6455	0.6455	28
4HA	4HA:11|4-HA:7	4-hydroxyanisole:18:0.6071	0.6071	18
4-HBA	4-HBA:10|4HBA:4	4-hydroxybenzoate:14:0.3611	0.3611	14
4-HBA	4-HBA:8|4HBA:2	4-hydroxybenzoic acid:10:0.3145	0.3145	10
4-HC	4-HC:108|4HC:39	4-hydroperoxycyclophosphamide:147:0.7807	0.7807	147
4-HNE	4-HNE:22|4HNE:21	4-hydroxy-2-nonenal:43:0.1765	0.1765	43
4HNE	4HNE:5|4-HNE:4	4-hydroxynon-2-enal:9:0.0336	0.0336	9
4-HPR	4-HPR:12	4-hydroxyphenylretinamide:12:0.0421	0.0421	12
4-HPR	4-HPR:44|4HPR:11	fenretinide:55:0.2031	0.2031	55
4-HPR	4-HPR:36|4HPR:8	N-(4-hydroxyphenyl) retinamide:33:0.4488|N-(4-hydroxyphenyl)-retinamide:11:0.0383	0.4488	44
4HPR	4HPR:7|4-HPR:6	synthetic retinoid N-(4-hydroxyphenyl)retinamide:13:0.4832	0.4832	13
4-HT	4-HT:5|4HT:5	4-hydroxytamoxifen:10:0.5000	0.5000	10
4-MA	4-MA:13|4MA:4	alpha-androstan-3-one:17:0.4571	0.4571	17
4-MC	4-MC:8|4MC:4	4-methylcatechol:12:0.7333	0.7333	12
4-META	4-META:39	trimellitate anhydride:39:0.6563	0.6563	39
4-MH	4-MH:9|4MH:1	4-methylhistamine:10:0.6923	0.6923	10
4-MI	4-MI:8|4MI:3	4-methylimidazole:11:0.8333	0.8333	11
4-MPR	4-MPR:8|4MPR:1	N-(4-methoxyphenyl)retinamide:9:0.5000	0.5000	9
4-MP	4-MP:54|4MP:10	4-methylpyrazole:64:0.7241	0.7241	64
4-MU	4-MU:23|4MU:18	4-methylumbelliferone:41:0.7273	0.7273	41
4-MU	4-MU:6|4MU:2|4Mu:1	4-methylumbelliferyl:9:0.1455	0.1455	9
4-NP	4-NP:23|4NP:11	4-nitrophenol:34:0.3667	0.3667	34
4-NP	4-NP:38|4NP:3	4-nonylphenol:41:0.4444	0.4444	41
4NQO	4NQO:210|4-NQO:85	4-Nitroquinoline 1-oxide:171:0.9312|4-nitroquinoline-1-oxide:124:0.2867	0.9312	295
4NQO	4NQO:49|4-NQO:40	4-nitroquinoline-N-oxide:55:0.1259|4-nitroquinoline N-oxide:34:0.7898	0.7898	89
4-NQO	4-NQO:8|4NQO:4	4-nitroquinoline oxide:12:0.7571	0.7571	12
4-OHA	4-OHA:8|4-OH-A:7	4-hydroxy-4-androstene-3,17-dione:15:0.1176	0.1176	15
4-OHA	4-OHA:5|4OHA:4	4-hydroxyantipyrine:9:0.0672	0.0672	9
4-OH-CP	4-OH-CP:9|4-OHCP:7|4OHCP:4	4-hydroxycyclophosphamide:20:0.7037	0.7037	20
4-OHE(2)	4-OHE(2):8|4-OH-E(2):1	4-hydroxyestradiol:9:0.6154	0.6154	9
4-OHE1	4-OHE1:5|4-OH-E1:2|4OHE1:1|4OH-E1:1	4-hydroxyestrone:9:0.8000	0.8000	9
4-OHE2	4-OHE2:21|4-OH-E2:9|4OHE2:1	4-hydroxyestradiol:31:0.6122	0.6122	31
4-OHEN	4-OHEN:15	4-hydroxyequilenin:15:0.8750	0.8750	15
4-OH-TAM	4-OH-TAM:10|4-OH-tam:3|4OH-TAM:3|4-OHTAM:3|4-OHTam:3|4OHtam:2|4-OH-Tam:2|4OHTAM:1	4-hydroxytamoxifen:27:0.5532	0.5532	27
4-OHT	4-OHT:35|4OHT:10	4-hydroxytamoxifen:45:0.6769	0.6769	45
4-OT	4-OT:29|4OT:3	4-oxalocrotonate tautomerase:32:0.9072	0.9072	32
4-PA	4-PA:39|4PA:6	4-pyridoxic acid:45:0.7270	0.7270	45
4PBA	4PBA:7|4-PBA:3	4-phenylbutyrate:10:0.6923	0.6923	10
4-PeCDF	4-PeCDF:8|4PeCDF:6	2,3,4,7,8-pentachlorodibenzofuran:14:0.7222	0.7222	14
4R	4R:9|4-R:1	four-repeat:10:0.1579	0.1579	10
4S	4S:76	Scandinavian Simvastatin Survival Study:76:0.9378	0.9378	76
4V	4V:8	fourth ventricle:8:0.4102	0.4102	8
4-VO	4-VO:29|4VO:19	occlusion:48:0.7833	0.7833	48
4D	4D:47|4-D:30	four-dimensional:77:0.4419	0.4419	77
4p-	4p-:9	short arm of chromosome 4:9:0.6794	0.6794	9
5'-AMP	5'-AMP:9	5'-adenosine monophosphate:9:0.3945	0.3945	9
5'-AMP	5'-AMP:14|5'AMP:1	adenosine 5'-monophosphate:15:0.7096	0.7096	15
5'-DFCR	5'-DFCR:13|5'DFCR:2	5'-deoxy-5-fluorocytidine:15:0.8750	0.8750	15
5'D-II	5'D-II:10|5'-DII:2|5'DII:1	Type II 5'-Deiodinase:13:0.7753	0.7753	13
5'D-II	5'D-II:8|5'DII:1|5'-D-II:1	type II iodothyronine 5'-deiodinase:10:0.7103	0.7103	10
5'DI	5'DI:6|5'D-I:4|5'-DI:3	deiodinase:13:0.1429	0.1429	13
5'D-I	5'D-I:5|5'DI:1	iodothyronine 5'-monodeiodinase:6:0.2243	0.2243	6
5'DI	5'DI:8|5'D-I:8|5'-DI:2	type I 5'-deiodinase:18:0.8365	0.8365	18
5'D	5'D:3	T4 5'-monodeiodinase:3:0.0736	0.0736	3
5'ETS	5'ETS:8|5'-ETS:2	5' external transcribed spacer:10:0.7103	0.7103	10
5'-GMP	5'-GMP:9	5'-guanosine monophosphate:9:0.5470	0.5470	9
5'-GMP	5'-GMP:21|5'GMP:1	guanosine 5'-monophosphate:11:0.7357|guanosine-5'-monophosphate:11:0.2632	0.7357	22
5'NCR	5'NCR:17|5'-NCR:3	5' non-coding region:20:0.8525	0.8525	20
5'NCR	5'NCR:23	5' noncoding region:23:0.8715	0.8715	23
5'-ND	5'-ND:8|5'ND:2	5'-nucleotidase:10:0.8182	0.8182	10
5'NTR	5'NTR:15|5'-NTR:4	5' nontranslated region:19:0.8449	0.8449	19
5'NTR	5'NTR:8	5' nontranslated RNA:8:0.6411	0.6411	8
5'-NT	5'-NT:45|5'NT:23	5'-nucleotidase:59:0.5370|5' nucleotidase:9:0.4587	0.5370	68
5'NT	5'NT:9|5'Nt:2|5'nt:2	5'nucleotidase:13:0.1111	0.1111	13
5'NT	5'NT:6|5'-NT:4	ecto-5'-nucleotidase:10:0.0833	0.0833	10
5'-Nu	5'-Nu:6|5'NU:2|5'-NU:1	5'-nucleotidase:9:0.4706	0.4706	9
5'-Nase	5'-Nase:29|5'Nase:3	5'-nucleotidase:32:0.8857	0.8857	32
5'N	5'N:26|5'-N:21	5'-nucleotidase:47:0.7188	0.7188	47
5'-UTR	5'-UTR:187|5'UTR:33	5'-untranslated region:208:0.5078|5'-untranslated regions:12:0.4153	0.5078	220
5'-DFUR	5'-DFUR:151|5'DFUR:7|5'-dFUR:6|5'dFUR:3|5'dFUr:1	5'-deoxy-5-fluorouridine:168:0.6761	0.6761	168
5'-DFUR	5'-DFUR:55|5'-dFUR:2|5'DFUR:2|5'dFUR:1	doxifluridine:60:0.2389	0.2389	60
5'-dFUrd	5'-dFUrd:27|5'dFUrd:4	5'-deoxy-5-fluorouridine:31:0.7895	0.7895	31
5'ss	5'SS:9|5'ss:9|5'-SS:1	5' splice site:19:0.7658	0.7658	19
5,6-EET	5,6-EET:14	5,6-epoxyeicosatrienoic acid:14:0.5111	0.5111	14
5,6-DHT	5,6-DHT:76|5,6DHT:1	5,6-dihydroxytryptamine:77:0.9268	0.9268	77
5,7-DHT	5,7-DHT:410|5,7DHT:3	5,7-dihydroxytryptamine:413:0.8996	0.8996	413
5-AIQ	5-AIQ:10	5-aminoisoquinolinone:10:0.9000	0.9000	10
5-FUR	5-FUR:12|5-FUr:1	5-fluorouridine:13:0.9231	0.9231	13
5-HT(1A)	5-HT(1A):25	5-hydroxytryptamine(1A):25:0.2400	0.2400	25
5-HT4	5-HT4:9	5-hydroxytryptamine 4:9:0.2500	0.2500	9
5-HT4	5-HT4:16	5-hydroxytryptamine4:16:0.2027	0.2027	16
5-IAF	5-IAF:10	5-iodoacetamidofluorescein:10:0.5294	0.5294	10
5-ISMN	5-ISMN:34	isosorbide-5-mononitrate:22:0.4565|isosorbide 5-mononitrate:12:0.7571	0.7571	34
5-OHDA	5-OHDA:37	5-hydroxydopamine:37:0.9000	0.9000	37
5-OT	5-OT:17	serotonin:17:0.8000	0.8000	17
5-foU	5-foU:11	5-formyluracil:11:0.9091	0.9091	11
5/6NX	5/6NX:4|5/6Nx:2|5/6-NX:2	5/6 nephrectomy:8:0.4102	0.4102	8
51Cr	51Cr:23	51Chromium:23:0.1497	0.1497	23
51Cr	51Cr:17	chromium-51:17:0.1088	0.1088	17
53BP1	53BP1:8	p53 binding protein 1:8:0.5006	0.5006	8
5-AC	5-AC:16|5AC:11|5aC:1	5-azacytidine:28:0.4737	0.4737	28
5-ALA	5-ALA:24	5-aminolaevulinic acid:24:0.1242	0.1242	24
5-ALA	5-ALA:78|5-Ala:1	5-aminolevulinic acid:79:0.5853	0.5853	79
5AR	5AR:8|5aR:1	5 alpha-reductase:9:0.6794	0.6794	9
5-ASA	5-ASA:15|5ASA:1	5-aminosalicylate:16:0.0341	0.0341	16
5-ASA	5-ASA:333|5ASA:12	5-Aminosalicylic acid:345:0.8732	0.8732	345
5-ASA	5-ASA:9	mesalamine:9:0.0182	0.0182	9
5-ASA	5-ASA:14	Mesalazine:14:0.0295	0.0295	14
5AzC	5AzC:6|5-AZC:5|5-AzC:3	5-Azacytidine:14:0.7857	0.7857	14
5-AZ	5-AZ:6|5Az:3|5AZ:3	5-azacytidine:12:0.6111	0.6111	12
5-aza-dC	5-aza-dC:17|5-azadC:6|5Aza-dC:5|5-Aza-dC:4|5AzadC:2|5-AZAdC:1|5aza-dC:1|5AZA-dC:1|5-aza-dc:1|5-AzadC:1	5-aza-2'-deoxycytidine:39:0.5429	0.5429	39
5-aza-dC	5-aza-dC:6|5-azadC:5	5-azadeoxycytidine:11:0.1429	0.1429	11
5-BrdU	5-BrdU:12|5BrdU:1	5-bromodeoxyuridine:13:0.6000	0.6000	13
5-CSRTT	5-CSRTT:14|5CSRTT:3	five-choice serial reaction time task:17:0.5760	0.5760	17
5-CSRT	5-CSRT:8|5CSRT:1	serial reaction time:9:0.6794	0.6794	9
5-CT	5-CT:190|5CT:2	5-carboxamidotryptamine:192:0.7958	0.7958	192
5-CT	5-CT:17	5-carboxyamidotryptamine:17:0.0667	0.0667	17
5-FC	5-FC:156|5FC:58|5-Fc:4|5-fc:1	5-fluorocytosine:219:0.6667	0.6667	219
5-FC	5-FC:40|5FC:27	flucytosine:67:0.2018	0.2018	67
5FMOrn	5FMOrn:9|5-FMOrn:4	5-Fluoromethylornithine:13:0.9231	0.9231	13
5-FU/LV	5-FU/LV:10|5FU/LV:1	5-fluorouracil/leucovorin:11:0.3030	0.3030	11
5-FUDR	5-FUDR:7|5-FUdR:6|5FUDR:1	5-fluorodeoxyuridine:14:0.3611	0.3611	14
5-FUra	5-FUra:55|5FUra:6	5-fluorouracil:61:0.9231	0.9231	61
5-FU	5-FU:9|5FU:1	5-flourouracil:10:0.0016	0.0016	10
5-FU	5-FU:11|5FU:1|5-Fu:1	5-fluoro-uracil:13:0.0021	0.0021	13
5-FU	5-FU:4457|5FU:423|5-Fu:74|5Fu:5|5--FU:1	5-fluorouracil:4960:0.8702	0.8702	4960
5-FU	5-FU:11|5FU:2	chemotherapy:13:0.0021	0.0021	13
5-FU	5-FU:434|5FU:65|5-Fu:7|5Fu:1|5-fu:1	fluorouracil:508:0.0880	0.0880	508
5-HD	5-HD:20|5HD:3	5-hydroxydecanoic acid:23:0.8715	0.8715	23
5-HIAA	5-HIAA:206|5HIAA:32|5hiaa:1	5-hydroxyindole acetic acid:239:0.7302	0.7302	239
5-HIAA	5-HIAA:11|5HIAA:1	5-hydroxyindoleacetic:12:0.0042	0.0042	12
5-HMF	5-HMF:13	5-hydroxymethylfurfural:13:0.3529	0.3529	13
5-HPETE	5-HPETE:35|5-HpETE:1|5HPETE:1	5-Hydroperoxyeicosatetraenoic acid:37:0.4933	0.4933	37
5-HT(3)	5-HT(3):10	5-hydroxytryptamine(3):10:0.1406	0.1406	10
5-HT(3)	5-HT(3):5	serotonin type 3:5:0.2818	0.2818	5
5-HT1A	5-HT1A:14|5-HT-1A:1	5-hydroxytryptamine:15:0.0369	0.0369	15
5-HT1A	5-HT1A:38|5HT1A:1|5-HT1a:1|5HT-1A:1|5-HT-1A:1	5-hydroxytryptamine 1A:23:0.2250|5-hydroxytryptamine-1A:19:0.0442	0.2250	42
5-HT1A	5-HT1A:112|5HT1A:1|5-HT1a:1	5-hydroxytryptamine1A:114:0.2776	0.2776	114
5-HT1A	5-HT1A:5|5HT1A:1	serotonin type 1A:6:0.1148	0.1148	6
5-HT1B	5-HT1B:15|5HT1B:1	5-hydroxytryptamine1B:16:0.1974	0.1974	16
5-HT1D	5-HT1D:10|5-HT1d:1	5-hydroxytryptamine1d:11:0.2857	0.2857	11
5-HT1	5-HT1:7|5HT1:1	5-hydroxytryptamine1:8:0.0920	0.0920	8
5-HT1	5-HT1:12|5HT1:1	serotonin1:13:0.1379	0.1379	13
5-HT2A	5-HT2A:18|5HT2A:1|5-HT2a:1	5-hydroxytryptamine2A:20:0.1301	0.1301	20
5-HT2	5-HT2:33|5HT2:1	5-hydroxytryptamine:34:0.0752	0.0752	34
5-HT2	5-HT2:12|5HT2:1|5HT-2:1	5-Hydroxytryptamine-2:14:0.0296	0.0296	14
5-HT2	5-HT2:64|5HT2:4	5-hydroxytryptamine2:68:0.1549	0.1549	68
5-HT2	5-HT2:10|5HT2:1|5HT-2:1	ketanserin:12:0.0251	0.0251	12
5-HT2	5-HT2:23|5HT-2:1|5HT2:1	serotonergic:25:0.0547	0.0547	25
5-HT2	5-HT2:48|5HT2:4|5-HT-2:2	serotonin-2:45:0.1002|serotonin 2:9:0.0758	0.1002	54
5-HT2	5-HT2:12|5HT2:3	serotonin type 2:15:0.4312	0.4312	15
5-HT2	5-HT2:56|5HT2:5	serotonin2:61:0.1367	0.1367	61
5-HT3	5-HT3:35|5HT3:7	5-hydroxytryptamine:42:0.0995	0.0995	42
5-HT3	5-HT3:22|5HT3:6|5HT-3:2	5-hydroxytryptamine-3:16:0.0364|5-hydroxytryptamine 3:14:0.0943	0.0943	30
5-HT3	5-HT3:19|5HT3:2	5-hydroxytryptamine type 3:21:0.3457	0.3457	21
5-HT3	5-HT3:125|5HT3:2	5-hydroxytryptamine3:127:0.3034	0.3034	127
5-HT3	5-HT3:24|5HT3:1	serotonin-3:25:0.0583	0.0583	25
5-HT3	5-HT3:12|5HT3:3	serotonin receptor:15:0.4312	0.4312	15
5-HT3	5-HT3:17	serotonin type 3:17:0.2533	0.2533	17
5-HT3	5-HT3:18	Serotonin3:18:0.0413	0.0413	18
5-HT-LI	5-HT-LI:9|5-HTLI:7|5HT-LI:2	immunoreactivity:18:0.6800	0.6800	18
5-HTOL	5-HTOL:24|5HTOL:17	5-hydroxytryptophol:41:0.9302	0.9302	41
5-HTP	5-HTP:41|5HTP:2	5-hydroxy-L-tryptophan:43:0.0552	0.0552	43
5-HTP	5-HTP:529|5HTP:43|5-htp:2|5-HTp:1	5-hydroxytryptophan:575:0.7530	0.7530	575
5-HTP	5-HTP:11	5-hydroxytryptophane:11:0.0131	0.0131	11
5-HTP	5-HTP:52|5HTP:9	L-5-Hydroxytryptophan:61:0.0775	0.0775	61
5-HTT	5-HTT:4	5-HT transporters:4:0.1838	0.1838	4
5-HTT	5-HTT:1	serotonin 5-HT transporter:1:0.0819	0.0819	1
5-HTT	5-HTT:178|5HTT:22|5HTt:3|5HT-T:2|5-HTt:1	serotonin transporter:206:0.6621	0.6621	206
5-HTT	5-HTT:22|5HTT:4	serotonin transporter gene:26:0.8861	0.8861	26
5-HT-ir	5-HT-ir:4|5-HT-IR:2|5-HTir:1	5-HT immunoreactive:7:0.1730	0.1730	7
5-HT-IR	5-HT-IR:8|5HT-IR:3|5-HT-ir:3|5HTir:2|5-HTir:2|5HT-ir:1|5-HTIR:1	serotonin-immunoreactive:20:0.3115	0.3115	20
5-HT	5-HT:7|5HT:2	[14C]5-hydroxytryptamine:9:0.0006	0.0006	9
5-HT	5-HT:49|5HT:9	[3H]5-Hydroxytryptamine:34:0.0027|[3H]-5-hydroxytryptamine:14:0.0011|3H-5-hydroxytryptamine:10:0.0007	0.0027	58
5-HT	5-HT:25|5HT:5	[3H]serotonin:18:0.0014|3H-serotonin:12:0.0009	0.0014	30
5-HT	5-HT:36|5HT:5	5-hydroxy-tryptamine:41:0.0033	0.0033	41
5-HT	5-HT:9	5-hydroxytrypamine:9:0.0006	0.0006	9
5-HT	5-HT:4278|5HT:277|5-ht:4|5-Ht:1|5-H-T:1	5-Hydroxytryptamine:4556:0.3683|5 hydroxytryptamine:5:0.0736	0.3683	4561
5-HT	5-HT:6|5HT:3	5-hydroxytryptophan:9:0.0006	0.0006	9
5-HT	5-HT:25|5HT:1	central serotonergic:26:0.0551	0.0551	26
5-HT	5-HT:6244|5HT:758|5-ht:2	serotonin:7004:0.5666	0.5666	7004
5-HT	5-HT:10|5HT:1	serotonine:11:0.0008	0.0008	11
5-HT	5-HT:65|5HT:9	serotoninergic:74:0.0059	0.0059	74
5-LOX	5-LOX:89|5LOX:5|5-Lox:3|5-lox:1|5-LOx:1	5-lipoxygenase:99:0.8981	0.8981	99
5-LO	5-LO:400|5LO:27	5-lipoxygenase:427:0.9463	0.9463	427
5mC	5mC:38|5-mC:10|5MC:8|5-MC:3|5-mc:2	5-methylcytosine:61:0.6897	0.6897	61
5-MTHF	5-MTHF:21|5MTHF:7|5mTHF:1|5-mTHF:1	5-methyltetrahydrofolate:30:0.8056	0.8056	30
5-MT	5-MT:38|5MT:5	5-methoxytryptamine:43:0.7241	0.7241	43
5-MeC	5-MeC:12	5-methylchrysene:12:0.2973	0.2973	12
5-MeC	5-MeC:8|5MeC:5|5meC:4	5-methylcytosine:17:0.4324	0.4324	17
5-MeOT	5-MeOT:43|5-MeO-T:4|5MeOT:2|5-Me-OT:1|5-MEOT:1|5-Me-O-T:1	5-methoxytryptamine:52:0.8947	0.8947	52
5NT	5NT:14|5nt:1	5'-nucleotidase:15:0.4828	0.4828	15
5-OHP	5-OHP:6|5-OH-P:2|5OHP:1	5-hydroxypropafenone:9:0.5000	0.5000	9
5-S-CD	5-S-CD:48|5SCD:4|5-SCD:2	5-S-Cysteinyldopa:54:0.9138	0.9138	54
5-TG	5-TG:10|5TG:9|5-T-G:3	5-thio-D-glucose:22:0.6364	0.6364	22
5-TG	5-TG:6|5TG:4	5-thioglucose:10:0.2727	0.2727	10
5-YSR	5-YSR:5|5YSR:3|5-y-SR:1|5-Y-SR:1|5-ysr:1|5ysr:1	survival rate:12:0.6460	0.6460	12
5-aza	5-aza:4|5AZA:3|5Aza:2|5-Aza:1	5-aza-2'-deoxycytidine:10:0.2093	0.2093	10
5-aza	5-aza:24|5aza:2|5-Aza:1	5-azacytidine:27:0.6047	0.6047	27
5-D	5-D:5|5D:5	5-deiodinase:10:0.1154	0.1154	10
5-ML	5-ML:13	5-methoxytryptophol:13:0.8000	0.8000	13
5-MU	5-MU:18|5MU:1	5-methylurapidil:19:0.6429	0.6429	19
5q-	5q-:19	long arm of chromosome 5:19:0.8525	0.8525	19
6-4PP	6-4PP:5	6-4 photoproducts:5:0.3524	0.3524	5
6-MBOA	6-MBOA:9	6-methoxy-2-benzoxazolinone:9:0.5000	0.5000	9
6-OHMS	6-OHMS:15	6-hydroxymelatonin sulfate:15:0.7096	0.7096	15
60Co	60Co:16	gamma-irradiation:9:0.0576|gamma irradiation:7:0.1895	0.1895	16
60Co	60Co:9	gamma radiation:9:0.4587	0.4587	9
6-4PPs	6-4PPs:14|64PPs:3	photoproducts:17:0.8000	0.8000	17
67Ga	67Ga:11	Gallium-67 citrate:11:0.2972	0.2972	11
67LR	67LR:44|67-LR:3	laminin receptor:47:0.9006	0.9006	47
6-AC	6-AC:7|6AC:2	6-aminochrysene:9:0.2353	0.2353	9
6-AHA	6-AHA:11|6AHA:3|6-AHa:1	6-aminohexanoic acid:15:0.5348	0.5348	15
6-AM	6-AM:20|6AM:6	6-acetylmorphine:26:0.5952	0.5952	26
6-AN	6-AN:84|6AN:20	6-aminonicotinamide:104:0.9099	0.9099	104
6-APA	6-APA:51|6APA:1	6-aminopenicillanic acid:52:0.6334	0.6334	52
6AU	6AU:8|6-AU:3	6-azauracil:11:0.7143	0.7143	11
6-CB	6-CB:10	2,2',4,4',5,5'-hexachlorobiphenyl:10:0.2571	0.2571	10
6-CB	6-CB:12	2,4,5,2',4',5'-hexachlorobiphenyl:12:0.3143	0.3143	12
6-CF	6-CF:15|6CF:4	6-carboxyfluorescein:19:0.6923	0.6923	19
6-Cl-ddG	6-Cl-ddG:10|6ClddG:1	6-chloro-2',3'-dideoxyguanosine:11:0.9091	0.9091	11
6-HDA	6-HDA:22|6HDA:4	6-hydroxydopamine:26:0.9259	0.9259	26
6-HDNO	6-HDNO:15|6HDNO:2	6-hydroxy-D-nicotine oxidase:17:0.8270	0.8270	17
6-HD	6-HD:13|6HD:5	6-hydroxydopamine:18:0.8095	0.8095	18
6-MAM	6-MAM:37|6MAM:3	6-monoacetylmorphine:40:0.8667	0.8667	40
6-MMP	6-MMP:11|6MMP:1	6-methylmercaptopurine:12:0.6471	0.6471	12
6-MP	6-MP:340|6MP:102|6-mp:2|6-Mp:1	6-mercaptopurine:445:0.8862	0.8862	445
6-MP	6-MP:11|6MP:10	mercaptopurine:21:0.0399	0.0399	21
6MWD	6MWD:11|6-MWD:1	6-min walking distance:12:0.2414	0.2414	12
6MWD	6MWD:29|6-MWD:2|6mwD:1|6MWd:1	walk distance:33:0.4211	0.4211	33
6MWD	6MWD:6	walking distance test:6:0.5290	0.5290	6
6-NC	6-NC:22|6NC:1	6-nitrochrysene:23:0.8800	0.8800	23
6-OHDA	6-OHDA:40|6-OH-DA:7	6-hydroxy-dopamine:35:0.0160|6-hydroxy dopamine:12:0.5664	0.5664	47
6-OHDA	6-OHDA:1928|6-OH-DA:58|6OHDA:30|6OH-DA:3	6-hydroxydopamine:2019:0.9488	0.9488	2019
6PG	6PG:14|6-PG:2	6-phosphogluconate:16:0.7500	0.7500	16
6R-BH4	6R-BH4:9	6R-L-erythro-5,6,7,8-tetrahydrobiopterin:9:0.3200	0.3200	9
6-SAI	6-SAI:6|6SAI:4	6-Sulfanilamidoindazole:10:0.7500	0.7500	10
6-SMT	6-SMT:7|6SMT:2	6-sulfatoxymelatonin:9:0.4706	0.4706	9
6-TGN	6-TGN:27|6TGN:10	6-thioguanine nucleotides:28:0.7154|6-thioguanine nucleotide:9:0.6794	0.7154	37
6-TGr	6-TGr:3|6TGR:3|6-TGR:2|6TGr:1	6-thioguanine resistance:9:0.6794	0.6794	9
6-TGr	6-TGr:10|6TGr:8|6-TGR:1|6TGR:1	6-thioguanine-resistant:20:0.3654	0.3654	20
6-TG	6-TG:158|6TG:55|6-tG:1	6-thioguanine:214:0.8912	0.8912	214
6-TG	6-TG:8|6TG:5	thioguanine:13:0.0502	0.0502	13
6-dEB	6-dEB:15|6dEB:4|6-DEB:3	6-deoxyerythronolide B:22:0.8657	0.8657	22
6p	6p:10	short arm of chromosome 6:10:0.7571	0.7571	10
6q	6q:20	long arm of chromosome 6:20:0.8525	0.8525	20
7,8-BF	7,8-BF:21	7,8-benzoflavone:21:0.9524	0.9524	21
7-NINA	7-NINA:8	monosodium salt:8:0.3463	0.3463	8
7-OH-MTX	7-OH-MTX:40	7-hydroxymethotrexate:40:0.7358	0.7358	40
7-OHMTX	7-OHMTX:17	7-hydroxymethotrexate:17:0.8889	0.8889	17
7-ACA	7-ACA:33|7ACA:7	7-aminocephalosporanic acid:40:0.7653	0.7653	40
7B2	7B2:14	novel pituitary protein:14:0.7753	0.7753	14
7-CKA	7-CKA:6|7CKA:3	7-chlorokynurenic acid:9:0.5470	0.5470	9
7-CK	7-CK:5|7CK:3	7-chlorokynurenic acid:8:0.5006	0.5006	8
7-DHC	7-DHC:42|7DHC:24	7-Dehydrocholesterol:66:0.9420	0.9420	66
7E3	7E3:11	monoclonal antibody:11:0.4232	0.4232	11
7-EC	7-EC:28|7EC:3|7-Ec:2	7-ethoxycoumarin:33:0.8000	0.8000	33
7-HC	7-HC:18|7HC:9	7-hydroxycoumarin:27:0.8125	0.8125	27
7KC	7KC:12|7-KC:11	7-ketocholesterol:23:0.9565	0.9565	23
7-MG	7mG:5|7-MG:5|7MG:3|7-mG:1	7-methylguanine:14:0.7222	0.7222	14
7-meG	7-meG:8|7-MeG:7|7MeG:3	7-methylguanine:18:0.6800	0.6800	18
7-NI	7-NI:44|7NI:2	7-nitro indazole:37:0.9197|7-nitro-indazole:9:0.0299	0.9197	46
7-NI	7-NI:9	nNOS inhibitor 7-nitroindazole:9:0.2001	0.2001	9
7-OHC	7-OHC:16|7OHC:5	7-hydroxycoumarin:21:0.8000	0.8000	21
7S	7S:8|7s:1	Low molecular weight:9:0.5470	0.5470	9
7S	7S:16	monomeric:16:0.1546	0.1546	16
7TM	7TM:11|7-TM:5	seven-transmembrane:16:0.2083	0.2083	16
7K	7K:7|7-k:2	7-ketocholesterol:9:0.4444	0.4444	9
8-MeIQx	8-MeIQx:10	2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline:10:0.7500	0.7500	10
8-OH-Gua	8-OH-Gua:44	8-hydroxyguanine:44:0.9773	0.9773	44
82Rb	82Rb:16	rubidium-82:16:0.7895	0.7895	16
86Rb	86Rb:9	86Rubidium:9:0.0727	0.0727	9
86Rb	86Rb:22	ouabain-sensitive potassium:22:0.3457	0.3457	22
89Sr	89Sr:11	strontium-89:11:0.3030	0.3030	11
8-AG	8-AG:16|8AG:9	8-azaguanine:25:0.8276	0.8276	25
8BrGuo	8BrGuo:5|8-BrGuo:4|8Brguo:1	8-bromoguanosine:10:0.7500	0.7500	10
8CB	8CB:11	octylcyanobiphenyl:11:0.4545	0.4545	11
8-CPT	8-CPT:11	8-cyclopentyltheophylline:11:0.3846	0.3846	11
8-HQ	8-HQ:9|8HQ:8|8-Hq:1	8-hydroxyquinoline:18:0.9444	0.9444	18
8MGuo	8MGuo:10|8-MGuo:2	8-mercaptoguanosine:12:0.8462	0.8462	12
8-MOP	8-MOP:12	8-methoxy-psoralen:12:0.0186	0.0186	12
8-MOP	8-MOP:530|8MOP:13	8-methoxypsoralen:543:0.9171	0.9171	543
8-N3ATP	8-N3ATP:9|8-N3-ATP:3|8N3ATP:3	8-azidoadenosine 5'-triphosphate:15:0.7096	0.7096	15
8-OHdG	8-OHdG:233|8-OH-dG:73|8OHdG:16|8-OhdG:1|8ohdG:1|8-OH-DG:1|8-OHDG:1	8-hydroxy-2'-deoxyguanosine:308:0.4132|8-hydroxy-2-deoxyguanosine:18:0.0229	0.4132	326
8-OHdG	8-OHdG:8|8OH-dG:1	8-hydroxy-2'deoxyguanosine:9:0.0108	0.0108	9
8-OH-dG	8-OH-dG:14|8-OHdG:10	8-Hydroxy-deoxyguanosine:24:0.0310	0.0310	24
8-OHdG	8-OHdG:174|8-OH-dG:78|8OHdG:40|8-OHDG:2|8-OH-dg:1|8-ohdG:1|8ohdG:1	8-hydroxydeoxyguanosine:297:0.3984	0.3984	297
8-OHdG	8-OHdG:9	8-hydroxyl-2'-deoxyguanosine:9:0.0108	0.0108	9
8-PN	8-PN:7|8PN:3	8-prenylnaringenin:10:0.8182	0.8182	10
8-PT	8-PT:115|8PT:9	8-phenyltheophylline:124:0.8978	0.8978	124
8p	8p:13	short arm of chromosome 8:13:0.7753	0.7753	13
8-SPT	8-SPT:13|8SPT:1	8-(p-sulfophenyl)theophylline:14:0.1625	0.1625	14
8-SPT	8-SPT:10|8SPT:4	8-sulfophenyltheophylline:14:0.1625	0.1625	14
8-SPT	8-SPT:7|8SPT:2	theophylline:9:0.1000	0.1000	9
8-OHG	8-OHG:15|8-OH-G:12|8OHG:4|8ohG:1	8-hydroxyguanine:32:0.6078	0.6078	32
8OHG	8OHG:6|8-OHG:6	8-hydroxyguanosine:12:0.2157	0.2157	12
8-oxoG	8-oxoG:57|8-OxoG:8|8-oxo-G:3|8oxoG:2	7,8-dihydro-8-oxoguanine:70:0.3136	0.3136	70
8-oxoG	8-oxoG:10	8-hydroxyguanine:10:0.0409	0.0409	10
8-oxoG	8-oxoG:26|8-oxo-G:3|8oxoG:2	8-oxo-7,8-dihydroguanine:31:0.1364	0.1364	31
8-oxodG	8-oxodG:10	7-hydro-8-oxo-2'-deoxyguanosine:10:0.0290	0.0290	10
8-oxo-dG	8-oxodG:4|8-oxo-dG:4	8-hydroxy-2'-deoxyguanosine:8:0.0258	0.0258	8
8-oxodG	8-oxodG:32|8-oxo-dG:19|8-OxodG:1	8-oxo-2'-deoxyguanosine:52:0.1645	0.1645	52
8-oxodG	8-oxodG:71|8-oxo-dG:26|8oxodG:2|8-Oxo-dG:1	8-oxo-7,8-dihydro-2'-deoxyguanosine:100:0.3194	0.3194	100
8-oxo-dG	8-oxo-dG:10|8-oxodG:3	8-oxo-deoxyguanosine:13:0.0387	0.0387	13
8-oxodG	8-oxodG:20|8-oxo-dG:3	8-oxodeoxyguanosine:23:0.0710	0.0710	23
8-oxodG	8-oxodG:4|8-oxo-dG:4	formation of 7,8-dihydro-8-oxo-2'-deoxyguanosine:8:0.0789	0.0789	8
90Y	90Y:56|90-Y:1	Yttrium-90:40:0.4194|yttrium 90:17:0.8270	0.8270	57
99Tcm	99Tcm:13	Technetium-99m:13:0.6667	0.6667	13
99mTc-P	99mTc-P:6	blood clearance of 99mTc-phytate:6:0.5290	0.5290	6
99mTc	99mTc:11	99mtechnetium:11:0.0268	0.0268	11
99mTc	99mTc:16	pertechnetate:16:0.0402	0.0402	16
99mTc	99mTc:195|99m-Tc:2	technetium-99m:157:0.4182|technetium 99m:31:0.7091|technetium-99m-:9:0.0214	0.7091	197
9AA	9AA:33|9-AA:17	9-aminoacridine:50:0.7206	0.7206	50
9-AC	9-AC:9|9AC:3	9-amino-20(S)-camptothecin:12:0.0688	0.0688	12
9-AC	9-AC:48|9AC:9	9-aminocamptothecin:57:0.3500	0.3500	57
9-AC	9-AC:31|9AC:4	anthracene-9-carboxylic acid:35:0.4766	0.4766	35
9NC	9NC:25|9-NC:20	9-nitrocamptothecin:45:0.7167	0.7167	45
9-cis-RA	9-cis-RA:70|9cisRA:2	9-cis-retinoic acid:72:0.8168	0.8168	72
9p	9p:6|9P:1	short arm of chromosome 9:7:0.5926	0.5926	7
A&E	A&E:654	Accident and Emergency:654:0.9902	0.9902	654
A&E	A&E:39	Accident and Emergency department:30:0.9011|Accident and Emergency departments:9:0.6794	0.9011	39
A&E	A&E:40	Accident&Emergency:40:0.0525	0.0525	40
A(1)AR	A(1)AR:16	A(1) adenosine receptor:16:0.8165	0.8165	16
A(2A)R	A(2A)R:5|A(2A)-R:1	adenosine A(2A) receptor:6:0.3728	0.3728	6
A(3)AR	A(3)AR:12	A(3) adenosine receptor:12:0.7571	0.7571	12
A(L)	A(L):9	human-hamster hybrid:9:0.6794	0.6794	9
A(y)	A(y):10	yellow:10:0.5625	0.5625	10
A(z)	A(z):20|A(Z):1	area under the ROC curve:18:0.7173|areas under the ROC curves:3:0.2818	0.7173	21
A(z)	A(z):7|A(Z):2	under the receiver operating characteristic curve:9:0.6460	0.6460	9
A-MLV	A-MLV:7	amphotropic murine leukemia virus:7:0.4438	0.4438	7
A-type	A-type:6	rapidly inactivating:6:0.1838	0.1838	6
A.a.	A.a.:37	Actinobacillus actinomycetemcomitans:37:0.7548	0.7548	37
A.A.	A.A.:8	Alcoholics Anonymous:8:0.5006	0.5006	8
a.a.	a.a.:65|A.A.:2	amino acids:36:0.8716|amino acid:31:0.4981	0.8716	67
a.i.	a.i.:10	active ingredient:10:0.7103	0.7103	10
A.L.L.	A.L.L.:8	acute lymphoblastic leukaemia:8:0.6411	0.6411	8
a.u.	a.u.:16|A.U.:6	arbitrary units:22:0.6178	0.6178	22
A/C	A/C:6	albumin/creatinine ratio:6:0.1320	0.1320	6
A/D	A/D:20	analog-to-digital:20:0.3065	0.3065	20
A/E	A/E:79	attaching and effacing:79:0.9401	0.9401	79
A/E	A/E:4	velocity ratio:4:0.0736	0.0736	4
A/G	A/G:19	albumin/globulin:19:0.1513	0.1513	19
A/G	A/G:9	ratio:9:0.0672	0.0672	9
A/J	A/J:26	resistant:26:0.2252	0.2252	26
A/J	A/J:15	Susceptible:15:0.1261	0.1261	15
A/R	A/R:13	anoxia/reoxygenation:13:0.1765	0.1765	13
A/Sn	A/Sn:7|A/SN:4	resistant:11:0.5000	0.5000	11
A/S	A/S:20	auxotype/serovar:20:0.2714	0.2714	20
a/a	a/a:9	black:9:0.0661	0.0661	9
A-007	A-007:10	4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone:10:0.7273	0.7273	10
A172	A172:4|A-172:1	Human glioblastoma cells:5:0.1973	0.1973	5
A1896	A1896:6	precore mutation:6:0.2243	0.2243	6
A1ARs	A1ARs:11	A1 adenosine receptors:11:0.7357	0.7357	11
A1AR	A1AR:37|A1ar:1	A1 adenosine receptor:29:0.7970|A1 adenosine receptors:9:0.6794	0.7970	38
A1AT	A1AT:92|A-1-AT:13|a1AT:5|A1-AT:3|a1-AT:3|a-1AT:1|A-1--AT:1	alpha-1-antitrypsin:79:0.4815|alpha 1-antitrypsin:32:0.9072|alpha-1 antitrypsin:7:0.1641	0.9072	118
A1AT	A1AT:12|A1-AT:2|a1AT:1	alpha1-antitrypsin:15:0.0864	0.0864	15
A1Rs	A1Rs:8	adenosine A1 receptors:8:0.6411	0.6411	8
A1R	A1R:16|A1-R:1	adenosine A1 receptor:12:0.6460|adenosine A1 receptors:5:0.4422	0.6460	17
A1c	A1C:7|A1c:7	glycosylated hemoglobin:14:0.4367	0.4367	14
A1c	A1c:9|A1C:8	hemoglobin A1C:17:0.5760	0.5760	17
A1	A1:9	aluminum:9:0.0108	0.0108	9
A1	A1:18|A-1:1	anterior cerebral artery:19:0.8449	0.8449	19
A-1	A-1:5|A1:4	monoclonal antibody:9:0.5470	0.5470	9
A1	A1:63	primary auditory cortex:63:0.8097	0.8097	63
A23187	A23187:269|A-23187:9	calcium ionophore:278:0.7041	0.7041	278
A23187	A23187:20	calcium ionophore A23187:20:0.5721	0.5721	20
A23187	A23187:4	ionophore calcimycin:4:0.1543	0.1543	4
A2780	A2780:11	ovarian cancer cell line:11:0.7357	0.7357	11
A2aR	A2AR:3|A2aR:3|A2A-R:1	adenosine A2a receptors:7:0.4438	0.4438	7
A2M	A2M:65|a2M:11|a2-M:3|A-2-M:2|A2-M:1|a2m:1|a-2-M:1	alpha-2-macroglobulin:43:0.3206|alpha 2-macroglobulin:20:0.7766|alpha-2 macroglobulin:14:0.3383|alpha 2 macroglobulin:7:0.4438	0.7766	84
A2M	A2M:19|a2M:1|a2-M:1	alpha2-macroglobulin:21:0.1527	0.1527	21
A375	A375:9|A-375:2	melanoma cell line:11:0.7357	0.7357	11
A3AR	A3AR:23	A3 adenosine receptor:23:0.8038	0.8038	23
A431	A431:29|A-431:2	human epidermoid carcinoma:31:0.7718	0.7718	31
A431	A431:5|A-431:3	human epidermoid carcinoma cells:8:0.3463	0.3463	8
A-4	A-4:10|A4:2	4-androstene-3,17-dione:12:0.0507	0.0507	12
A4	A4:71	androstenedione:71:0.3226	0.3226	71
A4	A4:6	deposition of amyloid:6:0.1148	0.1148	6
A549	A549:6	human alveolar epithelial:6:0.1320	0.1320	6
A549	A549:15	human alveolar epithelial cells:15:0.2522	0.2522	15
A549	A549:17	human lung epithelial:17:0.6748	0.6748	17
A549	A549:14|A-549:2	lung adenocarcinoma:16:0.4040	0.4040	16
A5P	A5P:8	arabinose 5-phosphate:8:0.2987	0.2987	8
A60	A60:18	antigen 60:18:0.6903	0.6903	18
A6	A6:12	distal nephron cell line:12:0.7571	0.7571	12
A6	A6:5	distal nephron epithelium:5:0.4422	0.4422	5
A6	A6:10	epithelial cells:10:0.1223	0.1223	10
A6	A6:11	kidney cells:11:0.1486	0.1486	11
A7r5	A7r5:25|A7R5:1	smooth muscle cells:26:0.8861	0.8861	26
A7r5	A7r5:12	smooth muscle cell line:12:0.7571	0.7571	12
A7r5	A7r5:8	vascular smooth muscle:8:0.4102	0.4102	8
A-9-C	A-9-C:8|A9C:4	anthracene-9-carboxylic acid:12:0.5050	0.5050	12
A9	A9:34|A-9:1	substantia nigra:35:0.9151	0.9151	35
A9	A9:13|A-9:1	substantia nigra pars compacta:14:0.8045	0.8045	14
AA-2G	AA-2G:17	2-O-alpha-D-glucopyranosyl-L-ascorbic acid:17:0.8270	0.8270	17
AA-2G	AA-2G:10	Ascorbic acid 2-O-alpha-glucoside:10:0.7103	0.7103	10
AA861	AA861:10|AA-861:3	2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone:13:0.2727	0.2727	13
AA-861	AA-861:9|AA861:1	5-lipoxygenase inhibitor:10:0.3145	0.3145	10
AAAD	AAAD:30|Aaad:1	aromatic L-amino acid decarboxylase:31:0.9043	0.9043	31
AAAV	AAAV:12	avian adeno-associated virus:12:0.7571	0.7571	12
AAAs	AAAs:297|AAAS:2	abdominal aortic aneurysms:299:0.9900	0.9900	299
AAAs	AAAs:8	aromatic amino acids:8:0.5006	0.5006	8
AAA	AAA:33	abdominal Aorta:33:0.8605	0.8605	33
AAA	AAA:1620	abdominal aortic aneurysm:1216:0.9805|abdominal aortic aneurysms:404:0.9734	0.9805	1620
AAA	AAA:7	abdominal aortic aneurysm repair:7:0.5926	0.5926	7
AAA	AAA:6	Aleuria aurantia agglutinin:6:0.5290	0.5290	6
AAA	AAA:8	Anguilla anguilla agglutinin:8:0.6411	0.6411	8
AAA	AAA:5	anti-albumin antibodies:5:0.0517	0.0517	5
AAA	AAA:35	aromatic amino acids:35:0.8681	0.8681	35
AAA	AAA:9	autoantibodies:9:0.0038	0.0038	9
AAA	AAA:5	autolyzed antigen-extracted allogeneic:5:0.3945	0.3945	5
AAA	AAA:14	cellular activities:14:0.5589	0.5589	14
AABB	AABB:26	American Association of Blood Banks:26:0.8861	0.8861	26
AABR	AABR:18|A-ABR:2	automated auditory brainstem response:20:0.8525	0.8525	20
AAb	AAb:17|aAb:14|AAB:12|Aab:8|aAB:6|aab:3|a-AB:2|A-Ab:1	autoantibodies:63:0.4733	0.4733	63
AACG	AACG:9	acute angle closure glaucoma:9:0.6794	0.6794	9
AACN	AACN:13	American Association of Colleges of Nursing:13:0.7753	0.7753	13
AACN	AACN:9	atypical acinar cell nodules:9:0.6794	0.6794	9
AACTG	AACTG:8	Adult AIDS Clinical Trials Group:8:0.6411	0.6411	8
AA-CoA	AA-CoA:9	arachidonoyl-CoA:9:0.6154	0.6154	9
AAc	AAc:30|AAC:1	acrylic acid:31:0.7388	0.7388	31
AAC	AAC:45	Acute acalculous cholecystitis:45:0.8964	0.8964	45
AAC	AAC:48	ADP/ATP carrier:48:0.8221	0.8221	48
AAC	AAC:14	antibiotic-associated colitis:14:0.5111	0.5111	14
AAC	AAC:1	area above curve:1:0.4438	0.4438	1
AAC	AAC:52	augmentative and alternative communication:52:0.9427	0.9427	52
AADC	AADC:182	aromatic L-amino acid decarboxylase:182:0.9494	0.9494	182
AADH	AADH:10	aromatic amine dehydrogenase:10:0.7103	0.7103	10
AADs	AADs:10	antiarrhythmic drugs:10:0.5000	0.5000	10
AAD	AAD:25	acute aortic dissection:25:0.7249	0.7249	25
AAD	AAD:13	American Academy of Dermatology:13:0.7753	0.7753	13
AAD	AAD:13	antiarrhythmic drugs:13:0.7753	0.7753	13
AAD	AAD:31	antibiotic-associated diarrhea:31:0.5933	0.5933	31
AAD	AAD:29	antibiotic-associated diarrhoea:21:0.5178|antibiotic associated diarrhoea:8:0.6411	0.6411	29
AAD	AAD:7	atlanto-axial dislocation:7:0.1111	0.1111	7
AAD	AAD:10	atlantoaxial dislocation:10:0.2643	0.2643	10
AAE	AAE:9	African American English:9:0.6794	0.6794	9
AAE	AAE:11	annulo-aortic ectasia:11:0.1037	0.1037	11
AAE	AAE:28	annuloaortic ectasia:28:0.4805	0.4805	28
AAF	AAF:9	2-(acetylamino)fluorene:9:0.0140	0.0140	9
AAF	AAF:288	2-acetylaminofluorene:288:0.5018	0.5018	288
AAF	AAF:40	acetylaminofluorene:40:0.0684	0.0684	40
AAF	AAF:11	anterior:11:0.0175	0.0175	11
AAF	AAF:54|-AAF:2	N-2-acetylaminofluorene:56:0.0965	0.0965	56
AAF	AAF:36	N-acetyl-2-aminofluorene:36:0.0614	0.0614	36
AAGL	AAGL:14	American Association of Gynecologic Laparoscopists:14:0.7909	0.7909	14
AAG	AAG:154	alpha 1-acid glycoprotein:154:0.9806	0.9806	154
AAG	AAG:8|Aag:5	DNA glycosylase:13:0.4444	0.4444	13
AAH	AAH:15	acute alcoholic hepatitis:15:0.8045	0.8045	15
AAH	AAH:126	atypical adenomatous hyperplasia:126:0.9761	0.9761	126
AAIRs	AAIRs:9	age-adjusted incidence rates:9:0.6794	0.6794	9
AAIR	AAIR:10	age-adjusted incidence rate:10:0.5856	0.5856	10
AAIS	AAIS:10	Adolescent Alcohol Involvement Scale:10:0.5856	0.5856	10
AAI	AAI:52	Adult Attachment Interview:52:0.9427	0.9427	52
AAI	AAI:11	Agrobacterium autoinducer:11:0.6182	0.6182	11
AAI	AAI:18|AA-I:5	aristolochic acid I:23:0.8715	0.8715	23
AAI	AAI:9	Atrial pacing:9:0.3945	0.3945	9
AAL	AAL:14	Aleuria aurantia lectin:14:0.7909	0.7909	14
AAMC	AAMC:55	Association of American Medical Colleges:55:0.9458	0.9458	55
AAMI	AAMI:5	acute anterior myocardial infarction:5:0.4422	0.4422	5
AAMI	AAMI:52	age-associated memory impairment:52:0.8572	0.8572	52
AAMI	AAMI:66	Association for the Advancement of Medical Instrumentation:66:0.9585	0.9585	66
AAMU	AAMU:10	5-acetylamino-6-amino-3-methyluracil:10:0.6923	0.6923	10
AAM	AAM:12	African-American men:12:0.7571	0.7571	12
AAM	AAM:14	aggressive angiomyxoma:14:0.7909	0.7909	14
AANS	AANS:13	American Association of Neurological Surgeons:13:0.7753	0.7753	13
AAO-HNS	AAO-HNS:20|AAOHNS:2	American Academy of Otolaryngology-Head and Neck Surgery:22:0.8657	0.8657	22
AAOS	AAOS:16	American Academy of Orthopaedic Surgeons:16:0.8165	0.8165	16
AAPBD	AAPBD:10	anomalous arrangement of the pancreaticobiliary duct:10:0.7103	0.7103	10
AAPCC	AAPCC:23	Adjusted Average Per Capita Cost:23:0.8715	0.8715	23
AAPCC	AAPCC:19	American Association of Poison Control Centers:19:0.8525	0.8525	19
AAPH	AAPH:9	2,2'-azobis(2-amidinopropane):9:0.0250	0.0250	9
AAPH	AAPH:65	2,2'-azobis(2-amidinopropane) dihydrochloride:46:0.2694|2,2'-azobis(2-amidinopropane)dihydrochloride:19:0.0563	0.2694	65
AAPI	AAPI:14	Asian American and Pacific Islander:14:0.8165	0.8165	14
AAPM	AAPM:41	American Association of Physicists in Medicine:41:0.9308	0.9308	41
AAP	AAP:66	acetaminophen:66:0.1030	0.1030	66
AAP	AAP:16	alanine-aminopeptidase:16:0.0238	0.0238	16
AAP	AAP:199	American Academy of Pediatrics:199:0.9849	0.9849	199
Aap	Aap:6|AAP:5|aap:1	amino acid permease:12:0.6460	0.6460	12
AAP	AAP:12	aminopeptidase from Aeromonas proteolytica:12:0.6701	0.6701	12
AAP	AAP:8	amplitude of the action potential:8:0.5000	0.5000	8
AAP	AAP:10	antiarrhythmic peptide:10:0.2643	0.2643	10
AARF	AARF:15	rotatory fixation:15:0.8045	0.8045	15
AAR	AAR:13	active anterior rhinomanometry:13:0.7753	0.7753	13
AAR	AAR:63	area at risk:63:0.8612	0.8612	63
AAR	AAR:11	rejection:11:0.0532	0.0532	11
AASK	AASK:28	African American Study of Kidney Disease and Hypertension:28:0.8861	0.8861	28
AAST	AAST:2	American Association for Surgery of Trauma:2:0.8270	0.8270	2
AASV	AASV:18	vasculitis:18:0.8095	0.8095	18
AAS	AAS:6	acetylsalicylic acid:6:0.1838	0.1838	6
AAs	AAs:26|A-As:1	African Americans:18:0.8365|African-Americans:9:0.0082	0.8365	27
AAS	AAS:7	AIDS Attitude Scale:7:0.5926	0.5926	7
AAS	AAS:4	Alcohol abstinence syndrome:4:0.0918	0.0918	4
AAs	AAs:8	alkylating agents:8:0.2987	0.2987	8
AAs	AAs:70|aas:3	amino acids:73:0.8329	0.8329	73
AAS	AAS:124	Anabolic-androgenic steroids:47:0.3209|anabolic androgenic steroids:40:0.9256|anabolic-androgenic steroid:37:0.5783	0.9256	124
AAs	AAs:16	anaplastic astrocytomas:16:0.8165	0.8165	16
AAS	AAS:5	Aplastic anemia serum:5:0.4422	0.4422	5
AAs	AAs:10	aromatic amines:10:0.7103	0.7103	10
AAS	AAS:11	atlanto-axial subluxation:11:0.1203	0.1203	11
AAS	AAS:27	atlantoaxial subluxation:27:0.5334	0.5334	27
AAS	AAS:157	atomic absorption spectrometry:157:0.9596	0.9596	157
AAS	AAS:14	trans-4-acetylaminostilbene:14:0.0133	0.0133	14
AATD	AATD:20|AAT-D:1	deficiency:21:0.9524	0.9524	21
AATP	AATP:9	acquired amegakaryocytic thrombocytopenic purpura:9:0.5006	0.5006	9
AATase	AATase:17	aspartate aminotransferase:17:0.8270	0.8270	17
AAT	AAT:15	Aachen aphasia test:15:0.6911	0.6911	15
AAT	AAT:16	acute acoustic trauma:16:0.8165	0.8165	16
AAT	AAT:18	alanine aminotransferase:18:0.0959	0.0959	18
AAT	AAT:335	alpha-1-antitrypsin:162:0.2152|alpha 1-antitrypsin:120:0.9751|alpha(1)-antitrypsin:29:0.0374|Alpha-1 antitrypsin:24:0.4622	0.9751	335
AAT	AAT:51	alpha1-antitrypsin:51:0.0668	0.0668	51
AAT	AAT:12	animal-assisted therapy:12:0.2293	0.2293	12
AAT	AAT:75|AAt:1	aspartate aminotransferase:76:0.6714	0.6714	76
AAU	AAU:83	acute anterior uveitis:83:0.9081	0.9081	83
AAV-1	AAV-1:6|AAV1:1	adeno-associated virus type 1:7:0.5926	0.5926	7
AAV-2	AAV-2:9|AAV2:2	Adeno-associated virus:11:0.7357	0.7357	11
AAV-2	AAV-2:46|AAV2:28	adeno-associated virus type 2:74:0.8819	0.8819	74
AAV5	AAV5:9|AAV-5:3	adeno-associated virus type 5:12:0.7571	0.7571	12
AAVs	AAVs:18	Adeno-associated viruses:18:0.7539	0.7539	18
AAV	AAV:65	Adeno-associated viral:65:0.8123	0.8123	65
AAV	AAV:731|A-AV:4	adeno-associated virus:714:0.9333|adeno-associated viruses:21:0.6400	0.9333	735
AAV	AAV:26	adeno-associated virus 2:26:0.8861	0.8861	26
AAV	AAV:54	adeno-associated virus type 2:54:0.9448	0.9448	54
AAV	AAV:14	vasculitis:14:0.0127	0.0127	14
AAN	AAN:9	alpha-amino nitrogen:9:0.2285	0.2285	9
AAN	AAN:27	American Academy of Neurology:27:0.8903	0.8903	27
AAN	AAN:6	amino acid nitrogen:6:0.5290	0.5290	6
AAN	AAN:21|AAn:1	aminoacetonitrile:22:0.1641	0.1641	22
AAN	AAN:9	analgesic-associated nephropathy:9:0.1409	0.1409	9
AAN	AAN:8	aristolochic acid nephropathy:8:0.6411	0.6411	8
AAO	AAO:18	age at onset:18:0.8365	0.8365	18
AAO	AAO:8	anodic aluminum oxide:8:0.5006	0.5006	8
AA	AA:24	abdominal aorta:24:0.3526	0.3526	24
AA	AA:43|Aa:1	acetaldehyde:44:0.0037	0.0037	44
AA	AA:33	acetaminophen:33:0.0028	0.0028	33
AA	AA:16	acetoacetate:16:0.0013	0.0013	16
AA	AA:63	acrylamide:63:0.0053	0.0053	63
Aa	Aa:89|AA:6	Actinobacillus actinomycetemcomitans:95:0.8460	0.8460	95
AA	AA:10	active avoidance:10:0.5856	0.5856	10
AA	AA:26	acupuncture analgesia:26:0.7760	0.7760	26
AA	AA:34|aA:1	acute appendicitis:35:0.9151	0.9151	35
AA	AA:17	Adjuvant Arthritic:17:0.4246	0.4246	17
AA	AA:206	adjuvant arthritis:206:0.7131	0.7131	206
AA	AA:7	adjuvant-induced arthritic:7:0.0655	0.0655	7
AA	AA:17	adrenal androgen:17:0.8270	0.8270	17
AA	AA:5	adrenal autoantibodies:5:0.0612	0.0612	5
AA	AA:15	afferent:15:0.0012	0.0012	15
AA	AA:9	afferent arteriolar:9:0.4587	0.4587	9
AA	AA:24	afferent arterioles:16:0.8165|afferent arteriole:8:0.5006	0.8165	24
AA	AA:225|A-A:1	African-American:108:0.0092|African American:72:0.8948|African Americans:33:0.7525|African-Americans:13:0.0010	0.8948	226
AA	AA:8	aggregative adherence:8:0.3463	0.3463	8
AA	AA:9	alcohol abuse:9:0.6794	0.6794	9
AA	AA:16	alcohol-preferring:16:0.0013	0.0013	16
AA	AA:2	alcohol-preferring Alko Alcohol:2:0.1148	0.1148	2
AA	AA:106	Alcoholics Anonymous:106:0.8809	0.8809	106
AA	AA:7	alkylating agents:7:0.3524	0.3524	7
AA	AA:14|aA:1	Allergic asthma:15:0.3614	0.3614	15
AA	AA:27	allyl alcohol:27:0.3880	0.3880	27
AA	AA:164|Aa:2	alopecia areata:166:0.9710	0.9710	166
A-a	A-a:16|Aa:2	alveolar-arterial:18:0.0015	0.0015	18
AA	AA:8	ambient air:8:0.2987	0.2987	8
aa	aa:1136|AA:313	amino acids:1417:0.9758|amino-acid:32:0.0027	0.9758	1449
aa	aa:17	amino acid residues:17:0.8270	0.8270	17
AA	AA:6|aa:4	aminoacid:10:0.0008	0.0008	10
AA	AA:13	amyloid angiopathy:13:0.7753	0.7753	13
AA	AA:1	amyloid protein:1:0.6839	0.6839	1
AA	AA:124	anaplastic astrocytoma:90:0.9668|anaplastic astrocytomas:34:0.8644	0.9668	124
AA	AA:10	androgen ablation:10:0.7103	0.7103	10
AA	AA:12	antioxidant activity:12:0.0545	0.0545	12
AA	AA:23	aortic aneurysm:18:0.5560|aortic aneurysms:5:0.0517	0.5560	23
AA	AA:141	aplastic anaemia:141:0.9661	0.9661	141
AA	AA:357|Aa:1	Aplastic anemia:358:0.9740	0.9740	358
AA	AA:64	arachidonate:64:0.0055	0.0055	64
AA	AA:45	arachidonic:45:0.0038	0.0038	45
AA	AA:3321|Aa:4	arachidonic acid:3325:0.5313	0.5313	3325
AA	AA:42	aromatase activity:42:0.3596	0.3596	42
AA	AA:6	ascaris antigen:6:0.1010	0.1010	6
AA	AA:20	ascending aorta:20:0.2678	0.2678	20
AA	AA:33	ascorbate:33:0.0028	0.0028	33
AA	AA:22	atomic absorption:22:0.6934	0.6934	22
AA	AA:8	atopic asthmatic:8:0.5006	0.5006	8
AA	AA:46	normal:46:0.0039	0.0039	46
AA	AA:19	normal haemoglobin:19:0.7044	0.7044	19
AA	AA:14	rats with adjuvant-induced arthritis:14:0.1343	0.1343	14
AA	AA:10	reactive:10:0.0008	0.0008	10
AA	AA:27	secondary:27:0.0022	0.0022	27
AA	AA:8	Secondary amyloidosis:8:0.2090	0.2090	8
AB.C.	AB.C.:10	aberrant cells:10:0.5856	0.5856	10
Ab3	Ab3:8|AB3:1	anti-anti-Id:9:0.0412	0.0412	9
Ab3	Ab3:14|ab3:7|Ab-3:2	anti-anti-idiotypic:23:0.1134	0.1134	23
Ab3	Ab3:37|ab3:6|ab-3:1|Ab-3:1	anti-anti-idiotypic antibodies:38:0.3561|anti-anti-idiotypic antibody:7:0.0655	0.3561	45
ABAE	ABAE:13	adult bovine aortic endothelial:13:0.6701	0.6701	13
ABAP	ABAP:17	dihydrochloride:17:0.3810	0.3810	17
ABA	ABA:14	3-aminobenzamide:14:0.0137	0.0137	14
ABA	ABA:721	abscisic acid:721:0.9226	0.9226	721
ABA	ABA:10	activity-based anorexia:10:0.7103	0.7103	10
ABA	ABA:9	atopic bronchial asthma:9:0.4587	0.4587	9
ABA	ABA:6	hapten azobenzenearsonate:6:0.0522	0.0522	6
ABBI	ABBI:42	advanced breast biopsy instrumentation:42:0.8893	0.8893	42
ABB	ABB:15	acid-base balance:15:0.5818	0.5818	15
ABCA1	ABCA1:14	ATP-binding cassette transporter 1:14:0.4367	0.4367	14
ABCA1	ABCA1:100|Abca1:1	ATP-binding cassette transporter A1:76:0.6089|ATP binding cassette transporter A1:25:0.8816	0.8816	101
ABCA1	ABCA1:5	cassette transporter:5:0.1132	0.1132	5
ABCD	ABCD:27	amphotericin B colloidal dispersion:27:0.8903	0.8903	27
ABCR	ABCR:6	ABC transporter:6:0.1148	0.1148	6
ABCR	ABCR:6	ATP-binding cassette transporter:6:0.3728	0.3728	6
ABCs	ABCs:18	Aneurysmal bone cysts:18:0.7539	0.7539	18
ABC	ABC:17	active breathing control:17:0.8270	0.8270	17
ABC	ABC:26	activity-based costing:26:0.6645	0.6645	26
ABC	ABC:14	Activities-specific Balance Confidence:14:0.6024	0.6024	14
ABC	ABC:8	Activities-Specific Balance Confidence Scale:8:0.6794	0.6794	8
ABC	ABC:7	adenoid basal carcinoma:7:0.5926	0.5926	7
ABC	ABC:49	advanced breast cancer:49:0.8254	0.8254	49
ABC	ABC:4	advanced breast carcinoma:4:0.1618	0.1618	4
ABC	ABC:77	aneurysmal bone cyst:55:0.9458|aneurysmal bone cysts:22:0.8657	0.9458	77
ABC	ABC:27	antibody binding capacity:27:0.6645	0.6645	27
ABC	ABC:14	Antigen-binding cells:14:0.3813	0.3813	14
ABC	ABC:23	Argon Beam Coagulator:23:0.8715	0.8715	23
ABC	ABC:31	Aspiration biopsy cytology:31:0.9043	0.9043	31
ABC	ABC:852	ATP-binding cassette:665:0.7365|ATP binding cassette:167:0.8898|ATP-binding-cassette:20:0.0082	0.8898	852
ABC	ABC:9	ATP-binding cassette transporter:9:0.5470	0.5470	9
ABC	ABC:36	Behavior Checklist:36:0.7183	0.7183	36
ABD-F	ABD-F:8|ABDF:1	4-(aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole:9:0.3810	0.3810	9
ABD	ABD:17|Abd:4	abdominal:21:0.0787	0.0787	21
ABD	ABD:15	actin-binding domain:15:0.3110	0.3110	15
ABD	ABD:27	adynamic bone disease:27:0.6455	0.6455	27
ABD	ABD:18	autologous blood donation:18:0.7539	0.7539	18
ABD	ABD:24	Automated border detection:24:0.6122	0.6122	24
ABD	ABD:6	Automatic boundary detection:6:0.2243	0.2243	6
ABECB	ABECB:13	acute bacterial exacerbations of chronic bronchitis:13:0.7753	0.7753	13
ABEE	ABEE:8	p-aminobenzoic acid ethyl ester:8:0.2987	0.2987	8
ABEM	ABEM:15	American Board of Emergency Medicine:15:0.8045	0.8045	15
ABEPs	ABEPs:12	auditory brainstem evoked potentials:12:0.7571	0.7571	12
ABEP	ABEP:20	auditory brainstem evoked potentials:20:0.8525	0.8525	20
ABER	ABER:8	evoked response:8:0.5006	0.5006	8
ABEn	ABEn:20|ABEN:1	Brazilian Association of Nursing:21:0.8594	0.8594	21
ABF	ABF:44	blood flow:44:0.9323	0.9323	44
ABFP	ABFP:10	American Board of Family Practice:10:0.7103	0.7103	10
ABGs	ABGs:29|ABGS:1	arterial blood gases:30:0.9011	0.9011	30
ABG	ABG:25	air-bone gap:25:0.7249	0.7249	25
ABG	ABG:99	arterial blood gas:99:0.9698	0.9698	99
ABG	ABG:47	arterial blood gases:47:0.8433	0.8433	47
ABG	ABG:11	Atrophic body gastritis:11:0.7357	0.7357	11
ABIM	ABIM:37	American Board of Internal Medicine:37:0.9197	0.9197	37
ABI	ABI:56	acquired brain injury:47:0.7960|acquired brain injuries:9:0.5470	0.7960	56
ABI	ABI:137	ankle-brachial index:137:0.3501	0.3501	137
ABI	ABI:9	ankle brachial indices:9:0.6794	0.6794	9
ABI	ABI:10	Applied BioSystems:10:0.7103	0.7103	10
ABI	ABI:16	atherothrombotic brain infarction:16:0.6577	0.6577	16
ABI	ABI:39	auditory brainstem implant:39:0.9217	0.9217	39
ABK	ABK:99|Abk:1	arbekacin:100:0.8684	0.8684	100
ABLC	ABLC:67	amphotericin B lipid complex:67:0.9548	0.9548	67
ABLES	ABLES:9	CDC's National Institute for Occupational Safety and Health Adult Blood Lead Epidemiology and Surveillance program:9:0.6794	0.6794	9
ABL	ABL:4	acute basophilic leukemia:4:0.1618	0.1618	4
ABL	ABL:8	Agaricus bisporus lectin:8:0.6411	0.6411	8
ABL	ABL:7	alveolar bone level:7:0.4438	0.4438	7
ABL	ABL:28	alveolar bone loss:28:0.7905	0.7905	28
ABL	ABL:9	Antigen-binding lymphocytes:9:0.3945	0.3945	9
ABL	ABL:20	basolateral amygdala:20:0.5279	0.5279	20
ABL	ABL:8	patients with abetalipoproteinemia:8:0.0863	0.0863	8
Abl	Abl:8|ABL:2|abl:1	tyrosine kinase:11:0.7357	0.7357	11
aBMD	aBMD:37|ABMD:1	areal bone mineral density:38:0.8417	0.8417	38
ABMR	ABMR:15	autologous bone marrow rescue:15:0.8045	0.8045	15
ABMS	ABMS:15	American Board of Medical Specialties:15:0.8045	0.8045	15
ABMS	ABMS:10	autologous bone marrow support:10:0.7103	0.7103	10
ABMTR	ABMTR:11	Autologous Blood and Marrow Transplant Registry:11:0.7357	0.7357	11
ABMT	ABMT:21|A-BMT:1	autologous BMT:22:0.6934	0.6934	22
ABMT	ABMT:15	autologous bone marrow:15:0.8045	0.8045	15
ABMT	ABMT:58|aBMT:1|-ABMT:1	autologous bone marrow transplant:60:0.9216	0.9216	60
ABMT	ABMT:692|A-BMT:4|aBMT:3	autologous bone marrow transplantation:699:0.9518	0.9518	699
ABP1	ABP1:15	auxin-binding protein:15:0.5818	0.5818	15
ABP1	ABP1:10|ABP-1:1	Auxin-binding protein 1:11:0.4232	0.4232	11
ABP-280	ABP-280:6	Actin-binding protein:6:0.2243	0.2243	6
ABPA	ABPA:331	Allergic bronchopulmonary aspergillosis:331:0.9717	0.9717	331
ABPC	ABPC:224|AB-PC:10	ampicillin:234:0.9031	0.9031	234
ABPI	ABPI:3	ankle brachial pressure indices:3:0.5290	0.5290	3
ABPM	ABPM:12	allergic bronchopulmonary mycosis:12:0.6460	0.6460	12
ABPM	ABPM:40	ambulatory blood pressure measurement:25:0.7249|ambulatory blood pressure measurements:15:0.7096	0.7249	40
ABPM	ABPM:9	ambulatory blood pressure monitor:9:0.6794	0.6794	9
ABPM	ABPM:453	Ambulatory blood pressure monitoring:453:0.9440	0.9440	453
ABPM	ABPM:20|ABPm:1	blood pressure:21:0.8594	0.8594	21
ABPN	ABPN:17	American Board of Psychiatry and Neurology:17:0.8270	0.8270	17
ABPP	ABPP:9	2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone:9:0.1860	0.1860	9
ABPP	ABPP:6	amyloid beta-protein precursor:6:0.5290	0.5290	6
ABPs	ABPs:15	actin-binding proteins:15:0.3614	0.3614	15
ABP	ABP:24	acute biliary pancreatitis:24:0.8768	0.8768	24
ABP	ABP:6	albumin-binding proteins:6:0.0899	0.0899	6
ABP	ABP:39|aBP:1	ambulatory BP:40:0.7907	0.7907	40
ABP	ABP:286|Abp:4	androgen-binding protein:171:0.3563|androgen binding protein:119:0.6728	0.6728	290
ABP	ABP:299|aBP:7	arterial blood pressure:306:0.5437	0.5437	306
ABP	ABP:11	human bladder carcinogen 4-aminobiphenyl:11:0.4728	0.4728	11
ABP	ABP:9	monitoring:9:0.0063	0.0063	9
ABRA	ABRA:10	repeat antigen:10:0.5856	0.5856	10
ABRM	ABRM:12|abrm:1	anterior byssal retractor muscle:13:0.7753	0.7753	13
ABRM	ABRM:34	anterior byssus retractor muscle:34:0.8644	0.8644	34
ABRS	ABRS:13	acute bacterial rhinosinusitis:13:0.7753	0.7753	13
ABRs	ABRs:201|ABRS:2	Auditory Brainstem Responses:203:0.9295	0.9295	203
ABR	ABR:17	American Board of Radiology:17:0.8270	0.8270	17
ABR	ABR:247	auditory brain stem response:199:0.9048|auditory brain stem responses:48:0.7074	0.9048	247
ABR	ABR:12	auditory brainstem:12:0.5050	0.5050	12
ABR	ABR:903	Auditory brainstem response:703:0.9474|auditory brainstem responses:200:0.8801	0.9474	903
ABR	ABR:7	response testing:7:0.3524	0.3524	7
ABSCT	ABSCT:43	autologous blood stem cell transplantation:43:0.7572	0.7572	43
ABSITE	ABSITE:14	American Board of Surgery In-Training Examination:14:0.7909	0.7909	14
ABSI	ABSI:8	Abbreviated Burn Severity Index:8:0.6411	0.6411	8
ABS	ABS:12	acrylonitrile-butadiene-styrene:12:0.0108	0.0108	12
ABS	ABS:9	acute bacterial sinusitis:9:0.6794	0.6794	9
ABS	ABS:28	Adaptive Behavior Scale:28:0.7505	0.7505	28
ABS	ABS:7	adult bovine serum:7:0.5926	0.5926	7
ABs	ABs:13	alveolar buds:13:0.7753	0.7753	13
ABS	ABS:14	American Board of Surgery:14:0.7909	0.7909	14
ABS	ABS:20	American Brachytherapy Society:20:0.8525	0.8525	20
ABS	ABS:16	amniotic band syndrome:16:0.8045	0.8045	16
Abs	Abs:441|abs:16|ABs:13|ABS:2|AbS:1	Antibodies:473:0.4646	0.4646	473
ABS	ABS:12	Antley-Bixler syndrome:12:0.1520	0.1520	12
ABs	ABs:10	apoptotic bodies:10:0.1057	0.1057	10
ABS	ABS:5	Aqueous biphasic systems:5:0.2818	0.2818	5
ABs	ABs:18	asbestos bodies:18:0.3058	0.3058	18
ABS	ABS:31	Australian Bureau of Statistics:31:0.9043	0.9043	31
Abs	Abs:21|ABs:2	autoantibodies:23:0.0217	0.0217	23
ABS	ABS:8	binding site:8:0.2327	0.2327	8
Abs	Abs:3|ABS:2|ABs:2	chromosomal aberrations:7:0.1329	0.1329	7
abs	ABS:3|abs:3|Abs:1	chromosome aberrations:7:0.1329	0.1329	7
ABTS	ABTS:2	acid diammonium salt:2:0.5470	0.5470	2
ABT	ABT:48	1-aminobenzotriazole:48:0.2070	0.2070	48
ABT	ABT:7	allogeneic blood transfusions:7:0.3524	0.3524	7
ABT	ABT:42	aminopyrine breath test:42:0.4760	0.4760	42
ABT	ABT:33	blood transfusion:33:0.9100	0.9100	33
ABU	ABU:28	asymptomatic bacteriuria:28:0.8941	0.8941	28
ABV	ABV:2	bleomycin and vincristine:2:0.8365	0.8365	2
ABW	ABW:14|aBW:1	actual body weight:15:0.4052	0.4052	15
ABZSO2	ABZSO2:7|ABZ-SO2:2	albendazole sulfone:9:0.6794	0.6794	9
ABZSO	ABZSO:17|ABZ-SO:3	albendazole sulfoxide:20:0.7173	0.7173	20
ABZSO	ABZSO:25|ABZ-SO:6	albendazole sulphoxide:31:0.5576	0.5576	31
ABZ	ABZ:130|Abz:3	albendazole:133:0.7630	0.7630	133
ABZ	ABZ:10	N-acetylbenzidine:10:0.0520	0.0520	10
AB	AB:45|A-B:2	able-bodied:47:0.0183	0.0183	47
AB	AB:8	acute bronchitis:8:0.3463	0.3463	8
AB	AB:79	Alcian blue:79:0.7381	0.7381	79
AB	AB:9	amobarbital:9:0.0032	0.0032	9
AB	AB:29	amphotericin B:29:0.6392	0.6392	29
AB	AB:29	anterior burster:29:0.8422	0.8422	29
AB	AB:24|Ab:1	antibiotic:14:0.0052|antibiotics:11:0.0040	0.0052	25
Ab	Ab:1222|AB:88|ab:55	antibody:896:0.3567|antibodies:469:0.1867	0.3567	1365
AB	AB:9|Ab:1	aortic banding:10:0.7103	0.7103	10
AB	ab:4|AB:4|A-B:3|a-b:2	apical-to-basolateral:13:0.0048	0.0048	13
AB	AB:9	arsenobetaine:9:0.0032	0.0032	9
AB	AB:44	asbestos bodies:32:0.5841|Asbestos body:12:0.4557	0.5841	44
AB	AB:53	attentional blink:53:0.9438	0.9438	53
Ab	Ab:18|AB:3	autoantibodies:21:0.0080	0.0080	21
AB	AB:6	autogenous bone:6:0.1838	0.1838	6
AB	AB:20	Autologous blood:20:0.4574	0.4574	20
AB	AB:13	autonomic blockade:13:0.4444	0.4444	13
Ac-	Ac-:9	acetate:9:0.4000	0.4000	9
AC/A	AC/A:16	accommodative convergence/accommodation:16:0.8165	0.8165	16
AC/A	AC/A:8	accommodative convergence to accommodation:8:0.6794	0.6794	8
AC1	AC1:5	type 1 adenylyl cyclase:5:0.4422	0.4422	5
ACAD	ACAD:9|aCAD:2	artery disease:11:0.7357	0.7357	11
ACAID	ACAID:126	anterior chamber-associated immune deviation:91:0.9473|anterior chamber associated immune deviation:35:0.9151	0.9473	126
ACASI	ACASI:8|A-CASI:1	self-interview:9:0.3636	0.3636	9
ACAT-1	ACAT-1:4|ACAT1:2	acyl-coenzyme A:cholesterol acyltransferase-1:6:0.5290	0.5290	6
ACAT	ACAT:223	acyl-CoA:cholesterol acyltransferase:215:0.3497|acyl-CoA cholesterol acyltransferase:8:0.4432	0.4432	223
ACAT	ACAT:22	acyl-CoA:cholesterol O-acyltransferase:21:0.2743|acyl-CoA cholesterol O-acyltransferase:1:0.4709	0.4709	22
ACAT	ACAT:109	acyl-coenzyme A:cholesterol acyltransferase:70:0.4715|acyl coenzyme A:cholesterol acyltransferase:39:0.9237	0.9237	109
ACAT	ACAT:50	acyl transferase:50:0.7866	0.7866	50
ACAs	ACAs:29	anticardiolipin antibodies:29:0.6928	0.6928	29
ACAS	ACAS:43	Asymptomatic Carotid Atherosclerosis Study:43:0.9308	0.9308	43
AcbC	AcbC:6	nucleus accumbens core:6:0.5926	0.5926	6
ACBG	ACBG:9	bypass grafting:9:0.5470	0.5470	9
ACBP	ACBP:79	Acyl-CoA binding protein:44:0.6264|Acyl-CoA-binding protein:35:0.2518	0.6264	79
ACBS	ACBS:9	aortocoronary bypass surgery:9:0.3945	0.3945	9
ACB	ACB:46	antibody-coated bacteria:46:0.7461	0.7461	46
ACB	ACB:20	aortocoronary bypass:20:0.5279	0.5279	20
Acb	Acb:81|ACB:42	nucleus accumbens:123:0.9486	0.9486	123
ACC/AHA	ACC/AHA:40	American College of Cardiology/American Heart Association:40:0.9256	0.9256	40
ACCESS	ACCESS:17	Access to Community Care and Effective Services and Supports:17:0.8270	0.8270	17
ACCESS	ACCESS:7	Case Control Etiologic Study of Sarcoidosis:7:0.5926	0.5926	7
ACCP	ACCP:49	American College of Chest Physicians:49:0.9392	0.9392	49
ACCR	ACCR:5	amylase creatinine clearance ratio:5:0.5926	0.5926	5
ACCs	ACCs:15	adenoid cystic carcinomas:15:0.8045	0.8045	15
ACC	ACC:112	1-aminocyclopropane-1-carboxylate:112:0.0663	0.0663	112
ACC	ACC:118	1-aminocyclopropane-1-carboxylic acid:118:0.7396	0.7396	118
ACC	ACC:5|Acc:4	acceleration:9:0.0048	0.0048	9
ACC	ACC:8	Accident Compensation Corporation:8:0.6411	0.6411	8
ACC	ACC:193	acetyl-CoA carboxylase:164:0.6818|acetyl CoA carboxylase:29:0.7237	0.7237	193
ACC	ACC:234|Acc:1	adenoid cystic carcinoma:200:0.9850|adenoid cystic carcinomas:35:0.9151	0.9850	235
ACC	ACC:45	adrenocortical carcinoma:45:0.1037	0.1037	45
ACC	ACC:29	advanced colorectal cancer:29:0.8422	0.8422	29
ACC	ACC:40	agenesis of the corpus callosum:40:0.8401	0.8401	40
ACC	ACC:37	American College of Cardiology:37:0.8051	0.8051	37
ACC	ACC:9|Acc:1	anterior cingulate:10:0.7103	0.7103	10
ACC	ACC:273|acc:1|ACc:1	anterior cingulate cortex:275:0.9825	0.9825	275
ACC	ACC:14	antibody-containing cells:14:0.2758	0.2758	14
ACC	ACC:10	aortic cross-clamping:10:0.7103	0.7103	10
ACC	ACC:27	aplasia cutis congenita:27:0.8903	0.8903	27
ACC	ACC:13	articular chondrocalcinosis:13:0.7753	0.7753	13
ACC	ACC:37|Acc:27	nucleus accumbens:64:0.8824	0.8824	64
ACD-CPR	ACD-CPR:14	Active compression-decompression cardiopulmonary resuscitation:14:0.7909	0.7909	14
ACDF	ACDF:18	anterior cervical discectomy and fusion:18:0.8449	0.8449	18
ACDH	ACDH:10|AcDH:3|AcdH:2	dehydrogenase:15:0.6667	0.6667	15
ACDK	ACDK:33	acquired cystic disease of the kidney:33:0.8716	0.8716	33
ACD	ACD:75	acid-citrate-dextrose:44:0.0473|acid citrate dextrose:31:0.8519	0.8519	75
ACD	ACD:24|AcD:17	Actinomycin D:41:0.9274	0.9274	41
ACD	ACD:38	active compression-decompression:38:0.8781	0.8781	38
ACD	ACD:208	allergic contact dermatitis:208:0.9770	0.9770	208
ACD	ACD:10	alveolar capillary dysplasia:10:0.7103	0.7103	10
ACD	ACD:47	anemia of chronic disease:47:0.5076	0.5076	47
ACD	ACD:11	anterior cervical discectomy:11:0.7357	0.7357	11
ACD	ACD:107	anterior chamber depth:107:0.9411	0.9411	107
ACD	ACD:9	Available Chemicals Directory:9:0.6794	0.6794	9
ACD	ACD:9	cell death:9:0.3069	0.3069	9
ACD	ACD:21	chronic disorders:21:0.7291	0.7291	21
ACE2	ACE2:39|ACE-2:1|ace2:1	angiotensin-converting enzyme 2:41:0.8224	0.8224	41
ACEIs	ACEIs:150|ACE-Is:9|ACEis:4	Angiotensin-converting enzyme inhibitors:119:0.5847|angiotensin converting enzyme inhibitors:44:0.6921	0.6921	163
ACEI	ACEI:3|ACE-I:2|ACEi:1	angiotensin converting enzyme:6:0.5290	0.5290	6
ACEI	ACEI:45|ACE-I:8|ACEi:6|ACE-i:3	angiotensin-converting enzyme inhibition:43:0.4912|angiotensin converting enzyme inhibition:19:0.6537	0.6537	62
ACEI	ACEI:406|ACE-I:106|ACEi:52|ACE-i:3	angiotensin-converting enzyme inhibitors:174:0.5017|angiotensin-converting enzyme inhibitor:170:0.4903|Angiotensin converting enzyme inhibitors:117:0.8818|angiotensin converting enzyme inhibitor:106:0.8146	0.8818	567
ACEP	ACEP:17	American College of Emergency Physicians:17:0.8365	0.8365	17
ACEs	ACEs:11	Adverse childhood experiences:11:0.7357	0.7357	11
ace	ace:10|Ace:1	acerebellar:11:0.0011	0.0011	11
ACE	ACE:5	acetylcholine esterase:5:0.1132	0.1132	5
ACE	ACE:28|Ace:1	acetylcholinesterase:29:0.0031	0.0031	29
ACE	ACE:9	Addenbrooke's Cognitive Examination:9:0.6794	0.6794	9
ACE	ACE:61	affinity capillary electrophoresis:61:0.8987	0.8987	61
ACE	ACE:10|ACe:9	amygdaloid central nucleus:19:0.7044	0.7044	19
ACE	ACE:5036|Ace:3|ace:1	angiotensin-converting enzyme:4870:0.5530|angiotensin-converting-enzyme:146:0.0153|angiotensin converting-enzyme:18:0.8365|angiotensin converting enzymes:6:0.5290	0.8365	5040
ACE	ACE:8	angiotensin converting enzyme gene:8:0.3463	0.3463	8
ACE	ACE:12	Angiotensin converting enzyme inhibitors:6:0.3728|Angiotensin-converting enzyme inhibitors:6:0.1148	0.3728	12
ACE	ACE:23	antegrade continence enema:23:0.8715	0.8715	23
ACE	ACE:6	arm crank ergometer:6:0.5290	0.5290	6
ACE	ACE:5	arm crank ergometry:5:0.4422	0.4422	5
ACE	ACE:11|ACe:6	central amygdaloid nucleus:17:0.8270	0.8270	17
ACe	ACe:21|ACE:10|Ace:1	central nucleus of the amygdala:32:0.9151	0.9151	32
ACE	ACE:3	cyclophosphamide and etoposide:3:0.5006	0.5006	3
ACFs	ACFs:15	Aberrant crypt foci:15:0.8045	0.8045	15
ACFs	ACFs:9	activated carbon fibers:9:0.6794	0.6794	9
ACF	ACF:11	aberrant crypt focus:11:0.7357	0.7357	11
ACF	ACF:9	activated carbon fiber:9:0.5470	0.5470	9
ACF	ACF:30	aortocaval fistula:30:0.7652	0.7652	30
ACF	ACF:12|acf:1	apobec-1 complementation factor:13:0.7909	0.7909	13
ACF	ACF:20	autocorrelation function:20:0.5568	0.5568	20
ACF	ACF:3	corpectomy and fusion:3:0.3213	0.3213	3
ACGIH	ACGIH:94|AC-GIH:1	American Conference of Governmental Industrial Hygienists:95:0.9689	0.9689	95
ACGME	ACGME:104	Accreditation Council for Graduate Medical Education:104:0.9344	0.9344	104
ACGs	ACGs:12	ambulatory care groups:12:0.7571	0.7571	12
ACG	ACG:8|Acg:3	acycloguanosine:11:0.0490	0.0490	11
ACG	ACG:5	Ambulatory Care Group:5:0.4422	0.4422	5
ACG	ACG:9	American College of Gastroenterology:9:0.6794	0.6794	9
ACG	ACG:23	angle-closure glaucoma:16:0.4536|angle closure glaucoma:7:0.5926	0.5926	23
ACG	ACG:14|Acg:1|acg:1	anterior cingulate gyrus:16:0.8165	0.8165	16
ACG	ACG:17	apexcardiogram:17:0.0784	0.0784	17
ACG	ACG:13	chronic gastritis:13:0.6701	0.6701	13
ACHD	ACHD:15|aCHD:1	heart disease:16:0.8165	0.8165	16
ACHS	ACHS:14	Australian Council on Healthcare Standards:14:0.8045	0.8045	14
ACIF	ACIF:45	immunofluorescence:45:0.7458	0.7458	45
ACIOL	ACIOL:7|AC-IOL:5	anterior chamber intraocular lens:12:0.7571	0.7571	12
ACIP	ACIP:38	Asymptomatic Cardiac Ischemia Pilot:38:0.9217	0.9217	38
ACIR	ACIR:14	Australian Childhood Immunisation Register:14:0.7909	0.7909	14
ACIS	ACIS:20	Adenocarcinoma in situ:20:0.7173	0.7173	20
ACIS	ACIS:10	Automated Cellular Imaging System:10:0.5470	0.5470	10
ACIT	ACIT:13	adoptive chemoimmunotherapy:13:0.7753	0.7753	13
ACI	ACI:13	acute cardiac ischemia:13:0.6701	0.6701	13
ACI	ACI:10	acute coronary insufficiency:10:0.7103	0.7103	10
ACI	ACI:10	Andersen cascade impactor:10:0.7103	0.7103	10
ACI	ACI:11	aortic calcification index:11:0.4728	0.4728	11
ACI	ACI:27	Autologous chondrocyte implantation:27:0.8312	0.8312	27
ACI	ACI:33	cerebral infarction:33:0.9100	0.9100	33
ACKD	ACKD:40	acquired cystic kidney disease:40:0.9237	0.9237	40
ACLAs	ACLAs:6|aCLAs:2	Anticardiolipin antibodies:8:0.5006	0.5006	8
ACLA	ACLA:8|Acla:6	aclarubicin:14:0.1970	0.1970	14
ACLA	ACLA:28|aCLA:3|aCLa:2|acLa:1|Acla:1|ACL-A:1	anticardiolipin antibodies:28:0.7505|anticardiolipin antibody:8:0.5006	0.7505	36
ACLD	ACLD:6|ACL-D:1	anterior cruciate ligament deficient:7:0.5926	0.5926	7
ACLR	ACLR:18|ACLr:1	anterior cruciate ligament reconstruction:19:0.7658	0.7658	19
ACLSV	ACLSV:13	apple chlorotic leaf spot virus:13:0.7753	0.7753	13
ACLS	ACLS:147	advanced cardiac life support:147:0.9569	0.9569	147
ACLs	ACLs:11	anterior cruciate ligaments:11:0.7571	0.7571	11
aCLs	aCLs:10|ACLs:3	anticardiolipin antibodies:13:0.7753	0.7753	13
ACLT	ACLT:35	Anterior cruciate ligament transection:35:0.9151	0.9151	35
ACMSD	ACMSD:17	alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase:17:0.5760	0.5760	17
ACMV	ACMV:34	African cassava mosaic virus:34:0.9126	0.9126	34
Acm	Acm:10	acetamidomethyl:10:0.0282	0.0282	10
ACM	ACM:28	aclacinomycin:28:0.0846	0.0846	28
ACM	ACM:9	Aclacinomycin-A:9:0.0251	0.0251	9
ACM	ACM:9	alcoholic cardiomyopathy:9:0.2757	0.2757	9
ACM	ACM:13	anterior chamber maintainer:13:0.7753	0.7753	13
ACM	ACM:25	Arnold-Chiari malformation:25:0.6539	0.6539	25
ACM	ACM:8	asbestos-containing materials:8:0.4102	0.4102	8
ACM	ACM:23	astrocyte-conditioned medium:23:0.5236	0.5236	23
ACNM	ACNM:18	American College of Nurse-Midwives:18:0.8449	0.8449	18
ACNP	ACNP:14	acute care nurse practitioner:14:0.7909	0.7909	14
ACNPs	ACNPs:13	acute care nurse practitioners:13:0.7753	0.7753	13
ACNU	ACNU:10	1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea:10:0.0378	0.0378	10
ACNU	ACNU:9	nitrosourea:9:0.0336	0.0336	9
ACN	ACN:94|AcN:2|acn:1	acetonitrile:97:0.3918	0.3918	97
ACN	ACN:66	acrylonitrile:66:0.2653	0.2653	66
ACOAs	ACOAs:24	adult children of alcoholics:24:0.8115	0.8115	24
ACOG	ACOG:92	American College of Obstetricians and Gynecologists:92:0.9675	0.9675	92
AcomA	AcomA:5|AComA:4|ACOMA:1	anterior communicating artery:10:0.7103	0.7103	10
Acom	Acom:7|A-com:5|ACom:2	anterior communicating artery:14:0.7909	0.7909	14
ACOX	ACOX:14	acyl-CoA oxidase:14:0.5111	0.5111	14
ACP1	ACP1:59|AcP1:3	acid phosphatase:62:0.8570	0.8570	62
ACPC	ACPC:36	1-aminocyclopropanecarboxylic acid:36:0.4303	0.4303	36
AC-PC	AC-PC:6	anterior commissure-posterior commissure:6:0.5290	0.5290	6
ACPI	ACPI:8	acid cysteine proteinase inhibitor:8:0.6411	0.6411	8
Acps	Acps:9	accessory gland proteins:9:0.6794	0.6794	9
ACPs	ACPs:17	Acyl carrier proteins:17:0.6748	0.6748	17
AcpS	AcpS:8|ACPS:3|acpS:2	carrier protein synthase:13:0.8045	0.8045	13
AcPase	AcPase:93|ACPase:55|acPase:4|Ac-Pase:3|AcP-ase:3|Acpase:2|ACP-ase:1|acPAse:1	acid phosphatase:162:0.9705	0.9705	162
AcP	AcP:11|ACP:2|acP:2|Ac-P:1	acetyl phosphate:16:0.0938	0.0938	16
ACP	ACP:186|AcP:130|Acp:5|acP:3|Ac-P:3	acid phosphatase:327:0.9594	0.9594	327
ACP	ACP:6|AcP:3|acP:1	acid phosphatase activity:10:0.7103	0.7103	10
ACP	ACP:184	acyl carrier protein:184:0.5174	0.5174	184
ACP	ACP:17	Advance care planning:17:0.8270	0.8270	17
ACP	ACP:9	alcoholic chronic pancreatitis:9:0.3069	0.3069	9
ACP	ACP:44	alternative complement pathway:44:0.7839	0.7839	44
ACP	ACP:27	American College of Physicians:27:0.8903	0.8903	27
ACP	ACP:64	amorphous calcium phosphate:64:0.8824	0.8824	64
ACP	ACP:9	antegrade cerebral perfusion:9:0.6794	0.6794	9
ACP	ACP:16	anterior clinoid process:16:0.8165	0.8165	16
ACP	ACP:8	antrochoanal polyp:8:0.4102	0.4102	8
AcP	AcP:9	muscle acylphosphatase:9:0.2757	0.2757	9
ACQ	ACQ:5	Agoraphobic Cognitions Questionnaire:5:0.1464	0.1464	5
ACQ	ACQ:11	Asthma Control Questionnaire:11:0.6182	0.6182	11
ACR20	ACR20:8	20% improvement:8:0.5006	0.5006	8
ACRC	ACRC:10|aCRC:3	advanced colorectal cancer:13:0.7753	0.7753	13
ACRF	ACRF:5|A-CRF:1	chronic renal failure:6:0.5290	0.5290	6
ACRF	ACRF:6	respiratory failure:6:0.1320	0.1320	6
ACRN	ACRN:8	Asthma Clinical Research Network:8:0.5006	0.5006	8
ACRS	ACRS:9	restriction sites:9:0.5470	0.5470	9
ACR	ACR:42	aclarubicin:42:0.0433	0.0433	42
ACR	ACR:16	acquired cellular resistance:16:0.8165	0.8165	16
ACR	ACR:14|acr:3	acrolein:17:0.0165	0.0165	17
ACR	ACR:58|Acr:1|acr:1	acrylamide:60:0.0608	0.0608	60
ACR	ACR:77	acute cellular rejection:77:0.9612	0.9612	77
ACR	ACR:35	adenomatosis of the colon and rectum:35:0.8716	0.8716	35
ACR	ACR:7	adequate clinical response:7:0.5926	0.5926	7
ACR	ACR:9	albumin creatinine ratio:9:0.6973	0.6973	9
ACR	ACR:89	American College of Radiology:89:0.9664	0.9664	89
ACR	ACR:303	American College of Rheumatology:303:0.9650	0.9650	303
ACR	ACR:18	urinary albumin/creatinine ratio:11:0.1430|urinary albumin:creatinine ratio:7:0.1111	0.1430	18
ACR	ACR:10	urinary albumin-to-creatinine ratio:10:0.1680	0.1680	10
ACSA	ACSA:11	adenylate cyclase-stimulating activity:11:0.7357	0.7357	11
ACSA	ACSA:6|acsa:1|A-CSA:1	cross-sectional area:8:0.3463	0.3463	8
ACSC	ACSC:11	ambulatory care sensitive conditions:11:0.7357	0.7357	11
ACSM	ACSM:31	American College of Sports Medicine:31:0.9072	0.9072	31
ACSs	ACSs:35	acute coronary syndromes:35:0.9151	0.9151	35
ACST	ACST:8	asymptomatic carotid surgery trial:8:0.6411	0.6411	8
ACSUS	ACSUS:11	Utilization Survey:11:0.7357	0.7357	11
ACS	ACS:84	abdominal compartment syndrome:84:0.8794	0.8794	84
ACS	ACS:14|Acs:10|acs:1	Acetyl-CoA synthetase:25:0.1856	0.1856	25
ACS	ACS:7|AcS:2	acetylstrophanthidin:9:0.0043	0.0043	9
ACS	ACS:15	Acute confusional state:15:0.8045	0.8045	15
ACS	ACS:802|acs:1	acute coronary syndromes:460:0.9935|acute coronary syndrome:343:0.9813	0.9935	803
ACS	ACS:38	acyl-CoA synthetase:38:0.3112	0.3112	38
ACs	ACs:22	adenocarcinomas:22:0.0112	0.0112	22
ACs	ACs:34|Acs:1	adenylyl cyclases:35:0.7647	0.7647	35
ACs	ACs:12	amacrine cells:12:0.2549	0.2549	12
ACS	ACS:11	ambulatory care sensitive:11:0.7357	0.7357	11
ACS	ACS:100	American Cancer Society:100:0.9231	0.9231	100
ACS	ACS:33	American College of Surgeons:33:0.9100	0.9100	33
ACS	ACS:14	anterior cricoid split:14:0.7909	0.7909	14
ACS	ACS:5	Anticoagulation Service:5:0.0517	0.0517	5
ACS	ACS:14	ARS consensus sequence:14:0.8045	0.8045	14
ACS	ACS:10	asymptomatic carotid stenosis:10:0.5000	0.5000	10
ACs	ACs:6	asymptomatic carriers:6:0.1320	0.1320	6
ACS	ACS:10	Automated Corneal Shaper:10:0.7103	0.7103	10
ACS	ACS:35|Acs:1	synthase:36:0.0187	0.0187	36
ACTA1	ACTA1:6|acta1:1	skeletal muscle alpha-actin:7:0.5926	0.5926	7
ACTA1	ACTA1:7	skeletal muscle alpha-actin gene:7:0.5926	0.5926	7
ACTA	ACTA:7	Academic Centre for Dentistry Amsterdam:7:0.6411	0.6411	7
ActD	ActD:65|Act-D:34|ACT-D:25|ACTD:17|actD:12|act-D:7	actinomycin D:123:0.9486|Actinomycin-D:37:0.2045	0.9486	160
ACTG	ACTG:91	AIDS Clinical Trials Group:91:0.9158	0.9158	91
ACTH-IR	ACTH-IR:8|ACTH-ir:1	immunoreactivity:9:0.5333	0.5333	9
ACTH-LI	ACTH-LI:9	immunoreactivity:9:0.7273	0.7273	9
ACTH	ACTH:10	adrenocorticotrophic:10:0.0017	0.0017	10
ACTH	ACTH:17	Adrenocorticotropic:17:0.0031	0.0031	17
ACTH	ACTH:2106|Acth:2	Adrenocorticotropic hormone:2108:0.6679	0.6679	2108
ACTH	ACTH:1027	adrenocorticotropin:1027:0.1970	0.1970	1027
ACTH	ACTH:99	corticotrophin:99:0.0188	0.0188	99
ACTH	ACTH:598	Corticotropin:598:0.1147	0.1147	598
ACTH	ACTH:23	plasma adrenocorticotrophin:23:0.0648	0.0648	23
ACTZ	ACTZ:24|Actz:1	acetazolamide:25:0.9600	0.9600	25
ACTase	ACTase:10	Aspartate carbamoyltransferase:10:0.7103	0.7103	10
ACTs	ACTs:18	activated clotting times:18:0.6903	0.6903	18
ACT	ACT:9	actinomycin D:9:0.6794	0.6794	9
Act	Act:13|act:7|ACT:4	actinorhodin:24:0.0155	0.0155	24
ACT	ACT:320	activated clotting time:302:0.9325|activated clotting times:18:0.8365	0.9325	320
ACT	ACT:87	Activated coagulation time:87:0.8962	0.8962	87
ACT	ACT:20|Act:8|act:3	activity:31:0.0209	0.0209	31
ACT	ACT:14	adenylate cyclase toxin:14:0.6911	0.6911	14
ACT	ACT:17	adjuvant chemotherapy:17:0.7407	0.7407	17
ACT	ACT:7	adrenocortical tumors:7:0.2902	0.2902	7
ACT	ACT:207	alpha 1-antichymotrypsin:96:0.8946|alpha-1-antichymotrypsin:68:0.0452|alpha(1)-antichymotrypsin:28:0.0182|alpha-1 antichymotrypsin:15:0.2119	0.8946	207
ACT	ACT:57	alpha1-antichymotrypsin:57:0.0378	0.0378	57
ACT	ACT:10	American College Testing:10:0.7103	0.7103	10
ACT	ACT:11	anticoagulant therapy:11:0.1330	0.1330	11
ACT	ACT:87	assertive community treatment:87:0.9455	0.9455	87
ACT	ACT:38	Australian Capital Territory:38:0.9217	0.9217	38
ACT	ACT:23	autologous chondrocyte transplantation:23:0.8038	0.8038	23
ACT	ACT:9	combination therapy:9:0.0866	0.0866	9
Act	Act:10	cytotoxic enterotoxin:10:0.5856	0.5856	10
ACVS	ACVS:12	delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-valine synthetase:12:0.3058	0.3058	12
ACV	ACV:9	9-(2-hydroxyethoxymethyl)guanine:9:0.0169	0.0169	9
ACV	ACV:17|Acv:1	aciclovir:18:0.0288	0.0288	18
ACV	ACV:406|acv:2|Acv:1	acyclovir:409:0.6904	0.6904	409
ACV	ACV:6	assist-control ventilation:6:0.2243	0.2243	6
ACV	ACV:27	delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-valine:27:0.0440	0.0440	27
ACV	ACV:6	tripeptide delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valine:6:0.1850	0.1850	6
ACx	ACx:10	auditory cortex:10:0.5856	0.5856	10
ACZ	ACZ:77|Acz:3	acetazolamide:80:0.9405	0.9405	80
AChA	AChA:33|AchA:2|acha:2	anterior choroidal artery:37:0.9197	0.9197	37
ACHA	ACHA:6|AChA:3	antibodies:9:0.1127	0.1127	9
AChBP	AChBP:20	acetylcholine binding protein:20:0.6537	0.6537	20
AChEIs	AChEIs:21|AChE-Is:2	acetylcholinesterase inhibitors:23:0.5997	0.5997	23
AChEI	AChEI:27|AChE-I:10|AchEI:2|ACHE-I:2|AChEi:1	acetylcholinesterase inhibitors:22:0.6531|Acetylcholinesterase inhibitor:20:0.6680	0.6680	42
AChEs	AChEs:17	acetylcholinesterases:17:0.6667	0.6667	17
AChE	AChE:40|AchE:5|ACHE:1	acetyl cholinesterase:28:0.4089|acetyl-cholinesterase:18:0.0040	0.4089	46
AChE	AChE:99|AchE:9|ACHE:3|ACh-E:1|Ach-E:1	acetylcholine esterase:113:0.9087	0.9087	113
AChE	AChE:3673|AchE:163|ACHE:41|AChe:18|Ache:7|Ach-E:6|ACh-E:5|ACHe:2|achE:1	acetylcholinesterase:3895:0.9108|acetylcholinesterases:21:0.0047	0.9108	3916
AChE	AChE:28|Ach-E:1|AchE:1	acetylcholinesterase activity:30:0.7315	0.7315	30
AChE	AChE:6	acetylcholinesterase enzyme:6:0.2243	0.2243	6
AChRs	AChRs:383|AchRs:11	acetylcholine receptors:394:0.8637	0.8637	394
AChR	AChR:1453|AchR:52|ACHR:7|ACh-R:4|Ach-R:2	acetylcholine receptor:1322:0.8960|acetylcholine receptors:196:0.9039	0.9039	1518
AChR	AChR:6	acetylcholine receptor channel:6:0.5290	0.5290	6
AChR	AChR:8|AchR:2	acetylcholine receptor protein:10:0.7103	0.7103	10
AChR	AChR:9	channel complex:9:0.5470	0.5470	9
AChase	AChase:7|Achase:5|ACHase:1	acetylcholinesterase:13:0.8000	0.8000	13
ACh	ACh:23	[14C]acetylcholine:23:0.0028	0.0028	23
ACh	ACh:12	3H-acetylcholine:12:0.0014	0.0014	12
ACh	ACh:6575|Ach:431|ACH:154|AcH:2|ach:2	acetylcholine:7153:0.9245|acetylcholine-:11:0.0013	0.9245	7164
ACh	ACh:19|Ach:3|ACH:1	acetylcholine chloride:23:0.8715	0.8715	23
Ach	Ach:15|ACH:14|ACh:1	achondroplasia:30:0.0037	0.0037	30
ACH	ACH:6	active chronic hepatitis:6:0.2827	0.2827	6
ACH	ACH:8|ach:3	air changes per hour:11:0.6182	0.6182	11
ACH	ACH:9|a-CH:1|aCH:1	alpha-Chlorohydrin:11:0.0013	0.0013	11
ACH	ACH:4	Arkansas Children's Hospital:4:0.0918	0.0918	4
AcH	AcH:10	blood acetaldehyde:10:0.0510	0.0510	10
ACh	ACh:25|Ach:3	cholinergic:28:0.0035	0.0035	28
ACH	ACH:9	hemorrhage:9:0.0010	0.0010	9
ACh	ACh:1	release [3H]acetylcholine:1:0.2740	0.2740	1
ACh	ACh:5	release of [3H]-acetylcholine:5:0.1132	0.1132	5
ACOA	ACOA:11	adult children of alcoholics:11:0.6182	0.6182	11
ACoA	ACoA:85|AcoA:6|ACOA:1	anterior communicating artery:92:0.9675	0.9675	92
AC	AC:15	aberrant crypts:15:0.6386	0.6386	15
AC	AC:101	accessory cells:80:0.4882|accessory cell:21:0.2813	0.4882	101
AC	AC:10	Acebutolol:10:0.0019	0.0019	10
Ac	Ac:14|AC:12	acetate:26:0.0053	0.0053	26
AC	AC:9|Ac:5|ac:1	acetone:15:0.0030	0.0030	15
AC	AC:13|Ac:1	acetylcholine:14:0.0027	0.0027	14
ac	ac:17|Ac:2|AC:1	achaete:20:0.0040	0.0040	20
AC	AC:9	acid ceramidase:9:0.7103	0.7103	9
AC	AC:66|A-C:2	acromioclavicular:68:0.0141	0.0141	68
AC	AC:9|Ac:1	acrylamide:10:0.0019	0.0019	10
AC	AC:36	activated carbon:36:0.6953	0.6953	36
AC	AC:60	activated charcoal:60:0.9216	0.9216	60
AC	AC:8	activation coefficient:8:0.0953	0.0953	8
AC	AC:9	activity coefficient:9:0.1267	0.1267	9
AC	AC:5	acute acalculous cholecystitis:5:0.0902	0.0902	5
AC	AC:39	acute cholecystitis:39:0.6230	0.6230	39
AC	AC:154	adenocarcinoma:117:0.0245|adenocarcinomas:37:0.0076	0.0245	154
AC	AC:569|ac:1|Ac:1	adenylate cyclase:571:0.4666	0.4666	571
AC	AC:11|Ac:1	adenylate cyclase activity:12:0.5664	0.5664	12
AC	AC:538	adenylyl cyclase:527:0.4292|adenylyl cyclases:11:0.4728	0.4728	538
AC	AC:22	adherent cells:22:0.0910	0.0910	22
AC	AC:7|A--C:1	Adriamycin and cyclophosphamide:8:0.1131	0.1131	8
AC	AC:28	aesthetic component:28:0.6839	0.6839	28
AC	AC:13	affinity chromatography:13:0.7753	0.7753	13
AC	AC:15	Air Conduction:15:0.8045	0.8045	15
AC	AC:15	allergic conjunctivitis:15:0.7096	0.7096	15
AC	AC:7	allyl chloride:7:0.1850	0.1850	7
AC	AC:9	alternating:9:0.0017	0.0017	9
AC	AC:89|ac:17	alternating current:106:0.9030	0.9030	106
AC	AC:5	ammonium chloride:5:0.0517	0.0517	5
AC	AC:21	amniocentesis:21:0.0042	0.0042	21
AC	AC:13	amygdaloid complex:13:0.5335	0.5335	13
AC	AC:12	anchor cell:12:0.1105	0.1105	12
AC	AC:12	anterior:12:0.0023	0.0023	12
AC	AC:157	anterior chamber:157:0.9696	0.9696	157
AC	AC:16	anterior cingulate:16:0.8165	0.8165	16
AC	AC:64|ac:1	anterior commissure:65:0.9541	0.9541	65
AC	AC:15|ac:1|Ac:1	anticoagulant:17:0.0034	0.0034	17
AC	AC:19	anticoagulation:19:0.0036	0.0036	19
AC	AC:9	aortic coarctation:9:0.5470	0.5470	9
AC	AC:23	aortic constriction:23:0.8038	0.8038	23
AC	AC:6	apatite cement:6:0.1320	0.1320	6
AC	AC:8	Arachnoid cysts:8:0.3463	0.3463	8
AC	AC:22	arm circumference:22:0.0789	0.0789	22
AC	AC:18	arterial compliance:18:0.5940	0.5940	18
AC	AC:30	articular cartilage:30:0.9011	0.9011	30
AC	AC:8	artificial circulation:8:0.1591	0.1591	8
AC	AC:6	asbestos cement:6:0.1320	0.1320	6
AC	AC:9	asymptomatic carriers:9:0.2757	0.2757	9
AC	AC:12	attenuation-corrected:12:0.0023	0.0023	12
AC	AC:38	attenuation correction:38:0.8417	0.8417	38
AC	AC:21	atypical carcinoid:21:0.8594	0.8594	21
AC	AC:65	auditory cortex:65:0.7458	0.7458	65
Ac	Ac:9	Autographa californica:9:0.6794	0.6794	9
AC	AC:8	axillary clearance:8:0.3463	0.3463	8
AC	AC:16	capacity:16:0.0032	0.0032	16
AC	AC:14	carcinoma:14:0.0027	0.0027	14
AC	AC:9	concentration:9:0.0017	0.0017	9
AC	AC:25	control:25:0.0051	0.0051	25
AC	AC:21	doxorubicin and cyclophosphamide:21:0.3419	0.3419	21
Ac	Ac:16|AC:1	maize Activator:17:0.0960	0.0960	17
Ac	Ac:15	maize transposable element Activator:15:0.4536	0.4536	15
Ac	Ac:8|AC:2	nucleus accumbens:10:0.7103	0.7103	10
AC	AC:1	patients had alcoholic cirrhosis:1:0.3039	0.3039	1
A-C	A-C:7	three groups:7:0.2113	0.2113	7
AD/HD	AD/HD:61	attention-deficit/hyperactivity disorder:31:0.3263|attention deficit/hyperactivity disorder:30:0.9011	0.9011	61
AD-32	AD-32:11|AD32:7	N-trifluoroacetyladriamycin-14-valerate:18:0.5312	0.5312	18
Ad6	Ad6:7	adenovirus type 6:7:0.4438	0.4438	7
ADAC	ADAC:10	adenosine amine congener:10:0.6794	0.6794	10
ADAM	ADAM:37	9-anthryldiazomethane:37:0.2022	0.2022	37
ADAM	ADAM:13	alkenyldiarylmethane:13:0.0674	0.0674	13
ADAM	ADAM:13	disintegrin and metalloprotease:13:0.7753	0.7753	13
ADAM	ADAM:19	disintegrin and metalloproteinase:19:0.7865	0.7865	19
ADAPs	ADAPs:34	AIDS Drug Assistance Programs:34:0.9151	0.9151	34
ADAP	ADAP:31	AIDS Drug Assistance Program:31:0.9043	0.9043	31
ADAR1	ADAR1:14	adenosine deaminase:14:0.7909	0.7909	14
ADARs	ADARs:17	adenosine deaminases that act on RNA:17:0.8270	0.8270	17
ADAS	ADAS:41	Alzheimer's Disease Assessment Scale:41:0.7057	0.7057	41
ADA	ADA:1186|Ada:3|ada:1	Adenosine deaminase:1181:0.9750|adenosine-deaminase:9:0.0039	0.9750	1190
ADA	ADA:29	Adenosine deaminase activity:29:0.8978	0.8978	29
ADA	ADA:6|Ada:1	adenosine deaminase gene:7:0.5926	0.5926	7
ADA	ADA:6	alcohol dependence and abuse:6:0.6411	0.6411	6
ADA	ADA:47	American Dental Association:47:0.8703	0.8703	47
ADA	ADA:183	American Diabetes Association:183:0.9836	0.9836	183
ADA	ADA:337	Americans with Disabilities Act:337:0.9535	0.9535	337
ADA	ADA:17	Americans with Disabilities Act of 1990:17:0.8270	0.8270	17
ADA	ADA:10	Azodicarbonamide:10:0.0044	0.0044	10
ADCAs	ADCAs:18	Autosomal dominant cerebellar ataxias:18:0.7539	0.7539	18
ADCA	ADCA:5|AdCa:4|AdCA:2	adenocarcinoma:11:0.0935	0.0935	11
ADCA	ADCA:66	Autosomal Dominant Cerebellar Ataxia:47:0.9366|Autosomal dominant cerebellar ataxias:19:0.8449	0.9366	66
AdCC	AdCC:6|ADCC:2	adenoid cystic carcinoma:8:0.6411	0.6411	8
ADCC	ADCC:17	antibody-dependent:17:0.0085	0.0085	17
ADCC	ADCC:15	antibody-dependent cell-mediated cytolysis:15:0.6748	0.6748	15
ADCC	ADCC:16	antibody-dependent cell-mediated cytotoxic:16:0.8270	0.8270	16
ADCC	ADCC:458	antibody-dependent cell-mediated cytotoxicity:458:0.8635	0.8635	458
ADCC	ADCC:833	antibody-dependent cellular cytotoxicity:833:0.8250	0.8250	833
ADCC	ADCC:5	cytotoxic activity:5:0.1132	0.1132	5
ADCC	ADCC:9	cytoxicity:9:0.0042	0.0042	9
ADCMC	ADCMC:10	antibody-dependent cell-mediated cytotoxicity:10:0.7103	0.7103	10
ADCP	ADCP:15	Adenosine deaminase complexing protein:15:0.7909	0.7909	15
ADCs	ADCs:8|AdCs:3	adenocarcinomas:11:0.0685	0.0685	11
ADCS	ADCS:9	Alzheimer's Disease Cooperative Study:9:0.6794	0.6794	9
ADCs	ADCs:106	apparent diffusion coefficients:106:0.9718	0.9718	106
ADCw	ADCw:17	apparent diffusion coefficient of water:17:0.7407	0.7407	17
ADC	ADC:51|AdC:7|Adc:1	adenocarcinoma:47:0.0360|adenocarcinomas:12:0.0086	0.0360	59
AdC	AdC:10|ADC:1	adenylate cyclase:11:0.6182	0.6182	11
ADC	ADC:136	AIDS dementia complex:136:0.8496	0.8496	136
ADC	ADC:5	analog-to-digital conversion:5:0.1132	0.1132	5
ADC	ADC:749	apparent diffusion coefficient:694:0.9768|apparent diffusion coefficients:55:0.9147	0.9768	749
ADC	ADC:18	apparent diffusion coefficient of water:18:0.8365	0.8365	18
ADC	ADC:59|adc:2	arginine decarboxylase:61:0.8042	0.8042	61
ADC	ADC:10	converter:10:0.0070	0.0070	10
ADC	ADC:10	cytotoxicity:10:0.0070	0.0070	10
ADD/H	ADD/H:6	Attention Deficit Disorder with Hyperactivity:6:0.5926	0.5926	6
ADD1	ADD1:5	Adipocyte determination and differentiation-dependent factor 1:5:0.4422	0.4422	5
ADD1	ADD1:7	adipocyte determination and differentiation factor 1:7:0.5926	0.5926	7
ADDH	ADDH:43|ADD-H:11	attention deficit disorder with hyperactivity:54:0.8954	0.8954	54
ADDTC	ADDTC:5	State of California Alzheimer's Disease Diagnostic and Treatment Centers:5:0.2818	0.2818	5
ADEM	ADEM:183	acute disseminated encephalomyelitis:183:0.9652	0.9652	183
ADEMG	ADEMG:9	automatic decomposition electromyography:9:0.6794	0.6794	9
ADEPT	ADEPT:85	antibody-directed enzyme prodrug therapy:63:0.6330|Antibody Directed Enzyme Prodrug Therapy:22:0.8594	0.8594	85
A-DES	A-DES:8	Adolescent Dissociative Experiences Scale:8:0.6411	0.6411	8
ADEs	ADEs:122	Adverse drug events:122:0.9755	0.9755	122
Ade	Ade:13|ADE:5	adenosine:18:0.0691	0.0691	18
ADE	ADE:19	adverse drug events:11:0.7357|adverse drug event:8:0.6411	0.7357	19
ADE	ADE:22	alcohol deprivation effect:22:0.8657	0.8657	22
ADE	ADE:39	Antibody-dependent enhancement:39:0.6392	0.6392	39
ADE	ADE:24	arrhythmogenic dose of epinephrine:24:0.8186	0.8186	24
ADFT	ADFT:15	atrial defibrillation threshold:15:0.8045	0.8045	15
ADF	ADF:25	actin depolymerizing factor:25:0.8186	0.8186	25
ADF	ADF:23	adult T cell leukemia-derived factor:12:0.7571|Adult T-cell leukemia-derived factor:11:0.6182	0.7571	23
ADF	ADF:5	Australian Defence Force:5:0.4422	0.4422	5
ADG	ADG:129	average daily gain:112:0.9437|average daily gains:17:0.8270	0.9437	129
ADH1	ADH1:10|Adh1:5|adh1:1	alcohol dehydrogenase:16:0.8165	0.8165	16
Adh1	Adh1:13|ADH1:8|Adh-1:4|adh1:1	alcohol dehydrogenase 1:13:0.7753|alcohol dehydrogenase-1:13:0.7753	0.7753	26
adh1	adh1:3|Adh-1:1|ADH1:1	alcohol dehydrogenase gene:5:0.4422	0.4422	5
ADH2	ADH2:13|ADH-2:3	alcohol dehydrogenase:16:0.7096	0.7096	16
ADH2	ADH2:41|Adh2:4|Adh-2:1	alcohol dehydrogenase 2:26:0.8861|alcohol dehydrogenase-2:20:0.8525	0.8861	46
ADH3	ADH3:19|Adh-3:1	alcohol dehydrogenase 3:20:0.8449	0.8449	20
ADHC	ADHC:12	Adult Day Health Care:12:0.7571	0.7571	12
ADHD	ADHD:8	attention deficit disorder with hyperactivity:8:0.7357	0.7357	8
ADHD	ADHD:1930	Attention Deficit Hyperactivity Disorder:1152:0.9931|attention-deficit/hyperactivity disorder:770:0.2448|attention deficit hyperactivity disorders:8:0.6411	0.9931	1930
ADHERE	ADHERE:8	Acute Decompensated Heart Failure National Registry:8:0.6411	0.6411	8
AD-HSP	AD-HSP:8|ADHSP:7	autosomal dominant hereditary spastic paraplegia:15:0.8045	0.8045	15
ADHF	ADHF:15	acute decompensated heart failure:15:0.7096	0.7096	15
ADHs	ADHs:36	alcohol dehydrogenases:36:0.8336	0.8336	36
ADH	ADH:14	adipic acid dihydrazide:14:0.7909	0.7909	14
ADH	ADH:991|Adh:149|adh:4	alcohol dehydrogenase:1115:0.9654|alcohol dehydrogenases:29:0.7970	0.9654	1144
Adh	Adh:14|ADH:6|adh:3	alcohol dehydrogenase gene:23:0.8715	0.8715	23
Adh	Adh:6	alcohol dehydrogenase locus:6:0.5290	0.5290	6
ADH	ADH:738|adh:1	antidiuretic hormone:739:0.9231	0.9231	739
ADH	ADH:103	atypical ductal hyperplasia:103:0.9245	0.9245	103
ADH	ADH:17	autosomal dominant hypocalcemia:17:0.8270	0.8270	17
ADH	ADH:93	vasopressin:93:0.0389	0.0389	93
ADIs	ADIs:25	acceptable daily intakes:25:0.8816	0.8816	25
ADIs	ADIs:12	AIDS-defining illnesses:12:0.7571	0.7571	12
ADI	ADI:137	acceptable daily intake:128:0.8581|Acceptable Daily Intakes:9:0.5470	0.8581	137
ADI	ADI:11	AIDS-defining illness:11:0.3829	0.3829	11
ADI	ADI:19	arginine deiminase:19:0.7173	0.7173	19
ADI	ADI:11	Autism Diagnostic Interview:11:0.6182	0.6182	11
ADK	ADK:12|AdK:3|Adk:2|adk:1	adenosine kinase:18:0.2771	0.2771	18
ADK	ADK:13|adk:4|AdK:4	adenylate kinase:21:0.3527	0.3527	21
ADLs	ADLs:301	activities of daily living:301:0.9789	0.9789	301
ADL	ADL:16	acid detergent lignin:16:0.8165	0.8165	16
ADL	ADL:39	activities of daily life:39:0.5479	0.5479	39
ADL	ADL:1222	Activities of Daily Living:1073:0.8479|activity of daily living:149:0.1062	0.8479	1222
ADL	ADL:11	Activities of Daily Living Scale:11:0.6182	0.6182	11
ADL	ADL:6	acute adenolymphangitis:6:0.0666	0.0666	6
ADL	ADL:8	aerobic dive limit:8:0.6411	0.6411	8
ADL	ADL:5	daily activities:5:0.0736	0.0736	5
ADM1	ADM1:1	Anaerobic Digestion Model No 1:1:0.6411	0.6411	1
ADMA	ADMA:7	asymmetric dimethyl arginine:7:0.3524	0.3524	7
ADMA	ADMA:6	Asymmetric dimethyl-L-arginine:6:0.1320	0.1320	6
ADMA	ADMA:176	Asymmetric dimethylarginine:176:0.7535	0.7535	176
ADMA	ADMA:36	asymmetrical dimethylarginine:36:0.1094	0.1094	36
ADMCKD	ADMCKD:8	medullary cystic kidney disease:8:0.6411	0.6411	8
ADME	ADME:1	Absorption Distribution Metabolism Excretion:1:0.8300	0.8300	1
ADMOS	ADMOS:6	C oil suspension:6:0.5290	0.5290	6
ADMR	ADMR:19	average daily metabolic rate:19:0.8449	0.8449	19
aDNA	aDNA:22	ancient DNA:22:0.6531	0.6531	22
ADNDI	ADNDI:9|AD-NDI:1|adNDI:1	Autosomal dominant neurohypophyseal diabetes insipidus:11:0.7357	0.7357	11
ADNFLE	ADNFLE:49	Autosomal dominant nocturnal frontal lobe epilepsy:49:0.9392	0.9392	49
ADNF	ADNF:22	Activity-dependent neurotrophic factor:22:0.7955	0.7955	22
ADOS	ADOS:10	Autism Diagnostic Observation Schedule:10:0.5856	0.5856	10
ADPEAF	ADPEAF:10	autosomal dominant partial epilepsy with auditory features:10:0.7103	0.7103	10
ADPKD	ADPKD:10	autosomal dominant PKD:10:0.7103	0.7103	10
ADPKD	ADPKD:622|AD-PKD:3	Autosomal dominant polycystic kidney disease:625:0.9742	0.9742	625
ADPRT	ADPRT:13	adenosine diphosphate ribosyl transferase:13:0.7753	0.7753	13
ADPRT	ADPRT:27|ADPrT:1|ADP-RT:1	ADP-ribosyltransferase:29:0.2435	0.2435	29
ADPase	ADPase:33	adenosine diphosphatase:33:0.8196	0.8196	33
ADP	ADP:275	adenosine 5'-diphosphate:235:0.9241|adenosine-5'-diphosphate:31:0.0159|adenosine-5-diphosphate:9:0.0042	0.9241	275
ADP	ADP:1150|adp:1	adenosine diphosphate:1136:0.9581|adenosine-diphosphate:15:0.0074	0.9581	1151
ADP	ADP:9	after-depolarization:9:0.0042	0.0042	9
ADP	ADP:23	afterdepolarization:23:0.0117	0.0117	23
ADP	ADP:36	air displacement plethysmography:26:0.8861|air-displacement plethysmography:10:0.1057	0.8861	36
ADP	ADP:7	aortic diastolic pressure:7:0.5926	0.5926	7
ADP	ADP:11	death protein:11:0.7357	0.7357	11
ADP	ADP:9	potential:9:0.0042	0.0042	9
ADP	ADP:5	presence of ATP:5:0.1010	0.1010	5
ADP	ADP:9	products:9:0.0042	0.0042	9
ADQI	ADQI:9	Acute dialysis quality initiative:9:0.6794	0.6794	9
ADRAC	ADRAC:7	Adverse Drug Reactions Advisory Committee:7:0.5926	0.5926	7
ADRD	ADRD:12	Alzheimer's disease and related disorders:12:0.7571	0.7571	12
ADRV	ADRV:11	Adult diarrhea rotavirus:11:0.7103	0.7103	11
ADRX	ADRX:7|Adrx:1|ADR-X:1	adrenalectomized:9:0.4706	0.4706	9
ADRs	ADRs:426|ADRS:1	Adverse drug reactions:427:0.9887	0.9887	427
ADSD	ADSD:17|AdSD:4	adductor spasmodic dysphonia:21:0.7865	0.7865	21
ADSL	ADSL:13	adenylosuccinate lyase:13:0.7753	0.7753	13
ADSS	ADSS:7	aged and diluted sidestream cigarette smoke:7:0.5926	0.5926	7
ADs	ADs:45	advance directives:45:0.8649	0.8649	45
ADs	ADs:11	after-discharges:11:0.0199	0.0199	11
ADS	ADS:14	Alcohol Dependence Scale:14:0.7909	0.7909	14
ADS	ADS:6	Alcohol Dependence Syndrome:6:0.3728	0.3728	6
ADs	ADs:22|ADS:1	antidepressants:23:0.0438	0.0438	23
ADs	ADs:9|ADS:2	antidepressant drugs:11:0.3829	0.3829	11
ADs	ADs:5	cortical epileptic afterdischarges:5:0.0736	0.0736	5
Ads	Ads:11	recombinant adenoviruses:11:0.0679	0.0679	11
ADTN	ADTN:14	2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene:14:0.2203	0.2203	14
ADTN	ADTN:6	anterodorsal thalami nuclei:6:0.5290	0.5290	6
ADT	ADT:15	afterdischarge threshold:15:0.3614	0.3614	15
ADT	ADT:8	agar diffusion test:8:0.6411	0.6411	8
ADT	ADT:76	androgen deprivation therapy:76:0.9607	0.9607	76
ADT	ADT:18	androsterone:18:0.0739	0.0739	18
ADVR	ADVR:12|aDVR:1	Anterior dorsal ventricular ridge:13:0.6701	0.6701	13
ADVS	ADVS:16	Activities of Daily Vision Scale:16:0.8165	0.8165	16
ADV	ADV:23	adefovir dipivoxil:23:0.8715	0.8715	23
AdV	AdV:13|ADV:5|Adv:5	adenoviral:23:0.0447	0.0447	23
AdV	AdV:11|Adv:10|adv:3|ADV:1	Adenoviral vectors:14:0.3383|adenoviral vector:11:0.4232	0.4232	25
AdV	AdV:51|ADV:45|Adv:26|adv:2|ad-v:1	adenovirus:107:0.2154|adenoviruses:18:0.0346	0.2154	125
AdV	AdV:10	adenovirus vectors:10:0.1774	0.1774	10
ADV	ADV:48	Aleutian mink disease parvovirus:48:0.9323	0.9323	48
ADV	ADV:116	Aujeszky's disease virus:116:0.5744	0.5744	116
AE1	AE1:23	anion exchanger:23:0.6653	0.6653	23
AE1	AE1:11	anion exchanger 1:11:0.7357	0.7357	11
AE2	AE2:9	Anion Exchanger 2:9:0.6794	0.6794	9
AEA	AEA:64	anandamide:64:0.2771	0.2771	64
AEA	AEA:5	anti-endomysium antibody:5:0.0612	0.0612	5
AEA	AEA:30	antibodies:30:0.1255	0.1255	30
AEA	AEA:16	Arachidonylethanolamide:16:0.0649	0.0649	16
AEBSF	AEBSF:6	fluoride hydrochloride:6:0.2243	0.2243	6
AEBS	AEBS:34	antiestrogen binding site:17:0.4035|antiestrogen binding sites:17:0.5038	0.5038	34
AECA	AECA:93	anti-endothelial cell antibodies:82:0.6320|anti-endothelial cell antibody:11:0.7357	0.7357	93
AECA	AECA:28|aECA:1	antiendothelial cell antibodies:29:0.1666	0.1666	29
AECA	AECA:11|aECA:1	endothelial cells:12:0.5664	0.5664	12
AECB	AECB:75	acute exacerbations of chronic bronchitis:75:0.9159	0.9159	75
AECG	AECG:14	ambulatory ECG:14:0.6911	0.6911	14
AECG	AECG:11	ambulatory electrocardiographic:11:0.7357	0.7357	11
AECG	AECG:9	ambulatory electrocardiography:9:0.6794	0.6794	9
AECOPD	AECOPD:8|AE-COPD:1	acute exacerbations of chronic obstructive pulmonary disease:9:0.6794	0.6794	9
AECs	AECs:38	alveolar epithelial cells:38:0.6678	0.6678	38
AEC	AEC:9	absolute eosinophil count:9:0.6794	0.6794	9
AEC	AEC:36	adenylate energy charge:36:0.7433	0.7433	36
AEC	AEC:68	alveolar epithelial cells:42:0.5018|alveolar epithelial cell:26:0.6645	0.6645	68
AEC	AEC:8	anion-exchange chromatography:8:0.2619	0.2619	8
AEC	AEC:15|aec:1	aortic endothelial cells:16:0.3831	0.3831	16
AEC	AEC:5	apical epithelial cap:5:0.4422	0.4422	5
AEC	AEC:17	automatic exposure control:17:0.8270	0.8270	17
AEDA	AEDA:24	aroma extract dilution analysis:24:0.8768	0.8768	24
AEDV	AEDV:7	Absent end-diastolic velocity:7:0.4438	0.4438	7
AEDs	AEDs:920|AEDS:5	antiepileptic drugs:925:0.9103	0.9103	925
AEDS	AEDS:36	atopic eczema/dermatitis syndrome:36:0.9174	0.9174	36
AEDs	AEDs:86	automated external defibrillators:86:0.6253	0.6253	86
AED	AED:10	aminoethyldextran:10:0.0100	0.0100	10
AED	AED:11	androstenediol:11:0.0111	0.0111	11
AED	AED:12	anhidrotic ectodermal dysplasia:12:0.7571	0.7571	12
AED	AED:613	antiepileptic drug:524:0.9110|antiepileptic drugs:89:0.8046	0.9110	613
AED	AED:50	automated external defibrillator:50:0.6009	0.6009	50
AED	AED:12	emission detection:12:0.6460	0.6460	12
AED	AED:11	external defibrillation:11:0.7357	0.7357	11
AED	AED:27	external defibrillators:27:0.8903	0.8903	27
AEEC	AEEC:17	Attaching and effacing Escherichia coli:17:0.8365	0.8365	17
AEE	AEE:43	energy expenditure:43:0.9308	0.9308	43
AEF	AEF:23	allogeneic effect factor:23:0.8038	0.8038	23
AEF	AEF:37	amyloid enhancing factor:37:0.8681	0.8681	37
AEF	AEF:18	aortoenteric fistula:18:0.2272	0.2272	18
AEF	AEF:19	Aortoesophageal fistula:19:0.2474	0.2474	19
AEF	AEF:19	auditory evoked field:14:0.7909|Auditory evoked fields:5:0.4422	0.7909	19
AEF	AEF:7	auditory evoked magnetic field:7:0.4438	0.4438	7
AEF	AEF:8	Axolemma-enriched fractions:8:0.4102	0.4102	8
AEF	AEF:5	ejection fraction:5:0.0612	0.0612	5
AEFC	AEFC:10	acellular extrinsic fiber cementum:10:0.7103	0.7103	10
AEFI	AEFI:8	Adverse Events Following Immunization:8:0.6411	0.6411	8
AEFs	AEFs:20	auditory evoked magnetic fields:20:0.8525	0.8525	20
AEG	AEG:12|Aeg:1	Acidic epididymal glycoprotein:13:0.6701	0.6701	13
AEG	AEG:7	esophagogastric junction:7:0.3524	0.3524	7
aEMG	aEMG:6|AEMG:4	average EMG:10:0.4363	0.4363	10
AEM	AEM:10	ambulatory ECG monitoring:10:0.7103	0.7103	10
AEM	AEM:17	ambulatory electrocardiographic monitoring:17:0.8270	0.8270	17
AEPs	AEPs:154	Auditory evoked potentials:154:0.7714	0.7714	154
AEP	AEP:7	2-aminoethylphosphonic acid:7:0.2452	0.2452	7
AEP	AEP:8	acute edematous pancreatitis:8:0.6411	0.6411	8
AEP	AEP:33	acute eosinophilic pneumonia:33:0.9100	0.9100	33
AEP	AEP:21	acute experimental pancreatitis:21:0.8594	0.8594	21
AEP	AEP:17	alkaline extracellular protease:17:0.8270	0.8270	17
AEP	AEP:55	Appropriateness Evaluation Protocol:55:0.8882	0.8882	55
AEP	AEP:10	artificial endocrine pancreas:10:0.7103	0.7103	10
AEP	AEP:5	asparaginyl endopeptidase:5:0.0902	0.0902	5
AEP	AEP:11	auditory:11:0.0180	0.0180	11
AEP	AEP:182	auditory evoked potentials:92:0.6761|auditory evoked potential:90:0.7683	0.7683	182
AEQ	AEQ:18	Alcohol Expectancy Questionnaire:18:0.8365	0.8365	18
AERD	AERD:11	aspirin-exacerbated respiratory disease:11:0.4728	0.4728	11
AERPs	AERPs:11	auditory event-related potentials:11:0.6182	0.6182	11
AERP	AERP:72|A-ERP:1	atrial effective refractory period:73:0.8789	0.8789	73
AERP	AERP:14	auditory event-related potentials:8:0.5006|auditory event-related potential:6:0.3728	0.5006	14
AERS	AERS:12	Adverse Event Reporting System:12:0.7571	0.7571	12
AERs	AERs:12	auditory evoked responses:12:0.4153	0.4153	12
aer	aer:13	aerobactin:13:0.0168	0.0168	13
AER	AER:15	agranular endoplasmic reticulum:15:0.5818	0.5818	15
AER	AER:331	albumin excretion rate:313:0.9702|albumin excretion rates:18:0.6903	0.9702	331
AER	AER:181|aer:1	apical ectodermal ridge:182:0.9835	0.9835	182
AER	AER:55	auditory evoked response:40:0.6628|Auditory evoked responses:15:0.4951	0.6628	55
AES	AES:8	Advanced Expert System:8:0.5006	0.5006	8
AEs	AEs:28	adverse effects:28:0.8369	0.8369	28
AEs	AEs:298	adverse events:298:0.9839	0.9839	298
AEs	AEs:16	adverse experiences:16:0.8165	0.8165	16
AES	AES:10	affinity enhancement system:10:0.7103	0.7103	10
AES	AES:11	anal endosonography:11:0.7357	0.7357	11
AES	AES:22|AEs:2	anterior ectosylvian sulcus:24:0.8768	0.8768	24
AES	AES:13	Apathy Evaluation Scale:13:0.7753	0.7753	13
AES	AES:32	auger electron spectroscopy:32:0.8563	0.8563	32
AES	AES:12	electrical stimulation:12:0.6460	0.6460	12
AET	AET:16	2-aminoethylisothiouronium bromide:16:0.3317	0.3317	16
AET	AET:11	atrial ectopic tachycardia:11:0.7357	0.7357	11
AET	AET:27	bromide hydrobromide:27:0.6745	0.6745	27
AEV	AEV:12	anterior ectosylvian visual area:12:0.7571	0.7571	12
AEV	AEV:22	avian encephalomyelitis virus:22:0.8657	0.8657	22
AEV	AEV:84	avian erythroblastosis virus:84:0.9636	0.9636	84
AE	AE:5	absence epilepsy:5:0.0736	0.0736	5
AE	AE:10	Absolute Error:10:0.3470	0.3470	10
AE	AE:28	Acoustic emission:28:0.8941	0.8941	28
AE	AE:8	acridinium ester:8:0.5006	0.5006	8
AE	AE:27	acrodermatitis enteropathica:27:0.8903	0.8903	27
AE	AE:9	acute exacerbation:9:0.6794	0.6794	9
AE	AE:14|Ae:1	adverse effects:15:0.5348	0.5348	15
AE	AE:129	adverse events:88:0.8845|adverse event:41:0.8867	0.8867	129
AE	AE:6	aerobic exercise:6:0.0899	0.0899	6
AE	AE:15	aldrin epoxidase:15:0.8045	0.8045	15
AE	AE:9	allylestrenol:9:0.0055	0.0055	9
AE	AE:110	alveolar echinococcosis:110:0.9728	0.9728	110
AE	AE:11	androstenedione:11:0.0069	0.0069	11
AE	AE:11	anion exchange:11:0.3829	0.3829	11
AE	AE:28	anion exchanger:28:0.6554	0.6554	28
AE	AE:11	aqueous extract:11:0.1612	0.1612	11
AE	AE:12	assimilation efficiency:12:0.3058	0.3058	12
AE	AE:72	atopic eczema:72:0.9585	0.9585	72
AE	AE:32	attaching and effacing:32:0.9100	0.9100	32
AE	AE:11	avian encephalomyelitis:11:0.4728	0.4728	11
AE	AE:11	ethanol:11:0.0069	0.0069	11
AF-1	AF-1:4|AF1:1	activation domain:5:0.0736	0.0736	5
AF-1	AF-1:8|AF1:2	activation function:10:0.4363	0.4363	10
AF-1	AF-1:37|AF1:8	activation function 1:23:0.6653|activation function-1:22:0.7955	0.7955	45
AF-2	AF-2:21|AF2:1	2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide:22:0.0977	0.0977	22
AF-2	AF-2:7|AF2:1	activation domain:8:0.1471	0.1471	8
AF-2	AF-2:12|AF2:4	activation function:16:0.5564	0.5564	16
AF-2	AF-2:43|AF2:14	activation function 2:32:0.7166|activation function-2:25:0.8186	0.8186	57
AF-2	AF-2:17|AF2:3	furylfuramide:20:0.0884	0.0884	20
AF64A	AF64A:36|AF-64A:1	ethylcholine aziridinium:37:0.6009	0.6009	37
AF64A	AF64A:37	ethylcholine aziridinium ion:37:0.3411	0.3411	37
AFAFP	AFAFP:10|AF-AFP:9	Amniotic fluid alpha-fetoprotein:19:0.8449	0.8449	19
AFAP	AFAP:8	Attenuated familial adenomatous polyposis:8:0.5006	0.5006	8
AFAR	AFAR:10|Afar:1	aldehyde reductase:11:0.3829	0.3829	11
AFA	AFA:17	amfonelic acid:17:0.5760	0.5760	17
AFA	AFA:11	antibodies:11:0.0741	0.0741	11
AFB(1)	AFB(1):83|AfB(1):3	aflatoxin B(1):86:0.9653	0.9653	86
AFB1	AFB1:849|AfB1:10|AFb1:1|AF-B1:1	aflatoxin B1:861:0.9505	0.9505	861
AFBN	AFBN:12	Acute focal bacterial nephritis:12:0.7571	0.7571	12
AFB	AFB:29	acetate-free biofiltration:29:0.6392	0.6392	29
AFB	AFB:349	acid-fast bacilli:279:0.7487|acid fast bacilli:70:0.9573	0.9573	349
AFB	AFB:29	acid-fast bacillus:29:0.7970	0.7970	29
AFB	AFB:61	aflatoxin B1:61:0.8971	0.8971	61
AFB	AFB:9	aortofemoral bypass:9:0.2500	0.2500	9
AFCL	AFCL:13	cycle length:13:0.7753	0.7753	13
AFCs	AFCs:21	Antibody-forming cells:21:0.5435	0.5435	21
AFC	AFC:7	7-amino-4-trifluoromethyl coumarin:7:0.3524	0.3524	7
AFC	AFC:20	alveolar fluid clearance:20:0.7173	0.7173	20
AFC	AFC:255	antibody-forming cells:137:0.6210|antibody-forming cell:60:0.4861|antibody forming cells:30:0.8032|antibody forming cell:28:0.8941	0.8941	255
AFC	AFC:13	antral follicle count:13:0.7753	0.7753	13
AFC	AFC:14	N-Acetyl-S-farnesyl-L-cysteine:14:0.0273	0.0273	14
AFDC	AFDC:82	Aid to Families with Dependent Children:82:0.9436	0.9436	82
AFD	AFD:11|AFd:5	Anderson-Fabry disease:16:0.7261	0.7261	16
AFD	AFD:9	appropriate-for-date:9:0.0667	0.0667	9
AFD	AFD:11	average-for-dates:11:0.0833	0.0833	11
AFE	AFE:11	age at first egg:11:0.7357	0.7357	11
AFE	AFE:40	Amniotic fluid embolism:40:0.8811	0.8811	40
AFFIRM	AFFIRM:29|AF-FIRM:1	Atrial Fibrillation Follow-up Investigation of Rhythm Management:30:0.9043	0.9043	30
AFF	AFF:17	atrial filling fraction:17:0.8270	0.8270	17
AFGPs	AFGPs:17	antifreeze glycoproteins:17:0.8270	0.8270	17
AFIGE	AFIGE:9	asymmetric field inversion gel electrophoresis:9:0.5470	0.5470	9
AFI	AFI:111	amniotic fluid index:111:0.9571	0.9571	111
AFI	AFI:11	atrial flutter:11:0.6182	0.6182	11
AFLP	AFLP:40	acute fatty liver of pregnancy:40:0.9274	0.9274	40
AFLP	AFLP:8	amplified fragment length polymorphic:8:0.6411	0.6411	8
AFLP	AFLP:499	amplified fragment length polymorphism:471:0.9366|amplified fragment length polymorphisms:28:0.8941	0.9366	499
AFM1	AFM1:73	Aflatoxin M1:73:0.8789	0.8789	73
AFMK	AFMK:14	N1-acetyl-N2-formyl-5-methoxykynuramine:14:0.5652	0.5652	14
AFMU	AFMU:25	5-acetylamino-6-formylamino-3-methyluracil:25:0.6154	0.6154	25
AFM	AFM:21|afm:1	antiferromagnetic:22:0.0128	0.0128	22
AFM	AFM:324	atomic force microscope:324:0.9711	0.9711	324
AFM	AFM:9	Atomic force microscopic:9:0.6794	0.6794	9
AFM	AFM:1181	Atomic force microscopy:1181:0.9945	0.9945	1181
AFO	AFO:40	ankle-foot orthosis:40:0.7419	0.7419	40
AFOs	AFOs:24	ankle-foot orthoses:24:0.7151	0.7151	24
AFP-L3	AFP-L3:21	alpha-fetoprotein:21:0.6897	0.6897	21
AFPs	AFPs:66	Antifreeze proteins:66:0.8329	0.8329	66
AFP	AFP:12	a-fetoprotein:12:0.0029	0.0029	12
AFP	AFP:166	acute flaccid paralysis:166:0.9712	0.9712	166
AFP	AFP:16	alfa-fetoprotein:16:0.0039	0.0039	16
AFP	AFP:65	alpha 1-fetoprotein:45:0.8964|alpha-1-fetoprotein:20:0.0049	0.8964	65
AFP	AFP:57	alpha-feto-protein:29:0.0073|alpha-feto protein:28:0.1271	0.1271	57
AFP	AFP:2779|afp:5|Afp:4|aFP:4|A-FP:1|a-FP:1	alpha-fetoprotein:2595:0.6716|alpha fetoprotein:189:0.8481|alpha-fetoproteins:10:0.0026	0.8481	2794
AFP	AFP:23	alpha1-fetoprotein:23:0.0057	0.0057	23
AFP	AFP:6	anterior fontanel pressure:6:0.5290	0.5290	6
AFP	AFP:7	anterior fontanelle pressure:7:0.5926	0.5926	7
AFP	AFP:17	anterior forebrain pathway:17:0.8270	0.8270	17
AFP	AFP:14	anti-alpha-fetoprotein:14:0.0034	0.0034	14
AFP	AFP:12	antifreeze polypeptide:12:0.5664	0.5664	12
AFP	AFP:73	antifreeze protein:57:0.3197|antifreeze proteins:16:0.6577	0.6577	73
AFP	AFP:17	antifungal protein:17:0.0610	0.0610	17
AFP	AFP:16	atypical facial pain:16:0.8165	0.8165	16
AFP	AFP:10	serum alpha-foetoprotein:10:0.0502	0.0502	10
AFP	AFP:38	serum alphafetoprotein:38:0.1285	0.1285	38
AFP	AFP:7	Serum alphafoetoprotein:7:0.0886	0.0886	7
AFQ1	AFQ1:13	aflatoxin Q1:13:0.5934	0.5934	13
AFROC	AFROC:12	operating characteristic:12:0.6460	0.6460	12
AFR	AFR:25	ascorbate free radical:25:0.5218	0.5218	25
AFR	AFR:13	flow rate:13:0.4849	0.4849	13
AFs	AFs:16	actin filaments:16:0.7261	0.7261	16
AFs	AFs:13|Afs:1	aflatoxins:14:0.0508	0.0508	14
AFS	AFS:55	Allergic fungal sinusitis:55:0.9147	0.9147	55
AFS	AFS:41	American Fertility Society:41:0.8867	0.8867	41
AFS	AFS:16	atomic fluorescence spectrometry:16:0.7261	0.7261	16
AFTN	AFTN:29	autonomously functioning thyroid nodules:15:0.7096|autonomously functioning thyroid nodule:14:0.7909	0.7909	29
AFTNs	AFTNs:11	Autonomously functioning thyroid nodules:11:0.7357	0.7357	11
AFT	AFT:6	Accelerated failure time:6:0.5290	0.5290	6
AFT	AFT:10	Anodic Fenton treatment:10:0.7103	0.7103	10
AFT	AFT:12	atrial fibrillation threshold:12:0.7571	0.7571	12
AFU	AFU:11	alpha-L-fucosidase:11:0.3125	0.3125	11
AFV	AFV:27	amniotic fluid volume:27:0.8903	0.8903	27
AFX	AFX:45	atypical fibroxanthoma:45:0.9338	0.9338	45
AFib	AFib:26|Afib:9|AFIB:8|a-fib:2|A-Fib:1	atrial fibrillation:46:0.9353	0.9353	46
AF	AF:14	abdominal fat:14:0.4709	0.4709	14
AF	AF:19	accelerated fractionation:19:0.8449	0.8449	19
AF	AF:7	accessory function:7:0.0777	0.0777	7
AF	AF:10	activation function:10:0.1878	0.1878	10
AF	AF:89	aflatoxin:68:0.0138|aflatoxins:21:0.0041	0.0138	89
AF	AF:14	aggregation factor:14:0.0928	0.0928	14
AF	AF:8	Aggressive fibromatosis:8:0.5006	0.5006	8
AF	AF:13	aldehyde fuchsin:13:0.4849	0.4849	13
AF	AF:23	amaurosis fugax:23:0.8038	0.8038	23
AF	AF:9	ameloblastic fibroma:9:0.6794	0.6794	9
AF	AF:14	aminofluorene:14:0.0027	0.0027	14
AF	AF:481	Amniotic fluid:481:0.8997	0.8997	481
AF	AF:10	anaerobic filter:10:0.2643	0.2643	10
AF	AF:11	anchoring fibrils:11:0.5355	0.5355	11
AF	AF:33	annulus fibrosus:33:0.5306	0.5306	33
AF	AF:22	antiferromagnetic:22:0.0043	0.0043	22
AF	AF:13	Antisecretory factor:13:0.0813	0.0813	13
AF	AF:15	anulus fibrosus:15:0.1605	0.1605	15
AF	AF:36	aortic flow:36:0.6738	0.6738	36
AF	AF:6	arterial filter:6:0.0666	0.0666	6
Af	Af:51|AF:13	Aspergillus fumigatus:64:0.8123	0.8123	64
AF	AF:2682|Af:49|af:7	atrial fibrillation:2738:0.9908	0.9908	2738
AF	AF:63	atrial flutter:63:0.7656	0.7656	63
AF	AF:9	attributable fraction:9:0.0898	0.0898	9
AF	AF:103	Auranofin:103:0.0210	0.0210	103
AF	AF:23	autonomic failure:23:0.6306	0.6306	23
AF	AF:9	factors:9:0.0016	0.0016	9
AF	AF:15	force:15:0.0029	0.0029	15
AF	AF:13	fundus autofluorescence:13:0.1824	0.1824	13
A-F	A-F:7	six groups:7:0.2113	0.2113	7
AGAs	AGAs:14	antibodies:14:0.3514	0.3514	14
AGAT	AGAT:6	O6-alkylguanine-DNA alkyltransferase:6:0.1838	0.1838	6
AGA	AGA:6	18-alpha-glycyrrhetinic acid:6:0.0564	0.0564	6
AGA	AGA:5	allergic granulomatosis and angiitis:5:0.5290	0.5290	5
AGA	AGA:11	allergic granulomatous angiitis:11:0.7357	0.7357	11
AGA	AGA:68	androgenetic alopecia:68:0.8075	0.8075	68
AGA	AGA:12	anti-gliadin:12:0.0111	0.0111	12
AGA	AGA:23	anti-gliadin antibodies:23:0.1191	0.1191	23
AGA	AGA:9	antibodies to gliadin:9:0.2500	0.2500	9
AGA	AGA:27	antigliadin:27:0.0262	0.0262	27
AGA	AGA:74	antigliadin antibodies:62:0.4417|Antigliadin antibody:12:0.1758	0.4417	74
AGA	AGA:15	appropriate:15:0.0141	0.0141	15
AGA	AGA:349	appropriate for gestational age:257:0.7575|appropriate-for-gestational-age:92:0.0917	0.7575	349
AGA	AGA:39	aspartylglucosaminidase:39:0.0383	0.0383	39
AGA	AGA:11	presents the official recommendations of the American Gastroenterological Association:11:0.7357	0.7357	11
AGCUS	AGCUS:7|AGC-US:1	atypical glandular cells of undetermined significance:8:0.6411	0.6411	8
AGC	AGC:22	absolute granulocyte count:22:0.7400	0.7400	22
AGC	AGC:29	advanced gastric cancer:29:0.7970	0.7970	29
AGC	AGC:12	advanced gastric carcinoma:12:0.6460	0.6460	12
AGC	AGC:13	atypical glandular cells:13:0.7753	0.7753	13
AGC	AGC:22	automatic gain control:22:0.6934	0.6934	22
AGD	AGD:13	agar gel diffusion:13:0.4849	0.4849	13
AGD	AGD:18	amoebic gill disease:18:0.8365	0.8365	18
AGD	AGD:47	anogenital distance:47:0.8703	0.8703	47
AGD	AGD:23|AgD:10	argyrophilic grain disease:33:0.9100	0.9100	33
AGEPC	AGEPC:12	1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine:12:0.0917	0.0917	12
AGEPC	AGEPC:28	Acetyl glyceryl ether phosphorylcholine:28:0.8978	0.8978	28
AGEP	AGEP:41	acute generalized exanthematous pustulosis:41:0.9256	0.9256	41
AGH	AGH:12	alpha-glucosidase:12:0.3333	0.3333	12
AGHD	AGHD:5	adult GH deficiency:5:0.1973	0.1973	5
AGHD	AGHD:9	Adult growth hormone deficiency:9:0.6794	0.6794	9
AGID	AGID:117	Agar gel immunodiffusion:117:0.9117	0.9117	117
AGID	AGID:8	agar gel immunodiffusion test:8:0.5006	0.5006	8
AGIDT	AGIDT:8	agar gel immunodiffusion test:8:0.6411	0.6411	8
AGIS	AGIS:35	Advanced Glaucoma Intervention Study:35:0.9043	0.9043	35
AGI	AGI:27	Alan Guttmacher Institute:27:0.8903	0.8903	27
AGLT	AGLT:11	acidified glycerol lysis test:11:0.6182	0.6182	11
AGL	AGL:8	acute granulocytic leukemia:8:0.5006	0.5006	8
AGL	AGL:1	caused by the deficiency of glycogen-debranching enzyme:1:0.3170	0.3170	1
AGMK	AGMK:35	African green monkey kidney:35:0.9151	0.9151	35
AGML	AGML:26	acute gastric mucosal lesion:18:0.8365|acute gastric mucosal lesions:8:0.6411	0.8365	26
AGMs	AGMs:20	African green monkeys:20:0.8525	0.8525	20
AGM	AGM:45|agm:4	African green monkey:36:0.9174|African green monkeys:13:0.7753	0.9174	49
Agm	Agm:20|AGM:4	agmatine:24:0.1173	0.1173	24
AGM	AGM:54	aorta-gonad-mesonephros:45:0.2245|aorta-gonads-mesonephros:9:0.0408	0.2245	54
AGm	AGm:20|Agm:1	medial agranular cortex:21:0.8594	0.8594	21
AGNB	AGNB:14	aerobic gram-negative bacilli:14:0.7909	0.7909	14
AGN	AGN:38	acute glomerulonephritis:38:0.5227	0.5227	38
AGN	AGN:14	acute poststreptococcal glomerulonephritis:14:0.6911	0.6911	14
AGPT	AGPT:18	agar gel precipitation test:18:0.8365	0.8365	18
AGPase	AGPase:35	ADP-glucose pyrophosphorylase:35:0.5771	0.5771	35
AGPs	AGPs:61	Arabinogalactan-proteins:34:0.4459|arabinogalactan proteins:27:0.8903	0.8903	61
AGP	AGP:17	ADP-glucose pyrophosphorylase:17:0.6211	0.6211	17
AGP	AGP:21	agar gel precipitation:14:0.7909|agar-gel precipitation:7:0.0886	0.7909	21
AGP	AGP:25	agar gel precipitin:16:0.8165|agar-gel precipitin:9:0.1334	0.8165	25
AgP	AgP:20|AGP:3	aggressive periodontitis:23:0.8038	0.8038	23
AGP	AGP:221	alpha 1-acid glycoprotein:221:0.9864	0.9864	221
AGP	AGP:88	alpha1-acid glycoprotein:88:0.1480	0.1480	88
AGP	AGP:16	arabinogalactan-protein:16:0.0214	0.0214	16
AGP	AGP:5	Growth Promoter:5:0.1132	0.1132	5
AGS3	AGS3:7	Activator of G protein signaling 3:7:0.5926	0.5926	7
AGSM	AGSM:22	anti-G straining maneuver:22:0.8657	0.8657	22
AGSP	AGSP:11	Australian Gonococcal Surveillance Programme:11:0.7357	0.7357	11
AGSs	AGSs:9	audiogenic seizures:9:0.6794	0.6794	9
AGTR1	AGTR1:8|Agtr1:1	angiotensin II type 1 receptor:9:0.6794	0.6794	9
AGT	AGT:3	alanine glyoxylate aminotransferase:3:0.5856	0.5856	3
AGT	AGT:245|Agt:6|agt:2	angiotensinogen:253:0.3619	0.3619	253
AGT	AGT:32|Agt:5	angiotensinogen gene:37:0.9174	0.9174	37
AGT	AGT:11|AgT:1|agT:1	antiglobulin test:13:0.4849	0.4849	13
AGT	AGT:23	average generation time:23:0.8715	0.8715	23
AGT	AGT:10	DNA repair protein O(6)-alkylguanine-DNA alkyltransferase:10:0.6701	0.6701	10
AGT	AGT:12	DNA repair protein O6-alkylguanine-DNA alkyltransferase:12:0.6106	0.6106	12
AGT	AGT:12	O6-alkylguanine-DNA-alkyltransferase:12:0.0157	0.0157	12
AGU	AGU:68	aspartylglucosaminuria:68:0.5280	0.5280	68
AGU	AGU:22	aspartylglycosaminuria:22:0.1680	0.1680	22
AGV	AGV:9	Ahmed glaucoma valve:9:0.6794	0.6794	9
aGVHD	aGVHD:135|aGvHD:23|AGVHD:18|AGvHD:3|A-GVHD:3|a-GVHD:2	acute graft-versus-host disease:184:0.9740	0.9740	184
AH/POA	AH/POA:6	anterior hypothalamic preoptic area:6:0.8594	0.8594	6
AH-130	AH-130:7|AH130:1	ascites hepatoma:8:0.2987	0.2987	8
AH2	AH2:9	Ascorbic acid:9:0.5470	0.5470	9
AH5183	AH5183:16|AH-5183:3	2-(4-phenylpiperidino)cyclohexanol:19:0.3600	0.3600	19
AHAS	AHAS:21	acetohydroxy acid synthase:21:0.8594	0.8594	21
AHAS	AHAS:27	acetohydroxyacid synthase:27:0.3978	0.3978	27
AHAs	AHAs:9	alpha-Hydroxy acids:9:0.2500	0.2500	9
AHA	AHA:12	2-amino-N6-hydroxyadenine:12:0.0184	0.0184	12
AHA	AHA:33|Aha:1	acetohydroxamic acid:34:0.5011	0.5011	34
AHA	AHA:201	American Heart Association:194:0.9087|American Heart Association's:7:0.5926	0.9087	201
AHA	AHA:44	American Hospital Association:44:0.9323	0.9323	44
AHA	AHA:76	anterior hypothalamic area:76:0.9378	0.9378	76
AHA	AHA:9	anterior hypothalamus:9:0.6794	0.6794	9
AHA	AHA:8	anti-histone antibodies:8:0.1196	0.1196	8
AHA	AHA:7	antihistone antibodies:7:0.0828	0.0828	7
AHA	AHA:10	autoimmune haemolytic anaemia:10:0.7103	0.7103	10
AHA	AHA:29	Autoimmune hemolytic anemia:29:0.7581	0.7581	29
AHBA	AHBA:14	3-amino-5-hydroxybenzoic acid:14:0.6173	0.6173	14
AHB	AHB:14|AH-B:3|aHB:1	acute hepatitis B:18:0.7539	0.7539	18
AHCC	AHCC:9	active hexose correlated compound:9:0.6794	0.6794	9
AHCCCS	AHCCCS:12	Arizona Health Care Cost Containment System:12:0.7571	0.7571	12
AHCPR	AHCPR:143	Agency for Health Care Policy and Research:143:0.9802	0.9802	143
AHCs	AHCs:60	academic health centers:60:0.9503	0.9503	60
AHCT	AHCT:6|aHCT:2	hematopoietic cell transplantation:8:0.4102	0.4102	8
AHD	AHD:17	alveolar hydatid disease:17:0.8270	0.8270	17
AHD	AHD:10	anterior:10:0.0826	0.0826	10
AHD	AHD:6	antihypertensive drugs:6:0.1838	0.1838	6
AHEC	AHEC:25	area health education center:25:0.8816	0.8816	25
AHFS	AHFS:8	Acute heart failure syndromes:8:0.6411	0.6411	8
AHF	AHF:15	acute heart failure:15:0.7096	0.7096	15
AHF	AHF:32	acute hepatic failure:32:0.8563	0.8563	32
AHF	AHF:58	altered hepatic foci:58:0.9486	0.9486	58
AHF	AHF:41	antihemophilic factor:41:0.5236	0.5236	41
AHF	AHF:8	Aqueous humor formation:8:0.6411	0.6411	8
AHF	AHF:39	Argentine hemorrhagic fever:39:0.8455	0.8455	39
AHGG	AHGG:10	aggregated human gamma-globulin:10:0.5856	0.5856	10
AHG	AHG:7	aggregated human IgG:7:0.2452	0.2452	7
AHG	AHG:53	globulin:53:0.4815	0.4815	53
AHH	AHH:552	aryl hydrocarbon hydroxylase:552:0.9665	0.9665	552
AHH	AHH:8	Aryl hydrocarbon hydroxylase activity:8:0.6411	0.6411	8
AHI	AHI:263	apnea-hypopnea index:206:0.3296|apnea hypopnea index:57:0.6740	0.6740	263
AHI	AHI:5	apnea-hypopnea indices:5:0.0736	0.0736	5
AHLG	AHLG:7	anti-human lymphocyte globulin:7:0.2902	0.2902	7
AHL	AHL:15|Ahl:3|ahl:1	age-related hearing loss:19:0.8449	0.8449	19
AHL	AHL:10	lactones:10:0.0638	0.0638	10
AHL	AHL:19	N-acyl homoserine lactone:19:0.4405	0.4405	19
AHL	AHL:18	N-acylhomoserine lactone:18:0.1381	0.1381	18
AHO	AHO:13	acute hematogenous osteomyelitis:13:0.7753	0.7753	13
AHO	AHO:61	hereditary osteodystrophy:61:0.9511	0.9511	61
AhpC	AhpC:17|ahpC:4	alkyl hydroperoxide reductase:21:0.8594	0.8594	21
AhpC	AhpC:3|ahpC:2	Alkyl hydroperoxide reductase subunit C:5:0.2818	0.2818	5
AHP-WS	AHPWS:4|AHP-WS:4	alkaline hydrogen peroxide-treated wheat straw:8:0.6411	0.6411	8
AHPs	AHPs:53	afterhyperpolarizations:53:0.4454	0.4454	53
AHP	AHP:9	acute hemorrhagic pancreatitis:9:0.5470	0.5470	9
AHP	AHP:87|ahp:2	after-hyperpolarization:76:0.1313|after hyperpolarization:13:0.6701	0.6701	89
AHP	AHP:7	after-hyperpolarizing potential:7:0.1111	0.1111	7
AHP	AHP:278|ahp:2	afterhyperpolarization:270:0.4711|afterhyperpolarizations:10:0.0158	0.4711	280
AHP	AHP:7	afterhyperpolarizing potential:7:0.1111	0.1111	7
AHP	AHP:32	analytic hierarchy process:32:0.6900	0.6900	32
AHP	AHP:9	anosognosia for hemiplegia:9:0.6794	0.6794	9
AHRF	AHRF:8	acute hypercapnic respiratory failure:8:0.6411	0.6411	8
AHRF	AHRF:11	acute hypoxemic respiratory failure:11:0.7357	0.7357	11
AHRQ	AHRQ:61	Agency for Healthcare Research and Quality:61:0.9511	0.9511	61
AHSCT	AHSCT:21	autologous hematopoietic stem cell transplantation:21:0.7291	0.7291	21
AHSG	AHSG:20	alpha 2-HS-glycoprotein:10:0.7103|alpha 2-HS glycoprotein:10:0.7103	0.7103	20
AHSV-4	AHSV-4:10	African horsesickness virus serotype 4:10:0.7103	0.7103	10
AHSV	AHSV:56	African horse sickness virus:56:0.9467	0.9467	56
AHSV	AHSV:39	African horsesickness virus:39:0.9217	0.9217	39
AHS	AHS:48	African horse sickness:48:0.9379	0.9379	48
AHS	AHS:15	African horsesickness:15:0.8045	0.8045	15
AHS	AHS:11	alien hand syndrome:11:0.7357	0.7357	11
AHS	AHS:5	Alpha-haemolytic streptococci:5:0.0612	0.0612	5
AHS	AHS:6	Alpha-hemolytic streptococci:6:0.1320	0.1320	6
AHS	AHS:24	Ammon's horn sclerosis:24:0.8115	0.8115	24
AHS	AHS:12	anticonvulsant hypersensitivity syndrome:12:0.2699	0.2699	12
AHs	AHs:10	aromatic hydrocarbons:10:0.2873	0.2873	10
AHS	AHS:24	Health Study:24:0.8768	0.8768	24
AHT	AHT:38	arterial hypertension:38:0.8098	0.8098	38
AHV-1	AHV-1:21|AHV1:3	Alcelaphine herpesvirus 1:13:0.7753|Alcelaphine herpesvirus-1:11:0.7357	0.7753	24
AHVR	AHVR:7	acute ventilatory response to hypoxia:7:0.4438	0.4438	7
AHXR	AHXR:15	acute humoral xenograft rejection:15:0.8045	0.8045	15
AHZ	AHZ:27	beta-alanyl-L-histidinato zinc:27:0.8903	0.8903	27
AHC	AHC:18	Acute haemorrhagic conjunctivitis:18:0.8365	0.8365	18
AHC	AHC:52	acute hemorrhagic conjunctivitis:52:0.9427	0.9427	52
AHC	AHC:13|AH-C:2|aHC:1	acute hepatitis C:16:0.8165	0.8165	16
AHC	AHC:46	adrenal hypoplasia congenita:46:0.8676	0.8676	46
AHC	AHC:2	Alternating hemiplegia in childhood:2:0.7571	0.7571	2
AHC	AHC:9	congenital adrenal hypoplasia:9:0.3945	0.3945	9
AHC	AHC:10	health center:10:0.7103	0.7103	10
AI/AN	AI/AN:16	American Indian/Alaska Native:16:0.8165	0.8165	16
AI/AN	AI/AN:29	American Indian and Alaska Native:21:0.8594|American Indians and Alaska Natives:8:0.6411	0.8594	29
AI/ANs	AI/ANs:10	American Indians and Alaska Natives:10:0.7103	0.7103	10
AI-2	AI-2:44	autoinducer 2:24:0.8115|autoinducer-2:20:0.3167	0.8115	44
AIAN	AIAN:6|AI-AN:1	American Indian and Alaska Native:7:0.5926	0.5926	7
AIA	AIA:69	adjuvant-induced arthritis:69:0.3019	0.3019	69
AIA	AIA:48|aia:1	allylisopropylacetamide:49:0.1079	0.1079	49
AIA	AIA:10	antibodies:10:0.0202	0.0202	10
AIA	AIA:74|AiA:6	Antigen-induced arthritis:80:0.3606	0.3606	80
AIA	AIA:52	aspirin-induced asthma:52:0.5131	0.5131	52
AIA	AIA:16	aspirin-intolerant asthma:16:0.0950	0.0950	16
AIBN	AIBN:9	azobisisobutyronitrile:9:0.1951	0.1951	9
AIB	AIB:10|Aib:1	2-aminoisobutyrate:11:0.0180	0.0180	11
AIB	AIB:5	airflow-induced bronchoconstriction:5:0.1132	0.1132	5
AIB	AIB:14	alpha-aminoisobutyrate:14:0.0233	0.0233	14
AIB	AIB:204|Aib:53	alpha-aminoisobutyric acid:257:0.5083	0.5083	257
AI-CAH	AI-CAH:13|AICAH:7|ai-CAH:1|AiCAH:1	autoimmune chronic active hepatitis:22:0.6531	0.6531	22
AICAR	AICAR:9|AICAr:2	5-amino-4-imidazolecarboxamide riboside:11:0.1243	0.1243	11
AICAR	AICAR:30	5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside:30:0.1408	0.1408	30
AICAR	AICAR:34	5-aminoimidazole-4-carboxamide ribonucleoside:34:0.6386	0.6386	34
AICAR	AICAR:12	5-aminoimidazole-4-carboxamide ribonucleotide:12:0.3524	0.3524	12
AICAR	AICAR:10|AICAr:2|AICA-r:1	5-aminoimidazole-4-carboxamide riboside:13:0.1944	0.1944	13
AICAR	AICAR:6	5-aminoimidazole-4-carboxamide ribotide:6:0.1320	0.1320	6
AICA	AICA:124|Aica:1	anterior inferior cerebellar artery:125:0.9759	0.9759	125
AICD	AICD:217	activation-induced cell death:217:0.8252	0.8252	217
AICD	AICD:13	APP intracellular domain:13:0.5335	0.5335	13
AICD	AICD:105	automatic implantable cardioverter defibrillator:61:0.9216|automatic implantable cardioverter-defibrillator:38:0.8839|automatic implantable cardioverter defibrillators:6:0.5290	0.9216	105
AIC	AIC:12	Autoimmune cholangitis:12:0.7571	0.7571	12
AIC	AIC:10	Information Criteria:10:0.5856	0.5856	10
AIC	AIC:93	information criterion:93:0.9490	0.9490	93
AIDH	AIDH:19	aldehyde dehydrogenase:19:0.7658	0.7658	19
AIDP	AIDP:37	Acute inflammatory demyelinating polyneuropathy:37:0.9174	0.9174	37
AIDP	AIDP:18	acute inflammatory demyelinating polyradiculoneuropathy:18:0.8365	0.8365	18
AIDS	AIDS:13	acquired immune deficiency:13:0.7753	0.7753	13
AIDS	AIDS:2376	acquired immune deficiency syndrome:2376:0.9735	0.9735	2376
AIDS	AIDS:12	acquired immunodeficiency:12:0.4153	0.4153	12
AIDS	AIDS:18	acquired immunodeficiency disease:18:0.6903	0.6903	18
AIDS	AIDS:6294|Aids:3	acquired immunodeficiency syndrome:6291:0.9743|acquired immunodeficiency syndromes:6:0.5290	0.9743	6297
AIDS	AIDS:11	acquired immunodeficiency virus:11:0.4728	0.4728	11
AID	AID:129	activation-induced cytidine deaminase:129:0.9294	0.9294	129
AID	AID:37	Agency for International Development:37:0.9217	0.9217	37
AID	AID:69	artificial insemination by donor:69:0.9415	0.9415	69
AID	AID:22|aid:1	artificial insemination with donor semen:23:0.8861	0.8861	23
AID	AID:6	artificial insemination with donor sperm:6:0.3728	0.3728	6
AID	AID:36	autoimmune diseases:22:0.7955|autoimmune disease:14:0.3585	0.7955	36
AID	AID:6	donor artificial insemination:6:0.1838	0.1838	6
AID	AID:15	donor insemination:15:0.3429	0.3429	15
AID	AID:8	interaction domain:8:0.1196	0.1196	8
AIED	AIED:13	autoimmune inner ear disease:13:0.6701	0.6701	13
AIEOP	AIEOP:4	Italian Association for Pediatric Hematology and Oncology:4:0.7103	0.7103	4
AIF-1	AIF-1:28|Aif-1:1	allograft inflammatory factor-1:29:0.8422	0.8422	29
AIF	AIF:51	arterial input function:51:0.9416	0.9416	51
AIF	AIF:20	cytochrome c and apoptosis-inducing factor:20:0.7151	0.7151	20
AIGF	AIGF:10	androgen-induced growth factor:10:0.5856	0.5856	10
AIG	AIG:24	anchorage-independent growth:16:0.4274|anchorage independent growth:8:0.6411	0.6411	24
AIG	AIG:21	autoimmune gastritis:21:0.7865	0.7865	21
AIHA	AIHA:91	autoimmune haemolytic anaemia:91:0.8185	0.8185	91
AIHA	AIHA:223	autoimmune hemolytic anemia:223:0.9583	0.9583	223
AIH	AIH:5	amiodarone-induced hypothyroidism:5:0.0612	0.0612	5
AIH	AIH:8	anastomotic intimal hyperplasia:8:0.6411	0.6411	8
AIH	AIH:7	artificial insemination by husband:7:0.7571	0.7571	7
AIH	AIH:2	Artificial insemination using the husband's semen:2:0.6911	0.6911	2
AIH	AIH:337|AiH:2|AI-H:1	autoimmune hepatitis:340:0.9329	0.9329	340
AIH	AIH:11	homologous artificial insemination:11:0.3829	0.3829	11
AIIA	AIIA:5|AII-A:1	receptor antagonist:6:0.1543	0.1543	6
AIIMS	AIIMS:15	India Institute of Medical Sciences:15:0.7096	0.7096	15
AIIRAs	AIIRAs:7	angiotensin II receptor antagonists:7:0.5926	0.5926	7
AIIt	AIIt:7	annexin II heterotetramer:7:0.5926	0.5926	7
AIIt	AIIt:14|A-IIt:1	Annexin II tetramer:15:0.8045	0.8045	15
AII	AII:31|A-II:3	angiotensin:34:0.0137	0.0137	34
AII	AII:2011|A-II:172	angiotensin II:2079:0.9582|Angiotensin-II:104:0.0428	0.9582	2183
AII	AII:10	auditory cortex:10:0.7103	0.7103	10
AILD	AILD:62	angioimmunoblastic lymphadenopathy:62:0.8407	0.8407	62
AILD	AILD:9	angioimmunoblastic lymphadenopathy with dysproteinaemia:9:0.5856	0.5856	9
AILD	AILD:60	angioimmunoblastic lymphadenopathy with dysproteinemia:60:0.8359	0.8359	60
AILD	AILD:7	angioimmunoblastic T-cell lymphoma:7:0.4438	0.4438	7
AIL	AIL:35|ail:1	Angioimmunoblastic lymphadenopathy:36:0.7183	0.7183	36
AIL	AIL:6	Angioimmunoblastic lymphoma:6:0.1543	0.1543	6
AIL	AIL:5	angioimmunoblastic T-cell lymphoma:5:0.4422	0.4422	5
AIMAH	AIMAH:19	macronodular adrenocortical hyperplasia:19:0.8365	0.8365	19
AIMI	AIMI:11	acute inferior myocardial infarction:11:0.7357	0.7357	11
AIMS2	AIMS2:10	Arthritis Impact Measurement Scales:10:0.7103	0.7103	10
AIMS2	AIMS2:17|AIMS-2:1	Arthritis Impact Measurement Scales 2:18:0.8365	0.8365	18
AIMs	AIMs:12|AIMS:2	abnormal involuntary movements:14:0.6911	0.6911	14
AIMS	AIMS:127	Abnormal Involuntary Movement Scale:127:0.9764	0.9764	127
AIMS	AIMS:18	anesthesia information management system:18:0.5560	0.5560	18
AIMS	AIMS:74	Arthritis Impact Measurement Scales:74:0.9596	0.9596	74
AIMS	AIMS:7	first 2000 incidents reported to the Australian Incident Monitoring Study:7:0.5926	0.5926	7
AIMV	AIMV:26	alfalfa mosaic virus:26:0.8861	0.8861	26
AIM	AIM:6	activation inducer molecule:6:0.5290	0.5290	6
AIM	AIM:13	acute infectious mononucleosis:13:0.7753	0.7753	13
AIM	AIM:16	acute myocardial infarction:16:0.6577	0.6577	16
AIM	AIM:6	Analytical ion microscopy:6:0.5290	0.5290	6
AIM	AIM:6	Artificial Intelligence in Medicine:6:0.5290	0.5290	6
AIN	AIN:66	acute interstitial nephritis:66:0.8329	0.8329	66
AIN	AIN:36	anal intraepithelial neoplasia:36:0.8716	0.8716	36
AIN	AIN:10	anterior interosseous nerve:10:0.7103	0.7103	10
AIN	AIN:25	autoimmune neutropenia:25:0.8186	0.8186	25
AIOD	AIOD:24	aortoiliac occlusive disease:24:0.6427	0.6427	24
AION	AION:22	anterior ischaemic optic neuropathy:22:0.8657	0.8657	22
AION	AION:88	anterior ischemic optic neuropathy:88:0.9461	0.9461	88
AIP1	AIP1:5|Aip1:1	actin-interacting protein 1:6:0.1148	0.1148	6
AIP1	AIP1:6|Aip1:1	interacting protein 1:7:0.1850	0.1850	7
AIPC	AIPC:28|AI-PC:1	androgen-independent prostate cancer:29:0.5376	0.5376	29
AIPT	AIPT:15	pulmonary toxicity:15:0.8045	0.8045	15
AIPcS4	AIPcS4:5|AIPCS4:3	aluminum phthalocyanine tetrasulfonate:8:0.5006	0.5006	8
AIP	AIP:6	2-aminoindan-2-phosphonic acid:6:0.2243	0.2243	6
AIP	AIP:241	acute intermittent porphyria:241:0.9798	0.9798	241
AIP	AIP:27	acute interstitial pneumonia:27:0.6745	0.6745	27
AIP	AIP:15|AI-P:2	Alkaline phosphatase:17:0.8270	0.8270	17
AIP	AIP:15	autoimmune pancreatitis:15:0.2421	0.2421	15
AIP	AIP:9	autoinducing peptide:9:0.1945	0.1945	9
AIP	AIP:7	inhibitory peptide:7:0.1025	0.1025	7
AIR(g)	AIR(G):4|AIR(g):4	acute insulin response to glucose:8:0.6411	0.6411	8
AIRE	AIRE:13	Acute Infarction Ramipril Efficacy:13:0.7909	0.7909	13
AIRE	AIRE:50|Aire:5|aire:1	autoimmune regulator:56:0.9467	0.9467	56
AIRE	Aire:4|AIRE:4	autoimmune regulator gene:8:0.6411	0.6411	8
AIRg	AIRg:17|AIRG:4	acute insulin response to glucose:21:0.8594	0.8594	21
AISA	AISA:11	acquired idiopathic sideroblastic anaemia:11:0.7103	0.7103	11
AISA	AISA:12	acquired idiopathic sideroblastic anemia:12:0.7571	0.7571	12
AIS	AIS:140	Abbreviated Injury Scale:140:0.9547	0.9547	140
AIS	AIS:23	Abbreviated Injury Score:23:0.5997	0.5997	23
AIS	AIS:6	acute ischaemic stroke:6:0.2243	0.2243	6
AIS	AIS:33	acute ischemic stroke:33:0.5600	0.5600	33
AIS	AIS:92	Adenocarcinoma in situ:92:0.8644	0.8644	92
AIS	AIS:84	adolescent idiopathic scoliosis:84:0.8926	0.8926	84
AIs	AIs:11	American Indians:11:0.5355	0.5355	11
AIS	AIS:105	androgen insensitivity syndrome:91:0.9473|Androgen insensitivity syndromes:14:0.7909	0.9473	105
AIS	AIS:7	Anemia-inducing substance:7:0.2902	0.2902	7
AIS	AIS:7	anti-insulin serum:7:0.2902	0.2902	7
AIs	AIs:7	Apoptotic indices:7:0.0692	0.0692	7
AIs	AIs:51	aromatase inhibitors:51:0.9416	0.9416	51
AIs	AIs:9	asymmetry indices:9:0.1334	0.1334	9
AITC	AITC:30	Allyl isothiocyanate:30:0.8090	0.8090	30
AITD	AITD:191	autoimmune thyroid disease:143:0.9661|autoimmune thyroid diseases:48:0.9027	0.9661	191
AITDs	AITDs:22	Autoimmune thyroid diseases:22:0.8657	0.8657	22
AITL	AITL:11	angioimmunoblastic T-cell lymphoma:11:0.7357	0.7357	11
AITP	AITP:31	autoimmune thrombocytopenia:31:0.9043	0.9043	31
AITP	AITP:84	autoimmune thrombocytopenic purpura:84:0.8167	0.8167	84
AIT	AIT:42	adoptive immunotherapy:42:0.7113	0.7113	42
AIT	AIT:33	Amiodarone-induced thyrotoxicosis:33:0.7525	0.7525	33
AIT	AIT:17	autoimmune thyroiditis:17:0.8270	0.8270	17
AIVR	AIVR:22	Accelerated idioventricular rhythm:22:0.8657	0.8657	22
AIV	AIV:10	angiotensin IV:10:0.4363	0.4363	10
AIV	AIV:17	anterior interventricular vein:17:0.8270	0.8270	17
AIV	AIV:58	avian influenza virus:58:0.9486	0.9486	58
AIV	AIV:9	influenza viruses:9:0.7103	0.7103	9
AIx	AIx:43	augmentation index:43:0.8590	0.8590	43
AJC	AJC:17	American Joint Committee:17:0.8270	0.8270	17
AJC	AJC:7	ankle joint complex:7:0.5926	0.5926	7
AJC	AJC:7	apical junctional complex:7:0.4438	0.4438	7
AJCC	AJCC:213	American Joint Committee on Cancer:213:0.9702	0.9702	213
AJPBD	AJPBD:7	anomalous junction of the pancreaticobiliary duct:7:0.6794	0.6794	7
AJs	AJs:69	adherens junctions:69:0.9100	0.9100	69
AJ	AJ:46|Aj:1	adherens junction:29:0.8422|adherens junctions:18:0.5228	0.8422	47
AJ	AJ:16	Ashkenazi Jewish:16:0.7261	0.7261	16
AK1	AK1:16|AK-1:2	adenylate kinase:18:0.8365	0.8365	18
AK1	AK1:11	adenylate kinase 1:11:0.7357	0.7357	11
AKAP	AKAP:13	A-kinase anchoring protein:13:0.2415	0.2415	13
AKAP	AKAP:12	kinase anchoring protein:12:0.2758	0.2758	12
AKAPs	AKAPs:14	A-kinase anchor proteins:14:0.3202	0.3202	14
AKAPs	AKAPs:55	A-kinase anchoring proteins:55:0.6160	0.6160	55
AKAPs	AKAPs:9	kinase anchor proteins:9:0.1334	0.1334	9
AKAPs	AKAPs:6	protein kinase A anchoring proteins:6:0.0807	0.0807	6
AKA	AKA:8	above-knee amputation:8:0.2987	0.2987	8
AKA	AKA:9	alcoholic ketoacidosis:9:0.6794	0.6794	9
AKA	AKA:37	antikeratin antibodies:26:0.5409|antikeratin antibody:11:0.3495	0.5409	37
AKBR	AKBR:75	arterial ketone body ratio:75:0.7741	0.7741	75
AKC	AKC:45	atopic keratoconjunctivitis:45:0.8649	0.8649	45
AKH	AKH:35	adipokinetic hormone:35:0.9151	0.9151	35
AKHs	AKHs:21	adipokinetic hormones:21:0.8594	0.8594	21
AKP	AKP:58|AkP:5|akp:1	alkaline phosphatase:64:0.9534	0.9534	64
AKRs	AKRs:23	aldo-keto reductases:23:0.8038	0.8038	23
AKR	AKR:69	aldo-keto reductase:59:0.8334|Aldo-keto reductases:10:0.7103	0.8334	69
AKs	AKs:48	actinic keratoses:48:0.9027	0.9027	48
Akt	Akt:96|AKT:12|akt:1	protein kinase B:109:0.7298	0.7298	109
AKUH	AKUH:33	Aga Khan University Hospital:33:0.9126	0.9126	33
AKU	AKU:16|aku:1	alkaptonuria:17:0.5000	0.5000	17
ALA-PDT	ALA-PDT:20	photodynamic therapy:20:0.6680	0.6680	20
ALAD	ALAD:157|ALA-D:61|ALA-d:4	delta-aminolevulinic acid dehydratase:222:0.7066	0.7066	222
ALA-D	ALA-D:7|ALAD:1	delta-aminolevulinic acid dehydratase activity:8:0.6411	0.6411	8
ALAS1	ALAS1:5|ALAS-1:3	5-aminolevulinate synthase:8:0.3463	0.3463	8
ALAS2	ALAS2:8|ALAS-2:3	5-aminolevulinate synthase:11:0.2422	0.2422	11
ALAS-N	ALAS-N:8	delta-aminolevulinate synthase:8:0.3463	0.3463	8
ALAS	ALAS:28|ALA-S:7	5-aminolevulinate synthase:35:0.1717	0.1717	35
ALAS	ALAS:21|ALA-S:8|ALAs:1	delta-aminolevulinate synthase:30:0.1397	0.1397	30
ALA-S	ALA-S:16|ALAS:12	delta-aminolevulinic acid synthetase:28:0.6839	0.6839	28
ALAU	ALAU:2	delta-aminolevulinic acid in the urine:2:0.2827	0.2827	2
ALA-U	ALA-U:9|ALAU:5	urinary delta-aminolevulinic acid:14:0.4367	0.4367	14
ALA	ALA:22	5-aminolevulinate:22:0.0121	0.0121	22
ALA	ALA:25|a-LA:2|aLA:1	alpha-lactalbumin:28:0.0156	0.0156	28
ALA	ALA:8	Anti-lymphocyte antibodies:8:0.1276	0.1276	8
ALA	ALA:16	antilymphocyte antibody:8:0.5006|antilymphocyte antibodies:8:0.1276	0.5006	16
ALA	ALA:13	antilysozyme activity:13:0.4102	0.4102	13
ALA	ALA:10	delta-aminolaevulinate:10:0.0052	0.0052	10
ALA	ALA:40	delta-aminolevulinate:40:0.0226	0.0226	40
Ala	Ala:14|ALA:2|ala:1	L-alanine:17:0.0093	0.0093	17
ALA	ALA:69	liver abscess:69:0.9567	0.9567	69
ALBP	ALBP:25|A-LBP:1	Adipocyte lipid-binding protein:16:0.8165|adipocyte lipid binding protein:10:0.7103	0.8165	26
ALCAM	ALCAM:15	activated leukocyte cell adhesion molecule:15:0.7096	0.7096	15
ALCAPA	ALCAPA:23|ALCA-PA:1	anomalous origin of the left coronary artery from the pulmonary artery:24:0.8251	0.8251	24
ALCAR	ALCAR:70|ALCar:1	Acetyl-L-carnitine:71:0.8750	0.8750	71
ALCA	ALCA:6	anomalous origin of the left coronary artery:6:0.5290	0.5290	6
ALCLs	ALCLs:28	anaplastic large cell lymphomas:28:0.8941	0.8941	28
ALCL	ALCL:407	anaplastic large cell lymphoma:299:0.9277|anaplastic large-cell lymphoma:70:0.9112|anaplastic large cell lymphomas:27:0.8861|anaplastic large-cell lymphomas:11:0.7357	0.9277	407
ALC	ALC:29	Absolute lymphocyte count:29:0.8978	0.8978	29
ALC	ALC:65	acetyl-L-carnitine:65:0.1720	0.1720	65
ALC	ALC:7	adult Leydig cells:7:0.5926	0.5926	7
ALC	ALC:30	alcoholic liver cirrhosis:30:0.8032	0.8032	30
ALC	ALC:8|Alc:1	alcoholism:9:0.0215	0.0215	9
ALC	ALC:10	Allogeneic lymphocyte cytotoxicity:10:0.7103	0.7103	10
ALC	ALC:12	alveolar liquid clearance:12:0.7571	0.7571	12
ALC	ALC:20	anaplastic large cell:20:0.8525	0.8525	20
ALDH1	ALDH1:18|ALDH-1:2	aldehyde dehydrogenase:20:0.7766	0.7766	20
ALDH1	ALDH1:9|Aldh1:3	aldehyde dehydrogenase 1:12:0.7753	0.7753	12
ALDH2	ALDH2:100|ALDH-2:11	aldehyde dehydrogenase:111:0.9064	0.9064	111
ALDH2	ALDH2:111|ALDH-2:2|Aldh2:1	aldehyde dehydrogenase 2:62:0.8788|aldehyde dehydrogenase-2:52:0.9427	0.9427	114
ALDH-3	ALDH-3:5|ALDH3:2|aldh3:1	class 3 aldehyde dehydrogenase:8:0.6411	0.6411	8
ALDHs	ALDHs:30|AlDHs:1	aldehyde dehydrogenases:31:0.9043	0.9043	31
ALDH	ALDH:29	aldehyde dehydrogenases:29:0.8422	0.8422	29
ALDLT	ALDLT:10	living donor liver transplantation:10:0.7103	0.7103	10
ALDO	ALDO:185|aldo:173|Aldo:6	aldosterone:364:0.9332	0.9332	364
ALD	ALD:9	adreno-leukodystrophy:9:0.0076	0.0076	9
ALD	ALD:10	adrenoleucodystrophy:10:0.0085	0.0085	10
ALD	ALD:239	alcoholic liver disease:239:0.8490	0.8490	239
ALD	ALD:54|Ald:4	aldolase:58:0.0550	0.0550	58
ALD	ALD:15	anterior:15:0.0133	0.0133	15
ALD	ALD:108|ald:1	anterior latissimus dorsi:109:0.9726	0.9726	109
ALD	ALD:9	anterior latissimus dorsi muscle:9:0.5470	0.5470	9
ALD	ALD:11	atomic layer deposition:11:0.7357	0.7357	11
ALD	ALD:15|Ald:11	plasma aldosterone:26:0.1354	0.1354	26
ALD	ALD:76	X-linked adrenoleukodystrophy:76:0.2028	0.2028	76
ALEs	ALEs:8	advanced lipoxidation end products:8:0.4102	0.4102	8
ALE	ALE:9	active life expectancy:9:0.6794	0.6794	9
ALE	ALE:8	artichoke leaf extract:8:0.4102	0.4102	8
ALFA	ALFA:8	aluminum-formaldehyde:8:0.3077	0.3077	8
ALFs	ALFs:10	assisted living facilities:10:0.7103	0.7103	10
ALF	ALF:165	acute liver failure:165:0.9819	0.9819	165
ALF	ALF:7	alveolar lining fluid:7:0.5926	0.5926	7
ALG	ALG:11|alg:9|Alg:3	alginate:23:0.0591	0.0591	23
ALG	ALG:193	antilymphocyte globulin:183:0.5953|antilymphocyte globulins:10:0.3145	0.5953	193
ALHE	ALHE:54	angiolymphoid hyperplasia with eosinophilia:54:0.9132	0.9132	54
ALHL	ALHL:8	acute low-tone sensorineural hearing loss:8:0.6411	0.6411	8
ALH	ALH:10	Allan Hills:10:0.7103	0.7103	10
ALH	ALH:70|Alh:1	amplitude of lateral head displacement:71:0.7603	0.7603	71
ALH	ALH:21	atypical lobular hyperplasia:21:0.8594	0.8594	21
ALIF	ALIF:44	anterior lumbar interbody fusion:44:0.9323	0.9323	44
ALIP	ALIP:9	abnormal localization of immature precursors:9:0.7103	0.7103	9
ALI	ALI:437	acute lung injury:437:0.9852	0.9852	437
ALI	ALI:22	air-liquid interface:22:0.8657	0.8657	22
ALI	ALI:5	annual limit of intake:5:0.6794	0.6794	5
ALK-1	ALK-1:11|ALK1:6	activin receptor-like kinase 1:10:0.7103|Activin receptor-like kinase-1:7:0.5926	0.7103	17
ALK	ALK:149|Alk:3|alk:1|AlK:1	anaplastic lymphoma kinase:154:0.9073	0.9073	154
ALK	ALK:11	automated lamellar keratoplasty:11:0.6182	0.6182	11
ALLHAT	ALLHAT:52	Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial:52:0.9416	0.9416	52
ALLN	ALLN:18	N-acetyl-leu-leu-norleucinal:18:0.2073	0.2073	18
ALLN	ALLN:23	N-acetyl-leucyl-leucyl-norleucinal:23:0.2683	0.2683	23
allo	allo:26|ALLO:6	allogeneic:32:0.2403	0.2403	32
ALLO	ALLO:16|allo:4	allopregnanolone:20:0.1473	0.1473	20
ALLO	ALLO:10|allo:7	allopurinol:17:0.1240	0.1240	17
ALLs	ALLs:38	acute lymphoblastic leukemias:38:0.9217	0.9217	38
ALL	ALL:36	acute lymphoblastic:36:0.5182	0.5182	36
ALL	ALL:1074	acute lymphoblastic leukaemia:1046:0.9568|acute lymphoblastic leukaemias:28:0.8941	0.9568	1074
ALL	ALL:4202|All:1	acute lymphoblastic leukemia:4110:0.9848|acute lymphoblastic leukemias:93:0.8914	0.9848	4203
ALL	ALL:5	acute lymphoblastic leukemic:5:0.2818	0.2818	5
ALL	ALL:12	acute lymphocytic:12:0.3813	0.3813	12
ALL	ALL:716	acute lymphocytic leukemia:716:0.9723	0.9723	716
ALL	ALL:8	acute lymphoid:8:0.2327	0.2327	8
ALL	ALL:11|All:1	allopurinol:12:0.0016	0.0016	12
All	All:11	angiotensin II:11:0.6182	0.6182	11
ALL	ALL:10	anterior longitudinal ligament:10:0.7103	0.7103	10
ALM	ALM:28	acral lentiginous melanoma:28:0.8941	0.8941	28
ALM	ALM:7|Alm:2	almitrine bismesylate:9:0.6794	0.6794	9
ALM	ALM:6	autoclaved Leishmania major:6:0.2827	0.2827	6
ALND	ALND:168	Axillary lymph node dissection:168:0.9715	0.9715	168
ALNs	ALNs:11	lymph nodes:11:0.7357	0.7357	11
ALN	ALN:45|Aln:3	alendronate:48:0.3431	0.3431	48
ALN	ALN:25	axillary lymph node:16:0.4536|axillary lymph nodes:9:0.5470	0.5470	25
ALOS	ALOS:30	average length of stay:30:0.8472	0.8472	30
ALPL	ALPL:15	alkaline phosphatase:15:0.8045	0.8045	15
ALPP	ALPP:10	abdominal leak point pressure:10:0.7103	0.7103	10
ALP	ALP:10|AlP:2|Alp:1	alkaline:13:0.0043	0.0043	13
ALP	ALP:2270|AlP:29|Alp:14|Al-P:11|AL-P:5|Al-p:5|alP:4|alp:2	alkaline phosphatase:2314:0.9892|alkaline phosphatases:17:0.7407|alkaline-phosphatase:9:0.0029	0.9892	2340
ALP	ALP:54	alkaline phosphatase activity:54:0.9132	0.9132	54
ALP	ALP:12	alkaline phosphate:12:0.3813	0.3813	12
Alp	Alp:10|ALP:5	alkaline protease:15:0.5348	0.5348	15
ALP	ALP:24	Alkyl-lysophospholipids:13:0.0043|alkyl-lysophospholipid:11:0.0036	0.0043	24
ALP	ALP:21	alprazolam:21:0.0072	0.0072	21
ALP	ALP:9|AlP:6	aluminium phosphide:15:0.5348	0.5348	15
ALP	ALP:21	antileukoprotease:21:0.0072	0.0072	21
ALP	ALP:13|aLP:1	antileukoproteinase:14:0.0043	0.0043	14
ALP	ALP:13	atherogenic lipoprotein phenotype:13:0.7753	0.7753	13
ALP	ALP:6	LIM protein:6:0.1838	0.1838	6
ALR1	ALR1:8	Aldehyde reductase:8:0.6794	0.6794	8
ALR2	ALR2:49	aldose reductase:49:0.9392	0.9392	49
ALRI	ALRI:67	acute lower respiratory infection:37:0.8749|acute lower respiratory infections:30:0.8422	0.8749	67
ALRI	ALRI:50	acute lower respiratory tract infection:31:0.8519|Acute lower respiratory tract infections:19:0.7539	0.8519	50
ALR	ALR:11	aldehyde reductase:11:0.6182	0.6182	11
ALR	ALR:21	augmenter of liver regeneration:21:0.7291	0.7291	21
ALS/PDC	ALS/PDC:12	amyotrophic lateral sclerosis/Parkinsonism-dementia complex:12:0.7571	0.7571	12
ALS-D	ALS-D:4|ALSD:1	Amyotrophic lateral sclerosis with dementia:5:0.4422	0.4422	5
ALSFRS	ALSFRS:9|ALS-FRS:4	ALS Functional Rating Scale:13:0.5934	0.5934	13
ALSPAC	ALSPAC:31	Avon Longitudinal Study of Pregnancy and Childhood:31:0.9043	0.9043	31
ALSS	ALSS:7	artificial liver support system:7:0.4438	0.4438	7
ALS	ALS:49	acetolactate synthase:49:0.7636	0.7636	49
ALS	ALS:23	acid labile subunit:23:0.8038	0.8038	23
ALS	ALS:228	advanced life support:228:0.9594	0.9594	228
ALS	ALS:10	alternating least squares:10:0.5856	0.5856	10
ALS	ALS:2625	amyotrophic lateral sclerosis:2625:0.9832	0.9832	2625
ALs	ALs:6|als:1	antennal lobes:7:0.3524	0.3524	7
ALS	ALS:47	anti-lymphocyte serum:47:0.1415	0.1415	47
ALS	ALS:8	antilymphocyte sera:8:0.2619	0.2619	8
ALS	ALS:143	antilymphocyte serum:143:0.5306	0.5306	143
ALTE	ALTE:69	apparent life-threatening event:36:0.7371|apparent life-threatening events:17:0.6024|apparent life threatening events:16:0.6577	0.7371	69
ALTEs	ALTEs:12	apparent life-threatening events:12:0.5664	0.5664	12
ALTS	ALTS:5	ASCUS-LSIL Triage Study:5:0.1211	0.1211	5
ALTS	ALTS:5	squamous intraepithelial lesion Triage Study:5:0.5926	0.5926	5
ALT	ALT:95	alanine amino transferase:67:0.8874|alanine amino-transferase:28:0.8941	0.8941	95
ALT	ALT:14	alanine aminotransaminase:14:0.7909	0.7909	14
ALT	ALT:30	alanine-aminotransferase:24:0.0064|alanine aminotransferases:6:0.1838	0.1838	30
ALT	ALT:18	alanine aminotransferase activity:18:0.8365	0.8365	18
ALT	ALT:36	alternative lengthening of telomeres:36:0.8336	0.8336	36
ALT	ALT:9	altitude:9:0.0022	0.0022	9
ALT	ALT:13	anterolateral thigh:13:0.5934	0.5934	13
ALT	ALT:112	argon laser trabeculoplasty:112:0.9432	0.9432	112
ALT	ALT:16	autolymphocyte therapy:16:0.7261	0.7261	16
ALT	ALT:8	auxiliary liver transplantation:8:0.6411	0.6411	8
ALT	ALT:573	Serum alanine aminotransferase:573:0.2211	0.2211	573
ALT	ALT:117	Serum alanine transaminase:117:0.2089	0.2089	117
ALT	ALT:14	serum alanine transferase:14:0.2081	0.2081	14
ALV-J	ALV-J:16	avian leukosis virus subgroup J:16:0.8365	0.8365	16
ALV-J	ALV-J:1	subgroup J of avian leukosis virus:1:0.7103	0.7103	1
ALVAC	ALVAC:14	canarypox virus:14:0.6173	0.6173	14
ALVAD	ALVAD:6	abdominal left ventricular assist device:6:0.5006	0.5006	6
ALVT	ALVT:12	aortico-left ventricular tunnel:12:0.4153	0.4153	12
ALVs	ALVs:16	avian leukosis viruses:16:0.8165	0.8165	16
ALV	ALV:154	avian leukosis virus:136:0.9534|avian leukosis viruses:18:0.7539	0.9534	154
ALV	ALV:13	lung ventilation:13:0.5934	0.5934	13
aly	aly:22|ALY:1	alymphoplasia:23:0.5676	0.5676	23
AL	AL:39	acute leukaemia:39:0.8811	0.8811	39
AL	AL:262	acute leukemia:237:0.9730|Acute Leukemias:25:0.8186	0.9730	262
AL	AL:15	ad lib:15:0.8045	0.8045	15
AL	AL:257|A-L:1	ad libitum:258:0.9815	0.9815	258
AL	AL:37	ad libitum fed:21:0.8594|ad libitum-fed:16:0.8165	0.8594	37
AL	AL:10	adductor longus:10:0.7103	0.7103	10
Al	Al:7|AL:4	albumin:11:0.0038	0.0038	11
Al	Al:193|AL:1	aluminium:194:0.0725	0.0725	194
Al	Al:450|AL:19	aluminum:469:0.1755	0.1755	469
AL	AL:10	amyotrophic leukospongiosis:10:0.7103	0.7103	10
AL	AL:34	annulate lamellae:34:0.8644	0.8644	34
AL	AL:46	antennal lobe:46:0.3251	0.3251	46
AL	AL:19	anterior:19:0.0068	0.0068	19
AL	AL:59	anterior lobe:59:0.4457	0.4457	59
AL	AL:20|al:2|A-L:1	anterolateral:23:0.0083	0.0083	23
AL	AL:10	argon laser:10:0.7103	0.7103	10
AL	AL:9	assisted living:9:0.6794	0.6794	9
AL	AL:9	attachment levels:9:0.3455	0.3455	9
AL	AL:6	atypical lymphocytes:6:0.1010	0.1010	6
AL	AL:48	Axial length:48:0.6121	0.6121	48
Al	Al:10	index:10:0.0034	0.0034	10
AL	AL:9	lateral:9:0.0030	0.0030	9
AL	AL:2	lateral nucleus of amygdala:2:0.5470	0.5470	2
AL	AL:9	ligament:9:0.0030	0.0030	9
AL	AL:28	light chain:28:0.8369	0.8369	28
AL	AL:12	light chain amyloidosis:12:0.6701	0.6701	12
AL	AL:11	patients with primary amyloidosis:11:0.1330	0.1330	11
AL	AL:48|Al:2	primary:50:0.0184	0.0184	50
AL	AL:43	primary systemic amyloidosis:43:0.8037	0.8037	43
AM-Gly	AM-Gly:6|AM-gly:2	glycine-extended AM:8:0.4102	0.4102	8
AM1	AM1:10	Austin Model 1:10:0.7103	0.7103	10
AM3	AM3:11	Antibiotic Medium 3:11:0.7357	0.7357	11
AMA-1	AMA-1:35|AMA1:33	apical membrane antigen 1:43:0.8893|apical membrane antigen-1:25:0.8816	0.8893	68
AMACR	AMACR:25|Amacr:2	alpha-methylacyl-CoA racemase:27:0.4190	0.4190	27
AMAD	AMAD:23	activity median aerodynamic diameter:23:0.8715	0.8715	23
AMAN	AMAN:45	acute motor axonal neuropathy:45:0.8964	0.8964	45
AMAs	AMAs:17	antimitochondrial antibodies:17:0.5760	0.5760	17
AMA	AMA:14	advanced maternal age:14:0.7909	0.7909	14
AMA	AMA:45|ama:1	against medical advice:46:0.9323	0.9323	46
AMA	AMA:14|ama:3	amantadine:17:0.0231	0.0231	17
AMA	AMA:133	American Medical Association:123:0.9612|American Medical Association's:10:0.7103	0.9612	133
AMA	AMA:10	anti-mitochondrial:10:0.0130	0.0130	10
AMA	AMA:53	anti-mitochondrial antibodies:30:0.1253|anti-mitochondrial antibody:23:0.1538	0.1538	53
AMA	AMA:9	antimitochondrial:9:0.0116	0.0116	9
AMA	AMA:134	antimitochondrial antibodies:92:0.5117|antimitochondrial antibody:42:0.3506	0.5117	134
AMA	AMA:19	Antimitochondrial autoantibodies:19:0.5404	0.5404	19
AMA	AMA:30	arm muscle area:30:0.7315	0.7315	30
AmB-d	AmB-d:5|AmBd:4|AmBD:1	amphotericin B deoxycholate:10:0.7103	0.7103	10
AMBP	AMBP:17|AmBP:2	ambulatory blood pressure:19:0.4852	0.4852	19
AmB	AmB:343|AMB:162|amB:4|Am-B:2	amphotericin B:511:0.9845	0.9845	511
Amb	Amb:10|AMB:8|amb:2	nucleus ambiguus:20:0.7173	0.7173	20
AMCA	AMCA:36	tranexamic acid:36:0.4471	0.4471	36
AMCC	AMCC:13	N-acetyl-S-(N-methylcarbamoyl)cysteine:13:0.3871	0.3871	13
AMCs	AMCs:42	academic medical centers:42:0.9308	0.9308	42
AMDC	AMDC:10	S-adenosyl-L-methionine decarboxylase:10:0.4363	0.4363	10
AMD	AMD:30	acid maltase deficiency:30:0.9011	0.9011	30
AMD	AMD:56	acid mine drainage:56:0.8901	0.8901	56
AMD	AMD:103|Amd:1|AmD:1	Actinomycin D:94:0.8914|actinomycin-D:11:0.0079	0.8914	105
AMD	AMD:818	age-related macular degeneration:818:0.8775	0.8775	818
AMD	AMD:7	age-related macular disease:7:0.4438	0.4438	7
AMD	AMD:11	amiodarone:11:0.0079	0.0079	11
AMD	AMD:13	automated multiple development:13:0.7753	0.7753	13
AMD	AMD:10	dactinomycin:10:0.0071	0.0071	10
AMEDD	AMEDD:9	Army Medical Department:9:0.6794	0.6794	9
AME	AME:12	absolute magnitude estimation:12:0.7571	0.7571	12
AME	AME:29|AmE:1	Amphotericin B methyl ester:30:0.9011	0.9011	30
AME	AME:24	apparent metabolisable energy:24:0.8768	0.8768	24
AME	AME:9	apparent metabolizable energy:9:0.6794	0.6794	9
AME	AME:55	apparent mineralocorticoid excess:55:0.9458	0.9458	55
AME	AME:6|AMe:5	medial amygdala:11:0.5355	0.5355	11
AME	AME:7|AMe:1	medial amygdaloid nucleus:8:0.6411	0.6411	8
AMFR	AMFR:9	amplitude-modulation following response:9:0.3069	0.3069	9
AMFR	AMFR:11|AMF-R:9	autocrine motility factor receptor:20:0.8525	0.8525	20
AMF	AMF:14	alternating magnetic field:14:0.4709	0.4709	14
AmF	AmF:17	amine fluoride:17:0.6577	0.6577	17
AMF	AMF:9	Angiomyofibroblastoma:9:0.0317	0.0317	9
AMF	AMF:48	Arbuscular mycorrhizal fungi:48:0.9379	0.9379	48
AMF	AMF:59	autocrine motility factor:59:0.9486	0.9486	59
AMG	AMG:10	Acoustic myography:10:0.7103	0.7103	10
AMG	AMG:10	alpha 2-Macroglobulin:10:0.7103	0.7103	10
AMG	AMG:9	alpha-methylglucoside:9:0.0259	0.0259	9
AMG	AMG:10	aminoglutethimide:10:0.0291	0.0291	10
AMG	AMG:30|amG:1|AmG:1	Aminoguanidine:32:0.1003	0.1003	32
AMG	AMG:35	amygdala:35:0.1100	0.1100	35
AMG	AMG:12	Autometallographic:12:0.0356	0.0356	12
AMG	AMG:23	autometallography:23:0.0712	0.0712	23
AMH	AMH:10	Accreditation Manual for Hospitals:10:0.7103	0.7103	10
AMH	AMH:163|Amh:9	anti-mullerian hormone:172:0.8916	0.8916	172
AMI-25	AMI-25:9	superparamagnetic iron oxide:9:0.6794	0.6794	9
AMIO	AMIO:8|Amio:2	amiodarone:10:0.8182	0.8182	10
AMIs	AMIs:14|AMIS:1	acute myocardial infarctions:15:0.8045	0.8045	15
AMIS	AMIS:10	Aspirin Myocardial Infarction Study:10:0.7103	0.7103	10
AMI	AMI:17	acute mesenteric ischemia:17:0.8270	0.8270	17
AMI	AMI:30|aMI:1|Ami:1	acute myocardial infarct:32:0.9072	0.9072	32
AMI	AMI:5305|aMI:3	acute myocardial infarction:5271:0.9718|acute myocardial infarctions:37:0.9197	0.9718	5308
AMI	AMI:14	acute myocardial ischemia:14:0.7909	0.7909	14
AMI	AMI:9|Ami:2	amifostine:11:0.0017	0.0017	11
AMI	AMI:10|Ami:4	amiodarone:14:0.0022	0.0022	14
AMI	AMI:101|Ami:5	amitriptyline:106:0.0179	0.0179	106
AMKL	AMKL:46|AMkL:4	acute megakaryoblastic leukemia:50:0.9404	0.9404	50
AMKL	AMKL:10|AMkL:1	acute megakaryocytic leukemia:11:0.4728	0.4728	11
AMK	AMK:126	amikacin:126:0.7622	0.7622	126
AMK	AMK:10	amikacin sulfate:10:0.7103	0.7103	10
AML-M2	AML-M2:10	acute myeloid leukemia:10:0.7103	0.7103	10
AML-M2	AML-M2:4	acute myeloid leukemia subtype M2:4:0.3170	0.3170	4
AML-M5	AML-M5:9	acute monocytic leukemia:9:0.6794	0.6794	9
AML1	AML1:7|AML-1:1	acute myeloid leukemia 1:8:0.6411	0.6411	8
AMLC	AMLC:11	autologous mixed lymphocyte culture:11:0.7357	0.7357	11
AMLL	AMLL:14	acute mixed lineage leukemia:14:0.7909	0.7909	14
AML-M0	AML-M0:23|AMLM0:1	minimally differentiated acute myeloid leukemia:24:0.8657	0.8657	24
AMLR	AMLR:8	auditory middle latency response:8:0.6411	0.6411	8
AMLR	AMLR:212|A-MLR:1|aMLR:1	autologous mixed lymphocyte reaction:202:0.9477|autologous mixed lymphocyte reactions:12:0.7571	0.9477	214
AMLR	AMLR:14	autologous mixed lymphocyte response:14:0.7909	0.7909	14
AMLs	AMLs:11	renal angiomyolipomas:11:0.1845	0.1845	11
AML	AML:14	acute myeloblastic:14:0.5111	0.5111	14
AML	AML:8	acute myelogenous:8:0.4102	0.4102	8
AML	AML:169	acute myelogenous leukaemia:169:0.9822	0.9822	169
AML	AML:1356	acute myelogenous leukemia:1338:0.9899|acute myelogenous leukemias:18:0.7539	0.9899	1356
AML	AML:27	acute myeloid:27:0.5729	0.5729	27
AML	AML:897	acute myeloid leukaemia:879:0.9861|acute myeloid leukaemias:18:0.8365	0.9861	897
AML	AML:3246	acute myeloid leukemia:3155:0.9932|acute myeloid leukemias:91:0.9479	0.9932	3246
AML	AML:19	acute myeloid leukemic:19:0.7658	0.7658	19
AML	AML:13	Amlodipine:13:0.0017	0.0017	13
AML	AML:11	anatomic medullary locking:11:0.4232	0.4232	11
AML	AML:26	anterior mitral leaflet:26:0.8861	0.8861	26
AML	AML:46	renal angiomyolipoma:39:0.2829|renal angiomyolipomas:7:0.1025	0.2829	46
AMML	AMML:31	acute myelomonocytic leukemia:31:0.9043	0.9043	31
AMMoL	AMMoL:30|AMMOL:4|AMMol:1	acute myelomonocytic leukemia:35:0.9151	0.9151	35
AMM	AMM:83	agnogenic myeloid metaplasia:83:0.9636	0.9636	83
AM-m	AM-m:7	mature AM:7:0.3524	0.3524	7
AMN	AMN:92	adrenomyeloneuropathy:92:0.4815	0.4815	92
amoA	amoA:12|AmoA:2	ammonia monooxygenase:14:0.7909	0.7909	14
AMOG	AMOG:14	adhesion molecule on glia:14:0.7909	0.7909	14
AMO	AMO:4|AMo:2|A-MO:2|aMO:1	alveolar macrophages:9:0.6794	0.6794	9
AMO	AMO:19|amo:2	ammonia monooxygenase:21:0.6812	0.6812	21
AMPAR	AMPAR:2|AMPAr:2|AMPA-R:1	AMPA receptors:5:0.1543	0.1543	5
AMPA	AMPA:10	2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate:10:0.0043	0.0043	10
AMPA	AMPA:11	acid hydrobromide:11:0.7357	0.7357	11
AMPA	AMPA:13	alpha-amino-3-hydroxy-5-methyl-4-isoxazole:13:0.0057	0.0057	13
AMPA	AMPA:117|ampa:1	alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate:88:0.5796|alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate:30:0.0139	0.5796	118
AMPA	AMPA:165	alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid:165:0.6262	0.6262	165
AMPA	AMPA:6	alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionate:6:0.1838	0.1838	6
AMPA	AMPA:9	alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate:9:0.0038	0.0038	9
AMPA	AMPA:22	alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate:22:0.0100	0.0100	22
AMPA	AMPA:9	L-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate:9:0.0038	0.0038	9
AmpB	AmpB:20|Amp-B:5|AMP-B:3|ampB:1	amphotericin B:29:0.8978	0.8978	29
AMPD	AMPD:25|AMP-D:5	AMP deaminase:30:0.5838	0.5838	30
AMphi	AMphi:11|A-MPhi:1|AMPhi:1|aMphi:1	alveolar macrophages:14:0.7909	0.7909	14
AMPH	AMPH:212|Amph:7|amph:2	amphetamine:221:0.5556	0.5556	221
AMPH	AMPH:28	amphotericin B:28:0.7905	0.7905	28
AMPH	AMPH:75|Amph:3|amph:2	d-amphetamine:80:0.1995	0.1995	80
AMPK	AMPK:375	AMP-activated protein kinase:375:0.7477	0.7477	375
AMP-PNP	AMP-PNP:14|AMPPNP:7	5'-adenylyl imidodiphosphate:21:0.1836	0.1836	21
AMP-PNP	AMP-PNP:43|AMPPNP:6	adenylyl imidodiphosphate:26:0.2507|adenylyl-imidodiphosphate:23:0.0789	0.2507	49
AMP-PNP	AMP-PNP:12|AMPPNP:5|AMP--PNP:1	adenylylimidodiphosphate:18:0.0609	0.0609	18
AMP-PNP	AMP-PNP:3|AMPPNP:1	ATP analogue 5'-adenylylimidodiphosphate:4:0.2113	0.2113	4
AMPS	AMPS:21|AMPs:2|aMPS:1	acid mucopolysaccharides:24:0.8115	0.8115	24
AMPs	AMPs:36	antimicrobial peptides:36:0.8716	0.8716	36
AMPS	AMPS:29	Assessment of Motor and Process Skills:29:0.8978	0.8978	29
AMPT	AMPT:75|aMPT:2|AMpT:1|aMpT:1|A-MPT:1	alpha-methyl-p-tyrosine:80:0.4817	0.4817	80
AMPT	AMPT:39	alpha-methyl-para-tyrosine:39:0.2317	0.2317	39
AMPC	AMPC:75	amoxicillin:75:0.6379	0.6379	75
AMP	AMP:9	2-amino-2-methyl-1-propanol:9:0.0063	0.0063	9
AMP	AMP:257	Adenosine 5'-monophosphate:213:0.9324|adenosine-5'-monophosphate:44:0.0339	0.9324	257
AMP	AMP:12	adenosine 5'-phosphate:12:0.5664	0.5664	12
AMP	AMP:7	allosteric activator:7:0.2113	0.2113	7
AMP	AMP:73|Amp:5	amphetamine:78:0.0607	0.0607	78
AMP	AMP:44|Amp:13|amp:2	ampicillin:59:0.0473	0.0473	59
AMP	AMP:30|Amp:8|amp:2	amplitude:40:0.0307	0.0307	40
AMP	AMP:10	antimicrobial peptide:10:0.5000	0.5000	10
AMP	AMP:10	antimicrobial prophylaxis:10:0.7103	0.7103	10
AMP	AMP:11	cyclic adenosine 3',5'-monophosphate:11:0.7357	0.7357	11
AMP	AMP:27|Amp:2	d-amphetamine:29:0.0221	0.0221	29
AMREF	AMREF:8|Amref:1	African Medical and Research Foundation:9:0.7357	0.7357	9
AMR	AMR:7|amr:2|Amr:2	amrinone:11:0.0926	0.0926	11
AMR	AMR:9	antibody-mediated rejection:9:0.6794	0.6794	9
AMSA	AMSA:17	4'-(9-acridinylamino)methanesulfon-m-anisidide:17:0.1569	0.1569	17
AMS	AMS:86	accelerator mass spectrometry:86:0.8807	0.8807	86
AMS	AMS:16	acute maxillary sinusitis:16:0.8165	0.8165	16
AMS	AMS:210	acute mountain sickness:210:0.9857	0.9857	210
AMs	AMs:15	adhesion molecules:15:0.8045	0.8045	15
AMS	AMS:7	altered mental status:7:0.3524	0.3524	7
AMs	AMs:430|AMS:4	alveolar macrophages:434:0.9852	0.9852	434
AMS	AMS:8	antimacrophage serum:8:0.1276	0.1276	8
AMS	AMS:12	atypical mole syndrome:12:0.7571	0.7571	12
AMS	AMS:6	automatic milking systems:6:0.5290	0.5290	6
AMS	AMS:12	automatic mode switching:12:0.6460	0.6460	12
AMS	AMS:20	Automicrobic System:20:0.4037	0.4037	20
AMT	AMT:16	2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine:16:0.0302	0.0302	16
AMT	AMT:31	3'-amino-3'-deoxythymidine:31:0.0604	0.0604	31
AMT	AMT:13	4'-aminomethyl-4,5',8-trimethylpsoralen:13:0.0241	0.0241	13
AMT	AMT:25	abbreviated mental test:25:0.8768	0.8768	25
AMT	AMT:9|aMT:1	active motor threshold:10:0.7103	0.7103	10
AMT	AMT:8	AEA membrane transporter:8:0.3069	0.3069	8
AMT	AMT:17	alpha-methyl-p-tyrosine:17:0.0322	0.0322	17
AMT	AMT:27|Amt:1	Amitriptyline:28:0.0543	0.0543	28
AMT	AMT:63	amniotic membrane transplantation:63:0.9253	0.9253	63
AMT	AMT:9	Autobiographical Memory Test:9:0.6794	0.6794	9
aMT	aMT:25	melatonin:25:0.0503	0.0503	25
AMVN	AMVN:18	2,2'-azobis(2,4-dimethylvaleronitrile):17:0.2909|2,2'-azobis 2,4-dimethylvaleronitrile:1:0.7103	0.7103	18
AMV	AMV:73	alfalfa mosaic virus:73:0.8961	0.8961	73
AMV	AMV:13	ammonium metavanadate:13:0.7753	0.7753	13
AMV	AMV:20	anterior medullary velum:20:0.8525	0.8525	20
AMV	AMV:17	apical membrane vesicles:17:0.7407	0.7407	17
AMV	AMV:8	assisted mechanical ventilation:8:0.4102	0.4102	8
AMV	AMV:190	avian myeloblastosis virus:190:0.9592	0.9592	190
AMX	AMX:32|Amx:4	amoxicillin:36:0.6364	0.6364	36
Amy	Amy:5|AMY:4	alpha-amylase:9:0.0537	0.0537	9
AMY	AMY:51|Amy:3|amy:1	amygdala:55:0.3624	0.3624	55
AMoL	AMoL:27|AMOL:6	acute monocytic leukemia:33:0.8605	0.8605	33
A-MuLV	A-MuLV:93|AMuLV:2	Abelson murine leukemia virus:95:0.7964	0.7964	95
AM	AM:22	acetoxymethyl:22:0.0053	0.0053	22
AM	AM:28	acetoxymethyl ester:28:0.4805	0.4805	28
AM	AM:14	acrylamide:14:0.0033	0.0033	14
AM	AM:13	actomyosin:13:0.0030	0.0030	13
AM	AM:21	adhesion molecules:21:0.7865	0.7865	21
AM	AM:25	adrenal medulla:25:0.8816	0.8816	25
AM	AM:574|Am:2	adrenomedullin:576:0.1446	0.1446	576
AM	AM:28|Am:1	adriamycin:29:0.0071	0.0071	29
AM	AM:11	alternative medicine:11:0.3829	0.3829	11
AM	AM:10	alveolar:10:0.0023	0.0023	10
AM	AM:1432|Am:1	alveolar macrophages:1179:0.9810|alveolar macrophage:254:0.9690	0.9810	1433
AM	AM:8	ambulatory monitoring:8:0.2619	0.2619	8
AM	AM:10	aminopyrine:10:0.0023	0.0023	10
AM	AM:44|Am:10	amiodarone:54:0.0134	0.0134	54
AM	AM:64	amniotic membrane:64:0.8283	0.8283	64
AM	AM:31	amphetamine:31:0.0076	0.0076	31
AM	AM:8|Am:7	ampicillin:15:0.0035	0.0035	15
AM	AM:29	amplitude modulated:29:0.8978	0.8978	29
AM	AM:83	amplitude modulation:83:0.9429	0.9429	83
AM	AM:83|Am:12|am:1	amygdala:96:0.0239	0.0239	96
AM	AM:17	amygdaloid:17:0.0040	0.0040	17
Am	Am:9|AM:3	amylase:12:0.0028	0.0028	12
AM	AM:19|Am:1|A-m:1	anteromedial:21:0.0050	0.0050	21
AM	AM:7	anteromedial nucleus:7:0.0951	0.0951	7
AM	AM:21	apparent motion:21:0.8594	0.8594	21
AM	AM:12	arbuscular mycorrhiza:12:0.7571	0.7571	12
AM	AM:165	arbuscular mycorrhizal:165:0.9710	0.9710	165
AM	AM:10	arithmetic mean:10:0.5856	0.5856	10
AM	AM:9	artemether:9:0.0020	0.0020	9
AM	AM:25	aseptic meningitis:25:0.8186	0.8186	25
AM	AM:8	aseptic meningo-encephalitis:8:0.5006	0.5006	8
AM	AM:12	aseptic meningoencephalitis:12:0.5664	0.5664	12
AM	AM:29	Astragalus membranaceus:29:0.8422	0.8422	29
AM	AM:7	Autobiographical Memory:7:0.3524	0.3524	7
AM	AM:44|am:2	morning:46:0.0116	0.0116	46
AM	AM:11	Sinusoidally amplitude-modulated:11:0.0732	0.0732	11
AN-201	AN-201:25	2-pyrrolinodoxorubicin:25:0.6316	0.6316	25
AN69	AN69:21|AN-69:4	polyacrylonitrile:25:0.5000	0.5000	25
ANAb	ANAb:6|ANab:1|AnAb:1|ANAB:1	antibodies:9:0.5333	0.5333	9
ANAE	ANAE:141	alpha-naphthyl acetate esterase:132:0.7399|alpha-naphthyl-acetate-esterase:9:0.0335	0.7399	141
ANAM	ANAM:9	Automated Neuropsychological Assessment Metrics:9:0.6794	0.6794	9
ANAPP3	ANAPP3:16	arylazido aminopropionyl ATP:16:0.8045	0.8045	16
ANAs	ANAs:74|ANAS:1	antinuclear antibodies:75:0.8988	0.8988	75
ANAs	ANAs:9	antinuclear autoantibodies:9:0.6794	0.6794	9
ANA	ANA:68	American Nurses Association:47:0.9366|American Nurses' Association:21:0.8594	0.9366	68
ANA	ANA:19	anandamide:19:0.0133	0.0133	19
ANA	ANA:20	anti-nuclear:20:0.0126	0.0126	20
ANA	ANA:101	Anti-nuclear antibodies:101:0.1133	0.1133	101
ANA	ANA:44	antinuclear:44:0.0286	0.0286	44
ANA	ANA:931	Antinuclear antibodies:605:0.8127|antinuclear antibody:326:0.7671	0.8127	931
ANA	ANA:15	antinuclear autoantibodies:15:0.5348	0.5348	15
ANA	ANA:7	aortic nerve activity:7:0.2113	0.2113	7
ANA	ANA:13	nuclear antigens:13:0.5335	0.5335	13
ANCAs	ANCAs:44	antineutrophil cytoplasmic antibodies:44:0.6404	0.6404	44
ANCAs	ANCAs:12	Antineutrophil cytoplasmic autoantibodies:12:0.6460	0.6460	12
ANCA	ANCA:15	anti-neutrophil cytoplasm autoantibodies:15:0.3821	0.3821	15
ANCA	ANCA:48	Anti-Neutrophil Cytoplasmic Antibody:48:0.2189	0.2189	48
ANCA	ANCA:9	antineutrophil cytoplasm autoantibodies:9:0.1409	0.1409	9
ANCA	ANCA:380|AN-CA:1	antineutrophil cytoplasmic antibodies:288:0.5200|antineutrophil cytoplasmic antibody:93:0.5184	0.5200	381
ANCA	ANCA:88	Antineutrophil cytoplasmic autoantibodies:73:0.5165|Antineutrophil cytoplasmic autoantibody:15:0.4052	0.5165	88
ANCA	ANCA:6	cytoplasmic auto-antibodies:6:0.2243	0.2243	6
ANCA	ANCA:9	neutrophils:9:0.0076	0.0076	9
ANCA	ANCA:27	neutrophil cytoplasmic antigens:27:0.7834	0.7834	27
ANC	ANC:385	absolute neutrophil count:332:0.9719|absolute neutrophil counts:53:0.8842	0.9719	385
ANC	ANC:18	acid neutralizing capacity:10:0.7103|acid-neutralizing capacity:8:0.0672	0.7103	18
ANC	ANC:10	Active noise control:10:0.7103	0.7103	10
ANC	ANC:46	antenatal care:46:0.8151	0.8151	46
ANC	ANC:43	antenatal clinic:34:0.7898|antenatal clinics:9:0.4102	0.7898	43
ANDA	ANDA:8	abbreviated new drug application:8:0.6794	0.6794	8
ANDAs	ANDAs:8	abbreviated new drug applications:8:0.5006	0.5006	8
ANE	ANE:8	Acute necrotizing encephalopathy:8:0.6411	0.6411	8
ANFH	ANFH:20	avascular necrosis of the femoral head:20:0.8038	0.8038	20
ANFIS	ANFIS:5	adaptive neuro-fuzzy inference system:5:0.4422	0.4422	5
ANFs	ANFs:10	Atrial natriuretic factors:10:0.7103	0.7103	10
ANFs	ANFs:17	auditory-nerve fibers:9:0.2285|auditory nerve fibers:8:0.6411	0.6411	17
ANFT	ANFT:18	2-amino-4-(5-nitro-2-furyl)thiazole:18:0.6296	0.6296	18
ANF	ANF:10	7,8-benzoflavone:10:0.0039	0.0039	10
ANF	ANF:83|aNF:1	alpha-naphthoflavone:84:0.0357	0.0357	84
ANF	ANF:2024|Anf:2|anf:1	atrial natriuretic factor:2003:0.9851|atrial natriuretic factors:24:0.8768	0.9851	2027
ANF	ANF:19	atrial natriuretic peptide:19:0.7658	0.7658	19
AngII	AngII:484|ANGII:79|Ang-II:60|ANG-II:37|angII:7	angiotensin II:620:0.9783|angiotensin-II:47:0.0664	0.9783	667
AngI	AngI:13|ANGI:6|ANG-I:3|Ang-I:2	angiotensin I:24:0.8768	0.8768	24
Ang	Ang:36|ang:2|ANG:1	angiopoietin:26:0.0253|Angiopoietins:13:0.0121	0.0253	39
Ang	Ang:527|ANG:212|ang:4	angiotensin:731:0.7374|angiotensins:12:0.0111	0.7374	743
ANG	ANG:23|Ang:16	Angiotensin II:39:0.8142	0.8142	39
ANG	ANG:2|Ang:1	expression of angiotensinogen:3:0.0889	0.0889	3
Ang	Ang:13|ANG:2	human angiogenin:15:0.1241	0.1241	15
ANH	ANH:15	Acute normovolaemic haemodilution:15:0.8045	0.8045	15
ANH	ANH:83	acute normovolemic hemodilution:83:0.8926	0.8926	83
ANH	ANH:15|AnH:2	aniline hydroxylase:17:0.8270	0.8270	17
ANH	ANH:12	artificial nutrition and hydration:12:0.5934	0.5934	12
ANH	ANH:52	atrial natriuretic hormone:52:0.9427	0.9427	52
ANIT	ANIT:23	alpha-naphthyl-isothiocyanate:14:0.0935|alpha-naphthyl isothiocyanate:9:0.5470	0.5470	23
ANIT	ANIT:97	alpha-naphthylisothiocyanate:97:0.6835	0.6835	97
ANK1	ANK1:5|Ank1:1	ankyrin gene:6:0.2243	0.2243	6
A-NK	A-NK:7|ANK:1	activated NK:8:0.1367	0.1367	8
A-NK	A-NK:5|ANK:3	IL-2-activated NK:8:0.1367	0.1367	8
A-NK	A-NK:44|ANK:1	natural killer:45:0.9338	0.9338	45
ANLL	ANLL:34	acute non-lymphoblastic leukaemia:30:0.8032|acute non-lymphoblastic leukaemias:4:0.0918	0.8032	34
ANLL	ANLL:45	acute non-lymphocytic leukaemia:45:0.8986	0.8986	45
ANLL	ANLL:125|AnLL:1	acute non-lymphocytic leukemia:126:0.9385	0.9385	126
ANLL	ANLL:483|AnLL:3	Acute nonlymphocytic leukemia:486:0.9867	0.9867	486
ANL	ANL:12	acute nonlymphocytic leukemia:12:0.7571	0.7571	12
ANMs	ANMs:10|ANMS:1	auxiliary nurse midwives:11:0.6182	0.6182	11
ANM	ANM:11	N-(1-anilinonaphthyl-4)maleimide:11:0.2000	0.2000	11
ANNA	ANNA:11	Artificial neural network analysis:11:0.7357	0.7357	11
ANNs	ANNs:231|ANNS:3	artificial neural networks:234:0.9795	0.9795	234
ANN	ANN:10	alloimmune neonatal neutropenia:10:0.5856	0.5856	10
Ann	Ann:10|ANN:1	Annamycin:11:0.0151	0.0151	11
ANN	ANN:572|aNN:2	artificial neural network:409:0.9738|artificial neural networks:165:0.9710	0.9738	574
ANN	ANN:9	auditory nerve neurophonic:9:0.6794	0.6794	9
ANN	ANN:6	axillary node-negative:6:0.2243	0.2243	6
ANPs	ANPs:25	atrial natriuretic peptides:25:0.8816	0.8816	25
ANP	ANP:67	acute necrotizing pancreatitis:67:0.9074	0.9074	67
ANP	ANP:4013	atrial natriuretic peptide:3915:0.9791|atrial natriuretic peptides:98:0.9515	0.9791	4013
ANP	ANP:175	atrial natriuretic polypeptide:175:0.9471	0.9471	175
ANP	ANP:12	atrial NP:12:0.7571	0.7571	12
ANP	ANP:11	atriopeptin:11:0.0022	0.0022	11
ANR	ANR:9	Active Noise Reduction:9:0.6794	0.6794	9
AN-R	AN-R:4	anorexia nervosa restricting type:4:0.4422	0.4422	4
ANR	ANR:10	neural ridge:10:0.7103	0.7103	10
ANSI	ANSI:46	American National Standards Institute:46:0.9353	0.9353	46
ANS	ANS:55	1-anilino-8-naphthalene sulfonate:55:0.3625	0.3625	55
ANS	ANS:12	1-anilino-8-naphthalene sulphonate:12:0.1991	0.1991	12
ANS	ANS:35	1-anilino-8-naphthalenesulfonate:35:0.0277	0.0277	35
ANS	ANS:9	1-anilino-naphthalene-8-sulfonate:9:0.0065	0.0065	9
ANS	ANS:32	1-anilinonaphthalene-8-sulfonic acid:32:0.1022	0.1022	32
ANS	ANS:9	1-anilinonaphthalene-8-sulphonate:9:0.0065	0.0065	9
ANS	ANS:31	8-anilino-1-naphthalene sulfonate:31:0.1725	0.1725	31
ANS	ANS:17	8-anilino-1-naphthalene sulfonic acid:17:0.2609	0.2609	17
ANS	ANS:7	8-anilino-1-naphthalene sulphonate:7:0.0565	0.0565	7
ANS	ANS:46|Ans:4	8-anilino-1-naphthalenesulfonate:50:0.0399	0.0399	50
ANS	ANS:38	8-anilino-1-naphthalenesulfonic acid:38:0.1281	0.1281	38
ANS	ANS:24	8-anilinonaphthalene-1-sulfonate:24:0.0187	0.0187	24
ANs	ANs:10	acoustic neuromas:10:0.5856	0.5856	10
ANS	ANS:8|Ans:1	anterior nasal spine:9:0.6794	0.6794	9
ANS	ANS:11	Anthocyanidin synthase:11:0.6182	0.6182	11
ANS	ANS:19	antineutrophil serum:19:0.3721	0.3721	19
ANS	ANS:386	autonomic nervous system:386:0.9376	0.9376	386
ANS	ANS:6|Ans:1	probe 1-anilinonaphthalene-8-sulfonate:7:0.0566	0.0566	7
ANT1	ANT1:8|Ant1:3|ANT-1:1	adenine nucleotide translocator:12:0.7571	0.7571	12
ANT1	ANT1:5|Ant1:1	adenine nucleotide translocator 1:6:0.5290	0.5290	6
ANTU	ANTU:48	alpha-naphthylthiourea:48:0.7231	0.7231	48
ANT	ANT:53|Ant:3	adenine nucleotide translocase:56:0.8901	0.8901	56
ANT	ANT:85	adenine nucleotide translocator:85:0.9442	0.9442	85
ANT	ANT:12|ant:2	AINTEGUMENTA:14:0.0329	0.0329	14
ANT	ANT:10	Alcohol-sensitive:10:0.0228	0.0228	10
AnT	AnT:8|ANT:1|Ant:1	anaerobic threshold:10:0.5856	0.5856	10
ANT	ANT:12|Ant:4|ant:1	anterior:17:0.0405	0.0405	17
ANT	ANT:13|Ant:5	anthracene:18:0.0430	0.0430	18
ANT	ANT:7	Attention Network Test:7:0.4438	0.4438	7
ANT	ANT:3|Ant:2	GnRH antagonist:5:0.1641	0.1641	5
ANT	ANT:10	neurofibrillary tangles:10:0.7103	0.7103	10
ANUG	ANUG:20	acute necrotizing ulcerative gingivitis:20:0.8525	0.8525	20
ANV	ANV:17	anticipatory nausea and vomiting:17:0.7539	0.7539	17
ANV	ANV:14	avian nephritis virus:14:0.7909	0.7909	14
anx	anx:9	anorexia:9:0.1778	0.1778	9
ANoA	ANoA:14	antinucleolar antibodies:14:0.5589	0.5589	14
AN	AN:52	acanthosis nigricans:52:0.8821	0.8821	52
AN	AN:5	acceptor number:5:0.0612	0.0612	5
AN	AN:6	accessory nuclei:6:0.1320	0.1320	6
AN	AN:18	Acetonitrile:18:0.0089	0.0089	18
AN	AN:61	acoustic neuroma:49:0.9046|acoustic neuromas:12:0.7571	0.9046	61
AN	AN:70	acrylonitrile:70:0.0363	0.0363	70
AN	AN:24	Adenine nucleotide:15:0.8045|adenine nucleotides:9:0.6794	0.8045	24
AN	AN:25	Alae nasi:25:0.8816	0.8816	25
AN	AN:9	amikacin:9:0.0042	0.0042	9
AN	AN:16	Analgesic nephropathy:16:0.4040	0.4040	16
AN	AN:14|an:1	aneuploid:15:0.0079	0.0079	15
an	an:6|AN:5	aneurysm:11:0.0053	0.0053	11
AN	AN:13	aniline:13:0.0063	0.0063	13
AN	AN:764	Anorexia nervosa:764:0.9961	0.9961	764
AN	AN:10	anticipatory nausea:10:0.7103	0.7103	10
AN	AN:54	arcuate nucleus:54:0.6216	0.6216	54
AN	AN:10|an:2	area of necrosis:12:0.1991	0.1991	12
AN	AN:10	areca nut:10:0.7103	0.7103	10
AN	AN:11	artificial nutrition:11:0.7357	0.7357	11
AN	AN:7	aseptic necrosis:7:0.0565	0.0565	7
AN	AN:61	auditory nerve:39:0.5418|auditory-nerve:22:0.0110	0.5418	61
AN	AN:18	Auditory neuropathy:18:0.1026	0.1026	18
AN	AN:74	autonomic neuropathy:74:0.6997	0.6997	74
AN	AN:7	Avascular necrosis:7:0.0565	0.0565	7
AN	AN:5	stimulation of the aortic nerve:5:0.2619	0.2619	5
AO7	AO7:15	acid orange 7:15:0.7096	0.7096	15
AOAA	AOAA:151	aminooxyacetic acid:151:0.7048	0.7048	151
AOAC	AOAC:23	Association of Official Analytical Chemists:23:0.7500	0.7500	23
AOAH	AOAH:12	Acyloxyacyl hydrolase:12:0.7571	0.7571	12
AoA	AoA:18|AOA:1	age of acquisition:19:0.7658	0.7658	19
AOA	AOA:14	Alpha Omega Alpha:14:0.7909	0.7909	14
AOA	AOA:7	American Optometric Association:7:0.5926	0.5926	7
AOA	AOA:12	American Osteopathic Association:12:0.7571	0.7571	12
AOA	AOA:9	Aminooxyacetate:9:0.0308	0.0308	9
AOA	AOA:14	aminooxyacetic acid:14:0.2010	0.2010	14
AOA	AOA:48	antioxidant activity:48:0.4512	0.4512	48
AOA	AOA:26	antioxidative activity:26:0.1978	0.1978	26
AOB	AOB:135	accessory olfactory bulb:135:0.9647	0.9647	135
AOB	AOB:52	ammonia-oxidizing bacteria:52:0.6963	0.6963	52
AOB	AOB:11	anterior open bite:11:0.7357	0.7357	11
AOC	AOC:12	advanced ovarian cancer:12:0.5664	0.5664	12
AOC	AOC:11	antioxidant capacity:11:0.3829	0.3829	11
AOC	AOC:27	assimilable organic carbon:27:0.8903	0.8903	27
AOD	AOD:19	accumulated oxygen deficit:19:0.8449	0.8449	19
AOD	AOD:66	alcohol and other drug:66:0.9344	0.9344	66
AOD	AOD:13	alcohol oxidase:13:0.6701	0.6701	13
AOD	AOD:13	antioxidant defense:13:0.4102	0.4102	13
AOD	AOD:5	antioxidative defense:5:0.0611	0.0611	5
AOD	AOD:10	atlanto-occipital dislocation:10:0.4363	0.4363	10
AOD	AOD:55	occlusive disease:55:0.5789	0.5789	55
AOEs	AOEs:21	antioxidant enzymes:21:0.7291	0.7291	21
AOE	AOE:52	antioxidant enzyme:30:0.8472|antioxidant enzymes:22:0.7400	0.8472	52
AOFAS	AOFAS:36	American Orthopaedic Foot and Ankle Society:36:0.8716	0.8716	36
AOH	AOH:26	alternariol:26:0.5319	0.5319	26
AOM	AOM:512	acute otitis media:512:0.9664	0.9664	512
AOM	AOM:12	angular overlap model:12:0.7571	0.7571	12
AOM	AOM:13	colon carcinogen azoxymethane:13:0.1687	0.1687	13
AOM	AOM:7	number and histology of colon tumors induced by azoxymethane:7:0.4438	0.4438	7
AONE	AONE:11	American Organization of Nurse Executives:11:0.7357	0.7357	11
AON	AON:5	accessory optic nuclei:5:0.4422	0.4422	5
AON	AON:28	anterior olfactory nucleus:28:0.8941	0.8941	28
AON	AON:9	aseptic osteonecrosis:9:0.3945	0.3945	9
AOPCP	AOPCP:8	adenosine 5'-diphosphate:8:0.2619	0.2619	8
AOPP	AOPP:41	advanced oxidation protein products:41:0.9274	0.9274	41
AOPs	AOPs:31|AOPS:1	Advanced Oxidation Processes:32:0.9072	0.9072	32
AOP	AOP:16	advanced oxidation process:16:0.8165	0.8165	16
AOP	AOP:7	anemia of prematurity:7:0.0951	0.0951	7
AOP	AOP:19	antioxidant potential:19:0.5732	0.5732	19
AoP	AoP:57|AOP:12|Aop:1	aortic pressure:70:0.7379	0.7379	70
AOP	AOP:10|AoP:1	apnea of prematurity:11:0.2764	0.2764	11
AORs	AORs:21|aORs:2	adjusted odds ratios:23:0.7500	0.7500	23
AOR	AOR:8	aldehyde ferredoxin oxidoreductase:8:0.6411	0.6411	8
AOSC	AOSC:8	acute obstructive suppurative cholangitis:8:0.6794	0.6794	8
AOSD	AOSD:93	adult onset Still's disease:55:0.9477|adult-onset Still's disease:38:0.2861	0.9477	93
AoSMC	AOSMC:4|AoSMC:4	human aortic smooth muscle cells:8:0.5006	0.5006	8
AOS	AOS:56	accessory optic system:56:0.9467	0.9467	56
AOS	AOS:65|aos:1	active oxygen species:66:0.7615	0.7615	66
AOS	AOS:9	Adams-Oliver syndrome:9:0.3945	0.3945	9
AOS	AOS:28	allene oxide synthase:28:0.8941	0.8941	28
AOS	AOS:14	apraxia of speech:14:0.7909	0.7909	14
AOTF	AOTF:13	Acousto-optic tunable filter:13:0.6701	0.6701	13
AOT	AOT:30	adenomatoid odontogenic tumor:17:0.8270|adenomatoid odontogenic tumour:13:0.7753	0.8270	30
AOT	AOT:13	Aerosol-OT:13:0.0563	0.0563	13
AOT	AOT:17	sodium bis(2-ethylhexyl)sulfosuccinate:17:0.6903	0.6903	17
AOT	AOT:38	sulfosuccinate:38:0.1690	0.1690	38
AOVMs	AOVMs:13	angiographically occult vascular malformations:13:0.7753	0.7753	13
AOX	AOX:10	Adsorbable organic halogens:10:0.7103	0.7103	10
AOX	AOX:74|Aox:4|aox:1	alternative oxidase:79:0.3976	0.3976	79
AOZ	AOZ:14	3-amino-2-oxazolidinone:14:0.7222	0.7222	14
AO	AO:330	acridine orange:330:0.9597	0.9597	330
AO	AO:10	Active oxygen:10:0.2873	0.2873	10
AO	AO:11	adaptive optics:11:0.7357	0.7357	11
AO	AO:9	adult-onset:9:0.0067	0.0067	9
AO	AO:8	adverse outcome:8:0.5006	0.5006	8
AO	AO:11	age of onset:11:0.6537	0.6537	11
AO	AO:12	Airway obstruction:12:0.3275	0.3275	12
AO	AO:10	Albino Oxford:10:0.7103	0.7103	10
AO	AO:25	alcohol oxidase:25:0.1673	0.1673	25
AO	AO:41|Ao:3	aldehyde oxidase:44:0.3590	0.3590	44
Ao	Ao:30|AO:1	angiotensinogen:31:0.0253	0.0253	31
AO	AO:34	antioxidants:17:0.0135|antioxidant:17:0.0135	0.0135	34
AO	AO:10	antisense oligonucleotide:10:0.7103	0.7103	10
Ao	Ao:25|AO:14	aortic:39:0.0320	0.0320	39
AO	AO:7	aortic output:7:0.1470	0.1470	7
Ao	Ao:15|AO:5	aortic root:20:0.8525	0.8525	20
Ao	Ao:11|AO:1	apoptosis:12:0.0093	0.0093	12
AO	AO:6	aqueous oxygen:6:0.0731	0.0731	6
AO	AO:10	Arbeitsgemeinschaft fur Osteosynthesefragen:10:0.5856	0.5856	10
AO	AO:8	arterial occlusion:8:0.2327	0.2327	8
Ao	Ao:10|AO:5	ascending aorta:15:0.0782	0.0782	15
AP/NTS	AP/NTS:7	area postrema/nucleus of the solitary tract:7:0.5926	0.5926	7
AP-1	AP-1:3	activated by the Fos/Jun heterodimeric complex:3:0.5290	0.5290	3
AP-1	AP-1:8	activating protein:8:0.0532	0.0532	8
AP-1	AP-1:138|AP1:3	activating protein-1:141:0.1115	0.1115	141
AP-1	AP-1:22|AP1:5	activator protein:27:0.4837	0.4837	27
AP-1	AP-1:1109|AP1:84|Ap-1:1	activator protein-1:850:0.7780|activator protein 1:344:0.7467	0.7780	1194
AP3	AP3:11|AP-3:1	2-Amino-3-phosphonopropionate:12:0.0846	0.0846	12
AP3	AP3:11|AP-3:3	2-amino-3-phosphonopropionic acid:14:0.3202	0.3202	14
AP3	AP3:42	APETALA3:42:0.3154	0.3154	42
AP-3	AP-3:4|AP3:3	protein 3:7:0.2902	0.2902	7
AP4	AP4:13|AP-4:2	2-amino-4-phosphonobutyric acid:15:0.2522	0.2522	15
AP5	AP5:4|AP-5:1	antagonist D-2-amino-5-phosphonovalerate:5:0.0899	0.0899	5
AP5	AP5:4|AP-5:2	NMDA receptor antagonist 2-amino-5-phosphonovalerate:6:0.7103	0.7103	6
AP5	AP5:2	NMDA receptor antagonist D-2-amino-5-phosphonopentanoate:2:0.4422	0.4422	2
APACHE	APACHE:332|Apache:1	Acute Physiology and Chronic Health Evaluation:333:0.9910	0.9910	333
APAC	APAC:10	acute primary angle closure:10:0.5856	0.5856	10
APAIS	APAIS:9	Amsterdam Preoperative Anxiety and Information Scale:9:0.6794	0.6794	9
APAP	APAP:315	acetaminophen:315:0.8626	0.8626	315
APAP	APAP:9	positive airway pressure:9:0.6794	0.6794	9
APAs	APAs:11	aldosterone-producing adenomas:11:0.7357	0.7357	11
APAs	APAs:30	anticipatory postural adjustments:30:0.8472	0.8472	30
APAs	APAs:27|aPAs:5	antiphospholipid antibodies:32:0.6900	0.6900	32
APAS	APAS:15|APAs:1	antiphospholipid antibody syndrome:16:0.8165	0.8165	16
APA	APA:9	abrus precatorius agglutinin:9:0.5470	0.5470	9
APA	APA:73	action potential amplitude:73:0.9591	0.9591	73
APA	APA:133	aldosterone-producing adenoma:92:0.6607|aldosterone-producing adenomas:23:0.8715|aldosterone producing adenoma:18:0.8365	0.8715	133
APA	APA:18|A-P-A:2	alginate-poly-L-lysine-alginate:11:0.0113|alginate/poly-L-lysine/alginate:9:0.0090	0.0113	20
APA	APA:11	alkaline phosphatase activity:11:0.6182	0.6182	11
APA	APA:32	American Psychiatric Association:32:0.9072	0.9072	32
APA	APA:33	American Psychological Association:33:0.9100	0.9100	33
APA	APA:13	amplitude of action potential:13:0.6173	0.6173	13
AP-A	AP-A:18|Ap-A:2|ApA:1	anthopleurin-A:21:0.0226	0.0226	21
APA	APA:30	Anticipatory postural adjustments:21:0.8594|anticipatory postural adjustment:9:0.6794	0.8594	30
APA	APA:125|aPA:17|ApA:1	antiphospholipid antibodies:126:0.6814|antiphospholipid antibody:17:0.3512	0.6814	143
APA	APA:13	AP amplitude:13:0.0656	0.0656	13
APA	APA:10	atypical polypoid adenomyoma:10:0.7103	0.7103	10
APBD	APBD:12	adult polyglucosan body disease:12:0.7571	0.7571	12
APBDJ	APBDJ:9|AP-BDJ:1	Anomalous pancreaticobiliary ductal junction:10:0.7103	0.7103	10
APBI	APBI:13	accelerated partial breast irradiation:13:0.7909	0.7909	13
APBSCT	APBSCT:42|aPBSCT:6|APB-SCT:1	autologous peripheral blood stem cell transplantation:49:0.9046	0.9046	49
APBs	APBs:13	atrial premature beats:13:0.7753	0.7753	13
APB	APB:67	2-amino-4-phosphonobutyrate:67:0.1432	0.1432	67
APB	APB:61	2-amino-4-phosphonobutyric acid:61:0.5262	0.5262	61
APB	APB:130	abductor pollicis brevis:130:0.9770	0.9770	130
APB	APB:21	abductor pollicis brevis muscle:21:0.8594	0.8594	21
APB	APB:25|aPB:1	adult peripheral blood:26:0.8861	0.8861	26
AP-B	AP-B:6|APB:4|Ap-B:4	aminopeptidase B:14:0.2421	0.2421	14
ApB	ApB:11	anthopleurin B:11:0.1547	0.1547	11
APC/C	APC/C:11	anaphase-promoting complex:11:0.4728	0.4728	11
APC/C	APC/C:62	anaphase-promoting complex/cyclosome:46:0.6125|anaphase promoting complex/cyclosome:16:0.8165	0.8165	62
APC/C	APC/C:19	anaphase-promoting complex or cyclosome:19:0.7658	0.7658	19
APCA	APCA:16	antibodies:16:0.4054	0.4054	16
APCC	APCC:5|aPCC:4	activated prothrombin complex concentrate:9:0.6794	0.6794	9
APCDs	APCDs:11	air pollution control devices:11:0.7357	0.7357	11
APCI-MS	APCI-MS:11	atmospheric pressure chemical ionization-mass spectrometry:11:0.7357	0.7357	11
APCI	APCI:40	atmospheric pressure chemical ionisation:40:0.8839	0.8839	40
APCs	APCs:15	aerobic plate counts:15:0.6386	0.6386	15
APCs	APCs:10	alkylphosphocholines:10:0.0089	0.0089	10
APCs	APCs:896	antigen-presenting cells:683:0.7059|antigen presenting cells:213:0.9566	0.9566	896
APC-SR	APC-SR:8|APC-sr:2|aPC-SR:1|APCsr:1	APC sensitivity ratio:12:0.4557	0.4557	12
APC	APC:19|aPC:2	activated PC:21:0.6812	0.6812	21
APC	APC:725|aPC:22	activated protein C:747:0.9576	0.9576	747
APC	APC:7|Apc:1	adenomatous polyposis:8:0.5470	0.5470	8
APC	APC:765|Apc:38|apc:3	adenomatous polyposis coli:806:0.9785	0.9785	806
APC	APC:21|Apc:5	adenomatous polyposis coli gene:26:0.8251	0.8251	26
APC	APC:9	adenomatous polyposis coli gene product:9:0.6794	0.6794	9
APC	APC:20	adenomatous polyposis coli protein:20:0.7658	0.7658	20
APC	APC:55	aerobic plate count:34:0.9126|aerobic plate counts:21:0.7865	0.9126	55
APC	APC:20|apc:1	age-period-cohort:21:0.0044	0.0044	21
APC	APC:12	air pollution control:12:0.6460	0.6460	12
APC	APC:16	alkylphosphocholines:16:0.0033	0.0033	16
APC	APC:35|apc:1	allophycocyanin:36:0.0076	0.0076	36
APC	APC:17	alternative pathway of complement:17:0.7539	0.7539	17
APC	APC:170	anaphase-promoting complex:144:0.7249|anaphase promoting complex:26:0.7340	0.7340	170
APC	APC:13	anaphase-promoting complex/cyclosome:13:0.6701	0.6701	13
APC	APC:17	anesthetic preconditioning:17:0.3844	0.3844	17
APC	APC:21|aPC:4	anterior piriform cortex:25:0.8816	0.8816	25
APC	APC:1835|apc:2	antigen-presenting cells:1115:0.6815|antigen presenting cells:392:0.9627|antigen-presenting cell:251:0.6307|antigen presenting cell:79:0.8443	0.9627	1837
APC	APC:39|Apc:5|apc:1	aphidicolin:45:0.0096	0.0096	45
APC	APC:9	aqueous protein concentration:9:0.6794	0.6794	9
APC	APC:111	argon plasma coagulation:111:0.9723	0.9723	111
APD(90)	APD(90):10	action potential duration at 90% repolarization:10:0.7357	0.7357	10
APD50	APD50:11	action potential duration:11:0.7357	0.7357	11
APD50	APD50:11	action potential duration at 50%:11:0.7571	0.7571	11
APD90	APD90:29	action potential duration:29:0.8422	0.8422	29
APD90	APD90:7	action potential duration at 90% of repolarization:7:0.9404	0.9404	7
APD90	APD90:4	action potential duration at 90% repolarisation:4:0.4422	0.4422	4
APDs	APDs:22	action potential durations:22:0.8657	0.8657	22
APDs	APDs:56	antipsychotic drugs:56:0.8667	0.8667	56
APDs	APDs:10	atrial premature depolarizations:10:0.7103	0.7103	10
APD	APD:15	(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate:15:0.0090	0.0090	15
APD	APD:24	action potential:24:0.8768	0.8768	24
APD	APD:796|ApD:1	action potential duration:777:0.9917|action potential durations:20:0.8525	0.9917	797
APD	APD:9	aminohydroxypropylidene bisphosphonate:9:0.1690	0.1690	9
APD	APD:9	aminohydroxypropylidene diphosphonate:9:0.3455	0.3455	9
APD	APD:14	aminopyrine N-demethylase:14:0.6911	0.6911	14
APD	APD:6	anteroposterior diameter:6:0.0731	0.0731	6
APD	APD:25	antipsychotic drug:13:0.6701|antipsychotic drugs:12:0.4153	0.6701	25
APD	APD:64	antisocial personality disorder:64:0.6371	0.6371	64
APD	APD:7	Auditory processing disorders:7:0.5926	0.5926	7
APD	APD:22	automated PD:22:0.6934	0.6934	22
APD	APD:122	automated peritoneal dialysis:122:0.9151	0.9151	122
APD	APD:22	avoidant personality disorder:22:0.1515	0.1515	22
APD	APD:11	Disodium pamidronate:11:0.0732	0.0732	11
APE1	APE1:7|Ape1:2	endonuclease 1:9:0.4587	0.4587	9
APEC	APEC:32	avian pathogenic Escherichia coli:32:0.9072	0.9072	32
APECED	APECED:49	autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy:49:0.9379	0.9379	49
APE	APE:8	Abdominoperineal excision:8:0.4102	0.4102	8
APE	APE:10	acute pulmonary edema:10:0.5856	0.5856	10
APE	APE:29	acute pulmonary embolism:29:0.7970	0.7970	29
aPE	aPE:10|APE:2	antiphosphatidylethanolamine antibodies:12:0.5050	0.5050	12
APE	APE:11	AP endonuclease:11:0.1882	0.1882	11
APE	APE:13|Ape:2	apurinic/apyrimidinic endonuclease:15:0.2119	0.2119	15
APE	APE:17	arecaidine propargyl ester:17:0.8270	0.8270	17
APE	APE:4	Atom Percent Excess:4:0.0918	0.0918	4
APFO	APFO:11	Ammonium perfluorooctanoate:11:0.7357	0.7357	11
APFT	APFT:12	Army Physical Fitness Test:12:0.7357	0.7357	12
APF	APF:66	acidulated phosphate fluoride:66:0.8858	0.8858	66
APF	APF:6	anionic polypeptide fraction:6:0.5290	0.5290	6
APF	APF:54	antiperinuclear factor:54:0.5046	0.5046	54
APGN	APGN:11	glomerulonephritis:11:0.9091	0.9091	11
APG	APG:28	Air plethysmography:28:0.6839	0.6839	28
APG	APG:13	anterior pituitary gland:13:0.7753	0.7753	13
APHAB	APHAB:15	Abbreviated Profile of Hearing Aid Benefit:15:0.8045	0.8045	15
APHA	APHA:19	American Public Health Association:19:0.8449	0.8449	19
APIII	APIII:12|AP-III:3	atriopeptin III:15:0.5348	0.5348	15
API-MS	API-MS:6	atmospheric pressure ionization mass spectrometry:6:0.5290	0.5290	6
APIs	APIs:13	active pharmaceutical ingredients:13:0.7753	0.7753	13
APIs	APIs:7	Pacific Islanders:7:0.2452	0.2452	7
API	API:12	Achromobacter protease I:12:0.6460	0.6460	12
API	API:36	active pharmaceutical ingredient:36:0.9174	0.9174	36
API	API:13	Acute Panic Inventory:13:0.7753	0.7753	13
API	API:10|Api:2	alpha-1-proteinase inhibitor:12:0.1299	0.1299	12
API	API:20	aminopeptidase I:20:0.3614	0.3614	20
API	API:13	Ankle Pressure Index:13:0.2802	0.2802	13
API	API:13	Annual Parasite Incidence:13:0.6701	0.6701	13
API	API:11	approximal plaque index:11:0.5355	0.5355	11
API	API:13	Asian/Pacific Islander:11:0.1486|Asian Pacific Islander:2:0.8525	0.8525	13
API	API:35	Atmospheric pressure ionization:35:0.7952	0.7952	35
API	API:6	Pacific Islanders:6:0.2243	0.2243	6
APKD	APKD:42	adult polycystic kidney disease:42:0.7311	0.7311	42
A-PK	A-PK:12|A-pk:1|APK:1	cyclic AMP-dependent protein kinase:14:0.7909	0.7909	14
APLA	APLA:42|aPLA:8|APLa:1	antiphospholipid antibodies:51:0.7715	0.7715	51
APLD	APLD:10	Adult polycystic liver disease:10:0.7103	0.7103	10
APLD	APLD:17	automated percutaneous lumbar discectomy:17:0.8270	0.8270	17
APLP2	APLP2:24	Amyloid precursor-like protein 2:24:0.8115	0.8115	24
APLs	APLs:9	Acute promyelocytic leukemias:9:0.6794	0.6794	9
APLS	APLS:6	advanced pediatric life support:6:0.5290	0.5290	6
APLs	APLs:30	altered peptide ligands:30:0.8472	0.8472	30
aPLs	aPLs:38|APLs:5	antiphospholipid antibodies:43:0.7839	0.7839	43
APLS	APLS:35|aPLS:4	antiphospholipid syndrome:39:0.6077	0.6077	39
APL	APL:24	abductor pollicis longus:24:0.8768	0.8768	24
APL	APL:8	Accreditation of Prior Learning:8:0.5006	0.5006	8
APL	APL:173	acute promyelocytic leukaemia:173:0.9827	0.9827	173
APL	APL:1304	acute promyelocytic leukemia:1295:0.9905|acute promyelocytic leukemias:9:0.6794	0.9905	1304
APL	APL:56	altered peptide ligands:32:0.8563|altered peptide ligand:24:0.8768	0.8768	56
aPL	aPL:12	Anti-phospholipid:12:0.0047	0.0047	12
APL	APL:4|aPL:3	antibodies to phospholipids:7:0.1641	0.1641	7
aPL	aPL:95|APL:13	antiphospholipid:108:0.0467	0.0467	108
aPL	aPL:415|APL:22|a-PL:1|aPl:1	Antiphospholipid antibodies:392:0.8961|antiphospholipid antibody:47:0.7749	0.8961	439
APL	APL:10	Atrichia with papular lesions:10:0.7103	0.7103	10
APML	APML:11	acute promyelocytic leukemia:11:0.7357	0.7357	11
APMPPE	APMPPE:37	acute posterior multifocal placoid pigment epitheliopathy:37:0.9197	0.9197	37
ApMV	ApMV:7	apple mosaic virus:7:0.5926	0.5926	7
APM	APM:17	affected-pedigree-member:17:0.0571	0.0571	17
APM	APM:29|AP-M:6	Aminopeptidase M:35:0.7647	0.7647	35
APM	APM:9	antigen processing machinery:9:0.6794	0.6794	9
APM	APM:11|apm:1	apical plasma membrane:12:0.6460	0.6460	12
APM	APM:24	aspartame:24:0.0821	0.0821	24
APM	APM:2	MHC class I antigen-processing machinery:2:0.2818	0.2818	2
APM	APM:19	particulate matter:19:0.8449	0.8449	19
APND	APND:18	aminopyrine N-demethylase:18:0.8365	0.8365	18
APN	APN:44	acute pyelonephritis:44:0.9323	0.9323	44
ApN	ApN:9|APN:1	Adiponectin:10:0.0264	0.0264	10
APN	APN:67	advanced practice nurse:67:0.9296	0.9296	67
APN	APN:124|ApN:9|AP-N:8	aminopeptidase N:131:0.8768|aminopeptidase-N:10:0.0264	0.8768	141
APO-SUS	APO-SUS:13|apo-sus:3	apomorphine-susceptible:16:0.5556	0.5556	16
apoA-1	apoA-1:17|Apo-A1:2|ApoA-1:2|apoA1:1|ApoA1:1	apolipoprotein A-1:23:0.8038	0.8038	23
apoA1	apoA1:23|ApoA1:18|Apo-A1:12|apo-A1:8|APOA1:4|APO-A1:2|apoA-1:1	apolipoprotein A1:58:0.6614|apolipoprotein-A1:10:0.0709	0.6614	68
apoE-KO	apoE-KO:12|apoEKO:2|ApoE-KO:2	apolipoprotein E-knockout:10:0.7103|Apolipoprotein E knockout:6:0.5290	0.7103	16
ApoH	ApoH:9|apoH:7|APOH:3|apo-H:1	apolipoprotein H:20:0.8449	0.8449	20
APOLT	APOLT:28	Auxiliary partial orthotopic liver transplantation:28:0.8369	0.8369	28
apoM	apoM:13	apolipoprotein M:13:0.7753	0.7753	13
apo	apo:9|Apo:1	anti-apolipoprotein:10:0.0027	0.0027	10
apo	apo:1945|Apo:424|APO:42	Apolipoprotein:2411:0.7266	0.7266	2411
Apo	Apo:7|APO:1	apomorphine HCl:8:0.5006	0.5006	8
apo	apo:114|Apo:19|APO:4	apoprotein:106:0.0317|apoproteins:31:0.0091	0.0317	137
APO	APO:4	DA receptor agonist apomorphine:4:0.3867	0.3867	4
AP-PCR	AP-PCR:78|APPCR:1	arbitrarily primed PCR:79:0.9401	0.9401	79
AP-PCR	AP-PCR:105	arbitrarily primed polymerase chain reaction:105:0.8908	0.8908	105
APPI	APPI:24	atmospheric pressure photoionization:24:0.8115	0.8115	24
APPs	APPs:53	acute phase proteins:37:0.9197|acute-phase proteins:16:0.1061	0.9197	53
APPs	APPs:7|APP-S:1	amyloid precursor protein:8:0.6411	0.6411	8
APPs	APPs:8|APP-S:1	derivatives:9:0.0597	0.0597	9
APPswe	APPswe:9	amyloid precursor protein:9:0.6794	0.6794	9
APP	APP:13|App:9	Actinobacillus pleuropneumoniae:22:0.7400	0.7400	22
APP	APP:92	acute phase proteins:61:0.9511|acute-phase proteins:31:0.1543	0.9511	92
APP	APP:17|AP-P:3	aminopeptidase P:20:0.6259	0.6259	20
APP	APP:50	amyloid beta-protein precursor:50:0.9064	0.9064	50
APP	APP:1580|App:1	amyloid precursor protein:1559:0.7423|amyloid precursor proteins:22:0.4510	0.7423	1581
APP	APP:97	amyloid protein precursor:97:0.4824	0.4824	97
APP	APP:46|aPP:7	avian pancreatic polypeptide:53:0.8166	0.8166	53
APP	APP:369	beta-amyloid precursor protein:359:0.1594|beta-amyloid precursor proteins:10:0.1134	0.1594	369
APP	APP:18	precursor protein gene:18:0.8365	0.8365	18
APQ	APQ:7	amplitude perturbation quotient:7:0.6411	0.6411	7
APQ	APQ:14	Questionnaire:14:0.4062	0.4062	14
APRF	APRF:11	response factor:11:0.6182	0.6182	11
APRPs	APRPs:5|aPRPs:1	acidic proline-rich proteins:6:0.5290	0.5290	6
APRP	APRP:7	acute phase reactant proteins:7:0.5926	0.5926	7
APRT	APRT:32|aprt:10|Aprt:1	adenine phosphoribosyl transferase:43:0.8300	0.8300	43
APRT	APRT:183|aprt:44|Aprt:8|A-PRT:1	adenine phosphoribosyltransferase:236:0.9495	0.9495	236
APRT	APRT:4|aprt:1	adenine phosphoribosyltransferase gene:5:0.4422	0.4422	5
APRV	APRV:37	airway pressure release ventilation:37:0.9197	0.9197	37
APRs	APRs:11	acute phase reactants:11:0.7357	0.7357	11
APS1	APS1:11|APS-1:8	autoimmune polyglandular syndrome type 1:19:0.8449	0.8449	19
APSAC	APSAC:78|AP-SAC:1	anisoylated plasminogen streptokinase activator complex:79:0.8888	0.8888	79
APSCT	APSCT:6	autologous peripheral stem cell transplantation:6:0.5290	0.5290	6
APSGN	APSGN:22	Acute post-streptococcal glomerulonephritis:22:0.7955	0.7955	22
APSGN	APSGN:55	acute poststreptococcal glomerulonephritis:55:0.8882	0.8882	55
APS	APS:10	5'-adenylylsulfate:10:0.0041	0.0041	10
APs	APs:52|Aps:2|APS:1	accessory pathways:55:0.9458	0.9458	55
APs	APs:369|aps:1|Aps:1|APS:1	action potentials:372:0.9712	0.9712	372
APS	APS:5	activated sulfate:5:0.1132	0.1132	5
APS	APS:43	acute pain service:35:0.8681|acute pain services:8:0.6411	0.8681	43
APS	APS:40	Acute Physiology Score:40:0.9256	0.9256	40
APS	APS:5	Addiction Potential Scale:5:0.4422	0.4422	5
APS	APS:71	adenosine 5'-phosphosulfate:52:0.7753|Adenosine-5'-phosphosulfate:19:0.0082	0.7753	71
APS	APS:5	Adult Protective Services:5:0.4422	0.4422	5
APS	APS:13	aerodynamic particle sizer:13:0.7753	0.7753	13
APs	APs:12	alkaline phosphatases:12:0.5050	0.5050	12
APs	APs:25	alkylphenols:25:0.0109	0.0109	25
APS	APS:11	American Pain Society:11:0.7357	0.7357	11
APs	APs:12	aminopeptidases:12:0.0050	0.0050	12
APS	APS:9	Ammonium persulfate:9:0.6794	0.6794	9
APs	APs:5	Amyloid plaques:5:0.1132	0.1132	5
APs	APs:12	anterior pituitaries:12:0.7571	0.7571	12
APs	APs:11|Aps:1	anterior pituitary glands:12:0.7571	0.7571	12
APs	APs:6	Antimicrobial peptides:6:0.1543	0.1543	6
aps	aps:11|APS:2	antiparallel-stranded:13:0.0059	0.0059	13
aPS	aPS:6|APS:3	antiphosphatidylserine:9:0.0036	0.0036	9
APS	APS:740|aPS:3	antiphospholipid syndrome:743:0.7573	0.7573	743
APS	APS:11	Antiplatelet serum:11:0.1131	0.1131	11
APS	APS:6	Atypical parkinsonian syndromes:6:0.5290	0.5290	6
APS	APS:6	autoimmune polyglandular syndromes:6:0.5290	0.5290	6
APS	APS:7	automatic positioning system:7:0.5926	0.5926	7
A-PS	A-PS:8	group A streptococcal polysaccharide:8:0.6411	0.6411	8
APS	APS:8	platelet serum:8:0.0548	0.0548	8
APs	APs:10	proteins:10:0.0041	0.0041	10
APTES	APTES:14	3-aminopropyltriethoxysilane:14:0.4194	0.4194	14
APTT	APTT:7|aPTT:5	activated partial thromboplastin:12:0.7571	0.7571	12
APTT	APTT:26|aPTT:14	Activated partial thromboplastin times:40:0.8839	0.8839	40
APTT	APTT:4|aPTT:1	partial thromboplastin time test:5:0.4422	0.4422	5
APUD	APUD:44	amine precursor uptake and decarboxylation:44:0.9379	0.9379	44
APV	APV:40|apv:1	amprenavir:41:0.0461	0.0461	41
APV	APV:9	artificial pulmonary ventilation:9:0.6794	0.6794	9
APV	APV:30	Average peak velocity:30:0.6252	0.6252	30
APV	APV:74	avian pneumovirus:74:0.9596	0.9596	74
APV	APV:18	Avian polyomavirus:18:0.8365	0.8365	18
APV	APV:4	NMDA antagonist D-2-amino-5-phosphonovalerate:4:0.3463	0.3463	4
APV	APV:6	NMDA receptor antagonist 2-amino-5-phosphonovalerate:6:0.4709	0.4709	6
APV	APV:4	NMDA receptor antagonist DL-2-amino-5-phosphonovalerate:4:0.6411	0.6411	4
APV	APV:9	NMDA receptor antagonist DL-2-amino-5-phosphonovaleric acid:9:0.7261	0.7261	9
APV	APV:6	peak flow velocity:6:0.1838	0.1838	6
APW	APW:10	alkaline peptone water:10:0.7103	0.7103	10
APW	APW:7	artificial pond water:7:0.5926	0.5926	7
APX	APX:85|APx:5	ascorbate peroxidase:90:0.9668	0.9668	90
APZ	APZ:13	alprazolam:13:0.4800	0.4800	13
APase	APase:28|AP-ase:2	acid phosphatase:30:0.1386	0.1386	30
APase	APase:107|Apase:2|AP-ase:1	alkaline phosphatase:110:0.7084	0.7084	110
APH	APH:17	2-amino-7-phosphonoheptanoic acid:17:0.3844	0.3844	17
APH	APH:21	acetylphenylhydrazine:21:0.0683	0.0683	21
APh	APh:13|APH:4|aPh:1|aph:1	acid phosphatase:19:0.2474	0.2474	19
APh	APh:17|APH:4|aPh:2|Aph:2	alkaline phosphatase:25:0.3966	0.3966	25
aph	aph:6|APH:2	aminoglycoside phosphotransferase gene:8:0.6411	0.6411	8
APH	APH:12	antepartum haemorrhage:12:0.6460	0.6460	12
APH	APH:14|Aph:5|aph:2	aphidicolin:21:0.0683	0.0683	21
APtN	APtN:14|APTN:3	anterior pretectal nucleus:17:0.8270	0.8270	17
AP	AP:31	[14C]aminopyrine:22:0.0024|[14C]-aminopyrine:9:0.0009	0.0024	31
AP	AP:16|Ap:6	2-aminopurine:22:0.0024	0.0024	22
AP	AP:68	Abasic:68:0.0075	0.0075	68
AP	AP:20	Absolute pitch:20:0.8525	0.8525	20
AP	AP:7	absolute power:7:0.0777	0.0777	7
AP	AP:61	accelerated phase:61:0.4963	0.4963	61
AP	AP:118	accessory pathway:94:0.4317|accessory pathways:24:0.6767	0.6767	118
AP	AP:6	accessory processes:6:0.2243	0.2243	6
AP	AP:5	accumulation of 14C-aminopyrine:5:0.0612	0.0612	5
aP	aP:15|AP:2|ap:1	acellular pertussis:18:0.8365	0.8365	18
AP	AP:10	acetaminophen:10:0.0010	0.0010	10
AP	AP:204|aP:4	acid phosphatase:208:0.1179	0.1179	208
AP	AP:19	Actinic prurigo:19:0.8449	0.8449	19
Ap	Ap:7|AP:2|ap:1	Actinobacillus pleuropneumoniae:10:0.5856	0.5856	10
AP	AP:899|ap:3|Ap:1	action potential:728:0.9646|action potentials:175:0.9330	0.9646	903
AP	AP:7|ap:2	activation peptide:9:0.0809	0.0809	9
AP	AP:19	acupuncture:19:0.0020	0.0020	19
AP	AP:424	acute pancreatitis:424:0.9457	0.9457	424
AP	AP:33	acute phase:23:0.1357|Acute-phase:10:0.0010	0.1357	33
AP	AP:22	acute pneumonia:22:0.4689	0.4689	22
AP	AP:31	adaptor protein:31:0.3005	0.3005	31
AP	AP:30	adductor pollicis:30:0.8472	0.8472	30
AP	AP:146	adult periodontitis:146:0.7834	0.7834	146
AP	AP:29	aerosolized pentamidine:29:0.6157	0.6157	29
AP	AP:1299|ap:3|Ap:2|aP:1|A-p:1	alkaline phosphatase:1296:0.8292|alkaline phosphatases:10:0.3829	0.8292	1306
AP	AP:26	alkaline phosphatase activity:26:0.8861	0.8861	26
AP	AP:6	alkaline phosphate:6:0.0731	0.0731	6
AP	AP:12	Allopregnanolone:12:0.0012	0.0012	12
AP	AP:15|Ap:2|ap:1	Allopurinol:18:0.0019	0.0019	18
A-P	A-P:20|AP:8|a-p:1	along the anterior-posterior:29:0.0792	0.0792	29
AP	AP:14	alpha 2-antiplasmin:14:0.7909	0.7909	14
AP	AP:61	alternative pathway:61:0.2570	0.2570	61
AP	AP:7	alveolar permeability:7:0.3524	0.3524	7
AP	AP:44|ap:1	aminopeptidase:36:0.0039|aminopeptidases:9:0.0009	0.0039	45
AP	AP:40|Ap:2	aminopyrine:42:0.0046	0.0046	42
AP	AP:12	ammonium perchlorate:12:0.7571	0.7571	12
Ap	Ap:33|AP:6|ap:5	ampicillin:44:0.0048	0.0048	44
AP	AP:11	amyloid P:11:0.1430	0.1430	11
AP	AP:54	amyloid P component:45:0.8369|amyloid P-component:9:0.5470	0.8369	54
AP	AP:5	amyloid plaques:5:0.1132	0.1132	5
AP	AP:12	anaphylactoid purpura:12:0.5050	0.5050	12
AP	AP:153	angina pectoris:153:0.9804	0.9804	153
AP	AP:5	Annular pancreas:5:0.1132	0.1132	5
AP	AP:20|ap:1	Anterior Pagoda:21:0.8594	0.8594	21
AP	AP:316|Ap:1|ap:1	anterior pituitary:308:0.9792|anterior pituitaries:10:0.7103	0.9792	318
AP	AP:28|ap:1	anterior pituitary gland:29:0.8978	0.8978	29
AP	AP:8|A-P:2	anterior/posterior:10:0.0010	0.0010	10
AP	AP:4|A-P:1	anterior to posterior:5:0.6182	0.6182	5
AP	AP:70|A-P:32|ap:2|a-p:1	antero-posterior:105:0.0117	0.0117	105
AP	AP:457|A-P:39|a-p:7|a--p:1|ap:1	anteroposterior:505:0.0566	0.0566	505
AP	AP:10	antigen presentation:10:0.4363	0.4363	10
AP	AP:9	Antiplasmin:9:0.0009	0.0009	9
AP	AP:10	antipsychotic:10:0.0010	0.0010	10
AP	AP:76|Ap:1|ap:1	antipyrine:78:0.0086	0.0086	78
AP	AP:8|ap:3	apatite:11:0.0011	0.0011	11
AP	AP:15|ap:3	apomorphine:18:0.0019	0.0019	18
AP	AP:8|ap:5|Ap:2	aprotinin:15:0.0016	0.0016	15
ap	ap:25|Ap:4	apterous:29:0.0031	0.0031	29
AP	AP:34	apurinic:34:0.0037	0.0037	34
AP	AP:258	apurinic/apyrimidinic:249:0.0279|apurinic-apyrimidinic:9:0.0009	0.0279	258
AP	AP:309|ap:9	area postrema:318:0.9752	0.9752	318
AP	AP:9	arterial:9:0.0009	0.0009	9
AP	AP:72	arterial blood pressure:72:0.8948	0.8948	72
AP	AP:558	arterial pressure:550:0.7467|arterial pressures:8:0.2987	0.7467	558
AP	AP:13	artificial perilymph:13:0.7753	0.7753	13
AP	AP:9	ascorbyl palmitate:9:0.6794	0.6794	9
AP	AP:8	asthmatic patients:8:0.1276	0.1276	8
AP	AP:28	atrial pacing:28:0.8369	0.8369	28
AP	AP:30	atriopeptin:30:0.0033	0.0033	30
AP	AP:6	autologous plasma:6:0.1320	0.1320	6
AP	AP:12|aP:8	available P:20:0.4037	0.4037	20
AP	AP:11|aP:4	available phosphorus:15:0.8045	0.8045	15
AP	AP:11	average power:11:0.2280	0.2280	11
AP	AP:9	proteinase:9:0.0009	0.0009	9
AP	AP:6	Pseudomonas aeruginosa alkaline protease:6:0.3728	0.3728	6
AQC	AQC:16	6-aminoquinolyl-N-hydroxysuccinimidyl carbamate:16:0.6577	0.6577	16
AQDS	AQDS:19	anthraquinone-2,6-disulfonate:19:0.6000	0.6000	19
AQLQ	AQLQ:73	Asthma Quality of Life Questionnaire:73:0.9136	0.9136	73
AQP0	AQP0:9|Aqp0:1	Aquaporin-0:10:0.4500	0.4500	10
AQP1	AQP1:161|AQP-1:19|aqp1:1|Aqp1:1	aquaporin-1:129:0.6124|aquaporin 1:53:0.8597	0.8597	182
AQP2	AQP2:188|AQP-2:40|Aqp2:1	Aquaporin-2:192:0.7500|Aquaporin 2:37:0.8377	0.8377	229
AQP3	AQP3:31|AQP-3:7	Aquaporin-3:20:0.4130|aquaporin 3:18:0.8365	0.8365	38
AQP4	AQP4:92|AQP-4:5|Aqp4:2	aquaporin-4:77:0.6786|Aquaporin 4:22:0.8657	0.8657	99
AQP5	AQP5:35|Aqp5:2	aquaporin-5:24:0.5111|aquaporin 5:13:0.7753	0.7753	37
AQP8	AQP8:9	aquaporin-8:9:0.4706	0.4706	9
AQPs	AQPs:92	aquaporins:92:0.9579	0.9579	92
AQP	AQP:106|Aqp:1	aquaporin:74:0.6460|aquaporins:33:0.2832	0.6460	107
AQoL	AQoL:18	Assessment of Quality of Life:18:0.4934	0.4934	18
AQ	AQ:27	Acoustic quantification:27:0.8312	0.8312	27
AQ	AQ:7	Aggression Questionnaire:7:0.1025	0.1025	7
AQ	AQ:52|Aq:1	amodiaquine:53:0.1919	0.1919	53
AQ	AQ:17	anthraquinone:17:0.0590	0.0590	17
AQ	AQ:5|Aq:3|aq:1	aqueous:9:0.0295	0.0295	9
AQ	AQ:14	areca quid:14:0.7909	0.7909	14
AQ	AQ:20	Quotient:20:0.0664	0.0664	20
AR1	AR1:7	activating region 1:7:0.4438	0.4438	7
AR4-2J	AR4-2J:4|AR42J:1	pancreatic acinar cells:5:0.1973	0.1973	5
AR4-2J	AR4-2J:6|AR42J:3	pancreatic acinar cell line:9:0.4587	0.4587	9
ARAS	ARAS:9	ascending reticular activating system:9:0.6794	0.6794	9
ARAS	ARAS:23	atherosclerotic renal artery stenosis:23:0.7500	0.7500	23
ARA	ARA:5	acetylene reduction activity:5:0.4422	0.4422	5
ARA	ARA:9	Action Research Arm:9:0.6794	0.6794	9
ARA	ARA:9	Action Research Arm Test:9:0.6794	0.6794	9
ARA	ARA:80	American Rheumatism Association:80:0.9627	0.9627	80
ARA	ARA:19	anorectal angle:19:0.7658	0.7658	19
ARA	ARA:12	antibody:12:0.0280	0.0280	12
ARA	ARA:5	antiradical activity:5:0.0517	0.0517	5
ARA	ARA:5	antireticulin antibodies:5:0.0517	0.0517	5
Ara	Ara:6|ARA:3	arabinose:9:0.0204	0.0204	9
ARA	ARA:20	receptor antagonists:11:0.4728|receptor antagonist:9:0.5470	0.5470	20
ARBD	ARBD:9	alcohol-related birth defects:9:0.5470	0.5470	9
ARB	ARB:60	angiotensin II receptor blocker:41:0.8224|Angiotensin II receptor blockers:19:0.7044	0.8224	60
ARB	ARB:22	angiotensin II type 1 receptor blocker:22:0.7955	0.7955	22
ARB	ARB:8	receptor blockade:8:0.5006	0.5006	8
ARCD	ARCD:20	acquired renal cystic disease:20:0.8525	0.8525	20
ARCI	ARCI:38	Addiction Research Center Inventory:38:0.9217	0.9217	38
ARCN	ARCN:7|ARCn:5|ArcN:4	arcuate nucleus:16:0.8165	0.8165	16
ARCON	ARCON:9	carbogen and nicotinamide:9:0.5856	0.5856	9
ARC	ARC:23	accessory radula closer:23:0.8715	0.8715	23
ARC	ARC:15	active renin concentration:15:0.8045	0.8045	15
Arc	Arc:11|arc:1	activity-regulated cytoskeleton-associated protein:12:0.7909	0.7909	12
ARC	ARC:15	adult rat cardiomyocytes:15:0.8045	0.8045	15
ARC	ARC:14	American Red Cross:14:0.7909	0.7909	14
ARC	ARC:15	anomalous retinal correspondence:15:0.5818	0.5818	15
ARC	ARC:8|Arc:1	arcuate nuclei:9:0.6794	0.6794	9
ARC	ARC:346|Arc:58|arc:1	arcuate nucleus:405:0.9577	0.9577	405
ARC	ARC:13|Arc:4	arcuate nucleus of the hypothalamus:17:0.8715	0.8715	17
ARC	ARC:5	Arthritis and Rheumatism Council:5:0.5290	0.5290	5
ARDRA	ARDRA:16	Amplified rDNA restriction analysis:16:0.4536	0.4536	16
ARDRA	ARDRA:58	amplified ribosomal DNA restriction analysis:58:0.7954	0.7954	58
ARDS	ARDS:10	acute respiratory failure:10:0.5000	0.5000	10
ARDS	ARDS:1352	Adult respiratory distress syndrome:1352:0.5094	0.5094	1352
ARDS	ARDS:6	lung failure:6:0.0564	0.0564	6
ARD	ARD:91	acute respiratory disease:46:0.7319|acute respiratory diseases:45:0.7664	0.7664	91
ARD	ARD:10	Antimicrobial Removal Device:10:0.5856	0.5856	10
AREDS	AREDS:29	Age-Related Eye Disease Study:29:0.8941	0.8941	29
ARF1	ARF1:55|ARF-1:8|Arf1:3	ADP-ribosylation factor 1:42:0.5632|ADP ribosylation factor 1:14:0.7096|ADP-ribosylation factor-1:10:0.4363	0.7096	66
ARF6	ARF6:25|Arf6:8	ADP-ribosylation factor 6:33:0.6976	0.6976	33
ARFs	ARFs:98|Arfs:3	ADP-ribosylation factors:101:0.7263	0.7263	101
ARF	ARF:1717|arf:1	acute renal failure:1718:0.9898	0.9898	1718
ARF	ARF:140	acute rheumatic fever:140:0.9544	0.9544	140
ARF	ARF:254|Arf:36	ADP-ribosylation factor:241:0.7366|ADP ribosylation factor:37:0.7704|ADP-ribosylation factors:12:0.3524	0.7704	290
ARF	ARF:17|Arf:1	reading frame:18:0.8365	0.8365	18
ARH	ARH:20	Adrenal regeneration hypertension:12:0.7571|adrenal-regeneration hypertension:8:0.1196	0.7571	20
ARH	ARH:26	arcuate nucleus:26:0.8861	0.8861	26
ARH	ARH:20	arcuate nucleus of the hypothalamus:20:0.8657	0.8657	20
ARH	ARH:17	autosomal recessive hypercholesterolemia:17:0.8270	0.8270	17
ARIA	ARIA:9	acetylcholine receptor-inducing activity:9:0.4102	0.4102	9
ARIC	ARIC:302	Atherosclerosis Risk in Communities:302:0.9788	0.9788	302
ARIC	ARIC:12	Atherosclerosis Risk in Communities Study:12:0.6460	0.6460	12
ARID	ARID:6	AT-rich interaction domain:6:0.2827	0.2827	6
ARIMA	ARIMA:31	autoregressive integrated moving average:31:0.7782	0.7782	31
ARIS	ARIS:9	acrosome reaction-inducing substance:9:0.6794	0.6794	9
ARIs	ARIs:8	activation-recovery intervals:8:0.2987	0.2987	8
ARIs	ARIs:34	acute respiratory infections:34:0.9126	0.9126	34
ARIs	ARIs:38	aldose reductase inhibitors:38:0.9217	0.9217	38
ARIS	ARIS:12	apoenzyme reactivation immunoassay system:12:0.7571	0.7571	12
ARI	ARI:31|ARi:1	activation-recovery interval:25:0.4917|activation-recovery intervals:7:0.2452	0.4917	32
ARI	ARI:17	acute renal insufficiency:17:0.6748	0.6748	17
ARI	ARI:19	acute respiratory illness:19:0.8449	0.8449	19
ARI	ARI:266	acute respiratory infections:171:0.9166|acute respiratory infection:95:0.9184	0.9184	266
ARI	ARI:17	acute respiratory insufficiency:17:0.7407	0.7407	17
ARI	ARI:23	acute respiratory tract infection:23:0.8038	0.8038	23
ARI	ARI:40	adhesive remnant index:40:0.9256	0.9256	40
ARI	ARI:91	aldose reductase inhibitor:86:0.9653|aldose reductase inhibitors:5:0.4422	0.9653	91
ARI	ARI:14	autoregulatory index:14:0.0872	0.0872	14
AR-JP	AR-JP:44|ARJP:8	Autosomal recessive juvenile parkinsonism:52:0.9082	0.9082	52
ARL	ARL:19	AIDS-related lymphoma:19:0.4405	0.4405	19
ARMA	ARMA:2	autoregressive and moving average:2:0.8649	0.8649	2
ARMD	ARMD:255	age-related macular degeneration:255:0.8766	0.8766	255
ARM	ARM:1	Adriamycin in a rat model:1:0.5926	0.5926	1
ARM	ARM:157	age-related maculopathy:157:0.8557	0.8557	157
ARM	ARM:61	anorectal malformations:36:0.8336|anorectal malformation:25:0.8816	0.8816	61
ARM	ARM:14	anorectal manometry:14:0.7909	0.7909	14
ARM	ARM:17	arginine-rich motif:17:0.5038	0.5038	17
Arm	Arm:25|arm:20|ARM:4	armadillo:49:0.0982	0.0982	49
ARM	ARM:13|Arm:1	Armstrong:14:0.0266	0.0266	14
ARM	ARM:6	ATP-regulated module:6:0.1010	0.1010	6
ARND	ARND:12	alcohol-related neurodevelopmental disorder:12:0.6460	0.6460	12
ARNSHL	ARNSHL:6	Autosomal recessive nonsyndromic hearing loss:6:0.5290	0.5290	6
ARNT	ARNT:21|Arnt:4|arnt:1	nuclear translocator protein:26:0.8251	0.8251	26
ARN	ARN:82	acute retinal necrosis:82:0.9636	0.9636	82
ARN	ARN:16	acute retinal necrosis syndrome:16:0.8165	0.8165	16
ARN	ARN:9	Afferent renal nerves:9:0.6794	0.6794	9
ARN	ARN:17	arcuate nucleus:17:0.8270	0.8270	17
ARO-ir	ARO-ir:16	aromatase-immunoreactive:16:0.7895	0.7895	16
AROM	AROM:20	active range of motion:20:0.8525	0.8525	20
ARO	ARO:21|Aro:1	Aroclor 1254:22:0.7955	0.7955	22
ARO	ARO:10|aro:2	aromatase:12:0.1250	0.1250	12
ArpA	ArpA:6	A-factor receptor protein:6:0.2827	0.2827	6
ARPE-19	ARPE-19:8	human retinal pigment epithelial cells:8:0.4438	0.4438	8
ARPE-19	ARPE-19:4|ARPE19:1	retinal pigment epithelial cell line:5:0.4422	0.4422	5
ARPKD	ARPKD:8	autosomal recessive PKD:8:0.6411	0.6411	8
ARPKD	ARPKD:111	autosomal recessive polycystic kidney disease:111:0.9567	0.9567	111
Arps	Arps:15|ARPs:12|arps:2	actin-related proteins:29:0.6392	0.6392	29
ARP	ARP:13	absolute refractory period:13:0.5934	0.5934	13
Arp	Arp:19|ARP:5|arp:1	actin-related protein:25:0.4751	0.4751	25
ARP	ARP:11	Aldehyde Reactive Probe:11:0.7357	0.7357	11
ARP	ARP:13	Arthromyces ramosus peroxidase:13:0.6701	0.6701	13
ARP	ARP:12|Arp:3	proteins:15:0.0651	0.0651	15
ARRM	ARRM:12	AIDS Risk Reduction Model:12:0.7571	0.7571	12
arRP	arRP:16|ARRP:12	autosomal recessive retinitis pigmentosa:28:0.8369	0.8369	28
ARRs	ARRs:10	response regulators:10:0.7103	0.7103	10
ARR	ARR:28	absolute risk reduction:28:0.8941	0.8941	28
ARS1	ARS1:7|ars1:2	autonomously replicating sequence 1:9:0.6794	0.6794	9
ARSACS	ARSACS:16	autosomal recessive spastic ataxia of Charlevoix-Saguenay:16:0.8165	0.8165	16
ARSA	ARSA:8	aberrant right subclavian artery:8:0.5006	0.5006	8
ArsC	ArsC:12	Arsenate reductase:12:0.6460	0.6460	12
ARSs	ARSs:13	aminoacyl-tRNA synthetases:13:0.6701	0.6701	13
ARSs	ARSs:31	autonomously replicating sequences:31:0.8519	0.8519	31
ARs	ARs:12	A(3) adenosine receptors:12:0.1379	0.1379	12
ARS	ARS:9	acute radiation sickness:9:0.6794	0.6794	9
ARs	ARs:13	adrenoceptors:13:0.0151	0.0151	13
ARS	ARS:12	Agricultural Research Service:12:0.5664	0.5664	12
ARS	ARS:16|AR-S:1	alizarin red S:17:0.7407	0.7407	17
ARS	ARS:5	aminoacyl-tRNA synthetase:5:0.0902	0.0902	5
ARs	ARs:60|ARS:1|Ars:1	androgen receptors:62:0.2519	0.2519	62
Ars	Ars:9	anti-p-azophenylarsonate:9:0.0101	0.0101	9
ARS	ARS:10	antigen recognition site:10:0.7103	0.7103	10
ARS	ARS:8	antireflux surgery:8:0.2987	0.2987	8
ars	ars:11|Ars:2	arsenical resistance:13:0.4849	0.4849	13
Ars	Ars:7|ARS:6|ars:2|ArS:1	arylsulfatase:16:0.0189	0.0189	16
ARS	ARS:7|ars:1	autonomous replication sequences:8:0.6411	0.6411	8
ARS	ARS:111|ars:10	autonomously replicating sequence:104:0.8294|autonomously replicating sequences:17:0.6211	0.8294	121
ARS	ARS:10	Axenfeld-Rieger syndrome:10:0.1519	0.1519	10
Ars	Ars:19	p-azophenylarsonate:19:0.0227	0.0227	19
ARs	ARs:15	reactions:15:0.0177	0.0177	15
ARTs	ARTs:12	acoustic reflex thresholds:12:0.7571	0.7571	12
ARTS	ARTS:9	Arterial Revascularization Therapies Study:9:0.6794	0.6794	9
ARTS	ARTS:9	artesunate:9:0.0792	0.0792	9
ARTs	ARTs:6	assisted reproductive techniques:6:0.5290	0.5290	6
ARTs	ARTs:24	assisted reproductive technologies:24:0.8186	0.8186	24
ART	ART:18|art:1	acoustic reflex threshold:19:0.8449	0.8449	19
ART	ART:15	adaptive resonance theory:15:0.8045	0.8045	15
ART	ART:5|aRT:1	adjuvant radiotherapy:6:0.1010	0.1010	6
ART	ART:19	Algebraic Reconstruction Technique:19:0.8449	0.8449	19
ART	ART:329	antiretroviral therapy:329:0.8698	0.8698	329
ART	ART:41	antiretroviral treatment:41:0.2160	0.2160	41
ART	ART:11	arm-retina time:11:0.1067	0.1067	11
ART	ART:7|Art:3	artemisinin:10:0.0068	0.0068	10
ART	ART:12|Art:1	Artesunate:13:0.0091	0.0091	13
ART	ART:22	assisted reproduction techniques:22:0.8657	0.8657	22
ART	ART:18	assisted reproduction technologies:18:0.7539	0.7539	18
ART	ART:48	assisted reproductive techniques:48:0.7790	0.7790	48
ART	ART:314	assisted reproductive technology:218:0.9780|assisted reproductive technologies:96:0.8936	0.9780	314
ART	ART:83	atraumatic restorative treatment:83:0.9627	0.9627	83
ART	ART:9	auditory reaction time:9:0.6794	0.6794	9
ART	ART:9	tachycardia:9:0.0061	0.0061	9
ARVC	ARVC:79	arrhythmogenic right ventricular cardiomyopathy:79:0.9401	0.9401	79
ARVD	ARVD:138	arrhythmogenic right ventricular dysplasia:138:0.8818	0.8818	138
ARVD	ARVD:11	atherosclerotic renovascular disease:11:0.6182	0.6182	11
ARVD/C	ARVD/C:9	Arrhythmogenic right ventricular dysplasia/cardiomyopathy:9:0.6794	0.6794	9
ARVI	ARVI:23	acute respiratory viral infections:15:0.8045|acute respiratory viral infection:8:0.6411	0.8045	23
ARVM	ARVM:22	adult rat ventricular myocytes:22:0.8657	0.8657	22
ARVMs	ARVMs:10	adult rat ventricular myocytes:10:0.7103	0.7103	10
ARV	ARV:13	AIDS-associated retrovirus:13:0.2959	0.2959	13
ARV	ARV:128	antiretroviral:128:0.4774	0.4774	128
ARV	ARV:11	antiretroviral therapy:11:0.7357	0.7357	11
ARV	ARV:8	average rectified value:8:0.5006	0.5006	8
ARV	ARV:27	Avian reovirus:27:0.8312	0.8312	27
ARX	ARX:13	exogenous input:13:0.6701	0.6701	13
AR	AR:13	access recirculation:13:0.5335	0.5335	13
AR	AR:8	Acid resistance:8:0.0566	0.0566	8
AR	AR:24	acoustic reflex:24:0.5160	0.5160	24
AR	AR:60	acoustic rhinometry:60:0.9216	0.9216	60
AR	AR:13	acrosome-reacted:13:0.0019	0.0019	13
AR	AR:295	acrosome reaction:287:0.8787|acrosome reactions:8:0.0672	0.8787	295
AR	AR:9	active recovery:9:0.5470	0.5470	9
AR	AR:33	active renin:33:0.8605	0.8605	33
AR	AR:9	acute allograft rejection:9:0.1150	0.1150	9
AR	AR:237	acute rejection:237:0.7904	0.7904	237
AR	AR:25	adaptive response:25:0.4451	0.4451	25
AR	AR:22	adrenoceptor:22:0.0033	0.0033	22
AR	AR:12	airway reactivity:12:0.5050	0.5050	12
AR	AR:52	airway responsiveness:52:0.6963	0.6963	52
AR	AR:256	Aldose reductase:256:0.8881	0.8881	256
AR	AR:197	Allergic rhinitis:197:0.7677	0.7677	197
AR	AR:12	alpha(1)-adrenoceptor:12:0.0017	0.0017	12
AR	AR:20	alpha1-adrenoceptor:20:0.0030	0.0030	20
AR	AR:117|Ar:5	Amphiregulin:122:0.0188	0.0188	122
AR	AR:12	anaphylactoid reactions:12:0.1631	0.1631	12
AR	AR:2172|A-R:2|Ar:2|ar:1	androgen receptor:1971:0.8410|Androgen receptors:194:0.6793|androgen-receptor:12:0.0017	0.8410	2177
AR	AR:35	androgen receptor gene:35:0.9151	0.9151	35
AR	AR:12	anhydroretinol:12:0.0017	0.0017	12
AR	AR:22	anterior resection:22:0.6934	0.6934	22
AR	AR:37	antigen retrieval:37:0.9197	0.9197	37
AR	AR:13	aortic:13:0.0019	0.0019	13
AR	AR:417	aortic regurgitation:417:0.9265	0.9265	417
AR	AR:14	apoptotic rate:14:0.1392	0.1392	14
AR	AR:11	applied relaxation:11:0.5355	0.5355	11
AR	AR:8|Ar:2	arcuate nucleus:10:0.7103	0.7103	10
AR	AR:36|Ar:4	area at risk:40:0.3124	0.3124	40
Ar	Ar:25	argon:25:0.0037	0.0037	25
AR	AR:15|Ar:3	aromatase:18:0.0026	0.0026	18
AR	AR:31	artificially reared:31:0.9043	0.9043	31
AR	AR:10	aspect ratio:10:0.0730	0.0730	10
AR	AR:41	atrophic rhinitis:41:0.1180	0.1180	41
AR	AR:15	attack rate:10:0.0730|attack rates:5:0.0517	0.0730	15
AR	AR:35	attributable risk:35:0.2536	0.2536	35
AR	AR:18	augmented reality:18:0.8365	0.8365	18
AR	AR:165	autoregressive:165:0.0255	0.0255	165
AR	AR:10	autoregulation:10:0.0014	0.0014	10
AR	AR:104|ar:3	autosomal recessive:107:0.9555	0.9555	107
Ar	Ar:9	p-azophenylarsonate:9:0.0012	0.0012	9
AS1	AS1:6|as1:3	asymmetric leaves1:9:0.6794	0.6794	9
ASADH	ASADH:9|ASA-DH:1	dehydrogenase:10:0.8182	0.8182	10
ASAH	ASAH:6|aSAH:2	aneurysmal subarachnoid haemorrhage:8:0.6411	0.6411	8
aSAH	aSAH:6|ASAH:4|a-SAH:1	aneurysmal subarachnoid hemorrhage:11:0.7357	0.7357	11
ASAM	ASAM:10	American Society of Addiction Medicine:10:0.7103	0.7103	10
ASAP	ASAP:13	atypical small acinar proliferation:13:0.7753	0.7753	13
ASAT	ASAT:9|AsAT:2	aspartate amino transferase:11:0.7357	0.7357	11
ASAT	ASAT:161|AsAT:11	aspartate aminotransferase:172:0.9042	0.9042	172
ASAS	ASAS:10	anterior spinal artery syndrome:10:0.7103	0.7103	10
ASAs	ASAs:14	antisperm antibodies:14:0.4709	0.4709	14
ASA	ASA:25	accessible surface area:25:0.5969	0.5969	25
ASA	ASA:12	acetylsalicylate:12:0.0043	0.0043	12
ASA	ASA:1072|Asa:1|AsA:1	acetylsalicylic acid:1074:0.7118	0.7118	1074
ASA	ASA:22	active systemic anaphylaxis:22:0.8657	0.8657	22
ASA	ASA:10	activity:10:0.0032	0.0032	10
ASA	ASA:8	acute severe asthma:8:0.6411	0.6411	8
ASA	ASA:25	allele-specific amplification:17:0.4480|Allele Specific Amplification:8:0.6411	0.6411	25
ASA	ASA:15	American Society of Anaesthesiologists:15:0.8045	0.8045	15
ASA	ASA:243	American Society of Anesthesiologists:229:0.9870|American Society of Anesthesiologists':14:0.7909	0.9870	243
ASA	ASA:50	American Society of Anesthesiology:50:0.9064	0.9064	50
ASA	ASA:16	anterior spinal artery:16:0.8165	0.8165	16
ASA	ASA:20	anti-sperm antibodies:20:0.1221	0.1221	20
ASA	ASA:76	antisperm antibodies:65:0.5997|Antisperm antibody:11:0.3495	0.5997	76
AsA	AsA:20|ASA:5	ascorbate:25:0.0086	0.0086	25
ASA	ASA:9	aspirin-sensitive asthma:9:0.1945	0.1945	9
ASA	ASA:56	Atrial septal aneurysm:56:0.9467	0.9467	56
ASBO	ASBO:8	small bowel obstruction:8:0.6411	0.6411	8
ASBT	ASBT:20|Asbt:2	apical sodium-dependent bile acid transporter:22:0.7400	0.7400	22
ASBV	ASBV:11	avocado sunblotch viroid:11:0.7357	0.7357	11
ASBVd	ASBVd:14	avocado sunblotch viroid:14:0.7909	0.7909	14
ASB	ASB:7	anencephaly and spina bifida:7:0.7103	0.7103	7
ASB	ASB:14	antisocial behavior:14:0.4709	0.4709	14
AsB	AsB:9	arsenobetaine:9:0.0588	0.0588	9
ASB	ASB:21|AS-B:1	Arylsulfatase B:22:0.3913	0.3913	22
ASB	ASB:19	asymptomatic bacteriuria:19:0.8449	0.8449	19
ASCA	ASCA:28	anti-Saccharomyces cerevisiae antibodies:28:0.7154	0.7154	28
ASCA	ASCA:15	cerevisiae antibody:15:0.8365	0.8365	15
ASCA	ASCA:13	Saccharomyces cerevisiae:13:0.5934	0.5934	13
ASCCP	ASCCP:9	American Society for Colposcopy and Cervical Pathology:9:0.7103	0.7103	9
ASCC	ASCC:8	cell carcinoma:8:0.4102	0.4102	8
ASC-H	ASC-H:9	squamous intraepithelial lesion:9:0.6411	0.6411	9
ASCI	ASCI:11	acute spinal cord injury:11:0.7357	0.7357	11
ASCO	ASCO:99	American Society of Clinical Oncology:99:0.9704	0.9704	99
ASCP	ASCP:11	American Society of Clinical Pathologists:11:0.7357	0.7357	11
ASCRS	ASCRS:6	American Society of Colon and Rectal Surgeons:6:0.5290	0.5290	6
ASCRS	ASCRS:7	members of the American Society of Cataract and Refractive Surgery:7:0.3524	0.3524	7
ASCR	ASCR:27	autologous stem cell rescue:18:0.7539|autologous stem-cell rescue:9:0.6794	0.7539	27
ASCT	ASCT:13	autologous stem cell transplant:13:0.4849	0.4849	13
ASCT	ASCT:258	autologous stem cell transplantation:258:0.7778	0.7778	258
ASCUS	ASCUS:193|ASC-US:17	atypical squamous cells of undetermined significance:210:0.9690	0.9690	210
ASCVD	ASCVD:31	atherosclerotic cardiovascular disease:31:0.7388	0.7388	31
ASCs	ASCs:10	Ambulatory Surgery Centers:10:0.7103	0.7103	10
ASCs	ASCs:29	antibody-secreting cells:29:0.4300	0.4300	29
AS-C	AS-C:32|ASC:6|as-c:2	achaete-scute complex:40:0.6147	0.6147	40
ASC	ASC:11	Acidified sodium chlorite:11:0.7357	0.7357	11
ASC	ASC:19	adenosquamous carcinoma:19:0.6537	0.6537	19
ASC	ASC:9	altered states of consciousness:9:0.6794	0.6794	9
ASC	ASC:18	ambulatory surgical center:18:0.8365	0.8365	18
ASC	ASC:169	antibody-secreting cells:102:0.4871|antibody-secreting cell:29:0.4410|antibody secreting cells:27:0.6745|antibody secreting cell:11:0.7357	0.7357	169
Asc	Asc:4|ASC:2	Ascaris suum extract:6:0.5290	0.5290	6
ASC	ASC:25|Asc:18	ascorbate:43:0.0611	0.0611	43
Asc	Asc:31|ASC:25|asc:1	ascorbic acid:57:0.7044	0.7044	57
ASC	ASC:8	Asthma Symptom Checklist:8:0.4102	0.4102	8
ASC	ASC:7|AsC:1	asymptomatic carriers:8:0.1471	0.1471	8
ASC	AsC:3|ASC:3	asymptomatic HBV carriers:6:0.5290	0.5290	6
Asc	Asc:8|ASC:4	L-ascorbic acid:12:0.0701	0.0701	12
ASDA	ASDA:12	American Sleep Disorders Association:12:0.7571	0.7571	12
ASDH	ASDH:41	acute subdural hematoma:41:0.8525	0.8525	41
ASDs	ASDs:74	atrial septal defects:74:0.9596	0.9596	74
ASDs	ASDs:17	autism spectrum disorders:17:0.3512	0.3512	17
ASDs	ASDs:13	autistic spectrum disorders:13:0.2211	0.2211	13
ASD	ASD:61	Acute Stress Disorder:61:0.9511	0.9511	61
ASD	ASD:21	adult Still's disease:21:0.6040	0.6040	21
ASD	ASD:14	androstenedione:14:0.0119	0.0119	14
ASD	ASD:6	anti-siphon device:6:0.1010	0.1010	6
ASD	ASD:6	antisiphon device:6:0.1010	0.1010	6
ASD	ASD:18	arthroscopic subacromial decompression:18:0.8365	0.8365	18
asd	asd:4|Asd:1	aspartate semialdehyde dehydrogenase:5:0.1973	0.1973	5
ASD	ASD:644|asd:1	atrial septal defect:570:0.9741|atrial septal defects:75:0.9370	0.9741	645
ASD	ASD:95	Autism Spectrum Disorder:54:0.5331|autism spectrum disorders:41:0.4772	0.5331	95
ASD	ASD:53	autistic spectrum disorder:27:0.2114|autistic spectrum disorders:26:0.2550	0.2550	53
ASEAN	ASEAN:7	Association of Southeast Asian Nations:7:0.6411	0.6411	7
ASES	ASES:11	aerosol solvent extraction system:11:0.7357	0.7357	11
ASES	ASES:19	American Shoulder and Elbow Surgeons:19:0.8449	0.8449	19
ASEX	ASEX:7	Arizona Sexual Experiences Scale:7:0.5926	0.5926	7
ASE	ASE:47	accelerated solvent extraction:47:0.9366	0.9366	47
ASE	ASE:5	adaptive signal enhancer:5:0.4422	0.4422	5
ASE	ASE:15	American Society of Echocardiography:15:0.8045	0.8045	15
a-Se	a-Se:25	amorphous selenium:25:0.8816	0.8816	25
ASE	ASE:12	amplified spontaneous emission:12:0.7571	0.7571	12
ASE	ASE:5	left side-specific enhancer:5:0.4422	0.4422	5
ASFV	ASFV:217	African swine fever virus:217:0.9706	0.9706	217
ASF	ASF:122	African swine fever:122:0.9755	0.9755	122
ASF	ASF:15	airway surface fluid:15:0.5348	0.5348	15
ASF	ASF:9	Animal source foods:9:0.6794	0.6794	9
ASF	ASF:12	antisecretory factor:12:0.1028	0.1028	12
ASF	ASF:34	asialofetuin:34:0.1012	0.1012	34
ASF	ASF:9	fraction:9:0.0245	0.0245	9
ASF	ASF:7	intensity function:7:0.2902	0.2902	7
ASGB	ASGB:26	adjustable silicone gastric banding:26:0.8861	0.8861	26
ASGE	ASGE:24	American Society for Gastrointestinal Endoscopy:24:0.8978	0.8978	24
ASGP-Rs	ASGP-Rs:6|ASGPRs:5	asialoglycoprotein receptors:11:0.7357	0.7357	11
ASGP-R	ASGP-R:94|ASGPR:41|ASGPr:15|ASGP-r:2	asialoglycoprotein receptor:140:0.9444|asialoglycoprotein receptors:12:0.7571	0.9444	152
ASGP	ASGP:37|AsGP:1	asialoglycoprotein:38:0.7551	0.7551	38
ASGV	ASGV:9	apple stem grooving virus:9:0.6794	0.6794	9
ASG	ASG:7	accessory sex glands:7:0.5926	0.5926	7
ASHD	ASHD:18	heart disease:18:0.8365	0.8365	18
ASHP	ASHP:6	American Society of Hospital Pharmacists:6:0.5290	0.5290	6
ASH	ASH:9	abnormal sperm heads:9:0.6794	0.6794	9
ASH	ASH:81	asymmetric septal hypertrophy:81:0.7113	0.7113	81
ASICs	ASICs:44	Acid-sensing ion channels:44:0.8037	0.8037	44
ASIC	ASIC:15	acid-sensing ion channel:15:0.4951	0.4951	15
ASIF	ASIF:11	Association for the Study of Internal Fixation:11:0.7571	0.7571	11
ASIP	ASIP:10	agouti signaling protein:10:0.7103	0.7103	10
ASIRs	ASIRs:8	incidence rates:8:0.5006	0.5006	8
ASIS	ASIS:21	anterior superior iliac spine:21:0.8594	0.8594	21
ASI	ASI:9	Active specific immunization:9:0.6794	0.6794	9
ASI	ASI:25	active specific immunotherapy:25:0.8816	0.8816	25
ASI	ASI:169	Addiction Severity Index:169:0.9161	0.9161	169
a-Si	a-Si:18|aSi:3	amorphous silicon:21:0.8594	0.8594	21
ASI	ASI:12	anterior segment ischemia:12:0.7571	0.7571	12
ASI	ASI:53	Anxiety Sensitivity Index:53:0.8842	0.8842	53
Asi	Asi:7|ASi:3|AsI:1|As-i:1	inorganic arsenic:12:0.6460	0.6460	12
ASI	ASI:6	Structured Interview:6:0.1838	0.1838	6
ASK1	ASK1:91|Ask1:3|ASK-1:1	Apoptosis signal-regulating kinase 1:95:0.9685	0.9685	95
ASK	ASK:7	apoptosis signal-regulating kinase:7:0.5926	0.5926	7
ASLO	ASLO:6	antistreptolysin O:6:0.2243	0.2243	6
ASLV	ASLV:1	avian sarcoma leukosis virus:1:0.7753	0.7753	1
ASL	ASL:62	airway surface liquid:62:0.9003	0.9003	62
ASL	ASL:91	American Sign Language:91:0.9672	0.9672	91
ASL	ASL:11	angiosarcoma of the liver:11:0.5355	0.5355	11
ASL	ASL:53	argininosuccinate lyase:53:0.6743	0.6743	53
ASL	ASL:46	arterial spin labeling:46:0.9353	0.9353	46
asl	asl:3|ASL:1	m above sea level:4:0.4438	0.4438	4
ASMA	ASMA:52|A-SMA:1|aSMA:1	alpha-smooth muscle actin:42:0.5519|alpha smooth muscle actin:12:0.4557	0.5519	54
ASMA	ASMA:6	morphometry analysis:6:0.1838	0.1838	6
ASMCs	ASMCs:39|aSMCs:2	smooth muscle cells:41:0.9274	0.9274	41
ASMC	ASMC:76|A-SMC:2|aSMC:2	smooth muscle cells:65:0.9541|smooth muscle cell:15:0.8045	0.9541	80
ASM	ASM:53	acid sphingomyelinase:53:0.8373	0.8373	53
ASM	ASM:284	airway smooth muscle:284:0.9091	0.9091	284
ASNHL	ASNHL:10	sensorineural hearing loss:10:0.7103	0.7103	10
AS-ODN	AS-ODN:46|ASODN:28|asODN:11|As-ODN:4|as-ODN:2	antisense oligodeoxynucleotide:55:0.8225|antisense oligodeoxynucleotides:36:0.7433	0.8225	91
AS-ODN	AS-ODN:26|ASODN:12|asODN:2	antisense oligonucleotides:22:0.7955|antisense oligonucleotide:18:0.6903	0.7955	40
asON	asON:5|AS-ON:4|ASON:4	antisense oligonucleotides:13:0.7753	0.7753	13
ASOs	ASOs:14	AIDS service organizations:14:0.6911	0.6911	14
ASOs	ASOs:47	Antisense oligonucleotides:47:0.6867	0.6867	47
ASO	ASO:23	allele-specific oligonucleotides:23:0.2679	0.2679	23
ASO	ASO:37	Amplatzer septal occluder:37:0.8051	0.8051	37
ASO	ASO:31	anti-streptolysin O:31:0.2951	0.2951	31
ASO	ASO:9	antisense oligodeoxynucleotide:9:0.5470	0.5470	9
ASO	ASO:27	antisense oligonucleotides:27:0.3381	0.3381	27
ASO	ASO:46	antistreptolysin O:37:0.3853|Antistreptolysin-O:9:0.0127	0.3853	46
ASO	ASO:72	arterial switch operation:72:0.9136	0.9136	72
ASO	ASO:89	arteriosclerosis obliterans:89:0.8008	0.8008	89
aspA	aspA:8	Aspartase Gene:8:0.2090	0.2090	8
ASPA	ASPA:22	aspartoacylase:22:0.3443	0.3443	22
AS-PCR	AS-PCR:17|ASPCR:6	allele-specific PCR:23:0.7046	0.7046	23
ASPCR	ASPCR:16|AS-PCR:15	allele-specific polymerase chain reaction:31:0.7091	0.7091	31
ASPC	ASPC:31	aspoxicillin:31:0.7500	0.7500	31
ASPD	ASPD:89	antisocial personality disorder:89:0.9296	0.9296	89
ASPM	ASPM:10	Acetylspiramycin:10:0.6000	0.6000	10
ASPs	ASPs:5	acid shock proteins:5:0.4422	0.4422	5
ASPs	ASPs:16	affected sib pairs:16:0.7261	0.7261	16
ASPs	ASPs:21	affected sibling pairs:21:0.8594	0.8594	21
ASPS	ASPS:62	alveolar soft part sarcoma:44:0.8941|Alveolar soft-part sarcoma:18:0.8365	0.8941	62
ASP	ASP:80	Acylation Stimulating Protein:44:0.8300|acylation-stimulating protein:36:0.1744	0.8300	80
ASP	ASP:27	affected sib pair:15:0.8045|affected-sib-pair:12:0.0095	0.8045	27
ASP	ASP:15	affected sibling pair:15:0.7096	0.7096	15
ASP	ASP:15	amnesic shellfish poisoning:15:0.8045	0.8045	15
ASP	ASP:25	antisocial personality:25:0.8186	0.8186	25
ASP	ASP:40	antisocial personality disorder:40:0.9256	0.9256	40
ASP	ASP:13|Asp:1	asparaginase:14:0.0112	0.0112	14
Asp	Asp:62|ASP:8|asp:4	aspartic acid:74:0.6907	0.6907	74
ASP	ASP:12	L-asparaginase:12:0.0095	0.0095	12
ASP	ASP:9	polysaccharide:9:0.0069	0.0069	9
ASP	ASP:11	pressure:11:0.0086	0.0086	11
ASRM	ASRM:12	American Society for Reproductive Medicine:12:0.8270	0.8270	12
ASRs	ASRs:7	startle responses:7:0.2902	0.2902	7
ASR	ASR:12	Absolute synthesis rate:12:0.5664	0.5664	12
ASR	ASR:34	acoustic startle reflex:34:0.7898	0.7898	34
ASR	ASR:12	aldosterone secretion rate:12:0.4153	0.4153	12
ASR	ASR:12	androgen-sterilized rats:12:0.2699	0.2699	12
ASR	ASR:13	reaction:13:0.0271	0.0271	13
ASR	ASR:10	speech recognition:10:0.7103	0.7103	10
ASSC	ASSC:9	Acute splenic sequestration crisis:9:0.6794	0.6794	9
ASSIST	ASSIST:15	American Stop Smoking Intervention Study:15:0.7909	0.7909	15
ASSRs	ASSRs:12	Auditory steady-state responses:12:0.7571	0.7571	12
ASSR	ASSR:20|aSSR:1	auditory steady-state response:21:0.8594	0.8594	21
ASST	ASST:12	Arylsulfate sulfotransferase:12:0.7571	0.7571	12
ASST	ASST:18	autologous serum skin test:18:0.8365	0.8365	18
ASS	ASS:19	acetylsalicylic acid:19:0.5732	0.5732	19
ASS	ASS:84	argininosuccinate synthetase:84:0.8402	0.8402	84
AST/ALT	AST/ALT:8	aspartate aminotransferase/alanine aminotransferase:8:0.6411	0.6411	8
ASTHO	ASTHO:12	Association of State and Territorial Health Officials:12:0.7571	0.7571	12
ASTM	ASTM:6	American Society for Testing Materials:6:0.9585	0.9585	6
ASTM	ASTM:19	astromicin:19:0.1538	0.1538	19
ASTRO	ASTRO:37|Astro:1	American Society for Therapeutic Radiology and Oncology:38:0.8986	0.8986	38
AST	AST:11	acute suppurative thyroiditis:11:0.7357	0.7357	11
AST	AST:4	androgen suppression therapy:4:0.1618	0.1618	4
AST	AST:15	Antimicrobial susceptibility testing:15:0.5348	0.5348	15
AST	AST:6	arginine stimulation test:6:0.1543	0.1543	6
AST	AST:11	Aryl sulfotransferase:11:0.6182	0.6182	11
AST	AST:32	aspartate:32:0.0151	0.0151	32
AST	AST:17	aspartate-aminotransferase:17:0.0078	0.0078	17
AST	AST:15	aspartate transferase:15:0.1078	0.1078	15
AST	AST:44|AsT:1	serum aspartate transaminase:45:0.1247	0.1247	45
ASU	ASU:5	avocado/soybean unsaponifiables:5:0.0902	0.0902	5
ASVD	ASVD:9	atherosclerotic vascular disease:9:0.6794	0.6794	9
ASVS	ASVS:7	arterial stimulation venous sampling:7:0.8165	0.8165	7
ASV	ASV:8	Adaptive support ventilation:8:0.6411	0.6411	8
ASV	ASV:2	aneurysm of sinus of Valsalva:2:0.4102	0.4102	2
ASV	ASV:32	anodic stripping voltammetry:32:0.8563	0.8563	32
ASV	ASV:11	anti-snake venom:6:0.0736|anti snake venom:5:0.4422	0.4422	11
ASV	ASV:14	autogenous saphenous vein:14:0.4071	0.4071	14
ASV	ASV:84	avian sarcoma virus:74:0.9361|Avian sarcoma viruses:10:0.7103	0.9361	84
ASW	ASW:34	artificial sea water:34:0.9126	0.9126	34
ASW	ASW:41	artificial seawater:41:0.8867	0.8867	41
ASMase	ASMase:15|A-SMase:8|aSMase:5|ASmase:1	acid sphingomyelinase:29:0.4104	0.4104	29
aSMase	aSMase:9|A-SMase:7|ASMase:4	acidic sphingomyelinase:20:0.2267	0.2267	20
AT(1)	AT(1):9	Angiotensin II:9:0.3945	0.3945	9
AT(1)	AT(1):8	angiotensin II receptor:8:0.4102	0.4102	8
AT(1)	AT(1):83	angiotensin II type 1:83:0.5542	0.5542	83
AT(1)	AT(1):22	type 1 receptor:22:0.7955	0.7955	22
AT(1)R	AT(1)R:24|AT(1)-R:9	type 1 receptor:33:0.9100	0.9100	33
AT(1A)R	AT(1A)R:5|AT(1a)R:1|AT(1A)-R:1	angiotensin II type 1A receptor:7:0.5926	0.5926	7
AT(2)	AT(2):14	Angiotensin II type 2:14:0.2238	0.2238	14
AT(2)	AT(2):7	II type 2 receptor:7:0.5856	0.5856	7
AT(2)R	AT(2)R:14|AT(2)-R:1	type 2 receptor:15:0.7096	0.7096	15
AT/RT	AT/RT:27	atypical teratoid/rhabdoid tumor:19:0.8449|atypical teratoid/rhabdoid tumors:8:0.6411	0.8449	27
AT1AR	AT1AR:5|AT1a-R:2	angiotensin II type 1A receptor:7:0.4438	0.4438	7
AT1A	AT1A:9|AT1a:1	angiotensin II:10:0.7103	0.7103	10
AT1A	AT1A:6	angiotensin II receptor:6:0.3728	0.3728	6
AT1A	AT1A:3|AT1a:1|AT1-A:1	angiotensin II type 1 receptor antagonist:5:0.4422	0.4422	5
AT1a	AT1a:5|AT1A:3|AT-1a:1	angiotensin II type 1A:9:0.4587	0.4587	9
AT1RA	AT1RA:11|AT1-RA:2|AT1ra:1	receptor antagonist:8:0.5006|receptor antagonists:6:0.2243	0.5006	14
AT1R	AT1R:17|AT1-R:5|AT-1R:1	Ang II type 1 receptor:23:0.2105	0.2105	23
AT1R	AT1R:62|AT1-R:13|AT-1R:1	angiotensin II type 1 receptor:76:0.5868	0.5868	76
AT1R	AT1R:5|AT1-R:4	receptor type 1:9:0.3069	0.3069	9
AT1	AT1:7	ANG II receptor:7:0.0849	0.0849	7
AT1	AT1:13|AT-1:3	ANG II type 1 receptor:13:0.1092|Ang II type 1 receptors:3:0.5290	0.5290	16
AT1	AT1:284|AT-1:5	angiotensin II type 1:271:0.6456|angiotensin II type-1:18:0.4672	0.6456	289
AT1	AT1:55|AT-1:2	angiotensin II type 1 receptor:57:0.6570	0.6570	57
AT1	AT1:112	angiotensin type 1:112:0.1475	0.1475	112
AT1	AT1:8|AT-1:1	subtype-1:9:0.0063	0.0063	9
AT1	AT1:6	type 1 Ang II:6:0.3728	0.3728	6
AT1	AT1:7	type 1 angiotensin:7:0.5926	0.5926	7
AT1	AT1:12	type 1 angiotensin II receptor:12:0.7571	0.7571	12
AT2R	AT2R:26|AT2-R:11|AT-2R:1	type 2 receptor:38:0.8098	0.8098	38
AT2	AT2:25	ANG II type 2:25:0.2456	0.2456	25
AT2	AT2:12	angiotensin II:12:0.1520	0.1520	12
AT2	AT2:58	angiotensin II type 2:58:0.5345	0.5345	58
AT2	AT2:18|AT-2:1	angiotensin II type 2 receptor:19:0.4618	0.4618	19
AT3	AT3:4|AT-3:3	antithrombin 3:7:0.2902	0.2902	7
AT3	AT3:20	Antithrombin III:20:0.7766	0.7766	20
ATA	ATA:14|ata:2	1 atmosphere absolute:16:0.2523	0.2523	16
ATA	ATA:6	absolute atmospheres:6:0.1543	0.1543	6
ATA	ATA:11	American Thyroid Association:11:0.7357	0.7357	11
ATA	ATA:5	anti-thyroglobulin antibody:5:0.0517	0.0517	5
ATA	ATA:12	antithyroid antibodies:12:0.2868	0.2868	12
ATA	ATA:10	aspirin-tolerant asthma:10:0.4232	0.4232	10
ATA	ATA:86|ata:3	atmospheres absolute:89:0.6056	0.6056	89
ATA	ATA:5	atmospheres of absolute pressure:5:0.3809	0.3809	5
ATA	ATA:22	Aurin tricarboxylic acid:22:0.6531	0.6531	22
ATA	ATA:120	aurintricarboxylic acid:120:0.7052	0.7052	120
ATA	ATA:9	thermolabile antigen:9:0.5470	0.5470	9
ATBC	ATBC:5	Alpha-Tocopherol Beta-Carotene Cancer Prevention:5:0.8715	0.8715	5
ATBF	ATBF:30	adipose tissue blood flow:30:0.9011	0.9011	30
ATCC	ATCC:82	American Type Culture Collection:82:0.9636	0.9636	82
ATCs	ATCs:10	air traffic controllers:10:0.7103	0.7103	10
ATCase	ATCase:61|AT-Case:1	aspartate transcarbamylase:62:0.8070	0.8070	62
ATCh	ATCh:9	acetylthiocholine:9:0.5000	0.5000	9
ATC	ATC:10	activated T cells:10:0.5000	0.5000	10
ATC	ATC:14	air traffic control:14:0.6173	0.6173	14
ATC	ATC:10	Anaplastic thyroid cancer:10:0.7103	0.7103	10
ATC	ATC:39	anaplastic thyroid carcinoma:39:0.7860	0.7860	39
ATC	ATC:6|atc:5|ATc:2|aTc:2	anhydrotetracycline:15:0.0418	0.0418	15
ATC	ATC:8	autologous tumor cells:8:0.5006	0.5006	8
ATC	ATC:21	automatic tube compensation:21:0.8594	0.8594	21
ATDs	ATDs:12	antithyroid drugs:12:0.5050	0.5050	12
ATD	ATD:40	Acute tryptophan depletion:40:0.9256	0.9256	40
ATD	ATD:9	alpha 1 antitrypsin deficiency:9:0.6794	0.6794	9
ATD	ATD:107	Alzheimer-type dementia:85:0.6285|Alzheimer type dementia:22:0.6178	0.6285	107
ATD	ATD:12	amino-terminal domain:7:0.1850|amino terminal domain:5:0.4422	0.4422	12
ATD	ATD:22	Amplatz thrombectomy device:22:0.8657	0.8657	22
ATD	ATD:65	antithyroid drugs:36:0.5563|antithyroid drug:29:0.8422	0.8422	65
ATD	ATD:13	aqueous tear deficiency:13:0.7753	0.7753	13
ATD	ATD:14	aromatase inhibitor 1,4,6-androstatriene-3,17-dione:14:0.7340	0.7340	14
ATD	ATD:31	autoimmune thyroid disease:31:0.9043	0.9043	31
ATD	ATD:9	Test Dummy:9:0.6794	0.6794	9
ATEE	ATEE:10|ATEe:2	N-acetyl-L-tyrosine ethyl ester:12:0.5355	0.5355	12
ATF-1	ATF-1:16|ATF1:3	Activating transcription factor-1:19:0.6106	0.6106	19
ATF1	ATF1:9|ATF-1:7	transcription factor 1:16:0.6577	0.6577	16
ATF-2	ATF-2:65|ATF2:38|Atf-2:1	Activating transcription factor 2:54:0.8842|Activating transcription factor-2:50:0.7676	0.8842	104
ATF3	ATF3:32|ATF-3:1	activating transcription factor 3:33:0.8605	0.8605	33
ATF4	ATF4:17|ATF-4:5	activating transcription factor 4:13:0.6701|activating transcription factor-4:9:0.5470	0.6701	22
ATFL	ATFL:9	anterior talofibular ligament:9:0.6794	0.6794	9
ATF	ATF:35	activating transcription factor:35:0.4220	0.4220	35
ATF	ATF:38	amino-terminal fragment:38:0.6005	0.6005	38
aTf	aTf:5	intracranial injection of apotransferrin:5:0.4422	0.4422	5
ATge	ATge:6|ATGE:1	gas exchange anaerobic threshold:7:0.5926	0.5926	7
ATG	ATG:11|Atg:4	angiotensinogen:15:0.0176	0.0176	15
ATG	ATG:109	anti-thymocyte globulin:109:0.1659	0.1659	109
ATG	ATG:375	antithymocyte globulin:362:0.6292|antithymocyte globulins:13:0.5934	0.6292	375
ATG	ATG:11	Aurothioglucose:11:0.0125	0.0125	11
ATH	ATH:5	covalent antithrombin-heparin complex:5:0.4422	0.4422	5
ATIC	ATIC:10	cyclohydrolase:10:0.7500	0.7500	10
ATIII	ATIII:344|AT-III:281|At-III:10|AtIII:2	antithrombin III:547:0.9294|antithrombin-III:90:0.1266	0.9294	637
ATII	ATII:70|AT-II:3	alveolar type II:73:0.7257	0.7257	73
ATII	ATII:60|AT-II:58|ATii:1	angiotensin II:97:0.4324|angiotensin-II:22:0.0854	0.4324	119
ATII	ATII:9|AT-II:3	type II cells:12:0.7571	0.7571	12
ATIN	ATIN:9	acute tubulointerstitial nephritis:9:0.4587	0.4587	9
ATI	ATI:16	abdominal trauma index:16:0.8165	0.8165	16
ATI	ATI:7	Treatment interaction:7:0.3524	0.3524	7
ATK	ATK:10	autologous tumor killing:10:0.7103	0.7103	10
ATL/L	ATL/L:9	adult T-cell leukemia/lymphoma:9:0.6794	0.6794	9
ATLL	ATLL:44	Adult T-cell Leukaemia/Lymphoma:37:0.8716|adult T-cell leukaemia lymphoma:7:0.5926	0.8716	44
ATLL	ATLL:214	adult T-cell leukemia/lymphoma:147:0.9675|adult T cell leukemia/lymphoma:34:0.9126|adult T-cell leukemia-lymphoma:26:0.8251|adult T-cell leukemia lymphoma:7:0.6411	0.9675	214
ATLL	ATLL:4	adult T-cell lymphoma/leukemia:4:0.1618	0.1618	4
ATLPL	ATLPL:12|AT-LPL:8	adipose tissue lipoprotein lipase:20:0.8525	0.8525	20
ATLS	ATLS:15	Acute tumor lysis syndrome:15:0.8045	0.8045	15
ATLS	ATLS:105	Advanced Trauma Life Support:105:0.9551	0.9551	105
ATL	ATL:74	adult T-cell leukaemia:63:0.9018|adult T cell leukaemia:11:0.7357	0.9018	74
ATL	ATL:16	adult T-cell leukaemia/lymphoma:16:0.7261	0.7261	16
ATL	ATL:868	adult T-cell leukemia:673:0.9818|adult T cell leukemia:195:0.9846	0.9846	868
ATL	ATL:208	adult T-cell leukemia/lymphoma:160:0.9813|adult T cell leukemia/lymphoma:26:0.8861|adult T-cell leukemia-lymphoma:22:0.8657	0.9813	208
ATL	ATL:7	adult T-cell lymphoma:7:0.4438	0.4438	7
ATL	ATL:16	American tegumentary leishmaniasis:16:0.8165	0.8165	16
ATL	ATL:96	anterior temporal lobectomy:96:0.9689	0.9689	96
ATL	ATL:11	ascending thin limb:11:0.7357	0.7357	11
ATL	ATL:9	temporal lobe:9:0.6794	0.6794	9
ATM	ATM:32	acute transverse myelitis:32:0.8563	0.8563	32
ATM	ATM:19	acute transverse myelopathy:19:0.8449	0.8449	19
ATM	ATM:24	Asynchronous transfer mode:24:0.8768	0.8768	24
ATM	ATM:15|Atm:2	ataxia telangiectasia:17:0.8270	0.8270	17
ATM	ATM:9|Atm:1	ataxia-telangiectasia gene:10:0.0787	0.0787	10
ATM	ATM:188|Atm:7|atm:1	ataxia telangiectasia mutated:88:0.9479|ataxia-telangiectasia mutated:68:0.3130|ataxia telangiectasia-mutated:21:0.8594|ataxia-telangiectasia-mutated:19:0.0338	0.9479	196
atm	atm:20	atmospheres:20:0.0356	0.0356	20
ATM	ATM:7	mutated protein:7:0.1850	0.1850	7
ATNC	ATNC:9	Apparent Total N-nitroso Compounds:9:0.6794	0.6794	9
ATNR	ATNR:11	tonic neck reflex:11:0.7357	0.7357	11
ATN	ATN:316	acute tubular necrosis:316:0.9705	0.9705	316
ATN	ATN:10	anterior thalamic nuclei:10:0.7103	0.7103	10
ATO	ATO:50	arsenic trioxide:50:0.9379	0.9379	50
ATP-TCA	ATP-TCA:23	Chemosensitivity Assay:23:0.7046	0.7046	23
ATPSs	ATPSs:12	aqueous two-phase systems:12:0.7571	0.7571	12
ATP[S]	ATP[S]:12	adenosine 5'-[gamma-thio]triphosphate:12:0.7571	0.7571	12
ATPase	ATPase:22|ATP-ase:1	adenosine-5'-triphosphatase:12:0.0088|adenosine 5'-triphosphatase:11:0.5355	0.5355	23
ATPase	ATPase:548|ATP-ase:15	adenosine triphosphatase:563:0.6764	0.6764	563
ATPase	ATPase:6	adenosine triphosphate:6:0.1838	0.1838	6
ATPase	ATPase:146|ATP-ase:4|ATP-ASE:1|AT-Pase:1	adenosinetriphosphatase:152:0.1219	0.1219	152
ATPi	ATPi:14	intracellular ATP:14:0.4367	0.4367	14
ATPo	ATPo:18	extracellular ATP:18:0.8365	0.8365	18
ATPS	ATPS:38	aqueous two-phase systems:24:0.8768|Aqueous two-phase system:14:0.7909	0.8768	38
ATP	ATP:1044	adenosine 5'-triphosphate:910:0.9715|adenosine-5'-triphosphate:115:0.0237|adenosine 5-triphosphate:10:0.5856|adenosine-5-triphosphate:9:0.0017	0.9715	1044
ATP	ATP:9	adenosine triphosphatase:9:0.6794	0.6794	9
ATP	ATP:2912	adenosine triphosphate:2890:0.9534|adenosine-triphosphate:22:0.0044	0.9534	2912
ATP	ATP:10	adenosine triphosphoric acid:10:0.7103	0.7103	10
ATP	ATP:41	adenosinetriphosphate:41:0.0083	0.0083	41
ATP	ATP:14	Annual Transmission Potential:14:0.6911	0.6911	14
ATP	ATP:41	antitachycardia pacing:41:0.8224	0.8224	41
ATP	ATP:56	autoimmune thrombocytopenic purpura:56:0.9176	0.9176	56
ATP	ATP:34	substrate:34:0.0069	0.0069	34
ATRA	ATRA:21|atRA:8|a-tRA:1|at-RA:1	all-trans RA:17:0.7407|all-trans-RA:14:0.0089	0.7407	31
ATRA	ATRA:1121|atRA:114|at-RA:15|AT-RA:5|aTRA:1|Atra:1	all-trans retinoic acid:886:0.9128|All-trans-retinoic acid:371:0.2416	0.9128	1257
ATR-IR	ATR-IR:8	attenuated total reflection infrared:8:0.6411	0.6411	8
ATRP	ATRP:33	atom transfer radical polymerization:33:0.9100	0.9100	33
ATR-X	ATR-X:7	X-linked alpha-thalassemia/mental retardation:7:0.4438	0.4438	7
ATR-X	ATR-X:8	X-linked alpha-thalassemia/mental retardation syndrome:8:0.3463	0.3463	8
ATR	ATR:8	Achilles tendon reflex:8:0.6411	0.6411	8
ATR	ATR:48	acid tolerance response:48:0.8463	0.8463	48
ATR	ATR:12|Atr:3	atractyloside:15:0.0263	0.0263	15
ATR	ATR:16	atrazine:16:0.0281	0.0281	16
ATR	ATR:34|Atr:23|atr:1	atropine:58:0.1069	0.1069	58
ATR	ATR:52	attenuated total reflectance:52:0.9427	0.9427	52
ATR	ATR:73	attenuated total reflection:73:0.8627	0.8627	73
ATR	ATR:12	Rad3-related protein:12:0.4557	0.4557	12
ATR	ATR:19|AT-R:1	receptor:20:0.0356	0.0356	20
ATSDR	ATSDR:78	Agency for Toxic Substances and Disease Registry:78:0.9393	0.9393	78
ATS	ATS:150	American Thoracic Society:150:0.9577	0.9577	150
ATS	ATS:46	anti-thymocyte serum:46:0.2088	0.2088	46
ATS	ATS:52	antithymocyte serum:52:0.2434	0.2434	52
ATS	ATS:9	Atherosclerosis:9:0.0136	0.0136	9
ATS	ATS:9	rabbit anti-rat thymocyte serum:9:0.3455	0.3455	9
ATS	ATS:16	syndrome:16:0.0255	0.0255	16
ATS	ATS:5	thymocyte antiserum:5:0.0902	0.0902	5
ATTR	ATTR:6	amyloidogenic transthyretin:6:0.1838	0.1838	6
ATVs	ATVs:25	All-terrain vehicles:25:0.6539	0.6539	25
ATV	ATV:19	all-terrain vehicle:19:0.6106	0.6106	19
ATV	ATV:7|Atv:2	Atorvastatin:9:0.1039	0.1039	9
ATx	ATx:8|ATX:3|aTx:1	adult thymectomized:12:0.2549	0.2549	12
ATx	ATx:18|ATX:2|aTx:1|A-Tx:1	adult thymectomy:22:0.8657	0.8657	22
ATX	ATX:33	Autotaxin:33:0.2991	0.2991	33
ATZ	ATZ:9	aminotriazole:9:0.0952	0.0952	9
ATZ	ATZ:14	anal transitional zone:14:0.7909	0.7909	14
ATZ	ATZ:14|Atz:2	atrazine:16:0.1786	0.1786	16
ATase	ATase:9	amidophosphoribosyltransferase:9:0.0721	0.0721	9
ATase	ATase:57|Atase:1	O6-alkylguanine-DNA alkyltransferase:30:0.4104|O6-alkylguanine-DNA-alkyltransferase:28:0.2432	0.4104	58
AUA	AUA:140	American Urological Association:140:0.9785	0.9785	140
AUASI	AUASI:12|AUA-SI:4	American Urological Association Symptom Index:16:0.8165	0.8165	16
AUASS	AUASS:5|AUA-SS:3	American Urological Association symptom score:8:0.5006	0.5006	8
AUB	AUB:31	abnormal uterine bleeding:31:0.8519	0.8519	31
AUC(0-24)	AUC(0-24):6|AUC(0--24):1	area under the concentration-time curve from 0 to 24 h:7:0.4438	0.4438	7
AUC(0-24)	AUC(0-24):4	concentration-time curve from time zero to 24 h:4:0.3170	0.3170	4
AUC0-12	AUC0-12:6	area under the concentration-time curve:6:0.5926	0.5926	6
AUC0-24	AUC0-24:6	area under the plasma concentration-time curve:6:0.3728	0.3728	6
AUC0-24	AUC0-24:7	concentration-time curve from 0 to 24 hours:7:0.3524	0.3524	7
AUC0-24	AUC0-24:5	under the concentration-time curve from 0 to 24 h:5:0.4422	0.4422	5
AUC0-t	AUC0-t:5	area under the curve:5:0.4422	0.4422	5
AUCs	AUCs:9	area under the concentration-time curves:9:0.1690	0.1690	9
AUCs	AUCs:86	areas under the curve:62:0.8824|areas under the curves:24:0.4668	0.8824	86
AUCs	AUCs:17	under the plasma concentration-time curves:17:0.8449	0.8449	17
AUC	AUC:23	analytical ultracentrifugation:23:0.8715	0.8715	23
AUC	AUC:3	areas under concentration-time curves:3:0.3412	0.3412	3
AUC	AUC:15	area-under-curve:15:0.0024	0.0024	15
AUC	AUC:13	area under the concentration:13:0.8270	0.8270	13
AUC	AUC:537	area under the concentration-time curve:524:0.9383|area under the concentration-time curves:13:0.2522	0.9383	537
AUC	AUC:2163|auc:4|AuC:1	area under the curve:2025:0.9299|area-under-the-curve:76:0.0129|areas under the curves:39:0.4622|Area under the curves:28:0.2861	0.9299	2168
AUC	AUC:8	area under the curve of concentration versus time:8:0.5470	0.5470	8
AUC	AUC:4	area under the plasma concentration:4:0.4422	0.4422	4
AUC	AUC:508	area under the plasma concentration-time curve:456:0.9249|area under the plasma concentration-time curves:28:0.3543|areas under the plasma concentration-time curves:24:0.3543	0.9249	508
AUC	AUC:8	concentration time-curve:8:0.2987	0.2987	8
AUC	AUC:7	concentration-time profiles:7:0.3524	0.3524	7
AUC	AUC:4	concentration vs time curves:4:0.4849	0.4849	4
AUC	AUC:5	curve values:5:0.0736	0.0736	5
AUC	AUC:13	drug exposure:13:0.1348	0.1348	13
AUC	AUC:8	extent of absorption:8:0.3463	0.3463	8
AUC	AUC:28	plasma concentration-time curve from time zero to time infinity:28:0.8941	0.8941	28
AUC	AUC:12	systemic exposure:12:0.1163	0.1163	12
AUC	AUC:4	under the plasma concentration-time profile:4:0.3170	0.3170	4
AUDIT	AUDIT:166	Alcohol Use Disorders Identification Test:166:0.9701	0.9701	166
AUDs	AUDs:41	Alcohol Use Disorders:41:0.8525	0.8525	41
AUD	AUD:40	alcohol use disorder:22:0.7955|Alcohol Use Disorders:18:0.7539	0.7955	40
AUIC	AUIC:12	area under the inhibitory curve:12:0.5664	0.5664	12
AUI	AUI:13	Alcohol Use Inventory:13:0.7753	0.7753	13
AUL	AUL:13	acute undifferentiated leukaemia:13:0.5335	0.5335	13
AUL	AUL:48	acute undifferentiated leukemia:48:0.8433	0.8433	48
AUMC	AUMC:6	area under the first moment curve:6:0.6411	0.6411	6
AUMC	AUMC:6|AuMC:1	area under the moment curve:7:0.5926	0.5926	7
AUM	AUM:17	Asymmetric unit membrane:17:0.6211	0.6211	17
AUN	AUN:15	Acute unilateral nephrectomy:15:0.8045	0.8045	15
AUROC	AUROC:6	under the receiver operating characteristic:6:0.7357	0.7357	6
AUR	AUR:54	Acute urinary retention:54:0.9448	0.9448	54
AUR	AUR:14|Aur:2	auranofin:16:0.1389	0.1389	16
AUR	AUR:11	auromomycin:11:0.0926	0.0926	11
AUS	AUS:43	artificial urinary sphincter:43:0.8917	0.8917	43
AV3V	AV3V:6	anteroventral third ventricle region:6:0.5290	0.5290	6
AV3V	AV3V:8	anteroventral third ventricular:8:0.3463	0.3463	8
AV3V	AV3V:7	anteroventral third ventricular region:7:0.4438	0.4438	7
AVAs	AVAs:47	arteriovenous anastomoses:47:0.7960	0.7960	47
AVA	AVA:11	Anthrax Vaccine Adsorbed:11:0.7909	0.7909	11
AVA	AVA:51	aortic valve area:51:0.9082	0.9082	51
AVA	AVA:27	arteriovenous anastomoses:27:0.6745	0.6745	27
AVA	AVA:1	main metabolite apovincaminic acid:1:0.1618	0.1618	1
AVB	AVB:80	atrioventricular block:80:0.6837	0.6837	80
AVCN	AVCN:12	anteroventral:12:0.0833	0.0833	12
AVCN	AVCN:96	anteroventral cochlear nucleus:96:0.7804	0.7804	96
AVCO2R	AVCO2R:10	Arteriovenous carbon dioxide removal:10:0.7103	0.7103	10
AVCT	AVCT:27	conduction time:27:0.8312	0.8312	27
AVCS	AVCS:6	atrioventricular conduction system:6:0.5290	0.5290	6
AVC	AVC:12	aortic valve calcification:12:0.6460	0.6460	12
AVC	AVC:22	atrioventricular canal:22:0.6531	0.6531	22
AVDO2	AVDO2:4|AVDo2:1	arteriovenous difference of oxygen:5:0.1464	0.1464	5
AVDO2	AVDO2:19|AVDo2:1	arteriovenous oxygen difference:20:0.5021	0.5021	20
AVDO2	AVDO2:30|avDO2:5|AVDo2:2|a-vDO2:1	oxygen content difference:30:0.7652|oxygen content differences:8:0.6411	0.7652	38
AVDO2	AVDO2:5	oxygen differences:5:0.0517	0.0517	5
AVD	AVD:12	aortic valve disease:12:0.7571	0.7571	12
AVD	AVD:15	apoptotic volume decrease:15:0.7096	0.7096	15
aVd	aVd:8|AVd:4|AVD:4|aVD:2	apparent volume of distribution:18:0.6903	0.6903	18
AVd	AVd:5|AVD:4	arteriovenous difference:9:0.2102	0.2102	9
AVD	AVD:14|AVd:1	atrioventricular delay:15:0.4312	0.4312	15
AVD	AVD:12	vascular disease:12:0.2183	0.2183	12
AVED	AVED:6	Ataxia with isolated vitamin E deficiency:6:0.3728	0.3728	6
AVED	AVED:8	Ataxia with vitamin E deficiency:8:0.1471	0.1471	8
AVE	AVE:10	active voluntary euthanasia:10:0.7103	0.7103	10
AVE	AVE:20	anterior visceral endoderm:20:0.8525	0.8525	20
AVFs	AVFs:104|AV-Fs:1	arteriovenous fistulas:105:0.8908	0.8908	105
AVFs	AVFs:18	arteriovenous fistulae:18:0.8365	0.8365	18
AVF	AVF:23	abdominal visceral fat:23:0.8715	0.8715	23
AVF	AVF:339|avF:1|AV-F:1	Arteriovenous fistula:289:0.8669|arteriovenous fistulas:52:0.6917	0.8669	341
AVF	AVF:50	Arteriovenous fistulae:50:0.8520	0.8520	50
AVGs	AVGs:12	arteriovenous grafts:12:0.3813	0.3813	12
AVG	AVG:21	arteriovenous graft:13:0.4102|arteriovenous grafts:8:0.1367	0.4102	21
AVG	AVG:6	autogenous vein grafts:6:0.2827	0.2827	6
AVG	AVG:6	inhibitor aminoethoxyvinylglycine:6:0.1838	0.1838	6
AVH	AVH:70	acute viral hepatitis:70:0.9573	0.9573	70
AVHB	AVHB:11|AVH-B:2	acute viral hepatitis B:13:0.7753	0.7753	13
AVID	AVID:55	Antiarrhythmics Versus Implantable Defibrillators:55:0.8842	0.8842	55
AVI	AVI:8|AVi:1	interval:9:0.2162	0.2162	9
AVJ	AVJ:11	atrioventricular junction:11:0.7357	0.7357	11
AVJRT	AVJRT:8	junctional reentrant tachycardia:8:0.6411	0.6411	8
AVLT	AVLT:36	auditory verbal learning test:36:0.9174	0.9174	36
AVL	AVL:33	American visceral leishmaniasis:33:0.8196	0.8196	33
AVL	AVL:9	artificial ventilation of the lungs:9:0.5856	0.5856	9
AVM's	AVM's:94	arteriovenous malformations:94:0.9045	0.9045	94
AVMs	AVMs:722|AVMS:1	arteriovenous malformations:723:0.9709	0.9709	723
AVM	AVM:914	arteriovenous malformation:695:0.9516|Arteriovenous malformations:219:0.8892	0.9516	914
AVM	AVM:9	Avermectin B1a:9:0.6794	0.6794	9
AVM	AVM:9	avian vacuolar myelinopathy:9:0.6794	0.6794	9
AVNRT	AVNRT:129	Atrioventricular nodal reentrant tachycardia:129:0.5538	0.5538	129
AVN	AVN:25	atrioventricular nodal:25:0.6240	0.6240	25
AVN	AVN:77	atrioventricular node:77:0.6777	0.6777	77
AVN	AVN:180|avn:1	avascular necrosis:181:0.9568	0.9568	181
AVN	AVN:11	avascular necrosis of bone:11:0.7357	0.7357	11
AVO2	AVO2:6|A-VO2:3|a-VO2:2	arteriovenous oxygen difference:11:0.6182	0.6182	11
aVOR	aVOR:14|AVOR:5	angular vestibulo-ocular reflex:19:0.8449	0.8449	19
aVOR	aVOR:8|AVOR:1	angular vestibuloocular reflex:9:0.6794	0.6794	9
AVP-A	AVPA:4|AVP-A:4|AVPa:2|AVP-a:1	antagonist:11:0.4348	0.4348	11
AVPD	AVPD:24	atrioventricular plane displacement:24:0.7593	0.7593	24
AVP-ir	AVP-ir:7|AVP-IR:3	AVP-immunoreactive:10:0.2727	0.2727	10
AVPV	AVPV:29|AVPv:19	anteroventral periventricular nucleus:48:0.9379	0.9379	48
AVP	AVP:13	adenovirus proteinase:13:0.5934	0.5934	13
AVP	AVP:28	ambulatory venous pressure:28:0.7905	0.7905	28
AVP	AVP:24	arg-vasopressin:24:0.0046	0.0046	24
AVP	AVP:72	[Arg8]vasopressin:39:0.0075|arg8-vasopressin:18:0.0034|[Arg8]-vasopressin:15:0.0028	0.0075	72
AVP	AVP:11	arginin-vasopressin:11:0.0020	0.0020	11
AVP	AVP:31	arginine-8-vasopressin:31:0.0060	0.0060	31
AVP	AVP:3573|aVP:4|A-VP:1|a-VP:1	arginine vasopressin:3034:0.7412|arginine-vasopressin:545:0.1079	0.7412	3579
AVP	AVP:8	arginine vasopression:8:0.5006	0.5006	8
AVP	AVP:26	arginine8-vasopressin:26:0.0050	0.0050	26
AVP	AVP:29	arteriovenous passage time:29:0.8422	0.8422	29
AVRT	AVRT:27	atrioventricular reciprocating tachycardia:27:0.6192	0.6192	27
AVRT	AVRT:27	atrioventricular reentrant tachycardia:27:0.5334	0.5334	27
AVRT	AVRT:10	AV reentrant tachycardia:10:0.1203	0.1203	10
AVR	AVR:43	acute vascular rejection:43:0.9308	0.9308	43
AVR	AVR:589	aortic valve replacement:557:0.9758|aortic valve replacements:32:0.9072	0.9758	589
AVR	AVR:9	arteriole-to-venule ratio:9:0.3455	0.3455	9
AVR	AVR:27	ascending vasa recta:27:0.8903	0.8903	27
Avr	Avr:8|avr:2	pathogen avirulence:10:0.0713	0.0713	10
AVSC	AVSC:31	Association for Voluntary Surgical Contraception:31:0.9072	0.9072	31
AVSD	AVSD:62	atrioventricular septal defect:52:0.8316|atrioventricular septal defects:10:0.5000	0.8316	62
AVSDs	AVSDs:10	atrioventricular septal defects:10:0.7103	0.7103	10
AVS	AVS:38	acid-volatile sulfide:13:0.2660|acid volatile sulfide:12:0.7571|acid-volatile sulfides:8:0.2327|acid volatile sulfides:5:0.2818	0.7571	38
AVS	AVS:13	aortic valve sclerosis:13:0.7753	0.7753	13
AVS	AVS:13	aortic valve stenosis:13:0.7753	0.7753	13
AVS	AVS:6	arteriovenous shunt:6:0.2243	0.2243	6
AVs	AVs:26	Autophagic vacuoles:26:0.8251	0.8251	26
AVS	AVS:6	visualization system:6:0.2243	0.2243	6
AVTD	AVTD:10	method of anomalous viscosity time dependence:10:0.5000	0.5000	10
AVT	AVT:13	area ventralis of Tsai:13:0.7753	0.7753	13
AVT	AVT:385	arginine vasotocin:348:0.8951|arginine-vasotocin:37:0.0720	0.8951	385
AvWS	AvWS:11|AVWS:9|avWS:3	acquired von Willebrand syndrome:23:0.8715	0.8715	23
AV	AV:12	abomasal volvulus:12:0.7571	0.7571	12
AV	AV:5	Adriamycin and vincristine:5:0.1320	0.1320	5
AV	AV:5	adriamycin plus vincristine:5:0.4422	0.4422	5
A-V	A-V:5|AV:4|a-v:1	animal-vegetal:10:0.0023	0.0023	10
AV	AV:6	annexin V:6:0.2243	0.2243	6
AV	AV:14	anterior ventral:14:0.7909	0.7909	14
AV	AV:5	anteroventral nucleus:5:0.0902	0.0902	5
AV	AV:32	aortic valve:32:0.7782	0.7782	32
A-V	A-V:14|a-v:2|AV:1	arterial-venous:17:0.0040	0.0040	17
A-V	A-V:40|AV:19|a-v:5|A--V:1	arterio-venous:65:0.0161	0.0161	65
AV	AV:382|A-V:111|a-v:24|av:4	arteriovenous:521:0.1309	0.1309	521
AV	AV:9	Artificial vagina:9:0.6794	0.6794	9
AV	AV:8	artificial ventilation:8:0.1591	0.1591	8
AV	AV:7	assisted ventilation:7:0.1111	0.1111	7
AV	AV:54|A-V:48|a-v:2	atrio-ventricular:104:0.0259	0.0259	104
AV	AV:2182|A-V:314|a-v:5|av:3|A--V:1|Av:1	Atrioventricular:2506:0.6309	0.6309	2506
AV	AV:14	Audiovisual:14:0.0033	0.0033	14
AV	AV:11|A-V:3	auditory-visual:14:0.0033	0.0033	14
AV	AV:18	autophagic vacuoles:18:0.7539	0.7539	18
AV	AV:7	femoral anteversion:7:0.2113	0.2113	7
AV	AV:9	human adenovirus:9:0.0674	0.0674	9
AV	AV:15	velocity:15:0.0035	0.0035	15
A-V	A-V:5|AV:3|A--V:1	venous:9:0.0020	0.0020	9
AWA	AWA:17	adult worm antigen:17:0.7407	0.7407	17
AWD	AWD:13	abdominal wall defects:13:0.7753	0.7753	13
AWD	AWD:8	alive with disease:8:0.5006	0.5006	8
AW-GC	AW-GC:17|AWGC:2|A-W-GC:1|A-WGC:1	glass ceramic:11:0.7357|glass-ceramic:10:0.3913	0.7357	21
AWM	AWM:10	wall motion:10:0.7103	0.7103	10
AWP	AWP:10|AwP:1	Airway pressure:11:0.6182	0.6182	11
AWP	AWP:9	average wholesale price:9:0.6794	0.6794	9
AWS	AWS:39	Alcohol withdrawal syndrome:39:0.8142	0.8142	39
AWW	AWW:11	Anganwadi workers:11:0.7357	0.7357	11
AXC	AXC:20	aortic cross-clamping:20:0.7766	0.7766	20
AX	AX:17	amoxicillin:17:0.0988	0.0988	17
AX	AX:20	arabinoxylans:10:0.0556|arabinoxylan:10:0.0556	0.0556	20
AYVV	AYVV:9	ageratum yellow vein virus:9:0.5470	0.5470	9
Ay	Ay:24	lethal yellow:24:0.6427	0.6427	24
AZA	AZA:12|Aza:4	5-azacytidine:16:0.0263	0.0263	16
AZA	AZA:357|Aza:103|AzA:1|aza:1	Azathioprine:462:0.8088	0.8088	462
AZA	AZA:9|AzA:2	azelaic acid:11:0.7357	0.7357	11
AZF	AZF:48	azoospermia factor:48:0.6967	0.6967	48
AZF	AZF:14	bovine adrenal zona fasciculata:14:0.5589	0.5589	14
AZI	AZI:18|azi:1	azithromycin:19:0.5806	0.5806	19
AZM	AZM:13	acetazolamide:13:0.1304	0.1304	13
AZM	AZM:66	Azithromycin:66:0.7065	0.7065	66
AZOOR	AZOOR:13	Acute zonal occult outer retinopathy:13:0.7753	0.7753	13
AZP	AZP:13|Azp:1	azathioprine:14:0.2708	0.2708	14
AZQ	AZQ:33	aziridinylbenzoquinone:33:0.2807	0.2807	33
AZQ	AZQ:55	diaziquone:55:0.4737	0.4737	55
AZTMP	AZTMP:9|AZT-MP:4	5'-monophosphate:13:0.2182	0.2182	13
AZTMP	AZTMP:15|AZT-MP:6	monophosphate:21:0.3455	0.3455	21
AZTTP	AZTTP:10|AZT-TP:1	3'-azido-3'-deoxythymidine 5'-triphosphate:11:0.2422	0.2422	11
AZT	AZT:77|az-T:1	3'-azido-2',3'-dideoxythymidine:78:0.0479	0.0479	78
AZT	AZT:384|AzT:1|Az-T:1	3'-azido-3'-deoxythymidine:386:0.2406	0.2406	386
AZT	AZT:9	3'-azido-3'deoxythymidine:9:0.0050	0.0050	9
AZT	AZT:10|AzT:1	3'-azidothymidine:11:0.0063	0.0063	11
AZT	AZT:239	azidothymidine:239:0.1486	0.1486	239
AZT	AZT:9	clinical studies on aztreonam:9:0.6911	0.6911	9
AZT	AZT:614	zidovudine:614:0.3841	0.3841	614
AaDO2	AaDO2:12|A-aDO2:11|A--adO2:1|A-aD-O-2:1	alveolar-arterial oxygen difference:25:0.4917	0.4917	25
A-aDO2	A-aDO2:13|AaDO2:8|AaDo2:2|AADO2:1|A-aDo2:1	alveolar-arterial oxygen gradient:25:0.6240	0.6240	25
AadAT	AadAT:7|AADAT:2	aminotransferase:9:0.8000	0.8000	9
Ab-MLV	Ab-MLV:11	Abelson murine leukemia virus:11:0.7357	0.7357	11
Ab1	Ab1:34|ab1:2|AB1:1|Ab-1:1	antibodies:38:0.1603	0.1603	38
Ab1	Ab1:9|ab1:1|AB1:1|Ab-1:1	monoclonal antibody:12:0.1692	0.1692	12
Ab2	Ab2:5	anti-Id mAb:5:0.0517	0.0517	5
Ab2	Ab2:15|ab2:6|AB2:1|Ab-2:1	anti-idiotypic:23:0.0721	0.0721	23
Ab2	Ab2:83|ab2:6|Ab-2:4	anti-idiotypic antibodies:62:0.4290|anti-idiotypic antibody:31:0.4399	0.4399	93
AbMV	AbMV:12	abutilon mosaic virus:12:0.7571	0.7571	12
Ab-MuLV	Ab-MuLV:7|AbMuLV:2	Abelson murine leukemia virus:9:0.6794	0.6794	9
AB-PAS	AB-PAS:9	Alcian blue-periodic acid schiff:9:0.6794	0.6794	9
Abd-B	Abd-B:44|AbdB:12|ABD-B:2|Abdb:1	Abdominal-B:45:0.7333|Abdominal B:14:0.7909	0.7909	59
Abeta	Abeta:499|A-beta:3	amyloid beta-peptide:220:0.9782|amyloid-beta peptide:112:0.2377|amyloid beta peptide:106:0.9406|amyloid-beta peptides:19:0.1631|amyloid beta peptides:17:0.8270|amyloid beta-peptides:15:0.8045|amyloid-beta-peptide:13:0.0057	0.9782	502
Abeta	Abeta:340|A-beta:2	amyloid beta-protein:185:0.9648|amyloid beta protein:121:0.9753|amyloid-beta protein:36:0.1114	0.9753	342
Abeta	Abeta:158|abeta:1|ABeta:1	beta-amyloid peptide:135:0.2939|beta-amyloid peptides:25:0.2452	0.2939	160
Abeta	Abeta:44|ABeta:1|A-beta:1	beta-amyloid protein:46:0.1523	0.1523	46
ABM	ABM:32	acute bacterial meningitis:32:0.8563	0.8563	32
ABM	ABM:12	basement membrane:12:0.5664	0.5664	12
ABM	ABM:52|aBM:1	bone marrow:53:0.9438	0.9438	53
ABM	ABM:10	Bone Matrix:10:0.5000	0.5000	10
Ac.f	Ac.f:10|Ac.F:1	activation frequency:11:0.7357	0.7357	11
AcAc	AcAc:62|ACAC:5|Ac-Ac:2|acac:1	acetoacetate:70:0.6330	0.6330	70
AcChE	AcChE:17	acetylcholinesterase:17:0.8421	0.8421	17
AcChR	AcChR:38	acetylcholine receptor:38:0.8417	0.8417	38
AcChoR	AcChoR:54|AcChOR:1	acetylcholine receptor:47:0.8433|acetylcholine receptors:8:0.5006	0.8433	55
AcCho	AcCho:57|AcCHo:1	acetylcholine:58:0.7703	0.7703	58
AcCh	AcCh:19	acetylcholine:19:0.6429	0.6429	19
AcINH	AcINH:9|acINH:1|ACINH:1	acetylisoniazid:11:0.6667	0.6667	11
AcMNPV	AcMNPV:9|ACMNPV:1	Autographa californica:10:0.7103	0.7103	10
AcMNPV	AcMNPV:22	Autographa californica MNPV:22:0.8657	0.8657	22
AcMNPV	AcMNPV:37	Autographa californica multicapsid nucleopolyhedrovirus:37:0.9174	0.9174	37
AcMNPV	AcMNPV:8	Autographa californica NPV:8:0.6411	0.6411	8
AcMNPV	AcMNPV:104|Ac-MNPV:1	Autographa californica nuclear polyhedrosis virus:105:0.9715	0.9715	105
AcMNPV	AcMNPV:44	Autographa californica nucleopolyhedrovirus:44:0.9323	0.9323	44
AcNPV	AcNPV:12	Autographa californica NPV:12:0.7571	0.7571	12
AcNPV	AcNPV:147|ACNPV:1	autographa californica nuclear polyhedrosis virus:148:0.9382	0.9382	148
AcNPV	AcNPV:14	Autographa californica nucleopolyhedrovirus:14:0.7909	0.7909	14
AcNPV	AcNPV:5	derived from the nuclear polyhedrosis virus of Autographa californica:5:0.2818	0.2818	5
AcPh	AcPh:9|Acph:2|ACPH:2|ACPh:1|AcPH:1	acid phosphatase:15:0.8045	0.8045	15
AcSDKP	AcSDKP:11|Ac-SDKP:1	N-acetyl-Ser-Asp-Lys-Pro:12:0.1279	0.1279	12
Ac-SDKP	Ac-SDKP:13|AcSDKP:8	N-acetyl-seryl-aspartyl-lysyl-proline:21:0.2326	0.2326	21
AcSDKP	AcSDKP:11	tetrapeptide acetyl-N-Ser-Asp-Lys-Pro:11:0.3058	0.3058	11
AcSDKP	AcSDKP:6	tetrapeptide acetyl-Ser-Asp-Lys-Pro:6:0.1838	0.1838	6
AcbSh	AcbSh:12	nucleus accumbens shell:12:0.6701	0.6701	12
AchRAb	AchRAb:3|AChR-Ab:2|AChRAB:1|AchRab:1	acetylcholine receptor:7:0.3524	0.3524	7
AchRAb	AchRAb:8|AChRAb:7|AChR-ab:6|AChR-Ab:3|AchRab:2|AChRab:2|AChR-AB:1|AchR-Ab:1	receptor antibody:20:0.8525|receptor antibodies:10:0.5856	0.8525	30
AckA	AckA:6|ackA:4	acetate kinase:10:0.7103	0.7103	10
ACO	ACO:52	acyl-CoA oxidase:35:0.3603|acyl CoA oxidase:17:0.8270	0.8270	52
ACO	ACO:12	anterior capsule opacification:12:0.6460	0.6460	12
Act1	Act1:4|act1:1	rice actin 1 gene:5:0.2818	0.2818	5
ActR-II	ActR-II:6|ActRII:2|actRII:1	activin type II receptor:9:0.5470	0.5470	9
Ad.lacZ	Ad.lacZ:8|Ad.LacZ:2	beta-galactosidase:10:0.5294	0.5294	10
Ad12	Ad12:110|Ad-12:4|AD12:2|ad12:1	adenovirus type 12:117:0.9117	0.9117	117
Ad2MLP	Ad2MLP:13	major late promoter:13:0.7753	0.7753	13
Ad2	Ad2:10	adenovirus:10:0.0298	0.0298	10
Ad2	Ad2:47|Ad-2:7|ad2:1|AD2:1	adenovirus 2:47:0.1301|adenovirus-2:9:0.0265	0.1301	56
Ad2	Ad2:167|Ad-2:6|ad2:2	adenovirus type 2:175:0.9058	0.9058	175
ad-3	ad-3:19	adenine-3:19:0.2466	0.2466	19
Ad3	Ad3:21	adenovirus type 3:21:0.7291	0.7291	21
Ad4	Ad4:17|Ad-4:1	adenovirus type 4:18:0.6903	0.6903	18
Ad5	Ad5:49	adenovirus serotype 5:49:0.5465	0.5465	49
Ad5	Ad5:215|AD5:2|Ad-5:2|ad5:1	adenovirus type 5:220:0.8463	0.8463	220
Ad5	Ad5:18	type 5 adenovirus:18:0.6381	0.6381	18
Ad7	Ad7:20|AD-7:1	adenovirus type 7:21:0.7291	0.7291	21
Ad8	Ad8:9	adenovirus type 8:9:0.6794	0.6794	9
Ad9	Ad9:12	human adenovirus type 9:12:0.5050	0.5050	12
AdDP	AdDP:13	adamantylamide dipeptide:13:0.7753	0.7753	13
AdGFP	AdGFP:12|Ad-GFP:10	green fluorescent protein:22:0.7955	0.7955	22
AdL3	AdL3:7|ADL3:1	advanced third-stage larvae:8:0.5006	0.5006	8
AdLacZ	AdLacZ:23|Ad-LacZ:12|AdlacZ:5|Ad-lacZ:3	beta-galactosidase:43:0.3853	0.3853	43
AdMLP	AdMLP:19|Ad-MLP:1	adenovirus major late promoter:20:0.7173	0.7173	20
AdML	AdML:7|Ad-ML:1	adenovirus major late:8:0.4102	0.4102	8
AdNT	AdNT:12	adenine nucleotide translocase:12:0.7571	0.7571	12
AD-SoS	AD-SoS:24|AD-SOS:8|Ad-SoS:6|Ad-SOS:5|Ad-Sos:1	amplitude-dependent speed of sound:44:0.8076	0.8076	44
AdeNOS	AdeNOS:4	vectors encoding eNOS:4:0.3463	0.3463	4
ADHR	ADHR:20	Autosomal dominant hypophosphatemic rickets:20:0.7766	0.7766	20
ADI-R	ADI-R:32|ADI-r:1	Autism Diagnostic Interview-Revised:33:0.9072	0.9072	33
ADIOL	ADIOL:5|Adiol:1	5-androstene-3 beta,17 beta-diol:6:0.1320	0.1320	6
Adiol	Adiol:8|ADIOL:4|A-diol:1|adiol:1	androstenediol:14:0.1566	0.1566	14
A-dione	A-dione:20|Adione:16|ADIONE:4|adione:1	androstenedione:41:0.7407	0.7407	41
ADM	ADM:86	abductor digiti minimi:86:0.9449	0.9449	86
ADM	ADM:14	abductor digiti minimi muscle:14:0.7909	0.7909	14
ADM	ADM:20	acellular dermal matrix:20:0.7173	0.7173	20
ADM	ADM:14|Adm:2|AdM:1	adrenodemedullated:17:0.0122	0.0122	17
ADM	ADM:260|Adm:8|AdM:5	Adrenomedullin:273:0.2070	0.2070	273
ADM	ADM:676|Adm:7|AdM:2|adm:1	Adriamycin:686:0.5213	0.5213	686
ADM	ADM:15	amyopathic dermatomyositis:15:0.6386	0.6386	15
ADM	ADM:53	doxorubicin:53:0.0411	0.0411	53
AdoCbl	AdoCbl:30|Ado-Cbl:4|Adocbl:1|Ado-CBL:1	adenosylcobalamin:36:0.6604	0.6604	36
AdoHcy	AdoHcy:73	S-adenosyl-L-homocysteine:73:0.2915	0.2915	73
AdoHcy	AdoHcy:155	S-adenosylhomocysteine:155:0.6235	0.6235	155
AdoMet	AdoMet:145|Ado-Met:4|Ado-met:1|Adomet:1	S-Adenosyl-L-methionine:151:0.2982	0.2982	151
AdoMet	AdoMet:8|Ado-Met:1	S-Adenosyl methionine:9:0.3455	0.3455	9
AdoMet	AdoMet:290|Ado-Met:2|Adomet:1	S-adenosylmethionine:293:0.5805	0.5805	293
AdoR	AdoR:7|ADOR:2	adenosine receptor:9:0.5470	0.5470	9
ADO	ADO:197|Ado:192|ado:3	adenosine:392:0.7899	0.7899	392
ADO	ADO:6	Allele drop-out:6:0.1838	0.1838	6
ADO	ADO:19	allele dropout:19:0.7658	0.7658	19
ADO	ADO:14	Amplatzer duct occluder:14:0.7909	0.7909	14
ADO	ADO:12	autosomal dominant osteopetrosis:12:0.7571	0.7571	12
Ad-p53	Ad-p53:5	p53-expressing adenovirus:5:0.0902	0.0902	5
ADX	ADX:9|Adx:1	adrenalectomised:10:0.0101	0.0101	10
ADX	ADX:371|Adx:30|adx:8|ADx:3|AdX:2|adX:2	adrenalectomized:416:0.4637	0.4637	416
ADX	ADX:9|AdX:1	adrenalectomized rats:10:0.7103	0.7103	10
ADX	ADX:350|Adx:21|adx:7|ADx:1	adrenalectomy:379:0.4212	0.4212	379
Adx	Adx:7|ADX:2	bovine adrenodoxin:9:0.0674	0.0674	9
AD	AD:27|Ad:1	actinomycin D:28:0.8369	0.8369	28
AD	AD:23	activation domain:23:0.5466	0.5466	23
AD	AD:12	Acute diarrhea:12:0.7571	0.7571	12
AD	AD:21|Ad:6|ad:1	adenocarcinoma:28:0.0016	0.0016	28
AD	AD:25|Ad:9	adenosine:34:0.0019	0.0019	34
AD	AD:9|Ad:2	adenosine deaminase:11:0.7357	0.7357	11
Ad	Ad:117|AD:1	adenoviral:118:0.0067	0.0067	118
Ad	Ad:18	adenoviral vectors:12:0.3275|adenoviral vector:6:0.0807	0.3275	18
Ad	Ad:16	adenovirus vector:9:0.2500|adenovirus vectors:7:0.0951	0.2500	16
Ad	Ad:7|AD:6	adherent:13:0.0007	0.0007	13
Ad	Ad:8|AD:2	adrenodoxin:10:0.0005	0.0005	10
AD	AD:16|Ad:9	Adriamycin:25:0.0014	0.0014	25
AD	AD:9|Ad:5	adult:14:0.0007	0.0007	14
AD	AD:9	adult-directed:9:0.0005	0.0005	9
AD	AD:23|Ad:3	advance directive:14:0.6911|advance directives:12:0.6460	0.6911	26
AD	AD:9	affective disorders:9:0.1205	0.1205	9
AD	AD:21	after-discharge:21:0.0012	0.0012	21
AD	AD:149	afterdischarge:128:0.0073|afterdischarges:21:0.0012	0.0073	149
AD	AD:40	alcohol dependence:40:0.8839	0.8839	40
AD	AD:63|aD:1	Alzheimer's:51:0.0029|Alzheimer:13:0.0007	0.0029	64
AD	AD:65|aD:3	Alzheimer's dementia:51:0.3956|Alzheimer dementia:17:0.0858	0.3956	68
AD	AD:10439|aD:141|Ad:31|ad:1	Alzheimer's disease:10612:0.8395	0.8395	10612
AD	AD:6	Alzheimer's disease patients:6:0.3728	0.3728	6
AD	AD:15	Alzheimer-type dementia:15:0.0698	0.0698	15
AD	AD:19|Ad:1	amiodarone:20:0.0011	0.0011	20
AD	AD:25|Ad:1	androgen-dependent:20:0.0011|androgen dependent:6:0.1838	0.1838	26
AD	AD:31	androgen deprivation:31:0.9043	0.9043	31
AD	AD:55|Ad:5	androstenedione:60:0.0034	0.0034	60
AD	AD:9	androsterone:9:0.0005	0.0005	9
AD	AD:30	anoxic depolarization:30:0.8472	0.8472	30
AD	AD:12	Anterodorsal:12:0.0006	0.0006	12
AD	AD:5	anterodorsal thalamic nucleus:5:0.2818	0.2818	5
AD	AD:49	antidepressant:33:0.0018|antidepressants:16:0.0009	0.0018	49
AD	AD:15	antidepressant drugs:10:0.2873|Antidepressant drug:5:0.0736	0.2873	15
AD	AD:12	anxiety disorders:12:0.2183	0.2183	12
AD	AD:13	aortic diameter:13:0.1599	0.1599	13
AD	AD:35	aortic dissection:35:0.5098	0.5098	35
AD	AD:11	apparent digestibility:11:0.4232	0.4232	11
AD	AD:6	arrhythmogenic dose:6:0.0807	0.0807	6
AD	AD:12	atherogenic diet:12:0.5664	0.5664	12
AD	AD:1352|Ad:9|ad:1	atopic dermatitis:1362:0.9931	0.9931	1362
AD	AD:10	atypical depression:10:0.5000	0.5000	10
AD	AD:47	autistic disorder:47:0.5009	0.5009	47
AD	AD:8	autoimmune diseases:8:0.2090	0.2090	8
AD	AD:8	autonomic dysfunction:8:0.3463	0.3463	8
AD	AD:37	Autonomic dysreflexia:37:0.9197	0.9197	37
AD	AD:96|ad:2	autosomal dominant:98:0.9515	0.9515	98
AD	AD:12	axillary dissection:12:0.0961	0.0961	12
AD	AD:1	dementia of an Alzheimer's type:1:0.6794	0.6794	1
AD	AD:19	dementia of the Alzheimer type:19:0.7679	0.7679	19
AD	AD:15	density:15:0.0008	0.0008	15
Ad	AD:5|Ad:5	duration:10:0.0005	0.0005	10
A-D	A-D:17	four groups:17:0.3366	0.3366	17
Ad	Ad:80	recombinant adenovirus:66:0.0781|recombinant adenoviruses:14:0.1063	0.1063	80
Af-Art	Af-Art:13	afferent arteriole:13:0.7753	0.7753	13
AFL	AFL:21|Afl:6	aflatoxicol:27:0.0959	0.0959	27
AFL	AFL:140|AFl:32|Afl:7	atrial flutter:179:0.9015	0.9015	179
AFL	AFL:9	Australian Football League:9:0.6794	0.6794	9
Ag5	Ag5:12	Antigen 5:12:0.7571	0.7571	12
Ag-Ab	Ag-Ab:24|AgAb:1|AG-AB:1|ag-ab:1	antigen-antibody:27:0.5306	0.5306	27
AgAb	AgAb:8	immune complexes:8:0.4102	0.4102	8
AGB	AGB:18	adjustable gastric banding:18:0.8365	0.8365	18
AgB	AgB:26	Antigen B:26:0.8861	0.8861	26
AGE	AGE:19	acute gastroenteritis:19:0.8449	0.8449	19
AGE	AGE:279|age:1	advanced glycation end products:161:0.9512|advanced glycation end product:57:0.9176|advanced glycation end-products:41:0.8525|advanced glycation end-product:21:0.8594	0.9512	280
AGE	AGE:80	advanced glycation endproducts:61:0.9229|advanced glycation endproduct:19:0.8449	0.9229	80
AGE	AGE:19	advanced glycosylation end-products:19:0.8449	0.8449	19
AGE	AGE:42|age:1	agarose gel electrophoresis:43:0.7168	0.7168	43
AGE	AGE:44	aged garlic extract:44:0.6704	0.6704	44
AgE	AgE:24	antigen E:24:0.8115	0.8115	24
AGE	AGE:20	arterial gas embolism:20:0.8525	0.8525	20
AgMNPV	AgMNPV:7	Anticarsia gemmatalis multicapsid nucleopolyhedrovirus:7:0.5926	0.5926	7
AgNO3	AgNO3:18	silver nitrate:18:0.8365	0.8365	18
Ag-NORs	Ag-NORs:3|AGNORs:1|AgNORs:1	associated protein:5:0.0517	0.0517	5
AgNORs	AgNORs:4	identified by silver staining:4:0.1618	0.1618	4
AgNORs	AgNORs:318|Ag-NORs:37|AgNORS:1|AGNORS:1|Ag-NORS:1	nucleolar organizer regions:358:0.8926	0.8926	358
AgNORs	AgNORs:28|Ag-NORs:6	Nucleolar organizer region-associated proteins:24:0.8768|nucleolar organizer region associated proteins:10:0.7103	0.8768	34
AgNORs	AgNORs:4|Ag-NORs:2	silver-stained NORs:6:0.0611	0.0611	6
AgNORs	AgNORs:5	silver-stained nucleolar organizer regions protein:5:0.4422	0.4422	5
AgNOR	AgNOR:71|Ag-NOR:7	argyrophilic nucleolar organizer region:78:0.4516	0.4516	78
AgNOR	AgNOR:5|Ag-NOR:1	argyrophilic technique:6:0.0899	0.0899	6
AgNOR	AgNOR:104|Ag-NOR:15|AGNOR:1	nucleolar organizer regions:120:0.8485	0.8485	120
Ag-NOR	Ag-NOR:5|AgNOR:2	Nucleolar organizer region-associated proteins:7:0.5926	0.5926	7
AgNOR	AgNOR:5|Ag-NOR:5	silver staining:10:0.5000	0.5000	10
AgSD	AgSD:16|Ag-SD:5	silver sulfadiazine:21:0.7865	0.7865	21
AGRP	AGRP:107|AgRP:56|Agrp:21	Agouti-related protein:184:0.8396	0.8396	184
agr	agr:53|Agr:5	accessory gene regulator:58:0.9486	0.9486	58
AgR	AgR:7	antigen receptor:7:0.1850	0.1850	7
AGS	AGS:22	Adrenogenital syndrome:22:0.1459	0.1459	22
AGS	AGS:55	Alagille syndrome:55:0.5032	0.5032	55
AGs	AGs:18|Ags:1	aminoglycosides:19:0.0336	0.0336	19
AGs	AGs:13	aminoglycoside antibiotics:13:0.7753	0.7753	13
Ags	Ags:116|AGs:1	antigens:117:0.2168	0.2168	117
AGS	AGS:99	audiogenic seizures:69:0.9567|audiogenic seizure:30:0.8978	0.9567	99
AGS	AGS:19	cell line:19:0.7658	0.7658	19
AGS	AGS:10	human gastric adenocarcinoma:10:0.7103	0.7103	10
AGUS	AGUS:54	atypical glandular cells of undetermined significance:54:0.8546	0.8546	54
Ag	Ag:698	antigen:565:0.2586|antigens:133:0.0603	0.2586	698
Ag	Ag:60	silver:60:0.0258	0.0258	60
AHRR	AHRR:6|AhRR:2	AhR repressor:8:0.1945	0.1945	8
AHRR	AHRR:5|AhRR:4	aryl hydrocarbon receptor repressor:9:0.6794	0.6794	9
AHR	AHR:19	acute humoral rejection:19:0.8449	0.8449	19
AHR	AHR:10|aHR:1	adjusted hazard ratio:11:0.6182	0.6182	11
AHR	AHR:12	airway hyper-reactivity:12:0.7571	0.7571	12
AHR	AHR:31	airway hyper-responsiveness:31:0.8519	0.8519	31
AHR	AHR:68	Airway hyperreactivity:68:0.7673	0.7673	68
AHR	AHR:368	airway hyperresponsiveness:368:0.9258	0.9258	368
AhR	AhR:479|AHR:182|Ahr:16|Ah-R:2	aryl hydrocarbon receptor:679:0.8847	0.8847	679
AIPL1	AIPL1:5	aryl hydrocarbon receptor-interacting protein-like 1:5:0.4422	0.4422	5
Al(OH)3	Al(OH)3:10	aluminium hydroxide:10:0.2275	0.2275	10
Al(OH)3	Al(OH)3:10	aluminum hydroxide:10:0.2275	0.2275	10
Al2O3	Al2O3:8	alumina ceramic:8:0.2619	0.2619	8
Al2O3	Al2O3:17	aluminum oxide:17:0.4742	0.4742	17
Al3+	Al3+:19	aluminum:19:0.5143	0.5143	19
AlCl3	AlCl3:24	aluminum chloride:24:0.6122	0.6122	24
AlF4-	AlF4-:18	aluminum fluoride:18:0.5228	0.5228	18
AlF4-	AlF4-:13	Fluoroaluminate:13:0.2708	0.2708	13
AlMV	AlMV:17	alfalfa mosaic virus:17:0.8270	0.8270	17
ALPase	ALPase:186|AlPase:19|Al-Pase:4|ALP-ase:4|Alpase:3|al-Pase:2	alkaline phosphatase:218:0.9342	0.9342	218
ALPase	ALPase:4|AlPase:1	alkaline phosphatase activity:5:0.4422	0.4422	5
ALPase	ALPase:5|AL-Pase:1	alkaline phosphatase specific activity:6:0.5290	0.5290	6
AlPcS4	AlPcS4:8|AlPCS4:1	aluminum phthalocyanine tetrasulfonate:9:0.3455	0.3455	9
AlPcTS	AlPcTS:7|AlPcTs:1|AlPCTS:1	phthalocyanine tetrasulfonate:9:0.5470	0.5470	9
AlPc	AlPc:11|AlPC:1	phthalocyanine:12:0.7333	0.7333	12
AlSPc	AlSPc:13|ALSPC:3	phthalocyanine:16:0.8235	0.8235	16
AlaAT	AlaAT:11|Ala-AT:2	alanine aminotransferase:13:0.6701	0.6701	13
Ala-Gln	Ala-Gln:11|ALA-GLN:2|ala-gln:1	L-alanyl-L-glutamine:14:0.4194	0.4194	14
AlaRS	AlaRS:17	alanyl-tRNA synthetase:17:0.8270	0.8270	17
ALB	ALB:18|Alb:12|alb:1	albendazole:31:0.0508	0.0508	31
ALB	ALB:6|Alb:3	albumin concentration:9:0.6794	0.6794	9
ALB	ALB:12	anxiety-like behavior:12:0.6460	0.6460	12
AldDH	AldDH:12	aldehyde dehydrogenase:12:0.7571	0.7571	12
ALPs	ALPs:15	alkaline phosphatases:15:0.8045	0.8045	15
ALPS	ALPS:73	autoimmune lymphoproliferative syndrome:73:0.9591	0.9591	73
AMC	AMC:19	academic medical center:19:0.6106	0.6106	19
AMC	AMC:7	age-matched controls:7:0.3524	0.3524	7
AMC	AMC:8	amoeboid microglial cells:8:0.5006	0.5006	8
AMC	AMC:10	anteromedial cortex:10:0.7103	0.7103	10
AMC	AMC:61	arthrogryposis multiplex congenita:61:0.8987	0.8987	61
AMC	AMC:11	Medical Centre:11:0.7357	0.7357	11
AMC	AMC:7	mononuclear cells:7:0.0886	0.0886	7
Ames	Ames:9	mutagenicity:9:0.0640	0.0640	9
Amin	Amin:11|A-min:1	cross-sectional area:12:0.7571	0.7571	12
AMP-FLP	AMP-FLP:7|Amp-FLP:3|amp-FLP:2|AmpFlp:1|AmpFLP:1	amplified fragment length polymorphism:14:0.5589	0.5589	14
AMPH-B	AMPH-B:17|AmphB:3|Amph-B:2	amphotericin B:22:0.7955	0.7955	22
AMY1	AMY1:6	barley alpha-amylase 1:6:0.5290	0.5290	6
Amy2	Amy2:4|AMY2:4|amy-2:1	pancreatic amylase:9:0.6794	0.6794	9
AN-9	AN-9:9	pivaloyloxymethyl butyrate:9:0.3945	0.3945	9
ANT-C	ANT-C:17|ANTC:1	Antennapedia complex:18:0.5560	0.5560	18
ANAES	ANAES:9|Anaes:1	Agence Nationale d'Accreditation et d'Evaluation en Sante:10:0.5856	0.5856	10
Ang-(1-7)	Ang-(1-7):19	Angiotensin-(1-7):19:0.9500	0.9500	19
Ang-1	Ang-1:80|Ang1:68|ang1:3|ang-1:2|ANG-1:2|ANG1:1	Angiopoietin-1:140:0.8274|angiopoietin 1:16:0.6024	0.8274	156
Ang2	Ang2:6|Ang-2:3	angiopoietin 2:9:0.5470	0.5470	9
AngIV	AngIV:13|ANGIV:2	angiotensin IV:15:0.8045	0.8045	15
Ani	Ani:12	Anisodamine:12:0.1594	0.1594	12
ANI	ANI:9	protein synthesis inhibitor anisomycin:9:0.7103	0.7103	9
anti-Ig	anti-Ig:31|Anti-Ig:1	anti-immunoglobulin:32:0.4429	0.4429	32
Antp	Antp:93|ANTP:3	Antennapedia:96:0.9048	0.9048	96
AOF	AOF:10	Active oxygen forms:10:0.5856	0.5856	10
AoF	AoF:11	aortic blood flow:11:0.7357	0.7357	11
AoF	AoF:8|AOF:1	aortic flow:9:0.1690	0.1690	9
Aogen	Aogen:14|AOGEN:9|aogen:1|A-ogen:1|AoGen:1	Angiotensinogen:26:0.9615	0.9615	26
Ap(4)A	Ap(4)A:12|AP(4)A:2	diadenosine tetraphosphate:14:0.5589	0.5589	14
Ap(5)A	Ap(5)A:11|AP(5)A:1	pentaphosphate:12:0.7857	0.7857	12
Ap3A	Ap3A:7|AP3A:2	diadenosine 5',5"'-P1,P3-triphosphate:9:0.4587	0.4587	9
Ap3A	Ap3A:24|AP3A:3	diadenosine triphosphate:27:0.5334	0.5334	27
Ap4A	Ap4A:19	adenosine(5')tetraphospho(5')adenosine:19:0.0684	0.0684	19
Ap4A	Ap4A:54|AP4A:7	diadenosine 5',5"'-P1,P4-tetraphosphate:32:0.7458|diadenosine 5',5'''-P1,P4-tetraphosphate:28:0.8369|diadenosine 5',5'''-p1 p4-tetraphosphate:1:0.4422	0.8369	61
Ap4A	Ap4A:66|AP4A:23	Diadenosine tetraphosphate:89:0.6590	0.6590	89
ApEn	ApEn:130|APEN:3	approximate entropy:133:0.9218	0.9218	133
Apaf-1	Apaf-1:41|APAF-1:9|Apaf1:2	apoptotic protease-activating factor-1:21:0.7291|Apoptotic protease activating factor-1:16:0.5564|apoptotic protease-activating factor 1:15:0.5348	0.7291	52
APCR	APCR:68|APC-R:27|APC-r:3|aPCR:2|APCr:2	activated protein C resistance:102:0.9383	0.9383	102
APCR	APCR:17|APC-R:9|APCr:2|aPCR:1|aPCr:1	Resistance to activated protein C:30:0.7388	0.7388	30
ApnA	ApnA:9|APnA:5	diadenosine polyphosphates:14:0.6911	0.6911	14
APNs	APNs:128	advanced practice nurses:128:0.9189	0.9189	128
apoB	apoB:627|ApoB:76|apo-B:43|APOB:25|Apo-B:18|Apob:2|APoB:1|APO-B:1	Apolipoprotein B:763:0.8667|apolipoprotein-B:30:0.0280	0.8667	793
apoB	apoB:47|APOB:4|apo-B:2|ApoB:1	apolipoprotein B-100:54:0.8401	0.8401	54
APOB	APOB:6|apoB:3|ApoB:1	apolipoprotein B gene:10:0.5856	0.5856	10
apoB	apoB:21|ApoB:2|Apo-B:1	Apolipoprotein B100:24:0.8115	0.8115	24
APOC	APOC:16	African Programme for Onchocerciasis Control:16:0.8270	0.8270	16
apoD	apoD:44|ApoD:15|apo-D:4|APOD:1|APO-D:1|Apo-D:1	apolipoprotein D:66:0.9548	0.9548	66
apo-SAA	apo-SAA:5|apoSAA:2	serum amyloid A protein:7:0.7571	0.7571	7
APRIL	APRIL:21	proliferation-inducing ligand:21:0.7291	0.7291	21
APR	APR:160	abdominoperineal resection:147:0.8170|abdominoperineal resections:13:0.7753	0.8170	160
APR	APR:5	absolute production rate:5:0.2818	0.2818	5
APR	APR:11	absolute proximal reabsorption:11:0.6182	0.6182	11
APR	APR:4	absolute proximal reabsorption rate:4:0.1618	0.1618	4
APR	APR:11	accessory planta retractor:11:0.7357	0.7357	11
APR	APR:39	acute phase reactants:20:0.8525|acute phase reactant:12:0.7571|acute-phase reactants:7:0.0622	0.8525	39
APR	APR:16	acute phase reaction:8:0.6411|acute-phase reaction:8:0.1471	0.6411	16
APR	APR:129	acute phase response:94:0.9682|acute-phase response:35:0.1771	0.9682	129
APR	APR:5	Adenosine 5'-phosphosulphate reductase:5:0.4422	0.4422	5
ApR	ApR:6|Apr:3	ampicillin resistance:9:0.3945	0.3945	9
APR	APR:5|Apr:3|apr:2	aprotinin:10:0.0151	0.0151	10
APR	APR:7	proximal tubular reabsorption:7:0.5926	0.5926	7
AqH	AqH:17	aqueous humor:17:0.8270	0.8270	17
ARE	ARE:9	ampicillin-resistant enterococci:9:0.6794	0.6794	9
ARE	are:3|ARE:3	androgen response elements:6:0.1543	0.1543	6
ARE	ARE:85|are:10	antioxidant response element:95:0.5864	0.5864	95
ARE	ARE:31|are:4	antioxidant responsive element:35:0.5771	0.5771	35
ARE	ARE:70|are:6	AU-rich element:58:0.1442|AU-rich elements:18:0.2771	0.2771	76
ArKO	ArKO:9	aromatase-deficient:9:0.0920	0.0920	9
ArKO	ArKO:42|ArKo:1	aromatase knockout:34:0.6386|aromatase-knockout:9:0.0920	0.6386	43
ArMV	ArMV:14	arabis mosaic virus:14:0.7909	0.7909	14
araT	araT:10|ara-T:8|Ara-T:1	1-beta-D-arabinofuranosylthymine:19:0.2368	0.2368	19
ARAT	ARAT:21	acyltransferase:21:0.2632	0.2632	21
ara-U	ara-U:11|Ara-U:4|araU:2	1-beta-D-arabinofuranosyluracil:17:0.3265	0.3265	17
ara-U	ara-U:7|Ara-U:5|araU:2|ARA-U:1|AraU:1	uracil arabinoside:16:0.6577	0.6577	16
ARFI	ARFI:10	acoustic radiation force impulse:10:0.7103	0.7103	10
ArgRS	ArgRS:16	arginyl-tRNA synthetase:16:0.7261	0.7261	16
Arg	Arg:4|ARG:3	Abl-related gene:7:0.2452	0.2452	7
Arg	Arg:180|ARG:60|arg:4	arginine:244:0.3744	0.3744	244
ARG	ARG:16	autoradiographic:16:0.0231	0.0231	16
ARG	ARG:41	autoradiography:41:0.0616	0.0616	41
Arg	Arg:65|ARG:31	L-arginine:96:0.1464	0.1464	96
Ark	Ark:14	Arkansas:14:0.3824	0.3824	14
Arp2/3	Arp2/3:10	actin-related protein 2/3:10:0.7103	0.7103	10
As(2)O(3)	As(2)O(3):94|AS(2)O(3):1	arsenic trioxide:95:0.9682	0.9682	95
As2O3	As2O3:176|AS2O3:2	arsenic trioxide:178:0.9730	0.9730	178
As3+	As3+:12	arsenite:12:0.5789	0.5789	12
ASOR	ASOR:10	125I-asialoorosomucoid:10:0.1011	0.1011	10
ASOR	ASOR:13	asialo-orosomucoid:13:0.1348	0.1348	13
ASOR	ASOR:41|AsOR:3|ASOr:1	asialoorosomucoid:45:0.4944	0.4944	45
ASPN	ASPN:19	Ambulatory Sentinel Practice Network:19:0.8449	0.8449	19
ASIA	ASIA:76	American Spinal Injury Association:76:0.9378	0.9378	76
AsnRS	AsnRS:10	asparaginyl-tRNA synthetase:10:0.7103	0.7103	10
Asn	Asn:51|ASN:9|asn:1	asparagine:61:0.3593	0.3593	61
AspAT	AspAT:68|ASP-AT:2|Asp-AT:1	aspartate aminotransferase:71:0.8146	0.8146	71
AspRS	AspRS:23	Aspartyl-tRNA synthetase:23:0.8715	0.8715	23
Asx	Asx:11|asx:1|ASX:1	Additional sex combs:13:0.7753	0.7753	13
AS	AS:11	absence seizures:11:0.1938	0.1938	11
AS	AS:9	acetosyringone:9:0.0017	0.0017	9
AS	AS:14	acetylstrophanthidin:14:0.0028	0.0028	14
AS	AS:18|As:1	activated sludge:19:0.8449	0.8449	19
AS	AS:20	active:20:0.0041	0.0041	20
A-S	A-S:9|AS:1	activity-stress:10:0.0020	0.0020	10
AS	AS:6	actual survival:6:0.0666	0.0666	6
AS	AS:7	actuarial survival:7:0.1111	0.1111	7
AS	AS:10	affective style:10:0.5856	0.5856	10
AS	AS:21	aggregation substance:21:0.7865	0.7865	21
AS	AS:6|As:1	alkaline secretion:7:0.3524	0.3524	7
AS	AS:7|as:2	alpha-synuclein:9:0.0017	0.0017	9
AS	AS:58	Alport syndrome:58:0.1008	0.1008	58
AS	AS:14	alternative splicing:14:0.6911	0.6911	14
AS	AS:22	Ammonium sulfate:22:0.2508	0.2508	22
AS	AS:11	ammonium sulphate:11:0.3495	0.3495	11
AS	AS:17|As:1	anabolic steroids:18:0.4934	0.4934	18
AS	AS:15	anaphylactic shock:15:0.5348	0.5348	15
AS	AS:6	androgen suppression:6:0.1838	0.1838	6
AS	AS:11	Angeli's salt:11:0.6182	0.6182	11
AS	AS:31	Angiosarcoma:31:0.0065	0.0065	31
AS	AS:8	ankylosing spondylarthritis:8:0.6794	0.6794	8
AS	AS:1167|As:13|as:1	ankylosing spondylitis:1181:0.9908	0.9908	1181
AS	AS:16|As:1	anthranilate synthase:17:0.2128	0.2128	17
AS	AS:9	antisaccades:9:0.0017	0.0017	9
AS	AS:173|As:9|as:8	antisense:190:0.0411	0.0411	190
AS	AS:23	antisense oligonucleotides:12:0.6460|antisense oligonucleotide:11:0.5355	0.6460	23
AS	AS:18|As:1	antiserum:19:0.0039	0.0039	19
AS	AS:62	Anxiety sensitivity:62:0.8788	0.8788	62
AS	AS:349|As:2	aortic stenosis:351:0.8152	0.8152	351
AS	AS:36|As:1	aortic valve stenosis:37:0.9197	0.9197	37
AS	AS:9|As:2	argininosuccinate synthase:11:0.0983	0.0983	11
AS	AS:42|As:2	argininosuccinate synthetase:44:0.3505	0.3505	44
As	As:233|AS:1	arsenic:234:0.0507	0.0507	234
AS	AS:9	arteriosclerosis:9:0.0017	0.0017	9
AS	AS:13	artesunate:13:0.0026	0.0026	13
AS	AS:9	artificial saliva:9:0.6794	0.6794	9
AS	AS:11|As:1	arylsulfatase:12:0.0024	0.0024	12
AS	AS:4|As:2	Ascorbic acid:6:0.0666	0.0666	6
AS	AS:32|As:8	asparagine synthetase:40:0.3096	0.3096	40
AS	AS:3|As:2	assisted suicide:5:0.1132	0.1132	5
AS	AS:7	atherometric system:7:0.1470	0.1470	7
AS	AS:39|As:3	atherosclerosis:42:0.0089	0.0089	42
AS	AS:9	atherosclerotic:9:0.0017	0.0017	9
AS	AS:15	audiogenic seizures:15:0.3429	0.3429	15
As	As:6	autism and Asperger syndrome:6:0.0749	0.0749	6
AS	AS:19	autologous serum:19:0.4405	0.4405	19
AS	AS:16	Plasmodium chabaudi chabaudi:16:0.7096	0.7096	16
AS	AS:28|As:2	score:30:0.0063	0.0063	30
AS	AS:20|As:2	sickle cell trait:22:0.8657	0.8657	22
AS	AS:8	sickle trait:8:0.0625	0.0625	8
As	As:6|AS:2	sodium arsenite:8:0.2327	0.2327	8
AS	AS:10	solution:10:0.0020	0.0020	10
AS	AS:19	stimulation:19:0.0039	0.0039	19
AS	AS:14|A-S:1	stress:15:0.0030	0.0030	15
AS	AS:9	surgery:9:0.0017	0.0017	9
AtT-20	AtT-20:6|AtT20:1	pituitary tumor:7:0.2452	0.2452	7
ATT	ATT:12	anterior tibial translation:12:0.7571	0.7571	12
ATT	ATT:5	antitubercular treatment:5:0.0612	0.0612	5
ATT	ATT:6	antituberculous therapy:6:0.0522	0.0522	6
att	att:24	attachment:24:0.1013	0.1013	24
att	att:8	attachment site:8:0.4102	0.4102	8
att	att:12	attenuated:12:0.0485	0.0485	12
ATT	ATT:13	tolerance test:13:0.3809	0.3809	13
att	att:1	ts and attenuation:1:0.2619	0.2619	1
ATE	ATE:6|Ate:6	atenolol:12:0.1642	0.1642	12
ATP7B	ATP7B:13	Copper-transporting P-type adenosine triphosphatase:13:0.7753	0.7753	13
ATP7B	ATP7B:5	Wilson disease protein:5:0.1973	0.1973	5
AT	AT:47|At:3	acceleration time:50:0.4036	0.4036	50
AT	AT:16	acetyltransferase:16:0.0041	0.0041	16
AT	AT:20	Achilles tendon:20:0.8525	0.8525	20
AT	AT:26	activation time:26:0.1689	0.1689	26
AT	AT:15	active tension:15:0.3614	0.3614	15
AT	AT:8	acyl transferase:8:0.2987	0.2987	8
AT	AT:38	acyltransferase:38:0.0102	0.0102	38
AT	AT:13|A-T:9	adenine-thymine:22:0.0058	0.0058	22
AT	AT:153	adipose tissue:153:0.9490	0.9490	153
AT	AT:8	alopecia totalis:8:0.5006	0.5006	8
AT	AT:41	alpha 1-antitrypsin:32:0.8145|Alpha-1-antitrypsin:9:0.0022	0.8145	41
AT	AT:46|At:1|at:1|A-T:1	alpha-tocopherol:49:0.0132	0.0132	49
AT	AT:13	alpha1-antitrypsin:13:0.0033	0.0033	13
AT	AT:5	ambient temperature:5:0.0517	0.0517	5
AT	AT:16	Aminotriazole:16:0.0041	0.0041	16
AT	AT:57|At:3	amitriptyline:60:0.0162	0.0162	60
AT	AT:320|At:3	anaerobic threshold:323:0.9367	0.9367	323
AT	AT:26	angiotensin:26:0.0069	0.0069	26
AT	AT:25	angiotensin II:25:0.6873	0.6873	25
AT	AT:5	angiotensin II receptor:5:0.2818	0.2818	5
AT	AT:10	anterior tibial:10:0.7103	0.7103	10
AT	AT:13	anterior tibialis:13:0.7753	0.7753	13
AT	AT:314|At:2	antithrombin:316:0.0867	0.0867	316
AT	AT:74|At:1	antithrombin III:75:0.9370	0.9370	75
At	At:15	Arabidopsis thaliana:15:0.7096	0.7096	15
AT	AT:15	area tempestas:15:0.8045	0.8045	15
AT	AT:30	Assistive technology:30:0.9011	0.9011	30
AT	AT:304|A-T:108|At:89	ataxia telangiectasia:501:0.9940	0.9940	501
AT	AT:22|At:3	atenolol:25:0.0066	0.0066	25
AT	AT:17|At:5	Atrial tachyarrhythmia:13:0.7753|atrial tachyarrhythmias:9:0.6794	0.7753	22
AT	AT:64|At:6|A-T:1	atrial tachycardia:71:0.9344	0.9344	71
AT	AT:13|At:6	atropine:19:0.0050	0.0050	19
AT	AT:29	Autogenic training:29:0.4539	0.4539	29
AT	AT:26	autoimmune thyroiditis:26:0.6351	0.6351	26
A-T	A-T:9|AT:3|At:1	autosomal recessive disorder ataxia-telangiectasia:13:0.6701	0.6701	13
AT	AT:5	catalase inhibitor 3-amino-1,2,4-triazole:5:0.4363	0.4363	5
A-T	A-T:5|AT:2	Cells from patients with ataxia-telangiectasia:7:0.0591	0.0591	7
A-T	A-T:21|AT:2	human genetic disorder ataxia-telangiectasia:23:0.4652	0.4652	23
AT	AT:23	O6-alkylguanine-DNA alkyltransferase:23:0.5025	0.5025	23
AT	AT:25	therapy:25:0.0066	0.0066	25
AT	AT:15	treatment:15:0.0039	0.0039	15
AuBMT	AuBMT:17	autologous bone marrow transplantation:17:0.8270	0.8270	17
AuTM	AuTM:6|Autm:4|AuTm:1	aurothiomalate:11:0.4545	0.4545	11
AuTM	AuTM:9	gold sodium thiomalate:9:0.6794	0.6794	9
AuTG	AuTG:9|AuTg:1	aurothioglucose:10:0.6000	0.6000	10
AU	AU:11	alopecia universalis:11:0.5355	0.5355	11
AU	AU:38	anterior uveitis:38:0.8811	0.8811	38
AU	AU:109|au:14|aU:2|Au:1	arbitrary units:120:0.6425|arbitrary unit:6:0.1010	0.6425	126
Av1	Av1:8	MoFe protein:8:0.4102	0.4102	8
AvFdI	AvFdI:10	Azotobacter vinelandii ferredoxin I:10:0.5856	0.5856	10
AvWD	AvWD:10|AVWD:2|aVWD:1	acquired von Willebrand disease:8:0.6411|acquired von Willebrand's disease:5:0.2818	0.6411	13
AZC	AZC:10	5-azacytidine:10:0.2432	0.2432	10
AZs	AZs:7	active zones:7:0.2902	0.2902	7
AZ	AZ:34|Az:9	acetazolamide:43:0.1117	0.1117	43
AZ	AZ:17|Az:3	antizyme:20:0.0505	0.0505	20
Az	Az:12|AZ:1	Areas:13:0.0319	0.0319	13
Az	Az:31|AZ:1	area under the ROC curve:27:0.8032|areas under the ROC curves:5:0.5926	0.8032	32
AZ	AZ:28|Az:21|az:1	azathioprine:50:0.1303	0.1303	50
Az	Az:8|AZ:1	Azone:9:0.0213	0.0213	9
Az	Az:17|AZ:1	under the receiver operating characteristic curve:18:0.6537	0.6537	18
B(0)	B(0):9	magnetic field:9:0.5470	0.5470	9
B(2)R	B(2)R:10	receptor:10:0.6923	0.6923	10
B(a)P	B(a)P:112|B(a)p:2|B(A)P:2|b(a)p:1	benzo(a)pyrene:94:0.7154|benzo[a]pyrene:23:0.1692	0.7154	117
B(max)	B(max):30	binding capacity:30:0.7315	0.7315	30
B(max)	B(max):27|B(MAX):1	number of binding sites:28:0.4302	0.4302	28
B(max)	B(max):32	receptor density:32:0.3138	0.3138	32
B-PLL	B-PLL:12	B-cell prolymphocytic leukemia:12:0.4153	0.4153	12
B-PLL	B-PLL:10	B-prolymphocytic leukaemia:10:0.2126	0.2126	10
B-PLL	B-PLL:9	B-prolymphocytic leukemia:9:0.1267	0.1267	9
B-PLL	B-PLL:10	prolymphocytic leukaemia:10:0.2126	0.2126	10
B.C.	B.C.:16	British Columbia:16:0.8165	0.8165	16
b.m.i.	b.m.i.:10|B.M.I.:1	body mass index:11:0.7357	0.7357	11
B.P.	B.P.:20|b.p.:1	blood pressure:21:0.8594	0.8594	21
B.t.	B.t.:16	Bacillus thuringiensis:16:0.8165	0.8165	16
B.t.i.	B.t.i.:1	Bacillus thuringiensis var israelensis:1:0.8941	0.8941	1
b/c	b/c:19|B/C:2	breaks per cell:21:0.7865	0.7865	21
B/I	B/I:7|b/i:2	bioactivity to immunoreactivity:9:0.6794	0.6794	9
B/W	B/W:9	F1 hybrid:9:0.4587	0.4587	9
B/W	B/W:19	NZB/NZW F1:19:0.4379	0.4379	19
B/W	B/W:11	NZB X NZW:11:0.7357	0.7357	11
B/W	B/W:35	NZB x NZW)F1:29:0.8978|NZB X NZW F1:6:0.6411	0.8978	35
B/Y	B/Y:12	blue-on-yellow:12:0.8462	0.8462	12
B10.A	B10.A:14	susceptible:14:0.3611	0.3611	14
B10	B10:8	C57BL/10ScSn:8:0.0383	0.0383	8
B12	B12:14	Cobalamin:14:0.1040	0.1040	14
B12	B12:10|B-12:1	cyanocobalamin:11:0.0800	0.0800	11
B12	B12:51	vitamin B12:51:0.8799	0.8799	51
B16M	B16M:14	B16 melanoma:14:0.6911	0.6911	14
B16a	B16a:16	B16 amelanotic melanoma:16:0.8165	0.8165	16
B16	B16:35|B-16:9	melanoma:44:0.4433	0.4433	44
B19	B19:21	human parvovirus:21:0.6040	0.6040	21
B19	B19:136	parvovirus B19:136:0.9329	0.9329	136
B1R	B1R:13	receptor:13:0.5217	0.5217	13
B1	B-1:6|B1:6	B cells:12:0.5050	0.5050	12
B1	B1:15	thiamine:15:0.0348	0.0348	15
B2-m	B2-m:4|B2m:3|B2M:2|b2M:1|b2-m:1|b2m:1|b2-M:1	b2-Microglobulin:13:0.0538	0.0538	13
B2M	B2M:90|B2m:31|B2-m:9|b2m:7|B2-M:6|b2M:4|B-2M:3|b2-m:2|B-2-m:1|B-2-M:1|b-2-m:1	beta-2-microglobulin:57:0.2511|beta 2-microglobulin:53:0.8842|beta-2 microglobulin:29:0.3912|beta 2 microglobulin:16:0.8165	0.8842	155
B2M	B2M:10|B2m:2|b2m:2	beta2-microglobulin:14:0.0583	0.0583	14
B2	B2:3|B-2:3	conventional B:6:0.1543	0.1543	6
B2	B2:10|B-2:1	riboflavin:11:0.0280	0.0280	11
B3LYP	B3LYP:10	density functional:10:0.3867	0.3867	10
B3	B3:5|b3:1	Band 3:6:0.1010	0.1010	6
b5	b5:43|B5:1	cytochrome b5:44:0.8620	0.8620	44
B6C3F1	B6C3F1:10	C57BL/6N x C3H/HeN)F1:10:0.7103	0.7103	10
B6	B6:23	C57B1/6:23:0.0163	0.0163	23
B6	B6:679	C57BL/6:679:0.5037	0.5037	679
B6	B6:8	C57BL/6 mice:8:0.1895	0.1895	8
B6	B6:13	C57BL/6By:13:0.0089	0.0089	13
B6	B6:11	C57BL/6ByJ:11:0.0074	0.0074	11
B6	B6:387|B-6:1	C57BL/6J:388:0.2886	0.2886	388
B6	B6:16	C57BL/6N:16:0.0111	0.0111	16
B6	B6:24	pyridoxine:24:0.0171	0.0171	24
B6	B6:12	vitamin B6:12:0.7571	0.7571	12
B72.3	B72.3:10	monoclonal antibody:10:0.4363	0.4363	10
BAAM	BAAM:15	bromoacetylalprenololmenthane:15:0.6087	0.6087	15
BaA	BaA:8|BAA:1	benz[a]anthracene:9:0.0615	0.0615	9
BAA	BAA:29	butoxyacetic acid:29:0.5212	0.5212	29
BABF	BABF:8	brachial artery blood flow:8:0.6411	0.6411	8
BAb	BAb:5|b-Ab:2|bAb:1|BAB:1	antibodies:9:0.0552	0.0552	9
BAb	BAb:5|bAb:1	bispecific antibody:6:0.1320	0.1320	6
BAB	BAB:60	blood-aqueous barrier:60:0.7161	0.7161	60
BACE1	BACE1:23|BACE-1:8	beta-secretase:31:0.5263	0.5263	31
BACE	BACE:35|Bace:1	beta-secretase:36:0.3571	0.3571	36
BACE	BACE:8	beta-site APP cleaving enzyme:8:0.3463	0.3463	8
BACs	BACs:127	bacterial artificial chromosomes:127:0.9625	0.9625	127
BACs	BACs:98|BACS:1	Blood alcohol concentrations:99:0.9365	0.9365	99
BACs	BACs:12	bronchioloalveolar carcinomas:12:0.5050	0.5050	12
BAC	BAC:12|Bac:2	baclofen:14:0.0081	0.0081	14
BAC	BAC:656	bacterial artificial chromosome:640:0.9769|bacterial artificial chromosomes:16:0.8165	0.9769	656
BAC	BAC:105	Benzalkonium chloride:105:0.8116	0.8116	105
BAC	BAC:7	biological activated carbon:7:0.5926	0.5926	7
BAC	BAC:311	blood alcohol concentration:271:0.9377|blood alcohol concentrations:40:0.8491	0.9377	311
BAC	BAC:18	blood alcohol content:18:0.8365	0.8365	18
BAC	BAC:7	bovine adrenal fasciculata cells:7:0.5926	0.5926	7
BAC	BAC:14	bovine adrenocortical:14:0.7909	0.7909	14
BAC	BAC:121	bronchioloalveolar carcinoma:121:0.6579	0.6579	121
BAC	BAC:18	bronchoalveolar cells:18:0.2608	0.2608	18
BADGE	BADGE:38	bisphenol A diglycidyl ether:38:0.8417	0.8417	38
BADH	BADH:24	betaine aldehyde dehydrogenase:24:0.8768	0.8768	24
BADL	BADL:24	Basic Activities of Daily Living:24:0.7593	0.7593	24
BAECs	BAECs:194	bovine aortic endothelial cells:194:0.9672	0.9672	194
BAEC	BAEC:10	bovine aorta:10:0.5856	0.5856	10
BAEC	BAEC:10	bovine aortic EC:10:0.7103	0.7103	10
BAEC	BAEC:354	bovine aortic endothelial cells:315:0.9661|bovine aortic endothelial cell:39:0.8811	0.9661	354
BAEE	BAEE:46|BAEe:4	ethyl ester:50:0.8776	0.8776	50
BAEE	BAEE:13|BAEe:1	ethylester:14:0.1529	0.1529	14
BAEP	BAEP:33	Brain stem auditory evoked potentials:33:0.9100	0.9100	33
BAEP	BAEP:250	Brainstem auditory evoked potentials:157:0.7014|brainstem auditory evoked potential:93:0.6013	0.7014	250
BAEPs	BAEPs:243|BAEPS:1	brainstem auditory evoked potentials:244:0.6313	0.6313	244
BAERs	BAERs:39	Brainstem auditory evoked responses:39:0.4892	0.4892	39
BAER	BAER:22	brain-stem auditory evoked response:22:0.1329	0.1329	22
BAER	BAER:113	brainstem auditory evoked response:63:0.5417|brainstem auditory evoked responses:50:0.7497	0.7497	113
BAEs	BAEs:8	Bovine aortic endothelial cells:8:0.6411	0.6411	8
BAE	BAE:95	bovine aortic endothelial:95:0.9339	0.9339	95
BAE	BAE:13	bovine aortic endothelial cells:13:0.7753	0.7753	13
BAE	BAE:28	bronchial artery embolization:28:0.8978	0.8978	28
BAFF	BAFF:6	B cell-activating factor belonging to the TNF family:6:0.5290	0.5290	6
BAFF	BAFF:1	factor from the TNF family:1:0.2582	0.2582	1
BAFME	BAFME:8	benign adult familial myoclonic epilepsy:8:0.5006	0.5006	8
BAFs	BAFs:18	bioaccumulation factors:18:0.5940	0.5940	18
Baf	Baf:7|BAF:4	bafilomycin A1:11:0.7357	0.7357	11
BAF	BAF:22	barrier-to-autointegration factor:22:0.3671	0.3671	22
BAF	BAF:8	biological aerated filter:8:0.5006	0.5006	8
BAF	BAF:6	bronchoalveolar fluid:6:0.1320	0.1320	6
BAG-75	BAG-75:9	bone acidic glycoprotein-75:9:0.6794	0.6794	9
BAHA	BAHA:49	bone-anchored hearing aid:49:0.6493	0.6493	49
BAHA	BAHA:15	bone anchored hearing aids:8:0.6411|bone-anchored hearing aids:7:0.1470	0.6411	15
BAH	BAH:11	bilateral adrenal hyperplasia:11:0.7357	0.7357	11
BAH	BAH:7	borderline arterial hypertension:7:0.4102	0.4102	7
BAI1	BAI1:10	brain-specific angiogenesis inhibitor 1:10:0.5856	0.5856	10
BAI	BAI:12	blunt aortic injury:12:0.6460	0.6460	12
BAI	BAI:6	brain atrophy index:6:0.5290	0.5290	6
BAI	BAI:15	bronchial arterial infusion:15:0.8045	0.8045	15
BAI	BAI:9|B-AI:1	bronchial artery infusion:10:0.5856	0.5856	10
BALC	BALC:11	bronchoalveolar lavage cells:11:0.7357	0.7357	11
BALFs	BALFs:16	bronchoalveolar lavage fluids:16:0.8165	0.8165	16
BALF	BALF:10	bronchoalveolar lavage:10:0.5000	0.5000	10
BALF	BALF:1584|BALf:6|BAL-F:1	bronchoalveolar lavage fluid:1503:0.9365|bronchoalveolar lavage fluids:88:0.8845	0.9365	1591
B-ALL	B-ALL:48|BALL:2	acute lymphoblastic leukemia:50:0.7828	0.7828	50
B-ALL	B-ALL:12	B-cell acute lymphoblastic leukaemia:12:0.5050	0.5050	12
BALP	BALP:66|B-ALP:46|b-ALP:14|bALP:11|B-Alp:1	alkaline phosphatase:138:0.9245	0.9245	138
BALT	BALT:141	bronchus-associated lymphoid tissue:141:0.7081	0.7081	141
BALs	BALs:45|BALS:1	blood alcohol levels:46:0.8676	0.8676	46
BAL	BAL:19	2,3-dimercapto-1-propanol:19:0.0034	0.0034	19
BAL	BAL:51	2,3-dimercaptopropanol:51:0.0096	0.0096	51
BAL	BAL:100	bioartificial liver:100:0.9231	0.9231	100
BAL	BAL:8	biphenotypic acute leukemia:8:0.6411	0.6411	8
BAL	BAL:75	blood alcohol level:50:0.8520|blood alcohol levels:25:0.8816	0.8816	75
BAL	BAL:15|Bal:1	British Anti-Lewisite:16:0.8165	0.8165	16
BAL	BAL:37	bronchoalveolar:37:0.0069	0.0069	37
BAL	BAL:4296	bronchoalveolar lavage:4221:0.9489|bronchoalveolar lavages:75:0.8103	0.9489	4296
BAL	BAL:144	bronchoalveolar lavage fluid:134:0.8638|bronchoalveolar lavage fluids:10:0.7103	0.8638	144
BAL	BAL:14|bal:1	dimercaptopropanol:15:0.0027	0.0027	15
BAMC	BAMC:7	bovine adrenal medullary chromaffin:7:0.5926	0.5926	7
BAMs	BAMs:11	macrophages:11:0.5882	0.5882	11
BAM	BAM:28	Bacteriological Analytical Manual:28:0.7905	0.7905	28
bam	bam:8|Bam:1	bag-of-marbles:9:0.0346	0.0346	9
BAM	BAM:11	bidirectional associative memory:11:0.5355	0.5355	11
BAM	BAM:27|bAM:5	bovine alveolar macrophages:32:0.8563	0.8563	32
BAM	BAM:28	Brewster angle microscopy:28:0.8941	0.8941	28
BAM	BAM:20	bronchoalveolar macrophages:20:0.2172	0.2172	20
BAM	BAM:4	metabolite 2,6-dichlorobenzamide:4:0.1132	0.1132	4
BANA	BANA:10	N-benzoyl-DL-arginine-2-naphthylamide:10:0.1250	0.1250	10
BAOT	BAOT:9	bed nucleus of the accessory olfactory tract:9:0.5470	0.5470	9
BAO	BAO:86	Basal Acid Output:86:0.8686	0.8686	86
BAPNA	BAPNA:13|BApNA:5	p-nitroanilide:18:0.2464	0.2464	18
BAPN	BAPN:85	Beta-Aminopropionitrile:85:0.6512	0.6512	85
BAPN	BAPN:15	beta-aminoproprionitrile:15:0.1085	0.1085	15
BAQ	BAQ:6	Body Attitudes Questionnaire:6:0.5290	0.5290	6
BARD1	BARD1:8	BRCA1-associated RING domain:8:0.5006	0.5006	8
BARI	BARI:74	Bypass Angioplasty Revascularization Investigation:74:0.8961	0.8961	74
BAROS	BAROS:14	Bariatric analysis and reporting outcome system:14:0.8165	0.8165	14
BAR	BAR:34	beta-adrenergic receptor:22:0.5863|beta-adrenergic receptors:12:0.4557	0.5863	34
bar	bar:7	bialaphos resistance gene:7:0.4438	0.4438	7
BAR	BAR:28	biofragmentable anastomosis ring:28:0.7154	0.7154	28
BAR	BAR:17	biofragmentable anastomotic ring:17:0.6748	0.6748	17
BASC	BASC:11	Assessment System for Children:11:0.7357	0.7357	11
BASCD	BASCD:15	British Association for the Study of Community Dentistry:15:0.8045	0.8045	15
BASDAI	BASDAI:51	Bath Ankylosing Spondylitis Disease Activity Index:51:0.9416	0.9416	51
BASFI	BASFI:41	Bath Ankylosing Spondylitis Functional Index:41:0.9291	0.9291	41
BASI	BASI:14	alpha-amylase/subtilisin inhibitor:14:0.7909	0.7909	14
BASMC	BASMC:8	bovine aortic smooth muscle cells:8:0.4102	0.4102	8
BASMCs	BASMCs:10	bovine aortic smooth muscle cells:10:0.5856	0.5856	10
BASMI	BASMI:10	Bath Ankylosing Spondylitis Metrology Index:10:0.7103	0.7103	10
BASP	BASP:12	bursal anti-steroidogenic peptide:12:0.7357	0.7357	12
BAS	BAS:9	Assessment Scale:9:0.1690	0.1690	9
BAS	BAS:24	Balloon atrial septostomy:24:0.8115	0.8115	24
BAS	BAS:10	Barnes Akathisia Scale:10:0.7103	0.7103	10
bas	bas:12	basilar arteries:12:0.7571	0.7571	12
BAS	BAS:10	behavioral activation system:10:0.5856	0.5856	10
BAs	BAs:22|BAS:1|bas:1	bile acids:24:0.6767	0.6767	24
BAS	BAS:9	Biologically active substances:9:0.6794	0.6794	9
BAT	BAT:16	basophil activation test:16:0.7261	0.7261	16
BAT	BAT:32	blunt abdominal trauma:32:0.9072	0.9072	32
BAT	BAT:7	brain adjacent to tumor:7:0.6411	0.6411	7
BAT	BAT:1097	brown adipose tissue:1089:0.9956|brown adipose tissues:8:0.6411	0.9956	1097
BAT	BAT:9	technique:9:0.0057	0.0057	9
BAU	BAU:10	5-benzylacyclouridine:10:0.3913	0.3913	10
BAV-3	BAV-3:17|BAV3:13	bovine adenovirus type 3:30:0.9011	0.9011	30
BAV	BAV:18	balloon aortic valvuloplasty:18:0.8365	0.8365	18
BAV	BAV:31	bicuspid aortic valve:31:0.8519	0.8519	31
BAV	BAV:9	bovine adenovirus:9:0.6794	0.6794	9
BAW	BAW:8	Bronchoalveolar washings:8:0.4102	0.4102	8
BAW	BAW:20	bulk acoustic wave:20:0.7766	0.7766	20
Bax	Bax:5|bax:4	apoptosis:9:0.0930	0.0930	9
Bax	BAX:7|Bax:7	BCL-2-associated X protein:14:0.3585	0.3585	14
BAY	BAY:13|Bay:2	BAY K 8644:15:0.6386	0.6386	15
BAbs	BAbs:5|bAbs:4|Babs:3|bABs:1	antibodies:13:0.5714	0.5714	13
BAd3	BAd3:10	bovine adenovirus type 3:10:0.5856	0.5856	10
BA	BA:11	6-benzyladenine:11:0.0040	0.0040	11
BA	BA:8|Ba:1	antigen:9:0.0032	0.0032	9
BA	BA:36	Bacillary angiomatosis:36:0.9174	0.9174	36
BA	BA:7	background activity:7:0.0592	0.0592	7
BA	BA:78	balloon angioplasty:78:0.9617	0.9617	78
Ba	Ba:40	barium:40:0.0156	0.0156	40
BA	BA:11	basilar:11:0.0040	0.0040	11
BA	BA:219	basilar artery:211:0.7900|basilar arteries:8:0.2090	0.7900	219
B-A	ba:3|B-A:3|BA:2|b-a:2	basolateral-to-apical:10:0.0036	0.0036	10
BA	BA:78	benz[a]anthracene:59:0.0232|benz(a)anthracene:19:0.0072	0.0232	78
BA	BA:9	benzaldehyde:9:0.0032	0.0032	9
BA	BA:12	Benzamide:12:0.0044	0.0044	12
BA	BA:17|Ba:1	benzanthracene:18:0.0068	0.0068	18
BA	BA:62	benzoic acid:62:0.1954	0.1954	62
BA	BA:18	benzyl alcohol:18:0.6903	0.6903	18
BA	BA:28	benzyladenine:28:0.0104	0.0104	28
BA	BA:106|ba:1	bile acids:55:0.8645|bile acid:52:0.1576	0.8645	107
BA	BA:201	biliary atresia:201:0.9683	0.9683	201
BA	BA:5	binding assay:5:0.0736	0.0736	5
BA	BA:43	bioavailability:43:0.0168	0.0168	43
BA	BA:12	biogenic amines:12:0.7571	0.7571	12
BA	BA:19	blood agar:19:0.6106	0.6106	19
BA	BA:118	bone age:118:0.8143	0.8143	118
BA	BA:31|ba:1|Ba:1	brachial artery:33:0.0854	0.0854	33
BA	BA:89	Brodmann area:49:0.2667|Brodmann's area:30:0.1408|Brodmann areas:10:0.2643	0.2667	89
BA	BA:289	bronchial asthma:289:0.9541	0.9541	289
BA	BA:7	Butyl acrylate:7:0.2113	0.2113	7
BA	BA:45	butyric acid:45:0.1317	0.1317	45
BA	BA:6	lymphoma cell bioassay:6:0.3728	0.3728	6
BA	BA:9	mg/L 6-benzylaminopurine:9:0.2757	0.2757	9
BA	BA:5	n-butyl acrylate:5:0.0612	0.0612	5
BA	BA:14	N6-benzyladenine:14:0.0052	0.0052	14
BB/W	BB/W:10	Bio-Breeding/Worcester:10:0.1875	0.1875	10
BB/W	BB/W:14	BioBreeding/Worcester:14:0.2708	0.2708	14
BB/Wor	BB/Wor:9	BioBreeding/Worcester:9:0.4444	0.4444	9
BB-94	BB-94:9	matrix metalloproteinase inhibitor batimastat:9:0.4363	0.4363	9
BBA	BBA:34	Balanced Budget Act:34:0.9126	0.9126	34
BBA	BBA:22	Balanced Budget Act of 1997:22:0.8657	0.8657	22
BBA	BBA:9	born before arrival:9:0.6794	0.6794	9
BBBD	BBBD:16|BBB-D:6	blood-brain barrier disruption:22:0.7400	0.7400	22
BBB	BBB:1	Basso Beattie Bresnahan:1:0.9100	0.9100	1
BBB	BBB:2786|bbb:11|B-BB:9|b-bb:2	blood-brain barrier:2747:0.9215|blood-brain-barrier:61:0.0191	0.9215	2808
BBB	BBB:68	Bundle branch block:68:0.9306	0.9306	68
BBdp	BBdp:15|BB-DP:7|BBDP:4	diabetes-prone:26:0.3788	0.3788	26
BBdp	BBdp:7|BBDP:3|BB-DP:1	diabetes-prone BB:11:0.7357	0.7357	11
BBdp	BBdp:7|BB-DP:1	diabetes-prone BioBreeding:8:0.3463	0.3463	8
BBD	BBD:87	benign breast disease:87:0.9656	0.9656	87
BBEC	BBEC:6	bovine brain endothelial cells:6:0.5290	0.5290	6
BBEC	BBEC:7	bovine bronchial epithelial cells:7:0.5926	0.5926	7
BBECs	BBECs:11	bovine bronchial epithelial cells:11:0.6182	0.6182	11
BBE	BBE:9	berberine bridge enzyme:9:0.7103	0.7103	9
BBE	BBE:15	Bickerstaff's brainstem encephalitis:15:0.5818	0.5818	15
BbF	BbF:10|BBF:1	benzo[b]fluoranthene:11:0.1282	0.1282	11
BBF	BBF:28	blood flow:28:0.7905	0.7905	28
BBG	BBG:9	bovine brain gangliosides:9:0.6794	0.6794	9
BBIC	BBIC:9	BBI concentrate:9:0.2285	0.2285	9
BBIC	BBIC:5	Bowman-Birk inhibitor concentrate:5:0.1464	0.1464	5
BBI	BBI:48	Bowman-Birk inhibitor:48:0.3053	0.3053	48
BBI	BBI:29	Bowman-Birk protease inhibitor:29:0.6157	0.6157	29
BBMEC	BBMEC:30	bovine brain microvessel endothelial cells:18:0.8365|bovine brain microvessel endothelial cell:12:0.7571	0.8365	30
BBMECs	BBMECs:11	bovine brain microvessel endothelial cells:11:0.7357	0.7357	11
BBMVs	BBMVs:43	brush border membrane vesicles:43:0.9308	0.9308	43
BBMV	BBMV:279|bbmv:1	brush border membrane vesicles:250:0.9879|brush border membrane vesicle:17:0.8270|brush-border membrane vesicle:13:0.2211	0.9879	280
BBMs	BBMs:21|BBMS:1	Brush border membranes:22:0.8715	0.8715	22
BBM	BBM:17	brush border:17:0.8270	0.8270	17
BBM	BBM:406|bbm:1	Brush border membrane:216:0.9778|brush-border membrane:136:0.3268|brush border membranes:55:0.9458	0.9778	407
BBM	BBM:10	renal brush-border membranes:10:0.1223	0.1223	10
BBN	BBN:17	Bayesian belief network:17:0.8270	0.8270	17
BBN	BBN:9	bombesin:9:0.0240	0.0240	9
BBN	BBN:13	broadband noise:13:0.4102	0.4102	13
BBN	BBN:212	N-butyl-N-(4-hydroxybutyl)nitrosamine:147:0.4384|N-Butyl-N-(4-hydroxybutyl) nitrosamine:38:0.5462|n-butyl-n-(4-hydroxybutyl)-nitrosamine:27:0.0781	0.5462	212
BBP	BBP:7	bilin-binding protein:7:0.0886	0.0886	7
BBP	BBP:39	butyl benzyl phthalate:39:0.7602	0.7602	39
BBP	BBP:17	butylbenzyl phthalate:17:0.1187	0.1187	17
BBS	BBS:75	Bardet-Biedl syndrome:75:0.8233	0.8233	75
BBS	BBS:29	Berg Balance Scale:29:0.8978	0.8978	29
BBS	BBS:113	Bombesin:113:0.3544	0.3544	113
BBS	BBS:7	Bulletin Board System:7:0.5926	0.5926	7
BBs	BBs:5	Bunina bodies:5:0.0736	0.0736	5
BBTD	BBTD:20	baby bottle tooth decay:20:0.8449	0.8449	20
BBTV	BBTV:19	banana bunchy top virus:19:0.8449	0.8449	19
BBT	BBT:139|BBt:1	Basal body temperature:140:0.9448	0.9448	140
BBV	BBV:7	black beetle virus:7:0.5926	0.5926	7
BBDR	BBDR:7|BB-DR:1	biologically based dose-response:8:0.6794	0.6794	8
BB	BB:12	Bachmann's bundle:12:0.6460	0.6460	12
BB	BB:11|bb:1	Benzyl benzoate:12:0.6460	0.6460	12
BB	BB:42|B-b:1	beta-blockers:25:0.0230|beta-blocker:10:0.0086|beta blockers:8:0.2619	0.2619	43
BB	BB:64|Bb:1	biceps brachii:65:0.9275	0.9275	65
BB	BB:24	Bio-Breeding:24:0.0220	0.0220	24
BB	BB:11	biopsy:11:0.0096	0.0096	11
Bb	Bb:7|BB:7	bisbenzimide:14:0.0125	0.0125	14
BB	BB:19	Bombesin:19:0.0172	0.0172	19
Bb	Bb:5|BB:4	Bordetella bronchiseptica:9:0.5470	0.5470	9
Bb	Bb:60|BB:10	Borrelia burgdorferi:70:0.8573	0.8573	70
BB	BB:13	brain:13:0.0115	0.0115	13
BB	BB:18|Bb:1	Brattleboro:19:0.0172	0.0172	19
BB	BB:38	bromobenzene:38:0.0354	0.0354	38
BB	BB:9	broth:9:0.0077	0.0077	9
BB	BB:52	Brush border:52:0.9427	0.9427	52
BB	BB:6	diabetes in the BioBreeding:6:0.1063	0.1063	6
Bb	Bb:8	factor B:8:0.5006	0.5006	8
BB	BB:9	spontaneously diabetic:9:0.4587	0.4587	9
BCAAs	BCAAs:94	branched-chain amino acids:71:0.6547|branched chain amino acids:23:0.8657	0.8657	94
BCAA	BCAA:7	branched-chain AA:7:0.2902	0.2902	7
BCAA	BCAA:438|BcAA:1	branched-chain amino acids:208:0.6016|Branched chain amino acids:103:0.9712|branched-chain amino acid:98:0.6466|branched chain amino acid:30:0.8032	0.9712	439
BCAL	BCAL:9	bilateral carotid artery ligation:9:0.4587	0.4587	9
BCAO	BCAO:26|BCA-O:1|BCAo:1	bilateral carotid artery occlusion:28:0.7905	0.7905	28
BCAT	BCAT:22|BcaT:1	aminotransferase:23:0.6471	0.6471	23
BCA	BCA:5	balloon coronary angioplasty:5:0.4422	0.4422	5
BCA	BCA:33	Bicinchoninic acid:33:0.5760	0.5760	33
BCA	BCA:6	bifunctional chelating agent:6:0.5290	0.5290	6
BCA	BCA:16	bovine coronary artery:9:0.6794|bovine coronary arteries:7:0.5926	0.6794	16
BCa	BCa:5|BCA:2	breast cancer:7:0.2452	0.2452	7
BCa	BCa:6|BCA:2	breast carcinoma:8:0.5006	0.5006	8
BCA	BCA:11	bronchial cross-sectional area:11:0.7357	0.7357	11
BCBL	BCBL:20	body cavity-based lymphoma:12:0.7571|body cavity-based lymphomas:8:0.6411	0.7571	20
BCBS	BCBS:6	Blue Cross and Blue Shield:6:0.6794	0.6794	6
BCB	BCB:10|bcb:1	blood-CSF barrier:11:0.2422	0.2422	11
BCB	BCB:16	Brilliant Cresyl Blue:16:0.7261	0.7261	16
BCCA	BCCA:8	bilateral clamping of carotid arteries:8:0.7096	0.7096	8
BCCA	BCCA:13	British Columbia Cancer Agency:13:0.7753	0.7753	13
BCCA	BCCA:4	min to bilateral clamping of the common carotid arteries:4:0.5290	0.5290	4
BCCAO	BCCAO:9|BCCAo:2|bCCA-o:1	bilateral common carotid artery occlusion:12:0.7571	0.7571	12
BCCP	BCCP:30	biotin carboxyl carrier protein:30:0.8472	0.8472	30
BCCs	BCCs:229|BCCS:1	Basal cell carcinomas:230:0.9870	0.9870	230
BCCs	BCCs:9	breast cancer cells:9:0.6794	0.6794	9
BCC	BCC:8	basal cell:8:0.1591	0.1591	8
BCC	BCC:9	basal cell cancer:9:0.6794	0.6794	9
BCC	BCC:885|bcc:2	Basal cell carcinoma:730:0.9891|basal cell carcinomas:157:0.9809	0.9891	887
bcc	bcc:7|BCC:1	body-centered cubic:8:0.2619	0.2619	8
BCC	BCC:9	breast cancer cell:9:0.6794	0.6794	9
Bcc	Bcc:12|BCC:10	Burkholderia cepacia complex:22:0.6934	0.6934	22
BCC	BCC:6	chromaffin cells:6:0.0899	0.0899	6
BCDDP	BCDDP:31	Breast Cancer Detection Demonstration Project:31:0.9151	0.9151	31
BCDF	BCDF:40	B cell differentiation factor:30:0.9011|B cell differentiation factors:10:0.7103	0.9011	40
BCEC	BCEC:26	bovine corneal endothelial cells:26:0.8861	0.8861	26
BCEC	BCEC:45	brain capillary endothelial cells:45:0.7507	0.7507	45
BCECF	BCECF:11	2',7'-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein:11:0.0222	0.0222	11
BCECTS	BCECTS:9	benign childhood epilepsy with centrotemporal spikes:9:0.6794	0.6794	9
BCECs	BCECs:31	brain capillary endothelial cells:31:0.9043	0.9043	31
BCEs	BCEs:9	basal cell epitheliomas:9:0.6794	0.6794	9
BCEs	BCEs:6	bovine capillary endothelial cells:6:0.5290	0.5290	6
BCE	BCE:28|bce:2	basal cell epithelioma:30:0.9011	0.9011	30
BCE	BCE:39	bovine capillary endothelial:39:0.9237	0.9237	39
BCE	BCE:20	bovine corneal endothelial:20:0.7766	0.7766	20
BCE	BCE:11	endothelial cells:11:0.4728	0.4728	11
BCFA	BCFA:8	branched-chain fatty acid:8:0.4102	0.4102	8
BCFs	BCFs:36	bioconcentration factors:36:0.8336	0.8336	36
BCF	BCF:24	beat cross frequency:24:0.8115	0.8115	24
BCF	BCF:91	bioconcentration factor:53:0.8166|Bioconcentration factors:38:0.7548	0.8166	91
BCF	BCF:37|bcf:1	breast cyst fluid:38:0.9197	0.9197	38
BCG-CWS	BCG-CWS:7	BCG cell-wall skeleton:7:0.2902	0.2902	7
BCG-CWS	BCG-CWS:7	cell wall skeleton:7:0.5926	0.5926	7
BCG-CWS	BCG-CWS:5	Mycobacterium bovis BCG:5:0.2818	0.2818	5
BCGF	BCGF:211	B cell growth factor:138:0.9538|B-cell growth factor:59:0.2246|B cell growth factors:14:0.7909	0.9538	211
BCG	BCG:63	bacille Calmette Guerin:63:0.2346	0.2346	63
BCG	BCG:9	Bacillus-Calmette-Guerin:9:0.0031	0.0031	9
BCG	BCG:14	Bacillus of Calmette and Guerin:14:0.5929	0.5929	14
BCG	BCG:11	ballistocardiogram:11:0.0039	0.0039	11
BCG	BCG:16	bromcresol green:16:0.2219	0.2219	16
BCG	BCG:24	bromocresol green:24:0.4187	0.4187	24
BCG	BCG:25	Calmette-Guerin bacillus:25:0.5370	0.5370	25
BCG	BCG:8	Calmette-Guerin vaccine:8:0.2619	0.2619	8
BCG	BCG:131	Mycobacterium bovis:131:0.6473	0.6473	131
BCG	BCG:20	Mycobacterium bovis BCG:20:0.8525	0.8525	20
BCH	BCH:25	basal cell hyperplasia:25:0.8816	0.8816	25
BCh	BCh:8|Bch:1|BCH:1	bethanechol:10:0.0455	0.0455	10
BCIE	BCIE:14	bullous congenital ichthyosiform erythroderma:14:0.7909	0.7909	14
bCII	bCII:8|B-CII:2	bovine type II collagen:10:0.4363	0.4363	10
BCIs	BCIs:11	brain-computer interfaces:11:0.6182	0.6182	11
BCI	BCI:87	Brain-Computer Interface:87:0.7439	0.7439	87
BCKA	BCKA:11	branched-chain alpha-keto acid:11:0.5355	0.5355	11
BCKA	BCKA:10	branched-chain keto acids:10:0.3470	0.3470	10
BCKAD	BCKAD:14	branched-chain alpha-keto acid dehydrogenase:14:0.6911	0.6911	14
BCKD	BCKD:10	branched-chain alpha-keto acid dehydrogenase:10:0.5856	0.5856	10
BCKD	BCKD:8	branched chain alpha-ketoacid dehydrogenase:8:0.6411	0.6411	8
BCKDC	BCKDC:5	branched-chain alpha-keto acid dehydrogenase complex:5:0.4422	0.4422	5
BCKDH	BCKDH:15	Branched-chain alpha-keto acid dehydrogenase:15:0.5818	0.5818	15
BCKDH	BCKDH:10	branched-chain alpha-ketoacid dehydrogenase:10:0.4363	0.4363	10
BCK	BCK:10|B-CK:7	creatine kinase:17:0.7407	0.7407	17
BCL1	BCL1:23	B cell leukemia:23:0.8657	0.8657	23
BCL1	BCL1:11	murine B-cell leukemia:11:0.2764	0.2764	11
Bcl-2	Bcl-2:7|bcl-2:4	anti-apoptotic:11:0.0412	0.0412	11
Bcl-2	Bcl-2:7|BCL-2:4|BCL2:1	B-cell lymphoma 2:6:0.1543|B-cell lymphoma-2:6:0.1838	0.1838	12
bcl-2	bcl-2:5|Bcl-2:2|BCL2:1|BCL-2:1	B-cell lymphoma/leukemia-2:9:0.3945	0.3945	9
Bcl-2	Bcl-2:9|bcl-2:3	bcl-2 protein:12:0.2211	0.2211	12
B-CLL	B-CLL:149|BCLL:2	B-cell chronic lymphocytic leukaemia:121:0.5660|B cell chronic lymphocytic leukaemia:30:0.9011	0.9011	151
B-CLL	B-CLL:533|BCLL:7	B-cell chronic lymphocytic leukemia:427:0.6236|B cell chronic lymphocytic leukemia:113:0.9735	0.9735	540
B-CLL	B-CLL:8|BCLL:1	chronic lymphocytic leukemias:9:0.5470	0.5470	9
B-CLL	B-CLL:3	Chronic lymphocytic leukemia of B-cell type:3:0.5926	0.5926	3
B-CLL	B-CLL:4	leukemia of B-cell origin:4:0.1618	0.1618	4
B-CLL	B-CLL:7	lymphocytic leukemia cells:7:0.4438	0.4438	7
BCLP	BCLP:36	bilateral cleft lip and palate:36:0.7082	0.7082	36
BCLS	BCLS:9	basic cardiac life support:9:0.6794	0.6794	9
BCL	BCL:16	B-cell lymphoma:8:0.4102|B-cell lymphomas:8:0.3463	0.4102	16
BCL	BCL:38	basic cycle length:24:0.6767|basic cycle lengths:14:0.7909	0.7909	38
BCMA	BCMA:8	B cell maturation antigen:8:0.6411	0.6411	8
BCME	BCME:9	bis(chloromethyl)ether:9:0.5333	0.5333	9
BCMV	BCMV:19	bean common mosaic virus:19:0.7658	0.7658	19
BCM	BCM:6	blue cone monochromatism:6:0.5290	0.5290	6
BCM	BCM:120|bcm:2	body cell mass:122:0.9609	0.9609	122
BCM	BCM:9	bovine cervical mucus:9:0.5470	0.5470	9
BCM	BCM:7	bulbocavernosus muscle:7:0.2902	0.2902	7
BCNS	BCNS:9	basal cell naevus syndrome:9:0.6794	0.6794	9
BCNS	BCNS:21	Basal cell nevus syndrome:21:0.8594	0.8594	21
BCNU	BCNU:9	1,3-bis(2-chlorethyl)-1-nitrosourea:9:0.0076	0.0076	9
BCNU	BCNU:466|bcnu:1	1,3-Bis(2-chloroethyl)-1-nitrosourea:385:0.3638|1,3-bis-(2-chloroethyl)-1-nitrosourea:53:0.0495|1,3-bis (2-chloroethyl)-1-nitrosourea:29:0.6157	0.6157	467
BCNU	BCNU:14	1,3-bis(chloroethyl)-1-nitrosourea:14:0.0124	0.0124	14
BCNU	BCNU:9	bis-chloroethylnitrosourea:9:0.0076	0.0076	9
BCNU	BCNU:13	bischloroethylnitrosourea:13:0.0114	0.0114	13
BCNU	BCNU:285	carmustine:285:0.2705	0.2705	285
BCNU	BCNU:18	N,N'-bis(2-chloroethyl)-N-nitrosourea:18:0.0162	0.0162	18
BCNU	BCNU:24	nitrosourea:24:0.0219	0.0219	24
BCO	BCO:13	bilateral carotid artery occlusion:13:0.6701	0.6701	13
BCO	BCO:55	bilateral carotid occlusion:55:0.8882	0.8882	55
BCP-ALL	BCP-ALL:7	B cell precursor acute lymphoblastic leukemia:7:0.5926	0.5926	7
BCPA	BCPA:11|b-CPA:1	cavopulmonary anastomosis:12:0.7571	0.7571	12
BCPN	BCPN:15	N-butyl-N-(3-carboxypropyl)nitrosamine:15:0.5000	0.5000	15
BCPT	BCPT:29	Breast Cancer Prevention Trial:29:0.8978	0.8978	29
BC-PS	BC-PS:14|BCPS:2	phosphatidylserine:16:0.2273	0.2273	16
BCP	BCP:48	B-cell precursor:24:0.7593|B-cell precursors:12:0.2414|B cell precursors:12:0.7571	0.7593	48
BCP	BCP:24	blood cardioplegia:24:0.8115	0.8115	24
BCP	BCP:9	bromcresol purple:9:0.1150	0.1150	9
BCP	BCP:19	bromocresol purple:19:0.4618	0.4618	19
BCP	BCP:94	calcium phosphate:94:0.9184	0.9184	94
BCP	BCP:29	core promoter:29:0.8978	0.8978	29
BCRP	BCRP:102|Bcrp:5	breast cancer resistance protein:107:0.9555	0.9555	107
BCRS	BCRS:11	Brief Cognitive Rating Scale:11:0.7357	0.7357	11
BCR	BCR:8	antigen receptors:8:0.0789	0.0789	8
BCR	BCR:264|BcR:3	B cell antigen receptor:193:0.9598|B-cell antigen receptor:74:0.2037	0.9598	267
BCR	BCR:118|BcR:4	B-cell receptor:105:0.1335|B cell receptors:9:0.6794|B-cell receptors:8:0.0789	0.6794	122
bcr	bcr:129|BCR:44|Bcr:1	breakpoint cluster region:174:0.9252	0.9252	174
BCR	BCR:34	bulbocavernosus reflex:34:0.6194	0.6194	34
BCR	BCR:25	Community Bureau of Reference:25:0.8186	0.8186	25
BCR	BCR:11|BcR:1	receptor complex:12:0.6460	0.6460	12
BCSFB	BCSFB:13|B-CSF-B:1	blood-cerebrospinal fluid barrier:14:0.5589	0.5589	14
BCSS	BCSS:10	Breast cancer-specific survival:10:0.7103	0.7103	10
BCs	BCs:8	basket cells:8:0.0584	0.0584	8
BCS	BCS:8	bathocuproinedisulfonic acid:8:0.2987	0.2987	8
BCS	BCS:29	biopharmaceutics classification system:29:0.5269	0.5269	29
BCs	BCs:12	bipolar cells:12:0.1423	0.1423	12
BCS	BCS:124	body condition score:106:0.9406|body condition scores:18:0.7539	0.9406	124
BCS	BCS:12	bovine calf serum:12:0.7571	0.7571	12
BCS	BCS:11	breast cancer survivors:11:0.7357	0.7357	11
BCS	BCS:114	breast-conserving surgery:76:0.4587|breast conserving surgery:38:0.9217	0.9217	114
BCS	BCS:116|B-CS:1	Budd-Chiari syndrome:117:0.8818	0.8818	117
BCs	BCs:11	buffy coats:11:0.7357	0.7357	11
BCTV	BCTV:19	beet curly top virus:19:0.8449	0.8449	19
BCT	BCT:11	basic combat training:11:0.7357	0.7357	11
BCT	BCT:15	Blood cell transplantation:15:0.7096	0.7096	15
BCT	BCT:40	breast conservation therapy:40:0.9237	0.9237	40
BCT	BCT:105	Breast-conserving therapy:105:0.4400	0.4400	105
BCT	BCT:31	breast-conserving treatment:17:0.1973|Breast conserving treatment:14:0.7909	0.7909	31
BCT	BCT:14	bromocriptine:14:0.0295	0.0295	14
BCT	BCT:9	buffy coat technique:9:0.6794	0.6794	9
BCV	BCV:113	bovine coronavirus:113:0.9316	0.9316	113
BCVA	BCVA:341|BcVA:1|bcva:1	best corrected visual acuity:207:0.9855|best-corrected visual acuity:136:0.3268	0.9855	343
B-CAM	B-CAM:6	Basal cell adhesion molecule:6:0.5290	0.5290	6
BChE	BChE:9	cholinesterase:9:0.0265	0.0265	9
BChls	BChls:6|Bchls:3	bacteriochlorophylls:9:0.7273	0.7273	9
BCoV	BCoV:9	bovine coronavirus:9:0.5470	0.5470	9
BC	BC:8|Bc:1	bacitracin:9:0.0044	0.0044	9
BC	BC:24	backcross:24:0.0126	0.0126	24
BC	BC:17	bacterial cellulose:17:0.7407	0.7407	17
BC	BC:9	basaloid carcinoma:9:0.0537	0.0537	9
BC	BC:9	basic copy:9:0.6794	0.6794	9
BC	BC:33	benzalkonium chloride:33:0.4589	0.4589	33
BC	BC:96	beta-carotene:96:0.0519	0.0519	96
BC	BC:11	bile canaliculi:11:0.7357	0.7357	11
BC	BC:7|bc:1	biliary complications:8:0.4102	0.4102	8
BC	BC:5	biochemical control:5:0.0612	0.0612	5
BC	BC:15	biotin carboxylase:15:0.8045	0.8045	15
BC	BC:9	biventer cervicis:9:0.6794	0.6794	9
BC	BC:36	black carbon:36:0.9174	0.9174	36
BC	BC:11	bladder capacity:11:0.2422	0.2422	11
BC	BC:85	blast crisis:85:0.6285	0.6285	85
BC	BC:31	blastic crisis:31:0.1741	0.1741	31
BC	BC:20|Bc:1	blood culture:11:0.6182|blood cultures:10:0.5856	0.6182	21
BC	BC:27	body composition:27:0.8903	0.8903	27
BC	BC:9	body condition:9:0.4587	0.4587	9
BC	BC:43|bc:3	bone conduction:32:0.9072|bone-conduction:14:0.0071	0.9072	46
BC	BC:20	brachium conjunctivum:20:0.8525	0.8525	20
BC	BC:306	Breast Cancer:297:0.8956|breast cancers:9:0.6794	0.8956	306
BC	BC:33	breast carcinoma:33:0.3750	0.3750	33
BC	BC:57	British Columbia:57:0.9477	0.9477	57
BC	BC:40|Bc:2	bromocriptine:42:0.0224	0.0224	42
BC	BC:23	bronchoconstriction:23:0.0120	0.0120	23
BC	BC:12	bronchogenic carcinoma:12:0.0776	0.0776	12
BC	BC:9	bronchogenic cyst:9:0.5470	0.5470	9
BC	BC:49|Bc:1	buffy coat:41:0.9274|buffy-coat:9:0.0044	0.9274	50
BC	BC:43	bulbocavernosus:43:0.0229	0.0229	43
BDAE	BDAE:18	Boston Diagnostic Aphasia Examination:18:0.8365	0.8365	18
BDA	BDA:23	anterograde tracer biotinylated dextran amine:23:0.5634	0.5634	23
BDA	BDA:11	beclomethasone dipropionate aerosol:11:0.7357	0.7357	11
BDA	BDA:6	biotinylated dextran-amine:6:0.1838	0.1838	6
BDA	BDA:9	biotinylated dextranamine:9:0.5470	0.5470	9
BDA	BDA:10	British Diabetic Association:10:0.7103	0.7103	10
BDCM	BDCM:49	bromodichloromethane:49:0.8421	0.8421	49
BDC	BDC:8	bile duct carcinoma:8:0.3463	0.3463	8
BDD	BDD:9	3-Butene-1,2-diol:9:0.0485	0.0485	9
BDD	BDD:98	body dysmorphic disorder:98:0.9695	0.9695	98
BDD	BDD:13	Boron-doped diamond:13:0.5335	0.5335	13
BDE	BDE:17	bond dissociation energy:17:0.8270	0.8270	17
BDE	BDE:12	bond dissociation enthalpy:12:0.7571	0.7571	12
BDE-209	BDE-209:9|BDE209:3	decabromodiphenyl ether:12:0.6460	0.6460	12
BDE-47	BDE-47:8|BDE47:1	2,2',4,4'-tetrabromodiphenyl ether:9:0.3945	0.3945	9
BDE-99	BDE-99:10	2,2',4,4',5-pentabromodiphenyl ether:10:0.5000	0.5000	10
BDEs	BDEs:16	bond dissociation energies:16:0.8165	0.8165	16
BDEs	BDEs:13	bond dissociation enthalpies:13:0.7753	0.7753	13
bDFS	bDFS:7|BDFS:6	Biochemical disease-free survival:13:0.7753	0.7753	13
BDGF	BDGF:10	growth factor:10:0.5856	0.5856	10
BDG	BDG:17	bilirubin diglucuronide:17:0.5038	0.5038	17
BDH	BDH:52	dehydrogenase:52:0.8095	0.8095	52
BDHC	BDHC:14	benzidine dihydrochloride:14:0.7909	0.7909	14
BDHI	BDHI:25	Buss-Durkee Hostility Inventory:25:0.5496	0.5496	25
BDI-II	BDI-II:30	Beck Depression Inventory-II:30:0.9011	0.9011	30
BDI	BDI:23	baseline dyspnea index:23:0.8038	0.8038	23
BDI	BDI:889	Beck Depression Inventory:889:0.9459	0.9459	889
BDI	BDI:14	Bile duct injury:14:0.7909	0.7909	14
BDI	BDI:6	bleomycin-detectable iron:6:0.2243	0.2243	6
BDI	BDI:9	diabetes insipidus:9:0.6794	0.6794	9
BDLS	BDLS:36	Brachmann-De Lange syndrome:36:0.9151	0.9151	36
BDL	BDL:75	Bile duct-ligated:41:0.9274|bile duct ligated:34:0.9126	0.9274	75
BDL	BDL:192|bdl:1	bile duct ligation:193:0.9752	0.9752	193
BDL	BDL:8	Ligation of the common bile duct:8:0.6794	0.6794	8
BDMP	BDMP:11	birth defects monitoring program:11:0.7357	0.7357	11
BDMV	BDMV:7	bean dwarf mosaic virus:7:0.5926	0.5926	7
BDM	BDM:24	2,3-butanedione 2-monoxime:24:0.8115	0.8115	24
BDM	BDM:170	2,3-butanedione monoxime:170:0.7801	0.7801	170
BDO	BDO:6	butadiene monoepoxide:6:0.2243	0.2243	6
BDOC	BDOC:20	biodegradable dissolved organic carbon:20:0.8449	0.8449	20
BDPs	BDPs:12	breakdown products:12:0.5664	0.5664	12
BDP	BDP:382|Bdp:3	beclomethasone dipropionate:385:0.9233	0.9233	385
BDP	BDP:7	inhaled beclomethasone:7:0.1850	0.1850	7
BDQ	BDQ:7	Bowel Disease Questionnaire:7:0.5926	0.5926	7
BDR	BDR:12	Background diabetic retinopathy:12:0.7571	0.7571	12
BDR	BDR:15	bile duct resection:15:0.8045	0.8045	15
BDR	BDR:9	bronchodilator response:9:0.5470	0.5470	9
BDS	BDS:15	Blessed Dementia Scale:15:0.8045	0.8045	15
BDs	BDs:13	blood donors:13:0.7753	0.7753	13
BDT	BDT:11	basophil degranulation test:11:0.6182	0.6182	11
BDX	BDX:10	xenograft:10:0.8182	0.8182	10
BDZR	BDZR:6|BDZ-R:2|BDZr:1	benzodiazepine receptor:9:0.3945	0.3945	9
BDZs	BDZs:29	benzodiazepines:29:0.9032	0.9032	29
BDZ	BDZ:215|Bdz:1	benzodiazepine:175:0.7197|benzodiazepines:41:0.1674	0.7197	216
BD	BD:151|Bd:1	1,3-Butadiene:152:0.0754	0.0754	152
BD	BD:17	1,3-butanediol:17:0.0080	0.0080	17
BD	BD:9	1,4-butanediol:9:0.0040	0.0040	9
BD	BD:39	basal diet:39:0.6230	0.6230	39
BD	BD:45	base deficit:45:0.8369	0.8369	45
BD	BD:9	Beclomethasone dipropionate:9:0.3069	0.3069	9
BD	BD:492|Bd:1	Behcet's disease:493:0.6663	0.6663	493
BD	BD:11	bicarbonate dialysis:11:0.7357	0.7357	11
BD	BD:22	bile duct:16:0.7261|bile ducts:6:0.2243	0.7261	22
BD	BD:12	binding domain:12:0.3275	0.3275	12
BD	BD:10	biotinylated dextran:10:0.3867	0.3867	10
BD	BD:151	Bipolar Disorder:145:0.8526|Bipolar Disorders:6:0.1543	0.8526	151
BD	BD:16	bladder drainage:16:0.6024	0.6024	16
BD	BD:12	blood donors:12:0.7571	0.7571	12
BD	BD:26|Bd:2	body density:28:0.2111	0.2111	28
BD	BD:11	Body Dissatisfaction:11:0.7571	0.7571	11
BD	BD:48	Bone density:48:0.4334	0.4334	48
BD	BD:12	bony defect:12:0.5050	0.5050	12
BD	BD:66	brain death:66:0.9286	0.9286	66
BD	BD:21|Bd:3	bronchodilator:14:0.0065|bronchodilators:10:0.0045	0.0065	24
BD	BD:33	Brownian Dynamics:33:0.9100	0.9100	33
BD	BD:20	Butadiene:20:0.0095	0.0095	20
bd	bd:14|BD:5	twice daily:19:0.8449	0.8449	19
BEAM	BEAM:14	brain electrical activity mapping:14:0.7753	0.7753	14
BEA	BEA:9	2-bromoethanamine:9:0.0777	0.0777	9
BEA	BEA:17	2-bromoethylamine hydrobromide:17:0.3670	0.3670	17
BEA	BEA:10	beauvericin:10:0.0874	0.0874	10
BECAIT	BECAIT:14	Bezafibrate Coronary Atherosclerosis Intervention Trial:14:0.7909	0.7909	14
BECRS	BECRS:6	Benign epilepsy of childhood with Rolandic spikes:6:0.3728	0.3728	6
BECTS	BECTS:11	benign childhood epilepsy with centrotemporal spikes:11:0.7357	0.7357	11
BECTS	BECTS:8	Benign epilepsy with centrotemporal spikes:8:0.1471	0.1471	8
BECs	BECs:11	blood ethanol concentrations:11:0.6182	0.6182	11
BECs	BECs:87	epithelial cells:87:0.7269	0.7269	87
BEC	BEC:45	blood ethanol concentration:35:0.7952|blood ethanol concentrations:10:0.5856	0.7952	45
BEC	BEC:15	Bose-Einstein condensate:15:0.8045	0.8045	15
BEC	BEC:9	Bose-Einstein condensation:9:0.6794	0.6794	9
BEC	BEC:10	bromocriptine:10:0.0269	0.0269	10
BEC	BEC:150	epithelial cells:128:0.8428|epithelial cell:22:0.6531	0.8428	150
BED	BED:241	binge eating disorder:205:0.9853|binge-eating disorder:36:0.1003	0.9853	241
BED	BED:64	biologically effective dose:60:0.5279|biologically effective doses:4:0.0918	0.5279	64
BEE	BEE:44	basal energy expenditure:44:0.8941	0.8941	44
BEFV	BEFV:15	bovine ephemeral fever virus:15:0.8045	0.8045	15
BEF	BEF:5	best excitatory frequency:5:0.4422	0.4422	5
BEF	BEF:28	bovine ephemeral fever:28:0.8941	0.8941	28
BEF	BEF:7	enhancing factor:7:0.2113	0.2113	7
BEI	BEI:27	backscattered electron imaging:27:0.5951	0.5951	27
BEI	BEI:13	binary ethylenimine:13:0.7753	0.7753	13
BEI	BEI:9	Bioelectrical impedance:9:0.3945	0.3945	9
BEI	BEI:26	Biological Exposure Index:26:0.8861	0.8861	26
B-ELISA	B-ELISA:7|bELISA:2	blocking enzyme-linked immunosorbent assay:9:0.5470	0.5470	9
B-ELI	BE-LI:2|B-ELI:2|BE-li:2|BELI:2	beta-endorphin-like immunoreactivity:8:0.5006	0.5006	8
BEL	BEL:11	bovine epithelial lens:11:0.7357	0.7357	11
BEL	BEL:49	bromoenol lactone:49:0.9392	0.9392	49
BEM	BEM:65	boundary element method:65:0.9541	0.9541	65
B-END	B-END:11|BEND:7|B-End:2|Bend:2|b-END:1|b-end:1	beta-endorphin:24:0.4894	0.4894	24
BEND	BEND:10	bovine endometrial:10:0.7103	0.7103	10
BEN	BEN:83	Balkan endemic nephropathy:83:0.9436	0.9436	83
BEP2D	BEP2D:9	human bronchial epithelial:9:0.6794	0.6794	9
B-EP	B-EP:12|B-Ep:1|BEP:1	B-endorphin:14:0.0528	0.0528	14
BeP	BeP:23|BEP:1	benzo[e]pyrene:13:0.0488|benzo(e)pyrene:11:0.0407	0.0488	24
B-EP	B-EP:17|BEP:11|B-Ep:7	beta-endorphin:35:0.1382	0.1382	35
BERKO	BERKO:6	ERbeta knockout:6:0.2243	0.2243	6
BER	BER:350	Base excision repair:350:0.9914	0.9914	350
BER	BER:14	basic electric rhythm:14:0.6911	0.6911	14
BER	BER:29	basic electrical rhythm:29:0.6928	0.6928	29
Ber	Ber:8|BER:3	berbamine:11:0.0191	0.0191	11
Ber	Ber:11|BER:1	Berberine:12:0.0229	0.0229	12
BER	BER:12	bit error rate:7:0.5926|bit-error rate:5:0.0612	0.5926	12
BER	BER:10	evoked response:10:0.3470	0.3470	10
BESA	BESA:10	brain electrical source analysis:10:0.7103	0.7103	10
BESPM	BESPM:7|BESpm:4|BE-Spm:1	N1,N12-bis(ethyl)spermine:12:0.4583	0.4583	12
BES	BES:10	balanced electrolyte solution:10:0.7103	0.7103	10
BES	BES:17	Binge Eating Scale:17:0.8270	0.8270	17
bET-1	bET-1:7|BET-1:4	big endothelin-1:11:0.7357	0.7357	11
BET	BET:16	Brunauer-Emmett-Teller:16:0.1020	0.1020	16
BEVS	BEVS:32	baculovirus expression vector system:32:0.9072	0.9072	32
BEV	BEV:21	beam's eye view:21:0.7865	0.7865	21
BEV	BEV:9	Berne virus:9:0.3069	0.3069	9
BEV	BEV:15	bovine enterovirus:15:0.8045	0.8045	15
BE	BE:34	2-butoxyethanol:34:0.0272	0.0272	34
BE	BE:39	bacterial endocarditis:39:0.8142	0.8142	39
BE	BE:35	barium enema:35:0.9151	0.9151	35
BE	BE:230	Barrett's esophagus:221:0.8678|Barrett's oesophagus:9:0.5470	0.8678	230
BE	BE:139|-BE:1	base excess:140:0.9786	0.9786	140
Be	Be:58	beryllium:58:0.0470	0.0470	58
BE	BE:90|B-E:5|bE:1	Beta-endorphin:96:0.0783	0.0783	96
BE	BE:20	bioequivalence:20:0.0157	0.0157	20
BE	BE:14	brain edema:14:0.7909	0.7909	14
BE	BE:15	bronchiectasis:15:0.0115	0.0115	15
BE	BE:9	cocaine and benzoylecgonine:9:0.1148	0.1148	9
BE	BE:11	cocaine metabolite benzoylecgonine:11:0.6024	0.6024	11
BE	BE:13	effect:13:0.0099	0.0099	13
BE	BE:12	epithelium:12:0.0091	0.0091	12
BE	BE:14|Be:1	extract:15:0.0115	0.0115	15
BF-1	BF-1:9|BF1:1	brain factor 1:10:0.7103	0.7103	10
BF-2	BF-2:10	Bluegill fry:10:0.7103	0.7103	10
BFA	BFA:9	bifunctional antibody:9:0.6794	0.6794	9
BFA	BFA:10	brefeldin-A:10:0.1084	0.1084	10
BFB	BFB:17	biofeedback:17:0.2222	0.2222	17
BFB	BFB:17	breakage-fusion-bridge:17:0.2222	0.2222	17
BFCN	BFCN:13	basal forebrain cholinergic neurons:13:0.7753	0.7753	13
BFCNs	BFCNs:13	basal forebrain cholinergic neurons:13:0.7753	0.7753	13
BFCS	BFCS:8	basal forebrain cholinergic system:8:0.6411	0.6411	8
BFDGE	BFDGE:9	bisphenol F diglycidyl ether:9:0.6794	0.6794	9
BFDV	BFDV:13	beak and feather disease virus:13:0.7753	0.7753	13
BFDV	BFDV:13	budgerigar fledgling disease virus:13:0.7571	0.7571	13
BFD	BFD:26	blackfoot disease:26:0.5840	0.5840	26
BFH	BFH:12	benign fibrous histiocytoma:12:0.7571	0.7571	12
BFHI	BFHI:25	Baby Friendly Hospital Initiative:13:0.7753|Baby-Friendly Hospital Initiative:12:0.2183	0.7753	25
BFIC	BFIC:14	benign familial infantile convulsions:14:0.7909	0.7909	14
BFI	BFI:9	blood flow index:9:0.6794	0.6794	9
BFI	BFI:10	Brief Fatigue Inventory:10:0.7103	0.7103	10
BFL	BFL:10	bird fancier's lung:10:0.7103	0.7103	10
BFM	BFM:44	Berlin-Frankfurt-Munster:44:0.3386	0.3386	44
BFM	BFM:23	body fat mass:23:0.7046	0.7046	23
BFNC	BFNC:44	benign familial neonatal convulsions:44:0.9323	0.9323	44
BFP	BFP:27	basic fetoprotein:27:0.8903	0.8903	27
BFP	BFP:9	biological false positive:9:0.5470	0.5470	9
BFP	BFP:19	blue fluorescent protein:19:0.7658	0.7658	19
BFP	BFP:11	buccal fat pad:11:0.7357	0.7357	11
BFP	BFP:16|bfp:2	bundle-forming pili:18:0.8365	0.8365	18
BFP	BFP:24|bfp:5|Bfp:1	bundle-forming pilus:30:0.8472	0.8472	30
BFR/BS	BFR/BS:23	bone formation rate:23:0.8715	0.8715	23
BFRs	BFRs:25	Brominated flame retardants:25:0.8816	0.8816	25
BFR	BFR:16|Bfr:3|bfr:1	bacterioferritin:20:0.1145	0.1145	20
BFR	BFR:83|bfr:1	bone formation rate:75:0.9169|bone formation rates:9:0.6794	0.9169	84
BFT	BFT:2	B fragilis toxin:2:0.3455	0.3455	2
BFT	BFT:7	backfat thickness:7:0.2452	0.2452	7
BFU-Es	BFU-Es:9	erythroid burst-forming units:9:0.3945	0.3945	9
BFU-E	BFU-E:277|BFU-e:9|BFUe:3|BFUE:1|bfu-e:1	burst-forming unit-erythroid:101:0.6770|burst-forming units-erythroid:100:0.7407|burst-forming unit erythroid:30:0.5929|burst forming unit-erythroid:30:0.8032|burst forming units-erythroid:20:0.8525|burst forming unit erythroid:10:0.7357	0.8525	291
BFU-E	BFU-E:26|BFUE:2|BFU-e:2	erythroid bursts:18:0.5940|erythroid burst:12:0.5664	0.5940	30
BFU-E	BFU-E:19|BFU-e:1	erythroid burst-forming cells:20:0.7766	0.7766	20
BFU-E	BFU-E:48|BFUe:3|bfu-E:1	erythroid burst-forming unit:52:0.7413	0.7413	52
BFU-E	BFU-E:9	erythroid colonies:9:0.3945	0.3945	9
BFU-E	BFU-E:11|BFUe:1|BFU-e:1	erythroid precursors:13:0.4102	0.4102	13
BFU-E	BFU-E:69|BFU-e:4|BFUe:4|BFUE:2	erythroid progenitors:69:0.7961|erythroid progenitor:10:0.4363	0.7961	79
BFU-E	BFU-E:35|BFU-e:4|BFUe:3|BFUE:1	erythroid progenitor cells:43:0.6491	0.6491	43
BFV	BFV:5|BFv:1	Barmah Forest virus:6:0.5290	0.5290	6
BFV	BFV:77|BFv:2	blood flow velocity:63:0.9253|blood flow velocities:16:0.8165	0.9253	79
BFV	BFV:9	blood flow volume:9:0.6794	0.6794	9
BFZ	BFZ:14	bifonazole:14:0.9286	0.9286	14
BFcrb	BFcrb:10	Cerebellar blood flow:10:0.4363	0.4363	10
BF	BF:13	7,8-benzoflavone:13:0.0075	0.0075	13
BF	BF:17	backfat:17:0.0100	0.0100	17
BF	BF:14	backfat thickness:14:0.7909	0.7909	14
Bf	Bf:8|BF:1	Bacteroides forsythus:9:0.5470	0.5470	9
BF	BF:103|Bf:1	basal forebrain:104:0.9715	0.9715	104
BF	BF:146	best frequency:122:0.7142|best-frequency:12:0.0069|Best frequencies:12:0.5664	0.7142	146
BF	BF:11|Bf:1	bezafibrate:12:0.0069	0.0069	12
BF	BF:86|bf:1	biceps femoris:87:0.9455	0.9455	87
BF	BF:20|bF:4	biochemical failure:24:0.8115	0.8115	24
BF	BF:21	biofeedback:21:0.0125	0.0125	21
BF	BF:21	Biofiltration:21:0.0118	0.0118	21
BF	BF:9	blister fluid:9:0.2285	0.2285	9
BF	BF:7	blocking factors:7:0.1329	0.1329	7
BF	BF:231|bf:2	blood flow:222:0.8726|blood flows:11:0.7357	0.8726	233
BF	BF:90	body fat:90:0.9304	0.9304	90
BF	BF:11	Boutonneuse fever:11:0.7357	0.7357	11
BF	BF:22	breast-fed:22:0.0131	0.0131	22
BF	BF:31	breast-feeding:19:0.0112|breast feeding:12:0.6460	0.6460	31
BF	BF:19	breastfeeding:19:0.0112	0.0112	19
BF	BF:13|bf:4	breathing frequency:17:0.0543	0.0543	17
BF	BF:36	bursa of Fabricius:36:0.8716	0.8716	36
B-F	B-F:26|BF:2	Class I:28:0.8941	0.8941	28
BF	BF:32|Bf:7	factor:39:0.0237	0.0237	39
Bf	Bf:90|BF:49	factor B:139:0.9657	0.9657	139
BF	BF:15|Bf:1	fraction:16:0.0093	0.0093	16
BGAT	BGAT:7	blood glucose awareness training:7:0.4102	0.4102	7
BGA	BGA:6	Blood gas analysis:6:0.5290	0.5290	6
BGA	BGA:13|bga:1	blood group antigens:14:0.7909	0.7909	14
BGA	BGA:9	brilliant green agar:9:0.6794	0.6794	9
BGC	BGC:10	basal ganglia calcification:10:0.6794	0.6794	10
BGD	BGD:29	N-Benzyl-D-glucamine dithiocarbamate:29:0.8978	0.8978	29
BGEs	BGEs:29	background electrolytes:29:0.8422	0.8422	29
BGG	BGG:86	bovine gamma globulin:52:0.8572|bovine gamma-globulin:34:0.6811	0.8572	86
BGL	BGL:21|bgl:1	blood glucose level:13:0.7753|blood glucose levels:9:0.4587	0.7753	22
BGMK	BGMK:10	Buffalo green monkey kidney:10:0.7103	0.7103	10
BGMV	BGMV:11	Bean golden mosaic virus:11:0.6182	0.6182	11
BGM	BGM:9	blood glucose monitoring:9:0.3455	0.3455	9
BGM	BGM:21	Buffalo Green Monkey:21:0.7865	0.7865	21
BGN	BGN:21|bgn:5|Bgn:3	biglycan:29:0.6829	0.6829	29
BGO	BGO:11	bismuth germanate:11:0.7357	0.7357	11
BGP	BGP:37|Bgp:10	biliary glycoprotein:47:0.9006	0.9006	47
BGP	BGP:195	bone GLA protein:158:0.9337|bone GLA-protein:37:0.8749	0.9337	195
BGP	BGP:38	serum osteocalcin:38:0.1904	0.1904	38
BGs	BGs:9|Bgs:2	Birbeck granules:11:0.7357	0.7357	11
BGT1	BGT1:14|BGT-1:11	transporter:25:0.6316	0.6316	25
Bgt	Bgt:8|BGT:8	alpha-bungarotoxin:16:0.2113	0.2113	16
BGT	BGT:6	Bender Gestalt Test:6:0.2827	0.2827	6
BG	BG:13	background:13:0.0116	0.0116	13
Bg	Bg:4|BG:1	Bacteroides gingivalis:5:0.0902	0.0902	5
BG	BG:113	basal ganglia:113:0.9735	0.9735	113
BG	BG:28|B-G:1	Basenji-Greyhound:29:0.0271	0.0271	29
bg	bg:38|BG:1|Bg:1	beige:40:0.0377	0.0377	40
BG	BG:39|B-G:2	beta-glucuronidase:41:0.0387	0.0387	41
BG	BG:35	bioactive glass:35:0.7647	0.7647	35
BG	BG:10	Bioglass:10:0.0087	0.0087	10
BG	BG:19|Bg:1	Birbeck granules:20:0.7766	0.7766	20
BG	BG:266|B-G:1	blood glucose:267:0.9282	0.9282	267
BG	BG:13	brilliant green:13:0.5934	0.5934	13
BG	BG:16|bg:1	group:17:0.0164	0.0164	17
BG	BG:31	O(6)-benzylguanine:31:0.0290	0.0290	31
BG	BG:52	O6-benzylguanine:52:0.0493	0.0493	52
BH(4)	BH(4):87	tetrahydrobiopterin:87:0.7890	0.7890	87
BH3	BH3:17	Bcl-2 homology 3:17:0.6748	0.6748	17
BH4	BH4:370	tetrahydrobiopterin:370:0.8218	0.8218	370
BH-AC	BH-AC:11|BHAC:5	N4-behenoyl-1-beta-D-arabinofuranosylcytosine:16:0.3191	0.3191	16
BHAP	BHAP:9	bis(heteroaryl)piperazine:9:0.5000	0.5000	9
BHAT	BHAT:26	Beta-Blocker Heart Attack Trial:26:0.5729	0.5729	26
BHA	BHA:36	2(3)-tert-butyl-4-hydroxyanisole:36:0.0459	0.0459	36
BHA	BHA:12	2-t-butyl-4-methoxyphenol:12:0.0144	0.0144	12
BHA	BHA:21	3-tert-butyl-4-hydroxyanisole:21:0.0262	0.0262	21
BHA	BHA:10	benzhydroxamic acid:10:0.1449	0.1449	10
BHA	BHA:16|Bha:1	benzohydroxamic acid:17:0.3844	0.3844	17
BHA	BHA:12	butylated hydroxy anisole:12:0.6460	0.6460	12
BHA	BHA:12	butylated hydroxyanisol:12:0.7571	0.7571	12
BHA	BHA:468	butylated hydroxyanisole:468:0.9605	0.9605	468
BHA	BHA:12	butylhydroxyanisole:12:0.0144	0.0144	12
BHBA	BHBA:19|B-HBA:1	beta-hydroxybutyrate:20:0.5938	0.5938	20
BHBN	BHBN:10	N-butyl-N-(4-hydroxybutyl)nitrosamine:10:0.4737	0.4737	10
BHB	BHB:43|B-HB:2	beta-hydroxybutyrate:45:0.4444	0.4444	45
BHb	bHb:4|BHb:4	bovine hemoglobin:8:0.3463	0.3463	8
BHCAG	BHCAG:8	Buyers Health Care Action Group:8:0.4102	0.4102	8
BHC	BHC:26	benzene hexachloride:26:0.6745	0.6745	26
BHC	BHC:10	hexachlorocyclohexane:10:0.0692	0.0692	10
BHD	BHD:16	Birt-Hogg-Dube:16:0.2308	0.2308	16
b-hGH	b-hGH:8|B-hGH:4|bhGH:2|BHGH:1	biosynthetic human growth hormone:15:0.7096	0.7096	15
B-Hg	B-Hg:8	whole blood:8:0.5006	0.5006	8
BHI	BHI:41	biosynthetic human insulin:41:0.8525	0.8525	41
BHI	BHI:128	brain heart infusion:101:0.9529|brain-heart infusion:27:0.1309	0.9529	128
BHI	BHI:16	Brain Heart Infusion Broth:16:0.8270	0.8270	16
BHI	BHI:12	breath-holding index:12:0.3524	0.3524	12
BHIA	BHIA:10	brain heart infusion agar:10:0.7103	0.7103	10
BHIB	BHIB:9	brain heart infusion broth:9:0.6794	0.6794	9
BHIVA	BHIVA:12	British HIV Association:12:0.7571	0.7571	12
BHK	BHK:384	baby hamster kidney:384:0.9833	0.9833	384
BHK	BHK:19	baby hamster kidney cells:19:0.8449	0.8449	19
BHK-21	BHK-21:91|BHK21:10	baby hamster kidney:101:0.9238	0.9238	101
BHK-21	BHK-21:5	baby hamster kidney fibroblasts:5:0.2818	0.2818	5
BHL	BHL:21	bilateral hilar lymphadenopathy:21:0.8594	0.8594	21
BHL	BHL:5	N-butanoyl-L-homoserine lactone:5:0.0902	0.0902	5
BHMT	BHMT:16	betaine-homocysteine methyltransferase:16:0.3262	0.3262	16
BHMT	BHMT:6	betaine-homocysteine S-methyltransferase:6:0.2243	0.2243	6
BHP	BHP:5	Tert-butyl hydroperoxide:5:0.0902	0.0902	5
B-HRP	B-HRP:16|BHRP:5	horseradish peroxidase:21:0.6400	0.6400	21
BHR	BHR:52	borderline hypertensive rats:33:0.9100|borderline hypertensive rat:19:0.8449	0.9100	52
BHR	BHR:54	bronchial hyper-responsiveness:54:0.9448	0.9448	54
BHR	BHR:107	bronchial hyperreactivity:107:0.8820	0.8820	107
BHR	BHR:371|B-HR:1	bronchial hyperresponsiveness:372:0.9712	0.9712	372
BHSP	BHSP:13|BH-SP:3	substance P:16:0.6577	0.6577	16
BHS	BHS:18	Beck Hopelessness Scale:18:0.5228	0.5228	18
BHS	BHS:10	Beta-hemolytic streptococci:10:0.1519	0.1519	10
BHS	BHS:53	British Hypertension Society:53:0.9438	0.9438	53
BHS	BHS:8	congenitally bronchial-hypersensitive:8:0.3463	0.3463	8
BHT	BHT:18	2,6-di-tert-butyl-4-methylphenol:18:0.0186	0.0186	18
BHT	BHT:13	3,5-di-tert-butyl-4-hydroxytoluene:13:0.0124	0.0124	13
BHT	BHT:5	antioxidant ionol:5:0.0902	0.0902	5
BHT	BHT:28|bHT:1|BHt:1	borderline hypertension:30:0.7012	0.7012	30
BHT	BHT:11	borderline hypertensive:11:0.7357	0.7357	11
BHT	BHT:12	Breath-holding time:12:0.4153	0.4153	12
BHT	BHT:10	breath hydrogen test:10:0.7103	0.7103	10
BHT	BHT:31	butylhydroxytoluene:31:0.0310	0.0310	31
BHV	BHV:8	bioprosthetic heart valves:8:0.5006	0.5006	8
BHV	BHV:12	bovine herpesvirus:12:0.6460	0.6460	12
BHV-1	BHV-1:18	bovine herpes virus-1:18:0.8365	0.8365	18
BHV-1	BHV-1:394|BHV1:75	bovine herpesvirus 1:292:0.9590|bovine herpesvirus-1:177:0.9728	0.9728	469
BHV-1	BHV-1:119|BHV1:7	Bovine herpesvirus type 1:113:0.9575|bovine herpesvirus type-1:13:0.7753	0.9575	126
BHV2	BHV2:4|BHV-2:2	Bovid herpesvirus 2:6:0.1320	0.1320	6
BHV-2	BHV-2:5|BHV2:1	bovine herpesvirus 2:6:0.1320	0.1320	6
BHV-2	BHV-2:6	bovine herpesvirus type 2:6:0.3728	0.3728	6
BHV-4	BHV-4:11	bovid herpesvirus-4:11:0.1845	0.1845	11
BHV-4	BHV-4:44|BHV4:10	bovine herpesvirus 4:38:0.8417|Bovine herpesvirus-4:16:0.3643	0.8417	54
BHV-5	BHV-5:10|BHV5:1	bovine herpesvirus 5:11:0.7571	0.7571	11
BH	BH:25	Bcl-2 homology:25:0.6873	0.6873	25
BH	BH:13	Bleomycin hydrolase:13:0.7753	0.7753	13
BH	BH:10	blood hypertension:10:0.1223	0.1223	10
BH	BH:19	body height:19:0.4211	0.4211	19
BH	BH:15|B-H:1	borderline hypertension:16:0.2923	0.2923	16
BH	BH:8	borderline hypertensive:8:0.5006	0.5006	8
BH	BH:15	breath-hold:15:0.0353	0.0353	15
BH	BH:8	bronchial hyperreactivity:8:0.5006	0.5006	8
BH	BH:10	hydrochloride:10:0.0227	0.0227	10
bias	bias:37	mean difference:28:0.5837|mean differences:9:0.3945	0.5837	37
BIA	BIA:13	bioelectric impedance:13:0.0813	0.0813	13
BIA	BIA:51	bioelectrical impedance:51:0.6063	0.6063	51
BIA	BIA:342	bioelectrical impedance analysis:342:0.7799	0.7799	342
BIA	BIA:10	bioimpedance:10:0.0124	0.0124	10
BICs	BICs:9	binaural interaction components:9:0.6794	0.6794	9
BIC	BIC:16	Bayesian information criterion:16:0.7261	0.7261	16
BIC	BIC:75|Bic:16	bicuculline:91:0.3191	0.3191	91
BIC	BIC:16|Bic:1|bic:1	bicuculline methiodide:18:0.7539	0.7539	18
BIC	BIC:17	binaural interaction component:17:0.8270	0.8270	17
BIC	BIC:11	bone-implant contact:11:0.1547	0.1547	11
BIC	BIC:17	bone-to-implant contact:17:0.3366	0.3366	17
BIC	BIC:4|Bic:1	sodium bicarbonate:5:0.0612	0.0612	5
BIH	BIH:71	benign intracranial hypertension:71:0.9335	0.9335	71
BIIT	BIIT:10	blood incubation infectivity test:10:0.7103	0.7103	10
BII	BII:11|B-II:4	Billroth II:15:0.4052	0.4052	15
BII	BII:10	BPH impact index:10:0.6182	0.6182	10
BILAG	BILAG:26	British Isles Lupus Assessment Group:26:0.8861	0.8861	26
BIL	BIL:17|Bil:3	bilirubin:20:0.5938	0.5938	20
BIMA	BIMA:13	internal mammary artery:13:0.6701	0.6701	13
BIM	BIM:15	bisindolylmaleimide I:15:0.5818	0.5818	15
bio	bio:9|BIO:2|Bio:1	bioactive:12:0.1134	0.1134	12
BIPS	BIPS:9	polyethylene spheres:9:0.6794	0.6794	9
BiP	BiP:23|Bip:2	immunoglobulin heavy chain binding protein:25:0.6240	0.6240	25
BI-RADS	BI-RADS:70|BIRADS:4	Breast Imaging Reporting and Data System:74:0.9602	0.9602	74
BIR	BIR:23	baculovirus IAP repeat:23:0.5466	0.5466	23
BIR	BIR:9	break-induced replication:9:0.6794	0.6794	9
BIS	BIS:7	Barratt Impulsivity Scale:7:0.2902	0.2902	7
BIS	BIS:17	behavioral inhibition system:17:0.7407	0.7407	17
BIS	BIS:20	bioelectrical impedance spectroscopy:20:0.5568	0.5568	20
BIS	BIS:19	bioimpedance spectroscopy:19:0.2296	0.2296	19
BIs	BIs:9	biological indicators:9:0.5470	0.5470	9
BIS	BIS:15	bispectral:15:0.0193	0.0193	15
BIS	BIS:6	Bispectral analysis:6:0.1838	0.1838	6
BIS	BIS:400|Bis:1	bispectral index:401:0.9666	0.9666	401
BIS	BIS:7	bispectral index scale:7:0.6411	0.6411	7
BIS	BIS:5	bispectral index score:5:0.2818	0.2818	5
Bis	Bis:6|BIS:4	N,N'-methylenebisacrylamide:10:0.0124	0.0124	10
BIS	BIS:1	PKC inhibitor bisindolylmaleimide:1:0.3728	0.3728	1
BITA	BITA:10	bilateral internal thoracic artery:10:0.5856	0.5856	10
BITC	BITC:53	benzyl isothiocyanate:53:0.9116	0.9116	53
BITE	BITE:5	Bulimic Investigatory Test Edinburgh:5:0.6873	0.6873	5
BIT	BIT:9	Behavioural Inattention Test:9:0.3945	0.3945	9
BiV	BiV:16|BIV:1|bi-v:1	biventricular:18:0.0846	0.0846	18
BIV	BIV:93	bovine immunodeficiency virus:93:0.9679	0.9679	93
BJP	BJP:22	Bence jones protein:22:0.7955	0.7955	22
BJP	BJP:8	Bence Jones proteinuria:8:0.6411	0.6411	8
BjV	BjV:12|BJV:3|Bjv:2	Bothrops jararaca venom:17:0.8270	0.8270	17
BJ	BJ:13	Bence Jones:13:0.7753	0.7753	13
B-J	B-J:7|BJ:3	Bezold-Jarisch:10:0.1343	0.1343	10
BK(Ca)	BK(Ca):13	Ca(2+)-activated K(+) channels:13:0.5335	0.5335	13
BK(Ca)	BK(Ca):9	Ca2+-activated K+ channels:9:0.2500	0.2500	9
BK(Ca)	BK(Ca):10	calcium-activated potassium channels:10:0.4363	0.4363	10
BK(Ca)	BK(Ca):20	large-conductance Ca(2+)-activated K(+):20:0.3671	0.3671	20
BK(Ca)	BK(Ca):5	large-conductance Ca(2+)-activated K(+) channel:5:0.2818	0.2818	5
BK(Ca)	BK(Ca):10	large-conductance Ca2+-activated K+:10:0.3275	0.3275	10
BK(Ca)	BK(Ca):4	large-conductance calcium-activated potassium:4:0.1320	0.1320	4
BKA	BKA:12	below-knee amputation:12:0.4153	0.4153	12
BKA	BKA:9	bongkrekic acid:9:0.6794	0.6794	9
BKB1R	BKB1R:5|BKB1-R:4	Bradykinin B1 receptor:9:0.4587	0.4587	9
BKC	BKC:18	benzalkonium chloride:18:0.8365	0.8365	18
BKCa	BKCa:6|BKca:2	calcium-activated potassium channel:8:0.4102	0.4102	8
BKCa	BKCa:10	large-conductance Ca2+-activated K+:10:0.2183	0.2183	10
BKCa	BKCa:4	large conductance calcium-activated potassium channels:4:0.3170	0.3170	4
BKD	BKD:26	bacterial kidney disease:26:0.8861	0.8861	26
BKKBN	BKKBN:10	National Family Planning Coordinating Board:10:0.7103	0.7103	10
BKME	BKME:17	bleached kraft mill effluent:17:0.8270	0.8270	17
BKV	BKV:30	human polyomavirus BK:30:0.6736	0.6736	30
BL-CFC	BL-CFC:6|Bl-CFC:1	blast colony-forming cell:7:0.4438	0.4438	7
BL-CFC	BL-CFC:5|Bl-CFC:4	colony-forming cells:9:0.4587	0.4587	9
BLAD	BLAD:34	bovine leukocyte adhesion deficiency:34:0.7458	0.7458	34
BLA	BLA:11	Bacillus licheniformis alpha-amylase:11:0.7357	0.7357	11
BLA	BLA:25|BLa:1|BlA:1	basolateral:27:0.0498	0.0498	27
BLA	BLA:165|BlA:1	basolateral amygdala:166:0.5897	0.5897	166
BLA	BLA:3|BLa:1|Bla:1	basolateral amygdaloid nucleus:5:0.1973	0.1973	5
BLA	BLA:5|BLa:1	basolateral nucleus:6:0.1010	0.1010	6
BLA	BLA:52|Bla:4	basolateral nucleus of the amygdala:56:0.9511	0.9511	56
bla	bla:26|Bla:23|BLA:8	beta-lactamase:57:0.1073	0.1073	57
bla	bla:7	beta-lactamase gene:7:0.1329	0.1329	7
BLA	BLA:6	biologics license application:6:0.5290	0.5290	6
BLa	BLa:24|BLA:3|Bla:3|B-La:2|bLA:1	Blood lactate:33:0.9100	0.9100	33
BLA	BLA:15	bovine alpha-lactalbumin:15:0.8045	0.8045	15
BLA	BLA:4	submitted a Biologics Licence Application:4:0.3170	0.3170	4
BLBP	BLBP:6|Blbp:1	brain lipid-binding protein:7:0.5926	0.5926	7
B-LCLs	B-LCLs:10|BLCLs:1	B-lymphoblastoid cell lines:11:0.1547	0.1547	11
B-LCL	B-LCL:6	B lymphoblastoid cells:6:0.3728	0.3728	6
BLCL	BLCL:10	bilateral common carotid artery ligation:10:0.7103	0.7103	10
BLC	BLC:6	B lymphoblastoid cells:6:0.5290	0.5290	6
BLC	BLC:16	B lymphocyte chemoattractant:9:0.6794|B-lymphocyte chemoattractant:7:0.1329	0.6794	16
BLC	BLC:4	basolateral amygdala complex:4:0.1618	0.1618	4
BLC	BLC:10	blood lactate concentration:10:0.7103	0.7103	10
BLECs	BLECs:21	bovine lens epithelial cells:21:0.8594	0.8594	21
BLEC	BLEC:15	bovine lens epithelial cells:15:0.8045	0.8045	15
BLEL	BLEL:6	benign lymphoepithelial lesion:6:0.2827	0.2827	6
ble	ble:5	resistance gene:5:0.1132	0.1132	5
bLF	bLF:31|bLf:13|BLF:11|BLf:9|b-LF:1	bovine lactoferrin:65:0.9047	0.9047	65
bLF	bLF:12|bLf:5|BLf:2|BLF:1|b-LF:1	bovine Lf:21:0.6812	0.6812	21
BLF	BLF:11	lavage fluid:11:0.6182	0.6182	11
BLG	BLG:168|Blg:5|BLg:2|b-LG:1|bLG:1	beta-lactoglobulin:177:0.8883	0.8883	177
B-LH	B-LH:14|b-LH:2|BLH:2|bLH:1	bioactive LH:19:0.4034	0.4034	19
bLH	bLH:7	bovine luteinizing hormone:7:0.2113	0.2113	7
BLIP	BLIP:8	beta-lactamase inhibitory protein:8:0.6411	0.6411	8
BLIS	BLIS:21	bacteriocin-like inhibitory substances:11:0.6182|bacteriocin-like inhibitory substance:10:0.7103	0.7103	21
BLI	BLI:28	bombesin-like immunoreactivity:28:0.6295	0.6295	28
BLI	BLI:5	labelling index:5:0.0612	0.0612	5
BLI	BLI:12	vivo bioluminescence imaging:12:0.3058	0.3058	12
BLL	BLL:7	Benign lymphoepithelial lesion:7:0.3524	0.3524	7
BLL	BLL:44	blood lead level:29:0.8978|blood lead levels:15:0.8045	0.8978	44
BLL	BLL:9	Burkitt-like lymphoma:9:0.2500	0.2500	9
BLMV	BLMV:11	basolateral:11:0.1075	0.1075	11
BLMV	BLMV:58	basolateral membrane vesicles:58:0.7954	0.7954	58
BLMVs	BLMVs:13	basolateral membrane vesicles:13:0.6701	0.6701	13
BLMs	BLMs:31	bilayer lipid membranes:31:0.5933	0.5933	31
BLM	BLM:47|blm:1	basolateral membranes:48:0.2079	0.2079	48
BLM	BLM:136|blm:1	bilayer lipid membranes:78:0.6470|bilayer lipid membrane:59:0.7984	0.7984	137
BLM	BLM:35	biotic ligand model:35:0.9151	0.9151	35
BLM	BLM:526|Blm:15|blm:1	Bleomycin:542:0.5172	0.5172	542
BLM	BLM:6	syndrome protein:6:0.2243	0.2243	6
BLNAR	BLNAR:10	beta-Lactamase-negative ampicillin-resistant:10:0.6381	0.6381	10
BLNAR	BLNAR:6	Haemophilus influenzae:6:0.1010	0.1010	6
BLNAR	BLNAR:1	negative but ampicillin resistant:1:0.1618	0.1618	1
BLPB	BLPB:14	beta-lactamase-producing bacteria:14:0.6173	0.6173	14
BLPD	BLPD:4	B cell lymphoproliferative disorder:4:0.3170	0.3170	4
BLPD	BLPD:5|B-LPD:4	lymphoproliferative disorders:9:0.3945	0.3945	9
BLPH	BLPH:5|B-LPH:4	beta-lipotropin:9:0.4706	0.4706	9
BLPs	BLPs:11|BLPS:1	bombesin-like peptides:12:0.6460	0.6460	12
BLP	BLP:8	Bacterial lipoprotein:8:0.2987	0.2987	8
BLP	BLP:9	bombesin-like peptides:9:0.4587	0.4587	9
BLSA	BLSA:35	Baltimore Longitudinal Study of Aging:35:0.8263	0.8263	35
BLSS	BLSS:6	bioartificial liver support system:6:0.5290	0.5290	6
BLSS	BLSS:6	bioregenerative life support system:6:0.2827	0.2827	6
BLS	BLS:32	bare lymphocyte syndrome:32:0.9072	0.9072	32
BLs	BLs:9	basal laminae:9:0.6794	0.6794	9
BLS	BLS:139	basic life support:139:0.9444	0.9444	139
BLS	BLS:23	Bureau of Labor Statistics:23:0.8038	0.8038	23
BLs	BLs:11	Burkitt's lymphomas:6:0.1148|Burkitt lymphomas:5:0.1148	0.1148	11
BLT	BLT:13	Bilateral lung transplantation:13:0.7753	0.7753	13
BLT	BLT:8	bright light therapy:8:0.6411	0.6411	8
BLT	BLT:13	thiobenzyl ester:13:0.5335	0.5335	13
BLUP	BLUP:22	Best Linear Unbiased Prediction:22:0.8657	0.8657	22
BLU	BLU:19	bluetongue:19:0.5143	0.5143	19
BLU	BLU:10	bluetongue virus:10:0.7103	0.7103	10
BLV	BLV:130	bovine leukaemia virus:130:0.9633	0.9633	130
BLV	BLV:530	bovine leukemia virus:530:0.9769	0.9769	530
BLyS	BLyS:39	B lymphocyte stimulator:39:0.9256	0.9256	39
BL	BL:8	bacterial levan:8:0.5006	0.5006	8
BL	BL:74	Basal lamina:74:0.9361	0.9361	74
BL	BL:88|bl:1	baseline:89:0.0503	0.0503	89
BL	BL:7	basolateral amygdaloid nucleus:7:0.5926	0.5926	7
BL	BL:5	basolateral nucleus:5:0.0612	0.0612	5
bL	BL:4|bL:4|bl:1	beta-lactamase:9:0.0045	0.0045	9
BL	BL:28	bilateral:28:0.0151	0.0151	28
BL	BL:13	bioluminescence:13:0.0067	0.0067	13
BL	BL:23	bleomycin:23:0.0123	0.0123	23
BL	BL:6|bl:2|Bl:1	blood:9:0.0045	0.0045	9
BL	BL:8|bl:1	blood lactate:9:0.4587	0.4587	9
BL	BL:5	blood loss:5:0.0736	0.0736	5
BL	BL:8	Blood lymphocytes:8:0.2619	0.2619	8
BL	BL:21	blue light:21:0.3221	0.3221	21
BL	BL:20	body length:20:0.4201	0.4201	20
BL	BL:6	bone loss:6:0.1543	0.1543	6
BL	BL:11	borderline:11:0.0056	0.0056	11
BL	BL:65	borderline lepromatous:65:0.9047	0.9047	65
BL	BL:8	borderline lepromatous leprosy:8:0.5006	0.5006	8
BL	BL:26	brassinolide:26:0.0140	0.0140	26
BL	BL:17	bright light:17:0.2311	0.2311	17
BL	BL:31	bronchial lavage:31:0.8519	0.8519	31
BL	BL:657	Burkitt's lymphoma:451:0.6649|Burkitt lymphoma:179:0.2431|Burkitt's lymphomas:17:0.3512|Burkitt lymphomas:10:0.1327	0.6649	657
B-L	B-L:17	Class II:17:0.8270	0.8270	17
BMAA	BMAA:7	2-Amino-3-(methylamino)-propanoic acid:7:0.2902	0.2902	7
BMAA	BMAA:26	beta-N-Methylamino-L-alanine:26:0.4630	0.4630	26
BMA	BMA:9	bone marrow aspirate:9:0.6794	0.6794	9
BMA	BMA:11	bone marrow aspiration:11:0.7357	0.7357	11
BMA	BMA:7	bovine mesenteric arteries:7:0.5926	0.5926	7
BMA	BMA:18	British Medical Association:18:0.7539	0.7539	18
BMA	BMA:13	butyl methacrylate:13:0.1506	0.1506	13
BmA	BmA:4	malayi adult worm antigen:4:0.3170	0.3170	4
BMBT	BMBT:8	buccal mucosal bleeding time:8:0.6411	0.6411	8
BMB	BMB:46	Bone marrow biopsy:33:0.9100|bone marrow biopsies:13:0.7753	0.9100	46
BMCC	BMCC:9	bacterial microcrystalline cellulose:9:0.6794	0.6794	9
BMCMC	BMCMC:13	bone marrow-derived cultured mast cells:13:0.7753	0.7753	13
BMCs	BMCs:118	bone marrow cells:118:0.9596	0.9596	118
BMC	BMC:14	Balloon mitral commissurotomy:14:0.7909	0.7909	14
BMC	BMC:5	benchmark concentration:5:0.1132	0.1132	5
BMC	BMC:5	bicuculline methochloride:5:0.1132	0.1132	5
BMC	BMC:16	biopartitioning micellar chromatography:16:0.7261	0.7261	16
BMC	BMC:297|bmc:1	bone marrow cells:248:0.9807|bone marrow cell:50:0.9404	0.9807	298
BMC	BMC:10	bone mass:10:0.4363	0.4363	10
BMC	BMC:1386	bone mineral content:1376:0.9819|bone mineral contents:10:0.5856	0.9819	1386
BMDCs	BMDCs:12|BM-DCs:5	bone marrow-derived DCs:17:0.8270	0.8270	17
BMDCs	BMDCs:8|BM-DCs:4	bone marrow-derived dendritic cells:12:0.7571	0.7571	12
BMDC	BMDC:10|BM-DC:7|Bm-DC:1|bm-DC:1	bone marrow-derived DC:19:0.8449	0.8449	19
BMDC	BMDC:15|BM-DC:3|BmDC:1	Bone marrow-derived dendritic cells:19:0.8449	0.8449	19
BMDMs	BMDMs:14	bone marrow-derived macrophages:14:0.7909	0.7909	14
BMDM	BMDM:38	bone marrow-derived macrophages:38:0.9217	0.9217	38
BMDs	BMDs:36	bone mineral densities:36:0.9174	0.9174	36
BMDvol	BMDvol:7	volumetric bone mineral density:7:0.5926	0.5926	7
BMD	BMD:43	benchmark dose:43:0.9308	0.9308	43
BMD	BMD:12	bone mineral densitometry:12:0.7571	0.7571	12
BMD	BMD:6495	bone mineral density:6432:0.9961|bone mineral densities:63:0.9526	0.9961	6495
BMD	BMD:15	broth microdilution:15:0.8045	0.8045	15
BMEC	BMEC:42	brain microvascular endothelial cells:42:0.6429	0.6429	42
BMEC	BMEC:5	primary cultures of bovine brain microvessel endothelial cell:5:0.4422	0.4422	5
BMES	BMES:15	Blue Mountains Eye Study:15:0.8045	0.8045	15
BME	BME:9	basal medium Eagle:9:0.6794	0.6794	9
BME	BME:12|bME:1	beta-mercaptoethanol:13:0.0902	0.0902	13
BME	BME:9	bovine microvascular endothelial:9:0.5470	0.5470	9
BMFs	BMFs:11	biomagnification factors:11:0.6182	0.6182	11
BMF	BMF:8	Best Modulation Frequency:8:0.6411	0.6411	8
BMF	BMF:9	biomagnification factor:9:0.3069	0.3069	9
BMF	BMF:14	bone marrow fibroblasts:14:0.7909	0.7909	14
BMG	BMG:27	benign monoclonal gammopathy:27:0.8903	0.8903	27
BMG	BMG:40	beta 2-microglobulin:40:0.9256	0.9256	40
BMG	BMG:13	bilirubin monoglucuronide:13:0.4849	0.4849	13
BMG	BMG:22	bone matrix gelatin:22:0.7955	0.7955	22
BMIs	BMIs:40	body mass indices:40:0.9256	0.9256	40
BMI	BMI:129	bicuculline methiodide:129:0.9768	0.9768	129
BMI	BMI:9520	body mass index:9474:0.9954|body mass indexes:27:0.8312|body-mass-index:19:0.0018	0.9954	9520
BMI	BMI:48	Body Mass Indices:48:0.9379	0.9379	48
BMI	BMI:6	body weight:6:0.0807	0.0807	6
BMI	BMI:9	Bone marrow involvement:9:0.6794	0.6794	9
BMI	BMI:9	brain-machine interface:9:0.6794	0.6794	9
BMJ	BMJ:15	British Medical Journal:15:0.8045	0.8045	15
BMK1	BMK1:10	Big MAP kinase 1:10:0.7103	0.7103	10
BMK1	BMK1:9	Big mitogen-activated protein kinase 1:9:0.6794	0.6794	9
BMK	BMK:10	baby mouse kidney:10:0.7103	0.7103	10
BmK	BmK:12	scorpion Buthus martensi Karsch:12:0.5050	0.5050	12
BmK	BmK:13|BMK:3	scorpion Buthus martensii Karsch:16:0.5171	0.5171	16
BMLD	BMLD:15	binaural masking level difference:15:0.8045	0.8045	15
BML	BML:10	benign metastasizing leiomyoma:10:0.7103	0.7103	10
BMMCs	BMMCs:47	bone marrow-derived mast cells:47:0.9366	0.9366	47
BMMCs	BMMCs:18	bone marrow mononuclear cells:18:0.8365	0.8365	18
BMMC	BMMC:123	bone marrow-derived mast cells:113:0.9735|bone marrow-derived mast cell:10:0.7103	0.9735	123
BMMC	BMMC:7	bone marrow-derived MC:7:0.5926	0.5926	7
BMMNCs	BMMNCs:12|BM-MNCs:8	bone marrow mononuclear cells:20:0.8525	0.8525	20
BMMNC	BMMNC:45|BM-MNC:3	bone marrow mononuclear cells:48:0.9027	0.9027	48
BMMP	BMMP:11	benign mucous membrane pemphigoid:11:0.7357	0.7357	11
BM-MSCs	BM-MSCs:8	mesenchymal stem cells:8:0.6411	0.6411	8
BMMs	BMMs:16	bone marrow-derived macrophages:16:0.8165	0.8165	16
BMM	BMM:73	bone marrow-derived macrophages:73:0.9591	0.9591	73
BMM	BMM:10	bone marrow micrometastases:10:0.7103	0.7103	10
BMNC	BMNC:25	blood mononuclear cells:25:0.6240	0.6240	25
BMN	BMN:19	bone marrow necrosis:19:0.8449	0.8449	19
BMOV	BMOV:17	bis(maltolato)oxovanadium(IV):16:0.4571|bis(maltolato)oxovanadium IV:1:0.3463	0.4571	17
BMO	BMO:8	butadiene monoepoxide:8:0.5006	0.5006	8
BMO	BMO:11	butadiene monoxide:11:0.7357	0.7357	11
BMP-15	BMP-15:14|BMP15:1	bone morphogenetic protein-15:15:0.8045	0.8045	15
BMP-1	BMP-1:36|BMP1:6|Bmp1:1	Bone Morphogenetic Protein-1:27:0.8312|Bone morphogenetic protein 1:16:0.8165	0.8312	43
BMP-2	BMP-2:6|BMP2:1	Bone Morphogenetic Protein:7:0.5926	0.5926	7
BMP-2	BMP-2:283|BMP2:45|Bmp2:4|Bmp-2:2|bmp-2:1	bone morphogenetic protein-2:237:0.9873|bone morphogenetic protein 2:98:0.9695	0.9873	335
BMP-4	BMP-4:103|BMP4:72|Bmp4:20|Bmp-4:3|bmp4:1	bone morphogenetic protein 4:117:0.9742|bone morphogenetic protein-4:82:0.9631	0.9742	199
BMP-6	BMP-6:23|BMP6:1	Bone morphogenetic protein-6:24:0.8768	0.8768	24
BMP-7	BMP-7:53|BMP7:9|Bmp7:3	Bone morphogenetic protein-7:47:0.8703|bone morphogenetic protein 7:18:0.8365	0.8703	65
BMPC	BMPC:10	bone marrow plasma cells:10:0.7103	0.7103	10
BMPR2	BMPR2:6	bone morphogenetic protein receptor II:6:0.5290	0.5290	6
BMPs	BMPs:14	bacterial magnetic particles:14:0.7909	0.7909	14
BMPs	BMPs:22	Best management practices:22:0.8657	0.8657	22
BMPs	BMPs:721|Bmps:18	Bone Morphogenetic Proteins:739:0.9934	0.9934	739
BMP	BMP:725|Bmp:13|bmp:1	bone morphogenetic protein:668:0.9629|bone morphogenetic proteins:71:0.9579	0.9629	739
BMRB	BMRB:10	BioMagResBank:10:0.7500	0.7500	10
BMRC	BMRC:13	British Medical Research Council:13:0.7753	0.7753	13
BMRs	BMRs:11	basal metabolic rates:11:0.7357	0.7357	11
BMR	BMR:383	basal metabolic rate:355:0.9819|basal metabolic rates:28:0.8369	0.9819	383
BMSCC	BMSCC:6	bulk milk somatic cell count:6:0.5290	0.5290	6
BMSCs	BMSCs:128|bMSCs:5	bone marrow stromal cells:133:0.9641	0.9641	133
BMSC	BMSC:74|bMSC:1|BMSc:1	bone marrow stromal cells:61:0.9511|bone marrow stromal cell:15:0.8045	0.9511	76
BMS	BMS:30	bare metal stents:15:0.8045|bare metal stent:8:0.6411|bare-metal stents:7:0.0777	0.8045	30
BMs	BMs:80	Basement membranes:80:0.9408	0.9408	80
BMS	BMS:11	Black Mexican Sweet:11:0.7357	0.7357	11
BMs	BMs:12	Blood monocytes:12:0.7571	0.7571	12
BMs	BMs:4|BMS:1	body movements:5:0.0612	0.0612	5
BMS	BMS:9	bone marrow stromal:9:0.6794	0.6794	9
BMs	BMs:5|bms:1	bowel movements:6:0.1320	0.1320	6
BMS	BMS:16	Bristol-Myers Squibb:16:0.8165	0.8165	16
BMS	BMS:11	bulk magnetic susceptibility:11:0.7357	0.7357	11
BMS	BMS:88	burning mouth syndrome:88:0.9653	0.9653	88
BMT-TM	BMT-TM:6	Bone marrow transplant-associated thrombotic microangiopathy:6:0.5290	0.5290	6
BMT	BMT:11	basement membrane thickness:11:0.7357	0.7357	11
BMT	BMT:15	Basic Military Training:15:0.8045	0.8045	15
BMT	BMT:18	behavioral marital therapy:18:0.7539	0.7539	18
BMT	BMT:22	bone marrow:22:0.7955	0.7955	22
BMT	BMT:728	Bone Marrow Transplant:643:0.9378|bone marrow transplants:85:0.9442	0.9442	728
BMT	BMT:3974|bmt:3	bone marrow transplantation:3952:0.9790|bone marrow transplantations:25:0.8816	0.9790	3977
BMT	BMT:8	Bone marrow transplanted:8:0.5006	0.5006	8
BMUs	BMUs:17	Basic Multicellular Units:17:0.5760	0.5760	17
BMU	BMU:17	basic multicellular unit:17:0.6748	0.6748	17
BMVEC	BMVEC:6|B-MVEC:1	brain microvascular endothelial cells:7:0.4438	0.4438	7
BMV	BMV:20	balloon mitral valvotomy:20:0.8525	0.8525	20
BMV	BMV:31	balloon mitral valvuloplasty:31:0.8090	0.8090	31
BMV	BMV:9	betamethasone valerate:9:0.6794	0.6794	9
BMV	BMV:14	brome mosaic bromovirus:14:0.7909	0.7909	14
BMV	BMV:196	Brome mosaic virus:196:0.9600	0.9600	196
BMZ	BMZ:187	Basement membrane zone:187:0.8231	0.8231	187
BM	BM:46	bacterial meningitis:46:0.8986	0.8986	46
BM	BM:18	Barrett's metaplasia:18:0.7539	0.7539	18
BM	BM:9	basal medium:9:0.3470	0.3470	9
BM	BM:586|bm:3	basement membrane:530:0.7292|basement membranes:59:0.7670	0.7670	589
BM	BM:118	basilar membrane:106:0.1237|basilar-membrane:12:0.0020	0.1237	118
BM	BM:19	betamethasone:19:0.0033	0.0033	19
BM	BM:8|Bm:1	bicuculline methiodide:9:0.6794	0.6794	9
BM	BM:11	biological monitoring:11:0.7357	0.7357	11
BM	BM:16|Bm:12	bleomycin:28:0.0051	0.0051	28
BM	BM:24	blood meal:24:0.6767	0.6767	24
BM	BM:95|bm:3	body mass:98:0.8609	0.8609	98
Bm	Bm:8|BM:1	Bombyx mori:9:0.6794	0.6794	9
BM	BM:3821|bm:15	Bone marrow:3813:0.9937|bone-marrow:23:0.0040	0.9937	3836
BM	BM:13	bone marrow cells:13:0.7753	0.7753	13
BM	BM:16	bone metastases:16:0.1879	0.1879	16
BM	BM:10	bone metastasis:10:0.4363	0.4363	10
BM	BM:30	brain metastases:30:0.4881	0.4881	30
BM	BM:9	breast milk:9:0.4587	0.4587	9
BM	BM:6	bronchial mucosa:6:0.0666	0.0666	6
BM	BM:8	buccal mucosa:8:0.1591	0.1591	8
BM	BM:10	butadiene monoxide:10:0.7103	0.7103	10
BN-PAGE	BN-PAGE:14	Blue native polyacrylamide gel electrophoresis:14:0.7909	0.7909	14
BN/GRP	BN/GRP:19	bombesin/gastrin-releasing peptide:10:0.2446|bombesin/gastrin releasing peptide:9:0.6794	0.6794	19
BNA	BNA:10	beta-naphthylamine:10:0.1765	0.1765	10
BNBAS	BNBAS:17	Brazelton Neonatal Behavioral Assessment Scale:17:0.8270	0.8270	17
BNB	BNB:43	blood-nerve barrier:43:0.8037	0.8037	43
BNCT	BNCT:361	boron neutron capture therapy:361:0.9665	0.9665	361
BNC	BNC:17	binucleate cells:17:0.5038	0.5038	17
BNC	BNC:13	boron neutron capture:13:0.7753	0.7753	13
BNE	BNE:14	bilateral neck exploration:14:0.7909	0.7909	14
BNF	BNF:221|B-NF:3	beta-naphthoflavone:224:0.7458	0.7458	224
BNF	BNF:9	beta-napthoflavone:9:0.0268	0.0268	9
BNF	BNF:10	British National Formulary:10:0.7357	0.7357	10
B-NHL	B-NHL:97|BNHL:1	B-cell non-Hodgkin's lymphoma:57:0.6065|B-cell non-Hodgkin lymphoma:21:0.6531|B-cell non-Hodgkin's lymphomas:20:0.4786	0.6531	98
BNI	BNI:12	bladder neck incision:12:0.7571	0.7571	12
BNLI	BNLI:15	British National Lymphoma Investigation:15:0.8045	0.8045	15
BNL	BNL:18	Brookhaven National Laboratory:18:0.8365	0.8365	18
BNML	BNML:9	leukemia model:9:0.3069	0.3069	9
BNML	BNML:9	rat model for human acute myelocytic leukemia:9:0.6794	0.6794	9
BNMPA	BNMPA:10	alpha-Benzyl-N-methylphenethylamine:10:0.9000	0.9000	10
BNPP	BNPP:12	bis(p-nitrophenyl)phosphate:12:0.1930	0.1930	12
BNP	BNP:332	B-type natriuretic peptide:332:0.2312	0.2312	332
BNP	BNP:16	brain natriuretic peptides:16:0.6024	0.6024	16
BNR	BNR:37	biological nutrient removal:37:0.9197	0.9197	37
BNST	BNST:212|BnST:6	bed nucleus of the stria terminalis:218:0.9802	0.9802	218
BNs	BNs:6	Ballooned neurons:6:0.1010	0.1010	6
BNs	BNs:8	burst neurons:8:0.2327	0.2327	8
BNT	BNT:55	Boston Naming Test:55:0.9458	0.9458	55
BNTX	BNTX:25	7-benzylidenenaltrexone:25:0.6316	0.6316	25
bnx	BNX:5|bnx:5	beige/nude/xid:10:0.1957	0.1957	10
BNX	BNX:6|BNx:2|bNX:1|bNx:1	bilateral nephrectomy:10:0.7103	0.7103	10
BNYVV	BNYVV:56	beet necrotic yellow vein virus:56:0.9467	0.9467	56
BN	BN:11	Balkan nephropathy:11:0.5355	0.5355	11
BN	BN:18	binucleated:18:0.0117	0.0117	18
BN	BN:13	bladder neck:13:0.7753	0.7753	13
BN	BN:127|Bn:21	bombesin:148:0.1010	0.1010	148
BN	BN:11	boron nitride:11:0.7357	0.7357	11
BN	BN:562|B-N:3	Brown Norway:432:0.9751|Brown-Norway:133:0.0907	0.9751	565
BN	BN:10	Brown Norway rats:5:0.4422|Brown-Norway rats:5:0.0902	0.4422	10
BN	BN:9|Bn:5	buprenorphine:14:0.0089	0.0089	14
BOAA	BOAA:21	beta-N-oxalylamino-L-alanine:21:0.7037	0.7037	21
BOAI	BOAI:16	balloon-occluded arterial infusion:8:0.1730|Balloon occluded arterial infusion:8:0.5006	0.5006	16
Boc	Boc:11|BOC:1	tert-butoxycarbonyl:12:0.1358	0.1358	12
Boc	Boc:7|BOC:2	tert-butyloxycarbonyl:9:0.0988	0.0988	9
BOD5	BOD5:29	biochemical oxygen demand:29:0.6157	0.6157	29
BOD	BOD:93	biochemical oxygen demand:93:0.6451	0.6451	93
BOD	BOD:9	Burden of disease:9:0.3867	0.3867	9
BOEC	BOEC:12	bovine oviduct epithelial cells:12:0.7571	0.7571	12
BOHB	BOHB:21|B-OHB:1	beta-hydroxybutyrate:22:0.7000	0.7000	22
BOLD	BOLD:246	blood oxygen level-dependent:117:0.9589|blood oxygen level dependent:97:0.9692|blood-oxygen-level-dependent:32:0.0457	0.9692	246
BOLD	BOLD:364	blood oxygenation level-dependent:199:0.9759|blood oxygenation level dependent:136:0.9780|blood-oxygenation-level-dependent:29:0.0412	0.9780	364
BOL	BOL:18	acid diethylamide:18:0.8365	0.8365	18
BOO	BOO:105	bladder outlet obstruction:105:0.9715	0.9715	105
BOOP	BOOP:49	Bronchiolitis obliterans with organizing pneumonia:49:0.9651	0.9651	49
BOPP	BOPP:9	boronated porphyrin:9:0.6794	0.6794	9
bop	bop:5	bacterio-opsin gene:5:0.0902	0.0902	5
BOP	BOP:164|BoP:5	bleeding on probing:169:0.9402	0.9402	169
BOP	BOP:174	N-nitrosobis(2-oxopropyl)amine:174:0.3212	0.3212	174
BOR	BOR:65	branchio-oto-renal:65:0.5872	0.5872	65
BOR	BOR:9	Branchio-oto-renal syndrome:9:0.6794	0.6794	9
BOSCC	BOSCC:10	bovine ocular squamous cell carcinoma:10:0.5856	0.5856	10
boss	boss:8|Boss:5	bride of sevenless:13:0.7753	0.7753	13
BOTMP	BOTMP:15	Bruininks-Oseretsky Test of Motor Proficiency:15:0.6386	0.6386	15
BOT	BOT:8	borderline ovarian tumor:8:0.5006	0.5006	8
BOT	BOT:19	Botzinger complex:19:0.8449	0.8449	19
Bot	Bot:8	Buthus occitanus tunetanus:8:0.6411	0.6411	8
bO	bO:8|BO:6	bacterio-opsin:14:0.0401	0.0401	14
bO	bO:8|BO:2	bacterioopsin:10:0.0278	0.0278	10
BO	BO:18	Barrett's oesophagus:18:0.7539	0.7539	18
BO	BO:9	benzene oxide:9:0.4587	0.4587	9
BO	BO:12	borage oil:12:0.5050	0.5050	12
Bo	Bo:17|bo:6	bovine:23:0.0679	0.0679	23
BO	BO:9	Bronchial obstruction:9:0.3945	0.3945	9
BO	BO:73	bronchiolitis obliterans:73:0.9353	0.9353	73
BP180	BP180:19	bullous pemphigoid antigen:19:0.8365	0.8365	19
BP180	BP180:11	bullous pemphigoid antigen 180:11:0.7357	0.7357	11
BP1	BP1:8|BP-1:1	protein 1:9:0.4587	0.4587	9
BPAD	BPAD:69	bipolar affective disorder:69:0.9567	0.9567	69
BPAE	BPAE:14	bovine pulmonary artery endothelial:14:0.7909	0.7909	14
BPAECs	BPAECs:24|bPAECs:2	bovine pulmonary artery endothelial cells:26:0.8251	0.8251	26
BPAEC	BPAEC:68	bovine pulmonary artery endothelial cells:62:0.9241|bovine pulmonary artery endothelial cell:6:0.5290	0.9241	68
BPAG1	BPAG1:17|BPAg1:3	bullous pemphigoid antigen:20:0.8449	0.8449	20
BPAG1	BPAG1:7|Bpag1:3|bpag1:2|BPAG-1:1	bullous pemphigoid antigen 1:13:0.6701	0.6701	13
BPAG1	BPAG1:7	bullous pemphigoid antigen gene:7:0.5926	0.5926	7
BPAG2	BPAG2:19|BPAg2:4	bullous pemphigoid antigen:23:0.8038	0.8038	23
BPAO	BPAO:11	bovine plasma amine oxidase:11:0.7357	0.7357	11
BPAR	BPAR:12	Biopsy-proven acute rejection:12:0.6460	0.6460	12
BPAS	BPAS:10	British Pregnancy Advisory Service:10:0.7103	0.7103	10
BPAT	BPAT:7	buffered antigen plate agglutination test:7:0.5926	0.5926	7
BPAU	BPAU:14	p-bromophenylacetylurea:14:0.8667	0.8667	14
BPBM	BPBM:11	bovine porous bone mineral:11:0.7357	0.7357	11
BPB	BPB:16	4-bromophenacyl bromide:16:0.1016	0.1016	16
BPB	BPB:11	black-pigmented Bacteroides:6:0.1320|black pigmented Bacteroides:5:0.4422	0.4422	11
BPb	BPb:55|B-Pb:13	blood lead:68:0.8706	0.8706	68
BPb	BPb:6|B-Pb:1	blood lead concentration:7:0.5926	0.5926	7
BPb	BPb:6	Blood lead levels:6:0.5290	0.5290	6
BPB	BPB:24	bromophenacyl bromide:24:0.1889	0.1889	24
BPB	BPB:24	bromophenol blue:24:0.6122	0.6122	24
BPB	BPB:30	p-bromophenacyl bromide:30:0.2468	0.2468	30
BPCO	BPCO:10	chronic airflow obstruction:10:0.7103	0.7103	10
BPD-DS	BPD-DS:4|BPDDS:1	biliopancreatic diversion with duodenal switch:5:0.5290	0.5290	5
BPDE	BPDE:49	benzo[a]pyrene diol epoxide:43:0.4749|benzo[a]pyrene diol-epoxide:6:0.1543	0.4749	49
BPDE	BPDE:12	benzo[a]pyrene diolepoxide:12:0.4153	0.4153	12
BPDE	BPDE:5	beta,8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene:5:0.4422	0.4422	5
BPD	BPD:32	benzoporphyrin derivative:32:0.9072	0.9072	32
BPD	BPD:101	biliopancreatic diversion:101:0.8868	0.8868	101
BPD	BPD:272	biparietal diameter:272:0.9423	0.9423	272
BPD	BPD:92	bipolar disorder:92:0.1432	0.1432	92
BPD	BPD:420	Borderline Personality Disorder:414:0.9884|borderline personality disorders:6:0.5290	0.9884	420
BPD	BPD:687	bronchopulmonary dysplasia:687:0.9785	0.9785	687
BPED	BPED:10	benign proliferative epithelial disorders:10:0.7103	0.7103	10
BPES	BPES:3	blepharophimosis ptosis epicanthus inversus syndrome:3:0.5664	0.5664	3
BPF	BPF:21	brain parenchymal fraction:21:0.8594	0.8594	21
BPF	BPF:8|BPf:1	Brazilian pemphigus foliaceus:9:0.6794	0.6794	9
BPF	BPF:35	Brazilian purpuric fever:35:0.9151	0.9151	35
BPF	BPF:44	bronchopleural fistula:44:0.8076	0.8076	44
BPG	BPG:11	2,3-bisphosphoglycerate:11:0.1613	0.1613	11
BPG	BPG:14	benzathine penicillin G:14:0.7753	0.7753	14
BPh	BPh:8|Bph:3	bacteriopheophytin:11:0.0030	0.0030	11
BPH	BPH:18	benign hyperplasia of the prostate:18:0.8449	0.8449	18
BPH	BPH:12	benign hyperplastic:12:0.2699	0.2699	12
BPH	BPH:2472	benign prostatic hyperplasia:2463:0.9924|benign prostatic hyperplasias:9:0.4587	0.9924	2472
BPH	BPH:386|bph:3	benign prostatic hypertrophy:389:0.9876	0.9876	389
BPH	BPH:10	benzo[a]pyrene hydroxylase:10:0.1680	0.1680	10
BPH	BPH:10	Brown Planthopper:10:0.7103	0.7103	10
BPH	BPH:6	hyperplastic prostate tissue:6:0.5290	0.5290	6
BPII	BPII:7|BP-II:4	Bipolar II disorder:11:0.7357	0.7357	11
BPI	BPI:227	Bactericidal/permeability-increasing protein:177:0.6420|bactericidal/permeability increasing protein:28:0.3807|bactericidal permeability increasing protein:22:0.8657	0.8657	227
BPI	BPI:10	Basic Personality Inventory:10:0.5000	0.5000	10
BPI	BPI:17|BP-I:6	bipolar I:23:0.6306	0.6306	23
BPI	BPI:8|BP-I:6	bipolar I disorder:14:0.7909	0.7909	14
BPI	BPI:10	brachial plexus injury:10:0.7103	0.7103	10
BPI	BPI:13	Brain perfusion index:13:0.7753	0.7753	13
BPI	BPI:48	Brief Pain Inventory:48:0.9379	0.9379	48
BPJ	BPJ:22	bile-pancreatic juice:22:0.6178	0.6178	22
BPL	BPL:54	beta-propiolactone:54:0.3136	0.3136	54
bPL	bPL:37	Bovine placental lactogen:37:0.8051	0.8051	37
BPMC	BPMC:9	2-sec-butylphenyl N-methylcarbamate:9:0.4587	0.4587	9
BPMV	BPMV:13	bean pod mottle virus:13:0.7753	0.7753	13
bpm	bpm:36|BPM:2	beats/min:38:0.0949	0.0949	38
bpm	bpm:12|BPM:2	beats per min:14:0.5589	0.5589	14
bpm	bpm:138|BPM:11	beats per minute:149:0.8310	0.8310	149
BPM	BPM:13	Behavioral Pattern Monitor:13:0.7753	0.7753	13
BPM	BPM:9	bovine peripheral nerve myelin:9:0.6794	0.6794	9
BPM	BPM:11	plasma membrane:11:0.5355	0.5355	11
BPN	BPN:4	backpropagation neural network:4:0.1618	0.1618	4
BPN	BPN:22	basilar pontine nuclei:22:0.7955	0.7955	22
BPNH	BPNH:14	Bilateral periventricular nodular heterotopia:14:0.7909	0.7909	14
BPNN	BPNN:11|BP-NN:1	neural network:12:0.7571	0.7571	12
BPOP	BPOP:14	Bizarre parosteal osteochondromatous proliferation:14:0.7909	0.7909	14
BPO	BPO:9	anti-benzylpenicilloyl:9:0.0398	0.0398	9
BPO	BPO:49|bpo:1	benzoyl peroxide:50:0.7866	0.7866	50
BPO	BPO:13	benzylpenicilloyl:13:0.0597	0.0597	13
BPPN	BPPN:5	benign paroxysmal positional nystagmus:5:0.4422	0.4422	5
BPPV	BPPV:188	benign paroxysmal positional vertigo:188:0.9439	0.9439	188
BPP	BPP:19	biophysical profile:19:0.6537	0.6537	19
BPP	BPP:35|bPP:8	bovine pancreatic polypeptide:43:0.8558	0.8558	43
bPP	bPP:6|BPP:1	bovine PP:7:0.2452	0.2452	7
BPQ	BPQ:8	Breathing Problems Questionnaire:8:0.6411	0.6411	8
BPRS	BPRS:652	Brief Psychiatric Rating Scale:652:0.9954	0.9954	652
BPSD	BPSD:47	behavioral and psychological symptoms of dementia:47:0.5633	0.5633	47
BPSE	BPSE:13	Beltsville Poultry Semen Extender:13:0.6701	0.6701	13
bps	bps:10	base pairs:10:0.7103	0.7103	10
BPS	BPS:35	beraprost sodium:35:0.9151	0.9151	35
BPs	BPs:58|Bps:1	binding proteins:59:0.6068	0.6068	59
BPs	BPs:66|Bps:2|BPS:1	bisphosphonates:69:0.1281	0.1281	69
BPs	BPs:61	Blood pressures:61:0.9511	0.9511	61
BPS	BPS:7	branch point sequence:7:0.5926	0.5926	7
BPS	BPS:16	branchpoint sequence:16:0.4274	0.4274	16
BPS	BPS:11	syndrome:11:0.0188	0.0188	11
BPs	BPs:7|BPS:2	systolic blood pressure:9:0.4587	0.4587	9
BPTB	BPTB:28|B-PT-B:4	bone-patellar tendon-bone:32:0.7782	0.7782	32
BPTI	BPTI:259|bPTI:4	bovine pancreatic trypsin inhibitor:263:0.7338	0.7338	263
BPTs	BPTs:11	biochemical phenotypes:11:0.7357	0.7357	11
BPT	BPT:48	bronchial provocation test:31:0.9043|bronchial provocation tests:17:0.8270	0.9043	48
BPV-1	BPV-1:10|BPV1:2	bovine papillomavirus:12:0.6460	0.6460	12
BPV-1	BPV-1:170|BPV1:42	bovine papillomavirus type 1:212:0.9700	0.9700	212
BPV-2	BPV-2:9	bovine papillomavirus type 2:9:0.6794	0.6794	9
BPV-4	BPV-4:34|BPV4:2	bovine papillomavirus type 4:36:0.9151	0.9151	36
BPV	BPV:16	Balloon pulmonary valvuloplasty:16:0.8165	0.8165	16
BPV	BPV:11	Benign paroxysmal vertigo:11:0.7357	0.7357	11
BPV	BPV:19	benign positional vertigo:19:0.8449	0.8449	19
BPV	BPV:9	Bordetella pertussis vaccine:9:0.5470	0.5470	9
BPV	BPV:50	bovine papilloma virus:50:0.9379	0.9379	50
BPV	BPV:95	bovine papillomavirus:95:0.9685	0.9685	95
BPV	BPV:12	bovine papillomavirus type 1:12:0.7571	0.7571	12
BPV	BPV:25	bovine parvovirus:25:0.8816	0.8816	25
BPV	BPV:6	pulmonary vein:6:0.1838	0.1838	6
BPW	BPW:28|BPw:2	buffered peptone water:30:0.8472	0.8472	30
Bpa	Bpa:5	amino acid p-benzoylphenylalanine:5:0.5290	0.5290	5
Bpa	Bpa:14	bare patches:14:0.7909	0.7909	14
BPA	BPA:26	Bauhinia purpurea:26:0.8251	0.8251	26
BPA	BPA:13|BpA:1	Bauhinia purpurea agglutinin:14:0.6911	0.6911	14
BPA	BPA:11	Bauhinia purpurea lectin:11:0.7357	0.7357	11
BPA	BPA:52|BP-A:4	bisphenol-A:56:0.0877	0.0877	56
BPA	BPA:37	boronophenylalanine:37:0.0574	0.0574	37
BPA	BPA:15	bovine plasma albumin:15:0.8045	0.8045	15
BPA	BPA:11	bovine pulmonary artery:11:0.7357	0.7357	11
BPA	BPA:23	bullous pemphigoid antigen:23:0.8715	0.8715	23
BPA	BPA:133	burst-promoting activity:104:0.6898|burst promoting activity:29:0.8978	0.8978	133
BPa	BPa:7	mean arterial blood pressure:7:0.5926	0.5926	7
Bpa	Bpa:16|BPA:1	p-benzoyl-L-phenylalanine:17:0.0255	0.0255	17
BPA	BPA:36	p-boronophenylalanine:36:0.0574	0.0574	36
BP	BP:15	[3H]benzo[a]pyrene:15:0.0009	0.0009	15
bp	bp:9	72-base-pair:9:0.0005	0.0005	9
BP	BP:18	Back-Propagation:9:0.0005|Back Propagation:9:0.3455	0.3455	18
BP	BP:16	backpropagation:16:0.0010	0.0010	16
BP	BP:9	bacterial pneumonia:9:0.5470	0.5470	9
bp	bp:1960|BP:29	base pairs:1400:0.9822|base pair:467:0.4546|base-pair:79:0.0050|base-pairs:43:0.0027	0.9822	1989
bp	bp:104|BP:1	basepairs:69:0.0043|basepair:36:0.0022	0.0043	105
BP	BP:16|bp:1	basilar papilla:17:0.7407	0.7407	17
BP	BP:11	beet pulp:11:0.7357	0.7357	11
BP	BP:10	Bell's palsy:10:0.5856	0.5856	10
BP	BP:17	bench press:17:0.5374	0.5374	17
BP	BP:36	benz(a)pyrene:36:0.0022	0.0022	36
BP	BP:274	benzo(a)pyrene:274:0.0175	0.0175	274
BP	BP:37	benzo[alpha]pyrene:27:0.0017|benzo(alpha)pyrene:10:0.0006	0.0017	37
BP	BP:19	benzophenone:19:0.0011	0.0011	19
BP	BP:30	benzoyl peroxide:30:0.8032	0.8032	30
BP	BP:27|Bp:1	benzylpenicillin:28:0.0017	0.0017	28
BP	BP:73|Bp:2	Bereitschaftspotential:75:0.0047	0.0047	75
BP	BP:122	binding potential:122:0.9482	0.9482	122
BP	BP:84|bp:3	binding protein:61:0.1507|binding proteins:26:0.4719	0.4719	87
BP	BP:18	biphenyl:18:0.0011	0.0011	18
BP	BP:56|bp:1	bipolar:57:0.0035	0.0035	57
BP	BP:12	bipolar affective disorder:12:0.7571	0.7571	12
BP	BP:55	bipolar disorder:55:0.6833	0.6833	55
BP	BP:25	Bisphosphonates:16:0.0010|Bisphosphonate:9:0.0005	0.0010	25
BP	BP:28|bp:1	blastic phase:29:0.6157	0.6157	29
BP	BP:16	blood plasma:16:0.7261	0.7261	16
BP	BP:9275|Bp:7|bp:3	Blood pressure:9266:0.9884|blood-pressure:19:0.0011	0.9884	9285
BP	BP:20	bodily pain:20:0.4201	0.4201	20
Bp	Bp:16|BP:13	Bordetella pertussis:29:0.7581	0.7581	29
BP	BP:20	bovine pericardium:20:0.8525	0.8525	20
BP	BP:21	bowenoid papulosis:21:0.8594	0.8594	21
BP	BP:11	brachial plexus:11:0.7357	0.7357	11
BP	BP:7|bp:3	brevipedicellus:10:0.0006	0.0006	10
BP	BP:15	British Pharmacopoeia:15:0.8045	0.8045	15
BP	BP:444	bullous pemphigoid:444:0.9855	0.9855	444
BP	BP:38	metabolism of benzo[a]pyrene:38:0.0544	0.0544	38
BP	BP:149	myelin basic protein:149:0.6742	0.6742	149
BP	BP:16|bp:2	point:18:0.0011	0.0011	18
BP	BP:18	Systolic and diastolic blood pressures:18:0.5113	0.5113	18
BP	BP:5	total biopterin:5:0.0612	0.0612	5
BQ-123	BQ-123:15|BQ123:14	receptor antagonist:29:0.5738	0.5738	29
BQR	BQR:10	brequinar:10:0.3913	0.3913	10
BQR	BQR:13	Brequinar sodium:13:0.7753	0.7753	13
BQ	BQ:30	1,4-benzoquinone:30:0.1543	0.1543	30
BQ	BQ:6	Barriers Questionnaire:6:0.0564	0.0564	6
BQ	BQ:27	benzoquinone:27:0.1383	0.1383	27
BQ	BQ:35	betel quid:35:0.9151	0.9151	35
BQ	BQ:15	p-benzoquinone:15:0.0745	0.0745	15
BRAC	BRAC:24	Bangladesh Rural Advancement Committee:24:0.8768	0.8768	24
BRAC	BRAC:9	Basic Rest-Activity Cycle:9:0.6794	0.6794	9
BrAC	BrAC:16|BRAC:1	breath alcohol concentration:17:0.8270	0.8270	17
BRAO	BRAO:23	branch retinal artery occlusion:23:0.8715	0.8715	23
BRBC	BRBC:10|b-RBC:1	red blood cells:11:0.7357	0.7357	11
BRBNS	BRBNS:18	blue rubber bleb nevus syndrome:18:0.8365	0.8365	18
BRB	BRB:129	blood-retinal barrier:129:0.7649	0.7649	129
BRCA1	BRCA1:14	breast cancer susceptibility gene 1:14:0.7909	0.7909	14
BRCA1	BRCA1:14	cancer susceptibility gene:14:0.6173	0.6173	14
BRCT	BRCT:20	BRCA1 C-terminal:20:0.6259	0.6259	20
BR-C	BR-C:36|BRC:1|Br-C:1	Broad-Complex:38:0.2434	0.2434	38
BRC	BRC:50|Brc:10|BrC:3	bromocriptine:63:0.4145	0.4145	63
BRECs	BRECs:15	bovine retinal endothelial cells:15:0.8045	0.8045	15
BREC	BREC:17	bovine retinal endothelial cells:17:0.8270	0.8270	17
BRENDA	BRENDA:11	bacterial restriction endonuclease DNA analysis:11:0.6182	0.6182	11
BRE	BRE:18	Benign rolandic epilepsy:18:0.8365	0.8365	18
bRFS	bRFS:15|BRFS:2	biochemical relapse-free survival:17:0.8270	0.8270	17
BRIC	BRIC:34	benign recurrent intrahepatic cholestasis:34:0.9100	0.9100	34
BRK	BRK:39	baby rat kidney:39:0.8142	0.8142	39
BRL	BRL:38	Buffalo rat liver:38:0.8098	0.8098	38
BRMS	BRMS:5	Bech-Rafaelsen Mania Scale:5:0.1464	0.1464	5
BRMS	BRMS:7	Bech-Rafaelsen Melancholia Scale:7:0.3524	0.3524	7
BRMs	BRMs:88	Biological response modifiers:88:0.7213	0.7213	88
BRM	BRM:84	biological response modifiers:84:0.8167	0.8167	84
BRNs	BRNs:7	basal retinal neurons:7:0.5926	0.5926	7
BROD	BROD:8	Benzyloxyresorufin O-dealkylase:8:0.3463	0.3463	8
BRP	BRP:10	bacteriocin release protein:10:0.7103	0.7103	10
BRP	BRP:13	Biological Reference Preparation:13:0.7753	0.7753	13
BRP	BRP:7	Bovine retinal pericytes:7:0.4438	0.4438	7
BRP	BRP:13	bovine retractor penis:13:0.7753	0.7753	13
BRP	BRP:9|BrP:4	pressure:13:0.1132	0.1132	13
BRRS	BRRS:13	Bannayan-Riley-Ruvalcaba syndrome:13:0.6701	0.6701	13
BRR	BRR:28	baroreceptor reflex:28:0.8941	0.8941	28
BRS-3	BRS-3:28|BRS3:1	bombesin receptor subtype 3:17:0.5374|bombesin receptor subtype-3:12:0.7571	0.7571	29
BRSD	BRSD:9	Rating Scale for Dementia:9:0.6794	0.6794	9
BRSV	BRSV:255|bRSV:1	bovine respiratory syncytial virus:256:0.9811	0.9811	256
BRS	BRS:283	Baroreflex sensitivity:283:0.7939	0.7939	283
BRS	BRS:14	bovine respiratory syncytial:14:0.7909	0.7909	14
BRs	BRs:63	Brassinosteroids:63:0.1174	0.1174	63
BrS	BrS:6|BRS:2	Brugada syndrome:8:0.4102	0.4102	8
BRS	BRS:11	rating scale:11:0.3829	0.3829	11
B-RTO	B-RTO:22|BRTO:7	Balloon-occluded retrograde transvenous obliteration:29:0.7505	0.7505	29
BRT	BRT:26	brachytherapy:26:0.3571	0.3571	26
BRVO	BRVO:108	branch retinal vein occlusion:108:0.9723	0.9723	108
BS-WC	BS-WC:7	B subunit-killed whole cell:7:0.5926	0.5926	7
BS3	BS3:21	bis(sulfosuccinimidyl)suberate:12:0.2973|bis(sulfosuccinimidyl) suberate:9:0.2757	0.2973	21
BSAC	BSAC:2	British Society of Antimicrobial Chemotherapy:2:0.7909	0.7909	2
BSAF	BSAF:10	accumulation factor:10:0.7103	0.7103	10
BSAFs	BSAFs:25	accumulation factors:25:0.8816	0.8816	25
BSAO	BSAO:22	bovine serum amine oxidase:22:0.8657	0.8657	22
BSAP	BSAP:23	B-cell-specific activator protein:13:0.2309|B cell-specific activator protein:10:0.7103	0.7103	23
BSAP	BSAP:34|bSAP:1	bone-specific alkaline phosphatase:35:0.5622	0.5622	35
BSA	BSA:509|bsa:1	body surface area:510:0.9392	0.9392	510
BSA	BSA:3425|bSA:7|-BSA:1	bovine serum albumin:3433:0.9270	0.9270	3433
BSA	BSA:12	bovine serum albumine:12:0.6460	0.6460	12
BSC-1	BSC-1:7|BSC1:1	bumetanide-sensitive Na-K-2Cl cotransporter:8:0.5006	0.5006	8
BSCB	BSCB:21	blood-spinal cord barrier:21:0.8594	0.8594	21
BSCC	BSCC:35	Basaloid squamous cell carcinoma:35:0.7371	0.7371	35
BSCC	BSCC:14|BScc:8|BS-CC:1	Bjork-Shiley convexo-concave:23:0.8038	0.8038	23
BSCT	BSCT:13	blood stem cell transplantation:13:0.7753	0.7753	13
BSC	BSC:13	balanced scorecard:13:0.7753	0.7753	13
BSC	BSC:17	Basaloid squamous carcinoma:17:0.8270	0.8270	17
BSC	BSC:39	best supportive care:39:0.8811	0.8811	39
BSC	BSC:20	blood stem cells:10:0.5856|blood stem cell:10:0.7103	0.7103	20
BSC	BSC:9	bundle sheath cells:9:0.6794	0.6794	9
BSDL	BSDL:24	bile salt-dependent lipase:24:0.8768	0.8768	24
BSD	BSD:9	Bjork-Shiley Delrin:9:0.6794	0.6794	9
Bsep	Bsep:38|BSEP:37|bsep:5	bile salt export pump:80:0.9627	0.9627	80
BSER	BSER:6	Brainstem Evoked Response:6:0.1838	0.1838	6
BSER	BSER:11	Evoked Responses:11:0.2280	0.2280	11
BSE	BSE:64	backscattered electron:55:0.7093|backscattered electrons:9:0.6794	0.7093	64
BSE	BSE:627	Bovine spongiform encephalopathy:627:0.9849	0.9849	627
BSE	BSE:13	breast self-exam:13:0.7753	0.7753	13
BSE	BSE:347	breast self-examination:325:0.9852|Breast self examination:22:0.8657	0.9852	347
BSF-1	BSF-1:26|BSF1:2	B cell stimulatory factor-1:14:0.7909|B cell stimulatory factor 1:14:0.7571	0.7909	28
BSF-2	BSF-2:6|BSF2:1	B cell stimulatory factor 2:7:0.5926	0.5926	7
BSF	BSF:7	B cell stimulatory factors:7:0.5926	0.5926	7
BSF	BSF:7	benzene soluble fraction:7:0.5926	0.5926	7
BSG	BSG:11	British Society of Gastroenterology:11:0.7357	0.7357	11
BSH	BSH:19|bsh:2|Bsh:1	bile salt hydrolase:22:0.8657	0.8657	22
BSH	BSH:19	borocaptate sodium:19:0.8449	0.8449	19
BSH	BSH:10	Mercaptoundecahydrododecaborate:10:0.0519	0.0519	10
BSH	BSH:16	Na2B12H11SH:16:0.1039	0.1039	16
BSH	BSH:14	sodium borocaptate:14:0.6173	0.6173	14
BSID	BSID:34	Bayley Scales of Infant Development:34:0.8644	0.8644	34
BSIF	BSIF:5	bile salt-independent bile flow:5:0.4422	0.4422	5
BSIs	BSIs:69	bloodstream infections:69:0.9100	0.9100	69
BSI	BSI:10	blood stream infections:10:0.7103	0.7103	10
BSI	BSI:121	bloodstream infection:79:0.9036|bloodstream infections:42:0.6586	0.9036	121
BSI	BSI:6	blunt splenic injury:6:0.5290	0.5290	6
BSI	BSI:10	bone strength index:10:0.7103	0.7103	10
BSI	BSI:144	Brief Symptom Inventory:144:0.9560	0.9560	144
BSL	BSL:8|bsL:1	Benign symmetric lipomatosis:9:0.6794	0.6794	9
BSL	BSL:9	British Sign Language:9:0.6794	0.6794	9
BSMA	BSMA:6	bulbospinal muscular atrophy:6:0.2827	0.2827	6
bsMAb	bsMAb:6|BsmAb:5|BsMab:3|BsMAb:3|bs-mAb:3|BSMAB:2|bsmAb:2|BS-MAb:1|bs-MAb:1	Bispecific monoclonal antibody:16:0.6577|bispecific monoclonal antibodies:10:0.5856	0.6577	26
BSMCs	BSMCs:11	smooth muscle cells:11:0.7357	0.7357	11
BSMC	BSMC:13|bSMC:1	smooth muscle cells:14:0.7909	0.7909	14
BSMV	BSMV:35	barley stripe mosaic virus:35:0.9151	0.9151	35
BSM	BSM:9	body surface maps:9:0.6794	0.6794	9
BSM	BSM:12	body surface mapping:12:0.7571	0.7571	12
BSM	BSM:33	bovine submaxillary mucin:33:0.8605	0.8605	33
BSM	BSM:13	bronchial smooth muscle:13:0.4849	0.4849	13
BSN	BSN:16	Bachelor of Science in Nursing:16:0.4246	0.4246	16
BSN	BSN:12	bismuth subnitrate:12:0.5050	0.5050	12
BSO	BSO:9	buthionine sulfoximide:9:0.6794	0.6794	9
BSO	BSO:507	buthionine sulfoximine:507:0.8314	0.8314	507
BSO	BSO:65	buthionine sulphoximine:65:0.7716	0.7716	65
BSO	BSO:16	D,L-buthionine-S,R-sulfoximine:16:0.0136	0.0136	16
BSO	BSO:36	DL-buthionine-S,R-sulfoximine:13:0.0108|DL-buthionine-(S,R)-sulfoximine:12:0.0099|DL-Buthionine-[S,R]-sulfoximine:11:0.0090	0.0108	36
BSO	BSO:128	L-buthionine-(S,R)-sulfoximine:64:0.0570|L-buthionine-[S,R]-sulfoximine:37:0.0325|L-buthionine-S,R-sulfoximine:27:0.0235	0.0570	128
BSO	BSO:13	L-buthionine-SR-sulfoximine:13:0.0108	0.0108	13
BSO	BSO:14	R-sulfoximine:14:0.0118	0.0118	14
BSPM	BSPM:23	body surface potential maps:15:0.8045|body surface potential map:8:0.6411	0.8045	23
BSPM	BSPM:34	Body surface potential mapping:34:0.9126	0.9126	34
BSPMs	BSPMs:36	body surface potential maps:36:0.8716	0.8716	36
BSPT	BSPT:7	tetrazolium chloride:7:0.3463	0.3463	7
BSPS	BSPS:8	Brief Social Phobia Scale:8:0.6411	0.6411	8
BSP	BSP:11	blepharospasm:11:0.0108	0.0108	11
BSP	BSP:336|bSP:2|Bsp:1|bsp:1	Bone sialoprotein:340:0.9811	0.9811	340
BSP	BSP:13|bSP:1	bovine seminal plasma:14:0.5589	0.5589	14
BSP	BSP:59	bromosulfophthalein:59:0.0627	0.0627	59
BSP	BSP:17	bromosulphophthalein:17:0.0173	0.0173	17
BSP	BSP:21	bromosulphthalein:21:0.0216	0.0216	21
BSP	BSP:18	bromsulphthalein:18:0.0184	0.0184	18
BSP	BSP:174	sulfobromophthalein:174:0.1859	0.1859	174
BSP	BSP:27	sulfobromophthalein sodium:27:0.7066	0.7066	27
BSP	BSP:21	sulphobromophthalein:21:0.0216	0.0216	21
BSQ	BSQ:21	Body Shape Questionnaire:21:0.8594	0.8594	21
BSRI	BSRI:32	Bem Sex Role Inventory:18:0.8365|Bem Sex-Role Inventory:14:0.7909	0.8365	32
BSR	BSR:10	blood sedimentation rate:10:0.7103	0.7103	10
BSR	BSR:36	brain stimulation reward:36:0.8716	0.8716	36
BSSL	BSSL:25|bssl:1|BS-SL:1	bile salt-stimulated lipase:27:0.8903	0.8903	27
BSSO	BSSO:31	bilateral sagittal split osteotomy:31:0.9043	0.9043	31
BSS	BSS:150	balanced salt solution:150:0.8986	0.8986	150
BSS	BSS:82|B-SS:1|BSs:1|B-Ss:1	Bernard-Soulier syndrome:85:0.6477	0.6477	85
BSS	BSS:39	bismuth subsalicylate:39:0.8811	0.8811	39
BSS	BSS:22	blind source separation:22:0.8657	0.8657	22
BSS	BSS:9	satiety sequence:9:0.6794	0.6794	9
BSTV	BSTV:5|BSTv:2	bed nucleus of the stria terminalis:7:0.6794	0.6794	7
BST	BST:115|bst:1	bed nucleus of the stria terminalis:116:0.9639	0.9639	116
BST	BST:8	biochemical systems theory:8:0.6411	0.6411	8
bST	bST:9|BST:6	bovine somatotrophin:15:0.8045	0.8045	15
bST	bST:132|BST:28|bSt:4|BSt:1	bovine somatotropin:165:0.9364	0.9364	165
BSV	BSV:8	banana streak virus:8:0.6411	0.6411	8
BSV	BSV:11	binocular single vision:11:0.7357	0.7357	11
BSV	BSV:7	bovine syncytial virus:7:0.5926	0.5926	7
Bs	Bs:12	B chromosomes:12:0.5664	0.5664	12
Bs	Bs:32|BS:5|bs:1	Bacillus subtilis:38:0.9217	0.9217	38
BS	BS:12	baroreflex sensitivity:12:0.3524	0.3524	12
BS	BS:47	bile salts:32:0.9072|bile salt:15:0.6386	0.9072	47
BS	BS:22|B-S:18	Bjork-Shiley:40:0.0283	0.0283	40
BS	BS:25	black smoke:25:0.8186	0.8186	25
BS	BS:10	Blasticidin S:10:0.7103	0.7103	10
BS	BS:7	blood serum:7:0.0951	0.0951	7
BS	BS:37	blood sugar:37:0.9197	0.9197	37
BS	BS:202	Bloom's syndrome:119:0.3277|Bloom syndrome:83:0.2159	0.3277	202
BS	BS:6|bs:1	body surface:7:0.2452	0.2452	7
BS	BS:15	bone scan:15:0.8045	0.8045	15
BS	BS:34|Bs:1	Bone scintigraphy:35:0.8292	0.8292	35
BS	BS:8	Borg scale:8:0.2090	0.2090	8
BS	BS:8	bovine serum:8:0.1367	0.1367	8
BS	BS:40|Bs:3	brain stem:43:0.9308	0.9308	43
BS	BS:20	brainstem:20:0.0138	0.0138	20
BS	BS:9	bronchial secretions:9:0.6794	0.6794	9
BS	BS:11	bulbospongiosus:11:0.0073	0.0073	11
BS	BS:12	bundle sheath:12:0.7571	0.7571	12
BS	BS:8	bursting strength:8:0.1061	0.1061	8
BS	BS:15	patients with Behcet's syndrome:15:0.1566	0.1566	15
BTA	BTA:13	Bladder tumor antigen:13:0.7753	0.7753	13
BtA	BtA:4|BT-A:2|BTA:1	botulinum toxin:7:0.2619	0.2619	7
BTB	BTB:32	blood-testis barrier:32:0.4207	0.4207	32
BTB	BTB:9	bone-patellar tendon-bone:9:0.5470	0.5470	9
BTB	BTB:11|bTB:1|bTb:1	bovine tuberculosis:13:0.5335	0.5335	13
BTB	BTB:18	breakthrough bleeding:18:0.8365	0.8365	18
BTB	BTB:12	bromothymol blue:12:0.3524	0.3524	12
BTCC	BTCC:7	bladder transitional cell carcinoma:7:0.5926	0.5926	7
BTCI	BTCI:6	black-eyed pea trypsin and chymotrypsin inhibitor:6:0.5926	0.5926	6
BTCP	BTCP:9	N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine:9:0.2759	0.2759	9
BTCh	BTCh:9	butyrylthiocholine:9:0.8889	0.8889	9
BTCs	BTCs:20	breakthrough curves:20:0.7766	0.7766	20
BTC	BTC:50|Btc:2	betacellulin:52:0.3208	0.3208	52
btd	btd:15	buttonhead:15:0.3043	0.3043	15
BTE	BTE:12	basic transcription element:12:0.4728	0.4728	12
BTE	BTE:12	Basic Treatment Equivalent:12:0.7571	0.7571	12
BTE	BTE:31	behind-the-ear:31:0.2727	0.2727	31
BTE	BTE:13	biphasic truncated exponential:13:0.7753	0.7753	13
BTEB	BTEB:6	Basic transcription element binding protein:6:0.3728	0.3728	6
BTEE	BTEE:12	ethyl ester:12:0.7571	0.7571	12
BTHS	BTHS:15	Barth syndrome:15:0.8045	0.8045	15
BTLA	BTLA:7|Btla:1	B and T lymphocyte attenuator:8:0.6411	0.6411	8
BTO	BTO:14	balloon test occlusion:14:0.7909	0.7909	14
BTSM	BTSM:18|bTSM:1	bovine tracheal smooth muscle:19:0.7658	0.7658	19
BTS	BTS:9	Blalock-Taussig shunt:9:0.6794	0.6794	9
BTS	BTS:9	Blood Transfusion Service:9:0.6794	0.6794	9
BTS	BTS:43	British Thoracic Society:43:0.9308	0.9308	43
BTs	BTs:11	butyltins:11:0.0503	0.0503	11
BTs	BTs:9	butyltin compounds:9:0.6794	0.6794	9
BTS	BTS:13	syndrome:13:0.0603	0.0603	13
BTT	BTT:12	transmission time:12:0.5664	0.5664	12
BTV-10	BTV-10:14|BTV10:1	bluetongue virus serotype 10:15:0.8045	0.8045	15
BTV	BTV:415|btv:1	bluetongue virus:416:0.9112	0.9112	416
BTX-A	BTX-A:6|BtxA:1	Botulinum toxin:7:0.4709	0.4709	7
BTX-B	BTX-B:11|BTXB:2	botulinum toxin type B:13:0.7753	0.7753	13
BTX	BTX:13|BTx:1	alpha-bungarotoxin:14:0.0478	0.0478	14
BTX	BTX:77	Batrachotoxin:77:0.2794	0.2794	77
BTX	BTX:102|BTx:3|Btx:2|btx:1|B-Tx:1	botulinum toxin:109:0.8954	0.8954	109
BTG	BTG:6|B-TG:2|b-TG:1	B-thromboglobulin:9:0.0437	0.0437	9
BTG	BTG:141|B-TG:12|bTG:1|btg:1	beta-thromboglobulin:141:0.6796|beta thromboglobulin:14:0.7909	0.7909	155
BTG	BTG:11	betathromboglobulin:11:0.0485	0.0485	11
BTG	BTG:5|bTG:3|BTg:2|bTg:2	bovine thyroglobulin:12:0.5664	0.5664	12
BTH	BTH:14	Benzothiadiazole:14:0.2241	0.2241	14
BT	BT:19	1,2,4-benzenetriol:19:0.0101	0.0101	19
Bt	Bt:207|BT:10	Bacillus thuringiensis:217:0.9178	0.9178	217
Bt	Bt:13	Bacillus thuringiensis Berliner:13:0.7753	0.7753	13
BT	BT:202|Bt:1	bacterial translocation:203:0.9764	0.9764	203
BT	BT:36|Bt:1	beef tallow:37:0.8377	0.8377	37
BT	BT:9	behavior therapy:9:0.2102	0.2102	9
BT	BT:14|bT:3	bioavailable testosterone:17:0.6748	0.6748	17
BT	BT:10	bladder tumor:10:0.1774	0.1774	10
BT	BT:7	blast transformation:7:0.0777	0.0777	7
BT	BT:15	blastic transformation:15:0.4052	0.4052	15
BT	BT:152	bleeding time:152:0.9073	0.9073	152
Bt	Bt:23|BT:2	Blomia tropicalis:25:0.8816	0.8816	25
BT	BT:62	blood transfusion:39:0.9237|blood transfusions:23:0.8715	0.9237	62
BT	BT:94	bluetongue:94:0.0521	0.0521	94
BT	BT:92|bt:2|bT:1	body temperature:95:0.8355	0.8355	95
BT	BT:65	borderline tuberculoid:65:0.9047	0.9047	65
BT	BT:9	borderline tuberculoid leprosy:9:0.6794	0.6794	9
BT	BT:55|Bt:1	botulinum toxin:56:0.8920	0.8920	56
BT	BT:8	bovine trypsin:8:0.5006	0.5006	8
BT	BT:10	bovine turbinate:10:0.7103	0.7103	10
BT	BT:74	brachytherapy:74:0.0409	0.0409	74
BT	BT:5	brain tumors:5:0.1132	0.1132	5
BT	BT:16	bretylium tosylate:16:0.8165	0.8165	16
BT	BT:8|B-T:3	modified Blalock-Taussig:11:0.1430	0.1430	11
BT	BT:9	training:9:0.0045	0.0045	9
BT	BT:14	treatment:14:0.0073	0.0073	14
Bu/Cy	Bu/Cy:4|BU/CY:3|Bu/CY:1	busulfan and cyclophosphamide:8:0.3470	0.3470	8
BUCY	BuCy:5|BUCY:5|BU-CY:4|bu-cy:1|Bucy:1|Bu-Cy:1	cyclophosphamide:17:0.4848	0.4848	17
BUC	BUC:10|Buc:2	bucillamine:12:0.4400	0.4400	12
BUI	BUI:67	brain uptake index:67:0.9554	0.9554	67
BUL	BUL:10	bilateral ureteral ligation:10:0.7103	0.7103	10
BUN	BUN:939	blood urea nitrogen:939:0.9467	0.9467	939
BUN	BUN:6	Blood urea nitrogen concentration:6:0.3728	0.3728	6
BUO	BUO:42	bilateral ureteral obstruction:42:0.8893	0.8893	42
BUPA	BUPA:9	British United Provident Association:9:0.6794	0.6794	9
BUP	BUP:13|bup:3	bupivacaine:16:0.2000	0.2000	16
BUP	BUP:29|bup:2	Buprenorphine:31:0.4000	0.4000	31
BUP	BUP:13|bup:1	bupropion:14:0.1733	0.1733	14
BUS	BUS:8|Bus:1	buspirone:9:0.1311	0.1311	9
BUdR	BUdR:44|BUDR:11|BudR:3|BUdr:1|BuDR:1|budR:1	5-bromo-2'-deoxyuridine:48:0.1313|5-bromo-2-deoxyuridine:13:0.0335	0.1313	61
BUdR	BUdR:69|BUDR:9|BudR:5|BUdr:1	5-bromodeoxyuridine:84:0.2318	0.2318	84
BUdR	BUdR:149|BUDR:17|BudR:3|BUdr:3|Budr:2|BuDR:1	bromodeoxyuridine:175:0.4860	0.4860	175
BU	BU:11	5-bromouracil:11:0.0261	0.0261	11
BU	BU:33	Bethesda units:33:0.4488	0.4488	33
BU	BU:12	Buruli ulcer:12:0.6460	0.6460	12
BU	BU:103|Bu:41	busulfan:144:0.3734	0.3734	144
BU	BU:17|Bu:9	Busulphan:26:0.0653	0.0653	26
Bu	Bu:14	unconjugated bilirubin:14:0.7909	0.7909	14
BV/TV	BV/TV:123	bone volume:123:0.8221	0.8221	123
BV/TV	BV/TV:29	bone volume fraction:29:0.8422	0.8422	29
BVAD	BVAD:25	biventricular assist device:25:0.7679	0.7679	25
BVAS	BVAS:18	Birmingham Vasculitis Activity Score:18:0.8365	0.8365	18
BVB	BVB:13	baroreflex vagal bradycardia:13:0.7753	0.7753	13
BVB	BVB:12	biventricular bypass:12:0.7571	0.7571	12
BVD-MD	BVD-MD:9	bovine viral diarrhea-mucosal disease:9:0.6794	0.6794	9
BVD-MD	BVD-MD:7	bovine virus diarrhoea-mucosal disease:7:0.5926	0.5926	7
BVDU	BVDU:24|BVdU:6	bromovinyldeoxyuridine:30:0.1737	0.1737	30
BVDU	BVDU:89|BVdU:12	(E)-5-(2-Bromovinyl)-2'-deoxyuridine:90:0.5329|E-5-(2-bromovinyl)-2'-deoxyuridine:11:0.0599	0.5329	101
BVDV	BVDV:484	bovine viral diarrhea virus:477:0.9834|bovine viral diarrhea viruses:7:0.5926	0.9834	484
BVDV	BVDV:233|BVDv:1	Bovine viral diarrhoea virus:223:0.9712|bovine viral diarrhoea viruses:11:0.7357	0.9712	234
BVDV	BVDV:111|BVDv:1	bovine virus diarrhoea virus:112:0.9728	0.9728	112
BVD	BVD:86	bovine viral diarrhea:86:0.9653	0.9653	86
BVD	BVD:40	bovine viral diarrhoea:40:0.9256	0.9256	40
BVD	BVD:35	bovine virus diarrhoea:35:0.9151	0.9151	35
BVF	BVF:5	bilateral vestibular failure:5:0.4422	0.4422	5
BVH	BVH:8	bilateral vestibular hypofunction:8:0.5006	0.5006	8
BVI	BVI:19	blood vessel invasion:19:0.8449	0.8449	19
BVI	BVI:8	volume index:8:0.5006	0.5006	8
BVL	BVL:7	bilateral vestibular loss:7:0.4438	0.4438	7
BVO	BVO:9	vein occlusion:9:0.4587	0.4587	9
BVP	BVP:22|BV-P:1	biventricular pacing:23:0.8715	0.8715	23
BVP	BVP:11	blood volume pulse:11:0.7357	0.7357	11
BVRT	BVRT:26	Benton Visual Retention Test:26:0.7760	0.7760	26
BVR	BVR:15|BvR:1	biliverdin reductase:16:0.4832	0.4832	16
BVR	BVR:13	vascular resistance:13:0.5664	0.5664	13
BVU	BVU:11	(E)-5-(2-Bromovinyl)uracil:11:0.4000	0.4000	11
BV-araU	BV-araU:15|BV-ara-U:2	1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil:17:0.3636	0.3636	17
BV	BV:305	bacterial vaginosis:305:0.9695	0.9695	305
BV	BV:11|bv:1	baculovirus:12:0.0100	0.0100	12
BV	BV:5	bed volumes:5:0.0612	0.0612	5
BV	BV:42|bv:1	bee venom:43:0.7795	0.7795	43
BV	BV:5	beta-chain variable:5:0.1132	0.1132	5
BV	BV:11	betamethasone 17-valerate:11:0.7357	0.7357	11
BV	BV:17|Bv:1	Biliverdin:18:0.0154	0.0154	18
BV	BV:5	biological values:5:0.0517	0.0517	5
BV	BV:18	biventricular:18:0.0154	0.0154	18
BV	BV:8|Bv:1	blood:9:0.0073	0.0073	9
BV	BV:18	blood viscosity:18:0.8365	0.8365	18
BV	BV:269|Bv:1	blood volume:264:0.7931|blood volumes:6:0.2113	0.7931	270
BV	BV:5	breeding values:5:0.0517	0.0517	5
BV	BV:10|B-V:1	Broncho-Vaxom:11:0.0091	0.0091	11
BV	BV:30	budded virus:30:0.4881	0.4881	30
BV	BV:7	monkey B virus:7:0.1641	0.1641	7
BWG	BWG:34	body weight gain:34:0.9126	0.9126	34
BWH	BWH:9	Brigham and Women's Hospital:9:0.6794	0.6794	9
BWL	BWL:14	body weight loss:14:0.7909	0.7909	14
BWSV	BWSV:21	Black widow spider venom:21:0.8594	0.8594	21
BWS	BWS:170	Beckwith-Wiedemann syndrome:170:0.8836	0.8836	170
BWS	BWS:24	body weight support:24:0.8768	0.8768	24
BWW	BWW:1	Biggers Whitten and Whittingham:1:0.6794	0.6794	1
BWYV	BWYV:17	beet western yellows virus:17:0.8270	0.8270	17
BWT	BWT:25	birth weight:25:0.2540	0.2540	25
BWt	BWt:17|bwt:14|Bwt:4|BWT:4	body weight:39:0.4710	0.4710	39
bwt	bwt:21|BWT:1	bodyweight:22:0.1544	0.1544	22
BW	BW:14|Bw:2	bandwidth:16:0.0081	0.0081	16
BW	BW:14	Biological warfare:14:0.7909	0.7909	14
BW	BW:9	birth weights:9:0.0577	0.0577	9
BW	BW:43|bw:1	birthweight:44:0.0231	0.0231	44
BW	BW:1086|bw:166	body weight:1212:0.8414|Body weights:40:0.6808	0.8414	1252
BW	BW:33|bw:11	bodyweight:44:0.0231	0.0231	44
BW	BW:9	bronchial wash:9:0.4587	0.4587	9
BW	BW:8	bronchial washings:8:0.5006	0.5006	8
BW	BW:16	water:16:0.0081	0.0081	16
BX-C	BX-C:55|BXC:1	Bithorax Complex:56:0.8453	0.8453	56
BXO	BXO:14	Balanitis xerotica obliterans:14:0.7909	0.7909	14
Bx	Bx:8|BX:4|bx:1	biopsy:13:0.1154	0.1154	13
Bx	Bx:10|BX:3	bursectomized:13:0.1154	0.1154	13
BY-2	BY-2:5|BY2:4	Bright Yellow 2:9:0.6794	0.6794	9
BYDV	BYDV:41	barley yellow dwarf virus:41:0.8867	0.8867	41
BYHWD	BYHWD:9	Buyang Huanwu decoction:9:0.6794	0.6794	9
BYMV	BYMV:17	bean yellow mosaic virus:17:0.8270	0.8270	17
BYV	BYV:16	beet yellows closterovirus:16:0.8165	0.8165	16
BYV	BYV:12	Beet yellows virus:12:0.7571	0.7571	12
BZC	BZC:11|BzC:1	benzalkonium chloride:12:0.5664	0.5664	12
BZDs	BZDs:74	benzodiazepines:74:0.9125	0.9125	74
BZE	BZE:39	benzoylecgonine:39:0.9268	0.9268	39
BZF	BZF:10|Bzf:2	bezafibrate:12:0.4783	0.4783	12
BZK	BZK:12	benzalkonium chloride:12:0.7571	0.7571	12
BZP	BZP:25	benzodiazepine:25:0.3934	0.3934	25
BZRs	BZRs:10	benzodiazepine receptors:10:0.5000	0.5000	10
BZs	BZs:81	benzodiazepines:81:0.6838	0.6838	81
BZ	BZ:13	Belousov-Zhabotinsky:13:0.0169	0.0169	13
BZ	BZ:22|Bz:3|bz:2	Benzene:27:0.0365	0.0365	27
BZ	BZ:29|Bz:3	benzidine:32:0.0449	0.0449	32
BZ	BZ:36|bz:1	benzimidazole:37:0.0506	0.0506	37
Bz	Bz:16|BZ:4|bz:2	Benznidazole:22:0.0295	0.0295	22
BZ	BZ:365|Bz:18	benzodiazepine:345:0.4831|benzodiazepines:38:0.0520	0.4831	383
BZ	BZ:9|Bz:8	benzylamine:17:0.0225	0.0225	17
BZ	BZ:13	border zone:13:0.2959	0.2959	13
B[a]P	B[a]P:562|B[a]p:7|B[A]P:2|b[a]p:1	benzo[a]pyrene:551:0.8842|benzo(a)pyrene:21:0.0322	0.8842	572
B[b]F	B[b]F:12|B[B]F:1	Benzo[b]fluoranthene:13:0.9286	0.9286	13
B[c]Ph	B[c]Ph:8|B[c]PH:1	benzo[c]phenanthrene:9:0.8000	0.8000	9
B[e]P	B[e]P:19	Benzo[e]pyrene:19:0.8571	0.8571	19
B[j]A	B[j]A:10	Benz[j]aceanthrylene:10:0.9000	0.9000	10
BaCl2	BaCl2:13	barium chloride:13:0.7753	0.7753	13
BaEV	BaEV:38	baboon endogenous virus:38:0.9217	0.9217	38
BaMMV	BaMMV:12	barley mild mosaic virus:12:0.7571	0.7571	12
BaMV	BaMV:14	bamboo mosaic potexvirus:14:0.7909	0.7909	14
BaMV	BaMV:10	bamboo mosaic virus:10:0.7103	0.7103	10
BAP	BAP:19	6-benzylaminopurine:19:0.0143	0.0143	19
BAP	BAP:174|bAP:30|B-AP:6|b-AP:3|Bap:1|bAp:1	alkaline phosphatase:215:0.9861	0.9861	215
BaP	BaP:693|BAP:40|Bap:2|bap:1	Benzo[a]pyrene:510:0.4049|benzo(a)pyrene:225:0.1782|Benzo a pyrene:1:0.2500	0.4049	736
BAP	BAP:6	beta-amyloid peptide:6:0.1148	0.1148	6
BAP	BAP:8	beta-amyloid protein:8:0.2090	0.2090	8
BAP	BAP:6	bioartificial pancreas:6:0.1838	0.1838	6
BAP	BAP:6	biotin acceptor peptide:6:0.5290	0.5290	6
BAP	BAP:6|BA-P:1	brachial artery pressure:7:0.4438	0.4438	7
BaYMV	BaYMV:14	barley yellow mosaic virus:14:0.7909	0.7909	14
Bactec	Bactec:5|BACTEC:2	radiometric method:7:0.2452	0.2452	7
BAK	BAK:9	Bagby and Kuslich:9:0.6794	0.6794	9
BAK	BAK:8	BCG-activated killer:8:0.1730	0.1730	8
BAK	BAK:37	benzalkonium chloride:37:0.8749	0.8749	37
BC1	BC1:13|Bc1:1	backcross:14:0.2131	0.2131	14
BcPh	BcPh:10	benzo[c]phenanthrene:10:0.6923	0.6923	10
BChl	BChl:81|Bchl:38|BChL:1	bacteriochlorophyll:120:0.9015	0.9015	120
BDV	BDV:302	Borna disease virus:302:0.7481	0.7481	302
BeFx	BeFx:15	beryllium fluoride:15:0.7096	0.7096	15
BeLPT	BeLPT:13|Be-LPT:1	beryllium lymphocyte proliferation test:14:0.6911	0.6911	14
BeO	BeO:8	beryllium oxide:8:0.5006	0.5006	8
BeWo	BeWo:13	choriocarcinoma cells:13:0.4849	0.4849	13
BeWo	BeWo:15	choriocarcinoma cell line:15:0.4609	0.4609	15
BeWo	BeWo:11	cultured human choriocarcinoma:11:0.2764	0.2764	11
BeWo	BeWo:8	human placental choriocarcinoma:8:0.2987	0.2987	8
BEAS-2B	BEAS-2B:4|Beas-2B:1|Beas2B:1|BEAS2-B:1	human bronchial epithelial:7:0.4438	0.4438	7
BEAS-2B	BEAS-2B:29|Beas-2B:2	human bronchial epithelial cells:31:0.7388	0.7388	31
BEAS-2B	BEAS-2B:16	human bronchial epithelial cell line:16:0.5564	0.5564	16
Becker	Becker:8	recessive generalized myotonia:8:0.5006	0.5006	8
Bell's	Bell's:10	idiopathic facial:10:0.5856	0.5856	10
BFs	BFs:37	best frequencies:37:0.9217	0.9217	37
BFS	BFS:7	biaxial flexure strength:7:0.4438	0.4438	7
BGK	BGK:9	Bhatnagar-Gross-Krook:9:0.5714	0.5714	9
BgTX	BgTX:5|BGTX:2|Bgtx:2|BgTx:1	alpha-bungarotoxin:10:0.9000	0.9000	10
BGE	BGE:157	background electrolyte:157:0.9809	0.9809	157
Bge	Bge:13	Biomphalaria glabrata embryonic:13:0.4849	0.4849	13
BHCG	BHCG:6|B-hCG:4|bHCG:1|B-HCG:1	human chorionic gonadotropin:12:0.3813	0.3813	12
BHPS	BHPS:10	British Household Panel Survey:10:0.7103	0.7103	10
BiPAP	BiPAP:67|BIPAP:30|Bi-PAP:5|biPAP:1|Bi-pap:1	positive airway pressure:104:0.9238	0.9238	104
BiPAP	BiPAP:3|BIPAP:2	positive airway pressure ventilation:5:0.4422	0.4422	5
Bio-AEP	Bio-AEP:3	diffusion chamber for a bioartificial endocrine pancreas:3:0.4422	0.4422	3
BI	BI:9	balloon injury:9:0.0932	0.0932	9
BI	BI:175	Barthel index:175:0.4257	0.4257	175
BI	BI:9	base-in:9:0.0085	0.0085	9
BI	BI:7	behavioral inhibition:7:0.2113	0.2113	7
Bi	Bi:12|B-I:4	Billroth I:16:0.5564	0.5564	16
Bi	Bi:12|BI:8	Binaural interaction:20:0.8525	0.8525	20
BI	BI:23|Bi:3	bioelectrical impedance:26:0.6084	0.6084	26
BI	BI:7|Bi:2	bioimpedance:9:0.0085	0.0085	9
Bi	Bi:22	bismuth:22:0.0224	0.0224	22
BI	BI:14	bovine insulin:14:0.4367	0.4367	14
BI	BI:25	brain infarction:25:0.7679	0.7679	25
BI	BI:23	brain injury:23:0.5025	0.5025	23
BI	BI:10	brief intervention:10:0.5000	0.5000	10
BI	BI:10	indices:10:0.0096	0.0096	10
Bi	BI:3|Bi:3	Partial gastrectomy:6:0.2243	0.2243	6
BkF	BkF:13|BKF:2	benzo[k]fluoranthene:15:0.4828	0.4828	15
BK	BK:44|B-K:2	below-knee:46:0.0214	0.0214	46
BK	BK:2	below the knee:2:0.7103	0.7103	2
BK	BK:1559|Bk:75|bk:3	bradykinin:1637:0.7771	0.7771	1637
BK	BK:34	Ca(2+)-activated K(+):23:0.4188|Ca(2+)-activated K+:11:0.0540	0.4188	34
BK	BK:5	calcium-activated potassium channels:5:0.1464	0.1464	5
BK	BK:13	K+ channel:7:0.1329|K+ channels:6:0.0522	0.1329	13
BK	BK:21	large conductance:11:0.4232|large-conductance:10:0.0043	0.4232	21
BK	BK:22	large-conductance Ca2+-activated K+:12:0.2038|large conductance Ca2+-activated K+:10:0.7357	0.7357	22
BK	BK:9	large-conductance calcium-activated potassium:9:0.2280	0.2280	9
BK	BK:7	potassium channel:7:0.1329	0.1329	7
BlaM	BlaM:7|blaM:2|Blam:1	beta-lactamase:10:0.7500	0.7500	10
BLNK	BLNK:13|Blnk:1	B cell linker protein:14:0.7909	0.7909	14
BmNPV	BmNPV:9	Bombyx mori NPV:9:0.5470	0.5470	9
BmNPV	BmNPV:33	Bombyx mori nuclear polyhedrosis virus:33:0.7238	0.7238	33
BmNPV	BmNPV:48	Bombyx mori nucleopolyhedrovirus:48:0.8221	0.8221	48
Bmax	Bmax:49	binding capacities:49:0.8492	0.8492	49
Bmax	Bmax:7	binding maximum:7:0.3524	0.3524	7
Bmax	Bmax:64	maximal binding:64:0.2112	0.2112	64
Bmax	Bmax:115	maximal number of binding sites:115:0.2424	0.2424	115
Bmax	Bmax:84	maximum binding:84:0.2921	0.2921	84
Bmax	Bmax:4	maximum binding value:4:0.1618	0.1618	4
Bmax	Bmax:161	maximum number of binding sites:161:0.3547	0.3547	161
Bmax	Bmax:9	maximum specific binding:9:0.1409	0.1409	9
Bmax	Bmax:6	number of beta-adrenoceptors:6:0.1543	0.1543	6
Bmax	Bmax:10	receptor concentration:10:0.1022	0.1022	10
Bmax	Bmax:198|BMAX:1	receptor density:180:0.2856|receptor densities:19:0.1966	0.2856	199
Bmax	Bmax:8	receptor numbers:8:0.2619	0.2619	8
BoHV-1	BoHV-1:17	bovine herpesvirus 1:17:0.8270	0.8270	17
BoHV-4	BoHV-4:17	bovine herpesvirus 4:17:0.8270	0.8270	17
BoLA	BoLA:24	Bovine Lymphocyte Antigen:16:0.7261|bovine lymphocyte antigens:8:0.5006	0.7261	24
BoLA	BoLA:12	bovine major histocompatibility complex:12:0.5050	0.5050	12
BoNT	BoNT:71	botulinum neurotoxin:62:0.9241|botulinum neurotoxins:9:0.5470	0.9241	71
BoNT	BoNT:8	botulinum toxin:8:0.3463	0.3463	8
BoNTs	BoNTs:38	botulinum neurotoxins:38:0.8781	0.8781	38
BoTx	BoTx:16|BoTX:9|Botx:2	Botulinum toxin:27:0.7237	0.7237	27
BOM	BOM:19|Bom:7	bombesin:26:0.4032	0.4032	26
BOS	BOS:9|BoS:3	base of support:12:0.7571	0.7571	12
BOS	BOS:16	bird's own song:16:0.8165	0.8165	16
BOS	BOS:164	bronchiolitis obliterans syndrome:164:0.9707	0.9707	164
Botox	Botox:43|botox:8|BOTOX:6|BoTox:3	botulinum toxin:60:0.7882	0.7882	60
Br-	Br-:15	bromide:15:0.4667	0.4667	15
BrACh	BrACh:9|brACh:1	bromoacetylcholine:10:0.8182	0.8182	10
BrCN	BrCN:13	cyanogen bromide:13:0.7753	0.7753	13
BrMRBC	BrMRBC:12|Br-MRBC:2|br-MRBC:1	bromelain-treated mouse red blood cells:15:0.4951	0.4951	15
BRV	BRV:45|brv:1	bovine rotavirus:46:0.9353	0.9353	46
BRW	BRW:39	Brown-Roberts-Wells:39:0.7037	0.7037	39
BrCa	BrCa:5|BRCA:3|BrCA:2	breast cancer:10:0.5856	0.5856	10
BrdUrd	BrdUrd:116|Brd-Urd:1|BrDUrd:1	5-bromo-2'-deoxyuridine:100:0.1518|5-bromo-2-deoxyuridine:18:0.0261	0.1518	118
BrdUrd	BrdUrd:103	5-bromodeoxyuridine:92:0.1396|5'-bromodeoxyuridine:11:0.0153	0.1396	103
BrdUrd	BrdUrd:372|Brd-Urd:3|Brdurd:1|BrDUrd:1|brdUrd:1	bromodeoxyuridine:378:0.5782	0.5782	378
BrdU	BrdU:683|BrDU:9|BRdU:4|BRDU:3|Brdu:2|Brd-U:1|Br-dU:1|brdU:1	5-bromo-2'-deoxyuridine:550:0.1807|5-bromo-2-deoxyuridine:98:0.0319|5'-bromo-2'-deoxyuridine:52:0.0168|5-bromo 2'-deoxyuridine:4:0.3524	0.3524	704
BrdU	BrdU:13	5-bromo-2'deoxyuridine:13:0.0039	0.0039	13
BrdU	BrdU:11|BRDU:1	5-bromo-deoxyuridine:12:0.0036	0.0036	12
BrdU	BrdU:328|BRDU:2|Brdu:1	5-bromodeoxyuridine:285:0.0935|5'-Bromodeoxyuridine:46:0.0148	0.0935	331
BrdU	BrdU:28|BRDU:1	anti-bromodeoxyuridine:29:0.0092	0.0092	29
BrdU	BrdU:28|BRDU:3|BrDU:2|Br-dU:1	bromo-deoxyuridine:34:0.0109	0.0109	34
BrdU	BrdU:11	bromodeoxy-uridine:11:0.0033	0.0033	11
BrdU	BrdU:1611|BrDU:34|BRDU:19|Brdu:11|BRdU:6|brdU:5|BrDu:3|Brd-U:2	bromodeoxyuridine:1691:0.5543	0.5543	1691
BrdU	BrdU:11|Brdu:1|BRDU:1|BrDU:1	deoxyuridine:14:0.0043	0.0043	14
BRET	BRET:55	bioluminescence resonance energy transfer:55:0.9448	0.9448	55
BRO	BRO:10|Bro:2	bromocriptine:12:0.2340	0.2340	12
bR	bR:263|BR:227|br:1	bacteriorhodopsin:491:0.3143	0.3143	491
BR	BR:49	Balbiani ring:49:0.9046	0.9046	49
BR	BR:7	base rate:7:0.0565	0.0565	7
BR	BR:7	basic region:7:0.2452	0.2452	7
BR	BR:66	bed rest:66:0.8858	0.8858	66
BR	BR:15	Benzamide riboside:15:0.8045	0.8045	15
BR	BR:55|Br:4	bilirubin:59:0.0372	0.0372	59
BR	BR:8	biochemical response:8:0.1125	0.1125	8
BR	BR:7	blink rate:7:0.0565	0.0565	7
BR	BR:64|Br:4	blink reflex:68:0.8706	0.8706	68
BR	BR:11	bone resorption:11:0.7357	0.7357	11
BR	BR:29|Br:5	brassinosteroid:34:0.0212	0.0212	34
BR	BR:6|Br:1	breathing rate:7:0.0565	0.0565	7
B-R	B-R:7|Br:2	Britton-Robinson:9:0.0051	0.0051	9
Br	Br:10|BR:2	bromide:12:0.0071	0.0071	12
Br	Br:15|--Br:1	bromine:16:0.0096	0.0096	16
Br	Br:38|BR:24	bromocriptine:62:0.0391	0.0391	62
BR	BR:10|Br:1	Bronchial reactivity:11:0.6182	0.6182	11
BR	BR:41|Br:6	bronchial responsiveness:47:0.8703	0.8703	47
BR	BR:12|Br:2	ratio:14:0.0083	0.0083	14
BR	BR:10	receptor:10:0.0058	0.0058	10
BsAb	BsAb:46|bsAb:18|BSAb:3|Bs-Ab:1	bispecific antibody:38:0.6678|Bispecific antibodies:30:0.6252	0.6678	68
Bti	Bti:16	Bacillus thuringiensis israelensis:16:0.6024	0.6024	16
Bti	Bti:2	Bacillus thuringiensis var israelensis:2:0.7834	0.7834	2
Btk	Btk:1	Bacillus thuringiensis var kurstaki:1:0.5926	0.5926	1
Btk	Btk:182|BTK:53|btk:10|BtK:1	Bruton's tyrosine kinase:246:0.7756	0.7756	246
BTN	BTN:7|Btn:2	butyrophilin:9:0.3200	0.3200	9
BuChE	BuChE:5	butyryl cholinesterase:5:0.0902	0.0902	5
BuTx	BuTx:4|BuTX:4|BUTX:1	alpha-bungarotoxin:9:0.5714	0.5714	9
BzAO	BzAO:14|BZAO:1	benzylamine oxidase:15:0.8045	0.8045	15
BzATP	BzATP:9|BZATP:1|Bz-ATP:1	adenosine 5'-triphosphate:11:0.1547	0.1547	11
BzPo	BzPo:7|BzPO:6	Benzoyl peroxide:13:0.7753	0.7753	13
BZR	BZR:114|BzR:27|BZ-R:2|BZr:1	benzodiazepine receptor:117:0.9339|benzodiazepine receptors:27:0.8312	0.9339	144
BZD	BZD:12|Bzd:2	benzidine:14:0.0399	0.0399	14
BZD	BZD:9	benzimidazole:9:0.0245	0.0245	9
BZD	BZD:271|Bzd:4|bzd:1	benzodiazepine:209:0.6380|benzodiazepines:67:0.2025	0.6380	276
C'-ADE	C'-ADE:5	complement-mediated antibody-dependent enhancement:5:0.6794	0.6794	5
C'AMC	C'AMC:8|C'-AMC:1	Complement-dependent antibody-mediated cytotoxicity:9:0.7103	0.7103	9
C(0)	C(0):10	concentration:10:0.2500	0.2500	10
C(Cr)	C(Cr):20|C(cr):6	creatinine clearance:26:0.8251	0.8251	26
C(IN)	C(in):4|C(IN):4|C(In):1	inulin clearance:9:0.6794	0.6794	9
C(m)	C(m):22	membrane capacitance:22:0.6934	0.6934	22
C(max)	C(max):5	concentration of drug in plasma:5:0.5926	0.5926	5
C(max)	C(max):4	maximum concentration in plasma:4:0.0545	0.0545	4
C(max)	C(max):10	maximum concentration of drug in serum:10:0.7103	0.7103	10
C(max)	C(max):72|c(max):2	maximum plasma concentration:58:0.3715|Maximum plasma concentrations:16:0.2523	0.3715	74
C(max)	C(max):63|c(max):1	peak plasma concentration:49:0.2944|peak plasma concentrations:15:0.2264	0.2944	64
C(min)	C(min):10	minimum concentration:10:0.3470	0.3470	10
C(rs)	C(rs):5|C(RS):1	respiratory system compliance:6:0.5290	0.5290	6
C(T)	C(T):8|C(t):5	threshold cycle:13:0.7753	0.7753	13
C-bands	C-bands:10	Constitutive heterochromatin:10:0.3867	0.3867	10
C-type	C-type:13	Calcium-dependent:13:0.1364	0.1364	13
c.d.	c.d.:26|C.D.:2	circular dichroism:28:0.8941	0.8941	28
C.D.	C.D.:5|C.d.:1	patients with Crohn's Disease:6:0.3728	0.3728	6
C.E.B.A.S.	C.E.B.A.S.:9	Closed Equilibrated Biological Aquatic System:9:0.6794	0.6794	9
C.F.	C.F.:19	cystic fibrosis:19:0.8449	0.8449	19
C.H.D.	C.H.D.:10	coronary heart-disease:10:0.7103	0.7103	10
c.i.	c.i.:91|C.I.:2	95 per cent confidence interval:93:0.9325	0.9325	93
C.I.	C.I.:9	cardiac index:9:0.1945	0.1945	9
C.I.	C.I.:11|c.i.:3	confidence intervals:14:0.7909	0.7909	14
c.i.	c.i.:15|C.I.:4	continuous infusion:19:0.7658	0.7658	19
C.O.	C.O.:14|c.o.:1	cardiac output:15:0.8045	0.8045	15
C.O.	C.O.:18	cytochrome oxidase:18:0.8365	0.8365	18
c.p.e.	c.p.e.:11|C.P.E.:1	cytopathic effect:12:0.7571	0.7571	12
C.R.	C.R.:7	achieved complete remission:7:0.3524	0.3524	7
C.T.	C.T.:5|C.t.:5	Chlamydia trachomatis:10:0.5856	0.5856	10
C.T.	C.T.:25|c.t.:2	tomography:27:0.5306	0.5306	27
C.V.s	C.V.s:12	coefficients of variation:12:0.7571	0.7571	12
C.V.	C.V.:69|c.v.:22	coefficient of variation:91:0.6113	0.6113	91
C.b.	C.b.:17	Coxiella burnetii:17:0.8270	0.8270	17
C/A	C/A:8|c/a:1	commissural/associational:9:0.1379	0.1379	9
C/D	C/D:10	concentration/dose:10:0.0841	0.0841	10
c/d	c/d:9	cycles/degree:9:0.0748	0.0748	9
C/D	C/D:18|c/d:2	ratio:20:0.1776	0.1776	20
C/EBP	C/EBP:314	CCAAT/enhancer-binding protein:142:0.3047|CCAAT/enhancer binding protein:140:0.5855|CCAAT/enhancer binding proteins:17:0.5374|CCAAT/enhancer-binding proteins:15:0.1933	0.5855	314
C/E	C/E:16	cost-effectiveness:16:0.1829	0.1829	16
C/E	C/E:9	extracellular concentration:9:0.2500	0.2500	9
C/E	C/E:11	ratio:11:0.1220	0.1220	11
C/F	C/F:20	ratio:20:0.3654	0.3654	20
C/MHCs	C/MHCs:9	community and migrant health centers:9:0.6794	0.6794	9
C/N	C/N:12	carbon to nitrogen:12:0.7753	0.7753	12
C/N	C/N:33	contrast-to-noise:33:0.2192	0.2192	33
C/N	C/N:56	contrast-to-noise ratio:48:0.6628|contrast-to-noise ratios:8:0.3463	0.6628	56
C/PL	C/PL:10	cholesterol/phospholipid:10:0.2727	0.2727	10
C/P	C/P:19|c/p:2	cholesterol/phospholipid:21:0.2299	0.2299	21
C/S	C/S:28|c/s:1	cesarean section:29:0.6928	0.6928	29
C0	C0:43|c0:4	concentration:33:0.1939|concentrations:14:0.0788	0.1939	47
C0	C0:9	Trough:9:0.0485	0.0485	9
C0	C0:21|C-0:1	trough levels:12:0.5050|trough level:10:0.3470	0.5050	22
C10	C10:6	capric acid:6:0.0666	0.0666	6
C10	C10:7|C-10:5	decamethonium:12:0.0753	0.0753	12
C10	C10:8	Decanoic acid:8:0.1591	0.1591	8
C10	C10:16	sodium caprate:16:0.4536	0.4536	16
C12E8	C12E8:6	n-dodecyl octaethylene glycol monoether:6:0.2243	0.2243	6
C12	C12:15	lauric acid:15:0.2729	0.2729	15
C12	C12:7	sodium laurate:7:0.1850	0.1850	7
C14	C14:9	myristic acid:9:0.2757	0.2757	9
C18	C18:9	stearic acid:9:0.4587	0.4587	9
C1E3	C1E3:6	Gyro centrifugal pump:6:0.5290	0.5290	6
C1-INH	C1-INH:52|C1INH:12|C1-Inh:7|C1-inh:4|C1Inh:2|C1inh:1	C1-esterase inhibitor:40:0.1543|C1 esterase inhibitor:38:0.8098	0.8098	78
C1qBA	C1qBA:6|C1q-BA:1|C1qbA:1|C1Q-BA:1	C1q binding assay:9:0.6794	0.6794	9
C1qR	C1qR:15|C1q-R:4	C1q receptor:19:0.8449	0.8449	19
C1q	C1q:4	first component of complement:4:0.1618	0.1618	4
C1	C1:21|C-1:2	atlas:23:0.0300	0.0300	23
C1	C1:9	complex:9:0.0109	0.0109	9
C-1	C-1:6|C1:4	component 1:10:0.1057	0.1057	10
C1	C1:12|c1:1|C-1:1	first:14:0.0177	0.0177	14
C1	C1:13	first complement component:13:0.6701	0.6701	13
C1	C1:7	first component:7:0.0622	0.0622	7
C1	C1:31	first component of complement:31:0.8472	0.8472	31
C1	C1:15	first component of human complement:15:0.7909	0.7909	15
C1	C1:10	Large:10:0.0123	0.0123	10
C1	C1:10	one-carbon:10:0.0123	0.0123	10
C23O	C23O:27	catechol 2,3-dioxygenase:27:0.8903	0.8903	27
C2	C2:8	2 hours postdose:8:0.5006	0.5006	8
C2	C2:10	Acetate:10:0.0105	0.0105	10
C2	C2:4	after administration:4:0.0736	0.0736	4
C2	C2:19|C-2:1	cervical:20:0.0222	0.0222	20
C2	C2:10	concentration:10:0.0105	0.0105	10
C2	C2:10	levels:10:0.0105	0.0105	10
C2	C2:36|C-2:1|c2:1	second:38:0.0432	0.0432	38
C2	C2:8|C-2:1	second cervical vertebra:9:0.6794	0.6794	9
C2	C2:13	second complement component:13:0.6701	0.6701	13
C2	C2:10	second component:10:0.1449	0.1449	10
C2	C2:38	second component of complement:38:0.8781	0.8781	38
C2	C2:10	second component of human complement:10:0.7103	0.7103	10
C3F8	C3F8:44	perfluoropropane:44:0.7167	0.7167	44
C3NeF	C3NeF:42|C3neF:1|C3Nef:1	C3 nephritic factor:44:0.7795	0.7795	44
C3PA	C3PA:9	C3 proactivator:9:0.6794	0.6794	9
C3aR	C3aR:16	C3a receptor:16:0.4832	0.4832	16
C3a	C3a:12	complement:12:0.1358	0.1358	12
C3a	C3a:5	complement 3a:5:0.1132	0.1132	5
C3a	C3a:8	complement activation:8:0.4102	0.4102	8
C3bR	C3bR:7|C3b-R:1	C3b receptor:8:0.4102	0.4102	8
C3b	C3b:10	third component of complement:10:0.5856	0.5856	10
C3d	C3d:7|C3D:1	breakdown products:8:0.2987	0.2987	8
C3	C3:21	C3H/HeJ:21:0.0154	0.0154	21
C3	C3:5	Clostridium botulinum C3 exoenzyme:5:0.1973	0.1973	5
C3	C3:28	complement 3:28:0.1400	0.1400	28
C3	C3:7	complement C3:7:0.0886	0.0886	7
C3	C3:51	complement component 3:51:0.9082	0.9082	51
C3	C3:26	complement factor 3:26:0.8861	0.8861	26
C3	C3:7	Flaveria pringlei:7:0.1850	0.1850	7
C3	C3:28	third:28:0.0208	0.0208	28
C3	C3:12	third carpal bone:12:0.7571	0.7571	12
C3	C3:41	third complement component:41:0.6691	0.6691	41
C3	C3:23	third component:23:0.1752	0.1752	23
C3	C3:240|C-3:1	third component of complement:241:0.9460	0.9460	241
C4BP	C4BP:130|C4bp:30	C4b-binding protein:160:0.6365	0.6365	160
C4D	C4D:10	C4-deficient:10:0.3462	0.3462	10
C4H	C4H:14	cinnamate 4-hydroxylase:14:0.5111	0.5111	14
C4S	C4S:28|C4-S:7|C-4-S:5|C-4S:5	chondroitin 4-sulfate:23:0.8715|chondroitin-4-sulfate:22:0.2471	0.8715	45
C4S	C4S:14|C-4-S:4	chondroitin-4-sulphate:18:0.2000	0.2000	18
C4bBP	C4bBP:14|C4b-BP:13|C4B-BP:1	C4b-binding protein:17:0.3670|C4b binding protein:11:0.6182	0.6182	28
C4	C4:10	complement 4:10:0.1385	0.1385	10
C4	C4:7	complement component 4:7:0.5926	0.5926	7
C4	C4:1	F trinervia:1:0.0731	0.0731	1
C4	C4:11	Flaveria trinervia:11:0.3495	0.3495	11
C4	C4:18	fourth complement component:18:0.7539	0.7539	18
C4	C4:100|C-4:1	fourth component of complement:101:0.9383	0.9383	101
C5a	C5a:18	complement 5a:18:0.2533	0.2533	18
C5a	C5a:11	complement factor 5a:11:0.7357	0.7357	11
C5a	C5a:6	complement fragment C5a:6:0.5290	0.5290	6
C5aR	C5aR:61|C5AR:1	C5a receptor:52:0.6743|C5a receptors:10:0.7103	0.7103	62
C5b-9	C5b-9:25	membrane attack complex:25:0.7679	0.7679	25
C5b-9	C5b-9:8	membrane attack complex of complement:8:0.5006	0.5006	8
C5	C5:4	complement component 5:4:0.1618	0.1618	4
C5	C5:6	fifth complement component:6:0.2243	0.2243	6
C5	C5:8	fifth component:8:0.1367	0.1367	8
C5	C5:54	fifth component of complement:54:0.9147	0.9147	54
C5	C5:6	five or more coughs:6:0.2827	0.2827	6
C677T	C677T:7	common mutation:7:0.1025	0.1025	7
C6ST	C6ST:12	Chondroitin 6-sulfotransferase:12:0.7571	0.7571	12
C6S	C6S:23|C-6-S:8|C-6S:4|C6-S:4	chondroitin-6-sulfate:26:0.3731|chondroitin 6-sulfate:13:0.4849	0.4849	39
C6	C6:39|C-6:1	hexamethonium:40:0.0922	0.0922	40
C6	C6:24|C-6:5	rat glioma:29:0.4410	0.4410	29
C6	C6:10	sixth:10:0.0213	0.0213	10
C6	C6:4|C-6:1	sixth cervical:5:0.0902	0.0902	5
C6	C6:5	sixth complement component:5:0.4422	0.4422	5
C6	C6:5	sixth component:5:0.0902	0.0902	5
C6	C6:24	sixth component of complement:24:0.8768	0.8768	24
C7	C7:5	seventh cervical:5:0.0902	0.0902	5
C7	C7:12	seventh component of complement:12:0.7753	0.7753	12
C8bp	C8bp:9	C8 binding protein:9:0.6794	0.6794	9
C8	C8:12	eighth component of complement:12:0.5355	0.5355	12
C8	C8:15	eighth component of human complement:15:0.8045	0.8045	15
C9	C9:5	ninth component:5:0.0736	0.0736	5
C9	C9:18	ninth component of complement:18:0.4934	0.4934	18
CA.OC	CA.OC:7	catechol oxidation current:7:0.3524	0.3524	7
CA125	CA125:58|CA-125:24|Ca125:1	cancer antigen 125:73:0.7466|cancer antigen-125:10:0.4363	0.7466	83
CA1	CA1:9	cornu ammonis 1:9:0.4587	0.4587	9
CA1	CA1:40|CA-1:2	hippocampus:42:0.2595	0.2595	42
cA2	cA2:9|CA2:1	monoclonal antibody:10:0.3145	0.3145	10
CA4DP	CA4DP:8	combretastatin A-4 disodium phosphate:8:0.6411	0.6411	8
CA4P	CA4P:14|CA-4-P:1	Combretastatin A4 Phosphate:15:0.8045	0.8045	15
CA-4	CA-4:10|CA4:1	combretastatin A-4:11:0.7357	0.7357	11
CA9	CA9:10|Ca9:1	carbonic anhydrase 9:11:0.7357	0.7357	11
cAAT	cAAT:9|c-AAT:3	aspartate aminotransferase:12:0.6182	0.6182	12
CAA	CAA:9	2-chloroacetaldehyde:9:0.0106	0.0106	9
CAA	CAA:8	amino acid:8:0.1276	0.1276	8
CAA	CAA:226|CAa:1	cerebral amyloid angiopathy:227:0.9212	0.9212	227
CAA	CAA:11	chicken anaemia agent:11:0.7357	0.7357	11
CAA	CAA:27	chicken anemia agent:27:0.8861	0.8861	27
CAA	CAA:36	chloroacetaldehyde:36:0.0463	0.0463	36
CAA	CAA:20	chronic aplastic anemia:20:0.7766	0.7766	20
CAA	CAA:70	circulating anodic antigen:70:0.9326	0.9326	70
CAA	CAA:19	coloanal anastomosis:19:0.5404	0.5404	19
CAA	CAA:16	coronary artery aneurysm:9:0.6794|coronary artery aneurysms:7:0.5926	0.6794	16
CAA	CAA:8	coronary artery atherosclerosis:8:0.4102	0.4102	8
CABGs	CABGs:13	coronary artery bypass grafts:13:0.7753	0.7753	13
CABGS	CABGS:14|CABGs:1	coronary artery bypass graft surgery:15:0.8045	0.8045	15
CABG	CABG:7	bypass graft operation:7:0.5926	0.5926	7
CABG	CABG:42	coronary artery bypass:42:0.8893	0.8893	42
CABG	CABG:972	coronary artery bypass graft:930:0.9799|coronary artery bypass grafts:42:0.8263	0.9799	972
CABG	CABG:298|cabg:1	coronary artery bypass graft surgery:299:0.9900	0.9900	299
CABG	CABG:2554	coronary artery bypass grafting:2554:0.9902	0.9902	2554
CABG	CABG:190	coronary artery bypass surgery:190:0.9665	0.9665	190
CABG	CABG:14	coronary bypass:14:0.0928	0.0928	14
CABG	CABG:40	coronary bypass surgery:40:0.1092	0.1092	40
CABG	CABG:10	coronary revascularization:10:0.1680	0.1680	10
CABS	CABS:62	coronary artery bypass surgery:62:0.9519	0.9519	62
CAb	CAb:5|CAB:2|C-Ab:1|Cab:1	antibodies:9:0.0180	0.0180	9
CAB	CAB:26|Cab:1	Cabergoline:27:0.0584	0.0584	27
CAB	CAB:13|CA-B:1	carbonic anhydrase B:14:0.7909	0.7909	14
CAB	CAB:21	cellulose acetate butyrate:21:0.7865	0.7865	21
CAB	CAB:10|Cab:6|cab:3	chlorophyll a/b-binding:10:0.5856|Chlorophyll a/b binding:9:0.6794	0.6794	19
CAB	CAB:16|cab:9|Cab:8	chlorophyll a/b-binding protein:18:0.8365|chlorophyll a/b binding protein:15:0.8045	0.8365	33
CAB	CAB:42	Combined androgen blockade:42:0.7311	0.7311	42
CAB	CAB:72	coronary artery bypass:72:0.9585	0.9585	72
CAB	CAB:10	coronary artery bypass surgery:10:0.7103	0.7103	10
CAC-8	CAC-8:11	canine adenocarcinoma:11:0.5355	0.5355	11
CACA	CACA:23	cis-4-aminocrotonic acid:23:0.5719	0.5719	23
CACD	CACD:10	Central areolar choroidal dystrophy:10:0.7103	0.7103	10
CACG	CACG:20	chronic angle-closure glaucoma:10:0.7103|chronic angle closure glaucoma:10:0.7103	0.7103	20
CACh	CACh:10	cold air challenge:10:0.4363	0.4363	10
cac	cac:12	cacophony:12:0.0222	0.0222	12
CAC	CAC:6	calcium aluminate cement:6:0.5290	0.5290	6
CAC	CAC:10	chronic acalculous cholecystitis:10:0.7103	0.7103	10
CAC	CAC:11	citric acid cycle:11:0.7357	0.7357	11
CAC	CAC:18	Conjunctival allergen challenge:18:0.8365	0.8365	18
CAC	CAC:101	coronary artery calcification:101:0.9704	0.9704	101
CAC	CAC:62	coronary artery calcium:62:0.9519	0.9519	62
CAC	CAC:11|cac:8	critical aggregation concentration:19:0.8449	0.8449	19
CAC	CAC:13|cac:2	critical association concentration:15:0.8045	0.8045	15
CADIA	CADIA:21	computer-assisted densitometric image analysis:21:0.5178	0.5178	21
CADI	CADI:18	chronic allograft damage index:18:0.8365	0.8365	18
CADO	CADO:33	2-chloroadenosine:33:0.6809	0.6809	33
CADs	CADs:12	cationic amphiphilic drugs:12:0.7571	0.7571	12
CAD	CAD:19	cadaveric:19:0.0026	0.0026	19
CAD	CAD:8	cadaveric donor:8:0.2619	0.2619	8
CAD	CAD:10	caspase-activated deoxyribonuclease:10:0.3867	0.3867	10
CAD	CAD:40	Caspase-activated DNase:40:0.8184	0.8184	40
CAD	CAD:21	Cervical artery dissection:21:0.6040	0.6040	21
CAD	CAD:31	chronic actinic dermatitis:31:0.9043	0.9043	31
CAD	CAD:9	chronic allograft dysfunction:9:0.5470	0.5470	9
CAD	CAD:19	Cinnamyl alcohol dehydrogenase:19:0.8449	0.8449	19
CAD	CAD:18	collision-activated dissociation:18:0.0970	0.0970	18
CAD	CAD:14	collisionally activated decomposition:14:0.5111	0.5111	14
CAD	CAD:62	collisionally activated dissociation:62:0.8070	0.8070	62
CAD	CAD:90	computer-aided design:61:0.4853|computer aided design:29:0.8978	0.8978	90
CAD	CAD:98	computer-aided detection:98:0.7292	0.7292	98
CAD	CAD:119	computer-aided diagnosis:119:0.7142	0.7142	119
CAD	CAD:15	computer-aided diagnostic:15:0.4052	0.4052	15
CAD	CAD:6	constitutive activation domain:6:0.2243	0.2243	6
CAD	CAD:5	coronary artery diameter:5:0.1973	0.1973	5
CAD	CAD:5546	coronary artery disease:5523:0.9943|coronary artery diseases:23:0.8715	0.9943	5546
CAD	CAD:11	coronary atherosclerosis:11:0.6182	0.6182	11
CaD	CaD:9	smooth muscle caldesmon:9:0.6794	0.6794	9
CAEBV	CAEBV:19	chronic active EBV infection:19:0.8525	0.8525	19
CAEBV	CAEBV:10	chronic active Epstein-Barr virus:10:0.7103	0.7103	10
CAEBV	CAEBV:23	chronic active Epstein-Barr virus infection:23:0.8715	0.8715	23
CAEC	CAEC:7	coronary artery endothelial cells:7:0.4438	0.4438	7
CAEP	CAEP:9	chronotropic assessment exercise protocol:9:0.6794	0.6794	9
CAEV	CAEV:176	caprine arthritis-encephalitis virus:114:0.9738|caprine arthritis encephalitis virus:62:0.9241	0.9738	176
cae	cae:8|CAE:2	caerulein:10:0.0254	0.0254	10
CAE	CAE:24	Capillary array electrophoresis:24:0.6427	0.6427	24
CAE	CAE:13	Caprine arthritis-encephalitis:13:0.7753	0.7753	13
CaE	CaE:23|CAE:1	carboxylesterase:24:0.0650	0.0650	24
CAE	CAE:10	cefuroxime axetil:10:0.7103	0.7103	10
CAE	CAE:16	cellulose acetate electrophoresis:16:0.8165	0.8165	16
CAE	CAE:50	childhood absence epilepsy:50:0.8254	0.8254	50
CAE	CAE:19	chloroacetate esterase:19:0.5404	0.5404	19
CAE	CAE:17	coronary artery ectasia:17:0.8270	0.8270	17
CAF-1	CAF-1:24|CAF1:2	chromatin assembly factor 1:26:0.8861	0.8861	26
CAFAS	CAFAS:14	Child and Adolescent Functional Assessment Scale:14:0.7909	0.7909	14
CAFCs	CAFCs:8	cobblestone area-forming cells:8:0.6794	0.6794	8
CAFC	CAFC:72	cobblestone area-forming cell:26:0.8861|cobblestone area-forming cells:23:0.8715|cobblestone area forming cell:13:0.7753|cobblestone area forming cells:10:0.5856	0.8861	72
CAF-I	CAF-I:8	Chromatin assembly factor I:8:0.6411	0.6411	8
CAFT	CAFT:11	Canadian Aerobic Fitness Test:11:0.7357	0.7357	11
CAF	CAF:19	antiviral factor:19:0.3582	0.3582	19
CAF	CAF:93|Caf:16	caffeine:109:0.2195	0.2195	109
CAF	CAF:4	carotid artery flow:4:0.0918	0.0918	4
CAF	CAF:8	chronic AF:8:0.5006	0.5006	8
CAF	CAF:9	Chronic allograft failure:9:0.4587	0.4587	9
CAF	CAF:28	chronic atrial fibrillation:28:0.8941	0.8941	28
CAF	CAF:16	coronary artery fistula:16:0.8165	0.8165	16
Caf	Caf:5	cytosolic free calcium:5:0.1973	0.1973	5
CAF	CAF:11	protease:11:0.0203	0.0203	11
CagA	CagA:6|cagA:1	cytotoxin-associated antigen:7:0.2902	0.2902	7
cagA	cagA:16|CagA:3	cytotoxin-associated gene:19:0.6106	0.6106	19
CagA	CagA:9|cagA:4	cytotoxin-associated protein:13:0.5335	0.5335	13
CAGE	CAGE:11	cerebral arterial gas embolism:11:0.7357	0.7357	11
CAG	CAG:84	chronic atrophic gastritis:84:0.9091	0.9091	84
CAg	CAg:9|cag:1	circulating antigen:10:0.1774	0.1774	10
CAG	CAG:11	coronary angiogram:11:0.4728	0.4728	11
CAG	CAG:133	Coronary angiography:133:0.8020	0.8020	133
CAG	CAG:33	coronary arteriography:33:0.9100	0.9100	33
CAG	CAG:53	trinucleotide:53:0.0825	0.0825	53
CAH-B	CAH-B:18|CAHB:5	chronic active hepatitis B:23:0.8715	0.8715	23
CAHPS	CAHPS:15	Consumer Assessment of Health Plans:15:0.8045	0.8045	15
CAHPS	CAHPS:29	Consumer Assessment of Health Plans Study:29:0.8978	0.8978	29
CAHPS	CAHPS:7	Consumer Assessment of Health Plans Survey:7:0.5926	0.5926	7
CAHs	CAHs:10	critical access hospitals:10:0.7103	0.7103	10
CAH	CAH:12	carbonic anhydrase:12:0.7571	0.7571	12
CAH	CAH:537	chronic active hepatitis:537:0.9702	0.9702	537
CAH	CAH:585|cah:1	congenital adrenal hyperplasia:586:0.9704	0.9704	586
CAIII	CAIII:29|CA-III:12	carbonic anhydrase III:41:0.9274	0.9274	41
CAII	CAII:15|CA-II:2	carbonic anhydrase:17:0.8270	0.8270	17
CAII	CAII:93|CA-II:10	carbonic anhydrase II:103:0.9538	0.9538	103
CAIs	CAIs:15	carbonic anhydrase inhibitors:15:0.8045	0.8045	15
CAIS	CAIS:39|cAIS:1	complete androgen insensitivity syndrome:40:0.8184	0.8184	40
CAIV-T	CAIV-T:10	influenza vaccine:10:0.3867	0.3867	10
CAIX	CAIX:11|CA-IX:1	carbonic anhydrase IX:12:0.6460	0.6460	12
Cai	Cai:11	Ca2+ concentration:11:0.1131	0.1131	11
Cai	Cai:10|CaI:1	calcium concentrations:11:0.5355	0.5355	11
CaI	CaI:15|Ca-I:1	calcium ionophore:16:0.8165	0.8165	16
CAI	CAI:12|CA-I:3	carbonic anhydrase I:15:0.8045	0.8045	15
CAI	CAI:24	carbonic anhydrase inhibitor:16:0.8165|carbonic anhydrase inhibitors:8:0.6411	0.8165	24
CAI	CAI:27	Carboxyamido-triazole:27:0.0333	0.0333	27
CAI	CAI:15	Carboxyamidotriazole:15:0.0187	0.0187	15
CAI	CAI:22	Clinical Activity Index:22:0.5863	0.5863	22
CAI	CAI:26	Codon Adaptation Index:26:0.8861	0.8861	26
CAI	CAI:109	computer-assisted instruction:84:0.5355|computer assisted instruction:25:0.8816	0.8816	109
CAI	CAI:8	computer-assisted instructional:8:0.3945	0.3945	8
Cai	Cai:14	cytosolic Ca2+:14:0.2226	0.2226	14
Cai	Cai:15	cytosolic free calcium:15:0.2729	0.2729	15
CAI	CAI:9	infections:9:0.0107	0.0107	9
CAI	CAI:12	infusion:12:0.0147	0.0147	12
Cai	Cai:16	intracellular Ca:16:0.3044	0.3044	16
Cai	Cai:16	intracellular Ca2+:16:0.2077	0.2077	16
Cai	Cai:30	intracellular calcium:30:0.1779	0.1779	30
Cai	Cai:8	intracellular free Ca2+:8:0.2987	0.2987	8
Cai	Cai:9	intracellular free calcium:9:0.1009	0.1009	9
Cai	Cai:13|CaI:11|CAI:1	ionized calcium:25:0.1381	0.1381	25
CAKUT	CAKUT:13	congenital anomalies of the kidney and urinary tract:13:0.7096	0.7096	13
CALB	CALB:10|Calb:1	calbindin-D28k:11:0.1000	0.1000	11
CALB	CALB:12|CAL-B:4	Candida antarctica lipase B:16:0.7261	0.7261	16
CALD	CALD:38	chronic active liver disease:38:0.9217	0.9217	38
CALGB	CALGB:151	Cancer and Leukemia Group B:151:0.9484	0.9484	151
CALI	CALI:20	chromophore-assisted laser inactivation:20:0.7766	0.7766	20
CALLA	CALLA:88|cALLA:4|cALLa:2	common acute lymphoblastic leukemia antigen:94:0.8925	0.8925	94
CALT	CALT:17	Conjunctiva-associated lymphoid tissue:17:0.5760	0.5760	17
CALUX	CALUX:11	luciferase expression:11:0.3213	0.3213	11
CALUX	CALUX:7	luciferase gene expression:7:0.5926	0.5926	7
CALs	CALs:9	artery lesions:9:0.6794	0.6794	9
CAL	CAL:16|Cal:1	California:17:0.0222	0.0222	17
CAL	CAL:50	chronic airflow limitation:50:0.9404	0.9404	50
CAL	CAL:35	clinical attachment levels:35:0.8292	0.8292	35
Cal	Cal:7	colicin A lysis protein:7:0.4438	0.4438	7
CAL	CAL:69	Computer-assisted learning:44:0.3821|computer assisted learning:25:0.8186	0.8186	69
CAL	CAL:9	coracoacromial ligament:9:0.6794	0.6794	9
CAL	CAL:25	coronary artery lesions:25:0.7679	0.7679	25
CAL	CAL:32	coronary artery ligation:32:0.9072	0.9072	32
CAMCOG	CAMCOG:36|CAM-COG:1	Cambridge Cognitive Examination:37:0.9197	0.9197	37
CAMDEX	CAMDEX:18|CAM-DEX:1	Cambridge Examination for Mental Disorders of the Elderly:19:0.8715	0.8715	19
CAMDEX	CAMDEX:14	Cambridge Mental Disorders of the Elderly Examination:14:0.6911	0.6911	14
CAMHS	CAMHS:23	Child and adolescent Mental Health Services:13:0.7753|child and adolescent mental health service:10:0.7103	0.7753	23
CAMI	CAMI:5	Civil Aeromedical Institute:5:0.5290	0.5290	5
CAML	CAML:13	cyclophilin ligand:13:0.7753	0.7753	13
CA-MRSA	CA-MRSA:19|CAMRSA:2	Community-acquired methicillin-resistant Staphylococcus aureus:21:0.5581	0.5581	21
CA-MRSA	CA-MRSA:11|CAMRSA:2	community-acquired MRSA:13:0.4444	0.4444	13
CAMs	CAMs:319|CAMS:3	cell adhesion molecules:322:0.7930	0.7930	322
CAMs	CAMs:28	chorioallantoic membranes:28:0.5837	0.5837	28
CAMs	CAMs:5|CAMS:1	complementary and alternative medicines:6:0.6794	0.6794	6
CaM	CaM:20	Ca(2+)/calmodulin:20:0.0051	0.0051	20
CaM	CaM:54|cam:2|CAM:2	Ca2+/calmodulin:42:0.0111|Ca2+-calmodulin:16:0.0041	0.0111	58
CaM	CaM:15	Calcium/calmodulin:15:0.0038	0.0038	15
CaM	CaM:1268|CAM:34|cam:6|Cam:5	calmodulin:1313:0.3535	0.3535	1313
CAM	CAM:160	cell adhesion molecules:81:0.6788|cell adhesion molecule:79:0.7424	0.7424	160
CAM	CAM:7	cell-associated matrix:7:0.2902	0.2902	7
CAM	CAM:139	chick chorioallantoic membrane:139:0.2081	0.2081	139
CAM	CAM:86	chick embryo chorioallantoic membrane:86:0.7640	0.7640	86
CAM	CAM:13|cam:2|Cam:2	Chloramphenicol:17:0.0043	0.0043	17
CAM	CAM:23	chorioallantoic membranes:23:0.5025	0.5025	23
CAM	CAM:20	chorioamnionitis:20:0.0051	0.0051	20
CAM	CAM:140	clarithromycin:140:0.0373	0.0373	140
CAM	CAM:26	complementary and alternative medical:26:0.8861	0.8861	26
CAM	CAM:4	Complementary and alternative medical therapies:4:0.3170	0.3170	4
CAM	CAM:583	complementary and alternative medicine:559:0.9766|complementary and alternative medicines:24:0.8186	0.9766	583
CAM	CAM:4	complementary and alternative therapies:4:0.4422	0.4422	4
CAM	CAM:39	confusion assessment method:39:0.8811	0.8811	39
CAM	CAM:8	congenital adenomatoid malformation:8:0.1004	0.1004	8
CAM	CAM:14	constitutively active mutant:14:0.7909	0.7909	14
CAM	CAM:59	crassulacean acid metabolism:59:0.9203	0.9203	59
CAM	CAM:17	cystic adenomatoid malformation:17:0.4480	0.4480	17
CAM	CAM:8	topoisomerase I inhibitor camptothecin:8:0.7103	0.7103	8
CANP	CANP:69	Calcium-activated neutral protease:69:0.6561	0.6561	69
CANP	CANP:21	Calcium-activated neutral proteinase:21:0.5568	0.5568	21
CANS	CANS:7	central auditory nervous system:7:0.5926	0.5926	7
CAN	CAN:6	amygdaloid nucleus:6:0.1838	0.1838	6
CAN	CAN:17	Camberwell Assessment of Need:17:0.8165	0.8165	17
CAN	CAN:44	cardiac autonomic neuropathy:44:0.4664	0.4664	44
CAN	CAN:30	cardiovascular autonomic neuropathy:30:0.2784	0.2784	30
CAN	CAN:3	child abuse or neglect:3:0.7261	0.7261	3
CAN	CAN:10	Chloroacetonitrile:10:0.0140	0.0140	10
CAN	CAN:164	chronic allograft nephropathy:164:0.9612	0.9612	164
CaN	CaN:5	protein phosphatase calcineurin:5:0.0731	0.0731	5
CAOD	CAOD:6	carotid artery occlusive disease:6:0.3728	0.3728	6
CAOD	CAOD:5	chronic arterial obstructive disease:5:0.4422	0.4422	5
CAOS	CAOS:5	Computer aided orthopedic surgery:5:0.4422	0.4422	5
CAOs	CAOs:11	copper amine oxidases:11:0.4728	0.4728	11
CaO	CaO:18	Calcium oxide:18:0.6903	0.6903	18
CAO	CAO:6|Cao:1	Chlorophyll a oxygenase:7:0.1641	0.1641	7
CAO	CAO:6	chlorophyllide a oxygenase:6:0.1010	0.1010	6
CAO	CAO:63	chronic airflow obstruction:63:0.9526	0.9526	63
CAO	CAO:17	chronic airway obstruction:17:0.6748	0.6748	17
CAO	CAO:61	coronary artery occlusion:61:0.6573	0.6573	61
Cao	Cao:5|CaO:1	Extracellular Ca:6:0.1320	0.1320	6
Cao	Cao:12	extracellular Ca2+:12:0.3813	0.3813	12
Cao	Cao:8	extracellular calcium:8:0.4102	0.4102	8
CAPA	CAPA:11	Child and Adolescent Psychiatric Assessment:11:0.7357	0.7357	11
CAPD	CAPD:28	central auditory processing disorder:16:0.8165|central auditory processing disorders:12:0.7571	0.8165	28
CAPD	CAPD:18	continuous ambulatory PD:18:0.7539	0.7539	18
CAPD	CAPD:2816|capd:1	continuous ambulatory peritoneal dialysis:2817:0.9528	0.9528	2817
CAPD	CAPD:7	continuous ambulatory peritoneal dialysis patients:7:0.4438	0.4438	7
CAPIT	CAPIT:15	Core assessment program for intracerebral transplantations:8:0.6411|Core Assessment Program for Intracerebral Transplantation:7:0.5926	0.6411	15
CAPPP	CAPPP:16	Captopril Prevention Project:16:0.8045	0.8045	16
CaPP	CaPP:8|CaPp:1	calcium pyrophosphate:9:0.6794	0.6794	9
CAPP	CAPP:8	ceramide-activated protein phosphatase:8:0.6411	0.6411	8
CAPRIE	CAPRIE:8	clopidogrel versus aspirin in patients at risk of ischaemic events:8:0.6794	0.6794	8
CAPV	CAPV:12	congenital absence of the portal vein:12:0.8165	0.8165	12
cap	cap:1|CAP:1	ACE inhibitor captopril:2:0.1148	0.1148	2
CaP	CaP:13|CAP:1	adenocarcinoma of the prostate:14:0.0821	0.0821	14
cap	cap:2|CAP:1	angiotensin-converting enzyme inhibitor captopril:3:0.0918	0.0918	3
CAP	CAP:7	artery pressure:7:0.0539	0.0539	7
CaP	CaP:106|Ca-P:65|CAP:3|cap:2|CA-P:1	calcium phosphate:159:0.8908|calcium-phosphate:18:0.0049	0.8908	177
CaP	CaP:14	calponin:14:0.0038	0.0038	14
CaP	CaP:25|CAP:6	cancer of the prostate:31:0.2371	0.2371	31
CAP	CAP:85|cap:12|Cap:7	capsaicin:104:0.0300	0.0300	104
CAP	CAP:7	carbonated apatite:7:0.2113	0.2113	7
CaP	CaP:28|CAP:11|cap:2	carcinoma of the prostate:41:0.3566	0.3566	41
CAP	CAP:10	carotid arterial pressure:10:0.2446	0.2446	10
CAP	CAP:41	catabolite activator protein:41:0.2267	0.2267	41
CAP	CAP:34	cellulose acetate phthalate:34:0.8605	0.8605	34
CAP	CAP:11	cellulose acetate polymer:11:0.7103	0.7103	11
CAP	CAP:9	central auditory processing:9:0.6794	0.6794	9
CAP	CAP:165	chloramphenicol:165:0.0477	0.0477	165
CAP	CAP:12	chlormadinone acetate:12:0.5050	0.5050	12
CAP	CAP:10	chronic alcoholic pancreatitis:10:0.7103	0.7103	10
CAP	CAP:88	College of American Pathologists:88:0.9461	0.9461	88
CAP	CAP:584	community-acquired pneumonia:584:0.8481	0.8481	584
CAP	CAP:468|cAP:9	compound action potential:400:0.9287|Compound action potentials:77:0.8146	0.9287	477
CAP	CAP:5	compound action potential of the auditory nerve:5:0.5290	0.5290	5
CAP	CAP:58	cyclic alternating pattern:58:0.9486	0.9486	58
CAP	CAP:13	cyclic AMP receptor protein:13:0.7753	0.7753	13
CAP	CAP:26	cystine aminopeptidase:26:0.6973	0.6973	26
CAP	CAP:9	particles:9:0.0023	0.0023	9
CAP	CAP:4	Pharmacia CAP System:4:0.1618	0.1618	4
CaP	CaP:233|CAP:13|Cap:2|cap:1	prostate cancer:249:0.9470	0.9470	249
CaP	CaP:15|CAP:2|cap:1	prostate carcinoma:18:0.2462	0.2462	18
CaP	CaP:8|CAP:3	prostatic adenocarcinoma:11:0.7357	0.7357	11
CaP	CaP:18|CAP:4	prostatic carcinoma:22:0.3359	0.3359	22
CAP	CAP:8|CaP:1	protease:9:0.0023	0.0023	9
cap	cap:8|CAP:3	transcription initiation:11:0.3829	0.3829	11
CAQ	CAQ:17	Questionnaire:17:0.4848	0.4848	17
CARD	CARD:53	caspase recruitment domain:53:0.7578	0.7578	53
CARD	CARD:30	catalyzed reporter deposition:30:0.6252	0.6252	30
CARES	CARES:10	Cancer Rehabilitation Evaluation System:10:0.7103	0.7103	10
CARE	CARE:12	Comprehensive Assessment and Referral Evaluation:12:0.6182	0.6182	12
CARE	CARE:25	Ryan White Comprehensive AIDS Resources Emergency:25:0.8861	0.8861	25
CARM1	CARM1:11	arginine methyltransferase 1:11:0.7357	0.7357	11
CARS-M	CARS-M:8	Clinician-Administered Rating Scale for Mania:8:0.3524	0.3524	8
CARS	CARS:33	Childhood Autism Rating Scale:33:0.9100	0.9100	33
CARS	CARS:22	Coherent anti-Stokes Raman scattering:22:0.8657	0.8657	22
CARs	CARs:16	conditioned avoidance responses:16:0.4832	0.4832	16
CARTIs	CARTIs:10	community-acquired respiratory tract infections:10:0.7103	0.7103	10
CARTO	CARTO:12|Carto:1	mapping system:13:0.5934	0.5934	13
Car	Car:10|CAR:1	beta-carotene:11:0.0069	0.0069	11
CAR	CAR:52	Cancer-associated retinopathy:52:0.8134	0.8134	52
CAR	CAR:7|Car:2	carbachol:9:0.0056	0.0056	9
Car	Car:13|CAR:1	carotenoid:14:0.0090	0.0090	14
CAR	CAR:26|Car:2	carrageenan:28:0.0188	0.0188	28
CAR	CAR:8	central activation ratio:8:0.5006	0.5006	8
CAR	CAR:49	Central African Republic:49:0.9379	0.9379	49
CAR	CAR:39	Cilia-associated respiratory:39:0.8455	0.8455	39
CAR	CAR:14	conditioned avoidance responding:14:0.7909	0.7909	14
CAR	CAR:107	conditioned avoidance response:93:0.8778|conditioned avoidance responses:14:0.6911	0.8778	107
CAR	CAR:9	coronary artery reperfusion:9:0.6794	0.6794	9
CAR	CAR:45	coxsackie and adenovirus receptor:45:0.2796	0.2796	45
CAR	CAR:88	coxsackievirus and adenovirus receptor:88:0.4410	0.4410	88
CaR	CaR:33|car:1	extracellular calcium-sensing receptor:34:0.1603	0.1603	34
CaR	CaR:11|CAR:8	receptors:19:0.0125	0.0125	19
CASA	CASA:13	cancer-associated serum antigen:13:0.4444	0.4444	13
CASA	CASA:35	computer-aided sperm analysis:35:0.2126	0.2126	35
CASA	CASA:47	computer-assisted semen analysis:47:0.5630	0.5630	47
CASA	CASA:5	computer-assisted semen analyzer:5:0.1464	0.1464	5
CASA	CASA:60	computer-assisted sperm analysis:60:0.4413	0.4413	60
CASE	CASE:16	Computer Automated Structure Evaluation:16:0.8045	0.8045	16
CASH	CASH:8	Cancer and Steroid Hormone:8:0.6411	0.6411	8
CASH	CASH:14	Cardiac Arrest Study Hamburg:14:0.7753	0.7753	14
CASMCs	CASMCs:7	coronary arterial smooth muscle cells:7:0.5926	0.5926	7
CASMCs	CASMCs:11	coronary artery smooth muscle cells:11:0.7357	0.7357	11
CASPc	CASPc:13	phthalocyanine:13:0.8000	0.8000	13
CaSR	CaSR:87|CASR:34|CasR:5|Casr:5|Ca-SR:2	calcium-sensing receptor:99:0.5281|calcium sensing receptor:34:0.7898	0.7898	133
CASS	CASS:135	Coronary Artery Surgery Study:135:0.9770	0.9770	135
CAST	CAST:106	Cardiac Arrhythmia Suppression Trial:106:0.9538	0.9538	106
CAST	CAST:9|Cast:1	castanospermine:10:0.0323	0.0323	10
CAST	CAST:7	cellular allergen stimulation test:7:0.5926	0.5926	7
CAST	CAST:8	cellular antigen stimulation test:8:0.6411	0.6411	8
CAST	CAST:20	Children of Alcoholics Screening Test:20:0.8449	0.8449	20
CatB	CatB:4|catB:3|CATB:2|Cat-B:1	cathepsin B:10:0.5000	0.5000	10
CATCH	CATCH:52	child and adolescent trial for cardiovascular health:52:0.9392	0.9392	52
CatD	CatD:18|catD:9|Cat-D:3|Catd:1|CATD:1	cathepsin D:32:0.8563	0.8563	32
CATH	CATH:8|cath:6|Cath:4	cardiac catheterization:18:0.5560	0.5560	18
CATI	CATI:14	telephone interviewing:14:0.7909	0.7909	14
catL	catL:6|CatL:4|CATL:1	cathepsin L:11:0.7357	0.7357	11
CAtr	CAtr:8|cAtr:1|CATR:1	carboxyatractylate:10:0.2571	0.2571	10
CATR	CATR:18	carboxyatractyloside:18:0.4857	0.4857	18
CATT	CATT:9	card agglutination test:9:0.6794	0.6794	9
CATT	CATT:17	card agglutination test for trypanosomiasis:17:0.8270	0.8270	17
CAUTI	CAUTI:12	catheter-associated urinary tract infection:12:0.7571	0.7571	12
CAV-2	CAV-2:14|CAV2:8	Canine adenovirus type 2:22:0.8657	0.8657	22
CAV3	CAV3:6|CAV-3:1|cav-3:1	caveolin-3 gene:8:0.5006	0.5006	8
CAV9	CAV9:13|CAV-9:13	coxsackievirus A9:26:0.8861	0.8861	26
CAVB	CAVB:33	complete atrioventricular block:33:0.7238	0.7238	33
CAVB	CAVB:11	complete AV block:11:0.4728	0.4728	11
CAVC	CAVC:19|cAVC:1	atrioventricular canal:20:0.8525	0.8525	20
CAVD	CAVD:15	congenital absence of the vas deferens:15:0.8045	0.8045	15
CAVEAT	CAVEAT:13	Coronary Angioplasty Versus Excisional Atherectomy Trial:13:0.7753	0.7753	13
CAVF	CAVF:13	coronary arteriovenous fistula:13:0.6701	0.6701	13
CAVH	CAVH:23	continuous arteriovenous haemofiltration:23:0.8715	0.8715	23
CAVH	CAVH:111	Continuous arteriovenous hemofiltration:111:0.9728	0.9728	111
CAVHD	CAVHD:17|CAVH-D:1	continuous arteriovenous hemodiafiltration:18:0.8365	0.8365	18
CAVHD	CAVHD:21	Continuous arteriovenous hemodialysis:21:0.8594	0.8594	21
CAX	CAX:9	central axis:9:0.4587	0.4587	9
CAZ	CAZ:192|Caz:3	ceftazidime:195:0.9327	0.9327	195
CAS	CAS:10	activated sludge:10:0.7103	0.7103	10
CAS	CAS:8	Analogue Scale:8:0.0726	0.0726	8
CAS	CAS:13	Analysis System:13:0.1762	0.1762	13
CAS	CAS:9	aortic stenosis:9:0.0898	0.0898	9
CAS	CAS:8	Assessment Scale:8:0.0726	0.0726	8
CAs	CAs:19	Calcium antagonists:19:0.8449	0.8449	19
CAs	CAs:28	carbonic anhydrases:28:0.8941	0.8941	28
CAS	CAS:5	carotid angioplasty and stent placement:5:0.3524	0.3524	5
CAS	CAS:41	carotid angioplasty and stenting:41:0.6608	0.6608	41
CAs	CAs:7	carotid arteries:7:0.1211	0.1211	7
CAS	CAS:14	carotid artery stenosis:14:0.3585	0.3585	14
CAS	CAS:61	carotid artery stenting:61:0.9503	0.9503	61
CAS	CAS:11	caspofungin:11:0.0076	0.0076	11
CAs	CAs:93|CAS:1	catecholamines:94:0.0702	0.0702	94
CAS	CAS:10	Central Anticholinergic Syndrome:10:0.7103	0.7103	10
CAS	CAS:12	Child Assessment Schedule:12:0.5664	0.5664	12
CAS	CAS:19	Chrome Azurol S:19:0.8365	0.8365	19
CAs	CAs:84|CAS:2	chromosomal aberrations:86:0.4894	0.4894	86
CAS	CAS:22	clinical activity score:22:0.7955	0.7955	22
CAs	CAs:8	cold agglutinins:8:0.5006	0.5006	8
CAS	CAS:63	computer-assisted surgery:38:0.2963|Computer assisted surgery:25:0.8186	0.8186	63
CAS	CAS:8	contralateral acoustic stimulation:8:0.6411	0.6411	8
CAs	CAs:11	contrast agents:11:0.6182	0.6182	11
CAs	CAs:9	coronary arteries:9:0.2285	0.2285	9
CAS	CAS:15	Coronary artery spasm:15:0.7096	0.7096	15
CAS	CAS:9	coronary artery stenosis:9:0.1492	0.1492	9
Cas	Cas:26|CAS:7	Crk-associated substrate:33:0.7525	0.7525	33
CAS	CAS:7	Harvard School of Public Health College Alcohol Study:7:0.5926	0.5926	7
CAS	CAS:10	supernatant:10:0.0068	0.0068	10
CAS	CAS:8|Cas:1	synthase:9:0.0060	0.0060	9
CA	CA:11	abnormalities:11:0.0012	0.0012	11
CA	CA:28	activity:28:0.0032	0.0032	28
CA	CA:10|Ca:1	adenocarcinoma:11:0.0012	0.0012	11
CA	CA:12	alcohol:12:0.0013	0.0013	12
CA	CA:9	antigens:9:0.0009	0.0009	9
CA	CA:5|Ca:4	arterial:9:0.0009	0.0009	9
CA	CA:12	Assay:12:0.0013	0.0013	12
CA	CA:48	caffeic acid:48:0.0942	0.0942	48
CA	CA:33	caffeine:33:0.0038	0.0038	33
Ca	Ca:1614|CA:34|-Ca:1	calcium:1649:0.1948	0.1948	1649
CA	CA:26|C-A:1	calcium antagonists:27:0.8312	0.8312	27
CA	CA:14	California:14:0.0015	0.0015	14
CA	CA:26|Ca:7|ca:1	cancer:34:0.0039	0.0039	34
CA	CA:32	cancer antigen:32:0.1339	0.1339	32
CA	CA:57|Ca:5	Candida albicans:62:0.8234	0.8234	62
CA	CA:97	capsid:97:0.0113	0.0113	97
CA	CA:33	capsid protein:33:0.8196	0.8196	33
CA	CA:5	carbonate apatite:5:0.0612	0.0612	5
CA	CA:5	carbonated apatite:5:0.0612	0.0612	5
CA	CA:748|Ca:2	carbonic anhydrase:737:0.9747|carbonic anhydrases:13:0.7753	0.9747	750
CA	CA:5|ca:1	carbonic anhydrase II:6:0.5290	0.5290	6
CA	CA:54|Ca:11|ca:1	carcinoma:56:0.0065|carcinomas:10:0.0011	0.0065	66
CA	CA:116	cardiac arrest:116:0.7567	0.7567	116
CA	CA:79	carotid artery:68:0.3296|carotid arteries:11:0.0812	0.3296	79
CA	CA:11|Ca:1	catalase:12:0.0013	0.0013	12
CA	CA:562	catecholamine:562:0.0663	0.0663	562
CA	CA:83	catecholaminergic:83:0.0097	0.0097	83
CA	CA:10	catheter ablation:10:0.4363	0.4363	10
CA	CA:6	Caucasian American:6:0.2243	0.2243	6
CA	CA:20	cellular automata:20:0.7766	0.7766	20
CA	CA:9	cellular automaton:9:0.6794	0.6794	9
CA	CA:97	cellulose acetate:97:0.2949	0.2949	97
CA	CA:5|cA:1|ca:1	central nucleus of the amygdala:7:0.5926	0.5926	7
CA	CA:13	cerebellar atrophy:13:0.1824	0.1824	13
CA	CA:14	cerebral atrophy:14:0.2081	0.2081	14
CA	CA:30	cerebral autoregulation:30:0.8472	0.8472	30
CA	CA:9	choanal atresia:9:0.3455	0.3455	9
CA	CA:14	cholate:14:0.0015	0.0015	14
CA	CA:18	Cholic:18:0.0020	0.0020	18
CA	CA:118	cholic acid:118:0.2733	0.2733	118
CA	CA:161	chromosomal aberrations:125:0.3924|chromosomal aberration:36:0.2694	0.3924	161
CA	CA:199	Chromosome aberrations:143:0.4579|chromosome aberration:56:0.4776	0.4776	199
CA	CA:150	chronological age:150:0.6237	0.6237	150
CA	CA:50	citric acid:50:0.0991	0.0991	50
CA	CA:21	cluster analysis:21:0.1330	0.1330	21
CA	CA:10	coarctation of the aorta:10:0.7357	0.7357	10
CA	CA:5	cobblestone areas:5:0.0517	0.0517	5
CA	CA:15	cochlear aqueduct:15:0.7096	0.7096	15
CA	CA:38|C-A:1	cold-acclimated:39:0.0045	0.0045	39
CA	CA:10	cold-acclimated rats:10:0.5000	0.5000	10
ca	ca:6|CA:1	cold adapted:7:0.3524	0.3524	7
CA	CA:57	Cold agglutinins:31:0.9043|cold agglutinin:26:0.8861	0.9043	57
CA	CA:14|C-A:1	community-acquired:15:0.0017	0.0017	15
CA	CA:6	complement activation:6:0.0899	0.0899	6
Ca	Ca:17|CA:6	concentration:23:0.0026	0.0026	23
CA	CA:9	condyloma acuminata:9:0.1809	0.1809	9
CA	CA:20	condyloma acuminatum:20:0.7173	0.7173	20
CA	CA:10	condylomata acuminata:10:0.2275	0.2275	10
CA	CA:6	congruence angle:6:0.0899	0.0899	6
CA	CA:14	conjoint analysis:14:0.0695	0.0695	14
ca	CA:3|ca:3	constitutively activated:6:0.2243	0.2243	6
CA	CA:17|ca:11|Ca:2|c-a:1	constitutively active:31:0.6820	0.6820	31
CA	CA:7	contact angle:7:0.1470	0.1470	7
CA	CA:37	contrast agent:26:0.7340|contrast agents:11:0.6182	0.7340	37
CA	CA:15	contrast arteriography:15:0.2189	0.2189	15
CA	CA:8	controlled atmosphere:8:0.5006	0.5006	8
CA	CA:17	conventional angiography:17:0.0732	0.0732	17
CA	CA:8	conventional arteriography:8:0.0604	0.0604	8
CA	CA:14	conversation analysis:14:0.0695	0.0695	14
CA	CA:38	cornu ammonis:38:0.8098	0.8098	38
CA	CA:70	coronary angiography:70:0.4988	0.4988	70
CA	CA:10	coronary arteriography:10:0.1022	0.1022	10
CA	CA:93	coronary artery:57:0.2657|coronary arteries:36:0.5303	0.5303	93
CA	CA:7	coronary atherosclerosis:7:0.1329	0.1329	7
CA	CA:95	corpora allata:95:0.9192	0.9192	95
CA	CA:25	corpora amylacea:25:0.8816	0.8816	25
CA	CA:32	corpus allatum:32:0.9072	0.9072	32
CA	CA:17	correspondence analysis:17:0.0960	0.0960	17
CA	CA:19	cortical area:19:0.1479	0.1479	19
CA	CA:33	cortisone acetate:33:0.0795	0.0795	33
CA	CA:107	cyproterone acetate:107:0.3308	0.3308	107
CA	CA:22	cytosine arabinoside:22:0.8657	0.8657	22
CA	CA:5	highly polymorphic:5:0.1132	0.1132	5
CA	CA:7	isolated a polymorphic dinucleotide:7:0.1470	0.1470	7
ca	ca:4	live attenuated cold-adapted:4:0.6182	0.6182	4
CA	CA:4	measurement of compressed air:4:0.0918	0.0918	4
CA	CA:32|Ca:1	plasma catecholamines:33:0.0673	0.0673	33
CA	CA:4	weeks of conceptional age:4:0.3168	0.3168	4
CB(1)	CB(1):10	Cannabinoid:10:0.2045	0.2045	10
CB(1)	CB(1):8	cannabinoid receptor:8:0.5006	0.5006	8
CB-153	CB-153:11|CB153:1	2,2',4,4',5,5'-hexachlorobiphenyl:12:0.6471	0.6471	12
CB-154	CB-154:18|CB154:2	2-Br-alpha-ergocryptine:20:0.1078	0.1078	20
CB-154	CB-154:30|CB154:5	2-bromo-alpha-ergocryptine:35:0.1976	0.1976	35
CB-154	CB-154:42|CB154:10	bromocriptine:52:0.3054	0.3054	52
CB-154	CB-154:11|CB154:2	bromocryptine:13:0.0659	0.0659	13
CB1R	CB1R:10|CB1-R:5	cannabinoid receptor:9:0.3455|cannabinoid receptors:6:0.2243	0.3455	15
CB1	CB1:50	cannabinoid:50:0.1769	0.1769	50
CB1	CB1:64|CB-1:3	cannabinoid receptor:51:0.7538|cannabinoid receptors:16:0.6577	0.7538	67
CB1	CB1:20	cannabinoid receptor 1:20:0.7766	0.7766	20
CB1	CB1:14	cannabinoid receptor type 1:14:0.7909	0.7909	14
CB1	CB1:13	cannabinoid type 1:13:0.2211	0.2211	13
CB2	CB2:8|Cb2:3	peripheral cannabinoid receptor:11:0.5000	0.5000	11
CB3717	CB3717:27|CB-3717:1	N10-propargyl-5,8-dideazafolic acid:28:0.5951	0.5951	28
CB3GA	CB3GA:8	Cibacron blue 3GA:8:0.5006	0.5006	8
CB3	CB3:49	coxsackievirus B3:49:0.5650	0.5650	49
CB4	CB4:13|CB-4:1	coxsackievirus B4:14:0.4709	0.4709	14
CBASP	CBASP:11	Cognitive Behavioral Analysis System of Psychotherapy:11:0.7357	0.7357	11
CBAVD	CBAVD:75	congenital bilateral absence of the vas deferens:75:0.9672	0.9672	75
CBA	CBA:5	binding activity:5:0.0902	0.0902	5
CBA	CBA:11|Cba:1	binding assay:12:0.4557	0.4557	12
CBA	CBA:9	congenital biliary atresia:9:0.7103	0.7103	9
CBA	CBA:47	Cost-benefit analysis:47:0.7191	0.7191	47
CBA	CBA:20	cutting balloon angioplasty:20:0.7766	0.7766	20
CBA	CBA:13	cytochemical bioassay:13:0.6701	0.6701	13
CBB	CBB:11	Calvin-Benson-Bassham:11:0.1087	0.1087	11
CBB	CBB:40	Coomassie Brilliant Blue:40:0.8839	0.8839	40
CB-CC	CB-CC:5|cb-cc:3|CBCC:1	centroblastic-centrocytic:9:0.5714	0.5714	9
CBCLs	CBCLs:9	cutaneous B-cell lymphomas:9:0.6794	0.6794	9
CBCL	CBCL:12	Child Behavior Check List:12:0.7571	0.7571	12
CBCL	CBCL:368	Child Behavior Checklist:310:0.9571|Child Behaviour Checklist:58:0.9203	0.9571	368
CBCL	CBCL:30	cutaneous B-cell lymphoma:22:0.8657|cutaneous B-cell lymphomas:8:0.6411	0.8657	30
CBCT	CBCT:17|CB-CT:2	computed tomography:19:0.8449	0.8449	19
CBCs	CBCs:22	complete blood counts:22:0.8657	0.8657	22
CBC	CBC:11	binding capacity:11:0.2582	0.2582	11
CBC	CBC:12	cannabichromene:12:0.0282	0.0282	12
CBC	CBC:6	cerebral-buccal connective:6:0.1838	0.1838	6
CBC	CBC:9	Chlorambucil:9:0.0205	0.0205	9
CBC	CBC:126	complete blood count:126:0.9278	0.9278	126
CBC	CBC:16	contralateral breast cancer:16:0.7261	0.7261	16
CBC	CBC:11	nuclear cap-binding complex:11:0.5355	0.5355	11
CBDC	CBDC:15	chronic bullous disease of childhood:15:0.8045	0.8045	15
CBDE	CBDE:24	common bile duct exploration:24:0.8768	0.8768	24
CBDI	CBDI:4|C-BDI:2	Chinese version of the Beck Depression Inventory:6:0.5926	0.5926	6
CBDL	CBDL:68	common bile duct ligation:68:0.8220	0.8220	68
CBDs	CBDs:21	cellulose-binding domains:21:0.4194	0.4194	21
CBDS	CBDS:51	common bile duct stones:51:0.9416	0.9416	51
CBD	CBD:11	carotid body-denervated:11:0.7357	0.7357	11
CBD	CBD:23|cbd:1	carotid body denervation:24:0.8115	0.8115	24
CBD	CBD:113	cellulose-binding domain:87:0.4133|cellulose binding domain:26:0.3346	0.4133	113
CBD	CBD:87	chronic beryllium disease:87:0.9660	0.9660	87
CBD	CBD:659|cbd:1	common bile duct:660:0.9858	0.9858	660
CBD	CBD:27	community-based distribution:27:0.6745	0.6745	27
CBD	CBD:18	Congenital biliary dilatation:18:0.8270	0.8270	18
CBED	CBED:29	convergent-beam electron diffraction:15:0.2845|Convergent beam electron diffraction:14:0.6911	0.6911	29
CBER	CBER:21	Center for Biologics Evaluation and Research:21:0.7400	0.7400	21
CbE	CbE:8|CBE:2	carboxylesterase:10:0.0319	0.0319	10
CBE	CBE:14	clinical breast exam:14:0.7909	0.7909	14
CBE	CBE:96	clinical breast examination:96:0.9346	0.9346	96
CBE	CBE:6	community-based education:6:0.1320	0.1320	6
CBE	CBE:13	conduritol B epoxide:13:0.7753	0.7753	13
CBE	CBE:11	cotton bracts:11:0.7357	0.7357	11
Cbfa1	Cbfa1:5|cbfa1:1	core binding factor alpha1:6:0.5290	0.5290	6
CBFV	CBFV:207|CBFv:7|CBF-V:1	cerebral blood flow velocity:198:0.7604|cerebral blood flow velocities:17:0.7407	0.7604	215
CBFs	CBFs:7	core-binding factors:7:0.1850	0.1850	7
CBF	CBF:18	CCAAT-binding factor:18:0.0873	0.0873	18
CBF	CBF:9	cerebral:9:0.0016	0.0016	9
CBF	CBF:3695	cerebral blood flow:3695:0.8208	0.8208	3695
CBF	CBF:25	cholinergic basal forebrain:25:0.6873	0.6873	25
CBF	CBF:265	ciliary beat frequency:265:0.9501	0.9501	265
CBF	CBF:60	core binding factor:43:0.5939|core-binding factor:17:0.0798	0.5939	60
CBF	CBF:10	cortical:10:0.0018	0.0018	10
CBGD	CBGD:17	ganglionic degeneration:17:0.6748	0.6748	17
CBGT	CBGT:12	group therapy:12:0.7571	0.7571	12
CBG	CBG:17|cBG:1	capillary blood glucose:18:0.8365	0.8365	18
CBG	CBG:371|Cbg:1	Corticosteroid-binding globulin:276:0.5397|corticosteroid binding globulin:96:0.5631	0.5631	372
CBG	CBG:40	cortisol binding globulin:40:0.1911	0.1911	40
CBG	CBG:21	transcortin:21:0.0329	0.0329	21
CBHI	CBHI:24|cbhI:2|CbhI:1	cellobiohydrolase I:27:0.7834	0.7834	27
CB-HRP	CB-HRP:11|CBHRP:2	horseradish peroxidase:13:0.7753	0.7753	13
CBH	CBH:9|Cbh:1	cellobiohydrolase:10:0.1034	0.1034	10
CBH	CBH:42	cutaneous basophil hypersensitivity:42:0.8893	0.8893	42
CBMCs	CBMCs:13	cord blood mononuclear cells:13:0.6701	0.6701	13
CBMC	CBMC:61	cord blood mononuclear cells:61:0.9229	0.9229	61
CBMNC	CBMNC:7|CB-MNC:3	cord blood mononuclear cells:10:0.7103	0.7103	10
CBMN	CBMN:28|CB-MN:1	cytokinesis-block micronucleus:29:0.5376	0.5376	29
CBMN	CBMN:8	micronucleus assay:8:0.3463	0.3463	8
CBMs	CBMs:27	carbohydrate-binding modules:27:0.5951	0.5951	27
CBM	CBM:7	capillary basement membrane:7:0.3524	0.3524	7
CBM	CBM:27	carbohydrate-binding module:27:0.5334	0.5334	27
CBN	CBN:8	contraction band necrosis:8:0.6411	0.6411	8
CBOs	CBOs:31	community-based organizations:31:0.8090	0.8090	31
CBO	CBO:12	cerebral blood oxygenation:12:0.6460	0.6460	12
CBPC	CBPC:15|CB-PC:4	carbenicillin:19:0.7500	0.7500	19
CBPI	CBPI:10	cytokinesis block proliferation index:10:0.7103	0.7103	10
CBPP	CBPP:87	contagious bovine pleuropneumonia:87:0.9656	0.9656	87
CBPR	CBPR:24	Community-based participatory research:24:0.8115	0.8115	24
CBPZ	CBPZ:15	cefbuperazone:15:0.8750	0.8750	15
CBPS	CBPS:11	congenital bilateral perisylvian syndrome:11:0.7103	0.7103	11
CBP	CBP:36|cBP:2	blood pressure:38:0.7548	0.7548	38
CBP	CBP:6	Calmodulin-binding peptide:6:0.2243	0.2243	6
CBP	CBP:15	cardiopulmonary bypass:15:0.6386	0.6386	15
CBP	CBP:12	chronic back pain:12:0.6460	0.6460	12
CBP	CBP:19	chronic bacterial prostatitis:19:0.8449	0.8449	19
CBP	CBP:127	CREB binding protein:127:0.6316	0.6316	127
CBP	CBP:22	proteins:22:0.0241	0.0241	22
CBQ	CBQ:18	Questionnaire:18:0.7083	0.7083	18
CBR	CBR:10|cbr:1	carbonyl reductase:11:0.6182	0.6182	11
CBR	CBR:13	carotid baroreflex:13:0.7753	0.7753	13
CBR	CBR:22	Case-Based Reasoning:22:0.5581	0.5581	22
CBR	CBR:16	central benzodiazepine receptor:10:0.3867|central benzodiazepine receptors:6:0.2827	0.3867	16
CBR	CBR:12	Clinical benefit response:12:0.7571	0.7571	12
CBR	CBR:41	community-based rehabilitation:31:0.5749|community based rehabilitation:10:0.7103	0.7103	41
CBR	CBR:9	critical body residue:9:0.6794	0.6794	9
CBR	CBR:24	crude birth rate:24:0.8768	0.8768	24
CBSCT	CBSCT:7	Cord blood stem cell transplantation:7:0.4438	0.4438	7
CBSM	CBSM:18	cognitive-behavioral stress management:10:0.2643|cognitive behavioral stress management:8:0.6411	0.6411	18
CBs	CBs:30	Cajal bodies:30:0.3263	0.3263	30
CBs	CBs:9	cannabinoids:9:0.0113	0.0113	9
CBs	CBs:12	carotid bodies:12:0.0737	0.0737	12
CBS	CBS:9	Central Bureau of Statistics:9:0.7357	0.7357	9
CBS	CBS:15	cerebroside sulfate:15:0.6386	0.6386	15
CBS	CBS:27	Charles Bonnet Syndrome:27:0.8903	0.8903	27
CBs	CBs:9	chlorinated biphenyls:9:0.2757	0.2757	9
CBs	CBs:12	chlorobiphenyls:12:0.0156	0.0156	12
CBs	CBs:15	Coiled bodies:15:0.1220	0.1220	15
CBS	CBS:83	colloidal bismuth subcitrate:83:0.8926	0.8926	83
CBS	CBS:6	combined behavioral score:6:0.5290	0.5290	6
CBS	CBS:8	coronary bypass surgery:8:0.5006	0.5006	8
CBS	CBS:209|Cbs:1	cystathionine beta-synthase:180:0.9565|cystathionine-beta-synthase:16:0.0213|cystathionine beta synthase:14:0.7909	0.9565	210
CBs	CBs:6	polychlorinated biphenyls:6:0.0899	0.0899	6
CBTs	CBTs:7	Carotid body tumors:7:0.5926	0.5926	7
CBTS	CBTS:9	Collaborative Behavioral Teratology Study:9:0.6794	0.6794	9
CBV3	CBV3:8|CBV-3:4	coxsackievirus B3:12:0.6460	0.6460	12
CBVD	CBVD:9	cerebrovascular disease:9:0.6794	0.6794	9
CBV	CBV:30	capillary blood cell velocity:30:0.5838	0.5838	30
CBV	CBV:7	capillary blood velocity:7:0.0951	0.0951	7
CBV	CBV:11	cerebral blood velocity:11:0.2764	0.2764	11
CBV	CBV:20	Coxsackie B Viruses:11:0.7357|Coxsackie B virus:9:0.6794	0.7357	20
CBX	CBX:27|Cbx:1	carbenoxolone:28:0.4030	0.4030	28
CBZ-E	CBZ-E:3|CBZ-e:1	active metabolite carbamazepine-10,11-epoxide:4:0.1329	0.1329	4
CBZ-E	CBZ-E:5|CBZE:2	carbamazepine 10,11-epoxide:7:0.2902	0.2902	7
CBZ-E	CBZ-E:15|CBZE:3	CBZ-10,11-epoxide:14:0.0915|CBZ 10,11 epoxide:4:0.0545	0.0915	18
cBZR	cBZR:5|cBZr:1|CBZR:1	central benzodiazepine receptor:7:0.4438	0.4438	7
CBZ	CBZ:1117|Cbz:1	carbamazepine:1118:0.9402	0.9402	1118
CBZ	CBZ:9	Carbimazole:9:0.0067	0.0067	9
CBIR	CBIR:9	content-based image retrieval:9:0.6794	0.6794	9
CB	CB:9	branch:9:0.0029	0.0029	9
CB	CB:9	bromocriptine:9:0.0029	0.0029	9
CB	CB:22	Calbindin D28K:22:0.8657	0.8657	22
CB	CB:10	calcium-binding proteins calbindin:10:0.5335	0.5335	10
CB	CB:5	calcium-binding protein calbindin-D28k:5:0.1132	0.1132	5
CB	CB:51	cannabinoid:51:0.0179	0.0179	51
Cb	Cb:6|CB:4	carbenicillin:10:0.0032	0.0032	10
CB	CB:40	carbon black:40:0.8839	0.8839	40
CB	CB:5|Cb:4	carboplatin:9:0.0029	0.0029	9
CB	CB:165	carotid body:155:0.7979|carotid bodies:10:0.1057	0.7979	165
CB	CB:57	cathepsin B:57:0.0994	0.0994	57
CB	CB:9|cb:2|Cb:1	centroblastic:12:0.0039	0.0039	12
CB	CB:67|Cb:12	cerebellum:79:0.0279	0.0279	79
CB	CB:22	chlorobenzene:22:0.0075	0.0075	22
CB	CB:12	chlorobiphenyl:12:0.0039	0.0039	12
CB	CB:139	chronic bronchitis:139:0.9544	0.9544	139
CB	CB:9	Cibacron blue 3GA:9:0.6794	0.6794	9
CB	CB:14|Cb:5	clenbuterol:19:0.0064	0.0064	19
CB	CB:11	cocoa butter:11:0.7357	0.7357	11
CB	CB:17|C-B:3	cognitive-behavioral:20:0.0068	0.0068	20
CB	CB:28	Conduction block:28:0.5837	0.5837	28
CB	CB:18	cone beam:9:0.6794|cone-beam:9:0.0032	0.6794	18
CB	CB:545|cb:1	cord blood:546:0.9553	0.9553	546
CB	CB:11	core biopsy:11:0.4232	0.4232	11
CB	CB:12	covalent binding:12:0.3813	0.3813	12
CB	CB:19	cuprolinic blue:19:0.2191	0.2191	19
CB	CB:14	cutting balloon:14:0.7909	0.7909	14
CB	CB:29	cyanogen bromide:29:0.8978	0.8978	29
CB	CB:309|cB:1	Cytochalasin B:310:0.6873	0.6873	310
CC-SIT	CC-SIT:9	Cross-Cultural Smell Identification Test:9:0.6794	0.6794	9
CC16	CC16:50|CC-16:3	Clara cell protein:53:0.9438	0.9438	53
CC16	CC16:3|CC-16:2	Clara cell protein 16:5:0.4422	0.4422	5
CCAB	CCAB:7	conventional coronary artery bypass:7:0.6411	0.6411	7
CCAD	CCAD:6	chronic cold agglutinin disease:6:0.5290	0.5290	6
CCA-IMT	CCA-IMT:9	common carotid artery intima-media thickness:9:0.6794	0.6794	9
C-CAM	C-CAM:5|CCAM:4	clocinnamox:9:0.0500	0.0500	9
CCAM	CCAM:84	congenital cystic adenomatoid malformation:84:0.8794	0.8794	84
CCAM	CCAM:26	congenital cystic adenomatoid malformation of the lung:26:0.8816	0.8816	26
CCAP	CCAP:36	crustacean cardioactive peptide:36:0.9174	0.9174	36
CCAT	CCAT:12	common carotid artery thrombosis:12:0.7571	0.7571	12
CCAVB	CCAVB:9	congenital complete atrioventricular block:9:0.6794	0.6794	9
CCAO	CCAO:9|CCAo:1|CCA-O:1	common carotid artery occlusion:11:0.7357	0.7357	11
CCAs	CCAs:8	calcium channel antagonists:8:0.6411	0.6411	8
CCA	CCA:11	Canonical correlation analysis:11:0.7357	0.7357	11
CCA	CCA:19	canonical correspondence analysis:19:0.7658	0.7658	19
CCA	CCA:8	cerebellar cortical atrophy:8:0.5006	0.5006	8
CCA	CCA:12	chick cell-agglutinating:12:0.7571	0.7571	12
CCA	CCA:35|CCa:1	Cholangiocarcinoma:36:0.0309	0.0309	36
CCA	CCA:33	chromated copper arsenate:33:0.9011	0.9011	33
CCA	CCA:8	Clear cell acanthoma:8:0.6411	0.6411	8
CCA	CCA:17	clear cell adenocarcinoma:17:0.8270	0.8270	17
CCA	CCA:6	Closed-circuit anesthesia:6:0.1320	0.1320	6
CCA	CCA:23	Common carotid:23:0.8038	0.8038	23
CCA	CCA:9	common carotid arterial:9:0.6794	0.6794	9
CCA	CCA:411	common carotid artery:369:0.9638|common carotid arteries:42:0.8263	0.9638	411
CCA	CCA:30	congenital contractural arachnodactyly:30:0.9011	0.9011	30
CCA	CCA:6	conjugated cholic acid:6:0.2243	0.2243	6
CCA	CCA:5	conventional cerebral angiography:5:0.1464	0.1464	5
CCA	CCA:6	conventional coronary angiography:6:0.5290	0.5290	6
CCA	CCA:11	conventional cytogenetic analysis:11:0.7357	0.7357	11
CCA	CCA:13	cortical cerebellar atrophy:13:0.4849	0.4849	13
CCA	CCA:6	cyclohexane carboxylic acid:6:0.2243	0.2243	6
CCA	CCA:18	Lobenzarit disodium:18:0.6577	0.6577	18
CCBF	CCBF:8	common carotid blood flow:8:0.6411	0.6411	8
CCBs	CCBs:176	calcium channel blockers:176:0.9477	0.9477	176
CCB	CCB:158	calcium channel blockers:91:0.9158|calcium channel blocker:67:0.8495	0.9158	158
CCB	CCB:9	cytochalasin B:9:0.6794	0.6794	9
CCCD	CCCD:6	centrifugal counter-current distribution:6:0.5290	0.5290	6
CCCD	CCCD:8	Centrifugal countercurrent distribution:8:0.6411	0.6411	8
CCCP	CCCP:39	carbonyl cyanide m-chlorophenyl hydrazone:23:0.8715|carbonyl cyanide m-chlorophenyl-hydrazone:16:0.8165	0.8715	39
CCCP	CCCP:178|cccp:1	carbonyl cyanide m-chlorophenylhydrazone:179:0.9648	0.9648	179
CCCP	CCCP:18	carbonylcyanide-m-chlorophenylhydrazone:18:0.0383	0.0383	18
CCCs	CCCs:4	child care centers:4:0.1618	0.1618	4
CCCs	CCCs:8	cholangiocellular carcinomas:8:0.4102	0.4102	8
CCCT	CCCT:15	clomiphene citrate challenge test:15:0.8045	0.8045	15
CCDS	CCDS:21	color-coded Duplex sonography:21:0.3767	0.3767	21
CCDs	CCDs:21	cortical collecting ducts:21:0.8594	0.8594	21
CCD	CCD:242	charge-coupled device:237:0.5948|charge coupled devices:5:0.2818	0.5948	242
CCD	CCD:66|Ccd:2	cleidocranial dysplasia:68:0.8889	0.8889	68
CCD	CCD:9	contactless conductivity detection:9:0.6794	0.6794	9
CCD	CCD:12	cortical:12:0.0092	0.0092	12
CCD	CCD:351|cCD:1	cortical collecting duct:285:0.9832|cortical collecting ducts:67:0.9554	0.9832	352
CCD	CCD:8	counter-current distribution:8:0.1125	0.1125	8
CCD	CCD:11	countercurrent distribution:11:0.2280	0.2280	11
CCD	CCD:41	crossed cerebellar diaschisis:41:0.8867	0.8867	41
CCEE	CCEE:9	countries of Central and Eastern Europe:9:0.6794	0.6794	9
CCEI	CCEI:14	Crown-Crisp Experiential Index:14:0.5589	0.5589	14
CCE	CCE:43	capacitative Ca(2+) entry:43:0.8917	0.8917	43
CCE	CCE:51	capacitative Ca2+ entry:51:0.9416	0.9416	51
CCE	CCE:42	Capacitative calcium entry:42:0.8893	0.8893	42
CCE	CCE:14	Cholesterol crystal embolization:14:0.7909	0.7909	14
CCE	CCE:7	citrate cleavage enzyme:7:0.4438	0.4438	7
CCE	CCE:12	cornified cell envelope:12:0.7571	0.7571	12
CCE	CCE:49	Counterflow centrifugal elutriation:49:0.5556	0.5556	49
CCFA	CCFA:8	cycloserine-cefoxitin-fructose agar:8:0.3463	0.3463	8
CCFNI	CCFNI:15	Critical Care Family Needs Inventory:15:0.8045	0.8045	15
CCF	CCF:5	blood flow:5:0.0517	0.0517	5
CCF	CCF:70	carotid-cavernous fistula:40:0.3373|carotid cavernous fistula:21:0.8594|carotid-cavernous fistulas:9:0.2500	0.8594	70
CCF	CCF:33	chronic cardiac failure:33:0.4127	0.4127	33
CCF	CCF:26	congestive cardiac failure:26:0.2951	0.2951	26
CCF	CCF:5	controlled continuous flow:5:0.4422	0.4422	5
CCF	CCF:12|ccf:1	cross-correlation function:13:0.5934	0.5934	13
CCF	CCF:11	fistulae:11:0.0340	0.0340	11
CCG	CCG:16	Cationic colloidal gold:16:0.7261	0.7261	16
CCG	CCG:97	Children's Cancer Group:70:0.5838|Childrens Cancer Group:27:0.1686	0.5838	97
CCHB	CCHB:14	complete congenital heart block:14:0.7909	0.7909	14
CCHB	CCHB:27	congenital complete heart block:27:0.7834	0.7834	27
CCHD	CCHD:27|C-CHD:1	cyanotic congenital heart disease:28:0.7154	0.7154	28
CCHF	CCHF:66|C-CHF:1	Crimean-Congo hemorrhagic fever:67:0.8874	0.8874	67
CCHS	CCHS:14	Canadian Community Health Survey:14:0.7909	0.7909	14
CCHS	CCHS:74	congenital central hypoventilation syndrome:74:0.9361	0.9361	74
CCHs	CCHs:9	cross-correlation histograms:9:0.6794	0.6794	9
CCII	CCII:12	controlled cortical impact injury:12:0.7571	0.7571	12
CCIP	CCIP:9	computer-controlled infusion pump:9:0.6794	0.6794	9
CCIs	CCIs:11	count increments:11:0.7357	0.7357	11
CCI	CCI:24	Charlson comorbidity index:24:0.8115	0.8115	24
CCI	CCI:203	chronic constriction injury:203:0.9479	0.9479	203
CCI	CCI:9	color confusion index:9:0.2757	0.2757	9
CCI	CCI:6	Complete cerebral ischemia:6:0.2827	0.2827	6
CCI	CCI:66	Controlled cortical impact:66:0.9548	0.9548	66
CCI	CCI:37	corrected count increment:25:0.7340|corrected count increments:12:0.5050	0.7340	37
CCI	CCI:7	craniocerebral injuries:7:0.3524	0.3524	7
CCI	CCI:6	patients with chronic cardiac insufficiency:6:0.3728	0.3728	6
CCJ	CCJ:21	junction:21:0.8000	0.8000	21
CCK-8-SE	CCK-8-SE:9	cholecystokinin octapeptide sulfate ester:9:0.6794	0.6794	9
CCK-PZ	CCK-PZ:53	cholecystokinin-pancreozymin:53:0.7222	0.7222	53
CCK-33	CCK-33:18|CCK33:3	cholecystokinin:21:0.6061	0.6061	21
CCK-4	CCK-4:66|CCK4:13	cholecystokinin tetrapeptide:58:0.6113|cholecystokinin-tetrapeptide:21:0.1351	0.6113	79
CCK-8-NS	CCK-8-NS:9|CCK8ns:1|CCK-8NS:1|CCK8NS:1	cholecystokinin octapeptide:12:0.5664	0.5664	12
CCK-8S	CCK-8S:13|CCK-8s:6|CCK8s:2|CCK-8-S:1|CCK8-S:1	sulfated cholecystokinin octapeptide:23:0.4053	0.4053	23
CCK-8S	CCK8S:1|CCK-8S:1	sulfated octapeptide cholecystokinin:2:0.1641	0.1641	2
CCK-8	CCK-8:26|CCK8:1	C-terminal octapeptide of cholecystokinin:27:0.2350	0.2350	27
CCK-8	CCK-8:13|CCK8:9	CCK-octapeptide:22:0.0196	0.0196	22
CCK-8	CCK-8:79|CCK8:7	cholecystokinin-8:86:0.0785	0.0785	86
CCK-8	CCK-8:546|CCK8:86	cholecystokinin octapeptide:511:0.8181|cholecystokinin-octapeptide:121:0.1121	0.8181	632
CCK8	CCK8:2	octapeptide CCK:2:0.6701	0.6701	2
CCK-A	CCK-A:9|CCKA:3	cholecystokinin:12:0.1325	0.1325	12
CCK-A	CCK-A:26	cholecystokinin-A:26:0.3012	0.3012	26
CCK-B	CCK-B:26|CCKB:9	cholecystokinin-B:23:0.2000|cholecystokinin B:12:0.3524	0.3524	35
CCKB	CCKB:10	cholecystokininB:10:0.0818	0.0818	10
CCK-LI	CCK-LI:66|CCKLI:2|CCK-li:2|CCK-Li:1	immunoreactivity:71:0.8642	0.8642	71
CCK-OP	CCK-OP:100|CCKOP:1	cholecystokinin octapeptide:55:0.8882|cholecystokinin-octapeptide:46:0.3333	0.8882	101
CCK-OP	CCK-OP:18	octapeptide of cholecystokinin:18:0.5560	0.5560	18
CCK	CCK:3290|Cck:1	cholecystokinin:3291:0.9419	0.9419	3291
CCK	CCK:17	cholecystokinin-8:17:0.0046	0.0046	17
CCK	CCK:58	cholecystokinin octapeptide:46:0.9353|cholecystokinin-octapeptide:12:0.0032	0.9353	58
CCK	CCK:13	cholecystokinin-pancreozymin:13:0.0035	0.0035	13
CCK	CCK:12	gastrin/cholecystokinin:12:0.0032	0.0032	12
CCL2	CCL2:8	CC chemokine ligand 2:8:0.6411	0.6411	8
CCL39	CCL39:17|CCl39:1|CCL-39:1	Chinese hamster lung fibroblasts:19:0.7044	0.7044	19
CCl4	CCl4:714|CCL4:16|CCl-4:1	carbon tetrachloride:731:0.9912	0.9912	731
CCl4	CCl4:10	carbontetrachloride:10:0.0113	0.0113	10
CCLE	CCLE:10	Chronic Cutaneous Lupus Erythematosus:10:0.7103	0.7103	10
CCLI	CCLI:7	Combined Clinical and Laboratory Index:7:0.3524	0.3524	7
CCLSG	CCLSG:17	Children's Cancer and Leukemia Study Group:17:0.8270	0.8270	17
CCL	CCL:9	canine ceroid-lipofuscinosis:9:0.5006	0.5006	9
CCL	CCL:93|CCl:2	cefaclor:95:0.3521	0.3521	95
CCL	CCL:11	centrocyte-like:11:0.0375	0.0375	11
CCL	CCL:38	cranial cruciate ligament:38:0.8417	0.8417	38
CCMs	CCMs:15	cerebral cavernous malformations:15:0.8045	0.8045	15
CCMV	CCMV:58	cowpea chlorotic mottle virus:58:0.9486	0.9486	58
CCM	CCM:29	Cerebral cavernous malformations:16:0.8165|Cerebral cavernous malformation:13:0.7753	0.8165	29
CCM	CCM:11	chemical cleavage of mismatch:11:0.7571	0.7571	11
CCM	CCM:7	Chronic Care Model:7:0.4438	0.4438	7
CCM	CCM:7	CO2-concentrating mechanism:7:0.1329	0.1329	7
CCM	CCM:22	congestive cardiomyopathy:22:0.6934	0.6934	22
CCM	CCM:9	critical care medicine:9:0.6794	0.6794	9
CCN2	CCN2:9	connective tissue growth factor:9:0.6794	0.6794	9
CCNU	CCNU:111	1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea:111:0.3716	0.3716	111
CCN	CCN:24	central cervical nucleus:24:0.8768	0.8768	24
CCN	CCN:13	cerebrocortical necrosis:13:0.6701	0.6701	13
CCOP	CCOP:24	Community Clinical Oncology Program:24:0.8768	0.8768	24
CCO	CCO:24	cardiac output:24:0.8768	0.8768	24
CCO	CCO:6	common carotid occlusion:6:0.2827	0.2827	6
CCO	CCO:68|CcO:64|cco:1|Cco:1	cytochrome c oxidase:134:0.9777	0.9777	134
CCPA	CCPA:6	adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine:6:0.4153	0.4153	6
CCPA	CCPA:7	agonist 2-chloro-N(6)-cyclopentyladenosine:7:0.3495	0.3495	7
CCPD	CCPD:25	continuous cyclic peritoneal dialysis:25:0.8816	0.8816	25
CCPP	CCPP:20	Contagious caprine pleuropneumonia:20:0.8525	0.8525	20
CCPR	CCPR:56	crypt cell production rate:56:0.9467	0.9467	56
CCPs	CCPs:14	Critical Control Points:14:0.7909	0.7909	14
CCP	CCP:9	Chronic calcific pancreatitis:9:0.6794	0.6794	9
CCP	CCP:24	chronic calcifying pancreatitis:24:0.8768	0.8768	24
CCP	CCP:17	chronic cor pulmonale:17:0.8270	0.8270	17
CCP	CCP:6	classical complement pathway:6:0.5290	0.5290	6
CCP	CCP:46	complement control protein:46:0.8676	0.8676	46
CCP	CCP:6	conditioned cue preference:6:0.5290	0.5290	6
CCP	CCP:18	Cooperative Cardiovascular Project:18:0.8365	0.8365	18
CCP	CCP:10|ccp:5	corpus cavernosum penis:15:0.8045	0.8045	15
CCP	CCP:13	critical closing pressure:13:0.6701	0.6701	13
CCP	CCP:59|CcP:51|ccp:1|Ccp:1	cytochrome c peroxidase:112:0.9310	0.9310	112
CCQ	CCQ:9	Questionnaire:9:0.5000	0.5000	9
CCR1	CCR1:23|CCR-1:1	chemokine receptor 1:24:0.8115	0.8115	24
CCR3	CCR3:29|CCR-3:1	CC chemokine receptor 3:19:0.4852|CC chemokine receptor-3:11:0.4232	0.4852	30
CCR4	CCR4:25	CC chemokine receptor 4:25:0.6873	0.6873	25
CCR5	CCR5:83	CC chemokine receptor 5:83:0.6256	0.6256	83
CCR5	CCR5:8|CCR-5:1	chemokine receptor:9:0.5470	0.5470	9
CCR5	CCR5:6|CCR-5:2	chemokine receptor-5:8:0.2987	0.2987	8
CCR6	CCR6:8	CC chemokine receptor 6:8:0.5006	0.5006	8
CCR7	CCR7:14|CCR-7:2	CC chemokine receptor 7:16:0.4832	0.4832	16
CCRCC	CCRCC:7|CC-RCC:6|ccRCC:2	clear cell renal cell carcinoma:15:0.8045	0.8045	15
CCRCs	CCRCs:11	continuing care retirement communities:11:0.7357	0.7357	11
CCRC	CCRC:24	continuing care retirement community:24:0.8768	0.8768	24
CCRG	CCRG:11	Cooperative Cataract Research Group:11:0.7357	0.7357	11
CCRT	CCRT:14|cCRT:1	concurrent chemoradiotherapy:15:0.4951	0.4951	15
CCRT	CCRT:16	Core Conflictual Relationship Theme:16:0.8165	0.8165	16
CCRs	CCRs:7	complex chromosomal rearrangements:7:0.5926	0.5926	7
CCSE	CCSE:14	Cognitive Capacity Screening Examination:14:0.7909	0.7909	14
CCSG	CCSG:33	Study Group:33:0.9100	0.9100	33
CCSK	CCSK:39	Clear cell sarcoma of the kidney:39:0.9338	0.9338	39
CCSM	CCSM:10	corpus cavernosum smooth muscle:10:0.7103	0.7103	10
CCSP	CCSP:60|ccsp:1	Clara cell secretory protein:61:0.9511	0.9511	61
CCSS	CCSS:12	Childhood Cancer Survivor Study:12:0.7571	0.7571	12
CCS	CCS:52	Canadian Cardiovascular Society:52:0.9099	0.9099	52
CCS	CCS:20	cardiac conduction system:20:0.7766	0.7766	20
CCS	CCS:8	central cord syndrome:8:0.6411	0.6411	8
CCs	CCs:7	chloride cells:7:0.0655	0.0655	7
CCS	CCS:13	chronic cerebellar stimulation:13:0.7909	0.7909	13
CCS	CCS:14	chronic compartment syndrome:14:0.6911	0.6911	14
CCS	CCS:27	Clear cell sarcoma:27:0.8903	0.8903	27
CCS	CCS:10	contrast sensitivity:10:0.7103	0.7103	10
CCS	CCS:8	copper chaperone for SOD1:8:0.4102	0.4102	8
CCS	CCS:2	copper chaperone for the superoxide dismutase:2:0.6411	0.6411	2
CCS	CCS:4	coronary calcium score:4:0.1618	0.1618	4
CCS	CCS:20	Corticosterone:20:0.0368	0.0368	20
CCS	CCS:8|C-C-S:1	Cronkhite-Canada syndrome:9:0.0713	0.0713	9
CCs	CCs:7	cumulus cells:7:0.0655	0.0655	7
CCTDI	CCTDI:10	California Critical Thinking Disposition Inventory:10:0.7103	0.7103	10
CCTGA	CCTGA:19|ccTGA:6|cc-TGA:1|CC-TGA:1	congenitally corrected transposition of the great arteries:27:0.8941	0.8941	27
CCTST	CCTST:9	California Critical Thinking Skills Test:9:0.6794	0.6794	9
CCTV	CCTV:22	closed circuit television:13:0.7753|closed-circuit television:9:0.1585	0.7753	22
CCTs	CCTs:8	cortical collecting tubules:8:0.6411	0.6411	8
CCT	CCT:10	California Consonant Test:10:0.7103	0.7103	10
CCT	CCT:119	Central conduction time:119:0.8744	0.8744	119
CCT	CCT:131	central corneal thickness:131:0.9636	0.9636	131
CCT	CCT:7	chaperonin containing T-complex polypeptide 1:7:0.5926	0.5926	7
CCT	CCT:27	chaperonin containing TCP-1:16:0.8165|chaperonin-containing TCP-1:11:0.1845	0.8165	27
CCT	CCT:16	chemotherapy:16:0.0151	0.0151	16
CCT	CCT:11	computed cranial tomography:11:0.3495	0.3495	11
CCT	CCT:6	Computerized cranial tomography:6:0.0731	0.0731	6
CCT	CCT:10|C-CT:1	conventional CT:11:0.2154	0.2154	11
CCT	CCT:12	cortical:12:0.0111	0.0111	12
CCT	CCT:142	cortical collecting tubule:94:0.9682|cortical collecting tubules:48:0.9379	0.9682	142
CCT	CCT:42|cCT:1	cranial computed tomography:43:0.4998	0.4998	43
CCT	CCT:17|cCT:3	Cranial computerized tomography:20:0.7173	0.7173	20
CCT	CCT:30	craniocerebral trauma:30:0.7012	0.7012	30
CCT	CCT:9	crude coal tar:9:0.5470	0.5470	9
CCT	CCT:28	CTP:phosphocholine cytidylyltransferase:28:0.4668	0.4668	28
CCUs	CCUs:30	Coronary care units:30:0.6252	0.6252	30
CCU	CCU:9	color-changing units:9:0.0735	0.0735	9
CCU	CCU:247	Coronary Care Unit:226:0.7880|coronary care units:21:0.6812	0.7880	247
CCVs	CCVs:41	clathrin-coated vesicles:41:0.7952	0.7952	41
CCV	CCV:48	canine coronavirus:48:0.9379	0.9379	48
CCV	CCV:28	channel catfish virus:28:0.8941	0.8941	28
CCV	CCV:18	clathrin-coated vesicles:9:0.3069|clathrin-coated vesicle:9:0.6794	0.6794	18
CCaMK	CCaMK:11	protein kinase:11:0.7357	0.7357	11
CCl(4)	CCl(4):109|CCL(4):1	carbon tetrachloride:110:0.9567	0.9567	110
CCoV	CCoV:11	canine coronavirus:11:0.7357	0.7357	11
Ccreat	Ccreat:7|CCreat:3	creatinine clearance:10:0.7103	0.7103	10
CC	CC:12	cage control:12:0.1423	0.1423	12
CC	CC:23	calcium carbonate:23:0.7500	0.7500	23
CC	CC:7	calf circumference:7:0.0951	0.0951	7
CC	CC:13	carcinomas:13:0.0037	0.0037	13
CC	CC:18	cardiac catheterization:18:0.7539	0.7539	18
CC	CC:14	cell culture:14:0.3813	0.3813	14
CC	CC:5	central complex:5:0.0736	0.0736	5
CC	CC:6|cc:3|Cc:3	centrocytic:12:0.0034	0.0034	12
CC	CC:59|Cc:2|cc:1	cerebral cortex:62:0.6114	0.6114	62
CC	CC:43	cervical cancer:43:0.4320	0.4320	43
CC	CC:15	cervical carcinoma:15:0.2189	0.2189	15
CC	CC:11|cc:1	chest circumference:12:0.3275	0.3275	12
CC	CC:14|Cc:1	chloride:15:0.0044	0.0044	15
CC	CC:14	cholangiocarcinomas:14:0.0041	0.0041	14
CC	CC:22	choledochal cyst:22:0.7400	0.7400	22
CC	CC:12	chondrocalcinosis:12:0.0034	0.0034	12
CC	CC:12	choriocapillaris:12:0.0034	0.0034	12
CC	CC:13	choriocarcinoma:13:0.0037	0.0037	13
CC	CC:12	circulation:12:0.0034	0.0034	12
CC	CC:9	Clear cell:9:0.1809	0.1809	9
CC	CC:10|cc:1	clomiphene:11:0.0031	0.0031	11
CC	CC:369	clomiphene citrate:369:0.9440	0.9440	369
CC	CC:39	closing capacity:39:0.7860	0.7860	39
CC	CC:16|C-C:1	coiled-coil:17:0.0050	0.0050	17
CC	CC:26	Collagenous colitis:26:0.5840	0.5840	26
CC	CC:9|cc:1	colloidal carbon:10:0.7103	0.7103	10
CC	CC:14	colon cancer:14:0.0835	0.0835	14
CC	CC:13	colorectal cancer:13:0.0732	0.0732	13
CC	CC:15	common carotid:15:0.8045	0.8045	15
CC	CC:7	community care:7:0.0886	0.0886	7
CC	CC:12	complete chimerism:12:0.3524	0.3524	12
CC	CC:6	complete donor chimerism:6:0.5290	0.5290	6
CC	CC:12	compliance coefficient:12:0.0983	0.0983	12
CC	CC:6	contractile component:6:0.2243	0.2243	6
CC	CC:16|C-C:1	controls:17:0.0053	0.0053	17
CC	CC:7|C-C:2	control group:9:0.3069	0.3069	9
CC	CC:6	conventional chemotherapy:6:0.1543	0.1543	6
CC	CC:6	conventional cholecystectomy:6:0.1838	0.1838	6
CC	CC:13	conventional colonoscopy:13:0.7753	0.7753	13
CC	CC:27	Conventional cytogenetics:27:0.8312	0.8312	27
CC	CC:7	coronary calcification:7:0.2452	0.2452	7
CC	CC:8	Coronary calcium:8:0.5006	0.5006	8
CC	CC:34|cc:1	corpora cardiaca:35:0.9151	0.9151	35
CC	CC:13	corpora cavernosa:13:0.6701	0.6701	13
CC	CC:219|cc:3	corpus callosum:222:0.9865	0.9865	222
CC	CC:19	corpus cardiacum:19:0.7658	0.7658	19
CC	CC:50|cc:1	corpus cavernosum:51:0.9082	0.9082	51
CC	CC:35|cc:6	correlation coefficient:30:0.4199|correlation coefficients:11:0.3213	0.4199	41
CC	CC:8|C-C:3	cranio-caudal:11:0.0031	0.0031	11
CC	CC:22	craniocaudal:22:0.0066	0.0066	22
CC	CC:25	creatinine clearance:25:0.6873	0.6873	25
Cc	Cc:5|CC:1	critical concentration:6:0.0731	0.0731	6
CC	CC:9	Cross-correlation:9:0.0025	0.0025	9
CC	CC:6	cross-sectional compliance:6:0.0731	0.0731	6
CC	CC:11	cryptogenic cirrhosis:11:0.5355	0.5355	11
CC	CC:12	cumulus cells:12:0.1028	0.1028	12
CC	CC:8|cC:1|Cc:1	Cyclocytidine:10:0.0028	0.0028	10
Cc	Cc:13|CC:6|cc:2	cytochrome C:21:0.2743	0.2743	21
CC	CC:9	nisoldipine coat core:9:0.5470	0.5470	9
CD-RAP	CD-RAP:17	cartilage-derived retinoic acid-sensitive protein:17:0.7407	0.7407	17
CD13	CD13:41|CD-13:1	aminopeptidase N:42:0.8558	0.8558	42
CD14	CD14:6	LPS receptor:6:0.1004	0.1004	6
CD16	CD16:9	Fc gamma receptor III:9:0.6794	0.6794	9
CD16	CD16:8	Fc gammaRIII:8:0.6794	0.6794	8
CD16	CD16:12	Fc receptor:12:0.2293	0.2293	12
CD16	CD16:30	FcgammaRIII:30:0.0689	0.0689	30
CD16	CD16:7	receptor type III:7:0.3524	0.3524	7
CD18	CD18:5	beta2 integrins:5:0.0612	0.0612	5
CD18	CD18:8|CD-18:1	common beta-chain:9:0.1945	0.1945	9
CD18	CD18:7	common beta subunit:7:0.1850	0.1850	7
CD1	CD1:15|cD1:1	cyclin D1:16:0.5564	0.5564	16
CD21	CD21:5	receptor type 2:5:0.4422	0.4422	5
CD23	CD23:24	low-affinity IgE receptor:12:0.2414|low affinity IgE receptor:12:0.7571	0.7571	24
CD23	CD23:25	receptor for IgE:25:0.5409	0.5409	25
CD25+	CD25+:7	activated T cells:7:0.6411	0.6411	7
CD25	CD25:28	IL-2 receptor alpha chain:17:0.3857|IL-2 receptor alpha-chain:11:0.4444	0.4444	28
CD25	CD25:10	IL-2R alpha chain:10:0.1053	0.1053	10
CD25	CD25:46	interleukin-2 receptor:38:0.1635|interleukin-2 receptors:8:0.1125	0.1635	46
CD25	CD25:7	receptor alpha:7:0.0951	0.0951	7
CD26	CD26:36|CD-26:1	dipeptidyl peptidase IV:37:0.8749	0.8749	37
CD28RE	CD28RE:11	CD28 response element:11:0.7357	0.7357	11
CD29	CD29:6	beta1 integrin:6:0.1010	0.1010	6
CD2AP	CD2AP:24	CD2-associated protein:24:0.7500	0.7500	24
CD2	CD2:9	receptor:9:0.0611	0.0611	9
CD32	CD32:20	FcgammaRIIa:20:0.0960	0.0960	20
CD34+	CD34+:30	CD34-positive:18:0.1504|CD34 positive:12:0.4557	0.4557	30
CD34+	CD34+:12	progenitor:12:0.0973	0.0973	12
CD34+	CD34+:19	progenitor cells:19:0.4618	0.4618	19
CD34	CD34:10	progenitor cell antigen:10:0.5856	0.5856	10
CD36	CD36:2	Expression of the thrombospondin receptor:2:0.0918	0.0918	2
CD36	CD36:15	glycoprotein IV:15:0.5348	0.5348	15
CD4+	CD4+:17	CD4-positive:17:0.0437	0.0437	17
CD4+	CD4+:29	helper/inducer:29:0.0820	0.0820	29
CD4+	CD4+:9	helper T cells:9:0.2285	0.2285	9
CD4+	CD4+:5	T helper lymphocytes:5:0.1973	0.1973	5
CD43	CD43:36	leukosialin:36:0.3402	0.3402	36
CD43	CD43:23	sialophorin:23:0.2165	0.2165	23
CD437	CD437:7	synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid:7:0.5000	0.5000	7
CD44H	CD44H:4	standard form of CD44:4:0.2818	0.2818	4
CD44s	CD44s:5	CD44 standard isoform:5:0.2818	0.2818	5
CD44s	CD44s:19|CD44S:3	standard form of CD44:22:0.7500	0.7500	22
CD44v	CD44v:16|CD44-V:1	variant isoforms:17:0.6211	0.6211	17
CD44	CD44:8	lymphocyte homing receptor:8:0.2987	0.2987	8
CD45	CD45:6	leucocyte common:6:0.0902	0.0902	6
CD45	CD45:63	leukocyte common antigen:63:0.6847	0.6847	63
CD4bs	CD4bs:10|CD4BS:3	CD4 binding site:13:0.6701	0.6701	13
CD4i	CD4i:9	CD4-induced:9:0.7273	0.7273	9
CD4	CD4:23	anti-L3T4:23:0.0494	0.0494	23
CD4	CD4:16	receptor:16:0.0322	0.0322	16
CD4	CD4:12	T helper cells:12:0.5050	0.5050	12
CD4	CD4:5	T helper/inducer:5:0.0611	0.0611	5
CD50	CD50:7	convulsant dose:7:0.1211	0.1211	7
CD54	CD54:10	intercellular adhesion molecule (ICAM)-1:10:0.5856	0.5856	10
CD56	CD56:11	neural cell adhesion molecule:11:0.7357	0.7357	11
CD59	CD59:7	membrane inhibitor of reactive lysis:7:0.5006	0.5006	7
CD61	CD61:6	glycoprotein IIIa:6:0.1543	0.1543	6
CD73	CD73:16	ecto-5'-nucleotidase:16:0.6250	0.6250	16
CD8+	CD8+:12	cytotoxic:12:0.0404	0.0404	12
CD8+	CD8+:7	cytotoxic T lymphocytes:7:0.2452	0.2452	7
CD89	CD89:7	IgA Fc receptor:7:0.2902	0.2902	7
CD8	CD8:15	anti-Lyt-2.2:15:0.0460	0.0460	15
CD8	CD8:9	cytotoxic/suppressor:9:0.0245	0.0245	9
CD8	CD8:16	suppressor/cytotoxic:16:0.0460	0.0460	16
CDAA	CDAA:13	choline-deficient L-amino acid-defined:13:0.8472	0.8472	13
CDAD	CDAD:36	Clostridium difficile-associated diarrhea:36:0.5563	0.5563	36
CDAD	CDAD:21|CdAD:1	Clostridium difficile-associated diarrhoea:22:0.5863	0.5863	22
CDAD	CDAD:14	Clostridium difficile-associated disease:14:0.3585	0.3585	14
CDA-II	CDA-II:9	congenital dyserythropoietic anemia type II:9:0.6794	0.6794	9
CDAI	CDAI:146	Crohn's Disease Activity Index:146:0.9289	0.9289	146
CDAS	CDAS:12	Dental Anxiety Scale:12:0.7571	0.7571	12
CdA	CdA:29|CDA:2	2-chloro-2'-deoxyadenosine:31:0.0628	0.0628	31
CdA	CdA:42|CDA:2	2-Chlorodeoxyadenosine:44:0.0931	0.0931	44
CDA	CDA:10	calcium-dependent antibiotic:10:0.5000	0.5000	10
CDA	CDA:11	California Dental Association:11:0.6182	0.6182	11
CDA	CDA:4	canonical discriminant analysis:4:0.0918	0.0918	4
CDA	CDA:7	cellulose diacetate:7:0.2902	0.2902	7
CDA	CDA:7	chenodeoxycholic acid:7:0.2452	0.2452	7
CDA	CDA:7	Chloride-depletion alkalosis:7:0.1641	0.1641	7
CDA	CDA:4	chloride-depletion metabolic alkalosis:4:0.0918	0.0918	4
CdA	CdA:15|CDA:2	cladribine:17:0.0346	0.0346	17
CDA	CDA:17	Clinical Document Architecture:17:0.8270	0.8270	17
CDA	CDA:1	cold dry air:1:0.7753	0.7753	1
CDA	CDA:35	congenital dyserythropoietic anaemia:35:0.9126	0.9126	35
CDA	CDA:39	congenital dyserythropoietic anemia:39:0.9237	0.9237	39
CDA	CDA:31|CdA:1	cytidine deaminase:32:0.9072	0.9072	32
CDBD	CDBD:7	Congenital dilatation of the bile duct:7:0.6411	0.6411	7
CdB	CdB:4|Cd-B:2	blood cadmium:6:0.1148	0.1148	6
Cd-B	Cd-B:6|CdB:5	Cadmium in blood:11:0.2549	0.2549	11
CDCA	CDCA:12	chenodeoxycholate:12:0.0342	0.0342	12
CDCA	CDCA:259	chenodeoxycholic acid:259:0.9133	0.9133	259
CDCH	CDCH:14	ovulation hormone:14:0.4709	0.4709	14
CDCs	CDCs:18	caudodorsal cells:18:0.3857	0.3857	18
CDC	CDC:15	Caudo-Dorsal Cells:15:0.3110	0.3110	15
CDC	CDC:11	caudodorsal cells:11:0.1760	0.1760	11
cdc	cdc:42|CDC:8|Cdc:2	cell division cycle:52:0.9427	0.9427	52
CDC	CDC:1	Center Disease Control:1:0.1196	0.1196	1
CDC	CDC:485	Centers for Disease Control:485:0.7731	0.7731	485
CDC	CDC:964	Centers for Disease Control and Prevention:925:0.9563|Centers for Disease Control and Prevention's:39:0.8455	0.9563	964
CDC	CDC:16	chenodeoxycholate:16:0.0070	0.0070	16
CDC	CDC:14	chenodeoxycholic:14:0.0061	0.0061	14
CDC	CDC:32	chenodeoxycholic acid:32:0.7458	0.7458	32
CDC	CDC:26	collecting duct carcinoma:26:0.7340	0.7340	26
CDC	CDC:126	Complement-dependent cytotoxicity:104:0.7082|complement dependent cytotoxicity:22:0.8657	0.8657	126
CDC	CDC:13	Disease Control's:13:0.7753	0.7753	13
CDDP	CDDP:9|cDDP:1	cis-diaminedichloroplatinum:10:0.0041	0.0041	10
CDDP	CDDP:16	cis-diammine-dichloroplatinum:16:0.0068	0.0068	16
CDDP	CDDP:145|cDDP:4|c-DDP:2	cis-diamminedichloroplatinum:151:0.0672	0.0672	151
CDDP	CDDP:123|cDDP:15|c-DDP:10	cis-diamminedichloroplatinum(II):137:0.0622|cis-Diamminedichloroplatinum II:11:0.5999	0.5999	148
CDDP	CDDP:11	cis-dichlorodiammine platinum:11:0.1430	0.1430	11
CDDP	CDDP:17	cis-dichlorodiammineplatinum:17:0.0073	0.0073	17
CDDP	CDDP:80|C-DDP:1|cDDP:1|c-DDP:1	cis-platinum:83:0.0368	0.0368	83
CDDP	CDDP:66|c-DDP:2	Cisplatinum:68:0.0304	0.0304	68
CD-DST	CD-DST:8|CDDST:1	collagen gel droplet embedded culture drug sensitivity test:9:0.6794	0.6794	9
CDDs	CDDs:17	chlorinated dibenzo-p-dioxins:17:0.8165	0.8165	17
CDD	CDD:9	cardiodilatin:9:0.0417	0.0417	9
CDD	CDD:9	Childhood disintegrative disorder:9:0.6794	0.6794	9
CDD	CDD:10	choledochoduodenostomy:10:0.0469	0.0469	10
CDD	CDD:10	Control of Diarrhoeal Diseases:10:0.7103	0.7103	10
CDD	CDD:17|cdd:5	cytidine deaminase:22:0.8657	0.8657	22
CDEI	CDEI:10	DNA element I:10:0.7103	0.7103	10
CDER	CDER:15	Center for Drug Evaluation and Research:15:0.8045	0.8045	15
CDF/LIF	CDF/LIF:6	cholinergic differentiation factor/leukemia inhibitory factor:6:0.3728	0.3728	6
CDFF	CDFF:10	film fermenter:10:0.7103	0.7103	10
CDFI	CDFI:48	color Doppler flow imaging:48:0.6918	0.6918	48
CDF	CDF:13	Cartilage-derived factor:13:0.1299	0.1299	13
CDF	CDF:23	cation diffusion facilitator:23:0.8715	0.8715	23
CDF	CDF:9|Cdf:2	Chlordimeform:11:0.0562	0.0562	11
CDGE	CDGE:30	constant denaturant gel electrophoresis:30:0.9011	0.9011	30
CDG-Ia	CDG-Ia:8	congenital disorder of glycosylation type IA:8:0.6411	0.6411	8
CDGP	CDGP:19	constitutional delay of growth and puberty:19:0.8768	0.8768	19
CDGP	CDGP:14	Nedaplatin:14:0.3250	0.3250	14
CDG	CDG:34	carbohydrate-deficient glycoprotein:34:0.6811	0.6811	34
CDG	CDG:53	Congenital disorders of glycosylation:53:0.9438	0.9438	53
CDH1	CDH1:26|Cdh1:1	E-cadherin gene:27:0.6973	0.6973	27
CDHP	CDHP:22	5-chloro-2,4-dihydroxypyridine:22:0.4038	0.4038	22
CDH	CDH:44	cellobiose dehydrogenase:44:0.6867	0.6867	44
CDH	CDH:9	ceramide dihexoside:9:0.4587	0.4587	9
CDH	CDH:95	chronic daily headache:95:0.9685	0.9685	95
CDH	CDH:635	congenital diaphragmatic hernia:621:0.9702|congenital diaphragmatic hernias:14:0.5589	0.9702	635
CDH	CDH:88	congenital dislocation of the hip:88:0.9296	0.9296	88
CDH	CDH:15	congenital dysplasia of the hip:15:0.5818	0.5818	15
CDH	CDH:9	cutaneous delayed hypersensitivity:9:0.6794	0.6794	9
CDIs	CDIs:5	cyclin-dependent kinase inhibitors:5:0.2818	0.2818	5
CDI	CDI:16	1,1'-carbonyldiimidazole:16:0.0249	0.0249	16
CDI	CDI:6	Ca(2+)-dependent inactivation:6:0.2243	0.2243	6
CDI	CDI:45	central diabetes insipidus:45:0.8115	0.8115	45
CDI	CDI:103	Children's Depression Inventory:103:0.7167	0.7167	103
CDI	CDI:113	Color Doppler imaging:113:0.6412	0.6412	113
CDI	CDI:30	Cotrel-Dubousset instrumentation:30:0.7315	0.7315	30
CDI	CDI:4	cyclin-dependent kinase inhibitor:4:0.1618	0.1618	4
CDJ	CDJ:11	choledochojejunostomy:11:0.3704	0.3704	11
CDJ	CDJ:13	junction:13:0.4444	0.4444	13
Cdk1	Cdk1:12|CDK1:11|cdk1:5|cdk-1:1	cyclin-dependent kinase 1:29:0.7154	0.7154	29
CDK9	CDK9:7|Cdk9:5|cdk9:1	cyclin-dependent kinase 9:13:0.6701	0.6701	13
CDKIs	CDKIs:47|CDK-Is:2|cdkis:1	cyclin-dependent kinase inhibitors:50:0.7902	0.7902	50
CDKI	CDKI:54|cdki:7|CDK-I:4|CDKi:4|CdKI:1|CdkI:1	cyclin-dependent kinase inhibitor:60:0.7855|cyclin-dependent kinase inhibitors:11:0.4728	0.7855	71
CDK	CDK:9	Climatic droplet keratopathy:9:0.6794	0.6794	9
CDK	CDK:501|cdk:229|Cdk:207|CdK:5	cyclin-dependent kinase:791:0.8012|cyclin-dependent kinases:128:0.7158|cyclin dependent kinases:23:0.8038	0.8038	942
CDLE	CDLE:9	chronic discoid lupus erythematosus:9:0.6794	0.6794	9
CDLQI	CDLQI:12	Children's Dermatology Life Quality Index:12:0.7357	0.7357	12
CDMA	CDMA:11	code division multiple access:11:0.7357	0.7357	11
CD-MPR	CD-MPR:23|CDMPR:1	cation-dependent mannose 6-phosphate receptor:24:0.8816	0.8816	24
CDMPs	CDMPs:8	cartilage-derived morphogenetic proteins:8:0.5006	0.5006	8
CDMS	CDMS:28|CD-MS:1	clinically definite MS:29:0.7970	0.7970	29
CDMS	CDMS:22	clinically definite multiple sclerosis:22:0.8657	0.8657	22
CDM	CDM:57	chemically defined medium:57:0.8920	0.8920	57
CDNB	CDNB:304	1-chloro-2,4-dinitrobenzene:304:0.8118	0.8118	304
CDOM	CDOM:12|cDOM:1	dissolved organic matter:13:0.7753	0.7753	13
CdO	CdO:14	cadmium oxide:14:0.7909	0.7909	14
CDO	CDO:29	cysteine dioxygenase:29:0.7970	0.7970	29
CDO	CDO:10	duodenal obstruction:10:0.7103	0.7103	10
CDP/cut	CDP/cut:11|CDP/Cut:1	CCAAT displacement protein:12:0.7571	0.7571	12
CDP-DG	CDP-DG:8|CDPDG:1	CDP-diacylglycerol:9:0.4706	0.4706	9
CDPH	CDPH:14	Department of Public Health:14:0.7909	0.7909	14
CDPKs	CDPKs:46	protein kinases:46:0.9353	0.9353	46
CDPs	CDPs:11	Cord dorsum potentials:11:0.7357	0.7357	11
CDPX	CDPX:9	chondrodysplasia punctata:9:0.6794	0.6794	9
CDPX2	CDPX2:10	X-linked dominant chondrodysplasia punctata:10:0.7103	0.7103	10
CDP	CDP:27	CCAAT displacement protein:27:0.7834	0.7834	27
CDP	CDP:172	chlordiazepoxide:172:0.3239	0.3239	172
CDP	CDP:9	chloroquine diphosphate:9:0.1267	0.1267	9
CDP	CDP:13	Chondrodysplasia punctata:13:0.6701	0.6701	13
CDP	CDP:9	collagenase-digestible:9:0.0152	0.0152	9
CDP	CDP:21	computerized dynamic posturography:21:0.6400	0.6400	21
CDP	CDP:6	constitutional delay of puberty:6:0.5290	0.5290	6
CDP	CDP:5	constitutional delayed puberty:5:0.4422	0.4422	5
CDP	CDP:10	continuous distending pressure:10:0.5000	0.5000	10
CDP	CDP:11	cord dorsum potential:11:0.7357	0.7357	11
CDP	CDP:9	cytidine 5'-diphosphate:9:0.6794	0.6794	9
CDP	CDP:12	Cytidine diphosphate:12:0.2293	0.2293	12
CDP	CDP:11	decongestive physiotherapy:11:0.5355	0.5355	11
CDP	CDP:13	incorporation of [3H]proline into collagenase-digestible protein:13:0.7753	0.7753	13
CDR2	CDR2:12|CDR-2:1	complementarity-determining region 2:13:0.3331	0.3331	13
CDR2	CDR2:7	second complementarity determining region:7:0.5926	0.5926	7
CDR3	CDR3:185|CDR-3:2	complementarity-determining region 3:114:0.4274|Complementarity determining region 3:73:0.6018	0.6018	187
CDR3	CDR3:23	complementary determining region 3:23:0.1314	0.1314	23
CDR3	CDR3:97|CDR-3:2	third complementarity-determining region:49:0.8034|third complementarity determining region:32:0.7782|third complementarity determining regions:12:0.6460|third complementarity-determining regions:6:0.3728	0.8034	99
CDRS-R	CDRS-R:9	Children's Depression Rating Scale-Revised:9:0.5470	0.5470	9
CDRS	CDRS:15	Rating Scale:15:0.8045	0.8045	15
Cdr	Cdr:6|CdR:4|Cd-R:1	cadmium-resistant:11:0.0155	0.0155	11
CDR	CDR:120	Clinical Dementia Rating:120:0.9606	0.9606	120
CDR	CDR:25	Clinical Dementia Rating scale:25:0.8816	0.8816	25
CDR	CDR:15	Cognitive Drug Research:15:0.7096	0.7096	15
CDR	CDR:235	complementarity-determining region:76:0.3439|complementarity determining region:73:0.7360|complementarity-determining regions:47:0.3772|complementarity determining regions:39:0.7602	0.7602	235
CDR	CDR:5	confluence dependent resistance:5:0.4422	0.4422	5
CDR	CDR:6	crude death rate:6:0.5290	0.5290	6
CdR	CdR:20	deoxycytidine:20:0.0294	0.0294	20
CDR	CDR:7	regulator protein:7:0.2113	0.2113	7
CDSN	CDSN:10|Cdsn:2	Corneodesmosin:12:0.6875	0.6875	12
CDSSs	CDSSs:12	clinical decision support systems:12:0.5664	0.5664	12
CDSS	CDSS:15	Calgary Depression Scale for Schizophrenia:15:0.8045	0.8045	15
CDSS	CDSS:16	Clinical Decision Support System:16:0.4536	0.4536	16
CDSs	CDSs:24	coding sequences:24:0.6122	0.6122	24
CDSS	CDSS:15	decision support systems:15:0.8045	0.8045	15
CDS	CDS:10	allogeneic cultured dermal substitute:10:0.4363	0.4363	10
CdS	CdS:12	cadmium sulfide:12:0.7571	0.7571	12
CDS	CDS:10	Calgary Depression Scale:10:0.3145	0.3145	10
CDS	CDS:8	CDP-diacylglycerol synthase:8:0.3463	0.3463	8
CDS	CDS:10	cervical dentine sensitivity:10:0.6794	0.6794	10
CDS	CDS:41	chemical delivery system:27:0.8369|chemical delivery systems:14:0.4709	0.8369	41
CDS	CDS:15	Chronic Disease Score:15:0.8045	0.8045	15
CDS	CDS:7	Clinical Decision Support:7:0.3524	0.3524	7
CDS	CDS:42	clonidine-displacing substance:32:0.6024|clonidine displacing substance:10:0.7103	0.7103	42
CDS	CDS:27|cds:3	coding sequences:15:0.4951|coding sequence:15:0.4609	0.4951	30
CDS	CDS:36	Color Doppler sonography:36:0.4956	0.4956	36
CDS	CDS:7	color duplex sonography:7:0.1025	0.1025	7
CDS	CDS:20	Community Dental Service:20:0.7766	0.7766	20
CDs	CDs:11	conjugated dienes:11:0.7357	0.7357	11
CDs	CDs:165|Cds:1|cds:1	cyclodextrins:167:0.2029	0.2029	167
CDS	CDS:10	duplex scanning:10:0.7103	0.7103	10
CDS	CDS:7|cds:1|cDS:1	syndrome:9:0.0097	0.0097	9
CDTI	CDTI:20	community-directed treatment with ivermectin:20:0.7766	0.7766	20
CDTR	CDTR:15	cefditoren:15:0.8750	0.8750	15
CDTR-PI	CDTR-PI:9	cefditoren pivoxil:9:0.6794	0.6794	9
CDTs	CDTs:12	cytolethal distending toxins:12:0.7571	0.7571	12
CDT	CDT:272	carbohydrate-deficient transferrin:272:0.8077	0.8077	272
CDT	CDT:36	Clock Drawing Test:36:0.9174	0.9174	36
CDT	CDT:5	contralateral descended testis:5:0.4422	0.4422	5
CDT	CDT:7	Cystic dysplasia of the testis:7:0.5926	0.5926	7
CDT	CDT:77|Cdt:11|cdt:4	cytolethal distending toxin:92:0.9668	0.9668	92
CDUS	CDUS:19	color Doppler ultrasonography:19:0.4405	0.4405	19
CDUS	CDUS:20|CD-US:1	color Doppler ultrasound:21:0.4733	0.4733	21
Cd-U	Cd-U:6|CdU:2	cadmium in urine:8:0.1585	0.1585	8
CDU	CDU:24	color Doppler ultrasonography:24:0.5370	0.5370	24
CDU	CDU:16	color Doppler ultrasound:8:0.1730|colour Doppler ultrasound:8:0.1730	0.1730	16
CDU	CDU:5	color duplex ultrasound:5:0.1132	0.1132	5
Cd-U	Cd-U:5|CdU:3	urinary cadmium:8:0.2619	0.2619	8
CDV	CDV:7	canine distemper:7:0.3524	0.3524	7
CDV	CDV:398	canine distemper virus:398:0.9663	0.9663	398
CDV	CDV:37	cidofovir:37:0.0744	0.0744	37
CDW	CDW:30	charge-density-wave:11:0.2083|charge-density wave:10:0.2446|charge density wave:9:0.6794	0.6794	30
CDX	CDX:14	cefadroxil:14:0.2955	0.2955	14
CDX	CDX:11	chlordiazepoxide:11:0.2273	0.2273	11
CDZM	CDZM:26	cefodizime:26:0.8929	0.8929	26
CDZ	CDZ:9	Calmidazolium:9:0.1569	0.1569	9
CDZ	CDZ:13	cefodizime:13:0.2353	0.2353	13
CDZ	CDZ:18|Cdz:1	chlordiazepoxide:19:0.3529	0.3529	19
CD	CD:9	alpha-cyclodextrin:9:0.0008	0.0008	9
CD	CD:35	beta-cyclodextrin:35:0.0034	0.0034	35
CD	CD:12	cadaver donor:12:0.1907	0.1907	12
CD	CD:17	cadaveric donor:17:0.3512	0.3512	17
Cd	Cd:1213|CD:11|cd:1	cadmium:1225:0.1218	0.1218	1225
Cd	Cd:17|CD:6	cadmium chloride:23:0.8715	0.8715	23
CD	CD:21|Cd:1	Campomelic dysplasia:22:0.1936	0.1936	22
CD	CD:22	canine distemper:22:0.7955	0.7955	22
CD	CD:41	Capillary density:41:0.5040	0.5040	41
CD	CD:10	carbidopa:10:0.0009	0.0009	10
CD	CD:13	cardiac death:13:0.3554	0.3554	13
CD	CD:10	cardiac-denervated:10:0.0009	0.0009	10
CD	CD:5	cardiac denervation:5:0.0517	0.0517	5
CD	CD:16|cd:3	catalytic domain:19:0.2759	0.2759	19
CD	CD:83	Cathepsin D:83:0.2385	0.2385	83
Cd	Cd:10|CD:3	caudate:13:0.0012	0.0012	13
Cd	Cd:26|CD:15	caudate nucleus:41:0.9274	0.9274	41
CD	CD:6	cell death:6:0.0522	0.0522	6
CD	CD:8	cerebellar degeneration:8:0.2987	0.2987	8
CD	CD:58	cervical dystonia:58:0.8937	0.8937	58
CD	CD:10	cesarean delivery:10:0.3470	0.3470	10
CD	CD:6	characteristic delay:6:0.0611	0.0611	6
CD	CD:54|Cd:4	chlordecone:58:0.0057	0.0057	58
CD	CD:9	choline deficiency:9:0.2102	0.2102	9
CD	CD:16	choline-devoid:16:0.0015	0.0015	16
CD	CD:11	choroidal detachment:11:0.5355	0.5355	11
CD	CD:118|cd:1	circular dichroic:119:0.9749	0.9749	119
CD	CD:2419|cd:2	circular dichroism:2421:0.9928	0.9928	2421
CD	CD:26	circular dichroism spectroscopy:26:0.8861	0.8861	26
CD	CD:15|Cd:3	Clostridium difficile:18:0.8365	0.8365	18
CD	CD:16	cluster designation:16:0.7261	0.7261	16
CD	CD:61	cluster of differentiation:46:0.5719|Clusters of Differentiation:15:0.0865	0.5719	61
CD	CD:5	cocaine dependent:5:0.1132	0.1132	5
CD	CD:5	coefficient of dispersion:5:0.0612	0.0612	5
CD	CD:86	collecting duct:68:0.6896|collecting ducts:18:0.8365	0.8365	86
CD	CD:6	colloidal dispersion:6:0.1320	0.1320	6
CD	CD:27	Color Doppler:27:0.5524	0.5524	27
CD	CD:13	colorectal distension:13:0.5934	0.5934	13
CD	CD:14	colostrum-deprived:14:0.0013	0.0013	14
CD	CD:19	communication deviance:19:0.8449	0.8449	19
CD	CD:10	compact disc:10:0.4363	0.4363	10
CD	CD:8	compact disk:8:0.5006	0.5006	8
CD	CD:247	conduct disorder:241:0.9453|conduct disorders:6:0.0736	0.9453	247
CD	CD:6	conduction delay:6:0.0611	0.0611	6
CD	CD:138	conjugated dienes:105:0.9547|conjugated diene:33:0.8196	0.9547	138
CD	CD:20	contact dermatitis:20:0.6680	0.6680	20
CD	CD:13|C-D:4	contrast-detail:17:0.0016	0.0016	17
CD	CD:30	control diet:30:0.3228	0.3228	30
CD	CD:4	cool dry:4:0.1132	0.1132	4
CD	CD:8	coronary diameter:8:0.0726	0.0726	8
CD	CD:14	correlation dimension:14:0.7909	0.7909	14
CD	CD:44	cortical dysplasia:44:0.5065	0.5065	44
CD	CD:38|C-D:3	Cotrel-Dubousset:41:0.0040	0.0040	41
CD	CD:1592|Cd:1	Crohn's disease:1593:0.5629	0.5629	1593
CD	CD:6|cd:1	cumulative dose:7:0.1329	0.1329	7
CD	CD:132|Cd:1	cyclodextrin:102:0.0101|cyclodextrins:31:0.0030	0.0101	133
CD	CD:22	Cytidine deaminase:22:0.0774	0.0774	22
CD	CD:181	cytochalasin D:181:0.5819	0.5819	181
CD	CD:13|cd:2	cytoplasmic domain:15:0.1879	0.1879	15
CD	CD:131|cd:4	cytosine deaminase:135:0.7663	0.7663	135
CD	CD:16	diseases:16:0.0015	0.0015	16
CD	CD:10	distance:10:0.0009	0.0009	10
CD	CD:9	duration:9:0.0008	0.0008	9
CD	CD:4	rats fed a choline-deficient:4:0.1543	0.1543	4
CE-LIF	CE-LIF:15	Capillary electrophoresis with laser-induced fluorescence:15:0.8449	0.8449	15
CE-LIF	CE-LIF:22	Capillary electrophoresis with laser-induced fluorescence detection:22:0.8657	0.8657	22
CE-LIF	CE-LIF:4	Capillary electrophoresis with laser-induced fluorescence detector:4:0.5290	0.5290	4
CE/MS	CE/MS:10	capillary electrophoresis/mass spectrometry:10:0.7103	0.7103	10
CEAs	CEAs:24	carotid endarterectomies:24:0.8768	0.8768	24
CEAs	CEAs:19	cost-effectiveness analyses:19:0.7044	0.7044	19
CEA	CEA:10	carcinoembryonic:10:0.0014	0.0014	10
CEA	CEA:7	carcinoembryonic Ag:7:0.2902	0.2902	7
CEA	CEA:4319	carcinoembryonic antigen:4296:0.8921|Carcinoembryonic antigens:23:0.6306	0.8921	4319
CEA	CEA:771	carotid endarterectomy:751:0.9704|carotid endarterectomies:20:0.8525	0.9704	771
CeA	CeA:27|CEA:7|ceA:1	central amygdala:35:0.1157	0.1157	35
CeA	CeA:16|CEA:1	central amygdaloid nucleus:17:0.8270	0.8270	17
CeA	CeA:119|CEA:22|ceA:1	central nucleus of the amygdala:142:0.9813	0.9813	142
CEA	CEA:8	continuous epidural analgesia:8:0.3463	0.3463	8
CEA	CEA:7	cost-effectiveness analyses:7:0.3524	0.3524	7
CEA	CEA:100	Cost-effectiveness analysis:100:0.8329	0.8329	100
CEA	CEA:8	cultured epidermal autograft:8:0.6411	0.6411	8
CEA	CEA:13	cultured epithelial autografts:7:0.4438|Cultured epithelial autograft:6:0.5290	0.5290	13
CEA	CEA:6	enzyme activity:6:0.1010	0.1010	6
CEBs	CEBs:12|CEBS:1	calcium entry blockers:13:0.5934	0.5934	13
CEB	CEB:27	calcium entry blockers:16:0.8165|calcium entry blocker:11:0.6182	0.8165	27
CEB	CEB:13	children ever born:13:0.7753	0.7753	13
CECT	CECT:22|CE-CT:13	contrast-enhanced computed tomography:35:0.6883	0.6883	35
CECT	CECT:9|CE-CT:3|ceCT:1	contrast-enhanced CT:13:0.3809	0.3809	13
CECS	CECS:17	chronic exertional compartment syndrome:17:0.8270	0.8270	17
CECs	CECs:70|cECs:2|C-ECs:1	endothelial cells:73:0.7257	0.7257	73
CEC	CEC:18	capillary electrochromatographic:18:0.8365	0.8365	18
CEC	CEC:327	capillary electrochromatography:327:0.9757	0.9757	327
CEC	CEC:47	cation exchange capacity:47:0.9366	0.9366	47
CEC	CEC:38	chick embryo cells:23:0.4332|chick embryo cell:15:0.7096	0.7096	38
CEC	CEC:14	chicken embryo cells:14:0.1944	0.1944	14
CEC	CEC:31	chlorethylclonidine:31:0.0347	0.0347	31
CEC	CEC:82	chloroethylclonidine:82:0.0936	0.0936	82
CEC	CEC:33|cEC:1	circulating endothelial cells:34:0.2941	0.2941	34
CEC	CEC:13	Commission of the European Communities:13:0.8525	0.8525	13
CEC	CEC:20	critical electrolyte concentration:20:0.7766	0.7766	20
CEC	CEC:13	endothelial cell:13:0.2038	0.2038	13
CEDIA	CEDIA:10	Cloned enzyme donor immunoassay:10:0.7103	0.7103	10
CEDPA	CEDPA:1	Development of Population Activities:1:0.7909	0.7909	1
CEDU	CEDU:11	5-(2-Chloroethyl)-2'-deoxyuridine:11:0.5882	0.5882	11
CED	CED:26	chronic energy deficiency:26:0.8861	0.8861	26
CED	CED:28	convection-enhanced delivery:28:0.6295	0.6295	28
CEES	CEES:8	2-chloroethyl ethyl sulfide:8:0.6411	0.6411	8
CEFs	CEFs:70	chicken embryo fibroblasts:70:0.6429	0.6429	70
CEF	CEF:7	cauda epididymal fluid:7:0.3524	0.3524	7
CEF	CEF:164	chick embryo fibroblasts:129:0.3632|chick embryo fibroblast:35:0.2126	0.3632	164
CEF	CEF:252	chicken embryo fibroblasts:174:0.5105|chicken embryo fibroblast:78:0.5877	0.5877	252
CEF	CEF:1	cyclophosphamide epirubicin and fluorouracil:1:0.7103	0.7103	1
CEH	CEH:20|CeH:1	Cervicogenic headache:21:0.7865	0.7865	21
CEH	CEH:45	Cholesteryl ester hydrolase:45:0.5506	0.5506	45
CEH	CEH:13	cystic endometrial hyperplasia:13:0.6701	0.6701	13
CEIA	CEIA:12|C-EIA:3|cEIA:3	immunoassay:18:0.6800	0.6800	18
CEIR	CEIR:6	Chronic energy intake restriction:6:0.5290	0.5290	6
CEIs	CEIs:13	converting enzyme inhibitors:13:0.6701	0.6701	13
CEI	CEI:11	continuous epidural infusion:11:0.7357	0.7357	11
CEI	CEI:40	converting enzyme inhibition:40:0.7653	0.7653	40
CEI	CEI:92	converting enzyme inhibitor:60:0.8181|converting enzyme inhibitors:32:0.7782	0.8181	92
CEJ	CEJ:94	cemento-enamel junction:94:0.5176	0.5176	94
cELISA	C-ELISA:13|cELISA:13|c-ELISA:4|CELISA:3	competitive ELISA:33:0.4300	0.4300	33
CELISA	CELISA:8|C-ELISA:1	competitive enzyme immunoassay:9:0.6794	0.6794	9
C-ELISA	C-ELISA:18|cELISA:15|CELISA:9|c-ELISA:7	competitive enzyme-linked immunosorbent assay:49:0.4766	0.4766	49
CELO	CELO:21	lethal orphan:21:0.8594	0.8594	21
CELSS	CELSS:72	Controlled Ecological Life Support System:46:0.7921|Controlled Ecological Life Support Systems:15:0.7096|Controlled Ecological Life-Support System:11:0.7357	0.7921	72
CEL	CEL:27	carboxyl ester lipase:27:0.8903	0.8903	27
CEL	CEL:8|cel:4	Celecoxib:12:0.0710	0.0710	12
CEL	CEL:9	Chronic eosinophilic leukemia:9:0.6794	0.6794	9
CE-MRI	CE-MRI:6|ceMRI:4|Ce-MRI:1|CeMRI:1|CEMRI:1	contrast-enhanced magnetic resonance imaging:13:0.5934	0.5934	13
ceMRI	ceMRI:5|CE-MRI:4|CEMRI:2	Contrast-enhanced MRI:11:0.3829	0.3829	11
CEMSA	CEMSA:6	capillary electrophoresis mobility shift assay:6:0.5290	0.5290	6
CE-MS	CE-MS:31	capillary electrophoresis-mass spectrometry:31:0.8519	0.8519	31
CEM	CEM:30	cell line:30:0.5652	0.5652	30
CEM	CEM:21	cellulose ester membranes:21:0.8525	0.8525	21
CEM	CEM:35	contagious equine metritis:35:0.8681	0.8681	35
CEM	CEM:8	leukemia cells:8:0.1196	0.1196	8
CENP-B	CENP-B:36|CENPB:1	centromere protein B:37:0.9197	0.9197	37
CENP-C	CENP-C:15|CENPC:3	centromere protein C:18:0.8365	0.8365	18
CENU	CENU:14	Chloroethylnitrosourea:14:0.6190	0.6190	14
CENUs	CENUs:27	chloroethylnitrosoureas:27:0.8966	0.8966	27
CEN	CEN:16	centromere:16:0.1181	0.1181	16
CEN	CEN:6	centromere DNA:6:0.2243	0.2243	6
CEN	CEN:7	continuous enteral nutrition:7:0.3524	0.3524	7
CEOAEs	CEOAEs:25|cEOAEs:3	click-evoked otoacoustic emissions:28:0.5729	0.5729	28
CEOOH	CEOOH:11|CE-OOH:11	cholesteryl ester hydroperoxide:12:0.6460|cholesteryl ester hydroperoxides:10:0.7103	0.7103	22
CEOP	CEOP:12	childhood epilepsy with occipital paroxysms:12:0.7571	0.7571	12
CEOT	CEOT:33	Calcifying epithelial odontogenic tumor:23:0.8715|Calcifying epithelial odontogenic tumour:10:0.7103	0.8715	33
CEOs	CEOs:34	chief executive officers:34:0.9126	0.9126	34
CEOs	CEOs:8	cumulus-enclosed oocytes:8:0.2619	0.2619	8
CEO	CEO:11	2-cyanoethylene oxide:11:0.1330	0.1330	11
CEO	CEO:28	chief executive officer:28:0.8941	0.8941	28
CEO	CEO:15	chloroethylene oxide:15:0.2344	0.2344	15
CEO	CEO:13	Cumulus cell-enclosed oocytes:13:0.7753	0.7753	13
CEPH	CEPH:47	Centre d'Etude du Polymorphisme Humain:47:0.9006	0.9006	47
CEPs	CEPs:16	evoked potentials:16:0.6577	0.6577	16
CEP	CEP:5	Care Evaluation Program:5:0.4422	0.4422	5
CEP	CEP:59	chronic eosinophilic pneumonia:59:0.9486	0.9486	59
CEP	CEP:44	congenital erythropoietic porphyria:44:0.9323	0.9323	44
CEP	CEP:8	Cortical evoked potentials:8:0.4102	0.4102	8
CEP	CEP:20	counterelectrophoresis:20:0.0565	0.0565	20
CEP	CEP:7	evoked potential:7:0.3524	0.3524	7
CERAD	CERAD:89	Consortium to Establish a Registry for Alzheimer's Disease:89:0.9682	0.9682	89
CERs	CERs:10	cost-effectiveness ratios:10:0.5000	0.5000	10
CER	CER:29	cephaloridine:29:0.0530	0.0530	29
Cer	Cer:72|CER:24|cer:3	ceramide:84:0.1758|ceramides:15:0.0297	0.1758	99
CER	CER:14|Cer:1	cerebellum:15:0.0297	0.0297	15
CER	CER:14|Cer:2	ceruloplasmin:16:0.0318	0.0318	16
CER	CER:8	Cholesterol esterification rate:8:0.6411	0.6411	8
CER	CER:70	conditioned emotional response:70:0.8741	0.8741	70
CER	CER:17	cost-effectiveness ratio:17:0.3670	0.3670	17
CER	CER:5|cER:4	estrogen receptor:9:0.5470	0.5470	9
CesA	CesA:12|CESA:1	cellulose synthase:13:0.7753	0.7753	13
CES-D	CES-D:74	Center for Epidemiologic Studies Depression:43:0.7238|Center for Epidemiologic Studies-Depression:31:0.7388	0.7388	74
CES-D	CES-D:190|CESD:5	Center for Epidemiologic Studies Depression Scale:150:0.8627|Center for Epidemiologic Studies-Depression scale:45:0.8676	0.8676	195
CES-D	CES-D:29|CESD:1	Center for Epidemiological Studies-Depression:30:0.7652	0.7652	30
CES-D	CES-D:28|CESD:1	Center for Epidemiological Studies-Depression Scale:29:0.7970	0.7970	29
CESD	CESD:1	Center of Epidemiological Studies Depression:1:0.6040	0.6040	1
CESD	CESD:45	cholesteryl ester storage disease:45:0.6704	0.6704	45
CEST	CEST:6	chemical exchange saturation transfer:6:0.5290	0.5290	6
CES	CES:8	carbohydrate-electrolyte solution:8:0.5006	0.5006	8
CEs	CEs:10	Carboxylesterases:10:0.0212	0.0212	10
CES	CES:21	cat eye syndrome:21:0.8594	0.8594	21
CES	CES:18	cauda equina syndrome:18:0.8365	0.8365	18
CES	CES:9	central excitatory state:9:0.6794	0.6794	9
CEs	CEs:11|CES:1	cholesterol esters:12:0.0983	0.0983	12
CEs	CEs:40	cholesteryl esters:40:0.6299	0.6299	40
CES	CES:13	congenital esophageal stenosis:13:0.7753	0.7753	13
CEs	CEs:7	cornified envelopes:7:0.3524	0.3524	7
CES	CES:9	Cranial electrotherapy stimulation:9:0.6411	0.6411	9
CETA	CETA:22	cholesteryl ester transfer activity:22:0.7400	0.7400	22
CETP	CETP:695	Cholesteryl Ester Transfer Protein:695:0.8898	0.8898	695
CET	CET:44	cephalothin:44:0.1741	0.1741	44
CET	CET:33	cholesteryl ester transfer:33:0.7841	0.7841	33
CET	CET:18	chronic ethanol treatment:18:0.8365	0.8365	18
CET	CET:8	competition exercise test:8:0.6411	0.6411	8
CET	CET:7	computed EEG topography:7:0.5926	0.5926	7
CET	CET:5	Computerized electroencephalographic topography:5:0.4422	0.4422	5
CEU	CEU:11	contrast-enhanced ultrasound:11:0.7357	0.7357	11
CEUS	CEUS:8	Contrast-enhanced ultrasonography:8:0.4102	0.4102	8
CEUS	CEUS:10|CE-US:1	contrast-enhanced ultrasound:11:0.4232	0.4232	11
CEVd	CEVd:14	citrus exocortis viroid:14:0.7909	0.7909	14
CEV	CEV:13	cell-associated enveloped virus:13:0.7753	0.7753	13
CEV	CEV:12	citrus exocortis viroid:12:0.7571	0.7571	12
CEX	CEX:76	cephalexin:76:0.7075	0.7075	76
CEZ	CEZ:140	cefazolin:140:0.8797	0.8797	140
CEZ	CEZ:10	cefazolin sodium:10:0.7103	0.7103	10
CEase	CEase:17|CE-ase:1	cholesterol esterase:18:0.8365	0.8365	18
Ce	Ce:9	Caenorhabditis elegans:9:0.6794	0.6794	9
CE	CE:24	California encephalitis:24:0.8115	0.8115	24
CE	CE:1658	capillary electrophoresis:1658:0.9758	0.9758	1658
CE	CE:72	capillary electrophoretic:72:0.9344	0.9344	72
CE	CE:22	capsule endoscopy:22:0.7400	0.7400	22
CE	CE:10	carbohydrate-electrolyte:10:0.0018	0.0018	10
CE	CE:7	Carboplatin and etoposide:7:0.2902	0.2902	7
CE	CE:9	carboxylesterases:9:0.0016	0.0016	9
CE	CE:5	cardiac events:5:0.0612	0.0612	5
CE	CE:82	Carotid endarterectomy:82:0.8628	0.8628	82
CE	CE:18|C-E:15	Carpentier-Edwards:33:0.0065	0.0065	33
CE	CE:6	cataract extraction:6:0.2243	0.2243	6
CE	CE:10	Catechol estrogens:10:0.1327	0.1327	10
CE	CE:11	Cathepsin E:11:0.2154	0.2154	11
CE	CE:6	cell extracts:6:0.0731	0.0731	6
CE	CE:9	cellulose:9:0.0016	0.0016	9
CE	CE:27	center-edge:17:0.0033|center edge:10:0.3145	0.3145	27
CE	CE:15|Ce:6	central:21:0.0041	0.0041	21
Ce	Ce:13|CE:1	central amygdaloid nucleus:14:0.7909	0.7909	14
CE	CE:6|Ce:4	central nucleus:10:0.1596	0.1596	10
Ce	Ce:28|CE:2	central nucleus of the amygdala:30:0.8196	0.8196	30
CE	CE:14	centrifugal elutriation:14:0.5589	0.5589	14
CE	CE:18|Ce:6|ce:1	cerebellum:25:0.0049	0.0049	25
CE	CE:9	chemoembolization:9:0.0016	0.0016	9
CE	CE:8	chest expansion:8:0.5006	0.5006	8
CE	CE:43	chick embryo:29:0.6157|chick embryos:14:0.6173	0.6173	43
CE	CE:8	chicken embryo:8:0.0604	0.0604	8
CE	CE:9	chicken erythrocytes:9:0.2285	0.2285	9
CE	CE:67	cholesterol ester:67:0.1306	0.1306	67
CE	CE:31	cholesterol esterase:31:0.6820	0.6820	31
CE	CE:475	cholesteryl ester:307:0.7388|cholesteryl esters:168:0.6771	0.7388	475
CE	CE:15	cholinesterase:15:0.0029	0.0029	15
CE	CE:19	ciliary epithelium:19:0.3453	0.3453	19
CE	CE:9	clinical engineering:9:0.6794	0.6794	9
CE	CE:12	clinical examination:12:0.3813	0.3813	12
CE	CE:25	cloning efficiency:25:0.2452	0.2452	25
CE	CE:11	coefficient of error:11:0.1612	0.1612	11
CE	CE:9	cold exposure:9:0.1585	0.1585	9
CE	CE:13	collection efficiency:13:0.0869	0.0869	13
CE	CE:14	combinatorial extension:14:0.3202	0.3202	14
CE	CE:40	competitive exclusion:40:0.8491	0.8491	40
Ce	Ce:20|CE:5	concentration:16:0.0031|concentrations:9:0.0016	0.0031	25
CE	CE:22	conjugated estrogens:14:0.2524|conjugated estrogen:8:0.1895	0.2524	22
CE	CE:10	constant estrous:10:0.5856	0.5856	10
CE	CE:6	constant estrus:6:0.1838	0.1838	6
CE	CE:124	continuing education:124:0.8791	0.8791	124
CE	CE:15	contractile element:15:0.3262	0.3262	15
CE	CE:18	contrast echocardiography:18:0.5940	0.5940	18
CE	CE:7	contrast enema:7:0.2902	0.2902	7
CE	CE:79|ce:1	Contrast-enhanced:69:0.0139|Contrast enhanced:11:0.7357	0.7357	80
CE	CE:28	Contrast enhancement:28:0.7505	0.7505	28
CE	CE:43	converting enzyme:43:0.6810	0.6810	43
CE	CE:9	corneal endothelial:9:0.3069	0.3069	9
CE	CE:31	cornified cell envelope:31:0.5933	0.5933	31
CE	CE:14	cornified envelope:14:0.1063	0.1063	14
CE	CE:49|C-E:3|c-e:1	cost-effectiveness:53:0.0106	0.0106	53
CE	CE:23	crude extract:23:0.1940	0.1940	23
CE	CE:11	cycle ergometer:11:0.7357	0.7357	11
CE	CE:15	cycle ergometry:15:0.8045	0.8045	15
CE	CE:121	cystic echinococcosis:121:0.9606	0.9606	121
CE	CE:8	Cytochalasin E:8:0.1061	0.1061	8
CE	CE:9|Ce:1	effect:10:0.0018	0.0018	10
CE	CE:9	epithelial:9:0.0016	0.0016	9
CE	CE:12	esterified cholesterol:12:0.5664	0.5664	12
CE	CE:6	included examination of the constant error:6:0.5926	0.5926	6
CE	CE:6	Liver carboxylesterase:6:0.0564	0.0564	6
CF1	CF1:5	chloroplast ATPase:5:0.0612	0.0612	5
CF1	CF1:25	chloroplast coupling factor:25:0.6240	0.6240	25
CF1	CF1:58	chloroplast coupling factor 1:58:0.6840	0.6840	58
CF1	CF1:15	chloroplast F1-ATPase:15:0.8045	0.8045	15
CF2	CF2:11	cytotoxin:11:0.2500	0.2500	11
CFA/I	CFA/I:47	colonization factor antigen I:47:0.8703	0.8703	47
CFA/II	CFA/II:9	colonization factor antigen II:9:0.5470	0.5470	9
CFA/III	CFA/III:9	colonization factor antigen III:9:0.6794	0.6794	9
CFAM	CFAM:14	Cerebral Function Analysing Monitor:14:0.7909	0.7909	14
CFAs	CFAs:24	colonization factor antigens:24:0.7679	0.7679	24
CFA	CFA:6	caudal forelimb area:6:0.5290	0.5290	6
CFA	CFA:18	cellular fatty acid:18:0.3857	0.3857	18
CFA	CFA:17	Chicken fetal antigen:17:0.8270	0.8270	17
CFA	CFA:21	Circulating filarial antigen:21:0.8594	0.8594	21
CFA	CFA:11	coal fly ash:11:0.7357	0.7357	11
CFA	CFA:33	colonization factor antigen:19:0.6381|colonization factor antigens:14:0.6173	0.6381	33
CFA	CFA:15|cfa:1	colony-forming ability:8:0.1895|colony forming ability:8:0.6411	0.6411	16
CFA	CFA:50	common femoral artery:50:0.9404	0.9404	50
CFA	CFA:657|cFA:3	complete Freund's adjuvant:660:0.9646	0.9646	660
CFA	CFA:19	confirmatory factor analyses:19:0.8449	0.8449	19
CFA	CFA:93	Confirmatory factor analysis:93:0.8657	0.8657	93
CFA	CFA:11	coronafacic acid:11:0.0812	0.0812	11
CFA	CFA:11	craniofacial anomalies:11:0.7357	0.7357	11
CFA	CFA:84	cryptogenic fibrosing alveolitis:84:0.9255	0.9255	84
CFA	CFA:8|cfa:1	cyclopropane fatty acid:9:0.1052	0.1052	9
CFA	CFA:11	fatty acids:11:0.7357	0.7357	11
CFB	CFB:12	clofibrate:12:0.1078	0.1078	12
CFB	CFB:10	Cytophaga-Flavobacterium-Bacteroides:10:0.0882	0.0882	10
CFCs	CFCs:75	chlorofluorocarbons:75:0.3645	0.3645	75
CFCs	CFCs:68|CFC-S:1	colony-forming cells:69:0.7348	0.7348	69
CFC	CFC:79	capillary filtration coefficient:79:0.9622	0.9622	79
CFC	CFC:34	cardio-facio-cutaneous:34:0.0486	0.0486	34
CFC	CFC:9	cardiofaciocutaneous:9:0.0118	0.0118	9
CFC	CFC:102	chlorofluorocarbon:86:0.1252|chlorofluorocarbons:16:0.0221	0.1252	102
CFC	CFC:251	colony-forming cells:160:0.6396|colony-forming cell:47:0.7025|colony forming cells:44:0.8076	0.8076	251
CFC	CFC:18	continuous flow centrifugation:10:0.7103|continuous-flow centrifugation:8:0.1471	0.7103	18
CFC	CFC:18	cytokine flow cytometry:18:0.8365	0.8365	18
CFC	CFC:10	fear conditioning:10:0.7103	0.7103	10
CFDA-SE	CFDA-SE:6|CFDASE:4|cFDA-SE:1	diacetate succinimidyl ester:11:0.6460	0.6460	11
CFDI	CFDI:11	duplex imaging:11:0.5355	0.5355	11
CFDS	CFDS:10	color flow Doppler sonography:10:0.4363	0.4363	10
CFD	CFD:9	color flow Doppler:9:0.4587	0.4587	9
CFD	CFD:274	Computational fluid dynamics:241:0.9735|computational fluid dynamic:33:0.9100	0.9735	274
CFEOM	CFEOM:16	Congenital fibrosis of the extraocular muscles:16:0.8365	0.8365	16
CFE	CFE:88	colony-forming efficiency:49:0.4337|colony forming efficiency:39:0.9237	0.9237	88
CFE	CFE:11	continuous flow electrophoresis:11:0.7357	0.7357	11
CF-FAB	CF-FAB:10|CFFAB:1	Fast Atom Bombardment:11:0.7357	0.7357	11
CFFT	CFFT:18	Critical Flicker Fusion Threshold:18:0.8365	0.8365	18
CFF	CFF:45|cff:1	Critical Flicker Frequency:46:0.9353	0.9353	46
CFF	CFF:59|cff:1	critical flicker fusion:60:0.9216	0.9216	60
CFF	CFF:26	critical flicker fusion frequency:26:0.7340	0.7340	26
CFF	CFF:9	critical flicker fusion threshold:9:0.6794	0.6794	9
CFF	CFF:13	critical fusion frequency:13:0.1423	0.1423	13
CFGE	CFGE:12	gel electrophoresis:12:0.7571	0.7571	12
CFG	CFG:9	counterflow geometry:9:0.6794	0.6794	9
CFIDS	CFIDS:4	Chronic fatigue and immune dysfunction syndrome:4:0.7103	0.7103	4
CFI	CFI:34	Camberwell Family Interview:34:0.9126	0.9126	34
CFI	CFI:20	chemotactic factor inactivator:20:0.7766	0.7766	20
CFI	CFI:19	collateral flow index:19:0.5732	0.5732	19
CFI	CFI:10	color flow imaging:10:0.7103	0.7103	10
CFLP	CFLP:8	Cleavase fragment length polymorphism:8:0.4102	0.4102	8
CFM	CFM:45	Cerebral Function Monitor:45:0.9338	0.9338	45
CFM	CFM:6	confocal fluorescence microscopy:6:0.3728	0.3728	6
CFM	CFM:13	flow mapping:13:0.6701	0.6701	13
cFN	cFN:4|CFN:3	caudal fastigial nucleus:7:0.1470	0.1470	7
cFN	cFN:7	caudal part of the fastigial nucleus:7:0.5926	0.5926	7
cFN	cFN:24|cFn:18|c-Fn:2|c-FN:1	cellular fibronectin:45:0.7881	0.7881	45
cFN	cFN:8|cFn:4|c-FN:1	Cellular FN:13:0.5335	0.5335	13
CFOI	CFOI:15	Census of Fatal Occupational Injuries:15:0.8045	0.8045	15
c-Fos	c-Fos:8|c-fos:1	c-fos protein:9:0.2500	0.2500	9
CFOs	CFOs:12	Chief financial officers:12:0.7571	0.7571	12
CFPD	CFPD:14	Continuous flow peritoneal dialysis:14:0.7909	0.7909	14
CFP	CFP:15	center of foot pressure:15:0.4052	0.4052	15
CFP	CFP:8	centre of foot pressure:8:0.1125	0.1125	8
CFP	CFP:13	common foundation programme:13:0.7753	0.7753	13
CFP	CFP:9	culture filtrate proteins:9:0.6794	0.6794	9
CFP	CFP:50	cyan fluorescent protein:50:0.8520	0.8520	50
CFQ	CFQ:11	Cognitive Failures Questionnaire:11:0.7357	0.7357	11
c-fra	c-fra:7|CFRA:1	common fragile sites:8:0.4102	0.4102	8
CFRC	CFRC:5	carbon fibre reinforced carbon:5:0.4422	0.4422	5
CFRD	CFRD:10	cystic fibrosis-related diabetes:10:0.7103	0.7103	10
CFRs	CFRs:6	case-fatality rates:6:0.1838	0.1838	6
CFRs	CFRs:9	climbing fiber responses:9:0.6794	0.6794	9
CFRs	CFRs:29	cyclic flow reductions:29:0.6648	0.6648	29
CFR	CFR:59	case fatality rate:53:0.9438|case-fatality rates:6:0.1320	0.9438	59
CFR	CFR:7	case fatality ratio:7:0.4438	0.4438	7
CFR	CFR:25	Code of Federal Regulations:25:0.8816	0.8816	25
CFR	CFR:12	Complement fixation reaction:12:0.6460	0.6460	12
CFR	CFR:24	coronary flow rate:24:0.8768	0.8768	24
CFR	CFR:225	coronary flow reserve:225:0.9589	0.9589	225
CFR	CFR:8	Cyclic flow reduction:8:0.5006	0.5006	8
CFR	CFR:7	FGF receptor:7:0.2987	0.2987	7
CFSS-DS	CFSS-DS:5	Dental Subscale of Children's Fear Survey Schedule:5:0.7753	0.7753	5
CFS	CFS:4	Canada Fitness Survey:4:0.1618	0.1618	4
CFs	CFs:15	cardiac fibroblasts:15:0.5348	0.5348	15
CFS	CFS:50	cefsulodin:50:0.0351	0.0351	50
CFS	CFS:14	cell-free supernatants:9:0.4587|cell-free supernatant:5:0.0736	0.4587	14
CFs	CFs:61|CFS:1	characteristic frequencies:62:0.7914	0.7914	62
CFS	CFS:924|cfs:1	Chronic fatigue syndrome:925:0.9948	0.9948	925
CFs	CFs:26	climbing fibers:26:0.6973	0.6973	26
CFs	CFs:20	colonization factors:20:0.2219	0.2219	20
CFS	CFS:4	color-flow duplex scanning:4:0.1618	0.1618	4
CFS	CFS:12	conditioned fear stress:12:0.7571	0.7571	12
CFS	CFS:9	Congenital fibrosarcoma:9:0.4587	0.4587	9
CFS	CFS:6	continuous flow system:6:0.5290	0.5290	6
CFS	CFS:7	Fatigue Scale:7:0.3524	0.3524	7
CFTD	CFTD:12	Congenital fiber type disproportion:12:0.6460	0.6460	12
CFTM-PI	CFTM-PI:13	cefteram pivoxil:13:0.7753	0.7753	13
CFTR	CFTR:21|Cftr:2	cystic fibrosis:23:0.8715	0.8715	23
CFTR	CFTR:16|cftr:1	cystic fibrosis gene:17:0.8270	0.8270	17
CFTR	CFTR:9	cystic fibrosis gene product:9:0.6794	0.6794	9
CFTR	CFTR:1596|Cftr:8|cftr:4	cystic fibrosis transmembrane conductance regulator:1608:0.9924	0.9924	1608
CFTR	CFTR:45|Cftr:1	cystic fibrosis transmembrane conductance regulator gene:46:0.9366	0.9366	46
CFTR	CFTR:16	cystic fibrosis transmembrane conductance regulator protein:16:0.8165	0.8165	16
CFT	CFT:19	complement fixation:19:0.8449	0.8449	19
CFT	CFT:289|cft:1	complement fixation test:279:0.9619|complement fixation tests:11:0.7357	0.9619	290
CFU-GMs	CFU-GMs:6	colony-forming units:6:0.2243	0.2243	6
CFU-E	CFU-E:89|CFU-e:5|cfu-e:1|CFUe:1	colony-forming unit-erythroid:35:0.4982|colony-forming units-erythroid:35:0.7117|colony forming unit-erythroid:18:0.8365|colony-forming unit erythroid:8:0.3867	0.8365	96
CFU-E	CFU-E:17|CFUE:5|CFU-e:1|CFUe:1	erythroid colony:16:0.7261|erythroid colonies:8:0.2987	0.7261	24
CFU-E	CFU-E:17|CFU-e:2	erythroid colony-forming cells:19:0.7658	0.7658	19
CFU-E	CFU-E:92|CFU-e:14|CFUe:5|CFUE:2	Erythroid colony-forming units:76:0.7444|erythroid colony-forming unit:27:0.5951|erythroid colony forming unit:10:0.7103	0.7444	113
CFU-E	CFU-E:23|CFU-e:3|CFUE:2|CFUe:1	erythroid progenitors:29:0.7237	0.7237	29
CFU-E	CFU-E:23|CFU-e:8	erythroid progenitor cells:26:0.6351|erythroid progenitor cell:5:0.2818	0.6351	31
CFU-L	CFU-L:13	clonogenic cells:13:0.2532	0.2532	13
CFU-MK	CFU-MK:16|CFU-Mk:2	colony-forming units:10:0.3470|colony-forming unit:8:0.3463	0.3470	18
CFU-MK	CFU-MK:29|CFU-Mk:8	colony-forming unit-megakaryocyte:13:0.3809|colony-forming units-megakaryocyte:11:0.5355|Colony Forming Unit-Megakaryocyte:7:0.5926|colony-forming unit megakaryocyte:6:0.2452	0.5926	37
CFU-MK	CFU-MK:10|CFU-Mk:3	megakaryocyte progenitors:13:0.3331	0.3331	13
CFU-MK	CFU-MK:5|CFU-Mk:5	megakaryocyte progenitor cells:10:0.2643	0.2643	10
CFU-Meg	CFU-Meg:13	megakaryocyte colony-forming units:13:0.6701	0.6701	13
CFU-Meg	CFU-Meg:10|CFU-meg:3	megakaryocyte progenitors:13:0.4849	0.4849	13
CFU-Meg	CFU-Meg:10|CFU-meg:1	progenitor cells:11:0.3495	0.3495	11
CFU-C	CFU-C:11|CFU-c:1|CFUC:1	colony formation:13:0.7571	0.7571	13
CFU-C	CFU-C:18|CFUc:10|CFU-c:5|CFUC:1	colony-forming units:22:0.4510|Colony forming units:12:0.7571	0.7571	34
CFU-C	CFU-C:7|CFU-c:4|CFUC:1	colony-forming unit-culture:9:0.3455|colony-forming unit culture:3:0.2275	0.3455	12
CFU-C	CFU-C:20|CFU-c:6|CFUc:4|CFUC:2	colony-forming units in culture:32:0.6250	0.6250	32
CFU-c	CFU-c:5|CFU-C:3|CFUc:3|CFUC:2	committed stem cells:13:0.0834	0.0834	13
CFU-C	CFU-C:9|CFU-c:1	myeloid progenitors:10:0.1057	0.1057	10
CFU-C	CFU-C:11|CFUc:4|CFU-c:1|CFu-c:1|CFUC:1	precursors:18:0.0239	0.0239	18
CFU-C	CFU-C:94|CFUc:37|CFU-c:15|CFUC:8	progenitor cells:132:0.3862|progenitor cell:22:0.2943	0.3862	154
CFU-F	CFU-F:8	bone marrow fibroblast colony-forming cells:8:0.5006	0.5006	8
CFU-F	CFU-F:8|CFU-f:4	colony-forming unit:12:0.5050	0.5050	12
CFU-F	CFU-F:18|CFUf:5|CFUF:1	fibroblasts:24:0.1022	0.1022	24
CFU-F	CFU-F:17|CFUF:1	fibroblast colony-forming units:18:0.3285	0.3285	18
CFU-GM	CFU-GM:15|CFUGM:1	colony formation:16:0.7261	0.7261	16
CFU-GM	CFU-GM:2	colony-forming units for granulocyte/macrophage:2:0.6748	0.6748	2
CFU-GM	CFU-GM:334|CFU-gm:2|cfu-gm:1|CFUGM:1	colony-forming unit granulocyte-macrophage:62:0.7270|colony-forming unit-granulocyte-macrophage:47:0.7749|colony-forming units-granulocyte/macrophage:40:0.6998|colony-forming unit-granulocyte/macrophage:30:0.6131|colony-forming units granulocyte-macrophage:29:0.6015|colony-forming units-granulocyte-macrophage:23:0.4831|colony-forming unit-granulocyte macrophage:23:0.4104|colony forming unit-granulocyte macrophage:19:0.8715|colony-forming unit granulocyte/macrophage:11:0.3213|colony forming units-granulocyte-macrophage:11:0.7357|colony-forming unit granulocyte macrophage:10:0.5856|colony forming unit-granulocyte/macrophage:9:0.6794|colony-forming units-granulocyte macrophage:9:0.1938|colony forming units granulocyte-macrophage:8:0.7103|Colony Forming Unit Granulocyte/Macrophage:7:0.5926	0.8715	338
CFU-GM	CFU-GM:3	colony-forming units of granulocytes and macrophages:3:0.3069	0.3069	3
CFU-GM	CFU-GM:11	granulocyte-macrophage CFU:11:0.5355	0.5355	11
CFU-GM	CFU-GM:4|CFU-gm:1	granulocyte-macrophage colony:5:0.0517	0.0517	5
CFU-GM	CFU-GM:32	granulocyte-macrophage colony-forming cells:32:0.4035	0.4035	32
CFU-GM	CFU-GM:241|CFU-gm:4|cfu-gm:1	granulocyte-macrophage colony-forming units:158:0.6840|granulocyte-macrophage colony-forming unit:56:0.6570|granulocyte-macrophage colony forming units:32:0.5213	0.6840	246
CFU-GM	CFU-GM:100|CFU-gm:7|CFUGM:2	granulocyte-macrophage progenitors:74:0.3154|granulocyte/macrophage progenitors:23:0.0697|granulocyte-macrophage progenitor:12:0.2549	0.3154	109
CFU-GM	CFU-GM:79|CFU-gm:3	granulocyte-macrophage progenitor cells:82:0.3649	0.3649	82
CFU-GM	CFU-GM:9	granulocyte-monocyte:9:0.0042	0.0042	9
CFU-GM	CFU-GM:30	myeloid progenitors:30:0.1010	0.1010	30
CFU-GM	CFU-GM:38|CFUGM:1|CFU-gm:1	myeloid progenitor cells:40:0.1508	0.1508	40
CFU-GM	CFU-GM:20	progenitor cell:20:0.4037	0.4037	20
CFU-G	CFU-G:8|CFU-g:5	granulocyte:13:0.2105	0.2105	13
CFU-Mix	CFU-Mix:10|CFU-mix:3|CFU-MIX:2	colony-forming units:15:0.5818	0.5818	15
CFUMIX	CFUMIX:3|CFU-mix:1	pluripotent hemopoietic precursors in vitro:4:0.3170	0.3170	4
CFU-mix	CFU-mix:5|CFU-Mix:3|CFU-MIX:1	progenitor cells:9:0.3069	0.3069	9
CFU-M	CFU-M:8|CFUm:1	colony-forming units:9:0.3069	0.3069	9
CFU-M	CFU-M:4|CFU-m:2	macrophage colonies:6:0.1148	0.1148	6
CFU-M	CFU-M:7|CFUm:2	megakaryocyte progenitors:9:0.2619	0.2619	9
CFU-M	CFU-M:8|CFUm:1|CFU-m:1	progenitor cells:10:0.2126	0.2126	10
CFUs	CFUs:54|CFU-S:15|CFU-s:4|cfus:2|CFUS:1|cfu-s:1	colony forming units:77:0.8848	0.8848	77
CFU-S	CFU-S:7|CFUs:3	colony-forming units in the spleen:10:0.5435	0.5435	10
CFU-S	CFU-S:74|CFU-s:3|CFUs:2|CFUS:1	colony-forming unit-spleen:35:0.6464|colony-forming units-spleen:24:0.5722|colony-forming unit spleen:13:0.5279|colony forming units-spleen:8:0.6411	0.6464	80
CFU-S	CFU-S:14|CFUS:2|CFU-s:1	pluripotent:17:0.0156	0.0156	17
CFU-S	CFU-S:16|CFUs:3|CFU-s:1	spleen colonies:20:0.4786	0.4786	20
CFU-S	CFU-S:116|CFU-s:17|CFUs:6	spleen colony-forming units:115:0.4338|spleen colony-forming unit:24:0.5160	0.5160	139
CFU	CFU:936|cfu:364|CFu:1	colony-forming units:612:0.5023|colony forming units:520:0.9820|colony-forming unit:105:0.5072|colony forming unit:64:0.8452	0.9820	1301
CFU	CFU:12	stem cells:12:0.1991	0.1991	12
CFVR	CFVR:69	coronary flow velocity reserve:69:0.8905	0.8905	69
CFVs	CFVs:30	cyclic flow variations:30:0.8472	0.8472	30
CFV	CFV:21	common femoral vein:21:0.7291	0.7291	21
CFV	CFV:19	constant-flow ventilation:19:0.4618	0.4618	19
CFV	CFV:41	flow velocity:41:0.9274	0.9274	41
CFW	CFW:15	calcofluor white:15:0.8045	0.8045	15
CFX	CFX:51	cefoxitin:51:0.3817	0.3817	51
CFX	CFX:14	ciprofloxacin:14:0.0992	0.0992	14
CFX	CFX:9|Cfx:1	circumflex:10:0.0687	0.0687	10
CFX	CFX:11|CFx:1	circumflex coronary artery:12:0.7571	0.7571	12
CFZ	CFZ:9	clofazimine:9:0.2500	0.2500	9
CFL	CFL:9	calcaneofibular ligament:9:0.6794	0.6794	9
CFSs	CFSs:8	common fragile sites:8:0.5006	0.5006	8
CF	CF:23	5(6)-carboxyfluorescein:23:0.0025	0.0025	23
CF	CF:12	6-carboxyfluorescein:12:0.0012	0.0012	12
CF	CF:17|Cf:6	caffeine:23:0.0025	0.0025	23
CF	CF:15	Canadian Forces:15:0.8045	0.8045	15
CF	CF:125|cF:5	carboxyfluorescein:130:0.0146	0.0146	130
CF	CF:21	cardiac failure:21:0.3419	0.3419	21
CF	CF:11	Cascade filtration:11:0.6182	0.6182	11
CF	CF:10	case fatality:10:0.7103	0.7103	10
CF	CF:29	cationic ferritin:29:0.1092	0.1092	29
CF	CF:130	cationized ferritin:130:0.7027	0.7027	130
CF	CF:8|c-f:1	cell-free:9:0.0009	0.0009	9
CF	CF:277	characteristic frequency:246:0.7335|characteristic frequencies:20:0.6680|characteristic-frequency:11:0.0011	0.7335	277
CF	CF:13	charcoal-filtered air:13:0.4102	0.4102	13
CF	CF:7	chicken fat:7:0.1211	0.1211	7
CF	CF:33	chloroform:33:0.0036	0.0036	33
CF	CF:20	chronic fatigue:20:0.7173	0.7173	20
CF	CF:13|cf:1	ciprofloxacin:14:0.0015	0.0015	14
CF	CF:8	Clastogenic factors:8:0.0517	0.0517	8
CF	CF:58	climbing fiber:50:0.5707|climbing fibers:8:0.4102	0.5707	58
CF	CF:12	climbing fibre:12:0.2083	0.2083	12
CF	CF:18	clofibrate:18:0.0019	0.0019	18
CF	CF:11	coelomic fluid:11:0.0632	0.0632	11
CF	CF:6	colony formation:6:0.3524	0.3524	6
CF	CF:10	colostrum-fed:10:0.0010	0.0010	10
CF	CF:517|cf:1	complement fixation:419:0.9534|Complement-fixation:99:0.0111	0.9534	518
CF	CF:26	complement fixation test:26:0.8861	0.8861	26
CF	CF:135|cf:3	complement-fixing:95:0.0105|Complement fixing:43:0.9323	0.9323	138
CF	CF:8	Concentration factors:8:0.0517	0.0517	8
CF	CF:13	constant-frequency:13:0.0014	0.0014	13
CF	CF:17	continuous-flow:17:0.0018	0.0018	17
CF	CF:40	contractile force:40:0.6998	0.6998	40
CF	CF:22	conventional fractionation:22:0.7046	0.7046	22
CF	CF:208	coronary flow:208:0.7875	0.7875	208
CF	CF:10	cortical fibroblasts:10:0.2126	0.2126	10
CF	CF:4|cf:1	counting fingers:5:0.1132	0.1132	5
CF	CF:20	Crevicular fluid:20:0.1764	0.1764	20
CF	CF:12	Crude fiber:12:0.0680	0.0680	12
CF	CF:15	crude fibre:15:0.3110	0.3110	15
CF	CF:47	culture filtrate:47:0.9379	0.9379	47
CF	CF:5517|cF:1|cf:1	cystic fibrosis:5519:0.9961	0.9961	5519
CF	CF:6	cytosolic fraction:6:0.0666	0.0666	6
CF	CF:42	cytotoxic factor:42:0.1385	0.1385	42
CF	CF:9	folinic acid:9:0.3455	0.3455	9
CF	CF:14	function:14:0.0015	0.0015	14
CF	CF:10	leucovorin:10:0.0010	0.0010	10
CGAP	CGAP:14	Cancer Genome Anatomy Project:14:0.7909	0.7909	14
CGAS	CGAS:26|C-GAS:5	Children's Global Assessment Scale:31:0.6572	0.6572	31
CGA	CGA:25	chlorogenic acid:25:0.8186	0.8186	25
CgA	CgA:21|CGA:5|CG-A:1|Cg-A:1	Chromogranin-A:28:0.1144	0.1144	28
CGA	CGA:78	Comprehensive geriatric assessment:78:0.9617	0.9617	78
CGCG	CGCG:16	central giant cell granuloma:16:0.8165	0.8165	16
CGCs	CGCs:67	cerebellar granule cells:67:0.9554	0.9554	67
CGC	CGC:13|cGC:6|C-GC:1	capillary gas chromatography:20:0.7173	0.7173	20
CGC	CGC:44|cgc:1	cerebellar granule cells:40:0.8839|cerebellar granule cell:5:0.4422	0.8839	45
CGD	CGD:573	chronic granulomatous disease:573:0.9948	0.9948	573
CGD	CGD:10	chronic granulomatous disease of childhood:10:0.7103	0.7103	10
CGD	CGD:19	constitutional growth delay:19:0.8449	0.8449	19
CGE	CGE:64	capillary gel electrophoresis:64:0.9033	0.9033	64
CGE	CGE:18	Cobalt Gray Equivalent:18:0.7539	0.7539	18
CGF	CGF:12	growth factor:12:0.5050	0.5050	12
CGI-BP	CGI-BP:9	bipolar disorder:9:0.5470	0.5470	9
CGIC	CGIC:21|CGI-C:5|CGI-c:1	Clinical Global Impression of Change:27:0.8312	0.8312	27
CGI-I	CGI-I:24	Clinical Global Impression-Improvement:15:0.7096|Clinical Global Impressions-Improvement:9:0.6794	0.7096	24
CGI-I	CGI-I:11	Clinical Global Impressions-Improvement scale:11:0.7357	0.7357	11
CGI-I	CGI-I:6	Clinical Global Impression of Improvement:6:0.7357	0.7357	6
CGIN	CGIN:9|cGIN:2	Cervical glandular intraepithelial neoplasia:11:0.7357	0.7357	11
CGI-S	CGI-S:14	Clinical Global Impression of Severity:14:0.8449	0.8449	14
CGIS	CGIS:13	Clinical Global Impression Scale:13:0.7753	0.7753	13
CGI-S	CGI-S:11	Clinical Global Impressions-Severity of Illness:11:0.7357	0.7357	11
CGI-S	CGI-S:14	Clinical Global Impressions-Severity of Illness scale:14:0.7909	0.7909	14
CGIs	CGIs:12	CpG islands:12:0.7571	0.7571	12
CGI	CGI:397	Clinical Global Impression:274:0.9766|Clinical Global Impressions:123:0.9757	0.9766	397
CGI	CGI:107	Clinical Global Impression Scale:59:0.8954|Clinical Global Impressions scale:48:0.9379	0.9379	107
CGI	CGI:10	Clinical Global Improvement:10:0.7103	0.7103	10
CGL	CGL:126|cgl:1	chronic granulocytic leukaemia:127:0.9764	0.9764	127
CGL	CGL:146	chronic granulocytic leukemia:146:0.9566	0.9566	146
CGL	CGL:19	Congenital generalized lipodystrophy:19:0.8449	0.8449	19
CGMH	CGMH:12	Chang Gung Memorial Hospital:12:0.7571	0.7571	12
CGMMV	CGMMV:15	Cucumber green mottle mosaic virus:15:0.8045	0.8045	15
CGMP	CGMP:14|cGMP:7	Current Good Manufacturing Practice:21:0.8038	0.8038	21
cGMP	cGMP:167|c-GMP:1	cyclic guanosine 3',5'-monophosphate:120:0.6796|cyclic guanosine-3',5'-monophosphate:29:0.6392|cyclic guanosine 3':5'-monophosphate:19:0.4211	0.6796	168
cGMP	cGMP:10	cyclic guanosine 3'5'-monophosphate:10:0.5000	0.5000	10
cGMP	cGMP:17	cyclic guanosine 5'-monophosphate:17:0.7407	0.7407	17
cGMP	cGMP:726|c-GMP:12|CGMP:2	cyclic guanosine monophosphate:740:0.8170	0.8170	740
cGMP	cGMP:489|C-GMP:2|Cgmp:1|CGMP:1|c-GMP:1	guanosine 3',5'-cyclic monophosphate:494:0.9288	0.9288	494
cGMP	cGMP:6	guanosine 3',5'-cyclic phosphate:6:0.2827	0.2827	6
CGMS	CGMS:63|CG-MS:1	Continuous Glucose Monitoring System:64:0.9526	0.9526	64
CGM	CGM:34|-CGM:1	corn gluten meal:35:0.9151	0.9151	35
CGM	CGM:4|cGM:3	cortical gray matter:7:0.2113	0.2113	7
CGNs	CGNs:70	cerebellar granule neurons:70:0.9573	0.9573	70
CGN	CGN:11	carrageenan:11:0.0341	0.0341	11
CGN	CGN:28	cerebellar granule neurons:28:0.8941	0.8941	28
CGN	CGN:170	chronic glomerulonephritis:170:0.7501	0.7501	170
CGRPI	CGRPI:13|CGRP-I:4	immunoreactive:17:0.3902	0.3902	17
CGRPI	CGRPI:5|CGRPi:4	immunoreactivity:9:0.1951	0.1951	9
CGRP-LI	CGRP-LI:9	calcitonin gene-related peptide:9:0.6794	0.6794	9
CGRP-LI	CGRP-LI:7	calcitonin gene-related peptide-like immunoreactive:7:0.5926	0.5926	7
CGRP-LI	CGRP-LI:52|CGRP-li:4	calcitonin gene-related peptide-like immunoreactivity:56:0.9477	0.9477	56
CGRP-LI	CGRP-LI:26|CGRP-li:2|CGRPLI:1	CGRP-like immunoreactivity:29:0.2012	0.2012	29
CGRP-IR	CGRP-IR:10|CGRP-ir:1	calcitonin gene-related peptide immunoreactivity:11:0.7357	0.7357	11
CGRP-IR	CGRP-IR:6|CGRP-ir:2	calcitonin gene-related peptide-like immunoreactivity:8:0.6411	0.6411	8
CGRP-IR	CGRP-IR:12	CGRP-immunoreactive:12:0.1358	0.1358	12
CGRP	CGRP:3565|CgRP:1	calcitonin gene-related peptide:3554:0.9690|calcitonin gene-related peptides:12:0.7571	0.9690	3566
CGRP	CGRP:6	Calcitonin gene-related polypeptide:6:0.3728	0.3728	6
CGRP	CGRP:12	calcitonin gene-related protein:12:0.7571	0.7571	12
CGR	CGR:12	Chaos Game Representation:12:0.7571	0.7571	12
CGTase	CGTase:24	cyclodextrin glucanotransferase:24:0.4788	0.4788	24
CGTase	CGTase:41	Cyclodextrin glycosyltransferase:41:0.7952	0.7952	41
CGT	CGT:13	UDP-galactose:ceramide galactosyltransferase:13:0.4102	0.4102	13
CGU	CGU:13	cerebral glucose utilization:13:0.4444	0.4444	13
CGs	CGs:10	caregivers:10:0.0462	0.0462	10
CGs	CGs:17	cortical granules:17:0.6211	0.6211	17
CGS	CGS:18|CgS:1	cystathionine gamma-synthase:19:0.8449	0.8449	19
CG	CG:9	capsular glaucoma:9:0.6794	0.6794	9
CG	CG:8	cardiac glycosides:8:0.5006	0.5006	8
CG	CG:6|Cg:4	carrageenan:10:0.0053	0.0053	10
CG	CG:6|Cg:2	(-)-catechin gallate:8:0.2619	0.2619	8
CG	CG:23	cathepsin G:23:0.5997	0.5997	23
CG	CG:31|cg:1	center of gravity:32:0.6024	0.6024	32
CG	CG:48	central gray:48:0.8221	0.8221	48
CG	CG:9	centre of gravity:9:0.0693	0.0693	9
CG	CG:6|-CG:1	cerebral ganglia:7:0.0777	0.0777	7
CG	CG:10	chlorhexidine gluconate:10:0.3867	0.3867	10
CG	CG:17	cholylglycine:17:0.0094	0.0094	17
CG	CG:11	choriogonadotropin:11:0.0059	0.0059	11
CG	CG:35	chorionic gonadotrophin:35:0.7647	0.7647	35
CG	CG:134|Cg:1	chorionic gonadotropin:135:0.8882	0.8882	135
CG	CG:10|Cg:9	chromogranin:19:0.0106	0.0106	19
CG	CG:48	chronic gastritis:48:0.7997	0.7997	48
CG	CG:9	chronic glomerulonephritis:9:0.5470	0.5470	9
CG	CG:9	ciliary ganglia:9:0.1492	0.1492	9
CG	CG:72	ciliary ganglion:72:0.7330	0.7330	72
Cg	Cg:8|CG:2	cingulate cortex:10:0.5856	0.5856	10
CG	CG:14	coagulating gland:14:0.4367	0.4367	14
CG	CG:11|C-G:4	Cockcroft-Gault:15:0.0082	0.0082	15
CG	CG:14	collapsing glomerulopathy:14:0.6173	0.6173	14
CG	CG:10	colloidal gold:10:0.5000	0.5000	10
CG	CG:9	computer graphics:9:0.6794	0.6794	9
CG	CG:11	conjugate gradient:11:0.7357	0.7357	11
CG	CG:37|C-G:2	control:25:0.0141|controls:14:0.0076	0.0141	39
CG	CG:293|Cg:1|cg:1|C-G:1	control group:296:0.8631	0.8631	296
CG	CG:50	cortical granule:30:0.6037|cortical granules:20:0.4786	0.6037	50
CG	CG:11|Cg:1	cryoglobulins:12:0.0065	0.0065	12
CG	CG:9	cycloguanil:9:0.0047	0.0047	9
CG	CG:10|cg:1	groups:11:0.0059	0.0059	11
CG	CG:10	mesencephalic central gray area:10:0.7103	0.7103	10
CG	CG:4	porous collagen-glycosaminoglycan:4:0.0612	0.0612	4
CH1	CH1:5	first constant domain:5:0.2818	0.2818	5
CH2Cl2	CH2Cl2:9	dichloromethane:9:0.2963	0.2963	9
CH2Cl2	CH2Cl2:11	methylene chloride:11:0.7357	0.7357	11
CH2O	CH2O:21	formaldehyde:21:0.1460	0.1460	21
CH2O	CH2O:69|C-H2O:1	free water clearance:70:0.9112	0.9112	70
CH3-B12	CH3-B12:10	methylcobalamin:10:0.6154	0.6154	10
CH3SH	CH3SH:12	Methyl mercaptan:12:0.7571	0.7571	12
CH40	CH40:7|CH-40:3	activated carbon particles:10:0.7103	0.7103	10
Ch4	Ch4:12	nucleus basalis:12:0.7571	0.7571	12
CH50	CH50:15	complement hemolytic activity:15:0.3472	0.3472	15
CH50	CH50:8	total hemolytic activity:8:0.0863	0.0863	8
CH50	CH50:39	total hemolytic complement:39:0.5794	0.5794	39
CH50	CH50:19	Total hemolytic complement activity:19:0.4618	0.4618	19
CHAPS	CHAPS:20|Chaps:3	3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate:14:0.1083|3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonate:9:0.0211	0.1083	23
CHAPS	CHAPS:14|Chaps:4	zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate:13:0.3383|zwitterionic detergent 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate:5:0.4438	0.4438	18
CHAPS	CHAPS:7	zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid:7:0.2902	0.2902	7
CHAQ	CHAQ:103|C-HAQ:3	Childhood Health Assessment Questionnaire:106:0.9148	0.9148	106
CHARM	CHARM:6	candesartan in heart failure assessment of reduction in mortality and morbidity:6:0.7357	0.7357	6
CHB	CHB:9	1-cyano-2-hydroxy-3-butene:9:0.0183	0.0183	9
CHB	CHB:163|CH-B:17|chB:1|cHB:1	chronic hepatitis B:182:0.9835	0.9835	182
CHB	CHB:150	heart block:150:0.9574	0.9574	150
cHb	cHb:5|CHb:2	hemoglobin concentration:7:0.2113	0.2113	7
CHC1	CHC1:8	clathrin heavy chain gene:8:0.5006	0.5006	8
CHCA	CHCA:23	alpha-cyano-4-hydroxycinnamic acid:23:0.6306	0.6306	23
CHCC	CHCC:9	Chapel Hill Consensus Conference:9:0.6794	0.6794	9
CHCs	CHCs:47	community health centers:47:0.8433	0.8433	47
CHCs	CHCs:14	community health centres:14:0.4367	0.4367	14
CHCS	CHCS:9	Composite Health Care System:9:0.5470	0.5470	9
CHCs	CHCs:9	cuticular hydrocarbons:9:0.2500	0.2500	9
CHCT	CHCT:10	Contracture Test:10:0.5000	0.5000	10
CHDF	CHDF:58	continuous hemodiafiltration:58:0.8937	0.8937	58
cHDL	C-HDL:3|cHDL:3|c-HDL:1	high density lipoproteins:7:0.5926	0.5926	7
C-HDL	C-HDL:9|c-HDL:1|cHDL:1	high density lipoprotein cholesterol:11:0.6182	0.6182	11
CHDs	CHDs:25	congenital heart defects:25:0.8186	0.8186	25
CHD	CHD:9	1,2-cyclohexanedione:9:0.0013	0.0013	9
CHD	CHD:17	canine hip dysplasia:17:0.5038	0.5038	17
CHD	CHD:9	chronic haemodialysis:9:0.3945	0.3945	9
CHD	CHD:56|cHD:1	chronic hemodialysis:57:0.5069	0.5069	57
CHD	CHD:19	common hepatic duct:19:0.8449	0.8449	19
CHD	CHD:119	congenital heart defects:85:0.9648|congenital heart defect:34:0.9126	0.9648	119
CHD	CHD:35	congenital heart diseases:35:0.3805	0.3805	35
CHD	CHD:20	Conventional hemodialysis:20:0.1221	0.1221	20
CHD	CHD:5318	coronary heart disease:5285:0.9057|coronary heart diseases:33:0.3521	0.9057	5318
CHEB	CHEB:16	barbituric acid:16:0.6386	0.6386	16
CHED	CHED:15	congenital hereditary endothelial dystrophy:15:0.8045	0.8045	15
CHEF	CHEF:52	contour-clamped homogeneous electric field:52:0.6334	0.6334	52
CHEF	CHEF:8	homogeneous electric fields:8:0.4102	0.4102	8
CHEF	CHEF:5	homogeneous electric field electrophoresis:5:0.4422	0.4422	5
CHEMS	CHEMS:16|Chems:1	hemisuccinate:17:0.8000	0.8000	17
CHEOPS	CHEOPS:20	Children's Hospital of Eastern Ontario Pain Scale:20:0.8525	0.8525	20
CHESS	CHESS:14	chemical shift selective:14:0.7909	0.7909	14
ChEs	ChEs:22|CHEs:1	cholinesterases:23:0.4074	0.4074	23
CHE	CHE:10	Chinese hamster embryo:10:0.7103	0.7103	10
ChE	ChE:5|CHE:2	cholesterol esterase:7:0.1850	0.1850	7
ChE	ChE:4|CHE:1	choline esterase:5:0.0517	0.0517	5
ChE	ChE:644|CHE:46|Ch-E:3|Che:3|CHe:2|chE:1	cholinesterase:673:0.7436|cholinesterases:26:0.0276	0.7436	699
ChE	ChE:18|CHE:3|Ch-E:1	cholinesterase activity:22:0.7955	0.7955	22
ChE	ChE:12|CHE:2	pseudocholinesterase:14:0.0155	0.0155	14
CHFV	CHFV:7	high frequency ventilation:7:0.5926	0.5926	7
CHF	CHF:26	Congenital hepatic fibrosis:26:0.7340	0.7340	26
CHF	CHF:3285	congestive heart failure:3285:0.7503	0.7503	3285
CHF	CHF:22	continuous hemofiltration:22:0.7955	0.7955	22
CHF	CHF:6	Crimean Haemorrhagic Fever:6:0.5290	0.5290	6
CHF	CHF:7	Crimean hemorrhagic fever:7:0.5926	0.5926	7
CHF	CHF:340|cHF:1	patients with chronic heart failure:341:0.3233	0.3233	341
CHG	CHG:32	chlorhexidine gluconate:32:0.8145	0.8145	32
CHIK	CHIK:31|Chik:1	Chikungunya:32:0.8857	0.8857	32
CHIP-AE	CHIP-AE:9	Child Health and Illness Profile-Adolescent Edition:9:0.6794	0.6794	9
CHIP	CHIP:8	carboxyl terminus of Hsc70-interacting protein:8:0.6794	0.6794	8
CHIP	CHIP:23	Children's Health Insurance Program:23:0.6653	0.6653	23
ChIP	ChIP:200|CHIP:4	Chromatin immunoprecipitation:204:0.9687	0.9687	204
CHIP	CHIP:11	platinum IV:11:0.5374	0.5374	11
CHIRPP	CHIRPP:12	Canadian Hospitals Injury Reporting and Prevention Program:12:0.7753	0.7753	12
CHK	CHK:12|Chk:6	Csk homologous kinase:18:0.7539	0.7539	18
CHL1	CHL1:7	close homologue of L1:7:0.5926	0.5926	7
chl-a	chl-a:4|Chla:2|Chl-a:2|chla:1	chlorophyll-a:9:0.3200	0.3200	9
CHLA	CHLA:4	Hospital of Los Angeles:4:0.6794	0.6794	4
CHLs	CHLs:12	chlordanes:12:0.1964	0.1964	12
CHLs	CHLs:23	chlordane compounds:23:0.7500	0.7500	23
Chls	Chls:14|chls:1	chlorophylls:15:0.2500	0.2500	15
CHL	CHL:14|ChL:1	cell line:15:0.8045	0.8045	15
CHL	CHL:77	Chinese hamster lung:77:0.9612	0.9612	77
CHL	CHL:25|Chl:5	chlorambucil:30:0.0384	0.0384	30
Chl	Chl:7|CHL:6|chl:2	chloramphenicol:15:0.0185	0.0185	15
Chl	Chl:214|chl:9|CHL:3	chlorophyll:213:0.2808|chlorophylls:13:0.0159	0.2808	226
CHL	CHL:57|Chl:4	chlorophyllin:61:0.0795	0.0795	61
CHL	CHL:9|Chl:5	chloroquine:14:0.0172	0.0172	14
CHL	CHL:16|Chl:8	cholesterol:24:0.0305	0.0305	24
cHL	cHL:32|CHL:5	Classical Hodgkin lymphoma:19:0.6537|classical Hodgkin's lymphoma:18:0.8365	0.8365	37
CHL	CHL:13	combined hyperlipidemia:13:0.6701	0.6701	13
CHL	CHL:15	conductive hearing loss:15:0.6386	0.6386	15
CHL	CHL:13|C-HL:1	crown-heel length:14:0.5111	0.5111	14
ChL	ChL:9	Luminol-dependent chemiluminescence:9:0.1334	0.1334	9
ChM-I	ChM-I:28	chondromodulin-I:28:0.6000	0.6000	28
CHM	CHM:19	Chinese Herbal Medicine:19:0.8449	0.8449	19
CHM	CHM:28	Choroideremia:28:0.1281	0.1281	28
CHM	CHM:48	complete hydatidiform mole:35:0.8681|complete hydatidiform moles:13:0.7753	0.8681	48
CHM	CHM:32	cycloheximide:32:0.1527	0.1527	32
CHNs	CHNs:32	Community health nurses:32:0.8145	0.8145	32
CHN	CHN:22	Chinese herbs nephropathy:22:0.8657	0.8657	22
CHN	CHN:13	community health nursing:13:0.7753	0.7753	13
CHN	CHN:8	congenital hypomyelinating neuropathy:8:0.6411	0.6411	8
CHO-K1	CHO-K1:153|CHOK1:4	Chinese Hamster Ovary:157:0.9696	0.9696	157
CHO-K1	CHO-K1:68|CHO-k1:2	Chinese hamster ovary cells:70:0.9573	0.9573	70
CHO-K1	CHO-K1:9	Chinese hamster ovary cell line:9:0.6794	0.6794	9
CHO-K1	CHO-K1:10	Chinese hamster ovary K1:10:0.7103	0.7103	10
Chol	Chol:207|CHOL:191|chol:39	cholesterol:437:0.8123	0.8123	437
CHOP	CHOP:18	C/EBP homologous protein:18:0.6812	0.6812	18
CHOP	CHOP:11	cyclophosphamide/doxorubicin/vincristine/prednisone:11:0.0253	0.0253	11
ChoP	ChoP:20	phosphorylcholine:20:0.0455	0.0455	20
ChOx	ChOx:5|CHOx:1|ChOX:1	choline oxidase:7:0.3524	0.3524	7
ChOx	ChOx:6|ChOX:3	oxidation products:9:0.6794	0.6794	9
CHOs	CHOs:10	carbohydrates:10:0.3913	0.3913	10
CHO	CHO:547|cho:1	carbohydrate:502:0.0838|carbohydrates:46:0.0075	0.0838	548
CHO	CHO:21	Chinese hamster:21:0.6040	0.6040	21
CHO	CHO:42	Chinese hamster ovarian:42:0.9291	0.9291	42
CHO	CHO:4337	Chinese hamster ovary:4337:0.9965	0.9965	4337
CHO	CHO:152	Chinese hamster ovary cells:141:0.9551|Chinese hamster ovary cell:11:0.7357	0.9551	152
CHO	CHO:13	Chinese hamster ovary cell line:13:0.7753	0.7753	13
Cho	Cho:132|CHO:12	choline-containing compounds:125:0.6890|choline containing compounds:19:0.8525	0.8525	144
ChO	ChO:7|Cho:3|CHO:1	choline oxidase:11:0.4728	0.4728	11
cho	cho:7|Cho:1|CHO:1	chondrodysplasia:9:0.0013	0.0013	9
CHO	CHO:11|cho:1	cyclohexene oxide:12:0.5050	0.5050	12
CHO	CHO:20	high-carbohydrate:20:0.0032	0.0032	20
Cho	Cho:8	N-acetylaspartate (NAA)/choline:8:0.4102	0.4102	8
CHO	CHO:8|Cho:1	serum cholesterol:9:0.0606	0.0606	9
CHPG	CHPG:8	agonist (RS)-2-chloro-5-hydroxyphenylglycine:8:0.2500	0.2500	8
CHPP	CHPP:45	Continuous hyperthermic peritoneal perfusion:45:0.9323	0.9323	45
CHP	CHP:10	Chandipura:10:0.0286	0.0286	10
CHP	CHP:12	Chlorpyrifos:12:0.0349	0.0349	12
ChP	ChP:9|chp:3	choroid plexus:12:0.7571	0.7571	12
CHP	CHP:17|chp:1	cricohyoidopexy:18:0.0540	0.0540	18
CHP	CHP:47|Chp:5|cHP:2	cumene hydroperoxide:54:0.8862	0.8862	54
CHP	CHP:13|cHP:4	Cyclo(His-Pro):16:0.0476|cyclo His-Pro:1:0.6794	0.6794	17
CHP	CHP:12	cytophagic histiocytic panniculitis:12:0.7571	0.7571	12
CHP	CHP:12	pullulan:12:0.0349	0.0349	12
CHQ-12	CHQ-12:9	Chinese Health Questionnaire:9:0.6794	0.6794	9
CHR3	CHR3:6	Choristoneura hormone receptor 3:6:0.5290	0.5290	6
CHRNA4	CHRNA4:8	neuronal nicotinic acetylcholine receptor alpha 4 subunit:8:0.6411	0.6411	8
CHRNA4	CHRNA4:4	neuronal nicotinic acetylcholine receptor alpha4 subunit:4:0.3170	0.3170	4
CHRNA4	CHRNA4:8	nicotinic acetylcholine receptor:8:0.6411	0.6411	8
CHRNA4	CHRNA4:6	nicotinic acetylcholine receptor alpha 4 subunit gene:6:0.5290	0.5290	6
CHRNA7	CHRNA7:7	receptor subunit gene:7:0.4438	0.4438	7
CHRPE	CHRPE:60	congenital hypertrophy of the retinal pigment epithelium:60:0.9548	0.9548	60
CHRS	CHRS:10	cerebro-hepato-renal syndrome:10:0.2446	0.2446	10
CHS1	CHS1:18|Chs1:7|chs-1:1	chitin synthase 1:26:0.8861	0.8861	26
cHSP60	CHSP60:4|cHSP60:4|chsp60:1|cHsp60:1|C-hsp60:1|c-hsp60:1	heat shock protein:12:0.7571	0.7571	12
cHSP60	cHSP60:5|CHSP60:4|cHsp60:1	heat shock protein 60:10:0.7103	0.7103	10
ChT	ChT:11|CHT:7|Cht:4	alpha-chymotrypsin:22:0.0784	0.0784	22
CHT	CHT:83|ChT:24|cht:1|Cht:1	Chemotherapy:109:0.4030	0.4030	109
CHT	CHT:9	choline transporter:9:0.5470	0.5470	9
ChT	ChT:4|CHT:4|Cht:3	chymotrypsin:11:0.0373	0.0373	11
CHT	CHT:20	closed head trauma:20:0.8525	0.8525	20
CHT	CHT:19	Congenital hypothyroidism:19:0.8449	0.8449	19
CHWs	CHWs:47	Community Health Workers:47:0.8703	0.8703	47
CHW	CHW:31	community health worker:22:0.7400|Community health workers:9:0.6794	0.7400	31
CHX	CHX:123|CHx:4|Chx:1	chlorhexidine:128:0.1716	0.1716	128
CHX	CHX:18	chlorhexidine digluconate:18:0.8365	0.8365	18
CHX	CHX:24|Chx:2	Chlorhexidine gluconate:26:0.8861	0.8861	26
CHX	CHX:64|Chx:1	protein synthesis inhibitor cycloheximide:65:0.9479	0.9479	65
CH	CH:16	calcium hydroxide:16:0.8165	0.8165	16
CH	CH:26	Calponin homology:26:0.7760	0.7760	26
CH	CH:22|ch:1	carbohydrate:14:0.0052|carbohydrates:9:0.0032	0.0052	23
CH	CH:10	cardiac hypertrophy:10:0.1519	0.1519	10
CH	CH:9	central hemodynamics:9:0.5470	0.5470	9
CH	CH:17	cerebral hemispheres:17:0.8270	0.8270	17
CH	CH:28	cerebral hemorrhage:28:0.6057	0.6057	28
CH	CH:14|C-H:3	Chediak-Higashi:17:0.0064	0.0064	17
CH	CH:7|Ch:3	chemotherapy:10:0.0040	0.0040	10
CH	CH:15	Chinese hamster:15:0.8045	0.8045	15
CH	CH:10|Ch:5	chitosan:15:0.0056	0.0056	15
CH	CH:94	chloral hydrate:94:0.9332	0.9332	94
CH	CH:27	chlorhexidine:27:0.0108	0.0108	27
Ch	Ch:8	chow and water:8:0.5006	0.5006	8
CH	CH:181	chronic hepatitis:181:0.8323	0.8323	181
CH	CH:45	chronic hypoxia:45:0.7664	0.7664	45
CH	CH:23	Chronically hypoxic:23:0.5997	0.5997	23
CH	CH:116	cluster headache:116:0.8450	0.8450	116
CH	CH:6	community hospital:6:0.1320	0.1320	6
CH	CH:8	concentric hypertrophy:8:0.0906	0.0906	8
CH	CH:5|ch:4	congenital hydrocephalus:9:0.2757	0.2757	9
CH	CH:9	congenital hypothyroid:9:0.4587	0.4587	9
CH	CH:210	congenital hypothyroidism:210:0.9047	0.9047	210
CH	CH:77	contact hypersensitivity:77:0.9190	0.9190	77
CH	CH:5	crypt height:5:0.1132	0.1132	5
CH	CH:11|ch:1	cyclic hematopoiesis:12:0.7571	0.7571	12
CH	CH:58	Cycloheximide:58:0.0228	0.0228	58
CH	CH:10	heavy chain constant:10:0.7103	0.7103	10
CH	CH:15	heavy chain constant region:15:0.6386	0.6386	15
CH	CH:28|Ch:6	total cholesterol:34:0.0817	0.0817	34
CI2	CI2:51|CI-2:8	chymotrypsin inhibitor 2:59:0.9494	0.9494	59
CIAP	CIAP:16	chronic idiopathic axonal polyneuropathy:16:0.8165	0.8165	16
CIAV	CIAV:21	chicken infectious anemia virus:21:0.8594	0.8594	21
CIA	CIA:11	carbon immunoassay:11:0.1938	0.1938	11
CIA	CIA:539	collagen-induced arthritis:539:0.7901	0.7901	539
CIA	CIA:25	common iliac artery:25:0.8186	0.8186	25
CIA	CIA:10	image analysis:10:0.3867	0.3867	10
CIBD	CIBD:29	chronic inflammatory bowel disease:29:0.7970	0.7970	29
CIBIS	CIBIS:15	Cardiac Insufficiency Bisoprolol Study:15:0.8045	0.8045	15
CICR	CICR:65	Ca(2+)-induced Ca(2+) release:65:0.8474	0.8474	65
CICR	CICR:77	Ca(2+)-induced Ca2+ release:77:0.3873	0.3873	77
CICR	CICR:68	Ca2+-induced Ca2+ release:68:0.3233	0.3233	68
CICR	CICR:79	calcium-induced calcium release:79:0.7838	0.7838	79
CICU	CICU:17	cardiac intensive care unit:17:0.5374	0.5374	17
CICs	CICs:110|CICS:1|CIC-s:1|cICs:1	Circulating immune complexes:113:0.9316	0.9316	113
CIC	CIC:7	central nucleus of the inferior colliculus:7:0.5926	0.5926	7
CIC	CIC:12|Cic:1	cicletanine:13:0.0103	0.0103	13
CIC	CIC:784|cIC:6|CiC:2|cic:2	circulating immune complexes:728:0.9568|circulating immune complex:66:0.8329	0.9568	794
CIC	CIC:20	clean intermittent catheterisation:20:0.8525	0.8525	20
CIC	CIC:96	clean intermittent catheterization:96:0.9685	0.9685	96
CIC	CIC:7	clean intermittent self-catheterization:7:0.3524	0.3524	7
CIC	CIC:36	conjunctival impression cytology:36:0.8716	0.8716	36
CIDNP	CIDNP:16	induced dynamic nuclear polarization:16:0.8165	0.8165	16
CIDP	CIDP:15	chronic inflammatory demyelinating neuropathy:15:0.8045	0.8045	15
CIDP	CIDP:289	chronic inflammatory demyelinating polyneuropathy:289:0.9896	0.9896	289
CIDP	CIDP:134	chronic inflammatory demyelinating polyradiculoneuropathy:134:0.9777	0.9777	134
CIDR	CIDR:18	Controlled Internal Drug Release:18:0.8365	0.8365	18
CIDR	CIDR:7	Controlled Internal Drug Releasing:7:0.5926	0.5926	7
CIDS	CIDS:20	Canadian Implantable Defibrillator Study:20:0.8449	0.8449	20
CID	CID:10	Central Institute for the Deaf:10:0.7357	0.7357	10
CID	CID:342	collision-induced dissociation:342:0.7677	0.7677	342
CID	CID:20	combined immunodeficiency:20:0.7173	0.7173	20
CID	CID:6	combined immunodeficiency disease:6:0.5290	0.5290	6
CID	CID:8	cytomegalic inclusion disease:8:0.6411	0.6411	8
CIEF	CIEF:81|cIEF:38	capillary isoelectric focusing:119:0.9749	0.9749	119
CIEF	CIEF:9	crossed immunoelectrofocusing:9:0.6794	0.6794	9
CIEIA	CIEIA:10	competitive inhibition enzyme immunoassay:10:0.7103	0.7103	10
CIEP	CIEP:39	counter immunoelectrophoresis:22:0.3457|counter-immunoelectrophoresis:17:0.1168	0.3457	39
CIEP	CIEP:50	counterimmunoelectrophoresis:50:0.3577	0.3577	50
CIE	CIE:5	Capillary ion electrophoresis:5:0.4422	0.4422	5
CIE	CIE:9	chronic intermittent ethanol:9:0.7103	0.7103	9
CIE	CIE:12	Congenital ichthyosiform erythroderma:12:0.7753	0.7753	12
CIE	CIE:31	counter-immunoelectrophoresis:31:0.0487	0.0487	31
CIE	CIE:220	counterimmunoelectrophoresis:220:0.3555	0.3555	220
CIE	CIE:141	Crossed immunoelectrophoresis:141:0.6048	0.6048	141
CIFN	CIFN:18|C-IFN:2	consensus interferon:20:0.7766	0.7766	20
CIF	CIF:20	inhibitory factor:20:0.2219	0.2219	20
CIGMA	CIGMA:25	continuous infusion of glucose with model assessment:25:0.8816	0.8816	25
CIGTS	CIGTS:21	Collaborative Initial Glaucoma Treatment Study:21:0.8594	0.8594	21
CIG	CIG:17|CIg:6	cold-insoluble globulin:14:0.3585|Cold insoluble globulin:9:0.6794	0.6794	23
cIg	cIg:5|CIg:3|c-Ig:1	cytoplasmic Ig:9:0.3945	0.3945	9
cIg	cIg:21|CIg:13|C-Ig:2|cig:1	cytoplasmic immunoglobulin:37:0.6610	0.6610	37
CIHD	CIHD:13	chronic ischemic heart disease:13:0.7753	0.7753	13
CIHI	CIHI:18	Canadian Institute for Health Information:18:0.8449	0.8449	18
CIH	CIH:14	Chronic intermittent hypoxia:14:0.6911	0.6911	14
CIH	CIH:9	colloidal iron hydroxide:9:0.5470	0.5470	9
CIIP	CIIP:17	chronic idiopathic intestinal pseudo-obstruction:17:0.7407	0.7407	17
CIITA	CIITA:13	class II trans-activator:13:0.7753	0.7753	13
CIITA	CIITA:191	class II transactivator:191:0.9749	0.9749	191
CIITA	CIITA:8	class II transcriptional activator:8:0.6411	0.6411	8
CII	CII:28	Collagen type II:28:0.5445	0.5445	28
CII	CII:291|cII:3|C-II:2	type II collagen:296:0.9392	0.9392	296
CIK	CIK:36	cytokine-induced killer:36:0.8003	0.8003	36
CILP	CILP:8	cartilage intermediate layer protein:8:0.6411	0.6411	8
CIMF	CIMF:17|cIMF:2	chronic idiopathic myelofibrosis:19:0.8449	0.8449	19
CI-MPR	CI-MPR:21|CIMPR:3	cation-independent mannose 6-phosphate receptor:24:0.7593	0.7593	24
CI-MS	CI-MS:4|CIMS:4	Chemical ionization mass spectrometry:8:0.6411	0.6411	8
CIMT	CIMT:29|c-IMT:1|cIMT:1	carotid intima-media thickness:31:0.7091	0.7091	31
CIMT	CIMT:20	Constraint-induced movement therapy:20:0.7766	0.7766	20
CIM	CIM:6	cardia intestinal metaplasia:6:0.2827	0.2827	6
CIM	CIM:12	cimaterol:12:0.0430	0.0430	12
CIM	CIM:52|Cim:16|cim:3	cimetidine:71:0.2734	0.2734	71
CIM	CIM:23	composite interval mapping:23:0.8715	0.8715	23
CIM	CIM:6	critical illness myopathy:6:0.5290	0.5290	6
CIM	CIM:10	monitoring:10:0.0352	0.0352	10
CIN3	CIN3:8|CIN-3:1	cervical intraepithelial neoplasia:9:0.6794	0.6794	9
CIN3	CIN3:10	cervical intraepithelial neoplasia grade 3:10:0.7103	0.7103	10
CINC	CINC:154	cytokine-induced neutrophil chemoattractant:154:0.8358	0.8358	154
CINC-1	CINC-1:25|CINC1:1	cytokine-induced neutrophil chemoattractant-1:26:0.8861	0.8861	26
CINCA	CINCA:2	chronic infantile neurologic cutaneous and articular:2:0.5926	0.5926	2
CINCA	CINCA:6	chronic infantile neurological cutaneous and articular:6:0.7571	0.7571	6
CINCs	CINCs:11	cytokine-induced neutrophil chemoattractants:11:0.7357	0.7357	11
CIND	CIND:3	cognitive impairment no dementia:3:0.5470	0.5470	3
CINV	CINV:36	chemotherapy-induced nausea and vomiting:36:0.8716	0.8716	36
CINs	CINs:10	cervical intraepithelial neoplasias:10:0.7103	0.7103	10
CIO	CIO:9	Chief Information Officer:9:0.5470	0.5470	9
CIPA	CIPA:33	congenital insensitivity to pain with anhidrosis:33:0.9100	0.9100	33
CIPC	CIPC:12	chlorpropham:12:0.3056	0.3056	12
CIPD	CIPD:9	chronic inflammatory periodontal disease:9:0.6794	0.6794	9
CIPII	CIPII:9	continuous intraperitoneal insulin infusion:9:0.6794	0.6794	9
CIPO	CIPO:12	chronic intestinal pseudo-obstruction:12:0.7571	0.7571	12
CIP	CIP:13	Caerulein-induced pancreatitis:13:0.5934	0.5934	13
CIP	CIP:14	Chronic intestinal pseudo-obstruction:14:0.7909	0.7909	14
CIP	CIP:7|Cip:2	ciprofibrate:9:0.0207	0.0207	9
CIP	CIP:92|Cip:10|cip:2	ciprofloxacin:104:0.2687	0.2687	104
CIP	CIP:10|CiP:3	Coprinus cinereus peroxidase:13:0.6701	0.6701	13
CIP	CIP:7	corticotropin-inhibiting peptide:7:0.2452	0.2452	7
CIP	CIP:33	critical illness polyneuropathy:33:0.8605	0.8605	33
CIQ	CIQ:29	community integration questionnaire:29:0.8941	0.8941	29
CIRC	CIRC:8|Circ:2	circumflex:10:0.2647	0.2647	10
CIREN	CIREN:9	crash injury research and engineering network:9:0.7753	0.7753	9
CIRS	CIRS:25	Cumulative Illness Rating Scale:25:0.8816	0.8816	25
CIR	CIR:12|Cir:1	cirrhosis:13:0.0698	0.0698	13
CIR	CIR:14	Cosmetic Ingredient Review:14:0.7909	0.7909	14
CIR	CIR:5	immune response:5:0.0902	0.0902	5
CISC	CISC:14	clean intermittent self-catheterization:14:0.8165	0.8165	14
CISD	CISD:23	Critical Incident Stress Debriefing:23:0.8657	0.8657	23
CISH	CISH:8	chromogenic in situ hybridisation:8:0.4102	0.4102	8
CISH	CISH:41	chromogenic in situ hybridization:41:0.5794	0.5794	41
CISH	CISH:5	intrafascial supracervical hysterectomy:5:0.4422	0.4422	5
CISM	CISM:33	Critical Incident Stress Management:33:0.9043	0.9043	33
CIS-R	CIS-R:34|CISR:1	Revised Clinical Interview Schedule:35:0.6883	0.6883	35
CISS	CISS:23	Chromosomal in situ suppression:23:0.5236	0.5236	23
CISS	CISS:4	constructive interference in the steady state:4:0.9072	0.9072	4
CISS	CISS:2	constructive interference steady-state:2:0.5470	0.5470	2
CISS	CISS:14	Coping Inventory for Stressful Situations:14:0.7753	0.7753	14
CIs	CIs:7	calcineurin inhibitors:7:0.2113	0.2113	7
CIS	CIS:45	Cancer Information Service:45:0.9338	0.9338	45
CIS	CIS:556|Cis:13|cis:5|CiS:1	carcinoma in situ:545:0.8885|carcinoma-in-situ:30:0.0127	0.8885	575
CIS	CIS:4|Cis:1	carcinoma in situ testis:5:0.7103	0.7103	5
CIS	CIS:5	cellular injury score:5:0.1973	0.1973	5
CIS	CIS:5	chronic immobilization stress:5:0.1464	0.1464	5
CIS	CIS:12|Cis:5|cis:1	cisplatin:18:0.0074	0.0074	18
CIS	CIS:65	clinical information system:41:0.7472|clinical information systems:24:0.7593	0.7593	65
CIS	CIS:32	Clinical Interview Schedule:32:0.8563	0.8563	32
CIS	CIS:31	clinically isolated syndromes:18:0.8365|clinically isolated syndrome:13:0.7753	0.8365	31
CIs	CIs:31	Cochlear implants:31:0.9043	0.9043	31
CIS	CIS:12	Commonwealth of Independent States:12:0.6460	0.6460	12
CIS	CIS:11	Continuous Interleaved Sampler:11:0.5856	0.5856	11
CIS	CIS:41	continuous interleaved sampling:41:0.8867	0.8867	41
CIS	CIS:5	Critical Incident Stress:5:0.4422	0.4422	5
CIS	CIS:10	cytokine-inducible SH2-containing protein:10:0.4363	0.4363	10
CIS	CIS:5|Cis:1	cytokine-inducible SH2 protein:6:0.1838	0.1838	6
CIU	CIU:88	chronic idiopathic urticaria:88:0.9660	0.9660	88
CIVD	CIVD:13	cold-induced vasodilatation:13:0.3809	0.3809	13
CIVI	CIVI:11|civi:1	continuous intravenous infusion:12:0.7571	0.7571	12
CIV	CIV:25	Chilo Iridescent Virus:25:0.8768	0.8768	25
CIV	CIV:12|C-IV:5	collagen IV:17:0.1720	0.1720	17
CIV	CIV:16|C-IV:8	collagen type IV:24:0.6427	0.6427	24
CIV	CIV:8	continuous infusion:8:0.1004	0.1004	8
CIV	CIV:10	continuous intravenous:10:0.7103	0.7103	10
CIV	CIV:12|civ:1	continuous intravenous infusion:13:0.7753	0.7753	13
CIV	CIV:18|C-IV:8|cIV:2	type IV collagen:28:0.8369	0.8369	28
CIN	CIN:12	cefsulodin-irgasan-novobiocin:12:0.0054	0.0054	12
CIN	CIN:5	cervical intraepithelial lesions:5:0.2818	0.2818	5
CIN	CIN:1367|cin:1	cervical intraepithelial neoplasia:1340:0.9555|cervical intraepithelial neoplasias:28:0.8369	0.9555	1368
CIN	CIN:19	cervical intraepithelial neoplasm:11:0.7357|cervical intraepithelial neoplasms:8:0.6411	0.7357	19
CIN	CIN:70	chromosomal instability:70:0.7270	0.7270	70
CIN	CIN:14	chromosome instability:14:0.0749	0.0749	14
CIN	CIN:12	chronic idiopathic neutropenia:12:0.7571	0.7571	12
cin	cin:7|CIN:2|Cin:1	Cinnarizine:10:0.0044	0.0044	10
Cin	Cin:12|CIn:10|CIN:7	clearance of inulin:20:0.2485|clearances of inulin:9:0.0577	0.2485	29
CIN	CIN:23	contrast-induced nephropathy:23:0.4652	0.4652	23
Cin	Cin:46|CIn:38|CIN:16|cin:2	inulin clearance:102:0.8556	0.8556	102
CI	CI:11	95% confidence internal:11:0.7357	0.7357	11
CI	CI:9497|ci:4	95% confidence interval:8193:0.9142|95% confidence intervals:1308:0.8581	0.9142	9501
CI	CI:12	95% confidence limits:12:0.6460	0.6460	12
CI	CI:17	calcineurin inhibitors:10:0.7103|calcineurin inhibitor:7:0.0886	0.7103	17
CI	CI:13	calcium ionophore:13:0.7753	0.7753	13
CI	CI:8	carbonyl iron:8:0.1367	0.1367	8
CI	CI:9	cardiac:9:0.0006	0.0006	9
CI	CI:1383|Ci:2	cardiac index:1380:0.7836|cardiac indexes:5:0.0902	0.7836	1385
CI	CI:9	cation-independent:9:0.0006	0.0006	9
CI	CI:7	cerebral infarct:7:0.3524	0.3524	7
CI	CI:104	cerebral infarction:104:0.8683	0.8683	104
CI	CI:6	cervical incompetence:6:0.0899	0.0899	6
CI	CI:8	chemical intolerance:8:0.5006	0.5006	8
CI	CI:10	chilling injury:10:0.1878	0.1878	10
CI	CI:9	chronotropic incompetence:9:0.2757	0.2757	9
Ci	Ci:9|CI:1	cirrhosis:10:0.0006	0.0006	10
CI	CI:136	cochlear implant:116:0.9109|cochlear implants:20:0.7766	0.9109	136
CI	CI:24	cochlear implantation:24:0.8768	0.8768	24
CI	CI:20	cognitive impairment:20:0.7173	0.7173	20
CI	CI:12	cold ischemia:12:0.2414	0.2414	12
CI	CI:7|C-I:3	collagen type I:10:0.3867	0.3867	10
CI	CI:11	colloidal iron:11:0.2764	0.2764	11
C-I	C-I:12	Combined-Integrated:12:0.0008	0.0008	12
Ci	Ci:8|ci:2|CI:1	compliance:11:0.0007	0.0007	11
CI	CI:9	conditioned inhibition:9:0.1334	0.1334	9
CI	CI:7	configuration interaction:7:0.2452	0.2452	7
CI	CI:10	constraint-induced:10:0.0006	0.0006	10
CI	CI:5	continuous improvement:5:0.1132	0.1132	5
CI	CI:118|ci:2	continuous infusion:120:0.8183	0.8183	120
CI	CI:12	Conventional imaging:12:0.4557	0.4557	12
CI	CI:14	convergence insufficiency:14:0.2524	0.2524	14
CI	CI:11	Cranial irradiation:11:0.2972	0.2972	11
CI	CI:14	cumulative incidence:14:0.7096	0.7096	14
CI	CI:12	cylindrical inclusion:12:0.3275	0.3275	12
CI	CI:7	cytoplasmic inclusion:7:0.0951	0.0951	7
CI	CI:70	Cytoplasmic incompatibility:70:0.9326	0.9326	70
CI	CI:15	indices:15:0.0010	0.0010	15
Ci	Ci:15	inorganic carbon:15:0.7096	0.7096	15
Ci	Ci:6	intercellular CO2 concentration:6:0.2827	0.2827	6
Ci	Ci:15|CI:1	transcription factor Cubitus interruptus:16:0.8365	0.8365	16
CI	CI:15	type I collagen:15:0.8045	0.8045	15
CJD	CJD:939|CjD:1	Creutzfeldt-Jakob disease:940:0.8948	0.8948	940
CJ	CJ:9|Cj:9	Campylobacter jejuni:18:0.7539	0.7539	18
CK+	CK+:11	cytokeratin-positive:11:0.4762	0.4762	11
CK14	CK14:7|Ck14:1|CK-14:1	cytokeratin 14:9:0.6794	0.6794	9
CK18	CK18:38|CK-18:14|ck18:1	cytokeratin 18:40:0.6998|cytokeratin-18:13:0.1875	0.6998	53
CK19	CK19:93|CK-19:38|Ck19:1	cytokeratin 19:107:0.9279|Cytokeratin-19:25:0.1538	0.9279	132
CK1	CK1:22|CK-1:13|Ck1:1	casein kinase 1:22:0.7955|casein kinase-1:14:0.7291	0.7955	36
CK-20	CK-20:16|CK20:5	cytokeratin-20:21:0.1282	0.1282	21
CK2	CK2:103|CK-2:40	Casein kinase 2:111:0.9055|casein kinase-2:32:0.7782	0.9055	143
CK2	CK2:19|CK-2:5|Ck2:1	casein kinase II:25:0.8816	0.8816	25
CK2	CK2:25	protein kinase CK2:25:0.8816	0.8816	25
CK7	CK7:46|CK-7:6	cytokeratin 7:52:0.7297	0.7297	52
CK8	CK8:22	cytokeratin 8:22:0.7046	0.7046	22
CK-BB	CK-BB:30|CKBB:8|ck-bb:1	creatine kinase:39:0.8811	0.8811	39
CK-BB	CK-BB:23|CKBB:7	creatine kinase BB:30:0.8032	0.8032	30
CK-BB	CK-BB:14|CKBB:1	Creatine Kinase BB isoenzyme:15:0.8045	0.8045	15
CK-BB	CK-BB:20	creatine kinase isoenzyme BB:20:0.8525	0.8525	20
CKB	CKB:10|ckb:2|CK-B:1	brain creatine kinase:13:0.2661	0.2661	13
CKB	CKB:17|CK-B:7|ckb:2	creatine kinase:26:0.8251	0.8251	26
CK-B	CK-B:16|CKB:13|ck-b:1	creatine kinase B:18:0.8365|Creatine kinase-B:12:0.7571	0.8365	30
CKD	CKD:446	chronic kidney disease:446:0.9932	0.9932	446
CKII	CKII:237|CK-II:39	casein kinase II:276:0.9714	0.9714	276
CKIs	CKIs:32|Ckis:1	cdk inhibitors:33:0.2266	0.2266	33
CKIs	CKIs:56|Ckis:1	cyclin-dependent kinase inhibitors:57:0.7044	0.7044	57
CKI	CKI:45|CK-I:3	Casein kinase I:48:0.9379	0.9379	48
CKI	CKI:7	CDK inhibitors:7:0.0953	0.0953	7
CKI	CKI:38|cki:2	cyclin-dependent kinase inhibitor:29:0.5376|cyclin-dependent kinase inhibitors:11:0.3495	0.5376	40
CK-MB	CK-MB:72|CKMB:9	creatine kinase:81:0.8612	0.8612	81
CK-MB	CK-MB:33	creatine kinase isoenzyme:28:0.8369|creatine kinase isoenzymes:5:0.5290	0.8369	33
CK-MB	CK-MB:37|CKMB:11	creatine kinase isoenzyme MB:48:0.9379	0.9379	48
CK-MB	CK-MB:142|CKMB:32	creatine kinase-MB:92:0.9484|creatine kinase MB:82:0.9422	0.9484	174
CK-MB	CKMB:3|CK-MB:3	creatine kinase MB fraction:6:0.6386	0.6386	6
CK-MB	CK-MB:35|CKMB:4	creatine kinase MB isoenzyme:39:0.8867	0.8867	39
CK-MB	CK-MB:19|CKMB:2	creatine kinase-myocardial band:14:0.7909|creatine kinase myocardial band:7:0.4438	0.7909	21
CK-MB	CK-MB:5|CKMB:1	isoenzyme of CK:6:0.1641	0.1641	6
CK-MM	CK-MM:10|CKMM:7	creatine kinase:17:0.7407	0.7407	17
CKm	CKm:9|CKM:4|CK-M:2|ckm:2	creatine kinase:17:0.6748	0.6748	17
CKS	CKS:10	classic Kaposi's sarcoma:10:0.3867	0.3867	10
CKs	CKs:131|Cks:10	cytokeratins:141:0.6087	0.6087	141
CKs	CKs:13|Cks:1	cytokines:14:0.0565	0.0565	14
CKs	CKs:8|Cks:3	cytokinins:11:0.0435	0.0435	11
CK	CK:11	anti-cytokeratin:11:0.0026	0.0026	11
CK	CK:6	casein kinases:6:0.1010	0.1010	6
CK	CK:11	chick kidney:11:0.1547	0.1547	11
CK	CK:11	chicken kidney:11:0.1547	0.1547	11
CK	CK:14	color kinesis:14:0.6173	0.6173	14
CK	CK:3|C-K:2	compound K:5:0.0612	0.0612	5
CK	CK:18	Conductive keratoplasty:18:0.8365	0.8365	18
CK	CK:2588|Ck:1	creatine kinase:2581:0.9340|creatine kinases:8:0.2327	0.9340	2589
CK	CK:35	creatine kinase activity:35:0.8681	0.8681	35
CK	CK:104	creatine phosphokinase:104:0.8495	0.8495	104
CK	CK:12	creatinkinase:12:0.0028	0.0028	12
CK	CK:496|Ck:11|ck:1	cytokeratin:508:0.1307	0.1307	508
CK	CK:13|ck:1	expression of cytokeratins:14:0.0761	0.0761	14
CK	CK:10	Serum creatine-kinase:10:0.0929	0.0929	10
CL(H)	CL(H):7|CL(h):3	hepatic clearance:10:0.7103	0.7103	10
CL(P)	CL(P):10	cleft lip with or without cleft palate:10:0.7103	0.7103	10
CL(p)	CL(p):8|CL(P):2|Cl(p):2	plasma clearance:12:0.6460	0.6460	12
CL(R)	CL(R):11|CL(r):5|Cl(r):3	renal clearance:19:0.7766	0.7766	19
CL(int)	CL(int):26|Cl(int):8|CL(INT):1	intrinsic clearance:35:0.6883	0.6883	35
CL-43	CL-43:14	Collectin-43:14:0.8667	0.8667	14
cl.	cl.:25	clearance:25:0.6316	0.6316	25
CL/F	CL/F:140|Cl/F:39|CL/f:18|Cl/f:6	clearance:203:0.8279	0.8279	203
CL/P	CL/P:52	Cleft lip with or without cleft palate:52:0.9467	0.9467	52
Cl2	Cl2:14	Chlorine:14:0.3023	0.3023	14
CLAD	CLAD:8	Canine leukocyte adhesion deficiency:8:0.6411	0.6411	8
CLARI	CLARI:11	clarithromycin:11:0.9091	0.9091	11
CLAS	CLAS:10	Cholesterol Lowering Atherosclerosis Study:10:0.6794	0.6794	10
CLAs	CLAs:22	conjugated linoleic acids:22:0.8657	0.8657	22
CL-A	CL-A:14|CLA:1	calyculin-A:15:0.0140	0.0140	15
CLA	CLA:14	caseous lymphadenitis:14:0.7909	0.7909	14
CLA	CLA:6|cla:1	cationic leukocyte antigen:7:0.0732	0.0732	7
CLA	CLA:22|cla:6	clarithromycin:28:0.0271	0.0271	28
CLA	CLA:13	common leukocyte antigen:13:0.2959	0.2959	13
CLA	CLA:583|Cla:1	conjugated linoleic acid:516:0.9396|conjugated linoleic acids:68:0.9561	0.9561	584
CLA	CLA:6	cutaneous lymphocyte Ag:6:0.5290	0.5290	6
CLA	CLA:39	cutaneous lymphocyte antigen:39:0.9237	0.9237	39
CLA	CLA:7	cutaneous lymphocyte-associated Ag:7:0.5926	0.5926	7
CLA	CLA:78	cutaneous lymphocyte-associated antigen:78:0.9617	0.9617	78
CLBBB	CLBBB:9	complete left bundle branch block:9:0.6794	0.6794	9
CLBP	CLBP:129|cLBP:1	chronic low back pain:130:0.9517	0.9517	130
ClC-1	ClC-1:7|CLC-1:2	chloride channel:9:0.5470	0.5470	9
CLCN1	CLCN1:13	chloride channel gene:13:0.7753	0.7753	13
CLC	CLC:12|cLC:2	capillary liquid chromatography:14:0.5111	0.5111	14
CLC	CLC:11	cardiotrophin-like cytokine:11:0.7357	0.7357	11
CLC	CLC:34	Charcot-Leyden crystal:24:0.7151|Charcot-Leyden crystals:10:0.7103	0.7151	34
CLC	CLC:9	colchicine:9:0.0404	0.0404	9
cLC	cLC:8	cultured LC:8:0.3463	0.3463	8
C-LDL	C-LDL:9|CLDL:1|c-LDL:1	Low density lipoprotein cholesterol:11:0.7357	0.7357	11
CLDT	CLDT:13	cytolethal distending toxin:13:0.7753	0.7753	13
CLD	CLD:11	central lung distance:11:0.7357	0.7357	11
Cld	Cld:6|CLD:4	Cephaloridine:10:0.0114	0.0114	10
CLD	CLD:232|C-LD:1	chronic liver disease:201:0.9474|chronic liver diseases:32:0.8145	0.9474	233
CLD	CLD:367	chronic lung disease:367:0.9746	0.9746	367
CLD	CLD:22	Chronic lung disease of prematurity:22:0.8657	0.8657	22
CLd	CLd:5|CLD:2|Cld:1|ClD:1	clearance:9:0.0101	0.0101	9
cld	cld:7|CLD:1	Combined lipase deficiency:8:0.6411	0.6411	8
CLD	CLD:14	Congenital chloride diarrhea:14:0.7909	0.7909	14
CLE0	CLE0:11	conserved lymphokine element 0:11:0.7357	0.7357	11
CLEIA	CLEIA:18|CL-EIA:2	enzyme immunoassay:20:0.6680	0.6680	20
CLEK	CLEK:29	Collaborative Longitudinal Evaluation of Keratoconus:29:0.8978	0.8978	29
CLFS	CLFS:12	Chronic low-frequency stimulation:12:0.5050	0.5050	12
CLF	CLF:3	fluorescent bile acid analogue cholyl-lysyl-fluorescein:3:0.5290	0.5290	3
ClF	ClF:3|CLf:2|Clf:1|CLF:1	formation clearance:7:0.3524	0.3524	7
CLH	CLH:13	chronic lobular hepatitis:13:0.7753	0.7753	13
CLH	CLH:11	Cutaneous lymphoid hyperplasia:11:0.7357	0.7357	11
CLh	CLh:5|ClH:4|CLH:2	hepatic clearance:11:0.4232	0.4232	11
CLIA	CLIA:6	chemiluminescent assay:6:0.2243	0.2243	6
CLIA	CLIA:22	Chemiluminescent immunoassay:22:0.4510	0.4510	22
CLIA	CLIA:11	Clinical Laboratory Improvement Amendments:11:0.7357	0.7357	11
CLIA	CLIA:28	Clinical Laboratory Improvement Amendments of 1988:28:0.8903	0.8903	28
CLIC	CLIC:11	chloride intracellular channel:11:0.7357	0.7357	11
CLIP	CLIP:21	Cancer of the Liver Italian Program:21:0.8115	0.8115	21
CLIP	CLIP:39	class II-associated invariant chain peptide:22:0.8657|Class II-associated invariant chain peptides:17:0.7407	0.8657	39
CLIP	CLIP:26	corticotropin-like intermediate lobe peptide:26:0.6084	0.6084	26
CLL/PL	CLL/PL:11	prolymphocytes:11:0.4762	0.4762	11
CLL/SLL	CLL/SLL:23	chronic lymphocytic leukemia/small lymphocytic lymphoma:23:0.8715	0.8715	23
CLL	CLL:9	chronic lymphocytic:9:0.6794	0.6794	9
CLL	CLL:604	chronic lymphocytic leukaemia:597:0.9688|chronic lymphocytic leukaemias:7:0.4438	0.9688	604
CLL	CLL:2058|Cll:1|cll:1	chronic lymphocytic leukemia:2041:0.9693|chronic lymphocytic leukemias:19:0.7044	0.9693	2060
CLL	CLL:5	chronic lymphocytic leukemia cells:5:0.4422	0.4422	5
CLL	CLL:14	chronic lymphocytic leukemic:14:0.7909	0.7909	14
CLM	CLM:8	colorectal liver metastases:8:0.6411	0.6411	8
CLM	CLM:17	cutaneous larva migrans:17:0.8270	0.8270	17
Clm	Clm:5|CLM:3|CLm:1|ClM:1	metabolic clearance:10:0.5000	0.5000	10
CLND	CLND:22	lymph node dissection:22:0.8657	0.8657	22
CLN	CLN:38|C-LN:1|cLN:1	cervical lymph nodes:28:0.8369|cervical lymph node:12:0.5050	0.8369	40
CLN	CLN:9	clonidine:9:0.0650	0.0650	9
CLOOH	CLOOH:6|CL-OOH:3	hydroperoxide:9:0.8889	0.8889	9
CLOs	CLOs:12	Campylobacter-like organisms:12:0.7571	0.7571	12
CLO	CLO:30	Campylobacter-like Organism:17:0.5038|campylobacter-like organisms:13:0.5335	0.5335	30
CLO	CLO:11	clofazimine:11:0.0324	0.0324	11
CLO	CLO:58|Clo:14	Clonidine:72:0.2298	0.2298	72
CLO	CLO:25	Cod liver oil:25:0.8186	0.8186	25
CLO	CLO:10	oesophagus:10:0.0291	0.0291	10
CLo	Clo:6|CLo:6|CLO:2	oral clearance:14:0.6173	0.6173	14
CLO	CLO:7	rapid urease:7:0.2452	0.2452	7
CLPs	CLPs:6	C-type lectin-like proteins:6:0.5290	0.5290	6
CLPs	CLPs:12	common lymphoid progenitors:12:0.7571	0.7571	12
CLPs	CLPs:20	core-like particles:20:0.7766	0.7766	20
CLSA	CLSA:5	closed-loop stripping analysis:5:0.1973	0.1973	5
CLSE	CLSE:39	calf lung surfactant extract:39:0.8811	0.8811	39
CLSM	CLSM:91|cLSM:1	confocal laser scanning microscope:92:0.9675	0.9675	92
CLSM	CLSM:491|cLSM:3	Confocal laser scanning microscopy:494:0.9902	0.9902	494
CLS	CLS:12	capillary leak syndrome:12:0.7571	0.7571	12
CLS	CLS:9	classical least-squares:9:0.3945	0.3945	9
CLS	CLS:29	clinical laboratory science:29:0.8978	0.8978	29
CLS	CLS:36	Coffin-Lowry syndrome:36:0.4653	0.4653	36
CLs	CLs:16	contact lenses:16:0.8165	0.8165	16
CLs	CLs:14|Cls:2	corpora lutea:16:0.7261	0.7261	16
CLs	CLs:25	cycle lengths:25:0.8186	0.8186	25
Cls	Cls:15|CLs:11|ClS:1	systemic clearance:27:0.4427	0.4427	27
CLTH	CLTH:10	chronic lymphocytic thyroiditis:10:0.7103	0.7103	10
CLV	CLV:18	corrected loss variance:18:0.8365	0.8365	18
CLZ	CLZ:13	chlorozotocin:13:0.1446	0.1446	13
CLZ	CLZ:40	clozapine:40:0.4699	0.4699	40
CLdyn	CLdyn:15|Cldyn:1	dynamic lung compliance:16:0.8165	0.8165	16
CLint	CLint:18|Clint:9	intrinsic clearance:27:0.7425	0.7425	27
CLP	CLP:48	cecal ligation and perforation:48:0.9027	0.9027	48
CLP	CLP:11	cecal ligation/puncture:11:0.7357	0.7357	11
CLP	CLP:120|clp:1	Cleft lip and palate:121:0.9502	0.9502	121
CLP	CLP:2	cleft lip or cleft palate:2:0.8715	0.8715	2
CLP	CLP:8	coactosin-like protein:8:0.0726	0.0726	8
CLP	CLP:12	cytotoxic lymphocyte precursors:12:0.6460	0.6460	12
CLP	CLP:5	human calmodulin-like protein:5:0.0902	0.0902	5
Clp	Clp:29|CLp:11|CLP:4|clp:1	plasma clearance:45:0.5609	0.5609	45
Clp	Clp:7	protease Ti:7:0.5006	0.5006	7
Cltot	Cltot:21|CLtot:17|ClTOT:1	total body clearance:39:0.8811	0.8811	39
Clu	Clu:5|CLU:4	clusterin:9:0.2667	0.2667	9
Cl	Cl:111|CL:1	95% confidence interval:112:0.8694	0.8694	112
CL	CL:156|Cl:1	95% confidence limits:131:0.8777|95% confidence limit:26:0.6084	0.8777	157
Cl	Cl:17	cardiac index:17:0.6211	0.6211	17
CL	CL:268	Cardiolipin:268:0.0436	0.0436	268
CL	CL:15	cathepsin L:15:0.4312	0.4312	15
CL	CL:17	cathodoluminescence:17:0.0026	0.0026	17
CL	CL:9|Cl:2	cellulose:11:0.0016	0.0016	11
CL	CL:18|cl:3	central lateral:21:0.7291	0.7291	21
CL	CL:26	central lateral nucleus:26:0.8861	0.8861	26
CL	CL:18|Cl:1	centralis lateralis:19:0.6537	0.6537	19
CL	CL:1262|Cl:6|cl:1	chemiluminescence:1269:0.2074	0.2074	1269
CL	CL:7	chemiluminescence response:7:0.2902	0.2902	7
CL	CL:64	chemiluminescent:64:0.0103	0.0103	64
CL	CL:12	chemoluminescence:12:0.0018	0.0018	12
Cl	Cl:30|--Cl:1|CL:1	chlorine:32:0.0051	0.0051	32
CL	CL:11	Cholesterol:11:0.0016	0.0016	11
CL	CL:5	chromosome loss:5:0.0736	0.0736	5
Cl	Cl:13|CL:12	clearances:25:0.0039	0.0039	25
CL	CL:13|Cl:8	clearance rate:21:0.8594	0.8594	21
CL	CL:50	cleft lip:50:0.8572	0.8572	50
CL	CL:21|Cl:3|cl:1	clonidine:25:0.0039	0.0039	25
CL	CL:6	confidence level:6:0.1543	0.1543	6
CL	CL:10	constant:10:0.0015	0.0015	10
CL	CL:9	constant light:9:0.1267	0.1267	9
C-L	C-L:92|CL:3|c-l:1	consultation-liaison:96:0.0159	0.0159	96
CL	CL:65	contact lens:54:0.8622|contact lenses:11:0.7357	0.8622	65
CL	CL:8	continuous light:8:0.0953	0.0953	8
CL	CL:11	contralateral:11:0.0016	0.0016	11
CL	CL:10|Cl:2	control:12:0.0018	0.0018	12
CL	CL:7	control line:7:0.1850	0.1850	7
CL	CL:16	coriaria lactone:16:0.8165	0.8165	16
CL	CL:455	Corpora lutea:455:0.9734	0.9734	455
CL	CL:594|Cl:1	corpus luteum:595:0.9892	0.9892	595
CL	CL:10	Crithidia luciliae:10:0.5000	0.5000	10
CL	CL:193	cutaneous leishmaniasis:193:0.9594	0.9594	193
CL	CL:158	cycle length:131:0.7857|cycle lengths:27:0.8312	0.8312	158
CL	CL:29	cytotoxic lymphocytes:20:0.3171|cytotoxic lymphocyte:9:0.5470	0.5470	29
CL	CL:18	epsilon-caprolactone:18:0.0028	0.0028	18
CL	CL:13	lesions:13:0.0020	0.0020	13
CL	CL:9	liver:9:0.0013	0.0013	9
CL	CL:46|Cl:5	lung compliance:51:0.5324	0.5324	51
CL	CL:13	lymph:13:0.0020	0.0020	13
CL	CL:5|Cl:1	lymph protein concentration:6:0.2827	0.2827	6
CL	CL:6	patients with cholelithiasis:6:0.0899	0.0899	6
CL	CL:95|Cl:49|cl:1	total body clearance:145:0.9280	0.9280	145
CL	CL:27|Cl:21|-Cl:1	total plasma clearance:49:0.2944	0.2944	49
CMA3	CMA3:27	chromomycin a3:27:0.8903	0.8903	27
CMAI	CMAI:38	Cohen-Mansfield Agitation Inventory:38:0.9217	0.9217	38
CMAPs	CMAPs:131|cMAPs:1|CMAPS:1	compound muscle action potentials:133:0.9775	0.9775	133
CMAP	CMAP:301	compound muscle action potential:243:0.9676|compound muscle action potentials:58:0.9190	0.9676	301
CMA	CMA:10	analysis:10:0.0173	0.0173	10
CMA	CMA:6	Canadian Medical Association:6:0.3728	0.3728	6
CMA	CMA:114	chlormadinone acetate:114:0.9102	0.9102	114
CMA	CMA:11	chromomycin A3:11:0.7357	0.7357	11
CMA	CMA:28	chronic metabolic acidosis:28:0.8369	0.8369	28
CMA	CMA:18	cingulate motor area:18:0.8365	0.8365	18
CMA	CMA:7	coronamic acid:7:0.2113	0.2113	7
CMA	CMA:15	cortical masticatory area:15:0.8045	0.8045	15
CMA	CMA:9	corticomedial amygdala:9:0.3945	0.3945	9
CMA	CMA:75	cow's milk allergy:75:0.7121	0.7121	75
CMA	CMA:9	mesenteric artery:9:0.6794	0.6794	9
CMBC	CMBC:8	concentration of moving blood cells:8:0.5006	0.5006	8
CMB	CMB:20	chemical mass balance:20:0.8525	0.8525	20
CMB	CMB:19	cosmic microwave background:19:0.8449	0.8449	19
CMCC	CMCC:13	Chronic mucocutaneous candidiasis:13:0.7753	0.7753	13
CMCT	CMCT:129	Central motor conduction time:129:0.9630	0.9630	129
CMCase	CMCase:17	carboxymethyl cellulase:17:0.6748	0.6748	17
CMCase	CMCase:27|CMC-ase:1	carboxymethylcellulase:28:0.4655	0.4655	28
CMCs	CMCs:12|cmcs:1	critical micelle concentrations:13:0.7753	0.7753	13
CMCs	CMCs:23	cultured mast cells:23:0.8038	0.8038	23
CMC	CMC:119	carboxymethyl cellulose:108:0.8011|carboxymethyl-cellulose:11:0.0080	0.8011	119
CMC	CMC:52	carpometacarpal:52:0.0408	0.0408	52
CMC	CMC:8	cell-mediated cytolysis:8:0.2327	0.2327	8
CMC	CMC:105	cell-mediated cytotoxicity:105:0.7435	0.7435	105
CMC	CMC:25	chronic mucocutaneous candidiasis:25:0.8816	0.8816	25
CMC	CMC:19	closed mitral commissurotomy:19:0.8449	0.8449	19
CMC	CMC:9	Computer-mediated communication:9:0.3945	0.3945	9
CMC	CMC:84|cmc:26	critical micellar concentration:99:0.9698|critical micellar concentrations:11:0.7357	0.9698	110
CMC	CMC:198|cmc:81	critical micelle concentration:255:0.9883|critical micelle concentrations:24:0.8768	0.9883	279
CMC	CMC:12	cultured mast cells:12:0.5664	0.5664	12
CMC	CMC:25	sodium carboxymethylcellulose:25:0.0846	0.0846	25
cmd	cmd:17|CMD:1	cartilage matrix deficiency:18:0.8270	0.8270	18
CMD	CMD:13	cassava mosaic disease:13:0.7753	0.7753	13
CMD	CMD:24	cefamandole:24:0.0443	0.0443	24
CMD	CMD:17	common mental disorders:17:0.8270	0.8270	17
CMD	CMD:152	congenital muscular dystrophy:130:0.9403|congenital muscular dystrophies:22:0.8657	0.9403	152
CMD	CMD:13	corticomedullary differentiation:13:0.4444	0.4444	13
CMD	CMD:16	craniomandibular disorder:16:0.6024	0.6024	16
CMD	CMD:27	craniomandibular dysfunction:27:0.5729	0.5729	27
CMD	CMD:17	Craniometaphyseal dysplasia:17:0.6748	0.6748	17
CMD	CMD:11	signs and symptoms of craniomandibular disorders:11:0.4849	0.4849	11
CMECs	CMECs:11	microvascular endothelial cells:11:0.7357	0.7357	11
CMEC	CMEC:31	microvascular endothelial cells:31:0.7718	0.7718	31
c-met	c-met:7|c-Met:1	c-met proto-oncogene product:8:0.6411	0.6411	8
CME	CME:10	chemically modified electrode:10:0.5856	0.5856	10
CME	CME:409	continuing medical education:409:0.9410	0.9410	409
CME	CME:183	cystoid macular edema:183:0.9836	0.9836	183
CMFL	CMFL:16	community microfilarial load:16:0.7261	0.7261	16
CMF	CMF:16	adjuvant chemotherapy:16:0.3174	0.3174	16
CMF	CMF:24	chondromyxoid fibroma:24:0.8768	0.8768	24
CMF	CMF:9	conditioned medium factor:9:0.6794	0.6794	9
CMF	CMF:20	constant magnetic field:20:0.6259	0.6259	20
CMF	CMF:8	cow's milk formula:8:0.3463	0.3463	8
CMF	CMF:16	cyclophosphamide/methotrexate/5-fluorouracil:15:0.0248|Cyclophosphamide methotrexate 5-fluorouracil:1:0.9275	0.9275	16
CMGM	CMGM:15	chronic megakaryocytic granulocytic myelosis:8:0.6411|chronic megakaryocytic-granulocytic myelosis:7:0.5926	0.6411	15
CMGP	CMGP:9	cartilage matrix glycoprotein:9:0.6794	0.6794	9
CMGT	CMGT:12	Chromosome-mediated gene transfer:12:0.5050	0.5050	12
CMGs	CMGs:10	case mix groups:10:0.7103	0.7103	10
CMG	CMG:9	carboxymethylglucan:9:0.0541	0.0541	9
CMG	CMG:22	cystometrogram:22:0.1419	0.1419	22
CMG	CMG:9	cystometrography:9:0.0541	0.0541	9
CMG	CMG:18	cystometry:18:0.1149	0.1149	18
CMHC	CMHC:37	community mental health center:37:0.8749	0.8749	37
CMHCs	CMHCs:43	community mental health centers:43:0.9308	0.9308	43
CMHNs	CMHNs:28	community mental health nurses:28:0.8941	0.8941	28
CMHT	CMHT:11	community mental health team:11:0.7357	0.7357	11
CMHTs	CMHTs:12	Community mental health teams:12:0.7571	0.7571	12
CMHs	CMHs:9	cardiomyopathic hamsters:9:0.5470	0.5470	9
CMHS	CMHS:9	Center for Mental Health Services:9:0.6794	0.6794	9
CMH	CMH:9	cardiomyopathic hamsters:9:0.5470	0.5470	9
CMH	CMH:13	Ceramide monohexoside:13:0.7753	0.7753	13
CMH	CMH:8	community mental health:8:0.5006	0.5006	8
CMIR	CMIR:16	cell-mediated immune response:16:0.5171	0.5171	16
CMI	CMI:12	cell-mediated:12:0.0096	0.0096	12
CMI	CMI:149	cell-mediated immune:149:0.8310	0.8310	149
CMI	CMI:560|cmi:1	cell-mediated immunity:485:0.8147|Cell mediated immunity:76:0.8388	0.8388	561
CMI	CMI:9	chronic mental illness:9:0.6794	0.6794	9
CMI	CMI:10	chronic mesenteric ischemia:10:0.7103	0.7103	10
CMI	CMI:65	clomipramine:65:0.0559	0.0559	65
CMI	CMI:48	Cornell Medical Index:48:0.9379	0.9379	48
CMI	CMI:7	cow's milk intolerance:7:0.3524	0.3524	7
CMI	CMI:16	Craniomandibular Index:16:0.0794	0.0794	16
CMI	CMI:37	immune response:27:0.8903|immune responses:10:0.7103	0.8903	37
CMJ	CMJ:13	rabbit craniomandibular joint:13:0.4367	0.4367	13
CMK	CMK:9	cell line:9:0.6794	0.6794	9
CML-BP	CML-BP:10	chronic myelogenous leukemia in blastic phase:10:0.7357	0.7357	10
CML-BC	CML-BC:5|CMLbc:1	chronic myelogenous leukemia:6:0.5290	0.5290	6
CML-BC	CML-BC:11	chronic myelogenous leukemia in blast crisis:11:0.7909	0.7909	11
CML-BC	CML-BC:9|CMLBC:1	chronic myeloid leukemia in blast crisis:10:0.8165	0.8165	10
CML	CML:38	carboxymethyllysine:38:0.0069	0.0069	38
CML	CML:17	cell-mediated lymphocytotoxicity:17:0.5760	0.5760	17
CML	CML:182	cell-mediated lympholysis:156:0.7836|Cell Mediated Lympholysis:26:0.7760	0.7836	182
CML	CML:12	cell-mediated lysis:12:0.1758	0.1758	12
CML	CML:215	chronic myelogenous leukaemia:215:0.9631	0.9631	215
CML	CML:1918	chronic myelogenous leukemia:1907:0.9943|chronic myelogenous leukemias:11:0.7357	0.9943	1918
CML	CML:527	chronic myeloid leukaemia:527:0.9878	0.9878	527
CML	CML:1619	chronic myeloid leukemia:1608:0.9941|chronic myeloid leukemias:11:0.7357	0.9941	1619
CML	CML:11	chronic myeloid leukemic:11:0.7357	0.7357	11
CML	CML:8	mediated lysis:8:0.0726	0.0726	8
CML	CML:80	N(epsilon)-(carboxymethyl)lysine:59:0.0108|N epsilon-(carboxymethyl)lysine:21:0.8594	0.8594	80
CML	CML:11	N epsilon-carboxymethyllysine:11:0.7357	0.7357	11
CML	CML:27	Nepsilon-(Carboxymethyl)lysine:27:0.0049	0.0049	27
CMMCs	CMMCs:9	colonic migrating motor complexes:9:0.6794	0.6794	9
CMML	CMML:77	chronic myelomonocytic leukaemia:77:0.9612	0.9612	77
CMML	CMML:206	chronic myelomonocytic leukemia:206:0.9487	0.9487	206
CMMoL	CMMoL:63|CMMOL:2|CMMol:1	chronic myelomonocytic leukemia:66:0.9548	0.9548	66
CMM	CMM:5	color M-mode:5:0.1132	0.1132	5
CMM	CMM:14	cross-modality matching:14:0.6911	0.6911	14
CMM	CMM:162	cutaneous malignant melanoma:162:0.9353	0.9353	162
CMN	CMN:6	caudal mediastinal lymph node:6:0.5290	0.5290	6
CMN	CMN:5	caudal mediastinal node:5:0.4422	0.4422	5
CMN	CMN:19	congenital melanocytic nevi:19:0.6537	0.6537	19
CMN	CMN:54	congenital mesoblastic nephroma:54:0.9132	0.9132	54
CMOS	CMOS:18	complementary metal oxide semiconductor:18:0.8365	0.8365	18
CMO	CMO:7|Cmo:1	choline monooxygenase:8:0.2987	0.2987	8
CMO	CMO:21	cystoid macular oedema:21:0.8594	0.8594	21
CMPA	CMPA:11	cow's milk protein allergy:11:0.4728	0.4728	11
CMPDs	CMPDs:22|cMPDs:1	chronic myeloproliferative disorders:23:0.8715	0.8715	23
CMPD	CMPD:11|c-MPD:1	chronic myeloproliferative diseases:12:0.6460	0.6460	12
CMPD	CMPD:62|cMPD:2|c-MPD:1	chronic myeloproliferative disorders:54:0.9448|chronic myeloproliferative disorder:11:0.6182	0.9448	65
CMPF	CMPF:15	3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid:15:0.3821	0.3821	15
CMPI	CMPI:29	cow's milk protein intolerance:29:0.7970	0.7970	29
CMPs	CMPs:11	common myeloid progenitors:11:0.7357	0.7357	11
CMPase	CMPase:14|CMP-ase:1	cytidine monophosphatase:15:0.8045	0.8045	15
CMP	CMP:54	cardiomyopathy:54:0.1359	0.1359	54
CMP	CMP:23	Cartilage matrix protein:23:0.5997	0.5997	23
CMP	CMP:12	caseinomacropeptide:12:0.0282	0.0282	12
CMP	CMP:7	chemical mechanical polishing:7:0.6411	0.6411	7
CMP	CMP:25	cow's milk protein:17:0.5038|cow's milk proteins:8:0.5006	0.5038	25
CMP	CMP:10	cytidine 5'-monophosphate:10:0.5000	0.5000	10
CMP	CMP:14	cytidine monophosphate:14:0.4709	0.4709	14
CMP	CMP:7	dynamic cardiomyoplasty:7:0.0655	0.0655	7
CMR(glc)	CMR(glc):2	cerebral metabolic rate for glucose:2:0.4422	0.4422	2
CMRA	CMRA:6|cMRA:2	coronary magnetic resonance angiography:8:0.6411	0.6411	8
CMRglc	CMRglc:8	cerebral glucose metabolic rate:8:0.5006	0.5006	8
CMRglc	CMRglc:10|CMRGlc:5	cerebral glucose metabolism:15:0.5348	0.5348	15
CMRglc	CMRglc:26|CMRGlc:13	cerebral metabolic rate of glucose:39:0.8858	0.8858	39
CMRglc	CMRglc:11|CMRGlc:7|CMR-Glc:1	glucose utilization:19:0.8449	0.8449	19
CMRG	CMRG:3	cerebral metabolic rate of glucose:3:0.5926	0.5926	3
CMRNG	CMRNG:3	resistant N gonorrhoeae:3:0.5006	0.5006	3
CMRO2	CMRO2:15|CMRo2:1	cerebral metabolic rate:16:0.3831	0.3831	16
CMRO2	CMRO2:7	Cerebral oxygen metabolic rate:7:0.2902	0.2902	7
CMRO2	CMRO2:5|CMRo2:1	cerebral oxygen uptake:6:0.3728	0.3728	6
CMRR	CMRR:15	common mode rejection ratio:8:0.6411|common-mode rejection ratio:7:0.1470	0.6411	15
CMRglu	CMRglu:6|CMRGlu:4	cerebral metabolic rate for glucose:10:0.8038	0.8038	10
CMRglu	CMRglu:9|CMRGlu:2|CMR-Glu:1	glucose metabolism:12:0.7571	0.7571	12
CMRglu	CMRglu:9	glucose utilization:9:0.6794	0.6794	9
CMRO(2)	CMRO(2):3|CMRo(2):1	cerebral metabolic rate of oxygen consumption:4:0.4422	0.4422	4
CMR	CMR:6	caffeine metabolic ratio:6:0.2827	0.2827	6
CMR	CMR:5	calculated maximal response:5:0.4422	0.4422	5
CMR	CMR:22	cardiac magnetic resonance:22:0.1106	0.1106	22
CMR	CMR:86	Cardiovascular magnetic resonance:86:0.6572	0.6572	86
CMR	CMR:5	Cellophane macular reflex:5:0.4422	0.4422	5
Cmr	Cmr:7|CmR:5	chloramphenicol:12:0.0230	0.0230	12
Cmr	Cmr:18|CmR:7	chloramphenicol resistance:25:0.8186	0.8186	25
CMR	CMR:63	comodulation masking release:63:0.8788	0.8788	63
CMR	CMR:17	contact microradiography:17:0.8270	0.8270	17
CMR	CMR:6	crude mortality rate:6:0.1320	0.1320	6
CMR	CMR:15	magnetic resonance imaging:15:0.8045	0.8045	15
CMs	CMs:20	cavernous malformations:20:0.5892	0.5892	20
CMS	CMS:46	Centers for Medicare and Medicaid Services:46:0.7921	0.7921	46
CMS	CMS:21	Centers for Medicare&Medicaid Services:21:0.7865	0.7865	21
CMS	CMS:19	cervical magnetic stimulation:19:0.7658	0.7658	19
CMS	CMS:53	chronic mild stress:53:0.8842	0.8842	53
CMS	CMS:29	chronic mountain sickness:29:0.8978	0.8978	29
CMs	CMs:12	chylomicrons:12:0.0145	0.0145	12
CMs	CMs:15	cochlear microphonics:15:0.8045	0.8045	15
CMs	CMs:9	Conditioned media:9:0.3455	0.3455	9
CMS	CMS:44	Congenital Myasthenic Syndromes:31:0.9043|Congenital myasthenic syndrome:13:0.7909	0.9043	44
CMS	CMS:7	cystadenoma with mesenchymal stroma:7:0.4438	0.4438	7
CMS	CMS:27|cms:7	cytoplasmic male sterile:18:0.8365|cytoplasmic male-sterile:16:0.7261	0.8365	34
CMS	CMS:72|cms:6	cytoplasmic male sterility:78:0.9200	0.9200	78
CMS	CMS:9	solubilization:9:0.0106	0.0106	9
CMT1A	CMT1A:6|CMT-1A:2	Charcot-Marie-Tooth disease:8:0.1895	0.1895	8
CMT1A	CMT1A:75|CMT1a:4|CMT-1A:2	Charcot-Marie-Tooth disease type 1A:81:0.9229	0.9229	81
CMT1A	CMT1A:23|CMT-1A:1	Charcot-Marie-Tooth type 1A:24:0.1177	0.1177	24
CMT1	CMT1:5|CMT-1:1	Charcot-Marie-Tooth disease:6:0.1838	0.1838	6
CMT1	CMT1:28	Charcot-Marie-Tooth disease type 1:28:0.8369	0.8369	28
CMT-3	CMT-3:6	chemically modified tetracycline:6:0.5290	0.5290	6
CMTC	CMTC:31	cutis marmorata telangiectatica congenita:31:0.9043	0.9043	31
CMTC	CMTC:13	cytoplasmic microtubule complex:13:0.7753	0.7753	13
CMTD	CMTD:12	Charcot-Marie-Tooth disease:12:0.7571	0.7571	12
CMTF	CMTF:11	confocal microscopy through focusing:11:0.7357	0.7357	11
CMTs	CMTs:28	chemically modified tetracyclines:28:0.8941	0.8941	28
CMT	CMT:37	California mastitis test:37:0.8377	0.8377	37
CMT	CMT:156	Charcot-Marie-Tooth:156:0.2392	0.2392	156
CMT	CMT:131	Charcot-Marie-Tooth disease:131:0.9106	0.9106	131
CMT	CMT:9	chemotherapy:9:0.0123	0.0123	9
CMT	CMT:14	choline magnesium trisalicylate:14:0.7909	0.7909	14
CMT	CMT:13	cimetidine:13:0.0185	0.0185	13
CMT	CMT:43	combined modality therapy:31:0.9043|combined-modality therapy:12:0.0921	0.9043	43
CMT	CMT:11	combined modality treatment:11:0.7357	0.7357	11
CMT	CMT:14	congenital muscular torticollis:14:0.8045	0.8045	14
CMT	CMT:6	cross-modal transfer:6:0.2243	0.2243	6
CMVs	CMVs:14|cMVs:1	canalicular membrane vesicles:15:0.8045	0.8045	15
CMV	CMV:46	anti-cytomegalovirus:46:0.0059	0.0059	46
CMV	CMV:17	canalicular membrane vesicles:17:0.7407	0.7407	17
CMV	CMV:151	conventional mechanical ventilation:151:0.6285	0.6285	151
CMV	CMV:21	cucumber mosaic cucumovirus:21:0.7865	0.7865	21
CMV	CMV:226	cucumber mosaic virus:226:0.9788	0.9788	226
CMV	CMV:22	cytomegaloviral:22:0.0027	0.0027	22
CMV	CMV:6860|Cmv:1	cytomegalovirus:6834:0.8872|Cytomegaloviruses:27:0.0034	0.8872	6861
CMV	CMV:21	cytomegalovirus infection:21:0.7291	0.7291	21
CMV	CMV:11	promoter:11:0.0013	0.0013	11
CMX	CMX:123	cefmenoxime:123:0.9037	0.9037	123
c-myc	c-myc:11	cellular myc:11:0.4232	0.4232	11
CMZ	CMZ:12|Cmz:2	calmidazolium:14:0.0625	0.0625	14
CMZ	CMZ:136	cefmetazole:136:0.6490	0.6490	136
CMZ	CMZ:10	ciliary marginal zone:10:0.7103	0.7103	10
CMZ	CMZ:11	clomethiazole:11:0.0481	0.0481	11
CM	CM:31	calmodulin:31:0.0060	0.0060	31
CM	CM:14	canola meal:14:0.4367	0.4367	14
CM	CM:16	CarboMedics:16:0.0030	0.0030	16
CM	CM:28	carboxymethyl:28:0.0054	0.0054	28
CM	CM:6	cardiac mucosa:6:0.1543	0.1543	6
CM	CM:9	Cardiac myosin:9:0.6794	0.6794	9
CM	CM:10	cardiomyocyte:10:0.0018	0.0018	10
CM	CM:46	cardiomyopathic:46:0.0091	0.0091	46
CM	CM:62|Cm:1|cm:1	cardiomyopathy:64:0.0127	0.0127	64
CM	CM:25	case management:25:0.2586	0.2586	25
CM	CM:14	cells:14:0.0026	0.0026	14
CM	CM:8	cell-associated matrix:8:0.1591	0.1591	8
CM	CM:9|Cm:2	cell membrane:11:0.0718	0.0718	11
CM	CM:48	center of mass:48:0.6007	0.6007	48
cM	cM:151|CM:2	centimorgans:102:0.0203|centiMorgan:51:0.0101	0.0203	153
CM	CM:12	centromedian:12:0.0022	0.0022	12
CM	CM:7	centromedian nucleus:7:0.0777	0.0777	7
CM	CM:23	centrum medianum:23:0.8715	0.8715	23
CM	CM:108	cerebral malaria:108:0.9559	0.9559	108
CM	CM:54	Cervical mucus:54:0.8401	0.8401	54
CM	CM:12	Chiari malformation:12:0.2699	0.2699	12
Cm	Cm:100|CM:21	chloramphenicol:121:0.0242	0.0242	121
CM	CM:12|C-M:4	chloroform-methanol:16:0.0030	0.0030	16
CM	CM:16	chorismate mutase:16:0.8165	0.8165	16
CM	CM:15	Chronic migraine:15:0.4609	0.4609	15
CM	CM:68	chylomicrons:47:0.0093|chylomicron:21:0.0040	0.0093	68
CM	CM:27	ciliary muscle:27:0.2033	0.2033	27
CM	CM:10|Cm:2	cimetidine:12:0.0022	0.0022	12
CM	CM:22|cm:1	cisterna magna:23:0.8768	0.8768	23
CM	CM:13	clinical mastitis:13:0.7753	0.7753	13
CM	CM:286	cochlear microphonics:147:0.9470|cochlear microphonic:139:0.9544	0.9544	286
CM	CM:32	cochlear microphonic potential:22:0.7955|cochlear microphonic potentials:10:0.7103	0.7955	32
CM	CM:6	common migraine:6:0.0522	0.0522	6
CM	CM:27	Complementary medicine:27:0.4555	0.4555	27
CM	CM:10	complete hydatidiform mole:10:0.7103	0.7103	10
CM	CM:7	complete mole:7:0.1211	0.1211	7
CM	CM:294|cm:1	Conditioned media:295:0.4774	0.4774	295
CM	CM:658|cm:2|Cm:1	conditioned medium:661:0.7240	0.7240	661
CM	CM:20	congenital malformations:20:0.5568	0.5568	20
CM	CM:9	consistent mapping:9:0.3455	0.3455	9
CM	CM:21	contingency management:21:0.2002	0.2002	21
CM	CM:9|cm:2	contrast material:11:0.2422	0.2422	11
CM	CM:233|cm:3	contrast media:236:0.3738	0.3738	236
CM	CM:31	corticomotoneuronal:31:0.0060	0.0060	31
CM	CM:51	cow's milk:51:0.6063	0.6063	51
CM	CM:18	Cryptococcal meningitis:18:0.3857	0.3857	18
CM	CM:7	culture material:7:0.0828	0.0828	7
CM	CM:45	cutaneous melanoma:45:0.8115	0.8115	45
CM	CM:6	cytokine mixture:6:0.1543	0.1543	6
CM	CM:23	cytoplasmic membrane:23:0.2470	0.2470	23
cm	cm:12|cM:1	distance:13:0.0024	0.0024	13
CM	CM:6	media conditioned:6:0.0731	0.0731	6
CM	CM:10|-CM:1	Medium conditioned:11:0.3495	0.3495	11
CM	CM:23|Cm:1|cm:1	membranes:25:0.0048	0.0048	25
Cm	Cm:70|CM:1|cm:1	membrane capacitance:72:0.7906	0.7906	72
CM	CM:17	method:17:0.0032	0.0032	17
CM	CM:6	neonatal rat cardiac myocytes:6:0.3728	0.3728	6
CM	CM:5	neonatal rat cardiomyocytes:5:0.1973	0.1973	5
cm	cm:4	tumor size:4:0.0612	0.0612	4
CM	CM:13	vivo confocal microscopy:13:0.3134	0.3134	13
CN(-)	CN(-):13	cyanide:13:0.8000	0.8000	13
CN-	CN-:45	cyanide:45:0.8302	0.8302	45
CNAP	CNAP:23	Compound nerve action potential:23:0.7046	0.7046	23
CNAP	CNAP:9	continuous negative airway pressure:9:0.5470	0.5470	9
CNAs	CNAs:29|CNAS:1	Certified Nursing Assistants:30:0.9011	0.9011	30
CNAs	CNAs:9	copy number aberrations:9:0.6794	0.6794	9
CNAs	CNAs:9	copy number alterations:9:0.6794	0.6794	9
CNA	CNA:7	Canadian Nurses Association:7:0.4438	0.4438	7
CNA	CNA:7	catalytic subunit:7:0.3524	0.3524	7
CNA	CNA:37	central nucleus of the amygdala:37:0.9256	0.9256	37
CNA	CNA:3|cna:3	collagen adhesin:6:0.2243	0.2243	6
cna	cna:6|CNA:1	collagen adhesin gene:7:0.5926	0.5926	7
CNa	CNa:21|C-Na:1	Sodium clearance:22:0.7955	0.7955	22
CNBD	CNBD:6	cyclic nucleotide-binding domain:6:0.5290	0.5290	6
CNBP	CNBP:12	cellular nucleic acid binding protein:12:0.7571	0.7571	12
CNBr	CNBr:189|CnBr:1	cyanogen bromide:190:0.9748	0.9748	190
CnB	CnB:4|CNB:3|CN-B:1	calcineurin B:8:0.4102	0.4102	8
CNB	CNB:30	core needle biopsy:30:0.6736	0.6736	30
CNB	CNB:8|CnB:1	regulatory subunit:9:0.4587	0.4587	9
CNCPS	CNCPS:17	Cornell Net Carbohydrate and Protein System:17:0.8270	0.8270	17
CN-Cbl	CN-Cbl:12|CNCbl:5	cyanocobalamin:17:0.6400	0.6400	17
CNC	CNC:34	Carney complex:34:0.5846	0.5846	34
CNC	CNC:25	neural crest:25:0.8816	0.8816	25
CNDI	CNDI:10|cNDI:1	congenital nephrogenic diabetes insipidus:11:0.6182	0.6182	11
CNEP	CNEP:9	continuous negative extrathoracic pressure:9:0.5470	0.5470	9
CNE	CNE:10	continuing nursing education:10:0.7103	0.7103	10
CNF1	CNF1:46|CNF-1:11|cnf1:8	cytotoxic necrotizing factor 1:55:0.9458|Cytotoxic necrotizing factor-1:10:0.7103	0.9458	65
CNF1	CNF1:25|cnf1:1|CNF-1:1	cytotoxic necrotizing factor type 1:27:0.8903	0.8903	27
CNF	CNF:41	congenital nephrotic syndrome of the Finnish type:41:0.9379	0.9379	41
CnF	CnF:5|CNF:4	cuneiform nucleus:9:0.4587	0.4587	9
CNF	CNF:23|cnf:2	cytotoxic necrotizing factor:25:0.8768	0.8768	25
CNG	CNG:11	Compressed natural gas:11:0.7357	0.7357	11
CNG	CNG:189|cng:3	cyclic nucleotide-gated:175:0.9727|Cyclic-nucleotide-gated:9:0.0319|cyclic nucleotide gated:8:0.6411	0.9727	192
CNIC	CNIC:14	central nucleus of the inferior colliculus:14:0.7909	0.7909	14
CNIs	CNIs:31	calcineurin inhibitors:31:0.9043	0.9043	31
CNI	CNI:41|CnI:1	calcineurin inhibitors:22:0.7955|calcineurin inhibitor:20:0.8525	0.8525	42
CNI	CNI:5	Care Need Index:5:0.3728	0.3728	5
CN-I	CN-I:6	Crigler-Najjar syndrome type I:6:0.5926	0.5926	6
CNKL	CNKL:6	chronic natural killer cell lymphocytosis:6:0.5290	0.5290	6
CNK	CNK:8|cnk:1|Cnk:1	connector enhancer of ksr:10:0.7103	0.7103	10
CNLD	CNLD:8	chronic neonatal lung disease:8:0.6411	0.6411	8
CNL	CNL:9	chronic neutrophilic leukaemia:9:0.6794	0.6794	9
CNL	CNL:50	chronic neutrophilic leukemia:50:0.9404	0.9404	50
CNMs	CNMs:48	certified nurse-midwives:48:0.9379	0.9379	48
CNM	CNM:11	cat nictitating membrane:11:0.7357	0.7357	11
CNM	CNM:14	centronuclear myopathy:14:0.3383	0.3383	14
CNM	CNM:9	congenital nemaline myopathy:9:0.6794	0.6794	9
CNNA	CNNA:6	culture-negative neutrocytic ascites:6:0.2827	0.2827	6
CNNs	CNNs:9	computational neural networks:9:0.4587	0.4587	9
cnn	cnn:6|CNN:2|Cnn:2	centrosomin:10:0.1957	0.1957	10
CNN	CNN:16	neural network:16:0.6577	0.6577	16
CNPAS	CNPAS:8	congenital nasal pyriform aperture stenosis:8:0.6411	0.6411	8
CNPA	CNPA:13	Chronic necrotizing pulmonary aspergillosis:13:0.7753	0.7753	13
CNPD	CNPD:16	chronic nonspecific pulmonary diseases:16:0.8165	0.8165	16
CNPase	CNPase:56	2',3'-Cyclic nucleotide 3'-phosphodiesterase:45:0.5716|2',3'-cyclic nucleotide-3'-phosphodiesterase:11:0.7357	0.7357	56
CNPase	CNPase:30|CNP-ase:1	2',3'-cyclic nucleotide 3'-phosphohydrolase:31:0.5749	0.5749	31
CNPase	CNPase:8	nucleotide phosphohydrolase:8:0.4102	0.4102	8
CNP	CNP:51|Cnp:1	2',3'-cyclic nucleotide 3'-phosphodiesterase:52:0.5633	0.5633	52
CNP	CNP:47	2',3'-cyclic nucleotide 3'-phosphohydrolase:47:0.6382	0.6382	47
CNP	CNP:16	chlornitrofen:16:0.0162	0.0162	16
CNP	CNP:12|cnp:1	continuous negative pressure:13:0.5335	0.5335	13
CNP	CNP:6	cyclic nucleotide phosphohydrolase:6:0.1838	0.1838	6
CNP	CNP:15	nucleotide phosphodiesterase:15:0.4951	0.4951	15
CNQX	CNQX:6	6-cyano-7-nitroquinoxaline-2,3 dione:6:0.1543	0.1543	6
CNQX	CNQX:5	antagonist 6-cyano-7-nitro-quinoxaline-2,3-dione:5:0.1612	0.1612	5
CNR1	CNR1:11	cannabinoid receptor gene:11:0.6182	0.6182	11
CNRs	CNRs:51	Contrast-to-noise ratios:51:0.8799	0.8799	51
CNR	CNR:42	contrast-to-noise ratios:42:0.7750	0.7750	42
CNSDC	CNSDC:10	destructive cholangitis:10:0.5856	0.5856	10
CNSHA	CNSHA:9	Chronic nonspherocytic hemolytic anemia:9:0.4587	0.4587	9
CNSHA	CNSHA:10	haemolytic anaemia:10:0.7103	0.7103	10
CNSLD	CNSLD:21	chronic non-specific lung disease:21:0.8594	0.8594	21
CNSLD	CNSLD:18	chronic nonspecific lung disease:13:0.7357|chronic nonspecific lung diseases:5:0.4422	0.7357	18
CNSL	CNSL:6|CNS-L:1	central nervous system leukemia:7:0.5926	0.5926	7
CNSS	CNSS:8	caudal neurosecretory system:8:0.6411	0.6411	8
CNSs	CNSs:81	clinical nurse specialists:81:0.9415	0.9415	81
CNSs	CNSs:8	Conserved noncoding sequences:8:0.6411	0.6411	8
CNS	CNS:19	Canadian Neurological Scale:19:0.8449	0.8449	19
CNS	CNS:13	central nervous:13:0.6701	0.6701	13
CNS	CNS:13554|cns:6	central nervous system:13497:0.9945|central nervous systems:53:0.9438|central-nervous-system:10:0.0006	0.9945	13560
CNS	CNS:160	clinical nurse specialist:137:0.9782|clinical nurse specialists:23:0.8715	0.9782	160
CNS	CNS:7	coagulase-negative staphylococcal:7:0.3524	0.3524	7
CNS	CNS:353|C-NS:13	coagulase-negative staphylococci:322:0.8379|Coagulase negative staphylococci:44:0.9323	0.9323	366
CNS	CNS:34|cnS:1|C-NS:1	coagulase-negative staphylococcus:27:0.5524|coagulase negative Staphylococcus:9:0.6794	0.6794	36
CNS	CNS:27	Congenital nephrotic syndrome:27:0.8903	0.8903	27
CNTB	CNTB:10	Computerized Neuropsychological Test Battery:10:0.7103	0.7103	10
CNTFR	CNTFR:6	ciliary neurotrophic factor receptor:6:0.5290	0.5290	6
CNTF	CNTF:764|cntf:1|Cntf:1	ciliary neurotrophic factor:766:0.9823	0.9823	766
CNTs	CNTs:48	carbon nanotubes:48:0.9379	0.9379	48
cNTS	cNTS:12	nucleus of the solitary tract:12:0.6460	0.6460	12
CNT	CNT:17	carbon nanotube:17:0.6748	0.6748	17
CNT	CNT:12|Cnt:1	concentrative nucleoside transporter:13:0.6701	0.6701	13
CNT	CNT:69	connecting tubule:58:0.9486|connecting tubules:11:0.7357	0.9486	69
CNU	CNU:15	1-(2-chloroethyl)-1-nitrosourea:15:0.3500	0.3500	15
CNVM	CNVM:44	choroidal neovascular membranes:22:0.8657|choroidal neovascular membrane:22:0.7955	0.8657	44
CNVMs	CNVMs:29	Choroidal neovascular membranes:29:0.8978	0.8978	29
CNV	CNV:37	choroidal neovascular membranes:23:0.8038|choroidal neovascular membrane:14:0.6173	0.8038	37
CNV	CNV:72	Choroidal neovascularisation:72:0.9585	0.9585	72
CNV	CNV:547	choroidal neovascularization:547:0.9431	0.9431	547
CNV	CNV:338	contingent negative variation:329:0.9674|contingent negative variations:9:0.5470	0.9674	338
CNV	CNV:22	cucumber necrosis virus:22:0.8657	0.8657	22
CNZ	CNZ:19	clonazepam:19:0.9000	0.9000	19
CN	CN:12	1-chloroacetophenone:12:0.0076	0.0076	12
CN	CN:13	caudate nuclei:13:0.1091	0.1091	13
CN	CN:148	caudate nucleus:148:0.3695	0.3695	148
CN	CN:11	cavernous nerve:11:0.0869	0.0869	11
CN	CN:15	cerebellar nuclei:15:0.1400	0.1400	15
CN	CN:9	cochlear nerve:9:0.0563	0.0563	9
CN	CN:8	cochlear nuclear complex:8:0.6411	0.6411	8
CN	CN:22	cochlear nuclei:22:0.2562	0.2562	22
CN	CN:138	cochlear nucleus:138:0.3413	0.3413	138
CN	CN:8	cognitively normal:8:0.5006	0.5006	8
CN	CN:13	congenital neutropenia:13:0.1650	0.1650	13
CN	CN:68	congenital nystagmus:68:0.8374	0.8374	68
CN	CN:9	Contrast nephropathy:9:0.3069	0.3069	9
CN	CN:20|Cn:2	control:22:0.0145	0.0145	22
CN	CN:10	coordination number:10:0.2126	0.2126	10
CN	CN:36	cranial nerve:26:0.3586|Cranial nerves:10:0.5000	0.5000	36
Cn	Cn:11	creatinine:11:0.0069	0.0069	11
CN	CN:9	Crigler-Najjar:9:0.0055	0.0055	9
Cn	Cn:13|CN:11	Cryptococcus neoformans:24:0.7593	0.7593	24
CN	CN:84|-CN:1	Cyanide:85:0.0580	0.0580	85
CN	CN:13	cyanopropyl:13:0.0083	0.0083	13
CN	CN:24	cyclic neutropenia:24:0.4188	0.4188	24
CN	CN:12	cyclic nucleotides:12:0.7571	0.7571	12
CN	CN:13	necrosis:13:0.0083	0.0083	13
CN	CN:5	protein phosphatase calcineurin:5:0.1690	0.1690	5
CO(2)	CO(2):191	carbon dioxide:191:0.9843	0.9843	191
CO1	CO1:9	mitochondrial cytochrome c oxidase subunit 1:9:0.3945	0.3945	9
CO2	CO2:1132|Co2:1	carbon dioxide:1133:0.9917	0.9917	1133
COAD	COAD:78	chronic obstructive airways disease:52:0.9099|chronic obstructive airway disease:26:0.8861	0.9099	78
COAG	COAG:26|CO-AG:1	chronic open-angle glaucoma:27:0.8312	0.8312	27
COAs	COAs:36	children of alcoholics:36:0.8716	0.8716	36
cob	cob:16|COB:7	apocytochrome b:23:0.3145	0.3145	23
COB	COB:66	chronic obstructive bronchitis:66:0.9548	0.9548	66
cob	cob:9	cobalamin biosynthetic:9:0.4587	0.4587	9
cob	cob:13|COB:6|Cob:1	cytochrome b:20:0.2547	0.2547	20
COCB	COCB:17	crossed olivocochlear bundle:17:0.8270	0.8270	17
COCM	COCM:23	congestive cardiomyopathy:23:0.7593	0.7593	23
COCP	COCP:13	combined oral contraceptive pill:13:0.7753	0.7753	13
COCs	COCs:53|cOCs:1	combined oral contraceptives:54:0.7051	0.7051	54
COCs	COCs:185	cumulus-oocyte complexes:163:0.6035|Cumulus-oocyte-complexes:22:0.0590	0.6035	185
COC	COC:38	calcifying odontogenic cyst:38:0.9217	0.9217	38
COC	COC:60	combined oral contraceptive:40:0.7653|combined oral contraceptives:20:0.7173	0.7653	60
COC	COC:9	continuity of care:9:0.6794	0.6794	9
COC	COC:95	cumulus-oocyte complexes:54:0.6432|cumulus-oocyte complex:19:0.3019|cumulus oocyte complexes:12:0.6460|cumulus oocyte complex:10:0.7103	0.7103	95
COD1	COD1:4|COD-1:2	X-linked cone-rod dystrophy:6:0.5290	0.5290	6
CODH	CODH:39|CO-DH:1	carbon monoxide dehydrogenase:40:0.9256	0.9256	40
COD	COD:31	Calcium oxalate dihydrate:31:0.9043	0.9043	31
COD	COD:413	chemical oxygen demand:413:0.9740	0.9740	413
CoD	CoD:12|COD:1	coeliac disease:13:0.1962	0.1962	13
CoD	CoD:6	coronary artery diameter:6:0.5290	0.5290	6
COD	COD:12	cystic ovarian disease:12:0.7571	0.7571	12
COFS	COFS:14	Cerebro-oculo-facio-skeletal:14:0.5909	0.5909	14
Cog-	Cog-:7|COG-:3	coaggregation-defective:10:0.9000	0.9000	10
COGA	COGA:52	Collaborative Study on the Genetics of Alcoholism:52:0.9467	0.9467	52
COGs	COGs:10	Clusters of Orthologous Groups of proteins:10:0.5856	0.5856	10
COG	COG:27|CoG:4	center of gravity:31:0.4981	0.4981	31
COG	COG:8	Children's Oncology Group:8:0.5006	0.5006	8
COHb	COHb:57|CO-Hb:1|CoHb:1	carboxyhaemoglobin:59:0.1648	0.1648	59
COHb	COHb:224|CO-Hb:17|COHB:3	carboxyhemoglobin:244:0.6903	0.6903	244
COHb	COHb:5|CO-Hb:2|CoHb:2	hemoglobin:9:0.0227	0.0227	9
COH	COH:9|CoH:1	coefficient of haze:10:0.7103	0.7103	10
Coh	Coh:7|COH:3	coherence:10:0.0269	0.0269	10
COH	COH:23	compensatory ovarian hypertrophy:23:0.8715	0.8715	23
COH	COH:212	controlled ovarian hyperstimulation:212:0.9774	0.9774	212
COH	COH:22|CoH:1|Coh:1	coumarin 7-hydroxylase:24:0.8768	0.8768	24
COII	COII:16	cytochrome c oxidase subunit II:16:0.8165	0.8165	16
COII	COII:4|CoII:2	cytochrome oxidase:6:0.1148	0.1148	6
COII	COII:17	cytochrome oxidase II:17:0.5760	0.5760	17
COII	COII:16|CoII:1	cytochrome oxidase subunit II:17:0.3109	0.3109	17
COL3A1	COL3A1:5	type III collagen gene:5:0.1973	0.1973	5
COL3A1	COL3A1:10	type III procollagen:10:0.5856	0.5856	10
COL7A1	COL7A1:5	gene encoding type VII collagen:5:0.4422	0.4422	5
COL7A1	COL7A1:81|Col7a1:3	type VII collagen gene:84:0.9644	0.9644	84
COLD	COLD:198|Cold:1	chronic obstructive lung disease:181:0.9650|chronic obstructive lung diseases:18:0.8365	0.9650	199
COLIA1	COLIA1:7	collagen type Ialpha1:7:0.5926	0.5926	7
COL	COL:66|Col:14|col:1	colchicine:81:0.2857	0.2857	81
COL	COL:30|Col:16|col:2	collagen:48:0.1679	0.1679	48
Col	Col:23	Columbia:23:0.0786	0.0786	23
COME	COME:13	chronic otitis media with effusion:13:0.7753	0.7753	13
COMMIT	COMMIT:36	Community Intervention Trial for Smoking Cessation:36:0.9100	0.9100	36
Comm	Comm:5|comm:3|COMM:1	commissureless:9:0.6667	0.6667	9
COMP	COMP:216|Comp:1	Cartilage oligomeric matrix protein:217:0.9861	0.9861	217
COMS	COMS:54	Collaborative Ocular Melanoma Study:54:0.9438	0.9438	54
COMT	COMT:133	catechol-O-methyl transferase:100:0.7407|catechol-O-methyl-transferase:33:0.0322	0.7407	133
COMT	COMT:739|Comt:2|comt:1	catechol-O-methyltransferase:636:0.6318|catechol O-methyltransferase:106:0.7124	0.7124	742
COMT	COMT:5	catechol-O-methyltransferase gene:5:0.0902	0.0902	5
COMT	COMT:9	catecholamine-O-methyltransferase:9:0.0080	0.0080	9
COM	COM:151	calcium oxalate monohydrate:151:0.9802	0.9802	151
COM	COM:77|CoM:21	center of mass:89:0.6590|center-of-mass:9:0.0154	0.6590	98
COM	COM:15|CoM:10	centre of mass:25:0.1281	0.1281	25
COM	COM:57	chronic otitis media:57:0.7759	0.7759	57
CoM	CoM:9	coenzyme M:9:0.3455	0.3455	9
Com	Com:6|COM:6	common carotid:12:0.7571	0.7571	12
c-onc	c-onc:6	cellular oncogenes:6:0.2243	0.2243	6
CONT	CONT:7|Cont:1	control group:8:0.4102	0.4102	8
CONV	CONV:31|Conv:1	Conventional:32:0.4493	0.4493	32
Cop-1	Cop-1:8|COP-1:2|Cop1:1	copolymer 1:11:0.2422	0.2422	11
COPA	COPA:53|Copa:1	cuffed oropharyngeal airway:54:0.9448	0.9448	54
COPC	COPC:51	community-oriented primary care:51:0.6869	0.6869	51
COPD	COPD:5003	chronic obstructive pulmonary disease:4919:0.9946|chronic obstructive pulmonary diseases:84:0.9436	0.9946	5003
COPES	COPES:8	Community-Oriented Programs Environment Scale:8:0.4102	0.4102	8
COPII	COPII:17	coat protein complex II:17:0.8270	0.8270	17
CoPP	CoPP:26	cobalt protoporphyrin:26:0.8861	0.8861	26
COPp	COPp:6|COPP:1	colloid osmotic pressure in plasma:7:0.6411	0.6411	7
CoPP	CoPP:5|COPP:1	Coronary perfusion pressure:6:0.5290	0.5290	6
COPp	COPp:7|COPP:1	Plasma colloid osmotic pressure:8:0.6411	0.6411	8
COPRO	COPRO:5|copro:4	coproporphyrin:9:0.6667	0.6667	9
COPT	COPT:22|copt:1	circumoval precipitin test:23:0.7046	0.7046	23
COPV	COPV:23	canine oral papillomavirus:23:0.8715	0.8715	23
COPI	COPI:11	coat protein I:11:0.5355	0.5355	11
COPi	COPi:10	colloid osmotic pressure:10:0.7103	0.7103	10
COPM	COPM:42	Canadian Occupational Performance Measure:42:0.8893	0.8893	42
COPs	COPs:12|COPS:2	Cholesterol oxidation products:14:0.7909	0.7909	14
COP	COP:19|CoP:1	center-of-pressure:20:0.0235	0.0235	20
COP	COP:14	cholesterol oxidation products:14:0.7909	0.7909	14
COP	COP:18	Circumoval precipitin:18:0.8365	0.8365	18
COP	COP:184	colloid osmotic pressure:184:0.9427	0.9427	184
COP	COP:23|Cop:15	Copenhagen:38:0.0458	0.0458	38
COP	COP:18	cryptogenic organizing pneumonia:18:0.7539	0.7539	18
CORBA	CORBA:14	Common Object Request Broker Architecture:14:0.7909	0.7909	14
CORIS	CORIS:14	Coronary Risk Factor Study:14:0.7909	0.7909	14
CORT	CORT:527|cort:56|Cort:3	corticosterone:586:0.7898	0.7898	586
COR	COR:10	center of rotation:10:0.7103	0.7103	10
COR	COR:28	cervico-ocular reflex:28:0.7154	0.7154	28
COR	COR:8|cor:1	coefficient of repeatability:9:0.6794	0.6794	9
COR	COR:6|cor:3	cold-regulated:9:0.0288	0.0288	9
COR	COR:18|Cor:3	corticosterone:21:0.0719	0.0719	21
COR	COR:19|Cor:2	cortisol:21:0.0719	0.0719	21
COR	COR:15	phytotoxin coronatine:15:0.3643	0.3643	15
COS-1	COS-1:9|COS1:1|Cos-1:1	monkey kidney:11:0.4728	0.4728	11
COS-7	COS-7:12|COS7:3	monkey kidney:15:0.2729	0.2729	15
COSS	COSS:11	Cooperative Osteosarcoma Study Group:11:0.5355	0.5355	11
COSY	COSY:6	two-dimensional correlated:6:0.0611	0.0611	6
COSY	COSY:15	two-dimensional correlated spectroscopy:15:0.1605	0.1605	15
COS	COS:21	carbonyl sulfide:21:0.8594	0.8594	21
COS	COS:27	childhood-onset schizophrenia:27:0.6745	0.6745	27
cos	cos:10	cohesive ends:10:0.7103	0.7103	10
cos	cos:8	cohesive end site:8:0.5006	0.5006	8
COS	COS:18	controlled ovarian stimulation:18:0.8365	0.8365	18
COT	COT:29	carnitine octanoyltransferase:29:0.8941	0.8941	29
cot	cot:7|COT:6	cotransport:13:0.0870	0.0870	13
COUP-TF	COUP-TF:64	chicken ovalbumin upstream promoter transcription factor:40:0.8867|Chicken ovalbumin upstream promoter-transcription factor:24:0.8768	0.8867	64
COUP	COUP:8	chicken ovalbumin upstream promoter:8:0.6411	0.6411	8
COV	COV:43|CoV:15	coefficient of variation:58:0.7489	0.7489	58
CoV	CoV:14	novel coronavirus:14:0.1244	0.1244	14
COWAT	COWAT:11	Controlled Oral Word Association Test:11:0.7357	0.7357	11
COWP	COWP:17	Cryptosporidium oocyst wall protein:17:0.6211	0.6211	17
COX-2	COX-2:4|Cox-2:1	Cox isoform:5:0.0666	0.0666	5
COX-2	COX-2:164|COX2:10|Cox-2:5|cox-2:1	cyclo-oxygenase-2:134:0.0404|cyclo-oxygenase 2:46:0.0809	0.0809	180
COX-2	COX-2:2384|Cox-2:119|COX2:56|cox-2:18|Cox2:9|cox2:1	cyclooxygenase-2:2282:0.6923|cyclooxygenase 2:305:0.7173	0.7173	2587
COX-2	COX-2:8	cyclooxygenase II:8:0.2619	0.2619	8
COX-2	COX-2:16|Cox-2:2	cycloxygenase-2:18:0.0052	0.0052	18
COX-2	COX-2:13	inducible COX:13:0.3331	0.3331	13
COX-2	COX-2:6|Cox-2:2|COX2:1	inducible cyclo-oxygenase:9:0.0969	0.0969	9
COX-2	COX-2:63|Cox-2:7|COX2:3|cox2:1	inducible cyclooxygenase:74:0.3212	0.3212	74
COX-2	COX-2:4	inducible isoform:4:0.0666	0.0666	4
coxIII	coxIII:6|COXIII:2	cytochrome c oxidase subunit III:8:0.6411	0.6411	8
COX	COX:203|Cox:7|cox:1|COx:1	Cyclo-oxygenase:203:0.0869|cyclo-oxygenases:9:0.0034	0.0869	212
COX	COX:1377|Cox:46|cox:6|COx:3	Cyclooxygenase:1367:0.5826|cyclooxygenases:65:0.0275	0.5826	1432
COX	COX:354|Cox:6|COx:4|cox:3|CoX:1	cytochrome c oxidase:368:0.9869	0.9869	368
COX	COX:92|COx:3|C-OX:1|cox:1	cytochrome oxidase:97:0.1564	0.1564	97
COI	COI:6	Cardiac output index:6:0.5290	0.5290	6
COI	COI:5	cytochrome c oxidase subunit 1:5:0.2818	0.2818	5
COI	COI:54|coI:1|CoI:1	cytochrome c oxidase subunit I:56:0.9467	0.9467	56
COI	COI:5	cytochrome c oxidase subunit I gene:5:0.4422	0.4422	5
COI	COI:62	cytochrome oxidase I:62:0.7113	0.7113	62
COI	COI:10	cytochrome oxidase I gene:10:0.7103	0.7103	10
CO	CO:1830	carbon monoxide:1830:0.9857	0.9857	1830
CO	CO:2456|co:2|Co:2	cardiac output:2449:0.9950|cardiac outputs:11:0.7357	0.9950	2460
CO	CO:12	centric occlusion:12:0.0961	0.0961	12
CO	CO:9|co:1	childhood-onset:10:0.0015	0.0015	10
CO	CO:23	cholesteryl oleate:23:0.6653	0.6653	23
Co	Co:90|CO:1	cobalt:91:0.0150	0.0150	91
CO	CO:27|Co:1	coconut oil:28:0.0623	0.0623	28
Co	Co:8|co:3|CO:1	concentration:12:0.0020	0.0020	12
CO	CO:32|co:1	constans:33:0.0053	0.0053	33
CO	CO:71|Co:26|co:1	control:61:0.0100|controls:37:0.0060	0.0100	98
CO	CO:11|Co:3|C-O:1	control group:15:0.4951	0.4951	15
CO	CO:5	control subjects:5:0.1132	0.1132	5
CO	CO:203|Co:3	corn oil:206:0.6968	0.6968	206
CO	CO:20	coronary occlusion:20:0.2267	0.2267	20
CO	CO:6|Co:4	cortisol:10:0.0015	0.0015	10
CO	CO:15	cyclo-oxygenase:15:0.0023	0.0023	15
CO	CO:101|co:1	cyclooxygenase:102:0.0165	0.0165	102
CO	CO:306	cytochrome oxidase:292:0.8488|cytochrome-oxidase:14:0.0022	0.8488	306
CP/CPK	CP/CPK:12	creatine phosphate/creatine phosphokinase:12:0.6460	0.6460	12
CP/CPPS	CP/CPPS:32	Chronic prostatitis/chronic pelvic pain syndrome:32:0.8563	0.8563	32
CP5	CP5:5	capsular polysaccharide type 5:5:0.4422	0.4422	5
CP94	CP94:17	1,2-diethyl-3-hydroxypyridin-4-one:17:0.6400	0.6400	17
CPAE	CPAE:43|C-PAE:1	pulmonary artery endothelial:44:0.9323	0.9323	44
CPAE	CPAE:13	pulmonary artery endothelial cells:13:0.7753	0.7753	13
CPAF	CPAF:15	chlorpropamide alcohol flush:8:0.6411|chlorpropamide-alcohol flush:7:0.1470	0.6411	15
CPAF	CPAF:13	chlorpropamide-alcohol flushing:8:0.1895|chlorpropamide alcohol flushing:5:0.3728	0.3728	13
CPAH	CPAH:8	para-aminohippuric acid:8:0.1591	0.1591	8
CPAP	CPAP:1239|C-PAP:2	continuous positive airway pressure:1241:0.9715	0.9715	1241
CPAP	CPAP:5	Continuous positive airway pressure breathing:5:0.4422	0.4422	5
CPAs	CPAs:20	cryoprotective agents:20:0.6680	0.6680	20
CPA	CPA:8	adenosine A(1) receptor agonist N(6)-cyclopentyladenosine:8:0.2987	0.2987	8
CPA	CPA:17	adenosine A1 receptor agonist N6-cyclopentyladenosine:17:0.6539	0.6539	17
CPA	CPA:13	analysis:13:0.0054	0.0054	13
CPA	CPA:9	Association:9:0.0039	0.0039	9
CPA	CPA:28	cardiopulmonary arrest:28:0.6839	0.6839	28
CPA	CPA:12	care programme approach:12:0.7571	0.7571	12
CPA	CPA:9	carotid phonoangiography:9:0.6794	0.6794	9
CPA	CPA:13	caudal pressor area:13:0.7753	0.7753	13
CPA	CPA:200|cpa:2	cerebellopontine angle:202:0.7937	0.7937	202
CPA	CPA:12	chlorpheniramine:12:0.0054	0.0054	12
CPA	CPA:17	circulating platelet aggregates:17:0.8270	0.8270	17
CPA	CPA:23	colony promoting activity:13:0.6701|colony-promoting activity:10:0.1519	0.6701	23
CPA	CPA:35	conditioned place aversion:35:0.7647	0.7647	35
CPA	CPA:8	Corneal polarization axis:8:0.6411	0.6411	8
CPA	CPA:13	cryoprotective agent:13:0.4444	0.4444	13
CPA	CPA:307|cpa:1|Cpa:1	Cyclophosphamide:309:0.1519	0.1519	309
CPA	CPA:327	Cyclopiazonic acid:327:0.8837	0.8837	327
CPA	CPA:265	cyproterone acetate:265:0.9503	0.9503	265
CPA	CPA:7	N6-cyclopentyl adenosine:7:0.1211	0.1211	7
CPA	CPA:13	physical abuse:13:0.7753	0.7753	13
CPA	CPA:5	receptor agonist cyclopentyladenosine:5:0.1641	0.1641	5
CPBP	CPBP:11	cardiopulmonary bypass:11:0.7357	0.7357	11
CPBS	CPBS:1	carcinogenicity prediction by battery selection:1:0.5006	0.5006	1
CPB	CPB:22|CpB:8	carboxypeptidase B:30:0.6252	0.6252	30
CPB	CPB:18	cardiopulmonary by-pass:18:0.7539	0.7539	18
CPB	CPB:3535|cpb:2	cardiopulmonary bypass:3537:0.9733	0.9733	3537
CPB	CPB:9	cardiopulmonary bypass surgery:9:0.5000	0.5000	9
CPB	CPB:6	cetylpyridinium bromide:6:0.2243	0.2243	6
CPB	CPB:13	Colorado potato beetle:13:0.7753	0.7753	13
CPB	CPB:19	competitive protein binding:19:0.7658	0.7658	19
CPB	CPB:10	plexus block:10:0.7103	0.7103	10
CPCR	CPCR:9	cardiopulmonary-cerebral resuscitation:9:0.2500	0.2500	9
cPCR	cPCR:14|C-PCR:4|CPCR:1	competitive PCR:19:0.6537	0.6537	19
cPCR	cPCR:15|C-PCR:2|c-PCR:2|CPCR:1	competitive polymerase chain reaction:20:0.7173	0.7173	20
CPCA	CPCA:11	5'-(N-cyclopropyl)-carboxamidoadenosine:11:0.2703	0.2703	11
CPCs	CPCs:14	Calcium phosphate cements:14:0.7909	0.7909	14
CPCs	CPCs:6	choroid plexus carcinomas:6:0.5290	0.5290	6
C-PC	C-PC:12|CPC:2|cpc:1	C-phycocyanin:15:0.0209	0.0209	15
CPC	CPC:78	Calcium phosphate cement:67:0.9296|calcium phosphate cements:11:0.7357	0.9296	78
CPC	CPC:11	calcium phosphate ceramic:11:0.7357	0.7357	11
CPC	CPC:8	capsular polysaccharide complex:8:0.6411	0.6411	8
CPC	CPC:15	cephalosporin C:15:0.5348	0.5348	15
CPC	CPC:20	cerebral performance category:11:0.7357|cerebral performance categories:9:0.6794	0.7357	20
CPC	CPC:134	Cetylpyridinium chloride:134:0.7445	0.7445	134
CPC	CPC:8	chest pain center:8:0.6411	0.6411	8
CPC	CPC:25	Choroid plexus carcinoma:18:0.8365|choroid plexus carcinomas:7:0.5926	0.8365	25
CPC	CPC:9	chronic persistent cough:9:0.6794	0.6794	9
CPC	CPC:11	circulating progenitor cells:11:0.6182	0.6182	11
CPC	CPC:9	coil planet centrifuge:9:0.6794	0.6794	9
CPC	CPC:10	cyclophotocoagulation:10:0.0135	0.0135	10
CPDB	CPDB:19	Carcinogenic Potency Database:19:0.7407	0.7407	19
CPDD	CPDD:5	Calcium pyrophosphate deposition disease:5:0.4422	0.4422	5
CPDN	CPDN:17	cystic partially differentiated nephroblastoma:17:0.8449	0.8449	17
CPDX	CPDX:11	cefpodoxime:11:0.7692	0.7692	11
CPDX-PR	CPDX-PR:13	cefpodoxime proxetil:13:0.7753	0.7753	13
CPDs	CPDs:150	Cyclobutane pyrimidine dimers:150:0.9303	0.9303	150
CPD	CPD:16	Carboxypeptidase D:16:0.4832	0.4832	16
CPD	CPD:33	cephalopelvic disproportion:33:0.7238	0.7238	33
CPD	CPD:88	chronic peritoneal dialysis:88:0.5620	0.5620	88
CPD	CPD:11	chronic pulmonary disease:11:0.7357	0.7357	11
CPD	CPD:53	citrate-phosphate-dextrose:53:0.0647	0.0647	53
CPD	CPD:11	color pixel density:11:0.6182	0.6182	11
CPD	CPD:53	continuing professional development:53:0.7616	0.7616	53
CPD	CPD:19	critical point drying:19:0.7658	0.7658	19
CPD	CPD:14|cPD:1	cumulative population doublings:15:0.6386	0.6386	15
cpd	cpd:53|CPD:1	cycles per degree:54:0.8036	0.8036	54
CPD	CPD:121	cyclobutane pyrimidine dimers:66:0.8670|cyclobutane pyrimidine dimer:55:0.8645	0.8670	121
CPEC	CPEC:19|CPE-C:12	cyclopentenyl cytosine:31:0.9043	0.9043	31
CPEO	CPEO:126	chronic progressive external ophthalmoplegia:126:0.9622	0.9622	126
CPET	CPET:31	cardiopulmonary exercise testing:31:0.9043	0.9043	31
CPEs	CPEs:6	carbon paste electrodes:6:0.3728	0.3728	6
CPE	CPE:31	carbon paste electrode:31:0.9043	0.9043	31
CPE	CPE:93|Cpe:4|CpE:2	carboxypeptidase E:99:0.9698	0.9698	99
CPE	CPE:15	cardiogenic pulmonary edema:15:0.7096	0.7096	15
CPE	CPE:23	chronic pulmonary emphysema:23:0.8715	0.8715	23
CPE	CPE:18	Clinical Pastoral Education:18:0.8365	0.8365	18
CPE	CPE:46	Clostridium perfringens enterotoxin:46:0.6974	0.6974	46
CPE	CPE:7	cloud-point extraction:7:0.1641	0.1641	7
CPE	CPE:28	continuing professional education:28:0.8369	0.8369	28
CPE	CPE:478|cpe:8	cytopathic effect:360:0.8501|cytopathic effects:126:0.8561	0.8561	486
CPE	CPE:30	cytoplasmic polyadenylation element:30:0.9011	0.9011	30
cpe	cpe:9	enterotoxin gene:9:0.3945	0.3945	9
CPE	CPE:18	partial epilepsy:18:0.8365	0.8365	18
CPFX	CPFX:107	ciprofloxacin:107:0.9381	0.9381	107
CPF	CPF:94	chlorpyrifos:94:0.3908	0.3908	94
CPF	CPF:6	Cleavage and polyadenylation factor:6:0.6411	0.6411	6
CPF	CPF:5	coronary perfusion flow:5:0.2818	0.2818	5
CPG2	CPG2:52	carboxypeptidase G2:52:0.8821	0.8821	52
CPGs	CPGs:39	central pattern generators:39:0.9237	0.9237	39
CPGs	CPGs:102	clinical practice guidelines:102:0.9707	0.9707	102
CpGV	CpGV:17	Cydia pomonella granulovirus:17:0.8270	0.8270	17
CPG	CPG:174	central pattern generator:174:0.9323	0.9323	174
CPG	CPG:18	choline phosphoglycerides:18:0.8365	0.8365	18
CPG	CPG:59	clinical practice guidelines:36:0.8681|clinical practice guideline:23:0.8038	0.8681	59
CPG	CPG:70	Controlled pore glass:50:0.8776|controlled-pore glass:20:0.1576	0.8776	70
CpG	CpG:9	CpG motifs:9:0.3945	0.3945	9
CpG	CpG:14	cytosine-phosphate-guanosine:14:0.0232	0.0232	14
CpG	CpG:18	dinucleotide:18:0.0304	0.0304	18
CPHD	CPHD:46	combined pituitary hormone deficiency:46:0.8676	0.8676	46
CPHI	CPHI:11	Communication Profile for the Hearing Impaired:11:0.7357	0.7357	11
CPH	CPH:14|CP-H:1	carboxypeptidase H:15:0.8045	0.8045	15
CPH	CPH:9	centrophenoxine:9:0.0198	0.0198	9
CPH	CPH:12	cephaloridine:12:0.0272	0.0272	12
CPH	CPH:45	chronic paroxysmal hemicrania:45:0.9338	0.9338	45
CPH	CPH:151|CpH:1	Chronic Persistent Hepatitis:152:0.9688	0.9688	152
CPH	CPH:7	chronic pulmonary hypertension:7:0.5926	0.5926	7
CPH	CPH:11|Cph:4	cyclophosphamide:15:0.0346	0.0346	15
CPH	CPH:25	Cyproheptadine:25:0.0593	0.0593	25
CPH	CPH:5	portal hypertension:5:0.0612	0.0612	5
CPIB	CPIB:18	clofibrate:18:0.1848	0.1848	18
CPIB	CPIB:15	clofibric acid:15:0.2430	0.2430	15
CPIB	CPIB:5	effect of p-chlorophenoxyisobutyrate:5:0.0612	0.0612	5
CPIR	CPIR:6	cephalic phase insulin release:6:0.5290	0.5290	6
CPITN	CPITN:97	Community Periodontal Index of Treatment Needs:88:0.9701|Community Periodontal Index of Treatment Need:9:0.6794	0.9701	97
CPIS	CPIS:13	Clinical pulmonary infection score:13:0.7753	0.7753	13
CPIs	CPIs:12	cysteine proteinase inhibitors:12:0.7571	0.7571	12
CPI	CPI:61	California Psychological inventory:61:0.9511	0.9511	61
CPI	CPI:8	carboxypeptidase inhibitor:8:0.0625	0.0625	8
CPI	CPI:6	chronic placental insufficiency:6:0.5290	0.5290	6
CPI	CPI:13	Clinical practice improvement:13:0.7753	0.7753	13
CPI	CPI:17	Community Periodontal Index:17:0.8270	0.8270	17
CPI	CPI:11	cyclopropylpyrroloindole:11:0.0288	0.0288	11
CPI	CPI:16	cysteine proteinase inhibitor:16:0.7261	0.7261	16
CPJ	CPJ:8	cartilage-pannus junction:8:0.3463	0.3463	8
CPK-MB	CPK-MB:13	creatine phosphokinase:13:0.7753	0.7753	13
CPK-MB	CPK-MB:6	creatine phosphokinase isoenzyme:6:0.2827	0.2827	6
CPK	CPK:9	Cell proliferation kinetics:9:0.6794	0.6794	9
CPK	CPK:43	creatine kinase:43:0.4998	0.4998	43
CPK	CPK:9	creatine phosphate kinase:9:0.5470	0.5470	9
CPK	CPK:766|cpk:1	creatine phosphokinase:758:0.8612|creatine-phosphokinase:9:0.0077	0.8612	767
CPK	CPK:10	creatinephosphokinase:10:0.0087	0.0087	10
CPK	CPK:14	phosphokinase activity:14:0.6173	0.6173	14
CPL	CPL:12|Cpl:1	ceruloplasmin:13:0.0816	0.0816	13
CPL	CPL:8	circularly polarized light:8:0.5006	0.5006	8
CPMG	CPMG:82	Carr-Purcell-Meiboom-Gill:82:0.7864	0.7864	82
CPMP	CPMP:26	Committee for Proprietary Medicinal Products:26:0.8978	0.8978	26
CPMS	CPMS:9|CP-MS:2	chronic progressive MS:11:0.6182	0.6182	11
CPMS	CPMS:8|CP-MS:1	chronic progressive multiple sclerosis:9:0.5470	0.5470	9
CPMV	CPMV:95|CpMV:1	cowpea mosaic virus:96:0.9352	0.9352	96
CPM	CPM:17	Carboxypeptidase M:17:0.8270	0.8270	17
CPM	CPM:47	Cefpiramide:47:0.0472	0.0472	47
CPM	CPM:115	central pontine myelinolysis:115:0.9740	0.9740	115
CPM	CPM:30	chlorpheniramine maleate:30:0.7652	0.7652	30
CPM	CPM:47	confined placental mosaicism:47:0.9366	0.9366	47
CPM	CPM:102	Continuous Passive Motion:102:0.9704	0.9704	102
cpm	cpm:66|CPM:20	counts per minute:86:0.5331	0.5331	86
CPM	CPM:8	critical path method:8:0.6411	0.6411	8
CPM	CPM:160	cyclophosphamide:160:0.1631	0.1631	160
cpm	cpm:4	percentage of normal 2-4 cycles/min:4:0.3170	0.3170	4
CPNs	CPNs:44	community psychiatric nurses:44:0.9323	0.9323	44
CPN	CPN:22|CpN:1	carboxypeptidase N:23:0.8715	0.8715	23
CPN	CPN:15	caudate-putamen nucleus:15:0.4951	0.4951	15
Cpn	Cpn:29|CPn:3|CPN:3	Chlamydia pneumoniae:35:0.8292	0.8292	35
CPN	CPN:22	chronic pyelonephritis:22:0.7955	0.7955	22
CPN	CPN:30	common peroneal nerve:30:0.9011	0.9011	30
CPN	CPN:18	community psychiatric nurse:18:0.8365	0.8365	18
CPN	CPN:11	parenteral nutrition:11:0.7357	0.7357	11
CPOE	CPOE:49	Computerized physician order entry:49:0.8753	0.8753	49
CPOE	CPOE:15	Computerized provider order entry:15:0.4951	0.4951	15
CPON	CPON:5|C-PON:1|c-PON:1	C-terminal flanking peptide of neuropeptide Y:7:0.3524	0.3524	7
CPON	CPON:6|C-PON:1	C-terminal flanking peptide of NPY:7:0.5926	0.5926	7
C-PON	C-PON:1	NPY and its C-terminal flanking peptide:1:0.3728	0.3728	1
CPO	CPO:39|Cpo:1	chloroperoxidase:40:0.2031	0.2031	40
CPO	CPO:11	chlorpyrifos oxon:11:0.6182	0.6182	11
CPO	CPO:24	cleft palate only:24:0.8861	0.8861	24
CPO	CPO:16|cpo:1	coproporphyrinogen oxidase:17:0.6211	0.6211	17
CPPD	CPPD:7	calcium pyrophosphate deposition disease:7:0.5926	0.5926	7
CPPD	CPPD:254	calcium pyrophosphate dihydrate:254:0.9811	0.9811	254
CPPD	CPPD:8	calcium pyrophosphate dihydrate deposition disease:8:0.5926	0.5926	8
cPPT	cPPT:13|cppt:1	central polypurine tract:14:0.7909	0.7909	14
CPPV	CPPV:40	continuous positive pressure ventilation:40:0.8184	0.8184	40
CPPV	CPPV:9	contralateral patent processus vaginalis:9:0.6794	0.6794	9
CPPs	CPPs:23	cell-penetrating peptides:23:0.7500	0.7500	23
CPPs	CPPs:15	choroid plexus papillomas:15:0.8045	0.8045	15
CPPs	CPPs:15	chronic pain patients:15:0.8045	0.8045	15
CPPS	CPPS:39	chronic pelvic pain syndrome:39:0.6005	0.6005	39
CPP	CPP:10	calcium polyphosphate:10:0.7103	0.7103	10
CPP	CPP:24	Casein phosphopeptides:24:0.8768	0.8768	24
CPP	CPP:103	central precocious puberty:103:0.9389	0.9389	103
CPP	CPP:27	choroid plexus papilloma:27:0.8941	0.8941	27
CPP	CPP:58	Chronic pelvic pain:58:0.9477	0.9477	58
CPP	CPP:16	Collaborative Perinatal Project:16:0.8165	0.8165	16
CPP	CPP:357	conditioned place preference:357:0.9267	0.9267	357
CPP	CPP:176	coronary perfusion pressure:176:0.2027	0.2027	176
CPP	CPP:14	cyclopenta[cd]pyrene:14:0.0066	0.0066	14
CPP	CPP:10	perfusion pressures:10:0.7103	0.7103	10
CPQ	CPQ:12	Questionnaire:12:0.5500	0.5500	12
CPRS	CPRS:76	Comprehensive Psychopathological Rating Scale:76:0.8988	0.8988	76
CPRS	CPRS:8	Computerized Patient Record System:8:0.6411	0.6411	8
CPRs	CPRs:19	patient records:19:0.7658	0.7658	19
CPR	CPR:54	C-peptide immunoreactivity:54:0.8401	0.8401	54
CPR	CPR:10	C-peptide reactivity:10:0.7103	0.7103	10
CPR	CPR:8	carboxypeptidase R:8:0.5006	0.5006	8
CPR	CPR:1539	cardiopulmonary resuscitation:1539:0.9681	0.9681	1539
CPR	CPR:40	cefpirome:40:0.0177	0.0177	40
CPR	CPR:10	cefpirome sulfate:10:0.7103	0.7103	10
cPR	cPR:13|CPR:1	chicken progesterone receptor:14:0.6173	0.6173	14
CPR	CPR:7	clinical pregnancy rate:7:0.1111	0.1111	7
CPR	CPR:51	computer-based patient record:51:0.5267	0.5267	51
CPR	CPR:19	Computerized Patient Record:19:0.1373	0.1373	19
CPR	CPR:26	contraceptive prevalence rate:26:0.8861	0.8861	26
CPR	CPR:8	cortisol production rate:8:0.2327	0.2327	8
CPR	CPR:9	cumulative pregnancy rate:9:0.2102	0.2102	9
CPR	CPR:6	cytochrome P450 oxidoreductase:6:0.2827	0.2827	6
CPR	CPR:48|Cpr:4	P450 reductase:52:0.8134	0.8134	52
CPR	CPR:11|cPR:4	response:15:0.0064	0.0064	15
CPS-K	CPS-K:10	capsular polysaccharide of Klebsiella pneumoniae:10:0.7103	0.7103	10
cPSA	cPSA:12|CPSA:1	complexed prostate-specific antigen:13:0.7753	0.7753	13
cPSA	cPSA:29|C-PSA:1	complexed PSA:30:0.7012	0.7012	30
CPSC	CPSC:31	Consumer Product Safety Commission:31:0.8519	0.8519	31
CPSE	CPSE:29	complex partial status epilepticus:29:0.8978	0.8978	29
CPSF	CPSF:35	cleavage and polyadenylation specificity factor:35:0.9151	0.9151	35
CPS-II	CPS-II:11|CPSII:1	Cancer Prevention Study II:12:0.7571	0.7571	12
CPSI	CPSI:6|CpsI:1	Carbamyl phosphate synthetase I:7:0.2452	0.2452	7
CPSI	CPSI:11	Chronic Prostatitis Symptom Index:11:0.4728	0.4728	11
CPSP	CPSP:15	central post-stroke pain:15:0.8045	0.8045	15
CPSP	CPSP:9	Central poststroke pain:9:0.6794	0.6794	9
CPT-11	CPT-11:21|CPT11:1	7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin:22:0.0312	0.0312	22
CPT-11	CPT-11:86	irinotecan hydrochloride:86:0.9449	0.9449	86
CPT1	CPT1:8|CPT-1:2	carnitine palmitoyltransferase:10:0.7103	0.7103	10
CPT-1	CPT-1:23|CPT1:7	carnitine palmitoyltransferase-1:22:0.8657|carnitine palmitoyltransferase 1:8:0.6411	0.8657	30
CPTE	CPTE:10	chronic pulmonary thromboembolism:10:0.7103	0.7103	10
CPT-II	CPT-II:6|CPTII:2	carnitine palmitoyltransferase II:8:0.6411	0.6411	8
cPTIO	cPTIO:5|c-PTIO:4|C-PTIO:1|CPTIO:1	2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide:11:0.2703	0.2703	11
CPTs	CPTs:14	camptothecins:14:0.2203	0.2203	14
CPT	CPT:5	A1 receptor antagonist 8-cyclopentyltheophylline:5:0.2757	0.2757	5
CPT	CPT:355|Cpt:5|cpt:1	camptothecin:361:0.2253	0.2253	361
CPT	CPT:33	Captopril:33:0.0200	0.0200	33
CPT	CPT:27	carnitine palmitoyl transferase:27:0.8903	0.8903	27
CPT	CPT:158	carnitine palmitoyltransferase:158:0.9697	0.9697	158
CPT	CPT:10	carnitine palmityl transferase:10:0.7103	0.7103	10
CPT	CPT:11	carnitine palmityltransferase:11:0.7357	0.7357	11
CPT	CPT:7	chest physical therapy:7:0.2452	0.2452	7
CPT	CPT:22	Chest physiotherapy:22:0.7955	0.7955	22
CPT	CPT:13	choline phosphotransferase:13:0.6701	0.6701	13
CPT	CPT:24|cpt:1	Cholinephosphotransferase:25:0.0150	0.0150	25
CPT	CPT:159	cold pressor test:159:0.9813	0.9813	159
CPT	CPT:12	cold pressor testing:12:0.7571	0.7571	12
CPT	CPT:7	congenital pseudarthrosis of the tibia:7:0.5926	0.5926	7
CPT	CPT:12	conjunctival provocation tests:12:0.7571	0.7571	12
CPT	CPT:50	continuous performance task:50:0.9404	0.9404	50
CPT	CPT:179	Continuous Performance Test:179:0.9341	0.9341	179
CPT	CPT:48	Current perception threshold:48:0.9379	0.9379	48
CPT	CPT:60	Current Procedural Terminology:60:0.8181	0.8181	60
CPT	CPT:13	cycling probe technology:13:0.7753	0.7753	13
CPT	CPT:9	receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine:9:0.5355	0.5355	9
CPu	CPu:144|CPU:25|Cpu:3	caudate-putamen:117:0.4014|caudate putamen:55:0.8427	0.8427	172
CPU	CPU:17	central processing unit:17:0.7407	0.7407	17
CPU	CPU:8	chest pain unit:8:0.6411	0.6411	8
CPu	CPu:8|Cpu:2|CPU:1	striatum:11:0.0346	0.0346	11
CPV-2	CPV-2:11|CPV2:1	Canine parvovirus type 2:12:0.7571	0.7571	12
cPVL	cPVL:7|CPVL:5|C-PVL:1|c-PVL:1	Cystic periventricular Leukomalacia:14:0.6173	0.6173	14
CPVT	CPVT:19	Catecholaminergic polymorphic ventricular tachycardia:19:0.6537	0.6537	19
CPV	CPV:217	canine parvovirus:217:0.9862	0.9862	217
CPV	CPV:32	Cowpox virus:32:0.3042	0.3042	32
CPV	CPV:32	cytoplasmic polyhedrosis virus:32:0.9043	0.9043	32
CPV	CPV:20	plasma volume:20:0.4574	0.4574	20
CPX	CPX:9	1,3-dipropyl-8-cyclopentylxanthine:9:0.0455	0.0455	9
CPX	CPX:7	antagonist 8-cyclopentyl-1,3-dipropylxanthine:7:0.2293	0.2293	7
CPX	CPX:30	Cardiopulmonary exercise testing:30:0.8472	0.8472	30
CPX	CPX:13	ciprofloxacin:13:0.0682	0.0682	13
CPY	CPY:95|CP-Y:6|CpY:3	carboxypeptidase Y:104:0.9715	0.9715	104
CPZSO	CPZSO:6|CPZ-SO:1	chlorpromazine sulfoxide:7:0.3524	0.3524	7
CPZ	CPZ:5	antagonist capsazepine:5:0.1329	0.1329	5
CPZ	CPZ:8	carboxypeptidase Z:8:0.5006	0.5006	8
CPZ	CPZ:150	cefoperazone:150:0.1765	0.1765	150
CPZ	CPZ:596|Cpz:5|cpz:1|CPz:1	chlorpromazine:603:0.7121	0.7121	603
CPZ	CPZ:19|cpz:1	Chlorpromazine hydrochloride:20:0.7766	0.7766	20
CP	CP:4|C-p:2|Cp:2|C-P:1	C peptide:9:0.1099	0.1099	9
Cp	Cp:11	C promoter:11:0.1845	0.1845	11
Cp	CP:8|Cp:8	Caeruloplasmin:16:0.0020	0.0020	16
CP	CP:46|Cp:6	Campylobacter pylori:52:0.8821	0.8821	52
CP	CP:9|Cp:2	campylobacter pyloridis:11:0.7357	0.7357	11
CP	CP:9	canal paresis:9:0.5470	0.5470	9
CP	CP:42	Cancer procoagulant:42:0.9274	0.9274	42
CP	CP:78|Cp:2	capsid protein:80:0.0691	0.0691	80
CP	CP:53	capsular polysaccharide:53:0.8572	0.8572	53
CP	CP:13|Cp:4	captopril:17:0.0021	0.0021	17
CP	CP:18	Carbamide peroxide:18:0.7539	0.7539	18
C-P	C-P:12	carbon-phosphorus:12:0.0015	0.0015	12
CP	CP:7	Carbopol 934P:7:0.3524	0.3524	7
CP	CP:11	carboxypeptidase:11:0.0013	0.0013	11
CP	CP:22|Cp:1	cardioplegia:23:0.0029	0.0029	23
CP	CP:19|C-P:2	cardiopulmonary:21:0.0026	0.0026	21
CP	CP:9	categorical perception:9:0.6794	0.6794	9
CP	CP:10	cationic proteins:10:0.0829	0.0829	10
CP	CP:98|C-P:2	caudate-putamen:73:0.0095|caudate putamen:27:0.6554	0.6554	100
CP	CP:5	cellulose powder:5:0.0517	0.0517	5
CP	CP:21	center of pressure:21:0.1314	0.1314	21
cp	cp:13|cP:10|Cp:1|CP:1	centipoise:25:0.0032	0.0032	25
CP	CP:18	centre of pressure:18:0.1039	0.1039	18
CP	CP:16	centrifugal pump:16:0.6024	0.6024	16
CP	CP:35|C-P:2|c-p:1	cerebellopontine:38:0.0049	0.0049	38
CP	CP:762|cp:2	cerebral palsy:764:0.9916	0.9916	764
CP	CP:21	cerebral peduncle:21:0.8594	0.8594	21
Cp	Cp:187|CP:158	ceruloplasmin:345:0.0454	0.0454	345
CP	CP:26	chest pain:26:0.3422	0.3422	26
C-P	CP:4|C-P:4	Child-Pugh:8:0.0011	0.0011	8
CP	CP:33|Cp:22	Chlamydia pneumoniae:55:0.7272	0.7272	55
CP	CP:55	chloramphenicol:55:0.0071	0.0071	55
CP	CP:10	chloropicrin:10:0.0012	0.0012	10
cp	cp:45|Cp:4	chloroplast:49:0.0063	0.0063	49
CP	CP:10	Chlorpheniramine:10:0.0012	0.0012	10
CP	CP:27	chlorphentermine:27:0.0034	0.0034	27
CP	CP:17|Cp:1	chlorpromazine:18:0.0022	0.0022	18
CP	CP:12|Cp:1	chlorpropamide:13:0.0016	0.0016	13
CP	CP:6	cholestasis of pregnancy:6:0.1148	0.1148	6
CP	CP:88	choroid plexus:88:0.9461	0.9461	88
CP	CP:13	chronic pain:13:0.1139	0.1139	13
CP	CP:317|cP:6	chronic pancreatitis:323:0.9628	0.9628	323
CP	CP:49	chronic periodontitis:49:0.9392	0.9392	49
CP	CP:130	chronic phase:130:0.8759	0.8759	130
CP	CP:17	chronic progressive:17:0.8270	0.8270	17
CP	CP:21	chronic prostatitis:21:0.6812	0.6812	21
CP	CP:21	chronic pyelonephritis:21:0.8594	0.8594	21
CP	CP:78	cicatricial pemphigoid:78:0.9025	0.9025	78
CP	CP:5	ciliary processes:5:0.0902	0.0902	5
CP	CP:68	cisplatin:68:0.0088	0.0088	68
CP	CP:10	Cisplatinum:10:0.0012	0.0012	10
CP	CP:13	classical:13:0.0016	0.0016	13
CP	CP:40	classical pathway:40:0.5063	0.5063	40
CP	CP:168	cleft palate:168:0.9622	0.9622	168
CP	CP:13	cleft palate only:13:0.7753	0.7753	13
CP	CP:9|Cp:1	clobetasol propionate:10:0.3145	0.3145	10
Cp	Cp:10	Clostridium pasteurianum:10:0.7103	0.7103	10
CP	CP:12|Cp:4	Clostridium perfringens:16:0.8165	0.8165	16
CP	CP:485|cp:9|Cp:1	coat protein:495:0.5180	0.5180	495
CP	CP:6	coat protein gene:6:0.5290	0.5290	6
cp	cp:13|CP:1	Cold-passaged:14:0.0017	0.0017	14
CP	CP:13	cold pressor:13:0.7753	0.7753	13
CP	CP:17|cp:7	commercially pure:24:0.7593	0.7593	24
CP	CP:19	common peroneal:19:0.8449	0.8449	19
Cp	Cp:8|CP:1	compliance:9:0.0011	0.0011	9
CP	CP:35	constrictive pericarditis:35:0.8681	0.8681	35
CP	CP:8	control patients:8:0.0953	0.0953	8
CP	CP:15	cor pulmonale:15:0.7096	0.7096	15
CP	CP:11	core particle:11:0.6182	0.6182	11
CP	CP:13|Cp:2	core promoter:15:0.3262	0.3262	15
CP	CP:38|cp:4	cortical plate:42:0.6280	0.6280	42
CP	CP:70|Cp:11	Corynebacterium parvum:81:0.7029	0.7029	81
CP	CP:17	cricopharyngeal:17:0.0021	0.0021	17
CP	CP:14	cricopharyngeus:14:0.0017	0.0017	14
CP	CP:29	critical power:29:0.5212	0.5212	29
CP	CP:45	Cross-polarization:33:0.0042|cross polarization:12:0.6460	0.6460	45
CP	CP:260	crude protein:260:0.2593	0.2593	260
CP	CP:10	cryopreserved:10:0.0012	0.0012	10
Cp	Cp:12|cp:1	cyclopentadienyl:13:0.0016	0.0016	13
CP	CP:635|Cp:8|cp:1	cyclophosphamide:644:0.0847	0.0847	644
CP	CP:9	cyclophosphane:9:0.0011	0.0011	9
CP	CP:15	cysteine proteinase:15:0.7096	0.7096	15
cp	cp:27|CP:23	cytopathic:50:0.0065	0.0065	50
cp	cp:40|CP:12	cytopathogenic:52:0.0067	0.0067	52
CP	CP:9	muscle:9:0.0011	0.0011	9
CP	CP:12	perfusion:12:0.0015	0.0015	12
CP	CP:9|cp:1	period:10:0.0012	0.0012	10
Cp	Cp:27|CP:6	plasma concentration:20:0.3271|plasma concentrations:13:0.3134	0.3271	33
Cp	Cp:3|CP:2	plasma protein concentration:5:0.1132	0.1132	5
CP	CP:18|Cp:1	point:19:0.0024	0.0024	19
CP	CP:9|Cp:1	polymer:10:0.0012	0.0012	10
CP	CP:9	process:9:0.0011	0.0011	9
CQI	CQI:333	Continuous quality improvement:333:0.9314	0.9314	333
CQR	CQR:13|CQ-R:1	Chloroquine resistance:14:0.6173	0.6173	14
CQS	CQS:8	Chloroquinoxaline sulfonamide:8:0.5006	0.5006	8
CQ	CQ:20	camphorquinone:20:0.0356	0.0356	20
CQ	CQ:62	Carboquone:62:0.1144	0.1144	62
CQ	CQ:336|Cq:10	Chloroquine:346:0.6454	0.6454	346
CQ	CQ:7	closed quotient:7:0.1211	0.1211	7
CQ	CQ:14|cq:1	questionnaire:15:0.0263	0.0263	15
CR/XL	CR/XL:7	metoprolol controlled release/extended release:7:0.1470	0.1470	7
CR/XL	CR/XL:7	metoprolol succinate controlled release/extended release:7:0.5926	0.5926	7
CR1	CR1:56	C3b/C4b receptor:45:0.2144|C3b/C4b receptors:11:0.0869	0.2144	56
CR1	CR1:99	C3b receptor:69:0.3641|C3b receptors:30:0.4404	0.4404	99
CR1	CR1:33	complement receptor:33:0.1434	0.1434	33
CR1	CR1:80|CR-1:2	Complement receptor 1:82:0.9229	0.9229	82
CR1	CR1:91	complement receptor type 1:91:0.9036	0.9036	91
CR1	CR1:11	complement receptor type one:11:0.6182	0.6182	11
CR1	CR1:62|CR-1:1	first complete remission:63:0.8407	0.8407	63
CR1	CR1:17|CR-1:1	first remission:18:0.1118	0.1118	18
CR1	CR1:21	receptors for C3b:13:0.2636|receptor for C3b:8:0.0825	0.2636	21
CR2	CR2:17	C3d receptor:17:0.2022	0.2022	17
CR2	CR2:35	complement receptor type 2:35:0.9151	0.9151	35
CR2	CR2:23	second complete remission:23:0.8715	0.8715	23
CR2	CR2:9	second remission:9:0.0969	0.0969	9
CR3	CR3:13	C3bi receptor:13:0.0986	0.0986	13
CR3	CR3:7	complement receptors:7:0.1111	0.1111	7
CR3	CR3:43	complement receptor 3:43:0.8917	0.8917	43
CR3	CR3:75	complement receptor type 3:75:0.8511	0.8511	75
CR3	CR3:11	complement receptor type three:11:0.7357	0.7357	11
CR3	CR3:6	complement type 3 receptors:6:0.5290	0.5290	6
CR3	CR3:13	iC3b receptor:13:0.0986	0.0986	13
CR3	CR3:9	type 3 complement receptor:9:0.5470	0.5470	9
CRABP-I	CRABP-I:7|CRABPI:6|crabp-I:1	cellular retinoic acid-binding protein I:8:0.6411|cellular retinoic acid binding protein-I:6:0.5290	0.6411	14
CRABPs	CRABPs:15	cellular retinoic acid-binding proteins:15:0.8045	0.8045	15
CRABP	CRABP:79|cRABP:10	cellular retinoic acid-binding protein:89:0.8257	0.8257	89
CRABP	CRABP:18|cRABP:4	retinoic acid binding proteins:11:0.7357|retinoic acid-binding proteins:11:0.7357	0.7357	22
CRAC	CRAC:17	Ca(2+) release-activated Ca(2+):17:0.6211	0.6211	17
CRAC	CRAC:16	Ca2+ release-activated Ca2+:16:0.6577	0.6577	16
CRAC	CRAC:6	calcium release-activated calcium:6:0.5290	0.5290	6
CRAD	CRAD:9	chronic renal allograft dysfunction:9:0.5470	0.5470	9
CRAG	CRAG:4|CrAg:3	cryptococcal antigen:7:0.3524	0.3524	7
CRAO	CRAO:61	central retinal artery occlusion:61:0.9511	0.9511	61
CRAds	CRAds:7|CRADs:4	Conditionally replicating adenoviruses:11:0.7357	0.7357	11
CRAds	CRAds:15	conditionally replicative adenoviruses:15:0.8045	0.8045	15
CRALBP	CRALBP:66|CR-ALBP:1|CRAlBP:1	cellular retinaldehyde-binding protein:48:0.9379|cellular retinaldehyde binding protein:20:0.8525	0.9379	68
CRA	CRA:26|cRA:25|c-RA:2	13-cis-retinoic acid:42:0.4527|13-cis retinoic acid:11:0.4232	0.4527	53
CRA	CRA:11	cardiorespiratory arrest:11:0.7357	0.7357	11
CRA	CRA:6	caregiver reaction assessment:6:0.5290	0.5290	6
CRA	CRA:10	community reinforcement approach:10:0.7103	0.7103	10
CRA	CRA:6	comparative risk assessment:6:0.1838	0.1838	6
CRA	CRA:11	release assay:11:0.3213	0.3213	11
CRB1	CRB1:9	crumbs homologue 1:9:0.6794	0.6794	9
CRBBB	CRBBB:21|cRBBB:1	complete right bundle branch block:22:0.8657	0.8657	22
CRBC	CRBC:30|cRBC:2	chicken erythrocytes:32:0.8563	0.8563	32
CRBC	CRBC:42|cRBC:3|Crbc:1	chicken red blood cells:39:0.6937|chicken red blood cell:7:0.3524	0.6937	46
CRBP-1	CRBP-1:6|CRBP1:1	cellular retinol-binding protein-1:7:0.5926	0.5926	7
CRBPII	CRBPII:7|CRBP-II:1	Cellular retinol binding protein II:8:0.6411	0.6411	8
CRBPII	CRBPII:4	cellular retinol-binding protein type II:4:0.6794	0.6794	4
CRBP-I	CRBP-I:5|CRBPI:3	cellular retinol-binding protein I:8:0.6411	0.6411	8
CRBPI	CRBPI:3|CRBP-I:2	cellular retinol-binding protein type I:5:0.5290	0.5290	5
CRBP	CRBP:164|cRBP:7|C-RBP:1|Crbp:1	cellular retinol-binding protein:142:0.9357|cellular retinol binding protein:31:0.7091	0.9357	173
CRBSIs	CRBSIs:7|CR-BSIs:2	catheter-related bloodstream infections:9:0.5470	0.5470	9
CRBSI	CRBSI:31|CR-BSI:18	catheter-related bloodstream infection:35:0.7647|Catheter-related bloodstream infections:14:0.6911	0.7647	49
CRB	CRB:10	catheter-related bacteremia:10:0.5000	0.5000	10
CRCC	CRCC:12|cRCC:4	renal cell carcinoma:16:0.8165	0.8165	16
cRCP	cRCP:11	chicken riboflavin carrier protein:11:0.5355	0.5355	11
CRCP	CRCP:11	continuous retrograde cerebral perfusion:11:0.7357	0.7357	11
CRCs	CRCs:63	Colorectal cancers:63:0.9253	0.9253	63
CRCs	CRCs:28	colorectal carcinomas:28:0.8369	0.8369	28
CRCs	CRCs:23	Concentration-response curves:23:0.5466	0.5466	23
CRC	CRC:21	calcium release channel:21:0.4733	0.4733	21
CRC	CRC:12	cerebrovascular reserve capacity:12:0.7571	0.7571	12
CRC	CRC:12	colorectal adenocarcinoma:12:0.7571	0.7571	12
CRC	CRC:1176|crc:2	colorectal cancer:1123:0.9833|colorectal cancers:55:0.9458	0.9833	1178
CRC	CRC:241	colorectal carcinoma:217:0.9450|colorectal carcinomas:24:0.8115	0.9450	241
CRC	CRC:57	concentration-response curve:40:0.7653|concentration-response curves:17:0.5374	0.7653	57
CrC	CrC:6|Crc:2|CRC:1	creatinine clearance:9:0.6794	0.6794	9
CRC	CRC:6	red cells:6:0.0611	0.0611	6
CRC	CRC:12	Research Center:12:0.6460	0.6460	12
CRD-BP	CRD-BP:8	coding region determinant-binding protein:8:0.6411	0.6411	8
CRDQ	CRDQ:21	Chronic Respiratory Disease Questionnaire:21:0.8594	0.8594	21
CRDs	CRDs:44	carbohydrate recognition domains:29:0.8978|carbohydrate-recognition domains:15:0.1241	0.8978	44
CRDS	CRDS:12	curdlan sulfate:12:0.7357	0.7357	12
CRD	CRD:83	carbohydrate recognition domain:73:0.9591|carbohydrate recognition domains:10:0.7103	0.9591	83
CRD	CRD:44	chronic renal disease:38:0.8781|chronic renal diseases:6:0.5290	0.8781	44
CRD	CRD:53	colorectal distension:53:0.9116	0.9116	53
CRD	CRD:18|CrD:1	colorectal distention:19:0.8449	0.8449	19
CRD	CRD:22	cone-rod dystrophy:22:0.7400	0.7400	22
CRD	CRD:16	cross-reacting determinant:16:0.4536	0.4536	16
CRD	CRD:41	cysteine-rich domain:41:0.1815	0.1815	41
CREAE	CREAE:5|CR-EAE:4|cr-EAE:1	chronic relapsing EAE:10:0.7103	0.7103	10
CREAE	CREAE:29|CR-EAE:19|Cr-EAE:2|crEAE:2|cr-EAE:1	Chronic relapsing experimental allergic encephalomyelitis:53:0.9438	0.9438	53
CR-EAE	CR-EAE:8|CREAE:7|crEAE:2	chronic relapsing experimental autoimmune encephalomyelitis:17:0.8270	0.8270	17
creat	creat:6|CREAT:1	creatine transporter:7:0.3524	0.3524	7
CREB	CREB:5	binding proteins:5:0.1838	0.1838	5
CREB	CREB:202	cAMP response element binding protein:202:0.5426	0.5426	202
CREB	CREB:44	element binding:44:0.7038	0.7038	44
CREB	CREB:11	response element-binding:11:0.2764	0.2764	11
CREB	CREB:5	response element binding factor:5:0.1973	0.1973	5
CREB	CREB:6	transcription factor:6:0.0731	0.0731	6
CREF	CREF:20	cloned rat embryo fibroblast:20:0.7766	0.7766	20
CREF	CREF:8	rat embryo fibroblasts:8:0.6411	0.6411	8
CREM	CREM:24|crem:1	cAMP response element modulator:25:0.6873	0.6873	25
CREM	CREM:18	cAMP-responsive element modulator:18:0.1499	0.1499	18
CREM	CREM:6	modulator protein:6:0.1543	0.1543	6
CREs	CREs:36	cAMP response elements:36:0.6003	0.6003	36
CRE	CRE:279	cAMP response element:267:0.6260|cAMP response elements:12:0.2802	0.6260	279
CRE	CRE:10	cAMP-responsive elements:10:0.0578	0.0578	10
Cre	Cre:7|CRE:1	Cre recombinase:8:0.4102	0.4102	8
Cre	Cre:18|CRE:15|cre:1	creatinine:34:0.0301	0.0301	34
CRE	CRE:28	Cumulative Radiation Effect:28:0.8941	0.8941	28
CRE	CRE:9	cyclic AMP response elements:9:0.6794	0.6794	9
CRE	CRE:10	enhancer:10:0.0082	0.0082	10
CRF-41	CRF-41:23|CRF41:1	corticotrophin-releasing factor:15:0.1992|corticotrophin releasing factor:9:0.3069	0.3069	24
CRF-41	CRF-41:18	corticotrophin-releasing factor-41:18:0.6381	0.6381	18
CRF-R	CRF-R:5|CRFR:2	corticotropin-releasing factor receptor:7:0.2902	0.2902	7
CRF-R	CRF-R:6|CRFR:5	CRF receptor:11:0.2868	0.2868	11
CRF-ir	CRF-ir:10|CRF-IR:6|CRFir:2	immunoreactivity:18:0.5862	0.5862	18
CRFs	CRFs:9	case report forms:9:0.5470	0.5470	9
CRFs	CRFs:20	circulating recombinant forms:20:0.8525	0.8525	20
CRFs	CRFs:7	risk factors:7:0.1850	0.1850	7
CRF	CRF:19	cancer-related fatigue:19:0.6106	0.6106	19
CRF	CRF:17	cardiorespiratory fitness:17:0.8270	0.8270	17
CRF	CRF:2086|crf:4	chronic renal failure:2090:0.9922	0.9922	2090
CRF	CRF:20	circulating recombinant form:13:0.7753|circulating recombinant forms:7:0.4438	0.7753	20
CRF	CRF:27|crf:1|cRF:1	classical receptive field:29:0.7237	0.7237	29
CRF	CRF:33	continuous reinforcement:33:0.7841	0.7841	33
CRF	CRF:14	continuously reinforced:14:0.7909	0.7909	14
CRF	CRF:16	Corticoliberin:16:0.0029	0.0029	16
CRF	CRF:2258	Corticotropin-Releasing Factor:1823:0.6970|corticotropin releasing factor:435:0.7684	0.7684	2258
CRF	CRF:23	corticotropin-releasing hormone:14:0.2758|corticotropin releasing hormone:9:0.5470	0.5470	23
CRF	CRF:9	fraction:9:0.0016	0.0016	9
CRF	CRF:24|cRF:1	risk factors:25:0.6873	0.6873	25
CRG	CRG:28	compensatory renal growth:28:0.8941	0.8941	28
CRH-BP	CRH-BP:27|CRHBP:2|CRHbp:1	CRH-binding protein:30:0.6252	0.6252	30
CRHD	CRHD:9	chronic rheumatic heart disease:9:0.4587	0.4587	9
CRH-R1	CRH-R1:6|CRHR1:2	CRH receptor type 1:8:0.3470	0.3470	8
CRHR1	CRHR1:5|CRH-R1:4	type 1 receptor:9:0.6794	0.6794	9
CRH	CRH:63	corticotrophin releasing hormone:63:0.1317	0.1317	63
CRH	CRH:1676|Crh:6|C-RH:1	Corticotropin-releasing hormone:1384:0.6784|corticotropin releasing hormone:283:0.7383|corticotropin-releasing-hormone:16:0.0073	0.7383	1683
CRIA	CRIA:12	cross-reactive idiotype:12:0.2868	0.2868	12
CRIA	CRIA:8|cRIA:3|C-RIA:1	radioimmunoassay:12:0.2292	0.2292	12
CRIE	CRIE:61	crossed radioimmunoelectrophoresis:61:0.8987	0.8987	61
CRIP	CRIP:19	Cysteine-rich intestinal protein:19:0.7539	0.7539	19
CRISPs	CRISPs:12	cysteine-rich secretory proteins:12:0.6460	0.6460	12
CRIs	CRIs:8	cross-reactive idiotypes:8:0.3463	0.3463	8
CRI	CRI:5	cardiac risk index:5:0.0736	0.0736	5
CRI	CRI:25	catheter-related infection:13:0.4849|catheter-related infections:12:0.4557	0.4849	25
CRI	CRI:9	chronic renal impairment:9:0.6794	0.6794	9
CRI	CRI:232	chronic renal insufficiency:232:0.9725	0.9725	232
CRI	CRI:7	cross-reactive idiotope:7:0.3524	0.3524	7
CRI	CRI:85	cross-reactive idiotype:56:0.7044|cross-reactive idiotypes:29:0.8978	0.8978	85
CRI	CRI:15	Inventory:15:0.0243	0.0243	15
CRLR	CRLR:110	calcitonin receptor-like receptor:110:0.8749	0.8749	110
CRL	CRL:13	Candida rugosa lipase:13:0.5934	0.5934	13
CRL	CRL:187|C-RL:1|crl:1	crown-rump length:165:0.8032|crown-rump-length:12:0.0324|crown-rump lengths:12:0.5050	0.8032	189
CRM1	CRM1:8	region maintenance 1:8:0.6411	0.6411	8
CRMO	CRMO:58	chronic recurrent multifocal osteomyelitis:58:0.9486	0.9486	58
CRMP-2	CRMP-2:14	collapsin response mediator protein-2:14:0.7909	0.7909	14
CRMs	CRMs:40	certified reference materials:40:0.7907	0.7907	40
CRM	CRM:41	certified reference material:26:0.8861|certified reference materials:15:0.7096	0.8861	41
CRM	CRM:14	circumferential resection margin:14:0.7909	0.7909	14
CRM	CRM:25	continual reassessment method:25:0.8816	0.8816	25
CRM	CRM:8	cremophor EL:8:0.5006	0.5006	8
CRM	CRM:46	Cross-reacting material:46:0.3585	0.3585	46
CRM	CRM:22	Resource Management:22:0.6531	0.6531	22
Crn	Crn:7|CRN:6|CrN:1	creatinine:14:0.1940	0.1940	14
CROM	CROM:8	Cervical Range of Motion:8:0.6411	0.6411	8
CROs	CROs:7	contract research organizations:7:0.3524	0.3524	7
CRPF	CRPF:9	Plasmodium falciparum:9:0.3945	0.3945	9
CRPS-I	CRPS-I:6	complex regional pain syndrome type I:6:0.6411	0.6411	6
CRPV	CRPV:86	cottontail rabbit papillomavirus:86:0.9272	0.9272	86
CrPV	CrPV:12	cricket paralysis virus:12:0.7571	0.7571	12
CRPs	CRPs:10	complement regulatory proteins:10:0.7103	0.7103	10
CRPS	CRPS:170	complex regional pain syndrome:154:0.9401|Complex Regional Pain Syndromes:16:0.8165	0.9401	170
CRQ	CRQ:31	chronic respiratory disease questionnaire:31:0.9043	0.9043	31
CRQ	CRQ:40	Chronic Respiratory Questionnaire:40:0.8839	0.8839	40
CRRTs	CRRTs:9	continuous renal replacement therapies:9:0.6794	0.6794	9
CRRT	CRRT:176	Continuous renal replacement therapy:155:0.9590|continuous renal replacement therapies:21:0.8657	0.9590	176
CRR	CRR:8	cysteine-rich region:8:0.1730	0.1730	8
CRs	CRs:10	cancer registries:10:0.7103	0.7103	10
CRS	CRS:31	catheter-related sepsis:31:0.7091	0.7091	31
CRS	CRS:80	chronic rhinosinusitis:80:0.9627	0.9627	80
CRS	CRS:1	cold and restraint stress:1:0.3463	0.3463	1
CRS	CRS:10	cold-restraint stress:10:0.1994	0.1994	10
CRs	CRs:11	complement receptors:11:0.4232	0.4232	11
CRs	CRs:55|CRS:1	Complete remissions:56:0.8667	0.8667	56
CRs	CRs:8	complete responders:8:0.5006	0.5006	8
Crs	Crs:33|CRS:13	compliance of the respiratory system:46:0.7191	0.7191	46
CRs	CRs:9	concentration ratios:9:0.1945	0.1945	9
CRs	CRs:115|CRS:2|Crs:1	conditioned responses:118:0.3224	0.3224	118
CRS	CRS:111	congenital rubella syndrome:111:0.9567	0.9567	111
CRs	CRs:9	conserved regions:9:0.3069	0.3069	9
CRS	CRS:5	cytoplasmic retention signal:5:0.4422	0.4422	5
CRS	CRS:17	Rating Scale:17:0.5760	0.5760	17
Crs	Crs:82|CRS:4	respiratory system compliance:86:0.9449	0.9449	86
CRS	CRS:16	risk score:16:0.5171	0.5171	16
CRS	CRS:37|crs:1	sequence:27:0.0202|sequences:11:0.0078	0.0202	38
Crs	Crs:11	total respiratory compliance:11:0.1612	0.1612	11
CRTH2	CRTH2:15|CRTh2:1	chemoattractant receptor-homologous molecule expressed on Th2 cells:16:0.6577	0.6577	16
CRTs	CRTs:8	cathode-ray tubes:8:0.2619	0.2619	8
CRT	CRT:87|Crt:6|crt:2	Calreticulin:95:0.0888	0.0888	95
CRT	CRT:154	cardiac resynchronization therapy:154:0.9690	0.9690	154
CRT	CRT:88|crt:1	cathode ray tube:62:0.9519|cathode-ray tube:27:0.1957	0.9519	89
CRT	CRT:10	concurrent chemoradiotherapy:10:0.0557	0.0557	10
CRT	CRT:25	conformal radiotherapy:25:0.3233	0.3233	25
CRT	CRT:14	cortisol:14:0.0123	0.0123	14
CRT	CRT:9	cortisone-resistant thymocytes:9:0.3945	0.3945	9
CRT	CRT:19	cranial irradiation:19:0.5113	0.5113	19
CRT	CRT:11	cranial radiation:11:0.3213	0.3213	11
CRT	CRT:6|CrT:3	creatine transporter:9:0.3945	0.3945	9
CRT	CRT:8	Preoperative chemoradiation:8:0.2619	0.2619	8
CRT	CRT:5	prophylactic cranial radiotherapy:5:0.0612	0.0612	5
CRT	CRT:10	reaction times:10:0.7103	0.7103	10
CRT	CRT:9	renal transplantation:9:0.6794	0.6794	9
CRT	CRT:11	temperature:11:0.0095	0.0095	11
CRU	CRU:7	competitive repopulating units:7:0.3524	0.3524	7
CRV	CRV:25	central retinal vein:25:0.8816	0.8816	25
CRVO	CRVO:12	central retinal vein obstruction:12:0.7571	0.7571	12
CRVO	CRVO:211	central retinal vein occlusion:211:0.9858	0.9858	211
CRX	CRX:12|Crx:2|crx:1	cone-rod homeobox:15:0.4951	0.4951	15
cry1	cry1:8|CRY1:2|Cry1:1	Cryptochrome 1:11:0.7357	0.7357	11
cry2	cry2:8|Cry2:1	Cryptochrome 2:9:0.6794	0.6794	9
CR	CR:41|C-R:5	Cajal-Retzius:46:0.0043	0.0043	46
CR	CR:16	calcium-binding protein calretinin:16:0.5940	0.5940	16
CR	CR:205	Caloric restriction:205:0.6624	0.6624	205
CR	CR:12	calorie-restricted:12:0.0010	0.0010	12
CR	CR:76	calorie restriction:76:0.2110	0.2110	76
CR	CR:15	Calreticulin:15:0.0013	0.0013	15
CR	CR:10	capture-recapture:10:0.0009	0.0009	10
CR	CR:22	carbonyl reductase:22:0.8657	0.8657	22
CR	CR:91	Cardiac Rehabilitation:91:0.9015	0.9015	91
CR	CR:7	cardiac rupture:7:0.3524	0.3524	7
CR	CR:8|C-R:1|cr:1	cardiorespiratory:10:0.0009	0.0009	10
CR	CR:12	caries-resistant:12:0.0010	0.0010	12
CR	CR:28	centric relation:28:0.8369	0.8369	28
CR	CR:9	charge recombination:9:0.6794	0.6794	9
CR	CR:11	Charles River:11:0.4728	0.4728	11
CR	CR:96	chronic rejection:96:0.7982	0.7982	96
CR	CR:29	circadian rhythm:29:0.7581	0.7581	29
CR	CR:13	cockroach:13:0.0011	0.0011	13
CR	CR:10	coefficient of repeatability:10:0.5000	0.5000	10
CR	CR:7	cognitive reserve:7:0.0655	0.0655	7
CR	CR:20	colonization resistance:20:0.1827	0.1827	20
CR	CR:67	complement receptor:35:0.6096|complement receptors:32:0.4827	0.6096	67
CR	CR:129	complete:129:0.0121	0.0121	129
CR	CR:26	complete regression:26:0.6973	0.6973	26
CR	CR:2961	complete remission:2844:0.9703|complete remissions:117:0.9744	0.9744	2961
CR	CR:14	complete remission rate:14:0.6911	0.6911	14
CR	CR:45	complete responders:45:0.8964	0.8964	45
CR	CR:2061	Complete response:1870:0.8686|complete responses:191:0.8495	0.8686	2061
CR	CR:19	complete response rate:19:0.7044	0.7044	19
CR	CR:9	completely:9:0.0008	0.0008	9
CR	CR:8	composite resin:8:0.4102	0.4102	8
CR	CR:12|Cr:1	compression ratio:13:0.0788	0.0788	13
CR	CR:10	computed radiographic:10:0.5856	0.5856	10
CR	CR:221	computed radiography:221:0.8350	0.8350	221
CR	CR:23	concentration ratios:12:0.2868|concentration ratio:11:0.0574	0.2868	23
CR	CR:6|C-R:4|cr:3|c-r:1	concentration-response:14:0.0012	0.0012	14
CR	CR:34	conditioned reflex:25:0.4596|conditioned reflexes:9:0.3945	0.4596	34
CR	CR:7	conditioned reinforcement:7:0.2452	0.2452	7
CR	CR:10	conditioned reward:10:0.7103	0.7103	10
CR	CR:42	Congo red:42:0.7750	0.7750	42
CR	CR:20	conserved region:12:0.0713|conserved regions:8:0.3463	0.3463	20
CR	CR:8	constant routine:8:0.5006	0.5006	8
CR	CR:11	contractile reserve:11:0.1938	0.1938	11
CR	CR:11	control rats:11:0.3495	0.3495	11
CR	CR:41	control region:41:0.4609	0.4609	41
CR	CR:179	controlled-release:117:0.0110|controlled release:62:0.8407	0.8407	179
CR	CR:8	conventional radiology:8:0.3463	0.3463	8
CR	CR:9	coronary resistance:9:0.0537	0.0537	9
CR	CR:5	coronary revascularization:5:0.0736	0.0736	5
CR	CR:8	coronary risk:8:0.2090	0.2090	8
CR	CR:6	cortical reaction:6:0.0522	0.0522	6
CR	CR:9	corticosteroid-resistant:9:0.0008	0.0008	9
Cr	Cr:22	creatine and phosphocreatine:22:0.2508	0.2508	22
CR	CR:9	cross-reactive:9:0.0008	0.0008	9
CR	CR:18|C-R:6|c-r:1	crown-rump:25:0.0023	0.0023	25
C-R	C-R:6|CR:4	crown-rump length:10:0.5856	0.5856	10
CR	CR:10	cysteine-rich:10:0.0009	0.0009	10
CR	CR:21	Czech Republic:21:0.7865	0.7865	21
Cr	Cr:8|CR:2	energy cost of running:10:0.4363	0.4363	10
C-R	C-R:8	followed by 20 min of running:8:0.6411	0.6411	8
CR	CR:19	rates:19:0.0017	0.0017	19
CR	CR:15	reactivity:15:0.0013	0.0013	15
CR	CR:9	remodeling:9:0.0008	0.0008	9
CR	CR:15|C-R:1	resistant:16:0.0014	0.0014	16
CR	CR:13	rotation:13:0.0011	0.0011	13
Cr	Cr:136|CR:9|cr:1	serum creatinine:146:0.2513	0.2513	146
Cr	Cr:7|CR:1	serum creatinine concentration:8:0.3463	0.3463	8
CS(2)	CS(2):18	carbon disulfide:18:0.8365	0.8365	18
CS-	CS-:15	flavor:15:0.0819	0.0819	15
CS-	CS-:7	ignore a different tone:7:0.2902	0.2902	7
CS-	CS-:28	stimulus:28:0.1579	0.1579	28
CS/DS	CS/DS:11	chondroitin/dermatan sulfate:11:0.2582	0.2582	11
CS/DS	CS/DS:8	chondroitin sulfate/dermatan sulfate:8:0.6411	0.6411	8
CS-1	CS-1:11|CS1:4	connecting segment-1:15:0.8045	0.8045	15
CS2	CS2:148	carbon disulfide:148:0.9675	0.9675	148
CS2	CS2:57	carbon disulphide:57:0.9477	0.9477	57
CSAD	CSAD:11	Cysteine sulfinic acid decarboxylase:11:0.7571	0.7571	11
CSAG	CSAG:11	Clinical Standards Advisory Group:11:0.7357	0.7357	11
CSAp	CSAp:8	Colon-specific antigen-p:8:0.2987	0.2987	8
CSAP	CSAP:14	cryosurgical ablation of the prostate:14:0.7909	0.7909	14
CSAs	CSAs:29	cross-sectional areas:29:0.7581	0.7581	29
CSA	CSA:22	analysis:22:0.0055	0.0055	22
CSA	CSA:9	Canadian Standards Association:9:0.6794	0.6794	9
CSA	CSA:17	catalyzed signal amplification:17:0.5374	0.5374	17
CSA	CSA:4	cell surface antigens:4:0.0545	0.0545	4
CSA	CSA:29	central sleep apnea:29:0.8978	0.8978	29
CSA	CSA:11	Central sleep apnoea:11:0.7357	0.7357	11
CSA	CSA:51|csa:1	chemical shift anisotropy:52:0.8821	0.8821	52
CSA	CSA:15	chicken serum albumin:15:0.4609	0.4609	15
CSA	CSA:126	childhood sexual abuse:126:0.5248	0.5248	126
CSA	CSA:8|CS-A:3	chondroitin-4-sulfate:11:0.0026	0.0026	11
CSA	CSA:12	chronic stable angina:12:0.7571	0.7571	12
CsA	CsA:17|CSA:2|CS-A:1	ciclosporin:20:0.0052	0.0052	20
CSA	CSA:13	clinical skills assessment:13:0.7753	0.7753	13
CSA	CSA:7	colon-specific antigen:7:0.0539	0.0539	7
CSA	CSA:341|csa:1	colony-stimulating activity:236:0.6231|colony stimulating activity:98:0.9359|colony-stimulating activities:8:0.2987	0.9359	342
CSA	CSA:22	compressed spectral array:22:0.8657	0.8657	22
CSA	CSA:6	computer science and applications:6:0.6794	0.6794	6
CSA	CSA:11	conformational space annealing:11:0.7357	0.7357	11
CSA	CSA:11	continuous spinal anaesthesia:11:0.7357	0.7357	11
CSA	CSA:17	continuous spinal anesthesia:17:0.7407	0.7407	17
CSA	CSA:13	Controlled Substances Act:13:0.7753	0.7753	13
CSA	CSA:20	coronary spastic angina:20:0.8525	0.8525	20
CSA	CSA:670|csa:1	cross-sectional area:596:0.8889|cross-sectional areas:75:0.8369	0.8889	671
CsA	CsA:195|CSA:31|Cs-A:1	cyclosporin:227:0.0587	0.0587	227
CsA	CsA:67|CSA:14|CS-A:8|Cs-A:4	cyclosporin-A:93:0.0239	0.0239	93
CsA	CsA:1246|CSA:156|CS-A:1|Csa:1	cyclosporine:1404:0.3637	0.3637	1404
CsA	CsA:40|CSA:10|Cs-A:6	cyclosporine-A:56:0.0143	0.0143	56
CSA	CSA:15	cysteine sulfinic acid:15:0.5818	0.5818	15
CSBF	CSBF:37	coronary sinus blood flow:37:0.9197	0.9197	37
C-SBM	C-SBM:19	corn-soybean meal:19:0.6537	0.6537	19
CSCC	CSCC:25	cholesterol side chain cleavage:13:0.7753|Cholesterol side-chain cleavage:12:0.7571	0.7753	25
CSCC	CSCC:5	cholesterol side-chain cleavage enzyme:5:0.4422	0.4422	5
CSCI	CSCI:8|C-SCI:2	cervical spinal cord injury:10:0.7103	0.7103	10
CSCR	CSCR:25	central serous chorioretinopathy:25:0.8816	0.8816	25
cSCS	cSCS:9|CSCS:4|C-SCS:1	cervical spinal cord stimulation:14:0.7909	0.7909	14
CSC	CSC:9	antagonist 8-(3-chlorostyryl)caffeine:9:0.2868	0.2868	9
CSC	CSC:79	central serous chorioretinopathy:79:0.9622	0.9622	79
CSC	CSC:97	cigarette smoke condensate:97:0.9692	0.9692	97
CSC	CSC:6	circulating stem cells:6:0.2827	0.2827	6
CSC	CSC:7	Correctional Service of Canada:7:0.7103	0.7103	7
CSC	CSC:35	cryogen spray cooling:35:0.9151	0.9151	35
CSDD	CSDD:18	Cornell Scale for Depression in Dementia:18:0.8365	0.8365	18
CSDHs	CSDHs:8|cSDHs:1	chronic subdural hematomas:9:0.6794	0.6794	9
CSDH	CSDH:15|cSDH:1	Chronic Subdural Haematoma:16:0.8165	0.8165	16
CSDH	CSDH:48|cSDH:1	chronic subdural hematoma:49:0.9392	0.9392	49
CSDs	CSDs:6	Critical-sized defects:6:0.2243	0.2243	6
CSD	CSD:26	Cambridge Structural Database:26:0.8861	0.8861	26
CSD	CSD:13	Cardiac Support Device:13:0.7753	0.7753	13
CSD	CSD:8	carotid sinus denervation:8:0.6411	0.6411	8
CSD	CSD:176	cat scratch disease:100:0.9698|cat-scratch disease:76:0.3313	0.9698	176
CSD	CSD:7	cervical spine disorders:7:0.5926	0.5926	7
CSD	CSD:34	cold shock domain:21:0.8594|cold-shock domain:13:0.1384	0.8594	34
CSD	CSD:18	conditioned suppression of drinking:18:0.8365	0.8365	18
CSD	CSD:156	cortical spreading depression:156:0.9500	0.9500	156
CSD	CSD:113	current source density:76:0.9607|current source-density:22:0.8657|current-source density:15:0.0755	0.9607	113
CSD	CSD:5	current source density analysis:5:0.4422	0.4422	5
CSD	CSD:22	cysteine sulfinate decarboxylase:22:0.8657	0.8657	22
CSD	CSD:10	Distribution:10:0.0110	0.0110	10
CSEA	CSEA:19	combined spinal-epidural anesthesia:13:0.6701|combined spinal epidural anesthesia:6:0.7357	0.7357	19
CSEP	CSEP:17|c-SEP:1	Cortical somatosensory evoked potentials:10:0.5000|Cortical somatosensory evoked potential:8:0.3463	0.5000	18
CSERP	CSERP:8	chemosensory event-related potentials:8:0.5006	0.5006	8
CSES	CSES:14	Self-Efficacy Scale:14:0.5589	0.5589	14
CSE	CSE:65	cigarette smoke extract:56:0.9467|cigarette smoke extracts:9:0.6794	0.9467	65
CSE	CSE:72	combined spinal-epidural:48:0.9379|combined spinal epidural:24:0.9011	0.9379	72
CSE	CSE:8	Combined spinal-epidural anesthesia:8:0.6411	0.6411	8
CSE	CSE:9	conventional SE:9:0.4587	0.4587	9
CSE	CSE:61	conventional spin-echo:43:0.8917|conventional spin echo:18:0.7539	0.8917	61
CSE	CSE:11	convulsive status epilepticus:11:0.6182	0.6182	11
CSE	CSE:9	cross-sectional echocardiography:9:0.5470	0.5470	9
CSE	CSE:9	cystathionine gamma-lyase:9:0.6794	0.6794	9
CSF's	CSF's:19	Contrast sensitivity functions:19:0.7658	0.7658	19
CSF-1R	CSF-1R:20|CSF1R:2	colony-stimulating factor 1 receptor:14:0.5589|colony stimulating factor-1 receptor:8:0.6411	0.6411	22
CSF-1	CSF-1:411|CSF1:3	Colony-stimulating factor-1:182:0.5781|colony-stimulating factor 1:130:0.7560|colony stimulating factor-1:102:0.9534	0.9534	414
CSF-1	CSF-1:110|Csf1:1	macrophage colony-stimulating factor:80:0.5105|macrophage colony stimulating factor:31:0.5117	0.5117	111
CSF-1	CSF-1:8	macrophage CSF:8:0.2619	0.2619	8
CSFD	CSFD:10	cerebrospinal fluid drainage:10:0.5856	0.5856	10
CSFII	CSFII:42	Continuing Survey of Food Intakes by Individuals:31:0.9100|continuing survey of food intake by individuals:11:0.7909	0.9100	42
CSFP	CSFP:68|CSFp:7|CSF-P:3|CSF-p:2	cerebrospinal fluid pressure:80:0.9219	0.9219	80
CSFV	CSFV:205	classical swine fever virus:205:0.9766	0.9766	205
CSFs	CSFs:21	cerebrospinal fluids:21:0.7291	0.7291	21
CSFs	CSFs:317	Colony-stimulating factors:245:0.6934|Colony stimulating factors:72:0.9579	0.9579	317
CSFs	CSFs:29	contrast sensitivity functions:29:0.8978	0.8978	29
CSF	CSF:38	cerebrospinal:38:0.0025	0.0025	38
CSF	CSF:12672|csf:24	cerebrospinal fluid:12583:0.9622|Cerebrospinal fluids:97:0.9510|cerebrospinal-fluid:16:0.0010	0.9622	12696
CSF	CSF:10	cerebrospinal fluid samples:10:0.7103	0.7103	10
CSF	CSF:152	classical swine fever:152:0.9681	0.9681	152
CSF	CSF:786|csf:1	Colony-stimulating factor:417:0.5329|colony stimulating factor:184:0.8749|Colony-stimulating factors:133:0.6242|colony stimulating factors:53:0.9438	0.9438	787
CSF	CSF:7	colony-stimulating factor(s):7:0.3524	0.3524	7
CSF	CSF:102	contrast sensitivity function:91:0.9672|Contrast sensitivity functions:11:0.6182	0.9672	102
CSF	CSF:14	coronary sinus blood flow:14:0.7909	0.7909	14
CSF	CSF:18	coronary sinus flow:18:0.8365	0.8365	18
CSF	CSF:63	cytostatic factor:63:0.0635	0.0635	63
CSGE	CSGE:49	Conformation-sensitive gel electrophoresis:27:0.3613|conformation sensitive gel electrophoresis:22:0.6934	0.6934	49
CSG	CSG:16	chronic superficial gastritis:16:0.8165	0.8165	16
CsG	CsG:19|CSG:1	cyclosporin G:20:0.4037	0.4037	20
CSHA	CSHA:40	Canadian Study of Health and Aging:40:0.9256	0.9256	40
CSHCN	CSHCN:69	Children with Special Health Care Needs:69:0.9316	0.9316	69
C-S-H	C-S-H:8|CSH:7	Calcium silicate hydrate:15:0.7096	0.7096	15
CSH	CSH:20	carotid sinus hypersensitivity:20:0.8525	0.8525	20
CSH	CSH:32	Cell surface hydrophobicity:32:0.9072	0.9072	32
CSH	CSH:9	chronic severe hepatitis:9:0.6794	0.6794	9
CSH	CSH:10	chronic subdural haematoma:10:0.7103	0.7103	10
CSH	CSH:41	chronic subdural hematoma:41:0.8839	0.8839	41
CsH	CsH:7|CSH:1	cyclosporin H:8:0.1591	0.1591	8
CSH	CSH:31	cysteamine:31:0.1038	0.1038	31
CSH	CSH:11	cysteine:11:0.0346	0.0346	11
CSIA	CSIA:12	isotope analysis:12:0.6460	0.6460	12
CSIC	CSIC:6	chondroitin sulfate iron colloid:6:0.5290	0.5290	6
CSII	CSII:364	continuous subcutaneous insulin infusion:364:0.9705	0.9705	364
CSI	CSI:14	cervical spine injury:14:0.7909	0.7909	14
CsI	CsI:8	cesium iodide:8:0.5006	0.5006	8
CSI	CSI:85	Chemical shift imaging:85:0.9264	0.9264	85
CSI	CSI:53	cholesterol saturation index:53:0.8842	0.8842	53
CSI	CSI:6	Chromosaponin I:6:0.0807	0.0807	6
CSI	CSI:4|CS-I:2	clinical stage I:6:0.5290	0.5290	6
CSI	CSI:15	continuous subcutaneous infusion:15:0.8045	0.8045	15
CSI	CSI:32	craniospinal irradiation:32:0.7782	0.7782	32
CSI	CSI:6	Salvia Injection:6:0.2243	0.2243	6
Csk	Csk:53|CSK:15	C-terminal Src kinase:68:0.6861	0.6861	68
CSK	CSK:10|Csk:1	cytoskeletal:11:0.0621	0.0621	11
CSK	CSK:32	cytoskeleton:32:0.1925	0.1925	32
CSLM	CSLM:11	confocal scanning laser microscope:11:0.7357	0.7357	11
CSLM	CSLM:74	confocal scanning laser microscopy:74:0.9596	0.9596	74
CSL	CSL:13	cerebellar soluble lectin:13:0.7753	0.7753	13
CSL	CSL:17	corn steep liquor:17:0.7407	0.7407	17
CSMC	CSMC:8|cSMC:6	smooth muscle cells:14:0.7909	0.7909	14
CSME	CSME:23	clinically significant macular edema:23:0.8715	0.8715	23
CSMI	CSMI:15	cross-sectional moment of inertia:15:0.7096	0.7096	15
CSMO	CSMO:10	clinically significant macular oedema:10:0.5856	0.5856	10
CSM	CSM:27	carotid sinus massage:27:0.8903	0.8903	27
CSM	CSM:68	cervical spondylotic myelopathy:68:0.9554	0.9554	68
CSM	CSM:19	Committee on Safety of Medicines:19:0.8861	0.8861	19
CSM	CSM:17	contraceptive social marketing:17:0.4742	0.4742	17
CSM	CSM:36	cottonseed meal:36:0.6538	0.6538	36
CSM	CSM:17	smooth muscle:17:0.7407	0.7407	17
CSN3	CSN3:10	kappa-casein:10:0.5294	0.5294	10
CSNA	CSNA:31	cardiac sympathetic nerve activity:31:0.9043	0.9043	31
CSNB	CSNB:53	congenital stationary night blindness:53:0.9438	0.9438	53
CSNB1	CSNB1:11	X-linked congenital stationary night blindness:11:0.4232	0.4232	11
CSNB2	CSNB2:10	congenital stationary night blindness:10:0.7103	0.7103	10
CSNRT	CSNRT:42|CS-NRT:1|cSNRT:1	Corrected Sinus Node Recovery Time:44:0.8941	0.8941	44
CSNS	CSNS:5	carotid sinus nerve stimulation:5:0.4422	0.4422	5
CSN	CSN:15	carotid sinus:15:0.8045	0.8045	15
CSN	CSN:120	carotid sinus nerve:106:0.9718|carotid sinus nerves:14:0.7909	0.9718	120
CSN	CSN:49	COP9 signalosome:49:0.8492	0.8492	49
CSN	CSN:8	corticospinal neurons:8:0.2327	0.2327	8
CSOM	CSOM:68	chronic suppurative otitis media:68:0.9306	0.9306	68
CSOs	CSOs:11	combined sewer overflows:11:0.7357	0.7357	11
CSO	CSO:6	Clarified Slurry Oil:6:0.5290	0.5290	6
CSO	CSO:5	Statistical office:5:0.1132	0.1132	5
CSPAMM	CSPAMM:9	complementary spatial modulation of magnetization:9:0.6794	0.6794	9
CSPGs	CSPGs:72|CS-PGs:5	chondroitin sulfate proteoglycans:77:0.9190	0.9190	77
CSPG	CSPG:133|CS-PG:18	chondroitin sulfate proteoglycan:122:0.9255|chondroitin sulfate proteoglycans:29:0.8978	0.9255	151
CSPs	CSPs:106	chiral stationary phases:106:0.9718	0.9718	106
CSPs	CSPs:11|Csps:7|csps:2	cold shock proteins:20:0.8525	0.8525	20
CSPs	CSPs:11|csps:6|Csps:5	Cysteine string proteins:22:0.8657	0.8657	22
CSP	CSP:47	carotid sinus pressure:47:0.5949	0.5949	47
CSP	CSP:33	cavum septi pellucidi:33:0.9100	0.9100	33
CSP	CSP:13	cavum septum pellucidum:13:0.7261	0.7261	13
CSP	CSP:153	chiral stationary phase:138:0.9783|Chiral Stationary Phases:15:0.8045	0.9783	153
CSP	CSP:100	circumsporozoite protein:100:0.4847	0.4847	100
CSP	CSP:7	community support program:7:0.4438	0.4438	7
CSP	CSP:19	competence-stimulating peptide:19:0.5732	0.5732	19
CSP	CSP:7	Cooperative Studies Program:7:0.5926	0.5926	7
CSP	CSP:5|csp:4	corpus spongiosum penis:9:0.7103	0.7103	9
CSP	CSP:52	cyclosporine:52:0.0606	0.0606	52
CSP	CSP:23|csp:8|Csp:3	cysteine string protein:34:0.8644	0.8644	34
CSP	CSP:8	cystosarcoma phyllodes:8:0.5006	0.5006	8
CSP	CSP:9|Csp:1	proteins:10:0.0107	0.0107	10
CSP	CSP:53|cSP:5|C-SP:4|c-SP:1	silent period:63:0.9526	0.9526	63
CSQ	CSQ:34	calsequestrin:34:0.3113	0.3113	34
CSQ	CSQ:37	Coping Strategies Questionnaire:37:0.9197	0.9197	37
CSR-CSA	CSR-CSA:12	Cheyne-Stokes respiration with central sleep apnea:12:0.6911	0.6911	12
CSRE	CSRE:10	carbon source-responsive element:10:0.7103	0.7103	10
CSRT	CSRT:9	corrected sinus node recovery time:9:0.6794	0.6794	9
CSRT	CSRT:9	corrected sinus recovery time:9:0.6794	0.6794	9
CSR	CSR:9	cardiac sarcoplasmic reticulum:9:0.5470	0.5470	9
CSR	CSR:25|csr:1	central serous retinopathy:26:0.8861	0.8861	26
CSR	CSR:51	Cheyne-Stokes respiration:51:0.8546	0.8546	51
CSR	CSR:109	class switch recombination:109:0.9563	0.9563	109
CSR	CSR:11	combat stress reaction:11:0.7357	0.7357	11
CSR	CSR:19	cumulative survival rate:19:0.8449	0.8449	19
CSS	CSS:6	Canadian Stroke Scale:6:0.2827	0.2827	6
CSS	CSS:14	cancer-specific survival:14:0.0730	0.0730	14
CSS	CSS:65	cause-specific survival:50:0.4569|cause specific survival:15:0.4052	0.4569	65
CSS	CSS:14	chronic serum sickness:14:0.7909	0.7909	14
CSS	CSS:9	Chronic Sinusitis Survey:9:0.6794	0.6794	9
CSS	CSS:159|CSs:1	Churg-Strauss syndrome:160:0.6832	0.6832	160
CSs	CSs:5	composite scores:5:0.0736	0.0736	5
CSs	CSs:18	conditional stimuli:18:0.0809	0.0809	18
CSs	CSs:94	conditioned stimuli:94:0.7277	0.7277	94
CSS	CSS:16	constitutional short stature:16:0.7261	0.7261	16
CSs	CSs:15	corticosteroids:15:0.0149	0.0149	15
CSS	CSS:17	cultured skin substitutes:17:0.8270	0.8270	17
Css	Css:13	steady state:13:0.7753	0.7753	13
Css	Css:36|css:1	steady-state concentration:22:0.1936|steady-state concentrations:15:0.1530	0.1936	37
Css	Css:32|CSS:2	steady-state plasma concentrations:17:0.5038|steady-state plasma concentration:17:0.5038	0.5038	34
Css	Css:6	steady-state plasma levels:6:0.1838	0.1838	6
CST3	CST3:11	cystatin C gene:11:0.7357	0.7357	11
CstF	CstF:14	Cleavage stimulation factor:14:0.7909	0.7909	14
CSTR	CSTR:55	stirred tank reactor:55:0.9458	0.9458	55
CSTs	CSTs:8	contraction stress tests:8:0.6411	0.6411	8
CST	CST:12	Cavernous sinus thrombosis:12:0.4153	0.4153	12
CST	CST:15|Cst:1	cerebroside sulfotransferase:16:0.5171	0.5171	16
CST	CST:31	cervical sympathetic trunk:31:0.8519	0.8519	31
CST	CST:16	Connected Speech Test:16:0.8165	0.8165	16
CST	CST:28	contraction stress test:28:0.7905	0.7905	28
CST	CST:115	corticospinal tract:115:0.9328	0.9328	115
CST	CST:18	cortistatin:18:0.0307	0.0307	18
CST	CST:14	Skills Training:14:0.5589	0.5589	14
CST	CST:11	stand trial:11:0.7357	0.7357	11
Cst	Cst:21|CST:2	static compliance:23:0.3492	0.3492	23
Cst	Cst:14	static lung compliance:14:0.6911	0.6911	14
CS-US	CS-US:10	conditioned stimulus-unconditioned stimulus:10:0.7103	0.7103	10
CSV	CSV:7	canine saphenous vein:7:0.3524	0.3524	7
CSV	CSV:4	chick syncytial virus:4:0.0918	0.0918	4
CSWD	CSWD:9	corticosteroid withdrawal:9:0.6794	0.6794	9
CSWS	CSWS:17	cerebral salt wasting syndrome:17:0.8270	0.8270	17
CSWs	CSWs:107	commercial sex workers:107:0.9555	0.9555	107
CSWS	CSWS:10	continuous spikes and waves during slow sleep:10:0.6794	0.6794	10
CSW	CSW:56	commercial sex workers:39:0.9256|commercial sex worker:17:0.8270	0.9256	56
CSW	CSW:3|csw:2|Csw:2	tyrosine phosphatase corkscrew:7:0.3945	0.3945	7
CS	CS:14	2-chlorobenzylidene malonitrile:14:0.6173	0.6173	14
CS	CS:10	2-chlorobenzylidene malononitrile:10:0.0807	0.0807	10
CS	CS:97	Caesarean Section:88:0.2643|caesarean sections:9:0.1809	0.2643	97
CS	CS:47	calf serum:47:0.5532	0.5532	47
CS	CS:29	calsequestrin:29:0.0037	0.0037	29
CS	CS:8	campaniform sensilla:8:0.5006	0.5006	8
CS	CS:10	carcinosarcoma:10:0.0012	0.0012	10
CS	CS:11	cardiac surgery:11:0.0704	0.0704	11
CS	CS:54	cardiogenic shock:54:0.8862	0.8862	54
CS	CS:6	carotid stenting:6:0.0611	0.0611	6
CS	CS:5|Cs:4	casein:9:0.0011	0.0011	9
CS	CS:8|Cs:2	castanospermine:10:0.0012	0.0012	10
CS	CS:52	cavernous sinus:52:0.0904	0.0904	52
CS	CS:11	celiac sprue:11:0.7357	0.7357	11
CS	CS:9	cell saver:9:0.6794	0.6794	9
CS	CS:15	central sulcus:15:0.4951	0.4951	15
CS	CS:12	cervical spondylosis:12:0.7571	0.7571	12
CS	CS:10	cervical stimulation:10:0.0829	0.0829	10
CS	CS:185|cs:1	cesarean section:175:0.5838|cesarean sections:11:0.2764	0.5838	186
Cs	Cs:20	Cesium:20:0.0025	0.0025	20
CS	CS:6	charge separation:6:0.1838	0.1838	6
CS	CS:19	chemical shift:19:0.7044	0.7044	19
CS	CS:20	Chinese Spring:20:0.3492	0.3492	20
CS	CS:48	chitosan:48:0.0062	0.0062	48
CS	CS:34	cholesterol sulfate:34:0.0531	0.0531	34
CS	CS:361	chondroitin sulfate:343:0.7888|chondroitin sulfates:18:0.8365	0.8365	361
CS	CS:85	chondroitin sulphate:85:0.8186	0.8186	85
CS	CS:13	chondrosarcoma:13:0.0016	0.0016	13
CS	CS:9	chorionic somatomammotropin:9:0.5470	0.5470	9
CS	CS:7	chromogenic substrate:7:0.3524	0.3524	7
CS	CS:23	chronic sinusitis:23:0.8715	0.8715	23
CS	CS:42|Cs:10	ciclosporin:52:0.0067	0.0067	52
CS	CS:95	cigarette smoke:95:0.9500	0.9500	95
CS	CS:13	cigarette smoking:13:0.4849	0.4849	13
CS	CS:32|cs:1	circumsporozoite protein:33:0.8196	0.8196	33
CS	CS:334	citrate synthase:334:0.8914	0.8914	334
CS	CS:11	citrate synthetase:11:0.4728	0.4728	11
CS	CS:9	clinical score:9:0.0550	0.0550	9
CS	CS:74|Cs:1|cS:1	clinical stage:57:0.7174|clinical stages:19:0.6106	0.7174	76
CS	CS:9	clinical supervision:9:0.6794	0.6794	9
cs	cs:22|CS:5|Cs:3	Cold-sensitive:30:0.0038	0.0038	30
CS	CS:31	cold storage:31:0.8519	0.8519	31
CS	CS:14	cold stress:14:0.3383	0.3383	14
CS	CS:7	completed stroke:7:0.1470	0.1470	7
CS	CS:28	complex spike:28:0.8941	0.8941	28
CS	CS:16	compressive strength:16:0.5171	0.5171	16
CS	CS:13	conditioned:13:0.0016	0.0016	13
CS	CS:64|Cs:1	conditioned stimuli:65:0.7585	0.7585	65
CS	CS:701|cs:1	conditioned stimulus:702:0.8141	0.8141	702
CS	CS:10	conditioning stimulation:10:0.0829	0.0829	10
CS	CS:10	conduction system:10:0.0929	0.0929	10
CS	CS:22	Congenital syphilis:22:0.8657	0.8657	22
CS	CS:14	conscious sedation:14:0.7909	0.7909	14
CS	CS:28	conservative surgery:28:0.3215	0.3215	28
CS	CS:133	contact sensitivity:133:0.4264	0.4264	133
CS	CS:126	contrast sensitivity:126:0.4007	0.4007	126
CS	CS:7|Cs:3	controls:10:0.0012	0.0012	10
CS	CS:48|Cs:3|C-S:1	control subjects:52:0.8572	0.8572	52
CS	CS:12	conventional smear:7:0.2113|conventional smears:5:0.0517	0.2113	12
CS	CS:25|Cs:5	Cordyceps sinensis:30:0.7315	0.7315	30
CS	CS:8	corn silage:8:0.4102	0.4102	8
CS	CS:10|C-S:2	corn-soybean meal:12:0.4557	0.4557	12
CS	CS:5	corn-soybean meal diet:5:0.4422	0.4422	5
CS	CS:5	corn starch:5:0.1132	0.1132	5
CS	CS:7	coronal scaling:7:0.3524	0.3524	7
CS	CS:333|cs:7	coronary sinus:340:0.7768	0.7768	340
CS	CS:11	coronary stenosis:11:0.2422	0.2422	11
CS	CS:7	coronary stenting:7:0.1025	0.1025	7
CS	CS:42	corpus striatum:42:0.7523	0.7523	42
CS	CS:34	corpuscles of Stannius:34:0.8644	0.8644	34
CS	CS:30	corticospinal:30:0.0038	0.0038	30
CS	CS:163|Cs:7|-CS:1	corticosteroids:109:0.0143|corticosteroid:62:0.0081	0.0143	171
CS	CS:10	corticosteroid-sensitive:10:0.0012	0.0012	10
CS	CS:20|Cs:2	cortisol:22:0.0028	0.0028	22
CS	CS:15	cromolyn sodium:15:0.4312	0.4312	15
CS	CS:20|cs:1	culture supernatant:12:0.3524|culture supernatants:9:0.4587	0.4587	21
CS	CS:11|cs:1	current smokers:12:0.4557	0.4557	12
CS	CS:22|Cs:18	cyclosporin:40:0.0052	0.0052	40
CS	CS:32|Cs:23	cyclosporine:55:0.0071	0.0071	55
CS	CS:10	group:10:0.0012	0.0012	10
CS	CS:11	Hb Constant Spring:11:0.4557	0.4557	11
CS	CS:12	light:12:0.0015	0.0015	12
CS	CS:27	O-chlorobenzylidene malononitrile:27:0.4305	0.4305	27
CS	CS:4	patients with cerebral stroke:4:0.0918	0.0918	4
CS	CS:24	Patients with Cushing's syndrome:24:0.1342	0.1342	24
CS	CS:57	plasma corticosterone:57:0.1631	0.1631	57
CS	CS:26	Plasmodium falciparum circumsporozoite:26:0.6973	0.6973	26
CS	CS:10	saccharin:10:0.0012	0.0012	10
CS	CS:13	scale:13:0.0016	0.0016	13
CS	CS:7|cs:4	sensitive:11:0.0013	0.0013	11
CS	CS:9	sequence:9:0.0011	0.0011	9
CS	CS:9	sites:9:0.0011	0.0011	9
CS	CS:26|Cs:1	solution:27:0.0034	0.0034	27
CS	CS:10	steroids:10:0.0012	0.0012	10
CS	CS:16|cs:1	strain:17:0.0021	0.0021	17
CS	CS:17	superior colliculus:17:0.8270	0.8270	17
CS	CS:11	surface:11:0.0013	0.0013	11
CS	CS:9	Survival:9:0.0011	0.0011	9
CS	CS:11	total cholesterol:11:0.1285	0.1285	11
CT/MRI	CT/MRI:12	resonance imaging:12:0.4557	0.4557	12
CTA2	CTA2:15|cTA2:1	Carbocyclic thromboxane A2:16:0.8165	0.8165	16
CTAB	CTAB:221	cetyltrimethylammonium bromide:221:0.6044	0.6044	221
CTAC	CTAC:32	cetyltrimethylammonium chloride:32:0.6024	0.6024	32
CTAL	CTAL:37|cTAL:13	cortical thick ascending limb:40:0.7907|cortical thick ascending limbs:10:0.7103	0.7907	50
cTAL	cTAL:6|CTAL:3	cortical thick ascending limb of Henle's loop:9:0.7103	0.7103	9
CTAP	CTAP:32|CT-AP:4	computed tomography during arterial portography:36:0.8893	0.8893	36
CTAP	CTAP:69|CT-AP:1	CT during arterial portography:70:0.6280	0.6280	70
CTAP	CTAP:16	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2:16:0.0627	0.0627	16
CTAs	CTAs:6	Cancer-testis antigens:6:0.1320	0.1320	6
CTAs	CTAs:15	Conditioned taste aversions:15:0.8045	0.8045	15
CTA	CTA:11	antigens:11:0.0088	0.0088	11
CTA	CTA:10	Cell Transit Analyzer:10:0.7103	0.7103	10
CTA	CTA:27	cellulose triacetate:27:0.8903	0.8903	27
CTA	CTA:9	composite tissue allograft:9:0.6794	0.6794	9
CTA	CTA:6	computed tomographic angiographic:6:0.5290	0.5290	6
CTA	CTA:112	computed tomographic angiography:112:0.8769	0.8769	112
CTA	CTA:12|CT-A:1	Computed tomographic arteriography:13:0.7753	0.7753	13
CTA	CTA:5	Computed tomographic arthrography:5:0.4422	0.4422	5
CTA	CTA:60	computed tomography angiography:60:0.8751	0.8751	60
CTA	CTA:381	conditioned taste aversion:372:0.9676|conditioned taste aversions:9:0.6794	0.9676	381
CTA	CTA:8	conditioned taste avoidance:8:0.5006	0.5006	8
CTA	CTA:11	cortical taste area:11:0.7357	0.7357	11
CTA	CTA:177|CT-A:2	CT angiography:168:0.4261|CT-angiography:11:0.0088	0.4261	179
CTA	CTA:1	CT during arteriography:1:0.2219	0.2219	1
CTA	CTA:6	CT hepatic arteriography:6:0.4438	0.4438	6
CTA	CTA:8	cytotoxic activity:8:0.4102	0.4102	8
CTA	CTA:5	task analysis:5:0.0902	0.0902	5
CTB-HRP	CTB-HRP:7|CTb-HRP:1	conjugated to horseradish peroxidase:8:0.6794	0.6794	8
CtBP	CtBP:27	C-terminal binding protein:27:0.5729	0.5729	27
CTB	CTB:36|CT-B:5|CTb:1	B subunit of cholera toxin:42:0.7595	0.7595	42
CTB	CTB:24|CTb:6|CT-B:3	cholera toxin B:33:0.9100	0.9100	33
CTB	CTB:157|CTb:42|CT-B:12|CT-b:2|Ctb:1|CtB:1	Cholera toxin B subunit:191:0.9590|cholera toxin B-subunit:24:0.8768	0.9590	215
CTb	CTb:33|CTB:27|CT-B:3|CtB:2	cholera toxin subunit B:65:0.9286	0.9286	65
CTB	CTB:10	cytotrophoblast:10:0.0153	0.0153	10
CTB	CTB:14	cytotrophoblastic cells:14:0.6911	0.6911	14
CTCL	CTCL:547	cutaneous T-cell lymphoma:378:0.9645|cutaneous T cell lymphoma:88:0.9660|cutaneous T-cell lymphomas:65:0.9047|Cutaneous T cell lymphomas:16:0.8165	0.9660	547
CTCb	CTCb:1	thiotepa 500 mg/m2 and carboplatin 800 mg/m2:1:0.7357	0.7357	1
CTCs	CTCs:14	circulating tumor cells:14:0.6911	0.6911	14
CTC	CTC:23	5-cyano-2,3-ditolyl tetrazolium chloride:23:0.4486	0.4486	23
CTC	CTC:43	chlorotetracycline:43:0.0670	0.0670	43
CTC	CTC:188|cTc:4	chlortetracycline:192:0.3046	0.3046	192
CTC	CTC:9	circulating tumor cells:9:0.5470	0.5470	9
CTC	CTC:46	Common toxicity criteria:46:0.9006	0.9006	46
CTC	CTC:14	Computed tomographic colonography:14:0.6911	0.6911	14
CTC	CTC:9	Computed tomography colonography:9:0.6794	0.6794	9
CTC	CTC:11	CT cisternography:11:0.3213	0.3213	11
CTC	CTC:17	CT colonography:17:0.2396	0.2396	17
CTC	CTC:17	cultured T cells:17:0.5760	0.5760	17
CTDI	CTDI:25	Computed Tomography Dose Index:25:0.7679	0.7679	25
CTDs	CTDs:29	connective tissue diseases:29:0.8978	0.8978	29
CTDs	CTDs:26	cumulative trauma disorders:26:0.8861	0.8861	26
CTD	CTD:203|C-td:2	C-terminal domain:205:0.4026	0.4026	205
CTD	CTD:165	connective tissue disease:85:0.9648|connective tissue diseases:80:0.9408	0.9648	165
CTD	CTD:8	connective tissue disorders:8:0.5006	0.5006	8
CTD	CTD:24	cumulative trauma disorder:13:0.7753|cumulative trauma disorders:11:0.7357	0.7753	24
CTEPH	CTEPH:60|CTE-PH:3	Chronic thromboembolic pulmonary hypertension:63:0.8612	0.8612	63
CTEP	CTEP:8	Cancer Therapy Evaluation Program:8:0.6794	0.6794	8
CTEV	CTEV:12|ctev:1	congenital talipes equinovarus:13:0.7753	0.7753	13
CTE	CTE:11	C-terminal extension:11:0.4728	0.4728	11
CTE	CTE:14	chronic toxic encephalopathy:14:0.7909	0.7909	14
CTE	CTE:8	coefficient of thermal expansion:8:0.6411	0.6411	8
CTE	CTE:51	constitutive transport element:51:0.9082	0.9082	51
CTFC	CTFC:15|cTFC:7|cTfc:1	corrected TIMI frame count:23:0.5719	0.5719	23
CTFE	CTFE:21	chlorotrifluoroethylene:21:0.9091	0.9091	21
CTF	CTF:17|Ctf:1	C-terminal fragment:18:0.4033	0.4033	18
CTF	CTF:9	central tegmental field:9:0.6794	0.6794	9
CTF	CTF:17	Colorado tick fever:17:0.8270	0.8270	17
CTF	CTF:8	Computed tomography fluoroscopy:8:0.6411	0.6411	8
CTF	CTF:7	contrast transfer function:7:0.3524	0.3524	7
CTF	CTF:7	CT fluoroscopy:7:0.1591	0.1591	7
CTF	CTF:9	transcription factor:9:0.1945	0.1945	9
CTGA	CTGA:15|C-TGA:8|cTGA:4|c-TGA:2	corrected transposition of the great arteries:29:0.7581	0.7581	29
CTGF	CTGF:372|Ctgf:1	connective tissue growth factor:373:0.9920	0.9920	373
CTG	CTG:28	cardiotocogram:28:0.0877	0.0877	28
CTG	CTG:22	cardiotocograph:22:0.0682	0.0682	22
CTG	CTG:17	cardiotocographic:17:0.0519	0.0519	17
CTG	CTG:69	cardiotocography:69:0.2208	0.2208	69
CTG	CTG:10	connective tissue graft:10:0.7103	0.7103	10
CTG	CTG:16	cytosine-thymine-guanine:16:0.0487	0.0487	16
CT-HRP	CT-HRP:7|CTHRP:1	cholera toxin conjugated to horseradish peroxidase:8:0.6794	0.6794	8
CTH	CTH:16|CTh:1	ceramide trihexoside:17:0.8270	0.8270	17
CTH	CTH:6	chronic tension headache:6:0.5290	0.5290	6
CTH	CTH:10	chronic tension-type headache:10:0.7103	0.7103	10
CTI	CTI:9|CTi:1	cardiothoracic index:10:0.1596	0.1596	10
CTI	CTI:24	cavotricuspid isthmus:24:0.8115	0.8115	24
CTI	CTI:10	trypsin inhibitor:10:0.5856	0.5856	10
CTLA-4	CTLA-4:98|CTLA4:39	cytotoxic T lymphocyte antigen-4:48:0.9027|cytotoxic T lymphocyte antigen 4:37:0.8749|Cytotoxic T-lymphocyte antigen 4:27:0.8903|cytotoxic T-lymphocyte antigen-4:25:0.8186	0.9027	137
CTLA-4	CTLA-4:43|CTLA4:5	cytotoxic T lymphocyte-associated antigen 4:48:0.7507	0.7507	48
CTLA-4	CTLA-4:7	cytotoxic T lymphocyte-associated molecule-4:7:0.5926	0.5926	7
CTLD	CTLD:8	C-type lectin-like domain:8:0.6411	0.6411	8
CTLDs	CTLDs:9	C-type lectin-like domains:9:0.6794	0.6794	9
CTLL	CTLL:6|CTL-L:1	cytotoxic T cell line:7:0.4438	0.4438	7
CTLN2	CTLN2:16	Adult-onset type II citrullinemia:16:0.6577	0.6577	16
CTLp	CTLp:24|CTL-P:1|CTLP:1	CTL precursor:26:0.1978	0.1978	26
CTLp	CTLp:78|CTL-p:16|CTL-P:16|CTLP:1	cytotoxic T lymphocyte precursors:67:0.7285|Cytotoxic T lymphocyte precursor:27:0.7425|cytotoxic T-lymphocyte precursor:17:0.8270	0.8270	111
CTL-P	CTL-P:8|CTLp:5|CTLP:2|CTL-p:1	precursor cells:16:0.5564	0.5564	16
CTL-P	CTL-P:7|CTL-p:1|CTLp:1|CTLP:1	T lymphocytes:10:0.5000	0.5000	10
CTLpf	CTLpf:13|CTLp-f:1|CTLPf:1|CTLpF:1	precursor frequencies:8:0.4102|precursor frequency:8:0.4102	0.4102	16
CTLs	CTLs:103	cytotoxic T cells:96:0.8696|cytotoxic T-cells:7:0.3524	0.8696	103
CTLs	CTLs:1031|CTLS:2|CTL-s:1	cytotoxic T lymphocytes:952:0.9127|cytotoxic T-lymphocytes:82:0.8914	0.9127	1034
CTL	CTL:6	comet tail length:6:0.5290	0.5290	6
CTL	CTL:26|Ctl:7	controls:33:0.0051	0.0051	33
CTL	CTL:14	control subjects:14:0.6911	0.6911	14
CTL	CTL:13	cytolytic T-cell:13:0.0511	0.0511	13
CTL	CTL:290	cytolytic T lymphocytes:290:0.1056	0.1056	290
CTL	CTL:11	cytotoxic:11:0.0016	0.0016	11
CTL	CTL:529	cytotoxic T cells:243:0.8067|cytotoxic T cell:173:0.8014|cytotoxic T-cell:91:0.7704|cytotoxic T-cells:22:0.7400	0.8067	529
CTL	CTL:4622	cytotoxic T lymphocytes:2114:0.8536|cytotoxic T lymphocyte:1682:0.8773|cytotoxic T-lymphocyte:637:0.9028|cytotoxic T-lymphocytes:157:0.8690|cytotoxic-T-lymphocyte:32:0.0049	0.9028	4622
CTL	CTL:10	cytotoxicity:10:0.0014	0.0014	10
CTL	CTL:12	response:12:0.0017	0.0017	12
CTMCs	CTMCs:16	connective tissue mast cells:16:0.8165	0.8165	16
CTMM	CTMM:9	Computed tomographic metrizamide myelography:9:0.6794	0.6794	9
CTMC	CTMC:37	connective tissue mast cells:37:0.9197	0.9197	37
CTM	CTM:185	cefotiam:185:0.5576	0.5576	185
CTM	CTM:14	computed tomographic myelography:14:0.5589	0.5589	14
CTM	CTM:11|CT-M:2	CT myelography:13:0.1762	0.1762	13
CTM	CTM:10	trunci muscle:10:0.2643	0.2643	10
CTNNB1	CTNNB1:30|Ctnnb1:4	beta-catenin gene:34:0.8681	0.8681	34
cTn	cTn:13	cardiac troponin:13:0.7753	0.7753	13
CTN	CTN:7|CTn:2	chorda tympani nerve:9:0.6794	0.6794	9
CTN	CTN:12	creatinine:12:0.0973	0.0973	12
CTO	CTO:21	chronic total occlusion:15:0.7096|chronic total occlusions:6:0.3728	0.7096	21
CTOP	CTOP:5	antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2:5:0.1367	0.1367	5
CTOs	CTOs:10	chronic total occlusions:10:0.5856	0.5856	10
CTPA	CTPA:9|CT-PA:2	computed tomographic pulmonary angiography:11:0.7357	0.7357	11
CTPA	CTPA:14|CT-PA:1	CT pulmonary angiography:15:0.3429	0.3429	15
CTPV	CTPV:8	cavernous transformation of the portal vein:8:0.6794	0.6794	8
CTPV	CTPV:7	coal tar pitch volatiles:7:0.5926	0.5926	7
CTP	CTP:24	Child-Turcotte-Pugh:24:0.0730	0.0730	24
CTP	CTP:8	citrate transport protein:8:0.6794	0.6794	8
CTP	CTP:8	CT perfusion:8:0.5006	0.5006	8
CTP	CTP:34	cytidine 5'-triphosphate:34:0.8245	0.8245	34
CTP	CTP:38	cytidine triphosphate:38:0.7810	0.7810	38
CTQ	CTQ:22	Childhood Trauma Questionnaire:22:0.8657	0.8657	22
CTRL	CTRL:7|Ctrl:4|ctrl:1	control group:12:0.7571	0.7571	12
CTRT	CTRT:6|CT-RT:5	chemoradiotherapy:11:0.3846	0.3846	11
CTRs	CTRs:7	calcitonin receptors:7:0.3524	0.3524	7
CTRS	CTRS:15	Rating Scale:15:0.8045	0.8045	15
CTR	CTR:76|CT-R:1	calcitonin receptor:68:0.6042|calcitonin receptors:9:0.5470	0.6042	77
CTR	CTR:20	capsular tension ring:20:0.7173	0.7173	20
CTR	CTR:58	cardiothoracic ratio:58:0.5849	0.5849	58
CTR	CTR:13	carpal tunnel release:13:0.7753	0.7753	13
CTR	CTR:20	Connecticut Tumor Registry:20:0.6680	0.6680	20
CTR	CTR:23|Ctr:1|ctr:1	controls:25:0.0521	0.0521	25
CTR	CTR:11	cricotracheal resection:11:0.5355	0.5355	11
CTR	CTR:16|CT-R:1	CT receptor:17:0.1434	0.1434	17
CTSB	CTSB:10|ctsb:2|Ctsb:1	cathepsin B:13:0.6701	0.6701	13
CTSC	CTSC:9	cathepsin C gene:9:0.6794	0.6794	9
CTSD	CTSD:11|ctsd:2|CtsD:2	Cathepsin D:15:0.8045	0.8045	15
CTSE	CTSE:11|Ctse:1	cathepsin E:12:0.7571	0.7571	12
CTSIB	CTSIB:1	Clinical Test of Sensory Interaction on Balance:1:0.6411	0.6411	1
CTSM	CTSM:10	canine tracheal smooth muscle:10:0.7103	0.7103	10
CTTH	CTTH:25	chronic tension-type headache:25:0.8816	0.8816	25
CTT	CTT:48	Cefotetan:48:0.2035	0.2035	48
CTT	CTT:30	colonic transit time:30:0.6037	0.6037	30
CTT	CTT:12	Computerized transaxial tomography:12:0.6460	0.6460	12
CTT	CTT:8	computerized transmission tomography:8:0.5006	0.5006	8
CTVS	CTVS:16	canine transmissible venereal sarcoma:16:0.8165	0.8165	16
CTVs	CTVs:8	clinical target volumes:8:0.5006	0.5006	8
CTVT	CTVT:8|cTVT:1	canine transmissible venereal tumor:9:0.6794	0.6794	9
CTX-II	CTX-II:5	C-terminal crosslinking telopeptide of type II collagen:5:0.4422	0.4422	5
CTX-I	CTX-I:6|CTx-I:1	telopeptide of type I collagen:7:0.4438	0.4438	7
cTxA2	cTxA2:6|c-TXA2:1|CTXA2:1|cTXA2:1|CTxA2:1	carbocyclic thromboxane A2:10:0.7103	0.7103	10
CTXs	CTXs:10	Cardiotoxins:10:0.5000	0.5000	10
CTX	CTX:21|CTx:8|Ctx:1	C-telopeptide:20:0.0128|C-telopeptides:10:0.0061	0.0128	30
CTX	CTX:10	canthaxanthin:10:0.0061	0.0061	10
CTX	CTX:20	cardiotoxin:20:0.0128	0.0128	20
CTX	CTX:224|Ctx:6|ctx:1	Cefotaxime:231:0.1560	0.1560	231
CTX	CTX:12	ceftriaxone:12:0.0074	0.0074	12
CTX	CTX:19|Ctx:1	cerebral cortex:20:0.2547	0.2547	20
CTX	CTX:160	cerebrotendinous xanthomatosis:160:0.9596	0.9596	160
CTX	CTX:104|CTx:2	Charybdotoxin:106:0.0709	0.0709	106
CTX	CTX:17|CTx:1	chemotaxis:18:0.0115	0.0115	18
CTX	CTX:19|CTx:11|ctx:1|Ctx:1	chemotherapy:32:0.0209	0.0209	32
CTX	CTX:142|CTx:17|Ctx:14|ctx:10	cholera toxin:183:0.9652	0.9652	183
ctx	ctx:9	cholera toxin gene:9:0.6794	0.6794	9
CTX	CTX:24	ciguatoxin:24:0.0155	0.0155	24
CTX	CTX:7|CTx:1|Ctx:1	cortical:9:0.0054	0.0054	9
CTx	CTx:6|CTX:3	Crosslaps:9:0.0054	0.0054	9
CTX	CTX:260|Ctx:3|CTx:1	cyclophosphamide:264:0.1776	0.1776	264
CTX	CTX:13	cytotoxicity:13:0.0081	0.0081	13
CTX	CTX:12	omega-conotoxin:12:0.0074	0.0074	12
CTX	CTX:10	omega-conotoxin GVIA:10:0.5856	0.5856	10
CTX	CTX:23|CTx:21	type I collagen:44:0.8941	0.8941	44
CTZ	CTZ:11	Ceftazidime:11:0.0917	0.0917	11
CTZ	CTZ:15	chemoreceptor trigger zone:15:0.7096	0.7096	15
CTZ	CTZ:16	chlorothiazide:16:0.1376	0.1376	16
CTZ	CTZ:13	clotrimazole:13:0.1101	0.1101	13
CTZ	CTZ:30	cyclothiazide:30:0.2661	0.2661	30
cTnC	cTnC:13|CTnC:2	cardiac TnC:15:0.6386	0.6386	15
cTnC	cTnC:58|CTnC:3|cTNC:1|C-TnC:1	cardiac troponin C:63:0.6156	0.6156	63
CTRX	CTRX:64	ceftriaxone:64:0.9265	0.9265	64
CT-scan	CT-scan:12|CT-Scan:1	Computed tomography:13:0.2959	0.2959	13
CT-scan	CT-scan:6|CT-Scan:2	Computerized tomography:8:0.1061	0.1061	8
CTS	CTS:723|CTs:1|cts:1	carpal tunnel syndrome:725:0.9890	0.9890	725
CTS	CTS:12	cataract Shionogi:12:0.7571	0.7571	12
CTS	CTS:9	central termination sequence:9:0.6794	0.6794	9
CTs	CTs:10	Chromosome territories:10:0.7103	0.7103	10
CTS	CTS:12	circadian timing system:12:0.5664	0.5664	12
CTs	CTs:9	complementary therapies:9:0.6794	0.6794	9
CTS	CTS:11	Conflict Tactics Scale:11:0.6182	0.6182	11
CTS	CTS:12	Congenital tracheal stenosis:12:0.5664	0.5664	12
CTs	CTs:10	cytotrophoblasts:10:0.0077	0.0077	10
CT	CT:7|Ct:2	alone:9:0.0002	0.0002	9
CT	CT:15	alpha-chymotrypsin:15:0.0004	0.0004	15
CT	CT:10|Ct:1	C-terminal:11:0.0003	0.0003	11
CT	CT:42|ct:6	calf thymus:48:0.9379	0.9379	48
CT	CT:74|C-T:2	cancer/testis:38:0.0011|cancer-testis:30:0.0010|cancer testis:8:0.5006	0.5006	76
CT	CT:47	carbon tetrachloride:47:0.9006	0.9006	47
CT	CT:17|Ct:1|C-t:1|ct:1	carboxyl-terminal:14:0.0004|carboxyl terminal:6:0.1543	0.1543	20
CT	CT:7	carboxyl terminus:7:0.1329	0.1329	7
CT	CT:11	cardiac tamponade:11:0.7357	0.7357	11
CT	CT:10	Cardiac transplantation:10:0.4363	0.4363	10
CT	CT:6|Ct:4	Catalase:10:0.0003	0.0003	10
CT	CT:7	celiac trunk:7:0.1850	0.1850	7
CT	CT:9	cellulose triacetate:9:0.6794	0.6794	9
CT	CT:5	central tendon:5:0.1132	0.1132	5
CT	CT:9	Cerebral toxoplasmosis:9:0.2285	0.2285	9
CT	CT:118|C-T:2	charge-transfer:68:0.0021|charge transfer:52:0.8572	0.8572	120
CT	CT:7	charge transport:7:0.3524	0.3524	7
CT	CT:7	chest tube:7:0.2452	0.2452	7
CT	CT:9	chlamydia:9:0.0002	0.0002	9
CT	CT:159|Ct:37	Chlamydia trachomatis:196:0.9271	0.9271	196
CT	CT:31	chloramine-T:19:0.0006|chloramine T:12:0.6460	0.6460	31
CT	CT:36	Cholera enterotoxin:36:0.7183	0.7183	36
CT	CT:954	cholera toxin:954:0.9655	0.9655	954
CT	CT:97	chorda tympani:97:0.9692	0.9692	97
CT	CT:25	chorda tympani nerve:25:0.8816	0.8816	25
CT	CT:12	chronic tonsillitis:12:0.7571	0.7571	12
CT	CT:15	chymotrypsin:15:0.0005	0.0005	15
CT	CT:101|ct:1	circadian time:89:0.2928|circadian times:13:0.2211	0.2928	102
CT	CT:10	clinical trial:10:0.3867	0.3867	10
CT	CT:27	closure time:27:0.0657	0.0657	27
CT	CT:75	cognitive therapy:75:0.4908	0.4908	75
CT	CT:14	collecting tubule:14:0.6911	0.6911	14
CT	CT:14|Ct:7	compliance:21:0.0006	0.0006	21
CT	CT:98	computed tomogram:55:0.6163|Computed tomograms:43:0.5939	0.6163	98
CT	CT:21	computed tomograph:21:0.4733	0.4733	21
CT	CT:3898	computed tomographic:3887:0.8816|computed-tomographic:11:0.0003	0.8816	3898
CT	CT:26	Computed tomographic scan:21:0.6040|computed tomographic scans:5:0.1973	0.6040	26
CT	CT:10	Computed tomographic scanning:10:0.3867	0.3867	10
CT	CT:17791|ct:2	computed tomography:17766:0.8269|computed tomographies:15:0.5818|Computed-tomography:12:0.0003	0.8269	17793
CT	CT:28	computed tomography scan:17:0.4742|computed tomography scans:11:0.4232	0.4742	28
CT	CT:7	computed tomography scanning:7:0.2902	0.2902	7
CT	CT:9	computed tomograpy:9:0.6794	0.6794	9
CT	CT:11	Computer-Tomography:11:0.0003	0.0003	11
CT	CT:25	computerized tomogram:14:0.0859|computerized tomograms:11:0.0718	0.0859	25
CT	CT:8	computerized tomograph:8:0.0756	0.0756	8
CT	CT:354	computerized tomographic:354:0.0729	0.0729	354
CT	CT:2576|C-t:1	computerized tomography:2577:0.1162	0.1162	2577
CT	CT:9	computertomography:9:0.0002	0.0002	9
Ct	Ct:12|CT:5	concentration:17:0.0005	0.0005	17
CT	CT:20	condensed tannins:20:0.8525	0.8525	20
C-T	C-T:14|CT:1	conditioning-test:15:0.0004	0.0004	15
CT	CT:29	conduction time:29:0.0724	0.0724	29
CT	CT:8	congenital Toxoplasmosis:8:0.1730	0.1730	8
CT	CT:11	Connecticut:11:0.0003	0.0003	11
CT	CT:35|ct:1	connective tissue:36:0.6175	0.6175	36
CT	CT:16	conservative treatment:16:0.2709	0.2709	16
CT	CT:26|Ct:1	control:27:0.0008	0.0008	27
Ct	Ct:10	control diet:10:0.3470	0.3470	10
CT	CT:5	control group:5:0.1132	0.1132	5
CT	CT:9	conventional treatment:9:0.0898	0.0898	9
CT	CT:12|cT:2	core temperature:14:0.3383	0.3383	14
CT	CT:19	corneal thickness:19:0.4618	0.4618	19
CT	CT:7	cortical thickness:7:0.0592	0.0592	7
CT	CT:15	corticosterone:15:0.0004	0.0004	15
CT	CT:17	corticothalamic:17:0.0005	0.0005	17
CT	CT:10	counseling and testing:10:0.3867	0.3867	10
CT	CT:15	countertransport:15:0.0004	0.0004	15
CT	CT:56	cricothyroid:56:0.0017	0.0017	56
CT	CT:13	cricothyroid muscle:13:0.6701	0.6701	13
CT	CT:39	crista terminalis:39:0.8811	0.8811	39
CT	CT:10	critical thinking:10:0.5000	0.5000	10
CT	CT:64	CTP:phosphocholine cytidylyltransferase:64:0.6371	0.6371	64
ct	ct:17|CT:2	curly tail:19:0.1719	0.1719	19
Ct	Ct:9|CT:4	cycle threshold:13:0.3554	0.3554	13
CT	CT:7	cytoplasmic domain:7:0.2452	0.2452	7
CT	CT:39	cytoplasmic tail:39:0.4799	0.4799	39
CT	CT:19	cytotrophoblast:19:0.0006	0.0006	19
Ct	Ct:14|CT:3	threshold cycle:17:0.7407	0.7407	17
CT	CT:22	training:22:0.0006	0.0006	22
CT	CT:7|ct:2|Ct:1	twitch contraction time:10:0.1022	0.1022	10
CUAVD	CUAVD:7	congenital unilateral absence of the vas deferens:7:0.4438	0.4438	7
CUC	CUC:42	chronic ulcerative colitis:42:0.8893	0.8893	42
CUD	CUD:12	crossed-uncrossed difference:12:0.5050	0.5050	12
CUE	CUE:9	confidential unit exclusion:9:0.6794	0.6794	9
cue	cue:6	discriminative stimulus:6:0.1838	0.1838	6
CUG-BP	CUG-BP:7|CUG-bp:1	CUG-binding protein:8:0.5006	0.5006	8
CUNS	CUNS:6	capacity of urea-N synthesis:6:0.5290	0.5290	6
CUNS	CUNS:5	capacity of urea nitrogen synthesis:5:0.5290	0.5290	5
CUPS	CUPS:10	unknown primary site:10:0.5856	0.5856	10
CUP	CUP:11|Cup:1|cup:1	cuprophane:13:0.1017	0.1017	13
CUP	CUP:25	unknown primary:25:0.8768	0.8768	25
CUP	CUP:14	unknown primary site:14:0.7909	0.7909	14
CURL	CURL:4	compartment of uncoupling of receptor and ligand:4:0.7357	0.7357	4
CURS	CURS:7	Columbia University Rating Scale:7:0.4438	0.4438	7
CUSA	CUSA:49	cavitron ultrasonic surgical aspirator:49:0.8463	0.8463	49
CUSES	CUSES:9	Condom Use Self-Efficacy Scale:9:0.7103	0.7103	9
CV-1808	CV-1808:17|CV1808:3	2-phenylaminoadenosine:20:0.5938	0.5938	20
CV-1	CV-1:9|CV1:1	African green monkey kidney cells:10:0.7103	0.7103	10
CVADs	CVADs:21	central venous access devices:21:0.6812	0.6812	21
CVAD	CVAD:8	Central venous access devices:8:0.5006	0.5006	8
CVAs	CVAs:31	cerebrovascular accidents:31:0.6572	0.6572	31
CVA	CVA:8	canonical variate analysis:8:0.6411	0.6411	8
CVA	CVA:14|cva:1	cerebral vascular accidents:15:0.8045	0.8045	15
CVA	CVA:288	cerebrovascular accident:222:0.7337|cerebrovascular accidents:66:0.7031	0.7337	288
CVA	CVA:11	cerebrovascular disease:11:0.7357	0.7357	11
CVA	CVA:13	Clavulanic acid:13:0.5335	0.5335	13
CVA	CVA:22	Cough variant asthma:22:0.8657	0.8657	22
CVB3m	CVB3m:7|CVB3-m:1	coxsackievirus B3:8:0.5006	0.5006	8
CVB3	CVB3:179|CVB-3:1|CV-B3:1	coxsackievirus B3:181:0.8473	0.8473	181
CVB3	CVB3:3	Coxsackievirus Group B type 3:3:0.6182	0.6182	3
CVB4	CVB4:27|CVB-4:1	coxsackievirus B4:28:0.7154	0.7154	28
CVB	CVB:14	coxsackievirus B:14:0.2326	0.2326	14
CVB	CVB:8	coxsackieviruses of group B:8:0.3069	0.3069	8
CVB	CVB:19	group B coxsackieviruses:19:0.8449	0.8449	19
CVCs	CVCs:163	central venous catheters:163:0.9816	0.9816	163
CVC	CVC:309|cvc:1	central venous catheter:200:0.9849|central venous catheters:110:0.9728	0.9849	310
CVC	CVC:15	central venous catheterization:15:0.8045	0.8045	15
CVC	CVC:17	citrus variegated chlorosis:17:0.8270	0.8270	17
CVC	CVC:40|c-v-c:1	consonant-vowel-consonant:41:0.0723	0.0723	41
CVC	CVC:56	Cutaneous vascular conductance:56:0.7725	0.7725	56
CVD	CVD:30	cardiovascular:30:0.0097	0.0097	30
CVD	CVD:2223|cvd:1	cardiovascular disease:2016:0.8098|cardiovascular diseases:208:0.6683	0.8098	2224
CVD	CVD:8|CvD:1	cerebrovascular dementia:9:0.3945	0.3945	9
CVD	CVD:56	cerebrovascular diseases:56:0.1452	0.1452	56
CVD	CVD:13	cerebrovascular disorders:13:0.3554	0.3554	13
CVD	CVD:42	chemical vapor deposition:34:0.8644|chemical vapour deposition:8:0.6411	0.8644	42
CVD	CVD:4	continuous ventricular drainage:4:0.1618	0.1618	4
CVEC	CVEC:8	Coronary Venular Endothelial Cells:8:0.6411	0.6411	8
CVF	CVF:249	cobra venom factor:249:0.9684	0.9684	249
CVF	CVF:17	collagen volume fraction:17:0.6211	0.6211	17
CVH	CVH:33|cvh:1	chronic viral hepatitis:34:0.9126	0.9126	34
CVH	CVH:7	common variable hypogammaglobulinaemia:7:0.5926	0.5926	7
CVH	CVH:12	common variable hypogammaglobulinemia:12:0.7753	0.7753	12
CVIBS	CVIBS:4|CV-IBS:1|cvIBS:1	Cyclic variation of integrated backscatter:6:0.5290	0.5290	6
CVIB	CVIB:7|CV-IB:3	integrated backscatter:10:0.5856	0.5856	10
CVICU	CVICU:8	Cardiovascular Intensive Care Unit:8:0.5006	0.5006	8
CVID	CVID:12	common variable immune deficiency:12:0.6460	0.6460	12
CVID	CVID:256	common variable immunodeficiency:256:0.9813	0.9813	256
CVID	CVID:9	common variable immunodeficiency syndrome:9:0.3945	0.3945	9
Cvi	Cvi:7	Cape Verde Islands:7:0.4438	0.4438	7
CVI	CVI:25	Children's Vaccine Initiative:25:0.8816	0.8816	25
CVI	CVI:263|cvi:2	Chronic Venous Insufficiency:265:0.9703	0.9703	265
CVI	CVI:125	common variable immunodeficiency:125:0.9622	0.9622	125
CVI	CVI:15	content validity index:15:0.8045	0.8045	15
CVI	CVI:6	continuous intravenous infusion:6:0.5290	0.5290	6
CVI	CVI:5	continuous venous infusion:5:0.4422	0.4422	5
CVI	CVI:10	cyclic variation index:10:0.7103	0.7103	10
CVI	CVI:22	visual impairment:22:0.7955	0.7955	22
CVJ	CVJ:13	craniovertebral junction:13:0.7753	0.7753	13
CVK	CVK:8	computerized videokeratography:8:0.3463	0.3463	8
CVLM	CVLM:105|cVLM:14	caudal ventrolateral medulla:119:0.9600	0.9600	119
CVLs	CVLs:15	central venous lines:15:0.8045	0.8045	15
CVLT	CVLT:112	California verbal learning test:112:0.9733	0.9733	112
CVLT-C	CVLT-C:13	California Verbal Learning Test-Children's Version:13:0.7753	0.7753	13
CVL	CVL:13	canine visceral leishmaniasis:13:0.6701	0.6701	13
CVL	CVL:22	caudal ventrolateral medulla:22:0.8657	0.8657	22
CVL	CVL:15	central venous line:15:0.8045	0.8045	15
CVL	CVL:33	cervicovaginal lavage:33:0.8605	0.8605	33
CVMs	CVMs:20	malformations:20:0.6786	0.6786	20
CVM	CVM:9	cardiovascular malformations:9:0.1585	0.1585	9
CVM	CVM:9	Center for Veterinary Medicine:9:0.5000	0.5000	9
CVM	CVM:10	congenital vascular malformations:10:0.5000	0.5000	10
CVM	CVM:8	contingent valuation method:8:0.6411	0.6411	8
CVM	CVM:18	malformation:18:0.1478	0.1478	18
CV-N	CV-N:38|CVN:4	Cyanovirin-N:42:0.5714	0.5714	42
CVOs	CVOs:44	circumventricular organs:44:0.9323	0.9323	44
CVO	CVO:17	circumventricular organs:17:0.8270	0.8270	17
CVPs	CVPs:8	virus particles:8:0.5006	0.5006	8
CVP	CVP:23	central venous:23:0.8715	0.8715	23
CVP	CVP:716|cvp:2	central venous pressure:718:0.9910	0.9910	718
CVP	CVP:13	chlorphenvinphos:13:0.0131	0.0131	13
CVRF	CVRF:18	cardiovascular risk factors:18:0.7539	0.7539	18
CVRI	CVRI:6	coronary vascular resistance index:6:0.5290	0.5290	6
CVR-R	CVR-R:2|CVRR:2	coefficient of variation of R-R intervals:4:0.5290	0.5290	4
CVR-R	CVR-R:1|CVRR:1	coefficient of variation of the R-R interval:2:0.6411	0.6411	2
CVRs	CVRs:9	contraceptive vaginal rings:9:0.5006	0.5006	9
CVR	CVR:25	cardiovascular reactivity:25:0.2586	0.2586	25
CVR	CVR:10	cerebral vasoreactivity:10:0.7103	0.7103	10
CVR	CVR:30	cerebrovascular reactivity:30:0.3347	0.3347	30
CVR	CVR:20	Cerebrovascular reserve:20:0.2547	0.2547	20
CVR	CVR:78	cerebrovascular resistance:78:0.2168	0.2168	78
CVR	CVR:10	chronic vascular rejection:10:0.7103	0.7103	10
CVR	CVR:16	contraceptive vaginal ring:16:0.6024	0.6024	16
CVR	CVR:7	coronary flow velocity reserve:7:0.5926	0.5926	7
CVR	CVR:120	coronary vascular resistance:120:0.5088	0.5088	120
CVR	CVR:9	coronary vasodilator reserve:9:0.6794	0.6794	9
CVSMCs	CVSMCs:13	smooth muscle cells:13:0.7753	0.7753	13
CVST	CVST:7	cerebral venous and sinus thrombosis:7:0.8525	0.8525	7
CVS	CVS:32	cardiovascular system:32:0.4827	0.4827	32
CVS	CVS:9	centrifugal visual system:9:0.6794	0.6794	9
CVS	CVS:12	cerebral vasospasm:12:0.5664	0.5664	12
CVS	CVS:12	cervicovaginal secretions:12:0.5664	0.5664	12
CVS	CVS:23	Challenge virus standard:23:0.8715	0.8715	23
CVS	CVS:53	chorionic villus samples:39:0.8811|chorionic villus sample:14:0.7909	0.8811	53
CVS	CVS:347|cvs:3	chorionic villus sampling:343:0.9085|chorionic villus samplings:7:0.4438	0.9085	350
CVS	CVS:12	chronic variable stress:12:0.6460	0.6460	12
CVs	CVs:8	clathrin-coated vesicles:8:0.0604	0.0604	8
CVs	CVs:16	Coated vesicles:16:0.2440	0.2440	16
CVs	CVs:279	coefficients of variation:245:0.9462|coefficient of variations:22:0.4668|coefficients of variations:12:0.1194	0.9462	279
CVs	CVs:27	conduction velocities:27:0.8903	0.8903	27
CVS	CVS:30	cyclic vomiting syndrome:30:0.7012	0.7012	30
CVT	CVT:94	cerebral venous thrombosis:94:0.8790	0.8790	94
Cvt	Cvt:26	cytoplasm to vacuole targeting:26:0.8251	0.8251	26
CVVH	CVVH:20	continuous veno-venous haemofiltration:20:0.8525	0.8525	20
CVVH	CVVH:53	continuous veno-venous hemofiltration:53:0.8842	0.8842	53
CVVH	CVVH:18	continuous venovenous haemofiltration:18:0.8365	0.8365	18
CVVH	CVVH:82	continuous venovenous hemofiltration:82:0.9238	0.9238	82
CVVHDF	CVVHDF:7	continuous veno-venous haemodiafiltration:7:0.5926	0.5926	7
CVVHDF	CVVHDF:12	continuous veno-venous hemodiafiltration:12:0.7571	0.7571	12
CVVHDF	CVVHDF:8	continuous venovenous haemodiafiltration:8:0.6411	0.6411	8
CVVHDF	CVVHDF:23	continuous venovenous hemodiafiltration:23:0.8715	0.8715	23
CVVHD	CVVHD:11	Continuous veno-venous hemodialysis:11:0.7357	0.7357	11
CVVHD	CVVHD:7	continuous venovenous haemodiafiltration:7:0.5926	0.5926	7
CVVHD	CVVHD:13	continuous venovenous hemodiafiltration:13:0.7753	0.7753	13
CVVHD	CVVHD:27	continuous venovenous hemodialysis:27:0.8903	0.8903	27
CVVHF	CVVHF:6	continuous venovenous hemofiltration:6:0.5290	0.5290	6
CVG	CVG:16	cochleovestibular ganglion:16:0.6024	0.6024	16
CVG	CVG:12	cutis verticis gyrata:12:0.7571	0.7571	12
CVX	CVX:9|Cvx:8	convulxin:17:0.5926	0.5926	17
CV	CV:429|C-V:3|c-v:1|cv:1	cardiovascular:434:0.0921	0.0921	434
CV	CV:18|cv:3|Cv:1	central venous:22:0.5095	0.5095	22
CV	CV:24|cv:1	chorionic villi:25:0.8816	0.8816	25
CV	CV:23	chorionic villus:23:0.8715	0.8715	23
CV	CV:9	Circularvection:9:0.0017	0.0017	9
CV	CV:71	closing volume:71:0.5228	0.5228	71
CV	CV:9	coated vesicles:9:0.3945	0.3945	9
CV	CV:11|cv:1	coefficient of variability:12:0.1227	0.1227	12
CV	CV:59	coefficient of variance:59:0.7113	0.7113	59
CV	CV:1736|cv:28|Cv:3	coefficient of variation:1329:0.7143|coefficients of variation:423:0.2127|coefficients of variations:9:0.1409|coefficient of variations:6:0.1061	0.7143	1767
CV	CV:214	conduction velocity:193:0.8861|conduction velocities:21:0.7865	0.8861	214
CV	CV:30	contingent valuation:30:0.9011	0.9011	30
CV	CV:11	contrast venography:11:0.4728	0.4728	11
CV	CV:11	contrast ventriculography:11:0.6182	0.6182	11
CV	CV:61	conventional ventilation:61:0.5459	0.5459	61
CV	CV:5	cowpox virus:5:0.0517	0.0517	5
CV	CV:13	Cross-validation:13:0.0026	0.0026	13
CV	CV:27	Crystal Violet:27:0.6192	0.6192	27
CV	CV:11	curriculum vitae:11:0.7357	0.7357	11
CV	CV:165	cyclic voltammetry:165:0.9820	0.9820	165
CV	CV:16	dichotic consonant-vowel:16:0.0683	0.0683	16
CV	CV:7	electrical cardioversion:7:0.0539	0.0539	7
CV	CV:10	vaccine:10:0.0019	0.0019	10
CV	CV:9	value:9:0.0017	0.0017	9
CV	CV:9	vasculitis:9:0.0017	0.0017	9
Cv	Cv:5	venous compliance:5:0.0736	0.0736	5
CWA	CWA:11	chemical warfare agents:11:0.7357	0.7357	11
CWA	CWA:10	correlation waveform analysis:10:0.5000	0.5000	10
CWC	CWC:10	water content:10:0.7103	0.7103	10
CWD	CWD:10	canal wall down:10:0.7103	0.7103	10
CWD	CWD:61	chronic wasting disease:61:0.9511	0.9511	61
CWD	CWD:17	continuous wave Doppler:17:0.8270	0.8270	17
CWL	CWL:10	cutaneous water loss:10:0.7103	0.7103	10
CWM	CWM:8	Cell wall material:8:0.6411	0.6411	8
CWPs	CWPs:10	cell wall proteins:10:0.3867	0.3867	10
CWP	CWP:9	chronic widespread pain:9:0.6794	0.6794	9
CWP	CWP:58	coal workers' pneumoconiosis:58:0.9486	0.9486	58
CWS	CWS:26	cell wall skeleton:15:0.4951|cell-wall skeleton:11:0.1547	0.4951	26
CWS	CWS:8	chest wall stimulation:8:0.5006	0.5006	8
CWS	CWS:14	children who stutter:14:0.7909	0.7909	14
CWS	CWS:19	cold-water swims:10:0.7103|cold water swim:9:0.6794	0.7103	19
CWs	CWs:11|CWS:2	Constructed wetlands:13:0.5934	0.5934	13
CWS	CWS:10	cotton-wool spots:5:0.0902|Cotton wool spots:5:0.4422	0.4422	10
CWT	CWT:14	circuit weight training:14:0.7909	0.7909	14
CWT	CWT:5	colour word test:5:0.1543	0.1543	5
CWT	CWT:40	continuous wavelet transform:40:0.8839	0.8839	40
CWT	CWT:6	cortical wall thickness:6:0.3728	0.3728	6
CW	CW:7|cw:1	calcofluor white:8:0.4102	0.4102	8
CW	CW:60	cell walls:30:0.9011|cell wall:30:0.3614	0.9011	60
CW	CW:23	chemical warfare:23:0.8715	0.8715	23
CW	CW:20|cw:3|Cw:1	chest wall:24:0.2628	0.2628	24
Cw	Cw:7|CW:1	Chest wall compliance:8:0.6411	0.6411	8
CW	CW:58|cw:3	clockwise:61:0.0716	0.0716	61
CW	CW:5	coconut water:5:0.0736	0.0736	5
CW	CW:18	constructed wetland:18:0.8365	0.8365	18
CW	CW:276|cw:63|C-W:2|c-w:2	continuous wave:224:0.9525|continuous-wave:119:0.1408	0.9525	343
CW	CW:9	contractional work:9:0.1492	0.1492	9
CW	CW:8	control women:8:0.5006	0.5006	8
CW	CW:13|cw:1	weight:14:0.0155	0.0155	14
CW	CW:12	width:12:0.0131	0.0131	12
CX3CR1	CX3CR1:9	fractalkine receptor:9:0.3867	0.3867	9
CXCL10	CXCL10:8	CXC chemokine ligand 10:8:0.6411	0.6411	8
CXCR	CXCR:10	CXC chemokine receptor:10:0.5856	0.5856	10
CXCR1	CXCR1:8	CXC chemokine receptor 1:8:0.6411	0.6411	8
CXCR2	CXCR2:13	CXC chemokine receptor 2:13:0.6701	0.6701	13
CXCR3	CXCR3:18	CXC chemokine receptor 3:18:0.6903	0.6903	18
CXD	CXD:28	cefroxadine:28:0.5870	0.5870	28
CXD	CXD:13	Computed X-ray densitometry:13:0.5664	0.5664	13
CXMD	CXMD:8|c-xmd:1	canine X-linked muscular dystrophy:9:0.6794	0.6794	9
CXM	CXM:29|cxm:1|Cxm:1	cefuroxime:31:0.3704	0.3704	31
CXM	CXM:42|Cxm:1	cycloheximide:43:0.5185	0.5185	43
CXRs	CXRs:27	chest radiographs:27:0.8903	0.8903	27
CXRs	CXRs:11	chest X-rays:11:0.7357	0.7357	11
CXR	CXR:82|CxR:2	chest radiograph:67:0.9074|chest radiographs:17:0.6748	0.9074	84
CXR	CXR:47	chest radiography:47:0.9006	0.9006	47
CXR	CXR:14	chest roentgenogram:14:0.7909	0.7909	14
CXR	CXR:116|cxr:1	chest X-ray:97:0.9510|chest X-rays:20:0.8525	0.9510	117
CY-BOCS	CY-BOCS:15	Children's Yale-Brown Obsessive Compulsive Scale:15:0.5348	0.5348	15
CYC1	CYC1:13|CYC-1:1	iso-1-cytochrome c:14:0.6173	0.6173	14
CYC	CYC:7|Cyc:2	cycloheximide:9:0.0316	0.0316	9
CYC	CYC:6|cyc:4	cycloidea:10:0.0356	0.0356	10
CYC	CYC:121|Cyc:9|cyc:2	cyclophosphamide:132:0.5217	0.5217	132
CYC	CYC:9|Cyc:1|cyc:1	cytochrome c:11:0.4232	0.4232	11
CYFRA	CYFRA:8	cytokeratin 19 fragment:8:0.6411	0.6411	8
CYMV	CYMV:5	clover yellow mosaic virus:5:0.1973	0.1973	5
CyMV	CyMV:6	Cymbidium mosaic virus:6:0.1148	0.1148	6
CYN	CYN:18	Cylindrospermopsin:18:0.4857	0.4857	18
CYO	CYO:15|CY-O:1	cytochrome oxidase:16:0.7261	0.7261	16
CYP101	CYP101:7	cytochrome p450(cam):7:0.3524	0.3524	7
CYP19	CYP19:10	aromatase cytochrome P450:10:0.7103	0.7103	10
CYP19	CYP19:10|Cyp19:5	aromatase gene:15:0.3110	0.3110	15
CYP19	CYP19:14|cyp19:1	aromatase P450:15:0.3614	0.3614	15
CYP1A1	CYP1A1:13	Cytochrome P-4501A1:13:0.7753	0.7753	13
CYP1A1	CYP1A1:133|Cyp1a1:4|cyp1a1:1|Cyp1A1:1	cytochrome P450 1A1:139:0.9437	0.9437	139
CYP1A1	CYP1A1:119|Cyp1a1:5	cytochrome P4501A1:124:0.8879	0.8879	124
CYP1A2	CYP1A2:59	cytochrome P450 1A2:59:0.9203	0.9203	59
CYP1A2	CYP1A2:62	cytochrome P4501A2:62:0.9241	0.9241	62
CYP1A2	CYP1A2:7	phenacetin O-deethylation:7:0.2902	0.2902	7
CYP1A	CYP1A:45	cytochrome P450 1A:45:0.9338	0.9338	45
CYP1A	CYP1A:92	cytochrome P4501A:92:0.9167	0.9167	92
CYP1B1	CYP1B1:46	cytochrome P450 1B1:46:0.8401	0.8401	46
CYP1B1	CYP1B1:28|Cyp1b1:4	Cytochrome P4501B1:32:0.7166	0.7166	32
CYP21	CYP21:29|Cyp21:1	21-hydroxylase gene:30:0.6736	0.6736	30
CYP21	CYP21:28	steroid 21-hydroxylase:28:0.3215	0.3215	28
CYP24	CYP24:24|Cyp-24:1	24-hydroxylase:25:0.3810	0.3810	25
CYP24	CYP24:4|Cyp24:2	25-hydroxyvitamin D3-24-hydroxylase:6:0.2243	0.2243	6
CYP27	CYP27:21|Cyp27:1	sterol 27-hydroxylase:22:0.6934	0.6934	22
CYP27	CYP27:12	sterol 27-hydroxylase gene:12:0.7357	0.7357	12
CYP2A6	CYP2A6:32	cytochrome P450 2A6:32:0.9072	0.9072	32
CYP2B1	CYP2B1:12	cytochrome P450 2B1:12:0.7571	0.7571	12
CYP2B6	CYP2B6:9	cytochrome P450 2B6:9:0.6794	0.6794	9
CYP2C9	CYP2C9:35	cytochrome P450 2C9:35:0.9151	0.9151	35
CYP2C9	CYP2C9:14	cytochrome P4502C9:14:0.8045	0.8045	14
CYP2D6	CYP2D6:110|Cyp2D6:1	cytochrome P450 2D6:111:0.9072	0.9072	111
CYP2D6	CYP2D6:49	cytochrome P4502D6:49:0.8433	0.8433	49
CYP2D6	CYP2D6:10	cytochrome P450IID6:10:0.5856	0.5856	10
CYP2D6	CYP2D6:22	debrisoquine 4-hydroxylase:22:0.7865	0.7865	22
CYP2D6	CYP2D6:15	debrisoquine hydroxylase:15:0.4951	0.4951	15
CYP2D6	CYP2D6:13	dextromethorphan:13:0.0304	0.0304	13
CYP2E1	CYP2E1:21	cytochrome P-4502E1:21:0.8594	0.8594	21
CYP2E1	CYP2E1:161|CYP2e1:1|Cyp2E1:1	cytochrome P450 2E1:163:0.9518	0.9518	163
CYP2E1	CYP2E1:86	cytochrome P4502E1:86:0.9449	0.9449	86
CYP2E1	CYP2E1:8	cytochrome P450IIE1:8:0.5006	0.5006	8
CYP3A4	CYP3A4:104	cytochrome P450 3A4:104:0.9259	0.9259	104
CYP3A4	CYP3A4:28	cytochrome P4503A4:28:0.8369	0.8369	28
CYP3A	CYP3A:97	cytochrome P450 3A:97:0.8936	0.8936	97
CYP3A	CYP3A:31|cyp3a:1	cytochrome P4503A:32:0.9072	0.9072	32
CyP40	CyP40:10|CyP-40:3|CYP40:1|Cyp40:1	cyclophilin 40:15:0.8045	0.8045	15
CYP4A	CYP4A:6|Cyp4a:1	cytochrome P450 4A:7:0.3524	0.3524	7
CYP51	CYP51:7|cyp51:2|cYP51:1	14 alpha-demethylase:10:0.7103	0.7103	10
CYP51	CYP51:18	lanosterol 14alpha-demethylase:18:0.2956	0.2956	18
CYP51	CYP51:13	sterol 14-demethylase P450:13:0.6701	0.6701	13
CYP51	CYP51:12	sterol 14alpha-demethylase:12:0.1470	0.1470	12
CYP7A1	CYP7A1:10|Cyp7a1:1	cholesterol 7 alpha-hydroxylase:11:0.7357	0.7357	11
CYP7A1	CYP7A1:58|Cyp7a1:6|cyp7a1:2|CYP7a1:1	cholesterol 7alpha-hydroxylase:67:0.9554	0.9554	67
CYP7A1	CYP7A1:17	cholesterol 7alpha-hydroxylase gene:17:0.8270	0.8270	17
CYP7A	CYP7A:12|cyp7a:5|CYP7a:2|Cyp7A:1|Cyp7a:1	cholesterol 7alpha-hydroxylase:21:0.8594	0.8594	21
CYP7	CYP7:9|cyp7:3	cholesterol 7 alpha-hydroxylase:12:0.6460	0.6460	12
CYP7	CYP7:9	cholesterol 7 alpha-hydroxylase gene:9:0.5470	0.5470	9
CYP8B1	CYP8B1:13|CYP8b1:2|Cyp8b1:2	Sterol 12alpha-hydroxylase:17:0.7261	0.7261	17
CYPOR	CYPOR:6	NADPH-cytochrome P450 oxidoreductase:6:0.2827	0.2827	6
CysNO	CysNO:5|CYSNO:3|Cys-NO:1|cysNO:1	S-nitroso-L-cysteine:10:0.2000	0.2000	10
CysNO	CysNO:15|cysNO:4|CySNO:3|Cys-NO:2|cys-NO:2|CYSNO:1	S-nitrosocysteine:27:0.5778	0.5778	27
CY	CY:13	calendar year:13:0.8045	0.8045	13
Cy	Cy:9|CY:7	cycloheximide:16:0.0093	0.0093	16
CY	CY:1031|Cy:346|cy:3	cyclophosphamide:1380:0.8545	0.8545	1380
Cy	Cy:21|CY:7	cyclosporine:28:0.0167	0.0167	28
Cy	Cy:7|cy:4|CY:2	cytoplasmic:13:0.0074	0.0074	13
CZE	CZE:740	capillary zone electrophoresis:740:0.9749	0.9749	740
CZE	CZE:26	capillary zone electrophoretic:26:0.8861	0.8861	26
CZOP	CZOP:60	cefozopran:60:0.9672	0.9672	60
CZP	CZP:70	clonazepam:70:0.7667	0.7667	70
CZX	CZX:89	ceftizoxime:89:0.8224	0.8224	89
CZX	CZX:16	chlorzoxazone:16:0.1402	0.1402	16
CZX-S	CZX-S:12	ceftizoxime suppository:12:0.5664	0.5664	12
CZ	CZ:12|cz:1	central zone:13:0.3134	0.3134	13
Cz	Cz:36	vertex:36:0.1691	0.1691	36
Ca(++)	Ca(++):10	calcium:10:0.9000	0.9000	10
Ca(2+)(i)	Ca(2+)(i):11|Ca(2+)(I):1	intracellular calcium:12:0.5050	0.5050	12
Ca(2+)	Ca(2+):33	calcium ion:18:0.8365|calcium ions:15:0.6386	0.8365	33
Ca(OH)2	Ca(OH)2:39	calcium hydroxide:39:0.8811	0.8811	39
Ca(i)(2+)	Ca(i)(2+):6	Intracellular calcium:6:0.2243	0.2243	6
Ca++	Ca++:147|CA++:4|ca++:1	calcium:152:0.7123	0.7123	152
Ca++	Ca++:29	calcium ion:20:0.7766|calcium ions:9:0.5470	0.7766	29
Ca/Cr	Ca/Cr:22|Ca/cr:2	calcium/creatinine:24:0.5000	0.5000	24
Ca/Cr	Ca/Cr:7	calcium/creatinine ratio:7:0.2902	0.2902	7
Ca2+e	Ca2+e:12	extracellular Ca2+:12:0.6460	0.6460	12
Ca2+i	Ca2+i:14	cytoplasmic Ca2+ concentration:14:0.2892	0.2892	14
Ca2+i	Ca2+i:7	cytoplasmic calcium concentration:7:0.1211	0.1211	7
Ca2+i	Ca2+i:13	cytosolic free calcium:13:0.3383	0.3383	13
Ca2+i	Ca2+i:49	intracellular Ca2+:49:0.4036	0.4036	49
Ca2+i	Ca2+i:36	intracellular calcium:36:0.3176	0.3176	36
Ca2+o	Ca2+o:22	extracellular Ca2+:22:0.4689	0.4689	22
Ca2+o	Ca2+o:5	extracellular Ca2+ concentration:5:0.4422	0.4422	5
Ca2+o	Ca2+o:13	extracellular calcium:13:0.5335	0.5335	13
Ca2+	Ca2+:12	calcium concentration:12:0.4557	0.4557	12
Ca2+	Ca2+:186	calcium ion:96:0.8946|calcium ions:90:0.8740	0.8946	186
Ca2+	Ca2+:11	ionized Ca:11:0.4728	0.4728	11
CaBI	CaBI:3	expressed as a calcium bone index:3:0.3524	0.3524	3
CaBP	CaBP:18	calbindin D-28K:18:0.7539	0.7539	18
CaBP	CaBP:16	Calbindin D28K:16:0.7261	0.7261	16
CaBP	CaBP:17	calcium-binding proteins:11:0.2764|calcium binding proteins:6:0.5290	0.5290	17
CaBP	CaBP:3	calcium-binding protein calbindin-D28k:3:0.2243	0.2243	3
CaBP	CaBP:31	vitamin D-dependent calcium-binding protein:31:0.9043	0.9043	31
CaCO(3)	CaCO(3):13	calcium carbonate:13:0.6701	0.6701	13
CaCO3	CaCO3:76	calcium carbonate:76:0.9378	0.9378	76
CaCV	CaCV:11	Canine calicivirus:11:0.7357	0.7357	11
CaCl(2)	CaCl(2):10	Calcium chloride:10:0.7103	0.7103	10
CaCl2	CaCl2:61|CaCl-2:1|CACl2:1	calcium chloride:63:0.9253	0.9253	63
CaF2	CaF2:9	calcium fluoride:9:0.3455	0.3455	9
CAM-DR	CAM-DR:6	Cell adhesion-mediated drug resistance:6:0.5290	0.5290	6
CaMKII	CaMKII:364|CaM-KII:31|CaMK-II:13|CAMKII:7|CamKII:7|CamK-II:2|CAMK-II:2|camkII:1|CAM-KII:1|CAM-K-II:1	protein kinase II:421:0.7246|protein kinase-II:8:0.5006	0.7246	429
CaMKIV	CaMKIV:30|CaM-KIV:4|caMKIV:1	protein kinase IV:35:0.5481	0.5481	35
CaMKI	CaMKI:12|CaM-KI:2	protein kinase I:14:0.5589	0.5589	14
CaMKK	CaMKK:9|CaM-KK:9	protein kinase kinase:18:0.5940	0.5940	18
CaMKs	CaMKs:23	protein kinases:23:0.4831	0.4831	23
CaMK	CaMK:66|CamK:3|CAMK:3|CaM-K:1	protein kinase:73:0.5785	0.5785	73
CaMK	CaMK:8	protein kinase II:8:0.5006	0.5006	8
CaMPDE	CaMPDE:5|CaM-PDE:4	calmodulin-dependent cyclic nucleotide phosphodiesterase:9:0.4363	0.4363	9
CaM-PK	CaM-PK:9|CaMPK:2|cAMPK:1	protein kinase:12:0.7571	0.7571	12
CaMV	CaMV:332|CAMV:2	cauliflower mosaic virus:334:0.9808	0.9808	334
CaO2	CaO2:6|Cao2:1	arterial O2 concentration:7:0.3524	0.3524	7
CaOx	CaOx:213|CaOX:2|Caox:2|Ca-Ox:1	calcium oxalate:218:0.9640	0.9640	218
CAPB	CAPB:9	cocamidopropyl betaine:9:0.5470	0.5470	9
CaPi	CaPi:7|Ca-Pi:2	calcium phosphate:9:0.6794	0.6794	9
CASI	CASI:6	Childhood Anxiety Sensitivity Index:6:0.3728	0.3728	6
CASI	CASI:40	Cognitive Abilities Screening Instrument:40:0.9237	0.9237	40
Ca-SP	Ca-SP:10	Calcium spirulan:10:0.7103	0.7103	10
Caco-2	Caco-2:19|CaCo-2:5|Caco2:2	colon carcinoma:26:0.6351	0.6351	26
Caco-2	Caco-2:12|CACO-2:1	Human colon adenocarcinoma:13:0.5335	0.5335	13
Caco-2	Caco-2:6|CaCo-2:2|CACO-2:1	human colon carcinoma cells:9:0.4587	0.4587	9
Caco-2	Caco-2:12|CaCo-2:1	human intestinal:13:0.1551	0.1551	13
Caco-2	Caco-2:40|Caco2:1|CACO-2:1	human intestinal epithelial:42:0.7311	0.7311	42
Caco-2	Caco-2:21|CaCo-2:2	intestinal epithelial cells:23:0.5997	0.5997	23
Caelyx	Caelyx:31|caelyx:2|CAELYX:1	Liposomal doxorubicin:34:0.7306	0.7306	34
Cai2+	Cai2+:9	Ca2+ concentration:9:0.3069	0.3069	9
Cai2+	Cai2+:11	cytosolic Ca2+:11:0.1009	0.1009	11
Cai2+	Cai2+:20	intracellular Ca2+:20:0.2825	0.2825	20
Cai2+	Cai2+:15	intracellular calcium:15:0.2053	0.2053	15
Cai2+	Cai2+:6	intracellular free calcium:6:0.1543	0.1543	6
CALR	CALR:4|Calr:4|CalR:2	calretinin:10:0.5556	0.5556	10
Calu-3	Calu-3:8	epithelial cells:8:0.4102	0.4102	8
Cao2+	Cao2+:13	extracellular Ca2+:13:0.4102	0.4102	13
CarMV	CarMV:13	carnation mottle virus:13:0.7753	0.7753	13
CarbE	CarbE:13	carboxylesterase:13:0.8000	0.8000	13
Carb	Carb:10|CARB:3|carb:2	carbamylcholine:15:0.1296	0.1296	15
CASL	CASL:14	continuous arterial spin labeling:14:0.6911	0.6911	14
CatG	CatG:8|Cat-G:2|cat-G:1|CAT-G:1|CATG:1	cathepsin G:13:0.7753	0.7753	13
CBI	CBI:6	Caregiver Burden Inventory:6:0.5290	0.5290	6
CBI	CBI:7	computer-based instruction:7:0.3524	0.3524	7
CBI	CBI:18	covalent binding index:18:0.8365	0.8365	18
CBL	CBL:10|Cbl:2	cerebellum:12:0.0364	0.0364	12
CBL	CBL:10|Cbl:1	chlorambucil:11:0.0331	0.0331	11
Cbl	Cbl:87|cbl:3|CBL:2	cobalamin:92:0.3046	0.3046	92
CBL	CBL:5	Computer-Based Learning:5:0.0517	0.0517	5
CBL	CBL:40	cord blood lymphocytes:40:0.9256	0.9256	40
CBL	CBL:9|CbL:1	Cystathionine beta-lyase:10:0.7103	0.7103	10
CCH	CCH:43	C-cell hyperplasia:34:0.6386|C cell hyperplasia:9:0.6794	0.6794	43
CCh	CCh:384|Cch:28|CCH:20	carbachol:432:0.6201	0.6201	432
CCh	CCh:61|Cch:12|CCH:6|C-Ch:1	carbamylcholine:80:0.1137	0.1137	80
CCH	CCH:6	Cook County Hospital:6:0.5290	0.5290	6
CCR2	CCR2:47|CCR-2:3	chemokine receptor 2:50:0.7497	0.7497	50
CCR2	CCR2:3	MCP-1 receptor:3:0.1591	0.1591	3
CCR	CCR:7	California Cancer Registry:7:0.2902	0.2902	7
CCR	CCR:36	carbon catabolite repression:36:0.9197	0.9197	36
CCR	CCR:41	CC chemokine receptor:41:0.7653	0.7653	41
CCR	CCR:10	central conserved region:10:0.7103	0.7103	10
CCR	CCR:11	chemokine receptors:11:0.5355	0.5355	11
CCR	CCR:5	cinnamoyl CoA reductase:5:0.1973	0.1973	5
CCr	CCr:7|Ccr:6	clearance of creatinine:13:0.1165	0.1165	13
cCR	cCR:12|CCR:6	clinical complete response:18:0.5228	0.5228	18
CCR	CCR:10|cCR:2	complete clinical remission:12:0.5664	0.5664	12
CCR	CCR:25	Complete cytogenetic response:25:0.8816	0.8816	25
CCR	CCR:17	complex chromosomal rearrangement:17:0.7407	0.7407	17
CCR	CCR:25	complex chromosome rearrangement:18:0.8365|complex chromosome rearrangements:7:0.5926	0.8365	25
CCR	CCR:66|cCR:2	continuous complete remission:68:0.7132	0.7132	68
CCR	CCR:12|cCR:1	continuous CR:13:0.4102	0.4102	13
Ccr	Ccr:357|CCr:202|CCR:19|C-Cr:2|C-cr:2	creatinine clearance:564:0.9694|creatinine clearances:18:0.8365	0.9694	582
Ccr	Ccr:12|CCR:5|CCr:5	creatinine clearance rate:22:0.7500	0.7500	22
CCr	CCr:5|cCr:4	Cyclocreatine:9:0.0064	0.0064	9
Cd2+	Cd2+:6	Cadmium ion:6:0.2243	0.2243	6
CdCl(2)	CdCl(2):24	cadmium chloride:24:0.8115	0.8115	24
CdCl2	CdCl2:140	cadmium chloride:140:0.9547	0.9547	140
CdLS	CdLS:10|CDLS:9	Cornelia de Lange Syndrome:19:0.7658	0.7658	19
CdMT	CdMT:20|Cd-MT:16|CdMt:5	cadmium-metallothionein:32:0.3690|cadmium metallothionein:9:0.2285	0.3690	41
Cd-MT	Cd-MT:6|CdMT:5|Cd-Mt:1	Cd-metallothionein:12:0.1310	0.1310	12
CdTe	CdTe:14|Cd-Te:1	Cadmium telluride:15:0.8045	0.8045	15
CDK7	CDK7:5|Cdk7:5	cyclin-dependent kinase 7:10:0.5856	0.5856	10
CDMP-1	CDMP-1:8|Cdmp1:1|CDMP1:1	Cartilage-derived morphogenetic protein-1:10:0.5856	0.5856	10
CEE	CEE:19	Central and Eastern Europe:19:0.8449	0.8449	19
CEE	CEE:10	Central and Eastern European:10:0.7357	0.7357	10
CEE	CEE:17	chick embryo extract:17:0.7407	0.7407	17
CEE	CEE:224	conjugated equine estrogen:101:0.9704|conjugated equine estrogens:100:0.9701|conjugated equine oestrogens:14:0.7909|conjugated equine oestrogen:9:0.6794	0.9704	224
CelB	CelB:9	Pyrococcus furiosus:9:0.5470	0.5470	9
CfMNPV	CfMNPV:6	Choristoneura fumiferana nucleopolyhedrovirus:6:0.5290	0.5290	6
Cg/Sg	Cg/Sg:8|CG/Sg:1	chromogranin/secretogranin:9:0.8000	0.8000	9
CGB	CGB:5	Canavanine-glycine-bromothymol blue:5:0.1132	0.1132	5
CgTx	CgTx:10|CgTX:2|CGTX:1	omega-conotoxin GVIA:13:0.5934	0.5934	13
CGalT	CGalT:11|CgalT:2	galactosyltransferase:13:0.7500	0.7500	13
CH3Hg	CH3Hg:8|Ch3Hg:1	methylmercury:9:0.6667	0.6667	9
ChAc	ChAc:42|ChAC:2|CHAC:1|Ch-Ac:1	choline acetyltransferase:46:0.9353	0.9353	46
ChAc	ChAc:6|CHAC:5	Chorea-acanthocytosis:11:0.1316	0.1316	11
ChAT-IR	ChAT-IR:8|ChAT-ir:5	ChAT-immunoreactive:13:0.2727	0.2727	13
ChAT-IR	ChAT-IR:7|ChAT-Ir:1	Choline acetyltransferase immunoreactivity:8:0.6411	0.6411	8
CHA	CHA:19	[3H]cyclohexyladenosine:19:0.0312	0.0312	19
CHA	CHA:4	adenosine A1 receptor agonist N6-cyclohexyladenosine:4:0.4102	0.4102	4
CHA	CHA:4|c-HA:2|C-HA:1	Carbonated hydroxyapatite:7:0.0516	0.0516	7
CHA	CHA:11	Catholic Health Association:11:0.7357	0.7357	11
CHA	CHA:16	chlorhexidine diacetate:16:0.8165	0.8165	16
CHA	CHA:6	cholic acid:6:0.0899	0.0899	6
ChA	ChA:14|Cha:1	choline acetyltransferase:15:0.8045	0.8045	15
CHA	CHA:10	common hepatic artery:10:0.7103	0.7103	10
CHA	CHA:9	congenital hypoplastic anemia:9:0.6794	0.6794	9
CHA	CHA:6|cHA:1	coralline hydroxyapatite:7:0.0516	0.0516	7
Cha	Cha:9	cyclohexylalanine:9:0.0139	0.0139	9
CHA	CHA:9	Cyclohexylamine:9:0.0139	0.0139	9
CHA	CHA:12	N6-cyclohexyl adenosine:12:0.4153	0.4153	12
CHA	CHA:7	receptor agonist cyclohexyladenosine:7:0.1470	0.1470	7
CHA	CHA:2	receptor agonist N(6)-cyclohexyladenosine:2:0.0545	0.0545	2
ChBD	ChBD:9	chitin-binding domain:9:0.3945	0.3945	9
ChBF	ChBF:32|CHBF:1	choroidal blood flow:33:0.8196	0.8196	33
ChEAT	ChEAT:6|CHEAT:1	Children's Eating Attitudes Test:7:0.4438	0.4438	7
ChEIs	ChEIs:23|ChE-Is:5	cholinesterase inhibitors:28:0.7505	0.7505	28
ChEI	ChEI:36|ChE-I:4	cholinesterase inhibitors:28:0.7505|cholinesterase inhibitor:12:0.7571	0.7571	40
CHH	CHH:37	Cartilage-hair hypoplasia:37:0.7019	0.7019	37
CHH	CHH:61|cHH:4	crustacean hyperglycemic hormone:65:0.8283	0.8283	65
CHLN	CHLN:10|Chln:3	chlorophyllin:13:0.8000	0.8000	13
CHS	CHS:71	Cardiovascular Health Study:71:0.9579	0.9579	71
CHS	CHS:146|chs:8|Chs:5	chalcone synthase:159:0.8769	0.8769	159
CHS	CHS:159|C-HS:5	Chediak-Higashi syndrome:164:0.7973	0.7973	164
CHS	CHS:9	cholesterol hemisuccinate:9:0.1585	0.1585	9
CHS	CHS:12	cholesteryl hemisuccinate:12:0.2868	0.2868	12
ChS	ChS:13|CHS:8|Ch-S:2|Chs:1|Ch-s:1	chondroitin sulfate:25:0.8186	0.8186	25
CHs	CHs:10	community hospitals:10:0.5856	0.5856	10
CHS	CHS:10	compression hip screw:10:0.5856	0.5856	10
CHS	CHS:230	contact hypersensitivity:230:0.9597	0.9597	230
CHS	CHS:11	health services:11:0.6182	0.6182	11
ChTX	ChTX:100|ChTx:18|Chtx:3|CHTX:1	Charybdotoxin:122:0.9030	0.9030	122
CHV	CHV:51	canine herpesvirus:51:0.9427	0.9427	51
ChAT	ChAT:11|Chat:1	cholinacetyltransferase:12:0.0049	0.0049	12
ChAT	ChAT:52|Chat:1|ChaT:1	choline acetyl transferase:43:0.9308|choline acetyl-transferase:11:0.7357	0.9308	54
ChAT	ChAT:1975|CHAT:21|ChaT:2|ChAt:1|Chat:1	Choline acetyltransferase:1972:0.9873|choline-acetyltransferase:28:0.0121	0.9873	2000
ChAT	ChAT:22|CHAT:1	Choline acetyltransferase activity:23:0.8715	0.8715	23
ChAT	ChAT:13	choline-O-acetyltransferase:13:0.0054	0.0054	13
ChAT	ChAT:23|CHAT:2	cholineacetyltransferase:25:0.0108	0.0108	25
CHC	CHC:17	alpha-cyano-4-hydroxycinnamate:17:0.0319	0.0319	17
CHC	CHC:8	Chlorinated hydrocarbon:8:0.3463	0.3463	8
CHC	CHC:225|CH-C:37|cHC:5|C-HC:1	chronic hepatitis C:268:0.9653	0.9653	268
CHC	CHC:11|Chc:3	clathrin heavy chain:14:0.7909	0.7909	14
CHC	CHC:21	community health center:21:0.6400	0.6400	21
CHC	CHC:12	Health Centre:12:0.7571	0.7571	12
Chk1	Chk1:9|CHK1:1	Checkpoint kinase 1:10:0.7103	0.7103	10
Cho/Cr	Cho/Cr:9|CHO/CR:1	choline/creatine:10:0.3462	0.3462	10
ChoK	ChoK:12	choline kinase:12:0.6460	0.6460	12
ChoRE	ChoRE:11|CHORE:2	carbohydrate response element:13:0.7753	0.7753	13
ChT-L	ChT-L:13|Cht-L:1|Chtl:1	chymotrypsin-like:15:0.7778	0.7778	15
CIB	CIB:6	calcium- and integrin-binding protein:6:0.3728	0.3728	6
Cipro	Cipro:19|CIPRO:6|cipro:3	ciprofloxacin:28:0.7297	0.7297	28
CITP	CITP:13|cITP:7|C-ITP:1	capillary isotachophoresis:21:0.7865	0.7865	21
CITP	CITP:10|cITP:6|C-ITP:1	chronic idiopathic thrombocytopenic purpura:17:0.7407	0.7407	17
CIT	CIT:36|Cit:7	citalopram:43:0.1210	0.1210	43
CIT	CIT:42	cold ischemia time:42:0.9291	0.9291	42
CIT	CIT:22	conventional insulin therapy:22:0.7955	0.7955	22
CIT	CIT:17	conventional insulin treatment:17:0.8270	0.8270	17
CIT	CIT:10	cortical imaging technique:10:0.7103	0.7103	10
CIT	CIT:8	critical incident technique:8:0.6411	0.6411	8
Cit	Cit:7|CIT:2	L-citrulline:9:0.0231	0.0231	9
CK13	CK13:9	cytokeratin 13:9:0.5470	0.5470	9
Cl(-)	Cl(-):30	chloride:30:0.6304	0.6304	30
CL(CR)	CL(CR):16|Cl(cr):5|CL(cr):3|Cl(Cr):3	creatinine clearance:27:0.8903	0.8903	27
CL(tot)	CL(tot):6|Cl(tot):2	Total body clearance:8:0.6411	0.6411	8
CL(tot)	CL(tot):8|Cl(tot):1	total clearance:9:0.1690	0.1690	9
Cl-	Cl-:170	chloride:170:0.5469	0.5469	170
Cl-	Cl-:41	chloride ion:24:0.7593|chloride ions:17:0.8270	0.8270	41
Cl2MBP	Cl2MBP:16|CL2MBP:2	dichloromethylene bisphosphonate:18:0.7539	0.7539	18
Cl2MDP	Cl2MDP:61|CL2MDP:8|Cl2-MDP:1	dichloromethylene diphosphonate:70:0.7608	0.7608	70
CLB	CLB:40	chlorambucil:40:0.1726	0.1726	40
CLB	CLB:32	clobazam:32:0.1372	0.1372	32
CLE	CLE:10	centrilobular emphysema:10:0.1134	0.1134	10
CLE	CLE:17	columnar-lined esophagus:17:0.5374	0.5374	17
CLE	CLE:24	Congenital lobar emphysema:24:0.8768	0.8768	24
CLE	CLE:7	cross-linked envelope:7:0.2902	0.2902	7
CLE	CLE:21	cutaneous lupus erythematosus:21:0.8594	0.8594	21
ClO2	ClO2:54	Chlorine dioxide:54:0.9448	0.9448	54
ClO4-	ClO4-:35	perchlorate:35:0.7333	0.7333	35
CLR	CLR:15	clarithromycin:15:0.0490	0.0490	15
CLR	CLR:9	collagen-like region:9:0.3455	0.3455	9
CLR	CLR:10	receptor:10:0.0315	0.0315	10
CLR	CLR:78|Clr:38|ClR:22|CLr:20	renal clearance:158:0.9034	0.9034	158
CLT	CLT:7	chemiluminescence test:7:0.1111	0.1111	7
CLT	CLT:18	chronic lymphocytic thyroiditis:18:0.8365	0.8365	18
CLT	CLT:5	clot lysis time:5:0.4422	0.4422	5
CLT	CLT:32	clotrimazole:32:0.1152	0.1152	32
ClT	ClT:18|Clt:10|CLt:9|CLT:8	total body clearance:45:0.8964	0.8964	45
ClT	ClT:9|Clt:7|CLT:7|CLt:6	total clearance:29:0.2035	0.2035	29
Clara	Clara:11	nonciliated bronchiolar:11:0.2582	0.2582	11
Clara	Clara:67	nonciliated bronchiolar epithelial:67:0.7174	0.7174	67
Clcr	Clcr:69|CLCR:61|CLcr:30|ClCr:15|ClCR:5|CLCr:2|Cl-CR:1|CLcR:1	creatinine clearance:174:0.9727|creatinine clearances:10:0.7103	0.9727	184
CldUrd	CldUrd:11	chlorodeoxyuridine:11:0.6250	0.6250	11
CLI	CLI:7	central lymphatic irradiation:7:0.3524	0.3524	7
CLi	CLi:8	clearance of lithium:8:0.2090	0.2090	8
CLI	CLI:11|Cli:1	clindamycin:12:0.0315	0.0315	12
CLI	CLI:13	clomipramine:13:0.0344	0.0344	13
CLI	CLI:52	critical limb ischaemia:52:0.8345	0.8345	52
CLI	CLI:53	critical limb ischemia:53:0.8166	0.8166	53
CLi	CLi:48|Cli:1|C-Li:1	lithium clearance:50:0.6009	0.6009	50
CLK	CLK:6	contralateral kidney:6:0.2243	0.2243	6
CLNR	CLNR:5|Clnr:4|ClNR:2|CLnr:1	nonrenal clearance:12:0.5050	0.5050	12
Clomid	Clomid:23|clomid:5	Clomiphene citrate:28:0.7905	0.7905	28
ClqBA	ClqBA:7|Clq-BA:4	Clq binding activity:11:0.5355	0.5355	11
CLQ	CLQ:7|Clq:3	chloroquine:10:0.3333	0.3333	10
Cmax	Cmax:8	binding capacity:8:0.2090	0.2090	8
Cmax	Cmax:8	concentrations in plasma:8:0.0548	0.0548	8
Cmax	Cmax:250|cmax:2|CMax:1|CMAX:1	maximum concentration:254:0.1712	0.1712	254
Cmax	Cmax:8	maximum concentration in plasma:8:0.1809	0.1809	8
Cmax	Cmax:7	maximum concentration in serum:7:0.2452	0.2452	7
Cmax	Cmax:8	maximum concentration of drug in serum:8:0.5470	0.5470	8
Cmax	Cmax:342|cmax:3|CMAX:1	maximum plasma concentration:282:0.4570|maximum plasma concentrations:64:0.3253	0.4570	346
Cmax	Cmax:7|cmax:1	Maximum plasma levels:8:0.1276	0.1276	8
Cmax	Cmax:18	maximum serum concentrations:18:0.2332	0.2332	18
Cmax	Cmax:44	peak concentrations:44:0.0904	0.0904	44
Cmax	Cmax:15	peak levels:15:0.1196	0.1196	15
Cmax	Cmax:253|cmax:5|CMax:1|CMAX:1	peak plasma concentration:194:0.3028|peak plasma concentrations:66:0.3377	0.3377	260
Cmax	Cmax:20|C-max:1	peak plasma level:13:0.3554|peak plasma levels:8:0.1276	0.3554	21
Cmax	Cmax:18	Peak serum concentrations:18:0.2332	0.2332	18
Cmax	Cmax:4	reached the maximum:4:0.0655	0.0655	4
Cmin	Cmin:26	concentrations:26:0.1678	0.1678	26
Cmin	Cmin:10	trough levels:10:0.5856	0.5856	10
CneF	CneF:10	cryptococcal culture filtrate antigen:10:0.5856	0.5856	10
CoA-IT	CoA-IT:12	CoA-independent transacylase:12:0.4557	0.4557	12
CoAo	CoAo:9	coarctation of the aorta:9:0.7103	0.7103	9
CoA	CoA:10|COA:1	aortic coarctation:11:0.3495	0.3495	11
COA	COA:10|Co-A:8|CoA:2	co-agglutination:20:0.0599	0.0599	20
COA	CoA:17|COA:17|Co-A:3	coagglutination:37:0.1136	0.1136	37
coa	coa:15|COA:1	coagulase:16:0.0473	0.0473	16
CoA	CoA:63|COA:9|coa:1	coarctation of the aorta:73:0.9238	0.9238	73
CoCl(2)	CoCl(2):14	cobalt chloride:14:0.7909	0.7909	14
CoCl2	CoCl2:39|COCl2:1	cobalt chloride:40:0.6003	0.6003	40
CoCrMo	CoCrMo:9|Co-Cr-Mo:2	cobalt-chromium-molybdenum:11:0.3846	0.3846	11
Co-Cr	Co-Cr:19|CoCr:6	cobalt-chromium:25:0.3692	0.3692	25
CoF	CoF:21|COF:2	cobra venom factor:23:0.8715	0.8715	23
COF	COF:10|CoF:1	coefficient of friction:11:0.6182	0.6182	11
CoMFA	CoMFA:345|COMFA:1|coMFA:1|CoMFa:1	Comparative molecular field analysis:348:0.9771	0.9771	348
CoNS	CoNS:8|CONS:5	coagulase-negative staphylococcal:13:0.4849	0.4849	13
CoNS	CoNS:108|CONS:24|ConS:1	Coagulase-negative staphylococci:133:0.8007	0.8007	133
CoNS	CoNS:10|CONS:2	coagulase-negative staphylococcus:12:0.3813	0.3813	12
CoQ9	CoQ9:10	coenzyme Q9:10:0.7103	0.7103	10
CoQ	CoQ:72|coq:1	Coenzyme Q:73:0.9147	0.9147	73
CoQ	CoQ:41	coenzyme Q10:41:0.9274	0.9274	41
CoVF	CoVF:19|COVF:1	cobra venom factor:20:0.8525	0.8525	20
COL1A1	COL1A1:5	alpha 1(I) procollagen gene:5:0.4422	0.4422	5
COL1A1	COL1A1:9	collagen type I alpha 1:9:0.6794	0.6794	9
COL1A1	COL1A1:15	type I procollagen:15:0.7096	0.7096	15
COMET	COMET:1	Carvedilol and Metoprolol European Trial:1:0.8165	0.8165	1
COMET	COMET:11	Correction of Myopia Evaluation Trial:11:0.7103	0.7103	11
comet	comet:77|Comet:47|COMET:2	single cell gel electrophoresis:69:0.9585|single-cell gel electrophoresis:57:0.3717	0.9585	126
ConA	ConA:16|Con-A:2	Canavalia ensiformis:18:0.4934	0.4934	18
ConA	ConA:10|Con-A:4|conA:1	concanavalin:15:0.0505	0.0505	15
Con-A	Con-A:117|ConA:21|CON-A:7|con-A:6|conA:2|con--A:1	concanavalin-A:154:0.5523	0.5523	154
ConA	ConA:11|Con-A:5|conA:1	ensiformis agglutinin:17:0.4742	0.4742	17
con-G	con-G:16|Con-G:2	Conantokin-G:18:0.8947	0.8947	18
Cosm	Cosm:16|COsm:2|COSM:1|CosM:1	osmolar clearance:20:0.4574	0.4574	20
coxibs	coxibs:9|Coxibs:1|COXIBs:1	selective COX-2 inhibitors:11:0.4444	0.4444	11
CpG-ODN	CpG-ODN:9	CpG-containing oligodeoxynucleotides:9:0.2285	0.2285	9
CpG-ODN	CpG-ODN:6	Oligodeoxynucleotides containing CpG motifs:6:0.3524	0.3524	6
CPT-I	CPT-I:7|CPTI:2|CPTi:1	carnitine palmitoyltransferase:10:0.7103	0.7103	10
CPT-I	CPT-I:63|CPTI:13	carnitine palmitoyltransferase I:53:0.9116|carnitine palmitoyltransferase-I:23:0.8715	0.9116	76
cpTi	cpTi:37|CpTi:4|CP-Ti:4|cp-Ti:1|CPTi:1	commercially pure titanium:47:0.9366	0.9366	47
CpTI	CpTI:9	cowpea trypsin inhibitor:9:0.5470	0.5470	9
CPSs	CPSs:14	capsular polysaccharides:14:0.7909	0.7909	14
CPSs	CPSs:21	complex partial seizures:21:0.8594	0.8594	21
Cpss	Cpss:6	steady-state plasma concentration:6:0.5290	0.5290	6
Cr(III)	Cr(III):11	Trivalent chromium:11:0.7357	0.7357	11
Cr(VI)	Cr(VI):23|Cr(vi):1	Hexavalent chromium:24:0.8115	0.8115	24
Cr3+	Cr3+:16	chromium:16:0.6250	0.6250	16
Cr6+	Cr6+:7	hexavalent chromium:7:0.2452	0.2452	7
CrCL	CrCL:12	cranial cruciate ligament:12:0.7571	0.7571	12
CrCl	CrCl:135|CRCL:11|CrCL:7|Crcl:3|Cr-Cl:3|CRCl:1	creatinine clearance:160:0.9603	0.9603	160
CrEL	CrEL:21|crEL:2	Cremophor EL:23:0.8715	0.8715	23
CRFK	CRFK:24|CrFK:18	Crandell feline kidney:42:0.5750	0.5750	42
CrFK	CrFK:4|CRFK:2	Crandell feline kidney cells:6:0.3728	0.3728	6
CrGN	CrGN:10|CRGN:4	crescentic glomerulonephritis:14:0.6911	0.6911	14
CrMP	CrMP:16	chromium mesoporphyrin:16:0.8165	0.8165	16
CrPic	CrPic:13|Cr-pic:3	chromium picolinate:16:0.8165	0.8165	16
CrVI	CrVI:10|Cr-VI:3	hexavalent chromium:13:0.7753	0.7753	13
CRISP	CRISP:15	cysteine-rich secretory protein:15:0.8045	0.8045	15
Crry	Crry:9	Complement receptor 1-related gene/protein y:9:0.6794	0.6794	9
Cs+	Cs+:12	cesium:12:0.0485	0.0485	12
CS+	CS+:16	conditional stimulus:16:0.1356	0.1356	16
CS+	CS+:25	conditioned stimulus:25:0.2683	0.2683	25
CS+	CS+:9	flavor:9:0.0352	0.0352	9
CS+	CS+:10	one tone:10:0.1449	0.1449	10
CsA-ME	CsA-ME:8|CsA-me:1	microemulsion:9:0.5000	0.5000	9
CsCl	CsCl:38|CsCL:1	cesium chloride:39:0.6392	0.6392	39
CSTRs	CSTRs:10	stirred tank reactors:10:0.7103	0.7103	10
CT-1	CT-1:117|CT1:2|ct-1:1	cardiotrophin-1:120:0.6842	0.6842	120
CTV	CTV:9	cell tracking velocimetry:9:0.6794	0.6794	9
CTV	CTV:67|Ctv:3	citrus tristeza virus:70:0.9573	0.9573	70
CTV	CTV:161	clinical target volume:161:0.9703	0.9703	161
CTV	CTV:10	CT venography:10:0.3470	0.3470	10
CtxB	CtxB:8|CTxB:1	B subunit of cholera toxin:9:0.6794	0.6794	9
CtxB	CtxB:3|ctxB:2|CTxB:1|CTXB:1	cholera toxin B subunit:7:0.3524	0.3524	7
Cu2+	Cu2+:14	Cupric ions:8:0.2619|cupric ion:6:0.1010	0.2619	14
CUA	CUA:19	cost-utility analysis:19:0.5732	0.5732	19
Cua	Cua:3|CUA:2|CuA:2	uric acid clearance:7:0.5926	0.5926	7
CuOOH	CuOOH:17|CUOOH:2|cu-OOH:1|cuOOH:1	cumene hydroperoxide:21:0.7865	0.7865	21
CuSO4	CuSO4:13	copper sulfate:13:0.4444	0.4444	13
CUS	CUS:22|C-US:2	compression ultrasonography:24:0.5598	0.5598	24
CUS	CUS:6	cranial ultrasound:6:0.0731	0.0731	6
CuZn	CuZn:8|Cu-Zn:5	copper-zinc:13:0.4615	0.4615	13
CumOOH	CumOOH:19|cumOOH:4|cum-OOH:1|Cum-OOH:1	cumene hydroperoxide:25:0.8186	0.8186	25
Cur	Cur:13|CUR:8	Curcumin:21:0.3448	0.3448	21
CU	CU:45	chronic urticaria:45:0.6065	0.6065	45
CU	CU:22	Clemson University:22:0.7955	0.7955	22
CU	CU:5	clinical units:5:0.0517	0.0517	5
Cu	Cu:8|CU:1	concentration:9:0.0059	0.0059	9
-Cu	-Cu:11	copper-deficient:11:0.0074	0.0074	11
CU	CU:25|Cu:22	Cuprophan:47:0.0340	0.0340	47
CU	CU:21|Cu:4	cuprophane:25:0.0177	0.0177	25
CVE	CVE:11	cardiovascular events:11:0.3495	0.3495	11
Cx26	Cx26:73|cx26:1|CX26:1	connexin 26:75:0.8661	0.8661	75
Cx26	Cx26:33|CX26:1	connexin26:34:0.2276	0.2276	34
Cx31	Cx31:10|CX31:1	Connexin 31:11:0.7357	0.7357	11
Cx32	Cx32:83|CX32:3|cx32:1	connexin 32:87:0.8573	0.8573	87
Cx32	Cx32:91|cx32:4|CX32:1	connexin32:96:0.4439	0.4439	96
Cx36	Cx36:8|cx36:1	connexin 36:9:0.6794	0.6794	9
Cx36	Cx36:33|CX36:1	connexin36:34:0.6600	0.6600	34
Cx37	Cx37:7|cx37:2|CX37:1	connexin 37:10:0.5856	0.5856	10
Cx37	Cx37:21	connexin37:21:0.6061	0.6061	21
Cx40	Cx40:10|cx40:2	connexin 40:12:0.5050	0.5050	12
Cx40	Cx40:51	connexin40:51:0.7353	0.7353	51
Cx43	Cx43:221|cx43:13|CX43:9	connexin 43:243:0.9509	0.9509	243
Cx-43	Cx-43:4|Cx43:3	gap junction protein connexin-43:7:0.7103	0.7103	7
Cx43	Cx43:54|cx43:1	gap junction protein connexin43:55:0.9607	0.9607	55
Cx46	Cx46:15	connexin46:15:0.5385	0.5385	15
Cx50	Cx50:12	connexin50:12:0.3793	0.3793	12
CX	CX:12	canthaxanthin:12:0.0150	0.0150	12
CX	CX:18|Cx:12	cerebral cortex:30:0.2624	0.2624	30
CX	CX:23|Cx:15	circumflex artery:38:0.3961	0.3961	38
CX	CX:18|Cx:16	circumflex coronary artery:34:0.9126	0.9126	34
Cx	Cx:234|cx:15|CX:4	connexin:173:0.2374|connexins:80:0.1078	0.2374	253
CX	CX:34|Cx:11|cx:1	cycloheximide:46:0.0614	0.0614	46
Cx	Cx:9|CX:3	left circumflex:12:0.0804	0.0804	12
Cy/+	Cy/+:8|cy/+:2	heterozygous:10:0.2895	0.2895	10
CyDs	CyDs:20	cyclodextrins:20:0.7308	0.7308	20
CyPB	CyPB:15|CypB:5|Cyp-B:1	cyclophilin B:21:0.8594	0.8594	21
CYP	CYP:4	couple years protection:3:0.4587|couple-years protection:1:0.0522	0.4587	4
CyP	CyP:45|Cyp:9|CYP:6|cyp:1	cyclophilin:61:0.0229	0.0229	61
CYP	CYP:36|CyP:24	cyclophosphamide:60:0.0226	0.0226	60
CYP	CYP:12|Cyp:11	cyproheptadine:23:0.0084	0.0084	23
CYP	CYP:26|CyP:1	cytochrome:27:0.0099	0.0099	27
CYP	CYP:273|Cyp:1	cytochrome P-450:260:0.9178|cytochrome P(450):14:0.6911	0.9178	274
CYP	CYP:1838|Cyp:4|cyp:1	cytochrome P450:1843:0.9289	0.9289	1843
CYP	CYP:8	cytochrome P450 enzymes:8:0.6411	0.6411	8
CYP	CYP:25|Cyp:1	cytochrome P450s:26:0.8251	0.8251	26
CyRE	CyRE:8	cytokine response element:8:0.6411	0.6411	8
CYCLO	CYCLO:9|Cyclo:6|cyclo:4	cyclophosphamide:19:0.5455	0.5455	19
CyD	CyD:10	cyclodextrin:10:0.1957	0.1957	10
Cyd	Cyd:15	cytidine:15:0.3043	0.3043	15
CYH	CYH:10|cyh:2|Cyh:1	Cycloheximide:13:0.8000	0.8000	13
CymMV	CymMV:9	cymbidium mosaic potexvirus:9:0.6794	0.6794	9
CYP17	CYP17:20|Cyp17:1	17alpha-hydroxylase:21:0.1316	0.1316	21
CYP17	CYP17:15	cytochrome P450c17:15:0.3614	0.3614	15
CYP17	CYP17:8|Cyp17:1	cytochrome P450c17alpha:9:0.6794	0.6794	9
CYP2B	CYP2B:11	cytochrome P450 2B:11:0.5856	0.5856	11
Cypro	Cypro:8|CYPRO:4|cypro:1	cyproheptadine:13:0.9231	0.9231	13
Cyps	Cyps:11|CyPs:8|CYPs:2	Cyclophilins:21:0.0913	0.0913	21
CYPs	CYPs:54	cytochromes P450:54:0.8004	0.8004	54
CYPs	CYPs:12	cytochrome P450 enzymes:12:0.7571	0.7571	12
CysLTs	CysLTs:41|cys-LTs:29|cysLTs:28|Cys-LTs:11|CYSLTs:1	cysteinyl leukotrienes:88:0.9131|cysteinyl-leukotrienes:22:0.1842	0.9131	110
CysRS	CysRS:13	cysteinyl-tRNA synthetase:13:0.6701	0.6701	13
Cys	Cys:14|CYS:4|CyS:2	cyclosporine:20:0.0461	0.0461	20
Cys	Cys:5|cys:5	cysteamine:10:0.0218	0.0218	10
Cys	Cys:205|cys:34	cysteine:239:0.5777	0.5777	239
Cys	Cys:31|cys:13	L-cysteine:44:0.1044	0.1044	44
cyt-c	cyt-c:10|Cyt-c:9|CytC:7|Cytc:6|cytc:4|cytC:2|CYTc:1|CYTC:1	cytochrome c:40:0.8839	0.8839	40
cyt	cyt:69|Cyt:19	cytochrome:88:0.3640	0.3640	88
cyt	cyt:13|Cyt:3	cytochrome c:16:0.6577	0.6577	16
cyt	cyt:9	cytocidal:9:0.0335	0.0335	9
cyt	cyt:11|Cyt:2	cytoplasmic:13:0.0502	0.0502	13
D&C	D&C:95	dilatation and curettage:95:0.6623	0.6623	95
D&E	D&E:26	dilatation and evacuation:26:0.4188	0.4188	26
D&E	D&E:18	Dilation and evacuation:18:0.2396	0.2396	18
D(2)O	D(2)O:16	deuterium oxide:16:0.8165	0.8165	16
D(2)R	D(2)R:5	Dopamine D(2) receptor:5:0.2818	0.2818	5
D-FISH	D-FISH:9	fluorescence in situ hybridization:9:0.6794	0.6794	9
D-GalN	D-GalN:39|d-GalN:2|D-Galn:2|D-galN:2	D-galactosamine:45:0.9167	0.9167	45
d-LSD	d-LSD:9|D-LSD:2	D-lysergic acid diethylamide:11:0.7357	0.7357	11
D-NMMA	D-NMMA:9	NG-monomethyl-D-arginine:9:0.4706	0.4706	9
D-PDMP	D-PDMP:15	D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol:15:0.6364	0.6364	15
D.A.R.E.	D.A.R.E.:9	Drug Abuse Resistance Education:9:0.6794	0.6794	9
d.c.	d.c.:17|D.C.:1	direct current:18:0.6381	0.6381	18
d.f.	d.f.:10	degrees of freedom:10:0.5856	0.5856	10
D.I.C.	D.I.C.:8	disseminated intravascular coagulation:8:0.6411	0.6411	8
D.p.	D.p.:7|D.P.:1	Dermatophagoides Pteronyssinus:8:0.4102	0.4102	8
d.s.	d.s.:4|D.S.:3	degrees of substitution:7:0.2987	0.2987	7
D.V.T.	D.V.T.:11	deep venous thrombosis:11:0.7357	0.7357	11
D/BMD	D/BMD:10	Duchenne/Becker muscular dystrophy:10:0.5856	0.5856	10
D/I	D/I:19	deletion/insertion:19:0.6429	0.6429	19
D/P	D/P:7	concentration ratios:7:0.1111	0.1111	7
D/P	D/P:18	Dialysate/plasma:18:0.1328	0.1328	18
D/P	D/P:36	dialysate-to-plasma:24:0.1797|Dialysate to plasma:12:0.5335	0.5335	36
D/P	D/P:15	dialysate-to-plasma ratio:15:0.2972	0.2972	15
D/V	D/V:10|d/v:1	dorsal/ventral:11:0.2632	0.2632	11
D/V	D/V:10|d/v:4	dorsoventral:14:0.3421	0.3421	14
D0	D0:9	mean lethal dose:9:0.5470	0.5470	9
D0	D0:9	treatment:9:0.0323	0.0323	9
D1R	D1R:11	D1 dopamine receptor:11:0.7357	0.7357	11
D1	D1:37	domain:37:0.0459	0.0459	37
D1	D1:16	domain 1:16:0.0731	0.0731	16
D1	D1:12|d1:3	first:15:0.0178	0.0178	15
D1	D1:6	first day:6:0.0807	0.0807	6
D1	D1:6	first diagonal branch:6:0.2827	0.2827	6
D1	D1:12	limited:12:0.0140	0.0140	12
D1	D1:11	type 1 deiodinase:11:0.7357	0.7357	11
D1	D1:6	Type 1 iodothyronine deiodinase:6:0.5290	0.5290	6
D1	D1:9	type I:9:0.6794	0.6794	9
D1	D1:14	type I deiodinase:14:0.6911	0.6911	14
D1	D1:7	type I iodothyronine deiodinase:7:0.5926	0.5926	7
D2O	D2O:138	deuterium oxide:138:0.9538	0.9538	138
D2O	D2O:43|D2-O:1	heavy water:44:0.6343	0.6343	44
D2R	D2R:41|D2-R:3|D2r:1	dopamine D2 receptor:35:0.5098|dopamine D2 receptors:10:0.3470	0.5098	45
D2	D2:35	correlation dimension:35:0.7952	0.7952	35
D2	D2:26	domain:26:0.0215	0.0215	26
D2	D2:18|D-2:4	dopamine-2:22:0.0181	0.0181	22
D2	D2:7	dopamine D2 receptor:7:0.4438	0.4438	7
D2	D2:6|D-2:1	dopamine receptor:7:0.0828	0.0828	7
D2	D2:27	extended:27:0.0224	0.0224	27
D2	D2:6	extended lymphadenectomy:6:0.2243	0.2243	6
D2	D2:12	lymph node dissection:12:0.6460	0.6460	12
D2	D2:7|D-2:2	receptors:9:0.0069	0.0069	9
D2	D2:23|D-2:2	type 2:25:0.1673	0.1673	25
D2	D2:16	Type 2 deiodinase:16:0.8165	0.8165	16
D2	D2:20	Type 2 iodothyronine deiodinase:20:0.8525	0.8525	20
D3R	D3R:8|D3r:1	dopamine D3 receptor:9:0.4587	0.4587	9
D3T	D3T:15	1,2-dithiole-3-thione:15:0.4516	0.4516	15
D3T	D3T:12	3H-1,2-dithiole-3-thione:12:0.3548	0.3548	12
D3	D3:19	1,25-dihydroxyvitamin D3:19:0.1080	0.1080	19
D3	D3:25	cholecalciferol:25:0.0508	0.0508	25
D3	D3:7|d3:3	diagnosed at the caries into dentine:10:0.7103	0.7103	10
D3	D3:10	Domain 3:10:0.0748	0.0748	10
D3	D3:8	Type 3 iodothyronine deiodinase:8:0.6411	0.6411	8
D3	D3:9	type III deiodinase:9:0.6794	0.6794	9
D3	D3:6	type III iodothyronine deiodinase:6:0.5290	0.5290	6
D3	D3:55	vitamin D3:55:0.4259	0.4259	55
D40	D40:7|D-40:1	dextran 40:8:0.4102	0.4102	8
D4DR	D4DR:15	Dopamine D4 receptor:15:0.8045	0.8045	15
D4	D4:28	octamethylcyclotetrasiloxane:28:0.1494	0.1494	28
D5W	D5W:8	5% dextrose:8:0.3463	0.3463	8
D5W	D5W:26	5% dextrose in water:26:0.7340	0.7340	26
D5W	D5W:9	5% dextrose injection:9:0.6794	0.6794	9
D5	D5:22|d5:1	Domain 5:23:0.3927	0.3927	23
D600	D600:44|D-600:23|D--600:1	Methoxyverapamil:68:0.5447	0.5447	68
D609	D609:23|D-609:1	tricyclodecan-9-yl-xanthogenate:24:0.3151	0.3151	24
D7	D7:11	diploid strain:11:0.6182	0.6182	11
D9	D9:8	Braun Oral-B Ultra Plaque Remover:8:0.6794	0.6794	8
DA1	DA1:9	dopamine1:9:0.0714	0.0714	9
DA1	DA1:9	receptor:9:0.0714	0.0714	9
DA1	DA1:6|DA-1:1	selective dopamine:7:0.1025	0.1025	7
DA-1	DA-1:5|DA1:4	selective dopamine-1:9:0.1205	0.1205	9
DA1	DA1:7	vascular dopamine:7:0.1025	0.1025	7
DAAO	DAAO:36|D-AAO:7	D-amino acid oxidase:43:0.9308	0.9308	43
DAA	DAA:17|daa:2	after anthesis:19:0.8449	0.8449	19
DAA	DAA:4	dispensable amino acids:4:0.0918	0.0918	4
DAA	DAA:6	double aortic arch:6:0.2827	0.2827	6
DAA	DAA:9	ductus arteriosus aneurysm:9:0.6794	0.6794	9
DABCO	DABCO:19|dabco:1	1,4-diazabicyclo[2.2.2]octane:20:0.3115	0.3115	20
DABM	DABM:10	demineralized allogeneic bone matrix:10:0.7103	0.7103	10
DAB	DAB:9	1,4-dideoxy-1,4-imino-D-arabinitol:9:0.0113	0.0113	9
DAB	DAB:91	3,3'-diaminobenzidine:91:0.1277	0.1277	91
DAB	DAB:11	3,3'-diaminobenzidine tetrahydrochloride:11:0.2582	0.2582	11
DAB	DAB:25	4-dimethylaminoazobenzene:25:0.0340	0.0340	25
DAB	DAB:41|dab:3	days after birth:44:0.7619	0.7619	44
DAB	DAB:213	diaminobenzidine:213:0.2993	0.2993	213
DAB	DAB:7	diaminobenzidine tetrahydrochloride:7:0.0886	0.0886	7
DAB	DAB:15	dimethylaminoazobenzene:15:0.0199	0.0199	15
dab	dab:4|Dab:3|DAB:2	disabled:9:0.0113	0.0113	9
DAB	DAB:26	N,N-dimethyl-4-aminoazobenzene:26:0.0355	0.0355	26
DAB	DAB:24	p-dimethylaminoazobenzene:24:0.0326	0.0326	24
DACL	DACL:26	Depression Adjective Check Lists:15:0.8045|Depression Adjective Check List:11:0.6182	0.8045	26
DACM	DACM:8	N-(7-dimethylamino-4-methyl-3-coumarinyl) maleimide:8:0.2090	0.2090	8
DACH	DACH:24|dach:6	1,2-diaminocyclohexane:30:0.3718	0.3718	30
DACH	DACH:19|dach:1	diaminocyclohexane:20:0.2436	0.2436	20
dac	dac:19|Dac:2|DAC:1	dachshund:22:0.0981	0.0981	22
DAC	DAC:7	demethylating agent 5-aza-2'-deoxycytidine:7:0.5470	0.5470	7
DAC	DAC:8	dry air challenge:8:0.6411	0.6411	8
DADLE	DADLE:116|DA-DLE:3	[D-Ala2,D-Leu5]enkephalin:58:0.1881|D-Ala2-D-Leu5-enkephalin:38:0.1221|[D-Ala2,D-Leu5]-enkephalin:11:0.0330|D-Ala2,D-Leu5-enkephalin:10:0.0297|D-Ala2 D-Leu5-enkephalin:1:0.3945|D-Ala2 D-Leu5 enkephalin:1:0.6411	0.6411	119
DADL	DADL:19	D-Ala2-D-Leu5-enkephalin:19:0.1856	0.1856	19
DADT	DADT:11|dadt:1	diaminedithiol:12:0.1196	0.1196	12
DADs	DADs:61	delayed afterdepolarizations:61:0.9511	0.9511	61
DADS	DADS:9	Diallyl disulphide:9:0.6794	0.6794	9
DAD	DAD:31	delayed afterdepolarization:19:0.7658|delayed afterdepolarizations:12:0.7571	0.7658	31
DAD	DAD:10	dianhydrodulcitol:10:0.0236	0.0236	10
DAD	DAD:78	diffuse alveolar damage:78:0.9190	0.9190	78
DAD	DAD:13	Disability Assessment for Dementia:13:0.8045	0.8045	13
DAEC	DAEC:1	diffusely adherent E coli:1:0.5290	0.5290	1
DAEC	DAEC:14	diffusely adhering Escherichia coli:14:0.7909	0.7909	14
DAF-2	DAF-2:25	4,5-diaminofluorescein:25:0.5750	0.5750	25
DAF	DAF:22|daf:1	days after flowering:23:0.7046	0.7046	23
DAF	DAF:313|Daf:1	decay-accelerating factor:314:0.6051	0.6051	314
DAF	DAF:48	delayed auditory feedback:48:0.9379	0.9379	48
DAF	DAF:23	dissolved air flotation:23:0.8715	0.8715	23
DAF	DAF:27	DNA amplification fingerprinting:27:0.8903	0.8903	27
DAF	DAF:16	drug-admixed food:16:0.7261	0.7261	16
DAGK	DAGK:18	diacylglycerol kinase:18:0.6903	0.6903	18
DAGO	DAGO:11	[D-Ala2,MePhe4,Gly-ol5]enkephalin:11:0.0397	0.0397	11
DAGO	DAGO:23	enkephalin:23:0.0873	0.0873	23
DAGO	DAGO:9	Gly-ol5]enkephalin:9:0.0317	0.0317	9
DAGs	DAGs:35	diacylglycerols:35:0.6296	0.6296	35
DAG	DAG:16	1,2-diacyl-sn-glycerol:16:0.0113	0.0113	16
DAG	DAG:130	1,2-diacylglycerol:130:0.0965	0.0965	130
DAG	DAG:14	acyl glucuronide:14:0.7909	0.7909	14
DAG	DAG:9	diacyglycerol:9:0.0060	0.0060	9
DAG	DAG:894	diacylglycerol:865:0.6503|diacylglycerols:29:0.0211	0.6503	894
DAG	DAG:22	dianhydrogalactitol:22:0.0158	0.0158	22
DAG	DAG:10	directed acyclic graph:10:0.7103	0.7103	10
DAG	DAG:52	sn-1,2-diacylglycerol:52:0.0384	0.0384	52
DAHP	DAHP:34	2,4-Diamino-6-hydroxypyrimidine:34:0.2946	0.2946	34
DAHP	DAHP:41	3-deoxy-D-arabino-heptulosonate 7-phosphate:26:0.5409|3-deoxy-D-arabino-heptulosonate-7-phosphate:15:0.1250	0.5409	41
DAH	DAH:31	diffuse alveolar hemorrhage:31:0.8519	0.8519	31
DALA	DALA:11	D-ala2-met-enkephalinamide:11:0.0990	0.0990	11
DALA	DALA:16	D-Ala2-Met5-enkephalinamide:16:0.1485	0.1485	16
DALCE	DALCE:10	[D-Ala2,Leu5,Cys6]enkephalin:10:0.6000	0.6000	10
DALI	DALI:11	direct adsorption of lipoproteins:11:0.7357	0.7357	11
DALM	DALM:12	Dysplasia-associated lesion or mass:12:0.5664	0.5664	12
DALT	DALT:9	duct-associated lymphoid tissue:9:0.6794	0.6794	9
DALY	DALY:78	disability-adjusted life year:30:0.4630|disability adjusted life years:18:0.8365|disability adjusted life year:17:0.8365|disability-adjusted life-year:13:0.6701	0.8365	78
DALYs	DALYs:101|DALYS:3	disability-adjusted life years:59:0.5298|disability adjusted life years:33:0.9100|disability-adjusted life-years:12:0.6460	0.9100	104
DAMC	DAMC:9	7,8-Diacetoxy-4-methylcoumarin:9:0.5333	0.5333	9
DAMGO	DAMGO:4	agonist [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin:4:0.3524	0.3524	4
DAMGO	DAMGO:11	[D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin:11:0.0218	0.0218	11
DAMGO	DAMGO:15	[D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin:15:0.0305	0.0305	15
DAMGO	DAMGO:21	Gly-ol5]enkephalin:21:0.0436	0.0436	21
DAMGO	DAMGO:11	Gly5-ol]-enkephalin:11:0.0218	0.0218	11
DAM	DAM:10	delayed amelanotic:10:0.7103	0.7103	10
Dam	Dam:12|dam:2	deoxyadenosine methylase:14:0.1579	0.1579	14
DAM	DAM:12	diacetyl monoxime:12:0.6460	0.6460	12
DAM	DAM:11	diacetylmonoxime:11:0.0510	0.0510	11
Dam	Dam:17|dam:9	DNA adenine methylase:26:0.8312	0.8312	26
Dam	Dam:6|DAM:1	DNA adenine methyltransferase:7:0.5926	0.5926	7
DAN	DAN:18	2,3-diaminonaphthalene:18:0.1104	0.1104	18
DAN	DAN:42	diabetic autonomic neuropathy:42:0.7995	0.7995	42
DAN	DAN:13	diazoacetyl-DL-norleucine methyl ester:13:0.5335	0.5335	13
DAOC	DAOC:10	Deacetoxycephalosporin C:10:0.5856	0.5856	10
DAOCS	DAOCS:17	deacetoxycephalosporin C synthase:17:0.7407	0.7407	17
DAP3	DAP3:9|Dap-3:2	death-associated protein 3:11:0.6182	0.6182	11
D-AP5	D-AP5:15	D-2-amino-5-phosphonovalerate:15:0.1037	0.1037	15
D-AP5	D-AP5:3	NMDA receptor antagonist D-2-amino-5-phosphonopentanoate:3:0.3728	0.3728	3
DAPA	DAPA:17	Diaminopimelic acid:17:0.2994	0.2994	17
DAPC	DAPC:12	dystrophin-associated protein complex:12:0.6460	0.6460	12
DAPI	DAPI:219	4',6-diamidino-2-phenylindole:174:0.3446|4'-6-diamidino-2-phenylindole:33:0.0618|4',6'-diamidino-2-phenylindole:12:0.0219	0.3446	219
DAPI	DAPI:11	4'6-diamidino-2-phenylindole:11:0.0199	0.0199	11
DAPI	DAPI:9	diamidino-2-phenylindole:9:0.0159	0.0159	9
DAPK	DAPK:37|DAPk:2|DAP-K:1	death-associated protein kinase:40:0.8142	0.8142	40
D-APV	D-APV:2	NMDA receptor antagonist D-2-amino-5-phosphonovalerate:2:0.3728	0.3728	2
DAPs	DAPs:14	depolarizing afterpotentials:14:0.7909	0.7909	14
DAPs	DAPs:25	dystrophin-associated proteins:25:0.6240	0.6240	25
DAP	DAP:22|Dap:2	1,3-diaminopropane:24:0.0289	0.0289	24
DAP	DAP:32	2,6-diaminopurine:32:0.0389	0.0389	32
DAP	DAP:35	3,4-diaminopyridine:35:0.0427	0.0427	35
DAP	DAP:23|dap:1	after pollination:24:0.8768	0.8768	24
DAP	DAP:12	days after planting:12:0.6460	0.6460	12
DAP	DAP:30	death-associated protein:24:0.2852|death associated protein:6:0.1543	0.2852	30
DAP	DAP:25	depolarizing afterpotential:25:0.8186	0.8186	25
DAP	DAP:15	diaminopimelate:15:0.0176	0.0176	15
DAP	DAP:38|dap:2|Dap:1	diaminopimelic acid:41:0.3996	0.3996	41
DAP	DAP:10	dipeptidyl aminopeptidase:10:0.5000	0.5000	10
DAP	DAP:102	dose-area product:82:0.7056|dose area product:20:0.8525	0.8525	102
DAP	DAP:10	Draw-a-Person:10:0.0113	0.0113	10
DAP	DAP:9	Draw-A-Person test:9:0.5470	0.5470	9
DAP	DAP:11	dystrophin-associated protein:11:0.0778	0.0778	11
DAP	DAP:10	phosphate:10:0.0113	0.0113	10
DAQ	DAQ:14	Questionnaire:14:0.4194	0.4194	14
DARP	DARP:8	dopamine-releasing protein:8:0.3463	0.3463	8
DARP	DARP:14	Drug Abuse Reporting Program:14:0.7909	0.7909	14
DARR	DARR:10	direct antiglobulin rosetting reaction:10:0.6794	0.6794	10
DAR	DAR:12	differential absorption ratio:12:0.4557	0.4557	12
DAR	DAR:6|DA-R:2|DAr:1	dopamine receptor:9:0.3945	0.3945	9
DAR	DAR:6	dual asthmatic response:6:0.2827	0.2827	6
DAS28	DAS28:40|DAS-28:2	Disease Activity Score:42:0.9291	0.9291	42
DAS28	DAS28:7	Disease Activity Score in 28 joints:7:0.6411	0.6411	7
DASE	DASE:17	dobutamine-atropine stress echocardiography:17:0.5760	0.5760	17
DASH-II	DASH-II:8	Diagnostic Assessment for the Severely Handicapped-II:8:0.7103	0.7103	8
DASH	DASH:1	arm shoulder and hand questionnaire:1:0.6411	0.6411	1
DASH	DASH:62	Dietary Approaches to Stop Hypertension:62:0.9519	0.9519	62
DASH	DASH:1	Disability of the Arm Shoulder and Hand:1:0.2639	0.2639	1
DASI	DASI:22	Duke Activity Status Index:22:0.8657	0.8657	22
DASO2	DASO2:9	diallyl sulfone:9:0.6794	0.6794	9
D-Asp	D-Asp:26|D-ASP:2|d-Asp:1|D-asp:1|d-ASP:1	D-aspartate:31:0.3093	0.3093	31
D-Asp	D-Asp:24|D-ASP:2|DAsp:1	D-aspartic acid:27:0.6455	0.6455	27
DASS	DASS:10	Depression Anxiety Stress Scales:10:0.7103	0.7103	10
DAST	DAST:8	Drug Abuse Screening Test:8:0.6411	0.6411	8
DAS	DAS:9	decay-associated spectra:9:0.3945	0.3945	9
DAS	DAS:59	Dental Anxiety Scale:59:0.7824	0.7824	59
DAS	DAS:18	developmental apraxia of speech:18:0.8365	0.8365	18
DAS	DAS:102	diallyl sulfide:102:0.9534	0.9534	102
DAS	DAS:11	Disability Assessment Schedule:11:0.7357	0.7357	11
DAS	DAS:8	disc angiogenesis system:8:0.6411	0.6411	8
DAS	DAS:63	disease activity score:63:0.9526	0.9526	63
DAs	DAs:8	Dopamine agonists:8:0.5006	0.5006	8
DAS	DAS:8	double antibody sandwich:8:0.6411	0.6411	8
DAS	DAS:26	Dyadic Adjustment Scale:26:0.8251	0.8251	26
DAS	DAS:4	T-2 toxin and diacetoxyscirpenol:4:0.2500	0.2500	4
DAT1	DAT1:21|DAT-1:1	dopamine transporter:22:0.8657	0.8657	22
DAT1	DAT1:43|DAT-1:1	dopamine transporter gene:44:0.9323	0.9323	44
DATCAP	DATCAP:12	Drug Abuse Treatment Cost Analysis Program:12:0.7571	0.7571	12
DATOS	DATOS:21	drawn from electronic files of data from the Drug Abuse Treatment outcome Study:21:0.8594	0.8594	21
DATOS	DATOS:12	Drug Abuse Treatment Outcome Studies:12:0.7571	0.7571	12
DATs	DATs:24	dopamine transporters:24:0.7593	0.7593	24
DAT	DAT:23	Alzheimer's disease:23:0.7400	0.7400	23
DAT	DAT:14	Alzheimer-type dementia:9:0.1809|Alzheimer's type dementia:5:0.1132	0.1809	14
DAT	DAT:3	cytosine arabinoside and 6-thioguanine:3:0.5290	0.5290	3
DAT	DAT:12	days after treatment:12:0.3813	0.3813	12
DAT	DAT:547	dementia of the Alzheimer type:424:0.9821|dementia of the Alzheimer's type:113:0.9634|dementia of the Alzheimer-type:10:0.7357	0.9821	547
DAT	DAT:8	digital audio tape:8:0.6411	0.6411	8
DAT	DAT:114	direct agglutination test:114:0.9579	0.9579	114
DAT	DAT:158	direct antiglobulin test:144:0.9456|Direct Antiglobulin Tests:14:0.7909	0.9456	158
DAT	DAT:21	dopamine:21:0.0097	0.0097	21
DAT	DAT:668|Dat:1|dat:1|DaT:1|DA-T:1	dopamine transporter:629:0.8512|dopamine transporters:43:0.7572	0.8512	672
DAU	DAU:19|Dau:3	daunomycin:22:0.2165	0.2165	22
DAU	DAU:31|Dau:11	daunorubicin:42:0.4227	0.4227	42
Dau	Dau:17	dauricine:17:0.1649	0.1649	17
DAVFs	DAVFs:50|dAVFs:3|DAVFS:1	dural arteriovenous fistulas:54:0.8862	0.8862	54
DAVFs	DAVFs:11|dAVFs:1|d-AVFs:1	dural arteriovenous fistulae:13:0.7753	0.7753	13
DAVF	DAVF:54|dAVF:5|D-AVF:1	dural arteriovenous fistula:60:0.8014	0.8014	60
DAVF	DAVF:15|dAVF:1	dural arteriovenous fistulae:16:0.8165	0.8165	16
DAVM	DAVM:14|dAVM:2	dural arteriovenous malformation:16:0.8165	0.8165	16
DAWN	DAWN:26	Drug Abuse Warning Network:26:0.8861	0.8861	26
DAZ	DAZ:28	Deleted in Azoospermia:28:0.8941	0.8941	28
DAI	DAI:27|dai:2	after infection:29:0.9011	0.9011	29
DAI	DAI:41|dai:1	days after inoculation:42:0.7750	0.7750	42
DAI	DAI:38	Dental Aesthetic Index:38:0.9217	0.9217	38
DAI	DAI:115	diffuse axonal injury:115:0.9740	0.9740	115
DAI	DAI:32	disease activity index:32:0.7782	0.7782	32
DAI	DAI:13	Drug Attitude Inventory:13:0.7753	0.7753	13
DAMB	DAMB:4|DAmB:3|d-AmB:2|D-AmB:1	amphotericin B:10:0.5856	0.5856	10
DA	DA:33	3H-dopamine:24:0.0018|[3H]-dopamine:9:0.0006	0.0018	33
DA	DA:14	activity:14:0.0010	0.0010	14
d-A	d-A:11	d-amphetamine:11:0.0008	0.0008	11
da	da:31|Da:8	daltons:29:0.0022|Dalton:10:0.0007	0.0022	39
DA	DA:119	Dark Agouti:110:0.9298|Dark-Agouti:9:0.0006	0.9298	119
da	da:23|Da:2|DA:1|dA:1	daughterless:27:0.0021	0.0021	27
DA	DA:17	degree of acetylation:17:0.5760	0.5760	17
DA	DA:21	delayed alternation:21:0.7865	0.7865	21
DA	DA:14	descending aorta:14:0.3383	0.3383	14
DA	DA:10	diagnostic accuracy:10:0.5000	0.5000	10
DA	DA:9	Diels-Alder:9:0.0006	0.0006	9
DA	DA:16	diffuse adherence:16:0.7261	0.7261	16
DA	DA:6	digital angiography:6:0.2243	0.2243	6
DA	DA:10	direct agglutination:10:0.7103	0.7103	10
DA	DA:12	directional asymmetry:12:0.7571	0.7571	12
DA	DA:9	directional atherectomy:9:0.6794	0.6794	9
DA	DA:36	discriminant analysis:36:0.4471	0.4471	36
DA	DA:8	displaced abomasum:8:0.5006	0.5006	8
DA	DA:8	dissecting aneurysm:8:0.4102	0.4102	8
DA	DA:11	divided attention:11:0.5355	0.5355	11
DA	DA:46	domoic acid:46:0.4882	0.4882	46
DA	DA:10468|Da:3|da:1	dopamine:10472:0.8169	0.8169	10472
DA	DA:26	dopamine agonists:14:0.6173|dopamine agonist:12:0.6460	0.6460	26
DA	DA:523	dopaminergic:523:0.0407	0.0407	523
DA	DA:8	dorsal aorta:8:0.1061	0.1061	8
DA	DA:131	ductus arteriosus:131:0.9772	0.9772	131
DA	DA:12	duodenal atresia:12:0.7571	0.7571	12
DA	DA:24	release of [3H]dopamine:24:0.1734	0.1734	24
DBA/2	DBA/2:10	allogeneic:10:0.0682	0.0682	10
DBAA	DBAA:11	dibromoacetic acid:11:0.6182	0.6182	11
DBAN	DBAN:13	dibromoacetonitrile:13:0.9231	0.9231	13
DBAs	DBAs:7	dentin bonding agents:7:0.2452	0.2452	7
DBA	DBA:8	bonding agents:8:0.4102	0.4102	8
DBA	DBA:25	Diamond-Blackfan anaemia:25:0.6873	0.6873	25
DBA	DBA:60	Diamond-Blackfan anemia:60:0.7703	0.7703	60
DBA	DBA:17	dibenz[a,h]anthracene:17:0.0216	0.0216	17
DBA	DBA:19	Dibromoacetic acid:19:0.3871	0.3871	19
DBA	DBA:13	dibutylamine:13:0.0162	0.0162	13
DBA	DBA:80	Dolichos biflorus:80:0.8888	0.8888	80
DBA	DBA:182	Dolichos biflorus agglutinin:182:0.9150	0.9150	182
DBA	DBA:9	Dolichos biflorus lectin:9:0.6794	0.6794	9
DBBF-Hb	DBBF-Hb:5	diaspirin cross-linked hemoglobin:5:0.1973	0.1973	5
DBB	DBB:59|dbB:6	diagonal band of Broca:65:0.9275	0.9275	65
DBCG	DBCG:42	Danish Breast Cancer Cooperative Group:42:0.9291	0.9291	42
DBCM	DBCM:13	dibromochloromethane:13:0.9231	0.9231	13
DBCP	DBCP:110	1,2-dibromo-3-chloropropane:110:0.6369	0.6369	110
DBCP	DBCP:46	dibromochloropropane:46:0.2560	0.2560	46
DBCs	DBCs:8	Depolarizing bipolar cells:8:0.5006	0.5006	8
DBC	DBC:34	7H-dibenzo[c,g]carbazole:34:0.2558	0.2558	34
DBC	DBC:8	Developmental Behaviour Checklist:8:0.6411	0.6411	8
DBDs	DBDs:25|Dbds:1	DNA binding domains:14:0.6173|DNA-binding domains:12:0.2083	0.6173	26
DBD	DBD:38	dibromodulcitol:38:0.1014	0.1014	38
DBD	DBD:21	disruptive behavior disorder:12:0.7571|disruptive behavior disorders:9:0.6794	0.7571	21
DBD	DBD:245|dbd:1	DNA-binding domain:121:0.4316|DNA binding domain:114:0.9447|DNA-binding domains:11:0.4232	0.9447	246
DBE	DBE:53	1,2-dibromoethane:53:0.4602	0.4602	53
DBE	DBE:10	dibasic esters:10:0.7103	0.7103	10
DbE	DbE:8|DBE:1	Dobutamine echocardiography:9:0.4587	0.4587	9
DBF	DBF:8	blood flow:8:0.5006	0.5006	8
DBF	DBF:10	dibenzo[a,e]fluoranthene:10:0.1304	0.1304	10
DBH	DBH:25	1,3-dibromo-5,5-dimethylhydantoin:25:0.0206	0.0206	25
dbh	dbh:7|DBH:6	diameter at breast height:13:0.8045	0.8045	13
DBH	DBH:20	dopamine-B-hydroxylase:10:0.0084|dopamine B-hydroxylase:10:0.7103	0.7103	20
DBH	DBH:28|DbH:1	dopamine beta hydroxylase:29:0.8978	0.8978	29
DBH	DBH:11	dopamine-beta-hydroxylase activity:11:0.6182	0.6182	11
DBH	DBH:7	dopamine beta-hydroxylase gene:7:0.5926	0.5926	7
DBH	DBH:12	dot blot hybridization:12:0.6460	0.6460	12
DBI	DBI:180	diazepam binding inhibitor:135:0.9412|Diazepam-binding inhibitor:45:0.1713	0.9412	180
DBI	DBI:15	diffuse brain injury:15:0.8045	0.8045	15
DBMC	DBMC:11	bone marrow cell:11:0.7357	0.7357	11
DBMC	DBMC:10	donor bone marrow cells:10:0.4363	0.4363	10
DBMIB	DBMIB:21	2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone:21:0.4667	0.4667	21
DBMIB	DBMIB:12	dibromothymoquinone:12:0.2222	0.2222	12
DBMS	DBMS:20	management system:20:0.8525	0.8525	20
DBM	DBM:139	demineralized bone matrix:139:0.8269	0.8269	139
DBM	DBM:12	dibenzoylmethane:12:0.0377	0.0377	12
DBM	DBM:9	dibromomethane:9:0.0274	0.0274	9
DBM	DBM:9	dopamine beta-monooxygenase:9:0.5470	0.5470	9
DBNBS	DBNBS:9	3,5-dibromo-4-nitrosobenzene sulfonate:9:0.4587	0.4587	9
DBNBS	DBNBS:8|DB-NBS:1	3,5-dibromo-4-nitrosobenzenesulfonic acid:9:0.2500	0.2500	9
DBN	DBN:10	dibutylnitrosamine:10:0.1250	0.1250	10
DBN	DBN:13	downbeat nystagmus:13:0.4849	0.4849	13
DBN	DBN:11	N,N-dibutylnitrosamine:11:0.1389	0.1389	11
DBPCFC	DBPCFC:19	double-blind placebo-controlled food challenge:16:0.8620|double-blind placebo-controlled food challenges:3:0.7096	0.8620	19
DBPC	DBPC:3	double-blind placebo-controlled:3:0.6794	0.6794	3
DBP-MAF	DBP-MAF:5|DBP-maf:2	vitamin D-binding protein-macrophage activating factor:7:0.5926	0.5926	7
DBPs	DBPs:73|Dbps:1	disinfection by-products:74:0.9353	0.9353	74
DBPs	DBPs:27	disinfection byproducts:27:0.8312	0.8312	27
DBP	DBP:10	adenovirus DNA-binding protein:10:0.0730	0.0730	10
DBP	DBP:34	demineralized bone powder:34:0.7898	0.7898	34
DBP	DBP:90	di-n-butyl phthalate:90:0.4022	0.4022	90
DBP	DBP:13	dibenzo[a,l]pyrene:13:0.0039	0.0039	13
DBP	DBP:73	dibutyl phthalate:73:0.3175	0.3175	73
DBP	DBP:25	Dibutylphthalate:25:0.0077	0.0077	25
DBP	DBP:10	disinfection by-product:10:0.7103	0.7103	10
DBP	DBP:54|dbp:1	DNA binding protein:45:0.1905|DNA-binding proteins:10:0.2873	0.2873	55
DBP	DBP:180	vitamin D-binding protein:101:0.8755|Vitamin D binding protein:79:0.9036	0.9036	180
DBQ	DBQ:9	Debrisoquine:9:0.3333	0.3333	9
DBQ	DBQ:5	Driver Behaviour Questionnaire:5:0.4422	0.4422	5
DBS	DBS:409	deep brain stimulation:409:0.9705	0.9705	409
DBS	DBS:7	Dental Beliefs Survey:7:0.5926	0.5926	7
DBS	DBS:9	dentin bonding systems:9:0.3945	0.3945	9
DBS	DBS:16	dibutyl sebacate:16:0.7261	0.7261	16
DBS	DBS:48	Dried blood spot:24:0.8768|Dried blood spots:24:0.8038	0.8768	48
DBS	DBS:6	duodenal bicarbonate secretion:6:0.3728	0.3728	6
DBTC	DBTC:36	dichloride:36:0.7447	0.7447	36
DBW	DBW:7|dBW:2	body weight:9:0.6794	0.6794	9
DB[a,h]A	DB[a,h]A:10|DB[a,H]A:1	dibenz[a,h]anthracene:11:0.6250	0.6250	11
DB[a,l]P	DB[a,l]P:58	dibenzo[a,l]pyrene:58:0.9048	0.9048	58
DBcAMP	DBcAMP:7|dbcAMP:3|dBcAMP:1|db-cAMP:1	adenosine 3':5'-monophosphate:12:0.6460	0.6460	12
DBcAMP	DBcAMP:30|dbcAMP:8|db-cAMP:5|DbcAMP:3|dBcAMP:1|DB-cAMP:1	dibutyryl adenosine 3',5'-cyclic monophosphate:48:0.6770	0.6770	48
dbcAMP	dbcAMP:10|DBcAMP:2|dB-cAMP:2|dBcAMP:2|DbcAMP:1|dbc-AMP:1	dibutyryl cyclic adenosine 3',5'-monophosphate:18:0.5560	0.5560	18
dbcAMP	dbcAMP:33|db-cAMP:18|DBcAMP:15|dBcAMP:7|DbcAMP:5|dB-cAMP:3|DB-cAMP:2|DBc-AMP:1|dbc-AMP:1	dibutyryl cyclic adenosine monophosphate:85:0.8075	0.8075	85
dbcAMP	dbcAMP:207|DBcAMP:82|db-cAMP:58|dBcAMP:43|dB-cAMP:8|DB-cAMP:8|DbcAMP:7|dbc-AMP:6|Db-cAMP:5|DBCAMP:1|Dbc-AMP:1|DBC-AMP:1|DBc-AMP:1|db-c-AMP:1	dibutyryl cyclic AMP:429:0.9161	0.9161	429
dbcGMP	dbcGMP:8|db-cGMP:6|DbcGMP:2|db-c-GMP:1|DB-cGMP:1|Db-cGMP:1	dibutyryl cyclic GMP:19:0.7044	0.7044	19
dbcGMP	dbcGMP:4|dbc-GMP:1|DBcGMP:1	dibutyryl cyclic guanosine monophosphate:6:0.3728	0.3728	6
Db	Db:31|DB:2	body density:33:0.7841	0.7841	33
DB	DB:13	database:13:0.0163	0.0163	13
dB	dB:52|db:1	decibels:38:0.0503|decibel:15:0.0190	0.0503	53
DB	DB:10	decidua basalis:10:0.7103	0.7103	10
DB	DB:16	deep breathing:16:0.4274	0.4274	16
DB	DB:13	dense bodies:13:0.3554	0.3554	13
db	db:11|DB:9|Db:6	diabetic:26:0.0340	0.0340	26
DB	DB:8	diaphragmatic breathing:8:0.1061	0.1061	8
db	db:14|DB:4|dB:2	dibutyryl:20:0.0258	0.0258	20
DB	DB:13	didemnin B:13:0.4102	0.4102	13
DB	DB:10|dB:1	direct bilirubin:11:0.6182	0.6182	11
DB	DB:15|Db:2	dobutamine:17:0.0217	0.0217	17
DB	DB:6	dorsal bodies:6:0.0522	0.0522	6
DB	DB:11|db:2	downstream box:13:0.5934	0.5934	13
DCAD	DCAD:10	dietary cation-anion difference:10:0.7103	0.7103	10
DCAN	DCAN:11	Dichloroacetonitrile:11:0.8333	0.8333	11
DCA	DCA:20	3,4-dichloroaniline:20:0.0200	0.0200	20
DCA	DCA:12	analysis:12:0.0116	0.0116	12
DCA	DCA:13	deoxycholate:13:0.0126	0.0126	13
DCA	DCA:167	deoxycholic acid:167:0.5188	0.5188	167
DCA	DCA:5	desoxycholate citrate agar:5:0.4422	0.4422	5
DCA	DCA:254|-DCA:1	Dichloroacetate:255:0.2668	0.2668	255
DCA	DCA:100	dichloroacetic acid:100:0.2920	0.2920	100
DCA	DCA:148	Directional coronary atherectomy:148:0.9569	0.9569	148
DCBE	DCBE:29	Double contrast barium enema:29:0.8941	0.8941	29
DCBE	DCBE:5	double-contrast barium enema examination:5:0.2818	0.2818	5
DCB	DCB:10	1,2-dichlorobenzene:10:0.0573	0.0573	10
DCB	DCB:20	1,4-Dichlorobenzene:20:0.1210	0.1210	20
DCB	DCB:18	3,3'-dichlorobenzidine:18:0.1083	0.1083	18
DCB	DCB:10	3',4'-dichlorobenzamil:10:0.0573	0.0573	10
DCB	DCB:9	Dichlorobenzamil:9:0.0510	0.0510	9
DCCD	DCCD:8	Dicyclohexyl carbodiimide:8:0.1895	0.1895	8
DCCD	DCCD:147	dicyclohexylcarbodiimide:147:0.3887	0.3887	147
DCCD	DCCD:6	N,N'-dicyclohexyl carbodiimide:6:0.0807	0.0807	6
DCCD	DCCD:138	N,N'-dicyclohexylcarbodiimide:138:0.3673	0.3673	138
DCCT	DCCT:167	Diabetes Control and Complications Trial:167:0.9710	0.9710	167
DCCs	DCCs:24	day-care centers:14:0.3383|day care centers:10:0.7103	0.7103	24
DCC	DCC:8	data coordinating center:8:0.6411	0.6411	8
DCC	DCC:30	day care center:12:0.7571|day-care centers:11:0.2972|day care centers:7:0.5926	0.7571	30
DCC	DCC:17|Dcc:1	deleted in colon cancer:18:0.8525	0.8525	18
DCC	DCC:58|Dcc:2|dcc:1	deleted in colorectal cancer:61:0.9229	0.9229	61
DCC	DCC:25	deleted in colorectal carcinoma:25:0.8941	0.8941	25
DCC	DCC:148	dextran-coated charcoal:119:0.7087|Dextran coated charcoal:29:0.8978	0.8978	148
DCC	DCC:8	dextran-coated charcoal assay:8:0.4102	0.4102	8
DCC	DCC:14	dextran-coated charcoal method:14:0.6173	0.6173	14
DCC	DCC:34	dicyclohexylcarbodiimide:34:0.0551	0.0551	34
DCC	DCC:10	direct current cardioversion:10:0.7103	0.7103	10
DCC	DCC:10	N,N'-dicyclohexylcarbodiimide:10:0.0150	0.0150	10
DCD	DCD:5	after cardiac death:5:0.4422	0.4422	5
DCD	DCD:72	Developmental Coordination Disorder:72:0.9585	0.9585	72
DCE-MRI	DCE-MRI:42|DCEMRI:3	dynamic contrast-enhanced magnetic resonance imaging:45:0.8964	0.8964	45
DCE-MRI	DCE-MRI:18|DCEMRI:2	dynamic contrast-enhanced MRI:20:0.8525	0.8525	20
DCE	DCE:38	1,1-dichloroethylene:38:0.1561	0.1561	38
DCE	DCE:45	1,2-Dichloroethane:45:0.1857	0.1857	45
DCE	DCE:9	dichloroethane:9:0.0338	0.0338	9
DCE	DCE:5	double-contrast barium enema:5:0.4422	0.4422	5
DCE	DCE:6	double-contrast enema:6:0.1543	0.1543	6
DCE	DCE:15	dynamic contrast-enhanced:15:0.8045	0.8045	15
DCFH	DCFH:29	2',7'-dichlorofluorescin:29:0.2353	0.2353	29
DCFH	DCFH:25	dichlorofluorescin:25:0.2017	0.2017	25
dCF	dCF:5|DCF:3|dcf:1	2'deoxycoformycin:9:0.0173	0.0173	9
dCF	dCF:4	adenosine deaminase inhibitor 2'-deoxycoformycin:4:0.6386	0.6386	4
DCF	DCF:7	conversion factor:7:0.3524	0.3524	7
dCF	dCF:29|DCF:25|dCf:4|dcf:1	deoxycoformycin:59:0.1253	0.1253	59
DCF	DCF:10	diclofenac:10:0.0194	0.0194	10
DCF	DCF:10	fluorescent 2',7'-dichlorofluorescein:10:0.0748	0.0748	10
DCF	DCF:16	fluorescent dichlorofluorescein:16:0.1031	0.1031	16
DCG-IV	DCG-IV:12	(2S,1'R,2'R,3'R)-2-(2,3-Dicarboxycyclopropyl)glycine:12:0.1410	0.1410	12
DCG-IV	DCG-IV:14	(2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine:14:0.1667	0.1667	14
DCGs	DCGs:8	Diagnostic Cost Groups:8:0.6411	0.6411	8
DCHA	DCHA:9	dicyclohexylamine:9:0.3200	0.3200	9
DCH	DCH:36	delayed cutaneous hypersensitivity:36:0.8716	0.8716	36
DCIA	DCIA:12	deep circumflex iliac artery:12:0.7571	0.7571	12
DCIP	DCIP:12	2,6-dichloroindophenol:12:0.1481	0.1481	12
DCIP	DCIP:20	2,6-dichlorophenolindophenol:20:0.2346	0.2346	20
DCIP	DCIP:5	dichlorophenol indophenol:5:0.0736	0.0736	5
DCIP	DCIP:9	dichlorophenolindophenol:9:0.0988	0.0988	9
DCIS	DCIS:11	carcinomas:11:0.0090	0.0090	11
DCIS	DCIS:917	ductal carcinoma in situ:883:0.9489|ductal carcinoma-in-situ:21:0.6812|ductal carcinoma in-situ:13:0.7753	0.9489	917
DCIS	DCIS:15	ductal carcinoma in situ of the breast:15:0.7909	0.7909	15
DCIS	DCIS:1	ductal carcinoma of breast:1:0.1973	0.1973	1
DCIS	DCIS:14	intraductal carcinoma:14:0.2758	0.2758	14
DCI	DCI:26	3,4-dichloroisocoumarin:26:0.1295	0.1295	26
DCI	DCI:41	decompression illness:41:0.9274	0.9274	41
DCI	DCI:12	delayed cerebral ischemia:12:0.7571	0.7571	12
DC-LD	DC-LD:9	Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation:9:0.6794	0.6794	9
DCLHb	DCLHb:7	Diaspirin cross-linked haemoglobin:7:0.4438	0.4438	7
DCLHb	DCLHb:70|DCLHB:1|DCL-Hb:1	diaspirin cross-linked hemoglobin:72:0.8934	0.8934	72
DCLHb	DCLHb:32|DCLHB:1	Diaspirin crosslinked hemoglobin:33:0.9072	0.9072	33
DCLSG	DCLSG:9	Dutch Childhood Leukemia Study Group:9:0.6794	0.6794	9
DCL	DCL:41	diffuse cutaneous leishmaniasis:41:0.8263	0.8263	41
DCL	DCL:4	metabolite descarboethoxyloratadine:4:0.0736	0.0736	4
DCMB	DCMB:9	2,3-dichloro-alpha-methylbenzylamine:9:0.6667	0.6667	9
DCMD	DCMD:11	descending contralateral movement detector:11:0.7357	0.7357	11
DCMU	DCMU:11	3-(3,4-dichlorophenyl)-1,1-dimethyl urea:11:0.2764	0.2764	11
DCMU	DCMU:57	3-(3,4-dichlorophenyl)-1,1-dimethylurea:57:0.4746	0.4746	57
DCM	DCM:7	Dementia Care Mapping:7:0.5926	0.5926	7
DCM	DCM:157	dichloromethane:157:0.1102	0.1102	157
DCM	DCM:1045	dilated cardiomyopathy:1035:0.9585|dilated cardiomyopathies:10:0.5000	0.9585	1045
DCNP	DCNP:40	2,6-dichloro-4-nitrophenol:40:0.9048	0.9048	40
DCN	DCN:44|dcn:1	deep cerebellar nuclei:45:0.9338	0.9338	45
DCN	DCN:196	dorsal cochlear nucleus:196:0.9756	0.9756	196
DCN	DCN:73|DCn:1	dorsal column nuclei:74:0.9602	0.9602	74
Dco	DCO:4|Dco:4	carbon monoxide diffusing capacity:8:0.6411	0.6411	8
DCO	DCO:8	death certificate only:8:0.6411	0.6411	8
DCPA	DCPA:10	dicalcium phosphate anhydrous:10:0.5000	0.5000	10
DCPD	DCPD:53	dicalcium phosphate dihydrate:53:0.8597	0.8597	53
DCPIP	DCPIP:9	dichlorophenol indophenol:9:0.3069	0.3069	9
DCPS	DCPS:9	dorsal column postsynaptic:9:0.6794	0.6794	9
DCP	DCP:10	1,2-Dichloropropane:10:0.0201	0.0201	10
DCP	DCP:15	1,3-dichloropropene:15:0.0312	0.0312	15
DCP	DCP:34	2,4-dichlorophenol:34:0.0759	0.0759	34
Dcp	Dcp:7	D-alanyl carrier protein:7:0.3524	0.3524	7
DCP	DCP:46	Des-gamma-carboxy prothrombin:46:0.7881	0.7881	46
DCP	DCP:13	Des-gamma-carboxyprothrombin:13:0.0268	0.0268	13
DCP	DCP:21	dicalcium phosphate:21:0.3221	0.3221	21
DCP	DCP:12	dicetyl phosphate:12:0.1262	0.1262	12
DCP	DCP:23	dicetylphosphate:23:0.0491	0.0491	23
DCP	DCP:15	digestible crude protein:15:0.7096	0.7096	15
DCP	DCP:13	Diphenylcyclopropenone:13:0.0268	0.0268	13
DCP	DCP:39	dynamic compression plate:39:0.9237	0.9237	39
DCQ	DCQ:15	desethylchloroquine:15:0.4375	0.4375	15
DcR1	DcR1:9	decoy receptor 1:9:0.6794	0.6794	9
DCRV	DCRV:16	double-chambered right ventricle:16:0.5171	0.5171	16
DCR	DCR:145	dacryocystorhinostomy:145:0.4866	0.4866	145
DCR	DCR:15	decidual cell reaction:15:0.8045	0.8045	15
DCR	DCR:9	decidual cell response:9:0.6794	0.6794	9
DCR	DCR:20	direct cortical response:20:0.8525	0.8525	20
DCR	DCR:11	dominant control region:11:0.6182	0.6182	11
DCR	DCR:7	ICD-10 Diagnostic Criteria for Research:7:0.4438	0.4438	7
DCS	DCS:259	decompression sickness:259:0.9884	0.9884	259
DCs	DCs:2646|DCS:2|Dcs:1	dendritic cells:2649:0.9860	0.9860	2649
DCS	DCS:8|dCS:1	distal coronary sinus:9:0.5470	0.5470	9
DCs	DCs:9|DCS:1	dorsal columns:10:0.7103	0.7103	10
DCS	DCS:26	dorsal column stimulation:26:0.8861	0.8861	26
DCS	DCS:26	dynamic condylar screw:26:0.7760	0.7760	26
DCS	DCS:2|D-CS:1	partial agonist D-cycloserine:3:0.1132	0.1132	3
DCS	DCS:12	syndrome:12:0.0034	0.0034	12
DCT	DCT:9|dCT:2|d-CT:2	computed tomography:13:0.5335	0.5335	13
DCT	DCT:6	direct contact test:6:0.5290	0.5290	6
DCt	DCt:9|dct:1|DCT:1	direct current:11:0.7357	0.7357	11
DCT	DCT:39	discrete cosine transform:39:0.9237	0.9237	39
DCT	DCT:132|dct:1	distal convoluted tubule:106:0.9406|distal convoluted tubules:27:0.8903	0.9406	133
DCT	DCT:19|Dct:12|dct:1	dopachrome tautomerase:32:0.7782	0.7782	32
DCT	DCT:7|dCT:1|D-CT:1	dynamic CT:9:0.2500	0.2500	9
DCVC	DCVC:68	S-(1,2-dichlorovinyl)-L-cysteine:68:0.5776	0.5776	68
DCVG	DCVG:14	S-(1,2-dichlorovinyl)glutathione:14:0.6842	0.6842	14
DCVs	DCVs:16|dcvs:2	dense core vesicles:18:0.8365	0.8365	18
DCVs	DCVs:13	dense-cored vesicles:13:0.1348	0.1348	13
DCV	DCV:24|dcv:1	dense core vesicles:11:0.7357|dense-core vesicles:8:0.1004|dense-core vesicle:6:0.2243	0.7357	25
DCV	DCV:11	Distribution of conduction velocities:11:0.2293	0.2293	11
DCV	DCV:13	distribution of nerve conduction velocities:13:0.6701	0.6701	13
DCV	DCV:13	Drosophila C virus:13:0.7909	0.7909	13
DCX	DCX:49|Dcx:5	doublecortin:54:0.7465	0.7465	54
dC	dC:11	2'-deoxycytidine:11:0.0018	0.0018	11
DC	DC:19	control:19:0.0033	0.0033	19
DC	DC:40	degree of conversion:40:0.7653	0.7653	40
DC	DC:3484	dendritic cells:2901:0.9790|dendritic cell:573:0.9573|Dendritic-cell:10:0.0016	0.9790	3484
DC	DC:26	deoxycholate:26:0.0045	0.0045	26
DC	DC:10	deoxycholic acid:10:0.4363	0.4363	10
dC	dC:34	deoxycytidine:34:0.0060	0.0060	34
DC	DC:17|Dc:1	dichorionic:18:0.0031	0.0031	18
DC	DC:38	diene conjugates:28:0.5837|diene conjugate:10:0.7103	0.7103	38
DC	DC:70	diffusion chambers:40:0.9256|diffusion chamber:30:0.8032	0.9256	70
DC	DC:45	dilated cardiomyopathy:45:0.8649	0.8649	45
DC	DC:8	Direct compression:8:0.2090	0.2090	8
DC	DC:352|dc:39|d-c:1	direct current:350:0.9479|direct-current:42:0.0074	0.9479	392
DC	DC:9	distensibility:9:0.0015	0.0015	9
DC	DC:30	distensibility coefficient:30:0.6484	0.6484	30
DC	DC:62	dorsal column:49:0.8753|dorsal columns:13:0.7753	0.8753	62
DC	DC:14	dorsal cortex:14:0.6911	0.6911	14
DC	DC:30|Dc:4	doxycycline:34:0.0060	0.0060	34
DC	DC:17	Dupuytren's contracture:17:0.7407	0.7407	17
DC	DC:6	dynamic compression:6:0.0899	0.0899	6
DC	DC:61	dyskeratosis congenita:61:0.9511	0.9511	61
DD5	DD5:9	double diffusion:9:0.6794	0.6794	9
DDAH	DDAH:54	Dimethylarginine dimethylaminohydrolase:54:0.8196	0.8196	54
DDAVP	DDAVP:101|dDAVP:28|d-DAVP:2|ddavp:1|dD-AVP:1	1-deamino-8-D-arginine vasopressin:103:0.2385|1-deamino-8-d-arginine-vasopressin:30:0.0315	0.2385	133
DDAVP	DDAVP:110|dDAVP:29	1-desamino-8-D-arginine vasopressin:125:0.2997|1-desamino-8-D-arginine-vasopressin:14:0.0141	0.2997	139
DDAVP	DDAVP:72|dDAVP:3	desmopressin acetate:75:0.9607	0.9607	75
DDAVP	DDAVP:8|dDAVP:3	vasopressin analogue:11:0.5355	0.5355	11
ddA	ddA:32|DDA:9	2',3'-dideoxyadenosine:41:0.1399	0.1399	41
DDA	DDA:5|ddA:1	cyclase inhibitor 2',5'-dideoxyadenosine:6:0.7103	0.7103	6
DDA	DDA:10|ddA:6	dideoxyadenosine:16:0.0490	0.0490	16
DDA	DDA:29	dimethyl dioctadecyl ammonium bromide:29:0.8941	0.8941	29
DDA	DDA:31	dimethyldioctadecylammonium bromide:31:0.2958	0.2958	31
DDA	DDA:8	disposition decomposition analysis:8:0.6411	0.6411	8
DDBJ	DDBJ:15	DNA Data Bank of Japan:15:0.8045	0.8045	15
DDB	DDB:9	biphenyl dimethyl dicarboxylate:9:0.6794	0.6794	9
DDB	DDB:8	damaged DNA-binding protein:8:0.3463	0.3463	8
DDB	DDB:8	dimethyl diphenyl bicarboxylate:8:0.6411	0.6411	8
DDCs	DDCs:8	dermal dendritic cells:8:0.5006	0.5006	8
ddC	ddC:9	2'3'-dideoxycytidine:9:0.0081	0.0081	9
DDC	DDC:11	3,5-diethoxycarbonyl-1,4-dihydrocollidine:11:0.0101	0.0101	11
DDC	DDC:11	analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine:11:0.2764	0.2764	11
DDC	DDC:5	dermal dendritic cells:5:0.2818	0.2818	5
DDC	DDC:8	diethyl dithiocarbamate:8:0.5006	0.5006	8
DDC	DDC:264|ddc:1	diethyldithiocarbamate:265:0.2659	0.2659	265
DDC	DDC:17	Diethyldithiocarbamic acid:17:0.8270	0.8270	17
DDC	DDC:97|Ddc:27	DOPA decarboxylase:124:0.7265	0.7265	124
Ddc	Ddc:15|DDC:1	DOPA decarboxylase gene:16:0.7261	0.7261	16
ddC	ddC:4	ZDV plus zalcitabine:4:0.0899	0.0899	4
DDDs	DDDs:52	defined daily doses:52:0.9438	0.9438	52
DDD	DDD:14	AV universal:14:0.2892	0.2892	14
DDD	DDD:150	defined daily doses:86:0.9449|Defined Daily Dose:64:0.9033	0.9449	150
DDD	DDD:12	degenerative disc disease:12:0.7571	0.7571	12
DDD	DDD:8	dense deposit disease:8:0.6411	0.6411	8
DDD	DDD:10	dichlorodiphenyldichloroethane:10:0.0184	0.0184	10
DDD	DDD:9	Digital Differential Display:9:0.6794	0.6794	9
DDD	DDD:50	dual-chamber:25:0.0491|dual chamber:25:0.8816	0.8816	50
DDD	DDD:14	dual chamber pacing:14:0.7909	0.7909	14
DDE	DDE:36	1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene:36:0.1190	0.1190	36
DDE	DDE:11	Developmental Defects of Enamel:11:0.6182	0.6182	11
DDE	DDE:11	ethylene:11:0.0340	0.0340	11
DDE	DDE:12	p,p'-dichlorodiphenyldichloroethylene:12:0.0374	0.0374	12
DDFS	DDFS:21	distant disease-free survival:21:0.8594	0.8594	21
DDFT	DDFT:22	deep digital flexor tendon:22:0.8657	0.8657	22
DDF	DDF:13	deep digital flexor:13:0.7753	0.7753	13
ddF	ddF:25|DDF:1	dideoxy fingerprinting:26:0.8861	0.8861	26
DDGS	DDGS:12	distillers dried grains with solubles:12:0.4557	0.4557	12
ddG	ddG:14	2',3'-dideoxyguanosine:14:0.2241	0.2241	14
DDH	DDH:112|ddh:1	Developmental dysplasia of the hip:113:0.9735	0.9735	113
DDH	DDH:13	dihydrodiol dehydrogenase:13:0.7753	0.7753	13
DDIA	DDIA:8	double determinant immunoassay:8:0.6411	0.6411	8
DDIs	DDIs:13|D-DIs:1	drug-drug interactions:14:0.6173	0.6173	14
ddI	ddI:123|DDI:13	2',3'-dideoxyinosine:136:0.2336	0.2336	136
ddI	ddI:227|DDI:25	didanosine:252:0.4360	0.4360	252
ddl	ddl:9	2',3'-dideoxyinosine:9:0.0988	0.0988	9
ddl	ddl:36	didanosine:36:0.4321	0.4321	36
DDME	DDME:11|dDME:1	diffuse diabetic macular edema:12:0.7571	0.7571	12
DDMS	DDMS:13	N-methylsulfonyl-12,12-dibromododec-11-enamide:13:0.3750	0.3750	13
DDPH	DDPH:9	hydrochloride:9:0.7273	0.7273	9
DDP	DDP:40	Cis-diamminedichloroplatinum:40:0.0622	0.0622	40
DDP	DDP:42	Cis-diamminedichloroplatinum(II):32:0.0494|cis-diamminedichloroplatinum II:10:0.3821	0.3821	42
DDP	DDP:4	Cis-dichlorodiammine platinum II:4:0.2327	0.2327	4
DDP	DDP:23	cis-dichlorodiammineplatinum(II):23:0.0351	0.0351	23
DDP	DDP:25	cis-platinum:25:0.0367	0.0367	25
DDP	DDP:298	cisplatin:298:0.4705	0.4705	298
DDP	DDP:12	cisplatinum:12:0.0175	0.0175	12
DDQ	DDQ:19	2,3-dichloro-5,6-dicyano-1,4-benzoquinone:19:0.2500	0.2500	19
DDQ	DDQ:10|ddq:1	direct dialysis quantification:11:0.7357	0.7357	11
DDR1	DDR1:16	Discoidin domain receptor 1:16:0.8165	0.8165	16
DDR2	DDR2:10	discoidin domain receptor 2:10:0.7103	0.7103	10
DDR	DDR:6	Diastolic descent rate:6:0.5290	0.5290	6
DDR	DDR:9	discoidin domain receptor:9:0.6794	0.6794	9
DDS-NOH	DDS-NOH:10	Dapsone hydroxylamine:10:0.5000	0.5000	10
DDSP	DDSP:15	dorsal displacement of the soft palate:15:0.8045	0.8045	15
DDST	DDST:40	Denver Developmental Screening Test:40:0.9256	0.9256	40
DDS	DDS:30	Denys-Drash syndrome:30:0.4752	0.4752	30
DDS	DDS:4	diamino diphenyl sulphone:4:0.1618	0.1618	4
DDS	DDS:5	dietary diversity score:5:0.1973	0.1973	5
DDs	DDs:9|DDS:1	disorders:10:0.0189	0.0189	10
DDS	DDS:94	drug delivery system:71:0.8757|drug delivery systems:23:0.8715	0.8757	94
DDTC	DDTC:138	diethyldithiocarbamate:138:0.8616	0.8616	138
DDT	DDT:17	1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane:17:0.0276	0.0276	17
DDT	DDT:71	1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane:60:0.1017|1,1,1-trichloro-2,2-bis-(p-chlorophenyl)ethane:11:0.0172	0.1017	71
DDT	DDT:10	dichloro-diphenyl-trichloroethane:10:0.0155	0.0155	10
DDT	DDT:19	dichlorodiphenyl trichloroethane:19:0.5404	0.5404	19
DDT	DDT:153	Dichlorodiphenyltrichloroethane:153:0.2603	0.2603	153
DDT	DDT:1	p-chlorophenyl ethane:1:0.1991	0.1991	1
DDT	DDT:17	p,p'-dichlorodiphenyltrichloroethane:17:0.0276	0.0276	17
DDVP	DDVP:73|ddvp:1	dichlorvos:74:0.5669	0.5669	74
DDW	DDW:10	double distilled water:10:0.4363	0.4363	10
DEA/NO	DEA/NO:9	diethylamine nonoate:9:0.6794	0.6794	9
DEAE	DEAE:9	diethylaminoethanol:9:0.0576	0.0576	9
DEAE-D	DEAE-D:12|DEAED:1	diethylaminoethyl-dextran:13:0.5000	0.5000	13
DEAFF	DEAFF:5	detection of early antigen fluorescent foci:5:0.2818	0.2818	5
DEA	DEA:73	Data Envelopment Analysis:73:0.9591	0.9591	73
DEA	DEA:16	deethylatrazine:16:0.0446	0.0446	16
DEA	DEA:26|dea:1	diethanolamine:27:0.0774	0.0774	27
DEA	DEA:38	diethylamine:38:0.1101	0.1101	38
DEA	DEA:31	Drug Enforcement Administration:31:0.8519	0.8519	31
DEA	DEA:8	metabolite desethylamiodarone:8:0.3109	0.3109	8
DEBQ	DEBQ:9	Dutch Eating Behaviour Questionnaire:9:0.6794	0.6794	9
DEBS	DEBS:43	6-deoxyerythronolide B synthase:43:0.8917	0.8917	43
DEB	DEB:17	1,2,3,4-diepoxybutane:17:0.0613	0.0613	17
DEB	DEB:100	diepoxybutane:100:0.3793	0.3793	100
DEB	DEB:54	dystrophic epidermolysis bullosa:54:0.8004	0.8004	54
DEC-C	DEC-C:8|DECC:5	diethylcarbamazine citrate:13:0.7753	0.7753	13
DEC	DEC:7|dEC:4	dendritic epidermal cells:11:0.6182	0.6182	11
DEC	DEC:304	Diethylcarbamazine:304:0.6130	0.6130	304
DEC	DEC:38	Diethylcarbamazine citrate:38:0.7810	0.7810	38
DEC	DEC:9	epithelial cells:9:0.1334	0.1334	9
DEDC	DEDC:13	diethyldithiocarbamate:13:0.6316	0.6316	13
DEDTC	DEDTC:40	diethyldithiocarbamate:40:0.7091	0.7091	40
DEDs	DEDs:16	death effector domains:16:0.8165	0.8165	16
DED	DED:13	de-epidermized dermis:13:0.2802	0.2802	13
DED	DED:23	death effector domain:23:0.8715	0.8715	23
DEET	DEET:6|deet:2|Deet:1	diethyltoluamide:9:0.0404	0.0404	9
DEET	DEET:20	insect repellent N,N-diethyl-m-toluamide:20:0.7955	0.7955	20
deet	deet:16|DEET:5|Deet:3	N,N-diethyl-3-methylbenzamide:24:0.1111	0.1111	24
DEE	DEE:35	Daily energy expenditure:35:0.9151	0.9151	35
DEFT	DEFT:21	direct epifluorescent filter technique:21:0.8525	0.8525	21
DEF	DEF:13|def:3	deficiens:16:0.0718	0.0718	16
DEF	DEF:6	dose enhancement factor:6:0.5290	0.5290	6
DEF	DEF:14	S,S,S-tributyl phosphorotrithioate:14:0.3134	0.3134	14
DEG	DEG:25	diethylene glycol:25:0.7046	0.7046	25
DEHA	DEHA:9	di-(2-ethylhexyl)adipate:9:0.1404	0.1404	9
DEHP	DEHP:508	di(2-ethylhexyl)phthalate:209:0.2680|Di(2-ethylhexyl) phthalate:138:0.3228|di-(2-ethylhexyl) phthalate:68:0.1422|di-(2-ethylhexyl)phthalate:67:0.0851|di-(2-ethylhexyl)-phthalate:26:0.0322	0.3228	508
DEHP	DEHP:16	di-2-ethylhexylphthalate:16:0.0193	0.0193	16
DEHP	DEHP:28	Diethylhexylphthalate:28:0.0335	0.0335	28
DEH	DEH:13	delayed endolymphatic hydrops:13:0.7753	0.7753	13
DEH	DEH:9	Dysplasia epiphysealis hemimelica:9:0.6794	0.6794	9
DEIA	DEIA:24	DNA enzyme immunoassay:24:0.6539	0.6539	24
DEI	DEI:7	Diffraction enhanced imaging:7:0.5926	0.5926	7
DEI	DEI:16	energy intake:16:0.6577	0.6577	16
DEJ	DEJ:108	junction:108:0.9643	0.9643	108
DELFIA	DELFIA:18	dissociation-enhanced lanthanide fluoroimmunoassay:18:0.5228	0.5228	18
DELFIA	DELFIA:9	lanthanide fluorescence immunoassay:9:0.2757	0.2757	9
DELM	DELM:6|D-ELM:3	Digital epiluminescence microscopy:9:0.6794	0.6794	9
del	del:10|DEL:4	deletion:14:0.1831	0.1831	14
DE-MRI	DE-MRI:7|DEMRI:4|de-MRI:1	magnetic resonance imaging:12:0.6460	0.6460	12
DEM	DEM:10	Developmental Eye Movement:10:0.7103	0.7103	10
DEM	DEM:161	diethyl maleate:161:0.9814	0.9814	161
DEM	DEM:139|dEM:1	diethylmaleate:140:0.3475	0.3475	140
DEM	DEM:8	direct electron microscopy:8:0.6411	0.6411	8
DEN-1	DEN-1:5|Den-1:1|DEN1:1	dengue virus type 1:7:0.4438	0.4438	7
DEN-2	DEN-2:13|DEN2:1	dengue type 2:14:0.1169	0.1169	14
DEN2	DEN2:5|DEN-2:3	dengue type 2 virus:8:0.4438	0.4438	8
DEN-2	DEN-2:30|DEN2:7	dengue virus type 2:37:0.9197	0.9197	37
DEN4	DEN4:10|DEN-4:1	Dengue type 4 virus:11:0.7357	0.7357	11
DEN4	DEN4:10|DEN-4:4	dengue virus type 4:14:0.7909	0.7909	14
DENA	DENA:138	diethylnitrosamine:138:0.7874	0.7874	138
DENA	DENA:12	N-nitrosodiethylamine:12:0.0632	0.0632	12
DENSPM	DENSPM:17|DENSpm:1	N1,N11-diethylnorspermine:18:0.4857	0.4857	18
DENV-2	DENV-2:6	Dengue virus type 2:6:0.5290	0.5290	6
DEN	DEN:20	Dengue virus:20:0.7766	0.7766	20
DEN	DEN:582	diethylnitrosamine:582:0.6314	0.6314	582
DEN	DEN:17	N-diethylnitrosamine:17:0.0174	0.0174	17
DEN	DEN:9	N,N-diethylnitrosamine:9:0.0087	0.0087	9
DEN	DEN:95	N-nitrosodiethylamine:95:0.1014	0.1014	95
DEPA	DEPA:13	N,N-diethylphenylacetamide:13:0.5217	0.5217	13
DEPC	DEPC:11	dielaidoylphosphatidylcholine:11:0.0448	0.0448	11
DEPC	DEPC:110	diethyl pyrocarbonate:110:0.9728	0.9728	110
DEPC	DEPC:78	diethylpyrocarbonate:78:0.3453	0.3453	78
DEPE	DEPE:15	dielaidoylphosphatidylethanolamine:15:0.3684	0.3684	15
DEPMPO	DEPMPO:9	5-(diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide:9:0.1633	0.1633	9
DEPMPO	DEPMPO:3	spin trap 5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide:3:0.4422	0.4422	3
DEPs	DEPs:42	diesel exhaust particles:42:0.9308	0.9308	42
DEP	DEP:13|dep:1	depression:14:0.0233	0.0233	14
DEP	DEP:14	dielectrophoresis:14:0.0233	0.0233	14
DEP	DEP:14	dielectrophoretic:14:0.0233	0.0233	14
DEP	DEP:176	Diesel exhaust particles:168:0.9535|diesel exhaust particle:8:0.6411	0.9535	176
DEP	DEP:23	diesel exhaust particulates:13:0.7753|diesel exhaust particulate:10:0.7103	0.7753	23
DEP	DEP:9	Diethyl phosphate:9:0.3945	0.3945	9
DEP	DEP:46	Diethyl phthalate:46:0.8401	0.8401	46
DEP	DEP:32	diethyl pyrocarbonate:32:0.8563	0.8563	32
DEP	DEP:10	diethylphosphate:10:0.0162	0.0162	10
DEP	DEP:11	Diethylphthalate:11:0.0180	0.0180	11
DEP	DEP:49	diethylpyrocarbonate:49:0.0862	0.0862	49
DE-QCT	DE-QCT:4|DEQCT:3	quantitative computed tomography:7:0.4438	0.4438	7
DER	DER:11	Dietary energy restriction:11:0.7357	0.7357	11
DER	DER:10	disulfiram-ethanol reaction:10:0.5000	0.5000	10
DER	DER:21	Drosophila EGF receptor:21:0.5435	0.5435	21
DER	DER:8	Drosophila EGF receptor homolog:8:0.5006	0.5006	8
DER	DER:14	epidermal growth factor receptor:14:0.7909	0.7909	14
DES-DP	DES-DP:11|DESDP:4|DESdP:2|DES-dp:1	diethylstilbestrol diphosphate:18:0.7539	0.7539	18
DESD	DESD:14	Detrusor-external sphincter dyssynergia:14:0.4709	0.4709	14
DES-P	DES-P:10|DESP:5	diethylstilbestrol diphosphate:15:0.8045	0.8045	15
DESs	DESs:11	drug-eluting stents:11:0.7357	0.7357	11
DES	DES:7|Des:4|des:1	desferrioxamine:12:0.0050	0.0050	12
DES	DES:17	Desflurane:17:0.0072	0.0072	17
DES	DES:15|Des:5	desipramine:20:0.0086	0.0086	20
DES	DES:25|Des:5	desmosine:30:0.0131	0.0131	30
DES	DES:15	diethyl sulfate:15:0.6386	0.6386	15
DES	DES:17	diethylstibestrol:17:0.0072	0.0072	17
DES	DES:29	diethylstilbesterol:29:0.0127	0.0127	29
DES	DES:1453|des:1|-DES:1	diethylstilbestrol:1455:0.6561	0.6561	1455
DES	DES:125	diethylstilboestrol:125:0.0562	0.0562	125
DES	DES:34	diffuse esophageal spasm:34:0.8245	0.8245	34
DES	DES:68	Dissociative Experiences Scale:54:0.9132|Dissociative Experience Scale:14:0.6173	0.9132	68
DES	DES:60	Drug-eluting stents:46:0.6974|drug-eluting stent:14:0.5589	0.6974	60
DES	DES:4	Dry eye syndrome:4:0.0918	0.0918	4
DES	DES:10	estrogen:10:0.0041	0.0041	10
DETA/NO	DETA/NO:5	diethylenetriamine nitric oxide adduct:5:0.4422	0.4422	5
DETA/NO	DETA/NO:9	diethylenetriamine/NO:9:0.1778	0.1778	9
DETA	DETA:17	diethylenetriamine:17:0.4103	0.4103	17
DETC	DETC:65	dendritic epidermal T cells:58:0.9486|dendritic epidermal T cell:7:0.5926	0.9486	65
DETC	DETC:37	diethyldithiocarbamate:37:0.2880	0.2880	37
DETC-Me	DETC-Me:8|DETC-ME:1	S-Methyl N,N-diethylthiolcarbamate:9:0.6794	0.6794	9
DETCA	DETCA:10	diethyldithiocarbamate:10:0.6000	0.6000	10
DETCs	DETCs:11	dendritic epidermal T cells:11:0.7357	0.7357	11
DET	DET:13	dipyridamole echocardiography test:13:0.6701	0.6701	13
DET	DET:6	double embryo transfer:6:0.2827	0.2827	6
DEV	DEV:6	Duck Embryo Vaccine:6:0.5290	0.5290	6
DEX/CRH	DEX/CRH:4|Dex/CRH:2	combined dexamethasone/corticotropin-releasing hormone:6:0.3728	0.3728	6
DEXA	DEXA:34|Dexa:33|dexa:8	dexamethasone:75:0.0701	0.0701	75
DEXA	DEXA:6	dual energy X-ray absorptiometer:6:0.5290	0.5290	6
DEXA	DEXA:397|DeXA:1|dexa:1	dual-energy X-ray absorptiometry:399:0.4568	0.4568	399
DE	DE:13	degree of esterification:13:0.3554	0.3554	13
DE	DE:11	delayed-early:11:0.0122	0.0122	11
DE	DE:12	delta efficiency:12:0.1573	0.1573	12
DE	DE:7	dermal equivalent:7:0.1641	0.1641	7
DE	DE:11	diatomaceous earth:11:0.7357	0.7357	11
DE	DE:62	Diesel exhaust:62:0.9229	0.9229	62
DE	DE:83	digestible energy:83:0.8035	0.8035	83
DE	DE:13	dissolution efficiency:13:0.1824	0.1824	13
DE	DE:47	dobutamine echocardiography:47:0.4856	0.4856	47
DE	DE:25|D-E:1	Doppler echocardiography:26:0.2180	0.2180	26
DE	DE:9	dual-energy:9:0.0097	0.0097	9
DE	DE:5	dynamic exercise:5:0.0517	0.0517	5
DE	DE:13	dyscirculatory encephalopathy:13:0.2415	0.2415	13
De	De:7	effective diffusion coefficient:7:0.3524	0.3524	7
DE	DE:3	pectins with different degrees of esterification:3:0.3170	0.3170	3
DF-2	DF-2:7	Dysgonic fermenter 2:7:0.5926	0.5926	7
DFA	DFA:13	deep femoral artery:13:0.5934	0.5934	13
DFA	DFA:31	detrended fluctuation analysis:31:0.8519	0.8519	31
DFA	DFA:106	direct fluorescent antibody:84:0.9091|direct fluorescent-antibody:22:0.8657	0.9091	106
DFA	DFA:8	direct fluorescent antibody test:8:0.6411	0.6411	8
DFA	DFA:13	Direct immunofluorescence:13:0.5335	0.5335	13
DFA	DFA:26	direct immunofluorescence assay:26:0.8251	0.8251	26
DFA	DFA:5	direct immunofluorescent staining:5:0.4422	0.4422	5
DFA	DFA:9	discriminant function analyses:9:0.6794	0.6794	9
DFA	DFA:32	discriminant function analysis:32:0.9072	0.9072	32
dFBS	dFBS:10|DFBS:2	dialyzed fetal bovine serum:12:0.7571	0.7571	12
DFB	DFB:6	desferrioxamine B:6:0.2243	0.2243	6
DFB	DFB:15	diflubenzuron:15:0.2456	0.2456	15
DFCI	DFCI:16	Dana-Farber Cancer Institute:16:0.5564	0.5564	16
DFC	DFC:37	dense fibrillar component:37:0.9197	0.9197	37
DFDB	DFDB:11	demineralized freeze-dried bone:11:0.7357	0.7357	11
DFDBA	DFDBA:74	demineralized freeze-dried bone allograft:59:0.6881|demineralized freeze-dried bone allografts:15:0.8165	0.8165	74
dFdC	dFdC:19|DFDC:1	2',2'-difluorodeoxycytidine:20:0.2533	0.2533	20
dFdC	dFdC:40	Gemcitabine:40:0.5200	0.5200	40
DFD	DFD:2	dark firm dry:2:0.6794	0.6794	2
Dfd	Dfd:47	Deformed:47:0.5287	0.5287	47
d-FEN	d-FEN:17|D-FEN:11|D-fen:4|d-Fen:4|d-fen:3|DFEN:3|dFEN:2	d-fenfluramine:44:0.5584	0.5584	44
DFEN	DFEN:20|d-FEN:2|d-fen:2|dFEN:1|D-fen:1|dFen:1|d-Fen:1|D-Fen:1	dexfenfluramine:29:0.3636	0.3636	29
DFF45	DFF45:5|DFF-45:4	DNA fragmentation factor:9:0.6794	0.6794	9
DFF45	DFF45:8	DNA fragmentation factor 45:8:0.6411	0.6411	8
DFG	DFG:14	difference frequency generation:8:0.6411|difference-frequency generation:6:0.1010	0.6411	14
DFI	DFI:4	daily feed intake:4:0.1618	0.1618	4
DFI	DFI:4	daily food intake:4:0.1618	0.1618	4
DFI	DFI:139	disease-free interval:139:0.7745	0.7745	139
DFI	DFI:15	DNA fragmentation index:15:0.8045	0.8045	15
DFLE	DFLE:7	Disability-free life expectancy:7:0.3524	0.3524	7
DFMA	DFMA:9	alpha-difluoromethylarginine:9:0.4000	0.4000	9
DFMO	DFMO:27	2-difluoromethylornithine:27:0.0254	0.0254	27
DFMO	DFMO:39	alpha-difluoromethyl ornithine:26:0.3586|alpha-difluoromethyl-ornithine:13:0.0117	0.3586	39
DFMO	DFMO:502	alpha-difluoromethylornithine:502:0.4883	0.4883	502
DFMO	DFMO:23	D,L-alpha-difluoromethylornithine:23:0.0215	0.0215	23
DFMO	DFMO:16	difluoromethyl ornithine:16:0.1530	0.1530	16
DFMO	DFMO:222|dfmo:1	difluoromethylornithine:223:0.2104	0.2104	223
DFMO	DFMO:80	DL-alpha-difluoromethylornithine:80:0.0773	0.0773	80
DFM	DFM:15	microscopy:15:0.2154	0.2154	15
DFO	DFO:205	deferoxamine:205:0.3434	0.3434	205
DFO	DFO:15	deferoxamine mesylate:15:0.3821	0.3821	15
DFO	DFO:303|dfo:1|DfO:1|Dfo:1	desferrioxamine:306:0.5126	0.5126	306
DFO	DFO:14	desferrioxamine B:14:0.7909	0.7909	14
DFPP	DFPP:66	double filtration plasmapheresis:66:0.9286	0.9286	66
DFP	DFP:24	di-isopropylfluorophosphate:24:0.0268	0.0268	24
DFP	DFP:8|dfp:1	diastolic filling period:9:0.6794	0.6794	9
DFP	DFP:160	Diisopropyl fluorophosphate:160:0.8290	0.8290	160
DFP	DFP:86	diisopropyl phosphorofluoridate:86:0.7978	0.7978	86
DFP	DFP:287	diisopropylfluorophosphate:287:0.3337	0.3337	287
DFP	DFP:18	diisopropylphosphofluoridate:18:0.0198	0.0198	18
DFP	DFP:45	diisopropylphosphorofluoridate:45:0.0513	0.0513	45
DFP	DFP:12	double filtration plasmapheresis:12:0.7571	0.7571	12
DFSP	DFSP:196|DF-SP:1	dermatofibrosarcoma protuberans:197:0.9459	0.9459	197
DFTs	DFTs:49	Defibrillation thresholds:49:0.9046	0.9046	49
DFT	DFT:196	defibrillation threshold:177:0.9558|defibrillation thresholds:19:0.8449	0.9558	196
DFT	DFT:6	dementia of frontal lobe type:6:0.4438	0.4438	6
DFT	DFT:2	dementia of the frontal type:2:0.5290	0.5290	2
DFT	DFT:22	density functional:22:0.8657	0.8657	22
DFT	DFT:5	density functional calculations:5:0.4422	0.4422	5
DFT	DFT:5	density functional theoretical:5:0.4422	0.4422	5
DFT	DFT:477	density functional theory:477:0.9937	0.9937	477
DFT	DFT:9	desferrithiocin:9:0.0089	0.0089	9
DFT	DFT:45	discrete Fourier transform:45:0.8964	0.8964	45
DFUR	DFUR:9|dFUR:8	5'-deoxy-5-fluorouridine:17:0.6957	0.6957	17
DFX	DFX:22|Dfx:2	Deferoxamine:24:0.2371	0.2371	24
DFX	DFX:56|DFx:2	desferrioxamine:58:0.5979	0.5979	58
DFZ	DFZ:18	deflazacort:18:0.8500	0.8500	18
DFS	DFS:2	decayed or filled surfaces:2:0.4102	0.4102	2
DFS	DFS:17	Dental Fear Survey:17:0.8270	0.8270	17
DFS	DFS:12	diabetic foot syndrome:12:0.7571	0.7571	12
DFS	DFS:8	diclofenac sodium:8:0.4102	0.4102	8
DFS	DFS:46	Disease-free:46:0.0257	0.0257	46
DFS	DFS:1455	disease-free survival:1275:0.8564|Disease free survival:171:0.9543|disease-free survivals:9:0.5470	0.9543	1455
DF	DF:5	ankle dorsiflexors:5:0.0902	0.0902	5
d-F	d-F:7|DF:5|dF:3|D-F:2	d-fenfluramine:17:0.0115	0.0115	17
DF	DF:35	deferoxamine:35:0.0244	0.0244	35
DF	DF:14|Df:1	defibrotide:15:0.0100	0.0100	15
df	df:27|DF:4	degrees of freedom:24:0.5848|degree of freedom:7:0.0516	0.5848	31
DF	DF:9	delayed fluorescence:9:0.3455	0.3455	9
DF	DF:108	Dengue fever:108:0.9559	0.9559	108
DF	DF:5	deposition fraction:5:0.0902	0.0902	5
DF	DF:13	dermal fibroblasts:13:0.5335	0.5335	13
DF	DF:26	Dermatofibroma:26:0.0179	0.0179	26
Df	Df:72|DF:23	Dermatophagoides farinae:95:0.7615	0.7615	95
DF	DF:43|df:2|Df:2	desferrioxamine:47:0.0330	0.0330	47
DF	DF:21|dF:1	developed force:22:0.7955	0.7955	22
dF	dF:25|DF:12|d-F:5|D-F:3	Dexfenfluramine:45:0.0323	0.0323	45
DF	DF:6	dialysis fluid:6:0.1320	0.1320	6
DF	DF:18	Dibenzofuran:18:0.0122	0.0122	18
DF	DF:11	diclofenac:11:0.0072	0.0072	11
DF	DF:55	dietary fiber:55:0.9147	0.9147	55
DF	DF:29	dietary fibre:29:0.8978	0.8978	29
DF	DF:22	diflunisal:22:0.0151	0.0151	22
DF	DF:21	discriminant function:21:0.3044	0.3044	21
DF	DF:9	disease-free:9:0.0057	0.0057	9
DF	DF:31	dominant follicle:31:0.7388	0.7388	31
DF	DF:20|dF:1	dominant frequency:21:0.4733	0.4733	21
DF	DF:26	dorsiflexion:26:0.0179	0.0179	26
DF	DF:32	factor:32:0.0222	0.0222	32
Df	Df:11|DF:8|dF:1|df:1	fractal dimension:21:0.8594	0.8594	21
DF	DF:11	tenofovir disoproxil fumarate:11:0.7357	0.7357	11
DG-DGGE	DG-DGGE:10	gradient gel electrophoresis:10:0.5856	0.5856	10
DG18	DG18:10	Dichloran 18% Glycerol agar:10:0.7103	0.7103	10
DGAI	DGAI:1	German Society for Anaesthesiology and Intensive Care Medicine:1:0.4422	0.4422	1
DGAT1	DGAT1:8	acyltransferase 1:8:0.3463	0.3463	8
DGAT	DGAT:59	diacylglycerol acyltransferase:59:0.5981	0.5981	59
dGA	dGA:9	days gestation:9:0.6537	0.6537	9
dGA	dGA:8|DGA:5|dga:1	days gestational age:14:0.7173	0.7173	14
dgA	dgA:12	deglycosylated ricin A chain:12:0.4232	0.4232	12
DGA	DGA:11	dental general anaesthesia:11:0.7357	0.7357	11
DGA	DGA:11	DiGeorge anomaly:11:0.6182	0.6182	11
DGA	DGA:4|D-GA:3	urinary excretion of D-glucaric acid:7:0.2902	0.2902	7
DGCs	DGCs:27	dentate granule cells:27:0.8312	0.8312	27
DGC	DGC:9	dorsal gray commissure:9:0.6794	0.6794	9
DGC	DGC:48	dystrophin-glycoprotein complex:48:0.5150	0.5150	48
DGE	DGE:36	delayed gastric emptying:36:0.8716	0.8716	36
DGE	DGE:9	differential gene expression:9:0.5470	0.5470	9
DGF	DGF:180|dGF:1	Delayed graft function:181:0.9568	0.9568	181
DGG	DGG:9	digestive gland-gonad complex:9:0.6794	0.6794	9
DGG	DGG:28	gamma-D-glutamylglycine:28:0.4821	0.4821	28
DGGE	DGGE:840	denaturing gradient gel electrophoresis:840:0.8910	0.8910	840
DGHs	DGHs:17	District General Hospitals:17:0.8270	0.8270	17
DGH	DGH:65	district general hospital:55:0.9147|District General Hospitals:10:0.7103	0.9147	65
DGI	DGI:9	dentinogenesis imperfecta:9:0.6794	0.6794	9
DGI	DGI:27	disseminated gonococcal infection:27:0.8903	0.8903	27
DGI	DGI:9	Dynamic Gait Index:9:0.6794	0.6794	9
DGKs	DGKs:15	Diacylglycerol kinases:15:0.7096	0.7096	15
DGK	DGK:87|dgk:1	diacylglycerol kinase:88:0.5528	0.5528	88
DGL	DGL:7	diacylglycerol lipase:7:0.2452	0.2452	7
DGM	DGM:10	dissolved gaseous mercury:10:0.5856	0.5856	10
DGOR	DGOR:9	duodenogastro-oesophageal reflux:9:0.6794	0.6794	9
DGPP	DGPP:19	Diacylglycerol pyrophosphate:19:0.7044	0.7044	19
DGR	DGR:73	Duodenogastric reflux:73:0.8474	0.8474	73
DGS	DGS:12	diabetic glomerulosclerosis:12:0.7571	0.7571	12
DGs	DGs:14	diacylglycerols:14:0.0765	0.0765	14
DGS	DGS:8	DiGeorge sequence:8:0.5006	0.5006	8
DGS	DGS:85	DiGeorge syndrome:85:0.8419	0.8419	85
dgt	dgt:9|Dgt:2	diageotropica:11:0.1471	0.1471	11
DGT	DGT:16	diffusive gradients in thin films:16:0.6386	0.6386	16
DG	DG:45	1,2-diacylglycerol:45:0.0261	0.0261	45
DG	DG:20	2-deoxy-D-glucose:20:0.0113	0.0113	20
DG	DG:26	2-deoxyglucose:26:0.0148	0.0148	26
dG	dG:72|d-G:2|DG:1	2'-deoxyguanosine:75:0.0438	0.0438	75
dg	dg:19|DG:12|dG:1	days of gestation:32:0.6147	0.6147	32
DG	DG:11	dentate granule:11:0.4232	0.4232	11
DG	DG:453|Dg:1|dg:1	dentate gyrus:455:0.9794	0.9794	455
DG	DG:19	deoxyglucose:19:0.0107	0.0107	19
dG	dG:98	deoxyguanosine:98:0.0581	0.0581	98
DG	DG:23|Dg:2	desogestrel:25:0.0142	0.0142	25
DG	DG:274	diacylglycerol:252:0.1487|diacylglycerols:22:0.0124	0.1487	274
DG	DG:49	diglyceride:32:0.0184|diglycerides:17:0.0095	0.0184	49
DG	DG:9	diradylglycerol:9:0.0047	0.0047	9
DG	DG:23	distance geometry:23:0.8715	0.8715	23
DG	DG:9	dorsal gastric:9:0.6794	0.6794	9
DG	DG:26|Dg:1	dystroglycan:27:0.0154	0.0154	27
DG	DG:22	group:22:0.0124	0.0124	22
DHAA	DHAA:16	dehydroabietic acid:16:0.1092	0.1092	16
DHAD	DHAD:20	mitoxantrone:20:0.5294	0.5294	20
DHAP	DHAP:72	dihydroxyacetone phosphate:72:0.8610	0.8610	72
DHAQ	DHAQ:10	dihydroxyanthraquinone:10:0.2432	0.2432	10
DHAQ	DHAQ:13	mitoxantrone:13:0.3243	0.3243	13
DHAS	DHAS:102|DHA-S:37|DHA-s:1	dehydroepiandrosterone sulfate:121:0.6872|dehydroepiandrosterone-sulfate:19:0.0554	0.6872	140
DHAS	DHAS:67|DHA-S:12|DHA-s:1	Dehydroepiandrosterone sulphate:80:0.7263	0.7263	80
DHAs	DHAs:12	district health authorities:12:0.7571	0.7571	12
DHA	DHA:17	2,8-dihydroxyadenine:17:0.0076	0.0076	17
DHA	DHA:8	active metabolite dihydroartemisinin:8:0.3470	0.3470	8
DHA	DHA:46	dehydroascorbate:46:0.0215	0.0215	46
DHA	DHA:269	dehydroepiandrosterone:269:0.1278	0.1278	269
DHA	DHA:9	dehydrogenase activity:9:0.5470	0.5470	9
DHA	DHA:12	Dehydroisoandrosterone:12:0.0052	0.0052	12
DHA	DHA:49|Dha:5|dha:1	dihydroxyacetone:55:0.0258	0.0258	55
DHA	DHA:9	District Health Authority:9:0.6794	0.6794	9
DHA	DHA:14	docosahexaenoate:14:0.0062	0.0062	14
DHBA	DHBA:7	2,3- and 2,5-dihydroxybenzoic acids:7:0.5926	0.5926	7
DHBA	DHBA:11	3,4-Dihydroxybenzylamine:11:0.0671	0.0671	11
DHBA	DHBA:28	Dihydroxybenzoic acid:28:0.1543	0.1543	28
DHBA	DHBA:7	reflected by the non-enzymatic formation of 2,3-dihydroxybenzoic acid:7:0.2902	0.2902	7
DHBE	DHBE:9	Dihydro-beta-erythroidine:9:0.4706	0.4706	9
DHBV	DHBV:311	Duck Hepatitis B Virus:311:0.9904	0.9904	311
DHBsAg	DHBsAg:8	duck hepatitis B surface antigen:8:0.6411	0.6411	8
DHB	DHB:37	2,5-dihydroxybenzoic acid:37:0.4832	0.4832	37
DHCA	DHCA:92	deep hypothermic circulatory arrest:92:0.9484	0.9484	92
dhCB	dhCB:8|DHCB:6	dihydrocytochalasin B:14:0.7909	0.7909	14
DHCP	DHCP:12	Decentralized Hospital Computer Program:12:0.7571	0.7571	12
DHCR7	DHCR7:7|Dhcr7:4	7-dehydrocholesterol reductase:11:0.3495	0.3495	11
DHC	DHC:17	dental health component:17:0.8270	0.8270	17
DHC	DHC:12	dihydrocodeine:12:0.0759	0.0759	12
DHC	DHC:8|Dhc:5	dynein heavy chain:13:0.6701	0.6701	13
DHDPS	DHDPS:13	dihydrodipicolinate synthase:13:0.6701	0.6701	13
DHD	DHD:10|D-HD:1	daily hemodialysis:11:0.6182	0.6182	11
DHEA-ST	DHEA-ST:15|DHEAST:1	dehydroepiandrosterone sulfotransferase:16:0.7261	0.7261	16
DHEAS	DHEAS:17|DHEA-S:7	dehydroepiandrosterone:24:0.0147	0.0147	24
DHEAS	DHEAS:528|DHEA-S:250|DHEAs:2	dehydroepiandrosterone sulfate:780:0.7913	0.7913	780
DHEAS	DHEAS:191|DHEA-S:97|DHEAs:3|DHEA-s:1	dehydroepiandrosterone sulphate:262:0.7982|dehydroepiandrosterone-sulphate:30:0.0185	0.7982	292
DHEAS	DHEAS:1	DHEA and its sulfated derivative:1:0.4422	0.4422	1
DHEA	DHEA:1807	dehydroepiandrosterone:1807:0.9445	0.9445	1807
DHEA	DHEA:15	dihydroepiandrosterone:15:0.0068	0.0068	15
DHET	DHET:14	Dihydroergotoxine:14:0.4643	0.4643	14
DHETs	DHETs:22	dihydroxyeicosatrienoic acids:22:0.6178	0.6178	22
DHE	DHE:9	[3H]dihydroergocryptine:9:0.0223	0.0223	9
DHE	DHE:16	dehydroergosterol:16:0.0419	0.0419	16
DHE	DHE:36	dihematoporphyrin ether:36:0.7433	0.7433	36
DHE	DHE:161|dhe:1	dihydroergotamine:162:0.4497	0.4497	162
DHE	DHE:18	dihydroethidium:18:0.0475	0.0475	18
DHE	DHE:17	Dihydroetorphine:17:0.0447	0.0447	17
DHF/DSS	DHF/DSS:11	dengue haemorrhagic fever/dengue shock syndrome:11:0.7357	0.7357	11
DHF/DSS	DHF/DSS:6	Dengue hemorrhagic fever and dengue shock syndrome:6:0.5926	0.5926	6
DHF/DSS	DHF/DSS:23	dengue hemorrhagic fever/dengue shock syndrome:23:0.8038	0.8038	23
DHFR-TS	DHFR-TS:45|dhfr-ts:4	dihydrofolate reductase-thymidylate synthase:49:0.9046	0.9046	49
DHFRs	DHFRs:13	dihydrofolate reductases:13:0.7753	0.7753	13
DHFR	DHFR:1163|dhfr:119|Dhfr:6	dihydrofolate reductase:1273:0.9704|dihydrofolate reductases:15:0.7096	0.9704	1288
DHFR	DHFR:11|dhfr:9|Dhfr:1	dihydrofolate reductase gene:21:0.7865	0.7865	21
DHF	DHF:89	dengue haemorrhagic fever:89:0.9664	0.9664	89
DHF	DHF:172	dengue hemorrhagic fever:172:0.9630	0.9630	172
DHF	DHF:29	diastolic heart failure:29:0.8978	0.8978	29
DHF	DHF:15	dihydrofolate:15:0.0365	0.0365	15
DHF	DHF:9	dihydroxyfumarate:9:0.0208	0.0208	9
DHG	DHG:19	depolymerized holothurian glycosaminoglycan:19:0.8449	0.8449	19
DHHS	DHHS:86	Department of Health and Human Services:86:0.9280	0.9280	86
Dhh	Dhh:10|DHH:8	Desert hedgehog:18:0.8365	0.8365	18
DHIA	DHIA:13	Dairy Herd Improvement Association:13:0.6701	0.6701	13
DHI	DHI:37	5,6-dihydroxyindole:37:0.2748	0.2748	37
DHI	DHI:15	Dairy Herd Improvement:15:0.8045	0.8045	15
DHI	DHI:32	Dizziness Handicap Inventory:32:0.9072	0.9072	32
DHI	DHI:7	dose homogeneity index:7:0.5926	0.5926	7
DHK	DHK:24	dihydrokainate:24:0.6216	0.6216	24
DHLA	DHLA:37	dihydrolipoic acid:37:0.4642	0.4642	37
DhlA	DhlA:7|dhlA:1	haloalkane dehalogenase:8:0.5006	0.5006	8
DHLNL	DHLNL:18	dihydroxylysinonorleucine:18:0.6538	0.6538	18
DhL	DhL:12	dehydroleucodine:12:0.1236	0.1236	12
DHL	DHL:35	diffuse histiocytic lymphoma:35:0.8336	0.8336	35
DHM	DHM:19	dihydromorphine:19:0.3396	0.3396	19
DHO	DHO:15	dihydro-ouabain:15:0.1867	0.1867	15
DHO	DHO:12	dihydroorotate:12:0.1467	0.1467	12
DHO	DHO:18	dihydroouabain:18:0.2267	0.2267	18
DHOD	DHOD:19	Dihydroorotate dehydrogenase:19:0.7658	0.7658	19
DHODH	DHODH:24|DHO-DH:7	dihydroorotate dehydrogenase:31:0.5933	0.5933	31
DHPC	DHPC:10	dihexadecylphosphatidylcholine:10:0.1000	0.1000	10
DHPC	DHPC:15	dihexanoylphosphatidylcholine:15:0.1556	0.1556	15
DHPC	DHPC:17|dHPC:2|D-HPC:1	dorsal hippocampus:20:0.8525	0.8525	20
DHPG	DHPG:12	3,4-Dihydroxyphenylethylene glycol:12:0.3058	0.3058	12
DHPG	DHPG:29	3,4-dihydroxyphenylethyleneglycol:29:0.0565	0.0565	29
DHPG	DHPG:39|dhpG:1	9-(1,3-dihydroxy-2-propoxymethyl)guanine:40:0.0786	0.0786	40
DHPG	DHPG:26	agonist (RS)-3,5-dihydroxyphenylglycine:26:0.6900	0.6900	26
DHPG	DHPG:24	agonist (S)-3,5-dihydroxyphenylglycine:24:0.4074	0.4074	24
DHPG	DHPG:33	Ganciclovir:33:0.0645	0.0645	33
DHPG	DHPG:4	group I mGluR agonist (R,S)-3,5-dihydroxyphenylglycine:4:0.4422	0.4422	4
DHPG	DHPG:4	intraneuronal NE metabolite dihydroxyphenylglycol:4:0.3524	0.3524	4
DHPG	DHPG:6	metabolites 3,4-dihydroxyphenylglycol:6:0.0563	0.0563	6
DHP-I	DHP-I:11	dehydropeptidase-I:11:0.5000	0.5000	11
DHPLC	DHPLC:257|dHPLC:36|D-HPLC:5|DH-PLC:1	denaturing high-performance liquid chromatography:199:0.9278|Denaturing high performance liquid chromatography:100:0.8976	0.9278	299
DHPLC	DHPLC:20|dHPLC:2|D-HPLC:1	denaturing HPLC:23:0.8038	0.8038	23
DHPN	DHPN:12	2,2'-dihydroxy-di-n-propylnitrosamine:12:0.1146	0.1146	12
DHPN	DHPN:11	dihydroxy-di-N-propylnitrosamine:11:0.1042	0.1042	11
DHPN	DHPN:45	N-bis(2-hydroxypropyl)nitrosamine:45:0.4583	0.4583	45
DHPRs	DHPRs:33	dihydropyridine receptors:33:0.9100	0.9100	33
DHPR	DHPR:71	dihydropteridine reductase:71:0.8436	0.8436	71
DHPR	DHPR:93|DHP-R:2|DHPr:1	dihydropyridine receptor:86:0.9111|dihydropyridine receptors:10:0.7103	0.9111	96
DHPs	DHPs:15	1,4-dihydropyridines:15:0.0567	0.0567	15
DHPs	DHPs:49	dihydropyridines:49:0.1943	0.1943	49
DHP	DHP:88	1,4-dihydropyridine:78:0.1113|1,4-dihydropyridines:10:0.0130	0.1113	88
DHP	DHP:6	17 alpha,20 beta-dihydroxy-4-pregnen-3-one:6:0.5290	0.5290	6
DHP	DHP:9	17alpha,20beta-dihydroxy-4-pregnen-3-one:9:0.0116	0.0116	9
DHP	DHP:10	dihexadecyl phosphate:10:0.5000	0.5000	10
DHP	DHP:17	dihydroprogesterone:17:0.0231	0.0231	17
DHP	DHP:290	dihydropyridine:265:0.3815|dihydropyridines:25:0.0347	0.3815	290
DHP	DHP:9	dihydropyrimidinase:9:0.0116	0.0116	9
DHP	DHP:36	direct hemoperfusion:36:0.9174	0.9174	36
DHP	DHP:9	phthalate:9:0.0116	0.0116	9
DHQ	DHQ:11	history questionnaire:11:0.7357	0.7357	11
DHRD	DHRD:12	honeycomb retinal dystrophy:12:0.7571	0.7571	12
DHR	DHR:13	delayed hypersensitivity reaction:13:0.4849	0.4849	13
DHR	DHR:20	delayed hypersensitivity response:20:0.8525	0.8525	20
DHR	DHR:17	dihydrorhodamine:17:0.0958	0.0958	17
DHR	DHR:41	dihydrorhodamine 123:41:0.9274	0.9274	41
DHR	DHR:10	hypertensive rats:10:0.5856	0.5856	10
DHSS	DHSS:28	Department of Health and Social Security:28:0.8978	0.8978	28
DHSs	DHSs:16|DHSS:5	DNase I hypersensitive sites:12:0.7571|DNAse I-hypersensitive sites:9:0.6794	0.7571	21
DHS	DHS:13	delayed hypersensitivity:13:0.4444	0.4444	13
DHS	DHS:131	Demographic and Health Survey:70:0.8934|Demographic and Health Surveys:61:0.9229	0.9229	131
DHS	DHS:14	deoxyhypusine synthase:14:0.7909	0.7909	14
DHS	DHS:6	Department of Health Services:6:0.2827	0.2827	6
DHS	DHS:25	DNAse I hypersensitive sites:19:0.7658|DNase I hypersensitive site:6:0.5290	0.7658	25
DHS	DHS:89	dynamic hip screw:78:0.9200|dynamic hip screws:11:0.7357	0.9200	89
DHS	DHS:6	hypersensitivity syndrome:6:0.1543	0.1543	6
DHTR	DHTR:15	delayed hemolytic transfusion reaction:15:0.8045	0.8045	15
DHT	DHT:28	[3H]dihydrotestosterone:18:0.0067|3H-dihydrotestosterone:10:0.0036	0.0067	28
DHT	DHT:22|-DHT:1	5,7-dihydroxytryptamine:23:0.0087	0.0087	23
DHT	DHT:5	5 alpha-androstan-17 beta-ol-3-one:5:0.4422	0.4422	5
DHT	DHT:6	5 alpha-androstane-17 beta-ol-3-one:6:0.5290	0.5290	6
DHT	DHT:18	5-alpha-dihydrotestosterone:18:0.0067	0.0067	18
DHT	DHT:16	androgen 5alpha-dihydrotestosterone:16:0.0541	0.0541	16
DHT	DHT:40	dihydrotachysterol:40:0.0154	0.0154	40
DHX	DHX:14	dihydrexidine:14:0.6842	0.6842	14
DH	DH:10	day hospital:10:0.4363	0.4363	10
DH	DH:74	Dbl homology:55:0.8427|Dbl-homology:19:0.0137	0.8427	74
DH	DH:21	degree of hydrolysis:15:0.4609|degrees of hydrolysis:6:0.0522	0.4609	21
DH	DH:208|dh:1	delayed hypersensitivity:209:0.7671	0.7671	209
DH	DH:13	Department of Health:13:0.6701	0.6701	13
DH	DH:218	dermatitis herpetiformis:218:0.9780	0.9780	218
DH	DH:15	Detrusor hyperreflexia:15:0.8045	0.8045	15
DH	DH:17	diapause hormone:17:0.4480	0.4480	17
DH	DH:23	diaphragmatic hernia:23:0.8038	0.8038	23
DH	DH:10	Diet History:10:0.5856	0.5856	10
DH	DH:8	diuretic hormone:8:0.1004	0.1004	8
DH	DH:12	DNase I hypersensitive:12:0.6460	0.6460	12
Dh	Dh:10	dominant hemimelia:10:0.7103	0.7103	10
DH	DH:8|dH:1	dorsal:9:0.0061	0.0061	9
DH	DH:45	dorsal hippocampus:45:0.9338	0.9338	45
DH	DH:52	dorsal horn:52:0.9427	0.9427	52
DH	DH:8	double haploid:8:0.0566	0.0566	8
DH	DH:53	doubled haploid:30:0.6037|doubled-haploid:23:0.0167	0.6037	53
DH	DH:10	ductal hyperplasia:10:0.4363	0.4363	10
DH	DH:13	Dynamic hyperinflation:13:0.4849	0.4849	13
DH	DH:10	dystrophic hamsters:10:0.7103	0.7103	10
DH	DH:10	hydrochloride:10:0.0068	0.0068	10
DIAS	DIAS:6	Diabetes Advisory System:6:0.5290	0.5290	6
DIB-R	DIB-R:8	Revised Diagnostic Interview for Borderlines:8:0.4102	0.4102	8
DIBs	DIBs:9	Diffuse interstellar bands:9:0.6794	0.6794	9
DIB	DIB:28	Diagnostic Interview for Borderlines:28:0.8978	0.8978	28
DIB	DIB:9	Diagnostic Interview for Borderline Patients:9:0.6794	0.6794	9
DICA	DICA:13	Diagnostic Interview for Children and Adolescents:13:0.7753	0.7753	13
DICC	DICC:14	dynamic infusion cavernosometry and cavernosography:14:0.7909	0.7909	14
DICOM	DICOM:111	Digital Imaging and Communications in Medicine:91:0.9325|digital imaging and communication in medicine:20:0.8594	0.9325	111
DICs	DICs:19	drug information centers:19:0.8449	0.8449	19
DIC	DIC:11	days in culture:11:0.4728	0.4728	11
DIC	DIC:11	deviance information criterion:11:0.7357	0.7357	11
DIC	DIC:108	differential interference contrast:108:0.9417	0.9417	108
DIC	DIC:10	diisopropylcarbodiimide:10:0.0042	0.0042	10
DIC	DIC:11	disseminated intravascular clotting:11:0.4232	0.4232	11
DIC	DIC:1633|dic:2	Disseminated intravascular coagulation:1635:0.9719	0.9719	1635
DIC	DIC:19	disseminated intravascular coagulation syndrome:19:0.7658	0.7658	19
DIC	DIC:87	disseminated intravascular coagulopathy:87:0.9280	0.9280	87
DIC	DIC:20	dissolved inorganic carbon:20:0.7173	0.7173	20
DIC	DIC:7	drip infusion cholangiography:7:0.4438	0.4438	7
DIC	DIC:12	drug information center:12:0.7571	0.7571	12
DIDS	DIDS:10	4,4'-diisothiocyanatostilbene-2,2'-disulfonate:10:0.0100	0.0100	10
DIDS	DIDS:11	4,4'-diisothiocyanatostilbene-2,2'-disulphonate:11:0.0111	0.0111	11
DIDS	DIDS:17	4,4'-diisothiocyano-2,2'-disulfonic acid stilbene:17:0.3109	0.3109	17
DIDS	DIDS:11	4,4'-diisothiocyano-2,2'-disulfonic stilbene:11:0.0869	0.0869	11
DIDS	DIDS:7	4,4'-diisothiocyano-2,2'-stilbene disulfonate:7:0.1850	0.1850	7
DIDS	DIDS:44	4,4'-diisothiocyanostilbene-2,2'-disulfonate:44:0.0491	0.0491	44
DIDS	DIDS:13	4,4'-diisothiocyanostilbene-2,2'-disulphonate:13:0.0134	0.0134	13
DID	DID:6	delayed ischemic deficit:6:0.5290	0.5290	6
DID	DID:44	dissociative identity disorder:44:0.9323	0.9323	44
DID	DID:34	double immunodiffusion:34:0.9126	0.9126	34
DID	DID:6	inhabitants per day:6:0.2827	0.2827	6
DIEA	DIEA:17	deep inferior epigastric artery:17:0.8270	0.8270	17
DIEP	DIEP:40	Deep Inferior Epigastric Perforator:40:0.9274	0.9274	40
DIEPSS	DIEPSS:8	drug-induced extrapyramidal symptoms scale:8:0.5926	0.5926	8
DIE	DIE:10	infiltrating endometriosis:10:0.7103	0.7103	10
DIF	DIF:35	differential item functioning:35:0.8681	0.8681	35
DIF	DIF:45	differentiation-inducing factor:26:0.2786|differentiation inducing factor:19:0.8365	0.8365	45
DIF	DIF:100	direct immunofluorescence:100:0.9701	0.9701	100
DIGAMI	DIGAMI:11	Infusion in Acute Myocardial Infarction:11:0.7357	0.7357	11
DIGS	DIGS:24	Diagnostic Interview for Genetic Studies:24:0.8657	0.8657	24
DIG	DIG:13	desmoplastic infantile ganglioglioma:13:0.7571	0.7571	13
DIG	DIG:7|Dig:4	digastric:11:0.0538	0.0538	11
DIG	DIG:19	Digitalis Investigation Group:19:0.8449	0.8449	19
DIG	DIG:58|Dig:4|dig:2	digoxigenin:64:0.3333	0.3333	64
dIII	dIII:10	NADP(H)-binding component:10:0.7103	0.7103	10
DiI	DiI:15|diI:3	carbocyanine dye:18:0.2533	0.2533	18
DII	DII:5|dII:3	domain II:8:0.2327	0.2327	8
DiI	DiI:152|Di-I:6|diI:5|DII:1	perchlorate:164:0.4824	0.4824	164
DII	DII:7	type II iodothyronine deiodinase:7:0.5926	0.5926	7
DILD	DILD:8	diffuse infiltrative lung disease:8:0.6411	0.6411	8
DILD	DILD:16	diffuse interstitial lung disease:16:0.8165	0.8165	16
DILS	DILS:21	Diffuse Infiltrative Lymphocytosis Syndrome:21:0.8594	0.8594	21
DIL	DIL:27|Dil:15|dil:2	Diltiazem:44:0.3050	0.3050	44
DIL	DIL:17	drug-induced lupus:17:0.8270	0.8270	17
DIMIT	DIMIT:19|Dimit:1	3,5-dimethyl-3'-isopropyl-L-thyronine:20:0.7917	0.7917	20
DIMP	DIMP:15	diisopropyl methylphosphonate:15:0.8045	0.8045	15
DIMS	DIMS:2	Disorders in initiating and maintaining sleep:2:0.3470	0.3470	2
DINDs	DINDs:8	delayed ischemic neurological deficits:8:0.6411	0.6411	8
DIND	DIND:25	delayed ischemic neurological deficit:15:0.8045|Delayed ischemic neurological deficits:10:0.7103	0.8045	25
DIN	DIN:11	dissolved inorganic nitrogen:11:0.6182	0.6182	11
din	din:8	DNA damage-inducible:8:0.2619	0.2619	8
DIOS	DIOS:4	Desorption/ionization on porous silicon:4:0.4422	0.4422	4
DIOS	DIOS:10	distal intestinal obstruction syndrome:10:0.7103	0.7103	10
DiO	DiO:5|diO:1	3,3'-dioctadecyloxacarbocyanine perchlorate:6:0.2243	0.2243	6
DIO	DIO:24|DiO:1	diet-induced obese:25:0.8816	0.8816	25
DIO	DIO:51	diet-induced obesity:51:0.8102	0.8102	51
DIPE	DIPE:7	diisopropyl ether:7:0.3524	0.3524	7
DIPI	DIPI:19	direct intraperitoneal insemination:19:0.8449	0.8449	19
DIPN	DIPN:10	diisopropanolnitrosamine:10:0.3333	0.3333	10
DIP	DIP:7	defective interfering particles:7:0.4438	0.4438	7
DIP	DIP:15	degradable intake protein:15:0.8045	0.8045	15
DIP	DIP:39	Desquamative interstitial pneumonia:39:0.8811	0.8811	39
DIP	DIP:9	desquamative interstitial pneumonitis:9:0.4587	0.4587	9
DIP	DIP:10	digital image processing:10:0.5856	0.5856	10
DIP	DIP:49|dip:6|Dip:3	dipyridamole:58:0.1012	0.1012	58
DIP	DIP:119	distal interphalangeal:119:0.9600	0.9600	119
DIP	DIP:18	distal interphalangeal joint:18:0.8365	0.8365	18
DIP	DIP:31	drip infusion pyelography:31:0.9043	0.9043	31
DIP	DIP:22	drug-induced parkinsonism:22:0.7955	0.7955	22
DIR	DIR:12	dorsal immobility response:12:0.7571	0.7571	12
DISC1	DISC1:17	Disrupted In Schizophrenia 1:9:0.6411|Disrupted-In-Schizophrenia 1:8:0.1895	0.6411	17
DISC	DISC:106	death-inducing signaling complex:106:0.8605	0.8605	106
DISC	DISC:33	Diagnostic Interview Schedule for Children:33:0.9100	0.9100	33
DISC	DISC:20	Dietary Intervention Study in Children:20:0.8270	0.8270	20
DiSC	DiSC:25|disc:1	differential staining cytotoxicity:26:0.8861	0.8861	26
DISH	DISH:190	diffuse idiopathic skeletal hyperostosis:190:0.9837	0.9837	190
DISH	DISH:6	DNA in situ hybridization:6:0.2827	0.2827	6
DISI	DISI:17	intercalated segment instability:17:0.8270	0.8270	17
DIS-Q	DIS-Q:8|DISQ:3	Questionnaire:11:0.7692	0.7692	11
DIS	DIS:203	Diagnostic Interview Schedule:203:0.9764	0.9764	203
DIS	DIS:8	Difficulty initiating sleep:8:0.5355	0.5355	8
DIS	DIS:27	dimerization initiation site:27:0.5524	0.5524	27
DIS	DIS:5|Dis:4	Disinhibition:9:0.0189	0.0189	9
DIs	DIs:10	DNA indices:10:0.3470	0.3470	10
DIS	DIS:10	Drug Information System:10:0.7103	0.7103	10
DITNC	DITNC:9	immortalized astrocytes:9:0.6794	0.6794	9
DIT	DIT:18	Defining Issues Test:18:0.8365	0.8365	18
DIT	DIT:65	diet-induced thermogenesis:65:0.6789	0.6789	65
DIT	DIT:16	Diffuse Intimal Thickening:16:0.8165	0.8165	16
DIT	DIT:25|Dit:1	diiodotyrosine:26:0.1196	0.1196	26
DIV	DIV:266|div:16|Div:1	days in vitro:283:0.7758	0.7758	283
DI	DI:29	Brattleboro:29:0.0129	0.0129	29
DI	DI:10	Brattleboro homozygous:10:0.2643	0.2643	10
DI	DI:8	Brattleboro rats:8:0.2987	0.2987	8
DI	DI:8	days of incubation:8:0.4102	0.4102	8
DI	DI:22	deep inhalation:22:0.7955	0.7955	22
DI	DI:34	deep inspiration:34:0.9126	0.9126	34
DI	DI:329|di:1	Defective interfering:275:0.9767|defective-interfering:55:0.0248	0.9767	330
DI	DI:34	Dentinogenesis imperfecta:34:0.9126	0.9126	34
DI	DI:51	detrusor instability:51:0.8316	0.8316	51
DI	DI:318|di:2	diabetes insipidus:320:0.9799	0.9799	320
DI	DI:10	dialyzed iron:10:0.2446	0.2446	10
DI	di:9|DI:9	diaphragm:18:0.0078	0.0078	18
DI	DI:11	diastolic interval:11:0.4728	0.4728	11
DI	DI:5	diestrus I:5:0.0612	0.0612	5
DI	DI:221	DNA Index:221:0.4009	0.4009	221
DI	DI:20	DNA indices:20:0.4379	0.4379	20
DI	DI:59	donor insemination:59:0.9494	0.9494	59
DI	DI:70	dose intensity:56:0.8453|dose-intensity:14:0.0060	0.8453	70
DI	DI:8|D-I:1	injury:9:0.0037	0.0037	9
DI	DI:10	Social Security Disability Insurance:10:0.7103	0.7103	10
DJD	DJD:77	degenerative joint disease:77:0.9612	0.9612	77
DJS	DJS:27	Dubin-Johnson syndrome:27:0.7834	0.7834	27
DJ	DJ:17	drop jump:9:0.6794|drop jumps:8:0.4102	0.6794	17
DKA	DKA:315	diabetic ketoacidosis:315:0.9277	0.9277	315
DKB	DKB:38	dibekacin:38:0.6852	0.6852	38
DKC	DKC:22	dyskeratosis congenita:22:0.8657	0.8657	22
Dkk	Dkk:10|DKK:2	Dickkopf:12:0.5500	0.5500	12
DKO	DKO:34|dKO:4|dko:2	double knockout:27:0.7066|double-knockout:13:0.1667	0.7066	40
DKP	DKP:18	diketopiperazine:18:0.3778	0.3778	18
DL(CO)	DL(CO):7	carbon monoxide diffusing capacity:7:0.5926	0.5926	7
DL(CO)	DL(CO):12	diffusing capacity for carbon monoxide:12:0.5335	0.5335	12
DL-TBOA	DL-TBOA:18|dl-TBOA:1	DL-threo-beta-Benzyloxyaspartate:19:0.8571	0.8571	19
DLA	DLA:14	Dalton's lymphoma ascites:14:0.7909	0.7909	14
DLA	DLA:22	diffusion-limited aggregation:14:0.3585|diffusion limited aggregation:8:0.6411	0.6411	22
DLA	DLA:12	dog leukocyte antigen:12:0.7571	0.7571	12
DLA	DLA:6|DL-A:3	histocompatibility complex:9:0.6794	0.6794	9
DLBCLs	DLBCLs:30	diffuse large B-cell lymphomas:30:0.9011	0.9011	30
DLBCL	DLBCL:289|DLB-CL:1	diffuse large B-cell lymphoma:240:0.9800|diffuse large B-cell lymphomas:50:0.9404	0.9800	290
DLBD	DLBD:75	diffuse Lewy body disease:75:0.9602	0.9602	75
DLBL	DLBL:43	diffuse large B-cell lymphoma:34:0.9126|diffuse large B-cell lymphomas:9:0.6794	0.9126	43
DLB	DLB:8	dementia with LB:8:0.5470	0.5470	8
DLB	DLB:410	dementia with Lewy bodies:410:0.9882	0.9882	410
DLCL	DLCL:138|DLC-L:1	diffuse large cell lymphoma:86:0.9455|diffuse large-cell lymphoma:40:0.9256|diffuse large cell lymphomas:13:0.7753	0.9455	139
DLCOsb	DLCOsb:5|DLCOSB:4|DLcoSB:1	diffusing capacity:10:0.7103	0.7103	10
DLCO	DLCO:53|DLco:12|Dlco:2|DlCO:1	carbon monoxide diffusing capacity:68:0.9561	0.9561	68
DLCO	DLCO:17|DLco:3	carbon monoxide diffusion capacity:20:0.8525	0.8525	20
DLCO	DLCO:69|DLco:12	diffusing capacity for carbon monoxide:81:0.6251	0.6251	81
DLCO	DLCO:17	diffusing capacity for CO:17:0.4934	0.4934	17
DLCO	DLCO:8|DLco:2	diffusing capacity of the lung:10:0.7357	0.7357	10
DLCO	DLCO:44|Dlco:4|DLco:2	diffusing capacity of the lung for carbon monoxide:50:0.6499	0.6499	50
DLCO	DLCO:21|DLco:7	diffusion capacity for carbon monoxide:28:0.1472	0.1472	28
DLCO	DLCO:11|Dlco:4	diffusion capacity of the lung for carbon monoxide:15:0.1181	0.1181	15
DLCO	DLCO:9|Dlco:1	transfer factor:10:0.5856	0.5856	10
DLCs	DLCs:8	dioxin-like compounds:8:0.5006	0.5006	8
DLC	DLC:29	diamond-like carbon:29:0.6157	0.6157	29
DLC	DLC:11	differential leukocyte count:11:0.7357	0.7357	11
DLC	DLC:8	Digitalis-like compounds:8:0.5006	0.5006	8
DLC	DLC:5	double-lumen catheter:5:0.0902	0.0902	5
D-LDH	D-LDH:13|DLDH:1|D-ldh:1|d-LDH:1	D-lactate dehydrogenase:16:0.5564	0.5564	16
DLD	DLD:27	Developmental language disorder:18:0.8365|developmental language disorders:9:0.6794	0.8365	27
Dld	Dld:4|DLD:3	dihydrolipoamide dehydrogenase:7:0.2113	0.2113	7
DLEK	DLEK:18	deep lamellar endothelial keratoplasty:18:0.8165	0.8165	18
DLE	DLE:5	Dialysable Leucocyte Extract:5:0.1973	0.1973	5
DLE	DLE:23	dialyzable leukocyte extracts:14:0.4849|dialyzable leukocyte extract:9:0.3455	0.4849	23
DLE	DLE:18	discoid LE:18:0.8449	0.8449	18
DLE	DLE:136	discoid lupus erythematosus:136:0.8732	0.8732	136
DLF	DLF:16	digitalis-like factor:16:0.2093	0.2093	16
DLF	DLF:12	dorsolateral funiculi:12:0.6460	0.6460	12
DLF	DLF:89	dorsolateral funiculus:89:0.7401	0.7401	89
dLGN	dLGN:249|DLGN:8|dlgn:2|dlGn:2|DLGn:1|dLGn:1	dorsal lateral geniculate nucleus:263:0.9404	0.9404	263
Dlg	Dlg:28|dlg:19|DLG:10	discs large:38:0.8781|discs-large:19:0.1731	0.8781	57
DLG	DLG:12|dLG:2	dorsal lateral geniculate nucleus:14:0.7909	0.7909	14
DLH	DLH:40	DL-homocysteic acid:40:0.4699	0.4699	40
DLH	DLH:6	excitatory amino acid D,L-homocysteic acid:6:0.3524	0.3524	6
DLIF	DLIF:45	Digoxin-like immunoreactive factor:24:0.6767|digoxin-like immunoreactive factors:21:0.7291	0.7291	45
DLIS	DLIS:64	digoxin-like immunoreactive substance:35:0.9151|digoxin-like immunoreactive substances:29:0.6928	0.9151	64
DLI	DLI:7	digoxin-like immunoreactivity:7:0.1329	0.1329	7
DLI	DLI:70	donor leukocyte infusion:41:0.8867|Donor leukocyte infusions:29:0.8978	0.8978	70
DLI	DLI:190	donor lymphocyte infusion:116:0.9333|donor lymphocyte infusions:74:0.9159	0.9333	190
DLKP	DLKP:11	deep lamellar keratoplasty:11:0.7357	0.7357	11
DLMO	DLMO:28	dim light melatonin onset:28:0.8941	0.8941	28
DLM	DLM:16	dominant lethal mutations:16:0.8165	0.8165	16
DLM	DLM:8	dorsal longitudinal flight muscle:8:0.6411	0.6411	8
DLM	DLM:13	dorsal longitudinal muscle:13:0.7753	0.7753	13
DLM	DLM:4	dorsolateral nucleus of the thalamus:4:0.2818	0.2818	4
DLM	DLM:6	dorsolateral thalamus:6:0.0807	0.0807	6
DLNs	DLNs:9	draining lymph nodes:9:0.3945	0.3945	9
DLN	DLN:70|D-LN:1|dLN:1	draining lymph nodes:48:0.7790|draining lymph node:24:0.7593	0.7790	72
D-loop	D-loop:47|d-loop:1|D-Loop:1	displacement loop:39:0.7907|displacement-loop:10:0.0957	0.7907	49
DLPC	DLPC:8	dilauroyl phosphatidylcholine:8:0.1895	0.1895	8
DLPC	DLPC:42|dlPC:2	dilauroylphosphatidylcholine:44:0.2945	0.2945	44
DLPC	DLPC:22	dilinoleoylphosphatidylcholine:22:0.1438	0.1438	22
DLPFC	DLPFC:209|dlPFC:13|dl-PFC:1	dorsolateral prefrontal cortex:223:0.9250	0.9250	223
DLPN	DLPN:22|dlpn:1	dorsolateral pontine nucleus:23:0.8715	0.8715	23
DLP	DLP:19	dorsolateral prostate:19:0.7044	0.7044	19
DLP	DLP:8	dorsolateralis posterior:8:0.5006	0.5006	8
DLP	DLP:9	dose-length product:9:0.3455	0.3455	9
DLP	DLP:12	dyslipoproteinemia:12:0.0815	0.0815	12
DLQI	DLQI:76	Dermatology Life Quality Index:76:0.9602	0.9602	76
DLR	DLR:28	digital luminescence radiography:28:0.8941	0.8941	28
DLSC	DLSC:8	deep layers of superior colliculus:8:0.5732	0.5732	8
DLSN	DLSN:42	dorsolateral septal nucleus:42:0.9291	0.9291	42
DLST	DLST:5	Dihydrolipoamide succinyltransferase:5:0.1132	0.1132	5
DLST	DLST:12	drug lymphocyte stimulation test:12:0.4153	0.4153	12
DLTs	DLTs:5	double-lumen endobronchial tubes:5:0.4422	0.4422	5
DLT	DLT:18	direct linear transformation:18:0.8365	0.8365	18
DLT	DLT:8	donor leukocyte transfusion:8:0.6411	0.6411	8
DLT	DLT:53	dose limiting toxicity:53:0.9438	0.9438	53
DLT	DLT:8	double-lumen endobronchial tube:8:0.4102	0.4102	8
DLT	DLT:30	double-lumen tube:21:0.2743|double lumen tube:9:0.6794	0.6794	30
DLT	DLT:5	double lung transplantation:5:0.4422	0.4422	5
DLV	DLV:17	delavirdine:17:0.3200	0.3200	17
DLV	DLV:12	differential lung ventilation:12:0.7571	0.7571	12
DLW	DLW:74	doubly labeled water:74:0.9596	0.9596	74
DLW	DLW:31	doubly labelled water:31:0.9043	0.9043	31
DLW	DLW:7	water method:7:0.3524	0.3524	7
DLS	DLS:7	dictyosome-like structures:7:0.3524	0.3524	7
DLs	DLs:32	difference limens:32:0.7782	0.7782	32
DLS	DLS:10|dls:1	differential light sensitivity:11:0.7357	0.7357	11
DLS	DLS:13	digitalis-like substance:13:0.2959	0.2959	13
DLS	DLS:8	digoxin-like substance:8:0.1061	0.1061	8
DLS	DLS:18	Dimer Linkage Structure:18:0.8365	0.8365	18
DLs	DLs:11	dose levels:11:0.7357	0.7357	11
DLS	DLS:159	dynamic light scattering:150:0.9220|Dynamic light-scattering:9:0.6794	0.9220	159
DM-COOK	DM-COOK:11	acid potassium salt:11:0.7357	0.7357	11
DM/PM	DM/PM:9	dermatomyositis/polymyositis:9:0.4444	0.4444	9
dm2	dm2:9	BALB/c-H-2dm2:9:0.0440	0.0440	9
DM2	DM2:13|DM-2:4	diabetes mellitus type 2:17:0.8365	0.8365	17
DM2	DM2:18	myotonic dystrophy type 2:18:0.8365	0.8365	18
DM2	DM2:16|DM-2:3	type 2 diabetes:19:0.8449	0.8449	19
DM2	DM2:57|DM-2:10	Type 2 Diabetes Mellitus:67:0.9554	0.9554	67
DMA(III)	DMA(III):15	dimethylarsinous acid:15:0.7096	0.7096	15
DMA(V)	DMA(V):20	dimethylarsinic acid:20:0.8525	0.8525	20
DMAA	DMAA:55	Dimethylarsinic acid:55:0.8882	0.8882	55
DMAA	DMAA:11	distal metatarsal articular angle:11:0.7357	0.7357	11
DMAB	DMAB:62	3,2'-dimethyl-4-aminobiphenyl:62:0.6742	0.6742	62
DMAC	DMAC:15|DMAc:9	dimethylacetamide:24:0.2949	0.2949	24
DMAC	DMAC:16|dMAC:1	disseminated Mycobacterium avium complex:17:0.8270	0.8270	17
DMAC	DMAC:7|DMAc:5	N,N-dimethylacetamide:12:0.1410	0.1410	12
DMAD	DMAD:15	dimethyl acetylenedicarboxylate:15:0.7096	0.7096	15
DMAE	DMAE:10	Dimethylaminoethanol:10:0.2093	0.2093	10
DMAP	DMAP:15	4-(dimethylamino)pyridine:15:0.1176	0.1176	15
DMAP	DMAP:17	4-Dimethylaminophenol:17:0.1345	0.1345	17
DMAP	DMAP:9|dmap:2	4-Dimethylaminopyridine:11:0.0840	0.0840	11
DMAP	DMAP:15	6-dimethylaminopurine:15:0.1176	0.1176	15
DMARD	DMARD:25	disease-modifying anti-rheumatic drug:17:0.4480|disease modifying anti-rheumatic drug:8:0.6411	0.6411	25
DMARD	DMARD:187	disease modifying antirheumatic drugs:77:0.9607|disease modifying antirheumatic drug:56:0.9467|disease-modifying antirheumatic drug:54:0.3865	0.9607	187
DMARDs	DMARDs:99|DMARDS:2|DMAR-Ds:1	disease-modifying anti-rheumatic drugs:73:0.6157|disease modifying anti-rheumatic drugs:29:0.8978	0.8978	102
DMARDs	DMARDs:184|DMARDS:1	disease-modifying antirheumatic drugs:139:0.6778|disease modifying antirheumatic drugs:46:0.8986	0.8986	185
DMA	DMA:27	5-(N,N-dimethyl)-amiloride:16:0.0217|5-(N,N-dimethyl)amiloride:11:0.0145	0.0217	27
DMA	DMA:12	dimethyl adipimidate:12:0.7571	0.7571	12
DMA	DMA:11	dimethyl amiloride:11:0.5050	0.5050	11
DMA	DMA:12	dimethylacetamide:12:0.0159	0.0159	12
DMA	DMA:31	dimethylamiloride:31:0.0434	0.0434	31
DMA	DMA:80|dma:1	dimethylamine:81:0.1158	0.1158	81
DMA	DMA:51	Dynamic mechanical analysis:51:0.8799	0.8799	51
DMA	DMA:13	N,N-dimethylacetamide:13:0.0174	0.0174	13
DMA	DMA:30	N,N-dimethylaniline:30:0.0420	0.0420	30
DMBA	DMBA:19	7,12-dimethyl-benz[a]anthracene:19:0.0102	0.0102	19
DMBA	DMBA:1004|dmba:1	7,12-dimethylbenz[a]anthracene:668:0.3756|7,12-dimethylbenz(a)anthracene:291:0.1636|7,12-dimethylbenz[a]-anthracene:20:0.0108|7,12 dimethylbenz(a)anthracene:14:0.1083|7,12-dimethylbenz(a) anthracene:12:0.0622	0.3756	1005
DMBA	DMBA:51	7,12-dimethylbenz[alpha]anthracene:29:0.0159|7,12-dimethylbenz(alpha)anthracene:22:0.0119	0.0159	51
DMBA	DMBA:72	7,12-dimethylbenzanthracene:72:0.0398	0.0398	72
DMBA	DMBA:66	9,10-dimethyl-1,2-benzanthracene:65:0.0364|9 10-dimethyl-1 2-benzanthracene:1:0.5290	0.5290	66
DMBA	DMBA:13	benzanthracene:13:0.0068	0.0068	13
DMBA	DMBA:12	carcinogen:12:0.0063	0.0063	12
DMBA	DMBA:51	dimethylbenz[a]anthracene:51:0.0278	0.0278	51
DMBA	DMBA:60	dimethylbenzanthracene:60:0.0335	0.0335	60
DMBT1	DMBT1:10	deleted in malignant brain tumors 1:10:0.5856	0.5856	10
DMB	DMB:12	1,9-dimethylmethylene blue:12:0.2699	0.2699	12
DMB	DMB:10	dimethylmethylene blue:10:0.1878	0.1878	10
dmcc	dmcc:6|DMCC:4	dorsomedial cell column:10:0.5856	0.5856	10
DMCM	DMCM:5	inverse agonist methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate:5:0.7357	0.7357	5
DMCM	DMCM:27	methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate:27:0.7834	0.7834	27
DMC	DMC:10	data monitoring committee:10:0.7103	0.7103	10
DMC	DMC:8	dimethyl carbonate:8:0.4102	0.4102	8
DMD/BMD	DMD/BMD:23	Duchenne and Becker muscular dystrophy:16:0.7291|Duchenne and Becker muscular dystrophies:7:0.6411	0.7291	23
DMD/BMD	DMD/BMD:20	Duchenne/Becker muscular dystrophy:20:0.2678	0.2678	20
DMDC	DMDC:11	2'-deoxy-2'-methylidenecytidine:11:0.3846	0.3846	11
DMDO	DMDO:16	dimethyldioxirane:16:0.9375	0.9375	16
DMDP	DMDP:9	dichloromethylene diphosphonate:9:0.6794	0.6794	9
DMDS	DMDS:23	dimethyl disulfide:23:0.8715	0.8715	23
DMDTC	DMDTC:12|DmDTC:3	dimethyldithiocarbamate:15:0.8750	0.8750	15
DMDZ	DMDZ:20	desmethyldiazepam:20:0.9500	0.9500	20
DMD	DMD:12	differentially methylated domain:12:0.7571	0.7571	12
DMD	DMD:13	DM digestibility:13:0.2415	0.2415	13
DMD	DMD:15	dry matter digestibility:15:0.8045	0.8045	15
DMD	DMD:58	Duchenne:58:0.0320	0.0320	58
DMD	DMD:1412|Dmd:3	Duchenne muscular dystrophy:1415:0.9049	0.9049	1415
DMD	DMD:10	dystonia musculorum deformans:10:0.7103	0.7103	10
DMD	DMD:4	progressive muscular dystrophy of the Duchenne type:4:0.4422	0.4422	4
DMEC	DMEC:14	dermal microvascular endothelial cells:14:0.6911	0.6911	14
DMED	DMED:7|dMED:1|D-med:1|D-MED:1	Dexmedetomidine:10:0.5000	0.5000	10
DMEM	DMEM:175|D-MEM:3	Dulbecco's modified Eagle's Medium:178:0.9338	0.9338	178
D-Met	D-Met:7|D-met:4	D-methionine:11:0.5556	0.5556	11
DME	DME:37	diabetic macular edema:37:0.8377	0.8377	37
DME	DME:15	dimethyl ether:15:0.8045	0.8045	15
DME	DME:5	drug-metabolizing enzymes:5:0.0902	0.0902	5
DME	DME:9	Dulbecco's modified Eagle's medium:9:0.4587	0.4587	9
DME	DME:20	durable medical equipment:20:0.8525	0.8525	20
DMFS	DMFS:26	distant metastasis-free survival:26:0.8861	0.8861	26
DMFs	DMFs:8	dose modification factors:8:0.6411	0.6411	8
DMFT	DMFT:10|DMF-T:3|dmft:2	caries experience:15:0.7096	0.7096	15
DMFT	DMFT:4|dmft:3|DMF-T:2	caries prevalence:9:0.6794	0.6794	9
DMFC	DMFC:12	dorsomedial frontal cortex:12:0.7571	0.7571	12
DMF	DMF:2	decayed missing and filled:2:0.6794	0.6794	2
DMF	DMF:21	dimethyl formamide:21:0.6040	0.6040	21
DMF	DMF:11	dimethyl fumarate:11:0.7357	0.7357	11
DMF	DMF:189|dmf:2	dimethylformamide:191:0.2793	0.2793	191
DMF	DMF:18	Dimethylfumarate:18:0.0255	0.0255	18
DMF	DMF:54	dose modification factor:40:0.9256|dose modification factors:14:0.7909	0.9256	54
DMF	DMF:30	dose modifying factor:30:0.9011	0.9011	30
DMF	DMF:179	N,N-dimethylformamide:179:0.2658	0.2658	179
DMG	DMG:15	dimethylglycine:15:0.1818	0.1818	15
DMG	DMG:12	dimethylglyoxime:12:0.1429	0.1429	12
DMH	DMH:6	1,2-dimethyl hydrazine:6:0.2243	0.2243	6
DMH	DMH:355	1,2-dimethylhydrazine:355:0.4573	0.4573	355
DMH	DMH:24	1,2-dimethylhydrazine dihydrochloride:24:0.7151	0.7151	24
DMH	DMH:106	dimethylhydrazine:106:0.1347	0.1347	106
DMH	DMH:26	dorsomedial:26:0.0324	0.0324	26
DMH	DMH:9	dorsomedial hypothalamic:9:0.6794	0.6794	9
DMH	DMH:33	dorsomedial hypothalamic nucleus:33:0.8605	0.8605	33
DMH	DMH:55	dorsomedial hypothalamus:55:0.6163	0.6163	55
DMH	DMH:14	dorsomedial nucleus:14:0.1392	0.1392	14
DMH	DMH:14	dorsomedial nucleus of the hypothalamus:14:0.8045	0.8045	14
DMI	DMI:11	Defense Mechanisms Inventory:6:0.5290|Defense Mechanism Inventory:5:0.4422	0.5290	11
DMI	DMI:9	desimipramine:9:0.0089	0.0089	9
DMI	DMI:371|dmi:2	desipramine:373:0.4168	0.4168	373
DMI	DMI:220	desmethylimipramine:220:0.2436	0.2436	220
DMI	DMI:14	diabetic muscle infarction:14:0.7909	0.7909	14
DMI	DMI:25	Doppler myocardial imaging:25:0.8816	0.8816	25
DMI	DMI:117	dry matter intake:117:0.9744	0.9744	117
DMJ	DMJ:8|dMJ:1	1-deoxymannojirimycin:9:0.3333	0.3333	9
DMLC	DMLC:12|dMLC:1	dynamic multileaf collimation:13:0.6701	0.6701	13
DMLC	DMLC:13|dMLC:3|D-MLC:1	dynamic multileaf collimator:17:0.8270	0.8270	17
DML	DML:32	distal motor latency:32:0.9072	0.9072	32
DMMP	DMMP:20	dimethyl methylphosphonate:20:0.8449	0.8449	20
dMM	dMM:20|DMM:2	1-deoxymannojirimycin:22:0.1207	0.1207	22
dMM	dMM:18|DMM:1	deoxymannojirimycin:19:0.1034	0.1034	19
DMM	DMM:19	desmoplastic malignant melanoma:19:0.6106	0.6106	19
DMM	DMM:8	diffuse malignant mesothelioma:8:0.3463	0.3463	8
Dmm	Dmm:8|DMM:1	disproportionate micromelia:9:0.6794	0.6794	9
DMNA	DMNA:54	dimethylnitrosamine:54:0.7361	0.7361	54
DMND	DMND:5|DMN-d:2	Dimethylnitrosamine demethylase:7:0.3524	0.3524	7
DMNQ	DMNQ:16	2,3-dimethoxy-1,4-naphthoquinone:16:0.4167	0.4167	16
DMNV	DMNV:21	dorsal motor nucleus of the vagus:21:0.7955	0.7955	21
DMN	DMN:410|dMN:1	dimethylnitrosamine:411:0.5631	0.5631	411
DMN	DMN:28	dorsal motor nucleus:28:0.8941	0.8941	28
DMN	DMN:36	dorsal motor nucleus of the vagus:36:0.9217	0.9217	36
DMN	DMN:15	dorsomedial:15:0.0194	0.0194	15
DMN	DMN:5	dorsomedial hypothalamic nuclei:5:0.2818	0.2818	5
DMN	DMN:14	dorsomedial hypothalamic nucleus:14:0.7909	0.7909	14
DMN	DMN:36	dorsomedial nucleus:36:0.2726	0.2726	36
DMN	DMN:15	dysplastic melanocytic nevi:15:0.8045	0.8045	15
DMN	DMN:9	N,N-dimethylnitrosamine:9:0.0111	0.0111	9
DMN	DMN:46	N-nitrosodimethylamine:46:0.0638	0.0638	46
DMO	DMO:35	5,5-dimethyl-2,4-oxazolidinedione:35:0.2036	0.2036	35
DMO	DMO:30	dimethadione:30:0.1737	0.1737	30
DMO	DMO:3	weak acid 5,5-dimethyloxazolidine-2,4-dione:3:0.1618	0.1618	3
DMPA	DMPA:13	Depo-Provera:13:0.0301	0.0301	13
DMPA	DMPA:126	depot medroxyprogesterone acetate:126:0.8186	0.8186	126
DMPA	DMPA:18	dimyristoylphosphatidic acid:18:0.2462	0.2462	18
DMPC	DMPC:48	1,2-dimyristoyl-sn-glycero-3-phosphocholine:48:0.0493	0.0493	48
DMPC	DMPC:9|dm-PC:1	dimyristoyl:10:0.0094	0.0094	10
DMPC	DMPC:10	dimyristoyl-L-alpha-phosphatidylcholine:10:0.0094	0.0094	10
DMPC	DMPC:18	dimyristoyl phosphatidyl choline:18:0.7539	0.7539	18
DMPC	DMPC:137	dimyristoyl phosphatidylcholine:113:0.8246|dimyristoyl-phosphatidylcholine:24:0.0241	0.8246	137
DMPC	DMPC:549	dimyristoylphosphatidylcholine:549:0.5755	0.5755	549
DMPC	DMPC:15	L-alpha-dimyristoylphosphatidylcholine:15:0.0147	0.0147	15
DMPG	DMPG:18	dimyristoyl phosphatidylglycerol:18:0.5560	0.5560	18
DMPG	DMPG:6	dimyristoylphosphatidyl glycerol:6:0.1838	0.1838	6
DMPG	DMPG:62	dimyristoylphosphatidylglycerol:62:0.4094	0.4094	62
DMPK	DMPK:5	3' untranslated region of the myotonic dystrophy protein kinase gene:5:0.4422	0.4422	5
DMPK	DMPK:45|DM-PK:3|Dmpk:1	myotonic dystrophy protein kinase:49:0.9392	0.9392	49
DMPM	DMPM:13	diffuse malignant pleural mesothelioma:13:0.7753	0.7753	13
DMPO	DMPO:17	5,5-dimethyl-1-pyrroline 1-oxide:17:0.5760	0.5760	17
DMPO	DMPO:9	5,5-dimethyl-pyrroline-N-oxide:9:0.0130	0.0130	9
DMPO	DMPO:13	5,5-dimethylpyrroline-N-oxide:13:0.0194	0.0194	13
DMPO	DMPO:9	spin trap 5,5-dimethyl-1-pyrroline-1-oxide:9:0.7357	0.7357	9
DMPO	DMPO:9	spin trap 5,5'-dimethyl-1-pyrroline-N-oxide:9:0.7103	0.7103	9
DMPP	DMPP:14	1,1-dimethyl-4-phenyl-piperazinium:14:0.0423	0.0423	14
DMPP	DMPP:37	1,1-dimethyl-4-phenylpiperazinium iodide:37:0.3082	0.3082	37
DMPP	DMPP:78	dimethylphenylpiperazinium:78:0.2476	0.2476	78
DMPP	DMPP:11	nicotinic agonist 1,1-dimethyl-4-phenylpiperazinium:11:0.4153	0.4153	11
DMPP	DMPP:11	piperazinium:11:0.0326	0.0326	11
DMPS	DMPS:8	2,3-dimercapto-1-propane sulfonate:8:0.1471	0.1471	8
DMPS	DMPS:9	2,3-dimercapto-1-propanesulfonate:9:0.0316	0.0316	9
DMPS	DMPS:21	2,3-dimercapto-1-propanesulfonic acid:21:0.1806	0.1806	21
DMPS	DMPS:6	dimyristoyl phosphatidylserine:6:0.1838	0.1838	6
DMPS	DMPS:16	dimyristoylphosphatidylserine:16:0.0593	0.0593	16
DMPS	DMPS:6	sodium 2,3-dimercaptopropane-1-sulfonate:6:0.0611	0.0611	6
DMPT	DMPT:8|DMpT:1	N,N-dimethyl-p-toluidine:9:0.2424	0.2424	9
DMP	DMP:9	2,2-dimethoxypropane:9:0.0251	0.0251	9
DMP	DMP:16	deep muscular plexus:16:0.7261	0.7261	16
DMP	DMP:25	dimethyl phthalate:25:0.7679	0.7679	25
DMP	DMP:11	Dimethylphosphate:11:0.0313	0.0313	11
DMP	DMP:9	dimethylphthalate:9:0.0251	0.0251	9
dMRI	dMRI:9|DMRI:3|d-MRI:2	magnetic resonance imaging:14:0.7909	0.7909	14
DMRs	DMRs:23	differentially methylated regions:23:0.8038	0.8038	23
DMRV	DMRV:14	Distal myopathy with rimmed vacuoles:14:0.7909	0.7909	14
DMR	DMR:28	differentially methylated region:28:0.8369	0.8369	28
DMSO2	DMSO2:11	dimethyl sulfone:11:0.7357	0.7357	11
DMSOR	DMSOR:8	dimethyl sulfoxide reductase:8:0.6411	0.6411	8
DMSO	DMSO:1576|dmso:4	dimethyl sulfoxide:1555:0.9847|dimethyl-sulfoxide:25:0.0078	0.9847	1580
DMSO	DMSO:250	dimethyl sulphoxide:250:0.9745	0.9745	250
DMSO	DMSO:862|dmso:1	dimethylsulfoxide:863:0.2794	0.2794	863
DMSO	DMSO:209	dimethylsulphoxide:209:0.0674	0.0674	209
DMSP	DMSP:23	dimethylsulfoniopropionate:23:0.4468	0.4468	23
DMSP	DMSP:9	dimethylsulphoniopropionate:9:0.1702	0.1702	9
DMSe	DMSe:11|DmSe:1	dimethylselenide:12:0.5000	0.5000	12
DMS	DMS:16	delayed match-to-sample:16:0.8165	0.8165	16
DMS	DMS:19	delayed matching-to-sample:19:0.8449	0.8449	19
DMS	DMS:9	delusional misidentification syndromes:9:0.6794	0.6794	9
DMS	DMS:18	demarcation membrane system:18:0.7539	0.7539	18
DMS	DMS:21|dms:1	dexamethasone:22:0.0266	0.0266	22
DMS	DMS:3	difficulty in maintaining sleep:3:0.5000	0.5000	3
DMS	DMS:24	diffuse mesangial sclerosis:24:0.8768	0.8768	24
DMS	DMS:6	dimercaptosuccinic acid:6:0.0807	0.0807	6
DMS	DMS:16	dimethyl suberimidate:16:0.6577	0.6577	16
DMS	DMS:68	dimethyl sulfate:68:0.9306	0.9306	68
DMS	DMS:60	dimethyl sulfide:60:0.9216	0.9216	60
DMS	DMS:26	dimethyl sulphate:26:0.8251	0.8251	26
DMS	DMS:9	dimethyl sulphide:9:0.6794	0.6794	9
DMS	DMS:16	dimethylsuberimidate:16:0.0190	0.0190	16
DMS	DMS:46	dimethylsulfate:46:0.0570	0.0570	46
DMS	DMS:16	dimethylsulfide:16:0.0190	0.0190	16
DMS	DMS:16	dimethylsulphate:16:0.0190	0.0190	16
DMs	DMs:48|DMS:1	double minutes:49:0.8753	0.8753	49
DMs	DMs:48|DMS:3	double minute chromosomes:40:0.9256|double-minute chromosomes:11:0.0830	0.9256	51
DMS	DMS:33	N,N-dimethylsphingosine:33:0.0405	0.0405	33
DMT1	DMT1:13|DMT-1:2	divalent metal transporter:15:0.7096	0.7096	15
DMT1	DMT1:65|DMT-1:13	Divalent metal transporter 1:55:0.9458|divalent metal transporter-1:23:0.8038	0.9458	78
DMTA	DMTA:14	dynamic mechanical thermal analysis:14:0.7909	0.7909	14
DMTP	DMTP:6	delayed matching to position:6:0.5290	0.5290	6
DMTP	DMTP:11	dimethylthiophosphate:11:0.1515	0.1515	11
DMTU	DMTU:16|dmtu:1	1,3-dimethyl-2-thiourea:17:0.0796	0.0796	17
DMTU	DMTU:12	dimethyl thiourea:12:0.7571	0.7571	12
DMTS	DMTS:54	delayed matching-to-sample:38:0.8781|delayed-matching-to-sample:10:0.1084|Delayed matching to sample:6:0.5926	0.8781	54
DMT	DMT:14	Defense Mechanism Test:14:0.4444	0.4444	14
DMT	DMT:10	dimethyltryptamine:10:0.0321	0.0321	10
DMT	DMT:68	N,N-dimethyltryptamine:68:0.2691	0.2691	68
DMVA	DMVA:11	Direct Mechanical Ventricular Actuation:11:0.7357	0.7357	11
DMV	DMV:15	Department of Motor Vehicles:15:0.6386	0.6386	15
DMV	DMV:12	dolphin morbillivirus:12:0.6460	0.6460	12
DMV	DMV:117	dorsal motor nucleus of the vagus:117:0.9273	0.9273	117
DMV	DMV:20	dorsal motor nucleus of the vagus nerve:20:0.8657	0.8657	20
DMXAA	DMXAA:90	5,6-Dimethylxanthenone-4-acetic acid:90:0.8588	0.8588	90
DMX	DMX:12	depressive mixed state:12:0.7571	0.7571	12
DMX	DMX:14|dmX:1|dMX:1	dorsal motor nucleus of the vagus:16:0.8165	0.8165	16
DMX	DMX:12	dorsal motor nucleus of the vagus nerve:12:0.7571	0.7571	12
DMZ	DMZ:8	demilitarized zone:8:0.1471	0.1471	8
DMZ	DMZ:14	dimetridazole:14:0.3421	0.3421	14
DMZ	DMZ:10	dorsal marginal zone:10:0.7103	0.7103	10
DMCs	DMCs:11	data monitoring committees:11:0.7357	0.7357	11
DN-1417	DN-1417:7	gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide citrate:7:0.2452	0.2452	7
DNA-MG	DNA-MG:8	DNA malignancy grade:8:0.6411	0.6411	8
DNA-SSB	DNA-SSB:12|DNA-ssb:1	DNA single-strand breaks:7:0.5926|DNA single strand breaks:6:0.5290	0.5926	13
DNAB	DNAB:17	dorsal noradrenergic bundle:17:0.8270	0.8270	17
DNA-PK	DNA-PK:355|DNAPK:4	DNA-dependent protein kinase:359:0.9064	0.9064	359
DNAPL	DNAPL:10	dense non-aqueous phase liquid:10:0.7753	0.7753	10
DNAPL	DNAPL:17	dense nonaqueous phase liquid:17:0.7539	0.7539	17
DNAPLs	DNAPLs:6	dense non-aqueous phase liquids:6:0.5006	0.5006	6
DNAP	DNAP:14|DNAp:14|DNA-P:7|DNA-p:2	DNA polymerase:37:0.8749	0.8749	37
DNAR	DNAR:11	Not Attempt Resuscitation:11:0.7357	0.7357	11
DNA	DNA:1761	deoxyribonucleic acid:1747:0.9053|deoxyribonucleic acids:14:0.3202	0.9053	1761
DNBS	DNBS:1	experimental model of colitis induced by dinitrobenzene sulfonic acid:1:0.5926	0.5926	1
DNB	DNB:14	1,3-dinitrobenzene:14:0.1625	0.1625	14
DNB	DNB:20	dorsal noradrenergic bundle:20:0.8525	0.8525	20
DNCB	DNCB:17	1-chloro-2,4-dinitrobenzene:17:0.0307	0.0307	17
DNCB	DNCB:110	2,4-dinitrochlorobenzene:110:0.2092	0.2092	110
DNCB	DNCB:321	dinitrochlorobenzene:321:0.6123	0.6123	321
DNC	DNC:18	4,4'-dinitrocarbanilide:18:0.1910	0.1910	18
DNDS	DNDS:17	4,4'-dinitrostilbene-2,2'-disulfonate:17:0.2133	0.2133	17
DND	DND:51	delayed neuronal death:51:0.9416	0.9416	51
DNES	DNES:11	Diffuse Neuroendocrine System:11:0.6182	0.6182	11
DNFB	DNFB:11	1-fluoro-2,4-dinitrobenzene:11:0.0292	0.0292	11
DNFB	DNFB:27	2,4-dinitro-1-fluorobenzene:27:0.0758	0.0758	27
DNFB	DNFB:111	2,4-dinitrofluorobenzene:111:0.3207	0.3207	111
DNFB	DNFB:148	dinitrofluorobenzene:148:0.4286	0.4286	148
d-NF	d-NF:2|dNF:1	metabolite D-norfenfluramine:3:0.1320	0.1320	3
d-Ng	d-Ng:7|D-Ng:1|d-NG:1|d-ng:1	d-norgestrel:10:0.2000	0.2000	10
DNG	DNG:16	dienogest:16:0.3333	0.3333	16
DNIC	DNIC:95	Diffuse noxious inhibitory controls:73:0.9579|'diffuse noxious inhibitory controls':12:0.7571|diffuse noxious inhibitory control:10:0.5856	0.9579	95
DNIC	DNIC:20	dinitrosyl iron complexes:12:0.4557|dinitrosyl iron complex:8:0.4102	0.4557	20
DNICs	DNICs:11	diffuse noxious inhibitory controls:11:0.7103	0.7103	11
DNJ	DNJ:10|dNJ:2	1-deoxynojirimycin:12:0.4583	0.4583	12
DNLL	DNLL:55	dorsal nucleus of the lateral lemniscus:55:0.9467	0.9467	55
DNL	DNL:21	de novo lipogenesis:21:0.8594	0.8594	21
DNMS	DNMS:23	delayed nonmatching-to-sample:23:0.8715	0.8715	23
DNMTP	DNMTP:7	delayed non-matching to position:7:0.5926	0.5926	7
DNMTs	DNMTs:22|Dnmts:6	DNA methyltransferases:28:0.7905	0.7905	28
dNM	dNM:12|DNM:6	1-deoxynojirimycin:18:0.1466	0.1466	18
DNM	DNM:29	daunomycin:29:0.2414	0.2414	29
dNM	dNM:7|DNM:3	deoxynojirimycin:10:0.0776	0.0776	10
DNM	DNM:31	descending necrotizing mediastinitis:31:0.9043	0.9043	31
DNP-BGG	DNP-BGG:6	bovine gamma-globulin:6:0.2243	0.2243	6
DNPH	DNPH:72	2,4-dinitrophenylhydrazine:72:0.6339	0.6339	72
DNPH	DNPH:17	dinitrophenylhydrazine:17:0.1429	0.1429	17
DNPI	DNPI:7	inorganic phosphate cotransporter:7:0.5926	0.5926	7
DNP-KLH	DNP-KLH:7	limpet haemocyanin:7:0.3524	0.3524	7
DNP-KLH	DNP-KLH:27|DNPKLH:1	limpet hemocyanin:28:0.8422	0.8422	28
DNP-SG	DNP-SG:12	2,4-dinitrophenyl-S-glutathione:12:0.1429	0.1429	12
DNP-SG	DNP-SG:4|Dnp-SG:2	Dinitrophenyl S-glutathione:6:0.2243	0.2243	6
DNP-SG	DNP-SG:13|DNPSG:3|Dnp-SG:2	S-(2,4-dinitrophenyl)-glutathione:9:0.1039|S-(2,4-dinitrophenyl)glutathione:9:0.1039	0.1039	18
DNP	DNP:275	2,4-dinitrophenol:275:0.2464	0.2464	275
DNP	DNP:66|Dnp:5	2,4-dinitrophenyl:71:0.0629	0.0629	71
DNP	DNP:18	anti-2,4-dinitrophenyl:18:0.0153	0.0153	18
DNP	DNP:26	anti-dinitrophenol:26:0.0225	0.0225	26
DNP	DNP:21	Dendroaspis natriuretic peptide:21:0.7865	0.7865	21
DNP	DNP:29	deoxyribonucleoprotein:29:0.0252	0.0252	29
DNP	DNP:10	diabetic nephropathy:10:0.7103	0.7103	10
DNP	DNP:125|Dnp:1	dinitrophenol:126:0.1124	0.1124	126
DNP	DNP:15	dinitrophenylated:15:0.0126	0.0126	15
DNP	DNP:13	dorsal nerve of the penis:13:0.7753	0.7753	13
DNP	DNP:22	dynamic nuclear polarization:22:0.8657	0.8657	22
DNP	DNP:2	mutagen 1,8-dinitropyrene:2:0.0517	0.0517	2
DNQX	DNQX:14	6,7-dinitro-quinoxaline-2,3-dione:14:0.0528	0.0528	14
DNR	DNR:11	daunomycin:11:0.0127	0.0127	11
DNR	DNR:414|Dnr:6|dnr:5	daunorubicin:425:0.5400	0.5400	425
DNR	DNR:196	do-not-resuscitate:186:0.2389|'do not resuscitate':10:0.5856	0.5856	196
DNR	DNR:77	not resuscitate:77:0.9386	0.9386	77
DNTC	DNTC:14	diffuse neurofibrillary tangles with calcification:14:0.7571	0.7571	14
DNT	DNT:24	2,4-dinitrotoluene:24:0.1060	0.1060	24
DNT	DNT:33	dermonecrotic toxin:33:0.7238	0.7238	33
DNT	DNT:29	dinitrotoluene:29:0.1290	0.1290	29
DNT	DNT:74	Dysembryoplastic neuroepithelial tumor:54:0.8821|dysembryoplastic neuroepithelial tumors:11:0.7357|Dysembryoplastic neuroepithelial tumour:9:0.6794	0.8821	74
DNV	DNV:7|Dnv:4	denervation:11:0.2381	0.2381	11
DNases	DNases:9	deoxyribonucleases:9:0.5714	0.5714	9
DNase	DNase:107|DNAse:8|DNASE:1	deoxyribonuclease:116:0.8214	0.8214	116
DNX	DNX:8|DNx:1	denervated:9:0.1600	0.1600	9
DNX	DNX:23|DNx:2|Dnx:1	renal denervation:26:0.8861	0.8861	26
DO(2)	DO(2):14|Do(2):2	Oxygen delivery:16:0.5171	0.5171	16
DO2I	DO2I:8	oxygen delivery:8:0.4102	0.4102	8
DO2I	DO2I:19|Do2I:1	oxygen delivery index:20:0.7766	0.7766	20
DO2	DO2:8	diffusing capacity:8:0.5006	0.5006	8
DO2	DO2:283|Do2:25	oxygen delivery:308:0.8078	0.8078	308
DO2	DO2:13|Do2:1	oxygen transport:14:0.6911	0.6911	14
DOAS	DOAS:11	differential optical absorption spectroscopy:11:0.6182	0.6182	11
DOA	DOA:16	dead on arrival:16:0.5171	0.5171	16
DOA	DOA:11	dominant optic atrophy:11:0.7357	0.7357	11
DOA	DOA:10	dopamine:10:0.0818	0.0818	10
DOBV	DOBV:10	Dobrava virus:10:0.5000	0.5000	10
DOB	DOB:57|dob:10	Dobutamine:67:0.4521	0.4521	67
DOCA	DOCA:20	deoxycorticosterone:20:0.0480	0.0480	20
DOCA	DOCA:241|doca:1|Doca:1	deoxycorticosterone acetate:243:0.7241	0.7241	243
DOCA	DOCA:9	desoxycorticosterone:9:0.0202	0.0202	9
DOCA	DOCA:52	desoxycorticosterone acetate:52:0.1236	0.1236	52
DOC	DOC:90	11-deoxycorticosterone:90:0.0900	0.0900	90
DOC	DOC:16	deoxycholic acid:16:0.8165	0.8165	16
DOC	DOC:254	deoxycorticosterone:254:0.2558	0.2558	254
DOC	DOC:9	Department of Corrections:9:0.5470	0.5470	9
DOC	DOC:27	desoxycorticosterone:27:0.0253	0.0253	27
DOC	DOC:291	dissolved organic carbon:291:0.9588	0.9588	291
DOC	DOC:24|doc:1	docetaxel:25:0.0243	0.0243	25
DOC	DOC:61	sodium deoxycholate:61:0.3679	0.3679	61
DOD	DOD:8	dead of disease:8:0.1276	0.1276	8
DoD	DoD:78|DOD:44	Department of Defense:122:0.9365	0.9365	122
DOD	DOD:8	died of disease:8:0.1690	0.1690	8
DOE	DOE:81|DoE:1	Department of Energy:82:0.9422	0.9422	82
DOE	DOE:9|DoE:5	design of experiments:14:0.7909	0.7909	14
DOF	DOF:18|dof:3	degrees of freedom:21:0.4538	0.4538	21
DOHMH	DOHMH:8	Department of Health and Mental Hygiene:8:0.6411	0.6411	8
DOI	DOI:4	agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl:4:0.5006	0.5006	4
DOI	DOI:4	agonist (+/-)-2,5-dimethoxy-4-iodoamphetamine:4:0.0902	0.0902	4
DOI	DOI:44	hydrochloride:44:0.1033	0.1033	44
DOI	DOI:5	receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane:5:0.2452	0.2452	5
DOJ	DOJ:12|DoJ:1	Department of Justice:13:0.7909	0.7909	13
DOMI	DOMI:8	Digestible organic matter intake:8:0.6411	0.6411	8
DOMS	DOMS:73	delayed onset muscle soreness:73:0.9612	0.9612	73
DOMV	DOMV:5	Double Orifice Mitral Valve:5:0.4422	0.4422	5
DOM	DOM:39	2,5-Dimethoxy-4-methylamphetamine:39:0.0854	0.0854	39
DOM	DOM:1	DA receptor antagonist domperidone:1:0.0918	0.0918	1
DOM	DOM:183	dissolved organic matter:183:0.8805	0.8805	183
Dom	Dom:11	Dominant megacolon:11:0.7357	0.7357	11
DOM	DOM:13|Dom:8	domoic acid:21:0.8594	0.8594	21
DOM	DOM:10	hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane:10:0.1134	0.1134	10
DONs	DONs:10	directors of nursing:10:0.7103	0.7103	10
DON	DON:62	6-diazo-5-oxo-L-norleucine:62:0.1101	0.1101	62
DON	DON:342	deoxynivalenol:342:0.6257	0.6257	342
DON	DON:19	diazo-oxo-norleucine:19:0.0294	0.0294	19
DON	DON:9	dissolved organic nitrogen:9:0.5470	0.5470	9
DON	DON:11	Dysthyroid optic neuropathy:11:0.7357	0.7357	11
DOP-PCR	DOP-PCR:24	degenerate oligonucleotide-primed PCR:13:0.6701|Degenerate Oligonucleotide Primed PCR:11:0.7357	0.7357	24
DOP-PCR	DOP-PCR:12	degenerate oligonucleotide primed polymerase chain reaction:12:0.5664	0.5664	12
DOPAC	DOPAC:2	dopamine and its metabolites dihydroxyphenylacetic acid:2:0.0876	0.0876	2
DOPAL	DOPAL:23|dopal:1	3,4-dihydroxyphenylacetaldehyde:24:0.9200	0.9200	24
DOPA	DOPA:8|dopa:1	3,4-dihydroxyphenyl-L-alanine:9:0.0103	0.0103	9
DOPA	DOPA:259|dopa:50|Dopa:22	3,4-dihydroxyphenylalanine:331:0.4223	0.4223	331
DOPA	DOPA:7	accumulation of L-dihydroxyphenylalanine:7:0.0951	0.0951	7
DOPA	DOPA:190|dopa:21|Dopa:5	dihydroxyphenylalanine:216:0.2760	0.2760	216
DOPA	DOPA:15|doPA:1	dioleoylphosphatidic acid:16:0.3472	0.3472	16
DOPA	DOPA:37|dopa:6|Dopa:3	L-3,4-dihydroxyphenylalanine:46:0.0578	0.0578	46
DOPC	DOPC:28	1,2-dioleoyl-sn-glycero-3-phosphocholine:28:0.0891	0.0891	28
DOPC	DOPC:27	dioleoyl phosphatidylcholine:17:0.6211|dioleoyl-phosphatidylcholine:10:0.0297	0.6211	27
DOPC	DOPC:163	dioleoylphosphatidylcholine:163:0.5314	0.5314	163
DOPEG	DOPEG:17	3,4-dihydroxyphenylethyleneglycol:17:0.1379	0.1379	17
DOPEG	DOPEG:47|DO-PEG:1	3,4-dihydroxyphenylglycol:48:0.4052	0.4052	48
DOPEG	DOPEG:21	dihydroxyphenylglycol:21:0.1724	0.1724	21
DOPE	DOPE:22	1,2-dioleoyl-sn-glycero-3-phosphoethanolamine:22:0.0712	0.0712	22
DOPE	DOPE:6	Dioleoyl phosphatidyl ethanolamine:6:0.3728	0.3728	6
DOPE	DOPE:143	dioleoylphosphatidylethanolamine:143:0.4814	0.4814	143
DOPG	DOPG:25	dioleoylphosphatidylglycerol:25:0.4138	0.4138	25
DOPPS	DOPPS:57	Dialysis Outcomes and Practice Patterns Study:57:0.9438	0.9438	57
DOPS	DOPS:9	3,4-dihydroxyphenylserine:9:0.0667	0.0667	9
DOPS	DOPS:22	dioleoylphosphatidylserine:22:0.1750	0.1750	22
DOPS	DOPS:16	L-threo-3,4-dihydroxyphenylserine:16:0.1250	0.1250	16
DOP	DOP:17	dioctyl phthalate:17:0.3366	0.3366	17
DOP	DOP:14|dop:4	dopamine:18:0.1164	0.1164	18
DOQI	DOQI:9	Dialysis outcome quality initiative:9:0.5355	0.5355	9
DOR-1	DOR-1:10|DOR1:7	delta-opioid receptor:10:0.2446|delta opioid receptor:7:0.3524	0.3524	17
DORV	DORV:49	double outlet right ventricle:49:0.9404	0.9404	49
DOR	DOR:102	delta opioid receptor:52:0.9427|delta-opioid receptor:45:0.3333|delta opioid receptors:5:0.4422	0.9427	102
DOR	DOR:7|dOR:1	diagnostic odds ratio:8:0.6411	0.6411	8
DOSS	DOSS:9	sulfosuccinate:9:0.4211	0.4211	9
DOSY	DOSY:20	spectroscopy:20:0.9048	0.9048	20
DOTC	DOTC:16	dichloride:16:0.4375	0.4375	16
DOT	DOT:10	Dictionary of Occupational Titles:10:0.7103	0.7103	10
DOT	DOT:19	diffuse optical tomography:19:0.8449	0.8449	19
DOT	DOT:108	directly observed therapy:108:0.9417	0.9417	108
DOT	DOT:51	directly observed treatment:51:0.9082	0.9082	51
DOT	DOT:11	disodium octaborate tetrahydrate:11:0.7357	0.7357	11
DOT	DOT:13	dissolved oxygen tension:13:0.7753	0.7753	13
DOVA	DOVA:11	4,5-dioxovaleric acid:11:0.7357	0.7357	11
DOXO	DOXO:19|Doxo:14|doxo:2	doxorubicin:35:0.7556	0.7556	35
DOXP	DOXP:9	1-deoxy-D-xylulose 5-phosphate:9:0.5470	0.5470	9
DOXol	DOXol:9|DOXOL:3	doxorubicinol:12:0.9167	0.9167	12
DOX	DOX:8|Dox:4	doxazosin:12:0.0095	0.0095	12
DOX	DOX:732|Dox:211|dox:18	doxorubicin:961:0.8333	0.8333	961
DOX	DOX:7|dox:1	doxorubicin hydrochloride:8:0.5470	0.5470	8
Dox	Dox:48|DOX:29|dox:21	Doxycycline:98:0.0842	0.0842	98
DOS	DOS:30	density of states:30:0.7652	0.7652	30
DOs	DOs:16	denuded oocytes:16:0.5564	0.5564	16
DOS	DOS:10	diabetes-obesity syndrome:10:0.5000	0.5000	10
DPAG	DPAG:24|dPAG:11|D-PAG:1	dorsal periaqueductal gray:36:0.6953	0.6953	36
DPAG	DPAG:18|dPAG:11	dorsal periaqueductal gray matter:29:0.7970	0.7970	29
DPAG	DPAG:8|dPAG:3	dorsal periaqueductal grey:11:0.6182	0.6182	11
DPAM	DPAM:9	disseminated peritoneal adenomucinosis:9:0.5470	0.5470	9
DPA	DPA:62|D-PA:14|D-Pa:2|d-PA:1	D-penicillamine:79:0.1175	0.1175	79
DPA	DPA:15	di-n-propylacetate:15:0.0211	0.0211	15
DPA	DPA:34	diphenylamine:34:0.0497	0.0497	34
DPA	DPA:55|Dpa:1	dipicolinic acid:56:0.3543	0.3543	56
DPA	DPA:5	dorsalis pedis artery:5:0.2818	0.2818	5
DPA	DPA:158	dual photon absorptiometry:88:0.8984|dual-photon absorptiometry:70:0.3327	0.8984	158
DPA	DPA:8|dpa:2	post anthesis:10:0.7103	0.7103	10
DPBF	DPBF:9	1,3-diphenylisobenzofuran:9:0.5333	0.5333	9
DPBS	DPBS:6|D-PBS:2	Dulbecco's phosphate buffered saline:8:0.5006	0.5006	8
DPBS	DPBS:5|D-PBS:2	phosphate-buffered saline:7:0.1329	0.1329	7
DPB	DPB:16|dPB:1	12-deoxyphorbol 13-isobutyrate:17:0.8270	0.8270	17
DPB	DPB:196	diffuse panbronchiolitis:196:0.9756	0.9756	196
DPCM	DPCM:6	differential pulse code modulation:6:0.5290	0.5290	6
DPCP	DPCP:11	Diphenylcyclopropenone:11:0.5000	0.5000	11
DPCPX	DPCPX:28	A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine:28:0.5846	0.5846	28
DPCPX	DPCPX:6	adenosine A1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine:6:0.5006	0.5006	6
dPCR	dPCR:4|D-PCR:2|DPCR:1	differential PCR:7:0.2452	0.2452	7
DPCR	DPCR:8|dPCR:7|D-PCR:3	differential polymerase chain reaction:18:0.6903	0.6903	18
DPCs	DPCs:13	dermal papilla cells:13:0.7753	0.7753	13
DPCs	DPCs:14|dpcs:1	DNA-protein cross-links:15:0.8045	0.8045	15
DPCs	DPCs:23	DNA-protein crosslinks:23:0.8038	0.8038	23
DPC	DPC:3	chloride channel blocker diphenylamine-2-carboxylate:3:0.3463	0.3463	3
D-Pc	D-Pc:8|D-PC:3|DPC:3|D-pc:1	D-penicillamine:15:0.0165	0.0165	15
dpc	dpc:110	days post coitum:88:0.7926|days post-coitum:22:0.7400	0.7926	110
dpc	dpc:40|DPC:2	days post coitus:28:0.7505|days post-coitus:14:0.7909	0.7909	42
dpc	dpc:83	days postcoitum:83:0.8264	0.8264	83
dpc	dpc:13	days postcoitus:13:0.5335	0.5335	13
dpc	dpc:8	days postconception:8:0.3463	0.3463	8
DPC	DPC:7	deep prepiriform cortex:7:0.5926	0.5926	7
DPC	DPC:5	deep prepyriform cortex:5:0.4422	0.4422	5
DPC	DPC:17	dermal papilla cells:17:0.8270	0.8270	17
DPC	DPC:9	Diagnosis Procedure Combination:9:0.6794	0.6794	9
DPC	DPC:12	Diagnostic Products Corporation:12:0.7571	0.7571	12
DPC	DPC:26	diphenylamine-2-carboxylic acid:26:0.3273	0.3273	26
DPC	DPC:32	DNA-protein cross-links:32:0.7458	0.7458	32
DPC	DPC:27|dpc:2	DNA-protein crosslinks:29:0.7237	0.7237	29
DPC	DPC:65	dodecylphosphocholine:65:0.0756	0.0756	65
DPC	DPC:14	dystrophin-associated protein complex:14:0.6173	0.6173	14
DPDPE	DPDPE:19	agonist [D-Pen2,D-Pen5]enkephalin:19:0.1879	0.1879	19
DPDPE	DPDPE:9	[D-Pen(2,5)]-enkephalin:9:0.0168	0.0168	9
DPDPE	DPDPE:10	[D-Pen(2),D-Pen(5)]-Enkephalin:10:0.0189	0.0189	10
DPDPE	DPDPE:31	[D-Pen2,5]enkephalin:31:0.0629	0.0629	31
DPDPE	DPDPE:24	[D-Pen2,D-Pen5]-enkephalin:21:0.0419|D-Pen2,D-Pen5 enkephalin:3:0.0638	0.0638	24
DPD	DPD:5|Dpd:3	deoxypyridinoline crosslinks:8:0.5006	0.5006	8
DPD	DPD:8	Depressive personality disorder:8:0.2987	0.2987	8
DPD	DPD:9	dipyridamole:9:0.0097	0.0097	9
DPD	DPD:40|Dpd:15|dpd:1|dPD:1	urinary deoxypyridinoline:57:0.1886	0.1886	57
DPEJ	DPEJ:8	direct percutaneous endoscopic jejunostomy:8:0.6411	0.6411	8
D-Pen	D-Pen:30|D-pen:17|D-PEN:13|DPEN:2|d-PEN:2	d-penicillamine:64:0.9130	0.9130	64
DPEs	DPEs:5	distortion product otoacoustic emissions:5:0.4422	0.4422	5
DPE	DPE:9	dipivalyl epinephrine:9:0.6794	0.6794	9
DPE	DPE:14	downstream promoter element:14:0.6911	0.6911	14
DPFC	DPFC:7|dPFC:5	prefrontal cortex:12:0.7571	0.7571	12
DPGN	DPGN:23	diffuse proliferative glomerulonephritis:23:0.6306	0.6306	23
DPG	DPG:167	2,3-diphosphoglycerate:153:0.4343|2,3 diphosphoglycerate:14:0.3202	0.4343	167
DPG	DPG:7	2,3-diphosphoglyceric acid:7:0.2452	0.2452	7
DPHM	DPHM:15	Diphenhydramine:15:0.7778	0.7778	15
DPH	DPH:9	1,6-diphenyl-1,3,5 hexatriene:9:0.1150	0.1150	9
DPH	DPH:12	1,6-diphenylhexatriene:12:0.0091	0.0091	12
DPH	DPH:16	5,5-diphenylhydantoin:16:0.0124	0.0124	16
dph	dph:8|DPH:1	days post-hatch:9:0.4587	0.4587	9
dph	dph:4|DPH:1	days posthatch:5:0.1132	0.1132	5
DPH	DPH:27|DPh:1	diphenhydramine:28:0.0222	0.0222	28
DPH	DPH:255|Dph:1|DpH:1	diphenylhydantoin:257:0.2109	0.2109	257
DPH	DPH:44	fluorescence polarization of 1,6-diphenyl-1,3,5-hexatriene:44:0.9099	0.9099	44
DPH	DPH:11	fluorescence polarization of diphenylhexatriene:11:0.4557	0.4557	11
DPH	DPH:114	phenytoin:114:0.0939	0.0939	114
DPH	DPH:14	Public Health:14:0.7909	0.7909	14
DPIs	DPIs:58|dpis:1	dry powder inhalers:59:0.9494	0.9494	59
DPIV	DPIV:25	Digital particle image velocimetry:25:0.8816	0.8816	25
DPIV	DPIV:8|DP-IV:7	Dipeptidyl peptidase IV:15:0.8045	0.8045	15
dpi	dpi:49|DPI:40	days post-infection:46:0.7507|days post infection:43:0.6343	0.7507	89
dpi	dpi:50|DPI:39|dPI:1	days post-inoculation:64:0.7825|days post inoculation:26:0.6645	0.7825	90
DPI	DPI:8	days postimplantation:8:0.5006	0.5006	8
dpi	dpi:29|DPI:26	days postinfection:55:0.8036	0.8036	55
DPI	DPI:60|dpi:26	days postinoculation:86:0.8833	0.8833	86
DPI	DPI:23	dietary protein intake:23:0.5466	0.5466	23
DPI	DPI:24	diphenyleneiodonium chloride:24:0.3828	0.3828	24
DPI	DPI:17	diphenyliodonium:17:0.0158	0.0158	17
DPI	DPI:15	diphosphoinositide:15:0.0138	0.0138	15
DPI	DPI:12	Doppler perfusion index:12:0.7571	0.7571	12
DPI	DPI:9	DPI 201-106:9:0.6794	0.6794	9
DPI	DPI:9	dry powder inhalation:9:0.6794	0.6794	9
DPI	DPI:84	dry powder inhaler:71:0.9579|Dry powder inhalers:13:0.7753	0.9579	84
DPI	DPI:3	NADPH oxidase inhibitor diphenyleneiodonium:3:0.1464	0.1464	3
DPLN	DPLN:20	diffuse proliferative lupus nephritis:20:0.8594	0.8594	20
dpl	dpl:6|DPL:2	days post-lesion:8:0.5006	0.5006	8
dpl	dpl:13	days postlesion:13:0.5335	0.5335	13
DPL	DPL:130	diagnostic peritoneal lavage:130:0.9510	0.9510	130
DPL	DPL:20	dipalmitoyl lecithin:20:0.7766	0.7766	20
DPM	DPM:11	diesel particulate matter:11:0.7357	0.7357	11
DPM	DPM:33	dipyridamole:33:0.1739	0.1739	33
dpm	dpm:12|DPM:4	disintegrations per minute:16:0.6577	0.6577	16
DPNB	DPNB:23	Dorsal penile nerve block:23:0.8715	0.8715	23
dpn	dpn:15|DPN:5|dPN:2	days postnatal:22:0.5581	0.5581	22
DPN	DPN:9	deep peroneal nerve:9:0.6794	0.6794	9
DPN	DPN:31	diabetic peripheral neuropathy:31:0.9043	0.9043	31
DPN	DPN:24	diabetic polyneuropathy:24:0.5848	0.5848	24
DPN	DPN:9	Dip-Pen Nanolithography:9:0.4587	0.4587	9
DPN	DPN:10	dorsal penile nerve:10:0.7103	0.7103	10
DPOAEs	DPOAEs:268|DP-OAEs:1	Distortion product otoacoustic emissions:195:0.9847|distortion-product otoacoustic emissions:74:0.2122	0.9847	269
DPOAE	DPOAE:5	distortion product OAE:5:0.5290	0.5290	5
DPOAE	DPOAE:234	distortion product otoacoustic emission:112:0.9735|Distortion product otoacoustic emissions:95:0.9500|distortion-product otoacoustic emission:27:0.1173	0.9735	234
DPOEs	DPOEs:13	distortion product otoacoustic emissions:13:0.7753	0.7753	13
dpo	dpo:7	days postoperation:7:0.3524	0.3524	7
dpo	dpo:5|DPO:4	days postoperative:9:0.3945	0.3945	9
dPPA	dPPA:7	12-deoxyphorbol 13-phenylacetate 20-acetate:7:0.4438	0.4438	7
DPPA	DPPA:15	dipalmitoylphosphatidic acid:15:0.2972	0.2972	15
DPPC	DPPC:16	1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine:16:0.0112	0.0112	16
DPPC	DPPC:61	1,2-dipalmitoyl-sn-glycero-3-phosphocholine:61:0.0447	0.0447	61
DPPC	DPPC:22	1,2-dipalmitoylphosphatidylcholine:22:0.0157	0.0157	22
DPPC	DPPC:13	dipalmitoyl:13:0.0089	0.0089	13
DPPC	DPPC:19	dipalmitoyl PC:10:0.5000|dipalmitoyl-PC:9:0.0060	0.5000	19
DPPC	DPPC:16	dipalmitoyl phosphatidyl choline:16:0.5171	0.5171	16
DPPC	DPPC:204|dpPC:2	dipalmitoyl phosphatidylcholine:169:0.7928|dipalmitoyl-phosphatidylcholine:37:0.0268	0.7928	206
DPPC	DPPC:12	dipalmitoylphosphatidyl choline:12:0.1470	0.1470	12
DPPC	DPPC:718|dpPC:2|DP-PC:1	dipalmitoylphosphatidylcholine:721:0.5369	0.5369	721
DPPC	DPPC:23	L-alpha-dipalmitoylphosphatidylcholine:23:0.0164	0.0164	23
DPPD	DPPD:44	N,N'-diphenyl-p-phenylenediamine:44:0.3697	0.3697	44
dppe	dppe:8|DPPE:1	1,2-bis(diphenylphosphino)ethane:9:0.0576	0.0576	9
DPPE	DPPE:6	dipalmitoyl phosphatidylethanolamine:6:0.1838	0.1838	6
DPPE	DPPE:39	dipalmitoylphosphatidylethanolamine:39:0.2734	0.2734	39
DPPE	DPPE:7	N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl:7:0.1211	0.1211	7
DPPH	DPPH:17	1,1-diphenyl-2-picryl-hydrazyl:17:0.0314	0.0314	17
DPPH	DPPH:228	1,1-diphenyl-2-picrylhydrazyl:228:0.4460	0.4460	228
DPPH	DPPH:9	1,1-diphenyl-2-picrylhydrazyl radical:9:0.0735	0.0735	9
DPPH	DPPH:16	alpha,alpha-diphenyl-beta-picrylhydrazyl:16:0.0295	0.0295	16
DPPH	DPPH:5	stable free radical 2,2-diphenyl-1-picrylhydrazyl:5:0.4422	0.4422	5
DPPHR	DPPHR:16	duodenum-preserving pancreatic head resection:16:0.6577	0.6577	16
DPPIV	DPPIV:111|DPP-IV:67	dipeptidyl peptidase IV:160:0.9045|Dipeptidyl peptidase-IV:18:0.8365	0.9045	178
DPPI	DPPI:23|DPP-I:1	dipeptidyl peptidase I:24:0.8115	0.8115	24
DPPP	DPPP:10	diphenyl-1-pyrenylphosphine:10:0.3600	0.3600	10
DPPS	DPPS:18	dipalmitoylphosphatidylserine:18:0.4474	0.4474	18
dpp	dpp:11|DPP:3	days postpartum:14:0.4367	0.4367	14
dpp	dpp:189|Dpp:101|DPP:21	decapentaplegic:311:0.4250	0.4250	311
DPP	DPP:5	dentin phosphophoryn:5:0.0902	0.0902	5
DPP	DPP:6	di-4-phloretin phosphate:6:0.1010	0.1010	6
DPP	DPP:31	Diabetes Prevention Program:31:0.9011	0.9011	31
DPP	DPP:12|dpp:1	differential pulse polarographic:13:0.7753	0.7753	13
DPP	DPP:44|dpp:1	differential pulse polarography:45:0.8986	0.8986	45
Dpp	Dpp:9|dpp:2	dipeptide permease:11:0.7357	0.7357	11
DPP	DPP:37	dipeptidyl peptidase:37:0.8377	0.8377	37
dpp	dpp:13|DPP:3	post partum:16:0.8165	0.8165	16
DPQ	DPQ:7	Dallas Pain Questionnaire:7:0.5926	0.5926	7
DPS	DPS:7	degree of phosphorus saturation:7:0.4438	0.4438	7
DPS	DPS:8	dipropyl sulfide:8:0.4102	0.4102	8
DPs	DPs:10	distortion products:10:0.3867	0.3867	10
DPTI	DPTI:17	diastolic pressure time index:17:0.8270	0.8270	17
Dpt	Dpt:42|DPT:10	Dermatophagoides pteronyssinus:52:0.8821	0.8821	52
DPT	DPT:67	diphtheria-pertussis-tetanus:66:0.1857|diphtheria pertussis tetanus:1:0.7905	0.7905	67
DPT	DPT:5	pertussis vaccine:5:0.0517	0.0517	5
DPU	DPU:15	delayed pressure urticaria:15:0.8045	0.8045	15
DPV	DPV:7	duck plague virus:7:0.5926	0.5926	7
DPX	DPX:10	1,3-diethyl-8-phenylxanthine:10:0.1139	0.1139	10
DPX	DPX:15	DNA-protein cross-links:15:0.8045	0.8045	15
DPH-PC	DPH-PC:6|DPhPC:4	phosphatidylcholine:10:0.2045	0.2045	10
DP	DP:18	CD4+CD8+:18:0.0076	0.0076	18
DP	DP:46	CD4+CD8+ double-positive:26:0.1165|CD4(+)CD8(+) double-positive:20:0.0737	0.1165	46
DP	DP:53|D-P:5|dP:1|D-p:1	D-penicillamine:60:0.0264	0.0264	60
DP	DP:11|dp:1	degree of polymerisation:12:0.6460	0.6460	12
DP	DP:99|dp:18|Dp:1	degree of polymerization:101:0.7732|degrees of polymerization:17:0.0719	0.7732	118
DP	DP:6	delayed puberty:6:0.2243	0.2243	6
DP	DP:7	delusional parasitosis:7:0.3524	0.3524	7
DP	DP:27	dermal papilla:27:0.8312	0.8312	27
DP	DP:12	dermatofibrosarcoma protuberans:12:0.7571	0.7571	12
Dp	Dp:73|DP:23	Dermatophagoides pteronyssinus:96:0.7655	0.7655	96
DP	DP:21|Dp:5|dp:1	desmoplakin:27:0.0116	0.0116	27
DP	DP:73|dp:4	diabetes-prone:64:0.0282|diabetes prone:13:0.5934	0.5934	77
DP	DP:11	diabetic polyneuropathy:11:0.3829	0.3829	11
DP	DP:93|Dp:2	dipyridamole:95:0.0421	0.0421	95
DP	DP:16	directed percolation:16:0.8165	0.8165	16
DP	DP:24	directional preponderance:24:0.7593	0.7593	24
DP	DP:42	disopyramide:42:0.0184	0.0184	42
DP	DP:5	disopyramide phosphate:5:0.0736	0.0736	5
DP	DP:12	distal pancreatectomy:12:0.7571	0.7571	12
DP	DP:14|dp:1	distortion product:15:0.1316	0.1316	15
DP	DP:7|Dp:2	dopamine:9:0.0036	0.0036	9
DP	DP:8|Dp:1	dorsal:9:0.0036	0.0036	9
DP	DP:14	dorsal prostate:14:0.6173	0.6173	14
DP	DP:115	double positive:115:0.9586	0.9586	115
DP	DP:6	double potential:6:0.0731	0.0731	6
DP	DP:37	double product:37:0.5038	0.5038	37
DP	DP:9	dynamic programming:9:0.6794	0.6794	9
DP	DP:14	left ventricular developed pressure:14:0.6173	0.6173	14
DP	DP:15	patients:15:0.0063	0.0063	15
DP	DP:15	pattern:15:0.0063	0.0063	15
DP	DP:9	phase:9:0.0036	0.0036	9
DP	DP:10|dP:1	pressures:11:0.0045	0.0045	11
DP	DP:11|dp:1	protein:12:0.0049	0.0049	12
DP	DP:12	receptor:12:0.0049	0.0049	12
DQC	DQC:7	double quantum coherence:7:0.5926	0.5926	7
DQF	DQF:12	Double quantum filtered:12:0.7571	0.7571	12
DQOL	DQOL:11	Diabetes Quality of Life:11:0.6182	0.6182	11
DQs	DQs:13|DQS:1	developmental quotients:14:0.6173	0.6173	14
DR1	DR1:8|DR-1:1	direct repeat 1:9:0.6794	0.6794	9
DR1	DR1:8|DR-1:4	one nucleotide:12:0.5664	0.5664	12
DR3	DR3:6	death receptor 3:6:0.5290	0.5290	6
DR3	DR3:5|DR-3:4	three nucleotides:9:0.4587	0.4587	9
DR4	DR4:23	Death receptor 4:23:0.8715	0.8715	23
DR5	DR5:18	death receptor 5:18:0.7539	0.7539	18
DRAG	DRAG:9	dinitrogenase reductase-activating glycohydrolase:9:0.5470	0.5470	9
DRAT	DRAT:14|DraT:1	dinitrogenase reductase ADP-ribosyltransferase:15:0.8045	0.8045	15
DRBC	DRBC:9	dichloran rose bengal chloramphenicol:9:0.6794	0.6794	9
DRB	DRB:10	5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole:10:0.1680	0.1680	10
DRB	DRB:92	5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole:92:0.3915	0.3915	92
DRB	DRB:9	5,6-dichlorobenzimidazole riboside:9:0.3945	0.3945	9
DRCs	DRCs:17	dendritic reticulum cells:17:0.8270	0.8270	17
DRCs	DRCs:24	dose-response curves:24:0.8768	0.8768	24
DRC	DRC:4	Democratic Republic of the Congo:4:0.8715	0.8715	4
DRC	DRC:30	dendritic reticulum cells:24:0.8768|dendritic reticulum cell:6:0.5290	0.8768	30
DRC	DRC:24	DNA repair capacity:24:0.8768	0.8768	24
DRC	DRC:42|D-RC:1	dose-response curve:24:0.8115|dose-response curves:14:0.4367|dose response curves:5:0.2818	0.8115	43
DRC	DRC:13	dry-rolled corn:13:0.7753	0.7753	13
DRC	DRC:6	dynamic reaction cell:6:0.5290	0.5290	6
DRD2	DRD2:45	D2 dopamine receptor:45:0.7461	0.7461	45
DRD2	DRD2:12	D2 dopamine receptor gene:12:0.3813	0.3813	12
DRD2	DRD2:89|Drd2:1	dopamine D2 receptor:90:0.9304	0.9304	90
DRD2	DRD2:46|drd2:1	dopamine D2 receptor gene:47:0.8433	0.8433	47
DRD2	DRD2:18	dopamine receptor D2:18:0.8365	0.8365	18
DRD3	DRD3:27|Drd3:1	Dopamine D3 receptor:28:0.7905	0.7905	28
DRD3	DRD3:24	dopamine D3 receptor gene:24:0.7151	0.7151	24
DRD4	DRD4:78	dopamine D4 receptor:78:0.9617	0.9617	78
DRD4	DRD4:46	dopamine D4 receptor gene:46:0.9353	0.9353	46
DRD4	DRD4:35	dopamine receptor D4:35:0.9151	0.9151	35
DRD5	DRD5:7	dopamine D5 receptor:7:0.5926	0.5926	7
DRD5	DRD5:10	receptor gene:10:0.5000	0.5000	10
DREEM	DREEM:7	Dundee Ready Education Environment Measure:7:0.5926	0.5926	7
DRESS	DRESS:7	Drug rash with eosinophilia and systemic symptoms:7:0.5926	0.5926	7
DREZ	DREZ:86	dorsal root entry zone:86:0.9653	0.9653	86
DRE	DRE:26	digital rectal exam:26:0.8251	0.8251	26
DRE	DRE:481	digital rectal examination:472:0.9832|digital rectal examinations:9:0.6794	0.9832	481
DRE	DRE:7	dioxin response element:7:0.1025	0.1025	7
DRE	DRE:12	dioxin responsive element:12:0.4153	0.4153	12
DRE	DRE:8	distal regulatory element:8:0.1367	0.1367	8
DRE	DRE:11	downstream regulatory element:11:0.2764	0.2764	11
DRE	DRE:11	elements:11:0.0150	0.0150	11
DRFS	DRFS:5	distant recurrence-free survival:5:0.4422	0.4422	5
DRF	DRF:21	differential renal function:21:0.6400	0.6400	21
DRF	DRF:30|drf:1	dose reduction factor:25:0.8816|dose reduction factors:6:0.5290	0.8816	31
DRGN	DRGN:4|DRGn:2	dorsal root ganglion neurons:6:0.5290	0.5290	6
DRGs	DRGs:326	Diagnosis-Related Groups:198:0.4633|Diagnosis Related Groups:128:0.6758	0.6758	326
DRGs	DRGs:170	dorsal root ganglia:170:0.9824	0.9824	170
DRGs	DRGs:9	Dorsal root ganglion cells:9:0.6794	0.6794	9
DRG	DRG:337	Diagnosis-related group:140:0.3777|diagnosis related group:93:0.6335|Diagnosis Related Groups:64:0.7198|Diagnosis-Related Groups:40:0.2395	0.7198	337
DRG	DRG:31	diagnostic related group:31:0.1582	0.1582	31
DRG	DRG:39	dorsal respiratory group:39:0.9237	0.9237	39
DRG	DRG:10	dorsal root:10:0.7103	0.7103	10
DRG	DRG:1043|drg:2	dorsal root ganglia:1045:0.9938	0.9938	1045
DRG	DRG:1451|drg:3	dorsal root ganglion:1454:0.9956	0.9956	1454
DRG	DRG:12	dorsal root ganglion neurons:12:0.7571	0.7571	12
DRIFTS	DRIFTS:14	diffuse reflectance infrared Fourier transform spectroscopy:14:0.7909	0.7909	14
DRIs	DRIs:22	Dietary Reference Intakes:22:0.8657	0.8657	22
DRI	DRI:12	Dietary Reference Intake:12:0.6460	0.6460	12
DRLs	DRLs:12	diagnostic reference levels:12:0.5664	0.5664	12
DRL	DRL:35	differential reinforcement of low rate:23:0.8115|differential reinforcement of low rates:12:0.6460	0.8115	35
DRL	DRL:9	differential reinforcement of low rates of responding:9:0.7103	0.7103	9
DRN	DRN:19	dorsal raphe:19:0.8525	0.8525	19
DRN	DRN:373|DRn:3	dorsal raphe nucleus:376:0.9872	0.9872	376
DRO	DRO:24	differential reinforcement of other behavior:24:0.8115	0.8115	24
DRO	DRO:10|Dro:1	droloxifene:11:0.1351	0.1351	11
DRPs	DRPs:23	dorsal root potentials:23:0.8715	0.8715	23
DRPs	DRPs:29	drug-related problems:29:0.7970	0.7970	29
dRP	dRP:12	5'-deoxyribose phosphate:12:0.3275	0.3275	12
dRP	dRP:5|dRp:1	deoxyribose phosphate:6:0.0564	0.0564	6
DRP	DRP:32	Dissolved reactive phosphorus:32:0.9072	0.9072	32
DRP	DRP:41	dorsal root potential:27:0.8903|dorsal root potentials:14:0.7909	0.8903	41
DRP	DRP:16	dystrophin-related protein:16:0.3643	0.3643	16
DRRs	DRRs:36|DRRS:1	digitally reconstructed radiographs:37:0.8749	0.8749	37
DRRs	DRRs:9	dorsal root reflexes:9:0.6794	0.6794	9
DRR	DRR:27	digitally reconstructed radiographs:19:0.8449|digitally reconstructed radiograph:8:0.5006	0.8449	27
DRR	DRR:15	dorsal root reflex:15:0.8045	0.8045	15
DRSP	DRSP:13	Drospirenone:13:0.2667	0.2667	13
DRSP	DRSP:12	drug-resistant Streptococcus pneumoniae:12:0.7571	0.7571	12
DRS	DRS:14	Diabetic Retinopathy Study:14:0.7909	0.7909	14
DRs	DRs:5	diet records:5:0.1132	0.1132	5
DRS	DRS:11	Diffuse reflectance spectroscopy:11:0.7357	0.7357	11
DRs	DRs:25	direct repeats:25:0.8816	0.8816	25
DRS	DRS:24	dose-response slope:24:0.6427	0.6427	24
DRS	DRS:30	Duane's retraction syndrome:20:0.4574|Duane retraction syndrome:10:0.1327	0.4574	30
DRS	DRS:147|D-RS:1	rating scale:148:0.9123	0.9123	148
DRS	DRS:9	renal scintigraphy:9:0.6794	0.6794	9
DRUJ	DRUJ:63	distal radioulnar joint:63:0.9526	0.9526	63
DRV	DRV:13	dehydration-rehydration vesicles:13:0.5335	0.5335	13
DRZ	DRZ:8	diagonal radioactive zone:8:0.5006	0.5006	8
DR	DR:47	class II:47:0.7790	0.7790	47
DR	DR:16	Dahl salt-resistant rats:16:0.5564	0.5564	16
DR	DR:18	dark-reared:18:0.0079	0.0079	18
DR	DR:11	daunorubicin:11:0.0047	0.0047	11
DR	DR:19	death receptor:19:0.3333	0.3333	19
DR	DR:24	delayed response:24:0.3721	0.3721	24
DR	DR:9	delivery room:9:0.3945	0.3945	9
DR	DR:17	detection rate:17:0.1720	0.1720	17
DR	DR:10|dr:1	diabetes resistant:11:0.0869	0.0869	11
DR	DR:235|dR:1	diabetic retinopathy:236:0.9339	0.9339	236
DR	DR:7	diameter reduction:7:0.3524	0.3524	7
DR	DR:31	diet-resistant:17:0.0075|diet resistant:14:0.1359	0.1359	31
DR	DR:9	diet-restricted:9:0.0037	0.0037	9
DR	DR:9	dietary records:9:0.3945	0.3945	9
DR	DR:10	dietary restricted:10:0.2446	0.2446	10
DR	DR:161	dietary restriction:161:0.8364	0.8364	161
DR	DR:34	Digital radiography:34:0.5687	0.5687	34
DR	DR:75	direct repeat:58:0.9190|direct repeats:17:0.8270	0.9190	75
DR	DR:10	distal radius:10:0.5000	0.5000	10
DR	DR:8	dopamine receptor:8:0.0625	0.0625	8
DR	DR:19|d-R:1	dorsal:20:0.0089	0.0089	20
DR	DR:98|d-R:2|dr:1|dR:1	dorsal raphe:102:0.9245	0.9245	102
DR	DR:83|dr:1	dorsal raphe nucleus:84:0.9644	0.9644	84
DR	DR:42	dorsal root:42:0.9291	0.9291	42
DR	DR:6|dr:1	dose ratios:7:0.1641	0.1641	7
DR	DR:14|D-R:6	Dose-response:20:0.0089	0.0089	20
DR	DR:14	drug resistance:14:0.3202	0.3202	14
DR	DR:9	drug-resistant:9:0.0037	0.0037	9
DR	DR:8	dynamic range:8:0.4102	0.4102	8
DR	DR:12	HLA-DR:12:0.0051	0.0051	12
DR	DR:11	nucleus raphe dorsalis:11:0.7357	0.7357	11
DR	DR:41|dr:3	ratio:44:0.0200	0.0200	44
DS86	DS86:10	Dosimetry System 1986:10:0.7103	0.7103	10
DSAP	DSAP:33	Disseminated superficial actinic porokeratosis:33:0.9126	0.9126	33
DSA	DSA:22	Datura stramonium agglutinin:22:0.8657	0.8657	22
DSA	DSA:11	delayed spatial alternation:11:0.7357	0.7357	11
DSA	DSA:16	destructive spondyloarthropathy:16:0.8165	0.8165	16
DSA	DSA:6	digital subtraction angiograms:6:0.5290	0.5290	6
DSA	DSA:23	digital subtraction angiographic:23:0.8715	0.8715	23
DSA	DSA:1164|dsa:2	digital subtraction angiography:1166:0.9872	0.9872	1166
DSA	DSA:26	digital subtraction arteriography:26:0.8861	0.8861	26
DSA	DSA:7	dog serum albumin:7:0.3524	0.3524	7
DSA	DSA:5	donor-specific antibodies:5:0.1132	0.1132	5
DSBR	DSBR:7	distal small bowel resection:7:0.5926	0.5926	7
DSBR	DSBR:11	DNA double-strand break repair:11:0.2972	0.2972	11
DSBR	DSBR:10	double-strand-break repair:10:0.1022	0.1022	10
DSBT	DSBT:13	Donor-specific blood transfusion:13:0.7753	0.7753	13
DSBs	DSBs:365|dsbs:35	DNA double-strand breaks:400:0.5647	0.5647	400
DSB	DSB:256|dsb:142	DNA double-strand breaks:191:0.5827|DNA double-strand break:160:0.4097|DNA double strand breaks:42:0.4527|DNA double-strand-break:5:0.0736	0.5827	398
dsb	dsb:7	DNA double-strand breakage:7:0.3524	0.3524	7
Dsb	Dsb:6	single-breath carbon monoxide diffusing capacity:6:0.5290	0.5290	6
DSC-MRI	DSC-MRI:6	dynamic susceptibility contrast-enhanced magnetic resonance imaging:6:0.5290	0.5290	6
DSC-MRI	DSC-MRI:6	Dynamic susceptibility contrast magnetic resonance imaging:6:0.5290	0.5290	6
Dscam	Dscam:6|DSCAM:4	Down syndrome cell adhesion molecule:10:0.5856	0.5856	10
DSCG	DSCG:11	Disodium chromoglycate:11:0.6182	0.6182	11
DSCG	DSCG:326	disodium cromoglycate:326:0.9336	0.9336	326
DSCI	DSCI:14	deep sclerectomy with collagen implant:14:0.8270	0.8270	14
DSCR	DSCR:9	Down syndrome critical region:9:0.6794	0.6794	9
DSCT	DSCT:57	dorsal spinocerebellar tract:57:0.9176	0.9176	57
DSC	DSC:7	decidual stromal cells:7:0.5926	0.5926	7
DSC	DSC:10	delayed sternal closure:10:0.7103	0.7103	10
DSC	DSC:12	dermal sheep collagen:12:0.7571	0.7571	12
Dsc	Dsc:23|DSC:2	desmocollin:14:0.0065|desmocollins:11:0.0050	0.0065	25
DSC	DSC:9	dextran sulfate cellulose:9:0.6794	0.6794	9
DSC	DSC:50	Differential Scanning Calorimeter:50:0.9404	0.9404	50
DSC	DSC:36	Differential scanning calorimetric:36:0.9174	0.9174	36
DSC	DSC:1590	Differential scanning calorimetry:1590:0.9923	0.9923	1590
DSC	DSC:20	differential scanning microcalorimetry:20:0.8525	0.8525	20
DSC	DSC:31	Dynamic susceptibility contrast:31:0.8519	0.8519	31
DSD	DSD:6	depression spectrum disease:6:0.1543	0.1543	6
DSD	DSD:43	detrusor-sphincter dyssynergia:26:0.3502|detrusor sphincter dyssynergia:17:0.5038	0.5038	43
DSE	DSE:16	distal sequence element:16:0.6577	0.6577	16
DSE	DSE:273	dobutamine stress echocardiography:273:0.9339	0.9339	273
DSE	DSE:16	dyad symmetry element:16:0.8165	0.8165	16
DSFI	DSFI:26	Derogatis Sexual Functioning Inventory:26:0.8861	0.8861	26
DSF	DSF:70	Disulfiram:70:0.4452	0.4452	70
Dsg1	Dsg1:26|DSG1:2|dsg-1:1|Dsg-1:1	desmoglein 1:30:0.7652	0.7652	30
Dsg2	Dsg2:9	Desmoglein 2:9:0.6794	0.6794	9
Dsg3	Dsg3:41	desmoglein 3:41:0.8224	0.8224	41
DSG	DSG:98	15-Deoxyspergualin:98:0.3099	0.3099	98
DSG	DSG:55	deoxyspergualin:55:0.1693	0.1693	55
Dsg	Dsg:56|DSG:5|dsg:1	desmoglein:50:0.1565|desmogleins:12:0.0351	0.1565	62
DSG	DSG:36	desogestrel:36:0.1118	0.1118	36
DSH	DSH:80	deliberate self-harm:69:0.9567|deliberate self harm:11:0.7357	0.9567	80
DSH	DSH:7	dexamethasone-suppressible hyperaldosteronism:7:0.2452	0.2452	7
Dsh	Dsh:32|dsh:27	dishevelled:59:0.2437	0.2437	59
DSH	DSH:12	disproportionate share hospital:12:0.7571	0.7571	12
DSH	DSH:18	dyschromatosis symmetrica hereditaria:18:0.7539	0.7539	18
DSIF	DSIF:7	DRB sensitivity-inducing factor:7:0.4438	0.4438	7
DSIP	DSIP:183	delta sleep-inducing peptide:98:0.9500|delta-sleep-inducing peptide:63:0.2267|delta sleep inducing peptide:22:0.7865	0.9500	183
DSIP-LI	DSIP-LI:15	immunoreactivity:15:0.7778	0.7778	15
DSIs	DSIs:12	dorsal swim interneurons:12:0.7571	0.7571	12
DSI	DSI:34	depolarization-induced suppression of inhibition:34:0.8245	0.8245	34
DSI	DSI:8	Dysphonia Severity Index:8:0.5006	0.5006	8
DSI	DSI:13	Inventory:13:0.0710	0.0710	13
DSM-III	DSM-III:18	Diagnostic and Statistical Manual of Mental Disorders:18:0.8365	0.8365	18
DSMB	DSMB:12	data and safety monitoring board:12:0.8657	0.8657	12
DSMC	DSMC:10	Data and Safety Monitoring Committee:10:0.7571	0.7571	10
DSM-IV	DSM-IV:82|DSMIV:1	Diagnostic and Statistical Manual of Mental Disorders:83:0.9653	0.9653	83
DSM-IV	DSM-IV:1	Diagnostic and Statistical Manual of Mental Disorders 4th edition:1:0.9011	0.9011	1
DSM-IV	DSM-IV:5	Diagnostic and Statistical Manual of Mental Disorders Fourth Edition:5:0.9640	0.9640	5
DSM-IV	DSM-IV:10	Diagnostic and Statistical Manual of Mental Disorders-IV:10:0.7103	0.7103	10
DSMs	DSMs:10	degradable starch microspheres:10:0.7103	0.7103	10
DSM	DSM:108|dsm:1	degradable starch microspheres:109:0.9286	0.9286	109
DSM	DSM:18	Diagnostic and Statistical Manual:18:0.8449	0.8449	18
DSM	DSM:47	Diagnostic and Statistical Manual of Mental Disorders:47:0.9379	0.9379	47
DSM	DSM:9	dried skim milk:9:0.6794	0.6794	9
DSO	DSO:13	daily sperm output:13:0.7753	0.7753	13
DSO	DSO:12	Diffuse sclerosing osteomyelitis:12:0.7571	0.7571	12
DSP4	DSP4:10|DSP-4:2	N-2-chloroethyl-N-ethyl-2-bromobenzylamine:12:0.0797	0.0797	12
DSP-4	DSP4:4|DSP-4:4	N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride:8:0.1730	0.1730	8
DSP-4	DSP-4:7|DSP4:3	noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine:10:0.2812	0.2812	10
DSPC	DSPC:8	disaturated PC:8:0.3463	0.3463	8
DSPC	DSPC:104	disaturated phosphatidylcholine:104:0.7146	0.7146	104
DSPC	DSPC:7	phosphatidyl choline:7:0.3524	0.3524	7
DSPE	DSPE:16	distearoylphosphatidylethanolamine:16:0.5000	0.5000	16
DSPG	DSPG:8|DS-PG:5	dermatan sulfate proteoglycan:13:0.7753	0.7753	13
DSPN	DSPN:9	peripheral neuropathy:9:0.6794	0.6794	9
DSPN	DSPN:12	polyneuropathy:12:0.5000	0.5000	12
DSPP	DSPP:42|Dspp:6|dspp:2	dentin sialophosphoprotein:50:0.8520	0.8520	50
DSPS	DSPS:59	delayed sleep phase syndrome:59:0.9203	0.9203	59
DSPs	DSPs:7	Dual-specificity protein phosphatases:7:0.3524	0.3524	7
DSP	DSP:39	daily sperm production:39:0.9237	0.9237	39
DSP	DSP:9	Deliberate self-poisoning:9:0.6794	0.6794	9
DSP	DSP:67|Dsp:2	dentin sialoprotein:69:0.9100	0.9100	69
DSP	DSP:13	dexamethasone sodium phosphate:13:0.7753	0.7753	13
DSP	DSP:51	diarrhetic shellfish poisoning:51:0.5859	0.5859	51
DSP	DSP:30	digital signal processing:30:0.8978	0.8978	30
DSP	DSP:15	digital signal processor:15:0.8045	0.8045	15
DSP	DSP:14	disseminated superficial porokeratosis:14:0.7909	0.7909	14
DSP	DSP:12	Distal sensory polyneuropathy:12:0.6460	0.6460	12
DSP	DSP:9	distal symmetric polyneuropathy:9:0.6794	0.6794	9
DSP	DSP:12	distal symmetrical polyneuropathy:12:0.7571	0.7571	12
DSP	DSP:4	dithiobis succinimidyl propionate:3:0.5290|dithiobis(succinimidyl propionate:1:0.1945	0.5290	4
DSP	DSP:10	dithiobis(succinimidylpropionate):10:0.0169	0.0169	10
DSQ	DSQ:28	Defense Style Questionnaire:28:0.6839	0.6839	28
DSRCT	DSRCT:67	desmoplastic small round cell tumor:59:0.9494|desmoplastic small round cell tumour:8:0.6411	0.9494	67
DSRS	DSRS:10	Depression Self-Rating Scale:10:0.5856	0.5856	10
DSRS	DSRS:57|D-SRS:1	distal splenorenal shunt:58:0.9190	0.9190	58
DSR	DSR:10	Dahl salt-resistant:10:0.5856	0.5856	10
DSR	DSR:10	daily spontaneous running:10:0.7103	0.7103	10
DSR	DSR:10	Daily Symptom Report:10:0.5856	0.5856	10
DSR	DSR:26	digital subtraction radiography:26:0.8251	0.8251	26
DSR	DSR:10|Dsr:2|dsr:1	dissimilatory sulfite reductase:13:0.7753	0.7753	13
DSR	DSR:28	Dynamic Spatial Reconstructor:28:0.8941	0.8941	28
DSST	DSST:84	digit symbol substitution test:65:0.9275|Digit-Symbol Substitution Test:19:0.1185	0.9275	84
DSS	DSS:17	Dahl salt-sensitive:17:0.5760	0.5760	17
DSS	DSS:87	decision support system:65:0.9541|Decision Support Systems:22:0.8657	0.9541	87
DSS	DSS:25	Dejerine-Sottas syndrome:25:0.1693	0.1693	25
DSS	DSS:14	Demographic Surveillance System:14:0.6911	0.6911	14
DSS	DSS:49	dextran sodium sulfate:49:0.9392	0.9392	49
DSS	DSS:19	dextran sodium sulphate:19:0.8449	0.8449	19
DSS	DSS:102	dextran sulfate sodium:102:0.9538	0.9538	102
DSS	DSS:30	dextran sulphate sodium:30:0.9011	0.9011	30
DSS	DSS:12	digit symbol substitution:12:0.7571	0.7571	12
DSS	DSS:14	dioctyl sodium sulfosuccinate:14:0.6911	0.6911	14
DSS	DSS:21	Disability status scale:21:0.8594	0.8594	21
DSS	DSS:20	discrete subaortic stenosis:20:0.7766	0.7766	20
DSS	DSS:85	disease-specific survival:85:0.8419	0.8419	85
DST	DST:645	dexamethasone suppression test:628:0.9610|Dexamethasone Suppression Tests:17:0.7407	0.9610	645
DST	DST:57	donor-specific blood transfusion:46:0.8151|donor-specific blood transfusions:11:0.5355	0.8151	57
DST	DST:64	donor-specific transfusion:56:0.3729|donor-specific transfusions:8:0.1125	0.3729	64
DST	DST:4	double stapling technique:4:0.1618	0.1618	4
DST	DST:15	drug susceptibility testing:15:0.7096	0.7096	15
DST	DST:10	dural sinus thrombosis:10:0.7103	0.7103	10
DST	DST:5	vitro drug sensitivity testing:5:0.1973	0.1973	5
DSU	DSU:11	Day Surgery Unit:11:0.7357	0.7357	11
DSVR	DSVR:12	velocity ratio:12:0.6460	0.6460	12
DSV	DSV:6|dSV:1	dog saphenous vein:7:0.3524	0.3524	7
DT104	DT104:8	definitive phage type 104:8:0.5006	0.5006	8
DT104	DT104:14	typhimurium definitive type 104:14:0.3813	0.3813	14
D-T4	D-T4:6|DT4:5	D-thyroxine:11:0.4000	0.4000	11
DTAC	DTAC:11	dodecyltrimethylammonium chloride:11:0.7357	0.7357	11
DTAF	DTAF:8	dichlorotriazinyl aminofluorescein:8:0.2987	0.2987	8
DTA	DTA:14	descending thoracic aorta:14:0.6173	0.6173	14
DTA	DTA:14|DT-A:9|DTa:1	diphtheria toxin:24:0.8768	0.8768	24
DT-A	DT-A:16|DTA:12	diphtheria toxin A chain:17:0.6211|diphtheria toxin A-chain:11:0.6182	0.6211	28
DTB	DTB:12	2,4-dithiobiuret:12:0.1930	0.1930	12
DTCA	DTCA:16	direct-to-consumer advertising:16:0.8165	0.8165	16
DTCs	DTCs:9	distal tip cells:9:0.6794	0.6794	9
DTCs	DTCs:13	dithiocarbamates:13:0.2553	0.2553	13
DTDST	DTDST:14	diastrophic dysplasia sulfate transporter:14:0.6911	0.6911	14
DTD	DTD:22	diastrophic dysplasia:22:0.8657	0.8657	22
DTD	DTD:13	document type definition:13:0.7753	0.7753	13
DTD	DTD:47|DT-d:3	DT-diaphorase:50:0.3740	0.3740	50
DTE	DTE:44	Dithioerythritol:44:0.4019	0.4019	44
d-TGA	d-TGA:32|D-TGA:19|DTGA:3|dTGA:3	great arteries:57:0.9477	0.9477	57
DTG	DTG:38	1,3-di(2-tolyl)guanidine:38:0.1504	0.1504	38
DTG	DTG:33	1,3-di-o-tolylguanidine:33:0.1301	0.1301	33
DTG	DTG:9	di-o-tolylguanidine:9:0.0325	0.0325	9
DTG	DTG:22	diffuse toxic goiter:22:0.8657	0.8657	22
DTG	DTG:11	guanidine:11:0.0407	0.0407	11
DTH	DTH:1760|DtH:1|Dth:1|dth:1	Delayed-type hypersensitivity:1751:0.7117|delayed-type-hypersensitivity:12:0.0043	0.7117	1763
DTH	DTH:17	delayed type hypersensitivity reaction:11:0.7357|delayed type hypersensitivity reactions:6:0.5290	0.7357	17
DTH	DTH:16	hypersensitivity response:16:0.5171	0.5171	16
DTH	DTH:5	hypersensitivity skin test:5:0.2818	0.2818	5
DTH	DTH:6	hypersensitivity test:6:0.1148	0.1148	6
DTIC	DTIC:28	5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide:14:0.0340|5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide:14:0.0340	0.0340	28
DTIC	DTIC:234	Dacarbazine:234:0.6099	0.6099	234
DTIC	DTIC:7	dimethyl triazeno imidazole carboxamide:7:0.5926	0.5926	7
DTIC	DTIC:9	dimethyltriazenoimidazole carboxamide:9:0.0809	0.0809	9
DTIC	DTIC:10	imidazole-4-carboxamide:10:0.0209	0.0209	10
DTICH	DTICH:9	delayed traumatic intracerebral hematoma:9:0.6794	0.6794	9
DTIs	DTIs:19	direct thrombin inhibitors:19:0.8449	0.8449	19
DTL	DTL:8	descending thin limb:8:0.6411	0.6411	8
DT-MRI	DT-MRI:19|DTMRI:3	diffusion tensor magnetic resonance imaging:22:0.8657	0.8657	22
DT-MRI	DT-MRI:12|DTMRI:2	diffusion tensor MRI:14:0.7753	0.7753	14
DTM	DTM:9	dermatophyte test medium:9:0.6794	0.6794	9
DTNB	DTNB:24	5,5'-dithiobis(2-nitrobenzoate):24:0.0504	0.0504	24
DTPa	DTPa:6	acellular pertussis vaccine:6:0.2827	0.2827	6
DTPA	DTPA:10	diethylenetriamine pentaacetate:10:0.1596	0.1596	10
DTPA	DTPA:25	diethylenetriaminepentaacetate:25:0.0264	0.0264	25
DTPA	DTPA:273|dtpa:2|DT-PA:1	diethylenetriaminepentaacetic acid:276:0.3602	0.3602	276
DTPa	DTPa:6|dTpa:4	diphtheria-tetanus-acellular pertussis:10:0.2643	0.2643	10
DTP	DTP:10	Developmental Therapeutics Program:10:0.7103	0.7103	10
DTP	DTP:8	diphtheria and tetanus toxoids and pertussis vaccine:8:0.6794	0.6794	8
DTP	DTP:1	diphtheria and tetanus toxoids with pertussis:1:0.7096	0.7096	1
DTP	DTP:123	diphtheria-tetanus-pertussis:109:0.2967|diphtheria/tetanus/pertussis:13:0.0330|diphtheria tetanus pertussis:1:0.8644	0.8644	123
DTP	DTP:17	diphtheria-tetanus-pertussis vaccine:17:0.1973	0.1973	17
DTSP	DTSP:3	propionate:3:0.5000	0.5000	3
DTSQ	DTSQ:12	Diabetes Treatment Satisfaction Questionnaire:12:0.6701	0.6701	12
DTT	DTT:13	1,4-Dithiothreitol:13:0.0084	0.0084	13
DTT	DTT:1272|dtt:1	dithiothreitol:1273:0.8882	0.8882	1273
DTT	DTT:22	dithiotreitol:22:0.0147	0.0147	22
DTT	DTT:20	DL-dithiothreitol:20:0.0147	0.0147	20
DTX-2	DTX-2:10|DTX2:3	dinophysistoxin-2:13:0.8571	0.8571	13
DTXI	DTXI:4|DTX-I:2|DTXi:1	Dendrotoxin I:7:0.3524	0.3524	7
DTZ	DTZ:63	Diltiazem:63:0.7045	0.7045	63
DTZ	DTZ:9	dithizone:9:0.0909	0.0909	9
DTaP	DTaP:21	acellular pertussis:21:0.2886	0.2886	21
DTaP	DTaP:11	diphtheria and tetanus toxoids and acellular pertussis vaccine:11:0.7571	0.7571	11
DTaP	DTaP:16|dTap:1	diphtheria-tetanus-acellular pertussis:17:0.2074	0.2074	17
DTaP	DTaP:5	pertussis vaccine combined with diphtheria and tetanus toxoids:5:0.4422	0.4422	5
DTI	DTI:211	Diffusion Tensor Imaging:211:0.9773	0.9773	211
DTI	DTI:11	direct thrombin inhibitor:11:0.7357	0.7357	11
DTI	DTI:7	drug targeting index:7:0.5926	0.5926	7
DTwP	DTwP:7	whole-cell pertussis vaccine:7:0.4438	0.4438	7
DTX	DTX:7|DTx:2|Dtx:1	alpha-Dendrotoxin:10:0.0900	0.0900	10
DTX	DTX:26|DTx:2|Dtx:1|DtX:1	dendrotoxin:30:0.2900	0.2900	30
DTx	DTx:15|DTX:11	diphtheria toxin:26:0.8861	0.8861	26
DTX	DTX:12	docetaxel:12:0.1100	0.1100	12
DT	DT:8|dt:2	decayed teeth:10:0.6182	0.6182	10
DT	DT:97|Dt:1	deceleration time:98:0.3223	0.3223	98
DT	DT:6	decidual tissue:6:0.2243	0.2243	6
DT	DT:14	definitive phage type:14:0.7909	0.7909	14
DT	DT:25	Delirium Tremens:25:0.8816	0.8816	25
dT	dT:20	deoxythymidine:20:0.0105	0.0105	20
DT	DT:7	desmoid tumor:7:0.2902	0.2902	7
DT	DT:68|dt:2	developed tension:70:0.9112	0.9112	70
DT	DT:9	diffraction tomography:9:0.6794	0.6794	9
DT	DT:42	diffusion tensor:32:0.9072|Diffusion-tensor:10:0.0050	0.9072	42
DT	DT:16	diphtheria and tetanus toxoids:16:0.8165	0.8165	16
DT	DT:19|D-T:2|dT:1	diphtheria-tetanus:22:0.0117	0.0117	22
DT	DT:225	diphtheria toxin:225:0.9471	0.9471	225
DT	DT:9	dipole tracing:9:0.6794	0.6794	9
DT	DT:32	distal tubules:18:0.5940|distal tubule:14:0.6911	0.6911	32
DT	DT:95|Dt:4|dt:3|dT:1	doubling time:91:0.2955|doubling times:12:0.2293	0.2955	103
DT	DT:11	drive for thinness:11:0.7571	0.7571	11
dt	dt:25	dystonia musculorum:25:0.8816	0.8816	25
dt	dt:13	genetically dystonic:13:0.4102	0.4102	13
DT	DT:5	impedance detection times:5:0.1464	0.1464	5
DT	DT:16	Sabin-Feldman dye test:16:0.2923	0.2923	16
DT	DT:4	Salmonella typhimurium definitive type:4:0.1973	0.1973	4
DT	DT:17	threshold:17:0.0089	0.0089	17
dT	dT:34	thymidine:34:0.0183	0.0183	34
DT	DT:13	treatment:13:0.0067	0.0067	13
DT	DT:9	vaccine:9:0.0044	0.0044	9
DU145	DU145:4|DU-145:1|Du145:1	prostate cancer cells:6:0.3728	0.3728	6
DUB	DUB:64	dysfunctional uterine bleeding:64:0.8807	0.8807	64
DUE	DUE:12	DNA unwinding element:12:0.7571	0.7571	12
DUE	DUE:52	evaluation:52:0.6538	0.6538	52
DUI	DUI:11	doubly uniparental inheritance:11:0.7357	0.7357	11
DUI	DUI:47	driving under the influence:38:0.8781|Driving-under-the-influence:9:0.0727	0.8781	47
DUI	DUI:23	driving under the influence of alcohol:23:0.8115	0.8115	23
DUM	DUM:61	Dorsal unpaired median:61:0.9511	0.9511	61
DUR	DUR:38	drug utilization review:38:0.9217	0.9217	38
DUR	DUR:5|dur:3|Dur:1	duration:9:0.0755	0.0755	9
DUR	DUR:12	uptake ratio:12:0.6460	0.6460	12
DUSI	DUSI:13	Drug Use Screening Inventory:13:0.7753	0.7753	13
DUSN	DUSN:14	diffuse unilateral subacute neuroretinitis:14:0.7909	0.7909	14
DUWL	DUWL:9	dental unit waterlines:9:0.6794	0.6794	9
DUS	DUS:14	Doppler ultrasonography:14:0.3202	0.3202	14
DUS	DUS:22	Doppler ultrasound:22:0.3359	0.3359	22
DUs	DUs:10	drug users:10:0.7103	0.7103	10
DUs	DUs:13|Dus:1	duodenal ulcers:14:0.7909	0.7909	14
DUS	DUS:8	Duplex ultrasonography:8:0.1004	0.1004	8
DUS	DUS:18	duplex ultrasound:18:0.2462	0.2462	18
DU	DU:7	densitometric units:7:0.1111	0.1111	7
dU	dU:33	deoxyuridine:33:0.0364	0.0364	33
DU	DU:71	Depleted uranium:71:0.9561	0.9561	71
DU	DU:9	Doppler ultrasound:9:0.1492	0.1492	9
DU	DU:21	duodenal:21:0.0228	0.0228	21
DU	DU:518	duodenal ulcer:479:0.9721|duodenal ulcers:39:0.8142	0.9721	518
DU	DU:11	duodenal ulcer disease:11:0.7357	0.7357	11
DU	DU:11	duodenal ulcer patients:11:0.7357	0.7357	11
DU	DU:20	duplex ultrasonography:20:0.5568	0.5568	20
DU	DU:14	duplex ultrasound:14:0.3585	0.3585	14
DVA	DVA:28	Department of Veterans Affairs:28:0.7905	0.7905	28
DVA	DVA:9	Developmental Venous Anomaly:9:0.6794	0.6794	9
DVA	DVA:22	dynamic visual acuity:22:0.5863	0.5863	22
DVAs	DVAs:15	developmental venous anomalies:15:0.8045	0.8045	15
DVC	DVC:17	Direct Viable Count:17:0.7407	0.7407	17
DVC	DVC:83	dorsal vagal complex:83:0.9640	0.9640	83
DVD	DVD:47	dissociated vertical deviation:47:0.9366	0.9366	47
DVD	DVD:6	double vessel disease:6:0.3728	0.3728	6
DVE	DVE:5	duck virus enteritis:5:0.2818	0.2818	5
DVHs	DVHs:138|DVHS:2	dose-volume histograms:116:0.7503|dose volume histograms:24:0.8115	0.8115	140
DVH	DVH:208	dose-volume histogram:94:0.6988|dose-volume histograms:65:0.6075|Dose Volume Histograms:25:0.8816|dose volume histogram:24:0.8768	0.8816	208
DVI	DVI:5	deep venous incompetence:5:0.4422	0.4422	5
Dvl	Dvl:32|DVL:4	Dishevelled:36:0.6034	0.6034	36
DVM	DVM:10	Delayed visual maturation:10:0.7103	0.7103	10
DVN	DVN:10	dorsal vagal nucleus:10:0.7103	0.7103	10
DVR	DVR:14	aortic and mitral valve replacement:14:0.7539	0.7539	14
DVR	DVR:33	descending vasa recta:33:0.9100	0.9100	33
DVR	DVR:13	distribution volume ratio:13:0.5934	0.5934	13
DVR	DVR:23	dorsal ventricular ridge:23:0.8715	0.8715	23
DVR	DVR:20	double valve replacement:20:0.3419	0.3419	20
DVR	DVR:9	valve replacements:9:0.4587	0.4587	9
DVSA	DVSA:9	digital video subtraction angiography:9:0.5470	0.5470	9
DVT	DVT:7	deep vein thrombophlebitis:7:0.5926	0.5926	7
DVT	DVT:11	deep vein thromboses:11:0.7357	0.7357	11
DVT	DVT:6	deep venous thrombophlebitis:6:0.5290	0.5290	6
DVT	DVT:13	deep venous thromboses:13:0.6701	0.6701	13
DVT	DVT:1128	deep venous thrombosis:1128:0.9880	0.9880	1128
DV	DV:21	dengue type 2 virus:21:0.8594	0.8594	21
DV	DV:52	dengue virus:52:0.5379	0.5379	52
DV	DV:39	distribution volume:39:0.6563	0.6563	39
DV	DV:77	domestic violence:77:0.9612	0.9612	77
D-V	D-V:19|DV:14|d-v:2	dorsal-ventral:35:0.0584	0.0584	35
DV	DV:6|D-V:4	dorso-ventral:10:0.0155	0.0155	10
DV	DV:75|D-V:9	dorsoventral:84:0.1426	0.1426	84
DV	DV:45	ductus venosus:45:0.9338	0.9338	45
DW-EPI	DW-EPI:6	diffusion-weighted echo-planar imaging:6:0.5290	0.5290	6
DWI	DWI:13	diffusion-:13:0.0156	0.0156	13
DWI	DWI:21	Diffusion-weighted:21:0.0260	0.0260	21
DWI	DWI:34	diffusion-weighted images:34:0.5537	0.5537	34
DWI	DWI:318|D-WI:1	diffusion-weighted imaging:319:0.6341	0.6341	319
DWI	DWI:52	Diffusion-weighted magnetic resonance imaging:52:0.6696	0.6696	52
DWI	DWI:87	diffusion-weighted MRI:87:0.8027	0.8027	87
DWI	DWI:19	driving while impaired:19:0.7658	0.7658	19
DWI	DWI:57	driving while intoxicated:48:0.9379|driving-while-intoxicated:9:0.0104	0.9379	57
DWM	DWM:16	Dandy-Walker malformation:16:0.7261	0.7261	16
DW-MRI	DW-MRI:14|DWMRI:4	diffusion-weighted magnetic resonance imaging:18:0.6381	0.6381	18
DW-MRI	DW-MRI:6|DWMRI:2	diffusion-weighted MRI:8:0.5470	0.5470	8
DWT	DWT:38	discrete wavelet transform:38:0.7810	0.7810	38
DW	DW:7	daily wear:7:0.3524	0.3524	7
DW	DW:15	deionized water:15:0.0842	0.0842	15
DW	DW:146	diffusion-weighted:146:0.2164	0.2164	146
DW	DW:53	distilled water:53:0.5060	0.5060	53
DW	DW:67|dw:49|Dw:1	dry weight:117:0.8299	0.8299	117
dw	dw:53|DW:1	dwarf:54:0.0791	0.0791	54
dw	dw:8	dwarf gene:8:0.1591	0.1591	8
dw	dw:5	sex-linked dwarfing gene:5:0.1464	0.1464	5
DXA	DXA:437	Dual energy X-ray absorptiometry:437:0.9931	0.9931	437
DXA	DXA:10	X-ray absorptiometer:10:0.5856	0.5856	10
DXA	DXA:15	x-ray absorptiometric:15:0.8045	0.8045	15
DXA	DXA:7	X-ray densitometry:7:0.1211	0.1211	7
DXM	DXM:195|Dxm:5|dxm:3	dexamethasone:203:0.8783	0.8783	203
DXP	DXP:21|Dxp:1	1-deoxy-D-xylulose 5-phosphate:13:0.4849|1-deoxy-D-xylulose-5-phosphate:9:0.1778	0.4849	22
DXP	DXP:8|dxp:1	dextropropoxyphene:9:0.1778	0.1778	9
DXR	DXR:11|Dxr:1	1-deoxy-D-xylulose 5-phosphate reductoisomerase:12:0.6460	0.6460	12
DXR	DXR:32	delayed xenograft rejection:32:0.9072	0.9072	32
DXR	DXR:15	digital X-ray radiogrammetry:15:0.6386	0.6386	15
DXR	DXR:268|Dxr:2	doxorubicin:270:0.7116	0.7116	270
DYN	DYN:65|Dyn:42|dyn:8	dynorphin:115:0.5816	0.5816	115
DYS	DYS:25|dys:4	dysplasia:29:0.4375	0.4375	29
DYT1	DYT1:10	torsion dystonia:10:0.4363	0.4363	10
DY	DY:13	diamidino yellow dihydrochloride:13:0.7753	0.7753	13
dy	dy:11	dystrophic:11:0.0472	0.0472	11
DZA	DZA:16	3-deazaadenosine:16:0.5357	0.5357	16
DZM	DZM:9	diazepam:9:0.6154	0.6154	9
DZP	DZP:186|Dzp:1|dzp:1	diazepam:188:0.9590	0.9590	188
DZ	DZ:5	definitive zone:5:0.0517	0.0517	5
DZ	DZ:194|Dz:8|dz:1	diazepam:203:0.2249	0.2249	203
DZ	DZ:15|Dz:2	diazoxide:17:0.0178	0.0178	17
DZ	DZ:20|Dz:2	diltiazem:22:0.0234	0.0234	22
DZ	DZ:10	dizygotic twins:10:0.5856	0.5856	10
Dab1	Dab1:8|DAB1:1	adaptor protein Disabled-1:9:0.5856	0.5856	9
Dahl-R	Dahl-R:17	salt-resistant:17:0.8000	0.8000	17
Dahl-S	Dahl-S:37	Dahl salt-sensitive:37:0.8051	0.8051	37
DAO	DAO:44	D-amino acid oxidase:44:0.9323	0.9323	44
DAo	DAo:6|DAO:1	descending aorta:7:0.2452	0.2452	7
DAO	DAO:211|dao:1	Diamine oxidase:212:0.7342	0.7342	212
DAO	DAO:24	dorsal accessory olive:24:0.8768	0.8768	24
Daudi	Daudi:9|DAUDI:1	human lymphoblastoid:10:0.5856	0.5856	10
DbetaH	DbetaH:35|D-beta-H:1	dopamine-beta-hydroxylase:36:0.4667	0.4667	36
DC2	DC2:11	dendritic cells:11:0.6182	0.6182	11
DcR3	DcR3:24|DCR3:1	decoy receptor 3:25:0.8816	0.8816	25
Dcytb	Dcytb:9	duodenal cytochrome b:9:0.6794	0.6794	9
DD	DD:8	1 disc diameter:8:0.3463	0.3463	8
DD	DD:61	constant dark:61:0.6490	0.6490	61
DD	DD:206|D-D:1	constant darkness:207:0.6646	0.6646	207
DD	DD:6	constant dim red light:6:0.3728	0.3728	6
DD	DD:56	continuous darkness:56:0.1452	0.1452	56
DD	DD:142|D-d:30|D-D:6|Dd:1	D-dimer:135:0.0735|D-dimers:32:0.0170|D Dimer:12:0.5934	0.5934	179
DD	DD:34	Darier's disease:23:0.1752|Darier disease:11:0.0510	0.1752	34
DD	DD:33	death domain:33:0.8196	0.8196	33
DD	DD:10	degree of deacetylation:10:0.4363	0.4363	10
DD	DD:6	delayed depolarization:6:0.0611	0.0611	6
DD	DD:11	deletion:11:0.0055	0.0055	11
DD	DD:10	deletion allele:10:0.5856	0.5856	10
DD	DD:12	delusional disorder:12:0.1105	0.1105	12
DD	DD:8	Density dependence:8:0.4102	0.4102	8
DD	DD:14	developmental disabilities:14:0.7909	0.7909	14
DD	DD:12	developmental dyslexia:12:0.7571	0.7571	12
DD	DD:13	diastolic depolarization:13:0.4102	0.4102	13
DD	DD:6|Dd:5	diastolic diameter:11:0.1612	0.1612	11
DD	DD:12	diastolic dysfunction:12:0.6460	0.6460	12
DD	DD:12	diastrophic dysplasia:12:0.3813	0.3813	12
DD	DD:16	Dibenzo-p-dioxin:16:0.0082	0.0082	16
Dd	Dd:15	Dictyostelium discoideum:15:0.8045	0.8045	15
DD	DD:111|dd:1|Dd:1	differential display:113:0.8980	0.8980	113
DD	DD:7	Digital dermatitis:7:0.2902	0.2902	7
DD	DD:14	dihydrodiol dehydrogenase:14:0.6701	0.6701	14
DD	DD:11	disc diameters:11:0.4728	0.4728	11
DD	DD:7	disc displacement:7:0.2113	0.2113	7
DD	DD:10	disk diffusion:10:0.1449	0.1449	10
DD	DD:12	disorders:12:0.0060	0.0060	12
DD	DD:11	diverticular disease:11:0.0510	0.0510	11
DD	DD:10	Dopamine-deficient:10:0.0049	0.0049	10
DD	DD:13	double diffusion:13:0.2415	0.2415	13
DD	DD:11|dd:1	doubling doses:12:0.6460	0.6460	12
DD	DD:19	drug discrimination:19:0.7044	0.7044	19
DD	DD:9	Duchenne dystrophy:9:0.3069	0.3069	9
DD	DD:30	dysthymic disorder:30:0.4752	0.4752	30
Dd	Dd:5	end-diastolic dimension:5:0.0902	0.0902	5
DEX	DEX:14|Dex:4	[3H]dexamethasone:18:0.0062	0.0062	18
Dex	Dex:3|DEX:2	agonist dexmedetomidine:5:0.1327	0.1327	5
DEX	DEX:1367|Dex:910|dex:109	Dexamethasone:2386:0.8767	0.8767	2386
DEX	DEX:6	dexamethasone phosphate:6:0.1320	0.1320	6
DEX	DEX:6	dexamethasone sodium phosphate:6:0.5290	0.5290	6
DEX	DEX:8|Dex:3	dexrazoxane:11:0.0037	0.0037	11
Dex	Dex:9|dex:1	dextranase:10:0.0033	0.0033	10
DEX	DEX:21|Dex:7	dextromethorphan:28:0.0099	0.0099	28
DIA	DIA:13	activity:13:0.0370	0.0370	13
DIA	DIA:55|Dia:25	diaphragm:80:0.2438	0.2438	80
DIA	DIA:7|Dia:1	diaphragmatic:8:0.0247	0.0247	8
DIA	DIA:23	digital image analysis:23:0.8038	0.8038	23
DIA	DIA:21	dot immunobinding assay:21:0.7865	0.7865	21
Dk/L	Dk/L:30|DK/L:1	oxygen transmissibility:22:0.6531|oxygen transmissibilities:9:0.6794	0.6794	31
Dk	Dk:25|DK:1	oxygen permeability:26:0.6973	0.6973	26
DLL3	DLL3:6|Dll3:3	delta-like 3:9:0.5470	0.5470	9
Dll	Dll:45|dll:1	Distal-less:46:0.4545	0.4545	46
DL	DL:10	decidual lymphocytes:10:0.7103	0.7103	10
Dl	Dl:39|DL:1	Delta:40:0.0449	0.0449	40
DL	DL:34	detection limit:25:0.8186|detection limits:9:0.5470	0.8186	34
DL	DL:5	Developmental Level:5:0.0736	0.0736	5
DL	DL:29	diagnostic laparoscopy:29:0.7581	0.7581	29
DL	DL:34	dichotic listening:34:0.8644	0.8644	34
DL	DL:17	difference limen:17:0.6748	0.6748	17
DL	DL:6	diffuse leiomyomatosis:6:0.1838	0.1838	6
DL	DL:28|Dl:1	diffusing capacity:29:0.8978	0.8978	29
DL	DL:6	dim light:6:0.1543	0.1543	6
DL	DL:11	direct laryngoscopy:11:0.6182	0.6182	11
DL	DL:16	distal latency:16:0.5564	0.5564	16
DL	DL:14	dominant lethal:14:0.7909	0.7909	14
D-L	D-L:5|DL:4	Donath-Landsteiner:9:0.0092	0.0092	9
DL	DL:34|dl:3	dorsolateral:37:0.0414	0.0414	37
DL	DL:5	dorsolateral area:5:0.0517	0.0517	5
DL	DL:7	dorsolateral visual area:7:0.5926	0.5926	7
dl	dl:8|DL:1|Dl:1|dL:1	downless:11:0.0115	0.0115	11
DL	DL:9	Ductal lavage:9:0.6794	0.6794	9
dl	dl:6	maternal morphogen dorsal:6:0.3728	0.3728	6
Dmax	Dmax:5|dmax:2	displacement limit:7:0.2902	0.2902	7
Dmax	Dmax:7|dmax:1	maximum diameter:8:0.1276	0.1276	8
Dmax	Dmax:6|dmax:3	maximum dose:9:0.3945	0.3945	9
DMP1	DMP1:41|Dmp1:8|DMP-1:5|Dmp-1:2	dentin matrix protein 1:46:0.8401|dentin matrix protein-1:10:0.7103	0.8401	56
DM	DM:44|Dm:2	daunomycin:46:0.0086	0.0086	46
DM	DM:6|Dm:3	daunorubicin:9:0.0015	0.0015	9
DM	DM:19	Defined Medium:19:0.3333	0.3333	19
DM	DM:9	deltamethrin:9:0.0015	0.0015	9
DM	DM:9|Dm:1	dermorphin:10:0.0017	0.0017	10
DM	DM:22	Descemet's membrane:22:0.2619	0.2619	22
DM	DM:13	Desmoplastic Melanoma:13:0.7753	0.7753	13
DM	DM:10	Deutschmarks:10:0.0017	0.0017	10
DM	DM:75|Dm:1	dexamethasone:76:0.0144	0.0144	76
DM	DM:152	dextromethorphan:152:0.0290	0.0290	152
DM	DM:60	Diabetic:47:0.0088|diabetics:13:0.0023	0.0088	60
DM	DM:6	diabetic group:6:0.1838	0.1838	6
DM	DM:9	diabetic patients:9:0.3455	0.3455	9
DM	DM:5	diabetic rats:5:0.1132	0.1132	5
DM	DM:8	differentiation medium:8:0.0625	0.0625	8
DM	DM:38	Disease management:38:0.7548	0.7548	38
DM	DM:36	distant metastases:36:0.8716	0.8716	36
DM	DM:43	Distant metastasis:43:0.8590	0.8590	43
DM	DM:9	dorsal medulla:9:0.1492	0.1492	9
DM	DM:50|dm:5	dorsomedial:55:0.0104	0.0104	55
DM	DM:14	dorsomedial medulla:14:0.3585	0.3585	14
DM	DM:13	dorsomedial nucleus:13:0.3331	0.3331	13
DM	DM:5	dorsomedial nucleus of the intercollicular complex:5:0.4422	0.4422	5
DM	DM:12	dorsomedial visual area:12:0.5664	0.5664	12
DM	DM:26|dm:4	double minutes:30:0.9011	0.9011	30
DM	DM:12	double minute chromosomes:12:0.7571	0.7571	12
DM	DM:11	double-muscled:11:0.0019	0.0019	11
Dm	Dm:36|dm:1	Drosophila melanogaster:37:0.7758	0.7758	37
DM	DM:6|dm:5	dry mass:11:0.6182	0.6182	11
DM	DM:515|dm:5	dry matter:520:0.9793	0.9793	520
dm	dm:7	dry muscle:7:0.2902	0.2902	7
DM	DM:9	dura mater:9:0.6794	0.6794	9
DM	DM:11|Dm:2	dystrophia myotonica:13:0.7753	0.7753	13
DM	DM:18	HLA-DM:18:0.0033	0.0033	18
Dm	Dm:18|DM:9	membrane diffusing capacity:27:0.7905	0.7905	27
DM	DM:9	method:9:0.0015	0.0015	9
DM	DM:374	Myotonic dystrophy:374:0.9609	0.9609	374
DM	DM:30	patients with dermatomyositis:30:0.0663	0.0663	30
DM	DM:249|Dm:1	patients with diabetes mellitus:250:0.1062	0.1062	250
DM	DM:20	Type 2 diabetes:20:0.8525	0.8525	20
Dnmt1	Dnmt1:15|DNMT1:4|dnmt1:2	DNA methyltransferase:21:0.6400	0.6400	21
DNMT1	DNMT1:22|Dnmt1:10|dnmt1:3|DNMT-1:1	DNA methyltransferase 1:36:0.7704	0.7704	36
DNMT	DNMT:30|Dnmt:8	DNA methyltransferase:38:0.8417	0.8417	38
DN	DN:13	CD4-CD8-:13:0.0110	0.0110	13
DN	DN:36	CD4-CD8- double-negative:22:0.1094|CD4(-)CD8(-) double-negative:14:0.0614	0.1094	36
DN	DN:25	dentate nucleus:25:0.6873	0.6873	25
DN	DN:252	diabetic nephropathy:252:0.9476	0.9476	252
DN	DN:26	diabetic neuropathy:26:0.5409	0.5409	26
DN	DN:12	dibucaine number:12:0.2414	0.2414	12
DN	DN:174|dn:68|D-N:2|Dn:1	Dominant negative:130:0.4567|dominant-negative:115:0.0967	0.4567	245
DN	DN:8	donor number:8:0.1004	0.1004	8
DN	DN:112|dn:1	double negative:113:0.3964	0.3964	113
DN	DN:31	dysplastic nevi:31:0.9043	0.9043	31
Dol-P	Dol-P:9	dolichyl monophosphate:9:0.3945	0.3945	9
Dol-P	Dol-P:29|dol-P:1|dol-p:1|DolP:1	dolichyl phosphate:32:0.6656	0.6656	32
DOPT	DOPT:9	directly observed preventive therapy:9:0.6794	0.6794	9
Doxil	Doxil:39|doxil:4|DOXIL:2	Liposomal doxorubicin:45:0.6343	0.6343	45
dpf	dpf:8	days post fertilization:8:0.5006	0.5006	8
dpf	dpf:31|DPF:2	days postfertilization:33:0.8196	0.8196	33
DQ	DQ:68	developmental quotient:58:0.6207|developmental quotients:10:0.3470	0.6207	68
DQ	DQ:11	diquat:11:0.0386	0.0386	11
DQ	DQ:33	double-quantum:22:0.0811|double quantum:11:0.7357	0.7357	33
DQ	DQ:11	duroquinone:11:0.0386	0.0386	11
DQ	DQ:9	questionnaire:9:0.0309	0.0309	9
DRMs	DRMs:43	detergent-resistant membranes:43:0.7795	0.7795	43
DRMs	DRMs:7	Detergent-resistant membrane domains:7:0.3524	0.3524	7
DSL	DSL:9	Delta/Serrate/lag-2:9:0.1081	0.1081	9
DTS	DTS:11	Davidson Trauma Scale:11:0.5856	0.5856	11
DTS	DTS:11	dense tubular system:11:0.7357	0.7357	11
DTS	DTS:35	diametral tensile strength:35:0.9174	0.9174	35
DTS	DTS:7	dipyridamole thallium scintigraphy:7:0.5926	0.5926	7
DtxR	DtxR:39|dtxR:3	diphtheria toxin repressor:42:0.9291	0.9291	42
DUP	DUP:61	duration of untreated psychosis:61:0.9229	0.9229	61
Duke	Duke:13	Duke Health Profile:13:0.7753	0.7753	13
DXS	DXS:8|Dxs:1	1-deoxy-D-xylulose 5-phosphate synthase:9:0.4587	0.4587	9
DxS	DxS:14|DXS:13	dextran sulphate:27:0.8312	0.8312	27
DXS	DXS:8	diagnostic x-ray spectrometry:8:0.5006	0.5006	8
DX	DX:70|Dx:50	dexamethasone:120:0.2761	0.2761	120
Dx	Dx:18|DX:4	dextran:22:0.0487	0.0487	22
DX	DX:80|Dx:43|dx:1	doxorubicin:124:0.2877	0.2877	124
DX	DX:7	metabolite dextrorphan:7:0.1334	0.1334	7
E&M	E&M:13	evaluation and management:13:0.6701	0.6701	13
E(1)S	E(1)S:9|E(1)-S:2	estrone sulfate:11:0.6182	0.6182	11
E(1)	E(1):47	estrone:47:0.6765	0.6765	47
E(2)	E(2):52	17 beta-estradiol:43:0.8300|17-beta-estradiol:9:0.0093	0.8300	52
E(2)	E(2):262	17beta-estradiol:249:0.2922|17beta-oestradiol:13:0.0140	0.2922	262
E(2)	E(2):363	estradiol:363:0.4214	0.4214	363
E(2)	E(2):18	estradiol-17 beta:18:0.8365	0.8365	18
E(2)	E(2):89	estradiol-17beta:89:0.1024	0.1024	89
E(2)	E(2):14	estrogen:14:0.0151	0.0151	14
E(2)	E(2):12	Oestradiol:12:0.0128	0.0128	12
E(h)	E(h):7|E(H):1	redox potential:8:0.4102	0.4102	8
E(K)	E(K):7|E(k):2	potential:9:0.4444	0.4444	9
E(LUMO)	E(LUMO):9|E(lumo):2	energy of the lowest unoccupied molecular orbital:11:0.6182	0.6182	11
E(a)	E(a):16|E(A):1	activation energies:17:0.8270	0.8270	17
E(a)	E(a):4	effective arterial elastance:4:0.0918	0.0918	4
E(es)	E(es):13|E(ES):2	end-systolic elastance:15:0.7096	0.7096	15
E(m)	E(m):39|E(M):7	membrane potential:46:0.5470	0.5470	46
E(m)	E(m):8|E(M):1	potentials:9:0.0769	0.0769	9
E(max)	E(max):10	maximal response:10:0.2873	0.2873	10
E(max)	E(max):6	maximum effect:6:0.1148	0.1148	6
E(rev)	E(rev):20	reversal potential:20:0.8525	0.8525	20
E(spl)-C	E(spl)-C:4|E-(SPL)-C:1|E(spl)C:1	Enhancer of split complex:6:0.5290	0.5290	6
E+P	E+P:11	progesterone:11:0.3704	0.3704	11
E-box	E-box:6	binding site:6:0.1543	0.1543	6
E-state	E-state:17|E-State:3	electrotopological state:20:0.8525	0.8525	20
e.e.g.	e.e.g.:6|E.E.G.:4	electroencephalogram:10:0.6000	0.6000	10
e.l.i.s.a.	e.l.i.s.a.:3|E.L.I.S.A.:3	enzyme-linked immunosorbent assay:6:0.2827	0.2827	6
E.M.	E.M.:6|e.m.:3	electron microscopy:9:0.6794	0.6794	9
E.coli	E.coli:11	Escherichia coli:11:0.7357	0.7357	11
E/A	E/A:12	filling velocity:12:0.1423	0.1423	12
E/A	E/A:10	velocities:10:0.0542	0.0542	10
E/I	E/I:9	expiration/inspiration:9:0.2963	0.2963	9
E/M	E/M:10	Evaluation and management:10:0.7103	0.7103	10
E/S	E/S:58	excretory/secretory:58:0.6196	0.6196	58
E/T	E/T:19	effector/target:19:0.2609	0.2609	19
E/T	E/T:10	ratio:10:0.1304	0.1304	10
E/[A]	E/[A]:16	concentration-effect:16:0.7895	0.7895	16
E0'	E0':11	potential:11:0.6250	0.6250	11
E1/2	E1/2:14|-E1/2:1	potential:15:0.4516	0.4516	15
E10	E10:48|E-10:1	embryonic day 10:49:0.8254	0.8254	49
E11	E11:9	monoclonal antibody:9:0.5470	0.5470	9
E12.5	E12.5:27|e12.5:2	embryonic day 12.5:29:0.7237	0.7237	29
E12	E12:86|E-12:4|e12:3	embryonic day 12:93:0.8778	0.8778	93
E13.5	E13.5:20|e13.5:2	Embryonic Day 13.5:22:0.7400	0.7400	22
E1-3-G	E1-3-G:9|E1-3G:3	estrone-3-glucuronide:12:0.6667	0.6667	12
E13	E13:87|E-13:2	embryonic day 13:89:0.7946	0.7946	89
E14.5	E14.5:14	embryonic day 14.5:14:0.7909	0.7909	14
E14	E14:130|E-14:2|e14:1	embryonic day 14:133:0.9218	0.9218	133
E15.5	E15.5:12	embryonic day 15.5:12:0.7571	0.7571	12
E15	E15:105|E-15:2|e15:1	embryonic day 15:108:0.8936	0.8936	108
E16	E16:77|E-16:2	embryonic day 16:79:0.8313	0.8313	79
E17	E17:55	embryonic day 17:55:0.7858	0.7858	55
E18	E18:68|E-18:2	embryonic day 18:70:0.7986	0.7986	70
E19	E19:19	embryonic day 19:19:0.6106	0.6106	19
E1C	E1C:16|E1c:3	estrone conjugates:19:0.7658	0.7658	19
E1G	E1G:6|E1-G:3	estrone glucuronide:9:0.2987	0.2987	9
E1P	E1P:7|E1--P:1	ADP-sensitive phosphoenzyme:8:0.4102	0.4102	8
E1p	E1p:12	pyruvate dehydrogenase:12:0.5664	0.5664	12
E1S	E1S:84|E1-S:13|E1s:1	estrone sulfate:98:0.9216	0.9216	98
E1S	E1S:17|E1-S:1	estrone sulphate:18:0.2462	0.2462	18
E1S	E1S:24	oestrone sulphate:24:0.3828	0.3828	24
E1A	E1A:101|E1a:8	early region 1a:109:0.9422	0.9422	109
E1B	E1B:16|E1b:6	Early region 1B:22:0.8657	0.8657	22
E1	E1:38	early region 1:38:0.8781	0.8781	38
E1	E1:12	envelope 1:12:0.0538	0.0538	12
E1	E1:6	Fecal elastase-1:6:0.1838	0.1838	6
E1	E1:15	pyruvate decarboxylase:15:0.3262	0.3262	15
E1	E1:74	pyruvate dehydrogenase:74:0.6907	0.6907	74
E1	E1:12	pyruvate dehydrogenase component:12:0.7571	0.7571	12
E1	E1:71	Ubiquitin-activating enzyme:71:0.6512	0.6512	71
E2020	E2020:13	hydrochloride:13:0.4800	0.4800	13
E20	E20:20	Embryonic Day 20:20:0.7766	0.7766	20
E21	E21:10	embryonic day 21:10:0.4363	0.4363	10
E22	E22:6	embryonic day 22:6:0.3728	0.3728	6
E2B	E2B:44	estradiol benzoate:44:0.6550	0.6550	44
E2-CDS	E2-CDS:14	delivery system:14:0.7909	0.7909	14
E2DH	E2DH:12|E2-DH:1	17 beta-hydroxysteroid dehydrogenase:13:0.7753	0.7753	13
E2P	E2P:5|E2-P:1	ADP-insensitive phosphoenzyme:6:0.0807	0.0807	6
E2p	E2p:8|E2P:2	component:10:0.0874	0.0874	10
E2p	E2p:9	dihydrolipoamide acetyltransferase:9:0.1585	0.1585	9
E2R	E2R:21|E2-R:1	receptor:22:0.5000	0.5000	22
E2V	E2V:27|E2v:2|E2-V:1	valerate:30:0.7838	0.7838	30
E2s	E2s:36	Ubiquitin-conjugating enzymes:36:0.7183	0.7183	36
E2	E2:1070	17 beta-estradiol:875:0.9575|17-beta-estradiol:115:0.0141|17 beta-oestradiol:71:0.9124|17-beta-oestradiol:9:0.0010	0.9575	1070
E2	E2:854|E-2:3	17beta-estradiol:812:0.1001|17beta-oestradiol:45:0.0054	0.1001	857
E2	E2:21	[3H]estradiol:21:0.0025	0.0025	21
E2	E2:25	dihydrolipoamide acetyltransferase:25:0.2222	0.2222	25
E2	E2:5	dihydrolipoamide acetyltransferase component:5:0.2818	0.2818	5
E2	E2:6	Dihydrolipoamide acyltransferase:6:0.1543	0.1543	6
E2	E2:28	dihydrolipoyl acetyltransferase:28:0.2609	0.2609	28
E2	E2:21	dihydrolipoyl transacetylase:21:0.6812	0.6812	21
E2	E2:15	dihydrolipoyl transacylase:15:0.4052	0.4052	15
E2	E2:10	early region 2:10:0.7103	0.7103	10
E2	E2:13|e2:1	envelope 2:14:0.0974	0.0974	14
E2	E2:3586|E-2:8	estradiol:3594:0.4425	0.4425	3594
E2	E2:534|e2:3|E-2:1	estradiol-17 beta:509:0.7752|estradiol 17-beta:18:0.6903|estradiol-17-beta:11:0.0012	0.7752	538
E2	E2:245|E-2:2	estradiol-17beta:238:0.0294|estradiol 17beta:9:0.3455	0.3455	247
E2	E2:18	Estradiol benzoate:18:0.5940	0.5940	18
E2	E2:159	estrogen:159:0.0194	0.0194	159
E2	E2:13	lipoate acetyltransferase:13:0.0788	0.0788	13
E2	E2:76	oestradiol-17 beta:76:0.0931	0.0931	76
E2	E2:18	oestradiol-17beta:18:0.0021	0.0021	18
E2	E2:17	Oestrogen:17:0.0020	0.0020	17
E2	E2:10	second:10:0.0011	0.0011	10
E2	E2:4	second envelope glycoprotein:4:0.0918	0.0918	4
E2	E2:15	second envelope protein:15:0.3821	0.3821	15
E2	E2:7|e2:2	second extracellular loop:9:0.6794	0.6794	9
E2	E2:32	serum oestradiol:32:0.0519	0.0519	32
E2	E2:8	ubiquitin carrier protein:8:0.4102	0.4102	8
E2	E2:24	ubiquitin-conjugating:19:0.0022|ubiquitin conjugating:5:0.0736	0.0736	24
E2	E2:65	ubiquitin-conjugating enzyme:55:0.5568|ubiquitin conjugating enzyme:10:0.4363	0.5568	65
E3.5	E3.5:10	embryonic day 3.5:10:0.7103	0.7103	10
E3s	E3s:27	ubiquitin-protein ligases:27:0.4190	0.4190	27
E3	E3:49	dihydrolipoamide dehydrogenase:49:0.3453	0.3453	49
E3	E3:34	Dihydrolipoyl dehydrogenase:34:0.2147	0.2147	34
E3	E3:48	Early region 3:48:0.7997	0.7997	48
E3	E3:27	embryonic day 3:27:0.7425	0.7425	27
E3	E3:27	lipoamide dehydrogenase:27:0.1488	0.1488	27
E3	E3:6	lipoamide dehydrogenase component:6:0.3728	0.3728	6
E3	E3:34	ubiquitin ligase:29:0.1822|ubiquitin ligases:5:0.1132	0.1822	34
E3	E3:13	ubiquitin-protein isopeptide ligase:13:0.4849	0.4849	13
E3	E3:48	ubiquitin-protein ligase:30:0.1909|ubiquitin protein ligase:18:0.6381	0.6381	48
E4P	E4P:8	erythrose 4-phosphate:8:0.2327	0.2327	8
E4	E4:39|E-4:1	early region 4:40:0.8491	0.8491	40
E4	E4:20	embryonic day 4:20:0.7173	0.7173	20
E4	E4:12	estetrol:12:0.0576	0.0576	12
E-5166	E-5166:6|E5166:6	polyprenoic acid:12:0.4153	0.4153	12
E5	E5:6	monoclonal antibody:6:0.1838	0.1838	6
E6-AP	E6-AP:15|E6AP:12	E6-associated protein:27:0.7066	0.7066	27
E6	E6:30	embryonic day 6:30:0.7315	0.7315	30
E7155	E7155:22	gadobenate dimeglumine formulation:22:0.8657	0.8657	22
E8	E8:37	embryonic day 8:37:0.8377	0.8377	37
EA/TEF	EA/TEF:4	esophageal atresia and tracheoesophageal fistula:4:0.7909	0.7909	4
EAAC1	EAAC1:16|EAAC-1:1	excitatory amino acid carrier 1:17:0.8270	0.8270	17
EAAT2	EAAT2:11	excitatory amino acid transporter 2:11:0.7357	0.7357	11
EAATs	EAATs:43	excitatory amino acid transporters:43:0.9308	0.9308	43
EAAT	EAAT:13	excitatory amino acid transporter:13:0.7753	0.7753	13
EAAU	EAAU:22	Experimental autoimmune anterior uveitis:22:0.8594	0.8594	22
EAAs	EAAs:235|EAAS:2	excitatory amino acids:237:0.9103	0.9103	237
EAA	EAA:19	electroacupuncture analgesia:19:0.4211	0.4211	19
EAA	EAA:12	essential AA:12:0.5664	0.5664	12
EAA	EAA:613	excitatory amino acid:465:0.8864|Excitatory amino acids:148:0.5899	0.8864	613
EAA	EAA:73	extrinsic allergic alveolitis:73:0.7060	0.7060	73
EABRs	EABRs:18	electrically evoked auditory brainstem responses:18:0.8365	0.8365	18
EABR	EABR:12	electrical auditory brainstem response:12:0.1163	0.1163	12
EABR	EABR:34|eABR:1|E-ABR:1	electrically evoked auditory brainstem response:30:0.9011|Electrically evoked auditory brainstem responses:6:0.3728	0.9011	36
EABV	EABV:10	effective arterial blood volume:10:0.7103	0.7103	10
EACA	EACA:149|E-ACA:4	epsilon-aminocaproic acid:153:0.4947	0.4947	153
EACC	EACC:14	external auditory canal cholesteatoma:14:0.7909	0.7909	14
EACh	EACh:7	reversal potential:7:0.4102	0.4102	7
EACs	EACs:20	endocrine-active compounds:20:0.5940	0.5940	20
EAC	EAC:9	air condensate:9:0.6794	0.6794	9
EAC	EAC:10	antibody and complement:10:0.2840	0.2840	10
EAC	EAC:5	Ascites Carcinoma cells:5:0.2818	0.2818	5
EAC	EAC:9	Early Arthritis Clinic:9:0.6794	0.6794	9
EAC	EAC:140	Ehrlich ascites carcinoma:140:0.8636	0.8636	140
EAC	EAC:13	Erythema annulare centrifugum:13:0.7753	0.7753	13
EAC	EAC:28	esophageal adenocarcinoma:28:0.5269	0.5269	28
EAC	EAC:70	external auditory canal:70:0.9573	0.9573	70
EADs	EADs:9	early after depolarizations:9:0.6794	0.6794	9
EADs	EADs:115	early afterdepolarizations:115:0.9740	0.9740	115
EAD	EAD:11	early after depolarization:11:0.7357	0.7357	11
EAD	EAD:55	early afterdepolarization:43:0.9308|early afterdepolarizations:12:0.7571	0.9308	55
EA-D	EA-D:12|EAD:1	early antigen:13:0.4557	0.4557	13
EAd	EAd:5	enteric adenovirus:5:0.1132	0.1132	5
EAD	EAD:5	extracranial arterial disease:5:0.4422	0.4422	5
EAEC	EAEC:55	enteroaggregative Escherichia coli:55:0.7858	0.7858	55
EAEP	EAEP:10	early auditory evoked potentials:10:0.5000	0.5000	10
eae	eae:1	E coli attaching and effacing:1:0.5006	0.5006	1
EAE	EAE:31	Experimental allergic encephalitis:31:0.9072	0.9072	31
EAE	EAE:18	Experimental Autoimmune Encephalitis:18:0.7539	0.7539	18
EAE	EAE:1477	experimental autoimmune encephalomyelitis:1477:0.9798	0.9798	1477
EAF	EAF:18	Enzyme-altered foci:18:0.4438	0.4438	18
EAF	EAF:36	EPEC adherence factor:36:0.6563	0.6563	36
eAg	eAg:8	e antigen:8:0.2619	0.2619	8
EAG	EAG:20	Electroantennogram:20:0.1138	0.1138	20
eag	eag:23|EAG:10|Eag:3	ether a go-go:20:0.8594|ether-a-go-go:16:0.0898	0.8594	36
EAG	EAG:22	Experimental autoimmune glomerulonephritis:22:0.8657	0.8657	22
EAH	EAH:15	essential arterial hypertension:15:0.8045	0.8045	15
EAH	EAH:8	Experimental autoimmune hepatitis:8:0.5006	0.5006	8
EAI	EAI:7	rosette inhibition:7:0.2902	0.2902	7
EAMG	EAMG:233	experimental autoimmune myasthenia gravis:233:0.9794	0.9794	233
EAM	EAM:62	Experimental autoimmune myocarditis:62:0.9519	0.9519	62
EAM	EAM:10	experimental autoimmune myositis:10:0.7103	0.7103	10
EAM	EAM:10	external acoustic meatus:10:0.7103	0.7103	10
EAM	EAM:18	external auditory meatus:18:0.8365	0.8365	18
EAN	EAN:186	experimental allergic neuritis:186:0.9659	0.9659	186
EAN	EAN:124	experimental autoimmune neuritis:124:0.9490	0.9490	124
EAO	EAO:28	experimental allergic orchitis:28:0.8941	0.8941	28
EAO	EAO:54	experimental autoimmune orchitis:54:0.8622	0.8622	54
EAPC	EAPC:14	Estimated annual percent change:14:0.7909	0.7909	14
EAPs	EAPs:27	employee assistance programs:27:0.8903	0.8903	27
EAP	EAP:10	electrically evoked compound action potential:10:0.7103	0.7103	10
EAP	EAP:19	electroacupuncture:19:0.0625	0.0625	19
EAP	EAP:5	embryonic alkaline phosphatase:5:0.2818	0.2818	5
EAP	EAP:24	employee assistance program:24:0.8115	0.8115	24
EAP	EAP:13	Erythrocyte acid phosphatase:13:0.6701	0.6701	13
EAP	EAP:14	Experimental autoimmune prostatitis:14:0.6911	0.6911	14
EARS	EARS:4	Electronic Appetite Rating System:4:0.3170	0.3170	4
EARS	EARS:9	European Atherosclerosis Research Study:9:0.6794	0.6794	9
EASF	EASF:11	immunosuppressor factor:11:0.7357	0.7357	11
EASI	EASI:17	Eczema Area and Severity Index:17:0.8449	0.8449	17
EAST1	EAST1:7	enteroaggregative Escherichia coli heat-stable enterotoxin 1:7:0.5290	0.5290	7
EAS	EAS:7	ectopic ACTH syndrome:7:0.2902	0.2902	7
EAS	EAS:15	electronic article surveillance:15:0.8045	0.8045	15
EAs	EAs:11|eas:1	European Americans:12:0.7571	0.7571	12
EAS	EAS:2	euthanasia and assisted suicide:2:0.2818	0.2818	2
EAS	EAS:5	euthanasia and physician-assisted suicide:5:0.4587	0.4587	5
EAs	EAs:13|eas:1	evolutionary algorithms:14:0.7909	0.7909	14
EAS	EAS:85	external anal sphincter:85:0.9101	0.9101	85
EAS	EAS:19	stimulation:19:0.0488	0.0488	19
EAT-26	EAT-26:32|EAT26:1	Eating Attitudes Test:33:0.9100	0.9100	33
EAT-26	EAT-26:5|EAT26:1	Eating Attitudes Test-26:6:0.5290	0.5290	6
EATC	EATC:28	Ehrlich ascites tumor cells:28:0.8941	0.8941	28
EA-TEF	EA-TEF:10|EATEF:2	esophageal atresia and tracheoesophageal fistula:12:0.8594	0.8594	12
EATL	EATL:13	enteropathy-associated T-cell lymphoma:13:0.4444	0.4444	13
EAT	EAT:87	Eating Attitudes Test:71:0.9579|eating attitude test:16:0.8165	0.9579	87
EAT	EAT:19	Ectopic atrial tachycardia:19:0.8449	0.8449	19
EAT	EAT:188|Eat:1	Ehrlich ascites tumor:126:0.9177|Ehrlich ascites tumour:63:0.9253	0.9253	189
EAT	EAT:160	experimental autoimmune thyroiditis:160:0.9420	0.9420	160
EAU	EAU:153	experimental autoimmune uveitis:153:0.9582	0.9582	153
EAU	EAU:279	experimental autoimmune uveoretinitis:279:0.9827	0.9827	279
EAV	EAV:9	Entity-attribute-value:9:0.0402	0.0402	9
EAV	EAV:161	equine arteritis virus:161:0.9812	0.9812	161
EAggEC	EAggEC:2	enteroaggregative E coli:2:0.7952	0.7952	2
EAST	EAST:13	Emory Angioplasty Versus Surgery Trial:13:0.7753	0.7753	13
EAST	EAST:23	enzyme allergosorbent test:23:0.8715	0.8715	23
EBA-175	EBA-175:7	erythrocyte binding antigen:7:0.4438	0.4438	7
EBA-175	EBA-175:7|eba-175:2	erythrocyte binding antigen-175:9:0.6794	0.6794	9
EBA	EBA:17	early bactericidal activity:17:0.8270	0.8270	17
EBA	EBA:6	electron beam angiography:6:0.5290	0.5290	6
EBA	EBA:29	endothelial barrier antigen:29:0.8422	0.8422	29
EBA	EBA:138	epidermolysis bullosa acquisita:138:0.9783	0.9783	138
EBA	EBA:9	epizootic bovine abortion:9:0.6794	0.6794	9
EBA	EBA:33	Evans blue albumin:22:0.7955|Evans Blue-albumin:11:0.5355	0.7955	33
EBA	EBA:25	expanded bed adsorption:25:0.8816	0.8816	25
EBB	EBB:9	Endobronchial biopsy:9:0.3945	0.3945	9
EBCC	EBCC:18	eyeblink classical conditioning:18:0.8365	0.8365	18
EBCT	EBCT:169	electron beam computed tomography:103:0.9710|electron-beam computed tomography:66:0.2984	0.9710	169
EBCT	EBCT:42	Electron Beam CT:29:0.8978|electron-beam CT:13:0.1463	0.8978	42
EBCT	EBCT:11	empty bed contact time:11:0.7357	0.7357	11
EBC	EBC:12	early breast cancer:12:0.7571	0.7571	12
EBC	EBC:68	exhaled breath condensate:68:0.8535	0.8535	68
EBDC	EBDC:13	ethylenebisdithiocarbamate:13:0.3000	0.3000	13
EBD	EBD:6	endoscopic biliary drainage:6:0.2827	0.2827	6
EBD	EBD:30	Evans blue dye:30:0.8032	0.8032	30
EBD	EBD:9	Extrahepatic bile duct:9:0.6794	0.6794	9
EBER-1	EBER-1:3|EBER1:2	EBV-encoded small RNA-1:5:0.1132	0.1132	5
EBER	EBER:11	EBV encoded RNA:11:0.3383	0.3383	11
EBER	EBER:9	EBV-encoded small nuclear RNAs:9:0.4587	0.4587	9
EBER	EBER:23	EBV-encoded small RNA:23:0.4188	0.4188	23
EBER	EBER:5	EBV-encoded small RNAs:5:0.1464	0.1464	5
EBER	EBER:7	Epstein-Barr virus encoded RNA:7:0.5926	0.5926	7
EBF	EBF:16	blood flow:16:0.8165	0.8165	16
EBF	EBF:36|Ebf:1	Early B cell factor:23:0.8715|Early B-cell factor:14:0.7909	0.8715	37
EBF	EBF:18	exclusive breastfeeding:18:0.8365	0.8365	18
EBHC	EBHC:9	Evidence-based health care:9:0.4587	0.4587	9
EBHS	EBHS:21	European brown hare syndrome:21:0.8594	0.8594	21
EBHSV	EBHSV:12	European brown hare syndrome virus:12:0.7571	0.7571	12
EBI	EBI:32	European Bioinformatics Institute:32:0.8145	0.8145	32
EBI	EBI:13	external beam irradiation:13:0.7753	0.7753	13
EBI3	EBI3:10	Epstein-Barr virus-induced gene 3:10:0.7103	0.7103	10
eBL	eBL:7	Endemic Burkitt's lymphoma:7:0.3524	0.3524	7
EBL	EBL:12	endoscopic band ligation:12:0.6460	0.6460	12
EBL	EBL:42	enzootic bovine leukosis:42:0.9291	0.9291	42
EBL	EBL:48	Estimated blood loss:48:0.7595	0.7595	48
EBMT	EBMT:88	European Group for Blood and Marrow Transplantation:88:0.9318	0.9318	88
EBM	EBM:18	basement membrane:18:0.8365	0.8365	18
EBM	EBM:320|EbM:14|E-BM:1	evidence-based medicine:335:0.8115	0.8115	335
EBM	EBM:18	expressed breast milk:18:0.7539	0.7539	18
EBNA-1	EBNA-1:28|EBNA1:22	Epstein-Barr virus nuclear antigen 1:36:0.9174|Epstein-Barr virus nuclear antigen-1:14:0.5589	0.9174	50
EBNA-1	EBNA-1:22|EBNA1:1	nuclear antigen:23:0.8038	0.8038	23
EBNA-2	EBNA-2:10|EBNA2:8	nuclear antigen-2:18:0.8365	0.8365	18
EBNA	EBNA:407|EB-NA:1	nuclear antigen:384:0.9616|nuclear antigens:24:0.8186	0.9616	408
EBOV	EBOV:24|EboV:2	Ebola virus:26:0.8861	0.8861	26
EBO	EBO:8|Ebo:1	Ebola virus:9:0.6794	0.6794	9
EBO	EBO:11	extrahepatic biliary obstruction:11:0.7357	0.7357	11
EBP50	EBP50:12	phosphoprotein 50:12:0.6460	0.6460	12
EBPR	EBPR:74	enhanced biological phosphorus removal:74:0.8975	0.8975	74
EBP	EBP:14	elastin binding protein:14:0.2758	0.2758	14
EBP	EBP:34	Epidural blood patch:34:0.8644	0.8644	34
EBP	EBP:74	Evidence-based practice:74:0.8212	0.8212	74
EBRT	EBRT:4	empty bed retention time:4:0.3170	0.3170	4
EBRT	EBRT:35	external beam irradiation:35:0.9151	0.9151	35
EBRT	EBRT:11	external beam radiation:11:0.6182	0.6182	11
EBRT	EBRT:130	external beam radiation therapy:130:0.9633	0.9633	130
EBRT	EBRT:192	external beam radiotherapy:192:0.9592	0.9592	192
EBRT	EBRT:8	external beam RT:8:0.6411	0.6411	8
EBR	EBR:9	external beam radiation:9:0.6794	0.6794	9
EBR	EBR:14	external beam radiotherapy:14:0.7909	0.7909	14
EBSD	EBSD:20	electron backscatter diffraction:20:0.8525	0.8525	20
EBSLN	EBSLN:16	external branch of the superior laryngeal nerve:16:0.8270	0.8270	16
EBSS	EBSS:18	Earle's balanced salt solution:18:0.6381	0.6381	18
EBS	EBS:24	binding sites:24:0.7046	0.7046	24
EBS	EBS:11	electrical brain stimulation:11:0.7357	0.7357	11
EBs	EBs:98	elementary bodies:98:0.3583	0.3583	98
EBs	EBs:123	embryoid bodies:123:0.4668	0.4668	123
EBS	EBS:75	epidermolysis bullosa simplex:75:0.9602	0.9602	75
EBS	EBS:9	ets binding site:9:0.2757	0.2757	9
EBT	EBT:109	electron beam tomography:109:0.9726	0.9726	109
EBT	EBT:8	erythromycin breath test:8:0.6411	0.6411	8
EBTB	EBTB:16	endobronchial tuberculosis:16:0.7261	0.7261	16
EBUS	EBUS:20	endobronchial ultrasonography:20:0.8525	0.8525	20
EBUS	EBUS:11	Endobronchial ultrasound:11:0.7357	0.7357	11
EBV-HLH	EBV-HLH:7	Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis:7:0.5926	0.5926	7
EBV-LPD	EBV-LPD:19	lymphoproliferative disease:19:0.7044	0.7044	19
EBVaGC	EBVaGC:15	gastric carcinoma:15:0.8045	0.8045	15
EBV	EBV:40	Epstein-Barr:40:0.0054	0.0054	40
EBV	EBV:37	Epstein-Barr viral:37:0.8377	0.8377	37
EBV	EBV:6747	Epstein-Barr virus:6717:0.9487|Epstein-Barr-virus:18:0.0024|Epstein-Barr virus-:7:0.2113|Epstein Barr virus-:5:0.4422	0.9487	6747
EBV	EBV:19	estimated blood volume:19:0.7658	0.7658	19
EBV	EBV:28	estimated breeding values:16:0.6577|Estimated breeding value:12:0.7571	0.7571	28
EBW	EBW:15	empty body weight:15:0.4951	0.4951	15
EBZ	EBZ:15	epicardial border zone:15:0.7096	0.7096	15
EB	EB:10	3,4-epoxy-1-butene:10:0.0039	0.0039	10
EB	EB:9	electron beam:9:0.5470	0.5470	9
EB	EB:102	elementary bodies:70:0.6348|elementary body:32:0.2908	0.6348	102
EB	EB:52	embryoid body:31:0.2785|Embryoid bodies:21:0.1269	0.2785	52
EB	EB:17	empirical Bayes:17:0.8270	0.8270	17
EB	EB:8	endometrial biopsy:8:0.1591	0.1591	8
EB	EB:30	energy balance:30:0.8032	0.8032	30
EB	EB:194	epidermolysis bullosa:194:0.9594	0.9594	194
EB	EB:9	epoxybutene:9:0.0035	0.0035	9
EB	EB:163|E-B:3	Epstein-Barr:166:0.0717	0.0717	166
EB	EB:8	erythromycin base:8:0.3463	0.3463	8
EB	EB:702|Eb:6	estradiol benzoate:699:0.9135|Estradiol-benzoate:9:0.0035	0.9135	708
EB	EB:233|Eb:3	ethidium bromide:236:0.9342	0.9342	236
EB	EB:14	ethylbenzene:14:0.0056	0.0056	14
EB	EB:152|Eb:2	Evans blue:154:0.8540	0.8540	154
EB	EB:22	Evans blue dye:22:0.7955	0.7955	22
EB	EB:17	eyeblink:17:0.0070	0.0070	17
EB	EB:1	metabolites 1,2-epoxybutene:1:0.1838	0.1838	1
EC(50)	EC(50):32	50% effective concentration:32:0.4805	0.4805	32
EC(50)	EC(50):13	effective concentrations:13:0.5335	0.5335	13
EC/IC	EC/IC:9	Extracranial-Intracranial:9:0.3810	0.3810	9
EC2	EC2:10	extracellular loop:10:0.7103	0.7103	10
EC4	EC4:6	European Communities Confederation of Clinical Chemistry:6:0.5290	0.5290	6
EC50s	EC50s:26|EC50S:2	effective concentrations:28:0.7905	0.7905	28
EC50	EC50:24	50% effective concentrations:24:0.2852	0.2852	24
EC50	EC50:8|EC-50:1	50% inhibition:9:0.2757	0.2757	9
EC50	EC50:1	50% maximal contraction:1:0.1320	0.1320	1
EC50	EC50:4	50% of maximal response:4:0.5348	0.5348	4
EC50	EC50:4	50% of the maximal effect:4:0.2102	0.2102	4
EC50	EC50:7	50% of the maximum effect:7:0.3455	0.3455	7
EC50	EC50:9	50% of the maximum response:9:0.4609	0.4609	9
EC50	EC50:9	apparent affinity:9:0.6794	0.6794	9
EC50	EC50:315|EC-50:1	effective concentration:316:0.7592	0.7592	316
EC50	EC50:7	effective dose:7:0.2452	0.2452	7
EC50	EC50:5	half maximal contraction:5:0.1320	0.1320	5
EC50	EC50:30	half-maximal response:30:0.2237	0.2237	30
EC50	EC50:19	half-maximal stimulation:19:0.4211	0.4211	19
EC50	EC50:1	half of the maximal effect:1:0.1111	0.1111	1
EC50	EC50:9	relaxation:9:0.0064	0.0064	9
ECAA	ECAA:11	European concerted action on anticoagulation:11:0.7103	0.7103	11
ECAMs	ECAMs:12	endothelial cell adhesion molecules:12:0.7571	0.7571	12
ECAR	ECAR:23	extracellular acidification rate:23:0.8038	0.8038	23
ECASS	ECASS:9	European Cooperative Acute Stroke Study:9:0.6794	0.6794	9
ECA	ECA:10	Economic Commission for Africa:10:0.7357	0.7357	10
ECA	ECA:33	electrical control activity:33:0.8196	0.8196	33
ECA	ECA:67	enterobacterial common antigen:67:0.9554	0.9554	67
ECA	ECA:25	eosinophil chemotactic activity:25:0.8816	0.8816	25
ECA	ECA:81	Epidemiologic Catchment Area:81:0.7029	0.7029	81
ECA	ECA:8	Epidemiologic Catchment Area Program:8:0.4102	0.4102	8
ECA	ECA:9	erythrina cristagalli:9:0.6794	0.6794	9
ECA	ECA:11	Erythrina cristagalli agglutinin:11:0.7357	0.7357	11
ECA	ECA:35	ethacrynic acid:35:0.8292	0.8292	35
ECA	ECA:10	external carotid:10:0.7103	0.7103	10
ECA	ECA:111	external carotid artery:111:0.9432	0.9432	111
ECBI	ECBI:9	Eyberg Child Behavior Inventory:9:0.6794	0.6794	9
ECCE	ECCE:313	extracapsular cataract extraction:313:0.9748	0.9748	313
ECCL	ECCL:19	encephalocraniocutaneous lipomatosis:19:0.7658	0.7658	19
ECCM	ECCM:8|EC-CM:2	endothelial cell-conditioned medium:10:0.5000	0.5000	10
ECCO2R	ECCO2R:7|ECCO2-R:2	extracorporeal CO2 removal:9:0.5470	0.5470	9
ECCS	ECCS:6	European Community for Coal and Steel:6:0.3524	0.3524	6
ECC	ECC:7	carcinoma cells:7:0.1111	0.1111	7
ECC	ECC:12	creatinine clearance:12:0.7571	0.7571	12
ECC	ECC:78	early childhood caries:78:0.9607	0.9607	78
ECC	ECC:61	endocervical curettage:61:0.9511	0.9511	61
ECC	ECC:24	Excitation-contraction coupling:24:0.5370	0.5370	24
ECC	ECC:5	external cardiac compression:5:0.4422	0.4422	5
ECC	ECC:15	extracorporeal circuit:15:0.5818	0.5818	15
ECC	ECC:352	extracorporeal circulation:352:0.9049	0.9049	352
ECDE	ECDE:7	7-ethoxycoumarin O-deethylase:7:0.2902	0.2902	7
ECDs	ECDs:61	equivalent current dipoles:61:0.9511	0.9511	61
ECDs	ECDs:18	extracellular domains:18:0.8365	0.8365	18
ECD	ECD:15	7-ethoxycoumarin O-deethylase:15:0.3821	0.3821	15
ECD	ECD:74	cysteinate dimer:74:0.7388	0.7388	74
ECD	ECD:36	electron capture detector:36:0.8336	0.8336	36
ECD	ECD:57	electron capture dissociation:57:0.9477	0.9477	57
ECD	ECD:16	endocardial cushion defect:16:0.7261	0.7261	16
ECD	ECD:50	endothelial cell density:50:0.9404	0.9404	50
ECD	ECD:7	endothelial cell dysfunction:7:0.5926	0.5926	7
ECD	ECD:77	equivalent current dipole:67:0.9296|equivalent current dipoles:10:0.7103	0.9296	77
ECD	ECD:35|E-Cd:1	Erdheim-Chester disease:36:0.6953	0.6953	36
ECD	ECD:9	ethoxycoumarin O-deethylase:9:0.1409	0.1409	9
ECD	ECD:11	expanded criteria donor:11:0.7357	0.7357	11
E-CD	E-CD:6|ECD:3	expression of E-cadherin:9:0.0667	0.0667	9
ECD	ECD:118|ecd:1	extracellular domain:112:0.8769|extracellular domains:7:0.3524	0.8769	119
ECE-1	ECE-1:11	endothelin-converting enzyme:11:0.1845	0.1845	11
ECE-1	ECE-1:110|ECE1:1	endothelin-converting enzyme-1:84:0.6074|endothelin converting enzyme-1:27:0.7425	0.7425	111
ECE	ECE:11	embryonated chicken eggs:11:0.2764	0.2764	11
ECE	ECE:9	embryonating chicken eggs:9:0.1809	0.1809	9
ECE	ECE:186	endothelin-converting enzyme:113:0.4669|endothelin converting enzyme:68:0.8220|endothelin-converting enzymes:5:0.1132	0.8220	186
ECE	ECE:45	extracapsular extension:45:0.7461	0.7461	45
ECF1F0	ECF1F0:6	Escherichia coli ATP synthase:6:0.3728	0.3728	6
ECF-A	ECF-A:27|ECFA:1	eosinophil chemotactic factor of anaphylaxis:28:0.7905	0.7905	28
ECFCs	ECFCs:12	erythroid colony-forming cells:12:0.7571	0.7571	12
ECFC	ECFC:11	erythroid colony-forming cells:11:0.6182	0.6182	11
ECFMG	ECFMG:17	Educational Commission for Foreign Medical Graduates:17:0.7658	0.7658	17
ECFP	ECFP:14	enhanced cyan fluorescent protein:14:0.6173	0.6173	14
ECFV	ECFV:90	extracellular fluid volume:90:0.9311	0.9311	90
ECFs	ECFs:8	eosinophil chemotactic factors:8:0.5006	0.5006	8
ECF	ECF:53	East Coast fever:53:0.9438	0.9438	53
ECF	ECF:64	eosinophil chemotactic factor:64:0.9033	0.9033	64
ECF	ECF:10	executive cognitive functioning:10:0.7103	0.7103	10
ECF	ECF:9	extracellular:9:0.0104	0.0104	9
ECF	ECF:393|ecf:2	extracellular fluid:395:0.9362	0.9362	395
ECF	ECF:19	Extracellular fluid volume:19:0.7658	0.7658	19
ECF	ECF:36	extracytoplasmic function:36:0.5563	0.5563	36
ECG's	ECG's:13|ECG'S:1	electrocardiograms:14:0.8125	0.8125	14
ECGF	ECGF:64	endothelial cell growth factor:64:0.9033	0.9033	64
ECGI	ECGI:12	electrocardiographic imaging:12:0.7103	0.7103	12
ECG-LVH	ECG-LVH:11|ECGLVH:1	left ventricular hypertrophy:12:0.6460	0.6460	12
ECGs	ECGs:444|ECGS:2	electrocardiograms:446:0.8725	0.8725	446
ECGS	ECGS:32	Endothelial cell growth supplement:32:0.8563	0.8563	32
ECG	ECG:2671|ecg:3|Ecg:1	electrocardiogram:2450:0.5029|electrocardiograms:225:0.0462	0.5029	2675
ECG	ECG:90	electrocardiograph:90:0.0183	0.0183	90
ECG	ECG:1166	electrocardiographic:1166:0.2392	0.2392	1166
ECG	ECG:18	Electrocardiographically:18:0.0035	0.0035	18
ECG	ECG:23|ECg:12	epicatechin gallate:35:0.2360	0.2360	35
eCG	eCG:13|ECG:1	equine CG:14:0.7909	0.7909	14
eCG	eCG:57|ECG:1	equine chorionic gonadotrophin:58:0.8502	0.8502	58
eCG	eCG:76	equine chorionic gonadotropin:76:0.9169	0.9169	76
ECG	ECG:43	exercise electrocardiography:43:0.0753	0.0753	43
ECH	ECH:8	enoyl-CoA hydratase:8:0.3463	0.3463	8
ECH	ECH:51	epichlorohydrin:51:0.3650	0.3650	51
ECIA	ECIA:9	extracorporeal immunoadsorption:9:0.5470	0.5470	9
ECIB	ECIB:3	extracorporeal irradiation of blood:3:0.7103	0.7103	3
EC-IC	EC-IC:61|ECIC:1	extracranial-intracranial:62:0.6778	0.6778	62
ECIS	ECIS:18	electric cell-substrate impedance sensing:18:0.6381	0.6381	18
ECL2	ECL2:9|ecl-2:1|ECL-2:1	extracellular loop 2:11:0.7357	0.7357	11
ECLA	ECLA:32	extracorporeal lung assist:32:0.8145	0.8145	32
ECLAM	ECLAM:10	European Consensus Lupus Activity Measure:10:0.7103	0.7103	10
ECLAM	ECLAM:13	European Consensus Lupus Activity Measurement:13:0.7753	0.7753	13
ECLAMC	ECLAMC:4	Latin American Collaborative Study on Congenital Malformations:4:0.8657	0.8657	4
ECLIA	ECLIA:12	Electrochemiluminescence Immunoassay:12:0.3813	0.3813	12
ECLP	ECLP:10	extracorporeal liver perfusion:10:0.5000	0.5000	10
ECLSS	ECLSS:9	Environmental Control and Life Support System:9:0.3945	0.3945	9
ECLS	ECLS:120	extracorporeal life support:120:0.9138	0.9138	120
ECLT	ECLT:58	euglobulin clot lysis time:58:0.9486	0.9486	58
ECL	ECL:80	Electrochemiluminescence:80:0.1038	0.1038	80
ECL	ECL:19	electrochemiluminescent:19:0.0237	0.0237	19
ECL	ECL:28	Electrogenerated chemiluminescence:28:0.1985	0.1985	28
ECL	ECL:55	enhanced chemiluminescence:55:0.4843	0.4843	55
ECL	ECL:9	enhanced chemiluminescent:9:0.3945	0.3945	9
ECL	ECL:280|ECl:1|EC-L:1	enterochromaffin-like:282:0.3706	0.3706	282
ECL	ECL:7	enterochromaffin-like cells:7:0.2902	0.2902	7
ECL	ECL:14	enterochromaffinlike:14:0.0171	0.0171	14
ECL	ECL:16	entorhinal cortex lesion:10:0.7103|entorhinal cortex lesions:6:0.5290	0.7103	16
ECl	ECl:51	equilibrium potential:51:0.8546	0.8546	51
ECl	ECl:3	equilibrium potential for Cl-:3:0.5470	0.5470	3
ECL	ECL:15	extracorporeal lithotripsy:15:0.7096	0.7096	15
ECMA	ECMA:8	ethylcholine mustard aziridinium:8:0.5006	0.5006	8
ECMO	ECMO:1130	Extracorporeal membrane oxygenation:1130:0.9493	0.9493	1130
ECMO	ECMO:17	Extracorporeal membrane oxygenator:17:0.4742	0.4742	17
ECMs	ECMs:51	extracellular matrices:51:0.8799	0.8799	51
ECM	ECM:10	caries monitor:10:0.7103	0.7103	10
ECM	ECM:19|EcM:1	ectomycorrhizal:20:0.0036	0.0036	20
ECM	ECM:10	endothelial cells:10:0.5856	0.5856	10
ECM	ECM:11	endothelial cell monolayers:11:0.7357	0.7357	11
ECM	ECM:8	energy-corrected milk:8:0.5006	0.5006	8
ECM	ECM:43	erythema chronicum migrans:43:0.8941	0.8941	43
ECM	ECM:15	experimental cerebral malaria:15:0.7096	0.7096	15
ECM	ECM:9	extracellular mass:9:0.5470	0.5470	9
ECM	ECM:8	extracellular material:8:0.1895	0.1895	8
ECM	ECM:59	extracellular matrices:59:0.9203	0.9203	59
ECM	ECM:4592|ecm:1	extracellular matrix:4580:0.9595|extracellular-matrix:13:0.0023	0.9595	4593
ECM	ECM:28	extracellular matrix components:28:0.8941	0.8941	28
ECM	ECM:25|ecm:1	extracellular matrix proteins:26:0.8861	0.8861	26
ecNOS	ecNOS:27|ec-NOS:1|ECNOS:1	endothelial cell nitric oxide synthase:29:0.8978	0.8978	29
ecNOS	ecNOS:39|ECNOS:1	endothelial constitutive nitric oxide synthase:40:0.7201	0.7201	40
ecNOS	ecNOS:13	endothelial constitutive NOS:13:0.7096	0.7096	13
ecNOS	ecNOS:35|ec-NOS:2|EC-NOS:1|EcNOS:1	endothelial nitric oxide synthase:39:0.2179	0.2179	39
ecNOS	ecNOS:15|EC-NOS:1|ECNOS:1	endothelial NOS:17:0.2074	0.2074	17
ECN	ECN:30	external cuneate nucleus:30:0.9011	0.9011	30
ECOD	ECOD:66	7-ethoxycoumarin O-deethylase:48:0.5592|7-ethoxycoumarin-O-deethylase:18:0.1104	0.5592	66
ECOD	ECOD:19	ethoxycoumarin-O-deethylase:19:0.1169	0.1169	19
ECPg	ECPg:8	embryonic chicken pepsinogen:8:0.6411	0.6411	8
ECPs	ECPs:34	emergency contraceptive pills:34:0.8644	0.8644	34
ECPs	ECPs:11	extracellular products:11:0.6182	0.6182	11
ECP	ECP:23	emergency contraceptive pills:15:0.8045|emergency contraceptive pill:8:0.6411	0.8045	23
ECP	ECP:28	energy charge potential:28:0.8941	0.8941	28
ECP	ECP:933	eosinophil cationic protein:933:0.8549	0.8549	933
ECP	ECP:25	estradiol cypionate:25:0.7249	0.7249	25
ECP	ECP:12	External Counterpulsation:12:0.6182	0.6182	12
ECP	ECP:39	extracellular products:39:0.8811	0.8811	39
ECP	ECP:54	extracorporeal photochemotherapy:54:0.8622	0.8622	54
ECP	ECP:43	Extracorporeal photopheresis:43:0.6984	0.6984	43
ECRB	ECRB:29|ECRb:1	extensor carpi radialis brevis:30:0.8472	0.8472	30
ECRL	ECRL:29	extensor carpi radialis longus:29:0.8978	0.8978	29
EcR	EcR:63|ECR:1	ecdysone receptor:64:0.5762	0.5762	64
EcR	EcR:20	ecdysteroid receptor:20:0.1221	0.1221	20
EC-SOD	EC-SOD:18|ECSOD:6|ecSOD:2|Ec-SOD:1	extracellular SOD:27:0.8903	0.8903	27
EC-SOD	EC-SOD:116|ecSOD:12|ECSOD:6|Ec-SOD:2	extracellular superoxide dismutase:136:0.9649	0.9649	136
ECS	ECS:9	cow serum:9:0.4587	0.4587	9
ECS	ECS:6	elective Caesarean section:6:0.5926	0.5926	6
ECS	ECS:5	elective cesarean section:5:0.2818	0.2818	5
ECS	ECS:10	electrocerebral silence:10:0.5856	0.5856	10
ECS	ECS:17	electrochemical stimulation:17:0.2609	0.2609	17
ECS	ECS:54	electroconvulsive seizures:33:0.7841|electroconvulsive seizure:21:0.7865	0.7865	54
ECS	ECS:420	electroconvulsive shock:384:0.9619|electroconvulsive shocks:36:0.8003	0.9619	420
ECS	ECS:10	electroconvulsive stimulation:10:0.0989	0.0989	10
ECS	ECS:13	electroconvulsive stimuli:13:0.6701	0.6701	13
ECs	ECs:6	endometrial carcinomas:6:0.1010	0.1010	6
ECs	ECs:1164	endothelial cells:1164:0.9430	0.9430	1164
ECS	ECS:6	Environmental Control System:6:0.3728	0.3728	6
ECS	ECS:12|ECs:1	Euro-Collins solution:13:0.2660	0.2660	13
ECS	ECS:21	Extracapsular spread:21:0.7291	0.7291	21
ECS	ECS:118	extracellular space:118:0.9124	0.9124	118
ECTR	ECTR:20	endoscopic carpal tunnel release:20:0.8525	0.8525	20
ECT	ECT:40	ecarin clotting time:40:0.8491	0.8491	40
eCT	eCT:8|ECT:3	eel calcitonin:11:0.2972	0.2972	11
ECT	ECT:26	electrochemotherapy:26:0.0147	0.0147	26
ECT	ECT:1245	electroconvulsive therapy:1245:0.9303	0.9303	1245
ECT	ECT:48	electroconvulsive treatment:48:0.6364	0.6364	48
ECT	ECT:67	Emission computed tomography:67:0.8874	0.8874	67
ECT	ECT:12	endocurietherapy:12:0.0065	0.0065	12
ECUM	ECUM:9	extracorporeal ultrafiltration method:9:0.5470	0.5470	9
ECU	ECU:6	Care Unit:6:0.1010	0.1010	6
ECU	ECU:5	Environmental Control Unit:5:0.2818	0.2818	5
ECU	ECU:43	extensor carpi ulnaris:43:0.9308	0.9308	43
ECV	ECV:6	electrical cardioversion:6:0.1838	0.1838	6
ECV	ECV:13	ethchlorvynol:13:0.0387	0.0387	13
ECV	ECV:78	external cephalic version:78:0.9617	0.9617	78
ECV	ECV:39	extracellular fluid volume:39:0.8811	0.8811	39
ECV	ECV:9	extracellular virus:9:0.4587	0.4587	9
ECV	ECV:88	extracellular volume:88:0.5268	0.5268	88
ECV304	ECV304:19|ECV-304:3	endothelial cell line:22:0.4883	0.4883	22
ECV304	ECV304:15|ECV-304:1	human umbilical vein endothelial cells:16:0.8165	0.8165	16
ECVAM	ECVAM:1	European Centre for Validation of Alternative Methods:1:0.8715	0.8715	1
ECVE	ECVE:17	extracellular volume expansion:17:0.5760	0.5760	17
ECW	ECW:14	extracellular:14:0.0663	0.0663	14
ECochG	ECochG:11|ECOchG:1	electrocochleogram:12:0.1089	0.1089	12
ECochG	ECochG:75|ECochg:1	electrocochleography:76:0.7426	0.7426	76
EC	EC:10	adenocarcinoma:10:0.0013	0.0013	10
EC	EC:9	committee:9:0.0011	0.0011	9
EC	EC:12	complex environment:12:0.5050	0.5050	12
EC	EC:16|Ec:2	concentration:18:0.0024	0.0024	18
EC	EC:9|e-c:3|Ec:1	contraction:13:0.0017	0.0017	13
EC	EC:34|E-C:1|Ec:1	control:24:0.0032|controls:12:0.0017	0.0032	36
EC	EC:8|Ec:1	E-cadherin:9:0.0011	0.0011	9
EC	EC:10	electrical cardioversion:10:0.5000	0.5000	10
EC	EC:61	electrical conductivity:61:0.8383	0.8383	61
EC	EC:55	electrochemical:55:0.0076	0.0076	55
EC	EC:14	electron capture:14:0.6911	0.6911	14
EC	EC:10	elimination capacity:10:0.1774	0.1774	10
EC	EC:9	elongation complex:9:0.1809	0.1809	9
EC	EC:560|ec:2	embryonal carcinoma:555:0.7824|embryonal carcinomas:7:0.0951	0.7824	562
EC	EC:121	emergency contraception:121:0.9606	0.9606	121
EC	EC:21	emulsifiable concentrate:21:0.8594	0.8594	21
EC	EC:10	endochondral:10:0.0013	0.0013	10
EC	EC:53	endometrial cancer:53:0.3250	0.3250	53
EC	EC:72	endometrial carcinoma:61:0.0663|endometrial carcinomas:11:0.2764	0.2764	72
EC	EC:33	endothelial:33:0.0045	0.0045	33
EC	EC:2558|Ec:2	endothelial cells:1728:0.8600|endothelial cell:832:0.8868	0.8868	2560
EC	EC:12	endothelium:12:0.0015	0.0015	12
EC	EC:83	Energy charge:83:0.9640	0.9640	83
EC	EC:7	energy cost:7:0.3524	0.3524	7
EC	EC:9	enkephalin-containing:9:0.0011	0.0011	9
EC	EC:8	enriched:8:0.0013	0.0013	8
EC	EC:11	enriched condition:11:0.3495	0.3495	11
EC	EC:8|ec:1	enteric-coated:9:0.0011	0.0011	9
EC	EC:96|Ec:1	enterochromaffin:97:0.0137	0.0137	97
EC	EC:246	entorhinal cortex:246:0.9414	0.9414	246
EC	EC:14	Enzyme Commission:14:0.1241	0.1241	14
EC	EC:10	eosinophilic cystitis:10:0.3470	0.3470	10
EC	EC:33	epicatechin:33:0.0045	0.0045	33
Ec	Ec:89|EC:47|ec:3	Escherichia coli:139:0.8539	0.8539	139
EC	EC:68	esophageal cancer:68:0.4348	0.4348	68
EC	EC:6	esophageal candidiasis:6:0.1838	0.1838	6
EC	EC:38	esterified cholesterol:38:0.7810	0.7810	38
EC	EC:25	ethyl carbamate:25:0.8816	0.8816	25
EC	EC:32	ethyl cellulose:32:0.8563	0.8563	32
EC	EC:56|Ec:1	ethylcellulose:57:0.0078	0.0078	57
EC	EC:23|E-C:1	Euro-Collins solution:24:0.4967	0.4967	24
EC	EC:30	Eurocollins:30:0.0041	0.0041	30
EC	EC:45	European Commission:45:0.6192	0.6192	45
EC	EC:108	European Community:108:0.9723	0.9723	108
E-C	E-C:190|EC:122|e-c:17|E--C:1	excitation-contraction:330:0.0460	0.0460	330
EC	EC:14	experimental immune-mediated blepharoconjunctivitis:14:0.7909	0.7909	14
EC	EC:78|ec:5	extracellular:83:0.0115	0.0115	83
EC	EC:20	extracorporeal circulation:20:0.7173	0.7173	20
ED(50)	ED(50):33	effective dose:33:0.7525	0.7525	33
ED2	ED2:10	macrophages:10:0.2500	0.2500	10
ED50s	ED50s:14|ED50S:3	effective doses:17:0.6211	0.6211	17
ED50	ED50:10	50% inhibition:10:0.2764	0.2764	10
ED50	ED50:1	50% of its maximal response:1:0.1211	0.1211	1
ED50	ED50:5	50% of the maximum response:5:0.2902	0.2902	5
ED50	ED50:297|ED-50:1	effective dose:253:0.8131|effective doses:45:0.5944	0.8131	298
ED50	ED50:14	half-maximal response:14:0.1124	0.1124	14
ED50	ED50:10	half-maximal stimulation:10:0.2446	0.2446	10
ED50	ED50:2	Half the maximal response:2:0.1730	0.1730	2
ED50	ED50:33	sensitivity:33:0.0315	0.0315	33
ED95	ED95:11	95% effective dose:11:0.6182	0.6182	11
EDAC	EDAC:13	carbodiimide:13:0.2692	0.2692	13
EDAMS	EDAMS:10	encephalo-duro-arterio-myo-synangiosis:10:0.8182	0.8182	10
EDAS	EDAS:28	encephalo-duro-arterio-synangiosis:28:0.4828	0.4828	28
EDAS	EDAS:14	encephaloduroarteriosynangiosis:14:0.2241	0.2241	14
EDAX	EDAX:4	analysis of x-ray:4:0.2243	0.2243	4
EDAcFN	EDAcFN:3|ED-AcFN:2|EDA-cFn:1|EDAcFn:1|EDA-cFN:1	cellular fibronectin:8:0.5006	0.5006	8
EDA	EDA:38	ectodermal dysplasia:38:0.9217	0.9217	38
EDA	EDA:80	electrodermal activity:80:0.8596	0.8596	80
EDA	EDA:9	electron donor-acceptor:9:0.6794	0.6794	9
EDA	EDA:6	electronic dental anesthesia:6:0.3728	0.3728	6
EDA	EDA:15|EDa:2	end-diastolic area:17:0.4480	0.4480	17
EDA	EDA:18	epidural analgesia:18:0.5560	0.5560	18
EDA	EDA:48|Eda:2	ethylenediamine:50:0.1228	0.1228	50
EDA	EDA:15	exploratory data analysis:15:0.7096	0.7096	15
EDB	EDB:18	1,2-dibromoethane:18:0.0881	0.0881	18
EDB	EDB:72	ethylene dibromide:72:0.9344	0.9344	72
EDB	EDB:46|Edb:1	extensor digitorum brevis:47:0.9366	0.9366	47
EDB	EDB:4|ED-B:3	extra domain B:7:0.4438	0.4438	7
EDCF	EDCF:12	contracting factors:12:0.5664	0.5664	12
EDCF	EDCF:28	endothelium-derived contracting factor:28:0.7505	0.7505	28
EDCFs	EDCFs:5|EDCFS:1	endothelium-derived contracting factors:6:0.5290	0.5290	6
EDCs	EDCs:126	endocrine disrupting chemicals:81:0.9631|endocrine-disrupting chemicals:45:0.2620	0.9631	126
EDCs	EDCs:30	endocrine disrupting compounds:17:0.8270|endocrine-disrupting compounds:13:0.2121	0.8270	30
EDC	EDC:9	1,2-dichloroethane:9:0.0138	0.0138	9
EDC	EDC:25	1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide:25:0.0415	0.0415	25
EDC	EDC:8	1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride:8:0.0517	0.0517	8
EDC	EDC:69	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide:36:0.0622|1-ethyl-3-(3-dimethylaminopropyl) carbodiimide:18:0.1339|1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide:15:0.0242	0.1339	69
EDC	EDC:5	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride:5:0.0902	0.0902	5
EDC	EDC:9	compounds:9:0.0138	0.0138	9
EDC	EDC:13	date of confinement:13:0.5335	0.5335	13
EDC	EDC:14	Endocrine disrupting chemicals:14:0.6911	0.6911	14
EDC	EDC:13	epidermal differentiation complex:13:0.7571	0.7571	13
EDC	EDC:34	ethanol-derived calories:34:0.5846	0.5846	34
EDC	EDC:13	ethylene dichloride:13:0.6701	0.6701	13
EDC	EDC:68|edc:1	extensor digitorum communis:69:0.9567	0.9567	69
EDC	EDC:9	N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide:9:0.0138	0.0138	9
EDDP	EDDP:8	metabolite:8:0.1429	0.1429	8
EDDP	EDDP:3	metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine:3:0.3331	0.3331	3
EDD	EDD:12	date of delivery:12:0.5050	0.5050	12
EDD	EDD:11	electron-dense deposits:6:0.1320|electron dense deposits:5:0.4422	0.4422	11
EDD	EDD:29	End-diastolic diameter:29:0.6392	0.6392	29
EDD	EDD:24|EdD:1	end-diastolic dimension:25:0.5969	0.5969	25
EDD	EDD:13	endothelium-dependent dilation:13:0.5335	0.5335	13
EDD	EDD:11	esophageal detector device:11:0.7357	0.7357	11
EDE	EDE:47	Eating Disorder Examination:31:0.8519|Eating Disorders Examination:16:0.8165	0.8519	47
EDE	EDE:16	effective dose equivalent:16:0.8165	0.8165	16
EDF	EDF:29	Erythroid differentiation factor:29:0.5212	0.5212	29
EDFV	EDFV:10	flow velocity:10:0.7103	0.7103	10
EDGF	EDGF:17	Growth Factor:17:0.8270	0.8270	17
EDG	EDG:28|Edg:15|edg:1	endothelial differentiation gene:44:0.7619	0.7619	44
EDHF	EDHF:349	endothelium-derived hyperpolarizing factor:349:0.8779	0.8779	349
EDHFs	EDHFs:12	endothelium-derived hyperpolarizing factors:12:0.5050	0.5050	12
EDH	EDH:18	epidural hematoma:18:0.3285	0.3285	18
EDH	EDH:7	Extradural haematoma:7:0.2452	0.2452	7
EDH	EDH:15	extradural hematoma:15:0.2430	0.2430	15
EDI-2	EDI-2:6	Eating Disorder Inventory:6:0.5290	0.5290	6
EDI-2	EDI-2:28	Eating Disorder Inventory-2:15:0.8165|Eating Disorders Inventory-2:13:0.7753	0.8165	28
EDIC	EDIC:11	Epidemiology of Diabetes Interventions and Complications:11:0.7357	0.7357	11
EDIM	EDIM:11	infant mice:11:0.7357	0.7357	11
EDISS	EDISS:12	Emergency Department Injury Surveillance System:12:0.7571	0.7571	12
EDITS	EDITS:8	Erectile Dysfunction Inventory of Treatment Satisfaction:8:0.6794	0.6794	8
Edi	Edi:14	activity:14:0.0393	0.0393	14
EDI	EDI:161	Eating Disorder Inventory:101:0.9704|Eating Disorders Inventory:60:0.9503	0.9704	161
EDI	EDI:40	electronic data interchange:40:0.9274	0.9274	40
Edi	Edi:4	integrated electrical activity of the diaphragm:4:0.2902	0.2902	4
EDJ	EDJ:28	junction:28:0.9310	0.9310	28
EDLF	EDLF:22|E-DLF:1	endogenous digitalis-like factor:17:0.8270|Endogenous digitalis-like factors:6:0.3728	0.8270	23
EDLI	EDLI:8	Endogenous digoxin-like immunoreactivity:8:0.6411	0.6411	8
EDL	EDL:12	efferent duct ligation:12:0.7571	0.7571	12
EDL	EDL:7	electric double layer:7:0.3524	0.3524	7
EDL	EDL:9|edL:3	end-diastolic length:12:0.2293	0.2293	12
EDL	EDL:9	end-diastolic segment length:9:0.5470	0.5470	9
EDL	EDL:1200|edl:11|Edl:1	extensor digitorum longus:1212:0.9911	0.9911	1212
EDL	EDL:63	extensor digitorum longus muscle:51:0.9082|extensor digitorum longus muscles:12:0.7571	0.9082	63
EDL	EDL:8|edl:1	fast-twitch:9:0.0055	0.0055	9
EDMA	EDMA:27	Euclidean distance matrix analysis:27:0.7425	0.7425	27
EDMC	EDMC:13	Electrostatically Driven Monte Carlo:13:0.7753	0.7753	13
EDMD	EDMD:68	Emery-Dreifuss muscular dystrophy:68:0.9561	0.9561	68
EDN1	EDN1:7|Edn1:1	endothelin-1 gene:8:0.3463	0.3463	8
EDN3	EDN3:26|Edn3:5|EDN-3:1	endothelin 3:18:0.7539|endothelin-3:14:0.3095	0.7539	32
EDNOS	EDNOS:40|ED-NOS:8	eating disorder not otherwise specified:33:0.9151|Eating disorders not otherwise specified:15:0.8045	0.9151	48
EDNO	EDNO:105|edno:1	endothelium-derived nitric oxide:106:0.8233	0.8233	106
EDNRB	EDNRB:31|EDNR-B:1|Ednrb:1	endothelin-B receptor:18:0.2687|endothelin B receptor:15:0.7096	0.7096	33
EDNRB	EDNRB:16|Ednrb:1	endothelin receptor B:17:0.6748	0.6748	17
EDN	EDN:12	experimental diabetic neuropathy:12:0.7571	0.7571	12
EDPVR	EDPVR:8	end-diastolic pressure-volume relation:8:0.6411	0.6411	8
EDPVR	EDPVR:8	end-diastolic pressure-volume relationship:8:0.4438	0.4438	8
EDP	EDP:9	elastin-derived peptides:9:0.6794	0.6794	9
EDP	EDP:20	electronic data processing:20:0.7766	0.7766	20
EDP	EDP:120	end-diastolic pressure:93:0.5146|end diastolic pressure:27:0.8312	0.8312	120
EDP	EDP:10	erythema dyschromicum perstans:10:0.7103	0.7103	10
EDP	EDP:13	estradiol dipropionate:13:0.6701	0.6701	13
EDQM	EDQM:12	European Directorate for the Quality of Medicines:12:0.7571	0.7571	12
EDRF/NO	EDRF/NO:23	Endothelium-derived relaxing factor/nitric oxide:23:0.8038	0.8038	23
EDRFs	EDRFs:27	endothelium-derived relaxing factors:27:0.7834	0.7834	27
EDRF	EDRF:856	endothelium-derived relaxing factor:840:0.8273|endothelium-derived relaxing factors:16:0.5564	0.8273	856
EDRF	EDRF:14	endothelium-derived relaxing factor(s):14:0.6911	0.6911	14
EDRF	EDRF:21	nitric oxide:21:0.8594	0.8594	21
EDR	EDR:28	electrodermal responses:16:0.8165|electrodermal response:12:0.3813	0.8165	28
EDR	EDR:70	endothelium-dependent relaxation:70:0.7855	0.7855	70
EDR	EDR:8	Excess Death Rate:8:0.6411	0.6411	8
EDR	EDR:10	extreme drug resistance:10:0.7103	0.7103	10
EDSS	EDSS:5	Expanded Disability Scale Score:5:0.1973	0.1973	5
EDSS	EDSS:368	expanded disability status scale:368:0.9256	0.9256	368
EDSS	EDSS:13	Expanded Disability Status Score:13:0.4444	0.4444	13
EDs	EDs:61|Eds:1	eating disorders:62:0.9241	0.9241	62
EDS	EDS:6	Edinburgh depression scale:6:0.5290	0.5290	6
EDS	EDS:215|EDs:3|ED-S:1	Ehlers-Danlos syndrome:209:0.8351|Ehlers-Danlos syndromes:10:0.7103	0.8351	219
EDs	EDs:283|EDS:1	emergency departments:284:0.9894	0.9894	284
EDs	EDs:9|EDS:1	endocrine disrupters:10:0.7103	0.7103	10
EDs	EDs:22	Endocrine disruptors:22:0.7955	0.7955	22
EDS	EDS:17	energy dispersive spectrometry:17:0.8270	0.8270	17
EDS	EDS:20	energy-dispersive spectroscopy:20:0.1140	0.1140	20
EDs	EDs:15|EDS:1	epileptiform discharges:16:0.7407	0.7407	16
EDS	EDS:21	ethane dimethane sulfonate:21:0.4041	0.4041	21
EDS	EDS:42	ethane dimethane sulphonate:42:0.6524	0.6524	42
EDS	EDS:19	ethane dimethanesulfonate:19:0.6106	0.6106	19
EDS	EDS:29	ethane dimethanesulphonate:29:0.5940	0.5940	29
EDS	EDS:14	ethylene dimethane sulfonate:14:0.2081	0.2081	14
EDS	EDS:9	ethylene dimethanesulphonate:9:0.0783	0.0783	9
EDS	EDS:155	excessive daytime sleepiness:155:0.9807	0.9807	155
EDS	EDS:22	Excessive daytime somnolence:22:0.8657	0.8657	22
EDS	EDS:10	X-ray microanalysis:10:0.4363	0.4363	10
EDTA	EDTA:16	acid disodium salt:16:0.6680	0.6680	16
EDTA	EDTA:6	calcium disodium ethylenediaminetetraacetate:6:0.0666	0.0666	6
EDTA	EDTA:23	disodium edetate:23:0.5997	0.5997	23
EDTA	EDTA:7	ethylene diamine tetraacetate:7:0.2902	0.2902	7
EDTA	EDTA:48	ethylene diamine tetraacetic acid:48:0.8463	0.8463	48
EDTA	EDTA:128	Ethylenediamine tetraacetic acid:128:0.5884	0.5884	128
EDTA	EDTA:573|edta:2	Ethylenediaminetetraacetic acid:575:0.4871	0.4871	575
EDT	EDT:8|Edt:4|E-DT:2	deceleration time:14:0.6911	0.6911	14
EDT	EDT:8|eDT:1	early distal tubule:9:0.6794	0.6794	9
EDU	EDU:16|EdU:1	5-ethyl-2'-deoxyuridine:17:0.2388	0.2388	17
EDU	EDU:15	ethylenediurea:15:0.2090	0.2090	15
EDVI	EDVI:76|EDVi:4	end-diastolic volume index:80:0.7548	0.7548	80
EDV	EDV:39	end-diastolic:39:0.0611	0.0611	39
EDV	EDV:6	end diastolic velocities:6:0.5290	0.5290	6
EDV	EDV:18	End-diastolic volumes:18:0.5560	0.5560	18
EDV	EDV:14	endothelium-dependent vasodilatation:14:0.6173	0.6173	14
EDV	EDV:23	endothelium-dependent vasodilation:23:0.6653	0.6653	23
EDW	EDW:17	enhanced dynamic wedge:17:0.8270	0.8270	17
EDWT	EDWT:11	wall thickness:11:0.7357	0.7357	11
EDX	EDX:11	edatrexate:11:0.0361	0.0361	11
EDX	EDX:16	electrodiagnostic:16:0.0542	0.0542	16
EDX	EDX:33	energy-dispersive X-ray:33:0.3618	0.3618	33
EDX	EDX:43	energy dispersive x-ray microanalysis:26:0.8251|energy-dispersive x-ray microanalysis:17:0.1925	0.8251	43
EDX	EDX:8	X-ray spectrometry:8:0.4102	0.4102	8
EDXA	EDXA:36	energy dispersive x-ray analysis:36:0.9174	0.9174	36
EDXA	EDXA:12	energy dispersive X-ray microanalysis:6:0.5290|energy-dispersive X-ray microanalysis:6:0.1148	0.5290	12
EDXRF	EDXRF:11|ED-XRF:2	energy-dispersive x-ray fluorescence:13:0.1463	0.1463	13
ED	ED:8|E-D:1	deprivation:9:0.0015	0.0015	9
ED	ED:10	duration:10:0.0017	0.0017	10
ED	ED:10	early distal:10:0.5856	0.5856	10
ED	ED:131	eating disorders:81:0.8901|eating disorder:50:0.8520	0.8901	131
ED	ED:19	ectodermal dysplasia:19:0.2759	0.2759	19
ED	ED:21	effective dose:21:0.4359	0.4359	21
ED	ED:5	effector domain:5:0.0902	0.0902	5
ED	ED:13	electrodialysis:13:0.0023	0.0023	13
ED	ED:16	electron diffraction:16:0.5564	0.5564	16
ED	ED:38	elemental diet:38:0.6678	0.6678	38
ED	ED:140|Ed:3|ed:2	embryonic day:115:0.8039|embryonic days:30:0.7652	0.8039	145
ED	ED:2575	emergency department:2499:0.9956|emergency departments:76:0.9378	0.9956	2575
ED	ED:51|Ed:1	end-diastole:27:0.0050|end diastole:25:0.8186	0.8186	52
ED	ED:76|ed:1	end-diastolic:68:0.0128|end diastolic:9:0.6794	0.6794	77
ED	ED:9	endogenous depression:9:0.5470	0.5470	9
ED	ED:10	endolymphatic duct:10:0.3145	0.3145	10
ED	ED:30	energy density:30:0.6736	0.6736	30
ED	ED:15	enteric drainage:15:0.4052	0.4052	15
ED	ED:17|E-D:1	Entner-Doudoroff:18:0.0032	0.0032	18
ED	ED:10	enumeration district:10:0.7103	0.7103	10
ED	ED:16	epithelial dysplasia:16:0.2093	0.2093	16
ED	ED:18	equilibrium dialysis:18:0.6903	0.6903	18
ED	ED:978	erectile dysfunction:978:0.9453	0.9453	978
ED	ED:7	erythrocyte deformability:7:0.2452	0.2452	7
ED	ED:9	essential dynamics:9:0.6794	0.6794	9
ED	ED:107	extensive disease:98:0.6548|extensive-disease:9:0.0015	0.6548	107
ED	ED:11	external diameter:11:0.6182	0.6182	11
EE2	EE2:19	17alpha-ethynylestradiol:19:0.0606	0.0606	19
EE2	EE2:61|eE2:1	ethinyl estradiol:62:0.6114	0.6114	62
EE2	EE2:51|EE-2:2	ethinylestradiol:53:0.1751	0.1751	53
EE2	EE2:21	ethinyloestradiol:21:0.0673	0.0673	21
EE2	EE2:36	ethynylestradiol:36:0.1178	0.1178	36
EEA1	EEA1:6	early endosomal autoantigen 1:6:0.5290	0.5290	6
EEA1	EEA1:14|EEA-1:1	early endosome antigen 1:15:0.8045	0.8045	15
EEA	EEA:11|EEa:1	activity:12:0.1038	0.1038	12
EEA	EEA:21	end-to-end anastomosis:21:0.6040	0.6040	21
EEA	EEA:8	European Economic Area:8:0.6411	0.6411	8
EEC	EEC:18	Ectrodactyly-ectodermal dysplasia-clefting:18:0.7539	0.7539	18
EEC	EEC:8	Endogenous erythroid colony:8:0.5006	0.5006	8
EEC	EEC:16	endometrial epithelial cells:16:0.6024	0.6024	16
EEC	EEC:6	enteropathogenic Escherichia coli:6:0.5290	0.5290	6
EEC	EEC:11	erythroid colonies:11:0.7357	0.7357	11
EEC	EEC:40	European Economic Community:40:0.8839	0.8839	40
EECP	EECP:65	enhanced external counterpulsation:65:0.9534	0.9534	65
EEDQ	EEDQ:173	N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline:163:0.7285|N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline:10:0.0407	0.7285	173
eed	eed:9|EED:2	embryonic ectoderm development:11:0.7357	0.7357	11
EED	EED:31	Erythema elevatum diutinum:31:0.9043	0.9043	31
EEEV	EEEV:10	Eastern equine encephalitis virus:10:0.7103	0.7103	10
EEEV	EEEV:10	eastern equine encephalomyelitis virus:10:0.7103	0.7103	10
EEE	EEE:87	eastern equine encephalitis:87:0.9653	0.9653	87
EEE	EEE:5	Eastern equine encephalitis virus:5:0.4422	0.4422	5
EEE	EEE:61	eastern equine encephalomyelitis:61:0.9229	0.9229	61
EEE	EEE:8	eastern equine encephalomyelitis virus:8:0.6411	0.6411	8
eEF-2	eEF-2:42|eEF2:26|EEF-2:1|Eef2:1|EEF2:1	elongation factor 2:48:0.9027|elongation factor-2:23:0.8715	0.9027	71
eEF	eEF:6	elongation factor:6:0.1543	0.1543	6
EEF	EEF:14	exoerythrocytic forms:14:0.6911	0.6911	14
EEG's	EEG's:13	electroencephalograms:13:0.7500	0.7500	13
EEGs	EEGs:235|EEG-s:1|EEGS:1	electroencephalograms:237:0.8872	0.8872	237
EEG	EEG:18	Brain electrical activity:18:0.4438	0.4438	18
EEG	EEG:6	electrical activity of the brain:6:0.3728	0.3728	6
EEG	EEG:39	electro-encephalogram:39:0.0067	0.0067	39
EEG	EEG:20	electro-encephalographic:20:0.0034	0.0034	20
EEG	EEG:2563|eeg:2	electroencephalogram:2428:0.4290|electroencephalograms:137:0.0240	0.4290	2565
EEG	EEG:128	electroencephalograph:128:0.0224	0.0224	128
EEG	EEG:1668|eeg:1	electroencephalographic:1669:0.2948	0.2948	1669
EEG	EEG:19	Electroencephalographic activity:19:0.1604	0.1604	19
EEG	EEG:11	electroencephalographically:11:0.0018	0.0018	11
EEG	EEG:874	Electroencephalography:874:0.1543	0.1543	874
EEG	EEG:14	video-electroencephalographic:14:0.0025	0.0025	14
EEG	EEG:13	video-electroencephalography:13:0.0021	0.0021	13
EEJ	EEJ:12	electroejaculation:12:0.8462	0.8462	12
EELV	EELV:104	end-expiratory lung volume:104:0.8683	0.8683	104
EELS	EELS:152	electron energy loss spectroscopy:95:0.9685|Electron energy-loss spectroscopy:57:0.8689	0.9685	152
EEMG	EEMG:8|eEMG:1	evoked electromyography:9:0.6794	0.6794	9
EEM	EEM:12	excitation-emission matrix:12:0.5050	0.5050	12
EEM	EEM:45	External elastic membrane:45:0.9338	0.9338	45
EEOAEs	EEOAEs:8	electrically evoked otoacoustic emissions:8:0.6411	0.6411	8
EEOC	EEOC:53	Equal Employment Opportunity Commission:53:0.9438	0.9438	53
EEPA	EEPA:7	energy expenditure of physical activity:7:0.6794	0.6794	7
EEP	EEP:20	end-expiratory pressure:20:0.4574	0.4574	20
EEP	EEP:27	ethanol extract of propolis:27:0.4805	0.4805	27
EEP	EEP:15	ethanolic extract of propolis:15:0.1827	0.1827	15
EER	EER:16	Electrically Evoked Response:16:0.7261	0.7261	16
EER	EER:10	ethanol elimination rate:10:0.7103	0.7103	10
Ees	Ees:64|EES:2|ees:1	End-systolic elastance:67:0.5929	0.5929	67
Ees	Ees:5	end-systolic pressure-volume relation:5:0.4422	0.4422	5
Ees	Ees:4	end-systolic pressure-volume relationship:4:0.0918	0.0918	4
EES	EES:15	Ewing's sarcoma:15:0.5818	0.5818	15
EET	EET:9	energy transfer:9:0.5470	0.5470	9
EET	EET:32	epoxyeicosatrienoic acid:23:0.3018|epoxyeicosatrienoic acids:9:0.4587	0.4587	32
EETs	EETs:168|EETS:1|EEts:1	epoxyeicosatrienoic acids:170:0.8378	0.8378	170
EEV	EEV:14	end-expiratory lung volume:14:0.6911	0.6911	14
EE	EE:12	17alpha-ethinylestradiol:12:0.0048	0.0048	12
EE	EE:10	2-ethoxyethanol:10:0.0043	0.0043	10
EE	EE:10	electroejaculation:10:0.0043	0.0043	10
EE	EE:9	Emotional Exhaustion:9:0.6794	0.6794	9
ee	ee:61|EE:2	enantiomeric excess:63:0.9526	0.9526	63
EE	EE:14	encapsulation efficiency:14:0.2758	0.2758	14
EE	EE:12|E-E:3	end-to-end:15:0.0068	0.0068	15
EE	EE:9	endocardial endothelial:9:0.6794	0.6794	9
EE	EE:20	Endocardial endothelium:20:0.8525	0.8525	20
EE	EE:454|Ee:3	energy expenditure:457:0.9826	0.9826	457
EE	EE:15	enriched environment:15:0.7096	0.7096	15
EE	EE:13	environmental enrichment:13:0.6701	0.6701	13
EE	EE:10	Eosinophilic esophagitis:10:0.2446	0.2446	10
EE	EE:8	erosive esophagitis:8:0.1471	0.1471	8
EE	EE:11	erythromycin estolate:11:0.6182	0.6182	11
EE	EE:23	ether extract:23:0.3492	0.3492	23
EE	EE:362	ethinyl estradiol:351:0.8716|ethinyl oestradiol:11:0.5355	0.8716	362
EE	EE:130	ethinylestradiol:130:0.0623	0.0623	130
EE	EE:21	ethinyloestradiol:21:0.0097	0.0097	21
EE	EE:33	ethynylestradiol:33:0.0155	0.0155	33
EE	EE:14	exercise:14:0.0063	0.0063	14
EE	EE:10	exercise echocardiography:10:0.5000	0.5000	10
EE	EE:26	Exoerythrocytic:26:0.0121	0.0121	26
EE	EE:239	Expressed Emotion:239:0.9733	0.9733	239
EF-1	EF-1:40|EF1:3	Elongation factor 1:32:0.8563|elongation factor-1:11:0.6182	0.8563	43
EF-3	EF-3:36|EF3:2	elongation factor 3:38:0.9217	0.9217	38
EFAD	EFAD:13|EFA-D:1	EFA-deficient:14:0.0760	0.0760	14
EFAD	EFAD:66	essential fatty acid deficiency:66:0.9548	0.9548	66
EFAD	EFAD:53	essential fatty acid deficient:29:0.8422|essential fatty acid-deficient:24:0.8768	0.8768	53
EFAD	EFAD:10|EFA-D:1	essential fatty acid deficient diet:6:0.5290|essential fatty acid-deficient diet:5:0.4422	0.5290	11
EFAs	EFAs:83	Essential fatty acids:83:0.9644	0.9644	83
EFA	EFA:6	enamel-free area:6:0.0899	0.0899	6
EFA	EFA:411	essential fatty acid:255:0.9749|essential fatty acids:156:0.8814	0.9749	411
EFA	EFA:9	ethoxyformic anhydride:9:0.6794	0.6794	9
EFA	EFA:12	euglobulin fibrinolytic activity:12:0.7571	0.7571	12
EFA	EFA:18	Exploratory factor analysis:18:0.5560	0.5560	18
EFE	EFE:23	endocardial fibroelastosis:23:0.8715	0.8715	23
EFE	EFE:8	Ethylene-forming enzyme:8:0.3463	0.3463	8
EFF	EFF:6|Eff:6	efficiency:12:0.1642	0.1642	12
EFF	EFF:9	electromagnetic field focusing:9:0.6794	0.6794	9
EFG	EFG:19|efg:1	electric field gradient:20:0.8525	0.8525	20
EF-G	EF-G:106|EFG:1	elongation factor G:107:0.9411	0.9411	107
EFL	EFL:24	expiratory flow limitation:24:0.8768	0.8768	24
EFM	EFM:51	Electronic fetal monitoring:51:0.9082	0.9082	51
EFM	EFM:7	epifluorescence microscopy:7:0.1470	0.1470	7
EFNEP	EFNEP:14	Expanded Food and Nutrition Education Program:14:0.7753	0.7753	14
EFPs	EFPs:11	field potentials:11:0.7357	0.7357	11
EFP	EFP:17	early follicular phase:17:0.8270	0.8270	17
EFP	EFP:18	Endoneurial fluid pressure:18:0.7539	0.7539	18
efp	efp:6|Efp:6|EFP:1	estrogen-responsive finger protein:13:0.5934	0.5934	13
EFP	EFP:17	field potentials:17:0.7407	0.7407	17
EFQM	EFQM:3	European Foundation of Quality Management:3:0.7753	0.7753	3
EFR	EFR:6	envelope following response:6:0.5290	0.5290	6
EFs	EFs:32	ejection fractions:32:0.4207	0.4207	32
EFs	EFs:12	electric fields:12:0.5050	0.5050	12
EFS	EFS:668	electrical field stimulation:668:0.9069	0.9069	668
EFs	EFs:9	embryonic fibroblasts:9:0.6794	0.6794	9
EFS	EFS:11	empty follicle syndrome:11:0.7357	0.7357	11
EFs	EFs:12	Enantiomer fractions:12:0.0902	0.0902	12
EFs	EFs:10	enantiomeric fractions:10:0.0626	0.0626	10
EFs	EFs:8	enrichment factors:8:0.1061	0.1061	8
EFS	EFS:27	event-free:27:0.0141	0.0141	27
EFS	EFS:742	event-free survival:742:0.8819	0.8819	742
EFs	EFs:10	executive functions:10:0.5000	0.5000	10
EFTEM	EFTEM:33|EF-TEM:4	transmission electron microscopy:37:0.9197	0.9197	37
EF-Ts	EF-Ts:34|EFTs:1	elongation factor Ts:35:0.8681	0.8681	35
EFTs	EFTs:3	family of tumors:3:0.7357	0.7357	3
EF-Tu	EF-Tu:9|EF-tu:2|EFTU:1	elongation factor:12:0.7571	0.7571	12
EF-Tu	EF-Tu:240|EFTu:3|Ef-Tu:1|EF-tu:1	elongation factor Tu:245:0.9878	0.9878	245
EFT	EFT:16	Embedded Figures Test:16:0.8165	0.8165	16
EFT	EFT:6	emotionally focused therapy:6:0.3728	0.3728	6
EFT	EFT:15	family of tumors:15:0.8115	0.8115	15
EFV	EFV:75	efavirenz:75:0.7872	0.7872	75
EFV	EFV:12	Extracellular fluid volume:12:0.7571	0.7571	12
EFW	EFW:41	Estimated fetal weight:41:0.6365	0.6365	41
EF	EF:17	early follicular:17:0.7407	0.7407	17
EF	EF:59	ejection fractions:59:0.7984	0.7984	59
EF	EF:31	electric field:24:0.4187|electric fields:7:0.2452	0.4187	31
EF	EF:62	elongation factor:50:0.1434|elongation factors:12:0.1758	0.1758	62
EF	EF:13	enrichment factors:13:0.2038	0.2038	13
EF	EF:6	enteral feeding:6:0.1320	0.1320	6
EF	EF:51	eosinophilic fasciitis:51:0.9082	0.9082	51
EF	EF:9	eosinophilic folliculitis:9:0.5470	0.5470	9
EF	EF:24	erectile function:24:0.2394	0.2394	24
EF	EF:41	executive function:26:0.2687|executive functions:15:0.8045	0.8045	41
EF	EF:17	executive functioning:17:0.6748	0.6748	17
EF	EF:7	exoplasmic face:7:0.0828	0.0828	7
EF	EF:11	external fixation:11:0.5355	0.5355	11
EF	EF:12	fluid:12:0.0036	0.0036	12
EG-VEGF	EG-VEGF:6	Endocrine gland-derived vascular endothelial growth factor:6:0.5290	0.5290	6
EG2	EG2:8	activated eosinophils:8:0.1730	0.1730	8
EG2	EG2:12|EG-2:1	eosinophil cationic protein:13:0.5934	0.5934	13
EGA	EGA:60	estimated gestational age:60:0.9216	0.9216	60
EGBE	EGBE:10	ethylene glycol monobutyl ether:10:0.7103	0.7103	10
EGb	EGb:13|EGB:5	extract of ginkgo biloba:18:0.4934	0.4934	18
EGb	EGb:6|EGB:1	extract of Ginkgo biloba leaves:7:0.4438	0.4438	7
EGb	EGb:12	Ginkgo biloba extract:12:0.7571	0.7571	12
EGCG	EGCG:253|EGCg:15	(-)-epigallocatechin-3-gallate:139:0.1818|epigallocatechin-3-gallate:102:0.1291|epigallocatechin 3-gallate:9:0.2102|(-)-epigallocatechin 3-gallate:9:0.2102|(-)epigallocatechin-3-gallate:9:0.0105	0.2102	268
EGCG	EGCG:29|EGCg:7	(-)-epigallocatechin-3-O-gallate:18:0.0224|Epigallocatechin-3-O-gallate:9:0.0105|(-)-epigallocatechin 3-O-gallate:9:0.3945	0.3945	36
EGCG	EGCG:310|EGCg:77|egcg:1	(-)-epigallocatechin gallate:198:0.4217|Epigallocatechin gallate:190:0.4004	0.4217	388
EGCT	EGCT:6	extragonadal germ cell tumors:6:0.3728	0.3728	6
EGCase	EGCase:10	Endoglycoceramidase:10:0.8182	0.8182	10
EGCs	EGCs:15	granule cells:15:0.3262	0.3262	15
EGC	EGC:130|egc:1	early gastric cancer:120:0.9600|early gastric cancers:11:0.7357	0.9600	131
EGC	EGC:24	early gastric carcinoma:24:0.8768	0.8768	24
EGD	EGD:138	esophagogastroduodenoscopy:138:0.6445	0.6445	138
EGD	EGD:10	upper endoscopy:10:0.2275	0.2275	10
EGDMA	EGDMA:27	ethylene glycol dimethacrylate:27:0.8312	0.8312	27
EGDS	EGDS:11	esophagogastroduodenoscopy:11:0.3571	0.3571	11
EGEE	EGEE:26	ethylene glycol monoethyl ether:26:0.8861	0.8861	26
EGE	EGE:11	eosinophilic gastroenteritis:11:0.7357	0.7357	11
EGF-URO	EGF-URO:25|EGF-Uro:1|EGF-uro:1	epidermal growth factor-urogastrone:25:0.8816|epidermal growth factor urogastrone:2:0.5926	0.8816	27
EGFRs	EGFRs:43|EGF-Rs:10	epidermal growth factor receptors:53:0.9438	0.9438	53
EGFR	EGFR:49|EGF-r:39|EGF-R:20|EGFr:1|Egfr:1	EGF-receptor:63:0.0126|EGF receptors:47:0.2136	0.2136	110
EGFR	EGFR:40|EGF-R:21|EGFr:8	epidermal growth factor:69:0.9100	0.9100	69
EGFR	EGFR:3014|EGF-R:521|EGFr:143|EGF-r:20|Egfr:19|egfr:2|Egf-r:1|EgfR:1	epidermal growth factor receptor:3567:0.9699|epidermal growth factor receptors:110:0.8954|Epidermal growth factor-receptor:44:0.9323	0.9699	3721
EGFR	EGFR:12|egfr:1|Egfr:1	epidermal growth factor receptor gene:14:0.6911	0.6911	14
eGFR	eGFR:14|EGFR:9	estimated glomerular filtration rate:23:0.7500	0.7500	23
EGFR	EGFR:5|EGF-r:1	receptor for EGF:6:0.2243	0.2243	6
EGFP	EGFP:35|eGFP:3|egfp:1	enhanced GFP:39:0.8184	0.8184	39
EGFP	EGFP:721|eGFP:98|egfp:2|E-GFP:1|EGFp:1	enhanced green fluorescent protein:823:0.8836	0.8836	823
egfp	EGFP:2|egfp:2|e-gfp:1	enhanced green fluorescent protein gene:5:0.2818	0.2818	5
EGF	EGF:10	epidermal:10:0.0009	0.0009	10
EGF	EGF:9735|egf:3|Egf:1	epidermal growth factor:9699:0.9790|epidermal growth factors:21:0.7291|epidermal-growth-factor:19:0.0018	0.9790	9739
EGF	EGF:36|egf:1	epidermal growth factor-like:37:0.9197	0.9197	37
EGF	EGF:9	epidermal growth factor receptor:9:0.6794	0.6794	9
EGI	EGI:15|EG-I:1	endoglucanase I:16:0.7261	0.7261	16
EGJ	EGJ:45	esophagogastric junction:45:0.8115	0.8115	45
EGL	EGL:71|egl:1	external granular layer:72:0.9585	0.9585	72
EGME	EGME:74	ethylene glycol monomethyl ether:74:0.9602	0.9602	74
EGMs	EGMs:18	electrograms:18:0.6538	0.6538	18
EGM	EGM:13	electrogram:13:0.1846	0.1846	13
EGM	EGM:9	ethylene glycol monomethyl ether:9:0.6794	0.6794	9
EGOT	EGOT:10|E-GOT:1|egot:1	transaminase:12:0.4583	0.4583	12
EGP-2	EGP-2:9	epithelial glycoprotein-2:9:0.6794	0.6794	9
EGPT	EGPT:11|E-GPT:1	transaminase:12:0.8462	0.8462	12
EGP	EGP:128	endogenous glucose production:128:0.9093	0.9093	128
EGP	EGP:14	ethanolamine glycerophospholipids:14:0.5589	0.5589	14
EGP	EGP:5|Egp:3|eGp:1	glycoprotein:9:0.0359	0.0359	9
Egr-1	Egr-1:5|EGR1:2|EGR-1:1|egr-1:1	early growth response:9:0.5470	0.5470	9
Egr-1	Egr-1:63|EGR-1:20|EGR1:9|Egr1:9|egr-1:5	early growth response-1:71:0.9579|early growth response 1:35:0.9151	0.9579	106
Egr-1	Egr-1:4|EGR-1:2|egr-1:1	early growth response-1 gene:7:0.5926	0.5926	7
Egr-1	Egr-1:26|EGR-1:4|egr-1:2|EGR1:1	early growth response factor-1:33:0.9072	0.9072	33
Egr-1	Egr-1:6|EGR-1:1	early growth response gene:7:0.5926	0.5926	7
Egr-1	Egr-1:49|egr-1:15|EGR1:8|EGR-1:8|Egr1:5	early growth response gene-1:57:0.9467|early growth response gene 1:28:0.8941	0.9467	85
Egr-1	Egr-1:9|Egr1:1	early growth response protein-1:10:0.7103	0.7103	10
EGR-1	EGR-1:3|Egr-1:2|EGR1:1|egr-1:1	transcription factor:7:0.2113	0.2113	7
EGR2	EGR2:10	early growth response 2:10:0.7103	0.7103	10
EGRAC	EGRAC:7|EGR-AC:2	erythrocyte glutathione reductase activation coefficient:9:0.6794	0.6794	9
EGRAC	EGRAC:9|EGR-AC:2	erythrocyte glutathione reductase activity coefficient:11:0.6182	0.6182	11
E-GSH-Px	E-GSH-Px:6|eGSHPx:2|E-GSHPx:1|EGSHPx:1	glutathione peroxidase:10:0.7103	0.7103	10
EGSs	EGSs:14	External guide sequences:14:0.7909	0.7909	14
EGS	EGS:12	Equine grass sickness:12:0.7571	0.7571	12
EGS	EGS:17	external guide sequence:17:0.8270	0.8270	17
EGTA	EGTA:8	calcium chelator:8:0.0825	0.0825	8
EGTA	EGTA:7	chelating agent:7:0.3524	0.3524	7
EGTA	EGTA:118	ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid:75:0.9370|ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid:43:0.9308	0.9370	118
egt	egt:14|EGT:7	ecdysteroid UDP-glucosyltransferase:21:0.8594	0.8594	21
EGT	EGT:9	ethanol gelation test:9:0.6794	0.6794	9
EGb761	EGb761:12	Ginkgo biloba extract:12:0.5664	0.5664	12
EGR	EGR:13|Egr:6|egr:3	early growth response:22:0.7955	0.7955	22
EGR	EGR:11	enterogastric reflux:11:0.6182	0.6182	11
EGR	EGR:16|E-GR:1|eGR:1	erythrocyte glutathione reductase:18:0.4934	0.4934	18
EG	EG:42	embryonic germ:42:0.8893	0.8893	42
EG	EG:12	enteroglucagon:12:0.0157	0.0157	12
EG	EG:16	Eosinophilic Gastroenteritis:16:0.8165	0.8165	16
EG	EG:31	eosinophilic granuloma:31:0.9043	0.9043	31
EG	EG:248	ethylene glycol:248:0.9573	0.9573	248
EG	EG:8	excitable gap:8:0.5006	0.5006	8
EG	EG:26	experimental group:26:0.4188	0.4188	26
EG	EG:7	local treatment with Essaven gel:7:0.2902	0.2902	7
EHA	EHA:7	2-ethylhexanoic acid:7:0.4102	0.4102	7
EHA	EHA:12	egg hatch assay:12:0.7571	0.7571	12
EHBA	EHBA:70	extrahepatic biliary atresia:70:0.8919	0.8919	70
EHBD	EHBD:11	Extrahepatic bile duct:11:0.7357	0.7357	11
EHBF	EHBF:26	hepatic blood flow:26:0.7340	0.7340	26
EHBN	EHBN:12	N-ethyl-N-(4-hydroxybutyl)nitrosamine:12:0.8462	0.8462	12
EHBR	EHBR:36	Eisai hyperbilirubinemic rats:25:0.8816|Eisai hyperbilirubinemic rat:11:0.5355	0.8816	36
EHBRs	EHBRs:10	Eisai hyperbilirubinemic rats:10:0.7103	0.7103	10
EHC	EHC:36	enterohepatic circulation:36:0.8716	0.8716	36
EHC	EHC:5	first drafts of Environmental Health Criteria:5:0.7571	0.7571	5
EHD	EHD:13	epizootic haemorrhagic disease:13:0.7753	0.7753	13
EHD	EHD:25	epizootic hemorrhagic disease:25:0.8816	0.8816	25
EHDI	EHDI:7	early hearing detection and intervention:7:0.5926	0.5926	7
EHDP	EHDP:25	diphosphonate:25:0.0879	0.0879	25
EHDP	EHDP:27	disodium ethane-1-hydroxy-1,1-diphosphonate:27:0.2368	0.2368	27
EHDP	EHDP:23	disodium etidronate:23:0.3592	0.3592	23
EHDP	EHDP:18	Etidronate disodium:18:0.8365	0.8365	18
EHDV	EHDV:21	epizootic haemorrhagic disease virus:21:0.8594	0.8594	21
EHDV	EHDV:51	epizootic hemorrhagic disease virus:51:0.9082	0.9082	51
EHDV-2	EHDV-2:6	epizootic hemorrhagic disease virus serotype 2:6:0.5926	0.5926	6
EHEC	EHEC:15	coli O157:H7:15:0.8045	0.8045	15
EHEC	EHEC:1	enterohaemorrhagic E coli:1:0.1898	0.1898	1
EHEC	EHEC:17	enterohemorrhagic:17:0.0329	0.0329	17
EHEC	EHEC:189	enterohemorrhagic Escherichia coli:189:0.6288	0.6288	189
EHEN	EHEN:43	N-ethyl-N-hydroxyethylnitrosamine:43:0.8542	0.8542	43
EHE	EHE:27|E-HE:1	epithelioid hemangioendothelioma:28:0.8369	0.8369	28
EHFV	EHFV:9	epidemic hemorrhagic fever virus:9:0.6794	0.6794	9
EHF	EHF:50	epidemic hemorrhagic fever:50:0.6118	0.6118	50
EHK	EHK:21	epidermolytic hyperkeratosis:21:0.7865	0.7865	21
EHL	EHL:47	electrohydraulic lithotripsy:47:0.8703	0.8703	47
EHL	EHL:9	Evaporative heat loss:9:0.6794	0.6794	9
EHL	EHL:25	extensor hallucis longus:25:0.8186	0.8186	25
EHNA	EHNA:10	Erythro-9-(2-hydroxy-3-nonyl)-adenine:10:0.0430	0.0430	10
EHNA	EHNA:10	hydrochloride:10:0.0484	0.0484	10
EHNV	EHNV:17	Epizootic haematopoietic necrosis virus:17:0.7261	0.7261	17
EHP	EHP:13	Experimental hypersensitivity pneumonitis:13:0.7753	0.7753	13
EHPVO	EHPVO:22	extrahepatic portal vein obstruction:22:0.7400	0.7400	22
EHPVO	EHPVO:22	extrahepatic portal venous obstruction:22:0.7955	0.7955	22
EHR	EHR:56	electronic health record:42:0.9274|Electronic Health Records:14:0.7909	0.9274	56
EHR	EHR:15|eHR:4	heart rate:19:0.7658	0.7658	19
EHS	EHS:89	Engelbreth-Holm-Swarm:89:0.4251	0.4251	89
EHs	EHs:11	epoxide hydrolases:11:0.7357	0.7357	11
EHS	EHS:9	Exertional Heat Stroke:9:0.6794	0.6794	9
EHTAH	EHTAH:16|EH-TAH:1	electrohydraulic total artificial heart:17:0.8270	0.8270	17
EHT	EHT:8	engineered heart tissue:8:0.5006	0.5006	8
EHT	EHT:115|eHT:1	essential hypertension:116:0.9589	0.9589	116
EHT	EHT:15	essential hypertensives:15:0.8045	0.8045	15
EHV-1	EHV-1:17	equid herpesvirus-1:17:0.1062	0.1062	17
EHV-1	EHV-1:193|EHV1:14	equine herpesvirus 1:141:0.8291|equine herpesvirus-1:66:0.6927	0.8291	207
EHV-1	EHV-1:133|EHV1:4	equine herpesvirus type 1:127:0.8979|equine herpesvirus type-1:10:0.5856	0.8979	137
EHV-4	EHV-4:9|EHV4:3	Equine herpesvirus 4:12:0.4557	0.4557	12
EHV-4	EHV-4:11|EHV4:1	equine herpesvirus type 4:12:0.7571	0.7571	12
EHW	EHW:13	external heart work:13:0.7753	0.7753	13
EI*	EI*:11	complex:11:0.8333	0.8333	11
EIA-2	EIA-2:6	enzyme immunoassay:6:0.2243	0.2243	6
EIAB	EIAB:14	arterial bypass:14:0.6911	0.6911	14
EIAH	EIAH:15	exercise-induced arterial hypoxemia:15:0.6386	0.6386	15
EIAV	EIAV:255	Equine infectious anemia virus:255:0.9881	0.9881	255
EIAs	EIAs:206	enzyme immunoassays:206:0.9248	0.9248	206
EIAs	EIAs:5	immunosorbent assays:5:0.1132	0.1132	5
EIA	EIA:17	electroimmunoassay:17:0.0044	0.0044	17
EIA	EIA:20	environmental impact assessment:20:0.8525	0.8525	20
EIA	EIA:82	enzyme immuno assay:44:0.8941|enzyme immuno-assay:21:0.7291|enzyme-immuno-assay:9:0.0022|enzyme immuno assays:8:0.6411	0.8941	82
EIA	EIA:2563	enzyme immunoassay:2304:0.9329|enzyme immunoassays:165:0.9142|enzyme-immunoassay:94:0.0257	0.9329	2563
EIA	EIA:6	enzyme immunoassay method:6:0.3728	0.3728	6
EIA	EIA:42	enzyme immunosorbent assay:42:0.3550	0.3550	42
EIA	EIA:49	enzyme-linked immunosorbent assay:43:0.3661|enzyme-linked immunosorbent assays:6:0.2827	0.3661	49
EIA	EIA:45	enzymeimmunoassay:45:0.0121	0.0121	45
EIA	EIA:12	enzymoimmunoassay:12:0.0030	0.0030	12
EIA	EIA:40	Equine infectious anemia:40:0.9274	0.9274	40
EIA	EIA:9	Exercise-induced anaphylaxis:9:0.4587	0.4587	9
EIA	EIA:246|E-IA:1	exercise-induced asthma:247:0.8800	0.8800	247
EIA	EIA:20	external iliac artery:20:0.8525	0.8525	20
EIB	EIB:88	exercise-induced bronchoconstriction:88:0.8150	0.8150	88
EIB	EIB:87	exercise-induced bronchospasm:87:0.8335	0.8335	87
EICAR	EICAR:12	5-Ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide:12:0.7333	0.7333	12
EIC	EIC:27	elastase inhibitory capacity:27:0.8903	0.8903	27
EIC	EIC:18	Endometrial intraepithelial carcinoma:18:0.8365	0.8365	18
EIC	EIC:41	extensive intraductal component:41:0.9274	0.9274	41
EID	EID:22	electroimmunodiffusion:22:0.3043	0.3043	22
EIDV	EIDV:12	endothelium-independent vasodilation:12:0.5050	0.5050	12
EIEC	EIEC:1	enteroinvasive E coli:1:0.8645	0.8645	1
EIEC	EIEC:63	enteroinvasive Escherichia coli:63:0.7943	0.7943	63
EIEE	EIEE:13	early infantile epileptic encephalopathy:13:0.7753	0.7753	13
eIF4G	eIF4G:33	initiation factor 4G:33:0.9100	0.9100	33
eIF-5A	eIF-5A:40|eIF5A:10	eukaryotic initiation factor 5A:50:0.5036	0.5036	50
eIF-5A	eIF-5A:15|eIF5A:10	eukaryotic translation initiation factor 5A:25:0.8186	0.8186	25
eIF	eIF:141|eIf:1	eukaryotic initiation factor:131:0.7059|eukaryotic initiation factors:11:0.4728	0.7059	142
EIH	EIH:10	exercise-induced hypoxaemia:10:0.5856	0.5856	10
EIH	EIH:19	exercise-induced hypoxemia:19:0.6106	0.6106	19
EILV	EILV:8	end-inspiratory lung volume:8:0.5006	0.5006	8
Einc	Einc:18|EINC:1	incremental elastic modulus:19:0.8449	0.8449	19
EIPA	EIPA:106	5-(N-ethyl-N-isopropyl)amiloride:57:0.2082|5-(N-ethyl-N-isopropyl) amiloride:28:0.2529|5-(N-ethyl-N-isopropyl)-amiloride:21:0.0743	0.2529	106
EIPA	EIPA:20	ethylisopropyl amiloride:20:0.1552	0.1552	20
EIPA	EIPA:70	ethylisopropylamiloride:70:0.2565	0.2565	70
EIPD	EIPD:12	esophageal intramural pseudodiverticulosis:12:0.7571	0.7571	12
EIPH	EIPH:37	exercise-induced pulmonary haemorrhage:37:0.6495	0.6495	37
EIPH	EIPH:31	Exercise-Induced Pulmonary Hemorrhage:31:0.9043	0.9043	31
EIPV	EIPV:3|E-IPV:2|eIPV:1	inactivated polio vaccine:6:0.3728	0.3728	6
EIPV	EIPV:4|eIPV:3|E-IPV:2	inactivated poliovirus vaccine:9:0.6794	0.6794	9
EIP	EIP:10	early intervention program:10:0.5856	0.5856	10
EIP	EIP:9	end-inspiratory pause:9:0.3945	0.3945	9
EIP	EIP:11	extensor indicis proprius:11:0.7357	0.7357	11
EIR	EIR:27	entomological inoculation rate:16:0.5171|Entomological inoculation rates:11:0.4728	0.5171	27
EIRs	EIRs:11	inoculation rates:11:0.7357	0.7357	11
EIS	EIS:18	electrical impedance scanning:18:0.8365	0.8365	18
EIS	EIS:66	electrochemical impedance spectroscopy:66:0.7882	0.7882	66
EIS	EIS:94	endoscopic injection sclerotherapy:94:0.8790	0.8790	94
EIS	EIS:14	Epidemic Intelligence Service:14:0.7909	0.7909	14
EITB	EITB:9	blot technique:9:0.5470	0.5470	9
EITB	EITB:65	enzyme-linked immunoelectrotransfer blot:65:0.8148	0.8148	65
EITB	EITB:10	enzyme-linked immunoelectrotransfer blot assay:10:0.7103	0.7103	10
EIT	EIT:194	electrical impedance tomography:194:0.9753	0.9753	194
EIT	EIT:10	electromagnetically induced transparency:10:0.7103	0.7103	10
EIU	EIU:101	Endotoxin-induced uveitis:101:0.8249	0.8249	101
EIgG	EIgG:27|E-IgG:6	erythrocytes:33:0.5333	0.5333	33
EJC	EJC:7	excitatory junction current:7:0.5926	0.5926	7
EJCs	EJCs:10	excitatory junction currents:10:0.5000	0.5000	10
EJCs	EJCs:8|ejcs:2	excitatory junctional currents:10:0.7103	0.7103	10
EJP	EJP:46|ejp:4	excitatory junction potential:50:0.9064	0.9064	50
EJV	EJV:22	external jugular vein:22:0.8657	0.8657	22
EKC	EKC:36	electrokinetic chromatography:36:0.7433	0.7433	36
EKC	EKC:40	epidemic keratoconjunctivitis:40:0.8839	0.8839	40
EKC	EKC:9	ethylketazocine:9:0.0333	0.0333	9
EKC	EKC:96|Ekc:2	ethylketocyclazocine:98:0.4042	0.4042	98
EKF	EKF:18	extended Kalman filter:18:0.8365	0.8365	18
EKGs	EKGs:17	electrocardiograms:17:0.9412	0.9412	17
EKG	EKG:132	electrocardiogram:123:0.6070|electrocardiograms:9:0.0398	0.6070	132
EKG	EKG:42	electrocardiographic:42:0.2040	0.2040	42
EKG	EKG:10|ekg:1	electrocardiography:11:0.0498	0.0498	11
EKLF	EKLF:67	Erythroid Kruppel-like factor:67:0.9554	0.9554	67
EKR	EKR:10	clearance:10:0.6000	0.6000	10
EKS	EKS:12|eKS:1	epidemic Kaposi's sarcoma:13:0.5111	0.5111	13
EKV	EKV:16	erythrokeratodermia variabilis:16:0.6024	0.6024	16
EK	EK:10	Electrophoretic karyotype:10:0.7103	0.7103	10
EK	EK:15	electrophoretic karyotyping:15:0.7096	0.7096	15
EK	EK:16	enterokinase:16:0.0551	0.0551	16
EK	EK:16	epidermal keratinocytes:16:0.8165	0.8165	16
EK	EK:4	equilibrium potential of K+:4:0.5934	0.5934	4
EK	EK:38|Ek:4	K+ equilibrium potential:42:0.4843	0.4843	42
EK	EK:8	potential for potassium:8:0.4587	0.4587	8
EL4	EL4:7|EL-4:5	lymphoma:12:0.1375	0.1375	12
ELAD	ELAD:8	extracorporeal liver assist device:8:0.6411	0.6411	8
ELAM-1	ELAM-1:30	Endothelial leucocyte adhesion molecule-1:30:0.9043	0.9043	30
ELAM-1	ELAM-1:11	endothelial leukocyte adhesion molecule:11:0.7357	0.7357	11
ELAM-1	ELAM-1:115|ELAM1:1	endothelial leukocyte adhesion molecule-1:77:0.8254|Endothelial leukocyte adhesion molecule 1:27:0.8903|endothelial-leukocyte adhesion molecule 1:12:0.1194	0.8903	116
ELAT	ELAT:17	enzyme-linked antiglobulin test:17:0.6748	0.6748	17
ELA	ELA:8|E-LA:1	activity:9:0.0702	0.0702	9
ELA	ELA:8	Equine lymphocyte antigen:8:0.6411	0.6411	8
ELBW	ELBW:145	extremely low birth weight:113:0.9199|extremely low-birth-weight:19:0.8449|extremely-low-birth-weight:13:0.0558	0.9199	145
ELBW	ELBW:38	extremely low birthweight:38:0.8417	0.8417	38
ELCA	ELCA:33	excimer laser coronary angioplasty:33:0.9100	0.9100	33
ELCAP	ELCAP:10	Early Lung Cancer Action Project:10:0.7103	0.7103	10
ELC	ELC:4	diagonal earlobe crease:4:0.1618	0.1618	4
ELC	ELC:5	ear lobe crease:5:0.4422	0.4422	5
ELC	ELC:11	EBI1-ligand chemokine:11:0.2582	0.2582	11
ELC	ELC:11	epidermal Langerhans cells:11:0.7357	0.7357	11
ELC	ELC:14|E-LC:2	essential light chain:16:0.6577	0.6577	16
ELC	ELC:9	expression-linked copy:9:0.2500	0.2500	9
ELC	ELC:9	ligand chemokine:9:0.1690	0.1690	9
ELDOR	ELDOR:12	electron-electron double resonance:12:0.7571	0.7571	12
ELEM	ELEM:17	equine leukoencephalomalacia:17:0.8270	0.8270	17
ELE	ELE:10|Ele:1	eledoisin:11:0.5263	0.5263	11
ELFA	ELFA:11	enzyme-linked fluorescent assay:11:0.4232	0.4232	11
ELF-MFs	ELF-MFs:5|ELFMFs:4	extremely low frequency magnetic fields:9:0.6794	0.6794	9
ELFMF	ELFMF:16|ELF-MF:11	extremely low frequency magnetic fields:14:0.7909|extremely low frequency magnetic field:13:0.7753	0.7909	27
ELF	ELF:233	epithelial lining fluid:233:0.9726	0.9726	233
ELF	ELF:190|elf:2	extremely low frequency:143:0.9456|Extremely-low-frequency:30:0.0540|extremely low-frequency:19:0.8449	0.9456	192
ELH	ELH:68	egg-laying hormone:68:0.6799	0.6799	68
ELH	ELH:14	endolymphatic hydrops:14:0.7909	0.7909	14
ELISAs	ELISAs:8	enzyme immunoassays:8:0.1125	0.1125	8
ELISAs	ELISAs:13	enzyme-linked immunoassays:13:0.3134	0.3134	13
ELISAs	ELISAs:567|ELISAS:2|ELI-SAs:1	enzyme-linked immunosorbent assays:570:0.8876	0.8876	570
ELISA	ELISA:196|Elisa:4	enzyme immunoassay:167:0.2532|Enzyme immunoassays:22:0.2359|enzyme-immunoassay:11:0.0006	0.2532	200
ELISA	ELISA:365|ELI-SA:1|Elisa:1	enzyme-linked immunoassay:295:0.4739|enzyme linked immunoassay:53:0.9438|Enzyme-linked immunoassays:19:0.1889	0.9438	367
ELISA	ELISA:39	enzyme-linked immunosorbent:39:0.6392	0.6392	39
ELISA	ELISA:4	enzyme-linked immunosorbent analysis:4:0.0918	0.0918	4
ELISA	ELISA:14538|Elisa:25|ElISA:1|ELisa:1|elisa:1	enzyme-linked immunosorbent assay:12517:0.8735|Enzyme linked immunosorbent assay:1488:0.9731|enzyme-linked immunosorbent assays:553:0.8353|enzyme-linked immunosorbent-assay:8:0.4102	0.9731	14566
ELISA	ELISA:15	immunoenzymatic:15:0.0008	0.0008	15
ELISA	ELISA:12	immunoenzymatic test:12:0.0941	0.0941	12
ELISA	ELISA:10|Elisa:1	immunoenzyme test:11:0.0795	0.0795	11
ELI	ELI:13	enkephalin-like immunoreactivity:13:0.5335	0.5335	13
ELI	ELI:11	expression library immunization:11:0.7357	0.7357	11
ELL	ELL:64	electrosensory lateral line lobe:64:0.9264	0.9264	64
ELM	ELM:46	Epiluminescence microscopy:46:0.7319	0.7319	46
ELND	ELND:54	Elective lymph node dissection:54:0.8004	0.8004	54
ELNEC	ELNEC:13	Nursing Education Consortium:13:0.7753	0.7753	13
ELNES	ELNES:7	energy-loss near-edge structure:7:0.5926	0.5926	7
ELN	ELN:18	elastin gene:18:0.6381	0.6381	18
ELP	ELP:9	elastase-like protease:9:0.3455	0.3455	9
ELP	ELP:11	elastin-like polypeptide:11:0.7357	0.7357	11
ELP	ELP:13	endozepine-like peptide:13:0.6460	0.6460	13
ELP	ELP:5	lipid pneumonia:5:0.0612	0.0612	5
ELP	ELP:6	lipoid pneumonia:6:0.1320	0.1320	6
ELSA	ELSA:23	European Lacidipine Study on Atherosclerosis:23:0.8903	0.8903	23
ELSD	ELSD:44	evaporative light scattering detection:28:0.7905|evaporative light-scattering detection:16:0.7261	0.7905	44
ELSD	ELSD:33	evaporative light scattering detector:22:0.7955|evaporative light-scattering detector:11:0.6182	0.7955	33
ELSO	ELSO:30	Extracorporeal Life Support Organization:30:0.9011	0.9011	30
ELS	ELS:6	Eaton-Lambert syndrome:6:0.2243	0.2243	6
ELS	ELS:23	endolymphatic sac:23:0.8038	0.8038	23
ELS	ELS:9	extended least squares:9:0.5470	0.5470	9
ELS	ELS:6	extralobar pulmonary sequestration:6:0.5290	0.5290	6
ELS	ELS:17	light scattering:17:0.8270	0.8270	17
ELT	ELT:12	Endoscopic laser therapy:12:0.5664	0.5664	12
ELT	ELT:76	euglobulin lysis time:76:0.7574	0.7574	76
ELUMO	ELUMO:7|Elumo:4	energy of the lowest unoccupied molecular orbital:11:0.6460	0.6460	11
ELV	ELV:9	Experimental left varicocele:9:0.6794	0.6794	9
EL	EL:6	ejaculation latency:6:0.1838	0.1838	6
EL	EL:34	Endothelial lipase:34:0.9151	0.9151	34
EL	EL:17	erythroleukemia:17:0.0300	0.0300	17
EL	EL:22	lung elastance:22:0.3561	0.3561	22
EM-1	EM-1:29|EM1:12	endomorphin-1:31:0.6122|endomorphin 1:10:0.5000	0.6122	41
EMAP	EMAP:9	echinoderm microtubule-associated protein:9:0.5470	0.5470	9
EMAP	EMAP:7	endothelial monocyte-activating polypeptide:7:0.5926	0.5926	7
EMAP	EMAP:10	Environmental Monitoring and Assessment Program:10:0.7103	0.7103	10
EMAs	EMAs:11|EmAs:1	antibodies:12:0.4231	0.4231	12
EMATE	EMATE:12	Oestrone-3-O-sulphamate:12:0.3929	0.3929	12
EMAT	EMAT:8	electromagnetic acoustic transducer:8:0.4102	0.4102	8
EmA	EmA:10|EMA:8	anti-endomysium antibodies:18:0.0794	0.0794	18
EMA	EMA:10|EmA:2	antiendomysial antibody:12:0.1163	0.1163	12
EMA	EMA:13|EmA:2	antiendomysium:15:0.0125	0.0125	15
EMA	EMA:12|EmA:4	Antiendomysium antibodies:16:0.0658	0.0658	16
EMA	EMA:12	Ecological Momentary Assessment:12:0.6460	0.6460	12
EMA	EMA:25|EmA:16	endomysial antibodies:28:0.1515|endomysial antibody:13:0.1348	0.1515	41
EMA	EMA:9|EmA:3	endomysium:12:0.0098	0.0098	12
EMA	EMA:9|EmA:6	endomysium antibodies:15:0.0591	0.0591	15
EMA	EMA:16	eosin-5-maleimide:16:0.0134	0.0134	16
EMA	EMA:656	epithelial membrane antigen:656:0.9372	0.9372	656
EMA	EMA:9	Eyelid myoclonia with absences:9:0.6794	0.6794	9
EMA	EMA:4|EmA:3	IgA antiendomysial antibodies:7:0.0732	0.0732	7
EMBP	EMBP:48	Estramustine-binding protein:28:0.4089|estramustine binding protein:20:0.8449	0.8449	48
EMBs	EMBs:19	endomyocardial biopsies:19:0.7044	0.7044	19
EMB	EMB:145	Endomyocardial biopsy:100:0.9100|Endomyocardial biopsies:45:0.8964	0.9100	145
EMB	EMB:115|Emb:5	ethambutol:120:0.3510	0.3510	120
EMB	EMB:6	methylene blue:6:0.1838	0.1838	6
EMC-D	EMC-D:8	D variant of encephalomyocarditis:8:0.5856	0.5856	8
EMC-D	EMC-D:20	D variant of encephalomyocarditis virus:20:0.7766	0.7766	20
EMCV	EMCV:264	encephalomyocarditis virus:264:0.9702	0.9702	264
EMC	EMC:12	electromagnetic compatibility:12:0.7571	0.7571	12
EMC	EMC:233	encephalomyocarditis:233:0.4444	0.4444	233
EMC	EMC:30|emc:1	encephalomyocarditis virus:31:0.8519	0.8519	31
EMC	EMC:18	epithelial-myoepithelial carcinoma:18:0.5940	0.5940	18
EMC	EMC:17	essential mixed cryoglobulinaemia:17:0.8270	0.8270	17
EMC	EMC:50	essential mixed cryoglobulinemia:50:0.9064	0.9064	50
emc	emc:14	extramacrochaetae:14:0.0249	0.0249	14
EMC	EMC:28	Extraskeletal myxoid chondrosarcoma:28:0.7905	0.7905	28
EMDA	EMDA:13	electromotive drug administration:13:0.7753	0.7753	13
EMDR	EMDR:80	Eye Movement Desensitization and Reprocessing:80:0.9378	0.9378	80
EMD	EMD:28	Electromechanical delay:28:0.7905	0.7905	28
EMD	EMD:63	electromechanical dissociation:63:0.8430	0.8430	63
EMD	EMD:9	EMDOGAIN:9:0.0207	0.0207	9
EMD	EMD:19	Emery-Dreifuss muscular dystrophy:19:0.8365	0.8365	19
EMD	EMD:85	Enamel Matrix Derivative:85:0.9648	0.9648	85
EMD	EMD:12	enamel matrix proteins:12:0.7571	0.7571	12
EMD	EMD:10	Enzymatic Mutation Detection:10:0.7103	0.7103	10
EMD	EMD:9	extramedullary disease:9:0.3455	0.3455	9
EMD	EMD:17	eye movement desensitization:17:0.8270	0.8270	17
EMEA	EMEA:29	European Agency for the Evaluation of Medicinal Products:29:0.9043	0.9043	29
EMEM	EMEM:13	Eagle's minimum essential medium:13:0.4849	0.4849	13
EME	EME:9	early myoclonic encephalopathy:9:0.6794	0.6794	9
EME	EME:39	ecgonine methyl ester:39:0.8455	0.8455	39
EMF	EMF:243	electromagnetic fields:156:0.6774|electromagnetic field:87:0.8204	0.8204	243
EMF	EMF:12	electromagnetic flowmeter:12:0.7571	0.7571	12
EMF	EMF:11|emf:6	electromotive force:17:0.6748	0.6748	17
EMF	EMF:61	endomyocardial fibrosis:61:0.9229	0.9229	61
EMGdi	EMGdi:22|EMGdI:1	diaphragmatic electromyogram:23:0.4486	0.4486	23
EMGdi	EMGdi:6|EMGDi:1|EMG-DI:1	diaphragmatic EMG:8:0.4102	0.4102	8
EMGs	EMGs:192|emgs:1	electromyograms:193:0.8421	0.8421	193
EMG	EMG:75	electromyograph:75:0.0129	0.0129	75
EMG	EMG:2562|emg:6|EMg:1	Electromyographic:2569:0.4478	0.4478	2569
EMG	EMG:162	electromyographic activity:162:0.6396	0.6396	162
EMG	EMG:30	electromyographical:30:0.0051	0.0051	30
EMG	EMG:13	electromyographically:13:0.0021	0.0021	13
EMG	EMG:11	experimental myasthenia gravis:11:0.7357	0.7357	11
EMG	EMG:183	surface electromyogram:148:0.1126|surface electromyograms:35:0.1653	0.1653	183
EMG	EMG:209	surface electromyography:209:0.1379	0.1379	209
EMH	EMH:11	Extramedullary haematopoiesis:11:0.7357	0.7357	11
EMH	EMH:47	Extramedullary hematopoiesis:47:0.9006	0.9006	47
EMHG	EMHG:8	European MH group:8:0.6411	0.6411	8
EMI	EMI:61	electromagnetic interference:61:0.9229	0.9229	61
EMI	EMI:13	myocardial infarction:13:0.7753	0.7753	13
EMIAT	EMIAT:12	European Myocardial Infarct Amiodarone Trial:12:0.7571	0.7571	12
EMIT	EMIT:70|Emit:5	enzyme immunoassay:75:0.5303	0.5303	75
EMIT	EMIT:52	enzyme multiplied immunoassay technique:52:0.9099	0.9099	52
EMIU	EMIU:8	Experimental melanin-protein induced uveitis:8:0.6411	0.6411	8
EMLA	EMLA:6|Emla:1	eutectic mixture of lidocaine and prilocaine:7:0.4438	0.4438	7
EMLA	EMLA:17	Eutectic Mixture of Local Anaesthetics:17:0.8270	0.8270	17
EMLA	EMLA:51	eutectic mixture of local anesthetics:41:0.9291|eutectic mixture of local anesthetic:10:0.6182	0.9291	51
EMMA	EMMA:27	electrophoretically mediated microanalysis:27:0.8312	0.8312	27
EMND	EMND:19	equine motor neuron disease:19:0.8449	0.8449	19
EMND	EMND:9	ethylmorphine-N-demethylase:9:0.1739	0.1739	9
EmOC	EmOC:25	emergency obstetric care:25:0.8816	0.8816	25
EMPD	EMPD:49	extramammary Paget's disease:49:0.8753	0.8753	49
EMPHO	EMPHO:5	Erlangen micro-lightguide spectrophotometer:5:0.4422	0.4422	5
EMPs	EMPs:11	endothelial microparticles:11:0.7357	0.7357	11
eMRI	eMRI:7|EMRI:4|E-MRI:2	magnetic resonance imaging:13:0.7753	0.7753	13
EMRSA	EMRSA:12	epidemic methicillin-resistant Staphylococcus aureus:12:0.6460	0.6460	12
EMRs	EMRs:32|EMRS:1	electronic medical records:33:0.9100	0.9100	33
EMRS	EMRS:8	Electronic Medical Record System:8:0.6411	0.6411	8
EMR	EMR:21	Eastern Mediterranean Region:21:0.7865	0.7865	21
EMR	EMR:12	educable mentally retarded:12:0.5664	0.5664	12
EMR	EMR:17	electromagnetic radiation:17:0.8270	0.8270	17
EMR	EMR:140	Electronic Medical Record:121:0.9753|Electronic Medical Records:19:0.8449	0.9753	140
EMR	EMR:176	endoscopic mucosal resection:176:0.9727	0.9727	176
Emr	Emr:8|EmR:1	erythromycin:9:0.0169	0.0169	9
Emr	Emr:11|EmR:2	Erythromycin resistance:13:0.6701	0.6701	13
EMSA	EMSA:9	Electrophoretic mobility shift analyses:9:0.6794	0.6794	9
EMSA	EMSA:262	electrophoretic mobility shift assays:262:0.8985	0.8985	262
EMSC	EMSC:16|EMS-C:4	Emergency Medical Services for Children:20:0.8449	0.8449	20
EMS	EMS:10	electrical muscle stimulation:10:0.4363	0.4363	10
EMS	EMS:24	Electromyostimulation:24:0.0117	0.0117	24
EMS	EMS:14	electrophoretic mobility shift:14:0.7909	0.7909	14
EMS	EMS:755	Emergency Medical Services:605:0.9822|emergency medical service:150:0.9800	0.9822	755
EMS	EMS:32	emergency medical system:24:0.8768|emergency medical systems:8:0.6411	0.8768	32
ems	ems:17	empty spiracles:17:0.8270	0.8270	17
EMS	EMS:15	encephalo-myo-synangiosis:15:0.0071	0.0071	15
EMS	EMS:10	encephalomyosynangiosis:10:0.0046	0.0046	10
EMS	EMS:135	eosinophilia-myalgia syndrome:119:0.7491|Eosinophilia Myalgia Syndrome:16:0.7261	0.7491	135
EMS	EMS:36	ethyl methane sulfonate:36:0.8716	0.8716	36
EMS	EMS:11	ethyl methane sulphonate:11:0.6182	0.6182	11
EMS	EMS:306	ethyl methanesulfonate:306:0.9791	0.9791	306
EMS	EMS:80	ethyl methanesulphonate:80:0.9408	0.9408	80
EMS	EMS:8	ethylmethane sulphonate:8:0.1276	0.1276	8
EMS	EMS:42	ethylmethanesulfonate:42:0.0208	0.0208	42
EMS	EMS:17	ethylmethanesulphonate:17:0.0081	0.0081	17
EMS	EMS:19	expandable metallic stent:14:0.5111|expandable metallic stents:5:0.1973	0.5111	19
EMs	EMs:12	extensive:12:0.0056	0.0056	12
EMs	EMs:19	extensive metabolisers:19:0.8449	0.8449	19
EMs	EMs:81	extensive metabolizers:81:0.9631	0.9631	81
EMT-Ps	EMT-Ps:8	emergency medical technician-paramedics:8:0.6411	0.6411	8
EMTALA	EMTALA:17	Emergency Medical Treatment and Active Labor Act:17:0.8270	0.8270	17
EMTALA	EMTALA:19	Emergency Medical Treatment and Labor Act:19:0.8449	0.8449	19
EMTs	EMTs:104	emergency medical technicians:104:0.9543	0.9543	104
EMTs	EMTs:5	Epithelial-mesenchymal transitions:5:0.1132	0.1132	5
EMT	EMT:34	emergency medical technician:25:0.8816|emergency medical technicians:9:0.6794	0.8816	34
EMT	EMT:6	epithelial-mesenchymal transdifferentiation:6:0.0731	0.0731	6
EMT	EMT:30	epithelial-mesenchymal transformation:30:0.3843	0.3843	30
EMT	EMT:71	epithelial-mesenchymal transition:71:0.3959	0.3959	71
EMT	EMT:27	epithelial to mesenchymal transition:27:0.9151	0.9151	27
EMT	EMT:18	extraneuronal monoamine transporter:18:0.8270	0.8270	18
EMT	EMT:9	transitions:9:0.0223	0.0223	9
EMU	EMU:12	early morning urine:12:0.7571	0.7571	12
Emu	Emu:12	enhancer:12:0.2245	0.2245	12
EMU	EMU:5	Extravehicular Mobility Unit:5:0.2818	0.2818	5
EMV	EMV:9	equine morbillivirus:9:0.6794	0.6794	9
Em	Em:5|EM:1|em:1	early diastolic velocity:7:0.3524	0.3524	7
EM	EM:12	ectomycorrhizal:12:0.0028	0.0028	12
EM	EM:12	egg mass:12:0.6460	0.6460	12
EM	EM:9|Em:3	elastic modulus:12:0.6460	0.6460	12
EM	EM:139|em:5	electromagnetic:144:0.0361	0.0361	144
EM	EM:9	electron micrographs:9:0.6794	0.6794	9
EM	EM:118	electron microscope:118:0.9021	0.9021	118
EM	EM:306	electron microscopic:282:0.9622|electron-microscopic:24:0.0058	0.9622	306
EM	EM:12	electron microscopical:12:0.7571	0.7571	12
EM	EM:1070|em:1	electron microscopy:1071:0.9724	0.9724	1071
EM	EM:11	electronmicroscopy:11:0.0025	0.0025	11
EM	EM:30	electrophoretic mobility:30:0.8472	0.8472	30
EM	EM:218	emergency medicine:218:0.9707	0.9707	218
em	em:4|EM:4|Em:2	emission:10:0.0023	0.0023	10
EM	EM:14|Em:3	endometriosis:17:0.0040	0.0040	17
EM	EM:14	epidural morphine:14:0.6173	0.6173	14
EM	EM:5	episodic memory:5:0.0902	0.0902	5
EM	EM:9	Ergonovine maleate:9:0.3945	0.3945	9
EM	EM:83|Em:1	erythema migrans:84:0.9436	0.9436	84
EM	EM:87	Erythema multiforme:87:0.9280	0.9280	87
EM	EM:7	erythrocyte membrane:7:0.3524	0.3524	7
EM	EM:203|Em:11	erythromycin:214:0.0537	0.0537	214
EM	EM:6	esophageal manometry:6:0.1838	0.1838	6
EM	EM:21	Estramustine:21:0.0050	0.0050	21
EM	EM:23	ethylmorphine:23:0.0055	0.0055	23
EM	EM:157|E-M:3	expectation-maximization:106:0.0265|expectation maximization:54:0.9486	0.9486	160
EM	EM:39	extensive:39:0.0096	0.0096	39
EM	EM:16	extensive metabolisers:16:0.8165	0.8165	16
EM	EM:93	extensive metabolizers:67:0.9296|extensive metabolizer:26:0.8251	0.9296	93
EM	EM:19	extracellular matrix:19:0.7044	0.7044	19
EM	EM:10	extramedullary:10:0.0023	0.0023	10
EM	EM:14	eye movement:14:0.7909	0.7909	14
EM	EM:13	eye muscle:13:0.6701	0.6701	13
Em	Em:258|EM:27	membrane potential:263:0.7097|membrane potentials:22:0.2739	0.7097	285
Em	Em:10|E-m:1	midpoint potentials:11:0.0849	0.0849	11
Em	Em:11|EM:6	potential difference:17:0.8270	0.8270	17
En-1	En-1:8|EN1:3|en-1:2|En1:2	engrailed-1:15:0.4516	0.4516	15
En-2	En-2:13|En2:1	Engrailed-2:14:0.5652	0.5652	14
ENA-78	ENA-78:11	epithelial neutrophil-activating peptide 78:6:0.3728|epithelial neutrophil-activating peptide-78:5:0.1464	0.3728	11
ENA-78	ENA-78:10	neutrophil-activating peptide:10:0.3867	0.3867	10
ENA-78	ENA-78:5	neutrophil activating peptide-78:5:0.2818	0.2818	5
ENA-78	ENA-78:6	neutrophil-activating protein-78:6:0.1838	0.1838	6
ENA	ENA:1|Ena:1	ACE inhibitor enalapril:2:0.0545	0.0545	2
Ena	Ena:6	Drosophila Enabled:6:0.0731	0.0731	6
ENA	ENA:13	erythrocytic nuclear abnormalities:13:0.5934	0.5934	13
ENA	ENA:101	extractable nuclear antigens:65:0.7854|extractable nuclear antigen:36:0.6009	0.7854	101
ENa	ENa:8	Na+ equilibrium potential:8:0.4102	0.4102	8
ENA	ENA:13	nucleic acids:13:0.7571	0.7571	13
ENBD	ENBD:15	endoscopic nasobiliary drainage:15:0.8045	0.8045	15
ENB	ENB:19	Esthesioneuroblastoma:19:0.2727	0.2727	19
ENC	ENC:15	endotoxin-neutralizing capacity:8:0.1895|endotoxin neutralizing capacity:7:0.5926	0.5926	15
EndoG	EndoG:7|endoG:4|ENDOG:2	endonuclease G:13:0.6701	0.6701	13
ENDOR	ENDOR:35|endor:1	electron-nuclear double resonance:36:0.1728	0.1728	36
END	END:15|-End:1	beta-endorphin:16:0.0785	0.0785	16
END	END:7	elective neck dissection:7:0.3524	0.3524	7
ENFs	ENFs:8	epidermal nerve fibers:8:0.5006	0.5006	8
ENGs	ENGs:14	electroneurograms:14:0.7647	0.7647	14
ENG	ENG:16	electroneurogram:16:0.0470	0.0470	16
ENG	ENG:14|eng:1	electroneurography:15:0.0439	0.0439	15
ENG	ENG:19	electronystagmogram:19:0.0564	0.0564	19
ENG	ENG:40	electronystagmographic:40:0.1223	0.1223	40
ENG	ENG:135	electronystagmography:135:0.4201	0.4201	135
ENG	ENG:11	endoglin:11:0.0313	0.0313	11
ENHR	ENHR:9	essential national health research:9:0.6794	0.6794	9
ENI	ENI:10	elective nodal irradiation:10:0.7103	0.7103	10
ENK	ENK:148|Enk:23|enk:1	enkephalin:158:0.5097|enkephalins:14:0.0422	0.5097	172
ENK	ENK:10|Enk:5	Leu-Enkephalin:15:0.0455	0.0455	15
ENK	ENK:13|Enk:6	Met-Enkephalin:19:0.0584	0.0584	19
ENK	ENK:14|enk:1	methionine-enkephalin:15:0.0455	0.0455	15
ENK	ENK:10	preproenkephalin:10:0.0292	0.0292	10
ENL	ENL:16|Enl:5	enterolactone:21:0.0917	0.0917	21
ENL	ENL:149	erythema nodosum leprosum:149:0.9577	0.9577	149
ENMG	ENMG:15	electroneuromyography:15:0.5185	0.5185	15
ENM	ENM:10	epileptic negative myoclonus:10:0.7103	0.7103	10
ENNG	ENNG:74	N-ethyl-N'-nitro-N-nitrosoguanidine:74:0.9241	0.9241	74
eNOS	eNOS:9	endothelial cells:9:0.6794	0.6794	9
eNOS	eNOS:6	endothelial isoform:6:0.1838	0.1838	6
eNOS	eNOS:12|e-NOS:1	endothelial nitric oxide:13:0.7753	0.7753	13
eNOS	eNOS:1024|e-NOS:8|ENOS:4	Endothelial nitric oxide synthase:1036:0.8921	0.8921	1036
eNOS	eNOS:7	endothelial nitric oxide synthase gene:7:0.5926	0.5926	7
eNOS	eNOS:5	Endothelial nitric oxide synthetase:5:0.2827	0.2827	5
eNOS	eNOS:10|e-NOS:1	endothelial NO-synthase:11:0.6182	0.6182	11
ENPs	ENPs:18	emergency nurse practitioners:18:0.8365	0.8365	18
ENP	ENP:9	emergency nurse practitioner:9:0.6794	0.6794	9
ENRD	ENRD:10	reflux disease:10:0.7103	0.7103	10
ENR	ENR:8	Enoyl acyl carrier protein reductase:8:0.6411	0.6411	8
ENR	ENR:14|Enr:2	enrofloxacin:16:0.2542	0.2542	16
ENSO	ENSO:48	El Nino Southern Oscillation:19:0.8449|El Nino-southern oscillation:17:0.7407|El Nino/Southern Oscillation:12:0.7571	0.8449	48
ENS	ENS:9	electrical nerve stimulation:9:0.5470	0.5470	9
ENs	ENs:12	enrolled nurses:12:0.6460	0.6460	12
ENS	ENS:192	enteric nervous system:192:0.9844	0.9844	192
ENS	ENS:10	epidermal nevus syndrome:10:0.7103	0.7103	10
ENS	ENS:5	extranodal spread:5:0.1132	0.1132	5
ENTH	ENTH:13	epsin N-terminal homology:13:0.7753	0.7753	13
ENT	ENT:3	ear nose and throat:3:0.9608	0.9608	3
ENT	ENT:18	ear-nose-throat:18:0.0501	0.0501	18
ENT	ENT:6	embryonic nervous tissue:6:0.3728	0.3728	6
ENT	ENT:7|Ent:2	entorhinal cortex:9:0.6794	0.6794	9
ENT	ENT:12|Ent:1	equilibrative nucleoside transporter:13:0.7753	0.7753	13
ENU	ENU:19	1-ethyl-1-nitrosourea:19:0.0252	0.0252	19
ENU	ENU:41	ethyl nitrosourea:31:0.6820|ethyl-nitrosourea:10:0.0126	0.6820	41
ENU	ENU:273	Ethylnitrosourea:273:0.3762	0.3762	273
ENU	ENU:303|Enu:1	N-ethyl-N-nitrosourea:304:0.4224	0.4224	304
ENU	ENU:13	N-ethylnitrosourea:13:0.0168	0.0168	13
ENU	ENU:10	N-nitroso-N-ethylurea:10:0.0126	0.0126	10
ENX	ENX:49	enoxacin:49:0.8889	0.8889	49
ENases	ENases:20	restriction endonucleases:20:0.7173	0.7173	20
ENase	ENase:43|Enase:1	restriction endonuclease:44:0.8335	0.8335	44
ENoG	ENoG:29|ENOG:5|EnoG:2	electroneurography:36:0.6250	0.6250	36
ENoG	ENoG:11|ENOG:2|EnoG:1	electroneuronography:14:0.2321	0.2321	14
EN	EN:5	egg number:5:0.0902	0.0902	5
EN	EN:9	electronic nose:9:0.6794	0.6794	9
EN	EN:16|En:1	enalapril:17:0.0210	0.0210	17
EN	EN:13	endemic nephropathy:13:0.5934	0.5934	13
en	en:94|En:21|EN:4	engrailed:119:0.1547	0.1547	119
EN	EN:9	enteral:9:0.0105	0.0105	9
EN	EN:137	enteral nutrition:137:0.9652	0.9652	137
EN	EN:11	epinephrine:11:0.0131	0.0131	11
EN	EN:66	erythema nodosum:66:0.9548	0.9548	66
EN	EN:8	ethyl nicotinate:8:0.4102	0.4102	8
en	en:29|En:1	ethylenediamine:30:0.0380	0.0380	30
EOAD	EOAD:11	early-onset AD:11:0.3829	0.3829	11
EOAD	EOAD:16	early-onset Alzheimer's disease:16:0.4536	0.4536	16
EOAEs	EOAEs:55|e-OAEs:3	evoked otoacoustic emissions:58:0.8710	0.8710	58
EOAE	EOAE:49|e-OAE:3	evoked otoacoustic emissions:41:0.7472|evoked otoacoustic emission:11:0.6182	0.7472	52
EOAI	EOAI:6|EOA-I:1|EOAi:1	effective orifice area index:8:0.6411	0.6411	8
EOCA	EOCA:7	Early Onset Cerebellar Ataxia:7:0.5926	0.5926	7
EOCA	EOCA:14	Early Onset Cerebellar Ataxia with retained tendon reflexes:14:0.6701	0.6701	14
EOC	EOC:113	epithelial ovarian cancer:113:0.9437	0.9437	113
EOC	EOC:28	epithelial ovarian carcinoma:28:0.8941	0.8941	28
EOC	EOC:10	obstetric care:10:0.3867	0.3867	10
EODs	EODs:40	Electric organ discharges:40:0.9256	0.9256	40
EOD	EOD:88	electric organ discharge:88:0.9660	0.9660	88
EOD	EOD:21	extent of disease:21:0.3267	0.3267	21
EOF	EOF:294	electroosmotic flow:294:0.8327	0.8327	294
EOF	EOF:10	erythrocyte osmotic fragility:10:0.7103	0.7103	10
EOG	EOG:91	Electro-oculogram:91:0.1974	0.1974	91
EOG	EOG:27	electro-oculographic:27:0.0570	0.0570	27
EOG	EOG:46	electro-oculography:46:0.0987	0.0987	46
EOG	EOG:37	electro-olfactogram:37:0.0789	0.0789	37
EOG	EOG:67	electrooculogram:67:0.1469	0.1469	67
EOG	EOG:25	Electrooculographic:25:0.0526	0.0526	25
EOG	EOG:53	electrooculography:53:0.1140	0.1140	53
EOG	EOG:22	electroolfactogram:22:0.0461	0.0461	22
EOI	EOI:18	emotional overinvolvement:18:0.7539	0.7539	18
EOMs	EOMs:51	Extraocular muscles:51:0.9082	0.9082	51
EOM	EOM:102|eom:1	extraocular muscle:72:0.8610|extraocular muscles:31:0.7091	0.8610	103
EOM	EOM:14	organic matter:14:0.7909	0.7909	14
EOPs	EOPs:26	Endogenous opioid peptides:26:0.8861	0.8861	26
EOP	EOP:77	early-onset periodontitis:51:0.5167|early onset periodontitis:26:0.8861	0.8861	77
EOP	EOP:76	endogenous opioid peptides:58:0.9486|Endogenous opioid peptide:18:0.8365	0.9486	76
EOP	EOP:15	equivalent oxygen percentage:15:0.6173	0.6173	15
EORTC	EORTC:60	European Organisation for Research and Treatment of Cancer:60:0.9596	0.9596	60
EORTC	EORTC:14	European Organization for Research on Treatment of Cancer:14:0.9537	0.9537	14
EOSs	EOSs:13	eosinophils:13:0.7500	0.7500	13
EOS	EOS:12	early-onset schizophrenia:7:0.2113|Early onset schizophrenia:5:0.4422	0.4422	12
EOS	EOS:10	endogenous opioid system:10:0.7103	0.7103	10
EOS	EOS:74|Eos:22|eos:8|EOs:3	Eosinophils:77:0.2542|eosinophil:30:0.0970	0.2542	107
EOS	EOS:9	equation of state:9:0.6794	0.6794	9
EOs	EOs:10	essential oils:10:0.7103	0.7103	10
EOS	EOS:10	ethanolamine-O-sulphate:10:0.0334	0.0334	10
EOS	EOS:2	GABA-transaminase inhibitor ethanolamine-O-sulfate:2:0.0918	0.0918	2
EOT	EOT:13	end of treatment:13:0.5934	0.5934	13
EOE	EOE:7	evoked otoacoustic emissions:7:0.3524	0.3524	7
EP's	EP's:10	evoked potentials:10:0.5856	0.5856	10
EPA-E	EPA-E:9	highly purified eicosapentaenoic acid ethyl ester:9:0.6794	0.6794	9
Epac	Epac:6|EPAC:3	exchange protein directly activated by cAMP:9:0.6794	0.6794	9
EPAP	EPAP:23|E-PAP:1	expiratory positive airway pressure:24:0.8768	0.8768	24
EPAS1	EPAS1:9|EPAS-1:1	Endothelial PAS domain protein 1:10:0.5856	0.5856	10
EPA	EPA:10	eicosapentaenoate:10:0.0046	0.0046	10
EPA	EPA:106	eicosapentaenoic:106:0.0534	0.0534	106
EPA	EPA:1006	eicosapentaenoic acid:1006:0.9102	0.9102	1006
EPA	EPA:531	Environmental Protection Agency:485:0.9671|Environmental Protection Agency's:46:0.9353	0.9671	531
EPA	EPA:28	erythroid-potentiating activity:16:0.1832|erythroid potentiating activity:12:0.5050	0.5050	28
EPA	EPA:5	extrapulmonary artery:5:0.0902	0.0902	5
EPBD	EPBD:13	Endoscopic papillary balloon dilation:13:0.7753	0.7753	13
EPBF	EPBF:6	Effective peritoneal blood flow:6:0.5290	0.5290	6
EPB	EPB:12	extensor pollicis brevis:12:0.7571	0.7571	12
EPCs	EPCs:8|epcs:3	end-plate currents:11:0.1378	0.1378	11
EPCs	EPCs:189	Endothelial progenitor cells:189:0.9663	0.9663	189
EPCs	EPCs:20	endplate currents:20:0.3885	0.3885	20
EPC	EPC:5	Early Prostate Cancer:5:0.4422	0.4422	5
EPC	EPC:26	ectoplacental cone:26:0.8861	0.8861	26
EPC	EPC:75|ePC:3	egg phosphatidylcholine:78:0.7117	0.7117	78
EPC	EPC:26|epc:3	end-plate currents:15:0.3110|end-plate current:14:0.2157	0.3110	29
EPC	EPC:39	endothelial progenitor cells:29:0.7970|endothelial progenitor cell:10:0.7103	0.7970	39
EPC	EPC:23|epc:2	endplate current:16:0.2709|endplate currents:9:0.1150	0.2709	25
EPC	EPC:9	enhanced primary care:9:0.6794	0.6794	9
EPC	EPC:44|epc:1|Epc:1	Epilepsia partialis continua:46:0.8676	0.8676	46
EPC	EPC:13	epithelioma papulosum cyprini:13:0.7753	0.7753	13
EPC	EPC:15	erosive prepyloric changes:15:0.8045	0.8045	15
EPC	EPC:5	exocrine pancreatic cancer:5:0.2818	0.2818	5
EPC	EPC:13	external pneumatic compression:13:0.7753	0.7753	13
EPDS	EPDS:163	Edinburgh Postnatal Depression Scale:163:0.9816	0.9816	163
EPD	EPD:12	Eukaryotic Promoter Database:12:0.7357	0.7357	12
EPD	EPD:8	expected progeny differences:8:0.6411	0.6411	8
EPD	EPD:15	extramammary Paget's disease:15:0.8045	0.8045	15
EPEC	EPEC:8	Education for Physicians on End-of-Life Care:8:0.6794	0.6794	8
EPEC	EPEC:57	enteropathogenic:57:0.0690	0.0690	57
EPEC	EPEC:2	enteropathogenic E coli:2:0.8887	0.8887	2
EPEC	EPEC:502	enteropathogenic Escherichia coli:502:0.9732	0.9732	502
EPESE	EPESE:36	Established Populations for Epidemiologic Studies of the Elderly:36:0.8525	0.8525	36
EPE	EPE:8	eosinophilic pleural effusion:8:0.4102	0.4102	8
EPE	EPE:21	Extraprostatic extension:21:0.7291	0.7291	21
EPFR	EPFR:16	Early proximal flow rate:16:0.8165	0.8165	16
EPF	EPF:113	early pregnancy factor:113:0.9733	0.9733	113
EPF	EPF:11	endemic pemphigus foliaceus:11:0.7357	0.7357	11
EPF	EPF:26	eosinophilic pustular folliculitis:26:0.8861	0.8861	26
E-PHA	E-PHA:14	erythroagglutinating phytohemagglutinin:14:0.6173	0.6173	14
EPHX	EPHX:14	epoxide hydrolase:14:0.6911	0.6911	14
EPHX1	EPHX1:10|Ephx1:1	microsomal epoxide hydrolase:11:0.4728	0.4728	11
EPH	EPH:15|Eph:5	ephedrine:20:0.2043	0.2043	20
EPH	EPH:6	extrahepatic portal hypertension:6:0.5290	0.5290	6
EPIC	EPIC:96	European Prospective Investigation into Cancer and Nutrition:96:0.9682	0.9682	96
EPIC	EPIC:4	European Prospective Investigation of Cancer:4:0.5926	0.5926	4
EPIC	EPIC:7	Evaluation of 7E3 for the Prevention of Ischemic Complications:7:0.5926	0.5926	7
EPIDs	EPIDs:26|EPIDS:1	electronic portal imaging devices:27:0.8903	0.8903	27
EPID	EPID:99	electronic portal imaging device:99:0.9365	0.9365	99
EPIR	EPIR:9|Epir:1	epirubicin:10:0.5625	0.5625	10
EPIs	EPIs:8	electronic portal images:8:0.6411	0.6411	8
EPI	EPI:10	echo-planar:10:0.0042	0.0042	10
EPI	EPI:323	Echo-planar imaging:208:0.4950|echo planar imaging:115:0.9328	0.9328	323
EPI	EPI:5	Electronic Portal Images:5:0.4422	0.4422	5
Epi	Epi:15|EPI:13|epi:4	epicardial:32:0.0149	0.0149	32
Epi	Epi:7|epi:4|EPI:3	epicardium:14:0.0060	0.0060	14
EPI	EPI:10|Epi:6	epididymal:16:0.0070	0.0070	16
EPI	EPI:15	epidoxorubicin:15:0.0065	0.0065	15
EPI	EPI:9	epidural:9:0.0037	0.0037	9
EPI	EPI:6|Epi:5|epi:1	epimastigotes:12:0.0051	0.0051	12
EPI	EPI:113|Epi:6|epi:1	Epirubicin:120:0.0554	0.0554	120
EPI	EPI:34|epi:1	exocrine pancreatic insufficiency:35:0.9151	0.9151	35
EPI	EPI:20	expanded program of immunization:20:0.9600	0.9600	20
EPI	EPI:3	expanded programme of immunisation:3:0.7044	0.7044	3
EPI	EPI:165	Expanded Programme on Immunization:165:0.9491	0.9491	165
EPI	EPI:35	Extrinsic pathway inhibitor:35:0.8245	0.8245	35
EPI	EPI:57	Eysenck Personality Inventory:57:0.8281	0.8281	57
EPI	EPI:13|Epi:10|epi:1	subepicardium:24:0.0107	0.0107	24
EPL	EPL:11	early pregnancy loss:11:0.7357	0.7357	11
EPL	EPL:17	essential phospholipids:17:0.5038	0.5038	17
EPL	EPL:10	expressed protein ligation:10:0.7103	0.7103	10
EPL	EPL:28	extensor pollicis longus:28:0.8369	0.8369	28
EPL	EPL:46|epl:1	external plexiform layer:47:0.8703	0.8703	47
EPL	EPL:20	extracorporeal piezoelectric lithotripsy:20:0.8594	0.8594	20
EPM1	EPM1:17	progressive myoclonus epilepsy:17:0.7407	0.7407	17
EPM1	EPM1:6	Progressive myoclonus epilepsy of Unverricht-Lundborg type:6:0.7571	0.7571	6
EPMA	EPMA:55	electron probe microanalysis:55:0.9458	0.9458	55
EPMA	EPMA:7	electron probe microanalyzer:7:0.5926	0.5926	7
EPMA	EPMA:23	electron probe x-ray microanalysis:23:0.8715	0.8715	23
EPMR	EPMR:9	progressive epilepsy with mental retardation:9:0.6794	0.6794	9
EPM	EPM:6	electronic performance monitoring:6:0.5290	0.5290	6
EPM	EPM:109|epm:1	electrophoretic mobility:97:0.9510|electrophoretic mobilities:13:0.7753	0.9510	110
EPM	EPM:158	elevated plus-maze:89:0.9664|elevated plus maze:69:0.9100	0.9664	158
EPM	EPM:67	equine protozoal myeloencephalitis:67:0.9554	0.9554	67
EPM	EPM:13	extrapontine myelinolysis:13:0.5335	0.5335	13
EPM	EPM:6	pH monitoring:6:0.1010	0.1010	6
EPNP	EPNP:13	1,2-epoxy-3-(p-nitrophenoxy)propane:13:0.3750	0.3750	13
EPN	EPN:21	emphysematous pyelonephritis:21:0.7865	0.7865	21
EPN	EPN:17	entopeduncular nucleus:17:0.6748	0.6748	17
EPN	EPN:8	O-ethyl O-p-nitrophenyl phenylphosphonothioate:8:0.5926	0.5926	8
EPOC	EPOC:23	excess postexercise oxygen consumption:23:0.8715	0.8715	23
EpoR	EpoR:53|EPOR:34|Epo-R:22|EPO-R:18	EPO receptor:119:0.3302|EPO receptors:8:0.1276	0.3302	127
EpoR	EpoR:116|EPOR:49|EPO-R:45|Epo-R:19|EPO-r:1|EPOr:1	erythropoietin receptor:220:0.4873|erythropoietin receptors:11:0.2582	0.4873	231
EPO	EPO:254	eosinophil peroxidase:254:0.9480	0.9480	254
Epo	Epo:5|EPO:3|epo:1	epoprostenol:9:0.0022	0.0022	9
EPO	EPO:1869|Epo:1171|epo:66|EpO:3|EPo:1|-EPO:1	erythropoietin:3111:0.8635	0.8635	3111
EPO	EPO:69	Evening Primrose Oil:69:0.9567	0.9567	69
EPPIC	EPPIC:8	Early Psychosis Prevention and Intervention Centre:8:0.6411	0.6411	8
EPPK	EPPK:17	Epidermolytic palmoplantar keratoderma:17:0.8270	0.8270	17
EPPS	EPPS:12	Edwards Personal Preference Schedule:12:0.7571	0.7571	12
EPPs	EPPs:49|epps:10|EPPS:1	endplate potentials:60:0.4004	0.4004	60
EPP	EPP:32|epp:10	end-plate potential:34:0.2753|end-plate potentials:8:0.1367	0.2753	42
EPP	EPP:44|epp:4	Endplate potential:42:0.3642|endplate potentials:6:0.0564	0.3642	48
EPP	EPP:8|Epp:1	Erythrocyte protoporphyrin:9:0.3455	0.3455	9
EPP	EPP:118	erythropoietic protoporphyria:118:0.9339	0.9339	118
EPP	EPP:8	ethyl phenylpropiolate:8:0.5006	0.5006	8
EPP	EPP:11	extra-pair paternity:11:0.5355	0.5355	11
EPP	EPP:14	extrapleural pneumonectomy:14:0.6911	0.6911	14
EPQ	EPQ:92	Eysenck Personality Questionnaire:92:0.9026	0.9026	92
EPR-1	EPR-1:17	effector cell protease receptor-1:17:0.8270	0.8270	17
EPRI	EPRI:23	Electron paramagnetic resonance imaging:23:0.8657	0.8657	23
EPRs	EPRs:13	electronic patient records:13:0.7753	0.7753	13
EPR	EPR:8	early-phase reaction:8:0.2619	0.2619	8
EPR	EPR:1811|epr:10	electron paramagnetic resonance:1821:0.9804	0.9804	1821
EPR	EPR:53	electron paramagnetic resonance spectroscopy:53:0.9116	0.9116	53
EPR	EPR:91|ePR:3	electronic patient record:79:0.9401|Electronic Patient Records:15:0.8045	0.9401	94
EPR	EPR:9	epirubicin:9:0.0036	0.0036	9
EpR	EpR:8	erythropoietin receptor:8:0.2619	0.2619	8
EPR	EPR:7	production rate:7:0.3524	0.3524	7
EPSCs	EPSCs:466|epscs:1|EPSCS:1	excitatory postsynaptic currents:468:0.9686	0.9686	468
EPSC	EPSC:114|epsc:1	excitatory postsynaptic current:92:0.9484|excitatory postsynaptic currents:23:0.8715	0.9484	115
EPSDT	EPSDT:3	early and periodic screening diagnosis and treatment:3:0.8590	0.8590	3
EPSI	EPSI:11	echo-planar spectroscopic imaging:11:0.5355	0.5355	11
EPSPS	EPSPS:21|EPSPs:2	5-enolpyruvylshikimate-3-phosphate synthase:23:0.4831	0.4831	23
EPSPs	EPSPs:1017|epsps:5|EP-SPs:4|EPSPS:3	excitatory postsynaptic potentials:1022:0.9829|excitatory postsynaptic potential:7:0.5926	0.9829	1029
EPSPs	EPSPs:13	excitatory PSPs:13:0.5934	0.5934	13
EPSP	EPSP:44	5-Enolpyruvylshikimate-3-phosphate:29:0.0386|5-enolpyruvylshikimate 3-phosphate:15:0.6386	0.6386	44
EPSP	EPSP:573|epsp:12	excitatory postsynaptic potential:520:0.9793|excitatory postsynaptic potentials:65:0.9541	0.9793	585
EPSs	EPSs:31	exopolysaccharides:31:0.3571	0.3571	31
EPSS	EPSS:13	septal separation:13:0.4849	0.4849	13
EPs	EPs:17	ectopic pregnancies:17:0.8270	0.8270	17
EPS	EPS:17	elastosis perforans serpiginosa:17:0.7407	0.7407	17
EPS	EPS:5	electrical promontory stimulation:5:0.4422	0.4422	5
EPS	EPS:126	electrophysiologic study:87:0.5606|electrophysiologic studies:39:0.4710	0.5606	126
EPS	EPS:55	electrophysiological study:34:0.1746|electrophysiological studies:21:0.1966	0.1966	55
EPs	EPs:85	Emergency physicians:85:0.9648	0.9648	85
EPS	EPS:7	emotional-pain stress:7:0.0655	0.0655	7
EPS	EPS:17	emotional-painful stress:10:0.1596|emotional painful stress:7:0.5926	0.5926	17
EPS	EPS:29	Encapsulating Peritoneal Sclerosis:29:0.8422	0.8422	29
EPs	EPs:319|EP-s:1|Eps:1	evoked potentials:321:0.8814	0.8814	321
EPS	EPS:244	exopolysaccharide:186:0.0951|exopolysaccharides:58:0.0293	0.0951	244
EPS	EPS:10	expanded polystyrene:10:0.7103	0.7103	10
EPS	EPS:57	expressed prostatic secretion:30:0.8032|expressed prostatic secretions:27:0.7066	0.8032	57
EPS	EPS:76	extracellular polymeric substances:65:0.8841|extracellular polymeric substance:11:0.6182	0.8841	76
EPS	EPS:88|EPs:1|Eps:1	extracellular polysaccharide:67:0.7644|extracellular polysaccharides:23:0.6306	0.7644	90
EPS	EPS:152	extrapyramidal side effects:117:0.9460|extrapyramidal side-effects:23:0.7046|extrapyramidal side effect:12:0.7571	0.9460	152
EPS	EPS:19	extrapyramidal signs:19:0.7044	0.7044	19
EPS	EPS:203	extrapyramidal symptoms:203:0.8812	0.8812	203
EPS	EPS:39	extrapyramidal syndromes:24:0.8768|extrapyramidal syndrome:15:0.5818	0.8768	39
E-PTA	E-PTA:20|EPTA:7	ethanolic phosphotungstic acid:27:0.6192	0.6192	27
EPTB	EPTB:8	extra-pulmonary tuberculosis:8:0.1004	0.1004	8
EPTB	EPTB:15|EP-TB:2	extrapulmonary tuberculosis:17:0.4480	0.4480	17
EPTs	EPTs:14	endocrine pancreatic tumors:14:0.7909	0.7909	14
EPT	EPT:56	Endoscopic papillotomy:56:0.8901	0.8901	56
EPXMA	EPXMA:19	electron probe X-ray microanalysis:19:0.8449	0.8449	19
EP	EP:5	bovine encephalitogenic protein:5:0.0902	0.0902	5
EP	EP:6	cisplatin and etoposide:6:0.2902	0.2902	6
EP	EP:25	E-prostanoid:25:0.0071	0.0071	25
EP	EP:6	early phase:6:0.1320	0.1320	6
EP	EP:209	ectopic pregnancy:197:0.9339|ectopic pregnancies:12:0.5664	0.9339	209
EP	EP:27	egg production:27:0.8903	0.8903	27
EP	EP:58	electrophysiologic:58:0.0175	0.0175	58
EP	EP:28	electrophysiological:28:0.0083	0.0083	28
EP	EP:32	Electrophysiology:32:0.0095	0.0095	32
EP	EP:36	emergency physician:36:0.8716	0.8716	36
EP	EP:6	encephalitogenic peptide:6:0.0899	0.0899	6
EP	EP:206|-EP:1	endocochlear potential:207:0.3889	0.3889	207
EP	EP:10	Endocrine-paracrine:10:0.0028	0.0028	10
EP	EP:62	endogenous pyrogen:62:0.9003	0.9003	62
EP	EP:13	endoscopic papillotomy:13:0.7753	0.7753	13
EP	EP:42|Ep:3	entopeduncular nucleus:45:0.8620	0.8620	45
EP	EP:9	enzootic pneumonia:9:0.1205	0.1205	9
EP	EP:13	eosinophilic pneumonia:13:0.2532	0.2532	13
EP	EP:10	ephedrine:10:0.0028	0.0028	10
EP	EP:5	equilibrium point:5:0.0612	0.0612	5
EP	EP:45	erythrocyte protoporphyrin:45:0.8964	0.8964	45
Ep	Ep:326|EP:95|ep:1	erythropoietin:422:0.1290	0.1290	422
EP	EP:9	escape protein:9:0.0809	0.0809	9
EP	EP:8|E-P:3	estrogen-progesterone:11:0.0031	0.0031	11
EP	EP:24	etoposide and cisplatin:24:0.4692	0.4692	24
EP	EP:11	etoposide phosphate:11:0.2972	0.2972	11
EP	EP:10	etoposide plus cisplatin:10:0.5000	0.5000	10
EP	EP:406|ep:1	evoked potentials:210:0.8275|evoked potential:197:0.3643	0.8275	407
ep	ep:10	pale ear:10:0.7103	0.7103	10
EP	EP:11	period:11:0.0031	0.0031	11
EP	EP:6	PGE(2) receptors:6:0.1838	0.1838	6
EP	EP:40|E-P:13	phosphoenzyme:53:0.0160	0.0160	53
EP	EP:8|E-P:2	phosphoenzyme intermediate:10:0.1022	0.1022	10
EP	EP:18|E-P:3	phosphorylated intermediate:21:0.3767	0.3767	21
EP	EP:23	pressure:23:0.0068	0.0068	23
Ep	Ep:19	pressure strain elastic modulus:19:0.8449	0.8449	19
EP	EP:16|E-P:1	progesterone:17:0.0049	0.0049	17
EP	EP:14	prostaglandin E:14:0.5589	0.5589	14
EP	EP:13	receptor:13:0.0037	0.0037	13
EP	EP:9	vivo electroporation:9:0.0783	0.0783	9
EQ-5D	EQ-5D:8	EuroQOL instrument:8:0.4102	0.4102	8
EQ-5D	EQ-5D:9|EQ5D:1	questionnaire:10:0.0744	0.0744	10
EQA	EQA:95	external quality assessment:95:0.9500	0.9500	95
EQA	EQA:24	external quality assurance:24:0.8768	0.8768	24
EQAS	EQAS:44	External Quality Assessment Scheme:25:0.8816|External Quality Assessment Schemes:19:0.8525	0.8816	44
EQCM	EQCM:11	electrochemical quartz crystal microbalance:11:0.7357	0.7357	11
EQ	EQ:6	efficiency quotient:6:0.0731	0.0731	6
eq	eq:7|EQ:2	equilin:9:0.0494	0.0494	9
EQ	EQ:39	ethoxyquin:39:0.2346	0.2346	39
ER+	ER+:17	ER-positive:17:0.0755	0.0755	17
ER+	ER+:86	estrogen receptor-positive:45:0.6462|estrogen receptor positive:41:0.7523	0.7523	86
ER-	ER-:16	ER-negative:16:0.1128	0.1128	16
ER-	ER-:49	estrogen receptor negative:28:0.6057|estrogen receptor-negative:21:0.6040	0.6057	49
ER/PR	ER/PR:6	Estrogen and progesterone receptors:6:0.5290	0.5290	6
ERAF	ERAF:10	atrial fibrillation:10:0.7103	0.7103	10
E-RAF	E-RAF:18	estrogen receptor activation factor:18:0.7261	0.7261	18
ERAS	ERAS:11	Electronic Residency Application Service:11:0.7357	0.7357	11
ERA	ERA:6	early rheumatoid arthritis:6:0.5290	0.5290	6
ERA	ERA:23	ecological risk assessment:23:0.5719	0.5719	23
ERA	ERA:11	electrical response activity:11:0.6460	0.6460	11
ErA	ErA:10|ERA:1	erythorbic acid:11:0.6182	0.6182	11
ERA	ERA:9	estrogen replacement and atherosclerosis:9:0.7103	0.7103	9
ERBD	ERBD:10	Endoscopic retrograde biliary drainage:10:0.7103	0.7103	10
ERBF	ERBF:25	effective renal blood flow:25:0.8186	0.8186	25
ERB	ERB:14	equivalent rectangular bandwidth:14:0.6911	0.6911	14
ERCP	ERCP:105	Endoscopic retrograde cholangio-pancreatography:91:0.9158|endoscopic retrograde cholangio pancreatography:14:0.7909	0.9158	105
ERCP	ERCP:36	endoscopic retrograde cholangiography:36:0.8336	0.8336	36
ERCP	ERCP:51	endoscopic retrograde cholangiopancreaticography:51:0.9099	0.9099	51
ERCP	ERCP:14	endoscopic retrograde cholangiopancreatogram:14:0.7909	0.7909	14
ERCP	ERCP:10	endoscopic retrograde cholangiopancreatographic:10:0.7103	0.7103	10
ERCP	ERCP:1372|ER-CP:1	endoscopic retrograde cholangiopancreatography:1373:0.9792	0.9792	1373
ERCP	ERCP:15	endoscopic retrograde pancreatography:15:0.7096	0.7096	15
ERCs	ERCs:5	extrachromosomal ribosomal DNA circles:5:0.4422	0.4422	5
ERc	ERc:7|ERC:3	cytosol estrogen:10:0.3867	0.3867	10
ERC	ERC:200	endoscopic retrograde cholangiography:200:0.9850	0.9850	200
ERC	ERC:32	entorhinal cortex:32:0.9072	0.9072	32
ERC	ERC:13	erythropoietin responsive cells:7:0.4438|erythropoietin-responsive cells:6:0.0807	0.4438	13
ERc	ERc:22|ERC:9	estrogen receptor:17:0.6211|estrogen receptors:14:0.4709	0.6211	31
ERC	ERC:23	European Resuscitation Council:23:0.8715	0.8715	23
ERD/ERS	ERD/ERS:12	event-related desynchronization/synchronization:12:0.5664	0.5664	12
erd	erd:10	early retinal degeneration:10:0.7103	0.7103	10
ERD	ERD:132	event-related desynchronization:132:0.9305	0.9305	132
ERD	ERD:12	extrapolated response dose:12:0.7571	0.7571	12
ER-EIA	ER-EIA:14|EREIA:1	enzyme immunoassay:15:0.5348	0.5348	15
ERE	ERE:231	estrogen response element:211:0.8282|estrogen response elements:20:0.6680	0.8282	231
ERE	ERE:6	estrogen responsive elements:6:0.2827	0.2827	6
E-RFC	E-RFC:18|ERFC:3	E-rosette forming cells:14:0.3383|E rosette-forming cells:7:0.1025	0.3383	21
E-RFC	E-RFC:8|ERFC:1	erythrocyte Rosette-forming cells:9:0.1945	0.1945	9
ERF	ERF:5	excitatory receptive field:5:0.4422	0.4422	5
ERF	ERF:13	external respiration function:13:0.7753	0.7753	13
ERF	ERF:10	External respiratory function:10:0.7103	0.7103	10
ERF	ERF:11	renal failure:11:0.6182	0.6182	11
ERG's	ERG's:9	Electroretinograms:9:0.8000	0.8000	9
ERGIC	ERGIC:14	endoplasmic reticulum-Golgi intermediate compartment:14:0.7909	0.7909	14
ERGIC	ERGIC:17	ER-Golgi intermediate compartment:17:0.2379	0.2379	17
ERGs	ERGs:5	early response genes:5:0.2818	0.2818	5
ERGs	ERGs:311|ERGS:1	electroretinograms:312:0.9311	0.9311	312
ERG	ERG:1056	electroretinogram:958:0.6051|Electroretinograms:98:0.0614	0.6051	1056
ERG	ERG:146	Electroretinographic:146:0.0918	0.0918	146
ERG	ERG:248	electroretinography:248:0.1563	0.1563	248
ERG	ERG:6|erg:5	ether-a-go-go-related gene:11:0.2582	0.2582	11
ERIC	ERIC:47	Enterobacterial Repetitive Intergenic Consensus:47:0.8676	0.8676	47
ERISA	ERISA:24	Employee Retirement Income Security Act:24:0.7249	0.7249	24
ERISA	ERISA:22	Employee Retirement Income Security Act of 1974:22:0.8115	0.8115	22
ERI	ERI:16	Effort-Reward Imbalance:16:0.8165	0.8165	16
ERK1/2	ERK1/2:142|Erk1/2:8|ERK-1/2:4|Erk-1/2:3|ERK-1/-2:1	extracellular signal-regulated kinase:97:0.9352|extracellular signal-regulated kinases:61:0.9229	0.9352	158
ERK1/2	ERK1/2:170|Erk1/2:13|ERK-1/2:6|Erk-1/2:1	extracellular signal-regulated kinase 1/2:144:0.9563|extracellular signal-regulated kinases 1/2:32:0.9072|extracellular signal-regulated kinase-1/2:14:0.6173	0.9563	190
ERK1/2	ERK1/2:94|Erk1/2:4|Erk-1/2:3|ERK-1/-2:1|ERK-1/2:1	extracellular signal-regulated kinases 1 and 2:97:0.9692|extracellular signal-regulated kinase-1 and -2:6:0.5290	0.9692	103
ERK1/2	ERK1/2:25|Erk1/2:1	extracellular signal-regulated kinase1/2:26:0.8251	0.8251	26
ERK1/2	ERK1/2:24|Erk-1/2:1	extracellular signal-regulated protein kinase:15:0.8045|extracellular signal-regulated protein kinases:10:0.7357	0.8045	25
ERK1/2	ERK1/2:14	Mitogen-activated protein kinase:14:0.2010	0.2010	14
ERK1	ERK1:43|Erk1:3	extracellular signal-regulated kinase 1:46:0.8401	0.8401	46
ERK2	ERK2:15|Erk2:1	extracellular signal-regulated kinase:16:0.8165	0.8165	16
ERK2	ERK2:80|ERK-2:8|Erk2:5|Erk-2:3	extracellular signal-regulated kinase 2:85:0.8807|extracellular signal-regulated kinase-2:11:0.7357	0.8807	96
ERK2	ERK2:20|ERK-2:1	extracellular signal-regulated protein kinase 2:21:0.8594	0.8594	21
ERK2	ERK2:6|ERK-2:1	mitogen-activated protein kinase:7:0.2113	0.2113	7
ERK5	ERK5:14|Erk5:1	extracellular signal-regulated kinase 5:15:0.8045	0.8045	15
ERKs	ERKs:249|Erks:11|erks:2|ErKs:1|ERKS:1	extracellular signal-regulated kinases:264:0.9648	0.9648	264
ERK	ERK:7|Erk:2	extracellular regulated kinases:9:0.2102	0.2102	9
ERK	ERK:11	extracellular regulated protein kinase:11:0.1683	0.1683	11
ERK	ERK:10|Erk:1	extracellular signal-regulated:11:0.7357	0.7357	11
ERK	ERK:1690|Erk:89|erk:3	extracellular signal-regulated kinase:1672:0.8804|Extracellular signal-regulated kinases:110:0.9298	0.9298	1782
ERK	ERK:246|Erk:7	extracellular signal-regulated protein kinase:224:0.8651|Extracellular signal-regulated protein kinases:20:0.8525|extracellular signal regulated protein kinase:9:0.5000	0.8651	253
ERMBT	ERMBT:14	erythromycin breath test:14:0.5111	0.5111	14
ERMS	ERMS:6|eRMS:3|E-RMS:1	embryonal rhabdomyosarcoma:10:0.5856	0.5856	10
ERMs	ERMs:25	epiretinal membranes:25:0.8816	0.8816	25
ERM	ERM:63	epiretinal membrane:41:0.8867|epiretinal membranes:22:0.7955	0.8867	63
ERM	ERM:10	epithelial rests of Malassez:10:0.5000	0.5000	10
ERM	ERM:81	ezrin/radixin/moesin:43:0.1571|ezrin-radixin-moesin:38:0.1341	0.1571	81
ERNA	ERNA:13	Equilibrium radionuclide angiocardiography:13:0.7753	0.7753	13
ERNA	ERNA:24	equilibrium radionuclide angiography:24:0.7151	0.7151	24
EROD	EROD:5	7-ethoxyresorufin O-dealkylation:5:0.1132	0.1132	5
EROD	EROD:233	7-ethoxyresorufin O-deethylase:137:0.3045|7-ethoxyresorufin-O-deethylase:96:0.1003	0.3045	233
EROD	EROD:23	7-ethoxyresorufin O-deethylation:23:0.2422	0.2422	23
EROD	EROD:9	deethylation:9:0.0084	0.0084	9
EROD	EROD:13	ethoxyresorufin:13:0.0127	0.0127	13
EROD	EROD:8	ethoxyresorufin deethylase:8:0.2619	0.2619	8
EROD	EROD:30	Ethoxyresorufin O-dealkylase:19:0.7044|ethoxyresorufin-O-dealkylase:11:0.0106	0.7044	30
EROD	EROD:438	ethoxyresorufin O-deethylase:236:0.5580|ethoxyresorufin-O-deethylase:202:0.2112	0.5580	438
EROD	EROD:36	Ethoxyresorufin O-deethylation:36:0.4560	0.4560	36
EROD	EROD:8	O-deethylase activity:8:0.1367	0.1367	8
EROS	EROS:9	event-related optical signal:9:0.6794	0.6794	9
ErPC	ErPC:11	erucylphosphocholine:11:0.3846	0.3846	11
ERPT	ERPT:16	endorectal pull-through:16:0.8165	0.8165	16
ERPs	ERPs:46	effective refractory periods:46:0.8986	0.8986	46
ERPs	ERPs:1412|ERPS:4	Event-related potentials:1416:0.6868	0.6868	1416
ERP	ERP:13	effective:13:0.0057	0.0057	13
ERP	ERP:538	effective refractory period:501:0.9758|effective refractory periods:37:0.9197	0.9758	538
ERP	ERP:6	eledoisin-related peptide:6:0.1148	0.1148	6
ERP	ERP:7	endoscopic retrograde pancreaticography:7:0.5926	0.5926	7
ERP	ERP:123	endoscopic retrograde pancreatography:123:0.9612	0.9612	123
ERP	ERP:5	enzyme-releasing peptide:5:0.0517	0.0517	5
ERP	ERP:24	estrogen receptor protein:24:0.8768	0.8768	24
ERP	ERP:238	event-related brain potential:206:0.9367|event-related brain potentials:32:0.7782	0.9367	238
ERP	ERP:905	event-related potential:649:0.6385|event-related potentials:213:0.6565|Event Related Potentials:43:0.8590	0.8590	905
ERP	ERP:4	exposure and response prevention:4:0.4438	0.4438	4
ERR	ERR:24	excess relative risk:24:0.7593	0.7593	24
ERSE	ERSE:6	ER stress response element:6:0.3728	0.3728	6
ERSNA	ERSNA:10	Efferent renal sympathetic nerve activity:10:0.7103	0.7103	10
ERSPC	ERSPC:21	European Randomized Study of Screening for Prostate Cancer:21:0.8657	0.8657	21
ERs	ERs:8|ers:1	Enantiomeric ratios:9:0.0932	0.0932	9
ERs	ERs:16	enhancement ratios:16:0.2812	0.2812	16
ERs	ERs:368|Ers:1	estrogen receptors:369:0.8701	0.8701	369
ERS	ERS:38	event-related synchronization:38:0.4933	0.4933	38
Ers	Ers:10	Respiratory system elastance:10:0.7103	0.7103	10
ERT	ERT:11	emergency room thoracotomy:11:0.7357	0.7357	11
ERT	ERT:437	estrogen replacement therapy:437:0.7317	0.7317	437
ERT	ERT:15	external beam radiotherapy:15:0.8045	0.8045	15
ERT	ERT:5	external irradiation:5:0.1132	0.1132	5
ERT	ERT:17|eRT:2	external radiotherapy:19:0.3019	0.3019	19
ERU	ERU:17	Equine recurrent uveitis:17:0.7407	0.7407	17
ERUS	ERUS:10	endorectal ultrasound:10:0.7103	0.7103	10
ERV	ERV:65	expiratory reserve volume:65:0.9047	0.9047	65
ERVs	ERVs:18	endogenous retroviruses:18:0.8365	0.8365	18
ERAV	ERAV:9	Equine rhinitis A virus:9:0.6794	0.6794	9
ERbeta	ERbeta:8|ER-beta:6	estrogen receptor:14:0.5818	0.5818	14
ERbeta	ERbeta:178|ER-beta:38	estrogen receptor beta:151:0.8320|estrogen receptor-beta:65:0.9061	0.9061	216
ER-IR	ER-IR:5|ERIR:1	estrogen receptor immunoreactivity:6:0.5290	0.5290	6
ER-IR	ER-IR:5|ERIR:3|ERir:2	immunoreactive:10:0.2045	0.2045	10
ERN	ERN:51	error-related negativity:51:0.8799	0.8799	51
ERn	ERn:7|ERN:2	nuclear ER:9:0.5470	0.5470	9
ERn	ERn:14|ERN:10	nuclear estrogen receptors:14:0.6911|nuclear estrogen receptor:10:0.5856	0.6911	24
ER	ER:15	early:15:0.0012	0.0012	15
ER	ER:8	early response:8:0.0672	0.0672	8
ER	ER:7	electrical resistance:7:0.1641	0.1641	7
ER	ER:14	electrorheological:14:0.0011	0.0011	14
ER	ER:316	Emergency Room:316:0.9704	0.9704	316
ER	ER:11	endoplasmic reticular:11:0.7357	0.7357	11
ER	ER:4567|er:1	endoplasmic reticulum:4568:0.9859	0.9859	4568
ER	ER:10	endoscopic resection:10:0.2873	0.2873	10
ER	ER:6	endovascular repair:6:0.1148	0.1148	6
ER	ER:10	energy-restricted:10:0.0007	0.0007	10
ER	ER:34	energy restriction:34:0.8644	0.8644	34
ER	ER:9	energy retention:9:0.5470	0.5470	9
ER	ER:12	enhanced reactivation:12:0.4557	0.4557	12
ER	ER:56	enhancement ratio:40:0.2957|enhancement ratios:16:0.3643	0.3643	56
Er	Er:15|ER:8	erythromycin:23:0.0018	0.0018	23
ER	ER:25|E-R:1	Estradiol:26:0.0021	0.0021	26
ER	ER:429	estrogen:429:0.0352	0.0352	429
ER	ER:4440|Er:5	estrogen receptor:3731:0.8299|Estrogen receptors:659:0.7979|estrogen-receptor:55:0.0044	0.8299	4445
ER	ER:85	Estrogen receptor alpha:60:0.8971|estrogen receptor-alpha:25:0.7249	0.8971	85
ER	ER:5	estrogen receptor protein:5:0.1973	0.1973	5
ER	ER:8	estrogen receptor status:8:0.2327	0.2327	8
ER	ER:9	ethoxyresorufin:9:0.0007	0.0007	9
ER	ER:24	evoked response:17:0.2994|evoked responses:7:0.2902	0.2994	24
ER	ER:161	extended-release:93:0.0076|extended release:68:0.8706	0.8706	161
ER	ER:15	external rotation:15:0.7096	0.7096	15
ER	ER:27	extraction ratio:27:0.1742	0.1742	27
ER	ER:107	oestrogen:107:0.0087	0.0087	107
ER	ER:94	oestrogen receptors:94:0.0937	0.0937	94
ER	ER:6	oestrogen receptor status:6:0.1010	0.1010	6
Er	Er:6|ER:5	rabbit erythrocytes:11:0.2280	0.2280	11
ER	ER:1	Receptors of estrogens:1:0.2452	0.2452	1
Er	Er:16|ER:3	reversal potential:19:0.4852	0.4852	19
ES/PNET	ES/PNET:10	sarcoma/primitive neuroectodermal tumor:10:0.5000	0.5000	10
ES-1	ES-1:11|Es-1:3	esterase-1:14:0.2826	0.2826	14
ES2	ES2:9	exteroceptive suppression period:9:0.5470	0.5470	9
ESACs	ESACs:10	Extra structurally abnormal chromosomes:10:0.6794	0.6794	10
ESAT-6	ESAT-6:6	early secretory antigenic target:6:0.5290	0.5290	6
ESAS	ESAS:10	Edmonton Symptom Assessment Scale:10:0.7103	0.7103	10
ESAS	ESAS:14	Edmonton Symptom Assessment System:14:0.7753	0.7753	14
ESA	ESA:15	Activity:15:0.0588	0.0588	15
ESA	ESA:22	antigens:22:0.0882	0.0882	22
ESA	ESA:4	endocardial surface area:4:0.0918	0.0918	4
ESA	ESA:5	epidermal surface antigen:5:0.1973	0.1973	5
ESA	ESA:7	ethanesulfonic acid:7:0.3524	0.3524	7
ESA	ESA:27	European Space Agency:27:0.8903	0.8903	27
ESA	ESA:5	excited state absorption:5:0.4422	0.4422	5
ESBL	ESBL:231	extended-spectrum beta-lactamase:144:0.7332|extended-spectrum beta-lactamases:37:0.4933|Extended Spectrum Beta-Lactamase:33:0.8605|extended spectrum beta-lactamases:17:0.6903	0.8605	231
ESBL-KP	ESBL-KP:2|ESBL-Kp:2	beta-lactamase producing Klebsiella pneumoniae:4:0.0918	0.0918	4
ESBL-KP	ESBL-KP:5|ESBLKp:1|ESBL-Kp:1	extended-spectrum beta-lactamase-producing Klebsiella pneumoniae:7:0.4438	0.4438	7
ESBLs	ESBLs:178	Extended-spectrum beta-lactamases:178:0.8349	0.8349	178
ESBM	ESBM:8	soybean meal:8:0.5006	0.5006	8
ESB	ESB:7	electrical stimulation of the brain:7:0.4438	0.4438	7
ESCA	ESCA:122	electron spectroscopy for chemical analysis:122:0.9370	0.9370	122
ESCAP	ESCAP:1	Economic and Social Commission for the Asia and Pacific:1:0.9404	0.9404	1
ESCCs	ESCCs:17	esophageal squamous cell carcinomas:17:0.8270	0.8270	17
ESCC	ESCC:220	esophageal squamous cell carcinoma:206:0.9083|esophageal squamous cell carcinomas:14:0.6173	0.9083	220
ESCP	ESCP:9	evoked spinal cord potential:9:0.6794	0.6794	9
ESCPs	ESCPs:16	Evoked spinal cord potentials:16:0.8165	0.8165	16
ESCs	ESCs:34	embryonic stem cells:34:0.7306	0.7306	34
ESCs	ESCs:11	endometrial stromal cells:11:0.4728	0.4728	11
ESCS	ESCS:11	enhanced S-cone syndrome:6:0.5290|enhanced S cone syndrome:5:0.4422	0.5290	11
ESCs	ESCs:9	esophageal squamous cell carcinomas:9:0.5470	0.5470	9
ESC	ESC:35	embryonic stem cells:26:0.6645|embryonic stem cell:9:0.6794	0.6794	35
ESC	ESC:50	endometrial stromal cells:50:0.7866	0.7866	50
ESC	ESC:7	enteric septicemia of catfish:7:0.5926	0.5926	7
ESC	ESC:11	environmental stress cracking:11:0.7357	0.7357	11
ESC	ESC:15	Esophageal squamous cell carcinoma:15:0.8045	0.8045	15
ESC	ESC:27	European Society of Cardiology:27:0.8312	0.8312	27
esc	esc:17|ESC:4|Esc:1	extra sex combs:22:0.8657	0.8657	22
ESEEM	ESEEM:97|eseem:1	electron spin echo envelope modulation:59:0.9494|electron spin-echo envelope modulation:39:0.9237	0.9494	98
ESEMeD	ESEMeD:1	European Study of Epidemiology on Mental Disorders:1:0.7753	0.7753	1
ESEM	ESEM:29	environmental scanning electron microscope:29:0.8978	0.8978	29
ESEM	ESEM:54	environmental scanning electron microscopy:54:0.9116	0.9116	54
ESES	ESES:7	Electrical status epilepticus during sleep:7:0.6460	0.6460	7
ESES	ESES:7	epidural spinal electrical stimulation:7:0.5926	0.5926	7
ESEs	ESEs:22	exonic splicing enhancers:22:0.8657	0.8657	22
ESE	ESE:34	exonic splicing enhancer:34:0.6015	0.6015	34
ESFA	ESFA:15	eccrine syringofibroadenoma:15:0.8045	0.8045	15
ESFT	ESFT:7	sarcoma family tumors:7:0.7525	0.7525	7
ESF	ESF:7	erythropoiesis stimulating factor(s):7:0.5926	0.5926	7
ESF	ESF:55|esf:1	erythropoietin:56:0.3481	0.3481	56
ESF	ESF:11	external skeletal fixator:11:0.7357	0.7357	11
ESG	ESG:8	eggshell gland:8:0.3463	0.3463	8
ESH	ESH:8	European Society of Hypertension:8:0.6794	0.6794	8
ESI/MS	ESI/MS:26	Electrospray ionization mass spectrometry:26:0.8861	0.8861	26
ESI-MS	ESI-MS:5|ESIMS:1	Electrospray ionization mass spectrometric:6:0.3728	0.3728	6
ESI-MS	ESI-MS:414|ESIMS:29|ESI--MS:1	electrospray ionization mass spectrometry:444:0.9558	0.9558	444
ESI-MS	ESI-MS:11	electrospray ionization mass spectroscopy:11:0.7357	0.7357	11
ESIN	ESIN:16	Elastic Stable Intramedullary Nailing:16:0.8165	0.8165	16
ESIPT	ESIPT:8	excited state intramolecular proton transfer:8:0.6411	0.6411	8
ESI	ESI:77	electron spectroscopic imaging:77:0.8848	0.8848	77
ESI	ESI:49	electrospray:49:0.0486	0.0486	49
ESI	ESI:75	electrospray ionisation:75:0.9169	0.9169	75
ESI	ESI:579	electrospray ionization:579:0.9387	0.9387	579
ESI	ESI:7	Emergency Severity Index:7:0.3524	0.3524	7
ESI	ESI:34	exit-site infection:21:0.6040|Exit-site infections:13:0.5335	0.6040	34
ESKD	ESKD:9	end-stage kidney disease:9:0.5470	0.5470	9
ESLD	ESLD:58	end-stage liver disease:58:0.8126	0.8126	58
ESL	ESL:18	English as a second language:18:0.8594	0.8594	18
ESMO	ESMO:3	European Society for Medical Oncology:3:0.6794	0.6794	3
ES-MS	ES-MS:52|ESMS:49	electrospray mass spectrometry:101:0.6891	0.6891	101
ESM	ESM:55	ethosuximide:55:0.4000	0.4000	55
ESM	ESM:17	Experience Sampling Method:17:0.7407	0.7407	17
ESN	ESN:7	exposed seronegative:7:0.3455	0.3455	7
E-SOD	E-SOD:8|ESOD:2|eSOD:2|e-SOD:1	Erythrocyte superoxide dismutase:13:0.4102	0.4102	13
ESPDR	ESPDR:7	end-systolic pressure-diameter relationship:7:0.5926	0.5926	7
ESPGAN	ESPGAN:5	European Society for Pediatric Gastroenterology and Nutrition:5:0.6411	0.6411	5
ESPI	ESPI:12	Electronic speckle pattern interferometry:12:0.6460	0.6460	12
ESPRIT	ESPRIT:12	Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy:12:0.7753	0.7753	12
ESPVR	ESPVR:50|ES-PVR:1	End-systolic pressure-volume relation:42:0.8893|end-systolic pressure-volume relations:9:0.5470	0.8893	51
ESPVR	ESPVR:41	end-systolic pressure-volume relationship:41:0.7952	0.7952	41
ESP	ESP:12	electrostatic potential:12:0.1423	0.1423	12
ESP	ESP:17	electrostatic precipitator:17:0.7407	0.7407	17
ESP	ESP:14	end-systolic pressure:14:0.5111	0.5111	14
Esp	Esp:6|esp:2	enterococcal surface protein:8:0.3463	0.3463	8
ESP	ESP:11	eosinophil stimulation promoter:11:0.7357	0.7357	11
ESP	ESP:9	European Spine Phantom:9:0.5470	0.5470	9
ESP	ESP:42	excretory-secretory products:18:0.2956|excretory-secretory product:16:0.6577|excretory/secretory products:8:0.0604	0.6577	42
ESP	ESP:9	extrasensory perception:9:0.3455	0.3455	9
ESP	ESP:9	proteins:9:0.0254	0.0254	9
ESR1	ESR1:18	estrogen receptor alpha:18:0.7539	0.7539	18
ESR2	ESR2:7|Esr2:1	estrogen receptor beta:8:0.4102	0.4102	8
ESRD	ESRD:2785|ES-RD:2|esrd:1	end-stage renal disease:2777:0.8595|end-stage renal diseases:11:0.5355	0.8595	2788
ESRD	ESRD:22	end-stage renal failure:22:0.5327	0.5327	22
ESRD	ESRD:9	renal disease patients:9:0.6794	0.6794	9
ESRF	ESRF:296	end-stage renal failure:248:0.7593|end stage renal failure:48:0.9392	0.9392	296
ESRS	ESRS:29	Extrapyramidal Symptom Rating Scale:29:0.8369	0.8369	29
ESR	ESR:1419|esr:11	electron spin resonance:1430:0.9869	0.9869	1430
ESR	ESR:54	electron spin resonance spectroscopy:54:0.9448	0.9448	54
ESR	ESR:1350	erythrocyte sedimentation rate:1315:0.9714|erythrocyte sedimentation rates:35:0.9151	0.9714	1350
ESR	ESR:20	estrogen receptor:20:0.5892	0.5892	20
ESSG	ESSG:19	European Spondylarthropathy Study Group:19:0.8449	0.8449	19
ESs	ESs:12	effect sizes:12:0.5664	0.5664	12
ESS	ESS:24	empty sella syndrome:24:0.8768	0.8768	24
ESS	ESS:16	end-systolic stress:16:0.1928	0.1928	16
ESS	ESS:13	end-systolic wall stress:13:0.3809	0.3809	13
ESS	ESS:69|Ess:1	endometrial stromal sarcoma:56:0.8901|endometrial stromal sarcomas:14:0.6911	0.8901	70
ESS	ESS:118	endoscopic sinus surgery:118:0.9237	0.9237	118
ESS	ESS:176	Epworth Sleepiness Scale:176:0.9728	0.9728	176
ESS	ESS:12	Epworth Sleepiness Score:12:0.7571	0.7571	12
ESS	ESS:10	euthyroid sick syndrome:10:0.7103	0.7103	10
ESS	ESS:48	evolutionarily stable strategy:38:0.6874|Evolutionarily Stable Strategies:10:0.4363	0.6874	48
ESs	ESs:13	expression sites:13:0.2415	0.2415	13
ESS	ESS:11	splicing silencer:11:0.5355	0.5355	11
ESTs	ESTs:10	empirically supported treatments:10:0.7103	0.7103	10
ESTs	ESTs:914|ests:1	expressed sequence tags:915:0.9473	0.9473	915
EST	EST:7	electroshock seizure threshold:7:0.5926	0.5926	7
EST	EST:6	electroshock treatment:6:0.1320	0.1320	6
EST	EST:12	embryonic stem cell test:12:0.7357	0.7357	12
EST	EST:66	endodermal sinus tumor:53:0.9438|endodermal sinus tumors:13:0.7753	0.9438	66
EST	EST:18	endoscopic sclerotherapy:18:0.5560	0.5560	18
EST	EST:117	Endoscopic Sphincterotomy:117:0.9005	0.9005	117
eST	eST:10|est:2	equine somatotropin:12:0.7571	0.7571	12
EST	EST:15|est:3	esterase:18:0.0133	0.0133	18
est	est:6|EST:5	estradiol:11:0.0078	0.0078	11
EST	EST:45	Estrogen sulfotransferase:45:0.8649	0.8649	45
EST	EST:16	Exercise Stress Test:16:0.4536	0.4536	16
EST	EST:15	exercise stress testing:15:0.6386	0.6386	15
EST	EST:566	expressed sequence tag:566:0.9763	0.9763	566
EST	EST:82	expressed sequence tags:82:0.8914	0.8914	82
ESVEM	ESVEM:27	Electrophysiologic Study Versus Electrocardiographic Monitoring:27:0.7425	0.7425	27
ESWA	ESWA:10	application:10:0.9000	0.9000	10
ESWL	ESWL:1040	extracorporeal shock wave lithotripsy:819:0.9326|extracorporeal shock-wave lithotripsy:221:0.9095	0.9326	1040
ESWL	ESWL:154	extracorporeal shockwave lithotripsy:154:0.9085	0.9085	154
ESWS	ESWS:25|ES-WS:1	end-systolic wall stress:26:0.6084	0.6084	26
ESWT	ESWT:55	extracorporeal shock wave therapy:55:0.7690	0.7690	55
ESWT	ESWT:7	extracorporeal shock wave treatment:7:0.4438	0.4438	7
ESWT	ESWT:24	Extracorporeal shockwave therapy:24:0.7593	0.7593	24
ES	ES:13	ectoplasmic specialization:13:0.7753	0.7753	13
ES	ES:108	effect size:75:0.9370|effect sizes:33:0.8605	0.9370	108
Es	Es:9|ES:1	ego strength:10:0.7103	0.7103	10
ES	ES:244	electrical stimulation:244:0.8343	0.8343	244
ES	ES:8	electrically stimulated:8:0.5006	0.5006	8
ES	ES:59	electrospray:59:0.0122	0.0122	59
ES	ES:24	electrostimulation:24:0.0049	0.0049	24
ES	ES:12	embolic signals:12:0.7571	0.7571	12
ES	ES:1782	Embryonic stem:1782:0.9663	0.9663	1782
ES	ES:15	embryonic stem cells:15:0.6386	0.6386	15
ES	ES:15	emotional stress:15:0.5818	0.5818	15
ES	ES:119	endolymphatic sac:119:0.9131	0.9131	119
ES	ES:10	endometrial stromal:10:0.7103	0.7103	10
ES	ES:19	endoscopic sclerotherapy:19:0.6537	0.6537	19
ES	ES:193	endoscopic sphincterotomy:193:0.9323	0.9323	193
ES	ES:18	endosonography:18:0.0036	0.0036	18
ES	ES:17	endostatin:17:0.0034	0.0034	17
ES	ES:9	endotoxic shock:9:0.1267	0.1267	9
ES	ES:7	Endotoxin shock:7:0.0655	0.0655	7
ES	ES:9	engraftment syndrome:9:0.0758	0.0758	9
ES	ES:20	enzyme estrone sulfatase:20:0.5568	0.5568	20
ES	ES:13|E-S:3	enzyme-substrate:16:0.0032	0.0032	16
ES	ES:10	enzyme-substrate complex:10:0.3470	0.3470	10
ES	ES:6	Epilepsy Surgery:6:0.1010	0.1010	6
ES	ES:25	epileptic seizures:25:0.7249	0.7249	25
ES	ES:23	epithelioid sarcoma:23:0.0679	0.0679	23
E-S	E-S:12	EPSP-spike:12:0.0023	0.0023	12
ES	ES:37|Es:1	erector spinae:38:0.9217	0.9217	38
ES	ES:11	erythromycin stearate:11:0.6182	0.6182	11
ES	Es:6|ES:6	esterase:12:0.0023	0.0023	12
Es	Es:8|ES:1	estrogens:9:0.0017	0.0017	9
ES	ES:14	estrone sulfate:14:0.4709	0.4709	14
ES	ES:168|Es:3	Ewing's sarcoma:133:0.6135|Ewing sarcoma:29:0.0939|Ewing's sarcomas:9:0.3069	0.6135	171
ES	ES:17	exanthem subitum:17:0.6748	0.6748	17
ES	ES:9|E-S:2	excretory and secretory:11:0.6812	0.6812	11
ES	ES:234|E-S:26	Excretory-secretory:173:0.0363|excretory/secretory:87:0.0184	0.0363	260
ES	ES:28|E-S:3	excretory-secretory products:17:0.2887|excretory/secretory products:14:0.2081	0.2887	31
ES	ES:9	exfoliation syndrome:9:0.0758	0.0758	9
ES	ES:30	expert system:21:0.6400|expert systems:9:0.6794	0.6794	30
ES	ES:14	expression site:14:0.4709	0.4709	14
ES	ES:15	extent score:15:0.2430	0.2430	15
es	es:7|ES:2	external sensory:9:0.6794	0.6794	9
ES	ES:7	extracellular space:7:0.2902	0.2902	7
es	es:7	nitrobenzylthioinosine (NBMPR)-sensitive:7:0.2452	0.2452	7
Es	Es:7|ES:3	sheep erythrocytes:10:0.5856	0.5856	10
ES	ES:9|Es:1	surface:10:0.0019	0.0019	10
ES	ES:6	sweetened ethanol solution:6:0.2827	0.2827	6
ET(A)	ET(A):44	endothelin-A:33:0.3765|endothelin-A-:11:0.1176	0.3765	44
ET(A)	ET(A):20	receptor:20:0.2235	0.2235	20
ET(B)	ET(B):32	endothelin B:18:0.2687|endothelin-B:14:0.1667	0.2687	32
ET(B)R	ET(B)R:7|ET(B)-R:2	endothelin B receptor:9:0.4587	0.4587	9
ET-1-LI	ET-1-LI:26	immunoreactivity:26:0.8621	0.8621	26
ET-LI	ET-LI:19	immunoreactivity:19:0.9474	0.9474	19
ET-3	ET3:13|ET-3:13|Et3:1	Endothelin 3:27:0.8312	0.8312	27
ET-743	ET-743:50|Et743:3|ET743:2|Et-743:1	Ecteinascidin-743:32:0.4366|ecteinascidin 743:24:0.8768	0.8768	56
ETAAS	ETAAS:5|ET-AAS:4	atomic absorption spectrophotometry:9:0.6794	0.6794	9
ETAAS	ETAAS:53|ET-AAS:7	electrothermal atomic absorption spectrometry:60:0.8042	0.8042	60
ETAF	ETAF:16	Epidermal cell-derived thymocyte activating factor:16:0.8165	0.8165	16
ETAR	ETAR:12	Endoscopic transanal resection:12:0.7571	0.7571	12
ETA	ETA:8	5,8,11,14-eicosatetraynoic acid:8:0.0825	0.0825	8
eta	eta:13	efficiency:13:0.0261	0.0261	13
ETA	ETA:8|ET-A:1	endothelin:9:0.0174	0.0174	9
ETA	ETA:32|ET-A:10|ETa:1	endothelin-A:43:0.0915	0.0915	43
ETA	ETA:6	endothelin receptor:6:0.3643	0.3643	6
ETA	ETA:13|Eta:1	etanidazole:14:0.0283	0.0283	14
ETA	ETA:10	ethionamide:10:0.0196	0.0196	10
ETA	ETA:13	European Thyroid Association:13:0.7753	0.7753	13
ETA	ETA:6	extrathoracic airway:6:0.1543	0.1543	6
eta	eta:13	microviscosity:13:0.0261	0.0261	13
eta	eta:36|ETA:2	viscosity:38:0.0806	0.0806	38
ETBF	ETBF:1	enterotoxigenic B fragilis:1:0.2500	0.2500	1
ETBF	ETBF:18	Enterotoxigenic Bacteroides fragilis:18:0.5228	0.5228	18
ETB	ETB:22|ET-B:7	endothelin-B:29:0.1421	0.1421	29
ETB	ETB:8|ET-B:1	endothelin B receptor:9:0.4587	0.4587	9
ETB	ETB:10|ET-B:1|ETb:1	endothelin type B:12:0.2183	0.2183	12
ETCO(2)	ETCO(2):12|EtCO(2):4|ETco(2):1|ET-CO(2):1	end-tidal carbon dioxide:18:0.5560	0.5560	18
ETCO2	ETCO2:5|EtCO2:1	carbon dioxide concentration:6:0.5290	0.5290	6
ETCO2	ETCO2:49|EtCO2:9|ET-CO2:3|Etco2:2	end-tidal carbon dioxide:63:0.7656	0.7656	63
ETCO2	ETCO2:7|EtCO2:1	end-tidal carbon dioxide tension:8:0.6411	0.6411	8
ETCO2	ETCO2:12	end-tidal CO2 concentration:12:0.6460	0.6460	12
ETC	ETC:76	electron transport chain:76:0.9607	0.9607	76
ETC	ETC:13	Esophageal tracheal combitube:13:0.7753	0.7753	13
ETDRS	ETDRS:79	Early Treatment Diabetic Retinopathy Study:79:0.9675	0.9675	79
ETDT	ETDT:13|e-TDT:1	extended transmission disequilibrium test:14:0.7909	0.7909	14
ETD	ETD:9	eye tracking dysfunction:9:0.6794	0.6794	9
ETEC	ETEC:12	Enterotoxigenic E coli:12:0.8544	0.8544	12
ETEC	ETEC:500	enterotoxigenic Escherichia coli:500:0.9358	0.9358	500
ETF	ETF:39	electron transfer flavoprotein:39:0.8811	0.8811	39
ETF	ETF:26	electron-transferring flavoprotein:26:0.1928	0.1928	26
ETF	ETF:8	enteral tube feeding:8:0.6794	0.6794	8
EtG	EtG:23	ethyl glucuronide:23:0.8038	0.8038	23
ETH	ETH:11	ecdysis-triggering hormone:11:0.6182	0.6182	11
ETH	ETH:19|Eth:1	ethionamide:20:0.1496	0.1496	20
ETI	ETI:10	5,8,11-eicosatriynoic acid:10:0.2446	0.2446	10
ETI	ETI:9	early transient incapacitation:9:0.6794	0.6794	9
ETI	ETI:53	endotracheal intubation:53:0.8842	0.8842	53
ETI	ETI:9	trypsin inhibitor:9:0.5470	0.5470	9
ETKA	ETKA:13|E-TKA:1	Erythrocyte transketolase activity:14:0.6911	0.6911	14
ETK	ETK:11	erythrocyte transketolase:11:0.6182	0.6182	11
ETL	ETL:14	echo train length:14:0.7909	0.7909	14
ETL	ETL:7	enteropathy-type T-cell lymphoma:7:0.5926	0.5926	7
ETM	ETM:10	elevated T-maze:10:0.7103	0.7103	10
ETn	ETn:13	Early transposon:13:0.6701	0.6701	13
Etn	Etn:20|EtN:1	ethanolamine:21:0.3175	0.3175	21
EtO	EtO:107|ETO:56|Eto:2	Ethylene oxide:165:0.9710	0.9710	165
ETO	ETO:19|Eto:7	Etoposide:26:0.0923	0.0923	26
ETO	ETO:13	eustachian tube obstruction:13:0.6701	0.6701	13
ETP	ETP:11	electron transport particles:11:0.7357	0.7357	11
ETP	ETP:36	endogenous thrombin potential:36:0.8716	0.8716	36
ETP	ETP:31	etoposide:31:0.2041	0.2041	31
ETR	ETR:15	effective thyroxine ratio:15:0.7096	0.7096	15
ETR	ETR:6	electron transport rate:6:0.5290	0.5290	6
ETR	ETR:12	end-of-treatment response:12:0.2699	0.2699	12
ET-R	ET-R:6|ETR:5	receptor:11:0.0813	0.0813	11
ETSHR	ETSHR:2|ETSHr:2	extracellular domain of human TSHR:4:0.5926	0.5926	4
ETTH	ETTH:13	episodic tension-type headache:13:0.7753	0.7753	13
ETTs	ETTs:21	endotracheal tubes:21:0.8594	0.8594	21
ETT	ETT:245	Endotracheal tube:230:0.9375|endotracheal tubes:15:0.8045	0.9375	245
ETT	ETT:12	epithelioid trophoblastic tumor:12:0.5664	0.5664	12
ETT	ETT:6	esophageal transit time:6:0.3728	0.3728	6
ETT	ETT:23	exercise tolerance test:23:0.7500	0.7500	23
ETT	ETT:6	exercise tolerance time:6:0.5290	0.5290	6
ETT	ETT:24	exercise treadmill test:24:0.7151	0.7151	24
ETT	ETT:20	exercise treadmill testing:20:0.6680	0.6680	20
ETU	ETU:11	erythron transferrin uptake:11:0.7357	0.7357	11
ETU	ETU:24	ethylene thiourea:24:0.8768	0.8768	24
ETU	ETU:110	ethylenethiourea:110:0.6606	0.6606	110
ETV	ETV:69	Endoscopic third ventriculostomy:69:0.9316	0.9316	69
ETV	ETV:9	extravascular thermal volume:9:0.6794	0.6794	9
ETX	ETX:51|Etx:6|etx:1	endotoxin:58:0.5135	0.5135	58
ETX	ETX:12	Ethanol withdrawal:12:0.7571	0.7571	12
ET	ET:86	ejection time:86:0.6441	0.6441	86
ET	ET:203|et:9|eT:1	electron transfer:184:0.3209|Electron-transfer:29:0.0057	0.3209	213
ET	ET:22	electrophoretic type:14:0.4709|electrophoretic types:8:0.5006	0.5006	22
ET	ET:8	embryo transfers:8:0.3463	0.3463	8
ET	ET:21|et:1|Et:1	End-tidal:23:0.0045	0.0045	23
ET	ET:11	endometrial thickness:11:0.3829	0.3829	11
ET	ET:1666|Et:12	endothelin:1591:0.3211|endothelins:87:0.0174	0.3211	1678
ET	ET:118|Et:3	endothelin-1:121:0.0241	0.0241	121
ET	ET:9	endotoxins:9:0.0016	0.0016	9
ET	ET:67	endotracheal:67:0.0134	0.0134	67
ET	ET:27|E-T:1	endotracheal tube:28:0.0946	0.0946	28
ET	ET:36	endurance-trained:26:0.0051|endurance trained:10:0.1878	0.1878	36
ET	ET:11	endurance training:11:0.0655	0.0655	11
ET	ET:9	epitestosterone:9:0.0016	0.0016	9
ET	ET:15	Escherichia coli endotoxin:15:0.4052	0.4052	15
ET	ET:14	esotropia:14:0.0026	0.0026	14
ET	ET:141	essential thrombocythaemia:141:0.9788	0.9788	141
ET	ET:363	essential thrombocythemia:363:0.9703	0.9703	363
ET	ET:32	Essential thrombocytosis:32:0.9072	0.9072	32
ET	ET:251	Essential tremor:251:0.9809	0.9809	251
ET	ET:20	Estrogen therapy:20:0.3492	0.3492	20
ET	ET:29|Et:9	ethanol:38:0.0075	0.0075	38
ET	ET:8|Et:5	etoposide:13:0.0024	0.0024	13
ET	ET:147	eustachian tube:147:0.7338	0.7338	147
ET	ET:9	evapotranspiration:9:0.0016	0.0016	9
ET	ET:10	evolutionary trace:10:0.7103	0.7103	10
ET	ET:19	Ewing tumors:12:0.2699|Ewing tumor:7:0.1025	0.2699	19
ET	ET:33	Exchange transfusion:33:0.8605	0.8605	33
ET	ET:27	exercise test:27:0.4190	0.4190	27
ET	ET:30	exercise testing:30:0.7652	0.7652	30
ET	ET:11	exercise tolerance:11:0.3213	0.3213	11
ET	ET:24	exercise-trained:13:0.0024|exercise trained:11:0.2280	0.2280	24
ET	ET:51	exercise training:51:0.6779	0.6779	51
ET	ET:26	exfoliative toxin:26:0.5218	0.5218	26
ET	ET:20	temperature:20:0.0038	0.0038	20
ET	ET:9	tests:9:0.0016	0.0016	9
ET	ET:10	treatment:10:0.0018	0.0018	10
EUA	EUA:11	examination under anaesthesia:11:0.7357	0.7357	11
EUA	EUA:14	examination under anesthesia:14:0.5111	0.5111	14
EUD	EUD:47	equivalent uniform dose:47:0.8703	0.8703	47
EULAR	EULAR:28	European League Against Rheumatism:28:0.7905	0.7905	28
EUP	EUP:12	pregnancy:12:0.4231	0.4231	12
EUS-FNA	EUS-FNA:12	aspiration biopsy:12:0.6460	0.6460	12
EUS-FNA	EUS-FNA:26	Endoscopic ultrasound-guided fine-needle aspiration:16:0.6748|endoscopic ultrasound-guided fine needle aspiration:10:0.7103	0.7103	26
EUS-FNA	EUS-FNA:12	EUS-guided fine-needle aspiration:12:0.1299	0.1299	12
EUS	EUS:7	Endoscopic sonography:7:0.2902	0.2902	7
EUS	EUS:11	Endoscopic Ultrasonographic:11:0.7357	0.7357	11
EUS	EUS:545	endoscopic ultrasonography:545:0.9407	0.9407	545
EUS	EUS:320	endoscopic ultrasound:320:0.8870	0.8870	320
EUS	EUS:28	endosonography:28:0.0246	0.0246	28
EUS	EUS:18	epizootic ulcerative syndrome:18:0.8165	0.8165	18
EUS	EUS:58	external urethral sphincter:58:0.9486	0.9486	58
EUV	EUV:25	extreme-ultraviolet:14:0.4483|extreme ultraviolet:11:0.6182	0.6182	25
EU	EU:15	ELISA units:15:0.1628	0.1628	15
EU	EU:18	endotoxin units:18:0.1968	0.1968	18
EU	EU:11|Eu:1	European:12:0.0152	0.0152	12
EU	EU:440	European Union:440:0.9787	0.9787	440
Eu	Eu:26|EU:1	europium:27:0.0359	0.0359	27
EU	EU:18	excretory urography:18:0.7539	0.7539	18
EV70	EV70:23|EV-70:5	enterovirus 70:28:0.4418	0.4418	28
EV70	EV70:16|EV-70:1	enterovirus type 70:17:0.7407	0.7407	17
EV71	EV71:75|EV-71:7|Ev71:1	enterovirus 71:83:0.9247	0.9247	83
EVAD	EVAD:6	Penn State Electric Ventricular Assist Device:6:0.5290	0.5290	6
EVAL	EVAL:9	ethylene vinyl alcohol copolymer:9:0.5470	0.5470	9
EVAR	EVAR:30	endovascular abdominal aortic aneurysm repair:30:0.8472	0.8472	30
EVAR	EVAR:73	endovascular aneurysm repair:73:0.4748	0.4748	73
EVAR	EVAR:19	endovascular aortic aneurysm repair:19:0.2242	0.2242	19
EVAc	EVAc:19|EVAC:1	acetate copolymer:20:0.7766	0.7766	20
EVA	EVA:12	enlarged vestibular aqueduct:12:0.5050	0.5050	12
EVA	EVA:15	equine viral arteritis:15:0.8045	0.8045	15
EVA	EVA:57	ethylene vinyl acetate:40:0.7201|ethylene-vinyl acetate:17:0.1137	0.7201	57
EVA	EVA:6	ethylene vinyl acetate copolymer:6:0.5290	0.5290	6
EVA	EVA:63	extravehicular activity:54:0.7191|extravehicular activities:9:0.5470	0.7191	63
EVBT	EVBT:9	endovascular brachytherapy:9:0.6794	0.6794	9
EVCPP	EVCPP:14	endoventricular circular patch plasty:14:0.7909	0.7909	14
EvC	EvC:6|EVC:5|Evc:1	Ellis-van Creveld:12:0.7571	0.7571	12
EVC	EVC:6|EvC:3	Ellis-van Creveld syndrome:9:0.4587	0.4587	9
EVD	EVD:11	external ventricular drain:11:0.7357	0.7357	11
EVD	EVD:24	external ventricular drainage:24:0.8768	0.8768	24
EVG	EVG:8	endovascular graft:8:0.4102	0.4102	8
EVH	EVH:19	eucapnic voluntary hyperventilation:19:0.8449	0.8449	19
EVLW	EVLW:246	Extravascular lung water:246:0.9464	0.9464	246
EVLW	EVLW:9	extravascular lung water volume:9:0.6794	0.6794	9
EVLWI	EVLWI:16|EVLWi:2	extravascular lung water index:18:0.6903	0.6903	18
EVL	EVL:70	Endoscopic variceal ligation:70:0.8266	0.8266	70
EVL	EVL:12	enveloping layer:12:0.6460	0.6460	12
EVOO	EVOO:10	extra virgin olive oil:10:0.7103	0.7103	10
EVP	EVP:10	episcleral venous pressure:10:0.7103	0.7103	10
EVR	EVR:6	early virological response:6:0.5290	0.5290	6
EVR	EVR:17|evr:1	endocardial viability ratio:18:0.6903	0.6903	18
EVR	EVR:23	endovascular repair:23:0.7500	0.7500	23
EVS	EVS:11	Endophthalmitis Vitrectomy Study:11:0.7357	0.7357	11
EVS	EVS:28	Endoscopic variceal sclerotherapy:28:0.5837	0.5837	28
EVs	EVs:12	enteroviruses:12:0.0803	0.0803	12
EVTs	EVTs:16	extravillous trophoblasts:16:0.8165	0.8165	16
EVT	EVT:43|EV-T:1	extravillous trophoblast:44:0.8620	0.8620	44
EV	EV:24	ectromelia virus:24:0.3116	0.3116	24
ev	ev:16	endogenous viral:16:0.8165	0.8165	16
ev	ev:6|EV:5	Endogenous virus:11:0.1005	0.1005	11
EV	EV:9	enteroviral:9:0.0142	0.0142	9
EV	EV:73	enterovirus:57:0.0996|enteroviruses:16:0.0267	0.0996	73
EV	EV:105|Ev:2|ev:1	epidermodysplasia verruciformis:108:0.9723	0.9723	108
EV	EV:5	erythrocyte volume:5:0.0522	0.0522	5
EV	EV:24	esophageal varices:24:0.7593	0.7593	24
EV	EV:76	estradiol valerate:76:0.8125	0.8125	76
EWB	EWB:9|EW-B:1	Well-Being:10:0.9000	0.9000	10
EWC	EWC:9	equilibrium water content:9:0.5470	0.5470	9
EWL	EWL:25	excess weight loss:25:0.6539	0.6539	25
EWS	EWS:17	Ewing's sarcoma:17:0.4035	0.4035	17
EW	EW:24|E-W:1	Edinger-Westphal nucleus:25:0.8816	0.8816	25
EW	EW:34	egg weight:34:0.6591	0.6591	34
EW	EW:9	egg white:9:0.4587	0.4587	9
EW	EW:7	emergency ward:7:0.2902	0.2902	7
EW	EW:9	ethanol withdrawal:9:0.5470	0.5470	9
EW	EW:21	extended wear:21:0.7865	0.7865	21
EW	EW:23	external work:23:0.5997	0.5997	23
EW	EW:7	nucleus of Edinger-Westphal:7:0.0906	0.0906	7
Ex-4	Ex-4:13|EX4:3|Ex4:1|EX-4:1	exendin-4:18:0.8095	0.8095	18
EXAFS	EXAFS:186|EX-AFS:2	extended X-ray absorption fine structure:188:0.9583	0.9583	188
EXAFS	EXAFS:14	extended X-ray absorption fine structure spectroscopy:14:0.7909	0.7909	14
EXIT25	EXIT25:10	Executive Interview:10:0.7103	0.7103	10
EXS	EXS:9	Exfoliation syndrome:9:0.5470	0.5470	9
EX	EX:69|ex:46|Ex:3|-EX:1	exercise:119:0.3063	0.3063	119
ex	ex:8|EX:5|Ex:1	exercise training:14:0.7909	0.7909	14
ex	EX:7|ex:7|Ex:1	exercised:15:0.0366	0.0366	15
eya	eya:33|EYA:6|Eya:6	eyes absent:45:0.9338	0.9338	45
EYFP	EYFP:45|eYFP:3	enhanced yellow fluorescent protein:48:0.7790	0.7790	48
EYL	EYL:15	egg yolk lecithin:15:0.8045	0.8045	15
EYPC	EYPC:36|EyPC:1	egg yolk phosphatidylcholine:37:0.8749	0.8749	37
ey	ey:23|Ey:3|EY:1	eyeless:27:0.4815	0.4815	27
EZ	EZ:20|E-Z:5	Edmonston-Zagreb:25:0.2330	0.2330	25
EZ	EZ:10	epileptogenic zone:10:0.1519	0.1519	10
EA1	EA1:8|EA-1:5	Episodic ataxia type 1:13:0.7753	0.7753	13
EA2	EA2:21|EA-2:16	Episodic ataxia type 2:37:0.9197	0.9197	37
Ea	Ea:142|EA:8	activation energy:110:0.9728|activation energies:40:0.8491	0.9728	150
EA	EA:17	antibody:17:0.0061	0.0061	17
EA	EA:15	cells:15:0.0053	0.0053	15
EA	EA:13|Ea:6	early:19:0.0069	0.0069	19
EA	EA:9|Ea:3	Early amniocentesis:12:0.6460	0.6460	12
EA	EA:62|Ea:2	early antigens:64:0.7686	0.7686	64
EA	EA:16	Effect of electro-acupuncture:16:0.1061	0.1061	16
EA	EA:80|Ea:5	effect of electroacupuncture:47:0.0969|effects of electroacupuncture:38:0.0704	0.0969	85
EA	EA:20	effort angina:20:0.7173	0.7173	20
EA	EA:45|Ea:5	egg albumin:50:0.8520	0.8520	50
EA	EA:12	Ehrlich Ascites:12:0.7571	0.7571	12
EA	EA:18|Ea:1	electrical activity:19:0.1659	0.1659	19
EA	EA:9	electron affinity:9:0.6794	0.6794	9
EA	EA:60	ellagic acid:60:0.2448	0.2448	60
EA	EA:9	endarterectomy:9:0.0030	0.0030	9
EA	EA:8	endometrial ablation:8:0.5006	0.5006	8
Ea	Ea:28|EA:2	energy of activation:30:0.6037	0.6037	30
EA	EA:9	entorhinal area:9:0.1492	0.1492	9
EA	EA:14	epidural anaesthesia:14:0.6173	0.6173	14
EA	EA:35	epidural analgesia:35:0.6274	0.6274	35
EA	EA:32	Epidural anesthesia:32:0.8563	0.8563	32
EA	EA:14	epileptiform activity:14:0.1008	0.1008	14
EA	EA:9|Ea:1	erythrocyte:10:0.0034	0.0034	10
EA	EA:13	erythrocyte aggregation:13:0.4444	0.4444	13
EA	EA:17	erythrocyte-antibody:17:0.0061	0.0061	17
EA	EA:11	erythromycin acistrate:11:0.7357	0.7357	11
EA	EA:9	Esophageal adenocarcinoma:9:0.2102	0.2102	9
EA	EA:114	esophageal atresia:114:0.9447	0.9447	114
EA	EA:103	ethacrynic acid:103:0.4672	0.4672	103
EA	EA:20	ethanolamine:20:0.0072	0.0072	20
EA	EA:26	ethyl acetate:26:0.6645	0.6645	26
EA	EA:21	ethyl acrylate:21:0.8594	0.8594	21
EA	EA:38|E-A:1	European American:20:0.8525|European-American:19:0.0072	0.8525	39
EA	EA:7	evolutionary algorithm:7:0.3524	0.3524	7
EA	EA:6	IgG antibodies:6:0.1838	0.1838	6
EA	EA:17	sensitized sheep erythrocytes:17:0.2527	0.2527	17
Ea	Ea:9	velocity:9:0.0030	0.0030	9
ECAP	ECAP:15|eCAP:2	Electrically evoked compound action potential:17:0.5760	0.5760	17
ECaC	ECaC:8	epithelial Ca(2+) channel:8:0.6411	0.6411	8
EchoCG	EchoCG:8|echoCG:2|echo-CG:2|Echo-CG:1	echocardiography:13:0.7500	0.7500	13
ECM1	ECM1:14|Ecm1:2|ECM-1:1	extracellular matrix protein 1:17:0.7407	0.7407	17
ECorL	ECorL:10|EcorL:7	Erythrina corallodendron lectin:17:0.8270	0.8270	17
EDIN	EDIN:8	Epidermal cell differentiation inhibitor:8:0.6411	0.6411	8
Edyn	Edyn:19	dynamic elastance:19:0.6537	0.6537	19
EF-2	EF-2:168|EF2:15	elongation factor 2:162:0.9705|elongation factor-2:21:0.8594	0.9705	183
EfOM	EfOM:8	effluent organic matter:8:0.5006	0.5006	8
Efamol	Efamol:15|efamol:1	evening primrose oil:16:0.8165	0.8165	16
eggPC	egg-PC:7|eggPC:7|EggPC:4	egg phosphatidylcholine:18:0.4438	0.4438	18
eIF4E	eIF4E:11|eIF-4E:9	cap-binding protein:12:0.2868|cap binding protein:8:0.6411	0.6411	20
eIF-4E	eIF-4E:15|eIF4E:3	eukaryotic initiation factor-4E:18:0.6381	0.6381	18
eIF4E	eIF4E:40|eIF-4E:12	eukaryotic translation initiation factor 4E:52:0.6570	0.6570	52
EIN	EIN:12	endometrial intraepithelial neoplasia:12:0.7357	0.7357	12
Eker	Eker:10	Tsc2 gene mutant:10:0.7103	0.7103	10
ELIPs	ELIPs:8|Elips:2	early light-inducible proteins:10:0.7103	0.7103	10
ELIP	ELIP:11	early light-inducible protein:11:0.7357	0.7357	11
Emax	Emax:12	contractility index:12:0.7571	0.7571	12
Emax	Emax:9	end-systolic pressure-volume relation:9:0.5470	0.5470	9
Emax	Emax:4	LV contractility:4:0.0731	0.0731	4
Emax	Emax:6	maximal contractile response:6:0.1543	0.1543	6
Emax	Emax:8	maximal contraction:8:0.1895	0.1895	8
Emax	Emax:39	maximal effect:39:0.2768	0.2768	39
Emax	Emax:8	maximal elastance:8:0.0502	0.0502	8
Emax	Emax:24	maximal response:17:0.1417|maximal responses:7:0.2113	0.2113	24
Emax	Emax:6	maximum contraction:6:0.0807	0.0807	6
Emax	Emax:39|EMAX:2	maximum effect:41:0.2955	0.2955	41
Emax	Emax:23	maximum response:23:0.2250	0.2250	23
Emax	Emax:5	slope of the end-systolic pressure-volume relationship:5:0.2902	0.2902	5
Emax	Emax:9	systolic elastance:9:0.0674	0.0674	9
emm	emm:13	M protein:13:0.6701	0.6701	13
emm	emm:7	M protein gene:7:0.5926	0.5926	7
EMP	EMP:11	electromagnetic pulse:11:0.6182	0.6182	11
EMP	EMP:20	Embden-Meyerhof-Parnas:20:0.0592	0.0592	20
EMP	EMP:6	Embden-Meyerhof pathway:6:0.2243	0.2243	6
EMP	EMP:12	enamel matrix proteins:12:0.6460	0.6460	12
EMP	EMP:11	endothelial microparticles:11:0.7571	0.7571	11
EMP	EMP:61	Estramustine phosphate:61:0.9229	0.9229	61
EMP	EMP:64	extramedullary plasmacytoma:49:0.9046|extramedullary plasmacytomas:15:0.8045	0.9046	64
ENaC	ENaC:147	epithelial Na(+) channel:101:0.8344|epithelial Na(+) channels:27:0.8312|epithelial Na+ channels:19:0.5732	0.8344	147
ENaC	ENaC:263|ENAC:1|eNaC:1	epithelial sodium channel:238:0.8930|epithelial sodium channels:27:0.7066	0.8930	265
Endo-A	Endo-A:8|endo-A:3	endo-beta-N-acetylglucosaminidase from Arthrobacter protophormiae:11:0.7357	0.7357	11
endoPG	endoPG:14|EndoPG:1|Endo-PG:1	endopolygalacturonase:16:0.6818	0.6818	16
Endo	Endo:12|ENDO:8|endo:5	endocardial:25:0.1176	0.1176	25
Endo	Endo:6|endo:3|ENDO:1	endocardium:10:0.0441	0.0441	10
Endo	Endo:8|endo:5	endoglycosidase:13:0.0588	0.0588	13
ENF	ENF:8|Enf:4	enflurane:12:0.2619	0.2619	12
Enf	Enf:5|ENF:4	Enfuvirtide:9:0.1905	0.1905	9
Envs	Envs:14	envelope glycoproteins:14:0.7909	0.7909	14
Eo-CSF	Eo-CSF:8|EO-CSF:1	eosinophil colony stimulating factor:9:0.6794	0.6794	9
EOA	EOA:58	effective orifice area:58:0.8937	0.8937	58
EOA	EOA:12	Erosive osteoarthritis:12:0.6460	0.6460	12
EOA	EOA:32	esophageal obturator airway:32:0.9072	0.9072	32
EoL-1	EoL-1:12|Eol-1:1	eosinophilic cell line:13:0.4849	0.4849	13
EOL	EOL:55|EoL:3	end-of-life:58:0.6628	0.6628	58
EO	EO:11	5% ethanolamine oleate:11:0.2764	0.2764	11
EO	EO:9	early onset:9:0.5470	0.5470	9
EO	EO:6	electric organ:6:0.2243	0.2243	6
EO	EO:17	electrolyzed oxidizing:17:0.8270	0.8270	17
EO	EO:10	endocrine ophthalmopathy:10:0.5000	0.5000	10
EO	EO:16	endogenous ouabain:16:0.7261	0.7261	16
Eo	Eo:24|EO:14	Eosinophil:21:0.0306|eosinophils:17:0.0245	0.0306	38
EO	EO:29	essential oil:17:0.7407|essential oils:12:0.7571	0.7571	29
EO	EO:178	ethylene oxide:178:0.9642	0.9642	178
EO	EO:40	eyes open:40:0.8491	0.8491	40
Ep-CAM	Ep-CAM:31|EpCAM:23|EPCAM:2|EpCam:1|epCAM:1|EP-CAM:1	epithelial cell adhesion molecule:59:0.9203	0.9203	59
EpDIF	EpDIF:11	epithelium-derived inhibitory factor:11:0.7357	0.7357	11
EpRE	EpRE:8|EPRE:4	electrophile response element:12:0.6460	0.6460	12
EpRE	EpRE:8|EPRE:1	electrophile responsive element:9:0.6794	0.6794	9
EPST	EPST:12	endoscopic papillosphincterotomy:12:0.7571	0.7571	12
EqtII	EqtII:6|EqT-II:2|EqTII:1|Eqt-II:1	Equinatoxin II:10:0.7103	0.7103	10
ERAD	ERAD:59	ER-associated degradation:59:0.3995	0.3995	59
ERAD	ERAD:19	ER-associated protein degradation:19:0.5732	0.5732	19
EREs	EREs:64	estrogen response elements:64:0.7825	0.7825	64
Eres	Eres:7	respiratory evaporative heat loss:7:0.5926	0.5926	7
Erev	Erev:70|EREV:2	reversal potential:72:0.8773	0.8773	72
ESD	ESD:8	Electrostatic spray deposition:8:0.6411	0.6411	8
ESD	ESD:13	End-systolic diameter:13:0.4444	0.4444	13
ESD	ESD:22|EsD:1	end-systolic dimension:23:0.7500	0.7500	23
ESD	ESD:30	entrance surface dose:30:0.9011	0.9011	30
ESD	ESD:11	Environmental sex determination:11:0.7357	0.7357	11
ESD	ESD:62|EsD:43	esterase D:105:0.9715	0.9715	105
ESW	ESW:10	extracorporeal shock waves:10:0.5856	0.5856	10
ET-1	ET-1:14	[125I]endothelin-1:14:0.0029	0.0029	14
ET-1	ET-1:174|ET1:9|Et-1:1	Endothelin:184:0.0413	0.0413	184
ET-1	ET-1:4048|ET1:50|Et-1:34|Et1:5	endothelin-1:3981:0.8984|endothelin 1:156:0.9329	0.9329	4137
ETBR	ETBR:4|ETB-R:2	endothelin B receptor:6:0.2827	0.2827	6
EtBr	EtBr:99|ETBR:1|Et-Br:1	ethidium bromide:101:0.9704	0.9704	101
EtNU	EtNU:28|EtNu:1	N-ethyl-N-nitrosourea:29:0.7368	0.7368	29
EtOH	EtOH:11|ETOH:5|Et-OH:1	ethyl alcohol:17:0.1393	0.1393	17
EtdBr	EtdBr:11	ethidium bromide:11:0.7357	0.7357	11
E-test	E-test:10|Etest:2	epsilometer test:12:0.5664	0.5664	12
ETE	ETE:9	extratemporal epilepsy:9:0.4587	0.4587	9
ETS	ETS:33	electron transport system:33:0.8605	0.8605	33
ETs	ETs:103	electrophoretic types:103:0.9004	0.9004	103
ETs	ETs:11	embryo transfers:11:0.7357	0.7357	11
ETs	ETs:6	Endocrine tumors:6:0.1320	0.1320	6
ETS	ETS:13	endoscopic thoracic sympathectomy:13:0.7753	0.7753	13
ETS	ETS:10	endoscopic transthoracic sympathicotomy:10:0.7103	0.7103	10
ETs	ETs:254|Et-s:1|Ets:1|ETS:1	Endothelins:257:0.1789	0.1789	257
ETS	ETS:17	endotracheal suctioning:17:0.8270	0.8270	17
ETS	ETS:726	environmental tobacco smoke:726:0.9851	0.9851	726
ETs	ETs:8	exfoliative toxins:8:0.3463	0.3463	8
ETS	ETS:46	external transcribed spacer:46:0.7507	0.7507	46
EtxB	EtxB:8	B subunit of Escherichia coli heat-labile enterotoxin:8:0.6411	0.6411	8
Eu3+	Eu3+:23	europium:23:0.6875	0.6875	23
exd	exd:20|EXD:13|Exd:12	extradenticle:45:0.8462	0.8462	45
EXE	EXE:9	exemestane:9:0.2500	0.2500	9
Ex-FABP	Ex-FABP:7|ExFABP:1|ex-FABP:1|EX-FABP:1	extracellular fatty acid binding protein:10:0.7103	0.7103	10
ExHC	ExHC:12|exHC:1	hypercholesterolemic:13:0.7500	0.7500	13
ExMI	ExMI:7|EXMI:2	extracorporeal magnetic innervation:9:0.6794	0.6794	9
ExPEC	ExPEC:10	extraintestinal pathogenic Escherichia coli:10:0.7103	0.7103	10
Exo1	Exo1:10|EXO-1:1|EXO1:1	exonuclease 1:12:0.7571	0.7571	12
ExoS	ExoS:11	Pseudomonas aeruginosa exoenzyme S:11:0.7357	0.7357	11
EXT	EXT:13|Ext:1	extinction:14:0.0903	0.0903	14
EXT	EXT:24	Hereditary multiple exostoses:24:0.7500	0.7500	24
F&V	F&V:15	fruit and vegetable:15:0.8045	0.8045	15
F(0)	F(0):13|f(0):2	fundamental frequency:15:0.8045	0.8045	15
F(1+2)	F(1+2):7	prothrombin fragment 1+2:7:0.5926	0.5926	7
F(ST)	F(ST):8|F(st):1	differentiation:9:0.2353	0.2353	9
F-MEL	F-MEL:6	Friend murine erythroleukemia:6:0.5290	0.5290	6
F-SFFV	F-SFFV:16	Friend spleen focus-forming virus:16:0.8165	0.8165	16
F-actin	F-actin:211|f-actin:15	filamentous actin:226:0.8343	0.8343	226
F.D.P.	F.D.P.:13	degradation products:13:0.5934	0.5934	13
F.F.A.	F.F.A.:7	free fatty acids:7:0.5926	0.5926	7
F.IX	F.IX:18	factor IX:18:0.6903	0.6903	18
f/t	f/t:9|F/T:4	free/total:13:0.1875	0.1875	13
F0F1	F0F1:11|F0-F1:2	ATP synthase:13:0.7753	0.7753	13
F0	F0:9	force:9:0.0157	0.0157	9
F0	F0:235|f0:26	fundamental frequency:261:0.8978	0.8978	261
F0	F0:9	fusion:9:0.0157	0.0157	9
F0	F0:11	membrane sector:11:0.7357	0.7357	11
F0	F0:9	precursor:9:0.0157	0.0157	9
F1+2	F1+2:97	prothrombin fragment 1+2:91:0.8400|prothrombin fragment 1 + 2:6:0.3728	0.8400	97
F1+2	F1+2:9	prothrombin fragment F1+2:9:0.5470	0.5470	9
F1.2	F1.2:28|f1.2:2	prothrombin fragment 1.2:30:0.7652	0.7652	30
F1.2	F1.2:6|f1.2:3	Prothrombin fragment F1.2:9:0.6794	0.6794	9
F-18	F-18:12	fluorine-18:12:0.5500	0.5500	12
F1B	F1B:11|F1b:2	hamsters:13:0.3636	0.3636	13
F1P	F-1-P:6|F1P:6	fructose-1-phosphate:12:0.5000	0.5000	12
F1	F1:9	adenosine triphosphatase:9:0.6794	0.6794	9
F1	F1:13	Beef heart mitochondrial ATPase:13:0.5934	0.5934	13
F1	F1:4|f1:1	blood flow:5:0.0517	0.0517	5
F1	F1:9	crossbred:9:0.0076	0.0076	9
f1	f1:10|F1:6|F-1:1	factor:17:0.0151	0.0151	17
F1	F1:17|f1:1	first formant:18:0.6381	0.6381	18
F1	F1:27|F-1:1	first generation:28:0.4950	0.4950	28
F1	F1:25|F-1:4|f1:1	fraction:30:0.0274	0.0274	30
F1	F1:21|F-1:2	Fraction 1:23:0.2792	0.2792	23
F1	F1:10	fragment 1:10:0.0626	0.0626	10
F1	F1:9|f1:3	frequency:12:0.0104	0.0104	12
F1	F1:6	granulosa cells from the first:6:0.4102	0.4102	6
F1	F1:1	granulosa cells obtained from the largest:1:0.3524	0.3524	1
F1	F1:20	hybrid:11:0.0095|Hybrids:9:0.0076	0.0095	20
F1	F1:15	largest follicle:15:0.2621	0.2621	15
F1	F1:7	largest preovulatory follicle:7:0.4438	0.4438	7
F1	F1:52|F-1:2	offspring:54:0.0511	0.0511	54
F-2,6-P2	F-2,6-P2:28|F2,6P2:4	fructose 2,6-bisphosphate:16:0.7261|fructose-2,6-bisphosphate:16:0.4054	0.7261	32
F2	F2:9	follicle:9:0.0150	0.0150	9
F2	F2:16|F-2:3	fraction:19:0.0338	0.0338	19
F2	F2:26|f2:1	second formant:27:0.8312	0.8312	27
F2	F2:12	second generation:12:0.3813	0.3813	12
F344	F344:378|F-344:76	Fischer 344:378:0.8851|Fischer-344:76:0.1140	0.8851	454
F344	F344:7	Fischer 344 rats:7:0.5926	0.5926	7
F344	F344:8|F-344:2	male Fischer:10:0.0537	0.0537	10
F3H	F3H:10|f3h:1	Flavanone 3-hydroxylase:11:0.7357	0.7357	11
F3	F3:18|F-3:1	fraction:19:0.0662	0.0662	19
F3	F3:12	third largest:12:0.7571	0.7571	12
F5	F5:12	fifth largest:12:0.7571	0.7571	12
F6H8	F6H8:9|f6h8:1	perfluorohexyloctane:10:0.8182	0.8182	10
F6P	F6P:22|F-6-P:4|F6-P:2	fructose 6-phosphate:28:0.6554	0.6554	28
F6	F6:8	coupling factor 6:8:0.4102	0.4102	8
F8C	F8C:9	factor VIII:9:0.6794	0.6794	9
F8C	F8C:11	factor VIII gene:11:0.7357	0.7357	11
F8RA	F8RA:3|F8-RA:3	Factor VIII-related antigen:6:0.5290	0.5290	6
F8	F8:11	factor VIII:11:0.7357	0.7357	11
F9	F9:16	factor IX gene:16:0.8165	0.8165	16
F9	F9:11	mouse embryonal carcinoma:11:0.4232	0.4232	11
FA-1	FA-1:17	fertilization antigen:17:0.8045	0.8045	17
FA1	FA1:20|FA-1:1	fetal antigen 1:21:0.8594	0.8594	21
FA2	FA2:14|FA-2:6	antigen 2:20:0.8449	0.8449	20
FAAH	FAAH:131	fatty acid amide hydrolase:131:0.9772	0.9772	131
FAAH	FAAH:11	fatty acid amidohydrolase:11:0.7357	0.7357	11
FAAS	FAAS:43|F-AAS:1	flame atomic absorption spectrometry:44:0.7619	0.7619	44
FAAs	FAAs:10|F-AAs:1	free amino acids:11:0.6182	0.6182	11
FAA	FAA:25	Federal Aviation Administration:25:0.8816	0.8816	25
FAA	FAA:100	Flavone acetic acid:100:0.9701	0.9701	100
FAA	FAA:19	Food-anticipatory activity:13:0.2121|Food anticipatory activity:6:0.2243	0.2243	19
FAA	FAA:40	free amino acids:40:0.8491	0.8491	40
FAA	FAA:27	N-2-fluorenylacetamide:27:0.0658	0.0658	27
FAB-MS	FAB-MS:127|FABMS:44|FAB-ms:1|FABms:1|Fab-MS:1	fast atom bombardment mass spectrometry:138:0.9783|Fast atom bombardment-mass spectrometry:36:0.9174	0.9783	174
FABP2	FABP2:27|FABP-2:1	fatty acid-binding protein 2:16:0.8165|fatty acid binding protein 2:12:0.7571	0.8165	28
FABPpm	FABPpm:17|FABPPM:3|FABP-pm:1	plasma membrane fatty acid binding protein:11:0.7357|plasma membrane fatty acid-binding protein:10:0.5856	0.7357	21
FABPs	FABPs:103	fatty acid-binding proteins:58:0.9486|fatty acid binding proteins:45:0.9338	0.9486	103
FABP	FABP:286|Fabp:1	fatty acid-binding protein:123:0.9486|fatty acid binding protein:119:0.9131|Fatty acid binding proteins:25:0.8186|Fatty acid-binding proteins:20:0.8449	0.9486	287
FABQ	FABQ:10	Fear-Avoidance Beliefs Questionnaire:10:0.7103	0.7103	10
FAC1	FAC1:6	fetal Alz-50 clone 1:6:0.5290	0.5290	6
FACC	FACC:8	complementation group C:8:0.3463	0.3463	8
FACES	FACES:9	Family Adaptability and Cohesion Evaluation Scales:9:0.7103	0.7103	9
FACE	FACE:9	Fatality Assessment and Control Evaluation:9:0.6794	0.6794	9
FACE	FACE:35	fluorophore-assisted carbohydrate electrophoresis:35:0.7117	0.7117	35
FACE	FACE:22	free-air CO2 enrichment:22:0.5863	0.5863	22
FACE	FACE:10	Freedom of Access to Clinic Entrances Act:10:0.7103	0.7103	10
FACO	FACO:8	fatty acyl-CoA oxidase:8:0.6411	0.6411	8
FACS	FACS:9	cell scanning:9:0.6794	0.6794	9
FACS	FACS:11	Facial Action Coding System:11:0.7357	0.7357	11
FACS	FACS:15	flow cytometric:15:0.6386	0.6386	15
FACS	FACS:20	flow cytometric analysis:20:0.8525	0.8525	20
FACS	FACS:13	fluorescence-activated cell-sorting:13:0.6701	0.6701	13
FACT-An	FACT-An:14	Functional Assessment of Cancer Therapy-Anemia:14:0.7909	0.7909	14
FACT-G	FACT-G:10	Functional Assessment of Cancer Therapy:10:0.7753	0.7753	10
FACT-G	FACT-G:36|Fact-G:1	Functional Assessment of Cancer Therapy-General:37:0.8811	0.8811	37
FACT-L	FACT-L:10	Functional Assessment of Cancer Therapy-Lung:10:0.7357	0.7357	10
FACT	FACT:3	Functional Assessment Cancer Therapy:3:0.9274	0.9274	3
FAC	FAC:2	Adriamycin and cyclophosphamide:2:0.1162	0.1162	2
FAC	FAC:33	ferric ammonium citrate:33:0.8605	0.8605	33
FAC	FAC:11|FAc:6	Fluoroacetate:17:0.0420	0.0420	17
FAC	FAC:44	Fractional area change:44:0.9338	0.9338	44
FAC	FAC:6|fac:1|Fac:1	group C gene:8:0.6411	0.6411	8
FADS	FADS:22	factor analysis of dynamic structures:22:0.8657	0.8657	22
FADS	FADS:14	fetal akinesia deformation sequence:14:0.7753	0.7753	14
FAD	FAD:66	familial AD:66:0.8670	0.8670	66
FAD	FAD:227	Familial Alzheimer's disease:227:0.8928	0.8928	227
FAD	FAD:47	Family Assessment Device:47:0.9366	0.9366	47
FAD	FAD:283	flavin adenine dinucleotide:283:0.9015	0.9015	283
FAD	FAD:8	Focal acantholytic dyskeratosis:8:0.5006	0.5006	8
FAEEs	FAEEs:30	fatty acid ethyl esters:30:0.9011	0.9011	30
FAEE	FAEE:45	Fatty acid ethyl esters:35:0.9151|Fatty acid ethyl ester:10:0.5856	0.9151	45
FAE	FAE:15	fetal alcohol-exposed:15:0.8045	0.8045	15
FAE	FAE:21	fetal alcohol exposure:21:0.7291	0.7291	21
FAE	FAE:6	follicle-associated epithelial:6:0.1838	0.1838	6
FAE	FAE:83	follicle-associated epithelium:83:0.7525	0.7525	83
FAE	FAE:15	fumaric acid esters:15:0.7096	0.7096	15
FAFLP	FAFLP:21|fAFLP:5	fluorescent amplified fragment length polymorphism:26:0.8251	0.8251	26
FAF	FAF:5	auditory feedback:5:0.1838	0.1838	5
FAF	FAF:7	Familial amyloidosis of the Finnish type:7:0.8861	0.8861	7
faf	faf:5|Faf:3|FAF:1	fat facets:9:0.6794	0.6794	9
FAF	FAF:10	fibroblast-activating factor:10:0.3145	0.3145	10
FAF	FAF:9	fundus autofluorescence:9:0.6794	0.6794	9
FAG	FAG:21	fluorescein angiography:21:0.6812	0.6812	21
FAH	FAH:5	caused by a deficiency of fumarylacetoacetate hydrolase:5:0.5355	0.5355	5
FAH	FAH:18	Foci of altered hepatocytes:18:0.8365	0.8365	18
FAH	FAH:12	fumarylacetoacetase:12:0.0909	0.0909	12
FAIMS	FAIMS:18	high-field asymmetric waveform ion mobility spectrometry:18:0.5940	0.5940	18
FAI	FAI:30	Frenchay Activities Index:30:0.9011	0.9011	30
FAI	FAI:13	functional aerobic impairment:13:0.7753	0.7753	13
FAK	FAK:944|Fak:8|fak:2	focal adhesion kinase:954:0.9872	0.9872	954
FALDH	FALDH:26	fatty aldehyde dehydrogenase:26:0.8251	0.8251	26
FALS	FALS:4	cases are familial:4:0.0612	0.0612	4
FALS	FALS:49|fALS:4	familial ALS:53:0.8373	0.8373	53
FALS	FALS:178|fALS:11|F-ALS:1	familial amyotrophic lateral sclerosis:190:0.8955	0.8955	190
FALS	FALS:7	forward angle light scatter:7:0.5926	0.5926	7
FAL	FAL:30	fractional allelic loss:30:0.7652	0.7652	30
FAMA	FAMA:9	fluorescence-assisted mismatch analysis:9:0.5470	0.5470	9
FAMA	FAMA:13	fluorescent antibody to membrane antigen:13:0.7909	0.7909	13
FAMEs	FAMEs:47|FAMES:1	fatty acid methyl esters:48:0.9379	0.9379	48
FAMIS	FAMIS:9	factor analysis of biomedical image sequences:9:0.6794	0.6794	9
FAMIS	FAMIS:17	factor analysis of medical image sequences:17:0.8270	0.8270	17
FAMMM	FAMMM:16	familial atypical multiple mole melanoma:16:0.8365	0.8365	16
FAMP	FAMP:20	Fludarabine:20:0.4318	0.4318	20
FAMTX	FAMTX:5	doxorubicin and methotrexate:5:0.3945	0.3945	5
FAME	FAME:101	fatty acid methyl ester:55:0.9147|fatty acid methyl esters:46:0.9353	0.9353	101
FAME	FAME:8	fatty acid modifying enzyme:8:0.6411	0.6411	8
FAM	FAM:2	doxorubicin and mitomycin:2:0.1895	0.1895	2
FAM	FAM:7	Family Assessment Measure:7:0.1470	0.1470	7
FAM	FAM:10|Fam:3|fam:1	famotidine:14:0.0594	0.0594	14
FAM	FAM:9	Faschingbauer Abbreviated MMPI:9:0.5470	0.5470	9
FAM	FAM:8	functional assessment measure:8:0.2090	0.2090	8
FANA	FANA:26	fluorescent antinuclear antibody:15:0.5818|fluorescent antinuclear antibodies:11:0.6182	0.6182	26
FANFT	FANFT:66	n-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide:50:0.4851|N-[4-(5-nitro-2-furyl)-2-thiazolyl] Formamide:16:0.4040	0.4851	66
fan	fan:1	TET and fangchinoline:1:0.2243	0.2243	1
FAO	FAO:14	fatty acid beta-oxidation:14:0.7909	0.7909	14
FAO	FAO:40	fatty acid oxidation:40:0.9256	0.9256	40
FAO	FAO:14	fatty acyl-CoA oxidase:14:0.6911	0.6911	14
FAO	FAO:12	Food and Agriculture Organization of the United Nations:12:0.7571	0.7571	12
Fao	Fao:9|FAO:2	hepatoma cells:11:0.7357	0.7357	11
FAP-1	FAP-1:21|Fap-1:1	Fas-associated phosphatase-1:22:0.6934	0.6934	22
FAP	FAP:10	arterial pressure:10:0.1327	0.1327	10
FAP	FAP:886	familial adenomatous polyposis:886:0.9877	0.9877	886
FAP	FAP:30	familial adenomatous polyposis coli:30:0.8472	0.8472	30
FAP	FAP:131	familial amyloid polyneuropathy:131:0.9305	0.9305	131
FAP	FAP:246	familial amyloidotic polyneuropathy:246:0.9805	0.9805	246
FAP	FAP:9	Femoral artery pressure:9:0.3945	0.3945	9
FAP	FAP:24	fibroblast activation protein:24:0.8115	0.8115	24
FAP	FAP:8|FAp:3|F-AP:1	fluorapatite:12:0.0070	0.0070	12
FAQ	FAQ:20	questionnaire:20:0.5758	0.5758	20
FARAD	FARAD:10	Food Animal Residue Avoidance Databank:10:0.6794	0.6794	10
FASD	FASD:21	Fetal Alcohol Spectrum Disorders:13:0.7753|fetal alcohol spectrum disorder:8:0.5006	0.7753	21
FasR	FasR:22|Fas-R:1|FAS-R:1	Fas receptor:24:0.5160	0.5160	24
FASSc	FASSc:10	fibrosing alveolitis associated with systemic sclerosis:10:0.7103	0.7103	10
FAS	FAS:11|fas:2|FA-S:1|Fas:1	acid synthesis:15:0.8045	0.8045	15
FAS	FAS:6	Facial Affective Scale:6:0.3728	0.3728	6
Fas	Fas:27	Fas antigen:27:0.7066	0.7066	27
Fas	Fas:8|FAS:2	Fas receptor:10:0.2275	0.2275	10
FAS	FAS:7	Fatigue Assessment Scale:7:0.4438	0.4438	7
FAs	FAs:159|FAS:3	fatty acids:162:0.9275	0.9275	162
FAS	FAS:391|fas:2|Fas:1	fatty acid synthase:394:0.9924	0.9924	394
FAS	FAS:92|Fas:3	fatty acid synthetase:95:0.9500	0.9500	95
FAS	FAS:420	fetal alcohol syndrome:420:0.9591	0.9591	420
FAS	FAS:10	fibrin adhesive system:10:0.4363	0.4363	10
FAS	FAS:9	fluorescence actin staining:9:0.1809	0.1809	9
FAS	FAS:11	fluorescent actin staining:11:0.2764	0.2764	11
FAs	FAs:24	focal adhesions:24:0.8768	0.8768	24
FAS	FAS:2	fractional area of shortening:2:0.7103	0.7103	2
FAS	FAS:16	free alpha-subunit:16:0.7261	0.7261	16
FAs	FAs:10	frequent attenders:10:0.7103	0.7103	10
FATP	FATP:23	fatty acid transport protein:23:0.8715	0.8715	23
FATP1	FATP1:7	fatty acid transport protein 1:7:0.5926	0.5926	7
fat	fat:4|FAT:1	body mass:5:0.0612	0.0612	5
fat	fat:6	body weight:6:0.1838	0.1838	6
FAT	FAT:16	fatty acid translocase:16:0.8045	0.8045	16
FAT	FAT:18	fluorescent antibody technique:18:0.6381	0.6381	18
FAT	FAT:56	fluorescent antibody test:56:0.8453	0.8453	56
FAT	FAT:17	Focal Adhesion Targeting:17:0.8270	0.8270	17
FAV	FAV:25	fowl adenovirus:25:0.8816	0.8816	25
fax	fax:13|FAX:1	facsimile:14:0.5200	0.5200	14
FAZ	FAZ:41	foveal avascular zone:41:0.8525	0.8525	41
FA	FA:9|fa:1	atrial fibrillation:10:0.7103	0.7103	10
FA	FA:8	data were acquired by frontal analysis:8:0.2987	0.2987	8
FA	FA:35	factor analysis:35:0.3436	0.3436	35
FA	FA:126	Fanconi anaemia:83:0.5558|Fanconi's anaemia:43:0.2451	0.5558	126
FA	FA:530	Fanconi anemia:423:0.7617|Fanconi's anemia:107:0.1649	0.7617	530
FA	FA:7	fast adapting:7:0.3524	0.3524	7
fa	fa:16	fatty:16:0.0036	0.0036	16
FA	FA:868	fatty acid:490:0.4307|fatty acids:378:0.9393	0.9393	868
FA	FA:14	femoral:14:0.0031	0.0031	14
FA	FA:54	femoral artery:54:0.8196	0.8196	54
FA	FA:33	fibrinolytic activity:33:0.5042	0.5042	33
FA	FA:33	fibroadenoma:24:0.0055|fibroadenomas:9:0.0019	0.0055	33
FA	FA:22	fibrosing alveolitis:22:0.7955	0.7955	22
FA	FA:55	filtered air:55:0.9458	0.9458	55
FA	FA:12	flip angle:12:0.4557	0.4557	12
FA	FA:98	fluctuating asymmetry:98:0.9515	0.9515	98
FA	FA:8	fluid accumulation:8:0.4102	0.4102	8
FA	FA:24	fluocinolone acetonide:24:0.7593	0.7593	24
FA	FA:11	Fluoranthene:11:0.0024	0.0024	11
FA	FA:12	fluorescein:12:0.0026	0.0026	12
FA	FA:141	fluorescein angiography:141:0.9661	0.9661	141
FA	FA:141	fluorescent antibody:127:0.7929|fluorescent-antibody:14:0.0031	0.7929	141
FA	FA:9	fluoroacetate:9:0.0019	0.0019	9
FA	FA:18	fly ash:18:0.8365	0.8365	18
FA	FA:22	focal adhesion:11:0.6182|focal adhesions:11:0.6182	0.6182	22
FA	FA:44	follicular adenoma:23:0.8038|follicular adenomas:21:0.7291	0.8038	44
FA	FA:32	food allergy:32:0.8563	0.8563	32
Fa	Fa:4|FA:4|fa:1|F-A:1	fraction:10:0.0022	0.0022	10
Fa	Fa:4|FA:1	fraction absorbed:5:0.1132	0.1132	5
FA	FA:158	fractional anisotropy:158:0.9181	0.9181	158
FA	FA:24	Freund's adjuvant:24:0.7593	0.7593	24
FA	FA:143	Friedreich's ataxia:111:0.6931|Friedreich ataxia:32:0.1468	0.6931	143
FA	FA:15	fructosamine:15:0.0034	0.0034	15
FA	FA:5	indirect immunofluorescence:5:0.0517	0.0517	5
Fa	Fa:6	local absorption ratio:6:0.3728	0.3728	6
FA	FA:6	protein phosphatase activating factor:6:0.3728	0.3728	6
FB(1)	FB(1):65	fumonisin B(1):65:0.9275	0.9275	65
FB1	FB1:266	Fumonisin B1:266:0.8961	0.8961	266
FBAL	FBAL:49	alpha-fluoro-beta-alanine:49:0.7619	0.7619	49
FBA	FBA:11	flux balance analysis:11:0.7357	0.7357	11
FBA	FBA:13	foreign body aspiration:13:0.7753	0.7753	13
FBCP	FBCP:8	familial benign chronic pemphigus:8:0.6411	0.6411	8
FBC	FBC:7	brain cells:7:0.3524	0.3524	7
FBC	FBC:9	breast cancer:9:0.6794	0.6794	9
FBC	FBC:21	full blood count:21:0.8594	0.8594	21
FBD	FBD:17	Familial British dementia:17:0.8270	0.8270	17
FBD	FBD:6	Fibrocystic breast disease:6:0.5290	0.5290	6
FBD	FBD:15	functional bowel disorders:15:0.8045	0.8045	15
FBF	FBF:455	forearm blood flow:455:0.8285	0.8285	455
FBGC	FBGC:20	foreign body giant cell:13:0.7753|foreign body giant cells:7:0.5926	0.7753	20
FBGCs	FBGCs:15	foreign body giant cells:15:0.8045	0.8045	15
FBG	FBG:174	fasting blood glucose:174:0.9122	0.9122	174
FBG	FBG:9	fiber Bragg grating:9:0.6794	0.6794	9
Fbg	Fbg:72|FBG:51|fbg:3	fibrinogen:126:0.3463	0.3463	126
FBH	FBH:7	familial benign hypercalcaemia:7:0.5926	0.5926	7
FBI	FBI:15	Federal Bureau of Investigation:15:0.8045	0.8045	15
FBMs	FBMs:17	fetal breathing movements:17:0.6748	0.6748	17
FBM	FBM:74	felbamate:74:0.2744	0.2744	74
FBM	FBM:18	fetal bone marrow:18:0.6381	0.6381	18
FBM	FBM:91	fetal breathing movements:91:0.9015	0.9015	91
fBm	fBm:10|FBM:4	fractional Brownian motion:14:0.6911	0.6911	14
FBN1	FBN1:11|Fbn-1:1|Fbn1:1	fibrillin 1:13:0.7753	0.7753	13
FBN1	FBN1:12|FBN-1:1|Fbn-1:1	fibrillin-1 gene:14:0.2326	0.2326	14
FBN1	FBN1:12	fibrillin gene:12:0.1758	0.1758	12
FBN	FBN:5|Fbn:4|FbN:1|fbn:1	fibronectin:11:0.4167	0.4167	11
FbpA	FbpA:7	ferric binding protein:7:0.2827	0.2827	7
FBPP	FBPP:10	Family Blood Pressure Program:10:0.7103	0.7103	10
FBPase	FBPase:108|FbPase:8|Fbpase:1|FBPASE:1	fructose-1,6-bisphosphatase:93:0.6093|fructose 1,6-bisphosphatase:25:0.8186	0.8186	118
FBP	FBP:12	blood pressure:12:0.7571	0.7571	12
FBP	FBP:7	fetal biophysical profile:7:0.5926	0.5926	7
FBP	FBP:39	filtered back-projection:25:0.8816|filtered back projection:14:0.6911	0.8816	39
FBP	FBP:81	filtered backprojection:81:0.9415	0.9415	81
FBP	FBP:89|fbp:1	folate-binding protein:43:0.2391|folate binding protein:33:0.4589|folate-binding proteins:10:0.2873|folate binding proteins:4:0.0918	0.4589	90
FBP	FBP:10	fructose-1,6-bisphosphatase:10:0.0183	0.0183	10
FBP	FBP:91	fructose-1,6-bisphosphate:52:0.1037|Fructose 1,6-bisphosphate:39:0.8224	0.8224	91
FBR	FBR:11	fluidized-bed reactor:11:0.1938	0.1938	11
FBR	FBR:8	foreign body reaction:8:0.6411	0.6411	8
FBSS	FBSS:28	failed back surgery syndrome:28:0.8941	0.8941	28
FBS	FBS:8	Fake Bad Scale:8:0.6411	0.6411	8
FBS	FBS:7	Fanconi-Bickel syndrome:7:0.2452	0.2452	7
FBS	FBS:11	Fasting blood glucose:11:0.7357	0.7357	11
FBS	FBS:57	fasting blood sugar:57:0.8920	0.8920	57
FBS	FBS:28	fetal blood sampling:28:0.8369	0.8369	28
FBs	FBs:8|Fbs:5	fibroblasts:13:0.0094	0.0094	13
FBs	FBs:28|Fbs:1	foreign bodies:29:0.5940	0.5940	29
FBS	FBS:12	forepaw barrel subfield:12:0.7571	0.7571	12
FBUT	FBUT:5	fluorescein break-up time:5:0.4422	0.4422	5
FBZ	FBZ:72	fenbendazole:72:0.9221	0.9221	72
FB	FB:9	bronchoscope:9:0.0090	0.0090	9
FB	FB:17|fB:2	factor B:19:0.4211	0.4211	19
FB	FB:205|Fb:1	Fast blue:206:0.9690	0.9690	206
FB	FB:16|Fb:1	feedback:17:0.0179	0.0179	17
FB	FB:10	ferruginous bodies:10:0.0929	0.0929	10
FB	FB:6	fetal blood:6:0.2243	0.2243	6
FB	FB:9	fetal breathing:9:0.1409	0.1409	9
FB	FB:30	fiberoptic bronchoscopy:30:0.3287	0.3287	30
Fb	Fb:26|FB:9|fb:1	fibrinogen:36:0.0392	0.0392	36
FB	FB:9|Fb:1	fibroblast:10:0.0101	0.0101	10
FB	FB:30	flexible bronchoscopy:30:0.3287	0.3287	30
FB	FB:7|Fb:2	Flurbiprofen:9:0.0090	0.0090	9
FB	FB:75|Fb:1	foreign body:39:0.7602|foreign bodies:27:0.4992|Foreign-body:10:0.0101	0.7602	76
FB	FB:10	free breathing:10:0.1774	0.1774	10
FB	FB:5	human skin fibroblasts:5:0.1132	0.1132	5
FC-43	FC-43:6	perfluorocarbon emulsion:6:0.1148	0.1148	6
FC-43	FC-43:9	perfluorotributylamine:9:0.1455	0.1455	9
FCAS	FCAS:8	Familial cold autoinflammatory syndrome:8:0.6411	0.6411	8
FCA	FCA:34	analysis:34:0.0665	0.0665	34
FCA	FCA:8	flow cytometric assay:8:0.6411	0.6411	8
FCA	FCA:316	Freund's complete adjuvant:316:0.9316	0.9316	316
FCB	FCB:9	fluocortin butylester:9:0.6794	0.6794	9
FCCL	FCCL:9	cell lymphoma:9:0.6794	0.6794	9
FCCL	FCCL:6	follicular center cell lymphomas:6:0.3728	0.3728	6
FCCP	FCCP:41	carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone:22:0.8657|carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone:11:0.7357|carbonyl cyanide p-trifluoromethoxy-phenylhydrazone:8:0.6794	0.8657	41
FCCP	FCCP:9	carbonyl cyanide p-trifluoromethoxyphenyl hydrazone:9:0.6794	0.6794	9
FCCP	FCCP:88	carbonyl cyanide p-trifluoromethoxyphenylhydrazone:88:0.9461	0.9461	88
fcc	fcc:28	face-centered cubic:19:0.5732|face-centered-cubic:9:0.0408	0.5732	28
FCC	FCC:8	Family-centered care:8:0.5006	0.5006	8
FCC	FCC:33	follicular center cell:33:0.7525	0.7525	33
FCD	FCD:18	fibrocystic disease:18:0.6903	0.6903	18
FCD	FCD:61	focal cortical dysplasia:61:0.9229	0.9229	61
FCD	FCD:62	functional capillary density:62:0.9519	0.9519	62
FCE	FCE:16	feed conversion efficiency:16:0.4274	0.4274	16
FCE	FCE:8	food conversion efficiency:8:0.1061	0.1061	8
FCE	FCE:23	Functional capacity evaluation:23:0.8715	0.8715	23
FCF	FCF:12	fencamfamine:12:0.2973	0.2973	12
FCHL	FCHL:17	familial combined hyperlipidaemia:17:0.8270	0.8270	17
FCHL	FCHL:140	familial combined hyperlipidemia:140:0.9661	0.9661	140
FCH	FCH:12	familial combined hyperlipidaemia:12:0.7571	0.7571	12
FCH	FCH:46	Familial Combined Hyperlipidemia:46:0.9353	0.9353	46
FCH	FCH:24	fibrosing cholestatic hepatitis:24:0.8768	0.8768	24
FCI	FCI:7	after transient focal cerebral ischemia:7:0.4438	0.4438	7
FCI	FCI:18	flow cytometric immunophenotyping:18:0.8365	0.8365	18
FCL	FCL:9	cycle length:9:0.6794	0.6794	9
FCL	FCL:25	follicle center lymphoma:19:0.6537|follicle center lymphomas:6:0.3728	0.6537	25
FCMD	FCMD:35	Fukuyama type congenital muscular dystrophy:35:0.9197	0.9197	35
FCM	FCM:11	family and community medicine:11:0.7571	0.7571	11
FCM	FCM:20	fat-corrected milk:20:0.7173	0.7173	20
FCM	FCM:23|F-CM:1	fibroblast-conditioned medium:14:0.2636|fibroblast conditioned medium:10:0.5856	0.5856	24
FCM	FCM:26	flow cytometer:26:0.8861	0.8861	26
FCM	FCM:197	flow cytometric:186:0.9839|Flow-cytometric:11:0.0063	0.9839	197
FCM	FCM:25	flow cytometric analysis:25:0.8816	0.8816	25
FCM	FCM:8	flow cytometric method:8:0.5006	0.5006	8
FCM	FCM:1086	flow cytometry:1073:0.9861|flow-cytometry:13:0.0075	0.9861	1086
FCM	FCM:9	fluorescence correlation microscopy:9:0.6411	0.6411	9
FCM	FCM:31	fuzzy c-means:31:0.9043	0.9043	31
FCN	FCN:7	fixed consecutive number:7:0.5926	0.5926	7
FCO	FCO:10|fCO:7	femoral chordotonal organ:17:0.8270	0.8270	17
FCPD	FCPD:34	fibrocalculous pancreatic diabetes:34:0.7306	0.7306	34
FCQ	FCQ:9	Frankfurt Complaint Questionnaire:9:0.6794	0.6794	9
FCSA	FCSA:9|F-CSA:1|f-csa:1	cross-sectional area:11:0.4232	0.4232	11
FCs	FCs:12	febrile convulsions:12:0.7571	0.7571	12
FCs	FCs:23	fibrillar centers:23:0.8715	0.8715	23
FCS	FCS:184	fluorescence correlation spectroscopy:184:0.9568	0.9568	184
FCs	FCs:8	fusion cells:8:0.0789	0.0789	8
FCS	FCS:11	medium supplemented with 10% fetal calf serum:11:0.1133	0.1133	11
FCT	FCT:9	fecal chymotrypsin:9:0.4587	0.4587	9
FCT	FCT:14	fever clearance time:14:0.7909	0.7909	14
FCT	FCT:20	functional communication training:20:0.7766	0.7766	20
FCU	FCU:12	first-catch urine:12:0.3275	0.3275	12
FCU	FCU:42|fcu:3	flexor carpi ulnaris:45:0.9338	0.9338	45
FCV	FCV:17	famciclovir:17:0.0658	0.0658	17
FCV	FCV:163	feline calicivirus:163:0.9521	0.9521	163
FCXM	FCXM:4	flow cytometric cross-match:4:0.1618	0.1618	4
FCXM	FCXM:10	flow cytometric crossmatch:10:0.7103	0.7103	10
FCXM	FCXM:4|FC-XM:1	flow cytometry cross-match:5:0.4422	0.4422	5
FCXM	FCXM:25	flow cytometry crossmatch:25:0.8816	0.8816	25
FCXM	FCXM:10|FC-XM:1	flow cytometry crossmatching:11:0.7357	0.7357	11
FCX	FCX:25|FCx:15	frontal cortex:40:0.7653	0.7653	40
FCZ	FCZ:48	fluconazole:48:0.8704	0.8704	48
FCoV	FCoV:36	feline coronavirus:36:0.8716	0.8716	36
FC	FC:14	capacity:14:0.0062	0.0062	14
fc	fc:10|fC:7|Fc:2|FC:1	cardiac frequency:20:0.1651	0.1651	20
FC	FC:42|F-c:1|Fc:1	cells:44:0.0206	0.0206	44
fc	fc:9|Fc:7	centroid frequency:16:0.1162	0.1162	16
Fc	Fc:8|FC:1	constant:9:0.0038	0.0038	9
Fc	Fc:7|FC:1	constant region:8:0.5006	0.5006	8
FC	FC:12	control:12:0.0053	0.0053	12
fc	fc:11	corner frequency:11:0.0592	0.0592	11
Fc	Fc:7	crystallizable fragment:7:0.2452	0.2452	7
FC	FC:15	Facilitated Communication:15:0.8045	0.8045	15
FC	FC:34	faecal coliforms:22:0.3267|Faecal coliform:12:0.2183	0.3267	34
FC	FC:60	febrile convulsions:46:0.8986|febrile convulsion:14:0.7909	0.8986	60
FC	FC:15	fecal coliform:15:0.3262	0.3262	15
FC	FC:25	feed consumption:25:0.5969	0.5969	25
FC	FC:18	Feed conversion:18:0.5940	0.5940	18
Fc	Fc:10	ferrocene:10:0.0043	0.0043	10
FC	FC:20	ferrochelatase:20:0.0091	0.0091	20
FC	FC:24	fibrillar center:12:0.4557|fibrillar centers:12:0.5664	0.5664	24
FC	FC:8	fibrillar centres:8:0.5006	0.5006	8
FC	FC:9	flow convergence:9:0.6794	0.6794	9
FC	FC:25	flow cytometric:25:0.8816	0.8816	25
FC	FC:197|fc:2	flow cytometry:199:0.9758	0.9758	199
FC	FC:14	fluorocarbon:14:0.0062	0.0062	14
FC	FC:13	fluorocitrate:13:0.0058	0.0058	13
FC	FC:32	follicular carcinoma:20:0.5568|follicular carcinomas:12:0.6460	0.6460	32
Fc	Fc:27|FC:8|fc:1	force of contraction:36:0.7704	0.7704	36
FC	FC:29	Free carnitine:29:0.8978	0.8978	29
FC	FC:151|fC:1	free cholesterol:152:0.8337	0.8337	152
fc	fc:7|Fc:2	frequencies:9:0.0038	0.0038	9
FC	FC:8	frequency of contractions:8:0.5006	0.5006	8
FC	FC:9	frontal:9:0.0038	0.0038	9
FC	FC:114|Fc:1	frontal cortex:115:0.8905	0.8905	115
FC	FC:45	functional class:45:0.9338	0.9338	45
FC	FC:5|F-C:1	Fusarin C:6:0.0807	0.0807	6
FC	FC:29	fusicoccin:29:0.0134	0.0134	29
fc	fc:81|FC:6|fC:4|Fc:1	heart rate:92:0.9318	0.9318	92
FDAMA	FDAMA:11	Food and Drug Administration Modernization Act:11:0.7357	0.7357	11
FDA	FDA:147	fluorescein diacetate:147:0.9675	0.9675	147
FDA	FDA:8|F-DA:6	Fluosol-DA 20%:14:0.5589	0.5589	14
FDA	FDA:2402|fda:1	Food and Drug Administration:2326:0.9841|Food and Drug Administration's:77:0.9612	0.9841	2403
FDBA	FDBA:11	Freeze-dried bone allograft:11:0.6182	0.6182	11
FDB	FDB:17	familial defective apo B-100:17:0.6748	0.6748	17
FDB	FDB:61	Familial defective apolipoprotein B-100:61:0.9503	0.9503	61
FDB	FDB:42|fdb:1	flexor digitorum brevis:43:0.9308	0.9308	43
FDCD	FDCD:10	circular dichroism:10:0.7103	0.7103	10
FDCs	FDCs:12	Fixed-dose combinations:6:0.1148|fixed dose combinations:6:0.5290	0.5290	12
FDCS	FDCS:10	Florida Dental Care Study:10:0.7103	0.7103	10
FDCs	FDCs:168|FDCS:1	follicular dendritic cells:169:0.9823	0.9823	169
FDC	FDC:10	familial dilated cardiomyopathy:10:0.5856	0.5856	10
FDC	FDC:33	fixed-dose combination:20:0.4037|fixed dose combination:13:0.7753	0.7753	33
FDC	FDC:296	Follicular dendritic cells:223:0.9866|follicular dendritic cell:73:0.9591	0.9866	296
FDD	FDD:11	fluorescent differential display:11:0.6182	0.6182	11
FDE	FDE:52	fixed drug eruption:52:0.9427	0.9427	52
FDG-PET	FDG-PET:287	positron emission tomography:287:0.7427	0.7427	287
FDG-PET	FDG-PET:6	positron emission tomography with 18-fluorodeoxyglucose:6:0.3728	0.3728	6
FDG-PET	FDG-PET:4	positron emission tomography with fluorine-18 fluorodeoxyglucose:4:0.4422	0.4422	4
FDG-PET	FDG-PET:7	positron emission tomography with fluorodeoxyglucose:7:0.6411	0.6411	7
FDG	FDG:37	[(18)F]fluorodeoxyglucose:37:0.0172	0.0172	37
FDG	FDG:15	18-fluoro-2-deoxyglucose:15:0.0067	0.0067	15
FDG	FDG:15	[18F]fluoro-2-deoxy-D-glucose:15:0.0067	0.0067	15
FDG	FDG:26	[18F]-fluorodeoxyglucose:26:0.0119	0.0119	26
FDG	FDG:14	18fluorodeoxyglucose:14:0.0062	0.0062	14
FDG	FDG:14	2-[(18)F]fluoro-2-deoxy-D-glucose:14:0.0057	0.0057	14
FDG	FDG:14	2-deoxy-2[18F]fluoro-D-glucose:14:0.0062	0.0062	14
FDG	FDG:15	2-deoxy-2-fluoro-D-glucose:15:0.0067	0.0067	15
FDG	FDG:10	2-[fluorine 18]fluoro-2-deoxy-D-glucose:10:0.7103	0.7103	10
FDG	FDG:34	2-fluoro-2-deoxy-D-glucose:34:0.0158	0.0158	34
FDG	FDG:12	D-glucose:12:0.0053	0.0053	12
FDG	FDG:9	deoxy-D-glucose:9:0.0038	0.0038	9
FDG	FDG:10	F-18 deoxyglucose:10:0.0639	0.0639	10
FDG	FDG:17	F-18-Fluorodeoxyglucose:17:0.0076	0.0076	17
FDG	FDG:12	fluorine-18 deoxyglucose:12:0.0921	0.0921	12
FDG	FDG:22	Fluorine-18-fluorodeoxyglucose:22:0.0100	0.0100	22
FDG	FDG:33	fluoro-2-deoxy-D-glucose:33:0.0153	0.0153	33
FDG	FDG:9	fluoro-2-deoxyglucose:9:0.0038	0.0038	9
FDG	FDG:16	fluoro-deoxyglucose:16:0.0072	0.0072	16
FDH	FDH:44	familial dysalbuminemic hyperthyroxinemia:44:0.9308	0.9308	44
FDH	FDH:13	Focal dermal hypoplasia:13:0.6701	0.6701	13
FDH	FDH:48|fdh:1|Fdh:1	formate dehydrogenase:50:0.4569	0.4569	50
FdI	FdI:9	Azotobacter vinelandii ferredoxin I:9:0.6794	0.6794	9
FDI	FDI:8	Disability Index:8:0.1591	0.1591	8
FDI	FDI:123	first dorsal interosseous:123:0.9757	0.9757	123
FDI	FDI:42	first dorsal interosseous muscle:42:0.9291	0.9291	42
FDI	FDI:56	first dorsal interosseus:56:0.9467	0.9467	56
FDI	FDI:14	first dorsal interosseus muscle:14:0.7909	0.7909	14
FDL	FDL:51	flexor digitorum longus:51:0.9416	0.9416	51
FDLE	FDLE:11	fetal distal lung epithelial:11:0.7357	0.7357	11
FDLE	FDLE:11	fetal distal lung epithelium:11:0.7357	0.7357	11
FDM	FDM:10	filter diagonalization method:10:0.7103	0.7103	10
FDM	FDM:29	Form-deprivation myopia:16:0.3317|form deprivation myopia:13:0.7753	0.7753	29
FDM	FDM:7	freedom from distant metastasis:7:0.3524	0.3524	7
FDNB	FDNB:15	1-fluoro-2,4-dinitrobenzene:15:0.3256	0.3256	15
FDNB	FDNB:19	fluorodinitrobenzene:19:0.4186	0.4186	19
FDOPA	FDOPA:10|F-dopa:1	6-[(18)F]fluoro-L-DOPA:11:0.0943	0.0943	11
FDOPA	FDOPA:21|Fdopa:1|F-DOPA:1	6-[18F]fluoro-L-DOPA:23:0.2075	0.2075	23
FDPB	FDPB:12	finite difference Poisson-Boltzmann:12:0.7571	0.7571	12
FDPM	FDPM:21	photon migration:21:0.8594	0.8594	21
FDPase	FDPase:17|FD-Pase:1	fructose-1,6-diphosphatase:18:0.4857	0.4857	18
FDPs	FDPs:59|FDPS:1	degradation products:60:0.8954	0.8954	60
FDP	FDP:562|fdp:5	degradation products:503:0.9494|degradation product:64:0.9033	0.9494	567
FDP	FDP:80|fdp:3	flexor digitorum profundus:83:0.9640	0.9640	83
FDP	FDP:22	Frequency Doubling Perimetry:14:0.7909|frequency-doubling perimetry:8:0.1196	0.7909	22
FDP	FDP:137|FdP:1	fructose-1,6-diphosphate:98:0.0959|fructose 1,6-diphosphate:40:0.8867	0.8867	138
FDRs	FDRs:29	first-degree relatives:29:0.7970	0.7970	29
FDR	FDR:45	false discovery rate:45:0.9338	0.9338	45
FDR	FDR:23	first-degree relatives:23:0.5719	0.5719	23
FDs	FDs:16	dextrans:16:0.0938	0.0938	16
FDS	FDS:42	flexor digitorum superficialis:42:0.9291	0.9291	42
FDTD	FDTD:102|FD-TD:2	finite-difference time-domain:71:0.8789|finite difference time domain:33:0.9100	0.9100	104
FDT	FDT:63	frequency doubling technology:41:0.8867|frequency-doubling technology:22:0.2071	0.8867	63
FDT	FDT:9	frequency doubling technology perimetry:9:0.6794	0.6794	9
fdx	fdx:8|Fdx:1	ferredoxin:9:0.4444	0.4444	9
FD	FD:16	dextran:16:0.0125	0.0125	16
FD	FD:18	Fabry disease:10:0.1022|Fabry's disease:8:0.0604	0.1022	18
FD	FD:79	familial dysautonomia:79:0.9622	0.9622	79
FD	FD:12	familial dysbetalipoproteinemia:12:0.7571	0.7571	12
FD	FD:17	fascia dentata:17:0.8270	0.8270	17
Fd	Fd:87|FD:1	ferredoxin:88:0.0727	0.0727	88
Fd	Fd:11|FD:6	fetal day:17:0.7407	0.7407	17
FD	FD:9	fetal distress:9:0.5470	0.5470	9
FD	FD:20	fiber density:20:0.4574	0.4574	20
FD	FD:7	fibre density:7:0.0539	0.0539	7
FD	FD:45	fibrous dysplasia:45:0.7881	0.7881	45
FD	FD:14	Field desorption:14:0.7909	0.7909	14
FD	FD:9	finite difference:9:0.6794	0.6794	9
FD	FD:13	fixation disparity:13:0.7753	0.7753	13
FD	FD:22	flavor dilution:22:0.8657	0.8657	22
FD	FD:18	food deprivation:18:0.5940	0.5940	18
FD	FD:37|fd:1	fractal dimension:38:0.8417	0.8417	38
FD	FD:11	freeze-dried:11:0.0084	0.0084	11
FD	FD:12|Fd:1	freeze-drying:13:0.0100	0.0100	13
FD	FD:9	Friedreich's disease:9:0.0809	0.0809	9
FD	FD:109	functional dyspepsia:109:0.9427	0.9427	109
FE(NO)	FE(NO):27|Fe(NO):2	exhaled nitric oxide:29:0.7970	0.7970	29
FE(Na)	FE(Na):1	fractional excretion sodium:1:0.8365	0.8365	1
FE(Na)	FE(Na):7	Fractional sodium excretion:7:0.4438	0.4438	7
FEA	FEA:109	Finite element analysis:109:0.9567	0.9567	109
FECG	FECG:32|fECG:1	fetal electrocardiogram:33:0.8196	0.8196	33
fECG	FECG:4|fECG:4	Fetal electrocardiography:8:0.5006	0.5006	8
FECH	FECH:15	ferrochelatase:15:0.6667	0.6667	15
FECR	FECR:18	Faecal Egg Count Reduction:18:0.7539	0.7539	18
FECRT	FECRT:18|FECRt:1	faecal egg count reduction test:19:0.7658	0.7658	19
FECV	FECV:22|FeCV:1	feline enteric coronavirus:23:0.8715	0.8715	23
FECa	FECa:6	fractional excretion of calcium:6:0.2827	0.2827	6
FECs	FECs:24	faecal egg counts:24:0.5370	0.5370	24
FEC	FEC:28	egg count:28:0.8369	0.8369	28
FEC	FEC:12	epirubicin and cyclophosphamide:12:0.7718	0.7718	12
FEC	FEC:39	faecal egg counts:39:0.5194	0.5194	39
FEESST	FEESST:14	endoscopic evaluation of swallowing with sensory testing:14:0.7753	0.7753	14
FEES	FEES:19|fees:1	fiberoptic endoscopic evaluation of swallowing:20:0.6680	0.6680	20
FEF50	FEF50:2	Forced expiratory flow at 50% vital capacity:2:0.1973	0.1973	2
FeFV	FeFV:12	feline foamy virus:12:0.7571	0.7571	12
FEFs	FEFs:18	frontal eye fields:18:0.8365	0.8365	18
FEF	FEF:10	forced expiratory flow:10:0.5856	0.5856	10
FEF	FEF:193	frontal eye field:145:0.9794|frontal eye fields:48:0.9379	0.9794	193
FEHB	FEHB:25	Federal Employees Health Benefits:25:0.8816	0.8816	25
FEHBP	FEHBP:15	Federal Employees Health Benefits Program:15:0.8045	0.8045	15
FEH	FEH:27	focal epithelial hyperplasia:27:0.8312	0.8312	27
FEIA	FEIA:14	enzyme immunoassay:14:0.6173	0.6173	14
FEIBA	FEIBA:4|Feiba:1	activated prothrombin complex concentrate:5:0.5290	0.5290	5
FEISEM	FEISEM:6	Field emission in-lens scanning electron microscopy:6:0.5290	0.5290	6
FEK	FEK:8|FeK:1	fractional potassium excretion:9:0.6794	0.6794	9
FELASA	FELASA:7	Report of the Federation of European Laboratory Animal Science Associations:7:0.3524	0.3524	7
FELC	FELC:10	Friend erythroleukemia cells:10:0.7103	0.7103	10
FELi	FELi:18|FeLi:1	fractional excretion of lithium:19:0.8525	0.8525	19
FELi	FELi:17|FeLi:1|FE-Li:1	fractional lithium excretion:19:0.8449	0.8449	19
FEM	FEM:9	finite element:9:0.6794	0.6794	9
FEM	FEM:185	finite element method:185:0.9741	0.9741	185
FEM	FEM:56	finite element model:45:0.8964|finite element models:11:0.7357	0.8964	56
FEM	FEM:20	Finite element modeling:20:0.8525	0.8525	20
FEN1	FEN1:7|FEN-1:3|Fen1:2	flap endonuclease:12:0.6460	0.6460	12
FEN-1	FEN-1:38|FEN1:26|Fen1:6|Fen-1:1	flap endonuclease 1:39:0.9237|Flap endonuclease-1:32:0.9072	0.9237	71
FENIB	FENIB:8	familial encephalopathy with neuroserpin inclusion bodies:8:0.5006	0.5006	8
FENa+	FENa+:8|FeNa+:1	fractional excretion of sodium:9:0.6794	0.6794	9
FEN	FEN:10	d,l-fenfluramine:10:0.0604	0.0604	10
FEN	FEN:37|Fen:10	fenfluramine:47:0.3087	0.3087	47
FEN	FEN:9|Fen:3	Fenoterol:12:0.0738	0.0738	12
FEO	FEO:11	familial expansile osteolysis:11:0.7357	0.7357	11
FEO	FEO:22	oscillator:22:0.3621	0.3621	22
FEPi	FEPi:18	fractional excretion of phosphate:18:0.8365	0.8365	18
FEPs	FEPs:25	flash evoked potentials:15:0.8045|Flash-evoked potentials:10:0.1449	0.8045	25
FEP	FEP:7	flash evoked potential:7:0.5926	0.5926	7
FEP	FEP:7	fluorinated ethylene propylene:7:0.4438	0.4438	7
FEP	FEP:4|FE-P:2|FEp:2	fractional excretion of phosphate:8:0.6411	0.6411	8
FEP	FEP:24	free energy perturbation:24:0.7679	0.7679	24
FEP	FEP:9	free erythrocyte porphyrin:9:0.6794	0.6794	9
FEP	FEP:76	Free erythrocyte protoporphyrin:76:0.9378	0.9378	76
FEP	FEP:10|Fe-P:1|FEp:1	phosphorus:12:0.0391	0.0391	12
FERG	FERG:11|fERG:6|F-ERG:2	electroretinogram:19:0.5143	0.5143	19
FER	FER:23|Fer:16	ferritin:39:0.3333	0.3333	39
FER	FER:10	food efficiency ratio:10:0.3145	0.3145	10
FER	FER:4	fractional esterification rate:4:0.1618	0.1618	4
FESEM	FESEM:5|FE-SEM:1	field emission scanning electron microscope:6:0.5290	0.5290	6
FESS	FESS:174	Functional endoscopic sinus surgery:174:0.9545	0.9545	174
FES	FES:13	Falls Efficacy Scale:13:0.6701	0.6701	13
FES	FES:49	Family Environment Scale:49:0.9392	0.9392	49
FES	FES:62	fat embolism syndrome:62:0.9519	0.9519	62
FES	FES:364	functional electrical stimulation:364:0.9463	0.9463	364
Fe-S	Fe-S:41|FeS:8	iron-sulfur:49:0.0640	0.0640	49
Fe-S	Fe-S:8|FeS:1	iron-sulphur:9:0.0107	0.0107	9
fes	fes:5|FES:1	tyrosine kinase:6:0.1838	0.1838	6
FETAX	FETAX:48	frog embryo teratogenesis assay-Xenopus:26:0.8861|Frog Embryo Teratogenesis Assay--Xenopus:21:0.8594|Frog Embryo Teratogenesis Assay Xenopus:1:0.7909	0.8861	48
FETs	FETs:6	field effect transistors:6:0.5290	0.5290	6
FETi	FETi:11	fast extensor tibiae:11:0.7357	0.7357	11
FET	FET:7	field-effect transistor:7:0.2113	0.2113	7
FET	FET:16	Fluorescence energy transfer:16:0.7261	0.7261	16
FET	FET:11	forced expiration technique:11:0.7103	0.7103	11
FET	FET:12	forced expiratory time:12:0.7571	0.7571	12
FET	FET:7	frozen embryo transfer:7:0.2902	0.2902	7
FEUA	FEUA:8|FEua:4|FEuA:1	fractional excretion of uric acid:13:0.6701	0.6701	13
FEV(1)	FEV(1):19	forced expiratory volume:19:0.8449	0.8449	19
FEV(1)	FEV(1):71	forced expiratory volume in 1 s:71:0.9361	0.9361	71
FEV(1)	FEV(1):25	forced expiratory volume in 1 sec:25:0.8861	0.8861	25
FEV(1)	FEV(1):135	forced expiratory volume in 1 second:135:0.9783	0.9783	135
FEV(1)	FEV(1):8	forced expiratory volume in 1s:8:0.6794	0.6794	8
FEV(1)	FEV(1):77	forced expiratory volume in one second:77:0.9622	0.9622	77
FEV(1)	FEV(1):22	forced expired volume in 1 sec:22:0.8657	0.8657	22
FEV1.0	FEV1.0:22	forced expiratory volume:22:0.8715	0.8715	22
FEV1.0	FEV1.0:15|FeV1.0:1	forced expiratory volume in 1 second:16:0.8270	0.8270	16
FEV1	FEV1:15	forced expiratory volume at one second:15:0.9906	0.9906	15
FEV1	FEV1:1	forced expiratory volume during first second of expiration:1:0.4422	0.4422	1
FEV1	FEV1:196	forced expiratory volume in 1 sec:196:0.9856	0.9856	196
FEV1	FEV1:504|FEV-1:3	forced expiratory volume in 1 second:507:0.9850	0.9850	507
FEV1	FEV1:30	forced expiratory volume in 1s:30:0.9072	0.9072	30
FEV1	FEV1:31	lung function:31:0.4852	0.4852	31
FEV1	FEV1:13	pulmonary function:13:0.1250	0.1250	13
FEV1	FEV1:8	vital capacity:8:0.2090	0.2090	8
FEV1	FEV1:4	volume of air expelled in the first second of forced expiration:4:0.3170	0.3170	4
FEVR	FEVR:38	familial exudative vitreoretinopathy:38:0.9217	0.9217	38
FEV	FEV:24	forced expiratory volume:24:0.8768	0.8768	24
FEV	FEV:10	forced expiratory volume in one second:10:0.7103	0.7103	10
FF-MAS	FF-MAS:6	follicular fluid meiosis-activating sterol:6:0.5290	0.5290	6
FFAs	FFAs:361	free fatty acids:361:0.9781	0.9781	361
FFA	FFA:2615|ffa:10	free fatty acids:1496:0.9733|free fatty acid:1129:0.9698	0.9733	2625
FFA	FFA:33	fundus fluorescein angiography:33:0.7238	0.7238	33
FFA	FFA:22	fusiform face area:22:0.8657	0.8657	22
FFB	FFB:39	flexible fiberoptic bronchoscopy:39:0.8811	0.8811	39
FFBM	FFBM:11	fat-free body mass:11:0.5355	0.5355	11
FFD	FFD:11	distance:11:0.2632	0.2632	11
FFDM	FFDM:20	full-field digital mammography:20:0.6259	0.6259	20
FFE	FFE:37	free-flow electrophoresis:21:0.3767|free flow electrophoresis:16:0.8165	0.8165	37
FFF	FFF:39	field-flow fractionation:39:0.6563	0.6563	39
FFH	FFH:15	Forel's field H:15:0.8165	0.8165	15
FFI	FFI:12	2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole:12:0.0753	0.0753	12
FFI	FFI:7	Foot Function Index:7:0.5926	0.5926	7
FFL	FFL:14|FFl:4	follicular fluid:18:0.8365	0.8365	18
FFMI	FFMI:18	fat-free mass index:18:0.8365	0.8365	18
FFM	FFM:858|ffm:1	fat-free mass:740:0.7941|fat free mass:119:0.9350	0.9350	859
FFM	FFM:31	five-factor model:31:0.5933	0.5933	31
FFM	FFM:12	five-factor model of personality:12:0.5664	0.5664	12
FFM	FFM:9	fundus flavimaculatus:9:0.5470	0.5470	9
FFPE	FFPE:27	formalin-fixed paraffin-embedded:24:0.9241|formalin fixed paraffin embedded:3:0.2818	0.9241	27
FFP	FFP:17	Federal Financial Participation:17:0.8270	0.8270	17
FFP	FFP:54	freedom from progression:54:0.8401	0.8401	54
FFP	FFP:416	fresh frozen plasma:332:0.9806|fresh-frozen plasma:84:0.1576	0.9806	416
FFQ	FFQ:254	food frequency questionnaire:241:0.9876|food frequency questionnaires:13:0.7753	0.9876	254
FFQs	FFQs:34	food frequency questionnaires:24:0.8768|food-frequency questionnaires:10:0.1134	0.8768	34
FFRmyo	FFRmyo:13	myocardial fractional flow reserve:13:0.6701	0.6701	13
FFRs	FFRs:10	Frequency-following responses:10:0.4363	0.4363	10
FFR	FFR:16	fluid filtration rate:16:0.7261	0.7261	16
FFR	FFR:10	force-frequency relation:10:0.7103	0.7103	10
FFR	FFR:13	force-frequency relationship:13:0.6701	0.6701	13
FFR	FFR:88	Fractional flow reserve:88:0.9288	0.9288	88
FFR	FFR:32	freedom from relapse:32:0.8145	0.8145	32
FFR	FFR:61	frequency-following response:43:0.5207|frequency following response:18:0.8365	0.8365	61
FFR	FFR:14	fructose-fed rats:14:0.5111	0.5111	14
FFS	FFS:120	failure-free survival:120:0.8258	0.8258	120
FFS	FFS:222	fee-for-service:213:0.4362|fee for service:9:0.6794	0.6794	222
FFs	FFs:12	follicular fluids:12:0.7571	0.7571	12
FFTP	FFTP:10	first full-term pregnancy:10:0.7103	0.7103	10
FFT	FFT:341|fft:2	fast Fourier transform:331:0.9719|Fast Fourier Transforms:12:0.6460	0.9719	343
FFT	FFT:83	Fast Fourier Transformation:83:0.9247	0.9247	83
FFV	FFV:9	Feline foamy virus:9:0.6794	0.6794	9
FFx	FFx:9	femur fracture:9:0.6794	0.6794	9
FFY	FFY:5	notice announces the final Federal fiscal year:5:0.4422	0.4422	5
fFN	fFN:26|FFN:14|Ffn:4	fetal fibronectin:44:0.7413	0.7413	44
FF	FF:19	fast fatigable:19:0.5178	0.5178	19
FF	FF:15	feeding:15:0.0102	0.0102	15
FF	FF:9	fenfluramine:9:0.0058	0.0058	9
FF	FF:9	fenofibrate:9:0.0058	0.0058	9
FF	FF:10	fibrotic focus:10:0.7103	0.7103	10
FF	FF:224	filtration fraction:224:0.8217	0.8217	224
FF	FF:42|F-F:1	fimbria-fornix:43:0.0305	0.0305	43
FF	FF:9	fluorescein flowmetry:9:0.6794	0.6794	9
FF	FF:397|ff:2	follicular fluid:370:0.9786|follicular fluids:29:0.7970	0.9786	399
FF	FF:22	form factor:22:0.5095	0.5095	22
FF	FF:20|ff:1	French Francs:21:0.7865	0.7865	21
FF	FF:2	rats fed a fiber-free:2:0.5290	0.5290	2
FG-7142	FG-7142:10	n-methyl-beta-carboline-3-carboxamide:10:0.5294	0.5294	10
FGAM	FGAM:8	formylglycinamidine ribonucleotide:8:0.5006	0.5006	8
FGAR	FGAR:9	ribonucleotide:9:0.5000	0.5000	9
FGA	FGA:9	fluorogestone acetate:9:0.3945	0.3945	9
FGC	FGC:10	female genital cutting:10:0.7103	0.7103	10
FGDs	FGDs:30	Focus group discussions:30:0.8472	0.8472	30
FGD	FGD:17	Familial glucocorticoid deficiency:17:0.8270	0.8270	17
FGD	FGD:18	flue gas desulfurization:18:0.8365	0.8365	18
FGD	FGD:9	Focus Group Discussions:9:0.5470	0.5470	9
FGF-10	FGF-10:13|Fgf10:12|FGF10:11	Fibroblast growth factor 10:23:0.8715|fibroblast growth factor-10:13:0.7753	0.8715	36
FGF-1	FGF-1:51|FGF1:9	acidic fibroblast growth factor:60:0.8181	0.8181	60
FGF-1	FGF-1:105|FGF1:26	fibroblast growth factor-1:76:0.9378|Fibroblast growth factor 1:55:0.9458	0.9458	131
FGF-23	FGF-23:24|FGF23:13	fibroblast growth factor-23:19:0.8449|fibroblast growth factor 23:18:0.7539	0.8449	37
FGF-2	FGF-2:285|FGF2:72|Fgf2:3	Basic fibroblast growth factor:360:0.8658	0.8658	360
FGF-2	FGF-2:524|FGF2:134|Fgf-2:1	fibroblast growth factor-2:450:0.9674|fibroblast growth factor 2:209:0.9771	0.9771	659
FGF3	FGF3:8|FGF-3:1|Fgf3:1	fibroblast growth factor 3:10:0.7103	0.7103	10
FGF-4	FGF-4:35|FGF4:11|fgf-4:4|Fgf4:3|Fgf-4:2	fibroblast growth factor-4:37:0.9197|Fibroblast growth factor 4:18:0.8365	0.9197	55
FGF-5	FGF-5:18|FGF5:3|Fgf5:1|Fgf-5:1	fibroblast growth factor-5:14:0.7909|Fibroblast growth factor 5:9:0.6794	0.7909	23
FGF7	FGF7:6|FGF-7:3	fibroblast growth factor 7:9:0.6794	0.6794	9
FGF-7	FGF-7:8|FGF7:2	keratinocyte growth factor:10:0.7103	0.7103	10
FGF8	FGF8:25|FGF-8:14|Fgf8:10|Fgf-8:1|fgf8:1	fibroblast growth factor 8:33:0.9100|fibroblast growth factor-8:18:0.8365	0.9100	51
FGF-9	FGF-9:13|FGF9:6|Fgf9:2|Fgf-9:1	fibroblast growth factor 9:13:0.7753|fibroblast growth factor-9:9:0.6794	0.7753	22
FGF-BP	FGF-BP:11	Fibroblast growth factor-binding protein:11:0.7357	0.7357	11
FGFR-1	FGFR-1:6|FGFR1:5|fgfr-1:1	fibroblast growth factor receptor:12:0.7753	0.7753	12
FGFR1	FGFR1:77|FGFR-1:50|FGF-R1:4|Fgfr1:4|fgfr1:2|fgfr-1:1|FGFr1:1	fibroblast growth factor receptor 1:73:0.8948|fibroblast growth factor receptor-1:66:0.9548	0.9548	139
FGFR2	FGFR2:3|FGFR-2:2	fibroblast growth factor receptor:5:0.4422	0.4422	5
FGFR2	FGFR2:84|FGFR-2:5|FGF-R2:4|Fgfr2:3|fgfr2:1	fibroblast growth factor receptor 2:87:0.9455|fibroblast growth factor receptor-2:10:0.7103	0.9455	97
FGFR2	FGFR2:10|Fgfr2:1	fibroblast growth factor receptor 2 gene:11:0.7357	0.7357	11
FGFR3	FGFR3:160|FGFR-3:20|Fgfr3:7|fgfr3:1|FGF-R3:1	Fibroblast growth factor receptor 3:174:0.9396|fibroblast growth factor receptor-3:15:0.8045	0.9396	189
FGFR3	FGFR3:9	fibroblast growth factor receptor 3 gene:9:0.5470	0.5470	9
FGFR4	FGFR4:18|FGFR-4:6|FGF-R4:1	fibroblast growth factor receptor 4:14:0.6911|fibroblast growth factor receptor-4:11:0.6182	0.6911	25
FGFR	FGFR:104|FGF-R:9|Fgfr:4|FgfR:3	FGF receptor:99:0.3045|FGF receptors:21:0.2586	0.3045	120
FGFR	FGFR:171|FGF-R:13|FGFr:3|Fgfr:1|fgfr:1	fibroblast growth factor receptor:162:0.9275|fibroblast growth factor receptors:27:0.8312	0.9275	189
FGFb	FGFb:7|FGF-b:3	basic fibroblast growth factor:10:0.7103	0.7103	10
FGFs	FGFs:453|Fgfs:15|fgfs:1|FGFS:1	Fibroblast growth factors:470:0.9801	0.9801	470
FGF	FGF:1732|Fgf:25|fgf:2	fibroblast growth factor:1656:0.9834|Fibroblast growth factors:103:0.9004	0.9834	1759
FGF	FGF:61	fresh gas flow:47:0.9366|Fresh gas flows:14:0.7909	0.9366	61
FGID	FGID:13	functional gastrointestinal disorders:13:0.7753	0.7753	13
FGIDs	FGIDs:14	functional gastrointestinal disorders:14:0.7909	0.7909	14
FGM	FGM:90	female genital mutilation:90:0.9461	0.9461	90
FGM	FGM:5	fibrous glass membrane:5:0.4422	0.4422	5
FGN	FGN:10	fibrillary glomerulonephritis:10:0.3145	0.3145	10
FGN	FGN:13|Fgn:6|fgn:3	fibrinogen:22:0.4118	0.4118	22
FGPs	FGPs:15	fundic gland polyps:15:0.8045	0.8045	15
FGP	FGP:11	fluorescent granular perithelial:11:0.7357	0.7357	11
FGR	FGR:88	fetal growth restriction:88:0.8984	0.8984	88
FGR	FGR:28	fetal growth retardation:28:0.8369	0.8369	28
FGS	FGS:13	Female genital schistosomiasis:13:0.7753	0.7753	13
FGS	FGS:56	focal glomerular sclerosis:56:0.7891	0.7891	56
FGS	FGS:91	focal glomerulosclerosis:91:0.6338	0.6338	91
FGS	FGS:23	focal segmental glomerulosclerosis:23:0.9100	0.9100	23
FGU	FGU:16	Forearm glucose uptake:16:0.7261	0.7261	16
FG	FG:44|Fg:5	fast glycolytic:40:0.3379|fast-glycolytic:9:0.0075	0.3379	49
FG	FG:13	fasting glucose:13:0.5335	0.5335	13
FG	FG:61	fibrin glue:61:0.9511	0.9511	61
Fg	Fg:165|FG:23|fg:16	Fibrinogen:204:0.1921	0.1921	204
FG	FG:6	fluorescein glucuronide:6:0.1838	0.1838	6
FG	FG:9	Fournier's Gangrene:9:0.6794	0.6794	9
FG	FG:18	fusiform gyrus:18:0.8365	0.8365	18
FG	FG:12|Fg:1	group:13:0.0113	0.0113	13
FG	FG:23	retrograde tracer Fluoro-Gold:23:0.5933	0.5933	23
FG	FG:25	retrograde tracer fluorogold:25:0.6024	0.6024	25
FH+	FH+:12	family history:12:0.7571	0.7571	12
FH+	FH+:11	family history of hypertension:11:0.6182	0.6182	11
FH+	FH+:6	family history positive:6:0.5290	0.5290	6
FH+	FH+:11	history of alcoholism:11:0.5355	0.5355	11
FH-	FH-:12	family history:12:0.7571	0.7571	12
FH-	FH-:13	negative:13:0.1765	0.1765	13
FH2	FH2:6	Formin Homology 2:6:0.5290	0.5290	6
FH4	FH4:11	tetrahydrofolate:11:0.6250	0.6250	11
FHA	FHA:8	family history of alcoholism:8:0.5006	0.5006	8
FHA	FHA:51	forkhead-associated:51:0.1114	0.1114	51
FHA	FHA:11	functional hypothalamic amenorrhea:11:0.6182	0.6182	11
FHBL	FHBL:28	familial hypobetalipoproteinemia:28:0.8369	0.8369	28
fHb	fHb:9|FHb:4|F-Hb:1|F-HB:1|f-Hb:1|FHB:1	free hemoglobin:17:0.7407	0.7407	17
FHB	FHB:32	Fusarium head blight:32:0.8563	0.8563	32
FHCM	FHCM:9|fHCM:2|F-HCM:1	Familial hypertrophic cardiomyopathy:12:0.6460	0.6460	12
FHC	FHC:14	familial hypercholesterolemia:14:0.6911	0.6911	14
FHC	FHC:118	familial hypertrophic cardiomyopathy:118:0.9465	0.9465	118
FHC	FHC:9|fhc:1	heavy chain:10:0.7103	0.7103	10
FHC	FHC:24	heterochromic cyclitis:24:0.8768	0.8768	24
FHD	FHD:7|FHd:2	Focal hand dystonia:9:0.6794	0.6794	9
FHD	FHD:10	frontal hypothalamic deafferentation:10:0.7103	0.7103	10
FHF	FHF:322	fulminant hepatic failure:322:0.9801	0.9801	322
FHH	FHH:23	familial hypocalciuric hypercalcaemia:23:0.8715	0.8715	23
FHH	FHH:56	familial hypocalciuric hypercalcemia:56:0.8281	0.8281	56
FHH	FHH:6	family history of hypertension:6:0.5290	0.5290	6
FH-II	FH-II:10	Familial Hyperaldosteronism Type II:10:0.7103	0.7103	10
FHIT	FHIT:121|Fhit:7|fhit:1	fragile histidine triad:129:0.9768	0.9768	129
FH-I	FH-I:10	familial hyperaldosteronism type I:10:0.7103	0.7103	10
FHI	FHI:59	Family Health International:59:0.9190	0.9190	59
FHI	FHI:9	fibrous hamartoma of infancy:9:0.6794	0.6794	9
FHL-1	FHL-1:14	factor H-like protein 1:14:0.7909	0.7909	14
FHL2	FHL2:6	LIM-only protein 2:6:0.2827	0.2827	6
FHLH	FHLH:13	familial hemophagocytic lymphohistiocytosis:13:0.7753	0.7753	13
FHL	FHL:42	familial hemophagocytic lymphohistiocytosis:42:0.8893	0.8893	42
FHL	FHL:36	flexor hallucis longus:36:0.9174	0.9174	36
FHM	FHM:88	Familial hemiplegic migraine:88:0.9455	0.9455	88
FHM	FHM:11	fathead minnow:11:0.6182	0.6182	11
FHNC	FHNC:11	functional hepatic nitrogen clearance:11:0.6182	0.6182	11
FHN	FHN:16|FH-N:1	family history negative:17:0.7407	0.7407	17
FHP	FHP:12	Family Health Program:12:0.7571	0.7571	12
FHP	FHP:17|FH-P:1	Family history positive:18:0.7539	0.7539	18
FHP	FHP:18	fasting heat production:18:0.7539	0.7539	18
FHRV	FHRV:9	fetal heart rate variability:9:0.5470	0.5470	9
FHR	FHR:7	familial hypophosphatemic rickets:7:0.4438	0.4438	7
FHR	FHR:13	fawn-hooded rat:13:0.7753	0.7753	13
FHR	FHR:726|fHR:1|fhr:1	fetal heart rate:719:0.9367|Fetal heart rates:9:0.5856	0.9367	728
FHSA	FHSA:22	family health services authority:22:0.8657	0.8657	22
FHS	FHS:10	Fetal Hydantoin Syndrome:10:0.5856	0.5856	10
FHS	FHS:8|F-HS:1	Floating-Harbor syndrome:9:0.1409	0.1409	9
FHS	FHS:13	Framingham Heart Study:13:0.2660	0.2660	13
FHS	FHS:11|-FHS:1	human serum:12:0.6460	0.6460	12
FHS	FHS:7	NHLBI Family Heart Study:7:0.3455	0.3455	7
FHTG	FHTG:9	familial hypertriglyceridemia:9:0.5470	0.5470	9
FHU	FHU:10	Fuchs' heterochromic uveitis:10:0.7103	0.7103	10
FHV-1	FHV-1:27|FHV1:7	feline herpesvirus 1:18:0.6903|feline herpesvirus-1:16:0.8165	0.8165	34
FHV-1	FHV-1:55|FHV1:2	feline herpesvirus type 1:57:0.9494	0.9494	57
FHV	FHV:21	feline herpesvirus:21:0.6400	0.6400	21
FHV	FHV:43	flock house virus:43:0.9308	0.9308	43
FI(O(2))	FI(O(2)):4|Fi(O(2)):2	inspired O(2) fraction:6:0.3728	0.3728	6
FI-RSV	FI-RSV:6	formalin-inactivated RSV:6:0.2243	0.2243	6
FIA	FIA:237	Flow injection analysis:192:0.9844|flow-injection analysis:45:0.1278	0.9844	237
FIA	FIA:13	fluorescence immunoassay:13:0.2660	0.2660	13
FIA	FIA:7	fluorescent immunoassay:7:0.0655	0.0655	7
FIA	FIA:22	fluoroimmunoassay:22:0.0439	0.0439	22
FIA	FIA:90	Freund's incomplete adjuvant:90:0.8740	0.8740	90
FIAM	FIAM:10	free ion activity model:10:0.7103	0.7103	10
FIAT	FIAT:6	Fatty acid incorporation into adipose tissue:6:0.5290	0.5290	6
FIAU	FIAU:18	fialuridine:18:0.2537	0.2537	18
FIAX	FIAX:9	immunoassay:9:0.3636	0.3636	9
FIC	FIC:6	feline interstitial cystitis:6:0.5290	0.5290	6
FIC	FIC:77	fractional inhibitory concentration:77:0.8564	0.8564	77
FID	FID:44	flame ionization detection:44:0.6608	0.6608	44
FID	FID:49	free induction decay:49:0.9392	0.9392	49
FIE	FIE:9	ENDOSPERM:9:0.5333	0.5333	9
FIF	FIF:37	formaldehyde-induced fluorescence:37:0.5643	0.5643	37
FIGE	FIGE:51	field inversion gel electrophoresis:51:0.9416	0.9416	51
FIGLU	FIGLU:22|FiGlu:2	formiminoglutamic acid:24:0.6427	0.6427	24
FIGO	FIGO:277	International Federation of Gynecology and Obstetrics:277:0.9716	0.9716	277
FIGO	FIGO:13	International Federation of Obstetrics and Gynecology:13:0.7753	0.7753	13
FIHP	FIHP:15	Familial isolated hyperparathyroidism:15:0.8045	0.8045	15
FII	FII:13|F-II:2	Factor II:15:0.3821	0.3821	15
FII	FII:16|fII:2	prothrombin:18:0.2125	0.2125	18
FIM+FAM	FIM+FAM:8	Functional Assessment Measure:8:0.5006	0.5006	8
FIMR	FIMR:13	fetal and infant mortality review:13:0.7571	0.7571	13
FIM	FIM:13	factor increasing monocytopoiesis:13:0.7753	0.7753	13
fim	fim:7|FIM:4	fimbriae:11:0.0185	0.0185	11
FIM	FIM:409	Functional Independence Measure:409:0.9882	0.9882	409
FIM	FIM:13	Functional Independence Measurement:13:0.7753	0.7753	13
FiO2	FiO2:54|FIO2:38|Fio2:2|FIo2:1	fraction of inspired oxygen:95:0.5017	0.5017	95
FIO2	FIO2:10	fractional inspired O2 concentration:10:0.3145	0.3145	10
FIO2	FIO2:30|FiO2:4|FIo2:1|Fio2:1	inspired O2:36:0.6807	0.6807	36
FIO2	FIO2:24|FIo2:3|FiO2:1	inspired O2 fraction:28:0.7905	0.7905	28
FIO2	FIO2:36|FiO2:35|Fio2:1	inspired oxygen concentration:63:0.7796|inspired oxygen concentrations:9:0.5000	0.7796	72
FIO2	FIO2:27|FiO2:17|Fio2:1	inspired oxygen fraction:45:0.7270	0.7270	45
FiO2	FiO2:5|FIO2:3	oxygen fractions:8:0.4102	0.4102	8
FIPV	FIPV:85	feline infectious peritonitis virus:85:0.9648	0.9648	85
FIP	FIP:107	feline infectious peritonitis:107:0.9718	0.9718	107
FiP	FiP:10|FIP:1	filiform papillae:11:0.7357	0.7357	11
FIQ	FIQ:51	Fibromyalgia Impact Questionnaire:51:0.9416	0.9416	51
FIRDA	FIRDA:13	Frontal intermittent rhythmic delta activity:13:0.6701	0.6701	13
FIRI	FIRI:22	fasting insulin resistance index:22:0.8657	0.8657	22
FIR	FIR:10	far-infrared:10:0.0849	0.0849	10
FIR	FIR:40	finite impulse response:40:0.9256	0.9256	40
FISP	FISP:31	fast imaging with steady-state precession:31:0.8644	0.8644	31
FIS	FIS:3	factor of inversion stimulation:3:0.8715	0.8715	3
FIS	FIS:18	fatigue impact scale:18:0.8365	0.8365	18
FITC	FITC:32	fluorescein:32:0.0300	0.0300	32
FITC	FITC:74|Fitc:1	fluorescein 5'-isothiocyanate:39:0.9237|fluorescein-5-isothiocyanate:19:0.0174|fluorescein 5-isothiocyanate:17:0.7407	0.9237	75
FITC	FITC:697	fluorescein isothiocyanate:655:0.8680|fluorescein-isothiocyanate:42:0.0397	0.8680	697
FITC	FITC:8	fluorescein isothiocynate:8:0.5006	0.5006	8
FIV	FIV:771|Fiv:1	feline immunodeficiency virus:772:0.9788	0.9788	772
FIX	FIX:121|fIX:8|F-IX:1	factor IX:130:0.8305	0.8305	130
FIX	FIX:7|Fix:1|fix:1	fixation:9:0.0437	0.0437	9
FIZ	FIZ:10	film in situ zymography:10:0.7103	0.7103	10
FI	FI:8|fI:3|fi:2	factor I:13:0.3554	0.3554	13
FI	FI:10	fasting insulin:10:0.3470	0.3470	10
FI	FI:19	fatigue index:19:0.0833	0.0833	19
FI	FI:24	fecal incontinence:24:0.5848	0.5848	24
FI	FI:34	Feed intake:34:0.1732	0.1732	34
FI	FI:43	fixed interval:43:0.7795	0.7795	43
FI	FI:99	flow injection:80:0.9627|flow-injection:19:0.0165	0.9627	99
FI	FI:58	fluorescence intensity:58:0.6959	0.6959	58
FI	FI:11	fluorescent intensity:11:0.0574	0.0574	11
FI	FI:91	food intake:91:0.5956	0.5956	91
f-I	f-I:11|F-I:7	frequency-current:18:0.0156	0.0156	18
FI	FI:17	fundamental imaging:17:0.8365	0.8365	17
FI	FI:10	furcation involvement:10:0.5856	0.5856	10
f-I	f-I:4|F-I:1	injected current:5:0.0736	0.0736	5
FI	FI:6	purified fraction:6:0.0611	0.0611	6
FI	FI:24	under a fixed-interval:24:0.1897	0.1897	24
FI	FI:1	under multiple fixed-interval:1:0.6024	0.6024	1
FJB	FJB:9|FJ-B:2	Fluoro-Jade B:11:0.4728	0.4728	11
FJHN	FJHN:10	familial juvenile hyperuricaemic nephropathy:10:0.6794	0.6794	10
FJHN	FJHN:13	Familial juvenile hyperuricemic nephropathy:13:0.7753	0.7753	13
FJN	FJN:9	familial juvenile nephronophthisis:9:0.6794	0.6794	9
FJ	FJ:12|F-J:1	Fluoro-Jade:13:0.3000	0.3000	13
FKBP-12	FKBP-12:6	binding protein-12:6:0.1148	0.1148	6
FKBP12	FKBP12:36|FKBP-12:10	FK506 binding protein:23:0.5025|FK506-binding protein:23:0.2268	0.5025	46
FKBP12	FKBP12:21	FK506 binding protein 12:11:0.6182|FK506-binding protein 12:10:0.1878	0.6182	21
FKBP	FKBP:7	binding proteins:7:0.1641	0.1641	7
FKBP	FKBP:105|FK-BP:1|FKbp:1	FK506-binding protein:61:0.3604|FK506 binding protein:40:0.6365|FK506-binding proteins:6:0.1010	0.6365	107
FKHR	FKHR:11	rhabdomyosarcoma:11:0.2564	0.2564	11
FKN	FKN:17|Fkn:2|fkn:1	fractalkine:20:0.7917	0.7917	20
FKRP	FKRP:11	fukutin-related protein:11:0.5355	0.5355	11
FLA-ABS	FLA-ABS:12	fluorescent leprosy antibody absorption:12:0.6460	0.6460	12
FLAIR	FLAIR:368	fluid-attenuated inversion recovery:211:0.6298|fluid-attenuated inversion-recovery:81:0.9415|fluid attenuated inversion recovery:76:0.9180	0.9415	368
FLAP	FLAP:98|flap:1	5-lipoxygenase-activating protein:58:0.2986|5-lipoxygenase activating protein:41:0.4829	0.4829	99
FLAP	FLAP:17	5-LO activating protein:17:0.1527	0.1527	17
FLCZ	FLCZ:41	fluconazole:41:0.9524	0.9524	41
FLCs	FLCs:10|flcs:1	light chains:11:0.7357	0.7357	11
FLC	FLC:18	Fibrolamellar carcinoma:18:0.5560	0.5560	18
FLC	FLC:33	FLOWERING LOCUS C:33:0.9100	0.9100	33
FLC	FLC:28	fluconazole:28:0.0783	0.0783	28
FLC	FLC:20|FLc:1	free light chains:12:0.7571|free light chain:9:0.4587	0.7571	21
fLC	fLC:4|FLC:1	freshly isolated LC:5:0.4422	0.4422	5
FLC	FLC:40	Friend erythroleukemia cells:36:0.8336|Friend erythroleukemia cell:4:0.1618	0.8336	40
FLC	FLC:39	Friend Leukemia Cells:39:0.8142	0.8142	39
FLC	FLC:10	Friend leukemia complex:10:0.7103	0.7103	10
FLD	FLD:20	farmer's lung disease:20:0.5279	0.5279	20
fld	fld:13	fatty liver dystrophy:13:0.7753	0.7753	13
Fld	Fld:17|FLD:2|fld:2	flavodoxin:21:0.1099	0.1099	21
FLD	FLD:9	frontal lobe degeneration:9:0.6794	0.6794	9
FLD	FLD:9	Frontal lobe degeneration of non-Alzheimer type:9:0.6794	0.6794	9
FLD	FLD:27	frontal lobe dementia:27:0.8903	0.8903	27
FLE	FLE:9	Family Life Education:9:0.6794	0.6794	9
FLE	FLE:48	frontal lobe epilepsy:48:0.9379	0.9379	48
FLF	FLF:9	fermented liquid feed:9:0.6794	0.6794	9
FLF	FLF:9	fulminant liver failure:9:0.6794	0.6794	9
FLHCC	FLHCC:7|FL-HCC:5	fibrolamellar hepatocellular carcinoma:12:0.6460	0.6460	12
FLHS	FLHS:8	fatty liver-hemorrhagic syndrome:8:0.6411	0.6411	8
flh	flh:13|Flh:1	floating head:14:0.6911	0.6911	14
FLICE	FLICE:7	interleukin-1beta-converting enzyme:7:0.1850	0.1850	7
fliC	fliC:14	flagellin gene:14:0.4367	0.4367	14
FLIC	FLIC:41|FLI-C:3	Functional Living Index-Cancer:41:0.9274|Functional Living Index Cancer:3:0.7909	0.9274	44
FLIE	FLIE:9	Functional Living Index-Emesis:9:0.6794	0.6794	9
FLIM	FLIM:26	fluorescence lifetime imaging:26:0.8251	0.8251	26
FLIM	FLIM:38	fluorescence lifetime imaging microscopy:38:0.8455	0.8455	38
FLIPR	FLIPR:37	Imaging Plate Reader:37:0.8749	0.8749	37
FLI	FLI:9	fetal liver infusion:9:0.6794	0.6794	9
FLI	FLI:22	Fos-like immunoreactive:22:0.6178	0.6178	22
FLI	FLI:146	Fos-like immunoreactivity:146:0.7057	0.7057	146
FLKS	FLKS:21	fatty liver and kidney syndrome:21:0.8594	0.8594	21
FLK	FLK:9	fetal lamb kidney:9:0.5470	0.5470	9
FLMP	FLMP:18	fuzzy logical model of perception:18:0.8365	0.8365	18
FLM	FLM:20	fetal lung maturity:20:0.7766	0.7766	20
FLM	FLM:4	fraction of labeled mitoses:4:0.1973	0.1973	4
FLM	FLM:9	fraction of labelled mitoses:9:0.5470	0.5470	9
FLN	FLN:11	Fluorescence line narrowing:11:0.7357	0.7357	11
FLP	FLP:4|Flp:2	site-specific recombinase:6:0.2902	0.2902	6
FLRG	FLRG:22	follistatin-related gene:22:0.7400	0.7400	22
FLRX	FLRX:19	fleroxacin:19:0.9000	0.9000	19
FLSs	FLSs:16	fibroblast-like synoviocytes:16:0.7261	0.7261	16
FLS	FLS:8	fibroblast-like synovial cells:8:0.6411	0.6411	8
FLS	FLS:111	fibroblast-like synoviocytes:111:0.9298	0.9298	111
FLs	FLs:37	follicular lymphomas:37:0.9197	0.9197	37
FLS	FLS:11	forward light scatter:11:0.7357	0.7357	11
Flt-1	Flt-1:18|flt-1:5|Flt1:2|FLT-1:2	fms-like tyrosine kinase:27:0.7066	0.7066	27
Flt-1	Flt-1:17|flt-1:4|FLT-1:4|flt1:2|FLT1:1	fms-like tyrosine kinase 1:14:0.7909|fms-like tyrosine kinase-1:14:0.7909	0.7909	28
flt-1	flt-1:3|Flt1:1|FLT-1:1|Flt-1:1	VEGF receptor:6:0.1845	0.1845	6
Flt-1	Flt-1:9|FLT-1:2|flt-1:1	VEGF receptor-1:12:0.3813	0.3813	12
FLT3	FLT3:25|Flt3:5|FLT-3:2|flt3:2	Fms-like tyrosine kinase 3:34:0.6735	0.6735	34
FLT	FLT:14	3'-fluoro-3'-deoxythymidine:14:0.1092	0.1092	14
FLU	FLU:11|flu:3	[3H]flunitrazepam:14:0.0305	0.0305	14
FLU	FLU:6|Flu:1	antiandrogen flutamide:7:0.0756	0.0756	7
FLU	FLU:31|flu:9|Flu:2	fluconazole:42:0.0962	0.0962	42
FLU	FLU:27|flu:8|Flu:1	Fludarabine:36:0.0822	0.0822	36
FLU	FLU:11|flu:3|Flu:1	flumazenil:15:0.0329	0.0329	15
FLU	FLU:13	flumequine:13:0.0282	0.0282	13
FLU	FLU:11|flu:6	Flunarizine:17:0.0376	0.0376	17
FLU	FLU:8|flu:1	Flunisolide:9:0.0188	0.0188	9
FLU	FLU:13|flu:5|Flu:1	fluorescein:19:0.0423	0.0423	19
FLU	FLU:43|flu:3	fluoxetine:46:0.1056	0.1056	46
FLU	FLU:22|flu:2	fluphenazine:24:0.0540	0.0540	24
flu	flu:14|FLU:3	influenza:17:0.0376	0.0376	17
flu	flu:9|FLU:5	influenza virus:14:0.8768	0.8768	14
FLV	FLV:14	fluvoxamine:14:0.1024	0.1024	14
FLV	FLV:60	Friend leukemia virus:60:0.8181	0.8181	60
FLX	FLX:51|Flx:7	fluoxetine:58:0.7500	0.7500	58
FLZ	FLZ:13	fluconazole:13:0.5217	0.5217	13
FL-SMC	FL-SMC:7|FLsmc:4	sensorimotor cortex:11:0.7357	0.7357	11
FL	FL:18	expiratory flow limitation:18:0.4934	0.4934	18
FL	FL:5	facial lobe:5:0.0517	0.0517	5
FL	FL:36	farmer's lung:36:0.8336	0.8336	36
FL	FL:109	Fetal liver:109:0.8190	0.8190	109
FL	FL:19	filtration leukapheresis:19:0.8449	0.8449	19
FL	FL:7|fl:3	Firefly luciferase:10:0.5856	0.5856	10
FL	FL:51	flt-3 ligand:51:0.1434	0.1434	51
FL	FL:156	flt3 ligand:156:0.5392	0.5392	156
FL	FL:10|Fl:2	fluoranthene:12:0.0064	0.0064	12
FL	FL:48|Fl:12	fluorescein:60:0.0341	0.0341	60
FL	FL:31|Fl:5	fluorescence:36:0.0203	0.0203	36
FL	FL:11|Fl:5	fluorescent:16:0.0087	0.0087	16
FL	FL:7	fluorescent light:7:0.3524	0.3524	7
FL	FL:9	flutamide:9:0.0046	0.0046	9
FL	FL:291	follicular lymphoma:236:0.9607|follicular lymphomas:55:0.8645	0.9607	291
FL	FL:9	Foreign Language:9:0.6794	0.6794	9
FL	FL:10	Friend erythroleukemia:10:0.7103	0.7103	10
FL	FL:11	Friend leukemia:11:0.7357	0.7357	11
FL	FL:8	frontal lobe:8:0.2619	0.2619	8
FL	FL:9	fructoselysine:9:0.0046	0.0046	9
FL	FL:25|fl:5|Fl:2|-FL:1	full-length:33:0.0185	0.0185	33
FM3A	FM3A:9	mammary carcinoma:9:0.6794	0.6794	9
FMAIT	FMAIT:17	fetomaternal alloimmune thrombocytopenia:17:0.5760	0.5760	17
FMA	FMA:15	fluorescein mercuric acetate:15:0.8045	0.8045	15
FMA	FMA:10	Foundational Model of Anatomy:10:0.7103	0.7103	10
FMA	FMA:10	Fugl-Meyer Assessment:10:0.3867	0.3867	10
FMCA	FMCA:43	fluorometric microculture cytotoxicity assay:43:0.8917	0.8917	43
FMCG	FMCG:7|fMCG:2	fetal magnetocardiogram:9:0.3945	0.3945	9
fMCG	fMCG:11|FMCG:8	Fetal magnetocardiography:19:0.7539	0.7539	19
FMDV	FMDV:632	foot-and-mouth disease virus:632:0.8411	0.8411	632
FMD	FMD:150	Fibromuscular dysplasia:150:0.8834	0.8834	150
FMD	FMD:138|fmd:1	Flow-mediated dilatation:120:0.7233|flow mediated dilatation:19:0.8449	0.8449	139
FMD	FMD:8	flow-mediated dilation of the brachial artery:8:0.6411	0.6411	8
FMD	FMD:22	Flow-mediated vasodilatation:22:0.5581	0.5581	22
FMD	FMD:70	Flow-mediated vasodilation:70:0.7729	0.7729	70
FMD	FMD:453|Fmd:1	foot-and-mouth disease:317:0.6341|Foot and Mouth Disease:137:0.9334	0.9334	454
FMD	FMD:11	foramen magnum decompression:11:0.7357	0.7357	11
FMEA	FMEA:15	Failure Mode and Effects Analysis:9:0.7103|Failure modes and effects analysis:6:0.5926	0.7103	15
FMEA	FMEA:3	Failure Mode Effect Analysis:3:0.6411	0.6411	3
FMF	FMF:476|fMf:1	familial Mediterranean fever:477:0.9864	0.9864	477
FMF	FMF:32	flow microfluorometry:32:0.9072	0.9072	32
FMGs	FMGs:28	foreign medical graduates:28:0.8978	0.8978	28
FMH	FMH:36	alpha-fluoromethylhistidine:36:0.2465	0.2465	36
FMH	FMH:8	fetomaternal haemorrhage:8:0.1591	0.1591	8
FMH	FMH:27	fetomaternal hemorrhage:27:0.5729	0.5729	27
FMH	FMH:8	fibromuscular hyperplasia:8:0.4102	0.4102	8
FMISO	FMISO:12	Fluoromisonidazole:12:0.4783	0.4783	12
FMI	FMI:14	fat mass index:14:0.7909	0.7909	14
Fmi	Fmi:7|fmi:4	Flamingo:11:0.1818	0.1818	11
FMLA	FMLA:11	Family and Medical Leave Act:11:0.7571	0.7571	11
FMLC	FMLC:8	fetal mouse liver cells:8:0.6411	0.6411	8
FMLP	FMLP:12|fMLP:6	chemotactic peptide:18:0.2687	0.2687	18
FMLP	FMLP:7|fMLP:4	chemotactic peptide f-met-leu-phe:11:0.5111	0.5111	11
fMLP	fMLP:6|FMLP:1	chemotactic peptide fMet-Leu-Phe:7:0.4728	0.4728	7
fMLP	fMLP:15|FMLP:14|f-MLP:1	chemotactic peptide formyl-methionyl-leucyl-phenylalanine:30:0.7995	0.7995	30
fMLP	FMLP:6|fMLP:6	chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine:12:0.7261	0.7261	12
FMLP	FMLP:5|fMLP:5	chemotactic peptide n-formyl-Met-Leu-Phe:10:0.5564	0.5564	10
FMLP	FMLP:37|fMLP:26|fmlp:1|f-MLP:1	chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine:65:0.6895	0.6895	65
fMLP	fMLP:10|FMLP:5	chemotactic peptide N-formylmethionyl-leucyl-phenylalanine:15:0.5038	0.5038	15
FMLP	FMLP:4|fMLP:2	chemotactic peptide N-formylmethionylleucylphenylalanine:6:0.3524	0.3524	6
fMLP	fMLP:4|FMLP:4|fmlp:1	f-methionyl-leucyl-phenylalanine:9:0.0034	0.0034	9
fMLP	fMLP:85|FMLP:26|f-MLP:2	Formyl-Met-Leu-Phe:108:0.0453|formyl Met-Leu-Phe:5:0.0902	0.0902	113
fMLP	fMLP:9|FMLP:8|f-MLP:1	formyl-methionine-leucine-phenylalanine:18:0.0072	0.0072	18
FMLP	FMLP:17|fMLP:10	formyl methionyl leucyl phenylalanine:17:0.3670|formyl methionyl-leucyl-phenylalanine:10:0.1690	0.3670	27
FMLP	FMLP:9|fMLP:8	formyl-methionyl-leucylphenylalanine:17:0.0068	0.0068	17
fMLP	fMLP:6|FMLP:3|f-MLP:1	formyl peptide:10:0.0929	0.0929	10
FMLP	FMLP:33|fMLP:27|f-MLP:2	formylmethionyl-leucyl-phenylalanine:62:0.0258	0.0258	62
fMLP	fMLP:22|FMLP:20	formylmethionylleucylphenylalanine:42:0.0174	0.0174	42
FMLP	FMLP:5|fMLP:4	N-formyl-methionine-leucine-phenylalanine:9:0.0034	0.0034	9
fMLP	fMLP:7|FMLP:7	N-formyl-methionyl-leucyl-phenyl-alanine:14:0.0055	0.0055	14
FMLP	FMLP:5|fMLP:3	N-formyl methionyl-leucyl-phenylalanine:8:0.1276	0.1276	8
FMLP	FMLP:10|fMLP:7|f-MLP:1	N-formyl-methionyl-leucylphenylalanine:18:0.0072	0.0072	18
FMLP	FMLP:11|fMLP:5|f-MLP:1|fmlp:1	N-formylmethionyl-leucylphenylalanine:18:0.0072	0.0072	18
FMNH2	FMNH2:8	reduced flavin mononucleotide:8:0.5006	0.5006	8
FMN	FMN:10	facial motor nucleus:10:0.7103	0.7103	10
FMN	FMN:217	flavin mononucleotide:217:0.9126	0.9126	217
FMN	FMN:11	riboflavin 5'-phosphate:11:0.7357	0.7357	11
FMO1	FMO1:9	flavin-containing monooxygenase 1:9:0.6794	0.6794	9
FMO3	FMO3:18	flavin-containing monooxygenase 3:18:0.6211	0.6211	18
FMOX	FMOX:9	flomoxef sodium:9:0.6794	0.6794	9
FMOs	FMOs:42|Fmos:1	flavin-containing monooxygenases:43:0.8300	0.8300	43
FMO	FMO:163	flavin-containing monooxygenase:141:0.8020|flavin-containing monooxygenases:22:0.6934	0.8020	163
FMPP	FMPP:10	Familial male-limited precocious puberty:10:0.7103	0.7103	10
FMP	FMP:10	final menstrual period:10:0.7103	0.7103	10
FMR1	FMR1:9|FMR-1:6|Fmr1:1	fragile X gene:16:0.8165	0.8165	16
FMR1	FMR1:17	Fragile X Mental Retardation:17:0.8270	0.8270	17
FMR1	FMR1:28|FMR-1:4|fmr1:4|Fmr1:2	fragile X mental retardation 1:29:0.8978|fragile X mental retardation-1:9:0.6794	0.8978	38
FMRP	FMRP:26	FMR1 protein:26:0.1318	0.1318	26
FMRP	FMRP:75	fragile X mental retardation protein:75:0.9602	0.9602	75
FMRP	FMRP:6	gene product:6:0.2243	0.2243	6
FMR	FMR:20	field metabolic rate:11:0.4232|field metabolic rates:9:0.4587	0.4587	20
fMR	fMR:43	Functional magnetic resonance:43:0.8917	0.8917	43
FMR	FMR:9	functional mitral regurgitation:9:0.6794	0.6794	9
fMR	fMR:23	functional MR:23:0.8715	0.8715	23
FMSS	FMSS:28	Five Minute Speech Sample:14:0.7909|Five-Minute Speech Sample:14:0.2524	0.7909	28
FMTC	FMTC:20	familial MTC:20:0.7173	0.7173	20
FMV	FMV:13	figwort mosaic virus:13:0.5934	0.5934	13
FMV	FMV:16	flow-mediated vasodilation:16:0.6577	0.6577	16
FMZ	FMZ:34	[11C]flumazenil:24:0.3833|11C-flumazenil:10:0.1500	0.3833	34
FMZ	FMZ:11	flumazenil:11:0.1667	0.1667	11
FMS	FMS:17	fibromyalgia:17:0.0449	0.0449	17
FMS	FMS:155	fibromyalgia syndrome:155:0.9090	0.9090	155
FMS	FMS:5|FMs:3	fluorescent microspheres:8:0.4102	0.4102	8
FMS	FMS:26	functional magnetic stimulation:26:0.8816	0.8816	26
Fms	Fms:3|fms:2	M-CSF receptor:5:0.1320	0.1320	5
F-MuLV	F-MuLV:87|FMuLV:8	Friend murine leukemia virus:95:0.8683	0.8683	95
FNABs	FNABs:29	fine needle aspiration biopsies:29:0.8978	0.8978	29
FNAB	FNAB:862|FNAb:2	fine-needle aspiration biopsy:471:0.5367|fine needle aspiration biopsy:349:0.9862|fine-needle aspiration biopsies:44:0.5342	0.9862	864
FNAC	FNAC:422	fine needle aspiration cytology:422:0.9812	0.9812	422
FNAs	FNAs:64	fine-needle aspirates:33:0.3750|fine needle aspirates:31:0.9043	0.9043	64
FNAs	FNAs:48	fine-needle aspirations:29:0.4410|fine needle aspirations:19:0.8449	0.8449	48
FNB	FNB:8	femoral nerve block:8:0.4102	0.4102	8
FNB	FNB:61	fine needle biopsy:33:0.9100|Fine-needle biopsy:22:0.2226|fine-needle biopsies:6:0.1838	0.9100	61
FNDI	FNDI:10	familial neurohypophyseal diabetes insipidus:10:0.5856	0.5856	10
FND	FND:9	Functional neck dissection:9:0.6794	0.6794	9
Fn-f	Fn-f:14|FN-f:4|FNf:3	fibronectin fragments:14:0.5589|fibronectin fragment:7:0.3524	0.5589	21
FNHTR	FNHTR:4	febrile nonhemolytic transfusion reactions:4:0.5290	0.5290	4
FNHTRs	FNHTRs:6	Febrile nonhemolytic transfusion reactions:6:0.5290	0.5290	6
FNH	FNH:244	Focal nodular hyperplasia:227:0.9719|focal nodular hyperplasias:17:0.8270	0.9719	244
FNH	FNH:9	focal nodular hyperplasia of the liver:9:0.6794	0.6794	9
FNIII	FNIII:22|FnIII:10|fnIII:4|FN-III:3|Fn-III:1	fibronectin type III:40:0.7907	0.7907	40
FNN	FNN:13	fuzzy neural network:13:0.6701	0.6701	13
FNP	FNP:16	Family Nurse Practitioner:16:0.8165	0.8165	16
FNR	FNR:21	false negative rate:11:0.7357|false-negative rate:10:0.2126	0.7357	21
FNR	FNR:10	ferredoxin-NADP+ oxidoreductase:10:0.1327	0.1327	10
FNR	FNR:32	ferredoxin-NADP+ reductase:32:0.2747	0.2747	32
FNR	FNR:23|FnR:11|FNr:1|FN-R:1	fibronectin receptor:36:0.6538	0.6538	36
FNs	FNs:14|Fns:3	fibronectins:17:0.0860	0.0860	17
FNS	FNS:9	Fine-needle sampling:9:0.3455	0.3455	9
FNS	FNS:97	functional neuromuscular stimulation:97:0.9695	0.9695	97
FNZ	FNZ:22	flunitrazepam:22:0.3818	0.3818	22
FNA	FNA:95	fine needle aspirates:35:0.9151|fine-needle aspirates:34:0.3464|fine-needle aspirate:15:0.3262|fine needle aspirate:11:0.7357	0.9151	95
FNA	FNA:2070	Fine Needle Aspiration:1045:0.9896|fine-needle aspiration:990:0.4615|fine-needle aspirations:19:0.3453|fine needle aspirations:16:0.8165	0.9896	2070
FNA	FNA:16	fine needle aspiration biopsy:16:0.8165	0.8165	16
FNA	FNA:42	fine needle aspiration cytology:25:0.8816|fine-needle aspiration cytology:17:0.2311	0.8816	42
FN	FN:22	facial nerve:22:0.4883	0.4883	22
FN	FN:14	facial nucleus:14:0.0621	0.0621	14
FN	FN:77|Fn:1	false negative:35:0.7647|false-negative:33:0.0103|false negatives:10:0.7103	0.7647	78
FN	FN:41	febrile neutropenia:41:0.8224	0.8224	41
FN	FN:9|Fn:1	femoral nerve:10:0.1223	0.1223	10
Fn	Fn:7|FN:2	fibrin:9:0.0026	0.0026	9
FN	FN:1788|Fn:550|fn:21	fibronectin:2343:0.7563|Fibronectins:16:0.0048	0.7563	2359
Fn	Fn:12|FN:4	Fusobacterium nucleatum:16:0.6024	0.6024	16
fn	fn:6	natural frequency:6:0.0899	0.0899	6
FN	FN:10	number:10:0.0029	0.0029	10
FOBT	FOBT:31	faecal occult blood test:31:0.1878	0.1878	31
FOBT	FOBT:79	fecal occult blood test:79:0.6225	0.6225	79
FOBT	FOBT:74	fecal occult blood testing:74:0.6568	0.6568	74
FOBT	FOBT:17	occult blood tests:17:0.8270	0.8270	17
FOBTs	FOBTs:11	fecal occult blood tests:11:0.4728	0.4728	11
FOB	FOB:24	faecal occult blood:24:0.3526	0.3526	24
FOB	FOB:22	fecal occult blood:22:0.3096	0.3096	22
FOB	FOB:9	fiberoptic bronchoscope:9:0.3069	0.3069	9
FOB	FOB:83	fiberoptic bronchoscopy:83:0.6417	0.6417	83
FOB	FOB:68	functional observational battery:68:0.9561	0.9561	68
FOCMA	FOCMA:36	feline oncornavirus-associated cell membrane antigen:36:0.8716	0.8716	36
FOC	FOC:21|FoC:1	force of contraction:22:0.8657	0.8657	22
FOE	FOE:10|FoE:1	focus of expansion:11:0.7357	0.7357	11
FOG-1	FOG-1:9	Friend of GATA-1:9:0.6794	0.6794	9
FOG	FOG:9	fast oxidative-glycolytic:9:0.2154	0.2154	9
FOG	FOG:25	fast-twitch-oxidative-glycolytic:15:0.0729|fast-twitch oxidative-glycolytic:10:0.2549	0.2549	25
FOG	FOG:16	Friend of GATA:16:0.7096	0.7096	16
fog	fog:5	ultrasonically nebulized distilled water:5:0.5290	0.5290	5
FOH	FOH:12|F-OH:6	farnesol:18:0.4474	0.4474	18
FOH	FOH:13	Functional ovarian hyperandrogenism:13:0.7753	0.7753	13
FOK	FOK:22	feeling-of-knowing:22:0.5833	0.5833	22
FOM	FOM:12|FoM:1	figure of merit:13:0.5335	0.5335	13
FOM	FOM:13	final oocyte maturation:13:0.7753	0.7753	13
FOM	FOM:113	fosfomycin:113:0.6364	0.6364	113
FOP	FOP:56	fibrodysplasia ossificans progressiva:56:0.8004	0.8004	56
FORE	FORE:13	Fourier rebinning:13:0.7753	0.7753	13
FORKO	FORKO:10	receptor knockout:10:0.4363	0.4363	10
FORL	FORL:6	feline odontoclastic resorptive lesions:6:0.3728	0.3728	6
FOR	FOR:13	fastigial oculomotor region:13:0.7753	0.7753	13
for	for:10	foraging:10:0.0682	0.0682	10
FOR	FOR:12|for:2	Forskolin:14:0.0985	0.0985	14
FOR	FOR:8	fractional outflow rate:8:0.5006	0.5006	8
FOR	FOR:12	free oxygen radicals:12:0.7571	0.7571	12
FOSQ	FOSQ:10	functional outcomes of sleep questionnaire:10:0.7357	0.7357	10
Fos-ir	Fos-ir:4|FOS-ir:3	Fos immunoreactive:7:0.2452	0.2452	7
Fos-IR	Fos-IR:32|Fos-ir:19|FOS-IR:6|FOSir:3|FOS-ir:3|fos-IR:1|FosIR:1	FOS immunoreactivity:36:0.3176|Fos-immunoreactivity:29:0.1556	0.3176	65
Fos-IR	Fos-IR:17|Fos-ir:8|FOS-IR:3	Fos-like immunoreactivity:28:0.2255	0.2255	28
Fos-IR	Fos-IR:6|Fos-ir:4|FOS-ir:1	number of Fos-immunoreactive:11:0.1166	0.1166	11
FOS	FOS:12	Framingham Offspring Study:12:0.7571	0.7571	12
FOS	FOS:28	fructo-oligosaccharides:28:0.0828	0.0828	28
FOS	FOS:84	fructooligosaccharides:64:0.1933|fructooligosaccharide:20:0.0583	0.1933	84
FOTI	FOTI:17	transillumination:17:0.7619	0.7619	17
FOT	FOT:70	forced oscillation technique:70:0.9316	0.9316	70
FOV	FOV:165|FoV:6	field of view:148:0.9679|field-of-view:23:0.1202	0.9679	171
FOXO	FOXO:4	forkhead box class O:4:0.6794	0.6794	4
FOX	FOX:6	ferrous oxidation in Xylenol Orange:6:0.5470	0.5470	6
Fox	Fox:16|FOX:2	forkhead box:18:0.8365	0.8365	18
FOY	FOY:62|Foy:8	gabexate mesilate:70:0.8573	0.8573	70
FOY	FOY:7|Foy:3	gabexate mesylate:10:0.7103	0.7103	10
Fo	Fo:7	1 sigma:7:0.0732	0.0732	7
FO	FO:8	fast-twitch oxidative:8:0.4102	0.4102	8
FO	FO:5	fecal output:5:0.0902	0.0902	5
FO	FO:222	fish oil:222:0.8905	0.8905	222
FO	FO:9|Fo:1	follicular:10:0.0138	0.0138	10
FO	FO:26|Fo:1	foramen ovale:27:0.8312	0.8312	27
FO	FO:8	forced oscillation:8:0.2090	0.2090	8
FO	FO:11	functional overload:11:0.6182	0.6182	11
Fo	Fo:50|fo:17|FO:9	fundamental frequency:68:0.7673|fundamental frequencies:8:0.5006	0.7673	76
Fo	Fo:6	isometric force:6:0.1320	0.1320	6
FP-12	FP-12:12|Fp-12:1	fecapentaene-12:13:0.8571	0.8571	13
FPAB	FPAB:11	Family Planning Association of Bangladesh:11:0.7357	0.7357	11
FPANS	FPANS:22	Fluticasone propionate aqueous nasal spray:22:0.7955	0.7955	22
FPAs	FPAs:17	Family Planning Associations:17:0.8270	0.8270	17
FPA	FPA:11|fPA:1	Activity:12:0.0482	0.0482	12
FPA	FPA:35|fpa:1	Family Planning Association:36:0.8716	0.8716	36
FPA	FPA:6|FpA:3|Fp-A:1	Fibrinopeptide-A:10:0.0395	0.0395	10
FPA	FPA:7	flavor profile analysis:7:0.2452	0.2452	7
FPA	FPA:17	fluorescence polarization anisotropy:17:0.8270	0.8270	17
FPA	FPA:15	fluorescence polarization assay:15:0.8045	0.8045	15
FPA	FPA:16	fundus pulsation amplitude:16:0.8165	0.8165	16
FPB	FPB:20|FpB:10|FP-B:1	fibrinopeptide B:31:0.7388	0.7388	31
FPCL	FPCL:18	fibroblast-populated collagen lattice:18:0.5560	0.5560	18
f-PCT	f-PCT:4|F-PCT:3|fPCT:2|FPCT:1	familial porphyria cutanea tarda:10:0.7103	0.7103	10
FPCs	FPCs:11	family planning clinics:11:0.7357	0.7357	11
FPC	FPC:70	familial polyposis coli:70:0.8573	0.8573	70
FPC	FPC:17	Family Planning Clinic:17:0.8270	0.8270	17
FPC	FPC:10	fish protein concentrate:10:0.7103	0.7103	10
FPDL	FPDL:23	pulsed dye laser:23:0.7500	0.7500	23
FPDs	FPDs:77	fixed partial dentures:77:0.9612	0.9612	77
FPD	FPD:5	filtered P wave duration:5:0.4422	0.4422	5
FPD	FPD:6	fine particle dose:6:0.5290	0.5290	6
FPD	FPD:72	fixed partial dentures:43:0.9308|fixed partial denture:29:0.8978	0.9308	72
FPD	FPD:12	flame photometric detector:12:0.6460	0.6460	12
FPD	FPD:10	flat-panel detector:10:0.1327	0.1327	10
FPD	FPD:4|fPD:2	Parkinson's disease:6:0.1838	0.1838	6
FPE	FPE:6	fluid-phase endocytosis:6:0.1838	0.1838	6
FPF	FPF:4	fibroblast pneumonocyte factor:4:0.1618	0.1618	4
FPF	FPF:35	fine particle fraction:35:0.8681	0.8681	35
FPGA	FPGA:8	field programmable gate array:8:0.6411	0.6411	8
FPGS	FPGS:101	folylpolyglutamate synthetase:101:0.5724	0.5724	101
FPG	FPG:6	endonuclease formamidopyrimidine-DNA N-glycosylase:6:0.2827	0.2827	6
FPG	FPG:464|fpg:2|F-PG:1	fasting plasma glucose:467:0.9741	0.9741	467
FPG	FPG:18	fluorescence plus Giemsa:18:0.5940	0.5940	18
Fpg	Fpg:70|FPG:18|fpg:6|FpG:1	formamidopyrimidine-DNA glycosylase:71:0.4589|formamidopyrimidine DNA glycosylase:24:0.7593	0.7593	95
FPG	Fpg:3|FPG:3	formamidopyrimidine DNA N-glycosylase:6:0.3728	0.3728	6
FPI	FPI:23	fasting plasma insulin:23:0.8038	0.8038	23
FPI	FPI:39	fluid percussion brain injury:39:0.9237	0.9237	39
FPI	FPI:53	fluid percussion injury:53:0.9438	0.9438	53
FPI	FPI:9	fluorescence polarization immunoassay:9:0.5470	0.5470	9
FPI	FPI:15	personality inventory:15:0.5171	0.5171	15
FPIA	FPIA:286	fluorescence polarization immunoassay:276:0.9341|fluorescence polarization immunoassays:10:0.7103	0.9341	286
FPIR	FPIR:7	first phase insulin release:7:0.6411	0.6411	7
FPIR	FPIR:26	first-phase insulin response:26:0.5840	0.5840	26
FPLC	FPLC:7	fast protein liquid chromatographic:7:0.5926	0.5926	7
FPLC	FPLC:307	fast protein liquid chromatography:307:0.9902	0.9902	307
FPLD	FPLD:31	familial partial lipodystrophy:31:0.8519	0.8519	31
FPLV	FPLV:20	feline panleukopenia virus:20:0.8525	0.8525	20
FPL	FPL:35	flexor pollicis longus:35:0.8292	0.8292	35
FPL	FPL:16	forced-choice preferential looking:16:0.6577	0.6577	16
FPM	FPM:14	first-pass metabolism:8:0.2327|First pass metabolism:6:0.5290	0.5290	14
FPPS	FPPS:11|FPPs:1	farnesyl diphosphate synthase:12:0.7571	0.7571	12
FPPS	FPPS:9	farnesyl pyrophosphate synthase:9:0.6794	0.6794	9
FPP	FPP:92	farnesyl diphosphate:92:0.9026	0.9026	92
FPP	FPP:63|F-P-P:3|Fpp:2|F-PP:2	farnesyl pyrophosphate:70:0.8573	0.8573	70
FPP	FPP:15|Fpp:1	farnesylpyrophosphate:16:0.0476	0.0476	16
FPP	FPP:22	fertilization promoting peptide:14:0.6911|fertilization-promoting peptide:8:0.1125	0.6911	22
FPP	FPP:11	Fetal pig pancreas:11:0.7357	0.7357	11
FPP	FPP:12	Free portal pressure:12:0.7571	0.7571	12
FPQ	FPQ:10	Questionnaire:10:0.5333	0.5333	10
FPRL1	FPRL1:18	formyl peptide receptor-like 1:18:0.7407	0.7407	18
FPRNA	FPRNA:17	first-pass radionuclide angiography:17:0.7407	0.7407	17
FPR	FPR:35	false positive rate:21:0.8594|false-positive rate:14:0.1669	0.8594	35
FPR	FPR:53	fluorescence photobleaching recovery:53:0.8920	0.8920	53
FPR	FPR:9	footpad reaction:9:0.3945	0.3945	9
FPR	FPR:48|fPR:1	formyl peptide receptor:49:0.4510	0.4510	49
FPR	FPR:33	N-formyl peptide receptor:33:0.2678	0.2678	33
FPR	FPR:8|fPR:1	receptors:9:0.0261	0.0261	9
fPSA	fPSA:17|f-PSA:11|FPSA:3|F-PSA:1	free prostate-specific antigen:18:0.8365|free prostate specific antigen:14:0.6173	0.8365	32
FPS	FPS:13	Faces Pain Scale:13:0.5934	0.5934	13
FPs	FPs:62	family physicians:62:0.8788	0.8788	62
FPs	FPs:8	family practitioners:8:0.5006	0.5006	8
FPS	FPS:8	farnesyl diphosphate synthase:8:0.6411	0.6411	8
FPS	FPS:17	fear-potentiated startle:17:0.6748	0.6748	17
FPs	FPs:35|fps:1	field potentials:36:0.5303	0.5303	36
FPs	FPs:13	fluorescent proteins:13:0.3331	0.3331	13
fps	fps:9	per second:9:0.6794	0.6794	9
FPTase	FPTase:47	Farnesyl protein transferase:24:0.8768|farnesyl-protein transferase:23:0.2570	0.8768	47
FPT	FPT:15	failure of passive transfer:15:0.8165	0.8165	15
FPT	FPT:28	farnesyl protein transferase:28:0.8369	0.8369	28
FPU	FPU:11	Fermi-Pasta-Ulam:11:0.2326	0.2326	11
FPU	FPU:6	fetoplacental unit:6:0.1543	0.1543	6
FPV	FPV:19	feline parvovirus:19:0.7044	0.7044	19
FPV	FPV:8	finger pulse volume:8:0.5006	0.5006	8
FPV	FPV:9	flow propagation velocity:9:0.6794	0.6794	9
FPV	FPV:72	Fowl plague virus:72:0.9136	0.9136	72
FPV	FPV:9	fowl poxvirus:9:0.6794	0.6794	9
FPV	FPV:60	fowlpox virus:60:0.2518	0.2518	60
fPV	fPV:10|fpv:2	fractional plasma volume:12:0.7571	0.7571	12
FP	FP:8	Facial paralysis:8:0.4102	0.4102	8
FP	FP:80	false positive:41:0.8224|false-positive:39:0.0159	0.8224	80
FP	FP:13	family physician:13:0.7753	0.7753	13
FP	FP:578	family planning:578:0.9813	0.9813	578
FP	FP:30	family practice:30:0.9011	0.9011	30
FP	FP:16	fast pathway:16:0.8165	0.8165	16
FP	FP:14	femoropopliteal:14:0.0054	0.0054	14
FP	FP:33	ferriprotoporphyrin IX:33:0.8605	0.8605	33
FP	FP:12	fibropapillomatosis:12:0.0046	0.0046	12
FP	FP:24|fp:7|Fp:1	Field potential:18:0.5228|field potentials:14:0.3585	0.5228	32
FP	FP:10|fp:1	first-pass:11:0.0042	0.0042	11
FP	FP:17|Fp:1	fixation point:18:0.4672	0.4672	18
FP	FP:14	flavopiridol:14:0.0054	0.0054	14
Fp	Fp:27|FP:8	flavoprotein:35:0.0146	0.0146	35
FP	FP:14	floor plate:14:0.4709	0.4709	14
FP	FP:111	Fluorescence polarization:111:0.9185	0.9185	111
FP	FP:21	flurbiprofen:21:0.0084	0.0084	21
FP	FP:302	fluticasone propionate:302:0.9739	0.9739	302
FP	FP:18	follicular phase:18:0.7539	0.7539	18
FP	FP:8	following lateral fluid-percussion:8:0.1591	0.1591	8
FP	FP:8|fp:1	footpad:9:0.0033	0.0033	9
fp	fp:7	free fraction:7:0.1850	0.1850	7
Fp	Fp:4|fp:3|FP:2	frequency:9:0.0033	0.0033	9
FP	FP:11	Fungal peritonitis:11:0.5355	0.5355	11
FP	FP:13	fusion peptide:13:0.6701	0.6701	13
FP	FP:22|fp:1	fusion protein:23:0.2211	0.2211	23
FP	FP:8	hamster female protein:8:0.1276	0.1276	8
FP	FP:33	lateral fluid percussion:33:0.5260	0.5260	33
FP	F-P:6|FP:6	parasagittal fluid-percussion:12:0.1423	0.1423	12
FP	FP:8	PGF2 alpha:8:0.3463	0.3463	8
FP	FP:8|fp:7|Fp:2	plasma:17:0.0067	0.0067	17
FP	FP:5	prostaglandin F:5:0.1132	0.1132	5
FP	FP:26	receptor:26:0.0104	0.0104	26
FQPA	FQPA:22	Food Quality Protection Act:22:0.8715	0.8715	22
FQs	FQs:29|FQS:1	fluoroquinolones:30:0.7250	0.7250	30
FQ	FQ:9	3-(2-furoyl)quinoline-2-carboxaldehyde:9:0.0593	0.0593	9
FQ	FQ:14	Fear Questionnaire:14:0.3383	0.3383	14
FQ	FQ:55	fluoroquinolone:35:0.2519|fluoroquinolones:20:0.1407	0.2519	55
FR-40	FR-40:10	fixed ratio-40:10:0.7103	0.7103	10
FR-860	FR-860:7	low molecular weight heparin:7:0.5926	0.5926	7
FR3	Fr3:5|FR3:5	framework 3:10:0.2126	0.2126	10
FR3	FR3:9	framework region 3:9:0.6794	0.6794	9
FR5	FR5:11	fixed ratio 5:11:0.7357	0.7357	11
fra-2	fra-2:5|Fra-2:2|FRA-2:1|FRA2:1	Fos-related antigen-2:9:0.6794	0.6794	9
FRAP	FRAP:21	ferric reducing ability of plasma:21:0.8594	0.8594	21
FRAP	FRAP:29	ferric reducing antioxidant power:20:0.8594|ferric reducing/antioxidant power:9:0.6794	0.8594	29
FRAP	FRAP:9	FKBP12-rapamycin-associated protein:9:0.1585	0.1585	9
FRAP	FRAP:254	fluorescence recovery after photobleaching:254:0.9434	0.9434	254
FRAP	FRAP:30	fluoride-resistant acid phosphatase:30:0.5940	0.5940	30
FRAXA	FRAXA:5	fragile X locus:5:0.4422	0.4422	5
FRAXA	FRAXA:17	fragile X syndrome:17:0.8365	0.8365	17
FraX	FraX:19|fraX:5|FRAX:4|Fra-X:2	fragile X syndrome:30:0.9011	0.9011	30
FRAs	FRAs:16|Fras:4	Fos-related antigens:20:0.6680	0.6680	20
FRA	FRA:14	flexor reflex afferents:14:0.7909	0.7909	14
FRA	FRA:16|Fra:6|fra:5	Fos-related antigens:14:0.2636|Fos-related antigen:13:0.1506	0.2636	27
fRA	fRA:8|fRa:6|FRa:3	fractional apical membrane resistance:17:0.8270	0.8270	17
fRa	fRa:7|FRa:2	fractional resistance:9:0.1205	0.1205	9
fRa	fRa:8|FRa:2|fRA:1|FRA:1	fractional resistance of the apical membrane:12:0.7571	0.7571	12
FRA	FRA:14	fructosamine:14:0.0634	0.0634	14
FRC	FRC:43	Fiber-reinforced composite:32:0.5357|fiber-reinforced composites:11:0.7357	0.7357	43
FRC	FRC:900|frc:1	functional residual capacity:901:0.9865	0.9865	901
FRC	FRC:13	lung volume:13:0.2802	0.2802	13
FRC	FRC:6	primary cultures of fetal rat calvaria:6:0.5290	0.5290	6
FRDA	FRDA:5	ataxia gene:5:0.0902	0.0902	5
FRDA	FRDA:11	ataxia locus:11:0.5355	0.5355	11
FRDA	FRDA:59	Friedreich's ataxia:59:0.4111	0.4111	59
FRET	FRET:810	fluorescence resonance energy transfer:810:0.8831	0.8831	810
FRG	FRG:43	Federal Republic of Germany:43:0.8590	0.8590	43
FRI	FRI:9	risk index:9:0.1945	0.1945	9
FRL	FRL:46	Flinders resistant line:46:0.8986	0.8986	46
FRL	FRL:7	future remnant liver:7:0.5926	0.5926	7
FRM	FRM:10	Federal Reference Method:10:0.7103	0.7103	10
FRNK	FRNK:11	FAK-related non-kinase:11:0.4232	0.4232	11
FRNK	FRNK:8	FAK-related nonkinase:8:0.3463	0.3463	8
FROC	FROC:13	free-response receiver operating characteristic:13:0.5934	0.5934	13
FRO	FRO:7	free-radical oxidation:7:0.1850	0.1850	7
FRP	FRP:11	Follicle regulatory protein:11:0.5355	0.5355	11
FRP	FRP:49	functional refractory period:49:0.9046	0.9046	49
FRS2	FRS2:6	fibroblast growth factor receptor substrate 2:6:0.3728	0.3728	6
FRTL-5	FRTL-5:27|FRTL5:11|FRT-L5:2	Rat thyroid cells:40:0.8455	0.8455	40
FRTL-5	FRTL-5:27|FRTL5:11	rat thyroid cell line:38:0.8417	0.8417	38
FRT	FRT:9	female reproductive tract:9:0.6794	0.6794	9
FRT	FRT:18	Fischer rat thyroid:18:0.4934	0.4934	18
FRT	FRT:18	FLP recognition target:18:0.7658	0.7658	18
FRT	FRT:7	FLP recombination target:7:0.2452	0.2452	7
FRT	FRT:7	Functional Reach Test:7:0.5926	0.5926	7
FRS	FRS:24	first-rank symptoms:13:0.2802|first rank symptoms:11:0.7357	0.7357	24
FRs	FRs:12	folate receptors:12:0.7571	0.7571	12
FRS	FRS:10	Framingham risk score:10:0.4363	0.4363	10
FRs	FRs:21	free radicals:21:0.8594	0.8594	21
FRS	FRS:11	phenylalanyl-tRNA synthetase:11:0.6182	0.6182	11
FRS	FRS:10	Rating Scale:10:0.5856	0.5856	10
fR	fR:12|fr:4	breathing frequency:16:0.0753	0.0753	16
FR	FR:11	family of repeats:11:0.7571	0.7571	11
FR	FR:19	far-red light:19:0.7044	0.7044	19
FR	FR:21	fasciculus retroflexus:21:0.7865	0.7865	21
FR	FR:6	fast fatigue-resistant:6:0.1895	0.1895	6
FR	FR:7	fast resistant:7:0.0622	0.0622	7
FR	FR:15	fatigue resistant:15:0.3262	0.3262	15
FR	FR:13	fertilization rate:13:0.0765	0.0765	13
FR	FR:12	firing rate:12:0.0659	0.0659	12
FR	FR:119	fixed ratio:119:0.8095	0.8095	119
FR	FR:7	flexor reflex:7:0.2452	0.2452	7
FR	FR:55	folate receptor:55:0.8036	0.8036	55
FR	FR:44	food-restricted:24:0.0147|food restricted:20:0.8525	0.8525	44
FR	FR:58	food restriction:58:0.7489	0.7489	58
fr	fr:11	fractions:11:0.0064	0.0064	11
FR	FR:8	fractional reabsorption:8:0.5006	0.5006	8
FR	FR:11	framework:11:0.0064	0.0064	11
FR	FR:23	framework regions:12:0.7571|framework region:11:0.6182	0.7571	23
FR	FR:70	free radicals:36:0.8336|free radical:34:0.9126	0.9126	70
Fr	Fr:22|fr:5|FR:1	French:28:0.0172	0.0172	28
FR	FR:6	fumarate reductase:6:0.2243	0.2243	6
FR	FR:15	functional reach:15:0.7096	0.7096	15
FR	FR:13|fR:1	rates:14:0.0083	0.0083	14
fR	fR:13|FR:2|fr:1	respiratory rate:16:0.1092	0.1092	16
FR	FR:35	under a fixed-ratio:35:0.1861	0.1861	35
FSAD	FSAD:11	Female sexual arousal disorder:11:0.7357	0.7357	11
FSBA	FSBA:12	5'-p-fluorosulfonylbenzoyl adenosine:12:0.5050	0.5050	12
FSBA	FSBA:35	5'-p-fluorosulfonylbenzoyladenosine:35:0.3208	0.3208	35
FSBP	FSBP:14	Finger systolic blood pressure:14:0.7909	0.7909	14
FSCE	FSCE:9	free solution capillary electrophoresis:9:0.6794	0.6794	9
FSCs	FSCs:15	Fat-storing cells:15:0.4312	0.4312	15
FSC	FSC:37	fat-storing cells:37:0.4385	0.4385	37
FSC	FSC:14	fetal spinal cord:14:0.6173	0.6173	14
FSC	FSC:25	forward scatter:25:0.4451	0.4451	25
FSC	FSC:26|fSC:2	free secretory component:28:0.8941	0.8941	28
FSC	FSC:11|fsc:1	light scatter:12:0.1338	0.1338	12
FSD	FSD:33	female sexual dysfunction:33:0.9100	0.9100	33
FSE	FSE:297|fse:1	fast spin-echo:185:0.9502|fast spin echo:97:0.9510|fast-spin-echo:16:0.0393	0.9510	298
FSFI	FSFI:21	Female Sexual Function Index:21:0.8449	0.8449	21
FSGS	FSGS:29	focal segmental glomerular sclerosis:29:0.9072	0.9072	29
FSGS	FSGS:458|FS-GS:1	focal segmental glomerulosclerosis:459:0.9878	0.9878	459
FSG	FSG:18	fasting serum glucose:18:0.8365	0.8365	18
FSG	FSG:18	focal segmental glomerulosclerosis:18:0.8768	0.8768	18
FSHD	FSHD:182	facioscapulohumeral muscular dystrophy:182:0.9197	0.9197	182
FSH-P	FSH-P:7	follicle stimulating hormone:7:0.5926	0.5926	7
FSHR	FSHR:33|FSH-R:10	follicle-stimulating hormone receptor:43:0.7572	0.7572	43
FSHR	FSHR:57|FSH-R:15|FSHr:11|Fshr:2	FSH receptor:79:0.4618|FSH receptors:6:0.1641	0.4618	85
FSH	FSH:11	facioscapulohumeral muscular dystrophy:11:0.4232	0.4232	11
FSH	FSH:33	follicle-stimulating:21:0.0036|follicle stimulating:12:0.6460	0.6460	33
FSH	FSH:8	follicle-stimulating hormones:8:0.2987	0.2987	8
FSH	FSH:4	patients with facioscapulohumeral:4:0.0612	0.0612	4
FSIGT	FSIGT:9	frequently sampled intravenous glucose tolerance:9:0.5470	0.5470	9
FSIGT	FSIGT:47	frequently sampled intravenous glucose tolerance test:47:0.9366	0.9366	47
FSIGTT	FSIGTT:12	frequently sampled intravenous glucose tolerance test:12:0.7571	0.7571	12
FSIQ	FSIQ:11	full-scale intelligence quotient:11:0.3829	0.3829	11
FSIQ	FSIQ:40	Full Scale IQ:25:0.8816|full-scale IQ:15:0.1933	0.8816	40
FSIS	FSIS:22	Food Safety and Inspection Service:22:0.7760	0.7760	22
FSK	FSK:154|Fsk:12|fsk:2	forskolin:168:0.9435	0.9435	168
FSL	FSL:65	Flinders Sensitive Line:65:0.8841	0.8841	65
FSM	FSM:11	Federated States of Micronesia:11:0.5355	0.5355	11
FSM	FSM:15	fluorescent speckle microscopy:15:0.8045	0.8045	15
FSP	FSP:16	Fallopian tube sperm perfusion:16:0.8165	0.8165	16
FSP	FSP:16	familial spastic paraplegia:16:0.6577	0.6577	16
FSP	FSP:7	Finger systolic blood pressure:7:0.5926	0.5926	7
FSP	FSP:11	Finger systolic pressure:11:0.6182	0.6182	11
FSP	FSP:16	split products:16:0.5171	0.5171	16
FSQ	FSQ:22	functional status questionnaire:22:0.8657	0.8657	22
FSRT	FSRT:27|F-SRT:1	Fractionated Stereotactic Radiotherapy:28:0.8903	0.8903	28
FSR	FSR:7	fractional rate of protein synthesis:7:0.5926	0.5926	7
FSR	FSR:85	fractional synthesis rate:58:0.7792|fractional synthesis rates:27:0.5951	0.7792	85
FSR	FSR:47	fractional synthetic rate:38:0.8781|fractional synthetic rates:9:0.4587	0.8781	47
FSR	FSR:35	fragmented sarcoplasmic reticulum:35:0.9151	0.9151	35
F-SSCP	F-SSCP:10|FSSCP:1|f-SSCP:1|fSSCP:1	conformation polymorphism:13:0.6701	0.6701	13
FSS	FSS:11	daily intake of fluid and salt supplementation:11:0.7357	0.7357	11
FSS	FSS:15	familial short stature:15:0.6386	0.6386	15
FSS	FSS:56	Fatigue Severity Scale:56:0.9162	0.9162	56
FSs	FSs:14	febrile seizures:14:0.7909	0.7909	14
FSS	FSS:15	fluid shear stress:15:0.7096	0.7096	15
FST	FST:21	finger skin temperature:21:0.7291	0.7291	21
FST	FST:69	forced swim test:69:0.9567	0.9567	69
FST	FST:97	forced swimming test:97:0.9695	0.9695	97
FSUs	FSUs:10	functional spinal units:10:0.7103	0.7103	10
FSU	FSU:35	former Soviet Union:35:0.9151	0.9151	35
FSU	FSU:10	functional spinal unit:10:0.5856	0.5856	10
FSV	FSV:34	Fujinami Sarcoma Virus:34:0.6386	0.6386	34
FSWs	FSWs:58	female sex workers:58:0.9190	0.9190	58
fsw	fsw:6|FSW:1	feet of seawater:7:0.1641	0.1641	7
FSW	FSW:26	female sex workers:26:0.8251	0.8251	26
fsw	fsw:12|FSW:3	sea water:15:0.8045	0.8045	15
FSa	FSa:21|FSA:14|Fsa:1	fibrosarcoma:36:0.2397	0.2397	36
FSA	FSA:8	fractal signature analysis:8:0.6411	0.6411	8
FSA	FSA:5	free sialic acid:5:0.4422	0.4422	5
FS	FS:20|-FS:3	familial sinistrality:23:0.8038	0.8038	23
FS	FS:64	Fast-spiking:47:0.0230|fast spiking:17:0.6748	0.6748	64
FS	FS:12|fs:1	fat saturation:13:0.7753	0.7753	13
FS	FS:11	fat suppression:11:0.4728	0.4728	11
FS	FS:47	febrile seizures:47:0.8703	0.8703	47
FS	FS:8	fecal streptococci:8:0.1276	0.1276	8
FS	FS:7	femoral shaft:7:0.2902	0.2902	7
fs	fs:14	femtosecond:14:0.0065	0.0065	14
FS	FS:8	Fermi surface:8:0.3463	0.3463	8
FS	FS:34	fibrin sealant:34:0.7898	0.7898	34
FS	FS:13	fibromyalgia:13:0.0060	0.0060	13
FS	FS:45	fibromyalgia syndrome:45:0.2017	0.2017	45
FS	FS:18	fibrosarcoma:18:0.0085	0.0085	18
FS	FS:21	fibrous sheath:21:0.8594	0.8594	21
FS	FS:48	field stimulation:48:0.9027	0.9027	48
FS	FS:18	Fisher syndrome:18:0.0568	0.0568	18
FS	FS:12	flaxseed:12:0.0055	0.0055	12
FS	FS:57	flexible sigmoidoscopy:57:0.8689	0.8689	57
FS	FS:16	flexural strength:16:0.4536	0.4536	16
FS	FS:20	Fogo selvagem:20:0.8525	0.8525	20
FS	FS:47|F-S:2	folliculo-stellate:49:0.0240	0.0240	49
FS	FS:21	folliculostellate:21:0.0100	0.0100	21
FS	FS:69	follistatin:69:0.0341	0.0341	69
FS	FS:12	foot shock:12:0.6460	0.6460	12
FS	FS:18	footshock:18:0.0085	0.0085	18
FS	FS:5	former smokers:5:0.0902	0.0902	5
FS	FS:243|fs:1|Fs:1	fractional shortening:245:0.9317	0.9317	245
FS	FS:27	fragile sites:19:0.8449|fragile site:8:0.4102	0.8449	27
FS	FS:8	freeze substitution:8:0.4102	0.4102	8
FS	FS:82	frozen section:67:0.9554|frozen sections:15:0.8045	0.9554	82
FS	FS:11	functional status:11:0.6182	0.6182	11
FS	FS:6	Functional Systems:6:0.2243	0.2243	6
FS	FS:11	furosemide-sensitive:11:0.0050	0.0050	11
FS	FS:16	patients with Felty's syndrome:16:0.2022	0.2022	16
FS	FS:14	Scale:14:0.0065	0.0065	14
FS	FS:12|Fs:1	score:13:0.0060	0.0060	13
fs	fs:8	signal frequency:8:0.2987	0.2987	8
FT	FT:13	1-(2-tetrahydrofuryl)-5-fluorouracil:13:0.0094	0.0094	13
FT	FT:16	farnesyltransferase:16:0.0118	0.0118	16
FT	FT:44	fast twitch:44:0.9323	0.9323	44
FT	FT:8	fat thickness:8:0.1895	0.1895	8
FT	FT:11	femur-tibia:11:0.0078	0.0078	11
FT	FT:24	fetal thymus:24:0.8115	0.8115	24
FT	FT:8	filled teeth:8:0.6794	0.6794	8
FT	FT:20	fixed-time:20:0.0149	0.0149	20
FT	FT:23	FLOWERING LOCUS T:23:0.8715	0.8715	23
FT	FT:92	Fourier transform:83:0.9247|Fourier-transform:9:0.0063	0.9247	92
FT	FT:10	free T:10:0.1992	0.1992	10
FT	FT:9	freeze-thaw:9:0.0071	0.0071	9
FT	FT:8	frozen-thawed:8:0.0071	0.0071	8
FT	FT:28	Ftorafur:28:0.0243	0.0243	28
FT	FT:19	fucosyltransferase:19:0.0141	0.0141	19
FT	FT:30	full-term:24:0.0180|full term:6:0.1543	0.1543	30
FT	FT:9	fullterm:9:0.0063	0.0063	9
FT	FT:11	Futraful:11:0.0078	0.0078	11
FT	FT:84	Tegafur:84:0.0651	0.0651	84
FT	FT:16	threshold:16:0.0125	0.0125	16
FT(3)	FT(3):13|fT(3):2	free triiodothyronine:15:0.8045	0.8045	15
FT-207	FT-207:16	1-(2-tetrahydrofuryl)-5-fluorouracil:16:0.1795	0.1795	16
FT3I	FT3I:25|fT3i:1|fT3I:1	free T3 index:27:0.8903	0.8903	27
FT4I	FT4I:49|FT4-I:8|fT4-I:1	free thyroxine index:58:0.8937	0.8937	58
FT4	FT4:73|fT4:13	free thyroxin:86:0.9272	0.9272	86
FTA-ABS	FTA-ABS:6|FTA-Abs:3	fluorescent treponemal antibody-absorbed:9:0.6794	0.6794	9
FTA-ABS	FTA-ABS:86|FTA-Abs:15|FTA-abs:3|fta-abs:1	fluorescent treponemal antibody absorption:60:0.8548|fluorescent treponemal antibody-absorption:45:0.9338	0.9338	105
FTA-ABS	FTA-ABS:10|FTA-abs:1	fluorescent treponemal antibody absorption test:11:0.7357	0.7357	11
FTA	FTA:13	femorotibial angle:13:0.4102	0.4102	13
FTBA	FTBA:12	perfluorotributylamine:12:0.7333	0.7333	12
FTBI	FTBI:26|fTBI:5|F-TBI:2|f-TBI:1	Fractionated total body irradiation:24:0.8768|fractionated total-body irradiation:10:0.7571	0.8768	34
FTCs	FTCs:10	follicular thyroid carcinomas:10:0.7103	0.7103	10
FTCs	FTCs:16	frequency tuning curves:16:0.6577	0.6577	16
FTC	FTC:14	emtricitabine:14:0.0509	0.0509	14
FTC	FTC:42	Federal Trade Commission:42:0.9308	0.9308	42
FTC	FTC:15	follicular:15:0.0509	0.0509	15
FTC	FTC:6	follicular carcinomas:6:0.0522	0.0522	6
FTC	FTC:15	follicular thyroid cancer:15:0.8045	0.8045	15
FTC	FTC:55	follicular thyroid carcinoma:40:0.9256|follicular thyroid carcinomas:15:0.8045	0.9256	55
FTC	FTC:9	Fumitremorgin C:9:0.6794	0.6794	9
FTDP-17	FTDP-17:29	frontotemporal dementia with parkinsonism linked to chromosome 17:29:0.9231	0.9231	29
FTDs	FTDs:9	frontotemporal dementias:9:0.6794	0.6794	9
FTD	FTD:12	formal thought disorder:12:0.7571	0.7571	12
FTD	FTD:12	frontotemporal degeneration:12:0.5664	0.5664	12
FTD	FTD:326	frontotemporal dementia:320:0.9057|Frontotemporal dementias:6:0.2243	0.9057	326
FTEs	FTEs:25	full-time equivalents:25:0.5288	0.5288	25
FTE	FTE:9	equivalents:9:0.0597	0.0597	9
FTE	FTE:66	full-time equivalent:66:0.7106	0.7106	66
FTE	FTE:5	number of full-time-equivalent:5:0.0612	0.0612	5
FTF	FTF:19|ftf:6|Ftf:3	fructosyltransferase:28:0.3418	0.3418	28
FTF	FTF:18	transcription factor:18:0.8365	0.8365	18
FTG	FTG:24	gigantocellular tegmental field:24:0.8768	0.8768	24
FTICR	FTICR:75|FT-ICR:46	Fourier transform ion cyclotron resonance:121:0.9478	0.9478	121
FTICR	FTICR:7|FT-ICR:1	Fourier transform ion cyclotron resonance mass spectrometry:8:0.6411	0.6411	8
FTIRI	FTIRI:8|FT-IRI:1	Fourier transform infrared imaging:9:0.6794	0.6794	9
FTIRM	FTIRM:8|FT-IR-M:2|FT-IRM:2	Fourier Transform Infrared Microspectroscopy:12:0.7571	0.7571	12
FTIR	FTIR:22|FT-IR:6	Fourier transform infra-red:22:0.8657|Fourier transform infra red:6:0.5290	0.8657	28
FTIR	FTIR:768|FT-IR:362|FT--IR:1|FT-ir:1	Fourier transform infrared:970:0.9708|Fourier-transform infrared:162:0.1138	0.9708	1132
FTIR	FTIR:10|FT-IR:2	Fourier transform infrared spectrometry:12:0.7571	0.7571	12
FTIR	FTIR:6	Fourier transform infrared spectrophotometry:6:0.5290	0.5290	6
FTIR	FTIR:5|FT-IR:2	Fourier transform infrared spectroscopic:7:0.5926	0.5926	7
FTIR	FTIR:268|FT-IR:130	Fourier transform infrared spectroscopy:338:0.9724|Fourier-transform infrared spectroscopy:60:0.1011	0.9724	398
FTIR	FTIR:14|FT-IR:1	Fourier transform ir:15:0.8045	0.8045	15
FTIs	FTIs:28	Farnesyl transferase inhibitors:28:0.5837	0.5837	28
FTIs	FTIs:69	farnesyltransferase inhibitors:69:0.4947	0.4947	69
FTI	FTI:14	farnesyl transferase inhibitor:14:0.6173	0.6173	14
FTI	FTI:32	farnesyltransferase inhibitor:22:0.3671|farnesyltransferase inhibitors:10:0.2873	0.3671	32
FTI	FTI:14	force-time integral:14:0.6911	0.6911	14
FTI	FTI:87	free thyroxine index:87:0.9455	0.9455	87
FTLD	FTLD:39	frontotemporal lobar degeneration:39:0.8811	0.8811	39
FTL	FTL:10	lateral tegmental field:10:0.7103	0.7103	10
FTMS	FTMS:7	Fourier transform mass spectrometer:7:0.5926	0.5926	7
FTMS	FTMS:26|FT-MS:2	Fourier transform mass spectrometry:28:0.8369	0.8369	28
FTM	FTM:10	fat tissue mass:10:0.7103	0.7103	10
FTND	FTND:56	Fagerstrom Test for Nicotine Dependence:56:0.8591	0.8591	56
FT-NIR	FT-NIR:17	Fourier transform near-infrared:17:0.8270	0.8270	17
FTOC	FTOC:41	fetal thymus organ culture:23:0.8715|fetal thymus organ cultures:18:0.8365	0.8715	41
FTOCs	FTOCs:9	fetal thymic organ cultures:9:0.6794	0.6794	9
FTP	FTP:9	Federal Test Procedure:9:0.6794	0.6794	9
FTP	FTP:11	Formycin triphosphate:11:0.7571	0.7571	11
FTQ	FTQ:25	Fagerstrom Tolerance Questionnaire:25:0.8186	0.8186	25
FTR	FTR:10	fast-twitch red:10:0.5000	0.5000	10
FTR	FTR:10	ferredoxin:thioredoxin reductase:10:0.3470	0.3470	10
FTR	FTR:8	fractional turnover rate:8:0.5006	0.5006	8
FTSG	FTSG:10	full-thickness skin graft:10:0.5000	0.5000	10
FTS	FTS:26	facteur thymique serique:26:0.8251	0.8251	26
FTS	FTS:13	Farnesylthiosalicylic acid:13:0.1470	0.1470	13
FTS	FTS:64	serum thymic factor:64:0.7970	0.7970	64
FTT	FTT:73	failure to thrive:60:0.9503|failure-to-thrive:13:0.0952	0.9503	73
FTT	FTT:9	finger tapping test:9:0.5470	0.5470	9
FTW	FTW:9	fast-twitch white:9:0.5470	0.5470	9
FTX	FTX:7	spider toxin:7:0.3524	0.3524	7
FTase	FTase:14|Ftase:1	farnesyl transferase:15:0.3614	0.3614	15
FTase	FTase:115|FT-ase:1|Ftase:1	farnesyltransferase:117:0.7582	0.7582	117
FUdR	FUdR:7|FUDR:3	2'-deoxy-5-fluorouridine:10:0.0263	0.0263	10
FUdR	FUdR:59|FUDR:22	5-fluoro-2'-deoxyuridine:81:0.2310	0.2310	81
FUdR	FUdR:44|FUDR:17|FudR:3|FUdr:1	5-fluorodeoxyuridine:65:0.1871	0.1871	65
FUDR	FUDR:61|FUdR:11|FUdr:1	floxuridine:73:0.2105	0.2105	73
FUdR	FUdR:37|FUDR:24|FudR:3|FuDr:1	fluorodeoxyuridine:65:0.1871	0.1871	65
FUO	FUO:206	Fever of unknown origin:206:0.9489	0.9489	206
FuP	FuP:15	fungiform papillae:15:0.8045	0.8045	15
FURTA	FURTA:12	Fur titration assay:12:0.7571	0.7571	12
FUSE	FUSE:8	far upstream element:8:0.6411	0.6411	8
FUT-187	FUT-187:15	benzoate dimethanesulfonate:15:0.7096	0.7096	15
FUT-175	FUT-175:28	nafamostat mesilate:28:0.7066	0.7066	28
FUT	FUT:11	fibrinogen uptake test:11:0.4232	0.4232	11
FUT	FUT:15	nafamostat mesilate:15:0.7096	0.7096	15
FUra	FUra:271|Fura:1	5-fluorouracil:272:0.8495	0.8495	272
FUra	FUra:31	fluorouracil:31:0.0940	0.0940	31
FU	FU:221	5-fluorouracil:221:0.3318	0.3318	221
fU	fU:8|fu:1	5-Formyluracil:9:0.0121	0.0121	9
FU	FU:115	fluorouracil:115:0.1719	0.1719	115
FU	FU:55	follow-up:55:0.0814	0.0814	55
fu	fu:6|fU:1	fraction unbound:7:0.2902	0.2902	7
FU	FU:10|fu:2	furosemide:12:0.0166	0.0166	12
Fu	Fu:4|fu:2	protein kinase Fused:6:0.2243	0.2243	6
fu	fu:28|Fu:3|fU:1	Unbound fraction:32:0.5357	0.5357	32
FU	FU:12|fu:1	units:13:0.0181	0.0181	13
FV3	FV3:49	frog virus 3:49:0.9392	0.9392	49
FVa	FVa:10	activated factor V:10:0.4363	0.4363	10
FVa	FVa:26|fVa:3	factor Va:29:0.7581	0.7581	29
FVC	FVC:32	Forearm vascular conductance:32:0.5509	0.5509	32
FVIIIC	FVIIIC:5|FVIIIc:2	Factor VIII coagulant activity:7:0.5926	0.5926	7
FVIII	FVIII:5|F-VIII:2	Factor VIII-related antigen:7:0.5926	0.5926	7
FVIIag	FVIIag:12|fVIIAg:1	factor VII antigen:13:0.7753	0.7753	13
FVI	FVI:17	flow velocity integral:17:0.8270	0.8270	17
FVL	FVL:103|fVL:3|FvL:2	Factor V Leiden:108:0.9559	0.9559	108
FVL	FVL:12|FvL:1	factor V Leiden mutation:13:0.6701	0.6701	13
FVPC	FVPC:11	follicular variant of papillary carcinoma:11:0.7357	0.7357	11
FVPTC	FVPTC:12|FV-PTC:1	follicular variant of papillary thyroid carcinoma:13:0.6701	0.6701	13
FVP	FVP:4|FV-P:4|FVp:1	strain of Friend virus:9:0.5050	0.5050	9
FVR	FVR:10	feline viral rhinotracheitis:10:0.5856	0.5856	10
FVR	FVR:147	Forearm vascular resistance:147:0.8361	0.8361	147
FVU	FVU:18	first void urine:18:0.8365	0.8365	18
FVWs	FVWs:20|FVWS:1	Flow velocity waveforms:21:0.8594	0.8594	21
FVW	FVW:45	flow velocity waveforms:28:0.8369|flow velocity waveform:17:0.8270	0.8369	45
FWAs	FWAs:28	fluorescent whitening agents:28:0.8369	0.8369	28
FWHM	FWHM:108|fwhm:2	full width at half maximum:90:0.9547|full width at half-maximum:20:0.7865	0.9547	110
FWHM	FWHM:9	full-width half-maximum:9:0.4002	0.4002	9
FWPV	FWPV:10	fowlpox virus:10:0.7103	0.7103	10
FWP	FWP:6	Fixed washed platelets:6:0.4438	0.4438	6
FWR	FWR:10	free wall rupture:10:0.7103	0.7103	10
FWS	FWS:7	free water surface:7:0.5926	0.5926	7
FWTM	FWTM:8	full width at tenth maximum:8:0.6794	0.6794	8
FXIIa	FXIIa:13	activated factor XII:13:0.5335	0.5335	13
FXI	FXI:68|fXI:3	factor XI:71:0.9579	0.9579	71
FXS	FXS:73	fragile X syndrome:73:0.9591	0.9591	73
FXTAS	FXTAS:11	Fragile X-associated tremor/ataxia syndrome:11:0.7357	0.7357	11
FXa	FXa:25|fXa:2|Fxa:1	activated factor X:28:0.4668	0.4668	28
FXa	FXa:118|fXa:64	factor Xa:182:0.9280	0.9280	182
FX	FX:98|fX:13|F-X:1	Factor X:112:0.8580	0.8580	112
FX	FX:14	Fluoxetine:14:0.0500	0.0500	14
FX	FX:10|F-X:6	fusarenon-X:16:0.0577	0.0577	16
Fy	Fy:8|FY:6	Duffy:14:0.0760	0.0760	14
FY	FY:114	fiscal year:98:0.9695|fiscal years:16:0.8165	0.9695	114
FZD	FZD:11|Fzd:3	Frizzled:14:0.5652	0.5652	14
FZP	FZP:19	flurazepam:19:0.5806	0.5806	19
FZ	FZ:18	fetal zone:18:0.5228	0.5228	18
Fz	Fz:5|FZ:3|fz:1	flunarizine:9:0.0252	0.0252	9
FZ	FZ:9|Fz:1	flunitrazepam:10:0.0283	0.0283	10
Fz	Fz:67|fz:31|FZ:2	frizzled:100:0.3113	0.3113	100
FZ	FZ:38|Fz:8	Furazolidone:46:0.1415	0.1415	46
FaRPs	FaRPs:64|FaRPS:1	FMRFamide-related peptides:65:0.7458	0.7458	65
Fab'	Fab':10	fragments:10:0.2195	0.2195	10
FabI	FabI:8|fabI:2	carrier protein reductase:10:0.6794	0.6794	10
Fab	Fab:28|FAB:1|FAb:1|F-Ab:1	antibody:19:0.0173|antibodies:12:0.0106	0.0173	31
Fab	Fab:41|FAB:1	antibody fragments:42:0.4251	0.4251	42
Fab	Fab:12	antigen-binding:12:0.0106	0.0106	12
Fab	Fab:54	antigen-binding fragment:35:0.5098|antigen-binding fragments:19:0.1393	0.5098	54
FAB	FAB:202	fast atom bombardment:202:0.9292	0.9292	202
FAB	FAB:400	French-American-British:388:0.3725|French American British:12:0.8365	0.8365	400
FAB	FAB:6	French-American-British Co-operative group:6:0.5290	0.5290	6
FAB	FAB:9	French-American-British Cooperative group:9:0.5470	0.5470	9
FAB	FAB:11	Frontal Assessment Battery:11:0.6794	0.6794	11
Fapy	Fapy:7|FaPy:3|FAPY:2	formamidopyrimidine:12:0.4231	0.4231	12
F-ara-A	F-ara-A:15|F-araA:1|Fara-A:1|F-Ara-A:1	9-beta-D-Arabinofuranosyl-2-fluoroadenine:18:0.2931	0.2931	18
F-ara-A	F-ara-A:9|F-Ara-A:1	arabinosyl-2-fluoroadenine:10:0.1552	0.1552	10
FasL	Fas-L:5|FasL:5	Fas and Fas-ligand:10:0.0800	0.0800	10
FasL	FasL:7|Fas-L:5	Fas/Fas-ligand:12:0.0078	0.0078	12
FbDP	FbDP:31	fibrin degradation products:31:0.8519	0.8519	31
FcR+	FcR+:9|Fc-R+:1	positive:10:0.4286	0.4286	10
FcRI	FcRI:8	Fc receptor:8:0.4102	0.4102	8
FcRn	FcRn:42	neonatal Fc receptor:42:0.6068	0.6068	42
FcRs	FcRs:42	Fc receptors:42:0.9291	0.9291	42
FCRs	FCRs:25	fractional catabolic rates:25:0.8816	0.8816	25
FcR	FcR:301|Fc-R:4|FCR:1	Fc receptor:155:0.7990|Fc receptors:136:0.8045|Fc-receptor:15:0.0132	0.8045	306
FCR	FCR:52	feed conversion ratio:52:0.7578	0.7578	52
FCR	FCR:123	flexor carpi radialis:123:0.9612	0.9612	123
FCR	FCR:13|Fcr:1	flexor carpi radialis muscle:14:0.7909	0.7909	14
FCR	FCR:271	fractional catabolic rate:217:0.9862|fractional catabolic rates:54:0.9448	0.9862	271
FCR	FCR:25	Fuji Computed Radiography:25:0.8186	0.8186	25
FdII	FdII:9	ferredoxin II:9:0.5470	0.5470	9
FdUMP	FdUMP:44	5-fluoro-2'-deoxyuridine-5'-monophosphate:24:0.1474|5-fluoro-2'-deoxyuridine 5'-monophosphate:20:0.4786	0.4786	44
FdUMP	FdUMP:18	5-fluoro-2'-deoxyuridylate:18:0.1090	0.1090	18
FdUMP	FdUMP:9	5-Fluorodeoxyuridine monophosphate:9:0.1150	0.1150	9
FdUMP	FdUMP:14	5-fluorodeoxyuridylate:14:0.0833	0.0833	14
FdUrd	FdUrd:117	5-Fluoro-2'-deoxyuridine:117:0.5659	0.5659	117
FdUrd	FdUrd:38	5-fluorodeoxyuridine:38:0.1805	0.1805	38
FdUrd	FdUrd:31|FdURD:1	fluorodeoxyuridine:32:0.1512	0.1512	32
FdU	FdU:11|FDU:4	5-fluoro-2'-deoxyuridine:15:0.3111	0.3111	15
FdU	FdU:10|FDU:1	5-fluorodeoxyuridine:11:0.2222	0.2222	11
F-ddA	F-ddA:8|FddA:2	2'-beta-fluoro-2',3'-dideoxyadenosine:10:0.3600	0.3600	10
Fe/S	Fe/S:19	iron-sulfur:19:0.7826	0.7826	19
Fe2+	Fe2+:10	ferrous ion:10:0.5856	0.5856	10
Fe2+	Fe2+:22	ferrous iron:22:0.2456	0.2456	22
Fe3+-NTA	Fe3+-NTA:10	ferric nitrilotriacetate:10:0.7103	0.7103	10
Fe3+	Fe3+:5	Ferric ion:5:0.1132	0.1132	5
Fe3+	Fe3+:14	ferric iron:14:0.1717	0.1717	14
FeCl3	FeCl3:22	ferric chloride:22:0.6934	0.6934	22
FeLV-B	FeLV-B:14	feline leukemia virus subgroup B:14:0.7909	0.7909	14
FeLVs	FeLVs:8	Feline leukemia viruses:8:0.6411	0.6411	8
FeLV	FeLV:78|FeLv:1	feline leukaemia virus:79:0.9200	0.9200	79
FeLV	FeLV:325|FELV:1|FeLv:1	feline leukemia virus:327:0.9631	0.9631	327
FEL	FEL:22	familial erythrophagocytic lymphohistiocytosis:22:0.7955	0.7955	22
FEL	FEL:6|Fel:3	felodipine:9:0.0714	0.0714	9
FEL	FEL:45	free-electron laser:24:0.3621|free electron laser:21:0.8594	0.8594	45
FEL	FEL:8	Friend erythroleukemia:8:0.6794	0.6794	8
FeMo-co	FeMo-co:27|FeMoco:21	iron-molybdenum cofactor:48:0.6820	0.6820	48
FENO	FENO:22|FeNO:9|Feno:2|FeNo:1	exhaled nitric oxide:34:0.8245	0.8245	34
Fe-NTA	Fe-NTA:91|FeNTA:15|FENTA:1	ferric nitrilotriacetate:107:0.8188	0.8188	107
Fe-NTA	Fe-NTA:6|FeNTA:2	nitrilotriacetic acid:8:0.2619	0.2619	8
FENa	FENa:15	fractional excretion of Na:15:0.8045	0.8045	15
FENa	FENa:150|FeNa:8|FEna:1|FENA:1	Fractional excretion of sodium:160:0.9515	0.9515	160
FENa	FENa:70|FeNa:5|FENA:1|FEna:1	fractional sodium excretion:77:0.9013	0.9013	77
FeSO4	FeSO4:12	ferrous sulfate:12:0.6460	0.6460	12
FeSOD	FeSOD:17|Fe-SOD:12	superoxide dismutase:29:0.6392	0.6392	29
FeSV	FeSV:43	feline sarcoma virus:43:0.8917	0.8917	43
FeTf	FeTf:5|FeTF:4|Fe-Tf:3|Fe-TF:2	transferrin:14:0.5200	0.5200	14
FecB	FecB:7	fecundity gene:7:0.2113	0.2113	7
FE	FE:37|Fe:7	feed efficiency:44:0.8620	0.8620	44
FE	FE:5|Fe:4	Fentanyl:9:0.0055	0.0055	9
FE	FE:22	fertilization envelope:22:0.8038	0.8038	22
FE	FE:224	finite element:195:0.9598|finite-element:29:0.0191	0.9598	224
FE	FE:64	fractional excretion:64:0.8123	0.8123	64
FFTF	FFTF:25	freedom from treatment failure:25:0.8816	0.8816	25
FgE	FgE:8	fragment E:8:0.4102	0.4102	8
FIO(2)	FIO(2):12|FiO(2):6|Fio(2):5|FIo(2):1	fraction of inspired oxygen:24:0.3828	0.3828	24
FIB	FIB:30|Fib:26|fib:4	fibrinogen:60:0.3224	0.3224	60
FIB	FIB:50	focused ion beam:50:0.9064	0.9064	50
flaA	flaA:11	flagellin gene:11:0.5050	0.5050	11
Flk-1	Flk-1:24|flk-1:4|Flk1:3|FLK-1:1	fetal liver kinase-1:22:0.8657|fetal liver kinase 1:10:0.5000	0.8657	32
flk-1	flk-1:5|Flk-1:3	VEGF receptor-2:8:0.3809	0.3809	8
Fmoc	Fmoc:29|FMOC:5|fmoc:1	9-fluorenylmethoxycarbonyl:35:0.2179	0.2179	35
FM	FM:9	face mask:9:0.5470	0.5470	9
FM	FM:9	family medicine:9:0.6794	0.6794	9
FM	FM:9|F-M:2	Farnsworth-Munsell:11:0.0050	0.0050	11
FM	FM:10	feather meal:10:0.0767	0.0767	10
F-M	F-M:8|FM:3	female-to-male:11:0.0050	0.0050	11
FM	FM:20	Ferromagnetic:20:0.0095	0.0095	20
FM	FM:37	Fetal movements:21:0.6812|fetal movement:16:0.5171	0.6812	37
FM	FM:43	Fibrin monomer:30:0.9011|fibrin monomers:13:0.7753	0.9011	43
FM	FM:36	fibromyalgia syndrome:36:0.9174	0.9174	36
FM	FM:34	fish meal:34:0.5687	0.5687	34
FM	FM:20	flunixin meglumine:20:0.8525	0.8525	20
FM	FM:21	fluorescence microscopy:21:0.6040	0.6040	21
FM	FM:12	Fluorescent microspheres:12:0.5050	0.5050	12
FM	FM:25	fragrance mix:25:0.8816	0.8816	25
FM	FM:137	frequency-modulated:91:0.0450|Frequency modulated:46:0.9353	0.9353	137
FM	FM:76	frequency modulation:76:0.9612	0.9612	76
FM	FM:10|fM:3	full mutation:13:0.7753	0.7753	13
fm	fm:5|Fm:4|FM:3	median frequency:12:0.1338	0.1338	12
FM	FM:96	patients with fibromyalgia:96:0.1929	0.1929	96
Fm	Fm:5	relationship between the estimated muscle force:5:0.4438	0.4438	5
Fn14	Fn14:9	fibroblast growth factor-inducible 14:9:0.5006	0.5006	9
Fn3	Fn3:5|FN3:4	fibronectin type III:9:0.6794	0.6794	9
FnBPs	FnBPs:19	fibronectin-binding proteins:19:0.5404	0.5404	19
Fos-LI	Fos-LI:16|Fos-li:7|FOS-LI:1	Fos-like immunoreactive:24:0.6427	0.6427	24
Fos-LI	Fos-LI:75|Fos-li:16|FOS-LI:3|fos-LI:2|FosLI:1|FOS-li:1	Fos-like immunoreactivity:98:0.8399	0.8399	98
Fos-lir	Fos-lir:11|Fos-LIR:4|fos-lir:1|FOS-lir:1|Foslir:1	Fos-like immunoreactivity:18:0.7539	0.7539	18
Fr-MLV	Fr-MLV:6|FrMLV:3	Friend murine leukemia virus:9:0.6794	0.6794	9
FrSBe	FrSBe:11	Frontal Systems Behavior Scale:11:0.7357	0.7357	11
Friend	Friend:9	mouse erythroleukemia:9:0.2757	0.2757	9
Fru-6-P	Fru-6-P:35|Fru6P:4|fru-6-P:2	fructose 6-phosphate:31:0.8090|fructose-6-phosphate:10:0.2000	0.8090	41
Fru	Fru:23|fru:8	fructose:31:0.3846	0.3846	31
fru	fru:29|Fru:5	fruitless:34:0.4231	0.4231	34
FTZ-F1	FTZ-F1:7|Ftz-F1:1	fushi tarazu factor 1:8:0.6411	0.6411	8
Fuc-T	Fuc-T:9|FucT:6	fucosyltransferase:15:0.3889	0.3889	15
Fugu	Fugu:14	Fugu rubripes:14:0.3821	0.3821	14
Furo	Furo:6|FURO:3	furosemide:9:0.8889	0.8889	9
FUR	FUR:19	5-fluorouridine:19:0.0882	0.0882	19
fur	fur:8|Fur:5	ferric uptake regulation:13:0.5934	0.5934	13
Fur	Fur:46|fur:8	ferric uptake regulator:54:0.8622	0.8622	54
Fur	Fur:9	ferric uptake repressor:9:0.6794	0.6794	9
FUR	FUR:23|Fur:6	furosemide:29:0.1373	0.1373	29
FUS	FUS:22	Focused ultrasound:22:0.7955	0.7955	22
FUS	FUS:11	Focused ultrasound surgery:11:0.7357	0.7357	11
FUS	FUS:11	syndrome:11:0.1075	0.1075	11
Fv/Fm	Fv/Fm:14	efficiency:14:0.3095	0.3095	14
FVs	FVs:24	Foamy viruses:24:0.8768	0.8768	24
FV	FV:173|F-V:1|fV:1	factor V:175:0.8995	0.8995	175
FV	FV:7	fasting volume:7:0.0777	0.0777	7
FV	FV:18|fv:2	femoral vein:20:0.6259	0.6259	20
FV	FV:48	flow velocity:48:0.7074	0.7074	48
F-V	F-V:10|FV:7	flow-volume:17:0.0230	0.0230	17
FV	FV:40	Foamy virus:28:0.2255|Foamy viruses:12:0.7571	0.7571	40
F-V	F-V:10|FV:8|F-v:5	Force-velocity:23:0.0316	0.0316	23
FV	FV:34|Fv:5	Friend virus:39:0.3533	0.3533	39
FV	FV:13	Friend virus complex:13:0.6701	0.6701	13
Fv	Fv:10	variable fragment:10:0.1680	0.1680	10
FW	FW:13	feed withdrawal:13:0.5934	0.5934	13
FW	FW:51	fresh water:51:0.7212	0.7212	51
FW	FW:33|fw:14	fresh weight:47:0.6183	0.6183	47
FW	FW:85	freshwater:85:0.2428	0.2428	85
FW	FW:9	width:9:0.0231	0.0231	9
Fx1A	Fx1A:6	brush border antigen:6:0.5290	0.5290	6
FXR	FXR:115	farnesoid X receptor:115:0.9205	0.9205	115
G(Cl)	G(Cl):13|G(Cl-):1	conductance:14:0.8125	0.8125	14
G(t)	G(t):11|G(T):5|g(t):1	conductance:17:0.3200	0.3200	17
G(t)	G(t):5	G protein transducin:5:0.5006	0.5006	5
G(i)	G(i):6	G protein:6:0.2902	0.2902	6
g(s)	g(s):22|G(s):1	stomatal conductance:23:0.8038	0.8038	23
G-EAT	G-EAT:9	granulomatous experimental autoimmune thyroiditis:9:0.6794	0.6794	9
g.a.	g.a.:7|G.A.:4	gestational age:11:0.6182	0.6182	11
G.F.R.	G.F.R.:13|g.f.r.:5	glomerular filtration rate:18:0.8365	0.8365	18
G.I.	G.I.:18|g.i.:6	gastrointestinal:24:0.7188	0.7188	24
g.w.	g.w.:11	gestational weeks:11:0.6182	0.6182	11
G/F	G/F:7	feed efficiency:7:0.3524	0.3524	7
G/F	G/F:13	gain/feed:13:0.1395	0.1395	13
G/F	G/F:11	gain:feed ratio:11:0.3495	0.3495	11
G/F	G/F:11	regulatory component:11:0.7357	0.7357	11
G0	G0:18	quiescence:18:0.0635	0.0635	18
G0	G0:17	quiescent state:17:0.3670	0.3670	17
G0	G0:9	resting state:9:0.1385	0.1385	9
G-1,6-P2	G-1,6-P2:7|G1,6P2:1	glucose 1,6-bisphosphate:8:0.4102	0.4102	8
G-17	G-17:15|G17:12	gastrin-17:22:0.1707|Gastrin 17:5:0.0736	0.1707	27
G-17	G-17:5|G17:4	gastrin heptadecapeptide:9:0.5470	0.5470	9
G1P	G1P:12|G-1-P:9	glucose-1-phosphate:13:0.3077|glucose 1-phosphate:8:0.5006	0.5006	21
G1	G1:9	activated:9:0.0104	0.0104	9
G1	G1:15|G-1:1	control group:16:0.2362	0.2362	16
G1	G1:7	first gap phase:7:0.5926	0.5926	7
G1	G1:7	First generation:7:0.2902	0.2902	7
G1	G1:7|G-1:1	first group:8:0.0584	0.0584	8
G1	G1:22	grade 1:22:0.1195	0.1195	22
G1	G1:54|G-1:4	Group 1:58:0.4362	0.4362	58
G1	G1:7|G-1:2	patients:9:0.0104	0.0104	9
G1	G1:16	Well-differentiated:16:0.0196	0.0196	16
G34	G34:10|G-34:7	big gastrin:17:0.5760	0.5760	17
G3PDH	G3PDH:83|G-3-PDH:6|G3pdh:1	dehydrogenase:90:0.9474	0.9474	90
G3PD	G3PD:21|G-3PD:4|G-3-PD:3	glyceraldehyde-3-phosphate dehydrogenase:28:0.4539	0.4539	28
g3p	g3p:8	gene 3 protein:8:0.6411	0.6411	8
G3P	G3P:9|G-3-P:2	glyceraldehyde-3-phosphate:11:0.0806	0.0806	11
G3P	G3P:42|G-3-P:5|G3-P:1	glycerol-3-phosphate:31:0.2419|glycerol 3-phosphate:17:0.2695	0.2695	48
G3P	G3P:7|G-3-P:3	sn-glycerol-3-phosphate:10:0.0726	0.0726	10
G3	G3:17	grade 3:17:0.1650	0.1650	17
G3	G3:30|G-3:2	group 3:32:0.4207	0.4207	32
G3	G3:7	third group:7:0.2113	0.2113	7
G4	G4:12|G-4:1	group 4:13:0.2660	0.2660	13
G4	G4:15	tetrameric:15:0.0765	0.0765	15
g5p	g5p:15|G5P:4	gene 5 protein:19:0.8449	0.8449	19
G6PDH	G6PDH:311|G-6-PDH:95|G6P-DH:14|G6-PDH:5|G-6PDH:2|-G-6-PDH:1|g-6-PDH:1|G-6-P-DH:1|G6Pdh:1|G6PDh:1|G-6-pDH:1	glucose-6-phosphate dehydrogenase:433:0.8340	0.8340	433
G6PD	G6PD:1068|G-6-PD:329|G-6PD:11|G6pd:7|G-6-P-D:4|G6-PD:3|G6P-D:2|g-6-pd:1|g6pd:1|g-6-PD:1	glucose-6-phosphate dehydrogenase:1399:0.8439|glucose-6-phosphate-dehydrogenase:28:0.0157	0.8439	1427
G6PD	G6PD:7|G-6-PD:3|G-6PD:1	glucose-6-phosphate dehydrogenase deficiency:11:0.4232	0.4232	11
G6PT	G6PT:17	transporter:17:0.8421	0.8421	17
G6Pase	G6Pase:245|G-6-Pase:106|G6-Pase:6|G6PASE:5|G-6-pase:4|G-6-P-ase:4|G-6Pase:3|G6P-ase:3	glucose-6-phosphatase:356:0.8575|glucose 6-phosphatase:20:0.8525	0.8575	376
G6P	G6P:21|G-6-P:6|G6p:1	glucose-6-phosphatase:28:0.0726	0.0726	28
G6P	G6P:183|G-6-P:116|G6-P:8|G-6P:2|g-6-p:1	glucose-6-phosphate:204:0.5457|glucose 6-phosphate:106:0.8605	0.8605	310
GA(3)	GA(3):11	gibberellic acid:11:0.6182	0.6182	11
GA3	GA3:73	gibberellic acid:73:0.8961	0.8961	73
GA3PD	GA3PD:6	glyceraldehyde 3-phosphate dehydrogenase:6:0.5290	0.5290	6
GAA	GAA:57|Gaa:1	acid alpha-glucosidase:43:0.8037|acid alpha glucosidase:15:0.8045	0.8045	58
GAA	GAA:21	gossypol acetic acid:21:0.5721	0.5721	21
GAA	GAA:11	guanidinoacetate:11:0.0413	0.0413	11
GAA	GAA:36	guanidinoacetic acid:36:0.3805	0.3805	36
GABA(A)	GABA(A):50	gamma-aminobutyric acid:50:0.7328	0.7328	50
GABA(A)	GABA(A):109	gamma-aminobutyric acid(A):72:0.8309|gamma-aminobutyric acid-A:37:0.8377	0.8377	109
GABA(A)	GABA(A):25	gamma-aminobutyric acidA:25:0.7679	0.7679	25
GABA(B)	GABA(B):8	gamma-aminobutyric acid:8:0.5006	0.5006	8
GABA(B)	GABA(B):27	gamma-aminobutyric acid(B):18:0.8365|gamma-aminobutyric acid-B:9:0.6794	0.8365	27
GABA(B)	GABA(B):14	gamma-aminobutyric acid type B:14:0.6577	0.6577	14
GABA-AT	GABA-AT:13	gamma-aminobutyric acid aminotransferase:13:0.7753	0.7753	13
GABAA	GABAA:94|GABA-A:2	gamma-aminobutyric acid:96:0.8186	0.8186	96
GABAA	GABAA:120|GABA-A:8|GABAa:1	gamma-aminobutyric acid-A:129:0.8670	0.8670	129
GABAA	GABAA:181	gamma-aminobutyric acidA:181:0.9284	0.9284	181
GABAB	GABAB:11|GABA-B:1	Gamma-aminobutyric acid:12:0.4557	0.4557	12
GABAB	GABAB:47|GABAb:1	Gamma-aminobutyric acid-B:33:0.7525|gamma-aminobutyric acid B:15:0.6386	0.7525	48
GABAB	GABAB:11|GABA-B:1	gamma-aminobutyric acid type B:12:0.7096	0.7096	12
GABAB	GABAB:46	gamma-aminobutyric acidB:46:0.7921	0.7921	46
GABA-T	GABA-T:49|GABAT:1	aminotransferase:50:0.2000	0.2000	50
GABA-T	GABA-T:9	GABA-aminotransferase:9:0.0327	0.0327	9
GABA-T	GABA-T:102|GABA-t:2|GABAT:1	GABA-transaminase:64:0.2571|GABA transaminase:41:0.3402	0.3402	105
GABA-T	GABA-T:23|GABAT:2	gamma-Aminobutyric acid transaminase:25:0.6873	0.6873	25
GABA-IR	GABA-IR:20|GABAir:6|GABA-ir:6|GABA-Ir:1	GABA-immunoreactive:33:0.4267	0.4267	33
GABA-IR	GABA-IR:8|GABA-ir:2	GABA immunoreactivity:10:0.2275	0.2275	10
GABA-LI	GABA-LI:9	GABA-like immunoreactivity:9:0.3069	0.3069	9
GABA	GABA:12	4-aminobutyrate:12:0.0015	0.0015	12
GABA	GABA:16	gamma-aminobutyric:16:0.0020	0.0020	16
GABA	GABA:6213|gaba:4|Gaba:3	gamma-aminobutyric acid:6220:0.8615	0.8615	6220
GABA	GABA:14	inhibitory:14:0.0018	0.0018	14
GABEB	GABEB:17	generalized atrophic benign epidermolysis bullosa:17:0.6748	0.6748	17
GABHS	GABHS:17	group A beta-haemolytic streptococci:17:0.8270	0.8270	17
GABHS	GABHS:54	group A beta-hemolytic streptococcal:54:0.9448	0.9448	54
GABHS	GABHS:55	Group A beta-hemolytic streptococci:55:0.9458	0.9458	55
GABHS	GABHS:37	group A beta-hemolytic streptococcus:37:0.9197	0.9197	37
GABP	GABP:33|Gabp:2	GA-binding protein:35:0.5929	0.5929	35
GAC	GAC:96	granular activated carbon:96:0.8583	0.8583	96
GAD(67)	GAD(67):10	glutamic acid decarboxylase:10:0.7103	0.7103	10
GAD-IR	GAD-IR:5	Glutamate decarboxylase immunoreactivity:5:0.1973	0.1973	5
GAD65	GAD65:31|GAD-65:2	glutamate decarboxylase:33:0.1651	0.1651	33
GAD65	GAD65:96|GAD-65:3	glutamic acid decarboxylase:99:0.9359	0.9359	99
GAD65	GAD65:39|GAD-65:5	glutamic acid decarboxylase 65:31:0.9011|glutamic acid decarboxylase-65:13:0.7753	0.9011	44
GAD67	GAD67:18	glutamate decarboxylase:18:0.1426	0.1426	18
GAD67	GAD67:44|GAD-67:6	glutamic acid decarboxylase:50:0.9064	0.9064	50
GAD67	GAD67:15|GAD-67:1	glutamic acid decarboxylase 67:16:0.8165	0.8165	16
GAD-Ab	GAD-Ab:11|GADab:8|GADAb:7|GAD-ab:2	glutamic acid decarboxylase:28:0.8941	0.8941	28
GAD-Ab	GADAb:3|GAD-Ab:3|GAD-AB:1	glutamic acid decarboxylase antibodies:7:0.3524	0.3524	7
GADD45	GADD45:4|gadd45:2	growth arrest and DNA damage-inducible gene 45:6:0.5290	0.5290	6
GADH	GADH:7|GaDH:3	dehydrogenase:10:0.7500	0.7500	10
GAD	GAD:10	anxiety disorders:10:0.7103	0.7103	10
GAD	GAD:9	decarboxylase activity:9:0.6794	0.6794	9
GAD	GAD:5	general acyl-CoA dehydrogenase:5:0.2818	0.2818	5
GAD	GAD:412	generalized anxiety disorder:412:0.8907	0.8907	412
GAD	GAD:399|Gad:2	glutamate decarboxylase:401:0.2324	0.2324	401
GAD	GAD:1052|gad:1	glutamic acid decarboxylase:1053:0.9294	0.9294	1053
GAD	GAD:21|gad:20	gracile axonal dystrophy:41:0.9274	0.9274	41
GAD	GAD:12	graft arterial disease:12:0.7571	0.7571	12
GAE	GAE:15	granulomatous amebic encephalitis:15:0.8045	0.8045	15
GAERS	GAERS:37	genetic absence epilepsy rats from Strasbourg:37:0.9256	0.9256	37
GAF	GAF:13	Activation Factor:13:0.1281	0.1281	13
GAF	GAF:15	Global Assessment of Function:15:0.8045	0.8045	15
GAF	GAF:141	Global Assessment of Functioning:141:0.9467	0.9467	141
GAF	GAF:33	Global Assessment of Functioning Scale:33:0.8292	0.8292	33
GAG's	GAG's:13	glycosaminoglycans:13:0.9231	0.9231	13
GAGPS	GAGPS:14	glycosaminoglycan polysulfate:14:0.7909	0.7909	14
GAgP	GAgP:8|G-AgP:1	generalized aggressive periodontitis:9:0.6794	0.6794	9
GAGs	GAGs:1012|GAGS:19|GAG-s:2|Gags:1	glycosaminoglycans:1034:0.9494	0.9494	1034
GAG	GAG:23	gamma-acetylenic GABA:23:0.5719	0.5719	23
GAG	GAG:1463|gag:1|Gag:1	glycosaminoglycan:924:0.5105|glycosaminoglycans:541:0.2996	0.5105	1465
gag	gag:10|Gag:5|GAG:2	group-specific antigen:9:0.1585|group specific antigen:8:0.6411	0.6411	17
gag	gag:7|Gag:5	structural:12:0.0061	0.0061	12
GAII	GAII:5	glutaric aciduria type II:5:0.4422	0.4422	5
GA-I	GA-I:5|GAI:2	Glutaric acidemia type I:7:0.6411	0.6411	7
GA-I	GA-I:11|GAI:2	glutaric aciduria type I:13:0.7753	0.7753	13
GalA	GalA:9	galacturonic acid:9:0.3945	0.3945	9
galK	galK:7	Escherichia coli galactokinase gene:7:0.5926	0.5926	7
galK	galK:20|GALK:19|GalK:10	galactokinase:49:0.6316	0.6316	49
GALNS	GALNS:19|Galns:1	N-acetylgalactosamine-6-sulfate sulfatase:20:0.7173	0.7173	20
GalR1	GalR1:10|GALR1:4|GAL-R1:4	galanin receptor 1:10:0.5856|galanin receptor-1:8:0.5006	0.5856	18
GALT	GALT:45|galT:2|Galt:1	galactose-1-phosphate uridyl transferase:48:0.8221	0.8221	48
GALT	GALT:70|galT:2	galactose-1-phosphate uridyltransferase:72:0.8773	0.8773	72
GALT	GALT:16|GalT:2	galactose-1-phosphate uridylyltransferase:18:0.7539	0.7539	18
GalT	GalT:18|gal-T:2|Gal-T:2|galT:1	galactosyltransferase:23:0.0394	0.0394	23
GALT	GALT:247	gut-associated lymphoid tissue:198:0.7741|gut-associated lymphoid tissues:49:0.7455	0.7741	247
GALV	GALV:52|GaLV:26	gibbon ape leukemia virus:78:0.9393	0.9393	78
GAL-IR	GAL-IR:7|Gal-IR:1|GAL-ir:1	galanin-immunoreactive:9:0.2424	0.2424	9
GAL-ir	GAL-ir:3|Gal-IR:2|GAL-IR:2|Gal-ir:1|GALir:1	immunoreactive:9:0.2424	0.2424	9
GAL-IR	GAL-IR:6|Gal-IR:2|GAL-ir:2|GALIR:1	immunoreactivity:11:0.3030	0.3030	11
GAMs	GAMs:8	generalized additive models:8:0.5006	0.5006	8
GAMT	GAMT:28	Guanidinoacetate methyltransferase:28:0.7066	0.7066	28
GAM	GAM:24	generalized additive model:14:0.5818|Generalized Additive Models:10:0.4363	0.5818	24
GAM	GAM:9	glucoamylase:9:0.0889	0.0889	9
GANS	GANS:6	granulomatous angiitis of the nervous system:6:0.5290	0.5290	6
GANT	GANT:8	Gastrointestinal autonomic nerve tumor:8:0.4438	0.4438	8
GAN	GAN:13	Gastrointestinal autonomic nerve:13:0.5934	0.5934	13
GAN	GAN:41	giant axonal neuropathy:41:0.9237	0.9237	41
GAOs	GAOs:18	glycogen-accumulating organisms:10:0.2446|glycogen accumulating organisms:8:0.6411	0.6411	18
GAO	GAO:29	General Accounting Office:29:0.7581	0.7581	29
GAO	GAO:7	glycolic acid oxidase:7:0.4438	0.4438	7
GAP1	GAP1:8|Gap1:3	general amino acid permease:11:0.7357	0.7357	11
GAP-43	GAP-43:63|GAP43:4|Gap43:1	growth-associated protein:68:0.6896	0.6896	68
GAP-43	GAP-43:184|GAP43:20|Gap43:3|Gap-43:1	growth-associated protein-43:84:0.6725|growth-associated protein 43:75:0.6264|growth associated protein-43:25:0.8816|growth associated protein 43:24:0.8768	0.8816	208
GAPDH	GAPDH:717|GAP-DH:3|gapdh:2|GapDH:1|gapDH:1|Gapdh:1	glyceraldehyde-3-phosphate dehydrogenase:713:0.7137|glyceraldehyde-3-phosphate dehydrogenases:12:0.5050	0.7137	725
GAPD	GAPD:30	glyceraldehyde-3-phosphate dehydrogenase:30:0.4404	0.4404	30
GAPN	GAPN:9	glyceraldehyde-3-phosphate dehydrogenase:9:0.4587	0.4587	9
GAP	GAP:7|G-AP:1	generalized aggressive periodontitis:8:0.4102	0.4102	8
GAP	GAP:7	glyceraldehyde 3-phosphate:7:0.1470	0.1470	7
GAP	GAP:15|gap:3|Gap:2	glyceraldehyde-3-phosphate dehydrogenase:20:0.7173	0.7173	20
GAP	GAP:32	GnRH-associated peptide:32:0.4119	0.4119	32
GAP	GAP:6	gonadotropin-releasing hormone associated peptide:6:0.2827	0.2827	6
GAP	GAP:6	Good Agricultural Practice:6:0.5290	0.5290	6
GAP	GAP:315	GTPase-activating protein:298:0.5417|GTPase-activating proteins:17:0.4246	0.5417	315
GAP	GAP:5	Guidelines Applied in Practice:5:0.1973	0.1973	5
GAQ	GAQ:13	Global Assessment Question:13:0.7753	0.7753	13
GARFT	GARFT:25	glycinamide ribonucleotide formyltransferase:25:0.8816	0.8816	25
GARS	GARS:8	Groningen Activity Restriction Scale:8:0.6411	0.6411	8
GART	GART:8	glycinamide ribonucleotide formyltransferase:8:0.6411	0.6411	8
GART	GART:8	glycinamide ribonucleotide transformylase:8:0.5006	0.5006	8
GAR	GAR:20	glycinamide ribonucleotide:20:0.8525	0.8525	20
GAr	GAr:6|GAR:2	glycine-alanine repeat:8:0.2619	0.2619	8
Gas1	Gas1:4|gas-1:1	Growth arrest specific gene 1:5:0.4422	0.4422	5
GAST	GAST:10|gast:8	gastrocnemius:18:0.5484	0.5484	18
GAS	GAS:9	activation sequence:9:0.0638	0.0638	9
GAS	GAS:9	gamma-activated sequence:9:0.0638	0.0638	9
GAS	GAS:22	gastric acid secretion:22:0.8657	0.8657	22
GAS	GAS:4|G-A-S:1	General Adaptation Syndrome:5:0.4422	0.4422	5
GAs	GAs:49	genetic algorithms:49:0.9046	0.9046	49
GAs	GAs:11	gestational ages:11:0.7357	0.7357	11
GAs	GAs:75|gas:3	Gibberellins:78:0.0671	0.0671	78
GAS	GAS:73	Global Assessment Scale:73:0.9591	0.9591	73
GAS	GAS:31	Goal Attainment Scaling:31:0.9043	0.9043	31
GAS	GAS:143	group A streptococcal:143:0.9100	0.9100	143
GAS	GAS:168	Group A streptococci:168:0.7965	0.7965	168
GAS	GAS:197	group A streptococcus:197:0.9219	0.9219	197
gas	gas:14|Gas:3|GAS:1	growth arrest-specific:18:0.8365	0.8365	18
GAS	GAS:15	IFN-gamma activation site:15:0.2729	0.2729	15
GAS	GAS:10	Streptococcus pyogenes:10:0.7103	0.7103	10
GAT-1	GAT-1:9|GAT1:8|Gat1:1	GABA transporter:18:0.5178	0.5178	18
GAT-1	GAT-1:17|GAT1:3	GABA transporter-1:13:0.4444|GABA transporter 1:7:0.4102	0.4444	20
GATs	GATs:17	GABA transporters:17:0.5721	0.5721	17
GATS	GATS:10	General Agreement on Trade in Services:10:0.7103	0.7103	10
GAT	GAT:8	galactosyltransferase associated with tumor:8:0.5006	0.5006	8
GAT	GAT:15	gelatin agglutination test:15:0.4609	0.4609	15
GAT	GAT:26	Goldmann applanation tonometer:26:0.8861	0.8861	26
GAT	GAT:20	Goldmann applanation tonometry:20:0.8525	0.8525	20
GAT	GAT:52	L-glutamic acid60-L-alanine30-L-tyrosine10:52:0.8187	0.8187	52
GAU	GAU:9	geriatric assessment unit:9:0.6794	0.6794	9
GAVE	GAVE:44	gastric antral vascular ectasia:44:0.9323	0.9323	44
GAV	GAV:21	gill-associated virus:21:0.8594	0.8594	21
GAW5	GAW5:10	Genetic Analysis Workshop 5:10:0.7103	0.7103	10
Gaw	Gaw:22|GAW:1	airway conductance:23:0.7046	0.7046	23
Ga	Ga:5|ga:4|GA:3|gA:2	conductance:14:0.0047	0.0047	14
GA	GA:41	gallic acid:41:0.0861	0.0861	41
Ga	Ga:39|GA:1	gallium:40:0.0130	0.0130	40
GA	GA:10	Gardner-Arnstein:10:0.0030	0.0030	10
GA	GA:14	general:14:0.0043	0.0043	14
GA	GA:83	general anaesthesia:83:0.9429	0.9429	83
GA	GA:10	general anaesthetic:10:0.7103	0.7103	10
GA	GA:156	general anesthesia:156:0.9808	0.9808	156
GA	GA:180	genetic algorithm:160:0.9603|genetic algorithms:20:0.8525	0.9603	180
GA	GA:26	geographic atrophy:26:0.3502	0.3502	26
GA	GA:9|Ga:1	Georgia:10:0.0030	0.0030	10
GA	GA:475	gestational age:453:0.9541|gestational ages:22:0.8657	0.9541	475
GA	GA:44	gibberellic acid:44:0.0941	0.0941	44
GA	GA:191	gibberellin:191:0.0633	0.0633	191
GA	GA:55	glatiramer acetate:55:0.8225	0.8225	55
GA	GA:26	glucoamylase:26:0.0083	0.0083	26
GA	GA:24	glutaminase:24:0.0077	0.0077	24
GA	GA:218	glutaraldehyde:218:0.0723	0.0723	218
GA	GA:20	glycated albumin:20:0.5892	0.5892	20
GA	GA:31	glycolic acid:31:0.0598	0.0598	31
GA	GA:33	Glycyrrhetic acid:33:0.0650	0.0650	33
GA	GA:88	Golgi apparatus:88:0.8995	0.8995	88
GA	GA:11	gouty arthritis:11:0.6182	0.6182	11
GA	GA:5	granulocyte agglutination:5:0.1132	0.1132	5
GA	GA:60	granuloma annulare:60:0.9503	0.9503	60
GA	GA:7	graphical analysis:7:0.3524	0.3524	7
GA	GA:16	gum arabic:16:0.7261	0.7261	16
GA	GA:21	Gyrate atrophy:21:0.2554	0.2554	21
GA	GA:10	hsp90 inhibitor geldanamycin:10:0.3275	0.3275	10
GA	GA:7	metabolite glycidamide:7:0.1409	0.1409	7
G----A	G----A:8|G-A:1	substitution:9:0.0027	0.0027	9
GBA	GBA:7	gamma-band activity:7:0.1470	0.1470	7
GBA	GBA:18|Gba:1	glucocerebrosidase:19:0.1683	0.1683	19
GBA	GBA:10	glucocerebrosidase gene:10:0.4363	0.4363	10
GBC	GBC:25	gallbladder cancer:25:0.7249	0.7249	25
GBC	GBC:27	gallbladder carcinoma:27:0.7834	0.7834	27
GBD	GBD:16	binding domain:16:0.2812	0.2812	16
GBD	GBD:17	global burden of disease:17:0.8365	0.8365	17
GBEC	GBEC:9	epithelial cells:9:0.6794	0.6794	9
GBEF	GBEF:16	Gallbladder ejection fraction:16:0.6748	0.6748	16
GBE	GBE:45|GbE:17|Gbe:3	Ginkgo biloba extract:65:0.9047	0.9047	65
GBE	GBE:12	glycogen branching enzyme:12:0.7571	0.7571	12
GBF	GBF:110	blood flow:110:0.9728	0.9728	110
GBF	GBF:6	G-box binding factor:6:0.3728	0.3728	6
GBF	GBF:25	germinated barley foodstuff:25:0.8816	0.8816	25
GBI	GBI:13	General Behavior Inventory:13:0.7753	0.7753	13
GBI	GBI:13	Glasgow Benefit Inventory:13:0.6701	0.6701	13
GBL	GBL:140|Gbl:1	gamma-butyrolactone:141:0.8225	0.8225	141
GBMs	GBMs:20	glioblastomas:20:0.2794	0.2794	20
GBMs	GBMs:22	glioblastomas multiforme:22:0.6531	0.6531	22
GBMs	GBMs:12	glomerular basement membranes:12:0.6460	0.6460	12
GBM	GBM:193	Anti-glomerular basement membrane:193:0.1457	0.1457	193
GBM	GBM:101	glioblastoma:70:0.0359|glioblastomas:31:0.0156	0.0359	101
GBM	GBM:533|gbm:3	glioblastoma multiforme:536:0.9633	0.9633	536
GBM	GBM:958	glomerular basement membrane:893:0.7567|glomerular basement membranes:65:0.8841	0.8841	958
GBP	GBP:25|Gbp:1	binding protein:26:0.1769	0.1769	26
GBP	GBP:15	blood pool:15:0.8045	0.8045	15
GBP	GBP:155	Gabapentin:155:0.4074	0.4074	155
GBP	GBP:45	Gastric bypass:45:0.9338	0.9338	45
GBP	GBP:18	growth-blocking peptide:18:0.8365	0.8365	18
GBP	GBP:9	proteins:9:0.0212	0.0212	9
GBRs	GBRs:7	Induced gamma band responses:7:0.3524	0.3524	7
GBRs	GBRs:11	receptor complexes:11:0.7357	0.7357	11
GBR	GBR:8	gamma band response:8:0.6411	0.6411	8
GBR	GBR:15	Great Barrier Reef:15:0.8045	0.8045	15
GBR	GBR:10	group B rotavirus:10:0.7103	0.7103	10
GBR	GBR:96|gbr:1	guided bone regeneration:97:0.9352	0.9352	97
GBR	GBR:5	Ringer's solution:5:0.0736	0.0736	5
GBSSI	GBSSI:8	granule-bound starch synthase I:8:0.5006	0.5006	8
GBSS	GBSS:11	granule-bound starch synthase:11:0.4232	0.4232	11
GBST	GBST:11	galvanic body sway test:11:0.7357	0.7357	11
GBS	GBS:232	group B streptococcal:232:0.9871	0.9871	232
GBS	GBS:403	Group B streptococci:403:0.9926	0.9926	403
GBS	GBS:417	group B Streptococcus:417:0.9885	0.9885	417
GBS	GBS:946	Guillain-Barre syndrome:946:0.9141	0.9141	946
GBS	GBS:15	Streptococcus agalactiae:15:0.7261	0.7261	15
GB	GB:3	cell surface protease guanidinobenzoatase:3:0.6411	0.6411	3
GB	GB:18	gall-bladder:9:0.0075|Gall bladder:9:0.6794	0.6794	18
GB	GB:141	gallbladder:141:0.1308	0.1308	141
G-B	G-B:7|GB:3	Gallyas-Braak:10:0.0084	0.0084	10
GB	GB:10	gastric banding:10:0.5856	0.5856	10
GB	GB:10	gastric bypass:10:0.7103	0.7103	10
GB	GB:24	generalized Born:24:0.8768	0.8768	24
Gb	Gb:8|GB:7	Ginkgo biloba:15:0.7096	0.7096	15
GB	GB:9|Gb:7	glibenclamide:16:0.0140	0.0140	16
GB	GB:28	glioblastoma:18:0.0159|glioblastomas:10:0.0084	0.0159	28
GB	GB:22	glycine betaine:22:0.8657	0.8657	22
gB	gB:368|GB:1	glycoprotein B:369:0.8670	0.8670	369
GB	GB:24	Great Britain:24:0.8768	0.8768	24
GB	GB:21	sarin:21:0.0187	0.0187	21
GB	GB:6	surface protease referred to as guanidinobenzoatase:6:0.3524	0.3524	6
GC-EAD	GC-EAD:16	gas chromatographic-electroantennographic detection:16:0.8165	0.8165	16
GC-ECD	GC-ECD:13	gas chromatography-electron capture detection:13:0.6701	0.6701	13
GC-ECD	GC-ECD:14	gas chromatography with electron-capture detection:14:0.8045	0.8045	14
GC-FID	GC-FID:14	gas chromatography with flame ionization detection:14:0.8165	0.8165	14
GC-FID	GC-FID:13	ionization detector:13:0.5335	0.5335	13
GC-HRMS	GC-HRMS:13	mass spectrometry:13:0.7753	0.7753	13
GC-IRMS	GC-IRMS:9	gas chromatography-isotope ratio mass spectrometry:9:0.6794	0.6794	9
GC-MS-MS	GC-MS-MS:18	gas chromatography-tandem mass spectrometry:18:0.8365	0.8365	18
GC-MSD	GC-MSD:5	gas chromatography-mass selective detection:5:0.4422	0.4422	5
GC-NPD	GC-NPD:7	gas chromatography with nitrogen-phosphorus detection:7:0.5926	0.5926	7
GC/ECD	GC/ECD:9	capture detector:9:0.6794	0.6794	9
GC/FID	GC/FID:3	gas chromatography with flame ionization detection:3:0.4422	0.4422	3
GC/MS	GC/MS:59	gas chromatographic/mass spectrometric:59:0.9494	0.9494	59
GC/MS	GC/MS:655|GC/mS:2	Gas Chromatography/Mass Spectrometry:657:0.9662	0.9662	657
GC/MS	GC/MS:30	gas chromatography/mass spectroscopy:30:0.9011	0.9011	30
GC/SIM	GC/SIM:13	gas chromatography/selected ion monitoring:13:0.7753	0.7753	13
gC-1	gC-1:12|gC1:1	glycoprotein C:13:0.6701	0.6701	13
GCAP1	GCAP1:6|GCAP-1:1	Guanylate cyclase-activating protein 1:7:0.3524	0.3524	7
GCAP	GCAP:6	cyclase-activating protein:6:0.1320	0.1320	6
GCAP	GCAP:15	germ cell alkaline phosphatase:15:0.8045	0.8045	15
gCa	gCa:4|GCa:1	Ca2+ conductance:5:0.0902	0.0902	5
GCA	GCA:8|GCa:2	gastric carcinoma:10:0.5000	0.5000	10
GCA	GCA:10	gastric cardia adenocarcinoma:10:0.7103	0.7103	10
GCA	GCA:7|gca:2	general combining ability:9:0.6794	0.6794	9
GCA	GCA:383	giant cell arteritis:383:0.9686	0.9686	383
GCA	GCA:12	glycocholic acid:12:0.3813	0.3813	12
GC-A	GC-A:7	guanylate cyclase-A:7:0.0777	0.0777	7
GC-A	GC-A:16	guanylyl cyclase-A:16:0.4536	0.4536	16
GC-B	GC-B:7	cyclase B:7:0.2452	0.2452	7
GCCB-S	GCCB-S:8	Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery:8:0.6411	0.6411	8
GCC	GCC:6	gastric cardia cancer:6:0.5290	0.5290	6
GCC	GCC:5	germ cell cancer:5:0.4422	0.4422	5
GCC	GCC:9	glassy cell carcinoma:9:0.3945	0.3945	9
GC-C	GC-C:22|GCC:3	guanylate cyclase C:25:0.1948	0.1948	25
GC-C	GC-C:41|GCC:23	Guanylyl cyclase C:56:0.5753|guanylyl cyclase-C:8:0.2987	0.5753	64
GCDCA	GCDCA:10	glycochenodeoxycholic acid:10:0.5000	0.5000	10
GCDC	GCDC:17	glycochenodeoxycholate:17:0.3333	0.3333	17
GCDC	GCDC:12	glycochenodeoxycholic acid:12:0.6460	0.6460	12
GCDH	GCDH:20	Glutaryl-CoA dehydrogenase:20:0.6259	0.6259	20
GCD	GCD:13	granular corneal dystrophy:13:0.7753	0.7753	13
GCD	GCD:8	gross cystic disease:8:0.6411	0.6411	8
GCE	GCE:32	glassy carbon electrode:32:0.8145	0.8145	32
GCF	GCF:6	GC factor:6:0.1838	0.1838	6
GCF	GCF:20	giant cell fibroblastoma:20:0.8525	0.8525	20
GCF	GCF:545	gingival crevicular fluid:545:0.9778	0.9778	545
GCH-I	GCH-I:7|GCHI:5	GTP cyclohydrolase I:12:0.5664	0.5664	12
GCIIS	GCIIS:9	Glucose Controlled Insulin Infusion System:9:0.6794	0.6794	9
GCIs	GCIs:36	glial cytoplasmic inclusions:36:0.6953	0.6953	36
GCI	GCI:13	General Cognitive Index:13:0.7753	0.7753	13
GCI	GCI:10	glial cytoplasmic inclusions:10:0.7103	0.7103	10
GCI	GCI:12	global cerebral ischemia:12:0.7571	0.7571	12
GCKD	GCKD:16	glomerulocystic kidney disease:16:0.8165	0.8165	16
GCK	GCK:10	germinal center kinase:10:0.5856	0.5856	10
GCK	GCK:36|Gck:2	glucokinase:38:0.5362	0.5362	38
GCLC	GCLC:10|GCLc:1|Gclc:1	catalytic subunit:12:0.5050	0.5050	12
GCLM	GCLM:5	modifier subunit:5:0.1838	0.1838	5
GC-MS	GC-MS:12|GCMS:1	gas chromatograph-mass spectrometer:13:0.7753	0.7753	13
GC-MS	GC-MS:131|GCMS:1	gas chromatographic-mass spectrometric:132:0.9412	0.9412	132
GC-MS	GC-MS:12	gas chromatography coupled with mass spectrometry:12:0.8716	0.8716	12
GC-MS	GC-MS:1231|GCMS:32|gc-ms:2|GC--MS:2	gas chromatography-mass spectrometry:1267:0.9766	0.9766	1267
GC-MS	GC-MS:38|GCMS:4|GC--MS:1	gas chromatography-mass spectroscopy:40:0.9256|gas chromatography mass spectroscopy:3:0.4422	0.9256	43
GCMs	GCMs:9	general circulation models:9:0.6794	0.6794	9
GCM	GCM:17	Giant cell myocarditis:17:0.8270	0.8270	17
gcm	gcm:20|GCM:8|Gcm:1	glial cells missing:29:0.8978	0.8978	29
GCNF	GCNF:32	germ cell nuclear factor:32:0.9072	0.9072	32
GC-O	GC-O:23|GCO:10	gas chromatography-olfactometry:33:0.8605	0.8605	33
GCP-2	GCP-2:15	granulocyte chemotactic protein-2:15:0.8045	0.8045	15
GCPII	GCPII:13	glutamate carboxypeptidase II:13:0.7753	0.7753	13
GCPS	GCPS:21	Greig Cephalopolysyndactyly Syndrome:21:0.8594	0.8594	21
GCPs	GCPs:9	Growth cone particles:9:0.6794	0.6794	9
GCP	GCP:8	glomerular capillary pressure:8:0.6411	0.6411	8
GCP	GCP:78	Good Clinical Practice:78:0.9401	0.9401	78
GCRG	GCRG:22	giant cell reparative granuloma:22:0.8657	0.8657	22
GCRs	GCRs:5|GcRs:2	glucocorticoid receptors:7:0.1850	0.1850	7
GCRs	GCRs:14	gross chromosomal rearrangements:14:0.7909	0.7909	14
GCSE	GCSE:12	Generalized convulsive status epilepticus:12:0.5664	0.5664	12
G-CSFR	G-CSFR:45|G-CSF-R:17|GCSFR:2|GCSF-R:2|G-CSFr:1	granulocyte colony-stimulating factor receptor:67:0.9554	0.9554	67
G-CSF	G-CSF:39|GCSF:1	filgrastim:40:0.0097	0.0097	40
G-CSF	G-CSF:3459|GCSF:78|g-CSF:2|G-csf:1|GCS-F:1	granulocyte colony-stimulating factor:2709:0.9816|granulocyte-colony stimulating factor:453:0.4975|granulocyte colony stimulating factor:370:0.9409|granulocyte colony-stimulating factors:9:0.6794	0.9816	3541
GCS	GCS:92|GC-s:1|GC-S:1	gamma-glutamylcysteine synthetase:94:0.7854	0.7854	94
GCs	GCs:20|GCS:1	ganglion cells:21:0.0700	0.0700	21
GCs	GCs:11	gastric carcinomas:11:0.7357	0.7357	11
GCs	GCs:100	germinal centers:100:0.9231	0.9231	100
GCs	GCs:13	germinal centres:13:0.6701	0.6701	13
GCS	GCS:13	Gianotti-Crosti syndrome:13:0.7753	0.7753	13
GCS	GCS:681	Glasgow Coma Scale:681:0.9746	0.9746	681
GCS	GCS:25	Glasgow Coma Scale score:25:0.8186	0.8186	25
GCS	GCS:183	Glasgow Coma Score:169:0.9538|Glasgow Coma Scores:14:0.7909	0.9538	183
GCs	GCs:296|GCS:13|gcs:1|Gcs:1	Glucocorticoids:311:0.1570	0.1570	311
GCS	GCS:80|GCs:8|gcs:1	glucocorticosteroids:70:0.0349|Glucocorticosteroid:19:0.0091	0.0349	89
GCS	GCS:23|GcS:1	glucosylceramide synthase:24:0.6767	0.6767	24
GCS	GCS:10	glycine cleavage system:10:0.5856	0.5856	10
GCs	GCs:9|Gcs:1	glycoconjugates:10:0.0046	0.0046	10
GCS	GCS:9	graduated compression stockings:9:0.3945	0.3945	9
GCs	GCs:37	granule cells:37:0.1529	0.1529	37
GCs	GCs:80|Gcs:1	granulosa cells:81:0.4044	0.4044	81
GCs	GCs:6	guanylate cyclases:6:0.0564	0.0564	6
GCs	GCs:14	guanylyl cyclases:14:0.4367	0.4367	14
GCTB	GCTB:6	giant cell tumor of bone:6:0.5290	0.5290	6
GCTTS	GCTTS:10	Giant cell tumor of the tendon sheath:10:0.8816	0.8816	10
GCTs	GCTs:132	germ cell tumors:115:0.6276|germ cell tumours:17:0.4480	0.6276	132
GCT	GCT:252	cell tumor:220:0.9088|cell tumour:32:0.6429	0.9088	252
GCT	GCT:120	germ cell tumors:92:0.5269|germ cell tumours:28:0.5445	0.5445	120
GCT	GCT:53	giant cell tumor of bone:46:0.9366|giant cell tumour of bone:7:0.5926	0.9366	53
GCT	GCT:50	glucose challenge test:50:0.9064	0.9064	50
GCT	GCT:62	granular convoluted tubule:44:0.8620|granular convoluted tubules:18:0.8365	0.8620	62
GCVF	GCVF:13	great cardiac vein flow:13:0.7753	0.7753	13
GCVF	GCVF:8	great cardiac venous flow:8:0.6411	0.6411	8
GCV	GCV:653|gcv:3|Gcv:3	ganciclovir:659:0.8361	0.8361	659
GCV	GCV:9	gancyclovir:9:0.0102	0.0102	9
GCV	GCV:39	great cardiac vein:39:0.9256	0.9256	39
GCV	GCV:7	Herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir:7:0.5926	0.5926	7
GCW	GCW:20	glomerular capillary wall:20:0.8525	0.8525	20
GCase	GCase:13	Acid beta-glucosidase:13:0.6701	0.6701	13
GCH	GCH:12	Glucocorticoid hormones:12:0.7571	0.7571	12
GCH	GCH:25	GTP cyclohydrolase I:25:0.7834	0.7834	25
GCL	GCL:33	cells in the ganglion cell layer:33:0.1290	0.1290	33
GCl	GCl:15|gCl:11|Gcl:3|gcl:1	chloride conductance:30:0.2550	0.2550	30
GCl	GCl:26|gCl:9|Gcl:2	Cl- conductance:37:0.3388	0.3388	37
GCL	GCL:8	ganglion cell:8:0.5006	0.5006	8
gcl	GCL:6|gcl:6|Gcl:1	germ cell-less:13:0.7753	0.7753	13
GCL	GCL:38	Glutamate-cysteine ligase:22:0.3179|glutamate cysteine ligase:16:0.8165	0.8165	38
GCxGC	GCxGC:9	comprehensive two-dimensional gas chromatography:9:0.6794	0.6794	9
GC	GC:11	anti-galactocerebroside:11:0.0020	0.0020	11
Gc	Gc:11	conductance:11:0.0020	0.0020	11
GC	GC:9	control group:9:0.4587	0.4587	9
GC	GC:78|Gc:2	galactocerebroside:80:0.0155	0.0155	80
GC	GC:55	gas chromatograph:55:0.9458	0.9458	55
GC	GC:262|gc:1	gas chromatographic:263:0.9359	0.9359	263
GC	GC:1005|gc:1	gas chromatography:995:0.9580|gas-chromatography:11:0.0020	0.9580	1006
GC	GC:174|Gc:1	gastric cancer:175:0.9399	0.9399	175
GC	GC:67	gastric carcinoma:67:0.8197	0.8197	67
GC	GC:6|G-C:1	gemcitabine and cisplatin:7:0.2113	0.2113	7
GC	GC:9	genomic control:9:0.0932	0.0932	9
GC	GC:369	germinal center:286:0.8816|germinal centers:83:0.9429	0.9429	369
GC	GC:55	germinal centre:39:0.7860|germinal centres:16:0.8165	0.8165	55
GC	GC:54	glassy carbon:54:0.8622	0.8622	54
GC	GC:28	Gliomatosis cerebri:28:0.8941	0.8941	28
GC	GC:588|Gc:5|gc:1	glucocorticoid:304:0.0603|glucocorticoids:290:0.0575	0.0603	594
GC	GC:10	Glucocorticoid hormones:10:0.7103	0.7103	10
GC	GC:16	glucocorticosteroids:16:0.0030	0.0030	16
GC	GC:22|Gc:1	glycocalicin:23:0.0044	0.0044	23
GC	GC:6	glycocholic acid:6:0.1850	0.1850	6
gC	gC:138	glycoprotein C:138:0.8826	0.8826	138
GC	GC:34	Golgi complex:34:0.8644	0.8644	34
GC	GC:10|Gc:1	gonococcal:11:0.0020	0.0020	11
GC	GC:9|Gc:5	gonococci:14:0.0026	0.0026	14
GC	GC:10	gonorrhea:10:0.0018	0.0018	10
GC	GC:14	granule cell:14:0.0555	0.0555	14
GC	GC:202|Gc:6|G-C:1|gc:1	granulosa cells:149:0.6004|granulosa cell:61:0.4415	0.6004	210
Gc	Gc:128|GC:76	Group-specific component:132:0.5074|group specific component:67:0.9548|group-specific components:5:0.0902	0.9548	204
GC	GC:9	growth cartilage:9:0.5470	0.5470	9
GC	GC:20|G-C:10	guanine-cytosine:30:0.0058	0.0058	30
GC	GC:6	guanine plus cytosine:6:0.3728	0.3728	6
GC	GC:142|G-C:1	guanylate cyclase:138:0.5360|guanylate cyclases:5:0.0517	0.5360	143
GC	GC:98	guanylyl cyclase:90:0.3215|guanylyl cyclases:8:0.2619	0.3215	98
GC	GC:10	gustatory cortex:10:0.5000	0.5000	10
GC	GC:17	human glucocerebrosidase:17:0.2451	0.2451	17
GC	GC:38|Gc:4	Neisseria gonorrhoeae:42:0.8263	0.8263	42
GC	GC:10	pituitary tumor:10:0.7103	0.7103	10
GC	GC:6	rat pituitary:6:0.1543	0.1543	6
GC	GC:8	sodium glycocholate:8:0.1367	0.1367	8
GC	GC:22|Gc:14|gc:1	vitamin D binding protein:21:0.8594|vitamin D-binding protein:16:0.8165	0.8594	37
gD-1	gD-1:15	glycoprotein D:15:0.7096	0.7096	15
gD2	gD2:7|gD-2:2	glycoprotein D:9:0.4587	0.4587	9
GDA	GDA:22	gastroduodenal artery:22:0.8657	0.8657	22
GDCs	GDCs:103	Guglielmi detachable coils:103:0.9389	0.9389	103
GDC	GDC:7	glycine decarboxylase:7:0.2113	0.2113	7
GDC	GDC:13	glycine decarboxylase complex:13:0.5934	0.5934	13
GDC	GDC:102	Guglielmi detachable coil:70:0.8919|Guglielmi detachable coils:32:0.6900	0.8919	102
GDC	GDC:6	sodium glycodeoxycholate:6:0.1148	0.1148	6
GDE	GDE:7	glycogen debranching enzyme:7:0.5926	0.5926	7
GDEE	GDEE:22	glutamic acid diethyl ester:22:0.4344	0.4344	22
GDEE	GDEE:22	Glutamic acid diethylester:22:0.5863	0.5863	22
GDEPT	GDEPT:39	gene-directed enzyme prodrug therapy:39:0.8455	0.8455	39
GDF-5	GDF-5:9	Growth and differentiation factor-5:9:0.6794	0.6794	9
GDF-5	GDF-5:16|GDF5:15|Gdf5:1|Gdf-5:1	Growth/differentiation factor 5:17:0.4742|Growth/differentiation factor-5:16:0.3831	0.4742	33
GDFs	GDFs:11	growth and differentiation factors:11:0.7753	0.7753	11
GDH	GDH:450|gdh:8|Gdh:1	glutamate dehydrogenase:459:0.7673	0.7673	459
GDI	GDI:52	GDP dissociation inhibitor:52:0.4506	0.4506	52
GDI	GDI:27	guanine nucleotide dissociation inhibitor:27:0.7425	0.7425	27
GDLD	GDLD:7	Gelatinous drop-like corneal dystrophy:7:0.5926	0.5926	7
GDL	GDL:11	glucono-delta-lactone:11:0.1887	0.1887	11
GDL	GDL:24	Graduated driver licensing:24:0.8768	0.8768	24
GDM	GDM:102	gestational diabetes:102:0.9383	0.9383	102
GDM	GDM:557	gestational diabetes mellitus:557:0.9857	0.9857	557
GDNF	GDNF:865|Gdnf:2	glial cell line-derived neurotrophic factor:867:0.9742	0.9742	867
GDN	GDN:13|GdN:1	glia-derived nexin:14:0.5934	0.5934	14
GDN	GDN:5	glyceryl dinitrate:5:0.1132	0.1132	5
GDP	GDP:28	gamma-detecting probe:21:0.4194|gamma detecting probe:7:0.2902	0.4194	28
GDP	GDP:10	general dental practitioner:10:0.7103	0.7103	10
GDP	GDP:20	glucose degradation products:20:0.7173	0.7173	20
GDP	GDP:150	gross domestic product:150:0.9681	0.9681	150
GDP	GDP:71	guanosine 5'-diphosphate:54:0.8862|guanosine-5'-diphosphate:17:0.0351	0.8862	71
GDP	GDP:74	guanosine diphosphate:74:0.7286	0.7286	74
GDP	GDP:7	purine nucleotide:7:0.3524	0.3524	7
GDP[S]	GDP[S]:19	guanosine 5'-[beta-thio]diphosphate:19:0.8449	0.8449	19
GDPs	GDPs:108|gdps:2	general dental practitioners:110:0.9427	0.9427	110
GDPs	GDPs:23	giant depolarizing potentials:23:0.8715	0.8715	23
GDPs	GDPs:52	glucose degradation products:52:0.9438	0.9438	52
GDR	GDR:53	German Democratic Republic:53:0.9438	0.9438	53
GDR	GDR:72	glucose disposal rate:63:0.9526|glucose disposal rates:9:0.6794	0.9526	72
GDS-15	GDS-15:23|GDS15:6	Geriatric Depression Scale:29:0.8422	0.8422	29
GDS	GDS:14	GDP dissociation stimulator:14:0.4709	0.4709	14
GDS	GDS:19	General Dental Service:19:0.8449	0.8449	19
GDS	GDS:226	Geriatric Depression Scale:226:0.9867	0.9867	226
GDs	GDs:8	gestation days:8:0.1367	0.1367	8
GDS	GDS:58	Global Deterioration Scale:58:0.9190	0.9190	58
GDS	GDS:6	Gordon Diagnostic System:6:0.5290	0.5290	6
GDU	GDU:14|G-DU:1	gastroduodenal ulcer:9:0.3945|gastroduodenal ulcers:6:0.2243	0.3945	15
GDV	GDV:37	gastric dilatation-volvulus:37:0.8749	0.8749	37
GDX	GDX:43|gdx:7|Gdx:2	gonadectomized:52:0.5050	0.5050	52
GDX	GDX:16	Gonadectomy:16:0.1485	0.1485	16
GDx	GDx:8	Nerve Fiber Analyzer:8:0.6411	0.6411	8
Gd	Gd:165|GD:1	gadolinium:166:0.0711	0.0711	166
Gd	Gd:14|GD:1	gadolinium-DTPA:15:0.0061	0.0061	15
Gd	Gd:5|GD:2	gadopentetate dimeglumine:7:0.2902	0.2902	7
GD	GD:13	gastroduodenal:13:0.0052	0.0052	13
GD	GD:8	germinal disc:8:0.5006	0.5006	8
GD	GD:255|gd:43	gestation day:210:0.3693|Gestation Days:88:0.2891	0.3693	298
GD	GD:376|gd:69|Gd:10	gestational day:293:0.5332|gestational days:162:0.5784	0.5784	455
GD	GD:43	gestational diabetes:43:0.9308	0.9308	43
GD	GD:11	Glucose deprivation:11:0.6182	0.6182	11
gD	gD:250	glycoprotein D:250:0.8740	0.8740	250
GD	GD:11	Gonadal dysgenesis:11:0.6182	0.6182	11
GD	GD:468|Gd:1	Graves' disease:469:0.7462	0.7462	469
GD	GD:7	growth delay:7:0.3524	0.3524	7
Gd	Gd:5|GD:1	patients with Graves' disease without ophthalmopathy:6:0.3728	0.3728	6
GEA	GEA:21	gastric electrical activity:21:0.8594	0.8594	21
GEA	GEA:88	gastroepiploic artery:88:0.8588	0.8588	88
GEC	GEC:42	galactose elimination capacity:42:0.9291	0.9291	42
GEC	GEC:9	gastric emptying coefficient:9:0.6794	0.6794	9
GEC	GEC:128	glomerular epithelial cells:86:0.6781|glomerular epithelial cell:42:0.7750	0.7750	128
GECs	GECs:35	glomerular epithelial cells:35:0.6464	0.6464	35
GED	GED:19	electron diffraction:19:0.8449	0.8449	19
GED	GED:9	gastric epithelial dysplasia:9:0.6794	0.6794	9
GED	GED:8	GTPase effector domain:8:0.6411	0.6411	8
GEEs	GEEs:14	generalized estimating equations:14:0.7909	0.7909	14
GEE	GEE:9	ethyl ester:9:0.3945	0.3945	9
GEE	GEE:204	generalized estimating equations:147:0.8414|generalized estimating equation:57:0.8097	0.8414	204
GEF	GEF:195	guanine nucleotide exchange factor:183:0.8756|guanine nucleotide exchange factors:12:0.6460	0.8756	195
GEFS+	GEFS+:39	generalized epilepsy with febrile seizures plus:39:0.8781	0.8781	39
GEFT	GEFT:12	Group Embedded Figures Test:12:0.7571	0.7571	12
GEFs	GEFs:155	guanine nucleotide exchange factors:155:0.9409	0.9409	155
GEI	GEI:5	environment interaction:5:0.1132	0.1132	5
GEJ	GEJ:47	gastroesophageal junction:47:0.5949	0.5949	47
GELA	GELA:7	Groupe d'Etude des Lymphomes de l'Adulte:7:0.5926	0.5926	7
GEL	GEL:15	granulocyte elastase:15:0.8045	0.8045	15
GEMs	GEMs:15|GEMS:1	genetically engineered microorganisms:16:0.8165	0.8165	16
GEMS	GEMS:12	Girls health Enrichment Multi-site Studies:12:0.6794	0.6794	12
GEMs	GEMs:6	glycolipid-enriched microdomains:6:0.0899	0.0899	6
GEMs	GEMs:7	membrane microdomains:7:0.1470	0.1470	7
GEM	GEM:105|Gem:6|gem:5	Gemcitabine:116:0.3775	0.3775	116
GEM	GEM:9|gem:3	gemfibrozil:12:0.0364	0.0364	12
GEM	GEM:9	genetically engineered mice:9:0.5470	0.5470	9
GEM	GEM:29	geriatric evaluation and management:29:0.8978	0.8978	29
GEM	GEM:17	glycolipid-enriched membrane:17:0.6211	0.6211	17
GEM	GEM:8	Guideline Elements Model:8:0.6411	0.6411	8
GEN	GEN:51|Gen:21	Genistein:72:0.4765	0.4765	72
GEN	GEN:16|Gen:4	gentamicin:20:0.1275	0.1275	20
GEN	GEN:15	glomerular endothelial cells:15:0.7096	0.7096	15
G-EOP	G-EOP:6|GEOP:4	early-onset periodontitis:10:0.5000	0.5000	10
GEPR	GEPR:54	genetically epilepsy-prone rat:43:0.8893|genetically epilepsy-prone rats:11:0.7357	0.8893	54
GEPR-9s	GEPR-9s:25	genetically epilepsy-prone rats:25:0.8816	0.8816	25
GEPRs	GEPRs:41	Genetically epilepsy-prone rats:41:0.9256	0.9256	41
GEPs	GEPs:7	GDP/GTP exchange proteins:7:0.5926	0.5926	7
GEPs	GEPs:7	guanine nucleotide-exchange proteins:7:0.5926	0.5926	7
GEP	GEP:46	Gastro-entero-pancreatic:46:0.1991	0.1991	46
GEP	GEP:85	gastroenteropancreatic:85:0.3717	0.3717	85
GEP	GEP:5	GDP/GTP exchange protein:5:0.1973	0.1973	5
GEP	GEP:6	guanine nucleotide-exchange protein:6:0.5290	0.5290	6
GERD	GERD:11	gastroesophageal reflux:11:0.4728	0.4728	11
GERD	GERD:1214|GER-D:1	gastroesophageal reflux disease:1215:0.8355	0.8355	1215
GERRI	GERRI:5	Geriatric Evaluation by Relative's Rating Instrument:5:0.6794	0.6794	5
GER	GER:13	gastric emptying rate:13:0.7753	0.7753	13
GER	GER:784	gastroesophageal reflux:784:0.8708	0.8708	784
GER	GER:27|gER:3|ger:1	granular endoplasmic reticulum:31:0.8519	0.8519	31
GESP	GESP:11	Gastroesophageal sphincter pressure:11:0.7357	0.7357	11
GES	GES:24	gastric electrical stimulation:24:0.8768	0.8768	24
GES	GES:12	guanidinoethane sulfonate:12:0.2549	0.2549	12
GES	GES:7	Guanidinoethanesulfonic acid:7:0.2113	0.2113	7
GES	GES:11	guanidinoethyl sulfonate:11:0.2154	0.2154	11
GET	GET:17	gas exchange threshold:17:0.8270	0.8270	17
GET	GET:30	gastric emptying time:30:0.9011	0.9011	30
GEU	GEU:11	geriatric evaluation unit:11:0.5856	0.5856	11
GEZI	GEZI:12	glucose effectiveness at zero insulin:12:0.7571	0.7571	12
GE	GE:9	Acute gastroenteritis:9:0.1945	0.1945	9
GE	GE:21	extract:21:0.0196	0.0196	21
GE	GE:17	ganglionic eminence:17:0.8270	0.8270	17
GE	GE:141	gastric emptying:141:0.9661	0.9661	141
GE	GE:50	gastroesophageal:50:0.0479	0.0479	50
GE	GE:7	gel electrophoresis:7:0.3524	0.3524	7
GE	GE:5|ge:1	genome equivalents:6:0.2243	0.2243	6
Ge	Ge:16	Gerbich:16:0.0147	0.0147	16
Ge	Ge:20	germanium:20:0.0186	0.0186	20
GE	GE:15	Glandular epithelial:15:0.5348	0.5348	15
GE	GE:28	glandular epithelium:28:0.6839	0.6839	28
gE	gE:52|ge:32|Ge:1	glycoprotein E:85:0.7480	0.7480	85
GE	GE:11	glycyrrhetinic acid:11:0.6182	0.6182	11
GE	GE:62	Gradient Echo:62:0.8407	0.8407	62
GE	GE:12|G-E:1	granulocyte elastase:13:0.7753	0.7753	13
GE	GE:9	Gross efficiency:9:0.2757	0.2757	9
GE	GE:22	gross energy:22:0.6531	0.6531	22
GFAAS	GFAAS:50|GF-AAS:8	graphite furnace atomic absorption spectrometry:58:0.9190	0.9190	58
GFAP-IR	GFAP-IR:10|GFAP-ir:3	glial fibrillary acidic protein immunoreactivity:13:0.7753	0.7753	13
GFAP	GFAP:3098|GFAp:17|Gfap:4|gfap:3|GFA-P:2	glial fibrillary acidic protein:3124:0.9607	0.9607	3124
GFAT	GFAT:24	Glutamine:fructose-6-phosphate amidotransferase:24:0.4486	0.4486	24
GFA	GFA:15	genetic function approximation:15:0.8045	0.8045	15
GFA	GFA:97	glial fibrillary acidic:97:0.9510	0.9510	97
GFA	GFA:72	Glial fibrillary acidic protein:72:0.9335	0.9335	72
GFA	GFA:16	glutamine:fructose-6-phosphate amidotransferase:16:0.5171	0.5171	16
GFC	GFC:19	gel filtration chromatography:19:0.8449	0.8449	19
GFC	GFC:13	global fibrinolytic capacity:13:0.7753	0.7753	13
GFD	GFD:100	gluten-free diet:100:0.7556	0.7556	100
GFD	GFD:7	growth factor domain:7:0.5926	0.5926	7
GFJ	GFJ:17	grapefruit juice:17:0.8270	0.8270	17
GFL	GFL:16	giant fiber lobe:16:0.8165	0.8165	16
GFLV	GFLV:14	grapevine fanleaf virus:14:0.7909	0.7909	14
GFLX	GFLX:12	gatifloxacin:12:0.8462	0.8462	12
GFN	GFN:19|GFn:1	genitofemoral nerve:20:0.7766	0.7766	20
GFOR	GFOR:10	Glucose-fructose oxidoreductase:10:0.5000	0.5000	10
GFPuv	GFPuv:17|gfpuv:2	green fluorescent protein:19:0.8449	0.8449	19
GFP	GFP:33	gel-filtered platelets:33:0.6111	0.6111	33
GFP	GFP:31	global field power:31:0.9043	0.9043	31
GFP	GFP:3318|gfp:54|Gfp:14	green fluorescent protein:3386:0.9298	0.9298	3386
gfp	gfp:21|GFP:9|Gfp:1	green fluorescent protein gene:31:0.8090	0.8090	31
GFP	GFP:9	proteins:9:0.0020	0.0020	9
GFP	GFP:6|gfp:5	reporter gene:11:0.0812	0.0812	11
GFRP	GFRP:8	GTP cyclohydrolase I feedback regulatory protein:8:0.6411	0.6411	8
GFR	GFR:11	Creatinine clearance:11:0.1683	0.1683	11
GFR	GFR:33	glomerular filtration:33:0.8605	0.8605	33
GFR	GFR:4673|gfr:3	glomerular filtration rate:4580:0.9906|glomerular filtration rates:96:0.9689	0.9906	4676
GFR	GFR:12	Inulin clearance:12:0.1991	0.1991	12
GFR	GFR:12	renal function:12:0.3524	0.3524	12
GFS	GFS:11	Geer Fear Scale:11:0.7357	0.7357	11
GFS	GFS:5	glaucoma filtration surgery:5:0.4422	0.4422	5
GFs	GFs:102	Growth factors:102:0.9538	0.9538	102
GF	GF:5|gf:4	force:9:0.0085	0.0085	9
GF	GF:15	gastric fistula:15:0.8045	0.8045	15
GF	GF:11	gel filtration:11:0.2154	0.2154	11
GF	GF:3|gf:2	gene frequency:5:0.1132	0.1132	5
GF	GF:147|Gf:3|gf:3	germ-free:143:0.1506|germ free:10:0.5856	0.5856	153
GF	GF:77|Gf:6	germfree:83:0.0870	0.0870	83
GF	GF:11	giant fiber:11:0.3829	0.3829	11
GF	GF:54	gingival fibroblasts:54:0.8862	0.8862	54
GF	GF:5	gingival fluid:5:0.0517	0.0517	5
GF	GF:17	glomerular filtrate:17:0.7407	0.7407	17
GF	GF:12	Glomerular filtration:12:0.2549	0.2549	12
GF	GF:10	graft failure:10:0.3867	0.3867	10
GF	GF:14	Granulocyte factor:14:0.1244	0.1244	14
GF	GF:8	Granuloma faciale:8:0.5006	0.5006	8
GF	GF:55|Gf:2	Griseofulvin:57:0.0583	0.0583	57
GF	GF:89|Gf:1	growth factors:52:0.8345|growth factor:38:0.5588	0.8345	90
GF	GF:60	growth fraction:60:0.8181	0.8181	60
GGA	GGA:55	geranylgeranylacetone:55:0.4030	0.4030	55
GGDP	GGDP:7|GGdP:2	geranylgeranyl diphosphate:9:0.6794	0.6794	9
GGE	GGE:29|gge:4	gradient gel electrophoresis:33:0.8605	0.8605	33
GGF2	GGF2:13|GGF-2:1	glial growth factor 2:14:0.7909	0.7909	14
GGH	GGH:10	gamma-glutamyl hydrolase:10:0.7103	0.7103	10
GGM	GGM:7	Glucose-Galactose Malabsorption:7:0.3524	0.3524	7
GGOH	GGOH:11|GG-OH:5	geranylgeraniol:16:0.7895	0.7895	16
GGO	GGO:10	geranylgeraniol:10:0.1406	0.1406	10
GGO	GGO:29	ground-glass opacity:29:0.6392	0.6392	29
GGPP	GGPP:40	geranylgeranyl diphosphate:40:0.7907	0.7907	40
GGPP	GGPP:49|GGpp:5|GG-P-P:2|GG-PP:1	geranylgeranyl pyrophosphate:57:0.8281	0.8281	57
GGR	GGR:25	global genome repair:25:0.8816	0.8816	25
GGR	GGR:19	global genomic repair:19:0.8449	0.8449	19
GGS	GGS:8	group G streptococci:8:0.6411	0.6411	8
GGT+	GGT+:10	positive:10:0.3333	0.3333	10
GGTP	GGTP:98|G-GTP:1|ggtp:1	gamma-Glutamyl transpeptidase:81:0.5806|gamma-glutamyl-transpeptidase:19:0.0878	0.5806	100
GGTP	GGTP:38	Gamma-Glutamyltranspeptidase:38:0.1805	0.1805	38
GGT	GGT:10	activity:10:0.0053	0.0053	10
GGT	GGT:315|gGT:2|G-GT:1	gamma-glutamyl transferase:221:0.6605|gamma glutamyl transferase:66:0.9061|gamma-glutamyl-transferase:31:0.0177	0.9061	318
GGT	GGT:432|G-GT:2|gGT:1|ggt:1|g-GT:1	gamma-glutamyl transpeptidase:408:0.7712|gamma-glutamyl-transpeptidase:29:0.0165	0.7712	437
GGT	GGT:51	gamma glutamyltransferase:51:0.8546	0.8546	51
GGT	GGT:208|Ggt:1|ggt:1	gamma-glutamyltranspeptidase:201:0.1177|Gamma Glutamyltranspeptidase:9:0.5470	0.5470	210
GGT	GGT:9	gammaglutamyltransferase:9:0.0047	0.0047	9
GGT	GGT:64	serum gamma-glutamyltransferase:64:0.1237	0.1237	64
GG	GG:7	geniculate ganglion:7:0.2452	0.2452	7
GG	GG:12|gg:1	genioglossal:13:0.0278	0.0278	13
GG	GG:68|Gg:5	genioglossus:73:0.1671	0.1671	73
GG	GG:9	glucosylglycerol:9:0.0186	0.0186	9
gG	gG:40	glycoprotein G:40:0.8491	0.8491	40
GG	GG:33	guar gum:33:0.7841	0.7841	33
GH-IGF	GH-IGF:6	growth hormone-insulin-like growth factor:6:0.5290	0.5290	6
GH1	GH1:7|GH-1:2	growth hormone:9:0.6794	0.6794	9
GH3	GH3:18	cell line:18:0.7539	0.7539	18
GH3	GH3:16	pituitary tumor cells:16:0.8165	0.8165	16
GH3	GH3:14	rat pituitary:14:0.2524	0.2524	14
GH3	GH3:7	rat pituitary cells:7:0.1641	0.1641	7
GH3	GH3:12	rat pituitary tumor:12:0.5050	0.5050	12
GH5	GH5:10	histone H5:10:0.4363	0.4363	10
GHAP	GHAP:19	glial hyaluronate-binding protein:19:0.8449	0.8449	19
GHBA	GHBA:25	Gamma-hydroxybutyric acid:25:0.5969	0.5969	25
GHBP	GHBP:4|GH-BP:3	GH-binding proteins:7:0.1850	0.1850	7
GHBP	GHBP:38|GH-BP:15	growth hormone-binding protein:53:0.9438	0.9438	53
GHB	GHB:270	gamma-hydroxybutyrate:249:0.3111|Gamma hydroxybutyrate:21:0.8594	0.8594	270
GHB	GHB:215	Gamma-Hydroxybutyric acid:215:0.8263	0.8263	215
GHB	GHB:13	gammahydroxybutyrate:13:0.0154	0.0154	13
GHb	GHb:8|gHb:1	glycated haemoglobin:9:0.1205	0.1205	9
GHb	GHb:32|gHb:7	Glycated hemoglobin:39:0.2125	0.2125	39
GHb	GHb:29|gHb:2|GHB:1	Glycohemoglobin:32:0.0384	0.0384	32
GHb	GHb:16|GHB:2	glycosylated haemoglobin:18:0.4438	0.4438	18
GHb	GHb:76|gHb:2|GHB:1|Ghb:1	glycosylated hemoglobin:80:0.5220	0.5220	80
GHC	GHC:25	Group Health Cooperative:25:0.8816	0.8816	25
GHC	GHC:26	Group Health Cooperative of Puget Sound:26:0.8903	0.8903	26
GHD	GHD:9	genetic hypertension development:9:0.6794	0.6794	9
GHD	GHD:371|GH-D:1	GH deficiency:372:0.5425	0.5425	372
GHD	GHD:96	GH-deficient:75:0.0845|GH deficient:21:0.3317	0.3317	96
GHD	GHD:287|GHd:1	growth hormone deficiency:288:0.9833	0.9833	288
GHD	GHD:36	growth hormone deficient:20:0.8525|growth hormone-deficient:16:0.8165	0.8525	36
GHG	GHG:18	greenhouse gas:18:0.8365	0.8365	18
GHIS	GHIS:8	GH insensitivity syndrome:8:0.1774	0.1774	8
GHIS	GHIS:14	growth hormone insensitivity syndrome:14:0.7909	0.7909	14
GHK	GHK:9|G-H-K:1	Goldman-Hodgkin-Katz:10:0.3462	0.3462	10
GHQ	GHQ:421	General Health Questionnaire:421:0.9886	0.9886	421
GHQ-12	GHQ-12:130|GHQ12:7	General Health Questionnaire:137:0.9782	0.9782	137
GHQ-28	GHQ-28:95|GHQ28:2	General Health Questionnaire:97:0.9692	0.9692	97
GHQ-28	GHQ-28:10	General Health Questionnaire-28:10:0.7103	0.7103	10
GHQ-30	GHQ-30:53|GHQ30:2|GHQ--30:1	general health questionnaire:56:0.9467	0.9467	56
GHRD	GHRD:11	receptor deficiency:11:0.7357	0.7357	11
GHRF	GHRF:39|GH-RF:6	growth hormone-releasing factor:28:0.8941|growth hormone releasing factor:17:0.8165	0.8941	45
GHRH-R	GHRH-R:7|GHRHR:4|GHRHr:1	GH-releasing hormone receptor:12:0.1520	0.1520	12
GHRH-R	GHRH-R:10|GHRHR:4	growth hormone-releasing hormone receptor:14:0.7909	0.7909	14
GHRH	GHRH:5	GH-releasing factor:5:0.0517	0.0517	5
GHRH	GHRH:431|GH-RH:9	GH-releasing hormone:440:0.3463	0.3463	440
GHRH	GHRH:4	growth hormone releasing factor:4:0.3170	0.3170	4
GH-RIH	GH-RIH:4|GHRIH:3	growth hormone release inhibiting hormone:7:0.5926	0.5926	7
GHRP	GHRP:12	Growth hormone-releasing peptide:12:0.7571	0.7571	12
GHRP-2	GHRP-2:12	GH-releasing peptide-2:12:0.2549	0.2549	12
GHRP-2	GHRP-2:11	growth hormone-releasing peptide-2:11:0.7357	0.7357	11
GHRP-6	GHRP-6:12	GH-releasing hexapeptide:12:0.2549	0.2549	12
GHRP-6	GHRP-6:8	GH-releasing peptide:8:0.1367	0.1367	8
GHRP-6	GHRP-6:22	GH-releasing peptide-6:22:0.3671	0.3671	22
GHRP-6	GHRP-6:5|GHRP6:1	growth hormone releasing peptide:6:0.5290	0.5290	6
GHRP-6	GHRP-6:9|GH-RP-6:1	His-D-Trp-Ala-Trp-D-Phe-Lys-NH2:10:0.0826	0.0826	10
GHRPs	GHRPs:21	GH-releasing peptides:21:0.2963	0.2963	21
GHRPs	GHRPs:15	Growth hormone-releasing peptides:15:0.8045	0.8045	15
GHRT	GHRT:5	growth hormone replacement therapy:5:0.4422	0.4422	5
GHRs	GHRs:19	GH receptors:19:0.7291	0.7291	19
GHR	GHR:230|GH-R:19|GHr:3	GH receptor:238:0.4866|GH receptors:14:0.3844	0.4866	252
GHR	GHR:195|GH-R:16|GHr:6|Ghr:3|ghr:1	growth hormone receptor:210:0.9696|growth hormone receptors:11:0.7357	0.9696	221
GHR	GHR:7	growth hormone receptor gene:7:0.5926	0.5926	7
GHR	GHR:5	growth hormone replacement:5:0.4422	0.4422	5
GHSA	GHSA:5|G-HSA:4	human serum albumin:9:0.6794	0.6794	9
GHSG	GHSG:14	German Hodgkin Study Group:14:0.7909	0.7909	14
GHS-R	GHS-R:5	endogenous ligand for the GH secretagogue receptor:5:0.5006	0.5006	5
GHSs	GHSs:17	GH secretagogues:17:0.2743	0.2743	17
GHSs	GHSs:26	growth hormone secretagogues:26:0.8861	0.8861	26
GHS	GHS:22	General Household Survey:22:0.8657	0.8657	22
GHS	GHS:11	genetic hypercalciuric stone-forming:11:0.7357	0.7357	11
GHS	GHS:62	GH secretagogue:39:0.4322|GH secretagogues:23:0.4067	0.4322	62
GHs	GHs:8	growth hormones:8:0.5006	0.5006	8
GHS	GHS:49	growth hormone secretagogue:32:0.9072|Growth hormone secretagogues:17:0.8270	0.9072	49
GHT	GHT:8	geniculo-hypothalamic tract:8:0.1276	0.1276	8
GHT	GHT:13	geniculohypothalamic tract:13:0.3554	0.3554	13
GHT	GHT:10	Glaucoma Hemifield Test:10:0.7103	0.7103	10
GH	GH:17	genetic haemochromatosis:17:0.7407	0.7407	17
GH	GH:31	genetic hemochromatosis:31:0.8519	0.8519	31
GH	GH:11|Gh:1	geniohyoid:12:0.0010	0.0010	12
GH	GH:14	genital herpes:14:0.7909	0.7909	14
GH	GH:31	gestational hypertension:31:0.7718	0.7718	31
GH	GH:13	gingival hyperplasia:13:0.5934	0.5934	13
GH	GH:7	gland of Harder:7:0.3524	0.3524	7
GH	GH:12	glenohumeral:12:0.0010	0.0010	12
gH	gH:59|gh:4	glycoprotein H:63:0.7943	0.7943	63
GH	GH:11	glycoside hydrolase:11:0.2582	0.2582	11
GH	GH:7	glycosylated hemoglobin:7:0.2452	0.2452	7
GH	GH:10045|Gh:4|gh:2|-gh:1	growth hormone:10000:0.9957|growth-hormone:38:0.0034|growth hormones:14:0.7909	0.9957	10052
Gh	Gh:10|gh:2	guanidinohydantoin:12:0.0010	0.0010	12
GH	GH:26	New Zealand genetically hypertensive:26:0.8861	0.8861	26
GH	GH:23	somatotropin:23:0.0020	0.0020	23
GI-GPx	GI-GPx:7	gastrointestinal glutathione peroxidase:7:0.4438	0.4438	7
GIA	GIA:9	gravito-inertial acceleration:9:0.3945	0.3945	9
GIA	GIA:8	growth inhibition assay:8:0.6411	0.6411	8
GIB	GIB:18	Gastrointestinal Bleeding:18:0.6903	0.6903	18
GICA	GICA:11	gastrointestinal cancer-associated antigen:11:0.7357	0.7357	11
GICs	GICs:53	glass ionomer cements:27:0.8903|glass-ionomer cements:26:0.3273	0.8903	53
GIC	GIC:93	glass ionomer cement:63:0.9018|glass ionomer cements:21:0.8594|glass-ionomer cements:9:0.1009	0.9018	93
GIC	GIC:22	graft-infiltrating cells:13:0.2802|graft infiltrating cells:9:0.6794	0.6794	22
GID	GID:12	gender identity disorder:12:0.7571	0.7571	12
GIF	GIF:22	glycosylation-inhibiting factor:22:0.1085	0.1085	22
GIF	GIF:6	gravito-inertial force:6:0.1838	0.1838	6
GIF	GIF:48	growth inhibitory factor:48:0.8433	0.8433	48
GIFT	GIFT:15	granulocyte immunofluorescence test:15:0.6386	0.6386	15
GIGT	GIGT:10|G-IGT:1	gestational impaired glucose tolerance:11:0.7357	0.7357	11
GIH	GIH:10	gastrointestinal hemorrhage:10:0.5000	0.5000	10
GIH	GIH:8	gonad-inhibiting hormone:8:0.2902	0.2902	8
GII	GII:9	Global Issues Initiative:9:0.6794	0.6794	9
GII	GII:5	second group:5:0.0517	0.0517	5
GIK	GIK:122|G-I-K:2	glucose-insulin-potassium:124:0.6543	0.6543	124
GIK	GIK:9	infusion:9:0.0426	0.0426	9
GILT	GILT:11	lysosomal thiol reductase:11:0.6182	0.6182	11
GILZ	GILZ:8	glucocorticoid-induced leucine zipper:8:0.5006	0.5006	8
GIMEMA	GIMEMA:6	Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto:6:0.5290	0.5290	6
GIM	GIM:16	general internal medicine:16:0.8165	0.8165	16
GINA	GINA:4	Global Initiative on Asthma:4:0.8644	0.8644	4
GIOP	GIOP:11	glucocorticoid-induced osteoporosis:11:0.7357	0.7357	11
GIPLs	GIPLs:21	glycoinositolphospholipids:21:0.5714	0.5714	21
GIP	GIP:85	gastric inhibitory peptide:85:0.9264	0.9264	85
GIP	GIP:538	gastric inhibitory polypeptide:538:0.9881	0.9881	538
GIP	GIP:10	general import pore:10:0.7103	0.7103	10
GIP	GIP:56	glucose-dependent insulinotropic peptide:56:0.8667	0.8667	56
GIP	GIP:176	Glucose-dependent insulinotropic polypeptide:176:0.9188	0.9188	176
GIQLI	GIQLI:43	Gastrointestinal Quality of Life Index:43:0.8335	0.8335	43
GIRK	GIRK:55	inwardly rectifying K+:32:0.7782|inwardly rectifying K(+):23:0.8715	0.8715	55
GIRK	GIRK:11	inwardly rectifying K+ channels:7:0.5926|inwardly rectifying K(+) channel:4:0.3170	0.5926	11
GIRK	GIRK:26	inwardly rectifying potassium:26:0.7760	0.7760	26
GIR	GIR:147	glucose infusion rate:127:0.9764|Glucose infusion rates:20:0.8525	0.9764	147
GISA	GISA:8	glycopeptide-intermediate Staphylococcus aureus:8:0.2327	0.2327	8
GISH	GISH:11	genomic in situ hybridisation:11:0.7357	0.7357	11
GISH	GISH:76	genomic in situ hybridization:76:0.9180	0.9180	76
GISSI-2	GISSI-2:10	Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico:10:0.5470	0.5470	10
GISSI	GISSI:6	Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico:6:0.5290	0.5290	6
GISTs	GISTs:309|gists:1	gastrointestinal stromal tumors:259:0.9391|gastrointestinal stromal tumours:51:0.9064	0.9391	310
GIST	GIST:367|Gist:1	gastrointestinal stromal tumor:177:0.9184|gastrointestinal stromal tumors:142:0.9012|Gastrointestinal stromal tumours:26:0.7760|gastrointestinal stromal tumour:23:0.8038	0.9184	368
GIS	GIS:315	geographic information system:214:0.5851|Geographic information systems:101:0.5002	0.5851	315
GIS	GIS:73	geographical information systems:73:0.3377	0.3377	73
GIs	GIs:30	giant interneurons:30:0.8472	0.8472	30
GIT	GIT:16	gastrointestinal:16:0.0384	0.0384	16
GIT	GIT:247	gastrointestinal tract:247:0.9008	0.9008	247
GIT	GIT:17	gastrointestinal transit:17:0.8270	0.8270	17
GIT	GIT:20	glucose-induced thermogenesis:20:0.6680	0.6680	20
GIT	GIT:11	glucose infusion test:11:0.7357	0.7357	11
GIT	GIT:11	glutathione-insulin transhydrogenase:11:0.7357	0.7357	11
GITR	GITR:8	glucocorticoid-induced tumor necrosis factor receptor:8:0.3463	0.3463	8
GITR	GITR:5	receptor family-related gene:5:0.1973	0.1973	5
GITS	GITS:64	nifedipine gastrointestinal therapeutic system:64:0.4812	0.4812	64
GITT	GITT:9	Geriatric Interdisciplinary Team Training:9:0.5470	0.5470	9
GIXD	GIXD:10	grazing incidence X-ray diffraction:10:0.5856	0.5856	10
Gi	Gi:7	adenylate cyclase:7:0.2113	0.2113	7
G-I	G-I:6|GI:1	control group:7:0.0951	0.0951	7
GI	GI:69|G-I:2	gastro-intestinal:71:0.0153	0.0153	71
GI	GI:12	gastroenterology:12:0.0024	0.0024	12
GI	GI:2980|G-I:6|gi:1	gastrointestinal:2987:0.6548	0.6548	2987
GI	GI:53	gastrointestinal tract:53:0.8597	0.8597	53
GI	GI:12	GIGANTEA:12:0.0024	0.0024	12
Gi	Gi:5|GI:1	gigantocellular reticular nucleus:6:0.3728	0.3728	6
GI	GI:5	gingival indices:5:0.0612	0.0612	5
GI	GI:7	Gingival inflammation:7:0.2902	0.2902	7
GI	GI:14	Glass ionomer:14:0.7909	0.7909	14
GI	GI:7	glass ionomer cement:7:0.5926	0.5926	7
GI	GI:7|gI:2	global ischemia:9:0.5470	0.5470	9
GI	GI:11	Glucagon immunoreactivity:11:0.7357	0.7357	11
GI	GI:12	glucose intolerance:12:0.7571	0.7571	12
GI	GI:5	glycaemic indices:5:0.0612	0.0612	5
GI	GI:96	glycemic index:96:0.1521	0.1521	96
gI	gI:44	glycoprotein I:44:0.2758	0.2758	44
GI	GI:34|G-I:7	Group I:41:0.2518	0.2518	41
GI	GI:12	growth inhibition:12:0.5664	0.5664	12
Gi	Gi:48	inhibitory G protein:21:0.5178|inhibitory G-protein:11:0.5355|inhibitory G proteins:9:0.3069|inhibitory G-proteins:7:0.3524	0.5355	48
Gi	Gi:27	inhibitory GTP-binding protein:27:0.7066	0.7066	27
Gi	Gi:27	inhibitory guanine nucleotide binding protein:15:0.7096|inhibitory guanine nucleotide-binding protein:12:0.5050	0.7096	27
Gi	Gi:12	inhibitory guanine nucleotide regulatory protein:12:0.7571	0.7571	12
GJB2	GJB2:39	connexin 26:39:0.9237	0.9237	39
GJB2	GJB2:17	connexin 26 gene:17:0.8270	0.8270	17
GJIC	GJIC:334	gap junctional intercellular communication:334:0.9859	0.9859	334
GJP	GJP:13	generalized juvenile periodontitis:13:0.7753	0.7753	13
gK+	gK+:7|GK+:1	conductance:8:0.8889	0.8889	8
GKAP	GKAP:11	guanylate kinase-associated protein:11:0.7357	0.7357	11
GKD	GKD:20	glycerol kinase deficiency:20:0.8525	0.8525	20
GKLF	GKLF:20	gut-enriched Kruppel-like factor:20:0.8525	0.8525	20
GKR	GKR:10	Gamma Knife radiosurgery:10:0.7103	0.7103	10
GKRP	GKRP:14	regulatory protein:14:0.7909	0.7909	14
GKRS	GKRS:39	gamma knife radiosurgery:39:0.9237	0.9237	39
GKT	GKT:9	guilty knowledge test:9:0.5470	0.5470	9
GKB	GKB:8|GkB:1	ginkgolide B:9:0.6794	0.6794	9
GKS	GKS:76	gamma knife radiosurgery:76:0.9378	0.9378	76
GKS	GKS:79	Gamma knife surgery:79:0.9622	0.9622	79
GK	GK:46|G-K:2	diabetic Goto-Kakizaki:48:0.2456	0.2456	48
GK	GK:8|gk:1	galactokinase:9:0.0131	0.0131	9
GK	GK:38	gamma knife:38:0.9217	0.9217	38
GK	GK:13	Glandular Kallikrein:13:0.7753	0.7753	13
GK	GK:179|Gk:2|gk:2	glucokinase:183:0.2645	0.2645	183
GK	GK:26	glycerol kinase:26:0.2894	0.2894	26
gK	gK:25	glycoprotein K:25:0.6767	0.6767	25
GK	GK:19	guanylate kinase:19:0.1817	0.1817	19
gK	gK:17|GK:7|gk:4	K+ conductance:28:0.2035	0.2035	28
gK	gK:21|GK:20|gk:4	potassium conductance:45:0.3652	0.3652	45
GL-3	GL-3:12|GL3:1	Globotriaosylceramide:13:0.4800	0.4800	13
GLC1A	GLC1A:6	open angle glaucoma:6:0.5290	0.5290	6
GLCL	GLCL:8	Glutamate-cysteine ligase:8:0.4102	0.4102	8
Glc	Glc:11	D-glucose:11:0.0126	0.0126	11
GLC	GLC:110	Gas-liquid chromatographic:110:0.7461	0.7461	110
GLC	GLC:287|glc:2	gas-liquid chromatography:289:0.6844	0.6844	289
GLDH	GLDH:91|GlDH:5|Gldh:2	glutamate dehydrogenase:98:0.7757	0.7757	98
GLd	GLd:6|GLD:4	dorsal lateral geniculate nucleus:10:0.7103	0.7103	10
gld	gld:9	Fas ligand:9:0.6794	0.6794	9
gld	gld:12	generalized lymphoproliferative disease:12:0.7571	0.7571	12
GLD	GLD:55	globoid cell leukodystrophy:55:0.9458	0.9458	55
Gld	Gld:9|GLD:4	glucose dehydrogenase:13:0.5335	0.5335	13
GLIF	GLIF:12	GuideLine Interchange Format:12:0.7571	0.7571	12
GLIR	GLIR:10	immunoreactivity:10:0.8182	0.8182	10
GLI	GLI:9|Gli:6	Glibenclamide:15:0.0819	0.0819	15
GLI	GLI:7	glucagon-like immunoreactive:7:0.3524	0.3524	7
GLI	GLI:79	glucagon-like immunoreactivity:79:0.8187	0.8187	79
GLI	GLI:5	grey level index:5:0.1973	0.1973	5
GLMM	GLMM:8	generalized linear mixed models:8:0.5006	0.5006	8
GLM	GLM:16	general linear models:16:0.4832	0.4832	16
GLM	GLM:22|glm:1	generalized linear model:23:0.2033	0.2033	23
GLNH	GLNH:10	giant lymph node hyperplasia:10:0.7103	0.7103	10
GLO1	GLO1:6|Glo1:1|Glo-1:1	glyoxalase I:8:0.5006	0.5006	8
G-LOC	G-LOC:63|GLOC:1	loss of consciousness:64:0.9534	0.9534	64
GLO	GLO:15|Glo:1	glyoxalase:16:0.1402	0.1402	16
GLO	GLO:39	glyoxalase I:39:0.8455	0.8455	39
GLO	GLO:7	L-gulono-gamma-lactone oxidase:7:0.1111	0.1111	7
GLP-I	GLP-I:26	glucagon-like peptide I:14:0.5111|Glucagon-like peptide-I:12:0.7571	0.7571	26
GLP-1	GLP-1:19|GLP1:1	Glucagon-like peptide:20:0.7766	0.7766	20
GLP-1	GLP-1:715|GLP1:2|glp-1:1	Glucagon-like peptide-1:524:0.9531|Glucagon-like peptide 1:194:0.9384	0.9531	718
GLP-1	GLP-1:36	glucagon-like peptide-1(7-36)amide:21:0.7865|Glucagon-like peptide-1-(7-36) amide:12:0.7571|glucagon-like peptide-1 7-36 amide:3:0.7548	0.7865	36
GLP-2	GLP-2:120|GLP2:1	glucagon-like peptide-2:66:0.8841|Glucagon-like peptide 2:55:0.8645	0.8841	121
GLPs	GLPs:13	germin-like proteins:13:0.5934	0.5934	13
GLPs	GLPs:9	glucagon-like peptides:9:0.5470	0.5470	9
GLP	GLP:21|Glp:1	glucagon-like peptide:22:0.6934	0.6934	22
GLP	GLP:17	glycolipoprotein:17:0.0808	0.0808	17
GLP	GLP:89	good laboratory practice:70:0.9573|good laboratory practices:19:0.8449	0.9573	89
GLRA1	GLRA1:9|Glra1:1	glycine receptor:10:0.7103	0.7103	10
GLS	GLS:20	generalized least squares:20:0.7766	0.7766	20
GLs	GLs:9	Granular lymphocytes:9:0.6794	0.6794	9
GLT-1	GLT-1:10|GLT1:4	glutamate transporter:14:0.6911	0.6911	14
GLT-1	GLT-1:18|GLT1:1	glutamate transporter-1:19:0.8449	0.8449	19
GltS	GltS:7|GLTS:1	glutamate synthase:8:0.5006	0.5006	8
GLUD	GLUD:9|Glud:1	glutamate dehydrogenase:10:0.5000	0.5000	10
GLURP	GLURP:28|glurp:1	glutamate-rich protein:29:0.5940	0.5940	29
GLUT1	GLUT1:7|GluT1:3	glucose transport protein:10:0.7103	0.7103	10
GLUT1	GLUT1:87|GLUT-1:44|Glut1:18|Glut-1:5	glucose transporter:154:0.9011	0.9011	154
GLUT1	GLUT1:74|GLUT-1:38|Glut-1:16|Glut1:5|glut-1:1|GluT-1:1	glucose transporter 1:81:0.9627|glucose transporter-1:54:0.9438	0.9627	135
GLUT2	GLUT2:34|GLUT-2:4|Glut2:2|Glut-2:1	glucose transporter:41:0.7057	0.7057	41
GLUT2	GLUT2:27|GLUT-2:8|Glut-2:5|glut-2:3|Glut2:3|glut2:1|GluT2:1	glucose transporter 2:36:0.9174|glucose transporter-2:12:0.7571	0.9174	48
GLUT3	GLUT3:5|Glut3:2	glucose transporter 3:7:0.5926	0.5926	7
GLUT4	GLUT4:164|GLUT-4:44|Glut4:9|Glut-4:2	glucose transporter:203:0.9355|glucose transporters:16:0.8165	0.9355	219
GLUT4	GLUT4:120|GLUT-4:13|Glut4:6|Glut-4:1	glucose transporter 4:110:0.9567|glucose transporter-4:30:0.9011	0.9567	140
GLUT-4	GLUT-4:5|GLUT4:4	glucose transporter protein:9:0.6794	0.6794	9
GLUTs	GLUTs:36|Gluts:6|GluTs:1	glucose transporters:43:0.7168	0.7168	43
GLV	GLV:14	giardiavirus:14:0.2000	0.2000	14
GLv	GLv:8|GLV:2	ventral lateral geniculate nucleus:10:0.5000	0.5000	10
GlyT1	GlyT1:4|GlyT-1:2|GLYT1:2|glyt-1:1	glycine transporter 1:9:0.6794	0.6794	9
GLYT2	GLYT2:9|GlyT2:2	glycine transporter 2:11:0.6182	0.6182	11
GLZ	GLZ:9	glycyrrhizin:9:0.6154	0.6154	9
GM-CSA	GM-CSA:13|gm-CSA:1	colony stimulating activity:14:0.7909	0.7909	14
GM-CSA	GM-CSA:28|gm-CSA:1	granulocyte-macrophage colony-stimulating activity:29:0.6392	0.6392	29
GM-CSFR	GM-CSFR:8|GM-CSFr:2	granulocyte-macrophage colony-stimulating factor receptor:10:0.5000	0.5000	10
GM1	GM1:11	ganglioside GM1:11:0.4232	0.4232	11
GM1	GM1:11	GM1 ganglioside:11:0.1612	0.1612	11
GM1	GM1:57|Gm1:1|GM-1:1	monosialoganglioside:59:0.3089	0.3089	59
GM2AP	GM2AP:10|GM2-AP:3	GM2 activator protein:7:0.5926|GM2-activator protein:6:0.1148	0.5926	13
GM3	GM3:13|Gm3:1	hematoside:14:0.1368	0.1368	14
GMAP	GMAP:17	Galanin message-associated peptide:17:0.8165	0.8165	17
GMA	GMA:8	gastric myoelectrical activity:8:0.6411	0.6411	8
GMA	GMA:10	geomagnetic activity:10:0.1878	0.1878	10
GMA	GMA:38	glycidyl methacrylate:38:0.2999	0.2999	38
GMA	GMA:51	glycol methacrylate:51:0.4396	0.4396	51
GMBF	GMBF:136	gastric mucosal blood flow:136:0.8439	0.8439	136
GM-CFCs	GM-CFCs:9	granulocyte-macrophage colony-forming cells:9:0.3069	0.3069	9
GM-CFU	GM-CFU:31	granulocyte-macrophage colony-forming unit:16:0.6024|granulocyte-macrophage colony-forming units:15:0.4951	0.6024	31
GM-CFU	GM-CFU:13	progenitor cells:13:0.5335	0.5335	13
GM-CSF	GM-CSF:9|GMCSF:1	colony stimulating factors:10:0.7103	0.7103	10
GM-CSF	GM-CSF:9	granulocyte-macrophage:9:0.0013	0.0013	9
GM-CSF	GM-CSF:4077|GMCSF:36|GmCSF:2|Gm-csf:1|Gm-CSF:1	granulocyte-macrophage colony-stimulating factor:3257:0.8078|Granulocyte-macrophage colony stimulating factor:584:0.6352|granulocyte macrophage-colony stimulating factor:259:0.9757|granulocyte-macrophage colony-stimulating factors:10:0.3867|granulocyte-macrophage colony-stimulating-factor:7:0.2902	0.9757	4117
GM-CSF	GM-CSF:34	granulocyte/macrophage-CSF:19:0.0030|granulocyte macrophage-CSF:15:0.8045	0.8045	34
GMCs	GMCs:18	geometric mean concentrations:18:0.8365	0.8365	18
GMCs	GMCs:17	giant migrating contractions:17:0.8270	0.8270	17
GMCs	GMCs:15	glomerular mesangial cells:15:0.7096	0.7096	15
GMC	GMC:7	ganglion mother cell:7:0.5926	0.5926	7
GMC	GMC:32	General Medical Council:32:0.9072	0.9072	32
GMC	GMC:6	general medicine clinic:6:0.5290	0.5290	6
GMC	GMC:21	geometric mean concentration:14:0.6911|geometric mean concentrations:7:0.5926	0.6911	21
GMC	GMC:27	glomerular mesangial cells:27:0.7425	0.7425	27
GMD	GMD:9	GDP-mannose dehydrogenase:9:0.5470	0.5470	9
GMEC	GMEC:12	geometric mean egg count:12:0.7571	0.7571	12
GMENAC	GMENAC:26	Graduate Medical Education National Advisory Committee:26:0.8861	0.8861	26
GME	GME:9	glucocorticoid modulatory element:9:0.6794	0.6794	9
GME	GME:117	graduate medical education:117:0.9593	0.9593	117
GMFCS	GMFCS:28	Gross Motor Function Classification System:28:0.8941	0.8941	28
GMFM	GMFM:55	Gross Motor Function Measure:55:0.9147	0.9147	55
GMF	GMF:20	geomagnetic field:20:0.8525	0.8525	20
GMF	GMF:45	glia maturation factor:45:0.9338	0.9338	45
GMG	GMG:70	granulated metrial gland:70:0.8919	0.8919	70
GMH	GMH:10	germinal matrix hemorrhage:10:0.7103	0.7103	10
GMHC	GMHC:9	Gay Men's Health Crisis:9:0.6794	0.6794	9
GMHT	GMHT:14	genetically modified herbicide-tolerant:14:0.7909	0.7909	14
GMK	GMK:16|gmk:1	green monkey kidney:17:0.7407	0.7407	17
GMOs	GMOs:73	genetically modified organisms:73:0.9353	0.9353	73
GMO	GMO:12	genetically modified organisms:12:0.7357	0.7357	12
GMO	GMO:9	glycerol monooleate:9:0.1690	0.1690	9
GMO	GMO:11	glyceryl monooleate:11:0.2582	0.2582	11
GMP-140	GMP-140:25|GMP140:3	granule membrane protein-140:15:0.5818|Granule membrane protein 140:13:0.4444	0.5818	28
GMP-140	GMP-140:34|Gmp-140:1	membrane protein:35:0.9151	0.9151	35
GMP-PNP	GMP-PNP:8|GMPPNP:1	guanylyl imidodiphosphate:9:0.2757	0.2757	9
GMPs	GMPs:4|GM-Ps:2	granulocyte-macrophage progenitors:6:0.1320	0.1320	6
GMP	GMP:78	cyclic guanosine monophosphate:78:0.5818	0.5818	78
GMP	GMP:8	generalized motor program:8:0.6411	0.6411	8
GMP	GMP:14	glycomacropeptide:14:0.0288	0.0288	14
GMP	GMP:34	Good Manufacturing Practices:34:0.9126	0.9126	34
GMP	GMP:60	guanosine 5'-monophosphate:42:0.8558|Guanosine-5'-monophosphate:18:0.0355	0.8558	60
GMSA	GMSA:10	Gel mobility shift assay:10:0.7103	0.7103	10
GMSPS	GMSPS:7	Glasgow Meningococcal Septicaemia Prognostic Score:7:0.5926	0.5926	7
GMS	GMS:29	general medical services:29:0.8978	0.8978	29
GMs	GMs:28	general movements:28:0.7505	0.7505	28
GMs	GMs:9	geometric means:9:0.6794	0.6794	9
GMS	GMS:15	Geriatric Mental State:15:0.8045	0.8045	15
GMS	GMS:13	Geriatric Mental State Schedule:13:0.7753	0.7753	13
GMS	GMS:14	glyceryl monostearate:14:0.5589	0.5589	14
GMS	GMS:10	Gomori methenamine silver:10:0.3145	0.3145	10
GMTs	GMTs:72	geometric mean titers:72:0.9585	0.9585	72
GMTs	GMTs:46	geometric mean titres:46:0.8676	0.8676	46
GMT	GMT:203	geometric mean titer:134:0.9528|geometric mean titers:69:0.9326	0.9528	203
GMT	GMT:133	geometric mean titre:82:0.9081|geometric mean titres:51:0.9438	0.9438	133
GNAT	GNAT:13	GCN5-related N-acetyltransferase:13:0.5934	0.5934	13
GNB3	GNB3:10	G protein beta3 subunit:10:0.7103	0.7103	10
GNB3	GNB3:16	G-protein beta3 subunit gene:9:0.2285|G protein beta3 subunit gene:7:0.5926	0.5926	16
GNBM	GNBM:11	gram-negative bacillary meningitis:11:0.6182	0.6182	11
GNB	GNB:54	Gram-negative bacilli:54:0.7338	0.7338	54
GNB	GNB:9	gram-negative bacteremia:9:0.5470	0.5470	9
GNB	GNB:31|GnB:1	gram-negative bacteria:32:0.7458	0.7458	32
GNDS	GNDS:13	Guy's Neurological Disability Scale:13:0.6460	0.6460	13
GNE	GNE:11	UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase:11:0.7357	0.7357	11
GNG	GNG:47	gluconeogenesis:47:0.7419	0.7419	47
GNM	GNM:14	Gaussian network model:14:0.7909	0.7909	14
GNMT	GNMT:30	Glycine N-methyltransferase:30:0.8422	0.8422	30
GNO	GNO:10	groundnut oil:10:0.5856	0.5856	10
GNPs	GNPs:8	gold nanoparticles:8:0.4102	0.4102	8
GNP	GNP:127	gross national product:127:0.9764	0.9764	127
GNR	GNR:13	Gram-negative rods:13:0.5335	0.5335	13
gnt	gnt:13	gluconate:13:0.2182	0.2182	13
GN	GN:15	Gallium nitrate:15:0.7096	0.7096	15
GN	GN:10	ganglioneuroma:10:0.0085	0.0085	10
GN	GN:723|gn:8|Gn:1	glomerulonephritis:732:0.6952	0.6952	732
GN	GN:7|gn:4|Gn:1	gnotobiotic:12:0.0104	0.0104	12
Gn	Gn:18|GN:2|gn:1	Gonadotropin:21:0.0190	0.0190	21
GN	GN:21	gram-negative:21:0.0190	0.0190	21
GN	GN:10	guanine nucleotides:10:0.7103	0.7103	10
GN	GN:16	gustatory neocortex:16:0.8165	0.8165	16
GOA	GOA:8	generalized osteoarthritis:8:0.3463	0.3463	8
GOC	GOC:14	glandular odontogenic cyst:14:0.7909	0.7909	14
GOD	GOD:103	glucose oxidase:103:0.8568	0.8568	103
GOG	GOG:111	Gynecologic Oncology Group:111:0.9185	0.9185	111
GOHAI	GOHAI:16	Oral Health Assessment Index:16:0.8165	0.8165	16
GOJ	GOJ:10	gastro-oesophageal junction:10:0.5856	0.5856	10
GoM	GoM:8|GOM:6	Grade of Membership:14:0.7909	0.7909	14
GOM	GOM:15	granular osmiophilic material:15:0.8045	0.8045	15
GON	GON:13	glaucomatous optic neuropathy:13:0.7753	0.7753	13
GON	GON:14	greater occipital nerve:14:0.7909	0.7909	14
GOO	GOO:17	gastric outlet obstruction:17:0.8270	0.8270	17
GORD	GORD:252	gastro-oesophageal reflux disease:252:0.8559	0.8559	252
GOR	GOR:134	gastro-oesophageal reflux:134:0.7837	0.7837	134
GOS	GOS:13	galacto-oligosaccharides:13:0.0285	0.0285	13
GOS	GOS:10|GO-S:1	galactose oxidase-Schiff:11:0.7357	0.7357	11
GOS	GOS:265	Glasgow Outcome Scale:265:0.9649	0.9649	265
GOS	GOS:54	Glasgow Outcome Score:54:0.9448	0.9448	54
GOT	GOT:48	aspartate aminotransferase:48:0.7074	0.7074	48
GOT	GOT:11	transferase:11:0.0172	0.0172	11
GOT	GOT:9	transminase:9:0.0137	0.0137	9
GOx	GOx:71|GOX:31|gox:1|Gox:1	Glucose oxidase:104:0.8482	0.8482	104
Gox	Gox:6|GOX:2	glucose oxidation:8:0.5006	0.5006	8
GO	GO:10	garlic oil:10:0.5000	0.5000	10
GO	GO:18	gemtuzumab ozogamicin:18:0.8365	0.8365	18
GO	GO:118	gene ontology:118:0.9744	0.9744	118
GO	GO:41	gingival overgrowth:41:0.9274	0.9274	41
GO	GO:57	glucose oxidase:57:0.5200	0.5200	57
GO	GO:14	glycolate oxidase:14:0.0703	0.0703	14
GO	GO:15	glyoxal:15:0.0194	0.0194	15
GO	GO:157|Go:1	Graves' ophthalmopathy:158:0.8337	0.8337	158
GO	GO:11	Graves' Orbitopathy:11:0.5355	0.5355	11
Go	Go:9	protein:9:0.0111	0.0111	9
GP's	GP's:43|gp's:1|GP'S:1	general practitioners:27:0.8903|General Practitioner's:18:0.8365	0.8903	45
gp130	gp130:40|GP130:1	glycoprotein 130:41:0.9274	0.9274	41
gp130	gp130:10	signal transducer:10:0.7103	0.7103	10
GP2	GP2:9|gp2:3|GP-2:2	glycoprotein 2:14:0.4367	0.4367	14
GPAT	GPAT:70	acyltransferase:70:0.7841	0.7841	70
GPAs	GPAs:37	grade point averages:25:0.8816|grade-point averages:12:0.1470	0.8816	37
G-PBMC	G-PBMC:8|GPBMC:1	peripheral blood mononuclear cells:9:0.6794	0.6794	9
GPb	GPb:11|Gpb:1	glycogen phosphorylase b:12:0.7571	0.7571	12
GPB	GPB:8|GpB:1	gram-positive bacteria:9:0.6794	0.6794	9
GPCMV	GPCMV:50|gpCMV:1|GP-CMV:1	guinea pig cytomegalovirus:52:0.9427	0.9427	52
GPCRs	GPCRs:987|GPCRS:1|GPC-Rs:1	G protein-coupled receptors:550:0.9805|G-protein-coupled receptors:300:0.2652|G-protein coupled receptors:116:0.7378|G protein coupled receptors:23:0.7593	0.9805	989
GPCR	GPCR:471|GPC-R:2|Gpcr:1	G protein-coupled receptor:246:0.9626|G-protein coupled receptor:81:0.7883|G protein-coupled receptors:79:0.9401|G-protein-coupled receptors:36:0.1534|G-protein coupled receptors:32:0.6900	0.9626	474
GPC	GPC:209	gel permeation chromatography:209:0.9857	0.9857	209
GPC	GPC:52	Giant papillary conjunctivitis:52:0.9427	0.9427	52
GPC	GPC:67	Glycerophosphocholine:67:0.0879	0.0879	67
GPC	GPC:72	glycerophosphorylcholine:72:0.0945	0.0945	72
GPC	GPC:27	glycerylphosphorylcholine:27:0.0346	0.0346	27
GPC	GPC:22	glycophorin C:22:0.5863	0.5863	22
GPC	GPC:16|GP-C:3	glycoprotein precursor:19:0.7044	0.7044	19
GPC	GPC:20	Gram-positive cocci:20:0.7173	0.7173	20
GPC	GPC:19	guinea pig complement:19:0.8449	0.8449	19
GP-DAP	GP-DAP:8|GPDAP:2	dipeptidyl aminopeptidase:10:0.5856	0.5856	10
GPDH	GPDH:215|Gpdh:9	dehydrogenase:224:0.9532	0.9532	224
GPD	GPD:10	gastric potential difference:10:0.3470	0.3470	10
gpd	gpd:18|GPD:15	glyceraldehyde-3-phosphate dehydrogenase:33:0.2218	0.2218	33
GPEE	GPEE:21	generator of pathologically enhanced excitation:21:0.7865	0.7865	21
GPe	GPe:12|Gpe:1	external globus pallidus:13:0.2415	0.2415	13
GPe	GPe:11	external segment:11:0.3829	0.3829	11
GPE	GPE:16	glycerophosphorylethanolamine:16:0.0591	0.0591	16
GPE	GPE:12	guinea pig embryo:12:0.7571	0.7571	12
GPFX	GPFX:19	grepafloxacin:19:0.9474	0.9474	19
GPI-1	GPI-1:14|GPI1:1|Gpi-1:1	glucose phosphate isomerase:16:0.8165	0.8165	16
GPIb	GPIb:117|GpIb:28|GP-Ib:2|gpIb:1	glycoprotein Ib:148:0.9378	0.9378	148
GPIC	GPIC:30|GP-IC:1	guinea pig inclusion conjunctivitis:31:0.9043	0.9043	31
GPIIIa	GPIIIa:39|GpIIIa:3|gpIIIa:1	glycoprotein IIIa:43:0.5699	0.5699	43
GPIIb	GPIIb:35|GpIIb:2|GPIIB:1	glycoprotein IIb:38:0.5227	0.5227	38
GPILSM	GPILSM:6	guinea pig ileum longitudinal smooth muscle:6:0.5290	0.5290	6
GPIs	GPIs:39	Glycosylphosphatidylinositols:39:0.6333	0.6333	39
GPi	GPi:15	globus pallidus interna:15:0.8045	0.8045	15
GPi	GPi:76|GPI:8|Gpi:3	globus pallidus internus:87:0.9455	0.9455	87
GPi	GPi:6|GPI:1	globus pallidus pars interna:7:0.5926	0.5926	7
GPI	GPI:45|Gpi:3	glucose-6-phosphate isomerase:48:0.1397	0.1397	48
GPI	GPI:114|Gpi:3	glucose phosphate isomerase:117:0.9589	0.9589	117
GPI	GPI:62|Gpi:2	glucosephosphate isomerase:64:0.1987	0.1987	64
GPI	GPI:9	glycerophosphoinositol:9:0.0045	0.0045	9
GPI	GPI:11	glycoinositol phospholipid:11:0.4232	0.4232	11
GPI	GPI:21	glycophosphatidylinositol:21:0.0106	0.0106	21
gpI	gpI:12|GPI:5	glycoprotein I:17:0.3232	0.3232	17
GPI	GPI:15	glycosyl phosphatidyl inositol:15:0.8045	0.8045	15
GPI	GPI:71	glycosyl phosphatidylinositol:71:0.7196	0.7196	71
GPI	GPI:28	glycosylphosphatidyl inositol:16:0.2154|glycosylphosphatidyl-inositol:12:0.0061	0.2154	28
GPI	GPI:537|G-PI:1	glycosylphosphatidylinositol:538:0.2969	0.2969	538
GPI	GPI:145|gpI:2	guinea pig ileum:111:0.9731|guinea-pig ileum:36:0.1586	0.9731	147
GPi	GPi:7	internal pallidal segment:7:0.3524	0.3524	7
GPi	GPi:15	internal pallidum:15:0.4951	0.4951	15
GPi	GPi:8	internal segment:8:0.1730	0.1730	8
GPI	GPI:4	plasma membrane by a glycosyl-phosphatidylinositol:4:0.1329	0.1329	4
G-PK	G-PK:6	cyclic GMP-dependent protein kinase:6:0.5290	0.5290	6
GPLs	GPLs:18	glycopeptidolipids:18:0.6538	0.6538	18
GPL	GPL:46	glycopeptidolipid:33:0.2963|glycopeptidolipids:13:0.1111	0.2963	46
GPMBP	GPMBP:5|gpMBP:1|GP-MBP:1	guinea pig myelin basic protein:7:0.5926	0.5926	7
GPMT	GPMT:47	guinea pig maximization test:47:0.9366	0.9366	47
GPN	GPN:9	glossopharyngeal nerve:9:0.1945	0.1945	9
GPN	GPN:10	glossopharyngeal neuralgia:10:0.7103	0.7103	10
GPN	GPN:6|gpn:1	greater petrosal nerve:7:0.4438	0.4438	7
GPOX	GPOX:8|G-POX:2|GPox:2|GPOx:1	glutathione peroxidase:13:0.7753	0.7753	13
GPO	GPO:16	glutathione peroxidase:16:0.5171	0.5171	16
GPP	GPP:18	generalized pustular psoriasis:18:0.8365	0.8365	18
GPP	GPP:16	geranyl diphosphate:16:0.8165	0.8165	16
GPP	GPP:9	geranyl pyrophosphate:9:0.5470	0.5470	9
gPRA	gPRA:12	progressive retinal atrophy:12:0.7571	0.7571	12
GPRD	GPRD:90	General Practice Research Database:90:0.9668	0.9668	90
GPRI	GPRI:9	Growth Potential Realization Index:9:0.6794	0.6794	9
GPRP	GPRP:9	Gly-Pro-Arg-Pro:9:0.4000	0.4000	9
GPR	GPR:11	G-protein regulatory:6:0.1543|G protein regulatory:5:0.4422	0.4422	11
GPR	GPR:10	gastropyloric receptor:10:0.2643	0.2643	10
GPR	GPR:9	general practice residency:9:0.6794	0.6794	9
GPR	GPR:7	germination protease:7:0.2113	0.2113	7
GPR	GPR:8	glucose production rate:8:0.4102	0.4102	8
GPR	GPR:6	Ground penetrating radar:6:0.5290	0.5290	6
GPS	GPS:9|G-P-S:1	gastrocnemius-plantaris-soleus:10:0.0039	0.0039	10
GPs	GPs:1905	general practitioners:1859:0.9814|general practitioners':46:0.9353	0.9814	1905
GPS	GPS:51	Global Positioning System:51:0.8799	0.8799	51
GPS	GPS:16	gray platelet syndrome:16:0.6386	0.6386	16
GPs	GPs:19|gps:1	guinea pigs:20:0.8525	0.8525	20
GPS	GPS:20|GpS:2|gps:1	guinea pig serum:23:0.8715	0.8715	23
GPs	GPs:8|GPS:1	platelet membrane glycoproteins:9:0.1945	0.1945	9
GPTE	GPTE:10	guinea pig tracheal epithelial:10:0.7103	0.7103	10
GPT	GPT:6	glucose pump test:6:0.5290	0.5290	6
GPT	GPT:9	Goniopora toxin:9:0.6794	0.6794	9
gpt	gpt:7|GPT:1	guanine phosphoribosyl transferase:8:0.1125	0.1125	8
gpt	gpt:11	guanine phosphoribosyltransferase:11:0.1991	0.1991	11
gpt	gpt:6|GPT:3	xanthine-guanine phosphoribosyl transferase:9:0.1492	0.1492	9
gpt	gpt:9|GPT:3	xanthine-guanine phosphoribosyltransferase:12:0.1991	0.1991	12
gpt	gpt:5	xanthine-guanine phosphoribosyltransferase gene:5:0.0902	0.0902	5
GPV	GPV:17|gpV:2	glycoprotein V:19:0.8449	0.8449	19
GPV	GPV:11	goose parvovirus:11:0.7357	0.7357	11
GPX1	GPX1:31|GPx-1:16|GPx1:13|Gpx1:6|GPX-1:5|Gpx-1:1	glutathione peroxidase:72:0.9585	0.9585	72
GPX1	GPX1:14|GPx1:9|Gpx1:8|GPx-1:7|Gpx-1:4|GPX-1:3	glutathione peroxidase-1:27:0.7760|glutathione peroxidase 1:18:0.8365	0.8365	45
GPX4	GPX4:8|GPx-4:2|GPx4:1|GPX-4:1	phospholipid hydroperoxide glutathione peroxidase:12:0.7571	0.7571	12
GPx	GPx:27|GPX:4|G-Px:1	glutathione peroxidases:23:0.8715|glutathione-peroxidase:9:0.0053	0.8715	32
GPx	GPx:6|GPX:3|Gpx:1	glutathione peroxidase activity:10:0.5000	0.5000	10
GPase	GPase:12	glycogen phosphorylase:12:0.7571	0.7571	12
GP	GP:7|Gp:1	against platelet glycoproteins:8:0.1599	0.1599	8
GP	GP:25|gp:1|Gp:1	anti-glycoprotein:27:0.0058	0.0058	27
gp	gp:15|GP:1	gene product:16:0.8165	0.8165	16
GP	GP:16	general population:16:0.8165	0.8165	16
GP	GP:78	general practice:78:0.9210	0.9210	78
GP	GP:915	general practitioner:777:0.9793|General practitioners:119:0.9749|general practitioners':19:0.8449	0.9793	915
GP	GP:24	Generalized Polarization:24:0.8115	0.8115	24
GP	GP:19	Genetic programming:19:0.7173	0.7173	19
GP	GP:312	globus pallidus:312:0.9846	0.9846	312
GP	GP:11	glucose polymer:11:0.7357	0.7357	11
GP	GP:45	Glucose production:45:0.8369	0.8369	45
GP	GP:83	glycogen phosphorylase:83:0.9429	0.9429	83
GP	GP:8	glycolytic potential:8:0.4102	0.4102	8
GP	GP:11	glycophorin:11:0.0022	0.0022	11
GP	GP:13	Goodpasture:13:0.0027	0.0027	13
GP	GP:10	Gossypol:10:0.0020	0.0020	10
GP	GP:8|Gp:1	Gram-positive:9:0.0018	0.0018	9
Gp	Gp:13|GP:6|gp:4	Group:23:0.0049	0.0049	23
GP	GP:13	growth plate:13:0.6701	0.6701	13
GP	GP:119|gp:29|Gp:2|g-p:1	guinea pig:102:0.9245|guinea pigs:37:0.9197|guinea-pig:12:0.0025	0.9245	151
GP	GP:17	Gutta-percha:17:0.0036	0.0036	17
GP	GP:9	phosphate:9:0.0018	0.0018	9
GP	GP:391|Gp:9	platelet glycoprotein:400:0.2142	0.2142	400
GP	GP:34|Gp:1	platelet membrane glycoproteins:35:0.5771	0.5771	35
GP	GP:10|gP:1	pressure:11:0.0022	0.0022	11
Gp	Gp:8|GP:7	protein:15:0.0031	0.0031	15
GRACE	GRACE:32	Global Registry of Acute Coronary Events:32:0.9072	0.9072	32
GRAM	GRAM:10	Generalized Rank Annihilation Method:10:0.5856	0.5856	10
GRASE	GRASE:17	gradient- and spin-echo:12:0.3058|gradient and spin-echo:5:0.1276	0.3058	17
GRA	GRA:46	glucocorticoid-remediable aldosteronism:33:0.5261|Glucocorticoid remediable aldosteronism:13:0.6701	0.6701	46
GRB2	GRB2:6|Grb-2:2	factor receptor binding protein-2:8:0.6411	0.6411	8
Grb2	Grb2:34|GRB2:9|Grb-2:1	growth factor receptor-bound protein 2:44:0.8620	0.8620	44
GRBs	GRBs:17	gamma-ray bursts:17:0.7407	0.7407	17
GRC	GRC:11|GRc:3	glucocorticoid-receptor complexes:14:0.4367	0.4367	14
grc	grc:8|Grc:4|GRC:1	growth and reproduction complex:13:0.7753	0.7753	13
GRd	GRd:14|GRD:14|G-Rd:1	glutathione reductase:29:0.7237	0.7237	29
GREACE	GREACE:9	GREek Atorvastatin and Coronary-heart-disease Evaluation:9:0.6794	0.6794	9
GREs	GREs:44	glucocorticoid response elements:44:0.7839	0.7839	44
GRE	GRE:122	glucocorticoid response element:122:0.8283	0.8283	122
GRE	GRE:26	glycopeptide-resistant enterococci:26:0.7760	0.7760	26
GRE	GRE:167|GrE:2	gradient-echo:120:0.1839|gradient echo:49:0.2456	0.2456	169
GRE	GRE:134	gradient-recalled echo:56:0.2901|gradient-recalled-echo:41:0.0618|gradient recalled echo:37:0.9197	0.9197	134
GRFs	GRFs:19	ground reaction forces:19:0.8449	0.8449	19
GRF	GRF:155	GH-releasing factor:155:0.2280	0.2280	155
GRF	GRF:6	GH-releasing hormone:6:0.0564	0.0564	6
GRF	GRF:98	ground reaction force:63:0.9526|Ground reaction forces:35:0.9151	0.9526	98
GRF	GRF:361	growth hormone-releasing factor:239:0.9607|growth hormone releasing factor:122:0.9755	0.9755	361
GRF	GRF:12	growth hormone-releasing hormone:12:0.7571	0.7571	12
GRF	GRF:9	somatocrinin:9:0.0097	0.0097	9
GRGD	GRGD:10	Gly-Arg-Gly-Asp:10:0.7500	0.7500	10
GRGDS	GRGDS:36	Gly-Arg-Gly-Asp-Ser:36:0.6364	0.6364	36
GRGDSP	GRGDSP:19|GRG-DSP:1	Gly-Arg-Gly-Asp-Ser-Pro:20:0.4524	0.4524	20
GRH	GRH:21	GH-releasing hormone:21:0.1471	0.1471	21
GRH	GRH:35	growth hormone-releasing hormone:24:0.8768|growth hormone releasing hormone:11:0.7357	0.8768	35
GRIN	GRIN:9	gradient-index:9:0.3810	0.3810	9
GRIP1	GRIP1:12|GRIP-1:2	glucocorticoid receptor interacting protein 1:14:0.4849	0.4849	14
GRK1	GRK1:9	Rhodopsin kinase:9:0.4587	0.4587	9
GRK2	GRK2:44	G protein-coupled receptor kinase 2:44:0.9308	0.9308	44
GRK2	GRK2:11	receptor kinase:11:0.7571	0.7571	11
GRK2	GRK2:9|GRK-2:6	receptor kinase-2:15:0.7096	0.7096	15
GRK3	GRK3:6	G protein-coupled receptor kinase 3:6:0.5290	0.5290	6
GRKs	GRKs:170|Grks:1	G protein-coupled receptor kinases:139:0.9786|G-protein-coupled receptor kinases:32:0.1095	0.9786	171
GRK	GRK:60	G protein-coupled receptor kinase:52:0.9427|G protein-coupled receptor kinases:8:0.6411	0.9427	60
GRL	GRL:13	glucocorticoid receptor:13:0.7753	0.7753	13
GRMD	GRMD:17	Golden retriever muscular dystrophy:17:0.8270	0.8270	17
GRNN	GRNN:15	Regression Neural Network:15:0.8045	0.8045	15
GRN	GRN:8	gigantocellular reticular nucleus:8:0.5006	0.5006	8
GRN	GRN:11	grifolan:11:0.2083	0.2083	11
GROD	GROD:10	granular osmiophilic deposits:10:0.7103	0.7103	10
GRO	GRO:8|gro:1	growth-related oncogene:9:0.2500	0.2500	9
GRP78	GRP78:40|grp78:7|Grp78:6|GRP-78:1|GRp78:1	glucose-regulated protein:55:0.6163	0.6163	55
GRP78	GRP78:21|Grp78:5|grp78:2	glucose-regulated protein 78:28:0.5634	0.5634	28
GRP94	GRP94:15|grp94:1|Grp94:1	glucose-regulated protein:17:0.5038	0.5038	17
GRP94	GRP94:4|grp94:3|Grp94:1	glucose-regulated protein 94:8:0.3463	0.3463	8
GRP-R	GRP-R:26|GRPR:17|GRPr:5|Grpr:2|GRP-r:1	gastrin-releasing peptide receptor:47:0.8187|gastrin-releasing peptide receptors:4:0.1618	0.8187	51
GRP-R	GRPr:3|GRP-R:3	GRP receptors:6:0.2113	0.2113	6
GRP	GRP:644	gastrin-releasing peptide:477:0.6341|gastrin releasing peptide:167:0.8950	0.8950	644
GRP	GRP:7	Gastrin-releasing polypeptide:7:0.3524	0.3524	7
GRP	GRP:20|grp:10|Grp:2	glucose-regulated protein:32:0.3138	0.3138	32
GRP	GRP:13|grp:3	proteins:16:0.0171	0.0171	16
GRs	GRs:126|GRS:1	glucocorticoid receptors:127:0.8651	0.8651	127
GRS	GRS:9	Rating Scale:9:0.5470	0.5470	9
Grs	Grs:8	respiratory conductance:8:0.2327	0.2327	8
GRTH	GRTH:37	Generalized resistance to thyroid hormone:37:0.8749	0.8749	37
GRT	GRT:12	gastric residence time:12:0.7571	0.7571	12
GRU	GRU:10	geriatric rehabilitation unit:10:0.7103	0.7103	10
GRU	GRU:19	glucocorticoid response unit:19:0.8449	0.8449	19
GRV	GRV:9	groundnut rosette virus:9:0.6794	0.6794	9
GRWR	GRWR:14	weight ratio:14:0.7909	0.7909	14
Grx	Grx:31|GRX:18|grx:5	glutaredoxin:54:0.6463	0.6463	54
GRx	GRx:9|GRX:2	glutathione reductase:11:0.7357	0.7357	11
GRb1	GRb1:9|G-Rb1:3	ginsenoside Rb1:12:0.6460	0.6460	12
GRed	GRed:6|GRED:4|G-Red:4|G-red:2	glutathione reductase:16:0.8165	0.8165	16
GRR	GRR:10	response region:10:0.3867	0.3867	10
GR	GR:11	beta-glucuronidase:11:0.0032	0.0032	11
GR	GR:7	effect of glycyrrhizin:7:0.1211	0.1211	7
GR	GR:1750|Gr:1|gr:1	glucocorticoid receptor:1522:0.9115|glucocorticoid receptors:230:0.9078	0.9115	1752
GR	GR:7	Glycyrrhizae radix:7:0.3524	0.3524	7
GR	GR:8	good recovery:8:0.5006	0.5006	8
GR	GR:9	good response:9:0.3945	0.3945	9
Gr	Gr:10	grade:10:0.0029	0.0029	10
Gr	Gr:12|GR:5|gr:1	group:9:0.0026|groups:9:0.0026	0.0026	18
GR	GR:12	growth rate:12:0.4153	0.4153	12
GS2	GS2:5	Gramicidin S synthetase 2:5:0.4422	0.4422	5
GSA-AT	GSA-AT:5	Glutamate 1-semialdehyde aminotransferase:5:0.4422	0.4422	5
gsb	gsb:14|Gsb:2	gooseberry:16:0.3409	0.3409	16
GSCs	GSCs:15	Germline stem cells:15:0.4951	0.4951	15
gsc	gsc:39|Gsc:7|GSC:2	goosecoid:48:0.4159	0.4159	48
GSD1b	GSD-1b:4|GSD1b:4	Glycogen storage disease type 1b:8:0.6794	0.6794	8
GSD-1	GSD-1:10|GSD1:2	glycogen storage disease type 1:12:0.7571	0.7571	12
GSD-III	GSD-III:9|GSDIII:2	glycogen storage disease type III:11:0.7357	0.7357	11
GSDII	GSDII:26|GSD-II:7	glycogen storage disease type II:33:0.9011	0.9011	33
GSD-Ia	GSD-Ia:8|GSDIa:4|GSD-IA:1	Glycogen storage disease type Ia:13:0.7753	0.7753	13
GSD-Ib	GSD-Ib:10|GSDIb:2	glycogen storage disease type Ib:12:0.7571	0.7571	12
GSD-I	GSD-I:18|GSDI:2	glycogen storage disease type I:20:0.8594	0.8594	20
GSD	GSD:62	geometric standard deviation:62:0.8788	0.8788	62
GSD	GSD:103|gsd:1	glycogen storage disease:93:0.9679|glycogen storage diseases:11:0.7357	0.9679	104
GSD	GSD:11	sex determination:11:0.7357	0.7357	11
GSEs	GSEs:15	genetic suppressor elements:15:0.8045	0.8045	15
GSE	GSE:10	General Solubility Equation:10:0.7103	0.7103	10
GSE	GSE:6	genetic suppressor element:6:0.5290	0.5290	6
GSE	GSE:41	gluten-sensitive enteropathy:41:0.6365	0.6365	41
GSE	GSE:7	gonadotrope-specific element:7:0.1111	0.1111	7
GSE	GSE:27	grape seed extract:27:0.7834	0.7834	27
GSF	GSF:11	genital skin fibroblasts:11:0.7357	0.7357	11
GSH-PO	GSH-PO:34|GSH-Po:1	glutathione-peroxidase:21:0.5714|glutathione peroxidase:14:0.7909	0.7909	35
GSH-Px	GSH-Px:26|GSH-px:3|GSH-PX:3|GSHPx:1|GSHpx:1	glutathione-peroxidase:34:0.0204	0.0204	34
GSH-Px	GSH-Px:16|GSH-px:2|GSHPx:2|GSHpx:1|GSH-PX:1	glutathione peroxidase activity:22:0.7955	0.7955	22
GSH-Px	GSH-Px:7|GSH-px:2|GSHpx:1|GSH-PX:1	GSH-peroxidase:11:0.0062	0.0062	11
GSH-R	GSH-R:17|GSHR:2	glutathione reductase:19:0.8449	0.8449	19
GSH-S	GSH-S:4|GSHS:4|gshs:1|GSH-s:1	synthetase:10:0.6429	0.6429	10
GSHt	GSHt:8|GSH-t:1|GSHT:1	total glutathione:10:0.7103	0.7103	10
GSHV	GSHV:25	ground squirrel hepatitis virus:25:0.8816	0.8816	25
GSH-Red	GSH-Red:5|GSH-red:3|GSH-RED:2|GSHred:1	glutathione reductase:11:0.6182	0.6182	11
GSH	GSH:11	Glucocorticoid-suppressible hyperaldosteronism:11:0.4232	0.4232	11
GSH	GSH:8271|G-SH:8	glutathione:8279:0.9469	0.9469	8279
GSH	GSH:26	glutathione content:26:0.8861	0.8861	26
GSH	GSH:1	glutathione in reduced:1:0.0584	0.0584	1
GSH	GSH:16	glutathione levels:16:0.8165	0.8165	16
GSH	GSH:9	gluthathione:9:0.0009	0.0009	9
GSH	GSH:17	reduced form:17:0.8365	0.8365	17
GSH	GSH:7	reduced glutathion:7:0.1329	0.1329	7
GSH	GSH:9	reduced-glutathione:9:0.0009	0.0009	9
GSIS	GSIS:69	glucose-stimulated insulin secretion:69:0.8905	0.8905	69
GSI	GSI:10	gametophytic self-incompatibility:10:0.7103	0.7103	10
GSI	GSI:93|gsi:1	genuine stress incontinence:94:0.9495	0.9495	94
GSI	GSI:25	Global Severity Index:25:0.5095	0.5095	25
GSI	GSI:10|gsI:1	glutamine synthetase I:11:0.7357	0.7357	11
GSI	GSI:81	gonadosomatic index:81:0.3842	0.3842	81
GS-I	GS-I:16|GSI:9	Griffonia simplicifolia I:15:0.8045|Griffonia simplicifolia-I:10:0.7103	0.8045	25
GSK-3	GSK-3:286|GSK3:84|Gsk3:1	glycogen synthase kinase-3:254:0.9690|Glycogen Synthase Kinase 3:117:0.9339	0.9690	371
GSK	GSK:11	GlaxoSmithKline:11:0.2632	0.2632	11
GSK	GSK:17	glycogen synthase kinase:17:0.8270	0.8270	17
GSLs	GSLs:167	glycosphingolipids:167:0.9540	0.9540	167
GSL	GSL:141	glycosphingolipid:95:0.5196|glycosphingolipids:46:0.2514	0.5196	141
GSMA	GSMA:5	genome scan meta-analysis:5:0.4422	0.4422	5
GSM	GSM:26	global system for mobile communication:15:0.8165|Global System for Mobile Communications:11:0.7357	0.8165	26
GSM	GSM:13	goat synovial membrane:13:0.7753	0.7753	13
GSM	GSM:9	gray scale median:9:0.2102	0.2102	9
GSM	GSM:9	grey scale median:9:0.2102	0.2102	9
GSNO	GSNO:10|GS-NO:1	nitrosoglutathione:11:0.0299	0.0299	11
GSNO	GSNO:33|GS-NO:1	S-nitroso-glutathione:34:0.0988	0.0988	34
GSNO	GSNO:258|GS-NO:7	S-nitrosoglutathione:265:0.7904	0.7904	265
GSN	GSN:12	greater splanchnic nerve:12:0.5664	0.5664	12
GSPECT	GSPECT:4|G-SPECT:1	single photon emission computed tomography:5:0.4422	0.4422	5
GSPE	GSPE:21	grape seed proanthocyanidin extract:21:0.8594	0.8594	21
GSPx	GSPx:9	glutathione peroxidase:9:0.5470	0.5470	9
GSP	GSP:19|Gsp:1|gsp:1	general secretory pathway:21:0.8594	0.8594	21
GSP	GSP:14	generalized social phobia:14:0.7909	0.7909	14
GSP	GSP:9	German shepherd dog pyoderma:9:0.6794	0.6794	9
GSP	GSP:13	greater superficial petrosal:13:0.7753	0.7753	13
GSP	GSP:15	Serum Protein:8:0.1895|serum proteins:7:0.2113	0.2113	15
GSRS	GSRS:41	Gastrointestinal Symptom Rating Scale:41:0.9274	0.9274	41
GSR	GSR:12	Galvanic skin resistance:12:0.6460	0.6460	12
GSR	GSR:40	galvanic skin response:40:0.9256	0.9256	40
GSR	GSR:15	Generalized Shwartzman reaction:15:0.8045	0.8045	15
GSR	GSR:25|Gsr:2|GS-R:1	glutathione reductase:28:0.8369	0.8369	28
GSR	GSR:28	Gunshot residue:20:0.7766|gunshot residues:8:0.4102	0.7766	28
GSSG	GSSG:33	glutathione disulphide:33:0.7841	0.7841	33
GSSG	GSSG:24	oxidized form:24:0.6767	0.6767	24
GSSG	GSSG:25	oxidized GSH:25:0.6539	0.6539	25
GSSG-Rd	GSSG-Rd:10|GSSG-RD:5|GSSG-rd:1|GSSGrd:1	glutathione reductase:17:0.5038	0.5038	17
GS-Se-SG	GS-Se-SG:7|GSSeSG:6	Selenodiglutathione:13:0.6000	0.6000	13
GSS	GSS:16	General Social Survey:16:0.8165	0.8165	16
GSS	GSS:29	Gerstmann-Straussler-Scheinker:29:0.0862	0.0862	29
GSS	GSS:33	Gerstmann-Straussler syndrome:33:0.2427	0.2427	33
GSS	GSS:11	global seasonality score:11:0.7357	0.7357	11
GSS	GSS:9	granulomatous slack skin:9:0.6794	0.6794	9
GSTM1	GSTM1:14	glutathione S-transferase:14:0.6911	0.6911	14
GSTM1	GSTM1:115	glutathione s-transferase M1:115:0.9582	0.9582	115
GSTM1	GSTM1:4	glutathione S-transferase M1 gene:4:0.3170	0.3170	4
GSTM1	GSTM1:9	glutathione S-transferase Mu:9:0.6794	0.6794	9
GSTM1	GSTM1:7	glutathione S-transferase Mu 1:7:0.5926	0.5926	7
GSTM	GSTM:47	gold sodium thiomalate:47:0.9366	0.9366	47
GSTM	GSTM:17	sodium aurothiomalate:17:0.6748	0.6748	17
GSTP1-1	GSTP1-1:21	glutathione S-transferase P1-1:21:0.7865	0.7865	21
GSTP1	GSTP1:19	glutathione s-transferase:19:0.7658	0.7658	19
GSTP1	GSTP1:50|GST-P1:1	glutathione S-transferase P1:51:0.9416	0.9416	51
GSTP1	GSTP1:4	glutathione S-transferase P1 gene:4:0.3170	0.3170	4
GSTP1	GSTP1:8	glutathione S-transferase pi:8:0.6411	0.6411	8
GST-P	GST-P:24|GSTP:2	glutathione S-transferase P:26:0.8861	0.8861	26
GST-P	GST-P:9	glutathione S-transferase P-form:9:0.6794	0.6794	9
GSTP	GSTP:5|GST-P:2|GSTp:1	glutathione S-transferase pi:8:0.6411	0.6411	8
GST-P	GST-P:88|GSTP:3	glutathione S-transferase placental form:91:0.9685	0.9685	91
GST-P	GST-P:14	Glutathione transferase P:14:0.7909	0.7909	14
GST-P	GST-P:17|GSTP:7|GSTp:2|GST-p:1	placental form of glutathione S-transferase:21:0.7291|placental form of glutathione-S-transferase:6:0.5290	0.7291	27
GST-P	GST-P:10	placental type:10:0.7103	0.7103	10
GST-P	GST-P:4	placental type of glutathione-S-transferase:4:0.5290	0.5290	4
GSTT1	GSTT1:25	glutathione S-transferase T1:25:0.8186	0.8186	25
GSTZ1-1	GSTZ1-1:9	Glutathione transferase zeta:9:0.6794	0.6794	9
GST-pi	GST-pi:104|GSTpi:15|GST-Pi:7|GSTPI:1	glutathione S-transferase pi:56:0.9162|glutathione S-transferase-pi:46:0.8986|glutathione-S-transferase-pi:25:0.1065	0.9162	127
GSTs	GSTs:467|GSTS:1	Glutathione S-transferases:468:0.9606	0.9606	468
GSTs	GSTs:72	glutathione transferases:72:0.8168	0.8168	72
GST	GST:5	general systems theory:5:0.4422	0.4422	5
GST	GST:6	generalized seizure triggering threshold:6:0.5290	0.5290	6
GST	GST:9|Gst:1	Genistein:10:0.0023	0.0023	10
GST	GST:9	glucagon stimulation test:9:0.6794	0.6794	9
GST	GST:3224|G-S-T:2|GS-T:2|gst:1|G-ST:1|Gst:1	glutathione S-transferase:2239:0.9489|glutathione-S-transferase:766:0.1943|glutathione S-transferases:199:0.9282|glutathione-S-transferases:27:0.0066	0.9489	3231
GST	GST:8	glutathione S-transferase activity:8:0.6411	0.6411	8
GST	GST:197	glutathione transferase:175:0.7323|glutathione transferases:22:0.6178	0.7323	197
GST	GST:83	gold sodium thiomalate:83:0.9640	0.9640	83
GST	GST:14	GSH-S-transferase:14:0.0033	0.0033	14
GSWs	GSWs:25	gunshot wounds:25:0.8816	0.8816	25
GSW	GSW:44	gunshot wounds:24:0.7593|gunshot wound:20:0.8525	0.8525	44
GS	GS:9	galactosialidosis:9:0.0031	0.0031	9
GS	GS:24	gallstones:15:0.0054|gallstone:9:0.0031	0.0054	24
GS	GS:36	Gardner's syndrome:21:0.0843|Gardner syndrome:15:0.0553	0.0843	36
GS	GS:11	gastrocnemius:11:0.0039	0.0039	11
GS	GS:22|G-S:6	gastrocnemius-soleus:28:0.0105	0.0105	28
GS	GS:22|Gs:1	gastroschisis:23:0.0086	0.0086	23
GS	GS:12	general surgery:12:0.4557	0.4557	12
GS	GS:14	gentamicin sulfate:14:0.2524	0.2524	14
GS	GS:12	gestational sac:12:0.7571	0.7571	12
GS	GS:17	Ginsenosides:17:0.0062	0.0062	17
GS	GS:19	Gitelman's syndrome:19:0.0725	0.0725	19
GS	GS:53|Gs:2	Gleason score:48:0.6007|Gleason scores:7:0.2452	0.6007	55
GS	GS:8	glomerular sclerosis:8:0.5006	0.5006	8
GS	GS:50|gs:1	glomerulosclerosis:51:0.0194	0.0194	51
GS	GS:9	glucosamine sulfate:9:0.1052	0.1052	9
GS	GS:13	glucose-sensitive:13:0.0047	0.0047	13
GS	GS:709|gs:1	glutamine synthetase:710:0.9217	0.9217	710
GS	GS:14	glutathione:14:0.0051	0.0051	14
GS	GS:167	Glycogen synthase:167:0.8102	0.8102	167
GS	GS:24|gs:1	graft survival:25:0.6873	0.6873	25
GS	GS:6	Gram stain:6:0.1838	0.1838	6
GS	GS:39	gramicidin S:39:0.8455	0.8455	39
GS	GS:83	granulocytic sarcoma:70:0.9326|granulocytic sarcomas:13:0.6701	0.9326	83
GS	GS:16	grip strength:16:0.8165	0.8165	16
gs	gs:23	group-specific:23:0.0093	0.0093	23
GS	GS:12	patients with Gilbert's syndrome:12:0.1692	0.1692	12
Gs	Gs:5|GS:1	protein of adenylate cyclase:6:0.1543	0.1543	6
Gs	Gs:8	protein of adenylyl cyclase:8:0.3069	0.3069	8
Gs	Gs:31|gs:1|GS:1	stimulatory:33:0.0124	0.0124	33
Gs	Gs:49|gs:2	stimulatory G protein:29:0.4913|stimulatory G-protein:16:0.4040|stimulatory G proteins:6:0.3728	0.4913	51
Gs	Gs:20|GS:2	stimulatory GTP-binding protein:22:0.5863	0.5863	22
Gs	Gs:34	stimulatory guanine nucleotide-binding protein:22:0.6934|stimulatory guanine nucleotide binding protein:12:0.5050	0.6934	34
Gs	Gs:8	stimulatory guanine nucleotide regulatory protein:8:0.4102	0.4102	8
gs	gs:31|Gs:4|GS:3|gS:1	stomatal conductance:39:0.6744	0.6744	39
GTA	GTA:35	Glutaraldehyde:35:0.3542	0.3542	35
GTA	GTA:7	Greater Toronto Area:7:0.5926	0.5926	7
GTB	GTB:7	glomerulotubular balance:7:0.2113	0.2113	7
GTCSs	GTCSs:12	generalized tonic-clonic seizures:12:0.7571	0.7571	12
GTCS	GTCS:71|GTCs:7	generalized tonic-clonic seizures:65:0.8306|generalized tonic-clonic seizure:13:0.7753	0.8306	78
GTD	GTD:155	gestational trophoblastic disease:140:0.9786|Gestational trophoblastic diseases:15:0.8045	0.9786	155
GTD	GTD:12	gestodene:12:0.0608	0.0608	12
GTE	GTE:43	green tea extract:43:0.9308	0.9308	43
GTFs	GTFs:23	general transcription factors:23:0.8715	0.8715	23
GTFs	GTFs:35|Gtfs:5	glucosyltransferases:40:0.4483	0.4483	40
GTF	GTF:23	glucose tolerance factor:23:0.8715	0.8715	23
GTF	GTF:104|Gtf:9|gtf:2	glucosyltransferase:99:0.5444|glucosyltransferases:16:0.0833	0.5444	115
GTG	GTG:46	gold thioglucose:46:0.9353	0.9353	46
GTG	GTG:19	goldthioglucose:19:0.1208	0.1208	19
GTH-II	GTH-II:13|GtH-II:7	gonadotropin-II:20:0.4318	0.4318	20
GTH	GTH:15|GtH:3	gonadotrophin:18:0.0664	0.0664	18
GTH	GTH:10	gonadotropic:10:0.0352	0.0352	10
GTH	GTH:17|GtH:9	Gonadotropic hormone:26:0.5218	0.5218	26
GtH	GtH:85|GTH:75|Gth:2	gonadotropin:162:0.6289	0.6289	162
GtH	GtH:6|GTH:4	gonadotropin hormone:10:0.1022	0.1022	10
GTN	GTN:39	gestational trophoblastic neoplasia:39:0.9237	0.9237	39
GTN	GTN:441	glyceryl trinitrate:441:0.9136	0.9136	441
GTN	GTN:23	glyceryltrinitrate:23:0.0307	0.0307	23
GTN	GTN:118	nitroglycerin:118:0.1632	0.1632	118
GTOs	GTOs:9	Golgi tendon organs:9:0.6794	0.6794	9
GTPCH	GTPCH:5|GTP-CH:2	GTP cyclohydrolase:7:0.2902	0.2902	7
GTPCH	GTPCH:49|GTP-CH:7	GTP cyclohydrolase I:56:0.7602	0.7602	56
GTPs	GTPs:9	green tea polyphenols:9:0.6794	0.6794	9
GTP[S]	GTP[S]:96	guanosine 5'-[gamma-thio]triphosphate:96:0.8802	0.8802	96
GTPase	GTPase:98	guanosine triphosphatase:98:0.8609	0.8609	98
GTP	GTP:8	gamma-glutamyl transpeptidase:8:0.3463	0.3463	8
GTP	GTP:22	green tea polyphenols:22:0.8657	0.8657	22
GTP	GTP:209	guanosine 5'-triphosphate:174:0.9257|guanosine-5'-triphosphate:35:0.0362	0.9257	209
GTP	GTP:325	guanosine triphosphate:325:0.8737	0.8737	325
GTP	GTP:12	nucleotide:12:0.0117	0.0117	12
GTTs	GTTs:10	gestational trophoblastic tumors:10:0.7103	0.7103	10
GTTs	GTTs:19	glucose tolerance tests:19:0.8449	0.8449	19
GTT	GTT:56	gestational trophoblastic tumor:36:0.9174|gestational trophoblastic tumors:20:0.8525	0.9174	56
GTT	GTT:245	glucose tolerance test:208:0.9556|glucose tolerance tests:37:0.8749	0.9556	245
GTV	GTV:88	gross tumor volume:88:0.9461	0.9461	88
GTVs	GTVs:9	gross tumor volumes:9:0.6794	0.6794	9
GTX	GTX:9	grayanotoxin:9:0.1905	0.1905	9
GTases	GTases:10	glucosyltransferases:10:0.6000	0.6000	10
GTase	GTase:18	glucosyltransferase:18:0.3953	0.3953	18
GTC	GTC:20	generalized tonic-clonic:20:0.6680	0.6680	20
GTC	GTC:15	generalized tonic-clonic seizures:15:0.8045	0.8045	15
GTC	GTC:16	Gill-Thomas-Cosman:16:0.1000	0.1000	16
GTC	GTC:19	green tea catechins:19:0.8449	0.8449	19
GTR	GTR:5	glutamyl-tRNA reductase:5:0.1132	0.1132	5
GTR	GTR:21	gross total resection:21:0.8594	0.8594	21
GTR	GTR:335	guided tissue regeneration:335:0.9808	0.9808	335
Gt	Gt:4|GT:1	G protein transducin:5:0.5050	0.5050	5
GT	GT:31	galactosyltransferase:31:0.0258	0.0258	31
GT	GT:11	Gambling Task:11:0.7357	0.7357	11
GT	GT:7	gamma-glutamyl transpeptidase:7:0.3524	0.3524	7
GT	GT:26	gamma-glutamyltransferase:26:0.0215	0.0215	26
GT	GT:6	gastrostomy tube:6:0.0807	0.0807	6
GT	GT:12|gt:1	gene therapy:13:0.3554	0.3554	13
GT	GT:5	Generation time:5:0.0902	0.0902	5
GT	GT:9	genital tubercle:9:0.6794	0.6794	9
GT	GT:8	germ tube:8:0.1895	0.1895	8
gt	gt:17|Gt:1|GT:1	giant:19:0.0155	0.0155	19
GT	GT:5	gingival tissue:5:0.0612	0.0612	5
GT	GT:89	Glanzmann's thrombasthenia:52:0.4508|Glanzmann thrombasthenia:37:0.2967	0.4508	89
GT	GT:9	Gliotoxin:9:0.0069	0.0069	9
GT	GT:32	glucose tolerance:32:0.9072	0.9072	32
GT	GT:6	glucose transport:6:0.1838	0.1838	6
GT	GT:28	glucose transporter:28:0.7154	0.7154	28
GT	GT:10	glucuronosyltransferase:10:0.0069	0.0069	10
GT	GT:18	glutathione transferase:18:0.2396	0.2396	18
GT	GT:7	granulation tissue:7:0.2113	0.2113	7
GT	GT:13	green tea:13:0.6701	0.6701	13
GT	GT:23	L-glutamic acid50-L-tyrosine50:23:0.8715	0.8715	23
Gt	Gt:22|GT:5	tissue conductance:27:0.1481	0.1481	27
GT	GT:9	UDP-Glc:glycoprotein glucosyltransferase:9:0.2757	0.2757	9
GT	GT:10	UDP-glucuronosyltransferase:10:0.0078	0.0078	10
GT	GT:14	UDP-glucuronyltransferase:14:0.0112	0.0112	14
GUCH	GUCH:9	grown-up congenital heart:9:0.6794	0.6794	9
GUD	GUD:80	genital ulcer disease:80:0.9200	0.9200	80
GUI	GUI:6	uptake index:6:0.1320	0.1320	6
GUSTO	GUSTO:12	Global Use of Strategies to Open Occluded Coronary Arteries:12:0.6460	0.6460	12
GUSTO	GUSTO:11	Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries:11:0.7103	0.7103	11
GUSTO	GUSTO:11	Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries:11:0.7357	0.7357	11
GUSTO-1	GUSTO-1:10	Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries:10:0.7103	0.7103	10
GUSTO-I	GUSTO-I:14	global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries:14:0.7909	0.7909	14
GUVs	GUVs:31	giant unilamellar vesicles:31:0.9043	0.9043	31
GU	GU:20	gastric:20:0.0406	0.0406	20
GU	GU:169	gastric ulcer:148:0.9571|gastric ulcers:21:0.7291	0.9571	169
GU	GU:117	genitourinary:117:0.2479	0.2479	117
GU	GU:25|Gu:1	Glucose uptake:26:0.8861	0.8861	26
GU	GU:20	glucose utilization:20:0.6680	0.6680	20
GU	GU:13	gonococcal urethritis:13:0.6701	0.6701	13
GU	GU:11|gu:2	units:13:0.0256	0.0256	13
GVB	GVB:57	germinal vesicle breakdown:57:0.9477	0.9477	57
GVB	GVB:9	grapevine virus B:9:0.7103	0.7103	9
GVD	GVD:22	graft vascular disease:22:0.8657	0.8657	22
GVD	GVD:11	granulovacuolar degeneration:11:0.7357	0.7357	11
GVEC	GVEC:9	glomerular visceral epithelial cells:9:0.6794	0.6794	9
GVG	GVG:69	gamma-vinyl GABA:35:0.7647|gamma-vinyl-GABA:34:0.3119	0.7647	69
GVG	GVG:20	vigabatrin:20:0.1743	0.1743	20
GVHD	GVHD:20|GvHD:1	acute graft-versus-host-disease:21:0.0978	0.0978	21
GVHD	GVHD:15|GvHD:1	chronic graft-versus-host-disease:16:0.0640	0.0640	16
GVHD	GVHD:3235|GvHD:417|GVH-D:3|G-VHD:1|GvH-D:1	graft-versus-host disease:3260:0.7501|Graft Versus Host Disease:390:0.9877|graft-versus-host diseases:7:0.2113	0.9877	3657
GVHD	GVHD:28|GvHD:5	graft vs host disease:33:0.9648	0.9648	33
GVHR	GVHR:215|GvHR:41|GVH-R:2|GvhR:1	graft-versus-host reaction:227:0.6096|graft-versus-host reactions:23:0.4344|graft-versus-host-reaction:9:0.0193	0.6096	259
GVH	GVH:232|GvH:80|gvh:1	graft-versus-host:257:0.5517|Graft versus host:56:0.9467	0.9467	313
GVH	GVH:5|GvH:2	graft-versus-host disease:7:0.1470	0.1470	7
GVH	GVH:10|GvH:5	Graft-Versus-Host reaction:10:0.2126|Graft versus host reaction:5:0.4422	0.4422	15
GVH	GVH:63|GvH:21	graft-vs-host:50:0.1056|graft-vs.-host:21:0.0431|graft vs host:13:0.8594	0.8594	84
GVI	GVI:5	growth velocity index:5:0.4422	0.4422	5
GVL	GVL:30|GvL:6	graft-versus-leukaemia:36:0.0808	0.0808	36
GVL	GVL:248|GvL:33	graft-versus-leukemia:243:0.5612|Graft versus leukemia:38:0.9217	0.9217	281
GVL	GVL:4|GvL:2	graft-versus-leukemia effect:6:0.1010	0.1010	6
GVL	GVL:12	graft-versus-lymphoma:12:0.0254	0.0254	12
GVL	GVL:49|GvL:1	graft-vs-leukemia:23:0.0508|graft-vs.-leukemia:20:0.0439|Graft vs leukemia:7:0.7571	0.7571	50
GVM	GVM:18|GvM:1	graft-versus-myeloma:19:0.4286	0.4286	19
GVS	GVS:50	galvanic vestibular stimulation:50:0.9064	0.9064	50
GVs	GVs:6	germinal vesicles:6:0.1148	0.1148	6
GVT	GVT:51|GvT:5	graft-versus-tumor:48:0.5341|graft versus tumor:8:0.6411	0.6411	56
GV	GV:18	gas ventilation:18:0.7539	0.7539	18
GV	GV:9	Gastric varices:9:0.5470	0.5470	9
GV	GV:19|Gv:4	gentian violet:23:0.8038	0.8038	23
GV	GV:272|gv:3	germinal vesicle:262:0.9817|germinal vesicles:13:0.3134	0.9817	275
GV	GV:9	germinal vesicle stage:9:0.6794	0.6794	9
GV	GV:8	gilvocarcin V:8:0.5006	0.5006	8
GV	GV:42	growth velocity:42:0.8893	0.8893	42
GV	GV:19|G-V:1	volume:20:0.0329	0.0329	20
GWN	GWN:9	gaussian white noise:9:0.6794	0.6794	9
GWR	GWR:11	gill withdrawal reflex:11:0.7357	0.7357	11
GWS	GWS:15	Gulf War Syndrome:15:0.8045	0.8045	15
GWVs	GWVs:9	Gulf War veterans:9:0.6794	0.6794	9
GW	GW:54|gw:12	gestational weeks:51:0.8316|gestational week:15:0.7096	0.8316	66
GW	GW:14	Gulf War:14:0.7909	0.7909	14
GW	GW:11	weeks of gestation:11:0.3829	0.3829	11
GXT	GXT:10	exercise tests:10:0.5856	0.5856	10
GXT	GXT:31	graded exercise test:31:0.6572	0.6572	31
GXT	GXT:7	graded exercise testing:7:0.5926	0.5926	7
GZ	GZ:14	beta-galactosidase:14:0.1757	0.1757	14
Ga-67	Ga-67:12	Gallium-67 citrate:12:0.5050	0.5050	12
GaAs	GaAs:45|Ga-As:7	Gallium arsenide:43:0.8590|gallium-arsenide:9:0.1159	0.8590	52
Gab1	Gab1:25|Gab-1:2|GAB1:2	Grb2-associated binder-1:20:0.5892|Grb2-associated binder 1:9:0.5470	0.5892	29
Gab2	Gab2:7	Grb2-associated binder 2:7:0.3524	0.3524	7
Gal-1-P	Gal-1-P:21|gal-1-P:7|gal-1P:1|Gal-1P:1|Gal1P:1	galactose-1-phosphate:31:0.7317	0.7317	31
GalCer	GalCer:15|gal-cer:1|Gal-Cer:1	galactosyl ceramide:17:0.8270	0.8270	17
GalCer	GalCer:64|gal-cer:4|GalCER:1|Galcer:1	galactosylceramide:70:0.6053	0.6053	70
GalC	GalC:11|Gal-C:3	anti-galactocerebroside:14:0.0695	0.0695	14
GALC	GALC:1	disorder caused by deficiency of galactocerebrosidase:1:0.2818	0.2818	1
GalC	GalC:68|galC:11|Gal-C:10|galc:1|Galc:1|GAlC:1	galactocerebroside:92:0.4866	0.4866	92
GalC	GalC:13	galactosylceramide:13:0.0642	0.0642	13
GAL-LI	GAL-LI:13|Gal-LI:3|GalLI:1	Galanin-like immunoreactivity:17:0.6211	0.6211	17
GalNAc	GalNAc:48|GalNAC:1	N-acetyl-D-galactosamine:49:0.1951	0.1951	49
GalNAc	GalNAc:17|galNAc:2|GalNac:2	N-acetyl-galactosamine:11:0.0407|N-acetyl galactosamine:10:0.7103	0.7103	21
GalNAc	GalNAc:113|GalNac:9|galNac:1|GalNAC:1	N-acetylgalactosamine:124:0.5000	0.5000	124
GalN	GalN:74|GALN:5|Gal-N:3|galN:1	D-Galactosamine:83:0.5616	0.5616	83
GalN	GalN:41|GALN:3|GaLN:1|galN:1	galactosamine:46:0.3082	0.3082	46
GALP	GALP:54	galanin-like peptide:54:0.9438	0.9438	54
GalR	GalR:9	Gal repressor:9:0.4587	0.4587	9
GALR	GALR:5|GalR:1	galanin receptor:6:0.1838	0.1838	6
GalT-2	GalT-2:9|Gal-T2:2	galactosyltransferase:11:0.4348	0.4348	11
GalXM	GalXM:9	galactoxylomannan:9:0.8889	0.8889	9
gal	gal:17|Gal:4	beta-galactosidase:21:0.0251	0.0251	21
Gal	Gal:6|gal:4	D-galactosamine:10:0.0113	0.0113	10
Gal	Gal:17	D-galactose:17:0.0201	0.0201	17
Gal	Gal:7|gal:4	galactosamine:11:0.0125	0.0125	11
Gal	Gal:130|gal:18	galactose:148:0.1844	0.1844	148
Gal	Gal:13	galactosyl:13:0.0151	0.0151	13
Gaw/VL	Gaw/VL:8	specific airway conductance:8:0.6411	0.6411	8
Gb(3)	Gb(3):12	globotriaosylceramide:12:0.5238	0.5238	12
Gb3Cer	Gb3Cer:7|Gb3-Cer:1|Gb3cer:1	globotriaosylceramide:9:0.7273	0.7273	9
Gb3	Gb3:10	globotriaosyl ceramide:10:0.2873	0.2873	10
Gb3	Gb3:80|GB3:1	Globotriaosylceramide:81:0.5755	0.5755	81
Gb4	Gb4:12	globoside:12:0.4074	0.4074	12
Gb4	Gb4:9	globotetraosylceramide:9:0.2963	0.2963	9
GCAT	GCAT:9	acyltransferase:9:0.4706	0.4706	9
Gd(3+)	Gd(3+):19	gadolinium:19:0.7200	0.7200	19
Gd+	Gd+:11	gadolinium-enhancing:11:0.6250	0.6250	11
Gd3+	Gd3+:63	gadolinium:63:0.8052	0.8052	63
GdCl(3)	GdCl(3):28	gadolinium chloride:28:0.8369	0.8369	28
GdCl3	GdCl3:85|GDCl3:1|GdCL3:1	gadolinium chloride:87:0.9656	0.9656	87
Gd-DTPA	Gd-DTPA:8	Gadolinium diethylene triamine pentaacetic acid:8:0.4102	0.4102	8
Gd-DTPA	Gd-DTPA:66|GD-DTPA:1	gadolinium-diethylenetriamine pentaacetic acid:40:0.2892|gadolinium diethylenetriamine pentaacetic acid:27:0.7505	0.7505	67
Gd-DTPA	Gd-DTPA:66	gadopentetate dimeglumine:66:0.8024	0.8024	66
Gd-MRI	Gd-MRI:7	Gadolinium-enhanced MRI:7:0.3524	0.3524	7
Gd-MRI	Gd-MRI:10|GdMRI:4	magnetic resonance imaging:14:0.7909	0.7909	14
GDF-9	GDF-9:46|GDF9:24|Gdf9:2	growth differentiation factor-9:39:0.9338|Growth differentiation factor 9:33:0.9100	0.9338	72
GdmCl	GdmCl:10	guanidine hydrochloride:10:0.3213	0.3213	10
GdmCl	GdmCl:82	guanidinium chloride:82:0.8495	0.8495	82
Gdn.HCl	Gdn.HCl:18	guanidine hydrochloride:18:0.7539	0.7539	18
GdnHCl	GdnHCl:128|Gdn-HCl:29|gdnHCl:1	Guanidine hydrochloride:158:0.8573	0.8573	158
GdnHCl	GdnHCl:21|Gdn-HCl:2	guanidinium chloride:23:0.7500	0.7500	23
GeO2	GeO2:9	germanium dioxide:9:0.6794	0.6794	9
GGF	GGF:24	glial growth factor:24:0.6767	0.6767	24
G-Gly	G-Gly:5|G-gly:2|Ggly:1	glycine-extended gastrin:8:0.2619	0.2619	8
GIL	GIL:8	graft-infiltrating lymphocytes:8:0.2327	0.2327	8
GJs	GJs:39|gjs:4|GJS:1	gap junctions:44:0.9323	0.9323	44
Gla	Gla:26|GLA:1	gamma-carboxyglutamate:27:0.0381	0.0381	27
Gla	Gla:181|gla:11|GLA:9	gamma-carboxyglutamic acid:201:0.3458	0.3458	201
Gla	Gla:16	gamma-carboxyglutamyl:16:0.0220	0.0220	16
GLA	GLA:214	gamma-linolenic acid:214:0.3728	0.3728	214
Glc-6-P	Glc-6-P:53|Glc6P:25|glc-6-P:2|Glc6-P:1|glc-6-p:1	glucose 6-phosphate:51:0.8799|glucose-6-phosphate:31:0.3297	0.8799	82
GlcA	GlcA:10	D-glucuronic acid:10:0.1177	0.1177	10
GlcA	GlcA:20	glucuronic acid:20:0.4037	0.4037	20
GlcCer	GlcCer:88|Glc-Cer:2|Glc-cer:1|glc-cer:1	glucosylceramide:92:0.7863	0.7863	92
GlcN-6-P	GlcN-6-P:7|GlcN6P:5	glucosamine-6-phosphate:12:0.5789	0.5789	12
GlcNAc	GlcNAc:89|GlcNAC:3|glcNAc:1|GlcNac:1	N-acetyl-D-glucosamine:94:0.1875	0.1875	94
GlcNAc	GlcNAc:29	N-acetyl glucosamine:16:0.8165|N-acetyl-glucosamine:13:0.0242	0.8165	29
GlcNAc	GlcNAc:291|GlcNac:4|Glc-NAc:1	N-acetylglucosamine:296:0.5948	0.5948	296
GlcN	GlcN:52|glcN:3	glucosamine:55:0.6667	0.6667	55
Glib	Glib:17|GLIB:6|glib:2|-GLIB:1	glibenclamide:26:0.8929	0.8929	26
Glk	Glk:4|glk:3|GLK:2	glucokinase:9:0.2857	0.2857	9
Glk	Glk:4|glk:2	glucose kinase:6:0.2243	0.2243	6
GLMs	GLMs:10	linear models:10:0.7103	0.7103	10
GlnRS	GlnRS:47	glutaminyl-tRNA synthetase:47:0.9006	0.9006	47
GLP-1R	GLP-1R:9|GLP1-R:1|GLP1R:1	glucagon-like peptide-1 receptor:11:0.7357	0.7357	11
GLTP	GLTP:8|GL-TP:1	Glycolipid transfer protein:9:0.6794	0.6794	9
Glu-P-1	Glu-P-1:9	2-amino-6-methyl-dipyrido[1,2-a:3',2'-d]imidazole:9:0.0860	0.0860	9
Glu-P-1	Glu-P-1:41	2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole:41:0.4194	0.4194	41
GluCls	GluCls:9	Glutamate-gated chloride channels:9:0.5470	0.5470	9
GluDH	GluDH:8|Glu-DH:2	glutamate dehydrogenase:10:0.7103	0.7103	10
GluR1	GluR1:21	glutamate receptor 1:21:0.7865	0.7865	21
GluR1	GluR1:8	receptor subunit:8:0.5006	0.5006	8
GluR2	GluR2:17	glutamate receptor 2:17:0.6748	0.6748	17
GluR2	GluR2:7	glutamate receptor subunit 2:7:0.4438	0.4438	7
GluR3	GluR3:5|GLUR3:1	receptor subunit 3:6:0.5290	0.5290	6
GluR5	GluR5:7	glutamate receptor 5:7:0.5926	0.5926	7
GluRs	GluRs:90|GLURs:1	glutamate receptors:91:0.9167	0.9167	91
GluRS	GluRS:24	glutamyl-tRNA synthetase:24:0.6767	0.6767	24
GluR	GluR:148|gluR:2|GLU-R:1|Glu-R:1|GLUR:1	glutamate receptor:127:0.9389|glutamate receptors:26:0.6973	0.9389	153
GLUT	GLUT:141|Glut:15|glut:1	glucose transporter:117:0.9589|glucose transporters:40:0.8184	0.9589	157
GLUT	GLUT:10|Glut:5	glutaraldehyde:15:0.0586	0.0586	15
GlxI	GlxI:9	glyoxalase I:9:0.6794	0.6794	9
Gly-Gln	Gly-Gln:10|GLY-GLN:2|gly-gln:1|GlyGln:1	glycyl-L-glutamine:14:0.4483	0.4483	14
GlyRs	GlyRs:71|glyRs:1	glycine receptors:72:0.9344	0.9344	72
GlyR	GlyR:127|Gly-R:4	glycine receptor:122:0.9151|glycine receptors:9:0.5470	0.9151	131
Gly-Sar	Gly-Sar:26|GlySar:7	glycylsarcosine:33:0.5614	0.5614	33
GM-CFC	GM-CFC:124|GM-CFc:1|GmCFC:1	granulocyte-macrophage colony-forming cells:84:0.6951|granulocyte-macrophage colony forming cells:22:0.5327|granulocyte-macrophage colony-forming cell:20:0.5279	0.6951	126
GM-CFC	GM-CFC:53	granulocyte-macrophage progenitor cells:39:0.5194|granulocyte/macrophage progenitor cell:7:0.1470|granulocyte-macrophage progenitor cell:7:0.1470	0.5194	53
Gmr	Gmr:10	gentamicin resistance:10:0.5856	0.5856	10
GMR	GMR:11	geometric mean ratio:11:0.7357	0.7357	11
GMR	GMR:13	glucose metabolic rate:13:0.7753	0.7753	13
GMR	GMR:10	GM-CSF receptor:10:0.4832	0.4832	10
GM	GM:27	Gabexate mesilate:27:0.8903	0.8903	27
GM	GM:26	Galactomannan:26:0.0130	0.0130	26
GM	GM:10	gastric metaplasia:10:0.5000	0.5000	10
GM	GM:19	gastric mucosa:19:0.7658	0.7658	19
GM	GM:45	gastrocnemius medialis:45:0.8369	0.8369	45
GM	GM:7	gastrocnemius medialis muscle:7:0.5926	0.5926	7
GM	GM:8	gastrocnemius muscle:8:0.1367	0.1367	8
GM	GM:160	genetically modified:160:0.9701	0.9701	160
GM	GM:242|Gm:14	Gentamicin:256:0.1325	0.1325	256
GM	GM:207|gm:4	geometric mean:200:0.9408|geometric means:11:0.5664	0.9408	211
GM	GM:9	germinal matrix:9:0.6794	0.6794	9
GM	GM:42	glioblastoma multiforme:42:0.8263	0.8263	42
GM	GM:11	gluteus maximus:11:0.7357	0.7357	11
GM	GM:15|Gm:1	gluteus medius:16:0.7261	0.7261	16
GM	GM:10	glyceryl methacrylate:10:0.5000	0.5000	10
gM	gM:14|gm:1	glycoprotein M:15:0.4052	0.4052	15
GM	GM:160|G-M:1	granulocyte-macrophage:124:0.0644|granulocyte/macrophage:31:0.0156|granulocyte macrophage:6:0.1543	0.1543	161
GM	GM:141|gm:1|Gm:1	gray matter:143:0.7894	0.7894	143
GM	GM:21	grey matter:21:0.0691	0.0691	21
GM	GM:10	growth medium:10:0.3470	0.3470	10
GM	GM:9	growth monitoring:9:0.5470	0.5470	9
Gm	Gm:10|GM:4	heavy chain:14:0.6911	0.6911	14
Gm	Gm:6	heavy chain allotypes:6:0.5290	0.5290	6
Gm	Gm:10|GM:2	Immunoglobulin:12:0.0057	0.0057	12
Gm	Gm:18|gm:6|GM:2|gM:1	membrane conductance:27:0.3177	0.3177	27
GM	GM:5	Rat medial gastrocnemius:5:0.1464	0.1464	5
GnRH-R	GnRH-R:23|GnRHR:5	GnRH receptors:28:0.6057	0.6057	28
GnRH-Ag	GnRH-Ag:4	administration of a gonadotropin-releasing hormone agonist:4:0.1618	0.1618	4
GnRHa	GnRHa:3	GnRH agonist [D-Ala6]des-Gly10-GnRH N-ethylamide:3:0.3170	0.3170	3
GnRHa	GnRHa:1	GnRH and its analogues:1:0.1299	0.1299	1
GnRHa	GnRHa:7|GnRH-A:5|GnRHA:4|GnRH-a:2	GnRH antagonist:18:0.5560	0.5560	18
GnRHa	GnRHa:88|GnRH-a:7|GNRHa:1	gonadotrophin-releasing hormone agonist:82:0.2143|gonadotrophin releasing hormone agonist:14:0.1063	0.2143	96
GnRHa	GnRHa:39|GnRH-a:5|GnRH-A:2	gonadotrophin-releasing hormone analogue:32:0.2996|gonadotrophin-releasing hormone analogues:14:0.3039	0.3039	46
GnRH-a	GnRH-a:3|GnRH-A:2|Gn-RH-a:1	gonadotropin-releasing hormone:6:0.0899	0.0899	6
GnRH-a	GnRH-a:136|GnRHa:97|GnRH-A:13|GnRHA:4|Gn-RHa:4|GNRHa:1	gonadotropin-releasing hormone agonist:158:0.4559|gonadotropin releasing hormone agonist:48:0.6493|gonadotropin-releasing hormone agonists:44:0.4084|gonadotropin-releasing hormone-agonist:5:0.0902	0.6493	255
GnRH-a	GnRH-a:14|GnRHa:12|GnRH-A:1	gonadotropin-releasing hormone analog:21:0.6040|gonadotropin-releasing hormone analogs:6:0.1838	0.6040	27
GnRHa	GnRHa:11|GnRH-a:10|GnRHA:1|Gn-RHa:1|GNRHa:1|GN-RH-a:1	gonadotropin-releasing hormone analogue:25:0.2123	0.2123	25
GnRH-ir	GnRH-ir:12|GnRH-IR:4|GnRHir:1	GnRH-immunoreactive:17:0.5333	0.5333	17
GnRHs	GnRHs:12	gonadotropin-releasing hormones:12:0.5050	0.5050	12
GnRH	GnRH:2	frequency LH:2:0.1850	0.1850	2
GnRH	GnRH:19	gonadoliberin:19:0.0042	0.0042	19
GnRH	GnRH:3115|Gn-RH:75|GNRH:11|Gnrh:2|GN-RH:2|GnrH:1|GnRh:1|Gn--RH:1|gnRH:1|Gn-Rh:1	gonadotropin-releasing hormone:2559:0.6012|gonadotropin releasing hormone:612:0.6725|gonadotropin-releasing hormones:13:0.4102|gonadotropin releasing-hormone:13:0.4557|gonadotropin-releasing-hormone:13:0.0028	0.6725	3210
GnSAF	GnSAF:37	gonadotrophin surge-attenuating factor:22:0.7291|gonadotrophin surge attenuating factor:15:0.6386	0.7291	37
GnT-V	GnT-V:21|GnTV:1	N-acetylglucosaminyltransferase V:22:0.5095	0.5095	22
GPA	GPA:11	beta-guanidinopropionic acid:11:0.2764	0.2764	11
GPA	GPA:7	generalized procrustes analysis:7:0.3524	0.3524	7
GPA	GPA:11	Global Program on AIDS:11:0.7357	0.7357	11
GPA	GPA:12	glomerular polyanion:12:0.7571	0.7571	12
GPA	GPA:8|GpA:1	glycophorin-A:9:0.0259	0.0259	9
GPA	GPA:96	grade point average:88:0.9660|grade point averages:8:0.5006	0.9660	96
GPA	GPA:14	growth-promoting activity:8:0.2090|growth promoting activity:6:0.5290	0.5290	14
Gpp(NH)p	Gpp(NH)p:41|GPP(NH)P:2|Gpp(NH)P:1	5'-guanylylimidodiphosphate:44:0.1886	0.1886	44
Gpp(NH)p	Gpp(NH)p:40|GPP(NH)P:1	guanyl-5'-yl imidodiphosphate:41:0.5563	0.5563	41
Gpp(NH)p	Gpp(NH)p:9	guanylyl-imidodiphosphate:9:0.0351	0.0351	9
Gpp(NH)p	Gpp(NH)p:14|Gpp-(NH)p:1	guanylylimidodiphosphate:15:0.0614	0.0614	15
GppNHp	GppNHp:31|GPPNHP:1	5'-guanylylimidodiphosphate:32:0.2138	0.2138	32
GppNHp	GppNHp:7	guanyl-5'-yl imidodiphosphate:7:0.1025	0.1025	7
GppNHp	GppNHp:10	guanylyl-5'-imidodiphosphate:10:0.0621	0.0621	10
GppNHp	GppNHp:15	guanylylimidodiphosphate:15:0.0966	0.0966	15
Gpp[NH]p	Gpp[NH]p:11	5'-guanylylimidodiphosphate:11:0.2778	0.2778	11
GQ	GQ:9	general quotient:9:0.3945	0.3945	9
GQ	GQ:8	Medical School Graduation Questionnaire:8:0.6411	0.6411	8
GrB	GrB:52|grB:6|GRB:1|Gr-B:1	granzyme B:60:0.7559	0.7559	60
GroEL	GroEL:5|groEL:3	Escherichia coli:8:0.5006	0.5006	8
GSTA	GSTA:6	glutathione transferase Alpha:6:0.5290	0.5290	6
GSV	GSV:22	great saphenous vein:22:0.1576	0.1576	22
GSV	GSV:61	greater saphenous vein:61:0.6246	0.6246	61
GTHs	GTHs:7|GtHs:5	gonadotropins:12:0.6111	0.6111	12
GTS	GTS:110	Gilles de la Tourette Syndrome:72:0.9585|Gilles de la Tourette's syndrome:38:0.9217	0.9585	110
GTS	GTS:16	Ginseng total saponin:16:0.8165	0.8165	16
GTs	GTs:5	glutamate transporters:5:0.1132	0.1132	5
GTs	GTs:11	glycosyltransferases:11:0.0398	0.0398	11
GTS	GTS:15	green tobacco sickness:15:0.8045	0.8045	15
G-tube	G-tube:10|g-tube:3	gastrostomy tube:13:0.5934	0.5934	13
GuHCl	GuHCl:124|Gu-HCl:4|GuHCL:1	guanidine hydrochloride:129:0.7649	0.7649	129
GuHCl	GuHCl:16|Gu-HCl:1	guanidinium chloride:17:0.8270	0.8270	17
Guo	Guo:19|GUO:2|guo:1	guanosine:22:0.8750	0.8750	22
GUR	GUR:16	glucose utilization rate:16:0.8165	0.8165	16
GUSB	GUSB:45	beta-glucuronidase:45:0.8627	0.8627	45
GUS	GUS:761|gus:46|Gus:16	beta-Glucuronidase:823:0.7988	0.7988	823
GUS	GUS:7|gus:4	beta-glucuronidase gene:11:0.1486	0.1486	11
GUS	GUS:9|Gus:2|gus:1	beta-glucuronidase reporter gene:12:0.3813	0.3813	12
GUS	GUS:11	glucuronidase:11:0.0097	0.0097	11
GUS	GUS:28	promoter-beta-glucuronidase:28:0.0262	0.0262	28
GVBD	GVBD:8	breakdown of the germinal vesicle:8:0.3945	0.3945	8
GVBD	GVBD:10	germinal vesicle break down:10:0.7103	0.7103	10
GVBD	GVBD:465|Gvbd:1	germinal vesicle breakdown:466:0.9936	0.9936	466
GX	GX:8|Gx:2	gastrectomy:10:0.0682	0.0682	10
GX	GX:6|Gx:2|gx:1	gonadectomized:9:0.0606	0.0606	9
Gx	Gx:8	superior cervical ganglionectomy:8:0.4102	0.4102	8
Gy	Gy:71	grays:71:0.2288	0.2288	71
H&E	H&E:10	haematoxylin-eosin:10:0.0161	0.0161	10
H&E	H&E:289	hematoxylin and eosin:289:0.7058	0.7058	289
H&E	H&E:6	hematoxylin and eosin staining:6:0.2827	0.2827	6
H&E	H&E:21	stained with haematoxylin and eosin:21:0.1756	0.1756	21
H&N	H&N:53	head and neck:53:0.9116	0.9116	53
H&RS	H&RS:12	Hodgkin and Reed-Sternberg:12:0.5050	0.5050	12
H&Y	H&Y:18	Hoehn and Yahr:18:0.8365	0.8365	18
H(+)-PPase	H(+)-PPase:12	pyrophosphatase:12:0.5789	0.5789	12
H(2)O(2)	H(2)O(2):639	hydrogen peroxide:639:0.9853	0.9853	639
H(2)S	H(2)S:41	hydrogen sulfide:41:0.8867	0.8867	41
h(2)	h(2):15	heritability:15:0.2917	0.2917	15
H(4)B	H(4)B:11	tetrahydrobiopterin:11:0.4348	0.4348	11
H(II)	H(II):27	hexagonal:27:0.7027	0.7027	27
H(E)	H(E):6|H(e):4	expected heterozygosity:10:0.5856	0.5856	10
H-FABPc	H-FABPc:11	fatty acid-binding protein:11:0.7357	0.7357	11
H-LAI	H-LAI:11	Humoral leukocyte adherence inhibition:11:0.5355	0.5355	11
H.D.	H.D.:11	Hodgkin's disease:11:0.3495	0.3495	11
H.E.L.P.	H.E.L.P.:12	precipitation:12:0.7333	0.7333	12
H.p.	H.p.:24|H.P.:6	Helicobacter pylori:30:0.7652	0.7652	30
H.R.	H.R.:8|h.r.:1	heart rate:9:0.4587	0.4587	9
H/A	H/A:12	height/age:12:0.2037	0.2037	12
H/D	H/D:75	hydrogen/deuterium:66:0.7065|hydrogen-deuterium:9:0.0870	0.7065	75
H/L	H/L:19	heterophil/lymphocyte:19:0.2466	0.2466	19
H/L	H/L:15	ratio:15:0.1918	0.1918	15
H/M	H/M:12	heart/mediastinum:12:0.0859	0.0859	12
H/M	H/M:34	heart-to-mediastinum:19:0.1406|heart to mediastinum:15:0.6903	0.6903	34
H/M	H/M:48	ratio:48:0.3672	0.3672	48
H/RS	H/RS:11	Hodgkin and Reed-Sternberg:11:0.5355	0.5355	11
H/RS	H/RS:13|H/R-S:2	Hodgkin/Reed-Sternberg:15:0.4242	0.4242	15
H/S	H/S:14	helper/suppressor:14:0.4194	0.4194	14
H/W	H/W:12	Han/Wistar:12:0.5000	0.5000	12
H-12	H-12:9	heterokaryon 12:9:0.2102	0.2102	9
H-12	H-12:8	two-component heterokaryon:8:0.4102	0.4102	8
H1K	H1K:9	Histone H1 kinase:9:0.5470	0.5470	9
H1N1	H1N1:6	influenza A/California/10/78:6:0.1838	0.1838	6
H1R	H1R:10|H1-R:1	histamine H1 receptor:11:0.4728	0.4728	11
H1	H1:11	histamine-1:11:0.0173	0.0173	11
H1	H1:14|H-1:1	histone:15:0.0225	0.0225	15
H1	H1:11	Histone 1:11:0.0869	0.0869	11
H-1	H-1:5|H1:4	proton:9:0.0138	0.0138	9
H-2(b)	H-2(b):11|H2(b):1	C57BL/6 mice:12:0.3524	0.3524	12
H202	H202:12	hydrogen peroxide:12:0.7571	0.7571	12
H2CB	H2CB:9	dihydrocytochalasin B:9:0.4587	0.4587	9
H2CO	H2CO:10	formaldehyde:10:0.8182	0.8182	10
H2O2	H2O2:2205	hydrogen peroxide:2205:0.9875	0.9875	2205
H2O2	H2O2:13	oxidative stress:13:0.6701	0.6701	13
H2RA	H2RA:57|H2-RA:13	H2-receptor antagonists:26:0.3203|H2-receptor antagonist:18:0.2687|H2 receptor antagonists:16:0.4536|H2 receptor antagonist:10:0.2643	0.4536	70
H2R	H2R:9|H2r:1	Histamine H2 receptor:10:0.4363	0.4363	10
H2S	H2S:140	hydrogen sulfide:140:0.9444	0.9444	140
H2S	H2S:32	hydrogen sulphide:32:0.8563	0.8563	32
H-2	H-2:9	antigens:9:0.0082	0.0082	9
H2	H2:64	Breath hydrogen:64:0.2840	0.2840	64
H-2	H-2:13	class I:13:0.7753	0.7753	13
h2	h2:11|h-2:1	genetic:12:0.0113	0.0113	12
h2	h2:143|H2:4	heritability:113:0.1155|heritabilities:34:0.0340	0.1155	147
H2	H2:54	Histamine:54:0.0546	0.0546	54
H2	H2:14|H-2:3	histamine-2:17:0.0165	0.0165	17
H2	H2:22	histamine type 2:22:0.6934	0.6934	22
H2	H2:9	histamine2:9:0.0082	0.0082	9
H-2	H-2:12	histocompatibility-2:12:0.0113	0.0113	12
H2	H2:12	hydrogen gas:12:0.7571	0.7571	12
H-2	H-2:22	major histocompatibility:22:0.3457	0.3457	22
H-2	H-2:58|H2:4	major histocompatibility complex:62:0.9003	0.9003	62
H-2	H-2:10	mouse:10:0.0093	0.0093	10
H3-K9	H3-K9:7|H3K9:4	Histone H3 lysine 9:11:0.6386	0.6386	11
H3PO4	H3PO4:18	phosphoric acid:18:0.6903	0.6903	18
H3R	H3R:8	H3 receptor:8:0.4102	0.4102	8
H3	H3:12	heavy chain:12:0.6460	0.6460	12
H3	H3:9	histone:9:0.0311	0.0311	9
H3	H3:9	histone 3:9:0.0866	0.0866	9
H3	H3:14	histone H3:14:0.7909	0.7909	14
H4-II-E	H4-II-E:12	cloned rat hepatoma cells:12:0.3813	0.3813	12
H4MPT	H4MPT:9|H4MPt:1	tetrahydromethanopterin:10:0.7500	0.7500	10
H5N1	H5N1:12	A/Hong Kong/156/97:12:0.7571	0.7571	12
H5	H5:5	Histone 5:5:0.0736	0.0736	5
H-7	H-7:5|H7:3	1-(5-Isoquinoline sulfonyl)-2-methylpiperazine:8:0.5006	0.5006	8
H-7	H-7:8|H7:2	1-(5-isoquinolinesulphonyl)-2-methylpiperazine:10:0.0150	0.0150	10
H-7	H-7:13|H7:1	1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine:14:0.0195	0.0195	14
H-7	H-7:9|H7:3	1-(5-isoquinolinylsulfonyl)-2-methyl-piperazine:12:0.0165	0.0165	12
H7	H7:9|H-7:9	protein kinase C inhibitor:18:0.8365	0.8365	18
H-7	H-7:4|H7:2	protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine:6:0.7357	0.7357	6
H7	H7:2|H-7:1	protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride:3:0.6411	0.6411	3
H-7	H-7:5|H7:3	protein kinase inhibitor:8:0.3463	0.3463	8
H7	H7:3|H-7:1	protein kinase inhibitor 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine:4:0.3170	0.3170	4
H-89	H-89:6|H89:3	hydrochloride:9:0.0488	0.0488	9
H-89	H-89:11|H89:5	N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide:16:0.0915	0.0915	16
H-8	H-8:15|H8:1	N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide:16:0.1260	0.1260	16
HA/TCP	HA/TCP:9	hydroxyapatite/tricalcium phosphate:9:0.3455	0.3455	9
HA1004	HA1004:14|HA-1004:5	N-(2-guanidinoethyl)-5-isoquinolinesulfonamide:19:0.3958	0.3958	19
HA1	HA1:9	heavy chain:9:0.3455	0.3455	9
HA-966	HA-966:14	1-hydroxy-3-amino-pyrrolidone-2:14:0.2203	0.2203	14
HAAF	HAAF:11	hypoglycemia-associated autonomic failure:11:0.6182	0.6182	11
HAART	HAART:2428	Highly active antiretroviral therapy:2387:0.9885|Highly active antiretroviral therapies:41:0.9274	0.9885	2428
HAART	HAART:89	highly active antiretroviral treatment:89:0.9664	0.9664	89
HAAs	HAAs:39	heterocyclic aromatic amines:39:0.9237	0.9237	39
HAA	HAA:8	haloacetic acid:8:0.1367	0.1367	8
HAA	HAA:9	heterocyclic aromatic amines:9:0.6794	0.6794	9
HAA	HAA:11	Hospital Activity Analysis:11:0.6182	0.6182	11
HABF	HABF:14	hepatic arterial blood flow:14:0.7909	0.7909	14
HABPs	HABPs:13	high activity binding peptides:13:0.7753	0.7753	13
HABR	HABR:7	hepatic arterial buffer response:7:0.5926	0.5926	7
HABR	HABR:6	hyaluronic acid-binding region:6:0.5290	0.5290	6
HAB	HAB:4	bred for high:4:0.2619	0.2619	4
HACCP	HACCP:71	Hazard Analysis Critical Control Point:58:0.9735|hazard analysis critical control points:13:0.9174	0.9735	71
HACE	HACE:8	hepatic arterial chemoembolization:8:0.6411	0.6411	8
HACE	HACE:7	hepatic artery chemoembolization:7:0.5926	0.5926	7
HACE	HACE:22	High-altitude cerebral edema:13:0.3058|high altitude cerebral edema:9:0.6794	0.6794	22
HACs	HACs:12	human artificial chromosomes:12:0.7571	0.7571	12
HACU	HACU:73	high-affinity choline uptake:48:0.5232|high affinity choline uptake:25:0.8816	0.8816	73
HAChT	HAChT:11	choline transport:11:0.6182	0.6182	11
HAChU	HAChU:9|HA-ChU:1	choline uptake:10:0.7103	0.7103	10
HAc	HAc:17|HAC:1|Hac:1	acetic acid:19:0.7044	0.7044	19
HAC	HAC:5	hepatic arterial chemotherapy:5:0.4422	0.4422	5
HAC	HAC:6	hepatic artery chemotherapy:6:0.5290	0.5290	6
HAC	HAC:10	human articular chondrocytes:10:0.7103	0.7103	10
HAC	HAC:24	hydroxyapatite cement:24:0.8038	0.8038	24
HAC	HAC:9	hyperadrenocorticism:9:0.0390	0.0390	9
HADH	HADH:33	dehydrogenase:33:0.7442	0.7442	33
HADS-D	HADS-D:11	Hospital Anxiety and Depression Scale:11:0.7357	0.7357	11
HADS	HADS:284	Hospital Anxiety and Depression Scale:284:0.9898	0.9898	284
HAD	HAD:15	3-hydroxyacyl-CoA dehydrogenase:15:0.1430	0.1430	15
HAD	HAD:15	haloacid dehalogenase:15:0.5818	0.5818	15
HAD	HAd:6|HAD:6|Had:1	hemadsorption:13:0.0199	0.0199	13
HAD	HAD:40	high-alcohol-drinking:28:0.0431|High alcohol drinking:12:0.7571	0.7571	40
HAD	HAD:36	HIV-1-associated dementia:36:0.2294	0.2294	36
HAD	HAD:46	HIV-associated dementia:46:0.3066	0.3066	46
HAD	HAD:126	hospital anxiety and depression:126:0.9416	0.9416	126
HAD	HAD:110	Hospital Anxiety and Depression Scale:110:0.9742	0.9742	110
HAECs	HAECs:97|hAECs:1	human aortic endothelial cells:98:0.9515	0.9515	98
HAEC	HAEC:13	human airway epithelial cells:13:0.7753	0.7753	13
HAEC	HAEC:14|hAEC:1	human amniotic epithelial cells:15:0.8045	0.8045	15
HAEC	HAEC:91|hAEC:1	human aortic endothelial cells:81:0.9415|Human aortic endothelial cell:11:0.4232	0.9415	92
HAES	HAES:10	hydroxyethyl starch:10:0.7103	0.7103	10
HAE	HAE:10	hepatic arterial embolization:10:0.7103	0.7103	10
HAE	HAE:20	hepatic artery embolization:20:0.7766	0.7766	20
HAE	HAE:10	hereditary angio-oedema:10:0.7103	0.7103	10
HAE	HAE:111	Hereditary angioedema:111:0.9733	0.9733	111
HAE	HAE:12	hereditary angioneurotic edema:12:0.7571	0.7571	12
HAE	HAE:12	Human amniotic epithelial:12:0.7571	0.7571	12
HAFP	HAFP:11|hAFP:7|h-AFP:1	human alpha-fetoprotein:19:0.7539	0.7539	19
HAF	HAF:8	hepatic arterial blood flow:8:0.6411	0.6411	8
HAF	HAF:9	hepatic arterial flow:9:0.6794	0.6794	9
HAF	HAF:13|hAF:1	human amniotic fluid:14:0.7909	0.7909	14
h-AF	h-AF:4|HAF:2	human angiogenic factor:6:0.3728	0.3728	6
HAGU	HAGU:5	high affinity glutamate uptake:5:0.4422	0.4422	5
HAG	HAG:7	heat-aggregated IgG:7:0.2902	0.2902	7
HAHs	HAHs:27	halogenated aromatic hydrocarbons:27:0.8941	0.8941	27
HAI-1	HAI-1:13	hepatocyte growth factor activator inhibitor type 1:13:0.7753	0.7753	13
HAI-2	HAI-2:7	Hepatocyte growth factor activator inhibitor type 2:7:0.5926	0.5926	7
HAIC	HAIC:33	hepatic arterial infusion chemotherapy:33:0.9072	0.9072	33
HAIs	HAIs:22	infections:22:0.8077	0.8077	22
HAIgG	HAIgG:10|HA-IgG:3	heat-aggregated IgG:13:0.4444	0.4444	13
HAI	HAI:5|hai:4	h after inoculation:9:0.3455	0.3455	9
HAI	HAI:49	haemagglutination inhibition:32:0.1501|Haemagglutination-inhibition:17:0.0196	0.1501	49
HAI	HAI:129|HA-I:1	hemagglutination inhibition:99:0.6175|hemagglutination-inhibition:31:0.0368	0.6175	130
HAI	HAI:132	hepatic arterial infusion:132:0.9521	0.9521	132
HAI	HAI:23	hepatic arterial infusion chemotherapy:23:0.8038	0.8038	23
HAI	HAI:55	hepatic artery infusion:55:0.9458	0.9458	55
HAI	HAI:75	Histological Activity Index:75:0.4625	0.4625	75
HAI	HAI:59	hospital-acquired infections:21:0.4194|hospital-acquired infection:19:0.3333|Hospital acquired infections:10:0.5856|hospital acquired infection:9:0.6794	0.6794	59
HAI	HAI:9	inhibition assay:9:0.4587	0.4587	9
HAI	HAI:12	inhibition test:12:0.4557	0.4557	12
HAI	HAI:8	Titers of hemagglutination-inhibiting:8:0.0698	0.0698	8
HALP	HALP:14	hyperalphalipoproteinemia:14:0.6500	0.6500	14
HALSS	HALSS:10	hybrid artificial liver support system:10:0.7103	0.7103	10
HALS	HALS:42	Hand-assisted laparoscopic surgery:42:0.8224	0.8224	42
HAM/TSP	HAM/TSP:11	HTLV-1 associated myelopathy/tropical spastic paraparesis:11:0.1091	0.1091	11
HAM/TSP	HAM/TSP:13	HTLV-I-associated myelopathy:13:0.1824	0.1824	13
HAM/TSP	HAM/TSP:133	HTLV-I-associated myelopathy/tropical spastic paraparesis:98:0.3181|HTLV-I associated myelopathy/tropical spastic paraparesis:35:0.5384	0.5384	133
HAM/TSP	HAM/TSP:9	human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis:9:0.6794	0.6794	9
HAM/TSP	HAM/TSP:16	human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis:16:0.8045	0.8045	16
HAM-A	HAM-A:26|HAMA:4|Ham-A:2	Hamilton anxiety rating scale:32:0.9072	0.9072	32
HAM-A	HAM-A:23|HAMA:21	Hamilton Anxiety Scale:44:0.8941	0.8941	44
HAM-A	HAM-A:56|HAMA:3|Ham-A:1	Hamilton rating scale for anxiety:60:0.8971	0.8971	60
HAMA	HAMA:89	Human anti-mouse antibody:48:0.8728|human anti-mouse antibodies:41:0.8525	0.8728	89
HAMA	HAMA:31	Human antimouse antibody:31:0.9043	0.9043	31
HAM-D-17	HAM-D-17:31|HAM-D17:4|HAMD17:2|Ham-D-17:2|HAMD-17:1	17-item Hamilton Rating Scale for Depression:40:0.6998	0.6998	40
HAMD-17	HAMD-17:7|HAM-D-17:4|HAM-D17:2|HAMD17:1	Hamilton Depression Rating Scale:14:0.7909	0.7909	14
HAM-D-21	HAM-D-21:7|HAM-D21:3|HAMD21:1|HAMD-21:1	21-item Hamilton Rating Scale for Depression:12:0.4557	0.4557	12
HAM-D	HAM-D:82|HAMD:41|Ham-D:15	Hamilton Depression Rating Scale:138:0.9541	0.9541	138
HAMD	HAMD:33|HAM-D:30|Ham-D:3|HamD:1	Hamilton Depression Scale:67:0.9554	0.9554	67
HAM-D	HAM-D:258|HAMD:26|Ham-D:13|HamD:2	Hamilton Rating Scale for Depression:299:0.9560	0.9560	299
HANE	HANE:41	hereditary angioneurotic edema:41:0.9256	0.9256	41
HANES	HANES:12	Health and Nutrition Examination Survey:12:0.7571	0.7571	12
HAN	HAN:10	High Altitude Natives:5:0.4422|high-altitude natives:5:0.0902	0.4422	10
HAN	HAN:53	Hyperplastic alveolar nodules:29:0.8978|hyperplastic alveolar nodule:24:0.8115	0.8978	53
HAO	HAO:28|hao:1	hydroxylamine oxidoreductase:29:0.8422	0.8422	29
HAP1	HAP1:6|HAP-1:2	huntingtin-associated protein:8:0.2902	0.2902	8
HAP1	HAP1:10|Hap1:2|HAP-1:1	Huntingtin-associated protein 1:13:0.5335	0.5335	13
HAPA-B	HAPA-B:16	isepamicin sulfate:16:0.8165	0.8165	16
HAPCs	HAPCs:8	high-amplitude propagated contractions:8:0.6411	0.6411	8
HAPE	HAPE:68	high altitude pulmonary edema:54:0.9448|high-altitude pulmonary oedema:7:0.1641|high altitude pulmonary oedema:7:0.5926	0.9448	68
HAPs	HAPs:21|HAPS:1	Hazardous Air Pollutants:22:0.8657	0.8657	22
HAPS	HAPS:5	Hepatic arterial perfusion scintigraphy:5:0.4422	0.4422	5
HAP	HAP:5	base analog 6-N-hydroxylaminopurine:5:0.5290	0.5290	5
HAP	HAP:12	hepatic arterial phase:12:0.7571	0.7571	12
HAP	HAP:33	hospital-acquired pneumonia:33:0.7238	0.7238	33
HAP	HAP:11	Human Activity Profile:11:0.7357	0.7357	11
HAP	HAP:293|HAp:97|Hap:6|HA-P:1	hydroxyapatite:397:0.5395	0.5395	397
HAP	HAP:28|HAp:1	hydroxylapatite:29:0.0395	0.0395	29
HAP	HAP:12	hyperthermic antiblastic perfusion:12:0.7571	0.7571	12
HAQ	HAQ:378	Health Assessment Questionnaire:378:0.9921	0.9921	378
HAQ-DI	HAQ-DI:5|HAQDI:2	Health Assessment Questionnaire disability index:7:0.4438	0.4438	7
HARP	HARP:12	harmonic phase:12:0.7571	0.7571	12
HARP	HARP:22	heparin affin regulatory peptide:22:0.8657	0.8657	22
HARS	HARS:33	Hamilton Anxiety Rating Scale:33:0.8605	0.8605	33
HART	HART:7	Hyperfractionated accelerated radiotherapy:7:0.6794	0.6794	7
hAR	hAR:65	human androgen receptor:65:0.9047	0.9047	65
HAR	HAR:107	hyperacute rejection:107:0.8820	0.8820	107
HAS2	HAS2:7|Has2:6|HAS-2:2|has2:2	hyaluronan synthase 2:17:0.4742	0.4742	17
HASMCs	HASMCs:19|hASMCs:5|haSMCs:4	human aortic smooth muscle cells:28:0.8941	0.8941	28
HASM	HASM:51|hASM:1	human airway smooth muscle:52:0.8572	0.8572	52
HASTE	HASTE:44	half-Fourier acquisition single-shot turbo spin-echo:37:0.9217|half-fourier acquisition single-shot turbo-spin-echo:7:0.5926	0.9217	44
HASTE	HASTE:27	turbo spin echo:27:0.8312	0.8312	27
HAS	HAS:16	HA synthase:16:0.1525	0.1525	16
HAs	HAs:15	haemagglutinins:15:0.0282	0.0282	15
HAS	HAS:22	Hamilton Anxiety Scale:22:0.8657	0.8657	22
HAs	HAs:13	health authorities:13:0.7753	0.7753	13
HAs	HAs:11	hearing aids:11:0.7357	0.7357	11
HAs	HAs:20	hemagglutinins:20:0.0383	0.0383	20
HAs	HAs:47	heterocyclic amines:47:0.6183	0.6183	47
HAs	HAs:14	Heterocyclic aromatic amines:14:0.7909	0.7909	14
HAS	HAS:13	high alcohol sensitivity:13:0.7753	0.7753	13
HAS	HAS:8	human albumin solution:8:0.6411	0.6411	8
HAs	HAs:28	humic acids:28:0.6554	0.6554	28
HAS	HAS:37|has:3	hyaluronan synthase:40:0.5268	0.5268	40
HAs	HAs:11	hydrophobic agents:11:0.6182	0.6182	11
HATT	HATT:4	Heparin-associated thrombocytopenia with thrombosis:4:0.7357	0.7357	4
HATs	HATs:131	histone acetyltransferases:131:0.9305	0.9305	131
HATS	HATS:5	transport system:5:0.1132	0.1132	5
HAT	HAT:11	after treatment:11:0.6701	0.6701	11
HAT	HAT:7	handgrip-apexcardiographic test:7:0.0777	0.0777	7
HAT	HAT:26	heparin-associated thrombocytopenia:26:0.6873	0.6873	26
HAT	HAT:80	hepatic artery thrombosis:80:0.9408	0.9408	80
HAT	HAT:12	histone acetyl transferase:12:0.7571	0.7571	12
HAT	HAT:201	histone acetyltransferase:191:0.9666|histone acetyltransferases:10:0.7103	0.9666	201
HAT	HAT:81	human African trypanosomiasis:81:0.9631	0.9631	81
HAT	HAT:9	humanized anti-Tac:9:0.4587	0.4587	9
HAT	HAT:10	hydrogen atom transfer:10:0.7103	0.7103	10
HAT	HAT:37	hypoxanthine-aminopterin-thymidine:23:0.0331|hypoxanthine/aminopterin/thymidine:12:0.0166|hypoxanthine aminopterin thymidine:2:0.8045	0.8045	37
HAU	HAU:4	HTLV-I associated uveitis:4:0.3524	0.3524	4
HAVS	HAVS:44	hand-arm vibration syndrome:44:0.8620	0.8620	44
HAV	HAV:1133	hepatitis A virus:1133:0.9580	0.9580	1133
HazMat	HAZMAT:7|HazMat:7|hazmat:5	hazardous materials:19:0.8449	0.8449	19
HAZ	HAZ:22|haz:1|HAz:1	height-for-age:15:0.1972|height for age:9:0.6794	0.6794	24
HAZ	HAZ:17	Height-for-age Z-scores:9:0.3945|height-for-age z-score:8:0.5006	0.5006	17
HAase	HAase:22	hyaluronidase:22:0.8750	0.8750	22
HABs	HABs:13	harmful algal blooms:13:0.7753	0.7753	13
HAd5	HAd5:8|hAd5:2	human adenovirus type 5:10:0.6182	0.6182	10
HaH	HaH:4|HAH:3	Hospital at Home:7:0.3524	0.3524	7
HAstV	HAstV:12	human astrovirus:12:0.7571	0.7571	12
Ha	Ha:11|HA:1	anterior:12:0.0014	0.0014	12
HA	HA:17	antibody:17:0.0021	0.0021	17
HA	HA:9	habitual abortion:9:0.2757	0.2757	9
HA	HA:20	haemagglutinating:20:0.0025	0.0025	20
HA	HA:92	haemagglutination:92:0.0118	0.0118	92
Ha	Ha:12	Harvey:12:0.0014	0.0014	12
HA	HA:15	head activator:15:0.8045	0.8045	15
HA	HA:17	headache:17:0.0021	0.0021	17
HA	HA:9	Health Authority:9:0.4587	0.4587	9
HA	HA:23	hearing aid:23:0.8715	0.8715	23
HA	HA:6	heart area:6:0.1010	0.1010	6
HA	HA:8	heat acclimation:8:0.4102	0.4102	8
HA	HA:5	height age:5:0.5664	0.5664	5
HA	HA:60	hemagglutinating:60:0.0076	0.0076	60
HA	HA:205	hemagglutination:205:0.0264	0.0264	205
HA	HA:9	hemagglutination activity:9:0.0674	0.0674	9
HA	HA:10	hemagglutination assay:10:0.3867	0.3867	10
HA	HA:5	hemagglutination test:5:0.0736	0.0736	5
HA	HA:24	hemagglutinins:24:0.0030	0.0030	24
HA	HA:10	hemagglutinin glycoprotein:10:0.3867	0.3867	10
HA	HA:8	hemagglutinin protein:8:0.4102	0.4102	8
HA	HA:11	hemolytic anemia:11:0.4728	0.4728	11
HA	HA:17	Hepatic Adenoma:11:0.2582|hepatic adenomas:6:0.2243	0.2582	17
HA	HA:22	hepatic arterial:22:0.8657	0.8657	22
HA	HA:78	hepatic artery:78:0.8862	0.8862	78
HA	HA:7	hepatocellular adenoma:7:0.0886	0.0886	7
HA	HA:10	heterocyclic amines:10:0.3867	0.3867	10
HA	HA:30	heteroduplex analysis:30:0.8032	0.8032	30
HA	HA:25	high-affinity:14:0.0017|high affinity:11:0.7357	0.7357	25
HA	HA:111	high altitude:91:0.9158|high-altitude:20:0.0025	0.9158	111
HA	HA:31	hippocampal atrophy:31:0.8519	0.8519	31
HA	HA:301|Ha:1	histamine:302:0.0389	0.0389	302
HA	HA:22	human albumin:22:0.5863	0.5863	22
HA	HA:41	humic acids:41:0.7258	0.7258	41
HA	HA:733	hyaluronan:733:0.0946	0.0946	733
HA	HA:1091	hyaluronic acid:1091:0.8138	0.8138	1091
HA	HA:7	hydrocortisone acetate:7:0.3524	0.3524	7
HA	HA:6	hydropic abortion:6:0.0899	0.0899	6
HA	HA:1215|Ha:3	hydroxyapatite:1218:0.1572	0.1572	1218
HA	HA:16	hydroxyapatite-coated:16:0.0019	0.0019	16
HA	HA:47	hydroxylamine:47:0.0059	0.0059	47
HA	HA:139	hydroxylapatite:139:0.0177	0.0177	139
HA	HA:13	hyperandrogenism:13:0.0016	0.0016	13
HA	HA:26	hyperstriatum accessorium:26:0.8251	0.8251	26
HA	HA:24	hypothalamic amenorrhea:24:0.8115	0.8115	24
HA	HA:2	influenza A hemagglutinin:2:0.0846	0.0846	2
HA	HA:6	influenza A virus haemagglutinin:6:0.5376	0.5376	6
HA	HA:182	influenza virus hemagglutinin:182:0.8432	0.8432	182
HA	HA:5	lines of chickens selected for high:5:0.1464	0.1464	5
HA	HA:1	lines selected for either a high:1:0.1680	0.1680	1
HA	HA:9	mice selectively bred for high:9:0.4587	0.4587	9
HA	HA:4	minor histocompatibility antigen:4:0.1618	0.1618	4
HA	HA:36	sodium hyaluronate:36:0.1534	0.1534	36
HA	HA:8	sperm hyperactivation:8:0.2090	0.2090	8
HBAg	HBAg:40|HB-Ag:4|HbAg:1	Hepatitis B antigen:45:0.9338	0.9338	45
HbAlc	HbAlc:5|HBAlc:1	glycosylated haemoglobin:6:0.1838	0.1838	6
HbAlc	HbAlc:12|HbAlC:3|Hbalc:1|Hb-Alc:1	Glycosylated hemoglobin:17:0.8270	0.8270	17
HbAlc	HbAlc:10	hemoglobin Alc:10:0.4363	0.4363	10
HBB	HBB:11	hexabromobenzene:11:0.0909	0.0909	11
HBCD	HBCD:24	hexabromocyclododecane:24:0.6970	0.6970	24
HBDC	HBDC:12	human bone-derived cells:12:0.7571	0.7571	12
HBDH	HBDH:55|HbDH:1|Hbdh:1	dehydrogenase:57:0.9048	0.9048	57
HBDT	HBDT:30	human basophil degranulation test:30:0.8472	0.8472	30
HBDs	HBDs:5	healthy blood donors:5:0.1973	0.1973	5
HBDs	HBDs:9	heart-beating donors:9:0.2285	0.2285	9
hBDs	hBDs:9|HBDs:6	Human beta-defensins:15:0.7096	0.7096	15
HBD	HBD:21	alpha-hydroxybutyrate dehydrogenase:21:0.2614	0.2614	21
HBD	HBD:7	healthy blood donors:7:0.4438	0.4438	7
HBD	HBD:7	heart-beating donor:7:0.1025	0.1025	7
HBD	HBD:18	heparin-binding domain:18:0.1245	0.1245	18
HBD	HBD:48	hormone binding domain:26:0.5616|hormone-binding domain:22:0.1688	0.5616	48
hBD	hBD:11|HBD:3	Human beta-defensins:14:0.7909	0.7909	14
HBD	HBD:13	hydroxybutyrate dehydrogenase:13:0.1192	0.1192	13
HBECs	HBECs:36	human bronchial epithelial cells:36:0.8336	0.8336	36
HBEC	HBEC:26	human breast epithelial cells:26:0.8861	0.8861	26
HBEC	HBEC:37	human bronchial epithelial cells:32:0.8519|human bronchial epithelial cell:5:0.4422	0.8519	37
HB-EGF	HB-EGF:22	heparin-binding EGF:22:0.6531	0.6531	22
HB-EGF	HB-EGF:167	heparin-binding epidermal growth factor-like growth factor:167:0.9016	0.9016	167
HB-GAM	HB-GAM:30|HBGAM:1	heparin-binding growth-associated molecule:31:0.6656	0.6656	31
HBGF	HBGF:21	growth factors:21:0.8594	0.8594	21
HBGF	HBGF:14	heparin-binding growth factor:14:0.6173	0.6173	14
HBGF-1	HBGF-1:9	growth factor 1:9:0.6794	0.6794	9
HBGF-1	HBGF-1:8	Heparin-binding growth factor-1:8:0.4102	0.4102	8
HBGFs	HBGFs:18	heparin-binding growth factors:18:0.5560	0.5560	18
HBGM	HBGM:11	home blood glucose monitoring:11:0.7357	0.7357	11
HBHA	HBHA:8|HbhA:1	heparin-binding hemagglutinin:9:0.6794	0.6794	9
HBHC	HBHC:10	hospital-based home care:10:0.7103	0.7103	10
HBIG	HBIG:86|HBIg:22	hepatitis B immune globulin:108:0.9555	0.9555	108
HBIG	HBIG:49|HBIg:35	Hepatitis B immunoglobulin:84:0.9255	0.9255	84
HBIG	HBIG:6|HBIg:5	immunoglobulins:11:0.0402	0.0402	11
HBI	HBI:18	half-body irradiation:18:0.2191	0.2191	18
HBI	HBI:22	hemibody irradiation:22:0.2739	0.2739	22
HBI	HBI:12	human blood index:12:0.7571	0.7571	12
HBK	HBK:12	arbekacin:12:0.5238	0.5238	12
HBLV	HBLV:9	human B-lymphotropic virus:9:0.6411	0.6411	9
HBL	HBL:13	Hemolysin BL:13:0.4444	0.4444	13
HBL	HBL:9	hepatoblastoma:9:0.0825	0.0825	9
HBL	HBL:10	hexagonal bilayer:10:0.7103	0.7103	10
HBL	HBL:10	hypobetalipoproteinemia:10:0.0928	0.0928	10
HBMECs	HBMECs:12	human brain microvascular endothelial cells:12:0.7571	0.7571	12
HBMEC	HBMEC:41	human brain microvascular endothelial cells:41:0.9274	0.9274	41
HBMSC	HBMSC:9|hBMSC:4	human bone marrow stromal cells:13:0.7753	0.7753	13
HBMS	HBMS:8|hBMS:3	human bone marrow stromal:11:0.6182	0.6182	11
HBM	HBM:134	Health Belief Model:134:0.9777	0.9777	134
HBOCs	HBOCs:26	hemoglobin-based oxygen carriers:26:0.6084	0.6084	26
HBOT	HBOT:38	hyperbaric oxygen therapy:38:0.9217	0.9217	38
HBOT	HBOT:10	hyperbaric oxygen treatment:10:0.7103	0.7103	10
HBO	HBO:503|HbO:1	hyperbaric oxygen:504:0.9759	0.9759	504
HBO	HBO:80	Hyperbaric oxygen therapy:80:0.9622	0.9622	80
HBO	HBO:13	hyperbaric oxygen treatment:13:0.7753	0.7753	13
HBO	HBO:216	hyperbaric oxygenation:216:0.9862	0.9862	216
HBP	HBP:8	7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch:8:0.5006	0.5006	8
HBP	HBP:19	hepatic binding protein:19:0.3582	0.3582	19
HBP	HBP:17	hexosamine biosynthesis pathway:17:0.8270	0.8270	17
HBP	HBP:7	hexosamine biosynthetic pathway:7:0.5926	0.5926	7
HBP	HBP:82	high blood pressure:82:0.7140	0.7140	82
HBP	HBP:16	hydrocortisone 17-butyrate 21-propionate:16:0.7261	0.7261	16
HBP	HBP:26	Hypertension:26:0.0694	0.0694	26
HBsAb	HBsAb:22|HBs-Ab:3|HbsAb:1	hepatitis B surface antibody:26:0.8861	0.8861	26
HBsAb	HBsAb:9|HbsAb:1	hepatitis B surface antigen:10:0.7103	0.7103	10
HBT	HBT:10	homologous blood transfusion:10:0.5856	0.5856	10
HbT	HbT:11|HBT:2|Hbt:1	total hemoglobin:14:0.7909	0.7909	14
HBV-DNA	HBV-DNA:9|HBVDNA:1	hepatitis B virus deoxyribonucleic acid:10:0.7103	0.7103	10
HBV-DNA	HBV-DNA:27	hepatitis B virus DNA:27:0.8903	0.8903	27
HBV	HBV:328	hepatitis B:328:0.8535	0.8535	328
HBV	HBV:9	hepatitis B infection:9:0.6794	0.6794	9
HBV	HBV:16	hepatitis B vaccine:16:0.8165	0.8165	16
HBV	HBV:52	hepatitis B viral:52:0.9427	0.9427	52
HBV	HBV:7253|Hbv:1|HBv:1|hbv:1	hepatitis B virus:7236:0.9864|Hepatitis-B-virus:12:0.0014|hepatitis B viruses:8:0.5006	0.9864	7256
HBV	HBV:25	hepatitis B virus infection:25:0.8816	0.8816	25
HBV	HBV:10	honey bee venom:10:0.7103	0.7103	10
HBV	HBV:8	honeybee venom:8:0.1367	0.1367	8
HBcAb	HBcAb:18|HBcAB:2|HbcAb:1|HBc-Ab:1	hepatitis B core antibody:22:0.8657	0.8657	22
HBcAb	HBcAb:10	hepatitis B core antigen:10:0.7103	0.7103	10
HBcAg	HBcAg:11	hepatitis B virus:11:0.7357	0.7357	11
HBc	HBc:10	core protein:10:0.5000	0.5000	10
HbC	HbC:6	haemoglobin C:6:0.0666	0.0666	6
HbC	HbC:9|Hb-C:1	hemoglobin C:10:0.2643	0.2643	10
HBc	HBc:31	hepatitis B core:31:0.6820	0.6820	31
HBC	HBC:13	Hereditary breast cancer:13:0.1762	0.1762	13
HBC	HBC:23	human breast cancer:23:0.4486	0.4486	23
HBC	HBC:21	human breast carcinoma:21:0.7291	0.7291	21
HBeAb	HBeAb:8|HbeAb:1	hepatitis B e antibody:9:0.4587	0.4587	9
HBeAg	HBeAg:585|HbeAg:4|HBeAG:2	hepatitis B e antigen:568:0.9836|hepatitis B e-antigen:23:0.8657	0.9836	591
HBe	HBe:11	hepatitis B e:11:0.4232	0.4232	11
HBE	HBE:52|hBE:1	human bronchial epithelial:53:0.9116	0.9116	53
HBE	HBE:15	normal human breast epithelial:15:0.8045	0.8045	15
HbR	HbR:11|Hb-R:1	deoxyhemoglobin:12:0.1558	0.1558	12
HBR	HBR:5	Hering-Breuer reflex:5:0.1132	0.1132	5
HBsAg	HBsAg:7	hepatitis B surface:7:0.5926	0.5926	7
HBsAg	HBsAg:22|HbsAg:1	hepatitis B surface Ag:23:0.8715	0.8715	23
HBsAg	HBsAg:2569|HbsAg:39|HBSAg:36|HBsAG:20|HBs-Ag:11|HB-sAg:3|HBSAG:3|Hbsag:1|HBS-Ag:1|HB-SAg:1|HB-s-Ag:1	Hepatitis B surface antigen:2667:0.9857|hepatitis B surface antigens:18:0.8365	0.9857	2685
HBsAg	HBsAg:20|HBSAg:1|HBs-Ag:1	surface antigen of Hepatitis B Virus:22:0.8422	0.8422	22
HBsAg	HBsAg:5	surface protein:5:0.0736	0.0736	5
HBS	HBS:4	balanced salt solution:4:0.1618	0.1618	4
HBS	HBS:10	binding site:10:0.3145	0.3145	10
HBs	HBs:10	hemangioblastomas:10:0.0169	0.0169	10
Hbs	Hbs:61|HBs:1	hemoglobins:62:0.1144	0.1144	62
HbS	HbS:36	hemoglobin S:36:0.6351	0.6351	36
HBs	HBs:47	hepatitis B surface:47:0.6918	0.6918	47
HBs	HBs:12	hepatitis B surface antigen:12:0.4557	0.4557	12
HBS	HBS:16	hepatobiliary scintigraphy:16:0.8165	0.8165	16
HBs	HBs:11	hepatoblastomas:11:0.0188	0.0188	11
HbS	HbS:17|Hbs:1	sickle cell hemoglobin:18:0.6903	0.6903	18
HbS	HbS:9|Hb-S:1	sickle haemoglobin:10:0.3145	0.3145	10
HbS	HbS:34	sickle hemoglobin:34:0.3980	0.3980	34
HBx	HBx:7|HBX:2	hepatitis B virus:9:0.6794	0.6794	9
HBx	HBx:16|HBX:2	hepatitis B virus X:18:0.7539	0.7539	18
HBx	HBx:51|HBX:11	hepatitis B virus X protein:62:0.9241	0.9241	62
HB	HB:13	bodies:13:0.0026	0.0026	13
hb	hb:11	gap gene hunchback:11:0.2868	0.2868	11
Hb	Hb:18|HB:2	habenula:20:0.0041	0.0041	20
Hb	Hb:787|HB:9|hb:1	haemoglobin:797:0.1704	0.1704	797
Hb	Hb:61	haemoglobin concentration:55:0.2921|Haemoglobin concentrations:6:0.1320	0.2921	61
Hb	Hb:16|HB:1	haemoglobin level:10:0.1327|haemoglobin levels:7:0.1211	0.1327	17
HB	HB:9	heart-beating:9:0.0017	0.0017	9
Hb	Hb:2490|HB:39|hb:4	hemoglobin:2502:0.5343|Hemoglobins:31:0.0064	0.5343	2533
Hb	Hb:89|HB:3|hb:1	hemoglobin concentration:88:0.5186|hemoglobin concentrations:5:0.0612	0.5186	93
Hb	Hb:9	hemoglobin content:9:0.2500	0.2500	9
Hb	Hb:27|HB:2	hemoglobin level:20:0.4574|hemoglobin levels:9:0.2285	0.4574	29
HB	HB:263	hepatitis B:263:0.7896	0.7896	263
HB	HB:84	hepatoblastoma:75:0.0158|hepatoblastomas:9:0.0017	0.0158	84
HB	HB:18	hexobarbital:18:0.0036	0.0036	18
HB	HB:21|Hb:3	His bundle:24:0.8768	0.8768	24
HB	HB:5	homologous blood:5:0.0736	0.0736	5
HB	HB:9|H-B:8	House-Brackmann:17:0.0034	0.0034	17
HB	HB:9|H-b:1	hydrogen bond:10:0.7103	0.7103	10
HB	HB:10	hydroxybutyrate:10:0.0019	0.0019	10
HB	HB:30	Hypocrellin B:30:0.0595	0.0595	30
hb	hb:9	segmentation gene hunchback:9:0.1585	0.1585	9
HC21	HC21:17	human chromosome 21:17:0.8270	0.8270	17
HC2	HC2:9|hc2:3|HC-2:1	Hybrid Capture 2:13:0.7753	0.7753	13
HC-3	HC-3:25|HC3:1	Hemicholinium:26:0.1371	0.1371	26
HC-3	HC-3:114|HC3:7|Hc-3:1	Hemicholinium-3:122:0.6142	0.6142	122
HCAECs	HCAECs:53	human coronary artery endothelial cells:53:0.8842	0.8842	53
HCAEC	HCAEC:36|hCAEC:1	human coronary artery endothelial cells:37:0.7758	0.7758	37
HCAII	HCAII:13|hCAII:4|hCA-II:1	human carbonic anhydrase II:18:0.8365	0.8365	18
HCAs	HCAs:9	health care assistants:9:0.6794	0.6794	9
HCAs	HCAs:95	heterocyclic amines:95:0.8683	0.8683	95
HCA	HCA:33	hepatocellular adenoma:23:0.5997|hepatocellular adenomas:10:0.2446	0.5997	33
HCA	HCA:24	heterocyclic amine:13:0.7753|heterocyclic amines:11:0.3213	0.7753	24
HCA	HCA:7	heterocyclic aromatic amines:7:0.5926	0.5926	7
HCA	HCA:28	homocysteic acid:28:0.3561	0.3561	28
hCA	hCA:6|HCA:4	human carbonic anhydrase:10:0.4363	0.4363	10
HCA	HCA:4	Hurthle cell adenomas:4:0.0918	0.0918	4
HCA	HCA:7	hybrid capture assay:7:0.5926	0.5926	7
HCA	HCA:16	hydrocortisone acetate:16:0.8165	0.8165	16
HCA	HCA:36	Hydrophobic Cluster Analysis:36:0.4302	0.4302	36
HCA	HCA:6	hydroxycarbonate apatite:6:0.0899	0.0899	6
HCA	HCA:9	(-)-Hydroxycitric acid:9:0.0504	0.0504	9
HCA	HCA:88	hypothermic circulatory arrest:88:0.9131	0.9131	88
HCBD	HCBD:36	Hexachloro-1,3-butadiene:36:0.4545	0.4545	36
HCBD	HCBD:23	hexachlorobutadiene:23:0.2857	0.2857	23
HCBS	HCBS:22	home and community-based services:13:0.3331|Home- and community-based services:9:0.1585	0.3331	22
HCB	HCB:15	2,2',4,4',5,5'-hexachlorobiphenyl:15:0.0177	0.0177	15
HCB	HCB:12	2,4,5,2',4',5'-hexachlorobiphenyl:12:0.0150	0.0150	12
HCB	HCB:15	3,4,5,3',4',5'-hexachlorobiphenyl:15:0.0190	0.0190	15
HCB	HCB:607|hcb:1	hexachlorobenzene:608:0.8245	0.8245	608
HCCAA	HCCAA:18	Hereditary cystatin C amyloid angiopathy:18:0.8365	0.8365	18
HCCC	HCCC:7	hyalinizing clear cell carcinoma:7:0.5926	0.5926	7
HCCs	HCCs:490	hepatocellular carcinomas:481:0.9667|hepatocellular carcinoma:9:0.6794	0.9667	490
HCC	HCC:22	Hepatocarcinoma:22:0.0027	0.0027	22
HCC	HCC:14	hepatocellular:14:0.0017	0.0017	14
HCC	HCC:44	hepatocellular cancer:44:0.7038	0.7038	44
HCC	HCC:7456|HC-C:1|hcc:1	hepatocellular carcinoma:7134:0.9877|hepatocellular carcinomas:324:0.8916	0.9877	7458
HCC	HCC:8	hepatoma:8:0.0010	0.0010	8
HCC	HCC:19	Human corpus cavernosum:19:0.7658	0.7658	19
HCDR3	HCDR3:4|H-CDR3:3	chain complementarity-determining region 3:7:0.5926	0.5926	7
HCD	HCD:17	heavy chain disease:9:0.3455|heavy chain diseases:8:0.5006	0.5006	17
HCD	HCD:25	high cholesterol diet:25:0.7249	0.7249	25
HCD	HCD:5|h-CD:2	high molecular weight caldesmon:7:0.5926	0.5926	7
HCD	HCD:8	hydrocolloid dressing:8:0.2987	0.2987	8
HCECs	HCECs:9	human corneal endothelial cells:9:0.6794	0.6794	9
HCECs	HCECs:19	human corneal epithelial cells:19:0.8449	0.8449	19
HCEC	HCEC:8	endothelial cell:8:0.5006	0.5006	8
HCEC	HCEC:19	Human corneal endothelial cells:19:0.8449	0.8449	19
HCEC	HCEC:12	human corneal epithelial cells:12:0.7571	0.7571	12
HCE	HCE:31	human corneal epithelial:31:0.9072	0.9072	31
HCE	HCE:9	hypercholesterolemia:9:0.0571	0.0571	9
HCFCs	HCFCs:18	hydrochlorofluorocarbons:18:0.7727	0.7727	18
HCFU	HCFU:67	1-hexylcarbamoyl-5-fluorouracil:67:0.5856	0.5856	67
HCF	HCF:11	host cell factor:11:0.7357	0.7357	11
HCF	HCF:5	human corneal fibroblasts:5:0.4422	0.4422	5
HCF	HCF:16	hydatid cyst fluid:16:0.8165	0.8165	16
hCG	hCG:152|HCG:12	Human choriogonadotropin:164:0.7280	0.7280	164
HCG	HCG:697|hCG:670|hcg:1	human chorionic gonadotrophin:1368:0.9170	0.9170	1368
hCG	hCG:2694|HCG:683|hcG:1	human chorionic gonadotropin:3357:0.9111|human chorionic gonadotropins:21:0.7291	0.9111	3378
hCG	hCG:7|HCG:2	human chorionic gonadotropin hormone:9:0.6794	0.6794	9
HCHO	HCHO:121	formaldehyde:121:0.8451	0.8451	121
HCHP	HCHP:11	Harvard Community Health Plan:11:0.7357	0.7357	11
HCHs	HCHs:50	hexachlorocyclohexanes:50:0.4757	0.4757	50
HCHs	HCHs:19	hexachlorocyclohexane isomers:19:0.6680	0.6680	19
HCHWA-D	HCHWA-D:14	hereditary cerebral hemorrhage with amyloidosis-Dutch type:14:0.7753	0.7753	14
HCHWA-D	HCHWA-D:7	hereditary cerebral hemorrhage with amyloidosis of the Dutch type:7:0.7096	0.7096	7
HCH	HCH:153	hexachlorocyclohexane:144:0.4747|hexachlorocyclohexanes:9:0.0269	0.4747	153
HCH	HCH:10|Hch:1	hypochondroplasia:11:0.0337	0.0337	11
HCII	HCII:128|HC-II:7|HCiI:1	Heparin cofactor II:136:0.9531	0.9531	136
HCI	HCI:20	Human-Computer Interaction:20:0.7173	0.7173	20
HCI	HCI:10	translational inhibitor:10:0.5000	0.5000	10
Hck	Hck:10|hck:2|HCK:1	hematopoietic cell kinase:13:0.3813	0.3813	13
HCMC	HCMC:9	Ho Chi Minh City:9:0.6794	0.6794	9
HCMP	HCMP:32	hypertrophic cardiomyopathy:32:0.8563	0.8563	32
HCMV	HCMV:2098|hCMV:39	human cytomegalovirus:2137:0.9773	0.9773	2137
HCM	HCM:8|hCM:1	conditioned medium:9:0.2285	0.2285	9
HCM	HCM:8|h-CM:1	human ciliary muscle:9:0.5470	0.5470	9
HCM	HCM:15	hypercalcemia of malignancy:15:0.5818	0.5818	15
HCM	HCM:11	hypertrophic:11:0.0090	0.0090	11
HCM	HCM:959	hypertrophic cardiomyopathy:959:0.9742	0.9742	959
hcn	hcn:8|HCN:1	high-copy-number:9:0.0406	0.0406	9
HCN	HCN:60	hydrogen cyanide:60:0.8359	0.8359	60
HCN	HCN:19	Hyperpolarization-activated cyclic nucleotide-gated:19:0.8716	0.8716	19
HCN	HCN:3	hyperpolarization-activated cyclic nucleotide-gated cation:3:0.4422	0.4422	3
HCO(3)(-)	HCO(3)(-):13	bicarbonate:13:0.5714	0.5714	13
HCO3-	HCO3-:66	bicarbonate:66:0.5078	0.5078	66
HCO3	HCO3:35|HCO-3:9	bicarbonate:44:0.5789	0.5789	44
HCOs	HCOs:5	health care organizations:5:0.4422	0.4422	5
HCO	HCO:49	hydrogenated coconut oil:49:0.9046	0.9046	49
HCPA	HCPA:10	Hospital de Clinicas de Porto Alegre:10:0.7103	0.7103	10
HCPT	HCPT:17	10-hydroxycamptothecin:17:0.3137	0.3137	17
hCPT	hCPT:10	Homocamptothecin:10:0.1765	0.1765	10
HCPT	HCPT:14	Hydroxycamptothecin:14:0.2549	0.2549	14
HCPS	HCPS:13	hantavirus cardiopulmonary syndrome:13:0.7753	0.7753	13
HCPs	HCPs:14	Health care professionals:14:0.7909	0.7909	14
HCPs	HCPs:20	health care providers:20:0.8525	0.8525	20
HCP	HCP:6	health care provider:6:0.5290	0.5290	6
HCP	HCP:12	hearing conservation program:12:0.7571	0.7571	12
HCP	HCP:11	Hematopoietic cell phosphatase:11:0.4728	0.4728	11
HCP	HCP:20	hereditary coproporphyria:20:0.8525	0.8525	20
HCP	HCP:38	Hexachlorophene:38:0.1440	0.1440	38
HCQ	HCQ:96	Hydroxychloroquine:96:0.8962	0.8962	96
HCQIP	HCQIP:19	Health Care Quality Improvement Program:19:0.8449	0.8449	19
Hcrt	Hcrt:6|HCRT:3|hcrt:3	hypocretin:12:0.4231	0.4231	12
HCR	HCR:5	control region:5:0.1132	0.1132	5
HCR	HCR:4	hemin-controlled translational repressor:4:0.0918	0.0918	4
HCR	HCR:44|Hcr:1	host cell reactivation:31:0.9043|host-cell reactivation:14:0.1538	0.9043	45
HCR	HCR:10	hyperthermo-chemo-radiotherapy:10:0.0523	0.0523	10
HCS-2/8	HCS-2/8:5	human chondrosarcoma-derived chondrocytic cell line:5:0.4422	0.4422	5
HCSA	HCSA:7	homocysteine sulfinic acid:7:0.5926	0.5926	7
HCSM	HCSM:9	human cerebrovascular smooth muscle:9:0.6794	0.6794	9
HCSMA	HCSMA:17	Hereditary canine spinal muscular atrophy:17:0.8270	0.8270	17
HCS	HCS:7	cord serum:7:0.3524	0.3524	7
HCS	HCS:5	haemoglobin colour scale:5:0.4422	0.4422	5
HCs	HCs:52	hairy cells:52:0.2967	0.2967	52
HCs	HCs:26	healthy controls:26:0.7340	0.7340	26
HCs	HCs:5|HCS:3	healthy control subjects:8:0.6411	0.6411	8
HCs	HCs:18|hcs:1	heavy chains:19:0.8449	0.8449	19
HCs	HCs:14	hepatocytes:14:0.0218	0.0218	14
HCS	HCS:29	Holocarboxylase synthetase:29:0.8941	0.8941	29
HCs	HCs:49	horizontal cells:49:0.2754	0.2754	49
hCS	hCS:39|HCS:33	Human Chorionic Somatomammotropin:72:0.7663	0.7663	72
HCS	HCS:6	Hybrid Capture System:6:0.5290	0.5290	6
HCs	HCs:21	hydrocarbons:21:0.0335	0.0335	21
HCTZ	HCTZ:343|Hctz:1	hydrochlorothiazide:344:0.9077	0.9077	344
HCTx	HCTx:5|HcTX:3|HcTx:3|HCTX:1	hepatocyte transplantation:12:0.5664	0.5664	12
HCT	HCT:9	haematocrit centrifugation technique:9:0.5470	0.5470	9
Hct	Hct:6	haematocrit value:6:0.1543	0.1543	6
HCT	HCT:11	Halstead Category Test:11:0.6182	0.6182	11
HCT	HCT:19|hCT:7	Helical Computed Tomography:26:0.5840	0.5840	26
HCT	HCT:16|hCT:1	helical CT:17:0.2379	0.2379	17
Hct	Hct:623|HCT:157|hct:19|HcT:1|HCt:1	hematocrit:779:0.4659|hematocrits:22:0.0126	0.4659	801
HCT	HCT:13	hematopoietic cell transplant:13:0.5335	0.5335	13
HCT	HCT:126	Hematopoietic cell transplantation:126:0.6988	0.6988	126
hCT	hCT:92|HCT:14|hCt:3|H-CT:2	human calcitonin:111:0.8568	0.8568	111
HCT	HCT:97|hct:2|Hct:1	hydrochlorothiazide:100:0.0592	0.0592	100
HCU	HCU:5	Hand-carried cardiac ultrasound:5:0.2818	0.2818	5
HCU	HCU:6	hand-carried ultrasound:6:0.1148	0.1148	6
HCVAb	HCVAb:7|HCV-Ab:5|HCVAB:1	hepatitis C virus antibody:13:0.5934	0.5934	13
HCV-RNA	HCV-RNA:11|HCVRNA:1	Hepatitis C virus RNA:12:0.7571	0.7571	12
HCVR	HCVR:16	hypercapnia:16:0.1442	0.1442	16
HCVR	HCVR:60	hypercapnic ventilatory response:49:0.8492|hypercapnic ventilatory responses:11:0.6182	0.8492	60
HCV	HCV:15	Hepatitis C infection:15:0.8045	0.8045	15
HCV	HCV:52	hepatitis C viral:52:0.8821	0.8821	52
HCV	HCV:9324	hepatitis C virus:9307:0.9728|hepatitis C viruses:10:0.3867|hepatitis C-virus:7:0.3524	0.9728	9324
HCV	HCV:35	hepatitis C virus infection:35:0.9151	0.9151	35
HCV	HCV:23	human coronavirus:23:0.7046	0.7046	23
HCWs	HCWs:181	health care workers:181:0.9648	0.9648	181
HCWs	HCWs:116	healthcare workers:116:0.2914	0.2914	116
HCW	HCW:73	Health Care Workers:52:0.9099|health care worker:21:0.8594	0.9099	73
HCW	HCW:14	Healthcare worker:14:0.1824	0.1824	14
HCW	HCW:12	hot carcass weight:12:0.7571	0.7571	12
Hcys	Hcys:19|HCYS:10|HCys:6|hCys:1	homocysteine:36:0.9459	0.9459	36
HC-Ad	HC-Ad:11	High-capacity adenoviral:11:0.7357	0.7357	11
HCAI	HCAI:7|hCA-I:2	carbonic anhydrase I:9:0.6794	0.6794	9
HCL	HCL:108	hairy cell leukaemia:108:0.9559	0.9559	108
HCL	HCL:581	hairy cell leukemia:581:0.9917	0.9917	581
HCl	HCl:141|HCL:2	hydrochloric acid:143:0.8008	0.8008	143
HCl	HCl:65	hydrochloride:65:0.0558	0.0558	65
HCl	HCl:23|HCL:1	hydrogen chloride:24:0.8768	0.8768	24
HCL	HCL:9	patients with hairy-cell leukaemia:9:0.1052	0.1052	9
HCoV	HCoV:8|hCoV:1	human coronavirus:9:0.6794	0.6794	9
HC	HC:5	fed a high-cholesterol:5:0.0953	0.0953	5
HC	HC:16	haemorrhagic colitis:16:0.3044	0.3044	16
HC	HC:13	haemorrhagic cystitis:13:0.0869	0.0869	13
HC	HC:12	hair cell:12:0.0867	0.0867	12
HC	HC:40|Hc:1	Hairy cells:29:0.2616|hairy cell:12:0.0867	0.2616	41
HC	HC:11|Hc:3	haptocorrin:14:0.0041	0.0041	14
HC	HC:8	Hassall's corpuscles:8:0.5006	0.5006	8
HC	HC:29	Health Centre:15:0.7096|Health Centres:14:0.7909	0.7909	29
HC	HC:11	healthy children:11:0.6182	0.6182	11
HC	HC:9	healthy comparison:9:0.6794	0.6794	9
HC	HC:204	healthy controls:171:0.8342|healthy control:33:0.5042	0.8342	204
HC	HC:12	healthy control subjects:12:0.5050	0.5050	12
HC	HC:8|Hc:1	heavy:9:0.0025	0.0025	9
HC	HC:151|hc:7|Hc:5	heavy chain:130:0.9403|heavy chains:21:0.8594|heavy-chain:12:0.0035	0.9403	163
HC	HC:16	helper component:16:0.7261	0.7261	16
HC	HC:31	hemicrania continua:31:0.9043	0.9043	31
Hc	Hc:24|HC:4	hemocyanin:28:0.0086	0.0086	28
HC	HC:5	hemoglobin concentration:5:0.1132	0.1132	5
HC	HC:15	hemorrhagic colitis:15:0.2729	0.2729	15
HC	HC:53	hemorrhagic cystitis:53:0.6872	0.6872	53
HC	HC:9	heparin cofactor II:9:0.6794	0.6794	9
HC	HC:23	hepatic cirrhosis:23:0.7046	0.7046	23
HC	HC:21	hepatitis C:21:0.5435	0.5435	21
HC	HC:12	hepatocellular carcinoma:12:0.5050	0.5050	12
HC	HC:46|Hc:2	hepatocytes:37:0.0114|hepatocyte:11:0.0032	0.0114	48
HC	HC:6	hereditary hemochromatosis:6:0.0611	0.0611	6
HC	HC:91|hc:1	high carbohydrate:48:0.7866|high-carbohydrate:44:0.0136	0.7866	92
HC	HC:20	high cholesterol:20:0.7173	0.7173	20
HC	HC:7	hippocampal commissure:7:0.3524	0.3524	7
HC	HC:46|Hc:9|hc:2	hippocampus:57:0.0178	0.0178	57
Hc	Hc:23|HC:8	Histoplasma capsulatum:31:0.8090	0.8090	31
HC	HC:23	hog cholera:23:0.8715	0.8715	23
HC	HC:18	home care:18:0.6381	0.6381	18
HC	HC:5	horizontal canal:5:0.0612	0.0612	5
HC	HC:33	horizontal cell:22:0.2359|horizontal cells:11:0.0548	0.2359	33
HC	HC:6	horizontal semicircular canal:6:0.5290	0.5290	6
HC	HC:31	Huntington's chorea:31:0.7388	0.7388	31
HC	HC:16	hybrid capture:16:0.7261	0.7261	16
HC	HC:48|hc:1	hydrocarbon:28:0.0086|hydrocarbons:21:0.0063	0.0086	49
HC	HC:10	hydrocephalus:10:0.0029	0.0029	10
HC	HC:382|Hc:3	hydrocortisone:385:0.1219	0.1219	385
HC	HC:10	hydrocortisone acetate:10:0.5856	0.5856	10
HC	HC:7	hydrogen clearance:7:0.2902	0.2902	7
HC	HC:10	hypercholesterolaemia:10:0.0029	0.0029	10
HC	HC:75	hypercholesterolemia:75:0.0235	0.0235	75
HC	HC:54|hc:1	hypercholesterolemic:55:0.0171	0.0171	55
HC	HC:156	hypertrophic cardiomyopathy:156:0.9694	0.9694	156
HC	HC:9	Plasma homocysteine:9:0.0713	0.0713	9
HD-MPA	HD-MPA:14	medroxyprogesterone acetate:14:0.7909	0.7909	14
HD11	HD11:7|HD-11:1	macrophage cell line:8:0.6411	0.6411	8
HDAC1	HDAC1:13	histone deacetylase:13:0.7753	0.7753	13
HDAC1	HDAC1:57|HDAC-1:2|hdac-1:1|Hdac1:1	histone deacetylase 1:61:0.9503	0.9503	61
HDAC3	HDAC3:16	histone deacetylase 3:16:0.7261	0.7261	16
HDAC4	HDAC4:9	Histone deacetylase 4:9:0.6794	0.6794	9
HDACIs	HDACIs:20|HDACis:2|HDAC-Is:1	Histone deacetylase inhibitors:23:0.8038	0.8038	23
HDACi	HDACi:6|HDACI:2|HDAC-i:1	histone deacetylase inhibitors:9:0.5470	0.5470	9
HDACs	HDACs:290|Hdacs:1	histone deacetylases:291:0.9299	0.9299	291
HDAC	HDAC:10|HdAC:1	high-dose cytarabine:11:0.5355	0.5355	11
HDAC	HDAC:476|HDAc:3	histone deacetylase:441:0.9556|histone deacetylases:38:0.8417	0.9556	479
HDAg	HDAg:72|HD-Ag:2	hepatitis delta antigen:74:0.7388	0.7388	74
HDARA-C	HDARA-C:4|HDAra-C:2|HDARAC:1|HD-AraC:1|HDara-C:1	High-dose cytarabine:9:0.4587	0.4587	9
HD-Ara-C	HD-Ara-C:4|HDara-C:3|HD-ara-C:2|HD-AraC:1|HDAra-C:1|HDARA-C:1	high-dose cytosine arabinoside:12:0.5050	0.5050	12
hDAT	hDAT:26	human dopamine transporter:26:0.8251	0.8251	26
HDA	HDA:5	1,6-hexamethylene diamine:5:0.0902	0.0902	5
HDA	HDA:5	electrical stimulation of the hypothalamic defense area:5:0.4422	0.4422	5
HDA	HDA:16	heteroduplex analysis:16:0.6024	0.6024	16
HDA	HDA:12	hypothalamic defence area:12:0.7571	0.7571	12
HDB	HDB:13|hDB:2	horizontal limb of the diagonal band:15:0.8045	0.8045	15
HDB	HDB:10|hDB:1	horizontal limb of the diagonal band of Broca:11:0.7357	0.7357	11
HDCA	HDCA:10	hyodeoxycholic acid:10:0.5856	0.5856	10
HDCP	HDCP:5	O-Hexyl O-2,5-dichlorophenyl phosphoramidate:5:0.5290	0.5290	5
HDCS	HDCS:9	human diploid cell strain:9:0.6794	0.6794	9
HD-CTX	HD-CTX:7|HDCTX:1	high-dose cyclophosphamide:8:0.3463	0.3463	8
HDCT	HDCT:155|HD-CT:14	High-dose chemotherapy:169:0.8273	0.8273	169
HDCV	HDCV:23	human diploid cell rabies vaccine:23:0.8715	0.8715	23
HDCV	HDCV:26	human diploid cell vaccine:26:0.8861	0.8861	26
HDCY	HDCY:5|HD-Cy:4|HD-CY:4|HDCy:3	high-dose cyclophosphamide:16:0.6577	0.6577	16
HDC	HDC:221|hdc:1	high-dose chemotherapy:222:0.8241	0.8241	222
HDC	HDC:291|Hdc:2	histidine decarboxylase:293:0.8076	0.8076	293
HDC	HDC:12	human diploid cells:12:0.7571	0.7571	12
HDEL	HDEL:8|H-D-E-L:1	His-Asp-Glu-Leu:9:0.3636	0.3636	9
HDE	HDE:10	high-dose epinephrine:10:0.5856	0.5856	10
HDFP	HDFP:49	Hypertension Detection and Follow-up Program:49:0.9046	0.9046	49
HDFs	HDFs:17|hDFs:8	human dermal fibroblasts:25:0.8816	0.8816	25
HDFs	HDFs:38	human diploid fibroblasts:38:0.9217	0.9217	38
HDF	HDF:24	haemodiafiltration:24:0.0721	0.0721	24
HDF	HDF:125	hemodiafiltration:125:0.3824	0.3824	125
HDF	HDF:29	human dermal fibroblasts:23:0.8038|human dermal fibroblast:6:0.5290	0.8038	29
HDF	HDF:87	human diploid fibroblasts:79:0.9622|human diploid fibroblast:8:0.6411	0.9622	87
HDGC	HDGC:26	hereditary diffuse gastric cancer:26:0.8861	0.8861	26
HDGF	HDGF:30	hepatoma-derived growth factor:30:0.7315	0.7315	30
HDH	HDH:8	histidinol dehydrogenase:8:0.2090	0.2090	8
HDIs	HDIs:14	histone deacetylase inhibitors:14:0.7909	0.7909	14
HDI	HDI:19	1,6-hexamethylene diisocyanate:19:0.1140	0.1140	19
HDI	HDI:72	hexamethylene diisocyanate:72:0.6230	0.6230	72
HDI	HDI:15	Human Development Index:15:0.8045	0.8045	15
HDL2	HDL2:6	high density lipoprotein:6:0.5290	0.5290	6
HDL2	HDL2:11|HDL-2:1	high-density lipoprotein 2:12:0.5050	0.5050	12
HDL2	HDL2:13	high density lipoprotein2:13:0.6701	0.6701	13
HDL2	HDL2:5	high density lipoproteins2:5:0.4422	0.4422	5
HDL3	HDL3:60|HDL-3:1	high-density lipoprotein:23:0.3310|high density lipoprotein:23:0.8715|high density lipoproteins:15:0.8165	0.8715	61
HDL3	HDL3:31|HDL-3:1	high density lipoprotein-3:13:0.7753|high-density lipoprotein 3:12:0.3524|high density lipoprotein 3:7:0.5926	0.7753	32
HDL3	HDL3:11	high density lipoprotein3:11:0.6182	0.6182	11
HDL-C	HDL-C:38|HDLc:11|HDLC:3	high density lipoprotein:24:0.8768|high-density lipoprotein:15:0.2311|high density lipoproteins:13:0.7753	0.8768	52
HDL-C	HDL-C:1191|HDLC:83|HDL-c:30|HDLc:24|hDL-C:1	high-density lipoprotein cholesterol:1034:0.6153|high-density lipoprotein-cholesterol:152:0.4335|high density lipoprotein-cholesterol:143:0.9361	0.9361	1329
HDLp	HDLp:30	high-density lipophorin:16:0.3174|high density lipophorin:14:0.7909	0.7909	30
HDLP	HDLP:32|HDLp:1|HDL-P:1	high density lipoproteins:12:0.6460|high-density lipoproteins:12:0.2414|high-density lipoprotein:5:0.0902|high density lipoprotein:5:0.4422	0.6460	34
HDL-Ch	HDL-Ch:4|HDL-ch:2|HDL-CH:1|HDLch:1	high density lipoprotein cholesterol:8:0.6411	0.6411	8
HDL	HDL:6981|HDl:1	high-density lipoprotein:2913:0.4937|high density lipoprotein:2683:0.9729|high density lipoproteins:917:0.9824|high-density lipoproteins:469:0.3077	0.9824	6982
HDL	HDL:138	high-density lipoprotein cholesterol:75:0.4442|high density lipoprotein cholesterol:63:0.9018	0.9018	138
HDL	HDL:7	high density lipoprotein fraction:7:0.5926	0.5926	7
HDMEC	HDMEC:71	human dermal microvascular endothelial cells:71:0.9335	0.9335	71
HDMECs	HDMECs:16	human dermal microvascular endothelial cells:16:0.8165	0.8165	16
HDMP	HDMP:33|HD-MP:1	high-dose methylprednisolone:34:0.5687	0.5687	34
HDMTX	HDMTX:72|HD-MTX:51|H-D-MTX:1	high-dose methotrexate:124:0.7177	0.7177	124
HDM	HDM:40	high-dose melphalan:40:0.6459	0.6459	40
HDM	HDM:7|HdM:1	high-dose Methotrexate:8:0.5006	0.5006	8
HDM	HDM:223|HDm:1|Hdm:1	house dust mite:187:0.9658|house dust mites:38:0.9217	0.9658	225
HDN	HDN:119	disease of the newborn:119:0.9158	0.9158	119
HDPE	HDPE:63	High-density polyethylene:42:0.5275|high density polyethylene:21:0.8594	0.8594	63
HDRA	HDRA:34	Histoculture Drug Response Assay:34:0.9126	0.9126	34
HDR-BT	HDR-BT:13|HDRBT:4	brachytherapy:17:0.8333	0.8333	17
HDRB	HDRB:14|HDR-B:3	brachytherapy:17:0.8000	0.8000	17
HDRIBT	HDRIBT:10	high-dose-rate intraluminal brachytherapy:10:0.7103	0.7103	10
HDRS	HDRS:246	Hamilton Depression Rating Scale:246:0.9620	0.9620	246
HDRS	HDRS:9	Hamilton Rating Scale for Depression:9:0.6794	0.6794	9
HDR	HDR:11	head-down rotation:11:0.7357	0.7357	11
HDR	HDR:9	hemodynamic response:9:0.2757	0.2757	9
HDR	HDR:402	High dose rate:206:0.9767|high-dose-rate:164:0.2703|high dose-rate:32:0.9072	0.9767	402
HDR	HDR:8	homology-directed repair:8:0.3463	0.3463	8
HDS-R	HDS-R:7	Hasegawa dementia scale:7:0.1850	0.1850	7
HDS-R	HDS-R:3|HDSR:2	revised version of Hasegawa's Dementia Scale:5:0.4422	0.4422	5
HDS	HDS:30	Hamilton Depression Scale:30:0.8032	0.8032	30
HDS	HDS:13	Hasegawa's Dementia Scale:13:0.2038	0.2038	13
HDS	HDS:9	head-down suspension:9:0.3069	0.3069	9
HDs	HDs:19	Hemidesmosomes:19:0.0650	0.0650	19
HDS	HDS:15	high-dose sequential:15:0.8045	0.8045	15
HDS	HDS:10	hydrodesulfurization:10:0.0325	0.0325	10
HDTMA	HDTMA:12	hexadecyltrimethylammonium:12:0.5500	0.5500	12
HDTV	HDTV:6	high definition television:6:0.5290	0.5290	6
HDT	HDT:30	High-dose chemotherapy:30:0.6736	0.6736	30
HDT	HDT:113	high-dose therapy:113:0.8246	0.8246	113
HDT	HDT:7	High-dose treatment:7:0.3524	0.3524	7
HDU	HDU:36	high dependency unit:24:0.7593|high-dependency unit:12:0.1262	0.7593	36
HDV	HDV:7	hepatitis D:7:0.1641	0.1641	7
HDV	HDV:138	hepatitis D virus:138:0.8656	0.8656	138
HDV	HDV:501	hepatitis delta virus:501:0.9445	0.9445	501
HD-Zip	HD-Zip:12|HDZip:2|Hd-Zip:1|HD-ZIP:1	Homeodomain-leucine zipper:16:0.4536	0.4536	16
HDZ	HDZ:12	hydralazine:12:0.7857	0.7857	12
hdIVIg	hdIVIg:9|HDIVIG:2|HD-IVIG:1|HdIVIg:1|HDivIG:1	high-dose intravenous immunoglobulin:14:0.6911	0.6911	14
HD	HD:34	2,5-hexanedione:34:0.0037	0.0037	34
HD	HD:11	dialysis:11:0.0011	0.0011	11
HD	HD:16	domain:16:0.0017	0.0017	16
HD	HD:7	enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase:7:0.4438	0.4438	7
HD	HD:9	haemodialysed:9:0.0009	0.0009	9
HD	HD:13	haemodialysis patients:13:0.1005	0.1005	13
HD	HD:10	hand dermatitis:10:0.5856	0.5856	10
HD	HD:21|H-D:19	Hanganutziu-Deicher:40:0.0044	0.0044	40
HD	HD:37	head direction:27:0.8312|head-direction:10:0.0010	0.8312	37
HD	HD:39	healthy donors:39:0.8142	0.8142	39
HD	HD:10	heavy distillate:10:0.7103	0.7103	10
HD	HD:5	heavy drinkers:5:0.1132	0.1132	5
HD	HD:15|hd:1	helper-dependent:16:0.0017	0.0017	16
HD	HD:9	hemidesmosomes:9:0.0009	0.0009	9
HD	HD:9	hemodialyses:9:0.0009	0.0009	9
HD	HD:9	hemodialysed:9:0.0009	0.0009	9
HD	HD:2455|hd:1|Hd:1	hemodialysis:2457:0.2767	0.2767	2457
HD	HD:23	hemodialysis patients:23:0.2519	0.2519	23
HD	HD:7	hemodialysis treatment:7:0.3524	0.3524	7
HD	HD:29	hemodialyzed:29:0.0032	0.0032	29
HD	HD:21	Hemodilution:21:0.0023	0.0023	21
HD	HD:6	hepatitis D:6:0.1320	0.1320	6
HD	HD:28	high density:28:0.8369	0.8369	28
HD	HD:115|hd:2|Hd:1	high-dose:76:0.0084|high dose:42:0.8263	0.8263	118
HD	HD:7	hip dysplasia:7:0.3524	0.3524	7
HD	HD:27	histidine decarboxylase:27:0.5951	0.5951	27
HD	HD:10	Hodgkin's:10:0.0010	0.0010	10
HD	HD:1912|Hd:1	Hodgkin's disease:1913:0.4320	0.4320	1913
HD	HD:11	Hodgkin's lymphoma:11:0.4232	0.4232	11
HD	HD:78	homeodomain:78:0.0087	0.0087	78
HD	HD:9	homozygous deletion:9:0.6794	0.6794	9
HD	HD:10	hormone-dependent:10:0.0010	0.0010	10
HD	HD:31	house dust:31:0.8519	0.8519	31
HD	HD:10	Huntington's:10:0.0010	0.0010	10
HD	HD:1535	Huntington's disease:1535:0.3440	0.3440	1535
H-D	H-D:23|HD:1	hydrogen-deuterium:24:0.0026	0.0026	24
Hd	Hd:10|hd:1	hypodactyly:11:0.0010	0.0010	11
HD	HD:8	hypoxic depolarization:8:0.4102	0.4102	8
HD	HD:9	patients on chronic haemodialysis:9:0.0747	0.0747	9
HD	HD:66	sulfur mustard:66:0.6673	0.6673	66
HD	HD:17	sulphur mustard:17:0.1106	0.1106	17
HEA	HEA:5	2-hydroxyethyl acrylate:5:0.1132	0.1132	5
HEBP	HEBP:33	1-hydroxyethylidene-1,1-bisphosphonate:33:0.4211	0.4211	33
HECs	HECs:11	ethics committees:11:0.7357	0.7357	11
HECs	HECs:6|hECs:3	human endothelial cells:9:0.5470	0.5470	9
HEC	HEC:54	human endothelial cells:48:0.4017|human endothelial cell:6:0.2243	0.4017	54
HEC	HEC:18	human umbilical vein endothelial cells:18:0.8365	0.8365	18
HEC	HEC:29	hydroxyethyl cellulose:29:0.8472	0.8472	29
HEC	HEC:48	hydroxyethylcellulose:48:0.1567	0.1567	48
HEDIS	HEDIS:91	Health Plan Employer Data and Information Set:91:0.9721	0.9721	91
HEDP	HEDP:18	hydroxyethylidene diphosphonate:18:0.3696	0.3696	18
HED	HED:4	C-11 hydroxyephedrine:4:0.2452	0.2452	4
HED	HED:54	ectodermal dysplasia:54:0.9448	0.9448	54
HEF	HEF:8	hamster embryo fibroblasts:8:0.1730	0.1730	8
HEF	HEF:7	hepatic erythropoietic factor:7:0.5926	0.5926	7
HEF	HEF:8	hepatic extraction fraction:8:0.4102	0.4102	8
HEF	HEF:14	human embryo fibroblasts:9:0.2285|human embryo fibroblast:5:0.1973	0.2285	14
HEF	HEF:19	human embryonic fibroblasts:11:0.6182|human embryonic fibroblast:8:0.5006	0.6182	19
HEI	HEI:25	Healthy Eating Index:25:0.7249	0.7249	25
HEK293	HEK293:93|HEK-293:47	human embryonic kidney:140:0.9444	0.9444	140
HEK293	HEK293:42|HEK-293:15	human embryonic kidney 293:48:0.9379|human embryonic kidney-293:9:0.6794	0.9379	57
HEK293	HEK293:38|HEK-293:26	human embryonic kidney cells:64:0.8632	0.8632	64
HEK	HEK:421	human embryonic kidney:421:0.9886	0.9886	421
HEK	HEK:6	human embryonic kidney cells:6:0.3728	0.3728	6
HEK	HEK:16	human epidermal keratinocytes:16:0.8165	0.8165	16
HELF	HELF:25|HEL-F:1	human embryonic lung fibroblast:14:0.7909|human embryonic lung fibroblasts:12:0.7753	0.7909	26
HELLP	HELLP:2	elevated liver enzymes and low platelet:2:0.6411	0.6411	2
HELLP	HELLP:1	hemolysis elevated liver enzymes and low platelets:1:0.6923	0.6923	1
HEL	HEL:7|hel:2	helicase:9:0.0104	0.0104	9
HEL	HEL:152	hen egg lysozyme:152:0.8329	0.8329	152
HEL	HEL:60	hen egg white lysozyme:60:0.7084	0.7084	60
HEL	HEL:27	human embryo lung:27:0.8903	0.8903	27
HEL	HEL:71	human embryonic lung:71:0.9579	0.9579	71
HEL	HEL:15	human embryonic lung fibroblasts:8:0.6411|human embryonic lung fibroblast:7:0.5926	0.6411	15
HEL	HEL:17	human erythroleukaemia:17:0.7407	0.7407	17
HEL	HEL:116	human erythroleukemia:116:0.9109	0.9109	116
HEL	HEL:15	human erythroleukemia cell line:15:0.8045	0.8045	15
HEL	HEL:12	human erythroleukemic:12:0.7571	0.7571	12
HEMA	HEMA:135	2-hydroxyethyl methacrylate:135:0.5321	0.5321	135
HEMA	HEMA:32	2-hydroxyethylmethacrylate:32:0.0854	0.0854	32
HEMA	HEMA:63	hydroxyethyl methacrylate:63:0.2150	0.2150	63
HEMA	HEMA:32|hema:1	Hydroxyethylmethacrylate:33:0.0882	0.0882	33
HEMS	HEMS:40	Helicopter Emergency Medical Service:23:0.8715|helicopter emergency medical services:17:0.8270	0.8715	40
HEM	HEM:15|Hem:3|hem:1	hemorrhage:19:0.1800	0.1800	19
HEM	HEM:18	human epidermal membrane:18:0.8365	0.8365	18
HEN	HEN:27	home enteral nutrition:27:0.7760	0.7760	27
HepB	HepB:10|hepB:1	hepatitis B:11:0.5355	0.5355	11
HepB	HepB:7	hepatitis B vaccine:7:0.5926	0.5926	7
HePC	HePC:42|He-PC:9	hexadecylphosphocholine:51:0.6944	0.6944	51
HEPM	HEPM:8	human embryonic palatal mesenchymal:8:0.6411	0.6411	8
HEPM	HEPM:6	Human embryonic palatal mesenchyme:6:0.5290	0.5290	6
HEPT	HEPT:27	1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine:27:0.4000	0.4000	27
HEPT	HEPT:9	hamster egg penetration test:9:0.6794	0.6794	9
HEPs	HEPs:5	high-energy phosphates:5:0.1132	0.1132	5
HEPS	HEPS:3	Highly exposed persistently seronegative:3:0.6794	0.6794	3
HER2	HER2:59|HER-2:16|Her2:1	human epidermal growth factor receptor 2:41:0.7860|Human epidermal growth factor receptor-2:35:0.7048	0.7860	76
HERS	HERS:68	Heart and Estrogen/Progestin Replacement Study:68:0.9573	0.9573	68
HERS	HERS:20	Hertwig's epithelial root sheath:20:0.8525	0.8525	20
HERV-K	HERV-K:21	human endogenous retrovirus K:21:0.8594	0.8594	21
HERVs	HERVs:57	Human endogenous retroviruses:57:0.8667	0.8667	57
HERV	HERV:50	human endogenous retrovirus:34:0.9126|human endogenous retroviruses:16:0.8165	0.9126	50
hESCs	hESCs:52|HESCs:2|h-ESCs:1	Human embryonic stem cells:55:0.9458	0.9458	55
hESC	hESC:18|HESC:1	human embryonic stem cell:10:0.7103|human embryonic stem cells:9:0.6794	0.7103	19
HESW	HESW:21	high energy shock waves:21:0.8594	0.8594	21
HES	HES:8|Hes:3	hairy/Enhancer of split:8:0.2090|Hairy Enhancer of split:3:0.5290	0.5290	11
HES	HES:10	hetastarch:10:0.0094	0.0094	10
HES	HES:15	hospital episode statistics:15:0.8045	0.8045	15
hES	hES:70|HES:5|hes:4	human embryonic stem:79:0.9401	0.9401	79
HES	HES:375|hes:1	hydroxyethyl starch:366:0.9339|hydroxyethyl starches:10:0.7103	0.9339	376
HES	HES:10	hydroxyethyl starch solution:10:0.5856	0.5856	10
HES	HES:57	hydroxyethylstarch:57:0.0582	0.0582	57
HES	HES:193	hypereosinophilic syndrome:193:0.9323	0.9323	193
HETCOR	HETCOR:14|HET-COR:1	heteronuclear correlation:15:0.4052	0.4052	15
HETE	HETE:16	hydroxyeicosatetraenoic acids:16:0.2613	0.2613	16
HETEs	HETEs:84|HETES:3	Hydroxyeicosatetraenoic acids:87:0.4587	0.4587	87
HETP	HETP:7	height equivalent to a theoretical plate:7:0.7103	0.7103	7
HEVs	HEVs:102	high endothelial venules:102:0.9704	0.9704	102
HEV	HEV:11	hepatitis E:11:0.2972	0.2972	11
HEV	HEV:479	hepatitis E virus:479:0.9488	0.9488	479
HEV	HEV:261	high endothelial venules:240:0.9612|high endothelial venule:21:0.6400	0.9612	261
HEWL	HEWL:79	hen egg white lysozyme:45:0.8649|hen egg-white lysozyme:34:0.7587	0.8649	79
HEW	HEW:8|hew:1	hen egg white:9:0.4587	0.4587	9
Hex	Hex:32|HEX:4	beta-Hexosaminidase:36:0.1400	0.1400	36
Hex	Hex:9|hex:1|HEX:1	beta-N-acetylhexosaminidase:11:0.0400	0.0400	11
HEX	HEX:12|Hex:6	Hexamethonium:18:0.0680	0.0680	18
HEX	HEX:27|Hex:8	Hexarelin:35:0.1360	0.1360	35
Hex	Hex:17|HEX:16|hex:6	hexosaminidase:39:0.1440	0.1440	39
HEp-2	HEp-2:5|Hep-2:2|HEP-2:2|HEp2:1	carcinoma cell line:10:0.1273	0.1273	10
HEp-2	HEp-2:11|Hep-2:1	epithelial cells:12:0.1631	0.1631	12
HEp-2	HEp-2:8	human epithelial cell line:8:0.5006	0.5006	8
HEp-2	HEp-2:9|Hep2:7|HEp2:5	laryngeal carcinoma:21:0.5178	0.5178	21
HE	HE:8	effective dose equivalent:8:0.6411	0.6411	8
He	He:9|HE:2	expected heterozygosity:11:0.4728	0.4728	11
HE	HE:13	haemagglutinin-esterase:13:0.0077	0.0077	13
HE	HE:15	haematoxylin and eosin:15:0.0831	0.0831	15
HE	HE:16|H-E:2	Haematoxylin-Eosin:18:0.0109	0.0109	18
HE	HE:6	hamster embryo:6:0.1838	0.1838	6
HE	H-E:8|HE:8	Haseman-Elston:16:0.0096	0.0096	16
HE	HE:14	Health Education:14:0.5589	0.5589	14
He	He:69|HE:1	helium:70:0.0443	0.0443	70
HE	HE:44	hemagglutinin-esterase:37:0.0225|hemagglutinin esterase:7:0.3524	0.3524	44
HE	HE:55|H-E:8	hematoxylin and eosin:63:0.6117	0.6117	63
HE	HE:18	hemorrhagic enteritis:18:0.5940	0.5940	18
HE	HE:13	heparin:13:0.0077	0.0077	13
HE	HE:328	hepatic encephalopathy:328:0.8866	0.8866	328
HE	HE:13	hepatitis E:13:0.6701	0.6701	13
HE	HE:88	hereditary elliptocytosis:88:0.9461	0.9461	88
HE	HE:42	high-energy:31:0.0193|high energy:11:0.4728	0.4728	42
HE	HE:13	hydroalcoholic extract:13:0.1423	0.1423	13
HE	HE:26	hydroethidine:26:0.0161	0.0161	26
HE	HE:18	Hypothalamic extract:18:0.2462	0.2462	18
HE	HE:4|H-E:1	sections were stained with hematoxylin-eosin:5:0.1471	0.1471	5
HFA	HFA:5	fatty acid:5:0.1132	0.1132	5
HFA	HFA:10	hexafluoroacetone:10:0.0263	0.0263	10
HFA	HFA:9	High Functioning Autism:9:0.5470	0.5470	9
HFA	HFA:15	human fetal adrenal:15:0.8045	0.8045	15
HFA	HFA:9	human-flora-associated:9:0.0234	0.0234	9
HFA	HFA:11	Humphrey field analyser:11:0.6182	0.6182	11
HFA	HFA:19	Humphrey Field Analyzer:19:0.6537	0.6537	19
HFA	HFA:63	hydrofluoroalkane:63:0.1813	0.1813	63
HFA	HFA:18	hydrofluoroalkane-134a:18:0.0497	0.0497	18
HFA	HFA:7	hypoglossal-facial nerve anastomosis:7:0.4438	0.4438	7
HFBA	HFBA:11	heptafluorobutyric acid:11:0.4728	0.4728	11
HFBA	HFBA:24	heptafluorobutyric anhydride:24:0.7593	0.7593	24
HFCC	HFCC:14	chest compression:14:0.7909	0.7909	14
HFCs	HFCs:6	high frequency cells:6:0.1148	0.1148	6
HFCs	HFCs:6	high SCE frequency cells:6:0.5290	0.5290	6
HFCs	HFCs:9	hydrofluorocarbons:9:0.1039	0.1039	9
HFCWO	HFCWO:8	high-frequency chest wall oscillation:8:0.5006	0.5006	8
HFC	HFC:15	high frequency cells:15:0.7096	0.7096	15
HFC	HFC:5	histamine formation capacity:5:0.4422	0.4422	5
HFD	HFD:99	high-fat diet:65:0.4264|high fat diet:34:0.8644	0.8644	99
HFEA	HFEA:24	Human Fertilisation and Embryology Authority:24:0.8768	0.8768	24
HFEPR	HFEPR:11|HF-EPR:2	electron paramagnetic resonance:13:0.7753	0.7753	13
HFE	HFE:17	haemochromatosis:17:0.0702	0.0702	17
HFE	HFE:55|Hfe:1	hemochromatosis:56:0.2412	0.2412	56
HFE	HFE:60|Hfe:3	hemochromatosis gene:63:0.5913	0.5913	63
HFE	HFE:5	hemochromatosis protein:5:0.0736	0.0736	5
HFE	HFE:16	human factors engineering:16:0.8165	0.8165	16
HFFs	HFFs:16	human foreskin fibroblasts:16:0.8165	0.8165	16
HFf	HFf:6|Hff:1	Hageman factor fragment:7:0.4438	0.4438	7
hFF	hFF:45|HFF:15	human follicular fluid:60:0.8181	0.8181	60
HFF	HFF:66	human foreskin fibroblasts:42:0.8263|human foreskin fibroblast:24:0.7593	0.8263	66
HFHS	HFHS:11	Henry Ford Health System:11:0.7357	0.7357	11
hFH	hFH:9|HFH:2	Heterozygous familial hypercholesterolemia:11:0.1760	0.1760	11
HFH	HFH:17	homozygous familial hypercholesterolemia:17:0.3844	0.3844	17
HFIP	HFIP:9	1,1,1,3,3,3-hexafluoro-2-propanol:9:0.1194	0.1194	9
HFIP	HFIP:11	hexafluoro-2-propanol:11:0.1493	0.1493	11
HFIP	HFIP:25	hexafluoroisopropanol:25:0.3582	0.3582	25
HFI	HFI:51	Hereditary fructose intolerance:51:0.9416	0.9416	51
HFI	HFI:13|Hfi:1	hyperostosis frontalis interna:14:0.7909	0.7909	14
HFJV	HFJV:244	high-frequency jet ventilation:141:0.5082|high frequency jet ventilation:103:0.9710	0.9710	244
HFKs	HFKs:13	human foreskin keratinocytes:13:0.6701	0.6701	13
HFM	HFM:41	hemifacial microsomia:41:0.9274	0.9274	41
HFN	HFN:8|hFn:2|hFN:1	human fibronectin:11:0.3213	0.3213	11
HFO	HFO:126	high-frequency oscillation:68:0.5056|high frequency oscillation:43:0.9308|high-frequency oscillations:15:0.4609	0.9308	126
HFO	HFO:18	high-frequency oscillatory ventilation:18:0.4672	0.4672	18
HFO	HFO:18	hydrous ferric oxide:18:0.8365	0.8365	18
HFOV	HFOV:244	high-frequency oscillatory ventilation:175:0.6522|High frequency oscillatory ventilation:69:0.9316	0.9316	244
HFOs	HFOs:28	high-frequency oscillations:28:0.6057	0.6057	28
HFPPV	HFPPV:46|hfppv:1	high-frequency positive-pressure ventilation:30:0.8032|high frequency positive pressure ventilation:17:0.8270	0.8270	47
HFPV	HFPV:15	percussive ventilation:15:0.7096	0.7096	15
HFP	HFP:11	heterochromatic flicker photometry:11:0.7357	0.7357	11
HFP	HFP:5	high-frequency power:5:0.1132	0.1132	5
HFP	HFP:9	human fetal pancreas:9:0.6794	0.6794	9
HFRPE	HFRPE:8	human fetal retinal pigment epithelial:8:0.6411	0.6411	8
HFRS	HFRS:66	haemorrhagic fever with renal syndrome:66:0.1272	0.1272	66
HFRS	HFRS:23	hemorrhagic fever with the renal syndrome:23:0.7816	0.7816	23
HFRT	HFRT:11	hyperfractionated radiotherapy:11:0.5355	0.5355	11
HFs	HFs:9|HFS:1	fibroblasts:10:0.0198	0.0198	10
HFS	HFS:17	hand-foot syndrome:17:0.5038	0.5038	17
HFS	HFS:111	Hemifacial spasm:111:0.9731	0.9731	111
HFS	HFS:5	high-fat sucrose:5:0.2243	0.2243	5
HFS	HFS:160	High-frequency stimulation:101:0.4874|high frequency stimulation:59:0.9494	0.9494	160
HFUPR	HFUPR:10	hourly fetal urine production rate:10:0.7103	0.7103	10
HFV	HFV:156	high-frequency ventilation:98:0.4852|high frequency ventilation:58:0.9486	0.9486	156
HFV	HFV:99|hFV:1	Human foamy virus:100:0.9525	0.9525	100
HF	HF:14	fluid:14:0.0038	0.0038	14
HF	HF:31	haemofiltration:31:0.0088	0.0088	31
HF	HF:21	Hageman factor:21:0.2554	0.2554	21
HF	HF:46	hair follicle:35:0.9151|hair follicles:11:0.7357	0.9151	46
HF	HF:18|Hf:16	Halofantrine:34:0.0097	0.0097	34
HF	HF:43	Hartree-Fock:43:0.0124	0.0124	43
HF	HF:1123	heart failure:1123:0.9868	0.9868	1123
HF	HF:8|Hf:1	Heart rate:9:0.3455	0.3455	9
HF	HF:6	Hemorrhagic fever:6:0.1010	0.1010	6
HF	HF:93	high fat:93:0.7785	0.7785	93
HF	HF:23	high-fat diet:14:0.2010|high fat diet:9:0.5856	0.5856	23
HF	HF:5	high fiber:5:0.0612	0.0612	5
HF	HF:5	high flow:5:0.0517	0.0517	5
HF	HF:10	high-flux:10:0.0027	0.0027	10
HF	HF:10	high frequencies:10:0.5000	0.5000	10
HF	HF:7	high frequency band:7:0.5926	0.5926	7
HF	HF:13	high-frequency component:13:0.3331	0.3331	13
HF	HF:9	hip fracture:9:0.5470	0.5470	9
HF	HF:99|Hf:1	hippocampal formation:100:0.8744	0.8744	100
HF	HF:6	hollow fiber:6:0.1320	0.1320	6
HF	HF:46	human fibroblasts:37:0.4735|human fibroblast:9:0.2757	0.4735	46
HF	HF:11	hydrofluoric:11:0.0029	0.0029	11
HF	HF:75	hydrofluoric acid:75:0.8819	0.8819	75
HF	HF:43	hydrogen fluoride:43:0.8590	0.8590	43
HF	HF:9	hydrops fetalis:9:0.6794	0.6794	9
HF	HF:16	hydroxyflutamide:16:0.0044	0.0044	16
HF	HF:8	hypoxic fraction:8:0.1591	0.1591	8
HF	HF:2	rats fed high-fat:2:0.3174	0.3174	2
HGA	HGA:22	homogentisic acid:22:0.7046	0.7046	22
HGC	HGC:7	human gastric cancer:7:0.3524	0.3524	7
HGDS	HGDS:9	Hemophilia Growth and Development Study:9:0.6794	0.6794	9
HGD	HGD:91	high-grade dysplasia:66:0.6038|high grade dysplasia:25:0.8816	0.8816	91
HGEC	HGEC:13	human gingival epithelial cells:13:0.7753	0.7753	13
HGEC	HGEC:7|hGEC:2	human glomerular epithelial cells:9:0.6794	0.6794	9
HGE	HGE:211	human granulocytic ehrlichiosis:211:0.9772	0.9772	211
HGF-SF	HGF-SF:10	hepatocyte growth factor-scatter factor:10:0.7103	0.7103	10
HGF/SF	HGF/SF:327	hepatocyte growth factor/scatter factor:327:0.9804	0.9804	327
HGFA	HGFA:21|HGF-A:1	hepatocyte growth factor activator:22:0.8657	0.8657	22
HGFA	HGFA:22	HGF activator:22:0.3179	0.3179	22
HGFR	HGFR:7|HGF-R:2|HGFr:1	growth factor receptor:10:0.7103	0.7103	10
HGFs	HGFs:89|hGFs:1	growth factors:90:0.9668	0.9668	90
HGFs	HGFs:37	human gingival fibroblasts:37:0.8377	0.8377	37
HGF	HGF:35|hGF:1	hematopoietic growth factors:36:0.4851	0.4851	36
HGF	HGF:2058|Hgf:1	Hepatocyte growth factor:2059:0.9532	0.9532	2059
HGF	HGF:20	HEREDITARY GINGIVAL FIBROMATOSIS:20:0.8525	0.8525	20
HGF	HGF:169|hGF:9	human gingival fibroblasts:156:0.9329|human gingival fibroblast:22:0.7955	0.9329	178
HGG	HGG:77|hGG:1	human gamma globulin:46:0.8151|human gamma-globulin:32:0.7458	0.8151	78
HGG	HGG:12	human gammaglobulin:12:0.4557	0.4557	12
hGH	hGH:1076|HGH:187|h-GH:3|hgh:2|hGh:2|hgH:1	human growth hormone:1271:0.8379	0.8379	1271
hGH	hGH:10	human growth hormone gene:10:0.7103	0.7103	10
HGI	HGI:9	high glycemic index:9:0.6794	0.6794	9
hGLCs	hGLCs:11|HGLCs:1	human granulosa-luteal cells:12:0.7571	0.7571	12
HGL	HGL:28|hGL:1	human gastric lipase:29:0.8422	0.8422	29
HGMF	HGMF:6	hydrophobic grid membrane filter:6:0.3728	0.3728	6
HGM	HGM:10	Heterotopic gastric mucosa:10:0.5856	0.5856	10
HG-NHL	HG-NHL:12|HGNHL:2	high-grade non-Hodgkin's lymphoma:14:0.6173	0.6173	14
HGN	HGN:23|HgN:3	hypogastric nerve:26:0.7760	0.7760	26
HGO	HGO:81	hepatic glucose output:81:0.9631	0.9631	81
HGPIN	HGPIN:70|HG-PIN:3	high-grade prostatic intraepithelial neoplasia:57:0.6525|High grade prostatic intraepithelial neoplasia:16:0.8165	0.8165	73
HGPRT	HGPRT:92|hgprt:4|HG-PRT:1	hypoxanthine-guanine phosphoribosyl transferase:66:0.4774|hypoxanthine guanine phosphoribosyl transferase:31:0.9043	0.9043	97
HGPRT	HGPRT:125|hgprt:8|HG-PRT:1	hypoxanthine-guanine phosphoribosyltransferase:111:0.6611|hypoxanthine guanine phosphoribosyltransferase:23:0.8816	0.8816	134
HGPS	HGPS:17	Hutchinson-Gilford progeria syndrome:17:0.7407	0.7407	17
HGP	HGP:183	hepatic glucose production:183:0.9577	0.9577	183
HGP	HGP:43	Human Genome Project:43:0.9308	0.9308	43
HGSIL	HGSIL:24|HG-SIL:4|Hg-SIL:1	high-grade squamous intraepithelial lesions:16:0.4832|high-grade squamous intraepithelial lesion:13:0.4444	0.4832	29
HGS	HGS:8	hand grip strength:8:0.6411	0.6411	8
HGs	HGs:10	hybridization groups:10:0.5856	0.5856	10
HGV	HGV:10	Hepatitis G:10:0.3867	0.3867	10
HGV	HGV:363	hepatitis G virus:363:0.8361	0.8361	363
HG	HG:23	group:23:0.0174	0.0174	23
HG	HG:32	handgrip:32:0.0244	0.0244	32
HG	HG:48|hg:3	Harderian gland:51:0.8799	0.8799	51
HG	HG:39	herpes gestationis:39:0.9237	0.9237	39
HG	HG:25	Heschl's gyrus:25:0.8186	0.8186	25
HG	HG:55	high glucose:55:0.5510	0.5510	55
HG	HG:34	high-grade:21:0.0166|high grade:13:0.2038	0.2038	34
hg	hg:13|HG:5	high growth:18:0.7658	0.7658	18
HG	HG:15	histological grade:15:0.2621	0.2621	15
HG	HG:23	hyperemesis gravidarum:23:0.8715	0.8715	23
HG	HG:15	hyperglycemia:15:0.0110	0.0110	15
HG	HG:17|hg:4	hypergravity:21:0.0158	0.0158	21
HG	HG:10	hypoglossal:10:0.0071	0.0071	10
Hg	Hg:467|hg:1	Mercury:468:0.3683	0.3683	468
HHANES	HHANES:58	Hispanic Health and Nutrition Examination Survey:58:0.9486	0.9486	58
HHAs	HHAs:36	home health agencies:36:0.9174	0.9174	36
HHA	HHA:9	schedule of limits on home health agency:9:0.6794	0.6794	9
HHBV	HHBV:11	hepatitis B virus:11:0.7357	0.7357	11
HHCS	HHCS:8	Hereditary Hyperferritinemia-Cataract Syndrome:8:0.5006	0.5006	8
HHC	HHC:38	hereditary hemochromatosis:38:0.9217	0.9217	38
HHC	HHC:33	home health care:24:0.8768|home health-care:9:0.6794	0.8768	33
HHD	HHD:21	Hailey-Hailey disease:21:0.1836	0.1836	21
HHD	HHD:10	hand-held dynamometer:10:0.5000	0.5000	10
HHD	HHD:10	home hemodialysis:10:0.7103	0.7103	10
HHD	HHD:41	hypertensive heart disease:41:0.8525	0.8525	41
HHE	HHE:7	hypobaric hypoxic environment:7:0.6411	0.6411	7
HHF35	HHF35:6|HHF-35:1	monoclonal antibody:7:0.3524	0.3524	7
HHG	HHG:11	hypogonadotropic hypogonadism:11:0.4728	0.4728	11
HHHQ	HHHQ:11	Health Habits and History Questionnaire:11:0.7357	0.7357	11
HhH	HhH:27	Helix-hairpin-helix:27:0.4179	0.4179	27
HHIE	HHIE:1	Hearing Handicap Inventory in the Elderly:1:0.8270	0.8270	1
HHL	HHL:9	hippuryl-L-histidyl-L-leucine:9:0.1212	0.1212	9
HHL	HHL:7	N-hexanoyl-L-homoserine lactone:7:0.1850	0.1850	7
HHM	HHM:127	humoral hypercalcemia of malignancy:127:0.9394	0.9394	127
HHNS	HHNS:20	neurosecretory system:20:0.7173	0.7173	20
HHPA	HHPA:32	hexahydrophthalic anhydride:32:0.8090	0.8090	32
HHP	HHP:33	high hydrostatic pressure:33:0.9100	0.9100	33
HHP	HHP:10	Honolulu Heart Program:10:0.7103	0.7103	10
HHRH	HHRH:8	Hereditary hypophosphatemic rickets with hypercalciuria:8:0.6411	0.6411	8
HHSiD	HHSiD:10	hexahydrosiladifenidol:10:0.2727	0.2727	10
HHS	HHS:64	Department of Health and Human Services:64:0.5921	0.5921	64
HHS	HHS:27	Harris hip score:27:0.7834	0.7834	27
HHs	HHs:10	Hypothalamic hamartomas:10:0.7103	0.7103	10
HHS	HHS:11	hypothenar hammer syndrome:11:0.7357	0.7357	11
HHT1	HHT1:12	hereditary hemorrhagic telangiectasia type 1:12:0.7571	0.7571	12
HHT	HHT:30	12-hydroxy-5,8,10-heptadecatrienoic acid:30:0.1745	0.1745	30
HHT	HHT:55	hereditary haemorrhagic telangiectasia:55:0.9458	0.9458	55
HHT	HHT:148	hereditary hemorrhagic telangiectasia:148:0.9798	0.9798	148
HHT	HHT:6	Hereditary hemorrhagic teleangiectasia:6:0.5290	0.5290	6
HHT	HHT:7	heterotopic heart transplantation:7:0.4438	0.4438	7
HHT	HHT:50	Homoharringtonine:50:0.1153	0.1153	50
HHV	HHV:38	human herpesvirus:27:0.8312|human herpesviruses:11:0.7357	0.8312	38
HHV-6B	HHV-6B:7	human herpesvirus 6 variant B:7:0.5926	0.5926	7
HHV-6B	HHV-6B:8	human herpesvirus 6B:8:0.6411	0.6411	8
HHV-6	HHV-6:33|HHV6:1	human herpes virus-6:34:0.8644	0.8644	34
HHV-6	HHV-6:731|HHV6:45	human herpesvirus 6:524:0.9848|human herpesvirus-6:252:0.9626	0.9848	776
HHV-7	HHV-7:108|HHV7:5	human herpesvirus 7:113:0.9579	0.9579	113
HHV-8	HHV-8:11|HHV8:4	herpesvirus:15:0.0163	0.0163	15
HHV-8	HHV-8:20|HHV8:3	human herpes virus-8:23:0.8715	0.8715	23
HHV-8	HHV-8:10|HHV8:8	human herpes virus type 8:18:0.7658	0.7658	18
HHV-8	HHV-8:503|HHV8:105	human herpesvirus 8:474:0.9560|human herpesvirus-8:134:0.9138	0.9560	608
HHV-8	HHV-8:45|HHV8:11	human herpesvirus type 8:56:0.8901	0.8901	56
HHVs	HHVs:9	human herpesviruses:9:0.6794	0.6794	9
HHb	HHb:5	deoxygenated hemoglobin:5:0.0902	0.0902	5
HHb	HHb:10|HHB:1	deoxyhemoglobin:11:0.1923	0.1923	11
HHcy	HHcy:39|Hhcy:6|HHCY:4|HHCy:2|H-Hcy:1	hyperhomocysteinemia:52:0.8226	0.8226	52
HH	HH:15|H-H:3	Hamburger and Hamilton:18:0.8449	0.8449	18
HH	HH:11|H-H:2	Hamburger-Hamilton:13:0.0087	0.0087	13
HH	HH:12|H-H:5|hh:2|h-h:1	head-to-head:20:0.0138	0.0138	20
HH	HH:12	heated humidifier:12:0.7571	0.7571	12
Hh	Hh:267|hh:82|HH:15	hedgehog:364:0.2646	0.2646	364
Hh	Hh:11	hemopoietic histocompatibility:11:0.4232	0.4232	11
HH	HH:12	hemorrhagic hypotension:12:0.4153	0.4153	12
HH	HH:62	hereditary haemochromatosis:62:0.9018	0.9018	62
HH	HH:175|hh:1	Hereditary hemochromatosis:176:0.9330	0.9330	176
HH	HH:16	Hereford:16:0.0109	0.0109	16
HH	HH:20	hiatal hernia:20:0.4379	0.4379	20
HH	HH:11	hiatus hernia:11:0.1547	0.1547	11
HH	HH:29|H-H:1	Hodgkin-Huxley:30:0.0211	0.0211	30
HH	HH:9	hyperhidrosis:9:0.0058	0.0058	9
HH	HH:9	Hyperhomocysteinemia:9:0.0058	0.0058	9
HH	HH:7	hypobaric hypoxia:7:0.0565	0.0565	7
HH	HH:17	hypogonadotrophic hypogonadism:17:0.1076	0.1076	17
HH	HH:64	hypogonadotropic hypogonadism:64:0.6751	0.6751	64
HH	HH:6	hyporeninemic hypoaldosteronism:6:0.1838	0.1838	6
HH	HH:20	hypothalamic hamartoma:20:0.8594	0.8594	20
HH	HH:13	hypoxic hypoxia:13:0.2309	0.2309	13
HIA	HIA:29	Health impact assessment:29:0.8978	0.8978	29
HIBD	HIBD:10	brain damage:10:0.7103	0.7103	10
HICPAC	HICPAC:19	Hospital Infection Control Practices Advisory Committee:19:0.5404	0.5404	19
HIC	HIC:14	handling-induced convulsions:14:0.6173	0.6173	14
HIC	HIC:11	head injury criterion:11:0.7357	0.7357	11
HIC	HIC:20	Health Insurance Commission:20:0.8525	0.8525	20
HIC	HIC:26	hepatic iron concentration:26:0.8861	0.8861	26
HIC	HIC:98	Hydrophobic interaction chromatography:98:0.9695	0.9695	98
HiDAC	HiDAC:7|HIDAC:4|HiDAc:1	high-dose cytarabine:12:0.5050	0.5050	12
HIDS	HIDS:10	hyper-IgD and periodic fever syndrome:10:0.1547	0.1547	10
HID	HID:43	high iron diamine:43:0.9308	0.9308	43
HIES	HIES:9	hyperimmunoglobulin E syndrome:9:0.5470	0.5470	9
HIE	HIE:6	hyperimmunoglobulin E:6:0.2243	0.2243	6
HIE	HIE:1	Hypoxic and ischemic encephalopathy:1:0.9011	0.9011	1
HIE	HIE:27	hypoxic-ischaemic encephalopathy:27:0.1070	0.1070	27
HIE	HIE:81	hypoxic-ischemic encephalopathy:81:0.4328	0.4328	81
HIE	HIE:10	RAND Health Insurance Experiment:10:0.5856	0.5856	10
HIE	HIE:16	syndrome:16:0.0649	0.0649	16
HIF-1	HIF-1:21	hypoxia-inducible factor:21:0.4037	0.4037	21
HIF-1	HIF-1:492|HIF1:7|Hif-1:1	hypoxia-inducible factor-1:233:0.7259|hypoxia-inducible factor 1:212:0.7981|hypoxia inducible factor-1:55:0.9458	0.9458	500
HIFU	HIFU:170|HiFU:1	High-intensity focused ultrasound:111:0.5615|high intensity focused ultrasound:60:0.9503	0.9503	171
HIF	HIF:120	hypoxia-inducible factor:111:0.6489|Hypoxia-inducible factors:9:0.1492	0.6489	120
HIF	HIF:7	hypoxia-inducible factor-1:7:0.3524	0.3524	7
HIF	HIF:7	hypoxia-inducible transcription factors:7:0.4438	0.4438	7
HIGM1	HIGM1:8	hyper-IgM syndrome:8:0.2619	0.2619	8
HIG	HIG:9	haemolysis-in-gel:9:0.0567	0.0567	9
HIG	HIG:20	Hemolysis-in-gel:15:0.0993|hemolysis in gel:5:0.0902	0.0993	20
H-Ig	H-Ig:8	homogeneous immunoglobulins:8:0.3463	0.3463	8
HIG	HIG:27|HIg:3|hIg:3	human immunoglobulin:33:0.5414	0.5414	33
HIG	HIG:10	immunoglobulin G:10:0.5000	0.5000	10
HIIC	HIIC:9	intraoperative intraperitoneal chemotherapy:9:0.6794	0.6794	9
HII	HII:6	hepatic iron index:6:0.5290	0.5290	6
HII	HII:11	hexagonal phase:11:0.6182	0.6182	11
HILIC	HILIC:13	hydrophilic interaction chromatography:13:0.7753	0.7753	13
HILP	HILP:29	hyperthermic isolated limb perfusion:29:0.8978	0.8978	29
HIMA	HIMA:10	human internal mammary artery:10:0.5856	0.5856	10
HIMEC	HIMEC:18	human intestinal microvascular endothelial cells:18:0.8365	0.8365	18
HINT	HINT:20	Hearing in Noise Test:20:0.8525	0.8525	20
HIOMT	HIOMT:16	hydroxyindole-O-methyl transferase:16:0.5564	0.5564	16
HIP1	HIP1:17|Hip1:2|Hip-1:1	Huntingtin interacting protein 1:11:0.6182|huntingtin-interacting protein 1:9:0.1585	0.6182	20
HIPAA	HIPAA:103	Health Insurance Portability and Accountability Act:103:0.9712	0.9712	103
HIPAA	HIPAA:47	Health Insurance Portability and Accountability Act of 1996:47:0.9416	0.9416	47
HIPA	HIPA:13	heparin-induced platelet activation:13:0.5934	0.5934	13
HIPA	HIPA:10	platelet aggregation:10:0.7103	0.7103	10
HIPEC	HIPEC:13	hyperthermic intraperitoneal chemotherapy:13:0.6701	0.6701	13
HiPIP	HiPIP:43|Hipip:2|HIPIP:1	high-potential iron-sulfur protein:31:0.4827|high potential iron-sulfur protein:15:0.7096	0.7096	46
HIPK2	HIPK2:21	homeodomain-interacting protein kinase 2:12:0.4557|homeodomain-interacting protein kinase-2:9:0.6794	0.6794	21
HIPP	HIPP:35|Hipp:8	hippocampus:43:0.7241	0.7241	43
HIP	HIP:11	Health Insurance Plan:11:0.6182	0.6182	11
Hip	Hip:8|HIP:4|hip:1	hedgehog-interacting protein:13:0.1506	0.1506	13
HIP	HIP:53|hip:13	hippocampus:66:0.1976	0.1976	66
HIP	HIP:9	Hypnotic Induction Profile:9:0.4587	0.4587	9
HIP	HIP:15|Hip:4|hip:1	interacting protein:20:0.2608	0.2608	20
hip	hip:15	proximal femur:15:0.6173	0.6173	15
HIRc	HIRc:10	insulin receptors:10:0.7103	0.7103	10
hIR	hIR:26|HIR:21	human insulin receptor:47:0.8703	0.8703	47
HIR	HIR:10	response:10:0.0698	0.0698	10
HIST	HIST:10	high-intensity sprint training:10:0.7103	0.7103	10
HISS	HISS:12	hepatic insulin sensitizing substance:12:0.7571	0.7571	12
HITB	HITB:9|HiTb:2	influenzae Type b:11:0.7357	0.7357	11
HITH	HITH:11	Hospital in the Home:11:0.7357	0.7357	11
HITTS	HITTS:8	Heparin-induced thrombocytopenia and thrombosis syndrome:8:0.7571	0.7571	8
HITT	HITT:13	heparin-induced thrombocytopenia and thrombosis:13:0.7865	0.7865	13
HIT	HIT:6	cell line:6:0.1838	0.1838	6
HIT	HIT:7	haemagglutination inhibition test:7:0.2113	0.2113	7
HIT	HIT:11	Headache Impact Test:11:0.7357	0.7357	11
HIT	HIT:5	hemagglutination inhibition test:5:0.0612	0.0612	5
HIT	HIT:436	heparin-induced thrombocytopenia:436:0.9054	0.9054	436
HIT	HIT:6	high-intensity interval training:6:0.3728	0.3728	6
HIT	HIT:19	histidine triad:19:0.8449	0.8449	19
HIT	HIT:18	Holtzman Inkblot Technique:18:0.8365	0.8365	18
HIT	HIT:10	home infusion therapy:10:0.7103	0.7103	10
HIT	HIT:8	Hydrothermal Isometric Tension:8:0.6794	0.6794	8
HIV+	HIV+:31	HIV-infected:31:0.1099	0.1099	31
HIV+	HIV+:55	HIV-positive:44:0.1575|HIV positive:11:0.3213	0.3213	55
HIV+	HIV+:50	HIV-seropositive:35:0.1245|HIV seropositive:15:0.2729	0.2729	50
HIV+	HIV+:12	human immunodeficiency virus:12:0.7571	0.7571	12
HIV+	HIV+:20	human immunodeficiency virus-positive:20:0.8525	0.8525	20
HIV-	HIV-:22	HIV-negative:22:0.1780	0.1780	22
HIV-	HIV-:22	HIV-seronegative:22:0.1780	0.1780	22
HIV-	HIV-:17	seronegative:17:0.1356	0.1356	17
HIV-I	HIV-I:9	human immunodeficiency virus:9:0.6794	0.6794	9
HIV-I	HIV-I:34	human immunodeficiency virus type I:34:0.9151	0.9151	34
HIV-1	HIV-1:602|HIV1:2	human immunodeficiency virus:604:0.9755	0.9755	604
HIV-1	HIV-1:457|HIV1:2	human immunodeficiency virus-1:459:0.9895	0.9895	459
HIV-1	HIV-1:24	human immunodeficiency virus type:24:0.8715	0.8715	24
HIV-1	HIV-1:8112|HIV1:30|hiv-1:1	human immunodeficiency virus type 1:7706:0.9856|human immunodeficiency virus type-1:437:0.9723	0.9856	8143
HIV-1	HIV-1:129|HIV1:1	human immunodeficiency virus type I:130:0.9528	0.9528	130
HIV-1	HIV-1:9	human immunodeficiency virus type one:9:0.6794	0.6794	9
HIV-2	HIV-2:242|HIV2:7|hiv-2:2	human immunodeficiency virus type 2:238:0.9798|human immunodeficiency virus type-2:13:0.7753	0.9798	251
HIVAN	HIVAN:23|HIV-AN:2|HI-VAN:1	human immunodeficiency virus-associated nephropathy:26:0.8861	0.8861	26
HIV-Ag	HIV-Ag:7|HIV-ag:1	human immunodeficiency virus antigen:8:0.6411	0.6411	8
HIVE	HIVE:10	encephalopathy:10:0.1111	0.1111	10
HIVE	HIVE:36|HIV-E:1	HIV encephalitis:37:0.4464	0.4464	37
HIVIG	HIVIG:9|hIVIG:2|HivIg:1	immunoglobulin:12:0.4400	0.4400	12
HIV-RT	HIV-RT:11	human immunodeficiency virus reverse transcriptase:11:0.7357	0.7357	11
HIV	HIV:59	human immunodeficiency:59:0.8954	0.8954	59
HIV	HIV:13	Human immunodeficiency syndrome:13:0.5335	0.5335	13
HIV	HIV:10	human immunodeficiency viral:10:0.7103	0.7103	10
HIV	HIV:16234|hiv:1|hIV:1	human Immunodeficiency virus:16159:0.9813|human immunodeficiency viruses:67:0.9554|human-immunodeficiency-virus:10:0.0005	0.9813	16236
HIV	HIV:23	human immunodeficiency virus-1:23:0.7400	0.7400	23
HIV	HIV:61	human immunodeficiency virus infection:61:0.9511	0.9511	61
HIV	HIV:117	Human Immunodeficiency Virus type 1:103:0.9726|human immunodeficiency virus type-1:14:0.7909	0.9726	117
HIV	HIV:10	human immunodeficiency virus type I:10:0.7357	0.7357	10
Hib	Hib:756|HIB:48|HIb:5|HiB:2	Haemophilus influenzae type b:811:0.8826	0.8826	811
Hib	Hib:9|HIB:1	Haemophilus influenzae type b vaccine:10:0.5856	0.5856	10
Hib	Hib:13|HIb:2	Haemophilus influenzae:15:0.4951	0.4951	15
HIB	HIB:13	hyperpnea-induced bronchoconstriction:13:0.2121	0.2121	13
HIB	HIB:10	hyperventilation-induced bronchoconstriction:10:0.1273	0.1273	10
HI	HI:20|H-I:2	after hypoxia-ischemia:22:0.1106	0.1106	22
HI	HI:15|H-I:2	cerebral hypoxia-ischemia:17:0.0746	0.0746	17
HI	HI:11	congenital hyperinsulinism:11:0.1612	0.1612	11
HI	HI:7	familial hyperinsulinism:7:0.0539	0.0539	7
HI	HI:59	Haemagglutination-inhibiting:34:0.0132|haemagglutination inhibiting:25:0.4451	0.4451	59
HI	HI:319	haemagglutination inhibition:213:0.3232|haemagglutination-inhibition:106:0.0422	0.3232	319
Hi	Hi:39|HI:30	Haemophilus influenzae:69:0.7961	0.7961	69
HI	HI:12	harlequin ichthyosis:12:0.7571	0.7571	12
HI	HI:15	harmonic imaging:15:0.7096	0.7096	15
HI	HI:41	head injury:41:0.7952	0.7952	41
HI	HI:15	healthy individuals:15:0.6386	0.6386	15
HI	HI:16	hearing-impaired:16:0.0060	0.0060	16
HI	HI:39	hearing impairment:39:0.8811	0.8811	39
HI	HI:54	hemagglutination-inhibiting:40:0.0157|hemagglutination inhibiting:14:0.1769	0.1769	54
HI	HI:606|hi:1	hemagglutination inhibition:354:0.5609|hemagglutination-inhibition:253:0.1012	0.5609	607
HI	HI:27	high-intensity:18:0.0068|high intensity:9:0.3455	0.3455	27
HI	HI:21|Hi:3	hippocampus:24:0.0092	0.0092	24
Hi	Hi:43|HI:23	histamine:66:0.0261	0.0261	66
HI	HI:17	Hospital Insurance:17:0.6211	0.6211	17
HI	HI:38|hI:2	Human insulin:40:0.7201	0.7201	40
HI	HI:11	humoral immunity:11:0.5355	0.5355	11
HI	HI:5	Hyperinsulinism of infancy:5:0.6182	0.6182	5
HI	HI:29	hypomelanosis of Ito:29:0.8472	0.8472	29
HI	HI:14	hypoxia-ischaemia:14:0.0052	0.0052	14
HI	HI:5|H-I:1	hypoxic ischemia:6:0.1010	0.1010	6
HI	HI:60|H-I:14	hypoxic-ischemic:74:0.0289	0.0289	74
HI	HI:112|Hi:1|hi:1	index:114:0.0454	0.0454	114
HI	HI:25	inhibition test:25:0.6539	0.6539	25
HI	HI:17	neonatal hypoxia-ischemia:17:0.0746	0.0746	17
H-JEB	H-JEB:16|HJEB:2	junctional epidermolysis bullosa:18:0.8365	0.8365	18
HJ	HJ:13	Highlands J:13:0.6701	0.6701	13
HJ	HJ:13	Holliday junction:13:0.7753	0.7753	13
HJ	HJ:6	Roux-en-Y hepaticojejunostomy:6:0.1838	0.1838	6
HK-2	HK-2:7|HK2:2	cell line:9:0.6794	0.6794	9
hK2	hK2:43	human glandular kallikrein:43:0.7311	0.7311	43
hK2	hK2:45|HK2:1	Human glandular kallikrein 2:46:0.8986	0.8986	46
hK2	hK2:31	Human kallikrein 2:31:0.2631	0.2631	31
HK-2	HK-2:5	human proximal tubular cells:5:0.1973	0.1973	5
HK-2	HK-2:11	proximal tubular:11:0.7357	0.7357	11
hK6	hK6:9	human kallikrein 6:9:0.5006	0.5006	9
HKa	HKa:6	cleaved HK:6:0.2243	0.2243	6
HKa	HKa:13	high molecular weight kininogen:13:0.6701	0.6701	13
hkb	hkb:15|Hkb:1	huckebein:16:0.5357	0.5357	16
HKc	HKc:10|HKC:4	human keratinocytes:14:0.4709	0.4709	14
HKII	HKII:27|HK-II:1	hexokinase II:28:0.8941	0.8941	28
HKLM	HKLM:10|hk-LM:1	heat-killed Listeria monocytogenes:11:0.6182	0.6182	11
HKL	HKL:10	heat-killed Listeria monocytogenes:10:0.5000	0.5000	10
HK	HK:9	head kidney:9:0.2102	0.2102	9
HK	HK:17|H-K:1	heat-killed:18:0.0193	0.0193	18
HK	HK:292|Hk:3	hexokinase:295:0.3345	0.3345	295
HK	HK:1	high in potassium:1:0.7407	0.7407	1
HK	HK:9	high K+:9:0.6794	0.6794	9
HK	HK:147	high molecular weight kininogen:119:0.9749|high-molecular-weight kininogen:28:0.1088	0.9749	147
HK	HK:8	histidine kinase:8:0.1895	0.1895	8
HK	HK:12	Hong Kong:12:0.7571	0.7571	12
HK	HK:6	horseshoe kidney:6:0.0666	0.0666	6
hK	hK:4|hk:1	human kallikrein:5:0.1132	0.1132	5
HK	HK:29	human keratinocytes:29:0.5551	0.5551	29
Hk	Hk:10|HK:1	Hyperkinetic:11:0.0114	0.0114	11
HK	HK:79|Hk:2	hypokinesia:81:0.0899	0.0899	81
HL60	HL60:5	human leukaemia 60:5:0.4422	0.4422	5
HL-60	HL-60:51|HL60:5	human leukemia:56:0.1596	0.1596	56
HL-60	HL-60:25|HL60:1	human leukemic:26:0.4438	0.4438	26
HL-60	HL-60:6	human promyelocytes:6:0.2243	0.2243	6
HL-60	HL-60:13|HL60:5	human promyelocytic:18:0.2956	0.2956	18
HL-60	HL-60:11|HL60:2	human promyelocytic leukaemia:13:0.4444	0.4444	13
HL-60	HL-60:130|HL60:11	human promyelocytic leukemia:141:0.7704	0.7704	141
HL-60	HL-60:113|HL60:9	human promyelocytic leukemia cells:117:0.7922|human promyelocytic leukemia cell:5:0.4422	0.7922	122
HL-60	HL-60:23|HL60:2	human promyelocytic leukemia cell line:25:0.5496	0.5496	25
HL-60	HL-60:11	human promyelocytic leukemic:11:0.6182	0.6182	11
HL7	HL7:21|HL-7:1	Health Level 7:22:0.8657	0.8657	22
HL7	HL7:24	Health Level Seven:24:0.8038	0.8038	24
HLA-B	HLA-B:5	human leukocyte antigen-B:5:0.4422	0.4422	5
HLADH	HLADH:23|HL-ADH:1	horse liver alcohol dehydrogenase:24:0.7955	0.7955	24
HLA-DR	HLA-DR:16	class II antigen:16:0.8165	0.8165	16
HLA-DR	HLA-DR:15	human leucocyte antigen-DR:15:0.7096	0.7096	15
HLA-DR	HLA-DR:16	human leukocyte antigen:16:0.6024	0.6024	16
HLA-DR	HLA-DR:68|HLADR:1	human leukocyte antigen-DR:49:0.8753|human leukocyte antigen DR:20:0.7766	0.8753	69
HLA-DR	HLA-DR:7	Major Histocompatibility Complex:7:0.4438	0.4438	7
HLA-G	HLA-G:28	human leukocyte antigen G:18:0.8365|Human leukocyte antigen-G:10:0.5856	0.8365	28
HLAR	HLAR:13	aminoglycoside resistance:13:0.7753	0.7753	13
HLa	HLa:7	blood lactate:7:0.2452	0.2452	7
HLA	HLA:5|HL-A:1	histocompatibility system:6:0.1320	0.1320	6
HLA	HLA:370	human leucocyte antigen:299:0.9162|Human leucocyte antigens:71:0.9335	0.9335	370
HLA	HLA:8|HL-A:1	human leukocyte:9:0.3455	0.3455	9
HLA	HLA:1565|HL-A:1	human leukocyte antigen:1337:0.9143|Human leukocyte antigens:229:0.8459	0.9143	1566
HLA	HLA:6	Human Major Histocompatibility:6:0.0731	0.0731	6
HLA	HLA:23	human major histocompatibility complex:23:0.4831	0.4831	23
HLA	HLA:7	human MHC:7:0.2452	0.2452	7
HLA	HLA:11	Symposium on major histocompatibility antigens:11:0.3213	0.3213	11
HLBI	HLBI:31|HL-BI:1	human lymphoblastoid interferon:32:0.9072	0.9072	32
HLC	HLC:31	Health Locus of Control:31:0.9072	0.9072	31
HLD	HLD:19	hepatolenticular degeneration:19:0.7044	0.7044	19
HLD	HLD:5	high-level disinfection:5:0.1132	0.1132	5
HLECs	HLECs:8|hLECs:1	Human lens epithelial cells:9:0.6794	0.6794	9
HLEC	HLEC:5|hLEC:1	human lens epithelial cells:6:0.5290	0.5290	6
HLE	HLE:29	human lens epithelial:29:0.8978	0.8978	29
HLE	HLE:151|hLE:3	human leukocyte elastase:154:0.9690	0.9690	154
HLF	HLF:13|Hlf:1	hepatic leukemia factor:14:0.4849	0.4849	14
hLF	hLF:25|hLf:17|HLf:8|HLF:4	human lactoferrin:54:0.8401	0.8401	54
HLF	HLF:22	human lung fibroblasts:22:0.7400	0.7400	22
HLGAGs	HLGAGs:10	glycosaminoglycans:10:0.9000	0.9000	10
HLGR	HLGR:13	high-level gentamicin resistance:13:0.5934	0.5934	13
HLHS	HLHS:151	hypoplastic left heart syndrome:151:0.9800	0.9800	151
hLIF	hLIF:9	human leukemia inhibitory factor:9:0.5856	0.5856	9
HLI	HLI:16	Human leukocyte interferon:16:0.8165	0.8165	16
HLL	HLL:11|Hll:1	Humicola lanuginosa lipase:12:0.7571	0.7571	12
HLM	HLM:10	hierarchical linear models:10:0.7103	0.7103	10
HLM	HLM:56	human liver microsomes:56:0.9162	0.9162	56
HLMC	HLMC:27	human lung mast cells:27:0.8903	0.8903	27
HLMs	HLMs:35|HLMS:1	human liver microsomes:36:0.9174	0.9174	36
HLNL	HLNL:10	hydroxylysinonorleucine:10:0.6000	0.6000	10
HLOC	HLOC:18	health locus of control:18:0.8365	0.8365	18
HLP	HLP:10	hairy leukoplakia:10:0.7103	0.7103	10
HLP	HLP:11|hlp:1	hyperlipidemia:12:0.0327	0.0327	12
HLP	HLP:50	hyperlipoproteinaemia:50:0.1458	0.1458	50
HLP	HLP:10|hlp:1	hyperlipoproteinemias:11:0.0298	0.0298	11
HLP	HLP:43	type III hyperlipoproteinemia:43:0.8917	0.8917	43
HLRCC	HLRCC:11	hereditary leiomyomatosis and renal cell cancer:11:0.7357	0.7357	11
HLR	HLR:12	heart-to-lung ratio:12:0.4153	0.4153	12
HLR	HLR:13	high-level resistance:13:0.3554	0.3554	13
HLR	HLR:12	hydraulic loading rate:12:0.7571	0.7571	12
HLS	HLS:12	syndrome:12:0.1183	0.1183	12
HL	HL:9	3-Hydroxy-3-methylglutaryl coenzyme A lyase:9:0.6411	0.6411	9
HL	HL:17	dB hearing level:17:0.3844	0.3844	17
HL	HL:57	hairy leukoplakia:57:0.9486	0.9486	57
HL	HL:16	haloperidol:16:0.0103	0.0103	16
HL	HL:70	hearing loss:70:0.7986	0.7986	70
HL	HL:11	heat-labile:11:0.0069	0.0069	11
HL	HL:15	high light:15:0.4951	0.4951	15
HL	HL:266	Hodgkin's lymphoma:166:0.5677|Hodgkin lymphoma:91:0.2837|Hodgkin's lymphomas:9:0.3945	0.5677	266
HL	HL:10	Human lymphocytes:10:0.3867	0.3867	10
HL	HL:8|hL:2	human lysozyme:10:0.3867	0.3867	10
HL	HL:9	hyaline layer:9:0.1945	0.1945	9
HL	HL:9	hybrid layer:9:0.1945	0.1945	9
HL	HL:17	hyperlipidemia:17:0.0110	0.0110	17
HL	HL:14	hyperlipidemic:14:0.0089	0.0089	14
HL	HL:6|Hl:1	lateral hypothalamus:7:0.3524	0.3524	7
HL	HL:12	length:12:0.0075	0.0075	12
HL	HL:6	selected for high:6:0.2113	0.2113	6
HMAbs	HMAbs:10|hMAbs:2|HmAbs:2|hmAbs:1|HMabs:1	Human monoclonal antibodies:16:0.6577	0.6577	16
hMAb	hMAb:12|hmAb:6|HmAb:4|HMAb:4|HMab:2|h-MAb:1	human monoclonal antibody:19:0.7658|human monoclonal antibodies:10:0.7103	0.7658	29
HMA	HMA:20	3-hydroxymethylantipyrine:20:0.0653	0.0653	20
HMA	HMA:17	5-(N,N-hexamethylene)amiloride:11:0.0344|5-(N,N-hexamethylene) amiloride:6:0.0522	0.0522	17
HMA	HMA:15	heteroduplex mobility analysis:15:0.8045	0.8045	15
HMA	HMA:99	heteroduplex mobility assay:99:0.9698	0.9698	99
HMA	HMA:7	hexamethylene amiloride:7:0.1690	0.1690	7
HMBA	HMBA:191	hexamethylene bisacetamide:182:0.9218|hexamethylene-bisacetamide:9:0.0265	0.9218	191
HMBA	HMBA:50	Hexamethylenebisacetamide:50:0.1623	0.1623	50
HMBA	HMBA:11	N,N'-hexamethylene-bis-acetamide:11:0.0331	0.0331	11
HMBS	HMBS:16|HMB-S:2	hydroxymethylbilane synthase:18:0.7539	0.7539	18
HMB	HMB:37|hmb:1	beta-hydroxy-beta-methylbutyrate:38:0.2450	0.2450	38
HMB	HMB:13	Heavy menstrual bleeding:13:0.7753	0.7753	13
HMB	HMB:10	hypersensitivity to mosquito bites:10:0.7103	0.7103	10
HMC-1	HMC-1:8	human leukemic mast cells:8:0.6411	0.6411	8
HMC-1	HMC-1:25	human mast cell line:25:0.5496	0.5496	25
HMCAS	HMCAS:13	hyperdense middle cerebral artery sign:13:0.7753	0.7753	13
HMCs	HMCs:31|hMCs:1	human mesangial cells:32:0.7166	0.7166	32
Hmc	Hmc:7|hmc:1|HMC:1	cytochrome c:9:0.5470	0.5470	9
HMC	HMC:11	high-moisture corn:11:0.5355	0.5355	11
HMC	HMC:105|hMC:1	human mesangial cells:96:0.8268|Human mesangial cell:10:0.5856	0.8268	106
HMC	HMC:9	Medical Center:9:0.5470	0.5470	9
HMDI	HMDI:9	hexamethylene diisocyanate:9:0.2757	0.2757	9
HMDMs	HMDMs:14|hMDMs:2	human monocyte-derived macrophages:16:0.8165	0.8165	16
HMDM	HMDM:28|hMDM:2|HMD-M:1	human monocyte-derived macrophages:31:0.8519	0.8519	31
HMDS	HMDS:25	hexamethyldisilazane:25:0.3636	0.3636	25
HMD	HMD:36	head-mounted display:27:0.4555|head mounted display:9:0.6794	0.6794	36
HMD	HMD:231	hyaline membrane disease:231:0.9724	0.9724	231
HMEC-1	HMEC-1:9	human dermal microvascular endothelial cell line:9:0.6794	0.6794	9
HMEC-1	HMEC-1:43	human microvascular endothelial cells:43:0.6810	0.6810	43
HMEC-1	HMEC-1:13	human microvascular endothelial cell line:13:0.3331	0.3331	13
HMECs	HMECs:63	human mammary epithelial cells:63:0.9018	0.9018	63
HMEC	HMEC:88	human mammary epithelial cells:76:0.8677|human mammary epithelial cell:12:0.7571	0.8677	88
HMEC	HMEC:20|hMEC:1|hmEC:1	human microvascular endothelial cells:22:0.5863	0.5863	22
HMEC	HMEC:6	microvascular endothelial cell:6:0.5290	0.5290	6
HMEs	HMEs:21	heat and moisture exchangers:21:0.8657	0.8657	21
HME	HME:62	heat and moisture exchanger:38:0.8839|heat and moisture exchangers:24:0.8816	0.8839	62
HME	HME:12	hemimegalencephaly:12:0.0364	0.0364	12
HME	HME:37	hereditary multiple exostoses:37:0.8749	0.8749	37
HME	HME:9	Hereditary multiple exostosis:9:0.6794	0.6794	9
HME	HME:23	human mammary epithelial:23:0.7500	0.7500	23
HME	HME:36	human monocytic ehrlichiosis:36:0.8716	0.8716	36
HMFG	HMFG:20	human milk fat globule:20:0.7766	0.7766	20
HMF	HMF:20	5-hydroxymethylfurfural:20:0.1275	0.1275	20
HMF	HMF:10	fraction:10:0.0604	0.0604	10
HMF	HMF:15	hydroxymethylfurfural:15:0.0940	0.0940	15
hMG-hCG	hMG-hCG:7|HMG-HCG:2	chorionic gonadotropin:9:0.5470	0.5470	9
hMG/hCG	hMG/hCG:11	human menopausal gonadotropin/human chorionic gonadotropin:11:0.7357	0.7357	11
HMG1	HMG1:18|HMG-1:9	high mobility group 1:19:0.8449|high mobility group-1:8:0.6411	0.8449	27
HMG1	HMG1:9|HMG-1:4	high mobility group 1 protein:13:0.7753	0.7753	13
HMG1	HMG1:7|HMG-1:4|hmg-1:1	high mobility group protein 1:12:0.7571	0.7571	12
HMG2	HMG2:3|HMG-2:2|Hmg2:1	high mobility group 2:6:0.5290	0.5290	6
HMGB1	HMGB1:20	High mobility group box 1:20:0.8525	0.8525	20
HMGB1	HMGB1:5	high mobility group box 1 protein:5:0.4422	0.4422	5
HMGB-1	HMGB-1:7|HMGB1:4	High mobility group box chromosomal protein 1:11:0.7357	0.7357	11
HMG-CoA	HMG-CoA:13	3-hydroxy-3-methyl-glutaryl-CoA:13:0.0393	0.0393	13
HMG-CoA	HMG-CoA:168|HMGCoA:10	3-hydroxy-3-methylglutaryl-CoA:129:0.4197|3-hydroxy-3-methylglutaryl CoA:49:0.6680	0.6680	178
HMG-CoA	HMG-CoA:12	3-Hydroxy-3-methylglutaryl coenzyme-A:12:0.4557	0.4557	12
HMG-CoA	HMG-CoA:22|HMGCoA:1	hydroxymethylglutaryl-CoA:23:0.0721	0.0721	23
HMGI-C	HMGI-C:4	high mobility group I-C:4:0.3170	0.3170	4
HMGI	HMGI:6	High Mobility Group I:6:0.5290	0.5290	6
HMG	HMG:15	3-Hydroxy-3-methylglutaric acid:15:0.5818	0.5818	15
HMG	HMG:21	3-hydroxy-3-methylglutaryl:21:0.0138	0.0138	21
HMG	HMG:493|Hmg:1	High mobility group:319:0.9849|high-mobility-group:91:0.0621|high-mobility group:84:0.1644	0.9849	494
HMG	HMG:10	high mobility group proteins:10:0.7103	0.7103	10
HMG	HMG:208|hMG:60	human menopausal gonadotrophin:236:0.8790|Human menopausal gonadotrophins:32:0.8563	0.8790	268
hMG	hMG:392|HMG:67	human menopausal gonadotropin:378:0.9275|human menopausal gonadotropins:81:0.9631	0.9631	459
HMIS	HMIS:11	Health Management Information System:11:0.5355	0.5355	11
HML	HML:23	human mononuclear leukocytes:23:0.7500	0.7500	23
HMMA	HMMA:14	4-hydroxy-3-methoxymandelic acid:14:0.3383	0.3383	14
HMMA	HMMA:11	4-hydroxy-3-methoxymethamphetamine:11:0.2381	0.2381	11
HMMECs	HMMECs:9	Human mucosal microvascular endothelial cells:9:0.6794	0.6794	9
HMMs	HMMs:86|HMMS:1	Hidden Markov models:87:0.9656	0.9656	87
HMM	HMM:233|HmM:1	heavy meromyosin:234:0.9284	0.9284	234
HMM	HMM:56	hexamethylmelamine:56:0.1067	0.1067	56
HMM	HMM:104	hidden Markov model:80:0.9627|hidden Markov models:24:0.8768	0.9627	104
HMM	HMM:29	high molecular mass:19:0.7658|high-molecular-mass:10:0.0178	0.7658	29
HMNC	HMNC:5|hMNC:2	human mononuclear cells:7:0.3524	0.3524	7
HMO's	HMO's:16	Health Maintenance Organizations:16:0.8165	0.8165	16
HMOs	HMOs:535|HMOS:1	health maintenance organizations:536:0.9774	0.9774	536
HMO	HMO:11	health maintenance organisation:11:0.7357	0.7357	11
HMO	HMO:727|HmO:1	health maintenance organization:702:0.9827|health maintenance organizations:26:0.8861	0.9827	728
HMPA	HMPA:43	hexamethylphosphoramide:43:0.7500	0.7500	43
HMPAO	HMPAO:7|HM-PAO:2	99mTc-hexamethylpropyleneamineoxime:9:0.0188	0.0188	9
HMPAO	HMPAO:8|HM-PAO:1	hexamethylpropyleneamineoxime:9:0.0188	0.0188	9
HMPAO	HMPAO:10	Tc-99m hexamethylpropylene amineoxime:10:0.5856	0.5856	10
HMPG	HMPG:11	4-hydroxy-3-methoxyphenyl glycol:11:0.4728	0.4728	11
HMPG	HMPG:21	4-hydroxy-3-methoxyphenylglycol:21:0.3922	0.3922	21
hMPV	hMPV:80|HMPV:32|hmpv:1	Human metapneumovirus:113:0.9575	0.9575	113
Hmp	Hmp:7	Escherichia coli flavohaemoglobin:7:0.5926	0.5926	7
HMP	HMP:43	hexose monophosphate:43:0.9308	0.9308	43
HMP	HMP:17	hexose monophosphate pathway:17:0.7407	0.7407	17
H-MRS	H-MRS:6|HMRS:3	proton magnetic resonance spectroscopy:9:0.5470	0.5470	9
HMR	HMR:5	heart-to-mediastinum ratio:5:0.0736	0.0736	5
HMR	HMR:13	Histiocytic medullary reticulosis:13:0.7753	0.7753	13
hMR	hMR:26	human mineralocorticoid receptor:26:0.7760	0.7760	26
hMSC	hMSC:23|HMSC:3	Human mesenchymal stem cells:26:0.6351	0.6351	26
HMSN	HMSN:129	hereditary motor and sensory neuropathy:104:0.9451|Hereditary Motor and Sensory Neuropathies:25:0.8903	0.9451	129
HMS	HMS:12	hairless mouse skin:12:0.7571	0.7571	12
HMs	HMs:10	heavy metals:10:0.7103	0.7103	10
HMS	HMS:54	hexose monophosphate shunt:54:0.9448	0.9448	54
HMS	HMS:6	hypermobility syndrome:6:0.1010	0.1010	6
HMS	HMS:6	Hyperreactive malarial splenomegaly:6:0.1543	0.1543	6
HMS	HMS:8	hyperreactive malarious splenomegaly:8:0.4102	0.4102	8
HMs	HMs:31	hypoglossal motoneurons:31:0.9043	0.9043	31
HMTase	HMTase:17	methyltransferase:17:0.8889	0.8889	17
HMT	HMT:25	4'-hydroxymethyl-4,5',8-trimethylpsoralen:13:0.0606|4'-(hydroxymethyl)-4,5',8-trimethylpsoralen:12:0.0556	0.0606	25
HMT	HMT:7	heparin management test:7:0.5926	0.5926	7
HMT	HMT:17	hexamethylenetetramine:17:0.0808	0.0808	17
HMT	HMT:12	Histamine methyltransferase:12:0.3524	0.3524	12
HMT	HMT:42	histamine N-methyltransferase:28:0.8941|histamine-N-methyltransferase:14:0.0657	0.8941	42
HMT	HMT:6	histone methyltransferase:6:0.0611	0.0611	6
hMT	hMT:7|HMT:1	human metallothionein:8:0.3463	0.3463	8
hmU	hmU:7|HmU:5|HMU:1	5-hydroxymethyluracil:13:0.4138	0.4138	13
HMVEC-L	HMVEC-L:6|HMVEC-l:1	human lung microvascular endothelial cells:7:0.5926	0.5926	7
HMVEC	HMVEC:27|hMVEC:5|HMvEC:1	human microvascular endothelial cells:33:0.6735	0.6735	33
HMVEC	HMVEC:9	microvascular endothelial cell:9:0.6794	0.6794	9
HMV	HMV:38	home mechanical ventilation:38:0.9217	0.9217	38
HMW-GS	HMW-GS:12	high molecular weight glutenin subunits:12:0.7571	0.7571	12
HMWCK	HMWCK:6|HMW-CK:2	high molecular weight cytokeratin:8:0.6411	0.6411	8
HMWK	HMWK:72|HMW-K:3|HMwK:2	high molecular weight kininogen:77:0.9386	0.9386	77
HMW-MAA	HMW-MAA:42|HMWMAA:3	high molecular weight-melanoma associated antigen:18:0.7539|high-molecular-weight melanoma-associated antigen:17:0.2788|high molecular weight melanoma-associated antigen:10:0.5000	0.7539	45
HMW	HMW:536|hmw:4	high molecular weight:390:0.9384|high-molecular-weight:150:0.2322	0.9384	540
HMdU	HMdU:18|hmdU:1|HmdU:1	5-hydroxymethyl-2'-deoxyuridine:20:0.6786	0.6786	20
HMVECs	HMVECs:17|hMVECs:6|HMvECs:1	human microvascular endothelial cells:24:0.4788	0.4788	24
HM	HM:9	heavy metals:9:0.5470	0.5470	9
HM	HM:5	heuristic method:5:0.1132	0.1132	5
Hm	Hm:11|HM:1	histamine:12:0.0162	0.0162	12
HM	HM:26|H-M:1	Holter monitoring:27:0.5524	0.5524	27
HM	HM:45	human milk:45:0.8115	0.8115	45
HM	HM:60	hydatidiform mole:45:0.8964|hydatidiform moles:15:0.8045	0.8964	60
HM	HM:12	hydromorphone:12:0.0162	0.0162	12
HM	HM:6	hypercalcemia of malignancy:6:0.0692	0.0692	6
HM	HM:9	malignancies:9:0.0118	0.0118	9
HM	HM:4	patients with hypercalcaemia of malignancy:4:0.0545	0.0545	4
HN2	HN2:21|HN-2:1	mechlorethamine:22:0.1200	0.1200	22
HN2	HN2:6	mechlorethamine hydrochloride:6:0.3524	0.3524	6
HN2	HN2:117|HN-2:6	nitrogen mustard:123:0.9757	0.9757	123
HNA	HNA:11	heparin neutralizing activity:11:0.7357	0.7357	11
HNA	HNA:24	hereditary neuralgic amyotrophy:24:0.8768	0.8768	24
HNA	HNA:8	higher nervous activity:8:0.6411	0.6411	8
HNCM	HNCM:17	hypertrophic nonobstructive cardiomyopathy:17:0.6748	0.6748	17
HNCM	HNCM:11	patients with hypertrophic non-obstructive cardiomyopathy:11:0.4153	0.4153	11
HNC	HNC:5	guinea pig hypothalamo-neurohypophyseal complex:5:0.4422	0.4422	5
HNC	HNC:72	head and neck cancer:72:0.9585	0.9585	72
HNC	HNC:10|hNC:1	Human neutrophil collagenase:11:0.7357	0.7357	11
HNECs	HNECs:11	human nasal epithelial cells:11:0.6182	0.6182	11
HNED	HNED:8	highest no-effect dose:8:0.6411	0.6411	8
HNE	HNE:15	4-Hydroxy-2,3-nonenal:15:0.0170	0.0170	15
HNE	HNE:14	4-hydroxy-2,3-trans-nonenal:14:0.0158	0.0158	14
HNE	HNE:11	4-hydroxy-2(E)-nonenal:11:0.0122	0.0122	11
HNE	HNE:142	4-hydroxy-2-nonenal:142:0.1703	0.1703	142
HNE	HNE:15	4-hydroxy-trans-2-nonenal:15:0.0170	0.0170	15
HNE	HNE:286	4-hydroxynonenal:286:0.3467	0.3467	286
HNE	HNE:10	(E)-4-Hydroxy-2-nonenal:10:0.0109	0.0109	10
HNE	HNE:11	human nasal epithelial:11:0.7357	0.7357	11
HNE	HNE:192|hNE:2	human neutrophil elastase:194:0.9390	0.9390	194
HNE	HNE:14	hydroxynonenal:14:0.0146	0.0146	14
HNE	HNE:17	trans-4-hydroxy-2-nonenal:17:0.0195	0.0195	17
HNF1	HNF1:12|HNF-1:6	Hepatic Nuclear Factor 1:18:0.1162	0.1162	18
HNF-1	HNF-1:54|HNF1:45|hnf1:1	hepatocyte nuclear factor 1:64:0.6789|hepatocyte nuclear factor-1:36:0.7433	0.7433	100
HNF-3	HNF-3:35|HNF3:21|Hnf3:1	hepatocyte nuclear factor 3:41:0.6524|hepatocyte nuclear factor-3:16:0.7261	0.7261	57
HNF-4	HNF-4:87|HNF4:34	hepatocyte nuclear factor 4:79:0.7624|hepatocyte nuclear factor-4:42:0.7523	0.7624	121
HNF-6	HNF-6:9	Hepatocyte nuclear factor-6:9:0.6794	0.6794	9
HNF	HNF:46	hepatocyte nuclear factor:46:0.7839	0.7839	46
HNF	HNF:9	heterotrophic nanoflagellates:9:0.6794	0.6794	9
HNF	HNF:10	nuclear factors:10:0.7103	0.7103	10
HNIG	HNIG:9	human normal immunoglobulin:9:0.6794	0.6794	9
HNL	HNL:27	histiocytic necrotizing lymphadenitis:27:0.7425	0.7425	27
HNL	HNL:36	human neutrophil lipocalin:36:0.8681	0.8681	36
HNMT	HNMT:39	Histamine N-methyltransferase:39:0.8455	0.8455	39
HNO3	HNO3:24	nitric acid:24:0.7151	0.7151	24
HNO	HNO:43	nitroxyl:43:0.8542	0.8542	43
HNPCC	HNPCC:48	hereditary non-polyposis colon cancer:48:0.9379	0.9379	48
HNPCC	HNPCC:18	Hereditary non-polyposis colorectal carcinoma:18:0.8365	0.8365	18
HNPCC	HNPCC:61|HN-PCC:1	hereditary nonpolyposis colon cancer:62:0.9519	0.9519	62
HNPCC	HNPCC:466|HN-PCC:1	hereditary nonpolyposis colorectal cancer:459:0.9859|hereditary nonpolyposis colorectal cancers:8:0.6411	0.9859	467
HNPCC	HNPCC:14	hereditary nonpolyposis colorectal cancer syndrome:14:0.7909	0.7909	14
HNPCC	HNPCC:39	Hereditary nonpolyposis colorectal carcinoma:39:0.8811	0.8811	39
HNPP	HNPP:190|HN-PP:1	hereditary neuropathy with liability to pressure palsies:170:0.9543|Hereditary neuropathy with liability to pressure palsy:21:0.8594	0.9543	191
HNPs	HNPs:10	Human neutrophil peptides:10:0.7103	0.7103	10
HNP	HNP:33	herniated nucleus pulposus:33:0.7841	0.7841	33
HNR	HNR:13	harmonics-to-noise ratio:13:0.4444	0.4444	13
HNSCCA	HNSCCA:6|HNSCCa:3	head and neck squamous cell carcinoma:9:0.6794	0.6794	9
HNSCCs	HNSCCs:56|HN-SCCs:1	head and neck squamous cell carcinomas:57:0.9477	0.9477	57
HNSCC	HNSCC:31	head and neck squamous cell cancer:31:0.9043	0.9043	31
HNSCC	HNSCC:637|HN-SCC:6|hnSCC:1|HNscc:1|H-NSCC:1	head and neck squamous cell carcinoma:525:0.9908|head and neck squamous cell carcinomas:121:0.9606	0.9908	646
HNSCC	HNSCC:93|HN-SCC:1	squamous cell carcinoma of the head and neck:68:0.9573|squamous cell carcinomas of the head and neck:26:0.8861	0.9573	94
hNSCs	hNSCs:9|HNSCs:6	Human neural stem cells:15:0.7096	0.7096	15
HNSC	HNSC:8	head and neck squamous carcinoma:8:0.6411	0.6411	8
HNSC	HNSC:6	head and neck squamous cell carcinoma:6:0.5290	0.5290	6
HNs	HNs:8	hyperplastic nodules:8:0.3463	0.3463	8
HN	HN:10	glycoprotein:10:0.0105	0.0105	10
HN	HN:81	haemagglutinin-neuraminidase:81:0.0932	0.0932	81
HN	HN:19|H-N:1	head and neck:20:0.7173	0.7173	20
HN	HN:290|H-N:1	hemagglutinin-neuraminidase:284:0.3298|hemagglutinin neuraminidase:7:0.2500	0.3298	291
HN	HN:10	hemagglutinin-neuraminidase protein:10:0.2275	0.2275	10
HN	HN:15	hereditary nephritis:15:0.0853	0.0853	15
hn	hn:14	heterogeneous nuclear:14:0.6911	0.6911	14
hn	hn:27	heteronuclear:27:0.0303	0.0303	27
HN	HN:59	Heymann nephritis:59:0.5896	0.5896	59
HN	HN:26	Humanin:26:0.0291	0.0291	26
HN	HN:19	hyaluronectin:19:0.0210	0.0210	19
HN	HN:9|Hn:1	hydronephrosis:10:0.0105	0.0105	10
HN	HN:17	hyperplastic nodules:17:0.5374	0.5374	17
HN	HN:9	hypoglossal nucleus:9:0.6794	0.6794	9
HO*	HO*:39	hydroxyl radical:25:0.8816|hydroxyl radicals:14:0.7909	0.8816	39
HO.	HO.:76	hydroxyl radical:49:0.8753|hydroxyl radicals:27:0.8903	0.8903	76
HO-1	HO-1:57|HO1:1|ho-1:1	heme oxygenase:59:0.8154	0.8154	59
HO-1	HO-1:725|HO1:12|ho-1:2|Ho-1:1	Heme oxygenase-1:660:0.9442|heme oxygenase 1:65:0.8306|heme-oxygenase-1:15:0.0148	0.9442	740
HO-1	HO-1:10	Inducible HO:10:0.4363	0.4363	10
HO-2	HO-2:5|HO2:2	heme oxygenase:7:0.3524	0.3524	7
HO-2	HO-2:47|HO2:5	heme oxygenase-2:46:0.8151|heme oxygenase 2:6:0.5290	0.8151	52
HO-2	HO-2:5	Heme oxygenase type 2:5:0.4422	0.4422	5
HOAD	HOAD:19	dehydrogenase:19:0.9474	0.9474	19
HOAs	HOAs:11	higher-order aberrations:11:0.4728	0.4728	11
hOAT1	hOAT1:15	human organic anion transporter 1:15:0.6386	0.6386	15
HOA	HOA:6	hemoglobin-oxygen affinity:6:0.2243	0.2243	6
HOA	HOA:51	hypertrophic osteoarthropathy:51:0.9082	0.9082	51
hOBs	hOBs:10|HOBs:7|HObs:1	human osteoblasts:18:0.6381	0.6381	18
HOBr	HOBr:9	hypobromous acid:9:0.6794	0.6794	9
HOCI	HOCI:11	hypochlorous acid:11:0.7357	0.7357	11
HOCM	HOCM:10	contrast media:10:0.5856	0.5856	10
HOCM	HOCM:276	hypertrophic obstructive cardiomyopathy:276:0.9891	0.9891	276
HOCl	HOCl:19	hypochlorite:19:0.0480	0.0480	19
HOCl	HOCl:335|HOCL:1	hypochlorous acid:336:0.9493	0.9493	336
HOCs	HOCs:24	hydrophobic organic compounds:24:0.8115	0.8115	24
HOCs	HOCs:20	hydrophobic organic contaminants:20:0.7766	0.7766	20
hOC	hOC:16	human osteocalcin:16:0.8165	0.8165	16
HOE140	HOE140:4|HOE-140:2|Hoe140:1	receptor antagonist:7:0.1543	0.1543	7
hOF	hOF:7|HOF:2	Human oviductal fluid:9:0.6794	0.6794	9
HOMA	HOMA:5	homeostasis assessment model:5:0.2818	0.2818	5
HOMA	HOMA:296	Homeostasis Model Assessment:296:0.8370	0.8370	296
HOMA	HOMA:23	insulin resistance:23:0.8715	0.8715	23
HOMA-IR	HOMA-IR:27|HOMAIR:1	homeostasis model assessment:28:0.6928	0.6928	28
HOMA-IR	HOMA-IR:3|HOMAIR:1	homeostasis model assessment insulin resistance:4:0.9047	0.9047	4
HOMA-IR	HOMA-IR:15|Homa-IR:1	insulin resistance index:16:0.6577	0.6577	16
HOMA-R	HOMA-R:16	homeostasis model assessment:16:0.6577	0.6577	16
HOMA-R	HOMA-R:2	homeostasis model assessment insulin resistance:2:0.8270	0.8270	2
HOMA-R	HOMA-R:10	resistance index:10:0.7103	0.7103	10
HOMA-S	HOMA-S:9	insulin sensitivity:9:0.6794	0.6794	9
HOME	HOME:40	Home Observation for Measurement of the Environment:40:0.9338	0.9338	40
HOME	HOME:14	human omental microvascular endothelial:14:0.7909	0.7909	14
HOMO	HOMO:43|homo:1	Highest Occupied Molecular Orbital:44:0.9323	0.9323	44
HONO	HONO:11	Nitrous acid:11:0.7357	0.7357	11
HOOH	HOOH:9	hydrogen peroxide:9:0.5470	0.5470	9
HOOP	HOOP:7	hydrogen out-of-plane:7:0.3524	0.3524	7
HOPA	HOPA:9	calcium hopantenate:9:0.5470	0.5470	9
HOPE	HOPE:63	Heart Outcomes Prevention Evaluation:63:0.9296	0.9296	63
HOPG	HOPG:27	highly oriented pyrolytic graphite:27:0.8312	0.8312	27
HOPS	HOPS:11	HIV Outpatient Study:11:0.7357	0.7357	11
HOPS	HOPS:9	hypophosphatasia:9:0.2222	0.2222	9
HOPWA	HOPWA:28	Housing Opportunities for People with AIDS:28:0.8941	0.8941	28
HOP	HOP:5	oocyte penetration:5:0.1132	0.1132	5
HOP	HOP:10	urinary hydroxyproline:10:0.2643	0.2643	10
HOSO	HOSO:17	sunflower oil:17:0.6748	0.6748	17
HOS	HOS:7	Health Opinion Survey:7:0.5926	0.5926	7
HOS	HOS:28	Holt-Oram syndrome:28:0.7425	0.7425	28
HOS	HOS:6	human osteoblast-like cells:6:0.5290	0.5290	6
HOS	HOS:14	human osteogenic sarcoma:14:0.6911	0.6911	14
HOS	HOS:22	Human osteosarcoma:22:0.6531	0.6531	22
HOS	HOS:7	human osteosarcoma cell line:7:0.4438	0.4438	7
HOS	HOS:27	hypo-osmotic swelling:27:0.2738	0.2738	27
HOS	HOS:38	hypoosmotic swelling:38:0.4162	0.4162	38
HOS	HOS:9	Medicare Health Outcomes Survey:9:0.3945	0.3945	9
HOS	HOS:16	swelling test:16:0.7261	0.7261	16
HOT	HOT:46	home oxygen therapy:46:0.7025	0.7025	46
HOT	HOT:64	Hypertension Optimal Treatment:64:0.9534	0.9534	64
Ho	Ho:7|ho:5|HO:3	Cook and Medley Hostility:15:0.8045	0.8045	15
Ho	Ho:6|HO:6|ho:4	Cook-Medley Hostility:16:0.2288	0.2288	16
HO	HO:445|H-O:1	Heme oxygenase:440:0.9179|Heme oxygenases:6:0.2243	0.9179	446
HO	HO:172	Heterotopic ossification:172:0.9826	0.9826	172
HO	HO:9|ho:3|Ho:2	Hoechst 33258:14:0.7909	0.7909	14
HO	HO:12|ho:4	Hoechst 33342:16:0.8270	0.8270	16
Ho	Ho:5|ho:3|HO:2	Hostility Scale:10:0.5000	0.5000	10
HO	HO:11	hyperbaric oxygenation:11:0.7357	0.7357	11
HPA-1	HPA-1:9	human platelet antigen 1:9:0.6794	0.6794	9
HPAC	HPAC:13	high-performance affinity chromatography:13:0.5934	0.5934	13
HPAE	HPAE:9	human pulmonary artery endothelial:9:0.6794	0.6794	9
HPAEC	HPAEC:45	high-performance anion-exchange chromatography:45:0.6608	0.6608	45
HPAEC	HPAEC:19	human pulmonary artery endothelial cells:19:0.7044	0.7044	19
HPAECs	HPAECs:11	human pulmonary artery endothelial cells:11:0.6182	0.6182	11
HPASMC	HPASMC:9|hPA-SMC:1	human pulmonary artery smooth muscle cells:10:0.7103	0.7103	10
HPA	HPA:8	activity of the hypothalamus-pituitary-adrenocortical:8:0.1004	0.1004	8
HPA	HPA:17	adrenocortical:17:0.0046	0.0046	17
HPA	HPA:9	habitual physical activity:9:0.5470	0.5470	9
HPA	HPA:52	Helix pomatia:52:0.9427	0.9427	52
HPA	HPA:88|HpA:3	helix pomatia agglutinin:91:0.9668	0.9668	91
HPA	HPA:17	Helix pomatia lectin:17:0.8270	0.8270	17
HPA	HPA:4|Hpa:3|hpa:2	heparanase:9:0.0023	0.0023	9
HPA	HPA:11	human pancreatic alpha-amylase:11:0.6182	0.6182	11
HPA	HPA:24	human platelet alloantigens:13:0.7753|human platelet alloantigen:11:0.7103	0.7753	24
HPA	HPA:51	Human platelet antigen:32:0.8563|human platelet antigens:19:0.8525	0.8563	51
HPA	HPA:26	hybridization protection assay:26:0.7679	0.7679	26
HPA	HPA:23	hyperphenylalaninaemia:23:0.0063	0.0063	23
HPA	HPA:58	hyperphenylalaninemia:58:0.0167	0.0167	58
HPA	HPA:1641|H-P-A:4	hypothalamic-pituitary-adrenal:1567:0.4504|hypothalamic pituitary adrenal:37:0.6610|hypothalamic-pituitary adrenal:29:0.1989|hypothalamic--pituitary--adrenal:12:0.0032	0.6610	1645
HPA	HPA:68	hypothalamic-pituitary-adrenal axis:68:0.3880	0.3880	68
HPA	HPA:5	hypothalamic-pituitary-adrenal cortical:5:0.0517	0.0517	5
HPA	HPA:228|H-P-A:3	hypothalamic-pituitary-adrenocortical:231:0.0661	0.0661	231
HPA	HPA:475|H-P-A:2	hypothalamo-pituitary-adrenal:464:0.1332|hypothalamo-pituitary adrenal:13:0.0575	0.1332	477
HPA	HPA:17	hypothalamo-pituitary-adrenal axis:17:0.0596	0.0596	17
HPA	HPA:7	hypothalamo-pituitary-adrenal cortical:7:0.1850	0.1850	7
HPA	HPA:130	hypothalamo-pituitary-adrenocortical:130:0.0371	0.0371	130
HPA	HPA:160	hypothalamus-pituitary-adrenal:160:0.0457	0.0457	160
HPA	HPA:12	pituitary-adrenal:12:0.0029	0.0029	12
HPB	HPB:22	4-hydroxy-1-(3-pyridyl)-1-butanone:22:0.2625	0.2625	22
HPB	HPB:13	portal blood:13:0.5335	0.5335	13
HPBCD	HPBCD:12|HP-B-CD:1	hydroxypropyl-beta-cyclodextrin:13:0.5217	0.5217	13
HPBL	HPBL:32|hPBL:6	Human peripheral blood lymphocytes:38:0.8781	0.8781	38
HPBM	HPBM:14|hPBM:1	human peripheral blood monocytes:15:0.8045	0.8045	15
HPCD	HPCD:11	2-hydroxypropyl-beta-cyclodextrin:11:0.1471	0.1471	11
HPCD	HPCD:26	hydroxypropyl-beta-cyclodextrin:26:0.3529	0.3529	26
HPCE	HPCE:127	high-performance capillary electrophoresis:100:0.6994|High performance capillary electrophoresis:27:0.8903	0.8903	127
HPCM	HPCM:16	Human placental conditioned medium:16:0.8165	0.8165	16
HPCT	HPCT:6	hematopoietic progenitor cell transplantation:6:0.3728	0.3728	6
HPCs	HPCs:11	hemangiopericytomas:11:0.0483	0.0483	11
HPCs	HPCs:119	hematopoietic progenitor cells:119:0.7681	0.7681	119
HPC	HPC:13	dorsal hippocampus:13:0.0732	0.0732	13
HPC	HPC:12	haemangiopericytoma:12:0.0122	0.0122	12
HPC	HPC:41	hemangiopericytoma:32:0.0345|hemangiopericytomas:9:0.0089	0.0345	41
HPC	HPC:183	hematopoietic progenitor cells:146:0.6732|hematopoietic progenitor cell:37:0.6250	0.6732	183
HPC	HPC:38	hereditary prostate cancer:38:0.8781	0.8781	38
HPC	HPC:39	Heterotrophic plate count:29:0.7970|Heterotrophic plate counts:10:0.7103	0.7970	39
HPC	HPC:26	hexadecylphosphocholine:26:0.0278	0.0278	26
HPC	HPC:17	hippocampal:17:0.0178	0.0178	17
HPC	HPC:14	hippocampal formation:14:0.7909	0.7909	14
HPC	HPC:13|hPC:6	Human Protein C:19:0.6537	0.6537	19
HPC	HPC:50	hydroxypropyl cellulose:50:0.8520	0.8520	50
HPC	HPC:52	hydroxypropylcellulose:52:0.0568	0.0568	52
HPC	HPC:6	hypopharyngeal carcinoma:6:0.0899	0.0899	6
HPC	HPC:7	hypoxic preconditioning:7:0.2902	0.2902	7
HPDL	HPDL:22|hPDL:4	human periodontal ligament:26:0.8251	0.8251	26
HPDP	HPDP:10	health promotion and disease prevention:10:0.7103	0.7103	10
HPDs	HPDs:27	hearing protection devices:27:0.8903	0.8903	27
HPD	Hpd:3|HPD:3	4-hydroxyphenylpyruvate dioxygenase:6:0.1543	0.1543	6
HpD	HpD:36|HPD:34|Hpd:2	haematoporphyrin derivative:72:0.1411	0.1411	72
HPD	HPD:27	haloperidol:27:0.0365	0.0365	27
HPD	HPD:155|HpD:149|Hpd:28	hematoporphyrin derivative:308:0.7353|hematoporphyrin derivatives:24:0.7593	0.7593	332
HPD	HPD:10	hepatopancreatoduodenectomy:10:0.0126	0.0126	10
HPD	HPD:8	hereditary progressive dystonia:8:0.6411	0.6411	8
HPD	HPD:13	hereditary progressive dystonia with marked diurnal fluctuation:13:0.6701	0.6701	13
HPD	HPD:11	high protein diet:11:0.5355	0.5355	11
HPD	HPD:11	hypothalamic-pituitary disconnection:11:0.1612	0.1612	11
HPD	HPD:17	hypothalamo-pituitary disconnected:17:0.5374	0.5374	17
HPD	HPD:17	hypothalamo-pituitary disconnection:17:0.3512	0.3512	17
HPEC	HPEC:6	high-performance electrophoresis chromatography:6:0.2827	0.2827	6
HPEV1	HPEV1:4|HPEV-1:1|HPeV1:1	Human parechovirus 1:6:0.5290	0.5290	6
HPE	HPE:1	H pylori water extract:1:0.5290	0.5290	1
HPE	HPE:98	holoprosencephaly:98:0.4554	0.4554	98
HPF3	HPF3:15	human parainfluenza virus type 3:15:0.8045	0.8045	15
HPFA	HPFA:12	High-performance frontal analysis:12:0.7571	0.7571	12
HPFC	HPFC:9	hemolytic plaque forming cells:9:0.6794	0.6794	9
HPFH	HPFH:25	Hereditary persistence of fetal haemoglobin:25:0.7679	0.7679	25
HPFH	HPFH:122	hereditary persistence of fetal hemoglobin:122:0.9365	0.9365	122
HPFS	HPFS:8	Health Professionals Follow-Up Study:8:0.6411	0.6411	8
HPFs	HPFs:18|hpfs:1	high-power fields:19:0.4852	0.4852	19
HPF	HPF:15|hPF:3	fibroblasts:18:0.0346	0.0346	18
hpf	hpf:32|hPF:1	h post-fertilization:18:0.4033|h post fertilization:15:0.4609	0.4609	33
hpf	hpf:24	h postfertilization:24:0.2978	0.2978	24
HPF	HPF:12	Heparin precipitable fraction:12:0.7571	0.7571	12
HPF	HPF:11	High-pressure freezing:11:0.6182	0.6182	11
hpf	hpf:15|hPF:1	hours postfertilization:16:0.1593	0.1593	16
HPF	HPF:33|hpf:7	per 10 high-power fields:25:0.8186|per 10 high power fields:15:0.4951	0.8186	40
HPF	HPF:20|hpf:11	per high-power field:31:0.5414	0.5414	31
HPGC	HPGC:10	chromatography:10:0.7500	0.7500	10
HPHIC	HPHIC:5|HP-HIC:1	hydrophobic interaction chromatography:6:0.5290	0.5290	6
HPH	HPH:12	Helix pomatia haemocyanin:12:0.7571	0.7571	12
hph	hph:8|HPH:2	hygromycin B phosphotransferase:10:0.7103	0.7103	10
hph	hph:8|Hph:1	hygromycin phosphotransferase:9:0.1690	0.1690	9
HPH	HPH:24	hypoxic pulmonary hypertension:24:0.7046	0.7046	24
HPIAC	HPIAC:10	High-performance immunoaffinity chromatography:10:0.7103	0.7103	10
HPIEC	HPIEC:7	high-performance ion-exchange chromatography:7:0.4438	0.4438	7
HPIN	HPIN:5|hPIN:1|H-PIN:1	high-grade prostatic intraepithelial neoplasia:7:0.5926	0.5926	7
HPIV-2	HPIV-2:7|hPIV-2:5|HPIV2:5|hPIV2:3	human parainfluenza virus type 2:20:0.8525	0.8525	20
HPIV3	HPIV3:35|HPIV-3:15|hPIV3:4|hPIV-3:1	human parainfluenza virus type 3:55:0.9458	0.9458	55
hpi	hpi:13|HPI:3	h post-infection:9:0.3945|h post infection:7:0.2113	0.3945	16
hpi	hpi:9	h post insemination:9:0.4587	0.4587	9
hpi	hpi:21	h postinfection:21:0.4733	0.4733	21
hpi	hpi:6|HPI:1	h postinsemination:7:0.2113	0.2113	7
HPI	HPI:12	Health Practice Index:12:0.7571	0.7571	12
HPI	HPI:33	hepatic perfusion index:33:0.9100	0.9100	33
HPI	HPI:33	high-pathogenicity island:33:0.8563	0.8563	33
HPI	HPI:11|hPI:4	human proinsulin:15:0.7096	0.7096	15
HPI	HPI:9	hydroperoxidase I:9:0.4587	0.4587	9
HPI	HPI:9	hypothalamic-pituitary-interrenal:9:0.0234	0.0234	9
hpi	hpi:8|HPI:1	post inoculation:9:0.6794	0.6794	9
hpi	hpi:7|HPI:2	postinoculation:9:0.0234	0.0234	9
HPK1	HPK1:23|hpk1:1	hematopoietic progenitor kinase 1:24:0.8768	0.8768	24
HPLC-MS	HPLC-MS:20	high-performance liquid chromatography-mass spectrometry:20:0.4786	0.4786	20
HPLC-UV	HPLC-UV:8	liquid chromatography with ultraviolet detection:8:0.6411	0.6411	8
HPLC-UV	HPLC-UV:6	liquid chromatography with UV detection:6:0.5290	0.5290	6
HPLC/MS	HPLC/MS:28	high-performance liquid chromatography/mass spectrometry:28:0.6295	0.6295	28
HPLC	HPLC:48	high performance liquid chromatograph:26:0.8861|high-performance liquid chromatograph:22:0.2619	0.8861	48
HPLC	HPLC:1623|hplc:2	high-performance liquid chromatographic:1310:0.7054|high performance liquid chromatographic:301:0.9738|high-performance liquid-chromatographic:14:0.6173	0.9738	1625
HPLC	HPLC:6	high-performance liquid chromatographic assay:6:0.3728	0.3728	6
HPLC	HPLC:31	high-performance liquid chromatographic method:17:0.3232|high performance liquid chromatographic method:14:0.7909	0.7909	31
HPLC	HPLC:8737|hplc:6|HP-LC:2	high-performance liquid chromatography:5513:0.5255|high performance liquid chromatography:3211:0.9856|High-Performance-Liquid-Chromatography:11:0.0008|high-performance liquid-chromatography:10:0.5000	0.9856	8745
HPLC	HPLC:9	High performance liquid chromotography:9:0.6794	0.6794	9
HPLC	HPLC:12	liquid chromatography method:12:0.6460	0.6460	12
HPLC	HPLC:5	liquid chromatography system:5:0.4422	0.4422	5
HPLF	HPLF:30|hPLF:1	human periodontal ligament fibroblasts:21:0.6812|human periodontal ligament fibroblast:10:0.5856	0.6812	31
HPMA	HPMA:116	N-(2-Hydroxypropyl)methacrylamide:103:0.7234|N-(2-hydroxypropyl) methacrylamide:13:0.7909	0.7909	116
HPMCAS	HPMCAS:23|HPMC-AS:1	acetate succinate:24:0.7593	0.7593	24
HPMCs	HPMCs:34	human peritoneal mesothelial cells:34:0.9126	0.9126	34
HPMC	HPMC:83	human peritoneal mesothelial cells:67:0.9548|human peritoneal mesothelial cell:16:0.8165	0.9548	83
HPMC	HPMC:14	hydroxypropyl methyl cellulose:14:0.3813	0.3813	14
HPMC	HPMC:160	hydroxypropyl methylcellulose:160:0.9266	0.9266	160
HPMC	HPMC:38	hydroxypropylmethyl cellulose:38:0.4464	0.4464	38
HPMC	HPMC:160	hydroxypropylmethylcellulose:160:0.2857	0.2857	160
HPMC	HPMC:8	propyl methyl cellulose:8:0.1196	0.1196	8
HPMEC	HPMEC:9	human pulmonary microvascular endothelial cells:9:0.6794	0.6794	9
HPMPA	HPMPA:12	(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine:12:0.3667	0.3667	12
HPMPC	HPMPC:22	(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine:22:0.2136	0.2136	22
HPMVs	HPMVs:14	plasma membrane vesicles:14:0.7909	0.7909	14
HP-NAP	HP-NAP:8|HpNAP:2	neutrophil-activating protein:10:0.5856	0.5856	10
HPNS	HPNS:33	high pressure nervous syndrome:33:0.8605	0.8605	33
HPNS	HPNS:29	high pressure neurological syndrome:29:0.8978	0.8978	29
HPN	HPN:209	home parenteral nutrition:209:0.9373	0.9373	209
HPOA	HPOA:15	hypertrophic pulmonary osteoarthropathy:15:0.7096	0.7096	15
HPOA	HPOA:27|H-POA:2	hypothalamus-preoptic area:29:0.5212	0.5212	29
HPOP	HPOP:23	N-Nitroso(2-hydroxypropyl)(2-oxopropyl)amine:23:0.4783	0.4783	23
HPO	HPO:9	hypertrophic pulmonary osteoarthropathy:9:0.6794	0.6794	9
HPO	HPO:9|H-P-O:1	hypothalamic-pituitary-ovarian:10:0.0750	0.0750	10
HPP-CFC	HPP-CFC:8	high proliferative potential:8:0.6411	0.6411	8
HPP-CFC	HPP-CFC:46	high proliferative potential colony-forming cells:34:0.9126|high proliferative potential colony-forming cell:12:0.7571	0.9126	46
HPPD	HPPD:17	4-hydroxyphenylpyruvate dioxygenase:17:0.3844	0.3844	17
HPPD	HPPD:7	hallucinogen persisting perception disorder:7:0.5926	0.5926	7
HPPH	HPPH:11	5-(p-hydroxyphenyl)-5-phenylhydantoin:11:0.1515	0.1515	11
HPPH	HPPH:3	metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin:3:0.1850	0.1850	3
HPPK	HPPK:16	6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase:16:0.6024	0.6024	16
HPRC	HPRC:8	Hereditary papillary renal carcinoma:8:0.6411	0.6411	8
HPRG	HPRG:14	Histidine-proline-rich glycoprotein:14:0.6173	0.6173	14
HPRT	HPRT:8|hprt:4	hypoxanthine-guanine phosphoribosyl-transferase:12:0.2699	0.2699	12
HPRT	HPRT:196|hprt:64|Hprt:9	hypoxanthine-guanine phosphoribosyltransferase:209:0.3420|hypoxanthine guanine phosphoribosyltransferase:60:0.9622	0.9622	269
HPRT	HPRT:83|hprt:22|Hprt:8	hypoxanthine phosphoribosyl transferase:113:0.3739	0.3739	113
HPRT	HPRT:183|hprt:35|Hprt:21	hypoxanthine phosphoribosyltransferase:239:0.3965	0.3965	239
HPRT	HPRT:7|Hprt:2|hprt:1	hypoxanthine phosphoribosyltransferase gene:10:0.3470	0.3470	10
HPr	HPr:32	histidine-containing phosphocarrier protein:32:0.5509	0.5509	32
HPr	HPr:30	histidine-containing protein:30:0.1950	0.1950	30
hPR	hPR:43	human progesterone receptor:43:0.7795	0.7795	43
HPr	HPr:4|hPr:2	human prolactin:6:0.1148	0.1148	6
HPR	HPR:12|Hpr:1	hydroxypyruvate reductase:13:0.7753	0.7753	13
HPR	HPR:9	hypoxic pressor response:9:0.6794	0.6794	9
HPR	HPR:22	N-(4-hydroxyphenyl)retinamide:22:0.0659	0.0659	22
HPR	HPR:5	synthetic retinoid Fenretinide:5:0.4422	0.4422	5
HPSAs	HPSAs:25	health professional shortage areas:25:0.8657	0.8657	25
HPSEC	HPSEC:40|HP-SEC:2	high-performance size exclusion chromatography:22:0.3096|high performance size exclusion chromatography:20:0.8525	0.8525	42
HPS	HPS:6	3-hexulose-6-phosphate synthase:6:0.1211	0.1211	6
HPS	HPS:166	hantavirus pulmonary syndrome:166:0.9447	0.9447	166
HPS	HPS:122	hemophagocytic syndrome:122:0.1931	0.1931	122
HPS	HPS:9	high-pressure sodium:9:0.4587	0.4587	9
HPS	HPS:40	His-Purkinje system:40:0.6998	0.6998	40
HPs	HPs:6	holding potentials:6:0.1838	0.1838	6
HPs	HPs:13	hyperplastic polyps:13:0.6701	0.6701	13
HPS	HPS:72	hypertrophic pyloric stenosis:72:0.9344	0.9344	72
HPT-JT	HPT-JT:6	hyperparathyroidism-jaw tumor syndrome:6:0.3728	0.3728	6
HPTC	HPTC:5|hPTC:2	proximal tubular cells:7:0.5926	0.5926	7
HPTE	HPTE:10	2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane:10:0.4737	0.4737	10
HPTLC	HPTLC:29	high-performance thin-layer chromatographic:29:0.8422	0.8422	29
HPTLC	HPTLC:155	high-performance thin-layer chromatography:118:0.7033|high performance thin layer chromatography:37:0.9217	0.9217	155
HPTS	HPTS:7	8-hydroxypyrene-1,3,6-trisulfonic acid:7:0.2113	0.2113	7
HPT	HPT:16|Hpt:10|hpt:1	haptoglobin:27:0.0300	0.0300	27
HPT	HPT:12	hepaplastin test:12:0.3813	0.3813	12
HPt	HPt:34|Hpt:1	histidine-containing phosphotransfer:35:0.7647	0.7647	35
HPT	HPT:29	human proximal tubule:29:0.8978	0.8978	29
hpt	hpt:13|HPT:11|Hpt:1	hygromycin phosphotransferase:25:0.5722	0.5722	25
hpt	hpt:7	hygromycin phosphotransferase gene:7:0.4438	0.4438	7
HPT	HPT:10	Hypertension Prevention Trial:10:0.6794	0.6794	10
HPT	HPT:8|H-P-T:2	Hypothalamic-pituitary-testicular:10:0.0104	0.0104	10
HPT	HPT:55|H-P-T:1	hypothalamic-pituitary-thyroid:56:0.0634	0.0634	56
HPT	HPT:13	hypothalamo-pituitary-thyroid:13:0.0138	0.0138	13
HPT	HPT:14	hypothalamus-pituitary-thyroid:14:0.0150	0.0150	14
HPT	HPT:56	patients with primary hyperparathyroidism:56:0.2223	0.2223	56
HPV-11	HPV-11:43|HPV11:9	human papillomavirus type 11:52:0.9099	0.9099	52
HPV-16	HPV-16:6|HPV16:5	human papillomavirus:11:0.7357	0.7357	11
HPV-16	HPV-16:11|HPV16:1	human papillomavirus-16:12:0.7571	0.7571	12
HPV-16	HPV-16:286|HPV16:186	human papillomavirus type 16:464:0.9861|Human papillomavirus type-16:8:0.6411	0.9861	472
HPV-18	HPV-18:37|HPV18:24	Human papillomavirus type 18:61:0.9519	0.9519	61
HPV-1	HPV-1:20|HPV1:7	Human papillomavirus type 1:27:0.8903	0.8903	27
HPV-31	HPV-31:4|HPV31:3	human papillomavirus type 31:7:0.5926	0.5926	7
HPV-5	HPV-5:5|HPV5:5	human papillomavirus type 5:10:0.7103	0.7103	10
HPV-6b	HPV-6b:8|HPV6b:6	human papillomavirus type 6b:14:0.7909	0.7909	14
HPV-6	HPV-6:29|HPV6:3	human papillomavirus type 6:32:0.9072	0.9072	32
HPV8	HPV8:5|HPV-8:3	Human papillomavirus type 8:8:0.6411	0.6411	8
HPV-B19	HPV-B19:12|HPVB19:4	human parvovirus B19:16:0.8165	0.8165	16
HPVG	HPVG:31	hepatic portal venous gas:31:0.9043	0.9043	31
HPV	HPV:22	heart period variability:22:0.8715	0.8715	22
HPV	HPV:10|hpv:1	hepatic portal vein:11:0.7357	0.7357	11
HPV	HPV:19	hepatopancreatic parvovirus:19:0.2095	0.2095	19
HPV	HPV:781	human papilloma virus:726:0.9778|human papilloma viruses:55:0.9448	0.9778	781
HPV	HPV:5226	human papillomavirus:4838:0.9889|human papillomaviruses:388:0.9528	0.9889	5226
HPV	HPV:20	human papillomavirus infection:20:0.7766	0.7766	20
HPV	HPV:31	human parvovirus:31:0.4299	0.4299	31
HPV	HPV:11	human parvovirus B19:11:0.7357	0.7357	11
HPV	HPV:289	hypoxic pulmonary vasoconstriction:289:0.9498	0.9498	289
HPX	HPX:13|Hpx:10	hemopexin:23:0.2018	0.2018	23
HPX	HPX:25|Hpx:2|HPx:1	hypophysectomized:28:0.2477	0.2477	28
HPX	HPX:13|Hpx:1	hypophysectomy:14:0.1193	0.1193	14
HPZ	HPZ:34	high pressure zone:18:0.8365|high-pressure zone:16:0.2709	0.8365	34
HPM	HPM:11	Health Promotion Model:11:0.7357	0.7357	11
HPP	HPP:13	allopurinol:13:0.0372	0.0372	13
HPP	HPP:32	hereditary pyropoikilocytosis:32:0.8145	0.8145	32
HPP	HPP:9	High-pressure processing:9:0.2500	0.2500	9
hPP	hPP:56|HPP:43|hpp:1	human pancreatic polypeptide:100:0.7713	0.7713	100
HPP	HPP:31	periodic paralysis:31:0.9043	0.9043	31
HPP	HPP:7	pressure processing:7:0.1329	0.1329	7
HP	HP:7	ATP to 6-hydroxymethyl-7,8-dihydropterin:7:0.5006	0.5006	7
HP	HP:17|Hp:6	haematoporphyrin:23:0.0058	0.0058	23
HP	HP:9	Haemoperfusion:9:0.0021	0.0021	9
HP	HP:48	haloperidol:48:0.0122	0.0122	48
Hp	Hp:363|HP:79|hp:4	haptoglobin:437:0.1156|Haptoglobins:9:0.0021	0.1156	446
HP	HP:10	Health Promotion:10:0.7103	0.7103	10
HP	HP:8	healthy persons:8:0.5006	0.5006	8
HP	HP:39	heart period:39:0.7860	0.7860	39
HP	HP:63|Hp:5	heat production:68:0.9561	0.9561	68
HP	HP:39	Heidenhain pouch:28:0.8369|Heidenhain pouches:11:0.7357	0.8369	39
HP	HP:458|Hp:362	Helicobacter pylori:820:0.9573	0.9573	820
HP	HP:12	Helix pomatia:12:0.6460	0.6460	12
HP	HP:8	Helix pomatia A hemagglutinin:8:0.7103	0.7103	8
HP	HP:12	Hemangiopericytoma:12:0.0029	0.0029	12
HP	HP:56|Hp:29	hematoporphyrin:85:0.0222	0.0222	85
HP	HP:24	hemoperfusion:24:0.0061	0.0061	24
HP	HP:19|Hp:3	heparin:22:0.0056	0.0056	22
HP	HP:42|hp:1	hereditary pancreatitis:43:0.8590	0.8590	43
HP	HP:12	Hewlett-Packard:12:0.0029	0.0029	12
HP	HP:8|Hp:1	high-pass:9:0.0021	0.0021	9
HP	HP:21	high pressure:12:0.1379|high-pressure:9:0.0021	0.1379	21
HP	HP:98	high protein:51:0.5131|high-protein:47:0.0122	0.5131	98
HP	HP:23	Highly pathogenic:23:0.8715	0.8715	23
HP	HP:8|hp:2	highly purified:10:0.7103	0.7103	10
HP	HP:34|Hp:10	hippocampus:44:0.0114	0.0114	44
HP	HP:32|hp:1	holding potential:33:0.7525	0.7525	33
HP	HP:21	horseradish peroxidase:21:0.7865	0.7865	21
HP	HP:16	hot-plate:16:0.0040	0.0040	16
HP	HP:8	human plasma:8:0.1895	0.1895	8
HP	HP:43	hydrogen peroxide:43:0.9308	0.9308	43
HP	HP:24|hp:1	hydrostatic pressure:25:0.4596	0.4596	25
HP	HP:9	Hydroxylysyl pyridinoline:9:0.5470	0.5470	9
HP	HP:57	Hydroxylysylpyridinoline:57:0.0151	0.0151	57
HP	HP:51|Hp:3	hydroxyproline:54:0.0140	0.0140	54
HP	HP:15	hyperparathyroidism:15:0.0037	0.0037	15
HP	HP:12	Hyperplastic Polyps:12:0.7571	0.7571	12
HP	HP:20	hyperpolarized:20:0.0050	0.0050	20
HP	HP:214	hypersensitivity pneumonitis:214:0.9633	0.9633	214
HP	HP:1	hypertension during pregnancy:1:0.2327	0.2327	1
HP	HP:14	hypoparathyroidism:14:0.0034	0.0034	14
HP	HP:9|H-P:5|h-p:2	hypothalamic-pituitary:16:0.0040	0.0040	16
HP	HP:10	hypoxic preconditioning:10:0.5856	0.5856	10
HP	HP:20	patients:20:0.0050	0.0050	20
HP	HP:8|hp:1	peptide:9:0.0021	0.0021	9
HP	HP:9	phosphate:9:0.0021	0.0021	9
HP	HP:8|Hp:1	proteins:9:0.0021	0.0021	9
HP	HP:5	protein diet:5:0.1543	0.1543	5
HQL	HQL:35	health-related quality of life:35:0.8681	0.8681	35
HQNO	HQNO:10	2-heptyl-4-hydroxyquinoline-N-oxide:10:0.2195	0.2195	10
HQOL	HQOL:11|HQoL:6|H-QoL:1	health-related quality of life:18:0.6903	0.6903	18
HQR	HQR:9	resistance:9:0.5333	0.5333	9
HQ	HQ:215	hydroquinone:215:0.7063	0.7063	215
HR1	HR1:7|HR-1:2	heptad repeat 1:9:0.6794	0.6794	9
HRA	HRA:39	Health Risk Appraisal:39:0.9237	0.9237	39
HRA	HRA:13	health risk assessment:13:0.6701	0.6701	13
HRA	HRA:40	high right atrium:40:0.8839	0.8839	40
HRA	HRA:17	Histamine-releasing activity:17:0.5038	0.5038	17
HRA	HRA:6	Human Reliability Assessment:6:0.3728	0.3728	6
HRBC	HRBC:16	horse erythrocytes:16:0.3317	0.3317	16
HRBC	HRBC:73|hRBC:4|h-RBC:2|H-RBC:2|hrbc:1	red blood cells:71:0.9579|red blood cell:11:0.7357	0.9579	82
HRB	HRB:14	Halstead-Reitan battery:14:0.3383	0.3383	14
HRCC	HRCC:12	human renal cell carcinoma:12:0.6460	0.6460	12
HRCT	HRCT:34|HR-CT:4	high resolution computed tomographic:20:0.8525|high-resolution computed tomographic:18:0.2860	0.8525	38
HRCT	HRCT:612|HR-CT:25|hrCT:1	high-resolution computed tomography:424:0.6124|high resolution computed tomography:214:0.9860	0.9860	638
HRCT	HRCT:290|HR-CT:8	high-resolution CT:213:0.6355|high resolution CT:85:0.9648	0.9648	298
HRECG	HRECG:5|HR-ECG:1	High resolution ECG:6:0.5290	0.5290	6
HRECs	HRECs:10	human retinal endothelial cells:10:0.7103	0.7103	10
HREM	HREM:12	High Resolution Electron Microscopy:12:0.7571	0.7571	12
HREs	HREs:30	hormone response elements:30:0.5478	0.5478	30
HRF20	HRF20:10	homologous restriction factor:10:0.7103	0.7103	10
HRF	HRF:27	Heidelberg Retina Flowmeter:27:0.8903	0.8903	27
HRF	HRF:12|hrf:1	hemodynamic response function:13:0.4444	0.4444	13
HRF	HRF:84	histamine-releasing factor:34:0.2651|histamine releasing factor:30:0.8032|histamine-releasing factors:12:0.2868|histamine releasing factors:8:0.6411	0.8032	84
HRGC	HRGC:11	high-resolution gas chromatography:11:0.1938	0.1938	11
HRGPs	HRGPs:22	hydroxyproline-rich glycoproteins:22:0.6531	0.6531	22
HRGP	HRGP:32|hrgp:1	glycoprotein:33:0.7805	0.7805	33
HRGs	HRGs:12	Heregulins:12:0.3929	0.3929	12
HRG	HRG:71|hrg:3|Hrg:1	heregulin:75:0.3188	0.3188	75
HRG	HRG:9	heregulin-beta1:9:0.0349	0.0349	9
HRG	HRG:92|Hrg:1	histidine-rich glycoprotein:93:0.9490	0.9490	93
HRIG	HRIG:15	human rabies immune globulin:15:0.8045	0.8045	15
hrIL-2	hrIL-2:7|HrIL-2:2|hr-IL-2:1	human recombinant IL-2:10:0.7103	0.7103	10
hrIL-2	hrIL-2:15|HrIL-2:3|hr-IL-2:1|hrIL2:1	human recombinant interleukin-2:12:0.7571|human recombinant interleukin 2:8:0.6411	0.7571	20
HRI	HRI:8	heme-regulated eIF-2 alpha kinase:8:0.5006	0.5006	8
HRI	HRI:11	heme-regulated inhibitor:11:0.2422	0.2422	11
H-RL	H-RL:8|HRL:1	H-reflex latency:9:0.5470	0.5470	9
HRMAS	HRMAS:24|HR-MAS:17|hr-MAS:3	high-resolution magic angle spinning:22:0.4689|high-resolution magic-angle spinning:11:0.6182|high resolution magic angle spinning:11:0.7357	0.7357	44
HR-MRI	HR-MRI:7|hr-MRI:1|hrMRI:1	magnetic resonance imaging:9:0.6794	0.6794	9
HRMS	HRMS:18|HR-MS:1	high-resolution mass spectrometry:19:0.4852	0.4852	19
HRM	HRM:8	heme regulatory motif:8:0.6411	0.6411	8
HRM	HRM:6	Human resource management:6:0.5290	0.5290	6
HRP-WGA	HRP-WGA:2	Horseradish peroxidase conjugated wheat germ agglutinin:2:0.8165	0.8165	2
HRP-WGA	HRP-WGA:18	horseradish peroxidase-wheat germ agglutinin:18:0.8365	0.8365	18
HRPC	HRPC:137	hormone-refractory prostate cancer:100:0.5535|hormone refractory prostate cancer:37:0.9197	0.9197	137
HRP-C	HRP-C:8|HRPC:4	horseradish peroxidase:12:0.7571	0.7571	12
HRPC	HRPC:8|HRP-C:3	horseradish peroxidase C:11:0.7357	0.7357	11
HRPC	HRPC:6|HRP-C:3|HRPc:2	horseradish peroxidase isoenzyme C:11:0.7357	0.7357	11
HRPC	HRPC:15	prostate carcinoma:15:0.7096	0.7096	15
HRPE	HRPE:34|hRPE:24|h-RPE:1	human retinal pigment epithelial:59:0.9203	0.9203	59
HRPE	HRPE:4|hRPE:2	human retinal pigment epithelial cells:6:0.5290	0.5290	6
hRPE	hRPE:11|HRPE:10	human retinal pigment epithelium:21:0.6812	0.6812	21
HRPII	HRPII:5|HRP-II:2	histidine-rich protein II:7:0.2902	0.2902	7
HRPO	HRPO:27	Horseradish peroxidase:27:0.5951	0.5951	27
HRP	HRP:20	high-pass resolution perimetry:20:0.7766	0.7766	20
HRP	HRP:18	Horseradish-peroxidase:18:0.0035	0.0035	18
hrp	hrp:4|Hrp:3	hypersensitive response and pathogenicity:7:0.5926	0.5926	7
HRP	HRP:86	retrograde axonal transport of horseradish peroxidase:86:0.8384	0.8384	86
HRP	HRP:259	retrograde transport of horseradish peroxidase:259:0.4896	0.4896	259
HRP	HRP:44	transganglionic transport of horseradish peroxidase:44:0.0619	0.0619	44
HRQL	HRQL:637|HR-QL:2	health-related quality of life:611:0.9005|health-related quality-of-life:28:0.8369	0.9005	639
HR-QOL	HR-QOL:8|HRQOL:6|HRQoL:4|hrQoL:1	health-related QoL:19:0.7044	0.7044	19
HRQOL	HRQOL:770|HRQoL:384|HR-QOL:70|HR-QoL:13|HrQoL:5|HrQOL:4|Hr-QoL:3|HRQol:1	health-related quality of life:1180:0.8552|health-related quality-of-life:70:0.9326	0.9326	1250
HRR	HRR:36	Haplotype Relative Risk:36:0.8336	0.8336	36
HRR	HRR:19	hazard rate ratio:19:0.7044	0.7044	19
HRR	HRR:16	Heart rate recovery:16:0.8165	0.8165	16
HRR	HRR:28	heart rate reserve:28:0.8369	0.8369	28
HRR	HRR:22	homologous recombination repair:22:0.8657	0.8657	22
HRR	HRR:11	homologous recombinational repair:11:0.6182	0.6182	11
HRSA	HRSA:11|HRS-A:4	Hamilton Rating Scale for Anxiety:15:0.8165	0.8165	15
HRSD	HRSD:142|HRS-D:9	Hamilton Rating Scale for Depression:151:0.9506	0.9506	151
HRSEM	HRSEM:20|HR-SEM:7|hrSEM:1	high resolution scanning electron microscopy:15:0.8045|high-resolution scanning electron microscopy:13:0.2415	0.8045	28
HRSV	HRSV:91|hRSV:22	human respiratory syncytial virus:113:0.9575	0.9575	113
HRS	HRS:9	Florida Department of Health and Rehabilitative Services:9:0.6794	0.6794	9
HRS	HRS:17	Hamilton Rating Scale:17:0.4246	0.4246	17
HRS	HRS:13	Hamilton Rating Scale for Depression:13:0.5934	0.5934	13
HRs	HRs:38	Heart rates:38:0.7306	0.7306	38
Hrs	Hrs:12|HRS:6	hepatocyte growth factor-regulated tyrosine kinase substrate:18:0.7539	0.7539	18
HRS	HRS:89	Hepatorenal syndrome:89:0.8857	0.8857	89
HRS	HRS:8	histidyl-tRNA synthetase:8:0.4102	0.4102	8
HRS	HRS:102|H-RS:49	Hodgkin and Reed-Sternberg:130:0.7208|Hodgkin's and Reed-Sternberg:17:0.0996|Hodgkin and Reed Sternberg:4:0.1618	0.7208	151
HRS	HRS:27|H-RS:9	Hodgkin/Reed-Sternberg:22:0.0252|Hodgkin-Reed-Sternberg:14:0.0156	0.0252	36
hrs	hrs:17	Homologous regions:17:0.4742	0.4742	17
HRS	HRS:7	Hyper-Rayleigh scattering:7:0.2902	0.2902	7
HRS	HRS:7	Low-dose hyper-radiosensitivity:7:0.1850	0.1850	7
HRs	HRs:9	receptors:9:0.0096	0.0096	9
H-RS	H-RS:6|HRS:5|HR-S:2	Reed-Sternberg cells:13:0.6701	0.6701	13
HRTEM	HRTEM:10	high-resolution transmission electron microscope:10:0.5000	0.5000	10
HRTEM	HRTEM:48|HR-TEM:4|HrTEM:1	high-resolution transmission electron microscopy:53:0.6499	0.6499	53
HRTF	HRTF:14	head-related transfer function:14:0.7909	0.7909	14
HRTFs	HRTFs:26	head-related transfer functions:26:0.7760	0.7760	26
HRTM	HRTM:9	Human Respiratory Tract Model:9:0.6794	0.6794	9
HRT	HRT:35	heart rate turbulence:35:0.9151	0.9151	35
HRT	HRT:98	Heidelberg Retina Tomograph:98:0.9695	0.9695	98
HRT	HRT:8	Heidelberg Retinal Tomography:8:0.6794	0.6794	8
HRT	HRT:20	histamine release test:20:0.8525	0.8525	20
HRT	HRT:9	hormone replacement:9:0.3455	0.3455	9
HRT	HRT:2376	hormone replacement therapy:2376:0.9133	0.9133	2376
HRT	HRT:14	hormone replacement treatment:14:0.6911	0.6911	14
HRT	HRT:213	Hydraulic Retention Time:181:0.9835|hydraulic retention times:32:0.9072	0.9835	213
HRUS	HRUS:6	High resolution ultrasound:6:0.5290	0.5290	6
HRV14	HRV14:34|HRV-14:16	human rhinovirus 14:50:0.9064	0.9064	50
HRV16	HRV16:7	human rhinovirus 16:7:0.4438	0.4438	7
HRV2	HRV2:10|HRV-2:3	human rhinovirus 2:13:0.6701	0.6701	13
HRV2	HRV2:22|HRV-2:2	human rhinovirus serotype 2:24:0.8768	0.8768	24
HRV2	HRV2:12|HRV-2:6	human rhinovirus type 2:18:0.8365	0.8365	18
HRVs	HRVs:29	human rhinoviruses:29:0.7970	0.7970	29
HRV	HRV:1592|HRv:1	heart rate variability:1593:0.9950	0.9950	1593
HRV	HRV:26	Heart rate variation:26:0.8861	0.8861	26
HRV	HRV:116|hRV:2	human rhinovirus:94:0.8914|human rhinoviruses:24:0.8768	0.8914	118
HRV	HRV:91	Human rotavirus:91:0.8881	0.8881	91
hr	hr:32|HR:5|Hr:3	hairless:40:0.0034	0.0034	40
HR	HR:6|hr:3	hairless gene:9:0.5470	0.5470	9
HR	HR:670|hr:1	hazard ratio:551:0.9027|Hazard ratios:120:0.8754	0.9027	671
HR	HR:10	heart:10:0.0008	0.0008	10
HR	HR:8980|Hr:3|hR:1|hr:1	heart rate:8805:0.9909|heart rates:134:0.9132|heart-rate:46:0.0039	0.9909	8985
hr	hr:11	hemerythrin:11:0.0009	0.0009	11
HR	HR:10|Hr:1	heparin-releasable:11:0.0009	0.0009	11
HR	HR:9	hepatic resection:9:0.3945	0.3945	9
HR	HR:24	heptad repeat:24:0.5848	0.5848	24
HR	HR:59|hr:1	high-resolution:31:0.0026|High Resolution:29:0.7581	0.7581	60
HR	HR:40	high responders:20:0.7766|high responder:10:0.5856|high-responder:10:0.0008	0.7766	40
HR	HR:5	high responders to novelty:5:0.2818	0.2818	5
HR	HR:156|hr:3|H-R:1	high-risk:91:0.0078|high risk:69:0.8243	0.8243	160
HR	HR:94	histamine release:94:0.9682	0.9682	94
HR	HR:14	homing receptor:9:0.2285|homing receptors:5:0.0736	0.2285	14
HR	HR:194	homologous recombination:194:0.9524	0.9524	194
hr	hr:10	homologous region:10:0.2873	0.2873	10
HR	HR:6	hormone receptor:6:0.0731	0.0731	6
hr	hr:14|HR:3	host range:17:0.7407	0.7407	17
hr	hr:11	hours:11:0.0009	0.0009	11
hr	hr:40	Human recombinant:40:0.8839	0.8839	40
HR	HR:12|Hr:2	Hybrid resistance:14:0.2636	0.2636	14
HR	HR:39	hypersensitive reaction:39:0.7143	0.7143	39
HR	HR:224	hypersensitive response:224:0.8481	0.8481	224
H-R	H-R:9	hypoxia-reoxygenation:9:0.0007	0.0007	9
HR	HR:3	light-driven chloride pump halorhodopsin:3:0.1618	0.1618	3
HR	HR:23	O-(beta-hydroxyethyl)-rutosides:14:0.0011|O-(beta-hydroxyethyl)-rutoside:9:0.0007	0.0011	23
HR	HR:9	resistant:9:0.0007	0.0007	9
HR	HR:8|H-R:1	rutosides:9:0.0007	0.0007	9
HS-HTP	HS-HTP:7	7-mercaptoheptanoylthreonine phosphate:7:0.3524	0.3524	7
HS1	HS1:7	lineage cell-specific protein 1:7:0.4438	0.4438	7
HS2	HS2:18|HS-2:3	hypersensitive site 2:21:0.4945	0.4945	21
HSA21	HSA21:12|Hsa21:5	human chromosome 21:17:0.7407	0.7407	17
HSAN	HSAN:11	hereditary sensory and autonomic neuropathy:11:0.8165	0.8165	11
HSAP	HSAP:21	heat stable alkaline phosphatase:12:0.7571|heat-stable alkaline phosphatase:9:0.1585	0.7571	21
HSAs	HSAs:18|HSAS:1	health systems agencies:19:0.8449	0.8449	19
HSAS	HSAS:10	X-linked hydrocephalus:10:0.3470	0.3470	10
HSA	HSA:14	Analysis:14:0.0057	0.0057	14
HSA	HSA:7	heat-stable Ag:7:0.3524	0.3524	7
HSA	HSA:70	heat-stable antigen:51:0.5167|heat stable antigen:19:0.8449	0.8449	70
HSA	HSA:10	hemangiosarcoma:10:0.0039	0.0039	10
HSA	HSA:19|Hsa:1	human chromosome:20:0.8525	0.8525	20
HSA	HSA:13	human salivary alpha-amylase:13:0.5934	0.5934	13
HSA	HSA:1758|hSA:6|Hsa:1	human serum albumin:1765:0.9234	0.9234	1765
HSA	HSA:9	humoral stimulatory activity:9:0.6794	0.6794	9
HSCAS	HSCAS:18	hydrated sodium calcium aluminosilicate:18:0.7658	0.7658	18
HSCCC	HSCCC:66	high-speed counter-current chromatography:66:0.9548	0.9548	66
HSCCC	HSCCC:13	high-speed countercurrent chromatography:13:0.4444	0.4444	13
HSCL-25	HSCL-25:16	Hopkins Symptom Checklist-25:16:0.8165	0.8165	16
HSCL	HSCL:22	Hopkins Symptom Checklist:22:0.7955	0.7955	22
HSCR	HSCR:86	Hirschsprung disease:86:0.5420	0.5420	86
HSCT	HSCT:64	hematopoietic stem cell transplant:64:0.6198	0.6198	64
HSCT	HSCT:476|hSCT:1	hematopoietic stem cell transplantation:477:0.7398	0.7398	477
HSCT	HSCT:20	stem cell transplants:20:0.8525	0.8525	20
HSCs	HSCs:492	Hematopoietic stem cells:492:0.8524	0.8524	492
HSC	HSC:6|Hsc:2|hsc:2	heat shock cognate:10:0.7103	0.7103	10
HSC	HSC:505|hsc:1	hematopoietic stem cells:289:0.6901|hematopoietic stem cell:217:0.7808	0.7808	506
HSC	HSC:310|hsc:1	hepatic stellate cells:237:0.9798|hepatic stellate cell:74:0.9596	0.9798	311
HSC	HSC:9	hepatosplenic candidiasis:9:0.6794	0.6794	9
HSC	HSC:28	Hospital for Sick Children:28:0.8369	0.8369	28
HSDD	HSDD:11	hypoactive sexual desire disorder:11:0.7357	0.7357	11
HSDH	HSDH:16|hSDH:1	dehydrogenase:17:0.6667	0.6667	17
HSDSC	HSDSC:12|HS-DSC:9	high-sensitivity differential scanning calorimetry:11:0.2582|High sensitivity differential scanning calorimetry:10:0.7103	0.7103	21
HSDS	HSDS:12|hSDS:4|H-SDS:2	height standard deviation score:18:0.8365	0.8365	18
HSDs	HSDs:12	hydroxysteroid dehydrogenases:12:0.3524	0.3524	12
HSD	HSD:12	17 beta-Hydroxysteroid dehydrogenase:12:0.1692	0.1692	12
HSD	HSD:41	dextran 70:29:0.8472|dextran-70:12:0.0285	0.8472	41
HSD	HSD:24	Hallervorden-Spatz disease:24:0.6122	0.6122	24
HSD	HSD:12	hypertonic saline-dextran:12:0.7571	0.7571	12
HSD	HSD:2	hypertonic saline in dextran:2:0.8768	0.8768	2
HSD	HSD:9	solution:9:0.0207	0.0207	9
HSEES	HSEES:22	Hazardous Substances Emergency Events Surveillance:22:0.8657	0.8657	22
HSES	HSES:4	Haemorrhagic Shock Encephalopathy Syndrome:4:0.1850	0.1850	4
HSEs	HSEs:38	heat shock elements:38:0.9217	0.9217	38
HSES	HSES:5	Hemorrhagic shock and encephalopathy syndrome:5:0.1148	0.1148	5
HSE	HSE:30	Health and Safety Executive:30:0.9011	0.9011	30
HSE	HSE:131	heat shock element:120:0.9603|heat shock elements:11:0.7357	0.9603	131
HSE	HSE:10	hepatic sinusoidal endothelial:10:0.7103	0.7103	10
HSE	HSE:10	hepatic sinusoidal endothelium:10:0.7103	0.7103	10
HSE	HSE:170	herpes simplex encephalitis:170:0.9719	0.9719	170
HSE	HSE:11	human skin equivalent:11:0.6182	0.6182	11
HSF1	HSF1:8|Hsf1:1|HSF-1:1	heat shock factor:10:0.7103	0.7103	10
HSF1	HSF1:81|HSF-1:22|Hsf1:4|hsf1:1	heat shock factor 1:85:0.9442|heat shock factor-1:23:0.8038	0.9442	108
HSF1	HSF1:4|HSF-1:4|Hsf1:1|hsf1:1	heat shock transcription factor:10:0.7103	0.7103	10
HSF1	HSF1:58|HSF-1:10|Hsf1:2	heat shock transcription factor 1:60:0.9503|heat shock transcription factor-1:10:0.7103	0.9503	70
HSF2	HSF2:11|Hsf2:1	Heat shock factor 2:12:0.7571	0.7571	12
HSFs	HSFs:31|Hsfs:1	heat shock transcription factors:32:0.9072	0.9072	32
HSFs	HSFs:10	human skin fibroblasts:10:0.7103	0.7103	10
HSF	HSF:124|Hsf:5|hsf:1	heat shock factor:120:0.9751|Heat shock factors:10:0.7103	0.9751	130
HSF	HSF:119|Hsf:1	heat shock transcription factor:115:0.9740|heat shock transcription factors:5:0.4422	0.9740	120
HSF	HSF:6	heated soya flour:6:0.5290	0.5290	6
HSF	HSF:50	human skin fibroblasts:43:0.8037|human skin fibroblast:7:0.5926	0.8037	50
HSF	HSF:11	human synovial fibroblasts:11:0.6182	0.6182	11
HSGAGs	HSGAGs:5|HS-GAGs:2	heparan sulfate glycosaminoglycans:7:0.5926	0.5926	7
HS-GAG	HS-GAG:8|HSGAG:3	heparan sulfate glycosaminoglycan:11:0.7103	0.7103	11
HS-GC	HS-GC:11|HSGC:10	gas chromatography:21:0.7291	0.7291	21
HSG	HSG:40	cell line:40:0.8811	0.8811	40
HSG	HSG:17	human salivary gland:17:0.6748	0.6748	17
HSG	HSG:27	hysterosalpingogram:27:0.0662	0.0662	27
HSG	HSG:217	hysterosalpingography:217:0.5471	0.5471	217
HSG	HSG:8	salivary gland tumor:8:0.5006	0.5006	8
HSILs	HSILs:21	high-grade squamous intraepithelial lesions:21:0.5178	0.5178	21
HSIL	HSIL:34	high-grade SIL:21:0.4194|high grade SIL:13:0.7753	0.7753	34
HSIL	HSIL:155|H-SIL:2|H-Sil:1	high-grade squamous intraepithelial lesions:59:0.6447|high-grade squamous intraepithelial lesion:55:0.5538|high grade squamous intraepithelial lesion:27:0.8903|high grade squamous intraepithelial lesions:17:0.8270	0.8903	158
HSI	HSI:22	hepatosomatic index:22:0.2619	0.2619	22
HSI	HSI:11	hippocampal sympathetic ingrowth:11:0.7357	0.7357	11
HSK	HSK:50	herpes simplex keratitis:50:0.9404	0.9404	50
HSK	HSK:53	herpetic stromal keratitis:53:0.6167	0.6167	53
HSL	HSL:6	homoserine lactone:6:0.1010	0.1010	6
HSL	HSL:238|hsl:1	hormone-sensitive lipase:239:0.8307	0.8307	239
HSMCs	HSMCs:8|hSMCs:1	smooth muscle cells:9:0.5470	0.5470	9
HSMC	HSMC:6	human skin mast cells:6:0.3728	0.3728	6
HSMC	HSMC:7|hSMC:4|h-SMC:1	smooth muscle cells:12:0.7571	0.7571	12
HSMSL	HSMSL:9	human submandibular-sublingual saliva:9:0.6794	0.6794	9
HSM	HSM:28	heparin-surface-modified:28:0.2213	0.2213	28
HSN	HSN:16	head-shaking nystagmus:16:0.7096	0.7096	16
HSN	HSN:11	Henoch-Schonlein nephritis:11:0.4728	0.4728	11
HSO	HSO:6	hydrogenated soybean oil:6:0.5290	0.5290	6
HSOs	HSOs:9	organizations:9:0.6667	0.6667	9
HSP20	HSP20:9|hsp-20:1	heat shock protein 20:10:0.5000	0.5000	10
HSP47	HSP47:9|Hsp47:3|hsp47:2|HSP-47:1	heat shock protein:15:0.7096	0.7096	15
HSP47	HSP47:28|Hsp47:9|hsp47:3|HSP-47:1	heat shock protein 47:41:0.8867	0.8867	41
HSP72	HSP72:60|Hsp72:13|hsp72:11|HSP-72:4	heat shock protein 72:88:0.9660	0.9660	88
HSPCs	HSPCs:12	Hematopoietic stem/progenitor cells:12:0.7571	0.7571	12
HSPC	HSPC:8	hematopoietic stem and progenitor cells:8:0.6794	0.6794	8
HSPC	HSPC:8	hematopoietic stem/progenitor cells:8:0.2987	0.2987	8
HSPGs	HSPGs:202|HS-PGs:4	heparan sulfate proteoglycans:206:0.9619	0.9619	206
HSPG	HSPG:388|HS-PG:16|hsPG:1	heparan sulfate proteoglycan:278:0.9392|Heparan sulfate proteoglycans:127:0.9183	0.9392	405
HSPG	HSPG:53|HS-PG:2	heparan sulphate proteoglycan:55:0.8645	0.8645	55
HSPN	HSPN:39	Henoch-Schonlein purpura nephritis:39:0.8142	0.8142	39
HSPs	HSPs:628|hsps:173|Hsps:166|Hsp-s:2|HSP-s:1|HSPS:1	heat shock proteins:971:0.9903	0.9903	971
hsp	hsp:4|HSP:3|Hsp:1	heat shock:8:0.4102	0.4102	8
HSP	HSP:844|hsp:487|Hsp:219	heat shock protein:874:0.9800|heat shock proteins:405:0.9770|heat-shock protein:185:0.1423|heat-shock proteins:86:0.1249	0.9800	1550
HSP	HSP:219	Henoch-Schonlein purpura:219:0.8035	0.8035	219
HSP	HSP:27	hereditary spastic paraparesis:27:0.8903	0.8903	27
HSP	HSP:73	Hereditary spastic paraplegia:73:0.8789	0.8789	73
HSP	HSP:18|hsp:1	human seminal plasma:19:0.7044	0.7044	19
HSQ	HSQ:8	Health Status Questionnaire:8:0.6411	0.6411	8
HSRV	HSRV:20	human spumaretrovirus:20:0.7766	0.7766	20
HSRs	HSRs:72|hsrs:8	homogeneously staining regions:80:0.8738	0.8738	80
HSRs	HSRs:27	hypersensitivity reactions:27:0.7834	0.7834	27
HSR	HSR:25	health services research:25:0.8816	0.8816	25
HSR	HSR:21	heat shock response:21:0.3527	0.3527	21
HSR	HSR:4	heavy fraction of SR:4:0.4422	0.4422	4
HSR	HSR:89|hsr:34	homogeneously staining region:78:0.7599|homogeneously staining regions:45:0.8649	0.8649	123
HSR	HSR:8	hypersensitivity reaction:8:0.5006	0.5006	8
HSR	HSR:18	hypotonic shock response:18:0.2771	0.2771	18
HSR	HSR:22	sarcoplasmic reticulum:22:0.8657	0.8657	22
HSSE	HSSE:8	Headspace sorptive extraction:8:0.5006	0.5006	8
HS-SPME	HS-SPME:90|HSSPME:2	headspace solid-phase microextraction:92:0.9158	0.9158	92
HSs	HSs:13|HSS:5	DNase I hypersensitive sites:18:0.7044	0.7044	18
HSS	HSS:11	Hallervorden-Spatz syndrome:11:0.0778	0.0778	11
HSS	HSS:33	hepatic stimulator substance:33:0.8605	0.8605	33
HSS	HSS:9	hepatosplenic schistosomiasis:9:0.5470	0.5470	9
HSS	HSS:7	high speed supernatant:7:0.5926	0.5926	7
HSS	HSS:9	Homospermidine synthase:9:0.3455	0.3455	9
HSS	HSS:57	Hospital for Special Surgery:57:0.9477	0.9477	57
HSs	HSs:12	humic substances:12:0.5664	0.5664	12
HSS	HSS:12	hypertonic saline solution:12:0.7571	0.7571	12
HSTF	HSTF:10	heat shock transcription factor:10:0.7103	0.7103	10
HST	HST:5	Head Shaking Test:5:0.4422	0.4422	5
HST	HST:9|hST:1	human serum transferrin:10:0.7103	0.7103	10
HST	HST:11	hydroxysteroid sulfotransferase:11:0.7357	0.7357	11
HSV1-tk	HSV1-tk:11|HSV1-TK:9|HSV-1-tk:2|HSV-1-TK:1	herpes simplex virus type 1 thymidine kinase:23:0.8038	0.8038	23
HSV1-tk	HSV1-tk:3|HSV1-TK:2|HSV-1-tk:1	type 1 thymidine kinase gene:6:0.5290	0.5290	6
HSV-1	HSV-1:12|HSV1:7	herpes simplex type 1 virus:19:0.8449	0.8449	19
HSV-1	HSV-1:108|HSV1:8	Herpes Simplex Virus:116:0.9744	0.9744	116
HSV-1	HSV-1:111|HSV1:3	herpes simplex virus-1:114:0.9735	0.9735	114
HSV-1	HSV-1:2880|HSV1:95|HSV--1:1	herpes simplex virus type 1:2849:0.9904|herpes simplex virus type-1:127:0.9630	0.9904	2976
HSV-1	HSV-1:30|HSV1:2	herpes simplex virus type I:32:0.9072	0.9072	32
HSV-2	HSV-2:25	herpes simplex virus-2:25:0.8816	0.8816	25
HSV-2	HSV-2:787|HSV2:28|hsv-2:1	herpes simplex virus type 2:787:0.9881|Herpes simplex virus type-2:29:0.8422	0.9881	816
HSV-2	HSV-2:11|HSV2:2	type 2 herpes simplex virus:13:0.7753	0.7753	13
HSV-2	HSV-2:10	type 2 virus:10:0.7103	0.7103	10
HSVEC	HSVEC:17	human saphenous vein endothelial cells:17:0.8270	0.8270	17
HSVECs	HSVECs:11	human saphenous vein endothelial cells:11:0.5355	0.5355	11
HSVE	HSVE:36	herpes simplex virus encephalitis:36:0.8716	0.8716	36
HSV-I	HSV-I:25|HSVI:3	herpes simplex virus type I:28:0.8941	0.8941	28
HSV-tk	HSV-tk:108|HSV-TK:102|HSVtk:64|HSVTK:5|hsvTK:1|hsv-TK:1	herpes simplex virus thymidine kinase:281:0.9893	0.9893	281
HSV-tk	HSV-tk:17|HSVtk:10|HSV-TK:10|hsv-tk:1	herpes simplex virus thymidine kinase gene:38:0.9217	0.9217	38
HSVtk	HSV-tk:2|HSVtk:2	thymidine kinase gene of herpes simplex virus:4:0.6794	0.6794	4
HSVd	HSVd:14	hop stunt viroid:14:0.7909	0.7909	14
HSV	HSV:63	herpes simplex:63:0.8612	0.8612	63
HSV	HSV:21	herpes simplex viral:21:0.7865	0.7865	21
HSV	HSV:3944|hsv:2	herpes simplex virus:3868:0.9874|herpes simplex viruses:78:0.9617	0.9874	3946
HSV	HSV:59	herpes simplex virus type 1:59:0.9264	0.9264	59
HSV	HSV:10	herpes simplex virus type I:10:0.7103	0.7103	10
HSV	HSV:82	highly selective vagotomy:82:0.9422	0.9422	82
HSV	HSV:11	hop stunt viroid:11:0.7357	0.7357	11
HSV	HSV:26	human saphenous vein:26:0.7760	0.7760	26
HSWP	HSWP:10|HS-WP:2	fibroblasts:12:0.8462	0.8462	12
HStk	HStk:10|HS-tk:5|HSTK:1	herpes simplex thymidine kinase:16:0.8165	0.8165	16
HS	HS:9|hs:4	bedtime:13:0.0034	0.0034	13
HS	HS:16	DNase I hypersensitive:16:0.8270	0.8270	16
HS	HS:26|hs:1	DNase I hypersensitive sites:16:0.7261|DNase I hypersensitive site:11:0.7357	0.7357	27
HS	HS:16|hs:1	haemorrhagic septicaemia:17:0.8270	0.8270	17
HS	HS:15	Harmonic Scalpel:15:0.6577	0.6577	15
HS	HS:26	Headspace:26:0.0070	0.0070	26
HS	HS:10	health status:10:0.7103	0.7103	10
HS	HS:7	healthy smokers:7:0.1641	0.1641	7
HS	HS:112	healthy subjects:112:0.8401	0.8401	112
HS	HS:152|hs:16|Hs:1	heat shock:143:0.4670|heat-shock:26:0.0070	0.4670	169
HS	HS:19	heat-stable:19:0.0050	0.0050	19
HS	HS:70|Hs:2|hs:1	heat stress:73:0.8329	0.8329	73
HS	HS:9	heat stroke:9:0.1334	0.1334	9
HS	HS:20	hemophagocytic syndrome:20:0.1529	0.1529	20
HS	HS:118|hs:1	hemorrhagic shock:119:0.3812	0.3812	119
HS	HS:13	hemorrhagic stroke:13:0.2802	0.2802	13
HS	HS:26	hemosorption:26:0.0070	0.0070	26
HS	HS:610	Heparan sulfate:589:0.9306|heparan sulfates:21:0.7865	0.9306	610
HS	HS:116	heparan sulphate:116:0.9109	0.9109	116
HS	HS:11	hepatosplenic:11:0.0028	0.0028	11
HS	HS:212	hereditary spherocytosis:212:0.9699	0.9699	212
HS	HS:14	herpes simplex:14:0.6173	0.6173	14
HS	HS:23	heterogeneous stock:23:0.6653	0.6653	23
HS	HS:37	hidradenitis suppurativa:37:0.8749	0.8749	37
HS	HS:56	high-salt:37:0.0101|high salt:19:0.8449	0.8449	56
HS	HS:6	high-salt diet:6:0.0899	0.0899	6
HS	HS:11|hs:1	high-spin:12:0.0031	0.0031	12
HS	HS:61	hindlimb suspension:61:0.8383	0.8383	61
HS	HS:128	hippocampal sclerosis:128:0.9510	0.9510	128
HS	HS:14	Hopelessness Scale:14:0.4367	0.4367	14
HS	HS:5	horizontal system:5:0.1132	0.1132	5
HS	HS:45|hS:1	horse serum:46:0.2765	0.2765	46
HS	HS:11	HS-142-1:11:0.0028	0.0028	11
HS	HS:71|hS:1	human serum:72:0.4837	0.4837	72
HS	HS:53	Humic substances:53:0.8842	0.8842	53
HS	HS:13	hunger sensation:13:0.7753	0.7753	13
HS	HS:131	hypertonic saline:131:0.8046	0.8046	131
HS	HS:5	hypertonic saline solution:5:0.2818	0.2818	5
HS	HS:7	hypertrophic scar:7:0.3524	0.3524	7
Hs	Hs:23|HS:2	Hypochondriasis:25:0.0067	0.0067	25
HS	HS:11	hyposensitization:11:0.0028	0.0028	11
HS	HS:7	hypothalamic stimulation:7:0.2452	0.2452	7
HS	HS:14|Hs:1	score:15:0.0039	0.0039	15
HT-1080	HT-1080:10|HT1080:9	human fibrosarcoma:19:0.3019	0.3019	19
HT-1080	HT-1080:11|HT1080:7	human fibrosarcoma cells:18:0.4672	0.4672	18
HT1	HT1:11	Hereditary tyrosinemia type 1:11:0.7357	0.7357	11
HT1	HT1:8	hereditary tyrosinemia type I:8:0.6411	0.6411	8
HT-22	HT-22:5|HT22:2	mouse hippocampal cell line:7:0.3524	0.3524	7
HT-29	HT-29:5|HT29:1	human colon adenocarcinoma cells:6:0.2827	0.2827	6
HT29	HT29:6|HT-29:3	human colon cancer:9:0.4587	0.4587	9
HT-29	HT-29:16|HT29:3	human colon carcinoma:19:0.5732	0.5732	19
HT-29	HT-29:11|HT29:5	human colon carcinoma cells:16:0.6024	0.6024	16
HTAB	HTAB:11	hexadecyltrimethylammonium bromide:11:0.4232	0.4232	11
HTA	HTA:110	Health technology assessment:110:0.9728	0.9728	110
HTA	HTA:18	heteroduplex tracking assay:18:0.7539	0.7539	18
HTA	HTA:24	hypertension:24:0.0996	0.0996	24
HTBF	HTBF:10	hepatic tissue blood flow:10:0.7103	0.7103	10
HTB	HTB:9	2-Hydroxy-4-trifluoromethylbenzoic acid:9:0.3945	0.3945	9
HTB	HTB:7	heterotopically transplanted rat urinary bladder:7:0.5926	0.5926	7
HTCA	HTCA:61	human tumor clonogenic assay:61:0.9229	0.9229	61
HTCFA	HTCFA:7	human tumor colony-forming assay:7:0.5926	0.5926	7
HTCs	HTCs:16	homozygous typing cells:16:0.8270	0.8270	16
HTC	HTC:9	cell line:9:0.6794	0.6794	9
Htc	Htc:19|HTC:5	hematocrit:24:0.0730	0.0730	24
HTC	HTC:62	hepatoma tissue culture:62:0.9519	0.9519	62
HTC	HTC:40	Homozygous typing cells:26:0.8861|homozygous typing cell:14:0.7909	0.8861	40
HTC	HTC:50	rat hepatoma:50:0.6597	0.6597	50
HTE	HTE:21	hamster tracheal epithelial:21:0.5435	0.5435	21
hTF	hTF:8|hTf:1	human serum transferrin:9:0.6794	0.6794	9
HTF	HTF:4|hTf:2	human Tenon's capsule fibroblasts:6:0.5290	0.5290	6
hTf	hTf:15|htf:2|HTf:2|HTF:2	human transferrin:21:0.4945	0.4945	21
HTF	HTF:46	human tubal fluid:46:0.8986	0.8986	46
HTF	HTF:7|hTF:1	human tubal fluid medium:8:0.6411	0.6411	8
HTF	HTF:9	Tiny Fragment:9:0.6794	0.6794	9
HTG	HTG:15	high-tension glaucoma:15:0.5818	0.5818	15
hTg	hTg:44|hTG:15|HTg:13|H-Tg:1|h-tg:1	human thyroglobulin:74:0.6122	0.6122	74
HTG	HTG:15	hypertriglyceridaemia:15:0.0398	0.0398	15
HTG	HTG:11	hypertriglyceridaemic:11:0.0284	0.0284	11
HTG	HTG:78	hypertriglyceridemia:78:0.2188	0.2188	78
HTG	HTG:57|HTg:1	hypertriglyceridemic:58:0.1619	0.1619	58
HTHQ	HTHQ:14	1-O-hexyl-2,3,5-trimethylhydroquinone:14:0.7647	0.7647	14
HTH	HTH:101|HtH:2|H-T-H:1	helix-turn-helix:104:0.4725	0.4725	104
HTH	HTH:5	homeostatic thymus hormone:5:0.2818	0.2818	5
hth	hth:22|HTH:8|Hth:6	homothorax:36:0.1606	0.1606	36
hTH	hTH:6|HTH:4	human tyrosine hydroxylase:10:0.7103	0.7103	10
HTH	HTH:8	hypertrehalosemic hormone:8:0.2090	0.2090	8
HTK	HTK:39	histidine-tryptophan-ketoglutarate:39:0.2815	0.2815	39
HTK	HTK:9	histidine-tryptophan-ketoglutarate solution:9:0.1267	0.1267	9
HTK	HTK:8|Htk:6|hTK:5|htk:4	thymidine kinase:23:0.8038	0.8038	23
HTLV	HTLV:10	human T-cell leukemia viruses:10:0.7103	0.7103	10
HTLV	HTLV:66	human T-cell lymphotropic virus:38:0.9217|human T cell lymphotropic virus:23:0.8715|human T-cell lymphotropic viruses:5:0.4422	0.9217	66
HTLV	HTLV:33	human T lymphotropic virus:33:0.9072	0.9072	33
HTLV	HTLV:10	retrovirus:10:0.0186	0.0186	10
HTLV-II	HTLV-II:30	human T-lymphotropic virus type II:30:0.9043	0.9043	30
HTLV-1	HTLV-1:19	human T-cell leukemia virus:19:0.7044	0.7044	19
HTLV-1	HTLV-1:6	human T-cell leukemia virus-1:6:0.3728	0.3728	6
HTLV-1	HTLV-1:364|HTLV1:5	human T-cell leukemia virus type 1:285:0.9894|human T cell leukemia virus type 1:62:0.9519|human T-cell leukemia virus type-1:22:0.8525	0.9894	369
HTLV-1	HTLV-1:5	human T-cell lymphotropic virus:5:0.4422	0.4422	5
HTLV-1	HTLV-1:119	human T-cell lymphotropic virus type 1:108:0.9432|human T-cell lymphotropic virus type-1:11:0.7357	0.9432	119
HTLV-1	HTLV-1:121	human T-lymphotropic virus type 1:85:0.9131|human T lymphotropic virus type 1:26:0.8312|human T lymphotropic virus type-1:10:0.5470	0.9131	121
HTLV-I	HTLV-I:6	human T-cell leukemia virus-I:6:0.5290	0.5290	6
HTLV-I	HTLV-I:14	human T-cell leukemia virus type 1:14:0.7909	0.7909	14
HTLV-I	HTLV-I:555|HTLVI:1	human T-cell leukemia virus type I:405:0.9881|human T cell leukemia virus type I:108:0.9411|human T-cell leukemia virus type-I:43:0.8917	0.9881	556
HTLV-I	HTLV-I:5	human T-cell lymphotrophic virus-I:5:0.4422	0.4422	5
HTLV-I	HTLV-I:12	human T-cell lymphotropic virus:12:0.7571	0.7571	12
HTLV-I	HTLV-I:345|HTLVI:2	human T-cell lymphotropic virus type I:255:0.9583|human T cell lymphotropic virus type I:72:0.9579|human T-cell lymphotropic virus type-I:20:0.8449	0.9583	347
HTLV-I	HTLV-I:12	human T-lymphotropic virus-I:12:0.7571	0.7571	12
HTLV-I	HTLV-I:18	human T-lymphotropic virus type 1:18:0.8449	0.8449	18
HTLV-I	HTLV-I:158	human T lymphotropic virus type I:120:0.9442|human T-lymphotropic virus type-I:28:0.7505|Human T lymphotropic virus type-I:10:0.7103	0.9442	158
HTLV-I	HTLV-I:9	Lymphotropic Virus-I:9:0.0638	0.0638	9
HTLV-I	HTLV-I:12	type I human T-cell leukemia virus:12:0.7571	0.7571	12
HTLp	HTLp:18|HTL-p:2|HTL-P:2	helper T lymphocyte precursor:13:0.5934|helper T lymphocyte precursors:9:0.6794	0.6794	22
HTL	HTL:18	hearing threshold level:18:0.8365	0.8365	18
Htl	Htl:7|htl:2|HTL:1	Heartless:10:0.0657	0.0657	10
HTL	HTL:53	helper T lymphocytes:33:0.8605|helper T lymphocyte:20:0.8525	0.8605	53
HTM	HTM:33	Haemophilus test medium:33:0.9100	0.9100	33
HTM	HTM:40|hTM:1|h-TM:1	human trabecular meshwork:42:0.8558	0.8558	42
HTNV	HTNV:29	Hantaan virus:29:0.7970	0.7970	29
HTN	HTN:12	Hantaan virus:12:0.7571	0.7571	12
HTN	HTN:156|htn:2|HTn:1	hypertension:159:0.6583	0.6583	159
HTO	HTO:49	High tibial osteotomy:49:0.9392	0.9392	49
HTO	HTO:64	tritiated water:64:0.8632	0.8632	64
HTPN	HTPN:11	home total parenteral nutrition:11:0.6182	0.6182	11
HTP	HTP:7	heart transplant patients:7:0.5926	0.5926	7
HTP	HTP:6	heart transplanted patients:6:0.5290	0.5290	6
HTP	HTP:11	high-throughput:11:0.0952	0.0952	11
HTQ	HTQ:15	Harvard Trauma Questionnaire:15:0.8045	0.8045	15
HTRF	HTRF:14	homogeneous time-resolved fluorescence:14:0.6173	0.6173	14
hTRT	hTRT:14	Human telomerase reverse transcriptase:14:0.6911	0.6911	14
HTRs	HTRs:9	heart transplant recipients:9:0.6794	0.6794	9
HTR	HTR:9	hard tissue replacement:9:0.6794	0.6794	9
HTR	HTR:32	head-twitch response:32:0.6220	0.6220	32
HTR	HTR:28	heart transplant recipients:28:0.8941	0.8941	28
hTR	hTR:78|HTR:1	human telomerase RNA:79:0.7729	0.7729	79
hTR	hTR:5	human transferrin receptor:5:0.4422	0.4422	5
hTR	hTR:18	RNA component of human telomerase:18:0.8365	0.8365	18
hTR	hTR:10	RNA component of telomerase:10:0.7103	0.7103	10
HTSCA	HTSCA:19	human tumor stem cell assay:19:0.8449	0.8449	19
HTSE	HTSE:13	hamster tracheal surface epithelial:13:0.7753	0.7753	13
htt	htt:57|Htt:22	huntingtin:79:0.6000	0.6000	79
Htt	Htt:7|htt:2	huntingtin protein:9:0.5470	0.5470	9
HTV	HTV:10	vibration:10:0.2812	0.2812	10
HTZ	HTZ:11|Htz:2	hydrochlorothiazide:13:0.7500	0.7500	13
HTST	HTST:6	high-temperature short-time:6:0.7357	0.7357	6
HUAEC	HUAEC:11	human umbilical arterial endothelial cells:11:0.7357	0.7357	11
HUAEC	HUAEC:7	human umbilical artery endothelial cells:7:0.5926	0.5926	7
HUA	HUA:23	human umbilical artery:23:0.8715	0.8715	23
HUCB	HUCB:44|hUCB:7	human umbilical cord blood:51:0.9416	0.9416	51
HuCV	HuCV:14	human calicivirus:14:0.7909	0.7909	14
HUFA	HUFA:16	highly unsaturated fatty acids:16:0.6577	0.6577	16
HUFAs	HUFAs:12	highly unsaturated fatty acids:12:0.7571	0.7571	12
HUI2	HUI2:17	Health Utilities Index Mark 2:17:0.8270	0.8270	17
HUI3	HUI3:19	Health Utilities Index Mark 3:19:0.8525	0.8525	19
HUK	HUK:12	human urinary kallikrein:12:0.7571	0.7571	12
HUMARA	HUMARA:42|HU-MARA:1	human androgen receptor:43:0.8917	0.8917	43
HUMARA	HUMARA:5	human androgen receptor assay:5:0.4422	0.4422	5
HUMARA	HUMARA:46|Humara:2|HU-MARA:1	human androgen receptor gene:49:0.7455	0.7455	49
Hup	Hup:6|hup:3	hydrogenase:9:0.1481	0.1481	9
HUSM	HUSM:10	Hospital Universiti Sains Malaysia:10:0.7103	0.7103	10
HUS	HUS:135|hus:1	haemolytic uraemic syndrome:136:0.9534	0.9534	136
HUS	HUS:6	head ultrasound:6:0.2243	0.2243	6
HUS	HUS:523	hemolytic uremic syndrome:523:0.9325	0.9325	523
HUs	HUs:7	Hounsfield units:7:0.3524	0.3524	7
HUTT	HUTT:13	head-up tilt test:13:0.4444	0.4444	13
HUVECs	HUVECs:15|HUVECS:2|HU-VECs:1	human umbilical veins:11:0.7357|human umbilical vein:7:0.4438	0.7357	18
HUVECs	HUVECs:38	human umbilical vein ECs:38:0.9217	0.9217	38
HUVECs	HUVECs:1156|HUVECS:4|hUVECs:4|Huvecs:4|HU-VECs:2|huvecs:2|HUV-ECs:1	Human umbilical vein endothelial cells:1173:0.9819	0.9819	1173
HUVEC	HUVEC:4	endothelial cells from human umbilical cord veins:4:0.5290	0.5290	4
HUVEC	HUVEC:40	human umbilical vein:30:0.4299|human umbilical veins:10:0.3145	0.4299	40
HUVEC	HUVEC:47	human umbilical vein EC:47:0.8703	0.8703	47
HUVEC	HUVEC:1828|HUV-EC:7|HuVEC:3|Huvec:2|HU-VEC:2|hUVEC:1|huvEC:1	human umbilical vein endothelial cells:1630:0.9789|Human umbilical vein endothelial cell:214:0.9776	0.9789	1844
HUVEC	HUVEC:10	umbilical vein endothelium:10:0.7103	0.7103	10
HUVE	HUVE:89|Huve:1	human umbilical vein endothelial:90:0.9668	0.9668	90
HUVE	HUVE:30	human umbilical vein endothelial cells:30:0.9011	0.9011	30
HUVE	HUVE:17	human umbilical vein endothelium:17:0.8270	0.8270	17
HUVS	HUVS:13	Hypocomplementemic urticarial vasculitis syndrome:13:0.7753	0.7753	13
HU	HU:47	hindlimb unloading:47:0.8187	0.8187	47
HU	HU:16	hindlimb unweighting:16:0.7261	0.7261	16
HU	HU:178	Hounsfield Units:154:0.7968|Hounsfield unit:24:0.5370	0.7968	178
HU	HU:7	HTLV-1 uveitis:7:0.3455	0.3455	7
Hu	Hu:50|hu:45	human:95:0.0698	0.0698	95
HU	HU:791|Hu:9|hu:1	Hydroxyurea:801:0.5939	0.5939	801
HV1	HV1:10	hypervariable region 1:10:0.7103	0.7103	10
HVAC	HVAC:10	air-conditioning:10:0.2432	0.2432	10
HVA	HVA:106	high voltage-activated:64:0.8283|high-voltage activated:28:0.4950|high voltage activated:14:0.7909	0.8283	106
HVA	HVA:14	homovanillic:14:0.0053	0.0053	14
HVD	HVD:12	hypoxic ventilatory decline:12:0.7571	0.7571	12
HVEM	HVEM:11	high-voltage electron microscope:11:0.5355	0.5355	11
HVEM	HVEM:16	high voltage electron microscopy:16:0.8165	0.8165	16
HVE	HVE:20	hepatic vascular exclusion:20:0.7766	0.7766	20
HVF	HVF:7	Humphrey visual field:7:0.4438	0.4438	7
HVG	HVG:33|HvG:11|hvg:1	host-versus-graft:37:0.5714|Host versus graft:8:0.6411	0.6411	45
HVH	HVH:20	Herpesvirus hominis:20:0.7766	0.7766	20
HVI.CHP	HVI.CHP:10	hepatic venous isolation and charcoal hemoperfusion:10:0.7103	0.7103	10
HVJ	HVJ:43	Hemagglutinating Virus of Japan:43:0.7523	0.7523	43
HVL	HVL:39	half-value layer:24:0.4187|Half Value Layer:15:0.8045	0.8045	39
HVO2	HVO2:6	hepatic oxygen consumption:6:0.5290	0.5290	6
HVOD	HVOD:18	hepatic veno-occlusive disease:18:0.8365	0.8365	18
HVOF	HVOF:9	high velocity oxy-fuel:9:0.6794	0.6794	9
HVOR	HVOR:26|hVOR:2|H-VOR:1|h-VOR:1	horizontal vestibulo-ocular reflex:30:0.8032	0.8032	30
HVP	HVP:29	Herpesvirus papio:29:0.7154	0.7154	29
HVP2	HVP2:8|HVP-2:2	Herpesvirus papio 2:10:0.7103	0.7103	10
HVPC	HVPC:9	High voltage pulsed current:9:0.6794	0.6794	9
HVPG	HVPG:84	hepatic venous pressure gradient:84:0.9644	0.9644	84
HVPT	HVPT:13	hyperventilation provocation Test:13:0.7753	0.7753	13
HVR1	HVR1:14|HVR-1:3	hypervariable region:17:0.7407	0.7407	17
HVR1	HVR1:142|HVR-1:14	hypervariable region 1:156:0.9412	0.9412	156
HVR3	HVR3:7|HVR-3:1	third hypervariable region:8:0.6411	0.6411	8
HVRI	HVRI:6|HVR-I:3	Hypervariable region I:9:0.4587	0.4587	9
HVRs	HVRs:16	hypervariable regions:16:0.7261	0.7261	16
HVR	HVR:86|hvr:3	hypervariable region:89:0.8602	0.8602	89
HVR	HVR:124	hypoxic ventilatory response:112:0.9437|Hypoxic ventilatory responses:12:0.5664	0.9437	124
HVR	HVR:14	vascular resistance:14:0.6173	0.6173	14
HVR	HVR:9	ventilatory response to hypoxia:9:0.6794	0.6794	9
HVS1	HVS1:6|HVS-1:2	hypervariable segment 1:8:0.6411	0.6411	8
HVS-I	HVS-I:7|HVSI:3	first hypervariable segment:10:0.7103	0.7103	10
HVs	HVs:12	health visitors:12:0.7571	0.7571	12
HVs	HVs:18	healthy volunteers:18:0.7539	0.7539	18
HVS	HVS:156	herpesvirus saimiri:156:0.9022	0.9022	156
HVS	HVS:10	high vaginal swab:10:0.7103	0.7103	10
HVS	HVS:12	high-voltage spindle:7:0.2113|high voltage spindles:5:0.4422	0.4422	12
HVS	HVS:9	human visual system:9:0.6794	0.6794	9
HVS	HVS:36	hyperventilation syndrome:36:0.6538	0.6538	36
HVT	HVT:118	herpesvirus of turkeys:98:0.8846|herpesvirus of turkey:20:0.6400	0.8846	118
HVT	HVT:61	turkey herpesvirus:61:0.9511	0.9511	61
HVc	HVc:16	caudal nucleus of the ventral hyperstriatum:16:0.8165	0.8165	16
HVC	HVC:63|HVc:9	high vocal center:72:0.5849	0.5849	72
HVC	HVC:29|HVc:4	higher vocal center:33:0.2149	0.2149	33
HVc	HVc:7	hyperstriatum ventrale pars caudale:7:0.5374	0.5374	7
HVc	HVc:6	hyperstriatum ventralis pars caudalis:6:0.6182	0.6182	6
HV	HV:15	hallux valgus:15:0.6386	0.6386	15
HV	HV:10	Hantaan virus:10:0.2126	0.2126	10
HV	HV:68	healthy volunteers:68:0.9306	0.9306	68
HV	HV:9	heart volume:9:0.1099	0.1099	9
HV	HV:71	height velocity:71:0.9112	0.9112	71
HV	HV:6	hemorrhagic vasculitis:6:0.0522	0.0522	6
HV	HV:46	hepatic vein:46:0.8986	0.8986	46
HV	HV:13	high voltage:13:0.6701	0.6701	13
HV	HV:8	hippocampal volume:8:0.0825	0.0825	8
HV	HV:11|H-V:2	His-ventricular:13:0.0163	0.0163	13
HV	HV:13	hydroa vacciniforme:13:0.7753	0.7753	13
HV	HV:11	hydroxyvalerate:11:0.0136	0.0136	11
HV	HV:12	hypersensitivity vasculitis:12:0.3058	0.3058	12
HV	HV:15	hyperstriatum ventrale:15:0.8045	0.8045	15
HV	HV:18	hypervariable:18:0.0231	0.0231	18
HV	HV:89|hv:1	hyperventilation:90:0.1211	0.1211	90
HW/BW	HW/BW:8	heart weight/body weight ratio:8:0.6411	0.6411	8
HWB	HWB:15	whole blood:15:0.8045	0.8045	15
HWE	HWE:56|HWe:1	Hardy-Weinberg equilibrium:57:0.8281	0.8281	57
HWE	HWE:15	Hardy-Weinberg expectations:15:0.8045	0.8045	15
HWE	HWE:14	healthy worker effect:14:0.7909	0.7909	14
HWE	HWE:10	Horner-Wadsworth-Emmons:10:0.0698	0.0698	10
HWI	HWI:11	hazardous waste incinerator:11:0.7357	0.7357	11
HWI	HWI:7	head-out water immersion:7:0.4438	0.4438	7
HWL	HWL:15	hindpaw withdrawal latency:15:0.7096	0.7096	15
HW	HW:3	dogs with heartworm:3:0.0736	0.0736	3
HW	HW:10|H-W:7	Hardy-Weinberg:17:0.0582	0.0582	17
HW	HW:28	heart weight:28:0.5837	0.5837	28
HW	HW:45	hydrostatic weighing:45:0.8964	0.8964	45
HW	HW:8	selected for high:8:0.2757	0.2757	8
HXR	HXR:8	hyperacute xenograft rejection:8:0.6411	0.6411	8
HXT	HXT:8|Hxt:2	hexose transporter:10:0.5856	0.5856	10
HX-XO	HX-XO:9|HXXO:1	hypoxanthine-xanthine oxidase:10:0.5000	0.5000	10
HYAL2	HYAL2:6|Hyal2:5|Hyal-2:1	hyaluronidase 2:12:0.7571	0.7571	12
HYAL	HYAL:10|Hyal:1	hyaluronidase:11:0.4545	0.4545	11
HYNIC	HYNIC:17	Hydrazinonicotinamide:17:0.3810	0.3810	17
HYPP	HYPP:11|HyPP:1	Hyperkalemic periodic paralysis:12:0.5050	0.5050	12
Hyp	Hyp:9	4-hydroxyproline:9:0.0142	0.0142	9
Hyp	Hyp:108|HYP:46|hyp:5	hydroxyproline:159:0.2819	0.2819	159
Hyp	Hyp:7|HYP:6|hyp:1	hypericin:14:0.0230	0.0230	14
HYP	HYP:64|Hyp:5	hypothalamus:69:0.1206	0.1206	69
Hyp	Hyp:14|HYP:9	hypoxanthine:23:0.0390	0.0390	23
Hyp	Hyp:30|HYP:4|hyp:1	X-linked hypophosphatemic:35:0.4141	0.4141	35
HYP	HYP:12|Hyp:2	X-linked hypophosphatemic rickets:14:0.7909	0.7909	14
HZA	HZA:61	hemizona assay:61:0.8525	0.8525	61
HZE	HZE:7	high charge and energy:7:0.5926	0.5926	7
HZE	HZE:20	high-energy:12:0.2037|high energy:8:0.1591	0.2037	20
HZI	HZI:9	hemizona index:9:0.5470	0.5470	9
HZO	HZO:36	herpes zoster ophthalmicus:36:0.9174	0.9174	36
HZ	HZ:95|Hz:1	herpes zoster:96:0.9689	0.9689	96
Hz	Hz:19	Hertz:19:0.0627	0.0627	19
HZ	HZ:10|Hz:2	heterozygous:12:0.0383	0.0383	12
Hz	Hz:7|HZ:6	hydrazine:13:0.0418	0.0418	13
HaCaT	HaCaT:33|HaCat:2|HACAT:1|Ha-CaT:1	human keratinocytes:37:0.4015	0.4015	37
HaCaT	HaCaT:30|HaCat:4|HACAT:1	human keratinocyte cell line:35:0.5771	0.5771	35
Ha-MSV	Ha-MSV:9|HaMSV:6	Harvey murine sarcoma virus:15:0.7096	0.7096	15
Ha-MuSV	Ha-MuSV:20|HaMuSV:2	Harvey murine sarcoma virus:22:0.7400	0.7400	22
HaPV	HaPV:12|HapV:1	hamster papovavirus:13:0.7753	0.7753	13
HaPV	HaPV:16	hamster polyomavirus:16:0.8165	0.8165	16
HARV	HARV:15	high aspect ratio vessel:15:0.8045	0.8045	15
HaSNPV	HaSNPV:15	nucleopolyhedrovirus:15:0.7368	0.7368	15
HaSV	HaSV:6|Ha-SV:3	Harvey sarcoma virus:9:0.3945	0.3945	9
HAdV	HAdV:11	human adenovirus:11:0.6182	0.6182	11
HALE	HALE:9	Life Expectancy:9:0.6794	0.6794	9
HAL	HAL:10	acute leukemia:10:0.7103	0.7103	10
HAL	HAL:212|Hal:35|hal:3	haloperidol:250:0.4950	0.4950	250
HAL	HAL:29|Hal:11	halothane:40:0.0775	0.0775	40
HAL	HAL:13	hand-assisted laparoscopic:13:0.6701	0.6701	13
HAL	HAL:48	hepatic artery ligation:48:0.8221	0.8221	48
HAL	HAL:27	hip axis length:27:0.8903	0.8903	27
HAM	HAM:5	high-dose cytarabine and mitoxantrone:5:0.2818	0.2818	5
HAM	HAM:25	HTLV-1 associated myelopathy:25:0.1263	0.1263	25
HAM	HAM:74	HTLV-I associated myelopathy:74:0.5858	0.5858	74
HAM	HAM:15|h-AM:1	Human alveolar macrophages:16:0.6577	0.6577	16
HAM	HAM:10|hAM:2	Human Amniotic Membrane:12:0.7571	0.7571	12
HAM	HAM:33	patients with HTLV-I-associated myelopathy:33:0.2318	0.2318	33
HASs	HASs:8	hyaluronan synthases:8:0.3463	0.3463	8
HbA(1c)	HbA(1c):7	Glycaemic control:7:0.0777	0.0777	7
HbA(1c)	HbA(1c):26|HbA(1C):2	glycated haemoglobin:28:0.4089	0.4089	28
HbA(1c)	HbA(1c):27|HbA(1C):2	glycated hemoglobin:29:0.2084	0.2084	29
HbA(1c)	HbA(1c):12	glycemic control:12:0.2699	0.2699	12
HbA(1c)	HbA(1c):20|HbA(1C):1	glycosylated haemoglobin:21:0.2677	0.2677	21
HbA(1c)	HbA(1c):54|HbA(1C):5|Hba(1c):1	glycosylated hemoglobin:60:0.5413	0.5413	60
HbA(1c)	HbA(1c):60|HbA(1C):5|HBA(1c):1	hemoglobin A(1c):66:0.7369	0.7369	66
HbA1c	HbA1c:102|HbA1C:7	glycated haemoglobin:109:0.3709	0.3709	109
HbA1c	HbA1c:82|HbA1C:11|HBA1c:1	glycated hemoglobin:94:0.2006	0.2006	94
HbA1c	HbA1c:16|HbA1C:2	glycemic control:18:0.1281	0.1281	18
HbA1c	HbA1c:15|HbA1C:4	glycohemoglobin:19:0.0153	0.0153	19
HbA1c	HbA1c:112|HbA1C:15|HBA1c:2|Hba1c:1|HBA1C:1	Glycosylated haemoglobin:131:0.4588	0.4588	131
HbA1c	HbA1c:223|HbA1C:31|HBA1C:4|HBA1c:1|Hb-A1C:1	glycosylated hemoglobin:260:0.6338	0.6338	260
HbA1c	HbA1c:52|HbA1C:3|HBA1c:1	haemoglobin A1c:56:0.1089	0.1089	56
HbA1c	HbA1c:289|HbA1C:29|HBA1c:1	Hemoglobin A1c:319:0.8042	0.8042	319
HbA1c	HbA1c:5	hemoglobin levels:5:0.0902	0.0902	5
HbA1	HbA1:28|Hba1:1	glycated haemoglobin:29:0.1619	0.1619	29
HbA1	HbA1:9	glycohemoglobin:9:0.0195	0.0195	9
HbA1	HbA1:78|HBA1:2	glycosylated haemoglobin:80:0.5945	0.5945	80
HbA1	HbA1:131|HBA1:2|Hba1:1	Glycosylated hemoglobin:134:0.8083	0.8083	134
HbA1	HbA1:27	haemoglobin A1:27:0.2086	0.2086	27
HbA1	HbA1:55	hemoglobin A1:55:0.5383	0.5383	55
HbA2	HbA2:15	hemoglobin A2:15:0.4609	0.4609	15
HbAS	HbAS:31|Hb-AS:2	sickle cell trait:33:0.9100	0.9100	33
HbA	HbA:10	adult haemoglobin:10:0.2446	0.2446	10
HbA	HbA:19|Hb-A:1	human adult hemoglobin:20:0.3614	0.3614	20
HbA	HbA:17	human hemoglobin:17:0.1554	0.1554	17
HBA	HBA:14	hydrogen bond acceptor:8:0.6411|hydrogen-bond acceptor:6:0.0731	0.6411	14
HBA	HBA:8	p-hydroxybenzoic acid:8:0.2090	0.2090	8
HbCO	HbCO:14|Hb-CO:1	carboxyhaemoglobin:15:0.1045	0.1045	15
HbCO	HbCO:81|Hbco:1	carboxyhemoglobin:82:0.6045	0.6045	82
hBD-1	hBD-1:23|HBD-1:11|hBD1:5|hbd-1:1	human beta-defensin-1:23:0.8038|human beta-defensin 1:17:0.8270	0.8270	40
HbF	HbF:38	fetal haemoglobin:38:0.4632	0.4632	38
HbF	HbF:224|Hb-F:2	fetal hemoglobin:226:0.9589	0.9589	226
HbF	HbF:23	foetal haemoglobin:23:0.2291	0.2291	23
HbF	HbF:14	haemoglobin F:14:0.1271	0.1271	14
HbF	HbF:33	hemoglobin F:33:0.4694	0.4694	33
HBF	HBF:67	hepatic blood flow:67:0.6155	0.6155	67
HBF	HBF:13	heterotopic bone formation:13:0.7753	0.7753	13
HbH	HbH:13	haemoglobin H:13:0.2415	0.2415	13
HbH	HbH:14	Hemoglobin H:14:0.2758	0.2758	14
HbNO	HbNO:12	nitrosyl hemoglobin:12:0.2414	0.2414	12
HbNO	HbNO:9|HB-NO:1|Hb-NO:1	nitrosylhemoglobin:11:0.1818	0.1818	11
HBO(2)	HBO(2):13	hyperbaric oxygen:13:0.6701	0.6701	13
HbO(2)	HbO(2):8	oxygenated hemoglobin:8:0.5006	0.5006	8
HbO(2)	HbO(2):13|Hb-O(2):1	oxyhemoglobin:14:0.2549	0.2549	14
HBO2	HBO2:83	hyperbaric oxygen:83:0.8511	0.8511	83
HBO2	HBO2:14	hyperbaric oxygen therapy:14:0.7909	0.7909	14
HBO2	HBO2:10	hyperbaric oxygenation:10:0.3470	0.3470	10
HbO2	HbO2:6	oxygen saturation:6:0.1010	0.1010	6
HbO2	HbO2:13	oxygenated hemoglobin:13:0.4444	0.4444	13
HbO2	HbO2:11	oxyhaemoglobin:11:0.0348	0.0348	11
HbO2	HbO2:87|Hb-O2:3|Hbo2:2	oxyhemoglobin:92:0.3206	0.3206	92
HbOC	HbOC:10|HbO-C:1|Hboc:1	conjugate vaccine:12:0.4557	0.4557	12
HBOC	HBOC:11	hemoglobin-based oxygen carriers:11:0.6182	0.6182	11
HBOC	HBOC:11	Hereditary Breast and Ovarian Cancer:11:0.5934	0.5934	11
HBOC	HBOC:11	hereditary breast-ovarian cancer:11:0.6182	0.6182	11
HBOC	HBOC:16	oxygen carrier:16:0.8165	0.8165	16
HBSS	HBSS:153	balanced salt solution:153:0.9005	0.9005	153
HbSS	HbSS:10|Hb-SS:1	sickle cell:11:0.7357	0.7357	11
HbSS	HbSS:33|HBSS:1|HbS-S:1	sickle cell anemia:35:0.9151	0.9151	35
HbSS	HbSS:23	sickle cell disease:23:0.8715	0.8715	23
HC-Pro	HC-Pro:40|HcPro:2|HCpro:1	helper component-proteinase:31:0.9043|helper component proteinase:12:0.7571	0.9043	43
Hcy	Hcy:439|HCY:60|hcy:8|HCy:5|hCy:1	homocysteine:513:0.8998	0.8998	513
Hcy	Hcy:8	Homocysteine thiolactone:8:0.2619	0.2619	8
HDX	HDX:11	exchange:11:0.5882	0.5882	11
HeLa	HeLa:13	cervical carcinoma cells:13:0.3809	0.3809	13
HeLa	HeLa:29	human cervical carcinoma:29:0.4300	0.4300	29
He-Ne	He-Ne:5	effect of low-energy laser:5:0.2818	0.2818	5
He-Ne	He-Ne:42|HeNe:15	helium-neon:57:0.6087	0.6087	57
He-O2	He-O2:16|HeO2:5	Helium-oxygen:21:0.2740	0.2740	21
He-O2	He-O2:3|HeO2:2	mixture of 80% helium and 20% oxygen:5:0.2818	0.2818	5
HePTP	HePTP:9	tyrosine phosphatase:9:0.3945	0.3945	9
Healon	Healon:96|HEALON:1	sodium hyaluronate:97:0.9365	0.9365	97
HEMF	HEMF:8	4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2H)-furanone:8:0.6411	0.6411	8
Hep3B	Hep3B:9|HEP3B:1	hepatocellular carcinoma:10:0.7103	0.7103	10
HepG2	HepG2:8|Hep-G2:2|hepg2:1	human hepatocellular carcinoma:11:0.4232	0.4232	11
HepG2	HepG2:103|Hep-G2:4|HEPG2:2	human hepatoma:109:0.7185	0.7185	109
HepG2	HepG2:73|HEP-G2:2|Hep-G2:2	human hepatoma cells:77:0.6969	0.6969	77
HEPA	HEPA:37	high-efficiency particulate air:37:0.5930	0.5930	37
Hepa	Hepa:11	mouse hepatoma:11:0.4232	0.4232	11
HEP	HEP:18|Hep:7	hepatoerythropoietic porphyria:25:0.8186	0.8186	25
HEP	HEP:74	high-energy phosphate:25:0.4451|high-energy phosphates:18:0.3168|high energy phosphates:17:0.8270|high energy phosphate:14:0.7909	0.8270	74
hFR	hFR:11	folate receptor:11:0.7357	0.7357	11
HFR	HFR:8	Hemodiafiltration reinfusion:8:0.3069	0.3069	8
HFR	HFR:7	high fluorescence reticulocytes:7:0.5926	0.5926	7
Hg(2+)	Hg(2+):8	Inorganic mercury:8:0.2619	0.2619	8
Hg0	Hg0:25	elemental mercury:25:0.5095	0.5095	25
Hg0	Hg0:16	mercury vapor:16:0.6024	0.6024	16
HgCl(2)	HgCl(2):30	Mercuric chloride:30:0.7652	0.7652	30
HgCl2	HgCl2:7	inorganic mercury:7:0.0951	0.0951	7
HgCl2	HgCl2:190	mercuric chloride:190:0.8960	0.8960	190
HGU	HGU:9	glucose uptake:9:0.6794	0.6794	9
Hgb	Hgb:11|HGB:8|hgb:2	haemoglobin:21:0.0897	0.0897	21
Hgb	Hgb:131|HGB:32|HgB:4|hgb:1	hemoglobin:168:0.7489	0.7489	168
Hgb	Hgb:7|HGB:3|hgb:1	hemoglobin concentration:11:0.4232	0.4232	11
HGT	HGT:46	horizontal gene transfer:46:0.8676	0.8676	46
HgT	HgT:9|Hgt:1|Hg-T:1	total mercury:11:0.6182	0.6182	11
His-64	His-64:4|His64:3	distal histidine:7:0.3524	0.3524	7
HisRS	HisRS:22	histidyl-tRNA synthetase:22:0.8657	0.8657	22
HIS	HIS:7	Hachinski ischemic score:7:0.5926	0.5926	7
HIS	HIS:13	Health Interview Survey:13:0.6701	0.6701	13
His	His:40|HIS:37|his:1	histamine:78:0.1114	0.1114	78
His	His:100|his:6|HIS:5	histidine:111:0.1592	0.1592	111
HIS	HIS:169	Hospital Information System:124:0.7455|hospital information systems:45:0.5828	0.7455	169
HIS	HIS:7	hyperimmune serum:7:0.0828	0.0828	7
His	His:17|HIS:3	L-histidine:20:0.0275	0.0275	20
HlyA	HlyA:9	alpha-haemolysin:9:0.0556	0.0556	9
HlyA	HlyA:7	Escherichia coli alpha-hemolysin:7:0.5926	0.5926	7
HlyA	HlyA:7|Hlya:1	Escherichia coli haemolysin:8:0.5006	0.5006	8
HlyA	HlyA:30|hlyA:1	Escherichia coli hemolysin:31:0.7718	0.7718	31
hlyA	hlyA:3|HlyA:2	hemolysin gene:5:0.0807	0.0807	5
hlyA	hlyA:7	structural gene:7:0.1329	0.1329	7
Hly	Hly:9|hly:2	alpha-haemolysin:11:0.0719	0.0719	11
Hly	Hly:7|hly:5|HLY:1	alpha-hemolysin:13:0.0863	0.0863	13
Hly	Hly:12|hly:5|HLY:3	haemolysin:20:0.1367	0.1367	20
Hly	Hly:21|hly:16|HLY:4|HLy:1	hemolysin:42:0.2950	0.2950	42
Hly	Hly:9|hly:2	listeriolysin:11:0.0719	0.0719	11
hmdUrd	hmdUrd:8|HmdUrd:4|HMdUrd:1	5-hydroxymethyl-2'-deoxyuridine:13:0.8571	0.8571	13
hnRNA	hnRNA:65|HnRNA:13|HNRNA:2	heterogeneous nuclear RNA:80:0.7861	0.7861	80
hnRNA	hnRNA:20|hn-RNA:2	heteronuclear RNA:22:0.1029	0.1029	22
HOI	HOI:8	head-out immersion:8:0.1471	0.1471	8
HOI	HOI:10	head-out water immersion:10:0.5856	0.5856	10
HoLEP	HoLEP:20	holmium laser enucleation of the prostate:20:0.7766	0.7766	20
HoLRP	HoLRP:14|HoLR-P:1	laser resection of the prostate:15:0.7096	0.7096	15
HoNOS	HoNOS:38	Health of the Nation Outcome Scales:38:0.9217	0.9217	38
HOPP	HOPP:7|HoPP:2	hypokalemic periodic paralysis:9:0.6794	0.6794	9
HoSF	HoSF:17	horse spleen ferritin:17:0.8270	0.8270	17
Holter	Holter:46	ambulatory electrocardiographic:46:0.6815	0.6815	46
Holter	Holter:9	electrocardiographic monitoring:9:0.1492	0.1492	9
HOX	HOX:34|Hox:33|hox:4	homeobox:71:0.5071	0.5071	71
Hox	Hox:10|HOX:2	Homeotic:12:0.0786	0.0786	12
HP1	HP1:103|HP-1:1	Heterochromatin Protein 1:104:0.8766	0.8766	104
HpCDD	HpCDD:18	1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin:18:0.6400	0.6400	18
HPDI	HPDI:7|H-PDI:3	Harmonic power Doppler imaging:10:0.7103	0.7103	10
HPGe	HPGe:15|HpGe:2	high-purity germanium:9:0.1409|high purity germanium:8:0.6411	0.6411	17
HPAI	HPAI:11	high-pathogenicity avian influenza:11:0.1486	0.1486	11
HPAI	HPAI:20	highly pathogenic avian influenza:20:0.8525	0.8525	20
HPrK/P	HPrK/P:6|HprK/P:2	HPr kinase/phosphatase:8:0.5006	0.5006	8
HRE	HRE:35	hormone response element:35:0.3743	0.3743	35
HRE	HRE:27	hypoxia response element:27:0.2518	0.2518	27
HRE	HRE:8	regeneration efficiency:8:0.5006	0.5006	8
HRE	HRE:11	responsive elements:11:0.1547	0.1547	11
HSP28	HSP28:4|hsp28:3|Hsp28:1	heat shock protein:8:0.6411	0.6411	8
hsp60	hsp60:33|HSP60:25|Hsp60:7|HSP-60:2	60-kDa heat shock protein:26:0.2279|60 kDa heat shock protein:20:0.8525|60-kDa heat-shock protein:11:0.1486|60 kDa heat-shock protein:10:0.5856	0.8525	67
hsp60	hsp60:48|HSP60:45|Hsp60:29|HSP-60:4	heat shock protein 60:126:0.9385	0.9385	126
HtSDS	HtSDS:7|Ht-SDS:3	height standard deviation score:10:0.5856	0.5856	10
HTx	HTx:21|HTX:5|Htx:1	heart transplant:27:0.8903	0.8903	27
HTx	HTx:128|HTX:57|Htx:9	heart transplantation:194:0.7751	0.7751	194
HT	HT:15	5-hydroxytryptamine:15:0.0062	0.0062	15
HT	HT:11|Ht:1	harringtonine:12:0.0049	0.0049	12
HT	HT:11|H-T:4|h-t:2|ht:1	head-to-tail:18:0.0075	0.0075	18
HT	HT:16	Head trauma:16:0.7261	0.7261	16
HT	HT:21	heart transplant:21:0.6812	0.6812	21
HT	HT:58	heart transplantation:58:0.7792	0.7792	58
Ht	Ht:25|HT:22|ht:7	height:54:0.0239	0.0239	54
HT	HT:38	hemorrhagic transformation:38:0.7548	0.7548	38
HT	HT:12	high threshold:12:0.3813	0.3813	12
HT	HT:10	high-throughput:10:0.0040	0.0040	10
HT	HT:8	highly trained:8:0.4102	0.4102	8
HT	HT:21	hormonal therapy:21:0.0757	0.0757	21
HT	HT:122	hormone therapy:122:0.7196	0.7196	122
HT	HT:122|Ht:2	hypertensive:100:0.0439|hypertensives:24:0.0102	0.0439	124
HT	HT:26	hypertensive patients:26:0.6084	0.6084	26
HT	HT:11	hypertensive subjects:11:0.6182	0.6182	11
HT	HT:13|Ht:1	hyperthyroidism:14:0.0058	0.0058	14
HT	HT:34|Ht:5	hypothalamus:39:0.0168	0.0168	39
HT	HT:20	hypothermia:20:0.0084	0.0084	20
HT	HT:10	Hypothyroidism:10:0.0040	0.0040	10
HT	HT:25	local hyperthermia:25:0.0929	0.0929	25
HT	HT:19	patients with essential hypertension:19:0.2007	0.2007	19
HT	HT:40	patients with Hashimoto's thyroiditis:40:0.1419	0.1419	40
HT	HT:11	training:11:0.0044	0.0044	11
HT	HT:15	treatment:15:0.0062	0.0062	15
HuAChE	HuAChE:20	human acetylcholinesterase:20:0.7766	0.7766	20
HuCVs	HuCVs:23	human caliciviruses:23:0.8038	0.8038	23
HUC	HUC:19	human uroepithelial cells:19:0.8449	0.8449	19
HUD	HUD:18	Department of Housing and Urban Development:18:0.6903	0.6903	18
HUD	HUD:11	head-up display:11:0.7357	0.7357	11
HuH-7	HuH-7:5|HuH7:2	human hepatoma cells:7:0.2452	0.2452	7
HuH-7	HuH-7:9|Huh7:6|HuH7:3|Huh-7:1	human hepatoma cell line:19:0.6903	0.6903	19
HuIFN	HuIFN:21|Hu-IFN:1|huIFN:1	human interferon:23:0.8038	0.8038	23
HUI	HUI:41	Health Utilities Index:41:0.9274	0.9274	41
HuMAbs	HuMAbs:15|Hu-MAbs:3|huMAbs:3|hu-mAbs:2|HumAbs:1|humAbs:1|huMabs:1	human monoclonal antibodies:26:0.7760	0.7760	26
HuMAb	HuMAb:13|humAb:3|HuMab:3|huMab:1|Hu-mAb:1|HumAb:1|humab:1	human monoclonal antibody:23:0.7500	0.7500	23
Hx	Hx:22|HX:1	hemopexin:23:0.0433	0.0433	23
Hx	Hx:12|HX:5	hepatectomy:17:0.0315	0.0315	17
HX	HX:34|H-X:4|Hx:1	histiocytosis X:39:0.9237	0.9237	39
HX	HX:29	hydrogen exchange:29:0.6157	0.6157	29
Hx	Hx:44|HX:40|hx:1	hypophysectomized:85:0.1654	0.1654	85
HX	HX:22|Hx:16|hx:1	hypophysectomy:39:0.0748	0.0748	39
HX	HX:81|Hx:46	Hypoxanthine:127:0.2480	0.2480	127
HYA	HYA:35|Hya:2|HyA:1	Hyaluronan:38:0.5139	0.5139	38
HYA	HYA:7|HyA:4|Hya:1	hyaluronic acid:12:0.4557	0.4557	12
HyCoSy	HyCoSy:9	hysterosalpingo contrast sonography:9:0.4587	0.4587	9
Hypro	Hypro:7|HyPro:5|HYPRO:4|HyPRO:1	hydroxyproline:17:0.7619	0.7619	17
hyd	hyd:19|Hyd:5	Hydralazine:24:0.2473	0.2473	24
hyd	hyd:8|Hyd:2	hydrocortisone:10:0.0968	0.0968	10
Hyl	Hyl:20	hydroxylysine:20:0.5588	0.5588	20
HypoPP	HypoPP:7|hypoPP:4	hypokalaemic periodic paralysis:11:0.1430	0.1430	11
HypoPP	HypoPP:14|hypoPP:8	hypokalemic periodic paralysis:22:0.4689	0.4689	22
HYPO	HYPO:13|Hypo:3	hypothalamus:16:0.1739	0.1739	16
HYPO	HYPO:7|Hypo:6	hypothyroid:13:0.1304	0.1304	13
H-Y	H-Y:9|HY:4|Hy:1	antigen:14:0.0374	0.0374	14
HY	HY:12|H-Y:5	Hoehn and Yahr:17:0.8270	0.8270	17
Hy	Hy:11	Hygromycin B:11:0.7357	0.7357	11
Hy	HY:8|Hy:8	hypericin:16:0.0431	0.0431	16
HY	HY:11|Hy:7	hypothalamus:18:0.0489	0.0489	18
H-Y	H-Y:9|HY:1	male-specific:10:0.0259	0.0259	10
I(A)	I(A):51	current:42:0.5541|currents:9:0.1081	0.5541	51
I(Ba)	I(Ba):17	currents:17:0.3478	0.3478	17
I(Ca)	I(Ca):13	Ca(2+) currents:13:0.1091	0.1091	13
I(Ca)	I(Ca):15|i(Ca):1	calcium currents:16:0.1559	0.1559	16
I(Ca)	I(Ca):10	channels:10:0.0444	0.0444	10
I(Ca)	I(Ca):6	L-type Ca2+ currents:6:0.1010	0.1010	6
I(Ca,L)	I(Ca,L):38	L-type Ca(2+) current:38:0.8417	0.8417	38
I(Ca,L)	I(Ca,L):5	L-type Ca2+ currents:5:0.4422	0.4422	5
I(Ca,L)	I(Ca,L):18	L-type calcium current:18:0.7539	0.7539	18
I(CaL)	I(CaL):9|I(Ca-L):6	L-type Ca(2+) current:15:0.6386	0.6386	15
I(Ca-L)	I(Ca-L):8|I(CaL):5	L-type Ca2+ current:13:0.7753	0.7753	13
I(Cl(Ca))	I(Cl(Ca)):6	Ca(2+)-activated Cl(-) current:6:0.5290	0.5290	6
I(h)	I(h):7	hyperpolarization-activated cation currents:7:0.4438	0.4438	7
I(K(Ca))	I(K(Ca)):8	Ca(2+)-activated K(+) current:8:0.4102	0.4102	8
I(K)	I(K):15|I(k):1	delayed rectifier:16:0.8165	0.8165	16
I(K)	I(K):34|I(k):1	delayed rectifier K(+) current:18:0.7539|delayed rectifier K+ current:17:0.8270	0.8270	35
I(K)	I(K):17	delayed rectifier potassium current:17:0.8270	0.8270	17
I(K)	I(K):8|I(k):2	K(+) currents:10:0.1680	0.1680	10
I(K)	I(K):7|I(k):1	potassium currents:8:0.1004	0.1004	8
I(K1)	I(K1):15	inward rectifier potassium current:15:0.8045	0.8045	15
I(Ks)	I(Ks):12	delayed rectifier K(+) current:12:0.7571	0.7571	12
I(Ks)	I(Ks):9	delayed rectifier potassium current:9:0.6794	0.6794	9
I(Ks)	I(Ks):3|I(ks):2	slow component:5:0.0736	0.0736	5
I(Ks)	I(Ks):6	slowly activating component:6:0.5290	0.5290	6
I(M)	I(M):10|I(m):4	current:14:0.4333	0.4333	14
I(Na)	I(Na):16	sodium currents:16:0.3174	0.3174	16
I(NaP)	I(NaP):11	persistent Na(+) current:11:0.7357	0.7357	11
I(p)	I(p):14|I(P):3	pump current:17:0.5760	0.5760	17
I(Kr)	I(Kr):10	delayed rectifier K(+) current:10:0.7103	0.7103	10
I(Kr)	I(Kr):13|I(kr):1	delayed rectifier potassium current:14:0.7909	0.7909	14
I(Kr)	I(Kr):6	rapidly activating component:6:0.5290	0.5290	6
I(sc)	I(sc):156|I(SC):53	short-circuit current:166:0.7495|short circuit current:35:0.8681|short-circuit currents:8:0.3463	0.8681	209
I(T)	I(T):13|I(t):10	current:23:0.6667	0.6667	23
I(ti)	I(ti):10|I(TI):2|I(Ti):1	transient inward current:13:0.7753	0.7753	13
I(to)	I(to):9	currents:9:0.0396	0.0396	9
I(to)	I(to):14|i(to):2	transient outward:16:0.8165	0.8165	16
I(to)	I(to):78|I(To):3|I(TO):1	transient outward current:82:0.9422	0.9422	82
I(to1)	I(to1):8	transient outward current:8:0.6411	0.6411	8
I(to1)	I(to1):7	transient outward K(+) current:7:0.5926	0.5926	7
I-65	I-65:8	3,6-dimethamidodibenzopyriodonium citrate:8:0.5006	0.5006	8
I-Smads	I-Smads:11|I-SMADs:1	Inhibitory SMADs:12:0.7571	0.7571	12
I-TEQ	I-TEQ:6|I-TEq:3	equivalent:9:0.3810	0.3810	9
I-V	I-V:395|i-V:8|i-v:1	current-voltage:399:0.6934|current voltage:5:0.2902	0.6934	404
i.c.p.	i.c.p.:8|I.C.P.:8	intracranial pressure:16:0.7261	0.7261	16
i.h.	i.h.:9	intrahippocampal:9:0.2222	0.2222	9
i.l.	i.l.:11	intralesional:11:0.2941	0.2941	11
i.m.	i.m.:12|I.M.:1	intramuscular injection:13:0.2532	0.2532	13
i.m.	i.m.:264|I.M.:4|I.m.:1	intramuscularly:269:0.2179	0.2179	269
i.o.p.	i.o.p.:9|I.O.P.:6	intraocular pressure:15:0.6386	0.6386	15
I.S.	I.S.:106|i.s.:5	internal standard:111:0.9185	0.9185	111
I.U.	I.U.:8|i.u.:4	international units:12:0.3813	0.3813	12
i.u.	i.u.:11|I.U.:1	intrauterine:12:0.2683	0.2683	12
I/CB	I/CB:6	iris and ciliary body:6:0.5290	0.5290	6
I/C	I/C:14	Imipenem/cilastatin:14:0.4643	0.4643	14
I/D	I/D:18	insertion/ deletion:9:0.4587|insertion-deletion:9:0.0154	0.4587	18
I/G	I/G:12	ratio:12:0.2973	0.2973	12
I/O	I/O:107|i/o:2	Input/Output:74:0.4620|input-output:35:0.2152	0.4620	109
I/R	I/R:71	Ischaemia/reperfusion:43:0.0304|ischaemia-reperfusion:28:0.0195	0.0304	71
I/R	I/R:136	ischemia and reperfusion:136:0.5089	0.5089	136
I/R	I/R:924|i/r:1	ischemia/reperfusion:517:0.3731|ischemia-reperfusion:408:0.2943	0.3731	925
I/R	I/R:14	ischemia/reperfusion injury:14:0.2758	0.2758	14
I1	I1:7	central imidazoline:7:0.0611	0.0611	7
I-1	I-1:4|I1:2	inhibitor 1:6:0.1320	0.1320	6
I-1	I-1:7	protein phosphatase inhibitor-1:7:0.4438	0.4438	7
I-2	I-2:27|I2:6|i-2:1	inhibitor-2:34:0.1833	0.1833	34
I2	I2:25	iodine:25:0.1333	0.1333	25
I3C	I3C:183|I-3-C:15	indole-3-carbinol:198:0.9751	0.9751	198
i3	i3:16|I3:2	third intracellular:18:0.8365	0.8365	18
i3	i3:17|I3:2	third intracellular loop:19:0.8449	0.8449	19
I50	I50:33	50% inhibition:33:0.6512	0.6512	33
IA-2A	IA-2A:7	IA-2 protein:7:0.3524	0.3524	7
IA-2	IA-2:6|IA2:1	tyrosine phosphatase:7:0.2902	0.2902	7
IAAA	IAAA:29	inflammatory abdominal aortic aneurysm:16:0.6024|inflammatory abdominal aortic aneurysms:13:0.7753	0.7753	29
IAAO	IAAO:14	indicator amino acid oxidation:14:0.7909	0.7909	14
IAAT	IAAT:11	intra-abdominal adipose tissue:11:0.4232	0.4232	11
IAAs	IAAs:34	insulin autoantibodies:34:0.8644	0.8644	34
IAA	IAA:17	ileoanal anastomosis:17:0.3844	0.3844	17
IAA	IAA:9	indispensable amino acids:9:0.5470	0.5470	9
IAA	IAA:323	indole-3-acetic acid:323:0.4960	0.4960	323
IAA	IAA:22	insulin autoantibody:22:0.8657	0.8657	22
IAA	IAA:8	internal auditory artery:8:0.6411	0.6411	8
IAA	IAA:41	interrupted aortic arch:41:0.5040	0.5040	41
IAA	IAA:21	interruption of the aortic arch:21:0.2250	0.2250	21
IAA	IAA:11	Intra-abdominal abscess:11:0.4232	0.4232	11
IAA	IAA:33	iodoacetamide:33:0.0284	0.0284	33
IAA	IAA:38	iodoacetate:38:0.0328	0.0328	38
IAA	IAA:80	Iodoacetic acid:80:0.1041	0.1041	80
IABCP	IABCP:8|iabcp:1	balloon counterpulsation:9:0.5470	0.5470	9
IABC	IABC:34	intra-aortic balloon counterpulsation:34:0.5687	0.5687	34
IABC	IABC:13	intraaortic balloon counterpulsation:13:0.1281	0.1281	13
IABP	IABP:264	balloon pump:264:0.9818	0.9818	264
IABP	IABP:8|IA-BP:1	blood pressure:9:0.5470	0.5470	9
IABP	IABP:32	intra-aortic balloon counterpulsation:32:0.3876	0.3876	32
IABP	IABP:113|I-ABP:1	intra-aortic balloon pumping:114:0.4792	0.4792	114
IABP	IABP:27	intraaortic balloon counterpulsation:27:0.3054	0.3054	27
IAB	IAB:18	intra-aortic balloon:18:0.3285	0.3285	18
IAB	IAB:15	Intraaortic balloon:15:0.2430	0.2430	15
IACNS	IACNS:8	isolated angiitis of the central nervous system:8:0.6411	0.6411	8
IACT	IACT:11|ia-CT:1|iaCT:1	conduction time:13:0.7753	0.7753	13
IACUC	IACUC:14|IA-CUC:1	Institutional Animal Care and Use Committee:15:0.8045	0.8045	15
IAC	IAC:36	immunoaffinity chromatography:36:0.7433	0.7433	36
IAC	IAC:14	immunoaffinity column:14:0.6911	0.6911	14
IAC	IAC:152	internal auditory canal:152:0.9582	0.9582	152
IAC	IAC:10	interposed abdominal compression:10:0.5856	0.5856	10
IAC	IAC:16	Intra-arterial chemotherapy:16:0.2288	0.2288	16
IAC	IAC:13	intraarterial chemotherapy:13:0.1599	0.1599	13
IAC	IAC:7	K+ current:7:0.3524	0.3524	7
IADL	IADL:9	Instrumental Activities of Daily Living Scale:9:0.6794	0.6794	9
IADN	IADN:9	Integrated Atmospheric Deposition Network:9:0.6794	0.6794	9
IADSA	IADSA:43|IA-DSA:39|iaDSA:2|IaDSA:1	digital subtraction angiography:85:0.9449	0.9449	85
IAD	IAD:10	implantable atrial defibrillator:10:0.7103	0.7103	10
IAD	IAD:9	inflammatory airway disease:9:0.6794	0.6794	9
IAD	IAD:10	Intermittent androgen deprivation:10:0.5000	0.5000	10
IAF	IAF:16	intra-abdominal fat:16:0.4040	0.4040	16
IAF	IAF:8	intraabdominal fat:8:0.1004	0.1004	8
IAHA	IAHA:32	immune adherence hemagglutination:32:0.9072	0.9072	32
IAHA	IAHA:9	immune adherence hemagglutination assay:9:0.6411	0.6411	9
IAHC	IAHC:7	Intra-arterial hepatic chemotherapy:7:0.3524	0.3524	7
IAHS	IAHS:8	idiopathic adult hydrocephalus syndrome:8:0.6411	0.6411	8
IAHS	IAHS:8	infection-associated hemophagocytic syndrome:8:0.4102	0.4102	8
IAH	IAH:14	intra-abdominal hypertension:14:0.6173	0.6173	14
IAIC	IAIC:13	intra-arterial infusion chemotherapy:13:0.5934	0.5934	13
IAIMS	IAIMS:39	Integrated Academic Information Management System:22:0.8657|Integrated Academic Information Management Systems:17:0.8365	0.8657	39
IAIMS	IAIMS:8	Integrated Advanced Information Management System:8:0.5006	0.5006	8
IAI	IAI:10	intra-amniotic infection:10:0.3145	0.3145	10
IALP	IALP:6|I-ALP:3|iALP:1	alkaline phosphatase:10:0.5856	0.5856	10
IAM	IAM:53	Immobilized artificial membrane:53:0.8597	0.8597	53
IAM	IAM:11	indole-3-acetamide:11:0.0503	0.0503	11
IAM	IAM:30	internal auditory meatus:30:0.9011	0.9011	30
IAM	IAM:17|IAm:1	iodoacetamide:18:0.0854	0.0854	18
IAN	IAN:9	indole-3-acetonitrile:9:0.0482	0.0482	9
IAN	IAN:121	inferior alveolar nerve:121:0.9753	0.9753	121
IAPAC	IAPAC:8	International Association of Physicians in AIDS Care:8:0.6794	0.6794	8
IAPA	IAPA:10	pulmonary arteries:10:0.7103	0.7103	10
IAPP	IAPP:292	Islet amyloid polypeptide:292:0.9587	0.9587	292
IAPs	IAPs:32|iaps:1	inhibitors of apoptosis:33:0.8196	0.8196	33
IAPs	IAPs:70	inhibitor of apoptosis proteins:70:0.6964	0.6964	70
IAPS	IAPS:13	International Affective Picture system:13:0.7753	0.7753	13
IAP	IAP:14	[14C]iodoantipyrine:14:0.0084	0.0084	14
IAP	IAP:163	immunosuppressive acidic protein:163:0.9437	0.9437	163
IAP	IAP:21	increased intraabdominal pressure:21:0.1932	0.1932	21
IAP	IAP:153|iap:13	inhibitor of apoptosis:133:0.8059|Inhibitors of Apoptosis:20:0.0714|inhibitor-of-apoptosis:13:0.0077	0.8059	166
IAP	IAP:102|iap:1	inhibitor of apoptosis protein:88:0.8727|inhibitor of apoptosis proteins:15:0.4609	0.8727	103
IAP	IAP:69|I-AP:4	intestinal alkaline phosphatase:73:0.8191	0.8191	73
IAP	IAP:154	intra-abdominal pressure:154:0.5346	0.5346	154
IAP	IAP:53	intracarotid amobarbital procedure:53:0.8597	0.8597	53
IAP	IAP:18	intracellular action potential:18:0.7539	0.7539	18
IAP	IAP:117	intracisternal A-particle:71:0.9326|intracisternal A particle:37:0.4642|intracisternal A-particles:9:0.6794	0.9326	117
IAP	IAP:12	Intrapartum antibiotic prophylaxis:12:0.7571	0.7571	12
IAP	IAP:129	islet-activating protein:129:0.2182	0.2182	129
IAP	IAP:19|iAp:5	particles:24:0.0148	0.0148	24
IAP	IAP:44	Pertussis toxin:44:0.8941	0.8941	44
IAP	IAP:10	pressures:10:0.0058	0.0058	10
IARC	IARC:148	International Agency for Research on Cancer:148:0.9681	0.9681	148
IARF	IARF:9|iARF:3	ischemic acute renal failure:12:0.4557	0.4557	12
IART	IART:17	reentrant tachycardia:17:0.4742	0.4742	17
IAR	IAR:11	immediate asthmatic reaction:11:0.7357	0.7357	11
IAR	IAR:27	immediate asthmatic response:27:0.8903	0.8903	27
IAsp	IAsp:10|Iasp:1	insulin aspart:11:0.6182	0.6182	11
IAT	IAT:36	implicit association test:36:0.9174	0.9174	36
IAT	IAT:48	indirect antiglobulin test:48:0.8463	0.8463	48
IAT	IAT:36	individual anaerobic threshold:36:0.9174	0.9174	36
IAT	IAT:11	intra-arterial thrombolysis:11:0.6182	0.6182	11
IAT	IAT:24	intraoperative autotransfusion:24:0.8115	0.8115	24
IAUC	IAUC:9|iAUC:6	incremental area under the curve:15:0.4832	0.4832	15
IAVI	IAVI:10	International AIDS Vaccine Initiative:10:0.7103	0.7103	10
IAV	IAV:40	Influenza A virus:40:0.8525	0.8525	40
IB4	IB4:28|I-B4:1	isolectin B4:29:0.8978	0.8978	29
I-BABP	I-BABP:13|IBABP:3	bile acid-binding protein:16:0.8165	0.8165	16
IBABP	IBABP:5|I-BABP:3	Ileal bile acid binding protein:8:0.4102	0.4102	8
IBAD	IBAD:11	deposition:11:0.7692	0.7692	11
IBAT	IBAT:37	interscapular BAT:37:0.9197	0.9197	37
IBAT	IBAT:220|iBAT:2	interscapular brown adipose tissue:222:0.9145	0.9145	222
IBa	IBa:53	Ba2+ current:28:0.3561|Ba2+ currents:25:0.3161	0.3561	53
IBa	IBa:1	carried either by Ba2+:1:0.0612	0.0612	1
IBA	IBA:8	immunoblot assay:8:0.0906	0.0906	8
IBA	IBA:35	indole-3-butyric acid:35:0.4982	0.4982	35
IBC	IBC:11	binding capacity:11:0.4728	0.4728	11
IBC	IBC:74	inflammatory breast cancer:74:0.7091	0.7091	74
IBC	IBC:24	inflammatory breast carcinoma:24:0.5598	0.5598	24
IBD1	IBD1:10	chromosome 16:10:0.4363	0.4363	10
IBDQ	IBDQ:47	Inflammatory Bowel Disease Questionnaire:47:0.9353	0.9353	47
IBDU	IBDU:10	bile duct units:10:0.7103	0.7103	10
IBDUs	IBDUs:11	intrahepatic bile duct units:11:0.4728	0.4728	11
IBDV	IBDV:468	infectious bursal disease virus:468:0.9936	0.9936	468
IBD	IBD:72|ibd:5	identical by descent:56:0.4505|identical-by-descent:21:0.0073	0.4505	77
IBD	IBD:95|ibd:3	identity-by-descent:57:0.0204|identity by descent:41:0.3020	0.3020	98
IBD	IBD:2375|ibd:1	inflammatory bowel disease:2188:0.9908|inflammatory bowel diseases:188:0.9586	0.9908	2376
IBD	IBD:10	isolation by distance:10:0.5000	0.5000	10
IBE	IBE:11	individual bioequivalence:11:0.7357	0.7357	11
IBF	IBF:19	immunoglobulin-binding factor:11:0.2040|immunoglobulin binding factor:8:0.3463	0.3463	19
IBF	IBF:12	intestinal blood flow:12:0.1631	0.1631	12
IBH	IBH:15	inclusion body hepatitis:15:0.8045	0.8045	15
IBI	IBI:10	Index of Biotic Integrity:10:0.7103	0.7103	10
IBI	IBI:25	interbeat interval:18:0.2687|interbeat intervals:7:0.1850	0.2687	25
IBK	IBK:46	infectious bovine keratoconjunctivitis:46:0.9353	0.9353	46
IBL	IBL:20	immunoblastic lymphadenopathy:20:0.8449	0.8449	20
IBL	IBL:9	immunoblastic lymphoma:9:0.6794	0.6794	9
IBMTR	IBMTR:36	International Bone Marrow Transplant Registry:36:0.9174	0.9174	36
IBMX	IBMX:20	1-methyl-3-isobutylxanthine:20:0.0158	0.0158	20
IBMX	IBMX:21	3-isobutyl-1-methyl xanthine:21:0.2339	0.2339	21
IBMX	IBMX:10	3-isobutyl 1-methylxanthine:10:0.7357	0.7357	10
IBMX	IBMX:29	3-isobutyl-l-methylxanthine:29:0.0233	0.0233	29
IBMX	IBMX:11	3-isobutylmethylxanthine:11:0.0083	0.0083	11
IBMX	IBMX:9	isobutyl methyl xanthine:9:0.6794	0.6794	9
IBMX	IBMX:61	isobutyl methylxanthine:31:0.7388|isobutyl-methylxanthine:30:0.0241	0.7388	61
IBMX	IBMX:11	isobutylmethyl xanthine:11:0.0778	0.0778	11
IBMX	IBMX:5	phosphodiesterase inhibitor:5:0.1132	0.1132	5
IBMX	IBMX:11	phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine:11:0.6903	0.6903	11
IBM	IBM:164	inclusion body myositis:164:0.9817	0.9817	164
IBNs	IBNs:10	inhibitory burst neurons:10:0.7103	0.7103	10
IBO	IBO:10	Ibogaine:10:0.0672	0.0672	10
IBO	IBO:12|Ibo:2|ibo:1	ibotenate:15:0.1045	0.1045	15
IBO	IBO:6|ibo:3	ibotenic:9:0.0597	0.0597	9
IBO	IBO:72|Ibo:7|ibo:1	ibotenic acid:80:0.9408	0.9408	80
IBO	IBO:9	intestinal bacterial overgrowth:9:0.6794	0.6794	9
IBP	IBP:7	binding protein:7:0.1850	0.1850	7
IBP	IBP:6|I-BP:1	blood pressure:7:0.1470	0.1470	7
IBP	IBP:12	ibuprofen:12:0.1196	0.1196	12
IBQ	IBQ:43	Illness Behaviour Questionnaire:23:0.8715|Illness Behavior Questionnaire:20:0.5568	0.8715	43
IBRV	IBRV:48	infectious bovine rhinotracheitis virus:48:0.9379	0.9379	48
IBR	IBR:27	Immediate breast reconstruction:27:0.8312	0.8312	27
IBR	IBR:146	infectious bovine rhinotracheitis:146:0.9467	0.9467	146
IBR	IBR:12	infectious bovine rhinotracheitis virus:12:0.7571	0.7571	12
IBS-C	IBS-C:10	constipation:10:0.4286	0.4286	10
IBS	IBS:8	binding site:8:0.5006	0.5006	8
IBS	IBS:14	ichthyosis bullosa of Siemens:14:0.7909	0.7909	14
IBS	IBS:5	identical by state:5:0.0902	0.0902	5
IBS	IBS:10	Imidazoline binding sites:10:0.3867	0.3867	10
IBs	IBs:30	inclusion bodies:30:0.9011	0.9011	30
IBS	IBS:10	injectable bone substitute:10:0.5000	0.5000	10
IBS	IBS:38	integrated backscatter:38:0.8781	0.8781	38
IBS	IBS:1125	irritable bowel syndrome:1125:0.9903	0.9903	1125
IBS	IBS:13	isolated bowel segment:13:0.7753	0.7753	13
IBTR	IBTR:43	ipsilateral breast tumor recurrence:43:0.9308	0.9308	43
IBT	IBT:15|iBT:3|IBt:1	brachytherapy:19:0.1259	0.1259	19
IBT	IBT:40	immunobead test:40:0.5164	0.5164	40
IBV	IBV:408	infectious bronchitis virus:408:0.9843	0.9843	408
IBW	IBW:142|ibw:1	ideal body weight:143:0.9106	0.9106	143
IBX	IBX:11	o-iodoxybenzoic acid:11:0.4232	0.4232	11
IBZM	IBZM:28	123I-iodobenzamide:17:0.2388|[123I]iodobenzamide:11:0.1493	0.2388	28
IBZM	IBZM:12	Iodobenzamide:12:0.1642	0.1642	12
IC(50)	IC(50):112	50% inhibitory concentration:86:0.6640|50% inhibitory concentrations:26:0.6084	0.6640	112
IC(50)	IC(50):3	inhibitory concentration of 50%:3:0.0902	0.0902	3
IC(50)s	IC(50)s:23	50% inhibitory concentrations:23:0.6306	0.6306	23
IC50s	IC50s:35|IC50S:3	50% inhibitory concentrations:38:0.6322	0.6322	38
IC50	IC50:190|IC-50:1	50% inhibition:191:0.4893	0.4893	191
IC50	IC50:10	50% inhibition of cell growth:10:0.5856	0.5856	10
IC50	IC50:9	50% inhibition of growth:9:0.5856	0.5856	9
IC50	IC50:363|IC-50:2	50% inhibitory concentration:297:0.5356|50% inhibitory concentrations:68:0.4102	0.5356	365
IC50	IC50:6	50% inhibitory dose:6:0.5290	0.5290	6
IC50	IC50:5	binding affinities:5:0.0902	0.0902	5
IC50	IC50:10	cell growth by 50%:10:0.2126	0.2126	10
IC50	IC50:5	inhibition constants:5:0.0902	0.0902	5
IC50	IC50:5	inhibition of protein synthesis:5:0.2818	0.2818	5
IC50	IC50:8	inhibitory concentration 50:8:0.5006	0.5006	8
IC50	IC50:9	sensitivity:9:0.0037	0.0037	9
IC90	IC90:8	90% inhibitory concentration:8:0.5006	0.5006	8
ICAD	ICAD:11	inhibitor of caspase-activated DNase:11:0.6182	0.6182	11
ICAD	ICAD:13	internal carotid artery dissection:13:0.6911	0.6911	13
ICAM-2	ICAM-2:27	intercellular adhesion molecule-2:18:0.5940|intercellular adhesion molecule 2:9:0.6794	0.6794	27
ICAM-I	ICAM-I:13	intercellular adhesion molecule-I:13:0.7753	0.7753	13
ICAM-1	ICAM-1:31	adhesion molecules:31:0.8519	0.8519	31
ICAM-1	ICAM-1:16	adhesion molecules-1:16:0.8165	0.8165	16
ICAM-1	ICAM-1:7	adhesion molecule I:7:0.4438	0.4438	7
ICAM-1	ICAM-1:8	Intercellular adhesion molecular-1:8:0.5470	0.5470	8
ICAM-1	ICAM-1:106|ICAM1:1	intercellular adhesion molecule:107:0.6790	0.6790	107
ICAM-1	ICAM-1:3291|ICAM1:15|Icam-1:1|Icam1:1|I-CAM-1:1	intercellular adhesion molecule-1:2656:0.8928|intercellular adhesion molecule 1:653:0.8876	0.8928	3309
ICAM-3	ICAM-3:31|ICAM3:2	intercellular adhesion molecule-3:18:0.7539|intercellular adhesion molecule 3:15:0.8045	0.8045	33
ICAM	ICAM:62	intercellular adhesion molecule:48:0.6121|intercellular adhesion molecules:14:0.5589	0.6121	62
ICARS	ICARS:8	International Cooperative Ataxia Rating Scale:8:0.6411	0.6411	8
ICAs	ICAs:40	internal carotid arteries:40:0.9256	0.9256	40
ICAS	ICAS:9	internal carotid artery stenosis:9:0.6794	0.6794	9
ICAs	ICAs:65	islet cell antibodies:65:0.9541	0.9541	65
ICAs	ICAs:9	islet cell autoantibodies:9:0.6794	0.6794	9
ICA	ICA:12	arthritis:12:0.0031	0.0031	12
ICa	ICa:7	Ca2+ channels:7:0.2452	0.2452	7
ICa	ICa:96|Ica:3	Ca2+ currents:99:0.3925	0.3925	99
ICa	ICa:78|Ica:3|iCa:2|ica:1	calcium currents:84:0.3196	0.3196	84
ICA	ICA:25	Immunocytochemical assay:25:0.4596	0.4596	25
ICA	ICA:198	Independent component analysis:198:0.9758	0.9758	198
ica	ica:8|ICA:1	intercellular adhesion:9:0.5470	0.5470	9
ICA	ICA:29	internal carotid:29:0.8978	0.8978	29
ICA	ICA:1442|ica:2	internal carotid artery:1396:0.9866|internal carotid arteries:48:0.9379	0.9866	1444
ICa	ICa:37|ica:2|Ica:1|iCa:1	inward calcium current:41:0.1261	0.1261	41
iCa	ICa:4|iCa:4|ica:2	ionized Ca:10:0.3145	0.3145	10
iCa	iCa:38|ICa:16|ica:11|i-Ca:4	ionized calcium:69:0.6476	0.6476	69
ICA	ICA:33|IC-A:2	islet cells:20:0.7173|islet cell:15:0.6386	0.7173	35
ICA	ICA:355	islet cell antibodies:267:0.9704|islet cell antibody:58:0.8937|Islet-cell antibodies:30:0.0571	0.9704	355
ICA	ICA:18	islet cell autoantibodies:18:0.8365	0.8365	18
ICa	ICa:83|Ica:4|iCa:3	L-type Ca2+ current:90:0.2414	0.2414	90
ICa	ICa:50|iCa:1	L-type calcium current:51:0.1608	0.1608	51
ICBDMS	ICBDMS:6|ICB-DMS:1	International Clearinghouse for Birth Defects Monitoring Systems:7:0.6411	0.6411	7
ICBF	ICBF:21|I-CBF:1	local cerebral blood flow:22:0.7955	0.7955	22
ICBT	ICBT:20	brachytherapy:20:0.8636	0.8636	20
ICB	ICB:7	intracavitary brachytherapy:7:0.2902	0.2902	7
ICB	ICB:28|I-CB:4	iris-ciliary body:32:0.5841	0.5841	32
ICCE	ICCE:51	intracapsular cataract extraction:51:0.8799	0.8799	51
ICCs	ICCs:62	interstitial cells of Cajal:62:0.9519	0.9519	62
ICCs	ICCs:11	intraclass correlations:11:0.6182	0.6182	11
ICCs	ICCs:208	intraclass correlation coefficients:208:0.8428	0.8428	208
ICCs	ICCs:48	Islet-like cell clusters:48:0.7074	0.7074	48
ICC	ICC:12|ICc:7	central nucleus:19:0.8449	0.8449	19
ICC	ICC:77|ICc:18	central nucleus of the inferior colliculus:95:0.9710	0.9710	95
ICC	ICC:11	fetal porcine islet-like cell clusters:11:0.6182	0.6182	11
ICC	ICC:70	immunocytochemical:70:0.0358	0.0358	70
ICC	ICC:270|icc:1	immunocytochemistry:271:0.1400	0.1400	271
ICC	ICC:8	immunoglobulin-containing cells:8:0.0625	0.0625	8
ICC	ICC:51	Indian Childhood Cirrhosis:51:0.9416	0.9416	51
ICC	ICC:5	intensive consolidation chemotherapy:5:0.4422	0.4422	5
ICC	ICC:9	Inter-Company Collaboration for AIDS Drug Development:9:0.5470	0.5470	9
ICC	ICC:8	intercalated cells:8:0.0625	0.0625	8
ICC	ICC:246	Interstitial cells of Cajal:246:0.9739	0.9739	246
ICC	ICC:13	intra-class correlation:13:0.0986	0.0986	13
ICC	ICC:59	intraclass correlation:37:0.4832|intraclass correlations:22:0.4883	0.4883	59
ICC	ICC:491	intraclass correlation coefficient:339:0.7742|intraclass correlation coefficients:152:0.7945	0.7945	491
ICC	ICC:82	intrahepatic cholangiocarcinoma:82:0.9238	0.9238	82
ICC	ICC:36	invasive cervical cancer:36:0.9174	0.9174	36
ICC	ICC:15	invasive cervical carcinoma:15:0.8045	0.8045	15
ICD-10	ICD-10:59|ICD10:1	International Classification of Diseases:60:0.8971	0.8971	60
ICD-10	ICD-10:1	International Classification of Diseases 10th edition:1:0.6411	0.6411	1
ICD-10	ICD-10:1	International Classification of Diseases 10th Revision:1:0.6911	0.6911	1
ICD-10	ICD-10:1	International Classification of diseases Tenth Edition:1:0.3170	0.3170	1
ICD-9-CM	ICD-9-CM:12|ICD9-CM:1	International Classification of Diseases:13:0.7909	0.7909	13
ICD-9	ICD-9:5|ICD9:1	International Classification of Diseases 9th revision:6:0.9011	0.9011	6
ICD-9	ICD-9:2	International Classification of Diseases ninth revision:2:0.9438	0.9438	2
ICDB	ICDB:9	interstitial Cystitis Data Base:9:0.6794	0.6794	9
ICDH	ICDH:104|iCDH:1|ICDh:1|IC-DH:1	isocitrate dehydrogenase:107:0.7996	0.7996	107
ICDO	ICDO:1	International Classification of the Diseases for Oncology:1:0.7103	0.7103	1
ICDs	ICDs:286	implantable cardioverter defibrillators:178:0.8949|implantable cardioverter-defibrillators:98:0.8609|Implantable cardioverter/defibrillators:10:0.7103	0.8949	286
ICDS	ICDS:40|ICDs:1	integrated child development services:41:0.8839	0.8839	41
ICDS	ICDS:6	integrated child development services scheme:6:0.5290	0.5290	6
ICD	ICD:18	I-cell disease:18:0.1381	0.1381	18
ICD	ICD:11	idiopathic cervical dystonia:11:0.7357	0.7357	11
ICD	ICD:19	immune complex-dissociated:11:0.7357|immune complex dissociated:8:0.6411	0.7357	19
ICD	ICD:13	immune complex dissociation:13:0.7753	0.7753	13
ICD	ICD:828	implantable cardioverter defibrillator:469:0.8871|implantable cardioverter-defibrillator:261:0.8900|implantable cardioverter defibrillators:49:0.7122|implantable cardioverter-defibrillators:29:0.7237|implantable cardioverter/defibrillator:20:0.4574	0.8900	828
ICD	ICD:24	induced circular dichroism:24:0.8768	0.8768	24
ICD	ICD:22	initial claudication distance:22:0.8657	0.8657	22
ICD	ICD:10	intercapillary distance:10:0.0902	0.0902	10
ICD	ICD:170	international Classification of Diseases:145:0.9467|International Classification of Disease:25:0.8816	0.9467	170
ICD	ICD:32	intracellular domain:32:0.6220	0.6220	32
ICD	ICD:52	irritant contact dermatitis:52:0.9099	0.9099	52
ICD	ICD:28|icd:2	isocitrate dehydrogenase:30:0.6736	0.6736	30
ICED	ICED:8	index of coexistent disease:8:0.6411	0.6411	8
ICE	ICE:16	caspase-1:16:0.0167	0.0167	16
ICE	ICE:14	ifosfamide/carboplatin/etoposide:14:0.0145	0.0145	14
ICE	ICE:35	IL-1 beta converting enzyme:22:0.1309|IL-1 beta-converting enzyme:13:0.0683	0.1309	35
ICE	ICE:4	insulin control element:4:0.1618	0.1618	4
ICE	ICE:5	integrative and conjugative element:5:0.4422	0.4422	5
ICE	ICE:142|Ice:3	interleukin-1 beta converting enzyme:90:0.6085|interleukin-1 beta-converting enzyme:55:0.5538	0.6085	145
ICE	ICE:53	interleukin-1beta converting enzyme:53:0.1500	0.1500	53
ICE	ICE:7	International collaborative effort:7:0.6411	0.6411	7
ICE	ICE:78	intracardiac echocardiography:78:0.9617	0.9617	78
ICE	ICE:36	iridocorneal endothelial:36:0.8003	0.8003	36
ICF	ICF:3	instability and facial anomalies:3:0.7103	0.7103	3
ICF	ICF:10	intermediate care facility:10:0.7103	0.7103	10
ICF	ICF:9	intermittent compressive force:9:0.5470	0.5470	9
ICF	ICF:4	International Classification of Functioning Disability and Health:4:0.9401	0.9401	4
ICF	ICF:26	intracellular fluid:26:0.6645	0.6645	26
IC-GH	IC-GH:5|ICGH:4	growth hormone:9:0.6794	0.6794	9
IC-GH	IC-GH:8|ICGH:3	integrated concentration of GH:11:0.6182	0.6182	11
ICGR15	ICGR15:3|ICGR-15:2|ICG-R15:2	retention rate at 15 minutes:7:0.5926	0.5926	7
ICGV	ICGV:6|ICG-V:3	indocyanine green videoangiography:9:0.6794	0.6794	9
ICG	ICG:46	impedance cardiography:46:0.9353	0.9353	46
ICG	ICG:873|IcG:1	indocyanine green:859:0.9726|Indocyanine-green:15:0.0129	0.9726	874
ICG	ICG:20	indocyanine green angiography:20:0.8525	0.8525	20
ICG	ICG:16	indocyanine green dye:16:0.7261	0.7261	16
ICHPPC	ICHPPC:1	International Classification of Health Problems for Primary Care:1:0.8045	0.8045	1
ICH	ICH:11	infectious canine hepatitis:11:0.7357	0.7357	11
ICH	ICH:22	International Conference on Harmonisation:22:0.8657	0.8657	22
ICH	ICH:17	intracerebral haematomas:9:0.5470|intracerebral haematoma:8:0.4102	0.5470	17
ICH	ICH:58	intracerebral haemorrhage:58:0.4317	0.4317	58
ICH	ICH:39|Ich:1	intracerebral hematoma:30:0.8090|intracerebral hematomas:10:0.7103	0.8090	40
ICH	ICH:410	intracerebral hemorrhage:401:0.6477|intracerebral hemorrhages:9:0.2643	0.6477	410
ICH	ICH:45	intracranial haemorrhage:45:0.3128	0.3128	45
ICH	ICH:182	intracranial hemorrhage:176:0.2622|intracranial hemorrhages:6:0.0666	0.2622	182
ICH	ICH:26	Intracranial Hypertension:26:0.7340	0.7340	26
ICIDH	ICIDH:2|IC-IDH:1	International Classification of Impairments Disabilities and Handicaps:3:0.9316	0.9316	3
ICISS	ICISS:11	Injury Severity Score:11:0.4728	0.4728	11
ICI	ICI:44	ICI 182,780:38:0.9237|ICI 182 780:6:0.6411	0.9237	44
ICI	ICI:11	interclick interval:11:0.1938	0.1938	11
ICI	ICI:9	intracavernosal injection:9:0.0713	0.0713	9
ICI	ICI:20	intracavernous injection:20:0.3077	0.3077	20
ICI	ICI:12	intracervical insemination:12:0.7571	0.7571	12
ICI	ICI:66	intracortical inhibition:66:0.8495	0.8495	66
ICJ	ICJ:16	junction:16:0.6250	0.6250	16
ICLs	ICLs:20	DNA interstrand cross-links:20:0.4786	0.4786	20
ICLs	ICLs:10	DNA interstrand crosslinks:10:0.3867	0.3867	10
ICl	ICl:24|Icl:3	chloride current:27:0.2601	0.2601	27
ICl	ICl:45|Icl:2	Cl- current:36:0.3869|Cl- currents:11:0.3829	0.3869	47
ICL	ICL:6	idiopathic CD4+ lymphocytopenia:6:0.5290	0.5290	6
ICL	ICL:15	Idiopathic CD4+ T-lymphocytopenia:9:0.6794|idiopathic CD4+ T lymphocytopenia:6:0.5290	0.6794	15
ICL	ICL:15	implantable contact lens:15:0.7096	0.7096	15
ICL	ICL:7	innermost chorionic layer:7:0.4438	0.4438	7
ICL	ICL:22	interstrand cross-links:14:0.6911|interstrand cross-link:8:0.5006	0.6911	22
ICL	ICL:50|Icl:2|icl:1	isocitrate lyase:53:0.9438	0.9438	53
ICMA	ICMA:21	immunochemiluminometric assay:21:0.6400	0.6400	21
ICMJE	ICMJE:9	International Committee of Medical Journal Editors:9:0.6794	0.6794	9
ICMR	ICMR:21	Indian Council of Medical Research:21:0.7955	0.7955	21
ICMs	ICMs:36	Inner cell masses:36:0.8336	0.8336	36
ICMS	ICMS:90	intracortical microstimulation:90:0.9005	0.9005	90
ICM	ICM:306	inner cell mass:284:0.9533|inner cell masses:22:0.5581	0.9533	306
ICM	ICM:10	intensive case management:10:0.3145	0.3145	10
ICM	ICM:11	intracytoplasmic membrane:11:0.4728	0.4728	11
ICM	ICM:8	Introduction to Clinical Medicine:8:0.6411	0.6411	8
ICM	ICM:10	iodinated contrast media:10:0.4363	0.4363	10
ICM	ICM:10	ischemic:10:0.0132	0.0132	10
ICM	ICM:49	ischemic cardiomyopathy:49:0.6680	0.6680	49
ICN	ICN:9	infection control nurse:9:0.6794	0.6794	9
ICN	ICN:9	inferior cardiac nerve:9:0.6794	0.6794	9
ICN	ICN:21	intensive care nursery:21:0.8594	0.8594	21
ICN	ICN:32	International Council of Nurses:32:0.9072	0.9072	32
ICN	ICN:7	intrinsic cardiac nerves:7:0.5926	0.5926	7
ICNIRP	ICNIRP:16	International Commission on Non-Ionizing Radiation Protection:16:0.8365	0.8365	16
ICNP	ICNP:11	International Classification of Nursing Practice:11:0.9217	0.9217	11
ICNs	ICNs:10	infection control nurses:10:0.7103	0.7103	10
ICON	ICON:1	index of complexity outcome and need:1:0.7357	0.7357	1
ICOS	ICOS:11	inducible co-stimulator:11:0.6182	0.6182	11
ICOS	ICOS:69	inducible costimulator:69:0.8724	0.8724	69
ICOS	ICOS:9	inducible costimulatory molecule:9:0.6794	0.6794	9
ICP/MS	ICP/MS:10	inductively coupled plasma/mass spectrometry:10:0.7103	0.7103	10
ICP0	ICP0:14	infected cell protein 0:14:0.7539	0.7539	14
ICP10	ICP10:17	large subunit of herpes simplex virus type 2 ribonucleotide reductase:17:0.8365	0.8365	17
ICP22	ICP22:5	infected cell protein 22:5:0.5290	0.5290	5
ICP4	ICP4:10|ICP-4:1	Infected cell protein 4:11:0.7909	0.7909	11
ICP8	ICP8:26	DNA-binding protein:26:0.6084	0.6084	26
ICP8	ICP8:7	infected cell protein 8:7:0.5926	0.5926	7
ICP-AES	ICP-AES:99|ICPAES:4	inductively coupled plasma atomic emission spectrometry:103:0.9538	0.9538	103
ICP-AES	ICP-AES:23	inductively coupled plasma-atomic emission spectroscopy:23:0.8715	0.8715	23
IC-PC	IC-PC:8|ICPC:2	internal carotid-posterior communicating artery:10:0.7103	0.7103	10
ICPD	ICPD:188	International Conference on Population and Development:188:0.9668	0.9668	188
ICPI	ICPI:15	intracerebral pathogenicity index:15:0.7096	0.7096	15
ICP-MS	ICP-MS:13|ICPMS:6	inductively coupled plasma mass spectrometer:19:0.8449	0.8449	19
ICP-MS	ICP-MS:7|ICPMS:2	inductively coupled plasma mass spectrometric:9:0.6794	0.6794	9
ICP-MS	ICP-MS:359|ICPMS:37	inductively coupled plasma mass spectrometry:266:0.9651|inductively coupled plasma-mass spectrometry:130:0.9513	0.9651	396
ICP-MS	ICP-MS:12|ICPMS:1	inductively coupled plasma mass spectroscopy:7:0.5926|Inductively coupled plasma-mass spectroscopy:6:0.5290	0.5926	13
ICPs	ICPs:19|ICPS:1	infection control practitioners:20:0.8525	0.8525	20
ICPs	ICPs:9	infection control professionals:9:0.6794	0.6794	9
ICPs	ICPs:12	insecticidal crystal proteins:12:0.7571	0.7571	12
ICPs	ICPs:11	Integrated care pathways:11:0.7357	0.7357	11
ICP	ICP:9	idiopathic chronic pancreatitis:9:0.6794	0.6794	9
ICP	ICP:7	immunocompromised patients:7:0.2243	0.2243	7
ICP	ICP:62	inductively coupled plasma:62:0.9519	0.9519	62
ICP	ICP:5	inductively coupled plasma emission spectroscopy:5:0.2818	0.2818	5
ICP	ICP:12	infancy-childhood-puberty:12:0.0039	0.0039	12
ICP	ICP:22	infantile cerebral paralysis:22:0.8657	0.8657	22
ICP	ICP:9	infected cell protein:9:0.6794	0.6794	9
ICP	ICP:12	infection control practitioner:12:0.7571	0.7571	12
ICP	ICP:12	insecticidal crystal protein:12:0.6460	0.6460	12
ICP	ICP:13	Integrated Care Pathway:13:0.7753	0.7753	13
ICP	ICP:30	intercuspal position:30:0.7012	0.7012	30
ICP	ICP:2110|icp:1	intracranial pressure:2099:0.9219|intracranial pressures:12:0.5664	0.9219	2111
ICP	ICP:78	intrahepatic cholestasis of pregnancy:78:0.9229	0.9229	78
ICP	ICP:11|iCP:1	isolated cleft palate:12:0.7571	0.7571	12
ICRAC	ICRAC:6|Icrac:4	calcium release-activated calcium current:10:0.7103	0.7103	10
ICRC	ICRC:16	International Committee of the Red Cross:16:0.8165	0.8165	16
I-CRF	I-CRF:13	immunoreactive corticotropin-releasing factor:13:0.6701	0.6701	13
ICRP	ICRP:170	International Commission on Radiological Protection:170:0.9829	0.9829	170
ICRS	ICRS:9	International Cartilage Repair Society:9:0.6794	0.6794	9
ICRS	ICRS:10|ICR-S:1	intracorneal ring segments:11:0.2154	0.2154	11
ICRS	ICRS:13|ICRs:1	intrastromal corneal ring segments:14:0.7753	0.7753	14
ICRU	ICRU:31	International Commission on Radiation Units and Measurements:31:0.8749	0.8749	31
ICR	ICR:67	control region:67:0.8024	0.8024	67
ICR	ICR:12	ion cyclotron resonance:12:0.7571	0.7571	12
ICR	ICR:14	rotation:14:0.0358	0.0358	14
ICSA	ICSA:7	Intracranial self-administration:7:0.3524	0.3524	7
ICSA	ICSA:65	islet cell surface antibodies:55:0.9147|islet cell surface antibody:10:0.7103	0.9147	65
ICSBP	ICSBP:63	consensus sequence binding protein:41:0.9274|consensus sequence-binding protein:22:0.8657	0.9274	63
ICSC	ICSC:18	Idiopathic central serous chorioretinopathy:18:0.8365	0.8365	18
ICSD	ICSD:18	International Classification of Sleep Disorders:18:0.8449	0.8449	18
ICSH	ICSH:15	International Council for Standardization in Haematology:15:0.8045	0.8045	15
ICSH	ICSH:6	interstitial cell-stimulating hormone:6:0.5290	0.5290	6
ICSS	ICSS:6	brain stimulation:6:0.1838	0.1838	6
ICSs	ICSs:65	inhaled corticosteroids:65:0.9541	0.9541	65
ICSS	ICSS:193	intracranial self-stimulation:193:0.8970	0.8970	193
ICS	ICS:7	Control Scale:7:0.1111	0.1111	7
ICS	ICS:16	ileocecal sphincter:16:0.2923	0.2923	16
ICS	ICS:11	image correlation spectroscopy:11:0.7357	0.7357	11
ICS	ICS:22	immotile cilia syndrome:22:0.8657	0.8657	22
ICs	ICs:164|Ics:1|ICS:1	Immune complexes:166:0.9368	0.9368	166
ICS	ICS:284|ICs:6	inhaled corticosteroids:208:0.9693|Inhaled corticosteroid:82:0.9636	0.9693	290
ICs	ICs:13	Intercalated cells:13:0.1192	0.1192	13
ICS	ICS:9	intercellular spaces:9:0.3945	0.3945	9
ICS	ICS:9	intercellular substance:9:0.2285	0.2285	9
ICS	ICS:6|ics:1	intercostal space:7:0.0886	0.0886	7
ICS	ICS:11	interferon consensus sequence:11:0.3829	0.3829	11
ICs	ICs:19	interstitial cells:19:0.2242	0.2242	19
ICS	ICS:9	intracellular cytokine staining:9:0.6794	0.6794	9
ICS	ICS:6	intracellular space:6:0.0522	0.0522	6
ICS	ICS:12	intracranial self-stimulation:12:0.7571	0.7571	12
ICS	ICS:9	intracranial stimulation:9:0.1196	0.1196	9
ICS	ICS:9	irritable colon syndrome:9:0.6794	0.6794	9
ICTP	ICTP:10	C-telopeptide:10:0.0213	0.0213	10
ICTP	ICTP:11	carboxy-terminal telopeptide:11:0.0704	0.0704	11
ICTP	ICTP:9	telopeptide of collagen I:9:0.6794	0.6794	9
ICTP	ICTP:5	telopeptide of collagen type I:5:0.4422	0.4422	5
ICTP	ICTP:13	type I collagen carboxyterminal telopeptide:13:0.7909	0.7909	13
ICTs	ICTs:12	Information and Communication Technologies:12:0.7753	0.7753	12
ICTV	ICTV:1	International Committee for the Taxonomy of Viruses:1:0.8165	0.8165	1
ICUs	ICUs:615	Intensive Care Units:615:0.9895	0.9895	615
ICUS	ICUS:80	intracoronary ultrasound:80:0.8596	0.8596	80
ICU	ICU:44	intensive care:44:0.9323	0.9323	44
ICU	ICU:3928	intensive care unit:3662:0.9915|intensive care units:257:0.9883|Intensive-Care-Unit:9:0.0019	0.9915	3928
ICVD	ICVD:29	ischemic cerebrovascular disease:20:0.6259|ischemic cerebrovascular diseases:9:0.6794	0.6794	29
ICWM	ICWM:10	integrative Chinese and western medicine:10:0.7103	0.7103	10
ICX	ICX:21|ICx:7	external nucleus of the inferior colliculus:28:0.8941	0.8941	28
ICx	ICx:5|ICX:2|Icx:2	immune complexes:9:0.6794	0.6794	9
ICYP	ICYP:25|I-CYP:2	[125I]iodocyanopindolol:27:0.1898	0.1898	27
ICYP	ICYP:16	iodocyanopindolol:16:0.1095	0.1095	16
ICZ	ICZ:11	Indolo[3,2-b]carbazole:11:0.3571	0.3571	11
ICa(L)	ICa(L):14|Ica(L):1	L-type Ca2+ current:15:0.7261	0.7261	15
ICa,L	ICa,L:67	L-type Ca2+ current:59:0.9203|L-type Ca2+ currents:8:0.6411	0.9203	67
ICa,L	ICa,L:29|Ica,L:1|iCa,L:1	L-type calcium current:31:0.8090	0.8090	31
ICa.L	ICa.L:5|Ica.L:1	L-type Ca2+ current:6:0.5290	0.5290	6
ICaL	ICaL:10|ICa-L:7	L-type Ca2+ current:17:0.7407	0.7407	17
ICAT	ICAT:31	isotope-coded affinity tag:31:0.6343	0.6343	31
ICAT	ICAT:9	isotope-coded affinity tags:9:0.6794	0.6794	9
Icat	Icat:10|ICat:1	non-selective cation current:11:0.3213	0.3213	11
ICo	ICo:9	nucleus intercollicularis:9:0.4728	0.4728	9
ID50	ID50:35|ID-50:1	50% inhibition:36:0.5066	0.5066	36
ID50	ID50:55	50% inhibitory dose:46:0.6063|50% inhibitory doses:9:0.3455	0.6063	55
ID50	ID50:8	infectious doses:8:0.0698	0.0698	8
IDA	IDA:112|Ida:18	idarubicin:130:0.2016	0.2016	130
IDA	IDA:16|Ida:1	idazoxan:17:0.0250	0.0250	17
IDA	IDA:14	iminodiacetate:14:0.0203	0.0203	14
IDA	IDA:70	iminodiacetic acid:70:0.7164	0.7164	70
IDA	IDA:8	interdigitated array:8:0.3463	0.3463	8
IDA	IDA:71	iron deficiency anaemia:59:0.9494|Iron-deficiency anaemia:12:0.0669	0.9494	71
IDA	IDA:185	iron deficiency anemia:143:0.9791|iron-deficiency anemia:42:0.1511	0.9791	185
IDCM	IDCM:61	idiopathic dilated cardiomyopathy:61:0.8770	0.8770	61
iDCs	iDCs:15|IDCs:1	immature DCs:16:0.7261	0.7261	16
iDCs	iDCs:31	immature dendritic cells:31:0.5749	0.5749	31
IDCs	IDCs:25	invasive ductal carcinomas:25:0.5095	0.5095	25
IDC	IDC:211	idiopathic dilated cardiomyopathy:211:0.9438	0.9438	211
iDC	iDC:31|IDC:1|i-DC:1	immature DC:33:0.8196	0.8196	33
iDC	iDC:11	immature dendritic cells:11:0.1845	0.1845	11
IDC	IDC:60	infiltrating ductal carcinoma:48:0.2217|infiltrating ductal carcinomas:12:0.1758	0.2217	60
IDC	IDC:51	interdigitating cells:44:0.3725|interdigitating cell:7:0.2902	0.3725	51
IDC	IDC:11	interdigitating dendritic cells:11:0.1845	0.1845	11
IDC	IDC:14	interdigitating reticulum cells:14:0.6911	0.6911	14
IDC	IDC:130	invasive ductal carcinoma:111:0.6142|invasive ductal carcinomas:19:0.3871	0.6142	130
IDDM	IDDM:11	diabetes mellitus type I:11:0.7357	0.7357	11
IDDM	IDDM:5	diabetic mothers:5:0.1132	0.1132	5
IDDM	IDDM:16	insulin dependent:16:0.8165	0.8165	16
IDDM	IDDM:166	insulin-dependent diabetes:137:0.5462|insulin dependent diabetes:29:0.8978	0.8978	166
IDDM	IDDM:3320	insulin-dependent diabetes mellitus:2935:0.8352|insulin dependent diabetes mellitus:385:0.9835	0.9835	3320
IDDM	IDDM:169	insulin-dependent diabetic:138:0.8548|insulin-dependent diabetics:17:0.2956|insulin dependent diabetics:14:0.7909	0.8548	169
IDDM	IDDM:23	insulin-dependent diabetic patients:23:0.5466	0.5466	23
IDDM	IDDM:11	patients with insulin-dependent:11:0.0545	0.0545	11
IDDM	IDDM:20	type 1 diabetes:20:0.8768	0.8768	20
IDDs	IDDs:11	insulin-dependent diabetics:11:0.5355	0.5355	11
IDDs	IDDs:7	iodine deficiency disorders:7:0.5926	0.5926	7
IDD	IDD:15	insulin-dependent:15:0.0317	0.0317	15
IDD	IDD:84|Idd:10|idd:1	insulin-dependent diabetes:95:0.7453	0.7453	95
IDD	IDD:14	insulin-dependent diabetes mellitus:14:0.7909	0.7909	14
IDD	IDD:70	insulin-dependent diabetics:33:0.6015|insulin-dependent diabetic:27:0.6455|insulin dependent diabetics:10:0.7103	0.7103	70
IDD	IDD:19	Inventory to Diagnose Depression:19:0.8449	0.8449	19
IDD	IDD:121	iodine deficiency disorders:112:0.9733|Iodine deficiency disorder:9:0.5470	0.9733	121
IDEA	IDEA:13	Individuals with Disabilities Education Act:13:0.7909	0.7909	13
IDF	IDF:9	Defense Force:9:0.6794	0.6794	9
IDF	IDF:12	insoluble dietary fiber:12:0.7571	0.7571	12
IDF	IDF:7	International Dairy Federation:7:0.5926	0.5926	7
IDF	IDF:13	International Diabetes Federation:13:0.7753	0.7753	13
IDF	IDF:23	Israel Defense Forces:23:0.5466	0.5466	23
IDH	IDH:10	Infectious Diseases Hospital:10:0.7103	0.7103	10
IDH	IDH:18	Intradialytic hypotension:18:0.7539	0.7539	18
IDH	IDH:83|Idh:2	isocitrate dehydrogenase:85:0.8300	0.8300	85
IDH	IDH:9	isolated diastolic hypertension:9:0.6794	0.6794	9
IDMEC	IDMEC:8	interdigestive myoelectric complex:8:0.6411	0.6411	8
IDMs	IDMs:34	infants of diabetic mothers:34:0.8644	0.8644	34
IDMS	IDMS:19|ID-MS:1	isotope dilution mass spectrometry:20:0.6680	0.6680	20
IDM	IDM:32|Idm:1	indomethacin:33:0.1839	0.1839	33
IDM	IDM:46	infants of diabetic mothers:46:0.7025	0.7025	46
IDM	IDM:14|IdM:1	intermediate-dose methotrexate:8:0.2090|Intermediate dose methotrexate:7:0.5926	0.5926	15
IDM	IDM:9	management:9:0.0460	0.0460	9
IDNT	IDNT:13	Irbesartan Diabetic Nephropathy Trial:13:0.6680	0.6680	13
IDOL	IDOL:9	idarubicinol:9:0.8000	0.8000	9
I-DOX	I-DOX:6|IDOX:2|I-Dox:1	4'-Iodo-4'-deoxydoxorubicin:9:0.5000	0.5000	9
IDO	IDO:235	indoleamine 2,3-dioxygenase:201:0.9234|indoleamine-2,3-dioxygenase:20:0.0648|indoleamine 2,3 dioxygenase:14:0.8045	0.9234	235
IDO	IDO:11	indoleamine dioxygenase:11:0.1760	0.1760	11
IDPH	IDPH:11	Department of Public Health:11:0.7357	0.7357	11
IDPN	IDPN:33	3,3'-iminodipropionitrile:33:0.1475	0.1475	33
IDPN	IDPN:65	beta,beta'-Iminodipropionitrile:64:0.2857|beta beta'-iminodipropionitrile:1:0.8449	0.8449	65
IDPN	IDPN:6	Chronic administration of iminodipropionitrile:6:0.1320	0.1320	6
IDPN	IDPN:31	intradialytic parenteral nutrition:31:0.8519	0.8519	31
IDPs	IDPs:11	internally displaced persons:11:0.7357	0.7357	11
IDPs	IDPs:10	interplanetary dust particles:10:0.7103	0.7103	10
IDRS	IDRS:11	Illicit Drug Reporting System:11:0.7357	0.7357	11
IDR	IDR:18	idarubicin:18:0.1104	0.1104	18
IDR	IDR:9	immunodominant region:9:0.4587	0.4587	9
IDR	IDR:15	incidence density ratio:15:0.8045	0.8045	15
IDR	IDR:5	intradermal reaction:5:0.1132	0.1132	5
IDSA	IDSA:41	Infectious Diseases Society of America:41:0.9291	0.9291	41
IDSs	IDSs:49	integrated delivery systems:49:0.9046	0.9046	49
IDS	IDS:7	deficiency of the lysosomal enzyme iduronate-2-sulfatase:7:0.4438	0.4438	7
IDS	IDS:16	DNA synthesis:16:0.8165	0.8165	16
Ids	Ids:13|ids:1	idiotypes:14:0.0378	0.0378	14
IDS	IDS:14	iduronate-2-sulphatase:14:0.0378	0.0378	14
IDS	IDS:31	integrated delivery system:25:0.8186|integrated delivery systems:6:0.3728	0.8186	31
IDS	IDS:9	sulphatase:9:0.0233	0.0233	9
IDTs	IDTs:11	interdigital transducers:11:0.7357	0.7357	11
IDT	IDT:6	interdivision time:6:0.0807	0.0807	6
IDT	IDT:21	intradermal test:11:0.2972|intradermal tests:10:0.5856	0.5856	21
IDT	IDT:10	intradermal testing:10:0.5856	0.5856	10
IDT	IDT:29	isometric developed tension:29:0.7970	0.7970	29
IDUA	IDUA:45|Idua:1	alpha-L-iduronidase:46:0.8182	0.8182	46
IDUs	IDUs:344	injecting drug users:344:0.3520	0.3520	344
IDUs	IDUs:458	injection drug users:458:0.4789	0.4789	458
IDUS	IDUS:42	Intraductal ultrasonography:42:0.9291	0.9291	42
IDUS	IDUS:12	intraductal ultrasound:12:0.7571	0.7571	12
IDU	IDU:34|IdU:2	5-iodo-2'-deoxyuridine:36:0.0749	0.0749	36
IdU	IdU:9	5-iododeoxyuridine:9:0.0171	0.0171	9
IDU	IDU:43	drug user:43:0.9308	0.9308	43
IDU	IDU:39|IdU:1	idoxuridine:40:0.0835	0.0835	40
IDU	IDU:155	injecting drug users:155:0.5601	0.5601	155
IdU	IdU:11|IDU:9	iododeoxyuridine:20:0.0407	0.0407	20
IDVG	IDVG:19|IDV-G:1	initial distribution volume of glucose:20:0.8525	0.8525	20
IDV	IDV:83|idv:1	Indinavir:84:0.8058	0.8058	84
IDWG	IDWG:17	interdialytic weight gain:17:0.8270	0.8270	17
IE1	IE1:6|IE-1:2|ie-1:1	immediate early:9:0.6794	0.6794	9
IE1	IE1:7|IE-1:2	immediate early 1:9:0.6794	0.6794	9
IE-1	IE-1:3|ie-1:2	immediate-early gene:5:0.0902	0.0902	5
IEA	IEA:14	Immediate early antigen:14:0.6911	0.6911	14
IEA	IEA:32	inferior epigastric artery:32:0.9072	0.9072	32
IEC-18	IEC-18:6|IEC18:1	rat intestinal epithelial cells:7:0.3524	0.3524	7
IEC-6	IEC-6:11	intestinal epithelial:11:0.7357	0.7357	11
IEC-6	IEC-6:31	intestinal epithelial cells:31:0.5933	0.5933	31
IECs	IECs:47|iECs:1	intestinal epithelial cells:48:0.8463	0.8463	48
IEC	IEC:1	information education and communication:1:0.9619	0.9619	1
IEC	IEC:17	International Electrotechnical Commission:17:0.8270	0.8270	17
IEC	IEC:124|i-EC:5|iEC:1	intestinal epithelial cells:98:0.9352|intestinal epithelial cell:32:0.8145	0.9352	130
IEC	IEC:29	ion-exchange chromatography:29:0.4648	0.4648	29
IEDs	IEDs:28	interictal epileptiform discharges:28:0.8941	0.8941	28
IED	IED:10	interictal epileptiform discharges:10:0.7103	0.7103	10
IED	IED:14	intermittent explosive disorder:14:0.7909	0.7909	14
IEE	IEE:10	inner enamel epithelium:10:0.7103	0.7103	10
IEF	IEF:951	isoelectric focusing:951:0.9703	0.9703	951
IEF	IEF:27	isoelectric focussing:27:0.8312	0.8312	27
IEF	IEF:57	isoelectrofocusing:57:0.0486	0.0486	57
IEGs	IEGs:136|IEGS:1	immediate early genes:137:0.9654	0.9654	137
IEG	IEG:198	immediate early gene:108:0.9559|immediate-early gene:46:0.2144|immediate early genes:32:0.9072|immediate-early genes:12:0.1163	0.9559	198
IEI	IEI:14	Idiopathic environmental intolerance:14:0.7909	0.7909	14
IEI	IEI:9	interval:9:0.2000	0.2000	9
IELISA	IELISA:7|I-ELISA:1|i-ELISA:1	indirect enzyme immunoassay:9:0.6794	0.6794	9
I-ELISA	I-ELISA:9|iELISA:6|IELISA:2|i-ELISA:2	indirect enzyme-linked immunosorbent assay:19:0.6106	0.6106	19
IELT	IELT:8	intravaginal ejaculation latency time:8:0.5006	0.5006	8
IELs	IELs:166	intraepithelial lymphocytes:166:0.8635	0.8635	166
IEL	IEL:113	internal elastic lamina:113:0.9735	0.9735	113
IEL	IEL:13	intraepithelial:13:0.0186	0.0186	13
IEL	IEL:10	intraepithelial leukocytes:10:0.4363	0.4363	10
IEL	IEL:411	intraepithelial lymphocytes:348:0.8456|intraepithelial lymphocyte:63:0.8612	0.8612	411
IEMA	IEMA:33	immunoenzymometric assay:33:0.6111	0.6111	33
iEMG	iEMG:18|IEMG:10|I-EMG:2	integrated electromyogram:30:0.6648	0.6648	30
IEMG	IEMG:30|iEMG:5	integrated electromyographic:35:0.8292	0.8292	35
iEMG	iEMG:5|IEMG:4	integrated electromyographic activity:9:0.6794	0.6794	9
IEMG	IEMG:8|iEMG:6|I-EMG:3|Iemg:1	Integrated electromyography:18:0.5228	0.5228	18
IEMG	IEMG:47|iEMG:36|I-EMG:1	integrated EMG:84:0.8527	0.8527	84
IEMG	IEMG:4|iEMG:3	neural activation:7:0.3524	0.3524	7
IEM	IEM:7	2-isocyanatoethyl methacrylate:7:0.3524	0.3524	7
IEM	IEM:80	immune electron microscopy:80:0.7649	0.7649	80
IEM	IEM:10	immunoelectron microscopic:10:0.3145	0.3145	10
IEM	IEM:126|iEM:2	Immunoelectron microscopy:128:0.4754	0.4754	128
IEM	IEM:40	Inborn errors of metabolism:40:0.9256	0.9256	40
IEM	IEM:8	ineffective esophageal motility:8:0.3524	0.3524	8
IEM	IEM:11	internal elastic membrane:11:0.7357	0.7357	11
IEN	IEN:11	intraepithelial neoplasia:11:0.5355	0.5355	11
IEOP	IEOP:19	immunoelectroosmophoresis:19:0.6429	0.6429	19
IEP	IEP:93	immunoelectrophoresis:93:0.4107	0.4107	93
IEP	IEP:33|iep:3	isoelectric point:36:0.8003	0.8003	36
IES-R	IES-R:6	Impact of Event Scale-Revised:6:0.5290	0.5290	6
IESs	IESs:21	internal eliminated sequences:21:0.7865	0.7865	21
IETS	IETS:11	International Embryo Transfer Society:11:0.7357	0.7357	11
IET	IET:6	incremental exercise test:6:0.3728	0.3728	6
IET	IET:8	intramolecular electron transfer:8:0.5006	0.5006	8
IEV	IEV:15	intracellular enveloped virus:15:0.8045	0.8045	15
IF1	IF1:22	inhibitor protein:22:0.6934	0.6934	22
IF2	IF2:19|IF-2:14	initiation factor 2:33:0.7782	0.7782	33
IF3	IF3:27|IF-3:9	initiation factor 3:36:0.8716	0.8716	36
I-FABP	I-FABP:67|IFABP:29|iFABP:3|i-FABP:1|i-fabp:1	intestinal fatty acid binding protein:65:0.8474|intestinal fatty acid-binding protein:36:0.8716	0.8716	101
IFAT	IFAT:205|IF-AT:1	indirect fluorescent antibody test:198:0.9759|Indirect fluorescent antibody tests:8:0.6411	0.9759	206
IFAT	IFAT:16	indirect immunofluorescence:16:0.4536	0.4536	16
IFAT	IFAT:46	indirect immunofluorescent antibody test:46:0.4389	0.4389	46
IFA	IFA:10	antibodies:10:0.0053	0.0053	10
IFA	IFA:12	idiopathic fibrosing alveolitis:12:0.7571	0.7571	12
IFA	IFA:9	immunofluorescence analysis:9:0.3069	0.3069	9
IFA	IFA:36	immunofluorescence assays:36:0.7704	0.7704	36
IFA	IFA:17	imported fire ant:17:0.8270	0.8270	17
IFA	IFA:170	incomplete Freund's adjuvant:170:0.9624	0.9624	170
IFA	IFA:301	indirect fluorescent antibody:275:0.9662|indirect fluorescent-antibody:26:0.8861	0.9662	301
IFA	IFA:8	indirect fluorescent antibody technique:8:0.6411	0.6411	8
IFA	IFA:26	indirect fluorescent antibody test:26:0.8251	0.8251	26
IFA	IFA:67	indirect immunofluorescence:67:0.6155	0.6155	67
IFA	IFA:223	indirect immunofluorescence assay:223:0.4935	0.4935	223
IFA	IFA:9	indirect immunofluorescence test:9:0.3945	0.3945	9
IFA	IFA:75	indirect immunofluorescent antibody:70:0.4432|indirect immunofluorescent-antibody:5:0.0902	0.4432	75
IFA	IFA:6	isoferulic acid:6:0.1148	0.1148	6
IFCC	IFCC:15	International Federation of Clinical Chemistry and Laboratory Medicine:15:0.8165	0.8165	15
IFE	IFE:33	immunofixation electrophoresis:33:0.8605	0.8605	33
IFFP	IFFP:12	intracellular fluorescein fluorescence polarization:12:0.7571	0.7571	12
IFF	IFF:11	ifosfamide:11:0.3846	0.3846	11
I-FISH	I-FISH:26|iFISH:6|IFISH:3|i-FISH:1	interphase fluorescence in situ hybridization:36:0.9174	0.9174	36
IFIs	IFIs:12	invasive fungal infections:12:0.7571	0.7571	12
IFI	IFI:30|IFi:2	indirect immunofluorescence:32:0.6429	0.6429	32
IFI	IFI:40	invasive fungal infections:23:0.8715|invasive fungal infection:17:0.7407	0.8715	40
IFLrA	IFLrA:3	leukocyte interferon:3:0.7357	0.7357	3
IFL	IFL:40|iFl:1	indirect immunofluorescence:41:0.4858	0.4858	41
IFL	IFL:9	leucovorin:9:0.0696	0.0696	9
IFMA	IFMA:55	immunofluorometric assay:47:0.7366|immunofluorometric assays:8:0.5006	0.7366	55
IFMs	IFMs:11	indirect flight muscles:11:0.7357	0.7357	11
IFM	IFM:16	ifosfamide:16:0.1027	0.1027	16
IFM	IFM:18	immunofluorescence microscopy:18:0.4033	0.4033	18
IFM	IFM:18	indirect flight muscle:18:0.4438	0.4438	18
IFM	IFM:10	interfibrillar mitochondria:10:0.3867	0.3867	10
IFN-a	IFN-a:8|IFN-A:4|IFNA:1	interferon-A:13:0.1319	0.1319	13
IFNA	IFNA:11|IFN-A:9|IFN-a:7|IFNa:4|Ifna:1|Ifn-a:1	interferon-alpha:25:0.2637|interferon alpha:8:0.5006	0.5006	33
IFNB	IFNB:9|IFN-B:1	interferon beta:10:0.5856	0.5856	10
IFNR	IFNR:6|IFN-R:2	IFN receptor:8:0.2987	0.2987	8
IFNG	IFNG:5	IFN-gamma gene:5:0.1329	0.1329	5
IFN-g	IFN-g:12	interferon-g:12:0.1100	0.1100	12
IFNg	IFNg:16|IFNG:16|IFN-g:15|IFN-G:8|Ifng:3	interferon gamma:32:0.8563|interferon-gamma:26:0.2500	0.8563	58
IFNs	IFNs:87	type I interferons:87:0.9461	0.9461	87
IFN	IFN:8	alpha- and gamma-Interferon:8:0.0622	0.0622	8
IFN	IFN:116	alpha-interferon:116:0.0239	0.0239	116
IFN	IFN:25	beta-interferon:25:0.0050	0.0050	25
IFN	IFN:3708	interferon:3708:0.7686	0.7686	3708
IFN	IFN:14	Interferon alfa:14:0.6911	0.6911	14
IFN	IFN:15	interferon alfa-2a:15:0.8045	0.8045	15
IFN	IFN:23	interferon alfa-2b:23:0.8038	0.8038	23
IFN	IFN:200	interferon-alpha:137:0.0282|interferon alpha:63:0.8807	0.8807	200
IFN	IFN:6	interferon-alpha 2:6:0.2243	0.2243	6
IFN	IFN:19	interferon alpha-2a:12:0.7571|interferon-alpha 2a:7:0.2902	0.7571	19
IFN	IFN:41	interferon-alpha-2b:15:0.0029|interferon alpha-2b:13:0.7753|interferon alpha 2b:7:0.5926|interferon-alpha 2b:6:0.0564	0.7753	41
IFN	IFN:10	interferon-alpha2b:10:0.0019	0.0019	10
IFN	IFN:23	interferon gamma:23:0.5997	0.5997	23
IFN	IFN:36	Type I interferons:36:0.9174	0.9174	36
IFOS	IFOS:17|Ifos:3	ifosfamide:20:0.7917	0.7917	20
IFPs	IFPs:12	intermediate filament proteins:12:0.7571	0.7571	12
IFP	IFP:26	inflammatory fibroid polyp:26:0.8861	0.8861	26
IFP	IFP:22	intermediate filament protein:11:0.7571|intermediate filament proteins:11:0.6182	0.7571	22
IFP	IFP:85	interstitial fluid pressure:85:0.9101	0.9101	85
IFRT	IFRT:5|IF-RT:1	involved field radiation therapy:6:0.5290	0.5290	6
IFRT	IFRT:12|IF-RT:6	involved-field radiotherapy:9:0.2102|involved field radiotherapy:9:0.6794	0.6794	18
IFT	IFT:52	immunofluorescence test:52:0.5816	0.5816	52
IFT	IFT:12	interfacial tension:12:0.7571	0.7571	12
IFT	IFT:54	intraflagellar transport:54:0.9116	0.9116	54
IFU	IFU:15|ifu:2	inclusion-forming units:17:0.3844	0.3844	17
IFV	IFV:6	Influenza virus:6:0.1543	0.1543	6
IFV	IFV:23	interstitial fluid volume:23:0.6306	0.6306	23
IFX	IFX:43	ifosfamide:43:0.7778	0.7778	43
IFs	IFs:6	initiation factors:6:0.1010	0.1010	6
IFs	IFs:224|Ifs:1	intermediate filaments:225:0.8742	0.8742	225
IF	IF:12	factor I:12:0.4557	0.4557	12
IF	IF:10|iF:4	fraction:14:0.0044	0.0044	14
If	If:12|if:7	hyperpolarization-activated current:19:0.1688	0.1688	19
If	If:11|if:1	hyperpolarization-activated inward current:12:0.5664	0.5664	12
IF	IF:5	immediate function:5:0.0612	0.0612	5
IF	IF:10	immunofixation:10:0.0031	0.0031	10
IF	IF:16|If:1	immunofluorescence assay:17:0.6211	0.6211	17
IF	IF:8	immunofluorescence method:8:0.3463	0.3463	8
IF	IF:14	immunofluorescence microscopy:14:0.4709	0.4709	14
IF	IF:7	immunofluorescence technique:7:0.1850	0.1850	7
IF	IF:16	immunofluorescence test:16:0.6577	0.6577	16
IF	IF:37	impact factor:32:0.1066|Impact Factors:5:0.0517	0.1066	37
IF	IF:296|iF:1	indirect immunofluorescence:297:0.2874	0.2874	297
IF	IF:21	Indirect immunofluorescent:21:0.1083	0.1083	21
IF	IF:5	initiation factors:5:0.0517	0.0517	5
IF	IF:16	integrate-and-fire:16:0.0051	0.0051	16
IF	IF:144|If:1	interferon:145:0.0489	0.0489	145
IF	IF:591	intermediate filament:418:0.9561|Intermediate filaments:173:0.8411	0.9561	591
IF	IF:7	intermediate frequency:7:0.0655	0.0655	7
IF	IF:21	interstitial fibrosis:21:0.8594	0.8594	21
IF	IF:11	intestinal failure:11:0.3213	0.3213	11
IF	IF:125	intrinsic factor:125:0.5670	0.5670	125
IF	IF:21	involved field:21:0.7865	0.7865	21
IF	IF:20	isoelectric focusing:20:0.8525	0.8525	20
If	If:13|if:8	pacemaker current:21:0.2107	0.2107	21
IF	IF:9	staining:9:0.0027	0.0027	9
IF	IF:40	testicular interstitial fluid:40:0.4175	0.4175	40
IGCCCG	IGCCCG:12	International Germ Cell Cancer Collaborative Group:12:0.7571	0.7571	12
IGCR	IGCR:10	in-gel competitive reassociation:10:0.7103	0.7103	10
IGCs	IGCs:12	interchromatin granule clusters:12:0.7571	0.7571	12
IGC	IGC:26	Interdisciplinary Generalist Curriculum:26:0.8861	0.8861	26
IGC	IGC:46	inverse gas chromatography:46:0.7921	0.7921	46
IGEs	IGEs:22	idiopathic generalized epilepsies:22:0.8657	0.8657	22
IGF-1R	IGF-1R:69|IGF1R:16|IGF1-R:5|IGF-1-R:3|Igf-1r:1|IGF-1r:1	insulin-like growth factor-1 receptor:56:0.8453|insulin-like growth factor 1 receptor:39:0.8811	0.8811	95
IGF-1R	IGF-1R:7|Igf1r:1	insulin-like growth factor type 1 receptor:8:0.6411	0.6411	8
IGF-1R	IGF-1R:12|IGF1R:11|Igf1r:3|IGF1-R:1	type 1 IGF receptor:27:0.8903	0.8903	27
IGF-1	IGF-1:117|IGF1:4|IgF1:1	insulin-like growth factor:122:0.7712	0.7712	122
IGF-1	IGF-1:1736|IGF1:112|Igf1:5|igf1:1|Igf-1:1	insulin-like growth factor-1:1154:0.9143|insulin-like growth factor 1:701:0.8815	0.9143	1855
IGF-1	IGF-1:70|IGF1:10|igf1:1|Igf-1:1	insulin-like growth factor I:56:0.7891|insulin-like growth factor-I:26:0.8251	0.8251	82
IGF-1	IGF1:5|IGF-1:5	somatomedin C:10:0.5000	0.5000	10
IGFBP-1	IGFBP-1:56|IGF-BP1:1	IGF binding protein-1:57:0.1819	0.1819	57
IGFBP-1	IGFBP-1:15|IGF-BP-1:1	insulin-like growth factor-binding protein:9:0.6794|insulin-like growth factor binding protein:7:0.4438	0.6794	16
IGFBP-1	IGFBP-1:316|IGFBP1:3|IGF-BP1:1|IG-FBP-1:1	insulin-like growth factor binding protein-1:194:0.9264|Insulin-like growth factor-binding protein-1:91:0.9311|insulin-like growth factor binding protein 1:36:0.8003	0.9311	321
IGFBP-2	IGFBP-2:66|IGFBP2:1	IGF-binding protein-2:40:0.2178|IGF binding protein-2:27:0.2736	0.2736	67
IGFBP-2	IGFBP-2:49|IGFBP2:10|IGF-BP-2:1	insulin-like growth factor binding protein-2:37:0.9197|insulin-like growth factor binding protein 2:23:0.8715	0.9197	60
IGFBP-3	IGFBP-3:11|IGFBP3:3|IGF-BP3:2	insulin-like growth factor binding protein:16:0.6577	0.6577	16
IGFBP-3	IGFBP-3:269|IGFBP3:13|IGF-BP3:6|Igfbp3:1|IG-FBP-3:1	insulin-like growth factor binding protein-3:208:0.9370|insulin-like growth factor binding protein 3:82:0.8628	0.9370	290
IGFBP-4	IGFBP-4:12	IGF binding protein-4:12:0.1329	0.1329	12
IGFBP-4	IGFBP-4:42|IGFBP4:5|Igfbp4:1	insulin-like growth factor binding protein-4:36:0.9174|Insulin-like growth factor binding protein 4:12:0.7571	0.9174	48
IGFBP-5	IGFBP-5:13	IGF binding protein-5:13:0.1430	0.1430	13
IGFBP-5	IGFBP-5:52|IGFBP5:3|IG-FBP-5:1	insulin-like growth factor binding protein-5:35:0.9151|insulin-like growth factor-binding protein-5:21:0.8525	0.9151	56
IGFBP-6	IGFBP-6:15|Igfbp-6:1|IGFBP6:1	insulin-like growth factor binding protein-6:11:0.7357|insulin-like growth factor binding protein 6:6:0.5290	0.7357	17
IGFBPs	IGFBPs:289|IGF-BPs:5|IG-FBPs:1	IGF binding proteins:295:0.3858	0.3858	295
IGFBPs	IGFBPs:218|IGF-BPs:7	insulin-like growth factor binding proteins:225:0.9651	0.9651	225
IGFBP	IGFBP:193|IGF-BP:8|IG-FBP:1	IGF binding proteins:73:0.4957|IGF-binding proteins:65:0.2172|IGF binding protein:64:0.3098	0.4957	202
IGFBP	IGFBP:125|IGF-BP:21|IGF-bp:3	Insulin-like growth factor binding protein:70:0.8789|Insulin-like growth factor-binding protein:41:0.8558|insulin-like growth factor binding proteins:38:0.9217	0.9217	149
IGFIIR	IGFIIR:9|IGF-IIR:8	insulin-like growth factor II receptor:17:0.7407	0.7407	17
IGF-II	IGF-II:9	insulin-like growth factor:9:0.3455	0.3455	9
IGF-II	IGF-II:731|IGFII:22|Igf-II:1|IGf-II:1	insulin-like growth factor II:495:0.9283|Insulin-like growth factor-II:260:0.9130	0.9283	755
IGF-IR	IGF-IR:9|IGF-I-R:1	IGF-I receptors:10:0.2699	0.2699	10
IGF-IR	IGF-IR:148|IGF-I-R:12|IGFIR:11|IGF-Ir:1	insulin-like growth factor I receptor:94:0.9325|insulin-like growth factor-I receptor:78:0.9200	0.9325	172
IGF-I	IGF-I:222|IGFI:2	insulin-like growth factor:224:0.9149	0.9149	224
IGF-I	IGF-I:87|IGFI:1	insulin-like growth factor-1:53:0.8842|insulin-like growth factor 1:35:0.7371	0.8842	88
IGF-I	IGF-I:5792|IGFI:21|Igf-I:3|igf-I:2	insulin-like growth factor-I:3044:0.9521|insulin-like growth factor I:2774:0.9338	0.9521	5818
IGFs	IGFs:964	Insulin-like growth factors:964:0.9544	0.9544	964
IGHD	IGHD:5|iGHD:1	idiopathic GHD:6:0.0807	0.0807	6
IGHD	IGHD:8|iGHD:1	isolated GHD:9:0.2500	0.2500	9
IGHD	IGHD:51|I-GHD:1	isolated growth hormone deficiency:52:0.6334	0.6334	52
Igh-V	Igh-V:4|IgHV:2|IGHv:1	immunoglobulin heavy chain variable region:7:0.4438	0.4438	7
IGIV	IGIV:7	immune globulin intravenous:7:0.5926	0.5926	7
IGIV	IGIV:6	Intravenous immune globulin:6:0.2827	0.2827	6
IGIV	IGIV:17|IgIV:11	intravenous immunoglobulin:23:0.8038|intravenous immunoglobulins:5:0.1132	0.8038	28
IGLEs	IGLEs:26	intraganglionic laminar endings:26:0.8861	0.8861	26
IGL	IGL:5	human immunoglobulin lambda:5:0.1464	0.1464	5
IGL	IGL:18	internal granular layer:18:0.6903	0.6903	18
IgL	IgL:22|IGL:2	light chain:24:0.7593	0.7593	24
IGRP	IGRP:6	islet-specific glucose-6-phosphatase catalytic subunit-related protein:6:0.5290	0.5290	6
IGRs	IGRs:23|IGRS:1	insect growth regulators:24:0.8768	0.8768	24
IGRS	IGRS:17	receptive sites:11:0.7103|receptive site:6:0.2243	0.7103	17
IGSS	IGSS:53	immunogold-silver staining:33:0.4211|ImmunoGold Silver Staining:20:0.6680	0.6680	53
IGT	IGT:9	glucose intolerance:9:0.6794	0.6794	9
IGT	IGT:1090|iGT:1	impaired glucose tolerance:1091:0.9783	0.9783	1091
IGT	IGT:10	Iowa Gambling Task:10:0.7103	0.7103	10
IgV	IgV:8|IGV:2	immunoglobulin variable region:10:0.7103	0.7103	10
IHAT	IHAT:24	indirect haemagglutination test:24:0.7593	0.7593	24
IHAT	IHAT:42	indirect hemagglutination test:42:0.8558	0.8558	42
IHA	IHA:5	idiopathic adrenal hyperplasia:5:0.4422	0.4422	5
IHA	IHA:9	immune hemolytic anemia:9:0.4587	0.4587	9
IHA	IHA:139|iha:1	indirect haemagglutination:140:0.9659	0.9659	140
IHA	IHA:17	indirect haemagglutination assay:17:0.8270	0.8270	17
IHA	IHA:40	indirect haemagglutination test:40:0.8839	0.8839	40
IHA	IHA:148	indirect hemagglutination:148:0.9294	0.9294	148
IHA	IHA:6	indirect hemagglutination antibody:6:0.5290	0.5290	6
IHA	IHA:27	indirect hemagglutination assay:27:0.8312	0.8312	27
IHA	IHA:36	indirect hemagglutination test:36:0.9174	0.9174	36
IHA	IHA:12	intermittent high altitude:12:0.7571	0.7571	12
IHb	IHb:11|IHB:9	hemoglobin concentration:20:0.7766	0.7766	20
IHCP	IHCP:8	idiopathic hypertrophic cranial pachymeningitis:8:0.6411	0.6411	8
IHCs	IHCs:152|IHCS:1	inner hair cells:153:0.9804	0.9804	153
IHC	IHC:10	idiopathic hemochromatosis:10:0.6794	0.6794	10
IHC	IHC:9|IHc:2	Idiopathic hypercalciuria:11:0.7357	0.7357	11
IHC	IHC:344	immunohistochemical:344:0.1855	0.1855	344
IHC	IHC:9	immunohistochemical analysis:9:0.6794	0.6794	9
IHC	IHC:34	Immunohistochemical staining:34:0.7898	0.7898	34
IHC	IHC:24	immunohistochemically:24:0.0124	0.0124	24
IHC	IHC:1081	immunohistochemistry:1081:0.5836	0.5836	1081
IHC	IHC:15	induced hypertension chemotherapy:15:0.4609	0.4609	15
IHC	IHC:108|ihc:1	inner hair cell:62:0.9519|inner hair cells:47:0.9366	0.9519	109
IHC	IHC:14	Intermountain Health Care:14:0.6173	0.6173	14
IHD	IHD:43	intermittent hemodialysis:43:0.7795	0.7795	43
IHD	IHD:614	ischaemic heart disease:614:0.3647	0.3647	614
IHD	IHD:970|IH-D:1	ischemic heart disease:951:0.5797|ischemic heart diseases:20:0.5892	0.5892	971
IHE	IHE:7	infantile hemangioendothelioma:7:0.3524	0.3524	7
IHE	IHE:7	isometric handgrip exercise:7:0.5926	0.5926	7
IHES	IHES:11	Idiopathic hypereosinophilic syndrome:11:0.7357	0.7357	11
IHF	IHF:340	Integration host factor:340:0.9726	0.9726	340
I-Hg	I-Hg:7|IHg:4|iHg:1	inorganic mercury:12:0.7571	0.7571	12
IHG	IHG:21	isometric handgrip:21:0.7865	0.7865	21
IHG	IHG:8	isometric handgrip exercise:8:0.5006	0.5006	8
IHHNV	IHHNV:17	infectious hypodermal and hematopoietic necrosis virus:17:0.8270	0.8270	17
IHH	IHH:62	idiopathic hypogonadotropic hypogonadism:62:0.6886	0.6886	62
Ihh	Ihh:103|IHH:22|ihh:4|IHh:1	Indian hedgehog:130:0.9770	0.9770	130
IHH	IHH:16	isolated hypogonadotropic hypogonadism:16:0.1031	0.1031	16
IHL	IHL:11	intrahepatic lymphocytes:11:0.4232	0.4232	11
IHLT	IHLT:11	indirect haemolysis test:11:0.7357	0.7357	11
IHN	IHN:9	infectious haematopoietic necrosis:9:0.6794	0.6794	9
IHN	IHN:10	Infectious hematopoietic necrosis:10:0.7103	0.7103	10
IHNV	IHNV:27	infectious haematopoietic necrosis virus:27:0.8903	0.8903	27
IHNV	IHNV:79	infectious hematopoietic necrosis virus:79:0.9622	0.9622	79
IHPS	IHPS:95	infantile hypertrophic pyloric stenosis:95:0.8252	0.8252	95
IHP	IHP:21	idiopathic hypoparathyroidism:21:0.7865	0.7865	21
IHP	IHP:12	inositol hexakisphosphate:12:0.5664	0.5664	12
IHP	IHP:75	inositol hexaphosphate:75:0.9169	0.9169	75
IHP	IHP:43	isolated hepatic perfusion:43:0.9308	0.9308	43
IHR	IHR:19	instantaneous heart rate:19:0.2840	0.2840	19
IHR	IHR:22	intrinsic heart rate:22:0.3561	0.3561	22
IHRP	IHRP:8	Inter-alpha-trypsin inhibitor family heavy chain-related protein:8:0.6411	0.6411	8
IHSS	IHSS:74	idiopathic hypertrophic subaortic stenosis:74:0.8804	0.8804	74
IHS	IHS:9	idiopathic hypereosinophilic syndrome:9:0.6794	0.6794	9
IHS	IHS:9	immunohistochemical staining:9:0.4587	0.4587	9
IHS	IHS:115	Indian Health Service:115:0.9451	0.9451	115
IHS	IHS:219	International Headache Society:219:0.9781	0.9781	219
IHT	IHT:13	intermittent hypoxic training:13:0.5335	0.5335	13
IHT	IHT:6	interstitial hyperthermia:6:0.1838	0.1838	6
IHTT	IHTT:12	interhemispheric transfer time:12:0.7571	0.7571	12
IHTT	IHTT:7	interhemispheric transmission time:7:0.4438	0.4438	7
Ih	Ih:4|ih:4|IH:2	current activated by hyperpolarization:10:0.7357	0.7357	10
Ih	Ih:29|IH:3	Hyperpolarization-activated cation current:32:0.6024	0.6024	32
Ih	Ih:37|IH:4|ih:2	hyperpolarization-activated current:37:0.1611|hyperpolarization-activated currents:6:0.0731	0.1611	43
Ih	Ih:16|IH:2|ih:1	hyperpolarization-activated inward current:19:0.3582	0.3582	19
IH	IH:8	idiopathic haemochromatosis:8:0.5006	0.5006	8
IH	IH:23|iH:1	idiopathic hemochromatosis:24:0.8768	0.8768	24
IH	IH:37	Idiopathic Hirsutism:37:0.8749	0.8749	37
IH	IH:53	idiopathic hypercalciuria:53:0.9116	0.9116	53
IH	IH:20	immunohistochemical:20:0.0186	0.0186	20
IH	IH:48|ih:1	immunohistochemistry:49:0.0470	0.0470	49
IH	IH:12	immunohistology:12:0.0108	0.0108	12
IH	IH:11	Indirect haemagglutination:11:0.6182	0.6182	11
IH	IH:8	Infantile Hydrocephalus:8:0.4102	0.4102	8
IH	IH:13	inguinal hernia:13:0.3809	0.3809	13
IH	IH:50	Intermittent hypoxia:50:0.7676	0.7676	50
IH	IH:131	intimal hyperplasia:131:0.9212	0.9212	131
IH	IH:15	intracranial hypertension:15:0.7096	0.7096	15
Ih	Ih:4|IH:2	inward rectifier:6:0.2243	0.2243	6
IIA	IIA:25	internal iliac artery:25:0.8816	0.8816	25
IIa	IIa:19	thrombin:19:0.0682	0.0682	19
IICP	IICP:8	increased intracranial pressure:8:0.4102	0.4102	8
IIDs	IIDs:35	interaural intensity differences:35:0.9151	0.9151	35
IIDs	IIDs:9	interaural intensity disparities:9:0.5470	0.5470	9
IID	IID:22	infectious intestinal disease:22:0.7955	0.7955	22
IID	IID:43	interaural intensity difference:32:0.8563|interaural intensity differences:11:0.7357	0.8563	43
IIEF	IIEF:177	international index of Erectile Function:177:0.9833	0.9833	177
IIEF-5	IIEF-5:31	International Index of Erectile Function:31:0.9043	0.9043	31
IIFA	IIFA:8|I-IFA:1	indirect immunofluorescence assay:9:0.6794	0.6794	9
IIFT	IIFT:15	indirect immunofluorescence test:15:0.7096	0.7096	15
IIF	IIF:463|iIF:2	indirect immunofluorescence:465:0.9712	0.9712	465
IIF	IIF:16	indirect immunofluorescence assay:16:0.8165	0.8165	16
IIF	IIF:15	indirect immunofluorescence technique:15:0.8045	0.8045	15
IIF	IIF:18	indirect immunofluorescence test:18:0.7539	0.7539	18
IIF	IIF:17	indirect immunofluorescent:17:0.8270	0.8270	17
IIF	IIF:7	indirect immunofluorescent test:7:0.5926	0.5926	7
IIF	IIF:29|iif:1	intracellular ice formation:30:0.8472	0.8472	30
IIH	IIH:82	idiopathic intracranial hypertension:82:0.8914	0.8914	82
IIH	IIH:7	insulin-induced hypoglycaemia:7:0.2902	0.2902	7
IIH	IIH:24	insulin-induced hypoglycemia:24:0.6653	0.6653	24
IIM	IIM:66	idiopathic inflammatory myopathies:45:0.9338|idiopathic inflammatory myopathy:21:0.8594	0.9338	66
IIo	IIo:9	lamina II:9:0.5470	0.5470	9
IIP	IIP:120	idiopathic interstitial pneumonia:120:0.9751	0.9751	120
IIP	IIP:21	indirect immunoperoxidase:21:0.7291	0.7291	21
IIP	IIP:16	Inventory of Interpersonal Problems:16:0.5940	0.5940	16
IIQ	IIQ:12	Incontinence Impact Questionnaire:12:0.7571	0.7571	12
IIQ-7	IIQ-7:13	Incontinence Impact Questionnaire:13:0.7753	0.7753	13
IIR	IIR:9	infinite impulse response:9:0.6794	0.6794	9
IIR	IIR:7	K+ current:7:0.1329	0.1329	7
IIR	IIR:10	reperfusion:10:0.0989	0.0989	10
IIS	IIS:5	Injury Impairment Scale:5:0.4422	0.4422	5
IIT	IIT:13	intensive insulin therapy:13:0.4102	0.4102	13
IIV	IIV:10	influenza vaccine:10:0.5856	0.5856	10
IJO	IJO:12	Idiopathic juvenile osteoporosis:12:0.6460	0.6460	12
IJPs	IJPs:65|ijps:2	inhibitory junction potentials:67:0.9554	0.9554	67
IJP	IJP:26	inhibitory junction potential:26:0.8861	0.8861	26
IJs	IJs:30	infective juveniles:30:0.9011	0.9011	30
IJV	IJV:107	internal jugular vein:98:0.9695|internal jugular veins:9:0.6794	0.9695	107
IK(Ca)	IK(Ca):5	Ca(2+)-activated K+ currents:5:0.1973	0.1973	5
IK(V)	IK(V):8	delayed rectifier current:8:0.6411	0.6411	8
IKC	IKC:11|ikc:1	infectious keratoconjunctivitis:12:0.7571	0.7571	12
IKDC	IKDC:68	International Knee Documentation Committee:68:0.9561	0.9561	68
IKK	IKK:55	I kappa B kinase:55:0.8427	0.8427	55
IKK	IKK:263	IkappaB kinase:254:0.6283|IkappaB kinases:9:0.3867	0.6283	263
IKK	IKK:14	kinase complex:14:0.7909	0.7909	14
IKK2	IKK2:6|IKK-2:3	IkappaB kinase 2:9:0.3945	0.3945	9
IKr	IKr:9|Ikr:1	delayed rectifier:10:0.7103	0.7103	10
IKr	IKr:10|Ikr:1	delayed rectifier potassium current:11:0.6182	0.6182	11
IKr	IKr:7	rapidly activating component:7:0.4438	0.4438	7
IKs	IKs:18	delayed rectifier K+ current:18:0.8365	0.8365	18
IKs	IKs:7	slow component:7:0.1111	0.1111	7
IKs	IKs:8	slowly activating component:8:0.6411	0.6411	8
IKur	IKur:4|Ikur:1	delayed rectifier K+ current:5:0.4422	0.4422	5
IK	IK:35|Ik:2	delayed rectifier:37:0.9197	0.9197	37
IK	IK:86|Ik:6|iK:1	delayed rectifier K+ current:93:0.9325	0.9325	93
IK	IK:45|Ik:3	delayed rectifier potassium current:48:0.9379	0.9379	48
Ik	Ik:8|IK:1	Ikaros:9:0.0121	0.0121	9
IK	IK:12|I-K:1	immunoconglutinin:13:0.0181	0.0181	13
IK	IK:22|Ik:2	K+ currents:24:0.2529	0.2529	24
IK	IK:12|Ik:1	potassium:13:0.0181	0.0181	13
IK	IK:14|Ik:5	potassium currents:19:0.1783	0.1783	19
IL-	IL-:25	Interleukin:15:0.4375|interleukin-:10:0.2812	0.4375	25
IL-10(-/-)	IL-10(-/-):12	IL-10-deficient:12:0.3056	0.3056	12
IL-21	IL-21:12	Interleukin-21:12:0.6875	0.6875	12
IL-22	IL-22:9	interleukin-22:9:0.6667	0.6667	9
IL-6(-/-)	IL-6(-/-):10	IL-6-deficient:10:0.2093	0.2093	10
IL-10	IL-10:23	anti-inflammatory:23:0.0106	0.0106	23
IL-10	IL-10:15	anti-inflammatory cytokine:10:0.1519|anti-inflammatory cytokines:5:0.0736	0.1519	15
IL-10	IL-10:1863|IL10:46|Il-10:4|Il10:1	interleukin-10:1471:0.7091|interleukin 10:443:0.9640	0.9640	1914
IL-11	IL-11:203|IL11:4|Il-11:1	interleukin-11:174:0.7900|interleukin 11:34:0.8245	0.8245	208
IL-12	IL-12:1330|IL12:19	interleukin-12:1016:0.7220|interleukin 12:333:0.9679	0.9679	1349
IL-13	IL-13:201|IL13:15|Il-13:1|Il13:1	interleukin-13:160:0.6737|interleukin 13:58:0.8502	0.8502	218
IL-15	IL-15:202|IL15:5|Il15:1	interleukin-15:158:0.7324|Interleukin 15:50:0.9064	0.9064	208
IL-16	IL-16:56|IL16:1	Interleukin-16:37:0.5714|interleukin 16:20:0.8525	0.8525	57
IL-17	IL-17:67|IL17:4	interleukin-17:48:0.6184|interleukin 17:23:0.8657	0.8657	71
IL-18BP	IL-18BP:27|IL18BP:1	IL-18 binding protein:28:0.5634	0.5634	28
IL-18	IL-18:358|IL18:9	interleukin-18:296:0.7708|interleukin 18:71:0.8741	0.8741	367
Il1b	Il1b:2|IL1B:2|IL-1b:1|IL-1B:1|IL1-B:1|IL-1-B:1	interleukin 1 beta:8:0.6411	0.6411	8
IL-1B	IL-1B:19|IL-1b:14	Interleukin-1b:26:0.2874|interleukin 1B:7:0.3524	0.3524	33
IL-1R1	IL-1R1:3|IL-1-R1:1|Il1r1:1	IL-1 receptor type 1:5:0.2818	0.2818	5
IL-1R1	IL-1R1:8	type 1 IL-1 receptor:8:0.6411	0.6411	8
IL-1RII	IL-1RII:7	IL-1 receptor type II:7:0.5926	0.5926	7
IL-1RII	IL-1RII:9	type II IL-1 receptor:9:0.6794	0.6794	9
IL-1RI	IL-1RI:27	IL-1 receptor Type I:27:0.4692	0.4692	27
IL-1RI	IL-1RI:11|IL1RI:1|IL-1-RI:1	interleukin-1 receptor type I:13:0.1463	0.1463	13
IL-1RI	IL-1RI:27	type I IL-1 receptor:27:0.8312	0.8312	27
IL-1RI	IL-1RI:20	type I receptor:20:0.8525	0.8525	20
IL-1RN	IL-1RN:20|IL1RN:13|IL1-RN:1	receptor antagonist:34:0.8644	0.8644	34
IL-1RN	IL1RN:10|IL-1RN:10	receptor antagonist gene:20:0.8525	0.8525	20
IL-1R	IL-1R:71|IL-1-R:4|IL1R:2|IL-1r:1	IL-1 receptor:59:0.3815|IL-1 receptors:19:0.3871	0.3871	78
IL-1ra	IL-1ra:475|IL-1Ra:249|IL-1RA:92|IL-1-Ra:3|Il-1ra:1|IL1-RA:1|Il-1Ra:1|IL-1-ra:1|Il-1RA:1	IL-1 receptor antagonist:824:0.5361	0.5361	824
IL-1ra	IL-1ra:5|IL-1Ra:2|IL-1RA:1	receptor agonist:8:0.5006	0.5006	8
IL-1ra	IL-1ra:3|IL-1RA:2|IL1-Ra:1	receptor antagonists:6:0.2243	0.2243	6
IL-1ra	IL-1ra:3|IL-1Ra:1	receptor antagonist of IL-1:4:0.4438	0.4438	4
IL-1ra	IL-1ra:18|IL-1Ra:7|Il-1ra:1|IL-1-Ra:1|IL-1RA:1	receptor antagonist protein:28:0.8369	0.8369	28
IL-1	IL-1:47|IL1:2|Il-1:1	interleukin:50:0.0077	0.0077	50
IL-1	IL-1:5635|IL1:173|Il-1:37|Il1:2	interleukin-1:4337:0.6824|interleukin 1:1510:0.9843	0.9843	5847
IL-1	IL-1:76|IL1:2|Il-1:2	interleukin-1 alpha:62:0.6380|interleukin 1 alpha:18:0.8365	0.8365	80
IL-1	IL-1:154|IL1:2|Il-1:2	interleukin-1 beta:127:0.7549|interleukin 1 beta:22:0.7400|interleukin 1-beta:9:0.6794	0.7549	158
IL-1	IL-1:17	interleukin-1alpha:17:0.0025	0.0025	17
IL-1	IL-1:53|IL1:3|Il-1:1	interleukin-1beta:50:0.0077|interleukin 1beta:7:0.3524	0.3524	57
IL-2R	IL-2R:74|IL-2r:1	IL-2 receptors:75:0.2912	0.2912	75
IL-2R	IL-2R:103|IL2R:11|IL2-R:2|IL-2-R:1|Il-2-R:1	interleukin-2 receptors:79:0.3002|interleukin 2 receptors:39:0.9237	0.9237	118
IL-2R	IL-2R:8|IL-2r:1	interleukin-2R:9:0.0059	0.0059	9
IL-2R	IL-2R:15|IL-2-R:1	receptors for interleukin-2:9:0.2102|receptor for interleukin-2:7:0.1111	0.2102	16
IL-2R	IL-2R:1	receptors of IL-2:1:0.0736	0.0736	1
IL-2	IL-2:13	anti-interleukin-2:13:0.0013	0.0013	13
IL-2	IL-2:61|Il-2:1|IL2:1	interleukin:63:0.0067	0.0067	63
IL-2	IL-2:8426|IL2:555|Il-2:43|Il2:6|il-2:1	interleukin-2:6304:0.6787|interleukin 2:2727:0.9860	0.9860	9031
IL-2	IL-2:9|IL2:1	T cell growth factor:10:0.7103	0.7103	10
IL-3	IL-3:7	growth factor:7:0.3524	0.3524	7
IL-3	IL-3:1993|IL3:89|Il-3:9|Il3:1	interleukin-3:1487:0.6798|interleukin 3:605:0.9777	0.9777	2092
IL-4R	IL-4R:67|IL-4-R:1|IL-4r:1|IL4R:1	IL-4 receptor:63:0.4822|IL-4 receptors:7:0.0732	0.4822	70
IL-4R	IL-4R:10|IL4R:2	Interleukin-4 receptors:12:0.2549	0.2549	12
IL-4	IL-4:9	anti-interleukin-4:9:0.0027	0.0027	9
IL-4	IL-4:12	cytokines:12:0.0037	0.0037	12
IL-4	IL-4:16	Interleukin:16:0.0050	0.0050	16
IL-4	IL-4:2679|IL4:98|Il4:3|Il-4:2	interleukin-4:2049:0.6806|interleukin 4:733:0.9696	0.9696	2782
IL-5	IL-5:650|IL5:20|Il5:1	Interleukin-5:535:0.7423|interleukin 5:136:0.9429	0.9429	671
IL-6R	IL-6R:139|IL-6-R:11|IL-6r:1|IL6-R:1	IL-6 receptor:146:0.5618|IL-6 receptors:6:0.1543	0.5618	152
IL-6R	IL-6R:36|IL-6-R:3|IL6R:2	Interleukin-6 receptor:41:0.1186	0.1186	41
IL-6sR	IL-6sR:13|IL-6-sR:1	IL-6 soluble receptor:14:0.4405	0.4405	14
IL-6	IL-6:15	Anti-interleukin-6:15:0.0017	0.0017	15
IL-6	IL-6:26|IL6:1	cytokines:14:0.0016|cytokine:13:0.0014	0.0016	27
IL-6	IL-6:26	interleukin:26:0.0030	0.0030	26
IL-6	IL-6:7820|IL6:187|Il-6:28|Il6:4|IL--6:1	Interleukin-6:6320:0.7622|interleukin 6:1720:0.9747	0.9747	8040
IL-6	IL-6:10|Il-6:1	interleukine-6:11:0.0012	0.0012	11
IL-7	IL-7:367|IL7:12	interleukin-7:260:0.6684|interleukin 7:119:0.9460	0.9460	379
IL-8	IL-8:11|IL8:2	interleukin:13:0.0042	0.0042	13
IL-8	IL-8:2666|IL8:33|Il-8:6|il-8:3	interleukin-8:2195:0.7698|interleukin 8:513:0.9525	0.9525	2708
IL-9R	IL-9R:7	IL-9 receptor:7:0.3945	0.3945	7
IL-9	IL-9:61|IL9:7	interleukin-9:53:0.7123|interleukin 9:15:0.7096	0.7123	68
ILAR	ILAR:10	International League of Associations for Rheumatology:10:0.5856	0.5856	10
ILA	ILA:15	insulin-like activity:15:0.3821	0.3821	15
ILA	ILA:14|ila:1	interlobular arteries:8:0.5006|interlobular artery:7:0.3524	0.5006	15
ILBP	ILBP:15|I-LBP:2|ilbp:1	ileal lipid binding protein:10:0.5000|ileal lipid-binding protein:8:0.2327	0.5000	18
ILBT	ILBT:10	intraluminal brachytherapy:10:0.7103	0.7103	10
ILCOR	ILCOR:25	International Liaison Committee on Resuscitation:25:0.8903	0.8903	25
ILCs	ILCs:11	carcinomas:11:0.5000	0.5000	11
ILC	ILC:10	immobilized liposome chromatography:10:0.5000	0.5000	10
ILC	ILC:35	Infiltrating lobular carcinoma:35:0.2722	0.2722	35
ILC	ILC:38	interstitial laser coagulation:38:0.9217	0.9217	38
ILC	ILC:54	invasive lobular carcinoma:54:0.4790	0.4790	54
ILC	ILC:11	lobular carcinomas:11:0.4232	0.4232	11
ILDs	ILDs:17	interaural level differences:17:0.6211	0.6211	17
ILDs	ILDs:22	interstitial lung diseases:22:0.8657	0.8657	22
ILD	ILD:11	incongruence length difference:11:0.7357	0.7357	11
ILD	ILD:42	interaural level difference:30:0.8472|interaural level differences:12:0.6460	0.8472	42
ILD	ILD:303	Interstitial lung disease:246:0.9270|interstitial lung diseases:57:0.8920	0.9270	303
ILI	ILI:73	influenza-like illness:73:0.8961	0.8961	73
IL-I	IL-I:13	interleukin-I:13:0.0795	0.0795	13
ILI	ILI:9	Isolated limb infusion:9:0.7103	0.7103	9
ILK	ILK:147|ilk:1|Ilk:1	integrin-linked kinase:149:0.8804	0.8804	149
ILL	ILL:15	interlibrary loan:15:0.8045	0.8045	15
ILL	ILL:18	intermediate lymphocytic lymphoma:18:0.7539	0.7539	18
ILM	ILM:30	inner limiting membrane:30:0.1016	0.1016	30
ILM	ILM:158	internal limiting membrane:158:0.7810	0.7810	158
ILM	ILM:12	intubating laryngeal mask:12:0.6460	0.6460	12
ILMA	ILMA:47|I-LMA:1|iLMA:1	intubating laryngeal mask airway:49:0.9027	0.9027	49
ILN	ILN:8	inferior laryngeal nerve:8:0.5006	0.5006	8
ILN	ILN:15	intralaminar nuclei:15:0.4951	0.4951	15
ILO	ILO:15|Ilo:4	Iloprost:19:0.0947	0.0947	19
ILO	ILO:48	International Labour Office:48:0.9379	0.9379	48
ILO	ILO:27	International Labour Organisation:27:0.8903	0.8903	27
ILO	ILO:62	International Labor Organization:40:0.9256|International Labour Organization:22:0.8657	0.9256	62
ILR	ILR:13	irreversible loss rate:13:0.7753	0.7753	13
ILR	ILR:23	loop recorder:23:0.8715	0.8715	23
ILSA	ILSA:14	Italian Longitudinal Study on Aging:14:0.7909	0.7909	14
ILS	ILS:14	Inbred Long-Sleep:14:0.6911	0.6911	14
ILS	ILS:38	increase in life span:32:0.5817|increase in life-span:6:0.1838	0.5817	38
ILS	ILS:1	increase of lifespan:1:0.4153	0.4153	1
ILS	ILS:28	intermittent light stimulation:28:0.8941	0.8941	28
ILs	ILs:12	ionic liquids:12:0.7571	0.7571	12
ILS	ILS:24	isolated lissencephaly sequence:24:0.8768	0.8768	24
ILTV	ILTV:69	infectious laryngotracheitis virus:69:0.9100	0.9100	69
ILT	ILT:7	Immunoglobulin-like transcript:7:0.2452	0.2452	7
ILT	ILT:44	infectious laryngotracheitis:44:0.9323	0.9323	44
ILT	ILT:13	Interstitial laser therapy:13:0.6701	0.6701	13
ILT	ILT:9	interstitial laser thermotherapy:9:0.6794	0.6794	9
ILVEN	ILVEN:28	Inflammatory linear verrucous epidermal nevus:28:0.8422	0.8422	28
ILVT	ILVT:19	Idiopathic left ventricular tachycardia:19:0.6537	0.6537	19
ILV	ILV:6	indolactam V:6:0.1543	0.1543	6
ILV	ILV:14	instantaneous lung volume:14:0.7909	0.7909	14
ILP	ILP:14	Inductive Logic Programming:14:0.7909	0.7909	14
ILP	ILP:6	insulin-like peptide:6:0.1543	0.1543	6
ILP	ILP:33	Interstitial laser photocoagulation:33:0.8563	0.8563	33
ILP	ILP:138	isolated limb perfusion:138:0.9069	0.9069	138
ILp	ILp:12|Ilp:1	pars principalis:13:0.7909	0.7909	13
IL	IL:10|Il:2	current:12:0.0060	0.0060	12
IL	IL:5	immunoblastic lymphoma:5:0.0612	0.0612	5
IL	IL:10	Independent Living:10:0.5856	0.5856	10
IL	IL:16|il:2	infralimbic:18:0.0093	0.0093	18
IL	IL:8	insertion loss:8:0.3463	0.3463	8
IL	IL:1259|Il:3	Interleukin:1074:0.5805|interleukins:162:0.0867|interleukin-:26:0.0136	0.5805	1262
IL	IL:94	intermediate lobe:94:0.9495	0.9495	94
IL	IL:24	Intralipid:24:0.0131	0.0131	24
IL	IL:14	intraluminal:14:0.0071	0.0071	14
IL	IL:12	Intravascular lymphomatosis:12:0.7571	0.7571	12
IL	IL:9	Ionic liquid:9:0.5470	0.5470	9
IM-9	IM-9:12	cultured human lymphocytes:12:0.6460	0.6460	12
IMAC	IMAC:111	immobilized metal affinity chromatography:111:0.8137	0.8137	111
IMAC	IMAC:45	immobilized metal ion affinity chromatography:45:0.6761	0.6761	45
IMAC	IMAC:10	inner membrane anion channel:10:0.5355	0.5355	10
IMAN	IMAN:13	lateral magnocellular nucleus of the anterior neostriatum:13:0.4709	0.4709	13
IMAT	IMAT:17	arc therapy:17:0.8165	0.8165	17
IMAs	IMAs:25	Internal mammary arteries:25:0.8816	0.8816	25
IMA	IMA:542	internal mammary artery:509:0.9874|internal mammary arteries:33:0.9100	0.9874	542
IMA	IMA:13	ischemia-modified albumin:7:0.1850|ischemia modified albumin:6:0.5290	0.5290	13
IMB	IMB:9	immobilization:9:0.0870	0.0870	9
IMB	IMB:11	immunomagnetic beads:11:0.6182	0.6182	11
IMB	IMB:12	information-motivation-behavioral skills:12:0.4557	0.4557	12
IMCDs	IMCDs:13	inner medullary collecting ducts:13:0.6701	0.6701	13
IMCD	IMCD:372	inner medullary collecting duct:332:0.9910|inner medullary collecting ducts:40:0.9256	0.9910	372
IMCHB	IMCHB:10	Interaction Model of Client Health Behavior:10:0.5856	0.5856	10
IMCI	IMCI:89	Integrated management of childhood illness:81:0.9401|integrated management of childhood illnesses:8:0.6411	0.9401	89
IMCL	IMCL:52	intramyocellular lipid:39:0.8142|intramyocellular lipids:13:0.5934	0.8142	52
IMC	IMC:36	indomethacin:36:0.1182	0.1182	36
IMC	IMC:7	instrument meteorological conditions:7:0.5926	0.5926	7
IMC	IMC:8	interdigestive migrating complex:8:0.6411	0.6411	8
IMC	IMC:16	interdigestive migrating contractions:16:0.8165	0.8165	16
IMC	IMC:16	internal mammary chain:16:0.8165	0.8165	16
IMC	IMC:10	intima-media complex:10:0.1177	0.1177	10
IMC	IMC:6	Invasive micropapillary carcinoma:6:0.5290	0.5290	6
IMC	IMC:8	isothermal microcalorimetry:8:0.5006	0.5006	8
Imc	Imc:6	isthmi pars magnocellularis:6:0.2827	0.2827	6
IMDM	IMDM:24	Iscove's modified Dulbecco's medium:24:0.8768	0.8768	24
imd	imd:9|Imd:6|IMD:3	immune deficiency:18:0.8365	0.8365	18
IMD	IMD:5	intramammary device:5:0.1132	0.1132	5
IMD	IMD:28	intratumoral microvessel density:28:0.4950	0.4950	28
IMD	IMD:18	invasive meningococcal disease:18:0.8365	0.8365	18
IMER	IMER:11	immobilized enzyme reactor:11:0.5355	0.5355	11
IMF	IMF:90	idiopathic myelofibrosis:90:0.8274	0.8274	90
IMF	IMF:19	immunofluorescence:19:0.0566	0.0566	19
IMF	IMF:5	Initial median frequency:5:0.4422	0.4422	5
IMF	IMF:38|IMf:1	intermaxillary fixation:39:0.8142	0.8142	39
IMF	IMF:9	intermediate filaments:9:0.6794	0.6794	9
IMF	IMF:18	intramuscular fat:18:0.8365	0.8365	18
IMF	IMF:9	magnetic field:9:0.4587	0.4587	9
IMGN	IMGN:10|iMGN:3	idiopathic membranous glomerulonephritis:13:0.7753	0.7753	13
IMGU	IMGU:28	insulin-mediated glucose uptake:28:0.8941	0.8941	28
IMGs	IMGs:50	International Medical Graduates:50:0.9404	0.9404	50
IMG	IMG:8	inferior mesenteric ganglia:8:0.6411	0.6411	8
IMG	IMG:65	inferior mesenteric ganglion:65:0.9047	0.9047	65
IMG	IMG:9	international medical graduate:9:0.6794	0.6794	9
iMg	iMg:24|IMg:6	Ionized magnesium:30:0.8472	0.8472	30
IMHA	IMHA:16	immune-mediated hemolytic anemia:16:0.7261	0.7261	16
IMHV	IMHV:25	intermediate and medial part of the hyperstriatum ventrale:25:0.8978	0.8978	25
IMHV	IMHV:32	intermediate medial hyperstriatum ventrale:32:0.7142	0.7142	32
IMH	IMH:26	intramural hematoma:26:0.8861	0.8861	26
IMIA	IMIA:23	International Medical Informatics Association:23:0.8715	0.8715	23
IMIP	IMIP:9|Imip:5	imipramine:14:0.6190	0.6190	14
IMIS	IMIS:10	Integrated Management Information System:10:0.7103	0.7103	10
IMI	IMI:9	imidacloprid:9:0.0175	0.0175	9
IMI	IMI:7|Imi:2	imipenem:9:0.0175	0.0175	9
IMI	IMI:181|Imi:1	imipramine:182:0.3969	0.3969	182
IMI	IMI:32	inferior myocardial infarction:32:0.6900	0.6900	32
IMI	IMI:17	intermeal interval:17:0.6211	0.6211	17
IMI	IMI:73	intramammary infection:37:0.8051|intramammary infections:36:0.8003	0.8051	73
IMLNS	IMLNS:9	idiopathic minimal lesion nephrotic syndrome:9:0.7103	0.7103	9
IML	IML:28|iml:2	inner molecular layer:30:0.7315	0.7315	30
IML	IML:26	intermediolateral:26:0.0814	0.0814	26
IML	IML:81	intermediolateral cell column:81:0.9415	0.9415	81
IML	IML:36	intermediolateral nucleus:36:0.7704	0.7704	36
IML	IML:11	internal medullary lamina:11:0.7357	0.7357	11
IML	IML:21	Intravascular malignant lymphomatosis:21:0.8594	0.8594	21
IML	IML:9	spinal cord:9:0.6794	0.6794	9
IMMC	IMMC:13	intestinal mucosal mast cells:13:0.7753	0.7753	13
IMMO	IMMO:15|immo:2	immobilization:17:0.5926	0.5926	17
imm	imm:10	immunity:10:0.0726	0.0726	10
IMM	IMM:17|imm:1	inner mitochondrial membrane:18:0.8365	0.8365	18
IMN	IMN:50|iMN:5	idiopathic membranous nephropathy:55:0.9147	0.9147	55
IMN	IMN:12	internal mammary lymph node:7:0.5926|internal mammary lymph nodes:5:0.4422	0.5926	12
IMN	IMN:15	internal mammary node:9:0.6794|internal mammary nodes:6:0.5290	0.6794	15
IMO	IMO:49|Imo:2	immobilization:51:0.3378	0.3378	51
IMO	IMO:29|Imo:1	immobilization stress:30:0.9011	0.9011	30
IMO	IMO:10	Inflammation-mediated osteopenia:10:0.5000	0.5000	10
IMO	IMO:9	intravenous membrane oxygenator:9:0.5470	0.5470	9
IMPA	IMPA:8	isopropyl methylphosphonic acid:8:0.4102	0.4102	8
IMPDH	IMPDH:43	IMP dehydrogenase:43:0.1656	0.1656	43
IMPDH	IMPDH:35|IMP-DH:1	Inosine 5'-monophosphate dehydrogenase:36:0.8336	0.8336	36
IMPDH	IMPDH:81|IMP-DH:1	inosine monophosphate dehydrogenase:82:0.8926	0.8926	82
IMPD	IMPD:11|IMPd:1	dehydrogenase:12:0.7857	0.7857	12
IMPT	IMPT:6	intensity modulated proton therapy:6:0.5290	0.5290	6
IMPase	IMPase:31	monophosphatase:31:0.8824	0.8824	31
IMPs	IMPs:13	inner membrane proteins:13:0.2660	0.2660	13
IMPS	IMPS:10	Inpatient Multidimensional Psychiatric Scale:10:0.5856	0.5856	10
IMPs	IMPs:11|Imps:2	integral membrane proteins:13:0.2660	0.2660	13
IMPs	IMPs:66|IMPS:1|Imps:1|imps:1	intramembrane particles:69:0.3803	0.3803	69
IMPs	IMPs:69|imps:1	intramembranous particles:70:0.3871	0.3871	70
IMP	IMP:11	123I-iodoamphetamine:11:0.0100	0.0100	11
IMP	IMP:7	electrical impedance:7:0.2113	0.2113	7
IMP	IMP:9	index of myocardial performance:9:0.6794	0.6794	9
IMP	IMP:79	inosine 5'-monophosphate:64:0.9264|inosine-5'-monophosphate:15:0.0140	0.9264	79
IMP	IMP:117	inosine monophosphate:117:0.8068	0.8068	117
IMP	IMP:15	intramammary pressure:15:0.0773	0.0773	15
IMP	IMP:86|imp:1	intramembrane particles:57:0.3528|Intramembrane particle:30:0.3926	0.3926	87
IMP	IMP:76	intramembranous particles:52:0.3146|intramembranous particle:24:0.2852	0.3146	76
IMP	IMP:30	intramuscular pressure:30:0.2183	0.2183	30
IMP	IMP:26	intramyocardial pressure:26:0.1887	0.1887	26
IMP	IMP:41	iodoamphetamine:41:0.0390	0.0390	41
IMP	IMP:9	N-isopropyl I-123 p-iodoamphetamine:9:0.7357	0.7357	9
IMP	IMP:35	N-isopropyl-p-[123I]iodoamphetamine:35:0.0330	0.0330	35
IMP	IMP:23	N-isopropyl-p-iodoamphetamine:23:0.0220	0.0220	23
IMR-32	IMR-32:9|IMR32:3	human neuroblastoma:12:0.5050	0.5050	12
IMR-32	IMR-32:15|IMR32:3	human neuroblastoma cells:18:0.7539	0.7539	18
I-MRI	I-MRI:5|iMRI:4|IMRI:1	interventional MRI:10:0.3470	0.3470	10
iMRI	iMRI:15|IMRI:5|I-MRI:1	magnetic resonance imaging:21:0.8594	0.8594	21
IMRT	IMRT:407	intensity-modulated radiation therapy:249:0.5439|Intensity Modulated Radiation Therapy:158:0.9503	0.9503	407
IMRT	IMRT:325	intensity-modulated radiotherapy:205:0.5539|intensity modulated radiotherapy:120:0.9603	0.9603	325
IMRT	IMRT:12	intensity-modulated RT:12:0.7571	0.7571	12
IMRs	IMRs:29	infant mortality rates:29:0.8978	0.8978	29
IMR	IMR:134	infant mortality rate:107:0.9279|infant mortality rates:27:0.8903	0.9279	134
IMR	IMR:30	ischemic mitral regurgitation:30:0.9011	0.9011	30
IMSS	IMSS:36	Mexican Institute of Social Security:36:0.9217	0.9217	36
IMSS	IMSS:18	Mexican Social Security Institute:18:0.6381	0.6381	18
IMS	IMS:138	immunomagnetic separation:138:0.9245	0.9245	138
IMS	IMS:6	Intermediate Myasthenia Syndrome:6:0.5290	0.5290	6
IMS	IMS:21	intermembrane space:21:0.7865	0.7865	21
IMS	IMS:33	Ion mobility spectrometry:33:0.8605	0.8605	33
IMS	IMS:11	mouse serum:11:0.7357	0.7357	11
IMTG	IMTG:7	intramuscular triacylglycerol:7:0.2113	0.2113	7
IMTG	IMTG:8|imTG:1	intramuscular triglyceride:9:0.2757	0.2757	9
IMT	IMT:105	carotid artery intima-media thickness:105:0.8617	0.8617	105
IMT	IMT:8	immune-mediated thrombocytopenia:8:0.5006	0.5006	8
IMT	IMT:7	immune modulation therapy:7:0.5926	0.5926	7
IMT	IMT:52	inflammatory myofibroblastic tumor:52:0.9427	0.9427	52
IMT	IMT:47	inspiratory muscle training:47:0.9006	0.9006	47
IMT	IMT:12	intima-media thickening:12:0.4153	0.4153	12
IMT	IMT:15	tyrosine:15:0.0101	0.0101	15
IMVP	IMVP:9	idiopathic mitral valve prolapse:9:0.6794	0.6794	9
IMV	IMV:17	inferior mesenteric vein:17:0.7407	0.7407	17
IMV	IMV:14	Inoue-Melnick virus:14:0.1044	0.1044	14
IMV	IMV:121	intermittent mandatory ventilation:121:0.9609	0.9609	121
IMV	IMV:9	intracellular mature virions:9:0.6794	0.6794	9
IMV	IMV:45	intracellular mature virus:45:0.9338	0.9338	45
IMZ	IMZ:10	123I-iomazenil:10:0.1139	0.1139	10
IMZ	IMZ:7	involuting marginal zone:7:0.5926	0.5926	7
IMZ	IMZ:12	Iomazenil:12:0.1392	0.1392	12
IMg2+	IMg2+:11|iMg2+:4	ionized magnesium:15:0.4609	0.4609	15
IMiDs	IMiDs:9	immunomodulatory drugs:9:0.6794	0.6794	9
INAD	INAD:28	infantile neuroaxonal dystrophy:28:0.8941	0.8941	28
INA	INA:14|iNA:1	2,6-dichloroisonicotinic acid:15:0.2621	0.2621	15
INA	INA:5|ina:1	ice nucleation active:6:0.5290	0.5290	6
INA	INA:5	intradental nerve activity:5:0.1973	0.1973	5
INA	INA:11	isonicotinic acid:11:0.1486	0.1486	11
INa	INa:127|iNa:6|Ina:1	Na+ current:99:0.2930|Na+ currents:35:0.3384	0.3384	134
INa	INa:143|iNa:4|INA:1	sodium current:120:0.3659|Sodium currents:28:0.2491	0.3659	148
INB	INB:8	nerve block:8:0.5006	0.5006	8
INCAP	INCAP:20	Institute of Nutrition of Central America and Panama:20:0.8657	0.8657	20
INCAT	INCAT:9	Inflammatory Neuropathy Cause and Treatment:9:0.6794	0.6794	9
INCENP	INCENP:30	inner centromere protein:30:0.8978	0.8978	30
INCLEN	INCLEN:18	International Clinical Epidemiology Network:18:0.8270	0.8270	18
INDO	INDO:183|Indo:97|indo:9	indomethacin:289:0.8862	0.8862	289
INEEL	INEEL:10	Idaho National Engineering and Environmental Laboratory:10:0.7103	0.7103	10
INF	INF:9	infected:9:0.0348	0.0348	9
INF	INF:7|inf:1|Inf:1	infundibulum:9:0.0348	0.0348	9
INF	INF:52	interferon:52:0.2217	0.2217	52
INHS	INHS:9	Italian National Health Service:9:0.6794	0.6794	9
INH	INH:9	immunoreactive inhibin:9:0.1945	0.1945	9
INH	INH:9|inh:7|-inh:1	inhibitor:17:0.0180	0.0180	17
INH	INH:641	isoniazid:641:0.7205	0.7205	641
INH	INH:9	isoniazide:9:0.0090	0.0090	9
INH	INH:96	isonicotinic acid hydrazide:96:0.9200	0.9200	96
INL	INL:270	inner nuclear layer:270:0.9656	0.9656	270
iNOS	iNOS:20	inducible isoform:20:0.3419	0.3419	20
iNOS	iNOS:37	inducible nitric oxide:37:0.8051	0.8051	37
iNOS	iNOS:2838|i-NOS:10|INOS:7|iNOs:3|iNos:2|inos:1	inducible nitric oxide synthase:2854:0.8488|inducible nitric oxide synthases:7:0.4438	0.8488	2861
iNOS	iNOS:3|i-NOS:1	inducible nitric oxide synthase enzyme:4:0.3170	0.3170	4
iNOS	iNOS:7	inducible nitric oxide synthase gene:7:0.4438	0.4438	7
iNOS	iNOS:38	inducible nitric oxide synthetase:38:0.7306	0.7306	38
iNOS	iNOS:23|iNOs:1	inducible NO-synthase:24:0.7151	0.7151	24
iNOS	iNOS:529|i-NOS:6|iNOs:1	inducible NOS:536:0.8323	0.8323	536
INPV	INPV:12	intermittent negative pressure ventilation:12:0.7571	0.7571	12
INPH	INPH:7|iNPH:3	idiopathic normal pressure hydrocephalus:10:0.7103	0.7103	10
INP	INP:5|Inp:1	ice nucleation protein:6:0.5290	0.5290	6
InP	InP:11	indium phosphide:11:0.7357	0.7357	11
INRs	INRs:56	International normalized ratios:56:0.9162	0.9162	56
Inr	Inr:87|INR:7	initiator:94:0.0831	0.0831	94
Inr	Inr:29|inr:2|INR:2|InR:1	initiator element:34:0.9126	0.9126	34
InR	InR:4|INR:2|Inr:1	insulin receptor:7:0.2113	0.2113	7
INR	INR:124	international normalised ratio:110:0.9726|International Normalised Ratios:14:0.7909	0.9726	124
INR	INR:751	international normalized ratio:725:0.9813|international normalized ratios:26:0.8861	0.9813	751
INR	INR:14	Prothrombin time:14:0.7909	0.7909	14
INS-1	INS-1:7	pancreatic beta-cell line:7:0.3524	0.3524	7
Insc	Insc:8|insc:4|INSC:1	inscuteable:13:0.5714	0.5714	13
INSR	INSR:17|InsR:6|Insr:3|INS-R:2|insR:1|Ins-R:1	insulin receptor:30:0.9011	0.9011	30
INSR	INSR:10|Insr:1	insulin receptor gene:11:0.7357	0.7357	11
INSS	INSS:24	International Neuroblastoma Staging System:24:0.8768	0.8768	24
INS	INS:96|iNS:2	idiopathic nephrotic syndrome:98:0.9082	0.9082	98
INS	INS:18	Immigration and Naturalization Service:18:0.8365	0.8365	18
INS	INS:21	inelastic neutron scattering:21:0.8594	0.8594	21
Ins	Ins:14	inositol:14:0.0183	0.0183	14
INS	INS:8|Ins:1	insular cortex:9:0.6794	0.6794	9
INS	INS:45|ins:1	insulin gene:46:0.9353	0.9353	46
INs	INs:15|Ins:1	interneurons:16:0.0211	0.0211	16
Ins	Ins:35	myo-inositol:35:0.0478	0.0478	35
INS	INS:6|Ins:2	nonselective cation current:8:0.4102	0.4102	8
iNT	iNT:8|int:1	immunoreactive NT:9:0.3945	0.3945	9
int	int:19|INT:1	integrase gene:20:0.6259	0.6259	20
Int	Int:8	integrase protein:8:0.5006	0.5006	8
Int	Int:9|INT:1	integrin:10:0.0205	0.0205	10
INT	INT:10|int:9|Int:4	intermediate:23:0.0501	0.0501	23
INT	INT:6	iodonitrotetrazolium violet:6:0.0611	0.0611	6
Int	Int:20	lambda integrase:20:0.1966	0.1966	20
INT	INT:9	p-iodonitrotetrazolium violet:9:0.1945	0.1945	9
INT	INT:11	tetrazolium chloride:11:0.2582	0.2582	11
INVEST	INVEST:11	International Verapamil SR/Trandolapril Study:11:0.7103	0.7103	11
INVM	INVM:1	isolated noncompaction of ventricular myocardium:1:0.5290	0.5290	1
INV	INV:5	intracellular naked vaccinia virus:5:0.4422	0.4422	5
INV	INV:8|Inv:2	Invertase:10:0.0738	0.0738	10
INV	INV:8|Inv:1|inv:1	involucrin:10:0.0738	0.0738	10
INa-Ca	INa-Ca:12|INaCa:12|iNaCa:1	exchange current:25:0.6539	0.6539	25
INaP	INaP:11	persistent Na+ current:11:0.5934	0.5934	11
INaP	INaP:5|INa-P:1	persistent sodium current:6:0.2827	0.2827	6
IN	IN:8	cerebellar interpositus nucleus:8:0.2619	0.2619	8
IN	IN:10	Indiana:10:0.0100	0.0100	10
in	in:10	indium:10:0.0100	0.0100	10
IN	IN:28|in:3	indomethacin:31:0.0333	0.0333	31
IN	IN:10	infundibular nucleus:10:0.1327	0.1327	10
IN	IN:19|in:3	insulin:22:0.0233	0.0233	22
IN	IN:11	intact:11:0.0111	0.0111	11
IN	IN:16	integrase protein:16:0.3174	0.3174	16
IN	IN:14	integration protein:14:0.2524	0.2524	14
in	in:8|IN:3	intermediate:11:0.0111	0.0111	11
IN	IN:12	interstitial nephritis:12:0.6460	0.6460	12
IN	IN:73|in:12	intranasal:85:0.0931	0.0931	85
IN	IN:36|in:4	intranasally:40:0.0432	0.0432	40
in	in:6|IN:3	inulin:9:0.0089	0.0089	9
IOC	IOC:11	inferior olivary complex:11:0.7357	0.7357	11
iOC	iOC:5|IOC:3|i-OC:3|I-OC:1	intact osteocalcin:12:0.5664	0.5664	12
IOC	IOC:48	International Olympic Committee:48:0.9379	0.9379	48
IOC	IOC:11	intraoperative cholangiogram:11:0.6182	0.6182	11
IOC	IOC:95	intraoperative cholangiography:95:0.8460	0.8460	95
IOD	IOD:10	distance:10:0.0732	0.0732	10
IOD	IOD:62|iod:1	integrated optical density:63:0.7796	0.7796	63
IOERT	IOERT:7	Intraoperative electron beam radiation therapy:7:0.5926	0.5926	7
IOERT	IOERT:6	intraoperative electron beam radiotherapy:6:0.5290	0.5290	6
IOERT	IOERT:8	intraoperative electron irradiation:8:0.6411	0.6411	8
IOFB	IOFB:47	intraocular foreign body:33:0.9100|intraocular foreign bodies:14:0.6911	0.9100	47
IOFBs	IOFBs:11	intraocular foreign bodies:11:0.7357	0.7357	11
IOH	IOH:18	idiopathic orthostatic hypotension:18:0.8365	0.8365	18
IOHDR	IOHDR:10	brachytherapy:10:0.8182	0.8182	10
IOI	IOI:9	integrated optical intensity:9:0.6794	0.6794	9
IOI	IOI:13	interval:13:0.2609	0.2609	13
IOLs	IOLs:559|IOLS:4|iols:1	intraocular lenses:555:0.9857|intraocular lens:9:0.6794	0.9857	564
IOL	IOL:9	interosseous ligament:9:0.6794	0.6794	9
IOL	IOL:73	intraocular lenses:73:0.9147	0.9147	73
IOL	IOL:11	intraocular lens implantation:11:0.6182	0.6182	11
IOM	IOM:148	Institute of Medicine:134:0.7720|Institute of Medicine's:14:0.7909	0.7909	148
IOM	IOM:8	international Organization for Migration:8:0.5470	0.5470	8
IOM	IOM:19	interosseous membrane:19:0.8449	0.8449	19
IONDT	IONDT:10	Ischemic Optic Neuropathy Decompression Trial:10:0.6794	0.6794	10
ION	ION:18	inferior olivary nucleus:18:0.8365	0.8365	18
ION	ION:35|ion:5	infraorbital nerve:40:0.7419	0.7419	40
ION	ION:20	Ischemic optic neuropathy:20:0.6680	0.6680	20
ION	ION:31	isthmo-optic nucleus:31:0.4299	0.4299	31
IOPTH	IOPTH:13|ioPTH:3|IO-PTH:3	intraoperative parathyroid hormone:19:0.8449	0.8449	19
IOP	IOP:4120	intraocular pressure:4086:0.9724|intraocular pressures:34:0.9126	0.9724	4120
IOP	IOP:27	iopanoic acid:27:0.8903	0.8903	27
IORT	IORT:14	intraoperative irradiation:14:0.4709	0.4709	14
IORT	IORT:169	intraoperative radiation therapy:169:0.8775	0.8775	169
IORT	IORT:173	intraoperative radiotherapy:173:0.8557	0.8557	173
IOR	IOR:117	inhibition of return:117:0.9596	0.9596	117
IOR	IOR:15	intraoperative radiotherapy:15:0.5818	0.5818	15
IOSS	IOSS:10	Intraoperative spinal sonography:10:0.7103	0.7103	10
IOSs	IOSs:12	intrinsic optical signals:12:0.7571	0.7571	12
IOS	IOS:17	impulse oscillometry:17:0.8270	0.8270	17
IOS	IOS:7	impulse oscillometry system:7:0.5926	0.5926	7
IOS	IOS:15	intrinsic optical signal:15:0.8045	0.8045	15
IOT	IOT:10	Interocular transfer:10:0.7103	0.7103	10
IOTF	IOTF:24	International Obesity Task Force:24:0.8768	0.8768	24
IOTN	IOTN:76	Index of Orthodontic Treatment need:76:0.9386	0.9386	76
IOUS	IOUS:42	Intraoperative ultrasonography:42:0.8263	0.8263	42
IOUS	IOUS:52	Intraoperative ultrasound:52:0.7753	0.7753	52
IOV	IOV:10	inside-out Vesicles:10:0.4363	0.4363	10
IOV	IOV:6	interoccasion variability:6:0.2452	0.2452	6
IO	IO:32	inferior oblique:32:0.5213	0.5213	32
IO	IO:10	inferior olivary:10:0.7103	0.7103	10
IO	IO:11	inferior olivary nucleus:11:0.7357	0.7357	11
IO	IO:84	inferior olive:84:0.9644	0.9644	84
I-O	I-O:15|IO:3	input-output:18:0.0366	0.0366	18
IO	IO:9|I-O:4|i-o:1	inside-out:14:0.0280	0.0280	14
IO	IO:36	intraosseous:36:0.0754	0.0754	36
Io	Io:14|IO:2	ionomycin:16:0.0323	0.0323	16
Io	Io:8	ionophore A23187:8:0.5006	0.5006	8
IO	IO:6	transection of the infraorbital:6:0.0666	0.0666	6
IP(3)	IP(3):22	inositol 1,4,5-triphosphate:22:0.6934	0.6934	22
IP(3)	IP(3):186	inositol 1,4,5-trisphosphate:164:0.8993|inositol-1,4,5-trisphosphate:22:0.0636	0.8993	186
IP(3)	IP(3):14	inositol triphosphate:14:0.5111	0.5111	14
IP(3)	IP(3):32	inositol trisphosphate:32:0.6429	0.6429	32
IP(3)Rs	IP(3)Rs:14	inositol 1,4,5-trisphosphate receptors:14:0.6911	0.6911	14
IP(3)R	IP(3)R:7	Inositol 1,4,5-trisphosphate receptors:7:0.5926	0.5926	7
IP-10	IP-10:36	interferon-inducible protein-10:36:0.2125	0.2125	36
IP-10	IP-10:3|IP10:1	protein 10 kDa:4:0.8903	0.8903	4
IP1	IP1:45|IP-1:3	inositol monophosphate:48:0.4992	0.4992	48
IP2	IP2:17	inositol 1,4-bisphosphate:17:0.7407	0.7407	17
IP3R1	IP3R1:11|IP3R-1:1	type 1 inositol 1,4,5-trisphosphate receptor:12:0.7571	0.7571	12
IP3R	IP3R:77|IP3-R:1	inositol 1,4,5-trisphosphate receptor:68:0.8724|Inositol 1,4,5-trisphosphate receptors:10:0.7357	0.8724	78
IP3R	IP3R:28	IP3 receptor:28:0.2143	0.2143	28
IP3	IP3:157	inositol 1,4,5-triphosphate:132:0.8544|inositol-1,4,5-triphosphate:25:0.0124	0.8544	157
IP3	IP3:887	inositol 1,4,5-trisphosphate:761:0.8952|inositol-1,4,5-trisphosphate:116:0.0591|Inositol (1,4,5)-trisphosphate:10:0.7103	0.8952	887
IP3	IP3:6	inositol phosphate:6:0.1320	0.1320	6
IP3	IP3:119|IP-3:1|ip3:1	inositol triphosphate:121:0.7648	0.7648	121
IP3	IP3:379|IP-3:1	inositol trisphosphate:380:0.7941	0.7941	380
IP3	IP3:11	inositoltrisphosphate:11:0.0052	0.0052	11
IP4	IP4:30	Inositol 1,3,4,5-tetrakisphosphate:30:0.7652	0.7652	30
IP4	IP4:17	inositol tetrakisphosphate:17:0.6211	0.6211	17
IP6	IP6:25	inositol hexakisphosphate:25:0.8186	0.8186	25
IP6	IP6:38	inositol hexaphosphate:38:0.7758	0.7758	38
IPAA	IPAA:153	ileal pouch-anal anastomosis:153:0.9239	0.9239	153
IPAMA	IPAMA:6	antibody to membrane antigen:6:0.2243	0.2243	6
IPAP	IPAP:13	inspiratory positive airway pressure:13:0.7753	0.7753	13
IPAQ	IPAQ:16	International Physical Activity Questionnaire:16:0.8165	0.8165	16
IPAs	IPAs:35	Independent Practice Associations:35:0.7371	0.7371	35
IPA	IPA:29	immunoperoxidase assay:29:0.4913	0.4913	29
IPA	IPA:12	immunoprecipitation assay:12:0.1194	0.1194	12
IPA	IPA:36	Independent Practice Association:36:0.6538	0.6538	36
IPA	IPA:9	Indole-3-propionic acid:9:0.1009	0.1009	9
IPA	IPA:11	International Pharmaceutical Abstracts:11:0.7357	0.7357	11
IPA	IPA:21	intrapulmonary artery:11:0.2422|intrapulmonary arteries:10:0.2873	0.2873	21
Ipa	Ipa:7	invasion plasmid antigens:7:0.5926	0.5926	7
IPA	IPA:122	invasive pulmonary aspergillosis:122:0.9755	0.9755	122
IPA	IPA:19	isopropanol:19:0.0287	0.0287	19
IPA	IPA:46	isopropyl alcohol:46:0.9366	0.9366	46
IPCC	IPCC:19	Intergovernmental Panel on Climate Change:19:0.7766	0.7766	19
IPCH	IPCH:17	intraperitoneal chemohyperthermia:17:0.6748	0.6748	17
IPCR	IPCR:19|iPCR:2	inverse PCR:21:0.7291	0.7291	21
IPCS	IPCS:36	International Programme on Chemical Safety:36:0.9197	0.9197	36
IPCV	IPCV:15	Idiopathic polypoidal choroidal vasculopathy:15:0.8045	0.8045	15
IPC	IPC:6	IFN-alpha producing cells:6:0.3728	0.3728	6
IPC	IPC:54	intermittent pneumatic compression:54:0.9448	0.9448	54
IPC	IPC:7	intraperitoneal chemotherapy:7:0.2452	0.2452	7
IPC	IPC:29	intrapulmonary chemoreceptors:29:0.7970	0.7970	29
IPC	IPC:7	ion-pair chromatography:7:0.3524	0.3524	7
IPC	IPC:243|I-PC:3|IPc:1	ischemic preconditioning:247:0.8612	0.8612	247
Ipc	Ipc:6	nucleus isthmi pars parvocellularis:6:0.4587	0.4587	6
IPDE	IPDE:10	International Personality Disorder Examination:10:0.7103	0.7103	10
IPDI	IPDI:11	isophorone diisocyanate:11:0.6182	0.6182	11
IPDT	IPDT:6|iPDT:2|i-PDT:1	photodynamic therapy:9:0.6794	0.6794	9
IPD	IPD:150|iPD:8	idiopathic Parkinson's disease:158:0.9696	0.9696	158
IPD	IPD:8|iPD:1	idiopathic PD:9:0.3945	0.3945	9
IPD	IPD:17	Immediate pigment darkening:17:0.8270	0.8270	17
IPD	IPD:25	individual patient data:25:0.8816	0.8816	25
IPD	IPD:74	intermittent peritoneal dialysis:74:0.9361	0.9361	74
IPD	IPD:20	interpupillary distance:20:0.5021	0.5021	20
IPD	IPD:47	Invasive pneumococcal disease:47:0.9366	0.9366	47
IPD	IPD:10	Iterated Prisoner's Dilemma:10:0.7103	0.7103	10
IPEH	IPEH:26	intravascular papillary endothelial hyperplasia:26:0.8861	0.8861	26
IPE	IPE:16	interprofessional education:16:0.8165	0.8165	16
IPE	IPE:24	iris pigment epithelial:24:0.8768	0.8768	24
IPE	IPE:20	iris pigment epithelium:20:0.7766	0.7766	20
IPF	IPF:619	idiopathic pulmonary fibrosis:619:0.9496	0.9496	619
IPF	IPF:7	immune protection factor:7:0.4438	0.4438	7
IPGTT	IPGTT:16|ipGTT:2	intraperitoneal glucose tolerance test:18:0.5940	0.5940	18
IPGs	IPGs:19	immobilized pH gradients:19:0.7044	0.7044	19
IPG	IPG:106|IpG:1	immobilized pH gradient:60:0.8359|immobilized pH gradients:47:0.7960	0.8359	107
IPG	IPG:58	impedance plethysmography:58:0.9190	0.9190	58
IPG	IPG:9	inositol phosphoglycan:9:0.5470	0.5470	9
IPG	IPG:10	pulse generator:10:0.5856	0.5856	10
IPHC	IPHC:12	Intraperitoneal hyperthermic chemotherapy:12:0.6460	0.6460	12
IPHP	IPHP:32	intraperitoneal hyperthermic perfusion:32:0.7091	0.7091	32
IPH	IPH:75	idiopathic portal hypertension:75:0.9159	0.9159	75
IPH	IPH:16	Idiopathic pulmonary haemosiderosis:16:0.8165	0.8165	16
IPH	IPH:32	idiopathic pulmonary hemosiderosis:32:0.8145	0.8145	32
IPH	IPH:10	intraparenchymal hemorrhage:10:0.5000	0.5000	10
IPH	IPH:6	isolated postchallenge hyperglycemia:6:0.5290	0.5290	6
IPI	IPI:178	international prognostic index:178:0.9483	0.9483	178
IPI	IPI:47|IpI:1|ipi:1	interpulse interval:40:0.5611|interpulse intervals:9:0.2757	0.5611	49
IPK	IPK:1	isolated and perfused rat kidney:1:0.9072	0.9072	1
IPK	IPK:23	isolated perfused kidney:23:0.8715	0.8715	23
IPLs	IPLs:37	interpeak latencies:37:0.8377	0.8377	37
IPL	IPL:10	inferior parietal lobe:10:0.7103	0.7103	10
IPL	IPL:35	inferior parietal lobule:35:0.9151	0.9151	35
IPL	IPL:410|ipl:1	inner plexiform layer:411:0.9644	0.9644	411
IPL	IPL:47	intense pulsed light:47:0.9006	0.9006	47
IPL	IPL:57	interpeak latency:41:0.8525|interpeak latencies:16:0.5564	0.8525	57
IPL	IPL:1	isolated and perfused rat lung:1:0.5926	0.5926	1
IPL	IPL:9	isolated perfused liver:9:0.6794	0.6794	9
IPL	IPL:24	isolated perfused lung:15:0.5818|isolated perfused lungs:9:0.6794	0.6794	24
IPM/CS	IPM/CS:25	imipenem/cilastatin:25:0.2759	0.2759	25
IPM/CS	IPM/CS:53	imipenem/cilastatin sodium:53:0.9116	0.9116	53
IPMA	IPMA:29	immunoperoxidase monolayer assay:29:0.8422	0.8422	29
IPMDH	IPMDH:24	3-isopropylmalate dehydrogenase:24:0.6767	0.6767	24
IPMN	IPMN:20	intraductal papillary mucinous neoplasm:12:0.7753|intraductal papillary-mucinous neoplasm:8:0.6411	0.7753	20
IPMNs	IPMNs:18	Intraductal papillary mucinous neoplasms:18:0.8365	0.8365	18
IPMTs	IPMTs:22	intraductal papillary-mucinous tumors:11:0.7357|intraductal papillary mucinous tumors:11:0.7357	0.7357	22
IPMT	IPMT:69	intraductal papillary mucinous tumor:35:0.9151|Intraductal papillary-mucinous tumor:21:0.8594|intraductal papillary mucinous tumors:13:0.8045	0.9151	69
IPMT	IPMT:9	Intraductal papillary-mucinous tumor of the pancreas:5:0.4422|intraductal papillary mucinous tumors of the pancreas:4:0.5290	0.5290	9
IPM	IPM:131	imipenem:131:0.2760	0.2760	131
IPM	IPM:71	integrated pest management:71:0.9579	0.9579	71
IPM	IPM:104	interphotoreceptor matrix:104:0.9712	0.9712	104
IPM	IPM:15	isophosphoramide mustard:15:0.6386	0.6386	15
IPM	IPM:51	isopropyl myristate:51:0.8799	0.8799	51
IPNs	IPNs:11	interpenetrating polymer networks:11:0.4232	0.4232	11
IPNS	IPNS:56	Isopenicillin N synthase:56:0.9467	0.9467	56
IPNS	IPNS:17	isopenicillin N synthetase:17:0.8270	0.8270	17
IPNV	IPNV:125	infectious pancreatic necrosis virus:125:0.9759	0.9759	125
IPN	IPN:28	Infectious pancreatic necrosis:28:0.6295	0.6295	28
IPN	IPN:82|IPn:1	interpeduncular nucleus:83:0.8385	0.8385	83
IPN	IPN:13	interpenetrating network:13:0.1962	0.1962	13
IPN	IPN:13	interpenetrating polymer network:13:0.5335	0.5335	13
IPN	IPN:14	isoproterenol:14:0.0536	0.0536	14
IPN	IPN:6	polymer networks:6:0.2243	0.2243	6
IPO	IPO:15	4-Ipomeanol:15:0.2692	0.2692	15
IPPB	IPPB:72	intermittent positive pressure breathing:47:0.9006|intermittent positive-pressure breathing:25:0.7679	0.9006	72
IPPF	IPPF:77	International Planned Parenthood Federation:77:0.9612	0.9612	77
IPPNW	IPPNW:14	International Physicians for the Prevention of Nuclear War:14:0.8165	0.8165	14
IPPSF	IPPSF:30	isolated perfused porcine skin flap:30:0.9011	0.9011	30
IPPV	IPPV:298	intermittent positive pressure ventilation:236:0.9444|intermittent positive-pressure ventilation:62:0.9241	0.9444	298
IPPWs	IPPWs:12	isolated pyloric pressure waves:12:0.7571	0.7571	12
IPP	IPP:11	ileal Peyer's patch:11:0.5355	0.5355	11
IPP	IPP:8	Induratio penis plastica:8:0.5006	0.5006	8
IPP	IPP:16	inflatable penile prosthesis:16:0.8165	0.8165	16
IPP	IPP:17	intraperitoneal pressure:17:0.1585	0.1585	17
IPP	IPP:76	isopentenyl diphosphate:76:0.9607	0.9607	76
IPP	IPP:31	isopentenyl pyrophosphate:31:0.7388	0.7388	31
IPP	IPP:10	precocious puberty:10:0.7103	0.7103	10
IPQ	IPQ:10	Illness Perception Questionnaire:10:0.7103	0.7103	10
IPRGCs	IPRGCs:5	ipsilaterally projecting retinal ganglion cells:5:0.4422	0.4422	5
IPRK	IPRK:27	isolated perfused rat kidney:27:0.8941	0.8941	27
IPRL	IPRL:69	isolated perfused rat liver:60:0.9216|isolated perfused rat livers:9:0.6794	0.9216	69
IPRL	IPRL:5	isolated perfused rat lung:5:0.5290	0.5290	5
IPR	IPR:11	Isoprenaline:11:0.0420	0.0420	11
IPR	IPR:93|Ipr:2	isoproterenol:95:0.3950	0.3950	95
IPSC	IPSC:42	inhibitory postsynaptic current:33:0.8196|inhibitory postsynaptic currents:9:0.6794	0.8196	42
IPSCs	IPSCs:323	inhibitory postsynaptic currents:323:0.9711	0.9711	323
IPSID	IPSID:46	immunoproliferative small intestinal disease:46:0.8964	0.8964	46
IPSP	IPSP:198|ipsp:2	inhibitory postsynaptic potential:175:0.9122|inhibitory postsynaptic potentials:25:0.8816	0.9122	200
IPSS	IPSS:20	Inferior petrosal sinus sampling:20:0.8525	0.8525	20
IPSS	IPSS:62	International Prognostic Scoring System:62:0.9519	0.9519	62
IPSS	IPSS:278|I-PSS:102	International Prostate Symptom Score:369:0.9826|International Prostate Symptom Scores:11:0.7357	0.9826	380
IPS	IPS:34	idiopathic pneumonia syndrome:34:0.8644	0.8644	34
IPS	IPS:14	Individual Placement and Support:14:0.7909	0.7909	14
IPS	IPS:27	inferior petrosal sinus:27:0.8903	0.8903	27
IPs	IPs:125	inositol phosphates:125:0.8104	0.8104	125
IPS	IPS:28	inspiratory pressure support:28:0.8941	0.8941	28
IPS	IPS:6	interim payment system:6:0.5290	0.5290	6
IPS	IPS:58	intermittent photic stimulation:58:0.9486	0.9486	58
IPS	IPS:10	International Prognostic Score:10:0.5856	0.5856	10
IPS	IPS:7	intracellular polysaccharide:7:0.1850	0.1850	7
IPS	IPS:66|IPs:2|iPs:1	intraparietal sulcus:69:0.9316	0.9316	69
IPS	IPS:5	iodophilic polysaccharide:5:0.0517	0.0517	5
IPS	IPS:14|Ips:1	ipsapirone:15:0.0200	0.0200	15
IPTG	IPTG:9	Isopropyl-1-thio-beta-D-galactopyranoside:9:0.0264	0.0264	9
IPTG	IPTG:122	Isopropyl-beta-D-thiogalactopyranoside:92:0.3003|isopropyl beta-D-thiogalactopyranoside:30:0.9043	0.9043	122
IPTG	IPTG:56	isopropyl-beta-D-thiogalactoside:39:0.1254|isopropyl beta-D-thiogalactoside:17:0.8270	0.8270	56
IPTR	IPTR:12	International Pancreas Transplant Registry:12:0.7571	0.7571	12
IPT	IPT:77	Inflammatory pseudotumor:64:0.9534|inflammatory pseudotumors:13:0.7753	0.9534	77
IPT	IPT:7	intermittent preventive treatment:7:0.4438	0.4438	7
IPT	IPT:75	interpersonal psychotherapy:75:0.9602	0.9602	75
IPT	IPT:15	interpersonal therapy:15:0.2264	0.2264	15
ipt	ipt:7|IPT:2	isopentenyl transferase:9:0.5470	0.5470	9
IPU	IPU:12	Isoproturon:12:0.4583	0.4583	12
IPV	IPV:27	inactivated polio vaccine:27:0.6745	0.6745	27
IPV	IPV:88	inactivated poliovirus vaccine:88:0.8845	0.8845	88
IPV	IPV:9	infectious pustular vulvovaginitis:9:0.5470	0.5470	9
IPV	IPV:186	intimate partner violence:186:0.9656	0.9656	186
IPV	IPV:12	intraperitoneal volume:12:0.2868	0.2868	12
IPX	IPX:6|IPx:3	immunoperoxidase:9:0.3333	0.3333	9
IP	IP:47|ip:32	administered intraperitoneally:79:0.1209	0.1209	79
IP	IP:10|ip:1	ibuprofen:11:0.0020	0.0020	11
IP	IP:12	idiopathic parkinsonism:12:0.7571	0.7571	12
IP	IP:19	imaging plate:19:0.6537	0.6537	19
IP	IP:13|ip:1	Imipramine:14:0.0026	0.0026	14
IP	IP:14	Immunophenotype:14:0.0026	0.0026	14
IP	IP:60	immunoprecipitation:60:0.0118	0.0118	60
IP	IP:10	in-phase:10:0.0018	0.0018	10
IP	IP:87|Ip:1	Incontinentia pigmenti:88:0.9656	0.9656	88
IP	IP:7|Ip:3	index:10:0.0018	0.0018	10
IP	IP:21	Indirect immunoperoxidase:21:0.0952	0.0952	21
IP	IP:30	inflammatory polyarthritis:30:0.9011	0.9011	30
IP	IP:7|iP:5|Ip:1	inorganic phosphorus:13:0.5934	0.5934	13
IP	IP:35	inositol monophosphate:35:0.7117	0.7117	35
IP	IP:332|ip:1|Ip:1	inositol phosphate:264:0.8291|inositol phosphates:70:0.7729	0.8291	334
IP	IP:35	Integrated Project:35:0.5346	0.5346	35
IP	IP:15	intercuspal position:15:0.8045	0.8045	15
IP	IP:18	interference pattern:18:0.6903	0.6903	18
IP	IP:10|ip:1	interpeduncular nucleus:11:0.2422	0.2422	11
IP	IP:53	interphalangeal:53:0.0104	0.0104	53
IP	IP:9	interpositus nucleus:9:0.1585	0.1585	9
IP	IP:81	interstitial pneumonia:81:0.9415	0.9415	81
IP	IP:80	interstitial pneumonitis:80:0.9627	0.9627	80
IP	IP:29	intestinal permeability:29:0.6928	0.6928	29
IP	IP:655|ip:404|Ip:2|i-p:1	intraperitoneal:1062:0.2122	0.2122	1062
ip	ip:14|IP:11	intraperitoneal injection:25:0.2963	0.2963	25
IP	IP:33	inverted papilloma:33:0.8196	0.8196	33
IP	IP:14|Ip:1	ionization potential:15:0.3821	0.3821	15
IP	IP:22	Ipriflavone:22:0.0042	0.0042	22
Ip	Ip:9|IP:5|ip:1	iron-sulfur protein:15:0.1115	0.1115	15
IP	IP:26	ischaemic preconditioning:26:0.0849	0.0849	26
IP	IP:158	Ischemic preconditioning:158:0.7959	0.7959	158
IP	IP:11	Isoprenaline:11:0.0020	0.0020	11
IP	IP:37|Ip:1	isoproterenol:38:0.0074	0.0074	38
ip	ip:19|IP:8	mg/kg intraperitoneally:27:0.0719	0.0719	27
ip	ip:4|IP:3	mice injected intraperitoneally:7:0.1344	0.1344	7
IP	IP:6	nucleus interpositus:6:0.2243	0.2243	6
IP	IP:9	particles:9:0.0016	0.0016	9
IP	IP:16	period:16:0.0030	0.0030	16
IP	IP:6|ip:5	peripheral:11:0.0020	0.0020	11
IP	IP:3	Planning Nutrition and Parasite Control Project:3:0.6182	0.6182	3
IP	IP:50|Ip:1	pressure:51:0.0100	0.0100	51
IP	IP:16	prostacyclin:16:0.0030	0.0030	16
IP	IP:21	prostacyclin receptor:21:0.4538	0.4538	21
Ip	Ip:36|ip:9	pump current:45:0.5764	0.5764	45
IQC	IQC:21	Quality Control:21:0.8594	0.8594	21
IQCODE	IQCODE:34	Informant Questionnaire on Cognitive Decline in the Elderly:34:0.9274	0.9274	34
IQR	IQR:182	interquartile range:182:0.9092	0.9092	182
I-QOL	I-QOL:8|I-QoL:1	Incontinence Quality of Life:9:0.3945	0.3945	9
IQs	IQs:11|IQS:1	Intelligence quotients:12:0.6460	0.6460	12
ir-ET-1	ir-ET-1:13|IR-ET-1:3	immunoreactive ET-1:16:0.7261	0.7261	16
ir-	ir-:94|IR-:33	immunoreactive:127:0.9545	0.9545	127
IRAK-1	IRAK-1:10|IRAK1:1	receptor-associated kinase-1:11:0.3213	0.3213	11
IRAP	IRAP:19	insulin-regulated aminopeptidase:19:0.2759	0.2759	19
IRAP	IRAP:8	receptor antagonist:8:0.5006	0.5006	8
IRAP	IRAP:44	receptor antagonist protein:44:0.8335	0.8335	44
IRAS	IRAS:4	infrared reflection absorption spectroscopy:4:0.1618	0.1618	4
IRA	IRA:17	colectomy with ileorectal anastomosis:17:0.4827	0.4827	17
IRA	IRA:6	immunoradiometric assay:6:0.1320	0.1320	6
IRA	IRA:129	infarct-related artery:103:0.6481|infarct related artery:26:0.8251	0.8251	129
IRBCs	IRBCs:7	Plasmodium falciparum-infected erythrocytes:7:0.5926	0.5926	7
IRBCs	IRBCs:21|iRBCs:3	red blood cells:24:0.8768	0.8768	24
IRBC	IRBC:6	Plasmodium falciparum-infected erythrocytes:6:0.3728	0.3728	6
IRBC	IRBC:15|iRBC:2	red blood cells:17:0.8270	0.8270	17
IR-BE	IR-BE:15|ir-BE:1	immunoreactive beta-endorphin:16:0.7261	0.7261	16
IRBP	IRBP:316|Irbp:1	interphotoreceptor retinoid-binding protein:245:0.9558|interphotoreceptor retinoid binding protein:72:0.8773	0.9558	317
IRB	IRB:118	Institutional Review Board:118:0.9746	0.9746	118
Irb	Irb:3	receptor antagonist irbesartan:3:0.1618	0.1618	3
IRCP	IRCP:8|IRC-P:2	immunoreactive C-peptide:10:0.4363	0.4363	10
IRDS	IRDS:53|irds:1	idiopathic respiratory distress syndrome:54:0.6065	0.6065	54
IRD	IRD:11	inner ring deiodination:11:0.7357	0.7357	11
IRE-BP	IRE-BP:21|IREBP:1	iron-responsive element binding protein:12:0.5050|iron-responsive element-binding protein:10:0.3867	0.5050	22
IRESes	IRESes:8	internal ribosome entry sites:8:0.6411	0.6411	8
IRESs	IRESs:24	internal ribosome entry sites:24:0.8768	0.8768	24
IRES	IRES:124	internal ribosomal entry site:124:0.9757	0.9757	124
IRES	IRES:35	internal ribosome entry segment:35:0.9151	0.9151	35
IRES	IRES:444	internal ribosome entry site:415:0.9883|internal ribosome entry sites:29:0.8978	0.9883	444
IREs	IREs:100	iron-responsive elements:78:0.5877|iron responsive elements:22:0.8657	0.8657	100
IRE	IRE:17	insulin response element:17:0.2994	0.2994	17
IRE	IRE:8	iron response element:8:0.0672	0.0672	8
IRE	IRE:141	iron-responsive element:86:0.3303|iron responsive element:35:0.6666|iron-responsive elements:11:0.2154|iron responsive elements:9:0.5470	0.6666	141
IRF-1	IRF-1:21|IRF1:1	IFN regulatory factor 1:22:0.1408	0.1408	22
IRF-1	IRF-1:219|IRF1:14|irf-1:1	interferon regulatory factor-1:151:0.6159|interferon regulatory factor 1:83:0.6696	0.6696	234
IRF-2	IRF-2:5|IRF2:3	interferon regulatory factor 2:8:0.5006	0.5006	8
IRF-2	IRF-2:19	regulatory factor-2:19:0.8449	0.8449	19
IRF-3	IRF-3:6|IRF3:1	IFN regulatory factor-3:7:0.2040	0.2040	7
IRF-3	IRF-3:39|IRF3:16	interferon regulatory factor 3:41:0.6215|interferon regulatory factor-3:14:0.3202	0.6215	55
IRF4	IRF-4:5|IRF4:5	interferon regulatory factor 4:10:0.4363	0.4363	10
IRF-7	IRF-7:9|IRF7:6	Interferon regulatory factor 7:15:0.5818	0.5818	15
IRF	IRF:25	idiopathic retroperitoneal fibrosis:25:0.8816	0.8816	25
IRF	IRF:9	immature reticulocyte fraction:9:0.6794	0.6794	9
IRF	IRF:11	impaired renal function:11:0.7357	0.7357	11
IRF	IRF:16	impulse response function:16:0.6024	0.6024	16
IRF	IRF:81	interferon regulatory factor:69:0.5255|interferon regulatory factors:12:0.3813	0.5255	81
irGH	IRGH:3|irGH:3|ir-GH:2|IR-GH:1	growth hormone:9:0.6794	0.6794	9
irGH	irGH:6|IR-GH:2|IRGH:1	immunoreactive GH:9:0.6794	0.6794	9
IR-GIP	IR-GIP:21|IRGIP:3	immunoreactive gastric inhibitory polypeptide:24:0.8115	0.8115	24
IR-GIP	IR-GIP:10	immunoreactive GIP:10:0.5856	0.5856	10
IRG	IRG:22|IR-G:1	Immunoreactive gastrin:23:0.5997	0.5997	23
IRG	IRG:157	immunoreactive glucagon:157:0.4724	0.4724	157
IRHC	IRHC:10	isolated rat hepatocyte couplets:10:0.7103	0.7103	10
IRHV	IRHV:8	inferior right hepatic vein:8:0.5006	0.5006	8
IRIV	IRIV:11	immunopotentiating reconstituted influenza virosomes:11:0.7753	0.7753	11
IRI	IRI:639|IR-I:2	immunoreactive insulin:641:0.6328	0.6328	641
IRI	IRI:6	insulin immunoreactivity:6:0.1010	0.1010	6
IRI	IRI:11	insulin level:11:0.7357	0.7357	11
IRI	IRI:7	insulin-like immunoreactivity:7:0.1641	0.1641	7
IRI	IRI:6	insulin resistance index:6:0.5290	0.5290	6
IRI	IRI:8	Interpersonal Reactivity Index:8:0.6411	0.6411	8
IRI	IRI:12	interval:12:0.0088	0.0088	12
IRI	IRI:104	ischemia-reperfusion injury:66:0.3576|ischemia/reperfusion injury:24:0.0958|ischemia reperfusion injury:14:0.4742	0.4742	104
IRK	IRK:28	insulin receptor kinase:28:0.8369	0.8369	28
IR-LH	IR-LH:9|IRLH:5|irLH:2|ir-LH:1	Immunoreactive LH:17:0.8270	0.8270	17
IRLSSG	IRLSSG:7	International Restless Legs Syndrome Study Group:7:0.5926	0.5926	7
IRL	IRL:8	inspiratory resistive load:8:0.6411	0.6411	8
IRL	IRL:20	inspiratory resistive loading:20:0.7173	0.7173	20
IRM	IRM:34	interference reflection microscopy:34:0.9126	0.9126	34
IRM	IRM:17	Intermediate Restorative Material:17:0.7407	0.7407	17
IRMAs	IRMAs:24|IRMAS:2	immunoradiometric assays:26:0.8251	0.8251	26
IRMA	IRMA:32	immunoradiometric:32:0.0459	0.0459	32
IRMA	IRMA:496|IR-MA:1	immunoradiometric assay:453:0.9089|immunoradiometric assays:44:0.8941	0.9089	497
IRMPD	IRMPD:41	Infrared multiphoton dissociation:41:0.9274	0.9274	41
IRMS	IRMS:9	isotope ratio mass spectrometer:9:0.6794	0.6794	9
IRMS	IRMS:41|IR-MS:2	isotope ratio mass spectrometry:43:0.8300	0.8300	43
IRN	IRN:13	iterated rippled noise:13:0.7753	0.7753	13
IROMPs	IROMPs:21|IROMPS:1	outer membrane proteins:22:0.8657	0.8657	22
iro	iro:6|Iro:3	iroquois:9:0.3200	0.3200	9
IRP1	IRP1:31|IRP-1:16	iron regulatory protein 1:30:0.8978|iron regulatory protein-1:17:0.8270	0.8978	47
IR-PRL	IR-PRL:9|ir-PRL:6	immunoreactive prolactin:15:0.7096	0.7096	15
IRPTC	IRPTC:7	proximal tubular cells:7:0.5926	0.5926	7
IRPTCs	IRPTCs:6	Rat immortalized renal proximal tubular cells:6:0.5290	0.5290	6
IRPs	IRPs:54	Iron regulatory proteins:54:0.9132	0.9132	54
IRP	IRP:49	International Reference Preparation:38:0.9217|International Reference Preparations:11:0.7357	0.9217	49
IRP	IRP:60	iron regulatory protein:49:0.8492|iron regulatory proteins:11:0.7357	0.8492	60
IRP	IRP:16	isovolumic relaxation period:16:0.6577	0.6577	16
IRQ	IRQ:10	Questionnaire:10:0.6000	0.6000	10
IRR	IRR:84	incidence rate ratio:59:0.8954|Incidence rate ratios:25:0.8186	0.8954	84
IRR	IRR:29	insulin receptor-related receptor:29:0.8978	0.8978	29
IRR	IRR:9	interrater reliability:9:0.3455	0.3455	9
IRR	IRR:8	intrarenal reflux:8:0.5006	0.5006	8
IRS-PCR	IRS-PCR:9	polymerase chain reaction:9:0.6794	0.6794	9
IRS-1	IRS-1:13|irs-1:1	insulin receptor substrate:14:0.8045	0.8045	14
IRS-1	IRS-1:619|IRS1:43|irs-1:1	Insulin receptor substrate-1:449:0.9823|insulin receptor substrate 1:214:0.9703	0.9823	663
IRS-2	IRS-2:39|Irs2:5|IRS2:3	insulin receptor substrate-2:32:0.8563|insulin receptor substrate 2:15:0.8045	0.8563	47
IRSG	IRSG:15	Intergroup Rhabdomyosarcoma Study Group:15:0.8045	0.8045	15
irSS	irSS:4|IR-SS:3|IRSS:1	immunoreactive somatostatin:8:0.5006	0.5006	8
IRSs	IRSs:8	insulin response sequences:8:0.6411	0.6411	8
IRS	IRS:18	activation of the inflammatory response system:18:0.5113	0.5113	18
IRs	IRs:12	imidazoline receptors:12:0.1470	0.1470	12
IRS	IRS:6	immune rabbit serum:6:0.1838	0.1838	6
IRS	IRS:4	immune rat serum:4:0.0918	0.0918	4
IRS	IRS:14	immunoreactive score:14:0.4071	0.4071	14
IRS	IRS:18	immunoreactive secretin:18:0.6903	0.6903	18
IRS	IRS:45	Immunoreactive somatostatin:45:0.8649	0.8649	45
IRs	IRs:21|irs:2	immunoreactivities:23:0.0259	0.0259	23
IRs	IRs:14	incidence rates:14:0.5589	0.5589	14
IRS	IRS:9	infrared spectroscopy:9:0.5470	0.5470	9
IRS	IRS:35	inner root sheath:35:0.9151	0.9151	35
IRs	IRs:19|IRS:1	insulin receptors:20:0.3492	0.3492	20
IRS	IRS:122|Irs:1	insulin receptor substrate:110:0.9726|insulin receptor substrates:13:0.7753	0.9726	123
IRS	IRS:93	insulin resistance syndrome:93:0.9679	0.9679	93
IRS	IRS:8	insulin response sequence:8:0.1730	0.1730	8
IRS	IRS:9	interferon response sequence:9:0.2285	0.2285	9
IRS	IRS:65	Intergroup Rhabdomyosarcoma Study:55:0.9116|Intergroup Rhabdomyosarcoma Studies:10:0.7103	0.9116	65
IRS	IRS:30	Internal Revenue Service:30:0.9011	0.9011	30
IRs	IRs:43	inverted repeats:43:0.8917	0.8917	43
IRTK	IRTK:12|IR-TK:2	insulin receptor tyrosine kinase:14:0.6911	0.6911	14
IRTs	IRTs:24	interresponse times:24:0.6427	0.6427	24
IRT	IRT:66	immunoreactive trypsin:66:0.8329	0.8329	66
IRT	IRT:33	immunoreactive trypsinogen:33:0.8605	0.8605	33
IRT	IRT:11	infrared thermography:11:0.6182	0.6182	11
IRT	IRT:19	inhibitor-resistant TEM:19:0.7766	0.7766	19
IRT	IRT:5	inter-response times:5:0.0736	0.0736	5
IRT	IRT:17	intracoronary radiation therapy:17:0.5038	0.5038	17
IRT	IRT:18	isovolumetric relaxation time:18:0.1360	0.1360	18
IRT	IRT:52	isovolumic relaxation time:52:0.6012	0.6012	52
IRT	IRT:90	item response theory:90:0.9668	0.9668	90
IRT	IRT:9	radiotherapy:9:0.0168	0.0168	9
IRU	IRU:9	Immune Recovery Uveitis:9:0.6794	0.6794	9
IRV	IRV:20	inverse ratio ventilation:20:0.4574	0.4574	20
IR	IR:9|ir:3	Calcitonin gene-related peptide (CGRP)-immunoreactive:12:0.7571	0.7571	12
IR	IR:8|Ir:2	current:10:0.0013	0.0013	10
IR	IR:10|I-R:3	imidazoline receptors:13:0.1314	0.1314	13
IR	IR:164	immediate-release:116:0.0161|immediate release:48:0.7238	0.7238	164
Ir	Ir:96|IR:15	immune response:111:0.7349	0.7349	111
IR	IR:412|ir:350|-IR:29|-ir:29|Ir:7	immunoreactive:827:0.1153	0.1153	827
IR	IR:681|ir:151|-ir:42|-IR:32|Ir:2	immunoreactivity:908:0.1269	0.1269	908
IR	IR:17	implantation rate:17:0.0782	0.0782	17
IR	IR:19	inactive renin:19:0.7044	0.7044	19
IR	IR:67	incidence rate:49:0.3418|incidence rates:18:0.3857	0.3857	67
IR	IR:9	Incomplete Repair:9:0.6794	0.6794	9
IR	IR:21	inferior rectus:21:0.8594	0.8594	21
IR	IR:24	information retrieval:24:0.8768	0.8768	24
IR	IR:24	Infra-red:24:0.0032	0.0032	24
IR	IR:555|ir:7	infrared:562:0.0784	0.0784	562
IR	IR:58|ir:2	infrared spectroscopy:60:0.7703	0.7703	60
IR	IR:23	inhibition rate:23:0.1237	0.1237	23
IR	IR:522|I-R:2|ir:1|Ir:1	insulin receptor:497:0.9511|insulin receptors:29:0.4648	0.9511	526
IR	IR:298	Insulin resistance:298:0.8795	0.8795	298
IR	IR:33	insulin-resistant:22:0.0029|insulin resistant:11:0.3829	0.3829	33
IR	IR:13	intergenic region:13:0.1762	0.1762	13
IR	IR:15	intermediate risk:15:0.4951	0.4951	15
IR	IR:16	internal rotation:16:0.7261	0.7261	16
IR	IR:19	Interventional radiology:19:0.8449	0.8449	19
ir	ir:7|IR:4	intrarenal:11:0.0014	0.0014	11
IR	IR:153	inversion recovery:102:0.9116|inversion-recovery:51:0.0070	0.9116	153
IR	IR:125|ir:2	inverted repeat:101:0.8647|inverted repeats:26:0.8251	0.8647	127
IR	IR:8	ionizing irradiation:8:0.0756	0.0756	8
IR	IR:403|ir:1|I-R:1	ionizing radiation:405:0.8737	0.8737	405
IR	IR:34|I-R:18	ischaemia-reperfusion:52:0.0068	0.0068	52
IR	IR:14|I-R:5	ischemia and reperfusion:19:0.3556	0.3556	19
IR	IR:180|I-R:83	Ischemia-reperfusion:233:0.0324|ischemia/reperfusion:30:0.0041	0.0324	263
IR	IR:5	isovolumic relaxation:5:0.1132	0.1132	5
IR	IR:2|I-R:2	min of reperfusion:4:0.0622	0.0622	4
IR	IR:23	near-infrared:23:0.0031	0.0031	23
IR	IR:32|Ir:2|ir:1	Ratio:35:0.0047	0.0047	35
IR	IR:9	reaction:9:0.0011	0.0011	9
IR	IR:5|Ir:1	resistance index:6:0.1148	0.1148	6
IS/AAR	IS/AAR:5	expressed as a percentage of the area at risk:5:0.2827	0.2827	5
IS-2-MN	IS-2-MN:12|IS2MN:1|IS-2MN:1	isosorbide-2-mononitrate:14:0.5909	0.5909	14
IS-5-MN	IS-5-MN:81|Is-5-Mn:11|IS-5MN:4|IS5MN:4	isosorbide-5-mononitrate:91:0.8108|isosorbide 5-mononitrate:9:0.5470	0.8108	100
ISAAC	ISAAC:155	International Study of Asthma and Allergies in Childhood:155:0.9703	0.9703	155
ISAAC	ISAAC:6	International Study of Asthma and Allergy in Children:6:0.5290	0.5290	6
ISAGA	ISAGA:23|ISAgA:1	immunosorbent agglutination assay:24:0.7046	0.7046	24
ISAT	ISAT:8	International Subarachnoid Aneurysm Trial:8:0.6411	0.6411	8
ISAV	ISAV:47	infectious salmon anaemia virus:47:0.9353	0.9353	47
ISAV	ISAV:19	infectious salmon anemia virus:19:0.8449	0.8449	19
ISA	ISA:11	Index of Spouse Abuse:11:0.7357	0.7357	11
ISA	ISA:22	infectious salmon anaemia:22:0.7865	0.7865	22
ISA	ISA:12	infectious salmon anemia:12:0.7571	0.7571	12
ISA	ISA:8	internal surface area:8:0.4102	0.4102	8
ISA	ISA:186	intrinsic sympathomimetic activity:186:0.9744	0.9744	186
ISA	ISA:6	isotopomer spectral analysis:6:0.5290	0.5290	6
ISBAT	ISBAT:10	interscapular brown adipose tissue:10:0.5856	0.5856	10
ISB	ISB:12	Interscalene brachial plexus block:12:0.7571	0.7571	12
ISCC	ISCC:14	invasive squamous cell carcinoma:14:0.6911	0.6911	14
ISCD	ISCD:13	International Society for Clinical Densitometry:13:0.7753	0.7753	13
iSCI	iSCI:5|ISCI:2	incomplete spinal cord injury:7:0.5926	0.5926	7
iscoms	iscoms:20|ISCOMs:17|ISCOMS:13|Iscoms:2	immune-stimulating complexes:27:0.1342|immune stimulating complexes:25:0.8186	0.8186	52
ISCOMs	ISCOMs:36|iscoms:18|ISCOMS:7	immunostimulating complexes:61:0.3872	0.3872	61
ISCOM	ISCOM:4|iscom:3	immune-stimulating complexes:7:0.1025	0.1025	7
ISCOM	ISCOM:21|iscom:9	immunostimulating complex:22:0.3913|immunostimulating complexes:8:0.1471	0.3913	30
ISCs	ISCs:23	irreversibly sickled cells:23:0.8715	0.8715	23
ISDN	ISDN:24	Integrated Services Digital Network:24:0.8186	0.8186	24
ISDN	ISDN:461	isosorbide dinitrate:461:0.9737	0.9737	461
ISD	ISD:7	infantile seborrheic dermatitis:7:0.5926	0.5926	7
ISD	ISD:37	intrinsic sphincter deficiency:37:0.8051	0.8051	37
ISD	ISD:17	isosorbide dinitrate:17:0.8270	0.8270	17
ISEL	ISEL:105	situ end labeling:54:0.7824|situ end-labeling:51:0.7902	0.7902	105
ISEL	ISEL:33	situ end labelling:17:0.4742|situ end-labelling:16:0.6577	0.6577	33
ISFET	ISFET:7	ion sensitive field effect transistor:7:0.4438	0.4438	7
ISFETs	ISFETs:9	field effect transistors:9:0.6794	0.6794	9
ISF	ISF:17	immunosuppressive factor:11:0.3213|immunosuppressive factors:6:0.1838	0.3213	17
ISF	ISF:126|isf:1	interstitial fluid:127:0.9183	0.9183	127
ISF	ISF:12	isosafrole:12:0.0485	0.0485	12
ISGF3	ISGF-3:3|ISGF3:3	IFN-stimulated gene factor-3:6:0.1320	0.1320	6
ISGF-3	ISGF-3:5|ISGF3:1	interferon-stimulated gene factor-3:6:0.1320	0.1320	6
ISGs	ISGs:14	immature secretory granules:14:0.7909	0.7909	14
ISG	ISG:18	IFN-stimulated genes:11:0.3829|IFN-stimulated gene:7:0.1329	0.3829	18
ISG	ISG:59	immune serum globulin:59:0.9494	0.9494	59
ISG	ISG:12	International Study Group:12:0.7571	0.7571	12
ISHH	ISHH:75	situ hybridization histochemistry:75:0.9602	0.9602	75
ISHL	ISHL:11	idiopathic sudden hearing loss:11:0.7357	0.7357	11
ISHLT	ISHLT:30	International Society for Heart and Lung Transplantation:30:0.9237	0.9237	30
ISH	ISH:7	isocapnic hyperventilation:7:0.3524	0.3524	7
ISH	ISH:162	isolated systolic hypertension:162:0.9815	0.9815	162
ISH	ISH:109	situ hybridisation:109:0.8945	0.8945	109
ISH	ISH:1454|isH:1	situ hybridization:1455:0.9462	0.9462	1455
ISH	ISH:24	situ hybridization histochemistry:24:0.8768	0.8768	24
ISIAH	ISIAH:6	rats with inherited stress-induced arterial hypertension:6:0.4438	0.4438	6
ISIS	ISIS:12	image selected in vivo spectroscopy:12:0.7571	0.7571	12
ISIs	ISIs:184	interstimulus intervals:184:0.6445	0.6445	184
ISI	ISI:97	insulin sensitivity index:97:0.3806	0.3806	97
ISI	ISI:18	inter-stimulus intervals:18:0.0840	0.0840	18
ISI	ISI:116	International Sensitivity Index:116:0.4692	0.4692	116
ISI	ISI:19	interspike intervals:19:0.0913	0.0913	19
ISI	ISI:328	interstimulus interval:258:0.6093|interstimulus intervals:70:0.5242	0.6093	328
ISI	ISI:9	sensitivity indices:9:0.5470	0.5470	9
Isi	Isi:71|isi:12|iSi:1|ISi:1	slow inward current:85:0.7764	0.7764	85
ISLN	ISLN:9|iSLN:3	internal branch of the superior laryngeal nerve:12:0.7571	0.7571	12
ISMN	ISMN:29|IsMn:1|IS-MN:1|Is-MN:1	isosorbide-5-mononitrate:32:0.4921	0.4921	32
ISMN	ISMN:16	isosorbide mononitrate:16:0.5171	0.5171	16
ISMs	ISMs:13	intersegmental muscles:13:0.7753	0.7753	13
ISM	ISM:10	interstellar medium:10:0.4363	0.4363	10
ISNT	ISNT:20	situ nick translation:20:0.6680	0.6680	20
ISN	ISN:6	intersegmental nerve:6:0.1838	0.1838	6
ISO2	ISO2:26	oxygen saturation:26:0.8251	0.8251	26
ISOM	ISOM:9	inner stripe of the outer medulla:9:0.7571	0.7571	9
Iso	ISO:5|Iso:5	beta-adrenergic agonist isoprenaline:10:0.2275	0.2275	10
ISO	ISO:67	International Organization for Standardization:67:0.9326	0.9326	67
ISO	ISO:10	International Standards Organisation:10:0.7103	0.7103	10
ISO	ISO:43	International Standards Organization:33:0.9100|International Standard Organization:10:0.7103	0.9100	43
ISO	ISO:68|Iso:13|iso:2	isoflurane:83:0.0540	0.0540	83
ISO	ISO:6|Iso:3	isometric:9:0.0053	0.0053	9
ISO	ISO:14	isoprinosine:14:0.0087	0.0087	14
ISO	ISO:625|Iso:168|iso:9	isoproterenol:802:0.5340	0.5340	802
ISPCR	ISPCR:16|IS-PCR:9|isPCR:1	situ polymerase chain reaction:26:0.8861	0.8861	26
ISPs	ISPs:10	inflammation-sensitive plasma proteins:10:0.7103	0.7103	10
iSP	iSP:20|I-SP:9|ISP:3	immunoreactive substance P:32:0.8145	0.8145	32
ISP	ISP:9	intrasinus pressure:9:0.1690	0.1690	9
iSP	iSP:4|isp:1|ISP:1	ipsilateral silent period:6:0.3728	0.3728	6
ISP	ISP:19	Isepamicin:19:0.0427	0.0427	19
ISP	ISP:9|Isp:1	Isoprenaline:10:0.0237	0.0237	10
ISP	ISP:79|Isp:7|IsP:2	isoproterenol:88:0.2062	0.2062	88
ISP	ISP:6	isovolumic systolic pressure:6:0.3728	0.3728	6
ISP	ISP:18	Rieske iron-sulfur protein:18:0.2840	0.2840	18
ISRE	ISRE:177	response element:165:0.8873|response elements:12:0.5664	0.8873	177
ISREs	ISREs:13	response elements:13:0.5934	0.5934	13
ISRP	ISRP:19	internal surface reversed-phase:10:0.7103|internal-surface reversed-phase:9:0.1945	0.7103	19
ISRs	ISRs:9	Injection site reactions:9:0.6794	0.6794	9
ISRs	ISRs:9	Insulin secretion rates:9:0.6794	0.6794	9
ISRs	ISRs:9	intergenic spacer regions:9:0.6794	0.6794	9
ISR	ISR:149	in-stent restenosis:149:0.9215	0.9215	149
ISR	ISR:21	induced systemic resistance:21:0.7291	0.7291	21
ISR	ISR:35	insulin secretion rate:24:0.6767|insulin secretion rates:11:0.6182	0.6767	35
ISR	ISR:10|Isr:1	isradipine:11:0.0275	0.0275	11
ISS-ODN	ISS-ODN:11	oligodeoxynucleotide:11:0.5882	0.5882	11
ISSD	ISSD:7	infantile free sialic acid storage disease:7:0.5926	0.5926	7
ISSD	ISSD:9	infantile sialic acid storage disease:9:0.2102	0.2102	9
ISSHL	ISSHL:18	idiopathic sudden sensorineural hearing loss:18:0.8365	0.8365	18
ISSI	ISSI:17	Interview Schedule for Social Interaction:17:0.8270	0.8270	17
ISSR	ISSR:36	inter-simple sequence repeat:29:0.4777|inter-simple sequence repeats:7:0.3524	0.4777	36
ISSs	ISSs:16	Injury Severity Scores:16:0.8165	0.8165	16
ISS	ISS:81	idiopathic short stature:81:0.9415	0.9415	81
ISS	ISS:17	immunostimulatory DNA sequences:17:0.7407	0.7407	17
ISS	ISS:16	immunostimulatory sequences:16:0.1263	0.1263	16
ISS	ISS:16	Injury Severity Scale:16:0.7261	0.7261	16
ISS	ISS:820	Injury Severity Score:753:0.9804|Injury Severity Scores:67:0.8874	0.9804	820
ISs	ISs:25	insertion sequences:25:0.2495	0.2495	25
ISS	ISS:9	Internal State Scale:9:0.5470	0.5470	9
ISS	ISS:159	International Space Station:159:0.9697	0.9697	159
ISS	ISS:7	International Staging System:7:0.3524	0.3524	7
ISS	ISS:19	Istituto Superiore di Sanita:19:0.8449	0.8449	19
IST	IST:26	immunosuppressive therapy:26:0.7249	0.7249	26
IST	IST:12	Inappropriate sinus tachycardia:12:0.7357	0.7357	12
IST	IST:9	insulin stress test:9:0.6794	0.6794	9
IST	IST:8	insulin suppression test:8:0.6411	0.6411	8
IST	IST:16	International Stroke Trial:16:0.8045	0.8045	16
ISV	ISV:13	internal spermatic vein:13:0.7753	0.7753	13
ISV	ISV:7	interstitial volume:7:0.2902	0.2902	7
ISVPs	ISVPs:10	infectious subvirion particles:10:0.7103	0.7103	10
ISVPs	ISVPs:6	intermediate subviral particles:6:0.1838	0.1838	6
ISQ	ISQ:8	implant stability quotient:8:0.5006	0.5006	8
I-TAC	I-TAC:12|I-Tac:1	T cell alpha chemoattractant:13:0.6701	0.6701	13
ITAM	ITAM:96	immunoreceptor tyrosine-based activation motif:96:0.8355	0.8355	96
ITAM	ITAM:13	tyrosine-based activation motifs:13:0.6701	0.6701	13
ITAMs	ITAMs:43	immunoreceptor tyrosine-based activation motifs:43:0.8037	0.8037	43
ITAs	ITAs:33	internal thoracic arteries:33:0.8605	0.8605	33
ITBFS	ITBFS:9	iliotibial band friction syndrome:9:0.6794	0.6794	9
ITBV	ITBV:33	intrathoracic blood volume:33:0.9100	0.9100	33
ITBVI	ITBVI:19|ITB-VI:1	intrathoracic blood volume index:20:0.8525	0.8525	20
ITB	ITB:16	iliotibial band:16:0.8165	0.8165	16
ITB	ITB:34	intrathecal baclofen:34:0.8644	0.8644	34
ITCL	ITCL:9	Intestinal T-cell lymphoma:9:0.6794	0.6794	9
ITCZ	ITCZ:13	itraconazole:13:0.8000	0.8000	13
ITCs	ITCs:6	isolated tumor cells:6:0.3728	0.3728	6
ITCs	ITCs:54	isothiocyanates:54:0.7260	0.7260	54
ITC	ITC:8	isolated tumor cells:8:0.4102	0.4102	8
ITC	ITC:215	isothermal titration calorimetry:215:0.9861	0.9861	215
ITC	ITC:16	isothermal titration microcalorimetry:16:0.8165	0.8165	16
ITC	ITC:10	isothiocyanates:10:0.0242	0.0242	10
ITD	ITD:44	idiopathic torsion dystonia:44:0.9323	0.9323	44
ITD	ITD:9	impedance threshold device:9:0.6794	0.6794	9
ITD	ITD:1	interaural differences of time:1:0.1618	0.1618	1
ITD	ITD:7	interaural time:7:0.2113	0.2113	7
ITD	ITD:20	interaural time delay:20:0.8525	0.8525	20
ITD	ITD:91	interaural time difference:73:0.9147|interaural time differences:18:0.6903	0.9147	91
ITD	ITD:66	internal tandem duplication:55:0.8225|internal tandem duplications:11:0.7357	0.8225	66
ITD	ITD:5	ion trap detector:5:0.4422	0.4422	5
ITDs	ITDs:20	interaural temporal disparities:20:0.8525	0.8525	20
ITDs	ITDs:8	interaural time delays:8:0.6411	0.6411	8
ITDs	ITDs:69	interaural time differences:69:0.9316	0.9316	69
ITDs	ITDs:22	internal tandem duplications:22:0.8657	0.8657	22
ITE	ITE:28	in-the-ear:28:0.3913	0.3913	28
ITE	ITE:10	In-Training Examination:10:0.5856	0.5856	10
ITFs	ITFs:18|iTFs:1	inducible transcription factors:19:0.8449	0.8449	19
ITF	ITF:8	inducible transcription factors:8:0.6411	0.6411	8
ITF	ITF:11	infratemporal fossa:11:0.6182	0.6182	11
ITF	ITF:48	intestinal trefoil factor:48:0.9379	0.9379	48
ITF	ITF:5	tissue fluid:5:0.1132	0.1132	5
ITGCN	ITGCN:17	intratubular germ cell neoplasia:17:0.7407	0.7407	17
ITGV	ITGV:12	intrathoracic gas volume:12:0.6460	0.6460	12
ITG	ITG:6|itg:1|iTG:1	inferior temporal gyrus:8:0.6411	0.6411	8
ITH	ITH:7	immediate type hypersensitivity:7:0.5926	0.5926	7
ith	ith:11|ITH:4|I-Th:1	Intrathecal:16:0.2419	0.2419	16
ITIES	ITIES:2	interface of two immiscible electrolyte solutions:2:0.6794	0.6794	2
ITIMs	ITIMs:26|ITIMS:1	immunoreceptor tyrosine-based inhibitory motifs:27:0.8312	0.8312	27
ITIM	ITIM:8	immunoreceptor tyrosine-based inhibition motifs:8:0.6411	0.6411	8
ITIM	ITIM:55	immunoreceptor tyrosine-based inhibitory motif:41:0.7113|immunoreceptor tyrosine-based inhibitory motifs:14:0.7909	0.7909	55
ITIs	ITIs:19	intertrial intervals:19:0.5732	0.5732	19
ITI	ITI:21	Immune tolerance induction:21:0.8594	0.8594	21
ITI	ITI:94	inter-alpha-trypsin inhibitor:81:0.8167|inter-alpha-trypsin-inhibitor:13:0.0341	0.8167	94
ITI	ITI:61	intertrial interval:55:0.5789|intertrial intervals:6:0.1838	0.5789	61
Iti	Iti:14|ITI:14|ITi:2	transient inward current:30:0.8472	0.8472	30
ITK	Itk:4|ITK:4	T cell kinase:8:0.6411	0.6411	8
ITL	ITL:10	intrathyroidal lymphocytes:10:0.2643	0.2643	10
ITLC	ITLC:7	instant thin-layer chromatography:7:0.5926	0.5926	7
ITMS	ITMS:11	ion trap mass spectrometer:11:0.7357	0.7357	11
ITMS	ITMS:10	ion trap mass spectrometry:10:0.5000	0.5000	10
IT-MTX	IT-MTX:8|ITMTX:5	intrathecal methotrexate:13:0.6701	0.6701	13
ITM	ITM:10	intrathecal morphine:10:0.5856	0.5856	10
ITN	ITN:10	idiopathic trigeminal neuralgia:10:0.7103	0.7103	10
ITN	ITN:6	insecticide-treated nets:6:0.1838	0.1838	6
ITNs	ITNs:9	insecticide-treated bednets:9:0.5470	0.5470	9
ITNs	ITNs:37	insecticide-treated nets:37:0.4229	0.4229	37
ITPA	ITPA:10	Illinois Test of Psycholinguistic Abilities:10:0.7103	0.7103	10
ITPV	ITPV:23	intratracheal pulmonary ventilation:23:0.8594	0.8594	23
ITP	ITP:27	capillary isotachophoresis:27:0.2172	0.2172	27
ITP	ITP:29	idiopathic thrombocytopenia:29:0.1761	0.1761	29
ITP	ITP:1091	idiopathic thrombocytopenic purpura:1091:0.6936	0.6936	1091
ITP	ITP:63	immune thrombocytopenia:63:0.4596	0.4596	63
ITP	ITP:12	inosine 5'-triphosphate:12:0.7571	0.7571	12
ITP	ITP:20	Inosine triphosphate:20:0.7766	0.7766	20
ITP	ITP:32	intrathoracic pressure:32:0.5670	0.5670	32
ITP	ITP:10	Ion transport peptide:10:0.6794	0.6794	10
ITP	ITP:12	isotachophoretic:12:0.0056	0.0056	12
ITRA	ITRA:12|itra:1|Itra:1	itraconazole:14:0.9286	0.9286	14
ITRs	ITRs:70	inverted terminal repeats:70:0.8741	0.8741	70
ITR	ITR:72|itr:1	inverted terminal repeat:54:0.9448|inverted terminal repeats:19:0.8449	0.9448	73
ITR	ITR:9	inverted terminal repetition:9:0.6794	0.6794	9
ITS1	ITS1:27|ITS-1:23	internal transcribed spacer:50:0.8776	0.8776	50
ITS1	ITS1:61|ITS-1:16	internal transcribed spacer 1:77:0.9617	0.9617	77
ITS2	ITS2:45|ITS-2:6	Internal Transcribed Spacer 2:51:0.7902	0.7902	51
ITS2	ITS2:51|ITS-2:39	second internal transcribed spacer:90:0.7341	0.7341	90
ITS-2	ITS-2:4|ITS2:2	second internal transcribed spacer region:6:0.5290	0.5290	6
ITSs	ITSs:19	internal transcribed spacers:19:0.7044	0.7044	19
ITs	ITs:70	immunotoxins:70:0.0810	0.0810	70
ITS	ITS:514	internal transcribed spacer:440:0.9021|internal transcribed spacers:74:0.8975	0.9021	514
ITS	ITS:12	internal transcribed spacer region:12:0.7571	0.7571	12
ITS	ITS:8	interrupted time series:8:0.6411	0.6411	8
ITS	ITS:5|ITs:1	interstitial telomeric sequences:6:0.2827	0.2827	6
ITTs	ITTs:9	insulin tolerance tests:9:0.6794	0.6794	9
ITT	ITT:6	immune tolerance therapy:6:0.5290	0.5290	6
ITT	ITT:5	Insulin-induced hypoglycaemia:5:0.0902	0.0902	5
ITT	ITT:11	insulin-induced hypoglycemia:11:0.4232	0.4232	11
ITT	ITT:180	insulin tolerance test:165:0.9010|insulin tolerance tests:15:0.8045	0.9010	180
ITT	ITT:91	Intent-to-treat:91:0.1415	0.1415	91
ITT	ITT:105|itt:1	intention-to-treat:106:0.1631	0.1631	106
ITT	ITT:6	intention-to-treat analysis:6:0.1838	0.1838	6
ITT	ITT:7	intestinal transit time:7:0.4438	0.4438	7
ITT	ITT:10	intratesticular testosterone:10:0.7103	0.7103	10
ITU	ITU:73	intensive therapy unit:73:0.9591	0.9591	73
ITV	ITV:12	threshold valve:12:0.7571	0.7571	12
ITx	ITx:25|Itx:4	Intestinal transplantation:29:0.6392	0.6392	29
ITZ	ITZ:55	itraconazole:55:0.9000	0.9000	55
IT	IT:8	administered intrathecally:8:0.0532	0.0532	8
IT	IT:12	Ca2+ current:12:0.1573	0.1573	12
IT	IT:9	Immune Tolerance:9:0.2285	0.2285	9
IT	IT:128	immunotoxin:94:0.0500|immunotoxins:34:0.0183	0.0500	128
IT	IT:63	inferior temporal:63:0.9526	0.9526	63
IT	IT:26	inferior temporal cortex:26:0.8861	0.8861	26
IT	IT:26	inferotemporal:26:0.0134	0.0134	26
IT	IT:17	inferotemporal cortex:17:0.2128	0.2128	17
IT	IT:212	information technology:212:0.9501	0.9501	212
IT	IT:5	information transfer:5:0.0517	0.0517	5
IT	IT:17	inspection time:17:0.1973	0.1973	17
IT	IT:8	intensive therapy:8:0.0906	0.0906	8
IT	IT:16	intermediate trophoblast:16:0.7261	0.7261	16
IT	IT:14	intestinal transplantation:14:0.5589	0.5589	14
IT	IT:10	intimal thickness:10:0.5000	0.5000	10
IT	IT:260|it:12|It:1	intrathecal:273:0.1458	0.1458	273
IT	IT:32	Intrathymic:32:0.0167	0.0167	32
IT	IT:84|it:10	intratracheal:94:0.0500	0.0500	94
IT	IT:19	intratracheal instillation:19:0.8449	0.8449	19
IT	IT:32|it:3	intratracheally:35:0.0183	0.0183	35
IT	IT:14|it:1	intratumoral:15:0.0075	0.0075	15
IT	IT:17	specific immunotherapy:17:0.0516	0.0516	17
IT	IT:13	treatment:13:0.0065	0.0065	13
IUCDs	IUCDs:15|IUCDS:1	intrauterine contraceptive devices:16:0.7261	0.7261	16
IUCD	IUCD:99	intrauterine contraceptive device:81:0.7649|intrauterine contraceptive devices:18:0.6903	0.7649	99
IUD	IUD:116	intrauterine contraceptive device:94:0.8236|intrauterine contraceptive devices:22:0.7400	0.8236	116
IUD	IUD:470	intrauterine device:401:0.7053|intrauterine devices:69:0.5605	0.7053	470
IUdR	IUdR:42|IUDR:16|I-UdR:2|IudR:1	5-iodo-2'-deoxyuridine:47:0.2421|5-iodo-2-deoxyuridine:14:0.0684	0.2421	61
IUdR	IUdR:13|IUDR:9	5-iododeoxyuridine:22:0.1105	0.1105	22
IUdR	IUdR:38|IUDR:6|IudR:2|IUdr:1	iododeoxyuridine:47:0.2421	0.2421	47
IUDs	IUDs:157|IUDS:1	intrauterine devices:158:0.6350	0.6350	158
IUFD	IUFD:37	intrauterine fetal death:37:0.7492	0.7492	37
IUFD	IUFD:9	intrauterine fetal demise:9:0.6794	0.6794	9
IUF	IUF:8|i-UF:3	isolated ultrafiltration:11:0.7357	0.7357	11
IUGR	IUGR:6	growth retarded fetuses:6:0.3728	0.3728	6
IUGR	IUGR:33	intrauterine growth-restricted:20:0.6259|intrauterine growth restricted:13:0.6701	0.6701	33
IUGR	IUGR:316	intrauterine growth restriction:316:0.8919	0.8919	316
IUGR	IUGR:850	intrauterine growth retardation:850:0.8597	0.8597	850
IUGR	IUGR:64	Intrauterine growth retarded:33:0.6976|intrauterine growth-retarded:31:0.6572	0.6976	64
IUI	IUI:324	intrauterine insemination:316:0.8214|intrauterine inseminations:8:0.4102	0.8214	324
IUPs	IUPs:12	intrauterine pregnancies:12:0.7571	0.7571	12
IUP	IUP:15	intraurethral pressure:15:0.1241	0.1241	15
IUP	IUP:52	intrauterine pregnancy:52:0.8345	0.8345	52
IUP	IUP:33	intrauterine pressure:33:0.4045	0.4045	33
IUSSP	IUSSP:8	International Union for the Scientific Study of Population:8:0.6794	0.6794	8
IUS	IUS:26	intrauterine system:26:0.5218	0.5218	26
IUT	IUT:19	intrauterine transfusion:19:0.6106	0.6106	19
IUT	IUT:8	utero transplantation:8:0.4102	0.4102	8
IU	IU:6	idiopathic uveitis:6:0.1010	0.1010	6
IU	IU:11	Indiana University:11:0.6182	0.6182	11
IU	IU:7	intermediate uveitis:7:0.1641	0.1641	7
IU	IU:130|iu:1	international units:122:0.7142|International Unit:9:0.2500	0.7142	131
IU	IU:8|iu:1	Intrauterine:9:0.0276	0.0276	9
IVAG	IVAG:18|ivag:5	intravaginal:23:0.7097	0.7097	23
IVAP	IVAP:9	access port:9:0.6794	0.6794	9
IVAP	IVAP:11	vitro antibody production:11:0.6182	0.6182	11
IVBAT	IVBAT:9|IV-BAT:2	intravascular bronchioloalveolar tumor:11:0.6182	0.6182	11
IVBT	IVBT:25	intravascular brachytherapy:25:0.8816	0.8816	25
IVBT	IVBT:9	vitro bleeding test:9:0.3867	0.3867	9
IVBT	IVBT:9	vitro bleeding time:9:0.6794	0.6794	9
IVCD	IVCD:11|IVCd:1	inferior vena cava diameter:12:0.7571	0.7571	12
IVCP	IVCP:5|IVCp:1	inferior vena cava pressure:6:0.5290	0.5290	6
IVC-TA	IVC-TA:6	inferior vena cava-tricuspid annulus:6:0.5290	0.5290	6
IVCT	IVCT:11	isovolumic contraction time:11:0.3829	0.3829	11
IVCT	IVCT:46	vitro contracture test:46:0.7507	0.7507	46
IVCY	IVCY:12	intravenous cyclophosphamide:12:0.5050	0.5050	12
IVDAs	IVDAs:49	intravenous drug abusers:49:0.9046	0.9046	49
IVDA	IVDA:28	intravenous drug abuse:28:0.7905	0.7905	28
IVDA	IVDA:34|ivda:1	intravenous drug abusers:35:0.7952	0.7952	35
IVDA	IVDA:24|ivDA:1	intravenous drug addicts:25:0.6873	0.6873	25
IVDMD	IVDMD:8	vitro dry matter digestibility:8:0.6411	0.6411	8
IV-DSA	IV-DSA:46|IVDSA:31|ivDSA:2	intravenous digital subtraction angiography:79:0.9200	0.9200	79
IVDUs	IVDUs:184	intravenous drug users:184:0.8396	0.8396	184
IVDU	IVDU:17|IVdU:1	(E)-5-(2-iodovinyl)-2'-deoxyuridine:18:0.0885	0.0885	18
IVDU	IVDU:145	intravenous drug users:136:0.8656|intravenous drug user:9:0.4587	0.8656	145
IVD	IVD:14	interactive videodisc:14:0.7909	0.7909	14
IVD	IVD:40	intervertebral disc:40:0.9256	0.9256	40
IVD	IVD:22	ischemic vascular dementia:22:0.6178	0.6178	22
IVD	IVD:22	Isovaleryl-CoA dehydrogenase:22:0.7955	0.7955	22
IVD	IVD:12	Vitro Diagnostic:12:0.7571	0.7571	12
IVEM	IVEM:9	electron microscopy:9:0.6794	0.6794	9
IVET	IVET:32	vivo expression technology:32:0.9072	0.9072	32
IVF/ET	IVF/ET:23	vitro fertilization and embryo transfer:23:0.5466	0.5466	23
IVF/ET	IVF/ET:20	vitro fertilization/embryo transfer:20:0.4574	0.4574	20
IVF-ET	IVF-ET:185|IVFET:2	vitro fertilization and embryo transfer:187:0.8383	0.8383	187
IVFTT	IVFTT:19	intravenous fat tolerance test:19:0.7658	0.7658	19
IVF	IVF:6	fertilization in vitro:6:0.1148	0.1148	6
IVF	IVF:16	idiopathic ventricular fibrillation:16:0.6577	0.6577	16
IVF	IVF:48	in-vitro fertilisation:48:0.1845	0.1845	48
IVF	IVF:10	intravenous fluid:10:0.5000	0.5000	10
IVF	IVF:145	vitro fertilisation:145:0.6700	0.6700	145
IVF	IVF:1931|ivf:1	vitro fertilization:1932:0.6537	0.6537	1932
IVF	IVF:7	vitro fertilization and embryo transfer:7:0.2902	0.2902	7
IVF	IVF:34	vitro fertilized:25:0.5288|vitro-fertilized:9:0.0024	0.5288	34
IVGG	IVGG:40|ivGG:1	intravenous gamma-globulin:25:0.7249|intravenous gamma globulin:16:0.5171	0.7249	41
IVGG	IVGG:24|ivGG:1	intravenous gammaglobulin:25:0.7249	0.7249	25
IVGTTs	IVGTTs:32|IVGTTS:1	intravenous glucose tolerance tests:33:0.7525	0.7525	33
IVGTT	IVGTT:273|ivGTT:9|IV-GTT:5|iv-GTT:4	intravenous glucose tolerance test:244:0.8751|intravenous glucose tolerance tests:47:0.7191	0.8751	291
IVH	IVH:76	intravenous hyperalimentation:76:0.8819	0.8819	76
IVH	IVH:118	intraventricular haemorrhage:118:0.9124	0.9124	118
IVH	IVH:356	intraventricular hemorrhage:347:0.9544|intraventricular hemorrhages:9:0.5470	0.9544	356
IVIAT	IVIAT:10	antigen technology:10:0.7103	0.7103	10
IVIGs	IVIGs:11|IVIgs:6	intravenous immunoglobulins:17:0.6211	0.6211	17
IVIG	IVIG:30|IVIg:4	intravenous gamma globulin:20:0.6680|intravenous gamma-globulin:14:0.5589	0.6680	34
IVIG	IVIG:20|IVIg:5	intravenous gammaglobulin:25:0.5722	0.5722	25
IVIg	IVIg:5|IVIG:2	intravenous Ig:7:0.1470	0.1470	7
IVIG	IVIG:10|IVIg:1	intravenous IgG:11:0.2040	0.2040	11
IVIG	IVIG:115|IVIg:12	intravenous immune globulin:127:0.7801	0.7801	127
IVIG	IVIG:664|IVIg:378|IvIg:20|ivIG:6|ivIg:5|IvIG:1|IV-Ig:1|IV-IG:1	intravenous immunoglobulin:895:0.9171|intravenous immunoglobulins:181:0.7743	0.9171	1076
IVIG	IVIG:22|IVIg:9|ivIG:2	intravenous immunoglobulin G:33:0.5600	0.5600	33
IVIG	IVIG:8|IVIg:1|ivIg:1	intravenous immunoglobulin preparations:10:0.3145	0.3145	10
IVIG	IVIG:8|IVIg:5	intravenous immunoglobulin therapy:13:0.5335	0.5335	13
IVIM	IVIM:32	Intravoxel incoherent motion:32:0.8145	0.8145	32
IVIVC	IVIVC:13|IV-IVC:2	vitro-in vivo correlation:15:0.5348	0.5348	15
IVIVC	IVIVC:7	vivo correlations:7:0.3524	0.3524	7
IVIgG	IVIgG:7|IV-IgG:4|ivIgG:1|IvIgG:1	intravenous gammaglobulin:13:0.6701	0.6701	13
IVIgG	IVIgG:11|IV-IgG:1|ivIgG:1	Intravenous immunoglobulin:13:0.6701	0.6701	13
IVI	IVI:5	intravenous infusion:5:0.0902	0.0902	5
IVL	IVL:25	Intravascular lymphoma:25:0.5969	0.5969	25
IVL	IVL:34	intravascular lymphomatosis:34:0.9126	0.9126	34
IVL	IVL:17	Intravenous leiomyomatosis:17:0.6748	0.6748	17
IVL	IVL:10	vitro lipogenesis:10:0.5856	0.5856	10
IVMP	IVMP:35|IV-MP:1	Intravenous methylprednisolone:36:0.6738	0.6738	36
IVM	IVM:23	intravital microscopy:23:0.4486	0.4486	23
IVM	IVM:90|Ivm:1	ivermectin:91:0.1991	0.1991	91
IVM	IVM:9	maturation in vitro:9:0.2757	0.2757	9
IVM	IVM:186	vitro maturation:186:0.7833	0.7833	186
IVM	IVM:41	vitro matured:28:0.6839|vitro-matured:13:0.0265	0.6839	41
IVNAA	IVNAA:16	vivo neutron activation analysis:16:0.8165	0.8165	16
IVN	IVN:4|ivn:2	inferior ventricular nerve:6:0.5290	0.5290	6
IVN	IVN:25|ivn:1	intravenous nutrition:26:0.7760	0.7760	26
IVOX	IVOX:14	intravascular oxygenator:14:0.3585	0.3585	14
IVPCA	IV-PCA:3|IVPCA:3	intravenous patient-controlled analgesia:6:0.2827	0.2827	6
IVPD	IVPD:16	vitro protein digestibility:16:0.7261	0.7261	16
IVPs	IVPs:9	intravenous pyelograms:9:0.5470	0.5470	9
IVP	IVP:16	excretory urogram:16:0.7261	0.7261	16
IVP	IVP:39	excretory urography:39:0.6744	0.6744	39
IVP	IVP:61	intravenous pyelogram:52:0.8572|intravenous pyelograms:9:0.6794	0.8572	61
IVP	IVP:107|ivp:1	intravenous pyelography:108:0.9047	0.9047	108
IVP	IVP:34	intraventricular pressure:34:0.4389	0.4389	34
IVP	IVP:11	intravesical pressure:11:0.0732	0.0732	11
IVP	IVP:8	vitro embryo production:8:0.6411	0.6411	8
IVP	IVP:54	vitro produced:27:0.8312|vitro-produced:27:0.0606	0.8312	54
IVP	IVP:18	vitro production:18:0.4226	0.4226	18
IVRA	IVRA:24	intravenous regional anaesthesia:24:0.6539	0.6539	24
IVRA	IVRA:44	intravenous regional anesthesia:44:0.7220	0.7220	44
IVRO	IVRO:11	intraoral vertical ramus osteotomy:11:0.7357	0.7357	11
IVRP	IVRP:9	relaxation period:9:0.6794	0.6794	9
IVRT	IVRT:47	isovolumetric relaxation time:47:0.2145	0.2145	47
IVRT	IVRT:111|ivrt:1	Isovolumic relaxation time:112:0.6165	0.6165	112
IVR	IVR:38	interactive voice response:38:0.9217	0.9217	38
IVR	IVR:15	interventional radiology:15:0.6386	0.6386	15
IVR	IVR:7	intramolecular vibrational energy redistribution:7:0.5926	0.5926	7
IVR	IVR:9	isovolumetric regulation:9:0.5470	0.5470	9
IVR	IVR:8	isovolumic relaxation:8:0.2619	0.2619	8
IVR	IVR:10	ivermectin:10:0.0570	0.0570	10
IVS1	IVS1:5|IVS-1:3	first intervening sequence:8:0.4102	0.4102	8
IVST	IVST:18	interventricular septal thickness:18:0.6903	0.6903	18
IVSs	IVSs:20	intervening sequences:20:0.8525	0.8525	20
IVS	IVS:96|ivs:2|IVs:1	intervening sequence:85:0.9442|intervening sequences:14:0.7909	0.9442	99
IVS	IVS:20	interventricular septal:20:0.6259	0.6259	20
IVS	IVS:11	interventricular septal thickness:11:0.5355	0.5355	11
IVS	IVS:180	interventricular septum:180:0.8676	0.8676	180
IVS	IVS:7	interventricular septum thickness:7:0.5926	0.5926	7
IVS	IVS:6	Intravaginal electrical stimulation:6:0.5290	0.5290	6
IVS	IVS:9	intravaginal slingplasty:9:0.6794	0.6794	9
IVS	IVS:13	vitro sensitization:13:0.7753	0.7753	13
IVS	IVS:7	vitro stimulation:7:0.1850	0.1850	7
IVU	IVU:49	intravenous urogram:40:0.8839|intravenous urograms:9:0.6794	0.8839	49
IVU	IVU:206	intravenous urography:206:0.9030	0.9030	206
IVUS	IVUS:30	Intravascular ultrasonography:30:0.8472	0.8472	30
IVUS	IVUS:818	Intravascular ultrasound:818:0.9742	0.9742	818
IVUS	IVUS:19	Intravascular ultrasound imaging:19:0.7658	0.7658	19
IVA	IVA:14	isovaleric acidemia:14:0.7909	0.7909	14
IVB	IVB:13	intravascular brachytherapy:13:0.6701	0.6701	13
IWF	IWF:13	international working formulation:13:0.7753	0.7753	13
IWG	IWG:14	interdialytic weight gain:14:0.6911	0.6911	14
IWL	IWL:12	Insensible water loss:12:0.7571	0.7571	12
IWT	IWT:7	ice-water test:7:0.3524	0.3524	7
IXth	IXth:16	glossopharyngeal:16:0.9375	0.9375	16
IAQ	IAQ:45	indoor air quality:45:0.8964	0.8964	45
IAS	IAS:10	Illness Attitude Scales:10:0.7103	0.7103	10
IAS	IAS:9	Image Analysis System:9:0.6794	0.6794	9
iAs	iAs:18|i-As:2|IAs:1	inorganic arsenic:21:0.7865	0.7865	21
IAS	IAS:13	insulin autoimmune syndrome:13:0.7753	0.7753	13
IAS	IAS:25	interatrial septum:25:0.6240	0.6240	25
IAS	IAS:9	intermittent androgen suppression:9:0.6794	0.6794	9
IAS	IAS:140	internal anal sphincter:140:0.9786	0.9786	140
IAs	IAs:18	intracranial aneurysms:18:0.5560	0.5560	18
IA	IA:21|iA:1	A-current:22:0.0084	0.0084	22
IA	IA:15	A-type K+ current:15:0.1241	0.1241	15
IA	IA:22	activity:22:0.0084	0.0084	22
Ia	Ia:22	class II antigen:13:0.7753|class II antigens:9:0.6794	0.7753	22
Ia	Ia:14|I-A:1	Class II major histocompatibility complex:15:0.8045	0.8045	15
Ia	Ia:28	class II MHC:28:0.8369	0.8369	28
Ia	Ia:10|I-A:1	class II molecules:11:0.6182	0.6182	11
Ia	Ia:9|IA:1	component:10:0.0036	0.0036	10
Ia	Ia:23	I region-associated:9:0.2757|I-region associated:9:0.1585|I region associated:5:0.1973	0.2757	23
IA	IA:30	ibotenic acid:30:0.3118	0.3118	30
IA	IA:16	Idiopathic anaphylaxis:16:0.8165	0.8165	16
IA	IA:46	image analysis:46:0.7707	0.7707	46
IA	IA:21	immune adherence:21:0.8594	0.8594	21
Ia	Ia:10	immune-associated:10:0.0036	0.0036	10
IA	IA:56	immunoadsorption:56:0.0221	0.0221	56
IA	IA:9	immunoassay:9:0.0032	0.0032	9
ia	ia:8	incisors absent:8:0.4102	0.4102	8
IA	IA:22	indocyanine green angiography:22:0.8657	0.8657	22
IA	IA:8	Induced abortion:8:0.4587	0.4587	8
IA	IA:10	infantile autism:10:0.5856	0.5856	10
IA	IA:11	infarct area:11:0.1067	0.1067	11
IA	IA:16	inflammatory arthritis:16:0.6748	0.6748	16
IA	IA:25	inhibitory avoidance:25:0.7679	0.7679	25
IA	IA:7	innominate artery:7:0.1111	0.1111	7
IA	IA:11	insulin:11:0.0040	0.0040	11
IA	IA:20	Insulin antibodies:20:0.7766	0.7766	20
IA	IA:13	interarytenoid:13:0.0048	0.0048	13
IA	IA:10	Intestinal atresia:10:0.4363	0.4363	10
IA	IA:15	intimal area:15:0.1879	0.1879	15
IA	IA:12	intra-abdominal:12:0.0044	0.0044	12
IA	IA:87|ia:9|I-A:2|Ia:1|i-a:1	intra-arterial:100:0.0398	0.0398	100
IA	IA:9|ia:7	intra-arterially:16:0.0060	0.0060	16
IA	IA:33|ia:2|i-a:1	intra-articular:36:0.0141	0.0141	36
IA	IA:59|ia:8	intraarterial:67:0.0265	0.0265	67
IA	IA:28|ia:3	intraarticular:31:0.0120	0.0120	31
IA	IA:16	intracranial aneurysm:16:0.5171	0.5171	16
IA	IA:116	invasive aspergillosis:116:0.9589	0.9589	116
IA	IA:20	iodoacetamide:20:0.0076	0.0076	20
ia	ia:16	osteopetrotic:16:0.0060	0.0060	16
IA	IA:18	transient K+ current:18:0.1817	0.1817	18
IA	IA:18	transient outward current:18:0.3696	0.3696	18
IA	IA:14|Ia:1	transient potassium current:15:0.2189	0.2189	15
IbTX	IbTX:58|IBTX:14|IbTx:12|Ibtx:1	iberiotoxin:85:0.9659	0.9659	85
IBU	IBU:55|Ibu:18|ibu:3	ibuprofen:76:0.8721	0.8721	76
IB	IB:12	binding:12:0.0134	0.0134	12
IB	IB:34|Ib:5	ibuprofen:39:0.0464	0.0464	39
IB	IB:38|I-B:1	Immunoblot:39:0.0464	0.0464	39
IB	IB:16	inclusion bodies:16:0.8165	0.8165	16
IB	IB:44	infectious bronchitis:44:0.8620	0.8620	44
IB	IB:45	integrated backscatter:45:0.8369	0.8369	45
IB	IB:10	intrinsic bursting:10:0.1385	0.1385	10
IB	IB:16	intrinsically bursting:16:0.3317	0.3317	16
IB	IB:63	ipratropium bromide:63:0.8807	0.8807	63
IC	IC:7	cardiac index:7:0.3524	0.3524	7
IC	IC:14	component:14:0.0030	0.0030	14
IC	IC:9	controls:9:0.0019	0.0019	9
IC	IC:10	iliac crest:10:0.7103	0.7103	10
IC	IC:860|Ic:3|ic:1	immune complexes:680:0.9571|immune complex:173:0.8684|immune-complexes:11:0.0023	0.9571	864
IC	IC:20	immunocytochemistry:20:0.0044	0.0044	20
IC	IC:20|Ic:1	immunocytoma:21:0.0047	0.0047	21
IC	IC:13	impedance cardiography:13:0.7753	0.7753	13
IC	IC:9	impoverished:9:0.0021	0.0021	9
IC	IC:8	impoverished condition:8:0.1276	0.1276	8
IC	IC:15	impression cytology:15:0.2729	0.2729	15
IC	IC:10	imprint cytology:10:0.1273	0.1273	10
IC	IC:23	imprinting center:23:0.5719	0.5719	23
IC	IC:27	indeterminate colitis:27:0.5334	0.5334	27
IC	IC:36|Ic:1	indirect calorimetry:37:0.9197	0.9197	37
IC	IC:21	induction chemotherapy:21:0.4359	0.4359	21
IC	IC:20	Infection control:20:0.1764	0.1764	20
IC	IC:8	infectious centers:8:0.5006	0.5006	8
IC	IC:15	inferior cardiac:15:0.7096	0.7096	15
IC	IC:22	inferior collicular:22:0.7955	0.7955	22
IC	IC:494	inferior colliculus:494:0.9939	0.9939	494
IC	IC:18	informed consent:18:0.8365	0.8365	18
IC	IC:9	inhibitory concentration:9:0.1334	0.1334	9
ic	IC:6|ic:6	inoculated intracerebrally:12:0.1692	0.1692	12
IC	IC:11	inorganic carbon:11:0.7357	0.7357	11
IC	IC:110	inspiratory capacity:110:0.9427	0.9427	110
IC	IC:38	insular cortex:38:0.4464	0.4464	38
IC	IC:15	integrated circuit:15:0.8045	0.8045	15
IC	IC:7	integrated concentration:7:0.0692	0.0692	7
IC	IC:13	intensive care:13:0.5934	0.5934	13
IC	IC:11	intercalated:11:0.0023	0.0023	11
IC	IC:18	intercalated cells:18:0.1670	0.1670	18
IC	IC:23	intercellular communication:23:0.8038	0.8038	23
IC	IC:10	intercostal:10:0.0021	0.0021	10
IC	IC:20	intermediate compartment:20:0.7173	0.7173	20
IC	IC:11	intermittent catheterization:11:0.7357	0.7357	11
IC	IC:123|Ic:1	intermittent claudication:124:0.9759	0.9759	124
IC	IC:29|ic:3	internal capsule:32:0.9072	0.9072	32
IC	IC:10	internal carotid artery:10:0.5856	0.5856	10
IC	IC:24	internal control:24:0.2312	0.2312	24
IC	IC:21	interstitial cells:21:0.2116	0.2116	21
IC	IC:271	interstitial cystitis:271:0.9656	0.9656	271
ic	ic:10|IC:2|iC:1	interstitial nucleus of Cajal:13:0.7753	0.7753	13
IC	IC:7|ic:2	intracameral:9:0.0019	0.0019	9
IC	IC:12|ic:7	intracarotid:19:0.0042	0.0042	19
IC	IC:37|ic:9	intracellular:46:0.0105	0.0105	46
IC	IC:33|ic:23	intracerebral:56:0.0128	0.0128	56
IC	IC:25|ic:17	Intracisternal:42:0.0096	0.0096	42
ic	ic:9|IC:8	intracisternally:17:0.0037	0.0037	17
IC	IC:48|ic:5	intracoronary:53:0.0121	0.0121	53
IC	IC:18|ic:2	Intracranial:20:0.0044	0.0044	20
IC	IC:8	invasive cancer:8:0.2327	0.2327	8
IC	IC:19	invasive carcinoma:14:0.2636|invasive carcinomas:5:0.0612	0.2636	19
IC	IC:21	ion chromatographic:21:0.7865	0.7865	21
IC	IC:131	ion chromatography:131:0.8688	0.8688	131
IC	IC:6	ischaemic cardiopathy:6:0.1543	0.1543	6
IC	IC:5	ischemic cardiopathy:5:0.0736	0.0736	5
IC	IC:18	ischiocavernosus:18:0.0040	0.0040	18
IC	IC:8	systemic immune-complex:8:0.1730	0.1730	8
IDI	IDI:9	interdose interval:9:0.2757	0.2757	9
ID-I	ID-I:12|IDI:2	type I iodothyronine deiodinase:14:0.7909	0.7909	14
IdUrd	IdUrd:35	5-iodo-2'-deoxyuridine:35:0.2061	0.2061	35
IdUrd	IdUrd:12	5-iododeoxyuridine:12:0.0667	0.0667	12
IdUrd	IdUrd:97|IDURD:1	iododeoxyuridine:98:0.5879	0.5879	98
IDET	IDET:15	intradiscal electrothermal therapy:15:0.6386	0.6386	15
IdoA	IdoA:9	L-iduronic acid:9:0.4587	0.4587	9
Id	Id:33|id:1	anti-idiotype:34:0.0152	0.0152	34
Id	Id:26|ID:2|id:2	anti-idiotypic:30:0.0133	0.0133	30
id	id:3|ID:1	given either iv or intraduodenally:4:0.1618	0.1618	4
ID	ID:30|Id:1	identification:31:0.0133	0.0133	31
ID	ID:22|Id:1|id:1	identifier:24:0.0106	0.0106	24
Id	Id:24|id:3	idiotopes:16:0.0069|idiotope:11:0.0046	0.0069	27
Id	Id:170|id:10|ID:4	idiotype:141:0.0643|idiotypes:43:0.0193	0.0643	184
Id	Id:31|ID:2|id:2	idiotypic:35:0.0156	0.0156	35
ID	ID:116	immunodiffusion:116:0.0528	0.0528	116
ID	ID:19	incidence density:19:0.4852	0.4852	19
ID	ID:8	index of difficulty:8:0.2090	0.2090	8
ID	ID:10|Id:6	indomethacin:16:0.0069	0.0069	16
ID	ID:12	infant-directed:12:0.0051	0.0051	12
ID	ID:50	infectious disease:29:0.6928|infectious diseases:21:0.5721	0.6928	50
ID	ID:8	infective dermatitis:8:0.5006	0.5006	8
ID	ID:4|Id:4|id:1	inhibitor of differentiation:9:0.3069	0.3069	9
Id	Id:6|ID:1	inhibitor of DNA binding:7:0.4438	0.4438	7
ID	ID:36|id:2	injected dose:38:0.6005	0.6005	38
ID	ID:15	insertion/deletion:15:0.0064	0.0064	15
ID	ID:228	intellectual disability:194:0.9753|intellectual disabilities:34:0.9126	0.9753	228
ID	ID:41	internal derangement:41:0.9274	0.9274	41
ID	ID:72|id:2	internal diameter:74:0.5242	0.5242	74
ID	ID:76|id:30	intradermal:106:0.0483	0.0483	106
ID	ID:19|id:10	intradermally:29:0.0129	0.0129	29
ID	ID:27|id:10	intraduodenal:37:0.0165	0.0165	37
ID	ID:25	iodine deficiency:25:0.1563	0.1563	25
ID	ID:66	iron deficiency:66:0.5611	0.5611	66
ID	ID:35	iron-deficient:20:0.0087|iron deficient:15:0.5348	0.5348	35
ID	ID:22	isosorbide dinitrate:22:0.8657	0.8657	22
ID	ID:14	isotope dilution:14:0.6911	0.6911	14
ID	ID:8	microm inner diameter:8:0.0906	0.0906	8
ID	ID:9|I-D:1	one-dimensional:10:0.0041	0.0041	10
ID	ID:5	primary immunodeficiency:5:0.0612	0.0612	5
Ieq	Ieq:11	equivalent short-circuit current:11:0.6182	0.6182	11
IEQ	IEQ:7	Involvement Evaluation Questionnaire:7:0.5926	0.5926	7
IEQ	IEQ:8|IEq:1	islet equivalents:9:0.4587	0.4587	9
IE	IE:9	erythrocytes:9:0.0049	0.0049	9
IE	IE:6	idiopathic epilepsy:6:0.1838	0.1838	6
IE	IE:10	Idiopathic Erythrocytosis:10:0.7103	0.7103	10
IE	IE:628|ie:3	immediate-early:377:0.2314|immediate early:254:0.9581	0.9581	631
IE	IE:17	immunoelectrophoresis:17:0.0098	0.0098	17
IE	IE:422	infective endocarditis:422:0.7838	0.7838	422
I-E	I-E:9|IE:3	internal-external:12:0.0068	0.0068	12
IE	IE:7	islet equivalents:7:0.3524	0.3524	7
IE	IE:8	isometric exercise:8:0.1276	0.1276	8
I-E	I-E:7|IE:1	Locus of control:8:0.5006	0.5006	8
IE	IE:15	patients with infectious endocarditis:15:0.0853	0.0853	15
IFG	IFG:142	impaired fasting glucose:142:0.9452	0.9452	142
IFG	IFG:13	Impaired Fasting Glycaemia:13:0.6701	0.6701	13
IFG	IFG:10	impaired fasting glycemia:10:0.7103	0.7103	10
IFG	IFG:47|ifg:1	inferior frontal gyrus:48:0.9379	0.9379	48
Ig's	Ig's:10	immunoglobulins:10:0.8182	0.8182	10
Ig-like	Ig-like:13	immunoglobulin-like:13:0.8000	0.8000	13
IgA-CIC	IgA-CIC:12	circulating immune complexes:12:0.6460	0.6460	12
IgA1	IgA1:80	immunoglobulin A1:80:0.9627	0.9627	80
IgAGN	IgAGN:10|IgA-GN:7	IgA glomerulonephritis:17:0.4480	0.4480	17
IgAGN	IgAGN:10|IgA-GN:2	IgA nephropathy:12:0.6460	0.6460	12
IgAIC	IgAIC:11|IgA-IC:8	immune complexes:19:0.7658	0.7658	19
IgAN	IgAN:530|IgA-N:26|IGAN:4	IgA nephropathy:560:0.8584	0.8584	560
IgA-RF	IgA-RF:7|IgARF:1	IgA rheumatoid factor:8:0.5006	0.5006	8
IgAD	IgAD:20|IgA-D:11|IgAd:1	IgA deficiency:32:0.6111	0.6111	32
IgA	IgA:7	IgA nephropathy:7:0.3524	0.3524	7
IgA	IgA:11	immunoglobulin:11:0.0439	0.0439	11
IgA	IgA:13	immunoglobulin-A:13:0.0526	0.0526	13
IgD	IgD:45	immunoglobulin D:45:0.8335	0.8335	45
IGD	IGD:9	interglobular domain:9:0.4587	0.4587	9
IGD	IGD:5	isolated gonadotropin deficiency:5:0.1464	0.1464	5
IgE-BF	IgE-BF:16|IgEBF:2	IgE-binding factors:10:0.3867|IgE-binding factor:8:0.3463	0.3867	18
IgE	IgE:23	antibody:14:0.0090|antibodies:9:0.0055	0.0090	23
IGE	IGE:18	idiopathic generalised epilepsy:18:0.8365	0.8365	18
IGE	IGE:116	idiopathic generalized epilepsy:104:0.9543|idiopathic generalized epilepsies:12:0.7571	0.9543	116
IgE	IgE:21	immunoglobulin:21:0.0139	0.0139	21
IgE	IgE:1073|Ig-E:2|IGE:1	immunoglobulin E:1062:0.9311|Immunoglobulin-E:14:0.0090	0.9311	1076
IGF	IGF:13	immediate graft function:13:0.7753	0.7753	13
IGF	IGF:1357|Igf:1	insulin-like growth factor:1135:0.8898|insulin-like growth factors:223:0.9253	0.9253	1358
IgG1	IgG1:272	immunoglobulin G1:272:0.9468	0.9468	272
IgG2b	IgG2b:11	immunoglobulin G2b:11:0.6182	0.6182	11
IgG2	IgG2:41	immunoglobulin G2:41:0.8525	0.8525	41
IgG3	IgG3:24	immunoglobulin G3:24:0.8768	0.8768	24
IgG4	IgG4:18	immunoglobulin G4:18:0.7539	0.7539	18
IgGs	IgGs:18|IGGs:1	immunoglobulins:19:0.3051	0.3051	19
IgGs	IgGs:7	immunoglobulins G:7:0.2113	0.2113	7
IgG	IgG:10	autoantibodies:10:0.0017	0.0017	10
IgG	IgG:25	gamma-globulin:13:0.0022|gamma globulin:12:0.2083	0.2083	25
IgG	IgG:8	immune globulin:8:0.0863	0.0863	8
IgG	IgG:326|IGG:1	immunoglobulin:254:0.0468|immunoglobulins:73:0.0133	0.0468	327
IgG	IgG:3984|Ig-G:1	Immunoglobulin G:3945:0.9517|immunoglobulin-G:40:0.0072	0.9517	3985
IgG	IgG:10	immunoglobulin gamma:10:0.7103	0.7103	10
IgG	IgG:10	response:10:0.0017	0.0017	10
IgH	IgH:12|Igh:1	Ig heavy-chain:13:0.0575	0.0575	13
IgH	IgH:9|Igh:1	immunoglobulin H:10:0.3867	0.3867	10
IgH	IgH:36|IGH:5	immunoglobulin heavy:41:0.6691	0.6691	41
IgH	IgH:471|IGH:45|Igh:23|igh:3|igH:1|Ig-H:1	immunoglobulin heavy chain:462:0.8166|Immunoglobulin heavy-chain:82:0.7696	0.8166	544
IgH	IgH:61|IGH:14|Igh:1	immunoglobulin heavy chain gene:66:0.8024|immunoglobulin heavy chain genes:10:0.5000	0.8024	76
IgH	IgH:12|IGH:8|Igh:1	immunoglobulin heavy chain locus:15:0.6386|immunoglobulin heavy-chain locus:6:0.3728	0.6386	21
IGK	IGK:7|IgK:2|Igk:1	immunoglobulin kappa:10:0.2643	0.2643	10
IgK	IgK:4|Igk:2|Ig-K:1|IGK:1	kappa light chain:8:0.6411	0.6411	8
IgMN	IgMN:10|IGMN:1	nephropathy:11:0.9091	0.9091	11
IgM-RF	IgM-RF:41|IgMRF:1	IgM rheumatoid factor:27:0.7834|IgM-rheumatoid factor:15:0.1777	0.7834	42
IgM	IgM:38	immunoglobulin:38:0.0191	0.0191	38
IgM	IgM:1273|Igm:1|IGM:1	immunoglobulin M:1275:0.9198	0.9198	1275
IGP	IGP:7	imidazole glycerol phosphate:7:0.5926	0.5926	7
IGP	IGP:19|IgP:1	intragastric pressure:20:0.6680	0.6680	20
IGR	IGR:10	impaired glucose regulation:10:0.7103	0.7103	10
IGR	IGR:21	insect growth regulator:21:0.8594	0.8594	21
IGR	IGR:5	integrated gastrin response:5:0.2818	0.2818	5
IGR	IGR:22	intergenic region:22:0.8657	0.8657	22
IgSF	IgSF:76|Ig-SF:8|Igsf:3|IGSF:3	immunoglobulin superfamily:90:0.7107	0.7107	90
IgY	IgY:17	egg yolk antibody:9:0.5470|egg yolk antibodies:8:0.3455	0.5470	17
IgY	IgY:11	egg yolk immunoglobulin:6:0.3728|egg yolk immunoglobulins:5:0.1464	0.3728	11
IgY	IgY:14	immunoglobulin Y:14:0.7909	0.7909	14
IGF2	IGF2:75|IGF-2:58|Igf2:26|Igf-2:7	insulin-like growth factor 2:125:0.9080|insulin-like growth factor-2:41:0.8867	0.9080	166
IGF2	IGF2:54|Igf2:8|Igf-2:2|IGF-2:1|igf-2:1	insulin-like growth factor II:54:0.8862|insulin-like growth factor-II:12:0.7571	0.8862	66
IGF2	IGF2:15|Igf2:4	insulin-like growth factor II gene:19:0.6537	0.6537	19
IGS	IGS:6	Immuno gold staining:6:0.3728	0.3728	6
Igs	Igs:197|IgS:3|IGs:1	immunoglobulins:201:0.3984	0.3984	201
IGS	IGS:10	Immunogold staining:10:0.2643	0.2643	10
IGs	IGs:7	interchromatin granules:7:0.2452	0.2452	7
IGS	IGS:155	intergenic spacer:155:0.9325	0.9325	155
IGS	IGS:13	internal guide sequence:13:0.7753	0.7753	13
IG	IG:7|ig:2	administered intragastrically:9:0.1052	0.1052	9
Ig	Ig:53|ig:1	anti-immunoglobulin:54:0.0100	0.0100	54
IG	IG:1	flavors that were paired with intragastric:1:0.1010	0.1010	1
Ig	Ig:9	gating current:9:0.6794	0.6794	9
IG	IG:13|Ig:9|ig:1	immune globulin:23:0.7046	0.7046	23
Ig	Ig:26	immunoglobin:26:0.0046	0.0046	26
Ig	Ig:4421|IG:33|ig:21	immunoglobulin:3983:0.7643|immunoglobulins:492:0.0943	0.7643	4475
Ig	Ig:28	immunoglobulin-like:28:0.0052	0.0052	28
IG	IG:11|ig:2	intergenic:13:0.0023	0.0023	13
IG	IG:23|ig:5	intervention group:28:0.5634	0.5634	28
IG	IG:5	intraductal growth:5:0.0902	0.0902	5
Iin	Iin:22|iin:1	inward current:23:0.8038	0.8038	23
Ij	Ij:6	junctional current:6:0.1148	0.1148	6
IKl	IKl:4|Ikl:1	inward rectifier K+ current:5:0.4422	0.4422	5
Ile	Ile:44|ILE:4|ile:1	isoleucine:49:0.4324	0.4324	49
ImAA	ImAA:5	imidazole acetic acid:5:0.4422	0.4422	5
ImmH	ImmH:7|Imm-H:2	immucillin-H:9:0.8889	0.8889	9
IM	IM:18|im:4	administered intramuscularly:22:0.0676	0.0676	22
IM	IM:16|Im:12	current:28:0.0094	0.0094	28
IM	IM:36	idiopathic myelofibrosis:36:0.9174	0.9174	36
IM	IM:10|Im:5	imatinib mesylate:15:0.7096	0.7096	15
Im	Im:27|IM:7|im:2	imidazole:36:0.0121	0.0121	36
IM	IM:16|Im:3	immobilization:19:0.0062	0.0062	19
IM	IM:142	Indomethacin:142:0.0489	0.0489	142
IM	IM:9	Induced motion:9:0.6794	0.6794	9
IM	IM:13	Infant mortality:13:0.5335	0.5335	13
IM	IM:20	infantile myofibromatosis:20:0.8525	0.8525	20
IM	IM:429|Im:3	infectious mononucleosis:432:0.9751	0.9751	432
IM	IM:9	inflammatory myopathy:9:0.6794	0.6794	9
IM	IM:31	inner medulla:31:0.8519	0.8519	31
IM	IM:12	inner medullary:12:0.7571	0.7571	12
IM	IM:26|Im:1	inner membrane:27:0.5524	0.5524	27
IM	IM:17	intermediate:17:0.0056	0.0056	17
IM	IM:14	intermetatarsal:14:0.0045	0.0045	14
IM	IM:18	internal mammary:18:0.8365	0.8365	18
IM	IM:48	internal medicine:48:0.9027	0.9027	48
IM	IM:14	interstitial macrophages:14:0.6173	0.6173	14
IM	IM:5	interval mapping:5:0.0902	0.0902	5
IM	IM:268	intestinal metaplasia:268:0.9554	0.9554	268
IM	IM:12|I-M:2	intima-media:14:0.0045	0.0045	14
IM	IM:5	intracellular membranes:5:0.0736	0.0736	5
IM	IM:15|im:6	intrahepatic metastasis:21:0.5721	0.5721	21
IM	IM:63|Im:2	intramedullary:65:0.0222	0.0222	65
IM	IM:10	intramembranous:10:0.0031	0.0031	10
IM	IM:377|im:118|Im:1	intramuscular:496:0.1722	0.1722	496
IM	IM:12|im:1	intramuscular injection:13:0.4102	0.4102	13
IM	IM:9	ionomycin:9:0.0028	0.0028	9
IM	IM:34|Im:2	M-current:36:0.0125	0.0125	36
IM	IM:11	myocardial infarction:11:0.7357	0.7357	11
INCL	INCL:46	infantile neuronal ceroid lipofuscinosis:35:0.7117|infantile neuronal ceroid-lipofuscinosis:11:0.5355	0.7117	46
Inc	Inc:19|inc:3	incompatibility:22:0.1193	0.1193	22
INC	INC:64|InC:1	interstitial nucleus of cajal:65:0.9275	0.9275	65
iNO	iNO:174|INO:44|I-NO:3	Inhaled nitric oxide:221:0.9043	0.9043	221
INO	INO:44	internuclear ophthalmoplegia:44:0.8941	0.8941	44
Ins1P	Ins1P:8|Ins-1-P:1	inositol-1-phosphate:9:0.6667	0.6667	9
InsP(3)R	InsP(3)R:16|insP(3)R:1	inositol 1,4,5-trisphosphate receptor:11:0.7357|inositol 1,4,5-trisphosphate receptors:6:0.5290	0.7357	17
InsP(3)	InsP(3):63|Ins-P(3):1	inositol 1,4,5-trisphosphate:64:0.9033	0.9033	64
InsP(3)	InsP(3):13	inositol trisphosphate:13:0.4849	0.4849	13
InsP(6)	InsP(6):13	inositol hexakisphosphate:13:0.5335	0.5335	13
InsP1	InsP1:12	inositol monophosphate:12:0.5050	0.5050	12
InsP2	InsP2:19	inositol bisphosphate:19:0.5404	0.5404	19
InsP3R	InsP3R:30|InsP3-R:1|InsP3r:1	inositol 1,4,5-trisphosphate receptor:27:0.8903|Inositol 1,4,5-trisphosphate receptors:5:0.4422	0.8903	32
InsP3	InsP3:18	inositol 1,4,5-triphosphate:18:0.7658	0.7658	18
InsP3	InsP3:433|Ins-P3:8|insP3:1|Insp3:1	Inositol 1,4,5-trisphosphate:417:0.9090|inositol-1,4,5-trisphosphate:26:0.0341	0.9090	443
InsP3	InsP3:9	inositol triphosphate:9:0.3455	0.3455	9
InsP3	InsP3:121|Ins-P3:6|Insp3:1	inositol trisphosphate:128:0.7462	0.7462	128
InsP4	InsP4:14|Insp4:1|Ins-P4:1	inositol tetrakisphosphate:16:0.6024	0.6024	16
InsP5	InsP5:6|Ins-P5:1	inositol pentakisphosphate:7:0.3524	0.3524	7
InsP6	InsP6:29|InSP6:1|Ins-P6:1	inositol hexakisphosphate:31:0.5162	0.5162	31
InsP6	InsP6:12	Inositol hexaphosphate:12:0.6460	0.6460	12
InsPs	InsPs:39|Ins-Ps:1	inositol phosphates:40:0.7419	0.7419	40
Intacs	Intacs:6|INTACS:4	corneal ring segments:10:0.7103	0.7103	10
Iout	Iout:21|IOUT:1	outward current:22:0.7400	0.7400	22
IpaB	IpaB:5|ipaB:3	invasion plasmid antigen B:8:0.6411	0.6411	8
IpaC	IpaC:9	Invasion plasmid antigen C:9:0.6794	0.6794	9
IPF-1	IPF-1:24|IPF1:12|Ipf1:1	Insulin promoter factor-1:19:0.8449|insulin promoter factor 1:18:0.8365	0.8449	37
ISE	ISE:65	ion-selective electrode:35:0.4872|ion selective electrode:16:0.6024|Ion-selective electrodes:14:0.4367	0.6024	65
ISC	ISC:16	Ig-secreting cells:16:0.0593	0.0593	16
ISC	ISC:66	immunoglobulin-secreting cells:52:0.3067|immunoglobulin secreting cells:14:0.5111	0.5111	66
ISC	ISC:19|Is-c:1	Indian Subcontinent:20:0.8525	0.8525	20
ISC	ISC:9	intermittent self-catheterization:9:0.6794	0.6794	9
ISC	ISC:11	interstrand cross-links:11:0.5355	0.5355	11
ISC	ISC:14|isc:1	intersystem crossing:15:0.8045	0.8045	15
ISC	ISC:6	iron-sulfur cluster:6:0.2243	0.2243	6
ISC	ISC:28	irreversibly sickled cells:19:0.8449|irreversibly sickled cell:9:0.6794	0.8449	28
ISC	ISC:7|Isc:4	ischemia:11:0.0064	0.0064	11
Isc	Isc:1029|ISC:109|I-sc:2	short-circuit current:921:0.7890|short circuit current:193:0.9846|short-circuit currents:18:0.4672|short circuit currents:8:0.6411	0.9846	1140
ISOP	ISOP:22|Isop:7	isoproterenol:29:0.5833	0.5833	29
IS	IS:34|is:1	idiopathic scoliosis:35:0.8681	0.8681	35
IS	IS:13	immobilization stress:13:0.3134	0.3134	13
IS	IS:7	immune serum:7:0.3524	0.3524	7
IS	IS:18	immune system:18:0.3412	0.3412	18
IS	IS:25	immunological synapse:25:0.6240	0.6240	25
IS	IS:52	immunoscintigraphy:52:0.0226	0.0226	52
IS	IS:9	immunostaining:9:0.0035	0.0035	9
IS	IS:13	immunosuppressed:13:0.0053	0.0053	13
IS	IS:30	immunosuppression:30:0.0128	0.0128	30
IS	IS:34	immunosuppressive:34:0.0146	0.0146	34
IS	IS:11	immunosuppressive substance:11:0.2422	0.2422	11
IS	IS:11	immunosuppressive therapy:11:0.7357	0.7357	11
IS	IS:7	imperative stimulus:7:0.1329	0.1329	7
IS	IS:15	incentive spirometry:15:0.8045	0.8045	15
IS	IS:11	indoxyl sulfate:11:0.7357	0.7357	11
IS	IS:55	induced sputum:55:0.9458	0.9458	55
IS	IS:32	inescapable shock:32:0.6024	0.6024	32
IS	IS:72|Is:2	Infantile spasms:74:0.9596	0.9596	74
IS	IS:144|Is:4	infarct size:148:0.9210	0.9210	148
IS	IS:39	information systems:28:0.7905|information system:11:0.1430	0.7905	39
IS	IS:20	initial segment:20:0.4379	0.4379	20
IS	IS:10	inner segments:10:0.5856	0.5856	10
IS	IS:7|Is:3	insertion:10:0.0040	0.0040	10
IS	IS:186|Is:1	insertion sequence:152:0.9312|insertion sequences:35:0.7952	0.9312	187
IS	IS:48	insulin sensitivity:48:0.9027	0.9027	48
IS	IS:246|Is:2	internal standard:236:0.7673|internal standards:12:0.2699	0.7673	248
IS	IS:55	International Standard:46:0.1131|International Standards:9:0.1492	0.1492	55
IS	IS:5	interventricular septum:5:0.0736	0.0736	5
IS	IS:16	ionic strength:16:0.4832	0.4832	16
IS	IS:12|Is:1	ischaemic stroke:13:0.0732	0.0732	13
IS	IS:7|is:1|Is:1	ischemia:9:0.0035	0.0035	9
IS	IS:59|Is:4	ischemic stroke:63:0.7149	0.7149	63
IS	IS:8	isotonic saline:8:0.5006	0.5006	8
IS	IS:13|Is:3	score:16:0.0062	0.0062	16
Is	Is:11|is:9|IS:1	slow inward current:21:0.7865	0.7865	21
IS	IS:10	space:10:0.0040	0.0040	10
ITA	ITA:6	In-training assessment:6:0.2243	0.2243	6
ITA	ITA:298	internal thoracic artery:273:0.9890|internal thoracic arteries:25:0.8816	0.9890	298
ITO	ITO:59|ito:5	indium tin oxide:43:0.8263|indium-tin oxide:21:0.1722	0.8263	64
Ito	Ito:15	transient outward:15:0.7096	0.7096	15
Ito	Ito:101|ITO:16|ito:9	transient outward current:119:0.9350|transient outward currents:7:0.4438	0.9350	126
J-PEM	J-PEM:10	prescription-event monitoring in Japan:10:0.7103	0.7103	10
J2	J2:8	second-stage juveniles:8:0.2987	0.2987	8
J5	J5:6|J-5:1	Escherichia coli O111:B4:7:0.3524	0.3524	7
J5	J5:7|J-5:1	monoclonal antibody:8:0.3463	0.3463	8
J-5	J-5:3|J5:1	mutant Escherichia coli:4:0.1850	0.1850	4
J774	J774:22|J-774:1	macrophage cell line:23:0.5997	0.5997	23
J82	J82:9	human bladder carcinoma cell line:9:0.5470	0.5470	9
Jab1	Jab1:6|JAB1:4|jab1:1	Jun activation domain-binding protein 1:11:0.6182	0.6182	11
JACC	JACC:13	Japan Collaborative Cohort:13:0.7753	0.7753	13
JAK1	JAK1:18|Jak1:6|jak1:1|JAK-1:1	Janus kinase 1:26:0.8251	0.8251	26
JAK2	JAK2:7|Jak2:1|JAK-2:1	Janus kinase:9:0.2102	0.2102	9
JAK2	JAK2:94|Jak2:37|JAK-2:7|Jak-2:1	Janus kinase 2:125:0.8395|Janus kinase-2:14:0.4367	0.8395	139
JAK2	JAK2:3|Jak2:2|JAK-2:1	tyrosine kinase:6:0.0666	0.0666	6
JAK	JAK:122|Jak:35|jak:1	Janus kinase:128:0.7892|Janus Kinases:30:0.5940	0.7892	158
JAM1	JAM1:4|JAM-1:3	junctional adhesion molecule 1:7:0.4438	0.4438	7
JAMA	JAMA:19	Journal of the American Medical Association:19:0.8449	0.8449	19
JAM	JAM:34	junctional adhesion molecule:34:0.8245	0.8245	34
JAR	JAR:9|Jar:1	choriocarcinoma cells:10:0.2873	0.2873	10
JAR	JAR:10|JAr:6	choriocarcinoma cell line:16:0.4832	0.4832	16
JAR	JAR:4|JAr:2	human choriocarcinoma:6:0.1010	0.1010	6
JAR	JAR:27	jamming avoidance response:27:0.8903	0.8903	27
JAS	JAS:10	ankylosing spondylitis:10:0.7103	0.7103	10
JAs	Jas:5|JAs:5	jasmonates:10:0.0756	0.0756	10
JAS	JAS:7|Jas:5	jasplakinolide:12:0.0924	0.0924	12
JAS	JAS:70	Jenkins Activity Survey:70:0.9112	0.9112	70
JA	JA:15	Jasmonate:15:0.0444	0.0444	15
JA	JA:195	Jasmonic acid:195:0.9598	0.9598	195
JA	JA:39	juvenile arthritis:39:0.8455	0.8455	39
JBE	JBE:8	Japanese B encephalitis:8:0.5006	0.5006	8
JCAHO	JCAHO:148	Joint Commission on Accreditation of Healthcare Organizations:139:0.9815|Joint Commission on Accreditation of Healthcare Organizations':9:0.7357	0.9815	148
JCAH	JCAH:13|jcah:1	Joint Commission on Accreditation of Hospitals:14:0.8165	0.8165	14
JCA	JCA:349|jcA:2|jca:1	juvenile chronic arthritis:352:0.9915	0.9915	352
JCML	JCML:52	juvenile chronic myelogenous leukemia:52:0.9427	0.9427	52
JCML	JCML:8|jCML:1	juvenile chronic myeloid leukaemia:9:0.6794	0.6794	9
JCML	JCML:14|jCML:1	Juvenile chronic myeloid leukemia:15:0.7096	0.7096	15
JCOG	JCOG:27	Japan Clinical Oncology Group:27:0.7834	0.7834	27
JCP	JCP:11|Jcp:1	Japanese cedar pollen:12:0.7571	0.7571	12
JCQ	JCQ:18	Job Content Questionnaire:18:0.8270	0.8270	18
JCR	JCR:1	Journal of Citation Reports:1:0.7357	0.7357	1
JCRT	JCRT:14	Joint Center for Radiation Therapy:14:0.7909	0.7909	14
JCS	JCS:9	Jalowiec Coping Scale:9:0.6794	0.6794	9
JCV	JCV:28	human polyomavirus JC:28:0.4950	0.4950	28
JCV	JCV:14	JC polyomavirus:14:0.6911	0.6911	14
JC	JC:24	Jamestown Canyon:24:0.8115	0.8115	24
JDF	JDF:16	Juvenile Diabetes Foundation:16:0.8165	0.8165	16
JDMS	JDMS:18	Juvenile dermatomyositis:18:0.8365	0.8365	18
JDM	JDM:9	diabetes mellitus:9:0.6794	0.6794	9
JDM	JDM:84	Juvenile dermatomyositis:84:0.9081	0.9081	84
Jdm	Jdm:9	maximal transport rate:9:0.6794	0.6794	9
JDP2	JDP2:8|JDP-2:1	Jun dimerization protein 2:9:0.5470	0.5470	9
JDS	JDS:15	Japan Diabetes Society:15:0.7096	0.7096	15
JDV	JDV:21	Jembrana disease virus:21:0.8594	0.8594	21
JEB	JEB:9	junctional EB:9:0.5470	0.5470	9
JEB	JEB:57	junctional epidermolysis bullosa:57:0.8478	0.8478	57
JEG-3	JEG-3:6|JEG3:1|Jeg-3:1	choriocarcinoma cells:8:0.3463	0.3463	8
JEG-3	JEG-3:5|JEG3:1	human choriocarcinoma:6:0.1543	0.1543	6
JEG-3	JEG-3:7|JEG3:1	human choriocarcinoma cell line:8:0.2987	0.2987	8
JEV	JEV:317	Japanese encephalitis virus:317:0.9661	0.9661	317
JE	JE:433	Japanese encephalitis:433:0.9576	0.9576	433
JE	JE:11	Japanese encephalitis virus:11:0.7357	0.7357	11
JE	JE:59	junctional epithelium:59:0.8731	0.8731	59
JFL	JFL:8	Jack fruit lectin:8:0.6411	0.6411	8
JGA	JGA:108	juxtaglomerular apparatus:108:0.9286	0.9286	108
JGC	JGC:11	juxtaglomerular cells:11:0.5355	0.5355	11
JGCT	JGCT:12	juvenile granulosa cell tumor:12:0.7571	0.7571	12
JGCT	JGCT:7	Juxtaglomerular Cell Tumor:7:0.1025	0.1025	7
JG	JG:114|jg:1	juxtaglomerular:115:0.7651	0.7651	115
JHA	JHA:10|JHa:3	juvenile hormone analogue:13:0.6701	0.6701	13
JHBP	JHBP:13	juvenile hormone binding protein:13:0.7753	0.7753	13
JHE	JHE:41	Juvenile hormone esterase:41:0.9274	0.9274	41
JHF	JHF:23	Juvenile hyaline fibromatosis:23:0.8715	0.8715	23
JHH	JHH:18	Johns Hopkins Hospital:18:0.8365	0.8365	18
JHMV	JHMV:15	JHM strain of mouse hepatitis virus:15:0.7261	0.7261	15
JHR	JHR:6|J-HR:4	Jarisch-Herxheimer reaction:10:0.5000	0.5000	10
JHs	JHs:12	Juvenile hormones:12:0.7571	0.7571	12
JH	JH:9	H+ secretion:9:0.2500	0.2500	9
JH	JH:15|Jh:1	heavy chain:16:0.8165	0.8165	16
JH	JH:12	Juvenile Hemochromatosis:12:0.5664	0.5664	12
JH	JH:331	juvenile hormone:315:0.9847|juvenile hormones:16:0.7261	0.9847	331
JIB	JIB:40	Jejunoileal bypass:40:0.6628	0.6628	40
JICA	JICA:39	Japan International Cooperation Agency:39:0.8184	0.8184	39
JIP-1	JIP-1:23|JIP1:8	JNK-interacting protein-1:13:0.3331|JNK interacting protein 1:7:0.5006|JNK-interacting protein 1:7:0.1591|JNK interacting protein-1:4:0.1464	0.5006	31
JIT	JIT:14	just-in-time:14:0.8125	0.8125	14
JI	JI:10	jejunoileal:10:0.2143	0.2143	10
JLNS	JLNS:13	Jervell and Lange-Nielsen syndrome:13:0.7909	0.7909	13
JLN	JLN:9|J-LN:1	Jervell and Lange-Nielsen:10:0.7103	0.7103	10
JLP	JLP:14	juvenile laryngeal papillomatosis:14:0.7909	0.7909	14
JM8	JM8:14|JM-8:7	carboplatin:21:0.7407	0.7407	21
JMDP	JMDP:11	Japan Marrow Donor Program:11:0.6182	0.6182	11
JMML	JMML:11	juvenile myelomonocytic leukaemia:11:0.6182	0.6182	11
JMML	JMML:78	Juvenile myelomonocytic leukemia:78:0.9386	0.9386	78
JMPR	JMPR:7	Joint FAO/WHO Meeting on Pesticide Residues:7:0.5926	0.5926	7
JM	JM:38	Juxtamedullary:38:0.1814	0.1814	38
JM	JM:41	juxtamembrane:41:0.1961	0.1961	41
JNCL	JNCL:9	Juvenile NCL:9:0.5470	0.5470	9
JNCL	JNCL:25	juvenile neuronal ceroid lipofuscinosis:25:0.6873	0.6873	25
JNC	JNC:17	Joint National Committee:17:0.8270	0.8270	17
JND	JND:18|jnd:6	noticeable difference:24:0.5160	0.5160	24
JNK1	JNK1:9|JNK-1:2	c-Jun N-terminal kinase:11:0.5355	0.5355	11
JNK1	JNK1:54|JNK-1:10	c-Jun N-terminal kinase 1:50:0.7636|c-Jun N-terminal kinase-1:14:0.7909	0.7909	64
JNKs	JNKs:110	c-jun N-terminal kinases:110:0.7667	0.7667	110
JNK	JNK:1165|Jnk:2	c-Jun N-terminal kinase:1131:0.8307|c-Jun N-terminal kinases:36:0.6538	0.8307	1167
JNK	JNK:251|Jnk:2	c-Jun NH2-terminal kinase:239:0.8533|c-Jun NH2-terminal kinases:14:0.5589	0.8533	253
JNA	JNA:43	Juvenile nasopharyngeal angiofibroma:43:0.9308	0.9308	43
Jo2	Jo2:8|JO2:2	anti-Fas antibody:10:0.3470	0.3470	10
JOA	JOA:59	Japanese Orthopaedic Association:59:0.8954	0.8954	59
JOAG	JOAG:10	juvenile open-angle glaucoma:10:0.4363	0.4363	10
JOAG	JOAG:8	open angle glaucoma:8:0.6411	0.6411	8
JOD	JOD:11	diabetes:11:0.2857	0.2857	11
JOLs	JOLs:19	judgments of learning:19:0.6211	0.6211	19
JOR	JOR:44	jaw-opening reflex:44:0.6550	0.6550	44
JPA	JPA:14	juvenile pilocytic astrocytoma:14:0.7909	0.7909	14
JPEG	JPEG:52	Joint Photographic Experts Group:40:0.9256|joint Photographic Expert Group:12:0.7571	0.9256	52
JPS	JPS:10	Japan Pancreas Society:10:0.5856	0.5856	10
JPS	JPS:12	joint position sense:12:0.7571	0.7571	12
JPS	JPS:11	juvenile polyposis syndrome:11:0.7357	0.7357	11
jp	jp:30	jimpy:30:0.1119	0.1119	30
JP	JP:12	joining peptide:12:0.7571	0.7571	12
JP	JP:10	Juvenile papillomatosis:10:0.7103	0.7103	10
JP	JP:18	juvenile parkinsonism:18:0.6903	0.6903	18
JP	JP:80	juvenile periodontitis:80:0.9048	0.9048	80
JP	JP:17	juvenile polyposis:17:0.8270	0.8270	17
JP	JP:10	psychotropic drugs in Japanese pharmacopoeia:10:0.7103	0.7103	10
JRA	JRA:752	juvenile rheumatoid arthritis:752:0.9894	0.9894	752
JR	JR:10	Junctional rhythm:10:0.7103	0.7103	10
JSA	JSA:16	Society of Anesthesiologists:16:0.8165	0.8165	16
JSN	JSN:61	joint space narrowing:61:0.9511	0.9511	61
JSRV	JSRV:61	jaagsiekte sheep retrovirus:61:0.9229	0.9229	61
JSR	JSR:9|jSR:6|J-SR:1|j-SR:1	junctional sarcoplasmic reticulum:17:0.6748	0.6748	17
JSTX	JSTX:21|JSTx:4	Joro spider toxin:25:0.4917	0.4917	25
JSW	JSW:69	joint space width:69:0.9567	0.9567	69
JT	JT:10|J-T:1	Jahn-Teller:11:0.1695	0.1695	11
JVP	JVP:10	jugular venous pressure:10:0.6794	0.6794	10
Jv	Jv:8|JV:1	fluid:9:0.0258	0.0258	9
Jv	Jv:32|JV:6	fluid absorption:38:0.6005	0.6005	38
Jv	Jv:3|JV:2	fluid absorption rate:5:0.2818	0.2818	5
Jv	Jv:10|JV:6	fluid reabsorption:16:0.4274	0.4274	16
JV	JV:21	jugular vein:21:0.7865	0.7865	21
JV	JV:64	Junin virus:64:0.8452	0.8452	64
Jv	Jv:5	net water flux:5:0.1464	0.1464	5
Jv	Jv:7	volume flow:7:0.0777	0.0777	7
Jv	Jv:11	volume flux:11:0.1760	0.1760	11
Jv	Jv:6|JV:1	water flow:7:0.0777	0.0777	7
JXG	JXG:54	juvenile xanthogranuloma:54:0.9448	0.9448	54
JZ	JZ:10|Jz:1	junctional zone:11:0.7357	0.7357	11
JAK3	JAK3:29|Jak3:15	Janus kinase 3:44:0.7168	0.7168	44
JcDNV	JcDNV:9	Junonia coenia densovirus:9:0.6794	0.6794	9
JD	JD:16	Johne's disease:16:0.5564	0.5564	16
Jd	Jd:5	rate of uptake:5:0.0902	0.0902	5
Jj	Jj:12|jj:2	heterozygous:14:0.1354	0.1354	14
jj	jj:14|Jj:5	homozygous:19:0.1875	0.1875	19
jj	jj:12|Jj:5	jaundiced:17:0.1562	0.1562	17
Jmax	Jmax:6	electron transport:6:0.2243	0.2243	6
Jmax	Jmax:12	transport rate:12:0.3058	0.3058	12
JME	JME:173	juvenile myoclonic epilepsy:173:0.9723	0.9723	173
Jm----s	Jm----s:5|Jms:4	mucosal-to-serosal flux:9:0.1945	0.1945	9
Js----m	Js----m:4|Jsm:2|Js-m:1	serosal-to-mucosal flux:7:0.1850	0.1850	7
JS	JS:18	Joubert syndrome:18:0.5560	0.5560	18
JW	JW:11	Japanese White:11:0.7357	0.7357	11
K(ATP)	K(ATP):11	ATP-sensitive:11:0.0137	0.0137	11
K(ATP)	K(ATP):8	ATP-sensitive K:8:0.2090	0.2090	8
K(ATP)	K(ATP):236	ATP-sensitive K(+):159:0.8520|ATP-sensitive K+:77:0.7273	0.8520	236
K(ATP)	K(ATP):54	ATP-sensitive K(+) channels:18:0.5940|ATP-sensitive K(+) channel:16:0.4536|ATP-sensitive K+ channels:12:0.3275|ATP-sensitive K+ channel:8:0.3463	0.5940	54
K(ATP)	K(ATP):175	ATP-sensitive potassium:175:0.6083	0.6083	175
K(ATP)	K(ATP):58	ATP-sensitive potassium channels:29:0.5551|ATP-sensitive potassium channel:29:0.6392	0.6392	58
K(Ca)	K(Ca):31	Ca(2+)-activated K(+):31:0.5261	0.5261	31
K(Ca)	K(Ca):15	Ca(2+)-activated K(+) channels:11:0.4232|Ca(2+)-activated K(+) channel:4:0.0918	0.4232	15
K(Ca)	K(Ca):16	Ca2+-activated K+:16:0.2613	0.2613	16
K(Ca)	K(Ca):12	calcium-activated potassium:12:0.2549	0.2549	12
K(Ca)	K(Ca):6|k(Ca):1	K+ channel:7:0.1025	0.1025	7
K(d)	K(d):52|K(D):18|k(d):1	Dissociation constants:71:0.7520	0.7520	71
K(d)	K(d):13|K(D):6	distribution coefficients:11:0.2764|distribution coefficient:8:0.2327	0.2764	19
K(d)	K(d):5|K(D):1	sorption coefficients:6:0.0564	0.0564	6
k(L)a	k(L)a:8|K(L)a:7	transfer coefficient:15:0.6386	0.6386	15
K(OA)	K(OA):7|K(oa):1	octanol-air partition coefficient:8:0.5006	0.5006	8
K(oc)	K(oc):8|K(OC):5	coefficients:13:0.4286	0.4286	13
K(PS)	K(PS):10	permeability:10:0.6000	0.6000	10
K(a)	K(a):27|K(A):7	association constant:22:0.2071|Association constants:12:0.1830	0.2071	34
K(a)	K(a):4|K(A):3	Binding affinity:7:0.1211	0.1211	7
K(i)	K(i):6|k(i):3	inhibition:9:0.0278	0.0278	9
K(i)	K(i):37|K(I):4	inhibition constants:41:0.4772	0.4772	41
K(I)	K(I):5|K(i):1	required for half-maximal inactivation:6:0.2827	0.2827	6
K(IR)	K(IR):6|K(ir):3	channels:9:0.1702	0.1702	9
K(IR)	K(IR):7	Inwardly rectifying K+:7:0.5926	0.5926	7
K(m)	K(m):94|K(M):4|k(M):1	Michaelis constant:99:0.4731	0.4731	99
K(m)	K(m):56|k(m):1	Michaelis-Menten constant:57:0.2435	0.2435	57
k(on)	k(on):29	association rate constant:19:0.4852|association rate constants:10:0.6182	0.6182	29
K(ow)	K(ow):22|K(OW):5	partition coefficient:17:0.6748|partition coefficients:10:0.5856	0.6748	27
K(p)	K(p):5|K(P):2|k(p):1	partition coefficients:8:0.2987	0.2987	8
K(p)	K(p):6|K(P):2|k(p):1	permeability coefficient:9:0.2757	0.2757	9
K(V)	K(V):4|K(v):1	K(+) channels:5:0.0902	0.0902	5
K(V)	K(v):7|K(V):7	voltage-gated K(+):14:0.2524	0.2524	14
K+ATP	K+ATP:28|K+-ATP:1	ATP-sensitive K+:29:0.6648	0.6648	29
K+ATP	K+ATP:14	ATP-sensitive potassium:14:0.4071	0.4071	14
K+o	K+o:6|K+O:1	extracellular K+:7:0.2113	0.2113	7
K-BIT	K-BIT:8	Kaufman Brief Intelligence Test:8:0.5006	0.5006	8
K-wire	K-wire:16	Kirschner wire:16:0.8165	0.8165	16
K/DOQI	K/DOQI:30	Kidney Disease Outcomes Quality Initiative:30:0.8605	0.8605	30
K/L	K/L:14	Kellgren/Lawrence:14:0.5000	0.5000	14
K0.5	K0.5:21	constant:21:0.1802	0.1802	21
k10	k10:6|K10:3	elimination rate constant:9:0.6794	0.6794	9
K10	K10:31	keratin 10:31:0.5749	0.5749	31
K12	K12:5	Keratin 12:5:0.0902	0.0902	5
k12	k12:5|K12:1	peripheral compartment:6:0.2243	0.2243	6
K13	K13:6	keratin 13:6:0.1838	0.1838	6
K14	K14:46	keratin 14:46:0.7270	0.7270	46
K17	K17:11	Keratin 17:11:0.6182	0.6182	11
K18	K18:32	keratin 18:32:0.5213	0.5213	32
K19	K19:20|K-19:1	Keratin 19:21:0.4945	0.4945	21
K562	K562:24|K-562:3	human erythroleukemia:27:0.4992	0.4992	27
K5	K5:26	keratin 5:26:0.4692	0.4692	26
K6	K6:20	keratin 6:20:0.7173	0.7173	20
K8/18	K8/18:8	keratins 8 and 18:8:0.1125	0.1125	8
K8/18	K8/18:11	keratin polypeptides 8 and 18:11:0.6182	0.6182	11
K8	K8:20|k-8:1	keratin 8:21:0.4733	0.4733	21
K-ABC	K-ABC:32|KABC:1	Kaufman Assessment Battery for Children:33:0.9100	0.9100	33
KACh	KACh:10	muscarinic K+:10:0.5000	0.5000	10
KAHRP	KAHRP:20	knob-associated histidine-rich protein:20:0.7173	0.7173	20
KAIT	KAIT:9	Kaufman Adolescent and Adult Intelligence Test:9:0.6794	0.6794	9
KAP	KAP:12	kerma-area product:7:0.1850|kerma area product:5:0.4422	0.4422	12
KAP	KAP:20|Kap:2	kidney androgen-regulated protein:22:0.8657	0.8657	22
KAP	KAP:1	knowledge attitude and practice:1:0.9448	0.9448	1
KARs	KARs:23|KA-Rs:2	Kainate receptors:25:0.5969	0.5969	25
KAR	KAR:7|KAr:1	kainate receptor:8:0.2619	0.2619	8
KATP	KATP:15	ATP-sensitive:15:0.0177	0.0177	15
KATP	KATP:12	ATP-sensitive K:12:0.4153	0.4153	12
KATP	KATP:218|K-ATP:4|Katp:1	ATP-sensitive K+:223:0.8248	0.8248	223
KATP	KATP:71|K-ATP:2	ATP-sensitive K+ channels:46:0.6815|ATP-sensitive K+ channel:27:0.6455	0.6815	73
KATP	KATP:159|K-ATP:9|Katp:1	ATP-sensitive potassium:169:0.5693	0.5693	169
KATP	KATP:69	ATP-sensitive potassium channels:36:0.5704|ATP-sensitive potassium channel:33:0.5600	0.5704	69
KBD	KBD:8	diffusive mass transport coefficients:8:0.5006	0.5006	8
KBD	KBD:23	Kashin-Beck disease:23:0.5466	0.5466	23
KBM	KBM:7	keratinocyte basal medium:7:0.4438	0.4438	7
KBR	KBR:29	ketone body ratio:29:0.8978	0.8978	29
KBr	KBr:9	potassium bromide:9:0.6794	0.6794	9
KBS	KBS:10	Kluver-Bucy syndrome:10:0.5000	0.5000	10
KBS	KBS:17	Knowledge-Based Systems:9:0.5470|knowledge-based system:8:0.2987	0.5470	17
KBrO(3)	KBrO(3):11	potassium bromate:11:0.7357	0.7357	11
KBrO3	KBrO3:43	potassium bromate:43:0.9308	0.9308	43
kb	kb:12	1.1-kilobase:12:0.0037	0.0037	12
kb	kb:17	1.3-kilobase:17:0.0054	0.0054	17
kb	kb:9|Kb:1	1.4-kilobase:10:0.0030	0.0030	10
kb	kb:11	1.6-kilobase:11:0.0034	0.0034	11
kb	kb:9	2-kilobase:9:0.0027	0.0027	9
kb	kb:17	2.4-kilobase:17:0.0054	0.0054	17
kb	kb:15	2.7-kilobase:15:0.0047	0.0047	15
kb	kb:11	3.2-kilobase:11:0.0034	0.0034	11
kb	kb:9	3.6-kilobase:9:0.0027	0.0027	9
kb	kb:14	7-kilobase:14:0.0044	0.0044	14
kb	kb:9	8-kilobase:9:0.0027	0.0027	9
Kb	Kb:10	Binding constants:10:0.0958	0.0958	10
KB	KB:17	cell line:17:0.6211	0.6211	17
KB	KB:31|Kb:11	dissociation constant:42:0.5632	0.5632	42
KB	KB:12	human epidermoid carcinoma:12:0.2309	0.2309	12
KB	KB:11	human oral epidermoid carcinoma:11:0.6182	0.6182	11
KB	KB:41|kb:2	ketone bodies:26:0.8861|Ketone body:17:0.6211	0.8861	43
kb	kb:1315|Kb:23|KB:3	kilobases:997:0.3366|kilobase:344:0.1159	0.3366	1341
kb	kb:200|Kb:3|kB:1	kilobase pairs:170:0.8842|kilobase pair:25:0.2061|kilobase-pairs:9:0.0027	0.8842	204
KB	KB:7|K-B:2	Kleihauer-Betke:9:0.0027	0.0027	9
KB	KB:13	Knowledge Base:13:0.4444	0.4444	13
KCBP	KCBP:10	kinesin-like calmodulin-binding protein:10:0.7103	0.7103	10
KCC	KCC:14	cotransport:14:0.3250	0.3250	14
KCC	KCC:14	cotransporter:14:0.3250	0.3250	14
KCC2	KCC2:10	cotransporter:10:0.4500	0.4500	10
KCCQ	KCCQ:13	Kansas City Cardiomyopathy Questionnaire:13:0.7753	0.7753	13
KCCs	KCCs:9	cotransporters:9:0.7273	0.7273	9
KCH	KCH:8	King's College Hospital:8:0.6411	0.6411	8
KCM	KCM:9|K-CM:1	Keratinocyte-conditioned medium:10:0.3470	0.3470	10
KCN	KCN:104|KCn:1	potassium cyanide:105:0.8593	0.8593	105
KCOs	KCOs:49	channel openers:49:0.8068	0.8068	49
KCO	KCO:11|Kco:1	alveolar volume:12:0.3275	0.3275	12
KCO	KCO:7|Kco:2	carbon monoxide:9:0.6794	0.6794	9
KCO	KCO:15	carbon monoxide transfer coefficient:15:0.8045	0.8045	15
KCO	KCO:13	channel opener:13:0.5335	0.5335	13
KCO	KCO:4	per unit lung volume:4:0.4422	0.4422	4
KCs	KCs:45	keratinocytes:45:0.1467	0.1467	45
KCS	KCS:143	keratoconjunctivitis sicca:143:0.9270	0.9270	143
KCs	KCs:75	Kupffer cells:75:0.8804	0.8804	75
KCT	KCT:41	kaolin clotting time:41:0.8867	0.8867	41
KCZ	KCZ:28	ketoconazole:28:0.8182	0.8182	28
KCa	KCa:31|Kca:2	Ca(2+)-activated K+:33:0.2427	0.2427	33
KCa	KCa:6	Ca-activated K:6:0.0899	0.0899	6
KCa	KCa:26	Ca2+-activated K+:26:0.1748	0.1748	26
KCa	KCa:26|Kca:1|K-Ca:1	calcium-activated potassium:28:0.4805	0.4805	28
KCa	KCa:6	calcium-activated potassium channel:6:0.2243	0.2243	6
KCa	KCa:42|Kca:4|KCA:1	K+ channels:27:0.5729|K+ channel:20:0.4201	0.5729	47
KClO4	KClO4:9|KCLO4:2	potassium perchlorate:11:0.7357	0.7357	11
KCl	KCl:6	high potassium:6:0.1148	0.1148	6
KCl	KCl:263|KCL:4	potassium chloride:267:0.9888	0.9888	267
KC	KC:8|Kc:8	coefficient:16:0.0211	0.0211	16
Kc	Kc:8|kc:2|KC:1	constants:11:0.0140	0.0140	11
KC	KC:16	epidermal keratinocytes:16:0.0850	0.0850	16
KC	KC:20	kangaroo care:20:0.7766	0.7766	20
KC	KC:26	keratinocyte:26:0.0351	0.0351	26
KC	KC:8	Keratinocyte chemoattractant:8:0.0906	0.0906	8
KC	KC:15	keratinocyte-derived chemokine:15:0.7096	0.7096	15
KC	KC:18	keratoconus:18:0.0239	0.0239	18
KC	KC:16|Kc:1	Ketoconazole:17:0.0225	0.0225	17
KC	KC:216|Kc:9	Kupffer cells:189:0.8839|Kupffer cell:36:0.6953	0.8839	225
kc	kc:7|Kc:6	rate constant:13:0.1882	0.1882	13
KDEL	KDEL:24	Lys-Asp-Glu-Leu:24:0.5111	0.5111	24
Kde	Kde:4|kde:2	kappa deleting element:6:0.3728	0.3728	6
KDG	KDG:11	3-keto-desogestrel:11:0.2632	0.2632	11
KDO8P	KDO8P:10|Kdo-8-P:1|KDO-8-P:1|Kdo8P:1	3-deoxy-D-manno-2-octulosonate-8-phosphate:13:0.4615	0.4615	13
KDO	KDO:26|Kdo:1	2-keto-3-deoxyoctonate:27:0.0939	0.0939	27
KDO	KDO:12|Kdo:2	3-deoxy-D-manno-octulosonate:14:0.0469	0.0469	14
KDPG	KDPG:9	2-keto-3-deoxy-6-phosphogluconate:9:0.6667	0.6667	9
KDQOL	KDQOL:9|KD-QOL:1	kidney disease quality of life:10:0.7103	0.7103	10
KDR	KDR:10	kinase domain receptor:10:0.2446	0.2446	10
KDR	KDR:34|kdr:2	kinase insert domain-containing receptor:36:0.9174	0.9174	36
KDR	KDR:7	kinase insert domain-containing region:7:0.5926	0.5926	7
KDR	KDR:7	kinase insert domain receptor:7:0.4438	0.4438	7
kdr	kdr:27|KDR:1	knockdown resistance:28:0.6295	0.6295	28
KDR	KDR:6	receptor 2:6:0.2243	0.2243	6
KDR	KDR:10	VEGF receptor-2:10:0.5335	0.5335	10
KEH	KEH:9	King Edward VIII Hospital:9:0.6794	0.6794	9
k-ELISA	k-ELISA:10|KELISA:4|K-ELISA:1|k-Elisa:1	enzyme-linked immunosorbent assay:16:0.8270	0.8270	16
KETO	keto:8|KETO:8|Keto:1	ketoconazole:17:0.4706	0.4706	17
KET	KET:30|Ket:3|ket:1	ketamine:34:0.2845	0.2845	34
KET	KET:11|Ket:5	ketanserin:16:0.1293	0.1293	16
KET	KET:13|Ket:3	ketoconazole:16:0.1293	0.1293	16
KET	KET:6|Ket:4	ketoprofen:10:0.0776	0.0776	10
Ke	Ke:3|ke:2	elimination rate:5:0.0517	0.0517	5
Ke	Ke:26|ke:19|KE:3	elimination rate constant:48:0.7074	0.7074	48
KE	KE:9	kinetic energy:9:0.5470	0.5470	9
KE	KE:21	knee extension:21:0.7865	0.7865	21
KE	KE:32	Knee extensor:20:0.7766|knee extensors:12:0.7571	0.7766	32
Ke	Ke:6	total exchangeable potassium:6:0.1838	0.1838	6
KFD	KFD:15	Kikuchi-Fujimoto disease:15:0.1731	0.1731	15
KFD	KFD:18	Kyasanur Forest disease:18:0.7539	0.7539	18
KFSD	KFSD:14	Keratosis follicularis spinulosa decalvans:14:0.7909	0.7909	14
KFSH&RC	KFSH&RC:8	King Faisal Specialist Hospital and Research Centre:8:0.6411	0.6411	8
KFS	KFS:12	Klippel-Feil syndrome:12:0.6460	0.6460	12
KG-1	KG-1:14|KG1:1	cell line:15:0.6386	0.6386	15
KGDH	KGDH:17	alpha-ketoglutarate dehydrogenase:17:0.8270	0.8270	17
KGDHC	KGDHC:40|KGDHc:1	alpha-ketoglutarate dehydrogenase complex:41:0.8867	0.8867	41
KGF-2	KGF-2:9	Keratinocyte growth factor-2:9:0.6794	0.6794	9
KGFR	KGFR:21	keratinocyte growth factor receptor:21:0.8594	0.8594	21
KGFR	KGFR:33|KGF-R:3|KgfR:1	KGF receptor:37:0.5283	0.5283	37
KGF	KGF:451|Kgf:1	keratinocyte growth factor:452:0.9732	0.9732	452
KGM	KGM:22	keratinocyte growth medium:22:0.8657	0.8657	22
KGM	KGM:9	konjac glucomannan:9:0.4587	0.4587	9
KHB	KHB:12	Krebs-Henseleit bicarbonate:12:0.5664	0.5664	12
KHB	KHB:13	Krebs-Henseleit bicarbonate buffer:13:0.5335	0.5335	13
KHB	KHB:40|K-Hb:1	Krebs-Henseleit buffer:41:0.4858	0.4858	41
KHC	KHC:17|Khc:3	kinesin heavy chain:20:0.8525	0.8525	20
KHC	KHC:16	Kurosawa and Kusanagi-hypercholesterolemic:16:0.8165	0.8165	16
KHD	KHD:11	homology domain:11:0.7357	0.7357	11
KHF	KHF:18	Korean hemorrhagic fever:18:0.8365	0.8365	18
KHG	KHG:9	Keratohyalin granules:9:0.6794	0.6794	9
KHN	KHN:7	Knoop Hardness:7:0.2113	0.2113	7
KHN	KHN:16	Knoop hardness number:16:0.8165	0.8165	16
KHQ	KHQ:17	King's Health Questionnaire:17:0.6211	0.6211	17
KHS	KHS:9	kinky hair syndrome:9:0.6794	0.6794	9
KHS	KHS:11|KHs:1	Krebs-Henseleit solution:12:0.5664	0.5664	12
KH	KH:43	K homology:33:0.9100|K-homology:10:0.0266	0.9100	43
KH	KH:13	Ketamine hydrochloride:13:0.7753	0.7753	13
KH	KH:59|K-H:44	Krebs-Henseleit:103:0.3018	0.3018	103
KH	KH:6|K-H:1	Krebs-Henseleit buffer:7:0.2452	0.2452	7
KH	KH:20|K-H:4	Krebs-Henseleit solution:24:0.7151	0.7151	24
Ki's	Ki's:8|KI'S:1	constants:9:0.7273	0.7273	9
KIC	KIC:69	alpha-ketoisocaproate:69:0.2764	0.2764	69
KIC	KIC:43	alpha-ketoisocaproic acid:43:0.4998	0.4998	43
KIC	KIC:29|KIc:8	fracture toughness:37:0.9197	0.9197	37
KIC	KIC:14	ketoisocaproate:14:0.0528	0.0528	14
KID	KID:16	keratitis-ichthyosis-deafness:16:0.1829	0.1829	16
KID	KID:9	kinase-inducible domain:9:0.2500	0.2500	9
KIEs	KIEs:34	kinetic isotope effects:34:0.9126	0.9126	34
KIFs	KIFs:18	kinesin superfamily proteins:18:0.8449	0.8449	18
KIHD	KIHD:6	Kuopio Ischemic Heart Disease Risk Factor Study:6:0.3728	0.3728	6
KIM	KIM:8	kinase interaction motif:8:0.6411	0.6411	8
KIRs	KIRs:23	killer cell inhibitory receptors:23:0.8038	0.8038	23
KISS	KISS:5	German Nosocomial Infection Surveillance System:5:0.4422	0.4422	5
KKS	KKS:68	Kallikrein-kinin system:68:0.8374	0.8374	68
K-K	K-K:16|KK:5	kallikrein-kinin:21:0.1258	0.1258	21
KK	K-K:5|KK:5	Kedem-Katchalsky:10:0.0566	0.0566	10
KK	KK:13	plasma kallikrein:13:0.2309	0.2309	13
KLBP	KLBP:6	keratinocyte lipid-binding protein:6:0.5290	0.5290	6
KLC	KLC:9	keratosis lichenoides chronica:9:0.6794	0.6794	9
KLC	KLC:10|Klc:2	kinesin light chain:12:0.6460	0.6460	12
KLF4	KLF4:9|Klf4:5|klf4:1	Kruppel-like factor 4:15:0.6386	0.6386	15
KLF5	KLF5:10	Kruppel-like factor 5:10:0.5000	0.5000	10
KLF6	KLF6:11	Kruppel-like factor 6:11:0.5355	0.5355	11
KLH	KLH:175	keyhole limpet haemocyanin:175:0.8933	0.8933	175
KLH	KLH:627	keyhole limpet hemocyanin:627:0.8705	0.8705	627
KLH	KLH:11	Keyhole limpet hemocyanine:11:0.7357	0.7357	11
KLK1	KLK1:10|KLK-1:1	kallikrein:11:0.6250	0.6250	11
KLK	KLK:20|Klk:1	kallikrein:21:0.7692	0.7692	21
KLPs	KLPs:5|klps:2|Klps:1	kinesin-like proteins:8:0.5006	0.5006	8
KLRG1	KLRG1:13	killer cell lectin-like receptor G1:13:0.7753	0.7753	13
KLS	KLS:12	Kleine-Levin syndrome:12:0.5664	0.5664	12
KLT	KLT:9	Karhunen-Loeve Transform:9:0.6794	0.6794	9
KL	KL:67	c-kit ligand:67:0.3488	0.3488	67
Kl	Kl:7|KL:6|kl:1|k-l:1	constant:15:0.0418	0.0418	15
KL	KL:11|K-L:3	Karhunen-Loeve:14:0.0388	0.0388	14
K-L	K-L:9|KL:2	Kellgren-Lawrence:11:0.0299	0.0299	11
KL	KL:94	kit ligand:81:0.4390|kit-ligand:13:0.0358	0.4390	94
kl	kl:7|KL:3	klotho:10:0.0269	0.0269	10
KMP-11	KMP-11:11	Kinetoplastid membrane protein-11:11:0.5355	0.5355	11
KMnO4	KMnO4:35|KMNO4:1	potassium permanganate:36:0.8716	0.8716	36
Kn1	Kn1:7|KN1:2	KNOTTED-1:9:0.2222	0.2222	9
kn1	kn1:12|KN1:5|Kn1:3	knotted1:20:0.5556	0.5556	20
KNN	KNN:14|k-NN:10|kNN:10|K-NN:1|Knn:1	k-nearest neighbor:23:0.5236|K-nearest neighbors:13:0.5335	0.5335	36
k-NN	k-NN:6|KNN:3	K-nearest neighbour:9:0.4587	0.4587	9
KNO3	KNO3:9	potassium nitrate:9:0.5470	0.5470	9
KNP	KNP:20	Kruger National Park:20:0.7766	0.7766	20
KO2	KO2:15	Potassium superoxide:15:0.8045	0.8045	15
KOH	KOH:73	potassium hydroxide:73:0.9591	0.9591	73
KORs	KORs:12	kappa-opioid receptors:6:0.1320|kappa opioid receptors:6:0.5290	0.5290	12
KOS	KOS:10	herpes simplex virus type 1:10:0.5470	0.5470	10
Ko	Ko:5	external K:5:0.1132	0.1132	5
KO	KO:95|ko:6|Ko:1	knock-out:85:0.0719|knock out:17:0.5760	0.5760	102
KO	KO:747|ko:20|Ko:2|-KO:1	knockout:770:0.6523	0.6523	770
KO	KO:9	knockout mice:9:0.3069	0.3069	9
Kp1	Kp1:7	MoFe protein:7:0.2902	0.2902	7
KPI	KPI:19	karyopyknotic index:19:0.5113	0.5113	19
KPI	KPI:47	protease inhibitor:47:0.7507	0.7507	47
KPMCP	KPMCP:11	Kaiser Permanente Medical Care Program:11:0.7357	0.7357	11
KPTT	KPTT:8	kaolin partial thromboplastin time:8:0.6411	0.6411	8
KPZ	KPZ:35	Kardar-Parisi-Zhang:35:0.9444	0.9444	35
KRAB	KRAB:53	Kruppel-associated box:53:0.7413	0.7413	53
KRB	KRB:46|KRb:1	Krebs-Ringer Bicarbonate:37:0.6424|Krebs-Ringer-bicarbonate:10:0.0703	0.6424	47
KRB	KRB:13	Krebs-Ringer bicarbonate buffer:13:0.5335	0.5335	13
KRB	KRB:10	Krebs-Ringer bicarbonate solution:10:0.5856	0.5856	10
KRG	KRG:10	red ginseng:10:0.7103	0.7103	10
KRP	KRP:9	phosphate:9:0.2581	0.2581	9
KRV	KRV:19	Kilham rat virus:19:0.6537	0.6537	19
Kr	Kr:6|KR:3|kr:1	coefficient:10:0.0232	0.0232	10
Kr	Kr:9	gap gene Kruppel:9:0.2500	0.2500	9
KR	KR:12	ketoreductase:12:0.0284	0.0284	12
KR	KR:9	knotted reactor:9:0.6794	0.6794	9
KR	KR:66	knowledge of results:66:0.9087	0.9087	66
kr	kr:13|Kr:4|KR:1	rate constant:18:0.4934	0.4934	18
K-SADS	K-SADS:6	Schedule for Affective Disorders and Schizophrenia:6:0.3728	0.3728	6
K-SADS	K-SADS:10|KSADS:1	Schedule for Affective Disorders and Schizophrenia for School-Age Children:11:0.7357	0.7357	11
KSA	KSA:65	Kingdom of Saudi Arabia:65:0.9296	0.9296	65
KSCN	KSCN:31	potassium thiocyanate:31:0.8090	0.8090	31
KSC	KSC:13	Kennedy Space Center:13:0.7753	0.7753	13
KSFM	KSFM:6|K-SFM:1	keratinocyte serum-free medium:7:0.5926	0.5926	7
KSHV	KSHV:20|kshv:1	Kaposi's sarcoma-associated herpes virus:21:0.6812	0.6812	21
KSHV	KSHV:349	Kaposi's sarcoma-associated herpesvirus:349:0.8424	0.8424	349
KSI	KSI:32	isomerase:32:0.8611	0.8611	32
KSOM	KSOM:6	potassium simplex optimized medium:6:0.3728	0.3728	6
KSPGs	KSPGs:9	Keratan sulfate proteoglycans:9:0.6794	0.6794	9
KSPG	KSPG:17|KS-PG:1	keratan sulfate proteoglycan:18:0.8365	0.8365	18
KSP	KSP:77	Karolinska Scales of Personality:77:0.9612	0.9612	77
KSP	KSP:15	Lys-Ser-Pro:15:0.0993	0.0993	15
KS-R1	KS-R1:30	ampicillin suppository:30:0.6736	0.6736	30
KSS	KSS:97	Kearns-Sayre syndrome:97:0.8399	0.8399	97
KSS	KSS:9	Knee Society Score:9:0.6794	0.6794	9
KSS	KSS:9	Sleepiness Scale:9:0.6794	0.6794	9
KSR	KSR:36|ksr:4	kinase suppressor of ras:40:0.9256	0.9256	40
KS	KS:9	beta-ketoacyl synthase:9:0.1492	0.1492	9
ks	ks:14|Ks:11|KS:2	fractional rates of protein synthesis:14:0.6911|fractional rate of protein synthesis:13:0.6701	0.6911	27
KS	KS:21	Kallmann's syndrome:21:0.0514	0.0514	21
KS	KS:1389	Kaposi's sarcoma:1379:0.8790|Kaposi's sarcomas:10:0.5856	0.8790	1389
KS	KS:7	Karnofsky Scale:7:0.2902	0.2902	7
KS	KS:58	Kawasaki syndrome:58:0.1972	0.1972	58
KS	KS:150	keratan sulfate:150:0.9481	0.9481	150
KS	KS:48	keratan sulphate:48:0.8728	0.8728	48
KS	KS:10	ketosynthase:10:0.0036	0.0036	10
KS	KS:24	Klinefelter syndrome:24:0.0624	0.0624	24
KS	KS:13|K-S:9	Kolmogorov-Smirnov:22:0.0084	0.0084	22
KS	KS:8	patients with Klinefelter's syndrome:8:0.0756	0.0756	8
Ks	Ks:11|KS:3	synonymous:14:0.0052	0.0052	14
ks	ks:8|Ks:7|kS:1|KS:1	synthesis rates:9:0.4587|synthesis rate:8:0.2090	0.4587	17
Kt/V	Kt/V:16|KT/V:4|Kt/v:1	dialysis:21:0.1527	0.1527	21
Kt/V	Kt/V:10	dialysis adequacy:10:0.5000	0.5000	10
Kt/V	Kt/V:16	dialysis dose:16:0.6024	0.6024	16
Kt/V	Kt/V:11|KT/V:1	urea clearance:12:0.3524	0.3524	12
KTA	KTA:7	kidney transplant alone:7:0.5926	0.5926	7
KTA	KTA:10	kidney transplantation alone:10:0.7103	0.7103	10
KTI	KTI:6|Kti:1|KTi:1	Kunitz trypsin inhibitor:8:0.4102	0.4102	8
KTP	KTP:18	ketoprofen:18:0.1349	0.1349	18
KTP	KTP:9	kidney transplant patients:9:0.6794	0.6794	9
KTP	KTP:70	potassium titanyl phosphate:43:0.9323|potassium-titanyl-phosphate:27:0.2063	0.9323	70
KTS	KTS:40	Klippel-Trenaunay syndrome:40:0.8491	0.8491	40
KTWS	KTWS:13	Klippel-Trenaunay-Weber syndrome:13:0.6701	0.6701	13
KTW	KTW:13|K-T-W:1	Klippel-Trenaunay-Weber:14:0.5652	0.5652	14
KTX	KTX:19	kaliotoxin:19:0.2093	0.2093	19
KTx	KTx:6|K-Tx:1|KTX:1	kidney transplant:8:0.5006	0.5006	8
KTx	KTx:26|KTX:7|K-Tx:1	kidney transplantation:34:0.8245	0.8245	34
KTZ	KTZ:32|Ktz:4	ketoconazole:36:0.8974	0.8974	36
Kt	Kt:8|KT:1	affinity:9:0.0187	0.0187	9
K-T	K-T:9|KT:4	Cretaceous-Tertiary:13:0.0280	0.0280	13
KT	KT:12	keratinized tissue:12:0.7571	0.7571	12
KT	KT:9	ketoconazole:9:0.0187	0.0187	9
KT	KT:11|kt:1	Ketoprofen:12:0.0257	0.0257	12
KT	KT:17	Ketorolac tromethamine:17:0.7407	0.7407	17
KT	KT:13	kidney transplant:13:0.7753	0.7753	13
KT	KT:34	kidney transplantation:34:0.8245	0.8245	34
KU-2	KU-2:10	cell line:10:0.7103	0.7103	10
KUN	KUN:15	Kunjin virus:15:0.8045	0.8045	15
Ku	Ku:4|ku:2	influx constant:6:0.1320	0.1320	6
KWW	KWW:12	Kohlrausch-Williams-Watts:12:0.7333	0.7333	12
KW	KW:25|kw:3	kidney weight:28:0.7905	0.7905	28
Kw	Kw:11|kw:3	weighted kappa:14:0.6911	0.6911	14
Kw	Kw:8|kw:2	weighted kappa statistic:10:0.7103	0.7103	10
KXRF	KXRF:10|K-XRF:6	fluorescence:16:0.8333	0.8333	16
KYNA	KYNA:14	kynurenate:14:0.1016	0.1016	14
KYNA	KYNA:109|KynA:1	kynurenic acid:110:0.9728	0.9728	110
KYN	KYN:51|Kyn:15	kynurenic acid:66:0.9286	0.9286	66
KYN	KYN:30|Kyn:10|kyn:2	kynurenine:42:0.2752	0.2752	42
KYN	KYN:8|Kyn:1	L-kynurenine:9:0.0537	0.0537	9
KYN	KYN:5|Kyn:2	receptor antagonist kynurenate:7:0.2987	0.2987	7
KAL	KAL:14|Kal:2	kallikrein:16:0.3191	0.3191	16
Kanr	Kanr:4|kanr:3|KanR:2|kanR:1	kanamycin resistance:10:0.7103	0.7103	10
KAN	KAN:8|Kan:4|kan:3	kanamycin:15:0.3125	0.3125	15
kan	kan:7	kanamycin resistance gene:7:0.5926	0.5926	7
Karst.	Karst.:9	ascomycete Lachnum papyraceum:9:0.6794	0.6794	9
Kass	Kass:8|kass:1	association constant:9:0.2285	0.2285	9
Kas	Kas:4|KAs:1	association constants:5:0.1132	0.1132	5
KAs	KAs:16	Keratoacanthomas:16:0.1630	0.1630	16
KAS	KAS:13|Kas:2	synthase:15:0.1522	0.1522	15
Ka	Ka:5|ka:2	absorption rate:7:0.1111	0.1111	7
ka	ka:64|Ka:41	absorption rate constant:92:0.7155|absorption rate constants:13:0.2802	0.7155	105
KA	KA:10	acid (AMPA)/kainate:10:0.2643	0.2643	10
Ka	Ka:142|KA:28|ka:3|-Ka:1	affinity constant:124:0.1775|Affinity constants:50:0.1535	0.1775	174
ka	ka:17|Ka:8|KA:2	association:27:0.0097	0.0097	27
Ka	Ka:273|KA:25|ka:6|K-a:1	association constant:203:0.3076|association constants:102:0.3603	0.3603	305
ka	ka:8|Ka:1	association rate constants:9:0.1334	0.1334	9
Ka	Ka:7|KA:4	binding affinities:11:0.2972	0.2972	11
KA	KA:25|Ka:3	dissociation constants:28:0.0688	0.0688	28
KA	KA:810|Ka:87	kainic acid:897:0.9270	0.9270	897
KA	KA:18|Ka:4	kala-azar:22:0.0079	0.0079	22
KA	KA:62|Ka:1	keratoacanthoma:49:0.0180|keratoacanthomas:14:0.0049	0.0180	63
Ka	Ka:5	weak acids:5:0.0736	0.0736	5
Kd's	Kd's:11|KD's:3|kd's:1	dissociation constants:15:0.8045	0.8045	15
kdiss	kdiss:5|Kdiss:1	dissociation rate constant:6:0.5290	0.5290	6
Kd	Kd:9|kd:7|KD:3|kD:1	degradation:20:0.0032	0.0032	20
Kd	Kd:5|kd:2	disappearance rate:7:0.0777	0.0777	7
Kd	Kd:2381|KD:711|kd:41|kD:3|K-d:1|-Kd:1	dissociation constant:2523:0.8911|dissociation constants:615:0.8514	0.8911	3138
KD	KD:3|Kd:2	dissociation constant values:5:0.2818	0.2818	5
Kd	Kd:55|KD:6|kd:1	distribution coefficient:31:0.3860|distribution coefficients:31:0.3347	0.3860	62
KD	KD:433	Kawasaki disease:433:0.8170	0.8170	433
KD	KD:44	ketogenic diet:44:0.8620	0.8620	44
kD	kD:117|kd:102|Kd:23|KD:19	kilodaltons:160:0.0268|kilodalton:101:0.0169	0.0268	261
KD	KD:6|kd:4	Kinase-dead:10:0.0015	0.0015	10
KD	KD:8	kinase domain:8:0.4102	0.4102	8
Kd	Kd:13|kd:1|KD:1	partition coefficients:15:0.1175	0.1175	15
KD	KD:16|Kd:1	Potassium depletion:17:0.5760	0.5760	17
Keq	Keq:19	equilibrium constant:11:0.4232|equilibrium constants:8:0.2327	0.4232	19
Kf,c	Kf,c:51|Kf,C:4|KF,C:2	capillary filtration coefficient:57:0.7923	0.7923	57
Kfc	Kfc:32|KfC:1	capillary filtration coefficient:33:0.6111	0.6111	33
Kf	Kf:29|KF:1	capillary filtration coefficient:30:0.2132	0.2132	30
KF	KF:8|Kf:5	DNA polymerase I:13:0.6460	0.6460	13
Kf	Kf:9	filtration capacity:9:0.5470	0.5470	9
Kf	Kf:20	glomerular capillary ultrafiltration coefficient:20:0.8525	0.8525	20
KF	KF:21|Kf:2	Klenow fragment:23:0.8816	0.8816	23
KF	KF:10	Kolliker-Fuse:10:0.0177	0.0177	10
KF	KF:15	Kolliker-Fuse nucleus:15:0.8045	0.8045	15
KF	KF:9	potassium fluoride:9:0.6794	0.6794	9
Ki-1	Ki-1:5|KI-1:1|Ki1:1	large cell anaplastic:7:0.5926	0.5926	7
Ki-67	Ki-67:25|Ki67:6	cell proliferation:31:0.2340	0.2340	31
Ki67	Ki67:8|Ki-67:4	growth fraction:12:0.5050	0.5050	12
Ki-67	Ki-67:8|KI-67:1	nuclear antigen:9:0.1273	0.1273	9
Ki-67	Ki-67:14|Ki67:6|KI-67:1	proliferation index:21:0.4945	0.4945	21
Ki-67	Ki-67:8|Ki67:2	proliferation marker:10:0.3470	0.3470	10
Ki-67	Ki-67:9|Ki67:1	proliferative activity:10:0.3867	0.3867	10
Ki-67	Ki-67:4|Ki67:2|ki-67:2	proliferative index:8:0.0789	0.0789	8
KiMSV	KiMSV:22|Ki-MSV:18|KiMsv:1	Kirsten murine sarcoma virus:41:0.7952	0.7952	41
Kir6.2	Kir6.2:6	inwardly rectifying K(+) channel:6:0.5290	0.5290	6
Kir6.2	Kir6.2:3|KIR6.2:1	inwardly rectifying potassium channel:4:0.1618	0.1618	4
Kir6.2	Kir6.2:8	pore-forming subunit:8:0.2619	0.2619	8
Kir	Kir:14|KIR:5	inward rectifier:19:0.8449	0.8449	19
Kir	Kir:7|KIR:3	Inward rectifier K+:10:0.7103	0.7103	10
Kir	Kir:4|KIR:1	inward rectifier potassium channels:5:0.4422	0.4422	5
Kir	Kir:34|KIR:6	inwardly rectifying K+:26:0.8251|inwardly rectifying K(+):14:0.6911	0.8251	40
Kir	Kir:4|KIR:2	inwardly rectifying K+ channel:6:0.5290	0.5290	6
Kir	Kir:23|KIR:1	inwardly rectifying potassium:24:0.8768	0.8768	24
KIR	KIR:5|Kir:3	K+ channels:8:0.1809	0.1809	8
KIR	KIR:28	Killer cell Ig-like receptor:15:0.8045|killer cell Ig-like receptors:13:0.7753	0.8045	28
KIR	KIR:51	killer cell immunoglobulin-like receptors:29:0.8978|killer cell immunoglobulin-like receptor:22:0.8657	0.8978	51
KIR	KIR:46	Killer cell inhibitory receptors:31:0.8090|killer cell inhibitory receptor:15:0.8045	0.8090	46
KIR	KIR:21	killer Ig-like receptors:13:0.2309|Killer Ig-like receptor:8:0.1004	0.2309	21
KIR	KIR:26	killer immunoglobulin-like receptor:14:0.1669|killer immunoglobulin-like receptors:12:0.1105	0.1669	26
KIR	KIR:30	killer inhibitory receptors:16:0.1593|killer inhibitory receptor:14:0.2524	0.2524	30
Ki	Ki:7|KI:2	complex:9:0.0049	0.0049	9
Ki	Ki:25|KI:6|ki:4	inhibition:35:0.0209	0.0209	35
Ki	Ki:495|KI:23|ki:5	inhibition constant:321:0.4744|inhibition constants:202:0.5312	0.5312	523
KI	KI:12|Ki:1	Karnofsky Index:13:0.0932	0.0932	13
KI	KI:78	potassium iodide:78:0.9025	0.9025	78
Ki	Ki:15	transfer coefficient:15:0.4052	0.4052	15
Ki	Ki:5	unidirectional influx rate:5:0.1973	0.1973	5
Ki	Ki:16	uptake:16:0.0098	0.0098	16
Km*	Km*:6	apparent Michaelis constant:6:0.2827	0.2827	6
KMC	KMC:18	kangaroo mother care:18:0.8365	0.8365	18
Kmf	Kmf:6	unidirectional maternofetal clearance:6:0.5290	0.5290	6
KmR	KmR:19|Kmr:17	kanamycin resistance:22:0.8657|kanamycin-resistance:14:0.1398	0.8657	36
kmr	kmr:5|KmR:2|Kmr:2	kanamycin resistance gene:9:0.6794	0.6794	9
Km	Km:5	apparent Michaelis:5:0.0902	0.0902	5
Km	Km:6|KM:3	apparent Michaelis-Menten:9:0.3455	0.3455	9
KM	KM:79|Km:56|km:1	kanamycin:136:0.0755	0.0755	136
KM	KM:21|K-M:6	Kaplan-Meier:27:0.0145	0.0145	27
Km	Km:4|KM:2	kappa light chain:6:0.2827	0.2827	6
KM	KM:12	Knowledge management:12:0.7571	0.7571	12
K-M	K-M:6|KM:3	Kubelka-Munk:9:0.0045	0.0045	9
Km	Km:93|KM:7|kM:1|km:1	Michaelis constants:102:0.5399	0.5399	102
Km	Km:25|KM:3	Michaelis-Menten constants:28:0.1067	0.1067	28
Kn	Kn:8|KN:7	kinetin:15:0.1458	0.1458	15
Koc	Koc:16|KOC:2	coefficients:18:0.3400	0.3400	18
Koc	Koc:9|KOC:1	partition coefficient:10:0.3867	0.3867	10
KOOS	KOOS:15	Knee injury and Osteoarthritis Outcome Score:15:0.7753	0.7753	15
KOR	KOR:67|kOR:1	kappa opioid receptor:32:0.9072|kappa-opioid receptor:31:0.3379|kappa-opioid receptors:5:0.1132	0.9072	68
Kow	Kow:11	Octanol-water partition coefficients:11:0.3495	0.3495	11
Kow	Kow:35|KOW:2	partition coefficient:37:0.7758	0.7758	37
KPS	KPS:63	karnofsky Performance Scale:63:0.9018	0.9018	63
KPS	KPS:49	Karnofsky Performance Score:49:0.8753	0.8753	49
KPS	KPS:215	Karnofsky performance status:215:0.9068	0.9068	215
Kp	Kp:20	concentration ratio:20:0.8525	0.8525	20
KP	KP:11	Kaiser Permanente:11:0.7357	0.7357	11
KP	KP:38|Kp:2	ketoprofen:40:0.0837	0.0837	40
KP	KP:10	kidney-pancreas:10:0.0193	0.0193	10
KP	KP:12|Kp:4	Klebsiella pneumoniae:16:0.8165	0.8165	16
KP	KP:5	knob protein:5:0.0736	0.0736	5
KP	KP:7	Korsakoff's psychosis:7:0.3524	0.3524	7
KP	KP:13	Kynurenine pathway:13:0.7753	0.7753	13
Kp	Kp:53|KP:3|kp:1	Partition coefficients:29:0.4752|Partition coefficient:28:0.4193	0.4752	57
Kp	Kp:29|kp:2	permeability coefficient:16:0.1787|permeability coefficients:15:0.1645	0.1787	31
Kp	Kp:13|kp:2|KP:1	permeability constants:8:0.1367|permeability constant:8:0.0863	0.1367	16
kq	kq:4|Kq:1|kQ:1	quenching rate constants:6:0.2243	0.2243	6
KRL	KRL:9	krypton red laser:9:0.6794	0.6794	9
L&H	L&H:14	lymphocytic and histiocytic:14:0.6173	0.6173	14
L(3)	L(3):17	larvae:17:0.4103	0.4103	17
l(o)	l(o):8|L(o):3	liquid-ordered:11:0.2632	0.2632	11
L(o)	L(o):6|l(o):1	optimal length:7:0.2113	0.2113	7
L(p)	L(p):29|L(P):1	hydraulic conductivity:30:0.9011	0.9011	30
L-5-HTP	L-5-HTP:63|l-5-HTP:2	L-5-hydroxytryptophan:65:0.7805	0.7805	65
L-5HTP	L-5HTP:21	L-5-hydroxytryptophan:21:0.6667	0.6667	21
L-AP3	L-AP3:12	L-2-amino-3-phosphonopropionate:12:0.1803	0.1803	12
L-CCG-I	L-CCG-I:11	(2S,1'S,2'S)-2-(carboxycyclopropyl)glycine:11:0.1852	0.1852	11
L-DOPS	L-DOPS:25	L-threo-3,4-dihydroxyphenylserine:25:0.6765	0.6765	25
L-FMAU	L-FMAU:9	2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil:9:0.3077	0.3077	9
L-Gln	L-Gln:18|L-GLN:1|L-gln:1	L-glutamine:20:0.9048	0.9048	20
L-Glu	L-Glu:88|L-glu:36|l-Glu:1	L-glutamate:125:0.6526	0.6526	125
L-Glu	L-Glu:32|L-glu:5	L-glutamic acid:37:0.6807	0.6807	37
L-KYN	L-KYN:12|l-KYN:1|L-Kyn:1	L-kynurenine:14:0.8667	0.8667	14
L-MTP-PE	L-MTP-PE:13	liposome-encapsulated muramyl tripeptide phosphatidylethanolamine:13:0.5050	0.5050	13
L-NIL	L-NIL:7|l-NIL:2|L-Nil:1	L-N(6)-(1-iminoethyl)lysine:10:0.0796	0.0796	10
L-NIL	L-NIL:30	L-N6-(1-Iminoethyl)lysine:15:0.1239|L-N6-(1-iminoethyl)-lysine:10:0.0796|L-N6-(1-Iminoethyl) lysine:5:0.0736	0.1239	30
L-NIL	L-NIL:9	N-iminoethyl-L-lysine:9:0.0708	0.0708	9
L-NOARG	L-NOARG:11	L-NG-nitro arginine:11:0.5355	0.5355	11
L-NOARG	L-NOARG:5|L-NOArg:3|L-Noarg:1	L-NG-nitroarginine:9:0.0305	0.0305	9
L-NOARG	L-NOARG:44|L-NOArg:5|L-NoArg:1|l-NOARG:1	N(G)-nitro-L-arginine:51:0.1908	0.1908	51
L-NOARG	L-NOARG:35|L-NOArg:3	N omega-nitro-L-arginine:24:0.8768|N(omega)-nitro-L-arginine:14:0.0496	0.8768	38
L-PGDS	L-PGDS:20	Lipocalin-type prostaglandin D synthase:20:0.7766	0.7766	20
L-SOP	L-SOP:25|l-SOP:1	L-serine-O-phosphate:26:0.8065	0.8065	26
L-cells	L-cells:13	mouse fibroblasts:13:0.3554	0.3554	13
L-type	L-type:16	dihydropyridine-sensitive:16:0.0714	0.0714	16
l.g.n.	l.g.n.:20|L.G.N.:2	Lateral Geniculate Nucleus:22:0.8657	0.8657	22
L.I.	L.I.:47	index:47:0.8214	0.8214	47
L/D	L/D:11	level/dose:11:0.1190	0.1190	11
L/D	L/D:17|l/d:1	light/dark:18:0.2024	0.2024	18
L/D	L/D:10|l/d:2	ratio:12:0.1310	0.1310	12
L/H	L/H:10	ratio:10:0.1500	0.1500	10
L/M	L/M:18	lactulose/mannitol:18:0.2099	0.2099	18
L/M	L/M:10	ratio:10:0.1111	0.1111	10
L/P	L/P:6	concentration ratios:6:0.1148	0.1148	6
L/P	L/P:45	lactate/pyruvate:45:0.1991	0.1991	45
L/P	L/P:16	Lymph/plasma:16:0.0679	0.0679	16
L/P	L/P:21	lymph-to-plasma protein concentration ratio:21:0.5435	0.5435	21
L/P	L/P:8	protein concentration:8:0.5006	0.5006	8
L/R	L/R:11	left/right:11:0.2222	0.2222	11
L/S	L/S:202	Lecithin/sphingomyelin:178:0.5446|lecithin-sphingomyelin:22:0.0646|lecithin sphingomyelin:2:0.7357	0.7357	202
L/S	L/S:31	Lecithin/sphingomyelin ratio:20:0.2371|lecithin-sphingomyelin ratio:11:0.0849	0.2371	31
L/S	L/S:7	lecithin to sphingomyelin ratio:7:0.7357	0.7357	7
L0	L0:17|l0:3	length:20:0.3725	0.3725	20
L1210	L1210:7	mouse leukemia cells:7:0.2113	0.2113	7
L1210	L1210:12|L-1210:1	murine leukemia:13:0.1551	0.1551	13
L1CAM	L1CAM:11|L1-CAM:3	cell adhesion molecule L1:14:0.7909	0.7909	14
L1CAM	L1CAM:9|L1-CAM:1	L1 cell adhesion molecule:10:0.5000	0.5000	10
L1	L1:13|L-1:1	first:14:0.0159	0.0159	14
L1	L1:22	first language:22:0.4344	0.4344	22
L1	L1:8	first larval stage:8:0.6411	0.6411	8
L1	L1:23	first-stage larvae:23:0.2861	0.2861	23
L1	L1:17	iron chelator deferiprone:17:0.7658	0.7658	17
L1	L1:53	LINE-1:53:0.0636	0.0636	53
L1	L1:9	major:9:0.0098	0.0098	9
L1	L1:12	major capsid protein:12:0.5664	0.5664	12
L1	L1:10	native language:10:0.1094	0.1094	10
L1	L1:14	oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one:14:0.6577	0.6577	14
L2	L2:10|L-2:2	cell line:12:0.7571	0.7571	12
L2	L2:36	second language:36:0.8003	0.8003	36
L2	L2:5	second lumbar:5:0.0612	0.0612	5
L2	L2:12	second-stage larvae:6:0.1010|second stage larvae:6:0.5290	0.5290	12
L3	L3:22|L-3:1	infective:23:0.0237	0.0237	23
L3	L3:174	infective larvae:174:0.3010	0.3010	174
L3	L3:7	infective larval:7:0.1329	0.1329	7
L3	L3:13	infective stage larvae:13:0.0665	0.0665	13
L3	L3:4	infective third-stage:4:0.0732	0.0732	4
L3	L3:38	infective third-stage larvae:38:0.1659	0.1659	38
L3	L3:16	larva:16:0.0162	0.0162	16
L3	L3:11	lumbar vertebra:11:0.6182	0.6182	11
L3	L3:28|L-3:1	third:29:0.0302	0.0302	29
L3	L3:8	third larval stage:8:0.2619	0.2619	8
L3	L3:11	third stage:11:0.1547	0.1547	11
L3	L3:69	third stage larvae:69:0.7238	0.7238	69
L4	L4:7	fourth larval stage:7:0.2452	0.2452	7
L4	L4:10	fourth lumbar:10:0.2275	0.2275	10
L4	L4:19	fourth-stage:10:0.0316|fourth stage:9:0.1809	0.1809	19
L4	L4:57|L-4:2	Fourth-stage larvae:30:0.2827|fourth stage larvae:29:0.6648	0.6648	59
L4	L4:6	layer 4:6:0.1320	0.1320	6
L5	L5:10	fifth lumbar:10:0.5856	0.5856	10
L5	L5:13|L-5:1	lumbar vertebra:14:0.6911	0.6911	14
L6-S1	L6-S1:9	lumbosacral:9:0.2963	0.2963	9
L-627	L-627:9	clinical studies on biapenem:9:0.6182	0.6182	9
L6	L6:5	rat skeletal muscle cell line:5:0.2818	0.2818	5
L6	L6:11|L-6:1	sixth lumbar:12:0.4557	0.4557	12
L-81	L-81:9	Pluronic L-81:9:0.6794	0.6794	9
La-	La-:12|LA-:3|la-:1	Lactate:16:0.7143	0.7143	16
LAAM	LAAM:25	1-alpha-acetylmethadol:25:0.1326	0.1326	25
LAAM	LAAM:64	l-alpha-acetylmethadol:64:0.3425	0.3425	64
LAAM	LAAM:39	Levo-alpha-acetylmethadol:39:0.2044	0.2044	39
L-AAO	LAAO:4|L-AAO:4	L-amino acid oxidase:8:0.6411	0.6411	8
LAAT	LAAT:7	leukocyte adhesiveness/aggregation test:7:0.4438	0.4438	7
LAA	LAA:10|L-AA:7|l-AA:1	L-ascorbic acid:18:0.3548	0.3548	18
LAA	LAA:28	laboratory animal allergy:28:0.8941	0.8941	28
LAA	LAA:129	left atrial appendage:129:0.9630	0.9630	129
LAA	LAA:7	leucocyte ascorbic acid:7:0.4438	0.4438	7
LAA	LAA:11	leukocyte adhesiveness/aggregation:11:0.4232	0.4232	11
LAA	LAA:7	low attenuation areas:7:0.5926	0.5926	7
LABA	LABA:10	balloon angioplasty:10:0.7103	0.7103	10
LABC	LABC:82	locally advanced breast cancer:82:0.9636	0.9636	82
LABC	LABC:12	locally advanced breast carcinoma:12:0.7571	0.7571	12
LABC	LABC:8|Labc:1	lymphadenosis benigna cutis:9:0.6794	0.6794	9
LABD	LABD:43	linear IgA bullous dermatosis:43:0.9291	0.9291	43
LABs	LABs:12	linear alkylbenzenes:12:0.7571	0.7571	12
lab	lab:5	homeotic gene labial:5:0.1973	0.1973	5
LAB	LAB:296	lactic acid bacteria:296:0.9898	0.9898	296
LAB	LAB:9	lactic acid bacterium:9:0.6794	0.6794	9
LACA	LACA:14	L-azetidine-2-carboxylic acid:14:0.6386	0.6386	14
LACV	LACV:12	La Crosse virus:12:0.7571	0.7571	12
LacS	LacS:9|lacS:1	lactose transport protein:10:0.7103	0.7103	10
lac	lac:6	Escherichia coli lactose:6:0.2827	0.2827	6
LAC	LAC:10|L-AC:3|L-Ac:3	L-acetylcarnitine:16:0.0224	0.0224	16
LAC	LAC:72|LaC:1	La Crosse:73:0.9591	0.9591	73
LAC	LAC:10	La Crosse virus:10:0.7103	0.7103	10
LAC	LAC:7	laparoscopic-assisted colectomy:7:0.1025	0.1025	7
LAC	LAC:10	Latin America and the Caribbean:10:0.7357	0.7357	10
LAC	LAC:18	Los Angeles County:18:0.8365	0.8365	18
LAC	LAC:155	lupus anticoagulant:144:0.9668|lupus anticoagulants:11:0.7357	0.9668	155
LADA	LADA:57	latent autoimmune diabetes in adults:57:0.9112	0.9112	57
LADA	LADA:8	latent autoimmune diabetes of the adult:8:0.7909	0.7909	8
LADA	LADA:5|LADa:2	left anterior descending artery:7:0.5926	0.5926	7
LADa	LADa:4|LADA:4	left anterior descending coronary artery:8:0.6411	0.6411	8
LADCA	LADCA:23	left anterior descending coronary artery:23:0.8715	0.8715	23
LADD	LADD:13	Lacrimo-auriculo-dento-digital:13:0.3871	0.3871	13
LADG	LADG:12	laparoscopy-assisted distal gastrectomy:12:0.5050	0.5050	12
LADH	LADH:44|L-ADH:10|LAdH:1	liver alcohol dehydrogenase:55:0.7378	0.7378	55
LADs	LADs:6	left anterior descending coronary arteries:6:0.5290	0.5290	6
LAD	LAD:916|lad:1	left anterior descending:917:0.9717	0.9717	917
LAD	LAD:630	left anterior descending artery:624:0.9645|left anterior descending arteries:6:0.3728	0.9645	630
LAD	LAD:23	left anterior descending branch:23:0.7046	0.7046	23
LAD	LAD:25	left anterior descending coronary:25:0.8816	0.8816	25
LAD	LAD:1213	left anterior descending coronary artery:1194:0.9743|left anterior descending coronary arteries:19:0.8449	0.9743	1213
LAD	LAD:35	left atrial diameter:35:0.9151	0.9151	35
LAD	LAD:37|LAd:1	left atrial dimension:38:0.9217	0.9217	38
LAD	LAD:23	left axis deviation:23:0.8038	0.8038	23
LAD	LAD:76	Leukocyte adhesion deficiency:76:0.7766	0.7766	76
LAD	LAD:28	ligament augmentation device:28:0.7154	0.7154	28
LAD	LAD:6	linear IgA bullous dermatosis:6:0.5290	0.5290	6
LAD	LAD:10	linear IgA dermatosis:10:0.5856	0.5856	10
LAD	LAD:37	linear IgA disease:37:0.8716	0.8716	37
LAD	LAD:10	Lipoamide dehydrogenase:10:0.5000	0.5000	10
LAE	LAE:16	left atrial enlargement:16:0.8165	0.8165	16
LAFB	LAFB:13	left anterior fascicular block:13:0.6701	0.6701	13
LAF	LAF:15	laminar air flow:15:0.8045	0.8045	15
LAF	LAF:9	lone atrial fibrillation:9:0.6794	0.6794	9
LAF	LAF:69	lymphocyte activating factor:35:0.8681|lymphocyte-activating factor:34:0.3158	0.8681	69
LAG-3	LAG-3:17	lymphocyte activation gene-3:17:0.8270	0.8270	17
LAGB	LAGB:9	laparoscopic adjustable gastric band:9:0.4587	0.4587	9
LAGB	LAGB:94	Laparoscopic Adjustable Gastric Banding:94:0.9184	0.9184	94
LAGC	LAGC:9	locally advanced gastric cancer:9:0.5470	0.5470	9
LAH	LAH:29	left anterior hemiblock:29:0.8978	0.8978	29
LAIF	LAIF:8	adherence inhibition factor:8:0.6411	0.6411	8
LAIR-1	LAIR-1:9	Leukocyte-associated Ig-like receptor-1:9:0.5470	0.5470	9
LAIV	LAIV:3	live attenuated influenza vaccine:3:0.5926	0.5926	3
LAI	LAI:10	Adherence Inhibition Assay:10:0.7103	0.7103	10
LAI	LAI:34	Leaf area index:34:0.9126	0.9126	34
LAI	LAI:5	leukemia associated inhibitor:5:0.4422	0.4422	5
LAI	LAI:155	leukocyte adherence inhibition:155:0.7491	0.7491	155
LAI	LAI:13	leukocyte adherence inhibition test:13:0.5934	0.5934	13
LAI	LAI:10	lupus activity index:10:0.5000	0.5000	10
L-ALDH	L-ALDH:12	aldehyde dehydrogenase:12:0.7571	0.7571	12
LALN	LALN:11	lung-associated lymph nodes:11:0.4232	0.4232	11
LAL	LAL:197	limulus amebocyte lysate:197:0.9848	0.9848	197
LAL	LAL:7	limulus amebocyte lysate test:7:0.5926	0.5926	7
LAL	LAL:115	Limulus amoebocyte lysate:115:0.9328	0.9328	115
LAL	LAL:11	long attack latency:11:0.7357	0.7357	11
LAL	LAL:9	lysate assay:9:0.3945	0.3945	9
LAL	LAL:18	lysinoalanine:18:0.0348	0.0348	18
LAL	LAL:41	Lysosomal acid lipase:41:0.9274	0.9274	41
LAM-1	LAM-1:6	leucocyte adhesion molecule-1:6:0.1148	0.1148	6
LAM-1	LAM-1:7	leukocyte adhesion molecule-1:7:0.1850	0.1850	7
LAMMA	LAMMA:37|LAM-MA:1	laser microprobe mass analysis:38:0.8811	0.8811	38
LAMP-1	LAMP-1:10|Lamp-1:3|LAMP1:1	lysosome-associated membrane protein-1:14:0.4367	0.4367	14
LAMP-1	LAMP-1:14|LAMP1:2|Lamp-1:1|lamp-1:1	membrane protein:18:0.7539	0.7539	18
LAMP-1	LAMP-1:9|LAMP1:3|Lamp1:2|lamp-1:2	membrane protein 1:16:0.8165	0.8165	16
LANA1	LANA1:6|LANA-1:4	Latency-associated nuclear antigen 1:10:0.7103	0.7103	10
LANA	LANA:66	latency-associated nuclear antigen:66:0.8329	0.8329	66
LANL	LANL:19	Los Alamos National Laboratory:19:0.8449	0.8449	19
LANP	LANP:9	Long-acting natriuretic peptide:9:0.4587	0.4587	9
LAN	LAN:17|Lan:1	lanreotide:18:0.1164	0.1164	18
LAN	LAN:9|Lan:1	lansoprazole:10:0.0616	0.0616	10
LAN	LAN:54	local area network:54:0.9448	0.9448	54
LAO	LAO:16|L-AO:1	L-amino acid oxidase:17:0.8270	0.8270	17
LAO	LAO:53	left anterior oblique:53:0.9438	0.9438	53
LAP2	LAP2:14	lamina-associated polypeptide 2:14:0.6173	0.6173	14
L-AP4	L-AP4:3	group III mGluR agonist L-2-amino-4-phosphonobutyrate:3:0.4422	0.4422	3
L-AP4	L-AP4:11|l-AP4:2|LAP4:1|l-AP-4:1	L-2-amino-4-phosphonobutanoate:15:0.0651	0.0651	15
LA-PF4	LA-PF4:8|LAPF4:3	low affinity platelet factor 4:11:0.7357	0.7357	11
LAPS	LAPS:6	light addressable potentiometric sensor:6:0.5290	0.5290	6
LAP	LAP:10	lamina-associated polypeptide:10:0.7103	0.7103	10
LAP	LAP:9|lap:6	laparoscopic:15:0.0138	0.0138	15
LAP	LAP:19|lap:3	laparotomy:22:0.0207	0.0207	22
LAP	LAP:56	latency-associated peptide:38:0.4162|latency associated peptide:18:0.7539	0.7539	56
LAP	LAP:11	left atrial:11:0.7357	0.7357	11
LAP	LAP:167|LAp:2	left atrial pressure:169:0.9717	0.9717	169
LAP	LAP:12	leucine amino peptidase:12:0.5664	0.5664	12
LAP	LAP:220|lap:2|Lap:1	leucine aminopeptidase:223:0.9149	0.9149	223
LAP	LAP:55|l-AP:1	leukocyte alkaline phosphatase:56:0.5669	0.5669	56
LAP	LAP:8	Lipid A-associated protein:8:0.3463	0.3463	8
LAP	LAP:6	liver activator protein:6:0.0807	0.0807	6
LAP	LAP:6	liver-enriched activating protein:6:0.1320	0.1320	6
LAP	LAP:23	lysosomal acid phosphatase:23:0.7500	0.7500	23
LAP	LAP:9	promoter:9:0.0079	0.0079	9
LARC	LARC:13	liver and activation-regulated chemokine:13:0.7753	0.7753	13
LARS	LARS:20	laparoscopic antireflux surgery:20:0.8525	0.8525	20
LARs	LARs:9	late asthmatic reactions:9:0.6794	0.6794	9
LAR	LAR:5	antigen-related phosphatase:5:0.1132	0.1132	5
LAR	LAR:7	late allergic reaction:7:0.2902	0.2902	7
LAR	LAR:49	late asthmatic reaction:42:0.8263|late asthmatic reactions:7:0.4438	0.8263	49
LAR	LAR:119	late asthmatic response:106:0.9406|late asthmatic responses:13:0.7753	0.9406	119
LAR	LAR:11	leaf area ratio:11:0.7357	0.7357	11
LAR	LAR:23	leukocyte common antigen-related:23:0.7500	0.7500	23
LAR	LAR:6	locus activation region:6:0.5290	0.5290	6
LAR	LAR:12	long-acting release:12:0.5355	0.5355	12
LAR	LAR:46	low anterior resection:46:0.8401	0.8401	46
LAR	LAR:7	lymphatic absorption rate:7:0.5926	0.5926	7
LASA	LASA:8	Linear Analog Scale Assessment:8:0.6411	0.6411	8
LASA	LASA:22	linear analogue self-assessment:16:0.8165|linear analogue self assessment:6:0.5290	0.8165	22
LASA	LASA:21	lipid-associated sialic acid:13:0.3134|lipid associated sialic acid:8:0.6411	0.6411	21
L-ASA	L-ASA:11|LASA:6	lysine acetylsalicylate:17:0.7407	0.7407	17
lasB	lasB:7	elastase gene:7:0.2902	0.2902	7
LASEC	LASEC:7	left atrial spontaneous echo contrast:7:0.5926	0.5926	7
LASEK	LASEK:26|LasEk:2	laser-assisted subepithelial keratectomy:28:0.7505	0.7505	28
LASEK	LASEK:27	laser epithelial keratomileusis:27:0.8861	0.8861	27
LASEK	LASEK:14	laser subepithelial keratomileusis:14:0.5589	0.5589	14
LASGB	LASGB:30|LAS-GB:1	laparoscopic adjustable silicone gastric banding:31:0.8519	0.8519	31
LASIK	LASIK:1000|Lasik:2	laser in situ keratomileusis:1002:0.9175	0.9175	1002
L-asp	L-asp:45|L-Asp:3|l-Asp:2	L-asparaginase:50:0.4537	0.4537	50
L-asp	L-asp:17	L-aspartic acid:17:0.7407	0.7407	17
LAS	LAS:7	40 microV:7:0.2113	0.2113	7
LAS	LAS:11	lateral amyotrophic sclerosis:11:0.7357	0.7357	11
LAS	LAS:8	linear alkyl benzene sulfonate:8:0.4102	0.4102	8
LAS	LAS:87	linear alkylbenzene sulfonate:50:0.9064|Linear alkylbenzene sulfonates:37:0.9197	0.9197	87
LAS	LAS:32	linear alkylbenzene sulphonate:21:0.6812|Linear alkylbenzene sulphonates:11:0.5856	0.6812	32
LAS	LAS:19	linear alkylbenzenesulfonates:11:0.7357|linear alkylbenzenesulfonate:8:0.5006	0.7357	19
LAs	LAs:9	local anaesthetics:9:0.6794	0.6794	9
LAs	LAs:40	local anesthetics:40:0.9256	0.9256	40
LAS	LAS:8	low amplitude signal:8:0.6411	0.6411	8
LAs	LAs:22	Lupus anticoagulants:22:0.8657	0.8657	22
LAS	LAS:78	lymphadenopathy syndrome:78:0.6777	0.6777	78
LAS	LAS:23|L-AS:2	lysine acetylsalicylate:25:0.8186	0.8186	25
LAT1	LAT1:13|LAT-1:1	L-type amino acid transporter 1:14:0.5934	0.5934	14
LATs	LATs:69	latency-associated transcripts:69:0.7829	0.7829	69
LATS	LATS:20	long acting thyroid stimulator:20:0.8525	0.8525	20
LAT	LAT:5	L-Lysine epsilon-aminotransferase:5:0.0736	0.0736	5
LAT	LAT:18	lactic acidosis threshold:18:0.8365	0.8365	18
LAT	LAT:166	latency-associated transcript:121:0.7508|latency associated transcript:25:0.8816|Latency-associated transcripts:13:0.3809|latency associated transcripts:7:0.5926	0.8816	166
LAT	LAT:89	latex agglutination test:89:0.9467	0.9467	89
LAT	LAT:74	linker for activation of T cells:74:0.9602	0.9602	74
LAT	LAT:4|lat:2	lysine epsilon-aminotransferase:6:0.1543	0.1543	6
LAT	LAT:12	lysolecithin acyltransferase:12:0.1991	0.1991	12
LAUP	LAUP:50	Laser-assisted uvulopalatoplasty:50:0.7168	0.7168	50
LAVA	LAVA:8	laser-assisted vascular anastomosis:8:0.5006	0.5006	8
LAVH	LAVH:60	laparoscopic-assisted vaginal hysterectomy:43:0.2431|Laparoscopic Assisted Vaginal Hysterectomy:17:0.1242	0.2431	60
LAVH	LAVH:52	laparoscopically assisted vaginal hysterectomy:52:0.5859	0.5859	52
LAVH	LAVH:11	vaginal hysterectomies:11:0.7357	0.7357	11
LAV	LAV:8	left atrial volume:8:0.6411	0.6411	8
LAV	LAV:43	lymphadenopathy-associated virus:43:0.4018	0.4018	43
LAXS	LAXS:10	large-angle X-ray scattering:10:0.4363	0.4363	10
LAMA	LAMA:7	laser-assisted microvascular anastomosis:7:0.5926	0.5926	7
LAMP	LAMP:38	limbic system-associated membrane protein:38:0.9174	0.9174	38
LAMP	LAMP:43	loop-mediated isothermal amplification:43:0.8917	0.8917	43
LAM	LAM:40	lactational amenorrhea method:40:0.9197	0.9197	40
LAM	LAM:17	lamivudine:17:0.0282	0.0282	17
LAM	LAM:9	levator ani muscle:9:0.6794	0.6794	9
LAM	LAM:139	lipoarabinomannan:139:0.2430	0.2430	139
LAM	LAM:50	pulmonary lymphangioleiomyomatosis:50:0.2613	0.2613	50
LAM	LAM:12	pulmonary lymphangiomyomatosis:12:0.1907	0.1907	12
LA	LA:24	alpha-lactalbumin:24:0.0052	0.0052	24
La	La:9|LA:2	anti-SS-B:11:0.0023	0.0023	11
LA	LA:8|La:1	antibodies:9:0.0018	0.0018	9
LA	LA:40|La:28	blood lactate:68:0.3253	0.3253	68
LA	LA:9|la:1|La:1	blood lactate concentration:11:0.3829	0.3829	11
LA	LA:9|L-A:3|L-a:1	L-arginine:13:0.0027	0.0027	13
LA	LA:110|La:3	lactic acid:113:0.1306	0.1306	113
LA	LA:10	lactic acidosis:10:0.7103	0.7103	10
LA	LA:8|La:3	laminin:11:0.0023	0.0023	11
La	La:45	Lanthanum:45:0.0100	0.0100	45
LA	LA:10	laparoscopic:10:0.0020	0.0020	10
LA	LA:30	Laparoscopic adrenalectomy:30:0.8032	0.8032	30
LA	LA:60	laparoscopic appendectomy:60:0.8751	0.8751	60
LA	LA:7	large aggregates:7:0.0886	0.0886	7
LA	LA:9	large aspiny:9:0.6794	0.6794	9
LA	LA:7	large surfactant aggregates:7:0.5926	0.5926	7
LA	LA:12	laser ablation:12:0.7571	0.7571	12
LA	LA:14	late antigen:14:0.4071	0.4071	14
LA	LA:17|La:2	lateral:19:0.0041	0.0041	19
LA	LA:32	lateral amygdala:32:0.3351	0.3351	32
LA	LA:6|La:2	lateral nucleus:8:0.1471	0.1471	8
LA	LA:29	lateral nucleus of the amygdala:29:0.9043	0.9043	29
LA	LA:155	latex agglutination:155:0.9166	0.9166	155
LA	LA:16	latex agglutination test:16:0.8165	0.8165	16
LA	LA:13	left atria:13:0.7753	0.7753	13
LA	LA:485	left atrial:485:0.9671	0.9671	485
LA	LA:224	left atrium:224:0.9786	0.9786	224
LA	LA:9|La:6	leucoagglutinin:15:0.0032	0.0032	15
LA	LA:9|L-A:1|La:1	leukoagglutinin:11:0.0023	0.0023	11
LA	LA:24	leukoaraiosis:24:0.0052	0.0052	24
LA	LA:85	leuprolide acetate:85:0.8075	0.8075	85
LA	LA:34	linoleic:34:0.0075	0.0075	34
LA	LA:396	linoleic acid:396:0.5198	0.5198	396
LA	LA:44	local anaesthesia:44:0.8941	0.8941	44
LA	LA:43	local anaesthetic:31:0.9043|local anaesthetics:12:0.7571	0.9043	43
LA	LA:42	local anesthesia:42:0.8893	0.8893	42
LA	LA:58	local anesthetic:33:0.9100|local anesthetics:25:0.8816	0.9100	58
LA	LA:34	localized adherence:34:0.6591	0.6591	34
LA	LA:44	locomotor activity:44:0.6003	0.6003	44
LA	LA:10	long-acting:10:0.0020	0.0020	10
LA	LA:21	Los Angeles:21:0.7865	0.7865	21
LA	LA:12	loss of attachment:12:0.3524	0.3524	12
LA	LA:8	low affinity:8:0.5006	0.5006	8
LA	LA:9	low altitude:9:0.5470	0.5470	9
LA	LA:7|L-A:2	low-average:9:0.0018	0.0018	9
LA	LA:27	lumen area:27:0.3880	0.3880	27
LA	LA:498	lupus anticoagulant:411:0.9525|Lupus anticoagulants:87:0.9455	0.9525	498
LA	LA:14	Lyme arthritis:14:0.6173	0.6173	14
LA	LA:10	lymphadenectomy:10:0.0020	0.0020	10
LA	LA:6	lymphoid aggregates:6:0.0522	0.0522	6
LBA	LBA:6	broncho-alveolar lavage:6:0.1543	0.1543	6
LBA	LBA:7	ligand binding assay:7:0.4438	0.4438	7
LBBB	LBBB:283|lbbb:1	left bundle branch block:284:0.9830	0.9830	284
LBB	LBB:15	left bundle branch:15:0.8045	0.8045	15
LBCL	LBCL:10	large B-cell lymphoma:10:0.7103	0.7103	10
LBC	LBC:20	liquid-based cytology:20:0.6680	0.6680	20
LBDs	LBDs:36	ligand-binding domains:22:0.4190|ligand binding domains:14:0.7909	0.7909	36
LBD	LBD:20	left brain-damaged:20:0.7766	0.7766	20
LBD	LBD:20	Lewy body dementia:20:0.8525	0.8525	20
LBD	LBD:39	Lewy body disease:39:0.8142	0.8142	39
LBD	LBD:301	ligand-binding domain:160:0.4775|ligand binding domain:128:0.9189|ligand-binding domains:7:0.1850|ligand binding domains:6:0.5290	0.9189	301
LBD	LBD:12	patients with left brain damage:12:0.4153	0.4153	12
LBF	LBF:96	blood flow:96:0.9505	0.9505	96
LBG	LBG:20	locust bean gum:20:0.6259	0.6259	20
LBHB	LBHB:12	hydrogen bond:12:0.7571	0.7571	12
LBHIs	LBHIs:10	Lewy body-like hyaline inclusions:10:0.7103	0.7103	10
LBK	LBK:11|LBk:2|L-BK:1	lysylbradykinin:14:0.3714	0.3714	14
LbL	LbL:21|LBL:12	layer-by-layer:33:0.2050	0.2050	33
LBL	LBL:61|lbL:1	lymphoblastic lymphoma:62:0.8591	0.8591	62
LBMD	LBMD:11|L-BMD:2	lumbar bone mineral density:13:0.5335	0.5335	13
LBMs	LBMs:9	live-bird markets:9:0.3945	0.3945	9
LBM	LBM:466|-lbm:1	lean body mass:467:0.9863	0.9863	467
LBNF1	LBNF1:4|LBN-F1:2	x Brown Norway F1:6:0.5290	0.5290	6
LBNP	LBNP:447	lower body negative pressure:447:0.9856	0.9856	447
LBPA	LBPA:14	lysobisphosphatidic acid:14:0.5111	0.5111	14
LBPP	LBPP:32	lower body positive pressure:32:0.9072	0.9072	32
LBP	LBP:5	ligand binding pocket:5:0.4422	0.4422	5
LBP	LBP:71	lipopolysaccharide binding protein:71:0.3406	0.3406	71
LBP	LBP:535|lbp:1	low back pain:536:0.9679	0.9679	536
LBP	LBP:181	LPS-binding protein:127:0.2360|LPS binding protein:54:0.3175	0.3175	181
LBP	LBP:10	Lycium barbarum polysaccharide:10:0.7103	0.7103	10
LBR	LBR:45	lamin B receptor:45:0.9338	0.9338	45
LBSA	LBSA:10	lipid-bound sialic acid:10:0.7103	0.7103	10
L-BSO	L-BSO:15|LBSO:1	L-buthionine sulfoximine:16:0.7261	0.7261	16
LBs	LBs:125|lbs:1	Lewy bodies:126:0.6767	0.6767	126
LBS	LBS:28	lysine-binding site:10:0.1774|lysine binding sites:9:0.4587|lysine binding site:9:0.3455	0.4587	28
LBTI	LBTI:18	lima bean trypsin inhibitor:18:0.8365	0.8365	18
LBT	LBT:21	lupus band test:21:0.8594	0.8594	21
LBT	LBT:15	Lymphocyte blast transformation:15:0.8045	0.8045	15
LBV	LBV:14	Lewy body variant:14:0.7909	0.7909	14
LBV	LBV:9	Lewy body variant of AD:9:0.6794	0.6794	9
LBWC	LBWC:9	limb-body wall complex:9:0.4587	0.4587	9
LBWI	LBWI:7	low birth weight infants:7:0.5926	0.5926	7
LBW	LBW:597	low birth weight:519:0.9667|low-birth-weight:78:0.0873	0.9667	597
LBW	LBW:172	low birthweight:148:0.9677|low-birthweight:24:0.0261	0.9677	172
LC-DAD	LC-DAD:9	array detection:9:0.6794	0.6794	9
LC-MS-MS	LC-MS-MS:70	liquid chromatography-tandem mass spectrometry:70:0.9573	0.9573	70
LC-MS-MS	LC-MS-MS:3	liquid chromatography with tandem mass spectrometry:3:0.8365	0.8365	3
LC-PCR	LC-PCR:8	LightCycler PCR:8:0.2987	0.2987	8
LC/MS	LC/MS:9	liquid chromatographic/mass spectrometric:9:0.6794	0.6794	9
LC/MS	LC/MS:236	liquid chromatography/mass spectrometry:236:0.9797	0.9797	236
LC/MS	LC/MS:7	liquid chromatography/mass spectroscopy:7:0.5926	0.5926	7
LC/SC	LC/SC:15	locus coeruleus/subcoeruleus:15:0.8045	0.8045	15
LC1	LC1:16|LC-1:1	light chain 1:17:0.8270	0.8270	17
LC1	LC1:33|Lc-1:1	lipocortin 1:34:0.4134	0.4134	34
LC20	LC20:46	light chain:46:0.9353	0.9353	46
LC2	LC2:21|LC-2:1	light chain:14:0.7909|light chains:8:0.4102	0.7909	22
LC2	LC2:19	light chain 2:19:0.8449	0.8449	19
LC3	LC3:24|LC-3:2	light chain 3:26:0.8861	0.8861	26
LC50	LC50:1	lethal concentration in 50%:1:0.4422	0.4422	1
LC50	LC50:85	Median lethal concentration:65:0.5504|median lethal concentrations:20:0.5021	0.5504	85
LCAD	LCAD:21	long-chain acyl-CoA dehydrogenase:21:0.5892	0.5892	21
LCAL	LCAL:10	large cell anaplastic lymphoma:10:0.7103	0.7103	10
L-CAM	L-CAM:11|LCAM:1	liver cell adhesion molecule:12:0.7571	0.7571	12
LCAP	LCAP:36	Leukocytapheresis:36:0.8333	0.8333	36
LCAS	LCAS:13	Lipoprotein and Coronary Atherosclerosis Study:13:0.7753	0.7753	13
LCAT	LCAT:705|Lcat:1	Lecithin:cholesterol acyltransferase:440:0.4678|lecithin-cholesterol acyltransferase:181:0.1770|lecithin cholesterol acyltransferase:74:0.9361|lecithin-cholesterol-acyltransferase:11:0.0094	0.9361	706
LCAT	LCAT:7	lecithin cholesterol acyltransferase activity:7:0.6794	0.6794	7
LCA	LCA:31	latent class analysis:31:0.9043	0.9043	31
LCA	LCA:94	Leber congenital amaurosis:72:0.6666|Leber's congenital amaurosis:22:0.1375	0.6666	94
LCA	LCA:98	left coronary artery:98:0.8203	0.8203	98
LCA	LCA:31	Lens culinaris:31:0.9043	0.9043	31
LCA	LCA:13	lentil lectin:13:0.4444	0.4444	13
LCA	LCA:131|L-CA:1	leukocyte common antigen:132:0.6699	0.6699	132
LCA	LCA:41	life cycle assessment:29:0.8978|life-cycle assessment:12:0.1299	0.8978	41
LCA	LCA:76	lithocholic acid:76:0.8529	0.8529	76
LCA	LCA:13	Littoral cell angioma:13:0.7753	0.7753	13
LCA	LCA:10	longitudinal chromatic aberration:10:0.5856	0.5856	10
LCA	LCA:7	lymphocytotoxic activity:7:0.2452	0.2452	7
LCA	LCA:20	lymphocytotoxic antibodies:20:0.7766	0.7766	20
LCBDE	LCBDE:13	Laparoscopic common bile duct exploration:13:0.7753	0.7753	13
LCBF	LCBF:212|lCBF:47|l-CBF:11|L-CBF:1	local cerebral blood flow:271:0.9709	0.9709	271
LCB	LCB:10|lcb:1	long-chain base:11:0.5355	0.5355	11
LCCA	LCCA:12	late cortical cerebellar atrophy:12:0.6460	0.6460	12
LCCA	LCCA:36	left circumflex coronary artery:36:0.8336	0.8336	36
LCCD	LCCD:8	late complement component deficiency:8:0.5006	0.5006	8
LCCs	LCCs:6	L-type Ca2+ channels:6:0.5290	0.5290	6
LCC	LCC:18	large cell carcinoma:18:0.4934	0.4934	18
LCDD	LCDD:31	light chain deposition disease:31:0.8519	0.8519	31
LCDs	LCDs:6	liquid crystal displays:6:0.5290	0.5290	6
LCD	LCD:17	lattice corneal dystrophy:17:0.8270	0.8270	17
LCD	LCD:36	liquid crystal display:36:0.9174	0.9174	36
LCD	LCD:26	liver cell dysplasia:26:0.6973	0.6973	26
LCD	LCD:10	low-calorie diet:10:0.1022	0.1022	10
LCE	LCE:11	laparoscopic cholecystectomy:11:0.7357	0.7357	11
LCFAs	LCFAs:44	long-chain fatty acids:29:0.4913|Long chain fatty acids:15:0.8045	0.8045	44
LCFA	LCFA:129|LC-FA:2	Long-chain fatty acids:53:0.6273|long-chain fatty acid:42:0.5411|long chain fatty acid:20:0.8525|long chain fatty acids:16:0.8165	0.8525	131
LCFU	LCFU:7|L-CFU:3	colony-forming units:10:0.3867	0.3867	10
L-CFU	L-CFU:7	leukemic progenitor cells:7:0.3524	0.3524	7
LCF	LCF:10	lymphocyte chemoattractant factor:10:0.7103	0.7103	10
LCF	LCF:8	lymphocyte chemotactic factor:8:0.2619	0.2619	8
LCG	LCG:16	cell granulomatosis:16:0.7261	0.7261	16
LCG	LCG:7	liquid cooling garment:7:0.5926	0.5926	7
LCGU	LCGU:253|lCGU:4|l-CGU:1	local cerebral glucose utilization:258:0.9754	0.9754	258
LCHE	LCHE:6|LChE:3|L-CHE:1	laparoscopic cholecystectomy:10:0.7103	0.7103	10
LCIS	LCIS:8	light chain isotype suppression:8:0.6411	0.6411	8
LCIS	LCIS:114|LCIs:1	lobular carcinoma in situ:115:0.9447	0.9447	115
L-Cit	L-Cit:9|L-cit:1|l-Cit:1	L-citrulline:11:0.7692	0.7692	11
LCI	LCI:13	lung clearance index:13:0.7753	0.7753	13
LCI	LCI:8|LC-I:1	myosin light chain I:9:0.6794	0.6794	9
LCLs	LCLs:7	Large cell lymphomas:7:0.5926	0.5926	7
LCLs	LCLs:237|LCL-s:1	lymphoblastoid cell lines:238:0.8301	0.8301	238
LCL	LCL:54	large cell lymphoma:30:0.8472|large-cell lymphoma:16:0.1495|large cell lymphomas:8:0.6411	0.8472	54
LCL	LCL:32	Lateral collateral ligament:32:0.9072	0.9072	32
LCL	LCL:34	localized cutaneous leishmaniasis:34:0.7306	0.7306	34
LCL	LCL:10	luminol chemiluminescence:10:0.0877	0.0877	10
LCL	LCL:7|L-CL:1	luminol-dependent chemiluminescence:8:0.0517	0.0517	8
LCL	LCL:9	luminol-enhanced chemiluminescence:9:0.0693	0.0693	9
LCL	LCL:8	lymphoblastoid cells:8:0.1367	0.1367	8
LCL	LCL:289	lymphoblastoid cell lines:188:0.7616|lymphoblastoid cell line:101:0.7576	0.7616	289
LCME	LCME:16	Liaison Committee on Medical Education:16:0.8165	0.8165	16
LCMRg	l-CMRg:2|LCMRg:2|lCMRg:1	local cerebral metabolic rate for glucose:5:0.6411	0.6411	5
LC-MS/MS	LC-MS/MS:3|LCMS/MS:1	liquid chromatography and tandem mass spectrometry:4:0.8978	0.8978	4
LC-MS/MS	LC-MS/MS:109	liquid chromatography-tandem mass spectrometry:109:0.9726	0.9726	109
LC-MS	LC-MS:17	liquid chromatographic-mass spectrometric:17:0.8270	0.8270	17
LC-MS	LC-MS:263|LCMS:4	liquid chromatography-mass spectrometry:267:0.9820	0.9820	267
LC-MS	LC-MS:9	liquid chromatography-mass spectroscopy:9:0.6794	0.6794	9
LC-MS	LC-MS:6	mass spectrometric detection:6:0.2827	0.2827	6
LCMV	LCMV:631|LCMv:1	Lymphocytic choriomeningitis virus:632:0.9808	0.9808	632
LCM	LCM:26|L-CM:1	conditioned medium:27:0.2645	0.2645	27
LCM	LCM:168	Laser capture microdissection:168:0.9822	0.9822	168
LCM	LCM:12	lincomycin:12:0.0205	0.0205	12
LCM	LCM:12|L-CM:1	lymphocyte-conditioned medium:13:0.0840	0.0840	13
LCM	LCM:140	lymphocytic choriomeningitis:140:0.9547	0.9547	140
LCM	LCM:8	Lymphocytic choriomeningitis virus:8:0.6411	0.6411	8
LCNECs	LCNECs:8	Large cell neuroendocrine carcinomas:8:0.6411	0.6411	8
LCNEC	LCNEC:52|LC-NEC:1	large cell neuroendocrine carcinoma:38:0.8781|large-cell neuroendocrine carcinoma:15:0.1400	0.8781	53
LCNEC	LCNEC:7	neuroendocrine carcinomas:7:0.3524	0.3524	7
LCN	LCN:44|LCn:1	lateral cervical nucleus:45:0.9338	0.9338	45
LCN	LCN:13|lcn:1	low copy number:14:0.7909	0.7909	14
LCOs	LCOs:10	lipo-chitin oligosaccharides:10:0.3145	0.3145	10
LCOS	LCOS:10	low cardiac output syndrome:10:0.7103	0.7103	10
L-CPA	L-CPA:15	L-2-chloropropionic acid:15:0.7096	0.7096	15
LCPD	LCPD:53	Legg-Calve-Perthes disease:53:0.7616	0.7616	53
LCPUFA	LCPUFA:69|LC-PUFA:43	long-chain polyunsaturated fatty acids:65:0.5955|long chain polyunsaturated fatty acids:24:0.8768|Long-chain polyunsaturated fatty acid:23:0.5236	0.8768	112
LCPs	LCPs:8|LCPS:1	long-chain polyunsaturated fatty acids:9:0.4587	0.4587	9
LCP	LCP:5	lectin complement pathway:5:0.4422	0.4422	5
LCP	LCP:12	Legg-Calve-Perthes:12:0.0453	0.0453	12
LCP	LCP:13	Locking Compression Plate:13:0.7753	0.7753	13
LCP	LCP:41	long-chain polyunsaturated fatty acids:31:0.6343|long-chain polyunsaturated fatty acid:10:0.4363	0.6343	41
LCRF	LCRF:7	luminal CCK-releasing factor:7:0.5926	0.5926	7
LCRs	LCRs:32	low-copy repeats:21:0.4359|low copy repeats:11:0.7357	0.7357	32
LCR	LCR:7	Laparoscopic colon resection:7:0.4438	0.4438	7
LCR	LCR:21	laryngeal chemoreflex:21:0.8594	0.8594	21
LCR	LCR:176	ligase chain reaction:176:0.9727	0.9727	176
LCR	LCR:285	locus control region:279:0.7106|locus control regions:6:0.2827	0.7106	285
LCR	LCR:12|lcr:2|Lcr:1	response:15:0.0200	0.0200	15
LCSG	LCSG:14	Lung Cancer Study Group:14:0.7909	0.7909	14
LCSS	LCSS:21	Lung Cancer Symptom Scale:21:0.8525	0.8525	21
LCST	LCST:85	lower critical solution temperature:85:0.8962	0.8962	85
LcS	LcS:11|LCS:3	Lactobacillus casei strain Shirota:14:0.7909	0.7909	14
LCs	LCs:249|LCS:1	Langerhans cells:250:0.7896	0.7896	250
LCS	LCS:12	Laparosonic Coagulating Shears:12:0.5050	0.5050	12
LCs	LCs:22	light chains:22:0.8657	0.8657	22
LCS	LCS:8	low contact stress:8:0.6411	0.6411	8
LCTs	LCTs:26	long-chain triglycerides:26:0.6973	0.6973	26
LCT	LCT:11	liquid crystal thermography:11:0.7357	0.7357	11
LCT	LCT:13	long-chain:13:0.0267	0.0267	13
LCT	LCT:98	long-chain triglyceride:38:0.4162|long chain triglycerides:33:0.8196|long chain triglyceride:27:0.8903	0.8903	98
LCT	LCT:8	lower critical temperature:8:0.6411	0.6411	8
LCT	LCT:15	Lymphocytotoxicity test:15:0.2264	0.2264	15
LCUs	LCUs:6	light curing units:6:0.5290	0.5290	6
LCU	LCU:5	light curing unit:5:0.5290	0.5290	5
LCV	LCV:18	lateral cerebral ventricle:18:0.8365	0.8365	18
LCV	LCV:20	leucovorin:20:0.1681	0.1681	20
LCV	LCV:18|LcV:2	leukocytoclastic vasculitis:20:0.7865	0.7865	20
LCV	LCV:13	lymphocryptovirus:13:0.1008	0.1008	13
LCX	LCX:62|LCx:38|Lcx:2	left circumflex artery:102:0.8455	0.8455	102
LCX	LCX:123|LCx:54	left circumflex coronary artery:177:0.8944	0.8944	177
LC	LC:13	controls:13:0.0019	0.0019	13
LC	LC:30	epidermal Langerhans' cells:24:0.1507|epidermal Langerhans' cell:6:0.0522	0.1507	30
LC	LC:35|L-C:12	L-carnitine:47:0.0072	0.0072	47
LC	LC:11	lab chow:11:0.4232	0.4232	11
LC	LC:8|lc:3	Lactobacillus casei:11:0.7357	0.7357	11
LC	LC:10	Lake Casitas:10:0.7103	0.7103	10
LC	LC:14	lamina cribrosa:14:0.7909	0.7909	14
LC	LC:876|Lc:4	Langerhans cells:786:0.8074|Langerhans cell:94:0.5941	0.8074	880
LC	LC:18	laparoscopic:18:0.0027	0.0027	18
LC	LC:734|Lc:1	laparoscopic cholecystectomy:698:0.9752|laparoscopic cholecystectomies:37:0.9197	0.9752	735
LC	LC:9	lateral column:9:0.6794	0.6794	9
LC	LC:27	left circumflex:27:0.7066	0.7066	27
LC	LC:9	left circumflex coronary artery:9:0.4587	0.4587	9
LC	LC:6	leukemia cutis:6:0.1543	0.1543	6
LC	LC:10	lidocaine:10:0.0014	0.0014	10
LC	LC:157|Lc:5|lc:4	light chain:106:0.9030|light chains:47:0.8703|light-chain:13:0.0019	0.9030	166
LC	LC:24	LightCycler:24:0.0036	0.0036	24
LC	LC:367	liquid chromatographic:367:0.9825	0.9825	367
LC	LC:613	liquid chromatography:613:0.9759	0.9759	613
LC	LC:19	liquid-condensed:10:0.0014|liquid condensed:9:0.4587	0.4587	19
LC	LC:52	liquid crystal:36:0.8336|liquid-crystal:16:0.0023	0.8336	52
LC	LC:14	liquid crystalline:14:0.6173	0.6173	14
LC	LC:7	Lithocholic acid:7:0.3524	0.3524	7
LC	LC:390	liver cirrhosis:390:0.9625	0.9625	390
LC	LC:70	local control:70:0.6119	0.6119	70
LC	LC:120	locus ceruleus:120:0.9603	0.9603	120
LC	LC:1365|Lc:1	locus coeruleus:1366:0.9942	0.9942	1366
LC	LC:15	long-chain:15:0.0022	0.0022	15
LC	LC:11	low-carbohydrate:11:0.0016	0.0016	11
LC	LC:25	lumped constant:25:0.8816	0.8816	25
LC	LC:72	lung cancer:72:0.7663	0.7663	72
LC	LC:10	lung carcinoma:10:0.1519	0.1519	10
Lc	Lc:24|lc:2	lurcher:26:0.0039	0.0039	26
LC	LC:6|Lc:2|lc:1	lymphocytes:9:0.0013	0.0013	9
LC	LC:12	Lysine clonixinate:12:0.7571	0.7571	12
LD(50)	LD(50):47	lethal dose:47:0.8433	0.8433	47
LD-PCR	LD-PCR:13	polymerase chain reaction:13:0.6701	0.6701	13
LD10	LD10:6	10% lethal dose:6:0.3728	0.3728	6
LD-1	LD-1:6|LD1:3	lactate dehydrogenase isoenzyme 1:9:0.6794	0.6794	9
LD50	LD50:35	acute toxicity:35:0.3837	0.3837	35
LD50	LD50:287|LD-50:2	lethal dose:246:0.9178|lethal doses:43:0.8917	0.9178	289
LD50	LD50:1	lethal dose at 50%:1:0.8165	0.8165	1
LDAO	LDAO:8	detergent lauryldimethylamine oxide:8:0.2987	0.2987	8
LD-AraC	LD-AraC:4|LDAraC:3|LDARA-C:2|LDARAc:1|LD-Ara-C:1|LD-araC:1	low-dose cytosine arabinoside:12:0.4557	0.4557	12
LDA	LDA:9	antibody:9:0.0143	0.0143	9
LDA	LDA:10	larval development assay:10:0.5856	0.5856	10
LDA	LDA:16	laser Doppler anemometer:16:0.8165	0.8165	16
LDA	LDA:32	laser doppler anemometry:32:0.9072	0.9072	32
LDA	LDA:18	left displaced abomasum:18:0.8365	0.8365	18
LDA	LDA:10|lda:1	left displacement of the abomasum:11:0.5934	0.5934	11
LDA	LDA:90	limiting dilution analysis:90:0.9149	0.9149	90
LDA	LDA:45	limiting dilution assay:33:0.9100|limiting dilution assays:12:0.7571	0.9100	45
LDA	LDA:136	linear discriminant analysis:136:0.9534	0.9534	136
LDA	LDA:10	local density approximation:10:0.7103	0.7103	10
LDA	LDA:11	low density area:11:0.7357	0.7357	11
LDA	LDA:7	low-dose aspirin:7:0.3524	0.3524	7
LDCC	LDCC:26	lectin-dependent cell-mediated cytotoxicity:26:0.8903	0.8903	26
LDCL	LDCL:51	luminol-dependent chemiluminescence:51:0.5668	0.5668	51
LDCV	LDCV:10	Large dense core vesicles:10:0.7103	0.7103	10
LDCVs	LDCVs:33	large dense core vesicles:17:0.8270|large dense-core vesicles:16:0.8270	0.8270	33
LDCs	LDCs:38	less developed countries:38:0.8417	0.8417	38
L-DC	L-DC:4|LDC:3	dendritic cells:7:0.0828	0.0828	7
LDC	LDC:7	less developed countries:7:0.5926	0.5926	7
LDC	LDC:13|ldc:2	lysine decarboxylase:15:0.7261	0.7261	15
LDDE	LDDE:13	low-dose dobutamine echocardiography:13:0.5934	0.5934	13
LDDST	LDDST:11	low-dose dexamethasone suppression test:11:0.5355	0.5355	11
LDEF	LDEF:15	Long Duration Exposure Facility:15:0.8045	0.8045	15
LDE	LDE:7	cholesterol-rich microemulsion:7:0.3524	0.3524	7
LDFS	LDFS:5	local disease-free survival:5:0.2818	0.2818	5
LDF	LDF:13	fraction:13:0.0151	0.0151	13
LDF	LDF:43	laser Doppler flow:28:0.8941|laser-Doppler flow:15:0.1400	0.8941	43
LDF	LDF:37	laser Doppler flowmeter:37:0.9197	0.9197	37
LDF	LDF:415	laser doppler flowmetry:415:0.9845	0.9845	415
LDF	LDF:54	laser Doppler flux:44:0.9323|Laser-Doppler flux:10:0.0578	0.9323	54
LDF	LDF:39|LDf:1	Laser Doppler fluxmetry:40:0.9256	0.9256	40
LDF	LDF:9	linear discriminant function:9:0.6794	0.6794	9
LDGL	LDGL:30	lymphoproliferative disease of granular lymphocytes:30:0.9011	0.9011	30
LDG	LDG:26	lactate dehydrogenase:26:0.7340	0.7340	26
LDH-C4	LDH-C4:33	lactate dehydrogenase C4:17:0.8270|lactate dehydrogenase-C4:16:0.8045	0.8270	33
LDH-1	LDH-1:4|LDH1:3|Ldh-1:1	lactate dehydrogenase:8:0.2987	0.2987	8
LDH-A	LDH-A:13|ldh-a:1|LDHA:1	Lactate dehydrogenase-A:15:0.6386	0.6386	15
LDH-B	LDH-B:15|LDHB:10|Ldh-B:4|LdhB:1	lactate dehydrogenase B:17:0.8270|lactate dehydrogenase-B:13:0.6701	0.8270	30
LDHs	LDHs:14	Layered double hydroxides:14:0.7909	0.7909	14
LDH-X	LDH-X:12	Lactate dehydrogenase-X:12:0.6460	0.6460	12
LDH	LDH:9	dehydrogenase level:9:0.6794	0.6794	9
LDH	LDH:4617|ldh:6|Ldh:5	lactate dehydrogenase:4599:0.8254|lactate-dehydrogenase:21:0.0034|lactate dehydrogenases:8:0.2987	0.8254	4628
LDH	LDH:26	lactate dehydrogenase activity:26:0.6645	0.6645	26
LDH	LDH:14	lactate dehydrogenase release:14:0.6911	0.6911	14
LDH	LDH:18	Lactatedehydrogenase:18:0.0029	0.0029	18
LDH	LDH:10	layered double hydroxide:10:0.5856	0.5856	10
LDH	LDH:9	low-dose heparin:9:0.2285	0.2285	9
LDH	LDH:14	lumbar disc herniation:14:0.7909	0.7909	14
LDH	LDH:101	Serum lactic dehydrogenase:101:0.1111	0.1111	101
LDI	LDI:10	laser desorption/ionization:10:0.7103	0.7103	10
LDI	LDI:13	laser Doppler imager:13:0.7753	0.7753	13
LDI	LDI:35	laser Doppler imaging:35:0.9151	0.9151	35
LDI	LDI:9	laser Doppler interferometry:9:0.6794	0.6794	9
LDI	LDI:6	Learning Disability Index:6:0.5290	0.5290	6
LDL-	LDL-:10	lipoprotein:10:0.3913	0.3913	10
LDL-ch	LDL-ch:6|LDLCH:1|LDL-CH:1	low-density lipoprotein cholesterol:8:0.2987	0.2987	8
LDL-C	LDL-C:49|LDLc:3|LDLC:2|LDL-c:1	low-density lipoprotein:24:0.3557|low density lipoprotein:22:0.7955|low density lipoproteins:9:0.6794	0.7955	55
LDL-C	LDL-C:1105|LDLC:55|LDL-c:24|LDLc:22	low-density lipoprotein cholesterol:979:0.7056|low-density lipoprotein-cholesterol:119:0.4535|low density lipoprotein-cholesterol:108:0.9723	0.9723	1206
LDLR(-/-)	LDLR(-/-):12	LDL receptor-deficient:12:0.4367	0.4367	12
LDLR-/-	LDLR-/-:11|LDLr-/-:2	LDL receptor-deficient:13:0.4480	0.4480	13
LDL-R	LDL-R:11|LDLR:8|LDLr:3	LDL-receptor:12:0.0165|LDL receptors:10:0.1177	0.1177	22
LDLR	LDLR:8|Ldlr:1	LDL receptor gene:9:0.2415	0.2415	9
LDLR	LDLR:338|LDL-R:68|LDLr:35|LDL-r:3|Ldlr:1	low density lipoprotein receptor:241:0.9800|low-density lipoprotein receptor:182:0.3802|low-density lipoprotein receptors:11:0.2422|Low density lipoprotein receptors:11:0.7357	0.9800	445
LDLR	LDLR:10	low density lipoprotein receptor gene:10:0.7103	0.7103	10
LDLT	LDLT:8	living donor liver transplant:8:0.6411	0.6411	8
LDLT	LDLT:148	living donor liver transplantation:148:0.8424	0.8424	148
LDLp	LDLp:23	low density lipophorin:13:0.7753|low-density lipophorin:10:0.1878	0.7753	23
LDLs	LDLs:9	Loudness discomfort levels:9:0.6794	0.6794	9
LDLs	LDLs:124	Low-density lipoproteins:124:0.5492	0.5492	124
LDL	LDL:23	loudness discomfort level:23:0.8715	0.8715	23
LDL	LDL:11035|LdL:1	low-density lipoprotein:4578:0.4967|low density lipoprotein:4349:0.9839|low density lipoproteins:1179:0.9842|low-density lipoproteins:724:0.3513|low-density-lipoprotein:206:0.0174	0.9842	11036
LDL	LDL:108	low-density lipoprotein cholesterol:63:0.4739|low density lipoprotein cholesterol:45:0.8964	0.8964	108
LDM	LDM:82	latissimus dorsi muscle:82:0.9422	0.9422	82
LDM	LDM:16	low-density microsomes:10:0.2873|low density microsomes:6:0.5290	0.5290	16
LDMF	LDMF:6	latissimus dorsi muscle flap:6:0.3728	0.3728	6
LDMS	LDMS:10|LD-MS:3	laser desorption mass spectrometry:13:0.7753	0.7753	13
LDN	LDN:44	Laparoscopic donor nephrectomy:44:0.6404	0.6404	44
LDOS	LDOS:14	local density of states:14:0.6911	0.6911	14
LDPE	LDPE:64	low-density polyethylene:46:0.5470|low density polyethylene:18:0.7539	0.7539	64
LDPI	LDPI:20	laser Doppler perfusion imaging:20:0.8594	0.8594	20
LDPM	LDPM:9	laser Doppler perfusion monitoring:9:0.6794	0.6794	9
LDRI	LDRI:9	low dose-rate irradiation:9:0.6794	0.6794	9
LDR	LDR:19	detection reaction:19:0.7044	0.7044	19
LDR	LDR:11	long-distance runners:11:0.4728	0.4728	11
LDR	LDR:17	low-dose radiation:9:0.1945|low dose radiation:8:0.6411	0.6411	17
LDR	LDR:189	low dose rate:92:0.9675|low-dose-rate:48:0.1433|low dose-rate:26:0.8861|low-dose rate:23:0.1137	0.9675	189
LD-SCLC	LD-SCLC:4|LDSCLC:1	small cell lung cancer:5:0.4422	0.4422	5
LDs	LDs:10	lipid droplets:10:0.7103	0.7103	10
LDS	LDS:11	lipodermatosclerosis:11:0.0500	0.0500	11
LDS	LDS:13	lithium dodecyl sulfate:13:0.7753	0.7753	13
LDTg	LDTg:15	laterodorsal tegmental nucleus:15:0.6386	0.6386	15
LDT	LDT:42	laterodorsal tegmental nucleus:42:0.8263	0.8263	42
LDT	LDT:14	lexical decision task:14:0.7909	0.7909	14
LDT	LDT:15	lymphocyte doubling time:15:0.5818	0.5818	15
LDV	LDV:114	lactate dehydrogenase-elevating virus:114:0.9087	0.9087	114
LDV	LDV:42	Lactic dehydrogenase virus:42:0.7113	0.7113	42
LDV	LDV:9	Laser Doppler velocimeter:9:0.6794	0.6794	9
LDV	LDV:75	laser Doppler velocimetry:75:0.9602	0.9602	75
LDV	LDV:11	vesicles:11:0.0296	0.0296	11
LD	LD:8|L-D:1	L-dopa:9:0.0021	0.0021	9
LD	LD:241|L-D:1	lactate dehydrogenase:242:0.8822	0.8822	242
LD	LD:17	lamina densa:17:0.8270	0.8270	17
LD	LD:69|L-D:4	laser Doppler:46:0.8703|laser-Doppler:27:0.0069	0.8703	73
LD	LD:11	lateral dorsal:11:0.6182	0.6182	11
LD	LD:10	laterodorsal:10:0.0024	0.0024	10
LD	LD:93	latissimus dorsi:93:0.6511	0.6511	93
LD	LD:11	latissimus dorsi muscle:11:0.6182	0.6182	11
LD	LD:273	Learning disabilities:220:0.9781|learning disability:53:0.8842	0.9781	273
LD	LD:74	learning disabled:43:0.9308|learning-disabled:31:0.0080	0.9308	74
LD	LD:68	Legionnaires' disease:68:0.1558	0.1558	68
LD	LD:6|Ld:3	Leishmania donovani:9:0.4587	0.4587	9
Ld	Ld:6|LD:3	Lepidoglyphus destructor:9:0.6794	0.6794	9
ld	ld:11|LD:3|Ld:1	lesion depth:15:0.8045	0.8045	15
LD	LD:12	lethal dose:12:0.0650	0.0650	12
LD	LD:66	levodopa:66:0.0174	0.0174	66
LD	LD:10|Ld:1	lidocaine:11:0.0027	0.0027	11
LD	LD:134	light:dark:70:0.0184|light/dark:62:0.0163|light dark:2:0.1519	0.1519	134
LD	LD:48|L-D:1	light-dark cycle:27:0.4692|light-dark cycles:14:0.5589|light/dark cycle:8:0.0517	0.5589	49
ld	ld:20|Ld:2	limb deformity:22:0.8657	0.8657	22
LD	LD:11	limit of detection:11:0.2972	0.2972	11
LD	LD:10	limited:10:0.0024	0.0024	10
LD	LD:43	limiting dilution:43:0.9308	0.9308	43
LD	LD:63	linear dichroism:63:0.9018	0.9018	63
LD	LD:542	linkage disequilibrium:531:0.9909|linkage-disequilibrium:11:0.0027	0.9909	542
LD	LD:34	lipodystrophy:34:0.0085	0.0085	34
LD	LD:35	living donor:30:0.5838|living donors:5:0.1132	0.5838	35
LD	LD:20	loading dose:20:0.1529	0.1529	20
LD	LD:88	long days:32:0.8563|long-day:31:0.0080|long day:25:0.5095	0.8563	88
LD	LD:10	longissimus:10:0.0024	0.0024	10
LD	LD:29|Ld:1|ld:1	Longissimus dorsi:31:0.1622	0.1622	31
LD	LD:6	longissimus muscle:6:0.0666	0.0666	6
LD	LD:30	low density:30:0.4630	0.4630	30
LD	LD:60|Ld:1|ld:1	low dose:38:0.3779|low-dose:24:0.0061	0.3779	62
LD	LD:12	lumen diameter:12:0.4102	0.4102	12
LD	LD:9	luminance-defined:9:0.0021	0.0021	9
LD	LD:84	Lyme disease:84:0.2000	0.2000	84
LD	LD:10	lymphocytic depletion:10:0.1022	0.1022	10
LD	LD:9|L-D:1	nucleus:10:0.0024	0.0024	10
LD	LD:39	patients with limited disease:39:0.3276	0.3276	39
LD	LD:9	photoperiod:9:0.0021	0.0021	9
LD	LD:29	under light-dark:29:0.0797	0.0797	29
LEAR	LEAR:8	low erucic acid rapeseed:8:0.6411	0.6411	8
LEAS	LEAS:10	Levels of Emotional Awareness Scale:10:0.5856	0.5856	10
LEAs	LEAs:12	lower extremity amputations:12:0.7571	0.7571	12
LECL	LECL:14	luminol-enhanced chemiluminescence:14:0.4709	0.4709	14
LECs	LECs:127	lens epithelial cells:127:0.8904	0.8904	127
LECs	LECs:10	liver endothelial cells:10:0.1134	0.1134	10
LECs	LECs:14	lymphatic endothelial cells:14:0.2157	0.2157	14
LEC	LEC:9	cinnamon-like coat color:9:0.6794	0.6794	9
LEC	LEC:26	lateral entorhinal cortex:26:0.8861	0.8861	26
LEC	LEC:62	lens epithelial cell:39:0.9237|lens epithelial cells:23:0.5236	0.9237	62
LEC	LEC:10	Leprosy Elimination Campaign:10:0.7103	0.7103	10
LEC	LEC:16	liver endothelial cells:16:0.3044	0.3044	16
LEC	LEC:160	Long-Evans Cinnamon:160:0.8355	0.8355	160
LEC	LEC:7	lymphoepithelial carcinoma:7:0.3524	0.3524	7
LEC	LEC:10	lymphoepithelial cyst:10:0.7103	0.7103	10
LEDGF	LEDGF:21	lens epithelium-derived growth factor:21:0.7044	0.7044	21
LEDVT	LEDVT:4|LE-DVT:1	lower extremity deep venous thrombosis:5:0.4422	0.4422	5
LEDs	LEDs:118|LEDS:6	light-emitting diodes:84:0.5795|light emitting diodes:40:0.9256	0.9256	124
LED	LED:224	light-emitting diode:123:0.5738|light emitting diode:61:0.9511|light emitting diodes:20:0.8525|light-emitting diodes:20:0.3171	0.9511	224
LEED	LEED:10	electron diffraction:10:0.7103	0.7103	10
LEEP	LEEP:70|Leep:1	loop electrosurgical excision procedure:71:0.9579	0.9579	71
LEE	LEE:83	locus of enterocyte effacement:83:0.9689	0.9689	83
LEF-1	LEF-1:9|LEF1:1|Lef-1:1	lymphoid enhancer factor-1:11:0.3829	0.3829	11
LEF	LEF:30|lef:7|Lef:2	Leflunomide:39:0.4043	0.4043	39
LEHR	LEHR:9	low-energy high-resolution:9:0.7103	0.7103	9
LEH	LEH:14	linear enamel hypoplasia:14:0.7909	0.7909	14
LEH	LEH:36	liposome-encapsulated hemoglobin:36:0.6464	0.6464	36
LEI	LEI:6	leukocyte-endothelial interaction:6:0.1838	0.1838	6
LEK	LEK:10	leu-enkephalin:10:0.3333	0.3333	10
LELC	LELC:38	lymphoepithelioma-like carcinoma:38:0.7810	0.7810	38
LE-LI	LE-LI:6|LELI:3	immunoreactivity:9:0.3478	0.3478	9
LELI	LELI:11	Laser Irradiation:11:0.6182	0.6182	11
LEMG	LEMG:11|L-EMG:1	laryngeal electromyography:12:0.7571	0.7571	12
LEMS	LEMS:170	Lambert-Eaton Myasthenic Syndrome:170:0.9459	0.9459	170
LEM	LEM:24	endogenous mediator:24:0.8768	0.8768	24
LEM	LEM:9	Lentinus edodes mycelia:9:0.6794	0.6794	9
LENK	LENK:15|l-ENK:3|L-ENK:3|L-Enk:3|L-enk:1	leu-enkephalin:25:0.2824	0.2824	25
L-ENK	L-ENK:16|LENK:14|L-Enk:9|L-enk:3|Lenk:2|lENK:1	leucine-enkephalin:36:0.4118|leucine enkephalin:9:0.5470	0.5470	45
LEO	LEO:13	low earth orbit:13:0.7753	0.7753	13
LEPs	LEPs:54	laser evoked potentials:33:0.5930|laser-evoked potentials:21:0.1696	0.5930	54
LEP	LEP:19	laser evoked potential:8:0.6411|Laser-evoked potentials:7:0.1329|laser evoked potentials:4:0.0918	0.6411	19
Lep	Lep:9|lep:2	Leader peptidase:11:0.6182	0.6182	11
LEP	LEP:7	leptin gene:7:0.3524	0.3524	7
LEP	LEP:11	limited English proficiency:11:0.7753	0.7753	11
LEP	LEP:8	lupus erythematosus profundus:8:0.6411	0.6411	8
LERG	LERG:10	local electroretinogram:10:0.5000	0.5000	10
LER	LER:14	lactate extraction ratio:14:0.7909	0.7909	14
Ler	Ler:38|LER:2	Landsberg erecta:40:0.8224	0.8224	40
LESP	LESP:126|LES-P:1|LESp:1	lower esophageal sphincter pressure:128:0.9766	0.9766	128
LES	LES:13	Lambert-Eaton myasthenic syndrome:13:0.7753	0.7753	13
LES	LES:6	Lambert-Eaton syndrome:6:0.0611	0.0611	6
LEs	LEs:12	lateral elements:12:0.5664	0.5664	12
LES	LES:763|les:1	lower esophageal sphincter:764:0.9916	0.9916	764
LETO	LETO:7	Long-Evans Tokushima:7:0.2902	0.2902	7
LETO	LETO:83	Long-Evans Tokushima Otsuka:83:0.8264	0.8264	83
LETS	LETS:5	Large external transformation-sensitive:5:0.6182	0.6182	5
LETZ	LETZ:9	loop excision of the transformation zone:9:0.7103	0.7103	9
LET	LET:6	esterase test:6:0.1838	0.1838	6
LET	LET:335	linear energy transfer:335:0.8502	0.8502	335
LET	LET:9	lupus erythematosus tumidus:9:0.6794	0.6794	9
Le	Le:8|LE:1	HuIFN-alpha:9:0.0054	0.0054	9
LE	LE:7	labelling efficiency:7:0.0886	0.0886	7
LE	LE:9	Lateral epicondylitis:9:0.6794	0.6794	9
LE	LE:6	left ear:6:0.1838	0.1838	6
LE	LE:12	left eye:12:0.7571	0.7571	12
LE	LE:7	leg exercise:7:0.2452	0.2452	7
LE	LE:7	leg extension:7:0.2452	0.2452	7
LE	LE:6	lens epithelial:6:0.0899	0.0899	6
LE	LE:13	Leu-enkephalin:13:0.0081	0.0081	13
LE	LE:17	leucine enkephalin:17:0.7407	0.7407	17
LE	LE:18	Leukocyte elastase:18:0.5940	0.5940	18
LE	LE:28	leukocyte esterase:28:0.6554	0.6554	28
Le	Le:51|LE:7	Lewis:58:0.0383	0.0383	58
LE	LE:10	life events:10:0.7103	0.7103	10
LE	LE:31	life expectancy:31:0.9043	0.9043	31
LE	LE:10	liquid-expanded:10:0.0060	0.0060	10
LE	LE:10	liver extract:10:0.2873	0.2873	10
LE	LE:18	local excision:18:0.7539	0.7539	18
LE	LE:194|L-E:19	Long-Evans:157:0.1047|Long Evans:56:0.9467	0.9467	213
LE	LE:18	Long-Evans rats:18:0.6381	0.6381	18
LE	LE:15	Loteprednol etabonate:15:0.8045	0.8045	15
LE	LE:21	low-energy:15:0.0094|low energy:6:0.3524	0.3524	21
LE	LE:34	lower extremity:34:0.9126	0.9126	34
LE	LE:6	luminal epithelial:6:0.0899	0.0899	6
LE	LE:31	luminal epithelium:31:0.5933	0.5933	31
LE	LE:307	lupus erythematosus:307:0.9791	0.9791	307
LE	LE:11|-LE:1	lymphedema:12:0.0074	0.0074	12
LF/HF	LF/HF:16	low frequency/high frequency:16:0.8165	0.8165	16
LF/HF	LF/HF:5	sympathovagal balance:5:0.0902	0.0902	5
LFA-1	LFA-1:10	function-associated Ag-1:10:0.5856	0.5856	10
LFA-1	LFA-1:13	function associated antigen:13:0.7753	0.7753	13
LFA-1	LFA-1:11	function-associated molecule-1:11:0.3213	0.3213	11
LFA-1	LFA-1:112|LFA1:1	leukocyte function-associated antigen-1:83:0.1968|leukocyte function-associated antigen 1:30:0.1419	0.1968	113
LFA-1	LFA-1:27	lymphocyte function-associated antigen:27:0.5524	0.5524	27
LFA-1	LFA-1:98|LFA1:1	lymphocyte function-associated antigen 1:99:0.6382	0.6382	99
LFA-3	LFA-3:26|LFA3:1	lymphocyte function-associated antigen 3:27:0.5840	0.5840	27
L-FABP	L-FABP:93|LFABP:9|L-Fabp:1|l-FABP:1	liver fatty acid binding protein:54:0.6960|Liver fatty acid-binding protein:50:0.7497	0.7497	104
LFA	LFA:22	Limax flavus:22:0.8657	0.8657	22
LFA	LFA:30	Limax flavus agglutinin:30:0.8472	0.8472	30
LFA	LFA:4	lymphocyte function-associated antigen:4:0.1618	0.1618	4
LFB	LFB:15	Luxol fast blue:15:0.7096	0.7096	15
LFCC	LFCC:3	low-fat complex-carbohydrate:3:0.7103	0.7103	3
LFCM	LFCM:8	laser flare-cell meter:8:0.6411	0.6411	8
LFCN	LFCN:15	lateral femoral cutaneous nerve:15:0.8045	0.8045	15
LFD	LFD:16	large-for-dates:16:0.1415	0.1415	16
LFD	LFD:10	low-fat diet:10:0.1878	0.1878	10
LFES	LFES:9	electrical stimulation:9:0.6794	0.6794	9
LFF	LFF:20	low-frequency fatigue:12:0.3058|low frequency fatigue:8:0.6411	0.6411	20
LFH	LFH:7	lymphoid follicular hyperplasia:7:0.4438	0.4438	7
LFLX	LFLX:39	lomefloxacin:39:0.9048	0.9048	39
LFM	LFM:9	lateral force microscopy:9:0.6794	0.6794	9
LFM	LFM:10	Leflunomide:10:0.1875	0.1875	10
LFPs	LFPs:65	local field potentials:65:0.9541	0.9541	65
LFP	LFP:15	laser flash photolysis:15:0.8045	0.8045	15
LFP	LFP:11	lateral fluid percussion:11:0.7357	0.7357	11
LFP	LFP:52|lfp:1	local field potential:36:0.9174|local field potentials:17:0.6748	0.9174	53
LFS	LFS:72	leukemia-free survival:72:0.6582	0.6582	72
LFS	LFS:77	Li-Fraumeni syndrome:77:0.8407	0.8407	77
LFS	LFS:67	low-frequency stimulation:48:0.5317|low frequency stimulation:19:0.8449	0.8449	67
LFTs	LFTs:82|LFTS:3	liver function tests:85:0.8950	0.8950	85
LFT	LFT:69	liver function tests:45:0.7664|liver function test:24:0.8115	0.8115	69
LFV	LFV:10	Lassa fever virus:10:0.7103	0.7103	10
LF	LF:1	fed either a low-fat:1:0.0581	0.0581	1
LF	LF:16	fluid:16:0.0070	0.0070	16
LF	LF:10	fraction:10:0.0042	0.0042	10
LF	LF:370|Lf:185	lactoferrin:555:0.2600	0.2600	555
LF	LF:12	laparoscopic fundoplication:12:0.7571	0.7571	12
LF	LF:12	Laser fluorescence:12:0.5664	0.5664	12
LF	LF:10	Lassa fever:10:0.7103	0.7103	10
LF	LF:12	lateral funiculus:12:0.7571	0.7571	12
LF	LF:12	leflunomide:12:0.0052	0.0052	12
Lf	Lf:12|LF:1|lf:1	length:14:0.0061	0.0061	14
LF	LF:13	lipofuscin:13:0.0056	0.0056	13
LF	LF:6	liver function:6:0.0564	0.0564	6
LF	LF:18	local failure:18:0.5560	0.5560	18
LF	LF:39	low fat:39:0.7653	0.7653	39
LF	LF:7	low-fat diet:7:0.1211	0.1211	7
LF	LF:9	low flow:9:0.2102	0.2102	9
LF	LF:447|lf:2	low frequency:228:0.9425|low-frequency:221:0.1032	0.9425	449
LF	LF:8	low frequency band:8:0.6411	0.6411	8
LF	LF:18	low-frequency component:11:0.2582|low frequency component:7:0.5926	0.5926	18
LF	LF:35	low frequency power:19:0.7658|low-frequency power:16:0.2154	0.7658	35
LF	LF:7	lung function:7:0.0951	0.0951	7
LF	LF:35	lymphatic filariasis:35:0.9151	0.9151	35
LF	LF:7	lymphoid follicles:7:0.2452	0.2452	7
LGAs	LGAs:16	local government areas:16:0.8165	0.8165	16
LGA	LGA:122	large for gestational age:86:0.8335|Large-for-gestational-age:36:0.1207	0.8335	122
LGA	LGA:11	left gastric artery:11:0.7357	0.7357	11
LGA	LGA:35	Local Government Area:35:0.9151	0.9151	35
LGA	LGA:18	low-grade astrocytomas:10:0.4363|low-grade astrocytoma:8:0.5006	0.5006	18
LGB	LGB:62|lgb:1|LGb:1	lateral geniculate body:56:0.9467|lateral geniculate bodies:8:0.6411	0.9467	64
LGC	LGC:8	luteinized granulosa cells:8:0.6411	0.6411	8
LGCs	LGCs:7	light green cells:7:0.5926	0.5926	7
LGE	LGE:32	lateral ganglionic eminence:32:0.9072	0.9072	32
LGE	LGE:9	Linear gingival erythema:9:0.6794	0.6794	9
LGFMS	LGFMS:10	low-grade fibromyxoid sarcoma:10:0.5856	0.5856	10
LGGs	LGGs:14	low-grade gliomas:14:0.6173	0.6173	14
LGIB	LGIB:9	lower gastrointestinal bleeding:9:0.6794	0.6794	9
LGICs	LGICs:14	ligand-gated ion channels:14:0.6173	0.6173	14
LGI	LGI:13	lower gastrointestinal:13:0.7753	0.7753	13
LGK	LGK:11	Leksell Gamma knife:11:0.7357	0.7357	11
LGLs	LGLs:83|LGLS:1	large granular lymphocytes:84:0.9091	0.9091	84
LGL	LGL:709	large granular lymphocytes:504:0.9872|large granular lymphocyte:205:0.9547	0.9872	709
LGL	LGL:17	large granular lymphocytic:17:0.7407	0.7407	17
lgl	lgl:12|Lgl:10	lethal giant larvae:22:0.7500	0.7500	22
LGL	LGL:3	patients with low-grade lymphoma:3:0.1618	0.1618	3
LGMD-1C	LGMD-1C:8|LGMD1C:3	muscular dystrophy:11:0.7357	0.7357	11
LGMD2A	LGMD2A:13	limb-girdle muscular dystrophy type 2A:13:0.4849	0.4849	13
LGMD2B	LGMD2B:19|LGMD-2B:1	muscular dystrophy type 2B:20:0.8525	0.8525	20
LGMD	LGMD:8	giant movement detector:8:0.6411	0.6411	8
LGMD	LGMD:83	Limb-Girdle Muscular Dystrophy:54:0.4915|limb girdle muscular dystrophy:29:0.8978	0.8978	83
LGMD	LGMD:19	muscular dystrophies:19:0.8449	0.8449	19
LGM	LGM:16	last glacial maximum:16:0.7261	0.7261	16
LGM	LGM:11	lymphogranulomatosis:11:0.1639	0.1639	11
LGN	LGN:15	lateral geniculate:15:0.7096	0.7096	15
LGN	LGN:13	lateral geniculate nuclei:13:0.7753	0.7753	13
LGN	LGN:709	lateral geniculate nucleus:709:0.9909	0.9909	709
LG-NHL	LG-NHL:16|LGNHL:10	Low-grade non-Hodgkin's lymphoma:21:0.7291|low-grade non-Hodgkin's lymphomas:5:0.2818	0.7291	26
LGNd	LGNd:102|LGND:1	dorsal lateral geniculate nucleus:103:0.8188	0.8188	103
LGNv	LGNv:14	ventral lateral geniculate nucleus:14:0.6173	0.6173	14
LGR7	LGR7:11	relaxin receptor:11:0.4728	0.4728	11
LGSIL	LGSIL:14|LG-SIL:2	low-grade squamous intraepithelial lesions:16:0.4832	0.4832	16
LGSIL	LGSIL:19|LG-SIL:1	squamous intraepithelial lesion:20:0.7766	0.7766	20
LGS	LGS:8|LG-S:3	lateral gastrocnemius-soleus:11:0.7357	0.7357	11
LGS	LGS:69	Lennox-Gastaut syndrome:69:0.6834	0.6834	69
LGs	LGs:23	linkage groups:23:0.8715	0.8715	23
LGT	LGT:31	Lateral gene transfer:31:0.9043	0.9043	31
LGU	LGU:12	leg glucose uptake:12:0.5050	0.5050	12
LGV	LGV:10	large granular vesicles:10:0.7103	0.7103	10
LGV	LGV:12	left gastric vein:12:0.7571	0.7571	12
LGV	LGV:72	lymphogranuloma venereum:72:0.9585	0.9585	72
LGv	LGv:12|LGV:4	ventral lateral geniculate nucleus:16:0.8165	0.8165	16
LGd	LGd:24	dorsal lateral geniculate nucleus:24:0.7593	0.7593	24
LGD	LGD:54	low-grade dysplasia:32:0.4395|low grade dysplasia:22:0.8657	0.8657	54
LG	LG:18	beta-lactoglobulin:18:0.0266	0.0266	18
LG	LG:9	granules:9:0.0125	0.0125	9
lg	lg:20	immunoglobulin:20:0.0297	0.0297	20
LG	LG:22	lacrimal gland:22:0.8657	0.8657	22
LG	LG:10	lateral gastric:10:0.7103	0.7103	10
LG	LG:87	lateral gastrocnemius:87:0.9121	0.9121	87
LG	LG:12	lateral geniculate:12:0.7571	0.7571	12
LG	LG:17	lateral giant:17:0.8270	0.8270	17
LG	LG:41	linkage group:41:0.6365	0.6365	41
LG	LG:6	loop gain:6:0.2243	0.2243	6
LG	LG:38	low-grade:22:0.0344|low grade:16:0.7261	0.7261	38
LG	LG:27	Lymphomatoid granulomatosis:27:0.8903	0.8903	27
LH/CG	LH/CG:13	Luteinizing hormone/chorionic gonadotropin:13:0.7753	0.7753	13
LH/CG	LH/CG:10	lutropin/choriogonadotropin:10:0.2195	0.2195	10
LH/FSH	LH/FSH:6	luteinizing hormone/follicle stimulating hormone:6:0.5290	0.5290	6
LH/hCG	LH/hCG:28	luteinizing hormone/human chorionic gonadotropin:28:0.8369	0.8369	28
LH1	LH1:10	core light-harvesting complex:10:0.7103	0.7103	10
LH2	LH2:10	light-harvesting 2:10:0.1994	0.1994	10
LHA	LHA:16	lateral hypothalamic:16:0.6577	0.6577	16
LHA	LHA:261|LHa:1	lateral hypothalamic area:262:0.9886	0.9886	262
LHA	LHA:39	lateral hypothalamus:39:0.8455	0.8455	39
LHb	LHb:13|Lhb:3|LHB:2	lateral habenula:18:0.8365	0.8365	18
LHb	LHb:8|LHB:4|Lhb:1|lHb:1	lateral habenular nucleus:14:0.7909	0.7909	14
LHB	LHB:37	Left heart bypass:37:0.9197	0.9197	37
LHCII	LHCII:31|LHC-II:5	light-harvesting complex II:36:0.6175	0.6175	36
LHCII	LHCII:13|LHC-II:4	light-harvesting complex of photosystem II:17:0.3721	0.3721	17
LHCII	LHCII:6|LHC-II:2	major light-harvesting complex:8:0.1895	0.1895	8
LHCI	LHCI:13|LHC-I:3	photosystem I:16:0.4832	0.4832	16
LHCP	LHCP:14	light-harvesting chlorophyll a/b-binding protein:14:0.6911	0.6911	14
LHCP	LHCP:14	light-harvesting chlorophyll a/b protein:14:0.7909	0.7909	14
L-HCs	L-HCs:5|LHCs:4	horizontal cells:9:0.6794	0.6794	9
LHCs	LHCs:9	light-harvesting complexes:9:0.6794	0.6794	9
LHC	LHC:7	Cern Large Hadron Collider:7:0.3524	0.3524	7
LHC	LHC:40|Lhc:2	light-harvesting complex:33:0.6305|light-harvesting complexes:9:0.3455	0.6305	42
LHD	LHD:14	left hemisphere damage:14:0.7909	0.7909	14
LHD	LHD:18	left-hemisphere-damaged:9:0.0678|left hemisphere damaged:9:0.6794	0.6794	18
LHD	LHD:15	local health department:15:0.8045	0.8045	15
LHDs	LHDs:23	local health departments:23:0.8715	0.8715	23
L-his	L-his:11|L-His:4	L-histidine:15:0.6667	0.6667	15
LHON	LHON:237	Leber's hereditary optic neuropathy:237:0.6897	0.6897	237
LHON	LHON:10	Leber hereditary optic neuroretinopathy:10:0.4363	0.4363	10
LHPA	LHPA:13	limbic-hypothalamic-pituitary-adrenal:13:0.3636	0.3636	13
LHP	LHP:13	late hyperpolarizing potential:13:0.7753	0.7753	13
LHP	LHP:22	lipid hydroperoxide:12:0.4153|lipid hydroperoxides:10:0.3867	0.4153	22
LHRBI	LHRBI:4|LH-RBI:3	receptor binding inhibitor:7:0.4438	0.4438	7
LH-RF	LH-RF:27|LHRF:4	luteinizing hormone releasing factor:17:0.8270|luteinizing hormone-releasing factor:14:0.6173	0.8270	31
LHRHa	LHRHa:9	D-Trp6-Pro9-NEt-LHRH:9:0.0410	0.0410	9
LHRH-a	LHRH-a:3|LHRHa:3|LH-RHA:1|LHRH-A:1	hormone agonists:8:0.2619	0.2619	8
LHRHa	LHRHa:5|LHRH-A:5|LHRHA:1|LH-RHa:1	hormone-releasing hormone:7:0.2113|hormone releasing hormone:5:0.4422	0.4422	12
LHRHa	LHRHa:3|LH-RH-a:3|LH-RH-A:2|LHRH-A:2|LH-RHa:1	luteinizing hormone-releasing hormone agonist:11:0.7357	0.7357	11
LHRHa	LHRHa:4|LH-RHa:2|LHRH-a:1|LHRHA:1	luteinizing hormone-releasing hormone analog:8:0.6411	0.6411	8
LH-RHa	LH-RHa:5|LHRH-A:4|LHRH-a:1|LHRHa:1|LH-RH-a:1|LH-RH-A:1	luteinizing hormone-releasing hormone analogue:13:0.5934	0.5934	13
LHRH	LHRH:1438|LH-RH:745	luteinizing hormone-releasing hormone:1624:0.9257|luteinizing hormone releasing hormone:559:0.8769	0.9257	2183
LHR	LHR:8	leukocyte histamine release:8:0.4102	0.4102	8
LHR	LHR:71|LH-R:13|LHr:12|Lhr:2	LH receptor:91:0.3801|LH receptors:7:0.1329	0.3801	98
LHR	LHR:15	Liquid-holding recovery:8:0.1895|Liquid holding recovery:7:0.5926	0.5926	15
LHR	LHR:7	lung/heart ratio:7:0.0777	0.0777	7
LHSS	LHSS:11	lateral hypothalamic self-stimulation:11:0.7357	0.7357	11
LHS	LHS:10	London handicap scale:10:0.7103	0.7103	10
LHS	LHS:11	Lung Health Study:11:0.7357	0.7357	11
LHV	LHV:9	left hepatic vein:9:0.5470	0.5470	9
LHbeta	LHbeta:10|LH-beta:3	luteinizing hormone beta:13:0.6701	0.6701	13
LHY	LHY:8|lhy:1	late elongated hypocotyl:9:0.5470	0.5470	9
LH	LH:34	genetically hypertensive:34:0.3067	0.3067	34
LH	LH:7	genetically hypertensive rats:7:0.3524	0.3524	7
LH	LH:12	gonadotropin:12:0.0012	0.0012	12
LH	LH:5	hypertensive rats of the Lyon strain:5:0.6411	0.6411	5
LH	LH:20	Laparoscopic hysterectomy:20:0.7173	0.7173	20
LH	LH:20	lateral:20:0.0020	0.0020	20
LH	LH:8|lH:1	lateral habenula:9:0.6794	0.6794	9
LH	LH:99	lateral hypothalamic:99:0.9365	0.9365	99
LH	LH:28	lateral hypothalamic area:28:0.8941	0.8941	28
LH	LH:9	lateral hypothalamic nucleus:9:0.5470	0.5470	9
LH	LH:326|lh:1	lateral hypothalamus:327:0.9674	0.9674	327
LH	LH:39	Learned helplessness:39:0.8811	0.8811	39
LH	LH:11	left-handed:11:0.0014	0.0014	11
LH	LH:90|L-H:1	left hemisphere:79:0.9036|left-hemisphere:12:0.0012	0.9036	91
LH	LH:17	light-harvesting:17:0.0017	0.0017	17
LH	LH:10	lipid hydroperoxides:10:0.7103	0.7103	10
LH	LH:13	loop of Henle:13:0.6701	0.6701	13
LH	LH:9	lung hypoplasia:9:0.6794	0.6794	9
LH	LH:25	luteinizing-hormone:15:0.0015|luteinizing hormones:10:0.5856	0.5856	25
LH	LH:32	Lyon hypertensive:32:0.2825	0.2825	32
LH	LH:25	Lysyl hydroxylase:25:0.6873	0.6873	25
LIAG	LIAG:10	light-induced avian glaucoma:10:0.7103	0.7103	10
LIA	LIA:11	inhibitory activity:11:0.1378	0.1378	11
LIA	LIA:25	line immunoassay:25:0.2222	0.2222	25
LIBS	LIBS:46	Laser-induced breakdown spectroscopy:46:0.8676	0.8676	46
LIBS	LIBS:29	ligand-induced binding sites:19:0.7658|ligand-induced binding site:10:0.4363	0.7658	29
LICI	LICI:9	intracortical inhibition:9:0.5470	0.5470	9
LIC	LIC:17	liver iron concentration:17:0.6748	0.6748	17
LIDs	LIDs:10	dyskinesias:10:0.3913	0.3913	10
LID	LID:25	Levodopa-induced dyskinesias:15:0.5348|levodopa-induced dyskinesia:10:0.3867	0.5348	25
LID	LID:17|Lid:13|lid:1	lidocaine:31:0.2123	0.2123	31
LID	LID:28	low iodine diet:16:0.8165|low-iodine diet:12:0.1692	0.8165	28
LIFA	LIFA:8	ligand-mediated immunofunctional assay:8:0.3463	0.3463	8
LIFE	LIFE:13	fluorescence endoscopy:13:0.6701	0.6701	13
LIFE	LIFE:13	Longitudinal Interval Follow-up Evaluation:13:0.7753	0.7753	13
LIFE	LIFE:12	Losartan Intervention For Endpoint:12:0.7571	0.7571	12
LIFE	LIFE:12	Losartan Intervention For Endpoint reduction:12:0.7571	0.7571	12
LIFE	LIFE:48	Losartan Intervention For Endpoint reduction in hypertension:48:0.9379	0.9379	48
LIFR	LIFR:32|LIF-R:8	leukemia inhibitory factor receptor:40:0.6077	0.6077	40
LIFR	LIFR:29|LIF-R:3	LIF receptor:32:0.3261	0.3261	32
LIF	LIF:271	laser-induced fluorescence:271:0.8237	0.8237	271
LIF	LIF:1040|lif:1	leukemia inhibitory factor:1041:0.6742	0.6742	1041
LiF	LiF:15|lif:1	lithium fluoride:16:0.8165	0.8165	16
LIF	LIF:16	local intra-arterial fibrinolysis:16:0.8165	0.8165	16
LILA	LILA:17	liposome immune lysis assay:17:0.8270	0.8270	17
LILR	LILR:10	laser radiation:10:0.7103	0.7103	10
LILT	LILT:9	laser therapy:9:0.6794	0.6794	9
LIM-HD	LIM-HD:9|LIM-hd:5	LIM-homeodomain:14:0.5200	0.5200	14
LIMA	LIMA:5	large intestinal mucin antigen:5:0.4422	0.4422	5
LIMA	LIMA:185	left internal mammary artery:185:0.9741	0.9741	185
LINCL	LINCL:17	late infantile neuronal ceroid lipofuscinosis:17:0.8270	0.8270	17
LINEs	LINEs:19|LINES:2	Long interspersed elements:21:0.8594	0.8594	21
LINEs	LINEs:15	Long interspersed nuclear elements:15:0.8045	0.8045	15
LIPC	LIPC:9|Lipc:4	hepatic lipase:13:0.6701	0.6701	13
LIPC	LIPC:18	hepatic lipase gene:18:0.8365	0.8365	18
LIPC	LIPC:13	left inferior prefrontal cortex:13:0.7753	0.7753	13
LiPc	LiPc:14	lithium phthalocyanine:14:0.7909	0.7909	14
LiPs	LiPs:6|LIPs:5	Lignin peroxidases:11:0.7357	0.7357	11
LIP	LIP:32	inhibitory protein:32:0.6656	0.6656	32
LIP	LIP:64	interstitial pneumonia:64:0.9264	0.9264	64
LIP	LIP:29	labile iron pool:29:0.8978	0.8978	29
LIP	LIP:45	lateral intraparietal area:45:0.9338	0.9338	45
LiP	LiP:116|LIP:10|lip:2|Lip:1	lignin peroxidase:129:0.9510	0.9510	129
LIP	LIP:21	lower inflection point:21:0.8594	0.8594	21
LIP	LIP:30	lymphocytic interstitial pneumonitis:30:0.4881	0.4881	30
LISL	LISL:9	lithotripsy:9:0.7273	0.7273	9
LISs	LISs:8	Laboratory information systems:8:0.6411	0.6411	8
LISS	LISS:18	Less Invasive Stabilization System:18:0.8270	0.8270	18
LISS	LISS:12	low ionic strength solution:12:0.7571	0.7571	12
LITA	LITA:120	left internal thoracic artery:120:0.9355	0.9355	120
LITT	LITT:70	laser-induced thermotherapy:70:0.4715	0.4715	70
LITT	LITT:5	laser interstitial thermal therapy:5:0.1973	0.1973	5
LIT	LIT:7	local intra-arterial thrombolysis:7:0.4438	0.4438	7
LIU	LIU:8	lens-induced uveitis:8:0.5006	0.5006	8
LIV	LIV:13	influenza vaccine:13:0.7753	0.7753	13
LIV	LIV:6	louping ill virus:6:0.5290	0.5290	6
LIYV	LIYV:14	lettuce infectious yellows virus:14:0.7753	0.7753	14
LJM	LJM:53	Limited joint mobility:53:0.9116	0.9116	53
LJP	LJP:146|ljp:1	localized juvenile periodontitis:147:0.9280	0.9280	147
LJ	LJ:16|L-J:1	Lennard-Jones:17:0.1212	0.1212	17
LJ	LJ:57|L-J:17	Lowenstein-Jensen:63:0.4697|Lowenstein Jensen:11:0.6182	0.6182	74
LKLF	LKLF:18	lung Kruppel-like factor:18:0.7539	0.7539	18
LKM1	LKM1:6|LKM-1:2	microsomal antibody type 1:8:0.5006	0.5006	8
LKM	LKM:7	kidney microsomal:7:0.1470	0.1470	7
LKM	LKM:7	microsomal antibodies:7:0.2902	0.2902	7
LKP	LKP:14	lamellar keratoplasty:14:0.6911	0.6911	14
LKT	LKT:9	liver-kidney transplantation:9:0.2757	0.2757	9
LKS	LKS:48	Landau-Kleffner syndrome:48:0.9006	0.9006	48
L-K	L-K:8|LK:4	Lillehei-Kaster:12:0.0368	0.0368	12
LK	LK:1	low in potassium:1:0.6748	0.6748	1
LK	LK:15	low molecular weight kininogen:15:0.8045	0.8045	15
LK	LK:77	Lymphokine:49:0.1572|lymphokines:28:0.0903	0.1572	77
LLA	LLA:12	left lung autotransplantation:12:0.7571	0.7571	12
LLA	LLA:6	lipoprotein lipase activity:6:0.3728	0.3728	6
LLC-LN7	LLC-LN7:9	metastatic Lewis lung carcinoma:9:0.3945	0.3945	9
LLC-PK(1)	LLC-PK(1):7	epithelial cells:7:0.3524	0.3524	7
LLC-MK2	LLC-MK2:9|LLCMK2:4|LLC-MK-2:2	monkey kidney cells:15:0.8045	0.8045	15
LLC-MK2	LLC-MK2:4|LLCMK2:1	monkey kidney cell line:5:0.4422	0.4422	5
LLC-PK1	LLC-PK1:9	cultured renal epithelial cells:9:0.1809	0.1809	9
LLC-PK1	LLC-PK1:8	renal epithelial:8:0.1196	0.1196	8
LLCs	LLCs:8	large luteal cells:8:0.6411	0.6411	8
LLC	LLC:13	large luteal cells:13:0.7753	0.7753	13
LLC	LLC:159|LLc:2	Lewis lung carcinoma:161:0.9605	0.9605	161
L-LDH	L-LDH:11	L-lactate dehydrogenase:11:0.4363	0.4363	11
LLDPE	LLDPE:8	Linear low-density polyethylene:8:0.6411	0.6411	8
LLDs	LLDs:11	lipid-lowering drugs:11:0.6182	0.6182	11
LLD	LLD:5	language-learning disabilities:5:0.1132	0.1132	5
LLD	LLD:7	Late-life depression:7:0.2113	0.2113	7
LLD	LLD:13	Leg length discrepancy:13:0.4102	0.4102	13
LLD	LLD:5	long-lasting depression:5:0.0612	0.0612	5
LLD	LLD:14	lower limit of detection:14:0.5589	0.5589	14
LLE	LLE:22	largest Lyapunov exponent:22:0.7955	0.7955	22
LLE	LLE:94	liquid-liquid extraction:94:0.8790	0.8790	94
LLETZ	LLETZ:73	large loop excision of the transformation zone:73:0.9169	0.9169	73
LLI	LLI:13	leg length inequality:13:0.5934	0.5934	13
LLLT	LLLT:56	low-level laser therapy:56:0.4719	0.4719	56
LLL	LLL:63	left lower lobe:54:0.9448|left lower lobes:9:0.6794	0.9448	63
LLNA	LLNA:116	local lymph node assay:116:0.9742	0.9742	116
LLNL	LLNL:19	Lawrence Livermore National Laboratory:19:0.8449	0.8449	19
LLO	LLO:9	lipid-linked oligosaccharide:9:0.5470	0.5470	9
LLO	LLO:12	listeriolysin:12:0.0663	0.0663	12
LLO	LLO:129	listeriolysin O:129:0.9630	0.9630	129
LLPDD	LLPDD:22	late luteal phase dysphoric disorder:22:0.8657	0.8657	22
LLP	LLP:20	long-lasting potentiation:20:0.7766	0.7766	20
L-LTP	L-LTP:9	late phase of long-term potentiation:9:0.6794	0.6794	9
L-LTP	L-LTP:4	late phase of LTP:4:0.5290	0.5290	4
LLT	LLT:8	Lewis lung tumor:8:0.6411	0.6411	8
l-LV	l-LV:17|L-LV:1|LLV:1	l-leucovorin:19:0.2308	0.2308	19
LLV	LLV:9	lymphoid leukosis virus:9:0.4587	0.4587	9
LL	LL:14	constant illumination:14:0.1717	0.1717	14
LL	LL:156|L--L:1|L-L:1	constant light:158:0.5595	0.5595	158
LL	LL:22	continuous illumination:22:0.3561	0.3561	22
LL	LL:55|L-L:2	continuous light:57:0.1691	0.1691	57
LL	LL:8	continuous lighting:8:0.2987	0.2987	8
LL	LL:12	genetically lean:12:0.3275	0.3275	12
LL	LL:12	late luteal:12:0.6460	0.6460	12
LL	LL:17	lateral lemniscus:17:0.8270	0.8270	17
LL	LL:12	lateral longissimus:12:0.7571	0.7571	12
LL	LL:7	left lateral:7:0.2452	0.2452	7
LL	LL:10	leg length:10:0.3470	0.3470	10
LL	LL:83	lepromatous:83:0.0644	0.0644	83
LL	LL:99	lepromatous leprosy:99:0.9223	0.9223	99
LL	LL:9	lesions:9:0.0063	0.0063	9
LL	LL:11	lesion load:11:0.3829	0.3829	11
LL	LL:18	Lewis Lung:18:0.5560	0.5560	18
LL	LL:12	Lewis lung carcinoma:12:0.7571	0.7571	12
LL	LL:5|ll:1	lining layer:6:0.1838	0.1838	6
LL	LL:16	long latency:16:0.6577	0.6577	16
LL	LL:19	longissimus lumborum:19:0.8449	0.8449	19
LL	LL:17	lymphoblastic lymphoma:17:0.4480	0.4480	17
LL	LL:24	Lymphoid leukosis:24:0.8768	0.8768	24
LL	LL:11	lysolecithin:11:0.0079	0.0079	11
LM/SL	LM/SL:17	Lymphatic mapping and sentinel lymphadenectomy:17:0.8365	0.8365	17
LMAN	LMAN:15|lMAN:8|L-MAN:3	lateral magnocellular nucleus of the anterior neostriatum:26:0.5616	0.5616	26
LMAT	LMAT:10	agarose test:10:0.7103	0.7103	10
LMAT	LMAT:5	leucocyte migration agarose technique:5:0.2818	0.2818	5
LMAs	LMAs:9	laryngeal mask airways:9:0.6794	0.6794	9
LMA	LMA:450	laryngeal mask airway:450:0.9893	0.9893	450
LMA	LMA:6	liver membrane antibodies:6:0.2827	0.2827	6
LMA	LMA:39	locomotor activity:39:0.5794	0.5794	39
LMA	LMA:7	locomotor and motor activity:7:0.3524	0.3524	7
LMA	LMA:30	longissimus muscle area:30:0.6484	0.6484	30
LMB	LMB:79|LmB:1	Leptomycin B:80:0.9408	0.9408	80
LMCA	LMCA:143	left main coronary artery:143:0.9791	0.9791	143
LMCT	LMCT:10	ligand-to-metal charge-transfer:10:0.3867	0.3867	10
LMC	LMC:37	lateral motor column:37:0.9197	0.9197	37
LMC	LMC:22	Lymphocyte-mediated cytotoxicity:22:0.6531	0.6531	22
LMD	LMD:12	laser microdissection:12:0.7571	0.7571	12
L-Met	L-Met:20|L-MET:2|LMET:1|L-met:1	L-methionine:24:0.9200	0.9200	24
LME	LME:3	lysosomotropic agent L-leucine methyl ester:3:0.4422	0.4422	3
LMF	LMF:11	fraction:11:0.1370	0.1370	11
LMG	LMG:18	lethal midline granuloma:18:0.8365	0.8365	18
LMG	LMG:10	leucomalachite green:10:0.5856	0.5856	10
LMH	LMH:10	hepatoma:10:0.2250	0.2250	10
LMIF	LMIF:22|lmif:1|L-MIF:1	Leukocyte migration inhibitory factor:24:0.6427	0.6427	24
LMIF	LMIF:20|L-MIF:2	migration inhibition factor:22:0.8657	0.8657	22
LMIT	LMIT:40	leukocyte migration inhibition test:40:0.5303	0.5303	40
LMI	LMI:12	lateral medullary infarction:12:0.7571	0.7571	12
LMI	LMI:80	leukocyte migration inhibition:80:0.5663	0.5663	80
LMI	LMI:9	Linear Matrix Inequality:9:0.6794	0.6794	9
LMMH	LMMH:8	low molecular mass heparin:8:0.6794	0.6794	8
LMMP	LMMP:16|LM-MP:12|lm-mp:2	longitudinal muscle-myenteric plexus:20:0.8525|longitudinal muscle myenteric plexus:10:0.8270	0.8525	30
LMM	LMM:46	lentigo maligna melanoma:46:0.9353	0.9353	46
LMM	LMM:58	light meromyosin:58:0.8502	0.8502	58
LMM	LMM:19|lmm:1	low molecular mass:11:0.7357|low-molecular-mass:9:0.0410	0.7357	20
LMNA	LMNA:13	lamin A/C gene:13:0.7753	0.7753	13
LMND	LMND:17|L-MND:2	lower motor neuron disease:19:0.8449	0.8449	19
LMN	LMN:31	lower motor neuron:31:0.9043	0.9043	31
LMP1	LMP1:30|LMP-1:28	latent membrane protein:58:0.8502	0.8502	58
LMP-1	LMP-1:92|LMP1:35	latent membrane protein-1:127:0.9177	0.9177	127
LMP2A	LMP2A:46|LMP-2A:2|LMP2a:1	latent membrane protein 2A:49:0.9392	0.9392	49
LMP2	LMP2:12	latent membrane protein 2:12:0.7571	0.7571	12
LMPCR	LMPCR:19|LM-PCR:8	ligation-mediated PCR:27:0.7066	0.7066	27
LMPCR	LMPCR:23|LM-PCR:11	ligation-mediated polymerase chain reaction:34:0.8245	0.8245	34
LMP	LMP:98	last menstrual period:98:0.9216	0.9216	98
LMP	LMP:156	latent membrane protein:156:0.8205	0.8205	156
LMP	LMP:117|lmp:1	low malignant potential:118:0.9746	0.9746	118
LMP	LMP:7	low molecular mass polypeptide:7:0.5926	0.5926	7
LMSs	LMSs:13	leiomyosarcomas:13:0.6842	0.6842	13
LMS	LMS:11	effect of levamisole:11:0.0869	0.0869	11
LMS	LMS:15	least mean square:15:0.8045	0.8045	15
LMS	LMS:140	leiomyosarcoma:95:0.2454|leiomyosarcomas:45:0.1149	0.2454	140
LMS	LMS:9	Leucomyosuppressin:9:0.0209	0.0209	9
LMS	LMS:10	linearized multistage:10:0.5856	0.5856	10
LMS	LMS:12	syndrome:12:0.0287	0.0287	12
LMT	LMT:26	left main trunk:26:0.8861	0.8861	26
LMT	LMT:16	leucocyte migration test:16:0.3174	0.3174	16
LMV	LMV:15	lettuce mosaic virus:15:0.8045	0.8045	15
LMWA	LMWA:14	low molecular weight antioxidants:14:0.7909	0.7909	14
LMWCr	LMWCr:6	low-molecular-weight chromium-binding substance:6:0.4438	0.4438	6
LMWD	LMWD:12	low molecular weight dextran:12:0.7571	0.7571	12
LMWH	LMWH:8	low molecular weight:8:0.6794	0.6794	8
LMWH	LMWH:715|lmwh:2|LMW-H:2	low molecular weight heparin:558:0.9914|low molecular weight heparins:106:0.9718|low-molecular-weight heparins:55:0.2494	0.9914	719
LMWK	LMWK:12	low molecular weight kininogen:12:0.7571	0.7571	12
LMWP	LMWP:19	low molecular weight proteins:14:0.6911|low molecular weight protein:5:0.4422	0.6911	19
LMW	LMW:579|lmw:2|LMw:1	low molecular weight:417:0.9589|low-molecular-weight:165:0.2394	0.9589	582
LMVEC	LMVEC:6|LMvEC:2	lung microvascular endothelial cells:8:0.6411	0.6411	8
LM	LM:11	lactose malabsorption:11:0.6182	0.6182	11
LM	LM:33	laryngeal mask:33:0.8605	0.8605	33
LM	LM:24	lean mass:24:0.5160	0.5160	24
LM	LM:57	left main:57:0.9176	0.9176	57
LM	LM:9	left main coronary artery:9:0.5470	0.5470	9
LM	LM:20	leiomyomas:10:0.0043|leiomyoma:10:0.0043	0.0043	20
LM	LM:49	lentigo maligna:49:0.9392	0.9392	49
LM	LM:20	leptomeningeal metastases:20:0.2318	0.2318	20
LM	LM:16	Leptomeningeal metastasis:16:0.5564	0.5564	16
LM	LM:10|L-M:1	Levenberg-Marquardt:11:0.0048	0.0048	11
LM	LM:72	light microscope:72:0.9591	0.9591	72
LM	LM:100	light microscopic:100:0.9701	0.9701	100
LM	LM:403	light microscopy:403:0.9841	0.9841	403
LM	LM:13	lipid microspheres:13:0.6701	0.6701	13
LM	LM:12	lipomannan:12:0.0053	0.0053	12
LM	LM:89|Lm:18	Listeria monocytogenes:107:0.9555	0.9555	107
LM	LM:27	liver metastases:27:0.3613	0.3613	27
LM	LM:12	Logical Memory:12:0.5664	0.5664	12
LM	LM:14	longissimus:14:0.0062	0.0062	14
LM	LM:33	longissimus muscle:33:0.2787	0.2787	33
LM	LM:21	longitudinal:21:0.0096	0.0096	21
LM	LM:40	longitudinal muscle:40:0.3603	0.3603	40
LM	LM:11	lymphatic mapping:11:0.5355	0.5355	11
Lm	Lm:31|LM:2	Mean linear intercept:33:0.8196	0.8196	33
LM	LM:8|Lm:1	membrane:9:0.0038	0.0038	9
LM	LM:7	pretectal nucleus lentiformis mesencephali:7:0.4587	0.4587	7
L-M	L-M:5|LM:2	stratum lacunosum-moleculare:7:0.2113	0.2113	7
LM	LM:1	studied at the light:1:0.0561	0.0561	1
LN-1	LN-1:7|Ln-1:4|LN1:1	laminin-1:12:0.5789	0.5789	12
LN2	LN2:37	liquid nitrogen:37:0.9197	0.9197	37
Ln-5	Ln-5:32|LN5:11|LN-5:6|ln-5:1|Ln5:1	Laminin-5:51:0.8644	0.8644	51
LNAAs	LNAAs:30	Large neutral amino acids:30:0.8032	0.8032	30
LNAA	LNAA:96	large neutral amino acids:67:0.9344|large neutral amino acid:29:0.7718	0.9344	96
L-NAC	L-NAC:7|LNAC:4|l-NAC:2	N-acetyl-L-cysteine:13:0.5714	0.5714	13
L-NAME	L-NAME:11	L-nitro-arginine-methyl-ester:11:0.0027	0.0027	11
L-NAME	L-NAME:46|l-NAME:2|L-Name:1	methyl ester hydrochloride:49:0.8799	0.8799	49
L-NAME	L-NAME:14	N(G)-nitro-L-arginine-methyl-ester:14:0.0035	0.0035	14
L-NAME	L-NAME:30	N(G)-nitro-L-arginine methylester:30:0.0994	0.0994	30
L-NAME	L-NAME:9	NG-nitro-L-arginine:9:0.0022	0.0022	9
L-NAME	L-NAME:13	NG-Nitro-L-arginine-methyl-ester:13:0.0033	0.0033	13
L-NAME	L-NAME:9	nitric oxide synthase:9:0.7357	0.7357	9
L-NAME	L-NAME:10	nitric oxide synthase inhibitor:10:0.7103	0.7103	10
L-NAME	L-NAME:15|l-NAME:2	nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester:17:0.9256	0.9256	17
L-NAME	L-NAME:11|l-NAME:1	nitric oxide synthase inhibitor N omega-nitro-L-arginine methyl ester:12:0.8941	0.8941	12
L-NAME	L-NAME:5	synthase inhibitor NG-nitro-L-arginine methylester:5:0.1148	0.1148	5
LNAs	LNAs:15	locked nucleic acids:15:0.8045	0.8045	15
LNA	LNA:21|LnA:2	alpha-linolenic acid:23:0.1418	0.1418	23
L-NA	L-NA:4|LNA:3|l-NA:1	inhibitor N(omega)-nitro-L-arginine:8:0.2422	0.2422	8
LNA	LNA:9|L-NA:1	L-nitro-arginine:10:0.0222	0.0222	10
L-NA	L-NA:9|LNA:2|l-NA:2	L-nitroarginine:13:0.0296	0.0296	13
LNA	LNA:7	latent nuclear antigen:7:0.4438	0.4438	7
LNA	LNA:71	locked nucleic acid:58:0.9467|locked nucleic acids:13:0.7357	0.9467	71
L-NA	L-NA:22|LNA:1|l-NA:1	N(G)-nitro-L-arginine:24:0.0568	0.0568	24
L-NA	L-NA:13|LNA:3	N-nitro-L-arginine:16:0.0370	0.0370	16
L-NA	L-NA:23|LNA:7	N omega-nitro-L-arginine:30:0.9011	0.9011	30
L-NA	L-NA:38|LNA:4|l-NA:2	NG-nitro-L-arginine:44:0.1062	0.1062	44
L-NA	L-NA:23|LNA:5|l-NA:1	Nitro-L-arginine:29:0.0691	0.0691	29
L-NA	L-NA:12|LNA:2	Nomega-nitro-L-arginine:14:0.0321	0.0321	14
LNB	LNB:10	Lyme neuroborreliosis:10:0.7103	0.7103	10
LNCaP	LNCaP:14|LnCaP:2|LNCap:1	androgen-dependent:17:0.0808	0.0808	17
LNCaP	LNCaP:9	androgen-sensitive:9:0.0404	0.0404	9
LNCaP	LNCaP:10	lymph node carcinoma of the prostate:10:0.7571	0.7571	10
LNCaP	LNCaP:5|LnCap:1	prostate cancer:6:0.2243	0.2243	6
LNCaP	LNCaP:20	prostate cancer cells:20:0.7173	0.7173	20
LNCaP	LNCaP:22|LNCAP:1|LnCaP:1	prostate cancer cell line:24:0.8115	0.8115	24
LNCs	LNCs:28	lymph node cells:28:0.8941	0.8941	28
LNC	LNC:276	lymph node cells:242:0.9876|lymph node cell:34:0.9126	0.9876	276
LND	LND:13	Lesch-Nyhan disease:13:0.7753	0.7753	13
LND	LND:69	Lonidamine:69:0.4789	0.4789	69
LND	LND:28	lymph node dissection:28:0.8941	0.8941	28
LNF	LNF:34	laparoscopic Nissen fundoplication:34:0.9151	0.9151	34
LNG-IUD	LNG-IUD:7|Lng-IUD:1	levonorgestrel-releasing intrauterine device:8:0.5006	0.5006	8
LNG-IUS	LNG-IUS:38|LNg-IUS:2|Lng-IUS:1	levonorgestrel-releasing intrauterine system:41:0.5236	0.5236	41
LNGFR	LNGFR:27|L-NGFR:1|LNGF-R:1|LNGFr:1|L-NGFr:1	low-affinity nerve growth factor receptor:31:0.6131	0.6131	31
LNG	LNG:203|LNg:13|L-NG:1|L-Ng:1|Lng:1	levonorgestrel:219:0.8577	0.8577	219
LNH	LNH:6	lymphonodular hyperplasia:6:0.2243	0.2243	6
L-NIO	L-NIO:20	N-iminoethyl-L-ornithine:20:0.2568	0.2568	20
LNIT	LNIT:20	local nasal immunotherapy:20:0.8525	0.8525	20
LNL	LNL:46	lymph node lymphocytes:46:0.9353	0.9353	46
L-NMA	L-NMA:27|LNMA:1	NG-methyl-L-arginine:28:0.3034	0.3034	28
L-NMA	L-NMA:15|LNMA:1|l-NMA:1	NG-monomethyl-L-arginine:17:0.1798	0.1798	17
LNMC	LNMC:11	lymph node mononuclear cells:11:0.6182	0.6182	11
L-NMMA	L-NMMA:10	L-N-monomethyl arginine:10:0.0578	0.0578	10
L-NMMA	L-NMMA:46|LNMMA:3	L-NG-monomethyl arginine:32:0.3876|L-NG-monomethyl-arginine:17:0.0114	0.3876	49
L-NMMA	L-NMMA:12|LNMMA:2	L-NG-monomethylarginine:14:0.0093	0.0093	14
L-NMMA	L-NMMA:9|LNMMA:2|l-NMMA:1	N(G)-methyl-l-arginine:12:0.0079	0.0079	12
L-NMMA	L-NMMA:11|LNMMA:1	N(G)-monomethyl L-arginine:12:0.0725	0.0725	12
L-NMMA	L-NMMA:7|l-NMMA:6	N(G)-monomethyl-L-arginine acetate:13:0.2038	0.2038	13
L-NMMA	L-NMMA:6	N(G)-monomethyl-L-arginine monoacetate:6:0.1148	0.1148	6
L-NMMA	L-NMMA:25|LNMMA:2|l-NMMA:1	N omega-monomethyl-L-arginine:16:0.8165|N(omega)-monomethyl-L-arginine:12:0.0079	0.8165	28
L-NMMA	L-NMMA:17	NG-methyl-L-arginine:17:0.0114	0.0114	17
L-NMMA	L-NMMA:44|LNMMA:7	NG-monomethyl L-arginine:45:0.5312|NG monomethyl-L-arginine:6:0.1010	0.5312	51
L-NMMA	L-NMMA:12|l-NMMA:2	nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine:14:0.8365	0.8365	14
L-NMMA	L-NMMA:12	nitric oxide synthase inhibitor NG-monomethyl-L-arginine:12:0.8768	0.8768	12
L-NMMA	L-NMMA:11|l-NMMA:1	NOS inhibitor N(G)-monomethyl-L-arginine:12:0.2173	0.2173	12
L-NMMA	L-NMMA:4|LNMMA:1	synthase inhibitor N-monomethyl-L-arginine:5:0.1895	0.1895	5
LNM	LNM:17	lymph node metastases:17:0.8270	0.8270	17
LNM	LNM:35	lymph node metastasis:35:0.9151	0.9151	35
L-NNA	L-NNA:29|LNNA:7	N-nitro-L-arginine:36:0.0468	0.0468	36
L-NNA	L-NNA:14|LNNA:1	Nitro-L-arginine:15:0.0187	0.0187	15
L-NNA	L-NNA:4	NOS inhibitor N(G)-nitro-L-arginine:4:0.1730	0.1730	4
l-NNA	l-NNA:1	NOS inhibitor N(omega)-nitro-L-arginine:1:0.0666	0.0666	1
L-NNA	L-NNA:3|l-NNA:1	synthase inhibitor N(G)-nitro-L-arginine:4:0.1211	0.1211	4
L-NNA	L-NNA:7|LNNA:1	synthase inhibitor N(omega)-nitro-L-arginine:8:0.1591	0.1591	8
L-NNA	L-NNA:4	synthase inhibitor Nomega-nitro-L-arginine:4:0.1132	0.1132	4
LNNB	LNNB:42	Luria-Nebraska Neuropsychological Battery:42:0.8263	0.8263	42
L-NOG	L-NOG:9|LNOG:1	levonorgestrel:10:0.8182	0.8182	10
LN-R	LN-R:3|LNR:3	laminin receptor:6:0.1838	0.1838	6
LNS	LNS:31	Lesch-Nyhan syndrome:31:0.7388	0.7388	31
LNS	LNS:10	Lipid Nano-Sphere:10:0.7103	0.7103	10
LNs	LNs:195|LNS:2	lymph nodes:197:0.9676	0.9676	197
LNT	LNT:15	lentinan:15:0.2222	0.2222	15
LNT	LNT:13	linear no-threshold:13:0.7753	0.7753	13
Ln	Ln:9	lanthanide:9:0.0044	0.0044	9
LN	LN:9	Laparoscopic nephrectomy:9:0.6794	0.6794	9
LN	LN:10	lateral nucleus:10:0.2873	0.2873	10
LN	LN:7	lead nitrate:7:0.2902	0.2902	7
LN	LN:11|L-N:2	Lesch-Nyhan:13:0.0066	0.0066	13
LN	LN:20	levonorgestrel:20:0.0104	0.0104	20
LN	LN:21	lingual nerve:21:0.5721	0.5721	21
LN	LN:14	lipoid nephrosis:14:0.7909	0.7909	14
LN	LN:21	liquid nitrogen:21:0.7865	0.7865	21
LN	LN:148	lupus nephritis:148:0.9675	0.9675	148
LN	LN:833	lymph node:482:0.9835|lymph nodes:351:0.9817	0.9835	833
LN	LN:10	Lyon normotensive:10:0.0519	0.0519	10
ln	ln:8|Ln:2	natural log:10:0.5856	0.5856	10
ln	ln:11|Ln:2|LN:1	natural logarithm:14:0.6173	0.6173	14
LOAEL	LOAEL:20	lowest-observed-adverse-effect level:20:0.1894	0.1894	20
LOAELs	LOAELs:7	adverse effect levels:7:0.5926	0.5926	7
LOA	LOA:23|LoA:18	limits of agreement:41:0.8525	0.8525	41
LOA	LOA:13	loss of attachment:13:0.5934	0.5934	13
LOCAH	LOCAH:9|LO-CAH:1	congenital adrenal hyperplasia:10:0.5856	0.5856	10
LOCF	LOCF:30	last observation carried forward:30:0.8090	0.8090	30
LOCM	LOCM:20|locm:1	contrast media:21:0.8594	0.8594	21
LOC	LOC:18	lateral occipital complex:18:0.8365	0.8365	18
LOC	LOC:11	lateral olivocochlear:11:0.7357	0.7357	11
LOC	LOC:45|LoC:2|Loc:1	locus of control:48:0.8728	0.8728	48
LOC	LOC:83	loss of consciousness:83:0.8264	0.8264	83
LODs	LODs:105	limits of detection:105:0.9715	0.9715	105
LOD	LOD:11	detection limits:11:0.7357	0.7357	11
LOD	LOD:10	laparoscopic ovarian drilling:10:0.7103	0.7103	10
LOD	LOD:367|LoD:3|lod:1	limit of detection:371:0.6851	0.6851	371
LOD	LOD:86|lod:22|Lod:1	logarithm of odds:109:0.7550	0.7550	109
LOD	LOD:17|Lod:1	odds ratio:18:0.5940	0.5940	18
LOEL	LOEL:7	lowest observed effect level:7:0.5926	0.5926	7
logMAR	logMAR:52|LogMAR:12	logarithm of the minimum angle of resolution:64:0.8515	0.8515	64
L-OHP	L-OHP:52|l-OHP:4|LOHP:3	oxaliplatin:59:0.8923	0.8923	59
LOH	LOH:11	allelic loss:11:0.6182	0.6182	11
LOH	LOH:3071|LoH:2	Loss of heterozygosity:3055:0.9748|loss-of-heterozygosity:18:0.0052	0.9748	3073
LOINC	LOINC:14	Logical observation identifier names and codes:14:0.7909	0.7909	14
LOI	LOI:12	lactate-oxygen index:7:0.1641|lactate oxygen index:5:0.2818	0.2818	12
LOI	LOI:78	loss of imprinting:78:0.8564	0.8564	78
LOOHs	LOOHs:25	lipid hydroperoxides:25:0.7249	0.7249	25
LOOH	LOOH:24	linoleic acid hydroperoxide:24:0.8768	0.8768	24
LOOH	LOOH:69	lipid hydroperoxides:48:0.8728|lipid hydroperoxide:21:0.2743	0.8728	69
LOOH	LOOH:9|L-OOH:1	lipid peroxides:10:0.7103	0.7103	10
LOO	LOO:25|loo:1	leave-one-out:26:0.8333	0.8333	26
LOP	LOP:4|L-o-p:1|LoP:1	levels of processing:6:0.1838	0.1838	6
LOP	LOP:5	Lipid ozonation products:5:0.4422	0.4422	5
LOQs	LOQs:11	Limits of quantitation:11:0.4728	0.4728	11
LOQ	LOQ:30|LoQ:1	limits of quantification:31:0.1098	0.1098	31
LORCA	LORCA:6	optical rotational red cell analyzer:6:0.5290	0.5290	6
LORETA	LORETA:12	Low resolution brain electromagnetic tomography:12:0.7571	0.7571	12
LORETA	LORETA:54	Low Resolution Electromagnetic Tomography:33:0.9100|low-resolution electromagnetic tomography:21:0.1471	0.9100	54
LORR	LORR:17|LoRR:1	loss of the righting reflex:18:0.8941	0.8941	18
LOR	LOR:9|lor:2	lorazepam:11:0.1429	0.1429	11
LOSP	LOSP:21	lower oesophageal sphincter pressure:21:0.8594	0.8594	21
LOS	LOS:10	late-onset schizophrenia:10:0.5000	0.5000	10
LOS	LOS:968|LoS:1	Length of stay:949:0.8227|length-of-stay:20:0.0101	0.8227	969
LOS	LOS:26	lipo-oligosaccharide:26:0.0133	0.0133	26
LOS	LOS:308	lipooligosaccharide:248:0.1313|lipooligosaccharides:60:0.0309	0.1313	308
LOS	LOS:18|Los:15	losartan:33:0.0171	0.0171	33
LOS	LOS:29	low cardiac output syndrome:29:0.8978	0.8978	29
LOS	LOS:20	low output syndrome:20:0.2485	0.2485	20
LOS	LOS:174	lower oesophageal sphincter:174:0.9725	0.9725	174
LOT	LOT:104	lateral olfactory tract:104:0.9712	0.9712	104
LOT	LOT:13	Life Orientation Test:13:0.7753	0.7753	13
LOV	LOV:21|Lov:2	Lovastatin:23:0.3385	0.3385	23
LOXL	LOXL:9	lysyl oxidase-like:9:0.6794	0.6794	9
LOXs	LOXs:23	lipoxygenases:23:0.8148	0.8148	23
LOX	LOX:11	5-lipoxygenase:11:0.0281	0.0281	11
Lox	Lox:5	lipid oxidation:5:0.1132	0.1132	5
LOX	LOX:24|Lox:1	lipoxygenases:25:0.0674	0.0674	25
LOX	LOX:45|Lox:2	lysyl oxidase:47:0.6867	0.6867	47
Lp-1	Lp-1:6|Lp1:5|LP1:3	Legionella pneumophila serogroup 1:14:0.6173	0.6173	14
L-PAM	L-PAM:56|L-pam:1|L-Pam:1|l-PAM:1|l-Pam:1	L-phenylalanine mustard:60:0.7703	0.7703	60
LpA	LpA:10	glomerular permeability coefficient:10:0.7103	0.7103	10
LpA	LpA:21	glomerular ultrafiltration coefficient:21:0.8594	0.8594	21
LPA	LPA:16	latex particle agglutination:16:0.8165	0.8165	16
LPA	LPA:45|lPA:1	left pulmonary artery:46:0.8676	0.8676	46
LPA	LPA:18	Limulus polyphemus:18:0.8365	0.8365	18
LPA	LPA:16	Limulus polyphemus agglutinin:16:0.8165	0.8165	16
LPA	LPA:20	linear polyacrylamide:20:0.8525	0.8525	20
LPA	LPA:14	lysophosphatidate:14:0.0111	0.0111	14
LPA	LPA:810	lysophosphatidic acid:810:0.9381	0.9381	810
LPA	LPA:6	physical activity:6:0.2243	0.2243	6
LPBE	LPBE:6	liquid-phase blocking ELISA:6:0.5290	0.5290	6
LPBN	LPBN:33|lPBN:3|L-PBN:1|l-PBN:1	lateral parabrachial nucleus:38:0.9217	0.9217	38
LPB	LPB:11|lPB:2	lateral parabrachial nucleus:13:0.7753	0.7753	13
LpB	LpB:8|LP-B:1	lipoproteins:9:0.1143	0.1143	9
LPCA	LPCA:9	posterior ciliary artery:9:0.6794	0.6794	9
LPC	LPC:9|L-PC:1	L-propionylcarnitine:10:0.0112	0.0112	10
LPC	LPC:13	late positive complex:13:0.7753	0.7753	13
LPC	LPC:29	late positive component:29:0.8422	0.8422	29
LPC	LPC:8	leukemic progenitor cell:8:0.6411	0.6411	8
LPC	LPC:38|L-PC:1	lysophosphatidyl choline:39:0.7860	0.7860	39
LPC	LPC:466|L-PC:5	lysophosphatidylcholine:471:0.5812	0.5812	471
LPDP	LPDP:12	lipoprotein-deficient plasma:12:0.4557	0.4557	12
LPDS	LPDS:44	lipoprotein-deficient serum:44:0.5545	0.5545	44
LPDs	LPDs:27	lymphoproliferative disorders:27:0.8312	0.8312	27
LPDV	LPDV:11	lymphoproliferative disease virus:11:0.7357	0.7357	11
LPD	LPD:5	lag phase duration:5:0.4422	0.4422	5
LPD	LPD:9	lateral patellar displacement:9:0.6794	0.6794	9
LPD	LPD:40	leiomyomatosis peritonealis disseminata:40:0.8839	0.8839	40
LPD	LPD:15|LpD:1	lipiodol:16:0.0262	0.0262	16
LPD	LPD:21	low potassium dextran:11:0.7357|Low-potassium dextran:10:0.1878	0.7357	21
LPD	LPD:57	low-protein diet:29:0.2012|low protein diet:23:0.5997|low protein diets:5:0.4422	0.5997	57
LPD	LPD:55	Luteal phase defect:46:0.9353|luteal phase defects:9:0.6794	0.9353	55
LPD	LPD:13	luteal phase deficiency:13:0.6701	0.6701	13
LPD	LPD:78|lpd:2	lymphoproliferative disease:63:0.8430|lymphoproliferative diseases:17:0.7407	0.8430	80
LPD	LPD:79	lymphoproliferative disorders:51:0.8799|lymphoproliferative disorder:28:0.7905	0.8799	79
LPFC	LPFC:12	prefrontal cortex:12:0.7571	0.7571	12
lpg	lpg:9|LPG:7	larvae per gram:16:0.8165	0.8165	16
LPG	LPG:158	lipophosphoglycan:158:0.5166	0.5166	158
LPG	LPG:17	Lipoprotein glomerulopathy:17:0.8270	0.8270	17
LPG	LPG:27	liquefied petroleum gas:27:0.6192	0.6192	27
L-PHA	L-PHA:6	leukoagglutinating phytohemagglutinin:6:0.2243	0.2243	6
LPHD	LPHD:10	Lymphocyte predominance Hodgkin's disease:10:0.5856	0.5856	10
LPHD	LPHD:10|LP-HD:1	lymphocyte predominant Hodgkin's disease:11:0.7357	0.7357	11
L-Phe	L-Phe:41|l-Phe:3|L-phe:3	L-phenylalanine:47:0.8364	0.8364	47
LPH	LPH:66|L-Ph:1	lactase-phlorizin hydrolase:67:0.6317	0.6317	67
LPH	LPH:10	lipotropin:10:0.0476	0.0476	10
L-PIA	L-PIA:25|l-PIA:1	L-N6-phenylisopropyladenosine:26:0.1773	0.1773	26
L-PIA	L-PIA:21|LPIA:2	L-phenylisopropyladenosine:23:0.1631	0.1631	23
LPI	LPI:16	laser peripheral iridotomy:16:0.8165	0.8165	16
LPI	LPI:7	Learning Preference Inventory:7:0.5926	0.5926	7
LPI	LPI:55	Lysinuric protein intolerance:55:0.9458	0.9458	55
LPI	LPI:16	lysophosphatidylinositol:16:0.0920	0.0920	16
LPJ	LPJ:10	lateral pancreaticojejunostomy:10:0.5856	0.5856	10
L-PK	L-PK:37|LPK:6	L-type pyruvate kinase:43:0.6202	0.6202	43
LPLA	LPLA:33|LPLa:2	lipoprotein lipase activity:35:0.9151	0.9151	35
L-PLA	L-PLA:7|l-PLA:2	Poly(l-lactide):9:0.1081	0.1081	9
LPLND	LPLND:12|L-PLND:2	laparoscopic pelvic lymph node dissection:14:0.6911	0.6911	14
LPL	LPL:16	lamina propria:16:0.8165	0.8165	16
LPL	LPL:94	lamina propria lymphocytes:78:0.9393|lamina propria lymphocyte:16:0.8165	0.9393	94
LPL	LPL:2036|LpL:86|Lpl:5|lpl:2	lipoprotein lipase:2120:0.9923|Lipoprotein-lipase:9:0.0032	0.9923	2129
LPL	LPL:15	lipoprotein lipase activity:15:0.8045	0.8045	15
LPL	LPL:13	lipoprotein lipase gene:13:0.7909	0.7909	13
LPL	LPL:23	lymphoplasmacytic lymphoma:23:0.4652	0.4652	23
LPL	LPL:8	lymphoplasmacytoid lymphoma:8:0.0648	0.0648	8
LPL	LPL:14	lysophospholipase:14:0.0053	0.0053	14
LPMC	LPMC:46	lamina propria mononuclear cells:46:0.9353	0.9353	46
LPMCs	LPMCs:18	lamina propria mononuclear cells:18:0.8365	0.8365	18
LPME	LPME:35	liquid-phase microextraction:35:0.9151	0.9151	35
LPMNC	LPMNC:9	lamina propria mononuclear cells:9:0.6794	0.6794	9
LPOA	LPOA:11|lPOA:1	lateral preoptic area:12:0.6460	0.6460	12
LPO	LPO:123|Lpo:1	lactoperoxidase:124:0.0775	0.0775	124
LPO	LPO:16	lateral preoptic area:16:0.8165	0.8165	16
LPO	LPO:24	lipid hydroperoxide:13:0.7753|lipid hydroperoxides:11:0.7357	0.7753	24
LPO	LPO:12	lipid peroxidase:12:0.4557	0.4557	12
LPO	LPO:897|LpO:1	lipid peroxidation:898:0.9895	0.9895	898
LPO	LPO:10	lipid peroxidation products:10:0.7103	0.7103	10
LPO	LPO:285|Lpo:1	lipid peroxide:194:0.9596|lipid peroxides:92:0.9675	0.9675	286
LPO	LPO:12	lipoperoxidation:12:0.0069	0.0069	12
LPO	LPO:36	lipoperoxide:24:0.0145|lipoperoxides:12:0.0069	0.0145	36
LPO	LPO:48	lobus parolfactorius:48:0.8728	0.8728	48
LPO	LPO:6	peroxide oxidation:6:0.1543	0.1543	6
LPPG	LPPG:12	lipopeptidophosphoglycan:12:0.5238	0.5238	12
LPPs	LPPs:9	lipid phosphate phosphatases:9:0.6794	0.6794	9
LPP	LPP:19	lateral perforant path:19:0.7658	0.7658	19
LPP	LPP:25	leak point pressure:25:0.8816	0.8816	25
LPP	LPP:11	lichen planus pemphigoides:11:0.7357	0.7357	11
LPP	LPP:14	lipid peroxidation products:14:0.7909	0.7909	14
lpp	lpp:7	lipoprotein gene:7:0.1850	0.1850	7
Lpp	Lpp:7|lpp:2	major outer membrane lipoprotein:9:0.5470	0.5470	9
LPQ	LPQ:9|LP-Q:4	left pulmonary vascular pressure-flow:13:0.7753	0.7753	13
LPR	LPR:46	laryngopharyngeal reflux:46:0.8986	0.8986	46
LPR	LPR:64	late-phase reaction:27:0.3787|late phase reaction:17:0.7407|late-phase reactions:12:0.2083|late phase reactions:8:0.6411	0.7407	64
LPR	LPR:27	late-phase response:14:0.1169|late phase response:13:0.7753	0.7753	27
lpr	lpr:34	lymphoproliferation:34:0.0764	0.0764	34
lpr	lpr:11|LPR:1	lymphoproliferative:12:0.0255	0.0255	12
LPR	LPR:25	lymphoproliferative response:18:0.1771|lymphoproliferative responses:7:0.1211	0.1771	25
lpr	lpr:10	MRL-lpr/lpr:10:0.0208	0.0208	10
LPSs	LPSs:207	lipopolysaccharides:207:0.9196	0.9196	207
LPS	LPS:38	anti-lipopolysaccharide:38:0.0022	0.0022	38
LPS	LPS:115	bacterial endotoxin:108:0.1453|bacterial endotoxins:7:0.0828	0.1453	115
LPS	LPS:190	bacterial lipopolysaccharides:190:0.1303	0.1303	190
LPS	LPS:6	bacterial products:6:0.0666	0.0666	6
LPS	LPS:10	endotoxin/lipopolysaccharide:10:0.0005	0.0005	10
LPS	LPS:10|LP-s:2	lactoperoxidase system:12:0.3058	0.3058	12
LPs	LPs:40|LPS:2	late potentials:42:0.8263	0.8263	42
LPs	LPs:10	leukapheresis products:10:0.2643	0.2643	10
LPS	LPS:16	levator palpebrae superioris:16:0.8165	0.8165	16
LPS	LPS:11	lipo-polysaccharide:11:0.0006	0.0006	11
LPS	LPS:24	lipolysaccharide:24:0.0014	0.0014	24
LPS	LPS:10	lipopolisaccharide:10:0.0005	0.0005	10
LPS	LPS:10	lipopoly-saccharide:10:0.0005	0.0005	10
LPS	LPS:41	lipopolysaccaride:41:0.0024	0.0024	41
LPS	LPS:13934|lps:5|Lps:1	lipopolysaccharide:13922:0.8308|lipopolysaccharide-:18:0.0010	0.8308	13940
LPS	LPS:7	Lipopolysaccharide from Escherichia coli:7:0.4849	0.4849	7
LPS	LPS:27	lipopolysacharide:27:0.0016	0.0016	27
LPs	LPs:9|Lps:2	lipoproteins:11:0.0006	0.0006	11
LPs	LPs:16	lumbar punctures:16:0.8165	0.8165	16
LPS	LPS:20	lypopolysaccharide:20:0.0011	0.0011	20
LPS	LPS:13	lysophosphatidylserine:13:0.0007	0.0007	13
LPT	LPT:14	lymphocyte proliferation test:14:0.7909	0.7909	14
LPV/r	LPV/r:14	Lopinavir/ritonavir:14:0.5909	0.5909	14
L-PVR	L-PVR:9|LPVR:3	pulmonary vascular resistance:12:0.7571	0.7571	12
LPV	LPV:28|Lpv:1	lopinavir:29:0.3111	0.3111	29
LPV	LPV:12	lymphotropic papovavirus:12:0.2549	0.2549	12
LPV	LPV:6	Monkey B-lymphotropic papovavirus:6:0.1320	0.1320	6
LP-X	LP-X:9	abnormal lipoprotein:9:0.2285	0.2285	9
LPX	LPX:11|LPx:9|L-px:1	lipid peroxidation:21:0.8594	0.8594	21
LP-X	LP-X:56|Lp-X:16|LPX:6|LpX:3|LPx:1|Lp-x:1|lp-X:1	lipoprotein-X:59:0.3642|lipoprotein X:25:0.7679	0.7679	84
LPZ	LPZ:23	lansoprazole:23:0.5000	0.5000	23
LPN	LPN:31	laparoscopic partial nephrectomy:31:0.9043	0.9043	31
LPN	LPN:11	lateral plantar nerve:11:0.7357	0.7357	11
LPN	LPN:8	licensed practical nurse:8:0.5006	0.5006	8
LQAS	LQAS:32	lot quality assurance sampling:32:0.8519	0.8519	32
LQOLP	LQOLP:6|LQoLP:3	Lancashire Quality of Life Profile:9:0.6794	0.6794	9
LQT	LQT:32	long QT syndrome:32:0.9072	0.9072	32
LQT2	LQT2:9	long QT syndrome:9:0.6794	0.6794	9
LQT3	LQT3:4|LQT-3:2	congenital long-QT syndrome:6:0.1838	0.1838	6
LQT3	LQT3:6|LQT-3:1	long QT syndrome:7:0.5926	0.5926	7
LQTS	LQTS:312|LQTs:2	long QT syndrome:304:0.9901|long QT syndromes:10:0.7103	0.9901	314
LQ	LQ:18	life quality:18:0.6381	0.6381	18
LQ	LQ:161|L-Q:6	linear-quadratic:124:0.4271|linear quadratic:43:0.8590	0.8590	167
LQ	LQ:53	lordosis quotient:40:0.6808|lordosis quotients:13:0.4849	0.6808	53
LR+	LR+:8	positive likelihood ratio:8:0.4102	0.4102	8
LRAT	LRAT:7	lecithin retinol acyl transferase:7:0.5926	0.5926	7
LRAT	LRAT:43	lecithin:retinol acyltransferase:29:0.3379|lecithin retinol acyltransferase:14:0.8594	0.8594	43
LRA	LRA:11	logistic regression analysis:11:0.5355	0.5355	11
LRA	LRA:10	right atrium:10:0.7103	0.7103	10
LRCs	LRCs:11	label-retaining cells:11:0.4728	0.4728	11
LRC	LRC:15	leukocyte receptor complex:15:0.6386	0.6386	15
LRC	LRC:39	Lipid Research Clinics:39:0.9237	0.9237	39
LRC	LRC:5	locomotor-respiratory coupling:5:0.0902	0.0902	5
LRC	LRC:21	locoregional control:21:0.4041	0.4041	21
LRD	LRD:90	living-related donor:35:0.3603|living related donor:28:0.7581|living-related donors:14:0.2326|living related donors:13:0.5934	0.7581	90
LRD	LRD:11	lysinated rhodamine dextran:11:0.7357	0.7357	11
LRECs	LRECs:15	local research ethics committees:15:0.8045	0.8045	15
LREH	LREH:12	essential hypertension:12:0.6460	0.6460	12
LRET	LRET:9	luminescence resonance energy transfer:9:0.6794	0.6794	9
LRE	LRE:26|lre:1	lamina rara externa:27:0.8903	0.8903	27
LRE	LRE:9	leukemic reticuloendotheliosis:9:0.3945	0.3945	9
LRE	LRE:5	light-responsive element:5:0.0736	0.0736	5
LRE	LRE:13	localization-related epilepsy:13:0.6701	0.6701	13
LRFS	LRFS:18	local recurrence-free survival:18:0.7539	0.7539	18
LRF	LRF:39|lrf:1	luteinizing hormone-releasing factor:40:0.8811	0.8811	40
LRG	LRG:9	leucine-rich glycoprotein:9:0.5470	0.5470	9
LRH-1	LRH-1:22|LRH1:1|Lrh-1:1	liver receptor homolog-1:15:0.7909|liver receptor homolog 1:9:0.6794	0.7909	24
LRH	LRH:85	luteinizing hormone-releasing hormone:62:0.8788|luteinizing hormone releasing hormone:23:0.8038	0.8788	85
LRIs	LRIs:5	lower respiratory illnesses:5:0.4422	0.4422	5
LRI	LRI:13|lri:1	lamina rara interna:14:0.7909	0.7909	14
LRI	LRI:22	lower respiratory illness:22:0.8657	0.8657	22
LRI	LRI:22	lower respiratory infection:15:0.8045|lower respiratory infections:7:0.5926	0.8045	22
LRI	LRI:9	lower respiratory tract illness:9:0.6794	0.6794	9
LRI	LRI:25	lower respiratory tract infection:20:0.8525|lower respiratory tract infections:5:0.4422	0.8525	25
LRLT	LRLT:48	living related liver transplantation:48:0.9379	0.9379	48
LRN	LRN:14	Laparoscopic radical nephrectomy:14:0.7909	0.7909	14
LRN	LRN:96|LRn:1	lateral reticular nucleus:97:0.9692	0.9692	97
LRP1	LRP1:4|LRP-1:3	lipoprotein receptor-related protein:7:0.5926	0.5926	7
LRP1	LRP1:8|LRP-1:1|Lrp1:1	lipoprotein receptor-related protein 1:10:0.3470	0.3470	10
LRP-1	LRP-1:5	low density lipoprotein receptor-related protein-1:5:0.4422	0.4422	5
LRP5	LRP5:12	LDL receptor-related protein 5:12:0.1830	0.1830	12
LRP5	LRP5:15	low-density lipoprotein receptor-related protein 5:15:0.6386	0.6386	15
LRPs	LRPs:12	Lateralized readiness potentials:12:0.7571	0.7571	12
LRP	LRP:6	laminin receptor precursor:6:0.5290	0.5290	6
LRP	LRP:37	laparoscopic radical prostatectomy:37:0.8749	0.8749	37
LRP	LRP:11	late receptor potential:11:0.7357	0.7357	11
LRP	LRP:53	lateralized readiness potential:53:0.8373	0.8373	53
LRP	LRP:265	low density lipoprotein receptor-related protein:162:0.8914|low-density lipoprotein receptor-related protein:103:0.2956	0.8914	265
LRP	LRP:12	low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor:12:0.7571	0.7571	12
LRRs	LRRs:69	Leucine-rich repeats:69:0.8099	0.8099	69
LRR	LRR:183	leucine-rich repeat:142:0.8044|leucine-rich repeats:41:0.6691	0.8044	183
LRR	LRR:14	light reflection rheography:14:0.7909	0.7909	14
LRR	LRR:10	local-regional recurrence:10:0.0730	0.0730	10
LRR	LRR:32	locoregional recurrence:32:0.4949	0.4949	32
LRR	LRR:22	loss of righting reflex:22:0.8422	0.8422	22
LRSS	LRSS:10	late respiratory systemic syndrome:10:0.7103	0.7103	10
LRS	LRS:30	Lactated Ringer's Solution:30:0.9011	0.9011	30
LRs	LRs:63	likelihood ratios:63:0.9253	0.9253	63
LRS	LRS:11	lymphoreticular system:11:0.2582	0.2582	11
LRTIs	LRTIs:38	lower respiratory tract infections:38:0.9217	0.9217	38
LRTI	LRTI:7|LRTi:2	lower respiratory tract illness:9:0.6794	0.6794	9
LRTI	LRTI:148|LRTi:2	lower respiratory tract infections:75:0.9596|lower respiratory tract infection:75:0.9370	0.9596	150
LRt	LRt:9|LRT:2	lateral reticular nucleus:11:0.7571	0.7571	11
LRT	LRT:17	likelihood ratio test:17:0.8270	0.8270	17
LRT	LRT:29	lower respiratory tract:29:0.8978	0.8978	29
LRV	LRV:26	left renal vein:26:0.8251	0.8251	26
LRYGB	LRYGB:10	laparoscopic Roux-en-Y gastric bypass:10:0.7103	0.7103	10
LRYGBP	LRYGBP:50	laparoscopic Roux-en-Y gastric bypass:50:0.8776	0.8776	50
LRZ	LRZ:9	lorazepam:9:0.8889	0.8889	9
LR	LR:95	lactated Ringer's:83:0.9081|lactated ringers:12:0.6460	0.9081	95
LR	LR:82|L-R:2	lactated Ringer's solution:73:0.9591|lactated Ringer solution:11:0.6182	0.9591	84
LR	LR:15	laminin receptor:15:0.3110	0.3110	15
LR	LR:8	late response:8:0.0517	0.0517	8
LR	LR:21	latency-related:21:0.0129	0.0129	21
LR	LR:27	lateral rectus:27:0.8312	0.8312	27
LR	LR:53|L-R:42	left-right:95:0.0608	0.0608	95
L-R	L-R:23|L----R:2|LR:1	left-to-right:19:0.0116|left to right:7:0.3524	0.3524	26
LR	LR:12	leptin receptor:12:0.2083	0.2083	12
LR	LR:9	Leukoregulin:9:0.0052	0.0052	9
LR	LR:10	light rough:10:0.7103	0.7103	10
LR	LR:130	likelihood ratio:90:0.7183|likelihood ratios:40:0.8839	0.8839	130
LR	LR:11	linear regression:11:0.0525	0.0525	11
LR	LR:8	livedo reticularis:8:0.5006	0.5006	8
LR	LR:10	Liver regeneration:10:0.5856	0.5856	10
LR	LR:13	liver resection:13:0.3331	0.3331	13
LR	LR:107	local recurrence:96:0.8583|local recurrences:11:0.3495	0.8583	107
LR	LR:5	local relapse:5:0.0902	0.0902	5
LR	LR:65	logistic regression:65:0.7336	0.7336	65
LR	LR:12	low level of response:12:0.4557	0.4557	12
LR	LR:43	low responders:21:0.7291|low-responder:11:0.0065|low responder:11:0.7357	0.7357	43
LR	LR:60|L-R:1	low-risk:31:0.0194|low risk:30:0.7315	0.7315	61
LR	LR:4	PCNA labeling rate:4:0.5290	0.5290	4
LR	LR:10	reaction:10:0.0058	0.0058	10
Lr	Lr:4	situ relaxation length:4:0.1618	0.1618	4
LSA-1	LSA-1:19|LSA1:2	liver stage antigen-1:12:0.7571|Liver-stage antigen 1:9:0.4587	0.7571	21
LSAS	LSAS:43	Liebowitz Social Anxiety Scale:43:0.8917	0.8917	43
LSA	LSA:8	Latent semantic analysis:8:0.6411	0.6411	8
LSA	LSA:12	lateral septal area:12:0.7571	0.7571	12
LSA	LSA:11	left subclavian artery:11:0.6182	0.6182	11
LSA	LSA:6	lenticulostriate artery:6:0.0564	0.0564	6
LSA	LSA:66	lichen sclerosus et atrophicus:66:0.9548	0.9548	66
LSA	LSA:9	liver-specific antigen:9:0.3455	0.3455	9
LSA	LSA:13|LS-A:3	lymphosarcoma:16:0.0500	0.0500	16
LS-BMD	LS-BMD:6|LSBMD:2	lumbar spine bone mineral density:8:0.5006	0.5006	8
LSB	LSB:15	long spike bursts:15:0.8045	0.8045	15
LSCC	LSCC:57	laryngeal squamous cell carcinoma:57:0.8920	0.8920	57
LSCCs	LSCCs:12	laryngeal squamous cell carcinomas:12:0.7571	0.7571	12
LSCD	LSCD:13	limbal stem cell deficiency:13:0.7753	0.7753	13
LSCLC	LSCLC:15|L-SCLC:6	small-cell lung cancer:13:0.3554|small cell lung cancer:8:0.6411	0.6411	21
LSCM	LSCM:25	laser scanning confocal microscope:25:0.8816	0.8816	25
LSCM	LSCM:78	laser scanning confocal microscopy:78:0.9393	0.9393	78
LSCS	LSCS:12	lower segment Caesarean section:12:0.7571	0.7571	12
LSDI	LSDI:8	line scan diffusion imaging:8:0.6411	0.6411	8
LSDs	LSDs:17	lysosomal storage diseases:17:0.8270	0.8270	17
LSDs	LSDs:12	lysosomal storage disorders:12:0.7571	0.7571	12
LSDV	LSDV:13	lumpy skin disease virus:13:0.7753	0.7753	13
LSD	LSD:7	Lumpy skin disease:7:0.5926	0.5926	7
LSD	LSD:264	lysergic acid diethylamide:264:0.6303	0.6303	264
LSD	LSD:16	lysergide:16:0.0252	0.0252	16
LSD	LSD:12	lysosomal storage diseases:12:0.7571	0.7571	12
LSD	LSD:10	Lysosomal storage disorders:10:0.7103	0.7103	10
LSECs	LSECs:18	liver sinusoidal endothelial cells:18:0.7539	0.7539	18
LSEC	LSEC:11	liver sinusoidal endothelial cells:11:0.7357	0.7357	11
LSEQ	LSEQ:15	Leeds sleep evaluation questionnaire:15:0.8045	0.8045	15
LSERs	LSERs:24	Linear solvation energy relationships:24:0.8768	0.8768	24
LSER	LSER:41	linear solvation energy relationship:27:0.8903|linear solvation energy relationships:14:0.7909	0.8903	41
LSE	LSE:15	Living Skin Equivalent:15:0.8045	0.8045	15
LSE	LSE:9	low self-esteem:9:0.6794	0.6794	9
LSFs	LSFs:7	line spread functions:7:0.5926	0.5926	7
LSF	LSF:33	line spread function:33:0.9100	0.9100	33
LSF	LSF:21	Lisofylline:21:0.1449	0.1449	21
LSGs	LSGs:7	labial salivary glands:7:0.3524	0.3524	7
LSG	LSG:55	labial salivary gland:28:0.6295|labial salivary glands:27:0.7425	0.7425	55
LSG	LSG:5	preoperative lymphoscintigraphy:5:0.0902	0.0902	5
LSH	LSH:12	laparoscopic supracervical hysterectomy:12:0.7571	0.7571	12
LSILs	LSILs:14	low-grade squamous intraepithelial lesions:14:0.4367	0.4367	14
LSIL	LSIL:21	low-grade SIL:21:0.6040	0.6040	21
LSIL	LSIL:64|L-SIL:2	low-grade squamous intraepithelial lesions:48:0.5690|low grade squamous intraepithelial lesions:18:0.8365	0.8365	66
LSIMS	LSIMS:43|L-SIMS:1	liquid secondary ion mass spectrometry:44:0.8941	0.8941	44
LSI	LSI:11	learning style inventory:11:0.7357	0.7357	11
LSI	LSI:10	light scattering intensity:10:0.7103	0.7103	10
LSI	LSI:16	Liver somatic index:16:0.8165	0.8165	16
LSM	LSM:5	laser scanning microscope:5:0.4422	0.4422	5
LSM	LSM:13	laser scanning microscopy:13:0.7753	0.7753	13
LSM	LSM:15	limited sampling model:15:0.7909	0.7909	15
Lsm	LSm:2|Lsm:2	Sm and Sm-like:4:0.0612	0.0612	4
LSNA	LSNA:36	lumbar sympathetic nerve activity:36:0.9174	0.9174	36
LSN	LSN:24	lateral septal nucleus:24:0.8768	0.8768	24
LSN	LSN:7|LSn:2|lsn:1	lateral spinal nucleus:10:0.7103	0.7103	10
LSN	LSN:12	Low Score Normal:12:0.7571	0.7571	12
LSN	LSN:8	lumbar splanchnic nerve:8:0.3463	0.3463	8
LSOA	LSOA:16	Longitudinal Study of Aging:16:0.8861	0.8861	16
LSOD	LSOD:4|L-SOD:4|l-SOD:1	superoxide dismutase:9:0.5470	0.5470	9
LSO	LSO:34	lateral superior olivary nucleus:34:0.8644	0.8644	34
LSO	LSO:137	lateral superior olive:137:0.9782	0.9782	137
LSO	LSO:14	lutetium oxyorthosilicate:14:0.7909	0.7909	14
LSR	LSR:6	lipolysis-stimulated receptor:6:0.2243	0.2243	6
LSR	LSR:9|L-SR:1	sarcoplasmic reticulum:10:0.7103	0.7103	10
lSSc	lSSc:7	limited cutaneous SSc:7:0.5926	0.5926	7
lSSc	lSSc:6|LSSc:1	limited cutaneous systemic sclerosis:7:0.5926	0.5926	7
lSSc	lSSc:6	limited SSc:6:0.1148	0.1148	6
LSS	LSS:10	laminar shear stress:10:0.7103	0.7103	10
LSS	LSS:5	life satisfaction scale:5:0.1973	0.1973	5
LSS	LSS:17	Life Span Study:17:0.8270	0.8270	17
LSS	LSS:14	life support systems:9:0.3945|Life Support System:5:0.1973	0.3945	14
LSS	LSS:9	limb-sparing surgery:9:0.3945	0.3945	9
LSS	LSS:12	limited sampling strategy:7:0.5926|limited-sampling strategy:5:0.0612	0.5926	12
LSS	LSS:24	lumbar spinal stenosis:24:0.8768	0.8768	24
LST	LST:13	Lateral sinus thrombosis:13:0.6701	0.6701	13
LST	LST:30	Leishmanin skin test:30:0.8472	0.8472	30
LST	LST:9	life-sustaining treatments:9:0.6794	0.6794	9
LST	LST:7	lumbar sympathetic trunk:7:0.5926	0.5926	7
LST	LST:60	lymphocyte stimulation test:53:0.8842|lymphocyte stimulation tests:7:0.5926	0.8842	60
LST	LST:9	treatment:9:0.0356	0.0356	9
LSUHSC	LSUHSC:9	Louisiana State University Health Sciences Center:9:0.6794	0.6794	9
LSU	LSU:90|LSu:1|lsu:1	large subunit:79:0.8066|large-subunit:13:0.0822	0.8066	92
LSU	LSU:10	Louisiana State University:10:0.7103	0.7103	10
LSVC	LSVC:32|l-SVC:1	left superior vena cava:33:0.8196	0.8196	33
LSV	LSV:58	long saphenous vein:58:0.7637	0.7637	58
LSC	LSC:32	laser scanning cytometer:32:0.9072	0.9072	32
LSC	LSC:88	laser scanning cytometry:88:0.9660	0.9660	88
LSC	LSC:13	least significant change:13:0.7753	0.7753	13
LSC	LSC:41	liquid scintillation counting:41:0.9274	0.9274	41
LSC	LSC:8	stem cells:8:0.5006	0.5006	8
LS	LS:91	laparoscopic splenectomy:91:0.9304	0.9304	91
LS	LS:14	laparoscopic surgery:14:0.5589	0.5589	14
LS	LS:12	laparoscopy:12:0.0055	0.0055	12
LS	LS:21|Ls:1|ls:1	large subunit:23:0.7046	0.7046	23
LS	LS:24	Laron syndrome:24:0.1765	0.1765	24
LS	LS:14	lateral septal nucleus:14:0.7909	0.7909	14
LS	LS:83	lateral septum:83:0.9429	0.9429	83
LS	LS:29	lateral suprasylvian:29:0.8978	0.8978	29
LS	LS:7	lateral suprasylvian area:7:0.5926	0.5926	7
LS	LS:14	lateral suprasylvian visual area:14:0.7909	0.7909	14
LS	LS:42	least squares:23:0.8715|least-squares:19:0.0090	0.8715	42
LS	LS:32	Leigh syndrome:32:0.2637	0.2637	32
Ls	Ls:6|LS:2	length:8:0.0040	0.0040	8
LS	LS:7	Leukocyte scintigraphy:7:0.1211	0.1211	7
LS	LS:77|Ls:1	lichen sclerosus:78:0.9617	0.9617	78
LS	LS:11	Lichen striatus:11:0.7357	0.7357	11
LS	LS:27	light scattering:27:0.7066	0.7066	27
LS	LS:13	liquid scintillation:13:0.7753	0.7753	13
LS	LS:10	litter size:10:0.5856	0.5856	10
LS	LS:15	localized scleroderma:15:0.4609	0.4609	15
LS	LS:168	long-sleep:130:0.0643|long sleep:38:0.7548	0.7548	168
LS	LS:13	low salt:13:0.6701	0.6701	13
LS	LS:16	low-sodium:9:0.0040|low sodium:7:0.3524	0.3524	16
LS	LS:12|ls:1	low-spin:13:0.0060	0.0060	13
LS	LS:172	lumbar spine:172:0.9389	0.9389	172
LS	LS:19|ls:1	lumbosacral:20:0.0095	0.0095	20
LS	LS:13	lung surfactant:13:0.7753	0.7753	13
LS	LS:7	lymphocyte stimulation:7:0.1850	0.1850	7
LS	LS:12	lymphosarcoma:12:0.0055	0.0055	12
LS	LS:28	lymphoscintigraphy:28:0.0135	0.0135	28
LS	LS:10	score:10:0.0045	0.0045	10
LS	LS:11	synthase:11:0.0050	0.0050	11
L-T(4)	L-T(4):9|LT(4):7|l-T(4):1	levothyroxine:17:0.6154	0.6154	17
L-T3	L-T3:12|LT3:1|l-T3:1	3,5,3'-triiodo-L-thyronine:14:0.1383	0.1383	14
L-T3	L-T3:30|LT3:8	L-triiodothyronine:38:0.3936	0.3936	38
L-T4	L-T4:75|LT4:18|l-T4:5	L-thyroxine:98:0.4170	0.4170	98
LT4	LT4:51|L-T4:32|l-T4:2|LT-4:1	levothyroxine:86:0.3617	0.3617	86
L-T4	L-T4:6|LT4:2	levothyroxine sodium:8:0.4102	0.4102	8
L-T4	L-T4:8|LT4:1|l-T4:1	thyroxine:10:0.0383	0.0383	10
LT50	LT50:13	Median lethal time:13:0.6701	0.6701	13
LTA(4)	LTA(4):12	leukotriene A(4):12:0.6460	0.6460	12
LTA4	LTA4:65	leukotriene A4:65:0.9541	0.9541	65
LTAg	LTAg:5|L-T-Ag:1|LTag:1	large T antigen:7:0.5926	0.5926	7
LTAs	LTAs:24	Lipoteichoic acids:24:0.8768	0.8768	24
LTAS	LTAS:7	long-term average spectrum:7:0.4438	0.4438	7
LTA	LTA:11	activity:11:0.0173	0.0173	11
LTA	LTA:7	laser thermal ablation:7:0.4438	0.4438	7
LTA	LTA:6	Laser trabecular ablation:6:0.3728	0.3728	6
LTA	LTA:8	latent transition analysis:8:0.6411	0.6411	8
LTA	LTA:349	lipoteichoic acid:332:0.9599|lipoteichoic acids:17:0.7407	0.9599	349
LTA	LTA:22	Lotus tetragonolobus:22:0.8657	0.8657	22
LTA	LTA:10	Lotus tetragonolobus agglutinin:10:0.5856	0.5856	10
LTB(4)	LTB(4):136	leukotriene B(4):136:0.9429	0.9429	136
LTB4	LTB4:12	leukotriene:12:0.0066	0.0066	12
LTB4	LTB4:1544|LtB4:1|LTB-4:1	leukotriene B4:1533:0.9631|leukotriene-B4:13:0.0072	0.9631	1546
LTB5	LTB5:12	leukotriene B5:12:0.7571	0.7571	12
LTBI	LTBI:51	latent tuberculosis infection:51:0.9082	0.9082	51
LTBMCs	LTBMCs:33	Long-term bone marrow cultures:33:0.9100	0.9100	33
LTBMC	LTBMC:177|LT-BMC:2	long-term bone marrow culture:91:0.8753|long-term bone marrow cultures:88:0.8452	0.8753	179
LTBP	LTBP:31	latent TGF-beta binding protein:31:0.7718	0.7718	31
LTBP-1	LTBP-1:6|LTBP1:3|Ltbp-1:1	binding protein:10:0.4587	0.4587	10
LTBP-1	LTBP-1:7|LTBP1:1	latent TGF-beta binding protein-1:8:0.4102	0.4102	8
LTB	LTB:8|LT-B:2	Escherichia coli heat-labile enterotoxin:10:0.7103	0.7103	10
LTB	LTB:5|LT-B:2	Escherichia coli heat-labile enterotoxin B subunit:7:0.5926	0.5926	7
LTB	LTB:4|LT-B:4	heat-labile toxin:8:0.3463	0.3463	8
LTB	LTB:17	laryngotracheobronchitis:17:0.1259	0.1259	17
LTB	LTB:10	leukotriene B:10:0.1596	0.1596	10
LT-B	LT-B:4|LTB:4	subunit B:8:0.0953	0.0953	8
LTC(4)	LTC(4):51	leukotriene C(4):51:0.8102	0.8102	51
LTC4S	LTC4S:9	leukotriene C4 synthase:9:0.6794	0.6794	9
LTC4	LTC4:525|ltc4:1	leukotriene C4:526:0.8843	0.8843	526
LTCCs	LTCCs:6	L-type Ca2+ channels:6:0.5290	0.5290	6
LTCF	LTCF:26	long-term care facility:16:0.7261|long-term care facilities:10:0.5856	0.7261	26
LTCFs	LTCFs:53	long-term care facilities:29:0.7581|long-term-care facilities:24:0.2792	0.7581	53
LTC-ICs	LTC-ICs:53|LTCICs:4	long-term culture-initiating cells:42:0.8300|long-term culture initiating cells:15:0.8045	0.8300	57
LTC-IC	LTC-IC:198|LTCIC:24|LT-CIC:1	long-term culture-initiating cells:106:0.8809|long-term culture-initiating cell:52:0.8821|long-term culture initiating cells:49:0.8753|long-term culture initiating cell:16:0.6577	0.8821	223
LTCI	LTCI:17|LTC-I:1	long-term care insurance:18:0.7539	0.7539	18
LTC	LTC:203	long-term care:188:0.8834|long-term-care:15:0.0329	0.8834	203
LTC	LTC:85	long-term culture:54:0.6788|long-term cultures:31:0.5414	0.6788	85
LTD(4)	LTD(4):24	leukotriene D(4):24:0.7593	0.7593	24
LTD4	LTD4:309	leukotriene D4:309:0.8481	0.8481	309
LTD	LTD:12	Laron-type dwarfism:12:0.4153	0.4153	12
LTE(4)	LTE(4):10	leukotriene E(4):10:0.5000	0.5000	10
LTE4	LTE4:123	leukotriene E4:123:0.8611	0.8611	123
LTE	LTE:13	long-term enhancement:13:0.4849	0.4849	13
LTF	LTF:9|ltf:1	lactotransferrin:10:0.0566	0.0566	10
LTF	LTF:24	lateral tegmental field:24:0.8768	0.8768	24
LTF	LTF:58	long-term facilitation:58:0.7792	0.7792	58
LTF	LTF:16	lymphocyte transformation:16:0.7261	0.7261	16
LTG	LTG:307	lamotrigine:307:0.7708	0.7708	307
LTG	LTG:58	low tension glaucoma:30:0.9011|low-tension glaucoma:28:0.3279	0.9011	58
l-THP	l-THP:12|L-THP:3	l-tetrahydropalmatine:15:0.8235	0.8235	15
LTH	LTH:12	long-term habituation:12:0.5664	0.5664	12
LTIP	LTIP:11	lipid transfer inhibitor protein:11:0.7357	0.7357	11
LT-I	LT-I:5	heat-labile enterotoxin:5:0.0902	0.0902	5
LTLE	LTLE:9|L-TLE:1	left temporal lobe epilepsy:10:0.5000	0.5000	10
LTMCs	LTMCs:11	long-term marrow cultures:11:0.7357	0.7357	11
LTMC	LTMC:48	long-term marrow cultures:26:0.6351|long-term marrow culture:22:0.6531	0.6531	48
LTM	LTM:42	lean tissue mass:42:0.8558	0.8558	42
LTM	LTM:125	long-term memory:125:0.8800	0.8800	125
LTM	LTM:7	long-term monitoring:7:0.1850	0.1850	7
LTM	LTM:35	low-threshold mechanoreceptive:35:0.6666	0.6666	35
LTNPs	LTNPs:10	long-term non-progressors:10:0.5856	0.5856	10
LTNPs	LTNPs:26|LT-NPs:1	long-term nonprogressors:27:0.8312	0.8312	27
LTNP	LTNP:18|LTnP:1|LT-NP:1	long-term non-progressors:20:0.8594	0.8594	20
LTNP	LTNP:29|LTnP:1|LT-NP:1	long-term nonprogressors:20:0.7173|long-term nonprogressor:11:0.7357	0.7357	31
LTN	LTN:7	lateral terminal nucleus:7:0.5926	0.5926	7
Ltn	Ltn:11|LTN:1	lymphotactin:12:0.2245	0.2245	12
LTOT	LTOT:119	Long-term oxygen therapy:119:0.7617	0.7617	119
LTOT	LTOT:10	long-term oxygen treatment:10:0.7103	0.7103	10
LTO	LTO:12	long-term oxygen therapy:12:0.4557	0.4557	12
LTPA	LTPA:41|ltpa:1	leisure time physical activity:42:0.9274	0.9274	42
LTPs	LTPs:30	lipid transfer proteins:30:0.9011	0.9011	30
LTP	LTP:8|L-TP:7	L-tryptophan:15:0.0042	0.0042	15
LTP	LTP:19	laser trabeculoplasty:19:0.8449	0.8449	19
LTP	LTP:23	lipid transfer particle:23:0.8038	0.8038	23
LTP	LTP:74	lipid transfer protein:62:0.9519|lipid transfer proteins:12:0.7357	0.9519	74
LTP	LTP:2965	long-term potentiation:2965:0.9558	0.9558	2965
LTRAs	LTRAs:27	leukotriene receptor antagonists:27:0.7425	0.7425	27
LTRA	LTRA:10	leukotriene receptor antagonist:10:0.3867	0.3867	10
LTRA	LTRA:7	long-term repopulating ability:7:0.5926	0.5926	7
L-TRP	L-TRP:36|L-Trp:23|L-trp:5|l-Trp:1|l-TRP:1	L-tryptophan:66:0.9155	0.9155	66
LTRs	LTRs:330	Long terminal repeats:330:0.9676	0.9676	330
LTR	LTR:32	laryngotracheal reconstruction:32:0.9072	0.9072	32
LTR	LTR:9	long-term retention:9:0.4587	0.4587	9
LTR	LTR:89	long terminal repeats:77:0.8848|long-terminal-repeat:12:0.0054	0.8848	89
LTR	LTR:14	lung transplant recipients:14:0.6173	0.6173	14
LTSEM	LTSEM:17|LT-SEM:2	low-temperature scanning electron microscopy:12:0.3524|Low temperature scanning electron microscopy:7:0.5926	0.5926	19
LTS	LTS:11	laryngotracheal stenosis:11:0.6182	0.6182	11
LTs	LTs:369|LTS:5|Lts:1	leukotrienes:375:0.5641	0.5641	375
LTS	LTS:8	long-term survival:8:0.4102	0.4102	8
LTS	LTS:33	long-term survivors:33:0.6976	0.6976	33
LTS	LTS:23	low-threshold spike:23:0.3399	0.3399	23
LTT	LTT:127	lymphocyte transformation test:116:0.7979|Lymphocyte transformation tests:11:0.6182	0.7979	127
LTV	LTV:6	long-term variability:6:0.1320	0.1320	6
LTV	LTV:6	lung thermal volume:6:0.5290	0.5290	6
Ltx	Ltx:3|LTX:2|ltx:1	Actinobacillus actinomycetemcomitans leukotoxin:6:0.5290	0.5290	6
LTX	LTX:10|LTx:2	alpha-latrotoxin:12:0.0341	0.0341	12
LTx	LTx:14|LTX:5	liver transplant:19:0.3871	0.3871	19
LTx	LTx:128|LTX:45|Ltx:4|ltx:1	liver transplantation:178:0.7037	0.7037	178
LTx	LTx:11|LTX:1	lung transplant:12:0.1758	0.1758	12
LT-beta	LTbeta:14|LT-beta:14|Ltbeta:1	lymphotoxin-beta:15:0.4516|lymphotoxin beta:14:0.6173	0.6173	29
LT	LT:9	after lung transplantation:9:0.0758	0.0758	9
LT	LT:12	Anthrax lethal toxin:12:0.1423	0.1423	12
LT	LT:16	cysteinyl-leukotrienes:16:0.0044	0.0044	16
LT	LT:23|lt:1	Escherichia coli heat-labile toxin:24:0.6767	0.6767	24
LT	LT:98	heat-labile:82:0.0238|heat labile:16:0.8270	0.8270	98
LT	LT:10	heat-labile enterotoxin of Escherichia coli:10:0.7261	0.7261	10
LT	LT:12	heat labile toxin:12:0.5050	0.5050	12
LT	LT:26|L-T:3	L-tryptophan:29:0.0081	0.0081	29
LT	LT:169	lactate threshold:169:0.7735	0.7735	169
LT	LT:10	lamina terminalis:10:0.7103	0.7103	10
LT	LT:21|lT:1	large T:22:0.7400	0.7400	22
LT	LT:33	large T antigen:33:0.7841	0.7841	33
LT	LT:9	large tumor antigen:9:0.6794	0.6794	9
LT	LT:11	laryngeal tube:11:0.4728	0.4728	11
LT	LT:7	laser therapy:7:0.1470	0.1470	7
LT	LT:8	latency time:8:0.0726	0.0726	8
LT	LT:991	leukotriene:760:0.2197|Leukotrienes:231:0.0667	0.2197	991
LT	LT:12	light transmittance:12:0.7571	0.7571	12
LT	LT:10	Lissauer's tract:10:0.5000	0.5000	10
LT	LT:24	liver transplant:24:0.3828	0.3828	24
LT	LT:273	liver transplantation:273:0.7850	0.7850	273
LT	LT:12|lt:1	long-term:13:0.0035	0.0035	13
LT	LT:11	longissimus thoracis:11:0.7357	0.7357	11
LT	LT:10	low temperature:10:0.5856	0.5856	10
LT	LT:36	low-threshold:36:0.0102	0.0102	36
LT	LT:13	lung transplant:13:0.1423	0.1423	13
LT	LT:12	lunotriquetral:12:0.0032	0.0032	12
LT	LT:54	lymphocyte transformation:54:0.7492	0.7492	54
LT	LT:36	lymphocytic thyroiditis:36:0.8716	0.8716	36
LT	LT:13	lymphoid tissue:13:0.2802	0.2802	13
LT	LT:13	thermolabile:13:0.0035	0.0035	13
LUCA	LUCA:15	Last Universal Common Ancestor:15:0.8045	0.8045	15
luc	luc:7|LUC:2	firefly luciferase gene:9:0.2285	0.2285	9
LUC	LUC:16	large unstained cells:16:0.8165	0.8165	16
luc	luc:129|LUC:86|Luc:3	luciferase:218:0.6677	0.6677	218
luc	luc:7|LUC:3	luciferase reporter gene:10:0.4363	0.4363	10
LUF	LUF:27	luteinized unruptured follicle:27:0.7066	0.7066	27
LUL	LUL:12	left upper lobe:12:0.7571	0.7571	12
LUMO	LUMO:48|lumo:1	lowest unoccupied molecular orbital:49:0.9046	0.9046	49
LUNA	LUNA:11	nerve ablation:11:0.7357	0.7357	11
LUQ	LUQ:23	Left Upper Quadrant:23:0.8715	0.8715	23
LUTS	LUTS:417	lower urinary tract symptoms:417:0.9810	0.9810	417
LUT	LUT:41	lower urinary tract:41:0.9274	0.9274	41
LUV	LUV:10	large unilamellar liposomes:10:0.7103	0.7103	10
LUV	LUV:141	Large unilamellar vesicles:127:0.9403|large unilamellar vesicle:14:0.7909	0.9403	141
LUVs	LUVs:7	large unilamellar liposomes:7:0.4438	0.4438	7
LUVs	LUVs:112	large unilamellar vesicles:112:0.8972	0.8972	112
LUS	LUS:25	laparoscopic ultrasonography:25:0.6539	0.6539	25
LUS	LUS:23	laparoscopic ultrasound:23:0.7046	0.7046	23
LUS	LUS:10	lower uterine segment:10:0.7103	0.7103	10
Lu	Lu:12|LU:4	Lutheran:16:0.0974	0.0974	16
LU	LU:20|lu:1	lytic units:21:0.6812	0.6812	21
LVAD	LVAD:444	left ventricular assist device:405:0.9804|left ventricular assist devices:39:0.9237	0.9804	444
LVADs	LVADs:80|LVADS:1	left ventricular assist devices:81:0.9627	0.9627	81
LVAS	LVAS:21	Large Vestibular Aqueduct Syndrome:21:0.8594	0.8594	21
LVAS	LVAS:94	left ventricular assist system:82:0.9636|Left ventricular assist systems:12:0.7357	0.9636	94
LVA	LVA:37|LV-A:1	left ventricular aneurysm:38:0.8781	0.8781	38
LVA	LVA:4|LVa:1	left ventricular apex:5:0.4422	0.4422	5
LVA	LVA:132|l-v-a:3	low-voltage-activated:80:0.2811|Low voltage-activated:35:0.8681|low-voltage activated:14:0.4367|low voltage activated:6:0.5290	0.8681	135
LVB	LVB:8	left ventricular bypass:8:0.6411	0.6411	8
L-VDCC	L-VDCC:5	voltage-dependent calcium channels:5:0.4422	0.4422	5
LVDF	LVDF:14|LVdf:1	left ventricular diastolic function:15:0.8045	0.8045	15
LVDP	LVDP:283|LVdp:1	left ventricular developed pressure:284:0.9894	0.9894	284
LVDT	LVDT:10	linear variable differential transformer:10:0.5856	0.5856	10
LVDd	LVDd:5|LVDD:4	left ventricular diastolic diameter:9:0.6794	0.6794	9
LVDD	LVDD:15	left ventricular diastolic dysfunction:15:0.7096	0.7096	15
LVDd	LVDd:7|LVDD:1	left ventricular end-diastolic diameter:8:0.6411	0.6411	8
LVDd	LVDd:32|LVDD:2	left ventricular end-diastolic dimension:34:0.9126	0.9126	34
LVDs	LVDs:6	left ventricular end-systolic dimension:6:0.5290	0.5290	6
LVD	LVD:8	Left ventricular diameter:8:0.6411	0.6411	8
LVD	LVD:73	left ventricular dysfunction:73:0.9591	0.9591	73
LVD	LVD:8	lymphatic vessel density:8:0.5006	0.5006	8
LVED	LVED:7	Left ventricular end-diastolic:7:0.5926	0.5926	7
LVEDA	LVEDA:7|LVEDa:1	left ventricular end-diastolic area:8:0.6411	0.6411	8
LVEDD	LVEDD:45|LVEDd:1	left ventricular end-diastolic diameter:33:0.9100|Left ventricular end diastolic diameter:13:0.7753	0.9100	46
LVEDD	LVEDD:25|LVEDd:3|LV-EDD:1	left ventricular end-diastolic dimension:29:0.8978	0.8978	29
LVEDP	LVEDP:8	left ventricular end-diastolic:8:0.6411	0.6411	8
LVEDP	LVEDP:620|LVedP:3|LVeDP:1	left ventricular end-diastolic pressure:503:0.9941|Left ventricular end diastolic pressure:108:0.9417|left ventricular end-diastolic pressures:13:0.7753	0.9941	624
LVEDVI	LVEDVI:39	left ventricular end-diastolic volume index:39:0.9237	0.9237	39
LVEDV	LVEDV:7	left ventricular end-diastolic:7:0.5926	0.5926	7
LVEDV	LVEDV:87	Left ventricular end-diastolic volume:87:0.9455	0.9455	87
LVEFs	LVEFs:7	left ventricular ejection fractions:7:0.5926	0.5926	7
LVEF	LVEF:1372|LV-EF:7|L-VEF:1	left ventricular ejection fraction:1355:0.9952|Left ventricular ejection fractions:25:0.8186	0.9952	1380
LVEF	LVEF:5	left ventricular function:5:0.4422	0.4422	5
LVESD	LVESD:13	left ventricular end-systolic diameter:13:0.7753	0.7753	13
LVESD	LVESD:7	left ventricular end-systolic dimension:7:0.5926	0.5926	7
LVETI	LVETI:20|LVETi:1	Left ventricular ejection time index:21:0.8594	0.8594	21
LVETc	LVETc:13	left ventricular ejection time:13:0.7753	0.7753	13
LVE	LVE:10	left ventricular enlargement:10:0.5856	0.5856	10
LVF-RH	LVF-RH:9|lvf-RH:1	left visual field-right hemisphere:10:0.7103	0.7103	10
LVFA	LVFA:16	low voltage fast activity:16:0.8365	0.8365	16
LVFP	LVFP:32	left ventricular filling pressure:32:0.9072	0.9072	32
LVFS	LVFS:15	Left ventricular fractional shortening:15:0.8045	0.8045	15
LVFW	LVFW:36	left ventricular free wall:36:0.9174	0.9174	36
LVFWR	LVFWR:18	left ventricular free wall rupture:18:0.8365	0.8365	18
LVFX	LVFX:88	levofloxacin:88:0.9775	0.9775	88
LVF	LVF:42	left ventricular failure:42:0.9291	0.9291	42
LVF	LVF:52	Left ventricular function:52:0.9427	0.9427	52
LVF	LVF:74	left visual field:74:0.9159	0.9159	74
LVF	LVF:1	presented in either the left:1:0.0732	0.0732	1
L-VGCC	L-VGCC:6	L-type voltage-gated Ca(2+) channel:6:0.5290	0.5290	6
LVG	LVG:10	left ventriculogram:10:0.7103	0.7103	10
LVG	LVG:81	left ventriculography:81:0.9229	0.9229	81
LVH	LVH:1522	left ventricular hypertrophy:1522:0.9911	0.9911	1522
LVID	LVID:5	left ventricular internal diameter:5:0.4422	0.4422	5
LVIDd	LVIDd:6	internal diameter:6:0.1148	0.1148	6
LVIDd	LVIDd:8|LVIDD:1	internal dimension:9:0.2757	0.2757	9
LVI	LVI:16	lymphatic vessel invasion:16:0.8165	0.8165	16
LVI	LVI:33	lymphovascular invasion:33:0.3683	0.3683	33
LVL	LVL:27	Large volume leukapheresis:15:0.8045|large-volume leukapheresis:12:0.2183	0.8045	27
LVMI	LVMI:11	body surface area:11:0.7357	0.7357	11
LVMI	LVMI:366|LVMi:28|LVmi:1	left ventricular mass index:395:0.9878	0.9878	395
LVMM	LVMM:7	Left ventricular muscle mass:7:0.5926	0.5926	7
LVMM	LVMM:8	left ventricular myocardial mass:8:0.6411	0.6411	8
LVM	LVM:401|LVm:1	left ventricular mass:402:0.9767	0.9767	402
LVN	LVN:88	lateral vestibular nucleus:88:0.9660	0.9660	88
LVNC	LVNC:9	left ventricular noncompaction:9:0.6794	0.6794	9
LVO	LVO:26	left ventricular output:26:0.8861	0.8861	26
LVOR	LVOR:19|L-VOR:1|lVOR:1	linear vestibulo-ocular reflex:21:0.8594	0.8594	21
LVOT	LVOT:167	left ventricular outflow tract:167:0.9619	0.9619	167
LVOTG	LVOTG:6	left ventricular outflow tract gradient:6:0.5290	0.5290	6
LVOTO	LVOTO:45	left ventricular outflow tract obstruction:45:0.9338	0.9338	45
LVPSP	LVPSP:10	left ventricular peak systolic pressure:10:0.7103	0.7103	10
LVPWT	LVPWT:11	left ventricular posterior wall thickness:11:0.7357	0.7357	11
LVP	LVP:10	large volume paracentesis:10:0.7103	0.7103	10
LVP	LVP:17	late ventricular potentials:17:0.7407	0.7407	17
LVP	LVP:335|LVp:1	left ventricular pressure:336:0.9566	0.9566	336
LVP	LVP:20	levator veli palatini:20:0.8525	0.8525	20
LVP	LVP:26	lysine-8-vasopressin:26:0.0347	0.0347	26
LVP	LVP:116|L-VP:1	lysine vasopressin:68:0.7673|Lysine-vasopressin:49:0.0667	0.7673	117
LVQ	LVQ:24	Learning Vector Quantization:24:0.8768	0.8768	24
LVR	LVR:16	Lung volume reduction:16:0.8165	0.8165	16
LVR	LVR:22	vascular resistance:22:0.7955	0.7955	22
LVRS	LVRS:251	Lung volume reduction surgery:251:0.9808	0.9808	251
LVSD	LVSD:46	left ventricular systolic dysfunction:46:0.9353	0.9353	46
LVSEM	LVSEM:11|LV-SEM:1	scanning electron microscopy:12:0.7571	0.7571	12
LVSF	LVSF:9	left ventricular shortening fraction:9:0.6794	0.6794	9
LVSF	LVSF:8	left ventricular systolic function:8:0.6411	0.6411	8
LVSI	LVSI:29	space invasion:29:0.8422	0.8422	29
LVSI	LVSI:21	space involvement:21:0.8594	0.8594	21
LVSP	LVSP:10	left ventricular systolic:10:0.7103	0.7103	10
LVSP	LVSP:112	left ventricular systolic pressure:112:0.9310	0.9310	112
LVST	LVST:10	lateral vestibulospinal tract:10:0.7103	0.7103	10
LVSW	LVSW:31	left ventricular stroke work:31:0.9043	0.9043	31
LVSWI	LVSWI:115|LVSWi:1	left ventricular stroke work index:116:0.9589	0.9589	116
LVS	LVS:18	Francisella tularensis live vaccine strain:18:0.4672	0.4672	18
LVs	LVs:11	left ventricles:11:0.6182	0.6182	11
LVs	LVs:8	lentiviral vectors:8:0.5006	0.5006	8
LVV	LVV:22	left ventricular volume:22:0.8657	0.8657	22
LVW	LVW:22	Left ventricular weight:22:0.8657	0.8657	22
LVW/BW	LVW/BW:6	ratio of left ventricular weight to body weight:6:0.3728	0.3728	6
LVWI	LVWI:11	left ventricular work index:11:0.7357	0.7357	11
LVWT	LVWT:14	left ventricular wall thickness:14:0.7909	0.7909	14
LVX	LVX:11	levofloxacin:11:0.7692	0.7692	11
LVdP/dt	LVdP/dt:4|LVdp/dt:1	first derivative of left ventricular pressure:5:0.4422	0.4422	5
LVdP/dt	LVdP/dt:8|LVdp/dt:2	left ventricular dP/dt:10:0.7103	0.7103	10
LV	LV:13	5-fluorouracil (5-FU)/leucovorin:13:0.5335	0.5335	13
LV	LV:9	Lassa Virus:9:0.0606	0.0606	9
LV	LV:1181|lv:3	left ventricle:1184:0.9320	0.9320	1184
LV	LV:8621|lv:2	left ventricular:8545:0.9947|left-ventricular:78:0.0069	0.9947	8623
LV	LV:5	left ventricular free wall:5:0.4422	0.4422	5
LV	LV:10	left ventricule:10:0.7103	0.7103	10
LV	LV:23	Lelystad virus:23:0.3435	0.3435	23
Lv	Lv:10|LV:6	length density:16:0.7261	0.7261	16
LV	LV:11	leukocytoclastic vasculitis:11:0.2764	0.2764	11
LV	LV:7|Lv:6	lipovitellin:13:0.0011	0.0011	13
LV	LV:13	liquid ventilation:13:0.3554	0.3554	13
LV	LV:7	lung ventilation:7:0.0886	0.0886	7
LV	LV:17	lung volume:17:0.1720	0.1720	17
LV	LV:9	Lupus vulgaris:9:0.6794	0.6794	9
LW/BW	LW/BW:5	lung weight to body weight ratio:5:0.4422	0.4422	5
LWAQ	LWAQ:10	Living with Asthma Questionnaire:10:0.7103	0.7103	10
LWD	LWD:14	Leri-Weill dyschondrosteosis:14:0.7909	0.7909	14
LWS	LWS:9	long-wavelength-sensitive:9:0.1667	0.1667	9
LW	LW:29	Large White:29:0.7970	0.7970	29
LW	LW:10	lateral wall:10:0.3867	0.3867	10
LW	LW:34|lw:2	live weight:36:0.3666	0.3666	36
L-W	L-W:28|LW:5	Lobund-Wistar:33:0.0936	0.0936	33
LXR	LXR:102	liver X receptor:85:0.9640|liver X receptors:17:0.8270	0.9640	102
LXRs	LXRs:53	liver X receptors:53:0.9438	0.9438	53
LXs	LXs:22|LXS:1	lipoxins:23:0.8800	0.8800	23
LX	LX:47	lipoxins:29:0.2523|lipoxin:18:0.1532	0.2523	47
LYG	LYG:12	cost per life-year gained:12:0.3813	0.3813	12
LYG	LYG:37|LyG:3	lymphomatoid granulomatosis:40:0.9256	0.9256	40
LYM	LYM:10|lym:4	lymphocytes:14:0.4483	0.4483	14
LYZ	LYZ:8|Lyz:3|lyz:1	lysozyme:12:0.8462	0.8462	12
LY	LY:34	L5178Y:34:0.0710	0.0710	34
LY	LY:187	Lucifer Yellow:187:0.9659	0.9659	187
LY	LY:23	lucifer yellow CH:23:0.8715	0.8715	23
LY	LY:12	LY294002:12:0.0237	0.0237	12
ly	ly:10	lymphatic invasion:10:0.3867	0.3867	10
Ly	Ly:18|LY:13|ly:1	lymphocytes:22:0.0452|lymphocyte:10:0.0194	0.0452	32
LZ-8	LZ-8:10	Ling Zhi-8:10:0.7103	0.7103	10
LZM	LZM:69|Lzm:1	Lysozyme:70:0.8415	0.8415	70
LZP	LZP:10	lorazepam:10:0.7500	0.7500	10
LZR	LZR:19	Lean Zucker rats:19:0.8449	0.8449	19
LZ	LZ:37	leucine zipper:37:0.7758	0.7758	37
LZ	LZ:11	Lorazepam:11:0.0699	0.0699	11
lz	lz:6|Lz:5|LZ:1	lozenge:12:0.0769	0.0769	12
LZ	LZ:29|Lz:10	lysozyme:39:0.2657	0.2657	39
La3+	La3+:72	lanthanum:72:0.6961	0.6961	72
La3+	La3+:8	lanthanum ions:8:0.4102	0.4102	8
LaCl3	LaCl3:12	lanthanum chloride:12:0.6460	0.6460	12
LacCer	LacCer:62|Lac-Cer:2|Lac-cer:1	lactosylceramide:65:0.7805	0.7805	65
LacNAc	LacNAc:11|LacNAC:1|lacNAc:1	N-acetyllactosamine:13:0.4000	0.4000	13
LacR	LacR:5|lacR:3	Lac repressor:8:0.4102	0.4102	8
L-ase	L-ase:6|L-ASE:2|L-Ase:2	L-asparaginase:10:0.7500	0.7500	10
LB	LB:57|lb:2	lamellar bodies:39:0.2256|lamellar body:20:0.2172	0.2256	59
LB	LB:105|L-B:7	Langmuir-Blodgett:112:0.1233	0.1233	112
LB	LB:10	large bowel:10:0.7103	0.7103	10
Lb	Lb:16|lb:3	leghemoglobin:19:0.0200	0.0200	19
LB	LB:101	Lewy bodies:73:0.5049|Lewy body:28:0.3561	0.5049	101
LB	LB:13	live births:13:0.7753	0.7753	13
LB	LB:9	liver biopsy:9:0.4587	0.4587	9
LB	LB:6|Lb:2	Low Back:8:0.3463	0.3463	8
LB	LB:57	Luria-Bertani:57:0.0622	0.0622	57
LB	LB:13	Luria broth:13:0.3331	0.3331	13
LB	LB:71|Lb:1	Lyme borreliosis:72:0.9585	0.9585	72
LB	LB:11	lymphoblastoid:11:0.0111	0.0111	11
Lc/+	Lc/+:18|lc/+:3	lurcher:21:0.7407	0.7407	21
LCH	LCH:424	Langerhans cell histiocytosis:322:0.7081|Langerhans' cell histiocytosis:102:0.1949	0.7081	424
LCH	LCH:10	Leydig cell hypoplasia:10:0.7103	0.7103	10
LCH	LCH:9	lobular capillary hemangioma:9:0.6794	0.6794	9
LDD	LDD:28	Lhermitte-Duclos disease:28:0.6839	0.6839	28
LDD	LDD:7	low-dose dobutamine:7:0.3524	0.3524	7
LDD	LDD:10	low-dose dopamine:10:0.7103	0.7103	10
LdMNPV	LdMNPV:16	nuclear polyhedrosis virus:16:0.8165	0.8165	16
LdMNPV	LdMNPV:14	nucleopolyhedrovirus:14:0.3333	0.3333	14
L-DOPA	L-DOPA:16|L-dopa:9|L-Dopa:2	3,4-dihydroxyphenylalanine:27:0.0362	0.0362	27
L-DOPA	L-DOPA:11|L-dopa:2|L-Dopa:1|l-dopa:1	dihydroxyphenylalanine:15:0.0195	0.0195	15
L-DOPA	L-DOPA:180|L-dopa:53|L-Dopa:9|l-DOPA:8|l-dopa:2	L-3,4-dihydroxyphenylalanine:252:0.3491	0.3491	252
L-DOPA	L-DOPA:12|L-dopa:4	L-beta-3,4-dihydroxyphenylalanine:16:0.0209	0.0209	16
L-DOPA	L-DOPA:89|L-dopa:25|l-DOPA:6|L-Dopa:6|l-dopa:1	L-Dihydroxyphenylalanine:127:0.1752	0.1752	127
LEL	LEL:8	lymphoepithelial lesions:8:0.5006	0.5006	8
LeTx	LeTx:23|Letx:1	Lethal Toxin:24:0.8768	0.8768	24
LEA	LEA:12	epidural analgesia:12:0.7571	0.7571	12
LEA	LEA:42|Lea:13|lea:4	late embryogenesis abundant:34:0.9126|late embryogenesis-abundant:15:0.8045|late-embryogenesis-abundant:10:0.0288	0.9126	59
LEA	LEA:11	lateral entorhinal area:11:0.7357	0.7357	11
LEA	LEA:5	loin eye area:5:0.5290	0.5290	5
LEA	LEA:20	Long-Evans Agouti:20:0.7173	0.7173	20
LEA	LEA:24	lower extremity amputation:12:0.7571|lower-extremity amputation:12:0.2414	0.7571	24
LEA	LEA:8	lumbar epidural anesthesia:8:0.5006	0.5006	8
LEB	LEB:8	listeria enrichment broth:8:0.5006	0.5006	8
LecR	LecR:9|Lecr:1	lectin-resistant:10:0.6923	0.6923	10
LEPR	LEPR:40|Lepr:10|lepr:1|lepR:1|Lep-R:1|LepR:1	leptin receptor:54:0.8821	0.8821	54
LEPR	LEPR:12|Lepr:3	leptin receptor gene:15:0.8045	0.8045	15
Leq	Leq:5	equivalent sound level:5:0.1973	0.1973	5
Leu-Enk	Leu-Enk:23|Leu-enk:14|Leu-ENK:9|leu-enk:4|LEU-ENK:2|leu-ENK:2	leucine-enkephalin:44:0.4624|leucine enkephalin:10:0.7103	0.7103	54
LeuRS	LeuRS:25|leuRS:1	leucyl-tRNA synthetase:26:0.8861	0.8861	26
Leu	Leu:14|leu:3	L-leucine:17:0.0708	0.0708	17
Li(+)	Li(+):9	lithium:9:0.6667	0.6667	9
Li+	Li+:57	Lithium:57:0.5957	0.5957	57
Li+	Li+:9	lithium ion:9:0.6794	0.6794	9
Li2CO3	Li2CO3:15	Lithium carbonate:15:0.7096	0.7096	15
LiCl	LiCl:202|LiCL:1	lithium chloride:203:0.9853	0.9853	203
LIs	LIs:44|lis:1	labeling indices:45:0.4729	0.4729	45
LIs	LIs:24|lis:2	labelling indices:26:0.2245	0.2245	26
LIS	LIS:38	Laboratory Information System:38:0.6807	0.6807	38
LIS	LIS:31|lis:2	lateral intercellular spaces:21:0.8594|lateral intercellular space:12:0.6460	0.8594	33
LIS	LIS:11|lis:2	lisinopril:13:0.0291	0.0291	13
LIS	LIS:14|LiS:1	lithium diiodosalicylate:15:0.8045	0.8045	15
LIS	LIS:16|LiS:4	locked-in syndrome:20:0.7766	0.7766	20
LIS	LIS:11|lis:1	low ionic strength:12:0.7571	0.7571	12
LIS	LIS:39	Lung Injury Score:39:0.8455	0.8455	39
LIS	LIS:10	lymphocytic infiltration of the skin:10:0.7103	0.7103	10
LIE	LIE:14	linear interaction energy:14:0.7909	0.7909	14
Lin-	Lin-:21|lin-:6	lineage-negative:15:0.1944|lineage negative:12:0.3524	0.3524	27
LINAC	LINAC:33|linac:31|Linac:9	linear accelerator:73:0.8948	0.8948	73
LIN	LIN:9	intraepithelial neoplasia:9:0.4587	0.4587	9
LIN	LIN:48|Lin:3	linearity:51:0.3597	0.3597	51
LipDH	LipDH:7|LIPDH:5	lipoamide dehydrogenase:12:0.6460	0.6460	12
LI	LI:25|-LI:11	immunoreactivities:36:0.0121	0.0121	36
LI	LI:13	intensity:13:0.0041	0.0041	13
li	li:17|LI:2	invariant chain:19:0.8449	0.8449	19
LI	LI:774|Li:3	labeling index:777:0.6034	0.6034	777
LI	LI:83	labeling indices:83:0.5710	0.5710	83
LI	LI:337|Li:2	labelling index:339:0.2493	0.2493	339
LI	LI:31	labelling indices:31:0.1636	0.1636	31
LI	LI:11	lacunar infarcts:11:0.5355	0.5355	11
LI	LI:11	lacunar infarction:11:0.7357	0.7357	11
LI	LI:33	lamellar ichthyosis:33:0.9100	0.9100	33
LI	LI:23	language-impaired:14:0.0045|Language Impaired:9:0.3945	0.3945	23
LI	LI:40	language impairment:30:0.8032|language impairments:10:0.7103	0.8032	40
LI	LI:5	Laser irradiation:5:0.0902	0.0902	5
LI	LI:163	Latent inhibition:163:0.9357	0.9357	163
Li	Li:166|LI:3	Lithium:169:0.0579	0.0579	169
Li	Li:18	lithium carbonate:18:0.8365	0.8365	18
LI	LI:11	low-intensity:11:0.0034	0.0034	11
LI	LI:10	lymphocytic infiltration:10:0.2275	0.2275	10
LktA	LktA:16|lktA:2	leukotoxin:18:0.6800	0.6800	18
Lmax	Lmax:6	maximum active force:6:0.5290	0.5290	6
LoVo	LoVo:4	human colon cancer cells:4:0.1618	0.1618	4
LoVo	LoVo:5	human colon carcinoma:5:0.2818	0.2818	5
LOX-1	LOX-1:18	lectin-like oxidized LDL receptor-1:18:0.7539	0.7539	18
LOX-1	LOX-1:10	lectin-like oxidized low-density lipoprotein receptor:10:0.5856	0.5856	10
LOX-1	LOX-1:23	Lectin-like oxidized low-density lipoprotein receptor-1:23:0.8038	0.8038	23
LOX-1	LOX-1:6|LOX1:1	soybean lipoxygenase-1:7:0.1850	0.1850	7
LO	LO:23	5-lipoxygenase:23:0.0353	0.0353	23
LO	LO:8	leucine oxidation:8:0.4102	0.4102	8
LO	LO:24	linseed oil:24:0.7151	0.7151	24
LO	LO:127	lipoxygenase:127:0.2019	0.2019	127
LO	LO:37	lysyl oxidase:37:0.8749	0.8749	37
Lo	Lo:23|lo:2	optimal length:25:0.2332	0.2332	25
Lp(a)	Lp(a):306|LP(a):5|lp(a):1	Lipoprotein(a):312:0.9341	0.9341	312
Lp(a)	Lp(a):4|Lp(a-):1	Lp(a) lipoprotein:5:0.1132	0.1132	5
Lp-PLA(2)	Lp-PLA(2):9	lipoprotein-associated phospholipase A(2):9:0.6794	0.6794	9
Lp-PLA2	Lp-PLA2:15	lipoprotein-associated phospholipase A2:15:0.7096	0.7096	15
LPAI	LPAI:16	avian influenza:16:0.8165	0.8165	16
LpA-I	LpA-I:4|LpAI:1	containing apo A-I but not apo A-II:5:0.2818	0.2818	5
LpA-I	LpA-I:2	containing apoA-I but no apoA-II:2:0.1973	0.1973	2
LpA-I	LpA-I:4|LPA-I:1	containing only apo A-I:5:0.4422	0.4422	5
LpA-I	LpA-I:6	containing only apoA-I:6:0.2827	0.2827	6
LpA-I	LpA-I:5|Lp-A-I:1|LP-A-I:1	lipoprotein A-I:7:0.1211	0.1211	7
Lp[a]	Lp[a]:30	lipoprotein[a]:30:0.2816	0.2816	30
LPM	LPM:24	lateral plate mesoderm:24:0.8768	0.8768	24
LPM	LPM:10|-LPM:1	lateral pterygoid muscle:11:0.7357	0.7357	11
LPM	LPM:28	liver plasma membranes:18:0.6381|liver plasma membrane:10:0.5000	0.6381	28
Lptn	Lptn:22|LPTN:1	lymphotactin:23:0.9167	0.9167	23
Lp	Lp:14	coefficient:14:0.0041	0.0041	14
Lp	Lp:22|LP:1	hydraulic conductance:23:0.8715	0.8715	23
Lp	Lp:138|LP:3	hydraulic conductivity:141:0.9551	0.9551	141
Lp	Lp:29	hydraulic permeability:29:0.4097	0.4097	29
LP	LP:10	insulin lispro:10:0.3829	0.3829	10
LP	LP:30	lactoperoxidase:30:0.0087	0.0087	30
LP	LP:137|Lp:2	lamina propria:139:0.9785	0.9785	139
LP	LP:15|lp:3|Lp:1	large-plaque:10:0.0028|large plaque:9:0.6794	0.6794	19
LP	LP:115	late potentials:92:0.8528|late potential:23:0.6653	0.8528	115
LP	LP:10	late proximal:10:0.5856	0.5856	10
LP	LP:6|Lp:1	latency period:7:0.0622	0.0622	7
LP	LP:14	latent period:14:0.2892	0.2892	14
LP	LP:21	lateral posterior:21:0.2963	0.2963	21
LP	LP:31	lateral posterior nucleus:31:0.9043	0.9043	31
LP	LP:15	lateral prostate:15:0.8045	0.8045	15
LP	LP:46	lateral pyloric:46:0.9353	0.9353	46
LP	LP:4|Lp:1	lateroposterior thalamic nucleus:5:0.0736	0.0736	5
LP	LP:11	leg press:11:0.7357	0.7357	11
LP	LP:5	legionella pneumonia:5:0.1132	0.1132	5
Lp	Lp:17|LP:7	Legionella pneumophila:24:0.7593	0.7593	24
LP	LP:9	leukapheresis:9:0.0025	0.0025	9
LP	LP:11	leukapheresis products:11:0.5355	0.5355	11
LP	LP:38	leukocytic pyrogen:38:0.7306	0.7306	38
LP	LP:194|Lp:2	lichen planus:196:0.9600	0.9600	196
LP	LP:9	light peak:9:0.6794	0.6794	9
LP	LP:15	light perception:15:0.8045	0.8045	15
LP	LP:11	linear prediction:11:0.7357	0.7357	11
LP	LP:17	linear programming:17:0.8270	0.8270	17
LP	LP:28	link protein:28:0.2139	0.2139	28
LP	LP:260	lipid peroxidation:260:0.9541	0.9541	260
LP	LP:36|Lp:1	lipid peroxides:21:0.8594|lipid peroxide:16:0.6577	0.8594	37
Lp	Lp:7|LP:5	Lipiodol:12:0.0034	0.0034	12
Lp	Lp:11	lipophorin:11:0.0034	0.0034	11
LP	LP:58|Lp:9	lipoproteins:67:0.0206	0.0206	67
Lp	Lp:3|LP:2	lipoprotein particles:5:0.0517	0.0517	5
LP	LP:16	long photoperiod:16:0.8165	0.8165	16
Lp	Lp:30	loop-tail:30:0.0091	0.0091	30
LP	LP:5	low passage:5:0.1132	0.1132	5
LP	LP:9	low-pressure:9:0.0025	0.0025	9
LP	LP:79|Lp:1	low-protein:41:0.0125|low protein:39:0.3348	0.3348	80
LP	LP:7	low protein diet:7:0.2452	0.2452	7
LP	LP:144	lumbar puncture:134:0.9320|lumbar punctures:10:0.7103	0.9320	144
LP	LP:21	Lumboperitoneal:21:0.0062	0.0062	21
LP	LP:21	luteal phase:21:0.4733	0.4733	21
LP	LP:19	lymphocyte predominance:19:0.3721	0.3721	19
LP	LP:14	lymphocyte predominant:14:0.6911	0.6911	14
LP	LP:33	Lymphocyte proliferation:33:0.9100	0.9100	33
LP	LP:6	lymphocyte proliferative:6:0.2243	0.2243	6
LP	LP:11	lymphocytic predominance:11:0.1430	0.1430	11
LP	LP:16	lymphomatoid papulosis:16:0.8165	0.8165	16
LP	LP:9	lymphoproliferation:9:0.0025	0.0025	9
LP	LP:20	lymphoproliferative:20:0.0059	0.0059	20
LP	LP:12|Lp:1	nucleus lateralis posterior:13:0.3809	0.3809	13
LP	LP:7|Lp:6	serum lipoprotein:13:0.0530	0.0530	13
Lp	Lp:21	water permeability:21:0.2554	0.2554	21
Lupron	Lupron:11|LUPRON:1	leuprolide acetate:12:0.7571	0.7571	12
LVSV	LVSV:16|LV-SV:1	left ventricular stroke volume:17:0.8270	0.8270	17
LyP	LyP:84|LYP:2|Lyp:1	lymphomatoid papulosis:87:0.9455	0.9455	87
lyp	lyp:8|Lyp:1	lymphopenia:9:0.0696	0.0696	9
LysRS	LysRS:24	lysyl-tRNA synthetase:24:0.6427	0.6427	24
LYS	LYS:25|Lys:15|lys:2|LyS:1	lysozyme:43:0.1250	0.1250	43
LYS	LYS:13	per life year saved:7:0.4438|per life-year saved:6:0.5290	0.5290	13
M&M	M&M:10	Morbidity and mortality:10:0.7103	0.7103	10
M(n)	M(n):13	molecular weight:13:0.7753	0.7753	13
M(r)	M(r):11	mol wt:11:0.6182	0.6182	11
M(r)	M(r):16	molecular masses:16:0.7261	0.7261	16
M(r)	M(r):111|M(R):1	molecular weight:98:0.9359|molecular weights:14:0.7909	0.9359	112
M(r)	M(r):69	relative molecular mass:69:0.5733	0.5733	69
M(w)	M(w):30|M(W):2	molecular weight:32:0.9100	0.9100	32
M+C	M+C:29	Medicare+Choice:29:0.9032	0.9032	29
M-MuSV	M-MuSV:10	murine sarcoma virus:10:0.4587	0.4587	10
M-SHRSP	M-SHRSP:9	stroke-prone spontaneously hypertensive rats:9:0.7103	0.7103	9
M-value	M-value:14	insulin sensitivity:14:0.7909	0.7909	14
M-wave	M-wave:17	muscle action potential:17:0.4246	0.4246	17
m.c.	m.c.:11	mucociliary:11:0.4348	0.4348	11
M.I.	M.I.:6	mitotic index:6:0.1838	0.1838	6
M.I.	M.I.:12|m.i.:1	myocardial infarction:13:0.7753	0.7753	13
M.R.I.	M.R.I.:16|m.r.i.:1	magnetic resonance imaging:17:0.8270	0.8270	17
M.S.	M.S.:26|m.s.:3	multiple sclerosis:29:0.8978	0.8978	29
m.v.c.	m.v.c.:7|M.V.C.:1	voluntary contraction:8:0.5006	0.5006	8
M.W.	M.W.:27|m.w.:25	molecular weight:41:0.8867|molecular weights:11:0.6182	0.8867	52
M.tb	M.tb:15|M.TB:2	Mycobacterium tuberculosis:17:0.7407	0.7407	17
M/F	M/F:11|m/f:1	male/female:12:0.1222	0.1222	12
M/I	M/I:11	insulin sensitivity index:11:0.5355	0.5355	11
M/M	M/M:10	macrophages:10:0.0545	0.0545	10
M/M	M/M:36|m/m:1	monocytes/macrophages:21:0.1212|Monocyte/macrophages:16:0.0909	0.1212	37
M/P	M/P:15	ratio:15:0.2745	0.2745	15
M/T	M/T:15	mitral/tufted:15:0.4828	0.4828	15
M/L	M/L:12	ratio:12:0.1692	0.1692	12
M0	M0:7	distant metastases:7:0.1329	0.1329	7
M109	M109:11	lung carcinoma:11:0.6182	0.6182	11
M14	M14:5|M-14:2	human melanoma cell line:7:0.4438	0.4438	7
m1G	m1G:9	1-methylguanosine:9:0.2667	0.2667	9
M1-R	M1-R:3|m1R:2|M1R:1|m1-R:1	m1 receptor:7:0.2902	0.2902	7
M1	M1:8	antagonists pirenzepine:8:0.1845	0.1845	8
M1	M1:21|M-1:5	cell line:26:0.8861	0.8861	26
M1	M1:9	deacetyldiltiazem:9:0.0051	0.0051	9
M1	M1:6	distant metastases:6:0.0807	0.0807	6
M1	M1:9	distant metastasis:9:0.6794	0.6794	9
M1	M1:18|m1:4|M-1:1	first:23:0.0146	0.0146	23
M1	M1:16	first molar:10:0.2275|first molars:6:0.1010	0.2275	16
M1	M1:5	first transmembrane domain:5:0.2818	0.2818	5
M1	M1:27	matrix:27:0.0165	0.0165	27
M1	M1:36	matrix protein:36:0.6538	0.6538	36
M1	M1:32|M-1:10	metabolite:42:0.0259	0.0259	42
M1	M1:13	metastatic:13:0.0076	0.0076	13
M1	M1:7	metastatic disease:7:0.2902	0.2902	7
M1	M1:9|M-1:1	middle cerebral artery:10:0.5856	0.5856	10
M1	M1:7	mouse myeloid leukemia:7:0.2113	0.2113	7
M1	M1:21	mouse myeloid leukemia cells:21:0.5721	0.5721	21
M1	M1:18|m1:1	muscarinic:19:0.0114	0.0114	19
M1	M1:10	primary:10:0.0057	0.0057	10
M1	M1:17	primary motor:17:0.4480	0.4480	17
M1	M1:24	primary motor area:24:0.7593	0.7593	24
M1	M1:185	primary motor cortex:185:0.8260	0.8260	185
M2-PK	M2-PK:8	pyruvate kinase:8:0.4102	0.4102	8
M2	M2:15	acute myeloid leukemia:15:0.6911	0.6911	15
M2	M2:8|m2:1	cardiac:9:0.0076	0.0076	9
M2	M2:5	guinea-pig atria:5:0.0612	0.0612	5
M2	M2:6	matrix protein:6:0.1838	0.1838	6
M2	M2:7|M-2:3	metabolite:10:0.0086	0.0086	10
M2	M2:13|m2:4	muscarinic:17:0.0153	0.0153	17
M2	M2:7	muscarinic receptors:7:0.2902	0.2902	7
M2	M2:8	second molar:8:0.3463	0.3463	8
M2	M2:6	second transmembrane domain:6:0.5290	0.5290	6
M2	M2:7	transmembrane segment:7:0.1641	0.1641	7
M3G	M3G:155|M-3-G:20|M-3G:1	morphine-3-glucuronide:176:0.8102	0.8102	176
M3v	M3v:1	microgranular or variant:1:0.2902	0.2902	1
M3	M3:29	acute promyelocytic leukemia:29:0.6295	0.6295	29
M3	M3:9|M-3:1	promyelocytic leukaemia:10:0.6794	0.6794	10
M3	M3:24	third molar:16:0.6577|third molars:8:0.5006	0.6577	24
M4Eo	M4Eo:6|M4EO:2|M4-Eo:2|M4eo:1	eosinophilia:11:0.4167	0.4167	11
M4	M4:13	myelomonocytic:13:0.0381	0.0381	13
M5	M5:11	acute monocytic leukemia:11:0.4557	0.4557	11
M6G	M6G:9	morphine-6-beta-D-glucuronide:9:0.0302	0.0302	9
M6G	M6G:3	morphine and morphine-6beta-glucuronide:3:0.0736	0.0736	3
m6G	m6G:10|m6-G:1	O6-methylguanine:11:0.0377	0.0377	11
M6P	M6P:48|M-6-P:11	mannose-6-phosphate:32:0.3875|mannose 6-phosphate:27:0.7066	0.7066	59
M73101	M73101:15	4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone:15:0.8750	0.8750	15
MA104	MA104:4|MA-104:2	monkey kidney cell line:6:0.5290	0.5290	6
MA-10	MA-10:10	Leydig tumor:10:0.5856	0.5856	10
MAACL	MAACL:10	Multiple Affect Adjective Check List:10:0.5000	0.5000	10
MAAS	MAAS:10	Maastricht aging study:10:0.7103	0.7103	10
MAAs	MAAs:19	melanoma-associated antigens:19:0.7044	0.7044	19
MAAs	MAAs:19	mycosporine-like amino acids:19:0.7658	0.7658	19
MAA	MAA:12	4-methylaminoantipyrine:12:0.0182	0.0182	12
MAA	MAA:19	Maackia amurensis:19:0.8449	0.8449	19
MAA	MAA:65|maa:1	macroaggregated albumin:66:0.4972	0.4972	66
MAA	MAA:6	marketing authorization application:6:0.5290	0.5290	6
MAA	MAA:81	melanoma-associated antigens:47:0.6575|melanoma-associated antigen:26:0.3674|melanoma associated antigen:8:0.2090	0.6575	81
MAA	MAA:59	methacrylic acid:59:0.2685	0.2685	59
MAA	MAA:60	Methoxyacetic acid:60:0.2685	0.2685	60
MAA	MAA:13	minimum audible angle:13:0.7753	0.7753	13
MAA	MAA:6	mitral annular area:6:0.5290	0.5290	6
MABA	MABA:13	Alamar blue assay:13:0.7753	0.7753	13
MABC	M-ABC:5|MABC:5|mABC:1	Movement Assessment Battery for Children:11:0.7357	0.7357	11
MABP	MABP:640|mABP:7	mean arterial blood pressure:647:0.9695	0.9695	647
MABV	MABV:11	marine birnavirus:11:0.7357	0.7357	11
MAB	MAB:29	maximal androgen blockade:29:0.5269	0.5269	29
MAB	MAB:12	maximum androgen blockade:12:0.1338	0.1338	12
MAB	MAB:22	mesenteric arterial bed:22:0.8657	0.8657	22
MAb	MAb:15|mAb:13|Mab:2|MAB:2	monoclonal:32:0.0032	0.0032	32
mAb	mAb:11|MAb:6	monoclonal Ab:17:0.7407	0.7407	17
mAb	mAb:5295|MAb:3270|Mab:543|MAB:182|mab:88|mAB:52|MaB:1	monoclonal antibody:6602:0.9872|Monoclonal antibodies:2829:0.9762	0.9872	9431
MAB	MAB:15	N-methyl-4-aminoazobenzene:15:0.0014	0.0014	15
Mac-1	Mac-1:5|MAC-1:1	macrophage-1 antigen:6:0.1320	0.1320	6
Maca	Maca:13|maca:2|MACA:2	Lepidium meyenii:17:0.8270	0.8270	17
MACDP	MACDP:26	Metropolitan Atlanta Congenital Defects Program:26:0.8861	0.8861	26
MACEs	MACEs:17	major adverse cardiac events:17:0.8270	0.8270	17
MACE	MACE:151	major adverse cardiac events:129:0.9768|Major adverse cardiac event:22:0.8657	0.9768	151
MACE	MACE:10	Malone antegrade continence enema:10:0.7103	0.7103	10
MACI	MACI:10	Millon Adolescent Clinical Inventory:10:0.7103	0.7103	10
MACP	MACP:9	polysaccharide:9:0.5000	0.5000	9
MACRIA	MACRIA:8	M-antibody capture radioimmunoassay:8:0.2327	0.2327	8
MACS	MACS:23	cell sorter:23:0.8715	0.8715	23
MACS	MACS:18	magnetic cell separation:18:0.3857	0.3857	18
MACs	MACs:7	malignancy-associated changes:7:0.3524	0.3524	7
MACs	MACs:10	mammalian artificial chromosomes:10:0.7103	0.7103	10
MACs	MACs:9	microflora-associated characteristics:9:0.4587	0.4587	9
MAC-T	MAC-T:10	bovine mammary epithelial cell line:10:0.5856	0.5856	10
mACh	mACh:32|m-ACh:2|mAch:2|M-ACh:1	muscarinic acetylcholine:37:0.8377	0.8377	37
mACh	mACh:8|M-Ach:2	muscarinic cholinergic:10:0.7103	0.7103	10
MAC	MAC:7	aerobic capacity:7:0.3524	0.3524	7
MAC	MAC:11	anesthetic requirement:11:0.1938	0.1938	11
MAC	MAC:20	MacAndrew Alcoholism Scale:20:0.7173	0.7173	20
MAC	MAC:40|Mac:3	macrophages:43:0.0153	0.0153	43
MAC	MAC:8	malignancy associated changes:8:0.6411	0.6411	8
MAC	MAC:12	Maximum allowable concentrations:12:0.6460	0.6460	12
MAC	MAC:9	Maximum Allowable Cost:9:0.6794	0.6794	9
MAC	MAC:265	membrane attack complex:254:0.9580|membrane attack complexes:11:0.7357	0.9580	265
MAC	MAC:30	membrane attack complex of complement:30:0.9011	0.9011	30
MAC	MAC:30	Mental Adjustment to Cancer:30:0.9011	0.9011	30
MAC	MAC:43	Microcystic adnexal carcinoma:43:0.9308	0.9308	43
MAC	MAC:58	mid-arm circumference:46:0.4269|mid arm circumference:12:0.3813	0.4269	58
MAC	MAC:16	Midarm circumference:16:0.0950	0.0950	16
MAC	MAC:9	Minimal Auditory Capabilities:9:0.6794	0.6794	9
MAC	MAC:135	minimum alveolar anesthetic concentration:135:0.8882	0.8882	135
MAC	MAC:411	minimum alveolar concentration:393:0.8392|minimum alveolar concentrations:18:0.4672	0.8392	411
MAC	MAC:37	mitral annular calcification:37:0.9197	0.9197	37
MAC	MAC:7	mitral annular calcium:7:0.5926	0.5926	7
MAC	MAC:19	mitral annulus calcification:19:0.8449	0.8449	19
MAC	MAC:9	mitral anular calcium:9:0.6794	0.6794	9
MAC	MAC:23	Monitored anesthesia care:23:0.8715	0.8715	23
MAC	MAC:10	Mycobacterium avium:10:0.4363	0.4363	10
MAC	MAC:698	Mycobacterium avium complex:698:0.8638	0.8638	698
MAC	MAC:8	Mycobacterium avium-intracellulare:8:0.4102	0.4102	8
MAD2	MAD2:5|Mad2:1	mitotic arrest deficient 2:6:0.5290	0.5290	6
MADD	MADD:15|mADD:1	deficiency:16:0.4516	0.4516	16
MADH	MADH:55	methylamine dehydrogenase:55:0.8882	0.8882	55
MADIT	MADIT:25	Multicenter Automatic Defibrillator Implantation Trial:25:0.8816	0.8816	25
MADRS	MADRS:45	Montgomery and Asberg Depression Rating Scale:45:0.9484	0.9484	45
MADRS	MADRS:178	Montgomery-Asberg Depression Rating Scale:178:0.5767	0.5767	178
MAD	MAD:7	absolute deviation:7:0.3524	0.3524	7
MAD	MAD:12	diameter:12:0.0271	0.0271	12
MAD	MAD:6	Major Affective Disorder:6:0.5290	0.5290	6
MAD	MAD:7	Mandibular advancement device:7:0.5926	0.5926	7
MAD	MAD:9	Mandibuloacral dysplasia:9:0.5470	0.5470	9
MAD	MAD:4	Maximum Acceptable Dose:4:0.1618	0.1618	4
Mad	Mad:12|mad:7|MAD:5	Mothers against dpp:24:0.8768	0.8768	24
MAD	MAD:61	multiwavelength anomalous diffraction:61:0.6026	0.6026	61
MAD	MAD:9	myoadenylate deaminase:9:0.5470	0.5470	9
MAEPs	MAEPs:7	Middle latency auditory evoked potentials:7:0.5926	0.5926	7
MAEs	MAEs:20	motion aftereffects:20:0.7173	0.7173	20
MAE	MAE:52	Microwave-assisted extraction:52:0.7578	0.7578	52
MAE	MAE:70	motion aftereffect:70:0.7986	0.7986	70
MAE	MAE:7	Myoclonic-astatic epilepsy:7:0.1850	0.1850	7
MAFP	MAFP:23	Methyl arachidonyl fluorophosphonate:23:0.8038	0.8038	23
MAF	MAF:16	amniotic fluid:16:0.6577	0.6577	16
MAF	MAF:90	macrophage-activating factor:90:0.3747	0.3747	90
MAF	MAF:6|Maf:2|maf:1	mafosfamide:9:0.0231	0.0231	9
MAG3	MAG3:35|MAG-3:1	99mTc-mercaptoacetyltriglycine:36:0.2273	0.2273	36
MAG3	MAG3:48|MAG-3:3	mercaptoacetyltriglycine:51:0.3182	0.3182	51
MAGE	MAGE:8	mean amplitude of glycemic excursions:8:0.6411	0.6411	8
MAGE	MAGE:13	melanoma antigen:13:0.3809	0.3809	13
MAGE	MAGE:6	melanoma antigen gene:6:0.2243	0.2243	6
MAGP-1	MAGP-1:10	Microfibril-associated glycoprotein-1:10:0.5856	0.5856	10
MAGP	MAGP:12	microfibril-associated glycoprotein:12:0.5664	0.5664	12
MAGUK	MAGUK:43|Maguk:1|MAGuK:1	Membrane-associated guanylate kinase:45:0.8401	0.8401	45
MAGUKs	MAGUKs:20	membrane-associated guanylate kinases:20:0.7766	0.7766	20
M-Ag	M-Ag:4|MAg:1	microsomal antigen:5:0.0736	0.0736	5
MAG	MAG:9	monoacylglycerol:9:0.0129	0.0129	9
MAG	MAG:460|Mag:1	myelin-associated glycoprotein:461:0.7792	0.7792	461
MAI	MAI:56	mitotic activity index:56:0.9467	0.9467	56
MAI	MAI:12	Movement Assessment of Infants:12:0.7571	0.7571	12
MAI	MAI:8	Multidimensional Anger Inventory:8:0.5006	0.5006	8
MAI	MAI:116	Mycobacterium avium-intracellulare:80:0.8207|Mycobacterium avium intracellulare:36:0.8336	0.8336	116
MAI	MAI:7	Mycobacterium avium-intracellulare complex:7:0.5926	0.5926	7
MAIDS	MAIDS:5	immunodeficiency disease:5:0.1132	0.1132	5
MAIDS	MAIDS:58	Murine acquired immunodeficiency syndrome:58:0.8710	0.8710	58
MAIDS	MAIDS:5	retrovirus-induced immunodeficiency:5:0.0902	0.0902	5
MAIEA	MAIEA:10	erythrocyte antigens:10:0.5856	0.5856	10
MAIPA	MAIPA:20	monoclonal antibody immobilization of platelet antigens:14:0.7909|monoclonal antibody immobilization of platelet antigen:6:0.5290	0.7909	20
MAIS	MAIS:7	Meaningful Auditory Integration Scale:7:0.5926	0.5926	7
MALDI	MALDI:22	matrix-assisted laser desorption/ionisation:22:0.7400	0.7400	22
MALDI	MALDI:532	matrix-assisted laser desorption/ionization:420:0.9399|Matrix-assisted laser desorption ionization:99:0.8568|matrix-assisted laser desorption-ionization:13:0.6701	0.9399	532
MALD	MALD:9	methoxyacetaldehyde:9:0.2963	0.2963	9
MALG	MALG:10|mALG:1	Minnesota antilymphoblast globulin:11:0.7357	0.7357	11
MALLS	MALLS:28	laser light scattering:28:0.8369	0.8369	28
MALP-2	MALP-2:11	macrophage-activating lipopeptide-2:11:0.7357	0.7357	11
MALT	MALT:16	mucosa-associated lymphoid tissues:16:0.4832	0.4832	16
MAL	MAL:13	medullary thick ascending limb:13:0.5335	0.5335	13
MAL	MAL:14	Motor Activity Log:14:0.7909	0.7909	14
MAL	MAL:6	Myelin and lymphocyte protein:6:0.5290	0.5290	6
MAMA	MAMA:11	midarm muscle area:11:0.4728	0.4728	11
MAMC	MAMC:58	muscle circumference:58:0.8937	0.8937	58
MAMP	MAMP:33|M-Amp:1|mAMP:1|mAmp:1	methamphetamine:36:0.8750	0.8750	36
MAMAc	MAMAc:5|MAMac:4|MAM-Ac:2|MAM-ac:1	Methylazoxymethanol acetate:12:0.4557	0.4557	12
mam	mam:7|Mam:6|MAM:2	mastermind:15:0.0326	0.0326	15
MAM	MAM:150	methylazoxymethanol:150:0.3473	0.3473	150
MAM	MAM:76	methylazoxymethanol acetate:76:0.8511	0.8511	76
MAM	MAM:12	Mitral annulus motion:12:0.7571	0.7571	12
MAM	MAM:10	Mycoplasma arthritidis mitogen:10:0.5000	0.5000	10
MAO-A	MAO-A:21|maoA:2	monoamine oxidase:23:0.7046	0.7046	23
MAO-A	MAO-A:58|MAOA:4|Mao-a:1	monoamine oxidase-A:63:0.9018	0.9018	63
MAO-B	MAO-B:228|MAOB:21|MaoB:1	monoamine oxidase B:162:0.9705|monoamine oxidase-B:88:0.9131	0.9705	250
MAO-B	MAO-B:19	type B monoamine oxidase:19:0.8449	0.8449	19
MAOD	MAOD:17	maximal accumulated oxygen deficit:17:0.6748	0.6748	17
MAOIs	MAOIs:159|MAO-Is:2	monoamine oxidase inhibitors:161:0.9515	0.9515	161
MAOI	MAOI:135|MAO-I:5|MAOi:1	monoamine oxidase inhibitor:100:0.9371|monoamine oxidase inhibitors:41:0.9274	0.9371	141
MAoP	mAoP:5|MAoP:5|mAOP:1	mean aortic pressure:11:0.6182	0.6182	11
MAOs	MAOs:18	monoamine oxidases:18:0.8365	0.8365	18
MAO	MAO:38	medial accessory olive:38:0.8781	0.8781	38
MAO	MAO:2036	monoamine oxidase:1987:0.9803|monoamine oxidases:38:0.8781|monoamine-oxidase:11:0.0043	0.9803	2036
MAO	MAO:24	Monoamine oxidase activity:24:0.8768	0.8768	24
MAO	MAO:15	monoamineoxidase:15:0.0060	0.0060	15
MAO	MAO:13	monoaminoxidase:13:0.0051	0.0051	13
MAP1A	MAP1A:16|MAP1a:1|MAP-1a:1	Microtubule-associated protein 1A:18:0.6381	0.6381	18
MAP1B	MAP1B:43|MAP-1B:4|MAP1b:2|MAP-1b:1	microtubule-associated protein 1B:50:0.7328	0.7328	50
MAP2c	MAP2c:6|MAP2C:1	Microtubule-associated protein 2c:7:0.3524	0.3524	7
MAP2	MAP-2:16|MAP2:16	microtubule-associated protein:32:0.5841	0.5841	32
MAP2	MAP2:330|MAP-2:172	microtubule-associated protein 2:370:0.8628|microtubule-associated protein-2:107:0.6882|microtubule associated protein-2:25:0.7679	0.8628	502
MAP3K	MAP3K:10	mitogen-activated protein kinase kinase kinase:10:0.5856	0.5856	10
MAP4	MAP4:20|MAP-4:3	microtubule-associated protein 4:23:0.7400	0.7400	23
MAP4	MAP4:5|MAP-4:1	(S)-2-amino-2-methyl-4-phosphonobutanoic acid:6:0.1838	0.1838	6
MAP5	MAP5:13	microtubule-associated protein 5:13:0.6701	0.6701	13
MAPCAs	MAPCAs:9	major aortopulmonary collateral arteries:9:0.6794	0.6794	9
MAPC	MAPC:8	migrating action potential complex:8:0.6411	0.6411	8
MAPD90	MAPD90:19	90% repolarization:19:0.8525	0.8525	19
MAPD90	MAPD90:5	monophasic action potential duration:5:0.4422	0.4422	5
MAPD	MAPD:32|MAPd:1	monophasic action potential duration:33:0.9100	0.9100	33
MAPI	MAPI:10	Millon Adolescent Personality Inventory:10:0.7103	0.7103	10
MAPKAP	MAPKAP:20|MAP-KAP:1	MAP kinase-activated protein:21:0.4945	0.4945	21
MAPKKK	MAPKKK:13	MAPK kinase kinase:13:0.1554	0.1554	13
MAPKKK	MAPKKK:18	mitogen-activated protein kinase kinase kinase:18:0.6903	0.6903	18
MAPKKs	MAPKKs:8	MAP kinase kinases:8:0.1471	0.1471	8
MAPKK	MAPKK:39	MAP kinase kinase:39:0.3285	0.3285	39
MAPKK	MAPKK:54	mitogen-activated protein kinase kinase:54:0.8401	0.8401	54
MAPKs	MAPKs:840|MAP-Ks:1	Mitogen-activated protein kinases:831:0.9193|mitogen-activated protein kinase:10:0.4363	0.9193	841
MAPK	MAPK:4141|MAP-K:8|MAPk:5|Mapk:1	Mitogen-activated protein kinase:3840:0.8795|mitogen-activated protein kinases:315:0.8370	0.8795	4155
MAPT	MAPT:6	microtubule-associated protein tau:6:0.2902	0.2902	6
MAPs	MAPs:13	mean arterial pressures:13:0.7753	0.7753	13
MAPs	MAPs:427|MAPS:3	microtubule-associated proteins:430:0.8180	0.8180	430
MAPs	MAPs:94	monophasic action potentials:94:0.8040	0.8040	94
MAPS	MAPS:10	Multidimensional Affect and Pain Survey:10:0.7103	0.7103	10
MAPs	MAPs:14	Multiple antigen peptides:14:0.7909	0.7909	14
MAPs	MAPs:13	multiple antigenic peptides:13:0.7753	0.7753	13
MAP	MAP:20	magnesium ammonium phosphate:20:0.8525	0.8525	20
MAP	MAP:9|map:2	maprotiline:11:0.0009	0.0009	11
MAP	MAP:21	maximal aerobic power:21:0.8657	0.8657	21
MAP	MAP:65	maximum a posteriori:65:0.9541	0.9541	65
MAP	MAP:12	maximum a posteriori probability:12:0.7571	0.7571	12
MAP	MAP:31	mean arterial:31:0.7091	0.7091	31
MAP	MAP:966|mAP:1	mean arterial blood pressure:954:0.9620|mean arterial blood pressures:13:0.6701	0.9620	967
MAP	MAP:21	mean arterial BP:21:0.8594	0.8594	21
MAP	MAP:4996|mAP:6|map:1	mean arterial pressure:4954:0.9757|mean arterial pressures:49:0.8753	0.9757	5003
MAP	MAP:57	medroxyprogesterone acetate:57:0.7416	0.7416	57
MAP	MAP:10|Map:1|map:1	Methionine aminopeptidase:12:0.5664	0.5664	12
MAP	MAP:16	microtubule-associated proteins:16:0.4040	0.4040	16
MAP	MAP:2766|Map:4	Mitogen-activated protein:2770:0.8340	0.8340	2770
MAP	MAP:13	mitogen-activated protein kinase:13:0.4444	0.4444	13
MAP	MAP:33	modified atmosphere packaging:33:0.9100	0.9100	33
MAP	MAP:214	monophasic action potential:154:0.7968|Monophasic action potentials:60:0.6921	0.7968	214
MAP	MAP:77	multiple antigen peptide:55:0.9458|Multiple antigen peptides:22:0.8657	0.9458	77
MAP	MAP:41	Multiple Antigenic Peptide:32:0.8563|multiple antigenic peptides:9:0.6794	0.8563	41
MAP	MAP:9|Map:1	Mycobacterium avium subsp paratuberculosis:10:0.8558	0.8558	10
MAP	MAP:11|Map:4	Mycobacterium avium subspecies paratuberculosis:15:0.8045	0.8045	15
MAP	MAP:9	putrescine:9:0.0007	0.0007	9
MAP	MAP:8	repeated administration of methamphetamine:8:0.1276	0.1276	8
MAQ	MAQ:12	Questionnaire:12:0.6875	0.6875	12
MARCKS	MARCKS:187|Marcks:1	myristoylated alanine-rich C kinase substrate:139:0.9477|myristoylated alanine-rich C-kinase substrate:49:0.8401	0.9477	188
MARCO	MARCO:10|Marco:1	macrophage receptor with collagenous structure:11:0.5355	0.5355	11
MARE	MARE:12	Maf recognition element:12:0.7753	0.7753	12
MARs	MARs:99	matrix attachment regions:99:0.9698	0.9698	99
MARS	MARS:68|Mars:1	molecular adsorbent recirculating system:39:0.9217|molecular adsorbents recirculating system:30:0.9011	0.9217	69
MARS	MARS:15	Monitored Atherosclerosis Regression Study:15:0.8045	0.8045	15
MARS	MARS:10	Rating Scale:10:0.5856	0.5856	10
MARV	MARV:10	Marburg virus:10:0.7103	0.7103	10
MAR	MAR:14	matrix association region:14:0.7909	0.7909	14
MAR	MAR:59	matrix attachment region:49:0.9392|matrix attachment regions:10:0.7103	0.9392	59
MAR	MAR:8	mean adequacy ratio:8:0.6411	0.6411	8
MAR	MAR:20	melanoma-associated retinopathy:20:0.7766	0.7766	20
MAR	MAR:12	Microautoradiography:12:0.0189	0.0189	12
MAR	MAR:72	mineral apposition rate:72:0.8948	0.8948	72
MAR	MAR:25	missing at random:25:0.8186	0.8186	25
MAR	MAR:47	mixed antiglobulin reaction:47:0.9006	0.9006	47
mar	mar:9	monoclonal antibody-resistant:9:0.6794	0.6794	9
mar	mar:28|MAR:14|Mar:12	multiple antibiotic resistance:54:0.9448	0.9448	54
Mar	Mar:7|mar:2|MAR:2	multiple-antibiotic-resistant:11:0.0172	0.0172	11
MAR	MAR:7	multivariate autoregressive:7:0.2902	0.2902	7
MAR	MAR:9|Mar:1|mar:1	resistant:11:0.0172	0.0172	11
MASA	MASA:36	amplification:36:0.7556	0.7556	36
MASCC	MASCC:6	Multinational Association of Supportive Care in Cancer:6:0.7357	0.7357	6
MASE	MASE:11	solvent extraction:11:0.7357	0.7357	11
MASPs	MASPs:29	serine proteases:29:0.8422	0.8422	29
MASP	MASP:20	serine protease:20:0.8449	0.8449	20
MAST	MAST:7	medical anti-shock trousers:7:0.1329	0.1329	7
MAST	MAST:113	Michigan Alcoholism Screening Test:113:0.9735	0.9735	113
MAST	MAST:8	military anti-shock trousers:8:0.1895	0.1895	8
MAST	MAST:31	military antishock trousers:23:0.5719|military antishock trouser:8:0.3463	0.5719	31
mAST	mAST:7|m-AST:6	mitochondrial aspartate aminotransferase:13:0.5335	0.5335	13
MAST	MAST:11	motion artifact suppression technique:11:0.7357	0.7357	11
MAS	MAS:10	exogenous metabolic activation system:10:0.5000	0.5000	10
MAS	MAS:4	German Multicentre Allergy Study:4:0.1618	0.1618	4
MAS	MAS:248	magic angle spinning:140:0.9786|magic-angle spinning:96:0.3255|magic-angle-spinning:12:0.0091	0.9786	248
MAS	MAS:15	mandibular advancement splint:15:0.8045	0.8045	15
MAS	MAS:26	Manifest Anxiety Scale:26:0.8251	0.8251	26
MAS	MAS:81	marker-assisted selection:64:0.6462|Marker Assisted Selection:17:0.8365	0.8365	81
MAS	MAS:10	maximal aerobic speed:10:0.5000	0.5000	10
MAS	MAS:62	McCune-Albright syndrome:62:0.1897	0.1897	62
MAS	MAS:138	meconium aspiration syndrome:138:0.9437	0.9437	138
MAS	MAS:16	Meiosis activating sterols:9:0.6794|meiosis-activating sterols:7:0.1329	0.6794	16
MAs	MAs:14	Mexican Americans:14:0.7909	0.7909	14
MAs	MAs:6	microsatellite alterations:6:0.2243	0.2243	6
MAS	MAS:26	minimal access surgery:26:0.8251	0.8251	26
MAS	MAS:34	modified Ashworth scale:34:0.9126	0.9126	34
MAs	MAs:28|mAs:1	monoclonal antibodies:29:0.7970	0.7970	29
MAS	MAS:21	Motor Assessment Scale:21:0.4538	0.4538	21
mas	mas:3|MAS:2	Mycocerosic acid synthase:5:0.4422	0.4422	5
MAS	MAS:13	Mycoplasma arthritidis:13:0.7753	0.7753	13
MAS	MAS:6	Mycoplasma arthritidis-derived superantigen:6:0.3728	0.3728	6
MATC	MATC:14	maximum acceptable toxicant concentration:14:0.7909	0.7909	14
MATSA	MATSA:16	Marek's disease tumor-associated surface antigen:16:0.8165	0.8165	16
MAT	MAT:39|mat:3	mating-type:23:0.0334|mating type:19:0.8449	0.8449	42
MAT	MAT:21|Mat:1	mating type locus:14:0.7909|mating-type locus:8:0.1004	0.7909	22
MAT	MAT:42	mean absorption time:42:0.8893	0.8893	42
MAT	MAT:72	methionine adenosyltransferase:72:0.9585	0.9585	72
MAT	MAT:134	microscopic agglutination test:134:0.6189	0.6189	134
MAT	MAT:19	Multifocal atrial tachycardia:19:0.7658	0.7658	19
MAU	MAU:28	microalbuminuria:28:0.5094	0.5094	28
MAU	MAU:8	multi-attribute utility:8:0.2619	0.2619	8
MAV	MAV:6	maximal aerobic velocity:6:0.5290	0.5290	6
MAV	MAV:10	myeloblastosis-associated virus:10:0.3867	0.3867	10
MAWL	MAWL:11	maximum acceptable weight of lift:11:0.6182	0.6182	11
MAZ	MAZ:12	Myc-associated zinc finger protein:12:0.7571	0.7571	12
MAb's	MAb's:16|mAb's:15|Mab's:9|MAB's:4|mab's:1	monoclonal antibodies:45:0.9338	0.9338	45
mAb2	mAb2:4|MAb2:2|Mab2:1|MAb-2:1|mab2:1	antibodies:9:0.3077	0.3077	9
MA	MA:12	2-mercaptoacetate:12:0.0038	0.0038	12
MA	MA:13	analysis:13:0.0042	0.0042	13
MA	MA:11	d-methamphetamine:11:0.0035	0.0035	11
MA	MA:10	macular amyloidosis:10:0.7103	0.7103	10
MA	MA:18	maleic anhydride:18:0.4672	0.4672	18
MA	MA:39	Malonaldehyde:39:0.0132	0.0132	39
MA	MA:45	mandelic acid:45:0.1793	0.1793	45
MA	MA:86	matrix:86:0.0295	0.0295	86
MA	MA:24	matrix protein:24:0.6767	0.6767	24
MA	MA:7|ma:5	maximal amplitude:12:0.0776	0.0776	12
MA	MA:38|ma:5|mA:1	maximum amplitude:44:0.5545	0.5545	44
MA	MA:8	mean acceleration:8:0.2987	0.2987	8
MA	MA:11	medial amygdala:11:0.3829	0.3829	11
MA	MA:106	megestrol acetate:106:0.8233	0.8233	106
MA	MA:12	meglumine antimoniate:12:0.7571	0.7571	12
MA	MA:63	membrane antigen:47:0.6183|membrane antigens:16:0.4274	0.6183	63
MA	MA:11	Meningioangiomatosis:11:0.0035	0.0035	11
MA	MA:32	mental age:32:0.4711	0.4711	32
MA	MA:31	mental arithmetic:31:0.9043	0.9043	31
MA	MA:28	mercaptoacetate:28:0.0094	0.0094	28
MA	MA:9	Mesaconitine:9:0.0028	0.0028	9
MA	MA:28	mesenteric artery:16:0.3044|mesenteric arteries:12:0.5050	0.5050	28
MA	MA:19	metabolic acidosis:19:0.8449	0.8449	19
MA	MA:6	metastatic adenocarcinoma:6:0.2243	0.2243	6
MA	MA:250	methamphetamine:250:0.0865	0.0865	250
MA	MA:15	methyl acrylate:15:0.8045	0.8045	15
MA	MA:28	methylamine:28:0.0094	0.0094	28
MA	MA:41|M-A:2	Mexican American:15:0.8045|Mexican-American:14:0.0045|Mexican Americans:14:0.7909	0.8045	43
MA	MA:46	microagglutination:46:0.0156	0.0156	46
MA	MA:95|Ma:1	Microalbuminuria:96:0.0330	0.0330	96
MA	MA:5	microbiological assay:5:0.0612	0.0612	5
MA	MA:6	microsatellite alterations:6:0.2243	0.2243	6
MA	MA:20	microscopic agglutination:20:0.5279	0.5279	20
MA	MA:11	middle-aged:11:0.0035	0.0035	11
MA	MA:64	migraine with aura:64:0.7998	0.7998	64
Ma	Ma:25	million years ago:25:0.8816	0.8816	25
MA	MA:13	mitotic activity:13:0.0588	0.0588	13
MA	MA:23	mitotic apparatus:23:0.8038	0.8038	23
MA	MA:19	mitral annulus:19:0.8449	0.8449	19
MA	MA:12	monoamine:12:0.0038	0.0038	12
MA	MA:11	monoaminergic:11:0.0035	0.0035	11
MA	MA:33	monoclonal antibodies:27:0.7425|monoclonal antibody:6:0.1320	0.7425	33
MA	MA:51	motor activity:51:0.4290	0.4290	51
MA	MA:15|M-A:2	mutation-accumulation:11:0.0035|mutation accumulation:6:0.2243	0.2243	17
mA	mA:6	tube current:6:0.1543	0.1543	6
MA	MA:2	weeks menstrual age:2:0.1838	0.1838	2
MBCD	MBCD:13	methyl-beta-cyclodextrin:13:0.6316	0.6316	13
MBCK	MBCK:6|MB-CK:5	creatine kinase:11:0.4232	0.4232	11
MBCL	MBCL:19	monocytoid B-cell lymphoma:19:0.7658	0.7658	19
MBCP	MBCP:11	macroporous biphasic calcium phosphate:11:0.7357	0.7357	11
MBCs	MBCs:11	mononuclear blood cells:11:0.7357	0.7357	11
MBC	MBC:25	breast carcinoma:25:0.8186	0.8186	25
MBC	MBC:24	carbendazim:24:0.0287	0.0287	24
MBC	MBC:37	maximal binding capacity:37:0.4229	0.4229	37
MBC	MBC:26	maximum binding capacity:26:0.2594	0.2594	26
MBC	MBC:218|mbc:3	metastatic breast cancer:221:0.8429	0.8429	221
MBC	MBC:8	methyl benzimidazol-2-yl carbamate:8:0.5006	0.5006	8
MBC	MBC:14	mononuclear blood cell:8:0.5006|mononuclear blood cells:6:0.2827	0.5006	14
MBD	MBD:20	Marchiafava-Bignami disease:20:0.4037	0.4037	20
MBD	MBD:8	metabolic bone disease:8:0.5006	0.5006	8
MBD	MBD:27	methyl-CpG binding domain:27:0.4555	0.4555	27
MBD	MBD:50	minimal brain dysfunction:50:0.9404	0.9404	50
MBDB	MBDB:9	N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine:9:0.2581	0.2581	9
MBDS	MBDS:12	minimum basic data set:12:0.7571	0.7571	12
MBED	MBED:8	9-Methyl-7-bromoeudistomin D:8:0.4102	0.4102	8
MBF1	MBF1:11	Multiprotein bridging factor 1:11:0.7357	0.7357	11
MBFV	MBFV:11	Mean blood flow velocity:11:0.5355	0.5355	11
MBF	MBF:8	bite force:8:0.2987	0.2987	8
MBF	MBF:377	Myocardial blood flow:377:0.5731	0.5731	377
MBGV	MBGV:10	Marburg virus:10:0.7103	0.7103	10
MBG	MBG:12	Marburg virus:12:0.7571	0.7571	12
MBG	MBG:21	marinobufagenin:21:0.1667	0.1667	21
MBG	MBG:24	Mean blood glucose:24:0.7151	0.7151	24
MBG	MBG:17	myocardial blush grade:17:0.8270	0.8270	17
MBHI	MBHI:13	Millon Behavioral Health Inventory:13:0.6701	0.6701	13
MBHOs	MBHOs:9	organizations:9:0.8889	0.8889	9
MBH	MBH:11	medial basal hypothalami:11:0.7357	0.7357	11
MBH	MBH:41	medial basal hypothalamic:41:0.9274	0.9274	41
MBH	MBH:300|mbh:1	medial basal hypothalamus:301:0.9602	0.9602	301
MBH	MBH:14	mediobasal hypothalami:14:0.3202	0.3202	14
MBH	MBH:23	mediobasal hypothalamic:23:0.2136	0.2136	23
MBH	MBH:182	mediobasal hypothalamus:182:0.3119	0.3119	182
MBI	MBI:6	brain injury:6:0.2243	0.2243	6
MBI	MBI:59	Maslach Burnout Inventory:59:0.8731	0.8731	59
MBI	MBI:26	modified Barthel Index:26:0.8861	0.8861	26
MBK	MBK:11	Methyl n-butyl ketone:11:0.7357	0.7357	11
MBLs	MBLs:11	metallo-beta-lactamases:11:0.4762	0.4762	11
MBL	MBL:146	mannan-binding lectin:133:0.2841|mannan binding lectin:13:0.1046	0.2841	146
MBL	MBL:242|mbl:1	mannose-binding lectin:200:0.4572|mannose binding lectin:43:0.6343	0.6343	243
MBL	MBL:65	menstrual blood loss:65:0.9047	0.9047	65
MBL	MBL:9	metallo-beta-lactamase:9:0.0148	0.0148	9
mBMMC	mBMMC:8|MBMMC:3	bone marrow-derived mast cells:11:0.7357	0.7357	11
MBM	MBM:46	meat and bone meal:46:0.8676	0.8676	46
MBNW	MBNW:6	multiple breath nitrogen washout:6:0.5290	0.5290	6
MBN	MBN:13	methylbenzylnitrosamine:13:0.2000	0.2000	13
MBOCA	MBOCA:9	4,4'-methylenebis(2-chloroaniline):9:0.2963	0.2963	9
MBO	MBO:12	management by objectives:12:0.7571	0.7571	12
MBP-SFs	MBP-SFs:5|MBP-SFS:1	Endogenous myelin basic protein-serum factors:6:0.5290	0.5290	6
MBP-1	MBP-1:6	c-myc promoter binding protein:6:0.5290	0.5290	6
MBPLM	MBPLM:9	myelin basic protein-like material:9:0.6794	0.6794	9
MBPs	MBPs:36	myelin basic proteins:36:0.8003	0.8003	36
MBP	MBP:69|mBP:4	mean arterial blood pressure:73:0.8627	0.8627	73
MBP	MBP:426|mBP:28|mbp:2	mean blood pressure:442:0.7983|mean blood pressures:14:0.6911	0.7983	456
Mbp	Mbp:5|mbp:3	megabase pairs:8:0.2327	0.2327	8
MBP	MBP:11|mBP:2	mono-n-butyl phthalate:13:0.2959	0.2959	13
MBP	MBP:8|mBP:1	monobutyl phthalate:9:0.1409	0.1409	9
MBP	MBP:2192|Mbp:7|mbp:1	myelin basic protein:2181:0.8537|myelin basic proteins:19:0.5404	0.8537	2200
MBP	MBP:6|Mbp:1	myelin basic protein gene:7:0.5926	0.5926	7
MBP	MBP:5	myosin-bound phosphatase:5:0.1132	0.1132	5
MBRs	MBRs:12	Membrane bioreactors:12:0.4153	0.4153	12
MBRs	MBRs:6	mitochondrial benzodiazepine receptors:6:0.2827	0.2827	6
MBR	MBR:34|mbr:29|Mbr:4	major breakpoint region:67:0.9554	0.9554	67
MBR	MBR:17	Medical Birth Registry:17:0.7407	0.7407	17
MBR	MBR:64	membrane bioreactor:64:0.8591	0.8591	64
MBR	MBR:9	mitochondrial benzodiazepine receptor:9:0.3945	0.3945	9
mBSA	mBSA:54|MBSA:29|M-BSA:2|m-BSA:2	methylated bovine serum albumin:87:0.7269	0.7269	87
mBSA	mBSA:4|MBSA:2	methylated BSA:6:0.1838	0.1838	6
MBSR	MBSR:17	mindfulness-based stress reduction:17:0.8270	0.8270	17
MBSS	MBSS:6	Miller Behavioral Style Scale:6:0.5290	0.5290	6
MBT-2	MBT-2:5|MBT2:3	bladder cancer cell line:8:0.6411	0.6411	8
MBT-2	MBT-2:28|MBT2:2	bladder tumor:30:0.9011	0.9011	30
MBT-2	MBT-2:6|MBT2:2	transitional cell carcinoma:8:0.6411	0.6411	8
MBTH	MBTH:16	3-methyl-2-benzothiazolinone hydrazone:16:0.4274	0.4274	16
MBTI	MBTI:41	Myers-Briggs type indicator:41:0.6869	0.6869	41
MBTS	MBTS:9	modified Blalock-Taussig shunt:9:0.6794	0.6794	9
MBT	MBT:26	2-mercaptobenzothiazole:26:0.0720	0.0720	26
MBT	MBT:7	mean body temperature:7:0.3524	0.3524	7
MBT	MBT:10	mercaptobenzothiazole:10:0.0259	0.0259	10
MBT	MBT:27	mid-blastula transition:27:0.1781	0.1781	27
MBT	MBT:63	midblastula transition:63:0.5417	0.5417	63
MBT	MBT:58|Mbt:1	Mycobacterium tuberculosis:59:0.7524	0.7524	59
MBVs	MBVs:10	micro-blood vessels:10:0.4363	0.4363	10
MBV	MBV:19	blood volume:19:0.5732	0.5732	19
MBV	MBV:14	mean blood velocity:14:0.6911	0.6911	14
MBV	MBV:9	mitral balloon valvotomy:9:0.6794	0.6794	9
MBV	MBV:10	Monodon baculovirus:10:0.4363	0.4363	10
MBW	MBW:15	mean birth weight:15:0.6386	0.6386	15
MBZ	MBZ:39|Mbz:1	mebendazole:40:0.9512	0.9512	40
MBS	MBS:6	m-maleimidobenzoic acid N-hydroxysuccinimide ester:6:0.5290	0.5290	6
MBS	MBS:9	m-maleimidobenzoyl-N-hydroxysuccinimide ester:9:0.1334	0.1334	9
MBs	MBs:53	Mallory bodies:53:0.4348	0.4348	53
MBS	MBS:14	Martin-Bell syndrome:14:0.4071	0.4071	14
MBs	MBs:21	medulloblastomas:21:0.0506	0.0506	21
MBS	MBS:13	modified barium swallow:13:0.7753	0.7753	13
MBs	MBs:29|mbs:1	mushroom bodies:30:0.2060	0.2060	30
MBS	MBS:21	myosin-binding subunit:21:0.4538	0.4538	21
MBS	MBS:14	Sodium metabisulfite:14:0.4709	0.4709	14
MBS	MBS:8	sodium metabisulphite:8:0.4102	0.4102	8
MC-26	MC-26:9	mouse colon cancer:9:0.6794	0.6794	9
MC/3T3	MC/3T3:9	3T3 fibroblasts:9:0.5470	0.5470	9
MC1R	MC1R:41|Mc1r:8|MC1-R:2	melanocortin 1 receptor:51:0.9099	0.9099	51
MC1R	MC1R:5|MC-1R:2	Melanocortin receptor 1:7:0.4438	0.4438	7
MC1R	MC1R:10|Mc1r:2	receptor gene:12:0.5664	0.5664	12
MC29	MC29:17	avian myelocytomatosis virus:17:0.6748	0.6748	17
MC3R	MC3R:15|MC3-R:10|Mc3r:1	melanocortin 3 receptor:14:0.6173|melanocortin-3 receptor:12:0.1830	0.6173	26
MC4R	MC4R:66|MC4-R:35|MC-4R:4|Mc4r:3|MC4-r:1	melanocortin-4 receptor:109:0.6275	0.6275	109
MC4R	MC4R:6|MC4-R:2|MC4r:1	melanocortin-4 receptor gene:9:0.3945	0.3945	9
MC4R	MC4R:4|MC4-R:3|MC-4R:1	melanocortin receptor 4:8:0.6411	0.6411	8
MC540	MC540:81|MC-540:6|Mc540:1	merocyanine 540:88:0.8984	0.8984	88
McAb	McAb:294|MCAB:16|mcAb:6|mcab:6|McAB:5|mcAB:3|MCAb:3|Mcab:2|MC-Ab:2|mc-ab:1	monoclonal antibodies:185:0.9430|monoclonal antibody:153:0.8603	0.9430	338
MCADH	MCADH:9	dehydrogenase:9:0.7273	0.7273	9
MCAD	MCAD:11	dehydrogenase deficiency:11:0.6182	0.6182	11
MCAD	MCAD:203	medium-chain acyl-CoA dehydrogenase:153:0.6803|medium chain acyl-CoA dehydrogenase:50:0.9046	0.9046	203
MCAF	MCAF:56	Monocyte chemotactic and activating factor:56:0.8667	0.8667	56
MCAK	MCAK:11	Mitotic centromere-associated kinesin:11:0.7103	0.7103	11
MCAO	MCAO:650|MCAo:112|MCA-O:7	middle cerebral artery occlusion:769:0.9916	0.9916	769
MCAO	MCAO:4|MCAo:1	occlusion of middle cerebral artery:5:0.6479	0.6479	5
MCAR	MCAR:8	missing completely at random:8:0.4102	0.4102	8
MCAT	MCAT:62	Medical College Admission Test:62:0.9241	0.9241	62
MCAT	MCAT:11	transacylase:11:0.0826	0.0826	11
MCAV	MCAV:4|MCAv:3	middle cerebral artery blood flow velocity:7:0.5926	0.5926	7
MCAV	MCAV:9|MCAv:2|MCA-V:1	middle cerebral artery velocity:12:0.7571	0.7571	12
MCAs	MCAs:89	middle cerebral arteries:89:0.9664	0.9664	89
MCAs	MCAs:35	monoclonal antibodies:35:0.8681	0.8681	35
MCAS	MCAS:7	Multnomah Community Ability Scale:7:0.5926	0.5926	7
MCA	MCA:13	20-methylcholanthrene:13:0.0034	0.0034	13
MCA	MCA:155	3-methylcholanthrene:155:0.0431	0.0431	155
MCA	MCA:13	carcinoma associated antigen:13:0.5335	0.5335	13
MCa	MCa:7|MCA:3	mammary carcinoma:10:0.7103	0.7103	10
MCA	MCA:28	Metabolic control analysis:28:0.8941	0.8941	28
MCA	MCA:46	methylcholanthrene:46:0.0126	0.0126	46
MCA	MCA:15	metoclopramide:15:0.0039	0.0039	15
MCA	MCA:7	microcytotoxicity assay:7:0.3524	0.3524	7
MCA	MCA:43	middle cerebral:43:0.8917	0.8917	43
MCA	MCA:12	middle cerebral arterial:12:0.7571	0.7571	12
MCA	MCA:2416|mca:6	middle cerebral artery:2333:0.9817|middle cerebral arteries:89:0.9296	0.9817	2422
MCA	MCA:19	minimal cross-sectional area:19:0.3221	0.3221	19
MCA	MCA:12	monochloroacetate:12:0.0031	0.0031	12
MCA	MCA:21	monochloroacetic acid:21:0.3130	0.3130	21
MCA	MCA:127|McA:1|mca:1	monoclonal antibodies:97:0.9352|monoclonal antibody:32:0.8145	0.9352	129
MCA	MCA:13	monocyte chemotactic activity:13:0.4444	0.4444	13
MCA	MCA:33	mucin-like carcinoma-associated antigen:33:0.6976	0.6976	33
MCA	MCA:37	multiple congenital anomalies:37:0.7492	0.7492	37
MCA	MCA:15	Multiple Correspondence Analysis:15:0.7096	0.7096	15
mCBF	mCBF:18	mean cerebral blood flow:18:0.5228	0.5228	18
MCBS	MCBS:57	Medicare Current Beneficiary Survey:57:0.9477	0.9477	57
MCBs	MCBs:8	membranous cytoplasmic bodies:8:0.5006	0.5006	8
MCB	MCB:8	cell cycle box:8:0.6411	0.6411	8
MCB	MCB:11	membranous cytoplasmic bodies:11:0.7357	0.7357	11
MCB	MCB:9	microcirculatory bed:9:0.6794	0.6794	9
MCB	MCB:15	monochlorobenzene:15:0.0848	0.0848	15
MCB	MCB:21	monochlorobimane:21:0.1212	0.1212	21
MCCA	MCCA:9	Medicare Catastrophic Coverage Act:9:0.6794	0.6794	9
MCCU	MCCU:18	mobile coronary care unit:18:0.8365	0.8365	18
MCC	MCC:10	3-methylcrotonyl-CoA carboxylase:10:0.4363	0.4363	10
MCC	MCC:17	mandibular condylar cartilage:17:0.8270	0.8270	17
MCC	MCC:11	maternal cell contamination:11:0.7357	0.7357	11
MCC	MCC:7	meningococcal C conjugate:7:0.1211	0.1211	7
MCC	MCC:9	meningococcal serogroup C conjugate:9:0.6794	0.6794	9
MCC	MCC:153|Mcc:1	Merkel cell carcinoma:143:0.9456|Merkel cell carcinomas:11:0.7357	0.9456	154
MCC	MCC:14	metacerebral cell:14:0.6173	0.6173	14
MCC	MCC:11	metastatic colorectal cancer:11:0.3829	0.3829	11
MCC	MCC:133	microcrystalline cellulose:133:0.9528	0.9528	133
MCC	MCC:4	minimum cidal concentration:4:0.1618	0.1618	4
MCC	MCC:6	moth cytochrome C:6:0.5290	0.5290	6
MCC	MCC:33	mucociliary clearance:33:0.8196	0.8196	33
MCC	MCC:5	multiple conductance channel:5:0.2818	0.2818	5
MCDF	MCDF:21	6-methyl-1,3,8-trichlorodibenzofuran:21:0.7692	0.7692	21
MCDK	MCDK:42	multicystic dysplastic kidney:33:0.9100|multicystic dysplastic kidneys:9:0.6794	0.9100	42
MCDP	MCDP:8	mast cell degranulating peptide:8:0.6411	0.6411	8
MCDR1	MCDR1:15	North Carolina macular dystrophy:15:0.8045	0.8045	15
MCDs	MCDs:14	malformations of cortical development:14:0.6173	0.6173	14
MCD	MCD:30	macular corneal dystrophy:30:0.7315	0.7315	30
MCD	MCD:180	magnetic circular dichroism:180:0.9734	0.9734	180
MCD	MCD:23	malformations of cortical development:23:0.6306	0.6306	23
MCD	MCD:23	malonyl-CoA decarboxylase:23:0.5997	0.5997	23
MCD	MCD:22	mast cell degranulating:22:0.8657	0.8657	22
MCD	MCD:9	mast cell degranulating peptide:9:0.6411	0.6411	9
MCD	MCD:6|mCd:1	mast cell density:7:0.2902	0.2902	7
MCD	MCD:6	mean consecutive difference:6:0.5290	0.5290	6
MCD	MCD:26	medullary collecting duct:26:0.8861	0.8861	26
MCD	MCD:17|M-CD:1	methyl-beta-cyclodextrin:18:0.0202	0.0202	18
MCD	MCD:87	minimal change disease:87:0.9656	0.9656	87
MCD	MCD:75	multicentric Castleman's disease:75:0.9169	0.9169	75
MCD	MCD:10	multiple carboxylase deficiency:10:0.7103	0.7103	10
MCE	MCE:11	capillary electrophoresis:11:0.2764	0.2764	11
MCE	MCE:8	malathion carboxylesterase:8:0.4102	0.4102	8
MCE	MCE:6	microchip electrophoresis:6:0.0564	0.0564	6
MCE	MCE:228	Myocardial contrast echocardiography:228:0.9655	0.9655	228
MCF-10A	MCF-10A:5|MCF10A:2	human breast epithelial cells:7:0.5926	0.5926	7
MCF-10A	MCF-10A:5	human mammary epithelial:5:0.4422	0.4422	5
MCF-7	MCF-7:16|MCF7:4	breast adenocarcinoma:20:0.7173	0.7173	20
MCF-7	MCF-7:25|MCF7:16	breast carcinoma:41:0.7258	0.7258	41
MCF-7	MCF-7:16	estrogen-dependent:16:0.0218	0.0218	16
MCF-7	MCF-7:44|MCF7:3|Mcf-7:1|mcf-7:1	human breast cancer:49:0.5747	0.5747	49
MCF-7	MCF-7:68|MCF7:7	human breast cancer cells:75:0.7315	0.7315	75
MCF-7	MCF-7:42|MCF7:6	human breast cancer cell line:48:0.5497	0.5497	48
MCF-7	MCF-7:14|MCF7:2	human breast carcinoma cells:16:0.8165	0.8165	16
MCF-7	MCF-7:12	human breast carcinoma cell line:12:0.3524	0.3524	12
MCF-7	MCF-7:5|MCF7:1	human mammary carcinoma cells:6:0.1838	0.1838	6
MCF-7	MCF-7:5|MCF7:1	human mammary carcinoma cell line:6:0.3728	0.3728	6
MCFA	MCFA:26	medium-chain fatty acids:26:0.5409	0.5409	26
MCFAs	MCFAs:16	medium-chain fatty acids:16:0.4536	0.4536	16
M-CFC	M-CFC:10	macrophage colony-forming cells:10:0.5856	0.5856	10
MCFG	MCFG:9	micafungin:9:0.7273	0.7273	9
MCFP	MCFP:71	mean circulatory filling pressure:71:0.9579	0.9579	71
MCFV	MCFV:11	malignant catarrhal fever virus:11:0.7357	0.7357	11
MCF	MCF:16	macrophage chemotactic factor:16:0.5564	0.5564	16
MCF	MCF:81	malignant catarrhal fever:81:0.9631	0.9631	81
MCF	MCF:18	mean channel fluorescence:18:0.5732	0.5732	18
MCF	MCF:11	middle cranial fossa:11:0.7357	0.7357	11
MCF	MCF:43	mink cell focus-forming:43:0.8590	0.8590	43
MCF	MCF:49	mink cell focus-inducing:49:0.9379	0.9379	49
MCF	MCF:10	mitochondrial carrier family:10:0.7103	0.7103	10
MCF	MCF:5	monocyte cytotoxic factors:5:0.4422	0.4422	5
MCF	MCF:20	mononuclear cell factor:20:0.6680	0.6680	20
MCF	MCF:11	myocardial contractile force:11:0.7357	0.7357	11
MCGN	MCGN:34	mesangiocapillary glomerulonephritis:34:0.6386	0.6386	34
MCGN	MCGN:9	mesangiocapillary GN:9:0.5470	0.5470	9
MCGs	MCGs:18	Magnetocardiograms:18:0.3953	0.3953	18
MCH-FP	MCH-FP:6	Maternal and Child Health and Family Planning:6:0.5290	0.5290	6
MCH/FP	MCH/FP:9	maternal and child health and family planning:9:0.7357	0.7357	9
MCH/FP	MCH/FP:7	maternal and child health/family planning:7:0.5926	0.5926	7
MCHA	MCHA:6|McHA:1	microsomal antibodies:7:0.2902	0.2902	7
MCHC	MCHC:9	hemoglobin content:9:0.3945	0.3945	9
MCHB	MCHB:14	Maternal and Child Health Bureau:14:0.7909	0.7909	14
MCI-186	MCI-186:1	free radical scavenger 3-methyl-1-phenyl-2-pyrazolin-5-one:1:0.3728	0.3728	1
MCI/MI	MCI/MI:10	Methylchloroisothiazolinone/methylisothiazolinone:10:0.4286	0.4286	10
MCID	MCID:24	minimal clinically important difference:24:0.5236	0.5236	24
MCI	MCI:5	mandibular cortical index:5:0.0902	0.0902	5
MCI	MCI:5	mass casualty incident:5:0.4422	0.4422	5
MCI	MCI:4|mCI:1	metacarpal cortical index:5:0.0902	0.0902	5
MCI	MCI:25	metacarpal index:25:0.3233	0.3233	25
MCI	MCI:380	mild cognitive impairment:380:0.9793	0.9793	380
Mcl-1	Mcl-1:14|MCL-1:4|MCL1:1|mcl-1:1	myeloid cell leukemia-1:14:0.7909|myeloid cell leukemia 1:6:0.5290	0.7909	20
MCLR	MCLR:47|MC-LR:32	microcystin-LR:79:0.8764	0.8764	79
MCLS	MCLS:10	Kawasaki disease:10:0.3945	0.3945	10
MCLs	MCLs:15	Magnetite cationic liposomes:15:0.7096	0.7096	15
MCLs	MCLs:26	Mantle cell lymphomas:26:0.8861	0.8861	26
MCLs	MCLs:17	medial collateral ligaments:17:0.8270	0.8270	17
MCLS	MCLS:33	Mucocutaneous lymph node syndrome:33:0.9126	0.9126	33
MCL	MCL:19	comfortable loudness:19:0.8449	0.8449	19
MCL	MCL:392	Mantle cell lymphoma:365:0.9868|mantle cell lymphomas:27:0.8903	0.9868	392
MCL	MCL:11	mast cell leukemia:11:0.4728	0.4728	11
MCL	MCL:25	maximum contaminant level:25:0.8816	0.8816	25
MCL	MCL:208	medial collateral ligament:198:0.9758|medial collateral ligaments:10:0.5856	0.9758	208
MCL	MCL:9|mcl:4	medium-chain-length:13:0.0128	0.0128	13
MCL	MCL:8|mcl:1	mitral cell layer:9:0.5470	0.5470	9
MCL	MCL:23	mucocutaneous leishmaniasis:23:0.6653	0.6653	23
MCL	MCL:6	myocardial chord length:6:0.2827	0.2827	6
MCM2	MCM2:5|Mcm2:3|MCM-2:1|Mcm-2:1	Minichromosome maintenance protein 2:10:0.7103	0.7103	10
MCMC	MCMC:153	Markov chain Monte Carlo:153:0.9804	0.9804	153
MCMI-II	MCMI-II:10	Millon Clinical Multiaxial Inventory:10:0.5856	0.5856	10
MCMI-II	MCMI-II:21	Millon Clinical Multiaxial Inventory-II:21:0.7291	0.7291	21
MCMI	MCMI:83	Millon Clinical Multiaxial Inventory:83:0.7905	0.7905	83
MCMV	MCMV:531|mCMV:6|M-CMV:1	Murine cytomegalovirus:538:0.8651	0.8651	538
MCM	MCM:9	conditioned media:9:0.2285	0.2285	9
MCM	MCM:22|M-CM:1	conditioned medium:23:0.2333	0.2333	23
MCM	MCM:29|Mcm:1	Methylmalonyl-CoA mutase:19:0.3871|methylmalonyl CoA mutase:11:0.7357	0.7357	30
MCM	MCM:76|Mcm:23|mcm:1	minichromosome maintenance:100:0.7634	0.7634	100
MCM	MCM:14	monocyte-conditioned medium:14:0.1063	0.1063	14
MCM	MCM:12	mucous cell metaplasia:12:0.6460	0.6460	12
MCN1	MCN1:12	modulatory commissural neuron 1:12:0.7571	0.7571	12
MCNP	MCNP:9	Monte Carlo N-Particle:9:0.6794	0.6794	9
MCNs	MCNs:10	magnocellular neurons:10:0.7103	0.7103	10
MCNS	MCNS:184	minimal change nephrotic syndrome:184:0.9656	0.9656	184
MCNs	MCNs:11	Mucinous cystic neoplasms:11:0.7357	0.7357	11
MCNS	MCNS:10	patients with minimal-change nephrotic syndrome:10:0.0829	0.0829	10
MCNU	MCNU:10	methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside:10:0.7103	0.7103	10
MCNU	MCNU:21	ranimustine:21:0.3846	0.3846	21
MCN	MCN:6	main cuneate nucleus:6:0.5290	0.5290	6
MCN	MCN:35	minimal change nephropathy:35:0.9151	0.9151	35
MCN	MCN:6	musculocutaneous nerve:6:0.1320	0.1320	6
MCOs	MCOs:222	managed care organizations:222:0.9864	0.9864	222
MCO	MCO:72	managed care organization:72:0.9585	0.9585	72
MCO	MCO:27	metal-catalyzed oxidation:27:0.7066	0.7066	27
MCP-4	MCP-4:6	monocyte chemoattractant protein-4:6:0.5290	0.5290	6
MCP-1	MCP-1:42	monocyte chemoattractant protein:42:0.8558	0.8558	42
MCP-1	MCP-1:1295|MCP1:9	monocyte chemoattractant protein-1:1104:0.9382|Monocyte chemoattractant protein 1:200:0.8998	0.9382	1304
MCP-1	MCP-1:29	monocyte chemotactic peptide-1:29:0.7970	0.7970	29
MCP-1	MCP-1:20	monocyte chemotactic protein:20:0.7766	0.7766	20
MCP-1	MCP-1:81|MCP1:1	monocyte chemotactic protein 1:82:0.8938	0.8938	82
MCP-3	MCP-3:14	monocyte chemoattractant protein-3:14:0.7909	0.7909	14
MCP-3	MCP-3:34|MCP3:6	Monocyte chemotactic protein-3:29:0.8978|monocyte chemotactic protein 3:11:0.7357	0.8978	40
MCPA	MCPA:31	2-methyl-4-chlorophenoxyacetic acid:31:0.2913	0.2913	31
MCPG	MCPG:5	antagonist (R,S)-alpha-methyl-4-carboxyphenylglycine:5:0.0612	0.0612	5
MCPG	MCPG:5	mGluR antagonist (+)-alpha-methyl-4-carboxyphenylglycine:5:0.2113	0.2113	5
MCPG	MCPG:5	mGluR antagonist (RS)-alpha-methyl-4-carboxyphenylglycine:5:0.2500	0.2500	5
MCPG	MCPG:4	receptor antagonist alpha-methyl-4-carboxyphenylglycine:4:0.0902	0.0902	4
MCPG	MCPG:12	(S)-alpha-methyl-4-carboxyphenylglycine:12:0.0705	0.0705	12
MCPM	MCPM:8	monocalcium phosphate monohydrate:8:0.4102	0.4102	8
mCPP	mCPP:8|m-CPP:4	1-(m-chlorophenyl)piperazine:12:0.0215	0.0215	12
m-CPP	m-CPP:14|MCPP:7|mCPP:5	agonist meta-chlorophenylpiperazine:26:0.2825	0.2825	26
mCPP	mCPP:9|m-CPP:5|MCPP:1	m-chlorophenyl-piperazine:15:0.0274	0.0274	15
MCPP	MCPP:20	Metacarpophalangeal pattern profile:20:0.8525	0.8525	20
mCPP	mCPP:7|m-CPP:5|MCPP:2	Metachlorophenylpiperazine:14:0.0254	0.0254	14
mCPP	mCPP:3|m-CPP:1	receptor agonist 1-(3-chlorophenyl)piperazine:4:0.1132	0.1132	4
mCPP	mCPP:8|m-CPP:7|MCPP:3	receptor agonist m-chlorophenylpiperazine:18:0.2569	0.2569	18
MCPs	MCPs:55	methyl-accepting chemotaxis proteins:55:0.9458	0.9458	55
MCP	MCP:9	1-methylcyclopropene:9:0.0078	0.0078	9
MCP	MCP:6	calcium phosphate:6:0.1838	0.1838	6
MCP	MCP:11	mean circulatory pressure:11:0.7357	0.7357	11
MCP	MCP:6	medial coronoid process:6:0.5290	0.5290	6
MCP	MCP:218|mcp:1	metacarpophalangeal:219:0.2129	0.2129	219
MCP	MCP:20	methylclofenapate:20:0.0186	0.0186	20
MCP	MCP:166|Mcp:5	metoclopramide:171:0.1660	0.1660	171
MCP	MCP:6	microchannel plate:6:0.1320	0.1320	6
MCP	MCP:13	monocrotophos:13:0.0117	0.0117	13
MCP	MCP:9	multicatalytic protease:9:0.5470	0.5470	9
MCP	MCP:35	multicatalytic proteinase:35:0.7371	0.7371	35
MCP	MCP:7	multifocal choroiditis and panuveitis:7:0.6411	0.6411	7
MCP	MCP:13|Mcp:1	proteins:14:0.0127	0.0127	14
MCQ	MCQ:46	multiple choice question:20:0.8525|multiple choice questions:10:0.7103|multiple-choice question:9:0.1099|Multiple-choice questions:7:0.1211	0.8525	46
MCQ	MCQ:8	multiple choice questionnaire:8:0.5006	0.5006	8
MCQs	MCQs:28	multiple choice questions:17:0.8270|multiple-choice questions:11:0.1760	0.8270	28
mcrA	mcrA:5	methyl coenzyme M reductase:5:0.4422	0.4422	5
MCRC	MCRC:12|mCRC:3	metastatic colorectal cancer:15:0.8045	0.8045	15
MCRg	MCRG:6|MCRg:6|MCR-g:1	metabolic clearance rate of glucose:13:0.7753	0.7753	13
MCRI	MCRI:6|MCR-I:2|MCRi:1	metabolic clearance rate of insulin:9:0.7103	0.7103	9
mCRP	mCRP:7	complement regulatory proteins:7:0.4438	0.4438	7
MCRs	MCRs:11|MC-Rs:4	melanocortin receptors:15:0.7096	0.7096	15
MCRs	MCRs:10	metabolic clearance rates:10:0.7103	0.7103	10
MCR	MCR:7	coronary resistance:7:0.3524	0.3524	7
MCR	MCR:13	macromomycin:13:0.0135	0.0135	13
MCR	MCR:5	major cytogenetic remission:5:0.4422	0.4422	5
MCR	MCR:10|Mcr:1	major cytogenetic response:11:0.5355	0.5355	11
MC-R	MC-R:11|MCR:10	melanocortin receptor:21:0.2743	0.2743	21
MCR	MCR:16	metabolic clearance:16:0.6577	0.6577	16
MCR	MCR:389	Metabolic clearance rate:315:0.9797|metabolic clearance rates:74:0.9596	0.9797	389
MCR	MCR:17	metabolic clearance rate of glucose:17:0.8365	0.8365	17
MCR	MCR:19	methyl-coenzyme M reductase:19:0.5404	0.5404	19
MCR	MCR:29	Micronomicin:29:0.0343	0.0343	29
MCR	MCR:19	mineralocorticoid receptor:19:0.2352	0.2352	19
MCR	MCR:5	multicomponent reaction:5:0.0612	0.0612	5
MCR	MCR:9	multivariate curve resolution:9:0.6794	0.6794	9
MCSA	MCSA:8	cell surface antigen:8:0.5006	0.5006	8
MCSA	MCSA:22|mCSA:3	cross-sectional area:25:0.6873	0.6873	25
M-CSFR	M-CSFR:8|M-CSF-R:1	macrophage colony-stimulating factor receptor:9:0.6794	0.6794	9
M-CSF	M-CSF:751|MCSF:38|m-CSF:1	macrophage colony-stimulating factor:790:0.9381	0.9381	790
MCSP	MCSP:7	chondroitin sulfate proteoglycan:7:0.5926	0.5926	7
MCST	MCST:14	Card Sorting Test:14:0.7753	0.7753	14
MCSS	MCSS:13	multiple copy simultaneous search:13:0.7753	0.7753	13
MCT1	MCT1:10|MCT-1:1	monocarboxylate transporter:11:0.5355	0.5355	11
MCT1	MCT1:24|MCT-1:1	monocarboxylate transporter 1:25:0.6873	0.6873	25
MCTD	MCTD:447	mixed connective tissue disease:447:0.9892	0.9892	447
MCTP	MCTP:41	monocrotaline pyrrole:41:0.8525	0.8525	41
MCTT	MCTT:19|M-CTT:1	transit time:20:0.7173	0.7173	20
MCTs	MCTs:13	Mast cell tumors:13:0.7753	0.7753	13
MCTs	MCTs:13	medium-chain triacylglycerols:13:0.6701	0.6701	13
MCTs	MCTs:38	medium-chain triglycerides:38:0.6322	0.6322	38
MCTs	MCTs:30	monocarboxylate transporters:30:0.7652	0.7652	30
MCTS	MCTS:10	multicellular tumor spheroids:10:0.7103	0.7103	10
MCT	MCT:11	cell tumor:11:0.3495	0.3495	11
MCT	MCT:13	injection of monocrotaline:13:0.0521	0.0521	13
MCT	MCT:9	mast cells:9:0.1809	0.1809	9
MCT	MCT:9	mast cell tryptase:9:0.6794	0.6794	9
MCT	MCT:13	mast cell tumors:13:0.6701	0.6701	13
MCT	MCT:13	Mean circulation time:13:0.7753	0.7753	13
MCT	MCT:37	medium-chain triacylglycerols:24:0.6427|medium-chain triacylglycerol:13:0.5934	0.6427	37
MCT	MCT:368	medium-chain triglycerides:158:0.5652|medium chain triglycerides:86:0.9653|medium-chain triglyceride:80:0.5176|medium chain triglyceride:44:0.8941	0.9653	368
MCT	MCT:94	medullary carcinoma of the thyroid:94:0.9695	0.9695	94
MCT	MCT:13	medullary carcinoma of the thyroid gland:13:0.6911	0.6911	13
MCT	MCT:30	medullary collecting tubules:16:0.7261|medullary collecting tubule:14:0.7909	0.7909	30
MCT	MCT:15	medullary thyroid carcinoma:15:0.8045	0.8045	15
MCT	MCT:7	Meta-Contrast Technique:7:0.0777	0.0777	7
MCT	MCT:6|mCT:2	microcomputed tomography:8:0.2090	0.2090	8
MCT	MCT:57	microwave coagulation therapy:57:0.9162	0.9162	57
MCT	MCT:24	mode-coupling theory:14:0.2892|mode coupling theory:10:0.7103	0.7103	24
MCT	MCT:45	monocarboxylate transporter:35:0.5098|monocarboxylate transporters:10:0.5856	0.5856	45
MCT	MCT:16	monocarboxylic acid transporter:16:0.8165	0.8165	16
MCT	MCT:7	mother-to-child transmission:7:0.3524	0.3524	7
MCT	MCT:6	motor conduction time:6:0.3728	0.3728	6
MCT	MCT:24	Mucociliary transport:24:0.6767	0.6767	24
MCU	MCU:14	micturating cystourethrogram:14:0.6911	0.6911	14
MCU	MCU:22	micturating cystourethrography:22:0.6178	0.6178	22
MCVs	MCVs:7	motor conduction velocities:7:0.3524	0.3524	7
MCV	MCV:13	conduction velocities:13:0.7753	0.7753	13
MCV	MCV:147	mean cell volume:147:0.7887	0.7887	147
MCV	MCV:525	mean corpuscular volume:519:0.9692|mean corpuscular volumes:6:0.5290	0.9692	525
MCV	MCV:10	measles-containing vaccine:10:0.1774	0.1774	10
MCV	MCV:10	melanoma cell vaccine:10:0.7103	0.7103	10
MCV	MCV:13	Middle cardiac vein:13:0.7753	0.7753	13
MCV	MCV:60	molluscum contagiosum virus:60:0.9503	0.9503	60
MCV	MCV:52	motor nerve conduction velocity:52:0.9427	0.9427	52
MCW	MCW:13	Medical College of Wisconsin:13:0.7753	0.7753	13
MCZ	MCZ:32	miconazole:32:0.8611	0.8611	32
MChR	MChR:5|mCh-R:2|m-ChR:1|mChR:1	muscarinic cholinergic receptor:5:0.4422|Muscarinic cholinergic receptors:4:0.1618	0.4422	9
MCh	MCh:10|Mch:1	acetyl-beta-methylcholine:11:0.0072	0.0072	11
MCh	MCh:3|Mch:2	intrafemoral artery infusions of the endothelium-dependent vasodilator methacholine chloride:5:0.5290	0.5290	5
MCH	MCH:169	Maternal and Child Health:169:0.8391	0.8391	169
MCH	MCH:9	mean corpuscular Hb:9:0.6794	0.6794	9
MCH	MCH:327	Melanin-concentrating hormone:327:0.7900	0.7900	327
MCh	MCh:261|Mch:43|MCH:34	methacholine:338:0.2438	0.2438	338
MCH	MCH:9	muscle contraction headache:9:0.6794	0.6794	9
MCx	MCx:11|Mcx:1	motor cortex:12:0.7571	0.7571	12
MC	MC:16	20-methylcholanthrene:16:0.0038	0.0038	16
MC	MC:12	3-methyl-cholanthrene:12:0.0028	0.0028	12
mC	mC:8|MC:1	5-methylcytosine:9:0.0020	0.0020	9
MC	MC:11	carcinomas:11:0.0026	0.0026	11
MC	MC:11	complex:11:0.0026	0.0026	11
MC	MC:11	contraction:11:0.0026	0.0026	11
MC	MC:14|M-C:1	controls:15:0.0036	0.0036	15
MC	MC:61	glomerular mesangial cells:61:0.1634	0.1634	61
MC	MC:30	magnetic coil:30:0.8472	0.8472	30
MC	MC:32|Mc:1|mc:1	magnocellular:34:0.0084	0.0084	34
MC	MC:14	Managed care:14:0.3813	0.3813	14
MC	MC:7	Marlowe-Crowne Social Desirability scale:7:0.4438	0.4438	7
MC	MC:313|Mc:1	mast cells:229:0.2908|mast cell:85:0.2976	0.2976	314
MC	MC:6	matched control:6:0.0666	0.0666	6
MC	MC:17	Medullary carcinoma:17:0.2022	0.2022	17
MC	MC:67	melanocortin:67:0.0168	0.0168	67
MC	MC:8|Mc:2	melanocytes:10:0.0023	0.0023	10
MC	MC:17	Meningeal carcinomatosis:17:0.5760	0.5760	17
MC	MC:9	Menstrual cycle:9:0.3945	0.3945	9
MC	MC:29	mercuric chloride:29:0.3379	0.3379	29
MC	MC:112	mesangial cell:112:0.4110	0.4110	112
Mc	MC:5|Mc:5|mc:5	metacercariae:15:0.0036	0.0036	15
MC	MC:20	methacholine:20:0.0048	0.0048	20
MC	MC:21|mc:1	methyl cellulose:22:0.5581	0.5581	22
MC	MC:61|Mc:1|mc:1	methylcellulose:63:0.0158	0.0158	63
MC	MC:34	methylcholanthrene:34:0.0084	0.0084	34
MC	MC:23|mc:1	methylene chloride:24:0.2578	0.2578	24
MC	MC:18	metoclopramide:18:0.0043	0.0043	18
MC	MC:9	microcirculation:9:0.0020	0.0020	9
MC	MC:35	microcystin:25:0.0061|microcystins:10:0.0023	0.0061	35
MC	MC:8	microscopic colitis:8:0.5006	0.5006	8
Mc	Mc:8|MC:5	microsomal:13:0.0031	0.0031	13
MC	MC:10	Microvessel count:10:0.2275	0.2275	10
MC	MC:40	mineralocorticoid:29:0.0071|mineralocorticoids:11:0.0026	0.0071	40
MC	MC:9	Minnesota code:9:0.4587	0.4587	9
MC	MC:12	minocycline:12:0.0028	0.0028	12
MC	MC:148|Mc:3|mc:1	mitomycin C:152:0.9230	0.9230	152
MC	MC:9	Mitotic count:9:0.1809	0.1809	9
MC	MC:74	mixed cellularity:74:0.9361	0.9361	74
MC	MC:11	mixed chimaerism:11:0.6182	0.6182	11
MC	MC:45	mixed chimerism:45:0.7461	0.7461	45
MC	MC:25	mixed cryoglobulinaemia:25:0.8816	0.8816	25
MC	MC:85	mixed cryoglobulinemia:85:0.9442	0.9442	85
MC	MC:17|mc:1	moisture content:18:0.5940	0.5940	18
MC	MC:34	Molluscum contagiosum:34:0.9126	0.9126	34
MC	MC:38|Mc:1	monochorionic:39:0.0097	0.0097	39
MC	MC:17	monoclonal component:11:0.2972|monoclonal components:6:0.2243	0.2972	17
MC	MC:17	monocomponent:17:0.0041	0.0041	17
MC	MC:14	monocytes:14:0.0033	0.0033	14
MC	MC:188	Monte Carlo:188:0.9745	0.9745	188
MC	MC:42	motor cortex:42:0.6429	0.6429	42
MC	MC:6|mC:2	mucociliary clearance:8:0.3463	0.3463	8
MC	MC:14|m-c:1	musculocutaneous:15:0.0036	0.0036	15
MC	MC:12	myocardial contractility:12:0.6460	0.6460	12
MC	MC:9	myocarditis:9:0.0020	0.0020	9
MC	MC:12	myotonia congenita:12:0.7571	0.7571	12
MC	MC:12|Mc:2	Neisseria meningitidis:14:0.5589	0.5589	14
MC	MC:5	peripheral blood mononuclear cells:5:0.0517	0.0517	5
MDA-LDL	MDA-LDL:11	low-density lipoprotein:11:0.3495	0.3495	11
MDA-LDL	MDA-LDL:15	malondialdehyde-modified LDL:15:0.2972	0.2972	15
MDA-LM	MDA-LM:8	malondialdehyde-like material:8:0.5006	0.5006	8
MDAS	MDAS:11	Memorial Delirium Assessment Scale:11:0.7357	0.7357	11
MDAS	MDAS:8	Modified Dental Anxiety Scale:8:0.6411	0.6411	8
MDA	MDA:10	3,4-(methylenedioxy)amphetamine:10:0.0018	0.0018	10
MDA	MDA:6	4,4'-methylene dianiline:6:0.1320	0.1320	6
MDA	MDA:32	4,4'-methylenedianiline:32:0.0063	0.0063	32
MDA	MDA:9	antibody:9:0.0016	0.0016	9
MDA	MDA:38	lipid peroxidation:38:0.9217	0.9217	38
MDA	MDA:11	lipid peroxidation products:11:0.7357	0.7357	11
MDA	MDA:18	lipid peroxide:9:0.6794|lipid peroxides:9:0.6794	0.6794	18
MDA	MDA:163	malonaldehyde:163:0.0328	0.0328	163
MDA	MDA:17	malondiadehyde:17:0.0034	0.0034	17
MDA	MDA:3388|mda:1	malondialdehyde:3389:0.6855	0.6855	3389
MDA	MDA:17	malonedialdehyde:17:0.0032	0.0032	17
MDA	MDA:111	malonic dialdehyde:111:0.5015	0.5015	111
MDA	MDA:10	malonildialdehyde:10:0.0018	0.0018	10
MDA	MDA:55	malonyl dialdehyde:55:0.2164	0.2164	55
MDA	MDA:215	malonyldialdehyde:215:0.0431	0.0431	215
MDA	MDA:26	Mass drug administration:26:0.8861	0.8861	26
MDA	MDA:17	Medical Devices Agency:17:0.8270	0.8270	17
MDa	MDa:31|Mda:4|mDa:1|MDA:1	megadaltons:23:0.0044|megadalton:14:0.0026	0.0044	37
MDA	MDA:5	methylene dianiline:5:0.0612	0.0612	5
MDA	MDA:52	methylenedioxyamphetamine:52:0.0093	0.0093	52
MDA	MDA:21	minimal deviation adenocarcinoma:21:0.8594	0.8594	21
MDA	MDA:10	minimum detectable activity:10:0.7103	0.7103	10
MDA	MDA:19	multiple displacement amplification:19:0.8449	0.8449	19
MDA	MDA:8	Multivariate discriminant analysis:8:0.2987	0.2987	8
MDBGN	MDBGN:9	methyldibromo glutaronitrile:9:0.6794	0.6794	9
MDBK	MDBK:9	bovine kidney cell line:9:0.6794	0.6794	9
MDBK	MDBK:69	Madin-Darby bovine kidney:69:0.4632	0.4632	69
MDBP	MDBP:10	methylated DNA-binding protein:10:0.4363	0.4363	10
MDCKII	MDCKII:6|MDCK-II:1	Madin-Darby canine kidney II:7:0.5926	0.5926	7
MDCK	MDCK:9	canine kidney epithelial cells:9:0.3069	0.3069	9
MDCK	MDCK:5	cultured renal epithelial:5:0.0902	0.0902	5
MDCK	MDCK:1054|MDCk:1	Madin-Darby canine kidney:1055:0.7976	0.7976	1055
MDCK	MDCK:32	Madin-Darby canine kidney cells:32:0.4601	0.4601	32
MDCT	MDCT:113|MD-CT:8	computed tomography:121:0.9606	0.9606	121
MDCT	MDCT:16|mDCT:1	immortalized mouse distal convoluted tubule:17:0.6748	0.6748	17
MDCT	MDCT:16	multi-detector row CT:16:0.3174	0.3174	16
MDCT	MDCT:64|MD-CT:2	multidetector CT:66:0.3161	0.3161	66
MDCT	MDCT:43	Multidetector-row CT:29:0.1127|multidetector row CT:14:0.2524	0.2524	43
mDCs	mDCs:12|MDCs:3|M-DCs:2	dendritic cells:17:0.5038	0.5038	17
MDC	MDC:14|mDC:12|M-DC:1	dendritic cells:27:0.4837	0.4837	27
mDC	mDC:14|m-DC:1	mature DC:15:0.2119	0.2119	15
MDC	MDC:12	minimum detectable concentration:12:0.4153	0.4153	12
MDC	MDC:26	monodansylcadaverine:26:0.0665	0.0665	26
MDC	MDC:12|mDC:7	myeloid DC:19:0.3117	0.3117	19
MDDCs	MDDCs:8|MD-DCs:2	monocyte-derived DCs:10:0.7103	0.7103	10
MDDCs	MDDCs:16|MD-DCs:2|md-DCs:1	monocyte-derived dendritic cells:19:0.7044	0.7044	19
MDDR	MDDR:7	MDL Drug Data Report:7:0.3524	0.3524	7
MDD	MDD:56	major depression:56:0.8901	0.8901	56
MDD	MDD:918	major depressive disorder:898:0.9849|major depressive disorders:20:0.8525	0.9849	918
MDEs	MDEs:13	major depressive episodes:13:0.7753	0.7753	13
MDF	MDF:25|mdf:1	median frequency:26:0.4719	0.4719	26
MDF	MDF:10	Membrane differential filtration:10:0.7103	0.7103	10
MDF	MDF:9	multiple daily fractionation:9:0.6794	0.6794	9
MDF	MDF:63	Myocardial depressant factor:63:0.9526	0.9526	63
MDGF	MDGF:17	growth factor:17:0.7407	0.7407	17
MDGI	MDGI:33	mammary-derived growth inhibitor:33:0.5357	0.5357	33
MDGs	MDGs:9	Millennium Development Goals:9:0.6794	0.6794	9
mDHFR	mDHFR:9|Mdhfr:1	dihydrofolate reductase:10:0.7103	0.7103	10
MDHV	MDHV:17	Marek's disease herpesvirus:17:0.8270	0.8270	17
MDH	MDH:353|mdh:9|Mdh:2	malate dehydrogenase:364:0.7435	0.7435	364
MDH	MDH:42	medullary dorsal horn:42:0.8558	0.8558	42
MDIPC	MDIPC:11|MDI-PC:2	dicloxacillin:13:0.9231	0.9231	13
MDIs	MDIs:139|mdis:1	metered-dose inhalers:73:0.4231|metered dose inhalers:67:0.9554	0.9554	140
MDI	MDI:16	diphenylmethane-4,4'-diisocyanate:16:0.0155	0.0155	16
MDI	MDI:41	diphenylmethane diisocyanate:41:0.2462	0.2462	41
MDI	MDI:10	isocyanate:10:0.0103	0.0103	10
MDI	MDI:11	Major Depression Inventory:11:0.4728	0.4728	11
MDI	MDI:24	manic-depressive illness:16:0.4246|manic depressive illness:8:0.5006	0.5006	24
MDI	MDI:52	Mental Development Index:52:0.9099	0.9099	52
MDI	MDI:44	Mental Developmental Index:44:0.8941	0.8941	44
MDI	MDI:457	metered dose inhaler:210:0.9626|metered-dose inhaler:191:0.4185|metered dose inhalers:34:0.9126|metered-dose inhalers:22:0.2406	0.9626	457
MDI	MDI:11	modulation detection interference:11:0.5355	0.5355	11
MDI	MDI:28	multiple daily injections:21:0.8594|multiple daily injection:7:0.5926	0.8594	28
MDLs	MDLs:26	method detection limits:26:0.7340	0.7340	26
MDL	MDL:26	method detection limit:26:0.6645	0.6645	26
MDL	MDL:25	minimum description length:25:0.8186	0.8186	25
MDM2	MDM2:12|mdm-2:3|Mdm2:3|MDM-2:2|mdm2:2	double minute-2:22:0.8657	0.8657	22
MDM2	MDM2:8|mdm2:3|Mdm2:2|MDM-2:1	mouse double minute 2:14:0.1299	0.1299	14
MDM2	MDM2:23|Mdm2:8|mdm2:4|MDM-2:1|mdm-2:1	murine double minute 2:37:0.5643	0.5643	37
MDMA	MDMA:25	(+/-)-3,4-methylenedioxymethamphetamine:14:0.0168|(+/-)3,4-Methylenedioxymethamphetamine:11:0.0126	0.0168	25
MDMA	MDMA:381	3,4-methylenedioxymethamphetamine:381:0.5231	0.5231	381
MDMA	MDMA:115	methylenedioxymethamphetamine:115:0.1515	0.1515	115
MDMS	MDMS:9	methylene dimethanesulphonate:9:0.6794	0.6794	9
MDMs	MDMs:98	monocyte-derived macrophages:98:0.9359	0.9359	98
MDMV	MDMV:8	Maize dwarf mosaic virus:8:0.6411	0.6411	8
MDM	MDM:15	midecamycin:15:0.0351	0.0351	15
MDM	MDM:260|MdM:5	monocyte-derived macrophages:242:0.8946|monocyte-derived macrophage:23:0.8715	0.8946	265
mDNA	mDNA:8	mitochondrial DNA:8:0.4102	0.4102	8
MDNCF	MDNCF:10	monocyte-derived neutrophil chemotactic factor:10:0.7103	0.7103	10
MDN	MDN:9|mdn:1	magnocellular dorsal nucleus:10:0.5000	0.5000	10
MDO	MDO:18	membrane-derived oligosaccharides:18:0.8365	0.8365	18
MDPB	MDPB:8	antibacterial monomer 12-methacryloyloxydodecylpyridinium bromide:8:0.6794	0.6794	8
MDPE	MDPE:14	median performance error:14:0.7909	0.7909	14
MDPH	MDPH:13	Massachusetts Department of Public Health:13:0.4444	0.4444	13
MDP	MDP:10	dihydrogen phosphate:10:0.7103	0.7103	10
MDP	MDP:13	major duodenal papilla:13:0.6701	0.6701	13
MDP	MDP:7	manic-depressive psychosis:7:0.3524	0.3524	7
MDP	MDP:50	maximum diastolic potential:50:0.6118	0.6118	50
MDP	MDP:107	methylene diphosphonate:107:0.5318	0.5318	107
MDP	MDP:8|mdp:1	minimal distending pressure:9:0.6794	0.6794	9
MDP	MDP:465|Mdp:2	muramyl dipeptide:455:0.9647|muramyl-dipeptide:12:0.0099	0.9647	467
MDP	MDP:54	muramyldipeptide:54:0.0475	0.0475	54
MDP	MDP:15	N-acetyl-muramyl-L-alanyl-D-isoglutamine:15:0.0125	0.0125	15
MDP	MDP:55	N-acetylmuramyl-L-alanyl-D-isoglutamine:55:0.0484	0.0484	55
MDQ	MDQ:39	Menstrual Distress Questionnaire:39:0.9237	0.9237	39
MDR1	MDR1:110|mdr1:27|MDR-1:20|mdr-1:8|Mdr1:3	multidrug resistance:156:0.8557|multidrug-resistance:12:0.0135	0.8557	168
MDR1	MDR1:90|MDR-1:30|mdr1:10|mdr-1:3	multidrug resistance 1:82:0.8226|multidrug resistance-1:51:0.8776	0.8776	133
MDR1	MDR1:84|mdr1:34|MDR-1:13|mdr-1:7|Mdr1:1	multidrug resistance gene:139:0.8205	0.8205	139
MDR1	MDR1:29|MDR-1:7|mdr1:4|mdr-1:3	multidrug resistance gene 1:34:0.8245|multidrug resistance gene-1:9:0.4587	0.8245	43
MDR1	MDR1:8|Mdr1:1|MDR-1:1|mdr-1:1	multidrug resistance protein:11:0.5355	0.5355	11
MDR1	MDR1:8	multidrug transporter:8:0.2619	0.2619	8
MDR1	MDR1:38|mdr1:9|MDR-1:6|Mdr1:2|mdr-1:1	P-glycoprotein:56:0.0677	0.0677	56
MDRD	MDRD:82	Modification of Diet in Renal Disease:82:0.9422	0.9422	82
MDR-TB	MDR-TB:17|MDRTB:3	multidrug-resistant TB:20:0.4574	0.4574	20
MDR-TB	MDR-TB:125|MDRTB:17|MDR-Tb:1|MDRTb:1	multidrug-resistant tuberculosis:144:0.5977	0.5977	144
MDRS	MDRS:23|mDRS:1	Mattis Dementia Rating Scale:24:0.8115	0.8115	24
MDR	MDR:5	DBI receptor:5:0.2987	0.2987	5
MDR	MDR:8|mdr:1	macrophage disappearance reaction:9:0.6794	0.6794	9
MDR	MDR:7	medium dose rate:7:0.4438	0.4438	7
MDR	MDR:81|mdr:3	multi-drug resistant:49:0.1083|multi-drug-resistant:35:0.0116	0.1083	84
MDR	MDR:1620|mdr:75|Mdr:2	multidrug resistance:1594:0.8813|multidrug-resistance:103:0.0349	0.8813	1697
mdr	mdr:7|MDR:3	multidrug resistance gene:10:0.5000	0.5000	10
MDR	MDR:8	multidrug resistance phenotype:8:0.5006	0.5006	8
MDR	MDR:6|Mdr:2|mdr:1	multidrug resistance protein:9:0.5006	0.5006	9
MDR	MDR:640|mdr:18|Mdr:2	multidrug-resistant:412:0.1411|multidrug resistant:248:0.7126	0.7126	660
MDR	MDR:6	multifactor dimensionality reduction:6:0.5290	0.5290	6
MDR	MDR:15|Mdr:1	multiple-drug-resistant:10:0.0031|multiple drug-resistant:6:0.2243	0.2243	16
MDS+	MDS+:11	Minimum Data Set Plus:11:0.7357	0.7357	11
MDS-HC	MDS-HC:11	Minimum Data Set for Home Care:11:0.7357	0.7357	11
MDS-HC	MDS-HC:7	Minimum Data Set-Home Care:7:0.4438	0.4438	7
MDSCs	MDSCs:12	Muscle-derived stem cells:12:0.7571	0.7571	12
MDSC	MDSC:13|mDSC:1	modulated differential scanning calorimetry:14:0.6173	0.6173	14
MDSs	MDSs:56	myelodysplastic syndromes:56:0.9467	0.9467	56
MDTB	MDTB:16	Mouse Defense Test Battery:16:0.8165	0.8165	16
MDT	MDT:32	mean dissolution time:32:0.7458	0.7458	32
MDT	MDT:7	mirror drawing test:7:0.5926	0.5926	7
MDT	MDT:16	multidisciplinary team:16:0.6577	0.6577	16
MDT	MDT:181	multidrug therapy:181:0.7006	0.7006	181
MDT	MDT:6	multidrug treatment:6:0.0899	0.0899	6
MDV1	MDV1:12|MDV-1:7	Marek's disease virus serotype 1:19:0.8525	0.8525	19
MDV1	MDV1:9|MDV-1:3	Marek's disease virus type 1:12:0.7571	0.7571	12
MDV2	MDV2:8	Marek's disease virus serotype 2:8:0.6411	0.6411	8
MDVP	MDVP:14	Voice Program:14:0.7909	0.7909	14
MDV	MDV:17	Marek's disease herpesvirus:17:0.8270	0.8270	17
MDV	MDV:363	Marek's disease virus:363:0.9368	0.9368	363
MDV	MDV:17	velocity:17:0.0317	0.0317	17
MDZ	MDZ:62|mdz:1	midazolam:63:0.9118	0.9118	63
MDDC	MDDC:12|mdDC:1|MD-DC:1|md-DC:1	monocyte-derived DC:15:0.5818	0.5818	15
MDDC	MDDC:20	Monocyte-derived dendritic cells:20:0.6680	0.6680	20
MDS	MDS:29	microdialysis system:29:0.3743	0.3743	29
MDS	MDS:159	minimum data set:159:0.9509	0.9509	159
MDS	MDS:130	multidimensional scaling:130:0.9106	0.9106	130
MDS	MDS:21	myelodysplastic:21:0.0058	0.0058	21
MDS	MDS:2639|M-DS:1	myelodysplastic syndrome:1522:0.9325|myelodysplastic syndromes:1118:0.9810	0.9810	2640
MDS	MDS:21	patients with myelodysplasia:21:0.0970	0.0970	21
MDs	MDs:15	physicians:15:0.0041	0.0041	15
MD	MD:10	diabetic:10:0.0026	0.0026	10
MD	MD:12	diseases:12:0.0032	0.0032	12
MD	MD:16	distance:16:0.0044	0.0044	16
MD	MD:70	macula densa:70:0.9573	0.9573	70
MD	MD:11	maintenance dose:11:0.3829	0.3829	11
MD	MD:180	major depression:180:0.9210	0.9210	180
MD	MD:5	major depressive disorder:5:0.4422	0.4422	5
MD	MD:250|md:1	Marek's disease:251:0.4711	0.4711	251
MD	MD:13	maternal deprivation:13:0.0702	0.0702	13
MD	MD:42	mean defect:42:0.8558	0.8558	42
MD	MD:124	Mean deviation:124:0.9616	0.9616	124
MD	MD:27	mean difference:27:0.6745	0.6745	27
MD	MD:31|Md:1	Meckel's diverticulum:32:0.7782	0.7782	32
MD	MD:10	medial dorsal:10:0.7103	0.7103	10
MD	MD:10	medialis dorsalis:10:0.5856	0.5856	10
MD	MD:52	mediodorsal:52:0.0149	0.0149	52
MD	MD:33	mediodorsal nucleus of the thalamus:33:0.7841	0.7841	33
MD	MD:39	mediodorsal thalamic nucleus:39:0.8142	0.8142	39
MD	MD:10	mediodorsal thalamus:10:0.0682	0.0682	10
Md	Md:26|MD:4	megadaltons:19:0.0053|Megadalton:11:0.0029	0.0053	30
MD	MD:15	menadione:15:0.0041	0.0041	15
MD	MD:9	methyldopa:9:0.0023	0.0023	9
MD	MD:19	microdensitometry:19:0.0050	0.0050	19
MD	MD:46|mD:1	microdialysis:47:0.0134	0.0134	47
MD	MD:11	microvessel density:11:0.2154	0.2154	11
MD	MD:9|md:1	Mixed Dementia:10:0.3867	0.3867	10
MD	MD:6	moderate disability:6:0.2243	0.2243	6
MD	MD:8|md:1	moderately differentiated:9:0.5470	0.5470	9
MD	MD:805	molecular dynamics:777:0.9861|molecular-dynamics:14:0.0038|Molecular dynamic:14:0.6911	0.9861	805
MD	MD:13	molecular dynamics simulations:13:0.7753	0.7753	13
MD	MD:54	Monocular deprivation:54:0.5568	0.5568	54
MD	MD:20	monocularly deprived:20:0.7766	0.7766	20
MD	MD:11	motion-defined:11:0.0029	0.0029	11
MD	MD:8	Movement disorders:8:0.1276	0.1276	8
md	md:5|MD:4	multiple dendritic:9:0.6794	0.6794	9
MD	MD:68	muscular dystrophy:56:0.2053|muscular dystrophies:12:0.7571	0.7571	68
md	md:6	Myelin deficiency:6:0.1132	0.1132	6
md	md:48|MD:4	myelin-deficient:37:0.0105|myelin deficient:15:0.7096	0.7096	52
M-D	M-D:9|MD:1	myoclonus-dystonia:10:0.0026	0.0026	10
MD	MD:149	myotonic dystrophy:149:0.6558	0.6558	149
MD	MD:18	patients with Meniere's disease:18:0.1026	0.1026	18
MD	MD:19	thalamic mediodorsal nucleus:19:0.2296	0.2296	19
MEAP	MEAP:10	Met-enkephalin-Arg-Phe:10:0.1875	0.1875	10
MEAs	MEAs:15	microelectrode arrays:15:0.4951	0.4951	15
MEA	MEA:14	activity:14:0.0385	0.0385	14
MEA	MEA:16	cysteamine:16:0.0444	0.0444	16
MEA	MEA:7	LHRH release from explants of the median eminence area:7:0.5926	0.5926	7
MEA	MEA:7	Malt Extract agar:7:0.5926	0.5926	7
MEA	MEA:10	mean electrical axis:10:0.7103	0.7103	10
MeA	MeA:23|MEA:4	medial amygdala:27:0.5729	0.5729	27
MEA	MEA:15	medial entorhinal area:15:0.8045	0.8045	15
MeA	MeA:8|MEA:1	medial nucleus of the amygdala:9:0.6794	0.6794	9
MEA	MEA:10	mercaptoethylamine:10:0.0266	0.0266	10
MEA	MEA:10	microelectrode array:10:0.2446	0.2446	10
MEA	MEA:12	microwave endometrial ablation:12:0.7571	0.7571	12
MEA	MEA:18	monoethanolamine:18:0.0503	0.0503	18
MEA	MEA:18	multiple endocrine adenomatosis:18:0.7539	0.7539	18
MEBO	MEBO:8	moist exposed burn ointment:8:0.6411	0.6411	8
MECC	MECC:123	micellar electrokinetic capillary chromatography:123:0.9486	0.9486	123
MECLR	MECLR:10	mixed epidermal cell-lymphocyte reaction:10:0.7103	0.7103	10
MEC	MEC:4|mec:1	antagonist mecamylamine:5:0.0828	0.0828	5
MEC	MEC:36	effective concentration:36:0.6175	0.6175	36
MEC	MEC:62|MEc:1	mammary epithelial cells:42:0.7523|mammary epithelial cell:21:0.8594	0.8594	63
mEC	MEC:10|mEC:10	medial entorhinal cortex:20:0.8525	0.8525	20
mec	mec:13	methicillin resistance determinant:13:0.7753	0.7753	13
MEC	MEC:24	microvascular endothelial cells:24:0.5598	0.5598	24
MEC	MEC:73	Mucoepidermoid carcinoma:59:0.9203|Mucoepidermoid carcinomas:14:0.7909	0.9203	73
MEDs	MEDs:11	minimal erythema doses:11:0.5355	0.5355	11
MED	MED:9	male erectile dysfunction:9:0.6794	0.6794	9
MED	MED:12|Med:2	Medetomidine:14:0.0210	0.0210	14
MED	MED:16	Medical Entities Dictionary:16:0.8165	0.8165	16
MED	MED:25	Minimal effective dose:25:0.2452	0.2452	25
MED	MED:175	minimal erythema dose:141:0.8355|minimal erythema doses:34:0.8245	0.8355	175
MED	MED:41	minimum effective dose:35:0.4229|minimum effective doses:6:0.1838	0.4229	41
med	med:6|MED:1	motor endplate disease:7:0.5926	0.5926	7
MED	MED:61	multiple epiphyseal dysplasia:61:0.9511	0.9511	61
MEE	MEE:36	energy expenditure:36:0.8716	0.8716	36
MEE	MEE:9	medial edge epithelia:9:0.6794	0.6794	9
MEE	MEE:17	medial edge epithelial:17:0.8270	0.8270	17
MEE	MEE:20	medial edge epithelium:20:0.8525	0.8525	20
MEE	MEE:188	middle ear effusion:141:0.9788|middle ear effusions:47:0.9366	0.9788	188
MEE	MEE:55	multilocus enzyme electrophoresis:55:0.9458	0.9458	55
MEEKC	MEEKC:51	microemulsion electrokinetic chromatography:51:0.9416	0.9416	51
MEEs	MEEs:52	middle ear effusions:52:0.9427	0.9427	52
MEF25	MEF25:12	vital capacity:12:0.7571	0.7571	12
MEF2A	MEF2A:7|MEF-2A:1	myocyte enhancer factor 2A:8:0.4102	0.4102	8
MEF2	MEF2:112|MEF-2:10|mef-2:1	Myocyte enhancer factor 2:75:0.7978|myocyte enhancer factor-2:48:0.8463	0.8463	123
MEF50	MEF50:4	expiratory flow at 50% of FVC:4:0.5926	0.5926	4
MEF50	MEF50:4	expiratory flow at 50% of vital capacity:4:0.5470	0.5470	4
MEFV	MEFV:36	flow volume:36:0.8716	0.8716	36
MEFV	MEFV:37	maximal expiratory flow-volume:37:0.2583	0.2583	37
MEFs	MEFs:165|mEFs:4	Mouse embryonic fibroblasts:169:0.7367	0.7367	169
MEFs	MEFs:35	murine embryonic fibroblasts:35:0.1100	0.1100	35
MEF	MEF:14	expiratory flow:14:0.5111	0.5111	14
MEF	MEF:74	middle ear fluid:74:0.9596	0.9596	74
MEF	MEF:8	migration enhancement factor:8:0.6411	0.6411	8
MEF	MEF:72	mouse embryo fibroblasts:59:0.8154|mouse embryo fibroblast:13:0.5335	0.8154	72
MEF	MEF:73	mouse embryonic fibroblasts:42:0.6138|mouse embryonic fibroblast:31:0.6820	0.6820	73
MEG-01	MEG-01:12|Meg-01:1	human megakaryoblastic cell line:13:0.4849	0.4849	13
MEGX	MEGX:11	monoethylglycine xylidide:11:0.4232	0.4232	11
MEGX	MEGX:9	monoethylglycinexylide:9:0.0392	0.0392	9
MEGX	MEGX:138|MEG-X:2	monoethylglycinexylidide:140:0.6765	0.6765	140
MEG	MEG:155	magnetoencephalographic:155:0.1598	0.1598	155
MEG	MEG:570	magnetoencephalography:570:0.5902	0.5902	570
meg	meg:10|Meg:1	megakaryocyte:11:0.0104	0.0104	11
MEG	MEG:27	mercaptoethylguanidine:27:0.0270	0.0270	27
MEHP	MEHP:48	mono(2-ethylhexyl)phthalate:33:0.1778|mono-(2-ethylhexyl)phthalate:15:0.0778	0.1778	48
mEH	mEH:143|MEH:2|meh:1|mEh:1	microsomal epoxide hydrolase:147:0.9470	0.9470	147
MEIA	MEIA:87	Microparticle Enzyme ImmunoAssay:87:0.8008	0.8008	87
MEIC	MEIC:12	Multicentre Evaluation of In Vitro Cytotoxicity:12:0.5050	0.5050	12
MEI	MEI:5	Medicare Economic Index:5:0.4422	0.4422	5
MEI	MEI:19	metabolizable energy intake:19:0.7766	0.7766	19
MeI	MeI:12	methyl iodide:12:0.7571	0.7571	12
MEK1/2	MEK1/2:7	MAP kinase kinase:7:0.1111	0.1111	7
MEK1	MEK1:13|MEK-1:8	MAP kinase kinase:21:0.2963	0.2963	21
MEK1	MEK1:8	MAP kinase kinase 1:8:0.1273	0.1273	8
MEK1	MEK1:12|MEK-1:3|Mek1:1	MAPK kinase:16:0.1076	0.1076	16
MEK1	MEK1:16|MEK-1:2	mitogen-activated protein kinase kinase:18:0.6903	0.6903	18
MEK-1	MEK-1:7|MEK1:6|Mek1:1	mitogen-activated protein kinase kinase-1:14:0.7909	0.7909	14
MEKC	MEKC:91	micellar electrokinetic capillary chromatography:91:0.9311	0.9311	91
MEKC	MEKC:21	Micellar electrokinetic chromatographic:21:0.8594	0.8594	21
MEKC	MEKC:307	Micellar electrokinetic chromatography:307:0.9650	0.9650	307
MEKK1	MEKK1:11|MEKK-1:2	kinase kinase-1:13:0.7909	0.7909	13
MEKK1	MEKK1:7|MEKK-1:2	mitogen-activated protein kinase kinase kinase 1:9:0.6794	0.6794	9
MEKP	MEKP:11	methyl ethyl ketone peroxide:11:0.7357	0.7357	11
MEK	MEK:11	Met-enkephalin:11:0.0102	0.0102	11
MEK	MEK:73	methyl ethyl ketone:73:0.9591	0.9591	73
MELAS	MELAS:2	lactic acidosis and stroke-like episode:2:0.5290	0.5290	2
MELCs	MELCs:10	erythroleukemia cells:10:0.5856	0.5856	10
MELC	MELC:50	Murine erythroleukemia cells:44:0.7619|murine erythroleukemia cell:6:0.3728	0.7619	50
MELC	MELC:5	murine erythroleukemic cell:5:0.4422	0.4422	5
MELD	MELD:102	Model for End-stage Liver Disease:102:0.8789	0.8789	102
MELM	MELM:13	Met-enkephalin-like material:13:0.5934	0.5934	13
MEMA	MEMA:14	middle ear muscle activity:8:0.6411|Middle-ear muscle activity:6:0.1010	0.6411	14
MEMRI	MEMRI:9	manganese-enhanced MRI:9:0.4587	0.4587	9
MEMS	MEMS:36	Medication Event Monitoring System:36:0.9174	0.9174	36
MEMS	MEMS:26|MEMs:1	microelectromechanical systems:27:0.4837	0.4837	27
MEM	MEM:53	Eagle's minimum essential medium:53:0.2790	0.2790	53
MEM	MEM:45	macrophage electrophoretic mobility:45:0.9338	0.9338	45
MEm	MEm:14	maintenance:14:0.0236	0.0236	14
MEM	MEM:37	maximum entropy method:37:0.7492	0.7492	37
MEM	MEM:110	minimal essential medium:110:0.3551	0.3551	110
MEM	MEM:10	mitochondrial encephalomyopathy:10:0.7103	0.7103	10
MEN-II	MEN-II:6	multiple endocrine neoplasia Type II:6:0.3728	0.3728	6
MEN1	MEN1:267|MEN-1:84|Men1:1	Multiple endocrine neoplasia type 1:344:0.9861|multiple endocrine neoplasia type-1:8:0.6411	0.9861	352
MEN1	MEN1:17|MEN-1:6	multiple endocrine neoplasia type I:23:0.8816	0.8816	23
MEN2A	MEN2A:47|MEN-2A:13|MEN2a:5	multiple endocrine neoplasia type 2A:65:0.9561	0.9561	65
MEN2B	MEN2B:10|MEN-2B:3|MEN2b:1	multiple endocrine neoplasia type 2B:14:0.8045	0.8045	14
MEN2	MEN2:38|MEN-2:14	multiple endocrine neoplasia type 2:52:0.9162	0.9162	52
MEN-I	MEN-I:31	multiple endocrine neoplasia type I:31:0.9151	0.9151	31
MENK	MENK:15|m-ENK:8|MEnk:7|M-ENK:4|M-Enk:2|mENK:2|Menk:1	Met-enkephalin:39:0.3423	0.3423	39
MENK	MENK:17|M-ENK:12|M-Enk:7|mENK:4|Menk:4|m-ENK:2|MEnk:2|M-enk:1|m-Enk:1	methionine-enkephalin:32:0.2793|methionine enkephalin:18:0.6903	0.6903	50
MENT	MENT:13	7 alpha-methyl-19-nortestosterone:13:0.6701	0.6701	13
MENT	MENT:10	7alpha-methyl-19-nortestosterone:10:0.2093	0.2093	10
MEN	MEN:8|men:2	menadione:10:0.0099	0.0099	10
MEn	MEn:12|men:2	metabolizable energy:14:0.7909	0.7909	14
MEN	MEN:29	mitotic exit network:29:0.8978	0.8978	29
MEN	MEN:365|Men:1	Multiple endocrine neoplasia:366:0.9745	0.9745	366
MEN	MEN:9	multiple endocrine neoplasia syndrome:9:0.6794	0.6794	9
MEOS	MEOS:71	microsomal ethanol oxidizing system:43:0.8893|microsomal ethanol-oxidizing system:28:0.8861	0.8893	71
MEO	MEO:37	malignant external otitis:37:0.9197	0.9197	37
MEPCs	MEPCs:25|mepcs:4|mEPCs:2|MEPCS:1	miniature end-plate currents:32:0.9072	0.9072	32
MEPCs	MEPCs:25|mEPCs:3|mepcs:3	miniature endplate currents:31:0.9072	0.9072	31
MEPC	MEPC:16|mepc:2	miniature end-plate currents:18:0.8365	0.8365	18
MEPC	MEPC:12|mepc:3|mEPC:1	miniature endplate current:16:0.8165	0.8165	16
MEPE	MEPE:18|Mepe:1	matrix extracellular phosphoglycoprotein:19:0.8449	0.8449	19
MEPM	MEPM:7	mouse embryo palate mesenchyme:7:0.5926	0.5926	7
MEPM	MEPM:18	murine embryonic palate mesenchymal:18:0.7539	0.7539	18
MEPPs	MEPPs:82|mepps:14|mEPPs:5|mEPPS:1|MEPPS:1	miniature endplate potentials:103:0.9710	0.9710	103
mEPSPs	mEPSPs:7|MEPSPs:5	Miniature excitatory postsynaptic potentials:12:0.7571	0.7571	12
MEPS	MEPS:57	Medical Expenditure Panel Survey:57:0.9477	0.9477	57
MEPs	MEPs:611|MEPS:1	motor evoked potentials:515:0.9483|Motor-evoked potentials:97:0.1187	0.9483	612
MEP	MEP:21	2-C-methyl-D-erythritol 4-phosphate:21:0.5435	0.5435	21
MEP	MEP:22	major excreted protein:22:0.8657	0.8657	22
MEP	MEP:10|Mep:1	mepyramine:11:0.0104	0.0104	11
MeP	MeP:6|MEP:3	methyl parathion:9:0.6794	0.6794	9
MEP	MEP:14	methylerythritol phosphate:14:0.6173	0.6173	14
MEP	MEP:11|ME-P:1	middle ear pressure:12:0.7571	0.7571	12
MEP	MEP:48	molecular electrostatic potential:48:0.9027	0.9027	48
MEP	MEP:6|mEP:2	monoethyl phthalate:8:0.4102	0.4102	8
MEP	MEP:405	motor evoked potential:212:0.9056|motor evoked potentials:139:0.8683|motor-evoked potential:54:0.1183	0.9056	405
MEP	MEP:16	Mucoid exopolysaccharide:16:0.8165	0.8165	16
MEP	MEP:20	multiple exposure photography:20:0.7766	0.7766	20
MER-25	MER-25:19|Mer-25:1	ethamoxytriphetol:20:0.6786	0.6786	20
merB	merB:4|MerB:4	organomercurial lyase:8:0.4102	0.4102	8
MERGs	MERGs:2|m-ERGs:2|M-ERGs:2|mERGs:1	Multifocal electroretinograms:7:0.3524	0.3524	7
mERG	mERG:9|MERG:7|M-ERG:3|m-ERG:1	multifocal electroretinogram:20:0.6680	0.6680	20
MERRF	MERRF:4	epilepsy and ragged-red fiber:4:0.5290	0.5290	4
MERRF	MERRF:14	epilepsy with ragged red fibers:14:0.6645	0.6645	14
MERRF	MERRF:18	myoclonic epilepsy with ragged-red fibers:18:0.3273	0.3273	18
MERRF	MERRF:10	myoclonus epilepsy and ragged-red fibers:10:0.3455	0.3455	10
MERRF	MERRF:4	Myoclonus epilepsy and ragged-red fibres:4:0.2827	0.2827	4
MERRF	MERRF:19	myoclonus epilepsy associated with ragged-red fibers:19:0.8365	0.8365	19
MESA	MESA:10	erythrocyte surface antigen:10:0.7103	0.7103	10
MESA	MESA:9	Marshfield Epidemiologic Study Area:9:0.6794	0.6794	9
MeSA	MeSA:10	methyl salicylate:10:0.7103	0.7103	10
MESA	MESA:49|mesa:1	microsurgical epididymal sperm aspiration:50:0.7636	0.7636	50
MESA	MESA:9	Multi-Ethnic Study of Atherosclerosis:9:0.6794	0.6794	9
MESA	MESA:14	myoepithelial sialadenitis:14:0.7909	0.7909	14
MESF	MESF:12	molecules of equivalent soluble fluorochrome:12:0.5664	0.5664	12
MESS	MESS:24	Mangled Extremity Severity Score:24:0.8768	0.8768	24
MEST	MEST:9	maximal electroshock seizure threshold:9:0.5470	0.5470	9
MEST	MEST:21	Mouse ear swelling test:21:0.8594	0.8594	21
MesV	MesV:9|Mes-V:1	mesencephalic trigeminal nucleus:10:0.7103	0.7103	10
MES	MES:8|Mes:5	2-(N-morpholino)ethanesulfonic acid:13:0.1025	0.1025	13
mES	mES:11	embryonic stem:11:0.7357	0.7357	11
MES	MES:6	maximal electrical stimulation:6:0.5290	0.5290	6
MES	MES:6	maximal electroconvulsive shock:6:0.3728	0.3728	6
MES	MES:170	maximal electroshock:170:0.8842	0.8842	170
MES	MES:13	maximal electroshock-induced seizures:13:0.6701	0.6701	13
MES	MES:128	maximal electroshock seizure:92:0.8644|maximal electroshock seizures:36:0.8336	0.8644	128
MES	MES:9	Melancholia Scale:9:0.3069	0.3069	9
MES	MES:8|mes:2	mesencephalon:10:0.0106	0.0106	10
MES	MES:7|mes:5|Mes:1	mesenteric:13:0.0142	0.0142	13
MES	MES:90	microembolic signals:90:0.8065	0.8065	90
MES	MES:12	myoelectric signal:12:0.3524	0.3524	12
METs	METs:52|METS:17	metabolic equivalents:69:0.9316	0.9316	69
MetS	MetS:31|METS:1	Metabolic Syndrome:32:0.9072	0.9072	32
MET	MET:12|Met:4	11C-methionine:16:0.0149	0.0149	16
MET	MET:4	cochlear mechano-electric transduction:4:0.0545	0.0545	4
MET	MET:7|Met:4	DL-methionine:11:0.0099	0.0099	11
Met	Met:22|MET:5|met:1	L-methionine:28:0.0267	0.0267	28
MET	MET:13	mechano-electrical transduction:13:0.3331	0.3331	13
MET	MET:21	medical emergency team:21:0.8525	0.8525	21
MET	MET:6	Melbourne Edge Test:6:0.5290	0.5290	6
MET	MET:43	metabolic equivalent:34:0.8644|metabolic equivalents:9:0.6794	0.8644	43
MET	MET:16|Met:6	Metformin:22:0.0208	0.0208	22
Met	Met:188|MET:43|met:9	methionine:240:0.2376	0.2376	240
Met	Met:14|MET:1	Methoprene-tolerant:15:0.0139	0.0139	15
MET	MET:5|Met:4	methoxamine:9:0.0079	0.0079	9
MET	MET:20|Met:5|met:1	metoclopramide:26:0.0248	0.0248	26
MET	MET:10|Met:6	metoprolol:16:0.0149	0.0149	16
MET	MET:12|Met:2	metronidazole:14:0.0129	0.0129	14
MET	MET:13	metyrapone:13:0.0119	0.0119	13
MET	MET:23	Motivational Enhancement Therapy:23:0.8715	0.8715	23
MEV	MEV:32	mink enteritis virus:32:0.9072	0.9072	32
mev	mev:27	viable motheaten:27:0.8312	0.8312	27
MEWDS	MEWDS:28	Multiple evanescent white dot syndrome:28:0.8941	0.8941	28
Mex	MEX:11|Mex:11	mexiletine:22:0.4200	0.4200	22
MEQ	MEQ:9	Morningness-Eveningness Questionnaire:9:0.2757	0.2757	9
ME	ME:32	2-mercaptoethanol:32:0.0122	0.0122	32
ME	ME:29	2-methoxyethanol:29:0.0110	0.0110	29
ME	ME:11	beta-mercaptoethanol:11:0.0039	0.0039	11
ME	ME:12	macular edema:12:0.4557	0.4557	12
ME	ME:17	magnitude estimation:17:0.7407	0.7407	17
ME	ME:189|me:5	malic enzyme:194:0.9461	0.9461	194
ME	ME:8	maximum entropy:8:0.5006	0.5006	8
ME	ME:13	McCollough Effect:13:0.2802	0.2802	13
ME	ME:21	mean prediction error:21:0.8657	0.8657	21
ME	ME:25	mechanical efficiency:25:0.6240	0.6240	25
ME	ME:6|me:4	medial:10:0.0035	0.0035	10
me	me:5	medial amygdala:5:0.0612	0.0612	5
me	me:13	medial amygdaloid nucleus:13:0.7753	0.7753	13
me	me:7	medial nucleus of the amygdala:7:0.5926	0.5926	7
ME	ME:581	median eminence:581:0.9640	0.9640	581
ME	ME:20	medical examiner:20:0.7766	0.7766	20
ME	ME:19	mercaptoethanol:19:0.0071	0.0071	19
ME	ME:46	Met-enkephalin:46:0.0176	0.0176	46
ME	ME:45	met5-enkephalin:20:0.0074|[met5]-enkephalin:15:0.0055|[Met5]enkephalin:10:0.0035	0.0074	45
ME	ME:57	metabolisable energy:57:0.1587	0.1587	57
ME	ME:204	metabolizable energy:204:0.7022	0.7022	204
ME	ME:10	methanolic extract:10:0.1774	0.1774	10
ME	ME:77|M-E:2	methionine-enkephalin:50:0.0192|methionine enkephalin:29:0.7970	0.7970	79
ME	ME:7|me:2	methoxamine:9:0.0031	0.0031	9
ME	ME:9|me:1	methyl ester:10:0.5000	0.5000	10
ME	ME:20	microemulsion:20:0.0074	0.0074	20
ME	ME:106	middle ear:106:0.9406	0.9406	106
ME	ME:11	minimum evolution:11:0.6182	0.6182	11
ME	ME:5	moderate exercise:5:0.0736	0.0736	5
me	me:21	motheaten:21:0.0082	0.0082	21
ME	ME:18	mouse embryo:18:0.8365	0.8365	18
ME	ME:20	myalgic encephalomyelitis:20:0.7291	0.7291	20
ME	ME:10	myoelectric:10:0.0035	0.0035	10
ME	ME:12	myoepithelial:12:0.0043	0.0043	12
MF/SS	MF/SS:10	mycosis fungoides/Sezary syndrome:10:0.7103	0.7103	10
MFABP	MFABP:5|M-FABP:2|mFABP:1	fatty acid binding protein:8:0.6411	0.6411	8
MFA	MFA:18	metabolic flux analysis:18:0.8365	0.8365	18
MFA	MFA:11	Musculoskeletal Function Assessment:11:0.7357	0.7357	11
MFBIA	MFBIA:11|MF-BIA:5	bioelectrical impedance analysis:16:0.6024	0.6024	16
MFB	MFB:249|mfb:6	medial forebrain bundle:255:0.9040	0.9040	255
MFB	MFB:14|m-f-b:1	myofibroblasts:15:0.0431	0.0431	15
MFCV	MFCV:42	muscle fiber conduction velocity:42:0.9291	0.9291	42
MFCV	MFCV:13	muscle fibre conduction velocity:13:0.7753	0.7753	13
MFCs	MFCs:8	microbial fuel cells:8:0.6411	0.6411	8
MFC	MFC:10	fungicidal concentrations:10:0.7103	0.7103	10
MFC	MFC:31|mfc:1	medial frontal cortex:32:0.8563	0.8563	32
MFC	MFC:10	medial prefrontal cortex:10:0.5856	0.5856	10
MFC	MFC:9	microbial fuel cell:9:0.6794	0.6794	9
MFD	MFD:17	mandibulofacial dysostosis:17:0.7407	0.7407	17
MFD	MFD:21	multiple fractions per day:21:0.7291	0.7291	21
MFD	MFD:19	mutation frequency decline:19:0.8449	0.8449	19
mfERG	mfERG:51|MF-ERG:5|MFERG:1	multifocal electroretinogram:57:0.9162	0.9162	57
mfERG	mfERG:25|MF-ERG:2|mfERg:1|mf-ERG:1|MFERG:1	multifocal electroretinography:30:0.9011	0.9011	30
mfERG	mfERG:12|mf-ERG:2|MF-ERG:2|MFERG:1	multifocal ERG:17:0.8270	0.8270	17
MFFT	MFFT:14	Matching Familiar Figures Test:14:0.8045	0.8045	14
MFF	MFF:12	Matching Familiar Figures Test:12:0.7571	0.7571	12
mff	mff:40|MFF:2	microfilariae:42:0.4020	0.4020	42
MFG	MFG:15	middle frontal gyrus:15:0.7096	0.7096	15
MFGM	MFGM:49	milk fat globule membrane:37:0.9197|Milk fat globule membranes:12:0.7571	0.9197	49
MFHs	MFHs:38	malignant fibrous histiocytomas:38:0.9217	0.9217	38
MFH	MFH:668	malignant fibrous histiocytoma:601:0.9843|malignant fibrous histiocytomas:67:0.9074	0.9843	668
MFH	MFH:11	N-methyl-N-formylhydrazine:11:0.0135	0.0135	11
MFI-20	MFI-20:10	multidimensional fatigue inventory:10:0.5000	0.5000	10
M-FISH	M-FISH:41|mFISH:10|MFISH:1|m-FISH:1	fluorescence in situ hybridization:53:0.6064	0.6064	53
M-FISH	M-FISH:9|mFISH:6|MFISH:1	multicolor FISH:16:0.3317	0.3317	16
M-FISH	M-FISH:10	multiplex-FISH:10:0.0652	0.0652	10
MFIS	MFIS:9|mFIS:1	modified fatigue impact scale:10:0.7103	0.7103	10
MFI	MFI:14	mean fluorescence index:14:0.7909	0.7909	14
MFI	MFI:156|mfi:2	mean fluorescence intensity:158:0.8346	0.8346	158
MFI	MFI:13	Multidimensional Fatigue Inventory:13:0.6701	0.6701	13
MFI	MFI:6	myofibrillar fragmentation index:6:0.2243	0.2243	6
MFM	MFM:9	maternal-fetal medicine:9:0.4587	0.4587	9
MFM	MFM:10	myofibrillar myopathy:10:0.7103	0.7103	10
MFNS	MFNS:7	mometasone furoate nasal spray:7:0.5926	0.5926	7
MFOs	MFOs:10	mixed-function oxidases:10:0.4363	0.4363	10
MFO	MFO:5	mixed-function monooxygenase:5:0.0517	0.0517	5
MFO	MFO:111	mixed function oxidase:77:0.9612|mixed function oxidases:21:0.8594|mixed-function oxidases:13:0.1890	0.9612	111
MFO	MFO:11	mixed function oxidase system:11:0.7357	0.7357	11
MFO	MFO:24	mixed-function oxygenase:13:0.2959|mixed function oxygenase:11:0.7357	0.7357	24
MFPR	MFPR:24	multifetal pregnancy reduction:24:0.8768	0.8768	24
mfp	mfp:3|MFP:3	mammary fat pad:6:0.2827	0.2827	6
MFP	MFP:15	membrane fusion protein:15:0.5348	0.5348	15
MFP	MFP:10	Myofascial pain:10:0.3145	0.3145	10
MFP	MFP:22	sodium monofluorophosphate:22:0.3267	0.3267	22
MFQ	MFQ:8	Mood and Feelings Questionnaire:8:0.6411	0.6411	8
MFR	MFR:12	maximum flow rate:12:0.2549	0.2549	12
MFR	MFR:11	myocardial flow reserve:11:0.5355	0.5355	11
MFR	MFR:17	receptor:17:0.1088	0.1088	17
MFs	MFs:10	actin microfilaments:10:0.0829	0.0829	10
MFs	MFs:71	magnetic fields:71:0.9579	0.9579	71
MFS	MFS:51	major facilitator superfamily:51:0.9416	0.9416	51
MFS	MFS:111|MfS:3	Marfan syndrome:114:0.4462	0.4462	114
MFS	MFS:23	Medicare Fee Schedule:23:0.8715	0.8715	23
MFS	MFS:31	metastasis-free survival:31:0.5414	0.5414	31
MFS	MFS:5|mFS:4	midwall fractional shortening:9:0.6794	0.6794	9
MFS	MFS:76	Miller Fisher syndrome:76:0.9607	0.9607	76
MFs	MFs:14	mossy fibers:14:0.3202	0.3202	14
MFS	MFS:12	mossy fiber sprouting:12:0.7571	0.7571	12
MFs	MFs:26|Mfs:13|MFS:1	mutant frequencies:40:0.7653	0.7653	40
MFs	MFs:12|Mfs:2	Myofibroblasts:14:0.0193	0.0193	14
MFTs	MFTs:13	marriage and family therapists:13:0.6701	0.6701	13
MFT	MFT:19	Family Therapy:19:0.6537	0.6537	19
MFT	MFT:13	magnetic field tomography:13:0.7753	0.7753	13
MFVR	MFVR:11	minimal forearm vascular resistance:11:0.7357	0.7357	11
MFV	MFV:47|mFV:1	mean flow velocity:48:0.5497	0.5497	48
MG63	MG63:5|MG-63:2	human osteoblast-like cells:7:0.3524	0.3524	7
MG-63	MG-63:5|MG63:4	human osteosarcoma cells:9:0.3069	0.3069	9
MGAT	MGAT:14	monoacylglycerol acyltransferase:14:0.3813	0.3813	14
MGA	MGA:8	medial giant axon:8:0.5006	0.5006	8
MGA	MGA:84	Melengestrol acetate:84:0.7821	0.7821	84
MGBCP	MGBCP:8	methylglyoxal bis(cyclopentylamidinohydrazone):8:0.5006	0.5006	8
MGBG	MGBG:105|mGBG:2	methylglyoxal bis(guanylhydrazone):73:0.8627|Methylglyoxal-bis(guanylhydrazone):22:0.1117|methylglyoxal bis-(guanylhydrazone):11:0.7357|methylglyoxal bis guanylhydrazone:1:0.5760	0.8627	107
MGBv	MGBv:9	medial geniculate body:9:0.6794	0.6794	9
MGB	MGB:123	medial geniculate body:123:0.9261	0.9261	123
MGB	MGB:17	minor groove binder:17:0.6748	0.6748	17
MGB	MGB:7|Mgb:2	myoglobin:9:0.0400	0.0400	9
MGCT	MGCT:11	germ cell tumors:11:0.6182	0.6182	11
MGCs	MGCs:38|MGCS:1	multinucleated giant cells:39:0.5932	0.5932	39
MGC	MGC:22	macroglomerular complex:22:0.6531	0.6531	22
MGC	MGC:5	Mucinous gastric carcinoma:5:0.1973	0.1973	5
MGC	MGC:60	multinucleated giant cells:54:0.7149|multinucleated giant cell:6:0.2827	0.7149	60
MGDF	MGDF:57	Megakaryocyte growth and development factor:57:0.8453	0.8453	57
MGDG	MGDG:11	monogalactosyl diacylglycerol:11:0.7357	0.7357	11
MGDG	MGDG:55	monogalactosyldiacylglycerol:55:0.6067	0.6067	55
MGD	MGD:17	mean glandular dose:17:0.8270	0.8270	17
MGD	MGD:24	Meibomian gland dysfunction:24:0.8115	0.8115	24
MGD	MGD:24	mixed gonadal dysgenesis:24:0.8715	0.8715	24
MGD	MGD:10	molybdopterin guanine dinucleotide:10:0.4363	0.4363	10
MGd	MGd:9	Motexafin gadolinium:9:0.5470	0.5470	9
MGD	MGD:28	Mouse Genome Database:28:0.8594	0.8594	28
MGD	MGD:13	multiglandular disease:13:0.3134	0.3134	13
MGD	MGD:15	N-methyl-D-glucamine dithiocarbamate:15:0.6386	0.6386	15
MGEs	MGEs:9	mobile genetic elements:9:0.6794	0.6794	9
MGF	MGF:58|Mgf:5	mast cell growth factor:63:0.9526	0.9526	63
MGG	MGG:58	May-Grunwald-Giemsa:51:0.5618|May-Grunwald Giemsa:7:0.2452	0.5618	58
mGH	mGH:5|MGH:1	growth hormone:6:0.2243	0.2243	6
MGH	MGH:8	microglandular hyperplasia:8:0.5006	0.5006	8
MGIT	MGIT:63	Mycobacteria Growth Indicator Tube:63:0.7943	0.7943	63
Mgi	Mgi:7	free magnesium:7:0.1850	0.1850	7
MGI	MGI:20|mGI:3	Modified Gingival Index:23:0.7500	0.7500	23
MGL	MGL:8	mean gray level:8:0.6411	0.6411	8
MGL	MGL:7	monoglyceride lipase:7:0.2113	0.2113	7
MGMT	MGMT:31	DNA repair protein O6-methylguanine-DNA methyltransferase:31:0.8292	0.8292	31
MGMT	MGMT:14	methyl transferase:14:0.6911	0.6911	14
MGMT	MGMT:97	O(6)-Methylguanine-DNA methyltransferase:66:0.1297|O(6)-methylguanine DNA methyltransferase:21:0.1899|O(6)-methylguanine-DNA-methyltransferase:10:0.0194	0.1899	97
MGMT	MGMT:5	O6-alkylguanine-DNA alkyltransferase:5:0.0612	0.0612	5
MGMT	MGMT:50	O6-Methylguanine DNA methyltransferase:33:0.3618|O6-methylguanine-DNA-methyltransferase:17:0.0344	0.3618	50
MGm	MGm:6|MGM:1	division of the medial geniculate nucleus:7:0.3524	0.3524	7
MGN	MGN:26	medial geniculate nucleus:26:0.8861	0.8861	26
MGN	MGN:151|mGn:1|mGN:1	membranous glomerulonephritis:153:0.9155	0.9155	153
MGN	MGN:14	membranous glomerulonephropathy:14:0.7909	0.7909	14
MGN	MGN:12	membranous glomerulopathy:12:0.7571	0.7571	12
MGN	MGN:17	membranous GN:17:0.8270	0.8270	17
MGN	MGN:19	membranous nephropathy:19:0.8449	0.8449	19
MgO	MgO:24	magnesium oxide:24:0.7151	0.7151	24
MGP	MGP:18	Manufactured Gas Plant:18:0.8365	0.8365	18
MGP	MGP:115|Mgp:1	Matrix Gla protein:116:0.9219	0.9219	116
MGP	MGP:8	mucous glycoprotein:8:0.1061	0.1061	8
MGP	MGP:10	mucus glycoprotein:10:0.1774	0.1774	10
MGSA	MGSA:22|Mgsa:3	melanoma growth stimulatory activity:25:0.7249	0.7249	25
MGST1	MGST1:6	Microsomal glutathione transferase 1:6:0.5290	0.5290	6
MGS	MGS:5	grading system:5:0.0902	0.0902	5
MGS	MGS:6|mgs:1	methylglyoxal synthase:7:0.2452	0.2452	7
MGS	MGS:5	Morning Glory Syndrome:5:0.4422	0.4422	5
MgTX	MgTX:16	margatoxin:16:0.8824	0.8824	16
MGUS	MGUS:349|mgus:1	monoclonal gammopathy of undetermined significance:350:0.9730	0.9730	350
MGU	MGU:22	glucose uptake:22:0.8657	0.8657	22
MGV	MGV:5|MGv:3	ventral division of the medial geniculate body:8:0.6411	0.6411	8
mGlu	mGlu:227|mglu:4|mGLU:1	metabotropic glutamate:232:0.9793	0.9793	232
mg	mg:11	amount:11:0.0024	0.0024	11
MG	MG:9	gastrocnemius medialis:9:0.6794	0.6794	9
MG	MG:15	group:15:0.0034	0.0034	15
MG	MG:47	malachite green:47:0.7191	0.7191	47
MG	MG:21	mammary gland:21:0.5178	0.5178	21
MG	MG:12	mammography:12:0.0027	0.0027	12
MG	MG:9	matrigel:9:0.0020	0.0020	9
MG	MG:6	mean gradient:6:0.1148	0.1148	6
MG	MG:18	medial:18:0.0042	0.0042	18
MG	MG:281	medial gastrocnemius:281:0.9275	0.9275	281
MG	MG:15	medial gastrocnemius muscle:15:0.7096	0.7096	15
MG	MG:10	medial geniculate:10:0.7103	0.7103	10
MG	MG:17	medial geniculate body:17:0.8270	0.8270	17
MG	MG:11	medial geniculate nucleus:11:0.7357	0.7357	11
MG	MG:13	meningeal gliomatosis:13:0.7753	0.7753	13
MG	MG:108	methylglyoxal:108:0.0262	0.0262	108
MG	MG:55	methylguanidine:55:0.0132	0.0132	55
MG	MG:9	microgravity:9:0.0020	0.0020	9
mG	mG:11	milligauss:11:0.0024	0.0024	11
MG	MG:20	molten globule:20:0.7766	0.7766	20
MG	MG:13	monoacylglycerol:13:0.0029	0.0029	13
MG	MG:57	monoclonal gammopathy:30:0.9011|monoclonal gammopathies:27:0.8903	0.9011	57
MG	MG:1353	myasthenia gravis:1353:0.9900	0.9900	1353
MG	MG:198|Mg:5	Mycoplasma gallisepticum:203:0.9413	0.9413	203
Mg	Mg:6|MG:2	Mycoplasma genitalium:8:0.5006	0.5006	8
MG	MG:8	serum myoglobin:8:0.0625	0.0625	8
MH+	MH+:7	molecular ion:7:0.2902	0.2902	7
MH/SA	MH/SA:10	mental health and substance abuse:10:0.7357	0.7357	10
MHA-TP	MHA-TP:17	Treponema pallidum:17:0.4246	0.4246	17
MHAQ	MHAQ:13|M-HAQ:10|mHAQ:3	Modified Health Assessment Questionnaire:26:0.6973	0.6973	26
MHA	MHA:15	May-Hegglin anomaly:15:0.8045	0.8045	15
MHA	MHA:9	methylhippuric acid:9:0.2102	0.2102	9
MHA	MHA:12	Microangiopathic hemolytic anemia:12:0.7571	0.7571	12
mHA	mHA:7|mha:2|mHa:2	minor histocompatibility antigens:11:0.6182	0.6182	11
MHA	MHA:17	Mueller-Hinton agar:17:0.7407	0.7407	17
MHC-II	MHC-II:6|MHCII:1	class II major histocompatibility complex:7:0.5926	0.5926	7
MHC-II	MHC-II:7|MHCII:1	class II molecules:8:0.6411	0.6411	8
MHC-II	MHC-II:56|MHCII:21	major histocompatibility complex class II:77:0.9190	0.9190	77
MHC-I	MHC-I:15|MHCI:1	class I major histocompatibility complex:16:0.8165	0.8165	16
MHC-I	MHC-I:75|MHCI:6	major histocompatibility complex class I:81:0.9415	0.9415	81
MHC-I	MHC-I:6	major histocompatibility complex class I molecules:6:0.5290	0.5290	6
MHCs	MHCs:50	myosin heavy chains:50:0.8520	0.8520	50
MHC	MHC:10	class I and class II major histocompatibility:10:0.8045	0.8045	10
MHC	MHC:9	major histocompatability:9:0.6794	0.6794	9
MHC	MHC:26	major histocompatibility antigens:18:0.8365|major histocompatibility antigen:8:0.5006	0.8365	26
MHC	MHC:17	major histocompatibility class:17:0.8270	0.8270	17
MHC	MHC:8063|Mhc:98	major histocompatibility complex:8132:0.9686|Major Histocompatibility Complexes:18:0.4934|major-histocompatibility-complex:11:0.0009	0.9686	8161
MHC	MHC:9	major histocompatibility complex antigens:9:0.6794	0.6794	9
MHC	MHC:8	major histocompatibility complex molecules:8:0.4102	0.4102	8
MHC	MHC:10	myosin heavy:10:0.5000	0.5000	10
MHC	MHC:1152|Mhc:6|mhc:3|mHC:2	myosin heavy chain:1044:0.8773|myosin heavy chains:61:0.8208|myosin heavy-chain:58:0.8710	0.8773	1163
MHD	MHD:6	Heart Disease:6:0.2243	0.2243	6
MHD	MHD:20	magnetohydrodynamic:20:0.1027	0.1027	20
MHD	MHD:10	maintenance haemodialysis:10:0.7103	0.7103	10
MHD	MHD:60	maintenance hemodialysis:60:0.9503	0.9503	60
MHE	MHE:9	MH equivocal:9:0.3145	0.3145	9
MHE	MHE:11|mHE:3	Minimal hepatic encephalopathy:14:0.7909	0.7909	14
MHHP	MHHP:16	Minnesota Heart Health Program:16:0.8165	0.8165	16
MHI	MHI:70	head injury:59:0.9494|head injuries:11:0.6182	0.9494	70
MHI	MHI:10	malignant histiocytosis of the intestine:10:0.7103	0.7103	10
MHI	MHI:7	Mental Health Index:7:0.4438	0.4438	7
MHI	MHI:22	Mental Health Inventory:22:0.7955	0.7955	22
MHLC	MHLC:38	Multidimensional Health Locus of Control:38:0.8098	0.8098	38
MHL	MHL:8	mesenchymal hamartoma of the liver:8:0.5006	0.5006	8
MHN	MHN:5	MH negative:5:0.0612	0.0612	5
MHN	MHN:15	non-susceptible:15:0.1321	0.1321	15
MHPG	MHPG:10	3-methoxy-4-hydroxy-phenylethyleneglycol:10:0.0096	0.0096	10
MHPG	MHPG:52	3-methoxy-4-hydroxy-phenylglycol:44:0.0456|3-methoxy-4-hydroxy phenylglycol:8:0.2987	0.2987	52
MHPG	MHPG:16	3-methoxy-4-hydroxyphenethyleneglycol:16:0.0159	0.0159	16
MHPG	MHPG:27	3-methoxy-4-hydroxyphenyl glycol:27:0.1342	0.1342	27
MHPG	MHPG:52	3-methoxy-4-hydroxyphenylethylene glycol:52:0.3173	0.3173	52
MHPG	MHPG:67|mhpg:1	3-methoxy-4-hydroxyphenylethyleneglycol:68:0.0711	0.0711	68
MHPG	MHPG:481	3-methoxy-4-hydroxyphenylglycol:481:0.5106	0.5106	481
MHPG	MHPG:10	4-hydroxy-3-methoxyphenylglycol:10:0.0096	0.0096	10
MHPG	MHPG:29	methoxyhydroxyphenylglycol:29:0.0297	0.0297	29
MHPs	MHPs:9	mental health professionals:9:0.6794	0.6794	9
MHP	MHP:14	mild hyperphenylalaninemia:14:0.7909	0.7909	14
MHQ	MHQ:20	Middlesex Hospital questionnaire:20:0.8525	0.8525	20
MHR	MHR:55|mHR:1	heart rate:56:0.9162	0.9162	56
MHR	MHR:19	major homology region:19:0.7658	0.7658	19
MHSA	MHSA:4|mHSA:3	methylated human serum albumin:7:0.3524	0.3524	7
MHS	MHS:21	Health Services:12:0.7571|Health Service:9:0.6794	0.7571	21
MHS	MHS:6	major histocompatibility system:6:0.3728	0.3728	6
MHS	MHS:16	malignant hyperthermia:16:0.8165	0.8165	16
MHS	MHS:23	malignant hyperthermia susceptibility:23:0.8715	0.8715	23
MHS	MHS:90|MHs:1	Malignant Hyperthermia Susceptible:52:0.9427|malignant hyperthermia-susceptible:39:0.9237	0.9427	91
MHS	MHS:6	MH susceptibility:6:0.0516	0.0516	6
MHS	MHS:81|MhS:1	MH-susceptible:50:0.0948|MH susceptible:32:0.2603	0.2603	82
MHS	MHS:20	Milan hypertensive:20:0.6259	0.6259	20
MHS	MHS:10	Milan hypertensive rats:10:0.4363	0.4363	10
MHS	MHS:32	Milan hypertensive strain:32:0.9072	0.9072	32
MHS	MHS:6	Milan hypertensive strain of rats:6:0.4438	0.4438	6
MHS	MHS:6	military health system:6:0.2827	0.2827	6
MHS	MHS:3	patients were susceptible to MH:3:0.1464	0.1464	3
MHS	MHS:10	syndrome:10:0.0174	0.0174	10
MHT	MHT:13	head trauma:13:0.6460	0.6460	13
MHT	MHT:15	malignant hypertension:15:0.4052	0.4052	15
MHV-A59	MHV-A59:12	mouse hepatitis virus:12:0.4557	0.4557	12
MHV-A59	MHV-A59:28	mouse hepatitis virus strain A59:28:0.7587	0.7587	28
MHV-JHM	MHV-JHM:12	mouse hepatitis virus strain JHM:12:0.8816	0.8816	12
MHV3	MHV3:24|MHV-3:2	mouse hepatitis virus 3:26:0.8251	0.8251	26
MHV3	MHV3:20|MHV-3:3	mouse hepatitis virus type 3:23:0.5848	0.5848	23
MHV-3	MHV-3:15	murine hepatitis virus strain 3:15:0.4951	0.4951	15
MHV-4	MHV-4:5|MHV4:1	mouse hepatitis virus type 4:6:0.5290	0.5290	6
MHV-68	MHV-68:58|MHV68:2	murine gammaherpesvirus 68:46:0.8986|murine gammaherpesvirus-68:14:0.7909	0.8986	60
MHVs	MHVs:12	mechanical heart valves:12:0.7571	0.7571	12
MHV	MHV:43	mechanical heart valve:25:0.8816|mechanical heart valves:18:0.7539	0.8816	43
MHV	MHV:8|mHV:1	medial hyperstriatum ventrale:9:0.5470	0.5470	9
MHV	MHV:46	middle hepatic vein:46:0.8676	0.8676	46
MHV	MHV:10	mouse hepatitis coronavirus:10:0.5856	0.5856	10
MHV	MHV:463|MHv:1	mouse hepatitis virus:457:0.9030|mouse hepatitis viruses:7:0.4438	0.9030	464
MHV	MHV:6	murine coronavirus:6:0.0731	0.0731	6
MHW	MHW:16	Ministry of Health and Welfare:16:0.8165	0.8165	16
MHb	MHb:10|MHB:2|Mhb:2	medial habenula:14:0.7909	0.7909	14
MHb	MHb:24|mHb:2|MHB:2|M-Hb:2|Mhb:1	methemoglobin:31:0.1714	0.1714	31
MHB	MHB:37|mhb:2	midbrain-hindbrain boundary:39:0.5932	0.5932	39
MHB	MHB:20	Mueller-Hinton broth:20:0.7173	0.7173	20
MH	MH:24	macular hole:24:0.8768	0.8768	24
MH	MH:51	maleic hydrazide:51:0.8546	0.8546	51
MH	MH:100	malignant histiocytosis:100:0.9525	0.9525	100
MH	MH:33	malignant hyperpyrexia:33:0.9100	0.9100	33
MH	MH:9	malignant hypertension:9:0.2285	0.2285	9
MH	MH:597|mh:1	malignant hyperthermia:598:0.9950	0.9950	598
MH	MH:10|M-H:2	Mantel-Haenszel:12:0.0073	0.0073	12
MH	MH:10	medial hypothalamic:10:0.7103	0.7103	10
MH	MH:37	medial hypothalamus:37:0.7246	0.7246	37
MH	MH:23|M-H:5	Medtronic Hall:17:0.8270|Medtronic-Hall:11:0.0066	0.8270	28
MH	MH:57	mental health:57:0.8689	0.8689	57
MH	MH:10	metal halide:10:0.7103	0.7103	10
mH	mH:21|MH:7	minor histocompatibility:28:0.7905	0.7905	28
MH	MH:18|M-H:1	Mueller-Hinton:19:0.0119	0.0119	19
mh	mh:4|MH:3	muscular hypertrophy:7:0.1211	0.1211	7
Mh	Mh:11|MH:2	Mycoplasma hyopneumoniae:13:0.7753	0.7753	13
MH	MH:7	myocardial hypertrophy:7:0.1211	0.1211	7
MH	MH:5	Selection for high:5:0.0902	0.0902	5
MI/R	MI/R:6	myocardial ischemia and reperfusion:6:0.5926	0.5926	6
MI/R	MI/R:23	myocardial ischemia-reperfusion:12:0.7571|myocardial ischemia/reperfusion:11:0.7357	0.7571	23
MIB-1	MIB-1:6	cell proliferation:6:0.0807	0.0807	6
MIB-1	MIB-1:18|MIB1:3|Mib-1:1	Ki-67 antigen:22:0.6531	0.6531	22
MIB-1	MIB-1:8|MIB1:1	monoclonal antibody:9:0.2500	0.2500	9
MIB-1	MIB-1:5	Proliferation index:5:0.1132	0.1132	5
MIB-1	MIB-1:9|Mib-1:1	proliferative activity:10:0.5000	0.5000	10
MIBE	MIBE:9	measles inclusion body encephalitis:9:0.6794	0.6794	9
MIBG	MIBG:21|mIBG:1	(123)I-metaiodobenzylguanidine:22:0.0237	0.0237	22
MIBG	MIBG:123|mIBG:1	123I-metaiodobenzylguanidine:110:0.1230|[123I]metaiodobenzylguanidine:14:0.0147	0.1230	124
MIBG	MIBG:11	131I-meta-iodobenzylguanidine:11:0.0113	0.0113	11
MIBG	MIBG:17	iodine-123-metaiodobenzylguanidine:17:0.0181	0.0181	17
MIBG	MIBG:22|mIBG:1	m-iodobenzylguanidine:23:0.0248	0.0248	23
MIBG	MIBG:17	meta-iodo-benzylguanidine:17:0.0181	0.0181	17
MIBG	MIBG:96|mIBG:15|M-IBG:1|m-IBG:1	meta-iodobenzylguanidine:113:0.1264	0.1264	113
MIBG	MIBG:5|mIBG:2	metaiodobenzyl guanidine:7:0.0951	0.0951	7
MIBG	MIBG:313|mIBG:15|m-IBG:1	Metaiodobenzylguanidine:329:0.3646	0.3646	329
MIBI	MIBI:12	(99m)Tc-Sestamibi:12:0.0247	0.0247	12
MIBI	MIBI:22	99mTc-methoxyisobutylisonitrile:22:0.0449	0.0449	22
MIBI	MIBI:34	99mTc-sestamibi:34:0.0742	0.0742	34
MIBI	MIBI:26|mibi:3	isobutyl isonitrile:29:0.2419	0.2419	29
MIBI	MIBI:9	methoxy-isobutyl-isonitrile:9:0.0180	0.0180	9
MIBI	MIBI:20	Tc-99m sestamibi:20:0.1193	0.1193	20
MIBI	MIBI:34	technetium-99m sestamibi:34:0.2526	0.2526	34
MIBK	MIBK:34|MiBK:12	methyl isobutyl ketone:46:0.9353	0.9353	46
MIB	MIB:18	2-methylisoborneol:18:0.1771	0.1771	18
MIB	MIB:18	Medical Information Bus:18:0.8365	0.8365	18
mib	mib:8|Mib:1	mind bomb:9:0.6794	0.6794	9
MIC(50)	MIC(50):6	MIC at which 50% of isolates are inhibited:6:0.6411	0.6411	6
MIC(90)	MIC(90):4	MIC at which 90% of the isolates were inhibited:4:0.3728	0.3728	4
MIC(90)s	MIC(90)s:7	MICs at which 90% of isolates are inhibited:7:0.5856	0.5856	7
MIC-1	MIC-1:25	macrophage inhibitory cytokine-1:25:0.8768	0.8768	25
MIC50	MIC50:4	MIC at which 50% of the isolates are inhibited:4:0.6182	0.6182	4
MIC90s	MIC90s:7	90% of strains tested:7:0.6182	0.6182	7
MIC90s	MIC90s:8|MIC90S:1	MICs at which 90% of the isolates are inhibited:9:0.6381	0.6381	9
MIC90	MIC90:3	90% of the isolates are inhibited:3:0.6411	0.6411	3
MIC90	MIC90:45|MIC-90:2	inhibitory concentration:47:0.8433	0.8433	47
MIC90	MIC90:5	MIC for 90% of strains tested:5:0.2902	0.2902	5
MICAs	MICAs:9	Mentally Ill Chemical Abusers:9:0.6794	0.6794	9
MICC	MICC:19	cytotoxicity:19:0.5294	0.5294	19
MICG	MICG:13	macromolecular insoluble cold globulin:13:0.7103	0.7103	13
MICU	MICU:10	intensive care units:10:0.7103	0.7103	10
MICU	MICU:37	medical ICU:37:0.9197	0.9197	37
MICU	MICU:112	medical intensive care unit:112:0.7065	0.7065	112
MICU	MICU:27	mobile intensive care unit:27:0.1173	0.1173	27
MICs	MICs:9	activities:9:0.0062	0.0062	9
MICS	MICS:6	Interaction Coding System:6:0.5290	0.5290	6
MICS	MICS:9	malnutrition-inflammation complex syndrome:9:0.5470	0.5470	9
MICS	MICS:15	Membrane Invasion Culture System:15:0.8045	0.8045	15
MICs	MICs:13	minimal inhibitory concentration:13:0.2959	0.2959	13
MICS	MICS:23	Minimally invasive cardiac surgery:23:0.8657	0.8657	23
MICs	MICs:702|MICS:3	minimum inhibitory concentrations:705:0.6053	0.6053	705
MIC	MIC:7	ifosfamide and cisplatin:7:0.7357	0.7357	7
MIC	MIC:16	methacholine inhalation challenge:16:0.6577	0.6577	16
MIC	MIC:92	methyl isocyanate:92:0.9675	0.9675	92
MIC	MIC:9	Methylisocyanate:9:0.0028	0.0028	9
MIC	MIC:5	MHC class I chain-related:5:0.3524	0.3524	5
MIC	MIC:12	microinvasive carcinoma:12:0.4153	0.4153	12
MIC	MIC:6	minimal inhibitory:6:0.0666	0.0666	6
MIC	MIC:7	minimum inhibitory:7:0.1591	0.1591	7
MIC	MIC:1429|MIc:1	minimum inhibitory concentration:1145:0.6254|minimum inhibitory concentrations:285:0.5171	0.6254	1430
MIDA	MIDA:22	Mass isotopomer distribution analysis:22:0.7955	0.7955	22
MIDAS	MIDAS:30	metal ion-dependent adhesion site:30:0.9011	0.9011	30
MIDAS	MIDAS:34	Migraine Disability Assessment:34:0.9126	0.9126	34
MIDAS	MIDAS:8	Migraine Disability Assessment Scale:8:0.6411	0.6411	8
MIDCAB	MIDCAB:110	Minimally invasive direct coronary artery bypass:110:0.9298	0.9298	110
MIDCAB	MIDCAB:27	Minimally invasive direct coronary artery bypass grafting:27:0.7834	0.7834	27
MIDCAB	MIDCAB:10|MID-CAB:1	minimally invasive direct coronary artery bypass surgery:11:0.7357	0.7357	11
MIDD	MIDD:32	maternally inherited diabetes and deafness:32:0.9126	0.9126	32
MID	MID:17	important difference:17:0.6748	0.6748	17
MID	MID:10	inclusion disease:10:0.5000	0.5000	10
MID	MID:10|mid:5|Mid:1	midazolam:16:0.0263	0.0263	16
MID	MID:224	multi-infarct dementia:224:0.8115	0.8115	224
MID	MID:22	multiple indicator dilution:22:0.8657	0.8657	22
MIEP	MIEP:18	major immediate-early promoter:18:0.8449	0.8449	18
MIE	MIE:43|mIE:1	major immediate-early:32:0.9072|major immediate early:12:0.7571	0.9072	44
MIF	MIF:637|Mif:2|mif:1	macrophage migration inhibitory factor:640:0.7630	0.7630	640
MIF	MIF:13	Maximal isometric force:13:0.4849	0.4849	13
MIF	MIF:15|mIF:1	micro-immunofluorescence:16:0.0106	0.0106	16
MIF	MIF:88	microimmunofluorescence:88:0.0617	0.0617	88
MIF	MIF:13	microimmunofluorescence test:13:0.4102	0.4102	13
MIF	MIF:6|Mif:6	mifepristone:12:0.0078	0.0078	12
MIF	MIF:16	migration inhibition:16:0.7261	0.7261	16
MIF	MIF:160	migration inhibition factor:160:0.9112	0.9112	160
MIF	MIF:12	Pro-Leu-Gly-NH2:12:0.0078	0.0078	12
MIGET	MIGET:41	multiple inert gas elimination technique:41:0.8867	0.8867	41
mIg	mIg:29	membrane Ig:29:0.6392	0.6392	29
mIg	mIg:55|MIg:1|M-Ig:1	membrane immunoglobulin:51:0.5859|membrane immunoglobulins:6:0.0522	0.5859	57
MIG	MIG:10	metal inert gas:10:0.7103	0.7103	10
MIg	MIg:4|M-Ig:3|mIg:2	monoclonal immunoglobulins:9:0.1690	0.1690	9
MIG	MIG:12|Mig:9|MiG:1	monokine induced by interferon-gamma:22:0.8657	0.8657	22
MIH	MIH:40	molt-inhibiting hormone:40:0.4238	0.4238	40
MIH	MIH:13	Myointimal hyperplasia:13:0.7753	0.7753	13
MIIC	MIIC:17	compartments:17:0.6154	0.6154	17
MIICs	MIICs:9	MHC class II compartments:9:0.7103	0.7103	9
MILIS	MILIS:9	Multicenter Investigation of the Limitation of Infarct Size:9:0.6182	0.6182	9
MIL	MIL:11	mean intercept length:11:0.7357	0.7357	11
MIL	MIL:9|mil:3	milrinone:12:0.1833	0.1833	12
MIMP	MIMP:7	Methyl inosine monophosphate:7:0.4438	0.4438	7
MIMS	MIMS:9	membrane inlet mass spectrometry:9:0.6794	0.6794	9
MIMS	MIMS:20	membrane introduction mass spectrometry:20:0.8525	0.8525	20
minIP	minIP:3|MinIP:2|MINIP:1|Min-IP:1	minimum intensity projection:7:0.4438	0.4438	7
MINO	MINO:109	minocycline:109:0.8571	0.8571	109
MIOL	MIOL:9	multifocal intraocular lens:9:0.6794	0.6794	9
MION	MION:12	Monocrystalline iron oxide nanoparticles:12:0.7571	0.7571	12
MIP26K	MIP26K:8	major intrinsic polypeptide:8:0.5006	0.5006	8
MIP26	MIP26:4|MIP-26:1	major intrinsic protein:5:0.2818	0.2818	5
MIP-2	MIP-2:292|MIP2:3|Mip-2:1	macrophage inflammatory protein-2:232:0.9599|macrophage inflammatory protein 2:64:0.9264	0.9599	296
MIPs	MIPs:10	major intrinsic proteins:10:0.7103	0.7103	10
MIPs	MIPs:16	maximum intensity projections:16:0.6577	0.6577	16
MIPs	MIPs:76	molecularly imprinted polymers:76:0.8834	0.8834	76
MIPs	MIPs:4	molluscan insulin-related peptides:4:0.1618	0.1618	4
MIPS	MIPS:8	Munich Information Center for Protein Sequences:8:0.6411	0.6411	8
MIP	MIP:9	imprinted polymers:9:0.5470	0.5470	9
MIP	MIP:8	inspiratory pressures:8:0.3463	0.3463	8
Mip	Mip:10|mip:7|MIP:1	macrophage infectivity potentiator:18:0.8365	0.8365	18
MIP	MIP:38	macrophage inflammatory protein:38:0.9174	0.9174	38
MIP	MIP:11	main intrinsic polypeptide:11:0.5856	0.5856	11
MIP	MIP:83|Mip:2	major intrinsic protein:85:0.7366	0.7366	85
MIP	MIP:13	maximal inspiratory:13:0.2802	0.2802	13
MIP	MIP:77	maximal inspiratory pressure:77:0.5843	0.5843	77
MIP	MIP:8	maximum inspiratory:8:0.1004	0.1004	8
MIP	MIP:244	maximum intensity projection:197:0.9044|Maximum intensity projections:26:0.6973|maximum-intensity-projection:21:0.0204	0.9044	244
MIP	MIP:7	methylation induced premeiotically:7:0.5926	0.5926	7
MIP	MIP:23	Minimally invasive parathyroidectomy:23:0.8715	0.8715	23
MIP	MIP:15|mip:1	mitochondrial intermediate peptidase:16:0.8045	0.8045	16
MIP	MIP:67	Molecularly imprinted polymer:67:0.8197	0.8197	67
MIRD	MIRD:44	medical internal radiation dose:44:0.9323	0.9323	44
MIRL	MIRL:11	membrane inhibitor of reactive lysis:11:0.6182	0.6182	11
MIRP	MIRP:14	minimally invasive radioguided parathyroidectomy:14:0.7909	0.7909	14
MIRUs	MIRUs:14	Mycobacterial interspersed repetitive units:14:0.7909	0.7909	14
MIR	MIR:65	main immunogenic region:65:0.9047	0.9047	65
MIR	MIR:23	mid-infrared:23:0.0751	0.0751	23
MIR	MIR:8	minimum infection rate:8:0.5006	0.5006	8
MIR	MIR:13	Myocardial Infarction Registry:13:0.7753	0.7753	13
MISO	MISO:246|miso:5|Miso:4	misonidazole:255:0.9071	0.9071	255
MISPE	MISPE:10	molecularly imprinted solid-phase extraction:10:0.7103	0.7103	10
MISS	MISS:10	Injury Severity Scale:10:0.7103	0.7103	10
MISS	MISS:10	Medical Interview Satisfaction Scale:10:0.7103	0.7103	10
MITC	MITC:18	Methyl isothiocyanate:18:0.6381	0.6381	18
MITE	MITE:10	miniature inverted-repeat transposable element:10:0.7103	0.7103	10
Mitf	Mitf:8|MITF:6	microphthalmia:14:0.0707	0.0707	14
MITF	MITF:102|Mitf:32|MiTF:6|mitf:1	transcription factor:141:0.9255	0.9255	141
mito	mito:10|MITO:3	mitochondrial:13:0.2791	0.2791	13
MITO	MITO:12|mito:1|Mito:1	mitoxantrone:14:0.3023	0.3023	14
MIT	MIT:8	injection therapy:8:0.0906	0.0906	8
MIT	MIT:12	intimal thickness:12:0.6460	0.6460	12
MIT	MIT:14	macrophage migration inhibition test:14:0.4071	0.4071	14
MIT	MIT:16	Magnetic induction tomography:16:0.8045	0.8045	16
MIT	MIT:17	Massachusetts Institute of Technology:17:0.8270	0.8270	17
MIT	MIT:7	Melodic Intonation Therapy:7:0.5926	0.5926	7
MIT	MIT:8	metal-insulator transition:8:0.2987	0.2987	8
MIT	MIT:9	Minimally invasive therapy:9:0.4587	0.4587	9
mit	mit:8|MIT:3	mitochondria:11:0.0314	0.0314	11
MIT	MIT:40|mit:3	mitoxantrone:43:0.1321	0.1321	43
MIT	MIT:16	monoiodotyrosine:16:0.0472	0.0472	16
MIUs	MIUs:6	minor injury units:6:0.5290	0.5290	6
MIU	MIU:21|mIU:1	million international units:22:0.6934	0.6934	22
MIVAP	MIVAP:8	minimally invasive video-assisted parathyroidectomy:8:0.6411	0.6411	8
MIVAT	MIVAT:6	minimally invasive video-assisted thyroidectomy:6:0.6411	0.6411	6
MIX	MIX:7	1-methyl-3-isobutyl xanthine:7:0.0828	0.0828	7
MIX	MIX:17	3-isobutyl-1-methylxanthine:17:0.0584	0.0584	17
MIX	MIX:38	methylisobutylxanthine:38:0.1350	0.1350	38
MIS	MIS:12	information systems:12:0.7571	0.7571	12
MIS	MIS:22	management information system:22:0.4047	0.4047	22
MIS	MIS:20	maturation-inducing steroid:20:0.8525	0.8525	20
MIS	MIS:13	Medical Information System:13:0.1704	0.1704	13
MIS	MIS:13	Melanoma in situ:13:0.6701	0.6701	13
MIS	MIS:18	microbial identification system:18:0.8365	0.8365	18
MIS	MIS:75	minimally invasive surgery:75:0.8819	0.8819	75
MIS	MIS:23	misonidazole:23:0.0351	0.0351	23
MIS	MIS:201|Mis:1	Mullerian Inhibiting Substance:161:0.9703|Mullerian-inhibiting substance:41:0.1262	0.9703	202
MIs	MIs:44	myocardial infarctions:44:0.9323	0.9323	44
MI	MI:118	after acute myocardial infarction:118:0.1060	0.1060	118
MI	MI:10	cardiac remodeling after myocardial infarction:10:0.0697	0.0697	10
MI	MI:7	first meiotic division:7:0.5926	0.5926	7
MI	MI:5	first meiotic metaphase:5:0.4422	0.4422	5
MI	MI:11	infection:11:0.0012	0.0012	11
MI	MI:11|Mi:1	intensity:12:0.0013	0.0013	12
MI	MI:12	intervention:12:0.0013	0.0013	12
MI	MI:5	macrophage migration inhibition:5:0.0517	0.0517	5
MI	MI:11	Magical Ideation:11:0.7357	0.7357	11
MI	MI:22	meconium ileus:22:0.8657	0.8657	22
MI	MI:23|M-I:2	Meiosis I:25:0.1205	0.1205	25
MI	MI:37	metabolic inhibition:37:0.5038	0.5038	37
MI	MI:13	Metabolic Intermediate:13:0.4444	0.4444	13
M-I	M-I:8|MI:4|Mi:1	metabolite:13:0.0014	0.0014	13
MI	MI:77|M-I:7|mi:1	metaphase I:85:0.5827	0.5827	85
mi	mi:9|MI:1	microphthalmic:10:0.0011	0.0011	10
MI	MI:145	microsatellite instability:145:0.8662	0.8662	145
MI	MI:18	mitotic:18:0.0020	0.0020	18
MI	MI:340	mitotic index:340:0.5182	0.5182	340
MI	MI:26	mitotic indices:26:0.4874	0.4874	26
MI	MI:33|Mi:1	mitral insufficiency:34:0.8245	0.8245	34
MI	MI:42	motivational interviewing:42:0.9291	0.9291	42
MI	MI:14	motor imagery:14:0.6911	0.6911	14
mi	mi:6|MI:3|Mi:1	mouse microphthalmia:10:0.0958	0.0958	10
MI	MI:13	multiple imputation:13:0.7753	0.7753	13
MI	MI:37	mutual information:37:0.8051	0.8051	37
MI	MI:49	myocardial infarct:49:0.8254	0.8254	49
MI	MI:9	myocardial infarcted:9:0.4587	0.4587	9
MI	MI:48	myocardial infarctions:48:0.8463	0.8463	48
MI	MI:45	myocardial ischemia:45:0.7664	0.7664	45
MI	MI:9	myometrial invasion:9:0.3455	0.3455	9
MI	MI:53|mi:1	patients after myocardial infarction:54:0.0675	0.0675	54
MI	MI:201	patients with acute myocardial infarction:201:0.1760	0.1760	201
MI	MI:26	primary motor:26:0.4874	0.4874	26
MI	MI:6	primary motor area:6:0.3728	0.3728	6
MI	MI:105|M-I:1	primary motor cortex:106:0.6768	0.6768	106
MI	MI:9	ventricular remodeling after myocardial infarction:9:0.0550	0.0550	9
MJA	MJA:8|M-JA:1	methyl jasmonate:9:0.6794	0.6794	9
MJD	MJD:171	Machado-Joseph disease:171:0.8281	0.8281	171
MJS	MJS:9	joint space:9:0.6794	0.6794	9
MJ	MJ:12	marijuana:12:0.0902	0.0902	12
MJ	MJ:40	methyl jasmonate:40:0.9256	0.9256	40
MK422	MK422:6|MK-422:4	enalaprilic acid:10:0.7103	0.7103	10
MK-4	MK-4:22|MK4:1	menaquinone-4:23:0.5116	0.5116	23
MK-7	MK-7:11|MK7:1	menaquinone-7:12:0.6875	0.6875	12
MK-801	MK-801:15	(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine:15:0.0146	0.0146	15
MK-801	MK-801:8|MK801:2	cyclohepten-5,10-imine:10:0.0101	0.0101	10
MK-801	MK-801:59|MK801:3	hydrogen maleate:62:0.1805	0.1805	62
MK-801	MK-801:8	NMDA receptor antagonist dizocilpine maleate:8:0.5589	0.5589	8
MK-801	MK-801:16|MK801:1	Non-competitive:17:0.0180	0.0180	17
MK-801	MK-801:18|MK801:6	receptor antagonist:24:0.4622	0.4622	24
MKHD	MKHD:21	Menkes Kinky hair disease:13:0.3554|Menkes' kinky hair disease:8:0.1276	0.3554	21
MKK	MKK:12	MAP kinase kinase:12:0.2758	0.2758	12
MKK	MKK:12	MAPK kinase:12:0.1338	0.1338	12
MKK1	MKK1:6	Mitogen-activated protein kinase kinase 1:6:0.5290	0.5290	6
MKK3	MKK3:9	mitogen-activated protein kinase kinase 3:9:0.6794	0.6794	9
MKK4	MKK4:16	mitogen-activated protein kinase kinase 4:16:0.8165	0.8165	16
MKK6	MKK6:9	mitogen-activated protein kinase kinase 6:9:0.6794	0.6794	9
MKK7	MKK7:9	mitogen-activated protein kinase kinase 7:9:0.6794	0.6794	9
MKN-45	MKN-45:4|MKN45:2	human gastric cancer cells:6:0.3728	0.3728	6
MKP-3	MKP-3:7|Mkp3:2|MKP3:1	kinase phosphatase-3:10:0.7103	0.7103	10
MKPs	MKPs:15	MAP kinase phosphatases:15:0.6381	0.6381	15
MKPs	MKPs:11	MAPK phosphatases:11:0.2010	0.2010	11
MKP	MKP:9	kinase phosphatase:9:0.3069	0.3069	9
MKS	MKS:9	McKusick-Kaufman syndrome:9:0.1945	0.1945	9
MKs	MKs:59|Mks:10	megakaryocytes:69:0.6476	0.6476	69
M-K	M-K:5|MK:2	corneas stored in McCarey-Kaufman:7:0.3945	0.3945	7
MK	MK:217|Mk:25	megakaryocyte:145:0.1941|megakaryocytes:97:0.1294	0.1941	242
MK	MK:17|Mk:7	megakaryocytic:24:0.0323	0.0323	24
MK	MK:16	menaquinone:16:0.0202	0.0202	16
MK	MK:20|Mk:1	mevalonate kinase:21:0.8594	0.8594	21
MK	MK:8	microbial keratitis:8:0.5006	0.5006	8
MK	MK:202	midkine:202:0.2709	0.2709	202
MK	MK:9	monkey kidney:9:0.2102	0.2102	9
ML-1	ML-1:7|ML1:1	cell line:8:0.5006	0.5006	8
ML-1	ML-1:7	mistletoe lectin:7:0.2452	0.2452	7
ML-1	ML-1:9	mistletoe lectin-1:9:0.3945	0.3945	9
MLAC	MLAC:14	minimum local analgesic concentration:14:0.7909	0.7909	14
MLAEPs	MLAEPs:19|ML-AEPs:2	Middle Latency Auditory Evoked Potentials:21:0.8594	0.8594	21
MLAEP	MLAEP:36|MLA-EP:1	auditory evoked potentials:37:0.9197	0.9197	37
MLAEP	MLAEP:8	middle latency auditory evoked potential:8:0.6411	0.6411	8
MLB	MLB:10	magnesium lithospermate B:10:0.7103	0.7103	10
MLC(20)	MLC(20):17	myosin light chain:17:0.6748	0.6748	17
MLC1	MLC1:8|MLC-1:2	myosin light chain 1:10:0.5856	0.5856	10
MLC20	MLC20:50|MLC-20:1	myosin light chain:51:0.8546	0.8546	51
MLC2v	MLC2v:5|MLC-2v:2|mlc-2v:1	myosin light chain 2:8:0.6411	0.6411	8
MLC2	MLC2:6|MLC-2:4	light chain:10:0.7103	0.7103	10
MLC-2	MLC-2:26|MLC2:20	myosin light chain 2:24:0.8768|myosin light chain-2:22:0.8657	0.8768	46
MLCK	MLCK:395	myosin light chain kinase:395:0.9764	0.9764	395
MLCP	MLCP:29	myosin light chain phosphatase:29:0.8978	0.8978	29
MLCP	MLCP:5|MLC-P:2|MLC-p:1	myosin light chain phosphorylation:8:0.6411	0.6411	8
MLCT	MLCT:62	metal-to-ligand charge-transfer:32:0.7841|metal-to-ligand charge transfer:30:0.7012	0.7841	62
MLCs	MLCs:11	lethal concentrations:11:0.7357	0.7357	11
MLCs	MLCs:26	mixed lymphocyte cultures:26:0.8861	0.8861	26
MLCs	MLCs:32	Multileaf collimators:32:0.8145	0.8145	32
MLCs	MLCs:11	myosin light chains:11:0.7357	0.7357	11
MLC	MLC:26	lethal concentration:26:0.8251	0.8251	26
MLC	MLC:7	light chain of myosin:7:0.5926	0.5926	7
MLC	MLC:7	macrophage-like cells:7:0.0732	0.0732	7
MLC	MLC:17	Megalencephalic leukoencephalopathy with subcortical cysts:17:0.7539	0.7539	17
MLC	MLC:10	metastatic liver cancer:10:0.7103	0.7103	10
MLC	MLC:29	micellar liquid chromatography:29:0.8978	0.8978	29
MLC	MLC:170	mixed leukocyte culture:121:0.9753|mixed leukocyte cultures:49:0.9404	0.9753	170
MLC	MLC:796	mixed lymphocyte culture:599:0.9843|mixed lymphocyte cultures:197:0.9676	0.9843	796
MLC	MLC:23	multi-leaf collimator:23:0.0595	0.0595	23
MLC	MLC:13	multileaf collimation:13:0.5934	0.5934	13
MLC	MLC:205	multileaf collimator:192:0.8174|Multileaf collimators:13:0.5335	0.8174	205
MLC	MLC:403	myosin light chain:352:0.8594|myosin light chains:30:0.7315|myosin light-chain:21:0.7291	0.8594	403
MLD-STZ	MLD-STZ:3|MLDSTZ:1	diabetes induced by multiple low doses of streptozotocin:4:0.4438	0.4438	4
MLDs	MLDs:16	masking-level differences:9:0.2500|masking level differences:7:0.5926	0.5926	16
MLD	MLD:11	lethal doses:11:0.6182	0.6182	11
MLD	MLD:5	liver disease:5:0.1132	0.1132	5
MLD	MLD:5	Manual lymph drainage:5:0.4422	0.4422	5
MLD	MLD:5	Manual lymphatic drainage:5:0.4422	0.4422	5
MLD	MLD:5	marine natural product manoalide:5:0.5290	0.5290	5
MLD	MLD:45	masking level difference:26:0.8861|masking-level difference:19:0.2412	0.8861	45
MLD	MLD:19	mean lung density:19:0.8449	0.8449	19
MLD	MLD:15	mean lung dose:15:0.8045	0.8045	15
MLD	MLD:15	median lethal dose:15:0.2972	0.2972	15
MLd	MLd:2|MLD:2	mesencephalicus lateralis pars dorsalis:4:0.4438	0.4438	4
MLD	MLD:18	metachromatic leucodystrophy:18:0.8365	0.8365	18
MLD	MLD:212	metachromatic leukodystrophy:212:0.9859	0.9859	212
MLD	MLD:79	Minimal lumen diameter:79:0.5971	0.5971	79
MLD	MLD:55	minimal luminal diameter:55:0.6593	0.6593	55
MLD	MLD:10	minimum lethal dose:10:0.1385	0.1385	10
MLD	MLD:34	minimum lumen diameter:34:0.2045	0.2045	34
mld	mld:24|Mld:1	myelin-deficient:15:0.0196|myelin deficient:10:0.7103	0.7103	25
MLEC	MLEC:7	mouse lung endothelial cells:7:0.3524	0.3524	7
MLEE	MLEE:101	multilocus enzyme electrophoresis:101:0.8985	0.8985	101
ML-EM	ML-EM:26|MLEM:8	maximum likelihood expectation maximization:15:0.8165|maximum likelihood-expectation maximization:11:0.7357|maximum-likelihood expectation-maximization:8:0.4102	0.8165	34
MLEs	MLEs:14	mariner-like elements:14:0.6173	0.6173	14
MLEs	MLEs:12	maximum likelihood estimates:12:0.7571	0.7571	12
mle	mle:16|MLE:3|Mle:2	maleless:21:0.1031	0.1031	21
MLE	MLE:13	maximum likelihood estimate:13:0.7753	0.7753	13
MLE	MLE:30	Maximum likelihood estimation:30:0.9011	0.9011	30
MLE	MLE:25|mle:1	maximum likelihood estimator:26:0.8861	0.8861	26
MLF1	MLF1:9	leukemia factor 1:9:0.6794	0.6794	9
MLF	MLF:10	logistic function:10:0.5856	0.5856	10
MLF	MLF:13	malolactic fermentation:13:0.6701	0.6701	13
MLF	MLF:11|mlf:3	medial longitudinal fascicle:14:0.6911	0.6911	14
MLF	MLF:104|mlf:3	medial longitudinal fasciculus:107:0.9156	0.9156	107
MLHFQ	MLHFQ:7|MLHF-Q:2	Minnesota Living with Heart Failure Questionnaire:9:0.6794	0.6794	9
MLIV	MLIV:20|ML-IV:3	mucolipidosis type IV:23:0.8768	0.8768	23
MLI	MLI:17	mean linear intercept:17:0.8270	0.8270	17
MLI	MLI:8	Met-enkephalin-like immunoreactivity:8:0.1591	0.1591	8
MLI	MLI:10|ML-I:8	mistletoe lectin I:18:0.8365	0.8365	18
MLK3	MLK3:10	mixed lineage kinase 3:10:0.7103	0.7103	10
MLKs	MLKs:12	Mixed lineage kinases:12:0.7571	0.7571	12
MLK	MLK:18	mixed lineage kinase:18:0.8365	0.8365	18
MLL	MLL:43|Mll:2	mixed lineage leukemia:45:0.8964	0.8964	45
MLMs	MLMs:22	Medical Logic Modules:22:0.8657	0.8657	22
MLM	MLM:48|Mlm:3	Mycobacterium lepraemurium:51:0.8102	0.8102	51
MLNC	MLNC:29|mLNC:1	mesenteric lymph node cells:30:0.8032	0.8032	30
MLNs	MLNs:82	mesenteric lymph nodes:82:0.8368	0.8368	82
MLNS	MLNS:19	mucocutaneous lymph node syndrome:19:0.8449	0.8449	19
MLN	MLN:482|mLN:8|mln:1	mesenteric lymph nodes:296:0.8724|mesenteric lymph node:195:0.8618	0.8724	491
MLO	MLO:13	mediolateral oblique:13:0.4444	0.4444	13
MLO	MLO:10	Mycoplasma-like organisms:10:0.3470	0.3470	10
MLP	MLP:63|mlp:1	major late promoter:64:0.9264	0.9264	64
MLP	MLP:10	molecular lipophilicity potential:10:0.7103	0.7103	10
MLP	MLP:55	multilayer perceptron:50:0.5613|multilayer perceptrons:5:0.0902	0.5613	55
MLP	MLP:15	multiple lymphomatous polyposis:15:0.7261	0.7261	15
MLP	MLP:27	Muscle LIM protein:27:0.8903	0.8903	27
MLRA	MLRA:9	multiple linear regression analysis:9:0.6794	0.6794	9
MLRs	MLRs:34	middle latency responses:34:0.8644	0.8644	34
MLRs	MLRs:34	mixed lymphocyte reactions:34:0.8644	0.8644	34
MLR	MLR:98	mesencephalic locomotor region:98:0.8720	0.8720	98
MLR	MLR:90	middle latency response:58:0.8710|middle latency responses:32:0.7782	0.8710	90
MLR	MLR:183	mixed leukocyte reaction:162:0.9815|Mixed leukocyte reactions:21:0.8594	0.9815	183
MLR	MLR:890	mixed lymphocyte reaction:734:0.9816|mixed lymphocyte reactions:156:0.9808	0.9816	890
MLR	MLR:16	mixed lymphocyte reactivity:16:0.8165	0.8165	16
MLR	MLR:96	mixed lymphocyte response:84:0.9436|mixed lymphocyte responses:12:0.7571	0.9436	96
MLR	MLR:123	multiple linear regression:123:0.9158	0.9158	123
MLR	MLR:9	multiple linear regression analysis:9:0.6794	0.6794	9
MLR	MLR:20	multiple logistic regression:20:0.4786	0.4786	20
MLSB	MLSB:11|MLSb:2	macrolide-lincosamide-streptogramin B:13:0.4102	0.4102	13
MLSS	MLSS:22	maximal lactate steady state:22:0.7400	0.7400	22
MLSS	MLSS:12	mixed liquor suspended solids:12:0.7571	0.7571	12
MLST	MLST:162	multilocus sequence typing:162:0.8727	0.8727	162
MLTC-1	MLTC-1:5|mLTC-1:4	Leydig tumor cells:9:0.6794	0.6794	9
MLTC	MLTC:24	mixed lymphocyte tumor cell culture:16:0.8165|mixed lymphocyte tumor cell cultures:8:0.6411	0.8165	24
MLTF	MLTF:11	major late transcription factor:11:0.6182	0.6182	11
MLTU	MLTU:10	major late transcription unit:10:0.7103	0.7103	10
MLUS	MLUS:10	lymphocytosis of undetermined significance:10:0.5470	0.5470	10
MLU	MLU:51	mean length of utterance:51:0.9438	0.9438	51
MLVs	MLVs:59	multilamellar vesicles:59:0.8334	0.8334	59
MLVs	MLVs:23	murine leukemia viruses:23:0.8038	0.8038	23
MLV	MLV:26	multilamellar:26:0.0471	0.0471	26
MLV	MLV:17	Multilamellar liposomes:17:0.6211	0.6211	17
MLV	MLV:112|mLV:1	multilamellar vesicles:100:0.7713|multilamellar vesicle:13:0.7753	0.7753	113
MLV	MLV:223|mLV:1	murine leukemia virus:212:0.9001|murine leukemia viruses:12:0.6460	0.9001	224
ML	ML:18	5-methoxytryptophol:18:0.0099	0.0099	18
ML	ML:12	machine learning:12:0.6460	0.6460	12
ML	ML:8	macrocyclic lactone:8:0.5006	0.5006	8
ML	ML:180|ml:4	malignant lymphoma:132:0.8943|malignant lymphomas:52:0.8134	0.8943	184
ML	ML:285	maximum likelihood:218:0.9780|maximum-likelihood:67:0.0384	0.9780	285
ML	ML:23|M-L:5|m-l:1|M--L:1	medial-lateral:30:0.0169	0.0169	30
ML	ML:19|ml:1	medial lemniscus:20:0.8525	0.8525	20
ML	ML:9	midluteal:9:0.0047	0.0047	9
ML	ML:8	mink lung:8:0.4102	0.4102	8
ML	ML:19	mistletoe lectins:10:0.7103|Mistletoe lectin:9:0.5470	0.7103	19
ML	ML:8|M-L:1	mitochondrial-lysosomal:9:0.0047	0.0047	9
ML	ML:44	molecular layer:44:0.6550	0.6550	44
ML	ML:14	monolayer:14:0.0076	0.0076	14
ML	ML:7	mononuclear leukocytes:7:0.3524	0.3524	7
ML	ML:7	mouse lysozyme:7:0.2902	0.2902	7
ML	ML:14	mucosal leishmaniasis:14:0.7909	0.7909	14
ML	ML:8|M-L:5	Muller-Lyer:13:0.0070	0.0070	13
ML	ML:17	muscle larvae:17:0.6748	0.6748	17
ML	ML:8	muscle length:8:0.1276	0.1276	8
ML	ML:10|Ml:1	Mycobacterium leprae:11:0.2154	0.2154	11
ML	ML:10|Ml:2	myeloid leukemia:12:0.4153	0.4153	12
MM3	MM3:9	molecular mechanics:9:0.6794	0.6794	9
MM6	MM6:16	Mono Mac 6:16:0.8165	0.8165	16
MM96L	MM96L:11	melanoma cell line:11:0.7357	0.7357	11
MMA(III)	MMA(III):27	Monomethylarsonous acid:27:0.8312	0.8312	27
MMA(V)	MMA(V):18	monomethylarsonic acid:18:0.6903	0.6903	18
MMAA	MMAA:9	monomethylarsonic acid:9:0.3945	0.3945	9
MMAD	MMAD:116	mass median aerodynamic diameter:107:0.9417|mass median aerodynamic diameters:9:0.6794	0.9417	116
MMAI	MMAI:11|MMAi:1	5-methoxy-6-methyl-2-aminoindan:12:0.8462	0.8462	12
MMAP	MMAP:6	maternal mean arterial pressure:6:0.5290	0.5290	6
MMAR	MMAR:10	mean mitotic activity rate:10:0.7103	0.7103	10
Mmax	Mmax:6|M-max:5	motor response:11:0.5355	0.5355	11
MMAS	MMAS:16	Massachusetts Male Aging Study:16:0.8165	0.8165	16
MMA	MMA:9	analysis:9:0.0085	0.0085	9
MMA	MMA:24	manual metal arc:24:0.8768	0.8768	24
MMA	MMA:8	maxillomandibular advancement:8:0.5006	0.5006	8
MMA	MMA:1	Medicare Prescription Drug Improvement and Modernization Act:1:0.7357	0.7357	1
MMA	MMA:189	methyl methacrylate:189:0.9184	0.9184	189
MMA	MMA:7	Methyl methacrylate monomer:7:0.5926	0.5926	7
MMA	MMA:14	Methylmalonic:14:0.0138	0.0138	14
MMA	MMA:163	methylmalonic acid:163:0.5560	0.5560	163
MMA	MMA:8	methylmalonic acidaemia:8:0.6794	0.6794	8
MMA	MMA:22	Methylmalonic acidemia:22:0.8657	0.8657	22
MMA	MMA:20	methylmalonic aciduria:20:0.7658	0.7658	20
MMA	MMA:58	methylmethacrylate:58:0.0606	0.0606	58
MMA	MMA:10	methylmethacrylate monomer:10:0.2446	0.2446	10
MMA	MMA:25|mmA:1	middle meningeal artery:26:0.8861	0.8861	26
MMA	MMA:19	monocyte monolayer assay:19:0.7658	0.7658	19
MMA	MMA:11	Monomethylamine:11:0.0106	0.0106	11
MMA	MMA:16	monomethylarsonate:16:0.0160	0.0160	16
MMA	MMA:67	monomethylarsonic acid:67:0.1975	0.1975	67
MMA	MMA:5	Monterrey Metropolitan Area:5:0.4422	0.4422	5
MM-CK	MM-CK:17|MMCK:1	creatine kinase:18:0.5940	0.5940	18
MMCM	MMCM:11	macromolecular contrast medium:11:0.6182	0.6182	11
mMCP-1	mMCP-1:10|MMCP-1:2	mouse mast cell protease-1:12:0.6460	0.6460	12
mMCP	mMCP:17|MMCP:2	mouse mast cell protease:19:0.7658	0.7658	19
MMCs	MMCs:27	migrating motor complexes:27:0.7425	0.7425	27
MMCs	MMCs:30	migrating myoelectric complexes:30:0.8472	0.8472	30
MMCs	MMCs:13	mucosal mast cells:13:0.6911	0.6911	13
MMCT	MMCT:25	Microcell-mediated chromosome transfer:25:0.6767	0.6767	25
MMCl	MMCl:9	methyl mercuric chloride:9:0.6794	0.6794	9
MMC	MMC:6	children with meningomyelocele:6:0.0611	0.0611	6
MMC	MMC:17	children with myelomeningocele:17:0.1106	0.1106	17
MMC	MMC:26	Medicaid managed care:26:0.4719	0.4719	26
MMC	MMC:11	Medical Center:11:0.7357	0.7357	11
MMC	MMC:37	methylmercuric chloride:37:0.2426	0.2426	37
MMC	MMC:47|mmc:1	Methylmercury chloride:48:0.3488	0.3488	48
MMC	MMC:11	Metropolis Monte Carlo:11:0.5355	0.5355	11
MMC	MMC:228	migrating motor complex:206:0.9192|migrating motor complexes:22:0.7955	0.9192	228
MMC	MMC:146	migrating myoelectric complex:118:0.9465|migrating myoelectric complexes:28:0.8941	0.9465	146
MMC	MMC:63	mitomycin:63:0.0205	0.0205	63
MMC	MMC:1872|MM-C:6	mitomycin C:1680:0.9830|mitomycin-C:198:0.0651	0.9830	1878
MMC	MMC:143	mucosal mast cells:105:0.8400|mucosal mast cell:38:0.9217	0.9217	143
MMC	MMC:12	patients with myelomeningocele:12:0.0605	0.0605	12
MMD	MMD:18	mass median diameter:18:0.8449	0.8449	18
MMD	MMD:6	minimal melanogenic dose:6:0.3728	0.3728	6
MMD	MMD:27	Moyamoya disease:27:0.6455	0.6455	27
MMD	MMD:18	myotonic muscular dystrophy:18:0.7539	0.7539	18
MMEC	MMEC:12	mouse mammary epithelial cells:12:0.5664	0.5664	12
MMEF	MMEF:7	maximum midexpiratory flow:7:0.1329	0.1329	7
MMEPs	mMEPs:5|MMEPs:5	motor evoked potentials:10:0.7103	0.7103	10
MME	MME:8	macrophage metalloelastase:8:0.2619	0.2619	8
MMF	MMF:9	fraction:9:0.0073	0.0073	9
MMF	MMF:11	macrophagic myofasciitis:11:0.7357	0.7357	11
MMF	MMF:33	maxillomandibular fixation:33:0.7238	0.7238	33
MMF	MMF:4	maximum mid-expiratory flow:4:0.0918	0.0918	4
MMF	MMF:17	mismatch field:17:0.6748	0.6748	17
MMF	MMF:890	Mycophenolate mofetil:890:0.9644	0.9644	890
MMG	MMG:16	mammography:16:0.0857	0.0857	16
MMG	MMG:32	mechanomyogram:32:0.1771	0.1771	32
MMG	MMG:40	mechanomyographic:40:0.2229	0.2229	40
MMG	MMG:22	mechanomyography:22:0.1200	0.1200	22
MMH	MMH:17	manual material handling:9:0.6794|manual materials handling:8:0.6411	0.6794	17
MMH	MMH:6	methylmercury hydroxide:6:0.1148	0.1148	6
MMH	MMH:14	monomethylhydrazine:14:0.1831	0.1831	14
MMIHS	MMIHS:45	megacystis-microcolon-intestinal hypoperistalsis syndrome:31:0.5315|megacystis microcolon intestinal hypoperistalsis syndrome:14:0.7753	0.7753	45
MMI	MMI:13	1-methyl-2-mercaptoimidazole:13:0.0293	0.0293	13
MMI	MMI:31|mmi:1	macrophage migration inhibition:32:0.9072	0.9072	32
MMI	MMI:214|MMi:1	methimazole:215:0.5232	0.5232	215
MMI	MMI:17	methylmercaptoimidazole:17:0.0391	0.0391	17
mMLC	mMLC:11|MMLC:6	Collimator:17:0.6400	0.6400	17
MMLV	MMLV:24|M-MLV:13	Moloney murine leukemia virus:37:0.8749	0.8749	37
MML	MML:9	molecular layer:9:0.4587	0.4587	9
MMMF	MMMF:16	man-made mineral fibers:16:0.5564	0.5564	16
MMMF	MMMF:11	Mineral Fibres:11:0.7357	0.7357	11
MMMTs	MMMTs:13	Malignant mixed mullerian tumors:13:0.7753	0.7753	13
MMMT	MMMT:14	Malignant mixed mesodermal tumor:14:0.8045	0.8045	14
MMMT	MMMT:49|mmMt:1	malignant mixed mullerian tumor:34:0.9126|Malignant mixed mullerian tumors:16:0.8165	0.9126	50
MMM	MMM:5	mass molecules:5:0.0902	0.0902	5
MMM	MMM:12	metastatic malignant melanoma:12:0.4557	0.4557	12
MMM	MMM:109	Myelofibrosis with Myeloid Metaplasia:109:0.9298	0.9298	109
MMM	MMM:9	myeloid metaplasia with myelofibrosis:9:0.6794	0.6794	9
MMNCB	MMNCB:5|MMN-CB:2	multifocal motor neuropathy with conduction block:7:0.6411	0.6411	7
MMNm	MMNm:16	mismatch negativity:16:0.8165	0.8165	16
MMN	MMN:5	medial mamillary nucleus:5:0.4422	0.4422	5
MMN	MMN:570	mismatch negativity:570:0.9915	0.9915	570
MMN	MMN:96	Multifocal motor neuropathy:96:0.9500	0.9500	96
MMOC	MMOC:5	mammary gland organ culture:5:0.4422	0.4422	5
MMOH	MMOH:8	methane monooxygenase hydroxylase:8:0.6411	0.6411	8
MMO	MMO:7	maximal mouth opening:7:0.1850	0.1850	7
MMO	MMO:6	maximum mouth opening:6:0.1148	0.1148	6
MMO	MMO:46	methane monooxygenase:46:0.8986	0.8986	46
MMP-12	MMP-12:15	macrophage elastase:15:0.8045	0.8045	15
MMP-12	MMP-12:17	macrophage metalloelastase:17:0.2788	0.2788	17
MMP-12	MMP-12:8|MMP12:1	matrix metalloproteinase-12:9:0.6794	0.6794	9
MMP-13	MMP-13:10	interstitial collagenase:10:0.2275	0.2275	10
MMP-13	MMP-13:43|MMP13:5|mmp13:2	matrix metalloproteinase-13:29:0.7581|matrix metalloproteinase 13:21:0.8594	0.8594	50
MMP-1	MMP-1:76|MMP1:1	collagenase-1:61:0.0962|collagenase 1:16:0.0821	0.0962	77
MMP-1	MMP-1:100|MMP1:4	interstitial collagenase:104:0.4443	0.4443	104
MMP-1	MMP-1:10	matrix metalloprotease-1:10:0.5856	0.5856	10
MMP-1	MMP-1:10|MMP1:1	matrix metalloproteinase:11:0.6182	0.6182	11
MMP-1	MMP-1:230|MMP1:20	matrix metalloproteinase-1:190:0.9069|matrix metalloproteinase 1:60:0.7885	0.9069	250
MMP-2	MMP-2:19|MMP2:2	gelatinase-A:21:0.0234	0.0234	21
MMP-2	MMP-2:16|MMP2:2	matrix metalloprotease-2:18:0.7539	0.7539	18
MMP-2	MMP-2:13|MMP2:1	matrix metalloproteinase:14:0.3585	0.3585	14
MMP-2	MMP-2:543|MMP2:39|Mmp2:1	matrix metalloproteinase-2:437:0.9294|matrix metalloproteinase 2:133:0.9315|Matrix metalloproteinases-2:13:0.6701	0.9315	583
MMP-2	MMP-2:25|MMP2:3	type IV collagenase:28:0.6057	0.6057	28
MMP-3	MMP-3:106|MMP3:10	matrix metalloproteinase-3:75:0.8834|matrix metalloproteinase 3:41:0.8558	0.8834	116
MMP-3	MMP-3:22|MMP3:1	stromelysin 1:23:0.6653	0.6653	23
MMP-7	MMP-7:41	Matrix metalloproteinase-7:41:0.9274	0.9274	41
MMP-8	MMP-8:18|Mmp8:1	collagenase-2:19:0.1513	0.1513	19
MMP-8	MMP-8:23	matrix metalloproteinase-8:23:0.7500	0.7500	23
MMP-8	MMP-8:38|MMP8:5	neutrophil collagenase:43:0.7363	0.7363	43
MMP-9	MMP-9:25	92-kDa gelatinase:14:0.1193|92 kDa gelatinase:11:0.7357	0.7357	25
MMP-9	MMP-9:15|MMP9:1	matrix metalloprotease-9:16:0.8165	0.8165	16
MMP-9	MMP-9:24	Matrix metalloproteinase:24:0.6240	0.6240	24
MMP-9	MMP-9:544|MMP9:27|mmp-9:2|Mmp9:1	matrix metalloproteinase-9:443:0.9093|matrix metalloproteinase 9:120:0.9138|matrix metalloproteinases-9:11:0.6182	0.9138	574
MMP-9	MMP-9:25	type IV collagenase:25:0.5722	0.5722	25
MMPI-A	MMPI-A:11	Minnesota Multiphasic Personality Inventory-Adolescent:11:0.6182	0.6182	11
MMPI-2	MMPI-2:22	Minnesota Multiphasic Personality Inventory:22:0.8657	0.8657	22
MMPI-2	MMPI-2:110|MMPI2:1	Minnesota Multiphasic Personality Inventory-2:101:0.9704|Minnesota Multiphasic Personality Inventory--2:10:0.7103	0.9704	111
MMPIs	MMPIs:13	matrix metalloproteinase inhibitors:13:0.6701	0.6701	13
MMPIs	MMPIs:18	MMP inhibitors:18:0.3168	0.3168	18
MMPI	MMPI:16|MMP-i:1|MMPi:1	matrix metalloproteinase inhibitor:18:0.8365	0.8365	18
MMPI	MMPI:548	Minnesota Multiphasic Personality Inventory:548:0.9912	0.9912	548
MMPI	MMPI:7|MMPi:2	MMP inhibitor:9:0.1327	0.1327	9
MMPR	MMPR:16	6-methylmercaptopurine riboside:16:0.5171	0.5171	16
MMPs	MMPs:9	Matrix metallo-proteinases:9:0.5470	0.5470	9
MMPs	MMPs:87|MMPS:1	matrix metalloproteases:88:0.8150	0.8150	88
MMPs	MMPs:2952|MMPS:7|MMP-s:1	matrix metalloproteinases:2926:0.9451|matrix-metalloproteinases:17:0.0049|matrix metalloproteinase:17:0.6211	0.9451	2960
MMP	MMP:54	matrix metalloprotease:34:0.6274|matrix metalloproteases:20:0.5892	0.6274	54
MMP	MMP:1351|Mmp:2	matrix metalloproteinase:952:0.9264|matrix metalloproteinases:401:0.8681	0.9264	1353
MMP	MMP:6	methadone maintenance program:6:0.5290	0.5290	6
MMP	MMP:17	microsatellite mutator phenotype:17:0.8270	0.8270	17
MMP	MMP:30	mitochondrial membrane permeabilization:30:0.9011	0.9011	30
MMP	MMP:95	mitochondrial membrane potential:95:0.8925	0.8925	95
MMP	MMP:31	Mucous membrane pemphigoid:31:0.9043	0.9043	31
MMP	MMP:10	peptides:10:0.0048	0.0048	10
MMR	MMR:14	macrophage mannose receptor:14:0.6911	0.6911	14
MMR	MMR:29	maternal mortality rate:29:0.8978	0.8978	29
MMR	MMR:38	maternal mortality ratio:38:0.9217	0.9217	38
MMR	MMR:167|M-M-R:1	measles-mumps-rubella:150:0.1110|measles/mumps/rubella:9:0.0060|measles mumps rubella:9:0.9622	0.9622	168
MMR	MMR:15	measles-mumps-rubella vaccine:15:0.2344	0.2344	15
MMR	MMR:12	midline malignant reticulosis:12:0.7571	0.7571	12
MMR	MMR:12	mild mental retardation:12:0.7571	0.7571	12
MMR	MMR:690	mismatch repair:667:0.9818|mismatch-repair:23:0.0164	0.9818	690
MMR	MMR:13	mismatch repair system:13:0.7753	0.7753	13
MMR	MMR:9	mouth-to-mouth resuscitation:9:0.6794	0.6794	9
MMR	MMR:9	mumps-measles-rubella:9:0.0060	0.0060	9
MMSE	MMSE:94	Mini-Mental State Exam:94:0.7432	0.7432	94
MMSE	MMSE:1119	Mini-Mental State Examination:886:0.7649|Mini Mental State Examination:224:0.9867|Mini-Mental-State-Examination:9:0.0054	0.9867	1119
MMSE	MMSE:30	Mini-Mental Status Exam:20:0.4201|Mini Mental Status Exam:10:0.7103	0.7103	30
MMSE	MMSE:5	minimum mean square error:5:0.4422	0.4422	5
MMSE	MMSE:9	State Evaluation:9:0.5470	0.5470	9
MMSP	MMSP:9	Malignant melanoma of soft parts:9:0.7103	0.7103	9
M-MSV	M-MSV:19|MMSV:1	Moloney murine sarcoma virus:20:0.7173	0.7173	20
MMs	MMs:27	Malignant melanomas:27:0.7425	0.7425	27
MMs	MMs:14	malignant mesotheliomas:14:0.6911	0.6911	14
MMS	MMS:37|mms:1	methyl methane sulfonate:29:0.8978|Methyl methane-sulfonate:9:0.6794	0.8978	38
MMS	MMS:9	methyl methane sulphonate:9:0.6794	0.6794	9
MMS	MMS:473	methyl methanesulfonate:473:0.9832	0.9832	473
MMS	MMS:102|mms:1	methyl methanesulphonate:103:0.9004	0.9004	103
MMS	MMS:52	methylmethane sulfonate:52:0.4798	0.4798	52
MMS	MMS:9	methylmethane sulphonate:9:0.1809	0.1809	9
MMS	MMS:37	methylmethanesulfonate:37:0.0295	0.0295	37
MMS	MMS:12	methylmethanesulphonate:12:0.0090	0.0090	12
MMS	MMS:63	Mini-Mental State:50:0.6597|Mini Mental State:13:0.6701	0.6701	63
MMS	MMS:17	Mini-Mental State Examination:17:0.5038	0.5038	17
MMS	MMS:62	Mohs micrographic surgery:62:0.6997	0.6997	62
MMS	MMS:7	multiple metabolic syndrome:7:0.5926	0.5926	7
MMTP	MMTP:13	methadone maintenance treatment program:13:0.6701	0.6701	13
MMTPs	MMTPs:9	methadone maintenance treatment programs:9:0.6794	0.6794	9
MMTS	MMTS:19	methyl methanethiosulfonate:19:0.5113	0.5113	19
MMTVs	MMTVs:14	mammary tumor viruses:14:0.7909	0.7909	14
MMTV	MMTV:707|M-MTV:1	mouse mammary tumor virus:690:0.9325|Mouse mammary tumor viruses:18:0.7539	0.9325	708
MMT	MMT:24	manual muscle test:24:0.8115	0.8115	24
MMT	MMT:37	Manual muscle testing:37:0.9197	0.9197	37
MMT	MMT:13	methadone maintenance therapy:13:0.7753	0.7753	13
MMT	MMT:76	methadone maintenance treatment:76:0.9607	0.9607	76
MMT	MMT:68	methylcyclopentadienyl manganese tricarbonyl:68:0.9306	0.9306	68
MMT	MMT:7	mixed mesodermal tumor:7:0.5926	0.5926	7
MMT	MMT:8	mixed Mullerian tumors:8:0.6411	0.6411	8
MMT	MMT:8|mmt:1	Montmorillonite:9:0.0220	0.0220	9
MMU16	MMU16:10	mouse chromosome 16:10:0.5000	0.5000	10
MMV	MMV:6	maize mosaic virus:6:0.2827	0.2827	6
MMVF	MMVF:28	man-made vitreous fibers:28:0.8369	0.8369	28
MMVF	MMVF:10	vitreous fibres:10:0.7103	0.7103	10
MMW	MMW:11	molecular weight:11:0.5355	0.5355	11
M-MuLV	M-MuLV:154|MMuLV:7|M-MulV:1	Moloney murine leukemia virus:162:0.9353	0.9353	162
mm	mm:6	circumference:6:0.0017	0.0017	6
mM	mM:18|mm:2	concentration:20:0.0041	0.0041	20
mm	mm:38	diameter:38:0.0085	0.0085	38
mm	mm:16|M-M:1	distance:17:0.0037	0.0037	17
MM	MM:328|mM:1|mm:1	malignant melanoma:294:0.8716|malignant melanomas:36:0.7433	0.8716	330
MM	MM:157	Malignant mesothelioma:146:0.8885|malignant mesotheliomas:11:0.6182	0.8885	157
MM	MM:4|Mm:4	masseter muscle:8:0.1004	0.1004	8
MM	MM:16	maternal mortality:16:0.6577	0.6577	16
MM	MM:6	meningococcal meningitis:6:0.1320	0.1320	6
MM	MM:9	Menstrual Migraine:9:0.3945	0.3945	9
MM	MM:15	mesangial matrix:15:0.5818	0.5818	15
MM	MM:11	metanephric mesenchyme:11:0.7357	0.7357	11
MM	MM:31	methadone maintenance:31:0.8090	0.8090	31
MM	MM:16	methylmercury:16:0.0033	0.0033	16
MM	MM:9|M-M:7	Michaelis-Menten:16:0.0033	0.0033	16
MM	MM:24	middle molecules:14:0.4709|middle molecule:10:0.7103	0.7103	24
MM	MM:11	minimal medium:11:0.1760	0.1760	11
MM	MM:8	Mirror movements:8:0.5006	0.5006	8
MM	MM:28|mm:1	mismatches:15:0.0030|mismatch:14:0.0028	0.0030	29
MM	MM:15	Mitochondrial myopathy:15:0.1933	0.1933	15
MM	MM:12	mixed micelles:12:0.7571	0.7571	12
MM	MM:23	Miyoshi myopathy:23:0.3808	0.3808	23
MM	MM:12	model:12:0.0024	0.0024	12
MM	MM:18|Mm:5	molecular mass:23:0.2377	0.2377	23
MM	MM:59	Molecular mechanics:59:0.9203	0.9203	59
MM	MM:2277|mm:2	multiple myeloma:2259:0.9852|multiple myelomas:20:0.8525	0.9852	2279
MM	MM:17|Mm:1	Muscle mass:18:0.1639	0.1639	18
MM	MM:11	muscularis mucosae:11:0.7357	0.7357	11
MM	MM:18	mycophenolate mofetil:18:0.8365	0.8365	18
MM	MM:13	Mycoplasma meleagridis:13:0.3331	0.3331	13
MM	MM:8	myeloid metaplasia:8:0.3463	0.3463	8
MM	MM:12	myelomeningocele:12:0.0024	0.0024	12
MM	MM:7	skeletal muscle:7:0.0692	0.0692	7
mM	mM:10|mm:4	values:14:0.0028	0.0028	14
mm	mm:9	wall thickness:9:0.1519	0.1519	9
mm	mm:8|M-M:1	width:9:0.0017	0.0017	9
MN-1695	MN-1695:9	2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate:9:0.5470	0.5470	9
MNAN	MNAN:13	methyl-n-amylnitrosamine:13:0.7500	0.7500	13
MNA	MNA:45	mean nuclear area:45:0.8964	0.8964	45
MNA	MNA:61	Mini Nutritional Assessment:61:0.9503	0.9503	61
MNA	MNA:9	MYCN amplification:9:0.5470	0.5470	9
MNA	MNA:9	N1-methylnicotinamide:9:0.0327	0.0327	9
MNB	MNB:8	C-1300 murine neuroblastoma:8:0.4102	0.4102	8
mnb	mnb:8|Mnb:3|MNB:2	minibrain:13:0.1500	0.1500	13
MNCE	MNCE:10	normochromatic erythrocytes:10:0.7103	0.7103	10
MNCPES	MNCPES:9	Minnesota Children's Pesticide Exposure Study:9:0.5470	0.5470	9
MNCV	MNCV:135|mNCV:1	motor nerve conduction velocity:136:0.9534	0.9534	136
MNC	MNC:10	micronuclei:10:0.0059	0.0059	10
MNC	MNC:14	mononuclear:14:0.0085	0.0085	14
MNC	MNC:183	mononuclear cell:183:0.8339	0.8339	183
MNC	MNC:8	mononuclear leukocytes:8:0.5006	0.5006	8
MNC	MNC:145	peripheral blood mononuclear cells:145:0.4942	0.4942	145
MND/ALS	MND/ALS:8	disease/amyotrophic lateral sclerosis:8:0.5006	0.5006	8
MND	MND:24	minor neurological dysfunction:24:0.8768	0.8768	24
MND	MND:9	Modified neck dissection:9:0.5470	0.5470	9
mnd	mnd:22|Mnd:17|MND:1	motor neuron degeneration:40:0.9256	0.9256	40
MND	MND:290	motor neuron disease:279:0.9617|motor neuron diseases:11:0.7357	0.9617	290
MND	MND:96	motor neurone disease:96:0.9192	0.9192	96
MNE	MNE:12|MN-E:1	micronucleated erythrocytes:13:0.6701	0.6701	13
MNF	MNF:18	frequency:18:0.2982	0.2982	18
MNGC	MNGC:14	multinucleated giant cells:14:0.5111	0.5111	14
MNGCs	MNGCs:10|MnGCs:1	multinucleated giant cells:11:0.7357	0.7357	11
MNGIE	MNGIE:34	mitochondrial neurogastrointestinal encephalomyopathy:34:0.8563	0.8563	34
MNG	MNG:47	multinodular goiter:38:0.7548|multinodular goiters:9:0.6794	0.7548	47
MNG	MNG:12	multinodular goitre:12:0.7571	0.7571	12
MNH	MNH:11	neostriatum/hyperstriatum ventrale:11:0.4232	0.4232	11
MNi	MNi:9|Mni:2	micronuclei:11:0.2703	0.2703	11
MNI	MNI:15	Montreal Neurological Institute:15:0.8045	0.8045	15
MNK	MNK:4|Mnk:1	Menkes disease gene:5:0.4422	0.4422	5
MNLs	MNLs:11	mononuclear leucocytes:11:0.7357	0.7357	11
MNLs	MNLs:37	mononuclear leukocytes:37:0.9197	0.9197	37
MNL	MNL:10	mononuclear cells:10:0.5856	0.5856	10
MNL	MNL:37	mononuclear leucocytes:37:0.9197	0.9197	37
MNL	MNL:155	mononuclear leukocytes:129:0.9630|mononuclear leukocyte:26:0.8861	0.9630	155
MNMS	MNMS:15	myonephropathic metabolic syndrome:15:0.8045	0.8045	15
MNNG	MNNG:27	1-methyl-3-nitro-1-nitrosoguanidine:27:0.0206	0.0206	27
MNNG	MNNG:14	N-methyl-N'-nitro-N-nitroso-guanidine:14:0.0103	0.0103	14
MNNG	MNNG:1003|MN-NG:1	N-methyl-N'-nitro-N-nitrosoguanidine:949:0.7488|N-methyl-N-nitro-N-nitrosoguanidine:48:0.0372|N-methyl-N'-nitro-N- nitrosoguanidine:7:0.1211	0.7488	1004
MNNG	MNNG:11	N-methyl-N'-nitro-nitrosoguanidine:11:0.0079	0.0079	11
MNNG	MNNG:24	N-Methyl-N'-nitrosoguanidine:15:0.0111|N-methyl-N-nitrosoguanidine:9:0.0063	0.0111	24
MNPCEs	MNPCEs:38|MnPCEs:7|MN-PCEs:3	Micronucleated polychromatic erythrocytes:48:0.8463	0.8463	48
MN-PCE	MN-PCE:13|MNPCE:12	micronucleated polychromatic erythrocytes:25:0.5496	0.5496	25
MNPT	MNPT:10	mean normal prothrombin time:10:0.7103	0.7103	10
MnP	MnP:138	manganese peroxidase:138:0.7401	0.7401	138
MNP	MNP:30	mononuclear phagocytes:30:0.9011	0.9011	30
MNP	MNP:5	spin trap 2-methyl-2-nitrosopropane:5:0.6794	0.6794	5
MNRETs	MNRETs:27|MN-RETs:3	micronucleated reticulocytes:30:0.7315	0.7315	30
MNSER	MNSER:8	mean normalized systolic ejection rate:8:0.6411	0.6411	8
MNSF	MNSF:21	Monoclonal nonspecific suppressor factor:21:0.8594	0.8594	21
MNTB	MNTB:109	medial nucleus of the trapezoid body:109:0.9728	0.9728	109
MNTI	MNTI:29	melanotic neuroectodermal tumor of infancy:29:0.8978	0.8978	29
mNTS	mNTS:5|m-NTS:1	medial nucleus of the solitary tract:6:0.3728	0.3728	6
mNTS	mNTS:14|mnTS:1	medial nucleus tractus solitarius:15:0.5564	0.5564	15
MNTX	MNTX:10	Methylnaltrexone:10:0.8182	0.8182	10
MNT	MNT:25	medical nutrition therapy:25:0.8816	0.8816	25
MNT	MNT:29	micronucleus test:29:0.3515	0.3515	29
MNT	MNT:15	mouse neutralization test:15:0.7096	0.7096	15
MNUA	MNUA:11	N-methyl-N-nitrosourea:11:0.6667	0.6667	11
MNU	MNU:45	1-methyl-1-nitrosourea:45:0.0485	0.0485	45
MNU	MNU:24	methyl nitrosourea:24:0.7593	0.7593	24
MNU	MNU:183	methylnitrosourea:183:0.1993	0.1993	183
MNU	MNU:497	N-methyl-N-nitrosourea:497:0.5463	0.5463	497
MNU	MNU:41	N-methylnitrosourea:41:0.0441	0.0441	41
MNU	MNU:17	N-nitroso-N-methylurea:17:0.0176	0.0176	17
MNV	MNV:36|mnv:1	mean nuclear volume:37:0.9197	0.9197	37
MNYC	MNYC:9	Modified New York City:9:0.6794	0.6794	9
MNZ	MNZ:25	metronidazole:25:0.8276	0.8276	25
MNase	MNase:47	Micrococcal nuclease:47:0.9006	0.9006	47
MNS	MNS:22	Milan normotensive strain:22:0.6178	0.6178	22
MNs	MNs:12	monocytes:12:0.0293	0.0293	12
MNs	MNs:76|Mns:9|mns:1|MNS:1	Motoneurons:87:0.2293	0.2293	87
MNs	MNs:24|Mns:3	motoneurones:27:0.0693	0.0693	27
MNs	MNs:41	motor neurons:41:0.8867	0.8867	41
MNS	MNS:17	nerve stimulation:17:0.8270	0.8270	17
MNS	MNS:13	normotensive controls:13:0.7753	0.7753	13
MNS	MNS:14	syndrome:14:0.0347	0.0347	14
MO2	MO2:34|Mo2:3	Oxygen consumption:37:0.7492	0.7492	37
MO2	MO2:5|Mo2:2	oxygen uptake:7:0.2452	0.2452	7
MOA	MOA:8	mode of action:8:0.1895	0.1895	8
MOBP	MOBP:10|Mobp:1	myelin-associated oligodendrocytic basic protein:11:0.5355	0.5355	11
MOB	MOB:94	main olfactory bulb:94:0.9682	0.9682	94
mob	mob:13|MOB:2	mobilization:15:0.0897	0.0897	15
MOCA	MOCA:12	4,4'-Methylene-bis(2-chloroaniline):12:0.1964	0.1964	12
MOCA	MOCA:13	4,4'-methylenebis(2-chloroaniline):13:0.2143	0.2143	13
MOCI	MOCI:14	Maudsley Obsessional-Compulsive Inventory:9:0.6794|Maudsley Obsessional Compulsive Inventory:5:0.4422	0.6794	14
MOCI	MOCI:5	Maudsley Obsessive Compulsive Inventory:5:0.4422	0.4422	5
MOCS	MOCS:9	medial olivocochlear system:9:0.6794	0.6794	9
MOCVD	MOCVD:10	chemical vapor deposition:10:0.7103	0.7103	10
MOC	MOC:31	medial olivocochlear:31:0.9043	0.9043	31
MOC	MOC:9	myositis ossificans circumscripta:9:0.6794	0.6794	9
MOC	MOC:11	oxygen consumption:11:0.4728	0.4728	11
MoDCs	MoDCs:17|moDCs:9|Mo-DCs:6|MO-DCs:1	monocyte-derived DCs:33:0.8605	0.8605	33
MoDCs	MoDCs:13|Mo-DCs:10|moDCs:6|mo-DCs:2|MO-DCs:1	monocyte-derived dendritic cells:32:0.7782	0.7782	32
MODE	MODE:6	3-methoxy-O-desmethyl encainide:6:0.2243	0.2243	6
MODY1	MODY1:9	maturity-onset diabetes of the young:9:0.4587	0.4587	9
MODY3	MODY3:12	maturity-onset diabetes of the young:12:0.4153	0.4153	12
MODY3	MODY3:11|MODY-3:1	maturity-onset diabetes of the young type 3:12:0.5589	0.5589	12
MODY	MODY:7	diabetes of young people:7:0.6794	0.6794	7
MODY	MODY:2	maturity-onset diabetes of young:2:0.7060	0.7060	2
MODS	MODS:10	multiple organ dysfunction:10:0.5856	0.5856	10
MODS	MODS:18|MODs:1	multiple organ dysfunction score:19:0.8449	0.8449	19
MODS	MODS:279	multiple organ dysfunction syndrome:279:0.9617	0.9617	279
MOD	MOD:10	magneto-optical disk:10:0.5856	0.5856	10
MOD	MOD:5	Maturity onset diabetes:5:0.4422	0.4422	5
MOD	MOD:23|mOD:1	Mean optical density:24:0.7593	0.7593	24
MOD	MOD:36	Multiple organ dysfunction:36:0.8716	0.8716	36
MOET	MOET:2	multiple ovulation embryo transfer:2:0.7909	0.7909	2
MOE	MOE:12	main olfactory epithelium:12:0.7571	0.7571	12
MOE	MOE:7	margin of exposure:7:0.2902	0.2902	7
MOE	MOE:9	massive ovarian edema:9:0.6794	0.6794	9
MOFs	MOFs:8	metal-organic frameworks:8:0.5006	0.5006	8
MOFS	MOFS:22	multiple organ failure syndrome:22:0.7955	0.7955	22
MOF	MOF:11	Methoxyflurane:11:0.0193	0.0193	11
MOF	MOF:374	multiple organ failure:374:0.9416	0.9416	374
MOG	MOG:238|Mog:1	myelin oligodendrocyte glycoprotein:239:0.9336	0.9336	239
MOH	MOH:9	medication overuse headache:9:0.6794	0.6794	9
MOH	MOH:108|MoH:18|MOh:1	Ministry of Health:127:0.8733	0.8733	127
MOIs	MOIs:28|mois:2	multiplicities of infection:30:0.9011	0.9011	30
MOI	MOI:11|moi:3	different multiplicities of infection:14:0.1124	0.1124	14
MOI	MOI:8	Mechanism of Injury:8:0.3463	0.3463	8
MOI	MOI:269|moi:29	multiplicity of infection:298:0.7855	0.7855	298
MOL	MOL:11	Muscle of Lawrence:11:0.7357	0.7357	11
MOMPs	MOMPs:12	major outer membrane proteins:12:0.7571	0.7571	12
MOMP	MOMP:239|momp:1	major outer membrane protein:240:0.9734	0.9734	240
MONICA	MONICA:12	MONItoring Trends and Determinants in CArdiovascular Disease:12:0.9217	0.9217	12
MOPD	MOPD:8	microcephalic osteodysplastic primordial dwarfism:8:0.6794	0.6794	8
MOPEG	MOPEG:9	3-methoxy-4-hydroxyphenylethylene glycol:9:0.2500	0.2500	9
MOPEG	MOPEG:11	3-methoxy-4-hydroxyphenylethyleneglycol:11:0.1887	0.1887	11
MOPEG	MOPEG:13	3-methoxy-4-hydroxyphenylglycol:13:0.2264	0.2264	13
MOPH	MOPH:15	Ministry of Public Health:15:0.8045	0.8045	15
MOPP	MOPP:7	combination chemotherapy:7:0.0828	0.0828	7
MOP	MOP:10	8-methoxypsoralen:10:0.0662	0.0662	10
MOR-LI	MOR-LI:12	immunoreactivity:12:0.9167	0.9167	12
MOR1	MOR1:13|MOR-1:6	mu-opioid receptor:19:0.4618	0.4618	19
MORs	MORs:16	mu-opioid receptors:16:0.4274	0.4274	16
MOS-HIV	MOS-HIV:15	Medical Outcomes Study HIV Health Survey:15:0.8045	0.8045	15
MOSES	MOSES:9	Multidimensional Observation Scale for Elderly Subjects:9:0.5000	0.5000	9
MOSF	MOSF:21	multiple organ system failure:21:0.7955	0.7955	21
MOSFET	MOSFET:14	metal oxide semiconductor field effect transistor:14:0.6911	0.6911	14
MOs	MOs:12|Mos:9|mos:2	macrophages:23:0.0681	0.0681	23
MOS	MOS:6	main olfactory system:6:0.5290	0.5290	6
MOS	MOS:91	Medical Outcomes Study:91:0.9479	0.9479	91
MOs	MOs:10|Mos:5	monocytes:15:0.0433	0.0433	15
MOs	MOs:13	morpholino oligonucleotides:13:0.5335	0.5335	13
MOTSA	MOTSA:6	Multiple overlapping thin slab acquisition:6:0.5290	0.5290	6
MOTT	MOTT:35	mycobacteria other than tuberculosis:35:0.6666	0.6666	35
MOUDI	MOUDI:7	uniform deposit impactor:7:0.5926	0.5926	7
MOU	MOU:13	Memorandum of Understanding:13:0.5335	0.5335	13
MOVC	MOVC:13	membranous obstruction of the inferior vena cava:13:0.7753	0.7753	13
MOV	MOV:6	mean ovarian volume:6:0.2827	0.2827	6
MOX	MOX:9|Mox:1	methanol oxidase:10:0.7103	0.7103	10
MOX	MOX:12	moxidectin:12:0.1146	0.1146	12
MOX	MOX:6|Mox:3	moxonidine:9:0.0833	0.0833	9
MP-11	MP-11:7|MP11:3	microperoxidase-11:10:0.6667	0.6667	10
mP2	mP2:8	Mouse protamine 2:8:0.6411	0.6411	8
MP2	MP2:5	Second-order Moller-Plesset perturbation theory:5:0.2818	0.2818	5
MP8	MP8:11|MP-8:8|mp8:1	microperoxidase-8:11:0.3929|Microperoxidase 8:9:0.5470	0.5470	20
MPAG	MPAG:8	glucuronide metabolite:8:0.5006	0.5006	8
MPAG	MPAG:23	mycophenolic acid glucuronide:23:0.8715	0.8715	23
MPAP	MPAP:96|mPAP:75|m-PAP:1	mean pulmonary arterial pressure:172:0.9389	0.9389	172
MPAP	MPAP:149|mPAP:62|MpaP:1|m-PAP:1|MPaP:1	mean pulmonary artery pressure:214:0.9568	0.9568	214
MPAs	MPAs:12	marine protected areas:12:0.7357	0.7357	12
MPAs	MPAs:20	minor physical anomalies:20:0.8525	0.8525	20
MPA	MPA:24	activity:24:0.0089	0.0089	24
MPA	MPA:34	Maclura pomifera:34:0.7898	0.7898	34
MPA	MPA:25	Maclura pomifera agglutinin:25:0.8816	0.8816	25
MPA	MPA:54|mPA:2	main pulmonary artery:56:0.8689	0.8689	56
mPA	mPA:6|MPA:1	mean pulmonary arterial pressure:7:0.5926	0.5926	7
MPA	MPA:58	medial preoptic area:58:0.8937	0.8937	58
MPA	MPA:34	Medroxyprogesterone:34:0.0128	0.0128	34
MPA	MPA:1147	medroxyprogesterone acetate:1147:0.9020	0.9020	1147
MPa	MPa:27	megapascals:27:0.0101	0.0101	27
MPA	MPA:17|mPA:3	microscopic polyarteritis:20:0.7766	0.7766	20
MPA	MPA:11	Minor physical anomalies:11:0.7357	0.7357	11
MPA	MPA:7	multiprobe assembly:7:0.2902	0.2902	7
MPA	MPA:384|mPA:1	Mycophenolic acid:385:0.7688	0.7688	385
MPA	MPA:5	peak amplitude:5:0.1132	0.1132	5
MPB	MPB:10	male pattern baldness:10:0.7571	0.7571	10
MPB	MPB:32|mPB:9	mobilized peripheral blood:41:0.7057	0.7057	41
MPCA	MPCA:12|mPCA:1	procoagulant activity:13:0.7753	0.7753	13
MPCE	MPCE:16|mPCE:1	micronucleated polychromatic erythrocytes:17:0.7407	0.7407	17
mPCR	mPCR:12|M-PCR:7|MPCR:5|m-PCR:2	multiplex PCR:26:0.7760	0.7760	26
MPCR	MPCR:11|M-PCR:9|mPCR:9|m-PCR:6	multiplex polymerase chain reaction:35:0.6883	0.6883	35
MPCs	MPCs:16	mesenchymal progenitor cells:16:0.3643	0.3643	16
MPC	MPC:64	2-methacryloyloxyethyl phosphorylcholine:64:0.8632	0.8632	64
MPC	MPC:21	maximum permissible concentration:21:0.7865	0.7865	21
MPC	MPC:8	mean platelet component:8:0.6411	0.6411	8
MPC	MPC:35	medial prefrontal cortex:35:0.9151	0.9151	35
MPC	MPC:5	mesenchymal progenitor cells:5:0.0902	0.0902	5
MPC	MPC:7	model predictive control:7:0.3524	0.3524	7
MPC	MPC:7	mouse plasmacytoma:7:0.2113	0.2113	7
MPC	MPC:23	multicatalytic proteinase complex:23:0.8715	0.8715	23
MPC	MPC:12	multiple primary cancer:12:0.7571	0.7571	12
mpc	mpc:13|MPC:4	muscle precursor cells:17:0.5374	0.5374	17
MPC	MPC:26	mutant prevention concentration:26:0.8251	0.8251	26
MPC	MPC:10	partially thiolated polycytidylic acid:10:0.7103	0.7103	10
m-PDA	m-PDA:7|mPDA:4|MPDA:2	m-phenylenediamine:13:0.5455	0.5455	13
MPDs	MPDs:52	myeloproliferative disorders:52:0.9099	0.9099	52
MPDS	MPDS:9	myofascial pain dysfunction syndrome:9:0.5000	0.5000	9
MPD	MPD:26	2-methyl-2,4-pentanediol:26:0.0311	0.0311	26
MPD	MPD:83	main pancreatic duct:83:0.9636	0.9636	83
MPD	MPD:5	maximum population density:5:0.4422	0.4422	5
MPD	MPD:35	methylphenidate:35:0.0411	0.0411	35
MPD	MPD:15	mevalonate pyrophosphate decarboxylase:15:0.8045	0.8045	15
MPD	MPD:34	minimal phototoxic dose:34:0.7306	0.7306	34
MPD	MPD:73	multiple personality disorder:73:0.9353	0.9353	73
MPD	MPD:44	myeloproliferative disease:26:0.5218|myeloproliferative diseases:18:0.7539	0.7539	44
MPD	MPD:222	myeloproliferative disorders:159:0.9106|myeloproliferative disorder:63:0.3646	0.9106	222
MPD	MPD:40	myofascial pain dysfunction:22:0.5863|myofascial pain-dysfunction:18:0.6903	0.6903	40
mPD	mPD:5	prescribed minimal peripheral dose:5:0.1132	0.1132	5
MPEP	MPEP:26	antagonist 2-methyl-6-(phenylethynyl)-pyridine:18:0.3586|antagonist 2-methyl-6-(phenylethynyl)pyridine:8:0.3813	0.3813	26
MPEP	MPEP:4	antagonist 2-methyl-6-(phenylethynyl) pyridine hydrochloride:4:0.3170	0.3170	4
MPE	MPE:37	Malignant pleural effusion:21:0.7865|malignant pleural effusions:16:0.8165	0.8165	37
MPE	MPE:19	massive pulmonary embolism:19:0.8449	0.8449	19
MPE	MPE:11	maximum permissible exposure:11:0.7357	0.7357	11
MPE	MPE:6	maximum possible effect:6:0.2243	0.2243	6
MPE	MPE:14|mpe:5	mean prediction error:19:0.7766	0.7766	19
MPE	MPE:12	micronucleated polychromatic erythrocytes:12:0.7571	0.7571	12
MPFF	MPFF:20	purified flavonoid fraction:20:0.8449	0.8449	20
MPFL	MPFL:13	medial patellofemoral ligament:13:0.7753	0.7753	13
MPF	MPF:57	M-phase promoting factor:57:0.2177	0.2177	57
Mpf	Mpf:13|mpf:1	mating pair formation:14:0.7909	0.7909	14
MPF	MPF:239|Mpf:1	maturation-promoting factor:127:0.2743|maturation promoting factor:113:0.4976	0.4976	240
MPF	MPF:161|mpf:2	mean power frequency:163:0.8797	0.8797	163
MPGN	MPGN:291	membranoproliferative glomerulonephritis:291:0.8341	0.8341	291
MPGN	MPGN:19	membranoproliferative GN:19:0.5732	0.5732	19
MPG	MPG:42	2-mercaptopropionylglycine:42:0.1192	0.1192	42
MPG	MPG:20	major pelvic ganglia:20:0.8525	0.8525	20
MPG	MPG:36	major pelvic ganglion:36:0.9174	0.9174	36
MPG	MPG:40	N-(2-mercaptopropionyl)-glycine:22:0.0610|N-2-mercaptopropionyl glycine:18:0.2860	0.2860	40
MPG	MPG:31	N-methylpurine-DNA glycosylase:31:0.5414	0.5414	31
MPG	MPG:4|mPG:2	pressure gradient:6:0.1320	0.1320	6
MPHD	MPHD:43|M-PHD:2	multiple pituitary hormone deficiency:25:0.8186|multiple pituitary hormone deficiencies:20:0.8525	0.8525	45
MPI	MPI:22	Mannheim Peritonitis Index:22:0.6934	0.6934	22
MPI	MPI:14|Mpi:3	mannose phosphate isomerase:17:0.8270	0.8270	17
MPI	MPI:32	Maudsley Personality Inventory:32:0.7166	0.7166	32
MPI	MPI:18	mucus proteinase inhibitor:18:0.6211	0.6211	18
MPI	MPI:36	Multidimensional Pain Inventory:36:0.9151	0.9151	36
MPI	MPI:61	myocardial performance index:61:0.8770	0.8770	61
MPI	MPI:96	myocardial perfusion imaging:96:0.9689	0.9689	96
MPLM	MPLM:12|MP-LM:1	myenteric plexus-longitudinal muscle:13:0.7753	0.7753	13
MPLV	MPLV:13	myeloproliferative leukemia virus:13:0.7753	0.7753	13
MPL	MPL:9	mass-per-length:9:0.0488	0.0488	9
MPL	MPL:25|Mpl:1|mPL:1	methylprednisolone:27:0.1585	0.1585	27
Mpl	Mpl:8|mpl:2|MPL:1	thrombopoietin receptor:11:0.4102	0.4102	11
MPL	Mpl:2|MPL:2	TPO receptor:4:0.0611	0.0611	4
MPMV	MPMV:75|M-PMV:42|M--PMV:1	Mason-Pfizer monkey virus:118:0.9344	0.9344	118
MPMs	MPMs:18	mouse peritoneal macrophages:18:0.6903	0.6903	18
MPM	MPM:130	malignant pleural mesothelioma:130:0.9633	0.9633	130
MPM	MPM:11	minor psychiatric morbidity:11:0.7357	0.7357	11
MPM	MPM:8	Mortality Prediction Model:8:0.6411	0.6411	8
MPM	MPM:7	Mortality Probability Model:7:0.5926	0.5926	7
MPM	MPM:85	mouse peritoneal macrophages:85:0.7667	0.7667	85
MPNSTs	MPNSTs:48	malignant peripheral nerve sheath tumors:48:0.9379	0.9379	48
MPNST	MPNST:162|mpnst:1	Malignant peripheral nerve sheath tumor:80:0.9408|malignant peripheral nerve sheath tumors:49:0.9392|malignant peripheral nerve sheath tumour:20:0.8525|malignant peripheral nerve sheath tumours:14:0.7909	0.9408	163
MPNc	MPNc:10	medial preoptic nucleus:10:0.7103	0.7103	10
MPN	MPN:9	4-O-methylpyridoxine:9:0.0180	0.0180	9
MPN	MPN:11|mPN:2	male pronucleus:13:0.7753	0.7753	13
MPN	MPN:97	medial preoptic nucleus:97:0.9352	0.9352	97
MPN	MPN:8|Mpn:1|MPn:1	methylprednisolone:10:0.0202	0.0202	10
MPN	MPN:7	modulatory proctolin neuron:7:0.5926	0.5926	7
MPN	MPN:47	Most-probable-number:47:0.1034	0.1034	47
MPN	MPN:158	probable number:158:0.9257	0.9257	158
MPOA-AH	MPOA-AH:10	medial preoptic-anterior hypothalamus:10:0.7103	0.7103	10
MPOA-AH	MPOA-AH:11	medial preoptic area-anterior hypothalamus:11:0.7357	0.7357	11
MPOD	MPOD:10	macular pigment optical density:10:0.7103	0.7103	10
MPO	MPO:43	anti-myeloperoxidase:43:0.0150	0.0150	43
MPO	MPO:13	antimyeloperoxidase:13:0.0043	0.0043	13
MPO	MPO:10	medial preoptic:10:0.5000	0.5000	10
MPO	MPO:94|mPO:2	medial preoptic area:96:0.9064	0.9064	96
MPO	MPO:14	medial preoptic nucleus:14:0.5589	0.5589	14
MPO	MPO:2362|Mpo:2|mpo:1	myeloperoxidase:2365:0.8458	0.8458	2365
MPO	MPO:62	myeloperoxidase activity:62:0.8788	0.8788	62
MPO	MPO:21	power output:21:0.7291	0.7291	21
MPO	MPO:5	release of mast cell peroxidase:5:0.3728	0.3728	5
MPP(+)	MPP(+):50	1-methyl-4-phenylpyridinium:50:0.4050	0.4050	50
MPP(+)	MPP(+):29	1-methyl-4-phenylpyridinium ion:29:0.5940	0.5940	29
MPP+	MPP+:17	1-methyl-4-phenyl-pyridinium:17:0.0230	0.0230	17
MPP+	MPP+:273|Mpp+:1	1-methyl-4-phenylpyridinium:274:0.3865	0.3865	274
MPP+	MPP+:6	1-methyl-4-phenylpyridinium cation:6:0.1543	0.1543	6
MPP+	MPP+:164|Mpp+:1	1-methyl-4-phenylpyridinium ion:165:0.5992	0.5992	165
MPP+	MPP+:7	metabolite 1-methyl-4-phenylpyridine:7:0.0578	0.0578	7
MPP+	MPP+:21	N-methyl-4-phenylpyridinium:21:0.0302	0.0302	21
MPPG	MPPG:9	(RS)-alpha-methyl-4-phosphonophenylglycine:9:0.2667	0.2667	9
MPPT	MPPT:10	pulse therapy:10:0.7103	0.7103	10
MPP	MPP:15	Massive periretinal proliferation:15:0.8045	0.8045	15
MPP	MPP:18|mPP:1	medial perforant path:19:0.8449	0.8449	19
MPP	MPP:64	mitochondrial processing peptidase:64:0.7553	0.7553	64
MPP	MPP:17	pressure:17:0.0625	0.0625	17
MPQ	MPQ:157	McGill Pain Questionnaire:157:0.9333	0.9333	157
mPRF	mPRF:39	medial pontine reticular formation:39:0.9237	0.9237	39
MP-RAGE	MP-RAGE:7	magnetization-prepared rapid gradient-echo:7:0.3524	0.3524	7
MP-RAGE	MP-RAGE:6|MPRAGE:2	rapid acquisition gradient-echo:8:0.6411	0.6411	8
MPRs	MPRs:31	mannose 6-phosphate receptors:31:0.9043	0.9043	31
MPRs	MPRs:8|MPRS:1	multiplanar reconstructions:9:0.6794	0.6794	9
MPR	MPR:5	cation-independent mannose-6-phosphate receptor:5:0.1132	0.1132	5
MPR	MPR:18|MP-R:1|Mpr:1	mannose 6-phosphate receptor:20:0.7766	0.7766	20
MPR	MPR:14	Medication Possession Ratio:14:0.6911	0.6911	14
MPR	MPR:13	mouse prostate reconstitution:13:0.7753	0.7753	13
MPR	MPR:14	Multiplanar:14:0.0335	0.0335	14
MPR	MPR:88	multiplanar reconstruction:70:0.7379|multiplanar reconstructions:18:0.6381	0.7379	88
MPR	MPR:38	multiplanar reformation:27:0.8312|multiplanar reformations:11:0.3470	0.8312	38
MPR	MPR:11	multiplanar reformatted:11:0.7357	0.7357	11
MPR	MPR:15	myocardial perfusion reserve:15:0.8045	0.8045	15
MPR	MPR:5	production rate:5:0.0517	0.0517	5
mPSCs	mPSCs:14|MPSCs:7	miniature postsynaptic currents:21:0.7865	0.7865	21
mPSL	mPSL:23|MPSL:10|m-PSL:9|M-PSL:2	methylprednisolone:44:0.8600	0.8600	44
MPSVII	MPSVII:10	mucopolysaccharidosis type VII:10:0.5856	0.5856	10
MPSV	MPSV:54	myeloproliferative sarcoma virus:54:0.9448	0.9448	54
MPSS	MPSS:25	massively parallel signature sequencing:25:0.7679	0.7679	25
MPSS	MPSS:10	methylprednisolone:10:0.0677	0.0677	10
MPSS	MPSS:58	Methylprednisolone sodium succinate:58:0.8710	0.8710	58
MPS	MPS:7	acid mucopolysaccharides:7:0.0622	0.0622	7
MPS	MPS:4	cells of the mononuclear phagocyte series:4:0.2818	0.2818	4
MPS	MPS:15	Macular Photocoagulation Study:15:0.8045	0.8045	15
MPs	MPs:5	membrane potentials:5:0.0612	0.0612	5
MPs	MPs:9	membrane proteins:9:0.0783	0.0783	9
MPs	MPs:13	metalloproteinases:13:0.0114	0.0114	13
MPS	MPS:26|mps:1	methylprednisolone:27:0.0247	0.0247	27
MPS	MPS:8	methylprednisolone sodium succinate:8:0.5006	0.5006	8
MPs	MPs:24|mps:1	microparticles:25:0.0228	0.0228	25
MPs	MPs:23|MPS:2	mononuclear phagocytes:25:0.8186	0.8186	25
MPS	MPS:133	mononuclear phagocyte system:133:0.9641	0.9641	133
MPS	MPS:56	mononuclear phagocytic system:56:0.8901	0.8901	56
MPs	MPs:5	motor potentials:5:0.0612	0.0612	5
MPs	MPs:24	movement proteins:24:0.4467	0.4467	24
MPS	MPS:64	mucopolysaccharidoses:64:0.0590	0.0590	64
MPS	MPS:9	Multidimensional Perfectionism Scale:9:0.6794	0.6794	9
MPs	MPs:11	muramyl peptides:11:0.7357	0.7357	11
MPS	MPS:7	myeloproliferative syndromes:7:0.3524	0.3524	7
MPS	MPS:16	myocardial perfusion scintigraphy:16:0.7261	0.7261	16
MPS	MPS:5	myocardial perfusion single-photon emission computed tomography:5:0.4422	0.4422	5
MPS	MPS:10	Myocardial perfusion SPECT:10:0.5856	0.5856	10
MPS	MPS:32	myofascial pain syndrome:32:0.9072	0.9072	32
MPS	MPS:13	patients with mucopolysaccharidosis:13:0.0588	0.0588	13
MPs	MPs:8|Mps:2	peritoneal macrophages:10:0.1385	0.1385	10
MPS	MPS:12	protein synthesis:12:0.6460	0.6460	12
MPTP	MPTP:11	1,2,3,6-tetrahydropyridine:11:0.0061	0.0061	11
MPTP	MPTP:1269	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine:1248:0.7483|1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine:11:0.1486|1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine:10:0.1223	0.7483	1269
MPTP	MPTP:37	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine:37:0.0208	0.0208	37
MPTP	MPTP:35|mPTP:19|MPTp:2	mitochondrial permeability transition pore:56:0.9162	0.9162	56
MPTP	MPTP:21	neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine:21:0.1443	0.1443	21
MPT	MPT:25	maximum phonation time:25:0.7249	0.7249	25
MPT	MPT:6	methylprednisolone pulse therapy:6:0.5290	0.5290	6
MPT	MPT:244|mPT:21	mitochondrial permeability transition:265:0.8203	0.8203	265
MPT	MPT:29	molybdopterin:29:0.0467	0.0467	29
MPT	MPT:19|MP-T:1	Munich Personality Test:20:0.8365	0.8365	20
MPT	MPT:6	primary cultures of mouse proximal tubular:6:0.5290	0.5290	6
MPV	MPV:12	main portal vein:12:0.6460	0.6460	12
MPV	MPV:6	Mason-Pfizer virus:6:0.0807	0.0807	6
MPV	MPV:5	maximum peak velocity:5:0.1973	0.1973	5
MPV	MPV:169	Mean platelet volume:169:0.8898	0.8898	169
MPV	MPV:8	Monkeypox virus:8:0.1895	0.1895	8
MPX	MPX:11	1-methyl-3-propylxanthine:11:0.4000	0.4000	11
MPZ	MPZ:6	myelin protein zero gene:6:0.3728	0.3728	6
MP	MP:14|mp:1	3-mercaptopropionic acid:15:0.8045	0.8045	15
MP	MP:14	6-mercaptopurine:14:0.0044	0.0044	14
MP	MP:17	machine perfusion:17:0.3512	0.3512	17
MP	MP:10|Mp:1	macrophage:11:0.0034	0.0034	11
MP	MP:32	macular pigment:32:0.7782	0.7782	32
MP	MP:8|mp:1	main process:9:0.3455	0.3455	9
MP	MP:16	mannoprotein:16:0.0051	0.0051	16
MP	MP:23	mastoparan:23:0.0074	0.0074	23
MP	MP:12	Matching pursuit:12:0.7571	0.7571	12
MP	MP:62	maximum parsimony:49:0.9046|maximum-parsimony:13:0.0041	0.9046	62
MP	MP:11	meconium peritonitis:11:0.6182	0.6182	11
MP	MP:30	Melphalan and prednisone:30:0.5652	0.5652	30
MP	MP:10|M-P:1	melphalan-prednisone:11:0.0034	0.0034	11
mp	mp:3|MP:2	melting points:5:0.1132	0.1132	5
MP	MP:93|mp:1	membrane potential:83:0.6287|membrane potentials:11:0.3213	0.6287	94
MP	MP:28	mercaptopurine:28:0.0091	0.0091	28
MP	MP:78	metacarpophalangeal:78:0.0260	0.0260	78
MP	MP:11	metalloproteinase:11:0.0034	0.0034	11
MP	MP:16|M-P:1	metatarsophalangeal:17:0.0054	0.0054	17
MP	MP:21	methapyrilene:21:0.0068	0.0068	21
MP	MP:20	Methyl palmoxirate:20:0.8525	0.8525	20
MP	MP:30	methyl parathion:30:0.9011	0.9011	30
MP	MP:10	methyl prednisolone:10:0.3867	0.3867	10
MP	MP:29	methylphenidate:29:0.0095	0.0095	29
MP	MP:11	methylphosphonate:11:0.0034	0.0034	11
MP	MP:533|M-P:2|mp:1|Mp:1	methylprednisolone:537:0.1812	0.1812	537
MP	MP:19	methylprednisolone sodium succinate:19:0.8449	0.8449	19
MP	MP:24	micronized progesterone:24:0.8816	0.8816	24
MP	MP:49|mp:2	microparticles:41:0.0135|microparticle:10:0.0030	0.0135	51
MP	MP:9|mp:1	microperoxidase:10:0.0030	0.0030	10
MP	MP:8	micturition pressure:8:0.0825	0.0825	8
MP	MP:16	migration percentage:16:0.8165	0.8165	16
MP	MP:10	mitral prolapse:10:0.7103	0.7103	10
MP	MP:29	Mononuclear phagocytes:29:0.8978	0.8978	29
MP	MP:10	monopolar:10:0.0030	0.0030	10
MP	MP:22	motor potential:22:0.1106	0.1106	22
MP	MP:151	movement protein:151:0.6625	0.6625	151
mp	mp:8|MP:3	muscularis propria:11:0.7357	0.7357	11
MP	MP:5	mycoplasma pneumoniae pneumonia:5:0.4422	0.4422	5
MP	MP:35|Mp:11|mp:1	Mycoplasma pneumoniae:47:0.9366	0.9366	47
MP	MP:14	myeloperoxidase:14:0.0044	0.0044	14
MP	MP:11	myenteric plexus:11:0.5355	0.5355	11
MP	MP:12	myocardial perfusion:12:0.1907	0.1907	12
MP	MP:12	myosin phosphatase:12:0.6460	0.6460	12
MP	MP:9	peptide:9:0.0027	0.0027	9
MP	MP:12	peritoneal macrophages:12:0.1299	0.1299	12
MP	MP:18	proteins:18:0.0057	0.0057	18
MQMAS	MQMAS:8	magic angle spinning:8:0.6411	0.6411	8
MQMAS	MQMAS:8	multiple-quantum magic-angle spinning:8:0.5006	0.5006	8
MQOL	MQOL:12	McGill Quality of Life Questionnaire:12:0.7571	0.7571	12
MQSA	MQSA:16	Mammography Quality Standards Act:16:0.8165	0.8165	16
MQSA	MQSA:9	Mammography Quality Standards Act of 1992:9:0.6794	0.6794	9
MQ	MQ:7	Maastricht Questionnaire:7:0.1641	0.1641	7
MQ	MQ:45	Mefloquine:45:0.3099	0.3099	45
MQ	MQ:19	multiple-quantum:10:0.0634|multiple quantum:9:0.6794	0.6794	19
MR/DD	MR/DD:7	mental retardation/developmental disabilities:7:0.5926	0.5926	7
MR/Har	MR/Har:15	Maudsley reactive:15:0.8045	0.8045	15
MR1	MR1:5|MR-1:1	anti-CD40L mAb:6:0.1543	0.1543	6
MR1	MR1:9|MR-1:1	antibody:10:0.1837	0.1837	10
MRAG	MRAG:10	modified rat male accessory glands:10:0.5856	0.5856	10
MRAP	MRAP:10|mRAP:5	mean right atrial pressure:15:0.7096	0.7096	15
MRA	MRA:14	activity:14:0.0078	0.0078	14
MRA	MRA:12	magnetic resonance angiogram:12:0.7571	0.7571	12
MRA	MRA:10	magnetic resonance angiographic:10:0.7103	0.7103	10
MRA	MRA:972|MR-A:2	magnetic resonance angiography:974:0.9795	0.9795	974
MRA	MRA:9	magnetic resonance arteriography:9:0.6794	0.6794	9
MRA	MRA:11|MRa:3	magnetic resonance arthrography:14:0.7909	0.7909	14
MRA	MRA:14	malignant rheumatoid arthritis:14:0.7909	0.7909	14
MRA	MRA:20	marrow repopulating ability:12:0.7571|marrow-repopulating ability:8:0.1367	0.7571	20
MRA	MRA:16|MrA:2	mesenteric resistance arteries:18:0.8365	0.8365	18
MRA	MRA:341	MR angiography:325:0.2206|MR-angiography:16:0.0090	0.2206	341
MRA	MRA:6|MRa:1	MR arthrography:7:0.0828	0.0828	7
MRA	MRA:22	Multiple regression analysis:22:0.5863	0.5863	22
MRA	MRA:13	risk assessment:13:0.6701	0.6701	13
MRBC	MRBC:9	mouse erythrocytes:9:0.4587	0.4587	9
MRBC	MRBC:31|mRBC:1	red blood cells:23:0.8715|red blood cell:9:0.6794	0.8715	32
MRBF	MRBF:8	mean renal blood flow:8:0.4102	0.4102	8
MRB	MRB:13	bacteria:13:0.2727	0.2727	13
MRC-5	MRC-5:8	fibroblast cells:8:0.2327	0.2327	8
MRC-5	MRC-5:9|MRC5:2	Human lung fibroblasts:11:0.2280	0.2280	11
MRC-5	MRC-5:4|MRC5:2	lung fibroblast:6:0.0731	0.0731	6
MRCC	MRCC:24|mRCC:10	metastatic renal cell carcinoma:34:0.8644	0.8644	34
MRCNS	MRCNS:12|MR-CNS:3|MRC-NS:1	Methicillin-resistant coagulase-negative Staphylococci:16:0.6024	0.6024	16
MRCPs	MRCPs:33	movement-related cortical potentials:33:0.8196	0.8196	33
MRCP	MRCP:6|MR-CP:1	Magnetic resonance cholangiography:7:0.5926	0.5926	7
MRCP	MRCP:214	Magnetic resonance cholangiopancreatography:214:0.9859	0.9859	214
MRCP	MRCP:20	movement-related cortical potentials:10:0.5856|movement-related cortical potential:10:0.5000	0.5856	20
MRCP	MRCP:99	MR cholangiopancreatography:99:0.2783	0.2783	99
MRCs	MRCs:13	mitochondria-rich cells:13:0.5934	0.5934	13
MRC	MRC:67	Magnetic resonance cholangiography:67:0.9554	0.9554	67
MRC	MRC:10	magnetic resonance colonography:10:0.7103	0.7103	10
MRC	MRC:205	Medical Research Council:205:0.9854	0.9854	205
MRC	MRC:13	mitochondria-rich cells:13:0.4102	0.4102	13
MRC	MRC:33	mitochondrial respiratory chain:33:0.8605	0.8605	33
MRC	MRC:20	MR cholangiography:20:0.1379	0.1379	20
MRDM	MRDM:19	malnutrition-related diabetes mellitus:19:0.5404	0.5404	19
MRDR	MRDR:30	modified relative dose response:21:0.8594|modified-relative-dose-response:9:0.2000	0.8594	30
MRDSA	MRDSA:6|MR-DSA:4	digital subtraction angiography:10:0.5000	0.5000	10
MRD	MRD:11	magnetic relaxation dispersion:11:0.7357	0.7357	11
MrD	MrD:13	marginal division:13:0.7753	0.7753	13
MRD	MRD:653	minimal residual disease:653:0.9715	0.9715	653
MRD	MRD:7	modified Robbins Device:7:0.4438	0.4438	7
MRD	MRD:13	rate of depolarization:13:0.7753	0.7753	13
MREE	MREE:8	measured resting energy expenditure:8:0.6182	0.6182	8
MREIT	MREIT:21|MR-EIT:3	magnetic resonance electrical impedance tomography:24:0.8657	0.8657	24
MRE	MRE:9	elements:9:0.0584	0.0584	9
MRE	MRE:25	magnetic resonance elastography:25:0.8816	0.8816	25
MRE	MRE:13	metal response element:13:0.5664	0.5664	13
MRFD	MRFD:9	rate of force development:9:0.5470	0.5470	9
MRFIT	MRFIT:145	Multiple Risk Factor Intervention Trial:145:0.9792	0.9792	145
MRFs	MRFs:56	myogenic regulatory factors:56:0.7003	0.7003	56
MRF	MRF:14	Markov random field:14:0.7909	0.7909	14
mRF	mRF:20|MRF:5	monoclonal rheumatoid factor:18:0.6903|monoclonal rheumatoid factors:7:0.5926	0.6903	25
MRF	MRF:8	muscle regulatory factor:8:0.1471	0.1471	8
MRF	MRF:15	myogenic regulatory factor:10:0.2446|myogenic regulatory factors:5:0.1132	0.2446	15
MRF	MRF:196|mRF:3|mRf:1|mrf:1|MRf:1	reticular formation:202:0.9686	0.9686	202
MRHA	MRHA:24	mannose-resistant haemagglutination:24:0.7151	0.7151	24
MRHA	MRHA:22|MR-HA:1	Mannose-resistant hemagglutination:23:0.7046	0.7046	23
MRH	MRH:14	Multicentric reticulohistiocytosis:14:0.7753	0.7753	14
MRI	MRI:73	magnetic resonance:73:0.8961	0.8961	73
MRI	MRI:500	magnetic resonance images:262:0.9886|Magnetic resonance image:238:0.9874	0.9886	500
MRI	MRI:11	magnetic resonance imagery:11:0.7357	0.7357	11
MRI	MRI:17531|MRi:1	magnetic resonance imaging:17519:0.9943|Magnetic resonance imagings:13:0.7753	0.9943	17532
MRI	MRI:8	Magnetic resonance imaging scan:8:0.6411	0.6411	8
MRI	MRI:24	magnetic resonance tomography:24:0.8768	0.8768	24
MRI	MRI:9	Research Institute:9:0.7103	0.7103	9
MRKH	MRKH:17	Mayer-Rokitansky-Kuster-Hauser:17:0.7273	0.7273	17
MRL/l	MRL/l:32	MRL/Mp-lpr/lpr:32:0.4769	0.4769	32
MRLC	MRLC:23	myosin regulatory light chain:23:0.5236	0.5236	23
MRLs	MRLs:15	maximum residue levels:15:0.7096	0.7096	15
MRLs	MRLs:11	minimal risk levels:11:0.7357	0.7357	11
MRL	MRL:15	maximum residue level:15:0.6386	0.6386	15
MRL	MRL:55	maximum residue limit:39:0.8811|maximum residue limits:16:0.8165	0.8811	55
MRM	MRM:15|MR-M:1	magnetic resonance mammography:16:0.8165	0.8165	16
MRM	MRM:44	magnetic resonance microscopy:44:0.9323	0.9323	44
MRM	MRM:9	mechanically recovered meat:9:0.6794	0.6794	9
MRM	MRM:63	modified radical mastectomy:63:0.9534	0.9534	63
MRM	MRM:17	MR mammography:17:0.3109	0.3109	17
MRM	MRM:9	murine respiratory mycoplasmosis:9:0.6794	0.6794	9
MRND	MRND:14	modified radical neck dissection:14:0.6911	0.6911	14
MRN	MRN:62|MRn:1	median raphe nucleus:63:0.8612	0.8612	63
MRN	MRN:11	raphe nuclei:11:0.7357	0.7357	11
MRP1	MRP1:60|MRP-1:3|Mrp1:3	multidrug resistance-associated protein:66:0.9548	0.9548	66
MRP1	MRP1:52|Mrp1:4|mrp1:3	multidrug resistance-associated protein 1:59:0.9486	0.9486	59
MRP1	MRP1:31|MRP-1:3	multidrug resistance protein:34:0.8245	0.8245	34
MRP1	MRP1:86|mrp1:3|Mrp1:1	multidrug resistance protein 1:90:0.9473	0.9473	90
MRP2	MRP2:3|Mrp2:2	multidrug resistance-associated protein:5:0.4422	0.4422	5
MRP2	MRP2:38|Mrp2:29|mrp2:5	multidrug resistance-associated protein 2:72:0.9585	0.9585	72
MRP2	MRP2:26|Mrp2:23|mrp2:3	multidrug resistance protein 2:52:0.9427	0.9427	52
MRP3	MRP3:7|Mrp3:4	multidrug resistance-associated protein 3:11:0.7357	0.7357	11
MRP3	MRP3:6|Mrp3:3|mrp3:1	multidrug resistance protein 3:10:0.7103	0.7103	10
MRPs	MRPs:25	Maillard reaction products:25:0.8816	0.8816	25
MRPs	MRPs:24	Movement-related potentials:24:0.4060	0.4060	24
MRPs	MRPs:14|Mrps:2	multidrug resistance proteins:16:0.7261	0.7261	16
MRP	MRP:11	maximum resting pressure:11:0.3213	0.3213	11
MRP	MRP:9	median root prior:9:0.6794	0.6794	9
MRP	MRP:10	mitochondrial RNA processing:10:0.7103	0.7103	10
MRP	MRP:380|Mrp:8|mrp:6	multidrug resistance-associated protein:383:0.9614|multidrug resistance-associated proteins:11:0.7357	0.9614	394
MRP	MRP:198|Mrp:3	multidrug resistance protein:201:0.9524	0.9524	201
MRP	MRP:24	potential:15:0.0127|potentials:9:0.0073	0.0127	24
MRP	MRP:5|mrp:2	protein gene:7:0.3524	0.3524	7
MRP	MRP:11	reaction products:11:0.7357	0.7357	11
MRP	MRP:9	requirements planning:9:0.6794	0.6794	9
MRR	MRR:9	maximal relaxation rate:9:0.2102	0.2102	9
MRR	MRR:9	maximum relaxation rate:9:0.2102	0.2102	9
MRR	MRR:8	mortality rate ratio:8:0.6411	0.6411	8
mRR	mRR:12	ribonucleotide reductase:12:0.7571	0.7571	12
MRSA	MRSA:64	methicillin-resistant:53:0.0162|methicillin resistant:11:0.4232	0.4232	64
MRSA	MRSA:17	Methicillin-resistant S aureus:17:0.7998	0.7998	17
MRSA	MRSA:2240|MR-SA:2|mrsa:1	Methicillin-resistant Staphylococcus aureus:2243:0.8475	0.8475	2243
MRSA	MRSA:7	Methicillin-resistant Staphylococcus aureus strains:7:0.3524	0.3524	7
MRSA	MRSA:12	methicillin-resistant strains:12:0.2083	0.2083	12
MRSA	MRSA:15	resistant to methicillin:15:0.5348	0.5348	15
MRSI	MRSI:94	magnetic resonance spectroscopic imaging:94:0.9175	0.9175	94
MRS	MRS:11	Magnetic resonance spectroscopic:11:0.7357	0.7357	11
MRS	MRS:1037	magnetic resonance spectroscopy:1037:0.9182	0.9182	1037
MRS	MRS:14	Mania Rating Scale:14:0.2211	0.2211	14
MRS	MRS:43	Melkersson-Rosenthal syndrome:43:0.8917	0.8917	43
MRS	MRS:17	Menopause Rating Scale:17:0.2524	0.2524	17
MRs	MRs:11|MRS:1	metabolic ratios:12:0.3058	0.3058	12
MRS	MRS:10	Methicillin-resistant staphylococci:10:0.4363	0.4363	10
MRs	MRs:8|MRS:1	mineralocorticoid:9:0.0043	0.0043	9
MRs	MRs:41	mineralocorticoid receptors:41:0.8224	0.8224	41
MRs	MRs:9	minor responses:9:0.3069	0.3069	9
mRS	mRS:68|MRS:29|m-RS:3|mRs:2	modified Rankin Scale:102:0.9707	0.9707	102
mRS	mRS:7|MRS:1	Modified Rankin Score:8:0.6411	0.6411	8
MRs	MRs:22	mortality rates:22:0.6531	0.6531	22
MRS	MRS:5	Rogosa and Sharpe:5:0.7766	0.7766	5
MRTK	MRTK:11	malignant rhabdoid tumor of the kidney:11:0.7571	0.7571	11
MRTs	MRTs:13	Mean residence times:13:0.7753	0.7753	13
MRT	MRT:113	Magnetic resonance tomography:113:0.9199	0.9199	113
MRT	MRT:65	malignant rhabdoid tumor:65:0.9534	0.9534	65
MRT	MRT:406	mean residence time:406:0.9736	0.9736	406
MRT	MRT:9	mental rotations test:9:0.6794	0.6794	9
MRT	MRT:6	Microbeam radiation therapy:6:0.5290	0.5290	6
MRT	MRT:7	microwave resonance therapy:7:0.5926	0.5926	7
MRT	MRT:18	milk ring test:18:0.8365	0.8365	18
MRT	MRT:11	Modified Rhyme Test:11:0.7357	0.7357	11
MRU	MRU:22	Magnetic resonance urography:22:0.8657	0.8657	22
MRU	MRU:15	MR urography:15:0.2189	0.2189	15
MRV	MRV:31	magnetic resonance venography:31:0.9043	0.9043	31
MRV	MRV:5	mouse rotavirus:5:0.0612	0.0612	5
MRV	MRV:5	murine rotavirus:5:0.0612	0.0612	5
MRX	MRX:63	mental retardation:63:0.9526	0.9526	63
MRglu	MRglu:1	metabolic rate for glucose:1:0.7103	0.7103	1
MR	MR:11	macrophage mannose receptor:11:0.0643	0.0643	11
MR	MR:10143	magnetic resonance:10129:0.9962|magnetic-resonance:14:0.0009	0.9962	10143
MR	MR:10	magnetoresistance:10:0.0006	0.0006	10
MR	MR:9	Maillard reaction:9:0.2500	0.2500	9
MR	MR:12	mandelate racemase:12:0.7571	0.7571	12
MR	MR:30	mannose-resistant:22:0.0014|mannose resistant:8:0.1895	0.1895	30
MR	MR:21	Maudsley Reactive:21:0.8594	0.8594	21
MR	MR:29	medial rectus:29:0.8978	0.8978	29
MR	MR:28	median raphe:28:0.5445	0.5445	28
MR	MR:31|mr:1	median raphe nucleus:32:0.8145	0.8145	32
MR	MR:19	Menstrual regulation:19:0.7658	0.7658	19
MR	MR:310	mental retardation:310:0.9699	0.9699	310
MR	MR:11	Mental Rotation:11:0.5355	0.5355	11
MR	MR:42	mentally retarded:42:0.9291	0.9291	42
MR	MR:104|Mr:1	metabolic rate:99:0.5140|metabolic rates:6:0.1010	0.5140	105
MR	MR:95	metabolic ratio:84:0.5401|metabolic ratios:11:0.2972	0.5401	95
MR	MR:25|M-R:1	methicillin-resistant:26:0.0017	0.0017	26
MR	MR:12	milk replacer:12:0.7571	0.7571	12
MR	MR:448	mineralocorticoid receptor:364:0.7405|mineralocorticoid receptors:84:0.7029	0.7405	448
MR	MR:13	minor responses:13:0.4849	0.4849	13
MR	MR:50|mr:1	mitochondria-rich:51:0.0035	0.0035	51
MR	MR:23	mitotic rate:23:0.0799	0.0799	23
MR	MR:764	mitral regurgitation:764:0.9487	0.9487	764
MR	MR:29	modified release:19:0.6537|modified-release:10:0.0006	0.6537	29
Mr	Mr:52	mol wt:52:0.9203	0.9203	52
MR	MR:11	molecular remission:11:0.3829	0.3829	11
MR	MR:9	molecular replacement:9:0.1945	0.1945	9
Mr	Mr:7	molecular size:7:0.2902	0.2902	7
Mr	Mr:429	molecular weight:355:0.9699|molecular weights:74:0.9596	0.9699	429
MR	MR:5	morbid risk:5:0.0612	0.0612	5
MR	MR:7	morphinone reductase:7:0.1025	0.1025	7
MR	MR:29	mortality rate:29:0.1105	0.1105	29
MR	MR:22	mortality ratio:22:0.0947	0.0947	22
MR	MR:13	mother-reared:13:0.0008	0.0008	13
MR	MR:20	Multicentric reticulohistiocytosis:20:0.8525	0.8525	20
MR	MR:10	multiresistant:10:0.0006	0.0006	10
Mr	Mr:314|MR:1	relative molecular mass:292:0.8178|relative molecular masses:23:0.4831	0.8178	315
MR	MR:17|M-R:1	resistance:18:0.0012	0.0012	18
MS/BS	MS/BS:12	mineralizing surface:12:0.5050	0.5050	12
MS/DB	MS/DB:11	medial septum/diagonal band:11:0.7357	0.7357	11
MS/MS	MS/MS:12	tandem mass:12:0.7571	0.7571	12
MS/MS	MS/MS:38|ms/ms:1	Tandem mass spectrometric:39:0.8811	0.8811	39
MS/MS	MS/MS:433|ms/ms:4	tandem mass spectrometry:437:0.8971	0.8971	437
MSA-1	MSA-1:5	Babesia bovis merozoite surface antigen 1:5:0.4422	0.4422	5
MSA-1	MSA-1:6	merozoite surface antigen:6:0.5290	0.5290	6
MSA-1	MSA-1:8|MSA1:3	merozoite surface antigen-1:11:0.7357	0.7357	11
MSA2	MSA2:9|MSA-2:7|msa-2:1	merozoite surface antigen 2:17:0.6748	0.6748	17
MSAFP	MSAFP:212|MS-AFP:10	maternal serum alpha-fetoprotein:213:0.9631|maternal serum alpha fetoprotein:9:0.6794	0.9631	222
MSAFP	MSAFP:9	maternal serum alphafetoprotein:9:0.6794	0.6794	9
MSAF	MSAF:35	meconium-stained amniotic fluid:24:0.4622|meconium stained amniotic fluid:11:0.7357	0.7357	35
MSAP	MSAP:22|mSAP:7	mean systemic arterial pressure:29:0.7581	0.7581	29
MSA-P	MSA-P:10	multiple system atrophy:10:0.7103	0.7103	10
MSAs	MSAs:18	Medical savings accounts:18:0.8365	0.8365	18
MSAS	MSAS:16	Memorial Symptom Assessment Scale:16:0.8165	0.8165	16
MSAs	MSAs:32	metropolitan statistical areas:32:0.9072	0.9072	32
MSA	MSA:18	mammary serum antigen:18:0.7539	0.7539	18
MSA	MSA:7	mannitol salt agar:7:0.5926	0.5926	7
MSA	MSA:28	master settlement agreement:28:0.8941	0.8941	28
MSA	MSA:65	medial septal area:65:0.9047	0.9047	65
MSA	MSA:17	methanesulfonic acid:17:0.2074	0.2074	17
MSA	MSA:16	metropolitan statistical area:16:0.6577	0.6577	16
MSA	MSA:13	Middle Stone Age:13:0.7753	0.7753	13
MSA	MSA:12	mouse serum albumin:12:0.4153	0.4153	12
MSA	MSA:15	Multiple sequence alignment:15:0.8045	0.8045	15
MSA	MSA:541	multiple system atrophy:541:0.9944	0.9944	541
MSA	MSA:116	multiplication-stimulating activity:73:0.2985|multiplication stimulating activity:43:0.8917	0.8917	116
MSA	MSA:8	multivariate statistical analysis:8:0.5006	0.5006	8
MSA	MSA:21	muscle nerve sympathetic activity:21:0.8594	0.8594	21
MSA	MSA:34	muscle-specific actin:24:0.4788|muscle specific actin:10:0.7103	0.7103	34
MSA	MSA:18	muscle sympathetic activity:18:0.2771	0.2771	18
MSA	MSA:29	muscle sympathetic nerve activity:29:0.8978	0.8978	29
MSBOS	MSBOS:25	maximum surgical blood order schedule:25:0.8186	0.8186	25
MSBP	MSBP:4|mSBP:4	mean systemic blood pressure:8:0.6411	0.6411	8
MSBP	MSBP:31|MSbP:4	Munchausen Syndrome by Proxy:35:0.7587	0.7587	35
MSBR	MSBR:15	massive small bowel resection:15:0.5348	0.5348	15
MSB	MSB:9	menadione sodium bisulfite:9:0.6794	0.6794	9
MSC-1	MSC-1:8	mouse Sertoli cell line:8:0.4438	0.4438	8
MSCC	MSCC:18	Metastatic spinal cord compression:18:0.5228	0.5228	18
MSCH	MSCH:14	mouse spinal cord homogenate:14:0.5589	0.5589	14
MSCIS	MSCIS:9	Model Spinal Cord Injury Systems:9:0.6794	0.6794	9
MSCP	MSCP:10	magnetically suspended centrifugal pump:10:0.7103	0.7103	10
MSCT	MSCT:28	multi-slice computed tomography:28:0.1103	0.1103	28
MSCT	MSCT:38|MS-CT:4	multislice CT:42:0.2505	0.2505	42
MSCT	MSCT:29|msCT:1	multislice spiral CT:30:0.4752	0.4752	30
MSCV	MSCV:19	murine stem cell virus:19:0.6537	0.6537	19
MSCs	MSCs:113	marrow stromal cells:113:0.8501	0.8501	113
MSCs	MSCs:341	mesenchymal stem cells:341:0.9331	0.9331	341
MSC	MSC:13	magnitude-squared coherence:13:0.4444	0.4444	13
MSC	MSC:44	marrow stromal cells:44:0.8076	0.8076	44
MSC	MSC:9	Mercurascan:9:0.0181	0.0181	9
MSC	MSC:148	mesenchymal stem cells:120:0.9603|mesenchymal stem cell:28:0.8369	0.9603	148
MSDB	MSDB:10|MS-DB:1	medial septum/diagonal band of Broca:11:0.7357	0.7357	11
MSDs	MSDs:38	musculoskeletal disorders:38:0.8417	0.8417	38
MSDV	MSDV:12	marble spleen disease virus:12:0.7571	0.7571	12
MSD	MSD:12|msd:1	displacement:13:0.0364	0.0364	13
MSD	MSD:8	Marble spleen disease:8:0.5006	0.5006	8
MSD	MSD:5	mean sac diameter:5:0.2818	0.2818	5
MSD	MSD:6	mean segment diameter:6:0.5290	0.5290	6
MSD	MSD:12	membrane-spanning domain:12:0.2868	0.2868	12
MSD	MSD:6	Merck Sharp and Dohme:6:0.6794	0.6794	6
MSD	MSD:20	multiple sulfatase deficiency:20:0.8525	0.8525	20
MSD	MSD:10	multiple sulphatase deficiency:10:0.7103	0.7103	10
MSD	MSD:5	multisomatoform disorder:5:0.0902	0.0902	5
MSD	MSD:28	musculoskeletal disorders:23:0.7500|musculoskeletal disorder:5:0.0902	0.7500	28
MSD	MSD:7	sibling donor:7:0.2452	0.2452	7
MSER	MSER:8|mSER:1	mean systolic ejection rate:9:0.5470	0.5470	9
MSE	MSE:11	mean spherical equivalent:11:0.4728	0.4728	11
MSE	MSE:35|mse:1	mean square error:36:0.9174	0.9174	36
MSE	MSE:32|mse:1	mean squared error:33:0.8605	0.8605	33
MSE	MSE:13	monocyte-specific esterase:13:0.6460	0.6460	13
MSFC	MSFC:15	MS Functional Composite:15:0.1777	0.1777	15
MSFC	MSFC:27	multiple sclerosis functional composite:27:0.8312	0.8312	27
MSF	MSF:16	Medecins sans Frontieres:16:0.6577	0.6577	16
MSF	MSF:42	Mediterranean spotted fever:42:0.9291	0.9291	42
MSF	MSF:10	methanesulfonyl fluoride:10:0.3945	0.3945	10
MSF	MSF:33	Modified sham feeding:33:0.9100	0.9100	33
MSF	MSF:12|msf:1	stimulating factor:13:0.1220	0.1220	13
MSG	MSG:8	administration of monosodium-L-glutamate:8:0.0726	0.0726	8
MSG	MSG:27|Msg:1	major surface glycoprotein:28:0.8941	0.8941	28
MSG	MSG:13	minor salivary gland:13:0.6701	0.6701	13
MSG	MSG:411	Monosodium glutamate:411:0.9521	0.9521	411
MSG	MSG:74	monosodium L-glutamate:74:0.9361	0.9361	74
MSHA	MSHA:7	Mannose-sensitive hemagglutination:7:0.3524	0.3524	7
MSHA	MSHA:19	mannose-sensitive hemagglutinin:19:0.6903	0.6903	19
MSHA	MSHA:20	Mine Safety and Health Administration:20:0.7865	0.7865	20
MSH	MSH:34	alpha-melanocyte stimulating hormone:34:0.2026	0.2026	34
MSH	MSH:214	melanocyte-stimulating hormone:149:0.3700|melanocyte stimulating hormone:58:0.4024|melanocyte-stimulating hormones:7:0.1111	0.4024	214
MSH	MSH:17	melanotropin:17:0.0313	0.0313	17
msh	msh:12	muscle segment homeobox:12:0.7571	0.7571	12
MSH	MSH:9	Mycothiol:9:0.0157	0.0157	9
MSH	MSH:8	stimulating hormones:8:0.1591	0.1591	8
MSI+	MSI+:10	microsatellite instability:10:0.7103	0.7103	10
MSI-L	MSI-L:19	low-frequency MSI:19:0.3117	0.3117	19
MSI-L	MSI-L:16	microsatellite instability:16:0.5564	0.5564	16
MSI-H	MSI-H:32	high-frequency MSI:32:0.3326	0.3326	32
MSI-H	MSI-H:94	microsatellite instability:94:0.8914	0.8914	94
MSI	MSI:42	magnetic source imaging:42:0.9291	0.9291	42
MSI	MSI:6	Marital Satisfaction Inventory:6:0.5290	0.5290	6
MSI	MSI:5	massive splenic injury:5:0.2818	0.2818	5
MSI	MSI:917|msi:1	microsatellite instability:918:0.9797	0.9797	918
MSI	MSI:5	muscle strength index:5:0.4422	0.4422	5
MSK1	MSK1:20|Msk1:1	mitogen- and stress-activated protein kinase 1:15:0.7096|Mitogen- and stress-activated protein kinase-1:6:0.5290	0.7096	21
MSKCC	MSKCC:86	Memorial Sloan-Kettering Cancer Center:86:0.9653	0.9653	86
MSK	MSK:18	medullary sponge kidney:18:0.8365	0.8365	18
MSK	MSK:22	musculoskeletal:22:0.3281	0.3281	22
MSLR	MSLR:6	cell lymphocyte culture reaction:6:0.5290	0.5290	6
MSLR	MSLR:6	mixed skin cell-lymphocyte culture reaction:6:0.5290	0.5290	6
MSLT	MSLT:256	Multiple Sleep Latency Test:229:0.9721|multiple sleep latency tests:27:0.8903	0.9721	256
MSL	MSL:13|msl:6	male-specific lethal:19:0.5732	0.5732	19
MSL	MSL:8	mean sleep latency:8:0.5006	0.5006	8
MSL	MSL:34	multiple symmetric lipomatosis:34:0.9126	0.9126	34
MSM	MSM:358	men who have sex with men:358:0.9571	0.9571	358
MSM	MSM:11	methylsulfonylmethane:11:0.0189	0.0189	11
MSNA	MSNA:384	muscle sympathetic nerve activity:384:0.9875	0.9875	384
MSNA	MSNA:10	skeletal muscle:10:0.1994	0.1994	10
MSNs	MSNs:13	medium spiny neurons:13:0.3809	0.3809	13
MSn	MSn:16	mass spectrometry:16:0.8165	0.8165	16
MSN	MSN:14	medial septal nucleus:14:0.7909	0.7909	14
mSOF	mSOF:7|m-SOF:4	modified synthetic oviduct fluid:11:0.7357	0.7357	11
MSOF	MSOF:40	multiple system organ failure:40:0.8839	0.8839	40
MSOF	MSOF:18	multisystem organ failure:18:0.1485	0.1485	18
MSOP	MSOP:8	Medical School Objectives Project:8:0.6411	0.6411	8
MSOX	MSOX:10	Monomeric sarcosine oxidase:10:0.7103	0.7103	10
MSO	MSO:12	L-methionine-DL-sulfoximine:12:0.0482	0.0482	12
MSO	MSO:11	management services organization:11:0.7357	0.7357	11
MSO	MSO:18	medial superior olivary nucleus:18:0.8365	0.8365	18
MSO	MSO:60	medial superior olive:60:0.9503	0.9503	60
MSO	MSO:53	methionine sulfoximine:53:0.8373	0.8373	53
MSP1(19)	MSP1(19):14|MSP-1(19):2|msp-1(19):1	merozoite surface protein 1:17:0.8270	0.8270	17
MSP-1	MSP-1:12|MSP1:3	merozoite surface protein:15:0.8045	0.8045	15
MSP-1	MSP-1:105|MSP1:58|msp-1:7|Msp-1:1|msp1:1|Msp1:1	merozoite surface protein 1:91:0.8384|merozoite surface protein-1:82:0.9238	0.9238	173
MSP-2	MSP-2:6|msp-2:1|msp2:1|MSP2:1	merozoite surface protein-2:9:0.3455	0.3455	9
MSP3	MSP3:9|MSP-3:1	merozoite surface protein 3:10:0.4363	0.4363	10
MSPD	MSPD:56	matrix solid-phase dispersion:56:0.9162	0.9162	56
MsPGN	MsPGN:10|MSPGN:1	Mesangial proliferative glomerulonephritis:11:0.6182	0.6182	11
MSPSS	MSPSS:13	Multidimensional Scale of Perceived Social Support:13:0.7753	0.7753	13
MSPs	MSPs:11|Msps:1	major surface proteins:12:0.5664	0.5664	12
msP	msP:9	Genetically selected Marchigian Sardinian alcohol-preferring:9:0.6794	0.6794	9
MSP	MSP:77	Macrophage-stimulating protein:42:0.1412|macrophage stimulating protein:35:0.9126	0.9126	77
MSP	MSP:48|msp:3	major sperm protein:51:0.8799	0.8799	51
MSP	MSP:5|msp:2	major surface protease:7:0.5926	0.5926	7
MSP	MSP:4	major surface proteins:4:0.1618	0.1618	4
MSP	MSP:13	maximum squeeze pressure:13:0.5335	0.5335	13
MSP	MSP:136	methylation-specific PCR:136:0.7423	0.7423	136
MSP	MSP:49	methylation-specific polymerase chain reaction:49:0.6967	0.6967	49
MSP	MSP:8|msp:1	microspectrophotometric:9:0.0111	0.0111	9
MSP	MSP:19|msp:1	microspectrophotometry:20:0.0263	0.0263	20
MSP	MSP:8	myelencephalon-specific protease:8:0.1895	0.1895	8
MSQ	MSQ:15	Mental Status Questionnaire:15:0.8045	0.8045	15
MSRB	MSRB:9	morantel sustained release bolus:9:0.6794	0.6794	9
MSRV	MSRV:9	modified semisolid Rappaport-Vassiliadis:9:0.6794	0.6794	9
MSRV	MSRV:8	multiple sclerosis-associated retrovirus:8:0.6411	0.6411	8
MSR	MSR:37	macrophage scavenger receptor:25:0.8816|Macrophage scavenger receptors:12:0.7571	0.8816	37
Msr	Msr:7|msr:1|MSR:1	methionine sulfoxide reductase:9:0.6794	0.6794	9
MSR	MSR:8	Methionine synthase reductase:8:0.6411	0.6411	8
MSR	MSR:10	monosynaptic:10:0.0391	0.0391	10
MSR	MSR:73	monosynaptic reflex:73:0.8627	0.8627	73
MSSA	MSSA:11	methicillin-sensitive:11:0.0248	0.0248	11
MSSA	MSSA:6	methicillin-sensitive S aureus:6:0.2564	0.2564	6
MSSA	MSSA:57	methicillin-sensitive Staphylococcus aureus:57:0.3468	0.3468	57
MSSA	MSSA:24	methicillin-susceptible:24:0.0569	0.0569	24
MSSA	MSSA:2	Methicillin-susceptible S aureus:2:0.4531	0.4531	2
MSSA	MSSA:50	methicillin-susceptible Staphylococcus aureus:50:0.2944	0.2944	50
MSS	MSS:9	Marinesco-Sjogren syndrome:9:0.1334	0.1334	9
MSS	MSS:7	Marshall-Smith syndrome:7:0.0692	0.0692	7
MSS	MSS:15	Maternal serum screening:15:0.8045	0.8045	15
MSS	MSS:91	microsatellite stable:74:0.8212|microsatellite-stable:17:0.0464	0.8212	91
MSS	MSS:7	moderate splenomegaly syndrome:7:0.5926	0.5926	7
MStV	MStV:10	maize stripe virus:10:0.7103	0.7103	10
MSTd	MSTd:11	medial superior temporal area:11:0.6182	0.6182	11
MSTS	MSTS:13	Musculoskeletal Tumor Society:13:0.7753	0.7753	13
MSTs	MSTs:21	survival times:21:0.8594	0.8594	21
MST	MST:5	Maximal Stimulation Test:5:0.1132	0.1132	5
MST	MST:322|mst:1|m-ST:1|M-ST:1	median survival time:299:0.6061|median survival times:26:0.5040	0.6061	325
MST	MST:5	mental arithmetic stress test:5:0.4422	0.4422	5
MST	MST:5	mental stress test:5:0.0902	0.0902	5
MST	MST:8	microbial source tracking:8:0.5006	0.5006	8
MST	MST:24	minimum spanning tree:24:0.7151	0.7151	24
MST	MST:8	Montenegro skin test:8:0.4102	0.4102	8
MST	MST:32	Multiple subpial transection:32:0.9072	0.9072	32
MST	MST:22	Multisystemic therapy:22:0.5095	0.5095	22
MST	MST:9	technique:9:0.0083	0.0083	9
MSUD	MSUD:182	maple syrup urine disease:182:0.9834	0.9834	182
MSUM	MSUM:32	Monosodium urate monohydrate:32:0.9072	0.9072	32
MSU	MSU:10	mid-stream urine:10:0.1680	0.1680	10
MSU	MSU:13	midstream urine:13:0.2802	0.2802	13
MSU	MSU:87	monosodium urate:87:0.9656	0.9656	87
MSU	MSU:10	Monosodium urate crystals:10:0.7103	0.7103	10
MSU	MSU:20	monosodium urate monohydrate:20:0.7766	0.7766	20
MSU	MSU:9	State University:9:0.6794	0.6794	9
MSV-M	MSV-M:10|MSVm:1	sarcoma virus:11:0.7357	0.7357	11
MSV	MSV:40	maize streak virus:40:0.9256	0.9256	40
MSV	MSV:102|msv:1	murine sarcoma virus:103:0.6151	0.6151	103
MSV	MSV:5	systolic velocity:5:0.0902	0.0902	5
MSWI	MSWI:26	municipal solid waste incineration:26:0.8861	0.8861	26
MSWI	MSWI:38	municipal solid waste incinerator:38:0.9197	0.9197	38
MSX	MSX:8|Msx:1	methionine sulfoximine:9:0.3945	0.3945	9
MSeA	MSeA:11	methylseleninic acid:11:0.7357	0.7357	11
MShCG	MShCG:16	maternal serum human chorionic gonadotropin:16:0.8165	0.8165	16
MStF	MStF:9|MSTF:1	migration stimulation factor:10:0.7103	0.7103	10
MS	MS:9	Chinese Meishan:9:0.0836	0.0836	9
ms	ms:8	duration:8:0.0006	0.0006	8
ms	ms:9	interval:9:0.0006	0.0006	9
MS	MS:9	magnetic source:9:0.5470	0.5470	9
MS	MS:23	magnetic stimulation:23:0.3492	0.3492	23
MS	MS:27	mainstream:27:0.0020	0.0020	27
MS	MS:17	mainstream smoke:17:0.7407	0.7407	17
MS	MS:7	malignant Schwannoma:7:0.2902	0.2902	7
MS	MS:5	Manchester Scale:5:0.0736	0.0736	5
MS	MS:35	mannose-sensitive:26:0.0020|mannose sensitive:9:0.3945	0.3945	35
MS	MS:8	marbling score:8:0.0953	0.0953	8
MS	MS:5	marijuana smokers:5:0.1132	0.1132	5
MS	MS:14	mass screening:14:0.7909	0.7909	14
MS	MS:8	mass spectral:8:0.3463	0.3463	8
MS	MS:46	mass spectrometer:46:0.8986	0.8986	46
MS	MS:127	mass spectrometric:127:0.7929	0.7929	127
MS	MS:1060|ms:3	mass spectrometry:1063:0.8168	0.8168	1063
MS	MS:19	maternal separation:19:0.8449	0.8449	19
MS	MS:46	Maternal serum:46:0.7507	0.7507	46
MS	MS:7	Meal size:7:0.3524	0.3524	7
MS	MS:30	Mean sensitivity:30:0.6484	0.6484	30
MS	MS:41|Ms:1	mechanosensitive:42:0.0032	0.0032	42
MS	MS:35	medial septal:35:0.9151	0.9151	35
MS	MS:18	medial septal nucleus:18:0.8365	0.8365	18
MS	MS:88	medial septum:88:0.9288	0.9288	88
MS	MS:9	median sternotomy:9:0.6794	0.6794	9
MS	MS:41|ms:1	median survival:42:0.7523	0.7523	42
MS	MS:11	medium:11:0.0008	0.0008	11
MS	MS:14	Mental Stress:14:0.5111	0.5111	14
MS	MS:147	metabolic syndrome:147:0.6317	0.6317	147
MS	MS:55	methionine synthase:55:0.5619	0.5619	55
MS	MS:10	methionine synthetase:10:0.5856	0.5856	10
MS	MS:9	methyl salicylate:9:0.6794	0.6794	9
MS	MS:30|ms:12	microsatellite:30:0.0023|microsatellites:12:0.0009	0.0023	42
MS	MS:88|Ms:9|ms:4	microspheres:89:0.0069|microsphere:12:0.0009	0.0069	101
MS	MS:9	middle suprasylvian:9:0.5470	0.5470	9
MS	MS:12|ms:1	mild steel:13:0.5335	0.5335	13
ms	ms:30|MS:1|mS:1	milliseconds:32:0.0024	0.0024	32
MS	MS:8	mineralizing surface:8:0.2987	0.2987	8
MS	MS:267	mitral stenosis:267:0.9282	0.9282	267
MS	MS:5	molar substitution:5:0.0902	0.0902	5
MS	MS:15	morphine:15:0.0011	0.0011	15
MS	MS:78	morphine sulfate:78:0.8862	0.8862	78
MS	MS:31	motion sickness:31:0.9043	0.9043	31
ms	ms:5|MS:2|m-s:1|M-S:1	mucosal-to-serosal:9:0.0006	0.0006	9
MS	MS:9	multiple-scattering:9:0.0006	0.0006	9
MS	MS:8068|ms:6	multiple sclerosis:8074:0.9969	0.9969	8074
MS	MS:9	multiple sderosis:9:0.6794	0.6794	9
MS	MS:60	Murashige and Skoog:45:0.9338|Murashige and Skoog's:15:0.8045	0.9338	60
MS	MS:9	Murashige-Skoog:9:0.0006	0.0006	9
MS	MS:117|ms:9	mutans streptococci:126:0.9385	0.9385	126
MS	MS:7	mutator strain:7:0.2452	0.2452	7
MS	MS:49|Ms:1	Mycoplasma synoviae:50:0.5434	0.5434	50
MS	MS:9	strength:9:0.0006	0.0006	9
MT-MMP	MT-MMP:19	Membrane-type matrix metalloproteinase:19:0.4852	0.4852	19
MT-MMP	MT-MMP:7	membrane-type MMP:7:0.3524	0.3524	7
MT-MMPs	MT-MMPs:27	Membrane-type matrix metalloproteinases:27:0.6192	0.6192	27
MT-MMPs	MT-MMPs:14	membrane-type MMPs:14:0.5111	0.5111	14
MT1-MMP	MT1-MMP:6	matrix metalloprotease:6:0.2243	0.2243	6
MT1-MMP	MT1-MMP:180	Membrane-type 1 matrix metalloproteinase:59:0.4868|membrane type-1 matrix metalloproteinase:48:0.9392|Membrane type 1 matrix metalloproteinase:38:0.8781|membrane type 1-matrix metalloproteinase:35:0.8681	0.9392	180
MT1-MMP	MT1-MMP:84	membrane type 1-MMP:24:0.8768|membrane type 1 MMP:24:0.8115|membrane type-1 MMP:18:0.7539|membrane-type 1 MMP:18:0.2462	0.8768	84
MT1-MMP	MT1-MMP:29	membrane-type matrix metalloproteinase-1:20:0.5568|membrane-type matrix metalloproteinase 1:9:0.3945	0.5568	29
MT-1	MT-1:27|MT1:5|Mt-1:1|mt-1:1	metallothionein-1:25:0.2202|Metallothionein 1:9:0.1492	0.2202	34
MT-2	MT-2:8|MT2:1	cell line:9:0.2285	0.2285	9
MT-3	MT-3:10	metallothionein-3:10:0.1731	0.1731	10
MTA1	MTA1:5|Mta1:1	metastasis-associated protein 1:6:0.3728	0.3728	6
MTAC	MTAC:34|MTaC:1	mass transfer area coefficient:23:0.8715|mass transfer area coefficients:12:0.7571	0.8715	35
mTALs	mTALs:7|MTALs:4	medullary thick ascending limbs:11:0.6182	0.6182	11
MTAL	MTAL:5|mTAL:4	medullary TAL:9:0.5470	0.5470	9
MTAL	MTAL:114|mTAL:70|Mtal:1	medullary thick ascending limb:166:0.9617|medullary thick ascending limbs:19:0.8449	0.9617	185
MTAL	MTAL:9|mTAL:7|mtal:1	medullary thick ascending limb of Henle:17:0.8270	0.8270	17
MTAL	MTAL:17|mTAL:9	medullary thick ascending limb of Henle's loop:26:0.8369	0.8369	26
mTAL	mTAL:3	medullary thick ascending limb of the loop of Henle:3:0.2818	0.2818	3
MTAP	MTAP:45	methylthioadenosine phosphorylase:45:0.6264	0.6264	45
MTAg	MTAg:9|MTag:1	middle T antigen:10:0.7103	0.7103	10
MTAg	MTAg:5	middle tumor antigen:5:0.1973	0.1973	5
MTA	MTA:28	5'-Deoxy-5'-Methylthioadenosine:28:0.0596	0.0596	28
MTA	MTA:43	5'-methylthioadenosine:43:0.0927	0.0927	43
MTA	MTA:10	LY231514:10:0.0199	0.0199	10
Mta	Mta:10	maternally transmitted antigen:10:0.7103	0.7103	10
MTA	MTA:10	medial temporal lobe atrophy:10:0.7103	0.7103	10
MTA	MTA:21	methylthioadenosine:21:0.0419	0.0419	21
MTA	MTA:118	mineral trioxide aggregate:118:0.9749	0.9749	118
MTA	MTA:8	moving time average:8:0.6411	0.6411	8
MTA	MTA:6	Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder:6:0.3728	0.3728	6
MTA	MTA:12	multitargeted antifolate:12:0.5050	0.5050	12
MTA	MTA:5	myoclonic twitch activity:5:0.1973	0.1973	5
MTBC	MTBC:27|MtbC:3	Mycobacterium tuberculosis complex:30:0.6736	0.6736	30
MTBE	MTBE:12	methyl-tert-butyl-ether:12:0.0239	0.0239	12
MTBI	MTBI:81|mTBI:11	mild traumatic brain injury:92:0.8291	0.8291	92
MTBS	MTBS:11	microtensile bond strength:11:0.5355	0.5355	11
MTB	MTB:202|Mtb:104|MTb:18|M-TB:2|mTB:1|MtB:1	Mycobacterium tuberculosis:328:0.8608	0.8608	328
MTB	MTB:23|Mtb:1	Mycobacterium tuberculosis complex:24:0.7593	0.7593	24
MTCT	MTCT:74	mother-to-child transmission:74:0.7388	0.7388	74
MTCs	MTCs:40	medullary thyroid carcinomas:40:0.9256	0.9256	40
MTC	MTC:12	concentration:12:0.0086	0.0086	12
MTC	MTC:89	Magnetization transfer contrast:89:0.9131	0.9131	89
MTC	MTC:29	major translocation cluster:29:0.8978	0.8978	29
MTC	MTC:5	Mass transfer area coefficients:5:0.4422	0.4422	5
MTC	MTC:19|mtc:1	mass transfer coefficient:12:0.7571|Mass Transfer Coefficients:8:0.6411	0.7571	20
MTC	MTC:22	medullary carcinoma of the thyroid:22:0.8657	0.8657	22
MTC	MTC:107	medullary thyroid cancer:107:0.9559	0.9559	107
MTC	MTC:702	medullary thyroid carcinoma:650:0.9833|medullary thyroid carcinomas:52:0.9099	0.9833	702
MTC	MTC:30	metoclopramide:30:0.0227	0.0227	30
MTC	MTC:9	Microwave tissue coagulation:9:0.6794	0.6794	9
MTC	MTC:14	Microwave Tissue Coagulator:14:0.7753	0.7753	14
MTC	MTC:10	mitomycin C:10:0.5856	0.5856	10
MTC	MTC:9	muscle-tendon complex:9:0.0674	0.0674	9
MTC	MTC:22	Mycobacterium tuberculosis complex:22:0.4689	0.4689	22
MTDSC	MTDSC:19	Modulated Temperature Differential Scanning Calorimetry:19:0.8449	0.8449	19
MTDs	MTDs:30	maximum tolerated doses:30:0.6037	0.6037	30
MTD	MTD:23	Amplified Mycobacterium Tuberculosis Direct Test:23:0.7046	0.7046	23
MTD	MTD:136	determine the maximum-tolerated dose:136:0.4379	0.4379	136
MTD	MTD:10	diameter:10:0.0053	0.0053	10
MTD	MTD:5	mannitol dehydrogenase:5:0.0736	0.0736	5
MTD	MTD:10	maximum tolerated dosage:10:0.5000	0.5000	10
MTD	MTD:967	maximum tolerated dose:929:0.8416|maximum tolerated doses:38:0.6678	0.8416	967
MTD	MTD:9|Mtd:4	methadone:13:0.0070	0.0070	13
MTD	MTD:11	tension dysphonia:11:0.7357	0.7357	11
MTF's	MTF's:12	modulation transfer functions:12:0.7571	0.7571	12
MTF-1	MTF-1:3|MTF1:2|Mtf1:1	transcription factor:6:0.1543	0.1543	6
MTF-1	MTF-1:40|MTF1:5|Mtf-1:2	transcription factor-1:37:0.9174|transcription factor 1:10:0.7103	0.9174	47
MTFs	MTFs:11	medical treatment facilities:11:0.4232	0.4232	11
MTFs	MTFs:41	modulation transfer functions:41:0.9274	0.9274	41
MTF	MTF:4	formylation of initiator methionyl-tRNA by methionyl-tRNA formyltransferase:4:0.4422	0.4422	4
MTf	MTf:12|MTF:1|mTf:1	Melanotransferrin:14:0.0296	0.0296	14
MTF	MTF:10	metrifonate:10:0.0205	0.0205	10
MTF	MTF:263	modulation transfer function:254:0.9748|modulation transfer functions:9:0.6794	0.9748	263
MTF	MTF:6	multiple-tube fermentation:6:0.1838	0.1838	6
mTF	mTF:8|MTF:6	tissue factor:14:0.3202	0.3202	14
MTF	MTF:9	treatment facility:9:0.6794	0.6794	9
MTGase	MTGase:7|mTgase:1|mTGase:1|M-TGase:1	microbial transglutaminase:10:0.4363	0.4363	10
MTG	MTG:11|mTG:1|m-TG:1	microbial transglutaminase:13:0.7753	0.7753	13
MTG	MTG:8|mtg:1	middle temporal gyrus:9:0.6794	0.6794	9
MTg	MTg:48|mTg:10|MTG:1	mouse thyroglobulin:59:0.8502	0.8502	59
MTHFR	MTHFR:739|Mthfr:3|MT-HFR:1	methylenetetrahydrofolate reductase:743:0.6765	0.6765	743
MTHFR	MTHFR:24	methylenetetrahydrofolate reductase gene:24:0.4788	0.4788	24
MTHPA	MTHPA:16	Methyltetrahydrophthalic anhydride:16:0.5171	0.5171	16
MTH	MTH:9	mild temperature hyperthermia:9:0.5470	0.5470	9
MTIIA	MTIIA:3|MTIIa:2|MT-IIA:1|Mt-IIA:1|MtIIA:1	metallothionein IIA:8:0.5006	0.5006	8
MTII	MTII:13|MT-II:10	melanotan-II:13:0.1690|melanotan II:10:0.1774	0.1774	23
MT-II	MT-II:18|MTII:5	metallothionein-II:12:0.1549|metallothionein II:11:0.2154	0.2154	23
MTI	MTI:40	Magnetization transfer imaging:40:0.6808	0.6808	40
MT-I	MT-I:15|MTI:2	metallothionein I:17:0.6748	0.6748	17
MT-I	MT-I:25	mouse metallothionein-I:25:0.2003	0.2003	25
MTJ	MTJ:27	junction:27:0.8966	0.8966	27
MTJs	MTJs:17	myotendinous junctions:17:0.5038	0.5038	17
MTLE-HS	MTLE-HS:11	hippocampal sclerosis:11:0.7357	0.7357	11
MTLE	MTLE:105|mTLE:19	mesial temporal lobe epilepsy:124:0.7573	0.7573	124
MTLP	MTLP:8	metallothionein-like protein:8:0.5006	0.5006	8
MTL	MTL:150|mTL:1	medial temporal lobe:143:0.8716|medial temporal lobes:8:0.4102	0.8716	151
MTM1	MTM1:19	myotubular myopathy:19:0.8449	0.8449	19
MTMM	MTMM:9	multitrait-multimethod:9:0.5714	0.5714	9
MTN	MTN:27	medial terminal nucleus:27:0.8903	0.8903	27
MTN	MTN:25	mesencephalic trigeminal nucleus:25:0.6873	0.6873	25
MTN	MTN:8|Mtn:1	mitoxantrone:9:0.0714	0.0714	9
MTOC	MTOC:85	microtubule organizing center:75:0.8103|microtubule organizing centers:10:0.7103	0.8103	85
MTOC	MTOC:18	microtubule-organizing centre:9:0.1585|microtubule organizing centre:9:0.6794	0.6794	18
MTOCs	MTOCs:36|MtOCs:1	microtubule organizing centers:37:0.9197	0.9197	37
MTOS	MTOS:32	Major Trauma Outcome Study:32:0.9100	0.9100	32
MTO	MTO:10|Mto:2	Mitoxantrone:12:0.2500	0.2500	12
MTPJ	MTPJ:8	metatarsophalangeal joint:8:0.6794	0.6794	8
MTP-PE	MTP-PE:13	muramyl tripeptide:13:0.7753	0.7753	13
MTP-PE	MTP-PE:30|MTPPE:2	muramyl tripeptide phosphatidylethanolamine:32:0.9072	0.9072	32
MTP	MTP:26	first metatarsophalangeal:26:0.1728	0.1728	26
MTP	MTP:14	maltose tetrapalmitate:14:0.6911	0.6911	14
MTP	MTP:7	median time to progression:7:0.5926	0.5926	7
MTP	MTP:7	median time to tumor progression:7:0.4438	0.4438	7
MTP	MTP:14	medical termination of pregnancy:14:0.7909	0.7909	14
MTP	MTP:196	microsomal triglyceride transfer protein:196:0.9847	0.9847	196
MTP	MTP:5	microtubule proteins:5:0.0612	0.0612	5
MTP	MTP:18	mitochondrial permeability transition pore:18:0.4033	0.4033	18
MTP	MTP:20	mitochondrial transmembrane potential:20:0.8525	0.8525	20
MTP	MTP:9	Treatment Project:9:0.6794	0.6794	9
MTRR	MTRR:28	methionine synthase reductase:28:0.8369	0.8369	28
MTRs	MTRs:17	Magnetization transfer ratios:17:0.6748	0.6748	17
MTR	MTR:130|MTr:1	magnetization transfer ratio:125:0.7901|magnetization transfer ratios:6:0.3728	0.7901	131
MTR	MTR:15|Mtr:1	methionine synthase:16:0.7261	0.7261	16
MTR	MTR:12	Mithramycin:12:0.0310	0.0310	12
MTR	MTR:7	MT ratios:7:0.1641	0.1641	7
MTR	MTR:7	mucociliary transport rate:7:0.2452	0.2452	7
MTS1	MTS1:4	multiple tumor suppressor 1:4:0.3170	0.3170	4
MTSEA	MTSEA:7|MTS-EA:1	2-aminoethyl methanethiosulfonate:8:0.5006	0.5006	8
MTSEA	MTSEA:13|MT-SEA:1	methanethiosulfonate ethylammonium:14:0.4071	0.4071	14
MTSET	MTSET:7|MTS-ET:2	[2-(trimethylammonium)ethyl]methanethiosulfonate:9:0.1143	0.1143	9
MTSET	MTSET:7|MTS-ET:1	methanethiosulfonate ethyltrimethylammonium:8:0.3463	0.3463	8
MTTs	MTTs:14	transit times:14:0.7909	0.7909	14
MTT	MTT:8	Malignant Triton Tumor:8:0.6411	0.6411	8
MTT	MTT:19	meal tolerance test:19:0.7658	0.7658	19
MTT	MTT:278	Mean transit time:278:0.9111	0.9111	278
MTT	MTT:5	mitochondrial dehydrogenase activity:5:0.2818	0.2818	5
MTT	MTT:10	myoblast transfer therapy:10:0.7103	0.7103	10
MTT	MTT:35	tetrazolium dye:35:0.7647	0.7647	35
MTU	MTU:10	Malignant teratoma undifferentiated:10:0.7103	0.7103	10
MTU	MTU:29	methylthiouracil:29:0.4000	0.4000	29
MTU	MTU:5	muscle-tendon unit:5:0.0902	0.0902	5
MTV	MTV:88|Mtv:4	mammary tumor virus:92:0.9675	0.9675	92
MTV	MTV:6	maximum tolerable volume:6:0.3728	0.3728	6
MTV	MTV:5	maximum tolerated volume:5:0.2818	0.2818	5
MTX-CH	MTX-CH:7	methotrexate bound to activated carbon particles:7:0.5926	0.5926	7
MTX	MTX:9	[3H]methotrexate:9:0.0021	0.0021	9
MTX	MTX:4|Mtx:1	agonist methoxamine:5:0.0807	0.0807	5
MTX	MTX:72	Maitotoxin:72:0.0188	0.0188	72
MTX	MTX:15	maurotoxin:15:0.0037	0.0037	15
MTX	MTX:3512|Mtx:30|mtx:5|MTx:1	methotrexate:3548:0.9378	0.9378	3548
MTX	MTX:19|Mtx:1	mitoxantrone:20:0.0050	0.0050	20
MTX	MTX:4|Mtx:3|mtx:1	mosquitocidal toxin:8:0.5006	0.5006	8
MTZ	MTZ:9	methimazole:9:0.0909	0.0909	9
MTZ	MTZ:28|Mtz:12	metronidazole:40:0.4432	0.4432	40
MTases	MTases:55|Mtases:5	methyltransferases:60:0.8676	0.8676	60
MTase	MTase:90|Mtase:14|mtase:1	methyltransferase:105:0.7410	0.7410	105
MT	MT:16	17 alpha-methyltestosterone:16:0.8165	0.8165	16
MT	MT:20	17alpha-methyltestosterone:20:0.0038	0.0038	20
MT	MT:2	aMT and 5-methoxytryptamine:2:0.0902	0.0902	2
MT	MT:259	Magnetization transfer:259:0.8706	0.8706	259
MT	MT:10	maintenance therapy:10:0.1385	0.1385	10
MT	MT:8|Mt:4	Malpighian tubules:12:0.6460	0.6460	12
MT	MT:16	mammary tumors:9:0.3945|mammary tumor:7:0.0951	0.3945	16
MT	MT:10|mt:4	mating-type:14:0.0026	0.0026	14
MT	MT:11	medial thalamus:11:0.6182	0.6182	11
MT	MT:118|Mt:1	melatonin:119:0.0235	0.0235	119
MT	MT:9	membrane type:9:0.1409	0.1409	9
MT	MT:1738|Mt:17|mT:1	metallothionein:1661:0.3301|Metallothioneins:95:0.0187	0.3301	1756
MT	MT:19	methanethiol:19:0.0036	0.0036	19
MT	MT:27	Methyltestosterone:27:0.0052	0.0052	27
MT	MT:10	methyltrienolone:10:0.0018	0.0018	10
MT	MT:376|Mt:9|mt:5	microtubule:257:0.0512|microtubules:133:0.0263	0.0512	390
mT	MT:14|mT:14	middle T:28:0.7905	0.7905	28
MT	MT:21|mT:9	Middle T antigen:30:0.9011	0.9011	30
MT	MT:64	middle temporal:64:0.8123	0.8123	64
MT	MT:73	middle temporal area:73:0.8627	0.8627	73
MT	MT:68	middle temporal visual area:68:0.9561	0.9561	68
MT	mT:7|MT:7	middle tumor antigen:14:0.6911	0.6911	14
mT	mT:8|MT:1	millitesla:9:0.0016	0.0016	9
MT	mt:19|MT:19|Mt:15	mitochondria:53:0.0104	0.0104	53
mt	mt:556|Mt:20|MT:6	mitochondrial:582:0.1155	0.1155	582
MT	MT:8|mt:1	morphological transformation:9:0.3069	0.3069	9
MT	MT:65	motor threshold:65:0.6690	0.6690	65
MT	MT:11	mouse metallothionein-I:11:0.5355	0.5355	11
MT	MT:54|Mt:18	mycobacterium tuberculosis:72:0.7126	0.7126	72
MT	MT:7	Myoblast transplantation:7:0.2902	0.2902	7
MT	MT:8	myogenic tone:8:0.5470	0.5470	8
MT	MT:10	O6-methylguanine-DNA methyltransferase:10:0.1022	0.1022	10
MT	MT:17|Mt:1	thickness:18:0.0034	0.0034	18
MT	MT:12	treatment:12:0.0022	0.0022	12
MUAC	MUAC:23	Mid-upper-arm circumference:23:0.1434	0.1434	23
MUAP	MUAP:64	motor unit action potential:55:0.9147|motor unit action potentials:9:0.6794	0.9147	64
MUAPs	MUAPs:86|MUAPS:1	motor unit action potentials:87:0.9656	0.9656	87
MUA	MUA:7	11-mercaptoundecanoic acid:7:0.1111	0.1111	7
MuA	MuA:11	Mu transposase:11:0.5355	0.5355	11
MUA	MUA:57	Multiple unit activity:57:0.8920	0.8920	57
MUA	MUA:63	multiunit activity:63:0.2965	0.2965	63
MUC7	MUC7:7	human salivary mucin:7:0.4438	0.4438	7
MUCP	MUCP:34	maximum urethral closure pressure:34:0.4784	0.4784	34
MUC	MUC:10	mucosal ulcerative colitis:10:0.6794	0.6794	10
MUC	MUC:10	trans,trans-muconaldehyde:10:0.0957	0.0957	10
MUD	MUD:46	matched unrelated donor:33:0.6194|matched unrelated donors:13:0.4849	0.6194	46
MUFA	MUFA:10	monounsaturated fat:10:0.7357	0.7357	10
MUFA	MUFA:142	monounsaturated fatty acids:100:0.8543|monounsaturated fatty acid:42:0.7523	0.8543	142
MUFAs	MUFAs:40	monounsaturated fatty acids:40:0.8491	0.8491	40
MUF	MUF:33	modified ultrafiltration:33:0.7841	0.7841	33
MUGA	MUGA:11	Multiple gated acquisition:11:0.5355	0.5355	11
MUGA	MUGA:6	radionuclide angiography:6:0.1838	0.1838	6
MUGA	MUGA:10	radionuclide ventriculography:10:0.4728	0.4728	10
MUIS	MUIS:6|M-UIS:1	Mishel Uncertainty in Illness Scale:7:0.3524	0.3524	7
MUN	MUN:16	Milk urea nitrogen:16:0.8165	0.8165	16
MUNE	MUNE:18	motor unit number estimate:18:0.8365	0.8365	18
MUNE	MUNE:38	motor unit number estimation:38:0.9197	0.9197	38
MUPs	MUPs:38|mups:2|Mups:1	major urinary proteins:41:0.8867	0.8867	41
MUPS	MUPS:8	medically unexplained physical symptoms:8:0.6411	0.6411	8
MUPs	MUPs:51	motor unit potentials:51:0.9082	0.9082	51
MUP	MUP:37|Mup:2	major urinary protein:39:0.7419	0.7419	39
MUP	MUP:10	maximum urethral pressure:10:0.5856	0.5856	10
MUP	MUP:59	motor unit potential:48:0.9379|motor unit potentials:11:0.7357	0.9379	59
MUSC	MUSC:14	Medical University of South Carolina:14:0.7909	0.7909	14
MUSE	MUSE:9	alprostadil:9:0.2581	0.2581	9
MUSE	MUSE:10	Medicated Urethral System for Erection:10:0.7103	0.7103	10
MUSTT	MUSTT:18	Multicenter Unsustained Tachycardia Trial:18:0.8165	0.8165	18
mus	mus:3	agonist muscimol:3:0.0807	0.0807	3
MUS	MUS:11	medically unexplained symptoms:11:0.7357	0.7357	11
MUs	MUs:153	motor units:153:0.7702	0.7702	153
M-VAC	M-VAC:1	methotrexate vinblastine doxorubicin and cisplatin:1:0.9370	0.9370	1
M-VAC	M-VAC:4|MVAC:1	Neoadjuvant chemotherapy:5:0.0612	0.0612	5
M-VATs	M-VATs:6	metacyclic variable antigen types:6:0.5290	0.5290	6
MVAs	MVAs:47	motor vehicle accidents:47:0.9366	0.9366	47
MVA	MVA:43	manual vacuum aspiration:43:0.9308	0.9308	43
MVA	MVA:43	mevalonate:43:0.0682	0.0682	43
MVA	MVA:51	mevalonic acid:51:0.7371	0.7371	51
MVA	MVA:127	mitral valve area:127:0.9502	0.9502	127
MVA	MVA:29	Modified vaccinia Ankara:29:0.8978	0.8978	29
MVA	MVA:92	Modified vaccinia virus Ankara:92:0.9005	0.9005	92
MVA	MVA:89	motor vehicle accident:54:0.9448|motor vehicle accidents:35:0.9151	0.9448	89
MVA	MVA:18	Multivariate analysis:18:0.6903	0.6903	18
MVBs	MVBs:73|mvbs:2	multivesicular bodies:75:0.8369	0.8369	75
MVB	MVB:20	mesenteric vascular bed:20:0.8525	0.8525	20
MVB	MVB:82|mvb:4	multivesicular bodies:63:0.8612|multivesicular body:23:0.7500	0.8612	86
mVcfc	mVcfc:6|MVCfc:1	velocity of circumferential fiber shortening:7:0.5926	0.5926	7
MVCT	MVCT:7	megavoltage computed tomography:7:0.4438	0.4438	7
MVCs	MVCs:38	maximal voluntary contractions:38:0.6874	0.6874	38
MVCs	MVCs:23	motor vehicle collisions:23:0.8715	0.8715	23
MVCs	MVCs:37	motor vehicle crashes:37:0.9197	0.9197	37
MVC	MVC:504	maximal voluntary contraction:454:0.5796|maximal voluntary contractions:50:0.6230	0.6230	504
MVC	MVC:276	maximum voluntary contraction:276:0.3380	0.3380	276
MVC	MVC:37	microvessel count:37:0.8051	0.8051	37
MVC	MVC:9	Minute virus of canines:9:0.6794	0.6794	9
MVC	MVC:12	motor vehicle collision:12:0.6460	0.6460	12
MVC	MVC:61|mvc:1	motor vehicle crash:42:0.9291|Motor Vehicle Crashes:20:0.8525	0.9291	62
MVC	MVC:25	voluntary contraction force:25:0.8186	0.8186	25
MVC	MVC:7	voluntary contraction strength:7:0.4438	0.4438	7
MVDP	MVDP:18	mouse vas deferens protein:18:0.8365	0.8365	18
MVD	MVD:130	microvascular decompression:130:0.9195	0.9195	130
MVD	MVD:611|mVd:1	microvessel density:612:0.8075	0.8075	612
MVD	MVD:19	mitral valve disease:19:0.8449	0.8449	19
MVD	MVD:25	multivessel disease:25:0.2155	0.2155	25
MVE-2	MVE-2:6	maleic anhydride divinyl ether:6:0.3728	0.3728	6
MVE-2	MVE-2:9	maleic anhydride divinyl ether copolymer:9:0.6794	0.6794	9
MVECs	MVECs:24	microvascular endothelial cells:24:0.6122	0.6122	24
MVEC	MVEC:50	microvascular endothelial cells:42:0.7311|microvascular endothelial cell:8:0.5006	0.7311	50
mVEP	mVEP:3|MVEP:3	visual evoked potential:6:0.2827	0.2827	6
MVE	MVE:68	Murray Valley encephalitis:68:0.9306	0.9306	68
MVE	MVE:27	Murray Valley encephalitis virus:27:0.8903	0.8903	27
MVF	MVF:7	voluntary force:7:0.1850	0.1850	7
MVG	MVG:23	myocardial velocity gradient:23:0.8715	0.8715	23
MVIC	MVIC:30	maximal voluntary isometric contraction:30:0.5017	0.5017	30
MVK	MVK:8	methyl vinyl ketone:8:0.6411	0.6411	8
MVMi	MVMi:12	minute virus of mice:12:0.7571	0.7571	12
MVMp	MVMp:30	minute virus of mice:30:0.9011	0.9011	30
MVM	MVM:14	microvillous membrane:14:0.1769	0.1769	14
MVM	MVM:18	microvillus membrane:18:0.2687	0.2687	18
MVM	MVM:154	minute virus of mice:154:0.9804	0.9804	154
MVM	MVM:6	syncytiotrophoblast microvillous:6:0.1543	0.1543	6
MVN	MVN:21	medial vestibular nuclei:21:0.8594	0.8594	21
MVN	MVN:130|mVN:1	medial vestibular nucleus:131:0.9772	0.9772	131
MVO(2)	MVO(2):46|MVo(2):5|MvO(2):2|mVO(2):1	myocardial oxygen consumption:54:0.7824	0.7824	54
MVO2	MVO2:5|MvO2:1	mixed venous oxygen saturation:6:0.5290	0.5290	6
MVO2	MVO2:64|MVo2:4	myocardial O2 consumption:68:0.6896	0.6896	68
MVO2	MVO2:327|MVo2:17|mVO2:3|Mvo2:1|MvO2:1	myocardial oxygen consumption:349:0.8068	0.8068	349
MVO2	MVO2:8|MVo2:1	myocardial oxygen uptake:9:0.3455	0.3455	9
MVOC	MVOC:12	microbial volatile organic compounds:12:0.6460	0.6460	12
MVOCs	MVOCs:10	microbial volatile organic compounds:10:0.6794	0.6794	10
MVO	MVO:8	Maximal Venous Outflow:8:0.1471	0.1471	8
MVO	MVO:11	maximum venous outflow:11:0.2972	0.2972	11
MVPA	MVPA:36	moderate to vigorous physical activity:20:0.8657|moderate-to-vigorous physical activity:16:0.2219	0.8657	36
MVPS	MVPS:23|MVPs:1	mitral valve prolapse syndrome:24:0.8768	0.8768	24
MVP	MVP:44|mvp:1	major vault protein:45:0.8964	0.8964	45
MVP	MVP:10	microvascular pressure:10:0.2446	0.2446	10
MVP	MVP:1	mitomycin vinblastine and cisplatin:1:0.2643	0.2643	1
MVP	MVP:438	mitral valve prolapse:438:0.9890	0.9890	438
MVP	MVP:10	mitral valve prolapse syndrome:10:0.7103	0.7103	10
MVP	MVP:8	mitral valvuloplasty:8:0.5006	0.5006	8
MVR-PCR	MVR-PCR:9	Minisatellite variant repeat mapping by PCR:9:0.6794	0.6794	9
MVR-PCR	MVR-PCR:1	Minisatellite variant repeat mapping by the polymerase chain reaction:1:0.5926	0.5926	1
MVR	MVR:20	Minisatellite variant repeat:20:0.8594	0.8594	20
MVR	MVR:7	mitral valve regurgitation:7:0.5926	0.5926	7
MVR	MVR:17|MVr:2	mitral valve repair:19:0.7658	0.7658	19
MVR	MVR:399	mitral valve replacement:372:0.9749|mitral valve replacements:27:0.8903	0.9749	399
MVR	MVR:25	vascular resistance:25:0.7679	0.7679	25
MVST	MVST:9	medial vestibulospinal tract:9:0.6794	0.6794	9
MVT	MVT:12	mesenteric vein thrombosis:12:0.7571	0.7571	12
MVT	MVT:20	mesenteric venous thrombosis:20:0.8525	0.8525	20
MVT	MVT:15	monomorphic ventricular tachycardia:15:0.6386	0.6386	15
MVV	MVV:67|mvv:2	maedi-visna virus:69:0.6740	0.6740	69
MVV	MVV:4	minute ventilation volume:4:0.0918	0.0918	4
MVV	MVV:145	voluntary ventilation:145:0.9794	0.9794	145
mVcf	mVcf:11|mVCF:4|MVCF:4|MVcf:2|mvcf:1|mVcF:1	mean velocity of circumferential fiber shortening:23:0.8768	0.8768	23
MVs	MVs:28	matrix vesicles:28:0.4668	0.4668	28
MV	MV:10|M-V:1	Maedi-Visna:11:0.0054	0.0054	11
MV	MV:17	maternal vein:17:0.3109	0.3109	17
MV	MV:12	Maternal venous:12:0.4557	0.4557	12
MV	MV:64	matrix vesicles:54:0.7654|matrix vesicle:10:0.4363	0.7654	64
MV	MV:17	maturation value:17:0.5038	0.5038	17
MV	MV:7|mV:2	mean flow velocity:9:0.3069	0.3069	9
MV	MV:21|mV:1	mean velocity:22:0.2456	0.2456	22
MV	MV:604	measles virus:595:0.8917|measles viruses:9:0.6794	0.8917	604
MV	MV:262|mv:1	mechanical ventilation:263:0.8130	0.8130	263
MV	MV:14|mv:1|Mv:1	mechanically ventilated:16:0.8165	0.8165	16
MV	MV:9|Mv:1	medial vestibular nucleus:10:0.7103	0.7103	10
MV	MV:12	megavoltage:12:0.0059	0.0059	12
MV	MV:38	methyl viologen:38:0.9217	0.9217	38
MV	MV:9	microvessels:9:0.0043	0.0043	9
MV	MV:16	Microvibration:16:0.0081	0.0081	16
MV	MV:31|mv:2|Mv:1	microvilli:34:0.0177	0.0177	34
MV	MV:31|Mv:1	minute volume:32:0.3241	0.3241	32
MV	MV:117	mitral valve:117:0.9225	0.9225	117
MWA	MWA:9|MwA:5	migraine without aura:14:0.8336	0.8336	14
MWCNTs	MWCNTs:15	carbon nanotubes:15:0.8045	0.8045	15
MWCO	MWCO:22|mwco:1	molecular weight cut-off:23:0.8715	0.8715	23
MWCO	MWCO:8	molecular weight cutoff:8:0.6411	0.6411	8
MWC	MWC:6	maximal working capacity:6:0.5926	0.5926	6
MWC	MWC:15	Monod-Wyman-Changeux:15:0.1772	0.1772	15
MWC	MWC:16	water content:16:0.8165	0.8165	16
MWC	MWC:6	work capacity:6:0.1148	0.1148	6
MWD	MWD:12	Maximal walking distance:12:0.1830	0.1830	12
MWD	MWD:19	maximum walking distance:19:0.4034	0.4034	19
MWD	MWD:14	molecular weight distribution:14:0.7909	0.7909	14
MWFs	MWFs:17	metalworking fluids:17:0.4480	0.4480	17
MWF	MWF:38	metalworking fluids:26:0.4874|metalworking fluid:12:0.3275	0.4874	38
MWF	MWF:10	Munich Wistar Fromter:10:0.7103	0.7103	10
MWI	MWI:12	microwave irradiation:12:0.7571	0.7571	12
MWIs	MWIs:9	waste incinerators:9:0.6794	0.6794	9
MWL	MWL:9	Milled wood lignin:9:0.6794	0.6794	9
MWM	MWM:7	medium-weight molecules:7:0.2452	0.2452	7
MWM	MWM:135	Morris water maze:135:0.9647	0.9647	135
MWNT	MWNT:10	carbon nanotube:10:0.5856	0.5856	10
MWNTs	MWNTs:28	carbon nanotubes:28:0.7154	0.7154	28
MWs	MWs:57|Mws:3	molecular weights:60:0.9503	0.9503	60
MWS	MWS:16	Muckle-Wells syndrome:16:0.2923	0.2923	16
MWT	MWT:38	Maintenance of Wakefulness Test:38:0.9237	0.9237	38
MWT	MWT:5	walk time:5:0.1132	0.1132	5
MWT	MWT:22	wall thickness:22:0.8657	0.8657	22
MWOA	MwoA:8|MWOA:8|MWoA:3	migraine without aura:19:0.7044	0.7044	19
MW	MW:13	High-molecular-weight:13:0.0073	0.0073	13
MW	MW:92|mw:3	microwave:95:0.0576	0.0576	95
MW	MW:5	millimeter waves:5:0.1132	0.1132	5
MW	MW:8|Mw:2	mol wt:10:0.7357	0.7357	10
Mw	Mw:7|MW:6	molecular mass:13:0.3331	0.3331	13
MW	MW:1019|Mw:121|mw:20	molecular weight:1017:0.9504|molecular weights:143:0.9666	0.9666	1160
MW	MW:9	Munich-Wistar:9:0.0049	0.0049	9
Mw	Mw:12|MW:2	slope:14:0.0080	0.0080	14
Mw	Mw:5	weight-average molar mass:5:0.1973	0.1973	5
MXA	MXA:20	morphometric X-ray absorptiometry:20:0.7044	0.7044	20
MXC	MXC:70|Mxc:1	methoxychlor:71:0.8537	0.8537	71
MXF	MXF:12	moxifloxacin:12:0.8462	0.8462	12
MXN	MXN:11	mitoxantrone:11:0.7692	0.7692	11
MXR	MXR:16|mxr:1	multixenobiotic resistance:17:0.6577	0.6577	17
MXT	MXT:9|Mxt:1	Methotrexate:10:0.3214	0.3214	10
MXT	MXT:9	mitoxantrone:9:0.2857	0.2857	9
MX	MX:110|mx:1	3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone:90:0.2549|3-chloro-4-(dichloromethyl)-5-hydroxy-2[5H]-furanone:21:0.0560	0.2549	111
MX	MX:10	methoxyamine:10:0.0252	0.0252	10
MX	MX:37|Mx:6	Mitoxantrone:43:0.1176	0.1176	43
MX	MX:18	musk xylene:18:0.8365	0.8365	18
MYA	MYA:30|mya:20|Mya:19	million years ago:69:0.9316	0.9316	69
MYH7	MYH7:10	beta-myosin heavy chain:10:0.5856	0.5856	10
MYH7	MYH7:13	heavy chain gene:13:0.7753	0.7753	13
MYMOP	MYMOP:7	measure yourself medical outcome profile:7:0.5926	0.5926	7
MYO	MYO:13|myo:12	myoglobin:25:0.4364	0.4364	25
MYPT1	MYPT1:10	myosin phosphatase target subunit 1:10:0.7357	0.7357	10
Myr	Myr:74|myr:6|MYR:1	million years:81:0.9415	0.9415	81
Myt1	Myt1:6|MyT1:4|MYT1:3	myelin transcription factor 1:13:0.7753	0.7753	13
MYTH	MYTH:23	Matthews Youth Test for Health:23:0.8186	0.8186	23
MY	MY:13	milk yield:13:0.7753	0.7753	13
MY	MY:20|my:14|My:5	million years:39:0.8455	0.8455	39
MZBCL	MZBCL:14	marginal zone B-cell lymphoma:14:0.7909	0.7909	14
MZB	MZB:6|MZ-B:3	marginal zone B:9:0.6794	0.6794	9
MZL	MZL:40	marginal zone lymphoma:28:0.4539|marginal zone lymphomas:12:0.5664	0.5664	40
MZR	MZR:26	mizoribine:26:0.9259	0.9259	26
MZ	MZ:14	identical:14:0.0128	0.0128	14
MZ	MZ:123	marginal zone:123:0.7939	0.7939	123
MZ	MZ:16|Mz:1	metronidazole:17:0.0158	0.0158	17
MZ	MZ:13|Mz:2	mizoribine:15:0.0138	0.0138	15
MZ	MZ:650|mz:1|Mz:1	monozygotic:652:0.6430	0.6430	652
MZ	MZ:10	monozygotic twins:10:0.5000	0.5000	10
MZ	MZ:42|Mz:2	monozygous:44:0.0424	0.0424	44
mAbs	mAbs:10|MAbs:9	monoclonal Abs:19:0.8449	0.8449	19
MAbs	MAbs:3751|mAbs:2740|Mabs:531|mabs:111|MABs:95|mABs:17|MABS:9|m-Abs:1|MAb-s:1	monoclonal antibodies:7256:0.9892	0.9892	7256
MalNEt	MalNEt:26|MalNet:1	N-ethylmaleimide:27:0.7879	0.7879	27
Man-6-P	Man-6-P:50|Man6P:15|Man6-P:4|man-6-P:4|man6P:1|Man-6P:1	mannose 6-phosphate:58:0.7135|mannose-6-phosphate:17:0.1702	0.7135	75
ManLAM	ManLAM:13|manLAM:1	lipoarabinomannan:14:0.4483	0.4483	14
ManNAc	ManNAc:9	N-acetyl-D-mannosamine:9:0.1860	0.1860	9
ManNAc	ManNAc:24|manNac:1	N-acetylmannosamine:25:0.5349	0.5349	25
MART	MART:8	maximal anaerobic running test:8:0.6411	0.6411	8
Mass	Mass:18	Massachusetts:18:0.0971	0.0971	18
MAV-1	MAV-1:21	mouse adenovirus type 1:21:0.6812	0.6812	21
MaxEPA	MaxEPA:2|Maxepa:2|MaxEpa:1	fish oil concentrate:5:0.5290	0.5290	5
Maxi-K	Maxi-K:5|maxi-K:4|MaxiK:1|maxiK:1	Ca2+-activated K+:11:0.1938	0.1938	11
maxi-K	maxi-K:12|Maxi-K:3|MaxiK:1|maxiK:1	calcium-activated potassium:17:0.4246	0.4246	17
Maxon	Maxon:19	Polyglyconate:19:0.4286	0.4286	19
MbCO	MbCO:10	carbonmonoxy myoglobin:10:0.3145	0.3145	10
MbCO	MbCO:13	carboxymyoglobin:13:0.2000	0.2000	13
MbO2	MbO2:20	oxymyoglobin:20:0.7308	0.7308	20
M-bcr	M-bcr:33|Mbcr:8|M-BCR:8|M-Bcr:1|mbcr:1	major breakpoint cluster region:51:0.7371	0.7371	51
MB	MB:9	bacteria:9:0.0041	0.0041	9
mb	mb:13|Mb:13|MB:2|mB:1	body mass:29:0.8422	0.8422	29
MB	MB:26	Mallory body:18:0.1262|Mallory bodies:8:0.0566	0.1262	26
MB	MB:25	mammillary body:15:0.0939|mammillary bodies:10:0.1166	0.1166	25
MB	MB:11	marginal band:11:0.2582	0.2582	11
MB	MB:13	maternal behavior:13:0.7753	0.7753	13
MB	MB:48|Mb:1	medulloblastoma:49:0.0245	0.0245	49
Mb	Mb:89|mb:1	megabases:58:0.0291|megabase:32:0.0158	0.0291	90
Mb	Mb:13|mb:3	megabase pairs:16:0.3831	0.3831	16
MB	MB:10|mb:6|M-B:3	membrane-bound:19:0.0092	0.0092	19
MB	MB:7|mb:3	mesiobuccal:10:0.0046	0.0046	10
MB	MB:10	methyl bromide:10:0.3867	0.3867	10
MB	MB:377|Mb:1	methylene blue:378:0.9248	0.9248	378
MB	MB:20|Mb:3	midbrain:23:0.0112	0.0112	23
Mb	Mb:8|mb:1	million base pairs:9:0.6794	0.6794	9
MB	MB:11	molecular beacon:11:0.7357	0.7357	11
MB	MB:130	multibacillary:130:0.0659	0.0659	130
MB	MB:44	mushroom body:34:0.3158|mushroom bodies:10:0.0958	0.3158	44
MB	MB:11	Myocardial bridge:11:0.5000	0.5000	11
MB	MB:7	myocardial bridging:7:0.3524	0.3524	7
Mb	Mb:423|MB:9	myoglobin:432:0.2201	0.2201	432
MC3	MC3:11|Mc3:3|MC-3:1	third metacarpal bone:15:0.8045	0.8045	15
MC4	MC4:5|MC-4:5	Melanocortin-4:10:0.2647	0.2647	10
McAbs	McAbs:174|mcAbs:6|MCABs:4|MCAbs:3|mcabs:3|Mcabs:2|McABS:1	monoclonal antibodies:193:0.9752	0.9752	193
MCK	MCK:55|mck:3|M-CK:3	muscle creatine kinase:61:0.6532	0.6532	61
MDE	MDE:13	3,4-Methylenedioxyethylamphetamine:13:0.0474	0.0474	13
MDE	MDE:137	major depressive episode:117:0.9744|major depressive episodes:20:0.8525	0.9744	137
MDE	MDE:14	N-ethyl-3,4-methylenedioxyamphetamine:14:0.0514	0.0514	14
Mdal	Mdal:27|MDal:2|mdal:1	megadaltons:19:0.4286|megadalton:11:0.2381	0.4286	30
Me(2)SO	Me(2)SO:28	dimethyl sulfoxide:28:0.8941	0.8941	28
Me2SO	Me2SO:132	dimethyl sulfoxide:132:0.9639	0.9639	132
Me2SO	Me2SO:16|ME2SO:1	dimethyl sulphoxide:17:0.8270	0.8270	17
Me2SO	Me2SO:33|ME2SO:1	dimethylsulfoxide:34:0.1701	0.1701	34
Me5	Me5:11	mesencephalic trigeminal nucleus:11:0.7357	0.7357	11
MeArg	MeArg:10	NG-monomethyl-L-arginine:10:0.6000	0.6000	10
MeBr	MeBr:32	Methyl bromide:32:0.9072	0.9072	32
MeCN	MeCN:27	acetonitrile:27:0.8667	0.8667	27
MeCbl	MeCbl:20|Me-Cbl:8	methylcobalamin:28:0.8438	0.8438	28
MeCh	MeCh:9|MeCH:1	methacholine:10:0.2727	0.2727	10
MeCl	MeCl:17	Methyl chloride:17:0.7407	0.7407	17
MeHg	MeHg:86|Me-Hg:1|meHg:1	methyl mercury:88:0.8845	0.8845	88
MeHg	MeHg:6	methyl mercury chloride:6:0.3728	0.3728	6
MeHg	MeHg:9	methylmercuric chloride:9:0.1205	0.1205	9
MeHg	MeHg:361|Me-Hg:5|meHg:2	methylmercury:368:0.6977	0.6977	368
MeHg	MeHg:8	methylmercury chloride:8:0.0906	0.0906	8
MeIQx	MeIQx:9	2-amino-3,8-dimethyl-imidazo[4,5-f]quinoxaline:9:0.0272	0.0272	9
MeIQx	MeIQx:207|MeIQX:2|Me-IQx:1	2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline:210:0.7041	0.7041	210
MeJA	MeJA:72|MeJa:8|Me-JA:2|meJA:1	methyl jasmonate:83:0.9429	0.9429	83
MeNU	MeNU:8|MeNu:1	N-methyl-N-nitrosourea:9:0.7273	0.7273	9
MeSH	MeSH:69|MESH:1	Medical Subject Headings:70:0.8919	0.8919	70
MeTase	MeTase:8	DNA methyltransferase:8:0.5006	0.5006	8
MeWo	MeWo:8|Mewo:1	melanoma cells:9:0.6794	0.6794	9
MEB	MEB:30	muscle-eye-brain disease:30:0.8032	0.8032	30
Meb	Meb:7	treated ig with mebendazole:7:0.5926	0.5926	7
MeCP2	MECP2:3|MeCP2:3	methyl-CpG-binding protein:6:0.1543	0.1543	6
MeCP2	MeCP2:13|MECP2:8	methyl-CpG binding protein 2:21:0.5435	0.5435	21
MECP2	MECP2:6	mutations in the methyl-CpG-binding protein 2 gene:6:0.2446	0.2446	6
MECS	MECS:9	current source:9:0.6794	0.6794	9
MECs	MECs:20|mecs:1	mammary epithelial cells:21:0.6400	0.6400	21
MECs	MECs:10|mECs:2	microvascular endothelial cells:12:0.6460	0.6460	12
MECs	MECs:6	minimal effective concentrations:6:0.3728	0.3728	6
MedDRA	MedDRA:13	medical dictionary for regulatory activities:13:0.7753	0.7753	13
Medpor	Medpor:20	porous polyethylene:20:0.6259	0.6259	20
Meg-CFC	Meg-CFC:7|MEG-CFC:4	megakaryocyte colony-forming cells:11:0.6182	0.6182	11
Meg-CSF	Meg-CSF:11	megakaryocyte colony-stimulating factor:11:0.7357	0.7357	11
MEL	MEL:11	erythroleukemia cells:11:0.5355	0.5355	11
MEL	MEL:151|Mel:72|mel:3	melatonin:226:0.2443	0.2443	226
Mel	Mel:8|MEL:5	melittin:13:0.0130	0.0130	13
MEL	MEL:28|Mel:20	melphalan:48:0.0510	0.0510	48
MEL	MEL:17	mouse erythroleukaemia:17:0.2074	0.2074	17
MEL	MEL:140|Mel:2	mouse erythroleukemia:142:0.3008	0.3008	142
MEL	MEL:6	mouse erythroleukemic:6:0.0611	0.0611	6
MEL	MEL:27	murine erythroleukaemia:27:0.4190	0.4190	27
MEL	MEL:252	murine erythroleukemia:252:0.5715	0.5715	252
MEL	MEL:13	murine erythroleukemic:13:0.4102	0.4102	13
Mena	Mena:9	Mammalian enabled:9:0.6794	0.6794	9
MePD	MePD:13	medial amygdala:13:0.5934	0.5934	13
mER	mER:5|Mer:1	estrogen receptor:6:0.1543	0.1543	6
mer	mer:23|Mer:9	mercury resistance:32:0.7458	0.7458	32
MER	MER:27	methanol extraction residue:27:0.8903	0.8903	27
MER	MER:8	methanol extraction residue of Bacillus Calmette-Guerin:8:0.6411	0.6411	8
MER	MER:12	methanol extraction residue of BCG:12:0.7571	0.7571	12
MER	MER:5	molar esterification rate:5:0.4422	0.4422	5
mesna	mesna:5|MESNA:3	2-mercaptoethane sulphonate:8:0.3463	0.3463	8
mesna	mesna:11|Mesna:4|MESNA:2|MesNa:1	Sodium 2-mercaptoethane sulfonate:18:0.4226	0.4226	18
mesna	mesna:7|Mesna:3|MESNA:1	sodium 2-mercaptoethanesulfonate:11:0.1938	0.1938	11
MetAP2	MetAP2:14|MetAP-2:8|MetAp2:1	methionine aminopeptidase-2:12:0.7571|methionine aminopeptidase 2:11:0.7357	0.7571	23
MetAP	MetAP:19|Met-AP:1	methionine aminopeptidase:20:0.7766	0.7766	20
metHb	metHb:13|MetHb:10|Met-Hb:4	methaemoglobin:27:0.1116	0.1116	27
MetHb	MetHb:90|metHb:61|Met-Hb:14|met-Hb:7|METHB:6|metHB:1|MetHB:1	methemoglobin:180:0.7682	0.7682	180
MetRS	MetRS:38	methionyl-tRNA synthetase:38:0.8098	0.8098	38
METH	METH:193|Meth:57|meth:7	methamphetamine:257:0.7642	0.7642	257
MEXFAM	MEXFAM:8|Mexfam:1	Mexican Foundation for Family Planning:9:0.5470	0.5470	9
MEZ	MEZ:30|Mez:3	mezerein:33:0.6957	0.6957	33
Mg(2+)	Mg(2+):30	magnesium:30:0.6304	0.6304	30
Mg(i)	Mg(i):10	magnesium:10:0.9000	0.9000	10
Mg++	Mg++:27|MG++:1	magnesium:28:0.6750	0.6750	28
Mg2+	Mg2+:11	divalent cation:11:0.4728	0.4728	11
Mg2+	Mg2+:145	magnesium:145:0.5760	0.5760	145
Mg2+	Mg2+:38	magnesium ions:20:0.7766|magnesium ion:18:0.8365	0.8365	38
MgCl2	MgCl2:24	magnesium chloride:24:0.7593	0.7593	24
MgSO(4)	MgSO(4):13	magnesium sulfate:13:0.7753	0.7753	13
MgSO4	MgSO4:91	magnesium sulfate:91:0.9015	0.9015	91
MgSO4	MgSO4:49	magnesium sulphate:49:0.9392	0.9392	49
MGE	MGE:17	medial ganglionic eminence:17:0.8270	0.8270	17
MGE	MGE:9	mobile genetic elements:9:0.6794	0.6794	9
Mi-ADMS	Mi-ADMS:10	Monoisoamyl meso-2,3-dimercaptosuccinate:10:0.5856	0.5856	10
Mi-CK	Mi-CK:8|MiCK:1	mitochondrial:9:0.1111	0.1111	9
Mi-CK	Mi-CK:5|mi-CK:2|MiCK:2	mitochondrial CK:9:0.3945	0.3945	9
Mi-CK	Mi-CK:34|mi-CK:7|MiCK:2	Mitochondrial creatine kinase:43:0.8917	0.8917	43
MIO	MIO:7	interincisal opening:7:0.2452	0.2452	7
MIPO	MIPO:12	minimally invasive plate osteosynthesis:12:0.7571	0.7571	12
MIA	MIA:33	melanoma inhibitory activity:33:0.8605	0.8605	33
MIA	MIA:7	methylisobutyl amiloride:7:0.1470	0.1470	7
MIA	MIA:16|Mia:3	mianserin:19:0.0698	0.0698	19
Mirena	Mirena:11	intrauterine system:11:0.6182	0.6182	11
MITRA	MITRA:21	Maximal Individual Therapy in Acute Myocardial Infarction:21:0.8715	0.8715	21
MLA	MLA:23	Medical Library Association:23:0.8715	0.8715	23
MLA	MLA:78	methyllycaconitine:78:0.3263	0.3263	78
MLA	MLA:7|mLA:1	minimum lumen area:8:0.2619	0.2619	8
MLA	MLA:22	mouse lymphoma assay:22:0.7955	0.7955	22
MLS	MLS:17	macrolide-lincosamide-streptogramin:17:0.0309	0.0309	17
MLS	MLS:25	macrolide-lincosamide-streptogramin B:25:0.3470	0.3470	25
MLs	MLs:12	malignant lymphomas:12:0.6460	0.6460	12
MLS	MLS:22	maximum length sequence:12:0.6460|maximum length sequences:10:0.7103	0.7103	22
MLS	MLS:13	maximum likelihood score:13:0.7753	0.7753	13
MLS	MLS:42	maximum lod score:36:0.5852|maximum lod scores:6:0.5290	0.5852	42
MLS	MLS:26	microphthalmia with linear skin defects:26:0.8768	0.8768	26
Mls	Mls:28|MLS:1	minor lymphocyte stimulating:20:0.8525|Minor lymphocyte-stimulating:9:0.6794	0.8525	29
Mls	Mls:18	Minor lymphocyte stimulatory:18:0.6903	0.6903	18
MLS	MLS:8	myxoid liposarcomas:8:0.5006	0.5006	8
MLS	MLS:9	Platelet mean life span:9:0.5470	0.5470	9
MLS	MLS:15	syndrome:15:0.0251	0.0251	15
Mm-MAST	Mm-MAST:5|MmMAST:1	Malmo modified Michigan Alcoholism Screening Test:6:0.5290	0.5290	6
Mn(2+)	Mn(2+):12	Manganese:12:0.4074	0.4074	12
Mn2+	Mn2+:5	agonist-induced Ca2+:5:0.0517	0.0517	5
Mn2+	Mn2+:45	manganese:45:0.3750	0.3750	45
Mn2+	Mn2+:23	manganese ion:13:0.5335|manganese ions:10:0.5000	0.5335	23
MnBK	MnBK:9|MNBK:1	Methyl n-butyl ketone:10:0.7103	0.7103	10
MnCl2	MnCl2:31	manganese chloride:31:0.7388	0.7388	31
MnDPDP	MnDPDP:18|Mn-DPDP:9|MN-DPDP:1	Mangafodipir trisodium:28:0.8251	0.8251	28
MnDPDP	MnDPDP:9|Mn-DPDP:1	manganese dipyridoxyl diphosphate:10:0.3867	0.3867	10
MnPO	MnPO:83|MnPo:2|mnpo:1|MNPO:1	median preoptic nucleus:87:0.9455	0.9455	87
MnSODs	MnSODs:8|Mn-SODs:4	superoxide dismutases:12:0.6460	0.6460	12
Mn-SOD	Mn-SOD:7|MnSOD:6|MnSod:2	manganese-containing SOD:15:0.1495	0.1495	15
MnSOD	MnSOD:496|Mn-SOD:147	manganese superoxide dismutase:643:0.7378	0.7378	643
MNX	MNX:9	hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine:9:0.4211	0.4211	9
MN	MN:11	blood monocytes:11:0.1285	0.1285	11
Mn	Mn:496|MN:2	manganese:498:0.2033	0.2033	498
MN	MN:9	Mauthner neurons:9:0.2500	0.2500	9
MN	MN:9	meal number:9:0.3069	0.3069	9
MN	MN:26	median nerve:26:0.4438	0.4438	26
MN	MN:19	Melanocytic nevi:19:0.8449	0.8449	19
MN	MN:176	Membranous nephropathy:176:0.9556	0.9556	176
MN	MN:10	mental nerve:10:0.0877	0.0877	10
MN	MN:16	methyl nicotinate:16:0.8165	0.8165	16
MN	MN:11	micrococcal nuclease:11:0.7357	0.7357	11
MN	MN:515|Mn:7|mn:1	micronuclei:523:0.2127	0.2127	523
MN	MN:402|Mn:4	micronucleus:406:0.1650	0.1650	406
MN	MN:9	micronucleus assay:9:0.6794	0.6794	9
MN	MN:8	micronucleus test:8:0.5006	0.5006	8
MN	MN:20	mononuclear cells:20:0.7173	0.7173	20
MN	MN:47|Mn:7	motoneuron:34:0.0134|motoneurons:20:0.0077	0.0134	54
MN	MN:13	motor neuron:7:0.2902|motor neurons:6:0.0807	0.2902	13
MN	MN:14	nucleus:14:0.0053	0.0053	14
Mn	Mn:9|MN:1	number average molecular weight:10:0.6182	0.6182	10
Mo5	Mo5:6	trigeminal motor nucleus:6:0.5290	0.5290	6
MoAb's	MoAb's:6|moab's:1|moAB's:1|MOAb's:1	Monoclonal antibodies:9:0.6794	0.6794	9
MoAbs	MoAbs:1101|moAbs:31|MoABs:15|Moabs:12|moabs:12|moABs:7|MOABs:4|Mo-Abs:3	monoclonal antibodies:1185:0.9874	0.9874	1185
MoAb	MoAb:1652|moAb:38|MoAB:15|Moab:13|moab:11|MOAB:7|moAB:5|Mo-Ab:1	monoclonal antibody:1191:0.9752|monoclonal antibodies:551:0.9856	0.9856	1742
MOAS	MOAS:8	Modified Overt Aggression Scale:8:0.6411	0.6411	8
Moco	Moco:23|MoCo:17	molybdenum cofactor:40:0.7201	0.7201	40
MoFe	MoFe:19|Mo-Fe:1	molybdenum-iron:20:0.8261	0.8261	20
MoLV	MoLV:9|MOLV:2	leukemia virus:11:0.6182	0.6182	11
MoMLV	MoMLV:73|Mo-MLV:26	Moloney murine leukemia virus:99:0.9352	0.9352	99
Mo-MSV	Mo-MSV:14|MoMSV:5|MO-MSV:1	Moloney murine sarcoma virus:20:0.8525	0.8525	20
MoMs	MoMs:6|MOMs:1	multiples of the median:7:0.3524	0.3524	7
Mo-MuLV	Mo-MuLV:77|MoMuLV:64	Moloney murine leukemia virus:141:0.9551	0.9551	141
Mo-MuSV	Mo-MuSV:11|MoMuSV:8	Moloney murine sarcoma virus:19:0.8449	0.8449	19
MoPn	MoPn:10	Chlamydia trachomatis:10:0.3470	0.3470	10
MoPn	MoPn:39	mouse pneumonitis:39:0.8839	0.8839	39
MON	MON:12|Mon:7	monensin:19:0.2500	0.2500	19
MON	MON:6|Mon:3	moniliformin:9:0.1111	0.1111	9
MOR	MOR:109|Mor:28	morphine:137:0.3077	0.3077	137
MOR	MOR:12|Mor:1	mortality odds ratio:13:0.3809	0.3809	13
MOR	MOR:152|mor:4|Mor:3|mOR:1	mu-opioid receptor:86:0.3978|mu opioid receptor:59:0.7824|mu-opioid receptors:15:0.5348	0.7824	160
Mphi	Mphi:315|MPhi:57|mphi:15|mPhi:1	macrophages:307:0.7077|macrophage:81:0.1856	0.7077	388
Mph	Mph:16|MPH:5|mph:1	macrophages:22:0.0524	0.0524	22
MPH	MPH:22	male pseudohermaphroditism:22:0.7955	0.7955	22
MPH	MPH:194|Mph:1|MPh:1	methylphenidate:196:0.4863	0.4863	196
MPH	MPH:6	methylphenidate hydrochloride:6:0.1148	0.1148	6
MPH	MPH:21	public health:21:0.8594	0.8594	21
MPS-I	MPS-I:7|MPSI:1	mucopolysaccharidosis type I:8:0.6411	0.6411	8
Mptb	Mptb:9|MPTB:1	paratuberculosis:10:0.9000	0.9000	10
MscL	MscL:1	mechanosensitive channel with very large conductance:1:0.6701	0.6701	1
MscL	MscL:10	mechanosensitive ion channel:10:0.7103	0.7103	10
MsrA	MsrA:24|MSRA:2|msrA:1	methionine sulfoxide reductase:27:0.7834	0.7834	27
msw	msw:7	meters of seawater:7:0.2090	0.2090	7
MSW	MSW:183	municipal solid waste:164:0.9817|municipal solid wastes:19:0.8449	0.9817	183
msw	msw:14|Msw:4|mSW:2|MSW:1	sweat rate:21:0.3899	0.3899	21
msw	msw:12|Msw:3	sweating rate:15:0.2264	0.2264	15
MtCK	MtCK:9|mtCK:5|mt-CK:2	Mitochondrial Creatine Kinase:16:0.7261	0.7261	16
MT-III	MT-III:15	metallothionein-III:15:0.3415	0.3415	15
MtPK	MtPK:10|Mt-PK:6|MT-PK:5|MTPK:2	myotonin protein kinase:23:0.8038	0.8038	23
MTS	MTS:13|M-t-S:1	matching-to-sample:14:0.0096	0.0096	14
MTS	MTS:97	mesial temporal sclerosis:97:0.9073	0.9073	97
MTs	MTs:298|Mts:2|MTS:2	Metallothioneins:302:0.2213	0.2213	302
MTS	MTS:51	methanethiosulfonate:51:0.0368	0.0368	51
MTs	MTs:412|Mts:18|mts:3	microtubules:433:0.3176	0.3176	433
MTS	MTS:17	Mitochondrial targeting sequence:17:0.8270	0.8270	17
MTS	MTS:9	mitochondrial targeting signal:9:0.6794	0.6794	9
MTs	MTs:7	motor thresholds:7:0.2902	0.2902	7
MTS	MTS:34	Muir-Torre syndrome:34:0.6386	0.6386	34
MTS	MTS:59	multicellular tumor spheroids:41:0.7952|multicellular tumour spheroids:10:0.5856|multicellular tumor spheroid:8:0.6411	0.7952	59
MTS	MTS:7	testing system:7:0.0951	0.0951	7
MuLVs	MuLVs:65	murine leukemia viruses:65:0.9541	0.9541	65
MuLV	MuLV:545|MULV:1	murine leukemia virus:481:0.9541|murine leukemia viruses:65:0.9047	0.9541	546
MuMTV	MuMTV:72	murine mammary tumor virus:72:0.5504	0.5504	72
MuSV	MuSV:16	murine sarcoma virus:16:0.7261	0.7261	16
MudPIT	MudPIT:16	multidimensional protein identification technology:16:0.7909	0.7909	16
MurA	MurA:13	UDP-N-acetylglucosamine enolpyruvyl transferase:13:0.5934	0.5934	13
MurB	MurB:10	UDP-N-acetylenolpyruvylglucosamine reductase:10:0.5856	0.5856	10
MurNAc	MurNAc:10	N-acetylmuramic acid:10:0.7103	0.7103	10
Mv1Lu	Mv1Lu:15|Mv1LU:1|Mv-1-Lu:1	mink lung epithelial cells:17:0.8270	0.8270	17
MyBP-C	MyBP-C:32|MyBPC:3	myosin binding protein C:24:0.8715|myosin binding protein-C:11:0.7357	0.8715	35
MYBP	MYBP:9|mybp:1	million years before present:10:0.7103	0.7103	10
MyD88	MyD88:64	myeloid differentiation factor 88:64:0.9264	0.9264	64
MyD	MyD:10	myeloid differentiation primary response:10:0.7103	0.7103	10
myd	myd:13	myodystrophy:13:0.0667	0.0667	13
MyD	MyD:121|MYD:5	Myotonic dystrophy:126:0.8406	0.8406	126
MyHC	MyHC:233|myHC:2|MYHC:1	myosin heavy chain:209:0.8892|myosin heavy-chain:14:0.7909|myosin heavy chains:13:0.7753	0.8892	236
N(2)O	N(2)O:109	nitrous oxide:109:0.9047	0.9047	109
N(2)	N(2):19	nitrogen:19:0.5143	0.5143	19
N(e)	N(e):18	effective population size:18:0.8365	0.8365	18
N-5'	N-5':17	anthranilic acid:17:0.5760	0.5760	17
N-BNP	N-BNP:25	natriuretic peptide:25:0.8816	0.8816	25
N-OH-AAF	N-OH-AAF:61|N-OH-AAf:1	N-hydroxy-2-acetylaminofluorene:62:0.6854	0.6854	62
N-OH-ABP	N-OH-ABP:15	N-hydroxy-4-aminobiphenyl:15:0.6364	0.6364	15
N-OH-AF	N-OH-AF:12	N-hydroxy-2-aminofluorene:12:0.5238	0.5238	12
N-WASP	N-WASP:30|N-WASp:1	Neural Wiskott-Aldrich Syndrome Protein:31:0.6572	0.6572	31
N.Acc.	N.Acc.:19|N.ACC.:1|N.acc.:1|n.Acc.:1	nucleus accumbens:22:0.7955	0.7955	22
N.Acc	N.Acc:10|n.acc:1|N.acc:1|n.Acc:1	nucleus accumbens:13:0.6701	0.6701	13
N/C	N/C:38|n/c:1	nuclear/cytoplasmic:24:0.1983|nuclear-cytoplasmic:9:0.0690|nuclear cytoplasmic:6:0.6182	0.6182	39
N/C	N/C:9	nucleocytoplasmic:9:0.0690	0.0690	9
N/C	N/C:19	ratio:19:0.1552	0.1552	19
N/OFQ	N/OFQ:131	Nociceptin/orphanin FQ:131:0.8842	0.8842	131
N/S	N/S:13	normal saline:13:0.7753	0.7753	13
N0	N0:9	clinically negative:9:0.1809	0.1809	9
N0	N0:6	clinically negative neck:6:0.5290	0.5290	6
N0	N0:5	lymph node involvement:5:0.4422	0.4422	5
N0	N0:26|n0:2	node-negative:18:0.1069|node negative:10:0.2275	0.2275	28
n-13	n-13:9	nitrogen-13:9:0.1127	0.1127	9
N18	N18:3|N-18:2	mouse neuroblastoma:5:0.1132	0.1132	5
N1	N1:13	action potential:13:0.3809	0.3809	13
N1	N1:12	lymph node metastases:12:0.5664	0.5664	12
N1	N1:25	negative:25:0.0456	0.0456	25
N1	N1:9	negative component:9:0.2500	0.2500	9
N1	N1:16|n1:1	negative peak:17:0.6211	0.6211	17
N1	N1:22	negative wave:22:0.6767	0.6767	22
N1	N1:14	negativity:14:0.0247	0.0247	14
N20	N20:8	primary cortical response:8:0.5000	0.5000	8
N-22	N-22:11	toxicity study of mofezolac:11:0.6182	0.6182	11
N2OR	N2OR:8	nitrous oxide reductase:8:0.6411	0.6411	8
N2O	N2O:626|n2o:1	nitrous oxide:627:0.9572	0.9572	627
N2A	N2A:14|N2a:11|N-2A:1	neuroblastoma:26:0.3086	0.3086	26
N2A	N2A:5|N2a:1	neuroblastoma 2A:6:0.1838	0.1838	6
N3-	N3-:9	azide:9:0.4211	0.4211	9
n-3FA	n-3FA:6|n-3-FA:2|n-3fa:1	fatty acids:9:0.5470	0.5470	9
n-3	n-3:44|n3:1	omega-3:39:0.0442|omega 3:6:0.1320	0.1320	45
n-6	n-6:9|n6:1	omega-6:10:0.0178	0.0178	10
N-9	N-9:94|N9:12	nonoxynol-9:106:0.4558	0.4558	106
Na(+)	Na(+):41|NA(+):1	sodium:42:0.6833	0.6833	42
NAA/Cr	NAA/Cr:5	creatine ratio:5:0.0902	0.0902	5
NAA/Cr	NAA/Cr:10	N-acetylaspartate/creatine:10:0.1731	0.1731	10
NA-AAF	NA-AAF:21	N-acetoxy-2-acetylaminofluorene:21:0.6250	0.6250	21
NAADP	NAADP:19	Nicotinic acid-adenine dinucleotide phosphate:19:0.8449	0.8449	19
NAAG	NAAG:30	N-acetyl-aspartyl-glutamate:30:0.1443	0.1443	30
NAAG	NAAG:129	N-Acetylaspartylglutamate:129:0.6368	0.6368	129
NAAG	NAAG:4	neuropeptide N-acetyl-L-aspartyl-L-glutamate:4:0.1148	0.1148	4
NAAQS	NAAQS:54|NAAQs:1	National Ambient Air Quality Standard:28:0.8369|national ambient air quality standards:27:0.8903	0.8903	55
NAATs	NAATs:21	nucleic acid amplification tests:21:0.8594	0.8594	21
NAbs	NAbs:25|NABs:8|nAbs:3|NABS:1|Nabs:1	neutralizing antibodies:38:0.5462	0.5462	38
NAB	NAB:11	acid breakthrough:11:0.7357	0.7357	11
NAb	NAb:31|nAb:3|Nab:2|N-Ab:1|N-AB:1|n-Ab:1	natural antibodies:26:0.1978|natural antibody:13:0.0949	0.1978	39
NAb	NAb:48|NAB:24|nAb:12|N-Ab:2|nab:2|Nab:2	Neutralizing antibodies:50:0.4758|neutralizing antibody:40:0.5164	0.5164	90
NaB	NaB:112|NAB:1	Sodium butyrate:113:0.9310	0.9310	113
NACB	NACB:5|NAcb:3|Nacb:3|nAcb:2|nACB:1	nucleus accumbens:14:0.7909	0.7909	14
NACDG	NACDG:12	North American Contact Dermatitis Group:12:0.6460	0.6460	12
NACE	NACE:16	Non-aqueous capillary electrophoresis:16:0.1526	0.1526	16
NACE	NACE:39	nonaqueous capillary electrophoresis:39:0.5663	0.5663	39
NACI	NACI:25	New Approaches to Coronary Intervention:25:0.8816	0.8816	25
NACO	NACO:12	National AIDS Control Organization:12:0.7571	0.7571	12
NACP	NACP:8	component of Alzheimer's disease amyloid:8:0.6411	0.6411	8
NACT	NACT:26|NA-CT:1	Neoadjuvant chemotherapy:27:0.7834	0.7834	27
NAC	NAC:13	antioxidant N-acetyl-cysteine:13:0.0749	0.0749	13
NAC	NAC:32	antioxidant N-acetyl-L-cysteine:32:0.0878	0.0878	32
NAC	NAC:12|nac:2	component:14:0.0042	0.0042	14
NAC	NAC:5	component of AD amyloid:5:0.1464	0.1464	5
NAC	NAC:11	component of Alzheimer's disease amyloid:11:0.7357	0.7357	11
NAC	NAC:113|NAc:2|N-ac:1|nAC:1	N-acetyl cysteine:117:0.9225	0.9225	117
NAC	NAC:14	N-Acetyl L-Cysteine:14:0.5111	0.5111	14
NAC	NAC:13	N-acetylcystein:13:0.0042	0.0042	13
NAC	NAC:1008|N-ac:5|N-Ac:5|Nac:2|NAc:2	N-acetylcysteine:1022:0.3601	0.3601	1022
NAC	NAC:14	nasal allergen challenge:14:0.7909	0.7909	14
NAC	NAC:20	nascent polypeptide-associated complex:20:0.8525	0.8525	20
NAC	NAC:9	needle aspiration cytology:9:0.6794	0.6794	9
NAC	NAC:66|NA-C:1	neoadjuvant chemotherapy:67:0.8075	0.8075	67
NAC	NAC:9	nipple-areola complex:9:0.0591	0.0591	9
NAC	NAC:11	non-adherent cells:11:0.2154	0.2154	11
NAC	NAC:9	nonadherent cells:9:0.1409	0.1409	9
NAc	NAc:447|NAC:215|Nac:12|nAc:5	nucleus accumbens:679:0.9709	0.9709	679
NaC	NaC:12|Na-C:1	sodium cholate:13:0.6911	0.6911	13
NAD(+)	NAD(+):28	nicotinamide adenine dinucleotide:28:0.6745	0.6745	28
NAD(P)H	NAD(P)H:6	nicotinamide adenine dinucleotide phosphate:6:0.6701	0.6701	6
NAD+	NAD+:100|NAD-+:1	nicotinamide adenine dinucleotide:101:0.8344	0.8344	101
NAD-GDH	NAD-GDH:17	glutamate dehydrogenase:17:0.7407	0.7407	17
NADA	NADA:21|NA-DA:1	N-acetyldopamine:22:0.5122	0.5122	22
NADH-TR	NADH-TR:7	NADH tetrazolium reductase:7:0.1111	0.1111	7
NADH-TR	NADH-TR:10	nicotinamide adenine dinucleotide tetrazolium reductase:10:0.7103	0.7103	10
NADH-D	NADH-D:3|NADHd:2	nicotinamide adenine dinucleotide diaphorase:5:0.4422	0.4422	5
NADH	NADH:2	nicotinamide adenine dinucleotide reduced:2:0.4438	0.4438	2
NADH	NADH:159	reduced nicotinamide adenine dinucleotide:159:0.5115	0.5115	159
NADP(+)	NADP(+):8	nicotinamide adenine dinucleotide phosphate:8:0.6411	0.6411	8
NADP+	NADP+:15	nicotinamide adenine dinucleotide phosphate:15:0.8045	0.8045	15
NADPH-d	NADPH-d:176|NADPHd:62|NADPH-D:9|NADPHD:2	NADPH-diaphorase:182:0.3148|NADPH diaphorase:67:0.2468	0.3148	249
NADPH-d	NADPH-d:197|NADPHd:39|NADPH-D:6|NADPHD:1	nicotinamide adenine dinucleotide phosphate diaphorase:129:0.9189|Nicotinamide adenine dinucleotide phosphate-diaphorase:114:0.8694	0.9189	243
NADPH	NADPH:2	adenine dinucleotide phosphate reduced form:2:0.7766	0.7766	2
NADPH	NADPH:377|NAD-PH:1	nicotinamide adenine dinucleotide phosphate:378:0.8898	0.8898	378
NADPH	NADPH:7	nicotinamide adenine dinucleotide phosphate reduced:7:0.8449	0.8449	7
NADP	NADP:11	malate dehydrogenase:11:0.2040	0.2040	11
NADP	NADP:44	nicotinamide adenine dinucleotide phosphate:44:0.7619	0.7619	44
NAD	NAD:8	dehydrogenase:8:0.0163	0.0163	8
NAD	NAD:19	Neuroaxonal dystrophy:19:0.8449	0.8449	19
NAD	NAD:225	nicotinamide adenine dinucleotide:225:0.8493	0.8493	225
NAd	NAd:15|NAD:7|Nad:3	noradrenaline:25:0.0488	0.0488	25
NAEMSP	NAEMSP:6	National Association of EMS Physicians:6:0.5290	0.5290	6
NAEP	NAEP:9	National Asthma Education Program:9:0.6794	0.6794	9
NAEPP	NAEPP:20	National Asthma Education and Prevention Program:20:0.8594	0.8594	20
NAEs	NAEs:30	N-acylethanolamines:30:0.7073	0.7073	30
NAFLD	NAFLD:52	non-alcoholic fatty liver disease:52:0.2187	0.2187	52
NAFLD	NAFLD:125	nonalcoholic fatty liver disease:125:0.6217	0.6217	125
NAFTA	NAFTA:18	North American Free Trade Agreement:18:0.8365	0.8365	18
NAG-ST	NAG-ST:10	heat-stable enterotoxin:10:0.7103	0.7103	10
NAGA	NAGA:9	N-acetyl-beta-D-glucosaminidase:9:0.2222	0.2222	9
NAGM	NAGM:5	normal-appearing gray matter:5:0.1464	0.1464	5
NAGM	NAGM:5	normal appearing grey matter:5:0.4422	0.4422	5
NAGO	NAGO:11|NaGo:2	neuraminidase and galactose oxidase:13:0.6701	0.6701	13
NAGase	NAGase:46|NAG-ase:2	N-acetyl-beta-D-glucosaminidase:48:0.5595	0.5595	48
NAGase	NAGase:12	N-acetyl-beta-glucosaminidase:12:0.1310	0.1310	12
NAG	NAG:13	beta-N-acetylglucosaminidase:13:0.0095	0.0095	13
NAG	NAG:11	N-acetyl-b-D-glucosaminidase:11:0.0079	0.0079	11
NAG	NAG:660|N-AG:1	N-acetyl-beta-D-glucosaminidase:660:0.5209|N-acetyl-beta D-glucosaminidase:1:0.1132	0.5209	661
NAG	NAG:13	N-acetyl-D-glucosamine:13:0.0095	0.0095	13
NAG	NAG:47	N-acetyl-glucosaminidase:28:0.0206|N-acetyl glucosaminidase:19:0.3333	0.3333	47
NAG	NAG:32|Nag:1|nag:1	N-acetylglucosamine:34:0.0261	0.0261	34
NAG	NAG:36	N-acetylglucosaminidase:36:0.0277	0.0277	36
NAG	NAG:11	N-acetylglutamate:11:0.0079	0.0079	11
NAG	NAG:29	Urinary N-acetyl-beta-glucosaminidase:29:0.1021	0.1021	29
NAHI	NAHI:12	non-accidental head injury:12:0.5050	0.5050	12
NAH	NAH:7	near-field acoustical holography:7:0.4438	0.4438	7
NAIM	NAIM:16	nucleotide analog interference mapping:16:0.8165	0.8165	16
NAION	NAION:33|n-AION:1|N-AION:1	nonarteritic anterior ischemic optic neuropathy:35:0.6738	0.6738	35
NAIT	NAIT:69	neonatal alloimmune thrombocytopenia:69:0.9567	0.9567	69
NAITP	NAITP:16	neonatal alloimmune thrombocytopenia:16:0.7261	0.7261	16
NAITP	NAITP:12	neonatal alloimmune thrombocytopenic purpura:12:0.7571	0.7571	12
NALT	NALT:12	lymphoid tissues:12:0.7571	0.7571	12
NALT	NALT:53	Nasal-associated lymphoid tissue:53:0.5816	0.5816	53
Nalt	Nalt:1	receptor antagonist naltrexone:1:0.1618	0.1618	1
NAL	NAL:11	Nacystelyn:11:0.0242	0.0242	11
NAL	NAL:26|Nal:16	Nalidixic acid:42:0.8558	0.8558	42
NAL	NAL:7|Nal:3	Naltrexone:10:0.0218	0.0218	10
NAL	NAL:30	nasal lavage:30:0.8472	0.8472	30
NAMCS	NAMCS:82	National Ambulatory Medical Care Survey:82:0.9636	0.9636	82
NAME	NAME:62|-NAME:2	methyl ester:64:0.8283	0.8283	64
NAME	NAME:11	methylester:11:0.0962	0.0962	11
NAMN	NAMN:4|NaMN:3	nicotinic acid mononucleotide:7:0.5926	0.5926	7
NAMS	NAMS:9	North American Menopause Society:9:0.6794	0.6794	9
NANA	NANA:92|N-ANA:2|Nana:2|NA-NA:1	N-acetylneuraminic acid:97:0.5773	0.5773	97
NANBH	NANBH:9	non-A non-B hepatitis:9:0.9685	0.9685	9
NANB	NANB:4	Non-A non-B hepatitis:4:0.9072	0.9072	4
NANC	NANC:193	non-adrenergic non-cholinergic:193:0.9475	0.9475	193
NANC	NANC:150	nonadrenergic noncholinergic:137:0.9635|nonadrenergic-noncholinergic:13:0.0166	0.9635	150
NANCi	NANCi:5|NANC-i:1|NANCI:1	nonadrenergic noncholinergic inhibitory:7:0.5926	0.5926	7
NANM	NANM:12	N-allylnormetazocine:12:0.3056	0.3056	12
NAN	NAN:18	non-ammonia-N:12:0.1146|non-ammonia N:6:0.0807	0.1146	18
NAN	NAN:6	nonammonia N:6:0.0807	0.0807	6
NAP-1	NAP-1:7	neutrophil attractant/activation protein-1:7:0.5926	0.5926	7
NAP-1	NAP-1:9|NAP1:7|Nap1:2	nucleosome assembly protein 1:11:0.7357|nucleosome assembly protein-1:7:0.5926	0.7357	18
NaPA	NaPA:16|NaPa:11	sodium phenylacetate:27:0.8903	0.8903	27
NAPCRG	NAPCRG:9	North American Primary Care Research Group:9:0.6794	0.6794	9
NAPE	NAPE:12	N-Acylphosphatidylethanolamine:12:0.3793	0.3793	12
NAPH	NAPH:5|naph:4	naphthalene:9:0.5333	0.5333	9
NAPLs	NAPLs:28	nonaqueous phase liquids:18:0.4672|nonaqueous-phase liquids:10:0.1057	0.4672	28
NAPL	NAPL:25	nonaqueous phase liquid:25:0.5722	0.5722	25
NAPQI	NAPQI:4	metabolite N-acetyl-p-benzoquinoneimine:4:0.2902	0.2902	4
NAPQI	NAPQI:58	N-acetyl-p-benzoquinone imine:58:0.7954	0.7954	58
NAPs	NAPs:13	nerve action potentials:13:0.6701	0.6701	13
NAPWA	NAPWA:12	National Association of People with AIDS:12:0.7571	0.7571	12
NAP	NAP:11	action potentials:11:0.7357	0.7357	11
NAP	NAP:14|Nap:6	naphthalene:20:0.0488	0.0488	20
NAP	NAP:20|Nap:4	naproxen:24:0.0591	0.0591	24
NAP	NAP:12	NAPVSIPQ:12:0.0283	0.0283	12
NAP	NAP:19	nerve action potential:19:0.6537	0.6537	19
NAP	NAP:71|N-AP:1	Neutrophil alkaline phosphatase:72:0.8948	0.8948	72
NAP	NAP:8	nucleoacidic protein:8:0.1895	0.1895	8
Nap	Nap:8|NAP:6	periplasmic nitrate reductase:14:0.6911	0.6911	14
NaP	NaP:20	sodium phosphate:20:0.7766	0.7766	20
NARES	NARES:10	rhinitis with eosinophilia syndrome:10:0.7103	0.7103	10
NARP	NARP:2	ataxia retinitis pigmentosa:2:0.8165	0.8165	2
NART	NART:72	National Adult Reading Test:72:0.9579	0.9579	72
NARs	NARs:8	Nagase analbuminemic rats:8:0.6411	0.6411	8
NAR	NAR:54	Nagase analbuminemic rats:46:0.6382|Nagase analbuminemic rat:8:0.5470	0.6382	54
NAR	NAR:87	nasal airway resistance:87:0.9455	0.9455	87
NaR	NaR:8|nar:4|Nar:4|NAR:3	Nitrate reductase:19:0.8449	0.8449	19
NASBA	NASBA:144|Nasba:1	Nucleic acid sequence-based amplification:113:0.9579|nucleic acid sequence based amplification:32:0.9072	0.9579	145
NASCET	NASCET:92	North American Symptomatic Carotid Endarterectomy Trial:92:0.9484	0.9484	92
NASHA	NASHA:10	hyaluronic acid:10:0.7103	0.7103	10
NASH	NASH:100	non-alcoholic steatohepatitis:100:0.2542	0.2542	100
NASH	NASH:209	nonalcoholic steatohepatitis:209:0.6028	0.6028	209
NASS	NASS:12	National Automotive Sampling System:12:0.7571	0.7571	12
NASS	NASS:12	North American Spine Society:12:0.7571	0.7571	12
NAS	NAS:74|N-aS:1|N-AS:1	N-acetylserotonin:76:0.1451	0.1451	76
NAs	NAs:7	Naphthenic acids:7:0.1641	0.1641	7
NAS	NAS:11	National Academy of Sciences:11:0.7357	0.7357	11
NAS	NAS:31	neonatal abstinence syndrome:31:0.9043	0.9043	31
NAs	NAs:5	Neutralizing antibodies:5:0.1132	0.1132	5
NAS	NAS:12	Normative Aging Study:12:0.7571	0.7571	12
NAs	NAs:6	nucleic acids:6:0.1010	0.1010	6
NAS	NAS:49|NAs:2|Nas:1	nucleus accumbens:52:0.9099	0.9099	52
NAS	NAS:63	nucleus accumbens septi:63:0.9018	0.9018	63
NAs	NAs:23	nursing assistants:23:0.8715	0.8715	23
NaS	NaS:14	sodium saccharin:14:0.7909	0.7909	14
NAT1	NAT1:4|NAT-1:1	arylamine N-acetyltransferase:5:0.0736	0.0736	5
NAT1	NAT1:38	N-acetyltransferase 1:38:0.5342	0.5342	38
NAT2	NAT2:142|NAT-2:6|Nat2:1	N-acetyltransferase 2:127:0.7074|N-acetyltransferase-2:22:0.0607	0.7074	149
NAT2	NAT2:26	polymorphic N-acetyltransferase:26:0.1582	0.1582	26
NATO	NATO:10	North Atlantic Treaty Organization:10:0.7103	0.7103	10
NATP	NATP:10	neonatal alloimmune thrombocytopenia:10:0.7103	0.7103	10
NATs	NATs:33	arylamine N-acetyltransferases:33:0.5171	0.5171	33
NAT	NAT:15	N-acetyl transferase:15:0.7096	0.7096	15
NAT	NAT:561|N-AT:2|Nat:1|nat:1	N-acetyltransferase:551:0.5889|N-acetyltransferases:14:0.0139	0.5889	565
NAT	NAT:11	N-acetyltransferase activity:11:0.4728	0.4728	11
NAT	NAT:9	neonatal alloimmune thrombocytopenia:9:0.5470	0.5470	9
NAT	NAT:11	Neospora agglutination test:11:0.7357	0.7357	11
NAT	NAT:19|NA-T:1	noradrenaline transporter:20:0.7766	0.7766	20
NAT	NAT:8	nucleic acid amplification techniques:8:0.6411	0.6411	8
NAT	NAT:30	Nucleic Acid Amplification Technology:30:0.9011	0.9011	30
NAT	NAT:17	nucleic acid amplification testing:17:0.8270	0.8270	17
NAT	NAT:32	nucleic acid testing:32:0.9072	0.9072	32
NAT	NAT:14	serotonin-N-acetyltransferase:14:0.0139	0.0139	14
NAWM	NAWM:133	normal-appearing white matter:82:0.5072|normal appearing white matter:51:0.9416	0.9416	133
NACS	NACS:18	Adaptive Capacity Scores:18:0.7539	0.7539	18
NACS	NACS:7	Neurologic and Adaptive Capacity Score:7:0.3524	0.3524	7
NAcS	NAcS:8	nucleus accumbens shell:8:0.6411	0.6411	8
NAcc	NAcc:181|NACC:29|Nacc:9|nAcc:7|nACC:1	nucleus accumbens:227:0.9869	0.9869	227
NAGS	NAGS:8	N-Acetylglutamate synthase:8:0.5006	0.5006	8
NaOCl	NaOCl:124|NaOCL:2	sodium hypochlorite:126:0.8986	0.8986	126
NA	NA:32	[3H]-noradrenaline:19:0.0025|3H-noradrenaline:13:0.0016	0.0025	32
NA	NA:21	activity:21:0.0027	0.0027	21
NA	NA:39	influenza virus neuraminidase:39:0.8433	0.8433	39
NA	NA:17	N-acetyl:17:0.0022	0.0022	17
NA	NA:5	N-acetyl compounds:5:0.0902	0.0902	5
Na	Na:7|NA:2	naked neck:9:0.6794	0.6794	9
NA	NA:75|Na:3	nalidixic acid:78:0.2445	0.2445	78
NA	NA:13	Naphthalene:13:0.0016	0.0016	13
NA	NA:45	negative affect:45:0.9338	0.9338	45
NA	NA:36	negative affectivity:36:0.8336	0.8336	36
NA	NA:11	Nephrogenic adenoma:11:0.7357	0.7357	11
NA	NA:51	neutralizing antibodies:26:0.5616|neutralizing antibody:25:0.5969	0.5969	51
NA	NA:6	neutrophil antigen:6:0.2243	0.2243	6
NA	NA:10	nicotianamine:10:0.0012	0.0012	10
NA	NA:58	nicotinamide:58:0.0078	0.0078	58
NA	NA:107	nicotinic acid:107:0.3540	0.3540	107
NA	NA:13	nocturnal asthma:13:0.6701	0.6701	13
NA	NA:9	non-adherent:9:0.0011	0.0011	9
NA	NA:22	nonadherent:22:0.0029	0.0029	22
NA	NA:40	noradrenalin:40:0.0053	0.0053	40
NA	NA:3997	noradrenaline:3979:0.5420|(-)-noradrenaline:18:0.0023	0.5420	3997
NA	NA:14	noradrenaline-storing:14:0.0018	0.0018	14
NA	NA:194	noradrenergic:194:0.0263	0.0263	194
NA	NA:30	norepinephrine:30:0.0044	0.0044	30
NA	NA:11	norethindrone acetate:11:0.2549	0.2549	11
NA	NA:11	North America:11:0.6182	0.6182	11
NA	NA:21	North American:21:0.5435	0.5435	21
NA	NA:55	nuclear area:55:0.6593	0.6593	55
NA	NA:41	nucleic acid:25:0.0575|nucleic acids:16:0.6577	0.6577	41
NA	NA:118	nucleus accumbens:118:0.9465	0.9465	118
NA	NA:13|nA:1	nucleus ambiguous:14:0.7909	0.7909	14
NA	NA:122|nA:13	nucleus ambiguus:135:0.9649	0.9649	135
NA	NA:20	nucleus angularis:20:0.6259	0.6259	20
NA	NA:22	numerical aperture:22:0.7400	0.7400	22
NA	NA:11	nutrient agar:11:0.5355	0.5355	11
NA	NA:11	release of [3H]noradrenaline:11:0.1005	0.1005	11
Na	Na:487|NA:12	sodium:499:0.0680	0.0680	499
NB4	NB4:9	cell line:9:0.6794	0.6794	9
NBAC	NBAC:13	National Bioethics Advisory Commission:13:0.7909	0.7909	13
NBAD	NBAD:9	N-beta-alanyldopamine:9:0.8000	0.8000	9
NBAS	NBAS:42	Neonatal Behavioral Assessment Scale:42:0.9291	0.9291	42
NBA	NBA:19	born alive:19:0.8449	0.8449	19
NBA	NBA:13	N-bromoacetamide:13:0.1277	0.1277	13
NBC-1	NBC-1:14|NBC1:8	cotransporter:22:0.7241	0.7241	22
NBCA	NBCA:19|n-BCA:1	N-butyl-2-cyanoacrylate:10:0.1429|n-butyl 2-cyanoacrylate:10:0.7103	0.7103	20
NBCA	NBCA:19|n-BCA:2|nBCA:1	n-butyl cyanoacrylate:22:0.7400	0.7400	22
NBCCS	NBCCS:66	nevoid basal cell carcinoma syndrome:66:0.7489	0.7489	66
NBCC	NBCC:8	nevoid basal cell carcinoma syndrome:8:0.6411	0.6411	8
NBCIE	NBCIE:7	congenital ichthyosiform erythroderma:7:0.5926	0.5926	7
NBCS	NBCS:15	newborn calf serum:15:0.8045	0.8045	15
NBC	NBC:54	Cotransporter:54:0.3397	0.3397	54
NBD-PE	NBD-PE:9	phosphatidylethanolamine:9:0.2105	0.2105	9
NBD1	NBD1:13|NBD-1:1	nucleotide binding domain:14:0.7909	0.7909	14
NBD1	NBD1:9|NBD-1:1	nucleotide-binding domain 1:10:0.4363	0.4363	10
NBD-Cl	NBD-Cl:9	4-chloro-7-nitrobenzofurazan:9:0.0833	0.0833	9
NBD-Cl	NBD-Cl:10	7-chloro-4-nitrobenz-2-oxa-1,3-diazole:10:0.0938	0.0938	10
NBD-Cl	NBD-Cl:37|NBDCl:1|Nbd-Cl:1	7-chloro-4-nitrobenzo-2-oxa-1,3-diazole:39:0.3958	0.3958	39
NB-DNJ	NB-DNJ:21|NBDNJ:1	N-butyldeoxynojirimycin:22:0.7000	0.7000	22
NBD-PC	NBD-PC:10	phosphatidylcholine:10:0.2500	0.2500	10
NBD-PS	NBD-PS:9	phosphatidylserine:9:0.3333	0.3333	9
NBDs	NBDs:30	nucleotide binding domains:30:0.9011	0.9011	30
NBDs	NBDs:24	two nucleotide-binding domains:24:0.2792	0.2792	24
NBD	NBD:23	7-nitrobenz-2-oxa-1,3-diazol-4-yl:23:0.0780	0.0780	23
NBD	NBD:13	7-nitrobenz-2-oxa-1,3-diazole:13:0.0461	0.0461	13
NBD	NBD:11	neuro-Behcet's disease:11:0.5355	0.5355	11
NBD	NBD:11	nitrobenzoxadiazole:11:0.0355	0.0355	11
NBD	NBD:56	nucleotide-binding domain:29:0.2974|nucleotide binding domain:20:0.5568|nucleotide binding domains:7:0.5926	0.5926	56
NBD	NBD:6	two nucleotide-binding domains:6:0.2243	0.2243	6
NBF1	NBF1:7|NBF-1:3	first nucleotide binding fold:10:0.5856	0.5856	10
NBF	NBF:38	nerve blood flow:38:0.6495	0.6495	38
NBF	NBF:10	neutral buffered formalin:10:0.5856	0.5856	10
NBI	NBI:10	nitrobenzylthioinosine:10:0.1525	0.1525	10
NBL	NBL:11	neuroblastic layer:11:0.5355	0.5355	11
NBL	NBL:56|Nbl:1	neuroblastoma:57:0.4341	0.4341	57
NBL	NBL:17	newborn larvae:17:0.7407	0.7407	17
NBME	NBME:91	National Board of Medical Examiners:91:0.9672	0.9672	91
NBMPR	NBMPR:6	binding of [3H]nitrobenzylthioinosine:6:0.1543	0.1543	6
NBMPR	NBMPR:6	nitrobenzylmercaptopurine ribonucleoside:6:0.2243	0.2243	6
NBMPR	NBMPR:11	nitrobenzylmercaptopurine riboside:11:0.3829	0.3829	11
NBMPR	NBMPR:108	nitrobenzylthioinosine:108:0.6127	0.6127	108
NBMPR	NBMPR:9	p-nitrobenzylthioinosine:9:0.0462	0.0462	9
NBMPR-P	NBMPR-P:8	nitrobenzylthioinosine 5'-monophosphate:8:0.2987	0.2987	8
NBM	NBM:24|N-BM:1	normal bone marrow:25:0.8186	0.8186	25
NBM	NBM:237|nbm:35|nBM:27|nbM:20|Nbm:4|NBm:4|NbM:2	nucleus basalis magnocellularis:329:0.9854	0.9854	329
nbM	nbM:70|NBM:60|NbM:16|nBM:7|nbm:1	nucleus basalis of Meynert:154:0.9694	0.9694	154
NBP2	NBP2:5|NB-P2:1	murine neuroblastoma:6:0.2243	0.2243	6
NBP	NBP:13	4-(p-nitrobenzyl)pyridine:13:0.0800	0.0800	13
NBP	NBP:6|NbP:1	binding protein:7:0.1641	0.1641	7
NBP	NBP:10	nonbacterial prostatitis:10:0.5000	0.5000	10
NBQX	NBQX:9	antagonist:9:0.0293	0.0293	9
NBQX	NBQX:5	antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)-quinoxaline:5:0.1132	0.1132	5
NBQX	NBQX:4	antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline:4:0.0731	0.0731	4
NBQX	NBQX:3	receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline:3:0.2113	0.2113	3
NBRE	NBRE:9	response element:9:0.3945	0.3945	9
NBS-LRR	NBS-LRR:9	nucleotide binding site-leucine rich repeat:9:0.6794	0.6794	9
NBSB	NBSB:9	National Biomonitoring Specimen Bank:9:0.6794	0.6794	9
NBSS	NBSS:25	Canadian National Breast Screening Study:25:0.4751	0.4751	25
NBS	NBS:24	bovine serum:24:0.8715	0.8715	24
NBS	NBS:99|N-BS:1	N-bromosuccinimide:100:0.1701	0.1701	100
NBS	NBS:22	National Bureau of Standards:22:0.8657	0.8657	22
NBs	NBs:19|Nbs:4	neuroblasts:23:0.0378	0.0378	23
NBs	NBs:22|NBS:1	neuroblastomas:23:0.0378	0.0378	23
NBS	NBS:26	newborn screening:26:0.8861	0.8861	26
NBS	NBS:125	Nijmegen breakage syndrome:125:0.9759	0.9759	125
NBs	NBs:57	Nuclear bodies:57:0.8901	0.8901	57
NBS	NBS:50	nucleotide binding site:27:0.8312|nucleotide-binding site:23:0.2797	0.8312	50
NBS	NBS:8	number of binding sites:8:0.5006	0.5006	8
NBTE	NBTE:37	nonbacterial thrombotic endocarditis:37:0.5859	0.5859	37
NBTI	NBTI:32	Nitrobenzylthioinosine:32:0.4133	0.4133	32
NBTI	NBTI:13	S-(4-nitrobenzyl)-6-thioinosine:13:0.1600	0.1600	13
NBTI	NBTI:11	S-(p-nitrobenzyl)-6-thioinosine:11:0.1333	0.1333	11
NBT	NBT:112	nitro blue tetrazolium:112:0.9437	0.9437	112
NBT	NBT:612|N-BT:2	nitroblue tetrazolium:600:0.7667|nitroblue-tetrazolium:14:0.0140	0.7667	614
NBT	NBT:11	Nitroblue tetrazolium dye:11:0.6182	0.6182	11
NBT	NBT:16	Nitroblue tetrazolium test:16:0.8165	0.8165	16
NBT	NBT:5	nitrotetrazolium blue:5:0.1132	0.1132	5
NBT	NBT:8	normal brain tissue:8:0.6411	0.6411	8
NBT	NBT:9	reduction test:9:0.1099	0.1099	9
NBW	NBW:67	normal birth weight:67:0.9074	0.9074	67
NBW	NBW:22	Normal Birthweight:22:0.8657	0.8657	22
NB	NB:9	negative binomial:9:0.6794	0.6794	9
NB	NB:9|Nb:2	neurobiotin:11:0.0074	0.0074	11
NB	NB:610|Nb:7|nb:3	neuroblastoma:594:0.4367|neuroblastomas:26:0.0184	0.4367	620
NB	NB:19	neuroborreliosis:19:0.0133	0.0133	19
NB	NB:10	Neuromedin B:10:0.4363	0.4363	10
NB	NB:43|nb:2|Nb:2	newborn:26:0.0184|newborns:21:0.0147	0.0184	47
NB	NB:8	nile blue:8:0.3463	0.3463	8
Nb	Nb:34|NB:9	Nippostrongylus brasiliensis:43:0.8590	0.8590	43
NB	NB:40	nitrobenzene:40:0.0287	0.0287	40
NB	NB:40|Nb:2	Nitrogen balance:42:0.6927	0.6927	42
NB	NB:9	nitrosobenzene:9:0.0059	0.0059	9
Nb	Nb:14	Noble:14:0.0096	0.0096	14
NB	NB:32	normalized blur:32:0.8145	0.8145	32
NB	NB:9|Nb:1	Novobiocin:10:0.0066	0.0066	10
NB	NB:15	Nuclear bodies:9:0.3945|nuclear body:6:0.2243	0.3945	15
NB	NB:47	nucleus basalis:47:0.9366	0.9366	47
NB	NB:23	nutrient broth:23:0.8038	0.8038	23
NC1	NC1:24|NC-1:7	non-collagenous:31:0.1852	0.1852	31
NC1	NC1:30|NC-1:2	Noncollagenous:32:0.1914	0.1914	32
NC1	NC1:13|NC-1:1	noncollagenous domain:14:0.2010	0.2010	14
NCAA	NCAA:34	National Collegiate Athletic Association:34:0.9126	0.9126	34
NC-AFM	NC-AFM:7|NCAFM:2|nc-AFM:1	atomic force microscopy:10:0.7103	0.7103	10
NCAFS	NCAFS:10	Nursing Child Assessment Feeding Scale:10:0.7357	0.7357	10
NCAH	NCAH:14	adrenal hyperplasia:14:0.7909	0.7909	14
NCAM-H	NCAM-H:4	highly polysialylated form of the neural cell adhesion molecule:4:0.5290	0.5290	4
NCAM-H	NCAM-H:6	Highly polysialylated neural cell adhesion molecule:6:0.5290	0.5290	6
NCAMs	NCAMs:24|N-CAMs:16	neural cell adhesion molecules:40:0.8491	0.8491	40
NCAM	NCAM:695|N-CAM:342|nCAM:1|Ncam:1	neural cell adhesion molecule:989:0.9434|neural cell adhesion molecules:50:0.8520	0.9434	1039
NCATS	NCATS:18	Nursing child Assessment Teaching scale:18:0.8365	0.8365	18
NCAs	NCAs:11	cross-reacting antigens:11:0.4232	0.4232	11
NCA	NCA:13	nested clade analysis:13:0.7753	0.7753	13
NCA	NCA:12	neurocirculatory asthenia:12:0.7571	0.7571	12
NCA	NCA:74	neutrophil chemotactic activity:74:0.9159	0.9159	74
NCA	NCA:30|nca:9	no-carrier-added:39:0.0776	0.0776	39
NCA	NCA:31	non-specific cross-reacting antigen:31:0.1608	0.1608	31
NCA	NCA:18	normal coronary arteries:18:0.6903	0.6903	18
NCB-20	NCB-20:5	brain explant hybrid cell line:5:0.4422	0.4422	5
NCB	NCB:11	needle core biopsy:11:0.6182	0.6182	11
NCC	NCC:8	cytotoxic cell:8:0.0789	0.0789	8
NCC	NCC:50	neural crest cells:29:0.8978|neural crest cell:21:0.8594	0.8978	50
NCC	NCC:99	neurocysticercosis:99:0.2776	0.2776	99
NCC	NCC:45	nonspecific cytotoxic cells:45:0.7881	0.7881	45
NCC	NCC:8	nucleated cell count:8:0.5006	0.5006	8
NCC	NCC:14	thiazide-sensitive Na-Cl cotransporter:14:0.4709	0.4709	14
NC-CAH	NC-CAH:6|NCCAH:4	congenital adrenal hyperplasia:10:0.7103	0.7103	10
NCCAM	NCCAM:10	National Center for Complementary and Alternative Medicine:10:0.5856	0.5856	10
NCCL	NCCL:9	cervical lesions:9:0.4587	0.4587	9
NCCLS	NCCLS:338|NCClS:1	National Committee for Clinical Laboratory Standards:339:0.9863	0.9863	339
NCCN	NCCN:47	National Comprehensive Cancer Network:47:0.9366	0.9366	47
NCCP	NCCP:24	noncardiac chest pain:24:0.5160	0.5160	24
NCCR	NCCR:9	c reductase:9:0.6794	0.6794	9
NCCR	NCCR:14	control region:14:0.7909	0.7909	14
NCCT	NCCT:10	computed tomography:10:0.4363	0.4363	10
NCCT	NCCT:6	Na-Cl cotransporter:6:0.1543	0.1543	6
NCCs	NCCs:28	neural crest cells:28:0.8941	0.8941	28
NCDV	NCDV:19	calf diarrhea virus:19:0.8449	0.8449	19
NCD	NCD:21	neurocirculatory dystonia:21:0.8594	0.8594	21
ncd	ncd:8|Ncd:4|NCD:1	non-claret disjunctional:13:0.2802	0.2802	13
ncd	ncd:6|Ncd:5	nonclaret disjunctional:11:0.2040	0.2040	11
NCD	NCD:6	noncommunicable diseases:6:0.1320	0.1320	6
NCE	NCE:5	Na+/Ca2+ exchanger:5:0.1132	0.1132	5
NCE	NCE:13	new chemical entity:13:0.5934	0.5934	13
nCEH	nCEH:4|NCEH:2	neutral cholesterol ester hydrolase:6:0.5290	0.5290	6
NCEH	NCEH:4|nCEH:3	neutral cholesteryl ester hydrolase:7:0.5926	0.5926	7
NCEP	NCEP:9	National Cholesterol Education Panel:9:0.5470	0.5470	9
NCEP	NCEP:327	National Cholesterol Education Program:327:0.9805	0.9805	327
NCEs	NCEs:56	new chemical entities:56:0.9467	0.9467	56
NCF	NCF:44	neutrophil chemotactic factor:44:0.9323	0.9323	44
NCGN	NCGN:8	necrotizing and crescentic glomerulonephritis:8:0.7539	0.7539	8
NCGS	NCGS:26	National Cooperative Growth Study:26:0.8861	0.8861	26
NCHS	NCHS:242	National Center for Health Statistics:242:0.9803	0.9803	242
NCIs	NCIs:8	neuronal cytoplasmic inclusions:8:0.6411	0.6411	8
NCIs	NCIs:10	noncompetitive inhibitors:10:0.3867	0.3867	10
NCI	NCI:14	cognitive impairment:14:0.6173	0.6173	14
NCI	NCI:571	National Cancer Institute:543:0.9802|National Cancer Institute's:28:0.8941	0.9802	571
NCI	NCI:31	negative chemical ionization:31:0.6572	0.6572	31
NCI	NCI:18	nuclear contour index:18:0.8365	0.8365	18
NCJ	NCJ:13	needle catheter jejunostomy:13:0.7753	0.7753	13
NCLs	NCLs:57	neuronal ceroid lipofuscinoses:57:0.9477	0.9477	57
NCL	NCL:10|Ncl:1	Neostriatum caudolaterale:11:0.5355	0.5355	11
NCL	NCL:80	neuronal ceroid lipofuscinoses:46:0.9353|neuronal ceroid-lipofuscinoses:34:0.8644	0.9353	80
NCL	NCL:117	neuronal ceroid lipofuscinosis:78:0.9393|neuronal ceroid-lipofuscinosis:39:0.8455	0.9393	117
NCMC	NCMC:46	Natural cell-mediated cytotoxicity:46:0.9353	0.9353	46
NCM	NCM:19|Ncm:1	caudomedial neostriatum:20:0.5568	0.5568	20
NCM	NCM:9	nailfold capillary microscopy:9:0.6794	0.6794	9
NCM	NCM:18	neurocutaneous melanosis:18:0.8365	0.8365	18
NCM	NCM:12	nitrocellulose membrane:12:0.7571	0.7571	12
nCPAP	nCPAP:183|NCPAP:84|n-CPAP:14|N-CPAP:12	nasal continuous positive airway pressure:293:0.9382	0.9382	293
NCPB	NCPB:15	neurolytic celiac plexus block:15:0.8045	0.8045	15
NCPE	NCPE:14	pulmonary edema:14:0.7909	0.7909	14
NCPF	NCPF:30	non-cirrhotic portal fibrosis:30:0.5652	0.5652	30
NCPs	NCPs:17	noncollagenous proteins:17:0.3670	0.3670	17
NCP	NCP:12	Neurocybernetic Prosthesis:12:0.5050	0.5050	12
NCP	NCP:9|ncp:8	non-cytopathic:17:0.0497	0.0497	17
ncp	ncp:7|NCP:6	non-cytopathogenic:13:0.0373	0.0373	13
NCP	NCP:11	noncollagenous proteins:11:0.2040	0.2040	11
ncp	ncp:8|NCP:1	noncytopathogenic:9:0.0248	0.0248	9
NCP	NCP:8	nucleus caudatus putamen:8:0.5006	0.5006	8
NCQA	NCQA:41	National Committee for Quality Assurance:41:0.9379	0.9379	41
NCRP	NCRP:33	National Council on Radiation Protection and Measurements:33:0.9151	0.9151	33
NCR	NCR:13	5' non-coding region:13:0.2660	0.2660	13
NCR	NCR:25	5' noncoding region:25:0.3233	0.3233	25
NCR	NCR:18	natural cytotoxicity receptors:18:0.8365	0.8365	18
NCR	NCR:15	nitrogen catabolite repression:15:0.8045	0.8045	15
NCR	NCR:7	non-coding regions:7:0.1850	0.1850	7
NCR	NCR:26	Noncontingent reinforcement:26:0.8251	0.8251	26
NCR	NCR:30	normotensive control rats:30:0.7315	0.7315	30
NCS-1	NCS-1:30|Ncs-1:1	Neuronal calcium sensor-1:31:0.8519	0.8519	31
NCSCs	NCSCs:22	neural crest stem cells:22:0.8657	0.8657	22
NCSE	NCSE:29	Neurobehavioral Cognitive Status Examination:29:0.7581	0.7581	29
NCSE	NCSE:54	Nonconvulsive status epilepticus:54:0.5486	0.5486	54
NCS-R	NCS-R:11	National Comorbidity Survey Replication:11:0.6794	0.6794	11
NCSU	NCSU:11	North Carolina State University:11:0.7357	0.7357	11
NCS	NCS:15	N-chlorosuccinimide:15:0.0181	0.0181	15
NCs	NCs:14	nanocrystals:14:0.0168	0.0168	14
NCS	NCS:35	National Comorbidity Survey:35:0.9151	0.9151	35
NCS	NCS:210	neocarzinostatin:210:0.2691	0.2691	210
NCS	NCS:125	Nerve conduction studies:95:0.9689|nerve conduction study:30:0.8472	0.9689	125
NCS	NCS:17	neurocardiogenic syncope:17:0.8270	0.8270	17
NCS	NCS:20	neuronal calcium sensor:20:0.8525	0.8525	20
NCS	NCS:24	newborn calf serum:24:0.7151	0.7151	24
NCS	NCS:15	Non-crystallographic symmetry:15:0.7096	0.7096	15
NCs	NCs:34	normal controls:34:0.8245	0.8245	34
NCs	NCS:5|NCs:5	normal control subjects:10:0.3867	0.3867	10
NCS	NCS:5	Nuclear Channel System:5:0.4422	0.4422	5
NCs	NCs:14	nucleated cells:14:0.3813	0.3813	14
NCS	NCS:14	nucleus centralis superior:14:0.6173	0.6173	14
NCS	NCS:10	syndrome:10:0.0116	0.0116	10
NCTB	NCTB:18	Neurobehavioral Core Test Battery:18:0.7539	0.7539	18
NCTD	NCTD:14	norcantharidin:14:0.9286	0.9286	14
NCTR	NCTR:26	National Center for Toxicological Research:26:0.8861	0.8861	26
NCT	NCT:5|nCT:4	cholera toxin:9:0.6794	0.6794	9
NCT	NCT:13	N-chlorotaurine:13:0.0472	0.0472	13
NCT	NCT:48	neutron capture therapy:48:0.9027	0.9027	48
NCT	NCT:13	non-contact tonometer:13:0.3134	0.3134	13
NCT	NCT:9	noncontact tonometer:9:0.1492	0.1492	9
NCT	NCT:24	number connection test:24:0.8768	0.8768	24
NCV	NCV:253	nerve conduction velocity:206:0.8978|nerve conduction velocities:47:0.8703	0.8978	253
NCVs	NCVs:32	nerve conduction velocities:32:0.9072	0.9072	32
N-CWS	N-CWS:7|N-cws:1	cell wall skeleton of Nocardia rubra:8:0.6411	0.6411	8
N-CWS	N-CWS:50	Nocardia rubra cell wall skeleton:50:0.9404	0.9404	50
N-CoR	N-CoR:10|NCoR:5|NCOR:1	nuclear receptor co-repressor:16:0.8165	0.8165	16
N-CoR	N-CoR:29|NCoR:23|NCOR:1	nuclear receptor corepressor:53:0.8842	0.8842	53
NCX	NCX:195|ncx:1|NCx:1	exchanger:197:0.6842	0.6842	197
NCX	NCX:12	Na(+)/Ca(2+) exchange:12:0.1105	0.1105	12
NCX	NCX:15	Na+-Ca2+ exchange:15:0.1645	0.1645	15
NC	NC:9	5' noncoding:9:0.3069	0.3069	9
NC	NC:204	Change:204:0.0760	0.0760	204
NC	NC:39	control subjects:39:0.6077	0.6077	39
NC	NC:11	nanocapsules:11:0.0037	0.0037	11
NC	NC:21	natural cytotoxicity:21:0.7291	0.7291	21
NC	NC:14	neck circumference:14:0.7909	0.7909	14
NC	NC:20	nephrocalcin:20:0.0071	0.0071	20
NC	NC:21|nc:1	nephrocalcinosis:22:0.0079	0.0079	22
NC	NC:90	neural crest:90:0.9668	0.9668	90
NC	NC:6	neurological complications:6:0.1838	0.1838	6
NC	NC:14|Nc:3|nc:1	nicardipine:18:0.0064	0.0064	18
NC	NC:11	nitrosocimetidine:11:0.0037	0.0037	11
NC	NC:29	Nociceptin:29:0.0105	0.0105	29
NC	NC:19	Nociceptin/orphanin FQ:19:0.8449	0.8449	19
NC	NC:9	non-collagenous:9:0.0030	0.0030	9
NC	NC:14	nonclassical:14:0.0049	0.0049	14
NC	NC:13	noncollagenous:13:0.0045	0.0045	13
NC	NC:5	normal children:5:0.0736	0.0736	5
NC	NC:12	normal comparison:12:0.5664	0.5664	12
NC	NC:361	normal controls:203:0.7191|normal control:158:0.7311	0.7311	361
NC	NC:10	normal control group:10:0.3145	0.3145	10
NC	NC:5	normal cycling:5:0.1132	0.1132	5
NC	NC:15	normocholesterolemic:15:0.0052	0.0052	15
NC	NC:29	North Carolina:29:0.8978	0.8978	29
NC	NC:45|nc:2	nucleated cells:35:0.4766|nucleated cell:12:0.3058	0.4766	47
NC	NC:225|nc:1	nucleocapsid:217:0.0808|nucleocapsids:9:0.0030	0.0808	226
NC	NC:66	nucleocapsid protein:66:0.9286	0.9286	66
NC	NC:13	nucleus caudatus:13:0.6701	0.6701	13
NC	NC:6|nc:1	nucleus circularis:7:0.3524	0.3524	7
NC	NC:8	onto nitrocellulose:8:0.0519	0.0519	8
NC	NC:10	patients with neurocysticercosis:10:0.0877	0.0877	10
ND10	ND10:23	Nuclear domain 10:23:0.8715	0.8715	23
ND1	ND1:14	NADH dehydrogenase subunit 1:14:0.6173	0.6173	14
ND2	ND2:15	NADH dehydrogenase subunit 2:15:0.7096	0.7096	15
ND3	ND3:7|ND-3:1	NADH dehydrogenase subunit 3:8:0.6411	0.6411	8
ND4	ND4:7	NADH dehydrogenase subunit 4:7:0.5926	0.5926	7
ND5	ND5:13	NADH dehydrogenase subunit 5:13:0.7753	0.7753	13
NDAs	NDAs:19	New Drug Applications:19:0.8449	0.8449	19
NDA	NDA:23	Naphthalene-2,3-dicarboxaldehyde:23:0.1732	0.1732	23
NDA	NDA:49	new drug application:49:0.9046	0.9046	49
NDBA	NDBA:29	N-nitrosodibutylamine:29:0.6744	0.6744	29
NDBzA	NDBzA:10	N-nitrosodibenzylamine:10:0.9000	0.9000	10
NDB	NDB:5|nDB:3	nucleus of the diagonal band:8:0.4102	0.4102	8
NDCM	NDCM:15	cell mitogen:15:0.6911	0.6911	15
NDDG	NDDG:36	National Diabetes Data Group:36:0.9174	0.9174	36
NDEA	NDEA:15	nitrosodiethylamine:15:0.0725	0.0725	15
NDELA	NDELA:58|NDElA:5	N-nitrosodiethanolamine:63:0.8611	0.8611	63
NDEs	NDEs:12	Near-Death Experiences:12:0.5664	0.5664	12
NDF	NDF:31	Neu differentiation factor:31:0.7388	0.7388	31
NDF	NDF:164	neutral detergent fiber:164:0.9708	0.9708	164
NDF	NDF:62	neutral detergent fibre:39:0.8839|neutral-detergent fibre:23:0.2250	0.8839	62
NDH-1	NDH-1:15	proton-translocating NADH-quinone oxidoreductase:15:0.4609	0.4609	15
NDHS	NDHS:20	N-(3,5-dichlorophenyl)-2-hydroxysuccinimide:20:0.7308	0.7308	20
NDH	NDH:13|ndh:6|Ndh:1	dehydrogenase:20:0.4130	0.4130	20
NDI	NDI:29	National Death Index:29:0.8978	0.8978	29
NDI	NDI:20	Neck Disability Index:20:0.7173	0.7173	20
NDI	NDI:147|N-DI:1	nephrogenic diabetes insipidus:148:0.9574	0.9574	148
Ndk	Ndk:22|NDK:10|ndk:3|NdK:2	nucleoside diphosphate kinase:37:0.9197	0.9197	37
NDMA	NDMA:10	dimethylnitrosamine:10:0.0180	0.0180	10
NDMA	NDMA:11	N-Nitroso-dimethylamine:11:0.0200	0.0200	11
NDMA	NDMA:395|N-DMA:1	N-nitrosodimethylamine:396:0.7884	0.7884	396
NDMA	NDMA:44	Nitrosodimethylamine:44:0.0858	0.0858	44
NDMS	NDMS:11	National Disaster Medical System:11:0.7357	0.7357	11
NDM	NDM:9	diabetes mellitus:9:0.4587	0.4587	9
NDO	NDO:21	naphthalene dioxygenase:21:0.7865	0.7865	21
NDO	NDO:9	neurogenic detrusor overactivity:9:0.6794	0.6794	9
NDO	NDO:7	non-digestible oligosaccharides:7:0.1850	0.1850	7
NDO	NDO:6	nondigestible oligosaccharides:6:0.1148	0.1148	6
NDPH	NDPH:21	new daily persistent headache:21:0.8449	0.8449	21
NDPKs	NDPKs:14	Nucleoside diphosphate kinases:14:0.7909	0.7909	14
NDPK	NDPK:60|ndpk:1	nucleoside diphosphate kinase:61:0.8383	0.8383	61
NDPO2	NDPO2:5	endoperoxide of 3,3'-(1,4-naphthylidene) dipropionate:5:0.2827	0.2827	5
NDPs	NDPs:10	nucleoside diphosphates:10:0.2873	0.2873	10
NDPase	NDPase:30|NDP-ase:1	nucleoside diphosphatase:31:0.8519	0.8519	31
NDP	NDP:4	antitumor efficacy of the combination of Nedaplatin:4:0.4422	0.4422	4
NDP	NDP:120	nucleoside diphosphate:111:0.7685|nucleoside diphosphates:9:0.5470	0.7685	120
NDRG1	NDRG1:8|Ndrg1:1	N-myc downstream-regulated gene 1:9:0.6794	0.6794	9
NDR	NDR:9	Negative Differential Resistance:9:0.6794	0.6794	9
NDS	NDS:16	neuropathy disability score:16:0.3317	0.3317	16
NDTI	NDTI:9	National Disease and Therapeutic Index:9:0.6794	0.6794	9
NDT	NDT:12	neurodevelopmental treatment:12:0.5050	0.5050	12
NDU	NDU:14	nursing development unit:14:0.6911	0.6911	14
NDUs	NDUs:14	nursing development units:14:0.7909	0.7909	14
NDVI	NDVI:49	normalized difference vegetation index:49:0.9046	0.9046	49
NDV	NDV:14	Newcastle disease:14:0.7909	0.7909	14
NDV	NDV:960|nDV:1|ndv:1	Newcastle disease virus:950:0.9829|Newcastle disease viruses:12:0.7571	0.9829	962
NDWG	NDWG:3	Normalized diurnal weight gain:3:0.6701	0.6701	3
ND	ND:10	discharge:10:0.0083	0.0083	10
ND	ND:11	NADH dehydrogenase:11:0.4728	0.4728	11
ND	ND:15|Nd:1	NADPH-diaphorase:16:0.0138	0.0138	16
ND	ND:37|Nd:1	nandrolone decanoate:38:0.8098	0.8098	38
ND	ND:24	neck dissection:24:0.8115	0.8115	24
Nd	Nd:15	negative difference:15:0.6386	0.6386	15
Nd	Nd:12	neodymium:12:0.0101	0.0101	12
ND	ND:9	neurologic deficit:9:0.3455	0.3455	9
ND	ND:13	neutral density:13:0.3331	0.3331	13
ND	ND:94	Newcastle disease:94:0.6306	0.6306	94
ND	ND:14	nicotine dependence:14:0.7909	0.7909	14
ND	ND:9	nocodazole:9:0.0074	0.0074	9
ND	ND:10	non-diabetic:10:0.0083	0.0083	10
ND	ND:9	nondemented:9:0.0074	0.0074	9
ND	ND:32|nd:1	nondiabetic:33:0.0295	0.0295	33
ND	ND:9	nondisabled:9:0.0074	0.0074	9
ND	ND:13	nordiazepam:13:0.0111	0.0111	13
ND	ND:34	normal diet:34:0.6194	0.6194	34
ND	ND:12	normally developing:12:0.7571	0.7571	12
ND	ND:29	Norrie disease:29:0.1288	0.1288	29
ND	ND:5|nd:3	not detected:8:0.5006	0.5006	8
ND	ND:19|nD:1	nucleus of Darkschewitsch:20:0.8525	0.8525	20
NEAA	NEAA:9	non-essential amino acids:9:0.1267	0.1267	9
NEAA	NEAA:17	nonessential amino acids:17:0.4246	0.4246	17
NEA	NEA:10	norethisterone acetate:10:0.5000	0.5000	10
NEBD	NEBD:21	nuclear envelope breakdown:21:0.8594	0.8594	21
NEBs	NEBs:56|NEBS:1	neuroepithelial bodies:57:0.9176	0.9176	57
NEB	NEB:10	nebulizer:10:0.0600	0.0600	10
NEB	NEB:12	negative energy balance:12:0.6460	0.6460	12
NEB	NEB:55	Neuroepithelial bodies:55:0.8036	0.8036	55
NEB	NEB:13	nuclear envelope breakdown:13:0.7753	0.7753	13
NECA	NECA:39	5'-N-ethylcarboxamide adenosine:39:0.2382	0.2382	39
NECA	NECA:40	5'-N-ethylcarboxamideadenosine:40:0.0528	0.0528	40
NECA	NECA:38	5'-(N-ethylcarboxamido)-adenosine:25:0.0325|5'-N-ethylcarboxamido-adenosine:13:0.0163	0.0325	38
NECA	NECA:4	adenosine receptor agonist 5'-(N-ethylcarboxamido)adenosine:4:0.1618	0.1618	4
NECA	NECA:17	adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine:17:0.5496	0.5496	17
NECA	NECA:4	agonist 5'-N-ethyl-carboxamidoadenosine:4:0.1010	0.1010	4
NECA	NECA:20	N-ethylcarboxamide adenosine:20:0.0942	0.0942	20
NECA	NECA:41	N-ethylcarboxamidoadenosine:41:0.0542	0.0542	41
NEC	NEC:618	necrotizing enterocolitis:618:0.8568	0.8568	618
NEC	NEC:17	neuroendocrine carcinoma:17:0.6748	0.6748	17
NEC	NEC:15	neuroendocrine cells:15:0.2845	0.2845	15
NEC	NEC:8	noise equivalent count:8:0.6411	0.6411	8
NEDH	NEDH:10	New England Deaconess Hospital:10:0.7103	0.7103	10
NED	NED:9	disease-free:9:0.0265	0.0265	9
NED	NED:185|ned:1	evidence of disease:186:0.8839	0.8839	186
NED	NED:8|Ned:1	nedocromil sodium:9:0.6794	0.6794	9
NED	NED:9	Neuroendocrine differentiation:9:0.4587	0.4587	9
NEFA	NEFA:660|NE-FA:1	fatty acids:661:0.9955	0.9955	661
NEG	NEG:12	nonenzymatic glycosylation:12:0.2699	0.2699	12
NEH	NEH:21	Neutrophilic eccrine hidradenitis:21:0.8594	0.8594	21
NEI-VFQ	NEI-VFQ:15	National Eye Institute Visual Function Questionnaire:15:0.8045	0.8045	15
NEISS	NEISS:31	National Electronic Injury Surveillance System:31:0.9043	0.9043	31
Nei	Nei:8|nei:1	endonuclease VIII:9:0.6794	0.6794	9
NEI	NEI:11	National Eye Institute:11:0.7357	0.7357	11
NEJM	NEJM:13	New England Journal of Medicine:13:0.7753	0.7753	13
NEL	NEL:2	net energy of lactation:2:0.7753	0.7753	2
NEL	NEL:5	no-effect level:5:0.1132	0.1132	5
NELF	NELF:7	negative elongation factor:7:0.4438	0.4438	7
NEMA	NEMA:19	National Electrical Manufacturers Association:19:0.7658	0.7658	19
NEMO	NEMO:26|nemo:1	Essential Modulator:27:0.8903	0.8903	27
NEM	NEM:78|nem:1	N-ethyl maleimide:40:0.9256|N-ethyl-maleimide:39:0.0311	0.9256	79
NEM	NEM:1023|N-EM:4	N-ethylmaleimide:1027:0.8403	0.8403	1027
NEO-PI	NEO-PI:22	NEO Personality Inventory:22:0.7400	0.7400	22
NEO-PI-R	NEO-PI-R:19	revised NEO Personality Inventory:19:0.7658	0.7658	19
neo	neo:26|NEO:4|Neo:1	neomycin:31:0.0725	0.0725	31
neo	neo:59|NEO:9	neomycin phosphotransferase:68:0.7431	0.7431	68
neo	neo:21|NEO:1	neomycin phosphotransferase gene:22:0.6531	0.6531	22
neo	neo:38|NEO:3	neomycin resistance:26:0.6351|neomycin-resistance:15:0.0338	0.6351	41
neo	neo:33|NEO:2	neomycin resistance gene:35:0.7952	0.7952	35
NEO	NEO:15|Neo:2	Neostigmine:17:0.0386	0.0386	17
NEPHGE	NEPHGE:29|NEpHGE:3	pH gradient electrophoresis:32:0.9072	0.9072	32
NEP-I	NEP-I:7|NEPI:1	Neutral endopeptidase inhibition:8:0.6411	0.6411	8
NEPI	NEPI:9|NEpi:2	norepinephrine:11:0.2941	0.2941	11
NEPs	NEPs:27	Needle exchange programs:27:0.8312	0.8312	27
NEP	NEP:29	needle exchange program:29:0.8978	0.8978	29
NEP	NEP:38	negative expiratory pressure:38:0.9217	0.9217	38
NEP	NEP:38|Nep:1	neprilysin:39:0.0432	0.0432	39
NEP	NEP:9	neuroepithelial:9:0.0091	0.0091	9
NEP	NEP:432	Neutral endopeptidase:432:0.9575	0.9575	432
NEP	NEP:116	neutral endopeptidase 24.11:104:0.8683|neutral endopeptidase-24.11:12:0.6460	0.8683	116
NEP	NEP:9	neutral endopeptidase 3.4.24.11:9:0.5856	0.5856	9
NEP	NEP:9	neutral endopeptidase EC 3.4.24.11:9:0.7357	0.7357	9
NEP	NEP:16	neutral metalloendopeptidase:16:0.8165	0.8165	16
NEP	NEP:16	RNA polymerase:16:0.7261	0.7261	16
NEQAS	NEQAS:14	national external quality assessment scheme:14:0.6911	0.6911	14
NEQ	NEQ:14	noise equivalent quanta:14:0.7909	0.7909	14
NER	NER:687	Nucleotide excision repair:687:0.9884	0.9884	687
NESB	NESB:23	non-English speaking background:15:0.7096|non-English speaking backgrounds:8:0.5006	0.7096	23
NESP	NESP:17	Novel erythropoiesis stimulating protein:17:0.8270	0.8270	17
NESs	NESs:29	nuclear export signals:29:0.8978	0.8978	29
NES	NES:15	Neurobehavioral Evaluation System:15:0.8045	0.8045	15
NES	NES:18	Neurological Evaluation Scale:18:0.6211	0.6211	18
NES	NES:11	Night Eating Syndrome:11:0.4728	0.4728	11
NES	NES:14	non-epileptic seizures:14:0.1579	0.1579	14
NES	NES:29	nonepileptic seizures:29:0.4913	0.4913	29
NES	NES:30	nuclear export sequence:30:0.9011	0.9011	30
NES	NES:206	nuclear export signal:190:0.9748|nuclear export signals:16:0.7261	0.9748	206
NET-OEN	NET-OEN:9	Norethisterone oenanthate:9:0.6794	0.6794	9
NETA	NETA:63	norethisterone acetate:63:0.6242	0.6242	63
NET-EN	NET-EN:34|Net-En:2|NET-En:2|Net-en:2|NETEN:1	norethisterone enanthate:41:0.7057	0.7057	41
NETSS	NETSS:9	National Electronic Telecommunications System for Surveillance:9:0.6794	0.6794	9
NETs	NETs:50	neuroendocrine tumors:35:0.8245|neuroendocrine tumours:15:0.7096	0.8245	50
NETs	NETs:7	norepinephrine transporters:7:0.1641	0.1641	7
NEU	NEU:17	N-nitrosoethylurea:17:0.1368	0.1368	17
neu	neu:10|NEU:3	neutrophils:13:0.1026	0.1026	13
NEXAFS	NEXAFS:9	x-ray absorption fine structure:9:0.6794	0.6794	9
NEXT	NEXT:12	Nationwide Evaluation of X-ray Trends:12:0.7571	0.7571	12
NE	NE:35	3H-norepinephrine:23:0.0022|[3H]-norepinephrine:12:0.0011	0.0022	35
Ne	Ne:42	effective population size:42:0.8893	0.8893	42
Ne	Ne:12	effective size:12:0.0921	0.0921	12
Ne	Ne:5|NE:2	error negativity:7:0.2452	0.2452	7
NE	NE:24	L-norepinephrine:24:0.0023	0.0023	24
NE	NE:14	necrotic enteritis:14:0.6911	0.6911	14
NE	NE:11	neonatal encephalopathy:11:0.6182	0.6182	11
NE	NE:85	nephropathia epidemica:85:0.9648	0.9648	85
NE	NE:10	net energy:10:0.6182	0.6182	10
NE	NE:335|ne:1	Neuroendocrine:336:0.0330	0.0330	336
NE	NE:6	neuroendocrine cells:6:0.2243	0.2243	6
NE	NE:12	neuroepithelium:12:0.0011	0.0011	12
NE	NE:12	neutropenic enterocolitis:12:0.5050	0.5050	12
NE	NE:225	neutrophil elastase:225:0.9359	0.9359	225
NE	NE:24	nocturnal enuresis:24:0.8768	0.8768	24
NE	NE:10	nonspecific esterase:10:0.3145	0.3145	10
NE	NE:13|nE:1	nor-epinephrine:14:0.0013	0.0013	14
NE	NE:78|Ne:2	Noradrenaline:80:0.0079	0.0079	80
NE	NE:81	noradrenergic:81:0.0079	0.0079	81
NE	NE:8100|Ne:1|nE:1	norepinephrine:8102:0.7970	0.7970	8102
NE	NE:7	norepinephrine levels:7:0.3524	0.3524	7
NE	NE:12	norethindrone:12:0.0011	0.0011	12
NE	NE:10	norethisterone:10:0.0009	0.0009	10
NE	NE:166	nuclear envelope:166:0.9712	0.9712	166
NE	NE:22	nuclear extracts:13:0.6701|nuclear extract:9:0.4587	0.6701	22
NE	NE:5	nutcracker esophagus:5:0.1132	0.1132	5
NE	NE:11	Nutritional encephalomalacia:11:0.7357	0.7357	11
NE	NE:9	plasma norepinephrine concentration:9:0.4587	0.4587	9
NE	NE:13	release of [3H]norepinephrine:13:0.0859	0.0859	13
NF-E2	NF-E2:7	nuclear factor-erythroid 2:7:0.5926	0.5926	7
NF-IL6	NF-IL6:5	nuclear factor for interleukin-6 expression:5:0.4422	0.4422	5
NF-IL6	NF-IL6:5	nuclear factor IL-6:5:0.6794	0.6794	5
NF1	NF1:170|NF-1:30|Nf1:3|Nf-1:1	neurofibromatosis 1:177:0.1543|neurofibromatosis-1:27:0.0195	0.1543	204
NF1	NF1:589|NF-1:106|Nf1:7	neurofibromatosis type 1:689:0.9787|neurofibromatosis type-1:13:0.7753	0.9787	702
NF1	NF1:6|Nf1:1	neurofibromatosis type 1 gene:7:0.5926	0.5926	7
NF1	NF1:35|NF-1:9	neurofibromatosis type I:44:0.8620	0.8620	44
NF1	NF1:9|Nf1:1	neurofibromin:10:0.0067	0.0067	10
NF-1	NF-1:25|NF1:2	nuclear factor-1:27:0.8903	0.8903	27
NF1	NF1:31|NF-1:8	type 1 neurofibromatosis:39:0.9237	0.9237	39
NF-1	NF-1:3|NF1:1	von Recklinghausen's disease:4:0.1618	0.1618	4
NF1	NF1:54|NF-1:15	Von Recklinghausen neurofibromatosis:69:0.9561	0.9561	69
NF200	NF200:6|NF-200:1	neurofilament protein:7:0.3524	0.3524	7
NF2	NF2:135|NF-2:6|Nf2:1	neurofibromatosis 2:142:0.3208	0.3208	142
NF2	NF2:215|NF-2:8|Nf2:2	neurofibromatosis type 2:225:0.9359	0.9359	225
NF2	NF2:9	neurofibromatosis type 2 gene:9:0.6794	0.6794	9
NF2	NF2:11|NF-2:2	neurofibromatosis type II:13:0.5934	0.5934	13
NF2	NF2:16	type 2 neurofibromatosis:16:0.8045	0.8045	16
NF68	NF68:7|NF-68:1	neurofilament protein:8:0.3463	0.3463	8
NFAT	NFAT:284|NF-AT:91	nuclear factor of activated T cells:311:0.9575|Nuclear factor of activated T-cells:34:0.7841|nuclear factor of activated T cell:23:0.7679|nuclear factor of activated T-cell:7:0.3524	0.9575	375
NFA	NFA:13	near-fatal asthma:13:0.6701	0.6701	13
NFA	NFA:20	niflumic acid:20:0.4379	0.4379	20
NFA	NFA:5	nonfunctioning pituitary adenomas:5:0.2818	0.2818	5
NFCS	NFCS:12	Nationwide Food Consumption Survey:12:0.5664	0.5664	12
NFCS	NFCS:13	Neonatal Facial Coding System:13:0.7753	0.7753	13
NFDM	NFDM:12	nonfat dry milk:12:0.6460	0.6460	12
NFD	NFD:17	Nephrogenic fibrosing dermopathy:17:0.8270	0.8270	17
NFD	NFD:13	neurofibrillary degeneration:13:0.5934	0.5934	13
NFD	NFD:12	nifedipine:12:0.1571	0.1571	12
NFG	NFG:10	normal fasting glucose:10:0.7103	0.7103	10
NFHS	NFHS:17	National Family Health Survey:17:0.7407	0.7407	17
NF-H	NF-H:4|NFH:2	heavy neurofilament:6:0.0807	0.0807	6
NF-H	NF-H:12|NFH:2	heavy neurofilament subunit:14:0.2326	0.2326	14
NF-H	NF-H:13|NFH:7|Nf-H:1	high molecular weight neurofilament protein:21:0.7291	0.7291	21
NF-H	NF-H:9|NFH:1	neurofilament heavy:10:0.1022	0.1022	10
NF-H	NF-H:6|NFH:1	subunit of neurofilaments:7:0.3524	0.3524	7
NFI	NFI:16	nerve function impairment:16:0.8165	0.8165	16
NFI	NFI:91|NF-I:25	nuclear factor I:116:0.9586	0.9586	116
NFLT	NFLT:11	nerve fiber layer thickness:11:0.7357	0.7357	11
NFLU	NFLU:6|N-FLU:3	norfluoxetine:9:0.8889	0.8889	9
NFLX	NFLX:100|Nflx:1	norfloxacin:101:0.8621	0.8621	101
NF-L	NF-L:7	light neurofilament:7:0.0886	0.0886	7
NFL	NFL:14	National Football League:14:0.7909	0.7909	14
NFL	NFL:80	nerve fiber layer:80:0.9627	0.9627	80
NF-L	NF-L:11	neurofilament-L:11:0.0250	0.0250	11
NF-L	NF-L:17|NFL:5	neurofilament light:22:0.3359	0.3359	22
NF-L	NF-L:12|NFL:1	neurofilament light chain:13:0.7753	0.7753	13
NF-L	NF-L:6|NFL:1	neurofilament light subunit:7:0.2113	0.2113	7
NF-L	NF-L:18|NFL:12	neurofilament protein:30:0.4299	0.4299	30
NF-L	NF-L:8|NFL:2	neurofilament subunit:10:0.1022	0.1022	10
NF-M	NF-M:6	middle molecular weight neurofilament protein:6:0.5290	0.5290	6
NF-M	NF-M:14|NFM:5	neurofilament:19:0.0849	0.0849	19
NF-M	NF-M:13|NFM:1	neurofilament subunit:14:0.3039	0.3039	14
NFM	NFM:10	northern fowl mite:10:0.7103	0.7103	10
NFPAs	NFPAs:9	pituitary adenomas:9:0.6794	0.6794	9
NFPA	NFPA:8	National Fire Protection Association:8:0.6411	0.6411	8
NFPA	NFPA:11|NF-PA:1	nonfunctioning pituitary adenomas:12:0.4153	0.4153	12
NFPLP	NFPLP:9	2-Nor-2-formylpyridoxal 5'-phosphate:9:0.6794	0.6794	9
NFPs	NFPs:29|NF-Ps:1	neurofilament proteins:30:0.9011	0.9011	30
NFP	NFP:130	natural family planning:130:0.9510	0.9510	130
NFP	NFP:97|NFp:1	neurofilament protein:78:0.8564|neurofilament proteins:20:0.8525	0.8564	98
NFP	NFP:12	nifedipine:12:0.0375	0.0375	12
NFP	NFP:11	not-for-profit:11:0.0341	0.0341	11
NFR	NFR:10	nociceptive flexion reflex:10:0.7103	0.7103	10
NFSa	NFSa:10|NFSA:4	fibrosarcoma:14:0.6111	0.6111	14
NFS	NFS:6	Fertility Survey:6:0.1543	0.1543	6
NFS	NFS:5	National Food Survey:5:0.4422	0.4422	5
NFs	NFs:123|Nfs:1	neurofilaments:124:0.4749	0.4749	124
NFs	NFs:9	Nod factors:9:0.1492	0.1492	9
NFs	NFs:10	nursing facilities:10:0.7103	0.7103	10
NFTs	NFTs:338|NFTS:1	neurofibrillary tangles:339:0.9684	0.9684	339
NFT	NFT:444	neurofibrillary tangles:362:0.9782|neurofibrillary tangle:82:0.9070	0.9782	444
NFT	NFT:8|nft:1	nitrofurantoin:9:0.0152	0.0152	9
NFV	NFV:68|Nfv:2	nelfinavir:70:0.8816	0.8816	70
Nfx	Nfx:9|NFX:8|nfx:1	nifurtimox:18:0.5312	0.5312	18
NF-Y	NF-Y:56|NFY:5	nuclear factor Y:42:0.8893|nuclear factor-Y:19:0.7658	0.8893	61
NF-kB	NF-kB:8|NFkB:2|NFKB:1	nuclear factor kappa B:11:0.6460	0.6460	11
NF-kB	NF-kB:25|NFkB:5|NF-KB:2	nuclear factor-kB:20:0.8525|nuclear factor kB:12:0.4557	0.8525	32
NF	NF:21	2-nitrofluorene:21:0.0114	0.0114	21
NF	NF:21	fluid:21:0.0114	0.0114	21
NF	NF:9	hearts:9:0.0046	0.0046	9
NF	NF:39	nanofiltration:39:0.0218	0.0218	39
NF	NF:25	native ferritin:25:0.8186	0.8186	25
NF	NF:80	Necrotizing fasciitis:80:0.6758	0.6758	80
NF	NF:172	Neurofibromatosis:172:0.0979	0.0979	172
NF	NF:526|Nf:4	Neurofilament:424:0.2416|neurofilaments:106:0.0601	0.2416	530
NF	NF:39|Nf:1	neurofilament protein:32:0.6900|neurofilament proteins:8:0.5006	0.6900	40
NF	NF:37|Nf:4|nf:1	nifedipine:42:0.0235	0.0235	42
NF	NF:9	Nissen fundoplication:9:0.3945	0.3945	9
NF	NF:26|Nf:1	Nitrofurantoin:27:0.0149	0.0149	27
NF	NF:13	nitrofurazone:13:0.0069	0.0069	13
NF	NF:15|nF:1	Nodular fasciitis:16:0.0753	0.0753	16
NF	NF:17	nonfailing:17:0.0092	0.0092	17
NF	NF:8|Nf:1	norfloxacin:9:0.0046	0.0046	9
NF	NF:11	normal:11:0.0057	0.0057	11
NF	NF:6	normal fibroblasts:6:0.1148	0.1148	6
NF	NF:58	nuclear factor:58:0.6113	0.6113	58
NGAL	NGAL:43|Ngal:3	neutrophil gelatinase-associated lipocalin:46:0.9353	0.9353	46
NGA	NGA:14	Galactosyl-neoglycoalbumin:14:0.2407	0.2407	14
NGA	NGA:9	neuroglandular antigen:9:0.6794	0.6794	9
Ngb	Ngb:19|NGB:3	Neuroglobin:22:0.5526	0.5526	22
NGC	NGC:11	neuroglycan C:11:0.3495	0.3495	11
NGC	NGC:9|nGC:1|NGc:1	nucleus gigantocellularis:11:0.1330	0.1330	11
NGC	NGC:15|NGc:2	Nucleus reticularis gigantocellularis:17:0.4742	0.4742	17
NGFB	NGFB:7|Ngfb:2	nerve growth factor:9:0.3945	0.3945	9
NGF-LI	NGF-LI:8|NGFLI:1	immunoreactivity:9:0.8889	0.8889	9
NGFR	NGFR:103|NGFr:34|NGF-R:30|NGF-r:1	nerve growth factor receptor:158:0.9423|nerve growth factor receptors:10:0.7103	0.9423	168
NGFR	NGFR:29|NGF-R:16|NGFr:10|NGF-r:2	NGF receptor:40:0.1724|NGF-receptor:9:0.0303|NGF receptors:8:0.1471	0.1724	57
NGF	NGF:5467|ngf:1	Nerve growth factor:5454:0.9772|Nerve growth factors:14:0.7909	0.9772	5468
NGF	NGF:15	nerve growth factor protein:15:0.8045	0.8045	15
NGMMA	NGMMA:11	NG-monomethyl-L-arginine:11:0.4762	0.4762	11
NGM	NGM:24	norgestimate:24:0.5238	0.5238	24
NGOs	NGOs:15	non-governmental organisations:15:0.4052	0.4052	15
NGOs	NGOs:54	non-governmental organizations:54:0.1436	0.1436	54
NGOs	NGOs:203	nongovernmental organizations:203:0.6575	0.6575	203
NGO	NGO:9	non-governmental organisation:9:0.3945	0.3945	9
NGO	NGO:11	non-governmental organizations:11:0.1131	0.1131	11
NGO	NGO:107	nongovernmental organization:80:0.6128|nongovernmental organizations:27:0.4992	0.6128	107
NGRI	NGRI:14	not guilty by reason of insanity:14:0.7909	0.7909	14
NGT	NGT:42	nasogastric tube:33:0.7841|nasogastric tubes:9:0.6794	0.7841	42
NGT	NGT:17	Nominal Group Technique:17:0.8270	0.8270	17
NGT	NGT:276|nGT:1	normal glucose tolerance:277:0.9827	0.9827	277
NGT	NGT:9	subjects:9:0.0192	0.0192	9
NGU	NGU:110|ngu:1	non-gonococcal urethritis:111:0.5108	0.5108	111
NGU	NGU:69	nongonococcal urethritis:69:0.2933	0.2933	69
NH(4)(+)	NH(4)(+):13	ammonium:13:0.6667	0.6667	13
NH(4)Cl	NH(4)Cl:12	ammonium chloride:12:0.7571	0.7571	12
NH2Cl	NH2Cl:37	monochloramine:37:0.9000	0.9000	37
NH2OH	NH2OH:18	Hydroxylamine:18:0.8500	0.8500	18
NH4	NH4:12	ammonium:12:0.2895	0.2895	12
NH4+	NH4+:79	ammonium:79:0.6446	0.6446	79
NH4+	NH4+:10	ammonium ion:10:0.5856	0.5856	10
NH4Cl	NH4Cl:66	ammonium chloride:66:0.9548	0.9548	66
NHAMCS	NHAMCS:52	National Hospital Ambulatory Medical Care Survey:52:0.9427	0.9427	52
NHANES	NHANES:151	National Health and Nutrition Examination Survey:130:0.9513|National Health and Nutrition Examination Surveys:21:0.8594	0.9513	151
NHAP	NHAP:13	nursing home-acquired pneumonia:13:0.7753	0.7753	13
NHBD	NHBD:80	non-heart-beating donors:43:0.5479|non-heart-beating donor:37:0.6250	0.6250	80
NHBDs	NHBDs:54	non-heart-beating donors:54:0.7492	0.7492	54
NHBE	NHBE:65	normal human bronchial epithelial:65:0.9275	0.9275	65
NHBE	NHBE:15	normal human bronchial epithelial cells:15:0.7096	0.7096	15
NHBPEP	NHBPEP:10	National High Blood Pressure Education Program:10:0.7103	0.7103	10
NHB	NHB:23	non-heart-beating:23:0.3284	0.3284	23
NHC	NHC:15	N-heterocyclic carbene:15:0.5818	0.5818	15
NHC	NHC:6	non-histone chromosomal:6:0.1838	0.1838	6
NHCP	NHCP:6	chromosomal protein:6:0.1838	0.1838	6
NHCU	NHCU:15	Nursing Home Care Unit:15:0.8045	0.8045	15
NHDF	NHDF:13	normal human dermal fibroblasts:13:0.6701	0.6701	13
NHDS	NHDS:38|NHDs:1	National Hospital Discharge Survey:39:0.9237	0.9237	39
NHD	NHD:15	nocturnal hemodialysis:15:0.6386	0.6386	15
NHE-1	NHE-1:35|NHE1:29	exchanger isoform 1:46:0.6867|exchanger isoform-1:18:0.6381	0.6867	64
NHE-1	NHE-1:4|NHE1:1	Na+/H+ antiporter:5:0.1132	0.1132	5
NHE1	NHE1:15|NHE-1:13	Na+/H+ exchanger:28:0.2835	0.2835	28
NHE-1	NHE-1:5	Na(+)/H(+) exchanger-1:5:0.0612	0.0612	5
NHE3	NHE3:29	exchanger isoform 3:29:0.7581	0.7581	29
NHE3	NHE3:14|NHE-3:5	Na+/H+ exchanger:19:0.1968	0.1968	19
NHE3	NHE3:30|NHE-3:1	Na(+)/H(+) exchanger 3:19:0.2681|Na+/H+ exchanger 3:12:0.1227	0.2681	31
NHEFS	NHEFS:12	NHANES I Epidemiologic Follow-up Study:12:0.6211	0.6211	12
NHEJ	NHEJ:169	end joining:169:0.9717	0.9717	169
NHEJ	NHEJ:63	non-homologous end-joining:63:0.3191	0.3191	63
NHEJ	NHEJ:83	nonhomologous end-joining:83:0.4457	0.4457	83
NHEKs	NHEKs:13	normal human epidermal keratinocytes:13:0.6701	0.6701	13
NHEK	NHEK:81	normal human epidermal keratinocytes:81:0.9415	0.9415	81
NHERF	NHERF:19|NHE-RF:5	exchanger regulatory factor:24:0.7151	0.7151	24
NHEXAS	NHEXAS:31	National Human Exposure Assessment Survey:31:0.8978	0.8978	31
NHE	NHE:53	Na+/H+ exchange:53:0.3307	0.3307	53
NHE	NHE:220	Na+/H+ exchanger:123:0.3627|Na(+)/H(+) exchanger:84:0.2331|Na+/H+ exchangers:13:0.2660	0.3627	220
NHFs	NHFs:14	normal human fibroblasts:14:0.7909	0.7909	14
NHF	NHF:6	National Heart Foundation:6:0.5290	0.5290	6
NHF	NHF:10	normal human fibroblasts:10:0.7103	0.7103	10
NHG	NHG:12	Dutch College of General Practitioners:12:0.6460	0.6460	12
NHGO	NHGO:14	net hepatic glucose output:14:0.7909	0.7909	14
NHGU	NHGU:36	Net hepatic glucose uptake:36:0.9174	0.9174	36
NHIS	NHIS:288	National Health Interview Survey:269:0.9822|National Health Interview Surveys:19:0.8449	0.9822	288
NHI	NHI:66	National Health Insurance:66:0.9548	0.9548	66
NHK	NHK:44	normal human keratinocytes:44:0.8620	0.8620	44
NHKs	NHKs:20	normal human keratinocytes:20:0.7173	0.7173	20
NHLBI	NHLBI:11	National Heart Lung and Blood Institute:11:0.9677	0.9677	11
NHLs	NHLs:203|NHLS:1	non-Hodgkin's lymphomas:204:0.7841	0.7841	204
NHL	NHL:16	non-Hodgkin's:16:0.0033	0.0033	16
NHL	NHL:4207|nHL:7|n-HL:2	non-Hodgkin's lymphoma:2973:0.7899|non-Hodgkin's lymphomas:556:0.7182|non-Hodgkin lymphoma:549:0.1368|non-Hodgkin lymphomas:138:0.1566	0.7899	4216
nHL	nHL:7	normal hearing level:7:0.5926	0.5926	7
NHMI	NHMI:10	N-nitrosoheptamethyleneimine:10:0.6429	0.6429	10
NHML	NHML:24	malignant lymphoma:14:0.7909|malignant lymphomas:10:0.7103	0.7909	24
NHMRC	NHMRC:41	National Health and Medical Research Council:41:0.9274	0.9274	41
NHOK	NHOK:21	normal human oral keratinocytes:21:0.7865	0.7865	21
NHOKs	NHOKs:11	normal human oral keratinocytes:11:0.7357	0.7357	11
NHPI	NHPI:15	N-hydroxyphthalimide:15:0.7778	0.7778	15
NHPs	NHPs:20	nonhuman primates:20:0.5279	0.5279	20
NHP	NHP:14	natural head position:14:0.7909	0.7909	14
NHP	NHP:15	natural head posture:15:0.8045	0.8045	15
NHP	NHP:25|nHP:1	non-histone proteins:18:0.2272|non-histone protein:8:0.2619	0.2619	26
NHP	NHP:4|Nhp:1|NhP:1|nhp:1	non-human primate:7:0.0692	0.0692	7
NHP	NHP:13	nonhistone proteins:13:0.1314	0.1314	13
NHP	NHP:20|Nhp:3	nonhuman primate:15:0.3614|nonhuman primates:8:0.2987	0.3614	23
NHP	NHP:18	normal human plasma:18:0.8365	0.8365	18
NHP	NHP:290	Nottingham Health Profile:290:0.9897	0.9897	290
NHP	NHP:14	nursing home placement:14:0.7909	0.7909	14
NHRs	NHRs:15	nuclear hormone receptors:15:0.8045	0.8045	15
NHR	NHR:11	nuclear hormone receptor:11:0.7357	0.7357	11
NHSBSP	NHSBSP:25	National Health Service Breast Screening Programme:25:0.8816	0.8816	25
NHSCR	NHSCR:8|NHS-CR:2	National Health Service Central Register:10:0.7103	0.7103	10
NHSCSP	NHSCSP:10	National Health Service Cervical Screening Programme:10:0.7103	0.7103	10
NHSC	NHSC:17	National Health Service Corps:17:0.8270	0.8270	17
NHST	NHST:10	null hypothesis significance testing:10:0.7103	0.7103	10
NHS	NHS:11	Nance-Horan syndrome:11:0.3829	0.3829	11
NHS	NHS:784	National Health Service:772:0.9917|National Health Services:12:0.6460	0.9917	784
NHS	NHS:20	National Health System:20:0.7766	0.7766	20
NHS	NHS:5	normal healthy subjects:5:0.1464	0.1464	5
NHS	NHS:29	normal human sera:29:0.8978	0.8978	29
NHS	NHS:274|nHS:1	normal human serum:275:0.9613	0.9613	275
NHS	NHS:7	normal human subjects:7:0.5926	0.5926	7
NHS	NHS:18	Nurses' Health Study:18:0.7539	0.7539	18
NHs	NHs:38|NHS:1	nursing homes:39:0.9237	0.9237	39
NHTBE	NHTBE:10	normal human tracheobronchial epithelial:10:0.6182	0.6182	10
NHT	NHT:28	neoadjuvant hormonal therapy:28:0.8369	0.8369	28
NHW	NHW:60	non-Hispanic white:39:0.9237|non-Hispanic whites:21:0.7865	0.9237	60
NHWs	NHWs:28	non-Hispanic whites:28:0.8941	0.8941	28
NHase	NHase:47	nitrile hydratase:47:0.9353	0.9353	47
NIA	NIA:28	National Institute on Aging:28:0.9100	0.9100	28
NIA	NIA:27	Neuroleptic-induced akathisia:27:0.7834	0.7834	27
NIA	NIA:11	nucleus interpositus anterior:11:0.7357	0.7357	11
NIBP	NIBP:27	blood pressure:27:0.8903	0.8903	27
NIBSC	NIBSC:13	National Institute for Biological Standards and Control:13:0.8165	0.8165	13
NIb	NIb:8	nuclear inclusion protein:8:0.6411	0.6411	8
NICD	NICD:21	Notch intracellular domain:21:0.4733	0.4733	21
NICE	NICE:91	National Institute for Clinical Excellence:91:0.9707	0.9707	91
NICHD	NICHD:51	National Institute of Child Health and Human Development:51:0.9438	0.9438	51
NICI	NICI:32	negative ion chemical ionization:32:0.8145	0.8145	32
NICTH	NICTH:10	cell tumor hypoglycemia:10:0.3867	0.3867	10
NICTH	NICTH:5	non-islet cell tumour hypoglycaemia:5:0.2818	0.2818	5
NICUs	NICUs:158	Neonatal Intensive Care Units:158:0.9181	0.9181	158
NICU	NICU:938	neonatal intensive care unit:872:0.9261|neonatal intensive care units:66:0.8651	0.9261	938
NICS	NICS:29	nucleus independent chemical shifts:11:0.6182|nucleus-independent chemical shifts:10:0.1994|nucleus independent chemical shift:8:0.6411	0.6411	29
NIDCAP	NIDCAP:13	Newborn Individualized Developmental Care and Assessment Program:13:0.4709	0.4709	13
NIDDM	NIDDM:7	diabetes mellitus Type II:7:0.5926	0.5926	7
NIDDM	NIDDM:33	diabetic patients:33:0.6976	0.6976	33
NIDDM	NIDDM:10	diabetic subjects:10:0.7103	0.7103	10
NIDDM	NIDDM:18	non-insulin dependent:18:0.5940	0.5940	18
NIDDM	NIDDM:217	non-insulin-dependent diabetes:156:0.4528|non-insulin dependent diabetes:61:0.7592	0.7592	217
NIDDM	NIDDM:2455	non-insulin-dependent diabetes mellitus:2455:0.7132	0.7132	2455
NIDDM	NIDDM:181	non-insulin-dependent diabetic:130:0.6840|non-insulin-dependent diabetics:23:0.2927|non-insulin dependent diabetic:20:0.6680|non-insulin dependent diabetics:8:0.4102	0.6840	181
NIDDM	NIDDM:6	non-insulin-dependent DM:6:0.1543	0.1543	6
NIDDM	NIDDM:12	noninsulin-dependent:12:0.0026	0.0026	12
NIDDM	NIDDM:27	noninsulin-dependent diabetes:27:0.0554	0.0554	27
NIDDY	NIDDY:3	non-insulin-dependent diabetes of the young:3:0.7357	0.7357	3
NIDD	NIDD:30	non-insulin-dependent diabetes:30:0.4881	0.4881	30
NIDD	NIDD:31	non-insulin-dependent diabetic:22:0.5327|non-insulin-dependent diabetics:9:0.1994	0.5327	31
NIDs	NIDs:66|NIDS:1	National Immunization Days:67:0.9554	0.9554	67
NID	NID:6	interaction domain:6:0.1838	0.1838	6
NID	NID:22	Neuronal intestinal dysplasia:22:0.8657	0.8657	22
NIEHS	NIEHS:35	National Institute of Environmental Health Sciences:35:0.9174	0.9174	35
NIE	NIE:11	negative inotropic effect:11:0.7357	0.7357	11
NifH	NifH:4|nifH:3	dinitrogenase reductase:7:0.2452	0.2452	7
nifH	nifH:12	nitrogenase:12:0.2157	0.2157	12
NIH3T3	NIH3T3:5|NIH-3T3:1	fibroblast cells:6:0.1838	0.1838	6
NIHF	NIHF:52	hydrops fetalis:52:0.9416	0.9416	52
NIHL	NIHL:136	noise-induced hearing loss:110:0.7267|noise induced hearing loss:26:0.8861	0.8861	136
NIHSS	NIHSS:175|NIH-SS:1	National Institutes of Health stroke scale:148:0.9798|National Institute of Health Stroke Scale:28:0.8978	0.9798	176
NIH	NIH:582	National Institutes of Health:582:0.9839	0.9839	582
NIH	NIH:16	neointimal hyperplasia:16:0.7261	0.7261	16
NIH	NIH:19	normalized index of hemolysis:19:0.8449	0.8449	19
NIIs	NIIs:25	neuronal intranuclear inclusions:25:0.8816	0.8816	25
NII	NII:10	Neuronal intranuclear inclusions:10:0.7103	0.7103	10
NILE	NILE:13	nerve growth factor-inducible large external:13:0.7909	0.7909	13
NILs	NILs:34	near-isogenic lines:27:0.4992|near isogenic lines:7:0.2452	0.4992	34
NILs	NILs:9|NILS:2	Neurointermediate lobes:11:0.5355	0.5355	11
NIL	NIL:9	near-isogenic line:9:0.2500	0.2500	9
NIL	NIL:106|N-IL:1	neurointermediate lobe:99:0.7460|neurointermediate lobes:8:0.4102	0.7460	107
NIL	NIL:17	neurointermediate lobe of the pituitary:17:0.8270	0.8270	17
NIMA	NIMA:10	maternal antigens:10:0.3867	0.3867	10
NIMGU	NIMGU:16	glucose uptake:16:0.8165	0.8165	16
NIMH	NIMH:125	National Institute of Mental Health:125:0.9763	0.9763	125
NIMS	NIMS:11	National Infant Mortality Surveillance:11:0.7357	0.7357	11
NIMV	NIMV:20	Noninvasive mechanical ventilation:20:0.4786	0.4786	20
NIM	NIM:23|Nim:1	Nimesulide:24:0.2130	0.2130	24
Nim	Nim:18|NIM:17	nimodipine:35:0.3148	0.3148	35
NINDS	NINDS:71	National Institute of Neurological Disorders and Stroke:71:0.9344	0.9344	71
NIND	NIND:20	non-inflammatory neurological diseases:15:0.4951|non-inflammatory neurological disease:5:0.2818	0.4951	20
NIOSH	NIOSH:291	National Institute for Occupational Safety and Health:291:0.9852	0.9852	291
NiO	NiO:20	nickel oxide:20:0.8525	0.8525	20
NIPAAm	NIPAAm:23|NIPAAM:2|NiPAAm:2	N-isopropylacrylamide:27:0.7879	0.7879	27
NIPAM	NIPAM:22|NiPAM:3	N-isopropylacrylamide:25:0.8000	0.8000	25
NIPA	NIPA:12	N-isopropylacrylamide:12:0.5500	0.5500	12
NIPD	NIPD:25	intermittent peritoneal dialysis:25:0.8816	0.8816	25
NIPSV	NIPSV:13	noninvasive pressure support ventilation:13:0.4444	0.4444	13
NIPS	NIPS:14	Neonatal Infant Pain Scale:14:0.7909	0.7909	14
NIPTS	NIPTS:13	noise-induced permanent threshold shift:13:0.7753	0.7753	13
NIP	NIP:9	negative inspiratory pressure:9:0.6794	0.6794	9
NIP	NIP:13	neuroleptic-induced parkinsonism:13:0.5934	0.5934	13
NIP	NIP:5|Nip:4	Normal Immunosuppressive Protein:9:0.6411	0.6411	9
NIP	NIP:8	nucleus interpositus posterior:8:0.6411	0.6411	8
NIRCA	NIRCA:18	RNase Cleavage Assay:18:0.8365	0.8365	18
NIRF	NIRF:10	near-infrared fluorescence:10:0.4363	0.4363	10
NIRF	NIRF:7	near-infrared fluorescent:7:0.3524	0.3524	7
NIRS	NIRS:26	Near-infrared spectrophotometry:17:0.3844|near infrared spectrophotometry:9:0.6794	0.6794	26
NIRS	NIRS:9	near-infrared spectroscopic:9:0.4587	0.4587	9
NIRS	NIRS:541|NIRs:4|nIRS:2	near-infrared spectroscopy:351:0.5330|near infrared spectroscopy:196:0.9673	0.9673	547
NISH	NISH:27	non-isotopic in situ hybridisation:27:0.7425	0.7425	27
NISH	NISH:38	situ hybridization:38:0.8098	0.8098	38
NISS	NISS:16	New Injury Severity Score:16:0.8165	0.8165	16
NIST	NIST:114	National Institute of Standards and Technology:114:0.9460	0.9460	114
NIS	NIS:10	information system:10:0.5000	0.5000	10
NIS	NIS:50	Na+/I- symporter:50:0.1608	0.1608	50
NIS	NIS:40	National Immunization Survey:40:0.9256	0.9256	40
NIS	NIS:28	Nationwide Inpatient Sample:28:0.6554	0.6554	28
NIS	NIS:10	Neuropsychological Impairment Scale:10:0.7103	0.7103	10
NIS	NIS:26	newly independent states:26:0.5840	0.5840	26
NIs	NIs:37	nosocomial infections:37:0.9197	0.9197	37
NIs	NIs:14	nuclear inclusions:14:0.6173	0.6173	14
NIS	NIS:73	sodium iodide symporter:73:0.9136	0.9136	73
NITBUT	NITBUT:8	tear break-up time:8:0.6411	0.6411	8
NITp	NITp:10|NITP:1	North Italy Transplant program:11:0.7103	0.7103	11
NIV	NIV:6	National Institute of Virology:6:0.6794	0.6794	6
NiV	NiV:21	Nipah virus:21:0.8594	0.8594	21
NIV	NIV:62	non-invasive ventilation:62:0.3662	0.3662	62
NIV	NIV:51	noninvasive ventilation:51:0.2872	0.2872	51
Ni	Ni:12	adenylate cyclase:12:0.5664	0.5664	12
Ni	Ni:13	guanine nucleotide regulatory protein:13:0.6701	0.6701	13
NI	NI:40|Ni:1	index:41:0.0380	0.0380	41
Ni	Ni:9	inhibitory guanine nucleotide-binding protein:9:0.4587	0.4587	9
NI	NI:10	intake:10:0.0085	0.0085	10
NI	NI:7	neurological impairment:7:0.2902	0.2902	7
NI	NI:10	neurologically impaired:10:0.5000	0.5000	10
Ni	Ni:197	nickel:197:0.1861	0.1861	197
NI	NI:16	Northern Ireland:16:0.8165	0.8165	16
NI	NI:119	nosocomial infections:71:0.9124|nosocomial infection:48:0.9379	0.9379	119
NI	NI:6	nuclear inclusions:6:0.0731	0.0731	6
NI	NI:22|Ni:1	nucleus isthmi:23:0.8715	0.8715	23
Ni	Ni:5	regulatory component:5:0.0902	0.0902	5
NI	NI:14	water immersion to the neck:14:0.6173	0.6173	14
NJ	NJ:58|N-J:2	neighbor-joining:50:0.3063|neighbor joining:10:0.3470	0.3470	60
NJ	NJ:10|N-J:1	neighbour-joining:11:0.0625	0.0625	11
NJ	NJ:37	New Jersey:37:0.9197	0.9197	37
NK(1)	NK(1):36	neurokinin-1:25:0.4528|neurokinin 1:11:0.5355	0.5355	36
NK-1R	NK-1R:52|NK1R:41|NK1-R:15|NK-1r:4|NK1r:2	neurokinin-1 receptor:73:0.4628|neurokinin 1 receptor:37:0.9197|neurokinin 1 receptors:4:0.1618	0.9197	114
NK-1	NK-1:6|NK1:5	neurokinin:11:0.0229	0.0229	11
NK1	NK1:139|NK-1:110	neurokinin-1:173:0.3576|Neurokinin 1:76:0.7548	0.7548	249
NK1	NK1:4|NK-1:1	Neurokinin-1 receptors:5:0.0902	0.0902	5
NK1	NK1:23	neurokinin1:23:0.0478	0.0478	23
NK1	NK1:41|NK-1:22	substance P:63:0.9541	0.9541	63
NK1	NK1:19|NK-1:4	substance P receptor:23:0.8816	0.8816	23
NK2	NK2:27|NK-2:12	neurokinin-2:25:0.2667|neurokinin 2:14:0.4367	0.4367	39
NK3	NK3:20|NK-3:12	neurokinin-3:23:0.2987|neurokinin 3:9:0.5470	0.5470	32
NK3	NK3:15	receptor:15:0.1688	0.1688	15
NKA-LI	NKA-LI:10|NKA-li:1	neurokinin A-like immunoreactivity:11:0.7357	0.7357	11
NKA	NKA:10|NKa:6|Nka:1	natural killer cell activity:17:0.8270	0.8270	17
NKCA	NKCA:45	Natural killer cell activity:45:0.9338	0.9338	45
NKCC	NKCC:49	cotransporter:49:0.3609	0.3609	49
NKCC	NKCC:30	natural killer cell cytotoxicity:30:0.9011	0.9011	30
NKCC	NKCC:12	NK cell cytotoxicity:12:0.1687	0.1687	12
NKCC1	NKCC1:45	cotransporter:45:0.5176	0.5176	45
NKCC1	NKCC1:8|Nkcc1:1	cotransporter isoform 1:9:0.4587	0.4587	9
NKCC2	NKCC2:22	Na-K-2Cl cotransporter:22:0.4344	0.4344	22
NKCF	NKCF:30	natural killer cytotoxic factor:30:0.8978	0.8978	30
NK-CMC	NK-CMC:9|NKCMC:2	cell-mediated cytotoxicity:11:0.6182	0.6182	11
NKC	NKC:48	natural killer cell:26:0.8861|natural killer cells:22:0.8657	0.8861	48
NKC	NKC:18	natural killer cytotoxicity:18:0.8365	0.8365	18
NKC	NKC:13	NK gene complex:13:0.3429	0.3429	13
NKH	NKH:13	Non-ketotic hyperglycinaemia:13:0.4849	0.4849	13
NKH	NKH:8	nonketotic hyperglycemia:8:0.2987	0.2987	8
NKH	NKH:33	nonketotic hyperglycinemia:33:0.6735	0.6735	33
NKRs	NKRs:6	natural killer cell receptors:6:0.5290	0.5290	6
NKR	NKR:20|NK-R:2|NKr:1	receptor:12:0.2750|receptors:11:0.2500	0.2750	23
NKSF	NKSF:17	Natural killer cell stimulatory factor:17:0.8270	0.8270	17
NKT	NKT:217|NK-T:2	natural killer T:219:0.9863	0.9863	219
NK	NK:9	kidney:9:0.0008	0.0008	9
NK	NK:9	natural:9:0.0008	0.0008	9
NK	NK:13	natural cytotoxicity:13:0.4557	0.4557	13
NK	NK:9405|nk:1	natural killer:9321:0.9909|natural-killer:54:0.0052|natural killers:31:0.8563	0.9909	9406
NK	NK:7	natural killer activity:7:0.5926	0.5926	7
NK	NK:331	natural killer cell:212:0.9774|natural killer cells:119:0.9749	0.9774	331
NK	NK:6	natural killer cell activity:6:0.5290	0.5290	6
NK	NK:70	Natural killing:70:0.9326	0.9326	70
NK	NK:114	neurokinin:104:0.0100|Neurokinins:10:0.0009	0.0100	114
NK	NK:8	normal kidneys:8:0.4102	0.4102	8
NLA	NLA:11	naphthoxylactic acid:11:0.3829	0.3829	11
NLA	NLA:27	neuroleptanalgesia:27:0.1548	0.1548	27
NLA	NLA:22	nitro-L-arginine:22:0.1250	0.1250	22
NLBB	NLBB:12	breast biopsy:12:0.7571	0.7571	12
NLBs	NLBs:9	nucleolus-like bodies:9:0.6794	0.6794	9
NLDO	NLDO:13	Nasolacrimal duct obstruction:13:0.6701	0.6701	13
NLD	NLD:16	nasolacrimal duct:16:0.8165	0.8165	16
NLD	NLD:11	necrobiosis lipoidica diabeticorum:11:0.7357	0.7357	11
NLD	NLD:17	nonverbal learning disabilities:17:0.5374	0.5374	17
NLEP	NLEP:14	National Leprosy Eradication Programme:14:0.7909	0.7909	14
NLF	NLF:21	nasal lavage fluid:21:0.8594	0.8594	21
NLH	NLH:13	nodular lymphoid hyperplasia:13:0.7753	0.7753	13
NLK	NLK:7|Nlk:3	NEMO-like kinase:10:0.5856	0.5856	10
NLK	NLK:15	neuroleukin:15:0.4828	0.4828	15
NLL	NLL:8	nuclei of the lateral lemniscus:8:0.5006	0.5006	8
NLM	NLM:107	National Library of Medicine:90:0.9672|National Library of Medicine's:17:0.8270	0.9672	107
NLM	NLM:8	nonlinear mapping:8:0.4102	0.4102	8
nLM	nLM:9	nucleus lentiformis mesencephali:9:0.6794	0.6794	9
NLN	NLN:19	National League for Nursing:19:0.8715	0.8715	19
NLO	NLO:28	nonlinear optical:28:0.7154	0.7154	28
NLPB	NLPB:9	nonlinear Poisson-Boltzmann:9:0.4587	0.4587	9
NLPHD	NLPHD:10|N-LPHD:1|nLP-HD:1|NLP-HD:1	nodular lymphocyte predominance Hodgkin's disease:13:0.7753	0.7753	13
NLPHL	NLPHL:7	nodular lymphocyte predominant Hodgkin lymphoma:7:0.5926	0.5926	7
NLP	NLP:16	light perception:16:0.8165	0.8165	16
NLP	NLP:59	Natural Language Processing:59:0.9494	0.9494	59
NLP	NLP:10	programming:10:0.0703	0.0703	10
NLRB	NLRB:9	National Labor Relations Board:9:0.6794	0.6794	9
NLRV	NLRV:9	Nilaparvata lugens reovirus:9:0.6794	0.6794	9
NLR	NLR:8	nonlinear regression:8:0.2619	0.2619	8
NLSs	NLSs:37	nuclear localization sequences:37:0.9197	0.9197	37
NLSs	NLSs:123	nuclear localization signals:123:0.9757	0.9757	123
NLS	NLS:9	neonatal lupus syndrome:9:0.6794	0.6794	9
NLS	NLS:8	nonlinear least squares:8:0.5006	0.5006	8
NLS	NLS:11	nonlinear Schrodinger:11:0.7357	0.7357	11
NLS	NLS:142|nls:1	nuclear localization sequence:125:0.9494|nuclear localization sequences:18:0.8365	0.9494	143
NLS	NLS:607|nls:3	nuclear localization signal:532:0.9850|nuclear localization signals:78:0.9617	0.9850	610
NLTCS	NLTCS:13	National Long Term Care Survey:7:0.5926|National Long-Term Care Survey:6:0.5290	0.5926	13
NLT	NLT:33	nucleus lateralis tuberis:33:0.9100	0.9100	33
NLVs	NLVs:60	Norwalk-like viruses:60:0.9216	0.9216	60
NLV	NLV:59	Norwalk-like virus:43:0.8590|Norwalk-like viruses:16:0.8165	0.8590	59
NLX	NLX:33|Nlx:1	naloxone:34:0.8049	0.8049	34
NL	NL:13	children with normal language:13:0.3554	0.3554	13
NL	NL:12	nasal lavage:12:0.7571	0.7571	12
NL	NL:6	native liver:6:0.0899	0.0899	6
NL	NL:22	Necrobiosis lipoidica:22:0.8657	0.8657	22
NL	NL:27	neural lobe:27:0.8312	0.8312	27
NL	NL:23	neuroleptic:13:0.0166|neuroleptics:10:0.0124	0.0166	23
NL	NL:38	neutral lipids:23:0.8038|neutral lipid:15:0.7096	0.8038	38
NL	NL:60|Nl:7|nl:1	normal:68:0.0927	0.0927	68
NL	NL:8	normal liver:8:0.2090	0.2090	8
NL	NL:12	normal subjects:12:0.3813	0.3813	12
NL	NL:10	normolipidemic:10:0.0124	0.0124	10
NMA	NMA:12	N-methyl-aspartate:12:0.0312	0.0312	12
NMA	NMA:51	N-methyl-d,l-aspartate:51:0.1416	0.1416	51
NMA	NMA:29	N-methyl-D,L-aspartic acid:29:0.4648	0.4648	29
NMA	NMA:18	N-methyl-DL-aspartate:18:0.0482	0.0482	18
NMA	NMA:11	N-methylacetamide:11:0.0283	0.0283	11
NMA	NMA:16	N-methylaspartate:16:0.0425	0.0425	16
NMA	NMA:10	N-Nitroso-N-methylaniline:10:0.0255	0.0255	10
NMA	NMA:10	N-nitrosomethylaniline:10:0.0255	0.0255	10
NMA	NMA:7	National Medical Association:7:0.3524	0.3524	7
NMA	NMA:14	NG-Methyl-L-arginine:14:0.0368	0.0368	14
NMA	NMA:29	NG-monomethyl-L-arginine:29:0.0793	0.0793	29
NMA	NMA:9	normal mode analysis:9:0.6794	0.6794	9
NMBAs	NMBAs:34	neuromuscular blocking agents:34:0.8644	0.8644	34
NMBA	NMBA:23	N-nitrosomethylbenzylamine:23:0.2933	0.2933	23
NMBA	NMBA:22	neuromuscular blocking agents:14:0.7909|Neuromuscular blocking agent:8:0.6411	0.7909	22
NMBDs	NMBDs:9	neuromuscular blocking drugs:9:0.6794	0.6794	9
NMB-R	NMB-R:17|NMBR:6	neuromedin B receptor:23:0.8038	0.8038	23
NMBzA	NMBzA:25|NMBZA:2	N-nitrosomethylbenzylamine:27:0.5532	0.5532	27
NMB	NMB:34	Neuromuscular block:34:0.9126	0.9126	34
NMB	NMB:31	neuromuscular blockade:31:0.8519	0.8519	31
NMB	NMB:16	neuromuscular blocking:16:0.8165	0.8165	16
NMCUES	NMCUES:17	National Medical Care Utilization and Expenditure Survey:17:0.8270	0.8270	17
NMC	NMC:13|NmC:1	neuromedin C:14:0.6911	0.6911	14
NMC	NMC:8	nucleus magnocellularis:8:0.2619	0.2619	8
NMDAR1	NMDAR1:9	N-methyl-D-aspartate receptor:9:0.1205	0.1205	9
NMDAR1	NMDAR1:7	N-methyl-D-aspartate receptor 1:7:0.1329	0.1329	7
NMDAR1	NMDAR1:7	NMDA receptor subunit:7:0.3524	0.3524	7
NMDAR1	NMDAR1:19|NMDA-R1:3|NMDAR-1:2	receptor subunit 1:24:0.8768	0.8768	24
NMDAR	NMDAR:150|NMDA-R:13|NMDAr:10	N-methyl-D-aspartate receptor:145:0.4839|N-methyl-D-aspartate receptors:28:0.3896	0.4839	173
NMDAR	NMDAR:14|NMDA-r:1	NMDA receptors:15:0.1838	0.1838	15
NMDA	NMDA:36	N-methyl--aspartate:36:0.0038	0.0038	36
NMDA	NMDA:34	N-methyl-D-asparate:34:0.0036	0.0036	34
NMDA	NMDA:8273|N-MDA:1	N-methyl-D-aspartate:8147:0.8783|N-methyl D-aspartate:75:0.5993|N-methyl- d-aspartate:32:0.1980|N-methyl-D aspartate:10:0.2643|N-methyl-D- aspartate:5:0.0666|N -methyl-d-aspartate:5:0.0736	0.8783	8274
NMDA	NMDA:18	N-methyl-D-aspartate receptor:18:0.7539	0.7539	18
NMDA	NMDA:10	N-methyl-D-aspartic:10:0.0010	0.0010	10
NMDA	NMDA:524|NM-DA:1	N-methyl-D-aspartic acid:525:0.8835	0.8835	525
NMDA	NMDA:10	N-Methyl-D,L-Aspartate:10:0.0010	0.0010	10
NMDA	NMDA:127|-NMDA:1	non-N-methyl-D-aspartate:128:0.0137	0.0137	128
NMDG	NMDG:58	N-methyl-D-glucamine:58:0.8286	0.8286	58
NMDLA	NMDLA:10	N-methyl-D,L-aspartate:10:0.1915	0.1915	10
NMDLA	NMDLA:16	N-methyl-DL-aspartate:16:0.3191	0.3191	16
NMDLA	NMDLA:8	N-methyl-DL-aspartic acid:8:0.2090	0.2090	8
NMDP	NMDP:44	National Marrow Donor Program:44:0.9323	0.9323	44
NMDs	NMDs:12	neuronal migration disorders:12:0.6460	0.6460	12
NMDS	NMDS:31	Nursing Minimum Data Set:31:0.8090	0.8090	31
NMD	NMD:32	neuromuscular disease:17:0.6211|Neuromuscular Diseases:15:0.7096	0.7096	32
NMD	NMD:14	neuromuscular disorders:9:0.1409|neuromuscular disorder:5:0.1132	0.1409	14
NMD	NMD:12	neuronal migration disorders:12:0.7571	0.7571	12
NMD	NMD:13	nimodipine:13:0.0386	0.0386	13
NMD	NMD:37	nonsense-mediated decay:37:0.1622	0.1622	37
NMD	NMD:105	nonsense-mediated mRNA decay:105:0.9022	0.9022	105
NMEP	NMEP:10	National Malaria Eradication Programme:10:0.7103	0.7103	10
NMES	NMES:26	1987 National Medical Expenditure Survey:26:0.6084	0.6084	26
NMES	NMES:59	neuromuscular electrical stimulation:59:0.8954	0.8954	59
NMEs	NMEs:9	new molecular entities:9:0.6794	0.6794	9
NMES	NMES:9	non-milk extrinsic sugars:9:0.6794	0.6794	9
NME	NME:20	Necrolytic migratory erythema:20:0.8525	0.8525	20
NMFS	NMFS:8	National Mortality Followback Survey:8:0.5006	0.5006	8
NMF	NMF:108|N-MF:8	N-methylformamide:116:0.6497	0.6497	116
NMG	NMG:21|N-MG:1	N-methyl-D-glucamine:22:0.3684	0.3684	22
NMHCs	NMHCs:10	non-methane hydrocarbons:10:0.5856	0.5856	10
NMIHS	NMIHS:15	1988 National Maternal and Infant Health Survey:15:0.6024	0.6024	15
NMJs	NMJs:135|nmjs:3	neuromuscular junctions:138:0.9654	0.9654	138
NMMA	NMMA:5	inhibitor N-monomethyl-L-arginine:5:0.0736	0.0736	5
NMMA	NMMA:78|N-MMA:1	NG-Monomethyl-L-arginine:79:0.4407	0.4407	79
NMMA	NMMA:2	NOS inhibitor N(G)-monomethyl-L-arginine:2:0.1132	0.1132	2
NMNAT	NMNAT:7|Nmnat:2|NMN-AT:1	nicotinamide mononucleotide adenylyltransferase:10:0.5856	0.5856	10
NMN	NMN:22	N-methylnicotinamide:13:0.0492|N'-methylnicotinamide:9:0.0328	0.0492	22
NMN	NMN:32|N-MN:2|nmn:1	N1-methylnicotinamide:35:0.1393	0.1393	35
NMN	NMN:11|NM-N:3	neuromedin N:14:0.7909	0.7909	14
NMN	NMN:38	nicotinamide mononucleotide:38:0.8417	0.8417	38
NMN	NMN:80	normetanephrine:80:0.3238	0.3238	80
NMO1	NMO1:7|NMO-1:1|Nmo1:1	oxidoreductase:9:0.7273	0.7273	9
NMOR	NMOR:55|N-MOR:1	N-nitrosomorpholine:56:0.8209	0.8209	56
NMP22	NMP22:7|NMP-22:2	nuclear matrix protein:9:0.6794	0.6794	9
NMP22	NMP22:25|NMP-22:1	nuclear matrix protein 22:26:0.8816	0.8816	26
NMPs	NMPs:20	nuclear matrix proteins:20:0.8525	0.8525	20
NMP	NMP:11	1-Methyl-2-pyrrolidinone:11:0.0450	0.0450	11
NMP	NMP:39	N-methyl-2-pyrrolidone:39:0.1577	0.1577	39
NMP	NMP:13	N-methylpyrrolidone:13:0.0541	0.0541	13
NMP	NMP:30	nuclear matrix protein:30:0.8472	0.8472	30
NMP	NMP:15	nucleoside monophosphate:15:0.7096	0.7096	15
NMRD	NMRD:33	Nuclear magnetic relaxation dispersion:33:0.7525	0.7525	33
NMRD	NMRD:12	respiratory disease:12:0.7571	0.7571	12
NMRI	NMRI:23|NMRi:1	Nuclear magnetic resonance imaging:24:0.8768	0.8768	24
NMRS	NMRS:17	nuclear magnetic resonance spectroscopy:17:0.6748	0.6748	17
NMR	NMR:9	classically conditioned nictitating membrane response:9:0.5470	0.5470	9
NMR	NMR:15	neonatal mortality rate:15:0.7096	0.7096	15
NMR	NMR:4140|nmr:18	nuclear magnetic resonance:4158:0.9315	0.9315	4158
NMR	NMR:23	nuclear magnetic resonance imaging:23:0.6306	0.6306	23
NMR	NMR:133	nuclear magnetic resonance spectroscopy:133:0.8785	0.8785	133
NMSC	NMSC:9	non-melanoma skin cancers:9:0.1690	0.1690	9
NMSC	NMSC:12	nonmelanoma skin cancers:12:0.3058	0.3058	12
NMSC	NMSC:137	skin cancer:137:0.9782	0.9782	137
NMSE	NMSE:7	normalized mean square error:7:0.5926	0.5926	7
NMSS	NMSS:6	reports are transmitted to CDC through the National Malaria Surveillance System:6:0.5290	0.5290	6
NMS	NMS:6	antagonist N-methylscopolamine:6:0.0777	0.0777	6
NMS	NMS:24	neurally mediated syncope:24:0.8768	0.8768	24
NMS	NMS:338	neuroleptic malignant syndrome:338:0.9911	0.9911	338
NMS	NMS:31	normal mouse serum:31:0.8519	0.8519	31
NMTT	NMTT:16	N-methyltetrazolethiol:16:0.3846	0.3846	16
NMTT	NMTT:8|N-MTT:1	N-methylthiotetrazole:9:0.2051	0.2051	9
NMT	NMT:30|Nmt:7	Myristoyl-CoA:protein N-myristoyltransferase:37:0.2827	0.2827	37
NMT	NMT:12	N-myristoyl transferase:12:0.4153	0.4153	12
NMT	NMT:10|nmt:1	neuromuscular transmission:11:0.7357	0.7357	11
NMT	NMT:6	Norepinephrine N-methyltransferase:6:0.1010	0.1010	6
NMU	NMU:25	N-methyl-N-nitrosourea:25:0.0744	0.0744	25
NMU	NMU:68	N-nitroso-N-methylurea:68:0.2168	0.2168	68
NMU	NMU:54	N-nitrosomethylurea:54:0.1715	0.1715	54
NMU	NMU:34|NmU:16	neuromedin U:50:0.9404	0.9404	50
NMU	NMU:47	nitrosomethylurea:47:0.1489	0.1489	47
NMV	NMV:18|nMV:1	mechanical ventilation:19:0.6537	0.6537	19
NMuMG	NMuMG:7	normal murine mammary gland:7:0.6411	0.6411	7
nM	nM:12	Ki values:12:0.1203	0.1203	12
NM	NM:9	N-nitrosomorpholine:9:0.0061	0.0061	9
NM	NM:36	Nafamostat mesilate:36:0.8716	0.8716	36
Nm	Nm:20|NM:6	Neisseria meningitidis:26:0.7760	0.7760	26
NM	NM:17	nemaline myopathy:17:0.5374	0.5374	17
Nm	Nm:10|NM:3	neomycin:13:0.0092	0.0092	13
NM	NM:14	neoplastic meningitis:14:0.5589	0.5589	14
NM	NM:31	neuromelanin:31:0.0230	0.0230	31
NM	NM:24|N-M:3|nm:2|n-m:2	neuromuscular:31:0.0230	0.0230	31
NM	NM:58	nictitating membrane:58:0.7453	0.7453	58
NM	NM:10	nimodipine:10:0.0069	0.0069	10
NM	NM:22	nitrogen mustard:22:0.7955	0.7955	22
NM	NM:11	nitrosomorpholine:11:0.0077	0.0077	11
NM	NM:27	nodular melanoma:27:0.8312	0.8312	27
NM	NM:8|nm:2|nM:1	non-muscle:11:0.0077	0.0077	11
NM	NM:14|nm:1	nonmuscle:15:0.0107	0.0107	15
NM	NM:8	normal mice:8:0.4102	0.4102	8
NM	NM:9	normal mucosa:9:0.2102	0.2102	9
NM	NM:29	normetanephrine:29:0.0215	0.0215	29
NM	NM:11	normorphine:11:0.0077	0.0077	11
NM	NM:59	nuclear matrix:59:0.8710	0.8710	59
NM	NM:15	nuclear medicine:15:0.7096	0.7096	15
NN/LM	NN/LM:9	National Network of Libraries of Medicine:9:0.6794	0.6794	9
NNAL	NNAL:93	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol:93:0.8679	0.8679	93
NNA	NNA:9	N-nitro-L-arginine:9:0.0690	0.0690	9
NNA	NNA:19	N omega-nitro-L-arginine:19:0.8449	0.8449	19
NNA	NNA:21	NG-nitro-L-arginine:21:0.1724	0.1724	21
NNBC	NNBC:10	node-negative breast cancer:10:0.5000	0.5000	10
NNDSS	NNDSS:26	National Notifiable Diseases Surveillance System:26:0.8251	0.8251	26
NND	NND:9	neonatal death:9:0.5470	0.5470	9
NNE	NNE:8	normalized noise energy:8:0.4102	0.4102	8
NNIS	NNIS:86	National Nosocomial Infections Surveillance:61:0.9526|National Nosocomial Infection Surveillance:25:0.8816	0.9526	86
NNIS	NNIS:7	National Nosocomial Infections Surveillance System:7:0.5290	0.5290	7
NNIs	NNIs:8	non-nucleoside inhibitors:8:0.2327	0.2327	8
NNK	NNK:17	4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone:17:0.0276	0.0276	17
NNK	NNK:27	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone:27:0.0449	0.0449	27
NNK	NNK:19	4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone:19:0.0311	0.0311	19
NNK	NNK:69	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone:65:0.6534|tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone:4:0.2818	0.6534	69
NNLA	NNLA:11	N-nitro-L-arginine:11:0.3030	0.3030	11
NNM	NNM:69	N-nitrosomorpholine:69:0.7010	0.7010	69
NNMT	NNMT:18	nicotinamide N-methyltransferase:18:0.7539	0.7539	18
NNN	NNN:31	N-nitrosonornicotine:31:0.1667	0.1667	31
NNN	NNN:12	nitrosonornicotine:12:0.0556	0.0556	12
nNOS	nNOS:5	neuronal isoform:5:0.0736	0.0736	5
nNOS	nNOS:668|n-NOS:5|NNOS:1	neuronal nitric oxide synthase:674:0.8125	0.8125	674
nNOS	nNOS:9	neuronal NO-synthase:9:0.5470	0.5470	9
nNOS	nNOS:287|n-NOS:2|NNOS:1	neuronal NOS:290:0.8575	0.8575	290
NNPs	NNPs:11	neonatal nurse practitioners:11:0.7357	0.7357	11
NNP	NNP:15	neonatal nurse practitioner:15:0.8045	0.8045	15
NNRTIs	NNRTIs:138	non-nucleoside reverse transcriptase inhibitors:138:0.5574	0.5574	138
NNRTIs	NNRTIs:18	non-nucleoside RT inhibitors:18:0.2161	0.2161	18
NNRTIs	NNRTIs:16	nonnucleoside RT inhibitors:16:0.1787	0.1787	16
NNRTI	NNRTI:132|nnRTI:1|nNRTI:1	non-nucleoside reverse transcriptase inhibitor:90:0.5876|non-nucleoside reverse transcriptase inhibitors:44:0.5764	0.5876	134
NNS	NNS:6	1980 National Natality Survey:6:0.3728	0.3728	6
NNS	NNS:11	National Nutrition Survey:11:0.7357	0.7357	11
NNs	NNs:31	neural networks:31:0.9043	0.9043	31
NNS	NNS:15	non-nutritive sucking:15:0.2430	0.2430	15
NNS	NNS:19	nonnutritive sucking:19:0.3582	0.3582	19
NNTs	NNTs:7	numbers needed to treat:7:0.3524	0.3524	7
NNT	NNT:3	calculate the relative benefit and the number-needed-to-treat:3:0.2827	0.2827	3
NNT	NNT:7	needed to be treated:7:0.2452	0.2452	7
NNT	NNT:49	neonatal tetanus:49:0.9027	0.9027	49
NNT	NNT:260|NnT:1	number needed to treat:252:0.8005|numbers-needed-to-treat:9:0.0171	0.8005	261
NNU	NNU:11	neonatal unit:11:0.7357	0.7357	11
NO(*)	NO(*):26|NO(*-):1	nitric oxide:27:0.8903	0.8903	27
NO(-)	NO(-):10	nitroxyl anion:10:0.5000	0.5000	10
NO(.)	NO(.):21|NO(.-):2	nitric oxide:23:0.8715	0.8715	23
NO(2)	NO(2):64	nitrogen dioxide:64:0.9033	0.9033	64
NO(3)(-)	NO(3)(-):10	nitrite (NO(2)(-)) and nitrate:10:0.8045	0.8045	10
NO(x)	NO(x):6	nitrate and nitrite:6:0.2902	0.2902	6
NO(x)	NO(x):11	nitrate/nitrite:11:0.0758	0.0758	11
NO(x)	NO(x):7	nitric oxide metabolites:7:0.5926	0.5926	7
NO(x)	NO(x):7	nitrite and nitrate:7:0.2757	0.2757	7
NO(x)	NO(x):16|NO(X):1	nitrogen oxides:17:0.6748	0.6748	17
NO(x)	NO(x):9	oxides of nitrogen:9:0.6794	0.6794	9
NO*	NO*:103	nitric oxide:103:0.9710	0.9710	103
NO-	NO-:11	nitroxyl:11:0.2571	0.2571	11
NO-	NO-:12	nitroxyl anion:12:0.7571	0.7571	12
NO.	NO.:238	Nitric oxide:238:0.9798	0.9798	238
NO2	NO2:538|No2:1	nitrogen dioxide:539:0.9751	0.9751	539
NO3-N	NO3-N:9	nitrate nitrogen:9:0.6794	0.6794	9
NOAEL	NOAEL:6	adverse effect levels:6:0.3728	0.3728	6
NOAEL	NOAEL:163	no-observed-adverse-effect level:136:0.4040|no-observed-adverse-effect-level:27:0.0743	0.4040	163
NOAEL	NOAEL:19	observable adverse effect level:19:0.1032	0.1032	19
NOAEL	NOAEL:66	observed adverse effect level:66:0.5546	0.5546	66
NOAR	NOAR:14	Norfolk Arthritis Register:14:0.7909	0.7909	14
NOARG	NOARG:18|NO-Arg:3|NOArg:2	NG-nitro-L-arginine:23:0.5116	0.5116	23
NOA	NOA:5	men with nonobstructive azoospermia:5:0.1132	0.1132	5
NOA	NOA:18	non-obstructive azoospermia:18:0.4438	0.4438	18
NOB	NOB:10	nitrite-oxidizing bacteria:10:0.3867	0.3867	10
NOCs	NOCs:10	N-Nitroso compounds:10:0.5000	0.5000	10
NOC	NOC:53	N-nitroso compounds:53:0.8373	0.8373	53
NOC	NOC:6|noc:3	nociceptin:9:0.0455	0.0455	9
NOC	NOC:28	Nursing Outcomes Classification:28:0.7425	0.7425	28
NOD	NOD:15	diabetic mice:15:0.7096	0.7096	15
NOD	NOD:8	Nocturnal oxygen desaturation:8:0.6411	0.6411	8
NOD	NOD:7	nocturnal oxyhemoglobin desaturation:7:0.5926	0.5926	7
nod	nod:77|NOD:2	nodulation:79:0.0511	0.0511	79
NOD	NOD:714	nonobese diabetic:714:0.5156	0.5156	714
NOD	NOD:7	nonobese diabetic mouse:7:0.3524	0.3524	7
NOE's	NOE's:9|nOe's:1	nuclear Overhauser effects:10:0.7103	0.7103	10
NOECs	NOECs:11	No-observed-effect concentrations:11:0.2154	0.2154	11
NOEC	NOEC:15|noec:1	observed effect concentration:16:0.3831	0.3831	16
NOEL	NOEL:6	no-observed-effect levels:6:0.1148	0.1148	6
NOESY	NOESY:92	nuclear Overhauser effect spectroscopy:92:0.9484	0.9484	92
NOESY	NOESY:9	nuclear Overhauser enhancement:9:0.6794	0.6794	9
NOESY	NOESY:6	two-dimensional NOE:6:0.1838	0.1838	6
NOEs	NOEs:114|nOes:1	nuclear Overhauser effects:115:0.9740	0.9740	115
NOEs	NOEs:30	nuclear Overhauser enhancements:30:0.9011	0.9011	30
NOE	NOE:10	nuclear Overhauser:10:0.7103	0.7103	10
NOE	NOE:323|nOe:6	nuclear Overhauser effect:273:0.9711|nuclear Overhauser effects:56:0.9162	0.9711	329
NOE	NOE:113|nOe:2	nuclear Overhauser enhancement:102:0.9534|nuclear Overhauser enhancements:13:0.5934	0.9534	115
NOFTT	NOFTT:14	nonorganic failure to thrive:14:0.5111	0.5111	14
NOF	NOF:12	National Osteoporosis Foundation:12:0.7571	0.7571	12
NOF	NOF:17	neurite outgrowth factor:17:0.8165	0.8165	17
NOLA	NOLA:16	N-nitro-L-arginine:16:0.2941	0.2941	16
NOLA	NOLA:9	NG-nitro-L-arginine:9:0.1569	0.1569	9
NOLD	NOLD:17	nonoxidative leucine disposal:17:0.5760	0.5760	17
noma	noma:14|Noma:2	cancrum oris:16:0.8045	0.8045	16
NOMID	NOMID:9	multisystem inflammatory disease:9:0.5470	0.5470	9
NOMI	NOMI:23	mesenteric ischemia:23:0.8715	0.8715	23
NOM	NOM:170	natural organic matter:170:0.9719	0.9719	170
NOM	NOM:16|Nom:7|nom:1	nomifensine:24:0.0846	0.0846	24
NOM	NOM:25	nonoperative management:25:0.6539	0.6539	25
NOM	NOM:19	normal oral mucosa:19:0.8449	0.8449	19
NONMEM	NONMEM:12|NON-MEM:1	Mixed Effects Modelling:7:0.5926|mixed effect modelling:6:0.5290	0.5926	13
NONMEM	NONMEM:14	nonlinear mixed-effects modeling:14:0.5589	0.5589	14
NOR's	NOR's:9	nucleolus organizer regions:9:0.2500	0.2500	9
NOR-1	NOR-1:8|Nor-1:1	neuron-derived orphan receptor-1:9:0.6794	0.6794	9
NORA	NORA:30	norantipyrine:30:0.4203	0.4203	30
NORs	NORs:270|NORS:1	nucleolar organizer regions:271:0.6140	0.6140	271
NORs	NORs:129	nucleolus organizer regions:129:0.2685	0.2685	129
NOR	NOR:17|Nor:5|nor:3	nitric oxide reductase:25:0.8861	0.8861	25
NOR	NOR:16|nor:3	noradrenaline:19:0.0288	0.0288	19
NOR	NOR:35|nor:2	Norfloxacin:37:0.0575	0.0575	37
NOR	NOR:7|Nor:1|nor:1	norgestomet:9:0.0128	0.0128	9
NOR	NOR:6	normal subjects:6:0.2243	0.2243	6
NOR	NOR:15|nor:1	nortriptyline:16:0.0240	0.0240	16
NOR	NOR:6	nucleolar organizer:6:0.2243	0.2243	6
NOR	NOR:107	nucleolar organizer region:58:0.3803|nucleolar organizer regions:49:0.7122	0.7122	107
NOR	NOR:30	nucleolar organizing region:22:0.4047|nucleolar organizing regions:8:0.2619	0.4047	30
NOR	NOR:60|nor:1	nucleolus organizer region:61:0.4050	0.4050	61
NOR	NOR:15	nucleolus organizing region:15:0.2189	0.2189	15
NOR	NOR:12	nucleus olfactoretinalis:12:0.7571	0.7571	12
NOS1	NOS1:22|NOS-1:7	neuronal nitric oxide synthase:29:0.5212	0.5212	29
NOS2	NOS2:65|NOS-2:36|Nos2:4	inducible nitric oxide synthase:105:0.5796	0.5796	105
NOS2	NOS2:9|NOS-2:1	inducible NOS:10:0.7103	0.7103	10
NOS2	NOS2:39|NOS-2:32	nitric oxide synthase 2:37:0.9217|nitric oxide synthase-2:34:0.9126	0.9217	71
NOS3	NOS3:30|NOS-3:4|Nos3:3	endothelial nitric oxide synthase:37:0.5384	0.5384	37
NOS3	NOS3:7|Nos3:1	endothelial nitric oxide synthase gene:8:0.4102	0.4102	8
NOS3	NOS3:6|NOS-3:2	endothelial NOS:8:0.2327	0.2327	8
NOS3	NOS3:5|NOS-3:2	nitric oxide synthase 3:7:0.5926	0.5926	7
NOSGER	NOSGER:8	Nurses' Observation Scale for Geriatric Patients:8:0.5006	0.5006	8
NOS-III	NOS-III:7	endothelial nitric oxide synthase:7:0.4438	0.4438	7
NOS-II	NOS-II:7|NOSII:6	nitric oxide synthase:13:0.7753	0.7753	13
NOSII	NOSII:4|NOS-II:2	nitric oxide synthase II:6:0.5290	0.5290	6
NOS-IR	NOS-IR:5|NOS-ir:1	nitric oxide synthase immunoreactivity:6:0.5290	0.5290	6
NOS-I	NOS-I:5	neuronal NOS:5:0.0902	0.0902	5
NOS-I	NOS-I:19	nitric oxide synthase:19:0.8449	0.8449	19
NOS	NOS:4226|NOs:7|NO-S:1	nitric oxide synthase:4085:0.9909|nitric oxide synthases:149:0.9585	0.9909	4234
NOS	NOS:10|NOs:2	nitric oxide synthesis:12:0.7753	0.7753	12
NOS	NOS:45	Nitric oxide synthetase:45:0.9323	0.9323	45
NOS	NOS:60	NO-synthase:60:0.0090	0.0090	60
NOS	NOS:111|nos:2	not otherwise specified:113:0.9437	0.9437	113
NOT-DTN	NOT-DTN:6	nucleus of the optic tract and dorsal terminal nucleus of the accessory optic system:6:0.6794	0.6794	6
NOT	NOT:119	nucleus of the optic tract:119:0.9749	0.9749	119
NOV	NOV:6|Nov:1	Nephroblastoma overexpressed gene:7:0.5926	0.5926	7
NoV	NoV:4|NOV:3	Nodamura virus:7:0.1850	0.1850	7
NOX	NOX:10|Nox:3|nox:1	NADH oxidase:14:0.2189	0.2189	14
NOX	NOX:8|Nox:7	NADPH oxidase:15:0.2189	0.2189	15
NOx	NOx:36|NOX:1	nitrate and nitrite:29:0.5376|nitrates and nitrites:8:0.4102	0.5376	37
NOx	NOx:28	nitrate/nitrite:28:0.0397	0.0397	28
NOx	NOx:26|NOX:1	nitric oxide:27:0.5524	0.5524	27
NOx	NOx:27|NOX:1	nitric oxide metabolites:25:0.8861|nitric oxide metabolite:3:0.4422	0.8861	28
NOx	NOx:56|NOX:1	nitrite and nitrate:47:0.5465|nitrites and nitrates:10:0.4363	0.5465	57
NOx	NOx:15	nitrite plus nitrate:15:0.8045	0.8045	15
NOx	NOx:76|Nox:1|NOX:1	nitrogen oxides:78:0.8293	0.8293	78
NOx	NOx:46|NOX:2	oxides of nitrogen:48:0.8728	0.8728	48
NOx	NOx:18	Plasma nitrite/nitrate:18:0.1077	0.1077	18
NOx	NOx:13	products:13:0.0176	0.0176	13
NO	NO:23598|No:2|no:1|-NO:1	nitric oxide:23572:0.9886|nitric-oxide:30:0.0012	0.9886	23602
NO	NO:8	nitric oxide gas:8:0.6411	0.6411	8
NO	NO:7	nitric oxide radical:7:0.5926	0.5926	7
NO	NO:64|no:1	nitrogen monoxide:65:0.8283	0.8283	65
NO	NO:7|N-o:1|no:1	nodes:9:0.0003	0.0003	9
NO	NO:7	nucleolar organizer:7:0.1641	0.1641	7
NO	NO:7	nucleolus organizer:7:0.1641	0.1641	7
NP(o)	NP(o):8|nP(o):2|NP(O):1	open probability:11:0.3829	0.3829	11
NP1EO	NP1EO:11	nonylphenol monoethoxylate:11:0.6182	0.6182	11
NP1	NP1:7	Neuronal pentraxin 1:7:0.5926	0.5926	7
NP-1	NP-1:20|NP1:4|np1:4|np-1:1|Np-1:1	neuropilin-1:30:0.3766	0.3766	30
NP1	NP1:9	nuclease P1:9:0.6794	0.6794	9
np2	np2:4|np-2:2|NP-2:2|Np-2:1|NP2:1	neuropilin-2:10:0.2093	0.2093	10
NP-40	NP-40:34|NP40:2	Nonidet P-40:36:0.7433	0.7433	36
NP40	NP40:7|NP-40:3	Nonidet P40:10:0.7103	0.7103	10
NP-59	NP-59:10	131I-6 beta-iodomethyl-19-norcholesterol:10:0.3867	0.3867	10
NPAHs	NPAHs:15	aromatic hydrocarbons:15:0.8045	0.8045	15
NPAs	NPAs:20	Nasopharyngeal aspirates:20:0.8525	0.8525	20
NPA	NPA:16	3-nitropropionic acid:16:0.1144	0.1144	16
NPA	NPA:9	activity:9:0.0204	0.0204	9
NPA	NPA:4	agonist N-propylnorapomorphine:4:0.0736	0.0736	4
NPA	NPA:12	asparagine-proline-alanine:12:0.0280	0.0280	12
NPA	NPA:25	N-n-propylnorapomorphine:25:0.0611	0.0611	25
NPA	NPA:43	nasopharyngeal aspirates:27:0.7834|nasopharyngeal aspirate:16:0.8165	0.8165	43
NPBI	NPBI:10	non-protein-bound iron:10:0.3867	0.3867	10
NPBM	NPBM:11	nucleus parabrachialis medialis:11:0.7357	0.7357	11
NPBs	NPBs:16	precursor bodies:16:0.7261	0.7261	16
NPC1L1	NPC1L1:12|Npc1l1:1	Niemann-Pick C1 Like 1:7:0.5926|Niemann-Pick C1-like 1:6:0.5290	0.5926	13
NPC1	NPC1:14|npc1:1	Niemann-Pick C1:15:0.2344	0.2344	15
NPC1	NPC1:15|npc1:1	Niemann-Pick type C1:16:0.5564	0.5564	16
NPCCs	NPCCs:9	porcine neonatal pancreatic cell clusters:9:0.5006	0.5006	9
NPC-KT	NPC-KT:8	hybrid cell line:8:0.5006	0.5006	8
nPCR	nPCR:56|N-PCR:9|n-PCR:8|NPCR:3	nested polymerase chain reaction:76:0.9180	0.9180	76
nPCR	nPCR:70|NPCR:19|npcr:1	normalized protein catabolic rate:90:0.8065	0.8065	90
NPCs	NPCs:31	nasopharyngeal carcinomas:31:0.9043	0.9043	31
NPCs	NPCs:32	neural progenitor cells:32:0.7166	0.7166	32
NPCs	NPCs:24	nonparenchymal cells:24:0.1525	0.1525	24
NPCs	NPCs:139	nuclear pore complexes:139:0.9544	0.9544	139
NPC	NPC:92	nasopharyngeal cancer:92:0.8291	0.8291	92
NPC	NPC:1712	nasopharyngeal carcinoma:1653:0.9878|nasopharyngeal carcinomas:59:0.9203	0.9878	1712
NPC	NPC:5	near point of convergence:5:0.4422	0.4422	5
NPC	NPC:5	nearpoint of convergence:5:0.0902	0.0902	5
NPC	NPC:13	net protein catabolism:13:0.7753	0.7753	13
NPC	NPC:16|NP-C:4	Niemann-Pick C:20:0.0565	0.0565	20
NPC	NPC:50|NP-C:23	Niemann-Pick disease type C:73:0.9393	0.9393	73
NPC	NPC:65|NP-C:14	Niemann-Pick type C:79:0.3958	0.3958	79
NPC	NPC:11|NP-C:4	Niemann-Pick type C disease:15:0.8045	0.8045	15
NPC	NPC:27	non-parenchymal cells:27:0.1390	0.1390	27
NPC	NPC:59	nonparenchymal cells:53:0.3367|nonparenchymal cell:6:0.0899	0.3367	59
NPC	NPC:10	nonparenchymal liver cells:10:0.3867	0.3867	10
NPC	NPC:224	nuclear pore complex:214:0.9776|nuclear pore complexes:10:0.7103	0.9776	224
NPC	NPC:5|nPC:1	nucleus of the posterior commissure:6:0.4102	0.4102	6
NPDB	NPDB:16	National Practitioner Data Bank:16:0.8165	0.8165	16
NPDS	NPDS:9	deep sclerectomy:9:0.6794	0.6794	9
NPD	NPD:12	4-nitro-o-phenylenediamine:12:0.0378	0.0378	12
NPD	NPD:13	narcissistic personality disorder:13:0.6701	0.6701	13
NPD	NPD:14	nasal potential difference:14:0.7909	0.7909	14
NPD	NPD:10	nocturnal paroxysmal dystonia:10:0.5856	0.5856	10
NPD	NPD:6	normal protein diet:6:0.3728	0.3728	6
NPEOs	NPEOs:11	nonylphenol ethoxylates:11:0.7357	0.7357	11
NPEOs	NPEOs:9	nonylphenol polyethoxylates:9:0.6794	0.6794	9
NPE	NPE:9	epithelial cells:9:0.6794	0.6794	9
NPE	NPE:46	neurogenic pulmonary edema:46:0.8151	0.8151	46
NPE	NPE:26	nonpigmented ciliary epithelial:26:0.5840	0.5840	26
NPE	NPE:9	nonpigmented ciliary epithelium:9:0.3945	0.3945	9
NPE	NPE:23	nonpigmented epithelial:23:0.2101	0.2101	23
NPE	NPE:8	nonpigmented epithelium:8:0.0825	0.0825	8
NPFF	NPFF:90	Neuropeptide FF:90:0.9304	0.9304	90
NPF	NPF:5	neurite-promoting factor:5:0.1132	0.1132	5
NPF	NPF:28	neuropeptide F:28:0.8941	0.8941	28
NPG	NPG:10	N-phenylglycine:10:0.0818	0.0818	10
NPG	n-PG:4|NPG:4|nPG:1	N-propyl gallate:9:0.6794	0.6794	9
NPG	NPG:23	Normal Pressure Glaucoma:23:0.8715	0.8715	23
NPH1	NPH1:8	juvenile nephronophthisis:8:0.3463	0.3463	8
NP-HPLC	NP-HPLC:9|NPHPLC:1	liquid chromatography:10:0.7103	0.7103	10
NPHS1	NPHS1:10	Congenital nephrotic syndrome of the Finnish type:10:0.7357	0.7357	10
NPHS	NPHS:83	National Population Health Survey:83:0.9644	0.9644	83
NPHS	NPHS:10	Northwick Park Heart Study:10:0.7103	0.7103	10
NPH	NPH:13	Familial juvenile nephronophthisis:13:0.4102	0.4102	13
NPH	NPH:51	neutral protamine Hagedorn:51:0.8821	0.8821	51
NPH	NPH:218	normal pressure hydrocephalus:218:0.9863	0.9863	218
NPH	NPH:8	NPH insulin:8:0.1591	0.1591	8
NPH	NPH:19|nph:4	nucleus prepositus hypoglossi:23:0.8715	0.8715	23
NPH	NPH:16	patients with normal-pressure hydrocephalus:16:0.1704	0.1704	16
NPIP	NPIP:27|N-PiP:1|NPip:1	N-nitrosopiperidine:29:0.7778	0.7778	29
NPL	NPL:10	linkage analysis:10:0.5856	0.5856	10
NPL	NPL:13	National Physical Laboratory:13:0.7753	0.7753	13
NPL	NPL:25	Non-parametric linkage:25:0.2032	0.2032	25
NPL	NPL:48	nonparametric linkage:48:0.4917	0.4917	48
NPM	NPM:9	N-(1-pyrenyl)maleimide:9:0.0473	0.0473	9
NPM	NPM:13	N-phenylmaleimide:13:0.0710	0.0710	13
NPM	NPM:68	nucleophosmin:68:0.3964	0.3964	68
NPM	NPM:12	nucleophosmin/B23:12:0.0592	0.0592	12
NPNL	NPNL:4	nonpregnant nonlactating:4:0.7357	0.7357	4
NPN	NPN:23	non-protein nitrogen:23:0.4053	0.4053	23
NPN	NPN:8	nonprotein N:8:0.3463	0.3463	8
NPN	NPN:13	nonprotein nitrogen:13:0.1599	0.1599	13
NPN	NPN:4	probe N-phenyl-1-naphthylamine:4:0.1471	0.1471	4
NPOH	NPOH:9	3-nitropropanol:9:0.8000	0.8000	9
N-POMC	N-POMC:9	pro-opiomelanocortin:9:0.4706	0.4706	9
NPo	NPo:5|nPo:3|NPO:1	channel activity:9:0.4587	0.4587	9
NPO	NPO:10	nucleus pontis oralis:10:0.5856	0.5856	10
NPO	NPO:27|nPO:1|npo:1|Npo:1	nucleus preopticus:30:0.9011	0.9011	30
NPo	NPo:32|nPo:1	open probability:33:0.5306	0.5306	33
NPPB	NPPB:135	5-nitro-2-(3-phenylpropylamino)benzoic acid:55:0.2412|5-nitro-2-(3-phenylpropylamino)-benzoic acid:42:0.1682|5-nitro-2-(3-phenylpropylamino) benzoic acid:38:0.6495	0.6495	135
NPPB	NPPB:8	channel blocker 5-nitro-2-(3-phenylpropylamino)-benzoate:8:0.7571	0.7571	8
NPPB	NPPB:10	normal perfusion pressure breakthrough:10:0.7103	0.7103	10
NPPE	NPPE:9	negative pressure pulmonary edema:9:0.6794	0.6794	9
NPP	NPP:13	net primary production:13:0.7753	0.7753	13
NPP	NPP:14	net primary productivity:14:0.7909	0.7909	14
NPP	NPP:7	new permeation pathways:7:0.5926	0.5926	7
NPP	NPP:13|nPP:4	nonphytate P:17:0.7407	0.7407	17
NPP	NPP:11|nPP:1	nonphytate phosphorus:12:0.3524	0.3524	12
NPP	NPP:15	Nuclear Power Plant:15:0.8045	0.8045	15
NPP	NPP:16|npp:1	nucleus preopticus periventricularis:17:0.8270	0.8270	17
NPP	NPP:5|NpP:2	p-nitrophenyl phosphate:7:0.3524	0.3524	7
NPQ	NPQ:28	non-photochemical quenching:28:0.5269	0.5269	28
NPR-B	NPR-B:17|NPRB:2	Natriuretic peptide receptor-B:10:0.7103|natriuretic peptide receptor B:9:0.6794	0.7103	19
NPR-B	NPR-B:3|NPRB:2	type B natriuretic peptide receptor:5:0.4422	0.4422	5
NPR-C	NPR-C:13|NPRC:1	natriuretic peptide clearance receptor:14:0.7909	0.7909	14
NPR-C	NPR-C:24|NPRC:4	natriuretic peptide receptor-C:17:0.8270|natriuretic peptide receptor C:11:0.7357	0.8270	28
NPRO	NPRO:69|N-Pro:1|NPro:1	N-nitrosoproline:71:0.7447	0.7447	71
NPRO	NPRO:12|NPro:1	nitrosoproline:13:0.1277	0.1277	13
NPRs	NPRs:9	natriuretic peptide receptors:9:0.6794	0.6794	9
NPR	NPR:25|NP-R:2|NPr:1	natriuretic peptide receptors:15:0.8045|natriuretic peptide receptor:13:0.7753	0.8045	28
NPR	NPR:8	P450 reductase:8:0.2757	0.2757	8
NPSG	NPSG:10|n-PSG:2|nPSG:1	nocturnal polysomnography:13:0.5335	0.5335	13
NPSH	NPSH:46|NP-SH:12	non-protein sulfhydryl:43:0.3963|non-protein sulfhydryls:15:0.2053	0.3963	58
NPSH	NPSH:5|NP-SH:1	non-protein sulfhydryl groups:6:0.1838	0.1838	6
NPSH	NPSH:7|NP-SH:4	non-protein sulphydryl:11:0.7357	0.7357	11
NPSH	NPSH:20|NP-SH:8|Np-SH:1	non-protein thiols:16:0.3044|non-protein thiol:13:0.4849	0.4849	29
NPSH	NPSH:51|NP-SH:8	Nonprotein sulfhydryl:36:0.3133|Nonprotein sulfhydryls:23:0.4053	0.4053	59
NPSH	NPSH:8	nonprotein thiols:8:0.0756	0.0756	8
NPSLE	NPSLE:11|NP-SLE:1	neuropsychiatric SLE:12:0.5050	0.5050	12
NPSLE	NPSLE:32|NP-SLE:5	neuropsychiatric systemic lupus erythematosus:37:0.6086	0.6086	37
NPSV	NPSV:12|nPSV:2	pressure support ventilation:14:0.7909	0.7909	14
NPTII	NPTII:17|nptII:12|NPT-II:1	neomycin phosphotransferase:30:0.8032	0.8032	30
NPTII	NPTII:16|nptII:15|NptII:1|NPT-II:1|npt-II:1	neomycin phosphotransferase II:34:0.9126	0.9126	34
NPTR	NPTR:15	National Pediatric Trauma Registry:15:0.8045	0.8045	15
NPTR	NPTR:14	nocturnal penile tumescence and rigidity:14:0.7261	0.7261	14
NPTs	NPTs:5|NPTS:1	nasal provocation tests:6:0.3728	0.3728	6
NPT	NPT:29	Nasal provocation test:21:0.7291|nasal provocation tests:8:0.6411	0.7291	29
NPT	NPT:7	Nasal provocation testing:7:0.5926	0.5926	7
NPT	NPT:16	nasopharyngeal temperature:16:0.2362	0.2362	16
NPT	NPT:9	near patient testing:9:0.6794	0.6794	9
NPT	NPT:19|npt:5|Npt:1	neomycin phosphotransferase:25:0.8816	0.8816	25
NPT	NPT:15|Npt:1	neopterin:16:0.0396	0.0396	16
NPT	NPT:125	nocturnal penile tumescence:125:0.9619	0.9619	125
NPT	NPT:12|npt:2	nonpermissive temperature:14:0.1882	0.1882	14
NPU	NPU:103	net protein utilization:103:0.9538	0.9538	103
NPVs	NPVs:16	nucleopolyhedroviruses:16:0.3061	0.3061	16
NPV	NPV:28	negative pressure ventilation:28:0.8941	0.8941	28
NPV	NPV:40	nuclear polyhedrosis virus:40:0.9256	0.9256	40
NPV	NPV:28	nucleopolyhedrovirus:28:0.0318	0.0318	28
NPX	NPX:10	nephrectomized:10:0.2000	0.2000	10
NPX	NPX:15	Uninephrectomized:15:0.3111	0.3111	15
NPY-LI	NPY-LI:9	neuropeptide Y:9:0.6794	0.6794	9
NPY-LI	NPY-LI:4|NPYLI:1	neuropeptide Y-like immunoreactive:5:0.4422	0.4422	5
NPY-LI	NPY-LI:85|NPYLI:11|NPY-li:2|NPY-Li:1	Neuropeptide Y-like immunoreactivity:99:0.9701	0.9701	99
NPY-LI	NPY-LI:34|NPY-li:3|NPYLI:1|NPY-Li:1	NPY-like immunoreactivity:39:0.1925	0.1925	39
NPYR	NPYR:82|N-Pyr:1	N-nitrosopyrrolidine:83:0.8723	0.8723	83
NPY-IR	NPY-IR:17|NPY-ir:13|NPYir:3	immunoreactivity:33:0.3516	0.3516	33
NPY-IR	NPY-IR:9|NPY-ir:7	neuropeptide Y-immunoreactive:16:0.8165	0.8165	16
NPY-IR	NPY-IR:8|NPY-ir:3|NPYir:1	NPY-immunoreactive:12:0.1209	0.1209	12
NPY	NPY:12	neuropeptide:12:0.0023	0.0023	12
NPY	NPY:93	neuropeptide tyrosine:93:0.9668	0.9668	93
NPY	NPY:4516|Npy:6|NpY:1	neuropeptide Y:4392:0.9878|neuropeptide-Y:122:0.0258|neuropeptide Y-:9:0.6794	0.9878	4523
NPe6	NPe6:39|Npe6:2	mono-L-aspartyl chlorin e6:41:0.7548	0.7548	41
NPs'	NPs':9	nurse practitioners':9:0.6794	0.6794	9
NPS	NPS:42	Nail-patella syndrome:27:0.3787|nail patella syndrome:15:0.8045	0.8045	42
NPs	NPs:27	nanoparticles:27:0.0316	0.0316	27
NPs	NPs:12|Nps:1	nasal polyps:13:0.7753	0.7753	13
NPS	NPS:46	nasopharyngeal secretions:32:0.9072|nasopharyngeal secretion:14:0.7909	0.9072	46
NPs	NPs:53	natriuretic peptides:53:0.9438	0.9438	53
NPs	NPs:29	neuritic plaques:29:0.7970	0.7970	29
NPS	NPS:12	Neuropathic Pain Scale:12:0.4153	0.4153	12
NPS	NPS:14	noise power spectra:14:0.7909	0.7909	14
NPS	NPS:8	non-point source:8:0.2987	0.2987	8
NPs	NPs:9	Noun Phrases:9:0.6794	0.6794	9
NPs	NPs:250	Nurse Practitioners:240:0.9734|nurse practitioners':10:0.7103	0.9734	250
NPS	NPS:6	Sodium nitroprusside:6:0.2243	0.2243	6
NP	NP:24	1-nitropyrene:24:0.0069	0.0069	24
NP	NP:20	4-hydroxy-3-nitrophenyl acetyl:20:0.5729	0.5729	20
NP	NP:9	4-hydroxy-3-nitrophenylacetyl:9:0.0023	0.0023	9
NP	NP:45	4-nonylphenol:45:0.0126	0.0126	45
NP	NP:7	alcohol nonpreferring:7:0.1111	0.1111	7
NP	NP:19	anti-(4-hydroxy-3-nitrophenyl)acetyl:19:0.0051	0.0051	19
NP	NP:18	hapten (4-hydroxy-3-nitrophenyl)acetyl:18:0.3130	0.3130	18
NP	NP:45	influenza virus nucleoprotein:45:0.6525	0.6525	45
NP	NP:5	metabolite norpropoxyphene:5:0.2243	0.2243	5
NP	NP:55|Np:2	nanoparticles:47:0.0131|nanoparticle:10:0.0026	0.0131	57
NP	NP:39|Np:1	nasal polyps:25:0.8816|nasal polyp:15:0.8045	0.8816	40
NP	NP:35	Nasal polyposis:35:0.9151	0.9151	35
NP	NP:80	nasopharyngeal:80:0.0226	0.0226	80
NP	NP:17	nasopharynx:17:0.0046	0.0046	17
NP	NP:74	natriuretic peptide:42:0.8263|natriuretic peptides:32:0.8563	0.8563	74
NP	NP:16	neck pressure:16:0.5171	0.5171	16
NP	NP:15	necrotizing pancreatitis:15:0.5818	0.5818	15
NP	NP:23	negative priming:23:0.8038	0.8038	23
NP	NP:15|Np:3	neopterin:18:0.0049	0.0049	18
NP	NP:11	neuritic plaque:11:0.6182	0.6182	11
NP	NP:11	neuropathic pain:11:0.3829	0.3829	11
NP	NP:36|Np:4	neurophysin:40:0.0111	0.0111	40
NP	NP:32	neuropsychiatric:32:0.0089	0.0089	32
NP	NP:97	neuropsychological:97:0.0274	0.0274	97
NP	NP:10	nifedipine:10:0.0026	0.0026	10
NP	NP:25	non-pregnant:25:0.0069	0.0069	25
NP	NP:57	nonpregnant:57:0.0160	0.0160	57
NP	NP:135	nonylphenol:135:0.0383	0.0383	135
NP	NP:13	normal:13:0.0034	0.0034	13
NP	NP:24	normal-phase:18:0.0049|normal phase:6:0.1838	0.1838	24
NP	NP:8	normal plasma:8:0.2327	0.2327	8
NP	NP:11	normal pregnancy:11:0.4232	0.4232	11
NP	NP:9	normal pregnant:9:0.4587	0.4587	9
NP	NP:6	normal pregnant women:6:0.3728	0.3728	6
NP	NP:8	normal prostate:8:0.5006	0.5006	8
NP	NP:52	nosocomial pneumonia:52:0.8546	0.8546	52
NP	NP:13	noun phrase:13:0.7753	0.7753	13
NP	NP:39	nucleocapsid:39:0.0109	0.0109	39
NP	NP:81	nucleocapsid protein:81:0.6356	0.6356	81
NP	NP:12	nucleoproteins:12:0.0031	0.0031	12
NP	NP:31|Np:2	nucleoside phosphorylase:33:0.8605	0.8605	33
np	np:19	nucleotide pair:19:0.7658	0.7658	19
np	np:36|NP:2	nucleotide position:28:0.7905|nucleotide positions:10:0.7103	0.7905	38
NP	NP:57	nucleus pulposus:57:0.9477	0.9477	57
NP	NP:152	nurse practitioner:139:0.9657|Nurse practitioners:13:0.7753	0.9657	152
NP	NP:29	p-nonylphenol:29:0.0080	0.0080	29
NP	NP:9|nP:1	patients:10:0.0026	0.0026	10
NP	NP:94	sodium nitroprusside:94:0.4032	0.4032	94
NQMI	NQMI:14	non-Q wave myocardial infarction:14:0.6173	0.6173	14
NQO1	NQO1:9	DT-diaphorase:9:0.0280	0.0280	9
NQO1	NQO1:86|Nqo1:2	NAD(P)H:Quinone Oxidoreductase:78:0.4933|NAD(P)H quinone oxidoreductase:10:0.6240	0.6240	88
NQO1	NQO1:64|Nqo1:1	NAD(P)H:quinone oxidoreductase 1:58:0.5410|NAD(P)H:quinone oxidoreductase-1:7:0.2452	0.5410	65
NQO1	NQO1:11	NAD(P)H:quinone oxidoreductase1:11:0.5355	0.5355	11
NQO2	NQO2:10	oxidoreductase 2:10:0.4363	0.4363	10
NQO	NQO:29	4-nitroquinoline-1-oxide:19:0.3158|4-nitroquinoline 1-oxide:10:0.7103	0.7103	29
NQO	NQO:7	NAD(P)H:quinone oxidoreductase:7:0.2452	0.2452	7
NQR	NQR:10	NADH-quinone reductase:10:0.3867	0.3867	10
NQR	NQR:15	nuclear quadrupole resonance:15:0.7096	0.7096	15
NQWMI	NQWMI:10	myocardial infarction:10:0.7103	0.7103	10
NQ	NQ:15	1,4-naphthoquinone:15:0.2188	0.2188	15
NR1	NR1:12	NMDA receptor 1:12:0.5818	0.5818	12
NR1	NR1:12	NMDA receptor subunit 1:12:0.4071	0.4071	12
NR2A	NR2A:4	tyrosine phosphorylation of NMDA receptor subunit 2A:4:0.4422	0.4422	4
NR2B	NR2B:6	NMDA receptor 2B:6:0.4438	0.4438	6
NR2B	NR2B:8|NR2b:1	receptor subunit 2B:9:0.4587	0.4587	9
NR2	NR2:7	NMDA receptor 2:7:0.5926	0.5926	7
NRAF	NRAF:20|NRAf:1	atrial fibrillation:21:0.8594	0.8594	21
NRAMP1	NRAMP1:3|Nramp1:2	natural resistance-associated macrophage protein:5:0.4422	0.4422	5
NRAMP1	NRAMP1:18|Nramp1:16|Nramp-1:1	natural resistance-associated macrophage protein 1:35:0.9151	0.9151	35
NRA	NRA:10	Neuroretinal rim area:10:0.7103	0.7103	10
NRA	NRA:14	nitrate reductase activity:14:0.6911	0.6911	14
NRA	NRA:19	nucleus retroambiguus:19:0.8449	0.8449	19
NRBC	NRBC:47|nRBC:3|n-rbc:1	nucleated red blood cells:36:0.7433|nucleated red blood cell:15:0.7096	0.7433	51
NRC	NRC:14	conditioner:14:0.0471	0.0471	14
NRC	NRC:90	National Research Council:90:0.9304	0.9304	90
NRC	NRC:12	Neo Red Cells:12:0.5856	0.5856	12
NRC	NRC:49	Nuclear Regulatory Commission:49:0.9392	0.9392	49
NRD	NRD:9	negative regulatory domain:9:0.4587	0.4587	9
NRD	NRD:50|nRD:8	nucleus raphe dorsalis:58:0.8126	0.8126	58
NREMS	NREMS:50|nREMS:1	non-rapid eye movement sleep:51:0.6696	0.6696	51
NREM	NREM:16	eye movement sleep:16:0.7261	0.7261	16
NREM	NREM:370|nREM:2|N-REM:2	non-rapid eye movement:260:0.6543|non-rapid-eye-movement:114:0.1628	0.6543	374
NREM	NREM:14	nonrapid-eye-movement:14:0.0187	0.0187	14
NREs	NREs:6	negative regulatory elements:6:0.5290	0.5290	6
NRE	NRE:97	negative regulatory element:97:0.9510	0.9510	97
NRF-1	NRF-1:42|NRF1:3|Nrf1:1|nrf-1:1	nuclear respiratory factor 1:25:0.8816|nuclear respiratory factor-1:22:0.8657	0.8816	47
NRF	NRF:23	normal renal function:23:0.8038	0.8038	23
NRG-1	NRG-1:30|NRG1:20|Nrg-1:7|nrg1:2|Nrg1:1	neuregulin-1:43:0.5600|neuregulin 1:17:0.7407	0.7407	60
NRGC	NRGC:35|NRGc:15	nucleus reticularis gigantocellularis:50:0.9404	0.9404	50
NRGs	NRGs:27	Neuregulins:27:0.9630	0.9630	27
NRG	NRG:45|Nrg:2|nrg:1	Neuregulin:48:0.4653	0.4653	48
NRG	NRG:12	nucleus reticularis gigantocellularis:12:0.7571	0.7571	12
NRH	NRH:42	Nodular regenerative hyperplasia:42:0.8893	0.8893	42
NRH	NRH:9	nodular regenerative hyperplasia of the liver:9:0.6794	0.6794	9
NRI	NRI:15	nutritional risk index:15:0.6386	0.6386	15
NRK-52E	NRK-52E:11|NRK52E:2|NRK52-E:1	epithelial cells:14:0.4709	0.4709	14
NRK-52E	NRK-52E:5|NRK52E:2	normal rat kidney:7:0.3524	0.3524	7
NRK	NRK:215	normal rat kidney:215:0.9171	0.9171	215
NRK	NRK:11	normal rat kidney cells:11:0.6182	0.6182	11
NRK	NRK:6	rat kidney fibroblasts:6:0.5290	0.5290	6
NRL	NRL:10	lateral reticular nucleus:10:0.7103	0.7103	10
NRL	NRL:151	natural rubber latex:151:0.9802	0.9802	151
NRL	NRL:4|Nrl:3	Neural retina leucine zipper:7:0.5926	0.5926	7
NRL	NRL:10|nrl:1	nucleus recessus lateralis:11:0.7357	0.7357	11
NRL	NRL:11	nucleus reticularis lateralis:11:0.7357	0.7357	11
NRMI	NRMI:12	National Registry of Myocardial Infarction:12:0.7909	0.7909	12
NRMP	NRMP:35	National Resident Matching Program:35:0.9151	0.9151	35
NRM	NRM:6	non-relapse mortality:6:0.0731	0.0731	6
NRM	NRM:11	nonrelapse mortality:11:0.3495	0.3495	11
NRM	NRM:229|nRM:1	nucleus raphe magnus:230:0.9092	0.9092	230
NRO	NRO:24|nRO:7|NRo:1	nucleus raphe obscurus:32:0.8145	0.8145	32
NRP-1	NRP-1:18|NRP1:17|Nrp-1:5|Nrp1:1	Neuropilin-1:41:0.7843	0.7843	41
NRPB	NRPB:22	National Radiological Protection Board:22:0.8657	0.8657	22
NRPG	NRPG:14	nucleus reticularis paragigantocellularis:14:0.6911	0.6911	14
NRPSs	NRPSs:36	Nonribosomal peptide synthetases:36:0.7183	0.7183	36
NRPS	NRPS:55	nonribosomal peptide synthetase:33:0.5306|nonribosomal peptide synthetases:22:0.5327	0.5327	55
NRR	NRR:9	neuroretinal rim:9:0.6794	0.6794	9
NRSE	NRSE:29	silencer element:29:0.7970	0.7970	29
NRSF	NRSF:18	neuron-restrictive silencer factor:18:0.4480	0.4480	18
NRSTS	NRSTS:7	nonrhabdomyosarcoma soft tissue sarcoma:7:0.3524	0.3524	7
NRSTS	NRSTS:11	soft tissue sarcomas:11:0.6182	0.6182	11
NRS	NRS:18|nrs:1	negative regulator of splicing:19:0.8449	0.8449	19
NRs	NRs:12	nonresponders:12:0.0203	0.0203	12
NRS	NRS:126	normal rabbit serum:126:0.8896	0.8896	126
NRs	NRs:89	Nuclear receptors:89:0.6590	0.6590	89
NRS	NRS:102	Rating Scale:102:0.9245	0.9245	102
NRTIs	NRTIs:205|nRTIs:2	nucleoside reverse transcriptase inhibitors:207:0.7388	0.7388	207
NRTI	NRTI:15	nucleoside analogue reverse transcriptase inhibitors:15:0.6386	0.6386	15
NRTI	NRTI:133|nRTI:2	nucleoside reverse transcriptase inhibitor:78:0.6398|nucleoside reverse transcriptase inhibitors:57:0.5638	0.6398	135
NRTP	NRTP:57|nrtp:1|Nrtp:1	nucleus reticularis tegmenti pontis:59:0.8731	0.8731	59
NRT	NRT:26	neural response telemetry:26:0.8861	0.8861	26
NRT	NRT:160	Nicotine replacement therapy:150:0.9800|nicotine replacement therapies:10:0.7103	0.9800	160
NRT	NRT:21|nRT:8|nRt:5	nucleus reticularis thalami:34:0.9126	0.9126	34
nRt	nRt:10|NRT:5|nRT:2	thalamic reticular nucleus:17:0.5760	0.5760	17
NRU	NRU:24	Neutral red uptake:24:0.8768	0.8768	24
NRVM	NRVM:16	neonatal rat ventricular myocytes:16:0.8165	0.8165	16
NRVMs	NRVMs:13	neonatal rat ventricular myocytes:13:0.7753	0.7753	13
NRY	NRY:20	Y chromosome:20:0.8525	0.8525	20
NR	NR:12	nasal resistance:12:0.2293	0.2293	12
NR	NR:10	natural resistance:10:0.1596	0.1596	10
NR	NR:15	natural rubber:15:0.8045	0.8045	15
NR	NR:23	neural retina:23:0.7046	0.7046	23
NR	NR:19	neuroretina:19:0.0124	0.0124	19
NR	NR:124	neutral red:124:0.8383	0.8383	124
NR	NR:149	nitrate reductase:149:0.8906	0.8906	149
NR	NR:17	nitroreductase:17:0.0110	0.0110	17
NR	NR:70	non-responders:61:0.0413|non-responder:9:0.0055	0.0413	70
NR	NR:49	nonresponders:49:0.0330	0.0330	49
NR	NR:11	normotensive:11:0.0069	0.0069	11
NR	NR:29	normotensive rats:29:0.3446	0.3446	29
NR	NR:71	nuclear receptor:54:0.4790|nuclear receptors:17:0.5038	0.5038	71
NR	NR:12	responders:12:0.0076	0.0076	12
NR	NR:91	response:91:0.0619	0.0619	91
NS'	NS':17|Ns':1	negative slope:18:0.6903	0.6903	18
NS-21	NS-21:6	oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate:6:0.5290	0.5290	6
NS1	NS1:9	non-structural protein:9:0.0932	0.0932	9
NS1	NS1:16	non-structural protein 1:16:0.2219	0.2219	16
NS1	NS1:13|NS-1:3	nonstructural:16:0.0829	0.0829	16
NS1	NS1:14|NS-1:2	nonstructural protein:16:0.2812	0.2812	16
NS1	NS1:23|NS-1:1	nonstructural protein 1:24:0.3927	0.3927	24
NS2	NS2:9	protein 2:9:0.4587	0.4587	9
NS-398	NS-398:14|NS398:3	COX-2 inhibitor:17:0.4574	0.4574	17
NS3	NS3:5	nonstructural 3 protein:5:0.1973	0.1973	5
NS3	NS3:63	nonstructural protein 3:63:0.5482	0.5482	63
NS5A	NS5A:25|NS5a:1	nonstructural 5A:26:0.2148	0.2148	26
NS5B	NS5B:10	RNA-dependent RNA polymerase:10:0.5000	0.5000	10
NSABP	NSABP:111	National Surgical Adjuvant Breast and Bowel Project:111:0.9731	0.9731	111
NSAIAs	NSAIAs:7	non-steroidal anti-inflammatory agents:7:0.2902	0.2902	7
NSAIDs	NSAIDs:66|NSAIDS:3	anti-inflammatory agents:69:0.7579	0.7579	69
NSAIDs	NSAIDs:5	non-steroidal anti-inflammatories:5:0.0517	0.0517	5
NSAIDs	NSAIDs:1379|NSAIDS:36|NS-AIDs:1|NSAID-s:1	Non-steroidal anti-inflammatory drugs:1411:0.4100|non-steroidal anti-inflammatory drug:6:0.2827	0.4100	1417
NSAIDs	NSAIDs:83|NSAIDS:3	non-steroidal antiinflammatory drugs:86:0.1014	0.1014	86
NSAIDs	NSAIDs:7|NSAIDS:1	nonsteroidal anti-inflammatories:8:0.2619	0.2619	8
NSAIDs	NSAIDs:1744|NSAIDS:36	nonsteroidal anti-inflammatory drugs:1780:0.5202	0.5202	1780
NSAIDs	NSAIDs:549|NSAIDS:11	Nonsteroidal antiinflammatory drugs:560:0.7950	0.7950	560
NSAID	NSAID:9	non-steroidal anti-inflammatory:9:0.2873	0.2873	9
NSAID	NSAID:18	non-steroidal anti-inflammatory agent:10:0.3829|non-steroidal anti-inflammatory agents:8:0.3463	0.3829	18
NSAID	NSAID:512	non-steroidal anti-inflammatory drug:324:0.4106|non-steroidal anti-inflammatory drugs:188:0.4001	0.4106	512
NSAID	NSAID:38	non-steroidal antiinflammatory drugs:38:0.1014	0.1014	38
NSAID	NSAID:563	nonsteroidal anti-inflammatory drug:382:0.4843|nonsteroidal anti-inflammatory drugs:181:0.3812	0.4843	563
NSAID	NSAID:377	nonsteroidal antiinflammatory drugs:197:0.7190|nonsteroidal antiinflammatory drug:180:0.8043	0.8043	377
NSAI	NSAI:27	anti-inflammatory:27:0.5306	0.5306	27
NSAP	NSAP:16	Non-specific abdominal pain:16:0.4274	0.4274	16
NSA	NSA:9	neck-shaft angle:9:0.3455	0.3455	9
NSA	NSA:10	serum albumin:10:0.5856	0.5856	10
NSBH	NSBH:9	bronchial hyperresponsiveness:9:0.6794	0.6794	9
NSBR	NSBR:12	bronchial responsiveness:12:0.7571	0.7571	12
NSB	NSB:11	non-specific binding:11:0.2972	0.2972	11
NSB	NSB:7	nonspecific binding:7:0.1025	0.1025	7
NSCCL	NSCCL:10	non-small cell carcinoma of the lung:10:0.7357	0.7357	10
NSCCs	NSCCs:11	nonselective cation channels:11:0.4232	0.4232	11
NSCC	NSCC:26	cation channel:17:0.7407|cation channels:9:0.3945	0.7407	26
NSCC	NSCC:8|N-SCC:1|nSCC:1	cell carcinoma:10:0.5355	0.5355	10
NSCLCs	NSCLCs:71	non-small cell lung cancers:71:0.8592	0.8592	71
NSCLCs	NSCLCs:53|NSCLCS:1	non-small cell lung carcinomas:41:0.7653|non-small-cell lung carcinomas:13:0.1005	0.7653	54
NSCLC	NSCLC:8	non-small cell carcinoma of the lung:8:0.5006	0.5006	8
NSCLC	NSCLC:2671|N-SCLC:7|NSC-LC:1	Non-small cell lung cancer:2611:0.9177|non-small cell lung cancers:68:0.7935	0.9177	2679
NSCLC	NSCLC:372	non-small cell lung carcinoma:248:0.5917|non-small-cell lung carcinoma:64:0.1051|non-small cell lung carcinomas:60:0.7855	0.7855	372
NSCLP	NSCLP:10	nonsyndromic cleft lip with or without cleft palate:10:0.7103	0.7103	10
NSCs	NSCs:166	neural stem cells:166:0.9447	0.9447	166
NSC	NSC:57	neural stem cells:33:0.9100|neural stem cell:24:0.8768	0.9100	57
NSC	NSC:25	neurosecretory cells:25:0.2061	0.2061	25
NSC	NSC:14	non-selective cation:14:0.1359	0.1359	14
NSC	NSC:28	Nonselective cation:28:0.3990	0.3990	28
NSC	NSC:8	nonstructural carbohydrate:8:0.4102	0.4102	8
NSDA	NSDA:15|NS-DA:1	nigrostriatal dopaminergic:16:0.8165	0.8165	16
NSD	NSD:23	nominal standard dose:23:0.8038	0.8038	23
NSE	NSE:1452	neuron-specific enolase:1111:0.6606|neuron specific enolase:341:0.8189	0.8189	1452
NSE	NSE:31|NsE:1|N-SE:1|NS-E:1	non-specific esterase:34:0.2651	0.2651	34
NSE	NSE:52	nonspecific esterase:52:0.4622	0.4622	52
NSFG	NSFG:60	National Survey of Family Growth:60:0.9503	0.9503	60
NSF	NSF:83	N-ethylmaleimide-sensitive factor:83:0.5277	0.5277	83
NSF	NSF:78	N-ethylmaleimide-sensitive fusion protein:78:0.6697	0.6697	78
NSF	NSF:42	National Service Framework:42:0.9291	0.9291	42
NSGCTT	NSGCTT:6	germ cell tumors of the testis:6:0.5290	0.5290	6
NSGCTs	NSGCTs:12	nonseminomatous germ cell tumors:12:0.4557	0.4557	12
NSGCT	NSGCT:121	germ cell tumors:61:0.9511|germ cell tumor:41:0.9256|germ cell tumour:19:0.8449	0.9511	121
NSGCT	NSGCT:8	germ cell tumors of the testis:8:0.6411	0.6411	8
NSGCT	NSGCT:35	non-seminomatous germ cell tumours:35:0.5481	0.5481	35
NSG	NSG:9	necrotizing sarcoid granulomatosis:9:0.6794	0.6794	9
NSG	NSG:34|nsg:1	neurosecretory granules:35:0.8292	0.8292	35
NSHD	NSHD:16	nodular sclerosing Hodgkin's disease:16:0.8165	0.8165	16
NSHI	NSHI:11	hearing impairment:11:0.7357	0.7357	11
NSHL	NSHL:17	hearing loss:17:0.8270	0.8270	17
NSILA-S	NSILA-S:20|NSILA-s:2|NSILAs:1	insulin-like activity:23:0.8715	0.8715	23
NSILA	NSILA:34|NSI-LA:1	insulin-like activity:35:0.7952	0.7952	35
NSIP	NSIP:25	non-specific interstitial pneumonia:25:0.1871	0.1871	25
NSIP	NSIP:59	nonspecific interstitial pneumonia:59:0.5896	0.5896	59
NSIP	NSIP:8	nonspecific interstitial pneumonia/fibrosis:8:0.5006	0.5006	8
NSI	NSI:6	needlestick injury:6:0.1838	0.1838	6
NSI	NSI:6	nitrogen solubility index:6:0.5290	0.5290	6
NSI	NSI:97	non-syncytium-inducing:88:0.3295|non-syncytium inducing:9:0.1690	0.3295	97
NSI	NSI:16	nonsyncytium-inducing:16:0.0568	0.0568	16
NSI	NSI:7	normalized slope index:7:0.4438	0.4438	7
NSI	NSI:11	Nutrition Screening Initiative:11:0.5355	0.5355	11
NSJ	NSJ:5	nevus sebaceus of Jadassohn:5:0.5926	0.5926	5
NSLAB	NSLAB:6	non-starter lactic acid bacteria:6:0.1010	0.1010	6
NSLAB	NSLAB:8	nonstarter lactic acid bacteria:8:0.2327	0.2327	8
NSLP	NSLP:9	National School Lunch Program:9:0.6794	0.6794	9
NSM	NSM:25	neurosecretory material:25:0.6240	0.6240	25
NSN	NSN:26	nephrotoxic serum nephritis:26:0.8861	0.8861	26
NSN	NSN:5	nicotine-stimulated neurophysin:5:0.1132	0.1132	5
NSOM	NSOM:16	near-field scanning optical microscope:16:0.7261	0.7261	16
NSOM	NSOM:32	near-field scanning optical microscopy:32:0.9072	0.9072	32
NSP	NSP:7	Neuroendocrine-specific protein:7:0.0565	0.0565	7
NSP	NSP:10	neurotoxic shellfish poisoning:10:0.5856	0.5856	10
NSP	NSP:23	Neurotropin:23:0.0701	0.0701	23
NSP	NSP:8	neutrophil storage pool:8:0.6411	0.6411	8
NSP	NSP:61	non-starch polysaccharides:44:0.4141|non-starch polysaccharide:17:0.3670	0.4141	61
NSP	NSP:6|Nsp:1	non-structural proteins:7:0.1111	0.1111	7
NSP	NSP:45	nonstarch polysaccharides:34:0.2941|Nonstarch polysaccharide:11:0.1683	0.2941	45
NSQIP	NSQIP:17	National Surgical Quality Improvement Program:17:0.6211	0.6211	17
NSRD	NSRD:14	recessive deafness:14:0.6173	0.6173	14
NSRT	NSRT:12	nonsurgical septal reduction therapy:12:0.7571	0.7571	12
NSR	NSR:11	negative slope resistance:11:0.7357	0.7357	11
NSR	NSR:68	normal sinus rhythm:68:0.8706	0.8706	68
NSS	NSS:47	Nephron-sparing surgery:36:0.5704|nephron sparing surgery:11:0.7357	0.7357	47
NSS	NSS:25	neurological severity score:25:0.6240	0.6240	25
NSS	NSS:32	neurological soft signs:32:0.9072	0.9072	32
NSS	NSS:11	Neuropathy Symptom Score:11:0.3495	0.3495	11
NSS	NSS:20	normal saline solution:20:0.8525	0.8525	20
NSS	NSS:15	normal sheep serum:15:0.5818	0.5818	15
NSTs	NSTs:8	nerve sheath tumors:8:0.6411	0.6411	8
NSTs	NSTs:27|NSTS:1	nonstress tests:28:0.6839	0.6839	28
NST	NST:9	nocistatin:9:0.0124	0.0124	9
NST	NST:19	non-shivering thermogenesis:19:0.1129	0.1129	19
NST	NST:37	non-stress test:37:0.1691	0.1691	37
NST	NST:6	nondirective supportive therapy:6:0.3728	0.3728	6
NST	NST:71	nonshivering thermogenesis:71:0.6719	0.6719	71
NST	NST:88	nonstress test:82:0.4553|nonstress tests:6:0.1543	0.4553	88
NST	NST:9	nonstress testing:9:0.4587	0.4587	9
NST	NST:141|nst:1	nucleus of the solitary tract:142:0.9792	0.9792	142
NST	NST:12	Nutrition Support Team:12:0.4557	0.4557	12
NST	NST:52	stem cell transplantation:52:0.9427	0.9427	52
NSU	NSU:22	non-specific urethritis:22:0.5095	0.5095	22
NSVT	NSVT:15|nsVT:3	Non-sustained ventricular tachycardia:18:0.1300	0.1300	18
NSVT	NSVT:48|nsVT:2	Nonsustained Ventricular Tachycardia:50:0.5434	0.5434	50
NSVT	NSVT:6|NS-VT:1	nonsustained VT:7:0.2902	0.2902	7
NSV	NSV:11	neuroadapted Sindbis virus:11:0.4232	0.4232	11
NSV	NSV:19	no-scalpel vasectomy:19:0.7044	0.7044	19
NSV	NSV:10	non-specific vaginitis:10:0.2446	0.2446	10
NSV	NSV:8	nonspecific vaginitis:8:0.1471	0.1471	8
NSW	NSW:208	New South Wales:208:0.9857	0.9857	208
NS	NS:21	0.9% NaCl:21:0.7865	0.7865	21
ns	ns:8|Ns:6	guanine nucleotide regulatory protein:14:0.6911	0.6911	14
ns	ns:13	nanosecond:13:0.0014	0.0014	13
NS	NS:16|Ns:1	nanospheres:17:0.0019	0.0019	17
NS	NS:10	naproxen sodium:10:0.1243	0.1243	10
NS	NS:8	nasal secretions:8:0.3463	0.3463	8
NS	NS:73	natural suppressor:73:0.9591	0.9591	73
NS	NS:15	neck suction:15:0.6386	0.6386	15
NS	NS:20	nedocromil sodium:20:0.3492	0.3492	20
NS	NS:6|N-S:1	negative symptoms:7:0.1850	0.1850	7
NS	NS:13|Ns:1	neostriatum:14:0.0015	0.0015	14
NS	NS:470|ns:1|N-S:1	nephrotic syndrome:472:0.8218	0.8218	472
NS	NS:25	nerve stimulation:25:0.4751	0.4751	25
NS	NS:26	nervous system:26:0.6351	0.6351	26
NS	NS:10|ns:1	neurosecretory:11:0.0012	0.0012	11
NS	NS:9	nevus sebaceus:9:0.6794	0.6794	9
NS	NS:9	Nigrostriatal:9:0.0009	0.0009	9
NS	NS:20	nodular sclerosing:20:0.8525	0.8525	20
NS	NS:69	nodular sclerosis:69:0.8555	0.8555	69
NS	NS:18|n-s:1	non-smokers:19:0.0021	0.0021	19
NS	NS:54|ns:3	non-structural:57:0.0066	0.0066	57
NS	NS:9|ns:2	nonsignificant:11:0.0012	0.0012	11
NS	NS:35|ns:2	nonsmokers:37:0.0042	0.0042	37
NS	NS:142|ns:7	nonstructural:149:0.0174	0.0174	149
NS	NS:4|ns:1	nonstructural proteins:5:0.1132	0.1132	5
NS	NS:51	Noonan syndrome:51:0.0659	0.0659	51
NS	NS:21	normal:21:0.0023	0.0023	21
NS	NS:256	normal saline:256:0.8225	0.8225	256
NS	NS:9	normal saline solution:9:0.4587	0.4587	9
NS	NS:8	normal salt:8:0.5006	0.5006	8
NS	NS:8|ns:2|Ns:1	normal serum:11:0.2972	0.2972	11
NS	NS:10	normal skin:10:0.5000	0.5000	10
NS	NS:55|ns:5|Ns:3	normal subjects:63:0.4691	0.4691	63
NS	NS:67	Novelty Seeking:67:0.9074	0.9074	67
NS	NS:15	nutritional status:15:0.4312	0.4312	15
NS	NS:7	nutritional support:7:0.3524	0.3524	7
NS	NS:11	phosphoprotein:11:0.0012	0.0012	11
Ns	Ns:10|ns:4	regulatory component:14:0.4709	0.4709	14
NS	NS:9	scale:9:0.0009	0.0009	9
NS	NS:9	sedentary:9:0.0009	0.0009	9
ns	ns:11|Ns:5|NS:1	stimulatory:17:0.0019	0.0019	17
NT/N	NT/N:18	neurotensin/neuromedin N:18:0.5560	0.5560	18
NT2/D1	NT2/D1:5	embryonal carcinoma cell line NTERA-2 clone D1:5:0.4422	0.4422	5
NT2	NT2:10	cell line:10:0.7103	0.7103	10
NT3R	NT3R:7	nuclear T3 receptors:7:0.5926	0.5926	7
NT4	NT4:11|NT-4:4	neurotrophin 4:15:0.6386	0.6386	15
NTA	NTA:12	natural thymocytotoxic autoantibody:12:0.6460	0.6460	12
NTA	NTA:60|nta:1	nitrilotriacetate:61:0.1867	0.1867	61
NTA	NTA:125|nta:1	nitrilotriacetic acid:126:0.7529	0.7529	126
NTA	NTA:10	thymocytotoxic autoantibodies:10:0.7103	0.7103	10
NTB	NTB:33	naltriben:33:0.1988	0.1988	33
NTB	NTB:13	necrotizing tracheobronchitis:13:0.5934	0.5934	13
NTB	NTB:16	netobimin:16:0.0932	0.0932	16
NTB	NTB:21	non-tumor-bearing:15:0.0870|non-tumor bearing:6:0.1543	0.1543	21
NTB	NTB:14	nontumor-bearing:9:0.0497|nontumor bearing:5:0.0736	0.0736	14
NTCA	NTCA:9	N-Nitrosothiazolidine 4-carboxylic acid:9:0.6794	0.6794	9
NTCB	NTCB:13	2-nitro-5-thiocyanobenzoic acid:13:0.5934	0.5934	13
NTCPs	NTCPs:14|ntcps:1	normal tissue complication probabilities:15:0.8045	0.8045	15
Ntcp	Ntcp:10|ntcp:3	cotransporter:13:0.0423	0.0423	13
Ntcp	Ntcp:27|NTCP:10|ntcp:8	cotransporting polypeptide:45:0.5342	0.5342	45
NTCP	NTCP:142|ntcp:2	normal tissue complication probability:119:0.9600|Normal tissue complication probabilities:25:0.8816	0.9600	144
NTC	NTC:9	neural tube closure:9:0.6794	0.6794	9
NTDs	NTDs:369|NTDS:1	neural tube defects:370:0.9827	0.9827	370
NTD	NTD:42|N-td:2|NtD:1	N-terminal domain:45:0.5045	0.5045	45
NTD	NTD:362|ntd:2	neural tube defects:244:0.9803|neural tube defect:120:0.9751	0.9803	364
NTD	NTD:12	Normalized Total Dose:12:0.5664	0.5664	12
NTEC	NTEC:10	necrotoxigenic Escherichia coli:10:0.4363	0.4363	10
NTE	NTE:10	nasal transitional epithelium:10:0.7103	0.7103	10
NTE	NTE:160	neuropathy target esterase:160:0.9509	0.9509	160
NTE	NTE:88	neurotoxic esterase:88:0.2877	0.2877	88
NTF2	NTF2:37	nuclear transport factor 2:37:0.8749	0.8749	37
NTFs	NTFs:26	neurotrophic factors:26:0.6973	0.6973	26
NTF	NTF:15|Ntf:1	N-terminal fragment:16:0.6577	0.6577	16
NTF	NTF:21	neurotrophic factor:12:0.5664|neurotrophic factors:9:0.5470	0.5664	21
NTG	NTG:29	N-methyl-N'-nitro-N-nitrosoguanidine:29:0.0269	0.0269	29
NTG	NTG:590|Ntg:2	nitroglycerin:592:0.5683	0.5683	592
NTG	NTG:34	nitroglycerine:34:0.0317	0.0317	34
NTG	NTG:5	nodular goiter:5:0.0517	0.0517	5
NTG	NTG:10|nTg:2|ntg:2|NTg:1|N-TG:1|N-Tg:1	non-transgenic:17:0.0154	0.0154	17
NTG	NTG:5	nontoxic goiter:5:0.0517	0.0517	5
NTG	NTG:24|nTg:8|NTg:5|Ntg:5|ntg:1	nontransgenic:43:0.0404	0.0404	43
NTG	NTG:194	normal-tension glaucoma:101:0.4316|normal tension glaucoma:93:0.9490	0.9490	194
NTG	NTG:11	normotriglyceridemic:11:0.0096	0.0096	11
NTHi	NTHi:68|NTHI:41	nontypeable Haemophilus influenzae:109:0.5909	0.5909	109
NTIS	NTIS:9	illness syndrome:9:0.6794	0.6794	9
NTI	NTI:3	delta opioid receptor antagonist naltrindole:3:0.2827	0.2827	3
NTI	NTI:17	non-thyroidal illness:17:0.1497	0.1497	17
NTI	NTI:38	nonthyroidal illness:38:0.4815	0.4815	38
NTI	NTI:8	patients with nonthyroidal illnesses:8:0.3145	0.3145	8
NTLI	NTLI:52|NT-LI:7	neurotensin-like immunoreactivity:59:0.6068	0.6068	59
NTL	NTL:9	near-total laryngectomy:9:0.6794	0.6794	9
NTL	NTL:31	netilmicin:31:0.2857	0.2857	31
NTM	NTM:48	non-tuberculous mycobacteria:48:0.1760	0.1760	48
NTM	NTM:12	non-tuberculous mycobacterial:12:0.1299	0.1299	12
NTM	NTM:135	nontuberculous mycobacteria:135:0.6069	0.6069	135
NTM	NTM:26	Nontuberculous mycobacterial:26:0.4574	0.4574	26
NTM	NTM:9	Nontuberculous mycobacteriosis:9:0.3069	0.3069	9
NTM	NTM:10	nontuberculous mycobacterium:10:0.3867	0.3867	10
Ntn	Ntn:11	N-terminal nucleophile:11:0.7357	0.7357	11
NTN	NTN:38	nephrotoxic nephritis:38:0.5859	0.5859	38
NTOF	NTOF:13	National Traumatic Occupational Fatalities:13:0.7753	0.7753	13
NTOS	NTOS:7|N-TOS:2	neurogenic thoracic outlet syndrome:9:0.5470	0.5470	9
NTPPPH	NTPPPH:13	nucleoside triphosphate pyrophosphohydrolase:13:0.7753	0.7753	13
NTPase	NTPase:37	nucleoside triphosphatase:37:0.7019	0.7019	37
NTPase	NTPase:11	nucleoside triphosphate hydrolase:11:0.7357	0.7357	11
NTPs	NTPs:37	nucleoside triphosphates:37:0.5384	0.5384	37
NTP	NTP:5	National TB Control Programme:5:0.1973	0.1973	5
NTP	NTP:214	National Toxicology Program:214:0.9702	0.9702	214
NTP	NTP:10	national tuberculosis control programme:10:0.7103	0.7103	10
NTP	NTP:23	National Tuberculosis Programme:23:0.8715	0.8715	23
NTP	NTP:121	nucleoside triphosphate:82:0.6070|nucleoside triphosphates:39:0.5794	0.6070	121
NTP	NTP:11	sodium nitroprusside:11:0.1845	0.1845	11
NTRs	NTRs:11	nontranslated regions:11:0.4232	0.4232	11
NTR	NTR:26	5' nontranslated region:26:0.5040	0.5040	26
NTR	NTR:5|ntr:1	Escherichia coli nitroreductase:6:0.1148	0.1148	6
NTR	NTR:5	NADP-thioredoxin reductase:5:0.0517	0.0517	5
NTR	NTR:18|NT-r:1|NT-R:1	neurotensin receptor:20:0.2988	0.2988	20
ntr	ntr:6|Ntr:4	nitrogen regulation:10:0.5856	0.5856	10
ntr	ntr:5|NTR:3|Ntr:1	nitrogen regulatory:9:0.6794	0.6794	9
NTR	NTR:14	normotensive:14:0.0418	0.0418	14
NTR	NTR:5	thioredoxin reductase:5:0.0517	0.0517	5
NTSB	NTSB:18	National Transportation Safety Board:18:0.8365	0.8365	18
NTSN	NTSN:5	accelerated autologous form of nephrotoxic serum nephritis:5:0.4422	0.4422	5
NTS	NTS:50	nephrotoxic serum:50:0.8068	0.8068	50
NTs	NTs:9	neuroblastic tumors:9:0.5470	0.5470	9
NTs	NTs:63|Nts:1	neurotrophins:64:0.0283	0.0283	64
NTS	NTS:20	Nevada Test Site:20:0.8525	0.8525	20
NTS	NTS:18	non-transcribed spacer:18:0.1552	0.1552	18
NTS	NTS:7	non-transcribed strand:7:0.2902	0.2902	7
NTS	NTS:5	non-typhi salmonellae:5:0.1132	0.1132	5
NTS	NTS:10	non-typhoidal Salmonella:10:0.1878	0.1878	10
NTS	NTS:44	nontranscribed spacer:44:0.5545	0.5545	44
NTS	NTS:5	nucleolar targeting signal:5:0.2818	0.2818	5
nts	nts:47|NTs:2|Nts:1	nucleotides:50:0.0220	0.0220	50
NTS	NTS:430|nTS:12|nts:1	nucleus of the solitary tract:443:0.9646	0.9646	443
NTS	NTS:451|nTS:24|nts:3|Nts:1	nucleus tractus solitarii:479:0.9901	0.9901	479
NTS	NTS:597|nTS:24|nts:4|nTs:1	nucleus tractus solitarius:626:0.9872	0.9872	626
NTS	NTS:8|nTS:1	solitary nucleus:9:0.0898	0.0898	9
NTS	NTS:20|nTS:1	solitary tract nucleus:21:0.8715	0.8715	21
NTUH	NTUH:17	National Taiwan University Hospital:17:0.8270	0.8270	17
NTU	NTU:7	nephelometric turbidity units:7:0.4438	0.4438	7
NTV	NTV:9	neuroendoscopic third ventriculostomy:9:0.6794	0.6794	9
NTZ	NTZ:18|Ntz:1	Nitazoxanide:19:0.5000	0.5000	19
NTx	NTX:2|Ntx:2|NTx:2	collagen I:6:0.1543	0.1543	6
NTx	NTx:3|NTX:2	collagen type I:5:0.4422	0.4422	5
NTx	NTx:6|NTX:3	I collagen cross-linked N-telopeptide:9:0.4587	0.4587	9
NTx	NTx:4|NTX:2	N-terminal telopeptide:6:0.0611	0.0611	6
NTx	NTx:4|nTx:2|NTX:1	neonatal thymectomy:7:0.2902	0.2902	7
NTx	NTx:14|NTX:3|nTx:3	neonatally thymectomized:20:0.7766	0.7766	20
NTX	NTX:20|NTx:2	Noxiustoxin:22:0.0375	0.0375	22
NTX	NTX:8	opioid antagonist naltrexone:8:0.4438	0.4438	8
NTx	NTx:7|NTX:2	telopeptides:9:0.0143	0.0143	9
NTx	NTx:5|NTX:1|N-Tx:1	type I collagen cross-linked N-telopeptides:7:0.5926	0.5926	7
NTX	NTX:6|NTx:5|Ntx:1	urinary N-telopeptide:12:0.0659	0.0659	12
NT	NT:25	Botulinum neurotoxin:25:0.5969	0.5969	25
NT	NT:18|Nt:4	N-terminal:22:0.0041	0.0041	22
N-T	N-T:10	nasal-temporal:10:0.0017	0.0017	10
NT	NT:14	natural T:14:0.6173	0.6173	14
NT	NT:26	Neonatal tetanus:26:0.7593	0.7593	26
Nt	Nt:17	Netropsin:17:0.0031	0.0031	17
NT	NT:10	neural tube:10:0.4363	0.4363	10
NT	NT:869|Nt:1	Neurotensin:870:0.1690	0.1690	870
NT	NT:28|Nt:1	neurotrophin:18:0.0033|neurotrophins:11:0.0019	0.0033	29
NT	NT:56|Nt:6	neutralization:62:0.0118	0.0118	62
NT	NT:61|Nt:1	neutralization test:55:0.6163|neutralization tests:7:0.2902	0.6163	62
NT	NT:38|Nt:10	neutralizing:48:0.0091	0.0091	48
NT	NT:9	nick translation:9:0.6794	0.6794	9
NT	NT:68	nitrotyrosine:68:0.0130	0.0130	68
NT	NT:10	non-typable:10:0.0017	0.0017	10
NT	NT:12|N-T:1	nontrained:13:0.0023	0.0023	13
NT	NT:9	nontypable:9:0.0016	0.0016	9
NT	NT:13	nontypeable:13:0.0023	0.0023	13
NT	NT:5	normal training:5:0.0902	0.0902	5
NT	NT:9	normotension:9:0.0016	0.0016	9
NT	NT:239|Nt:3	normotensive:204:0.0394|normotensives:38:0.0072	0.0394	242
NT	NT:20	normotensive controls:20:0.5892	0.5892	20
NT	NT:65	normotensive subjects:65:0.6891	0.6891	65
NT	NT:10	Normotest:10:0.0017	0.0017	10
NT	NT:9	normothermia:9:0.0016	0.0016	9
NT	NT:48	Northern Territory:48:0.9379	0.9379	48
NT	NT:114|Nt:3	nortriptyline:117:0.0225	0.0225	117
NT	NT:175	nuchal translucency:175:0.9727	0.9727	175
NT	NT:25	nuchal translucency thickness:25:0.8861	0.8861	25
NT	NT:149	nuclear transfer:149:0.9574	0.9574	149
NT	NT:17	nucleation time:17:0.6211	0.6211	17
nt	nt:1728|NT:32|Nt:2	nucleotide:1013:0.1964|nucleotides:749:0.1454	0.1964	1762
nt	nt:14	nucleotide position:14:0.7909	0.7909	14
NT	NT:11	therapy:11:0.0021	0.0021	11
NT	NT:9|Nt:1	tissue:10:0.0017	0.0017	10
NT	NT:32	treatment:32:0.0060	0.0060	32
NUD	NUD:137	non-ulcer dyspepsia:137:0.5554	0.5554	137
NUG	NUG:18	necrotizing ulcerative gingivitis:18:0.6903	0.6903	18
Nups	Nups:7|nups:2	nucleoporins:9:0.8000	0.8000	9
NUP	NUP:13	necrotizing ulcerative periodontitis:13:0.7753	0.7753	13
NURF	NURF:8	nucleosome remodeling factor:8:0.6411	0.6411	8
NUV	NUV:13|nuv:3	near-ultraviolet:16:0.3061	0.3061	16
NVAF	NVAF:23	patients with nonvalvular atrial fibrillation:23:0.3145	0.3145	23
NVB	NVB:16	Navelbine:16:0.2581	0.2581	16
NVB	NVB:16	neurovascular bundle:16:0.8165	0.8165	16
NVB	NVB:11	Vinorelbine:11:0.1613	0.1613	11
NVBs	NVBs:9	neurovascular bundles:9:0.6794	0.6794	9
NVC	NVC:12	neurovascular compression:12:0.7571	0.7571	12
NVD	NVD:6	Neovascularization of the disc:6:0.1470	0.1470	6
NVD	NVD:9	Neurovesical dysfunction:9:0.5470	0.5470	9
NVD	NVD:8	optic disc:8:0.2090	0.2090	8
NVE	NVE:35	native valve endocarditis:35:0.9151	0.9151	35
NVGs	NVGs:7	night vision goggles:7:0.5926	0.5926	7
NVG	NVG:41	neovascular glaucoma:41:0.9274	0.9274	41
NVP	NVP:6	Nausea and vomiting during pregnancy:6:0.9256	0.9256	6
NVP	NVP:117|Nvp:4	nevirapine:121:0.5085	0.5085	121
NVQ	NVQ:11	National Vocational Qualification:11:0.7357	0.7357	11
NVQs	NVQs:11	National Vocational Qualifications:11:0.7357	0.7357	11
NVSS	NVSS:10	National Vital Statistics System:10:0.7103	0.7103	10
NVSS	NVSS:6	normal variant short stature:6:0.5926	0.5926	6
NVs	NVs:12	Noroviruses:12:0.1486	0.1486	12
NVS	NVS:20	nutritionally variant streptococci:20:0.7173	0.7173	20
NV	NV:11	nausea and vomiting:11:0.6182	0.6182	11
NV	NV:21	normal volunteers:21:0.6400	0.6400	21
NV	NV:25	norovirus:16:0.0299|Noroviruses:9:0.0160	0.0299	25
NV	NV:81	Norwalk virus:81:0.8753	0.8753	81
Nv	Nv:35|NV:5	numerical density:40:0.6628	0.6628	40
NV	NV:6|Nv:5	per unit volume:11:0.6182	0.6182	11
NV	NV:10	Retinal neovascularization:10:0.0639	0.0639	10
NWB	NWB:9	non-weight-bearing:9:0.2667	0.2667	9
NWFP	NWFP:15	North West Frontier Province:15:0.8165	0.8165	15
NWL	NWL:9	normal white Leghorn:9:0.6794	0.6794	9
NWSM	NWSM:19	Nocardia water-soluble mitogen:10:0.4363|Nocardia Water Soluble Mitogen:9:0.6794	0.6794	19
NWT	NWT:15	Northwest Territories:15:0.8045	0.8045	15
NWTSG	NWTSG:10	National Wilms Tumor Study Group:10:0.7103	0.7103	10
NWTS	NWTS:36	National Wilms' Tumor Study:36:0.9174	0.9174	36
NW	NW:25|Nw:1	normal weight:26:0.8251	0.8251	26
NW	NW:7	normal Wistar:7:0.1641	0.1641	7
NW	NW:5	normal women:5:0.0902	0.0902	5
NW	NW:6	normotensive Wistar:6:0.1010	0.1010	6
NXG	NXG:19	necrobiotic xanthogranuloma:19:0.8449	0.8449	19
NYCDOH	NYCDOH:13|NYC-DOH:1	New York City Department of Health:14:0.7909	0.7909	14
NYC	NYC:113	New York City:113:0.9735	0.9735	113
NYHA	NYHA:985	New York Heart Association:985:0.9970	0.9970	985
NYHA	NYHA:4	New York Heart Association classification:4:0.4422	0.4422	4
NYSDOH	NYSDOH:14	New York State Department of Health:14:0.7909	0.7909	14
NYS	NYS:48	New York State:48:0.9379	0.9379	48
NYS	NYS:10|Nys:3	nystatin:13:0.1600	0.1600	13
NY	NY:24	New York:24:0.8768	0.8768	24
NY	NY:39	nuclear yellow:39:0.9237	0.9237	39
NZ-105	NZ-105:10	efonidipine hydrochloride:10:0.5856	0.5856	10
NZB	NZB:163	New Zealand Black:163:0.9816	0.9816	163
NZB/W	NZB/W:7	Zealand White:7:0.3524	0.3524	7
NZHIS	NZHIS:9	New Zealand Health Information Service:9:0.6794	0.6794	9
NZO	NZO:27	New Zealand Obese:27:0.8861	0.8861	27
NZW	NZW:244	New Zealand White:244:0.9877	0.9877	244
NZ	NZ:74	New Zealand:74:0.9596	0.9596	74
Na+i	Na+i:17	intracellular Na+:17:0.4246	0.4246	17
Na+	Na+:274|Na-+:1	sodium:275:0.6395	0.6395	275
Na+	Na+:33	sodium ion:18:0.5940|sodium ions:15:0.6386	0.6386	33
Na/K	Na/K:11	sodium/potassium:11:0.2703	0.2703	11
Na/K	Na/K:5	sodium/potassium ratio:5:0.1132	0.1132	5
Na/K	Na/K:4	sodium to potassium:4:0.2243	0.2243	4
Na2CO3	Na2CO3:9	Sodium carbonate:9:0.6794	0.6794	9
Na3VO4	Na3VO4:23	Sodium orthovanadate:23:0.6306	0.6306	23
Na-AsA	Na-AsA:15|NaAsA:1	sodium L-ascorbate:16:0.8165	0.8165	16
NaAc	NaAc:11	sodium acetate:11:0.6182	0.6182	11
NAA	NAA:338|N-AA:1	N-acetyl aspartate:212:0.9501|N-acetyl-aspartate:127:0.1026	0.9501	339
NAA	NAA:41	N-acetyl-L-aspartate:41:0.0318	0.0318	41
NAA	NAA:424|Naa:5	N-Acetylaspartate:429:0.3485	0.3485	429
NAA	NAA:14	N-acetylaspartic acid:14:0.0516	0.0516	14
NAA	NAA:13	naphthalene acetic acid:13:0.3134	0.3134	13
NAA	NAA:12	neutral amino acids:12:0.7571	0.7571	12
NAA	NAA:105	neutron activation analysis:105:0.9400	0.9400	105
NAA	NAA:17	Nucleic acid amplification:17:0.8270	0.8270	17
NaBH4	NaBH4:22	sodium borohydride:22:0.7955	0.7955	22
NABT	NABT:15	normal-appearing brain tissue:15:0.5348	0.5348	15
NaBT	NaBT:18|NaBt:8|NABT:1	sodium butyrate:27:0.8312	0.8312	27
NaBr	NaBr:14	sodium bromide:14:0.7909	0.7909	14
NaBut	NaBut:22|Na-But:2|Na-but:1|Nabut:1	sodium butyrate:26:0.8861	0.8861	26
NaBu	NaBu:35|NA-BU:1	sodium butyrate:36:0.8336	0.8336	36
NaCMC	NaCMC:24|Na-CMC:3	sodium carboxymethylcellulose:27:0.7834	0.7834	27
NaCN	NaCN:61	sodium cyanide:61:0.8383	0.8383	61
NaChs	NaChs:17	sodium channels:17:0.6748	0.6748	17
NaClO	NaClO:22	sodium hypochlorite:22:0.8657	0.8657	22
NaCl	NaCl:8	normal saline:8:0.0566	0.0566	8
NaCl	NaCl:6	saline solution:6:0.0899	0.0899	6
NaCl	NaCl:279|NaCL:1	sodium chloride:280:0.9619	0.9619	280
NaDCC	NaDCC:18	sodium dichloroisocyanurate:18:0.7539	0.7539	18
NaDC	NaDC:14|Na-DC:2	sodium deoxycholate:16:0.7261	0.7261	16
NaDOC	NaDOC:16	sodium deoxycholate:16:0.8165	0.8165	16
naER	naER:14	estrogen receptor:14:0.6911	0.6911	14
NaE	NaE:13|Nae:11|Na-e:1	exchangeable sodium:25:0.6240	0.6240	25
NAE	NAE:10	neoplastic angioendotheliomatosis:10:0.7103	0.7103	10
NAE	NAE:9	neoplastic angioendotheliosis:9:0.6794	0.6794	9
NAE	NAE:33	net acid excretion:33:0.9100	0.9100	33
NAFL	NAFL:9	Nonalcoholic fatty liver:9:0.4587	0.4587	9
NaFl	NaFl:8|NaFL:1|NAFl:1	sodium fluorescein:10:0.7103	0.7103	10
NAF	NAF:18|Naf:2|naf:1	nafenopin:21:0.0337	0.0337	21
NAF	NAF:9	National Abortion Federation:9:0.6794	0.6794	9
NAF	NAF:8	Neutrophil-activating factor:8:0.1125	0.1125	8
NAF	NAF:44	nipple aspirate fluid:44:0.9323	0.9323	44
NaF	NaF:9|Na-F:3|Naf:2	sodium fluorescein:14:0.7909	0.7909	14
NaF	NaF:338	sodium fluoride:338:0.9323	0.9323	338
NaGC	NaGC:16|Na-GC:7	sodium glycocholate:23:0.7500	0.7500	23
NAGLU	NAGLU:5|NaGlu:2|Naglu:2	alpha-N-acetylglucosaminidase:9:0.3636	0.3636	9
Na-HA	Na-HA:12|NaHA:10|NaHa:1	sodium hyaluronate:23:0.8715	0.8715	23
NaHCO(3)	NaHCO(3):13	sodium bicarbonate:13:0.7753	0.7753	13
NaHCO3	NaHCO3:116	sodium bicarbonate:116:0.9109	0.9109	116
NaIO4	NaIO4:17	sodium periodate:17:0.7407	0.7407	17
NAMI	NAMI:9	National Alliance for the Mentally Ill:9:0.6794	0.6794	9
NAM	NAM:28|NAm:13|Nam:4	nicotinamide:45:0.3697	0.3697	45
NaN(3)	NaN(3):25	sodium azide:25:0.8816	0.8816	25
NaN3	NaN3:85	sodium azide:85:0.9442	0.9442	85
NaNO2	NaNO2:50	sodium nitrite:50:0.8776	0.8776	50
N-ANP	N-ANP:9|NANP:1	N-terminal atrial natriuretic peptide:10:0.3867	0.3867	10
NaNP	NaNP:35|NaNp:3|NANP:1	sodium nitroprusside:39:0.8811	0.8811	39
NaOH	NaOH:61	sodium hydroxide:61:0.9511	0.9511	61
NaPi-2	NaPi-2:25|NaPi2:3	cotransporter:28:0.4219	0.4219	28
NASA	NASA:73	National Aeronautics and Space Administration:73:0.9591	0.9591	73
NaSCN	NaSCN:11	sodium thiocyanate:11:0.6182	0.6182	11
NaSac	NaSac:7|Na-Sac:2	sodium saccharin:9:0.6794	0.6794	9
NaTDC	NaTDC:9	sodium taurodeoxycholate:9:0.5470	0.5470	9
NaTT	NaTT:11	sodium tetrathionate:11:0.7357	0.7357	11
NaTC	NaTC:19|NaTc:5|Na-TC:4|Na-Tc:2	sodium taurocholate:30:0.7166	0.7166	30
NaVO3	NaVO3:13	Sodium metavanadate:13:0.7753	0.7753	13
nACh	nACh:32|nAch:1	nicotinic acetylcholine:33:0.8196	0.8196	33
NaCh	NaCh:8	sodium channel:8:0.2090	0.2090	8
Nai	Nai:9	concentration:9:0.0381	0.0381	9
Nai	Nai:11	intracellular Na:11:0.3813	0.3813	11
Nai	Nai:9	intracellular Na+:9:0.2500	0.2500	9
Nai	Nai:15	intracellular sodium:15:0.3821	0.3821	15
NAI	NAI:9|N-AI:1	N-acetylimidazole:10:0.0429	0.0429	10
NAI	NAI:19	non-accidental injury:19:0.6537	0.6537	19
NaI	NaI:20	sodium iodide:20:0.7173	0.7173	20
Nao	Nao:11	extracellular Na:11:0.3275	0.3275	11
NAO	NAO:17	nonyl acridine orange:17:0.3844	0.3844	17
NAO	NAO:26	North Atlantic oscillation:26:0.8861	0.8861	26
NAP-2	NAP-2:55	neutrophil-activating peptide-2:29:0.5551|neutrophil-activating peptide 2:26:0.7760	0.7760	55
NarGHI	NarGHI:9	nitrate reductase:9:0.6794	0.6794	9
Nase	Nase:9|N-ase:2|NAse:2|NASE:1	Neuraminidase:14:0.3824	0.3824	14
Nase	Nase:12	staphylococcal nuclease:12:0.4557	0.4557	12
Nbs2	Nbs2:7|NbS2:3	5,5'-dithiobis(2-nitrobenzoate):10:0.1698	0.1698	10
Nbs2	Nbs2:1	5,5'-dithiobis(2-nitrobenzoic acid:1:0.3232	0.3232	1
NCDS	NCDS:14	National Cooperative Dialysis Study:14:0.7909	0.7909	14
NCDs	NCDs:9	non-communicable diseases:9:0.1809	0.1809	9
NCDs	NCDs:9	noncommunicable diseases:9:0.1809	0.1809	9
NCp7	NCp7:25|Ncp7:1	nucleocapsid protein:26:0.7340	0.7340	26
NCp7	NCp7:4|Ncp7:1	nucleocapsid protein p7:5:0.5290	0.5290	5
Nd-YAG	Nd-YAG:18|NdYAG:1	neodymium-yttrium-aluminum-garnet:10:0.1059|Neodymium Yttrium Aluminum Garnet:9:0.5000	0.5000	19
NEF	NEF:6|NeF:5	C3 nephritic factor:11:0.3495	0.3495	11
NEF	NEF:7	pharmacokinetics of nefazodone:7:0.1329	0.1329	7
NERD	NERD:37	reflux disease:37:0.9151	0.9151	37
Neoral	Neoral:18|neoral:1	cyclosporine microemulsion:19:0.3927	0.3927	19
Neoral	Neoral:9	formulation of cyclosporin:9:0.1052	0.1052	9
neor	neor:6|neoR:4|NEOR:1|NeoR:1	neomycin phosphotransferase:12:0.7571	0.7571	12
neor	neor:17|neoR:11|NeoR:10|Neor:3|neo-r:1|NEO-R:1	neomycin resistance:43:0.8300	0.8300	43
neoR	neoR:8|neor:6|Neor:3|NeoR:2	neomycin resistance gene:19:0.8449	0.8449	19
Neu5Ac	Neu5Ac:70	N-acetylneuraminic acid:70:0.6476	0.6476	70
NeuAc	NeuAc:67	N-acetylneuraminic acid:67:0.6317	0.6317	67
NeuGc	NeuGc:38	N-glycolylneuraminic acid:38:0.6005	0.6005	38
NeuN	NeuN:17	neuron-specific nuclear protein:17:0.3670	0.3670	17
NeuN	NeuN:14	Neuronal nuclear antigen:14:0.4557	0.4557	14
Ng-CAM	Ng-CAM:17|NgCAM:5	neuron-glia cell adhesion molecule:22:0.6934	0.6934	22
NgR	NgR:43	receptor:43:0.7636	0.7636	43
Ngn2	Ngn2:7|ngn2:2|NGN2:1	Neurogenin2:10:0.6429	0.6429	10
NG	NG:23	group:23:0.0310	0.0310	23
Ng	Ng:5|NG:5	levonorgestrel:10:0.0127	0.0127	10
NG	NG:12	N-methyl-N'-nitro-N-nitrosoguanidine:12:0.0155	0.0155	12
NG	NG:71|ng:1	Nasogastric:72:0.1000	0.1000	72
NG	NG:26|Ng:14	Neisseria gonorrhoeae:40:0.7907	0.7907	40
NG	NG:9	net grains/nucleus:9:0.6794	0.6794	9
Ng	Ng:10|NG:5	neurogranin:15:0.0197	0.0197	15
NG	NG:7	neutrophil granulocytes:7:0.3524	0.3524	7
NG	NG:76|Ng:1|ng:1	nitroglycerin:78:0.1085	0.1085	78
NG	NG:12	Nitroglycerine:12:0.0155	0.0155	12
NG	NG:9	nitrosoguanidine:9:0.0113	0.0113	9
NG	NG:21	nodose ganglia:21:0.8594	0.8594	21
NG	NG:26	nodose ganglion:26:0.8251	0.8251	26
NG	NG:9	nodular goiter:9:0.6794	0.6794	9
NG	NG:12|Ng:2	norgestrel:14:0.0183	0.0183	14
NG	NG:11	normal glucose:11:0.3813	0.3813	11
NG	NG:20|ng:1	nuclear grade:21:0.7865	0.7865	21
NhaA	NhaA:9|nhaA:1	Na+/H+ antiporter:10:0.5856	0.5856	10
Ni3S2	Ni3S2:48	Nickel subsulfide:48:0.9027	0.9027	48
NiCl2	NiCl2:34	nickel chloride:34:0.8644	0.8644	34
NIR	NIR:444	near-infrared:332:0.4749|Near infrared:112:0.9733	0.9733	444
NIR	NIR:15	near-infrared interactance:15:0.7096	0.7096	15
NIR	NIR:5	near-infrared radiation:5:0.0902	0.0902	5
NIR	NIR:15	Near-infrared reflectance:10:0.2873|near infrared reflectance:5:0.2818	0.2873	15
NIR	NIR:32	near-infrared spectroscopy:19:0.3582|near infrared spectroscopy:13:0.7753	0.7753	32
NiR	NiR:45|NIR:19|nir:7|Nir:4	nitrite reductase:75:0.8661	0.8661	75
NiSO4	NiSO4:15	nickel sulfate:15:0.7909	0.7909	15
NiSO4	NiSO4:9	nickel sulphate:9:0.6794	0.6794	9
NiTi	NiTi:81|Ni-Ti:22|Niti:1	nickel-titanium:89:0.7395|nickel titanium:15:0.8045	0.8045	104
NIC	NIC:14	neonatal intensive care:14:0.6173	0.6173	14
Nic	Nic:17|NIC:14	nicardipine:31:0.0809	0.0809	31
NIC	NIC:12|Nic:7|nic:1	nicorandil:20:0.0512	0.0512	20
NIC	NIC:16|Nic:7	nicotinamide:23:0.0593	0.0593	23
NIC	NIC:48|Nic:21	nicotine:69:0.1806	0.1806	69
NIC	NIC:7|Nic:1	nicotinic acid:8:0.5006	0.5006	8
NIC	NIC:51	Nursing Interventions Classification:51:0.9404	0.9404	51
NLE	NLE:64	Neonatal lupus erythematosus:64:0.9264	0.9264	64
Nle	Nle:13	norleucine:13:0.1121	0.1121	13
Nmt1p	Nmt1p:6	Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase:6:0.5290	0.5290	6
NN	NN:7|nn:1|N-N:1|n-n:1	nearest-neighbor:10:0.0189	0.0189	10
NN	NN:8	Neoplastic nodules:8:0.5006	0.5006	8
NN	NN:134	neural network:100:0.9100|Neural networks:34:0.9126	0.9126	134
NN	NN:9|Nn:5|N-N:2	normal:16:0.0315	0.0315	16
NOP	NOP:9	4-nitro-o-phenylenediamine:9:0.0727	0.0727	9
NOP	NOP:9	N/OFQ receptor:9:0.2326	0.2326	9
nosZ	nosZ:12|NosZ:3	nitrous oxide reductase:15:0.8045	0.8045	15
Novo	Novo:25	human insulin:25:0.7249	0.7249	25
NPI	NPI:132	Neuropsychiatric Inventory:132:0.7635	0.7635	132
NPI	NPI:54	Nottingham Prognostic Index:54:0.8622	0.8622	54
Npn-1	Npn-1:12|npn-1:2|Npn1:1	neuropilin-1:15:0.9333	0.9333	15
NPRM	NPRM:13	notice of proposed rulemaking:13:0.6911	0.6911	13
Npys	Npys:10	3-nitro-2-pyridinesulfenyl:10:0.5294	0.5294	10
Nramp	Nramp:12|NRAMP:2	natural resistance-associated macrophage protein:14:0.7909	0.7909	14
Nrf2	Nrf2:8	NF-E2-related factor-2:8:0.2987	0.2987	8
NT-ANP	NT-ANP:6|NtANP:1	N-terminal atrial natriuretic peptide:7:0.5926	0.5926	7
NuMA	NuMA:9	nuclear mitotic apparatus:9:0.6794	0.6794	9
NuMA	NuMA:32	nuclear mitotic apparatus protein:32:0.9043	0.9043	32
NUC	NUC:5	nonspecific ulcerative colitis:5:0.2818	0.2818	5
Nuc	Nuc:14|nuc:1	nucleobindin:15:0.1795	0.1795	15
Nuc	Nuc:8|nuc:2	staphylococcal nuclease:10:0.2643	0.2643	10
Nx	Nx:25|NX:5	5/6 nephrectomy:30:0.2631	0.2631	30
NX	NX:37|Nx:33	Naloxone:70:0.2066	0.2066	70
NX	NX:21|Nx:18|nx:1	nephrectomized:40:0.1168	0.1168	40
Nx	Nx:8|NX:2	nephrectomized rats:10:0.5000	0.5000	10
O(-)(2)	O(-)(2):14	superoxide:14:0.5000	0.5000	14
O(2)(-)	O(2)(-):95	superoxide:95:0.4000	0.4000	95
O(2)(-)	O(2)(-):113|O(2)():3	superoxide anion:102:0.9534|superoxide anions:14:0.7909	0.9534	116
O(2)(-)	O(2)(-):5	superoxide anion radical:5:0.4422	0.4422	5
O(2)(-)	O(2)(-):8	superoxide radical:8:0.2619	0.2619	8
O(2)(*)(-)	O(2)(*)(-):9	superoxide:9:0.3636	0.3636	9
O(2)(*-)	O(2)(*-):19	superoxide:19:0.4615	0.4615	19
O(2)(*-)	O(2)(*-):11	superoxide anion:11:0.7357	0.7357	11
O(2)(-).	O(2)(-).:11	superoxide anion:11:0.7357	0.7357	11
O(2)(.-)	O(2)(.-):15|O(2)(-.):4|O(2)(.):1	superoxide:20:0.4750	0.4750	20
O(2)(.-)	O(2)(.-):8|O(2)(-.):2	superoxide anion:10:0.5856	0.5856	10
O(2)	O(2):9	dioxygen:9:0.0354	0.0354	9
O(2)	O(2):102	oxygen:102:0.4469	0.4469	102
O(2)	O(2):8|o(2):1	oxygen consumption:9:0.6794	0.6794	9
O(2)	O(2):13	oxygen uptake:13:0.6701	0.6701	13
O(2)	O(2):13|O(2-):3|O-(2):2	superoxide:18:0.0752	0.0752	18
O(2)	O(2):12|O(2-):4|O(-2):3|O-(2):2	superoxide anion:21:0.8594	0.8594	21
O(3)	O(3):149	ozone:149:0.9737	0.9737	149
O(6)-BG	O(6)-BG:11|O(6)BG:3|O(6)-bG:1	O(6)-benzylguanine:15:0.9333	0.9333	15
O(6)MeG	O(6)-MeG:6|O(6)MeG:6|O(6)-meG:5|O(6)meG:1	O(6)-methylguanine:18:0.8500	0.8500	18
O-.2	O-.2:7|O.2:1|O.-2:1	superoxide:9:0.2581	0.2581	9
O-.2	O-.2:8|O.-2:1	superoxide anion:9:0.6794	0.6794	9
O-.2	O-.2:6|O.-2:1	superoxide anion radical:7:0.5926	0.5926	7
o.c.	o.c.:22|O.C.:10	oral contraceptive:21:0.8594|oral contraceptives:11:0.7357	0.8594	32
O.I.	O.I.:10	osteogenesis imperfecta:10:0.7103	0.7103	10
O.R.	O.R.:15|o.r.:2	odds ratio:17:0.7407	0.7407	17
o.d.	o.d.:51	once daily:51:0.9099	0.9099	51
O.D.	O.D.:42|o.d.:2	optical density:44:0.8620	0.8620	44
O/E	O/E:20	observed to expected:10:0.3867|observed-to-expected:10:0.1169	0.3867	20
O/E	O/E:11	ratio:11:0.1299	0.1299	11
o/w	o/w:54|O/W:51	oil-in-water:89:0.6111|oil in water:16:0.7261	0.7261	105
O/W	O/W:10|o/w:8	oil/water:18:0.1181	0.1181	18
O157	O157:7	Escherichia coli O157:H7:7:0.5926	0.5926	7
O2(-)	O2(-):12	superoxide anion:12:0.7571	0.7571	12
O2*-	O2*-:79	superoxide:79:0.3679	0.3679	79
O2*-	O2*-:70	superoxide anion:62:0.7766|superoxide anions:8:0.4102	0.7766	70
O2*-	O2*-:28	superoxide anion radical:22:0.8657|superoxide anion radicals:6:0.5290	0.8657	28
O2*-	O2*-:18	superoxide radical:11:0.1378|superoxide radicals:7:0.1470	0.1470	18
O2-*	O2-*:10|O2*:3	superoxide:13:0.2609	0.2609	13
O2-*	O2-*:13|O2*:3	superoxide anion:16:0.6024	0.6024	16
O2-	O2-:595	superoxide:595:0.3250	0.3250	595
O2-	O2-:956	superoxide anion:875:0.9625|superoxide anions:81:0.8753	0.9625	956
O2-	O2-:48	superoxide anion radical:37:0.9197|superoxide anion radicals:11:0.7357	0.9197	48
O2-	O2-:15	superoxide ion:15:0.7096	0.7096	15
O2-	O2-:8	superoxide production:8:0.2987	0.2987	8
O2-	O2-:96	superoxide radical:57:0.4360|superoxide radicals:39:0.5303	0.5303	96
O2.-	O2.-:97	superoxide:97:0.3441	0.3441	97
O2.-	O2.-:100	superoxide anion:83:0.9247|superoxide anions:17:0.8270	0.9247	100
O2.-	O2.-:30	superoxide anion radical:24:0.8768|superoxide anion radicals:6:0.5290	0.8768	30
O2.-	O2.-:22	superoxide radical:22:0.2678	0.2678	22
O2-.	O2-.:95|O2.:8|O-2.:1	superoxide:104:0.3140	0.3140	104
O2-.	O2-.:110|O2.:7|O-2.:3|-O2.:1	superoxide anion:106:0.9273|superoxide anions:15:0.6386	0.9273	121
O2-.	O2-.:39	superoxide anion radical:31:0.8563|superoxide anion radicals:8:0.6411	0.8563	39
O2-.	O2-.:34|O2.:2|O-2.:1	superoxide radical:24:0.2578|superoxide radicals:13:0.2959	0.2959	37
O2ER	O2ER:17	oxygen extraction ratio:17:0.5760	0.5760	17
O2Hb	O2Hb:16|O2-Hb:2	oxyhemoglobin:18:0.3953	0.3953	18
O-2A	O-2A:63|O2A:4	oligodendrocyte-type-2 astrocyte:40:0.3507|oligodendrocyte-type 2 astrocyte:27:0.6745	0.6745	67
O2SAT	O2sat:3|O2SAT:3|O2Sat:2	Oxygen saturation:8:0.5006	0.5006	8
O2	O2:11	dioxygen:11:0.0100	0.0100	11
O2	O2:17|o2:15	opaque-2:32:0.0308	0.0308	32
O2	O2:13|o2:6	Opaque2:19:0.0179	0.0179	19
O2	O2:543	oxygen:543:0.5403	0.5403	543
O-2	O-2:73|O2:31	superoxide:104:0.1025	0.1025	104
O-2	O-2:68|O2:41|-O2:1|O--2:1	superoxide anion:111:0.9072	0.9072	111
O-2	O2:3|O-2:3	superoxide anion radical:6:0.5290	0.5290	6
O-2	O-2:9|O2:6|-O-2:1	superoxide radicals:10:0.3145|superoxide radical:6:0.1148	0.3145	16
O3	O3:602	ozone:602:0.9392	0.9392	602
O4MeT	O4MeT:5|O4-meT:2|O4-MeT:2|O4meT:1	O4-methylthymine:10:0.9000	0.9000	10
O6-AGT	O6-AGT:12	O6-Alkylguanine-DNA alkyltransferase:12:0.5664	0.5664	12
O6-MT	O6-MT:13	O6-methylguanine-DNA methyltransferase:13:0.4849	0.4849	13
O6-beG	O6-beG:7|O6-BeG:2	O6-benzylguanine:9:0.8889	0.8889	9
O6-BG	O6-BG:21|O6BG:4|O6-bG:2|O6-Bg:1	O6-Benzylguanine:28:0.8182	0.8182	28
O6-MeG	O6-MeG:45|O6-meG:37|O6MeG:24|O6meG:5|O6-Me-G:1	O6-methylguanine:112:0.9167	0.9167	112
O6-EtG	O6-EtG:5|O6-etG:2|O6EtG:1|O6etG:1	O6-ethylguanine:9:0.7273	0.7273	9
O6-mGua	O6-mGua:10|O6mGua:6|O6MGua:1	O6-methylguanine:17:0.8000	0.8000	17
O6MG	O6MG:16|O6-mG:9|O6mG:8|O6-MG:6	O6-methylguanine:39:0.8636	0.8636	39
O6-MedG	O6-MedG:8|O6-MEdG:2|O6-medG:1	O6-methyldeoxyguanosine:11:0.4167	0.4167	11
OA1	OA1:15	ocular albinism:15:0.8045	0.8045	15
OA1	OA1:17|Oa1:1	Ocular albinism type 1:18:0.8365	0.8365	18
OAA	OAA:30	oxaloacetate:30:0.4203	0.4203	30
OAA/S	OAA/S:25	Observer's Assessment of Alertness/Sedation:25:0.7834	0.7834	25
OAB	OAB:138	Overactive bladder:138:0.9783	0.9783	138
OAC	OAC:31	oral anticoagulants:19:0.8449|oral anticoagulant:12:0.7571	0.8449	31
OAC	OAC:15	oral anticoagulation:15:0.8045	0.8045	15
OAD	OAD:21	obliterative airway disease:21:0.5178	0.5178	21
OAD	OAD:15	obstructive airways disease:15:0.5818	0.5818	15
OAD	OAD:10	overanxious disorder:10:0.3470	0.3470	10
OAE	OAE:92	Otoacoustic emissions:58:0.9486|Otoacoustic emission:34:0.7587	0.9486	92
OAEs	OAEs:100	otoacoustic emissions:100:0.8857	0.8857	100
OAF	OAF:34	osteoclast activating factor:19:0.7044|osteoclast-activating factor:15:0.1879	0.7044	34
OAG	OAG:16	1-oleoyl-2-acetyl glycerol:9:0.0783|1-oleoyl 2-acetyl glycerol:7:0.4438	0.4438	16
OAG	OAG:16	1-oleoyl-2-acetyl-rac-glycerol:16:0.0274	0.0274	16
OAG	OAG:86|OaG:1	1-oleoyl-2-acetyl-sn-glycerol:87:0.1551	0.1551	87
OAG	OAG:104	1-oleoyl-2-acetylglycerol:104:0.1880	0.1880	104
OAG	OAG:9	1-oleyl-2-acetylglycerol:9:0.0146	0.0146	9
OAG	OAG:9	oleoylacetylglycerol:9:0.0146	0.0146	9
OAG	OAG:118	open-angle glaucoma:88:0.6435|open angle glaucoma:30:0.9011	0.9011	118
OAG	OAG:1	TPA and 1-oleoyl-2-acetyl-glycerol:1:0.0502	0.0502	1
OAM	OAM:19	outer acrosomal membrane:19:0.8449	0.8449	19
OAPs	OAPs:9	orthogonal arrays of particles:9:0.6794	0.6794	9
OARS	OARS:11	Older Americans Resources and Services:11:0.7571	0.7571	11
OARs	OARs:24	organs at risk:24:0.8768	0.8768	24
OAR	OAR:11	Office of AIDS Research:11:0.7357	0.7357	11
OAR	OAR:30	organs at risk:30:0.6484	0.6484	30
OAR	OAR:17	Ottawa Ankle Rules:17:0.8270	0.8270	17
OASI	OASI:12	Old-Age and Survivors Insurance:12:0.7571	0.7571	12
OASIS	OASIS:11	Organization to Assess Strategies for Ischemic Syndromes:11:0.7103	0.7103	11
OASIS	OASIS:13	outcome and Assessment information Set:13:0.5113	0.5113	13
OASS	OASS:13	O-Acetylserine sulfhydrylase:13:0.6701	0.6701	13
OAS	OAS:26	2'-5' oligoadenylate synthetase:15:0.3831|2',5'-oligoadenylate synthetase:11:0.0869	0.3831	26
OAS	OAS:30	O-acetyl-L-serine:30:0.0876	0.0876	30
OAS	OAS:45	oral allergy syndrome:45:0.9338	0.9338	45
OAS	OAS:24	Overt Aggression Scale:24:0.8768	0.8768	24
OAS	OAS:49	survival:49:0.1450	0.1450	49
OAT1	OAT1:20|Oat1:2	organic anion transporter 1:22:0.8657	0.8657	22
OAT3	OAT3:10|Oat3:2	organic anion transporter 3:12:0.7571	0.7571	12
OAV	OAV:11	oculo-auriculo-vertebral:11:0.2381	0.2381	11
OA	OA:16	actively sensitized to ovalbumin:16:0.2038	0.2038	16
OA	OA:2	guinea pigs sensitized with ovalbumin:2:0.7103	0.7103	2
OA	OA:38	human osteoarthritic:38:0.1022	0.1022	38
OA	OA:41	normal and osteoarthritic:41:0.1162	0.1162	41
OA	OA:11	obstructive azoospermia:11:0.7357	0.7357	11
OA	OA:96	occupational asthma:96:0.9505	0.9505	96
OA	OA:53	Octopamine:53:0.0088	0.0088	53
OA	OA:29	oesophageal atresia:29:0.8978	0.8978	29
OA	OA:11	oleic:11:0.0017	0.0017	11
OA	OA:233	oleic acid:233:0.2339	0.2339	233
OA	OA:11	open adrenalectomy:11:0.7357	0.7357	11
OA	OA:40	open appendectomy:40:0.9256	0.9256	40
OA	OA:95	ophthalmic artery:95:0.7299	0.7299	95
OA	OA:27	oral anticoagulants:17:0.8270|oral anticoagulant:10:0.7103	0.8270	27
OA	OA:10	oral appliance:10:0.7103	0.7103	10
OA	OA:3255	osteoarthritis:3255:0.5481	0.5481	3255
OA	OA:23	patients with osteoarthrosis:23:0.0952	0.0952	23
OA	OA:48	phosphatase inhibitor okadaic acid:48:0.6959	0.6959	48
OA	OA:1	rats sensitized to ovalbumin:1:0.0679	0.0679	1
OB/GYN	OB/GYN:7|Ob/Gyn:4|ob/gyn:2	obstetrics and gynecology:13:0.5934	0.5934	13
OBCAM	OBCAM:18	opioid-binding cell adhesion molecule:18:0.6024	0.6024	18
OBF	OBF:20	ocular blood flow:20:0.4574	0.4574	20
OB-GYNs	OB-GYNs:6|Ob-Gyns:2|ob-gyns:2	obstetrician-gynecologists:10:0.6429	0.6429	10
OB-GYN	OB-GYN:4|OBGYN:3|Ob-Gyn:1|ObGyn:1	obstetrics and gynecology:9:0.4587	0.4587	9
OB-GYN	OB-GYN:5|ob-gyn:3|Ob-Gyn:2	obstetrics-gynecology:10:0.3750	0.3750	10
OBLA	OBLA:36	onset of blood lactate accumulation:36:0.8716	0.8716	36
OBN	OBN:2	octave band of noise:2:0.6794	0.6794	2
OBPP	OBPP:13	brachial plexus palsy:13:0.7753	0.7753	13
OBPs	OBPs:45	Odorant-binding proteins:34:0.5537|odorant binding proteins:11:0.5355	0.5537	45
OBP	OBP:5	HSV-1 origin-binding protein:5:0.0807	0.0807	5
OBP	OBP:18	odorant-binding protein:18:0.1552	0.1552	18
OBP	OBP:19|oBP:1	Office blood pressure:20:0.7173	0.7173	20
OBP	OBP:19	origin binding protein:19:0.5732	0.5732	19
OBQI	OBQI:8	Outcome-Based Quality Improvement:8:0.4102	0.4102	8
OBRA	OBRA:25	Omnibus Budget Reconciliation Act:25:0.8941	0.8941	25
OB-R	OB-R:57|Ob-R:48|OBR:12|ObR:5	leptin receptor:108:0.7722|leptin receptors:14:0.4951	0.7722	122
OBR	OBR:5	origin of bidirectional DNA replication:5:0.4422	0.4422	5
OBR	OBR:9	origin of bidirectional replication:9:0.6794	0.6794	9
obs	obs:10|Obs:3|OBS:1	observed:14:0.0695	0.0695	14
OBs	OBs:22	occlusion bodies:22:0.7955	0.7955	22
OBs	OBs:8	olfactory bulbs:8:0.5006	0.5006	8
OBs	OBs:9	oligoclonal bands:9:0.6794	0.6794	9
OBS	OBS:26	organic brain syndrome:26:0.7760	0.7760	26
OBs	OBs:18|Obs:3	osteoblasts:21:0.1070	0.1070	21
OBT	OBT:8	breath test:8:0.4102	0.4102	8
OBT	OBT:20	organically bound tritium:20:0.8449	0.8449	20
OBX	OBX:31|Obx:1	olfactory bulbectomy:32:0.8563	0.8563	32
OBZ	OBZ:17	oxibendazole:17:0.8421	0.8421	17
OB	OB:18|ob:8|Ob:1	leptin:27:0.0205	0.0205	27
ob	ob:14|OB:3	obese gene:17:0.5374	0.5374	17
OB	OB:130	obliterative bronchiolitis:130:0.9633	0.9633	130
OB	OB:8	occlusion bodies:8:0.5006	0.5006	8
OB	OB:66	oestradiol benzoate:66:0.8670	0.8670	66
OB	OB:362|ob:2|Ob:1	olfactory bulb:344:0.9814|olfactory bulbs:21:0.7865	0.9814	365
OB	OB:22	olfactory bulbectomized:22:0.8657	0.8657	22
OB	OB:10	Olfactory bulbectomy:10:0.7103	0.7103	10
OB	OB:23	Oligoclonal bands:23:0.5025	0.5025	23
OB	OB:9	oligoclonal IgG bands:9:0.5470	0.5470	9
OB	OB:51|ob:7	osteoblasts:38:0.0292|osteoblast:20:0.0150	0.0292	58
ob	ob:16|OB:1	osteoblast-enriched:17:0.0126	0.0126	17
OB	OB:12|ob:1	osteoblast-like:13:0.0095	0.0095	13
OB	OB:9|ob:3	osteoblastic:12:0.0087	0.0087	12
OB	OB:8	Otilonium bromide:8:0.1809	0.1809	8
OB	OB:20	oxidative burst:20:0.7658	0.7658	20
OB	OB:5|ob:4	product of the obesity:9:0.1273	0.1273	9
OCA1	OCA1:10	oculocutaneous albinism:10:0.5856	0.5856	10
OCA1	OCA1:11	oculocutaneous albinism type 1:11:0.6794	0.6794	11
OCA2	OCA2:15	oculocutaneous albinism:15:0.7096	0.7096	15
OCAs	OCAs:7	oral contraceptive agents:7:0.5926	0.5926	7
OCA	OCA:6	occlusal contact area:6:0.5290	0.5290	6
OCA	OCA:78	oculocutaneous albinism:78:0.9025	0.9025	78
OCA	OCA:9	oral contraceptive agents:9:0.6794	0.6794	9
OCBZ	OCBZ:42	oxcarbazepine:42:0.9318	0.9318	42
OCBs	OCBs:9	oligoclonal bands:9:0.3945	0.3945	9
OCB	OCB:21	oligoclonal bands:21:0.5721	0.5721	21
OCB	OCB:29	olivocochlear bundle:29:0.6392	0.6392	29
OCB	OCB:13	organizational citizenship behavior:13:0.7753	0.7753	13
OCC	OCC:7|occ:3	occlusion:10:0.0776	0.0776	10
OCC	OCC:10	Oocyte-cumulus cell complexes:10:0.7103	0.7103	10
OCC	OCC:23	oocyte-cumulus complexes:18:0.3696|oocyte-cumulus complex:5:0.0902	0.3696	23
OCDD	OCDD:22	octachlorodibenzo-p-dioxin:22:0.5000	0.5000	22
OCDF	OCDF:14	octachlorodibenzofuran:14:0.7647	0.7647	14
OCDS	OCDS:17	Obsessive Compulsive Drinking Scale:17:0.7261	0.7261	17
OCD	OCD:11	obsessive-compulsive:11:0.0050	0.0050	11
OCD	OCD:1521	obsessive-compulsive disorder:1489:0.8233|obsessive-compulsive disorders:20:0.3077|obsessive compulsive disorders:12:0.6701	0.8233	1521
OCD	OCD:15	occupational contact dermatitis:15:0.8045	0.8045	15
OCD	OCD:5	organ-confined disease:5:0.1132	0.1132	5
OCD	OCD:57	Osteochondritis dissecans:57:0.7891	0.7891	57
OCD	OCD:9	oxygen cost diagram:9:0.6794	0.6794	9
OCIF	OCIF:33	osteoclastogenesis inhibitory factor:33:0.5261	0.5261	33
OCI	OCI:9|OC-I:2	oryzacystatin I:11:0.6182	0.6182	11
OCLs	OCLs:13|OCLS:1	osteoclasts:14:0.1781	0.1781	14
OCLs	OCLs:38|Ocls:1	osteoclast-like cells:39:0.5794	0.5794	39
OCLs	OCLs:15	osteoclast-like multinucleated cells:15:0.8045	0.8045	15
OCME	OCME:10	Office of the Chief Medical Examiner:10:0.7571	0.7571	10
OCN	OCN:66|Ocn:3	osteocalcin:69:0.7312	0.7312	69
OCPD	OCPD:16	obsessive-compulsive personality disorder:16:0.5564	0.5564	16
OCPs	OCPs:21	oral contraceptive pills:21:0.8594	0.8594	21
OCPs	OCPs:102	organochlorine pesticides:102:0.8455	0.8455	102
OCP	OCP:90|ocp:1	octacalcium phosphate:91:0.9015	0.9015	91
OCP	OCP:64	Ocular cicatricial pemphigoid:64:0.9033	0.9033	64
OCP	OCP:11	Onchocerciasis Control Program:11:0.7357	0.7357	11
OCP	OCP:23	Onchocerciasis Control Programme:23:0.8038	0.8038	23
OCP	OCP:22	Onchocerciasis Control Programme in West Africa:22:0.8657	0.8657	22
OCP	OCP:11	open circuit potential:11:0.7357	0.7357	11
OCP	OCP:71	oral contraceptive pill:49:0.8492|oral contraceptive pills:22:0.8657	0.8657	71
OCP	OCP:18	organochlorine pesticide:10:0.5856|organochlorine pesticides:8:0.2987	0.5856	18
OCRL	OCRL:22	Oculocerebrorenal syndrome of Lowe:22:0.7400	0.7400	22
OCR	OCR:20	Cancer Registry:20:0.8525	0.8525	20
OCR	OCR:17	Ocular counterrolling:17:0.8270	0.8270	17
OCR	OCR:21	oculocardiac reflex:21:0.4359	0.4359	21
OCR	OCR:12	oxygen consumption rate:12:0.7571	0.7571	12
OCTT	OCTT:56	transit time:56:0.9467	0.9467	56
OCTase	OCTase:13	ornithine carbamoyltransferase:13:0.7753	0.7753	13
OCT	OCT:47	22-oxacalcitriol:47:0.0362	0.0362	47
OCT	OCT:16|Oct:6	octopamine:22:0.0162	0.0162	22
OCT	OCT:54|Oct:4	octreotide:58:0.0439	0.0439	58
OCT	OCT:17	optical coherence tomographic:17:0.8270	0.8270	17
OCT	OCT:719	optical coherence tomography:719:0.9759	0.9759	719
OCT	OCT:24|Oct:1	organic cation transporter:25:0.8816	0.8816	25
OCT	OCT:16|Oct:1	ornithine carbamoyl transferase:17:0.8270	0.8270	17
OCT	OCT:54	ornithine carbamoyltransferase:54:0.9448	0.9448	54
OCT	OCT:20	ornithine carbamyl transferase:20:0.8594	0.8594	20
OCT	OCT:49	oxytocin challenge test:40:0.8491|oxytocin challenge tests:9:0.6794	0.8491	49
OCl-	OCl-:12	hypochlorite:12:0.3929	0.3929	12
OCL	OCL:23|Ocl:1|ocl:1	osteoclast:25:0.2308	0.2308	25
OCL	OCL:12|Ocl:2	osteoclast-like cell:14:0.5111	0.5111	14
OCs	OCs:6	Concentrations of persistent organochlorines:6:0.0899	0.0899	6
OCS	OCS:25	obsessive-compulsive symptoms:25:0.6122	0.6122	25
OCs	OCs:34	obstetric complications:34:0.7306	0.7306	34
OCS	OCS:17	octachlorostyrene:17:0.0071	0.0071	17
ocs	ocs:14	octopine synthase:14:0.7909	0.7909	14
OCS	OCS:45	open canalicular system:45:0.9338	0.9338	45
OCs	OCs:1713|OCS:5|Ocs:2	oral contraceptives:1707:0.9812|Oral contraceptive:13:0.5934	0.9812	1720
OCS	OCS:29|OCs:1	oral contraceptive steroids:30:0.9011	0.9011	30
OCS	OCS:8|OCs:1	oral corticosteroids:9:0.6794	0.6794	9
OCs	OCs:9	organic cations:9:0.6794	0.6794	9
OCs	OCs:24	organochlorine compounds:24:0.7593	0.7593	24
OCs	OCs:15	organochlorine contaminants:15:0.8045	0.8045	15
OCs	OCs:10	organochlorine pesticides:10:0.5856	0.5856	10
OCs	OCs:34|Ocs:2	Osteoclasts:36:0.0156	0.0156	36
OC	OC:19|O-C:1	control:11:0.0026|controls:9:0.0021	0.0026	20
OC	OC:57|o-c:1|O-C:1	obsessive-compulsive:59:0.0149	0.0149	59
OC	OC:1	obsessive or compulsive:1:0.7103	0.7103	1
OC	OC:11	occipital cortex:11:0.1938	0.1938	11
OC	OC:8|Oc:1	octreotide:9:0.0021	0.0021	9
OC	OC:11	oleoresin capsicum:11:0.7571	0.7571	11
OC	OC:36	olivocochlear:36:0.0090	0.0090	36
OC	OC:11	open cholecystectomies:11:0.7357	0.7357	11
oc	OC:8|oc:8	open circular:16:0.8165	0.8165	16
OC	OC:10	open colectomy:10:0.5856	0.5856	10
OC	OC:20	oral candidiasis:20:0.7173	0.7173	20
OC	OC:124	oral contraception:124:0.9616	0.9616	124
OC	OC:1657|oc:3	Oral contraceptive:1240:0.9839|oral contraceptives:420:0.9811	0.9839	1660
OC	OC:11	organ culture:11:0.6182	0.6182	11
OC	OC:39	organ of Corti:39:0.9237	0.9237	39
OC	OC:106	organic carbon:106:0.9718	0.9718	106
OC	OC:123	organochlorine:123:0.0314	0.0314	123
OC	OC:10	organochlorine compounds:10:0.5000	0.5000	10
OC	OC:19	osteochondrosis:19:0.0046	0.0046	19
OC	OC:59|Oc:3	osteoclast:41:0.0103|Osteoclasts:21:0.0052	0.0103	62
OC	OC:9	outer cortex:9:0.1267	0.1267	9
OC	OC:56	ovarian cancer:56:0.6113	0.6113	56
OC	OC:24	ovarian carcinoma:24:0.6767	0.6767	24
OC	OC:7	oxidized cellulose:7:0.2902	0.2902	7
OC	OC:115|Oc:7	Serum osteocalcin:122:0.1530	0.1530	122
ODB	ODB:29	oestradiol benzoate:29:0.8422	0.8422	29
ODCs	ODCs:13	ocular dominance columns:13:0.7753	0.7753	13
ODC	ODC:72	dissociation curve:61:0.9229|dissociation curves:11:0.7357	0.9229	72
ODC	ODC:2353|odc:8|Odc:7	ornithine decarboxylase:2368:0.9713	0.9713	2368
ODC	ODC:34	ornithine decarboxylase activity:34:0.9126	0.9126	34
ODDD	ODDD:11	Oculodentodigital dysplasia:11:0.5355	0.5355	11
ODDS	ODDS:13	Osteotropic drug delivery system:13:0.7753	0.7753	13
odd	odd:11	odd-skipped:11:0.0439	0.0439	11
ODD	ODD:7	oxygen-dependent degradation:7:0.3524	0.3524	7
ODE	ODE:6	O-demethyl encainide:6:0.1010	0.1010	6
ODE	ODE:8	O-desmethyl encainide:8:0.2327	0.2327	8
ODE	ODE:11	ordinary differential equation:11:0.7357	0.7357	11
ODEs	ODEs:17	ordinary differential equations:17:0.7407	0.7407	17
ODFR	ODFR:20	oxygen-derived free radicals:20:0.5021	0.5021	20
ODF	ODF:42|Odf:1	osteoclast differentiation factor:43:0.8037	0.8037	43
ODF	ODF:20	outer dense fibers:20:0.8525	0.8525	20
ODI	ODI:33	Oswestry Disability Index:33:0.9100	0.9100	33
ODI	ODI:47	oxygen desaturation index:47:0.8703	0.8703	47
ODM	ODM:11	ophthalmodynamometry:11:0.1786	0.1786	11
O-DMA	O-DMA:11|O-Dma:3|ODMA:2	O-desmethylangolensin:16:0.8333	0.8333	16
ODMR	ODMR:35	Optically detected magnetic resonance:35:0.9151	0.9151	35
ODNs	ODNs:185|ODNS:1	antisense oligodeoxynucleotides:186:0.3822	0.3822	186
ODNs	ODNs:15	Antisense oligodeoxyribonucleotides:15:0.1076	0.1076	15
ODNs	ODNs:46|oDNS:1	Antisense oligonucleotides:47:0.3082	0.3082	47
ODN	ODN:131	Antisense oligodeoxynucleotide:131:0.4034	0.4034	131
ODN	ODN:26	antisense oligodeoxyribonucleotides:16:0.3643|antisense oligodeoxyribonucleotide:10:0.1878	0.3643	26
ODN	ODN:47	antisense oligonucleotide:24:0.2266|antisense oligonucleotides:23:0.1502	0.2266	47
ODN	ODN:2	endogenous benzodiazepine receptor ligand octadecaneuropeptide:2:0.3170	0.3170	2
ODN	ODN:16	open donor nephrectomy:16:0.7261	0.7261	16
ODQ	ODQ:25	1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one:13:0.0315|1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one:12:0.0289	0.0315	25
ODQ	ODQ:9	guanylate cyclase inhibitor:9:0.5470	0.5470	9
ODQ	ODQ:4	inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one:4:0.1838	0.1838	4
ODQ	ODQ:11	Oswestry Disability Questionnaire:11:0.4728	0.4728	11
ODQ	ODQ:4	soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one:4:0.2452	0.2452	4
ODR	ODR:10	oculomotor delayed-response:10:0.7103	0.7103	10
ODT	ODT:8	Oculodynamic Test:8:0.5006	0.5006	8
ODTS	ODTS:19	organic dust toxic syndrome:19:0.8449	0.8449	19
ODV	ODV:3	active metabolite O-desmethylvenlafaxine:3:0.1973	0.1973	3
ODV	ODV:24	occlusion-derived virus:24:0.7593	0.7593	24
ODS	ODS:34	octadecylsilane:34:0.1065	0.1065	34
ODS	ODS:29	octadecylsilica:29:0.0903	0.0903	29
ODs	ODs:24|ODS:2	optical densities:26:0.8861	0.8861	26
ODS	ODS:6	osmotic demyelination syndrome:6:0.5290	0.5290	6
ODS	ODS:33	osteogenic disorder Shionogi:33:0.8563	0.8563	33
ODS	ODS:9	silica gel:9:0.6794	0.6794	9
OD	OD:10	development:10:0.0082	0.0082	10
OD	OD:25	disease:15:0.0127|diseases:10:0.0082	0.0127	25
OD	OD:32	ocular dominance:32:0.8563	0.8563	32
OD	OD:17	Oesophageal dysfunction:17:0.4742	0.4742	17
OD	OD:36|od:18	once daily:43:0.9308|Once-daily:11:0.0091	0.9308	54
OD	OD:7	oocyte donation:7:0.2452	0.2452	7
OD	OD:513	optical density:477:0.9565|optical densities:36:0.8716	0.9565	513
OD	OD:10	Orthostatic dysregulation:10:0.7103	0.7103	10
OD	OD:16	osteochondritis dissecans:16:0.6024	0.6024	16
OD	OD:15|od:1	outer diameter:16:0.4274	0.4274	16
OD	OD:16	right eye:16:0.7261	0.7261	16
OEA	OEA:13	oleoylethanolamide:13:0.2927	0.2927	13
OECD	OECD:77	Organization for Economic Cooperation and Development:77:0.7753	0.7753	77
OECs	OECs:56	Olfactory ensheathing cells:56:0.9467	0.9467	56
OEC	OEC:10	olfactory ensheathing cell:10:0.5856	0.5856	10
OEC	OEC:11	Oviduct epithelial cells:7:0.1111|oviduct epithelial cell:4:0.1973	0.1973	11
OEC	OEC:10	oviductal epithelial cells:10:0.3213	0.3213	10
OEC	OEC:21	oxygen equilibrium curve:14:0.4709|oxygen equilibrium curves:7:0.4438	0.4709	21
OEC	OEC:50	oxygen-evolving complex:50:0.5905	0.5905	50
OEF	OEF:129	oxygen extraction fraction:129:0.9195	0.9195	129
OEG	OEG:14	olfactory ensheathing glia:14:0.6911	0.6911	14
OELs	OELs:43	Occupational exposure limits:43:0.9308	0.9308	43
OEL	OEL:41	occupational exposure limit:41:0.9274	0.9274	41
OEM	OEM:16	occupational and environmental medicine:16:0.8165	0.8165	16
OEPs	OEPs:8	evoked potentials:8:0.5006	0.5006	8
OEP	OEP:19	common antigen:19:0.4618	0.4618	19
OEP	OEP:9	common protective antigen:9:0.6794	0.6794	9
oep	oep:14|Oep:4	one-eyed pinhead:18:0.7539	0.7539	18
OERP	OERP:13	olfactory event-related potential:13:0.7753	0.7753	13
OERs	OERs:10	oxygen enhancement ratios:10:0.7103	0.7103	10
OER	OER:76|oer:1	oxygen enhancement ratio:69:0.9567|Oxygen enhancement ratios:8:0.6411	0.9567	77
OER	OER:33	oxygen extraction ratio:33:0.7898	0.7898	33
OE	OE:120|oe:1	olfactory epithelium:121:0.9044	0.9044	121
OE	OE:11	otitis externa:11:0.7357	0.7357	11
OE	OE:11	outer envelope:11:0.7357	0.7357	11
OFAGE	OFAGE:36	gel electrophoresis:36:0.8336	0.8336	36
OFC	OFC:14	head circumference:14:0.1882	0.1882	14
OFC	OFC:16	occipitofrontal circumference:16:0.2362	0.2362	16
OFC	OFC:95|OfC:1	orbitofrontal cortex:96:0.7804	0.7804	96
OFDS	OFDS:17	oral-facial-digital syndrome:9:0.3945|oral-facial-digital syndromes:8:0.5006	0.5006	17
OFG	OFG:14	orofacial granulomatosis:14:0.6911	0.6911	14
OFL	OFL:22|Ofl:9	ofloxacin:31:0.6522	0.6522	31
OFMSW	OFMSW:12|OF-MSW:1	organic fraction of municipal solid waste:13:0.7753	0.7753	13
OFMT	OFMT:9	Ossifying fibromyxoid tumor:9:0.6794	0.6794	9
OFO	OFO:8	oxidized frying oil:8:0.6411	0.6411	8
OFQ	OFQ:49	orphanin FQ:49:0.7828	0.7828	49
OFQ/N	OFQ/N:51	orphanin FQ/nociceptin:51:0.9427	0.9427	51
OFRs	OFRs:50	Oxygen free radicals:50:0.7676	0.7676	50
OFR	OFR:120	oxygen free radicals:87:0.7108|oxygen free radical:33:0.6976	0.7108	120
OFS	OFS:11	oligofructose:11:0.2083	0.2083	11
OFT	OFT:15	open field test:15:0.8045	0.8045	15
OFT	OFT:23	outflow tract:23:0.8715	0.8715	23
OFX	OFX:28	ofloxacin:28:0.9310	0.9310	28
OFZ	OFZ:29	oxfendazole:29:0.7778	0.7778	29
OFD	OFD:13	open flap debridement:13:0.7753	0.7753	13
OFD	OFD:12|O-F-D:1	oral-facial-digital:13:0.1463	0.1463	13
OF	OF:27	opacity factor:27:0.6455	0.6455	27
OF	OF:75|O-F:3|O--F:1|of:1	open field:60:0.9503|open-field:20:0.0590	0.9503	80
OF	OF:7	oral fluid:7:0.2452	0.2452	7
OF	OF:8	orbital fibroblasts:8:0.5006	0.5006	8
OF	OF:9	organ failure:9:0.5470	0.5470	9
OF	OF:19	osmotic fragility:19:0.8449	0.8449	19
OF	OF:10	osteitis fibrosa:10:0.7103	0.7103	10
OGAT	OGAT:9	alkyltransferase:9:0.5714	0.5714	9
OGD	OGD:17	oesophagogastroduodenoscopy:17:0.0648	0.0648	17
OGD	OGD:46	oxygen and glucose deprivation:46:0.9511	0.9511	46
OGD	OGD:107	oxygen-glucose deprivation:107:0.5032	0.5032	107
OGDC	OGDC:17	dehydrogenase complex:17:0.7407	0.7407	17
OGDH	OGDH:17	dehydrogenase:17:0.6957	0.6957	17
OGE	OGE:9	oral gingival epithelium:9:0.6794	0.6794	9
OGF	OGF:45	opioid growth factor:45:0.7881	0.7881	45
OGFr	OGFr:7	opioid growth factor receptor:7:0.6411	0.6411	7
OGJ	OGJ:10	oesophagogastric junction:10:0.5000	0.5000	10
OGL	OGL:9	oral glucose load:9:0.6794	0.6794	9
OGP	OGP:24	osteogenic growth peptide:24:0.7955	0.7955	24
OGP	OGP:8	oviduct-specific glycoprotein:8:0.1591	0.1591	8
OGS	OGS:11	osteogenic sarcoma:11:0.7357	0.7357	11
OGT	OGT:5	effects of oren-gedoku-to:5:0.0736	0.0736	5
OGT	OGT:16	O-GlcNAc transferase:16:0.2812	0.2812	16
OGT	OGT:14	oral glucose tolerance:14:0.7909	0.7909	14
OG	OG:10	ganglion:10:0.0325	0.0325	10
OG	OG:11	group:11:0.0361	0.0361	11
OG	OG:11	n-octyl-beta-D-glucopyranoside:11:0.0361	0.0361	11
OG	OG:26	octyl glucoside:26:0.6351	0.6351	26
OG	OG:16	octylglucoside:16:0.0542	0.0542	16
OH*	OH*:47	hydroxyl radical:38:0.9217|hydroxyl radicals:9:0.3069	0.9217	47
OH.	OH.:20	hydroxyl:20:0.0725	0.0725	20
OH.	OH.:220|OH-.:1	hydroxyl radical:152:0.9234|hydroxyl radicals:69:0.8905	0.9234	221
OHAp	OHAp:17|OH-AP:7|OHAP:2	hydroxyapatite:26:0.8065	0.8065	26
OHAs	OHAs:13	oral hypoglycaemic agents:13:0.7753	0.7753	13
OHAs	OHAs:14	oral hypoglycemic agents:14:0.7909	0.7909	14
OHA	OHA:29	oral hypoglycaemic agents:22:0.8657|oral hypoglycaemic agent:7:0.5926	0.8657	29
OHA	OHA:27	oral hypoglycemic agents:21:0.8594|oral hypoglycemic agent:6:0.3728	0.8594	27
OHCA	OHCA:53	out-of-hospital cardiac arrest:53:0.8373	0.8373	53
OH-Cbl	OH-Cbl:9|OHCbl:3|OHcbl:1	Hydroxocobalamin:13:0.6667	0.6667	13
OHCs	OHCs:362|OHCS:2	outer hair cells:364:0.9824	0.9824	364
OHC	OHC:307|ohc:1	outer hair cell:187:0.9744|outer hair cells:121:0.9606	0.9744	308
OHE	OHE:10	oral health education:10:0.7103	0.7103	10
OHF	OHF:11|OH-F:1	hydroxyflutamide:12:0.4074	0.4074	12
OHHL	OHHL:15	N-(3-oxohexanoyl)-L-homoserine lactone:15:0.4951	0.4951	15
OHIP-14	OHIP-14:12|OHIP14:1	Oral Health Impact Profile:13:0.7753	0.7753	13
OHIP	OHIP:14	Ontario Health Insurance Plan:14:0.6911	0.6911	14
OHIP	OHIP:37	Oral Health Impact Profile:37:0.9197	0.9197	37
OHI-S	OHI-S:12	Simplified Oral Hygiene Index:12:0.5335	0.5335	12
OHI	OHI:11	oral hygiene instruction:11:0.7357	0.7357	11
OHL	OHL:49	oral hairy leukoplakia:49:0.9046	0.9046	49
OHO	OHO:10	oncogenic hypophosphatemic osteomalacia:10:0.7103	0.7103	10
o-HPAA	o-HPAA:9	o-hydroxyphenylacetic acid:9:0.5470	0.5470	9
o-HPA	o-HPA:12	o-hydroxyphenylacetaldehyde:12:0.7333	0.7333	12
OH-PCBs	OH-PCBs:9|OHPCBs:1	polychlorinated biphenyls:10:0.5856	0.5856	10
OH-Pro	OH-Pro:8|OH-pro:4|OHPro:4|OHPRO:1|OH-PRO:1|OHpro:1	hydroxyproline:19:0.7500	0.7500	19
OHPr	OHPr:7|OH-Pr:2	hydroxyproline:9:0.8889	0.8889	9
OHP	OHP:26	high pressure:26:0.7340	0.7340	26
OHP	OHP:43|OH-P:6	hydroxyproline:49:0.2275	0.2275	49
OHP	OHP:11	hyperbaric oxygen:11:0.6182	0.6182	11
OHP	OHP:13	Oregon Health Plan:13:0.7753	0.7753	13
OHP	OHP:11	potential:11:0.0474	0.0474	11
OHRQoL	OHRQoL:11|OHRQOL:4|OHR-QoL:1	oral health-related quality of life:16:0.8165	0.8165	16
OHSs	OHSs:9	occupational health services:9:0.6794	0.6794	9
OHSS	OHSS:497	ovarian hyperstimulation syndrome:497:0.9838	0.9838	497
OHSU	OHSU:9	Oregon Health Sciences University:9:0.6794	0.6794	9
OHS	OHS:23	obesity hypoventilation syndrome:23:0.8715	0.8715	23
OHS	OHS:22	occupational health and safety:22:0.8657	0.8657	22
OHS	OHS:45	Occupational Health Services:27:0.8312|occupational health service:18:0.7539	0.8312	45
OHS	OHS:11	Ontario Health Survey:11:0.7357	0.7357	11
OHS	OHS:24	open heart surgery:17:0.8270|open-heart surgery:7:0.0692	0.8270	24
OHS	OHS:24	ovarian hyperstimulation syndrome:24:0.8715	0.8715	24
OHS	OHS:7	Oxford hip score:7:0.5926	0.5926	7
OHTAM	OHTAM:7|OH-TAM:6|OH-Tam:4|OHTam:3|OH-tam:1	4-hydroxytamoxifen:21:0.3846	0.3846	21
OH-TAM	OH-TAM:5|OH-Tam:4|OHTAM:2	hydroxytamoxifen:11:0.1923	0.1923	11
OHTS	OHTS:17	Ocular Hypertension Treatment Study:17:0.8270	0.8270	17
OHT	OHT:11	4-hydroxy-tamoxifen:11:0.0352	0.0352	11
OHT	OHT:31	4-hydroxytamoxifen:31:0.1056	0.1056	31
OHT	OHT:100	ocular hypertension:100:0.8976	0.8976	100
OHT	OHT:17	ocular hypertensive:17:0.8270	0.8270	17
OHT	OHT:10	orthotopic heart transplant:10:0.5856	0.5856	10
OHT	OHT:49|oHT:1	orthotopic heart transplantation:50:0.7497	0.7497	50
OHV-2	OHV-2:10	ovine herpesvirus-2:10:0.6794	0.6794	10
OH	OH:9	hydroxy:9:0.0095	0.0095	9
OH	OH:55|-OH:15	hydroxyl:70:0.0818	0.0818	70
OH	OH:104|-OH:5	hydroxyl radical:64:0.7825|Hydroxyl radicals:45:0.6921	0.7825	109
OH	OH:18	occupational health:18:0.7539	0.7539	18
OH	OH:6	ocular hypertensive:6:0.2243	0.2243	6
OH	OH:108	Orthostatic hypotension:108:0.9563	0.9563	108
OIA	OIA:8	oil-induced arthritis:8:0.2619	0.2619	8
OIA	OIA:15	optical immunoassay:15:0.8045	0.8045	15
OIDP	OIDP:16	Oral Impacts on Daily Performance:9:0.6794|Oral Impacts on Daily Performances:7:0.5926	0.6794	16
OIE	OIE:44	Office International des Epizooties:44:0.9323	0.9323	44
OIF	OIF:7	osteoinductive factor:7:0.3524	0.3524	7
OIG	OIG:10	Office of the Inspector General:10:0.7548	0.7548	10
OIH	OIH:13	131I-orthoiodohippurate:13:0.1132	0.1132	13
OIH	OIH:18	orthoiodohippurate:18:0.1604	0.1604	18
OIND	OIND:9	other inflammatory neurological diseases:9:0.6794	0.6794	9
OIR	OIR:33	Oxygen-induced retinopathy:33:0.6976	0.6976	33
OIS	OIS:11	ocular ischemic syndrome:11:0.7357	0.7357	11
OIs	OIs:82	opportunistic infections:82:0.9238	0.9238	82
OI	OI:81	opportunistic infections:47:0.9006|opportunistic infection:34:0.7587	0.9006	81
OI	OI:32	orthostatic intolerance:32:0.9072	0.9072	32
OI	OI:470|oi:1	osteogenesis imperfecta:471:0.9864	0.9864	471
OI	OI:8	ovulation induction:8:0.5006	0.5006	8
OI	OI:108	oxygenation index:108:0.6160	0.6160	108
OJ	OJ:41	obstructive jaundice:41:0.9274	0.9274	41
OJ	OJ:11	orange juice:11:0.7357	0.7357	11
OK-432	OK-432:41|OK432:3	streptococcal preparation:44:0.7168	0.7168	44
OK-432	OK-432:9	Streptococcus pyogenes:9:0.5470	0.5470	9
OKAN	OKAN:58	optokinetic after-nystagmus:58:0.8126	0.8126	58
OKAN	OKAN:36	optokinetic afternystagmus:36:0.8716	0.8716	36
OKA	OKA:49	okadaic acid:49:0.9046	0.9046	49
OKC	OKC:48	odontogenic keratocyst:36:0.9174|odontogenic keratocysts:12:0.7571	0.9174	48
OKCs	OKCs:11	odontogenic keratocysts:11:0.6182	0.6182	11
OKG	OKG:31	ornithine alpha-ketoglutarate:31:0.8519	0.8519	31
OKN	OKN:20	optokinetic:20:0.0416	0.0416	20
OKN	OKN:406	optokinetic nystagmus:406:0.9608	0.9608	406
OKP	OKP:14	oculokinetic perimetry:14:0.5589	0.5589	14
OKR	OKR:22	optokinetic response:22:0.7955	0.7955	22
OKS	OKS:22	optokinetic stimulation:22:0.8657	0.8657	22
OKT3	OKT3:6|OKT-3:1	anti-CD3 antibodies:7:0.0951	0.0951	7
OKT3	OKT3:13	anti-CD3 monoclonal antibody:13:0.1704	0.1704	13
OKT3	OKT3:7	murine monoclonal anti-CD3 antibody:7:0.3524	0.3524	7
OKT3	OKT3:13|OKT-3:2	muromonab-CD3:15:0.0509	0.0509	15
OKT8	OKT8:5	suppressor/cytotoxic T cells:5:0.1464	0.1464	5
OKY-046	OKY-046:20	thromboxane A2 synthetase inhibitor:20:0.8525	0.8525	20
OK	OK:9	cells:9:0.0236	0.0236	9
OK	OK:248	opossum kidney:248:0.9370	0.9370	248
OK	OK:13	optokinetic:13:0.0354	0.0354	13
OLAP	OLAP:10	analytical processing:10:0.7103	0.7103	10
OLA	OLA:37	oligonucleotide ligation assay:37:0.8749	0.8749	37
OLA	OLA:6	ouabain-like activity:6:0.1543	0.1543	6
OLB	OLB:45	open lung biopsy:45:0.8649	0.8649	45
OLC	OLC:6	oligodendrocyte-like cells:6:0.1010	0.1010	6
OLC	OLC:17	ouabain-like compound:17:0.4742	0.4742	17
OLEDs	OLEDs:9	organic light-emitting diodes:9:0.6794	0.6794	9
OLETF	OLETF:219	Otsuka Long-Evans Tokushima Fatty:219:0.9782	0.9782	219
OLF	OLF:19	ossification of the ligamentum flavum:19:0.7173	0.7173	19
OLF	OLF:17	ouabain-like factor:17:0.5374	0.5374	17
OLGs	OLGs:51|Olgs:1	oligodendrocytes:52:0.9623	0.9623	52
OLG	OLG:26	oligodendrocyte:14:0.3250|oligodendrocytes:12:0.2750	0.3250	26
OLI	OLI:9	immunoreactivity:9:0.3077	0.3077	9
OLL	OLL:9	oral lichenoid lesions:9:0.6794	0.6794	9
OLM	OLM:9	ocular Larva migrans:9:0.6794	0.6794	9
OLM	OLM:15	outer limiting membrane:15:0.8045	0.8045	15
OLPs	OLPs:9	oligodendrocyte progenitors:9:0.5470	0.5470	9
OLP	OLP:255	oral lichen planus:255:0.9635	0.9635	255
OLP	OLP:11	oropharyngeal leak pressure:11:0.7357	0.7357	11
OLR	OLR:10	oral lichenoid reactions:10:0.7103	0.7103	10
OLR	OLR:67	organic loading rate:46:0.9353|organic loading rates:21:0.8594	0.9353	67
OLs	OLs:93|Ols:1	oligodendrocytes:94:0.3843	0.3843	94
OLS	OLS:72	ordinary least squares:60:0.8971|ordinary least-squares:12:0.7571	0.8971	72
OLS	OLS:5	ouabain-like substance:5:0.1132	0.1132	5
OLTx	OLTx:8|OLTX:7	liver transplant:15:0.7096	0.7096	15
OLTx	OLTx:81|OLTX:29|oLTX:1	orthotopic liver transplantation:111:0.7045	0.7045	111
OLT	OLT:88	orthotopic liver transplant:68:0.7673|orthotopic liver transplants:20:0.8525	0.8525	88
OLT	OLT:1159|oLT:2	orthotopic liver transplantation:1133:0.9033|orthotopic liver transplantations:28:0.8369	0.9033	1161
OLV	OLV:105	one-lung ventilation:86:0.7245|one lung ventilation:19:0.7658	0.7658	105
OLZ	OLZ:33|Olz:2	olanzapine:35:0.7907	0.7907	35
OL	OL:85|ol:3	oligodendrocyte:55:0.1656|oligodendrocytes:33:0.0982	0.1656	88
OL	OL:14	olive oil:14:0.7909	0.7909	14
OL	OL:6	optic layer:6:0.1320	0.1320	6
OL	OL:11	oral leukoplakia:11:0.7357	0.7357	11
OMC	OMC:33	open mitral commissurotomy:33:0.9100	0.9100	33
OMC	OMC:12	ostiomeatal complex:12:0.1631	0.1631	12
OMCDi	OMCDi:5	inner stripe of the outer medullary collecting duct:5:0.4422	0.4422	5
OMCD	OMCD:17	outer medullary collecting ducts:17:0.8270	0.8270	17
OMDVR	OMDVR:19|OM-DVR:1	Outer medullary descending vasa recta:20:0.8525	0.8525	20
OMD	OMD:15	oromandibular dystonia:15:0.8045	0.8045	15
OME	OME:22|ome:3	omeprazole:25:0.0326	0.0326	25
OME	OME:639	otitis media with effusion:639:0.9953	0.9953	639
OMFS	OMFS:9	oral and maxillofacial surgery:9:0.6794	0.6794	9
OMF	OMF:14	ohmefentanyl:14:0.2063	0.2063	14
OMGE	OMGE:5	Research Committee of the World Organization of Gastroenterology:5:0.4422	0.4422	5
OMG	OMG:8|oMG:1	ocular myasthenia gravis:9:0.6794	0.6794	9
OMHA	OMHA:10	O-methylhydroxylamine:10:0.8182	0.8182	10
OMI	OMI:78	Old myocardial infarction:78:0.8293	0.8293	78
OMI	OMI:11	oocyte maturation inhibitor:11:0.6182	0.6182	11
OML	OML:13|oml:1	outer molecular layer:14:0.6911	0.6911	14
OMM	OMM:20	outer mitochondrial membrane:20:0.8525	0.8525	20
OMPC	OMPC:10	Otitis media purulenta chronica:10:0.7103	0.7103	10
OMPC	OMPC:10	outer membrane protein complex:10:0.7103	0.7103	10
OMPFC	OMPFC:10	orbital and medial prefrontal cortex:10:0.7103	0.7103	10
OMPs	OMPs:200|Omps:9|OMPS:2|omps:1	outer membrane proteins:212:0.9774	0.9774	212
OMP	OMP:129	olfactory marker protein:129:0.9399	0.9399	129
OMP	OMP:22|Omp:1	orotidine 5'-monophosphate:23:0.8715	0.8715	23
OMP	OMP:322|Omp:13|omp:3	outer membrane protein:236:0.9729|outer membrane proteins:102:0.9710	0.9729	338
OMST	OMST:13	O-methylsterigmatocystin:13:0.9231	0.9231	13
OMS	OMS:16	opsoclonus-myoclonus syndrome:16:0.5564	0.5564	16
OMs	OMs:12	outer membranes:12:0.7571	0.7571	12
OMT	OMT:14	O-methyltransferase:14:0.1074	0.1074	14
OMT	OMT:10	ocular microtremor:10:0.6794	0.6794	10
OMT	OMT:44	osteopathic manipulative treatment:44:0.9308	0.9308	44
OMTKY3	OMTKY3:24	turkey ovomucoid third domain:24:0.8115	0.8115	24
OMTs	OMTs:12	O-methyltransferases:12:0.7333	0.7333	12
OMV	OMV:16	Oncorhynchus masou virus:16:0.7261	0.7261	16
OMV	OMV:70	outer membrane vesicles:35:0.9151|outer membrane vesicle:35:0.9151	0.9151	70
OMVs	OMVs:23	outer membrane vesicles:23:0.8715	0.8715	23
OMW	OMW:25	olive mill wastewater:18:0.5228|olive mill wastewaters:7:0.4438	0.5228	25
OMgp	OMgp:22|OMGP:2|OMgP:1	oligodendrocyte-myelin glycoprotein:14:0.3039|oligodendrocyte myelin glycoprotein:11:0.7103	0.7103	25
OM	OM:9	Occupational medicine:9:0.2757	0.2757	9
OM	OM:15	olfactory mucosa:15:0.3821	0.3821	15
OM	OM:15|Om:2	omeprazole:17:0.0121	0.0121	17
OM	OM:9	oncomodulin:9:0.0060	0.0060	9
OM	OM:62	Oncostatin M:62:0.8971	0.8971	62
OM	OM:24	operative mortality:24:0.7151	0.7151	24
OM	OM:24	optical microscopy:24:0.8115	0.8115	24
OM	OM:9	oral mucosa:9:0.1409	0.1409	9
OM	OM:14	Oral mucositis:14:0.6173	0.6173	14
OM	OM:21|O-M:5	Osborne-Mendel:26:0.0189	0.0189	26
OM	OM:26	osteomalacia:26:0.0189	0.0189	26
OM	OM:20	osteomyelitis:20:0.0144	0.0144	20
OM	OM:201	otitis media:201:0.9762	0.9762	201
OM	OM:25	outer medulla:25:0.8816	0.8816	25
OM	OM:228	outer membrane:203:0.8862|Outer membranes:14:0.6911|outer-membrane:11:0.0076	0.8862	228
OM	OM:12	ovomucoid:12:0.0083	0.0083	12
OM	OM:11	ovulation method:11:0.5355	0.5355	11
Om	Om:10	Ovum mutant:10:0.7103	0.7103	10
ONAPO	ONAPO:17	National Office of Population:17:0.8365	0.8365	17
ONB	ONB:15	olfactory neuroblastoma:15:0.8045	0.8045	15
ONCs	ONCs:11	occult neoplastic cells:11:0.7357	0.7357	11
ONFH	ONFH:20	osteonecrosis of the femoral head:20:0.8525	0.8525	20
ONH	ONH:190|onh:1	optic nerve head:191:0.9590	0.9590	191
ONH	ONH:15	Optic nerve hypoplasia:15:0.8045	0.8045	15
ONL	ONL:150|onl:2	outer nuclear layer:152:0.9803	0.9803	152
ONN	ONN:9	O'nyong-nyong:9:0.6667	0.6667	9
ONOO(-)	ONOO(-):184	peroxynitrite:184:0.9150	0.9150	184
ONOO-	ONOO-:363	Peroxynitrite:363:0.8705	0.8705	363
ONOO-	ONOO-:38	peroxynitrite anion:38:0.8417	0.8417	38
ONPG	ONPG:33|o-NPG:2|oNPG:2	o-nitrophenyl-beta-D-galactopyranoside:37:0.4865	0.4865	37
ONR	ONR:13	optic nerve response:13:0.7753	0.7753	13
ONSD	ONSD:11	optic nerve sheath decompression:11:0.7357	0.7357	11
ONSD	ONSD:8	optic nerve sheath diameter:8:0.6411	0.6411	8
ONSM	ONSM:9	optic nerve sheath meningioma:9:0.6794	0.6794	9
ONS	ONS:19	Office for National Statistics:19:0.8312	0.8312	19
ONS	ONS:33	Oncology Nursing Society:33:0.9100	0.9100	33
ONS	ONS:9	optic nerve section:9:0.6794	0.6794	9
ONTD	ONTD:6|oNTD:1|ontd:1	open neural tube defects:8:0.6411	0.6411	8
ONTT	ONTT:17	Optic Neuritis Treatment Trial:17:0.8270	0.8270	17
ON	ON:7	Antisense oligonucleotides:7:0.0828	0.0828	7
ON	ON:8|on:1	depolarizing:9:0.0114	0.0114	9
ON	ON:26	olfactory nerve:26:0.1156	0.1156	26
ON	ON:22	oligonucleotide:22:0.0300	0.0300	22
ON	ON:5|on:4	onset:9:0.0128	0.0128	9
ON	ON:5	Onuf's nucleus:5:0.0902	0.0902	5
ON	ON:111	optic nerve:111:0.7286	0.7286	111
ON	ON:178	optic neuritis:178:0.9832	0.9832	178
ON	ON:63	osteonecrosis:63:0.0884	0.0884	63
ON	ON:46	osteonectin:46:0.0642	0.0642	46
OOHCA	OOHCA:10|OOH-CA:3	out-of-hospital cardiac arrest:13:0.7753	0.7753	13
OOI	OOI:8	orbicularis oris inferior:8:0.6411	0.6411	8
OOM	OOM:12	orbicularis oculi muscle:12:0.7571	0.7571	12
OONO(-)	OONO(-):9	peroxynitrite:9:0.8889	0.8889	9
OONO-	OONO-:22	peroxynitrite:22:0.8750	0.8750	22
OOS-TMP	OOS-TMP:22	O,O,S-trimethyl phosphorothioate:22:0.7955	0.7955	22
OOX	OOX:11	oophorectomy:11:0.3704	0.3704	11
OO	OO:55	olive oil:55:0.9458	0.9458	55
OO	OO:21|oo:3	orbicularis oculi:24:0.8816	0.8816	24
OO	OO:10	osteoid osteoma:10:0.7103	0.7103	10
OP-CCK	OP-CCK:15	octapeptide of cholecystokinin:15:0.8045	0.8045	15
OP-FTIR	OP-FTIR:11	Fourier transform infrared:11:0.7357	0.7357	11
OP-2507	OP-2507:7|OP2507:1	prostacyclin analogue:8:0.5006	0.5006	8
OPA1	OPA1:11	Dominant optic atrophy:11:0.7357	0.7357	11
OPAA	OPAA:6	organophosphorus acid anhydrolase:6:0.2827	0.2827	6
OPALS	OPALS:13	Ontario Prehospital Advanced Life Support:13:0.7753	0.7753	13
OPAT	OPAT:28	outpatient parenteral antibiotic therapy:28:0.7905	0.7905	28
OPA	OPA:11	derivatization with o-phthaldialdehyde:11:0.0934	0.0934	11
OPA	OPA:78|o-PA:1	o-phthalaldehyde:79:0.1940	0.1940	79
OPA	OPA:6|opa:1	occupational physical activity:7:0.5926	0.5926	7
OPA	OPA:22	ocular pulse amplitude:22:0.8657	0.8657	22
Opa	Opa:14	opacity-associated:14:0.0323	0.0323	14
Opa	Opa:7	opacity proteins:7:0.3524	0.3524	7
OPA	OPA:6	opsonophagocytic activity:6:0.1010	0.1010	6
OPA	OPA:7	opsonophagocytic assay:7:0.3524	0.3524	7
OPA	OPA:20	ortho-phthalaldehyde:20:0.0473	0.0473	20
OPA	OPA:18	Ovine pulmonary adenocarcinoma:18:0.8365	0.8365	18
OPBZ	OPBZ:10	oxyphenbutazone:10:0.9000	0.9000	10
opb	opb:9	open brain:9:0.6794	0.6794	9
OPCA	OPCA:184	olivopontocerebellar atrophy:184:0.7763	0.7763	184
OPCABG	OPCABG:18	off-pump coronary artery bypass grafting:18:0.7539	0.7539	18
OPCAB	OPCAB:147|OP-CAB:3	off-pump coronary artery bypass:150:0.8635	0.8635	150
OPCAB	OPCAB:71|OP-CAB:1	off-pump coronary artery bypass grafting:72:0.8309	0.8309	72
OPCAB	OPCAB:11	off-pump coronary artery bypass surgery:11:0.6182	0.6182	11
OPCS	OPCS:38	Office of Population Censuses and Surveys:38:0.9308	0.9308	38
OPCs	OPCs:43	Oligodendrocyte precursor cells:43:0.8037	0.8037	43
OPCs	OPCs:36	oligodendrocyte progenitor cells:36:0.7704	0.7704	36
OPC	OPC:6	Involuntary outpatient commitment:6:0.3728	0.3728	6
OPC	OPC:11|Opc:1	Oligodendrocyte progenitor cells:6:0.2827|oligodendrocyte progenitor cell:6:0.5290	0.5290	12
OPC	OPC:10	Organophosphorus compounds:10:0.5856	0.5856	10
OPC	OPC:39	oropharyngeal candidiasis:39:0.8455	0.8455	39
OPC	OPC:9	ovine pulmonary carcinoma:9:0.6794	0.6794	9
OPDs	OPDs:7	hospital outpatient departments:7:0.2902	0.2902	7
OPD	OPD:26|o-PD:9|opd:1	o-phenylenediamine:36:0.1311	0.1311	36
OPD	OPD:8	other personality disorders:8:0.5006	0.5006	8
OPD	OPD:11	oto-palato-digital:11:0.0375	0.0375	11
OPD	OPD:51	Outpatient Department:45:0.5312|outpatient departments:6:0.1838	0.5312	51
OPFC	OPFC:8|oPFC:2	orbital prefrontal cortex:10:0.7103	0.7103	10
OPF	OPF:5	osteoplastic flap:5:0.1132	0.1132	5
OPG-Gee	OPG-Gee:13	ocular pneumoplethysmography:13:0.7753	0.7753	13
OPGL	OPGL:23|OPG-L:3	osteoprotegerin ligand:26:0.5840	0.5840	26
OPG	OPG:9	ocular pneumoplethysmography:9:0.6794	0.6794	9
OPG	OPG:19	oculoplethysmography:19:0.0266	0.0266	19
OPG	OPG:537|opg:1	Osteoprotegerin:538:0.7843	0.7843	538
OPH	OPH:37	organophosphorus hydrolase:37:0.5263	0.5263	37
OPIDN	OPIDN:61	delayed neuropathy:61:0.9511	0.9511	61
OPIDN	OPIDN:17	organophosphorus compound-induced delayed neurotoxicity:17:0.4035	0.4035	17
OPIDN	OPIDN:18	organophosphorus ester-induced delayed neurotoxicity:18:0.8365	0.8365	18
OPIDP	OPIDP:45	delayed polyneuropathy:45:0.8941	0.8941	45
OPI	OPI:7	organophosphorus inhibitors:7:0.3524	0.3524	7
OPLC	OPLC:15|oplc:1	chromatography:16:0.8824	0.8824	16
OPLL	OPLL:170|opll:1	ossification of the posterior longitudinal ligament:171:0.9158	0.9158	171
OPLL	OPLL:22	ossification of the posterior longitudinal ligament of the spine:22:0.8186	0.8186	22
OPLs	OPLs:9	oral premalignant lesions:9:0.6794	0.6794	9
OPL	OPL:163|opl:1	outer plexiform layer:164:0.9817	0.9817	164
oPL	oPL:65|OPL:1	ovine placental lactogen:66:0.8858	0.8858	66
OPMD	OPMD:100	oculopharyngeal muscular dystrophy:100:0.9359	0.9359	100
OPM	OPM:25	Office of Personnel Management:25:0.8816	0.8816	25
OPNs	OPNs:29	omnipause neurons:29:0.7237	0.7237	29
OPN	OPN:9	olivary pretectal nucleus:9:0.6794	0.6794	9
OPN	OPN:701|Opn:23|opn:2	osteopontin:726:0.9379	0.9379	726
OPO	OPO:22	optical parametric oscillator:22:0.8657	0.8657	22
OPO	OPO:21	organ procurement organization:21:0.8594	0.8594	21
OPOs	OPOs:23	organ procurement organizations:23:0.8715	0.8715	23
OPP-Na	OPP-Na:11	sodium o-phenylphenate:11:0.7357	0.7357	11
OPPP	OPPP:11	oxidative pentose phosphate pathway:11:0.7357	0.7357	11
OPPV	OPPV:10	ovine progressive pneumonia virus:10:0.7103	0.7103	10
OPPs	OPPs:9	organophosphorus pesticides:9:0.5470	0.5470	9
OPP	OPP:33|o-PP:1	o-phenylphenol:34:0.1315	0.1315	34
OPP	OPP:40	ocular perfusion pressure:40:0.9256	0.9256	40
OPP	OPP:13	Office of Pesticide Programs:13:0.7753	0.7753	13
Opp	Opp:19|opp:10	oligopeptide permease:29:0.8978	0.8978	29
Opp	Opp:10	oligopeptide transport system:10:0.7103	0.7103	10
OPP	OPP:9	Organophosphate poisoning:9:0.5470	0.5470	9
OPP	OPP:17	ortho-phenylphenol:17:0.0637	0.0637	17
OPP	OPP:13	ovine progressive pneumonia:13:0.7753	0.7753	13
OPRM1	OPRM1:12	mu-opioid receptor gene:12:0.4557	0.4557	12
OPRT	OPRT:18	orotate phosphoribosyl transferase:18:0.8365	0.8365	18
OPRT	OPRT:17	orotate phosphoribosyltransferase:17:0.8270	0.8270	17
OPR	OPR:6	oxidative phosphorylation rate:6:0.5290	0.5290	6
OPSI	OPSI:13	Overwhelming post-splenectomy infection:13:0.7753	0.7753	13
OPSI	OPSI:26	overwhelming postsplenectomy infection:26:0.8861	0.8861	26
OPTN	OPTN:12|Optn:1	optineurin:13:0.4800	0.4800	13
OPT	OPT:16	o-phthalaldehyde:16:0.0968	0.0968	16
OPT	OPT:9	o-phthaldialdehyde:9:0.0516	0.0516	9
OPU	OPU:8	oocyte pickup:8:0.2327	0.2327	8
OPU	OPU:27	ovum pick-up:27:0.6192	0.6192	27
OPV	OPV:14	oral poliovaccine:14:0.7909	0.7909	14
OPV	OPV:11	oral poliovirus:11:0.7357	0.7357	11
OPV	OPV:159	oral poliovirus vaccine:159:0.9117	0.9117	159
OPV	OPV:9	orthopoxvirus:9:0.0193	0.0193	9
OPZ	OPZ:18	oltipraz:18:0.1932	0.1932	18
OPZ	OPZ:17	omeprazole:17:0.1818	0.1818	17
OPZ	OPZ:27|OpZ:12	opsonized zymosan:39:0.7860	0.7860	39
O-PS	O-PS:21|OPS:17|O-ps:2|O-Ps:1	O-polysaccharide:26:0.0430|O polysaccharide:10:0.1177|O polysaccharides:5:0.1132	0.1177	41
O-PS	O-PS:8|OPS:5	O-specific polysaccharide:13:0.1692	0.1692	13
OPS	OPS:11	objective pain scale:11:0.7357	0.7357	11
OPS	OPS:5	Objective Pain Score:5:0.4422	0.4422	5
OPS	OPS:34	Open Pulled Straw:23:0.8715|open pulled straws:11:0.7571	0.8715	34
OPs	OPs:51	organophosphates:51:0.0859	0.0859	51
OPs	OPs:7	organophosphate insecticides:7:0.0692	0.0692	7
OPs	OPs:7|OPS:1	organophosphate pesticides:8:0.0566	0.0566	8
OPs	OPs:24	Organophosphorus compounds:24:0.7151	0.7151	24
OPs	OPs:16	organophosphorus insecticides:16:0.4040	0.4040	16
OPs	OPs:23	organophosphorus pesticides:23:0.4053	0.4053	23
OPS	OPS:5	Orpington Prognostic Score:5:0.4422	0.4422	5
OPS	OPS:20	orthogonal polarization spectral:20:0.8525	0.8525	20
OPs	OPs:134|Ops:2	oscillatory potentials:136:0.9780	0.9780	136
OPS	OPS:9	syndrome:9:0.0137	0.0137	9
OP	OP:35	1,10-phenanthroline:35:0.0208	0.0208	35
OP	OP:42	4-Tert-octylphenol:42:0.0251	0.0251	42
op	op:8	mice homozygous for the osteopetrosis:8:0.6411	0.6411	8
OP	OP:10	o-phenanthroline:10:0.0055	0.0055	10
OP	OP:9	obesity-prone:9:0.0049	0.0049	9
OP	OP:15	oligodendrocyte progenitor:11:0.6182|oligodendrocyte progenitors:4:0.1132	0.6182	15
OP	OP:7	opening pressure:7:0.0592	0.0592	7
OP	OP:10	opponens pollicis:10:0.5856	0.5856	10
OP	OP:17	organizing pneumonia:17:0.7407	0.7407	17
OP	OP:255|op:1	organophosphate:227:0.1381|organophosphates:29:0.0171	0.1381	256
OP	OP:11	organophosphate pesticide:6:0.1148|organophosphate pesticides:5:0.0612	0.1148	11
OP	OP:23	organophosphorous:23:0.0134	0.0134	23
OP	OP:215	organophosphorus:215:0.1308	0.1308	215
OP	OP:20	organophosphorus compounds:12:0.4557|organophosphorus compound:8:0.5006	0.5006	20
OP	OP:10	Organophosphorus pesticides:5:0.0612|organophosphorus pesticide:5:0.0517	0.0612	10
OP	OP:10	oropharyngeal:10:0.0055	0.0055	10
OP	OP:8|op:1	oropharynx:9:0.0049	0.0049	9
OP	OP:48	oscillatory potentials:30:0.9011|oscillatory potential:18:0.6381	0.9011	48
OP	OP:8	osmotic pressure:8:0.0863	0.0863	8
op	op:24	osteopetrotic:24:0.0141	0.0141	24
OP	OP:95|Op:1	osteoporosis:96:0.0587	0.0587	96
OP	OP:9	osteoporotic:9:0.0049	0.0049	9
OP	OP:13	outpatient:13:0.0073	0.0073	13
OQ	OQ:12	open quotient:12:0.7571	0.7571	12
ORAC	ORAC:81	oxygen radical absorbance capacity:81:0.9631	0.9631	81
ORBC	ORBC:7	ox erythrocytes:7:0.2902	0.2902	7
ORBC	ORBC:11	ox red blood cells:11:0.7357	0.7357	11
ORCC	ORCC:13	outwardly rectifying chloride channel:13:0.7753	0.7753	13
ORCC	ORCC:5	outwardly rectifying Cl- channels:5:0.2818	0.2818	5
ORCH	ORCH:7|orch:4|Orch:1	orchidectomized:12:0.4583	0.4583	12
ORCs	ORCs:18	olfactory receptor cells:18:0.8365	0.8365	18
ORD	ORD:21	optical rotatory dispersion:21:0.8594	0.8594	21
ORD	ORD:14	outer ring deiodination:14:0.7909	0.7909	14
ORF's	ORF's:13	open reading frames:13:0.7753	0.7753	13
ORF1	ORF1:69|ORF-1:6|orf1:6|orf-1:3|Orf1:1	open reading frame:85:0.9442	0.9442	85
ORF1	ORF1:33|ORF-1:3	Open reading frame 1:36:0.9174	0.9174	36
ORF2	ORF2:35|ORF-2:5|orf2:3|orf-2:1	open reading frame:44:0.8941	0.8941	44
ORF2	ORF2:40|ORF-2:5	open reading frame 2:45:0.9338	0.9338	45
ORF3	ORF3:19|orf3:4|ORF-3:1	open reading frame:24:0.8115	0.8115	24
ORF3	ORF3:21	open reading frame 3:21:0.8594	0.8594	21
ORF4	ORF4:11	open reading frame 4:11:0.7357	0.7357	11
ORF50	ORF50:12	open reading frame 50:12:0.6460	0.6460	12
ORFs	ORFs:2496|orfs:28|ORFS:4|Orfs:1	open reading frames:2529:0.9957	0.9957	2529
ORIF	ORIF:68	Open reduction and internal fixation:68:0.9408	0.9408	68
ori	ori:19	origin of DNA replication:19:0.3871	0.3871	19
ori	ori:86|ORI:4	origin of replication:90:0.5985	0.5985	90
ori	ori:35|ORI:1	replication origin:36:0.4956	0.4956	36
ORL1	ORL1:6|ORL-1:1	endogenous ligand of the opioid receptor-like 1:7:0.4587	0.4587	7
ORL1	ORL1:39|ORL-1:10	opioid receptor-like:49:0.9046	0.9046	49
ORL1	ORL1:7|ORL-1:5	opioid receptor-like receptor:12:0.6460	0.6460	12
ORL1	ORL1:13|ORL-1:1	opioid receptor-like1:14:0.7909	0.7909	14
ORLS	ORLS:12	Oxford Record Linkage Study:12:0.7571	0.7571	12
ORM	ORM:61	orosomucoid:61:0.7692	0.7692	61
ORNL	ORNL:19	Oak Ridge National Laboratory:19:0.8449	0.8449	19
ORNs	ORNs:176|ORNS:1	olfactory receptor neurons:177:0.9831	0.9831	177
ORO	ORO:10	Oropouche:10:0.1837	0.1837	10
ORP150	ORP150:20	oxygen-regulated protein:20:0.7766	0.7766	20
ORP	ORP:56	oxidation-reduction potential:45:0.5506|oxidation reduction potential:11:0.5050	0.5506	56
ORRs	ORRs:9	response rates:9:0.6794	0.6794	9
ORR	ORR:94	response rate:94:0.9495	0.9495	94
ORSA	ORSA:18	oxacillin-resistant Staphylococcus aureus:18:0.5228	0.5228	18
ORSV	ORSV:7	odontoglossum ringspot virus:7:0.5926	0.5926	7
ORS	ORS:8	oculo-respiratory syndrome:8:0.1471	0.1471	8
ORS	ORS:6	oculorespiratory syndrome:6:0.0611	0.0611	6
ORs	ORs:13|ORS:1	odds ratio:14:0.7909	0.7909	14
ORs	ORs:20	odorant receptors:20:0.1600	0.1600	20
ORs	ORs:30|ors:1	olfactory receptors:31:0.3005	0.3005	31
ORs	ORs:20	operating rooms:20:0.8525	0.8525	20
ORS	ORS:109	oral rehydration salts:77:0.9617|oral rehydration salt:32:0.9072	0.9617	109
ORS	ORS:285	oral rehydration solution:220:0.9516|oral rehydration solutions:65:0.9541	0.9541	285
ORs	ORs:10	orienting responses:10:0.1994	0.1994	10
ORS	ORS:69	outer root sheath:69:0.9567	0.9567	69
ORT	ORT:271	oral rehydration therapy:271:0.9890	0.9890	271
ORT	ORT:14	Ornithobacterium rhinotracheale:14:0.6911	0.6911	14
ORT	ORT:7	orthodromic reciprocating tachycardia:7:0.4438	0.4438	7
ORX	ORX:17|orx:2|Orx:1	orchidectomized:20:0.2714	0.2714	20
ORX	ORX:13|orx:3	orchidectomy:16:0.2143	0.2143	16
ORX	ORX:16|orx:1	orchiectomized:17:0.2286	0.2286	17
OSAHS	OSAHS:78	obstructive sleep apnea-hypopnea syndrome:54:0.9132|Obstructive sleep apnea hypopnea syndrome:24:0.8816	0.9132	78
OSAS	OSAS:23|oSAS:1	obstructive sleep apnea:24:0.8115	0.8115	24
OSAS	OSAS:807	obstructive sleep apnea syndrome:807:0.9849	0.9849	807
OSAS	OSAS:183	Obstructive sleep apnoea syndrome:183:0.9738	0.9738	183
OSA	OSA:1093	obstructive sleep apnea:1093:0.9901	0.9901	1093
OSA	OSA:25	obstructive sleep apnea syndrome:25:0.6873	0.6873	25
OSA	OSA:315	obstructive sleep apnoea:315:0.9797	0.9797	315
OSA	OSA:18	obstructive sleep apnoea syndrome:18:0.8365	0.8365	18
OSA	OSA:5	ordered subset analysis:5:0.4422	0.4422	5
OSA	OSA:23	osteosarcoma:23:0.0140	0.0140	23
OSBP	OSBP:36	oxysterol binding protein:22:0.8594|oxysterol-binding protein:14:0.2081	0.8594	36
OSCCs	OSCCs:57	oral squamous cell carcinomas:57:0.8920	0.8920	57
OSCC	OSCC:309|O-SCC:5	oral squamous cell carcinoma:273:0.8692|oral squamous cell carcinomas:41:0.7472	0.8692	314
OSCE	OSCE:270	objective structured clinical examination:270:0.9824	0.9824	270
OSCEs	OSCEs:31	Objective Structured Clinical Examinations:31:0.8090	0.8090	31
OSCN-	OSCN-:16	hypothiocyanite:16:0.5556	0.5556	16
OSCP	OSCP:54	oligomycin sensitivity conferring protein:27:0.8903|oligomycin sensitivity-conferring protein:17:0.8270|oligomycin-sensitivity conferring protein:10:0.1022	0.8903	54
OSCs	OSCs:12	Organosulfur compounds:12:0.5664	0.5664	12
OS-CS	OS-CS:9|OSCS:1	Osteopathia striata with cranial sclerosis:10:0.7103	0.7103	10
OSC	OSC:9	carcinoma:9:0.0667	0.0667	9
OSC	OSC:11	orthogonal signal correction:11:0.7357	0.7357	11
OSC	OSC:8|Osc:5	osteocalcin:13:0.1000	0.1000	13
OSC	OSC:19	oxidosqualene cyclase:19:0.4618	0.4618	19
OSD	OSD:10	occupational skin disease:10:0.3470	0.3470	10
OSEM	OSEM:5|OS-EM:3	ordered subsets expectation maximisation:8:0.6411	0.6411	8
OSEM	OSEM:8|OS-EM:7	ordered subsets expectation maximization:10:0.7103|ordered-subset expectation-maximization:5:0.1543	0.7103	15
OSE	OSE:26	ovarian surface epithelial:26:0.8251	0.8251	26
OSE	OSE:92	ovarian surface epithelium:92:0.9484	0.9484	92
OSF	OSF:104	oral submucous fibrosis:104:0.9538	0.9538	104
OSF	OSF:18	organ system failure:18:0.8365	0.8365	18
OSH	OSH:23	Occupational Safety and Health:23:0.8715	0.8715	23
OSHA's	OSHA's:9	Occupational Safety and Health Administration's:9:0.6794	0.6794	9
OSHA	OSHA:306	Occupational Safety and Health Administration:295:0.9838|Occupational Safety and Health Administration's:11:0.7357	0.9838	306
OSHPD	OSHPD:14	Office of Statewide Health Planning and Development:14:0.7909	0.7909	14
OSIQ	OSIQ:16	Offer Self-Image Questionnaire:16:0.8165	0.8165	16
OSL	OSL:31	optically stimulated luminescence:31:0.8519	0.8519	31
OSMF	OSMF:17	oral submucous fibrosis:17:0.8270	0.8270	17
OSNs	OSNs:45	Olfactory sensory neurons:45:0.9338	0.9338	45
OSN	OSN:10	olfactory sensory neuron:10:0.7103	0.7103	10
OSN	OSN:7|Osn:3	osteonectin:10:0.2195	0.2195	10
OSOM	OSOM:8|osOM:1	outer stripe of the outer medulla:9:0.6182	0.6182	9
OspC	OspC:40|ospC:5	outer surface protein C:45:0.8335	0.8335	45
OSPT	OSPT:16	prothrombin time:16:0.8165	0.8165	16
O-SP	O-SP:10	O-specific polysaccharide:10:0.7103	0.7103	10
Osp	Osp:40|osp:1	outer surface protein:29:0.9011|outer surface proteins:12:0.7571	0.9011	41
OSSN	OSSN:12	Ocular surface squamous neoplasia:12:0.7571	0.7571	12
OST	OST:24	Oligosaccharyltransferase:24:0.2035	0.2035	24
OSU	OSU:17	Ohio State University:17:0.5760	0.5760	17
OS	OS:10	core oligosaccharide:10:0.1327	0.1327	10
OS	OS:14	left eye:14:0.7909	0.7909	14
OS	OS:9|os:1	Ocimum sanctum:10:0.5856	0.5856	10
OS	OS:16	oligosaccharides:16:0.0047	0.0047	16
os	os:9	oligosyndactylism:9:0.0025	0.0025	9
OS	OS:9	Omenn syndrome:9:0.0713	0.0713	9
OS	OS:13	One-Step:13:0.0038	0.0038	13
OS	OS:28	open splenectomy:28:0.8312	0.8312	28
OS	OS:9	open surgery:9:0.3069	0.3069	9
OS	OS:8	Opitz syndrome:8:0.0532	0.0532	8
OS	OS:9	opposite-sex:9:0.0025	0.0025	9
OS	OS:18	osteogenic sarcoma:18:0.8365	0.8365	18
OS	OS:134	osteosarcoma:115:0.0358|osteosarcomas:19:0.0057	0.0358	134
OS	OS:18|O-S:1	ouabain-sensitive:19:0.0057	0.0057	19
OS	OS:65	outer segments:35:0.9151|outer segment:30:0.9011	0.9151	65
OS	OS:18|os:1	overshoot:19:0.0057	0.0057	19
OS	OS:108	oxidative stress:108:0.8628	0.8628	108
OS	OS:1957|os:2	survival:1959:0.6152	0.6152	1959
OS	OS:15	survival rate:15:0.8045	0.8045	15
OS	OS:11	survival time:11:0.6182	0.6182	11
OS	OS:10	system:10:0.0028	0.0028	10
OTA	OTA:15	Office of Technology Assessment:15:0.8045	0.8045	15
OTA	OTA:11	oxytocin antagonist:11:0.2764	0.2764	11
OTB	OTB:10	Ochratoxin B:10:0.4363	0.4363	10
OTB	OTB:10	operant test battery:10:0.7103	0.7103	10
OTB	OTB:9	Oxitropium bromide:9:0.6794	0.6794	9
OTCD	OTCD:23	ornithine transcarbamylase deficiency:23:0.8715	0.8715	23
OT-CEC	OT-CEC:9|OTCEC:6	open-tubular capillary electrochromatography:15:0.4052	0.4052	15
OTCase	OTCase:15	ornithine carbamoyltransferase:15:0.8045	0.8045	15
OTCase	OTCase:9	ornithine transcarbamoylase:9:0.7103	0.7103	9
OTCase	OTCase:18|OTC-ase:1	Ornithine transcarbamylase:19:0.8449	0.8449	19
OTCs	OTCs:9	open-top chambers:9:0.5470	0.5470	9
OTC	OTC:17	L-2-oxothiazolidine-4-carboxylate:17:0.0138	0.0138	17
OTC	OTC:17	L-2-oxothiazolidine-4-carboxylic acid:17:0.4035	0.4035	17
OTC	OTC:8	open-top chambers:8:0.5006	0.5006	8
OTC	OTC:22|Otc:1	ornithine transcarbamoylase:23:0.8038	0.8038	23
OTC	OTC:275	ornithine transcarbamylase:275:0.9713	0.9713	275
OTC	OTC:464	over-the-counter:428:0.3719|over the counter:36:0.7433	0.7433	464
OTC	OTC:203|otc:2	oxytetracycline:205:0.1760	0.1760	205
otd	otd:37|Otd:1	orthodenticle:38:0.7255	0.7255	38
OTE	OTE:8	oolong tea extract:8:0.6411	0.6411	8
OTFC	OTFC:45	oral transmucosal fentanyl citrate:45:0.9323	0.9323	45
OTF	OTF:13	optical transfer function:13:0.5934	0.5934	13
OTf	OTf:6|OTF:4|oTF:1	ovotransferrin:11:0.2222	0.2222	11
OTM	OTM:14	Olive Tail Moment:14:0.7909	0.7909	14
OTM	OTM:11	orthodontic tooth movement:11:0.7357	0.7357	11
Otp	Otp:4|OTP:1	gene Orthopedia:5:0.2243	0.2243	5
OTRs	OTRs:17	oxytocin receptors:17:0.4035	0.4035	17
OTs	OTs:15	occupational therapists:15:0.8045	0.8045	15
OTS	OTS:14	Octadecyltrichlorosilane:14:0.1193	0.1193	14
OTS	OTS:10	overtraining syndrome:10:0.3867	0.3867	10
OTT	OTT:23	treatment time:23:0.5719	0.5719	23
OTUs	OTUs:56|OTUS:1	operational taxonomic units:57:0.9477	0.9477	57
OTU	OTU:10	operational taxonomic unit:10:0.7103	0.7103	10
otu	otu:14|Otu:1	ovarian tumor:15:0.8045	0.8045	15
OTR	OTR:12	ocular tilt reaction:12:0.7571	0.7571	12
OTR	OTR:11|OTr:1|OT-R:1	OT receptors:13:0.2093	0.2093	13
OTR	OTR:11	oxygen transfer rate:11:0.6182	0.6182	11
OTR	OTR:108|OT-R:3|OTr:2	oxytocin receptor:89:0.6166|oxytocin receptors:24:0.3940	0.6166	113
OT	OT:11	occlusion time:11:0.1760	0.1760	11
OT	OT:11	Ocular torsion:11:0.4728	0.4728	11
OT	OT:9	old tuberculin:9:0.3945	0.3945	9
OT	OT:58	olfactory tubercle:58:0.9486	0.9486	58
OT	OT:15	oligosaccharyl transferase:15:0.8045	0.8045	15
OT	OT:7	operating theatre:7:0.2452	0.2452	7
OT	OT:32	optic tectum:32:0.9072	0.9072	32
OT	OT:35	optic tract:35:0.4220	0.4220	35
OT	OT:12	oral tolerance:12:0.3524	0.3524	12
OT	OT:18	orthostatic tremor:18:0.8365	0.8365	18
OT	OT:23	outflow tract:23:0.2333	0.2333	23
OT	OT:1295|Ot:3	oxytocin:1298:0.6609	0.6609	1298
OUC	OUC:10|O-UC:1	ornithine-urea cycle:11:0.4728	0.4728	11
OUES	OUES:11	oxygen uptake efficiency slope:11:0.7357	0.7357	11
OUR	OUR:57	oxygen uptake rate:57:0.9477	0.9477	57
OVAR	OVAR:51	off-vertical axis rotation:40:0.6808|off-vertical axis rotations:11:0.7357	0.7357	51
OVA	OVA:12	anti-ovalbumin:12:0.0083	0.0083	12
OVA	OVA:1149|Ova:40|ova:15	ovalbumin:1204:0.9063	0.9063	1204
OVCAR-3	OVCAR-3:7	ovarian carcinoma:7:0.2902	0.2902	7
OVCAR-3	OVCAR-3:5	ovarian carcinoma cells:5:0.4422	0.4422	5
OVCA	OVCA:10|OvCa:7|OvCA:2	ovarian carcinoma:19:0.7044	0.7044	19
OVDs	OVDs:14	ophthalmic viscosurgical devices:14:0.7909	0.7909	14
OVD	OVD:19	occlusal vertical dimension:19:0.7658	0.7658	19
OVD	OVD:9	ophthalmic viscosurgical device:9:0.6794	0.6794	9
OVEX	OVEX:18|ovex:8|Ovex:3	ovariectomized:29:0.5490	0.5490	29
OVEX	OVEX:6|Ovex:2|ovex:1	ovariectomy:9:0.1569	0.1569	9
OVLT	OVLT:86|ovlt:1	organum vasculosum laminae terminalis:87:0.9296	0.9296	87
OVLT	OVLT:103	organum vasculosum of the lamina terminalis:103:0.9390	0.9390	103
OVM	OVM:10	ovomucoid:10:0.5625	0.5625	10
OVX	OVX:54|ovx:7|Ovx:3	after ovariectomy:64:0.1344	0.1344	64
OVX	OVX:11|ovx:2|Ovx:1	oophorectomized:14:0.0056	0.0056	14
OVX	OVX:28|ovx:2|OvX:2|Ovx:1	ovariectomised:33:0.0139	0.0139	33
OVX	OVX:1366|ovx:213|Ovx:109|OVx:4|OvX:4|OV-X:2	ovariectomized:1698:0.7384	0.7384	1698
OVX	OVX:12|ovx:2	ovariectomized rats:14:0.4367	0.4367	14
OV	OV:5	functional overload:5:0.1132	0.1132	5
OV	OV:4	liver fluke Opisthorchis viverrini:4:0.5290	0.5290	4
Ov	Ov:6|OV:1	Nucleus ovoidalis:7:0.3463	0.3463	7
OV	OV:19	orf virus:19:0.7658	0.7658	19
OV	OV:15|Ov:13|ov:3	ovalbumin:31:0.1293	0.1293	31
OV	OV:16	ovariectomized:16:0.0647	0.0647	16
ov	ov:6|Ov:4	ovine:10:0.0388	0.0388	10
OWAS	OWAS:7	Ovako Working posture Analysing System:7:0.5926	0.5926	7
OWAS	OWAS:6	Ovako Working posture Analysis System:6:0.5290	0.5290	6
OWLD	OWLD:14	Ovine white-liver disease:14:0.7909	0.7909	14
OWT	OWT:8	open window thoracostomy:8:0.6411	0.6411	8
OW	OW:13|Ow:2	overweight:15:0.2414	0.2414	15
OX-1	OX-1:4|OX1:2	leukocyte common antigen:6:0.2827	0.2827	6
OX-42	OX-42:6|OX42:4	complement receptor type 3:10:0.7103	0.7103	10
OX-6	OX6:3|OX-6:3	class II antigen:6:0.2827	0.2827	6
OX7	OX7:12|OX-7:7	antibody:19:0.7200	0.7200	19
OXA	OXA:9|Oxa:2	oxaliplatin:11:0.1031	0.1031	11
OXA	OXA:11	oxazolone:11:0.1134	0.1134	11
OXA	OXA:8	oxolinic acid:8:0.1895	0.1895	8
OXC	OXC:82	oxcarbazepine:82:0.8182	0.8182	82
OXM	OXM:19|Oxm:1	Oxyntomodulin:20:0.7917	0.7917	20
OXPHOS	OXPHOS:127|OxPhos:6|Oxphos:2|oxphos:2|ox-phos:1|OX-PHOS:1|Ox-phos:1	oxidative phosphorylation:140:0.9547	0.9547	140
oxy-Hb	oxy-Hb:9|OxyHb:4|oxyHb:3|Oxy-Hb:1	Oxygenated hemoglobin:17:0.7539	0.7539	17
oxyHb	oxyHb:8|Oxy-Hb:2|oxy-Hb:1	oxyhaemoglobin:11:0.0840	0.0840	11
oxyHb	oxyHb:28|OxyHb:27|Oxy-Hb:10|oxy-Hb:2|OXYHb:1	oxyhemoglobin:68:0.5630	0.5630	68
OXY	OXY:9|oxy:1	oxymetazoline:10:0.0479	0.0479	10
OYE	OYE:26	old yellow enzyme:26:0.8861	0.8861	26
OYL	OYL:3	ossification of yellow ligament:3:0.6386	0.6386	3
OZR	OZR:35	obese Zucker rats:23:0.8715|obese Zucker rat:12:0.7571	0.8715	35
oatp1	oatp1:4|oatp-1:2|Oatp1:2	organic anion transporting polypeptide:8:0.6411	0.6411	8
Oatp1	Oatp1:6|oatp1:6	organic anion transporting polypeptide 1:12:0.7571	0.7571	12
OCT1	OCT1:5|Oct1:3|OCT-1:1	organic cation transporter 1:9:0.6794	0.6794	9
Odh	Odh:8|ODH:6	dehydrogenase:14:0.3824	0.3824	14
Oe1	Oe1:9|Oe-1:1|OE1:1	oestrone:11:0.7143	0.7143	11
OE2	OE2:18|Oe2:11|Oe-2:1	oestradiol:30:0.4028	0.4028	30
OE2	OE2:10|Oe2:6	oestradiol-17 beta:16:0.6024	0.6024	16
Oe2	Oe2:7|OE2:2	oestradiol-17beta:9:0.1111	0.1111	9
OeB	OeB:12|OEB:3	oestradiol benzoate:15:0.8045	0.8045	15
omlA	omlA:5|OmlA:4	outer membrane lipoprotein:9:0.6794	0.6794	9
OMP2	OMP2:6|Omp2:5	outer membrane protein 2:11:0.7357	0.7357	11
OND	OND:18|Ond:5	Ondansetron:23:0.0764	0.0764	23
OND	OND:14	other neurological disease:14:0.6173	0.6173	14
OND	OND:65	patients with other neurological diseases:65:0.3811	0.3811	65
OND	OND:8	patients with other neurological disorders:8:0.3463	0.3463	8
Op18	Op18:19|op18:1	oncoprotein 18:20:0.8525	0.8525	20
OpMNPV	OpMNPV:6	multicapsid nuclear polyhedrosis virus of Orgyia pseudotsugata:6:0.3728	0.3728	6
OpMNPV	OpMNPV:9	Orgyia pseudotsugata MNPV:9:0.5470	0.5470	9
OpMNPV	OpMNPV:14	Orgyia pseudotsugata multicapsid nuclear polyhedrosis virus:14:0.7909	0.7909	14
OpMNPV	OpMNPV:6	Orgyia pseudotsugata multicapsid nucleopolyhedrovirus:6:0.5926	0.5926	6
OpMNPV	OpMNPV:14	Orgyia pseudotsugata multinucleocapsid nuclear polyhedrosis virus:14:0.7909	0.7909	14
Opn4	Opn4:9|opn4:1	Melanopsin:10:0.8889	0.8889	10
OprF	OprF:1	outer membrane is protein F:1:0.5926	0.5926	1
ORE	ORE:20	response element:20:0.7044	0.7044	20
Orn	Orn:7|ORN:3	L-ornithine:10:0.0469	0.0469	10
ORN	ORN:35	olfactory receptor neuron:25:0.8816|olfactory receptor neurons:10:0.7103	0.8816	35
Orn	Orn:42|ORN:10|orn:1	ornithine:53:0.2708	0.2708	53
ORN	ORN:65	osteoradionecrosis:65:0.3333	0.3333	65
OsO4	OsO4:35|OSO4:1	osmium tetroxide:36:0.9174	0.9174	36
OSM	OSM:23	ovine submaxillary mucin:23:0.8715	0.8715	23
Osm	Osm:7|OSM:1	plasma osmolality:8:0.0726	0.0726	8
OspB	OspB:8	outer surface protein B:8:0.6411	0.6411	8
OU	OU:11	observation unit:11:0.7357	0.7357	11
OU	OU:7|O-U:2	Ornstein-Uhlenbeck:9:0.1212	0.1212	9
OvHV-2	OvHV-2:14	ovine herpesvirus 2:14:0.7909	0.7909	14
OvLV	OvLV:33|OvLv:1	ovine lentivirus:34:0.9126	0.9126	34
oxLDL	oxLDL:210|ox-LDL:126|Ox-LDL:112|OxLDL:86|OX-LDL:19	oxidized low-density lipoprotein:276:0.8264|oxidized low density lipoprotein:182:0.7753|oxidized low-density lipoproteins:56:0.7923|Oxidized low density lipoproteins:39:0.6077	0.8264	553
oxPC	oxPC:4|OxPC:3|ox-PC:1|Ox-PC:1	oxidized phosphatidylcholine:9:0.6794	0.6794	9
OXO	OXO:14|Oxo:13|oxo:1	oxotremorine:28:0.2872	0.2872	28
Oxo	Oxo:26	potassium oxonate:26:0.8861	0.8861	26
OX	OX:23	optic chiasm:23:0.8715	0.8715	23
OX	OX:11|Ox:2|ox:1	ovariectomized:14:0.0419	0.0419	14
Ox	Ox:23|OX:2|ox:1	oxalate:26:0.0806	0.0806	26
Ox	Ox:6|OX:5	Oxandrolone:11:0.0323	0.0323	11
OX	OX:19|Ox:3	oxazepam:22:0.0677	0.0677	22
OX	OX:14|Ox:10|ox:1	oxazolone:25:0.0774	0.0774	25
Ox	Ox:6|OX:2|ox:1	oxidation:9:0.0258	0.0258	9
Ox	Ox:7|ox:5|OX:1	oxidized:13:0.0387	0.0387	13
OX	OX:17|Ox:3	oxytocin:20:0.0613	0.0613	20
P&I	P&I:23	pneumonia and influenza:23:0.8715	0.8715	23
P&S	P&S:18	primary and secondary:18:0.6903	0.6903	18
P&T	P&T:47	pharmacy and therapeutics:47:0.9366	0.9366	47
P(0.1)	P(0.1):9	occlusion pressure:9:0.6794	0.6794	9
P(4)	P(4):115	progesterone:115:0.9194	0.9194	115
P(c)	P(c):6|p(c):2|P(C):1	pressure:9:0.2759	0.2759	9
P(a)	P(a):8|P(A):2	pressure:10:0.2812	0.2812	10
P(alb)	P(alb):11	albumin permeability:11:0.7357	0.7357	11
P(app)	P(app):21	apparent permeability:21:0.5435	0.5435	21
P(app)	P(app):24|P(App):1	Apparent permeability coefficients:13:0.4849|apparent permeability coefficient:12:0.6460	0.6460	25
P(eff)	P(eff):9	permeability:9:0.5333	0.5333	9
P(f)	P(f):22	osmotic water permeability:22:0.5327	0.5327	22
P(i)	P(i):155	inorganic phosphate:155:0.6738	0.6738	155
P(i)	P(i):7	inorganic phosphorus:7:0.3524	0.3524	7
P(i)	P(i):12	orthophosphate:12:0.0410	0.0410	12
P(if)	P(if):11|P(IF):2|p(if):1	interstitial fluid pressure:14:0.7909	0.7909	14
P(o)	P(o):6	isometric tetanic force:6:0.2827	0.2827	6
P(o)	P(o):99|P(O):3|p(o):1	open probability:103:0.8671	0.8671	103
P(osm)	P(osm):12	plasma osmolality:12:0.7571	0.7571	12
P(PA)	P(PA):3|P(pa):3	pulmonary arterial pressure:6:0.5290	0.5290	6
P-loop	P-loop:7	phosphate binding loop:7:0.3524	0.3524	7
p.f.u.	p.f.u.:19|P.F.U.:2	plaque-forming units:11:0.2582|plaque forming units:10:0.7103	0.7103	21
P.g.	P.g.:11	Porphyromonas gingivalis:11:0.3829	0.3829	11
P.II	P.II:13	protein II:13:0.6701	0.6701	13
p.p.	p.p.:25	post partum:25:0.8816	0.8816	25
P.R.A.	P.R.A.:13|p.r.a.:1	plasma renin activity:14:0.6911	0.6911	14
P.S.	P.S.:12	performance status:12:0.6460	0.6460	12
p.v.	p.v.:7|P.V.:1	portal vein:8:0.5006	0.5006	8
p.v.	p.v.:16|P.V.:1	portal venous:17:0.8270	0.8270	17
P/L	P/L:9	powder/liquid:9:0.1667	0.1667	9
P/Q	P/Q:10	pulmonary vascular pressure-cardiac index:10:0.7103	0.7103	10
P/S	P/S:20	fatty acids:20:0.8525	0.8525	20
P/S	P/S:7	fatty acid ratio:7:0.2902	0.2902	7
P/S	P/S:19	polyunsaturated/saturated:19:0.1098	0.1098	19
P/S	P/S:9	polyunsaturated/saturated fatty acid:9:0.1267	0.1267	9
P/S	P/S:6	polyunsaturated to saturated fat:6:0.5290	0.5290	6
P/S	P/S:14	polyunsaturated to saturated fatty acid:14:0.7909	0.7909	14
P/T	P/T:14	Piperacillin/tazobactam:14:0.3824	0.3824	14
P/V	P/V:27	pressure/volume:18:0.3333|pressure-volume:9:0.1569	0.3333	27
P0.1	P0.1:7	after the onset of inspiration:7:0.6460	0.6460	7
P0.1	P0.1:88|p0.1:1	mouth occlusion pressure:89:0.4847	0.4847	89
P0.1	P0.1:10|p0.1:1	respiratory drive:11:0.2764	0.2764	11
P0	P0:39|P-0:5	day of birth:44:0.3169	0.3169	44
P0	P0:11	isometric force:11:0.2422	0.2422	11
P0	P0:9	isometric tension:9:0.0898	0.0898	9
P0	P0:5	major myelin glycoprotein:5:0.2818	0.2818	5
P0	P0:18|P-0:1	newborn:19:0.0331	0.0331	19
P0	P0:74|P-0:1	postnatal day 0:75:0.8819	0.8819	75
P0	P0:13|p0:1	pressure:14:0.0239	0.0239	14
P0	P0:64	protein zero:64:0.7656	0.7656	64
P0	P0:9	tetanic tension:9:0.0898	0.0898	9
P100	P100:14|p100:1	occlusion pressure:15:0.7096	0.7096	15
P100	P100:6	positive component:6:0.1838	0.1838	6
P11	P11:8	postnatal day 11:8:0.5006	0.5006	8
P13K	P13K:11|P13-K:5	phosphatidylinositol 3-kinase:16:0.6577	0.6577	16
P17	P17:10	postnatal day 17:10:0.4363	0.4363	10
P1CP	P1CP:6	Carboxy-terminal propeptide of type 1 procollagen:6:0.2827	0.2827	6
P1CP	P1CP:8	carboxyterminal propeptide:8:0.3463	0.3463	8
P1I	P1I:14|P1-I:1	Plaque Index:15:0.8045	0.8045	15
P1	P1:12	day of birth:12:0.2414	0.2414	12
P1	P1:13|P-1:1	first:14:0.0093	0.0093	14
P1	P1:6|P-1:1	first peak:7:0.0592	0.0592	7
P1	P1:5	first phalanx:5:0.0736	0.0736	5
P1	P1:10	first positive peak:10:0.3145	0.3145	10
P1	P1:9	first postnatal day:9:0.5470	0.5470	9
P1	P1:11	inorganic phosphate:11:0.4728	0.4728	11
P1	P1:8|P-1:2	peptide:10:0.0065	0.0065	10
P1	P1:14	positive:14:0.0101	0.0101	14
P1	P1:10	positive component:10:0.3145	0.3145	10
P1	P1:18	positive wave:18:0.4852	0.4852	18
P1	P1:146|p1:1	postnatal day 1:147:0.9123	0.9123	147
P1	P1:57|p1:3|P-1:1	promoter:61:0.0431	0.0431	61
P1	P1:27	protein:27:0.0187	0.0187	27
p20	p20:6	20-kDa protein:6:0.1010	0.1010	6
P20	P20:19|P-20:2	postnatal day 20:21:0.7865	0.7865	21
p21	p21:6	cyclin-dependent kinase inhibitor p21WAF1/Cip1:6:0.3728	0.3728	6
p21	p21:7	inhibitor p21(WAF1/Cip1):7:0.0726	0.0726	7
p21	p21:13	p21(Cip1/WAF1):13:0.0234	0.0234	13
p21	p21:9	p21CIP1/WAF1:9:0.0156	0.0156	9
P21	P21:33|P-21:1	postnatal day 21:34:0.7587	0.7587	34
p21	p21:9|P21:1	proteins:10:0.0175	0.0175	10
p21	p21:8|P21:1	protein product:9:0.0866	0.0866	9
p21	p21:10	ras gene product:10:0.3213	0.3213	10
P2S	P2S:10	pralidoxime mesylate:10:0.7103	0.7103	10
P2X	P2X:8|P2x:1	ionotropic:9:0.2286	0.2286	9
P2	P2:9	crude mitochondrial:9:0.3069	0.3069	9
P2	P2:5	crude mitochondrial pellet:5:0.2818	0.2818	5
P2	P2:20	crude synaptosomal:20:0.4037	0.4037	20
P2	P2:14|P-2:2	Crude synaptosomal fractions:10:0.4363|crude synaptosomal fraction:6:0.1838	0.4363	16
P2	P2:9	nucleotide:9:0.0068	0.0068	9
P2	P2:11|P-2:2	peptide:13:0.0102	0.0102	13
P2	P2:7	positive component:7:0.1329	0.1329	7
P2	P2:7	positive peak:7:0.1850	0.1850	7
P2	P2:10	positive wave:10:0.4232	0.4232	10
P2	P2:9	positivity:9:0.0068	0.0068	9
P2	P2:78	postnatal day 2:78:0.8564	0.8564	78
P2	P2:56|p2:2	promoter:58:0.0485	0.0485	58
P2	P2:14|p2:1|P-2:1	protein:16:0.0128	0.0128	16
P2	P2:9	Purinergic:9:0.0068	0.0068	9
P300	P300:70	event-related potentials:42:0.4947|event-related potential:28:0.4539	0.4947	70
P3	P3:7	late positive component:7:0.3524	0.3524	7
P3	P3:12	microsomal:12:0.0162	0.0162	12
P3	P3:5	microsomal fraction:5:0.0612	0.0612	5
P3	P3:68	postnatal day 3:68:0.8555	0.8555	68
P3	P3:13|p3:1	protein:14:0.0191	0.0191	14
P4.2	P4.2:12	protein 4.2:12:0.6460	0.6460	12
P-407	P-407:12|P407:7	Poloxamer 407:19:0.8449	0.8449	19
P-448	P-448:9	cytochrome P-450:9:0.6794	0.6794	9
P450R	P450R:8	P450 oxidoreductase:8:0.2987	0.2987	8
P450R	P450R:16	P450 reductase:16:0.7539	0.7539	16
P-450s	P-450s:7	cytochromes P-450:7:0.3524	0.3524	7
P450s	P450s:54|p450s:3	cytochromes P450:57:0.8920	0.8920	57
P450s	P450s:19|p450s:1	cytochrome P450 monooxygenases:20:0.8525	0.8525	20
P450s	P450s:26|p450s:2	cytochrome P450s:28:0.8941	0.8941	28
P-450	P-450:234|P450:35	cytochrome P-450:269:0.9083	0.9083	269
P450	P450:628|p450:20	cytochrome P450:648:0.8970	0.8970	648
P450	P450:6	cytochrome P450 monooxygenase:6:0.5290	0.5290	6
P450	P450:11	cytochrome P450s:11:0.6182	0.6182	11
P-450	P-450:96|P450:17	NADPH-cytochrome c:86:0.4894|NADPH cytochrome c:27:0.6111	0.6111	113
P47	P47:4	Rapid phosphorylation of a platelet protein of Mr 47,000:4:0.4422	0.4422	4
P4H	P4H:10|P4-H:7	prolyl 4-hydroxylase:17:0.7407	0.7407	17
P4S	P4S:15	piperidine-4-sulphonic acid:15:0.5348	0.5348	15
P-4	P-4:19|P4:1	propiverine hydrochloride:20:0.8525	0.8525	20
P50	P50:9|p50:1	half-saturation pressure:10:0.2126	0.2126	10
P50	P50:7	half-saturation pressure of hemoglobin:7:0.5926	0.5926	7
P50	P50:3|p50:1	hemoglobin is 50% saturated:4:0.1618	0.1618	4
p50	p50:25	NF-kappaB1:25:0.0573	0.0573	25
P50	P50:16|p50:2|P-50:1	oxygen affinity:19:0.4211	0.4211	19
P50	P50:5	postnatal day 50:5:0.4422	0.4422	5
p56	p56:6	56-kDa protein:6:0.1320	0.1320	6
P5CS	P5CS:8	delta 1-pyrroline-5-carboxylate synthetase:8:0.6411	0.6411	8
P5C	P5C:6	delta 1-pyrroline-5-carboxylate:6:0.2243	0.2243	6
P5C	P5C:19|P-5-C:2	pyrroline-5-carboxylate:21:0.4082	0.4082	21
P5N	P5N:52	pyrimidine 5'-nucleotidase:52:0.9427	0.9427	52
P600	P600:13	positivity:13:0.4615	0.4615	13
p65	p65:9	65-kDa protein:9:0.1267	0.1267	9
P6	P6:9|p6:6	protein:15:0.0791	0.0791	15
P7	P7:114|p7:2	postnatal day 7:116:0.8715	0.8715	116
P815	P815:9	mastocytoma cells:9:0.1809	0.1809	9
PA-	PA-:9	pyridylaminated:9:0.2000	0.2000	9
PA-	PA-:23	pyridylamino:23:0.5500	0.5500	23
PA/IVS	PA/IVS:8	pulmonary atresia with intact ventricular septum:8:0.7753	0.7753	8
PA6	PA6:11	MC3T3-G2/PA6:11:0.4348	0.4348	11
PAAF	PAAF:9	pancreatitis-associated ascitic fluid:9:0.5470	0.5470	9
PAAG	PAAG:13|Paag:1	polyacrylamide gel:14:0.4367	0.4367	14
PAA	PAA:10	particle agglutination assay:10:0.7103	0.7103	10
PAA	PAA:5	period amplitude analysis:5:0.4422	0.4422	5
PAA	PAA:13	phosphonoacetate:13:0.0158	0.0158	13
PAA	PAA:48	plasminogen activator activity:48:0.9379	0.9379	48
PAA	PAA:34	polyacrylamide:34:0.0434	0.0434	34
PAA	PAA:15	Popliteal artery aneurysms:8:0.4102|popliteal artery aneurysm:7:0.1641	0.4102	15
PAA	PAA:7	Pulmonary artery aneurysm:7:0.1641	0.1641	7
PABA	PABA:9|pABA:3	p-Aminobenzoate:12:0.0284	0.0284	12
PABA	PABA:197|pABA:11|p-ABA:1	p-aminobenzoic acid:209:0.5502	0.5502	209
PABA	PABA:96|pABA:8	para-aminobenzoic acid:104:0.2438	0.2438	104
PABD	PABD:27	preoperative autologous blood donation:27:0.7066	0.7066	27
PABPs	PABPs:10	poly(A)-binding proteins:10:0.5856	0.5856	10
PABP	PABP:95	poly(A)-binding protein:71:0.5407|poly(A) binding protein:24:0.5848	0.5848	95
pAbs	pAbs:30|PAbs:22|Pabs:2	polyclonal antibodies:54:0.9132	0.9132	54
Pab	Pab:13	abdominal pressure:13:0.6701	0.6701	13
PAB	PAB:14	bacteria:14:0.0364	0.0364	14
PAb	pAb:7|PAb:7|Pab:1|PAB:1	polyclonal:16:0.0420	0.0420	16
pAb	pAb:40|PAb:33|Pab:6|PAB:2|pab:2|pAB:1	polyclonal antibody:55:0.7858|polyclonal antibodies:29:0.7237	0.7858	84
PAB	PAB:47	pulmonary artery banding:47:0.9366	0.9366	47
PAC1	PAC1:5	PACAP type 1:5:0.4438	0.4438	5
PACAP	PACAP:110	Pituitary Adenylate Cyclase Activating Peptide:110:0.9559	0.9559	110
PACAP	PACAP:1008|PA-CAP:3|Pacap:1	Pituitary adenylate cyclase-activating polypeptide:653:0.9790|Pituitary adenylate cyclase activating polypeptide:359:0.9863	0.9863	1012
PACIA	PACIA:19	Particle counting immunoassay:19:0.7658	0.7658	19
PACl	PACl:11|PACL:1	polyaluminum chloride:12:0.4557	0.4557	12
PACNS	PACNS:17	Primary angiitis of the central nervous system:17:0.6748	0.6748	17
PACNS	PACNS:8	Primary angiitis of the CNS:8:0.6794	0.6794	8
PAcP	PAcP:29|PACP:2	prostatic acid phosphatase:31:0.8519	0.8519	31
PACQLQ	PACQLQ:7	Asthma Caregiver's Quality of Life Questionnaire:7:0.5926	0.5926	7
PACS	PACS:447	Picture Archiving and Communication System:239:0.9627|Picture Archiving and Communication Systems:159:0.9615|Picture Archiving and Communications Systems:49:0.9046	0.9627	447
PACs	PACs:50	polycyclic aromatic compounds:50:0.8520	0.8520	50
PACs	PACs:12	premature atrial contractions:12:0.7571	0.7571	12
PACs	PACs:8	prostatic adenocarcinomas:8:0.3463	0.3463	8
PACs	PACs:15	pulmonary artery catheters:15:0.8045	0.8045	15
PACT	PACT:13	prescribing analysis and cost:13:0.7753	0.7753	13
PACT	PACT:3	Program for Assertive Community Treatment:3:0.5290	0.5290	3
PACTG	PACTG:21	Pediatric AIDS Clinical Trials Group:21:0.6040	0.6040	21
PACU	PACU:204	postanesthesia care unit:204:0.5958	0.5958	204
Pac	Pac:9	Endothelial permeability:9:0.5470	0.5470	9
PAC	PAC:11|pac:4	paclitaxel:15:0.0103	0.0103	15
PAC	PAC:11|pac:2	penicillin acylase:13:0.4849	0.4849	13
PAC	PAC:11	perennial allergic conjunctivitis:11:0.7357	0.7357	11
PAC	PAC:7	Peritoneal adherent cells:7:0.4438	0.4438	7
PAC	PAC:13	perturbed angular correlation:13:0.6701	0.6701	13
PAC	PAC:6	perturbed angular correlation of gamma-rays:6:0.5290	0.5290	6
PAC	PAC:17	plasma aldosterone:17:0.2074	0.2074	17
PAC	PAC:9	Plasma Arc Curing:9:0.6794	0.6794	9
PAC	PAC:8	polyaluminum chloride:8:0.1895	0.1895	8
PAC	PAC:24	polycyclic aromatic compounds:24:0.7151	0.7151	24
PAC	PAC:10	Port-a-Cath:10:0.0074	0.0074	10
PAC	PAC:13	post-acute care:13:0.4444	0.4444	13
PAC	PAC:48	powdered activated carbon:48:0.7595	0.7595	48
PAC	PAC:10	premature atrial contraction:10:0.7103	0.7103	10
PAC	PAC:12	primary auditory cortex:12:0.7571	0.7571	12
PAC	PAC:10|PAc:3	prostatic adenocarcinoma:13:0.1704	0.1704	13
PAC	PAC:99	pulmonary artery catheter:92:0.9479|Pulmonary artery catheters:7:0.5926	0.9479	99
PAC	PAC:11	pulmonary artery catheterization:11:0.7357	0.7357	11
PAC	PAC:8	pulmonary artery constriction:8:0.6411	0.6411	8
PAc	PAc:26	surface protein antigen:26:0.6645	0.6645	26
PADAM	PADAM:9	Partial Androgen Deficiency of the Aging Male:9:0.7753	0.7753	9
PADL	PADL:12	Physical Activities of Daily Living:12:0.6460	0.6460	12
pADPr	pADPr:6|pADPR:3|PADPR:1	poly(ADP-ribose):10:0.5294	0.5294	10
PADP	PADP:17|PAdP:1	pulmonary artery diastolic pressure:18:0.8365	0.8365	18
PADs	PADs:9	primary afferent depolarizations:9:0.6794	0.6794	9
PAD	PAD:26	Peptidylarginine deiminase:26:0.8251	0.8251	26
PAD	PAD:18	percutaneous abscess drainage:18:0.6903	0.6903	18
PAD	PAD:492	peripheral arterial disease:492:0.9902	0.9902	492
PAD	PAD:12	preoperative autologous blood donation:12:0.6460	0.6460	12
PAD	PAD:21	preoperative autologous donation:21:0.8594	0.8594	21
PAD	PAD:8	primary affective disorders:8:0.5006	0.5006	8
PAD	PAD:80	primary afferent depolarization:80:0.9631	0.9631	80
PAD	PAD:18	public access defibrillation:18:0.8365	0.8365	18
PAD	PAD:6|PAd:1	Pulmonary artery diastolic pressure:7:0.5926	0.5926	7
PAD	PAD:7	pulsatile assist device:7:0.5926	0.5926	7
PAECs	PAECs:29	pulmonary artery endothelial cells:29:0.8422	0.8422	29
PAEC	PAEC:72	porcine aortic endothelial cells:72:0.7330	0.7330	72
PAEC	PAEC:83	pulmonary artery endothelial cells:76:0.9180|pulmonary artery endothelial cell:7:0.5926	0.9180	83
PAEE	PAEE:20	physical activity energy expenditure:20:0.8525	0.8525	20
PAEP	PAEP:6|pAEP:2|P-AEP:1	Appropriateness Evaluation Protocol:9:0.5470	0.5470	9
PAEs	PAEs:16	Phthalic acid esters:16:0.6024	0.6024	16
PAES	PAES:27	Popliteal artery entrapment syndrome:27:0.8903	0.8903	27
PAEs	PAEs:36	postantibiotic effects:36:0.6738	0.6738	36
PAE	PAE:18	air embolism:18:0.6903	0.6903	18
PAE	PAE:31	porcine aortic endothelial:31:0.7458	0.7458	31
PAE	PAE:179	postantibiotic effect:171:0.5686|postantibiotic effects:8:0.2987	0.5686	179
PAF-1	PAF-1:8	peroxisome assembly factor-1:8:0.5006	0.5006	8
PAF-AH	PAF-AH:40|PAFAH:2	PAF-acetylhydrolase:42:0.2158	0.2158	42
PAF-AH	PAF-AH:81|PAFAH:2	platelet-activating factor acetylhydrolase:68:0.7431|Platelet-activating factor-acetylhydrolase:9:0.2757|Platelet activating factor-acetylhydrolase:6:0.5290	0.7431	83
PAFE	PAFE:14	post-antifungal effect:14:0.2081	0.2081	14
PAFE	PAFE:21	postantifungal effect:21:0.4041	0.4041	21
PAF-R	PAF-R:22|PAFR:20|PAFr:3|PAF-r:1|paf-R:1	PAF receptor:38:0.3925|PAF receptors:9:0.3455	0.3925	47
PAFR	PAFR:16|PAF-R:7|PAFr:6	platelet-activating factor receptor:29:0.7237	0.7237	29
paf	paf:24|PAF:22|Paf:1	paf-acether:47:0.0087	0.0087	47
PAF	PAF:19|pAF:1	paroxysmal AF:20:0.6680	0.6680	20
PAF	PAF:178|Paf:8|PAf:6|paf:1	paroxysmal atrial fibrillation:193:0.9140	0.9140	193
PAF	PAF:4604|Paf:34|paf:4	platelet-activating factor:3269:0.6768|platelet activating factor:1355:0.9780|platelet-activating-factor:18:0.0032	0.9780	4642
PAF	PAF:20	population attributable fraction:20:0.8525	0.8525	20
PAF	PAF:6	posterior auditory field:6:0.2827	0.2827	6
PAF	PAF:22	Premenstrual Assessment Form:22:0.7400	0.7400	22
PAF	PAF:52	pure autonomic failure:52:0.7255	0.7255	52
PAGE	PAGE:14	polyacrylamide gels:14:0.5111	0.5111	14
PAGE	PAGE:992	polyacrylamide gel electrophoresis:992:0.7586	0.7586	992
PAGE	PAGE:12	polyacrylamide gel electrophoretic:12:0.6460	0.6460	12
PAGIEF	PAGIEF:14|PAG-IEF:4	polyacrylamide gel isoelectric focusing:18:0.8365	0.8365	18
PAGs	PAGs:18	pregnancy-associated glycoproteins:18:0.5228	0.5228	18
PAG	PAG:9	midbrain:9:0.0057	0.0057	9
PAG	PAG:9	midbrain periaqueductal grey region:9:0.3945	0.3945	9
PAG	PAG:653	periaqueductal gray:653:0.9419	0.9419	653
PAG	PAG:12	periaqueductal gray area:12:0.7571	0.7571	12
PAG	PAG:160	periaqueductal gray matter:160:0.9266	0.9266	160
PAG	PAG:14	periaqueductal gray region:14:0.7909	0.7909	14
PAG	PAG:122	periaqueductal grey:122:0.8955	0.8955	122
PAG	PAG:6	periaqueductal grey area:6:0.5290	0.5290	6
PAG	PAG:49	periaqueductal grey matter:49:0.8753	0.8753	49
PAG	PAG:43	Phosphate-activated glutaminase:29:0.5058|Phosphate activated glutaminase:14:0.7909	0.7909	43
PAG	PAG:6|PAg:5	platelet aggregation:11:0.6182	0.6182	11
PAG	PAG:36	polyacrylamide gel:36:0.8003	0.8003	36
PAG	PAG:24	Pregnancy-associated glycoproteins:12:0.6182|pregnancy-associated glycoprotein:12:0.2868	0.6182	24
PAg	PAg:5|pag:3	protective antigen:8:0.2619	0.2619	8
PAG	PAG:13|pAg:10	protein A-gold:23:0.8715	0.8715	23
PAHO	PAHO:76	Pan American Health Organization:76:0.9378	0.9378	76
PAHs	PAHs:1875|PAHS:4|PaHs:2|pahs:1|Pahs:1	polycyclic aromatic hydrocarbons:1883:0.9263	0.9263	1883
PAH	PAH:1	inulin or para-aminohippurate:1:0.0522	0.0522	1
PAH	PAH:5	p-amino hippurate:5:0.0612	0.0612	5
PAH	PAH:395	p-aminohippurate:395:0.1366	0.1366	395
PAH	PAH:121	p-aminohippuric acid:121:0.4690	0.4690	121
PAH	PAH:5	para-amino hippurate:5:0.0612	0.0612	5
PAH	PAH:57	Para-aminohippuric acid:57:0.1904	0.1904	57
PAH	PAH:20	paraaminohippurate:20:0.0066	0.0066	20
PAH	PAH:338|Pah:2	phenylalanine hydroxylase:340:0.9859	0.9859	340
PAH	PAH:13	phenylalanine hydroxylase gene:13:0.7753	0.7753	13
PAH	PAH:1140	polycyclic aromatic hydrocarbons:713:0.9045|polycyclic aromatic hydrocarbon:427:0.9110	0.9110	1140
PAH	PAH:6	postatrophic hyperplasia:6:0.1320	0.1320	6
PAH	PAH:21	predicted adult height:21:0.5721	0.5721	21
PAH	PAH:5	primary adrenal hyperplasia:5:0.4422	0.4422	5
PAH	PAH:201	pulmonary arterial hypertension:201:0.9479	0.9479	201
PAH	PAH:31	pulmonary artery hypertension:31:0.9043	0.9043	31
PAI-Fx	PAI-Fx:9	plasminogen activator inhibitor activity:9:0.6794	0.6794	9
PAI-1	PAI-1:9	inhibitor of plasminogen activator:9:0.4728	0.4728	9
PAI-1	PAI-1:15|pAI-1:1	plasminogen activator-inhibitor:16:0.8165	0.8165	16
PAI-1	PAI-1:1879|PAI1:10|Pai-1:1	plasminogen activator inhibitor-1:1498:0.9866|plasminogen activator inhibitor 1:381:0.9755|Plasminogen-activator-inhibitor-1:11:0.0028	0.9866	1890
PAI-1	PAI-1:6	plasminogen activator inhibitor activity:6:0.5290	0.5290	6
PAI-1	PAI-1:5	plasminogen activator inhibitor antigen:5:0.4422	0.4422	5
PAI-1	PAI-1:679|PAI1:4	plasminogen activator inhibitor type 1:455:0.9798|plasminogen activator inhibitor type-1:228:0.9721	0.9798	683
PAI-1	PAI-1:16|PAI1:1	plasminogen activator inhibitor type I:17:0.8365	0.8365	17
PAI-1	PAI-1:108	type 1 plasminogen activator inhibitor:108:0.9723	0.9723	108
PAI-2	PAI-2:18	plasminogen activator inhibitor:18:0.8365	0.8365	18
PAI-2	PAI-2:54|PAI2:3	plasminogen activator inhibitor-2:57:0.9477	0.9477	57
PAI-2	PAI-2:80|PAI2:3	plasminogen activator inhibitor type 2:62:0.9526|plasminogen activator inhibitor type-2:21:0.7955	0.9526	83
PAIVS	PAIVS:8|PA-IVS:6	pulmonary atresia with intact ventricular septum:14:0.8657	0.8657	14
PAIgG	PAIgG:135|PA-IgG:23|paIgG:1|Pa-IgG:1|PaIgG:1|PAIGG:1	platelet-associated IgG:128:0.7041|platelet associated IgG:34:0.9126	0.9126	162
PAIgG	PAIgG:16|PA-IgG:5	platelet-associated immunoglobulin G:21:0.7291	0.7291	21
PAIS	PAIS:10	Partial androgen insensitivity syndrome:10:0.7103	0.7103	10
PAIs	PAIs:25|Pais:2|pais:1	pathogenicity islands:28:0.8941	0.8941	28
PAIs	PAIs:24	plasminogen activator inhibitors:24:0.8768	0.8768	24
PAIS	PAIS:30	Psychosocial Adjustment to Illness Scale:30:0.7970	0.7970	30
PAI	PAI:56|PaI:1	cag pathogenicity island:57:0.4984	0.4984	57
PAI	PAI:10	percutaneous acetic acid injection:10:0.7103	0.7103	10
PAI	PAI:7	Percutaneous alcohol injection:7:0.5926	0.5926	7
PAI	PAI:12	periapical index:12:0.0713	0.0713	12
PAI	PAI:17	Personality Assessment Inventory:17:0.8270	0.8270	17
PAI	PAI:21	Physical Activity Index:21:0.7291	0.7291	21
PAI	PAI:10|PA-I:1	plasminogen activator:11:0.7357	0.7357	11
PAI	PAI:374|PA-I:5|PAi:3	plasminogen activator inhibitor:361:0.9595|plasminogen activator inhibitors:21:0.8594	0.9595	382
PAI	PAI:10	plasminogen activator inhibitor-1:10:0.7103	0.7103	10
PAI	PAI:14	plasminogen activator inhibitor activity:14:0.7909	0.7909	14
PAI	PAI:6	primary adrenal insufficiency:6:0.5290	0.5290	6
PAK2	PAK2:11|PAK-2:1	p21-activated kinase 2:12:0.5664	0.5664	12
PAKs	PAKs:10|Paks:9	p21-activated protein kinases:19:0.7044	0.7044	19
PAK	PAK:111|Pak:13|pak:1	p21-activated kinase:125:0.6842	0.6842	125
PAK	PAK:12	pancreas after kidney:12:0.6460	0.6460	12
PALA	PALA:141	N-(phosphonacetyl)-L-aspartate:92:0.3321|N-phosphonacetyl-L-aspartate:49:0.1733	0.3321	141
PALA	PALA:36	N-(Phosphonacetyl)-L-aspartic acid:36:0.4303	0.4303	36
PALA	PALA:32	N-(phosphonoacetyl)-L-aspartate:20:0.0686|N-phosphonoacetyl-L-aspartate:12:0.0397	0.0686	32
PALA	PALA:10	phosphonacetyl-L-aspartate:10:0.0325	0.0325	10
PALN	PALN:9	para-aortic lymph nodes:9:0.4587	0.4587	9
PALP	PALP:11|P-ALP:1|PAlP:1	placental alkaline phosphatase:13:0.6701	0.6701	13
PALP	PALP:6|PAL-P:2|Pal-P:1	pyridoxal phosphate:9:0.5470	0.5470	9
PALS	PALS:28	Pediatric Advanced Life Support:28:0.8369	0.8369	28
PALS	PALS:12	periarterial lymphatic sheath:12:0.2699	0.2699	12
PALS	PALS:9	periarterial lymphoid sheath:9:0.1150	0.1150	9
PALS	PALS:18	periarteriolar lymphatic sheath:11:0.2280|periarteriolar lymphatic sheaths:7:0.1850	0.2280	18
PALS	PALS:21|PALs:2	periarteriolar lymphoid sheath:16:0.3472|periarteriolar lymphoid sheaths:7:0.2113	0.3472	23
PALs	PALs:10	progressive addition lenses:10:0.7103	0.7103	10
PAL	PAL:10	attachment loss:10:0.5000	0.5000	10
PAL	PAL:5	passive avoidance learning:5:0.2818	0.2818	5
PAL	PAL:26|Pal:2	peptidoglycan-associated lipoprotein:28:0.6839	0.6839	28
PAL	PAL:156|Pal:2	phenylalanine ammonia-lyase:120:0.8496|phenylalanine ammonia lyase:38:0.7306	0.8496	158
PAL	PAL:68	physical activity level:68:0.9561	0.9561	68
PAL	PAL:8|PAl:1	primary aldosteronism:9:0.6794	0.6794	9
PAL	PAL:10	probing attachment levels:10:0.5856	0.5856	10
PAL	PAL:33	Pyothorax-associated lymphoma:33:0.6656	0.6656	33
PAMAM	PAMAM:27	poly(amidoamine):27:0.2921	0.2921	27
PAMAM	PAMAM:45	polyamidoamine:45:0.4944	0.4944	45
PAMP-1	PAMP-1:14	Pregnancy-associated murine protein-1:14:0.7909	0.7909	14
PAMPA	PAMPA:8	parallel artificial membrane permeability assay:8:0.6411	0.6411	8
PAMPA	PAMPA:9	parallel artificial membrane permeation assay:9:0.6794	0.6794	9
PAMPs	PAMPs:48	pathogen-associated molecular patterns:48:0.7238	0.7238	48
PAMP	PAMP:13	Pathogen-associated molecular patterns:13:0.4102	0.4102	13
PAMP	PAMP:84	proadrenomedullin N-terminal 20 peptide:84:0.8167	0.8167	84
PAMP	PAMP:8	Pulmonary artery mean pressure:8:0.6411	0.6411	8
PAMs	PAMs:53	pulmonary alveolar macrophages:53:0.8373	0.8373	53
PAM	PAM:9	alpha-amidating mono-oxygenase:9:0.6794	0.6794	9
PAm	PAm:5	mean pulmonary arterial pressure:5:0.4422	0.4422	5
PAM	PAM:108	peptidylglycine alpha-amidating monooxygenase:108:0.8011	0.8011	108
PAM	PAM:5	periodic acid-methenamine silver:5:0.4422	0.4422	5
PAM	PAM:9	phosphoramide mustard:9:0.3945	0.3945	9
PAM	PAM:23	polyacrylamide:23:0.0257	0.0257	23
PAM	PAM:30	Potential Acuity Meter:30:0.9011	0.9011	30
PAM	PAM:9	pralidoxime:9:0.0094	0.0094	9
PAM	PAM:14	Pregnancy-associated malaria:14:0.6911	0.6911	14
PAM	PAM:24	primary acquired melanosis:24:0.8768	0.8768	24
PAM	PAM:21	Primary amebic meningoencephalitis:21:0.8594	0.8594	21
PAM	PAM:12	Primary amoebic meningoencephalitis:12:0.7571	0.7571	12
PAM	PAM:183	Pulmonary alveolar macrophages:162:0.8317|pulmonary alveolar macrophage:21:0.7865	0.8317	183
PAM	PAM:19	pulmonary alveolar microlithiasis:19:0.8449	0.8449	19
PAm	PAm:4|PAM:1	pulmonary arterial mean pressure:5:0.4422	0.4422	5
PAm	PAm:3|PAM:2	pulmonary artery mean pressure:5:0.4422	0.4422	5
PANAS	PANAS:9	Positive and Negative Affect Schedule:9:0.3945	0.3945	9
PANDAS	PANDAS:7	autoimmune neuropsychiatric disorders associated with streptococcal infection:7:0.5926	0.5926	7
PANDAS	PANDAS:13|PANDAs:1	Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections:14:0.6911	0.6911	14
PANDO	PANDO:9	Primary acquired nasolacrimal duct obstruction:9:0.5470	0.5470	9
PANI	PANI:27|PAni:2|Pani:1|PANi:1	polyaniline:31:0.8333	0.8333	31
PANSS	PANSS:385	Positive and Negative Syndrome Scale:385:0.9922	0.9922	385
PANSS	PANSS:12	Positive and Negative Syndrome Scale for Schizophrenia:12:0.7571	0.7571	12
PAN	PAN:15	aminonucleoside of puromycin:15:0.5818	0.5818	15
PAN	PAN:15	lymph node:15:0.5818	0.5818	15
PAN	PAN:16	periodic alternating nystagmus:16:0.8270	0.8270	16
PAN	PAN:28	peroxyacetyl nitrate:28:0.7425	0.7425	28
PAN	PAN:100	polyacrylonitrile:100:0.1071	0.1071	100
PAN	PAN:250	polyarteritis nodosa:250:0.8590	0.8590	250
PAN	PAN:11	positional alcohol nystagmus:11:0.7357	0.7357	11
PAN	PAN:21	posterior articular nerve:21:0.8594	0.8594	21
PAN	PAN:146	Puromycin aminonucleoside:146:0.9569	0.9569	146
PAN	PAN:27	Puromycin Aminonucleoside nephrosis:27:0.8312	0.8312	27
PAOD	PAOD:256|pAOD:2	peripheral arterial occlusive disease:258:0.9815	0.9815	258
PAOP	PAOP:71|Paop:1	pulmonary artery occlusion pressure:72:0.9585	0.9585	72
Pao	Pao:20|PaO:2|PAO:1	airway opening:23:0.8038	0.8038	23
Pao	Pao:32|PaO:5	airway opening pressure:37:0.8749	0.8749	37
Pao	Pao:5|PAO:2|PAo:1|PaO:1	mean aortic pressure:9:0.2285	0.2285	9
PAO	PAO:37	peak acid output:37:0.7246	0.7246	37
PAO	PAO:9|pAO:1	peripheral arterial occlusion:10:0.3145	0.3145	10
PAO	PAO:153	phenylarsine oxide:153:0.9397	0.9397	153
PAO	PAO:61	polyamine oxidase:61:0.6738	0.6738	61
PAO	PAO:13	polyphosphate-accumulating organisms:8:0.1591|polyphosphate accumulating organisms:5:0.1464	0.1591	13
PAPG	PAPG:11	pyloric glands:11:0.7357	0.7357	11
PAP-I	PAP-I:5	Phytolacca acinosa polysaccharides I:5:0.4422	0.4422	5
PAPM/BP	PAPM/BP:32	panipenem/betamipron:32:0.9118	0.9118	32
PAPm	PAPm:10|PAPM:1	mean pulmonary artery pressure:11:0.5664	0.5664	11
PAPP-A	PAPP-A:178|PAPPA:1	pregnancy-associated plasma protein-A:179:0.8375	0.8375	179
Papp	Papp:19	apparent permeability:19:0.6106	0.6106	19
Papp	Papp:41	apparent permeability coefficients:23:0.5466|apparent permeability coefficient:18:0.4438	0.5466	41
PAPP	PAPP:13	p-aminopropiophenone:13:0.0876	0.0876	13
PAPS	PAPS:179	3'-phosphoadenosine 5'-phosphosulfate:119:0.6405|3'-phosphoadenosine-5'-phosphosulfate:60:0.1117	0.6405	179
PAPS	PAPS:9	3'-phosphoadenosine 5'-phosphosulphate:9:0.1690	0.1690	9
PAPS	PAPS:33	adenosine 3'-phosphate 5'-phosphosulfate:33:0.9151	0.9151	33
PAPS	PAPS:12	adenosine 3'-phosphate 5'-phosphosulphate:12:0.7571	0.7571	12
PAPS	PAPS:89|PaPS:1|pAPS:1	primary antiphospholipid syndrome:91:0.9473	0.9473	91
PAPS	PAPS:16|pAPS:2	primary APS:18:0.8449	0.8449	18
PAPs	PAPs:7	pulmonary artery pressures:7:0.4438	0.4438	7
PAPs	PAPs:14	Purple acid phosphatases:14:0.6911	0.6911	14
PAPVC	PAPVC:20	partial anomalous pulmonary venous connection:20:0.8525	0.8525	20
PAPase	PAPase:9	acid phosphatase:9:0.6794	0.6794	9
PAPase	PAPase:12	phosphatidate phosphohydrolase:12:0.3275	0.3275	12
PAQ	PAQ:27	Questionnaire:27:0.7027	0.7027	27
PAQLQ	PAQLQ:17	Quality of Life Questionnaire:17:0.8165	0.8165	17
PAR-1	PAR-1:73|PAR1:50	Protease-activated receptor-1:77:0.5559|Protease-activated receptor 1:46:0.6005	0.6005	123
PAR1	PAR1:10	pseudoautosomal region:10:0.7103	0.7103	10
PAR-1	PAR-1:48|PAR1:10|par-1:1	thrombin receptor:59:0.7670	0.7670	59
PAR-2	PAR-2:72|PAR2:9	protease-activated receptor-2:81:0.4847	0.4847	81
PAR-2	PAR-2:33|PAR2:12	Proteinase-activated receptor-2:45:0.2278	0.2278	45
Par-4	Par-4:19|PAR-4:3|par-4:3|PAR4:1	prostate apoptosis response-4:26:0.8861	0.8861	26
PARK	PARK:25	photoastigmatic refractive keratectomy:25:0.7679	0.7679	25
PARN	PARN:9	ribonuclease:9:0.8000	0.8000	9
PARP-1	PARP-1:28|PARP1:3|Parp1:1	poly(ADP-ribose) polymerase:32:0.7091	0.7091	32
PARP-1	PARP-1:197|PARP1:7|Parp-1:2|Parp1:1	poly(ADP-ribose) polymerase-1:166:0.8142|poly(ADP-ribose) polymerase 1:30:0.8032|poly(ADP-ribose)polymerase-1:11:0.0386	0.8142	207
PARPs	PARPs:18	poly(ADP-ribose) polymerases:18:0.7539	0.7539	18
PARP	PARP:4|Parp:1	cleavage of poly-(ADP-ribose)-polymerase:5:0.0517	0.0517	5
PARP	PARP:2	cleavage of the poly(ADP-ribose)polymerase:2:0.0782	0.0782	2
PARP	PARP:789|Parp:3	poly(ADP-ribose) polymerase:761:0.5857|poly ADP-ribose polymerase:31:0.9606	0.9606	792
PARP	PARP:33|parp:2	procyclic acidic repetitive protein:35:0.9151	0.9151	35
PARS	PARS:13	nuclear enzyme poly(ADP-ribose) synthetase:13:0.7753	0.7753	13
PARs	PARs:8	population attributable risks:8:0.5006	0.5006	8
PARs	PARs:125	Protease-activated receptors:125:0.5793	0.5793	125
PARs	PARs:34	proteinase-activated receptors:34:0.1200	0.1200	34
PARV	PARV:31|Parv:10|ParV:1	parvalbumin:42:0.9130	0.9130	42
PAR	PAR:20	4-(2-pyridylazo)resorcinol:20:0.0202	0.0202	20
PAR	PAR:6	appearance rate:6:0.0564	0.0564	6
PAR	PAR:11|par:1	paracetamol:12:0.0117	0.0117	12
PAR	PAR:37	participatory action research:37:0.8749	0.8749	37
par	par:13	partition:13:0.0127	0.0127	13
PAR	PAR:9	passive anterior rhinomanometry:9:0.6794	0.6794	9
PAR	PAR:10	passive avoidance reaction:10:0.7103	0.7103	10
PAR	PAR:27	passive avoidance response:27:0.8903	0.8903	27
PAR	PAR:52	Peer Assessment Rating:52:0.9427	0.9427	52
PAR	PAR:59	perennial allergic rhinitis:59:0.8334	0.8334	59
PAR	PAR:50	photosynthetically active radiation:50:0.7497	0.7497	50
PAR	PAR:11	physical activity recall:11:0.7357	0.7357	11
PAR	PAR:11	platelet aggregate ratio:11:0.7357	0.7357	11
PAR	PAR:9	Platelet aggregation rate:9:0.6794	0.6794	9
PAR	PAR:26	poly(ADP-ribose):26:0.0265	0.0265	26
PAR	PAR:76	population attributable risk:63:0.9018|population attributable risks:13:0.7753	0.9018	76
PAR	PAR:32	protease-activated receptor:24:0.4060|protease-activated receptors:8:0.1591	0.4060	32
PAR	PAR:43	pseudoautosomal region:43:0.7795	0.7795	43
PAR	PAR:7	pulmonary arterial resistance:7:0.3524	0.3524	7
PAR	PAR:18|PaR:1	pulmonary arteriolar resistance:19:0.8449	0.8449	19
PAR	PAR:9	reactions:9:0.0085	0.0085	9
Pas1	Pas1:14	pulmonary adenoma susceptibility 1:14:0.7909	0.7909	14
PASAT	PASAT:24	Paced Auditory Serial Addition Task:24:0.8657	0.8657	24
PASAT	PASAT:41	paced auditory serial addition test:41:0.9274	0.9274	41
PASA	PASA:10	PCR amplification of specific alleles:10:0.4709	0.4709	10
PASG	PASG:30	pneumatic antishock garment:30:0.8472	0.8472	30
PASH	PASH:19	Pseudoangiomatous stromal hyperplasia:19:0.7658	0.7658	19
PASMC	PASMC:14	pulmonary arterial smooth muscle cells:14:0.7909	0.7909	14
PASMC	PASMC:51	pulmonary artery smooth muscle cells:41:0.8525|pulmonary artery smooth muscle cell:10:0.7103	0.8525	51
PASMCs	PASMCs:31	pulmonary arterial smooth muscle cells:31:0.8090	0.8090	31
PASMCs	PASMCs:59|PA-SMCs:5	pulmonary artery smooth muscle cells:64:0.9534	0.9534	64
PASM	PASM:13	smooth muscle:13:0.7753	0.7753	13
PASP	PASP:7	pancreas-specific protein:7:0.3524	0.3524	7
PASP	PASP:11	Polymer-assisted solution-phase:11:0.7357	0.7357	11
PASP	PASP:32|PAsP:3	pulmonary artery systolic pressure:35:0.9151	0.9151	35
PASS	PASS:12	Pain Anxiety Symptoms Scale:12:0.7357	0.7357	12
PASI	PASI:169	psoriasis area and severity index:169:0.9747	0.9747	169
PATH	PATH:17	Program for Appropriate Technology in Health:17:0.8365	0.8365	17
PATI	PATI:30	penetrating abdominal trauma index:30:0.8472	0.8472	30
PAT	PAT:17	paroxysmal atrial tachycardia:17:0.6748	0.6748	17
PAT	PAT:12|pat:1	patagialis:13:0.0289	0.0289	13
PAT	PAT:8	phosphinothricin acetyltransferase:8:0.4102	0.4102	8
PAT	PAT:12	platelet aggregation test:12:0.6460	0.6460	12
PAT	PAT:12	Proficiency Analytical Testing:12:0.7571	0.7571	12
PAVF	PAVF:26|P-AVF:2	pulmonary arteriovenous fistula:28:0.7905	0.7905	28
PAVMs	PAVMs:53|pAVMs:1	pulmonary arteriovenous malformations:54:0.8862	0.8862	54
PAVM	PAVM:60	Pulmonary arteriovenous malformation:33:0.7841|pulmonary arteriovenous malformations:27:0.8312	0.8312	60
PAV	PAV:7	porcine aortic valve:7:0.4438	0.4438	7
PAV	PAV:57	proportional assist ventilation:57:0.9477	0.9477	57
PAWP	PAWP:27	pulmonary arterial wedge pressure:27:0.8903	0.8903	27
PAWP	PAWP:80	Pulmonary artery wedge pressure:80:0.9627	0.9627	80
PAldo	PAldo:4|PALDO:2|pAldo:1|p-Aldo:1|P-aldo:1|P-Aldo:1	plasma aldosterone:10:0.4363	0.4363	10
Palv	Palv:16|PAlv:4	alveolar pressure:20:0.7291	0.7291	20
PAS	PAS:7	atrial stimulation:7:0.2113	0.2113	7
PAS	PAS:9	p-aminosalicylate:9:0.0037	0.0037	9
PAS	PAS:5	paired associative stimulation:5:0.4422	0.4422	5
PAS	PAS:57|pas:1	para-aminosalicylic acid:58:0.3605	0.3605	58
PAS	PAS:10	patient administration system:10:0.7103	0.7103	10
PAS	PAS:35	Per-Arnt-Sim:35:0.0158	0.0158	35
PAS	PAS:12	Perceptual Aberration Scale:12:0.7571	0.7571	12
PAS	PAS:607|paS:1	periodic acid-Schiff:464:0.9577|periodic acid Schiff:133:0.8957|periodic-acid-Schiff:11:0.0051	0.9577	608
PAS	PAS:17	periodic acid-Schiff reagent:17:0.8270	0.8270	17
PAS	PAS:13	peripheral anionic site:13:0.7753	0.7753	13
PAS	PAS:8	Peripheral anterior synechia:8:0.6794	0.6794	8
PAS	PAS:25	peripheral anterior synechiae:25:0.8816	0.8816	25
PAS	PAS:6	Personality Assessment Schedule:6:0.1320	0.1320	6
PAs	PAs:6	phosphatidic acids:6:0.1320	0.1320	6
PAS	PAS:15	photoacoustic spectroscopy:15:0.5818	0.5818	15
PAS	PAS:8	physical activity score:8:0.6411	0.6411	8
PAS	PAS:13	physical anhedonia scale:13:0.7753	0.7753	13
PAS	PAS:72	physician-assisted suicide:72:0.7782	0.7782	72
PAs	PAs:171	plasminogen activators:171:0.9628	0.9628	171
PAS	PAS:4	platelet additive solution:4:0.1618	0.1618	4
PAs	PAs:9	pleomorphic adenomas:9:0.2500	0.2500	9
PAs	PAs:31	polyamines:31:0.0140	0.0140	31
PAS	PAS:13|pas:1	posterior airway space:14:0.4071	0.4071	14
PAS	PAS:6	pre-autophagosomal structure:6:0.1543	0.1543	6
PAS	PAS:19	Premorbid Adjustment Scale:19:0.7539	0.7539	19
PAS	PAS:10	primary antiphospholipid syndrome:10:0.7103	0.7103	10
PAS	PAS:6	Psychiatric Assessment Schedule:6:0.1320	0.1320	6
PAs	PAs:34	pulmonary arteries:34:0.7306	0.7306	34
PAs	PAs:65	pyrrolizidine alkaloids:65:0.9541	0.9541	65
PAS	PAS:16	reaction:16:0.0070	0.0070	16
PAS	PAS:5	systolic blood pressure:5:0.4422	0.4422	5
PA	PA:11	2-aminopyridine:11:0.0012	0.0012	11
PA	PA:17	abscess:17:0.0020	0.0020	17
Pa	Pa:4|PA:3	acidic protein:7:0.2452	0.2452	7
PA	PA:6|Pa:2|pa:1	agreement:9:0.0010	0.0010	9
PA	PA:12	alcohol:12:0.0014	0.0014	12
PA	PA:43|Pa:2	alveolar pressure:36:0.1152|alveolar pressures:9:0.2102	0.2102	45
PA	PA:12	analysis:12:0.0014	0.0014	12
Pa	Pa:1	apparent permeability coefficient to albumin:1:0.4102	0.4102	1
Pa	Pa:13|PA:3|pa:1	arterial blood pressure:17:0.5374	0.5374	17
Pa	Pa:73|PA:25	arterial pressure:98:0.3931	0.3931	98
Pa	Pa:10|PA:1	Children's Hospital of Philadelphia:11:0.7357	0.7357	11
Pa	Pa:7|PA:2	Children's Hospital of Pittsburgh:9:0.5470	0.5470	9
PA	PA:13	D-penicillamine:13:0.0015	0.0015	13
PA	PA:9|Pa:4	nucleus:13:0.0015	0.0015	13
PA	PA:11	paleostriatum augmentatum:11:0.6182	0.6182	11
pa	pa:9|Pa:1	pallid:10:0.0011	0.0011	10
PA	PA:7	pancreatic adenocarcinoma:7:0.1211	0.1211	7
PA	PA:13	panic attacks:13:0.7909	0.7909	13
Pa	Pa:9|PA:1	Paranoia:10:0.0011	0.0011	10
PA	PA:65	particle agglutination:65:0.8452	0.8452	65
PA	PA:8	particle agglutination assay:8:0.6411	0.6411	8
PA	PA:5	particle agglutination test:5:0.1973	0.1973	5
PA	PA:30	parvalbumin:30:0.0036	0.0036	30
PA	PA:69	passive avoidance:69:0.9316	0.9316	69
PA	PA:9	penicillamine:9:0.0010	0.0010	9
PA	PA:15	Pennsylvania:15:0.0017	0.0017	15
PA	PA:8	perceptual asymmetry:8:0.5006	0.5006	8
PA	PA:8	performance assessment:8:0.3463	0.3463	8
PA	PA:29	perinatal asphyxia:29:0.8978	0.8978	29
PA	PA:7	permeability-area product:7:0.0777	0.0777	7
PA	PA:10	permeability-surface area product:10:0.3145	0.3145	10
PA	PA:39	pernicious anaemia:39:0.8811	0.8811	39
PA	PA:43	pernicious anemia:43:0.8917	0.8917	43
PA	PA:10	phase angle:10:0.4363	0.4363	10
PA	PA:39	phenylacetate:39:0.0047	0.0047	39
PA	PA:6	phonological awareness:6:0.2243	0.2243	6
PA	PA:42	phosphatidate:42:0.0050	0.0050	42
PA	PA:833	phosphatidic acid:823:0.6321|phosphatidic acids:10:0.2873	0.6321	833
PA	PA:30	photoacoustic:30:0.0036	0.0036	30
PA	PA:31	phthalic anhydride:31:0.8472	0.8472	31
PA	PA:268	physical activity:268:0.6807	0.6807	268
PA	PA:31	physician assistant:31:0.6820	0.6820	31
PA	PA:16	pilocytic astrocytoma:16:0.8165	0.8165	16
PA	PA:10|P-A:1	pituitary-adrenal:11:0.0012	0.0012	11
PA	PA:13	plaque area:13:0.0967	0.0967	13
PA	PA:33	plasmapheresis:33:0.0039	0.0039	33
PA	PA:21	plasminogen activation:21:0.4733	0.4733	21
PA	PA:826	plasminogen activator:716:0.9690|plasminogen activators:110:0.9567	0.9690	826
PA	PA:80	platelet aggregation:80:0.8738	0.8738	80
PA	PA:62	pleomorphic adenoma:50:0.5707|pleomorphic adenomas:12:0.2868	0.5707	62
PA	PA:14	Polyacrylamide:14:0.0016	0.0016	14
PA	PA:26	Polyacrylate:26:0.0031	0.0031	26
pA	PA:5|pA:5	polyadenylation:10:0.0011	0.0011	10
PA	PA:17	polyamide:17:0.0020	0.0020	17
PA	PA:76|Pa:1	polyamine:47:0.0056|polyamines:30:0.0036	0.0056	77
PA	PA:39	positive affect:39:0.8455	0.8455	39
PA	PA:9	positive affectivity:9:0.6794	0.6794	9
PA	PA:11|pa:1	postabsorptive:12:0.0014	0.0014	12
PA	PA:36|P-A:4|pa:1	posterior-anterior:41:0.0049	0.0049	41
PA	PA:41|p-a:2|P-A:1	postero-anterior:44:0.0053	0.0053	44
PA	PA:141|P-A:2	posteroanterior:143:0.0174	0.0174	143
Pa	Pa:6|PA:4	pregnancy-associated:10:0.0011	0.0011	10
PA	PA:8	preinfarction angina:8:0.4102	0.4102	8
PA	PA:17	premature adrenarche:17:0.5760	0.5760	17
P-A	P-A:10|PA:2	presence-absence:12:0.0014	0.0014	12
PA	PA:118	primary aldosteronism:118:0.9746	0.9746	118
PA	PA:9	primary angioplasty:9:0.5470	0.5470	9
PA	PA:14	proanthocyanidin:14:0.0016	0.0016	14
PA	PA:89	procainamide:89:0.0108	0.0108	89
PA	PA:5	progressive aphasia:5:0.0736	0.0736	5
PA	PA:10	propionic acidaemia:10:0.7103	0.7103	10
PA	PA:23	propionic acidemia:23:0.8715	0.8715	23
PA	PA:7	prostate adenocarcinoma:7:0.1211	0.1211	7
PA	PA:218	protective antigen:218:0.6806	0.6806	218
PA	PA:11	proton affinity:11:0.7357	0.7357	11
PA	PA:17	Pseudoaneurysm:17:0.0020	0.0020	17
PA	PA:112|Pa:28	Pseudomonas aeruginosa:140:0.8999	0.8999	140
PA	PA:62	Psoriatic arthritis:62:0.7624	0.7624	62
PA	PA:6	psoriatic arthropathy:6:0.1148	0.1148	6
PA	PA:6	pullulan acetate:6:0.0899	0.0899	6
PA	PA:9	pulmonary:9:0.0010	0.0010	9
PA	PA:14	pulmonary angiography:14:0.6173	0.6173	14
PA	PA:70|Pa:1|P-A:1	pulmonary arterial:72:0.6753	0.6753	72
PA	PA:714|Pa:2	pulmonary artery:661:0.9254|pulmonary arteries:55:0.8427	0.9254	716
PA	PA:22	pulmonary atresia:22:0.4883	0.4883	22
PA	PA:26	pulse amplitude:26:0.5409	0.5409	26
PA	PA:39	puromycin aminonucleoside:39:0.9237	0.9237	39
PA	PA:10	pyloric atresia:10:0.1223	0.1223	10
PA	PA:16	pyridylaminated:16:0.0018	0.0018	16
PA	PA:11	Pyridylamino:11:0.0012	0.0012	11
PA	PA:6	Pyrophosphate arthropathy:6:0.1148	0.1148	6
PA	PA:55	pyrrolizidine alkaloid:32:0.8563|pyrrolizidine alkaloids:23:0.8715	0.8715	55
PA	PA:5	solitary parathyroid adenoma:5:0.0517	0.0517	5
Pa	Pa:7	University of Pittsburgh:7:0.1111	0.1111	7
PB1	PB1:15|pb1:2|Pb1:2	first polar body:19:0.8449	0.8449	19
PB2	PB2:9|PB-2:1	second polar body:10:0.7103	0.7103	10
PBAN	PBAN:45	pheromone biosynthesis activating neuropeptide:45:0.7881	0.7881	45
PBAs	PBAs:5	polyclonal B-cell activators:5:0.4422	0.4422	5
PBA	PBA:15	phenylboronic acid:15:0.1316	0.1316	15
PbA	PbA:22	Plasmodium berghei ANKA:22:0.7955	0.7955	22
PBA	PBA:26	polyclonal B cell activation:16:0.8165|polyclonal B-cell activation:10:0.5856	0.8165	26
PBA	PBA:43	polyclonal B-cell activator:15:0.8045|polyclonal B-cell activators:15:0.7096|polyclonal B cell activators:13:0.7753	0.8045	43
PBBs	PBBs:81	polybrominated biphenyls:81:0.8901	0.8901	81
PBCA	PBCA:10	polybutylcyanoacrylate:10:0.3462	0.3462	10
PBCO	PBCO:19	Prudhoe Bay Crude Oil:19:0.8449	0.8449	19
PBCs	PBCs:16	peripheral blood cells:16:0.8165	0.8165	16
PBC	PBC:15	perceived behavioural control:8:0.6411|perceived behavioral control:7:0.5926	0.6411	15
PBC	PBC:29	peripheral blood cells:21:0.6812|peripheral blood cell:8:0.5006	0.6812	29
PBC	PBC:19|pBC:3	pre-Botzinger complex:22:0.5863	0.5863	22
PBC	PBC:1400	primary biliary cirrhosis:1400:0.9943	0.9943	1400
PBC	PBC:5	protected brush catheter:5:0.4422	0.4422	5
PBDDs	PBDDs:13	polybrominated dibenzo-p-dioxins:13:0.5934	0.5934	13
PBDE	PBDE:56	polybrominated diphenyl ether:42:0.8893|polybrominated diphenyl ethers:14:0.6911	0.8893	56
PBDEs	PBDEs:200|PBDES:1	polybrominated diphenyl ethers:201:0.9469	0.9469	201
PBDEs	PBDEs:14	polybrominated diphenylethers:14:0.6173	0.6173	14
PBDs	PBDs:31	peroxisome biogenesis disorders:31:0.7718	0.7718	31
PBDs	PBDs:21	Postburn Days:21:0.8594	0.8594	21
PBD	PBD:25	biliary drainage:25:0.8816	0.8816	25
PBD	PBD:20	pancreaticobiliary diversion:20:0.4037	0.4037	20
PBD	PBD:18	peroxisome biogenesis disorders:18:0.7539	0.7539	18
PBD	PBD:12	pigeon breeder's disease:12:0.7571	0.7571	12
PBD	PBD:11	polybutadiene:11:0.0333	0.0333	11
PBD	PBD:24	postburn day:18:0.5940|postburn days:6:0.1320	0.5940	24
PBD	PBD:10	proliferative breast disease:10:0.7103	0.7103	10
PBD	PBD:10	pyrrolo[2,1-c][1,4]benzodiazepine:10:0.0300	0.0300	10
PBE	PBE:12	bifunctional enzyme:12:0.7571	0.7571	12
PBE	PBE:9	peripheral blood eosinophils:9:0.6794	0.6794	9
PBFD	PBFD:19	psittacine beak and feather disease:19:0.8449	0.8449	19
PBF	PBF:8	binding factor:8:0.2327	0.2327	8
PBF	PBF:209|pBF:1|pbf:1	blood flow:211:0.9773	0.9773	211
PBF	PBF:16	percent body fat:16:0.3232	0.3232	16
PBF	PBF:11	percentage body fat:11:0.2621	0.2621	11
PBGD	PBGD:103|PBG-D:40|PBG-d:2	porphobilinogen deaminase:145:0.9369	0.9369	145
PBGS	PBGS:33|PBG-S:5	Porphobilinogen synthase:38:0.9217	0.9217	38
PBGase	PBGase:12|PBG-ase:2	porphobilinogenase:14:0.8125	0.8125	14
PBG	PBG:10	blood glucose:10:0.5856	0.5856	10
PBG	PBG:36	phenylbiguanide:36:0.1220	0.1220	36
PBG	PBG:9	photonic band gap:9:0.6794	0.6794	9
PBG	PBG:8	pressure breathing during G:8:0.7357	0.7357	8
PBG	PBG:10	progesterone-binding globulin:10:0.5856	0.5856	10
PBHs	PBHs:25	postburn hours:25:0.8816	0.8816	25
PBH	PBH:10	postburn hour:10:0.7103	0.7103	10
PBI	PBI:23	Papillary Bleeding Index:23:0.4332	0.4332	23
PBI	PBI:102	Parental Bonding Instrument:102:0.9704	0.9704	102
PBI	PBI:8	partial breast irradiation:8:0.6411	0.6411	8
PBI	PBI:16	penile brachial index:16:0.8165	0.8165	16
PBI	PBI:36|pbi:2	protein-bound iodine:38:0.5012	0.5012	38
PBK	PBK:23	pseudophakic bullous keratopathy:23:0.8038	0.8038	23
PBL's	PBL's:9	peripheral blood lymphocytes:9:0.6794	0.6794	9
PBLs	PBLs:105	peripheral blood leukocytes:105:0.9715	0.9715	105
PBLs	PBLs:578|PBLS:3	peripheral blood lymphocytes:581:0.9838	0.9838	581
PBL	PBL:5|Pbl:3|PBl:1	lateral parabrachial nucleus:9:0.5470	0.5470	9
PBL	PBL:110|pBL:1	peripheral blood:111:0.8859	0.8859	111
PBL	PBL:115|pbl:1	peripheral blood leucocytes:104:0.9712|peripheral blood leucocyte:12:0.7571	0.9712	116
PBL	PBL:407	peripheral blood leukocytes:365:0.9868|peripheral blood leukocyte:42:0.9291	0.9868	407
PBL	PBL:2630|pbl:3	peripheral blood lymphocytes:2428:0.9867|peripheral blood lymphocyte:205:0.9766	0.9867	2633
PBL	PBL:30	peripheral blood mononuclear cells:30:0.8032	0.8032	30
PBL	PBL:7	Plasmablastic lymphoma:7:0.0565	0.0565	7
PBL	PBL:21	portal branch ligation:21:0.6934	0.6934	21
PBL	PBL:9	Primary breast lymphoma:9:0.5470	0.5470	9
PBL	PBL:384	Problem-based learning:348:0.8739|problem based learning:36:0.9174	0.9174	384
PBMA	PBMA:7	program budgeting and marginal analysis:7:0.1061	0.1061	7
PBMA	PBMA:15	programme budgeting and marginal analysis:15:0.4274	0.4274	15
PBMCs	PBMCs:15	Peripheral blood monocytes:15:0.8045	0.8045	15
PBMCs	PBMCs:2333|PB-MCs:3|PBMCS:1	peripheral blood mononuclear cells:2337:0.9931	0.9931	2337
PBMC	PBMC:7	percutaneous balloon mitral commissurotomy:7:0.5926	0.5926	7
PBMC	PBMC:31	peripheral blood:31:0.8519	0.8519	31
PBMC	PBMC:16	peripheral blood lymphocytes:16:0.6577	0.6577	16
PBMC	PBMC:36	peripheral blood monocytes:36:0.8716	0.8716	36
PBMC	PBMC:9	peripheral blood mononuclear:9:0.6794	0.6794	9
PBMC	PBMC:6558|pbmc:2|PB-MC:1	Peripheral blood mononuclear cells:6041:0.9915|peripheral blood mononuclear cell:520:0.9877	0.9915	6561
PBMC	PBMC:8	peripheral blood mononuclear leukocytes:8:0.6411	0.6411	8
PBML	PBML:15	peripheral blood mononuclear leucocytes:15:0.8045	0.8045	15
PBML	PBML:55	peripheral blood mononuclear leukocytes:55:0.9458	0.9458	55
PBMLs	PBMLs:12	peripheral blood mononuclear leukocytes:12:0.7571	0.7571	12
PBMNCs	PBMNCs:84|PB-MNCs:4|PBMNCS:1	peripheral blood mononuclear cells:89:0.9664	0.9664	89
PBMNC	PBMNC:223|PB-MNC:6|PBMNc:1	Peripheral blood mononuclear cells:216:0.9861|peripheral blood mononuclear cell:14:0.7909	0.9861	230
PBMN	PBMN:20	peripheral blood mononuclear:20:0.8525	0.8525	20
PBMN	PBMN:25	peripheral blood mononuclear cells:25:0.8816	0.8816	25
PBMV	PBMV:12	Percutaneous balloon mitral valvotomy:12:0.7571	0.7571	12
PBMV	PBMV:31	percutaneous balloon mitral valvuloplasty:31:0.8090	0.8090	31
PBMo	PBMo:9|PBMO:4|PB-MO:1	peripheral blood monocytes:14:0.7909	0.7909	14
PBMs	PBMs:26	peripheral blood monocytes:26:0.8861	0.8861	26
PBMs	PBMs:31	peripheral blood mononuclear cells:31:0.9043	0.9043	31
PBMs	PBMs:10	pharmacy benefit managers:10:0.7103	0.7103	10
PBM	PBM:6	benefit management:6:0.2243	0.2243	6
PBM	PBM:34	Pancreaticobiliary maljunction:34:0.7898	0.7898	34
PBM	PBM:19	peak bone mass:19:0.8449	0.8449	19
PBM	PBM:13|pbm:1	peribacteroid membrane:14:0.4367	0.4367	14
PBM	PBM:170	peripheral blood monocytes:155:0.9692|peripheral blood monocyte:15:0.8045	0.9692	170
PBM	PBM:81	Peripheral blood mononuclear:81:0.9631	0.9631	81
PBM	PBM:264	Peripheral blood mononuclear cells:253:0.9528|peripheral blood mononuclear cell:11:0.7357	0.9528	264
PBM	PBM:6	pharmacy benefit manager:6:0.5290	0.5290	6
PBM	PBM:6	poultry by-product meal:6:0.5290	0.5290	6
PBN	PBN:6	agent alpha-phenyl-N-t-butylnitrone:6:0.0886	0.0886	6
PBN	PBN:73	alpha-phenyl-N-tert-butyl nitrone:57:0.2478|alpha-phenyl-N-tert-butyl-nitrone:16:0.0210	0.2478	73
PBN	PBN:47	alpha-phenyl-N-tert-butylnitrone:47:0.0631	0.0631	47
PBN	PBN:10	alpha-phenyl-tert-butyl-nitrone:10:0.0126	0.0126	10
PBN	PBN:17	alpha-phenyl-tert-butylnitrone:17:0.0224	0.0224	17
PBN	PBN:17	N-t-butyl-alpha-phenylnitrone:17:0.0224	0.0224	17
PBN	PBN:24|PbN:6	parabrachial nuclei:30:0.8472	0.8472	30
PBN	PBN:150|PbN:2|PBn:2	parabrachial nucleus:154:0.9405	0.9405	154
PbN	PbN:9|PBN:1	parabrachial nucleus of the pons:10:0.7103	0.7103	10
PBN	PBN:9	phenyl N-tert-butyl nitrone:9:0.1052	0.1052	9
PBN	PBN:25	phenyl-N-tert-butylnitrone:13:0.0168|Phenyl N-tert-butylnitrone:12:0.3813	0.3813	25
PBN	PBN:6	spin trap alpha-phenyl N-tert-butyl nitrone:6:0.5006	0.5006	6
PBN	PBN:12	spin trap N-tert-butyl-alpha-phenylnitrone:12:0.7753	0.7753	12
PBOO	PBOO:11	partial bladder outlet obstruction:11:0.6182	0.6182	11
PBP2'	PBP2':10|PBP-2':2	penicillin-binding protein 2':12:0.5050	0.5050	12
PBP2a	PBP2a:14|PBP2A:3	penicillin-binding protein 2a:17:0.5374	0.5374	17
PBP2	PBP2:23|PBP-2:5	penicillin-binding protein 2:28:0.7905	0.7905	28
PBP3	PBP3:17|PBP-3:4	penicillin-binding protein 3:21:0.6812	0.6812	21
PBP4	PBP4:8	penicillin-binding protein 4:8:0.4102	0.4102	8
PBP5	PBP5:10	penicillin-binding protein 5:10:0.5856	0.5856	10
PBPCT	PBPCT:41|PBPC-T:1	Peripheral blood progenitor cell transplantation:42:0.9291	0.9291	42
PBPCs	PBPCs:115	peripheral blood progenitor cells:115:0.9740	0.9740	115
PBPC	PBPC:570	peripheral blood progenitor cells:310:0.9744|peripheral blood progenitor cell:249:0.9880|peripheral-blood progenitor-cell:11:0.7357	0.9880	570
PBPI	PBPI:5	penile blood pressure index:5:0.4422	0.4422	5
PBPK/PD	PBPK/PD:8|PB-PK/PD:1	physiologically based pharmacokinetic/pharmacodynamic:9:0.6794	0.6794	9
PBPK	PBPK:293|PB-PK:45|pbpk:3	Physiologically based pharmacokinetic:341:0.9686	0.9686	341
PBPK	PBPK:8|PB-PK:1	physiologically based pharmacokinetic model:9:0.6794	0.6794	9
PBPs	PBPs:378|PBPS:1|Pbps:1	penicillin-binding proteins:343:0.7469|penicillin binding proteins:37:0.4305	0.7469	380
PBPs	PBPs:17	pheromone binding proteins:17:0.1263	0.1263	17
PBP	PBP:236|pbp:8	penicillin-binding protein:186:0.4767|Penicillin binding protein:32:0.2673|penicillin-binding proteins:26:0.5840	0.5840	244
PBP	PBP:10	progressive bulbar palsy:10:0.5856	0.5856	10
PBP	PBP:18	prostatic binding protein:18:0.1162	0.1162	18
p-BQ	p-BQ:20|pBQ:5|PBQ:4	p-benzoquinone:29:0.3457	0.3457	29
PBQ	PBQ:12	phenylbenzoquinone:12:0.1358	0.1358	12
PBQ	PBQ:12	Questionnaire:12:0.1358	0.1358	12
PBREM	PBREM:16	enhancer module:16:0.7261	0.7261	16
PBRs	PBRs:30	peripheral benzodiazepine receptors:30:0.5017	0.5017	30
PBR	PBR:61	benzodiazepine receptors:61:0.7455	0.7455	61
PBR	PBR:10	parabrachial region:10:0.1273	0.1273	10
PBR	PBR:10	peptide-binding region:10:0.1273	0.1273	10
PBR	PBR:116|pBR:2	peripheral benzodiazepine receptor:118:0.4715	0.4715	118
PBR	PBR:94	peripheral-type benzodiazepine receptor:94:0.3614	0.3614	94
PBSCT	PBSCT:6	peripheral blood stem cells:6:0.5290	0.5290	6
PBSCT	PBSCT:42	peripheral blood stem cell transplant:31:0.9043|peripheral blood stem cell transplants:11:0.7357	0.9043	42
PBSCT	PBSCT:384|PBS-CT:1|PB-SCT:1	peripheral blood stem cell transplantation:386:0.9794	0.9794	386
PBSCs	PBSCs:114	peripheral blood stem cells:114:0.9582	0.9582	114
PBSC	PBSC:9	peripheral blood:9:0.5470	0.5470	9
PBSC	PBSC:828|PB-SC:1	peripheral blood stem cells:403:0.9803|peripheral blood stem cell:401:0.9925|peripheral-blood stem-cell:16:0.3831|peripheral blood stem-cell:9:0.6794	0.9925	829
PBSS	PBSS:10	phosphate-buffered saline solution:10:0.5000	0.5000	10
PBSt	PBSt:15|PBST:1	posterior biceps and semitendinosus:16:0.8365	0.8365	16
PBS	PBS:19	binding sites:19:0.6537	0.6537	19
PBS	PBS:29	Pharmaceutical Benefits Scheme:29:0.8472	0.8472	29
PBS	PBS:45	phosphate buffer solution:45:0.8964	0.8964	45
PBS	PBS:803|pbs:1	phosphate-buffered saline:804:0.5998	0.5998	804
PBS	PBS:19	phosphate-buffered saline solution:19:0.5113	0.5113	19
PBS	PBS:33|Pbs:1|PbS:1	Phycobilisomes:22:0.0104|phycobilisome:13:0.0059	0.0104	35
PBs	PBs:15	Pick bodies:15:0.1879	0.1879	15
PBS	PBS:139|pbs:1|-PBS:1	primer binding site:101:0.8755|primer-binding site:40:0.1897	0.8755	141
PBS	PBS:28	prune belly syndrome:18:0.8365|prune-belly syndrome:10:0.0989	0.8365	28
PBS	PBS:9	pulsating bubble surfactometer:9:0.6794	0.6794	9
PBS	PBS:3	saline pH 7.4:3:0.4587	0.4587	3
PBTK	PBTK:16|PB-TK:3	physiologically based toxicokinetic:19:0.8449	0.8449	19
PBT	PBT:10	peripheral blood T:10:0.7103	0.7103	10
PBT	PBT:14|PB-T:1	peripheral blood T cells:15:0.8045	0.8045	15
PBT	PBT:13	pulmonary barotrauma:13:0.7753	0.7753	13
PBV	PBV:13	balloon valvuloplasty:13:0.6701	0.6701	13
PBV	PBV:53	pulmonary blood volume:53:0.7789	0.7789	53
PBZr	PBZr:5|pBZr:3|PBZR:1	benzodiazepine receptors:9:0.6794	0.6794	9
PBZ	PBZ:62|Pbz:4|pbz:1	phenoxybenzamine:67:0.4258	0.4258	67
PBZ	PBZ:64|pbz:1	phenylbutazone:65:0.4129	0.4129	65
PBt2	PBt2:8	phorbol dibutyrate:8:0.3463	0.3463	8
PBut	PBut:11|Pbut:1	phosphatidylbutanol:12:0.6875	0.6875	12
PB	PB:12|Pb:3|pB:1	barometric pressure:16:0.3317	0.3317	16
pb	pb:6	homeotic gene proboscipedia:6:0.3728	0.3728	6
Pb	Pb:10	lead acetate:10:0.7103	0.7103	10
PB	PB:24	parabrachial:24:0.0040	0.0040	24
PB	PB:49|Pb:3	parabrachial nucleus:52:0.8572	0.8572	52
Pb	Pb:16	Paracoccidioides brasiliensis:16:0.6024	0.6024	16
PB	PB:6	particle beam:6:0.0611	0.0611	6
PB	PB:101	paucibacillary:101:0.0172	0.0172	101
P-B	P-B:13|PB:3	Paul-Bunnell:16:0.0026	0.0026	16
PB	PB:10	pencil beam:10:0.2446	0.2446	10
PB	PB:119|Pb:4|pb:2	pentobarbital:125:0.0213	0.0213	125
PB	PB:9	pentobarbital sodium:9:0.1585	0.1585	9
PB	PB:9	pentobarbitone:9:0.0014	0.0014	9
PB	PB:11	peribrachial:11:0.0017	0.0017	11
PB	PB:64	periodic breathing:64:0.8651	0.8651	64
PB	PB:1531|pb:7|pB:4	peripheral blood:1542:0.9838	0.9838	1542
PB	PB:8	peroneus brevis:8:0.2987	0.2987	8
PB	PB:1559|Pb:22	phenobarbital:1581:0.2719	0.2719	1581
PB	PB:12|Pb:1	phenobarbital sodium:13:0.3331	0.3331	13
PB	PB:131|Pb:2	phenobarbitone:133:0.0227	0.0227	133
PB	PB:15	Phenoxybenzamine:15:0.0024	0.0024	15
PB	PB:24	phenylbutazone:24:0.0040	0.0040	24
PB	PB:36	phosphate buffer:36:0.9174	0.9174	36
PB	PB:10	Pick bodies:10:0.1177	0.1177	10
PB	PB:29	piperonyl butoxide:29:0.7970	0.7970	29
Pb	Pb:6|PB:3	Plasmodium berghei:9:0.5470	0.5470	9
PB	PB:34|P-B:2	Poisson-Boltzmann:36:0.0060	0.0060	36
PB	PB:25|Pb:1	polar body:26:0.6084	0.6084	26
PB	PB:9|Pb:1	Polybrene:10:0.0015	0.0015	10
PB	PB:22	polymyxin B:22:0.4344	0.4344	22
PB	PB:9	postburn:9:0.0014	0.0014	9
PB	PB:10	Prime&Bond 2.1:10:0.5000	0.5000	10
PB	PB:9	primed burst:9:0.6794	0.6794	9
PB	PB:10|Pb:1	probenecid:11:0.0017	0.0017	11
PB	PB:10	prostate brachytherapy:10:0.5000	0.5000	10
PB	PB:8	protein breakdown:8:0.3463	0.3463	8
PB	PB:21	prussian blue:21:0.6812	0.6812	21
PB	PB:13	Pulmonary blastoma:13:0.7753	0.7753	13
PB	PB:56	pyridostigmine bromide:56:0.7135	0.7135	56
PB	PB:5|Pb:2	rat probasin:7:0.0886	0.0886	7
PB	PB:9	sodium phenylbutyrate:9:0.0713	0.0713	9
PC's	PC's:10	phosphatidylcholines:10:0.5000	0.5000	10
PC-Fix	PC-Fix:8	Point Contact Fixator:8:0.6411	0.6411	8
PC-PLD	PC-PLD:17	phospholipase D:17:0.5760	0.5760	17
PC-SOD	PC-SOD:8	lecithinized superoxide dismutase:8:0.6411	0.6411	8
PC12	PC12:11	dilauroylphosphatidylcholine:11:0.0129	0.0129	11
PC12	PC12:20|PC-12:5	pheochromocytoma 12:14:0.5589|pheochromocytoma-12:11:0.0129	0.5589	25
PC12	PC12:27|PC-12:4	rat phaeochromocytoma:31:0.5261	0.5261	31
PC12	PC12:270|PC-12:23	rat pheochromocytoma:293:0.5613	0.5613	293
PC12	PC12:35|PC-12:9	rat pheochromocytoma cells:44:0.5154	0.5154	44
PC20	PC20:14	20% fall in forced expiratory volume in one second:14:0.8045	0.8045	14
PC20	PC20:9	concentration:9:0.0227	0.0227	9
PC20	PC20:2	FEV1 by 20% of baseline:2:0.0918	0.0918	2
PC20	PC20:16	methacholine:16:0.0425	0.0425	16
PC20	PC20:5	provocative concentration causing a 20% fall in FEV1 from baseline:5:0.4422	0.4422	5
PC20	PC20:12	provocative concentration of histamine causing a 20% fall in FEV1:12:0.3813	0.3813	12
PC20	PC20:14	provocative concentration of methacholine causing a 20% fall in FEV1:14:0.8045	0.8045	14
PC2	PC2:39	prohormone convertase 2:39:0.7364	0.7364	39
PC-3	PC-3:9|PC3:5	human prostate:14:0.2524	0.2524	14
PC-3	PC-3:10|PC3:2	human prostate cancer cells:12:0.3813	0.3813	12
PC-3	PC-3:6|PC3:3	prostate cancer:9:0.3945	0.3945	9
PC-3	PC-3:17|PC3:9	prostate cancer cell line:26:0.6973	0.6973	26
PC3	PC3:3|PC-3:2	prostatic carcinoma:5:0.0517	0.0517	5
PC4	PC4:7	positive cofactor 4:7:0.5926	0.5926	7
PCAA	PCAA:10	cancer-associated antigen:10:0.5000	0.5000	10
PCAR	PCAR:17	presumed circle area ratio:17:0.8270	0.8270	17
PCAs	PCAs:9	posterior ciliary arteries:9:0.6794	0.6794	9
PCAs	PCAs:6	principal components analyses:6:0.5290	0.5290	6
pCa	pCa:5	Ca2+ concentration:5:0.0612	0.0612	5
PCA	PCA:185|pCA:13|p-CA:4|P-CA:1	p-chloroamphetamine:203:0.0397	0.0397	203
PCA	PCA:19|p-CA:1|pCA:1	Para-chloroamphetamine:21:0.0039	0.0039	21
PCA	PCA:18|pCA:1	parachloroamphetamine:19:0.0036	0.0036	19
PCA	PCA:8	parietal cell:8:0.4102	0.4102	8
PCA	PCA:32	parietal cell antibodies:26:0.7760|parietal cell antibody:6:0.2827	0.7760	32
PCA	PCA:28	Passive cutaneous anaphylactic:28:0.8941	0.8941	28
PCA	PCA:425	passive cutaneous anaphylaxis:425:0.9887	0.9887	425
PCA	PCA:771	patient-controlled analgesia:678:0.8328|patient controlled analgesia:93:0.9325	0.9325	771
PCA	PCA:8	patient-controlled analgesic:8:0.5006	0.5006	8
PCA	PCA:11	pentachloroanisole:11:0.0020	0.0020	11
PCA	PCA:4	percent cortical area:4:0.0918	0.0918	4
PCA	PCA:64	perchloric acid:64:0.3230	0.3230	64
PCa	PCa:5|P-Ca:1	plasma calcium:6:0.2243	0.2243	6
PCA	PCA:15	plate count agar:15:0.8045	0.8045	15
PCA	PCA:48	Porous-coated anatomic:29:0.4410|porous coated anatomic:19:0.8449	0.8449	48
PCA	PCA:64	portacaval anastomosis:64:0.5955	0.5955	64
PCA	PCA:19	portocaval anastomosis:19:0.1143	0.1143	19
PCA	PCA:87	postconceptional age:87:0.6107	0.6107	87
PCA	PCA:11	posterior cerebral:11:0.7357	0.7357	11
PCA	PCA:174	posterior cerebral artery:164:0.9283|posterior cerebral arteries:10:0.7103	0.9283	174
PCA	PCA:12	posterior ciliary arteries:12:0.7571	0.7571	12
PCA	PCA:19|pCA:1	Posterior cortical atrophy:20:0.8525	0.8525	20
PCA	PCA:126	posterior cricoarytenoid:126:0.9763	0.9763	126
PCA	PCA:32	posterior cricoarytenoid muscle:32:0.9072	0.9072	32
PCA	PCA:27	principal component analyses:19:0.8449|principal components analyses:8:0.6411	0.8449	27
PCA	PCA:1056	principal component analysis:799:0.9508|principal components analysis:257:0.9440	0.9508	1056
PCA	PCA:4	probe competition assay:4:0.1618	0.1618	4
PCA	PCA:304	procoagulant activity:304:0.8633	0.8633	304
PCa	PCa:5|Pca:3|PCA:3	prostate adenocarcinoma:11:0.1845	0.1845	11
PCa	PCa:328|PCA:92|Pca:26|P-CA:1|pCa:1	prostate cancer:448:0.9173	0.9173	448
PCa	PCa:36|PCA:18|Pca:6	prostate carcinoma:60:0.4239	0.4239	60
PCA	PCA:8|PCa:7	prostatic adenocarcinoma:15:0.3262	0.3262	15
PCa	PCa:23|PCA:17|Pca:1	prostatic carcinoma:41:0.2615	0.2615	41
PCA	PCA:4	protein fragment complementation assay:4:0.3170	0.3170	4
PCA	PCA:15|pca:4|Pca:1	protocatechuate:20:0.0037	0.0037	20
PCA	PCA:27	protocatechuic acid:27:0.1063	0.1063	27
PCA	PCA:10	weeks post-conceptional age:10:0.3813	0.3813	10
PCB's	PCB's:28|PCB'S:1	Polychlorinated biphenyls:29:0.8978	0.8978	29
PCB126	PCB126:18|PCB-126:7	3,3',4,4',5-pentachlorobiphenyl:25:0.6000	0.6000	25
PCB77	PCB77:5|PCB-77:4	3,3',4,4'-tetrachlorobiphenyl:9:0.4000	0.4000	9
PCBF	PCBF:7	capillary blood flow:7:0.3524	0.3524	7
PCBM	PCBM:13	particulate cancellous bone and marrow:13:0.7753	0.7753	13
PCBP2	PCBP2:7	poly(rC) binding protein 2:7:0.4438	0.4438	7
PCBs	PCBs:2085|Pcbs:2|PCBS:2	polychlorinated biphenyls:2073:0.9640|polychlorinated biphenyl:16:0.8165	0.9640	2089
PCBs	PCBs:14	Polychlorinated biphenyl congeners:14:0.7909	0.7909	14
PCBs	PCBs:49	Polychlorobiphenyls:49:0.0213	0.0213	49
PCB	PCB:34	Aroclor 1254:34:0.8681	0.8681	34
PCB	PCB:24	paracervical block:24:0.5160	0.5160	24
PCB	PCB:11	pentachlorobenzene:11:0.0073	0.0073	11
PCB	PCB:33	phycocyanobilin:33:0.0234	0.0234	33
PCB	PCB:8	placental/umbilical cord blood:8:0.3463	0.3463	8
PCB	PCB:1004|pcb:1	polychlorinated biphenyl:648:0.9620|polychlorinated biphenyls:357:0.9420	0.9620	1005
PCB	PCB:35	Polychlorobiphenyl:20:0.0139|polychlorobiphenyls:15:0.0102	0.0139	35
PCB	PCB:13	printed circuit board:13:0.7753	0.7753	13
PCB	PCB:27	procarbazine:27:0.0190	0.0190	27
PCB	PCB:8	psoas compartment block:8:0.6794	0.6794	8
PCCC	PCCC:14	posterior continuous curvilinear capsulorhexis:14:0.7909	0.7909	14
PCCs	PCCs:7	poison control centers:7:0.5926	0.5926	7
PCCs	PCCs:21	prothrombin complex concentrates:21:0.8594	0.8594	21
PCC	PCC:11	chloride:11:0.0137	0.0137	11
PCC	PCC:9|Pcc:2	Correlation Coefficient:11:0.7357	0.7357	11
PCC	PCC:5	patient-centered care:5:0.0736	0.0736	5
PCC	PCC:10	percutaneous cervical cordotomy:10:0.7103	0.7103	10
PCC	PCC:9	peripheral cholangiocarcinoma:9:0.5470	0.5470	9
PCC	PCC:10|pcc:3	pigeon cytochrome c:13:0.6701	0.6701	13
PCC	PCC:5	plasma corticosterone concentration:5:0.2818	0.2818	5
PCC	PCC:5|pcc:1	plasma cortisol concentration:6:0.3728	0.3728	6
PCC	PCC:10	poison control center:10:0.7103	0.7103	10
PCC	PCC:5	Postcoital contraception:5:0.1132	0.1132	5
PCC	PCC:19	posterior cingulate cortex:19:0.8449	0.8449	19
PCC	PCC:181	Premature chromosome condensation:181:0.9835	0.9835	181
PCC	PCC:35	prematurely condensed chromosomes:35:0.8681	0.8681	35
PCC	PCC:5	primary care center:5:0.2818	0.2818	5
PCC	PCC:14	Primary Care Centre:14:0.7909	0.7909	14
PCC	PCC:46	Propionyl-CoA carboxylase:32:0.5078|propionyl CoA carboxylase:14:0.6911	0.6911	46
PCC	PCC:61	prothrombin complex concentrate:33:0.8605|prothrombin complex concentrates:28:0.8941	0.8941	61
PCC	PCC:9	Pyridinium chlorochromate:9:0.6794	0.6794	9
PCDAI	PCDAI:22	Crohn's Disease Activity Index:22:0.7955	0.7955	22
PCDD	PCDD:84	polychlorinated dibenzo-p-dioxins:56:0.8067|polychlorinated dibenzo-p-dioxin:28:0.7154	0.8067	84
PCDD	PCDD:7	polychlorinated dibenzodioxin:7:0.3524	0.3524	7
PCDD/F	PCDD/F:23	polychlorinated dibenzo-p-dioxins and dibenzofurans:23:0.8115	0.8115	23
PCDD/F	PCDD/F:6	polychlorinated dioxins and furans:6:0.5290	0.5290	6
PCDD/Fs	PCDD/Fs:54	polychlorinated dibenzo-p-dioxins and dibenzofurans:54:0.8731	0.8731	54
PCDD/Fs	PCDD/Fs:8	polychlorinated dibenzo-p-dioxins and furans:8:0.5006	0.5006	8
PCDDs	PCDDs:336|PCDDS:1	polychlorinated dibenzo-p-dioxins:337:0.8865	0.8865	337
PCDDs	PCDDs:31	polychlorinated dibenzodioxins:31:0.7388	0.7388	31
PCDDs	PCDDs:7	polychlorinated dioxins:7:0.2452	0.2452	7
PCDEs	PCDEs:11	polychlorinated diphenyl ethers:11:0.5000	0.5000	11
PCDF	PCDF:11	2,3,4,7,8-pentachlorodibenzofuran:11:0.0649	0.0649	11
Pcdh	Pcdh:10	protocadherin:10:0.6923	0.6923	10
PCEA	PCEA:103	patient-controlled epidural analgesia:103:0.7848	0.7848	103
pCEC	pCEC:11	Pressurized capillary electrochromatography:11:0.4232	0.4232	11
PCEC	PCEC:14	Purified Chick Embryo Cell:14:0.6701	0.6701	14
PCEs	PCEs:56	polychromatic erythrocytes:56:0.9467	0.9467	56
PCE	PCE:88	perchloroethylene:88:0.1693	0.1693	88
PCE	PCE:76	polychromatic erythrocytes:67:0.8874|polychromatic erythrocyte:9:0.6794	0.8874	76
PCE	PCE:81	tetrachloroethene:81:0.1556	0.1556	81
PCE	PCE:91	tetrachloroethylene:91:0.1751	0.1751	91
PCFIA	PCFIA:25|PC-FIA:1	particle concentration fluorescence immunoassay:26:0.8861	0.8861	26
PCF	PCF:8	photonic crystal fiber:8:0.6411	0.6411	8
PCF	PCF:14	platelet contractile force:14:0.6911	0.6911	14
PCF	PCF:11	polycationic ferritin:11:0.3213	0.3213	11
PCF	PCF:6	polycationized ferritin:6:0.0666	0.0666	6
PCF	PCF:10	posterior cranial fossa:10:0.7103	0.7103	10
PCGs	PCGs:38	primary care groups:38:0.9217	0.9217	38
PCG	PCG:28|PcG:3|Pc-G:1|PC-G:1	benzylpenicillin:33:0.0635	0.0635	33
PCG	PCG:21|PC-G:6|PcG:2	penicillin G:29:0.8978	0.8978	29
PCG	PCG:25	phonocardiogram:25:0.0476	0.0476	25
PCG	PCG:13	plasma cell granuloma:13:0.7753	0.7753	13
PcG	PcG:185|Pc-G:52	Polycomb group:200:0.9057|Polycomb-group:37:0.0714	0.9057	237
PCG	PCG:29	Primary Congenital Glaucoma:29:0.8978	0.8978	29
PCHI	PCHI:10	permanent childhood hearing impairment:10:0.7103	0.7103	10
PCH	PCH:23	paroxysmal cold hemoglobinuria:23:0.8715	0.8715	23
PCh	PCh:8|PCH:1	phosphatidylcholine:9:0.0447	0.0447	9
PCh	PCh:9|Pch:1	phosphocholine:10:0.0503	0.0503	10
PCH	PCH:8	photon counting histogram:8:0.6411	0.6411	8
PCH	PCH:13	Pulmonary capillary hemangiomatosis:13:0.7753	0.7753	13
PCIA	PCIA:5	patient controlled intravenous analgesia:5:0.4422	0.4422	5
PC-IOLs	PC-IOLs:8|PCIOLs:5	posterior chamber intraocular lenses:13:0.7753	0.7753	13
PC-IOL	PC-IOL:65|PCIOL:33	posterior chamber intraocular lens:90:0.9668|posterior chamber intraocular lenses:8:0.6411	0.9668	98
PC-IRV	PC-IRV:9|PCIRV:7	inverse ratio ventilation:16:0.5171	0.5171	16
PCIT	PCIT:7	Parent-Child Interaction Therapy:7:0.5926	0.5926	7
PCIs	PCIs:5	pharmacological cdk inhibitors:5:0.1973	0.1973	5
Pci	Pci:10	Isogravimetric capillary pressure:10:0.7103	0.7103	10
PCI	PCI:18	partial coherence interferometry:18:0.8365	0.8365	18
PCI	PCI:1140	percutaneous coronary intervention:993:0.9812|percutaneous coronary interventions:147:0.9566	0.9812	1140
PCI	PCI:7	peritoneal cancer index:7:0.2452	0.2452	7
PCI	PCI:8	Phenomenology of Consciousness Inventory:8:0.6411	0.6411	8
PCI	PCI:12	Photochemical internalisation:12:0.7571	0.7571	12
PCI	PCI:15	photochemical internalization:15:0.7909	0.7909	15
PCI	PCI:25	physiological cost index:25:0.7679	0.7679	25
PCI	PCI:61	Pneumatosis cystoides intestinalis:61:0.9511	0.9511	61
PCI	PCI:11	positive chemical ionization:11:0.5355	0.5355	11
PCI	PCI:17	Potato carboxypeptidase inhibitor:17:0.8270	0.8270	17
PCI	PCI:5	proliferating cell index:5:0.0736	0.0736	5
PCI	PCI:123	prophylactic cranial irradiation:123:0.9370	0.9370	123
PCI	PCI:113	Protein C inhibitor:113:0.8779	0.8779	113
PcjO2	PcjO2:16|Pcjo2:1|PCJO2:1|pcjO2:1	conjunctival oxygen tension:19:0.6381	0.6381	19
PCKD	PCKD:8	polycystic kidney disease:8:0.5006	0.5006	8
PCK	PCK:42|Pck:3|pck:2	phosphoenolpyruvate carboxykinase:47:0.9006	0.9006	47
PCL-C	PCL-C:10|PCLC:1	PTSD Checklist-Civilian version:11:0.6182	0.6182	11
PCLD	PCLD:14	polycystic liver disease:14:0.7909	0.7909	14
PCLI	PCLI:11	plasma cell labeling index:11:0.7357	0.7357	11
PCL-R	PCL-R:12	Psychopathy Checklist:12:0.7571	0.7571	12
PCL-R	PCL-R:36	Psychopathy Checklist-Revised:36:0.9174	0.9174	36
PCLS	PCLS:8	Precision-cut liver slices:8:0.3463	0.3463	8
PCl	PCl:3|Pcl:1|pCl:1	Cl- permeability:5:0.0612	0.0612	5
PCL	PCL:12	pacing cycle length:12:0.4444	0.4444	12
PCl	PCl:26|PCL:5|Pcl:2	picryl chloride:33:0.6656	0.6656	33
PCL	PCL:19	plasma cell leukaemia:19:0.7658	0.7658	19
PCL	PCL:69	plasma cell leukemia:69:0.9561	0.9561	69
PCL	PCL:134|p-CL:1	poly(epsilon-caprolactone):120:0.1221|poly-epsilon-caprolactone:12:0.0112|poly epsilon-caprolactone:3:0.4363	0.4363	135
PCL	PCL:47	polycaprolactone:47:0.0458	0.0458	47
Pcl	Pcl:9|PCL:3	Polycomblike:12:0.0112	0.0112	12
PCL	PCL:14	posterior chamber lenses:7:0.5926|posterior chamber lens:7:0.5926	0.5926	14
PCL	PCL:9	posterior collagenous layer:9:0.6794	0.6794	9
PCL	PCL:270	posterior cruciate ligament:270:0.9763	0.9763	270
PCL	PCL:13	primary cardiac lymphoma:13:0.7753	0.7753	13
PCL	PCL:9	Primary cerebral lymphoma:9:0.6794	0.6794	9
PCL	PCL:8	Psychopathy Checklist:8:0.1196	0.1196	8
PCL	PCL:9	PTSD Checklist:9:0.1994	0.1994	9
PCL	PCL:5	Purkinje cell layer:5:0.1464	0.1464	5
PCMBS	PCMBS:30|pCMBS:11|p-CMBS:2|pcmbs:1	p-chloromercuribenzene sulfonate:44:0.7619	0.7619	44
PCMBS	PCMBS:3|pCMBS:3|p-CMBS:1	p-chloromercuribenzene sulphonate:7:0.3524	0.3524	7
pCMBS	pCMBS:14|PCMBS:6|p-CMBS:3	p-chloromercuribenzenesulfonate:23:0.1014	0.1014	23
pCMBS	pCMBS:6|PCMBS:3	p-chloromercuribenzenesulphonate:9:0.0369	0.0369	9
PCMH	PCMH:11	p-cresol methylhydroxylase:11:0.6182	0.6182	11
pCMPS	pCMPS:4|PCMPS:3|p-CMPS:1	p-chloromercuriphenyl sulfonate:8:0.4102	0.4102	8
pCMPS	pCMPS:7|PCMPS:2|p-CMPS:2	p-chloromercuriphenylsulfonate:11:0.1695	0.1695	11
pCMPS	pCMPS:8|PCMPS:3|p-CMPS:1	p-chloromercuriphenylsulfonic acid:12:0.2549	0.2549	12
PCMS	PCMS:7	p-chloromercuriphenylsulfonic acid:7:0.2113	0.2113	7
PCMV	PCMV:24	porcine cytomegalovirus:24:0.5848	0.5848	24
PCM	PCM:9	case management:9:0.3945	0.3945	9
PCM	PCM:17	conditioned medium:17:0.4246	0.4246	17
PCM	PCM:6	pericellular matrix:6:0.1320	0.1320	6
PCM	PCM:36	pericentriolar material:36:0.8003	0.8003	36
PCM	PCM:24	Phase contrast microscopy:13:0.6701|phase-contrast microscopy:11:0.1845	0.6701	24
PCM	PCM:150	protein-calorie malnutrition:103:0.5654|protein calorie malnutrition:47:0.9379	0.9379	150
PCM	PCM:4	sera from patients with paracoccidioidomycosis:4:0.1591	0.1591	4
PCNA-LI	PCNA-LI:10|PCNALI:1	proliferating cell nuclear antigen labeling index:11:0.6182	0.6182	11
PCNA	PCNA:9	proliferating cell nuclear Ag:9:0.6794	0.6794	9
PCNA	PCNA:3317|Pcna:3|pCNA:1|pcna:1	proliferating cell nuclear antigen:3309:0.9162|proliferating cell nuclear antigens:13:0.6701	0.9162	3322
PCNA	PCNA:5	proliferation index:5:0.1132	0.1132	5
PCNB	PCNB:24	pentachloronitrobenzene:24:0.5000	0.5000	24
PCNL	PCNL:104	percutaneous nephrolithotomy:104:0.9543	0.9543	104
PCNL	PCNL:21	percutaneous nephrolithotripsy:21:0.8594	0.8594	21
PCNSLs	PCNSLs:14	Primary central nervous system lymphomas:14:0.7909	0.7909	14
PCNSL	PCNSL:216|pC-NSL:1|PCNS-L:1	primary central nervous system lymphoma:182:0.9835|Primary central nervous system lymphomas:36:0.9151	0.9835	218
PCNSL	PCNSL:65|P-CNSL:1	Primary CNS lymphoma:55:0.8645|Primary CNS lymphomas:11:0.7357	0.8645	66
PCNs	PCNs:58	polychlorinated naphthalenes:58:0.8281	0.8281	58
PCN	PCN:24	penicillin:24:0.0590	0.0590	24
PCN	PCN:14	percutaneous nephrolithotomy:14:0.7909	0.7909	14
PCN	PCN:49	percutaneous nephrostomy:49:0.9392	0.9392	49
PCN	PCN:70	pregnenolone-16 alpha-carbonitrile:70:0.6868	0.6868	70
PCN	PCN:62	pregnenolone-16alpha-carbonitrile:47:0.1154|pregnenolone 16alpha-carbonitrile:15:0.7096	0.7096	62
pCO(2)	pCO(2):5	CO(2) partial pressure:5:0.1464	0.1464	5
PCO(2)	PCO(2):12|pCO(2):5|Pco(2):3	partial pressure of carbon dioxide:20:0.8525	0.8525	20
PCOD	PCOD:144	polycystic ovarian disease:144:0.9791	0.9791	144
PCOD	PCOD:37	polycystic ovary disease:37:0.9197	0.9197	37
PcomA	PcomA:10|PComA:8	posterior communicating artery:18:0.7539	0.7539	18
PCOOH	PCOOH:66|PC-OOH:12	phosphatidylcholine hydroperoxide:78:0.8709	0.8709	78
PCOS	PCOS:296|PCOs:1	polycystic ovarian syndrome:297:0.9784	0.9784	297
PCOS	PCOS:9|PCOs:8	polycystic ovaries:17:0.8270	0.8270	17
PCOS	PCOS:1308|PCOs:4|pcos:1	polycystic ovary syndrome:1313:0.9907	0.9907	1313
PCOs	PCOs:16	Potassium channel openers:16:0.6024	0.6024	16
PCO	PCO:21	photocatalytic oxidation:21:0.6040	0.6040	21
PCO	PCO:20	polycystic ovarian:20:0.8525	0.8525	20
PCO	PCO:42	polycystic ovarian disease:42:0.9291	0.9291	42
PCO	PCO:35	polycystic ovarian syndrome:35:0.9151	0.9151	35
PCO	PCO:200	polycystic ovaries:153:0.9320|polycystic ovary:47:0.8703	0.9320	200
PCO	PCO:118	polycystic ovary syndrome:118:0.9744	0.9744	118
PCO	PCO:49	posterior capsular opacification:49:0.9046	0.9046	49
PCO	PCO:220	Posterior capsule opacification:220:0.9864	0.9864	220
PCO	PCO:7	potassium channel opener:7:0.3524	0.3524	7
PCO	PCO:9	pulp canal obliteration:9:0.6794	0.6794	9
PCPB	PCPB:7|p-CPB:1	cardiopulmonary bypass:8:0.5006	0.5006	8
PCPB	PCPB:6	procarboxypeptidase B:6:0.2243	0.2243	6
PCPs	PCPs:5	peptidyl carrier proteins:5:0.2818	0.2818	5
PCPS	PCPS:109	percutaneous cardiopulmonary support:109:0.9559	0.9559	109
PCPS	PCPS:21	Percutaneous cardiopulmonary support system:21:0.7291	0.7291	21
PCPs	PCPs:121	primary care physicians:121:0.9606	0.9606	121
PCPs	PCPs:9	primary care practitioners:9:0.6794	0.6794	9
PCPs	PCPs:42	primary care providers:42:0.8893	0.8893	42
PCPT	PCPT:20	Prostate Cancer Prevention Trial:20:0.8525	0.8525	20
PCP	PCP:12	[3H]Phencyclidine:12:0.0029	0.0029	12
PCP	PCP:559|pcp:1	pentachlorophenol:560:0.1487	0.1487	560
PCP	PCP:20	peptidyl carrier protein:20:0.8525	0.8525	20
PCP	PCP:1205	phencyclidine:1205:0.3185	0.3185	1205
PCP	PCP:18	phencyclidine hydrochloride:18:0.5940	0.5940	18
PCP	PCP:10	phenol-chloroform-petroleum ether:10:0.4363	0.4363	10
PCP	PCP:55	planar cell polarity:55:0.8427	0.8427	55
PCP	PCP:10	pneumococcal capsular polysaccharide:10:0.5000	0.5000	10
PCP	PCP:28|PcP:2	Pneumocystis carinii:30:0.8519	0.8519	30
PCP	PCP:1042|PcP:10|Pcp:1|pcp:1	Pneumocystis carinii pneumonia:1054:0.8799	0.8799	1054
PCP	PCP:14	Pneumocystis carinii pneumonitis:14:0.4071	0.4071	14
PCP	PCP:80	primary care physician:59:0.9203|primary care physicians:21:0.8594	0.9203	80
PCP	PCP:42	primary care provider:42:0.9291	0.9291	42
PCP	PCP:10|pCP:1	Procollagen C-proteinase:11:0.7357	0.7357	11
PCP	PCP:6	protein C activation peptide:6:0.5290	0.5290	6
PCP	PCP:38|Pcp:1	pulmonary capillary pressure:39:0.8142	0.8142	39
Pcp	Pcp:8|PCP:1	pyrrolidone carboxyl peptidase:9:0.6794	0.6794	9
PCQ	PCQ:10	Questionnaire:10:0.5294	0.5294	10
PCR-EIA	PCR-EIA:8	enzyme immunoassay:8:0.1125	0.1125	8
PCR-EIA	PCR-EIA:10	polymerase chain reaction-enzyme immunoassay:10:0.7103	0.7103	10
PCR-ISH	PCR-ISH:9	situ hybridization:9:0.6794	0.6794	9
PCR-SSP	PCR-SSP:18	PCR amplification with sequence-specific primers:18:0.5721	0.5721	18
PCR-SSP	PCR-SSP:10	polymerase chain reaction:10:0.5000	0.5000	10
PCR-SSP	PCR-SSP:13	polymerase chain reaction-sequence-specific primer:13:0.7753	0.7753	13
PCR-SSP	PCR-SSP:33	polymerase chain reaction using sequence-specific primers:33:0.9612	0.9612	33
PCR-SSP	PCR-SSP:12	polymerase chain reaction with sequence specific primers:12:0.7909	0.7909	12
pCREB	pCREB:24|p-CREB:5	element binding protein:29:0.7581	0.7581	29
pCREB	pCREB:10|p-CREB:1	phosphorylated cAMP response element-binding protein:11:0.5355	0.5355	11
pCREB	pCREB:32|P-CREB:10|p-CREB:9|PCREB:1	phosphorylated CREB:52:0.6223	0.6223	52
PCRn	PCRN:9|PCRn:9	normalized protein catabolic rate:18:0.6381	0.6381	18
PCRS	PCRS:7	Patient Competency Rating Scale:7:0.5926	0.5926	7
PCRt	PCRt:7	Parvocellular reticular nucleus:7:0.3524	0.3524	7
pCR	pCR:15|PCR:2	complete remission:17:0.8270	0.8270	17
PCR	PCR:10	enzymatic amplification:10:0.0578	0.0578	10
pCR	pCR:38|PCR:7	pathologic complete response:45:0.3835	0.3835	45
PCr	PCr:12	phosphocreatinine:12:0.0004	0.0004	12
PCR	PCR:8	plaque control record:8:0.6411	0.6411	8
PCr	PCr:12|Pcr:7|P-Cr:3|pCr:2	plasma creatinine:24:0.5598	0.5598	24
PCr	PCr:6|Pcr:3	plasma creatinine concentration:9:0.5470	0.5470	9
PCR	PCR:10	polymerase chain:10:0.7103	0.7103	10
PCR	PCR:22630|pcr:6|PcR:1|PCr:1	polymerase chain reaction:22404:0.9737|polymerase chain reactions:152:0.9487|polymerase-chain-reaction:67:0.0026|polymerase chain-reaction:15:0.7096	0.9737	22638
PCR	PCR:13	polymerase chain reaction amplification:13:0.7753	0.7753	13
PCR	PCR:20	polymerase chain reaction assay:20:0.7766	0.7766	20
PCR	PCR:25	polymerase chain reaction method:25:0.8816	0.8816	25
PCR	PCR:26	polymerase chain reaction technique:26:0.7760	0.7760	26
PCR	PCR:51	Principal Component Regression:51:0.8799	0.8799	51
PCR	PCR:97|pcr:10	protein catabolic rate:107:0.9721	0.9721	107
PCR	PCR:9	psychiatric case register:9:0.6794	0.6794	9
PCS-12	PCS-12:10	physical component summary:10:0.7103	0.7103	10
PCSA	PCSA:26|P-CSA:1	physiological cross-sectional area:27:0.7834	0.7834	27
Pcsf	Pcsf:7|PCSF:6	cerebrospinal fluid pressure:13:0.6701	0.6701	13
PCs	PCs:14	carcinomas:14:0.0067	0.0067	14
PCS	PCS:7	care services:7:0.2902	0.2902	7
PCS	PCS:8	Pain Catastrophizing Scale:8:0.6411	0.6411	8
PCS	PCS:6	palliative care service:6:0.5290	0.5290	6
PCS	PCS:6	paracingulate sulcus:6:0.2243	0.2243	6
PCs	PCs:19|pcs:1	partition coefficients:20:0.7173	0.7173	20
PCS	PCS:17	Patient Classification System:12:0.7571|patient classification systems:5:0.4422	0.7571	17
PCS	PCS:25	patient-controlled sedation:25:0.7249	0.7249	25
PCS	PCS:44	Patterns of Care Study:44:0.9323	0.9323	44
PCs	PCs:10	penicillins:10:0.0046	0.0046	10
PCs	PCs:11	pericytes:11:0.0052	0.0052	11
PCs	PCs:79	phosphatidylcholines:79:0.0403	0.0403	79
PCS	PCS:33	physical:33:0.0165	0.0165	33
PCS	PCS:10	Physical Component Scale:10:0.5000	0.5000	10
PCS	PCS:11	physical component score:11:0.6182	0.6182	11
PCS	PCS:79	Physical component summary:79:0.9210	0.9210	79
PCS	PCS:5	Physical Component Summary Score:5:0.4422	0.4422	5
PCs	PCs:30	Phytochelatins:30:0.0150	0.0150	30
PCS	PCS:8	Phytochelatin synthase:8:0.0863	0.0863	8
PCs	PCs:54	plasma cells:54:0.1503	0.1503	54
PCs	PCs:198|PCS:2|Pcs:1	platelet concentrates:201:0.8752	0.8752	201
PCS	PCS:84|pcs:2	portacaval shunt:74:0.7286|portacaval shunts:12:0.6460	0.7286	86
PCS	PCS:17	portacaval shunted:17:0.7407	0.7407	17
PCS	PCS:10	portacaval shunting:10:0.5856	0.5856	10
PCS	PCS:6	post-concussion symptoms:6:0.0666	0.0666	6
PCS	PCS:12	post-concussion syndrome:12:0.0659	0.0659	12
PCS	PCS:16	postconcussion syndrome:16:0.1092	0.1092	16
PCS	PCS:7	postconcussive symptoms:7:0.1111	0.1111	7
PCS	PCS:5	Premature centromere separation:5:0.4422	0.4422	5
PCS	PCS:5	premature chromatid separation:5:0.4422	0.4422	5
PCs	PCs:51|PCS:1	principal components:52:0.8821	0.8821	52
PCs	PCs:31	proprotein convertases:31:0.2785	0.2785	31
PCs	PCs:146	Purkinje cells:146:0.4840	0.4840	146
pCTL	pCTL:6|PCTL:1	cytotoxic T lymphocytes:7:0.4438	0.4438	7
pCTL	pCTL:12	precursors:12:0.1864	0.1864	12
pCTL	pCTL:11|p-CTL:1	precursor CTL:12:0.6701	0.6701	12
PC-TP	PC-TP:22|PCTP:5|Pc-tp:1	phosphatidylcholine transfer protein:28:0.6839	0.6839	28
PCTs	PCTs:5	clinical trials:5:0.0902	0.0902	5
PCTs	PCTs:5	placebo-controlled trials:5:0.0902	0.0902	5
PCTs	PCTs:15|Pcts:1	plasmacytomas:16:0.1136	0.1136	16
PCTs	PCTs:11	polychlorinated terphenyls:11:0.5355	0.5355	11
PCTs	PCTs:9	postcoital tests:9:0.6794	0.6794	9
PCTs	PCTs:7	Primary Care teams:7:0.3524	0.3524	7
PCTs	PCTs:36	primary care trusts:36:0.9174	0.9174	36
PCT	PCT:4	papillary cystic tumor:4:0.4422	0.4422	4
PCT	PCT:17	parasite clearance time:17:0.8270	0.8270	17
PCT	PCT:7	perfusion CT:7:0.1641	0.1641	7
PCT	PCT:25	photochemical treatment:25:0.6539	0.6539	25
PCT	PCT:11	photochemotherapy:11:0.0067	0.0067	11
PCT	PCT:9|Pct:1	plasmacytoma:10:0.0061	0.0061	10
PCT	PCT:18	polychemotherapy:18:0.0114	0.0114	18
pCT	pCT:8|PCT:3	porcine calcitonin:11:0.5355	0.5355	11
PCT	PCT:321|Pct:1	Porphyria cutanea tarda:322:0.9625	0.9625	322
PCT	PCT:22	positron computed tomography:22:0.5581	0.5581	22
PCT	PCT:14	post-coital test:14:0.1103	0.1103	14
PCT	PCT:27	postcoital test:27:0.3054	0.3054	27
PCT	PCT:9	postcoital testing:9:0.3945	0.3945	9
PCT	PCT:30	Primary Care Team:16:0.4536|primary care teams:14:0.7909	0.7909	30
PCT	PCT:16	primary care trust:16:0.8165	0.8165	16
PCT	PCT:6|P-CT:1	primary chemotherapy:7:0.1329	0.1329	7
PCT	PCT:289	procalcitonin:289:0.1939	0.1939	289
PCT	PCT:25	proximal convoluted:25:0.7249	0.7249	25
PCT	PCT:248	proximal convoluted tubule:160:0.9813|proximal convoluted tubules:88:0.9660	0.9813	248
PCT	PCT:9	pupil cycle time:9:0.4587	0.4587	9
PCU	PCU:21	palliative care unit:21:0.7291	0.7291	21
PCU	PCU:7|PC-U:3	unawareness:10:0.1324	0.1324	10
PCV1	PCV1:15|PCV-1:1	Porcine circovirus type 1:16:0.8165	0.8165	16
PCV2	PCV2:30|PCV-2:6	porcine circovirus 2:36:0.9174	0.9174	36
PCV2	PCV2:93|PCV-2:21	Porcine circovirus type 2:114:0.9579	0.9579	114
PCV2	PCV2:6|PCV-2:1	Type 2 porcine circovirus:7:0.5926	0.5926	7
PCV7	PCV7:25|PCV-7:3	pneumococcal conjugate vaccine:28:0.8369	0.8369	28
PCVs	PCVs:10	packed cell volumes:10:0.7103	0.7103	10
PCV	PCV:19	haematocrit:19:0.0169	0.0169	19
PCV	PCV:470|pcv:1	packed cell volume:453:0.9272|packed cell volumes:18:0.6381	0.9272	471
PCV	PCV:55	parietal cell vagotomy:55:0.9458	0.9458	55
PCV	PCV:12	peanut clump virus:12:0.7571	0.7571	12
PCV	PcV:5|PCV:5|pcV:3	phenoxymethylpenicillin:13:0.0113	0.0113	13
PCV	PCV:31	pneumococcal conjugate vaccine:31:0.7388	0.7388	31
PCV	PCV:8	polycythemia vera:8:0.4102	0.4102	8
PCV	PCV:27	polypoidal choroidal vasculopathy:27:0.8903	0.8903	27
PCV	PCV:52	porcine circovirus:52:0.8821	0.8821	52
PCV	PCV:13	post-capillary venules:13:0.1962	0.1962	13
PCV	PCV:17	postcapillary venules:17:0.3109	0.3109	17
PCV	PCV:9	pressure control ventilation:9:0.6794	0.6794	9
PCV	PCV:33	pressure-controlled ventilation:33:0.4488	0.4488	33
Pcv	Pcv:8|PCV:1	venous pressure:9:0.4587	0.4587	9
PCWP	PCWP:481|Pcwp:1	pulmonary capillary wedge pressure:466:0.9770|pulmonary capillary wedge pressures:16:0.6748	0.9770	482
PCW	PCW:8	cell walls:8:0.5006	0.5006	8
PCW	PCW:18|Pcw:1	pulmonary capillary wedge:19:0.8449	0.8449	19
PCW	PCW:30|Pcw:4|PCw:1	pulmonary capillary wedge pressure:35:0.9151	0.9151	35
PCx	PCx:7	piriform cortex:7:0.2452	0.2452	7
PCZ	PCZ:13	Procarbazine:13:0.3750	0.3750	13
PCZ	PCZ:11	prochlorperazine:11:0.3125	0.3125	11
PCase	PCase:10	penicillinase:10:0.5294	0.5294	10
PCCM	PCCM:10	primary care case management:10:0.7103	0.7103	10
PChE	PChE:14|PCHE:7|pChe:5|P-ChE:1|pChE:1	plasma cholinesterase:28:0.7905	0.7905	28
PChE	PChE:16|PCHE:7|pChE:2|PChe:1	Pseudocholinesterase:26:0.3472	0.3472	26
PCho	PCho:40|P-Cho:5|Pcho:2	phosphocholine:47:0.6389	0.6389	47
PCho	PCho:12|P-Cho:2|PCHO:1	phosphorylcholine:15:0.1944	0.1944	15
PCoA	PCoA:35|PcoA:1	posterior communicating artery:36:0.8716	0.8716	36
PCr/Pi	PCr/Pi:14	phosphate ratio:14:0.7909	0.7909	14
PCr/Pi	PCr/Pi:14	phosphocreatine/inorganic phosphate:14:0.1623	0.1623	14
PCr/Pi	PCr/Pi:12	ratio of phosphocreatine to inorganic phosphate:12:0.4102	0.4102	12
PC	PC:17	Anti-phosphocholine:17:0.0017	0.0017	17
PC	PC:33	anti-phosphorylcholine:33:0.0034	0.0034	33
Pc	Pc:53|PC:5	capillary pressure:58:0.4877	0.4877	58
PC	PC:8	cells of the parvocellular:8:0.0756	0.0756	8
PC	PC:10|pc:1	chemotherapy:11:0.0011	0.0011	11
PC	PC:9	cholesterol:9:0.0008	0.0008	9
PC	PC:11	cine phase-contrast:11:0.0691	0.0691	11
PC	PC:10	circulation:10:0.0010	0.0010	10
PC	PC:21	complex:21:0.0021	0.0021	21
PC	PC:26|Pc:2	concentration:28:0.0029	0.0029	28
PC	PC:15	controls:15:0.0015	0.0015	15
PC	PC:5|Pc:1	control group:6:0.2113	0.2113	6
Pc	Pc:7|pc:1	corrected P:8:0.5006	0.5006	8
PC	PC:5|pc:1	days post-challenge:6:0.2243	0.2243	6
PC	PC:8|pc:1	days postchallenge:9:0.2757	0.2757	9
pc	pc:8|PC:1	days postcoitum:9:0.1409	0.1409	9
PC	PC:7	egg lecithin:7:0.1025	0.1025	7
PC	PC:153	ischemic preconditioning:153:0.4815	0.4815	153
PC	PC:19	liver parenchymal cells:19:0.3019	0.3019	19
PC	PC:17	Pachyonychia congenita:17:0.2022	0.2022	17
PC	PC:17	Pacinian corpuscle:17:0.8270	0.8270	17
PC	PC:7	pancreatic adenocarcinoma:7:0.2113	0.2113	7
PC	PC:23	pancreatic carcinoma:23:0.0915	0.0915	23
PC	PC:47	papillary carcinoma:31:0.1386|papillary carcinomas:16:0.4832	0.4832	47
PC	PC:29	paramyotonia congenita:29:0.4526	0.4526	29
PC	PC:9	parenchymal:9:0.0008	0.0008	9
PC	PC:16	parietal cortex:16:0.0738	0.0738	16
PC	PC:27|Pc:2	partition coefficient:20:0.5892|partition coefficients:9:0.5470	0.5892	29
PC	PC:11	patients with pancreatic cancer:11:0.0667	0.0667	11
PC	PC:10	patients with prostatic cancer:10:0.0713	0.0713	10
PC	PC:9	pelvic control:9:0.0504	0.0504	9
PC	PC:8|Pc:6|pc:1	penicillin:15:0.0015	0.0015	15
PC	PC:9	pentose cycle:9:0.4587	0.4587	9
PC	PC:20	percutaneous cholecystostomy:20:0.7173	0.7173	20
PC	PC:27	peritoneal carcinomatosis:27:0.8903	0.8903	27
PC	PC:11|Pc:1	peritoneal cavity:12:0.5050	0.5050	12
PC	PC:93|Pc:1	peritoneal cells:78:0.1960|peritoneal cell:16:0.0557	0.1960	94
PC	PC:153|pc:1	personal computer:140:0.9444|personal computers:14:0.7909	0.9444	154
PC	PC:9	pharyngeal constrictor:9:0.6794	0.6794	9
PC	PC:43	phase contrast:43:0.7795	0.7795	43
PC	PC:14	pheochromocytoma:14:0.0014	0.0014	14
PC	PC:108	phosphatidyl choline:92:0.7637|phosphatidyl-choline:16:0.0016	0.7637	108
PC	PC:3074|pC:1|Pc:1	phosphatidylcholine:2991:0.3166|phosphatidylcholines:85:0.0089	0.3166	3076
PC	PC:92	phosphocholine:92:0.0096	0.0096	92
PC	PC:12	phosphocitrate:12:0.0012	0.0012	12
PC	PC:227|Pc:4|P-C:1	phosphorylcholine:232:0.0241	0.0241	232
Pc	Pc:17|PC:2	phthalocyanine:19:0.0019	0.0019	19
PC	PC:19|Pc:1	Phycocyanin:20:0.0020	0.0020	20
PC	PC:21	phytochelatin:12:0.0012|phytochelatins:9:0.0008	0.0012	21
PC	PC:9	picryl chloride:9:0.2757	0.2757	9
PC	PC:16	pineal calcification:16:0.7261	0.7261	16
PC	PC:55	piriform cortex:55:0.4123	0.4123	55
PC	PC:105|Pc:2	plasma cells:67:0.1637|plasma cell:40:0.2060	0.2060	107
PC	PC:6	plasma concentrations:6:0.2243	0.2243	6
PC	PC:12	plasmacytoma:12:0.0012	0.0012	12
PC	PC:36|Pc:12|pc:5	plastocyanin:53:0.0055	0.0055	53
PC	PC:211|Pc:1	Platelet concentrates:161:0.9605|platelet concentrate:51:0.6647	0.9605	212
PC	PC:51|Pc:1|pc:1	platelet count:43:0.7363|platelet counts:10:0.4363	0.7363	53
PC	PC:83|Pc:38|pc:16	Pneumocystis carinii:137:0.9437	0.9437	137
PC	PC:5	pneumotaxic center:5:0.1132	0.1132	5
PC	PC:49	polycarbonate:49:0.0051	0.0051	49
PC	PC:10	polycarbophil:10:0.0010	0.0010	10
Pc	Pc:59|PC:5	Polycomb:64:0.0066	0.0066	64
PC	PC:11|pc:3|P-C:1	positive control:15:0.1371	0.1371	15
pc	pc:12|PC:3	post coitum:15:0.8045	0.8045	15
pc	pc:11|PC:6	postcoitus:17:0.0017	0.0017	17
PC	PC:11|pc:6	postconception:17:0.0017	0.0017	17
PC	PC:5	posterior canal:5:0.0517	0.0517	5
PC	PC:29	Posterior chamber:29:0.8978	0.8978	29
PC	PC:8	posterior compartment:8:0.1730	0.1730	8
PC	PC:5	posterior semicircular canal:5:0.4422	0.4422	5
PC	PC:9	preconditioned:9:0.0010	0.0010	9
PC	PC:10	Prednicarbate:10:0.0010	0.0010	10
PC	PC:5	preoperative complications:5:0.0736	0.0736	5
PC	PC:90	primary care:90:0.6369	0.6369	90
PC	PC:16	primary closure:16:0.7261	0.7261	16
PC	PC:83|pc:1	principal component:63:0.8259|principal components:21:0.8594	0.8594	84
PC	PC:14	procerebral:14:0.0014	0.0014	14
PC	PC:14	procerebrum:14:0.0014	0.0014	14
PC	PC:9	procollagen:9:0.0008	0.0008	9
PC	PC:26	prohormone convertase:20:0.2759|prohormone convertases:6:0.1838	0.2759	26
PC	PC:16	proprotein convertase:16:0.1879	0.1879	16
PC	PC:10	propylene carbonate:10:0.4363	0.4363	10
PC	PC:248	prostate cancer:248:0.6186	0.6186	248
PC	PC:25	prostate carcinoma:25:0.0972	0.0972	25
PC	PC:41	prostatic carcinoma:41:0.2002	0.2002	41
PC	PC:366|pC:2	protein C:368:0.9503	0.9503	368
PC	PC:21	protein carbonyls:11:0.7357|protein carbonyl:10:0.7103	0.7357	21
PC	PC:8	Pseudotumor cerebri:8:0.4102	0.4102	8
PC	PC:82|Pc:6	Purkinje cell:55:0.3082|Purkinje cells:33:0.0675	0.3082	88
PC	PC:96|Pc:2	pyruvate carboxylase:98:0.9082	0.9082	98
PD20	PD20:54	20% fall in FEV1:54:0.9203	0.9203	54
PD20	PD20:14	20% fall in forced expiratory volume in one second:14:0.8045	0.8045	14
PD35	PD35:9	conductance:9:0.2424	0.2424	9
PDAI	PDAI:16	Pouchitis Disease Activity Index:16:0.5564	0.5564	16
PDAC	PDAC:41	pancreatic ductal adenocarcinoma:41:0.9274	0.9274	41
PDAs	PDAs:71|PDAS:1	personal digital assistants:72:0.9344	0.9344	72
PDA	PDA:18	cis-2,3-piperidine dicarboxylic acid:18:0.3548	0.3548	18
PDA	PDA:6	Dorsal aortic blood pressure:6:0.5290	0.5290	6
PDA	PDA:5	pancreatic ductal adenocarcinoma:5:0.2818	0.2818	5
PDA	PDA:12	pancreaticoduodenal artery:12:0.1692	0.1692	12
PDA	PDA:7	panic disorder and agoraphobia:7:0.9126	0.9126	7
PDA	PDA:690	patent ductus arteriosus:690:0.8829	0.8829	690
PDA	PDA:84	Personal Digital Assistant:68:0.9306|Personal Digital Assistants:16:0.8165	0.9306	84
PDA	PDA:32	phorbol 12,13-diacetate:19:0.7173|phorbol-12,13-diacetate:13:0.0082	0.7173	32
PDA	PDA:28	photodiode array:28:0.5837	0.5837	28
PDA	PDA:4	polymorphic delta activity:4:0.0918	0.0918	4
PDA	PDA:13	Population and Community Development Association:13:0.6911	0.6911	13
PDA	PDA:19	posterior descending artery:19:0.8449	0.8449	19
PDA	PDA:31	potato dextrose agar:31:0.8519	0.8519	31
PDA	PDA:11	prolonged depolarizing afterpotential:11:0.7357	0.7357	11
PDBu	PDBu:13|PDBU:2	[3H]phorbol-12,13-dibutyrate:15:0.0173	0.0173	15
PDBu	PDBu:350|PDBU:18|PdBu:17|PdBU:3|Pdbu:2|PDbU:1	phorbol 12,13-dibutyrate:288:0.7374|phorbol-12,13-dibutyrate:103:0.1259	0.7374	391
PDBu	PDBu:90|PDBU:15|PdBu:10|pDBu:1|PdBU:1	phorbol dibutyrate:117:0.5803	0.5803	117
PDBu	PDBu:11	phorbol ester:11:0.4232	0.4232	11
PDB	PDB:21	Paget's disease of bone:21:0.4883	0.4883	21
PDB	PDB:127	phorbol 12,13-dibutyrate:90:0.7424|phorbol-12,13-dibutyrate:26:0.0439|phorbol 12,13 dibutyrate:11:0.6182	0.7424	127
PDB	PDB:40|PdB:1	Phorbol dibutyrate:41:0.5136	0.5136	41
PDB	PDB:208	Protein Data Bank:208:0.9769	0.9769	208
PDB	PDB:11	Protein Databank:11:0.5355	0.5355	11
PDC-E2	PDC-E2:7	E2 component of the pyruvate dehydrogenase complex:7:0.7103	0.7103	7
PDC-E2	PDC-E2:4	E2 subunit of pyruvate dehydrogenase complex:4:0.7103	0.7103	4
PDCAAS	PDCAAS:6	protein digestibility-corrected amino acid score:6:0.5290	0.5290	6
p-DCB	p-DCB:15|pDCB:3|PDCB:1	p-dichlorobenzene:19:0.7200	0.7200	19
PDCs	PDCs:14|pDCs:13	plasmacytoid DCs:27:0.7425	0.7425	27
PDCs	PDCs:29|pDCs:28|P-DCs:3	Plasmacytoid dendritic cells:60:0.8359	0.8359	60
PDC	PDC:10	dialysis capacity:10:0.7103	0.7103	10
PDC	PDC:25	L-trans-pyrrolidine-2,4-dicarboxylate:25:0.0327	0.0327	25
PDC	PDC:16	L-trans-pyrrolidine-2,4-dicarboxylic acid:16:0.2362	0.2362	16
PDC	PDC:4	parkinsonism-dementia complex on Guam:4:0.3524	0.3524	4
PDC	PDC:19	Paroxysmal Dystonic Choreoathetosis:19:0.8449	0.8449	19
PDC	PDC:6|Pdc:2|pdc:1	phosducin:9:0.0109	0.0109	9
PDC	PDC:37|pDC:22|P-DC:1	plasmacytoid dendritic cells:39:0.8142|plasmacytoid dendritic cell:21:0.7865	0.8142	60
PDC	PDC:9	poorly differentiated carcinoma:9:0.6794	0.6794	9
PDC	PDC:60|pdc:8|Pdc:2	pyruvate decarboxylase:70:0.9112	0.9112	70
PDC	PDC:188	pyruvate dehydrogenase complex:188:0.9661	0.9661	188
PDDNOS	PDDNOS:12|PDD-NOS:10	Pervasive Developmental Disorder Not Otherwise Specified:22:0.8115	0.8115	22
PDDR	PDDR:9	D Deficiency Rickets:9:0.6794	0.6794	9
PDDs	PDDs:7	depth doses:7:0.2113	0.2113	7
PDDs	PDDs:41	pervasive developmental disorders:41:0.9274	0.9274	41
PDD	PDD:17	papillomatous digital dermatitis:17:0.8270	0.8270	17
PDD	PDD:13|PD-d:1|PD-D:1	Parkinson's disease with dementia:15:0.6539	0.6539	15
PDD	PDD:10	percent depth dose:10:0.1273	0.1273	10
PDD	PDD:21	percentage depth dose:21:0.4733	0.4733	21
PDD	PDD:131	pervasive developmental disorder:74:0.9361|Pervasive Developmental Disorders:57:0.9477	0.9477	131
PDD	PDD:32|Pdd:1	phorbol 12,13-didecanoate:18:0.4672|phorbol-12,13-didecanoate:15:0.0282	0.4672	33
PDD	PDD:25	photodynamic diagnosis:25:0.8186	0.8186	25
PDD	PDD:11	prescribed daily dose:11:0.7357	0.7357	11
PDD	PDD:15	primary degenerative dementia:15:0.7096	0.7096	15
PDD	PDD:8	pulse dye densitometry:8:0.6411	0.6411	8
PDE1	PDE1:9	phosphodiesterase:9:0.2667	0.2667	9
PDE2	PDE2:13	phosphodiesterase:13:0.4000	0.4000	13
PDE3B	PDE3B:11	phosphodiesterase 3B:11:0.4728	0.4728	11
PDE3	PDE3:20|PDE-3:2	phosphodiesterase:22:0.2838	0.2838	22
PDE3	PDE3:24|PDE-3:1	phosphodiesterase 3:25:0.5095	0.5095	25
PDE4	PDE4:85|PDE-4:5	phosphodiesterase 4:70:0.5583|phosphodiesterase-4:20:0.0776	0.5583	90
PDE4	PDE4:28|PDE-4:2	phosphodiesterase type 4:30:0.8032	0.8032	30
PDE4	PDE4:14|PDE-4:3	type 4 phosphodiesterase:17:0.8270	0.8270	17
PDE5	PDE5:14|PDE-5:2	cGMP-binding cGMP-specific phosphodiesterase:16:0.4618	0.4618	16
PDE5	PDE5:67|PDE-5:16	phosphodiesterase 5:47:0.2531|phosphodiesterase-5:36:0.1316	0.2531	83
PDE5	PDE5:84|PDE-5:13|Pde-5:1	phosphodiesterase type 5:89:0.9467|phosphodiesterase type-5:9:0.6794	0.9467	98
PDE6	PDE6:21|PDE-6:1	phosphodiesterase:22:0.5714	0.5714	22
PD-ECGF	PD-ECGF:137|PDECGF:6	platelet-derived endothelial cell growth factor:143:0.8441	0.8441	143
PDEIs	PDEIs:9|PDEis:1	phosphodiesterase inhibitors:10:0.7103	0.7103	10
PDEI	PDEI:7|PDEi:1	phosphodiesterase inhibitor:8:0.5006	0.5006	8
PDEase	PDEase:15	phosphodiesterase:15:0.9333	0.9333	15
PDEs	PDEs:10	phosphodiesters:10:0.0318	0.0318	10
PDE	PDE:28	cAMP-phosphodiesterase:28:0.0133	0.0133	28
PDE	PDE:28	cGMP-phosphodiesterase:28:0.0133	0.0133	28
PDE	PDE:23	cyclic nucleotide phosphodiesterases:23:0.8715	0.8715	23
PDE	PDE:20|pde:1	partial differential equation:21:0.8594	0.8594	21
PDE	PDE:8	peritoneal dialysate effluent:8:0.6411	0.6411	8
PDE	PDE:27	peritoneal dialysis effluent:27:0.8312	0.8312	27
PDE	PDE:47	pulsed Doppler echocardiography:47:0.9366	0.9366	47
PDFs	PDFs:17	peritoneal dialysis fluids:17:0.8270	0.8270	17
PDFs	PDFs:18|pdfs:9	probability density functions:27:0.8903	0.8903	27
PDF	PDF:46	peptide deformylase:46:0.7921	0.7921	46
PDF	PDF:36	Peritoneal dialysis fluid:20:0.8525|peritoneal dialysis fluids:16:0.8165	0.8525	36
PDF	PDF:17|pdf:1	pigment-dispersing factor:18:0.3857	0.3857	18
PDF	PDF:8	primary dysfunction:8:0.4102	0.4102	8
PDF	PDF:50|pdf:33	probability density function:74:0.9596|probability density functions:9:0.6794	0.9596	83
PDGF	PDGF:3600	platelet-derived growth factor:3580:0.9054|platelet-derived growth factors:20:0.4786	0.9054	3600
PDGF	PDGF:20	Platelet-derived growth factor-BB:20:0.7766	0.7766	20
PDGF-AB	PDGF-AB:11|PDGFAB:1	platelet-derived growth factor:12:0.5050	0.5050	12
PDGF-AB	PDGF-AB:29|PDGFAB:2	platelet-derived growth factor-AB:16:0.5564|platelet-derived growth factor AB:15:0.6386	0.6386	31
PDGF-A	PDGF-A:33|PDGFA:1	platelet-derived growth factor-A:34:0.8245	0.8245	34
PDGF-A	PDGF-A:19|PDGFA:2	platelet-derived growth factor A chain:12:0.7571|platelet-derived growth factor A-chain:9:0.6794	0.7571	21
PDGF-B	PDGF-B:8	platelet-derived growth factor:8:0.4102	0.4102	8
PDGF-B	PDGF-B:50|PDGFB:7|PDGF-b:1	platelet-derived growth factor-B:37:0.7246|platelet-derived growth factor B:21:0.6040	0.7246	58
PDGF-B	PDGF-B:20|PDGFB:6	platelet-derived growth factor B-chain:19:0.8449|platelet-derived growth factor B chain:7:0.4438	0.8449	26
PDGFR	PDGFR:6|PDGF-R:3	PDGF receptors:9:0.2280	0.2280	9
PDGFR	PDGFR:100|PDGF-R:25|PDGFr:11|PDGF-r:5	platelet-derived growth factor receptor:134:0.8490|platelet-derived growth factor receptors:7:0.4438	0.8490	141
PDGF-AA	PDGF-AA:7	platelet-derived growth factor:7:0.3524	0.3524	7
PDGF-AA	PDGF-AA:30|PDGFaa:1	platelet-derived growth factor-AA:22:0.6531|platelet-derived growth factor aa:9:0.4587	0.6531	31
PDGF-BB	PDGF-BB:6	B-chain homodimer:6:0.0731	0.0731	6
PDGF-BB	PDGF-BB:56|PDGFbb:1	platelet-derived growth factor:57:0.8478	0.8478	57
PDGF-BB	PDGF-BB:185|PDGFBB:2|PDGFbb:1|PDGF-bb:1|PD-GF-BB:1	platelet-derived growth factor-BB:141:0.8355|Platelet-derived growth factor bb:49:0.7284	0.8355	190
PDG	PDG:17	phenyldiguanide:17:0.0808	0.0808	17
PDG	PDG:29	phosphate-dependent glutaminase:29:0.6648	0.6648	29
PdG	PdG:9|PDG:2	pregnanediol-3 alpha-glucuronide:11:0.6182	0.6182	11
PdG	PdG:16|PDG:2	pregnanediol-3-glucuronide:18:0.0859	0.0859	18
PdG	PdG:15|Pdg:2|PDG:1	pregnanediol glucuronide:18:0.6381	0.6381	18
PdG	PdG:9	propanodeoxyguanosine:9:0.0404	0.0404	9
PDHC	PDHC:10|PDHc:1	Pyruvate dehydrogenase:11:0.7357	0.7357	11
PDHC	PDHC:103|PDHc:19	pyruvate dehydrogenase complex:122:0.9478	0.9478	122
PDHK	PDHK:11|PDH-K:1	pyruvate dehydrogenase kinase:12:0.7571	0.7571	12
PDHa	PDHa:13|PDHA:2	active form:15:0.4832	0.4832	15
PDHa	PDHa:13|PDHA:2	pyruvate dehydrogenase:15:0.7096	0.7096	15
PDH	PDH:25	dogs with pituitary-dependent hyperadrenocorticism:25:0.4596	0.4596	25
PDH	PDH:21	pigment-dispersing hormone:21:0.5435	0.5435	21
PDH	PDH:9	Progressive disseminated histoplasmosis:9:0.5470	0.5470	9
PDH	PDH:431|pdh:2	pyruvate dehydrogenase:433:0.9314	0.9314	433
PDH	PDH:32|pdh:1	pyruvate dehydrogenase complex:33:0.9100	0.9100	33
PDK4	PDK4:11|pdk4:2|PDK-4:2|Pdk4:1	pyruvate dehydrogenase kinase 4:16:0.8165	0.8165	16
PDK	PDK:10	primary dog kidney:10:0.7103	0.7103	10
PDK	PDK:40	pyruvate dehydrogenase kinase:40:0.9237	0.9237	40
PDLF	PDLF:20	periodontal ligament fibroblasts:20:0.8525	0.8525	20
PDLFs	PDLFs:9	Periodontal ligament fibroblasts:9:0.6794	0.6794	9
PDLLA	PDLLA:25|P-DL-LA:1|PDL-LA:1	poly(D,L-lactide):27:0.2364	0.2364	27
PDLLA	PDLLA:8|PDL-LA:2	poly(DL-lactide):10:0.0818	0.0818	10
PDLs	PDLs:14	population doubling levels:14:0.7909	0.7909	14
PDL	PDL:14	pancreatic duct ligation:14:0.6911	0.6911	14
PDL	PDL:454	periodontal ligament:454:0.9734	0.9734	454
PDL	PDL:29	poly-D-lysine:29:0.0364	0.0364	29
PDL	PDL:75	population doubling level:63:0.9526|population doubling levels:12:0.7571	0.9526	75
PDL	PDL:65	pulsed dye laser:53:0.7972|pulsed-dye laser:12:0.0690	0.7972	65
PDME	PDME:9	phosphatidyldimethylethanolamine:9:0.3636	0.3636	9
PDMP	PDMP:19	1-phenyl-2-decanoylamino-3-morpholino-1-propanol:19:0.2338	0.2338	19
PDMP	PDMP:10	D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol:10:0.1169	0.1169	10
PDMS	PDMS:33	patient data management system:20:0.8594|patient data management systems:13:0.7753	0.8594	33
PDMS	PDMS:11	Peabody Developmental Motor Scales:11:0.7357	0.7357	11
PDMS	PDMS:21|PD-MS:3	plasma desorption mass spectrometry:24:0.7593	0.7593	24
PDMS	PDMS:128	poly(dimethylsiloxane):128:0.2779	0.2779	128
PDMS	PDMS:176	polydimethylsiloxane:176:0.3851	0.3851	176
PDM	PDM:8	participatory decision-making:8:0.5006	0.5006	8
PDNS	PDNS:18	porcine dermatitis and nephropathy syndrome:18:0.8365	0.8365	18
PDN	PDN:13	diabetic neuropathy:13:0.5335	0.5335	13
PDN	PDN:12	prednisolone:12:0.0821	0.0821	12
PDN	PDN:50	prednisone:50:0.3657	0.3657	50
PDO	PDO:10	pancreatic duct obstruction:10:0.5000	0.5000	10
PDPH	PDPH:92	postdural puncture headache:92:0.5956	0.5956	92
PDPK	PDPK:13	Proline-directed protein kinase:13:0.7753	0.7753	13
PDQ-39	PDQ-39:35	Parkinson's Disease Questionnaire:35:0.9126	0.9126	35
PDQ-R	PDQ-R:18	Personality Diagnostic Questionnaire-Revised:18:0.8365	0.8365	18
PDQ	PDQ:12	Personality Diagnostic Questionnaire:12:0.7571	0.7571	12
PDQ	PDQ:22	Physician Data Query:22:0.7955	0.7955	22
PDRN	PDRN:13	polydeoxyribonucleotide:13:0.7500	0.7500	13
PDRT	PDRT:9	Portland Digit Recognition Test:9:0.6794	0.6794	9
PDR	PDR:27	Desk Reference:27:0.8903	0.8903	27
PDR	PDR:5	pancreaticoduodenal resection:5:0.0902	0.0902	5
PDR	PDR:6	Phthalate dioxygenase reductase:6:0.5290	0.5290	6
PDR	PDR:20|Pdr:2	pleiotropic drug resistance:22:0.7955	0.7955	22
PDR	PDR:285	Proliferative diabetic retinopathy:285:0.9832	0.9832	285
PDR	PDR:11	proliferative DR:11:0.7357	0.7357	11
PDR	PDR:38	Pulsed dose rate:27:0.6455|pulsed-dose-rate:11:0.0178	0.6455	38
PdR	PdR:7|Pdr:3	Putidaredoxin reductase:10:0.2126	0.2126	10
PDSQ	PDSQ:13	Psychiatric Diagnostic Screening Questionnaire:13:0.7753	0.7753	13
PDSS	PDSS:9	Panic Disorder Severity Scale:9:0.6794	0.6794	9
PDSs	PDSs:27	paroxysmal depolarization shifts:27:0.8903	0.8903	27
PDSs	PDSs:12	Paroxysmal depolarizing shifts:12:0.7571	0.7571	12
PDSS	PDSS:9	Postpartum Depression Screening Scale:9:0.6794	0.6794	9
PDS	PDS:9	Dental Services:9:0.6794	0.6794	9
PDS	PDS:37	paroxysmal depolarization shifts:27:0.8903|paroxysmal depolarization shift:10:0.5856	0.8903	37
PDS	PDS:27	paroxysmal depolarizing shift:19:0.8449|paroxysmal depolarizing shifts:8:0.6411	0.8449	27
PDs	PDs:6	paroxysmal discharges:6:0.1838	0.1838	6
PDS	PDS:12	Pendred syndrome:12:0.0834	0.0834	12
PDS	PDS:7	Pendred syndrome gene:7:0.3524	0.3524	7
PDS	PDS:13	peritoneal dialysis solution:13:0.7753	0.7753	13
PDs	PDs:149|PDS:2	personality disorders:151:0.9307	0.9307	151
PDS	PDS:23|Pds:6|pds:3	phytoene desaturase:32:0.8563	0.8563	32
PDS	PDS:19	pigment dispersion syndrome:19:0.6537	0.6537	19
PDS	PDS:40	plasma-derived serum:40:0.7201	0.7201	40
PDS	PDS:12	polydimethylsiloxane:12:0.0110	0.0110	12
PDS	PDS:14	Polydioxanon:14:0.0130	0.0130	14
PDS	PDS:107	polydioxanone:107:0.1033	0.1033	107
PDS	PDS:10	polydioxanone suture:10:0.4363	0.4363	10
PDs	PDs:33	population doublings:33:0.9100	0.9100	33
PDS	PDS:5	Posttraumatic Diagnostic Scale:5:0.1973	0.1973	5
PDs	PDs:11	potential differences:11:0.6182	0.6182	11
PDS	PDS:14	power density spectrum:14:0.7909	0.7909	14
PDS	PDS:18	power Doppler sonography:18:0.6381	0.6381	18
PDs	PDs:16	program directors:16:0.6577	0.6577	16
PDS	PDS:8	Progressive Deterioration Scale:8:0.6411	0.6411	8
PDS	PDS:10	Public Dental Service:10:0.5856	0.5856	10
PDTC	PDTC:309	pyrrolidine dithiocarbamate:309:0.9160	0.9160	309
PDTC	PDTC:54	pyrrolidinedithiocarbamate:54:0.1188	0.1188	54
PDT	PDT:20	pedigree disequilibrium test:20:0.7766	0.7766	20
PDT	PDT:42	Percutaneous dilatational tracheostomy:42:0.8893	0.8893	42
PDT	PDT:6	percutaneous dilatational tracheotomy:6:0.5290	0.5290	6
PDT	PDT:33	Percutaneous dilational tracheostomy:33:0.9100	0.9100	33
PDT	PDT:9	percutaneous dilational tracheotomy:9:0.6794	0.6794	9
PDT	PDT:2147	photodynamic therapy:2147:0.9828	0.9828	2147
PDT	PDT:48	photodynamic treatment:48:0.7790	0.7790	48
PDT	PDT:9	population doubling time:9:0.6794	0.6794	9
PDt	PDt:9|PDT:2	potential difference:11:0.7357	0.7357	11
PDUS	PDUS:10	Doppler ultrasound:10:0.7103	0.7103	10
PDUS	PDUS:13|PD-US:1	power Doppler ultrasonography:14:0.6173	0.6173	14
PDVs	PDVs:11	Polydnaviruses:11:0.7692	0.7692	11
PDV	PDV:9	patent ductus venosus:9:0.6794	0.6794	9
PDV	PDV:12	phocid distemper virus:12:0.1262	0.1262	12
PDV	PDV:29	phocine distemper virus:29:0.5478	0.5478	29
PDV	PDV:5	plasma-derived vaccine:5:0.0902	0.0902	5
PDV	PDV:70	portal-drained viscera:70:0.8266	0.8266	70
Pdx	Pdx:34|PdX:1	putidaredoxin:35:0.5763	0.5763	35
PDZ	PDZ:6	large/zona occludens-1:6:0.0807	0.0807	6
PDZ	PDZ:9	PSD-95/Dlg-A/ZO-1:9:0.0721	0.0721	9
PDZ	PDZ:21	PSD-95/Dlg/ZO-1:21:0.1802	0.1802	21
PDbl	PDbl:6	PD across the basolateral membrane:6:0.4438	0.4438	6
PDI	PDI:5	Delusions Inventory:5:0.0736	0.0736	5
PDI	PDI:1	Pain and Disability Index:1:0.5012	0.5012	1
PDI	PDI:29	Power Doppler imaging:29:0.8978	0.8978	29
PDI	PDI:333|Pdi:2	protein disulfide isomerase:320:0.9665|protein disulfide-isomerase:15:0.8045	0.9665	335
PDI	PDI:16	protein disulphide-isomerase:16:0.8165	0.8165	16
PDI	PDI:19	Psoriasis Disability Index:19:0.1852	0.1852	19
Pdi	Pdi:25|PDI:1	transdiaphragmatic:26:0.0236	0.0236	26
Pdi	Pdi:254|PDI:6|pdi:1|PDi:1	transdiaphragmatic pressure:247:0.9416|transdiaphragmatic pressures:15:0.7096	0.9416	262
PDte	PDte:14	transepithelial potential difference:14:0.8045	0.8045	14
PEA-BP	PEA-BP:8	prepubertal and early adolescent bipolar disorder phenotype:8:0.6411	0.6411	8
PEA3	PEA3:8|PEA-3:1	enhancer activator 3:9:0.6794	0.6794	9
PEA	PEA:18	2-phenylethylamine:18:0.0260	0.0260	18
PEA	PEA:105	beta-phenylethylamine:105:0.1547	0.1547	105
PEA	PEA:6	H1-receptor agonist 2-pyridylethylamine:6:0.1838	0.1838	6
PEA	PEA:21	palmitoylethanolamide:21:0.0306	0.0306	21
PEA	PEA:17	peak endocardial acceleration:17:0.8270	0.8270	17
PEA	PEA:19	phacoemulsification and aspiration:19:0.8525	0.8525	19
PEA	PEA:10	Phenethyl alcohol:10:0.1519	0.1519	10
PEA	PEA:9	phenethylamine:9:0.0123	0.0123	9
PEA	PEA:8	phenyl ethyl alcohol:8:0.6411	0.6411	8
PEA	PEA:83	phenylethylamine:83:0.1256	0.1256	83
PEA	PEA:12	Phosphatidylethanolamine:12:0.0168	0.0168	12
PEA	PEA:40|P-EA:1	phosphoethanolamine:41:0.0613	0.0613	41
PEA	PEA:28	pulseless electrical activity:28:0.8903	0.8903	28
PEBP	PEBP:14	phosphatidylethanolamine-binding protein:14:0.3813	0.3813	14
PEBV	PEBV:11	pea early browning virus:11:0.7357	0.7357	11
PEB	PEB:1	cisplatin etoposide bleomycin:1:0.6386	0.6386	1
PEB	PEB:15	phycoerythrobilin:15:0.1918	0.1918	15
PECAM-1	PECAM-1:94|PECAM1:2|PE-CAM-1:2	platelet-endothelial cell adhesion molecule-1:67:0.2649|platelet/endothelial cell adhesion molecule-1:31:0.1000	0.2649	98
PECO2	PECO2:6|PeCO2:3|PEco2:1	carbon dioxide tension:10:0.7103	0.7103	10
PECO	PECO:9	circulatory occlusion:9:0.5470	0.5470	9
PECVD	PECVD:7|PE-CVD:1	plasma-enhanced chemical vapor deposition:8:0.5006	0.5006	8
PEComa	PEComa:14	Perivascular epithelioid cell tumor:14:0.8045	0.8045	14
PECs	PECs:7	parietal epithelial cells:7:0.0777	0.0777	7
PECS	PECS:6	Patient Evaluation and Conference System:6:0.7571	0.7571	6
PECs	PECs:57	peritoneal exudate cells:57:0.9477	0.9477	57
PECS	PECS:10	Picture Exchange Communication System:10:0.7103	0.7103	10
PECs	PECs:11	pigmented epithelial cells:11:0.2280	0.2280	11
PECs	PECs:15	Predicted environmental concentrations:15:0.6386	0.6386	15
PEC	PEC:421	peritoneal exudate cells:395:0.9838|peritoneal exudate cell:26:0.8861	0.9838	421
PEC	PEC:8	peritoneal macrophages:8:0.4102	0.4102	8
PEC	PEC:9|pec:1	phycoerythrocyanin:10:0.0119	0.0119	10
PEC	PEC:19	polyelectrolyte complex:19:0.6106	0.6106	19
PEC	PEC:10	porcine enteric calicivirus:10:0.7103	0.7103	10
PEC	PEC:22	Predicted Environmental Concentration:22:0.8657	0.8657	22
PEDF	PEDF:153	Pigment epithelium-derived factor:153:0.9684	0.9684	153
PEDI	PEDI:45	Pediatric Evaluation of Disability Inventory:45:0.7319	0.7319	45
PEDRI	PEDRI:7	Proton electron double resonance imaging:7:0.5926	0.5926	7
PEDV	PEDV:35	Porcine epidemic diarrhea virus:35:0.9151	0.9151	35
PEDV	PEDV:16	porcine epidemic diarrhoea virus:16:0.8165	0.8165	16
PEDro	PEDro:10	Physiotherapy Evidence Database:10:0.7103	0.7103	10
PEDs	PEDs:9	pigment epithelial detachments:9:0.6794	0.6794	9
PED	PED:40	pediatric emergency department:40:0.8491	0.8491	40
PED	PED:32	pigment epithelial detachment:32:0.9072	0.9072	32
PED	PED:9	potential energy distribution:9:0.6794	0.6794	9
PEEK	PEEK:20|peek:1	polyetheretherketone:21:0.5385	0.5385	21
PEEPe	PEEPe:8	positive end-expiratory pressure:8:0.6411	0.6411	8
PEEPi	PEEPi:21	intrinsic PEEP:21:0.7955	0.7955	21
PEEPi	PEEPi:64|Peepi:1	intrinsic positive end-expiratory pressure:65:0.9047	0.9047	65
PEEP	PEEP:21	positive and expiratory pressure:21:0.0709	0.0709	21
PEEP	PEEP:1267|Peep:1	positive end-expiratory pressure:1106:0.9820|positive end expiratory pressure:146:0.9285|positive end-expiratory pressures:16:0.7261	0.9820	1268
PEEP	PEEP:19	positive end-expiratory pressure ventilation:19:0.8449	0.8449	19
PEE	PEE:15	energy expenditure:15:0.7096	0.7096	15
PEFR	PEFR:11	peak expiratory flow:11:0.7357	0.7357	11
PEFR	PEFR:775|PEF-R:1	peak expiratory flow rate:680:0.9821|peak expiratory flow rates:96:0.9346	0.9821	776
PEFV	PEFV:16	partial expiratory flow-volume:16:0.7261	0.7261	16
pEFS	pEFS:8|p-EFS:1	probability of event-free survival:9:0.3331	0.3331	9
PEF	PEF:5	belongs to the penta-EF-hand:5:0.0736	0.0736	5
PEF	PEF:985	peak expiratory flow:972:0.9889|peak expiratory flows:13:0.7753	0.9889	985
PEF	PEF:92	peak expiratory flow rate:77:0.9612|Peak expiratory flow rates:15:0.8045	0.9612	92
PEF	PEF:17|Pef:5	pefloxacin:22:0.0160	0.0160	22
PEF	PEF:58	pulsed electric field:32:0.8563|pulsed electric fields:26:0.8861	0.8861	58
PEG-ELS	PEG-ELS:16	polyethylene glycol electrolyte lavage solution:9:0.6794|Polyethylene glycol-electrolyte lavage solution:7:0.5926	0.6794	16
PEG-PE	PEG-PE:12	phosphatidylethanolamine:12:0.2973	0.2973	12
PEG-400	PEG-400:4|PEG400:2	polyethylene glycol:6:0.2243	0.2243	6
PEG-400	PEG-400:8|PEG400:6	polyethylene glycol 400:14:0.7909	0.7909	14
PEG-Hb	PEG-Hb:11	bovine hemoglobin:11:0.5355	0.5355	11
PEG-SOD	PEG-SOD:16	Polyethylene glycol-conjugated superoxide dismutase:16:0.8165	0.8165	16
PEG-SOD	PEG-SOD:11|PEGSOD:1	polyethylene glycol-superoxide dismutase:12:0.7571	0.7571	12
PEGs	PEGs:53|PEGS:2	polyethylene glycols:55:0.8036	0.8036	55
PEG	PEG:11	pegylated:11:0.0029	0.0029	11
PEG	PEG:565	percutaneous endoscopic gastrostomy:565:0.9781	0.9781	565
PEG	PEG:20	pneumoencephalography:20:0.0054	0.0054	20
PEG	PEG:17	poly(ethyleneglycol):17:0.0046	0.0046	17
PEG	PEG:1702|peg:2|Peg:1|pEG:1	polyethylene glycol:1645:0.6955|polyethylene glycols:35:0.7117|polyethylene-glycol:26:0.0072	0.7117	1706
PEG	PEG:11	polyethylene glycol 400:11:0.4232	0.4232	11
PEG	PEG:13	polyethylene glycol 4000:13:0.6701	0.6701	13
PEG	PEG:25	polyethylene glycol 6000:25:0.7249	0.7249	25
PEG	PEG:10	polyethylene glycol 8000:10:0.7103	0.7103	10
PEG	PEG:4	polyethylene glycol solution:4:0.1618	0.1618	4
PEG	PEG:114	Polyethyleneglycol:114:0.0324	0.0324	114
PEG	PEG:9	polyethylenglycol:9:0.0023	0.0023	9
PEH	PEH:8	papillary endothelial hyperplasia:8:0.6411	0.6411	8
PEH	PEH:11	postexercise hypotension:11:0.3829	0.3829	11
PEH	PEH:10	pseudoepitheliomatous hyperplasia:10:0.2275	0.2275	10
PEIA	PEIA:10	enzyme immunoassay:10:0.7103	0.7103	10
PEIs	PEIs:10	Polyethylenimines:10:0.5000	0.5000	10
PEIT	PEIT:119	percutaneous ethanol injection therapy:119:0.9749	0.9749	119
PEITC	PEITC:96	phenethyl isothiocyanate:96:0.7035	0.7035	96
PEITC	PEITC:9	phenethylisothiocyanate:9:0.0563	0.0563	9
PEI	PEI:7	excretion index:7:0.1850	0.1850	7
PEI	PEI:8	Patient Enablement Instrument:8:0.5926	0.5926	8
PEI	PEI:231	percutaneous ethanol injection:231:0.9320	0.9320	231
PEI	PEI:16	poly(ethyleneimine):16:0.0170	0.0170	16
PEI	PEI:20	poly(ethylenimine):20:0.0215	0.0215	20
PEI	PEI:189|pEI:2	Polyethyleneimine:191:0.2149	0.2149	191
PEI	PEI:222	polyethylenimine:222:0.2466	0.2466	222
PEI	PEI:10	postejaculatory interval:10:0.2873	0.2873	10
PEI	PEI:15	Prince Edward Island:15:0.8045	0.8045	15
PEJ	PEJ:11	percutaneous endoscopic jejunostomy:11:0.7357	0.7357	11
PELA	PELA:1	poly-DL-lactide-poly(ethylene glycol:1:0.2619	0.2619	1
PELD	PELD:7	pediatric end-stage liver disease:7:0.4438	0.4438	7
PELF	PELF:9	pulmonary epithelial lining fluid:9:0.6794	0.6794	9
PELs	PELs:18	Permissible Exposure Limits:18:0.8365	0.8365	18
PELs	PELs:15	primary effusion lymphomas:15:0.8045	0.8045	15
Pel	Pel:16|pel:2|PEL:2	Pectate lyase:20:0.7766	0.7766	20
PEL	PEL:15	peritoneal exudate lymphocytes:15:0.8045	0.8045	15
PEL	PEL:11	permissible exposure level:11:0.7357	0.7357	11
PEL	PEL:197	primary effusion lymphoma:176:0.9830|primary effusion lymphomas:21:0.8594	0.9830	197
PEMA	PEMA:23	phenylethylmalonamide:23:0.4151	0.4151	23
PEMF	PEMF:98	pulsed electromagnetic fields:55:0.7378|pulsed electromagnetic field:43:0.5246	0.7378	98
PEMFs	PEMFs:42	pulsed electromagnetic fields:42:0.5682	0.5682	42
PEMI	PEMI:11	muscle ischemia:11:0.7357	0.7357	11
PEMS	PEMS:14	Poult Enteritis and Mortality Syndrome:14:0.7766	0.7766	14
PEMs	PEMs:6	proembryogenic masses:6:0.2243	0.2243	6
PEM	PEM:19	paraneoplastic encephalomyelitis:19:0.8449	0.8449	19
PEM	PEM:31	pediatric emergency medicine:31:0.8090	0.8090	31
PEM	PEM:50	peritoneal exudate macrophages:50:0.9404	0.9404	50
PEM	PEM:10|PeM:1	peritoneal macrophages:11:0.0583	0.0583	11
PEM	PEM:17	Polioencephalomalacia:17:0.0225	0.0225	17
PEM	PEM:9	polyelectrolyte multilayer:9:0.6794	0.6794	9
PEM	PEM:40	polymorphic epithelial mucin:40:0.8811	0.8811	40
PEM	PEM:9	positron emission mammography:9:0.6794	0.6794	9
PEM	PEM:39	Prescription-event monitoring:39:0.6563	0.6563	39
PEM	PEM:4	protein energy malnourished:4:0.4422	0.4422	4
PEM	PEM:336	protein-energy malnutrition:211:0.5691|protein energy malnutrition:116:0.9744|protein-energy-malnutrition:9:0.0112	0.9744	336
penA	penA:5	penicillin-binding protein 2 gene:5:0.4422	0.4422	5
PENK	PENK:7|Penk:2|pENK:1	preproenkephalin:10:0.1268	0.1268	10
PENK	PENK:34|Penk:12|PEnk:6|pENK:4	proenkephalin:56:0.7746	0.7746	56
PEN	PEN:7|Pen:6	D-penicillamine:13:0.0667	0.0667	13
PEN	PEN:6	pain-excitation neurons:6:0.1838	0.1838	6
Pen	Pen:8|PEN:2	penicillamine:10:0.0500	0.0500	10
PEN	PEN:14|Pen:3|pen:1	penicillin:18:0.0944	0.0944	18
PeN	PeN:25|PEN:1	periventricular nucleus:26:0.8251	0.8251	26
PEO	PEO:9	polyethyleneoxide:9:0.0198	0.0198	9
PEO	PEO:55	progressive external ophthalmoplegia:55:0.9458	0.9458	55
PEPCK	PEPCK:562|PEPck:8|Pepck:2|PEPcK:2|PepCK:2|PEP-CK:1|PEPCk:1	phosphoenolpyruvate carboxykinase:578:0.9003	0.9003	578
PEPC	PEPC:108|PEPc:4|PEP-C:1|PepC:1	phosphoenolpyruvate carboxylase:114:0.8426	0.8426	114
PEPc	PEPc:6	pre-ejection period:6:0.1148	0.1148	6
PEPc	PEPc:7	preejection period:7:0.1850	0.1850	7
PEPD	PEPD:10|pepD:1	peptidase D:11:0.5355	0.5355	11
PEPI	PEPI:20	Postmenopausal Estrogen/Progestin Interventions:20:0.7766	0.7766	20
PEPI	PEPI:21	pre-ejection period index:21:0.5435	0.5435	21
Pep	Pep:7	Pedal peptide:7:0.1850	0.1850	7
PEP	PEP:14	Pepleomycin:14:0.0086	0.0086	14
PEP	PEP:14	phospho(enol)pyruvate:14:0.0086	0.0086	14
PEP	PEP:18	phosphoenol pyruvate:18:0.5940	0.5940	18
PEP	PEP:385	Phosphoenolpyruvate:385:0.2533	0.2533	385
PEP	PEP:18	polyestradiol phosphate:18:0.5228	0.5228	18
PEP	PEP:45	positive expiratory pressure:45:0.8964	0.8964	45
PEP	PEP:60	post-exposure prophylaxis:60:0.3278	0.3278	60
PEP	PEP:70	postexposure prophylaxis:70:0.3959	0.3959	70
PEP	PEP:198	pre-ejection period:198:0.5447	0.5447	198
PEP	PEP:7	pre-ejection time:7:0.3524	0.3524	7
PEP	PEP:120	preejection period:120:0.3087	0.3087	120
PEP	PEP:24	primer extension preamplification:24:0.8115	0.8115	24
PEP	PEP:5	progestagen-associated endometrial protein:5:0.1464	0.1464	5
PEP	PEP:52	prolyl endopeptidase:52:0.8821	0.8821	52
PEP	PEP:20	RNA polymerase:20:0.7766	0.7766	20
PEQ	PEQ:14	Questionnaire:14:0.5909	0.5909	14
PERG	PERG:161|P-ERG:10|p-ERG:2	Pattern electroretinogram:151:0.8578|pattern electroretinograms:13:0.3813|pattern-electroretinogram:9:0.0307	0.8578	173
PERG	PERG:9	pattern electroretinography:9:0.6794	0.6794	9
PERG	PERG:18|P-ERG:2	pattern ERG:20:0.7766	0.7766	20
PERI	PERI:9	Psychiatric Epidemiology Research Interview:9:0.5470	0.5470	9
p-ERK	p-ERK:10|pERK:6|P-ERK:3	phosphorylated ERK:19:0.5404	0.5404	19
pERK	p-ERK:5|pERK:5|P-ERK:2	phosphorylated extracellular signal-regulated kinase:12:0.5050	0.5050	12
PERK	PERK:49	prospective evaluation of radial keratotomy:49:0.9392	0.9392	49
PERT	PERT:12	product-enhanced reverse transcriptase:12:0.5664	0.5664	12
PERT	PERT:5	Program evaluation and review technique:5:0.3728	0.3728	5
PERV	PERV:100	Porcine endogenous retrovirus:63:0.7521|porcine endogenous retroviruses:37:0.6953	0.7521	100
PERVs	PERVs:32	porcine endogenous retroviruses:32:0.8563	0.8563	32
PER	PER:61	peak ejection rate:61:0.8770	0.8770	61
PER	PER:10	per protein:10:0.1774	0.1774	10
PER	PER:14	perchloroethylene:14:0.0186	0.0186	14
PER	PER:10|Per:1	period protein:11:0.2154	0.2154	11
PER	PER:21	proboscis extension reflex:21:0.8594	0.8594	21
PER	PER:14	Proboscis Extension Response:14:0.7909	0.7909	14
PER	PER:153	protein efficiency ratio:143:0.9791|protein efficiency ratios:10:0.7103	0.9791	153
PER	PER:13|Per:1	tetrachloroethylene:14:0.0186	0.0186	14
PESA	PESA:45	percutaneous epididymal sperm aspiration:45:0.9338	0.9338	45
PESDA	PESDA:11	perfluorocarbon-exposed sonicated dextrose albumin:11:0.5355	0.5355	11
PESP	PESP:56	postextrasystolic potentiation:56:0.6417	0.6417	56
PET/CT	PET/CT:20	positron emission tomography/computed tomography:20:0.8525	0.8525	20
PETCO2	PETCO2:13|Petco2:1|PetCO2:1	carbon dioxide pressure:15:0.8045	0.8045	15
PETCO2	PETCO2:18|PetCO2:6|Petco2:1	end-tidal carbon dioxide:25:0.3557	0.3557	25
PETCO2	PETCO2:4|PetCO2:2|PEtco2:1|PET-CO2:1|Petco2:1|petCO2:1	end-tidal carbon dioxide partial pressure:10:0.7103	0.7103	10
PETCO2	PETCO2:21|PetCO2:6	end-tidal carbon dioxide tension:27:0.8312	0.8312	27
PETCO2	PETCO2:5|PetCO2:2	end-tidal CO2 partial pressure:7:0.4438	0.4438	7
PETCO2	PETCO2:12|PetCO2:1	end-tidal CO2 pressure:13:0.5934	0.5934	13
PETCO2	PETCO2:14|PetCO2:4	end-tidal CO2 tension:18:0.6903	0.6903	18
PETCO2	PETCO2:9|PetCO2:1	end-tidal partial pressure of carbon dioxide:10:0.5050	0.5050	10
PetE	PetE:5|petE:3	pea plastocyanin gene:8:0.5006	0.5006	8
PETN	PETN:40	pentaerythritol tetranitrate:40:0.6628	0.6628	40
PEtn	PEtn:13|pEtN:6|PEtN:1	phosphoethanolamine:20:0.2111	0.2111	20
PETT	PETT:9	positron emission transaxial tomography:9:0.6794	0.6794	9
PETs	PETs:44	Pancreatic endocrine tumors:33:0.8196|pancreatic endocrine tumours:11:0.5355	0.8196	44
PET	PET:12	functional:12:0.0013	0.0013	12
PET	PET:7	pancreatic endocrine tumors:7:0.5926	0.5926	7
PET	PET:13	paraffin-embedded tissue:13:0.7753	0.7753	13
PET	PET:4|pET:2	patulous eustachian tube:6:0.5290	0.5290	6
PET	PET:209	Peritoneal Equilibration Test:191:0.9843|peritoneal equilibration tests:18:0.8365	0.9843	209
PEt	PEt:82|PET:2|Pet:1|P-Et:1	phosphatidylethanol:86:0.0101	0.0101	86
PET	PET:37|PeT:2	photoinduced electron transfer:39:0.7602	0.7602	39
PET	PET:10	polyester:10:0.0010	0.0010	10
PET	PET:5	polyethylene terephtalate:5:0.0902	0.0902	5
PET	PET:112	polyethylene terephthalate:112:0.5486	0.5486	112
PET	PET:15	Polyethyleneterephthalate:15:0.0017	0.0017	15
PET	PET:21	positron emission tomograph:21:0.8594	0.8594	21
PET	PET:201	positron emission tomographic:201:0.9349	0.9349	201
PET	PET:6909|Pet:1	Positron emission tomography:6895:0.9788|positron-emission-tomography:15:0.0017	0.9788	6910
PET	PET:11	pre-eclamptic toxaemia:11:0.6182	0.6182	11
PET	PET:9	treatment:9:0.0010	0.0010	9
PEU	PEU:14	polyetherurethane:14:0.2653	0.2653	14
PeVN	PeVN:10|PEVN:1	periventricular nucleus:11:0.7357	0.7357	11
PeV	PeV:15|PEV:1	periventricular nucleus:16:0.8165	0.8165	16
PEV	PEV:87	position-effect variegation:45:0.3985|position effect variegation:42:0.9291	0.9291	87
PEWV	PEWV:11	pulmonary extravascular water volume:11:0.7357	0.7357	11
PEX	PEX:16|PEx:2	plasma exchange:18:0.7539	0.7539	18
PEX	PEX:29	Pseudoexfoliation:29:0.1905	0.1905	29
PEX	PEX:29	pseudoexfoliation syndrome:29:0.8978	0.8978	29
PEmax	PEmax:11|Pemax:2	maximal expiratory pressure:13:0.4102	0.4102	13
Pes	Pes:36	esophageal:36:0.0413	0.0413	36
Pes	Pes:107|PES:2	esophageal pressure:109:0.7025	0.7025	109
PES	PES:9	Paclitaxel-eluting stents:9:0.5470	0.5470	9
PEs	PEs:6	parasitized erythrocytes:6:0.1320	0.1320	6
PES	PES:16|pes:1	pharyngoesophageal segment:17:0.7407	0.7407	17
PEs	PEs:7	phorbol esters:7:0.1641	0.1641	7
PEs	PEs:14	phosphatidylethanolamines:14:0.0153	0.0153	14
PES	PES:10	photoelectron spectroscopy:10:0.5000	0.5000	10
PEs	PEs:7	Phthalate esters:7:0.1641	0.1641	7
PES	PES:16	polyethersulfone:16:0.0177	0.0177	16
PES	PES:6	post-enumeration survey:6:0.1320	0.1320	6
PES	PES:11	postextrasystolic:11:0.0118	0.0118	11
PES	PES:48	potential energy surface:38:0.9217|potential energy surfaces:10:0.7103	0.9217	48
PES	PES:6	preepiglottic space:6:0.1148	0.1148	6
PES	PES:9	primary empty sella:9:0.4587	0.4587	9
PES	PES:124	programmed electrical stimulation:124:0.7953	0.7953	124
PES	PES:5	prostaglandin endoperoxide synthase:5:0.2818	0.2818	5
PES	PES:9	pseudoexfoliation syndrome:9:0.1945	0.1945	9
PES	PES:15	psychiatric emergency service:15:0.6386	0.6386	15
PEth	PEth:24|Peth:7|PETH:1	phosphatidylethanol:32:0.5536	0.5536	32
PE	PE:3	ACE inhibitor perindopril:3:0.3463	0.3463	3
PE	PE:6	after phacoemulsification:6:0.0564	0.0564	6
PE	PE:59	agonist phenylephrine:59:0.0832	0.0832	59
PE	PE:11	beta-phenylethylamine:11:0.0014	0.0014	11
PE	PE:14	cisplatin and etoposide:14:0.4709	0.4709	14
PE	PE:10	cisplatin-etoposide:10:0.0012	0.0012	10
PE	PE:11	days postexposure:11:0.0958	0.0958	11
Pe	Pe:4|PE:1	early promoter:5:0.1132	0.1132	5
PE	PE:19	elastase:19:0.0025	0.0025	19
PE	PE:11	element:11:0.0014	0.0014	11
PE	PE:13	epithelial cells:13:0.5335	0.5335	13
PE	PE:11|Pe:2	errors:13:0.0016	0.0016	13
Pe	Pe:5	error positivity:5:0.1132	0.1132	5
PE	PE:3|Pe:3	esophageal pressure:6:0.1543	0.1543	6
PE	PE:56	extract:44:0.0059|extracts:12:0.0015	0.0059	56
PE	PE:10	parasitized erythrocytes:10:0.1223	0.1223	10
PE	PE:21	parietal endoderm:21:0.7865	0.7865	21
PE	PE:7	partial epilepsy:7:0.3524	0.3524	7
PE	PE:13	pectinesterase:13:0.0016	0.0016	13
PE	PE:18	pectus excavatum:18:0.8365	0.8365	18
PE	PE:9	Pemphigus erythematosus:9:0.5470	0.5470	9
PE	PE:24	penile erection:14:0.6911|penile erections:10:0.5856	0.6911	24
PE	PE:38	pericardial effusion:38:0.3561	0.3561	38
PE	PE:48	peritoneal exudate:48:0.7790	0.7790	48
Pe	Pe:4|PE:2	periventricular hypothalamic nucleus:6:0.5290	0.5290	6
Pe	Pe:7|PE:2	periventricular nucleus:9:0.2102	0.2102	9
Pe	Pe:9|P-e:1	permeability:10:0.0012	0.0012	10
PE	PE:11	persistent estrus:11:0.5355	0.5355	11
PE	PE:13	petroleum ether:13:0.5934	0.5934	13
PE	PE:14	pharyngoesophageal:14:0.0018	0.0018	14
PE	PE:5	phorbol esters:5:0.0902	0.0902	5
PE	PE:22	phosphatidyl-ethanolamine:22:0.0029	0.0029	22
PE	PE:27|Pe:1	phosphoethanolamine:28:0.0037	0.0037	28
PE	PE:18	phosphorylethanolamine:18:0.0023	0.0023	18
PE	PE:49	physical education:49:0.8492	0.8492	49
PE	PE:45	physical examination:45:0.6761	0.6761	45
PE	PE:10	physical exercise:10:0.2643	0.2643	10
PE	PE:9	phytoestrogens:9:0.0011	0.0011	9
PE	PE:16	pigment epithelial:16:0.1495	0.1495	16
PE	PE:33	pigment epithelium:33:0.3769	0.3769	33
PE	PE:12	pigmented ciliary epithelial:12:0.7571	0.7571	12
PE	PE:21	pigmented epithelial:21:0.2291	0.2291	21
PE	PE:20	pigmented epithelium:20:0.1764	0.1764	20
PE	PE:8	plasma epinephrine:8:0.2327	0.2327	8
PE	PE:354	plasma exchange:306:0.9743|plasma exchanges:31:0.9043|plasma-exchange:17:0.0022	0.9743	354
PE	PE:15	plasma extravasation:15:0.4951	0.4951	15
PE	PE:44	plating efficiency:44:0.7413	0.7413	44
PE	PE:51	pleural effusion:38:0.3561|pleural effusions:13:0.4849	0.4849	51
PE	PE:8	polychromatic erythrocytes:8:0.0726	0.0726	8
PE	PE:13	polyelectrolyte:13:0.0016	0.0016	13
PE	PE:231	polyethylene:231:0.0317	0.0317	231
PE	PE:6	porcine pancreatic endocrine:6:0.2827	0.2827	6
P-E	P-E:5|PE:4	Portal-enteric:9:0.0011	0.0011	9
PE	PE:9	portoenterostomy:9:0.0011	0.0011	9
PE	PE:16|pe:1	post-exposure:17:0.0022	0.0022	17
PE	PE:13	potential energy:13:0.6701	0.6701	13
PE	PE:9	power of exclusion:9:0.1205	0.1205	9
PE	PE:49	pre-eclampsia:49:0.0066	0.0066	49
PE	PE:10	precedence effect:10:0.1878	0.1878	10
PE	PE:9	prediction error:9:0.2102	0.2102	9
PE	PE:103	preeclampsia:103:0.0140	0.0140	103
PE	PE:16	preeclamptic:16:0.0021	0.0021	16
Pe	Pe:7|PE:3	pregnenolone:10:0.0012	0.0012	10
PE	PE:40	premature ejaculation:40:0.8839	0.8839	40
PE	PE:4	preoperative portal embolization:4:0.1618	0.1618	4
PE	PE:11	probability of exclusion:11:0.1845	0.1845	11
PE	PE:31	Proenkephalin:31:0.0041	0.0041	31
PE	PE:13	Proestrus:13:0.0016	0.0016	13
PE	PE:10	proliferative enteritis:10:0.5856	0.5856	10
PE	PE:10	proliferative enteropathy:10:0.7103	0.7103	10
PE	PE:8	prolonged exposure:8:0.1895	0.1895	8
PE	PE:8	prolyl endopeptidase:8:0.4102	0.4102	8
PE	PE:11	protective efficacy:11:0.6182	0.6182	11
PE	PE:11	Pseudo-exfoliation:11:0.0014	0.0014	11
PE	PE:9	pseudoexfoliation:9:0.0011	0.0011	9
PE	PE:114	Pseudomonas exotoxin:114:0.8789	0.8789	114
PE	PE:32	pulmonary edema:32:0.6656	0.6656	32
PE	PE:55|Pe:1	pulmonary emboli:56:0.9467	0.9467	56
PE	PE:45	pulmonary embolus:45:0.9338	0.9338	45
PE	PE:18	pulmonary emphysema:18:0.8365	0.8365	18
PE	PE:14	pulmonary thromboembolism:14:0.7909	0.7909	14
PF3	PF3:31|PF-3:5|Pf3:1|P-F-3:1	Platelet factor 3:38:0.9217	0.9217	38
PF4	PF4:27|PF-4:21	platelet factor-4:48:0.8463	0.8463	48
PF4	PF4:15|PF-4:3|Pf4:2	platelet factor four:20:0.8525	0.8525	20
PFA-100	PFA-100:21|PFA100:1	Platelet Function Analyser:22:0.8657	0.8657	22
PFA-100	PFA-100:34|PFA100:1	Platelet Function Analyzer:35:0.8681	0.8681	35
PFA	PFA:12	fatty acids:12:0.7571	0.7571	12
PFA	PFA:53|pFA:1	paraformaldehyde:54:0.1468	0.1468	54
PFA	PFA:42	Phosphonoformate:42:0.1136	0.1136	42
PFA	PFA:59	phosphonoformic acid:59:0.7984	0.7984	59
PFA	PFA:10	Principal Factor Analysis:10:0.7103	0.7103	10
PFA	PFA:10	profunda femoris artery:10:0.7103	0.7103	10
PFBHA	PFBHA:18	hydrochloride:18:0.5667	0.5667	18
PFB	PFB:27	pentafluorobenzyl:27:0.2826	0.2826	27
PFB	PFB:10	perflubron:10:0.0978	0.0978	10
PFB	PFB:10	Pseudofolliculitis barbae:10:0.7103	0.7103	10
PFCL	PFCL:24	perfluorocarbon liquid:13:0.7753|perfluorocarbon liquids:11:0.4728	0.7753	24
PFCs	PFCs:28	Perfluorocarbons:28:0.2523	0.2523	28
PFCs	PFCs:19	perfluorochemicals:19:0.1682	0.1682	19
PFCs	PFCs:19	plaque-forming cells:19:0.4405	0.4405	19
PFCx	PFCx:6|PFCX:6|PfCX:1	prefrontal cortex:13:0.6701	0.6701	13
PFC	PFC:9	pair-fed control:9:0.3455	0.3455	9
PFC	PFC:12	Patient-Focused Care:12:0.6460	0.6460	12
PFC	PFC:125	Perfluorocarbon:106:0.0419|perfluorocarbons:19:0.0071	0.0419	125
PFC	PFC:111|pfc:1	perfluorochemical:92:0.0360|perfluorochemicals:20:0.0075	0.0360	112
PFC	PFC:21	persistent fetal circulation:21:0.6934	0.6934	21
PFC	PFC:1203|pfc:3	plaque-forming cell:510:0.7634|plaque-forming cells:453:0.6926|plaque forming cells:123:0.8372|plaque forming cell:120:0.9243	0.9243	1206
PFC	PFC:10	Plasma Fibrinogen Concentration:10:0.7103	0.7103	10
PFC	PFC:9	prefrontal:9:0.0032	0.0032	9
PFC	PFC:725|PFc:8|Pfc:8|pFC:3|PfC:2	prefrontal cortex:746:0.9784	0.9784	746
PFC	PFC:24	prefrontal cortical:24:0.8768	0.8768	24
PFDA	PFDA:18	perfluoro-n-decanoic acid:18:0.1360	0.1360	18
PFDA	PFDA:53	perfluorodecanoic acid:53:0.6167	0.6167	53
PFD	PFD:16	paired filtration dialysis:16:0.8165	0.8165	16
PFD	PFD:8	pelvic floor dysfunction:8:0.6411	0.6411	8
PFD	PFD:20	Perfluorodecalin:20:0.0969	0.0969	20
PFD	PFD:14	photon flux density:14:0.6173	0.6173	14
PFD	PFD:13	pirfenidone:13:0.0612	0.0612	13
PFD	PFD:23	protein-free diet:23:0.8038	0.8038	23
PFE	PFE:9	papillary fibroelastoma:9:0.6794	0.6794	9
PFE	PFE:6	Pressurised fluid extraction:6:0.1320	0.1320	6
PFE	PFE:6	Pressurized fluid extraction:6:0.1320	0.1320	6
PFFD	PFFD:17	Proximal femoral focal deficiency:17:0.8270	0.8270	17
pFF	pFF:44|PFF:28|pff:3	porcine follicular fluid:75:0.8988	0.8988	75
PFG-NMR	PFG-NMR:9	magnetic resonance:9:0.6794	0.6794	9
PFGE	PFGE:2031	pulsed-field gel electrophoresis:1683:0.7732|pulsed field gel electrophoresis:348:0.8816	0.8816	2031
PFGE	PFGE:16	pulsed-field gel electrophoretic:16:0.6024	0.6024	16
PFG	PFG:7	gel electrophoresis:7:0.2902	0.2902	7
PFG	PFG:6	pulsed field gel:6:0.5290	0.5290	6
PFG	PFG:52|pfg:1	pulsed field gradient:53:0.8842	0.8842	53
PFH	PFH:29	perifornical hypothalamus:29:0.6928	0.6928	29
PFH	PFH:15	progressive facial hemiatrophy:15:0.8045	0.8045	15
PFIC	PFIC:37	progressive familial intrahepatic cholestasis:37:0.8716	0.8716	37
PFIC1	PFIC1:7	progressive familial intrahepatic cholestasis type 1:7:0.4438	0.4438	7
PFII	PFII:5|PF-II:4|PfII:3	Photofrin II:12:0.7571	0.7571	12
PFI	PFI:18	flow index:18:0.3548	0.3548	18
PFI	PFI:32	progression-free interval:32:0.6220	0.6220	32
PFJ	PFJ:14	patellofemoral joint:14:0.6173	0.6173	14
PFK-1	PFK-1:15|PFK1:2|Pfk-1:1	6-phosphofructo-1-kinase:18:0.3953	0.3953	18
PFK-1	PFK-1:9|Pfk-1:1	phosphofructokinase-1:10:0.2093	0.2093	10
PFK-2	PFK-2:24|PFK2:3	6-Phosphofructo-2-kinase:27:0.4727	0.4727	27
PFK-2	PFK-2:6|Pfk-2:4	phosphofructokinase-2:10:0.1636	0.1636	10
PFKL	PFKL:10	phosphofructokinase:10:0.6000	0.6000	10
PFK-M	PFK-M:5|PFKM:4	phosphofructokinase:9:0.3810	0.3810	9
PFK	PFK:24	6-phosphofructo-1-kinase:24:0.0395	0.0395	24
PFK	PFK:19|Pfk:1	6-phosphofructokinase:20:0.0326	0.0326	20
PFK	PFK:487|pfk:3|Pfk:2	phosphofructokinase:492:0.8436	0.8436	492
PFL	PFL:16	leucovorin:16:0.1136	0.1136	16
PFL	PFL:43|pfl:4|Pfl:2	pyruvate formate-lyase:40:0.9237|pyruvate formate lyase:9:0.6794	0.9237	49
PFMT	PFMT:10	pelvic floor muscle training:10:0.7103	0.7103	10
PFM	PFM:8	peak flow meter:8:0.6411	0.6411	8
PFM	PFM:19	pelvic floor muscle:19:0.8449	0.8449	19
PFM	PFM:32	porcelain-fused-to-metal:32:0.1792	0.1792	32
pFN	pFN:46|pFn:18|PFN:15|PFn:9|P-FN:1	plasma fibronectin:89:0.8857	0.8857	89
pFN	pFN:10|pFn:5	plasma Fn:15:0.5818	0.5818	15
PFN	PFN:20	proximal femoral nail:20:0.8270	0.8270	20
PFOA	PFOA:88	perfluorooctanoic acid:88:0.7926	0.7926	88
PFOB	PFOB:15	perfluoroctylbromide:15:0.1970	0.1970	15
PFOB	PFOB:13	perfluorooctyl bromide:13:0.5934	0.5934	13
PFOB	PFOB:21	perfluorooctylbromide:21:0.3030	0.3030	21
PFOS	PFOS:31	Perfluorooctane sulfonate:31:0.9043	0.9043	31
PFOS	PFOS:12	perfluorooctane sulfonic acid:12:0.7571	0.7571	12
PFOS	PFOS:25	perfluorooctanesulfonate:25:0.3288	0.3288	25
PFO	PFO:306	patent foramen ovale:306:0.8951	0.8951	306
PFO	PFO:9	perfluoro-n-octane:9:0.0201	0.0201	9
PFO	PFO:20|pfo:1	perfringolysin O:21:0.8594	0.8594	21
PFO	PFO:6	pyruvate:ferredoxin oxidoreductase:6:0.1543	0.1543	6
PFPS	PFPS:39	patellofemoral pain syndrome:39:0.7860	0.7860	39
PFP	PFP:18	patellofemoral pain:18:0.7539	0.7539	18
PFP	PFP:12	pentafluoropropionyl:12:0.0533	0.0533	12
PFP	PFP:6|Pfp:5|pfp:3	Perforin:14:0.0578	0.0578	14
PFP	PFP:9	peripheral facial palsy:9:0.6794	0.6794	9
PFP	PFP:21	platelet-free plasma:21:0.6812	0.6812	21
PFP	PFP:17|Pfp:1	Pore-forming protein:18:0.7539	0.7539	18
PFR	PFR:7	Flow Rates:7:0.1850	0.1850	7
Pfr	Pfr:10	form of phytochrome:10:0.2643	0.2643	10
PFR	PFR:14	paraflagellar rod:14:0.7909	0.7909	14
PFR	PFR:33	peak flow rate:33:0.4211	0.4211	33
PFR	PFR:9	plain film radiography:9:0.6794	0.6794	9
PFTase	PFTase:18	protein farnesyltransferase:18:0.8365	0.8365	18
PFTs	PFTs:178|PFTS:1	pulmonary function tests:179:0.9833	0.9833	179
PFT	PFT:17	protein farnesyltransferase:17:0.8270	0.8270	17
PFT	PFT:8	pulmonary function:8:0.5006	0.5006	8
PFT	PFT:231	Pulmonary function tests:142:0.9554|pulmonary function test:89:0.8368	0.9554	231
PFT	PFT:50	pulmonary function testing:50:0.9404	0.9404	50
PFU	PFU:226|pfu:145	plaque-forming units:229:0.5860|plaque forming units:116:0.9219|plaque-forming unit:15:0.2344|plaque forming unit:11:0.4728	0.9219	371
Pfu	Pfu:12	Pyrococcus furiosus:12:0.7571	0.7571	12
PFV	PFV:26	flow velocity:26:0.7340	0.7340	26
PFV	PFV:9	foamy virus:9:0.6794	0.6794	9
PFWD	PFWD:13	pain-free walking distance:13:0.5934	0.5934	13
PFs	PFs:17|Pfs:1	parallel fibers:18:0.5560	0.5560	18
PFs	PFs:9	periplasmic flagella:9:0.6794	0.6794	9
PFS	PFS:9	Piper Fatigue Scale:9:0.5470	0.5470	9
PFS	PFS:13|P-FS:1	pressure-flow study:9:0.2757|pressure flow studies:5:0.4422	0.4422	14
PFS	PFS:31	primary fibromyalgia syndrome:31:0.8978	0.8978	31
PFS	PFS:29	Progression-free:29:0.0298	0.0298	29
PFS	PFS:553	progression-free survival:553:0.8470	0.8470	553
PFs	PFs:7	Protection factors:7:0.2902	0.2902	7
PFS	PFS:14	pyrogen-free saline:14:0.6911	0.6911	14
PF	PF:5	3.0% added poultry fat:5:0.5290	0.5290	5
PF	PF:9	5-fluorouracil:9:0.0031	0.0031	9
pf	pf:3|PF:2	days post-fertilization:5:0.0736	0.0736	5
PF	PF:11	effect was the prevented fraction:11:0.2972	0.2972	11
PF	PF:18|pF:1	fibroblasts:19:0.0070	0.0070	19
PF	PF:7	fracture face:7:0.0732	0.0732	7
PF	PF:10	group:10:0.0035	0.0035	10
PF	PF:4|Pf:4|pf:1	nucleus parafascicularis:9:0.1690	0.1690	9
PF	Pf:2|PF:2	nucleus parafascicularis thalami:4:0.1618	0.1618	4
Pf	Pf:5	osmotic water:5:0.1132	0.1132	5
Pf	Pf:124	Osmotic water permeability:124:0.7822	0.7822	124
Pf	Pf:11	osmotic water permeability coefficient:11:0.6182	0.6182	11
PF	PF:14	paeoniflorin:14:0.0051	0.0051	14
PF	PF:11|pf:1	pair fed:12:0.7571	0.7571	12
PF	PF:9	pancreatic fistula:9:0.4587	0.4587	9
Pf	Pf:17|PF:14	parafascicular nucleus:31:0.6131	0.6131	31
PF	PF:9	Parafollicular:9:0.0031	0.0031	9
PF	PF:14|Pf:1	Paraformaldehyde:15:0.0054	0.0054	15
PF	PF:36|Pf:1	parallel fiber:26:0.6973|parallel fibers:11:0.1009	0.6973	37
PF	PF:10	pars flaccida:10:0.7103	0.7103	10
PF	PF:19|P-F:1	patellofemoral:20:0.0074	0.0074	20
PF	PF:27	Peak Flow:27:0.3787	0.3787	27
PF	PF:17	peak force:17:0.6211	0.6211	17
PF	PF:11	peak frequency:11:0.1612	0.1612	11
PF	PF:18|Pf:2	Pentoxifylline:20:0.0074	0.0074	20
PF	PF:180	peritoneal fluid:173:0.6465|peritoneal fluids:7:0.2113	0.6465	180
PF	PF:11	permeability factor:11:0.0679	0.0679	11
PF	PF:9|Pf:1	Photofrin:10:0.0035	0.0035	10
PF	PF:15	physical function:15:0.2119	0.2119	15
PF	PF:38	physical functioning:38:0.8417	0.8417	38
PF	PF:6	plasma fibrinogen:6:0.2243	0.2243	6
PF	PF:10|pF:1	Plasma fibronectin:11:0.6182	0.6182	11
Pf	Pf:36|PF:14|pf:1	Plasmodium falciparum:51:0.7371	0.7371	51
PF	PF:30|Pf:3	pleural fluid:33:0.0879	0.0879	33
PF	PF:30	posterior fossa:30:0.6736	0.6736	30
pf	pf:8|PF:4	postfertilization:12:0.0047	0.0047	12
PF	PF:24|pF:1	prefrontal:25:0.0093	0.0093	25
PF	PF:8	prefrontal cortex:8:0.5006	0.5006	8
P-F	P-F:10|PF:3|p-F:1	pressure-flow:14:0.0051	0.0051	14
PF	PF:6	preterm formula:6:0.2243	0.2243	6
PF	PF:13	primary fibromyalgia:13:0.7753	0.7753	13
PF	PF:14	Proflavine:14:0.0051	0.0051	14
PF	PF:21	protection factor:13:0.0932|protection factors:8:0.1276	0.1276	21
PF	PF:14	protein-free:14:0.0051	0.0051	14
PF	PF:11	protoplasmic face:11:0.2549	0.2549	11
PF	PF:8	protoplasmic fracture:8:0.2327	0.2327	8
PF	PF:14	proximal femur:14:0.7909	0.7909	14
PF	PF:38	pulmonary fibrosis:38:0.4632	0.4632	38
PF	PF:17|pf:1	pulmonary function:18:0.2860	0.2860	18
PF	PF:32	Purkinje fibers:32:0.5670	0.5670	32
PF	PF:17	purpura fulminans:17:0.8270	0.8270	17
Pf	Pf:14|PF:1	Pyrococcus furiosus:15:0.8045	0.8045	15
P-F	P-F:4|PF:1	Rosenzweig picture-frustration:5:0.1132	0.1132	5
PG's	PG's:36|PG'S:1	prostaglandins:37:0.9474	0.9474	37
PG-APS	PG-APS:15	peptidoglycan-polysaccharide:15:0.3714	0.3714	15
PG12	PG12:11	prostacyclin:11:0.7143	0.7143	11
PG910	PG910:9|PG-910:1	polyglactin 910:10:0.7103	0.7103	10
PGA1	PGA1:54	prostaglandin A1:54:0.8622	0.8622	54
PGA2	PGA2:34	Prostaglandin A2:34:0.7898	0.7898	34
PGAM-M	PGAM-M:10	phosphoglycerate mutase:10:0.7103	0.7103	10
PGAM	PGAM:28|PGaM:1	phosphoglycerate mutase:29:0.8422	0.8422	29
PGA	PGA:9	3-phosphoglycerate:9:0.0111	0.0111	9
Pga	Pga:17|PGA:1|pga:1	gastric pressure:19:0.5732	0.5732	19
PGA	PGA:27	global assessment:27:0.8861	0.8861	27
PGA	PGA:35	penicillin G acylase:35:0.9151	0.9151	35
PGA	PGA:13	polyglandular autoimmune:13:0.7753	0.7753	13
PGA	PGA:8	polyglandular autoimmune syndrome:8:0.6411	0.6411	8
PGA	PGA:176|PgA:1	polyglycolic acid:177:0.4386	0.4386	177
PGA	PGA:23|PGa:1	polyglycolide:24:0.0320	0.0320	24
PGA	PGA:13	propylene glycol alginate:13:0.7753	0.7753	13
PGB1	PGB1:8	prostaglandin B1:8:0.5006	0.5006	8
PGCG	PGCG:10	peripheral giant cell granuloma:10:0.7103	0.7103	10
PGCs	PGCs:294|PGCS:1	Primordial germ cells:295:0.9783	0.9783	295
PGC	PGC:9	carcinoma:9:0.0203	0.0203	9
PGC	PGC:24|-PGC:2	glomerular capillary hydraulic pressure:26:0.8861	0.8861	26
PGC	PGC:27|Pgc:13	glomerular capillary pressure:40:0.8839	0.8839	40
PGC	PGC:7|Pgc:2	nucleus reticularis paragigantocellularis:9:0.6794	0.6794	9
pGC	pGC:5|PGC:1	particulate guanylate cyclase:6:0.5290	0.5290	6
pGC	pGC:6	particulate guanylyl cyclase:6:0.5290	0.5290	6
PGC	PGC:31	porous graphitic carbon:31:0.9043	0.9043	31
PGC	PGC:10	porous graphitized carbon:10:0.7103	0.7103	10
PGC	PGC:87	primordial germ cells:54:0.9132|primordial germ cell:33:0.8605	0.9132	87
PGD(2)	PGD(2):46	prostaglandin D(2):46:0.8151	0.8151	46
PGD2	PGD2:359|PgD2:3	prostaglandin D2:362:0.9527	0.9527	362
PGDH	PGDH:116	dehydrogenase:116:0.8984	0.8984	116
PGDPs	PGDPs:9	proglucagon-derived peptides:9:0.6794	0.6794	9
PGDS	PGDS:13|PGD-S:1	prostaglandin D synthase:14:0.5111	0.5111	14
PGD	PGD:28|Pgd:2	6-phosphogluconate dehydrogenase:30:0.4299	0.4299	30
PGD	PGD:18|Pgd:1	phosphogluconate dehydrogenase:19:0.2191	0.2191	19
PGD	PGD:337	preimplantation genetic diagnosis:337:0.9096	0.9096	337
PGE(1)	PGE(1):65|PG-E(1):2	prostaglandin E(1):67:0.9296	0.9296	67
PGE(2)	PGE(2):746|PgE(2):2	prostaglandin E(2):737:0.9765|prostaglandin-E(2):11:0.0138	0.9765	748
PGE(2)	PGE(2):18	prostaglandin E2:18:0.7539	0.7539	18
PGE1	PGE1:16	alprostadil:16:0.0093	0.0093	16
PGE1	PGE1:24|PGE-1:3	prostaglandin:27:0.0161	0.0161	27
PGE-1	PGE-1:9	prostaglandin E-1:9:0.5470	0.5470	9
PGE1	PGE1:1414|PGE-1:7|PgE1:6|PG-E1:4|PGe1:1	prostaglandin E1:1422:0.9530|prostaglandin-E1:10:0.0056	0.9530	1432
PGE2	PGE2:111|PgE2:2|PGE-2:1	prostaglandin:81:0.0136|prostaglandins:33:0.0053	0.0136	114
PGE2	PGE2:10	prostaglandin E:10:0.5856	0.5856	10
PGE-2	PGE-2:9|PGE2:2|PgE-2:1	prostaglandin E-2:12:0.7571	0.7571	12
PGE2	PGE2:5615|PgE2:22|PGE-2:5|PG-E2:4|pge2:1	prostaglandin E2:5594:0.9683|prostaglandin-E2:53:0.0086	0.9683	5647
PGEM	PGEM:8|PGE-m:1	13,14-dihydro-15-keto-PGE2:9:0.1429	0.1429	9
PGEM	PGEM:8|PGEm:2	metabolite:10:0.1607	0.1607	10
PGES	PGES:18|PGEs:1	PGE synthase:19:0.2352	0.2352	19
PGEs	PGEs:7	platinum group elements:7:0.5926	0.5926	7
PGEs	PGEs:9	prostaglandins:9:0.0784	0.0784	9
PGES	PGES:12|PGE-S:3	prostaglandin E synthase:15:0.5348	0.5348	15
PGE	PGE:8	E-series prostaglandins:8:0.1061	0.1061	8
PGE	PGE:10	graphite electrode:10:0.7103	0.7103	10
PGE	PGE:20	primary generalized epilepsy:20:0.8525	0.8525	20
PGE	PGE:15	Prostaglandin:15:0.0172	0.0172	15
PGE	PGE:473|PgE:5	prostaglandin E:478:0.9011	0.9011	478
PGE	PGE:25	prostaglandin E1:25:0.8816	0.8816	25
PGE	PGE:25	Prostaglandin E2:25:0.5095	0.5095	25
PGE	PGE:32|PgE:1	prostaglandins of the E series:33:0.7433	0.7433	33
PGF2a	PGF2a:21|PGF2A:1	prostaglandin F2a:22:0.7400	0.7400	22
PGF2a	PGF2a:10	prostaglandin F2alpha:10:0.5856	0.5856	10
PGFM	PGFM:14	13,14-dihydro-15-keto-prostaglandin F:14:0.3039	0.3039	14
PGFM	PGFM:56	13,14-dihydro-15-keto-prostaglandin F2 alpha:50:0.3404|13,14-dihydro-15-keto prostaglandin F2 alpha:6:0.0732	0.3404	56
PGFM	PGFM:12	13,14-dihydro-15-keto-prostaglandin F2alpha:7:0.1025|13,14-dihydro-15-keto prostaglandin F2alpha:5:0.1132	0.1132	12
PGFM	PGFM:6	prostaglandin F2 alpha metabolite:6:0.3728	0.3728	6
PGFS	PGFS:7	prostaglandin F synthase:7:0.5926	0.5926	7
PGF	PGF:29	growth factor:29:0.8978	0.8978	29
PGF	PGF:12	primary graft failure:12:0.5664	0.5664	12
PGF	PGF:46	prostaglandin F2 alpha:46:0.7707	0.7707	46
PGF	PGF:22	prostaglandin F2alpha:22:0.7400	0.7400	22
PGG2	PGG2:11	prostaglandin G2:11:0.6182	0.6182	11
PGG	PGG:11	photoglottography:11:0.1961	0.1961	11
PGH2	PGH2:74	Prostaglandin H2:74:0.5796	0.5796	74
PGHS-1	PGHS-1:17	prostaglandin H synthase-1:17:0.4480	0.4480	17
PGHS-2	PGHS-2:15	prostaglandin endoperoxide H synthase-2:15:0.7096	0.7096	15
PGHS-2	PGHS-2:22	prostaglandin G/H synthase-2:22:0.6531	0.6531	22
PGHS-2	PGHS-2:6	prostaglandin H synthase:6:0.5290	0.5290	6
PGHS-2	PGHS-2:32|PGHS2:2	prostaglandin H synthase-2:29:0.4410|prostaglandin H synthase 2:5:0.1973	0.4410	34
PGHS	PGHS:30	prostaglandin G/H synthase:30:0.7652	0.7652	30
PGHS	PGHS:96|PGHs:2	Prostaglandin H synthase:98:0.7220	0.7220	98
PGI(2)	PGI(2):131|PgI(2):2|PG-I(2):1	prostacyclin:134:0.8110	0.8110	134
PGI(2)	PGI(2):22	prostaglandin I(2):22:0.7955	0.7955	22
PGI2	PGI2:8	6-keto-PGF1 alpha:8:0.2987	0.2987	8
PGI2	PGI2:15	epoprostenol:15:0.0054	0.0054	15
PGI2	PGI2:2382|PGI-2:8|PgI2:4|PG-I2:3|PGi2:2	prostacyclin:2399:0.8638	0.8638	2399
PGI2	PGI2:14	prostacycline:14:0.0047	0.0047	14
PGI2	PGI2:9	prostaglandin:9:0.0033	0.0033	9
PGI2	PGI2:248	prostaglandin I2:248:0.8731	0.8731	248
PGIPs	PGIPs:16	Polygalacturonase-inhibiting proteins:16:0.6577	0.6577	16
PGIP	PGIP:20	Polygalacturonase-inhibiting protein:20:0.4852	0.4852	20
PGIS	PGIS:34	prostacyclin synthase:34:0.4872	0.4872	34
PGi	PGi:26	nucleus paragigantocellularis:26:0.8861	0.8861	26
PGI	PGI:8	patient generated index:8:0.6411	0.6411	8
PGI	PGI:26|PG-I:3|PgI:2	pepsinogen I:31:0.6572	0.6572	31
PGI	PGI:6|Pgi:2|pgi:1	phosphoglucoisomerase:9:0.0274	0.0274	9
PGI	PGI:77|pgi:7|Pgi:6	phosphoglucose isomerase:90:0.8740	0.8740	90
PGI	PGI:12	prostacyclin:12:0.0377	0.0377	12
PGK-1	PGK-1:24|PGK1:19|Pgk-1:1|Pgk1:1|pgk-1:1|pgk1:1	phosphoglycerate kinase:47:0.8986	0.8986	47
PGK1	PGK1:17|PGK-1:15|Pgk-1:1|Pgk1:1	phosphoglycerate kinase 1:18:0.6903|phosphoglycerate kinase-1:16:0.8165	0.8165	34
PGK1	PGK1:5|Pgk-1:1	phosphoglycerate kinase gene:6:0.2243	0.2243	6
PGK	PGK:57|Pgk:1	3-phosphoglycerate kinase:58:0.1159	0.1159	58
PGK	PGK:288|pgk:12|Pgk:7	phosphoglycerate kinase:307:0.7800	0.7800	307
PGK	PGK:11|pgk:2|Pgk:1	phosphoglycerate kinase gene:14:0.5111	0.5111	14
PGK	PGK:1	restriction fragment length polymorphism of X-chromosome-linked phosphoglycerokinase:1:0.4422	0.4422	1
PGL-1	PGL-1:16	phenolic glycolipid-1:10:0.4363|phenolic glycolipid 1:6:0.5290	0.5290	16
PGL-I	PGL-I:73	phenolic glycolipid-I:59:0.7213|Phenolic glycolipid I:14:0.6173	0.7213	73
PGL	PGL:5	Hereditary paraganglioma:5:0.0612	0.0612	5
PGL	PGL:22	nucleus paragigantocellularis lateralis:22:0.6934	0.6934	22
PGL	PGL:92	Persistent generalized lymphadenopathy:92:0.9223	0.9223	92
PGL	PGL:9	phenolic glycolipid:9:0.6794	0.6794	9
PGL	PGL:25	primary gastric lymphoma:25:0.8251	0.8251	25
PGM1	PGM1:59|PGM-1:1	phosphoglucomutase:60:0.3636	0.3636	60
PGM1	PGM1:44|PGM-1:2	Phosphoglucomutase 1:24:0.4788|phosphoglucomutase-1:22:0.1273	0.4788	46
PGME	PGME:26	propylene glycol monomethyl ether:26:0.8768	0.8768	26
PGM	PGM:16	gastric mucin:16:0.8165	0.8165	16
PGM	PGM:21	Peptidoglycan monomer:21:0.7865	0.7865	21
PGM	PGM:8	periaqueductal gray matter:8:0.5006	0.5006	8
PGM	PGM:171|Pgm:15|pgm:9	phosphoglucomutase:195:0.5273	0.5273	195
PGM	PGM:17|Pgm:2	phosphoglycerate mutase:19:0.7044	0.7044	19
PGNs	PGNs:15	preganglionic neurons:15:0.7096	0.7096	15
PGN	PGN:78	peptidoglycan:78:0.3500	0.3500	78
PGN	PGN:10	perigeniculate:10:0.0409	0.0409	10
PGN	PGN:27	perigeniculate nucleus:27:0.6455	0.6455	27
Pgn	Pgn:7|PGn:6|PGN:4	plasminogen:17:0.0773	0.0773	17
PGN	PGN:8	preganglionic neurons:8:0.3463	0.3463	8
PGN	PGN:24	proliferative glomerulonephritis:24:0.4788	0.4788	24
PGO	PGO:28	phenylglyoxal:28:0.1667	0.1667	28
PGO	PGO:89|pgo:1	ponto-geniculo-occipital:90:0.5556	0.5556	90
PGO	PGO:9	pontogeniculo-occipital:9:0.0494	0.0494	9
PGO	PGO:12	pontogeniculooccipital:12:0.0679	0.0679	12
PGP9.5	PGP9.5:42|PGP-9.5:4	protein gene product 9.5:46:0.8986	0.8986	46
PGPH	PGPH:8	peptide hydrolyzing:8:0.2090	0.2090	8
PGPH	PGPH:7	peptidylglutamyl-peptide hydrolyzing:7:0.1470	0.1470	7
PGPR	PGPR:24	plant growth-promoting rhizobacteria:15:0.8045|plant growth promoting rhizobacteria:9:0.6794	0.8045	24
PGPR	PGPR:11	polyglycerol polyricinoleate:11:0.7357	0.7357	11
P-gps	P-gps:12|Pgps:10|PGPs:1	P-glycoproteins:23:0.2651	0.2651	23
PG-PS	PG-PS:26	peptidoglycan-polysaccharide:26:0.3012	0.3012	26
PGPs	PGPs:10	prepaid group practices:10:0.7103	0.7103	10
P-gp	P-gp:7|Pgp:2	anti-P-glycoprotein:9:0.0027	0.0027	9
P-gp	P-gp:1426|Pgp:837|PGP:138|pgp:34|p-gp:32|P-GP:21|PgP:14|P-Gp:10|P-gP:8|p-Gp:1|pGP:1|p-GP:1|P-G-P:1	P-glycoprotein:2465:0.8210|P glycoprotein:37:0.4642|P-glycoproteins:22:0.0070	0.8210	2524
P-gp	P-gp:8|Pgp:2	P-glycoprotein 170:10:0.5856	0.5856	10
PGP	PGP:7|PG-P:2	phosphatidylglycerophosphate:9:0.0027	0.0027	9
PGP	PGP:30	phosphoglycolate phosphatase:30:0.7970	0.7970	30
PGP	PGP:7|pgp:1	prepaid group practice:8:0.5006	0.5006	8
PGP	PGP:136	protein gene product:136:0.9234	0.9234	136
PGP	PGP:48	protein gene product 9.5:48:0.8433	0.8433	48
PGRPs	PGRPs:16	peptidoglycan recognition proteins:16:0.7261	0.7261	16
PGSE	PGSE:10|pgse:1	gradient spin-echo:11:0.2280	0.2280	11
PGSE	PGSE:20	pulsed gradient spin echo:20:0.7173	0.7173	20
PGSI	PGSI:7	prostaglandin synthetase inhibitors:7:0.5926	0.5926	7
PGST	PGST:6|P-GST:1	Placental glutathione S-transferase:7:0.1329	0.1329	7
PGST	PGST:7	placental isozyme of glutathione S-transferase:7:0.5926	0.5926	7
PGT	PGT:7	prostaglandin transporter:7:0.2452	0.2452	7
PGU	PGU:22	urethritis:22:0.5526	0.5526	22
PGV	PGV:98	proximal gastric vagotomy:98:0.9695	0.9695	98
PGW	PGW:16	Persian Gulf War:16:0.8165	0.8165	16
PGWB	PGWB:39	Psychological General Well-Being:39:0.8455	0.8455	39
PGWB	PGWB:22	Psychological General Well-Being Index:22:0.8657	0.8657	22
PGWBI	PGWBI:11	Psychological General Well-being Index:11:0.7357	0.7357	11
PGY-1	PGY-1:6|PGY1:4	postgraduate year 1:10:0.7103	0.7103	10
PGY	PGY:16	postgraduate year:16:0.7261	0.7261	16
PGl2	PGl2:14|Pgl2:2	prostacyclin:16:0.6818	0.6818	16
PGS	PGS:6	gelatin sponge:6:0.1838	0.1838	6
PGS	PGS:8	paraglottic space:8:0.5006	0.5006	8
PGs	PGs:19	polygalacturonases:19:0.0075	0.0075	19
PGs	PGs:1750|PGS:7|Pgs:3|pgs:1	prostaglandins:1749:0.7239|prostaglandin:12:0.0046	0.7239	1761
PGS	PGS:6	prostaglandin endoperoxide synthase:6:0.1838	0.1838	6
PGS	PGS:9	prostaglandin synthase:9:0.1099	0.1099	9
PGs	PGs:354|PGS:3	proteoglycans:357:0.1474	0.1474	357
PGs	PGs:23	prothoracic glands:23:0.8038	0.8038	23
PGS	PGS:9	syndrome:9:0.0033	0.0033	9
PG	PG:60	6-keto-prostaglandin:60:0.0073	0.0073	60
PG	PG:10	6-ketoprostaglandin:10:0.0011	0.0011	10
PG	PG:13	8-iso-prostaglandin:13:0.0015	0.0015	13
PG	PG:37	cartilage proteoglycan:37:0.0652	0.0652	37
Pg	Pg:12|PG:2	gastric:14:0.0016	0.0016	14
PG	PG:9	glands:9:0.0010	0.0010	9
PG	PG:5	Glomerular capillary hydrostatic pressure:5:0.2818	0.2818	5
PG	PG:6|Pg:2	Glomerular capillary pressure:8:0.5006	0.5006	8
PG	PG:10|Pg:1	Panax ginseng:11:0.5355	0.5355	11
PG	PG:15	pancreatic glucagon:15:0.8045	0.8045	15
PG	PG:16	pancreaticogastrostomy:16:0.0018	0.0018	16
PG	PG:5	paracervical ganglia:5:0.0612	0.0612	5
PG	PG:7	parotid gland:7:0.0539	0.0539	7
PG	PG:19	pathological gambling:19:0.5732	0.5732	19
PG	PG:25	Pemphigoid gestationis:25:0.8186	0.8186	25
PG	PG:8	Penicillin G:8:0.1471	0.1471	8
PG	PG:43|Pg:9	pentagastrin:52:0.0063	0.0063	52
Pg	Pg:5|PG:4	pepsinogens:9:0.0010	0.0010	9
PG	PG:143	peptidoglycan:133:0.0162|Peptidoglycans:10:0.0011	0.0162	143
PG	PG:10	Percutaneous gastrostomy:10:0.7103	0.7103	10
PG	PG:14	periglomerular:14:0.0016	0.0016	14
PG	PG:13	petrosal ganglion:13:0.3554	0.3554	13
PG	PG:6	phenolphthalein glucuronide:6:0.0522	0.0522	6
PG	PG:19	phenylglyoxal:19:0.0021	0.0021	19
PG	PG:21	phosphatidyl glycerol:21:0.6812	0.6812	21
PG	PG:489	phosphatidylglycerol:489:0.0599	0.0599	489
pg	pg:13	picograms:13:0.0015	0.0015	13
PG	PG:7	pigmentary glaucoma:7:0.2452	0.2452	7
PG	PG:11	Placebo Group:11:0.1430	0.1430	11
PG	PG:7|Pg:5	plakoglobin:12:0.0014	0.0014	12
PG	PG:127|pg:1	plasma glucose:128:0.9093	0.9093	128
Pg	Pg:66|PG:21	plasminogen:87:0.0106	0.0106	87
PG	PG:72	polygalacturonase:72:0.0087	0.0087	72
PG	PG:5	polypoid growth:5:0.1132	0.1132	5
PG	PG:20	pressure gradient:20:0.4379	0.4379	20
PG	PG:12	proguanil:12:0.0014	0.0014	12
PG	PG:45	propyl gallate:45:0.7881	0.7881	45
PG	PG:226	propylene glycol:226:0.9062	0.9062	226
PG	PG:4502|Pg:8	prostaglandin:3662:0.4504|prostaglandins:848:0.1043	0.4504	4510
PG	PG:12	prostaglandin F2 alpha:12:0.7571	0.7571	12
PG	PG:3|pG:3	protein G:6:0.0611	0.0611	6
PG	PG:163|Pg:1	proteoglycans:164:0.0201	0.0201	164
PG	PG:6	proximal gastrectomy:6:0.1010	0.1010	6
PG	PG:102	Pyoderma gangrenosum:102:0.9707	0.9707	102
PG	PG:13	pyogenic granuloma:13:0.7753	0.7753	13
PG	PG:29	pyrolytic graphite:29:0.8978	0.8978	29
PG	PG:25	serum pepsinogen:25:0.3026	0.3026	25
Ph-	Ph-:14	Philadelphia chromosome-negative:8:0.5006|Philadelphia chromosome negative:6:0.5290	0.5290	14
pH0	pH0:12|PH0:1	extracellular pH:13:0.4102	0.4102	13
PHA1	PHA1:8|PHA-1:7	Pseudohypoaldosteronism type 1:15:0.8045	0.8045	15
PHAHs	PHAHs:9|pHAHs:1	planar halogenated aromatic hydrocarbons:10:0.7103	0.7103	10
PHAHs	PHAHs:23	polyhalogenated aromatic hydrocarbons:23:0.5025	0.5025	23
PHA-LCM	PHA-LCM:9	conditioned by leukocytes in the presence of phytohemagglutinin:9:0.5470	0.5470	9
PHA-LCM	PHA-LCM:5	medium conditioned by phytohemagglutinin-stimulated leukocytes:5:0.2818	0.2818	5
PHA-L	PHA-L:12	Phaseolus vulgaris leukoagglutinin:12:0.7571	0.7571	12
PHA-P	PHA-P:10	phytohaemagglutinin:10:0.0545	0.0545	10
PHA-P	PHA-P:12	phytohaemagglutinin-P:12:0.0667	0.0667	12
PHA-P	PHA-P:68|PHAP:2|PHA-p:1	phytohemagglutinin-P:60:0.3697|phytohemagglutinin P:11:0.5355	0.5355	71
PHAT	PHAT:11	passive hemagglutination test:11:0.7357	0.7357	11
PHAs	PHAs:14	poly(3-hydroxyalkanoates):14:0.0833	0.0833	14
PHAs	PHAs:85	Polyhydroxyalkanoates:85:0.5321	0.5321	85
pHa	pHa:13	arterial blood pH:13:0.7753	0.7753	13
pHa	pHa:49	arterial pH:49:0.5905	0.5905	49
PHA	PHA:35	passive haemagglutination:35:0.9151	0.9151	35
PHA	PHA:83	passive hemagglutination:83:0.9640	0.9640	83
PHA	PHA:18	passive hemagglutination assay:18:0.8365	0.8365	18
PHA	PHA:7	passive hemagglutination test:7:0.5926	0.5926	7
PHA	PHA:7	people living with HIV/AIDS:7:0.4438	0.4438	7
PHA	PHA:7	persistent primitive hypoglossal artery:7:0.3524	0.3524	7
PHA	PHA:15	Phaseolus vulgaris:15:0.8045	0.8045	15
PHA	PHA:15	Phaseolus vulgaris agglutinin:15:0.7096	0.7096	15
PHA	PHA:17	phytohaemagglutin:17:0.0030	0.0030	17
PHA	PHA:1205	phytohaemagglutinin:1205:0.2277	0.2277	1205
PHA	PHA:18	Phytohaemagglutinin-P:18:0.0032	0.0032	18
PHA	PHA:14	phytohaemaglutinin:14:0.0025	0.0025	14
PHA	PHA:12	phytohaemoagglutinin:12:0.0021	0.0021	12
PHA	PHA:43|pha:1	Phytohemagglutin:44:0.0081	0.0081	44
PHA	PHA:2791	phytohemagglutinin:2782:0.5247|phytohemagglutinins:9:0.0015	0.5247	2791
PHA	PHA:47	phytohemagglutinin-P:37:0.0068|phytohemagglutinin P:10:0.5856	0.5856	47
PHA	PHA:40	phytohemaglutinin:40:0.0074	0.0074	40
PHA	PHA:11	phytohemoagglutinin:11:0.0019	0.0019	11
PHA	PHA:11	poly(3-hydroxyalkanoate):11:0.0019	0.0019	11
PHA	PHA:12	poly-beta-hydroxyalkanoate:12:0.0021	0.0021	12
PHA	PHA:142	polyhydroxyalkanoate:142:0.0266	0.0266	142
PHA	PHA:24	polyhydroxyalkanoic acid:19:0.2840|polyhydroxyalkanoic acids:5:0.0902	0.2840	24
PHA	PHA:9|pHA:1	porous hydroxyapatite:10:0.7103	0.7103	10
PHA	PHA:13	posterior hypothalamic area:13:0.7753	0.7753	13
PHA	PHA:9	primary hyperaldosteronism:9:0.5470	0.5470	9
PHA	PHA:7	production of polyhydroxyalkanoates:7:0.0516	0.0516	7
PHA	PHA:6	proper hepatic artery:6:0.5290	0.5290	6
PHA	PHA:35	Pseudohypoaldosteronism:35:0.0062	0.0062	35
PHBA	PHBA:8|p-HBA:3|pHBA:3	p-hydroxybenzoic acid:14:0.4071	0.4071	14
PHBH	PHBH:20	p-Hydroxybenzoate hydroxylase:20:0.7173	0.7173	20
PHBV	PHBV:10	poly(3-hydroxybutyrate-co-3-hydroxyvalerate):10:0.2195	0.2195	10
PhB	PhB:34|PHB:25|Phb:3	phenobarbital:62:0.1013	0.1013	62
PHB	PHB:118	poly(3-hydroxybutyrate):81:0.1296|poly-3-hydroxybutyrate:37:0.0581	0.1296	118
PHB	PHB:114	poly-beta-hydroxybutyrate:96:0.1561|poly(beta-hydroxybutyrate):18:0.0282	0.1561	114
PHB	PHB:17	poly-beta-hydroxybutyric acid:17:0.1881	0.1881	17
PHB	PHB:84	polyhydroxybutyrate:84:0.1379	0.1379	84
PHCA	PHCA:11	Profound hypothermic circulatory arrest:11:0.6182	0.6182	11
PHCCs	PHCCs:9	primary health care centers:9:0.6794	0.6794	9
PHCTs	PHCTs:10	primary health care teams:10:0.7103	0.7103	10
PHCT	PHCT:9	primary health care team:9:0.6794	0.6794	9
PHCl	PHCl:4|PHCL:3|P-HCl:2	hydrochloride:9:0.5000	0.5000	9
PHCs	PHCs:14	health centers:14:0.7909	0.7909	14
PHCs	PHCs:6	Primary Health Centres:6:0.3728	0.3728	6
PHC	PHC:15	health center:15:0.8045	0.8045	15
pHc	pHc:7	Intracellular pH:7:0.0565	0.0565	7
PHC	PHC:521|phc:1	primary health care:522:0.9669	0.9669	522
PHC	PHC:7	primary health centers:7:0.3524	0.3524	7
PHC	PHC:14	primary health centre:14:0.6911	0.6911	14
PHC	PHC:11	primary healthcare:11:0.7357	0.7357	11
PHC	PHC:9	primary hepatic cancer:9:0.6794	0.6794	9
PHC	PHC:24	primary hepatic carcinoma:24:0.8768	0.8768	24
PHC	PHC:9	primary hepatocellular cancer:9:0.6794	0.6794	9
PHC	PHC:118	primary hepatocellular carcinoma:118:0.9596	0.9596	118
PHDPE	PHDPE:8	porous high-density polyethylene:8:0.6411	0.6411	8
Phd	Phd:8|PHD:1	Phosducin:9:0.0482	0.0482	9
PHD	PHD:19	Plant homeodomain:19:0.8449	0.8449	19
PHEMA	PHEMA:7|pHEMA:2	poly(2-hydroxyethylmethacrylate):9:0.0523	0.0523	9
PHEMA	PHEMA:10|pHEMA:1	Polyhydroxyethylmethacrylate:11:0.0654	0.0654	11
PHEO	PHEO:14|Pheo:13|pheo:6	pheochromocytoma:33:0.5926	0.5926	33
PHFO	PHFO:14	partially hydrogenated fish oil:14:0.7909	0.7909	14
PHFs	PHFs:158	paired helical filaments:158:0.9811	0.9811	158
PHF	PHF:259	paired helical filaments:202:0.9474|paired helical filament:57:0.8689	0.9474	259
PHF	PHF:30	parathyroid hypertensive factor:30:0.9011	0.9011	30
PHF	PHF:13	Potomac horse fever:13:0.7753	0.7753	13
PHF	PHF:8	precultured heart fragments:8:0.4102	0.4102	8
PHGG	PHGG:11	partially hydrolyzed guar gum:11:0.7357	0.7357	11
PHGPx	PHGPx:92|PHGPX:37|PhGPx:4|PH-GPx:2|phGPx:2	phospholipid hydroperoxide glutathione peroxidase:137:0.9652	0.9652	137
PHG	PHG:23	parahippocampal gyrus:23:0.8715	0.8715	23
PHG	PHG:63	portal hypertensive gastropathy:63:0.9526	0.9526	63
PHG	PHG:15	pulmonary hyalinizing granuloma:15:0.8045	0.8045	15
PHHI	PHHI:11	persistent hyperinsulinaemic hypoglycaemia of infancy:11:0.7357	0.7357	11
PHHI	PHHI:55	Persistent Hyperinsulinemic Hypoglycemia of Infancy:55:0.9458	0.9458	55
PHHP	PHHP:9	Pawtucket Heart Health Program:9:0.6794	0.6794	9
PHH	PHH:19	posthemorrhagic hydrocephalus:19:0.4211	0.4211	19
PHITC	PHITC:16	6-phenylhexyl isothiocyanate:16:0.7261	0.7261	16
PHKs	PHKs:8	primary human keratinocytes:8:0.6411	0.6411	8
PhK	PhK:24|Phk:13|PHK:12	phosphorylase kinase:49:0.8254	0.8254	49
PHLA	PHLA:47	lipolytic activity:47:0.6867	0.6867	47
PhLP	PhLP:19|PhlP:1	phosducin-like protein:20:0.7766	0.7766	20
Phl	Phl:8|PHL:5	2,4-diacetylphloroglucinol:13:0.1132	0.1132	13
PHL	PHL:6|PhL:4|Phl:2	phospholipids:12:0.1038	0.1038	12
PHL	PHL:6	Primary hepatic lymphoma:6:0.3728	0.3728	6
PHNO	PHNO:14	(+)-4-propyl-9-hydroxynaphthoxazine:14:0.5417	0.5417	14
PHNs	PHNs:66|PHNS:1	Public health nurses:67:0.9554	0.9554	67
PHN	PHN:85|pHN:2	passive Heymann nephritis:87:0.9664	0.9664	87
PHN	PHN:46	post-herpetic neuralgia:46:0.1659	0.1659	46
PHN	PHN:9	posterior hypothalamic nucleus:9:0.4587	0.4587	9
PHN	PHN:151	Postherpetic neuralgia:151:0.6888	0.6888	151
PHN	PHN:10	public health nurse:10:0.7103	0.7103	10
PHN	PHN:11	public health nursing:11:0.6182	0.6182	11
PHO5	PHO5:8	acid phosphatase gene:8:0.5006	0.5006	8
Phos	Phos:9|PHOS:2	glycogen phosphorylase:11:0.3829	0.3829	11
PHOs	PHOs:9	physician-hospital organizations:9:0.3455	0.3455	9
PHP-Ib	PHP-Ib:8|PHPIB:2	Pseudohypoparathyroidism type IB:10:0.7103	0.7103	10
PHP-Ia	PHP-Ia:14|PHPIa:1	pseudohypoparathyroidism type Ia:15:0.8165	0.8165	15
PHPT	PHPT:261|pHPT:175|P-HPT:2	primary hyperparathyroidism:438:0.9853	0.9853	438
PHPV	PHPV:74	persistent hyperplastic primary vitreous:74:0.9596	0.9596	74
PHP	PHP:24	Patients with pseudohypoparathyroidism:24:0.1412	0.1412	24
pHp	pHp:5|pHP:2	plasma pH:7:0.3524	0.3524	7
PHP	PHP:10	post-heparin plasma:10:0.1273	0.1273	10
PHP	PHP:18	postheparin plasma:18:0.3696	0.3696	18
PHP	PHP:94	primary hyperparathyroidism:94:0.9682	0.9682	94
PHP	PHP:19	Pyridoxalated hemoglobin polyoxyethylene conjugate:19:0.7044	0.7044	19
PHQ	PHQ:24	Patient Health Questionnaire:24:0.6767	0.6767	24
PHQ	PHQ:16	phenylhydroquinone:16:0.2083	0.2083	16
pHSA	pHSA:17|PHSA:4	polymerized human serum albumin:21:0.4945	0.4945	21
PHSBO	PHSBO:11	partially hydrogenated soybean oil:11:0.7357	0.7357	11
PHS	PHS:12	Pallister-Hall syndrome:12:0.0921	0.0921	12
PHS	PHS:12	Physicians' Health Study:12:0.5664	0.5664	12
PHS	PHS:12	pooled human serum:12:0.5664	0.5664	12
PHS	PHS:7	PROLENE Hernia System:7:0.5926	0.5926	7
PHS	PHS:84	prostaglandin H synthase:84:0.9644	0.9644	84
PHS	PHS:158	Public Health Service:158:0.9506	0.9506	158
PHS	PHS:34	pulmonary hypertension syndrome:34:0.8644	0.8644	34
pHs	pHs:17	surface pH:17:0.6211	0.6211	17
PHTLS	PHTLS:7	Prehospital Trauma Life Support:7:0.3524	0.3524	7
PHTN	PHTN:9	hypertension:9:0.8889	0.8889	9
PHT	PHT:6	passive haemagglutination test:6:0.5290	0.5290	6
PHT	PHT:605|Pht:1|pht:1	phenytoin:607:0.6113	0.6113	607
PHT	PHT:57	portal hypertension:57:0.2526	0.2526	57
PHT	PHT:21	portal hypertensive:21:0.7291	0.7291	21
PHT	PHT:6	postmenopausal hormone therapy:6:0.2243	0.2243	6
PHT	PHT:47	pressure half-time:28:0.8369|pressure half time:19:0.8449	0.8449	47
PHT	PHT:107	pulmonary hypertension:107:0.5386	0.5386	107
pHt	pHt:7	tissue pH:7:0.2113	0.2113	7
PHVD	PHVD:13	ventricular dilatation:13:0.7753	0.7753	13
PHWE	PHWE:9	hot water extraction:9:0.6794	0.6794	9
PHx	PHx:2	after a 70% partial hepatectomy:2:0.2757	0.2757	2
PHx	PHx:5	liver regeneration after partial hepatectomy:5:0.5290	0.5290	5
PHX	PHX:10	predicted highly expressed:10:0.7103	0.7103	10
PHYSO	PHYSO:14|Physo:2|physo:1	Physostigmine:17:0.9412	0.9412	17
Phys	Phys:7|PHYS:3	physostigmine:10:0.3333	0.3333	10
PHY	PHY:7|Phy:2	physalaemin:9:0.0494	0.0494	9
PHY	PHY:41|Phy:34	physostigmine:75:0.4568	0.4568	75
phy	phy:22|PHY:5|Phy:3	phytochrome:30:0.1790	0.1790	30
PHZ	PHZ:41|Phz:2|PhZ:1	phenylhydrazine:44:0.7049	0.7049	44
PI(3)K	PI(3)K:21	phosphatidylinositol-3-OH kinase:21:0.4733	0.4733	21
PI(4,5)P(2)	PI(4,5)P(2):17	phosphatidylinositol 4,5-bisphosphate:17:0.8270	0.8270	17
PI(4,5)P2	PI(4,5)P2:13|PI(4,5)-P2:1	phosphatidylinositol 4,5-bisphosphate:14:0.7909	0.7909	14
Pi(max)	Pi(max):4|PI(max):3	Maximal inspiratory pressure:7:0.5926	0.5926	7
PI2	PI2:5	parainfluenza virus type 2:5:0.4422	0.4422	5
PI3Ks	PI3Ks:58|PI3-Ks:2|PI-3Ks:1	Phosphoinositide 3-kinases:61:0.7455	0.7455	61
PI3K	PI3K:9|PI3-K:1|PI-3K:1	Phosphatidyl-inositol-3-kinase:11:0.0045	0.0045	11
PI3K	PI3K:1007|PI3-K:254|PI-3K:104|PI-3-K:15|PI3k:11|PI3-k:4|PI-3k:3	phosphatidylinositol 3-kinase:1037:0.6575|phosphatidylinositol-3 kinase:129:0.3162|phosphatidylinositol-3-kinase:96:0.0430|phosphatidylinositol 3'-kinase:88:0.8468|phosphatidylinositol 3 kinase:32:0.4827|phosphatidylinositol-3'-kinase:16:0.0068	0.8468	1398
PI3K	PI3K:32|PI3-K:6|PI-3K:2|PI-3-K:2	phosphoinositide-3-kinase:23:0.0100|phosphoinositide 3-kinases:19:0.5113	0.5113	42
PI3P	PI3P:11|PI-3-P:1	phosphatidylinositol 3-phosphate:12:0.6460	0.6460	12
PI-3	PI-3:34|PI3:6|Pi3:1	Parainfluenza-3:41:0.1404	0.1404	41
PI-3	PI-3:10|PI3:9	parainfluenza type 3:19:0.3019	0.3019	19
PI-3	PI-3:7|PI3:6|Pi3:1	Parainfluenza virus type 3:14:0.8045	0.8045	14
PI-3	PI-3:54|PI3:39	phosphatidylinositol-3:67:0.2316|phosphatidylinositol 3:26:0.1708	0.2316	93
PI4P	PI4P:5|PI-4-P:4	phosphatidylinositol 4-phosphate:9:0.4587	0.4587	9
PI-6	PI-6:8|PI6:2	proteinase inhibitor 6:10:0.5000	0.5000	10
PI-9	PI-9:12|PI9:7	proteinase inhibitor 9:19:0.5732	0.5732	19
PIAS1	PIAS1:14	protein inhibitor of activated STAT1:14:0.8045	0.8045	14
PIAS3	PIAS3:8|PIAS-3:1	protein inhibitor of activated STAT3:9:0.6794	0.6794	9
PIAS	PIAS:13	protein inhibitor of activated STAT:13:0.7753	0.7753	13
PIAT	PIAT:9	Peabody Individual Achievement Test:9:0.6794	0.6794	9
PIBF	PIBF:10	progesterone induced blocking factor:10:0.7103	0.7103	10
PIBF	PIBF:7	protein named the progesterone-induced blocking factor:7:0.6794	0.6794	7
PIBs	PIBs:10|pibs:1	inclusion bodies:11:0.7357	0.7357	11
PIB	PIB:8	inclusion bodies:8:0.5006	0.5006	8
PIB	PIB:23	partial ileal bypass:23:0.8715	0.8715	23
PIB	PIB:16	polyisobutylene:16:0.1456	0.1456	16
PIB	PIB:14	propranolol-induced bronchoconstriction:14:0.6173	0.6173	14
PICA	PICA:189	posterior inferior cerebellar artery:189:0.9309	0.9309	189
PICCs	PICCs:61	peripherally inserted central catheters:61:0.9511	0.9511	61
PICCs	PICCs:16	peripherally inserted central venous catheters:16:0.8165	0.8165	16
PICC	PICC:58	peripherally inserted central catheter:43:0.8558|peripherally inserted central catheters:15:0.7096	0.8558	58
PICH	PICH:7|pICH:1	primary intracerebral hemorrhage:8:0.5006	0.5006	8
PICI	PICI:15	positive ion chemical ionization:8:0.6411|positive-ion chemical ionization:7:0.1470	0.6411	15
PICP	PICP:98|P-I-CP:1	carboxyterminal propeptide of type I procollagen:99:0.5127	0.5127	99
PICP	PICP:7	I carboxy-terminal propeptide:7:0.0886	0.0886	7
PICP	PICP:8	procollagen I carboxyterminal propeptide:8:0.2285	0.2285	8
PICP	PICP:5	procollagen type I C-terminal peptide:5:0.4422	0.4422	5
PICP	PICP:8	procollagen type I C-terminal propeptide:8:0.6411	0.6411	8
PICP	PICP:4	procollagen type I carboxy-terminal extension peptide:4:0.3170	0.3170	4
PICP	PICP:8	procollagen type I carboxyterminal propeptide:8:0.6411	0.6411	8
PICP	PICP:33	propeptide of type I collagen:33:0.7525	0.7525	33
PICP	PICP:8	type I procollagen carboxy-terminal propeptide:8:0.6411	0.6411	8
PICSO	PICSO:10|P-ICSO:1	pressure-controlled intermittent coronary sinus occlusion:11:0.4728	0.4728	11
PICT	PICT:12	community tolerance:12:0.7571	0.7571	12
PICUs	PICUs:36	pediatric intensive care units:36:0.5182	0.5182	36
PICU	PICU:20	pediatric ICU:20:0.7173	0.7173	20
PICU	PICU:303|P-ICU:1	Pediatric Intensive Care Unit:289:0.6806|pediatric intensive care units:15:0.4609	0.6806	304
PICs	PICs:7	persistent inward currents:7:0.3524	0.3524	7
PICs	PICs:22	preintegration complexes:22:0.4945	0.4945	22
PIC	PIC:13	complexes:13:0.0163	0.0163	13
PIC	PIC:4|Pic:3	intracranial pressure:7:0.3524	0.3524	7
PIC	PIC:5	islet cells:5:0.1132	0.1132	5
PIC	PIC:10	Paediatric intensive care:10:0.4363	0.4363	10
PIC	PIC:11	particle-in-cell:11:0.0136	0.0136	11
PIC	PIC:25	Personality Inventory for Children:25:0.8861	0.8861	25
PiC	PiC:8|PIC:4|Pic:1	phosphate carrier:13:0.6701	0.6701	13
PIC	PIC:34	phosphoinositidase C:34:0.5846	0.5846	34
PIC	PIC:8|pic:1	phospholipase C:9:0.0621	0.0621	9
PIC	PIC:91	polymorphism information content:91:0.6518	0.6518	91
PIC	PIC:39	preinitiation complex:39:0.1345	0.1345	39
PID	PID:23	Pain intensity difference:23:0.8715	0.8715	23
PID	PID:779	pelvic inflammatory disease:770:0.9859|pelvic inflammatory diseases:9:0.5470	0.9859	779
PID	PID:6	phosphotyrosine interaction domain:6:0.5290	0.5290	6
PID	PID:9	photoionization detector:9:0.3945	0.3945	9
PID	PID:15|pid:2	post-inoculation day:17:0.0719	0.0719	17
PID	PID:102|pid:1	postinoculation day:68:0.4721|postinoculation days:35:0.4569	0.4721	103
PID	PID:6	preimplantation diagnosis:6:0.2243	0.2243	6
PID	PID:11	primary immunodeficiencies:11:0.7357	0.7357	11
PID	PID:8	primary immunodeficiency diseases:8:0.6411	0.6411	8
PID	PID:34	proportional-integral-derivative:34:0.0259	0.0259	34
PIE	PIE:59	positive inotropic effect:59:0.9494	0.9494	59
PIE	PIE:10	pulmonary infiltration with eosinophilia:10:0.7103	0.7103	10
PIE	PIE:43	Pulmonary interstitial emphysema:43:0.9308	0.9308	43
PIFR	PIFR:13	peak inspiratory flow rate:13:0.6701	0.6701	13
PIFT	PIFT:17	platelet immunofluorescence test:17:0.5374	0.5374	17
Pif	Pif:32|PIF:3	interstitial fluid pressure:35:0.8681	0.8681	35
PIF	PIF:52	peak inspiratory flow:52:0.9099	0.9099	52
PIF	PIF:15	prolactin inhibiting factor:15:0.3429	0.3429	15
PIF	PIF:8	Pulmonary interstitial fibrosis:8:0.6411	0.6411	8
PIGF	PIGF:28	placenta growth factor:28:0.5729	0.5729	28
PIH	PIH:7	postinjection hours:7:0.1329	0.1329	7
PIH	PIH:7	postinoculation hour:7:0.1211	0.1211	7
PIH	PIH:363	pregnancy-induced hypertension:363:0.5434	0.5434	363
PIH	PIH:53	pyridoxal isonicotinoyl hydrazone:53:0.8842	0.8842	53
PIIA	PIIA:7	inspiratory activity:7:0.3524	0.3524	7
PIIINP	PIIINP:35	amino-terminal propeptide of type III procollagen:35:0.1561	0.1561	35
PIIINP	PIIINP:7|P-III-NP:1	aminoterminal propeptide:8:0.0825	0.0825	8
PIIINP	PIIINP:4|PII-INP:1	procollagen III peptide:5:0.1464	0.1464	5
PIIINP	PIIINP:8	procollagen type III aminoterminal peptide:8:0.6411	0.6411	8
PIIINP	PIIINP:9|P-III-NP:2	propeptide of procollagen type III:11:0.4232	0.4232	11
PIIINP	PIIINP:12	propeptide of type III collagen:12:0.6460	0.6460	12
PIIIP	PIIIP:20|P-III-P:10|PIIIp:1	procollagen III peptide:19:0.5113|procollagen-III-peptide:12:0.0655	0.5113	31
PIIIP	PIIIP:10|P-III-P:2	procollagen type III:12:0.4557	0.4557	12
PIIIP	PIIIP:19|P-III-P:13	Type III procollagen:32:0.9072	0.9072	32
PIIIP	PIIIP:11|P-III-P:9	type III procollagen peptide:20:0.8525	0.8525	20
pIII	pIII:4|PIII:3	Protein III:7:0.1211	0.1211	7
PII	PII:32|P-II:3	Photofrin II:35:0.3787	0.3787	35
PII	PII:25	Plaque index:25:0.3557	0.3557	25
PII	PII:7	plasma inorganic iodine:7:0.4438	0.4438	7
PILBD	PILBD:9	paucity of interlobular bile ducts:9:0.7103	0.7103	9
PIL	PIL:10	Patient Information Leaflet:10:0.7103	0.7103	10
PIL	PIL:7	Purpose in Life Test:7:0.5926	0.5926	7
PIMRA	PIMRA:12	psychopathology instrument for mentally retarded adults:12:0.7357	0.7357	12
PIMT	PIMT:14|Pimt:1	protein L-isoaspartyl methyltransferase:15:0.8045	0.8045	15
PIMs	PIMs:10	Phosphatidylinositol mannosides:10:0.4363	0.4363	10
PIMS	PIMS:6	programmable implantable medication system:6:0.2818	0.2818	6
PIMs	PIMs:51|PIMS:2	pulmonary intravascular macrophages:53:0.9427	0.9427	53
PINI	PINI:16	prognostic inflammatory and nutritional index:16:0.6748	0.6748	16
PINP	PINP:14	Procollagen type I N-terminal propeptide:14:0.7909	0.7909	14
PINP	PINP:11	propeptide of type I collagen:11:0.5355	0.5355	11
PINP	PINP:29	propeptide of type I procollagen:29:0.7237	0.7237	29
PINP	PINP:5	type I procollagen aminoterminal propeptide:5:0.4422	0.4422	5
PINV	PINV:33	negative variation:33:0.9100	0.9100	33
Pin	Pin:8|PIN:3	pinacidil:11:0.0161	0.0161	11
PIN	PIN:23	posterior interosseous nerve:23:0.8715	0.8715	23
PIN	PIN:9	posterior intralaminar nucleus:9:0.6794	0.6794	9
PIN	PIN:375	prostatic intraepithelial neoplasia:375:0.8784	0.8784	375
PIO2	PIO2:11|PiO2:1	inspired PO2:12:0.3058	0.3058	12
PIOC	PIOC:13	primary intraosseous carcinoma:13:0.7753	0.7753	13
PIOL	PIOL:12	phakic intraocular lens:12:0.7571	0.7571	12
PIOL	PIOL:15	Primary intraocular lymphoma:15:0.8045	0.8045	15
PION	PION:12	posterior ischemic optic neuropathy:12:0.7571	0.7571	12
PIOPED	PIOPED:51|PIO-PED:1	Prospective Investigation of Pulmonary Embolism Diagnosis:52:0.9099	0.9099	52
PIP(2)	PIP(2):97	phosphatidylinositol 4,5-bisphosphate:82:0.8495|phosphatidylinositol-4,5-bisphosphate:15:0.1029	0.8495	97
PIP(3)	PIP(3):14	phosphatidylinositol 3,4,5-trisphosphate:14:0.6911	0.6911	14
PIP2	PIP2:19	phosphatidylinositol 4,5-biphosphate:19:0.6903	0.6903	19
PIP2	PIP2:447|PI-P2:11	phosphatidylinositol 4,5-bisphosphate:450:0.8890|phosphatidylinositol 4,5 bisphosphate:8:0.4363	0.8890	458
PIP2	PIP2:59|PI-P2:1	phosphatidylinositol bisphosphate:60:0.5215	0.5215	60
PIP3	PIP3:29	phosphatidylinositol 3,4,5-trisphosphate:29:0.8422	0.8422	29
PIP3	PIP3:6	phosphatidylinositol trisphosphate:6:0.2243	0.2243	6
PIPAAm	PIPAAm:30|PI-PAAm:1|PIPAAM:1	poly(N-isopropylacrylamide):32:0.8857	0.8857	32
PIPC	PIPC:118	piperacillin:118:0.8797	0.8797	118
PIPJ	PIPJ:11	proximal interphalangeal joint:11:0.7357	0.7357	11
PI-PLC	PI-PLC:283|PIPLC:73|PiPLC:1|piPLC:1	Phosphatidylinositol-specific phospholipase C:358:0.5935	0.5935	358
PI-PLC	PI-PLC:4|PIPLC:1	phosphatidylinositol-specific PLC:5:0.0902	0.0902	5
PIPP	PIPP:19	Premature Infant Pain Profile:19:0.7044	0.7044	19
PIP	PIP:5	carboxy-terminal propeptide of procollagen type I:5:0.2818	0.2818	5
PIP	PIP:10	peak inflation pressures:10:0.7103	0.7103	10
PIP	PIP:161|pip:1	peak inspiratory pressure:143:0.8947|peak inspiratory pressures:19:0.8449	0.8947	162
PIP	PIP:10|PI-P:1	phosphatidylinositol monophosphate:11:0.3495	0.3495	11
PIP	PIP:28|PI-P:2	phosphatidylinositol phosphate:30:0.5838	0.5838	30
PIP	PIP:25|Pip:1|pip:1	Piperacillin:27:0.0233	0.0233	27
PIP	PIP:7	prevention of immune precipitation:7:0.4438	0.4438	7
PIP	PIP:14	prolactin-inducible protein:14:0.2758	0.2758	14
PIP	PIP:9	prostatic inhibin peptide:9:0.3945	0.3945	9
PIP	PIP:197	proximal interphalangeal:197:0.9602	0.9602	197
PIP	PIP:20	proximal interphalangeal joint:20:0.7766	0.7766	20
PIR	PIR:10|Pir:1	piracetam:11:0.0510	0.0510	11
PIR	PIR:7|Pir:3|pir:1	pirenzepine:11:0.0510	0.0510	11
Pir	Pir:6|PIR:4	piriform cortex:10:0.5856	0.5856	10
PIR	PIR:5|Pir:4	piroxicam:9:0.0408	0.0408	9
PIR	PIR:15	postinhibitory rebound:15:0.6386	0.6386	15
PIR	PIR:16	Protein Information Resource:16:0.8165	0.8165	16
PISA	PISA:48	proximal isovelocity surface area:48:0.9379	0.9379	48
PISF	PISF:7	peri-implant sulcular fluid:7:0.5926	0.5926	7
PISF	PISF:6	peri-implant sulcus fluid:6:0.3728	0.3728	6
PITC	PITC:14	phenyl isothiocyanate:14:0.6911	0.6911	14
PITC	PITC:37	Phenylisothiocyanate:37:0.6102	0.6102	37
PITPs	PITPs:15|PI-TPs:4	Phosphatidylinositol transfer proteins:19:0.6537	0.6537	19
PITP	PITP:31|PI-TP:18	phosphatidylinositol transfer protein:49:0.8254	0.8254	49
PIT	PIT:15	Pancreatic islet transplantation:15:0.8045	0.8045	15
PIT	PIT:20|pit:7	pituitary:27:0.1262	0.1262	27
PIT	PIT:12	Plasma Iron Turnover:12:0.7571	0.7571	12
PIT	PIT:9	tosylate:9:0.0388	0.0388	9
PIV3	PIV3:8|PIV-3:4	parainfluenza type 3 virus:12:0.7571	0.7571	12
PIV3	PIV3:46|PIV-3:26	parainfluenza virus type 3:72:0.9579	0.9579	72
PIVC	PIVC:8	parieto-insular vestibular cortex:8:0.5006	0.5006	8
PIVH	PIVH:10	haemorrhage:10:0.1915	0.1915	10
PIVH	PIVH:30	hemorrhage:30:0.6170	0.6170	30
PIV	PIV:43|PiV:1	parainfluenza virus:35:0.8681|parainfluenza viruses:9:0.6794	0.8681	44
PIV	PIV:47	Particle image velocimetry:47:0.9366	0.9366	47
PIV	PIV:13	pulsatility index for veins:13:0.7753	0.7753	13
PIXE	PIXE:141	x-ray emission:141:0.9661	0.9661	141
PIXE	PIXE:10	X-ray emission analysis:10:0.7103	0.7103	10
PImax	PImax:8|Pimax:2	Inspiratory muscle strength:10:0.7103	0.7103	10
PImax	PImax:12|Pimax:1|PIMAX:1	maximal inspiratory:14:0.2524	0.2524	14
PImax	PImax:34|Pimax:8|PIMax:1	maximal inspiratory pressure:43:0.5375	0.5375	43
PJRT	PJRT:9	permanent form of junctional reciprocating tachycardia:9:0.5470	0.5470	9
PJS	PJS:138|P-JS:2|PJs:1	Peutz-Jeghers syndrome:141:0.8773	0.8773	141
PK/PD	PK/PD:19	Pharmacokinetics and pharmacodynamics:10:0.7103|pharmacokinetic and pharmacodynamic:9:0.5856	0.7103	19
PK/PD	PK/PD:149|pk/pd:2	pharmacokinetic/pharmacodynamic:113:0.6286|pharmacokinetic-pharmacodynamic:28:0.1543|pharmacokinetics/pharmacodynamics:10:0.0514	0.6286	151
PK-15	PK-15:5|PK15:4	porcine kidney:9:0.1690	0.1690	9
PKAI	PKAI:7	protein kinase A type I:7:0.6460	0.6460	7
PKAc	PKAc:7|PKA-C:3|PKAC:3|Pka-C:1|PKA-c:1	catalytic subunit:15:0.8045	0.8045	15
PKAc	PKA-C:1|PKAc:1	catalytic subunit of a cAMP-dependent protein kinase:2:0.6411	0.6411	2
PKAc	PKAc:9|PKA-C:3|PKA-c:1	catalytic subunit of PKA:13:0.7753	0.7753	13
PKB/Akt	PKB/Akt:16|PKB/akt:2|Pkb/Akt:1	protein kinase B/Akt:19:0.8449	0.8449	19
Pkc1	Pkc1:5|PKC1:3|PK-C1:1|pkc1:1	protein kinase C:10:0.7103	0.7103	10
PKCs	PKCs:19	protein kinases C:19:0.8449	0.8449	19
PKCs	PKCs:25	protein kinase Cs:25:0.8186	0.8186	25
PKC	PKC:34	paroxysmal kinesigenic choreoathetosis:34:0.8644	0.8644	34
PKC	PKC:126|PKc:4|PK-C:4|Pk-C:1	protein kinase:135:0.8292	0.8292	135
PKC	PKC:12938|PK-C:193|pkC:16|PKc:11|pKC:9|PkC:6|Pk-C:3|pkc:1	protein kinase C:13056:0.9920|protein kinase-C:121:0.9355	0.9920	13177
PKD1	PKD1:12	autosomal dominant polycystic kidney disease:12:0.7571	0.7571	12
PKD1	PKD1:40|PKD-1:1|Pkd1:1	polycystic kidney disease 1:42:0.9291	0.9291	42
PKD1	PKD1:7	polycystic kidney disease 1 gene:7:0.5926	0.5926	7
PKD1	PKD1:6|Pkd1:1	polycystic kidney disease gene:7:0.5926	0.5926	7
PKD2	PKD2:8	polycystic kidney disease 2:8:0.6411	0.6411	8
PKDL	PKDL:71	Post-Kala-azar Dermal Leishmaniasis:40:0.3853|post kala-azar dermal leishmaniasis:31:0.8978	0.8978	71
PKD	PKD:21	paroxysmal kinesigenic dyskinesia:21:0.8594	0.8594	21
PKD	PKD:251	polycystic kidney disease:251:0.8559	0.8559	251
PKD	PKD:76	Protein kinase D:76:0.9602	0.9602	76
PKG	PKG:215|PK-G:2	cGMP-dependent protein kinase:209:0.6934|cGMP-dependent protein kinases:8:0.6411	0.6934	217
PKG	PKG:124|PK-G:1	protein kinase G:125:0.8879	0.8879	125
PKI	PKI:2	inhibitor of the cAMP-dependent protein kinase:2:0.5470	0.5470	2
PKI	PKI:62	protein kinase inhibitor:62:0.9316	0.9316	62
PKI	PKI:9	Public Key Infrastructure:9:0.6794	0.6794	9
PKK	PKK:22	prekallikrein:22:0.7241	0.7241	22
PKLR	PKLR:10|pklr:1|PK-LR:1|Pklr:1	pyruvate kinase:13:0.7753	0.7753	13
PKM2	PKM2:6|PK-M2:1	pyruvate kinase M2:7:0.5926	0.5926	7
PKM	PKM:8|PK-M:1	protein kinase M:9:0.4587	0.4587	9
PK-PD	PK-PD:78|PKPD:3|pk-pd:1	pharmacokinetic-pharmacodynamic:82:0.8265	0.8265	82
PKP	PKP:152|pKP:1|pKp:1	penetrating keratoplasty:154:0.9011	0.9011	154
PKR	PKR:48	double-stranded RNA-activated protein kinase:48:0.6918	0.6918	48
PKR	PKR:53|pkr:1	double-stranded RNA-dependent protein kinase:54:0.3905	0.3905	54
PKR	PKR:51	protein kinase R:51:0.9416	0.9416	51
PKSs	PKSs:103	polyketide synthases:103:0.9389	0.9389	103
PKT	PKT:12	combined pancreas-kidney transplantation:12:0.5664	0.5664	12
PKU	PKU:876	phenylketonuria:876:0.9347	0.9347	876
PKU	PKU:35	phenylketonuric:35:0.0364	0.0364	35
PKS	PKS:13	Pallister-Killian syndrome:13:0.5934	0.5934	13
PKS	PKS:205|pks:3|Pks:1|PKs:1	polyketide synthase:179:0.9644|polyketide synthases:31:0.9043	0.9644	210
PKs	PKs:26|PKS:1	protein kinases:27:0.7834	0.7834	27
PK	PK:11	K+ permeability:11:0.1760	0.1760	11
PK	PK:15	kidney:15:0.0066	0.0066	15
PK	PK:165	penetrating keratoplasty:165:0.9288	0.9288	165
PK	PK:9	Perilla ketone:9:0.6794	0.6794	9
PK	PK:617|Pk:5|pK:2|P-K:1|pk:1	pharmacokinetic:366:0.1715|pharmacokinetics:260:0.1214	0.1715	626
PK	PK:18	plasma kallikrein:18:0.8365	0.8365	18
PK	PK:6	plasma potassium:6:0.1010	0.1010	6
PK	PK:6	plasma potassium concentration:6:0.5290	0.5290	6
PK	PK:21	plasma prekallikrein:21:0.1511	0.1511	21
PK	PK:9	potassium permeability:9:0.1150	0.1150	9
P-K	P-K:15|PK:10	Prausnitz-Kustner:25:0.0112	0.0112	25
Pk	Pk:7|PK:6	prediction probability:13:0.6701	0.6701	13
pk	pk:8|Pk:5	prickle:13:0.0056	0.0056	13
PK	PK:263|Pk:1|pk:1	protein kinase:245:0.2832|protein kinases:20:0.6259	0.6259	265
PK	PK:38	proteinase K:38:0.6322	0.6322	38
PK	PK:507	pyruvate kinase:507:0.6170	0.6170	507
PK	PK:7	Serum pyruvate-kinase:7:0.0692	0.0692	7
PL-Ca-PK	PL-Ca-PK:9	Phospholipid-sensitive Ca2+-dependent protein kinase:9:0.5470	0.5470	9
PLA(2)s	PLA(2)s:11	phospholipases A(2):11:0.7357	0.7357	11
PLA(2)	PLA(2):306|PL-A(2):1	phospholipase A(2):307:0.9225	0.9225	307
PLA2-II	PLA2-II:19	group II phospholipase A2:19:0.6259	0.6259	19
PLA2-I	PLA2-I:15	group I phospholipase A2:15:0.8045	0.8045	15
PLA2s	PLA2s:40|PLA2S:4|PL-A2S:1	phospholipases A2:45:0.7664	0.7664	45
PLA2s	PLA2s:11	phospholipase A2s:11:0.7357	0.7357	11
PLA2	PLA2:9	phospholipase:9:0.0038	0.0038	9
PLA2	PLA2:12	phospholipase A(2):12:0.7571	0.7571	12
PLA2	PLA2:1931|PL-A2:13|PLA-2:4|pla2:2|PlA2:1	phospholipase A2:1933:0.9422|phospholipase-A2:18:0.0080	0.9422	1951
PLAP	PLAP:16	phospholipase A2-activating protein:9:0.6794|phospholipase A2 activating protein:7:0.5926	0.6794	16
PLAP	PLAP:250|PlAP:4|plap:2|PL-AP:1	placental alkaline phosphatase:257:0.8119	0.8119	257
P-LAP	P-LAP:49	placental leucine aminopeptidase:49:0.8728	0.8728	49
PLB	PLB:9	breathing:9:0.0233	0.0233	9
PLB	PLB:6	percutaneous liver biopsy:6:0.5290	0.5290	6
PLB	PLB:223|Plb:2	Phospholamban:225:0.6531	0.6531	225
PLB	PLB:19	phospholipase B:19:0.4405	0.4405	19
PLB	PLB:20	Primary lymphoma of bone:20:0.6040	0.6040	20
PLCC	PLCC:7	Postoperative long-term cancer chemotherapy:7:0.5926	0.5926	7
PLCs	PLCs:9	phospholipases C:9:0.6794	0.6794	9
PLC	PLC:5	lung centroid pressure:5:0.4422	0.4422	5
PLC	PLC:7	pathological laughing and crying:7:0.3524	0.3524	7
PLC	PLC:6	peripheral lymphocyte count:6:0.5290	0.5290	6
PLC	PLC:11	phospholipase:11:0.0040	0.0040	11
PLC	PLC:1801|PL-C:35|plc:3	phospholipase C:1811:0.9478|phospholipase-C:28:0.0107	0.9478	1839
PLC	PLC:9	Pigmented Lesion Clinic:9:0.6794	0.6794	9
PLC	PLC:11	pityriasis lichenoides chronica:11:0.7357	0.7357	11
PLC	PLC:5	prelysosomal compartment:5:0.1132	0.1132	5
PLC	PLC:162	primary liver cancer:162:0.9703	0.9703	162
PLC	PLC:24	primary liver carcinoma:24:0.8768	0.8768	24
PLC	PLC:39	propionyl-L-carnitine:39:0.0151	0.0151	39
PLD1	PLD1:44	phospholipase D1:44:0.9323	0.9323	44
PLD2	PLD2:14	phospholipase D2:14:0.7909	0.7909	14
PLDD	PLDD:34	percutaneous laser disc decompression:34:0.9072	0.9072	34
pLDH	pLDH:29|PLDH:1	lactate dehydrogenase:30:0.8472	0.8472	30
PLDR	PLDR:18	potentially lethal damage:18:0.7539	0.7539	18
PLDR	PLDR:9	potentially lethal damage recovery:9:0.6794	0.6794	9
PLDR	PLDR:39	potentially lethal damage repair:39:0.8811	0.8811	39
PLD	PLD:9	Partial lipodystrophy:9:0.6794	0.6794	9
PLD	PLD:30	Pegylated liposomal doxorubicin:30:0.9100	0.9100	30
PLD	PLD:1180|PL-D:3|Pld:1	phospholipase D:1184:0.9635	0.9635	1184
PLD	PLD:12	Polycystic liver disease:12:0.4153	0.4153	12
PLD	PLD:15	posterior:15:0.0088	0.0088	15
PLD	PLD:134	potentially lethal damage:134:0.9777	0.9777	134
PLD	PLD:9	pulsed laser deposition:9:0.6794	0.6794	9
PLEDs	PLEDs:71|PLEDS:5	periodic lateralized epileptiform discharges:76:0.8961	0.8961	76
PLEVA	PLEVA:25	pityriasis lichenoides et varioliformis acuta:25:0.8816	0.8816	25
PLE	PLE:13	liver esterase:13:0.7753	0.7753	13
PLE	PLE:14	paraneoplastic limbic encephalitis:14:0.7909	0.7909	14
PLE	PLE:42	Polymorphic light eruption:42:0.3951	0.3951	42
PLE	PLE:39	polymorphous light eruption:39:0.3582	0.3582	39
PLE	PLE:16	Pressurised liquid extraction:16:0.1526	0.1526	16
PLE	PLE:40	pressurized liquid extraction:40:0.5663	0.5663	40
PLE	PLE:38	protein-losing enteropathy:38:0.6874	0.6874	38
PLFAs	PLFAs:12	phospholipid fatty acids:12:0.6460	0.6460	12
PLFA	PLFA:61|PL-FA:2	phospholipid fatty acid:47:0.7749|phospholipid fatty acids:16:0.7261	0.7749	63
PLF	PLF:31	perilymphatic fistula:31:0.5933	0.5933	31
PLF	PLF:10	periodontal ligament fibroblasts:10:0.7103	0.7103	10
PLF	PLF:13	peritoneal lavage fluid:13:0.6701	0.6701	13
P-LF	P-LF:6|PLF:4	phagosome-lysosome fusion:10:0.1385	0.1385	10
PLF	PLF:20	Placental isoferritin:20:0.7173	0.7173	20
PLF	PLF:11	posterolateral fusion:11:0.1683	0.1683	11
PLF	PLF:19	Proliferin:19:0.0861	0.0861	19
PLGA	PLGA:66	poly(d,l-lactide-co-glycolide):66:0.0796	0.0796	66
PLGA	PLGA:34	poly(dl-lactide-co-glycolide):34:0.0404	0.0404	34
PLGA	PLGA:12	poly(L-lactide-co-glycolide):12:0.0135	0.0135	12
PLGA	PLGA:122	poly(lactide-co-glycolide):119:0.1444|poly lactide-co-glycolide:3:0.2619	0.2619	122
PLGA	PLGA:11	polylactide-co-glycolide:11:0.0135	0.0135	11
PLGA	PLGA:30	polymorphous low-grade adenocarcinoma:30:0.9043	0.9043	30
PLG	PLG:1	co-glycolide:1:0.0194	0.0194	1
PLG	PLG:24	L-prolyl-L-leucyl-glycinamide:24:0.0497	0.0497	24
PLG	PLG:100|Plg:74|plg:13|PLg:3	plasminogen:190:0.4082	0.4082	190
PLG	PLG:19	poly(D,L-lactide-co-glycolide):19:0.0389	0.0389	19
PLG	PLG:13	poly(DL-lactide-co-glycolide):13:0.0259	0.0259	13
PLG	PLG:43	poly(lactide-co-glycolide):43:0.0907	0.0907	43
PLG	PLG:11	Pro-Leu-Gly-NH2:11:0.0216	0.0216	11
PLG	PLG:24	prolyl-leucyl-glycinamide:24:0.0497	0.0497	24
PLIC	PLIC:12	posterior limb of the internal capsule:12:0.7571	0.7571	12
PLIF	PLIF:81	Posterior lumbar interbody fusion:81:0.9631	0.9631	81
PL-II	PL-II:10	placental lactogen-II:10:0.7103	0.7103	10
PLI	PLI:5	pancreastatin-like immunoreactivity:5:0.0517	0.0517	5
PL-I	PL-I:12	placental lactogen-I:12:0.7571	0.7571	12
PlI	PlI:57|PLI:29|Pl-I:2	plaque index:88:0.6590	0.6590	88
Plks	Plks:19|PLKs:5	Polo-like kinases:24:0.7593	0.7593	24
PLLA	PLLA:65	poly-L-lactic acid:65:0.2760	0.2760	65
PLLA	PLLA:97|P-L-LA:2	poly(L-lactide):64:0.2006|poly-l-lactide:32:0.0987|Poly L-lactide:3:0.7357	0.7357	99
PLL	PLL:170|pLL:7	poly-L-lysine:125:0.2854|poly(L-lysine):52:0.1183	0.2854	177
PLL	PLL:9	polylysine:9:0.0186	0.0186	9
PLL	PLL:31	posterior longitudinal ligament:31:0.8519	0.8519	31
PLL	PLL:26	prolymphocytic leukaemia:26:0.7340	0.7340	26
PLL	PLL:77	prolymphocytic leukemia:77:0.8146	0.8146	77
PLMD	PLMD:42	periodic limb movement disorder:42:0.9274	0.9274	42
PLMs	PLMs:12|PLMS:4	periodic leg movements:16:0.8165	0.8165	16
PLMS	PLMS:21	periodic leg movements in sleep:21:0.9308	0.9308	21
PLMs	PLMs:10|PLMS:2	periodic limb movements:12:0.7571	0.7571	12
PLMS	PLMS:33	Periodic limb movements in sleep:33:0.9416	0.9416	33
PLMVd	PLMVd:18	Peach latent mosaic viroid:18:0.8365	0.8365	18
PLM	PLM:9	percent labeled mitoses:9:0.5470	0.5470	9
PLM	PLM:5	percentage labelled mitoses:5:0.4363	0.4363	5
PLM	PLM:43	periodic leg movements:31:0.9011|periodic leg movement:12:0.7571	0.9011	43
PLM	PLM:26	periodic limb movements:17:0.8270|periodic limb movement:9:0.6794	0.8270	26
PLM	PLM:28|Plm:1	Phospholemman:29:0.0976	0.0976	29
PLM	PLM:11	phospholipomannan:11:0.0348	0.0348	11
PLM	PLM:21	polarized light microscopy:21:0.5435	0.5435	21
PLNA	PLNA:34	popliteal lymph node assay:34:0.9126	0.9126	34
PLND	PLND:22	pelvic lymph node dissection:22:0.7400	0.7400	22
PLN	PLN:77|pLN:2|pln:1|P-LN:1	lymph nodes:81:0.9631	0.9631	81
PLN	PLN:58	phospholamban:58:0.1652	0.1652	58
PLN	PLN:10|Pln:2	plantaris:12:0.0319	0.0319	12
PLN	PLN:94|P-LN:1	popliteal lymph node:95:0.5734	0.5734	95
PLP-AMP	PLP-AMP:10	5'-diphospho-5'-adenosine:10:0.7500	0.7500	10
PLP-A	PLP-A:8	PRL-like protein-A:8:0.4102	0.4102	8
PLP	PLP:10	myelin proteolipid:10:0.2154	0.2154	10
PLP	PLP:150|Plp:4	myelin proteolipid protein:154:0.2046	0.2046	154
PLP	PLP:10	Parathyroid hormone-like peptide:10:0.7103	0.7103	10
PLP	PLP:36	periodate-lysine-paraformaldehyde:36:0.0203	0.0203	36
PLP	PLP:21	phantom limb pain:21:0.8594	0.8594	21
PLP	PLP:22	Plasma pyridoxal-5'-phosphate:22:0.1020	0.1020	22
PLP	PLP:16	proteolipid apoprotein:16:0.7261	0.7261	16
PLP	PLP:24|Plp:1	proteolipid protein gene:25:0.8816	0.8816	25
PLP	PLP:378	Pyridoxal 5'-phosphate:331:0.9855|pyridoxal 5-phosphate:24:0.8768|Pyridoxal-5-phosphate:23:0.0131	0.9855	378
PLP	PLP:157|Plp:1	pyridoxal phosphate:158:0.8901	0.8901	158
PLRP1	PLRP1:6	pancreatic lipase-related protein 1:6:0.5290	0.5290	6
PLRV	PLRV:17	potato leafroll luteovirus:17:0.8270	0.8270	17
PLRV	PLRV:53	potato leafroll virus:53:0.9438	0.9438	53
PLR	PLR:5	positive likelihood ratio:5:0.4422	0.4422	5
PLR	PLR:16	pupillary light reflex:16:0.4536	0.4536	16
PLS-1	PLS-1:7|PLS1:2	partial least squares:9:0.5470	0.5470	9
PLSCR1	PLSCR1:13	Phospholipid scramblase 1:13:0.7753	0.7753	13
PLS-DA	PLS-DA:7|PLSDA:1	Partial least squares discriminant analysis:8:0.6411	0.6411	8
PLSR	PLSR:36	partial least squares regression:19:0.8449|partial least-squares regression:17:0.8270	0.8449	36
PLSVC	PLSVC:41	persistent left superior vena cava:41:0.8525	0.8525	41
PLS	PLS:59|PLs:1	Papillon-Lefevre Syndrome:60:0.5627	0.5627	60
PLS	PLS:400|pls:1	partial least squares:275:0.9825|partial least-squares:100:0.9525|partial least square:26:0.8251	0.9825	401
PLS	PLS:32	partial least squares regression:19:0.8449|partial least-squares regression:13:0.7753	0.8449	32
PLS	PLS:11	perpendicular light scatter:11:0.7357	0.7357	11
PLs	PLs:93	phospholipids:93:0.0969	0.0969	93
PLs	PLs:11	placental lactogens:11:0.7357	0.7357	11
PLS	PLS:46	Primary lateral sclerosis:46:0.8986	0.8986	46
PLS	PLS:15	projections to latent structures:15:0.1992	0.1992	15
PLS	PLS:14	prostaglandin-like substances:14:0.5111	0.5111	14
PLTP	PLTP:195|Pltp:1	phospholipid transfer protein:196:0.9668	0.9668	196
PLT	PLT:10	liver transplantation:10:0.5856	0.5856	10
PLT	PLT:10	Pancreolauryl Test:10:0.0682	0.0682	10
PLT	PLT:6|Plt:4	plantaris:10:0.0161	0.0161	10
PLT	PLT:126|Plt:14|plt:6	platelet:146:0.2594	0.2594	146
PLT	PLT:56|Plt:10	platelet count:56:0.9162|platelet counts:10:0.7103	0.9162	66
PLT	PLT:10	posterolateral thoracotomy:10:0.7103	0.7103	10
PLT	PLT:32	primed lymphocyte test:32:0.9072	0.9072	32
PLT	PLT:9	primed lymphocyte testing:9:0.6794	0.6794	9
PLT	PLT:62	primed lymphocyte typing:62:0.8971	0.8971	62
PLV	PLV:8|Plv:1	left ventricular pressure:9:0.5470	0.5470	9
PLV	PLV:5|Plv:1	LV pressure:6:0.1025	0.1025	6
PLV	PLV:60	Partial left ventriculectomy:60:0.9503	0.9503	60
PLV	PLV:156	partial liquid ventilation:156:0.9694	0.9694	156
PLWHA	PLWHA:22	people living with HIV/AIDS:22:0.6531	0.6531	22
PLWS	PLWS:11	Prader-Labhart-Willi syndrome:11:0.5355	0.5355	11
PLZ	PLZ:15	Phenelzine:15:0.7368	0.7368	15
PLZF	PLZF:23	Promyelocytic leukemia zinc finger:23:0.7500	0.7500	23
PLZF	PLZF:7	promyelocytic leukemia zinc finger protein:7:0.5926	0.5926	7
PLase	PLase:19|Plase:1	phospholipase:20:0.7917	0.7917	20
PLY	PLY:14|Ply:10|ply:5	Pneumolysin:29:0.5091	0.5091	29
pl	pl:36	isoelectric point:36:0.8336	0.8336	36
PL	PL:7|Pl:1	lateral pulvinar:8:0.5006	0.5006	8
PL	PL:6|pl:4|pL:2	leftward promoter:12:0.3058	0.3058	12
PL	PL:17|P-L:2	length:19:0.0056	0.0056	19
PL	PL:11	lymphocytes:11:0.0031	0.0031	11
PL	PL:22	Pancreatic lipase:22:0.7400	0.7400	22
PL	PL:8	pars lateralis:8:0.2619	0.2619	8
PL	PL:26	pectate lyase:26:0.5616	0.5616	26
PL	PL:21	perilymph:21:0.0062	0.0062	21
PL	PL:24	periodontal ligament:24:0.7151	0.7151	24
PL	PL:10	perivitelline layer:10:0.3470	0.3470	10
PL	PL:26	peroneus longus:26:0.5616	0.5616	26
PL	PL:41	persistent lymphocytosis:41:0.9274	0.9274	41
P-L	P-L:18|PL:2	phagosome-lysosome:20:0.0059	0.0059	20
Pl	Pl:7|pl:2|PL:1	phosphatidylinositol:10:0.0028	0.0028	10
PL	PL:68	phospholipase:68:0.0209	0.0209	68
PL	PL:1017|Pl:1	phospholipid:521:0.1621|phospholipids:497:0.1547	0.1621	1018
PL	PL:66	Photoluminescence:66:0.0203	0.0203	66
PL	PL:194|pl:43|Pl:4	placebo:241:0.0755	0.0755	241
PL	PL:97	placental lactogen:97:0.8956	0.8956	97
PL	PL:18|pl:11	plasma:29:0.0087	0.0087	29
PL	PL:17|pl:1	plasmin:18:0.0053	0.0053	18
PL	PL:29|pl:1	Poly-l-lysine:30:0.0090	0.0090	30
PL	PL:17	polylysine:17:0.0050	0.0050	17
PL	PL:21|pl:3|P-L:1	posterolateral:25:0.0075	0.0075	25
PL	PL:10	poultry litter:10:0.7103	0.7103	10
PL	PL:39	preferential looking:39:0.9237	0.9237	39
PL	PL:18|pl:2	prelimbic:20:0.0059	0.0059	20
PL	PL:18|Pl:1	prolactin:19:0.0056	0.0056	19
PL	PL:34	propranolol:34:0.0103	0.0103	34
PL	PL:34|Pl:2	transpulmonary pressure:29:0.4299|transpulmonary pressures:7:0.2902	0.4299	36
PM&R	PM&R:45	physical medicine and rehabilitation:45:0.9338	0.9338	45
PM(10)	PM(10):7	10 microm in aerodynamic diameter:7:0.2902	0.2902	7
PM(10)	PM(10):11	particulate matter:11:0.7357	0.7357	11
PM(2.5)	PM(2.5):7	aerodynamic diameter:7:0.2113	0.2113	7
PM(2.5)	PM(2.5):7	fine particles:7:0.2452	0.2452	7
PM(2.5)	PM(2.5):12	fine particulate matter:12:0.5664	0.5664	12
PM/DM	PM/DM:64	polymyositis/dermatomyositis:64:0.6531	0.6531	64
PM/DM	PM/DM:6	polymyositis or dermatomyositis:6:0.7151	0.7151	6
PM10	PM10:11	inhalable particles:11:0.1486	0.1486	11
PM10	PM10:12	particles with a 50% cut-off aerodynamic diameter of 10 microm:12:0.6460	0.6460	12
PM10	PM10:8	particulate air pollution:8:0.5006	0.5006	8
PM10	PM10:52	particulate matter:52:0.8572	0.8572	52
PM10	PM10:5	particulate matter less than 10 microm in aerodynamic diameter:5:0.6411	0.6411	5
PM10	PM10:1	particulate matter of less than 10 microm in diameter:1:0.5290	0.5290	1
PM10	PM10:9	particulate pollution:9:0.2102	0.2102	9
PM2.5	PM2.5:1	2.5 microm aerodynamic diameter:1:0.1973	0.1973	1
PM2.5	PM2.5:7	aerodynamic diameter less than 2.5 microm:7:0.2902	0.2902	7
PM2.5	PM2.5:7|PM-2.5:1	aerodynamic diameter less than or equal to 2.5 microm:8:0.6794	0.6794	8
PM2.5	PM2.5:20	fine particles:20:0.6680	0.6680	20
PM2.5	PM2.5:32	fine particulate matter:32:0.6024	0.6024	32
PM2.5	PM2.5:5	less than 2.5 microns in aerodynamic diameter:5:0.4422	0.4422	5
PMA	PMA:61	4 beta-phorbol 12 beta-myristate 13 alpha-acetate:50:0.9427|4 beta-phorbol-12 beta-myristate-13 alpha-acetate:11:0.7357	0.9427	61
PMA	PMA:21	4 beta-phorbol-12-myristate-13-acetate:21:0.8594	0.8594	21
PMA	PMA:14	activity:14:0.0016	0.0016	14
PMA	PMA:29|pma:6	muscular atrophy:35:0.8644	0.8644	35
PMA	PMA:11|p-MA:1	p-methoxyamphetamine:12:0.0014	0.0014	12
PMA	PMA:14	para-methoxyamphetamine:14:0.0016	0.0016	14
PMA	PMA:15	paramethoxyamphetamine:15:0.0017	0.0017	15
PMA	PMA:5	phorbol 12-myristate 12-acetate:5:0.4422	0.4422	5
PMA	PMA:3404	phorbol 12-myristate 13-acetate:2837:0.9115|phorbol-12-myristate-13-acetate:473:0.0584|phorbol 12-myristate-13-acetate:94:0.8446	0.9115	3404
PMA	PMA:7	phorbol 13-myristate 12-acetate:7:0.5926	0.5926	7
PMA	PMA:311	phorbol ester:271:0.9250|phorbol esters:40:0.9256	0.9256	311
PMA	PMA:12	phorbol myristate:12:0.3524	0.3524	12
PMA	PMA:2735|pma:1	phorbol myristate acetate:2668:0.9823|Phorbol-myristate-acetate:68:0.0083	0.9823	2736
PMA	PMA:21	phorbol myristic acid:21:0.7865	0.7865	21
PMA	PMA:16	phorbolester:16:0.0019	0.0019	16
PMA	PMA:47	postmenstrual age:47:0.7552	0.7552	47
PMA	PMA:6	premenstrual asthma:6:0.2243	0.2243	6
PMA	PMA:15	premotor area:15:0.4312	0.4312	15
PMA	PMA:9	protein kinase C activator:9:0.6794	0.6794	9
PMBC	PMBC:10	peripheral mononuclear blood cells:10:0.7103	0.7103	10
PMBCs	PMBCs:9	peripheral blood mononuclear cells:9:0.6794	0.6794	9
PMBL	PMBL:9	Primary mediastinal B-cell lymphoma:9:0.6794	0.6794	9
PMBN	PMBN:25	polymyxin B nonapeptide:25:0.8186	0.8186	25
PMBSF	PMBSF:27	posteromedial barrel subfield:27:0.6745	0.6745	27
PMBV	PMBV:12	percutaneous mitral balloon valvuloplasty:12:0.7571	0.7571	12
PMB	PMB:8|p-MB:1	p-hydroxymercuribenzoate:9:0.0421	0.0421	9
PMB	PMB:61|PmB:12|PM-B:1|Pmb:1	polymyxin B:75:0.9169	0.9169	75
PMB	PMB:24	postmenopausal bleeding:24:0.6122	0.6122	24
pMCAO	pMCAO:19|PMCAO:7|pMCAo:2	Permanent Middle Cerebral Artery Occlusion:28:0.7905	0.7905	28
PMCA	PMCA:50	plasma membrane Ca(2+)-ATPase:50:0.9404	0.9404	50
PMCA	PMCA:14	plasma membrane Ca(2+) pump:14:0.7909	0.7909	14
PMCA	PMCA:29	plasma membrane Ca2+-ATPase:29:0.8978	0.8978	29
PMCA	PMCA:13	plasma membrane Ca2+ pump:13:0.7753	0.7753	13
PMCA	PMCA:16|Pmca:1	plasma membrane calcium ATPase:17:0.8270	0.8270	17
PMCA	PMCA:20	plasma membrane calcium pump:20:0.8525	0.8525	20
PMCA	PMCA:9	protein misfolding cyclic amplification:9:0.6794	0.6794	9
PMCD	PMCD:11	pellucid marginal corneal degeneration:11:0.7357	0.7357	11
Pmcf	Pmcf:13	Mean circulatory filling pressure:13:0.7753	0.7753	13
PMCT	PMCT:37	Percutaneous microwave coagulation therapy:37:0.9197	0.9197	37
PMCT	PMCT:10	postmortem computed tomography:10:0.5006	0.5006	10
PMC	PMC:10	papillary microcarcinoma:10:0.5000	0.5000	10
PMC	PMC:20	percutaneous mitral commissurotomy:20:0.7173	0.7173	20
PMC	PMC:25	Peripheral mononuclear cells:25:0.4751	0.4751	25
PMC	PMC:48	peritoneal mast cells:48:0.7595	0.7595	48
PMC	PMC:20	pharmacokinetic modulating chemotherapy:20:0.8525	0.8525	20
PMC	PMC:21	pontine micturition center:21:0.8594	0.8594	21
PMC	PMC:24	premotor cortex:24:0.6122	0.6122	24
PMC	PMC:9|pmc:1	primary mesenchyme cell:10:0.7103	0.7103	10
PMC	PMC:68	Pseudomembranous colitis:68:0.9087	0.9087	68
PMC	PMC:6	rat peritoneal MC:6:0.3728	0.3728	6
PMDD	PMDD:145	premenstrual dysphoric disorder:145:0.9563	0.9563	145
pMDI	pMDI:100|P-MDI:3	pressurized metered dose inhaler:48:0.5897|pressurized metered-dose inhaler:44:0.7413|pressurized metered dose inhalers:7:0.3524|pressurized metered-dose inhalers:4:0.0918	0.7413	103
PM-DM	PM-DM:14	Polymyositis-dermatomyositis:14:0.5652	0.5652	14
PMDS	PMDS:22	persistent Mullerian duct syndrome:22:0.8715	0.8715	22
PMd	PMd:10	dorsal premotor:10:0.7103	0.7103	10
PMd	PMd:7|PMD:2	dorsal premotor area:9:0.6794	0.6794	9
PMd	PMd:32|PMD:1	dorsal premotor cortex:33:0.7525	0.7525	33
PMD	PMD:91	Pelizaeus-Merzbacher disease:91:0.8291	0.8291	91
PMD	PMD:8	pellucid marginal degeneration:8:0.6411	0.6411	8
PMD	PMD:17	piecemeal degranulation:17:0.7407	0.7407	17
PMD	PMD:13	polarization mode dispersion:13:0.7753	0.7753	13
PMD	PMD:25	progressive muscular dystrophy:25:0.8816	0.8816	25
PMEA	PMEA:17	9-[2-(phosphonomethoxy)ethyl]adenine:17:0.0879	0.0879	17
PMEA	PMEA:6	9-(2-phosphonomethoxyethyl) adenine:6:0.0611	0.0611	6
PMEA	PMEA:104	9-(2-phosphonylmethoxyethyl)adenine:96:0.5220|9-(2-phosphonylmethoxyethyl) adenine:8:0.1471	0.5220	104
PMEDAP	PMEDAP:15	9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine:15:0.4333	0.4333	15
PMEs	PMEs:17	Phosphomonoesters:17:0.2963	0.2963	17
PMEs	PMEs:9	progressive myoclonus epilepsies:9:0.6794	0.6794	9
PME	PME:12	methyl ester:12:0.5355	0.5355	12
PME	PME:14	particle mesh ewald:14:0.7909	0.7909	14
PME	PME:12|pme:1	pectin methyl esterase:13:0.7753	0.7753	13
PME	PME:49|pme:1	pectin methylesterase:50:0.8492	0.8492	50
PME	PME:9	pectinmethylesterase:9:0.0162	0.0162	9
PME	PME:9	phosphatidylmonomethylethanolamine:9:0.0162	0.0162	9
PME	PME:171|Pme:1	phosphomonoester:90:0.1805|phosphomonoesters:82:0.1643	0.1805	172
PME	PME:17	progressive myoclonic epilepsy:17:0.8270	0.8270	17
PME	PME:38|pme:1	progressive myoclonus epilepsy:39:0.9237	0.9237	39
PMFV	PMFV:7	type D retrovirus:7:0.5926	0.5926	7
PMF	PMF:11|PM-F:1|Pmf:1	fraction:13:0.0314	0.0314	13
PMF	PMF:19	magnetic field:19:0.6537	0.6537	19
PMF	PMF:39	peptide mass fingerprinting:39:0.8811	0.8811	39
PMF	PMF:15	positive matrix factorization:15:0.8045	0.8045	15
PMF	PMF:18|pmf:2	potential of mean force:20:0.6040	0.6040	20
PMF	PMF:21	primary myelofibrosis:21:0.7291	0.7291	21
PMF	PMF:53	progressive massive fibrosis:53:0.8842	0.8842	53
PMF	PMF:24|pmf:18	proton motive force:42:0.9291	0.9291	42
PMF	PMF:13	pulsed magnetic fields:13:0.6701	0.6701	13
PMGH	PMGH:14	Port Moresby General Hospital:14:0.7909	0.7909	14
pMHC	pMHC:12|P-MHC:1|p-MHC:1	peptide-major histocompatibility complex:14:0.5111	0.5111	14
pMHC	pMHC:13	peptide-MHC:13:0.1818	0.1818	13
PMH	PMH:23	Princess Margaret Hospital:23:0.8715	0.8715	23
PMH	PMH:7	pure motor hemiparesis:7:0.5926	0.5926	7
PMI	PMI:12	Pain Management Index:12:0.7571	0.7571	12
PMI	PMI:55	perioperative myocardial infarction:55:0.5619	0.5619	55
PMI	PMI:39|pmi:2	phosphomannose isomerase:41:0.8525	0.8525	41
PMI	PMI:68|pmi:1	postmortem interval:69:0.7238	0.7238	69
PMLE	PMLE:10	polymorphic light eruption:10:0.1596	0.1596	10
PMLE	PMLE:15	polymorphous light eruption:15:0.3831	0.3831	15
PMLs	PMLs:9	polymorphonuclear leukocytes:9:0.4587	0.4587	9
PMLS	PMLS:21	posteromedial lateral suprasylvian:21:0.6400	0.6400	21
PMLS	PMLS:14	posteromedial lateral suprasylvian area:14:0.5111	0.5111	14
PML	PML:2	fasting and post-methionine load:2:0.0918	0.0918	2
PML	PML:26	paramedian lobule:26:0.8861	0.8861	26
PML	PML:8|pml:1	polymorphonuclear leucocytes:9:0.4587	0.4587	9
PML	PML:26	polymorphonuclear leukocytes:26:0.7340	0.7340	26
PML	PML:13	posterior mitral leaflet:13:0.7753	0.7753	13
PML	PML:35	progressive multifocal leucoencephalopathy:35:0.9151	0.9151	35
PML	PML:525	progressive multifocal leukoencephalopathy:525:0.9908	0.9908	525
PML	PML:33	promyelocytic leukaemia:33:0.8605	0.8605	33
PML	PML:135	promyelocytic leukemia:135:0.9649	0.9649	135
PML	PML:12	promyelocytic leukemia gene:12:0.7571	0.7571	12
PML	PML:75	promyelocytic leukemia protein:75:0.8975	0.8975	75
PMM2	PMM2:10	phosphomannomutase 2:10:0.7103	0.7103	10
PMMA	PMMA:9	Bone cement:9:0.4587	0.4587	9
PMMA	PMMA:39	poly(methylmethacrylate):39:0.0281	0.0281	39
PMMA	PMMA:174|pMMA:1	polymethyl methacrylate:151:0.2504|polymethyl-methacrylate:24:0.0166	0.2504	175
PMMA	PMMA:19	polymethylmetacrylate:19:0.0130	0.0130	19
PMMA	PMMA:625	polymethylmethacrylate:625:0.4485	0.4485	625
PMMC	PMMC:8|PM-MC:2	pectoralis major myocutaneous:10:0.7103	0.7103	10
PMME	PMME:11	phosphatidyl-N-monomethylethanolamine:11:0.4000	0.4000	11
PMMF	PMMF:12	pectoralis major myocutaneous flap:12:0.7571	0.7571	12
PMM	PMM:26	pentamethylmelamine:26:0.1404	0.1404	26
PMM	PMM:34|Pmm:1|pmm:1	phosphomannomutase:36:0.1966	0.1966	36
PMM	PMM:9	Prevention of Maternal Mortality:9:0.6794	0.6794	9
PMN's	PMN's:34|PMN'S:1	polymorphonuclear leukocytes:35:0.8245	0.8245	35
PMNCs	PMNCs:5	peripheral mononuclear cells:5:0.2818	0.2818	5
PMNCs	PMNCs:6	polymorphonuclear cells:6:0.1320	0.1320	6
PMNC	PMNC:13|pMNC:2	peripheral blood mononuclear cells:15:0.8045	0.8045	15
PMNC	PMNC:25	peripheral mononuclear cells:25:0.4451	0.4451	25
PMNC	PMNC:16	polymorphonuclear cells:16:0.1436	0.1436	16
PMN-E	PMN-E:11|PMNE:11	polymorphonuclear elastase:22:0.2146	0.2146	22
PMNE	PMNE:18|PMN-E:9	polymorphonuclear leukocyte elastase:27:0.8903	0.8903	27
PMNLs	PMNLs:49	polymorphonuclear leucocytes:49:0.7828	0.7828	49
PMNLs	PMNLs:248|PMNL-s:1|PMNLS:1	polymorphonuclear leukocytes:250:0.9147	0.9147	250
PMNL	PMNL:14	granulocytes:14:0.0137	0.0137	14
PMNL	PMNL:15	neutrophil:15:0.0147	0.0147	15
PMNL	PMNL:7	polymorphonuclear cells:7:0.3524	0.3524	7
PMNL	PMNL:169|pmnl:1	Polymorphonuclear leucocytes:122:0.9151|polymorphonuclear leucocyte:48:0.8463	0.9151	170
PMNL	PMNL:659|PMN-L:2|PM-NL:1|pMNL:1|pmnl:1	polymorphonuclear leukocytes:521:0.9446|polymorphonuclear leukocyte:143:0.9019	0.9446	664
PMNL	PMNL:9	polymorphonuclear neutrophils:9:0.1334	0.1334	9
PMNs	PMNs:12	phrenic motoneurons:12:0.5050	0.5050	12
PMNs	PMNs:13	polymorphonuclears:13:0.0041	0.0041	13
PMNs	PMNs:189|PMNS:1	polymorphonuclear cells:190:0.9011	0.9011	190
PMNs	PMNs:53	polymorphonuclear granulocytes:53:0.3700	0.3700	53
PMNs	PMNs:189|PMNS:1	polymorphonuclear leucocytes:190:0.9069	0.9069	190
PMNs	PMNs:1419|PMNS:3	polymorphonuclear leukocytes:1422:0.9703	0.9703	1422
PMNs	PMNs:497|PMNS:2	polymorphonuclear neutrophils:499:0.5603	0.5603	499
PMNs	PMNs:12	Polymorphonuclear neutrophil granulocytes:12:0.3275	0.3275	12
PMN	PMN:55	human polymorphonuclear:55:0.0665	0.0665	55
PMN	PMN:25	polymorphonuclears:25:0.0038	0.0038	25
PMN	PMN:394	polymorphonuclear cells:310:0.9163|polymorphonuclear cell:84:0.9436	0.9436	394
PMN	PMN:6	Polymorphonuclear cell count:6:0.5290	0.5290	6
PMN	PMN:122	polymorphonuclear granulocytes:99:0.3938|polymorphonuclear granulocyte:23:0.2377	0.3938	122
PMN	PMN:415|pmn:1	polymorphonuclear leucocytes:303:0.9562|polymorphonuclear leucocyte:113:0.9442	0.9562	416
PMN	PMN:2426|pmn:1	polymorphonuclear leukocytes:1710:0.9611|polymorphonuclear leukocyte:717:0.9515	0.9611	2427
PMN	PMN:1090	polymorphonuclear neutrophils:764:0.5994|polymorphonuclear neutrophil:326:0.4228	0.5994	1090
PMN	PMN:29	polymorphonuclear neutrophil granulocytes:23:0.3310|polymorphonuclear neutrophil granulocyte:6:0.2452	0.3310	29
PMN	PMN:17	polymorphonuclear neutrophilic granulocytes:17:0.3512	0.3512	17
pmn	pmn:17	progressive motor neuronopathy:17:0.8270	0.8270	17
PMO	PMO:29|PMo:6|pMO:2|pMo:1	peritoneal macrophage:20:0.6680|peritoneal macrophages:18:0.6903	0.6903	38
PMO	PMO:9	phosphorodiamidate Morpholino oligomers:9:0.5470	0.5470	9
PMO	PMO:17	postmenopausal osteoporosis:17:0.5760	0.5760	17
PMP22	PMP22:8|PMP-22:2	peripheral myelin protein:10:0.7103	0.7103	10
PMP22	PMP22:138|PMP-22:37|pmp22:4|Pmp22:3|pmp-22:1	Peripheral myelin protein 22:140:0.9255|peripheral myelin protein-22:43:0.8917	0.9255	183
PMP22	PMP22:11|Pmp22:1|PMP-22:1	peripheral myelin protein 22 gene:13:0.7753	0.7753	13
PMP70	PMP70:15|pmp70:1	70-kDa peroxisomal membrane protein:16:0.4040	0.4040	16
PMPA	PMPA:16	(R)-9-(2-phosphonylmethoxypropyl)adenine:16:0.1852	0.1852	16
PMphi	PMphi:12|pMphi:5|PMPhi:2	peritoneal macrophages:19:0.8449	0.8449	19
PMPS	PMPS:8	pain syndrome:8:0.5006	0.5006	8
PMPs	PMPs:19	Patient management problems:19:0.8449	0.8449	19
PMPs	PMPs:23	Peroxisomal membrane proteins:23:0.5719	0.5719	23
PMPs	PMPs:12	platelet-derived microparticles:12:0.2868	0.2868	12
PMPs	PMPs:9	Platelet microparticles:9:0.1585	0.1585	9
PMP	PMP:21	1-phenyl-3-methyl-5-pyrazolone:21:0.0494	0.0494	21
PMP	PMP:5|Pmp:2	membrane proteins:7:0.3524	0.3524	7
pmp	pmp:30|PMP:5	per million population:35:0.9217	0.9217	35
PMP	PMP:10|Pmp:1	peroxisomal membrane protein:11:0.3495	0.3495	11
PMP	PMP:4	plasma membrane potential:4:0.0918	0.0918	4
PMP	PMP:8	platelet-derived microparticles:8:0.1004	0.1004	8
PMP	PMP:15	Platelet microparticles:15:0.3614	0.3614	15
PMP	PMP:34	Pseudomyxoma peritonei:34:0.8245	0.8245	34
PMP	PMP:11	pyridoxamine phosphate:11:0.5355	0.5355	11
PMR/GCA	PMR/GCA:5	polymyalgia rheumatica/giant cell arteritis:5:0.4422	0.4422	5
PMRD	PMRD:11	partially mismatched related donor:11:0.7357	0.7357	11
P-MRS	P-MRS:6|PMRS:3	magnetic resonance Spectroscopy:9:0.5470	0.5470	9
PMRs	PMRs:26	proportional mortality ratios:26:0.3502	0.3502	26
PMRs	PMRs:25	proportionate mortality ratios:25:0.3308	0.3308	25
PMRT	PMRT:10	postmastectomy radiotherapy:10:0.3867	0.3867	10
pMRI	pMRI:8|P-MRI:1|PMRI:1	magnetic resonance imaging:10:0.7103	0.7103	10
PMR	PMR:9	mortality rates:9:0.5470	0.5470	9
PMR	PMR:50	mortality ratio:50:0.8520	0.8520	50
PMR	PMR:7	palmomental reflex:7:0.2452	0.2452	7
PMR	PMR:5	Percutaneous myocardial laser revascularization:5:0.4422	0.4422	5
PMR	PMR:49	perinatal mortality rate:49:0.7122	0.7122	49
PMR	PMR:302	polymyalgia rheumatica:302:0.9900	0.9900	302
PMR	PMR:26	progressive muscle relaxation:26:0.8861	0.8861	26
PMR	PMR:14	proportional mortality ratios:14:0.4709	0.4709	14
PMR	PMR:42|pmr:4	proton magnetic resonance:46:0.8151	0.8151	46
PMSF	PMSF:56	phenylmethanesulfonyl fluoride:56:0.1132	0.1132	56
PMSG	PMSG:176	pregnant mare serum gonadotrophin:114:0.9582|pregnant mares' serum gonadotrophin:32:0.9072|pregnant mare's serum gonadotrophin:30:0.9011	0.9582	176
PMSG	PMSG:267	pregnant mare serum gonadotropin:151:0.9802|pregnant mare's serum gonadotropin:116:0.9742	0.9802	267
PMSR	PMSR:6	peptide methionine sulfoxide reductase:6:0.3728	0.3728	6
PMS	PMS:4	IU pregnant mare's serum gonadotrophin:4:0.5290	0.5290	4
PMS	PMS:13	Periodic movements in sleep:13:0.7291	0.7291	13
PMs	PMs:31|pMs:1	peritoneal macrophages:32:0.7458	0.7458	32
PMS	PMS:7	Personal Medical Services:7:0.3524	0.3524	7
PMS	PMS:86	phenazine methosulfate:86:0.8452	0.8452	86
PMS	PMS:28	phenazine methosulphate:28:0.7154	0.7154	28
PMs	PMs:10	plasma membranes:10:0.2446	0.2446	10
PMs	PMs:24	poor metabolisers:24:0.8768	0.8768	24
PMs	PMs:124	poor metabolizers:124:0.9759	0.9759	124
PMS	PMS:24	post-marketing surveillance:24:0.3828	0.3828	24
PMS	PMS:11|pms:1	post-mitochondrial supernatant:12:0.1692	0.1692	12
PMS	PMS:13	postmarketing surveillance:13:0.1423	0.1423	13
PMS	PMS:19	Postmitochondrial supernatant:19:0.3721	0.3721	19
PMS	PMS:36	pregnant mare's serum:18:0.8365|pregnant mare serum:18:0.8365	0.8365	36
PMS	PMS:33	pregnant mare serum gonadotropin:21:0.8594|pregnant mare's serum gonadotropin:12:0.7571	0.8594	33
PMS	PMS:8	premenstrual symptoms:8:0.2987	0.2987	8
PMS	PMS:417	premenstrual syndrome:403:0.9084|premenstrual syndromes:14:0.7753	0.9084	417
PMS	PMS:14	pyrolysis mass spectrometry:14:0.6911	0.6911	14
PMTCT	PMTCT:8|pMTCT:2	prevention of mother-to-child transmission:10:0.4363	0.4363	10
PMTS	PMTS:9	premenstrual tension syndrome:9:0.6794	0.6794	9
PMTV	PMTV:15	potato mop-top virus:15:0.8045	0.8045	15
PMV-1	PMV-1:6|PMV1:1	paramyxovirus type 1:7:0.4438	0.4438	7
PMVT	PMVT:8	polymorphic ventricular tachycardia:8:0.4102	0.4102	8
PMWS	PMWS:40	post-weaning multisystemic wasting syndrome:40:0.1997	0.1997	40
PMWS	PMWS:99	Postweaning multisystemic wasting syndrome:99:0.6125	0.6125	99
PMW	PMW:46	postmenopausal women:46:0.8151	0.8151	46
PMX-F	PMX-F:12	polymyxin B-immobilized fiber:12:0.6460	0.6460	12
PMXB	PMXB:7|PmxB:2|PMX-B:2	polymyxin B:11:0.7357	0.7357	11
PMg	PMg:6|p-Mg:1	Plasma magnesium:7:0.2452	0.2452	7
PMG	PMG:10	Polymicrogyria:10:0.1023	0.1023	10
PM	PM:5|pm:1	intrapulmonary metastasis:6:0.1010	0.1010	6
PM	PM:11	medial pulvinar:11:0.7357	0.7357	11
PM	PM:9	method:9:0.0021	0.0021	9
PM	PM:9	monocytes:9:0.0021	0.0021	9
Pm	Pm:30|PM:1	mouth pressure:31:0.4852	0.4852	31
PM	PM:97	pacemaker:76:0.0200|pacemakers:21:0.0053	0.0200	97
PM	PM:9	Palatal myoclonus:9:0.6794	0.6794	9
PM	PM:60	papillary muscle:46:0.5889|papillary muscles:14:0.4709	0.5889	60
PM	PM:9	partial mole:9:0.3069	0.3069	9
PM	PM:418	particulate matter:418:0.9776	0.9776	418
PM	PM:12|Pm:3	Pasteurella multocida:15:0.8045	0.8045	15
PM	PM:41	patients with polymyositis:41:0.1081	0.1081	41
PM	PM:45|Pm:1	pectoralis major:46:0.5672	0.5672	46
PM	PM:8	perfect match:8:0.5006	0.5006	8
PM	PM:9	perinatal mortality:9:0.4587	0.4587	9
PM	PM:9	Periodontal mechanosensitive:9:0.6794	0.6794	9
PM	PM:159|pM:4	peritoneal macrophages:146:0.7716|peritoneal macrophage:17:0.5760	0.7716	163
PM	PM:5	peritoneal mesothelioma:5:0.0612	0.0612	5
PM	PM:20	peritrophic matrix:20:0.5568	0.5568	20
PM	PM:37	phosphoramide mustard:37:0.8377	0.8377	37
PM	PM:8	placental malaria:8:0.5006	0.5006	8
PM	PM:8|Pm:1	plasma:9:0.0021	0.0021	9
PM	PM:537|pm:2|Pm:1	plasma membrane:455:0.7776|plasma membranes:85:0.6978	0.7776	540
PM	PM:7	pleural mesothelioma:7:0.2113	0.2113	7
PM	PM:10|P-M:1	pons-medulla:11:0.0027	0.0027	11
PM	PM:32	poor metabolisers:17:0.8270|poor metaboliser:15:0.7096	0.8270	32
PM	PM:155	poor metabolizers:89:0.9664|poor metabolizer:66:0.9548	0.9664	155
PM	PM:14|pm:1	post-mortem:15:0.0037	0.0037	15
PM	PM:17	postmenopausal:17:0.0043	0.0043	17
PM	PM:25|pm:6	postmortem:31:0.0080	0.0080	31
PM	PM:7	prediction model:7:0.2452	0.2452	7
PM	PM:18	premotor:18:0.0045	0.0045	18
PM	PM:6	premotor area:6:0.1543	0.1543	6
PM	PM:26	premotor cortex:26:0.8251	0.8251	26
PM	PM:9	promethazine:9:0.0021	0.0021	9
PM	PM:16|pM:1	prophylactic mastectomy:17:0.5038	0.5038	17
PM	PM:18	prospective memory:18:0.5560	0.5560	18
PM	PM:18|pm:1	psoas major:19:0.1631	0.1631	19
PM	PM:10	Psychological Mindedness:10:0.7103	0.7103	10
PM	PM:25	pulmonary macrophages:25:0.0851	0.0851	25
PM	PM:14	pulmonary metastases:14:0.4071	0.4071	14
PM	PM:11|Pm:1	puromycin:12:0.0029	0.0029	12
PM	PM:5	pyogenic meningitis:5:0.1132	0.1132	5
PM	PM:38	pyridoxamine:38:0.0099	0.0099	38
PN1	PN1:9	postnatal day 1:9:0.6794	0.6794	9
PN-1	PN-1:56|PN1:10|Pn-1:2	protease nexin-1:53:0.9438|Protease nexin 1:15:0.5589	0.9438	68
PN2	PN2:10	postnatal day 2:10:0.7103	0.7103	10
PNAC	PNAC:8|PN-AC:1	parenteral nutrition-associated cholestasis:9:0.6794	0.6794	9
PNAP	PNAP:13	p-nitroacetophenone:13:0.5217	0.5217	13
PNAd	PNAd:9	peripheral lymph node addressin:9:0.6794	0.6794	9
PNAd	PNAd:20	peripheral node addressin:20:0.4379	0.4379	20
PNAs	PNAs:155|PNAS:1	Peptide nucleic acids:156:0.9487	0.9487	156
PNB	PNB:16	needle biopsy:16:0.6577	0.6577	16
PnC	PnC:17|PNC:1	caudal pontine reticular nucleus:18:0.8365	0.8365	18
Pnc	Pnc:8|PNC:6	pneumococcal:14:0.0634	0.0634	14
PnC	PnC:8	pneumococcal C-polysaccharide:8:0.2987	0.2987	8
PnC	PnC:7|PNC:1|Pnc:1	polysaccharide:9:0.0390	0.0390	9
PNC	PNC:13	prenatal care:13:0.6701	0.6701	13
PNC	PNC:9	purine nucleotide cycle:9:0.5470	0.5470	9
Pnc	Pnc:11|PNC:1|PnC:1	Streptococcus pneumoniae:13:0.7753	0.7753	13
PND1	PND1:11	postnatal day 1:11:0.7357	0.7357	11
PNDs	PNDs:47|pnds:1|Pnds:1	postnatal days:49:0.9392	0.9392	49
PND	PND:5	nipple discharge:5:0.0612	0.0612	5
PND	PND:7	phrenic nerve discharge:7:0.5926	0.5926	7
PND	PND:608|pnd:46|Pnd:1|PnD:1|PNd:1	postnatal day:495:0.9164|postnatal days:162:0.9275	0.9275	657
PND	PND:28	Postnatal depression:28:0.7905	0.7905	28
PND	PND:55	prenatal diagnosis:55:0.8882	0.8882	55
PND	PND:37	principal neutralizing determinant:37:0.7758	0.7758	37
PND	PND:20	principal neutralizing domain:20:0.7173	0.7173	20
PNEC	PNEC:25	pulmonary neuroendocrine cells:25:0.8186	0.8186	25
PNECs	PNECs:8	predicted no-effect concentrations:8:0.6411	0.6411	8
PNECs	PNECs:14	Pulmonary neuroendocrine cells:14:0.6911	0.6911	14
PNES	PNES:10	psychogenic non-epileptic seizures:10:0.7357	0.7357	10
PNES	PNES:22	psychogenic nonepileptic seizures:22:0.8038	0.8038	22
PNETs	PNETs:134	primitive neuroectodermal tumors:114:0.8513|primitive neuroectodermal tumours:20:0.6680	0.8513	134
PNET	PNET:355	Primitive neuroectodermal tumor:219:0.8182|primitive neuroectodermal tumors:85:0.8075|primitive neuroectodermal tumour:34:0.7306|Primitive Neuroectodermal Tumours:17:0.4742	0.8182	355
PNE	PNE:13	nerve evaluation:13:0.5335	0.5335	13
PNE	PNE:52|P-NE:4|pNE:3|PNe:2	plasma norepinephrine:61:0.7076	0.7076	61
PNE	PNE:8|pNE:2	plasma norepinephrine concentration:10:0.7103	0.7103	10
PNE	PNE:37	Primary nocturnal enuresis:37:0.9197	0.9197	37
PNE	PNE:10	pulmonary neuroendocrine:10:0.7103	0.7103	10
PNF	PNF:21	prednisolone farnesylate:21:0.8270	0.8270	21
PNF	PNF:23	primary non-function:23:0.7500	0.7500	23
PNF	PNF:28	primary nonfunction:28:0.5634	0.5634	28
PNF	PNF:29	proprioceptive neuromuscular facilitation:29:0.8978	0.8978	29
PNGase	PNGase:15	peptide:N-glycanase:15:0.3684	0.3684	15
PNG	PNG:156	Papua New Guinea:156:0.9809	0.9809	156
PNH	PNH:203	paroxysmal nocturnal haemoglobinuria:203:0.9850	0.9850	203
PNH	PNH:514	paroxysmal nocturnal hemoglobinuria:514:0.9790	0.9790	514
PNH	PNH:15	periventricular nodular heterotopia:15:0.7096	0.7096	15
PNHS	PNHS:13|pNHS:1	pooled normal human serum:14:0.7909	0.7909	14
PNIF	PNIF:25	peak nasal inspiratory flow:25:0.8816	0.8816	25
PNIPAM	PNIPAM:14|pNIPAm:1|PNIPAm:1|pNIPAM:1	poly(N-isopropylacrylamide):17:0.5517	0.5517	17
PNIPA	PNIPA:8|pNIPA:1	poly(N-isopropylacrylamide):9:0.5714	0.5714	9
PNI	PNI:9	field of psychoneuroimmunology:9:0.0969	0.0969	9
PNI	PNI:14	nerve injury:14:0.7909	0.7909	14
PNI	PNI:39|pni:1	Perineural invasion:40:0.8839	0.8839	40
PNI	PNI:29	Prognostic Nutritional Index:29:0.8978	0.8978	29
PNI	PNI:21	Protease nexin I:21:0.8594	0.8594	21
PNL	PNL:16	peanut lectin:16:0.6577	0.6577	16
PNL	PNL:46	percutaneous nephrolithotomy:46:0.9353	0.9353	46
PNL	PNL:23	percutaneous nephrolithotripsy:23:0.8715	0.8715	23
PNL	PNL:11	polymorphonuclear leukocytes:11:0.7357	0.7357	11
PNMR	PNMR:34	perinatal mortality rate:34:0.7587	0.7587	34
PNMT	PNMT:88	phenylethanolamine-N-methyl transferase:44:0.4664|phenylethanolamine N-methyl transferase:25:0.8816|phenylethanolamine-N-methyl-transferase:10:0.0133|phenylethanolamine N-methyl-transferase:9:0.6794	0.8816	88
PNMT	PNMT:320|Pnmt:1	phenylethanolamine N-methyltransferase:321:0.9666	0.9666	321
PNN	PNN:23	probabilistic neural network:23:0.8038	0.8038	23
PNPase	PNPase:82|PNP-ase:1	polynucleotide phosphorylase:83:0.6817	0.6817	83
PNPase	PNPase:20	purine nucleoside phosphorylase:20:0.7173	0.7173	20
PNRSV	PNRSV:19	prunus necrotic ringspot virus:19:0.8449	0.8449	19
PNR	PNR:12	proximal negative response:12:0.7571	0.7571	12
PNST	PNST:9	peripheral nerve sheath tumor:9:0.6794	0.6794	9
PNs	PNs:11	C3-C4 propriospinal neurones:11:0.2764	0.2764	11
PNS	PNS:77	nerve stimulation:77:0.7905	0.7905	77
PNS	PNS:13|Pns:1|PnS:1	Panax notoginseng saponins:15:0.8045	0.8045	15
PNS	PNS:13	paraneoplastic neurological syndromes:13:0.7753	0.7753	13
PNS	PNS:8	perineural spread:8:0.5006	0.5006	8
PNs	PNs:12	perineuronal nets:12:0.6460	0.6460	12
PNs	PNs:6	persistent nodules:6:0.1838	0.1838	6
PNS	PNS:16	primary nephrotic syndrome:16:0.7261	0.7261	16
PNs	PNs:29	projection neurons:29:0.3379	0.3379	29
PNs	PNs:13	Purkinje neurons:13:0.0967	0.0967	13
PNS	PNS:8|PnS:1	saponins of Panax notoginseng:9:0.4587	0.4587	9
PNTML	PNTML:41	pudendal nerve terminal motor latency:41:0.9274	0.9274	41
PNT	PNT:9	pneumotachograph:9:0.0650	0.0650	9
PNU	PNU:13	N-Propyl-N-nitrosourea:13:0.2449	0.2449	13
PNU	PNU:7|pnu:1	protein nitrogen units:8:0.6411	0.6411	8
PNV	PNV:5	nigriventer venom:5:0.1838	0.1838	5
PNX	PNX:22|Pnx:1	pneumonectomy:23:0.4583	0.4583	23
PNZ	PNZ:6	posterior necrotic zone:6:0.5290	0.5290	6
PNA	PNA:84	Arachis hypogaea:84:0.9449	0.9449	84
PNa	PNa:9	Na permeability:9:0.1945	0.1945	9
PNA	PNA:16	nitrogen appearance:16:0.8165	0.8165	16
pNA	pNA:9|-pNA:1|pNa:1	p-nitroanilide:11:0.0055	0.0055	11
pNA	pNA:12|PNA:6|p-NA:2	p-nitroaniline:20:0.0105	0.0105	20
p-NA	p-NA:9|pNA:7|PNA:4|p-Na:1	p-nitroanisole:21:0.0111	0.0111	21
PNA	PNA:721	peanut agglutinin:721:0.9168	0.9168	721
PNA	PNA:52	peanut lectin:52:0.5816	0.5816	52
PNA	PNA:362	peptide nucleic acid:316:0.9381|Peptide nucleic acids:46:0.8151	0.9381	362
PNA	PNA:40	phrenic nerve activity:40:0.8184	0.8184	40
PNA	PNA:17|pNA:2|P-NA:1	plasma noradrenaline:20:0.6259	0.6259	20
pNA	pNA:7|PNA:6|P-NA:1	plasma noradrenaline concentration:14:0.7909	0.7909	14
PNa	PNa:7|P-Na:1|pNa:1	plasma sodium:9:0.2102	0.2102	9
PNa	PNa:11|pNa:3	plasma sodium concentration:14:0.6911	0.6911	14
PNA	PNA:6	polynitroxyl albumin:6:0.1838	0.1838	6
PNA	PNA:19	postnatal age:19:0.7658	0.7658	19
PN	PN:5	cerebellar Purkinje neurons:5:0.1973	0.1973	5
Pn	Pn:10|PN:1	Net photosynthesis:11:0.4232	0.4232	11
Pn	Pn:13|PN:1	net photosynthetic rate:14:0.4312	0.4312	14
PN	PN:9|Pn:1	number:10:0.0044	0.0044	10
Pn	Pn:7|PN:2	pacemaker nucleus:9:0.1267	0.1267	9
PN	PN:10	Palmerston North:10:0.7103	0.7103	10
PN	PN:19	papillary or nodular:19:0.7400	0.7400	19
PN	PN:15	parenteral nutrient:15:0.8045	0.8045	15
PN	PN:352	parenteral nutrition:352:0.9735	0.9735	352
PN	PN:8	partial nephrectomy:8:0.4102	0.4102	8
PN	PN:15	partner notification:15:0.7096	0.7096	15
PN	PN:4	peripheral lymph nodes:4:0.1618	0.1618	4
PN	PN:85	peripheral nerve:85:0.5388	0.5388	85
PN	PN:9	peripheral neuroepithelioma:9:0.6794	0.6794	9
PN	PN:82	peripheral neuropathy:82:0.8368	0.8368	82
PN	PN:43	peroxynitrite:43:0.0201	0.0201	43
PN	PN:6|P-N:3	phosphoramidate:9:0.0039	0.0039	9
PN	PN:28	phrenic nerve:28:0.1311	0.1311	28
PN	PN:7|Pn:2	pneumonia:9:0.0039	0.0039	9
PN	PN:44	polyarteritis nodosa:44:0.7168	0.7168	44
PN	PN:16	polyneuropathy:16:0.0074	0.0074	16
PN	PN:30|Pn:1	pontine nuclei:31:0.8519	0.8519	31
PN	PN:10	pontine nucleus:10:0.1596	0.1596	10
PN	PN:73|pn:5|Pn:1	postnatal:79:0.0383	0.0383	79
PN	PN:138|pn:3	postnatal day:95:0.9192|postnatal days:46:0.8676	0.9192	141
PN	PN:24	Processing negativity:24:0.8768	0.8768	24
PN	PN:15	pronuclear:15:0.0069	0.0069	15
PN	PN:19	pronuclei:19:0.0088	0.0088	19
PN	PN:19	pronucleus:19:0.0088	0.0088	19
PN	PN:6	pulp necrosis:6:0.1148	0.1148	6
PN	PN:6	Purkinje neuron:6:0.1838	0.1838	6
PN	PN:27	pyelonephritis:27:0.0128	0.0128	27
PN	PN:26	pyridine nucleotides:17:0.7407|pyridine nucleotide:9:0.4587	0.7407	26
PN	PN:60	pyridoxine:60:0.0290	0.0290	60
Pn	Pn:8	Streptococcus pneumoniae R36a:8:0.5006	0.5006	8
Pn	Pn:9	Streptococcus pneumoniae:9:0.5470	0.5470	9
pO(2)	pO(2):12|PO(2):6|Po(2):2	oxygen partial pressure:20:0.5568	0.5568	20
pO(2)	pO(2):17|PO(2):9|Po(2):3	oxygen tension:29:0.7237	0.7237	29
pO(2)	pO(2):7	partial oxygen pressure:7:0.2902	0.2902	7
pO(2)	pO(2):9|PO(2):8|Po(2):3	partial pressure of oxygen:20:0.8525	0.8525	20
PO/AH	PO/AH:12	hypothalamic area:12:0.6460	0.6460	12
PO/AH	PO/AH:12	preoptic/anterior hypothalamic:12:0.2549	0.2549	12
PO/AH	PO/AH:4	preoptic anterior hypothalamus:4:0.4379	0.4379	4
PO/AH	PO/AH:9	preoptic area and anterior hypothalamus:9:0.7103	0.7103	9
pO2	pO2:64|PO2:41|Po2:4|po2:1	oxygen partial pressure:100:0.7556|oxygen partial pressures:10:0.3470	0.7556	110
PO2	PO2:158|pO2:127|Po2:12|Po-2:1	oxygen tension:288:0.8385|oxygen tensions:10:0.3867	0.8385	298
pO2	pO2:17|PO2:11|Po2:1	partial oxygen pressure:29:0.2217	0.2217	29
PO2	PO2:18|pO2:4|Po2:2	partial pressure of O2:24:0.8115	0.8115	24
PO2	PO2:97|pO2:49|Po2:8	partial pressure of oxygen:154:0.9593	0.9593	154
PO2	PO2:4|pO2:2	tissue oxygenation:6:0.1543	0.1543	6
PO4	PO4:50	phosphate:50:0.7538	0.7538	50
PO4	PO4:10	phosphorus:10:0.1385	0.1385	10
POA-AH	POA-AH:23	preoptic area-anterior hypothalamus:23:0.8715	0.8715	23
POA-AHA	POA-AHA:10	preoptic-anterior hypothalamic area:10:0.4363	0.4363	10
POA/AH	POA/AH:15	preoptic area/anterior hypothalamus:15:0.8045	0.8045	15
POAD	POAD:29	peripheral occlusive arterial disease:29:0.8422	0.8422	29
POAG	POAG:696|pOAG:2|poag:1	primary open-angle glaucoma:446:0.9699|primary open angle glaucoma:253:0.9633	0.9699	699
POAH	POAH:8|PO-AH:1	hypothalamic area:9:0.3069	0.3069	9
POAH	POAH:9|PO-AH:3	preoptic-anterior hypothalamic:8:0.1367|preoptic anterior hypothalamic:4:0.7103	0.7103	12
POAH	POAH:38	preoptic anterior hypothalamus:21:0.4945|preoptic/anterior hypothalamus:17:0.1469	0.4945	38
POBF	POBF:76|pOBF:3	pulsatile ocular blood flow:79:0.9210	0.9210	79
POBN	POBN:5	alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone:5:0.0902	0.0902	5
POBN	POBN:22	alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone:22:0.3182	0.3182	22
POB	POB:42	phenoxybenzamine:42:0.5676	0.5676	42
POCD	POCD:13	postoperative cognitive dysfunction:13:0.5934	0.5934	13
PO-CL	PO-CL:11|POCL:1	Peroxyoxalate chemiluminescence:12:0.7571	0.7571	12
POCT	POCT:61	Point-of-care testing:61:0.6738	0.6738	61
POC	POC:23	particulate organic carbon:23:0.8715	0.8715	23
POC	POC:6	Peroperative cholangiography:6:0.2243	0.2243	6
POC	POC:63	point-of-care:52:0.2152|Point Of Care:11:0.3829	0.3829	63
POC	POC:14	products of conception:14:0.6911	0.6911	14
POD	POD:9	perception of dyspnea:9:0.6794	0.6794	9
POD	POD:90	peroxidase:90:0.1391	0.1391	90
POD	POD:370|pOD:1|pod:1	postoperative day:287:0.8439|postoperative days:85:0.8419	0.8439	372
POE	POE:19	physician order entry:19:0.6106	0.6106	19
POE	POE:27	Polyoxyethylene:27:0.1926	0.1926	27
POF	POF:13	ossifying fibroma:13:0.5335	0.5335	13
POF	POF:28|pof:1	pentoxifylline:29:0.0886	0.0886	29
POF	POF:220	premature ovarian failure:220:0.9578	0.9578	220
POHEM	POHEM:13	POpulation HEalth Model:13:0.7571	0.7571	13
POHS	POHS:33	presumed ocular histoplasmosis syndrome:33:0.9100	0.9100	33
POH	POH:32	perillyl alcohol:32:0.8519	0.8519	32
POH	POH:5	pressure overload hypertrophy:5:0.4422	0.4422	5
POI	POI:15	Personal Orientation Inventory:15:0.8045	0.8045	15
POI	POI:15	postoperative ileus:15:0.5818	0.5818	15
POLG	POLG:14|PolG:1|Polg:1	polymerase gamma:16:0.8270	0.8270	16
pols	pols:11|Pols:6	DNA polymerases:17:0.5760	0.5760	17
POLs	POLs:9|POLS:1	office laboratories:10:0.7103	0.7103	10
pol	pol:6|POL:2	catalytic subunit:8:0.4102	0.4102	8
pol	pol:161|POL:6	DNA polymerase:145:0.3310|DNA polymerases:22:0.5327	0.5327	167
POL	POL:10|pol:1	flagellin:11:0.0163	0.0163	11
POL	POL:14	peroxide oxidation of lipids:14:0.5589	0.5589	14
pol	pol:14	polymerase gene:14:0.6173	0.6173	14
pol	pol:9|Pol:1	reverse transcriptase:10:0.7103	0.7103	10
pol	pol:135	RNA polymerase:135:0.3079	0.3079	135
POMC	POMC:504|pomc:1	pro-opiomelanocortin:505:0.3886	0.3886	505
POMC	POMC:712	proopiomelanocortin:712:0.5475	0.5475	712
POMC	POMC:7	proopiomelanocortin gene:7:0.2452	0.2452	7
POMR	POMR:22	Medical Record:22:0.8657	0.8657	22
POMs	POMs:9	polyoxometalates:9:0.0174	0.0174	9
POMS	POMS:363	Profile of Mood States:345:0.9691|profile of mood state:18:0.5940	0.9691	363
POMS	POMS:7	Profile of Mood States questionnaire:7:0.5926	0.5926	7
POM	POM:37|pom:1	medial preoptic nucleus:38:0.8417	0.8417	38
POM	POM:10	nucleus preopticus medialis:10:0.5856	0.5856	10
POM	POM:14	particulate organic matter:14:0.3813	0.3813	14
POM	POM:9	pivaloyloxymethyl:9:0.0289	0.0289	9
POM	POM:8	polycyclic organic matter:8:0.1196	0.1196	8
POm	POm:5|Pom:2|POM:1	posterior group:8:0.4102	0.4102	8
POM	POM:15	purulent otitis media:15:0.4951	0.4951	15
PON1	PON1:37	Human serum paraoxonase:37:0.4084	0.4084	37
PON1	PON1:99|PON-1:8|Pon1:1	paraoxonase 1:71:0.8934|paraoxonase-1:37:0.1056	0.8934	108
PON1	PON1:9|Pon1:1	paraoxonase gene:10:0.3470	0.3470	10
PON1	PON1:11	paraoxonase1:11:0.0293	0.0293	11
PONV	PONV:448	postoperative nausea and vomiting:448:0.9203	0.9203	448
PON	PON:120|Pon:1	paraoxonase:121:0.6051	0.6051	121
PON	PON:12	preoptic nucleus:12:0.2549	0.2549	12
PON	PON:7	pretectal olivary nucleus:7:0.5926	0.5926	7
Popcom	Popcom:11|POPCOM:10	Commission on Population:21:0.8657	0.8657	21
POPC	POPC:26	1-palmitoyl-2-oleoyl-phosphatidylcholine:15:0.0376|1-palmitoyl-2-oleoyl phosphatidylcholine:11:0.1131	0.1131	26
POPC	POPC:10	1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine:10:0.0242	0.0242	10
POPC	POPC:54	1-palmitoyl-2-oleoylphosphatidylcholine:54:0.1425	0.1425	54
POPC	POPC:8	membranes composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine:8:0.1061	0.1061	8
POPC	POPC:9	palmitoyloleoyl phosphatidylcholine:9:0.0735	0.0735	9
POPC	POPC:37	palmitoyloleoylphosphatidylcholine:37:0.0968	0.0968	37
POPG	POPG:13	1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol:13:0.1714	0.1714	13
POP-Q	POP-Q:10|POPQ:8	pelvic organ prolapse quantification:18:0.8365	0.8365	18
POP-Q	POP-Q:5|POPQ:4	Pelvic Organ Prolapse Quantification System:9:0.6794	0.6794	9
POPs	POPs:173	persistent organic pollutants:173:0.9628	0.9628	173
POPs	POPs:5	progestin-only pills:5:0.0902	0.0902	5
POPV	POPV:8	Postobstructive pulmonary vasculopathy:8:0.5006	0.5006	8
POP	POP:22	pelvic organ prolapse:22:0.8657	0.8657	22
POP	POP:10	persistent organic pollutant:10:0.7103	0.7103	10
POP	POP:14|PoP:2	plaster of paris:16:0.8165	0.8165	16
POP	POP:8|Pop:2|PoP:1	pressure:11:0.0424	0.0424	11
POP	POP:6	progestogen-only pill:6:0.1320	0.1320	6
POP	POP:16|Pop:1	prolyl oligopeptidase:17:0.8270	0.8270	17
PORH	PORH:13	reactive hyperemia:13:0.7753	0.7753	13
PORN	PORN:14	Progressive outer retinal necrosis:14:0.7909	0.7909	14
PORP	PORP:13	partial ossicular replacement prosthesis:13:0.6701	0.6701	13
PORT	PORT:41	Patient Outcomes Research Team:41:0.8491	0.8491	41
PORT	PORT:10|PoRT:1	postoperative radiotherapy:11:0.2972	0.2972	11
POR	POR:20	NADPH:protochlorophyllide oxidoreductase:20:0.1734	0.1734	20
POR	POR:9|Por:1	porfiromycin:10:0.0383	0.0383	10
POR	POR:46|pOR:1	prevalence odds ratio:32:0.7841|prevalence odds ratios:15:0.6386	0.7841	47
POSCH	POSCH:34	Program on the Surgical Control of the Hyperlipidemias:34:0.8811	0.8811	34
POSC	POSC:7	preoptic suprachiasmatic area:7:0.5926	0.5926	7
POSIT	POSIT:8	Problem Oriented Screening Instrument for Teenagers:8:0.6411	0.6411	8
POTS	POTS:24	postural orthostatic tachycardia syndrome:24:0.8768	0.8768	24
POTS	POTS:43	Postural tachycardia syndrome:43:0.5087	0.5087	43
POV	POV:27	postoperative vomiting:27:0.7834	0.7834	27
POWs	POWs:37	prisoners of war:37:0.8336	0.8336	37
POW	POW:9	Powassan:9:0.1356	0.1356	9
POW	POW:8	prisoner of war:8:0.4102	0.4102	8
PP(i)	PP(i):33	pyrophosphate:33:0.9697	0.9697	33
PP10	PP10:17	Placental protein 10:17:0.6748	0.6748	17
PP14	PP14:96	placental protein 14:96:0.9064	0.9064	96
PP1c	PP1c:14|PP1C:9|PP-1c:3|PP-1C:1	catalytic subunit:27:0.8903	0.8903	27
PP1C	PP1C:4|PP1c:3	catalytic subunit of PP1:7:0.5926	0.5926	7
PP1C	PP-1c:2|PP1C:2|PP1c:1|PP-1C:1	catalytic subunit of protein phosphatase-1:6:0.5290	0.5290	6
PP-1G	PP-1G:6|PP1G:5	protein phosphatase-1:11:0.7357	0.7357	11
PP1	PP1:8	4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine:8:0.0130	0.0130	8
PP1	PP1:8|PP-1:1	protein phosphatases:9:0.3455	0.3455	9
PP1	PP1:258|PP-1:57	protein phosphatase 1:197:0.9157|protein phosphatase-1:118:0.8827	0.9157	315
PP1	PP1:35|PP-1:8	protein phosphatase type 1:39:0.8142|Protein phosphatase type-1:4:0.1618	0.8142	43
PP1	PP1:29|PP-1:2	type 1 protein phosphatase:31:0.9072	0.9072	31
PP2Ac	PP2Ac:13|PP2A-C:3|PP2AC:3|PP2a-C:1	catalytic subunit:20:0.7766	0.7766	20
PP2Ac	PP2Ac:5|PP2A-C:1|PP2AC:1	catalytic subunit of PP2A:7:0.5926	0.5926	7
PP2Ac	PP2Ac:11|PP2AC:1	catalytic subunit of protein phosphatase 2A:12:0.6460	0.6460	12
PP2A	PP2A:415|PP-2A:26|PP2a:2|PP-2a:1	protein phosphatase 2A:414:0.8991|protein phosphatase-2A:30:0.7315	0.8991	444
PP2A	PP2A:13|PP-2A:1|PP2a:1	type 2A protein phosphatase:15:0.7096	0.7096	15
PP2B	PP2B:12|PP-2B:1	protein phosphatase:13:0.5335	0.5335	13
PP2B	PP2B:20|PP-2B:1|PP2b:1	protein phosphatase 2B:22:0.7400	0.7400	22
PP2C	PP2C:37	protein phosphatase 2C:37:0.8377	0.8377	37
PP5	PP5:59|PP-5:1	placental protein 5:60:0.9486	0.9486	60
PP5	PP5:23	Protein phosphatase 5:23:0.5997	0.5997	23
PPACK	PPACK:23	chloromethyl ketone:23:0.4047	0.4047	23
PPAG	PPAG:10	Planned Parenthood Association of Ghana:10:0.7103	0.7103	10
PPARs	PPARs:427|PPARS:5	Peroxisome proliferator-activated receptors:432:0.9687	0.9687	432
PPAR	PPAR:551	peroxisome proliferator-activated receptor:415:0.9523|peroxisome proliferator-activated receptors:64:0.9033|peroxisome proliferator activated receptor:58:0.8525|peroxisome proliferator activated receptors:14:0.7909	0.9523	551
PPAT	PPAT:10	Phosphopantetheine adenylyltransferase:10:0.7103	0.7103	10
PPBG	PPBG:8|ppBG:1	blood glucose:9:0.6794	0.6794	9
PPBL	PPBL:13	Persistent polyclonal B-cell lymphocytosis:13:0.6386	0.6386	13
PPCM	PPCM:32	Peripartum cardiomyopathy:32:0.8563	0.8563	32
PPCPs	PPCPs:11	pharmaceuticals and personal care products:11:0.7357	0.7357	11
PPCs	PPCs:13	postoperative pulmonary complications:13:0.7753	0.7753	13
PPC	PPC:11	complexes:11:0.0182	0.0182	11
PPC	PPC:10|ppc:1	peak plasma concentration:11:0.7357	0.7357	11
PPC	PPC:10	phenprocoumon:10:0.0164	0.0164	10
PPC	PPC:8|pPC:1	phosphatidylcholine:9:0.0146	0.0146	9
PPC	PPC:10	Plasma protein concentration:10:0.7103	0.7103	10
PPC	PPC:26	polyenylphosphatidylcholine:26:0.0455	0.0455	26
PPC	PPC:10	posterior parietal:10:0.7103	0.7103	10
PPC	PPC:100	posterior parietal cortex:100:0.9701	0.9701	100
PPC	PPC:15	postoperative pulmonary complications:15:0.6386	0.6386	15
PPC	PPC:9	primary peritoneal carcinoma:9:0.5470	0.5470	9
PPC	PPC:6	progenitor cells:6:0.2243	0.2243	6
Ppc	Ppc:12	Pulmonary capillary pressure:12:0.5664	0.5664	12
PPC	PPC:14	push-pull cannula:14:0.7909	0.7909	14
PPDA	PPDA:8|pPDA:1	p-Phenylenediamine:9:0.2286	0.2286	9
PPDK	PPDK:14|PPdK:1	pyruvate orthophosphate dikinase:15:0.8715	0.8715	15
PPDK	PPDK:26	pyruvate phosphate dikinase:26:0.8941	0.8941	26
ppDyn	ppDyn:7|PPDYN:3|ppDYN:2|ppdyn:1	preprodynorphin:13:0.9231	0.9231	13
PPD-S	PPD-S:1	M tuberculosis:1:0.0902	0.0902	1
PPD-S	PPD-S:4|PPDs:1	Mycobacterium tuberculosis:5:0.0902	0.0902	5
PPDs	PPDs:13	Purified Protein Derivatives:13:0.7753	0.7753	13
PPD	PPD:28|pPD:2|p-PD:1|pPd:1	p-phenylenediamine:32:0.0153	0.0153	32
PPD	PPD:57	Paired-pulse depression:43:0.2808|paired pulse depression:14:0.7909	0.7909	57
PPD	PPD:25|pPD:3|p-PD:1	para-phenylenediamine:29:0.0139	0.0139	29
PPD	PPD:25	paraphenylenediamine:25:0.0119	0.0119	25
PPD	PPD:20	pocket probing depth:20:0.4786	0.4786	20
PPD	PPD:8	posterior polymorphous dystrophy:8:0.6411	0.6411	8
PPD	PPD:6	postpartum day:6:0.1010	0.1010	6
PPD	PPD:46	postpartum depression:46:0.3061	0.3061	46
PPD	PPD:45	preprodynorphin:45:0.0218	0.0218	45
PPD	PPD:111	probing pocket depth:101:0.8755|probing pocket depths:10:0.4363	0.8755	111
PPD	PPD:35|ppd:4	proximal pars distalis:39:0.9237	0.9237	39
PPD	PPD:899	purified protein derivative:864:0.9621|purified protein derivatives:35:0.9151	0.9621	899
PPD	PPD:3	purified protein derivative from tuberculin:3:0.9348	0.9348	3
PPD	PPD:14	purified protein derivative of Mycobacterium tuberculosis:14:0.8594	0.8594	14
PPD	PPD:9	tuberculin skin test:9:0.3069	0.3069	9
PPE	PPE:17	palmar-plantar erythrodysesthesia:17:0.6211	0.6211	17
PPE	PPE:62	personal protective equipment:62:0.9519	0.9519	62
PPE	PPE:28	plasma protein extravasation:28:0.8941	0.8941	28
PPE	PPE:96	porcine pancreatic elastase:96:0.9685	0.9685	96
PPE	PPE:6	preparticipation physical examination:6:0.2243	0.2243	6
PPE	PPE:156	preproenkephalin:156:0.2601	0.2601	156
PPE	PPE:9	Pruritic papular eruption:9:0.6794	0.6794	9
PPE	PPE:8	pulmonary edema:8:0.5006	0.5006	8
PPFD	PPFD:18	photosynthetic photon flux density:18:0.6903	0.6903	18
PPF	PPF:129|ppf:1	paired-pulse facilitation:130:0.7549	0.7549	130
PPF	PPF:13	papillary plasma flow:13:0.7753	0.7753	13
PPF	PPF:14	periportal fibrosis:14:0.6911	0.6911	14
PPF	PPF:44	photosynthetic photon flux:44:0.8620	0.8620	44
PPF	PPF:5	plasma-polymerized film:5:0.0902	0.0902	5
PPF	PPF:27	plasma protein fraction:27:0.8903	0.8903	27
PPF	PPF:16	propafenone:16:0.0342	0.0342	16
PPF	PPF:15|ppf:1	propentofylline:16:0.0342	0.0342	16
PPF	PPF:7	proplatelet formation:7:0.3524	0.3524	7
PPF	PPF:9	pterygopalatine fossa:9:0.6794	0.6794	9
PPG	PPG:12	photoplethysmograph:12:0.0318	0.0318	12
PPG	PPG:19	photoplethysmographic:19:0.0520	0.0520	19
PPG	PPG:69	photoplethysmography:69:0.1965	0.1965	69
PPG	PPG:8	postprandial glucose:8:0.0906	0.0906	8
PPG	PPG:11	postprandial plasma glucose:11:0.4232	0.4232	11
PPG	PPG:17	pressure gradient:17:0.7407	0.7407	17
PPG	PPG:10|PpG:1	pterygopalatine ganglion:11:0.7357	0.7357	11
PPG	PPG:26	pylorus-preserving gastrectomy:26:0.7760	0.7760	26
PPHN	PPHN:37	persistent pulmonary hypertension:37:0.8377	0.8377	37
PPHN	PPHN:10	persistent pulmonary hypertension of the neonate:10:0.4728	0.4728	10
PPHN	PPHN:151	Persistent pulmonary hypertension of the newborn:151:0.9506	0.9506	151
PPHP	PPHP:23	Pseudopseudohypoparathyroidism:23:0.5789	0.5789	23
PPHTN	PPHTN:17	portopulmonary hypertension:17:0.7407	0.7407	17
PPII	PPII:4	polyproline II helix:4:0.1618	0.1618	4
PPIP	PPIP:12	Put Prevention into Practice:12:0.6182	0.6182	12
PPIs	PPIs:16	patient package inserts:16:0.6577	0.6577	16
PPIs	PPIs:10	polyphosphoinositides:10:0.0295	0.0295	10
PPIs	PPIs:221	proton pump inhibitors:221:0.9864	0.9864	221
PPJ	PPJ:33	Pure pancreatic juice:33:0.8605	0.8605	33
PPK	PPK:38	palmoplantar keratoderma:29:0.7581|palmoplantar keratodermas:9:0.6794	0.7581	38
PPK	PPK:12	Plasma prekallikrein:12:0.6460	0.6460	12
PPK	PPK:33|ppk:8|Ppk:1	polyphosphate kinase:42:0.7523	0.7523	42
PPK	PPK:11	population pharmacokinetic:11:0.5355	0.5355	11
PPL	PPL:10	penicilloyl-polylysine:10:0.0262	0.0262	10
Ppl	Ppl:41|PPL:1	pleural pressure:42:0.5874	0.5874	42
PPL	PPL:14|pPL:1	porcine pancreatic lipase:15:0.8045	0.8045	15
PPL	PPL:10	posterior probability of linkage:10:0.7103	0.7103	10
PPL	PPL:25|Ppl:1	propranolol:26:0.0729	0.0729	26
PPL	PPL:6	purified phospholipids:6:0.1543	0.1543	6
PPMA	PPMA:17	muscular atrophy:17:0.7407	0.7407	17
PPMCs	PPMCs:11	Physician practice management companies:11:0.7357	0.7357	11
PPMD	PPMD:7	posterior polymorphous dystrophy:7:0.4438	0.4438	7
PPMS	PPMS:21|PP-MS:3	primary progressive MS:24:0.8768	0.8768	24
PPMS	PPMS:37|PP-MS:2	primary progressive multiple sclerosis:39:0.9237	0.9237	39
PPNAD	PPNAD:31	Primary pigmented nodular adrenocortical disease:31:0.9011	0.9011	31
pPNET	pPNET:30|PPNET:11	peripheral primitive neuroectodermal tumor:28:0.7505|peripheral primitive neuroectodermal tumour:13:0.7753	0.7753	41
PPNG	PPNG:5	penicillinase producers:5:0.1132	0.1132	5
PPNG	PPNG:20	penicillinase-producing:12:0.0365|penicillinase producing:8:0.3463	0.3463	20
PPNG	PPNG:15	penicillinase producing N gonorrhoeae:10:0.8038|penicillinase-producing N gonorrhoeae:5:0.3618	0.8038	15
PPNG	PPNG:122	Penicillinase-producing Neisseria gonorrhoeae:77:0.4043|penicillinase producing Neisseria gonorrhoeae:45:0.8964	0.8964	122
PPNG	PPNG:22	penicillinase-producing strains of Neisseria gonorrhoeae:11:0.1845|penicillinase producing strains of Neisseria gonorrhoeae:11:0.6173	0.6173	22
PPND	PPND:14	pallido-ponto-nigral degeneration:14:0.6701	0.6701	14
PPN	PPN:9	pedunculopontine:9:0.0365	0.0365	9
PPN	PPN:61	pedunculopontine nucleus:61:0.4459	0.4459	61
PPN	PPN:24	pedunculopontine tegmental nucleus:24:0.8115	0.8115	24
PPN	PPN:20	peripheral parenteral nutrition:20:0.5021	0.5021	20
PPOX	PPOX:19	protoporphyrinogen oxidase:19:0.8449	0.8449	19
PPO	PPO:14	2,5-diphenyloxazole:14:0.0344	0.0344	14
PPO	PPO:22	peak power output:22:0.6531	0.6531	22
PPO	PPO:35|P-PO:1	platelet peroxidase:36:0.8336	0.8336	36
PPO	PPO:90	polyphenol oxidase:90:0.6818	0.6818	90
PPO	PPO:14	polyphenoloxidase:14:0.0344	0.0344	14
PPO	PPO:54	preferred provider organization:54:0.9448	0.9448	54
PPO	PPO:8|pPO:1	prophenoloxidase:9:0.0212	0.0212	9
PPPD	PPPD:27|PpPD:1	Pylorus-preserving pancreaticoduodenectomy:28:0.7905	0.7905	28
PPPD	PPPD:35|PpPD:6	pylorus-preserving pancreatoduodenectomy:41:0.5935	0.5935	41
PPP	PPP:9	palatopharyngoplasty:9:0.0114	0.0114	9
PPP	PPP:53	palmoplantar pustulosis:53:0.7789	0.7789	53
PPP	PPP:96|ppp:1	pentose phosphate pathway:97:0.9692	0.9692	97
PPP	PPP:6	Plasma Proteome Project:6:0.5290	0.5290	6
PPP	PPP:56	platelet poor plasma:56:0.9467	0.9467	56
PPP	PPP:39	Polyphloretin phosphate:39:0.7860	0.7860	39
PPP	PPP:13	primary proliferative polycythaemia:13:0.7753	0.7753	13
PPP	PPP:8	pulmonary perfusion pressure:8:0.4102	0.4102	8
PPP	PPP:16	push-pull perfusion:16:0.8165	0.8165	16
PPP	PPP:44	pustulosis palmaris et plantaris:44:0.9323	0.9323	44
PPP	PPP:14	pustulosis palmoplantaris:14:0.7909	0.7909	14
PPQ	PPQ:14	Questionnaire:14:0.3158	0.3158	14
PPREs	PPREs:12	peroxisome proliferator response elements:12:0.7571	0.7571	12
PPRE	PPRE:29	peroxisome proliferator response element:29:0.7581	0.7581	29
PPRE	PPRE:17	PPAR response element:17:0.1443	0.1443	17
PPRF	PPRF:36	paramedian pontine reticular formation:36:0.8336	0.8336	36
PPROM	PPROM:30|pPROM:6|P-PROM:1	preterm premature rupture of the membranes:37:0.9389	0.9389	37
PPRs	PPRs:9	Photoparoxysmal responses:9:0.3945	0.3945	9
PPR	PPR:7	averaged photopalpebral reflex:7:0.3524	0.3524	7
PPR	PPR:9	paired-pulse ratio:9:0.1409	0.1409	9
PPR	PPR:13	Patient-practitioner-remedy:13:0.0369	0.0369	13
PPR	PPR:12	pentatricopeptide repeat:12:0.6460	0.6460	12
PPR	PPR:57	peste des petits ruminants:57:0.8689	0.8689	57
ppR	ppR:10	pharaonis phoborhodopsin:10:0.7103	0.7103	10
PPR	PPR:40	photoparoxysmal response:33:0.5600|photoparoxysmal responses:7:0.2902	0.5600	40
PPR	PPR:6	PTH/PTHrP receptor:6:0.2113	0.2113	6
P-PST	P-PST:10	phenol sulfotransferase:10:0.5856	0.5856	10
PPS	PPS:15	parapharyngeal space:15:0.5818	0.5818	15
PPS	PPS:39	pentosan polysulfate:39:0.9237	0.9237	39
PPS	PPS:11	Pentosan polysulfate sodium:11:0.7357	0.7357	11
PPS	PPS:21	pentosan polysulphate:21:0.8594	0.8594	21
PPS	PPS:9	pentose phosphate shunt:9:0.6794	0.6794	9
PPS	PPS:5	perforant path stimulation:5:0.4422	0.4422	5
PPS	PPS:6	peripheral pulmonary stenosis:6:0.5290	0.5290	6
PPs	PPs:77	Peroxisome proliferators:77:0.9612	0.9612	77
PPs	PPs:58|Pps:3	Peyer's patches:61:0.8383	0.8383	61
PPS	PPS:29|pps:2	pneumococcal polysaccharide:19:0.4211|pneumococcal polysaccharides:12:0.3813	0.4211	31
PPS	PPS:20	post-polio syndrome:20:0.0835	0.0835	20
PPS	PPS:16	Postpericardiotomy syndrome:16:0.0589	0.0589	16
PPS	PPS:17	postpolio syndrome:17:0.0649	0.0649	17
PPS	PPS:8	Preputial separation:8:0.5006	0.5006	8
PPS	PPS:282	Prospective Payment System:282:0.9670	0.9670	282
PPs	PPs:27	protein phosphatases:27:0.6192	0.6192	27
pps	pps:44|PPS:1	pulses per second:45:0.9338	0.9338	45
PPs	PPs:15	Slow waves or pacesetter potentials:15:0.8165	0.8165	15
PPT1	PPT1:13	palmitoyl protein thioesterase 1:7:0.5926|palmitoyl-protein thioesterase 1:6:0.1148	0.5926	13
PPTA	PPTA:11	persistent primitive trigeminal artery:11:0.7357	0.7357	11
PPT-A	PPT-A:23|PPTA:3|pptA:1	preprotachykinin-A:27:0.5778	0.5778	27
PPTD	PPTD:22	Postpartum thyroid dysfunction:22:0.6178	0.6178	22
PPTs	PPTs:29	pressure pain thresholds:29:0.8978	0.8978	29
PPTg	PPTg:59	pedunculopontine tegmental nucleus:59:0.8954	0.8954	59
PPTN	PPTN:10|PPTn:2	pedunculopontine tegmental nucleus:12:0.7571	0.7571	12
PPT	PPT:39|ppt:1	palmitoyl-protein thioesterase:27:0.4837|palmitoyl protein thioesterase:13:0.7753	0.7753	40
ppt	ppt:39	parts per trillion:39:0.8455	0.8455	39
PPT	PPT:6	paw pressure threshold:6:0.0807	0.0807	6
PPT	PPT:15	pedunculopontine tegmental:15:0.8045	0.8045	15
PPT	PPT:30|PpT:1	pedunculopontine tegmental nucleus:31:0.8519	0.8519	31
PPT	PPT:13	pedunculopontine tegmentum:13:0.6701	0.6701	13
PPT	PPT:18	phosphinothricin:18:0.0223	0.0223	18
PPT	PPT:29	Physical Performance Test:29:0.8978	0.8978	29
PPT	PPT:6	Platelet production time:6:0.5290	0.5290	6
PPT	PPT:67|ppt:2	polypurine tract:69:0.7961	0.7961	69
PPT	PPT:8	post-partum thyroiditis:8:0.0502	0.0502	8
PPT	PPT:33	postpartum thyroiditis:33:0.6111	0.6111	33
PPT	PPT:88	preprotachykinin:88:0.1139	0.1139	88
PPT	PPT:59	pressure pain threshold:47:0.8433|pressure pain thresholds:12:0.7571	0.8433	59
PPT	PPT:8	propyl pyrazole triol:8:0.6411	0.6411	8
PPU	PPU:10	perforated peptic ulcer:10:0.7103	0.7103	10
PPVL	PPVL:13	partial portal vein ligation:13:0.7753	0.7753	13
PPVs	PPVs:35	positive predictive values:35:0.9151	0.9151	35
PPVT	PPVT:24	Peabody Picture Vocabulary Test:24:0.8768	0.8768	24
PPVT-R	PPVT-R:17	Peabody Picture Vocabulary Test-Revised:17:0.8270	0.8270	17
PPV	PPV:9	Papaverine:9:0.0046	0.0046	9
PPV	PPV:10|ppv:1	paroxysmal positional vertigo:11:0.7357	0.7357	11
PPV	PPV:151|ppV:4|ppv:1	pars plana vitrectomy:156:0.9808	0.9808	156
PPV	PPV:12	patent processus vaginalis:12:0.7571	0.7571	12
PPV	PPV:6	Phakomatosis pigmentovascularis:6:0.1838	0.1838	6
PPV	PPV:6	phobic postural vertigo:6:0.5290	0.5290	6
PPV	PPV:31	plum pox potyvirus:31:0.9043	0.9043	31
PPV	PPV:84	plum pox virus:84:0.9644	0.9644	84
PPV	PPV:24	pneumococcal polysaccharide vaccine:24:0.8115	0.8115	24
PPV	PPV:146	porcine parvovirus:146:0.9374	0.9374	146
Ppv	Ppv:5|PPV:2	portal venous pressure:7:0.1211	0.1211	7
PPV	PPV:61|ppv:2	positive predictive values:63:0.9526	0.9526	63
PPV	PPV:64	positive pressure ventilation:43:0.9308|positive-pressure ventilation:21:0.1836	0.9308	64
Ppv	Ppv:9|PPV:1	pulmonary venous pressure:10:0.2873	0.2873	10
PPX	PPX:11	Pramipexole:11:0.1724	0.1724	11
PPy	PPy:35|PPY:10|Ppy:1	Polypyrrole:46:0.5412	0.5412	46
PPZ	PPZ:12	perphenazine:12:0.3667	0.3667	12
PPases	PPases:11	inorganic pyrophosphatases:11:0.4232	0.4232	11
PPases	PPases:12	protein phosphatases:12:0.5664	0.5664	12
PPase	PPase:44|PP-ase:1	inorganic pyrophosphatase:45:0.5716	0.5716	45
PPase	PPase:16	protein phosphatase:16:0.5564	0.5564	16
Ppaw	Ppaw:7|pPAw:1	wedge pressure:8:0.4102	0.4102	8
ppb	ppb:218	parts per billion:218:0.9181	0.9181	218
PPB	PPB:13	permanent prostate brachytherapy:13:0.7753	0.7753	13
PPB	PPB:26	Pleuropulmonary blastoma:26:0.8251	0.8251	26
PPB	PPB:22	positive pressure breathing:22:0.7955	0.7955	22
ppENK	ppENK:10|PPenk:8|ppEnk:6|PPEnk:2|PPENK:2	preproenkephalin:28:0.9310	0.9310	28
PPi-PFK	PPi-PFK:11	Pyrophosphate-dependent phosphofructokinase:11:0.3829	0.3829	11
PPiase	PPiase:6|PPi-ase:1	inorganic pyrophosphatase:7:0.2113	0.2113	7
PPIase	PPIase:83|PPiase:1|Ppiase:1	peptidyl-prolyl cis-trans isomerase:62:0.6289|peptidyl-prolyl cis/trans isomerase:23:0.5025	0.6289	85
PPi	PPi:114|-PPi:1|P-Pi:1	inorganic pyrophosphate:116:0.3870	0.3870	116
PPI	PPI:9	paired-pulse index:9:0.0504	0.0504	9
PPI	PPI:8	Patient Package Insert:8:0.5006	0.5006	8
PPI	PPI:5	peptidyl prolyl cis-trans isomerase:5:0.2818	0.2818	5
PPI	PPI:26	phosphoinositide:26:0.0152	0.0152	26
PPI	PPI:68|ppI:1	polyphosphoinositide:46:0.0274|polyphosphoinositides:23:0.0134	0.0274	69
PPI	PPI:6	postpartum interval:6:0.0564	0.0564	6
PPI	PPI:8|ppI:3	preproinsulin:11:0.0061	0.0061	11
PPI	PPI:450|ppi:1	prepulse inhibition:451:0.9222	0.9222	451
PPI	PPI:11	prepulse inhibition of acoustic startle:11:0.7753	0.7753	11
PPI	PPI:33	present pain intensity:33:0.8605	0.8605	33
PPI	PPI:7	protein-protein interaction:7:0.2902	0.2902	7
PPI	PPI:317	proton pump inhibitor:224:0.9786|proton pump inhibitors:93:0.9490	0.9786	317
PPI	PPI:8	Psychopathic Personality Inventory:8:0.4102	0.4102	8
PPI	PPI:7	pulse polio immunization:7:0.5926	0.5926	7
PPI	PPI:13	purified pork insulin:13:0.7753	0.7753	13
PPRV	PPRV:27	peste des petits ruminants virus:27:0.8903	0.8903	27
PP	PP:10	pacesetter potentials:10:0.5000	0.5000	10
PP	PP:11|pp:1	paired-pulse:12:0.0024	0.0024	12
PP	PP:952|pp:3	pancreatic polypeptide:955:0.9791	0.9791	955
PP	PP:17	pancreatic pseudocyst:9:0.6794|Pancreatic pseudocysts:8:0.5006	0.6794	17
PP	PP:7	parkinsonian patients:7:0.2113	0.2113	7
PP	PP:7	particulate P:7:0.2452	0.2452	7
PP	PP:8	particulate phosphorus:8:0.3463	0.3463	8
PP	PP:32	Peak power:32:0.7166	0.7166	32
p-p	p-p:6|PP:3|P-P:2	peak-to-peak:11:0.0022	0.0022	11
PP	PP:19	pentose phosphate:19:0.3721	0.3721	19
PP	PP:69	per-protocol:39:0.0084|Per Protocol:30:0.7315	0.7315	69
PP	PP:6|pp:1	percent positivity:7:0.2902	0.2902	7
PP	PP:66|pp:2	perforant path:68:0.9561	0.9561	68
PP	PP:12|pp:3	perforant pathway:15:0.5818	0.5818	15
PP	PP:130|Pp:7|pp:1	perfusion pressure:130:0.2069|perfusion pressures:8:0.2090	0.2090	138
PP	PP:5	peripeduncular nucleus:5:0.0517	0.0517	5
PP	PP:38|pp:6|Pp:1	periportal:45:0.0097	0.0097	45
PP	PP:65	Peroxisome proliferators:38:0.8781|peroxisome proliferator:27:0.7834	0.8781	65
PP	PP:444|Pp:4	Peyer's patches:327:0.9517|Peyer's patch:121:0.9144	0.9517	448
pp	pp:7|PP:2	phosphoprotein:9:0.0018	0.0018	9
PP	PP:6	plasma perfusion:6:0.0807	0.0807	6
PP	PP:21|pp:1	plasma proteins:11:0.3213|plasma protein:11:0.2040	0.3213	22
PP	PP:63	plasmapheresis:63:0.0137	0.0137	63
PP	PP:11	pleural plaques:11:0.4232	0.4232	11
PP	PP:46|Pp:2	pneumoperitoneum:48:0.0104	0.0104	48
PP	PP:114|pp:1	Polypropylene:115:0.0251	0.0251	115
PP	PP:9	porous polyethylene:9:0.5470	0.5470	9
pp	pp:20|PP:11|Pp:1	post partum:18:0.8365|post-partum:14:0.0029	0.8365	32
PP	PP:33	posterior pituitary:33:0.9100	0.9100	33
PP	PP:6	posterior pretectal nucleus:6:0.5290	0.5290	6
PP	PP:63|pp:34	postpartum:97:0.0211	0.0211	97
PP	PP:22|pp:9	postprandial:31:0.0066	0.0066	31
PP	PP:23	potential:23:0.0048	0.0048	23
PP	PP:9	Precautionary Principle:9:0.6794	0.6794	9
PP	PP:23	precocious pubarche:23:0.4831	0.4831	23
PP	PP:23|pp:1	precocious puberty:24:0.7593	0.7593	24
PP	PP:11	premature pubarche:11:0.1378	0.1378	11
PP	PP:6	preparatory period:6:0.0611	0.0611	6
PP	PP:11	prepubertal periodontitis:11:0.5355	0.5355	11
PP	PP:49	primary progressive:49:0.9404	0.9404	49
PP	PP:9	prone position:9:0.3455	0.3455	9
PP	PP:131|pp:1	protein phosphatase:93:0.7410|protein phosphatases:39:0.6563	0.7410	132
PP	PP:8	proteose peptone:8:0.5006	0.5006	8
PP	PP:47	protoporphyrin:47:0.0101	0.0101	47
PP	PP:20	Protoporphyrin IX:20:0.7173	0.7173	20
Pp	Pp:9|pp:1|PP:1	Pseudomonas putida:11:0.5355	0.5355	11
PP	PP:7	pulsatile perfusion:7:0.1329	0.1329	7
PP	PP:14|pp:1|P-P:1	pulse:16:0.0033	0.0033	16
PP	PP:309|Pp:2	pulse pressure:311:0.5462	0.5462	311
PP	PP:10	pulsus paradoxus:10:0.7103	0.7103	10
PP	PP:17|Pp:1	pyrophosphate:18:0.0037	0.0037	18
PQ2+	PQ2+:9	paraquat:9:0.8889	0.8889	9
PQC	PQC:13	piezoelectric quartz crystal:13:0.6701	0.6701	13
PQOL	PQOL:8|pQOL:1	Perceived Quality of Life:9:0.5470	0.5470	9
PQQ	PQQ:175	pyrroloquinoline quinone:175:0.8684	0.8684	175
PQS	PQS:14	Pseudomonas quinolone signal:14:0.7753	0.7753	14
PQ	PQ:16	9,10-phenanthrenequinone:16:0.0398	0.0398	16
PQ	PQ:146|Pq:5	paraquat:151:0.3979	0.3979	151
PQ	PQ:24	plastoquinone:24:0.0610	0.0610	24
P-Q	P-Q:25|PQ:1|p-Q:1	pressure-flow:27:0.0690	0.0690	27
PQ	PQ:40	primaquine:40:0.1061	0.1061	40
PQ	PQ:13	Questionnaire:13:0.0292	0.0292	13
PQ	PQ:12|-PQ:1	quotient:13:0.0318	0.0318	13
PR3	PR3:221|PR-3:28|Pr3:13|Pr-3:2|pr3:1	proteinase 3:230:0.9118|proteinase-3:35:0.1153	0.9118	265
PR8	PR8:8	A/Puerto Rico/8/34:8:0.5006	0.5006	8
PR8	PR8:7|PR-8:1	influenza virus:8:0.5934	0.5934	8
PR8	PR8:6|PR-8:1	influenza virus A/PR/8/34:7:0.5926	0.5926	7
PRAD	PRAD:7	proline-rich attachment domain:7:0.5006	0.5006	7
PRAMS	PRAMS:46	Pregnancy Risk Assessment Monitoring System:46:0.9353	0.9353	46
PRAT	PRAT:7	platelet radioactive antiglobulin test:7:0.4438	0.4438	7
PRA	PRA:15	fragment length polymorphism analysis:15:0.7909	0.7909	15
PRA	PRA:173	panel reactive antibody:62:0.8407|panel-reactive antibody:46:0.3003|panel reactive antibodies:43:0.8590|panel-reactive antibodies:22:0.1763	0.8590	173
PRA	PRA:11	participatory rural appraisal:11:0.7357	0.7357	11
PRA	PRA:5	PCR-restriction enzyme analysis:5:0.0736	0.0736	5
PRA	PRA:10	plaque reduction assay:10:0.7103	0.7103	10
PRA	PRA:12	plasma renin:12:0.1262	0.1262	12
PRA	PRA:3130|Pra:1|pRA:1|pra:1	plasma renin activity:3116:0.9477|Plasma renin activities:17:0.7407	0.9477	3133
pra	pra:14	praziquantel:14:0.0033	0.0033	14
PRA	PRA:13|pra:3|Pra:2	prazosin:18:0.0043	0.0043	18
PRA	PRA:22	progressive retinal atrophy:22:0.8657	0.8657	22
PRA	PRA:5	restriction enzyme analysis:5:0.0736	0.0736	5
Pra	Pra:30|PRA:12	right atrial pressure:42:0.8917	0.8917	42
PRBCs	PRBCs:33|pRBCs:7	packed red blood cells:40:0.4874	0.4874	40
PRBs	PRBs:17	Permeable reactive barriers:17:0.8270	0.8270	17
PRBS	PRBS:19	pseudorandom binary sequence:19:0.4852	0.4852	19
pRb	pRb:5|pRB:1	p53 and retinoblastoma:6:0.0667	0.0667	6
PRB	PRB:15	permeable reactive barrier:15:0.8045	0.8045	15
pRb	pRb:7|pRB:4	product of the retinoblastoma gene:11:0.4728	0.4728	11
pRb	pRb:4|pRB:2	product of the retinoblastoma tumor suppressor gene:6:0.5290	0.5290	6
PrB	PrB:8|PRB:3	proteinase B:11:0.1067	0.1067	11
pRb	pRb:66|pRB:46	retinoblastoma gene product:112:0.6735	0.6735	112
pRb	pRb:286|pRB:191	retinoblastoma protein:477:0.7640	0.7640	477
pRb	pRb:5|pRB:3	retinoblastoma susceptibility gene:8:0.6411	0.6411	8
pRb	pRb:5|pRB:4	retinoblastoma tumor suppressor:9:0.6794	0.6794	9
PRCs	PRCs:41	phase response curves:28:0.8941|Phase-response curves:13:0.1423	0.8941	41
PRC	PRC:13	packed red cells:13:0.7753	0.7753	13
PRC	PRC:48	People's Republic of China:48:0.8728	0.8728	48
PRC	PRC:24	perirhinal cortex:24:0.8115	0.8115	24
PRC	PRC:78	phase response curve:54:0.8862|phase-response curve:24:0.1789	0.8862	78
PRC	PRC:10	plasma renin:10:0.1596	0.1596	10
PRC	PRC:13	plasma renin concentrations:13:0.7753	0.7753	13
PRc	PRc:15|PRC:5	progesterone receptor:12:0.5664|progesterone receptors:8:0.2619	0.5664	20
PrC	PrC:6	protein C:6:0.1543	0.1543	6
PRC	PRC:11	Proximal row carpectomy:11:0.7357	0.7357	11
PRC	PRC:9	response curves:9:0.5470	0.5470	9
PRDX5	PRDX5:7|Prdx5:2	Peroxiredoxin 5:9:0.6794	0.6794	9
PRD	PRD:4	percent root-mean-square difference:2:0.1973|percent root mean square difference:2:0.3170	0.3170	4
PRD	PRD:21|Prd:1	prednisolone:22:0.1010	0.1010	22
PRD	PRD:17	proline-rich domain:17:0.2186	0.2186	17
PrEC	PrEC:14	prostate epithelial cells:14:0.4709	0.4709	14
PREE	PREE:41	partial reinforcement extinction effect:41:0.9237	0.9237	41
PREGS	PREGS:16|PREG-S:13|PregS:6|Preg-S:3	pregnenolone sulfate:38:0.8098	0.8098	38
PREG	PREG:55|Preg:6|preg:1	pregnenolone:62:0.8026	0.8026	62
PREPs	PREPs:10	Pattern reversal evoked potentials:10:0.7103	0.7103	10
PRESTO	PRESTO:10	Prevention of REStenosis with Tranilast and its Outcomes:10:0.7103	0.7103	10
PRES	PRES:19	Posterior reversible encephalopathy syndrome:19:0.8449	0.8449	19
PREs	PREs:35|PRES:1	response elements:36:0.8003	0.8003	36
PRE	PRE:9	photoreactivating enzyme:9:0.5470	0.5470	9
PRE	PRE:9	Positive Regulatory Element:9:0.1409	0.1409	9
PRE	PRE:10	posttranscriptional regulatory element:10:0.1774	0.1774	10
PRE	PRE:9	progressive resistance exercise:9:0.6794	0.6794	9
PRE	PRE:11	relaxation enhancement:11:0.7357	0.7357	11
PRE	PRE:37	response element:37:0.3294	0.3294	37
PRF	PRF:9	partial reinforcement:9:0.6794	0.6794	9
PRF	PRF:8	Personality Research Form:8:0.6411	0.6411	8
PRF	PRF:44|pRF:12	pontine reticular formation:56:0.9467	0.9467	56
PRF	PRF:16	prolactin-releasing factor:16:0.1220	0.1220	16
PRF	PRF:20	proton resonance frequency:20:0.8525	0.8525	20
PRF	PRF:26|prf:1	pulse repetition frequency:27:0.8903	0.8903	27
PRGF	PRGF:8|PrGF:3	growth factor:11:0.7357	0.7357	11
PRGR	PRGR:9	percutaneous retrogasserian glycerol rhizotomy:9:0.6794	0.6794	9
PRG	PRG:8	pontine respiratory group:8:0.6411	0.6411	8
PRG	PRG:8	proline-rich glycoprotein:8:0.5006	0.5006	8
PRHO	PRHO:14	pre-registration house officer:14:0.6911	0.6911	14
PRHOs	PRHOs:28	Pre-registration house officers:28:0.6554	0.6554	28
PRID	PRID:19	progesterone-releasing intravaginal device:19:0.4405	0.4405	19
PRIG	PRIG:8|PRIg:1	polyreactive immunoglobulins:9:0.6794	0.6794	9
PRINS	PRINS:50	primed in situ labeling:50:0.9366	0.9366	50
PRINS	PRINS:29	PRimed IN Situ labelling:29:0.8978	0.8978	29
PRINS	PRINS:7	situ DNA synthesis:7:0.5926	0.5926	7
PRIR	PRIR:2|PRir:2|PR-IR:2|PR-ir:1	receptor immunoreactivity:7:0.2902	0.2902	7
PRISM	PRISM:74	Pediatric Risk of Mortality:74:0.7388	0.7388	74
PRISM	PRISM:6	pediatric risk of mortality score:6:0.3524	0.3524	6
PRIST	PRIST:16	paper radioimmunosorbent test:16:0.8165	0.8165	16
PRIT	PRIT:9	Pretargeted radioimmunotherapy:9:0.6794	0.6794	9
PRI	PRI:13	placental ribonuclease inhibitor:13:0.7753	0.7753	13
PRK2	PRK2:8	protein kinase C-related kinase 2:8:0.6411	0.6411	8
PRKO	PRKO:12	PR knockout:12:0.2083	0.2083	12
PRKO	PRKO:16	progesterone receptor knockout:16:0.8165	0.8165	16
PRK	PRK:204	excimer laser photorefractive keratectomy:204:0.9624	0.9624	204
PRK	PRK:34	Phosphoribulokinase:34:0.0325	0.0325	34
PRK	PRK:8|pRK:1	primary rabbit kidney:9:0.6794	0.6794	9
PRLs	PRLs:9|Prls:1	prolactins:10:0.5625	0.5625	10
PRL	PRL:13	photoreactivating light:13:0.6701	0.6701	13
PRL	PRL:14	preferred retinal locus:14:0.7909	0.7909	14
PRL	PRL:5633|Prl:453|prl:4|PrL:3|PRl:1	prolactin:6094:0.9650	0.9650	6094
PRL	PRL:8	prolactin levels:8:0.4102	0.4102	8
PRM1	PRM1:8|Prm1:6|Prm-1:3	protamine 1:17:0.8270	0.8270	17
PRM	PRM:9	particle repositioning maneuver:9:0.6794	0.6794	9
PRM	PRM:8	premature rupture of the membranes:8:0.6701	0.6701	8
prM	prM:35|PrM:1	premembrane:36:0.1464	0.1464	36
PRM	PRM:42	primidone:42:0.1715	0.1715	42
PRNP	PRNP:11|Prnp:1	prion protein:12:0.7571	0.7571	12
PRNP	PRNP:88|Prnp:8|Prn-p:4|prnp:1	prion protein gene:101:0.9704	0.9704	101
PRNT	PRNT:37	plaque reduction neutralization test:37:0.9197	0.9197	37
PRN	PRN:9|prn:4	as-needed:13:0.0458	0.0458	13
PRN	PRN:29	paramedian reticular nucleus:29:0.8422	0.8422	29
PRN	PRN:27	plaque reduction neutralization:27:0.8903	0.8903	27
PRN	PRN:11	post-rotatory nystagmus:11:0.2582	0.2582	11
PRN	PRN:6|PR-N:1	postrotatory nystagmus:7:0.0886	0.0886	7
PRN	PRN:1	practice and research network:1:0.3945	0.3945	1
PRN	PRN:8|prn:7	pro re nata:15:0.8045	0.8045	15
PROCAM	PROCAM:28|PRO-CAM:2	Prospective Cardiovascular Munster:30:0.9011	0.9011	30
Prodan	Prodan:9|PRODAN:6|prodan:1	6-propionyl-2-(dimethylamino)naphthalene:16:0.4688	0.4688	16
PROD	PROD:13	7-pentoxyresorufin O-depentylase:13:0.2802	0.2802	13
PROD	PROD:46	Pentoxyresorufin O-dealkylase:33:0.6735|pentoxyresorufin-O-dealkylase:13:0.0597	0.6735	46
PROH	PROH:19|PrOH:2	1,2-propanediol:21:0.3922	0.3922	21
PROH	PROH:16	propanediol:16:0.2941	0.2941	16
PROMM	PROMM:33	proximal myotonic myopathy:33:0.9100	0.9100	33
PROM	PROM:31	passive range of motion:31:0.7388	0.7388	31
PROM	PROM:8	premature rupture of membrane:8:0.4709	0.4709	8
PROM	PROM:145	premature rupture of the membranes:145:0.8471	0.8471	145
PROST	PROST:6	pronuclear stage tubal transfer:6:0.5290	0.5290	6
PROs	PROs:7	Patient-reported outcomes:7:0.3524	0.3524	7
Pro	Pro:15|PRO:2	L-proline:17:0.0291	0.0291	17
PRO	PRO:6|Pro:3	proestrus:9:0.0145	0.0145	9
PRO	PRO:7|Pro:3	progesterone:10:0.0164	0.0164	10
Pro	Pro:7|PRO:2	propafenone:9:0.0145	0.0145	9
PRO	PRO:38|Pro:19	propranolol:57:0.1018	0.1018	57
Pro	Pro:8|PRO:4|pro:3	protease:15:0.0255	0.0255	15
PRO	PRO:16	utilization and quality control peer review organization:16:0.7909	0.7909	16
PRP1	PRP1:5|PRP-1:3	proline-rich protein 1:8:0.5006	0.5006	8
PRPH	PRPH:15	recovery per hour:15:0.7096	0.7096	15
PRPP	PRPP:93	5-phosphoribosyl-1-pyrophosphate:61:0.2062|5-phosphoribosyl 1-pyrophosphate:32:0.8145	0.8145	93
PRPP	PRPP:11	alpha-D-5-phosphoribosyl-1-pyrophosphate:11:0.0344	0.0344	11
PRPP	PRPP:27	phosphoribosyl pyrophosphate:27:0.7505	0.7505	27
PRPP	PRPP:91	phosphoribosylpyrophosphate:91:0.3093	0.3093	91
PRP-T	PRP-T:21	conjugate vaccine:21:0.5435	0.5435	21
PRP-T	PRP-T:1	conjugated with tetanus toxoid:1:0.5355	0.5355	1
PRP-T	PRP-T:22	toxoid conjugate:22:0.5327	0.5327	22
PRPs	PRPs:9	penicillinase-resistant penicillins:9:0.6794	0.6794	9
PRPs	PRPs:70|PRPS:1	proline-rich proteins:71:0.7095	0.7095	71
PRP	PRP:10	Haemophilus influenzae type b capsular polysaccharide:10:0.7103	0.7103	10
PRP	PRP:7	PACAP-related peptide:7:0.1470	0.1470	7
PRP	PRP:73	panretinal photocoagulation:73:0.7690	0.7690	73
PRP	PRP:17	penicillin-resistant pneumococci:17:0.6211	0.6211	17
PRP	PRP:34	pityriasis rubra pilaris:34:0.9126	0.9126	34
PRP	PRP:1097|prp:2	platelet-rich plasma:788:0.6828|platelet rich plasma:294:0.9731|platelet-rich-plasma:17:0.0061	0.9731	1099
PRP	PRP:15	polyribosyl ribitol phosphate:15:0.7261	0.7261	15
PRP	PRP:30	polyribosylribitol phosphate:30:0.3228	0.3228	30
PRP	PRP:9	polyribosylribitolphosphate:9:0.0030	0.0030	9
PRP	PRP:30	pressure-rate product:16:0.2812|pressure rate product:14:0.8045	0.8045	30
PRP	PRP:39	primary Raynaud's phenomenon:39:0.9237	0.9237	39
PrP	PrP:749|Prp:1	prion protein:733:0.8701|prion proteins:17:0.2186	0.8701	750
PRP	PRP:31	proline-rich polypeptide:31:0.8519	0.8519	31
PRP	PRP:17	proline-rich proteins:17:0.2186	0.2186	17
PRP	PRP:29	psychological refractory period:29:0.8422	0.8422	29
PRP	PRP:10	pulmonary rehabilitation program:10:0.7103	0.7103	10
PRQ	PRQ:10	Personal Resource Questionnaire:10:0.5856	0.5856	10
PRQ	PRQ:6	pressure-rate quotient:6:0.2243	0.2243	6
PrRP	PrRP:60	prolactin-releasing peptide:60:0.5366	0.5366	60
PRRs	PRRs:24	pattern recognition receptors:15:0.5818|pattern-recognition receptors:9:0.1205	0.5818	24
PRRS	PRRS:157	porcine reproductive and respiratory syndrome:157:0.9809	0.9809	157
PRRT	PRRT:12	peptide receptor radionuclide therapy:12:0.7571	0.7571	12
PRR	PRR:12	parietal reach region:12:0.7571	0.7571	12
PRR	PRR:11	pattern recognition receptors:11:0.7357	0.7357	11
PRR	PRR:14	postreplication repair:14:0.2524	0.2524	14
PRR	PRR:21	proline-rich region:21:0.3317	0.3317	21
PRR	PRR:10	water proton relaxation rate:10:0.5000	0.5000	10
PRSp	PRSp:1	penicillin-resistant S pneumoniae:1:0.5315	0.5315	1
PRSP	PRSP:57	Penicillin-resistant Streptococcus pneumoniae:57:0.8097	0.8097	57
PRSS1	PRSS1:23	cationic trypsinogen:23:0.7500	0.7500	23
PRSS1	PRSS1:11	cationic trypsinogen gene:11:0.7357	0.7357	11
PRSV	PRSV:10	papaya ringspot virus:10:0.7103	0.7103	10
PRSW	PRSW:50	preload recruitable stroke work:50:0.8776	0.8776	50
PRS	PRS:7	Parry-Romberg syndrome:7:0.0539	0.0539	7
PRs	PRs:26	partial remissions:26:0.8861	0.8861	26
PRs	PRs:195|PRS:1	partial responses:196:0.9529	0.9529	196
PRS	PRS:8	phosphoribosylpyrophosphate synthetase:8:0.1471	0.1471	8
PRS	PRS:13	photon radiosurgery system:13:0.7753	0.7753	13
PRS	PRS:15	Pierre Robin Sequence:15:0.8045	0.8045	15
PRS	PRS:36	plasma renin substrate:36:0.8336	0.8336	36
PRS	PRS:7	Postreperfusion syndrome:7:0.0539	0.0539	7
PRS	PRS:7	postribosomal supernatant:7:0.2902	0.2902	7
PRs	PRs:138|prs:1	pregnancy rates:139:0.8269	0.8269	139
PRs	PRs:11	proteases:11:0.0114	0.0114	11
PRS	PRS:13	Rating Scale:13:0.3134	0.3134	13
pRTA	pRTA:8|PRTA:2	proximal renal tubular acidosis:10:0.7103	0.7103	10
PRTH	PRTH:8	pituitary resistance:8:0.5006	0.5006	8
PRTH	PRTH:11	pituitary resistance to thyroid hormone:11:0.5664	0.5664	11
PRTase	PRTase:9	phosphoribosyltransferase:9:0.8000	0.8000	9
PRT	PRT:43	photoradiation therapy:43:0.5411	0.5411	43
PRT	PRT:12	plasma recalcification time:12:0.7571	0.7571	12
PRT	PRT:19	progressive resistance training:19:0.7658	0.7658	19
Prt	Prt:14|PRT:2|prt:2	protease:18:0.0599	0.0599	18
PRT	PRT:9	Proton radiation therapy:9:0.2757	0.2757	9
PRT	PRT:12|pRT:1	radiotherapy:13:0.0423	0.0423	13
PRU	PRU:11	peripheral resistance units:11:0.7357	0.7357	11
PRV-1	PRV-1:9	rubra vera-1:9:0.6794	0.6794	9
pRV/LV	pRV/LV:4|PRV/LV:4|P-RV/LV:1	pressure ratio:9:0.6794	0.6794	9
PRVEPs	PRVEPs:5|PR-VEPs:4	pattern reversal visual evoked potentials:9:0.6794	0.6794	9
PRVEP	PRVEP:3|PR-VEP:2	pattern reversal visual evoked potential:5:0.4422	0.4422	5
PR-VEP	PR-VEP:7|PRVEP:5|prVEP:1	Visual Evoked Potentials:13:0.7753	0.7753	13
PrV	PrV:16	nucleus principalis:16:0.6577	0.6577	16
PrV	PrV:8	principal sensory nucleus:8:0.6411	0.6411	8
PRV	PRV:622|PrV:184	pseudorabies virus:806:0.9607	0.9607	806
PRV	PRV:30	rubra vera:30:0.8472	0.8472	30
PRW	PRW:11	polymerized ragweed:11:0.7357	0.7357	11
PRWORA	PRWORA:9	Personal Responsibility and Work Opportunity Reconciliation Act:9:0.6794	0.6794	9
Prxs	Prxs:28|prxs:1|PRXs:1|PRxs:1	Peroxiredoxins:31:0.8824	0.8824	31
Prx	Prx:50|prx:2|PRx:2|PRX:1	peroxiredoxin:45:0.4632|peroxiredoxins:10:0.0947	0.4632	55
PRZ	PRZ:10|Prz:1	Pirenzepine:11:0.3846	0.3846	11
P-Rh*	P-Rh*:10|PRh*:1	rhodopsin:11:0.7692	0.7692	11
P-Rib-PP	P-Rib-PP:3|PRibPP:1|PRib-PP:1	5-phosphoribosyl 1-pyrophosphate:5:0.1132	0.1132	5
PR	PR:22	expression of pathogenesis-related:22:0.0858	0.0858	22
Pr	Pr:6	form of phytochrome:6:0.2243	0.2243	6
PR	PR:9	Paeoniae radix:9:0.3455	0.3455	9
PR	PR:9	pain relief:9:0.3455	0.3455	9
PR	PR:7	panoramic radiography:7:0.1329	0.1329	7
PR	PR:9	pars recta:9:0.5470	0.5470	9
PR	PR:9	partial regression:9:0.3455	0.3455	9
PR	PR:624	partial remission:541:0.9776|partial remissions:83:0.9429	0.9776	624
PR	PR:26	partial responders:26:0.6351	0.6351	26
PR	PR:1520|pr:1	partial response:1260:0.9604|partial responses:261:0.9184	0.9604	1521
PR	PR:8	passive recovery:8:0.2327	0.2327	8
PR	PR:9	pattern recognition:9:0.5470	0.5470	9
PR	PR:9|pr:2	pattern reversal:11:0.6182	0.6182	11
PR	PR:22	peripheral resistance:22:0.3561	0.3561	22
PR	PR:9	perirenal:9:0.0011	0.0011	9
PR	PR:9	perirhinal cortex:9:0.6794	0.6794	9
PR	PR:17	phenol red:17:0.5038	0.5038	17
PR	PR:20	Photoreactivation:20:0.0025	0.0025	20
PR	PR:25	pityriasis rosea:25:0.8816	0.8816	25
PR	PR:5	placental restriction:5:0.0517	0.0517	5
PR	PR:9	Plain radiography:9:0.2500	0.2500	9
PR	PR:10	plaque reduction:10:0.4363	0.4363	10
PR	PR:9	pneumatic retinopexy:9:0.6794	0.6794	9
PR	PR:15	polymorphic reticulosis:15:0.4951	0.4951	15
Pr	Pr:8|PR:2	prealbumin:10:0.0012	0.0012	10
Pr	Pr:11|PR:6	prednisolone:17:0.0021	0.0021	17
PR	PR:193	pregnancy rate:170:0.3369|pregnancy rates:23:0.2679	0.3369	193
Pr	Pr:6|PR:3	pregnant:9:0.0011	0.0011	9
PR	PR:57	prevalence ratio:46:0.1742|Prevalence ratios:11:0.4728	0.4728	57
PR	PR:94	progressive ratio:94:0.4146	0.4146	94
PR	PR:33	Projection reconstruction:33:0.8605	0.8605	33
PR	PR:10|pr:1	proliferative retinopathy:11:0.6182	0.6182	11
PR	PR:5|Pr:4	proline-rich:9:0.0011	0.0011	9
PR	PR:29|Pr:11	propranolol:40:0.0052	0.0052	40
PR	PR:10|pr:1	prorenin:11:0.0013	0.0013	11
PR	PR:10|Pr:8|-Pr:1	protein:19:0.0027	0.0027	19
PR	PR:6	protein restriction:6:0.1148	0.1148	6
PR	PR:12	pseudorabies:12:0.0015	0.0015	12
PR	PR:14	Puerto Rico:14:0.7909	0.7909	14
PR	PR:50	pulmonary regurgitation:50:0.8285	0.8285	50
PR	PR:27	pulmonary rehabilitation:27:0.8903	0.8903	27
PR	PR:12	reaction:12:0.0015	0.0015	12
PR	PR:11	region:11:0.0013	0.0013	11
PR	PR:10|Pr:6	Release:16:0.0020	0.0020	16
Pr	Pr:6|pr:1	release probability:7:0.5470	0.5470	7
PR	PR:9	retention:9:0.0011	0.0011	9
PR	PR:11	under a progressive-ratio:11:0.1650	0.1650	11
PR	PR:10	viral proteinase:10:0.1273	0.1273	10
PS/PC	PS/PC:12	phosphatidylserine/phosphatidylcholine:12:0.7333	0.7333	12
PS1	PS1:348|PS-1:155|Ps1:2	presenilin 1:260:0.9095|presenilin-1:245:0.4053	0.9095	505
PS-1	PS-1:5|PS1:5	presenilin-1 gene:10:0.3470	0.3470	10
PSA-ACT	PSA-ACT:5	alpha 1-antichymotrypsin:5:0.1132	0.1132	5
PSACH	PSACH:49	pseudoachondroplasia:49:0.9600	0.9600	49
PSADT	PSADT:18|PSA-DT:5	PSA doubling time:23:0.5095	0.5095	23
PSAD	PSAD:42	prostate-specific antigen density:21:0.3130|prostate specific antigen density:21:0.7865	0.7865	42
PSAD	PSAD:88|PSAd:2|PSA-D:1	PSA density:91:0.6002	0.6002	91
PSARP	PSARP:34	Posterior sagittal anorectoplasty:34:0.9126	0.9126	34
PSA-TZ	PSA-TZ:9|PSATZ:2	transition zone:11:0.7357	0.7357	11
PSAV	PSAV:10	PSA velocity:10:0.5335	0.5335	10
PSAS	PSAS:9	Psychiatric Symptom Assessment Scale:9:0.6794	0.6794	9
PSAs	PSAs:27	public service announcements:27:0.8903	0.8903	27
PSA	PSA:17	activity:17:0.0023	0.0023	17
PSA	PSA:12	Antigens:12:0.0016	0.0016	12
PSA	PSA:16	biochemical:16:0.0022	0.0022	16
PSA	PSA:15	persistent sciatic artery:15:0.8045	0.8045	15
PSA	PSA:21	Pisum sativum:21:0.8594	0.8594	21
PSA	PSA:33|PsA:1	Pisum sativum agglutinin:34:0.7898	0.7898	34
PSA	PSA:15	polar surface area:15:0.5818	0.5818	15
PSA	PSA:138	polysialic acid:138:0.7401	0.7401	138
PSA	PSA:17	population spike amplitude:17:0.8270	0.8270	17
PSA	PSA:10	porcine serum albumin:10:0.4363	0.4363	10
PSA	PSA:12	potentiometric stripping analysis:12:0.6460	0.6460	12
PSA	PSA:53	Power spectral analysis:53:0.9438	0.9438	53
PSA	PSA:11	pressure sensitive adhesive:6:0.3728|pressure-sensitive adhesive:5:0.0517	0.3728	11
PSA	PSA:5404	prostate-specific antigen:3497:0.6036|prostate specific antigen:1907:0.8986	0.8986	5404
PsA	PsA:315|PSA:9	psoriatic arthritis:324:0.9802	0.9802	324
PSA	PSA:15	puromycin-sensitive aminopeptidase:15:0.7096	0.7096	15
Psa	Psa:19|PSA:4	systemic arterial pressure:23:0.7046	0.7046	23
PSBP	PSBP:8	steroid binding protein:8:0.6411	0.6411	8
PSB	PSB:72	protected specimen brush:72:0.9344	0.9344	72
PSB	PSB:10	protected specimen brushing:10:0.7103	0.7103	10
PSB	PSB:15|pSB:1	protonated Schiff base:16:0.8165	0.8165	16
PSCC	PSCC:8	squamous cell carcinoma:8:0.6411	0.6411	8
PscO2	PscO2:6	subcutaneous oxygen tension:6:0.2827	0.2827	6
PSCP	PSCP:14	papillary serous carcinoma of the peritoneum:14:0.7909	0.7909	14
PSCT	PSCT:30|-PSCT:1	peripheral stem cell transplantation:31:0.6343	0.6343	31
PSCs	PSCs:49	pancreatic stellate cells:49:0.9046	0.9046	49
PSCs	PSCs:15	perisynaptic Schwann cells:15:0.7096	0.7096	15
PSCs	PSCs:12	posterior subcapsular cataracts:12:0.7571	0.7571	12
PSCs	PSCs:46	postsynaptic currents:46:0.8151	0.8151	46
PSC	PSC:4	Echinococcus granulosus protoscoleces:4:0.1618	0.1618	4
PSC	PSC:8	pancreatic stellate cells:8:0.2090	0.2090	8
PSC	PSC:26	Pediatric Symptom Checklist:26:0.6645	0.6645	26
PSC	PSC:10	peripheral blood stem cell:10:0.7103	0.7103	10
PSC	PSC:13	platelet shape change:13:0.7753	0.7753	13
PSC	PSC:11	posterior semicircular canal:11:0.7357	0.7357	11
Psc	Psc:15|PSC:2	Posterior sex combs:17:0.8270	0.8270	17
PSC	PSC:37	posterior subcapsular:37:0.8749	0.8749	37
PSC	PSC:47	posterior subcapsular cataract:34:0.9126|posterior subcapsular cataracts:13:0.7753	0.9126	47
PSC	PSC:8	postsynaptic current:8:0.5006	0.5006	8
PSC	PSC:535	Primary sclerosing cholangitis:535:0.9910	0.9910	535
PSC	PSC:12	SDZ PSC 833:12:0.5050	0.5050	12
PSC	PSC:21	stem cells:21:0.2677	0.2677	21
PSD-95	PSD-95:20|PSD95:3	postsynaptic density-95:23:0.6537	0.6537	23
PSD-95	PSD-95:11|PSD95:4	postsynaptic density protein 95:15:0.6386	0.6386	15
PSDA	PSDA:37	Patient Self-Determination Act:37:0.9197	0.9197	37
PSDC	PSDC:13	postsynaptic dorsal column:13:0.5335	0.5335	13
PS-DVB	PS-DVB:8|PSDVB:3	poly(styrene-divinylbenzene):11:0.3571	0.3571	11
PS-DVB	PS-DVB:11	polystyrene-divinylbenzene:11:0.3571	0.3571	11
PSDs	PSDs:89|psds:1	postsynaptic densities:90:0.8168	0.8168	90
PSDs	PSDs:9	Presynaptic dendrites:9:0.6794	0.6794	9
PSD	PSD:10	dementia:10:0.0097	0.0097	10
PSD	PSD:39	paradoxical sleep deprivation:39:0.4710	0.4710	39
PSD	PSD:24	partial sleep deprivation:24:0.2394	0.2394	24
PSD	PSD:31	particle size distribution:31:0.7782	0.7782	31
PSD	PSD:28	periodic synchronous discharge:16:0.8165|periodic synchronous discharges:12:0.7571	0.8165	28
PSD	PSD:6|Psd:1|psd:1	phosphatidylserine decarboxylase:8:0.5006	0.5006	8
PSD	PSD:109	post-source decay:87:0.5867|post source decay:22:0.7955	0.7955	109
PSD	PSD:29	post-stroke depression:29:0.3515	0.3515	29
PSD	PSD:5	poststenotic dilatation:5:0.1132	0.1132	5
PSD	PSD:24	poststroke depression:24:0.2681	0.2681	24
PSD	PSD:230|psd:1	postsynaptic density:211:0.6178|postsynaptic densities:20:0.4379	0.6178	231
PSD	PSD:79|psd:2	power spectral density:74:0.9596|Power spectral densities:7:0.5926	0.9596	81
P-Ser	P-Ser:4|pSer:3|p-ser:2|p-Ser:1|Pser:1|P-ser:1	phosphoserine:12:0.4783	0.4783	12
PSE	PSE:44	partial splenic embolization:44:0.9323	0.9323	44
PSE	PSE:7	Photosensitive epilepsy:7:0.2113	0.2113	7
PSE	PSE:12	point of subjective equality:12:0.7753	0.7753	12
PSE	PSE:71	portal-systemic encephalopathy:53:0.4677|portal systemic encephalopathy:18:0.8365	0.8365	71
PSE	PSE:112	Present State Examination:112:0.9575	0.9575	112
PSE	PSE:47	proximal sequence element:47:0.9353	0.9353	47
PSFV	PSFV:14	peak systolic flow velocity:14:0.7909	0.7909	14
PSF	PSF:9	peak systolic frequency:9:0.6794	0.6794	9
PSF	PSF:126|psf:5	point spread function:98:0.9695|point-spread function:33:0.1665	0.9695	131
PSF	PSF:10	polypyrimidine tract-binding protein-associated splicing factor:10:0.5856	0.5856	10
PSf	PSf:15|PSF:11|Psf:1	polysulfone:27:0.0594	0.0594	27
PSF	PSF:6	post-spike facilitation:6:0.0899	0.0899	6
PSF	PSF:9	postspike facilitation:9:0.2757	0.2757	9
Psf	Psf:8|PSF:4|psf:1	proximal tubular stop-flow pressure:13:0.5934	0.5934	13
PSGAG	PSGAG:11	polysulfated glycosaminoglycan:11:0.4232	0.4232	11
PSGL-1	PSGL-1:174|PSGL1:1	P-selectin glycoprotein ligand-1:142:0.9361|P-selectin glycoprotein ligand 1:33:0.8196	0.9361	175
PSGN	PSGN:31|P-SGN:1	poststreptococcal glomerulonephritis:32:0.5509	0.5509	32
PSGs	PSGs:14	polysomnograms:14:0.3095	0.3095	14
PSGs	PSGs:14	pregnancy-specific glycoproteins:14:0.6173	0.6173	14
PSG	PSG:7	peak systolic gradient:7:0.4438	0.4438	7
PSG	PSG:6	peak systolic pressure gradient:6:0.5290	0.5290	6
PSG	PSG:25	polysomnogram:25:0.0372	0.0372	25
PSG	PSG:52|psg:1	polysomnographic:53:0.0806	0.0806	53
PSG	PSG:331	polysomnography:331:0.5116	0.5116	331
PSG	PSG:9|psg:1	posterior silk gland:10:0.7103	0.7103	10
PSG	PSG:30|Psg:1	pregnancy-specific glycoprotein:26:0.6351|pregnancy-specific glycoproteins:5:0.0902	0.6351	31
PSG	PSG:4	prostate secretory granules:4:0.0918	0.0918	4
PSH	PSH:6	plasma thiol:6:0.0807	0.0807	6
PSH	PSH:18|P-SH:6	protein thiols:15:0.3262|protein thiol:9:0.2500	0.3262	24
PSIFT	PSIFT:32	platelet suspension immunofluorescence test:32:0.9072	0.9072	32
PSII	PSII:579|PS-II:7	photosystem II:586:0.9664	0.9664	586
PSIs	PSIs:11	Patient Safety Indicators:11:0.7357	0.7357	11
PSIS	PSIS:7	posterior superior iliac spine:7:0.5926	0.5926	7
PSK	PSK:20	polysaccharide K:20:0.8525	0.8525	20
PSK	PSK:28|PS-K:5	protein-bound polysaccharide:33:0.6976	0.6976	33
PSLs	PSLs:14	pigmented skin lesions:14:0.6911	0.6911	14
PSL	PSL:7	photostimulated luminescence:7:0.2452	0.2452	7
PSL	PSL:9	pigmented skin lesions:9:0.5470	0.5470	9
PSL	PSL:176	prednisolone:176:0.5570	0.5570	176
PSMA	PSMA:174	prostate-specific membrane antigen:136:0.6578|prostate specific membrane antigen:38:0.7758	0.7758	174
pSMC	pSMC:7|PSMC:4|p-SMC:1	smooth muscle cells:12:0.7571	0.7571	12
PSMF	PSMF:13	protein-sparing modified fast:13:0.5335	0.5335	13
PSM	PSM:6	porcine stomach mucin:6:0.5290	0.5290	6
PSM	PSM:4	porcine submaxillary mucin:4:0.0918	0.0918	4
PSM	PSM:42|psm:3	presomitic mesoderm:45:0.8649	0.8649	45
PSM	PSM:9	propagated sensation along meridians:9:0.6794	0.6794	9
PSNL	PSNL:17|pSNL:1	partial sciatic nerve ligation:18:0.8365	0.8365	18
PSNR	PSNR:7	Peak signal-to-noise ratio:7:0.5926	0.5926	7
PSN	PSN:6	pontosubicular necrosis:6:0.1010	0.1010	6
PSN	PSN:6	pontosubicular neuron necrosis:6:0.5290	0.5290	6
PSN	PSN:9	principal sensory nucleus of the trigeminal nerve:9:0.6794	0.6794	9
PSN	PSN:11	sensory neuropathy:11:0.6182	0.6182	11
PSN	PSN:8	splanchnic nerve:8:0.1276	0.1276	8
PS-OCT	PS-OCT:9|PSOCT:2	Polarization-sensitive optical coherence tomography:11:0.4728	0.4728	11
PSOs	PSOs:11	provider-sponsored organizations:11:0.4728	0.4728	11
PSO	PSO:10	particle swarm optimization:10:0.7103	0.7103	10
PSO	PSO:6	provider-sponsored organization:6:0.2243	0.2243	6
PSP94	PSP94:13|PSP-94:1	secretory protein of 94 amino acids:14:0.6911	0.6911	14
PSPB	PSPB:33|PSPb:1	Pregnancy-specific protein B:20:0.3744|pregnancy specific protein B:14:0.6911	0.6911	34
PSPMT	PSPMT:7	pulse-spray pharmacomechanical thrombolysis:7:0.3524	0.3524	7
PSPs	PSPs:174|psps:2|PSPS:1	Postsynaptic potentials:177:0.9068	0.9068	177
PSP	PSP:26	pancreatic spasmolytic polypeptide:26:0.7500	0.7500	26
PSP	PSP:24	pancreatic stone protein:24:0.7593	0.7593	24
PSP	PSP:34	paralytic shellfish poison:25:0.8816|Paralytic shellfish poisons:9:0.6794	0.8816	34
PSP	PSP:95	Paralytic shellfish poisoning:95:0.9685	0.9685	95
PSP	PSP:29	parotid secretory protein:29:0.5551	0.5551	29
PSP	PSP:19	peak systolic pressure:19:0.5732	0.5732	19
PSP	PSP:46	phenolsulfonphthalein:46:0.0288	0.0288	46
PSP	PSP:18	phenyl saligenin phosphate:18:0.7539	0.7539	18
PSP	PSP:13	phosphoserine phosphatase:13:0.5335	0.5335	13
PSP	PSP:11	photostimulable phosphor:11:0.3495	0.3495	11
PSP	PSP:11	polysaccharide peptide:11:0.3213	0.3213	11
PSP	PSP:6	polystyrene particles:6:0.2243	0.2243	6
PSP	PSP:61|psp:1	postsynaptic potential:55:0.6711|postsynaptic potentials:7:0.2113	0.6711	62
PSP	PSP:6	postsynaptic potentiation:6:0.1838	0.1838	6
PSP	PSP:45	primary spontaneous pneumothorax:45:0.9338	0.9338	45
PSP	PSP:662	progressive supranuclear palsy:662:0.9903	0.9903	662
PSP	PSP:40|psp:6|PsP:2	pseudopregnancy:48:0.0301	0.0301	48
PSP	PSP:23|psp:7	pseudopregnant:30:0.0186	0.0186	30
PSP	PSP:7|P-SP:1	silent period:8:0.4102	0.4102	8
PSQI	PSQI:87	Pittsburgh sleep quality index:87:0.8700	0.8700	87
PSQ	PSQ:27	Questionnaire:27:0.5200	0.5200	27
PSRO	PSRO:20	Professional Standards Review Organization:20:0.7766	0.7766	20
PSROs	PSROs:20	Professional Standards Review Organizations:20:0.8525	0.8525	20
PSR	PSR:10|PS-R:1	phosphatidylserine receptor:11:0.2040	0.2040	11
PSR	PSR:18	proliferative sickle retinopathy:18:0.8449	0.8449	18
PSR	PSR:19	protein synthesis rate:19:0.8449	0.8449	19
PSR	PSR:26	pulmonary stretch receptors:15:0.7096|pulmonary stretch receptor:11:0.7357	0.7357	26
PSSD	PSSD:11	Sensory Device:11:0.7357	0.7357	11
PSSM	PSSM:11	polysaccharide storage myopathy:11:0.7357	0.7357	11
PSSM	PSSM:8	scoring matrix:8:0.4102	0.4102	8
PSSP	PSSP:1	penicillin-susceptible S pneumoniae:1:0.4246	0.4246	1
PSST	PSST:9	Pressure Sore Status Tool:9:0.6794	0.6794	9
PSS	PSS:32	Perceived Stress Scale:32:0.7782	0.7782	32
PSS	PSS:6	phosphatidylserine synthase:6:0.1838	0.1838	6
PSS	PSS:33	physiological saline solution:33:0.7238	0.7238	33
PSS	PSS:121	physiological salt solution:121:0.7347	0.7347	121
PSs	PSs:23	polysaccharides:23:0.0140	0.0140	23
PSs	PSs:41	population spikes:41:0.9274	0.9274	41
PSS	PSS:44	portosystemic shunts:24:0.7151|portosystemic shunt:20:0.5568	0.7151	44
PSS	PSS:6	Portosystemic shunting:6:0.1010	0.1010	6
PSS	PSS:8	postsystolic shortening:8:0.2090	0.2090	8
PSs	PSs:20	presenilins:20:0.0121	0.0121	20
pSS	pSS:160|PSS:35|pSs:2|p-SS:1|P-SS:1	primary Sjogren's syndrome:199:0.9529	0.9529	199
pSS	pSS:10|PSS:3|P-SS:1	primary SS:14:0.6173	0.6173	14
PSS	PSS:26	progressive systemic scleroderma:26:0.6973	0.6973	26
PSS	PSS:465|pss:1	progressive systemic sclerosis:466:0.9605	0.9605	466
PSS	PSS:6	severity score:6:0.0807	0.0807	6
PSTH	PSTH:72|psth:2	time histogram:48:0.7595|time histograms:26:0.7340	0.7595	74
PSTI	PSTI:151	pancreatic secretory trypsin inhibitor:151:0.9580	0.9580	151
PSTT	PSTT:69	placental site trophoblastic tumor:69:0.9100	0.9100	69
PSTVd	PSTVd:83	potato spindle tuber viroid:83:0.9640	0.9640	83
PStV	PStV:10	peanut stripe virus:10:0.7103	0.7103	10
PSTV	PSTV:50	Potato spindle tuber viroid:50:0.9392	0.9392	50
PST	PST:42|Pst:5	pancreastatin:47:0.0593	0.0593	47
PST	PST:9	paroxysmal supraventricular tachycardia:9:0.6794	0.6794	9
PST	PST:7|P-ST:4	phenol ST:11:0.2972	0.2972	11
PST	PST:62|P-ST:2|pST:1	phenol sulfotransferase:65:0.9275	0.9275	65
PST	PST:10|P-ST:1	phenol sulphotransferase:11:0.6182	0.6182	11
PST	PST:26	phenolsulfotransferase:26:0.0322	0.0322	26
pst	pst:6|Pst:4|PST:1	phosphate-specific transport:11:0.2764	0.2764	11
pST	pST:75|PST:14|pst:1	porcine somatotropin:90:0.9664	0.9664	90
pST	pST:7	porcine ST:7:0.1025	0.1025	7
PST	PST:7|pst:1	post-stimulus time:8:0.0548	0.0548	8
PST	PST:8	Poststimulus time:8:0.0548	0.0548	8
PST	PST:9	primary systemic therapy:9:0.6794	0.6794	9
PST	PST:79	proximal straight tubules:43:0.8590|proximal straight tubule:36:0.8716	0.8716	79
Pst	Pst:1	Pseudomonas syringae pv tomato:1:0.8657	0.8657	1
Pst	Pst:7	recoil pressure:7:0.2902	0.2902	7
PST	PST:10	survival time:10:0.0929	0.0929	10
PSUD	PSUD:16	Psychoactive Substance Use Disorder:16:0.8165	0.8165	16
PSUDs	PSUDs:9	psychoactive substance use disorders:9:0.6794	0.6794	9
PSVT	PSVT:166	paroxysmal supraventricular tachycardia:166:0.9368	0.9368	166
PSVs	PSVs:12	peak systolic velocities:12:0.7571	0.7571	12
PSV	PSV:9	Peak systolic:9:0.6794	0.6794	9
PSV	PSV:284	peak systolic velocity:274:0.9712|peak systolic velocities:10:0.7103	0.9712	284
PSV	PSV:9	peanut stunt virus:9:0.6794	0.6794	9
PSV	PSV:144	pressure support ventilation:144:0.9792	0.9792	144
PSV	PSV:12	primary systemic vasculitides:12:0.7571	0.7571	12
PSV	PSV:12	proximal selective vagotomy:12:0.7571	0.7571	12
PsV	PsV:7|PSV:2	psoriasis vulgaris:9:0.6794	0.6794	9
PSV	PSV:6	seminal vesicles:6:0.1838	0.1838	6
PSWCs	PSWCs:8	Periodic sharp wave complexes:8:0.6411	0.6411	8
PSWQ	PSWQ:23	Penn State Worry Questionnaire:23:0.8715	0.8715	23
PSW	PSW:5|pSW:2	positive Slow Wave:7:0.5926	0.5926	7
PSbMV	PSbMV:6	pea seed-borne mosaic potyvirus:6:0.5290	0.5290	6
PSbMV	PSbMV:9	pea seed-borne mosaic virus:9:0.6794	0.6794	9
PS	PS:5|ps:1	capillary diffusion capacity:6:0.2827	0.2827	6
PS	PS:40|Ps:4	capsular polysaccharide:36:0.1534|capsular polysaccharides:8:0.0625	0.1534	44
PS	PS:13	contractile properties analyzed included peak shortening:13:0.7753	0.7753	13
PS	PS:6	Drosophila position-specific:6:0.1641	0.1641	6
PS	PS:10	mutations in the presenilin:10:0.1127	0.1127	10
PS	PS:11	pachytene spermatocytes:11:0.5355	0.5355	11
PS	PS:12|P-S:4	Palmaz-Schatz:16:0.0021	0.0021	16
PS	PS:444	paradoxical sleep:444:0.9506	0.9506	444
ps	ps:14|PS:4	parallel-stranded:18:0.0024	0.0024	18
PS	PS:12	partial seizures:12:0.2699	0.2699	12
PS	PS:31	pathologic stage:31:0.4852	0.4852	31
PS	PS:13|ps:1	pathological stage:14:0.1425	0.1425	14
PS	PS:17	peak slope:17:0.8270	0.8270	17
PS	PS:10	pentasaccharide:10:0.0013	0.0013	10
PS	PS:464	performance status:464:0.9656	0.9656	464
PS	PS:6	peritoneal sclerosis:6:0.2243	0.2243	6
Ps	Ps:12|PS:5|P-s:1	permeability:18:0.0024	0.0024	18
PS	PS:58	permeability-surface area:47:0.5089|permeability surface area:11:0.2972	0.5089	58
PS	PS:165	permeability-surface area product:87:0.5155|permeability surface area product:39:0.7860|permeability-surface area products:26:0.4574|permeability surface area products:13:0.5934	0.7860	165
PS	PS:10	phosphatidyl-L-serine:10:0.0013	0.0013	10
PS	PS:92	phosphatidyl serine:79:0.8443|phosphatidyl-serine:13:0.0017	0.8443	92
PS	PS:1532|pS:2	phosphatidylserine:1518:0.2128|phosphatidylserines:16:0.0021	0.2128	1534
PS	PS:17	photic stimulation:17:0.2695	0.2695	17
PS	PS:29	photosensitizer:18:0.0024|photosensitizers:11:0.0014	0.0024	29
PS	PS:10	photostimulation:10:0.0013	0.0013	10
PS	PS:122	photosystem:122:0.0169	0.0169	122
PS	PS:14	physiological saline:14:0.5111	0.5111	14
PS	PS:14	phytosterols:14:0.0018	0.0018	14
ps	ps:9	picosecond:9:0.0011	0.0011	9
pS	pS:27	picoSiemens:27:0.0036	0.0036	27
PS	PS:6	planar scintigraphy:6:0.0807	0.0807	6
PS	PS:209|Ps:1	polystyrene:210:0.0294	0.0294	210
PS	PS:65|Ps:1	polysulfone:66:0.0091	0.0091	66
PS	PS:26	Polysulphone:26:0.0035	0.0035	26
PS	PS:236	population spike:179:0.9644|population spikes:57:0.8920	0.9644	236
PS	PS:7|pS:2	porcine serum:9:0.1009	0.1009	9
PS	PS:6	porcine stable kidney:6:0.5290	0.5290	6
PS	PS:10|ps:1	power spectra:11:0.7357	0.7357	11
PS	PS:10	power spectrum:10:0.5856	0.5856	10
PS	PS:9	prednisolone:9:0.0011	0.0011	9
PS	PS:60	pregnenolone sulfate:60:0.4239	0.4239	60
PS	PS:9	pregnenolone sulphate:9:0.1492	0.1492	9
PS	PS:11	prenatal stress:11:0.2582	0.2582	11
PS	PS:11|P-S:4	prenatally stressed:15:0.8045	0.8045	15
PS	PS:5	preparatory signal:5:0.0736	0.0736	5
PS	PS:29	presenilins:29:0.0039	0.0039	29
Ps	Ps:25|PS:6	pressure:31:0.0042	0.0042	31
PS	PS:42	pressure support:42:0.8893	0.8893	42
PS	PS:9	primary snoring:9:0.6794	0.6794	9
PS	PS:15	primitive streak:15:0.8045	0.8045	15
PS	PS:12	principal sulcus:12:0.7571	0.7571	12
Ps	Ps:19|PS:5|pS:1|ps:1	probability of survival:26:0.5218	0.5218	26
PS	PS:43|Ps:1	protamine sulfate:44:0.2864	0.2864	44
PS	PS:10	protamine sulphate:10:0.1878	0.1878	10
PS	PS:36|ps:1	protein synthesis:37:0.7246	0.7246	37
PS	PS:15|Ps:11	psoriasis:26:0.0035	0.0035	26
PS	PS:8	psychogenic seizures:8:0.1125	0.1125	8
PS	PS:11	pubertal spurt:11:0.7357	0.7357	11
PS	PS:13	pulmonary sequestration:13:0.6701	0.6701	13
PS	PS:70	pulmonary stenosis:70:0.5242	0.5242	70
PS	PS:38	pulmonary surfactant:38:0.8417	0.8417	38
PS	PS:9	pyloric sphincter:9:0.6794	0.6794	9
PS	PS:6	pyriform sinus:6:0.1320	0.1320	6
PS	PS:11|P-S:2	pyrimethamine-sulfadoxine:13:0.0017	0.0017	13
PS	PS:16	scale:16:0.0021	0.0021	16
PS	PS:61|Ps:1	score:48:0.0066|scores:14:0.0018	0.0066	62
PS	PS:9|P-S:2	sensitivity:11:0.0014	0.0014	11
PS	PS:15	solution:15:0.0020	0.0020	15
PS	PS:13	space:13:0.0017	0.0017	13
PS	PS:10	symptoms:10:0.0013	0.0013	10
PS	PS:77	syndrome:77:0.0106	0.0106	77
PS	PS:12	system:12:0.0015	0.0015	12
Ps	Ps:10|PS:5	systolic:15:0.0020	0.0020	15
PTA2	PTA2:8	Pinane thromboxane A2:8:0.6411	0.6411	8
PTAH	PTAH:34	phosphotungstic acid hematoxylin:21:0.8594|phosphotungstic acid-hematoxylin:13:0.7753	0.8594	34
PTAV	PTAV:11	aortic valvuloplasty:11:0.7357	0.7357	11
PTAs	PTAs:9	pure-tone averages:9:0.6794	0.6794	9
PTBD	PTBD:112	percutaneous transhepatic biliary drainage:112:0.9310	0.9310	112
PTB	PTB:7	patellar tendon bearing:7:0.4438	0.4438	7
PTB	PTB:15	Pentobarbital:15:0.0201	0.0201	15
Ptb	Ptb:4|PTB:4|ptb:2	phosphotransbutyrylase:10:0.0129	0.0129	10
PTB	PTB:151	phosphotyrosine binding:86:0.7786|Phosphotyrosine-binding:65:0.0918	0.7786	151
PTB	PTB:6	phosphotyrosine-binding domain:6:0.1838	0.1838	6
PTB	PTB:111|Ptb:1	polypyrimidine tract binding protein:58:0.7954|polypyrimidine tract-binding protein:54:0.8401	0.8401	112
PTB	PTB:24	preterm birth:24:0.8768	0.8768	24
PTB	PTB:20|pTB:1	pulmonary TB:21:0.8594	0.8594	21
PTB	PTB:193|PTb:2|pTB:1|P-TB:1	pulmonary tuberculosis:197:0.9534	0.9534	197
PTCA	PTCA:10	percutaneous transluminal coronary angiography:10:0.4363	0.4363	10
PTCA	PTCA:2775	percutaneous transluminal coronary angioplasty:2763:0.9829|Percutaneous Transluminal Coronary Angioplasties:12:0.7571	0.9829	2775
PTCA	PTCA:18	pyrrole-2,3,5-tricarboxylic acid:18:0.4672	0.4672	18
PTCD	PTCD:13	percutaneous transhepatic cholangio-drainage:13:0.7753	0.7753	13
PTCD	PTCD:16	percutaneous transhepatic cholangiodrainage:16:0.8165	0.8165	16
PTCER	PTCER:11	pulmonary transcapillary escape rate:11:0.7357	0.7357	11
PTCLs	PTCLs:22	peripheral T-cell lymphomas:22:0.8657	0.8657	22
PTCL	PTCL:107	peripheral T-cell lymphoma:75:0.9370|peripheral T-cell lymphomas:32:0.8145	0.9370	107
PTCP	PTCP:10	pseudothrombocytopenia:10:0.5625	0.5625	10
PTCR	PTCR:15	percutaneous transluminal coronary recanalization:15:0.8045	0.8045	15
PTCR	PTCR:7	percutaneous transluminal coronary revascularization:7:0.5926	0.5926	7
PTCH	PTCH:9	PATCHED gene:9:0.4587	0.4587	9
PTCs	PTCs:34	papillary thyroid carcinomas:34:0.8644	0.8644	34
PTCS	PTCS:43	percutaneous transhepatic cholangioscopy:43:0.9291	0.9291	43
PTCs	PTCs:10	peritubular capillaries:10:0.7103	0.7103	10
PTCs	PTCs:29	Premature termination codons:29:0.6157	0.6157	29
PTCs	PTCs:14	proximal tubular cells:14:0.7909	0.7909	14
PTCs	PTCs:24	psychophysical tuning curves:24:0.7151	0.7151	24
PTC	PTC:9	ability to taste Phenylthiocarbamide:9:0.3945	0.3945	9
PTC	PTC:19	papillary:19:0.0129	0.0129	19
PTC	PTC:55	papillary thyroid cancer:46:0.9353|papillary thyroid cancers:9:0.6794	0.9353	55
PTC	PTC:272	papillary thyroid carcinoma:222:0.9464|papillary thyroid carcinomas:50:0.9404	0.9464	272
PTC	PTC:21	Peptichemio:21:0.0143	0.0143	21
PTC	PTC:31	peritubular capillaries:20:0.8525|peritubular capillary:11:0.7357	0.8525	31
PTC	PTC:5	phase transition curve:5:0.4422	0.4422	5
PTC	PTC:17	phenylthiocarbamyl:17:0.0114	0.0114	17
PTC	PTC:8|PtC:6	phosphatidylcholine:14:0.0093	0.0093	14
Pt-C	Pt-C:9	platinum-carbon:9:0.0057	0.0057	9
PTC	PTC:10	plugged telescoping catheter:10:0.7103	0.7103	10
PTC	PTC:16	Portal triad clamping:16:0.8165	0.8165	16
PTC	PTC:21	post-tetanic count:21:0.3767	0.3767	21
PTC	PTC:13	posttetanic count:13:0.1704	0.1704	13
PTC	PTC:19	premature termination codon:19:0.8449	0.8449	19
PTC	PTC:39	proximal tubular cells:30:0.9011|proximal tubular cell:9:0.6794	0.9011	39
PTC	PTC:38	proximal tubule cells:28:0.8941|proximal tubule cell:10:0.7103	0.8941	38
PTC	PTC:49	pseudotumor cerebri:49:0.7455	0.7455	49
PTC	PTC:6	tuning curve:6:0.1543	0.1543	6
PtdA	PtdA:7	phosphatidic acid:7:0.3524	0.3524	7
PTDM	PTDM:75	diabetes mellitus:75:0.9602	0.9602	75
PTD	PTD:10	Arrow-Trerotola percutaneous thrombolytic device:10:0.5000	0.5000	10
PTD	PTD:9	peak tension developed:9:0.6794	0.6794	9
PTD	PTD:10	percutaneous transhepatic drainage:10:0.7103	0.7103	10
PTD	PTD:8	Percutaneous transluminal dilatation:8:0.6411	0.6411	8
PTD	PTD:16	persistent trophoblastic disease:16:0.5564	0.5564	16
PTD	PTD:7	Post-tetanic depression:7:0.1470	0.1470	7
PTD	PTD:37	preterm delivery:37:0.7758	0.7758	37
PTD	PTD:17	Primary torsion dystonia:17:0.7407	0.7407	17
PTD	PTD:49	protein transduction domain:39:0.8811|Protein transduction domains:10:0.7103	0.8811	49
PTD	PTD:21	pyrithiamine-induced thiamine deficiency:21:0.8594	0.8594	21
PTEC	PTEC:62	proximal tubular epithelial cells:56:0.9467|proximal tubular epithelial cell:6:0.5290	0.9467	62
PTECs	PTECs:18|pTECs:1	proximal tubular epithelial cells:19:0.7658	0.7658	19
PTEN	PTEN:15	phosphatase and tensin homolog:15:0.6386	0.6386	15
PTEN	PTEN:9	phosphatase and tensin homolog deleted on chromosome 10:9:0.8165	0.8165	9
PTEN	PTEN:7	phosphatase and tensin homolog deleted on chromosome ten:7:0.7103	0.7103	7
PTEN	PTEN:7	phosphatase and tensin homologue:7:0.6794	0.6794	7
PTE	PTE:48	parathyroid extract:48:0.8221	0.8221	48
PTE	PTE:21	phosphotriesterase:21:0.0480	0.0480	21
PTE	PTE:11	post-transplant erythrocytosis:11:0.1131	0.1131	11
PTE	PTE:7	post-traumatic epilepsy:7:0.0732	0.0732	7
PTE	PTE:15	Posttransplant erythrocytosis:15:0.1992	0.1992	15
PTE	PTE:16	Posttraumatic epilepsy:16:0.4274	0.4274	16
PTE	PTE:133	pulmonary thromboembolism:133:0.9641	0.9641	133
PTE	PTE:38	pulmonary thromboendarterectomy:38:0.8417	0.8417	38
PTFE	PTFE:26	poly(tetrafluoroethylene):26:0.0201	0.0201	26
PTFE	PTFE:9	polytetraflouroethylene:9:0.0064	0.0064	9
PTFE	PTFE:59	Polytetrafluorethylene:59:0.0483	0.0483	59
PTFE	PTFE:1016|pTFE:1	polytetrafluoroethylene:1017:0.8174	0.8174	1017
PTF	PTF:14	patient treatment file:14:0.7909	0.7909	14
PTF	PTF:25	pentoxifylline:25:0.1558	0.1558	25
PTF	PTF:13	primary tissue failure:13:0.7753	0.7753	13
PTF	PTF:10	tissue fraction:10:0.7103	0.7103	10
PTGBD	PTGBD:10	percutaneous transhepatic gallbladder drainage:10:0.7103	0.7103	10
PTGC	PTGC:7	Progressive transformation of germinal centers:7:0.4438	0.4438	7
PT-GVHD	PT-GVHD:9|PTGVHD:1	Post-transfusion graft-versus-host disease:10:0.3470	0.3470	10
PTGS	PTGS:98	post-transcriptional gene silencing:98:0.5644	0.5644	98
PTGS	PTGS:50	Posttranscriptional gene silencing:50:0.2483	0.2483	50
PTG	PTG:31	parathyroid gland:18:0.5940|parathyroid glands:13:0.5934	0.5940	31
pTg	pTg:7|PTg:1|pTG:1	porcine thyroglobulin:9:0.6794	0.6794	9
PTG	PTG:13	protein targeting to glycogen:13:0.7753	0.7753	13
PTHR1	PTHR1:9	receptor type 1:9:0.6794	0.6794	9
PTHi	PTHi:6|PTH-I:1	intact parathyroid hormone:7:0.3524	0.3524	7
PTHrP	PTHrP:242|PTHRP:29|PTH-rP:11|PTHrp:6|PTH-rp:5|PthrP:1|PTH-RP:1|PTHr-P:1|Pthrp:1	parathyroid hormone-related peptide:297:0.9388	0.9388	297
PTHrP	PTHrP:686|PTH-rP:43|PTHRP:20|PTHrp:7|PTH-rp:5|PTH-RP:2	parathyroid hormone-related protein:763:0.9805	0.9805	763
PTH	PTH:214	parathormone:214:0.0376	0.0376	214
PTH	PTH:20	parathyrin:20:0.0034	0.0034	20
PTH	PTH:20	parathyroid:20:0.0034	0.0034	20
PTH	PTH:4990|PTh:1|Pth:1	parathyroid hormone:4983:0.9890|parathyroid hormones:9:0.6794	0.9890	4992
PTH	PTH:4	parathyroid hormone 1-34:4:0.8165	0.8165	4
PTH	PTH:8	parathyroid hormone gene:8:0.6411	0.6411	8
PTH	PTH:11	parathyroid hormone levels:11:0.7357	0.7357	11
Pth	Pth:17|PTH:2	peptidyl-tRNA hydrolase:19:0.7044	0.7044	19
PTH	PTH:34|Pth:4	phenylthiohydantoin:38:0.0065	0.0065	38
PTH	PTH:7	post-tetanic hyperpolarization:7:0.1470	0.1470	7
PTH	PTH:40	post-transfusion hepatitis:40:0.4242	0.4242	40
PTH	PTH:6	Posttetanic hyperpolarization:6:0.0899	0.0899	6
PTH	PTH:20	posttransfusion hepatitis:20:0.1600	0.1600	20
Pth	Pth:9	pressure threshold:9:0.2757	0.2757	9
Pth	Pth:15|PTh:1	threshold pressure:16:0.7261	0.7261	16
PT-INR	PT-INR:8	normalized ratio:8:0.5006	0.5006	8
PTKs	PTKs:328	Protein tyrosine kinases:328:0.9594	0.9594	328
PTK	PTK:744	protein tyrosine kinase:630:0.9745|Protein tyrosine kinases:114:0.9205	0.9745	744
PTLA	PTLA:10	Percutaneous transluminal laser angioplasty:10:0.7103	0.7103	10
PTLD	PTLD:196	lymphoproliferative disease:196:0.9675	0.9675	196
PTLD	PTLD:310	lymphoproliferative disorder:221:0.9782|lymphoproliferative disorders:89:0.9296	0.9782	310
PTLDs	PTLDs:64	lymphoproliferative disorders:64:0.9534	0.9534	64
PT-LPDs	PT-LPDs:15|PTLPDs:3	lymphoproliferative disorders:18:0.8365	0.8365	18
PTMA	PTMA:9	phenyltrimethylammonium:9:0.3810	0.3810	9
PTMC	PTMC:97	percutaneous transvenous mitral commissurotomy:97:0.9685	0.9685	97
PTMR	PTMR:12	revascularization:12:0.6471	0.6471	12
PTMs	PTMs:24	post-translational modifications:24:0.4322	0.4322	24
PTMs	PTMs:12	posttranslational modifications:12:0.1379	0.1379	12
PTMV	PTMV:8	percutaneous transluminal mitral valvuloplasty:8:0.6411	0.6411	8
PTNs	PTNs:37|PTNS:2	pyramidal tract neurons:39:0.8811	0.8811	39
PTNs	PTNs:10	Pyramidal tract neurones:10:0.7103	0.7103	10
PTN	PTN:103|Ptn:2	Pleiotrophin:105:0.4643	0.4643	105
PTN	PTN:37	Posterior Tibial nerve:37:0.9197	0.9197	37
PTOX	PTOX:10	plastid terminal oxidase:10:0.5856	0.5856	10
PTO	PTO:9	percutaneous transhepatic obliteration:9:0.5470	0.5470	9
PTO	PTO:11	Person Trade-Off:11:0.6182	0.6182	11
PTO	PTO:6	portal triad occlusion:6:0.5290	0.5290	6
PTP1B	PTP1B:4|PTP-1B:1	protein tyrosine phosphatase:5:0.2818	0.2818	5
PTP1B	PTP1B:97|PTP-1B:30|ptp1b:1|Ptp1b:1	protein tyrosine phosphatase 1B:80:0.9219|protein-tyrosine phosphatase 1B:25:0.1354|protein tyrosine phosphatase-1B:24:0.8768	0.9219	129
PTPA	PTPA:10	phosphotyrosyl phosphatase activator:10:0.5856	0.5856	10
PTPC	PTPC:27	permeability transition pore complex:27:0.8903	0.8903	27
PTPE	PTPE:9	percutaneous transhepatic portal vein embolization:9:0.6794	0.6794	9
PTPase	PTPase:40	phosphotyrosine phosphatase:40:0.1041	0.1041	40
PTPase	PTPase:164|PT-Pase:1	protein tyrosine phosphatase:152:0.9230|protein tyrosine phosphatases:13:0.6701	0.9230	165
PTPS	PTPS:22	6-Pyruvoyl-tetrahydropterin synthase:13:0.1599|6-Pyruvoyl tetrahydropterin synthase:9:0.5470	0.5470	22
PTPS	PTPS:12	6-pyruvoyltetrahydropterin synthase:12:0.1379	0.1379	12
PTPs	PTPs:9	previously treated patients:9:0.6794	0.6794	9
PTPs	PTPs:217	protein tyrosine phosphatases:217:0.9638	0.9638	217
PTP	PTP:21	percutaneous transhepatic portography:21:0.8594	0.8594	21
PTP	PTP:150	permeability transition pore:150:0.9800	0.9800	150
PTP	PTP:13	phosphate transport protein:13:0.7753	0.7753	13
PTP	PTP:87	post-tetanic potentiation:87:0.4750	0.4750	87
PTP	PTP:46	post-transfusion purpura:46:0.5375	0.5375	46
PTP	PTP:59	Posttetanic potentiation:59:0.2965	0.2965	59
PTP	PTP:18	Posttransfusion purpura:18:0.1426	0.1426	18
pTP	pTP:2	precursor to terminal protein:2:0.6024	0.6024	2
PTP	PTP:34	pressure-time product:19:0.3582|pressure time product:15:0.8045	0.8045	34
pTP	pTP:22	preterminal protein:22:0.1817	0.1817	22
PTP	PTP:6	pretest probability:6:0.2243	0.2243	6
PTP	PTP:9	prohormone thiol protease:9:0.6794	0.6794	9
PTP	PTP:306	protein tyrosine phosphatase:214:0.9633|protein-tyrosine phosphatase:56:0.1345|protein tyrosine phosphatases:36:0.7433	0.9633	306
PTP	PTP:12	protein tyrosine phosphorylation:12:0.7571	0.7571	12
Ptp	Ptp:75|PTP:6	transpulmonary pressure:68:0.6355|transpulmonary pressures:13:0.6701	0.6701	81
PTR1	PTR1:12	pteridine reductase:12:0.5664	0.5664	12
PTRA	PTRA:97	percutaneous transluminal renal angioplasty:97:0.9510	0.9510	97
PTR-MS	PTR-MS:15|PTRMS:1	proton transfer reaction-mass spectrometry:11:0.7357|proton-transfer-reaction mass spectrometry:5:0.1464	0.7357	16
P-TR	P-TR:5|PTR:1	phagocytic cells of the thymic reticulum:6:0.5926	0.5926	6
PTR	PTR:14	pressure transmission ratio:14:0.7909	0.7909	14
PTR	PTR:11	prothrombin time ratio:11:0.7357	0.7357	11
Ptr	Ptr:9|ptr:1	tracheal:10:0.0381	0.0381	10
Ptr	Ptr:25|PTR:3|PTr:2	tracheal pressure:30:0.6484	0.6484	30
PTS2	PTS2:5	targeting signal type 2:5:0.2818	0.2818	5
PTSD	PTSD:805	post-traumatic stress disorder:794:0.2481|post-traumatic stress disorders:11:0.2582	0.2582	805
PTSD	PTSD:2125	posttraumatic stress disorder:2115:0.6906|posttraumatic stress disorders:10:0.2126	0.6906	2125
PTSMA	PTSMA:31	percutaneous transluminal septal myocardial ablation:31:0.9043	0.9043	31
PTSS-10	PTSS-10:5	Post Traumatic Symptom Scale:5:0.4422	0.4422	5
PTSS	PTSS:15	posttraumatic stress symptoms:15:0.5818	0.5818	15
pts	pts:1116|PTS:24|Pts:17|PTs:4	patients:1161:0.5206	0.5206	1161
PTS	PTS:28	Pediatric Trauma Score:28:0.8369	0.8369	28
PTS	PTS:75	permanent threshold shift:52:0.9099|permanent threshold shifts:23:0.8715	0.9099	75
PTS	PTS:13	peroxisomal targeting signal:13:0.3331	0.3331	13
PTS	PTS:9	peroxisome targeting signal:9:0.1585	0.1585	9
PTs	PTs:18	phage types:18:0.8365	0.8365	18
PTS	PTS:20|Pts:2	phosphotransferase:22:0.0094	0.0094	22
PTS	PTS:441|pts:4	phosphotransferase system:437:0.8949|phosphotransferase systems:8:0.5006	0.8949	445
PTs	PTs:7	phyllodes tumors:7:0.1641	0.1641	7
PTs	PTs:13	physical therapists:13:0.7753	0.7753	13
PTS	PTS:37	post-thrombotic syndrome:37:0.4015	0.4015	37
PTS	PTS:8	post-traumatic syringomyelia:8:0.2327	0.2327	8
PTS	PTS:22	postthrombotic syndrome:22:0.1936	0.1936	22
PTS	PTS:16	posttraumatic stress:16:0.5171	0.5171	16
PTs	PTs:18	prothrombin times:18:0.8365	0.8365	18
PTS	PTS:13	proximal tubular segments:13:0.7753	0.7753	13
PTs	PTs:20	proximal tubules:20:0.8525	0.8525	20
PTS	PTS:7	proximal tubule segments:7:0.5926	0.5926	7
PTTG	PTTG:53|pttg:3	pituitary tumor transforming gene:34:0.9126|pituitary tumor-transforming gene:22:0.8594	0.9126	56
PTTH	PTTH:85	prothoracicotropic hormone:85:0.9255	0.9255	85
PTTK	PTTK:10|PTT-K:1	partial thromboplastin time with kaolin:11:0.7357	0.7357	11
PTTs	PTTs:9	thresholds:9:0.2963	0.2963	9
PTT	PTT:10	2beta-propanoyl-3beta-(4-tolyl)-tropane:10:0.0135	0.0135	10
PTT	PTT:7	partial thromboplastin:7:0.3524	0.3524	7
PTT	PTT:16	posterior tibial tendon:16:0.8165	0.8165	16
PTT	PTT:109	protein truncation test:109:0.9726	0.9726	109
PTT	PTT:9	threshold:9:0.0120	0.0120	9
PTU	PTU:42	6-n-propyl-2-thiouracil:42:0.0524	0.0524	42
PTU	PTU:34	6-propyl-2-thiouracil:34:0.0422	0.0422	34
PTU	PTU:11	6-propylthiouracil:11:0.0128	0.0128	11
PTU	PTU:15	phenylthiourea:15:0.0179	0.0179	15
PTU	PTU:592	propylthiouracil:592:0.7532	0.7532	592
PTVs	PTVs:7	Periotest values:7:0.2452	0.2452	7
PTV	PTV:17	patient triggered ventilation:17:0.8270	0.8270	17
PTV	PTV:11|PTv:1	Periotest values:12:0.7571	0.7571	12
PTV	PTV:281	planning target volume:268:0.9284|planning target volumes:13:0.7753	0.9284	281
PTV	PTV:15	Punta Toro virus:15:0.8045	0.8045	15
PTWI	PTWI:43	Provisional Tolerable Weekly Intake:43:0.8590	0.8590	43
Ptx1	Ptx1:4|PTX1:1|Ptx-1:1	Pituitary homeobox 1:6:0.5290	0.5290	6
PTX-2	PTX2:6|PTX-2:6	pectenotoxin-2:12:0.8462	0.8462	12
PTX3	PTX3:11|Ptx3:1	pentraxin 3:12:0.7571	0.7571	12
PTXF	PTXF:26	Pentoxifylline:26:0.8929	0.8929	26
PTX	PTX:23|PTx:11|Ptx:1	after parathyroidectomy:35:0.1181	0.1181	35
PTX	PTX:11	antagonist picrotoxin:11:0.0525	0.0525	11
PTX	PTX:89|PTx:1	paclitaxel:90:0.0422	0.0422	90
PTX	PTX:58|PTx:2	palytoxin:60:0.0275	0.0275	60
PTX	PTX:17|PTx:15	pancreas transplantation:32:0.6656	0.6656	32
PTX	PTX:104|PTx:3|ptx:1	parathyroidectomized:108:0.0508	0.0508	108
PTX	PTX:383|Ptx:14|ptx:2|PTx:1	pentoxifylline:400:0.1888	0.1888	400
PTX	PTX:849|PTx:80|Ptx:31|ptx:5|PtX:3	pertussis toxin:968:0.9833	0.9833	968
PTX	PTX:11	picrotoxinin:11:0.0047	0.0047	11
PTX	PTX:23	piritrexim:23:0.0104	0.0104	23
PTX	PTX:26|Ptx:1	pneumothorax:27:0.0123	0.0123	27
pt-yr	pt-yr:35	patient-years:35:0.1799	0.1799	35
pTyr	pTyr:33|P-Tyr:22|p-Tyr:6|p-tyr:6|P-tyr:5|ptyr:4|Ptyr:3|PTyr:2|PTYR:1	phosphotyrosine:82:0.4233	0.4233	82
pTyr	pTyr:18|P-Tyr:2|p-Tyr:2|P-tyr:1|p-tyr:1	phosphotyrosyl:24:0.1217	0.1217	24
PTZ	PTZ:14	pentetrazol:14:0.0169	0.0169	14
PTZ	PTZ:459	pentylenetetrazol:459:0.5935	0.5935	459
PTZ	PTZ:210	pentylenetetrazole:210:0.2701	0.2701	210
PTZ	PTZ:10	pentylentetrazol:10:0.0117	0.0117	10
PTZ	PTZ:15	phenothiazine:15:0.0182	0.0182	15
p-tau	p-tau:8|P-Tau:1|P-tau:1	phosphorylated tau:10:0.4363	0.4363	10
pT	pT:5	depth of tumor invasion:5:0.2818	0.2818	5
Pt	Pt:6	isometric twitch:6:0.0522	0.0522	6
PT	PT:33	Pain threshold:27:0.3880|pain thresholds:6:0.2243	0.3880	33
PT	PT:10	pancreas transplantation:10:0.5856	0.5856	10
pt	pt:14|PT:1	paralytic tremor:15:0.2264	0.2264	15
PT	PT:34	parathyroid:34:0.0067	0.0067	34
PT	PT:93|pt:3|Pt:1	pars tuberalis:97:0.9692	0.9692	97
PT	PT:45	patellar tendon:45:0.7881	0.7881	45
pt	pt:30|PT:8|Pt:5	patients:27:0.0053|patient:16:0.0031	0.0053	43
PT	PT:88|pT:1	peak torque:89:0.8602	0.8602	89
PT	PT:12	percutaneous tracheostomy:12:0.6460	0.6460	12
PT	PT:13	perinuclear theca:13:0.7753	0.7753	13
PT	PT:82	permeability transition:82:0.9070	0.9070	82
PT	PT:5	permissive temperature:5:0.0902	0.0902	5
PT	PT:568|Pt:2	pertussis toxin:570:0.9742	0.9742	570
PT	PT:14	pertussis toxoid:14:0.5589	0.5589	14
PT	PT:78|pt:1	phage type:64:0.9033|phage types:15:0.5818	0.9033	79
PT	PT:15	phenytoin:15:0.0029	0.0029	15
PT	PT:12	phototherapy:12:0.0022	0.0022	12
PT	PT:9	photothermal:9:0.0016	0.0016	9
PT	PT:16	phyllodes tumor:11:0.2280|Phyllodes tumour:5:0.0517	0.2280	16
PT	PT:96	physical therapy:96:0.7175	0.7175	96
PT	PT:21	physical training:21:0.5435	0.5435	21
PT	PT:24	physiotherapy:24:0.0047	0.0047	24
PT	PT:9	picrotoxin:9:0.0016	0.0016	9
PT	PT:56	Planum Temporale:56:0.9458	0.9458	56
pt	pt:8|Pt:1	plastid:9:0.0016	0.0016	9
Pt	Pt:218|PT:2	platinum:220:0.0446	0.0446	220
PT	PT:9	pneumotachograph:9:0.0016	0.0016	9
PT	PT:21|pt:4	post-treatment:25:0.0049	0.0049	25
PT	PT:10	posterior tibial:10:0.7103	0.7103	10
PT	PT:13|Pt:3	pretectum:16:0.0031	0.0031	16
PT	PT:37	preterm:37:0.0073	0.0073	37
PT	PT:17	primary thrombocythaemia:17:0.7407	0.7407	17
PT	PT:10	primary thrombocythemia:10:0.5000	0.5000	10
PT	PT:4|pT:1	primary tumour:5:0.0517	0.0517	5
PT	PT:54	proficiency testing:54:0.6546	0.6546	54
PT	PT:65|Pt:1	prothrombin:66:0.0132	0.0132	66
PT	PT:1042|pt:1	Prothrombin time:1006:0.9541|prothrombin times:37:0.8051	0.9541	1043
PT	PT:15	proton transfer:15:0.4312	0.4312	15
PT	PT:12	proximal:12:0.0022	0.0022	12
PT	PT:55	proximal tubular:55:0.9458	0.9458	55
PT	PT:145|Pt:1	proximal tubule:96:0.9505|proximal tubules:50:0.9404	0.9505	146
PT	PT:10	ptaquiloside:10:0.0018	0.0018	10
PT	PT:14	pulmonary trunk:14:0.6173	0.6173	14
PT	PT:26	pulmonary tuberculosis:26:0.6084	0.6084	26
PT	PT:83|Pt:1	pyramidal tract:84:0.9644	0.9644	84
PT	PT:12	tests:12:0.0022	0.0022	12
PT	PT:9|pt:1	tissue:10:0.0018	0.0018	10
PT	Pt:10|PT:10	tracheal pressure:20:0.2427	0.2427	20
PT	PT:14|pt:1	treatment:15:0.0029	0.0029	15
PT	PT:16|pT:1	tumors:17:0.0033	0.0033	17
pT	pT:6|p-T:1	tumor stage:7:0.0951	0.0951	7
Pt	Pt:7|PT:1	twitch force:8:0.5006	0.5006	8
Pt	Pt:27|PT:6	Twitch tension:33:0.6735	0.6735	33
PUA	PUA:8	Plasma uric acid:8:0.6411	0.6411	8
PUBS	PUBS:25	percutaneous umbilical blood sampling:25:0.8816	0.8816	25
PUBS	PUBS:10	purple urine bag syndrome:10:0.7103	0.7103	10
puc	puc:6|Puc:2|PUC:1	puckered:9:0.2353	0.2353	9
PUD	PUD:140	peptic ulcer disease:140:0.9547	0.9547	140
PUFA's	PUFA's:13	polyunsaturated fatty acids:13:0.7753	0.7753	13
PUFAs	PUFAs:10	polyunsaturated FAs:10:0.7103	0.7103	10
PUFAs	PUFAs:576|PUFAS:2|PuFAs:1|PUfas:1|PU-FAs:1	polyunsaturated fatty acids:581:0.9368	0.9368	581
PUFA	PUFA:15	polyunsaturated:15:0.0093	0.0093	15
PUFA	PUFA:16	polyunsaturated FA:16:0.7261	0.7261	16
PUFA	PUFA:12	polyunsaturated fat:12:0.5664	0.5664	12
PUFA	PUFA:1381|Pufa:1	polyunsaturated fatty acids:1010:0.9607|polyunsaturated fatty acid:372:0.9542	0.9607	1382
PUF	PUF:9|pUF:3	plasma ultrafiltrate:12:0.7571	0.7571	12
PUF	PUF:9	polyunsaturated fat:9:0.6794	0.6794	9
PUF	PUF:38	polyurethane foam:38:0.8781	0.8781	38
PUJ	PUJ:83	junction:83:0.9318	0.9318	83
PUJO	PUJO:10	junction obstruction:10:0.7103	0.7103	10
PUK	PUK:17	peripheral ulcerative keratitis:17:0.8270	0.8270	17
PUMC	PUMC:8	Peking Union Medical College:8:0.6411	0.6411	8
PUPPP	PUPPP:19	pruritic urticarial papules and plaques of pregnancy:19:0.7658	0.7658	19
PUs	PUs:18	polyurethanes:18:0.2833	0.2833	18
PUs	PUs:11	pressure ulcers:11:0.6182	0.6182	11
PUUV	PUUV:13	Puumala hantavirus:13:0.7753	0.7753	13
PUUV	PUUV:20	Puumala virus:20:0.8525	0.8525	20
PUVA	PUVA:26	long-wave ultraviolet light:26:0.3766	0.3766	26
PUVA	PUVA:9	plus UVA radiation:9:0.2757	0.2757	9
PUVA	PUVA:32	psoralen plus UVA:32:0.5670	0.5670	32
PUVA	PUVA:11	psoralen-UVA:11:0.0163	0.0163	11
PUVA	PUVA:1	ultraviolet irradiation:1:0.0863	0.0863	1
PUVA	PUVA:25	ultraviolet radiation:25:0.4387	0.4387	25
PUVA	PUVA:12	UVA irradiation:12:0.2415	0.2415	12
PUV	PUV:75	posterior urethral valves:63:0.9519|posterior urethral valve:12:0.7571	0.9519	75
Pu	Pu:5	operon promoter:5:0.1132	0.1132	5
PU	PU:41	peptic ulcer:41:0.6524	0.6524	41
PU	PU:46|pu:2	perfusion units:48:0.6628	0.6628	48
Pu	Pu:12|PU:2	plutonium:14:0.0208	0.0208	14
PU	PU:174|pu:1	polyurethane:175:0.2784	0.2784	175
PU	PU:18	Pressure ulcers:9:0.2757|pressure ulcer:9:0.0538	0.2757	18
PU	PU:15	proteinuria:15:0.0224	0.0224	15
PU	PU:15|Pu:6|pu:1	putrescine:22:0.0352	0.0352	22
Pu	Pu:8	urea permeability:8:0.5006	0.5006	8
PV+	PV+:11|Pv+:1	positive:12:0.2444	0.2444	12
PV-IVH	PV-IVH:13	periventricular-intraventricular hemorrhage:13:0.6701	0.6701	13
PV1	PV1:24|PV-1:14	poliovirus type 1:38:0.8098	0.8098	38
PV2	PV2:5|PV-2:4	poliovirus type 2:9:0.6794	0.6794	9
PV3	PV3:8	poliovirus type 3:8:0.5006	0.5006	8
PVA-H	PVA-H:10	polyvinyl alcohol-hydrogel:10:0.7103	0.7103	10
PVAN	PVAN:10	nephropathy:10:0.9000	0.9000	10
PVARP	PVARP:15	postventricular atrial refractory period:15:0.7096	0.7096	15
PVA	PVA:5	Pemphigus vulgaris antigen:5:0.4422	0.4422	5
PVA	PVA:359	polyvinyl alcohol:359:0.6374	0.6374	359
PVA	PVA:7	polyvinyl alcohol particles:7:0.4438	0.4438	7
PVA	PVA:46	polyvinylalcohol:46:0.0463	0.0463	46
PVA	PVA:122|P-VA:1	pressure-volume area:123:0.6730	0.6730	123
PVB19	PVB19:35|PV-B19:3|PVB-19:1	parvovirus B19:39:0.9237	0.9237	39
PVBF	PVBF:10	portal venous blood flow:10:0.7103	0.7103	10
PVBs	PVBs:18	premature ventricular beats:18:0.8365	0.8365	18
PVB	PVB:13	premature ventricular beats:13:0.7753	0.7753	13
PVB	PVB:11	venous blood:11:0.6182	0.6182	11
PVCN	PVCN:25	posteroventral cochlear nucleus:25:0.6240	0.6240	25
PVCs	PVCs:98	premature ventricular complexes:98:0.9695	0.9695	98
PVCs	PVCs:147	premature ventricular contractions:147:0.9675	0.9675	147
PVC	PVC:9	paravestibular canaliculus:9:0.5470	0.5470	9
PVC	PVC:430	polyvinyl chloride:430:0.7525	0.7525	430
PVC	PVC:156	polyvinylchloride:156:0.1473	0.1473	156
PVC	PVC:34	premature ventricular complexes:19:0.8449|premature ventricular complex:15:0.8045	0.8449	34
PVC	PVC:88	premature ventricular contractions:53:0.9132|premature ventricular contraction:35:0.8681	0.9132	88
PVC	PVC:8	prevacuolar compartment:8:0.1367	0.1367	8
PVC	PVC:12	vaginal cornification:12:0.7571	0.7571	12
PVDF	PVDF:148|PVdF:2	polyvinylidene difluoride:150:0.8201	0.8201	150
PVDF	PVDF:59	polyvinylidene fluoride:59:0.6158	0.6158	59
PVD	PVD:400	peripheral vascular disease:400:0.9397	0.9397	400
PVD	PVD:6	portal vein diameter:6:0.3728	0.3728	6
PVD	PVD:104	posterior vitreous detachment:104:0.9712	0.9712	104
PVECPs	PVECPs:9|P-VECPs:1	evoked cortical potentials:10:0.7103	0.7103	10
PVEPs	PVEPs:34|P-VEPs:10|pVEPs:3|PVEPS:1	visual evoked potentials:48:0.9027	0.9027	48
PVER	PVER:6	pattern reversal visual evoked response:6:0.5290	0.5290	6
PVE	PVE:7	partial volume effect:7:0.5926	0.5926	7
PVE	PVE:10	plasma volume expansion:10:0.7103	0.7103	10
PVE	PVE:47	portal vein embolization:47:0.9366	0.9366	47
PVE	PVE:149	prosthetic valve endocarditis:149:0.9574	0.9574	149
PVE	PVE:17	pseudostratified ventricular epithelium:17:0.8270	0.8270	17
PVFS	PVFS:11	fatigue syndrome:11:0.7357	0.7357	11
PVF	PVF:13	polyvinyl formal:13:0.6701	0.6701	13
PVF	PVF:8|PVf:1	Primary ventricular fibrillation:9:0.6794	0.6794	9
PVF	PVF:49	pulmonary venous flow:49:0.4905	0.4905	49
PVG	PVG:10	periventricular gray:10:0.5856	0.5856	10
PVG	PVG:6	portal venous gas:6:0.5290	0.5290	6
PVH-IVH	PVH-IVH:8	periventricular-intraventricular hemorrhage:8:0.5006	0.5006	8
PVHs	PVHs:10	periventricular hyperintensities:10:0.5856	0.5856	10
PVH	PVH:23	hypothalamic paraventricular nucleus:23:0.3310	0.3310	23
PVH	PVH:25	paraventricular:25:0.0694	0.0694	25
PVH	PVH:36	paraventricular hypothalamic nucleus:36:0.9174	0.9174	36
PVH	PVH:89	paraventricular nucleus of the hypothalamus:89:0.9668	0.9668	89
PVH	PVH:5|PV-H:3	perivenous hepatocytes:8:0.5006	0.5006	8
PVH	PVH:25	periventricular haemorrhage:25:0.7679	0.7679	25
PVH	PVH:9	periventricular hemorrhage:9:0.3945	0.3945	9
PVH	PVH:43	periventricular hyperintensity:34:0.9126|periventricular hyperintensities:9:0.6794	0.9126	43
PVI	PVI:9	invasion:9:0.0364	0.0364	9
Pvi	Pvi:8	isovolumetric venous pressure:8:0.5006	0.5006	8
PVI	PVI:59	pressure-volume index:43:0.5179|pressure volume index:16:0.7261	0.7261	59
PVI	PVI:24	protracted venous infusion:24:0.6767	0.6767	24
PVI	PVI:13	pulmonary vein isolation:13:0.7753	0.7753	13
PVL	PVL:20|pvl:1	Panton-Valentine leukocidin:21:0.5721	0.5721	21
PVL	PVL:257	periventricular leukomalacia:257:0.9691	0.9691	257
PVL	PVL:11	periventricular lucency:11:0.7357	0.7357	11
pVL	pVL:20|PVL:10|Pvl:1	plasma viral load:31:0.8472	0.8472	31
PVL	PVL:7	portal hypertension induced by partial portal vein ligation:7:0.6577	0.6577	7
PVL	PVL:10	portal vein-ligated:10:0.7103	0.7103	10
PVL	PVL:13	proliferative verrucous leukoplakia:13:0.7571	0.7571	13
PVM	PVM:12	parasitophorous vacuolar membrane:12:0.7571	0.7571	12
PVM	PVM:26|pvm:1	parasitophorous vacuole membrane:27:0.8312	0.8312	27
PVM	PVM:55	pneumonia virus of mice:55:0.9458	0.9458	55
PVM	PVM:11	potato virus M:11:0.7357	0.7357	11
PVNO	PVNO:14	polyvinylpyridine-N-oxide:14:0.6500	0.6500	14
PVNS	PVNS:124	pigmented villonodular synovitis:124:0.9761	0.9761	124
PVN	PVN:49	hypothalamic paraventricular:49:0.1130	0.1130	49
PVN	PVN:1760|PVn:1	paraventricular nucleus:1761:0.9425	0.9425	1761
PVN	PVN:238|PvN:2	paraventricular nucleus of the hypothalamus:240:0.9880	0.9880	240
PVN	PVN:5	predictive value negative:5:0.5290	0.5290	5
PvO2	PvO2:23|PVO2:17|PVo2:1	Mixed venous oxygen tension:41:0.6524	0.6524	41
pVO2	pVO2:8|PVO2:2|pVo2:1	peak oxygen consumption:11:0.4232	0.4232	11
PVO2	PVO2:4|pVO2:3|PVo2:1	peak oxygen uptake:8:0.6411	0.6411	8
PvO2	PvO2:3|pVO2:1	venous oxygen pressure:4:0.1618	0.1618	4
PVOD	PVOD:14	pulmonary vascular obstructive disease:14:0.6911	0.6911	14
PVOD	PVOD:24	pulmonary veno-occlusive disease:24:0.8768	0.8768	24
PVO	PVO:27	paraventricular organ:27:0.8903	0.8903	27
PVO	PVO:9	portal vein occlusion:9:0.6794	0.6794	9
PVO	PVO:14	pulmonary venous obstruction:14:0.7909	0.7909	14
PVP-I	PVP-I:12	polyvinylpyrrolidone-iodine:12:0.1000	0.1000	12
PVP-I	PVP-I:73|PVPI:3	povidone-iodine:70:0.6273|povidone iodine:6:0.1320	0.6273	76
PVPP	PVPP:11	polyvinylpolypyrrolidone:11:0.4348	0.4348	11
PVP	PVP:19|pVp:1	Percutaneous vertebroplasty:20:0.8525	0.8525	20
PVP	PVP:14	peripheral venous pressure:14:0.1193	0.1193	14
PVP	PVP:5|pVP:1|pVp:1	plasma vasopressin:7:0.2902	0.2902	7
PVP	PVP:43	poly(vinylpyrrolidone):43:0.0444	0.0444	43
PVP	PVP:65	polyvinyl pyrrolidone:65:0.4980	0.4980	65
PVP	PVP:372|pvp:1	polyvinylpyrrolidone:373:0.3937	0.3937	373
PVP	PVP:13	portal vein pressure:13:0.5934	0.5934	13
PVP	PVP:15	portal venous phase:15:0.8045	0.8045	15
PVP	PVP:35	portal venous pressure:35:0.4766	0.4766	35
PVP	PVP:9	Position-vestibular-pause:9:0.0085	0.0085	9
PVP	PVP:45	posteroventral pallidotomy:45:0.8649	0.8649	45
PVP	PVP:16	predictive value positive:16:0.8365	0.8365	16
PVRI	PVRI:10|PVRi:1	pulmonary vascular resistance:11:0.6182	0.6182	11
PVRI	PVRI:93|PVRi:1	pulmonary vascular resistance index:94:0.9184	0.9184	94
PVRV	PVRV:13	purified Vero cell rabies vaccine:13:0.6701	0.6701	13
PVR	PVR:36|Pvr:3	poliovirus receptor:39:0.5932	0.5932	39
PVR	PVR:11	post-void residual:11:0.1378	0.1378	11
PVR	PVR:12	post-void residual volume:12:0.2414	0.2414	12
PVR	PVR:16	postvoid residual:16:0.2709	0.2709	16
PVR	PVR:524	Proliferative vitreoretinopathy:524:0.9794	0.9794	524
PVR	PVR:17	pulmonary valve replacement:17:0.6211	0.6211	17
PVR	PVR:839|pvR:1|Pvr:1	pulmonary vascular resistance:841:0.8999	0.8999	841
PVR	PVR:19	Pulse Volume Recording:10:0.5856|pulse volume recordings:9:0.6794	0.6794	19
PVR	PVR:20	residual urine:20:0.8525	0.8525	20
PVR	PVR:38	residual urine volume:38:0.9217	0.9217	38
PVSG	PVSG:22	Polycythemia Vera Study Group:22:0.6934	0.6934	22
PVs	PVs:18	papillomaviruses:18:0.0279	0.0279	18
PVS	PVS:15	Penile vibratory stimulation:15:0.8045	0.8045	15
PVS	PVS:17	peritoneovenous shunt:17:0.6211	0.6211	17
PVS	PVS:11	perivascular space:11:0.1203	0.1203	11
PVS	PVS:24|PvS:1	perivitelline space:25:0.4751	0.4751	25
PVS	PVS:71|Pvs:1	persistent vegetative state:72:0.8592	0.8592	72
PVS	PVS:25	pigmented villonodular synovitis:25:0.8816	0.8816	25
PVS	PVS:9	polyvinyl sulfate:9:0.6794	0.6794	9
PVS	PVS:5	portal vein stenosis:5:0.1464	0.1464	5
PVS	PVS:13	potato virus S:13:0.7753	0.7753	13
PVS	PVS:54	programmed ventricular stimulation:54:0.8401	0.8401	54
PVS	PVS:12	pubovaginal sling:12:0.7571	0.7571	12
PVS	PVS:6	pulmonary valve stenosis:6:0.3728	0.3728	6
PVs	PVs:97	pulmonary veins:97:0.8489	0.8489	97
PVS	PVS:12	venous sampling:12:0.7571	0.7571	12
PVTT	PVTT:9	portal vein tumor thrombosis:9:0.6794	0.6794	9
PVTT	PVTT:14	portal vein tumor thrombus:14:0.7909	0.7909	14
PVT	PVT:8	paraventricular nucleus of the thalamus:8:0.6411	0.6411	8
PVT	PVT:13	paraventricular thalamic nucleus:13:0.7753	0.7753	13
PVT	PVT:19|pVT:2	polymorphic ventricular tachycardia:21:0.4538	0.4538	21
PVT	PVT:108	portal vein thrombosis:108:0.9417	0.9417	108
PVT	PVT:15	psychomotor vigilance task:15:0.7096	0.7096	15
PVV	PVV:7|PV-V:2	velocity:9:0.2857	0.2857	9
PVX	PVX:161	potato virus X:161:0.9814	0.9814	161
PVY	PVY:101	potato virus Y:101:0.9704	0.9704	101
PV	PV:66	calcium-binding protein parvalbumin:31:0.4224|calcium-binding proteins parvalbumin:16:0.4427|calcium binding protein parvalbumin:12:0.5934|calcium binding proteins parvalbumin:7:0.7357	0.7357	66
P-V	P-V:15|PV:1|p-V:1	force-velocity:17:0.0040	0.0040	17
PV	PV:46	papillomavirus:37:0.0091|papillomaviruses:9:0.0020	0.0091	46
PV	PV:60|Pv:1|pv:1	parasitophorous vacuole:48:0.9027|parasitophorous vacuoles:14:0.6911	0.9027	62
PV	PV:5|pv:2	paraventricular nucleus:7:0.0886	0.0886	7
PV	PV:9|Pv:1	paraventricular thalamic nucleus:10:0.7103	0.7103	10
PV	PV:18	parietal ventral area:18:0.8365	0.8365	18
PV	PV:44	patients with polycythaemia vera:44:0.2236	0.2236	44
PV	PV:6	patients with psoriasis vulgaris:6:0.0789	0.0789	6
PV	PV:30|pv:2|pV:1	peak velocity:33:0.4488	0.4488	33
PV	PV:287|Pv:3	pemphigus vulgaris:290:0.8637	0.8637	290
PV	PV:10|pv:2	percutaneous vertebroplasty:12:0.7357	0.7357	12
PV	PV:13	periventricular:13:0.0030	0.0030	13
PV	PV:17	peroxide value:17:0.1443	0.1443	17
pV	pV:11	peroxovanadium:11:0.0025	0.0025	11
PV	PV:12|pv:1	Pertussis vaccine:13:0.2802	0.2802	13
PV	PV:13|pV:3	pervanadate:16:0.0038	0.0038	16
PV	PV:11	phenyl valerate:11:0.7357	0.7357	11
PV	PV:10	Pichinde virus:10:0.1134	0.1134	10
PV	PV:15	Pityriasis versicolor:15:0.8045	0.8045	15
PV	PV:16	plasma:16:0.0038	0.0038	16
PV	PV:71|pv:2|Pv:1	Plasma viscosity:74:0.8493	0.8493	74
PV	PV:447|Pv:1	plasma volume:443:0.8201|plasma volumes:5:0.0902	0.8201	448
Pv	Pv:5|PV:4	Plasmodium vivax:9:0.2102	0.2102	9
PV	PV:114	poliovirus:114:0.0285	0.0285	114
PV	PV:411|pv:1	polycythemia vera:412:0.6797	0.6797	412
PV	PV:8	polyoma virus:8:0.0672	0.0672	8
PV	PV:10	polyomavirus:10:0.0023	0.0023	10
PV	PV:206|pv:7|Pv:1	portal vein:214:0.4751	0.4751	214
PV	PV:31|pv:6	portal venous:37:0.2700	0.2700	37
PV	PV:12|pv:2	postvaccination:14:0.0033	0.0033	14
PV	PV:11	pravastatin:11:0.0025	0.0025	11
PV	PV:40|-PV:3	predictive value:36:0.4303|predictive values:7:0.2452	0.4303	43
PV	PV:11	processus vaginalis:11:0.6182	0.6182	11
PV	PV:14	pulmonary valve:14:0.4709	0.4709	14
PV	PV:199	pulmonary vein:161:0.3456|pulmonary veins:38:0.5720	0.5720	199
PV	PV:35	pulmonary venous:35:0.2508	0.2508	35
PV	PV:17|P-V:15	static pressure-volume:32:0.0622	0.0622	32
Pv	Pv:53|PV:10	venous pressure:63:0.7034	0.7034	63
PWACR	PWACR:9	critical region:9:0.6794	0.6794	9
PWA	PWA:17	people with AIDS:17:0.2609	0.2609	17
PWA	PWA:9	Pulse wave analysis:9:0.6794	0.6794	9
PWA	PWA:9	wave amplitude:9:0.5470	0.5470	9
PWB	PWB:19	well-being:19:0.4500	0.4500	19
PWCFT	PWCFT:5|PWCft:1	physical working capacity at the fatigue threshold:6:0.6411	0.6411	6
PWC	PWC:20|pwc:1	physical work capacity:21:0.6812	0.6812	21
PWC	PWC:15	physical working capacity:15:0.8045	0.8045	15
PWD	PWD:10	duration of filtered P-wave:10:0.7103	0.7103	10
PWD	PWD:16|PWd:1	P-wave dispersion:9:0.2102|P wave dispersion:8:0.6411	0.6411	17
PWD	PWD:5	wave Doppler:5:0.0902	0.0902	5
PWE	PWE:11	people with epilepsy:11:0.4728	0.4728	11
PWF	PWF:8	posterior wiring and fusion:8:0.6794	0.6794	8
PWI	PWI:9	perfusion-weighted MRI:9:0.3945	0.3945	9
PWI	PWI:13	pressure-work index:7:0.1850|pressure work index:6:0.5290	0.5290	13
PWL	PWL:49	paw withdrawal latency:49:0.9046	0.9046	49
PWM-SCM	PWM-SCM:10|PWMSCM:2	spleen cell conditioned medium:12:0.7571	0.7571	12
PWM	PWM:28	pokeweed mitogen-:19:0.7658|Pokeweed-Mitogen:9:0.0060	0.7658	28
PWP	PWP:59|Pwp:3|PW-P:1	pulmonary wedge pressure:63:0.6854	0.6854	63
PWR	PWR:12	plasmon-waveguide resonance:12:0.5664	0.5664	12
PWSs	PWSs:23	port-wine stains:15:0.4052|Port wine stains:8:0.6411	0.6411	23
PWT	PWT:5	paw withdrawal threshold:5:0.1973	0.1973	5
PWT	PWT:38	posterior wall thickness:38:0.8811	0.8811	38
PWV	PWV:358	pulse wave velocity:358:0.9916	0.9916	358
PWS	PWS:9	paternal:9:0.0109	0.0109	9
PWS	PWS:90	port wine stains:40:0.9256|port wine stain:31:0.9043|port-wine stain:19:0.2142	0.9256	90
PWS	PWS:22	Prader-Willi:22:0.0285	0.0285	22
PWS	PWS:462	Prader-Willi syndrome:462:0.9331	0.9331	462
PWS	PWS:9	Prince William Sound:9:0.6794	0.6794	9
PWS	PWS:15	treatment of port-wine stains:15:0.2527	0.2527	15
Pw	Pw:5	pertussis vaccine:5:0.1132	0.1132	5
PW	PW:45|pW:1	posterior wall:46:0.8676	0.8676	46
PW	PW:8	pulse width:8:0.1895	0.1895	8
PW	PW:15|pw:2	pulsed-wave:17:0.0376	0.0376	17
PW	PW:10|Pw:1|pw:1	water:12:0.0258	0.0258	12
Pw	Pw:12|PW:6|pw:1	wedge pressure:19:0.5113	0.5113	19
PXAs	PXAs:8|PXA-s:1	pleomorphic xanthoastrocytomas:9:0.6794	0.6794	9
PXA	PXA:56	pleomorphic xanthoastrocytoma:56:0.9467	0.9467	56
PXB	PxB:9|PXB:9	polymyxin B:18:0.8365	0.8365	18
PXE	PXE:173|pxe:1	pseudoxanthoma elasticum:174:0.9551	0.9551	174
PXF	PXF:11	pentoxifylline:11:0.3846	0.3846	11
PXR	PXR:179	pregnane X receptor:179:0.9560	0.9560	179
PXRD	PXRD:29|pXRD:1|p-XRD:1	powder X-ray diffraction:31:0.8519	0.8519	31
PXS	PXS:15	pseudoexfoliation syndrome:15:0.8045	0.8045	15
Px	Px:5|PX:1	90% pancreatectomized:6:0.1320	0.1320	6
Px	Px:3|px:1|PX:1	after 90% pancreatectomy:5:0.0902	0.0902	5
pX	pX:8	hepatitis B virus X protein:8:0.6411	0.6411	8
Px	Px:14	partial pancreatectomy:14:0.1579	0.1579	14
PX	Px:5|PX:5	pentoxifylline:10:0.0196	0.0196	10
Px	Px:14|PX:1	peroxidase:15:0.0304	0.0304	15
PX	PX:47	phox homology:47:0.8703	0.8703	47
PX	PX:37|Px:33|px:3|P-X:1	pinealectomized:74:0.1587	0.1587	74
PX	PX:26|Px:18|px:1	pinealectomy:45:0.0978	0.0978	45
PX	PX:12|Px:7	piroxicam:19:0.0391	0.0391	19
PYD	PYD:70|Pyd:39|PyD:1	Pyridinoline:110:0.7315	0.7315	110
Pyk2	Pyk2:6|PYK2:5	proline-rich tyrosine kinase:11:0.4728	0.4728	11
Pyk2	Pyk2:43|PYK2:37|PYK-2:2|pyk2:2|Pyk-2:1	Proline-rich tyrosine kinase 2:73:0.8058|proline-rich tyrosine kinase-2:12:0.7571	0.8058	85
PYLL	PYLL:41	potential years of life lost:41:0.7703	0.7703	41
PYM	PYM:11	Pingyangmycin:11:0.3226	0.3226	11
PYP	PYP:12	99mTc-pyrophosphate:12:0.0692	0.0692	12
PYP	PYP:94|pyp:2	photoactive yellow protein:96:0.9689	0.9689	96
PYP	PYP:11	Tc-99m pyrophosphate:11:0.1547	0.1547	11
PYR	PYR:3|P-YR:1|pyr:1	person-years at risk:5:0.1132	0.1132	5
PYR	PYR:6|Pyr:5	pyrazole:11:0.0216	0.0216	11
PYR	PYR:24|Pyr:9	pyridostigmine:33:0.0691	0.0691	33
PYR	PYR:13|Pyr:2	Pyridostigmine bromide:15:0.8045	0.8045	15
PYR	PYR:38|Pyr:11	pyrimethamine:49:0.1037	0.1037	49
pyr	pyr:6|Pyr:1	pyrimidine biosynthetic:7:0.2452	0.2452	7
Pyr	Pyr:17|PYR:11|pyr:3	pyruvate:31:0.0648	0.0648	31
Pyr	Pyr:30|PYR:5|pyr:1	urinary pyridinoline:36:0.1755	0.1755	36
PYY	PYY:48	peptide tyrosine tyrosine:34:0.8644|peptide tyrosine-tyrosine:14:0.7909	0.8644	48
PYY	PYY:13	peptide-YY:13:0.0169	0.0169	13
PYs	PYs:7|pys:2	person-years:9:0.2353	0.2353	9
PZA	PZA:163|pza:1	pyrazinamide:164:0.7751	0.7751	164
PZA	PZA:25	pyrazoloacridine:25:0.1148	0.1148	25
PZC	PZC:10|pzc:3	point of zero charge:13:0.4444	0.4444	13
PZD	PZD:34	partial zona dissection:34:0.8644	0.8644	34
PZFX	PZFX:10	pazufloxacin:10:0.7500	0.7500	10
PZG	PZG:14	Pyrazinoylguanidine:14:0.8667	0.8667	14
PZI	PZI:8	protamine zinc insulin:8:0.6411	0.6411	8
PZP	PZP:18|pZP:6	Porcine zona pellucida:24:0.7151	0.7151	24
PZP	PZP:54	pregnancy zone protein:54:0.9132	0.9132	54
PZQ	PZQ:124|Pzq:5	praziquantel:129:0.9624	0.9624	129
PZT	PZT:17	lead zirconate titanate:17:0.8270	0.8270	17
PZase	PZase:17|Pzase:1	pyrazinamidase:18:0.8947	0.8947	18
PZ	PZ:57	peripheral zone:57:0.5975	0.5975	57
PZ	PZ:8|Pz:2	piezoelectric:10:0.0252	0.0252	10
PZ	PZ:37|Pz:5	pirenzepine:42:0.1176	0.1176	42
PZ	PZ:8|Pz:1	praziquantel:9:0.0224	0.0224	9
PZ	PZ:20|Pz:5	prazosin:25:0.0672	0.0672	25
PZ	PZ:12	pregnancy zone protein:12:0.7571	0.7571	12
PZ	PZ:9	promazine:9:0.0224	0.0224	9
PZ	PZ:15	protein Z:15:0.8045	0.8045	15
Pa(O(2))	Pa(O(2)):14|Pa(o(2)):1	arterial PO(2):15:0.8045	0.8045	15
Pa5	Pa5:8	paratrigeminal nucleus:8:0.5006	0.5006	8
PaCO(2)	PaCO(2):12|Paco(2):1	arterial carbon dioxide tension:13:0.7753	0.7753	13
PaCO(2)	PaCO(2):15|Paco(2):1|paCO(2):1	carbon dioxide:17:0.8270	0.8270	17
PaCO2	PaCO2:13|Paco2:1	arterial carbon dioxide partial pressure:14:0.4709	0.4709	14
PaCO2	PaCO2:27|paCO2:2|PaCO-2:1|Paco2:1|PACO2:1	arterial carbon dioxide pressure:32:0.7166	0.7166	32
PaCO2	PaCO2:230|Paco2:6|paCO2:4|PacO2:1|PaCo2:1|PACO2:1	arterial carbon dioxide tension:243:0.8826	0.8826	243
PaCO2	PaCO2:34|Paco2:2	arterial CO2 partial pressure:36:0.8003	0.8003	36
PaCO2	PaCO2:12|Paco2:1	arterial CO2 pressure:13:0.3809	0.3809	13
PaCO2	PaCO2:76|Paco2:3	arterial CO2 tension:73:0.8329|Arterial CO2 tensions:6:0.3728	0.8329	79
PaCO2	PaCO2:19|Paco2:2	arterial partial pressure of CO2:21:0.5178	0.5178	21
PaCO2	PaCO2:14|Paco2:1|PACO2:1	carbon dioxide tensions:16:0.8165	0.8165	16
PaCO2	PaCO2:14|paCO2:1	Partial pressure of carbon dioxide in arterial blood:15:0.8270	0.8270	15
PaCO2	PaCO2:11	partial pressure of CO2 in arterial blood:11:0.7357	0.7357	11
pAkt	pAkt:17|p-Akt:12|pAKT:5|P-Akt:4|p-AKT:1	phosphorylated Akt:39:0.6937	0.6937	39
PaLoc	PaLoc:12	pathogenicity locus:12:0.7571	0.7571	12
PaO(2)	PaO(2):8|Pao(2):1	Arterial oxygen pressure:9:0.3455	0.3455	9
PaO(2)	PaO(2):21	arterial oxygen tension:21:0.7291	0.7291	21
PaO(2)	PaO(2):7	arterial partial pressure of oxygen:7:0.3524	0.3524	7
PaO(2)	PaO(2):5	partial pressure of arterial oxygen:5:0.4422	0.4422	5
PaO2	PaO2:27|paO2:1|Pao2:1	arterial O2 partial pressure:29:0.7581	0.7581	29
PaO2	PaO2:27|Pao2:2|paO2:1|PAO2:1	arterial oxygen partial pressure:31:0.5749	0.5749	31
PaO2	PaO2:59|Pao2:7|paO2:6|PaO-2:1|PAO2:1	arterial oxygen pressure:74:0.7286	0.7286	74
PaO2	PaO2:414|Pao2:37|paO2:5|Pao-2:1|PAO2:1	arterial oxygen tension:444:0.8775|Arterial oxygen tensions:14:0.6173	0.8775	458
PaO2	PaO2:22|Pao2:1	arterial oxygenation:23:0.5466	0.5466	23
PaO2	PaO2:1	arterial partial pressure for oxygen:1:0.4242	0.4242	1
PaO2	PaO2:15|Pao2:4	arterial partial pressure of O2:19:0.6537	0.6537	19
PaO2	PaO2:109|Pao2:7|PAO2:1	arterial PO2:117:0.8379	0.8379	117
PaO2	PaO2:28|Pao2:2	partial pressure of arterial oxygen:30:0.8519	0.8519	30
PaO2	PaO2:18|Pao2:1	partial pressure of oxygen in arterial blood:19:0.8594	0.8594	19
PAK1	PAK1:8|Pak1:4	p21-activated kinase:12:0.4153	0.4153	12
PAK1	PAK1:31|Pak1:28|PAK-1:3|Pak-1:2	p21-activated kinase 1:54:0.8196|p21-activated kinase-1:10:0.3867	0.8196	64
PanIN	PanIN:39	pancreatic intraepithelial neoplasia:39:0.9217	0.9217	39
PanINs	PanINs:9	pancreatic intraepithelial neoplasias:9:0.6794	0.6794	9
PAP	PAP:26	3'-phosphoadenosine 5'-phosphate:17:0.5374|3'-phosphoadenosine-5'-phosphate:9:0.0019	0.5374	26
PAP	PAP:29|p-AP:5|pAP:5	p-aminophenol:39:0.0090	0.0090	39
PAP	PAP:61	pancreatitis-associated protein:61:0.2570	0.2570	61
Pap	Pap:518|PAP:1	Papanicolaou:519:0.1231	0.1231	519
Pap	Pap:18	Papanicolau:18:0.0043	0.0043	18
PAP	PAP:22|Pap:13|pap:2	papaverine:37:0.0085	0.0085	37
PAP	PAP:10	para-aminophenol:10:0.0021	0.0021	10
PAP	PAP:9	peroxidase:9:0.0019	0.0019	9
PAP	PAP:22	phosphatidate phosphohydrolase:22:0.3788	0.3788	22
PAP	PAP:9	phosphatidic acid phosphohydrolase:9:0.6794	0.6794	9
PAP	PAP:9	plasmin-alpha 2-antiplasmin:9:0.6794	0.6794	9
PAP	PAP:14	plasmin-alpha 2-antiplasmin complex:14:0.5589	0.5589	14
PAP	PAP:12	plasmin-antiplasmin:12:0.0026	0.0026	12
PAP	PAP:28|P-AP:2	plasmin-antiplasmin complexes:17:0.2311|plasmin-antiplasmin complex:13:0.0595	0.2311	30
PAP	PAP:77	pokeweed antiviral protein:77:0.7315	0.7315	77
PAP	PAP:61	poly(A) polymerase:61:0.8097	0.8097	61
PAP	PAP:8	postactivation potentiation:8:0.4102	0.4102	8
PAP	PAP:8	Prostatic acid phosphate:8:0.5006	0.5006	8
PAP	PAP:8|PAp:1|Pap:1	pulmonary:10:0.0021	0.0021	10
PAP	PAP:138|Pap:1	pulmonary alveolar proteinosis:139:0.9659	0.9659	139
PAP	PAP:16	pulmonary arterial:16:0.8165	0.8165	16
PAP	PAP:306|Pap:4|PAp:2|pap:1|pAP:1	pulmonary arterial pressure:298:0.9392|pulmonary arterial pressures:16:0.8165	0.9392	314
PAP	PAP:18	pulmonary artery:18:0.8365	0.8365	18
PAP	PAP:537|Pap:6|PAp:3|-PAP:1|PA-P:1|PaP:1	pulmonary artery pressure:526:0.9878|pulmonary artery pressures:23:0.8715	0.9878	549
Pap	Pap:10|pap:7|PAP:1	Pyelonephritis-associated pili:18:0.7658	0.7658	18
PASE	PASE:16	Physical Activity Scale for the Elderly:16:0.7909	0.7909	16
PAU	PAU:8	penetrating atherosclerotic ulcer:8:0.6411	0.6411	8
Pax	Pax:8|PAX:3	paired box:11:0.7357	0.7357	11
PBAC	PBAC:10	assessment chart:10:0.7103	0.7103	10
PbAc	PbAc:14|Pb-Ac:2|PbAC:2	lead acetate:18:0.7407	0.7407	18
PbB	PbB:128|Pb-B:28|Pb-b:1	blood lead:157:0.8755	0.8755	157
PbB	PbB:36|Pb-B:12	blood lead concentration:24:0.7151|Blood lead concentrations:24:0.8115	0.8115	48
PbB	PbB:33|Pb-B:7	blood lead levels:25:0.8251|blood lead level:15:0.7096	0.8251	40
PbB	PbB:18|Pb-B:4|Pb--B:1	lead in blood:23:0.2951	0.2951	23
PBB	PBB:123	Polybrominated biphenyl:69:0.9567|polybrominated biphenyls:54:0.9448	0.9567	123
PBO	PBO:60	piperonyl butoxide:60:0.8971	0.8971	60
PC1	PC1:11	first principal component:11:0.7357	0.7357	11
PC-1	PC-1:6	pancreatic cancer cell line:6:0.5290	0.5290	6
PC-1	PC-1:9	plasma cell membrane glycoprotein-1:9:0.6794	0.6794	9
PC1	PC1:13|PC-1:1	polycystin-1:14:0.0774	0.0774	14
PC1	PC1:31	prohormone convertase 1:31:0.8519	0.8519	31
Pcap	Pcap:9	pulmonary capillary pressure:9:0.3455	0.3455	9
pCO2	pCO2:10|PCO2:8	carbon dioxide partial pressure:18:0.8365	0.8365	18
PCO2	PCO2:75|pCO2:12|Pco2:5|PCo2:1	carbon dioxide tension:93:0.9679	0.9679	93
PCO2	PCO2:36|pCO2:4|Pco2:1	CO2 partial pressure:41:0.5341	0.5341	41
PCO2	PCO2:61|pCO2:14|Pco2:8|PCo2:1	partial pressure of carbon dioxide:84:0.8807	0.8807	84
PCO2	PCO2:32|pCO2:8|Pco2:1	partial pressure of CO2:41:0.8867	0.8867	41
Pcrit	Pcrit:30	critical pressure:30:0.5478	0.5478	30
PDE4D	PDE4D:12	phosphodiesterase 4D:12:0.7571	0.7571	12
PDEB	PDEB:9|Pdeb:1	phosphodiesterase:10:0.5000	0.5000	10
PDGFRA	PDGFRA:10|Pdgfra:1	platelet-derived growth factor receptor alpha:11:0.5355	0.5355	11
Pdimax	Pdimax:25	transdiaphragmatic pressure:25:0.8186	0.8186	25
PDW	Pdw:4|PDW:4	diffusional water permeability:8:0.6411	0.6411	8
PECB	PECB:6|PeCB:5	pentachlorobenzene:11:0.3333	0.3333	11
PeCDD	PeCDD:11	1,2,3,7,8-pentachlorodibenzo-p-dioxin:11:0.5263	0.5263	11
PEMV	PEMV:8	pea enation mosaic virus:8:0.6411	0.6411	8
PePHD	PePHD:7	phosphorylation homology domain:7:0.3524	0.3524	7
PedsQL	PedsQL:12	Pediatric Quality of Life Inventory:12:0.7571	0.7571	12
Peff	Peff:15	permeability:15:0.4375	0.4375	15
Peg3	PEG3:5|Peg3:5	Paternally expressed gene 3:10:0.7103	0.7103	10
PEG-3	PEG-3:11	progression elevated gene-3:11:0.7357	0.7357	11
PEG-IFN	PEG-IFN:15|peg-IFN:3|pegIFN:1	pegylated interferon:19:0.7658	0.7658	19
PenCB	PenCB:10	3,3',4,4',5-pentachlorobiphenyl:10:0.3103	0.3103	10
PenCDF	PenCDF:11	2,3,4,7,8-pentachlorodibenzofuran:11:0.6667	0.6667	11
PENs	PENs:10	Pancreatic endocrine neoplasms:10:0.7103	0.7103	10
PENS	PENS:15	percutaneous electrical nerve stimulation:15:0.7909	0.7909	15
Penh	Penh:22|PenH:3|penh:1|PENH:1	enhanced pause:27:0.8903	0.8903	27
Pept-1	Pept-1:9|PEPT1:5|PepT1:5|PepT-1:3	oligopeptide transporter:22:0.3267	0.3267	22
PERC	PERC:17|Perc:6	perchloroethylene:23:0.4314	0.4314	23
PerC	PerC:12	peritoneal cavity:12:0.7571	0.7571	12
PfCSP	PfCSP:9	Plasmodium falciparum circumsporozoite protein:9:0.6794	0.6794	9
PfEMP1	PfEMP1:67|PfEMP-1:7	erythrocyte membrane protein 1:74:0.8975	0.8975	74
PfEMP-1	PfEMP-1:8|PfEMP1:4	falciparum erythrocyte membrane protein-1:12:0.5664	0.5664	12
Ph'	Ph':18	Philadelphia:18:0.5000	0.5000	18
Ph'	Ph':14	Philadelphia chromosome:14:0.7909	0.7909	14
Ph(+)	Ph(+):14	Philadelphia chromosome-positive:14:0.6911	0.6911	14
Ph+	Ph+:77	Philadelphia chromosome-positive:44:0.9323|Philadelphia chromosome positive:33:0.8605	0.9323	77
Ph+	Ph+:29	Philadelphia positive:15:0.1271|Philadelphia-positive:14:0.0798	0.1271	29
PHAB	PHAB:8	Profile of Hearing Aid Benefit:8:0.6411	0.6411	8
PhAsO	PhAsO:18	phenylarsine oxide:18:0.8365	0.8365	18
PhIP	PhIP:10	2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine:10:0.0148	0.0148	10
PhIP	PhIP:541	2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine:471:0.7463|2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine:17:0.0264|2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine:16:0.6577|2-Amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine:14:0.0214|2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine:12:0.2699|2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine:11:0.0165	0.7463	541
PheRS	PheRS:24|pheRS:2	phenylalanyl-tRNA synthetase:26:0.7340	0.7340	26
PhoA	PhoA:64|phoA:28	alkaline phosphatase:92:0.9026	0.9026	92
phoA	phoA:14	alkaline phosphatase gene:14:0.6173	0.6173	14
PHR	PHR:8	percentage hepatic replacement:8:0.4363	0.4363	8
PHR	PHR:5	Personal Health Record:5:0.2818	0.2818	5
Pi/PCr	Pi/PCr:11	ratio of inorganic phosphate to phosphocreatine:11:0.4232	0.4232	11
PIV2	PIV2:5|PIV-2:4	human parainfluenza type 2 virus:9:0.5470	0.5470	9
PIV2	PIV2:5|PIV-2:3|PiV2:1	parainfluenza virus type 2:9:0.6794	0.6794	9
PiZZ	PiZZ:9|PIZZ:1	alpha 1-antitrypsin deficiency:10:0.6794	0.6794	10
PiZ	PiZ:22	deficiency:22:0.5526	0.5526	22
PIM	PIM:7	paediatric index of mortality:7:0.1591	0.1591	7
PIM	PIM:10	Pediatric Index of Mortality:10:0.2643	0.2643	10
PIM	PIM:21|Pim:4	pimozide:25:0.1364	0.1364	25
PIM	PIM:10	polymorphic immunodominant molecule:10:0.7753	0.7753	10
pio	pio:23|Pio:10	pioglitazone:33:0.6531	0.6531	33
Pit-1	Pit-1:7|PIT1:1|PIT-1:1	pituitary-specific transcription factor:9:0.3069	0.3069	9
Pit-1	Pit-1:10|pit-1:1|PIT-1:1	transcription factor-1:12:0.7571	0.7571	12
PJ	PJ:8	pancreatic juice:8:0.1895	0.1895	8
PJ	PJ:19|P-J:1	pancreaticojejunostomy:20:0.1919	0.1919	20
Pj	Pj:9	Parietaria judaica:9:0.6794	0.6794	9
PKAN	PKAN:13	Pantothenate kinase-associated neurodegeneration:13:0.6701	0.6701	13
PLA1	PLA1:15|PL-A1:1	phospholipase A1:16:0.7261	0.7261	16
PLA	PLA:9	activity:9:0.0079	0.0079	9
Pla	Pla:50|PLA:15|PLa:1|-PLA:1	left atrial pressure:67:0.9306	0.9306	67
PLA	PLA:5|Pla:4	plantaris:9:0.0079	0.0079	9
PLA	PLA:23	poly(D,L-lactide):23:0.0217	0.0217	23
PLA	PLA:10	Poly(dl-lactide):10:0.0089	0.0089	10
PLA	PLA:13	poly(L-lactide):13:0.0118	0.0118	13
PLA	PLA:25	poly(lactide):25:0.0237	0.0237	25
PLA	PLA:123	Polylactic acid:123:0.3116	0.3116	123
PLA	PLA:37|PLa:2	polylactide:39:0.0375	0.0375	39
PLA	PLA:12	processed lipoaspirate:12:0.7571	0.7571	12
PLA	PLA:15	pyogenic liver abscess:15:0.8045	0.8045	15
PLCH	PLCH:8	pulmonary Langerhans cell histiocytosis:8:0.6411	0.6411	8
PLESS	PLESS:8	Proscar Long-Term Efficacy and Safety Study:8:0.5006	0.5006	8
Pliq	Pliq:11	liquid pressure:11:0.7357	0.7357	11
Plk1	Plk1:40|PLK1:17	polo-like kinase 1:57:0.9477	0.9477	57
PmO2	PmO2:10|Pmo2:1	oxygen tension:11:0.6182	0.6182	11
Pmax	Pmax:12	Maximal power:12:0.1830	0.1830	12
Pmus	Pmus:7	respiratory muscle pressure:7:0.2902	0.2902	7
PMV	PMV:6	avian paramyxovirus:6:0.1320	0.1320	6
PMV	PMV:9	mitral valve:9:0.4587	0.4587	9
PMV	PMV:17	mosaic virus:17:0.5038	0.5038	17
PMV	PMV:12	percutaneous mitral balloon valvotomy:12:0.7357	0.7357	12
PMV	PMV:6	percutaneous mitral valvotomy:6:0.2243	0.2243	6
PMV	PMV:33	Percutaneous mitral valvuloplasty:33:0.8196	0.8196	33
PMV	PMV:16	plasma membrane vesicles:16:0.7261	0.7261	16
PMv	PMv:6|PMV:5	premammillary nucleus:11:0.7357	0.7357	11
PMv	PMv:19|PMV:1	premotor cortex:20:0.8525	0.8525	20
PMV	PMV:15	prolonged mechanical ventilation:15:0.7096	0.7096	15
Pmv	Pmv:17	pulmonary microvascular pressure:17:0.4246	0.4246	17
PMZ	PMZ:16|Pmz:1	promethazine:17:0.5333	0.5333	17
PNK	PNK:13|pnk:3|Pnk:3	polynucleotide kinase:19:0.5732	0.5732	19
PNPs	PNPs:25	pediatric nurse practitioners:25:0.8186	0.8186	25
PoAb	PoAb:8	polyclonal antibody:8:0.5006	0.5006	8
Poes	Poes:11|POES:1	oesophageal pressure:12:0.5050	0.5050	12
PolI	PolI:14|polI:5	polymerase I:19:0.8449	0.8449	19
Poleta	Poleta:13|poleta:7	DNA polymerase eta:20:0.8525	0.8525	20
Popen	Popen:7|P-open:1	open probability:8:0.3463	0.3463	8
Posmol	Posmol:19|pOsmol:1|POSMOL:1	plasma osmolality:21:0.7865	0.7865	21
Posm	Posm:7	osmotic water permeability:7:0.4438	0.4438	7
Posm	Posm:45|pOsm:17|POsm:5|POSM:4|pOSM:3|posm:1|posM:1|p-osm:1	plasma osmolality:77:0.8023	0.8023	77
POST	POST:9	Plastic Occlusion Stress Test:9:0.6794	0.6794	9
POS	POS:11	Palliative Care Outcome Scale:11:0.7357	0.7357	11
POS	POS:17	photoreceptor outer segments:17:0.8270	0.8270	17
POS	POS:14	point-of-service:14:0.0558	0.0558	14
POS	POS:7	polycystic ovary syndrome:7:0.5926	0.5926	7
POX	POX:21|Pox:1	paraoxon:22:0.2222	0.2222	22
POX	POX:25|POx:2|Pox:1	peroxidase:28:0.3000	0.3000	28
Pp/Ps	Pp/Ps:10|PP/PS:1	pressure ratio:11:0.7357	0.7357	11
PpIX	PpIX:221|PPIX:87|PP-IX:2|ppIX:2|PPix:1	protoporphyrin IX:313:0.9659	0.9659	313
Ppao	Ppao:7	pulmonary artery occlusion pressure:7:0.5926	0.5926	7
PPA	PPA:7	parahippocampal place area:7:0.5926	0.5926	7
PPA	PPA:10	passive peritoneal anaphylaxis:10:0.7103	0.7103	10
PPA	PPA:127|Ppa:2	Phenylpropanolamine:129:0.1216	0.1216	129
PPA	PPA:15	Phenylpropanolamine hydrochloride:15:0.7096	0.7096	15
PPA	PPA:10	phenylpyruvic acid:10:0.0510	0.0510	10
PPA	PPA:22	Pipemidic acid:22:0.2001	0.2001	22
PPA	PPA:28	porcine pancreatic alpha-amylase:28:0.7505	0.7505	28
PPA	PPA:11	postpartum amenorrhea:11:0.4728	0.4728	11
PPA	PPA:56	primary progressive aphasia:56:0.9467	0.9467	56
PPA	PPA:6	procoagulant activity:6:0.1838	0.1838	6
Ppa	Ppa:28	pulmonary arterial:28:0.8941	0.8941	28
Ppa	Ppa:184|PPA:22|pPA:1	pulmonary arterial pressure:202:0.9852|pulmonary arterial pressures:5:0.4422	0.9852	207
Ppa	Ppa:22|PPA:1	pulmonary artery:23:0.7500	0.7500	23
Ppa	Ppa:139|PPA:27|pPA:2|ppa:1|PPa:1	pulmonary artery pressure:164:0.9817|pulmonary artery pressures:6:0.5290	0.9817	170
Pplat	Pplat:9	plateau pressure:9:0.4587	0.4587	9
Ppw	Ppw:15	wedge pressure:15:0.7096	0.7096	15
PRCC	PRCC:8|pRCC:1	papillary renal cell carcinoma:9:0.5470	0.5470	9
PRCA	PRCA:9|PrCa:5|PRCa:4	Prostate cancer:18:0.8365	0.8365	18
PRCA	PRCA:268	pure red cell aplasia:268:0.9647	0.9647	268
PRh	PRh:5|PRH:4|Prh:2	perirhinal:11:0.1031	0.1031	11
PRh	PRh:16|PRH:3|Prh:2	perirhinal cortex:21:0.8594	0.8594	21
PRH	PRH:7	postocclusive reactive hyperemia:7:0.4438	0.4438	7
PRH	PRH:7	primary rat hepatocytes:7:0.5926	0.5926	7
PrP(C)	PrP(C):6|PrP(c):1	cellular form:7:0.2902	0.2902	7
PrP(C)	PrP(C):94|PrP(c):38|Prp(C):1|Prp(c):1	cellular prion protein:134:0.5552	0.5552	134
PrP(C)	PrP(C):5|PrP(c):2	cellular PrP:7:0.1329	0.1329	7
PrP(d)	PrP(d):10	prion protein:10:0.7103	0.7103	10
PRP-D	PRP-D:10	diphtheria toxoid:10:0.4363	0.4363	10
PRP-D	PRP-D:11	toxoid conjugate vaccine:11:0.4728	0.4728	11
PrPC	PrPC:7|PrPc:6	cellular isoform:13:0.4849	0.4849	13
PrPC	PrPC:75|PrPc:56|PrP-C:1	cellular prion protein:132:0.5019	0.5019	132
PrPC	PrPC:10|PrPc:4	cellular PrP:14:0.3585	0.3585	14
PrP-res	PrP-res:4|PrPres:1	protease-resistant isoform:5:0.0612	0.0612	5
PrP-res	PrP-res:7|PrPres:3|PrPRES:1	protease-resistant PrP:11:0.1683	0.1683	11
PRRSV	PRRSV:446|PRRSv:2	porcine reproductive and respiratory syndrome virus:448:0.9892	0.9892	448
PRBC	PRBC:12|pRBC:7|Prbc:1	erythrocytes:20:0.1180	0.1180	20
PRBC	PRBC:68|pRBC:6|prbc:1	packed red blood cells:48:0.4992|Packed red blood cell:27:0.5951	0.5951	75
Pre-I	Pre-I:14|pre-I:2|PreI:1	pre-inspiratory:17:0.5161	0.5161	17
PRFA	PRFA:8	percutaneous radiofrequency ablation:8:0.6411	0.6411	8
PRL-R	PRL-R:76|PRLR:74|PrlR:10|PRLr:9|Prlr:2	prolactin receptor:137:0.4789|prolactin receptors:34:0.6015	0.6015	171
PRODH	PRODH:10|ProDH:5	proline dehydrogenase:15:0.5348	0.5348	15
ProPTH	ProPTH:8|pro-PTH:2|proPTH:1	proparathyroid hormone:11:0.7357	0.7357	11
ProRS	ProRS:14	prolyl-tRNA synthetase:14:0.5111	0.5111	14
PROG	PROG:74|Prog:58|prog:3	progesterone:135:0.8121	0.8121	135
PROP	PROP:58|Prop:2	6-n-propylthiouracil:60:0.3558	0.3558	60
PROP	PROP:37|Prop:17|prop:2	propranolol:56:0.3374	0.3374	56
Protox	Protox:11|protox:2|PROTOX:1	protoporphyrinogen oxidase:14:0.6911	0.6911	14
Proto	Proto:9|PROTO:2|proto:1	PROTOPORPHYRIN IX:12:0.7571	0.7571	12
PSMS	PSMS:11	Physical Self-Maintenance Scale:11:0.6460	0.6460	11
PSTs	PSTs:12	paralytic shellfish toxins:12:0.7357	0.7357	12
PSTs	PSTs:8|P-STs:1	Phenol sulfotransferases:9:0.4587	0.4587	9
PSY	PSY:8|Psy:5|psy:4	phytoene synthase:17:0.8270	0.8270	17
PSY	PSY:8|Psy:2	psyllium:10:0.1698	0.1698	10
PtO2	PtO2:7|ptO2:6|Pto2:2	Tissue oxygen pressure:15:0.5818	0.5818	15
PtO2	PtO2:13|Pto2:3|ptO2:2|PTO2:2	Tissue oxygen tension:20:0.7955	0.7955	20
PtcCO2	PtcCO2:6	transcutaneous carbon dioxide tension:6:0.3728	0.3728	6
PtcCO2	PtcCO2:30|ptcCO2:1|PTcCO2:1	transcutaneous PCO2:32:0.8145	0.8145	32
PtcO2	PtcO2:10	transcutaneous:10:0.0455	0.0455	10
PtcO2	PtcO2:23|PtCO2:1|PTCO2:1	transcutaneous oxygen:25:0.4451	0.4451	25
PtcO2	PtcO2:5|PtCO2:1|PTCO2:1|ptCO2:1	Transcutaneous oxygen pressure:8:0.6411	0.6411	8
PtcO2	PtcO2:38|ptcO2:5|PtCO2:5|Ptco2:4|pTcO2:4|PTCO2:1	transcutaneous oxygen tension:57:0.8097	0.8097	57
PtcO2	PtcO2:19|PtCO2:2|ptcO2:1|Ptco2:1|PTCO2:1	transcutaneous pO2:24:0.6122	0.6122	24
PtdCho	PtdCho:204|Ptd-Cho:1	phosphatidylcholine:205:0.9273	0.9273	205
PtdGro	PtdGro:9	phosphatidylglycerol:9:0.6667	0.6667	9
PtdIns	PtdIns:274|Ptd-Ins:2	phosphatidylinositol:276:0.8703	0.8703	276
PtdIns	PtdIns:10	phosphoinositide:10:0.0285	0.0285	10
PtdOH	PtdOH:42	phosphatidic acid:42:0.8558	0.8558	42
PtdSer	PtdSer:103|Ptd-Ser:1	Phosphatidylserine:104:0.9450	0.9450	104
PTDs	PTDs:24	Protein transduction domains:24:0.8768	0.8768	24
PtiO2	ptiO2:3|PtiO2:3	brain tissue oxygenation:6:0.2827	0.2827	6
PtiO2	PtiO2:6|ptiO2:1	oxygen pressure:7:0.2113	0.2113	7
PTL	PTL:9	pancreatic triglyceride lipase:9:0.6794	0.6794	9
PTL	PTL:23	peripheral T-cell lymphoma:12:0.6182|peripheral T-cell lymphomas:11:0.7357	0.7357	23
PTL	PTL:52	preterm labor:43:0.8590|preterm labour:9:0.4363	0.8590	52
PTM	PTM:7	Perceptual Template Model:7:0.5926	0.5926	7
PTM	PTM:8	post-translational modification:8:0.4102	0.4102	8
PTM	PTM:11	pretibial myxedema:11:0.6182	0.6182	11
PTM	PTM:17	proximal tibial metaphysis:17:0.8270	0.8270	17
Ptm	Ptm:19|PTM:1	transmural pressure:20:0.5892	0.5892	20
PUI	PUI:6	pupillary unrest index:6:0.5290	0.5290	6
PUO	PUO:42	pyrexia of unknown origin:42:0.8893	0.8893	42
PvMSP-1	PvMSP-1:6|PvMsp-1:1	Plasmodium vivax:7:0.3524	0.3524	7
PvCO2	PvCO2:9|PVCO2:7|Pv-CO2:1	mixed venous PCO2:17:0.5228	0.5228	17
PvCO2	PvCO2:5|PVCO2:3	venous carbon dioxide tension:8:0.6411	0.6411	8
PxxP	PxxP:8|PXXP:2	proline-rich:10:0.3214	0.3214	10
Py-GC-MS	Py-GC-MS:12	pyrolysis-gas chromatography-mass spectrometry:12:0.5664	0.5664	12
Py-GC	Py-GC:12|PyGC:1	pyrolysis-gas chromatography:13:0.5335	0.5335	13
PyMS	PyMS:34|Py-MS:11|PYMS:3|pyMS:1	pyrolysis mass spectrometry:49:0.8753	0.8753	49
PYO	PYO:9|pyo:4	person years of observation:7:0.5926|person-years of observation:6:0.1470	0.5926	13
PyV	PyV:15	polyoma virus:15:0.8045	0.8045	15
PyV	PyV:25|PYV:1	polyomavirus:26:0.4167	0.4167	26
pYV	pYV:12	virulence plasmid:12:0.4728	0.4728	12
PyMT	PyMT:10|Py-MT:4|PymT:3	polyoma middle T:17:0.7407	0.7407	17
Py	Py:16	N-methylpyrrole:16:0.0214	0.0214	16
PY	PY:12|py:3|p-y:2	patient-years:17:0.0228	0.0228	17
PY	PY:6	peptide Y:6:0.0807	0.0807	6
PY	PY:13|py:7|p-y:2	per 100 person-years:22:0.7955	0.7955	22
PY	PY:14|py:9	person years:23:0.5997	0.5997	23
pY	pY:18|PY:11	phosphotyrosine:29:0.0399	0.0399	29
Py	Py:23|PY:2|py:1	Polyoma:26:0.0356	0.0356	26
Py	Py:36|PY:3|py:1	polyoma virus:40:0.9256	0.9256	40
Py	Py:87	polyomavirus:87:0.1225	0.1225	87
Py	Py:16|PY:14|py:1	pyrene:31:0.0427	0.0427	31
py	py:26|Py:10|PY:7	pyridine:43:0.0598	0.0598	43
PY	PY:8|Py:3	pyrimethamine:11:0.0142	0.0142	11
PY	PY:4|Py:3	Pyronin Y:7:0.1329	0.1329	7
Py	Py:14|PY:1	pyrrole:15:0.0199	0.0199	15
Q10	Q10:9	coenzyme Q10:9:0.6794	0.6794	9
Q10	Q10:50	temperature coefficient:50:0.9064	0.9064	50
Q10	Q10:9|Q-10:3	ubiquinone:12:0.0769	0.0769	12
Q-10	Q-10:6|Q10:4	ubiquinone-10:10:0.0629	0.0629	10
Q-1	Q-1:7|Q1:3	ubiquinone-1:10:0.0865	0.0865	10
q2	q2:8|Q2:1	cross-validated R2:9:0.5856	0.5856	9
QACs	QACs:39	quaternary ammonium compounds:39:0.7860	0.7860	39
QAC	QAC:22	quaternary ammonium compounds:11:0.7357|quaternary ammonium compound:11:0.5355	0.7357	22
QALE	QALE:14	quality-adjusted life expectancy:14:0.7909	0.7909	14
QALY	QALY:36	cost per quality-adjusted life year:36:0.3266	0.3266	36
QALY	QALY:35	quality adjusted life years:22:0.8657|quality-adjusted life-years:13:0.5335	0.8657	35
QALYs	QALYs:397|Qalys:1	quality-adjusted life years:171:0.6050|quality-adjusted life-years:145:0.9031|quality adjusted life years:82:0.9636	0.9636	398
QAP	QAP:18	Quality Assurance Program:18:0.8365	0.8365	18
QAP	QAP:8	quality assurance project:8:0.6411	0.6411	8
QAR	QAR:17	quantitative autoradiography:17:0.7407	0.7407	17
Qa	Qa:7	access blood flow:7:0.1329	0.1329	7
Qa	Qa:7|QA:3	Access flow:10:0.0682	0.0682	10
QA	QA:6	electron acceptor:6:0.0899	0.0899	6
QA	QA:15	glomerular plasma flow:15:0.5348	0.5348	15
QA	QA:26	glomerular plasma flow rate:26:0.6084	0.6084	26
QA	QA:9	primary:9:0.0076	0.0076	9
QA	QA:5	primary quinone:5:0.0902	0.0902	5
QA	QA:6	primary quinone acceptor:6:0.2827	0.2827	6
QA	QA:16	Quality Assessment:16:0.8165	0.8165	16
QA	QA:473|qa:1	quality assurance:464:0.9862|quality-assurance:10:0.0085	0.9862	474
QA	QA:21	Quaternary ammonium:21:0.7291	0.7291	21
QA	QA:150	quinolinic acid:150:0.6142	0.6142	150
QBC	QBC:33	quantitative buffy coat:33:0.9100	0.9100	33
Qb	Qb:20|QB:15	blood flow:35:0.7952	0.7952	35
Qb	Qb:5|QB:3	blood flow rate:8:0.5006	0.5006	8
QB	QB:13	quiet breathing:13:0.7753	0.7753	13
QB	QB:13	secondary quinone:13:0.5335	0.5335	13
QB	QB:4	secondary quinone acceptor:4:0.1618	0.1618	4
QCA	QCA:8	Quantitative coronary analysis:8:0.6411	0.6411	8
QCA	QCA:11	quantitative coronary angiographic:11:0.7357	0.7357	11
QCA	QCA:140|qCA:1	quantitative coronary angiography:141:0.9352	0.9352	141
QCA	QCA:16	quantitative coronary arteriography:16:0.8165	0.8165	16
QCM-D	QCM-D:9	quartz crystal microbalance with dissipation monitoring:9:0.6794	0.6794	9
QCM	QCM:152	quartz crystal microbalance:152:0.9585	0.9585	152
QC-PCR	QC-PCR:19|qcPCR:2|QCPCR:2|QC--PCR:1	quantitative competitive PCR:24:0.8816	0.8816	24
QC-PCR	QC-PCR:20|qc-PCR:3|QCPCR:2|qcPCR:1	quantitative competitive polymerase chain reaction:16:0.8270|Quantitative-competitive polymerase chain reaction:10:0.1273	0.8270	26
QCP	QCP:10	quantum critical point:10:0.7103	0.7103	10
QCT	QCT:303|qCT:9	quantitative computed tomography:312:0.9420	0.9420	312
QCT	QCT:32	quantitative CT:32:0.9072	0.9072	32
Qc	Qc:56|QC:5	cardiac output:61:0.9511	0.9511	61
Qc	Qc:25|QC:1	pulmonary capillary blood flow:26:0.7760	0.7760	26
Qc	Qc:7	pulmonary capillary blood volume:7:0.3524	0.3524	7
QC	QC:376	quality control:350:0.9774|quality-control:26:0.0391	0.9774	376
QC	QC:10	quiescent center:10:0.7103	0.7103	10
QDC	QDC:8	Qualitative diagnostic calibration:8:0.5006	0.5006	8
QDR	QDR:10	Quantitative digital radiography:10:0.7103	0.7103	10
QDs	QDs:71	quantum dots:71:0.9579	0.9579	71
Qdi	Qdi:12	diaphragmatic blood flow:12:0.5664	0.5664	12
QD	QD:4|Qd:3	dialysate flow:7:0.3524	0.3524	7
QD	QD:8|qd:1	once a day:9:0.6794	0.6794	9
QD	QD:31|qd:16|qD:1	once daily:38:0.5720|once-daily:10:0.0383	0.5720	48
QD	QD:17	quantum dot:17:0.8270	0.8270	17
QD	QD:17|Qd:5	quinidine:22:0.0894	0.0894	22
Q-D	Q-D:17|QD:3	quinupristin-dalfopristin:20:0.0809	0.0809	20
QECH	QECH:22	Queen Elizabeth Central Hospital:22:0.8657	0.8657	22
QEEG	QEEG:50|qEEG:48	quantitative EEG:98:0.7440	0.7440	98
QEEG	QEEG:9|qEEG:8	quantitative electroencephalogram:17:0.5038	0.5038	17
QEEG	QEEG:16|qEEG:7	quantitative electroencephalographic:23:0.7500	0.7500	23
QEEG	QEEG:34|qEEG:20|q-EEG:2	quantitative electroencephalography:56:0.8453	0.8453	56
QENS	QENS:7	Quasielastic neutron scattering:7:0.3524	0.3524	7
QFD	QFD:10	Quality Function Deployment:10:0.7103	0.7103	10
QF-DE	QF-DE:20	quick-freezing and deep-etching:20:0.7291	0.7291	20
QFIA	QFIA:12	Quantitative fluorescence image analysis:12:0.7571	0.7571	12
Q-FISH	Q-FISH:17|QFISH:1|qFISH:1	quantitative fluorescence in situ hybridization:19:0.7658	0.7658	19
QF-PCR	QF-PCR:7|QFPCR:1	Quantitative fluorescent PCR:8:0.6411	0.6411	8
QF-PCR	QF-PCR:16	quantitative fluorescent polymerase chain reaction:16:0.8165	0.8165	16
QFR	QFR:9	reductase:9:0.5333	0.5333	9
QFS	QFS:14	Quebec Family Study:14:0.7909	0.7909	14
QF	QF:36	quadriceps femoris:36:0.9174	0.9174	36
QF	QF:14|Q-F:4	quantity-frequency:18:0.1181	0.1181	18
QGS	QGS:6	quantitative gated single photon emission computed tomography:6:0.3728	0.3728	6
QGS	QGS:33	quantitative gated SPECT:33:0.8196	0.8196	33
Q-HCl	Q-HCl:6|QHCl:4	quinine-HCl:10:0.1800	0.1800	10
QHCl	QHCl:23|Q-HCl:3|QHCL:1	quinine hydrochloride:27:0.7834	0.7834	27
QHS	QHS:9	qinghaosu:9:0.2667	0.2667	9
QIO	QIO:11	Quality Improvement Organization:11:0.7357	0.7357	11
QIOs	QIOs:13	Quality Improvement Organizations:13:0.7753	0.7753	13
QIs	QIs:18	quality indicators:18:0.8365	0.8365	18
QI	QI:202	quality improvement:202:0.9612	0.9612	202
QI	QI:11	quality index:11:0.1037	0.1037	11
QI	QI:23	Quetelet Index:23:0.3592	0.3592	23
QLDS	QLDS:16|Qlds:1	Quality of Life in Depression Scale:17:0.8365	0.8365	17
Q-LES-Q	Q-LES-Q:15|QLESQ:3	Quality of Life Enjoyment and Satisfaction Questionnaire:18:0.8449	0.8449	18
QLF	QLF:36	quantitative light-induced fluorescence:36:0.8196	0.8196	36
QLI	QLI:39	Quality of Life Index:39:0.9237	0.9237	39
QLQ	QLQ:7	Quality of Life Questionnaire:7:0.5926	0.5926	7
QLS	QLS:26	Light Scattering:26:0.8861	0.8861	26
QLS	QLS:29	Quality of Life Scale:29:0.8978	0.8978	29
QLV	QLV:9	quasi-linear viscoelastic:9:0.3455	0.3455	9
QL	QL:91|Ql:2	lymph flow:93:0.7331	0.7331	93
QL	QL:13	lymph flow rate:13:0.6701	0.6701	13
QL	QL:254|Q-L:1	Quality of life:236:0.9874|quality-of-life:19:0.0393	0.9874	255
QM/MM	QM/MM:16	Quantum Mechanics/Molecular Mechanics:16:0.8165	0.8165	16
QM/MM	QM/MM:30	quantum mechanical/molecular mechanical:30:0.9011	0.9011	30
QMI	QMI:14|Q-MI:4	myocardial infarction:18:0.6903	0.6903	18
QMR	QMR:27	Quick Medical Reference:27:0.8312	0.8312	27
QMRA	QMRA:7	quantitative microbial risk assessment:7:0.5926	0.5926	7
QMS	QMS:8	quality management system:8:0.6411	0.6411	8
Qm	Qm:9|qm:2|QM:2	blood flow:13:0.5934	0.5934	13
QM	QM:34	quality management:34:0.9151	0.9151	34
QM	QM:11	quantum mechanics:11:0.7357	0.7357	11
QM	QM:26	quantum mechanical:26:0.8861	0.8861	26
QM	QM:16|Q-M:1	quinacrine mustard:17:0.8270	0.8270	17
QNB	QNB:11	quinuclidinyl benzylate:11:0.1612	0.1612	11
QN	QN:25|Qn:6	quinine:31:0.3614	0.3614	31
QO2	QO2:20|Qo2:1	O2 delivery:21:0.4344	0.4344	21
QO2	QO2:109|Qo2:7|qO2:1	oxygen consumption:117:0.7649	0.7649	117
QO2	QO2:17|qO2:2|Qo2:1	oxygen consumption rate:20:0.8525	0.8525	20
QO2	QO2:13	oxygen delivery:13:0.1824	0.1824	13
QO2	QO2:7|QO-2:1|qO2:1	respiration:9:0.0319	0.0319	9
QOD	QOD:5|qod:4	every other day:9:0.6794	0.6794	9
QOLRAD	QOLRAD:14	Quality of Life in Reflux and Dyspepsia:14:0.7909	0.7909	14
QOL	QOL:2759|QoL:1136|Qol:7|qol:3	quality of life:3637:0.9966|quality-of-life:268:0.0674	0.9966	3905
QOR	QOR:15	oxidoreductase:15:0.4118	0.4118	15
QOR	QOR:10	quality of object relations:10:0.7103	0.7103	10
Qpa	Qpa:3|QPA:2|qPA:1	blood flow:6:0.1838	0.1838	6
QPCR	QPCR:43|Q-PCR:34|qPCR:27|q-PCR:1	quantitative PCR:105:0.6476	0.6476	105
QPCR	QPCR:38|Q-PCR:25|qPCR:18|q-PCR:2	quantitative polymerase chain reaction:83:0.7341	0.7341	83
qPCR	qPCR:13|QPCR:6|Q-PCR:5	quantitative real-time PCR:24:0.6873	0.6873	24
Q-PCR	Q-PCR:4|QPCR:2|qPCR:1	quantitative RT-PCR:7:0.2452	0.2452	7
QPRT	QPRT:8	quinolinic acid phosphoribosyltransferase:8:0.6411	0.6411	8
QPTH	QPTH:9|qPTH:1	parathyroid hormone:10:0.7103	0.7103	10
QQ	QQ:9	quisqualate:9:0.3077	0.3077	9
QRA	QRA:18	quantitative risk assessment:18:0.7539	0.7539	18
QRDR	QRDR:48	quinolone resistance-determining region:41:0.8867|quinolone resistance-determining regions:7:0.5926	0.8867	48
QRDRs	QRDRs:24	quinolone resistance-determining regions:24:0.8768	0.8768	24
QRNG	QRNG:6	Quinolone-resistant Neisseria gonorrhoeae:6:0.5290	0.5290	6
QRS-VD	QRS-VD:8	QRS vector difference:8:0.6411	0.6411	8
QRSd	QRSd:15|QRSD:12|QRS-D:1	QRS duration:28:0.7905	0.7905	28
QRT-PCR	QRT-PCR:8|qrt-PCR:4|Q-RT-PCR:3|qRT-PCR:2	quantitative real-time PCR:17:0.5940	0.5940	17
QRT-PCR	QRT-PCR:8|qRT-PCR:5|QRTPCR:1|Q-Rt-PCR:1|Q-RT-PCR:1	quantitative real-time polymerase chain reaction:16:0.7261	0.7261	16
Q-RT-PCR	Q-RT-PCR:5|qRT-PCR:4|QRT-PCR:4	quantitative reverse transcriptase polymerase chain reaction:13:0.5934	0.5934	13
QRT-PCR	QRT-PCR:5|qRT-PCR:2|Q-RT-PCR:2	quantitative reverse transcription-PCR:9:0.6794	0.6794	9
Q-RT-PCR	Q-RT-PCR:19|qRT-PCR:13|QRT-PCR:13	quantitative reverse transcription-polymerase chain reaction:26:0.7340|Quantitative reverse transcription polymerase chain reaction:19:0.5732	0.7340	45
qRT-PCR	qRT-PCR:12|QRT-PCR:9|Q-RT-PCR:2	quantitative RT-PCR:23:0.5025	0.5025	23
QR	QR:9	NAD(P)H:Quinone oxidoreductase:9:0.1809	0.1809	9
Qr	Qr:8|QR:2	perfusion:10:0.0372	0.0372	10
QR	QR:2|Qr:2|qR:1	Regional blood flow:5:0.2818	0.2818	5
QS2I	QS2I:9|QS2i:4|Q-S2I:1	electromechanical systole:14:0.6911	0.6911	14
QS2I	QS2I:6	electromechanical systole index:6:0.5290	0.5290	6
QS2c	QS2c:12	electromechanical systole:12:0.7571	0.7571	12
QS2	QS2:51|Q-S2:5	electromechanical systole:56:0.8478	0.8478	56
QSAR	QSAR:640	quantitative structure-activity relationship:470:0.9633|Quantitative structure-activity relationships:170:0.9543	0.9633	640
QSART	QSART:23|Q-SART:2	quantitative sudomotor axon reflex test:25:0.8768	0.8768	25
QSARs	QSARs:168|QSARS:1	Quantitative structure-activity relationships:169:0.9717	0.9717	169
QSPR	QSPR:58	quantitative structure-property relationship:47:0.9366|quantitative structure-property relationships:11:0.7357	0.9366	58
QSRL	QSRL:13	Q-switched ruby laser:13:0.5934	0.5934	13
QSRR	QSRR:36	quantitative structure-retention relationship:21:0.8594|quantitative structure-retention relationships:15:0.8045	0.8594	36
QSRRs	QSRRs:6	quantitative structure-retention relationships:6:0.5290	0.5290	6
QSS	QSS:7	quantitative sacroiliac scintigraphy:7:0.5926	0.5926	7
QSTR	QSTR:6	quantitative structure-toxicity relationship:6:0.5290	0.5290	6
QST	QST:58	quantitative sensory testing:58:0.8710	0.8710	58
QS	QS:9	quiet:9:0.0195	0.0195	9
QS	QS:29	Quinacrine sterilization:29:0.7970	0.7970	29
QS	QS:5	quinidine sulfate:5:0.1132	0.1132	5
QS	QS:53	Quorum sensing:37:0.9197|quorum-sensing:16:0.0365	0.9197	53
Qs	Qs:9|QS:2	systemic blood flow:11:0.7357	0.7357	11
QTL	QTL:874	quantitative trait loci:874:0.9892	0.9892	874
QTL	QTL:491	quantitative trait locus:491:0.9753	0.9753	491
QTLs	QTLs:572	quantitative trait loci:572:0.9861	0.9861	572
QTVI	QTVI:9|QTvi:2	QT variability index:11:0.5355	0.5355	11
Q-TWiST	Q-TWiST:3|Q-TwiST:1	Quality-adjusted Time Without Symptoms and Toxicity:4:0.7407	0.7407	4
QTcd	QTcd:6|QTcD:4|QTc-d:2	corrected QT dispersion:12:0.4153	0.4153	12
QTcd	QTcd:11|QTcD:1	corrected QTd:12:0.4557	0.4557	12
QTcd	QTcd:8|QTc-d:1|QTcD:1	QTc dispersion:10:0.1449	0.1449	10
QTc	QTc:9|Q-Tc:1	Bazett's formula:10:0.5856	0.5856	10
QTc	QTc:11|Q-Tc:1	corrected:12:0.0202	0.0202	12
QTc	QTc:128	corrected QT:128:0.6804	0.6804	128
QTc	QTc:142|Q-Tc:1	corrected QT interval:133:0.6820|corrected QT intervals:10:0.3470	0.6820	143
QTc	QTc:33|QTC:1	QT interval corrected for heart rate:34:0.7433	0.7433	34
QUART	QUART:4	axillary dissection and radiotherapy:4:0.5926	0.5926	4
QUERI	QUERI:14	Quality Enhancement Research Initiative:14:0.7753	0.7753	14
QUICKI	QUICKI:62|QUICK-I:1	quantitative insulin sensitivity check index:63:0.9526	0.9526	63
QUIN	QUIN:5	agonist quinpirole:5:0.0736	0.0736	5
QUIN	QUIN:18|Quin:1	quinolinate:19:0.0700	0.0700	19
QUIN	QUIN:191|Quin:11	quinolinic acid:202:0.9763	0.9763	202
QUIS	QUIS:8|quis:4	quisqualic:12:0.0748	0.0748	12
QUIS	QUIS:32|quis:10|Quis:1	quisqualic acid:43:0.8335	0.8335	43
QUS	QUS:15	quantitative ultrasonometry:15:0.5818	0.5818	15
QUS	QUS:313|qUS:2	quantitative ultrasound:315:0.9142	0.9142	315
QU	QU:14|Qu:5	quercetin:19:0.3273	0.3273	19
QWB	QWB:36	Quality of Well-being:36:0.9174	0.9174	36
QWB	QWB:36	quality of well-being scale:36:0.9174	0.9174	36
QW	QW:3|qw:3	once weekly:6:0.2243	0.2243	6
QW	QW:15|Qw:3	quiet wakefulness:18:0.7539	0.7539	18
QW	QW:11|Qw:1	quiet waking:12:0.6460	0.6460	12
QAU	QAU:13	quality assurance unit:13:0.7753	0.7753	13
Qaw	Qaw:10	airway mucosal blood flow:10:0.5856	0.5856	10
Qbr	Qbr:18	bronchial blood flow:18:0.5560	0.5560	18
Qlym	Qlym:27	Pulmonary lymph flow:27:0.4992	0.4992	27
Qmax	Qmax:17	maximal cardiac output:17:0.6748	0.6748	17
QMB	QMB:9	Qualified Medicare Beneficiary:9:0.6794	0.6794	9
Qp/Qs	Qp/Qs:11	pulmonary to systemic blood flow:11:0.7357	0.7357	11
Qp/Qs	Qp/Qs:6|QP/QS:1	pulmonary to systemic blood flow ratio:7:0.5926	0.5926	7
Qp/Qs	Qp/Qs:18|QP/QS:1	pulmonary to systemic flow ratio:19:0.7044	0.7044	19
Qp/Qs	Qp/Qs:16	ratio of pulmonary to systemic flow:16:0.6537	0.6537	16
Qp	Qp:10|QP:4	pulmonary:14:0.0833	0.0833	14
Qp	Qp:22|QP:1	pulmonary blood flow:23:0.5466	0.5466	23
Qs/Qt	Qs/Qt:27|QS/QT:10|Qs/QT:4	intrapulmonary shunt:41:0.2774	0.2774	41
Qs/Qt	Qs/Qt:10	intrapulmonary shunting:10:0.1878	0.1878	10
Qs/Qt	Qs/Qt:17|QS/QT:4|Qs/QT:2|QS/Qt:1	pulmonary shunt:24:0.1342	0.1342	24
Qs/Qt	Qs/Qt:37|QS/QT:10|Qs/QT:7	shunt fraction:54:0.9448	0.9448	54
Qs/Qt	Qs/Qt:29|QS/QT:8|QS/Qt:1	venous admixture:38:0.9217	0.9217	38
Qsp/Qt	Qsp/Qt:14	intrapulmonary shunt:14:0.2892	0.2892	14
Qsp/Qt	Qsp/Qt:14	shunt fraction:14:0.7909	0.7909	14
Qsp/Qt	Qsp/Qt:17|QSP/QT:1	venous admixture:18:0.8365	0.8365	18
QTd	QTd:111|QTD:29|QT-d:1|QT-D:1	QT dispersion:142:0.7664	0.7664	142
QTH	QTH:21	quartz-tungsten-halogen:11:0.3226|quartz tungsten halogen:10:0.7103	0.7103	21
QT	QT:56|Qt:47	cardiac output:103:0.9710	0.9710	103
QT	QT:9|Q-T:2	electrical systole:11:0.5355	0.5355	11
Que	Que:11|QUE:2|que:1	Quercetin:14:0.7222	0.7222	14
QUI	QUI:18	quantitative ultrasound index:18:0.6903	0.6903	18
Qui	Qui:7|QUI:2	quinidine:9:0.1429	0.1429	9
Qva/Qt	Qva/Qt:23|QVA/QT:19|Qva/QT:5|QVA/Qt:1|QVa/QT:1	venous admixture:49:0.9046	0.9046	49
R&D	R&D:90	research and development:90:0.9668	0.9668	90
r(2)	r(2):19|R(2):14	correlation coefficient:33:0.6976	0.6976	33
R(h)	R(h):8|R(H):1	hydrodynamic radius:9:0.6794	0.6794	9
R(N)	R(N):7|R(n):2	input resistance:9:0.6794	0.6794	9
R(te)	R(te):7|R(TE):6	resistance:13:0.9231	0.9231	13
R(a)	R(a):10	glucose production:10:0.5856	0.5856	10
R(a)	R(a):26	rate of appearance:26:0.3863	0.3863	26
R(a)	R(a):6	surface roughness:6:0.1320	0.1320	6
R(aw)	R(aw):25	airway resistance:25:0.6539	0.6539	25
R(g)	R(g):11|R(G):2	radius of gyration:13:0.5111	0.5111	13
R(in)	R(in):17	input resistance:17:0.8270	0.8270	17
R(L)	R(L):39|R(l):1	resistance:40:0.8125	0.8125	40
r(m)	r(m):8	intrinsic rate of natural increase:8:0.6411	0.6411	8
R(p)	R(p):6|R(P):1	polarization resistance:7:0.2902	0.2902	7
R(rs)	R(rs):14	resistance:14:0.8667	0.8667	14
R(t)	R(t):18|R(T):6	resistance:24:0.6389	0.6389	24
R-Smads	R-Smads:21	Receptor-regulated Smads:21:0.4945	0.4945	21
R.A.	R.A.:25|r.A.:1	rheumatoid arthritis:26:0.8251	0.8251	26
R.I.A.	R.I.A.:14|r.i.a.:8	radioimmunoassay:22:0.5676	0.5676	22
R.I.	R.I.:11	Index:11:0.5882	0.5882	11
R.S.D.s	R.S.D.s:13	relative standard deviations:13:0.7753	0.7753	13
R/M	R/M:12	restriction and modification:12:0.7571	0.7571	12
R0	R0:6	basic reproduction number:6:0.2243	0.2243	6
R0	R0:25	Complete resection:25:0.2092	0.2092	25
R0	R0:29|R-0:1	curative resection:30:0.2701	0.2701	30
R0	R0:8	reproduction ratio:8:0.3463	0.3463	8
R123	R123:100|R-123:19	rhodamine 123:98:0.9695|rhodamine-123:21:0.1587	0.9695	119
R1881	R1881:18|R-1881:1	[3H]methyltrienolone:19:0.1259	0.1259	19
R1881	R1881:15	synthetic androgen methyltrienolone:15:0.6024	0.6024	15
R18	R18:10|R-18:1	octadecyl rhodamine B chloride:11:0.7357	0.7357	11
R18	R18:12|R-18:1	octadecylrhodamine:13:0.1333	0.1333	13
R18	R18:8	octadecylrhodamine B:8:0.2987	0.2987	8
R18	R18:10	octadecylrhodamine B chloride:10:0.2126	0.2126	10
R1	R1:11|R-1:1	early:12:0.0178	0.0178	12
R1	R1:7	early component:7:0.1111	0.1111	7
R1	R1:7	early response:7:0.1641	0.1641	7
R1	R1:8	large subunit:8:0.4102	0.4102	8
R1	R1:28	relaxation rate:19:0.7658|relaxation rates:9:0.5470	0.7658	28
R1	R1:30|r1:2	resistance:32:0.0501	0.0501	32
r4	r4:19	rhombomere 4:19:0.6537	0.6537	19
R5P	R5P:6|R-5-P:1	ribose 5-phosphate:7:0.2902	0.2902	7
R5	R5:11	CCR5-dependent:11:0.0662	0.0662	11
R5	R5:15	CCR5-using:15:0.0927	0.0927	15
R6G	R6G:22|R-6G:5	Rhodamine 6G:27:0.8903	0.8903	27
R7000	R7000:12|R-7000:1	7-methoxy-2-nitronaphtho[2,1-b]furan:13:0.4783	0.4783	13
RAAAs	RAAAs:6|rAAAs:4	ruptured abdominal aortic aneurysms:10:0.7103	0.7103	10
RAAA	RAAA:47|rAAA:17	ruptured abdominal aortic aneurysm:45:0.8369|ruptured abdominal aortic aneurysms:19:0.7658	0.8369	64
RAAS	RAAS:285|RAAs:1	renin-angiotensin-aldosterone system:286:0.8465	0.8465	286
rAAV	rAAV:5	adeno-associated viral vectors:5:0.4422	0.4422	5
rAAV	rAAV:40	recombinant AAV:40:0.8839	0.8839	40
rAAV	rAAV:36	recombinant adeno-associated viral:36:0.9174	0.9174	36
rAAV	rAAV:10	recombinant adeno-associated viral vector:10:0.7103	0.7103	10
rAAV	rAAV:242	recombinant adeno-associated virus:223:0.9644|Recombinant adeno-associated viruses:19:0.8449	0.9644	242
rAAV	rAAV:9	recombinant adeno-associated virus type 2:9:0.6794	0.6794	9
rAAV	rAAV:13	recombinant adeno-associated virus vector:7:0.5926|recombinant adeno-associated virus vectors:6:0.5290	0.5926	13
RAA	RAA:10	renal artery aneurysm:10:0.7103	0.7103	10
RAA	RAA:78|R-A-A:9	renin-angiotensin-aldosterone:87:0.3909	0.3909	87
RAA	RAA:9	right aortic arch:9:0.3945	0.3945	9
RAA	RAA:37	right atrial appendage:37:0.8749	0.8749	37
rABP	rABP:11|R-ABP:1	androgen binding protein:12:0.7571	0.7571	12
RABV	RABV:9	rabies virus:9:0.5470	0.5470	9
RACGP	RACGP:12	Royal Australian College of General Practitioners:12:0.7571	0.7571	12
RACK1	RACK1:8|RACK-1:3	receptor for activated C kinase:11:0.7357	0.7357	11
RACK1	RACK1:11|RACK-1:1	Receptor for activated C kinase 1:12:0.6701	0.6701	12
RACS	RACS:11	Royal Australasian College of Surgeons:11:0.7357	0.7357	11
RAC	RAC:20	rabbit articular chondrocytes:20:0.7173	0.7173	20
RAC	RAC:11|rac:2	ractopamine:13:0.0472	0.0472	13
RAC	RAC:11|rac:1	radial alveolar count:12:0.7571	0.7571	12
RAC	RAC:31	recombinant DNA advisory committee:31:0.9072	0.9072	31
RAc	RAc:5|RAC:3	retinyl acetate:8:0.2987	0.2987	8
RAEB-T	RAEB-T:18|RAEB-t:17|RAEBt:6	refractory anemia with excess of blasts in transformation:41:0.9436	0.9436	41
RAECs	RAECs:14	rat aortic endothelial cells:14:0.5589	0.5589	14
RAEC	RAEC:19	aortic endothelial cells:19:0.5404	0.5404	19
rAFS	rAFS:10|RAFS:4|r-AFS:2|R-AFS:1	Revised American Fertility Society:17:0.8365	0.8365	17
RAFTK	RAFTK:19	related adhesion focal tyrosine kinase:19:0.7658	0.7658	19
RAG-1	RAG-1:19|RAG1:11|Rag-1:2|rag-1:2|Rag1:1|rag1:1	recombination activating gene 1:19:0.6537|recombination activating gene-1:17:0.5374	0.6537	36
RAG	RAG:15	rat male accessory glands:15:0.8045	0.8045	15
RAG	RAG:37|Rag:2	recombination activating gene:24:0.5997|recombination activating genes:15:0.6386	0.6386	39
RAG	RAG:13	retinoyl beta-glucuronide:13:0.4849	0.4849	13
RAID	RAID:16|RaID:1	Radioimmunodetection:17:0.5333	0.5333	17
RAIR	RAIR:20	rectoanal inhibitory reflex:20:0.5568	0.5568	20
RAIT	RAIT:36	radioimmunotherapy:36:0.8750	0.8750	36
RAIU	RAIU:47	radioactive iodine uptake:47:0.9379	0.9379	47
RAI	RAI:52|RaI:1	radioactive iodine:53:0.9438	0.9438	53
RAI	RAI:19|RaI:1	radioiodine:20:0.0864	0.0864	20
RAI	RAI:35	Resident Assessment Instrument:35:0.9126	0.9126	35
RAI	RAI:22	Ritchie Articular Index:22:0.6934	0.6934	22
Raji	Raji:7	human Burkitt's lymphoma:7:0.2902	0.2902	7
Raji	Raji:5|raji:1	human lymphoblastoid cells:6:0.1838	0.1838	6
RALBP	RALBP:8	retinal-binding protein:8:0.5006	0.5006	8
Raldh2	Raldh2:11|RALDH2:9|RALDH-2:3|raldh2:1	retinaldehyde dehydrogenase 2:15:0.8045|retinaldehyde dehydrogenase-2:9:0.5470	0.8045	24
RALDH-2	RALDH-2:6|RALDH2:2	retinaldehyde dehydrogenase type 2:8:0.5006	0.5006	8
RAL	RAL:16|Ral:15|ral:1	raloxifene:32:0.2348	0.2348	32
RAL	RAL:11	relative adduct labeling:11:0.7357	0.7357	11
RAL	RAL:14	relative attachment level:14:0.7909	0.7909	14
RAL	RAL:10	retinaldehyde:10:0.0682	0.0682	10
Rama	Rama:6	cell line Rat Mammary:6:0.5926	0.5926	6
RAMBS	RAMBS:9	rabbit anti-mouse brain serum:9:0.5470	0.5470	9
RAMP1	RAMP1:7	receptor activity-modifying protein 1:7:0.5926	0.5926	7
RAMPS	RAMPS:8	rabbit anti-mouse platelet serum:8:0.6411	0.6411	8
RAMPs	RAMPs:20	Receptor activity-modifying proteins:20:0.8525	0.8525	20
RANKL	RANKL:167|RANK-L:3	receptor activator of NF-kappaB ligand:170:0.9642	0.9642	170
RANKL	RANKL:18	receptor activator of nuclear factor-kappa B ligand:18:0.8449	0.8449	18
RANKL	RANKL:66|RANK-L:1	Receptor activator of nuclear factor-kappaB ligand:67:0.8905	0.8905	67
RANTES	RANTES:21	regulated on activation normal T cell expressed and secreted:21:0.9231	0.9231	21
RANTES	RANTES:5	regulated upon activation normal T-cell expressed and secreted:5:0.8452	0.8452	5
RANZCP	RANZCP:10	Royal Australian and New Zealand College of Psychiatrists:10:0.7103	0.7103	10
RAN	RAN:24|Ran:5	ranitidine:29:0.2772	0.2772	29
RAN	RAN:14	Rapid Automatized Naming:14:0.7909	0.7909	14
rAOM	rAOM:17|RAOM:15	recurrent acute otitis media:32:0.7166	0.7166	32
RAO	RAO:31	Recurrent airway obstruction:31:0.7388	0.7388	31
RAO	RAO:27	Renal artery occlusion:27:0.5334	0.5334	27
RAO	RAO:49	right anterior oblique:49:0.9392	0.9392	49
RAO	RAO:18	Rotational acetabular osteotomy:18:0.8365	0.8365	18
RAP-PCR	RAP-PCR:17	arbitrarily primed PCR:17:0.8270	0.8270	17
RAP-PCR	RAP-PCR:22	arbitrarily primed polymerase chain reaction:22:0.7400	0.7400	22
RAP-1	RAP-1:9|rap-1:2	rhoptry-associated protein-1:11:0.4728	0.4728	11
RAPDs	RAPDs:30	random amplified polymorphic DNAs:30:0.7091	0.7091	30
RAPD	RAPD:9	amplified polymorphic DNA fingerprinting:9:0.6794	0.6794	9
RAPD	RAPD:5	arbitrary primers:5:0.0902	0.0902	5
RAPD	RAPD:188	random amplification of polymorphic DNA:188:0.9456	0.9456	188
RAPD	RAPD:873|RAP-D:1	random amplified polymorphic DNA:874:0.6625	0.6625	874
RAPD	RAPD:19	random amplified polymorphic DNA analysis:19:0.8449	0.8449	19
RAPD	RAPD:30	relative afferent pupillary defect:30:0.9011	0.9011	30
RAP	RAP:19	atrial pacing:19:0.8449	0.8449	19
RAP	RAP:38|rap:9|Rap:1	rapamycin:48:0.0493	0.0493	48
RAP	RAP:194	receptor-associated protein:194:0.7211	0.7211	194
RAP	RAP:95	recurrent abdominal pain:95:0.9339	0.9339	95
RAP	RAP:11	regional acceleratory phenomenon:11:0.7357	0.7357	11
RAP	RAP:8	Rehabilitation Activities Profile:8:0.6411	0.6411	8
RAP	RAP:46	renal arterial pressure:46:0.8676	0.8676	46
RAP	RAP:5	resistance-area product:5:0.1132	0.1132	5
RAP	RAP:10	retinal angiomatous proliferation:10:0.7103	0.7103	10
RAP	RAP:14|rap:1	right atrial:15:0.8045	0.8045	15
RAP	RAP:216	right atrial pressure:216:0.9779	0.9779	216
RARA	RARA:30|Rara:3|RARa:2|RAR-a:1	retinoic acid receptor alpha:36:0.8051	0.8051	36
RAREs	RAREs:22	retinoic acid response elements:22:0.8657	0.8657	22
RARS	RARS:15	RA with ring sideroblasts:15:0.2219	0.2219	15
RARS	RARS:16	refractory anemia with ring sideroblasts:16:0.8165	0.8165	16
RARS	RARS:35	refractory anemia with ringed sideroblasts:35:0.9174	0.9174	35
RARs	RARs:337	retinoic acid receptors:337:0.9683	0.9683	337
RAR	RAR:24	retinoic acid:24:0.8115	0.8115	24
RAR	RAR:395	retinoic acid receptor:327:0.9336|retinoic acid receptors:68:0.8889	0.9336	395
RASFs	RASFs:7|RA-SFs:1	rheumatoid arthritis synovial fibroblasts:8:0.6411	0.6411	8
RASF	RASF:6|RA-SF:3	rheumatoid arthritis synovial fibroblasts:9:0.6794	0.6794	9
RA-SF	RA-SF:5|RASF:2	rheumatoid arthritis synovial fluid:7:0.5926	0.5926	7
RASMCs	RASMCs:38	rat aortic smooth muscle cells:38:0.8098	0.8098	38
RASMC	RASMC:51|raSMC:1|RA-SMC:1|rASMC:1	rat aortic smooth muscle cells:54:0.9132	0.9132	54
RASM	RASM:34	rat aortic smooth muscle:34:0.7898	0.7898	34
RASM	RASM:9	rat aortic smooth muscle cells:9:0.6794	0.6794	9
RASTs	RASTs:10	Radioallergosorbent tests:10:0.5000	0.5000	10
RAST	RAST:12	IgE antibodies:12:0.6460	0.6460	12
RAST	RAST:11|Rast:1	Radio-Allergo-Sorbent-Test:12:0.0127	0.0127	12
RAST	RAST:41	Radioallergosorbent:41:0.0463	0.0463	41
RAST	RAST:493|Rast:1	radioallergosorbent test:456:0.7841|radioallergosorbent tests:38:0.5720	0.7841	494
RAST	RAST:16	radioallergosorbent testing:16:0.7261	0.7261	16
RAST	RAST:38	specific IgE:38:0.4547	0.4547	38
RAS	RAS:11	aortic strips:11:0.7357	0.7357	11
-ras	-ras:5|ras:4|RAS:1	oncogene:10:0.0040	0.0040	10
RAS	RAS:9	rate of ankle swelling:9:0.5470	0.5470	9
RAS	RAS:91	recurrent aphthous stomatitis:91:0.9672	0.9672	91
RAS	RAS:11	renal artery stenoses:11:0.7357	0.7357	11
RAS	RAS:253	renal artery stenosis:253:0.9882	0.9882	253
RAS	RAS:13	renin-angiotensin:13:0.0054	0.0054	13
RAS	RAS:1267	renin-angiotensin system:1218:0.8482|renin-angiotensin systems:29:0.6928|renin-angiotensin-system:20:0.0085	0.8482	1267
RAs	RAs:26	Retinoic acids:26:0.6645	0.6645	26
RAS	RAS:17	retinoic acid syndrome:17:0.7407	0.7407	17
RATG	RATG:32|rATG:3|r-ATG:1	rabbit antithymocyte globulin:36:0.8336	0.8336	36
RAU	RAU:40	recurrent aphthous ulcers:40:0.8867	0.8867	40
RAU	RAU:53	recurrent aphthous ulceration:41:0.7952|recurrent aphthous ulcerations:12:0.7571	0.7952	53
RAVLT	RAVLT:26	Rey Auditory Verbal Learning Test:26:0.8861	0.8861	26
RAWP	RAWP:15	Resource Allocation Working Party:15:0.8045	0.8045	15
RA	RA:10|Ra:3	afferent:13:0.0006	0.0006	13
RA	RA:12|Ra:1	afferent arteriolar resistance:13:0.7753	0.7753	13
RA	RA:9	amplitude:9:0.0004	0.0004	9
RA	RA:9	analysis:9:0.0004	0.0004	9
Ra	Ra:24|RA:1	appearance rate:25:0.5288	0.5288	25
Ra	Ra:13|RA:2	arterial:15:0.0007	0.0007	15
Ra	Ra:10|RA:2	arterial resistance:12:0.0854	0.0854	12
Ra	Ra:87	glucose production:87:0.8700	0.8700	87
ra	ra:28|RA:11|Ra:9	IL-1 receptor antagonist:48:0.6770	0.6770	48
RA	RA:32	nucleus robustus archistriatalis:32:0.5930	0.5930	32
RA	RA:121	radial artery:121:0.6579	0.6579	121
RA	RA:23	radiographic absorptiometry:23:0.8715	0.8715	23
RA	RA:9	Radionuclide angiography:9:0.2757	0.2757	9
Ra	Ra:11	ragged:11:0.0005	0.0005	11
RA	RA:77	rapidly adapting:77:0.9386	0.9386	77
RA	RA:9	rat aorta:9:0.2285	0.2285	9
Ra	Ra:10	rates:10:0.0005	0.0005	10
Ra	Ra:142|RA:1	rate of appearance:107:0.4360|rates of appearance:36:0.1141	0.4360	143
Ra	Ra:30|RA:1	rates of glucose appearance:18:0.2060|rate of glucose appearance:13:0.1192	0.2060	31
RA	RA:48|ra:1	rectus abdominis:49:0.9046	0.9046	49
RA	RA:93	refractory anaemia:93:0.9490	0.9490	93
RA	RA:238	Refractory anemia:238:0.9395	0.9395	238
RA	RA:11	regional anaesthesia:11:0.6182	0.6182	11
RA	RA:10	regional anesthesia:10:0.4363	0.4363	10
RA	RA:18	relative anisotropy:18:0.8365	0.8365	18
RA	RA:47	renal artery:39:0.1647|renal arteries:8:0.1895	0.1895	47
RA	RA:17	Renin activity:17:0.2186	0.2186	17
RA	RA:18|R-A:16|r-a:1	Renin-angiotensin:35:0.0018	0.0018	35
RA	RA:7	Repeated acquisition:7:0.3524	0.3524	7
Ra	Ra:10	resistance to reabsorption of CSF:10:0.7103	0.7103	10
RA	RA:3221	retinoic acid:3202:0.8444|Retinoic acids:19:0.7658	0.8444	3221
RA	RA:8	Retinol acetate:8:0.0566	0.0566	8
RA	RA:25	retinyl acetate:25:0.4596	0.4596	25
RA	RA:19	retrograde amnesia:19:0.8449	0.8449	19
RA	RA:40	rheumatoid:40:0.0021	0.0021	40
RA	RA:23	rheumatoid arthritic:23:0.8038	0.8038	23
RA	RA:11798|rA:2|ra:1	rheumatoid arthritis:11801:0.9952	0.9952	11801
RA	RA:11	rheumatoid arthritis patients:11:0.7357	0.7357	11
RA	RA:8	ricin A chain:8:0.4102	0.4102	8
RA	RA:12	right:12:0.0006	0.0006	12
RA	RA:13	right atria:13:0.7753	0.7753	13
RA	RA:202|ra:1	right atrial:203:0.9479	0.9479	203
RA	RA:10	right atrial pressure:10:0.7103	0.7103	10
RA	RA:222	right atrium:222:0.9523	0.9523	222
RA	RA:11	risk area:11:0.2040	0.2040	11
RA	RA:12	Risk assessment:12:0.6460	0.6460	12
RA	RA:97	robust nucleus of the archistriatum:97:0.9223	0.9223	97
RA	RA:58	room air:58:0.8710	0.8710	58
RA	RA:30	rotational atherectomy:30:0.8032	0.8032	30
RA	RA:12	rounded atelectasis:12:0.5050	0.5050	12
Ra	Ra:57	surface roughness:57:0.6358	0.6358	57
RB1	RB1:37|Rb1:6|RB-1:4|Rb-1:3	retinoblastoma:50:0.2500	0.2500	50
RB1	RB1:34|Rb-1:8|RB-1:7|Rb1:2|rb1:1	retinoblastoma gene:52:0.4398	0.4398	52
RB1	RB1:5	retinoblastoma locus:5:0.0902	0.0902	5
RB1	RB1:19|RB-1:3|Rb-1:1	retinoblastoma susceptibility gene:23:0.8038	0.8038	23
RBANS	RBANS:13	Repeatable Battery for the Assessment of Neuropsychological Status:13:0.7909	0.7909	13
RBAs	RBAs:26	Relative Binding Affinities:26:0.8861	0.8861	26
RBBB	RBBB:182	right bundle branch block:182:0.9737	0.9737	182
RBBs	RBBs:9	resin-bonded bridges:9:0.5470	0.5470	9
RBB	RBB:20	right bundle branch:20:0.8525	0.8525	20
RBC's	RBC's:15	red blood cells:15:0.8045	0.8045	15
RBC2	RBC2:17	randombred control line:17:0.6211	0.6211	17
RBCC	RBCC:13	red blood cell concentrates:13:0.7753	0.7753	13
RBCV	RBCV:10|RBC-V:2	red blood cell velocity:12:0.7571	0.7571	12
RBCV	RBCV:6	respiratory bovine coronavirus:6:0.5290	0.5290	6
rBCG	rBCG:7	bacillus Calmette-Guerin:7:0.3524	0.3524	7
rBCG	rBCG:20	recombinant BCG:20:0.5568	0.5568	20
RBCs	RBCs:100|rbcs:1	erythrocytes:101:0.0590	0.0590	101
RBCs	RBCs:1307|rbcs:6|rbc-s:1|RBCS:1|RbCs:1	red blood cells:1316:0.9897	0.9897	1316
rbcS	rbcS:22|rbcs:2|RbcS:2|RBCS:2	small subunit:28:0.8941	0.8941	28
rbcS	rbcS:5|RBCS:2	small subunit of ribulose-1,5-bisphosphate carboxylase:7:0.6411	0.6411	7
RBC	RBC:20	erythrocyte count:14:0.0601|erythrocyte counts:6:0.0731	0.0731	20
RBC	RBC:48|rbc:2	human erythrocytes:25:0.0649|human erythrocyte:25:0.0803	0.0803	50
RBC	RBC:59|Rbc:1	Ranitidine bismuth citrate:60:0.8971	0.8971	60
RBC	RBC:3609|rbc:48|Rbc:2	red blood cell:2040:0.9825|red blood cells:1619:0.9876	0.9876	3659
RBC	RBC:84	red blood cell count:75:0.9607|red blood cell counts:9:0.5470	0.9607	84
RBC	RBC:36	resin-based composite:28:0.8941|resin-based composites:8:0.5006	0.8941	36
RBC	RBC:23	Rotating Biological Contactor:23:0.8715	0.8715	23
RBD	RBD:13	Ras binding domain:13:0.1005	0.1005	13
RBD	RBD:25	receptor-binding domain:25:0.1120	0.1120	25
RBD	RBD:23	Recurrent brief depression:23:0.8715	0.8715	23
RBD	RBD:7	Regional Basic Diet:7:0.5926	0.5926	7
RBD	RBD:22	right brain damage:22:0.6531	0.6531	22
RBD	RBD:59	right brain-damaged:34:0.9126|right-brain-damaged:16:0.0364|right brain damaged:9:0.6794	0.9126	59
RBD	RBD:26	RNA binding domain:26:0.3010	0.3010	26
RBDs	RBDs:36	RNA-binding domains:21:0.3221|RNA binding domains:15:0.5348	0.5348	36
RBE4	RBE4:5|RBE-4:2	rat brain endothelial cells:7:0.5926	0.5926	7
RBE	RBE:12	binding element:12:0.3524	0.3524	12
RBE	RBE:441|rbe:2	relative biological effectiveness:443:0.9855	0.9855	443
RBE	RBE:18	relative biological efficiency:18:0.7044	0.7044	18
RBE	RBE:6	Rev-binding element:6:0.0611	0.0611	6
RBFNN	RBFNN:10|RBF-NN:1	radial basis function neural network:11:0.6182	0.6182	11
RBF	RBF:11	blood flows:11:0.7357	0.7357	11
RBF	RBF:59	Radial Basis Function:59:0.9494	0.9494	59
RBF	RBF:1155|rbf:3	renal blood flow:1158:0.8935	0.8935	1158
RBH	RBH:6	repeat-breeder heifers:6:0.2243	0.2243	6
RB-ILD	RB-ILD:12|RBILD:5	Respiratory bronchiolitis-associated interstitial lung disease:17:0.7261	0.7261	17
RBL-1	RBL-1:14	rat basophilic leukaemia:14:0.7909	0.7909	14
RBL-1	RBL-1:49	rat basophilic leukemia:49:0.9392	0.9392	49
RBL-1	RBL-1:8	rat basophilic leukemia cells:8:0.6411	0.6411	8
RBL-2H3	RBL-2H3:16	rat basophilic leukaemia:16:0.8165	0.8165	16
RBL-2H3	RBL-2H3:145	rat basophilic leukemia:145:0.9671	0.9671	145
RBL-2H3	RBL-2H3:69|RBL2H3:1	rat basophilic leukemia cells:65:0.9275|rat basophilic leukemia cell:5:0.4422	0.9275	70
RBL-2H3	RBL-2H3:11	rat basophilic leukemia cell line:11:0.7357	0.7357	11
RBL	RBL:26	rat basophilic leukaemia:26:0.8251	0.8251	26
RBL	RBL:153	rat basophilic leukemia:153:0.9690	0.9690	153
RBL	RBL:7	rat basophilic leukemia cells:7:0.4438	0.4438	7
RBL	RBL:14	rubber band ligation:14:0.7909	0.7909	14
RBMT	RBMT:20	Rivermead Behavioural Memory Test:20:0.8525	0.8525	20
RBM	RBM:35|Rbm:4|rBM:3|rbm:1	basement membrane:43:0.8917	0.8917	43
RBM	RBM:14	rat bone marrow:14:0.4709	0.4709	14
RBM	RBM:8	RNA-binding motif:8:0.2619	0.2619	8
RBM	RBM:14	Roll Back Malaria:14:0.6911	0.6911	14
RBO	RBO:18	rice bran oil:18:0.8365	0.8365	18
RBPC	RBPC:8	Revised Behavior Problem Checklist:8:0.6411	0.6411	8
RBPT	RBPT:21	Rose Bengal plate test:21:0.8594	0.8594	21
RBP	RBP:9	proteins:9:0.0091	0.0091	9
RBP	RBP:733|rbp:1	retinol-binding protein:530:0.6232|retinol binding protein:204:0.8974	0.8974	734
RBRVS	RBRVS:69	Resource-Based Relative Value Scale:69:0.7961	0.7961	69
RBSDV	RBSDV:6	rice black streaked dwarf virus:6:0.5290	0.5290	6
RBT	RBT:9	random breath testing:9:0.6794	0.6794	9
RBT	RBT:19	rifabutin:19:0.1748	0.1748	19
RBT	RBT:23	Rose Bengal Test:23:0.8715	0.8715	23
RBV	RBV:24|rBV:5|rbv:1	blood volume:30:0.7652	0.7652	30
RBV	RBV:8	relative bioavailability:8:0.5006	0.5006	8
RBV	RBV:13	relative biological value:13:0.7753	0.7753	13
RBV	RBV:68|Rbv:6	ribavirin:74:0.4591	0.4591	74
RBW	RBW:15|rbw:1	relative body weight:16:0.6577	0.6577	16
RBZ	RBZ:13	ricobendazole:13:0.6667	0.6667	13
RBs	RBs:17	reticulate bodies:17:0.5374	0.5374	17
RBS	RBS:92|rbs:4	ribosome-binding site:48:0.3025|ribosome binding site:36:0.4386|ribosome binding sites:12:0.5664	0.5664	96
RBS	RBS:16	Rutherford backscattering spectrometry:16:0.8165	0.8165	16
Rb	Rb:10	minnesota R345:10:0.5856	0.5856	10
rb	rb:15|Rb:4	rabbit:19:0.0076	0.0076	19
RB	RB:13|Rb:1	rebreathing:14:0.0055	0.0055	14
rb	rb:11	recombinant bovine:11:0.6182	0.6182	11
RB	RB:28	Repetition blindness:28:0.8941	0.8941	28
RB	RB:47	respiratory burst:47:0.9366	0.9366	47
RB	RB:29	reticulate bodies:17:0.4035|reticulate body:12:0.3813	0.4035	29
Rb	Rb:530|RB:388|rb:1	retinoblastoma:919:0.3886	0.3886	919
RB	RB:44|Rb:32|rb:1	retinoblastoma gene:77:0.4159	0.4159	77
Rb	Rb:37|RB:12	retinoblastoma gene product:49:0.4766	0.4766	49
Rb	Rb:172|RB:96|rb:1	retinoblastoma protein:269:0.7711	0.7711	269
Rb	Rb:13|RB:11	retinoblastoma susceptibility:24:0.8115	0.8115	24
Rb	Rb:26|RB:22	retinoblastoma susceptibility gene:48:0.9392	0.9392	48
Rb	Rb:20|RB:7	retinoblastoma susceptibility gene product:27:0.8903	0.8903	27
Rb	Rb:9|RB:7	retinoblastoma tumor suppressor:16:0.8165	0.8165	16
Rb	Rb:21|RB:15	retinoblastoma tumor suppressor protein:36:0.9174	0.9174	36
RB	RB:14	Rhodamine B:14:0.3813	0.3813	14
RB	RB:9|Rb:4	riboflavin:13:0.0051	0.0051	13
RB	RB:9	rice bran:9:0.4587	0.4587	9
Rb	Rb:40	Robertsonian:40:0.0165	0.0165	40
RB	RB:10|R-B:2	Rohon-Beard:12:0.0047	0.0047	12
RB	RB:104|rb:1|Rb:1	rose bengal:106:0.9551	0.9551	106
Rb	Rb:28|RB:2	rubidium:30:0.0123	0.0123	30
RC-160	RC-160:14	D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2:14:0.5000	0.5000	14
RCA120	RCA120:12|RCA-120:5	Ricinus communis agglutinin:17:0.8270	0.8270	17
RCA1	RCA1:9|RCA-1:6	Ricinus communis agglutinin:15:0.6386	0.6386	15
RCA-1	RCA-1:29|RCA1:4	Ricinus communis agglutinin-1:23:0.8715|Ricinus communis agglutinin 1:10:0.7103	0.8715	33
RCA-I	RCA-I:24|RCAI:6	Ricinus communis:30:0.9011	0.9011	30
RCA-I	RCA-I:16|RCAI:2	Ricinus Communis Agglutinin:18:0.6381	0.6381	18
RCA-I	RCA-I:54|RCAI:14	Ricinus communis agglutinin I:37:0.8781|Ricinus communis agglutinin-I:31:0.9043	0.9043	68
RCAS1	RCAS1:11	Receptor-binding cancer antigen expressed on SiSo cells:11:0.6182	0.6182	11
RCA	RCA:51	complement activation:51:0.9416	0.9416	51
RCA	RCA:14	red cell aggregation:14:0.6911	0.6911	14
RCA	RCA:12	replication-competent adenovirus:12:0.4557	0.4557	12
RCA	RCA:9	retrochiasmatic area:9:0.3069	0.3069	9
RCA	RCA:16	Ricinus communis:16:0.7261	0.7261	16
RCA	RCA:82|RcA:1	Ricinus communis agglutinin:83:0.8767	0.8767	83
RCA	RCA:14	Ricinus Communis Agglutinin I:14:0.6911	0.6911	14
RCA	RCA:14	right coronary:14:0.7909	0.7909	14
RCA	RCA:591	right coronary artery:570:0.9887|right coronary arteries:21:0.8594	0.9887	591
RCA	RCA:27	rolling circle amplification:19:0.8449|Rolling-circle amplification:8:0.0825	0.8449	27
RCA	RCA:8	root cause analysis:8:0.6411	0.6411	8
RCA	RCA:4|rca:3|Rca:2	RubisCO activase:9:0.5664	0.5664	9
RCC1	RCC1:11	regulator of chromosome condensation:11:0.7357	0.7357	11
RCCA	RCCA:14	right common carotid artery:14:0.6911	0.6911	14
RCCs	RCCs:10	cell concentrates:10:0.7103	0.7103	10
RCCS	RCCS:11	Cell Culture System:11:0.5856	0.5856	11
RCCs	RCCs:9	cleft cysts:9:0.6794	0.6794	9
RCCs	RCCs:14	Rapid cooling contractures:14:0.7909	0.7909	14
RCCs	RCCs:177	renal cell carcinomas:177:0.9730	0.9730	177
RCC	RCC:5	carcinoma cells:5:0.0736	0.0736	5
RCC	RCC:8	cell count:8:0.4102	0.4102	8
RCC	RCC:8	rapid cooling contracture:8:0.6411	0.6411	8
RCC	RCC:14	Rathke's Cleft Cyst:14:0.5589	0.5589	14
RCC	RCC:37	red cell concentrates:28:0.6839|red cell concentrate:9:0.5470	0.6839	37
RCC	RCC:121	renal cell cancer:121:0.9603	0.9603	121
RCC	RCC:2022	renal cell carcinoma:1874:0.9927|renal cell carcinomas:148:0.9571	0.9927	2022
RCDP	RCDP:45	rhizomelic chondrodysplasia punctata:45:0.7091	0.7091	45
RCD	RCD:13	red cell deformability:13:0.5335	0.5335	13
RCEC	RCEC:9	endothelial cells:9:0.1334	0.1334	9
RCEC	RCEC:8	rabbit corneal epithelial cells:8:0.6411	0.6411	8
RCE	RCE:15	rabbit corneal epithelial:15:0.8045	0.8045	15
RCE	RCE:6	relative coefficient of excretion:6:0.5290	0.5290	6
RCE	RCE:7	retinoblastoma control element:7:0.3524	0.3524	7
RCFT	RCFT:12	Rey-Osterrieth Complex Figure Test:12:0.6460	0.6460	12
RCF	RCF:9	Radiochromic film:9:0.5470	0.5470	9
RCF	RCF:16	Red cell folate:16:0.5171	0.5171	16
RCF	RCF:33	refractory ceramic fibers:17:0.7407|refractory ceramic fiber:16:0.8165	0.8165	33
RCF	RCF:9	refractory ceramic fibres:9:0.6794	0.6794	9
RCF	RCF:9	responder cell frequency:9:0.6794	0.6794	9
RCGP	RCGP:23	Royal College of General Practitioners:23:0.8715	0.8715	23
RCH	RCH:14	Royal Children's Hospital:14:0.7096	0.7096	14
RCIA	RCIA:9	Red cell immune adherence:9:0.6411	0.6411	9
RCIN	RCIN:16	Radiocontrast-induced nephropathy:16:0.5564	0.5564	16
RCI	RCI:63	respiratory control index:63:0.9526	0.9526	63
RCMAS	RCMAS:26|R-CMAS:1	Revised Children's Manifest Anxiety Scale:27:0.8903	0.8903	27
RCMV	RCMV:62|R-CMV:1	rat cytomegalovirus:63:0.9264	0.9264	63
RCMV	RCMV:12	red clover mottle virus:12:0.7571	0.7571	12
RCM	RCM:16	radiocontrast media:16:0.1002	0.1002	16
RCM	RCM:58	radiographic contrast media:58:0.8710	0.8710	58
RCM	RCM:7	radiographic contrast medium:7:0.5926	0.5926	7
RCM	RCM:36	red cell mass:36:0.8003	0.8003	36
RCM	RCM:4	Reflectance confocal microscopy:4:0.0918	0.0918	4
RCM	RCM:12	Reflection contrast microscopy:12:0.7357	0.7357	12
RCM	RCM:17	restrictive cardiomyopathy:17:0.6748	0.6748	17
RCNMV	RCNMV:11	red clover necrotic mosaic dianthovirus:11:0.7357	0.7357	11
RCNMV	RCNMV:20	red clover necrotic mosaic virus:20:0.8525	0.8525	20
RCN	RCN:9	raccoon poxvirus:9:0.6794	0.6794	9
RCN	RCN:8	Radiocontrast nephropathy:8:0.2619	0.2619	8
RCN	RCN:16|Rcn:1	Royal College of Nursing:17:0.8270	0.8270	17
RCof	RCof:10|RCoF:7|Rcof:3|RCOF:1	ristocetin cofactor:21:0.7865	0.7865	21
RCOG	RCOG:15	Royal College of Obstetricians and Gynaecologists:15:0.7909	0.7909	15
RCOs	RCOs:9	reactive carbonyl compounds:9:0.6794	0.6794	9
RCPM	RCPM:14	Raven's coloured progressive matrices:14:0.6173	0.6173	14
RCPSC	RCPSC:10	Royal College of Physicians and Surgeons of Canada:10:0.7103	0.7103	10
RCPs	RCPs:12	respiratory care practitioners:12:0.7571	0.7571	12
RCP	RCP:36	radiochemical purity:36:0.9174	0.9174	36
RCP	RCP:11	receptor component protein:11:0.3069	0.3069	11
RCP	RCP:9	respiratory compensation point:9:0.6794	0.6794	9
RCP	RCP:86	retrograde cerebral perfusion:86:0.8318	0.8318	86
RCP	RCP:16	retruded contact position:16:0.6024	0.6024	16
RCP	RCP:23	riboflavin carrier protein:23:0.8657	0.8657	23
RCR	RCR:27	replication-competent retrovirus:27:0.6745	0.6745	27
RCR	RCR:10	respiratory control rate:10:0.5856	0.5856	10
RCR	RCR:112	respiratory control ratio:112:0.9316	0.9316	112
RCR	RCR:14	rolling circle replication:14:0.7909	0.7909	14
Rcs	Rcs:9	collateral resistance:9:0.1690	0.1690	9
Rcs	Rcs:8	collateral system:8:0.3463	0.3463	8
Rcs	Rcs:12	collateral system resistance:12:0.7571	0.7571	12
RCS	RCS:9	rat chondrosarcoma:9:0.6794	0.6794	9
RCs	RCs:85	reaction centers:85:0.9101	0.9101	85
RCs	RCs:8	reaction centres:8:0.3463	0.3463	8
RCS	RCS:20	Recombinant congenic strains:20:0.8525	0.8525	20
RCS	RCS:7	recurrent carotid stenosis:7:0.5926	0.5926	7
RCs	RCs:12	relative contents:12:0.7571	0.7571	12
RCs	RCs:10	renal carcinomas:10:0.3470	0.3470	10
RCs	RCs:7	Renshaw cells:7:0.0951	0.0951	7
RCS	RCS:8	Repeated cold stress:8:0.6411	0.6411	8
RCs	RCs:6	replication complexes:6:0.1838	0.1838	6
RCS	RCS:46	reticulum cell sarcoma:34:0.9126|reticulum cell sarcomas:12:0.7571	0.9126	46
RCS	RCS:199	Royal College of Surgeons:199:0.9850	0.9850	199
RCTT	RCTT:9	red cell transit time:9:0.3455	0.3455	9
RCTs	RCTs:30	randomised clinical trials:30:0.0927	0.0927	30
RCTs	RCTs:143	randomized clinical trials:143:0.6039	0.6039	143
RCTs	RCTs:26|RCTS:1	randomized controlled clinical trials:27:0.6736	0.6736	27
RCTs	RCTs:587|RCTS:1	randomized controlled trials:588:0.5744	0.5744	588
RCT	RCT:9	computed tomography:9:0.6794	0.6794	9
RCT	RCT:35	Radiochemotherapy:35:0.0362	0.0362	35
RCT	RCT:15	randomised clinical trials:15:0.1154	0.1154	15
RCT	RCT:56	randomised controlled trials:56:0.2600	0.2600	56
RCT	RCT:96	randomized clinical trial:57:0.5686|randomized clinical trials:39:0.4710	0.5686	96
RCT	RCT:286	randomized controlled trial:174:0.6245|randomized controlled trials:112:0.5776	0.6245	286
RCT	RCT:8	renal cell tumors:8:0.6411	0.6411	8
RCT	RCT:59	Reverse cholesterol transport:59:0.9494	0.9494	59
RCT	RCT:9	root canal treatment:9:0.6794	0.6794	9
RCU	RCU:10	calcium urolithiasis:10:0.5856	0.5856	10
RCV	RCV:39	red cell volume:39:0.8455	0.8455	39
RCV	RCV:5	replication-competent virus:5:0.1132	0.1132	5
RD114	RD114:9	feline endogenous virus:9:0.6794	0.6794	9
RD50	RD50:5	50% decrease in respiratory rate:5:0.6794	0.6794	5
RD-50	RD-50:3|RD50:3	respiratory rate by 50%:6:0.7753	0.7753	6
RDAs	RDAs:81	Recommended Dietary Allowances:81:0.9059	0.9059	81
RDA	RDA:68	recommended daily allowance:68:0.9561	0.9561	68
RDA	RDA:270	Recommended dietary allowance:159:0.9423|recommended dietary allowances:111:0.9072	0.9423	270
RDA	RDA:161	Representational difference analysis:161:0.9271	0.9271	161
RDB	RDB:12	reverse dot blot:12:0.7571	0.7571	12
RDC/TMD	RDC/TMD:35	Research Diagnostic Criteria for Temporomandibular Disorders:35:0.9151	0.9151	35
RDCs	RDCs:51	Residual dipolar couplings:51:0.8546	0.8546	51
RDC	RDC:222	Research Diagnostic Criteria:222:0.9784	0.9784	222
RDC	RDC:22|rdc:2	residual dipolar couplings:13:0.7753|residual dipolar coupling:11:0.7357	0.7753	24
RDDP	RDDP:13	RNA-dependent DNA polymerase:13:0.6701	0.6701	13
RDD	RDD:16	random digit dialing:16:0.8165	0.8165	16
RDD	RDD:45	Rosai-Dorfman disease:45:0.8964	0.8964	45
RDEB	RDEB:10	recessive dystrophic EB:10:0.7103	0.7103	10
RDEB	RDEB:63|R-DEB:1	recessive dystrophic epidermolysis bullosa:64:0.8824	0.8824	64
RDE	RDE:10	receptor-destroying enzyme:10:0.3145	0.3145	10
RDE	RDE:17	rotating disk electrode:17:0.8270	0.8270	17
RDF	RDF:18|rdf:1	radial distribution function:19:0.7658	0.7658	19
RDF	RDF:17	refuse-derived fuel:9:0.2102|refuse derived fuel:8:0.6411	0.6411	17
RDGF	RDGF:9	growth factor:9:0.6794	0.6794	9
RDH	RDH:10	Royal Darwin Hospital:10:0.7103	0.7103	10
RDIs	RDIs:7	recommended dietary intakes:7:0.5926	0.5926	7
RDI	RDI:9	recommended daily intake:9:0.4587	0.4587	9
RDI	RDI:26	recommended dietary intake:13:0.7753|Recommended dietary intakes:13:0.7753	0.7753	26
RDI	RDI:36|rDI:1	relative dose intensity:30:0.9011|relative dose-intensity:7:0.3524	0.9011	37
RDI	RDI:225	respiratory disturbance index:225:0.9867	0.9867	225
RDLN	RDLN:15	retrodorsolateral nucleus:15:0.6386	0.6386	15
RDP	RDP:10	Ribosomal Database Project:10:0.5856	0.5856	10
RDP	RDP:7	rumen degradable protein:7:0.1641	0.1641	7
RDP	RDP:7	ruminally degradable protein:7:0.1641	0.1641	7
RDQ	RDQ:9	Disability Questionnaire:9:0.4587	0.4587	9
RdRps	RdRps:13|RdRPs:5|RDRPs:4	RNA-dependent RNA polymerases:22:0.7955	0.7955	22
RDR	RDR:31	relative dose response:31:0.8519	0.8519	31
RDSs	RDSs:11	stereograms:11:0.6667	0.6667	11
RDS	RDS:20	random-dot stereograms:12:0.3275|random dot stereograms:8:0.6411	0.6411	20
RDs	RDs:16|rds:1	registered dietitians:17:0.8270	0.8270	17
RDS	RDS:8	renal duplex sonography:8:0.6411	0.6411	8
RDS	RDS:34	replicative DNA synthesis:34:0.5132	0.5132	34
RDS	RDS:1161	respiratory distress syndrome:1161:0.9944	0.9944	1161
rds	rds:41|RDS:7	retinal degeneration slow:48:0.7284	0.7284	48
RDs	RDs:20	retinal detachments:20:0.8525	0.8525	20
RDTs	RDTs:7	Rapid diagnostic tests:7:0.5926	0.5926	7
RDT	RDT:7	regular dialysis therapy:7:0.2452	0.2452	7
RDT	RDT:55	regular dialysis treatment:55:0.9458	0.9458	55
RDT	RDT:18	regular hemodialysis treatment:18:0.8365	0.8365	18
RDT	RDT:9	remaining dentin thickness:9:0.5470	0.5470	9
RDT	RDT:7	remaining dentine thickness:7:0.5926	0.5926	7
RDV	RDV:12	rice dwarf phytoreovirus:12:0.7571	0.7571	12
RDV	RDV:28	rice dwarf virus:28:0.8941	0.8941	28
RDW	RDW:72	red cell distribution width:72:0.7330	0.7330	72
RDX	RDX:83	hexahydro-1,3,5-trinitro-1,3,5-triazine:83:0.6457	0.6457	83
RD	RD:11|rd:1	density:12:0.0062	0.0062	12
RD	RD:9	duration:9:0.0045	0.0045	9
Rd	Rd:13	Glucose disappearance rate:13:0.5335	0.5335	13
Rd	Rd:36|RD:1	glucose disposal:37:0.6610	0.6610	37
Rd	Rd:9	glucose disposal rate:9:0.6794	0.6794	9
Rd	Rd:23	glucose uptake:23:0.7046	0.7046	23
Rd	Rd:30|RD:1	glucose utilization:31:0.4504	0.4504	31
RD	RD:26	human rhabdomyosarcoma:26:0.2735	0.2735	26
RD	RD:25	raphe dorsalis:25:0.7679	0.7679	25
Rd	Rd:16	rate of disappearance:16:0.0903	0.0903	16
Rd	Rd:10	rate of glucose disappearance:10:0.1449	0.1449	10
RD	RD:13	Raynaud's disease:13:0.0640	0.0640	13
RD	RD:86	reading disability:49:0.9392|reading disabilities:37:0.9197	0.9392	86
RD	RD:13	reading disabled:13:0.7753	0.7753	13
RD	RD:14	recession depth:14:0.6911	0.6911	14
RD	RD:9	rectal distension:9:0.3455	0.3455	9
RD	RD:21	redistribution:21:0.0113	0.0113	21
RD	RD:10	reference diameter:10:0.5000	0.5000	10
RD	RD:15	regular diet:15:0.3110	0.3110	15
RD	RD:9	regulatory domain:9:0.1585	0.1585	9
RD	RD:15	Reiter's disease:15:0.0821	0.0821	15
RD	RD:11	relative dispersion:11:0.6182	0.6182	11
RD	RD:10	renal dysfunction:10:0.7103	0.7103	10
RD	RD:15	residual disease:15:0.0821	0.0821	15
RD	RD:19	respiratory distress:19:0.8449	0.8449	19
rd	rd:52|RD:3	retinal degeneration:55:0.9458	0.9458	55
RD	RD:234	retinal detachment:222:0.9865|retinal detachments:12:0.7571	0.9865	234
RD	RD:16	rheumatic diseases:16:0.5564	0.5564	16
Rd	Rd:15|rd:1	rubredoxin:16:0.0085	0.0085	16
RD	RD:7	runt domain:7:0.0828	0.0828	7
REACH	REACH:10	Reaching for Excellence in Adolescent Care and Health:10:0.7103	0.7103	10
REACH	REACH:10	Resources for Enhancing Alzheimer's Caregiver Health:10:0.7103	0.7103	10
REACT	REACT:17	Rapid Early Action for Coronary Treatment:17:0.8270	0.8270	17
REAG	REAG:11	restriction endonuclease analysis of genomic DNA:11:0.7357	0.7357	11
REALM	REALM:25	Rapid Estimate of Adult Literacy in Medicine:25:0.8816	0.8816	25
REAP	REAP:13	plasmid DNA:13:0.7753	0.7753	13
REAT	REAT:7	real-ear attenuation at threshold:7:0.3524	0.3524	7
REA	REA:9	Rapid Epidemiological Assessment:9:0.6794	0.6794	9
ReA	ReA:252|REA:3	reactive arthritis:255:0.9637	0.9637	255
REA	REA:8	repressor of estrogen receptor activity:8:0.6411	0.6411	8
REA	REA:133	restriction endonuclease analysis:133:0.9775	0.9775	133
REA	REA:48	restriction enzyme analysis:48:0.9027	0.9027	48
REA	REA:67	right ear advantage:42:0.9291|right-ear advantage:25:0.2411	0.9291	67
RECD	RECD:13	difference:13:0.7059	0.7059	13
RECs	RECs:9	endothelial cells:9:0.3069	0.3069	9
RECs	RECs:20	research ethics committees:20:0.8525	0.8525	20
REC	REC:22	epithelial cells:22:0.3018	0.3018	22
REC	REC:15	gingival recession:15:0.2845	0.2845	15
REC	REC:9	rabbit ear chamber:9:0.6794	0.6794	9
REC	REC:11	rat embryo cells:11:0.7357	0.7357	11
rec	rec:15|Rec:2	recombinant:17:0.0597	0.0597	17
rec	rec:7|REC:3|Rec:1	recombination:11:0.0373	0.0373	11
REC	REC:20|Rec:3|rec:1	recovery:24:0.0858	0.0858	24
REDOR	REDOR:37	rotational echo double resonance:20:0.8525|Rotational-echo double-resonance:17:0.6259	0.8525	37
REDP	REDP:10	restriction endonuclease digestion profiles:10:0.7103	0.7103	10
REDV	REDV:10	Arg-Glu-Asp-Val:10:0.6000	0.6000	10
REE	REE:36	rare earth elements:22:0.8657|rare earth element:14:0.7909	0.8657	36
REE	REE:655	resting energy expenditure:655:0.9794	0.9794	655
REFs	REFs:25|Refs:1	rat embryo fibroblasts:26:0.8861	0.8861	26
REF	REF:74	rat embryo fibroblasts:53:0.8373|rat embryo fibroblast:21:0.7865	0.8373	74
REF	REF:8|Ref:3	reference:11:0.0395	0.0395	11
REF	REF:9|rEF:8|R-EF:1	regional ejection fraction:18:0.4934	0.4934	18
REF	REF:21	restriction endonuclease fingerprinting:21:0.8449	0.8449	21
REH	REH:25	retinyl ester hydrolase:25:0.8186	0.8186	25
REIN	REIN:14	Ramipril Efficacy In Nephropathy:14:0.7909	0.7909	14
REML	REML:47|ReML:5	Restricted Maximum Likelihood:52:0.7106	0.7106	52
REMO	REMO:9	rapid epidemiological mapping of onchocerciasis:9:0.6794	0.6794	9
REMPI	REMPI:6	resonance enhanced multiphoton ionization:6:0.5290	0.5290	6
REMSD	REMSD:15|REMSd:1	REM sleep deprivation:16:0.5038	0.5038	16
REMs	REMs:46	rapid eye movements:46:0.8676	0.8676	46
REMS	REMS:146|REMs:7	rapid eye movement sleep:106:0.9551|rapid-eye-movement sleep:47:0.1678	0.9551	153
REMD	REMD:8|REMd:8|REM-D:1	sleep deprivation:17:0.7407	0.7407	17
REM	REM:13	electron microscopy:13:0.7753	0.7753	13
REM	REM:1900|rem:1	rapid eye movement:1564:0.9680|rapid-eye-movement:291:0.1268|rapid eye movements:46:0.9353	0.9680	1901
REM	REM:69	rapid eye movement sleep:69:0.9567	0.9567	69
REM	REM:24	Relative electrophoretic mobility:24:0.8115	0.8115	24
REM	REM:14	reticular erythematous mucinosis:14:0.7909	0.7909	14
REN	REN:8	human renin gene:8:0.2987	0.2987	8
Reo-3	Reo-3:8|REO3:1|Reo3:1	reovirus type 3:10:0.7103	0.7103	10
REP-1	REP-1:7|REP1:2	Rab Escort Protein-1:9:0.6794	0.6794	9
rep	rep:8|REP:2|Rep:1	proteins:11:0.0239	0.0239	11
REP	REP:28	Rab escort protein:28:0.8369	0.8369	28
rEP	rEP:3|rep:2|rEp:1	recombinant human erythropoietin:6:0.5290	0.5290	6
REP	REP:9|rep:7	reperfusion:16:0.0358	0.0358	16
REP	REP:50|rep:1	repetitive extragenic palindromic:51:0.9082	0.9082	51
rep	rep:35	replication:35:0.0811	0.0811	35
RER+	RER+:26	replication error:17:0.8270|replication errors:9:0.5470	0.8270	26
RER+	RER+:11	replication error phenotype:11:0.7357	0.7357	11
RER+	RER+:12	replication error positive:12:0.5664	0.5664	12
RERF	RERF:30	Radiation Effects Research Foundation:30:0.9011	0.9011	30
RER	RER:14	recurrent exertional rhabdomyolysis:14:0.7909	0.7909	14
RER	RER:103	replication error:75:0.9169|replication errors:28:0.8941	0.9169	103
RER	RER:206	respiratory exchange ratio:206:0.9767	0.9767	206
RER	RER:654|rER:135|r-ER:6|rer:6	rough endoplasmic reticulum:801:0.9083	0.9083	801
RESA	RESA:60	ring-infected erythrocyte surface antigen:60:0.7385	0.7385	60
RES	RES:20|res:2|Res:1	reserpine:23:0.0259	0.0259	23
res	res:7	resolution site:7:0.2452	0.2452	7
res	res:15	response elements:15:0.3429	0.3429	15
res	res:21|REs:7	restriction endonucleases:28:0.8941	0.8941	28
RES	RES:23|res:8|Res:1	resveratrol:32:0.0364	0.0364	32
RES	RES:11	reticuloendothelial:11:0.0118	0.0118	11
RES	RES:447|res:1	Reticuloendothelial system:448:0.8436	0.8436	448
RET	RET:21	Rational-Emotive Therapy:13:0.2802|Rational Emotive Therapy:8:0.6411	0.6411	21
RET	RET:9|Ret:2	receptor tyrosine kinase:11:0.6182	0.6182	11
RET	RET:78	resonance energy transfer:78:0.8425	0.8425	78
RET	RET:7|ret:1	RET proto-oncogene:8:0.4102	0.4102	8
REV-T	REV-T:16	reticuloendotheliosis virus:16:0.7261	0.7261	16
REV-T	REV-T:12|Rev-T:6	reticuloendotheliosis virus strain T:18:0.7865	0.7865	18
REV	REV:102|Rev:3	Reticuloendotheliosis virus:93:0.9175|Reticuloendotheliosis viruses:12:0.7571	0.9175	105
REV	REV:10	reverse phase evaporation:10:0.7103	0.7103	10
REV	REV:7	reverse-phase evaporation vesicles:7:0.2452	0.2452	7
REZ	REZ:25	root entry zone:25:0.8816	0.8816	25
REZ	REZ:12	root exit zone:12:0.5664	0.5664	12
RE	RE:6	cells of the reticulo-epithelial:6:0.1010	0.1010	6
RE	RE:8|Re:2	efferent arteriolar resistance:10:0.7103	0.7103	10
Re	Re:15|RE:14	estrogen receptor:29:0.5634	0.5634	29
Re	Re:10|RE:1	molar ratios:11:0.7357	0.7357	11
RE	RE:6	patients with Rasmussen encephalitis:6:0.1320	0.1320	6
RE	RE:5	rapid ejaculation:5:0.0612	0.0612	5
RE	RE:24	Rasmussen's encephalitis:24:0.4788	0.4788	24
Re	Re:5|RE:4	ratio:9:0.0056	0.0056	9
RE	RE:44	reflux esophagitis:44:0.8941	0.8941	44
RE	RE:7	rejection episodes:7:0.3524	0.3524	7
RE	RE:6	relative enhancement:6:0.1838	0.1838	6
RE	RE:26	relative error:26:0.4874	0.4874	26
RE	RE:6	removal efficiency:6:0.0899	0.0899	6
RE	RE:14	resistance exercise:14:0.6173	0.6173	14
RE	RE:12	respiratory epithelium:12:0.5664	0.5664	12
RE	RE:9	response element:9:0.1205	0.1205	9
RE	RE:7	Response entropy:7:0.3524	0.3524	7
RE	RE:74	restriction endonuclease:54:0.9448|Restriction endonucleases:20:0.8525	0.9448	74
RE	RE:21|Re:1	restriction enzyme:22:0.6934	0.6934	22
RE	RE:9	Retained energy:9:0.3455	0.3455	9
RE	RE:5	reticular nucleus:5:0.1132	0.1132	5
RE	RE:6	reticularis thalami:6:0.1838	0.1838	6
RE	RE:90|R-E:1	reticuloendothelial:91:0.0632	0.0632	91
RE	RE:8	retinal extract:8:0.2327	0.2327	8
RE	RE:37	retinol equivalents:30:0.8472|retinol equivalent:7:0.2902	0.8472	37
RE	RE:26	retinyl ester:13:0.7753|retinyl esters:13:0.5934	0.7753	26
Re	Re:50	Reynolds number:37:0.8377|Reynolds numbers:13:0.6701	0.8377	50
RE	RE:9	right ear:9:0.6794	0.6794	9
RE	RE:12	right eye:12:0.5050	0.5050	12
RE	RE:9	Rolandic epilepsy:9:0.1809	0.1809	9
RE	RE:34	running economy:34:0.9126	0.9126	34
RE	RE:25	thalamic reticular:25:0.5496	0.5496	25
RF1	RF1:7|RF-1:4	release factor 1:11:0.7357	0.7357	11
RF2	RF2:12|RF-2:7	release factor 2:19:0.7658	0.7658	19
RFA	RFA:348|RF-A:1	radiofrequency ablation:349:0.7630	0.7630	349
RFA	RFA:28	resonance frequency analysis:28:0.8941	0.8941	28
RFB	RFB:7	radial-flow bioreactor:7:0.3524	0.3524	7
RFB	RFB:16	replication fork barrier:16:0.8165	0.8165	16
RFC1	RFC1:17|RFC-1:10|rfc1:1	reduced folate carrier:28:0.8369	0.8369	28
RFCA	RFCA:82|RF-CA:6	radiofrequency catheter ablation:88:0.8027	0.8027	88
RFC	RFC:11	radiofrequency current:11:0.7357	0.7357	11
RFC	RFC:89	reduced folate carrier:89:0.9664	0.9664	89
RfC	RfC:21	reference concentration:21:0.8594	0.8594	21
RFC	RFC:81|RF-C:43	replication factor C:124:0.9616	0.9616	124
RFC	RFC:6	Residual feed consumption:6:0.5290	0.5290	6
RFC	RFC:122	rosette-forming cells:83:0.5608|rosette forming cells:22:0.4883|rosette-forming cell:17:0.5038	0.5608	122
RFETS	RFETS:10	Rocky Flats Environmental Technology Site:10:0.7103	0.7103	10
RFE	RFE:9|RFe:4	radiofrequency energy:13:0.6701	0.6701	13
RFFF	RFFF:11	radial forearm free flap:11:0.7357	0.7357	11
RFFIT	RFFIT:38	rapid fluorescent focus inhibition test:38:0.9217	0.9217	38
RFGD	RFGD:17	glow discharge:17:0.8270	0.8270	17
RFH	RFH:12	reactive follicular hyperplasia:12:0.7571	0.7571	12
RFIPC	RFIPC:8	Rating Form of IBD Patient Concerns:8:0.6411	0.6411	8
RFI	RFI:10	Relapse-free interval:10:0.2446	0.2446	10
RFI	RFI:14|rFI:1	relative fluorescence intensity:15:0.8045	0.8045	15
RFI	RFI:8	renal failure index:8:0.5006	0.5006	8
RFLP	RFLP:19	restriction fragment length polymorphic:19:0.8449	0.8449	19
RFLP	RFLP:3272	restriction fragment length polymorphism:2992:0.9046|restriction fragment length polymorphisms:280:0.9355	0.9355	3272
RFLP	RFLP:20	Restriction fragment length polymorphism analysis:20:0.7766	0.7766	20
RFLPs	RFLPs:13	restriction fragment length polymorphism:13:0.6701	0.6701	13
RFLS	RFLS:7	rheumatoid factor-like substance:7:0.5926	0.5926	7
RFN	RFN:11	retrofacial nucleus:11:0.4728	0.4728	11
RFOs	RFOs:5	Raffinose family oligosaccharides:5:0.5926	0.5926	5
RFp	RFp:9	parvicellular reticular formation:9:0.6794	0.6794	9
RFP	RFP:31	red fluorescent protein:31:0.7718	0.7718	31
RFP	RFP:32	Request for Proposal:32:0.8563	0.8563	32
RFP	RFP:11|rfp:1	restriction fragment pattern:12:0.6460	0.6460	12
RFP	RFP:5	restrictive filling pattern:5:0.1464	0.1464	5
RFP	RFP:11|rfp:4|Rfp:1	ret finger protein:16:0.8165	0.8165	16
RFP	RFP:14	rifampin:14:0.0447	0.0447	14
RFR	RFR:38	radiofrequency radiation:38:0.4722	0.4722	38
RFR	RFR:13	red cell filtration rate:13:0.7753	0.7753	13
RFR	RFR:37	renal functional reserve:37:0.8749	0.8749	37
RFTA	RFTA:8	radiofrequency thermal ablation:8:0.3463	0.3463	8
RFT	RFT:8	Rod-and-Frame Test:8:0.1591	0.1591	8
RFVTR	RFVTR:9	radiofrequency volumetric tissue reduction:9:0.6794	0.6794	9
RFX	RFX:19	Regulatory Factor X:19:0.7044	0.7044	19
RFs	RFs:231|rfs:1	receptive fields:232:0.9328	0.9328	232
RFS	RFS:6	reflux finding score:6:0.5290	0.5290	6
RFS	RFS:18	relapse-free:18:0.0176	0.0176	18
RFS	RFS:319	relapse-free survival:319:0.6784	0.6784	319
RFs	RFs:18	release factors:18:0.0753	0.0753	18
RFs	RFs:77	rheumatoid factors:77:0.5254	0.5254	77
RFs	RFs:22	risk factors:22:0.1020	0.1020	22
RFs	RFs:12	Rosenthal fibers:12:0.5664	0.5664	12
RF	RF:10	force:10:0.0017	0.0017	10
RF	RF:10	frequencies:10:0.0017	0.0017	10
RF	RF:416|rf:68|r-f:1	radio frequency:268:0.6730|radio-frequency:217:0.0399	0.6730	485
RF	RF:1266|rf:42|Rf:1	radiofrequency:1309:0.2416	0.2416	1309
RF	RF:9	radiofrequency ablation:9:0.3945	0.3945	9
RF	RF:9	radiofrequency current:9:0.5470	0.5470	9
RF	RF:302|rf:1	receptive field:235:0.8398|receptive fields:50:0.8068|Receptive-field:18:0.0031	0.8398	303
RF	RF:15	recirculation fraction:15:0.0782	0.0782	15
RF	RF:44	regurgitant fraction:44:0.3679	0.3679	44
RF	RF:46	Reissner's fiber:46:0.6761	0.6761	46
RF	RF:14	Reissner's fibre:14:0.7909	0.7909	14
RF	RF:71	renal failure:71:0.5390	0.5390	71
RF	RF:8	renal function:8:0.2090	0.2090	8
RF	RF:141|Rf:1	replicative form:114:0.9582|replicative-form:19:0.0033|replicative forms:9:0.4587	0.9582	142
RF	RF:36	respiratory failure:36:0.2188	0.2188	36
RF	RF:50|Rf:14	respiratory frequency:64:0.1308	0.1308	64
RF	RF:7	resting flux:7:0.3524	0.3524	7
RF	RF:10	Restricted daily feeding:10:0.7103	0.7103	10
RF	RF:21	restricted feeding:21:0.4041	0.4041	21
RF	RF:130|rf:3	reticular formation:133:0.9416	0.9416	133
RF	RF:13	retroperitoneal fibromatosis:13:0.7753	0.7753	13
RF	RF:124	rheumatic fever:124:0.9375	0.9375	124
RF	RF:1388|Rf:2	rheumatoid factor:1122:0.8752|rheumatoid factors:268:0.6557	0.8752	1390
RF	RF:61|Rf:10	riboflavin:71:0.0129	0.0129	71
RF	RF:91|rf:1	risk factors:92:0.1957	0.1957	92
RF	RF:8	Rosenthal fibers:8:0.5006	0.5006	8
RGAs	RGAs:17	resistance gene analogs:17:0.7407	0.7407	17
RGAs	RGAs:12	resistance gene analogues:12:0.6460	0.6460	12
RGCs	RGCs:503|RGCS:2	retinal ganglion cells:505:0.9787	0.9787	505
Rgc	Rgc:4|RGc:1	nucleus reticularis gigantocellularis:5:0.1973	0.1973	5
RGC	RGC:9	respiratory glycoconjugate:9:0.6794	0.6794	9
RGC	RGC:334|rgc:3	retinal ganglion cell:266:0.9760|retinal ganglion cells:71:0.9124	0.9760	337
RGDS	RGDS:136	Arg-Gly-Asp-Ser:136:0.7258	0.7258	136
RGDS	RGDS:9	arginine-glycine-aspartic acid-serine:9:0.5470	0.5470	9
RGD	RGD:567	Arg-Gly-Asp:567:0.6361	0.6361	567
RGD	RGD:31	arginine-glycine-aspartate:31:0.0340	0.0340	31
RGD	RGD:150	arginine-glycine-aspartic acid:150:0.8505	0.8505	150
RGEA	RGEA:68|rGEA:4|R-GEA:1	right gastroepiploic artery:73:0.9591	0.9591	73
RG-II	RG-II:21	rhamnogalacturonan II:21:0.6812	0.6812	21
RG-I	RG-I:15|RGI:2	rhamnogalacturonan I:17:0.7407	0.7407	17
RGM	RGM:19	rapidly growing mycobacteria:19:0.8449	0.8449	19
RGM	RGM:8	reactive gaseous mercury:8:0.6411	0.6411	8
RGM1	RGM1:4|RGM-1:1	rat gastric epithelial cells:5:0.2818	0.2818	5
RGM-1	RGM-1:3|RGM1:2	rat gastric mucosal cells:5:0.2818	0.2818	5
RGNs	RGNs:8	retinal ganglion neurons:8:0.6411	0.6411	8
RGO	RGO:27	reciprocating gait orthosis:27:0.7425	0.7425	27
Rgp	Rgp:10|RGP:2|rgp:1	Arg-gingipain:13:0.0414	0.0414	13
RGP	RGP:5	rabies virus glycoprotein:5:0.4422	0.4422	5
RGP	RGP:21	radial growth phase:21:0.7865	0.7865	21
RGP	RGP:176	Rigid gas permeable:130:0.9639|rigid gas-permeable:46:0.8703	0.9639	176
RGR	RGR:64|rgr:1	relative growth rate:53:0.8597|relative growth rates:12:0.6460	0.8597	65
RGR	RGR:12	retinal G protein-coupled receptor:12:0.6460	0.6460	12
RGS-2	RGS-2:3|RGS2:2	G protein signaling-2:5:0.4422	0.4422	5
RGS2	RGS2:3|Rgs2:1	regulator of G protein signaling 2:4:0.3170	0.3170	4
RGS4	RGS4:8	regulator of G-protein signaling 4:8:0.6794	0.6794	8
RGS	RGS:161	G protein signaling:161:0.9814	0.9814	161
RGS	RGS:10	G protein signalling:10:0.7103	0.7103	10
RGS	RGS:7	radio-guided surgery:7:0.1211	0.1211	7
RGS	RGS:8	radioguided surgery:8:0.1730	0.1730	8
RGS	RGS:114|Rgs:1	regulators of G-protein signaling:69:0.4996|Regulator of G-protein signaling:46:0.2837	0.4996	115
RGS	RGS:21	Regulators of G-protein signalling:12:0.2868|regulator of G-protein signalling:9:0.1585	0.2868	21
RGT	RGT:11	rectal gland tubules:11:0.7357	0.7357	11
Rg	Rg:7	glucose metabolic rate:7:0.5926	0.5926	7
Rg	Rg:9	glucose uptake:9:0.6794	0.6794	9
Rg	Rg:44|RG:4	radius of gyration:48:0.7595	0.7595	48
RG	RG:24	red gastrocnemius:24:0.7593	0.7593	24
RG	RG:8|R-G:6|r-g:2	red-green:16:0.0291	0.0291	16
RG	RG:8|Rg:1	reference group:9:0.0526	0.0526	9
RG	RG:22	renormalization group:22:0.2619	0.2619	22
RG	RG:10	rhamnogalacturonan:10:0.0175	0.0175	10
Rg	Rg:11	Rodgers:11:0.0194	0.0194	11
Rg	Rg:11	rough:11:0.0194	0.0194	11
RhAG	RhAG:9	glycoprotein:9:0.6667	0.6667	9
RHAMM	RHAMM:24|Rhamm:1	receptor for hyaluronan-mediated motility:17:0.8270|receptor for hyaluronan mediated motility:8:0.6411	0.8270	25
RHAs	RHAs:13	regional health authorities:13:0.7753	0.7753	13
rha	rha:11	L-rhamnose:11:0.0658	0.0658	11
rHA	rHA:10	recombinant human albumin:10:0.7103	0.7103	10
RHA	RHA:13	Regional Health Authority:13:0.7753	0.7753	13
rha	rha:7|RHA:1|Rha:1	rhamnose:9:0.0526	0.0526	9
RHA	RHA:9	right hepatic artery:9:0.6794	0.6794	9
RHA	RHA:11	Roman High Avoidance:11:0.6182	0.6182	11
RHDV	RHDV:58	rabbit haemorrhagic disease virus:58:0.9190	0.9190	58
RHDV	RHDV:39	rabbit hemorrhagic disease virus:39:0.8781	0.8781	39
RHD	RHD:18	Rel homology domain:18:0.4934	0.4934	18
RHD	RHD:146|Rhd:1	rheumatic heart disease:147:0.9205	0.9205	147
RHD	RHD:21	right hemisphere damage:21:0.7865	0.7865	21
RHD	RHD:36	Right-hemisphere-damaged:20:0.0445|right hemisphere damaged:16:0.8165	0.8165	36
RHF	RHF:17	right heart failure:17:0.4742	0.4742	17
RHI	RHI:7|rHI:2|rhI:2	human insulin:11:0.7357	0.7357	11
RHL	RHL:17	recurrent herpes labialis:17:0.6211	0.6211	17
RHL	RHL:13	respiratory heat loss:13:0.7753	0.7753	13
RHPA	RHPA:53	reverse hemolytic plaque assay:53:0.9438	0.9438	53
RHR	RHR:9	Rel Homology Region:9:0.6794	0.6794	9
RHR	RHR:7	relative hazard rate:7:0.5926	0.5926	7
RHR	RHR:17	renovascular hypertensive rats:17:0.1121	0.1121	17
RHR	RHR:10|rHR:1	resting heart rate:11:0.5355	0.5355	11
RHS	RHS:12	reactive hemophagocytic syndrome:12:0.7571	0.7571	12
RHT	RHT:15	regional hyperthermia:15:0.5818	0.5818	15
RHT	RHT:78	retinohypothalamic tract:78:0.8293	0.8293	78
RHT	RHT:10	Ruthenium hexammine trichloride:10:0.5470	0.5470	10
rhu	rhu:25|rHu:18|r-Hu:3	recombinant human:46:0.8401	0.8401	46
RHV	RHV:22	right hepatic vein:22:0.8657	0.8657	22
RIAS	RIAS:32	Roter Interaction Analysis System:32:0.7388	0.7388	32
RIA	RIA:22	radioimmune assay:22:0.1299	0.1299	22
RIA	RIA:14	radioimmuno assay:14:0.0634	0.0634	14
RIA	RIA:4450	radioimmunoassay:4450:0.8222	0.8222	4450
RIA	RIA:13	radioimmunological assay:13:0.0556	0.0556	13
RIBA-2	RIBA-2:23|RIBA2:2	recombinant immunoblot assay:25:0.6873	0.6873	25
RIBA	RIBA:9	immunoblot:9:0.0516	0.0516	9
RIBA	RIBA:110	recombinant immunoblot assay:110:0.9298	0.9298	110
RICO	RICO:9	genetically hypercholesterolemic:9:0.6794	0.6794	9
RICU	RICU:19	respiratory intensive care unit:19:0.6537	0.6537	19
RIC	RIC:63|ric:1	reduced-intensity conditioning:41:0.4947|reduced intensity conditioning:23:0.8715	0.8715	64
RIC	RIC:16	Renomedullary interstitial cells:16:0.7261	0.7261	16
RID	RID:115	radial immunodiffusion:115:0.9212	0.9212	115
RIE-1	RIE-1:22	rat intestinal epithelial:22:0.7955	0.7955	22
RIE	RIE:13	Rat intestinal epithelial:13:0.6701	0.6701	13
RIE	RIE:22|R-IE:1	rocket immunoelectrophoresis:23:0.8715	0.8715	23
RIF-1	RIF-1:20	radiation-induced fibrosarcoma:20:0.5021	0.5021	20
RIF	RIF:17	radiation-induced fibrosarcoma:17:0.5374	0.5374	17
RIF	RIF:11	radiation-induced fibrosis:11:0.3213	0.3213	11
RIF	RIF:8	Renal interstitial fibrosis:8:0.5926	0.5926	8
RIF	RIF:15	renal interstitial fluid:15:0.7096	0.7096	15
RIF	RIF:20	rigid internal fixation:20:0.8525	0.8525	20
RIF	RIF:6	Rosette inhibitory factor:6:0.1148	0.1148	6
RIGS	RIGS:71	Radioimmunoguided surgery:71:0.9335	0.9335	71
RIG	RIG:9	rabies immune globulin:9:0.5470	0.5470	9
RIHP	RIHP:48	renal interstitial hydrostatic pressure:48:0.9379	0.9379	48
RIII	RIII:6	nociceptive flexion reflex:6:0.2827	0.2827	6
RII	RII:15	radioimmunoimaging:15:0.0440	0.0440	15
RII	RII:13	regulatory:13:0.0377	0.0377	13
RII	RII:10	regulatory subunits:10:0.7103	0.7103	10
RII	RII:4|R-II:1	regulatory subunit of type II cAMP-dependent protein kinase:5:0.5290	0.5290	5
RII	RII:36|R-II:1	type II receptor:37:0.9197	0.9197	37
RII	RII:19	type II regulatory subunit:19:0.8449	0.8449	19
RIJV	RIJV:10	right internal jugular vein:10:0.7103	0.7103	10
rIL-4	rIL-4:11|rIL4:2|RIL4:1	interleukin 4:14:0.7909	0.7909	14
rIL-4	rIL-4:19	recombinant IL-4:19:0.5732	0.5732	19
rIL-4	rIL-4:25|rIL4:1	recombinant Interleukin-4:26:0.7760	0.7760	26
RILD	RILD:13	Radiation-induced liver disease:13:0.7753	0.7753	13
RILs	RILs:82	recombinant inbred lines:82:0.9636	0.9636	82
RIL	RIL:14	rabbit ileal loop:14:0.6173	0.6173	14
RIL	RIL:28	recombinant inbred line:28:0.8941	0.8941	28
RIMA	RIMA:34	right internal mammary artery:34:0.9126	0.9126	34
RIM	RIM:5	Rorschach Inkblot Method:5:0.4422	0.4422	5
RIND	RIND:10	reversible ischemic neurologic deficit:10:0.7103	0.7103	10
RIND	RIND:18	reversible ischemic neurological deficit:18:0.8365	0.8365	18
RINm5F	RINm5F:20	rat insulinoma cells:20:0.7173	0.7173	20
RIP140	RIP140:26|RIP-140:1	receptor interacting protein 140:14:0.7909|receptor-interacting protein 140:13:0.2532	0.7909	27
RIPA	RIPA:71	radioimmunoprecipitation assay:63:0.7943|radioimmunoprecipitation assays:8:0.4102	0.7943	71
RIPA	RIPA:11	ristocetin-induced platelet agglutination:11:0.6182	0.6182	11
RIPA	RIPA:28	ristocetin-induced platelet aggregation:28:0.7154	0.7154	28
RIPs	RIPs:112|RIPS:1|Rips:1	ribosome-inactivating proteins:114:0.7104	0.7104	114
RIP	rip:4|RIP:4	nucleus raphe interpositus:8:0.5006	0.5006	8
RIP	RIP:9	radioimmune precipitation:9:0.6794	0.6794	9
RIP	RIP:70	radioimmunoprecipitation:70:0.1106	0.1106	70
RIP	RIP:32	receptor-interacting protein:32:0.1187	0.1187	32
RIP	RIP:15|Rip:2	regulated intramembrane proteolysis:17:0.7539	0.7539	17
RIP	RIP:55	repeat-induced point mutation:55:0.7690	0.7690	55
RIP	RIP:11	respiratory inductance plethysmograph:11:0.7357	0.7357	11
RIP	RIP:19	Respiratory inductance plethysmography:19:0.7658	0.7658	19
RIP	RIP:23	respiratory inductive plethysmograph:23:0.8768	0.8768	23
RIP	RIP:57	respiratory inductive plethysmography:57:0.9176	0.9176	57
RIP	RIP:112	ribosome-inactivating protein:94:0.4532|ribosome-inactivating proteins:18:0.6903	0.6903	112
RIP	RIP:6	RNAIII-inhibiting peptide:6:0.0807	0.0807	6
RIP	RIP:5	under the control of the rat insulin promoter:5:0.7103	0.7103	5
RIR	RIR:22	Rhode Island Red:22:0.8657	0.8657	22
RISA	RISA:14	ribosomal intergenic spacer analysis:14:0.7909	0.7909	14
RISA	RISA:66	serum albumin:66:0.5816	0.5816	66
RISC	RISC:41	RNA-induced silencing complex:41:0.7472	0.7472	41
RISH	RISH:20|rISH:1	situ hybridization:21:0.7766	0.7766	21
RIST	RIST:13	radioimmunosorbent test:13:0.2415	0.2415	13
RIST	RIST:12	Rapid insulin sensitivity test:12:0.7571	0.7571	12
RIST	RIST:40	stem cell transplantation:40:0.9256	0.9256	40
RITA	RITA:9	Intervention Treatment of Angina:9:0.6794	0.6794	9
RITA	RITA:8	Radiofrequency interstitial tumor ablation:8:0.6411	0.6411	8
RITA	RITA:36	right internal thoracic artery:36:0.8716	0.8716	36
RITARD	RITARD:5	removable intestinal tie adult rabbit diarrhea:5:0.2818	0.2818	5
RITC	RITC:28	rhodamine B isothiocyanate:14:0.7909|rhodamine-B-isothiocyanate:14:0.2889	0.7909	28
RITh	RITh:9|RITH:2	radioiodine therapy:11:0.6182	0.6182	11
RIT	RIT:3|Rit:1	5-HT2 antagonist ritanserin:4:0.2818	0.2818	4
RIT	RIT:262	radioimmunotherapy:262:0.6141	0.6141	262
RIT	RIT:21	radioiodine therapy:21:0.4041	0.4041	21
RIT	RIT:8	repetitive irritation test:8:0.6411	0.6411	8
RIT	RIT:13|R-IT:1	Rush immunotherapy:14:0.7909	0.7909	14
RIXS	RIXS:9	Resonant Inelastic X-ray Scattering:9:0.6794	0.6794	9
RJM	RJM:20	jaw movements:20:0.8525	0.8525	20
RJMs	RJMs:10	jaw movements:10:0.7103	0.7103	10
Rj	Rj:10|rj:1	junctional resistance:11:0.2972	0.2972	11
RJ	RJ:11	Rio de Janeiro:11:0.7357	0.7357	11
RJ	RJ:28	royal jelly:28:0.8941	0.8941	28
RK13	RK13:18|RK-13:13	rabbit kidney:31:0.9043	0.9043	31
RK13	RK13:5|RK-13:3	rabbit kidney cells:8:0.6411	0.6411	8
RKIP	RKIP:11	Raf kinase inhibitor protein:11:0.4728	0.4728	11
RKM	RKM:45	rokitamycin:45:0.7458	0.7458	45
RLAR	RLAR:12	rat lens aldose reductase:12:0.7571	0.7571	12
RLA	RLA:8	radioligand assay:8:0.2327	0.2327	8
RLA	RLA:8	renin-like activity:8:0.4102	0.4102	8
RLA	RLA:13	retroperitoneal lymphadenectomy:13:0.6701	0.6701	13
RLB	RLB:11	reverse line blot:11:0.6182	0.6182	11
RLCs	RLCs:12|R-LCs:2	regulatory light chains:14:0.7909	0.7909	14
RLC	RLC:100|R-LC:14	regulatory light chain:96:0.9346|regulatory light chains:18:0.8365	0.9346	114
RLD	RLD:8	restrictive lung disease:8:0.5006	0.5006	8
RLEC	RLEC:10	rat liver epithelial cells:10:0.7103	0.7103	10
RLE	RLE:9	epithelial cells:9:0.4587	0.4587	9
RLE	RLE:27	rat liver epithelial:27:0.8903	0.8903	27
RLE	RLE:10	rat lung endothelial:10:0.7103	0.7103	10
RLF	RLF:9	rat lung fibroblasts:9:0.5470	0.5470	9
RLF	RLF:46	Relaxin-like factor:46:0.6264	0.6264	46
RLF	RLF:44	Retrolental fibroplasia:44:0.9323	0.9323	44
RLGS	RLGS:75	restriction landmark genomic scanning:75:0.9602	0.9602	75
RLI	RLI:12	RNase L inhibitor:12:0.5050	0.5050	12
RLKs	RLKs:16	receptor-like kinases:16:0.4274	0.4274	16
RLKs	RLKs:8	receptor-like protein kinases:8:0.6411	0.6411	8
RLL	RLL:17	right lower lobe:17:0.8270	0.8270	17
RLM	RLM:7	latex microspheres:7:0.2452	0.2452	7
RLM	RLM:14	rat liver mitochondria:14:0.7909	0.7909	14
RLND	RLND:13	retroperitoneal lymph node dissection:13:0.4444	0.4444	13
RLNL	RLNL:17	regional lymph node lymphocytes:17:0.8270	0.8270	17
RLNP	RLNP:8	recurrent laryngeal nerve paralysis:8:0.6411	0.6411	8
RLNs	RLNs:11|rLNs:1|RLN-s:1	recurrent laryngeal nerves:13:0.7753	0.7753	13
RLNs	RLNs:8	regional lymph nodes:8:0.5006	0.5006	8
RLN	RLN:10	lymph node:10:0.7103	0.7103	10
RLN	RLN:192	recurrent laryngeal nerve:192:0.9666	0.9666	192
RLN	RLN:11	regional lymph nodes:11:0.4232	0.4232	11
RLP-C	RLP-C:28|RLPC:1	remnant-like particle cholesterol:15:0.5348|remnant-like particle-cholesterol:14:0.7909	0.7909	29
RLP-C	RLP-C:12	RLP-cholesterol:12:0.1325	0.1325	12
RLPs	RLPs:10	remnant-like particles:10:0.2275	0.2275	10
R-LPS	R-LPS:10|RLPS:1	Rough lipopolysaccharide:11:0.5355	0.5355	11
RLP	RLP:35	remnant-like particles:20:0.4201|remnant-like particle:15:0.5818	0.5818	35
RLP	RLP:8	remnant lipoprotein:8:0.5006	0.5006	8
RLQ	RLQ:23	right lower quadrant:23:0.8715	0.8715	23
RLS85	RLS85:10	Reaction Level Scale:10:0.7103	0.7103	10
rLT	rLT:11	lymphotoxin:11:0.2273	0.2273	11
RLU	RLU:18	relative light units:18:0.8365	0.8365	18
RLV	RLV:7	liver volume:7:0.1850	0.1850	7
RLV	RLV:49	Rauscher leukemia virus:49:0.5954	0.5954	49
RLV	RLV:16	Rauscher murine leukemia virus:16:0.7261	0.7261	16
RLW	RLW:8	relative liver weight:8:0.6411	0.6411	8
RLS	RLS:49	resonance light scattering:37:0.5930|resonance light-scattering:12:0.5664	0.5930	49
RLS	RLS:344	restless legs syndrome:344:0.9912	0.9912	344
RLS	RLS:15	right-to-left shunt:15:0.8045	0.8045	15
RL	RL:14	form of Ringer lactate:14:0.3383	0.3383	14
RL	RL:16	lactated Ringer's solution:16:0.8165	0.8165	16
RL	RL:11	latency:11:0.0080	0.0080	11
RL	RL:11|rl:2	length:13:0.0096	0.0096	13
RL	RL:231|Rl:7	lung resistance:238:0.3601	0.3601	238
RL	RL:274|Rl:1	pulmonary resistance:275:0.4219	0.4219	275
rl	rl:13|RL:8	rat liver:21:0.6040	0.6040	21
RL	RL:8	red light:8:0.2987	0.2987	8
RL	RL:8	Reinforcement learning:8:0.2327	0.2327	8
RL	RL:6|Rl:1	resistance of the lung:7:0.2972	0.2972	7
RL	RL:9	right lateral:9:0.3945	0.3945	9
RL	RL:10|R-L:5	right-left:14:0.0104|right left:1:0.1329	0.1329	15
R-L	R-L:8	right minus left:8:0.6411	0.6411	8
R-L	R-L:18|RL:2|R--L:1	right-to-left:21:0.0159	0.0159	21
RL	RL:71	Ringer's lactate:71:0.6156	0.6156	71
RL	RL:6	Ringer's lactate solution:6:0.2243	0.2243	6
RMA	RMA:11	activity:11:0.0794	0.0794	11
RMA	RMA:5	rabbit mesenteric artery:5:0.1973	0.1973	5
RMBF	RMBF:112|rMBF:12|r-MBF:1	regional myocardial blood flow:125:0.9273	0.9273	125
RMCA	RMCA:9|rMCA:1	right middle cerebral artery:10:0.5000	0.5000	10
RMCE	RMCE:11	recombinase-mediated cassette exchange:11:0.5355	0.5355	11
RMCP	RMCP:13	rat mast cell protease:13:0.6701	0.6701	13
RMCPII	RMCPII:11|RMCP-II:6	rat mast cell protease II:17:0.6211	0.6211	17
RMCs	RMCs:10	rat mesangial cells:10:0.5856	0.5856	10
RMC	RMC:10	rat mast cells:10:0.1994	0.1994	10
RMC	RMC:22|rMC:2	rat mesangial cells:24:0.5848	0.5848	24
RMC	RMC:11	rat peritoneal mast cells:11:0.6182	0.6182	11
RMDQ	RMDQ:18	Roland-Morris Disability Questionnaire:10:0.2643|Roland Morris Disability Questionnaire:8:0.6411	0.6411	18
rMD	rMD:18|RMD:10	restrained molecular dynamics:28:0.6839	0.6839	28
RMD	RMD:16	Rippling muscle disease:16:0.8165	0.8165	16
RME	RME:8	normal rat mammary epithelial:8:0.4102	0.4102	8
RME	RME:41	rapid maxillary expansion:41:0.9274	0.9274	41
RME	RME:53|Rme:1	receptor-mediated endocytosis:54:0.8196	0.8196	54
RME	RME:16	resting metabolic expenditure:16:0.8165	0.8165	16
RMF	RMF:6|rmf:1	remanent magnetic field:7:0.3524	0.3524	7
RMF	RMF:15	Ribosome modulation factor:15:0.7096	0.7096	15
RMGICs	RMGICs:7	resin-modified glass-ionomer cements:7:0.5926	0.5926	7
RMGIC	RMGIC:17|RM-GIC:5|RmGIC:1	resin-modified glass ionomer cement:16:0.6577|resin-modified glass ionomer cements:7:0.4438	0.6577	23
RMGI	RMGI:13	resin-modified glass ionomer:13:0.5335	0.5335	13
RMg	RMg:7	nucleus raphe magnus:7:0.3524	0.3524	7
RMH	RMH:7	Royal Melbourne Hospital:7:0.5926	0.5926	7
RMICs	RMICs:7	renal medullary interstitial cells:7:0.4438	0.4438	7
RMICs	RMICs:6	Renomedullary interstitial cells:6:0.1010	0.1010	6
RMIC	RMIC:15	interstitial cells:15:0.8045	0.8045	15
RMI	RMI:13	myocardial infarction:13:0.6701	0.6701	13
RMI	RMI:17	reticulocyte maturity index:17:0.8270	0.8270	17
RMI	RMI:30	Rivermead Mobility Index:30:0.9011	0.9011	30
rMLC	rMLC:9|RMLC:3	regulatory myosin light chain:12:0.6460	0.6460	12
RML	RML:13	right middle lobe:13:0.7753	0.7753	13
RMN	RMN:21	Rolling Mouse Nagoya:21:0.8594	0.8594	21
RMP	RMP:189	resting membrane potential:179:0.9644|resting membrane potentials:10:0.5856	0.9644	189
RMQ	RMQ:9	Questionnaire:9:0.7273	0.7273	9
RMRs	RMRs:14	resting metabolic rates:14:0.7909	0.7909	14
RMR	RMR:18	renal mass reduction:18:0.8365	0.8365	18
RMR	RMR:577	resting metabolic rate:555:0.9666|resting metabolic rates:22:0.7955	0.9666	577
RMS40	RMS40:7	40 ms of the QRS complex:7:0.5926	0.5926	7
RMS40	RMS40:1	voltage in the terminal 40 ms:1:0.0918	0.0918	1
RMSD	RMSD:95|rmsd:30|RMSd:1	root-mean-square deviation:64:0.3631|root mean square deviation:50:0.9404|root-mean-square deviations:6:0.0899|root mean square deviations:6:0.5290	0.9404	126
RMSD	RMSD:3|RMSd:1|rmsd:1	root mean square difference:5:0.4422	0.4422	5
RMSEP	RMSEP:11	root mean square error of prediction:11:0.7571	0.7571	11
RMSE	RMSE:48	root mean square error:48:0.8492	0.8492	48
RMSF	RMSF:106	Rocky Mountain spotted fever:106:0.9551	0.9551	106
RMSSD	RMSSD:13|rMSSD:3	root mean square of successive differences:16:0.8525	0.8525	16
RMSSD	RMSSD:4|r-MSSD:3	root mean square successive difference:7:0.5926	0.5926	7
rMSSD	rMSSD:4|RMSSD:1|r-MSSD:1	square root of the mean of the squared differences between adjacent normal RR intervals:6:0.6411	0.6411	6
RMSs	RMSs:15	Rhabdomyosarcomas:15:0.7000	0.7000	15
RMS	RMS:10	rat milk substitute:10:0.7103	0.7103	10
RMs	RMs:25|rms:1	Reference materials:26:0.8861	0.8861	26
RMS	RMS:12	respiratory muscle strength:12:0.7571	0.7571	12
RMS	RMS:453	rhabdomyosarcoma:398:0.2573|rhabdomyosarcomas:55:0.0350	0.2573	453
RMS	RMS:430|rms:202	root mean square:409:0.9843|root-mean-square:223:0.1445	0.9843	632
RMS	RMS:30|rms:10	root mean squared:27:0.8903|root-mean-squared:13:0.0078	0.8903	40
RMS	RMS:55	rostral migratory stream:55:0.9458	0.9458	55
RMS	RMS:7	signal amplitude:7:0.0692	0.0692	7
RMT	RMT:9	random matrix theory:9:0.6794	0.6794	9
RMT	RMT:11	Recognition Memory Test:11:0.3829	0.3829	11
RMT	RMT:18|rMT:5	resting motor threshold:23:0.8715	0.8715	23
R-MuLV	R-MuLV:29|RMuLV:7	Rauscher murine leukemia virus:36:0.8716	0.8716	36
RNAPII	RNAPII:95|RNApII:3	RNA polymerase II:98:0.9695	0.9695	98
RNAPs	RNAPs:23	RNA polymerases:23:0.8715	0.8715	23
RNAP	RNAP:43	Escherichia coli RNA polymerase:43:0.7363	0.7363	43
RNAP	RNAP:18	RNA polymerases:18:0.8365	0.8365	18
RNAi	RNAi:976|RNAI:1	RNA interference:967:0.8892|RNA-interference:10:0.0080	0.8892	977
RNAs	RNAs:21	ribonucleic acids:21:0.7865	0.7865	21
RNA	RNA:735	Northern:735:0.4190	0.4190	735
RNA	RNA:21	radionuclide angiocardiography:21:0.8594	0.8594	21
RNA	RNA:97	radionuclide angiography:97:0.9692	0.9692	97
RNA	RNA:64	renal nerve activity:64:0.5805	0.5805	64
RNA	RNA:28	renal sympathetic nerve activity:28:0.8941	0.8941	28
RNA	RNA:602|RnA:1	ribonucleic acid:589:0.9566|ribonucleic acids:14:0.6911	0.9566	603
RND	RND:35|rND:2	radical neck dissection:37:0.9197	0.9197	37
RND	RND:14	resistance-nodulation-cell division:14:0.4071	0.4071	14
RNFA	RNFA:12	first assistant:12:0.6460	0.6460	12
RNFL	RNFL:203	retinal nerve fiber layer:203:0.9614	0.9614	203
RNFL	RNFL:51	retinal nerve fibre layer:51:0.9416	0.9416	51
RNFLT	RNFLT:9	retinal nerve fiber layer thickness:9:0.6794	0.6794	9
RNFLT	RNFLT:8	retinal nerve fibre layer thickness:8:0.6411	0.6411	8
RNG	RNG:14	random number generation:14:0.7909	0.7909	14
RNIs	RNIs:16	Reactive nitrogen intermediates:16:0.8165	0.8165	16
RNI	RNI:16	Nutrient Intake:16:0.6577	0.6577	16
RNI	RNI:141	reactive nitrogen intermediates:128:0.9627|reactive nitrogen intermediate:13:0.7753	0.9627	141
RNL	RNL:10	reintegration to normal living:10:0.7103	0.7103	10
RNm	RNm:21	magnocellular red nucleus:21:0.7865	0.7865	21
RNN	RNN:11	Neural Network:11:0.7357	0.7357	11
RNNs	RNNs:10	Recurrent neural networks:10:0.5856	0.5856	10
RNOS	RNOS:8	reactive nitrogen oxide species:8:0.5006	0.5006	8
RNOS	RNOS:5	reactive nitrogen oxygen species:5:0.5290	0.5290	5
RNO	RNO:22	rat chromosome:13:0.7753|rat Chromosomes:9:0.6794	0.7753	22
RNPs	RNPs:67	ribonucleoproteins:67:0.5546	0.5546	67
RNPs	RNPs:11	ribonucleoprotein complexes:11:0.6182	0.6182	11
RNPs	RNPs:31	Ribonucleoprotein particles:31:0.9043	0.9043	31
RNP	RNP:6	ribonuclear protein:6:0.0899	0.0899	6
RNP	RNP:497|RN-P:1	ribonucleoprotein:468:0.6863|ribonucleoproteins:30:0.0427	0.6863	498
RNP	RNP:10	ribonucleoprotein complex:10:0.3145	0.3145	10
RNP	RNP:24	ribonucleoprotein particle:12:0.7571|ribonucleoprotein particles:12:0.6460	0.7571	24
RNP	RNP:11	RNA-protein:11:0.0147	0.0147	11
RNRs	RNRs:29	ribonucleotide reductases:29:0.8978	0.8978	29
RNR	RNR:109|RnR:3	ribonucleotide reductase:112:0.9575	0.9575	112
rNST	rNST:20	nucleus of the solitary tract:20:0.8525	0.8525	20
RNS	RNS:100|R-NS:1	nerve stimulation:101:0.9377	0.9377	101
RNs	RNs:19	recombination nodules:19:0.5732	0.5732	19
RNs	RNs:197|RNS:1	registered nurses:198:0.9278	0.9278	198
RNTCP	RNTCP:8	Revised National TB Control Programme:8:0.6411	0.6411	8
RNTCP	RNTCP:17	Revised National Tuberculosis Control Programme:17:0.8270	0.8270	17
RNVG	RNVG:14	radionuclide ventriculography:14:0.7909	0.7909	14
RNV	RNV:22	Radionuclide venography:22:0.8657	0.8657	22
RNV	RNV:105	radionuclide ventriculography:105:0.9543	0.9543	105
rNV	rNV:8	recombinant Norwalk virus:8:0.4102	0.4102	8
ROA	ROA:12	radiographic osteoarthritis:12:0.3524	0.3524	12
ROA	ROA:27	Raman optical activity:27:0.8903	0.8903	27
ROA	ROA:11	regurgitant orifice area:11:0.5355	0.5355	11
Robo	Robo:41|robo:5	roundabout:46:0.9200	0.9200	46
ROB	ROB:5|rOB:2	rat osteoblasts:7:0.2452	0.2452	7
ROB	ROB:7	rat osteoblast-like:7:0.3524	0.3524	7
ROCF	ROCF:17	Rey-Osterrieth Complex Figure:17:0.7407	0.7407	17
ROCs	ROCs:21	receiver operating characteristics:21:0.7291	0.7291	21
ROCs	ROCs:9	receptor-operated Ca2+ channels:9:0.5470	0.5470	9
ROC	ROC:421	receiver operating characteristics:322:0.9399|receiver-operating-characteristic:52:0.0141|Receiver-operating characteristics:47:0.0749	0.9399	421
ROC	ROC:48	receiver operating characteristic curve:33:0.8605|receiver operating characteristic curves:15:0.8045	0.8605	48
ROC	ROC:5	receptor-operated channels:5:0.0612	0.0612	5
ROC	ROC:5|roc:5	rocuronium:10:0.0025	0.0025	10
ROESY	ROESY:10	rotating frame nuclear Overhauser effect spectroscopy:10:0.5856	0.5856	10
ROESY	ROESY:5	rotating frame nuclear Overhauser enhancement spectroscopy:5:0.4422	0.4422	5
ROI's	ROI's:12|ROI'S:1	Regions of Interest:13:0.6701	0.6701	13
ROIs	ROIs:126|ROIS:1	reactive oxygen intermediates:127:0.9502	0.9502	127
ROIs	ROIs:555|ROIS:1	regions of interest:519:0.9847|regions-of-interest:19:0.0257|regions of interests:11:0.3213|region of interests:7:0.1111	0.9847	556
ROI	ROI:398|roi:1	Reactive oxygen intermediates:344:0.9770|reactive oxygen intermediate:55:0.9458	0.9770	399
ROI	ROI:907|RoI:2	region of interest:509:0.6198|Regions of interest:265:0.3058|region-of-interest:116:0.0824|regions-of-interest:19:0.0129	0.6198	909
ROI	ROI:14	return on investment:14:0.7096	0.7096	14
ROK	ROK:13	Republic of Korea:13:0.7753	0.7753	13
ROK	ROK:12	Rho-kinase:12:0.1134	0.1134	12
ROMs	ROMs:47	Reactive oxygen metabolites:47:0.9366	0.9366	47
ROM	ROM:594|RoM:5|rom:1	range of motion:579:0.9350|range-of-motion:21:0.0235	0.9350	600
ROM	ROM:25	range of movement:25:0.8186	0.8186	25
ROM	ROM:84	reactive oxygen metabolites:71:0.9579|reactive oxygen metabolite:13:0.6701	0.9579	84
ROM	ROM:10	recurrent otitis media:10:0.5856	0.5856	10
ROM	ROM:4	rupture of the membranes:4:0.5560	0.5560	4
RONS	RONS:13	reactive oxygen and nitrogen species:13:0.7909	0.7909	13
RON	RON:9	optic nerve:9:0.6794	0.6794	9
RON	RON:12	Radial optic neurotomy:12:0.7571	0.7571	12
ROO.	ROO.:8	peroxyl radical:8:0.2987	0.2987	8
ROOH	ROOH:12	hydroperoxides:12:0.5000	0.5000	12
ROOHs	ROOHs:10	hydroperoxides:10:0.9000	0.9000	10
ROPS	ROPS:14	Rollover protective structures:14:0.5589	0.5589	14
ROP	ROP:741|RoP:1	retinopathy of prematurity:742:0.9893	0.9893	742
ROP	ROP:13	ring-opening polymerization:13:0.6701	0.6701	13
ROR	ROR:7	rapid onset rate:7:0.5926	0.5926	7
ROS-GC	ROS-GC:7	rod outer segment membrane guanylate cyclase:7:0.5926	0.5926	7
ROS/RNS	ROS/RNS:10	reactive oxygen and nitrogen species:10:0.7571	0.7571	10
ROSC	ROSC:137	return of spontaneous circulation:137:0.6245	0.6245	137
ROSI	ROSI:6|Rosi:3|rosi:1	rosiglitazone:10:0.2308	0.2308	10
ROSI	ROSI:22	round spermatid injection:22:0.8657	0.8657	22
Ros	Ros:6|ROS:1	oscillatory resistance:7:0.1211	0.1211	7
ROS	ROS:10	oxygen radicals:10:0.3867	0.3867	10
ROS	ROS:23	Rat osteosarcoma:23:0.7500	0.7500	23
ROS	ROS:28	reactive oxygen:28:0.6554	0.6554	28
ROS	ROS:6665|ROs:2|Ros:1	reactive oxygen species:6668:0.9888	0.9888	6668
ROS	ROS:6	reactive oxygen substances:6:0.5290	0.5290	6
Ros	Ros:9	respiratory resistance:9:0.2285	0.2285	9
ROS	ROS:510|ros:2	rod outer segments:311:0.8967|rod outer segment:201:0.9612	0.9612	512
ROT	ROT:6	roll-over test:6:0.2452	0.2452	6
ROU	ROU:13	recurrent oral ulcers:13:0.7753	0.7753	13
ROU	ROU:10	recurrent oral ulceration:10:0.7103	0.7103	10
Rox	Rox:8|ROX:2	oxidation:10:0.2647	0.2647	10
Rox	ROX:4|Rox:4	roxithromycin:8:0.2353	0.2353	8
Ro	Ro:8	binding capacity:8:0.4102	0.4102	8
Ro	Ro:4	CSF outflow resistance:4:0.2113	0.2113	4
Ro	Ro:13	input resistance:13:0.1463	0.1463	13
Ro	Ro:13	net reproductive rate:13:0.6701	0.6701	13
RO	RO:15	rapeseed oil:15:0.6386	0.6386	15
RO	RO:15	Reality Orientation:15:0.7096	0.7096	15
RO	RO:20	relative odds:20:0.8525	0.8525	20
RO	RO:86	reverse osmosis:86:0.9272	0.9272	86
RPAH	RPAH:13	Royal Prince Alfred Hospital:13:0.7753	0.7753	13
RPAR	RPAR:19	passive Arthus reaction:19:0.8449	0.8449	19
RPA	RPA:9	approach:9:0.0109	0.0109	9
RPA	RPA:229	protection assay:229:0.9372	0.9372	229
RPA	RPA:8	random phase approximation:8:0.6411	0.6411	8
RPa	RPa:13|Rpa:7|RPA:5	raphe pallidus:25:0.8816	0.8816	25
RPA	RPA:9	rapid plate agglutination:9:0.6794	0.6794	9
rPA	rPA:7	recombinant PA:7:0.2902	0.2902	7
rPA	rPA:16	Recombinant protective antigen:16:0.5564	0.5564	16
RPA	RPA:56	recursive partitioning analysis:56:0.9467	0.9467	56
RPA	RPA:10	recursive partitioning and amalgamation:10:0.7103	0.7103	10
Rpa	Rpa:7|RPA:2	resistance:9:0.0109	0.0109	9
r-PA	r-PA:10|rPA:5	reteplase:15:0.0164	0.0164	15
RPA	RPA:10	retropharyngeal abscess:10:0.7103	0.7103	10
RPA	RPA:15	reversed passive Arthus:15:0.4609	0.4609	15
RPA	RPA:38|rPA:1	right pulmonary artery:39:0.5194	0.5194	39
RPB1	RPB1:6|Rpb1:1	largest subunit:7:0.3524	0.3524	7
RPB1	RPB1:5|rpb1:2|Rpb1:2	largest subunit of RNA polymerase II:9:0.5856	0.5856	9
RPCH	RPCH:21	red pigment concentrating hormone:13:0.7909|red pigment-concentrating hormone:8:0.5006	0.7909	21
RPCT	RPCT:13	renal papillary collecting tubule:13:0.6701	0.6701	13
RPC	RPC:10	nucleus reticularis pontis caudalis:10:0.3867	0.3867	10
RPC	RPC:9	peritoneal cells:9:0.3069	0.3069	9
RPC	RPC:11	Radiological Physics Center:11:0.6182	0.6182	11
RPC	RPC:10	Reactive perforating collagenosis:10:0.5856	0.5856	10
RPC	RPC:10	Recurrent pyogenic cholangitis:10:0.7103	0.7103	10
RPC	RPC:16	relapsing polychondritis:16:0.8165	0.8165	16
RPC	RPC:13	Restorative proctocolectomy:13:0.7753	0.7753	13
RPC	RPC:24	reversed-phase chromatography:24:0.4622	0.4622	24
RPDs	RPDs:46|RPDS:1	removable partial dentures:47:0.8703	0.8703	47
RPD	RPD:77	removable partial denture:50:0.9404|removable partial dentures:27:0.8903	0.9404	77
RPD	RPD:36|rPD:1|rpd:1	rostral pars distalis:38:0.8781	0.8781	38
RPE	RPE:450	perceived exertion:450:0.9731	0.9731	450
RPE	RPE:23	pulmonary edema:23:0.8715	0.8715	23
R-PE	R-PE:22|RPE:9	R-phycoerythrin:31:0.0086	0.0086	31
RPE	RPE:13	Rapid palatal expansion:13:0.7753	0.7753	13
RPE	RPE:866|rpe:1	retinal pigment epithelial:867:0.9771	0.9771	867
RPE	RPE:89	retinal pigment epithelial cells:89:0.9664	0.9664	89
RPE	RPE:1615|rpe:3	retinal pigment epithelium:1618:0.9759	0.9759	1618
RPF	RPF:11	rate of pacemaker firing:11:0.7357	0.7357	11
RPF	RPF:11	renal plasma flow rate:11:0.7357	0.7357	11
Rpf	Rpf:5|rpf:2|RPF:1	resuscitation-promoting factor:8:0.1591	0.1591	8
RPF	RPF:45	retroperitoneal fibrosis:45:0.8941	0.8941	45
RPGN	RPGN:118	rapidly progressive glomerulonephritis:118:0.8735	0.8735	118
RPGR	RPGR:23	retinitis pigmentosa GTPase regulator:23:0.8657	0.8657	23
RPG	RPG:6	random plasma glucose:6:0.5290	0.5290	6
RPHA	RPHA:19|rPHA:1|R-PHA:1	passive haemagglutination:21:0.8594	0.8594	21
RPHA	RPHA:41|R-PHA:5	passive hemagglutination:46:0.8676	0.8676	46
RPHA	RPHA:9	passive hemagglutination assay:9:0.6794	0.6794	9
RPH	RPH:9	retinyl palmitate hydrolase:9:0.6794	0.6794	9
RPH	RPH:7	Royal Perth Hospital:7:0.5926	0.5926	7
R-PIA	R-PIA:5	agonist R-phenylisopropyl-adenosine:5:0.2243	0.2243	5
R-PIA	R-PIA:6	agonist R-phenylisopropyladenosine:6:0.0787	0.0787	6
R-PIA	R-PIA:13|RPIA:1	N6-R-phenylisopropyladenosine:14:0.0417	0.0417	14
R-PIA	R-PIA:9	R(-)-N6-(2-phenylisopropyl)adenosine:9:0.0256	0.0256	9
R-PIA	R-PIA:30	R-N6-phenylisopropyladenosine:30:0.0929	0.0929	30
R-PIA	R-PIA:2|RPIA:1	receptor agonist R-phenylisopropyl adenosine:3:0.2818	0.2818	3
RPI	RPI:5|Rpi:3	ribose-5-phosphate isomerase:8:0.5006	0.5006	8
RPI	RPI:8	RNA polymerase I:8:0.3463	0.3463	8
RPK	RPK:11|rPK:2	Rat plasma kallikrein:13:0.7753	0.7753	13
RPLC	RPLC:10|RP-LC:1	Reversed-phase liquid chromatographic:11:0.5355	0.5355	11
RPLC	RPLC:95|RP-LC:15	reversed-phase liquid chromatography:110:0.7025	0.7025	110
RPLND	RPLND:138	retroperitoneal lymph node dissection:138:0.9783	0.9783	138
RPLND	RPLND:14	retroperitoneal lymphadenectomy:14:0.7909	0.7909	14
RPMCs	RPMCs:3	histamine release from rat peritoneal mast cells:3:0.6411	0.6411	3
RPMI	RPMI:8	culture medium:8:0.1591	0.1591	8
RPM	RPM:20	rapamycin:20:0.0876	0.0876	20
RPM	RPM:14	rat pleural mesothelial:14:0.7909	0.7909	14
RPM	RPM:11	Raven's Progressive Matrices:11:0.5355	0.5355	11
RPM	RPM:18|R-PM:1	resident peritoneal macrophages:19:0.5732	0.5732	19
rpm	rpm:20|RPM:7	revolutions per minute:27:0.7066	0.7066	27
RPN	RPN:44	renal papillary necrosis:44:0.9338	0.9338	44
RPo	RPo:5|RPO:2	open complex:7:0.2452	0.2452	7
RPO	RPO:12	Red palm oil:12:0.7571	0.7571	12
RPO	RPO:11|rpo:1|Rpo:1	reticularis pontis oralis:13:0.5335	0.5335	13
RPP	RPP:20	radical perineal prostatectomy:20:0.8525	0.8525	20
RPP	RPP:73	rapidly progressive periodontitis:73:0.9147	0.9147	73
RPP	RPP:274|R-P-P:1	Rate-pressure product:151:0.4854|rate pressure product:105:0.8046|rate-pressure-product:11:0.0156|rate pressure products:8:0.6411	0.8046	275
RPP	RPP:149	renal perfusion pressure:149:0.9386	0.9386	149
RPR	RPR:139	rapid plasma reagin:139:0.9654	0.9654	139
RPR	RPR:13	rapid plasma reagin test:13:0.7753	0.7753	13
RPs	RPs:9	refractory periods:9:0.5470	0.5470	9
RPS	RPS:14	Relative Percent Survival:14:0.7909	0.7909	14
RPs	RPs:9	released proteins:9:0.1334	0.1334	9
RPs	RPs:12|rps:1	ribosomal proteins:13:0.2802	0.2802	13
RPTC	RPTC:15	renal proximal tubular cells:15:0.5818	0.5818	15
RPTC	RPTC:13	renal proximal tubule cells:13:0.4849	0.4849	13
RPTD	RPTD:9	recommended Phase II dose:9:0.6794	0.6794	9
RPTE	RPTE:7	proximal tubular epithelial:7:0.5926	0.5926	7
RPTE	RPTE:6	proximal tubule epithelial:6:0.5290	0.5290	6
RPTEC	RPTEC:5|RPTEc:1	renal proximal tubular epithelial cells:6:0.3728	0.3728	6
RPTPs	RPTPs:18|rPTPs:2	receptor protein tyrosine phosphatases:20:0.4201	0.4201	20
RPTP	RPTP:13|R-PTP:1	receptor protein tyrosine phosphatase:14:0.4071	0.4071	14
RPT	RPT:38	renal proximal tubule:21:0.5435|renal proximal tubules:17:0.5760	0.5760	38
RPT	RPT:9	residual pleural thickening:9:0.6794	0.6794	9
RPV	RPV:16|rPV:1	portal vein:17:0.7407	0.7407	17
RPV	RPV:9	rabbit poxvirus:9:0.5470	0.5470	9
RPV	RPV:98	rinderpest virus:98:0.7270	0.7270	98
Rpv	Rpv:6	vascular resistance:6:0.2243	0.2243	6
RPY	RPY:15	pouch young:15:0.8045	0.8045	15
RPase	RPase:10	RNA polymerase:10:0.7103	0.7103	10
RPeD1	RPeD1:12	Right Pedal Dorsal 1:12:0.7571	0.7571	12
Rp	Rp:18|RP:5	Peripheral airway resistance:23:0.7500	0.7500	23
Rp	Rp:14|RP:1	peripheral resistance:15:0.0670	0.0670	15
Rp	Rp:12|RP:8|rP:1	progesterone receptor:21:0.7865	0.7865	21
Rp	Rp:15|RP:1	pulmonary resistance:16:0.0746	0.0746	16
Rp	Rp:19|RP:1	pulmonary vascular resistance:20:0.5568	0.5568	20
RP	RP:24	radiation pneumonitis:24:0.8115	0.8115	24
RP	RP:307	Radical prostatectomy:307:0.9053	0.9053	307
RP	RP:10|Rp:1	raphe pallidus:11:0.6182	0.6182	11
RP	RP:30	Rapid prototyping:30:0.9011	0.9011	30
RP	RP:234	Raynaud's phenomenon:234:0.8913	0.8913	234
RP	RP:10	Reaction product:10:0.3867	0.3867	10
RP	RP:6	reactivity pattern:6:0.2243	0.2243	6
RP	RP:38	readiness potential:38:0.1801	0.1801	38
RP	RP:20	recognition potential:20:0.0739	0.0739	20
RP	RP:10	red pulp:10:0.5856	0.5856	10
RP	RP:34	refractory period:22:0.4047|refractory periods:12:0.6460	0.6460	34
RP	RP:14	regulatory particle:14:0.5111	0.5111	14
RP	RP:9	regulatory peptides:9:0.5470	0.5470	9
RP	RP:28	relapse prevention:28:0.8369	0.8369	28
RP	RP:82	Relapsing polychondritis:82:0.9640	0.9640	82
RP	RP:11|rp:2	relative potency:13:0.6701	0.6701	13
RP	RP:14	relative power:14:0.5589	0.5589	14
RP	RP:21|Rp:3	reperfusion:24:0.0074	0.0074	24
RP	RP:71	resting potential:65:0.3536|resting potentials:6:0.1010	0.3536	71
RP	RP:9	resting pressure:9:0.2102	0.2102	9
RP	RP:9	restorative proctocolectomy:9:0.6794	0.6794	9
RP	RP:10	retained placenta:10:0.5000	0.5000	10
RP	RP:14	Reticulated platelets:14:0.6173	0.6173	14
RP	RP:551|rp:1	retinitis pigmentosa:552:0.9856	0.9856	552
RP	RP:78|rp:1	retinyl palmitate:79:0.8443	0.8443	79
RP	RP:15	retrograde pyelography:15:0.8045	0.8045	15
RP	RP:34|Rp:1	retroperitoneal:35:0.0109	0.0109	35
RP	RP:6	retruded position:6:0.0807	0.0807	6
RP	RP:14|rp:1	reverse-phase:15:0.0045	0.0045	15
RP	RP:106	reversed-phase:106:0.0337	0.0337	106
RP	RP:11	rheumatoid polyarthritis:11:0.7357	0.7357	11
rp	rp:59|RP:40|Rp:3|r-p:1	ribosomal protein:94:0.7432|ribosomal proteins:9:0.3455	0.7432	103
RP	RP:10	rinderpest:10:0.0029	0.0029	10
RP	RP:8	Rock phosphate:8:0.4102	0.4102	8
RP	RP:11	roller pump:11:0.4728	0.4728	11
RQA	RQA:17	Recurrence Quantification Analysis:17:0.7407	0.7407	17
RQLQ	RQLQ:26	Rhinoconjunctivitis Quality of Life Questionnaire:26:0.6351	0.6351	26
RQ	RQ:11	questionnaire:11:0.0218	0.0218	11
RQ	RQ:344|Rq:4|rq:1	respiratory quotient:335:0.9353|Respiratory quotients:14:0.6911	0.9353	349
RR1	RR1:6	large subunit of ribonucleotide reductase:6:0.5290	0.5290	6
RRA	RRA:219	radioreceptor assay:207:0.7452|radioreceptor assays:12:0.5050	0.7452	219
RRA	RRA:11	radioreceptorassay:11:0.0274	0.0274	11
RRA	RRA:8	renin activity:8:0.2987	0.2987	8
RRBC	RRBC:13|rRBC:1|Rrbc:1	rabbit erythrocytes:15:0.4312	0.4312	15
RRBC	RRBC:19|rRBC:1	rabbit red blood cells:20:0.5021	0.5021	20
RRC	RRC:8	Renal renin content:8:0.6411	0.6411	8
RRC	RRC:28	Residency Review Committee:28:0.7905	0.7905	28
RRD	RRD:67	rhegmatogenous retinal detachment:67:0.9296	0.9296	67
RRFs	RRFs:15	Ragged-red fibers:15:0.4951	0.4951	15
RRF	RRF:24	ragged-red fibers:24:0.5848	0.5848	24
RRF	RRF:7	ragged-red fibres:7:0.2902	0.2902	7
RRF	RRF:99	residual renal function:99:0.9091	0.9091	99
RRF	RRF:11	retrorubral field:11:0.5355	0.5355	11
RRF	RRF:49	ribosome recycling factor:49:0.9392	0.9392	49
RRI	RRI:38	R-R interval:30:0.4514|R-R intervals:8:0.2619	0.4514	38
RRI	RRI:10	Recurrent respiratory infections:10:0.5856	0.5856	10
RRI	RRI:12|RRi:1	RR interval:13:0.1220	0.1220	13
RRL	RRL:62	rabbit reticulocyte lysate:53:0.9438|rabbit reticulocyte lysates:9:0.6794	0.9438	62
RRMS	RRMS:6|RR-MS:4	relapsing-remitting:10:0.0276	0.0276	10
RRMS	RRMS:54|RR-MS:14	relapsing-remitting MS:68:0.6996	0.6996	68
RRMS	RRMS:83|RR-MS:18	relapsing-remitting multiple sclerosis:101:0.7355	0.7355	101
RRMs	RRMs:7	retinoid-related molecules:7:0.3524	0.3524	7
RRMs	RRMs:69	RNA recognition motifs:69:0.9567	0.9567	69
RRM	RRM:6	random regression model:6:0.5290	0.5290	6
RRM	RRM:19	reduced renal mass:19:0.6106	0.6106	19
RRM	RRM:9|rrm:1	Resonant Recognition Model:10:0.7103	0.7103	10
RRM	RRM:116	RNA recognition motif:100:0.9520|RNA recognition motifs:16:0.8270	0.9520	116
RRP	RRP:184|rrP:1	radical retropubic prostatectomy:185:0.9654	0.9654	185
RRP	RRP:34	readily releasable pool:34:0.9126	0.9126	34
RRP	RRP:77	recurrent respiratory papillomatosis:77:0.9386	0.9386	77
RRP	RRP:15	relative refractory period:15:0.8045	0.8045	15
RRR	RRR:36	relative risk reduction:36:0.9174	0.9174	36
RRSV	RRSV:9	rice ragged stunt virus:9:0.6794	0.6794	9
RRT	RRT:27	regimen-related toxicity:27:0.7066	0.7066	27
RRT	RRT:4	Relative retention time:4:0.0918	0.0918	4
RRT	RRT:298	renal replacement therapy:298:0.9899	0.9899	298
RRV-TV	RRV-TV:17	rotavirus vaccine:17:0.3844	0.3844	17
RRVP	RRVP:10	Rapid right ventricular pacing:10:0.7103	0.7103	10
RRV	RRV:14	Rhesus monkey rhadinovirus:14:0.7753	0.7753	14
RRV	RRV:8	rhesus rhadinovirus:8:0.1125	0.1125	8
RRV	RRV:41	rhesus rotavirus:41:0.7258	0.7258	41
RRV	RRV:57|RRv:4	Ross River virus:61:0.9511	0.9511	61
RR	RR:9	blood pressure:9:0.6794	0.6794	9
RR	RR:8|R-R:2	cycle length:10:0.5000	0.5000	10
RR	R-R:4|RR:4	heart period:8:0.4102	0.4102	8
RR	R-R:7|RR:7	intervals:14:0.0019	0.0019	14
RR	RR:27|R-R:1	patients with relapsing-remitting:28:0.1841	0.1841	28
RR	RR:17|R-R:3	R-R interval:20:0.4037	0.4037	20
RR	RR:302	rate ratio:216:0.3923|Rate ratios:86:0.4586	0.4586	302
RR	RR:8|rr:2	reactive:10:0.0013	0.0013	10
RR	RR:20	recovery room:20:0.7766	0.7766	20
RR	RR:7|rr:2	recurrence:9:0.0011	0.0011	9
RR	RR:9	region:9:0.0011	0.0011	9
RR	RR:32	relapsing remitting:32:0.9072	0.9072	32
RR	RR:7	relative recovery:7:0.1850	0.1850	7
RR	RR:21	relative response:14:0.2892|relative responses:7:0.1641	0.2892	21
RR	RR:3947|rr:9|rR:1	relative risk:3465:0.9866|relative risks:492:0.9701	0.9866	3957
RR	RR:5	Relative risk of death:5:0.2818	0.2818	5
RR	RR:17	renin release:17:0.5038	0.5038	17
RR	RR:200|rR:9|rr:1	Resonance Raman:210:0.9772	0.9772	210
RR	RR:13	Respiratory rates:13:0.1046	0.1046	13
RR	RR:166	response rate:145:0.1929|response rates:21:0.2291	0.2291	166
RR	RR:10	response regulator:10:0.5856	0.5856	10
RR	RR:15	reversal reaction:15:0.7261	0.7261	15
RR	RR:21	reverse redistribution:21:0.7291	0.7291	21
RR	RR:138|rr:1	ribonucleotide reductase:139:0.9250	0.9250	139
RR	RR:14	righting reflex:14:0.7909	0.7909	14
RR	RR:287|rr:2	risk ratio:230:0.4225|risk ratios:59:0.2904	0.4225	289
RR	RR:26	Ross River:26:0.8861	0.8861	26
RR	RR:9	Roundup Ready:9:0.6794	0.6794	9
RR	RR:180	ruthenium red:180:0.9646	0.9646	180
RS3PE	RS3PE:31	remitting seronegative symmetrical synovitis with pitting edema:31:0.8472	0.8472	31
RSA	RSA:14	hippocampal rhythmic slow activity:14:0.2892	0.2892	14
RSA	RSA:21	hippocampal rhythmical slow activity:21:0.3527	0.3527	21
RSA	RSA:39	radiostereometric analysis:39:0.2125	0.2125	39
RSA	RSA:17	radiostereometry:17:0.0171	0.0171	17
RSA	RSA:189	recurrent spontaneous abortion:126:0.9278|recurrent spontaneous abortions:63:0.8430	0.9278	189
RSA	RSA:13	Republic of South Africa:13:0.7753	0.7753	13
RSA	RSA:228	respiratory sinus arrhythmia:228:0.9719	0.9719	228
RSA	RSA:62	roentgen stereophotogrammetric analysis:62:0.9519	0.9519	62
RSA	RSA:76|rsa:1	serum albumin:77:0.9386	0.9386	77
RSCA	RSCA:9	reference strand mediated conformation analysis:9:0.6794	0.6794	9
RSCA	RSCA:7	reference strand-mediated conformational analysis:7:0.5926	0.5926	7
RSCL	RSCL:32	Rotterdam Symptom Checklist:32:0.9072	0.9072	32
RSC	RSC:11	rheumatoid synovial cells:11:0.5355	0.5355	11
RSDR	RSDR:30|RSDr:11	relative standard deviation:41:0.8546	0.8546	41
RSDR	RSDR:9|RSDr:7	repeatability relative standard deviations:16:0.2379	0.2379	16
RSDR	RSDR:19	Reproducibility relative standard deviations:19:0.3077	0.3077	19
RSDS	RSDS:57	reflex sympathetic dystrophy syndrome:57:0.9477	0.9477	57
RSDs	RSDs:104	relative standard deviations:104:0.9395	0.9395	104
RSD	RSD:260	reflex sympathetic dystrophy:260:0.9815	0.9815	260
RSD	RSD:399|rsd:1	relative standard deviation:400:0.9667	0.9667	400
RSD	RSD:13	REM sleep deprivation:13:0.7096	0.7096	13
RSE	RSE:20	refractory status epilepticus:20:0.8525	0.8525	20
RSE	RSE:14	Self-Esteem Scale:14:0.6911	0.6911	14
RSF	RSF:13	raw soya flour:13:0.7753	0.7753	13
RSF	RSF:18	rheumatoid synovial fibroblasts:18:0.6903	0.6903	18
RSIV	RSIV:8	red sea bream iridovirus:8:0.6411	0.6411	8
RSI	RSI:10	Interval:10:0.0495	0.0495	10
RSI	RSI:9	rapid sequence induction:9:0.6794	0.6794	9
RSI	RSI:46	rapid sequence intubation:30:0.9011|Rapid-sequence intubation:16:0.1787	0.9011	46
RSI	RSI:36	repetitive strain injury:28:0.6192|Repetitive Strain Injuries:8:0.5006	0.6192	36
RSJ	RSJ:11	rectosigmoid junction:11:0.6182	0.6182	11
RSK1	RSK1:10	Ribosomal S6 kinase 1:10:0.7103	0.7103	10
RSK2	RSK2:11|Rsk2:1	ribosomal S6 kinase 2:12:0.7571	0.7571	12
RSL	RSL:23	reactive site loop:23:0.8715	0.8715	23
RSMC	RSMC:7|R-SMC:1|rSMC:1	smooth muscle cells:9:0.6794	0.6794	9
RSMG	RSMG:8|rSMG:1	rat submandibular gland:9:0.6794	0.6794	9
RSM	RSM:26	radix Salviae miltiorrhizae:26:0.8186	0.8186	26
RSM	RSM:17|Rsm:1	rapeseed meal:18:0.6903	0.6903	18
RSM	RSM:4	receptor surface model:4:0.1618	0.1618	4
RSM	RSM:6	Response Surface Method:6:0.5290	0.5290	6
RSM	RSM:25	restriction site mutation:25:0.8816	0.8816	25
RSND	RSND:13	renal sympathetic nerve discharge:13:0.7753	0.7753	13
RSNOs	RSNOs:20	S-nitrosothiols:20:0.7037	0.7037	20
RSNO	RSNO:17|RS-NO:8|R-SNO:2	S-nitrosothiols:27:0.6047	0.6047	27
RSO	RSO:9	Radiosynoviorthesis:9:0.1538	0.1538	9
RSO	RSO:16	rapeseed oil:16:0.7261	0.7261	16
RSPs	RSPs:7	Recombinant subviral particles:7:0.5926	0.5926	7
RSPs	RSPs:6	restriction site polymorphisms:6:0.5290	0.5290	6
RSP	RSP:10	regulated secretory pathway:10:0.7103	0.7103	10
RSP	RSP:11	respirable suspended particles:11:0.6182	0.6182	11
Rsp	Rsp:10|rsp:1	Responder:11:0.0671	0.0671	11
RSQ	RSQ:11	Questionnaire:11:0.7692	0.7692	11
RSR	RSR:6	relative survival rates:6:0.5290	0.5290	6
RSR	RSR:38	renin secretion rate:38:0.9217	0.9217	38
RSSE	RSSE:5	Russian spring-summer encephalitis:5:0.4422	0.4422	5
RSSF	RSSF:9	Rapid-scanning stopped-flow:9:0.5000	0.5000	9
RSS	RSS:72|Rss:1	recombination signal sequences:39:0.8455|recombination signal sequence:34:0.7048	0.8455	73
RSS	RSS:7	responsive search score:7:0.5926	0.5926	7
RSS	RSS:23	Russell-Silver syndrome:23:0.4831	0.4831	23
RST	RST:11	restraint stress:11:0.7357	0.7357	11
RST	RST:14	rubrospinal tract:14:0.6173	0.6173	14
RSVCEF	RSVCEF:4|RSV-CEF:1	Rous sarcoma virus-transformed chick embryo fibroblasts:5:0.4422	0.4422	5
RSVE	RSVE:12	reconstituted Sendai virus envelopes:12:0.6460	0.6460	12
RSVIG	RSVIG:10|RSV-IG:3|RSV-Ig:1	immune globulin:14:0.6911	0.6911	14
RSV-LTR	RSV-LTR:6|RSVLTR:1	Rous sarcoma virus long terminal repeat:7:0.5926	0.5926	7
RSVP	RSVP:72	rapid serial visual presentation:72:0.9585	0.9585	72
RSV	RSV:9	regurgitant stroke volume:9:0.6794	0.6794	9
RSV	RSV:10	respiratory syncytial:10:0.7103	0.7103	10
RSV	RSV:10	Respiratory syncytial viral:10:0.7103	0.7103	10
RSV	RSV:2297|RSv:1	respiratory syncytial virus:2286:0.9912|respiratory syncytial viruses:12:0.7571	0.9912	2298
RSV	RSV:617|rsv:1	Rous sarcoma virus:618:0.9871	0.9871	618
RSV	RSV:9	saphenous vein:9:0.4587	0.4587	9
RSG	RSG:32	rosiglitazone:32:0.4079	0.4079	32
RS	RS:10	arginine/serine-rich:10:0.0033	0.0033	10
RS	RS:9	radical surgery:9:0.1945	0.1945	9
RS	RS:34	Radiosurgery:34:0.0121	0.0121	34
RS	RS:13	Raman spectroscopy:13:0.4102	0.4102	13
RS	RS:20	Rankin Scale:20:0.1764	0.1764	20
RS	RS:10|rS:1	rat serum:11:0.3829	0.3829	11
RS	RS:21	rating scale:21:0.1899	0.1899	21
rs	rs:9	recombinant soluble:9:0.6794	0.6794	9
RS	RS:156|R-S:36	Reed-Sternberg:192:0.0700	0.0700	192
RS	RS:45	regular spiking:32:0.8563|Regular-spiking:13:0.0044	0.8563	45
RS	RS:71	Reiter's syndrome:71:0.1287	0.1287	71
RS	RS:7	related medullary inhibitory reticulospinal:7:0.2902	0.2902	7
RS	RS:28|Rs:1	remote sensing:29:0.8978	0.8978	29
RS	RS:9	renin secretion:9:0.6794	0.6794	9
RS	RS:11	renin substrate:11:0.5355	0.5355	11
RS	RS:5	repeated sequences:5:0.1132	0.1132	5
RS	RS:98	Resistant starch:98:0.8299	0.8299	98
RS	RS:242	Respiratory syncytial:242:0.9876	0.9876	242
rs	rs:12|RS:10	respiratory system:22:0.7400	0.7400	22
RS	RS:9	response signal:9:0.1945	0.1945	9
RS	RS:16	Restraint Scale:16:0.1241	0.1241	16
RS	RS:22	restraint stress:22:0.6178	0.6178	22
RS	RS:185	Rett syndrome:185:0.3849	0.3849	185
RS	RS:49	Reye's syndrome:49:0.0822	0.0822	49
RS	RS:6	Ringer's solution:6:0.0899	0.0899	6
RS	RS:16	Rio Grande do Sul:16:0.8165	0.8165	16
RS	RS:6|Rs:1	Robin sequence:7:0.0622	0.0622	7
RS	RS:9	rubrospinal:9:0.0029	0.0029	9
RS	RS:23	score:23:0.0081	0.0081	23
rs	rs:10	steady-state fluorescence anisotropy:10:0.2446	0.2446	10
Rs	Rs:5|rs:3|RS:1	Stokes radii:9:0.3945	0.3945	9
Rs	Rs:14|rs:5|RS:5|r-s:1	Stokes radius:25:0.5722	0.5722	25
Rs	Rs:5|rs:2|RS:2	systemic vascular resistance:9:0.6794	0.6794	9
RS	RS:15	X-linked juvenile retinoschisis:15:0.4951	0.4951	15
RT-nPCR	RT-nPCR:14|RT-NPCR:1	reverse transcription-nested polymerase chain reaction:15:0.8045	0.8045	15
RT/PCR	RT/PCR:4	reverse transcription and the polymerase chain reaction:4:0.7261	0.7261	4
RT1/2	RT1/2:7	relaxation time:7:0.3524	0.3524	7
RT1	RT1:18	major histocompatibility complex:18:0.8365	0.8365	18
RT1	RT1:7	major histocompatibility complex of the rat:7:0.5926	0.5926	7
RT3DE	RT3DE:8	real-time three-dimensional echocardiography:8:0.6411	0.6411	8
RT3D	RT3D:9|RT-3D:2	echocardiography:11:0.3448	0.3448	11
RTAs	RTAs:36|RTAS:1	road traffic accidents:37:0.9197	0.9197	37
RTA	RTA:18	activity:18:0.0364	0.0364	18
RTA	RTA:5	chain of ricin:5:0.0736	0.0736	5
RTA	RTA:124	renal tubular acidosis:124:0.9757	0.9757	124
RTA	RTA:15|Rta:2	replication and transcription activator:17:0.8270	0.8270	17
RTA	RTA:28	retinal thickness analyzer:28:0.8941	0.8941	28
RTA	RTA:59	ricin A chain:38:0.4632|ricin A-chain:21:0.4733	0.4733	59
RTA	RTA:14	ricin toxin A chain:14:0.5589	0.5589	14
RTA	RTA:55	road traffic accidents:29:0.8978|road traffic accident:26:0.8861	0.8978	55
RTA	RTA:9	Royal Thai Army:9:0.6794	0.6794	9
RTBV	RTBV:34	rice tungro bacilliform virus:34:0.9126	0.9126	34
RTC	RTC:5	rapid thoracoabdominal compression:5:0.4422	0.4422	5
RTD	RTD:6	rate of torque development:6:0.5290	0.5290	6
RTD	RTD:15	Renal tubular dysgenesis:15:0.8045	0.8045	15
RTD	RTD:16	residence time distribution:16:0.6577	0.6577	16
RTD	RTD:5	respiratory tract disease:5:0.4422	0.4422	5
RTD	RTD:16	routine test dilution:16:0.8165	0.8165	16
RTECS	RTECS:9	registry of toxic effects of chemical substances:9:0.6794	0.6794	9
RTEs	RTEs:13	recent thymic emigrants:13:0.7753	0.7753	13
RTE	RTE:69	rat tracheal epithelial:69:0.8555	0.8555	69
RTE	RTE:39	Ready-to-Eat:39:0.1456	0.1456	39
RTE	RTE:21	recent thymic emigrants:21:0.8594	0.8594	21
RTE	RTE:7	renal tubular epithelium:7:0.4438	0.4438	7
Rte	Rte:19|RTE:3	transepithelial resistance:22:0.4467	0.4467	22
RTF	RTF:11	Regeneration and tolerance factor:11:0.7357	0.7357	11
RTF	RTF:30	rete testis fluid:30:0.9011	0.9011	30
RTILs	RTILs:14	room-temperature ionic liquids:8:0.2327|room temperature ionic liquids:6:0.5290	0.5290	14
RTIs	RTIs:37	reproductive tract infections:37:0.2332	0.2332	37
RTIs	RTIs:74	respiratory tract infections:74:0.5618	0.5618	74
RTIs	RTIs:22	reverse transcriptase inhibitors:22:0.8657	0.8657	22
RTI	RTI:8	redox tolerance index:8:0.6411	0.6411	8
RTI	RTI:29	reproductive tract infections:15:0.1241|reproductive tract infection:14:0.1579	0.1579	29
RTI	RTI:75	respiratory tract infections:45:0.6192|respiratory tract infection:30:0.5162	0.6192	75
RTI	RTI:23	reverse transcriptase inhibitor:14:0.7909|reverse transcriptase inhibitors:9:0.6794	0.7909	23
Rti	Rti:31	tissue resistance:31:0.8519	0.8519	31
RTK	RTK:263	receptor tyrosine kinase:218:0.9130|Receptor tyrosine kinases:45:0.8369	0.9130	263
RTK	RTK:2	Rhabdoid tumor of kidney:2:0.8525	0.8525	2
RTKs	RTKs:264	receptor tyrosine kinases:264:0.9317	0.9317	264
RTLA	RTLA:6	rabbit thymic lymphocyte antigen:6:0.5290	0.5290	6
RTN	RTN:18	reticular thalamic nucleus:18:0.8365	0.8365	18
RTN	RTN:35	retrotrapezoid nucleus:35:0.3769	0.3769	35
RTOG	RTOG:317	Radiation Therapy Oncology Group:317:0.9752	0.9752	317
RT-PCR	RT-PCR:18	chain reaction assay:18:0.8365	0.8365	18
RT-PCR	RT-PCR:260|rtPCR:2|RTPCR:1	reverse transcriptase PCR:152:0.9803|reverse transcriptase-PCR:111:0.9731	0.9803	263
RT-PCR	RT-PCR:2993|RT--PCR:1|rt-pcr:1|rt-PCR:1|rtPCR:1|RTPCR:1	reverse transcriptase-polymerase chain reaction:2998:0.9955	0.9955	2998
RT-PCR	RT-PCR:5	reverse transcription and polymerase chain reaction technique:5:0.6411	0.6411	5
RT-PCR	RT-PCR:480|RTPCR:2|rtPCR:1	reverse transcription-PCR:353:0.9863|reverse transcription PCR:130:0.9654	0.9863	483
RTPR	RTPR:12	ribonucleoside triphosphate reductase:12:0.7571	0.7571	12
RT-qPCR	RT-qPCR:5|RTQ-PCR:3|RT-QPCR:3|RTQPCR:1|RT-Q-PCR:1|rtqPCR:1	polymerase chain reaction:14:0.7909	0.7909	14
RTQ-PCR	RTQ-PCR:11|RTQPCR:1|RT-QPCR:1	real-time quantitative PCR:13:0.5934	0.5934	13
RTR	RTR:51	renal transplant recipients:51:0.9082	0.9082	51
RTSV	RTSV:15	rice tungro spherical virus:15:0.8045	0.8045	15
RTT	RTT:114	Rett syndrome:114:0.9579	0.9579	114
RTV	RTV:83|Rtv:3|rtv:1	ritonavir:87:0.6466	0.6466	87
RTV	RTV:5	room-temperature vulcanizing:5:0.1132	0.1132	5
RTW	RTW:40	return to work:31:0.8090|return-to-work:9:0.1356	0.8090	40
RTX	RTX:18	[3H]resiniferatoxin:18:0.0570	0.0570	18
RTX	RTX:5|RTx:3|Rtx:2	radiotherapy:10:0.0302	0.0302	10
RTX	RTX:13	raltitrexed:13:0.0403	0.0403	13
RTx	RTx:16|RTX:3|Rtx:1	renal transplant:20:0.7766	0.7766	20
RTx	RTx:5|RTX:3|rTX:1	renal transplant recipients:9:0.5470	0.5470	9
RTx	RTx:41|RTX:12|Rtx:3	renal transplantation:56:0.8453	0.8453	56
RTX	RTX:94	resiniferatoxin:94:0.3154	0.3154	94
RTX	RTX:11	rituximab:11:0.0336	0.0336	11
RTase	RTase:11	reverse transcriptase:11:0.7357	0.7357	11
RTH	RTH:129	resistance to thyroid hormone:129:0.9768	0.9768	129
RTH	RTH:9	thyroid hormone resistance:9:0.6794	0.6794	9
RTs	RTs:251	Reaction times:251:0.7250	0.7250	251
RTs	RTs:12	respiratory therapists:12:0.5664	0.5664	12
RTs	RTs:62	reverse transcriptases:62:0.9003	0.9003	62
RTS	RTS:80	Revised Trauma Score:80:0.9627	0.9627	80
RTS	RTS:32	Rothmund-Thomson syndrome:32:0.2443	0.2443	32
RTS	RTS:45|RTs:1	Rubinstein-Taybi syndrome:46:0.3946	0.3946	46
RT	RT:118|Rt:1	irradiation:119:0.0142	0.0142	119
Rt	Rt:10|RT:1	nucleus rotundus:11:0.6182	0.6182	11
RT	RT:84	radiation:84:0.0100	0.0100	84
RT	RT:893	radiation therapy:893:0.9498	0.9498	893
RT	RT:8	radiation treatment:8:0.1276	0.1276	8
RT	RT:1603|Rt:5|rt:2	radiotherapy:1610:0.1937	0.1937	1610
RT	RT:29	radiotherapy alone:29:0.4777	0.4777	29
rt	rt:9|RT:4	rainbow trout:13:0.7753	0.7753	13
RT	RT:10	reaction:10:0.0011	0.0011	10
RT	RT:1205|Rt:1|rt:1	reaction time:1092:0.7977|reaction times:71:0.5281|reaction-time:44:0.0052	0.7977	1207
RT	RT:34	reactive thrombocytosis:34:0.9126	0.9126	34
RT	RT:12	real-time:12:0.0013	0.0013	12
RT	RT:10|rt:1	reciprocal translocations:11:0.4728	0.4728	11
RT	RT:7	reciprocating tachycardia:7:0.3524	0.3524	7
RT	RT:74	rectal temperature:66:0.2508|rectal temperatures:8:0.5006	0.5006	74
RT	RT:18	recurrent tonsillitis:18:0.8365	0.8365	18
RT	RT:12	relaxation training:12:0.0749	0.0749	12
RT	RT:65|rT:1	renal transplant:56:0.9162|renal transplants:10:0.7103	0.9162	66
RT	RT:79	renal transplantation:79:0.9210	0.9210	79
RT	RT:35	resistance training:35:0.3921	0.3921	35
RT	RT:17	respiratory tract:17:0.5760	0.5760	17
RT	RT:14	response times:14:0.0550	0.0550	14
RT	RT:23	resting tension:23:0.8715	0.8715	23
Rt	Rt:5|RT:4	reticular:9:0.0010	0.0010	9
RT	RT:8|Rt:6	reticular thalamic nucleus:14:0.6911	0.6911	14
RT	RT:14	reverse transcribed:14:0.7909	0.7909	14
RT	RT:53	reverse-transcriptase:30:0.0035|reverse transcriptases:23:0.8715	0.8715	53
RT	RT:249|rt:2	reverse transcription:251:0.9809	0.9809	251
RT	RT:131|rt:4|Rt:2|rT:1	room temperature:138:0.5993	0.5993	138
Rt	Rt:15|RT:10	thalamic reticular nucleus:25:0.7679	0.7679	25
RT	RT:6|Rt:2	total pulmonary vascular resistance:8:0.6411	0.6411	8
Rt	Rt:4|RT:3	total vascular resistance:7:0.0692	0.0692	7
Rt	Rt:11|RT:7	transepithelial electrical resistance:18:0.5228	0.5228	18
Rt	Rt:56|RT:26	transepithelial resistance:82:0.2461	0.2461	82
RT	RT:9	tumor:9:0.0010	0.0010	9
RU486	RU486:4|RU-486:2	glucocorticoid receptor antagonist:6:0.1543	0.1543	6
Rua	Rua:7|RUA:1	upper airway resistance:8:0.6411	0.6411	8
RUBF	RUBF:12	uterine blood flow:12:0.7571	0.7571	12
RUB	RUB:26	rubella virus:26:0.8861	0.8861	26
RUG-III	RUG-III:3	Resource Utilization Groups Version III:3:0.6411	0.6411	3
RUL	RUL:21	right unilateral:21:0.8594	0.8594	21
RUL	RUL:20	right upper lobe:20:0.7766	0.7766	20
RUPP	RUPP:9	uterine perfusion pressure:9:0.3945	0.3945	9
RUQ	RUQ:22	right upper quadrant:22:0.8657	0.8657	22
RUS	RUS:5	real-time ultrasonography:5:0.0736	0.0736	5
RUS	RUS:5	renal ultrasonography:5:0.0736	0.0736	5
RUs	RUs:5	renal units:5:0.0736	0.0736	5
RUS	RUS:8	ultrasound spectroscopy:8:0.4102	0.4102	8
RUT	RUT:63	rapid urease test:63:0.9253	0.9253	63
rut	rut:13	rutabaga:13:0.1043	0.1043	13
RU	RU:5	research utilization:5:0.1132	0.1132	5
ru	ru:10	ruthenium:10:0.0423	0.0423	10
RU	RU:48	units:48:0.2207	0.2207	48
RU	RU:9|Ru:2	uptake:11:0.0469	0.0469	11
RV-PA	RV-PA:8	right ventricle to pulmonary artery:8:0.6794	0.6794	8
RV/TLC	RV/TLC:5	ratio of residual volume to total lung capacity:5:0.2818	0.2818	5
RV/TLC	RV/TLC:8	residual volume/total lung capacity:8:0.6411	0.6411	8
RVAD	RVAD:32	right ventricular assist device:32:0.9072	0.9072	32
RVA	RVA:14	Retinal Vessel Analyzer:14:0.7753	0.7753	14
RVA	RVA:28|RVa:3	right ventricular apex:31:0.9043	0.9043	31
RVD	RVD:9	diameter:9:0.0154	0.0154	9
RVD	RVD:22|rVD:1	rat vas deferens:23:0.7046	0.7046	23
RVD	RVD:364	regulatory volume decrease:364:0.9743	0.9743	364
RVD	RVD:18	renovascular disease:18:0.4672	0.4672	18
RVD	RVD:7	Right ventricular dimension:7:0.5926	0.5926	7
RVD	RVD:11	right ventricular dysfunction:11:0.7357	0.7357	11
RVD	RVD:17	right ventricular dysplasia:17:0.8270	0.8270	17
RVEDP	RVEDP:21|RV-EDP:1	right ventricular end-diastolic pressure:22:0.8657	0.8657	22
RVEDVI	RVEDVI:28|RVEDVi:1	right ventricular end-diastolic volume index:29:0.8978	0.8978	29
RVEDV	RVEDV:31|RV-EDV:1	right ventricular end-diastolic volume:32:0.9072	0.9072	32
RVEF	RVEF:215|RV-EF:1	right ventricular ejection fraction:216:0.9705	0.9705	216
RVET	RVET:23	right ventricular ejection time:23:0.8038	0.8038	23
RVF-LH	RVF-LH:8|rvf-LH:1	right visual field-left hemisphere:9:0.6794	0.6794	9
RVF/LH	RVF/LH:8	right visual field/left hemisphere:8:0.6411	0.6411	8
RVFV	RVFV:59	Rift Valley fever virus:59:0.9203	0.9203	59
RVFW	RVFW:20	right ventricular free wall:20:0.8525	0.8525	20
RVF	RVF:138	Rift Valley fever:138:0.9783	0.9783	138
RVF	RVF:15	right ventricular failure:15:0.8045	0.8045	15
RVG	RVG:35	radionuclide ventriculography:35:0.7952	0.7952	35
RVG	RVG:14	RadioVisioGraphy:14:0.1494	0.1494	14
RVHT	RVHT:19	renovascular hypertension:19:0.8449	0.8449	19
RVH	RVH:148	renovascular hypertension:148:0.9294	0.9294	148
RVH	RVH:124	Right ventricular hypertrophy:124:0.9759	0.9759	124
RVIP	RVIP:15	rapid visual information processing:15:0.8045	0.8045	15
RVI	RVI:90	regulatory volume increase:90:0.9668	0.9668	90
RVI	RVI:29	right ventricular infarction:29:0.8978	0.8978	29
RVL	RVL:9	nucleus reticularis rostroventrolateralis:9:0.6794	0.6794	9
RVL	RVL:101	rostral ventrolateral medulla:101:0.9377	0.9377	101
RVL	RVL:9	rostral ventrolateral reticular nucleus:9:0.6794	0.6794	9
RVLM	RVLM:524|rVLM:35	rostral ventrolateral medulla:559:0.9858	0.9858	559
RVMI	RVMI:12	right ventricular myocardial infarction:12:0.7571	0.7571	12
RVMM	RVMM:8	rostral ventromedial medulla:8:0.6411	0.6411	8
RVM	RVM:131	rostral ventromedial medulla:131:0.9517	0.9517	131
RVO	RVO:69	retinal vein occlusion:69:0.8724	0.8724	69
rVOR	rVOR:8|RVOR:4	vestibuloocular reflex:12:0.6460	0.6460	12
RVOT	RVOT:204	right ventricular outflow tract:204:0.9765	0.9765	204
RVOTO	RVOTO:18	right ventricular outflow tract obstruction:18:0.8365	0.8365	18
RVOTR	RVOTR:9	right ventricular outflow tract reconstruction:9:0.6794	0.6794	9
RVPO	RVPO:8	right ventricular pressure overload:8:0.6411	0.6411	8
RVP	RVP:12	Rapid ventricular pacing:12:0.4153	0.4153	12
RVP	RVP:14	rat ventral prostate:14:0.7909	0.7909	14
RVP	RVP:26|RVp:1	right ventricular pressure:27:0.8903	0.8903	27
RVRR	RVRR:10	renal vein renin ratio:10:0.7103	0.7103	10
RVR	RVR:429	renal vascular resistance:417:0.9619|renal vascular resistances:12:0.6460	0.9619	429
RVR	RVR:8	renal vein renin:8:0.6411	0.6411	8
RVR	RVR:14	repetitive ventricular response:14:0.6911	0.6911	14
RVR	RVR:9|Rvr:1	resistance to venous return:10:0.7103	0.7103	10
RVSP	RVSP:79	right ventricular systolic pressure:79:0.9622	0.9622	79
RVSW	RVSW:8	right ventricular stroke work:8:0.6411	0.6411	8
RVSWI	RVSWI:18|RVSWi:2	right ventricular stroke work index:20:0.8525	0.8525	20
RVT	RVT:46	renal vein thrombosis:46:0.8151	0.8151	46
RVU	RVU:26	relative value unit:26:0.8861	0.8861	26
RVUs	RVUs:61	Relative Value Units:61:0.9511	0.9511	61
RVVC	RVVC:17	recurrent vulvovaginal candidiasis:17:0.7407	0.7407	17
RVVT	RVVT:11	viper venom time:11:0.7357	0.7357	11
rVVs	rVVs:16|RVVs:5	recombinant vaccinia viruses:21:0.8594	0.8594	21
rVV	rVV:67|RVV:17|rvv:4|r-VV:1	recombinant vaccinia virus:59:0.8751|Recombinant vaccinia viruses:30:0.9011	0.9011	89
RVV	RVV:26	Russell's viper venom:26:0.6351	0.6351	26
RVW	RVW:8	right ventricular wall:8:0.6411	0.6411	8
RV	RV:92|Rv:1	rabies virus:93:0.2887	0.2887	93
RV	RV:24	Rappaport-Vassiliadis:24:0.0066	0.0066	24
RV	RV:26	rat virus:26:0.0584	0.0584	26
RV	RV:11	renal vein:11:0.4728	0.4728	11
RV	RV:6	Renal venous:6:0.0731	0.0731	6
RV	RV:360	residual volume:353:0.8503|Residual volumes:7:0.1470	0.8503	360
RV	RV:12	retinal vasculitis:12:0.1573	0.1573	12
RV	RV:12	retroviral vector:12:0.6460	0.6460	12
RV	RV:21	rheumatoid vasculitis:21:0.4041	0.4041	21
RV	RV:73	Rhinovirus:61:0.0179|rhinoviruses:12:0.0033	0.0179	73
RV	RV:526	right ventricle:506:0.9787|right ventricles:20:0.8525	0.9787	526
RV	RV:1412	right ventricular:1399:0.9875|right-ventricular:13:0.0036	0.9875	1412
RV	RV:6	right ventricular free wall:6:0.5290	0.5290	6
RV	RV:104|Rv:2	rotavirus:106:0.0313	0.0313	106
RV	RV:125	rubella virus:125:0.4066	0.4066	125
Rv	Rv:8|RV:2	Venous resistance:10:0.2275	0.2275	10
RWC	RWC:25	relative water content:25:0.8186	0.8186	25
RWJF	RWJF:12	Robert Wood Johnson Foundation:12:0.7571	0.7571	12
RWL	RWL:10	respiratory water loss:10:0.5000	0.5000	10
RWMAs	RWMAs:10	regional wall motion abnormalities:10:0.7103	0.7103	10
RWMA	RWMA:32|RW-MA:1	regional wall motion abnormalities:21:0.7865|regional wall motion abnormality:12:0.7571	0.7865	33
RWM	RWM:55	regional wall motion:55:0.9147	0.9147	55
RWM	RWM:52	round window membrane:52:0.9427	0.9427	52
RWT	RWT:65	relative wall thickness:65:0.9047	0.9047	65
RWV	RWV:21	rotating wall vessel:21:0.7865	0.7865	21
RW	RW:22	ragweed:22:0.0811	0.0811	22
RW	RW:10	relative weight:10:0.3145	0.3145	10
RW	RW:61	round window:61:0.9511	0.9511	61
RXLI	RXLI:20	recessive X-linked ichthyosis:20:0.8525	0.8525	20
RXM	RXM:63	roxithromycin:63:0.7949	0.7949	63
RXR	RXR:467	retinoid X receptor:467:0.8301	0.8301	467
RYGB	RYGB:53	Roux-en-Y gastric bypass:53:0.9438	0.9438	53
RYGBP	RYGBP:113	Roux-en-Y gastric bypass:113:0.9579	0.9579	113
RYMV	RYMV:16	rice yellow mottle virus:16:0.8165	0.8165	16
RyR2	RyR2:31|RyR-2:1|RYR-2:1	cardiac ryanodine receptor:33:0.4392	0.4392	33
RyR2	RyR2:4|RYR2:2	release channel:6:0.1543	0.1543	6
RyR2	RyR2:4|RYR2:2	ryanodine receptor 2:6:0.5290	0.5290	6
RY	RY:6|R-Y:3	purine-pyrimidine:9:0.0792	0.0792	9
RY	RY:8|R-Y:2	Roux-en-Y:10:0.0891	0.0891	10
ry	ry:15|RY:14|-RY:1	ryanodine:30:0.2871	0.2871	30
Rzs	Rzs:9|RZs:3	ribozymes:12:0.6471	0.6471	12
RZWQM	RZWQM:11	Root Zone Water Quality Model:11:0.7103	0.7103	11
RAE	RAE:9	reactive angioendotheliomatosis:9:0.6794	0.6794	9
RaLV	RaLV:7	rat leukemia virus:7:0.5926	0.5926	7
RaRF	RaRF:8	Ra-reactive factor:8:0.3463	0.3463	8
RabGDI	RabGDI:7|rab-GDI:1|rabGDI:1	dissociation inhibitor:9:0.5470	0.5470	9
RadLV	RadLV:43	radiation leukemia virus:43:0.8893	0.8893	43
RAF	RAF:9	relative activity factor:9:0.6794	0.6794	9
RAF	RAF:10	repetitive atrial firing:10:0.7103	0.7103	10
RALDH	RALDH:10|RalDH:1	retinal dehydrogenase:11:0.4232	0.4232	11
RalGDS	RalGDS:7|Ral-GDS:2	Ral GDP dissociation stimulator:9:0.6794	0.6794	9
RalGDS	RalGDS:9|ralGDS:2	ral guanine nucleotide dissociation stimulator:11:0.7357	0.7357	11
RanBP1	RanBP1:9|RanBP-1:1	Ran-binding protein 1:10:0.7103	0.7103	10
RanBP2	RanBP2:7|RANBP2:2|Ran-BP2:1	Ran-binding protein 2:10:0.7103	0.7103	10
RANA	RANA:14	rheumatoid arthritis nuclear antigen:14:0.6911	0.6911	14
RAV-1	RAV-1:8	Rous-associated virus type 1:8:0.5006	0.5006	8
Raw	Raw:254|RAW:9	airway resistance:263:0.7703	0.7703	263
Rb+	Rb+:16	rubidium:16:0.1829	0.1829	16
Rb-82	Rb-82:9	rubidium-82:9:0.8000	0.8000	9
Rb.	Rb.:21	Rhodobacter:21:0.9091	0.9091	21
RB2	RB2:14|RB-2:7	Reactive blue 2:21:0.8594	0.8594	21
RBA	RBA:120	relative binding affinity:82:0.8914|relative binding affinities:38:0.8098	0.8914	120
RBA	RBA:8	respiratory burst activity:8:0.6411	0.6411	8
rbcL	rbcL:15	carboxylase/oxygenase:15:0.1505	0.1505	15
rbcL	rbcL:13|rbc-L:1|RBCL:1	large subunit:15:0.8045	0.8045	15
rbcL	rbcL:7	large subunit gene:7:0.6411	0.6411	7
rbcL	rbcL:5	large subunit of ribulose-1,5-bisphosphate carboxylase:5:0.4422	0.4422	5
rCHO	rCHO:23	recombinant Chinese hamster ovary:23:0.8038	0.8038	23
Rcoll	Rcoll:19	collateral resistance:19:0.7044	0.7044	19
Rdl	Rdl:8	Resistance to dieldrin:8:0.5006	0.5006	8
RdRp	RdRp:210|RDRP:34|RdRP:29	RNA-dependent RNA polymerase:255:0.9206|RNA-dependent RNA polymerases:18:0.8365	0.9206	273
REMI	REMI:30	restriction enzyme-mediated integration:30:0.9011	0.9011	30
REAL	REAL:21	Revised European-American Classification of Lymphoid Neoplasms:21:0.8449	0.8449	21
Rec-	Rec-:6|rec-:3	recombination-deficient:9:0.2424	0.2424	9
RECIST	RECIST:29|Recist:1	Response evaluation criteria in solid tumors:30:0.9043	0.9043	30
REEs	REEs:37	Rare earth elements:37:0.9197	0.9197	37
REES	REES:16	Red Edge Excitation Shift:16:0.8165	0.8165	16
Renca	Renca:8|RENCA:2	murine renal carcinoma:10:0.2275	0.2275	10
Renca	Renca:10|RENCA:6|renca:2|RenCa:1	murine renal cell carcinoma:19:0.4618	0.4618	19
REX	REX:9|REx:1	resistance exercise:10:0.5000	0.5000	10
RfDs	RfDs:15	reference doses:15:0.8045	0.8045	15
RFD	RFD:21	rate of force development:21:0.6812	0.6812	21
RfD	RfD:81	reference dose:81:0.9627	0.9627	81
RGB	RGB:11|R-G-B:1	Red-Green-Blue:12:0.2000	0.2000	12
Rh*	Rh*:12	rhodopsin:12:0.7333	0.7333	12
rHb	rHb:5|RHb:3|r-Hb:1|R-Hb:1	hemoglobin:10:0.1667	0.1667	10
RHC	RHC:15	right heart catheterization:15:0.8045	0.8045	15
RhIG	RhIG:12|RhIg:4	Rh immune globulin:16:0.6024	0.6024	16
RHIC	RHIC:10	Relativistic Heavy Ion Collider:10:0.7103	0.7103	10
RhIc	RhIc:7|RhIC:3	rhodamine isothiocyanate:10:0.5856	0.5856	10
rhLH	rhLH:8|r-hLH:4	recombinant human LH:12:0.7571	0.7571	12
RhPV	RhPV:10	Rhopalosiphum padi virus:10:0.7103	0.7103	10
Rho-GDI	Rho-GDI:8|RhoGDI:5	Rho GDP dissociation inhibitor:13:0.7753	0.7753	13
Rh	Rh:8	anti-D:8:0.0035	0.0035	8
rh	rh:7	human recombinant:7:0.2113	0.2113	7
Rh	Rh:9|rh:1|RH:1	hydrodynamic radius:11:0.7357	0.7357	11
RH	RH:12	Radial haemolysis:12:0.7571	0.7571	12
RH	RH:175	radiation hybrid:166:0.9529|radiation hybrids:9:0.5470	0.9529	175
RH	RH:21	radical hysterectomy:21:0.7865	0.7865	21
RH	RH:11	reactive hyperaemia:11:0.6182	0.6182	11
RH	RH:51	reactive hyperemia:51:0.9099	0.9099	51
rH	rH:9|RH:1	recombinant hirudin:10:0.5856	0.5856	10
rh	rh:476|rH:10|RH:4|Rh:2	recombinant human:492:0.9869	0.9869	492
RH	RH:12	reduced haloperidol:12:0.7571	0.7571	12
RH	RH:5	Rel homology:5:0.0902	0.0902	5
RH	RH:113	relative hazard:100:0.9525|relative hazards:13:0.7753	0.9525	113
RH	RH:470|rh:24|rH:5|Rh:4	relative humidity:467:0.9800|relative humidities:36:0.9174	0.9800	503
RH	RH:7	relative hypoglycemia:7:0.3524	0.3524	7
RH	RH:11	renal hypercalciuria:11:0.5355	0.5355	11
RH	RH:7	renovascular hypertension:7:0.0777	0.0777	7
RH	RH:67	reproductive health:67:0.9554	0.9554	67
RH	RH:12	resistant hepatocyte:12:0.7571	0.7571	12
RH	RH:4	RGS homology:4:0.0902	0.0902	4
RH	Rh:5|RH:5	rhein:10:0.0039	0.0039	10
Rh	Rh:62|rh:3|RH:1	rhesus:66:0.0280	0.0280	66
Rh	Rh:11|rh:1|RH:1	rhodamine:13:0.0053	0.0053	13
Rh	Rh:17|rh:1	rhodopsin:18:0.0074	0.0074	18
RH	RH:11|rh:1	right-handed:12:0.0061	0.0061	12
RH	RH:126	right hemisphere:113:0.8779|right-hemisphere:13:0.0053	0.8779	126
RiCof	RiCof:7|RiCoF:2|Ricof:1	ristocetin cofactor:10:0.7103	0.7103	10
RiCof	RiCof:5|Ricof:3|RiCoF:1	Ristocetin Cofactor activity:9:0.6794	0.6794	9
RifR	RifR:5|Rifr:4|rifR:1	rifampicin-resistant:10:0.2093	0.2093	10
RIfS	RIfS:15|RIFS:1	reflectometric interference spectroscopy:16:0.8165	0.8165	16
Rint	Rint:19	interrupter technique:19:0.7658	0.7658	19
Rint	Rint:21	resistance:21:0.4000	0.4000	21
Rluc	Rluc:14|RLuc:4	Renilla luciferase:18:0.6381	0.6381	18
Rmax	Rmax:5	maximum relaxation:5:0.0612	0.0612	5
Rmax	Rmax:10	maximum response:10:0.2275	0.2275	10
Rmax	Rmax:6	removal rate:6:0.1320	0.1320	6
Rmin	Rmin:9	resistance:9:0.4211	0.4211	9
Rm	Rm:15|rm:1	input resistance:16:0.0746	0.0746	16
rm	rm:9	intrinsic rate of natural increase:9:0.6794	0.6794	9
Rm	Rm:57|RM:2|rm:1	Membrane resistance:60:0.4651	0.4651	60
Rm	Rm:16	membrane resistivity:16:0.8165	0.8165	16
RM	RM:9	method:9:0.0069	0.0069	9
RM	RM:13	radical mastectomy:13:0.7753	0.7753	13
RM	RM:5	radioactive microspheres:5:0.0902	0.0902	5
RM	RM:34|rm:3|Rm:1	raphe magnus:38:0.8417	0.8417	38
rm	rm:29|rM:1	recombinant murine:30:0.8032	0.8032	30
RM	RM:19	recurrent miscarriage:19:0.6537	0.6537	19
RM	RM:10	red marrow:10:0.5856	0.5856	10
RM	RM:6	red muscle:6:0.0731	0.0731	6
RM	RM:9	Reissner's membrane:9:0.1945	0.1945	9
Rm	Rm:12|RM:3	relative mobility:15:0.5348	0.5348	15
RM	RM:9	relative movement:9:0.4587	0.4587	9
RM	RM:37	repetition maximum:37:0.6250	0.6250	37
RM	RM:9	respiratory muscle:9:0.2285	0.2285	9
R-M	R-M:86|RM:17|r-m:1|R--M:1	restriction-modification:103:0.0885|Restriction modification:2:0.8422	0.8422	105
RM	RM:7	risk management:7:0.2452	0.2452	7
RM	RM:4	rough microsomal membranes:4:0.1618	0.1618	4
RM	RM:11	rough microsomes:11:0.7357	0.7357	11
RnBP	RnBP:27	renin-binding protein:16:0.3643|renin binding protein:11:0.7357	0.7357	27
Rnaw	Rnaw:6	nasal airflow resistance:6:0.5290	0.5290	6
RN	RN:42|Rn:7	input resistance:49:0.5052	0.5052	49
Rn	Rn:14|RN:2	Nasal Resistance:16:0.1031	0.1031	16
RN	RN:19	Radical Nephrectomy:19:0.7044	0.7044	19
RN	RN:34|Rn:1	radionuclide:35:0.0511	0.0511	35
Rn	Rn:13	radon:13:0.0180	0.0180	13
RN	RN:17	raphe nuclei:17:0.7407	0.7407	17
RN	RN:129	red nucleus:129:0.9294	0.9294	129
RN	RN:33	Reflux nephropathy:33:0.9100	0.9100	33
RN	RN:109	registered nurse:90:0.8740|registered nurses:19:0.7044	0.8740	109
RN	RN:5	rheumatoid nodules:5:0.1132	0.1132	5
ROFA	ROFA:78	residual oil fly ash:78:0.9617	0.9617	78
ROSE	ROSE:11	rat ovarian surface epithelial:11:0.7357	0.7357	11
ROSs	ROSs:24|ROS-s:1	Reactive oxygen species:25:0.8816	0.8816	25
ROSs	ROSs:9	rod outer segments:9:0.6794	0.6794	9
Rp/Rs	Rp/Rs:17|RP/RS:1	resistance ratio:18:0.8365	0.8365	18
Rp/Rs	Rp/Rs:5|RP/RS:1	vascular resistance:6:0.2243	0.2243	6
Rps.	Rps.:13	Rhodopseudomonas:13:0.9231	0.9231	13
Rrel	Rrel:6	rate of calcium release:6:0.5290	0.5290	6
rrs	rrs:17	16S rRNA gene:17:0.8270	0.8270	17
RRs	RRs:8	outcome of interest was a summary relative risk:8:0.6411	0.6411	8
Rrs	Rrs:14|RRS:2	resistance of the respiratory system:16:0.6400	0.6400	16
RRS	RRS:11	resonance Rayleigh scattering:11:0.5355	0.5355	11
Rrs	Rrs:80|RRS:5	respiratory system resistance:85:0.9264	0.9264	85
RRs	RRs:12	Response rates:12:0.2549	0.2549	12
Rrs	Rrs:60	total respiratory resistance:60:0.2497	0.2497	60
RTCs	RTCs:9	residential treatment centers:9:0.6794	0.6794	9
Rtot	Rtot:11|RTOT:1	resistance:12:0.6875	0.6875	12
RTP	RTP:27	replication terminator protein:27:0.8312	0.8312	27
RTP	RTP:13	room temperature phosphorescence:13:0.7753	0.7753	13
RTP	RTP:18	treatment planning:18:0.6381	0.6381	18
RTRs	RTRs:30	renal transplant recipients:30:0.8472	0.8472	30
RuBP	RuBP:29	ribulose-1,5-bisphosphate:16:0.3261|ribulose 1,5-bisphosphate:13:0.5335	0.5335	29
RuBP	RuBP:8	ribulose bisphosphate:8:0.5006	0.5006	8
RuMP	RuMP:8	ribulose monophosphate:8:0.5006	0.5006	8
RUP	RUP:30	rumen-undegradable protein:15:0.1687|rumen undegradable protein:15:0.3831	0.3831	30
RuR	RuR:32	ruthenium red:32:0.9072	0.9072	32
Ruaw	Ruaw:7	upper airway resistance:7:0.5926	0.5926	7
RxFISH	RxFISH:10|Rx-FISH:1	cross-species color banding:11:0.6182	0.6182	11
Rx	Rx:9	prescription:9:0.0606	0.0606	9
Rx	Rx:11	treatment:11:0.0758	0.0758	11
RyRs	RyRs:9	release channels:9:0.2757	0.2757	9
RyRs	RyRs:168|RYRs:10|ryRs:1	Ryanodine receptors:179:0.9141	0.9141	179
RyR	RyR:10|RYR:1	release channel:11:0.2280	0.2280	11
RyR	RyR:398|RYR:31|ryr:3	ryanodine receptor:353:0.9023|ryanodine receptors:79:0.8724	0.9023	432
RyR3	RyR3:11|RYR3:2|RyR-3:1	ryanodine receptor type 3:14:0.7909	0.7909	14
RyR3	RyR3:8	type 3 ryanodine receptor:8:0.5006	0.5006	8
Rz	Rz:13|RZ:2	hammerhead ribozyme:10:0.1994|Hammerhead ribozymes:5:0.0612	0.1994	15
Rz	Rz:10|RZ:1	Retzius:11:0.0901	0.0901	11
S(0)	S(0):8	elemental sulfur:8:0.5006	0.5006	8
S(2)	S(2):11	order parameters:11:0.7357	0.7357	11
S(G)	S(G):19|S(g):1	glucose effectiveness:20:0.8525	0.8525	20
S(I)	S(I):83|S(i):12	insulin sensitivity:95:0.9685	0.9685	95
S(I)	S(I):30|S(i):8	insulin sensitivity index:38:0.9237	0.9237	38
S-1090	S-1090:11	Toxicity study of cefmatilen hydrochloride hydrate:11:0.5856	0.5856	11
S-SCAM	S-SCAM:17	Synaptic scaffolding molecule:17:0.8270	0.8270	17
S-phase	S-phase:3	DNA synthesis phase:3:0.2818	0.2818	3
S.A.	S.A.:6|s.a.:3	specific activity:9:0.5470	0.5470	9
S.D.	S.D.:14	Sprague-Dawley:14:0.0075	0.0075	14
S.D.	S.D.:108|s.d.:56	standard deviation:133:0.9132|standard deviations:31:0.9043	0.9132	164
S.E.M.	S.E.M.:19|s.e.m.:3	scanning electron microscopy:22:0.8657	0.8657	22
S.I.	S.I.:24|s.i.:1	stimulation index:25:0.3744	0.3744	25
S.L.E.	S.L.E.:19	systemic lupus erythematosus:19:0.7658	0.7658	19
s/c	s/c:8|S/C:2	subcutaneous:10:0.1579	0.1579	10
S/D	S/D:17	solvent/detergent:17:0.0860	0.0860	17
S/D	S/D:47	Systolic/diastolic:47:0.2473	0.2473	47
S/D	S/D:19	systolic-diastolic ratio:19:0.2840	0.2840	19
S/D	S/D:14	systolic to diastolic:14:0.6577	0.6577	14
S/HMO	S/HMO:5	social health maintenance organization:5:0.4422	0.4422	5
S/JR	S/JR:5|S/Jr:1	inbred Dahl salt-sensitive:6:0.2827	0.2827	6
S/M	S/M:8	concentration ratio:8:0.2619	0.2619	8
S/N	S/N:9|s/n:1	signal/noise:10:0.0220	0.0220	10
S/N	S/N:174|s/n:1	signal-to-noise:154:0.3732|signal to noise:21:0.6400	0.6400	175
S/N	S/N:165|s/n:2	signal-to-noise ratio:146:0.7899|signal-to-noise ratios:21:0.8594	0.8594	167
s/o/w	S/O/W:9|s/o/w:9	solid-in-oil-in-water:18:0.7083	0.7083	18
S/P	S/P:9	sulfadoxine/pyrimethamine:9:0.1111	0.1111	9
S/S	S/S:13	solidification/stabilization:13:0.1463	0.1463	13
S/S	S/S:10|s/s:3	stabilization/solidification:13:0.1463	0.1463	13
S0	S0:14	elemental sulfur:14:0.6911	0.6911	14
S-14	S-14:39|S14:9	Somatostatin-14:48:0.4747	0.4747	48
S-14	S-14:5|S14:1	tetradecapeptide somatostatin:6:0.1010	0.1010	6
S-180	S-180:59|S180:30	Sarcoma 180:55:0.8645|Sarcoma-180:34:0.2821	0.8645	89
S19	S19:11|S-19:1	Brucella abortus strain 19:12:0.3813	0.3813	12
S1P	S1P:11|s1p:1	Site-1 protease:12:0.5050	0.5050	12
S1P	S1P:471|S-1-P:17|S1-P:4|S-1P:2	sphingosine 1-phosphate:266:0.9759|sphingosine-1-phosphate:221:0.4220|sphingosine-1 phosphate:7:0.2902	0.9759	494
S1	S1:9	early:9:0.0044	0.0044	9
S1	S1:6	early proximal tubule:6:0.2827	0.2827	6
S1	S1:8	Excited singlet:8:0.4102	0.4102	8
S1	S1:26	first:26:0.0138	0.0138	26
S1	S1:24	first heart sound:24:0.8715	0.8715	24
S1	S1:6	first sacral:6:0.1838	0.1838	6
S1	S1:15	first stimulus:15:0.1316	0.1316	15
S1	S1:9	insulin sensitivity index:9:0.6794	0.6794	9
S1	S1:6|S-1:4	myosin:10:0.0050	0.0050	10
S1	S1:1	myosin and subfragment-1:1:0.6388	0.6388	1
S1	S1:20|S-1:3	myosin head:15:0.4609|myosin heads:8:0.2987	0.4609	23
S1	S1:213|S-1:83	myosin subfragment 1:296:0.7558	0.7558	296
S1	S1:11	primary:11:0.0055	0.0055	11
S1	S1:18	primary somatosensory:18:0.4672	0.4672	18
S1	S1:7	primary somatosensory area:7:0.5926	0.5926	7
S1	S1:74|S-1:4	primary somatosensory cortex:78:0.7208	0.7208	78
S1	S1:20	stimuli:20:0.0111	0.0111	20
S1	S1:9	subunit:9:0.0044	0.0044	9
S1	S1:10	warning:10:0.0050	0.0050	10
S1	S1:13	warning stimulus:13:0.1025	0.1025	13
S2P	S2P:8	Site-2 protease:8:0.4102	0.4102	8
S2	S2:11	allele:11:0.0098	0.0098	11
S2	S2:6	deep slow wave sleep:6:0.3728	0.3728	6
S2	S2:16	Drosophila Schneider 2:16:0.4274	0.4274	16
S2	S2:19	extrastimulus:19:0.0177	0.0177	19
S2	S2:15	imperative stimulus:15:0.0746	0.0746	15
S2	S2:17	premature stimulus:17:0.0916	0.0916	17
S2	S2:14	second heart sound:14:0.7909	0.7909	14
S2	S2:10	second somatosensory area:10:0.5000	0.5000	10
S2	S2:26	second stimulus:26:0.1728	0.1728	26
S2	S2:14|S-2:1	secondary somatosensory cortex:15:0.5818	0.5818	15
S2	S2:18	stimulation:18:0.0167	0.0167	18
S2	S2:13	stimuli:13:0.0118	0.0118	13
S-2	S-2:21|S2:13	subfragment-2:17:0.0157|subfragment 2:17:0.0949	0.0949	34
S2	S2:9	supernatant:9:0.0079	0.0079	9
S3P	S3P:29|S-3-P:1	shikimate 3-phosphate:17:0.8270|shikimate-3-phosphate:13:0.3529	0.8270	30
S3	S3:9	proximal tubule:9:0.4587	0.4587	9
S3	S3:14	sacral:14:0.0349	0.0349	14
S3	S3:10	third:10:0.0241	0.0241	10
S3	S3:24	third heart sound:24:0.8768	0.8768	24
S3	S3:13	Type III pneumococcal polysaccharide:13:0.7753	0.7753	13
S-49	S-49:8|S49:5	lymphoma:13:0.2444	0.2444	13
S-49	S-49:6|S49:5|s-49:1	mouse T-lymphoma:12:0.6460	0.6460	12
s4U	s4U:14|S4U:4|s-4U:1	4-thiouridine:19:0.8571	0.8571	19
S4	S4:9	fourth heart sound:9:0.6794	0.6794	9
S4	S4:6	fourth transmembrane segment:6:0.3728	0.3728	6
S5	S5:8	segment 5:8:0.3463	0.3463	8
S6K	S6K:48	S6 kinase:48:0.7997	0.7997	48
S6K1	S6K1:15	ribosomal protein S6 kinase 1:15:0.8045	0.8045	15
S6K1	S6K1:11	ribosomal S6 kinase 1:11:0.1203	0.1203	11
S6b	S6b:12	sarafotoxin 6b:12:0.7571	0.7571	12
S6c	S6c:51|S6C:2	sarafotoxin 6c:53:0.9116	0.9116	53
S6c	S6c:35	sarafotoxin S6c:35:0.9151	0.9151	35
S6	S6:6	segment 6:6:0.2243	0.2243	6
S8	S8:6	segment 8:6:0.1320	0.1320	6
S9-mix	S9-mix:6|S-9mix:2	metabolic activation system:8:0.5006	0.5006	8
S9	S9:14|S-9:9	9000 X g supernatant:23:0.6653	0.6653	23
S9	S9:10|S-9:9	fractions:19:0.0431	0.0431	19
S9	S9:6|S-9:3	g supernatant fraction:9:0.2500	0.2500	9
S9	S9:28|S-9:9|-S9:2	liver homogenate:27:0.7425|liver homogenates:12:0.5050	0.7425	39
S9	S9:21	metabolic activation:21:0.5721	0.5721	21
S9	S9:18|S-9:7	metabolic activation system:25:0.6240	0.6240	25
S9	S9:9|S-9:3	microsomal:12:0.0263	0.0263	12
S9	S9:6|S-9:3	preparations:9:0.0191	0.0191	9
S9	S9:5|S-9:4	supernatants:9:0.0191	0.0191	9
SA-MCF	SA-MCF:8	sheep-associated malignant catarrhal fever:8:0.5006	0.5006	8
SA-11	SA-11:15|SA11:10	simian rotavirus:25:0.4751	0.4751	25
SA1	SA1:9	slowly adapting type 1:9:0.7103	0.7103	9
SA4503	SA4503:12	dihydrochloride:12:0.7857	0.7857	12
SA7	SA7:9|SA-7:3	simian adenovirus type 7:12:0.7571	0.7571	12
SA8	SA8:9	simian agent 8:9:0.6794	0.6794	9
SAA1	SAA1:12	serum amyloid A1:12:0.7571	0.7571	12
SAA3	SAA3:10	serum amyloid A3:10:0.7103	0.7103	10
SAAG	SAAG:17	albumin gradient:17:0.6211	0.6211	17
SAARDs	SAARDs:17	slow-acting antirheumatic drugs:10:0.2873|slow acting antirheumatic drugs:7:0.5926	0.5926	17
SAAST	SAAST:22	self-administered alcoholism screening test:22:0.8594	0.8594	22
SAAs	SAAs:16|sAAs:1|S-AAs:1	amino acids:18:0.8365	0.8365	18
SAA	SAA:31|sAA:2|Saa:1|S-AA:1	amino acids:35:0.9151	0.9151	35
SAA	SAA:21|SaA:1	serum amyloid-A:22:0.8657	0.8657	22
SAA	SAA:145	serum amyloid A protein:145:0.9467	0.9467	145
SAA	SAA:6	serum anticholinergic activity:6:0.5290	0.5290	6
SAA	SAA:83	severe aplastic anaemia:83:0.9415	0.9415	83
SAA	SAA:203|sAA:2	severe aplastic anemia:205:0.9614	0.9614	205
SAA	SAA:11	splenic artery aneurysms:11:0.7357	0.7357	11
SAA	SAA:20	sulfur amino acid:20:0.4574	0.4574	20
SABP	SABP:5	Secretory actin-binding protein:5:0.1973	0.1973	5
SABP	SABP:14	systemic arterial blood pressure:14:0.4071	0.4071	14
SAB	SAB:5	solid-adherent bacteria:5:0.1132	0.1132	5
SAB	SAB:31	spontaneous abortion:31:0.9043	0.9043	31
SAB	SAB:10	spontaneous alternation behavior:10:0.7103	0.7103	10
SAB	SAB:21	Staphylococcus aureus bacteremia:21:0.5721	0.5721	21
SAB	SAB:7	subarachnoid block:7:0.1470	0.1470	7
SACE	SACE:85|S-ACE:10|sACE:9|s-ACE:1	Serum angiotensin-converting enzyme:60:0.8359|Serum angiotensin converting enzyme:45:0.7664	0.8359	105
SACE	SACE:6|S-ACE:1|s-ACE:1|sACE:1	Serum angiotensin-converting enzyme activity:9:0.6794	0.6794	9
SACM	SACM:27	simulated aerial combat maneuver:20:0.8525|simulated aerial combat maneuvers:7:0.4438	0.8525	27
SACs	SACs:19	stretch-activated channels:19:0.3117	0.3117	19
SACs	SACs:10	stretch-activated ion channels:10:0.5856	0.5856	10
SACS	SACS:6	Supplemented ambulatory control subjects:6:0.5290	0.5290	6
SACT	SACT:76	sinoatrial conduction time:76:0.6714	0.6714	76
SADBE	SADBE:19	squaric acid dibutylester:19:0.7658	0.7658	19
SADD	SADD:7	Short Alcohol Dependence Data:7:0.4438	0.4438	7
SADS-L	SADS-L:1	Schedule of Affective Disorders and Schizophrenia-Lifetime Version:1:0.5470	0.5470	1
SADS	SADS:58	Schedule for Affective Disorders and Schizophrenia:58:0.9253	0.9253	58
SAD	SAD:14	Depression:14:0.0126	0.0126	14
SAD	SAD:14	sagittal abdominal diameter:14:0.7909	0.7909	14
SAD	SAD:369	seasonal affective disorder:354:0.9737|seasonal affective disorders:15:0.5348	0.9737	369
SAD	SAD:23	Secalonic acid D:23:0.8715	0.8715	23
SAD	SAD:15	single-wavelength anomalous diffraction:15:0.8045	0.8045	15
SAD	SAD:13	single-wavelength anomalous dispersion:13:0.6701	0.6701	13
SAD	SAD:7	sino-aortic deafferentation:7:0.0886	0.0886	7
SAD	SAD:20	sino-aortic denervation:20:0.0809	0.0809	20
SAD	SAD:20	Sinoaortic baroreceptor denervation:20:0.7865	0.7865	20
SAD	SAD:14	sinoaortic deafferentation:14:0.4071	0.4071	14
SAD	SAD:68	sinoaortic-denervated:38:0.0359|sinoaortic denervated:30:0.4404	0.4404	68
SAD	SAD:90	sinoaortic denervation:90:0.5699	0.5699	90
SAD	SAD:6	source to axis distance:6:0.5290	0.5290	6
SAD	SAD:14|sAD:1	sporadic AD:15:0.5564	0.5564	15
SAD	SAD:11|sAD:3	sporadic Alzheimer's Disease:14:0.6173	0.6173	14
SAD	SAD:8	succinic acid dimethyl ester:8:0.6411	0.6411	8
SAECGs	SAECGs:19|SA-ECGs:5	Signal-averaged electrocardiograms:24:0.8115	0.8115	24
SAECG	SAECG:59|SA-ECG:2	signal-averaged ECG:61:0.6847	0.6847	61
SAECG	SAECG:93|SA-ECG:8	signal-averaged electrocardiogram:90:0.8168|signal-averaged electrocardiograms:11:0.5355	0.8168	101
SAECG	SAECG:41	Signal-Averaged electrocardiography:41:0.6691	0.6691	41
SAED	SAED:16	selected area electron diffraction:16:0.8165	0.8165	16
SAEIA	SAEIA:10	selected antibody enzyme immunoassay:10:0.7103	0.7103	10
SAEM	SAEM:28	Society for Academic Emergency Medicine:28:0.8941	0.8941	28
SAEs	SAEs:21	serious adverse events:21:0.7865	0.7865	21
SAE	SAE:15	serious adverse events:15:0.7096	0.7096	15
SAE	SAE:8	signal-averaged electrocardiogram:8:0.3463	0.3463	8
SAE	SAE:9	stimulated acoustic emission:9:0.4587	0.4587	9
SAE	SAE:24	subcortical arteriosclerotic encephalopathy:24:0.8115	0.8115	24
SAFA	SAFA:14	soluble antigen fluorescent antibody:14:0.7909	0.7909	14
SAFs	SAFs:6	Specific absorbed fractions:6:0.5290	0.5290	6
SAF	SAF:9	activating factor:9:0.0953	0.0953	9
SAF	SAF:20|saf:2	safflower oil:22:0.8657	0.8657	22
SAF	SAF:45	scrapie-associated fibrils:45:0.6921	0.6921	45
SAG1	SAG1:7	surface antigen 1:7:0.5926	0.5926	7
SAGB	SAGB:25	Swedish adjustable gastric band:25:0.8715	0.8715	25
SAGB	SAGB:7	Swedish Adjustable Gastric Banding:7:0.3524	0.3524	7
SAGE	SAGE:357	serial analysis of gene expression:357:0.9660	0.9660	357
SAGE	SAGE:6	Systematic Assessment of Geriatric Drug Use via Epidemiology:6:0.7103	0.7103	6
SAGM	SAGM:16|SAG-M:2	saline-adenine-glucose-mannitol:18:0.4615	0.4615	18
SAGP	SAGP:15|sagp:1|sAGP:1	glycoprotein:17:0.6667	0.6667	17
SAg	SAg:10|Sag:2	bacterial superantigens:12:0.0776	0.0776	12
S-Ag	S-Ag:30|S-ag:4|SAg:1|SAG:1|Sag:1	Retinal S-antigen:37:0.3082	0.3082	37
S-Ag	S-Ag:10|SAg:4	retinal soluble antigen:14:0.5111	0.5111	14
SAG	SAG:6	Sensitive to Apoptosis Gene:6:0.5290	0.5290	6
SAG	SAG:16	Sodium antimony gluconate:16:0.8165	0.8165	16
SAG	SAG:10|SAg:1	statoacoustic ganglion:11:0.5355	0.5355	11
SAg	SAg:76|Sag:14|SAG:12|sAg:2|sag:1	superantigen:105:0.2213	0.2213	105
SAHA	SAHA:79	suberoylanilide hydroxamic acid:79:0.8875	0.8875	79
SAHH	SAHH:17|SahH:1|Sahh:1	S-adenosylhomocysteine hydrolase:19:0.5113	0.5113	19
SAHS	SAHS:37	sleep apnea/hypopnea syndrome:37:0.9197	0.9197	37
SAHS	SAHS:44	sleep apnoea/hypopnoea syndrome:44:0.9323	0.9323	44
SAH	SAH:48	S-adenosyl-L-homocysteine:48:0.0172	0.0172	48
SAH	SAH:10	self-assessed health:10:0.3470	0.3470	10
SAH	SAH:6	severe alcoholic hepatitis:6:0.3728	0.3728	6
SAH	SAH:491	subarachnoid haemorrhage:491:0.9700	0.9700	491
SAH	SAH:8	subarachnoid hemorrhages:8:0.5006	0.5006	8
SAH	SAH:11	systemic arterial hypertension:11:0.5355	0.5355	11
SAIB	SAIB:24	sucrose acetate isobutyrate:24:0.8657	0.8657	24
SAIDS	SAIDS:13	simian acquired immune deficiency syndrome:13:0.7753	0.7753	13
SAIDS	SAIDS:29|sAIDS:1	simian acquired immunodeficiency syndrome:30:0.8032	0.8032	30
SAII	SAII:9	Slowly adapting type II:9:0.6794	0.6794	9
SAI	SAI:20|SA-I:1	slowly adapting type I:21:0.8594	0.8594	21
SAI	SAI:12|S-AI:1	State Anxiety Inventory:13:0.6701	0.6701	13
SAK	SAK:26|Sak:21|sak:4	staphylokinase:51:0.6622	0.6622	51
sAlb	SAlb:4|sAlb:4|Salb:3|sALB:2|S-Alb:2|S-alb:1|s-alb:1	serum albumin:17:0.8270	0.8270	17
SALS	SALS:23	small angle light scattering:13:0.7753|Small-angle light scattering:10:0.1878	0.7753	23
SALS	SALS:14|sALS:10|s-ALS:1	sporadic ALS:25:0.7679	0.7679	25
SALS	SALS:23|sALS:12|S-ALS:3	sporadic amyotrophic lateral sclerosis:38:0.8417	0.8417	38
sal	sal:7|SAL:4	homeotic gene spalt:11:0.6182	0.6182	11
SAL	SAL:18|Sal:5|sal:2	salbutamol:25:0.0404	0.0404	25
SAL	SAL:11|Sal:1	salicylic acid:12:0.6460	0.6460	12
SAL	SAL:31|Sal:2	salsolinol:33:0.0539	0.0539	33
Sal	Sal:10|SAL:2	Schisanhenol:12:0.0185	0.0185	12
SAL	SAL:7	Sensorineural Acuity Level:7:0.4438	0.4438	7
SAL	SAL:10	short attack latency:10:0.7103	0.7103	10
SAL	SAL:4|Sal:3	sodium salicylate:7:0.0655	0.0655	7
SAMC	SAMC:9	S-allylmercaptocysteine:9:0.4444	0.4444	9
SAMD	SAMD:10|SAM-D:1	decarboxylase:11:0.4167	0.4167	11
SAMHSA	SAMHSA:39	Substance Abuse and Mental Health Services Administration:39:0.9256	0.9256	39
SAMP8	SAMP8:11|SAM-P8:2	senescence-accelerated mice:13:0.2309	0.2309	13
SAMP8	SAMP8:12|SAM-P8:1	senescence-accelerated mouse:13:0.3809	0.3809	13
SAMP	SAMP:4|S-AMP:3|sAMP:2	adenylosuccinate:9:0.1356	0.1356	9
SAMe	SAMe:104|S-AMe:1|SaMe:1	S-adenosyl-L-methionine:106:0.4204	0.4204	106
SAMe	SAMe:87|SAME:2|SAM-e:1	S-adenosylmethionine:90:0.3633	0.3633	90
SAM-S	SAM-S:3|SAMS:2|SAM-s:1	S-adenosyl-L-methionine synthetase:6:0.1010	0.1010	6
SAMS	SAMS:5|SAM-S:2	S-adenosylmethionine synthetase:7:0.1641	0.1641	7
SAMs	SAMs:182|SAMS:2	Self-assembled monolayers:184:0.9101	0.9101	184
SAMs	SAMs:9	Shoot apical meristems:9:0.6794	0.6794	9
SAM	SAM:6	Activity Monitor:6:0.1543	0.1543	6
SAM	SAM:178	S-adenosyl-L-methionine:178:0.1083	0.1083	178
SAM	SAM:55	S-adenosyl methionine:29:0.7581|S-adenosyl-methionine:26:0.0153	0.7581	55
SAM	SAM:305|S-AM:2	S-adenosylmethionine:307:0.1872	0.1872	307
SAM	SAM:26	salicylamide:26:0.0153	0.0153	26
SAM	SAM:13	scanning acoustic microscope:13:0.7753	0.7753	13
SAM	SAM:26	scanning acoustic microscopy:26:0.8251	0.8251	26
SAM	SAM:121	self-assembled monolayer:105:0.8908|self-assembled monolayers:16:0.7261	0.8908	121
SAM	SAM:63	Senescence-accelerated mice:40:0.4710|senescence accelerated mice:23:0.8657	0.8657	63
SAM	SAM:143	senescence-accelerated mouse:90:0.5172|senescence accelerated mouse:53:0.8776	0.8776	143
SAM	SAM:64	shoot apical meristem:64:0.9534	0.9534	64
SAM	SAM:29|sam:1	Significance Analysis of Microarrays:23:0.8115|Significance Analysis of Microarray:7:0.4102	0.8115	30
SAM	SAM:12	sinusoidal amplitude modulation:12:0.7571	0.7571	12
SAM	SAM:48	sinusoidally amplitude-modulated:33:0.6735|sinusoidally amplitude modulated:15:0.6386	0.6735	48
SAM	SAM:7	smoking-attributable mortality:7:0.2902	0.2902	7
SAM	SAM:26	sterile alpha motif:26:0.8861	0.8861	26
SAM	SAM:8	substrate-attached material:8:0.0566	0.0566	8
SAM	SAM:11	surface active material:11:0.7357	0.7357	11
SAM	SAM:10	surface-associated material:10:0.0958	0.0958	10
SAM	SAM:19	synthetic aperture magnetometry:19:0.8449	0.8449	19
SAM	SAM:62	systolic anterior motion:62:0.8788	0.8788	62
SAM	SAM:19	systolic anterior motion of the mitral valve:19:0.8594	0.8594	19
SAM	SAM:10	systolic anterior movement:10:0.7103	0.7103	10
SANE	SANE:11	sexual assault nurse examiner:11:0.7357	0.7357	11
SANS	SANS:106	Scale for the Assessment of Negative Symptoms:106:0.7897	0.7897	106
SANS	SANS:88	small-angle neutron scattering:58:0.5459|small angle neutron scattering:30:0.9011	0.9011	88
SaO2	SaO2:386|Sao2:21|SAO2:6|saO2:4|Sa-O2:1	arterial oxygen saturation:418:0.5643	0.5643	418
SaO2	SaO2:7	oxygen saturations:7:0.1641	0.1641	7
SaO2	SaO2:9	pulse oximetry:9:0.5470	0.5470	9
SaO2	SaO2:4	saturation of oxygen:4:0.1838	0.1838	4
SAO	SAO:17	Southeast Asian ovalocytosis:17:0.6211	0.6211	17
SAO	SAO:52	splanchnic artery occlusion:52:0.9099	0.9099	52
SAP97	SAP97:11	synapse-associated protein 97:11:0.6182	0.6182	11
SAPHO	SAPHO:1	synovitis acne pustulosis hyperostosis osteitis:1:0.8045	0.8045	1
SAPK	SAPK:138	stress-activated protein kinase:119:0.6539|stress-activated protein kinases:19:0.7044	0.7044	138
SAPKs	SAPKs:61	stress-activated protein kinases:61:0.7455	0.7455	61
SAPL	SAPL:20	surface-active phospholipid:20:0.8525	0.8525	20
sAPP	sAPP:11	amyloid precursor protein:11:0.2972	0.2972	11
sAPP	sAPP:8	beta-amyloid precursor protein:8:0.1471	0.1471	8
sAPP	sAPP:14	soluble APP:14:0.2157	0.2157	14
SAPs	SAPs:10	action potentials:10:0.7103	0.7103	10
SAPS	SAPS:49	Scale for the Assessment of Positive Symptoms:49:0.7855	0.7855	49
SAPS	SAPS:90	simplified acute physiology score:90:0.9668	0.9668	90
SAPs	SAPs:29	Sphingolipid activator proteins:29:0.8978	0.8978	29
SAP	SAP:18|sAP:2	action potentials:20:0.8525	0.8525	20
Sap	Sap:12|SAP:6	aspartyl proteinase:18:0.4934	0.4934	18
SAP	SAP:9	Assessment of Personality:9:0.6794	0.6794	9
SAP	SAP:11|Sap:4	protease:15:0.0083	0.0083	15
SAP	SAP:18	sensory action potential:18:0.4672	0.4672	18
SAP	SAP:7	serum acid phosphatase:7:0.0951	0.0951	7
SAP	SAP:53|sAP:10|S-AP:5|s-AP:2	serum alkaline phosphatase:70:0.6512	0.6512	70
SAP	SAP:45	serum amyloid P:45:0.8964	0.8964	45
SAP	SAP:277|Sap:1	Serum amyloid P component:225:0.9651|serum amyloid P-component:53:0.8842	0.9651	278
SAP	SAP:83|sAP:1	severe acute pancreatitis:84:0.9091	0.9091	84
SAP	SAP:6	Sphingolipid activator proteins:6:0.5290	0.5290	6
SAP	SAP:46|sAP:1	stable angina pectoris:47:0.8433	0.8433	47
SAP	SAP:34	standard automated perimetry:34:0.6386	0.6386	34
SAP	SAP:9	steroidogenesis activator polypeptide:9:0.5470	0.5470	9
SAP	SAP:16	stress-activated protein:16:0.0850	0.0850	16
SAP	SAP:7	Symptom association probability:7:0.4438	0.4438	7
SAP	SAP:165	systemic arterial pressure:165:0.3725	0.3725	165
SAP	SAP:52|sAP:1	systolic:53:0.0309	0.0309	53
SAP	SAP:217|sAP:1	systolic arterial pressure:218:0.5089	0.5089	218
SAQ	SAQ:31	Seattle Angina Questionnaire:31:0.8519	0.8519	31
SARA	SARA:11	sexually acquired reactive arthritis:11:0.6182	0.6182	11
SARA	SARA:12	Smad anchor for receptor activation:12:0.7753	0.7753	12
SARA	SARA:11	Subacute ruminal acidosis:11:0.7103	0.7103	11
SARMs	SARMs:14	selective androgen receptor modulators:14:0.6911	0.6911	14
SARs	SARs:12	Scaffold-associated regions:12:0.1692	0.1692	12
SARs	SARs:10	scaffold attachment regions:10:0.5856	0.5856	10
SARS	SARS:1265	severe acute respiratory syndrome:1265:0.9948	0.9948	1265
SARs	SARs:16	slowly adapting pulmonary stretch receptors:16:0.8165	0.8165	16
SARs	SARs:46	Specific absorption rates:46:0.9006	0.9006	46
sar	sar:2	ANG II antagonist saralasin:2:0.3170	0.3170	2
SAR	SAR:3|sar:2	patients with sarcoidosis:5:0.0517	0.0517	5
SAR	SAR:16	scaffold attachment region:16:0.8165	0.8165	16
SAR	SAR:131	seasonal allergic rhinitis:131:0.9636	0.9636	131
SAR	SAR:9	slowly adapting pulmonary stretch receptor:9:0.6794	0.6794	9
SAR	SAR:6	slowly adapting receptors:6:0.5290	0.5290	6
SAR	SAR:6	slowly adapting stretch receptors:6:0.5290	0.5290	6
SAR	SAR:352	specific absorption rate:322:0.8968|specific absorption rates:30:0.8032	0.8968	352
SAR	SAR:13	synthetic aperture radar:13:0.7753	0.7753	13
SAR	SAR:119	systemic acquired resistance:119:0.9749	0.9749	119
SAR	SAR:5	systemic anaphylactic reaction:5:0.4422	0.4422	5
SASA	SASA:10	solvent accessible surface area:10:0.7103	0.7103	10
SASB	SASB:30	structural analysis of social behavior:30:0.8472	0.8472	30
SASI	SASI:9	Separation Anxiety Symptom Inventory:9:0.6794	0.6794	9
SASP	SASP:30	Salazosulfapyridine:30:0.1111	0.1111	30
SASP	SASP:10	salazosulphapyridine:10:0.0333	0.0333	10
SASP	SASP:28	Salicylazosulfapyridine:28:0.1000	0.1000	28
SASP	SASP:1	small acid-soluble proteins:1:0.8715	0.8715	1
SASP	SASP:3	small acid-soluble spore protein:2:0.7103|small acid-soluble spore proteins:1:0.8816	0.8816	3
SASP	SASP:50	sulfasalazine:50:0.1815	0.1815	50
SASP	SASP:68	sulphasalazine:68:0.2481	0.2481	68
SASS	SASS:13	Social Adaptation Self-evaluation Scale:13:0.7753	0.7753	13
SAS	SAS:22	Self-rating Anxiety Scale:22:0.6531	0.6531	22
SAS	SAS:223	sleep apnea syndrome:223:0.9866	0.9866	223
SAS	SAS:19	Social Adjustment Scale:19:0.8449	0.8449	19
SAS	SAS:24	subaortic stenosis:24:0.3526	0.3526	24
SAS	SAS:32	subarachnoid space:32:0.7782	0.7782	32
SAS	SAS:10	supravalvular aortic stenosis:10:0.2643	0.2643	10
SAS	SAS:8	surface-active substances:8:0.2619	0.2619	8
SAS	SAS:15	surface anatomy scanning:15:0.8045	0.8045	15
SAS	SAS:26	sympathoadrenal system:26:0.1566	0.1566	26
SATSA	SATSA:12	Swedish Adoption/Twin Study of Aging:12:0.7571	0.7571	12
SAT	SAT:11	African Territories:11:0.7357	0.7357	11
SAT	SAT:5	oxygen saturation:5:0.0902	0.0902	5
sat	sat:5|SAT:4|Sat:2	satellite:11:0.0143	0.0143	11
SAT	SAT:12|Sat:4|sat:2	saturated:18:0.0243	0.0243	18
SAT	SAT:6|sat:1	saturated fat:7:0.2902	0.2902	7
SAT	SAT:6	self-administered therapy:6:0.1543	0.1543	6
SAT	SAT:26	serine acetyltransferase:26:0.6084	0.6084	26
SAT	SAT:41	serum agglutination test:41:0.3722	0.3722	41
SAT	SAT:11	soil aquifer treatment:11:0.7357	0.7357	11
SAT	SAT:20	spermidine/spermine N1-acetyltransferase:20:0.6680	0.6680	20
SAT	SAT:33	spontaneous autoimmune thyroiditis:33:0.6976	0.6976	33
SAT	SAT:8	subacute stent thrombosis:8:0.6411	0.6411	8
SAT	SAT:7	subacute thrombosis:7:0.1470	0.1470	7
SAT	SAT:42	subacute thyroiditis:42:0.3690	0.3690	42
SAT	SAT:7	substance abuse treatment:7:0.4438	0.4438	7
SAVE	SAVE:46	Survival and Ventricular Enlargement:46:0.9353	0.9353	46
SAWs	SAWs:11	surface acoustic waves:11:0.7357	0.7357	11
SAW	SAW:121	surface acoustic wave:109:0.9726|surface acoustic waves:12:0.7571	0.9726	121
SAXS	SAXS:232	small-angle X-ray scattering:152:0.5855|small angle X-ray scattering:80:0.9627	0.9627	232
SAX	SAX:23	strong anion exchange:12:0.6460|strong anion-exchange:11:0.6182	0.6460	23
S-Ado	S-Ado:8|SAdo:1	succinyladenosine:9:0.6154	0.6154	9
SAgs	SAgs:55|SAGs:23|Sags:3|sAgs:1	superantigens:82:0.7941	0.7941	82
SA	SA:10	antigens:10:0.0022	0.0022	10
SA	SA:10	cocaine self-administration:10:0.0852	0.0852	10
SA	SA:8	heroin self-administration:8:0.0502	0.0502	8
SA	SA:4	isolated rabbit sino-atrial:4:0.1196	0.1196	4
SA	SA:7|S-A:1	isolated rabbit sinoatrial:8:0.1022	0.1022	8
SA	SA:583	salicylic acid:583:0.6999	0.6999	583
SA	SA:15	saline:15:0.0035	0.0035	15
SA	SA:18|Sa:1	sarcoidosis:19:0.0045	0.0045	19
SA	SA:7	satellite association:7:0.2113	0.2113	7
SA	SA:9	separation anxiety:9:0.1690	0.1690	9
SA	SA:16	septic arthritis:16:0.5171	0.5171	16
SA	SA:9	serrated adenoma:9:0.3069	0.3069	9
SA	SA:12	serratus anterior:12:0.5664	0.5664	12
SA	SA:67	serum albumin:67:0.9087	0.9087	67
SA	SA:8	serum aldosterone:8:0.4102	0.4102	8
SA	SA:11|S-A:1	short-axis:12:0.0027	0.0027	12
SA	SA:113	sialic acid:113:0.1188	0.1188	113
SA	SA:7	sideroblastic anaemia:7:0.1329	0.1329	7
SA	SA:50	simulated annealing:50:0.9404	0.9404	50
SA	SA:7	sinus arrhythmia:7:0.3524	0.3524	7
SA	SA:5	Situation Awareness:5:0.1132	0.1132	5
SA	SA:10	Skeletal age:10:0.5000	0.5000	10
SA	SA:34	sleep apnea:34:0.7587	0.7587	34
SA	SA:12	Sleep apnoea:12:0.7571	0.7571	12
SA	SA:8	slide agglutination:8:0.2987	0.2987	8
SA	SA:76	slowly adapting:76:0.9607	0.9607	76
SA	SA:9	sodium alginate:9:0.6794	0.6794	9
SA	SA:14	sodium arsenite:14:0.7909	0.7909	14
SA	SA:14	sodium L-ascorbate:14:0.7909	0.7909	14
SA	SA:21	Sodium salicylate:21:0.2339	0.2339	21
SA	SA:13	South Africa:13:0.7753	0.7753	13
SA	SA:16	South African:16:0.8165	0.8165	16
SA	SA:19	South Australia:19:0.7658	0.7658	19
SA	SA:84	specific activity:77:0.4897|specific activities:7:0.3524	0.4897	84
SA	SA:15	spectral analysis:15:0.1992	0.1992	15
SA	SA:8	spherical aberration:8:0.5006	0.5006	8
Sa	Sa:20|SA:3	sphinganine:23:0.0055	0.0055	23
SA	SA:15	spinal anaesthesia:15:0.5818	0.5818	15
SA	SA:19	Spinal anesthesia:19:0.7044	0.7044	19
SA	SA:13	splenic artery:13:0.1506	0.1506	13
SA	SA:25	Spontaneous abortion:15:0.5348|spontaneous abortions:10:0.7103	0.7103	25
SA	SA:19	spontaneous activity:19:0.0766	0.0766	19
SA	SA:11	spontaneous alternation:11:0.5355	0.5355	11
SA	SA:52|sa:1	stable angina:53:0.7972	0.7972	53
SA	SA:94|Sa:18	Staphylococcus aureus:112:0.8869	0.8869	112
SA	SA:11	Staphylococcus aureus Cowan I:11:0.7357	0.7357	11
SA	SA:10	state anxiety:10:0.2126	0.2126	10
SA	SA:13	Status asthmaticus:13:0.7753	0.7753	13
SA	SA:35	stearylamine:35:0.0085	0.0085	35
SA	SA:61	streptavidin:61:0.0150	0.0150	61
SA	SA:21	streptococcal antigen:21:0.2677	0.2677	21
SA	SA:36	stretch-activated:36:0.0090	0.0090	36
SA	SA:15|Sa:1	subclavian artery:16:0.2154	0.2154	16
SA	SA:24	substance abuse:24:0.6122	0.6122	24
SA	SA:10	succinic anhydride:10:0.5856	0.5856	10
SA	SA:40	succinylacetone:40:0.0097	0.0097	40
SA	SA:9	sulcus angle:9:0.1690	0.1690	9
SA	SA:9	sulfanilamide:9:0.0020	0.0020	9
SA	SA:18|Sa:2	sulfonamide:11:0.0025|sulfonamides:9:0.0020	0.0025	20
SA	SA:54|Sa:14	surface area:68:0.5384	0.5384	68
SA	SA:10	surgery alone:10:0.2275	0.2275	10
SA	SA:21	sympathoadrenal:21:0.0050	0.0050	21
SB-75	SB-75:12	antagonist cetrorelix:12:0.5664	0.5664	12
SBAs	SBAs:9	serum bactericidal activities:9:0.6794	0.6794	9
SBA	SBA:44	Glycine max:44:0.8941	0.8941	44
SBA	SBA:56	serum bactericidal activity:56:0.9467	0.9467	56
SBA	SBA:17	Serum bactericidal antibody:17:0.8270	0.8270	17
SBA	SBA:12	serum bactericidal assay:12:0.6460	0.6460	12
SBA	SBA:41|S-BA:1	serum bile acids:29:0.7970|serum bile acid:13:0.5934	0.7970	42
SBA	SBA:19	sheep blood agar:19:0.7658	0.7658	19
SBA	SBA:22	sodium 5,6-benzylidene-L-ascorbate:22:0.8657	0.8657	22
SBA	SBA:290	soybean agglutinin:290:0.8251	0.8251	290
SBA	SBA:6	soybean lectin:6:0.1543	0.1543	6
SBBO	SBBO:12	small bowel bacterial overgrowth:12:0.7571	0.7571	12
SBB	SBB:17	Sudan black B:17:0.8270	0.8270	17
SBC-3	SBC-3:5|SBC3:1	small cell lung cancer cell line:6:0.5290	0.5290	6
sBCC	sBCC:6|SBCC:2	superficial basal cell carcinoma:8:0.5006	0.5006	8
SBCs	SBCs:9	sunburn cells:9:0.3945	0.3945	9
SBC	SBC:20	selective brain cooling:20:0.8525	0.8525	20
SBC	SBC:8|sbc:1	simple bone cyst:9:0.4587	0.4587	9
SBC	SBC:19	sunburn cell:12:0.4153|sunburn cells:7:0.2113	0.4153	19
SBC	SBC:7	superficial bladder cancer:7:0.3524	0.3524	7
SBD	SBD:15	selective bowel decontamination:15:0.8165	0.8165	15
SBD	SBD:15	starch-binding domain:15:0.2344	0.2344	15
SBEs	SBEs:7	Smad Binding Elements:7:0.2902	0.2902	7
SBE	SBE:24	single base extension:13:0.7753|single-base extension:11:0.2040	0.7753	24
SBE	SBE:16	SMAD-binding element:11:0.1938|Smad binding element:5:0.1132	0.1938	16
SBE	SBE:10	starch branching enzyme:10:0.7103	0.7103	10
SBE	SBE:34	subacute bacterial endocarditis:34:0.8245	0.8245	34
SBFI	SBFI:30|SBFi:1	sodium-binding benzofuran isophthalate:31:0.5576	0.5576	31
SBFT	SBFT:8	small bowel follow-through:8:0.6794	0.6794	8
SBF	SBF:248	simulated body fluid:240:0.9672|simulated body fluids:8:0.5006	0.9672	248
SBF	SBF:67	skin blood flow:67:0.4963	0.4963	67
SBF	SBF:7	suppressive B cell factor:7:0.5926	0.5926	7
SBGM	SBGM:5	self blood glucose monitoring:5:0.4422	0.4422	5
SBHCs	SBHCs:25|SB-HCs:1	School-based health centers:26:0.8861	0.8861	26
SBH	SBH:5	Sabra hypertension-prone:5:0.0899	0.0899	5
SBH	SBH:10	salt-sensitive:10:0.0592	0.0592	10
SBH	SBH:26|SbH:1	sequencing by hybridization:27:0.3346	0.3346	27
SBH	SBH:25	Southern blot hybridization:25:0.8816	0.8816	25
SBH	SBH:21	Subcortical band heterotopia:21:0.8594	0.8594	21
SBIs	SBIs:8	silicone breast implants:8:0.5006	0.5006	8
SBI	SBI:11	screening and brief intervention:11:0.7571	0.7571	11
SBI	SBI:15	serious bacterial infection:15:0.6386	0.6386	15
SBI	SBI:4	severe brain injury:4:0.1618	0.1618	4
SBI	SBI:11	Silent brain infarction:11:0.7357	0.7357	11
SBI	SBI:9	silicone breast implants:9:0.4587	0.4587	9
SBI	SBI:6	small bowel injury:6:0.5290	0.5290	6
SBI	SBI:30	Sulcus Bleeding Index:30:0.6736	0.6736	30
SBL	SBL:3	serine protease subtilisin Bacillus lentus:3:0.4422	0.4422	3
SBL	SBL:7	soybean lectin:7:0.2902	0.2902	7
SBMA	SBMA:97	spinal and bulbar muscular atrophy:97:0.9710	0.9710	97
SBMT	SBMT:9|sBMT:1	syngeneic bone marrow transplantation:10:0.5856	0.5856	10
SBMV	SBMV:13	southern bean mosaic virus:13:0.7753	0.7753	13
SBM	SBM:207	soybean meal:207:0.7653	0.7653	207
SBO	SBO:6	Side branch occlusion:6:0.5290	0.5290	6
SBO	SBO:75	small bowel obstruction:75:0.9602	0.9602	75
SBO	SBO:43	soybean oil:43:0.7795	0.7795	43
SBO	SBO:11	spina bifida occulta:11:0.7357	0.7357	11
SBPC	SBPC:30|SB-PC:3	sulbenicillin:33:0.6667	0.6667	33
sBPT	sBPT:7|SBPT:1	specific bronchial provocation test:8:0.6411	0.6411	8
sBPT	sBPT:7	specific bronchial provocative test:7:0.5926	0.5926	7
SBP	SBP:5	serotonin binding proteins:5:0.2818	0.2818	5
SBP	SBP:86	sex steroid-binding protein:46:0.8676|Sex steroid binding protein:40:0.9256	0.9256	86
SBP	SBP:10	soybean peroxidase:10:0.5856	0.5856	10
SBP	SBP:187	spontaneous bacterial peritonitis:187:0.9659	0.9659	187
SBP	SBP:526|sBP:8	systolic:534:0.1336	0.1336	534
SBP	SBP:2377|sBP:34|S-BP:2|SBp:2	systolic blood pressure:2389:0.9570|Systolic blood pressures:26:0.8861	0.9570	2415
SBP	SBP:389|sBP:4	systolic BP:393:0.9762	0.9762	393
SBRs	SBRs:32	sequencing batch reactors:32:0.8563	0.8563	32
SBR	SBR:8	saliva-binding region:8:0.5006	0.5006	8
SBR	SBR:1	Scarff Bloom and Richardson:1:0.3728	0.3728	1
SBR	SBR:14	Scarff-Bloom-Richardson:14:0.0302	0.0302	14
SBR	SBR:161	sequencing batch reactor:146:0.9038|sequencing batch reactors:15:0.4951	0.9038	161
SBR	SBR:60|SBr:1	small bowel resection:61:0.9511	0.9511	61
SBR	SBR:9	spontaneous baroreflex:9:0.6794	0.6794	9
SBR	SBR:6	stillbirth rate:6:0.0731	0.0731	6
SBR	SBR:12	styrene-butadiene rubber:12:0.3813	0.3813	12
SBSE	SBSE:36	Stir bar sorptive extraction:36:0.9174	0.9174	36
SBSL	SBSL:11	sonoluminescence:11:0.9091	0.9091	11
SBS	SBS:10	secondary bilateral synchrony:10:0.7103	0.7103	10
SBS	SBS:86	shear bond strength:57:0.9477|shear bond strengths:29:0.8978	0.9477	86
SBS	SBS:113	short bowel syndrome:113:0.9735	0.9735	113
SBS	SBS:15	spino-bulbo-spinal:15:0.0266	0.0266	15
SBS	SBS:13	stimulated Brillouin scattering:13:0.7753	0.7753	13
SBs	SBs:5	synaptic bodies:5:0.0612	0.0612	5
SBT/CPZ	SBT/CPZ:66	sulbactam/cefoperazone:66:0.9559	0.9559	66
SBTI	SBTI:108|SbTI:1	soybean trypsin inhibitor:109:0.7311	0.7311	109
SBTPC	SBTPC:24	sultamicillin:24:0.9200	0.9200	24
SBTT	SBTT:14	Small Bowel Transit Time:14:0.7909	0.7909	14
SBTx	SBTx:30|SBTX:6|SbTx:1	small bowel transplantation:37:0.9197	0.9197	37
SBTs	SBTs:12	serous borderline tumors:12:0.7571	0.7571	12
SBTs	SBTs:8	Serum bactericidal titers:8:0.5006	0.5006	8
SBV	SBV:7	sacbrood virus:7:0.2113	0.2113	7
SBV	SBV:9	shed blood volume:9:0.3455	0.3455	9
SBWMV	SBWMV:12	soil-borne wheat mosaic virus:12:0.5664	0.5664	12
SB	SB:8|Sb:1|S-B:1	blood:10:0.0072	0.0072	10
Sb	Sb:12	pentavalent antimony:12:0.0884	0.0884	12
SB	SB:6|Sb:3	Saccharomyces boulardii:9:0.6794	0.6794	9
SB	SB:8|Sb:4	salbutamol:12:0.0088	0.0088	12
SB	SB:13	Schiff base:13:0.6701	0.6701	13
SB	SB:11	scleral buckling:11:0.6182	0.6182	11
sb	sb:9	seabream:9:0.0064	0.0064	9
SB	SB:18	serum bilirubin:18:0.7539	0.7539	18
SB	SB:37	Single Bond:37:0.8749	0.8749	37
SB	SB:11	single-breath:11:0.0080	0.0080	11
SB	SB:9	sinus bradycardia:9:0.6794	0.6794	9
SB	SB:12	sleep bruxism:12:0.7571	0.7571	12
SB	SB:34	Sleeping Beauty:34:0.9126	0.9126	34
SB	SB:46|S-B:1	small bowel:47:0.8433	0.8433	47
SB	SB:14	sodium bicarbonate:14:0.4709	0.4709	14
SB	SB:52	sodium butyrate:52:0.9427	0.9427	52
SB	SB:22	Southern blot:22:0.7955	0.7955	22
SB	SB:14	Southern blotting:14:0.7909	0.7909	14
SB	SB:4|sb:1	Specific binding:5:0.0612	0.0612	5
SB	SB:58	spina bifida:58:0.9486	0.9486	58
SB	SB:48|sb:1	spontaneous breathing:49:0.8285	0.8285	49
SB	SB:15	stereotyped behavior:8:0.2619|stereotyped behaviour:7:0.3524	0.3524	15
SB	SB:8	strand breaks:8:0.2619	0.2619	8
SC115	SC115:26|SC-115:1	Shionogi carcinoma 115:27:0.8903	0.8903	27
SC115	SC115:7	Shionogi mouse mammary carcinoma:7:0.5926	0.5926	7
SC-3	SC-3:12	cell line:12:0.7571	0.7571	12
SC-560	SC-560:6|SC560:1	selective COX-1 inhibitor:7:0.5926	0.5926	7
SC5b-9	sC5b-9:4|SC5b-9:4	terminal complement complex:8:0.5006	0.5006	8
SCA1	SCA1:18|SCA-1:1	spinocerebellar ataxia:19:0.7658	0.7658	19
SCA1	SCA1:126|SCA-1:7	Spinocerebellar ataxia type 1:133:0.9407	0.9407	133
Sca-1	Sca-1:9	stem cell antigen-1:9:0.6794	0.6794	9
SCA2	SCA2:7	spinocerebellar ataxia:7:0.1641	0.1641	7
SCA2	SCA2:81|SCA-2:1	spinocerebellar ataxia type 2:82:0.9415	0.9415	82
SCA3	SCA3:19	spinocerebellar ataxia type 3:19:0.6040	0.6040	19
SCA6	SCA6:60|SCA-6:4	spinocerebellar ataxia type 6:64:0.9018	0.9018	64
SCA7	SCA7:16	spinocerebellar ataxia 7:16:0.8165	0.8165	16
SCA7	SCA7:42	Spinocerebellar ataxia type 7:42:0.9291	0.9291	42
SCA8	SCA8:12	spinocerebellar ataxia type 8:12:0.7571	0.7571	12
SCAD	SCAD:35	short-chain acyl-CoA dehydrogenase:35:0.6464	0.6464	35
sCAD	sCAD:6|SCAD:4	spontaneous cervical artery dissection:10:0.7103	0.7103	10
SCAD	SCAD:16	spontaneous coronary artery dissection:16:0.8165	0.8165	16
SCAG	SCAG:11	Sandoz Clinical Assessment Geriatric:11:0.7357	0.7357	11
SCAG	SCAG:10	Sandoz Clinical Assessment Geriatric scale:10:0.5856	0.5856	10
SCAMPs	SCAMPs:20	secretory carrier membrane proteins:20:0.8525	0.8525	20
SCAN	SCAN:48	Schedules for Clinical Assessment in Neuropsychiatry:48:0.7328	0.7328	48
SCARED	SCARED:15	Screen for Child Anxiety Related Emotional Disorders:15:0.7571	0.7571	15
SCARMD	SCARMD:21	severe childhood autosomal recessive muscular dystrophy:21:0.8594	0.8594	21
SCAT	SCAT:10	subcutaneous adipose tissue:10:0.7103	0.7103	10
SCAs	SCAs:45	spinocerebellar ataxias:45:0.9338	0.9338	45
SCA	SCA:13	analysis:13:0.0147	0.0147	13
sca	sca:11|Sca:1	scabrous:12:0.0134	0.0134	12
SCA	SCA:10	selective coronary angiography:10:0.5856	0.5856	10
SCA	SCA:6	Senescent cell antigen:6:0.5290	0.5290	6
SCa	SCa:6|S-Ca:5|sCa:5|s-Ca:4	serum calcium:20:0.4201	0.4201	20
SCA	SCA:6	sex chromosome abnormalities:6:0.5290	0.5290	6
SCA	SCA:82	sickle cell anaemia:82:0.9640	0.9640	82
SCA	SCA:140	sickle cell anemia:140:0.9659	0.9659	140
SCA	SCA:11|scA:1	single-chain antibody:7:0.1850|Single chain antibody:5:0.4422	0.4422	12
SCA	SCA:110	spinocerebellar ataxia:87:0.8833|spinocerebellar ataxias:23:0.7500	0.8833	110
SCA	SCA:6	structural chromosomal aberration:6:0.3728	0.3728	6
SCA	SCA:12	subclavian artery:12:0.0573	0.0573	12
SCA	SCA:23	sudden cardiac arrest:23:0.8038	0.8038	23
SCA	SCA:61	superior cerebellar artery:61:0.7885	0.7885	61
SCA	SCA:13	suppressor cell activity:13:0.7753	0.7753	13
SCBA	SCBA:27	self-contained breathing apparatus:27:0.8312	0.8312	27
SCBC	SCBC:9	bronchogenic carcinoma:9:0.6794	0.6794	9
SCBF	SCBF:128	Spinal cord blood flow:128:0.9768	0.9768	128
SCBU	SCBU:31|scbu:1	Special Care Baby Unit:32:0.9072	0.9072	32
SCC-Ag	SCC-Ag:34|SCCAg:6|SCC-ag:5	squamous cell carcinoma antigen:45:0.9338	0.9338	45
SCCA	SCCA:41|SCCa:7	squamous cell carcinoma:48:0.9379	0.9379	48
SCCA	SCCA:36|SCCa:2|SCC-A:2	squamous cell carcinoma antigen:40:0.9256	0.9256	40
SCCE	SCCE:11	squamous cell carcinoma of the esophagus:11:0.6182	0.6182	11
SCCE	SCCE:23	Stratum corneum chymotryptic enzyme:23:0.8715	0.8715	23
SCCH	SCCH:13	sternocostoclavicular hyperostosis:13:0.4444	0.4444	13
SCCHN	SCCHN:6|SCC-HN:1	head and neck squamous cell carcinoma:7:0.5926	0.5926	7
SCCHN	SCCHN:327|SCC-HN:10	squamous cell carcinoma of the head and neck:337:0.9913	0.9913	337
SCCL	SCCL:94	small cell carcinoma of the lung:94:0.9500	0.9500	94
SCCMS	SCCMS:7	slow-channel congenital myasthenic syndrome:7:0.3524	0.3524	7
SCCM	SCCM:6|SC-CM:1	Sertoli cell-conditioned medium:7:0.2902	0.2902	7
SCCM	SCCM:14	Society of Critical Care Medicine:14:0.5589	0.5589	14
SC-CO2	SC-CO2:14|scCO2:10|SCCO2:2|sc-CO2:1	supercritical carbon dioxide:27:0.7760	0.7760	27
SCCs	SCCs:9	semicircular canals:9:0.5470	0.5470	9
SCCs	SCCs:5	solitary chemosensory cells:5:0.4422	0.4422	5
SCCs	SCCs:12	squamous cell cancers:12:0.7571	0.7571	12
SCCs	SCCs:388	squamous cell carcinomas:388:0.9591	0.9591	388
SCCS	SCCS:21	surface-connected canalicular system:21:0.6040	0.6040	21
SCCmec	SCCmec:34	staphylococcal cassette chromosome mec:34:0.7898	0.7898	34
SCD1	SCD1:21|SCD-1:16|Scd1:2|scd-1:1	stearoyl-CoA desaturase 1:22:0.6178|stearoyl-CoA desaturase-1:18:0.6903	0.6903	40
SCDs	SCDs:8	sequential compression devices:8:0.5006	0.5006	8
SCD	SCD:27	patients with spinocerebellar degeneration:27:0.2886	0.2886	27
SCD	SCD:16	Scalp current density:16:0.6577	0.6577	16
SCD	SCD:7	sequential compression device:7:0.3524	0.3524	7
SCD	SCD:672	sickle cell disease:672:0.9955	0.9955	672
SCD	SCD:27	sister chromatid differentiation:27:0.8903	0.8903	27
SCD	SCD:10	spinocerebellar degenerations:10:0.7103	0.7103	10
SCD	SCD:8	spondylocostal dysostosis:8:0.5006	0.5006	8
SCD	SCD:9	spreading cortical depression:9:0.6794	0.6794	9
SCD	SCD:72|Scd:3|scd:1	stearoyl-CoA desaturase:76:0.7245	0.7245	76
SCD	SCD:5	stromelysin catalytic domain:5:0.1973	0.1973	5
SCD	SCD:20	subacute combined degeneration:20:0.8525	0.8525	20
SCD	SCD:284|scd:2	sudden cardiac death:279:0.9717|sudden cardiac deaths:7:0.5926	0.9717	286
SCD	SCD:11	systemic carnitine deficiency:11:0.7357	0.7357	11
SCE's	SCE's:11|SCE'S:1	sister chromatid exchanges:12:0.7571	0.7571	12
SCEPs	SCEPs:11	spinal cord evoked potentials:11:0.7357	0.7357	11
SCEP	SCEP:17	Spinal cord evoked potentials:17:0.7407	0.7407	17
SCEs	SCEs:838|SCES:2	sister chromatid exchanges:534:0.9944|sister-chromatid exchanges:298:0.3226|sister chromatid exchange:8:0.6411	0.9944	840
SCE	SCE:1871	sister chromatid exchange:906:0.9947|sister chromatid exchanges:473:0.9937|sister-chromatid exchange:293:0.2150|sister-chromatid exchanges:199:0.2559	0.9947	1871
SCE	SCE:14	specialized columnar epithelium:14:0.5589	0.5589	14
SCE	SCE:10	Stiles-Crawford effect:10:0.7103	0.7103	10
SCFA	SCFA:392	short-chain fatty acids:193:0.6669|short-chain fatty acid:95:0.6333|short chain fatty acids:69:0.9567|short chain fatty acid:35:0.9151	0.9567	392
SCFAs	SCFAs:175	short-chain fatty acids:131:0.6596|short chain fatty acids:44:0.9323	0.9323	175
SCFE	SCFE:10	Slipped capital femoral epiphyses:10:0.7103	0.7103	10
SCFE	SCFE:138|scfe:2	Slipped capital femoral epiphysis:140:0.9659	0.9659	140
SCFR	SCFR:5|SCF-R:1	stem cell factor receptor:6:0.3728	0.3728	6
SCF	SCF:6	c-kit ligand:6:0.2243	0.2243	6
SCF	SCF:12	self-consistent field:12:0.6460	0.6460	12
SCF	SCF:10	slow coronary flow:10:0.5856	0.5856	10
SCF	SCF:1550|scf:1|Scf:1	stem cell factor:1552:0.9816	0.9816	1552
SCF	SCF:9	supercritical fluid:9:0.2102	0.2102	9
SCGE	SCGE:109	single cell gel electrophoresis:109:0.9726	0.9726	109
SCGE	SCGE:6	single cell gel electrophoresis assay:6:0.5290	0.5290	6
SCGF	SCGF:9	stem cell growth factor:9:0.6794	0.6794	9
SCGX	SCGX:13|SCGx:1	superior cervical ganglionectomized:14:0.6911	0.6911	14
SCGx	SCGx:52|SCGX:13|SCG-X:2	superior cervical ganglionectomy:67:0.9554	0.9554	67
SCG	SCG:5	alkaline single-cell gel:5:0.1132	0.1132	5
SCG	SCG:7	alkaline single-cell gel electrophoresis:7:0.2902	0.2902	7
SCG	SCG:24	single cell gel:24:0.8816	0.8816	24
SCG	SCG:14	single cell gel electrophoresis:14:0.7909	0.7909	14
SCG	SCG:133	sodium cromoglycate:133:0.9524	0.9524	133
SCG	SCG:19	superior cervical:19:0.7658	0.7658	19
SCG	SCG:222|scg:1	superior cervical ganglia:223:0.9785	0.9785	223
SCG	SCG:528|scg:2	superior cervical ganglion:530:0.9879	0.9879	530
SCHIP	SCHIP:95|S-CHIP:3	State Children's Health Insurance Program:98:0.9352	0.9352	98
SCID-D	SCID-D:5	Structured Clinical Interview for DSM-IV Dissociative Disorders:5:0.4422	0.4422	5
SCID-II	SCID-II:24	Structured Clinical Interview for DSM-III-R Personality Disorders:24:0.8816	0.8816	24
SCID-IV	SCID-IV:10	Structured Clinical Interview for DSM-IV:10:0.7357	0.7357	10
SCID-P	SCID-P:7	Structured Clinical Interview for DSM-III-R-Patient Version:7:0.4438	0.4438	7
SCID-X1	SCID-X1:7|SCIDX1:6	X-linked severe combined immunodeficiency:13:0.5934	0.5934	13
SCID	SCID:18|scid:2	C.B-17 scid/scid:20:0.5892	0.5892	20
SCID	SCID:124|scid:27	severe combined immune deficiency:151:0.9580	0.9580	151
SCID	SCID:81|scid:10|Scid:1	severe combined immune deficient:61:0.8987|severe combined immune-deficient:31:0.8090	0.8987	92
SCID	SCID:788|scid:85|Scid:1	severe combined immunodeficiency:860:0.9645|Severe combined immunodeficiencies:14:0.7909	0.9645	874
SCID	SCID:101|scid:3	severe combined immunodeficiency disease:104:0.9712	0.9712	104
SCID	SCID:12|scid:1	severe combined immunodeficiency syndrome:13:0.7753	0.7753	13
SCID	SCID:704|scid:75|Scid:5	severe combined immunodeficient:784:0.9499	0.9499	784
SCID	SCID:8	severe combined immunodeficient mice:8:0.6411	0.6411	8
SCID	SCID:14	Structured Clinical Interview for DSM-III:14:0.7909	0.7909	14
SCIM	SCIM:9	Structured Clinical Instruction Module:9:0.6794	0.6794	9
SCIs	SCIs:55	spinal cord injuries:55:0.9458	0.9458	55
SCI	SCI:10	Inventory:10:0.0031	0.0031	10
SCI	SCI:44	Science Citation Index:44:0.8941	0.8941	44
SCI	SCI:20	silent cerebral infarction:20:0.7766	0.7766	20
SCI	SCI:7	spinal cord impairment:7:0.5926	0.5926	7
SCI	SCI:264|sci:1	spinal cord injured:204:0.9766|spinal cord-injured:61:0.9229	0.9766	265
SCI	SCI:2351	spinal cord injury:2225:0.9921|spinal cord injuries:126:0.9763	0.9921	2351
SCI	SCI:11	spinal cord ischemia:11:0.7357	0.7357	11
SCJ	SCJ:24	squamocolumnar junction:24:0.8115	0.8115	24
SCJ	SCJ:19	sternoclavicular joint:19:0.7044	0.7044	19
SCK	SCK:12|S-CK:4	serum creatine kinase:16:0.4832	0.4832	16
SCL-90-R	SCL-90-R:17|SCL-90R:7|SCL90-R:1	Symptom Check List:25:0.8768	0.8768	25
SCL-90-R	SCL-90-R:17|SCL-90R:8|SCL90-R:1	Symptom Checklist:26:0.6973	0.6973	26
SCL-90-R	SCL-90-R:8|SCL90-R:1	Symptom Checklist-90-R:9:0.6794	0.6794	9
SCL-90-R	SCL-90-R:64|SCL-90R:8|SCL90-R:2|SCL90R:1	Symptom Checklist-90-Revised:45:0.8649|Symptom Checklist 90-Revised:15:0.8045|Symptom Checklist-90 Revised:10:0.7753|symptom checklist 90 revised:5:0.5290	0.8649	75
SCL-90	SCL-90:17	Symptom Check List-90:17:0.6748	0.6748	17
SCL-90	SCL-90:29	Symptom Checklist:29:0.6157	0.6157	29
SCL-90	SCL-90:67|SCL90:2	Symptom Checklist-90:44:0.7413|Symptom Checklist 90:25:0.7679	0.7679	69
SCLCs	SCLCs:19	small cell lung cancers:19:0.8449	0.8449	19
SCLCs	SCLCs:28	Small cell lung carcinomas:28:0.8941	0.8941	28
SCLC	SCLC:21	small cell carcinoma of the lung:21:0.8594	0.8594	21
SCLC	SCLC:1995	small cell lung cancer:1324:0.9907|small-cell lung cancer:641:0.3031|Small cell lung cancers:30:0.8472	0.9907	1995
SCLC	SCLC:378	small cell lung carcinoma:342:0.9859|small cell lung carcinomas:36:0.8716	0.9859	378
SCLE	SCLE:25	subacute cutaneous LE:25:0.8816	0.8816	25
SCLE	SCLE:99	subacute cutaneous lupus erythematosus:99:0.9698	0.9698	99
SCLM	SCLM:8	Scanning confocal laser microscopy:8:0.6411	0.6411	8
SCLs	SCLs:11	soft contact lenses:11:0.7357	0.7357	11
SCLs	SCLs:9	synthetic combinatorial libraries:9:0.6794	0.6794	9
SCLS	SCLS:18	systemic capillary leak syndrome:18:0.8365	0.8365	18
Scl	Scl:7|SCL:3	scleroderma:10:0.0184	0.0184	10
SCL	SCL:13|SCl:1	Serum copper levels:14:0.7909	0.7909	14
SCL	SCL:69	sinus cycle length:69:0.7462	0.7462	69
SCL	SCL:75	skin conductance level:75:0.9370	0.9370	75
SCL	SCL:39	soft contact lens:27:0.8312|soft contact lenses:12:0.7571	0.8312	39
SCL	SCL:20|SCl:1	spinal cord lesion:15:0.8045|spinal cord lesions:6:0.5290	0.8045	21
SCL	SCL:7	Spindle cell lipoma:7:0.5926	0.5926	7
SCL	SCL:27|scl:1	stem cell leukemia:28:0.8369	0.8369	28
SCL	SCL:19	Symptom Checklist:19:0.7658	0.7658	19
SCMC	SCMC:9	mucus contact:9:0.6794	0.6794	9
S-CMC	S-CMC:12|SCMC:7	S-carboxymethylcysteine:19:0.1406	0.1406	19
SCMC	SCMC:18	sodium carboxymethylcellulose:18:0.8365	0.8365	18
SCMC	SCMC:47	spontaneous cell-mediated cytotoxicity:47:0.9366	0.9366	47
SCMPT	SCMPT:10	mucus penetration test:10:0.5856	0.5856	10
SCMV	SCMV:9	simian cytomegalovirus:9:0.6794	0.6794	9
SCMV	SCMV:12	sugarcane mosaic virus:12:0.7571	0.7571	12
SCM	SCM:11	secretory cell metaplasia:11:0.4232	0.4232	11
SCM	SCM:9	serum-containing medium:9:0.0591	0.0591	9
Scm	Scm:12|SCM:5	Sex comb on midleg:17:0.8165	0.8165	17
SCM	SCM:5	solids-corrected milk:5:0.0902	0.0902	5
SCM	SCM:9	spleen conditioned medium:9:0.1809	0.1809	9
SCM	SCM:16|scm:1	split cord malformation:17:0.8270	0.8270	17
SCM	SCM:80	sternocleidomastoid:80:0.1779	0.1779	80
SCM	SCM:38	sternocleidomastoid muscle:38:0.7306	0.7306	38
SCM	SCM:7	streptococcal cell membrane:7:0.3524	0.3524	7
SCM	SCM:1	structuredness of the cytoplasmic matrix:1:0.5856	0.5856	1
SCM	SCM:7	surface complexation model:7:0.5926	0.5926	7
SCN-	SCN-:90	thiocyanate:90:0.7295	0.7295	90
SCN-	SCN-:9	thiocyanate ion:9:0.5470	0.5470	9
SCN4A	SCN4A:7	skeletal muscle sodium channel gene:7:0.3524	0.3524	7
SCN4A	SCN4A:10	sodium channel:10:0.7103	0.7103	10
SCN5A	SCN5A:10	sodium channel:10:0.5856	0.5856	10
SCNB	SCNB:17|S-CNB:1	stereotactic core needle biopsy:18:0.6381	0.6381	18
SCNT	SCNT:35|SC-NT:1	somatic cell nuclear transfer:36:0.9197	0.9197	36
ScN	ScN:8|SCN:1	sciatic nerve:9:0.3455	0.3455	9
SCN	SCN:13	severe chronic neutropenia:13:0.7753	0.7753	13
SCN	SCN:67	severe congenital neutropenia:67:0.9554	0.9554	67
SCN	SCN:18	solid cell nests:18:0.8365	0.8365	18
SCN	SCN:12	soybean cyst nematode:12:0.7571	0.7571	12
SCN	SCN:12	Special Care Nursery:12:0.7571	0.7571	12
SCN	SCN:40	suprachiasmatic:40:0.0163	0.0163	40
SCN	SCN:562	suprachiasmatic nuclei:562:0.9737	0.9737	562
SCN	SCN:10	suprachiasmatic nuclei of the hypothalamus:10:0.7103	0.7103	10
SCN	SCN:1428|ScN:1	suprachiasmatic nucleus:1429:0.9869	0.9869	1429
SCN	SCN:25	suprachiasmatic nucleus of the hypothalamus:25:0.8861	0.8861	25
SCN	SCN:56|-SCN:1	thiocyanate:57:0.0235	0.0235	57
SCOD	SCOD:13|sCOD:1	soluble chemical oxygen demand:14:0.7909	0.7909	14
SCOD	SCOD:9	soluble COD:9:0.6794	0.6794	9
SCORAD	SCORAD:13	scoring of atopic dermatitis:13:0.8903	0.8903	13
SCORAD	SCORAD:2	Scoring of Atopic Dermatitis Index:2:0.5290	0.5290	2
SCOR	SCOR:6	skin conductance orienting response:6:0.5290	0.5290	6
SCOT	SCOT:10	CoA transferase:10:0.5856	0.5856	10
SCO	SCO:6|Sco:1	antagonist scopolamine:7:0.1211	0.1211	7
SCO	SCO:19	Sertoli cell-only:10:0.7103|Sertoli-cell-only:9:0.0300	0.7103	19
SCO	SCO:5	Sertoli Cell Only syndrome:5:0.4422	0.4422	5
SCO	SCO:164	subcommissural organ:164:0.9360	0.9360	164
SCP1	SCP1:5|SCP-1:1	synaptonemal complex protein 1:6:0.5290	0.5290	6
SCP-2	SCP-2:54|SCP2:50|Scp2:2	Sterol carrier protein-2:67:0.9554|Sterol carrier protein 2:39:0.8455	0.9554	106
SCP2	SCP2:23	sterol carrier protein2:23:0.8594	0.8594	23
SCPL	SCPL:16	supracricoid partial laryngectomy:16:0.7261	0.7261	16
SCPP	SCPP:11	spinal cord perfusion pressure:11:0.7357	0.7357	11
SCPB	SCPB:19|SCPb:1	small cardioactive peptide B:20:0.8594	0.8594	20
SCPs	SCPs:28|SCPS:1	Slow cortical potentials:29:0.8978	0.8978	29
SCPs	SCPs:18	small cardioactive peptides:18:0.8365	0.8365	18
SCPx	SCPx:12	Sterol carrier protein X:12:0.6460	0.6460	12
SCP	SCP:9	proteins:9:0.0190	0.0190	9
SCP	SCP:13	scopolamine:13:0.0286	0.0286	13
SCP	SCP:73	Selective cerebral perfusion:73:0.9147	0.9147	73
SCP	SCP:10	Sheep choroid plexus:10:0.7103	0.7103	10
SCP	SCP:11	single cell protein:11:0.6182	0.6182	11
SCP	SCP:25	slow cortical potentials:13:0.7753|slow cortical potential:12:0.7571	0.7753	25
SCP	SCP:12	small cardioactive peptide:12:0.7571	0.7571	12
SCP	SCP:13	sterol carrier protein:13:0.6701	0.6701	13
SCP	SCP:15	supercooling point:15:0.8045	0.8045	15
SCQ	SCQ:9	Situational Confidence Questionnaire:9:0.6794	0.6794	9
sCR1	sCR1:23	soluble complement receptor 1:23:0.5997	0.5997	23
sCR1	sCR1:35	soluble complement receptor type 1:35:0.6464	0.6464	35
sCR1	sCR1:13	soluble CR1:13:0.4444	0.4444	13
sCRP	sCRP:7|S-CRP:5|s-CRP:4|SCRP:1	Serum C-reactive protein:17:0.5038	0.5038	17
SCRT	SCRT:11	Stereotactic conformal radiotherapy:11:0.3213	0.3213	11
SCRs	SCRs:65	short consensus repeats:65:0.9541	0.9541	65
SCRs	SCRs:62	Skin conductance responses:62:0.9519	0.9519	62
SCR	SCR:6	c reductase:6:0.2243	0.2243	6
Scr	Scr:12	homeotic gene Sex combs reduced:12:0.7096	0.7096	12
SCR	SCR:14|scr:2	SCARECROW:16:0.0160	0.0160	16
ScR	ScR:3|Scr:1|SCR:1	scavenger receptors:5:0.0736	0.0736	5
SCR	SCR:14	selective catalytic reduction:14:0.7909	0.7909	14
SCr	SCr:177|Scr:94|sCr:42|s-Cr:29|S-Cr:17|SCR:6|sCR:2|S-cr:1|S-CR:1	serum creatinine:369:0.9536	0.9536	369
SCr	SCr:11|Scr:8|S-Cr:3|sCr:3	serum creatinine concentration:25:0.8816	0.8816	25
SCR	SCR:105|scr:1	short consensus repeat:62:0.8591|short consensus repeats:44:0.9323	0.9323	106
SCR	SCR:9	Shumiya Cataract Rat:9:0.6794	0.6794	9
SCR	SCR:93	skin conductance response:83:0.9640|skin conductance responses:10:0.7103	0.9640	93
sCR	sCR:3|SCR:2	Soluble cytokine receptors:5:0.2818	0.2818	5
SCSA	SCSA:62	sperm chromatin structure assay:62:0.9519	0.9519	62
SCSB	SCSB:39	static charge sensitive bed:26:0.8861|static-charge-sensitive bed:13:0.1220	0.8861	39
SCTAT	SCTAT:18	sex cord tumor with annular tubules:18:0.8365	0.8365	18
SCTA	SCTA:10|S-CTA:1	spiral CT angiography:11:0.7357	0.7357	11
SCTG	SCTG:9	subepithelial connective tissue graft:9:0.4587	0.4587	9
SCTT	SCTT:6	transit time:6:0.2243	0.2243	6
SCT	SCT:5	cell tumors:5:0.0902	0.0902	5
SCT	SCT:51	sacrococcygeal teratoma:37:0.7758|sacrococcygeal teratomas:14:0.6911	0.7758	51
sCT	sCT:252|SCT:87|S-CT:5|sCt:4|s-CT:4	salmon calcitonin:352:0.9198	0.9198	352
sCT	sCT:17|SCT:3|s-CT:1	salmon CT:21:0.2614	0.2614	21
SCT	SCT:36	Sickle cell trait:36:0.9174	0.9174	36
SCT	SCT:5	Silica clotting time:5:0.4422	0.4422	5
SCT	SCT:13	social cognitive theory:13:0.7753	0.7753	13
SCT	SCT:8	solid and cystic tumor:8:0.6701	0.6701	8
SCT	SCT:18	spinal cord transection:18:0.8365	0.8365	18
SCT	SCT:9	spinocerebellar tract:9:0.0621	0.0621	9
SCT	SCT:30|SCt:1	spinocervical tract:31:0.5117	0.5117	31
SCT	SCT:36|sCT:2|S-CT:2	Spiral computed tomography:40:0.9256	0.9256	40
SCT	SCT:20|sCT:2|S-CT:1	Spiral CT:23:0.2996	0.2996	23
SCT	SCT:78	stem cell transplant:64:0.9264|stem cell transplants:14:0.7909	0.9264	78
SCT	SCT:572	stem cell transplantation:572:0.9861	0.9861	572
SCT	SCT:7	subcutaneous connective tissue:7:0.4438	0.4438	7
SCUBA	SCUBA:10|scuba:5|Scuba:1	self-contained underwater breathing apparatus:16:0.7261	0.7261	16
SCUC	SCUC:7	small cell undifferentiated carcinoma:7:0.5926	0.5926	7
SCUs	SCUs:28	special care units:28:0.8369	0.8369	28
SCu	SCu:8|S-Cu:4|sCu:1	Serum copper:13:0.5934	0.5934	13
SCU	SCU:19	special care unit:19:0.7658	0.7658	19
ScvO2	ScvO2:16|Scvo2:1	venous oxygen saturation:17:0.7407	0.7407	17
SCVs	SCVs:29	Small-colony variants:15:0.2972|Small colony variants:14:0.7909	0.7909	29
SCV	SCV:19	Salmonella-containing vacuole:19:0.7658	0.7658	19
SCV	SCV:33	sensory conduction velocity:33:0.4805	0.4805	33
SCV	SCV:22	sensory nerve conduction velocity:16:0.6577|sensory nerve conduction velocities:6:0.5290	0.6577	22
SCV	SCV:11|ScV:1	Subclavian vein:12:0.3275	0.3275	12
SCV	SCV:10	variants:10:0.0439	0.0439	10
SCWL	SCWL:43	Single Comb White Leghorn:43:0.9308	0.9308	43
SCWT	SCWT:2	Stroop Color and Word Test:2:0.6411	0.6411	2
SCWs	SCWs:7	surface contraction waves:7:0.5926	0.5926	7
SCW	SCW:15	snail-conditioned water:15:0.3110	0.3110	15
SCW	SCW:36	streptococcal cell wall:25:0.7679|streptococcal cell walls:11:0.7357	0.7679	36
SCZ	SCZ:28	schizophrenia:28:0.4355	0.4355	28
SCb	SCb:32	slow component b:32:0.9072	0.9072	32
SCH	SCH:9|Sch:1	cell hyperplasia:10:0.5856	0.5856	10
SCH	SCH:9|Sch:1	SCH 23390:10:0.5856	0.5856	10
SCH	SCH:16|Sch:3	schizophrenia:19:0.0525	0.0525	19
SCH	SCH:8	spinal cord homogenate:8:0.6411	0.6411	8
SCH	SCH:11	Subclinical hypothyroidism:11:0.6182	0.6182	11
SCh	SCh:72|Sch:16|SCH:4|sch:1	succinylcholine:93:0.2682	0.2682	93
SCh	SCh:9|SCH:7	suprachiasmatic nucleus:16:0.8165	0.8165	16
SCH	SCH:5	suprachoroidal hemorrhage:5:0.0902	0.0902	5
SCoV	SCoV:8|SCOV:1	coronavirus:9:0.8889	0.8889	9
SCS	SCS:9	Saethre-Chotzen Syndrome:9:0.1809	0.1809	9
SCs	SCs:113|Scs:3	Schwann cells:116:0.4839	0.4839	116
SCS	SCS:7	Self-Control Schedule:7:0.3524	0.3524	7
SCS	SCS:23	somatic cell score:23:0.8715	0.8715	23
SCS	SCS:8	spatial contrast sensitivity:8:0.6411	0.6411	8
SCS	SCS:244	spinal cord stimulation:244:0.9803	0.9803	244
SCS	SCS:8	spinal cord stimulator:8:0.6411	0.6411	8
SCS	SCS:14|Scs:1	succinyl-CoA synthetase:15:0.5348	0.5348	15
SCs	SCs:86	synaptonemal complexes:86:0.9653	0.9653	86
SCX	SCX:39	strong cation exchange:24:0.8115|strong cation-exchange:15:0.8045	0.8115	39
SC	SC:36|sc:20	administered subcutaneously:56:0.1188	0.1188	56
SC	SC:8|sc:1	C disease:9:0.1945	0.1945	9
SC	SC:9	carcinomas:9:0.0013	0.0013	9
SC	SC:8|S-C:1	chemotherapy:9:0.0013	0.0013	9
SC	SC:9|sc:1	chloride:10:0.0014	0.0014	10
SC	SC:10	control group:10:0.2643	0.2643	10
SC	SC:10	cortex:10:0.0014	0.0014	10
SC	SC:10	culture:10:0.0014	0.0014	10
SC	Sc:3|SC:3	immature rat Sertoli cells:6:0.2243	0.2243	6
SC	SC:4|sc:1	nucleus subcoeruleus:5:0.0902	0.0902	5
sc	sc:5|SC:1	rats were injected subcutaneously:6:0.0929	0.0929	6
Sc	Sc:26|sc:9|SC:6	Saccharomyces cerevisiae:41:0.8224	0.8224	41
SC	SC:7	scatter correction:7:0.3524	0.3524	7
sc	sc:15|SC:10|Sc:2	schizophrenia:27:0.0041	0.0041	27
SC	SC:25	Schlemm's canal:25:0.4596	0.4596	25
SC	SC:123|Sc:5	Schwann cells:76:0.1500|Schwann cell:52:0.2991	0.2991	128
SC	SC:14	sclerosing cholangitis:14:0.6911	0.6911	14
SC	SC:42	scrotal circumference:42:0.7995	0.7995	42
SC	SC:9	sebaceous carcinoma:9:0.0836	0.0836	9
SC	SC:469|sc:5|Sc:1	secretory component:468:0.9224|secretory components:7:0.2902	0.9224	475
SC	SC:24	sedentary control:13:0.1005|sedentary controls:11:0.2280	0.2280	24
SC	SC:12	Selenite cystine:12:0.7571	0.7571	12
SC	SC:7|sc:1|Sc:1	self-compatible:9:0.0013	0.0013	9
SC	SC:11	semicarbazide:11:0.0016	0.0016	11
SC	SC:7|sc:1	semicircular canal:8:0.0566	0.0566	8
SC	SC:15	seroconversion:15:0.0022	0.0022	15
SC	SC:10	serum cholesterol:10:0.3145	0.3145	10
SC	SC:19	serum creatinine:19:0.7658	0.7658	19
SC	SC:13	sickle cell-haemoglobin C:13:0.7753	0.7753	13
SC	SC:23|Sc:3	sieving coefficient:16:0.3831|sieving coefficients:10:0.5000	0.5000	26
SC	SC:12	sigmoid colon:12:0.5664	0.5664	12
SC	SC:7	sildenafil citrate:7:0.1470	0.1470	7
sc	sc:37	single-chain:27:0.0041|single chain:10:0.3145	0.3145	37
SC	SC:6	sodium citrate:6:0.0899	0.0899	6
SC	SC:5	specific concordance:5:0.1132	0.1132	5
SC	SC:10	speech produced during simultaneous communication:10:0.5856	0.5856	10
SC	SC:149|sc:1|Sc:1	spinal cord:151:0.9580	0.9580	151
SC	SC:134|sc:1	spleen cells:135:0.2908	0.2908	135
SC	SC:9	splenocytes:9:0.0013	0.0013	9
SC	SC:22	standard care:22:0.3267	0.3267	22
SC	SC:23	stem cell:23:0.1010	0.1010	23
SC	SC:9	Stepped Care:9:0.0655	0.0655	9
SC	SC:11	stomach cancer:11:0.2582	0.2582	11
SC	SC:393|sc:5	stratum corneum:398:0.9664	0.9664	398
SC	SC:467|sc:217|Sc:4	subcutaneous:688:0.1075	0.1075	688
SC	SC:14|sc:4	subcutaneous injection:18:0.4934	0.4934	18
SC	SC:8|sc:1	subtilisin Carlsberg:9:0.6794	0.6794	9
SC	SC:25|sc:11	Supercoiled:36:0.0055	0.0055	36
SC	SC:12	superconducting:12:0.0017	0.0017	12
SC	SC:11|sc:3	supercritical:14:0.0020	0.0020	14
SC	SC:25	superior colliculi:25:0.8816	0.8816	25
SC	SC:920|sc:1	superior colliculus:921:0.9948	0.9948	921
SC	SC:11	supportive counseling:11:0.7357	0.7357	11
SC	SC:9|Sc:1	suprachiasmatic nucleus:10:0.5000	0.5000	10
SC	SC:24	Sydenham's chorea:24:0.5370	0.5370	24
SC	SC:227	synaptonemal complex:194:0.9204|synaptonemal complexes:33:0.8196	0.9204	227
SC	SC:9	synovial chondromatosis:9:0.6794	0.6794	9
SC	SC:13	Tc-99m sulfur colloid:13:0.3331	0.3331	13
Sd1	Sd1:6|SD1:2	Shigella dysenteriae type 1:8:0.6411	0.6411	8
SDAP	SDAP:10	spray-dried animal plasma:10:0.7103	0.7103	10
SDAT	SDAT:13	Alzheimer's disease:13:0.6701	0.6701	13
SDAT	SDAT:5	senile dementia:5:0.1132	0.1132	5
SDAT	SDAT:1	Senile dementia Alzheimer-type:1:0.6794	0.6794	1
SDAT	SDAT:196|sDAT:1	senile dementia of the Alzheimer type:197:0.9450	0.9450	197
SDAV	SDAV:21	Sialodacryoadenitis virus:21:0.7291	0.7291	21
SDApc	SDApc:4	sexually dimorphic area pars compacta:4:0.5926	0.5926	4
SDA	SDA:16	Sabouraud dextrose agar:16:0.5564	0.5564	16
SDA	SDA:27	Seventh-day Adventist:19:0.7658|Seventh-Day Adventists:8:0.5006	0.7658	27
SDA	SDA:19	sexually dimorphic area:19:0.8449	0.8449	19
SDA	SDA:20	sialodacryoadenitis:20:0.0691	0.0691	20
SDA	SDA:7	sodium diacetate:7:0.3524	0.3524	7
SDA	SDA:18	specific dynamic action:18:0.8449	0.8449	18
SDA	SDA:8	stepwise discriminant analysis:8:0.5006	0.5006	8
SDA	SDA:34	Strand Displacement Amplification:34:0.9126	0.9126	34
SDBP	SDBP:68|sDBP:3	diastolic blood pressure:71:0.8948	0.8948	71
SDBS	SDBS:6	sodium dodecyl benzene sulfonate:6:0.3728	0.3728	6
SDB	SDB:306	sleep-disordered breathing:236:0.7069|sleep disordered breathing:70:0.8919	0.8919	306
SDCC	SDCC:11	cytotoxicity:11:0.5882	0.5882	11
SDCN	SDCN:7	neurons acutely dissociated from the rat sacral dorsal commissural nucleus:7:0.4438	0.4438	7
SDCs	SDCs:9|SDCS:1	serum digoxin concentrations:10:0.7103	0.7103	10
SDC	SDC:3|sDC:2	dendritic cells:5:0.1132	0.1132	5
SDC	SDC:36|sdc:1	Salivary duct carcinoma:37:0.9197	0.9197	37
SDC	SDC:28	serum digoxin concentration:28:0.8941	0.8941	28
SDC	SDC:29	sodium deoxycholate:29:0.8422	0.8422	29
SDD	SDD:85	selective decontamination of the digestive tract:85:0.9455	0.9455	85
SDD	SDD:30	selective digestive decontamination:30:0.9011	0.9011	30
SDD	SDD:29	smallest detectable difference:29:0.8978	0.8978	29
SDD	SDD:4	standard deviation of differences:4:0.7357	0.7357	4
SDD	SDD:11	standard deviation of the difference:11:0.7357	0.7357	11
SDD	SDD:2	subantimicrobial dose of doxycycline:2:0.3945	0.3945	2
SDD	SDD:11	sulphadimidine:11:0.0321	0.0321	11
SDE	SDE:7	simultaneous distillation extraction:7:0.5664	0.5664	7
SDE	SDE:8	standard-dose epinephrine:8:0.3463	0.3463	8
SDE	SDE:13	subdural empyema:13:0.7753	0.7753	13
SDF-1	SDF-1:8|SDF1:1	Stromal cell-derived factor:9:0.6794	0.6794	9
SDF-1	SDF-1:206|SDF1:8	stromal cell-derived factor-1:124:0.9603|stromal cell-derived factor 1:75:0.9169|stromal cell derived factor-1:15:0.7909	0.9603	214
SDF-1	SDF-1:6	Stromal-derived factor:6:0.0807	0.0807	6
SDFT	SDFT:43	superficial digital flexor tendon:43:0.9308	0.9308	43
SDF	SDF:26	superficial digital flexor:26:0.8861	0.8861	26
SDGF	SDGF:16	growth factor:16:0.8165	0.8165	16
SDG	SDG:18	secoisolariciresinol diglucoside:18:0.7539	0.7539	18
SDG	SDG:19	secoisolariciresinol diglycoside:19:0.7539	0.7539	19
SDG	SDG:17	succinate dehydrogenase:17:0.5038	0.5038	17
SDG	SDG:18	sucrose density gradient:18:0.8365	0.8365	18
SDHACU	SDHACU:5	sodium-dependent high-affinity choline uptake:5:0.5926	0.5926	5
SDHs	SDHs:14	subdural hematomas:14:0.7909	0.7909	14
SDH	SDH:10	dehydrogenase activity:10:0.7103	0.7103	10
SDH	SDH:10	hypertension:10:0.0070	0.0070	10
SDH	SDH:19	serine dehydratase:19:0.5113	0.5113	19
SDH	SDH:18	step-down heating:18:0.6381	0.6381	18
SDH	SDH:37	Subdural haematoma:27:0.8903|subdural haematomas:10:0.7103	0.8903	37
SDH	SDH:84	subdural hematoma:71:0.9326|subdural hematomas:13:0.6701	0.9326	84
SDH	SDH:548|sdh:7|Sdh:3	succinate dehydrogenase:558:0.5494	0.5494	558
SDH	SDH:182|sdh:1	succinic dehydrogenase:183:0.1643	0.1643	183
SDH	SDH:9	succinodehydrogenase:9:0.0062	0.0062	9
SDH	SDH:12|sDH:1	superficial dorsal horn:13:0.4849	0.4849	13
SDIA	SDIA:12	steroid-dependent intractable asthma:12:0.7571	0.7571	12
SDI	SDI:7	Lupus International Collaborating Clinics/American College of Rheumatology Damage Index:7:0.5926	0.5926	7
SDI	SDI:46	succinate dehydrogenase inhibition:46:0.7921	0.7921	46
sdLDL	sdLDL:3|SDLDL:1	small dense LDL:4:0.6794	0.6794	4
SDLT	SDLT:10	senile dementia of Lewy body type:10:0.8165	0.8165	10
SDL	SDL:15	self-directed learning:15:0.3614	0.3614	15
SDL	SDL:8	State-Dependent Learning:8:0.1004	0.1004	8
SDL	SDL:6	step-down latency:6:0.2243	0.2243	6
SDMA	SDMA:18	symmetric dimethylarginine:18:0.4672	0.4672	18
SDMH	SDMH:16	1,2-dimethylhydrazine:16:0.7500	0.7500	16
SDMT	SDMT:17	Symbol Digit Modalities Test:17:0.8270	0.8270	17
SDM	SDM:12	shared decision making:12:0.7571	0.7571	12
SDM	SDM:12	site-directed mutagenesis:12:0.6460	0.6460	12
SDM	SDM:47	sulfadimethoxine:47:0.2289	0.2289	47
SDM	SDM:14	sulphadimethoxine:14:0.0647	0.0647	14
SDM	SDM:18	sulphadimidine:18:0.0846	0.0846	18
SDN-POA	SDN-POA:60	sexually dimorphic nucleus of the preoptic area:60:0.9286	0.9286	60
SDNN	SDNN:6	RR interval:6:0.1320	0.1320	6
SDNN	SDNN:8	standard deviation of normal R-R intervals:8:0.7357	0.7357	8
SDNN	SDNN:8	standard deviation of normal RR intervals:8:0.8365	0.8365	8
SDNR	SDNR:8	signal difference-to-noise ratio:8:0.6411	0.6411	8
SDNS	SDNS:14	steroid-dependent nephrotic syndrome:14:0.7909	0.7909	14
SDN	SDN:15	sexually dimorphic nucleus:15:0.8045	0.8045	15
SDP	SDP:14	strain distribution pattern:14:0.7909	0.7909	14
SDQ	SDQ:66	Strengths and Difficulties Questionnaire:66:0.9264	0.9264	66
SDRs	SDRs:10	short-chain dehydrogenases/reductases:10:0.5000	0.5000	10
SDRs	SDRs:6	specificity-determining residues:6:0.1838	0.1838	6
SDRs	SDRs:10	Sprague-Dawley rats:10:0.2873	0.2873	10
SDR	SDR:40	selective dorsal rhizotomy:40:0.9274	0.9274	40
SDR	SDR:86	short-chain dehydrogenase/reductase:62:0.5949|Short-chain dehydrogenases/reductases:20:0.6106|Short-chain dehydrogenase reductase:4:0.1618	0.6106	86
SDR	SDR:6	short-duration response:6:0.1010	0.1010	6
SDR	SDR:9	social disruption:9:0.6794	0.6794	9
SDR	SDR:6	Spatial Delayed Response:6:0.5290	0.5290	6
SDR	SDR:13	spontaneous dwarf rat:13:0.7753	0.7753	13
SDR	SDR:35	Sprague-Dawley rats:28:0.4193|Sprague-Dawley rat:7:0.0756	0.4193	35
SDS-CGE	SDS-CGE:9	sodium dodecyl sulfate-capillary gel electrophoresis:9:0.6794	0.6794	9
SDSL	SDSL:10	site-directed spin labeling:10:0.5856	0.5856	10
SDSs	SDSs:11	standard deviation scores:11:0.7357	0.7357	11
SDS	SDS:10	depression:10:0.0022	0.0022	10
SDS	SDS:20	height SD score:20:0.2267	0.2267	20
SDS	SDS:157	self-rating depression scale:157:0.8755	0.8755	157
SDS	SDS:24	Severity of Dependence Scale:24:0.8768	0.8768	24
SDs	SDs:8	short days:8:0.2619	0.2619	8
SDS	SDS:35	Shwachman-Diamond syndrome:35:0.1815	0.1815	35
SDS	SDS:38	Shy-Drager syndrome:38:0.2021	0.2021	38
SDS	SDS:1874|sds:1	sodium dodecyl sulfate:1875:0.9791	0.9791	1875
SDS	SDS:445	sodium dodecyl sulphate:445:0.9728	0.9728	445
SDS	SDS:165	sodium dodecylsulfate:165:0.9364	0.9364	165
SDS	SDS:52	sodium dodecylsulphate:52:0.9427	0.9427	52
SDs	SDs:83|SDS:2	standard deviations:85:0.9648	0.9648	85
SDS	SDS:402|sds:2|SDs:2	standard deviation score:261:0.9755|standard deviation scores:145:0.9794	0.9794	406
SDS	SDS:6	stent delivery system:6:0.5290	0.5290	6
SDS	SDS:35	sudden death syndrome:35:0.9151	0.9151	35
SDS	SDS:24	Symptom Distress Scale:24:0.7151	0.7151	24
SDT	SDT:40	signal detection theory:40:0.9256	0.9256	40
SDV	SDV:6	satsuma dwarf virus:6:0.2827	0.2827	6
SDX	SDX:12|Sdx:1	sulfadoxine:13:0.4800	0.4800	13
SDZ	SDZ:34	sulfadiazine:34:0.4648	0.4648	34
SDZ	SDZ:17	sulphadiazine:17:0.2254	0.2254	17
SD	SD:6	children with speech delay:6:0.3524	0.3524	6
Sd	Sd:17	Danforth's short tail:17:0.8270	0.8270	17
SD	SD:12	density:12:0.0006	0.0006	12
SD	SD:9	depletion:9:0.0004	0.0004	9
SD	SD:13	diameter:13:0.0007	0.0007	13
SD	SD:7|Sd:1	discriminative stimulus:8:0.5006	0.5006	8
SD	SD:13	duration:13:0.0007	0.0007	13
SD	SD:125|S-D:18	male Sprague-Dawley:143:0.1058	0.1058	143
sd	sd:8|Sd:2|SD:2	scalloped:12:0.0006	0.0006	12
SD	SD:21	seborrheic dermatitis:21:0.4538	0.4538	21
SD	SD:11	seborrhoeic dermatitis:11:0.1486	0.1486	11
SD	SD:26|Sd:1	segregation distorter:27:0.8903	0.8903	27
SD	SD:13	selective decontamination:13:0.5335	0.5335	13
SD	SD:20	self-directedness:20:0.0011	0.0011	20
SD	SD:28	semantic dementia:28:0.4089	0.4089	28
SD	SD:8|S-D:2	semantic differential:10:0.5856	0.5856	10
SD	SD:18	senile dementia:18:0.2109	0.2109	18
SD	SD:18	serologically defined:18:0.6381	0.6381	18
SD	SD:21	sexual dysfunction:21:0.6040	0.6040	21
SD	SD:108|S-D:4	Shine-Dalgarno:112:0.0062	0.0062	112
SD	SD:91	short-day:37:0.0020|short days:33:0.4920|short day:21:0.8594	0.8594	91
SD	SD:9	short photoperiod:9:0.2757	0.2757	9
SD	SD:19|S-D:1	single dose:11:0.1378|single-dose:9:0.0004	0.1378	20
SD	SD:171	sleep deprivation:171:0.9103	0.9103	171
SD	SD:5	sleep disorders:5:0.1132	0.1132	5
SD	SD:8	social desirability:8:0.6794	0.6794	8
SD	SD:9	solid dispersion:9:0.4587	0.4587	9
SD	SD:2	solvent and detergent:2:0.6460	0.6460	2
SD	SD:14	solvent/detergent:14:0.0007	0.0007	14
SD	SD:26	somatization disorder:26:0.5616	0.5616	26
SD	SD:39	spasmodic dysphonia:39:0.7653	0.7653	39
SD	SD:22	Spatial disorientation:22:0.8657	0.8657	22
SD	SD:11|Sd:6|sd:1	spermidine:18:0.0009	0.0009	18
SD	SD:14	splice donor:14:0.6173	0.6173	14
SD	SD:154|S-D:5|S--D:1	Sprague Dawley:150:0.9303|Sprague--Dawley:10:0.0005	0.9303	160
SD	SD:49|S-D:2	Sprague-Dawley rats:46:0.7142|Sprague-Dawley rat:5:0.0736	0.7142	51
SD	SD:284	spreading depression:284:0.9578	0.9578	284
SD	SD:9	stable:9:0.0004	0.0004	9
SD	SD:360	stable disease:360:0.8160	0.8160	360
SD	SD:237|sd:3	standard deviations:240:0.9876	0.9876	240
SD	SD:12	standard diet:12:0.2083	0.2083	12
SD	SD:20	standard dose:11:0.1378|standard-dose:9:0.0004	0.1378	20
SD	SD:10	steroid-dependent:10:0.0005	0.0005	10
SD	SD:6	striated duct:6:0.1543	0.1543	6
SD	SD:6	stroke distance:6:0.1543	0.1543	6
SD	SD:54	succinate dehydrogenase:54:0.7191	0.7191	54
SD	SD:13	sudden deafness:13:0.7753	0.7753	13
SD	SD:61	sudden death:61:0.7198	0.7198	61
SD	SD:10|Sd:1	sulfadiazine:11:0.0006	0.0006	11
SD	SD:23	swine dysentery:23:0.8715	0.8715	23
SEAP	SEAP:84|SeAP:1|seAP:1	secreted alkaline phosphatase:86:0.5654	0.5654	86
SEAR	SEAR:12	South-East Asia Region:12:0.5664	0.5664	12
SEAR	SEAR:9	surfactant-enhanced aquifer remediation:9:0.6794	0.6794	9
SEA	SEA:7	patients with stable exertional angina:7:0.4438	0.4438	7
SEA	SEA:4	Schistosoma mansoni eggs:4:0.0918	0.0918	4
SEA	SEA:201	soluble egg antigen:144:0.7249|soluble egg antigens:57:0.6160	0.7249	201
SEA	SEA:5	soluble egg antigen preparation:5:0.2818	0.2818	5
SEA	SEA:5|--SEA:1	Southeast Asia:6:0.2243	0.2243	6
SEA	SEA:9|--SEA:1	Southeast Asian:10:0.4363	0.4363	10
SEA	SEA:28	Spinal epidural abscess:28:0.8941	0.8941	28
SEA	SEA:5	spontaneous electrical activity:5:0.4422	0.4422	5
SEA	SEA:6	statistical energy analysis:6:0.5290	0.5290	6
SEBs	SEBs:13	surrogate endpoint biomarkers:13:0.7753	0.7753	13
SEB	SEB:8|SE-B:1	enterotoxin-B:9:0.0102	0.0102	9
SEB	SEB:549|seb:2	staphylococcal enterotoxin B:551:0.7958	0.7958	551
SEB	SEB:11	superantigen:11:0.0128	0.0128	11
SEB	SEB:7	surrogate endpoint biomarker:7:0.5926	0.5926	7
Sec14p	Sec14p:8	yeast phosphatidylinositol transfer protein:8:0.3463	0.3463	8
SEC1	SEC1:6	staphylococcal enterotoxin C1:6:0.2243	0.2243	6
SECIS	SECIS:49|SE-CIS:1	selenocysteine insertion sequence:50:0.6597	0.6597	50
SECM	SECM:18	scanning electrochemical microscope:18:0.8365	0.8365	18
SECM	SECM:82	Scanning electrochemical microscopy:82:0.9631	0.9631	82
SECs	SECs:69	Sinusoidal endothelial cells:69:0.9100	0.9100	69
SEDC	SEDC:14	Spondyloepiphyseal dysplasia congenita:14:0.7909	0.7909	14
SEDDS	SEDDS:10	Self-emulsifying drug delivery systems:10:0.5856	0.5856	10
SEDL	SEDL:9	spondyloepiphyseal dysplasia tarda:9:0.6794	0.6794	9
SEDT	SEDT:12|SED-T:1	spondyloepiphyseal dysplasia tarda:13:0.6701	0.6701	13
SEDS	SEDS:9	Solution Enhanced Dispersion by Supercritical Fluids:9:0.7103	0.7103	9
SED	SED:48|Sed:36|sed:1	sedentary:85:0.2507	0.2507	85
SED	SED:16	serious emotional disturbance:16:0.5564	0.5564	16
SED	SED:27	spondyloepiphyseal dysplasia:27:0.6455	0.6455	27
SED	SED:12|SE-D:1	staphylococcal enterotoxin D:13:0.5335	0.5335	13
SED	SED:15	strain energy density:15:0.7096	0.7096	15
SEEG	SEEG:12	stereoelectroencephalographic:12:0.1236	0.1236	12
SEEG	SEEG:15	stereoelectroencephalography:15:0.1573	0.1573	15
SEER	SEER:6	National Cancer Institute's Surveillance Epidemiology and End Results:6:0.9648	0.9648	6
SEE	SEE:11	energy expenditure:11:0.7357	0.7357	11
SEE	SEE:11	Salisbury Eye Evaluation:11:0.7357	0.7357	11
Se-E	Se-E:9	selenium-vitamin E:9:0.0898	0.0898	9
SEE	SEE:7	standard error of estimation:7:0.5926	0.5926	7
SEE	SEE:63	standard error of the estimate:63:0.9772	0.9772	63
SEE	SEE:12	staphylococcal enterotoxin E:12:0.4153	0.4153	12
SEF	SEF:7	ejection fraction:7:0.1850	0.1850	7
SEF	SEF:4	salivary excretion fraction:4:0.1618	0.1618	4
SEF	SEF:10	Sclerosing epithelioid fibrosarcoma:10:0.7103	0.7103	10
SEF	SEF:10	sinusoidal endothelial fenestrae:10:0.7103	0.7103	10
SEF	SEF:9	somatosensory evoked fields:9:0.6794	0.6794	9
SEF	SEF:7	somatosensory evoked magnetic fields:7:0.5926	0.5926	7
SEF	SEF:48	Spectral edge frequency:48:0.9379	0.9379	48
SEF	SEF:7	staphylococcal enterotoxin F:7:0.4438	0.4438	7
SEF	SEF:5	suction effusion fluid:5:0.4422	0.4422	5
SEF	SEF:7	supplementary eye fields:7:0.5926	0.5926	7
SEFs	SEFs:34	somatosensory evoked fields:34:0.8245	0.8245	34
SEFs	SEFs:60	somatosensory evoked magnetic fields:60:0.8525	0.8525	60
SEGAs	SEGAs:9	subependymal giant cell astrocytomas:9:0.6794	0.6794	9
SEGA	SEGA:11	subependymal giant cell astrocytoma:11:0.7357	0.7357	11
SEG	SEG:11	ganglion:11:0.1639	0.1639	11
SE-HPLC	SE-HPLC:5	size exclusion-high performance liquid chromatography:5:0.4422	0.4422	5
sEH	sEH:39|SEH:1	Soluble epoxide hydrolase:40:0.8839	0.8839	40
SEH	SEH:18	spinal epidural hematoma:18:0.8365	0.8365	18
SEH	SEH:8	subependymal hemorrhage:8:0.2619	0.2619	8
S-EIA	S-EIA:7|SEIA:4	enzyme immunoassay:11:0.6182	0.6182	11
SEIQoL	SEIQoL:14|SEIQOL:1	schedule for the evaluation of individual quality of life:15:0.8365	0.8365	15
SEIRA	SEIRA:7	surface-enhanced infrared absorption:7:0.4438	0.4438	7
SEI	SEI:13	Self-Esteem Inventory:13:0.7753	0.7753	13
SEK	SEK:14	Swedish Crowns:14:0.7909	0.7909	14
SEK	SEK:28	Swedish kronor:28:0.8941	0.8941	28
SELDI	SELDI:10	laser desorption ionization:10:0.8045	0.8045	10
SELDI	SELDI:45	Surface-enhanced laser desorption/ionization:32:0.5357|Surface Enhanced Laser Desorption/Ionization:13:0.7753	0.7753	45
SELECT	SELECT:9	Selenium and Vitamin E Cancer Prevention Trial:9:0.6794	0.6794	9
SELEX	SELEX:47	systematic evolution of ligands by exponential enrichment:47:0.8728	0.8728	47
SELEX	SELEX:6	vitro selection:6:0.1838	0.1838	6
sELISA	sELISA:6|S-ELISA:5|SELISA:3|s-ELISA:1	Sandwich enzyme-linked immunosorbent assay:15:0.6386	0.6386	15
SEL	SEL:8	size exclusion limit:8:0.6411	0.6411	8
SEL	SEL:15	socioeconomic level:15:0.5818	0.5818	15
SEL	SEL:10	Spinal epidural lipomatosis:10:0.7103	0.7103	10
SEL	SEL:24	subependymal layer:24:0.8768	0.8768	24
SEMDJL	SEMDJL:13	dysplasia with joint laxity:13:0.7571	0.7571	13
SEMD	SEMD:15	spondyloepimetaphyseal dysplasia:15:0.6386	0.6386	15
SEMFs	SEMFs:9	subepithelial myofibroblasts:9:0.6794	0.6794	9
SEMG	SEMG:17|sEMG:8	surface electromyogram:25:0.8816	0.8816	25
sEMG	sEMG:20|SEMG:17	surface electromyographic:37:0.7492	0.7492	37
SEMG	SEMG:37|sEMG:37|S-EMG:1|s-EMG:1	surface electromyography:76:0.8677	0.8677	76
sEMG	sEMG:14|SEMG:9	surface EMG:23:0.8715	0.8715	23
SEMs	SEMs:19	eye movements:19:0.8449	0.8449	19
SEMS	SEMS:6|S-EMS:1	metallic stent:7:0.1641	0.1641	7
SEMS	SEMS:6	self-expandable metallic stents:6:0.1010	0.1010	6
SEMS	SEMS:14	Self-expanding metal stents:14:0.3383	0.3383	14
SEMS	SEMS:8	Self-expanding metallic stents:8:0.2327	0.2327	8
SEMs	SEMs:8	standard errors of measurement:8:0.6794	0.6794	8
SEM	SEM:1	AVS and simultaneously extracted metals:1:0.3463	0.3463	1
SEM	SEM:19	eye movements:19:0.8365	0.8365	19
SEM	SEM:16	scanning electron:16:0.8165	0.8165	16
SEM	SEM:21	Scanning electron micrographs:21:0.8594	0.8594	21
SEM	SEM:982|sem:1	scanning electron microscope:973:0.9821|scanning electron microscopes:10:0.7103	0.9821	983
SEM	SEM:203|sEM:1	scanning electron microscopic:204:0.9687	0.9687	204
SEM	SEM:3668	scanning electron microscopy:3659:0.9883|Scanning electron-microscopy:9:0.6794	0.9883	3668
SEM	SEM:14	scanning electronmicroscopy:14:0.7909	0.7909	14
SEM	SEM:6	standard error of measurements:6:0.5926	0.5926	6
SEM	SEM:4|SEm:1	standard error of the measurement:5:0.9046	0.9046	5
SEM	SEM:14	structural equation model:14:0.7909	0.7909	14
SEM	SEM:82	structural equation modeling:82:0.9636	0.9636	82
SEM	SEM:23	Structural equation modelling:23:0.8038	0.8038	23
SEM	SEM:2	studied with scanning:2:0.0530	0.0530	2
SEM	SEM:9	subendothelial matrix:9:0.6794	0.6794	9
SENIC	SENIC:12	Study on the Efficacy of Nosocomial Infection Control:12:0.8165	0.8165	12
SENS	SENS:8|sens:6|Sens:1	Sensitivity:15:0.4242	0.4242	15
SEN	SEN:8|Sen:3|sen:1	sensitivity:12:0.1864	0.1864	12
SEOV	SEOV:11	Seoul virus:11:0.7357	0.7357	11
SEP's	SEP's:26	somatosensory evoked potentials:26:0.8251	0.8251	26
sEPSP	sEPSP:4|s-EPSP:2|S-EPSP:1	slow excitatory postsynaptic potential:7:0.3524	0.3524	7
SEPs	SEPs:15	somatosensory:15:0.0117	0.0117	15
SEPs	SEPs:933|SEPS:4	somatosensory evoked potentials:937:0.9375	0.9375	937
SEPs	SEPs:6	somatosensory evoked responses:6:0.5290	0.5290	6
SEPS	SEPS:25	subfascial endoscopic perforator surgery:25:0.7679	0.7679	25
SEPS	SEPS:14	subfascial endoscopic perforator vein surgery:14:0.7753	0.7753	14
SEPs	SEPs:18	syringe exchange programs:18:0.8365	0.8365	18
SEP	SEP:35	sclerosing encapsulating peritonitis:35:0.9151	0.9151	35
SeP	SeP:10|Se-P:2	selenoprotein P:12:0.7571	0.7571	12
SEP	SEP:19	socioeconomic position:19:0.5113	0.5113	19
SEP	SEP:43	Somatosensory:43:0.0315	0.0315	43
SEP	SEP:733	somatosensory evoked potentials:404:0.8689|somatosensory evoked potential:329:0.8869	0.8869	733
SEP	SEP:37	standard error of prediction:37:0.9197	0.9197	37
SEP	SEP:11	syringe exchange program:11:0.7357	0.7357	11
SEQ	SEQ:17	questionnaire:17:0.2586	0.2586	17
SEQ	SEQ:10	spherical equivalent:10:0.7103	0.7103	10
SERCA1	SERCA1:5|SERCa1:1|SERCA-1:1	reticulum Ca(2+)-ATPase:7:0.2902	0.2902	7
SERCA2	SERCA2:23	reticulum Ca(2+)-ATPase:23:0.5997	0.5997	23
SERCA2	SERCA2:6	sarcoplasmic reticulum:6:0.1838	0.1838	6
SERCA2	SERCA2:7	sarcoplasmic reticulum Ca2+-ATPase:7:0.2452	0.2452	7
SERCA	SERCA:6	endoplasmic reticulum:6:0.0666	0.0666	6
SERCA	SERCA:75	reticulum Ca(2+)-ATPase:75:0.6850	0.6850	75
SERCA	SERCA:84	reticulum Ca2+-ATPase:57:0.5975|reticulum Ca2+ ATPase:27:0.5951	0.5975	84
SERCA	SERCA:30	reticulum calcium ATPase:30:0.7012	0.7012	30
SEREX	SEREX:14	Serological analysis of recombinant cDNA expression libraries:14:0.6911	0.6911	14
SERM	SERM:155	selective estrogen receptor modulator:138:0.9245|selective estrogen receptor modulators:17:0.8270	0.9245	155
SERMs	SERMs:254|SERMS:9|serms:1	selective estrogen receptor modulators:264:0.9546	0.9546	264
SerRS	SerRS:23	seryl-tRNA synthetase:23:0.8715	0.8715	23
SERRS	SERRS:41	surface-enhanced resonance Raman scattering:28:0.4950|Surface enhanced resonance Raman scattering:13:0.7753	0.7753	41
SERT	SERT:247|SerT:1	serotonin transporter:229:0.7029|serotonin transporters:19:0.6106	0.7029	248
SERs	SERs:14	evoked responses:14:0.6911	0.6911	14
SERS	SERS:120	Surface-enhanced Raman scattering:97:0.7270|Surface enhanced Raman scattering:23:0.8715	0.8715	120
SERS	SERS:39	surface-enhanced Raman spectroscopy:27:0.5157|Surface enhanced Raman spectroscopy:12:0.7571	0.7571	39
SESs	SESs:11	sirolimus-eluting stents:11:0.7357	0.7357	11
SES	SES:5	Rosenberg Self-Esteem scale:5:0.1464	0.1464	5
SES	SES:52	sirolimus-eluting stent:34:0.7306|sirolimus-eluting stents:18:0.5940	0.7306	52
SES	SES:17	socioeconomic:17:0.0100	0.0100	17
SES	SES:1009|ses:1	Socioeconomic status:1010:0.8075	0.8075	1010
SEs	SEs:43	Staphylococcal enterotoxins:43:0.8300	0.8300	43
SETTLE	SETTLE:9	Spindle epithelial tumor with thymus-like differentiation:9:0.5926	0.5926	9
SETI	SETI:9	search for extraterrestrial intelligence:9:0.4587	0.4587	9
SET	SET:26	exercise test:26:0.7760	0.7760	26
SET	SET:9	single electron transfer:9:0.5470	0.5470	9
SET	SET:16	single embryo transfer:16:0.6024	0.6024	16
SEVO	SEVO:5|Sevo:3|sevo:2	sevoflurane:10:0.6000	0.6000	10
SEV	SEV:10	Saccadic eye velocity:10:0.7103	0.7103	10
SeV	SeV:81|sev:3|Sev:1|Se-V:1	Sendai virus:86:0.9449	0.9449	86
sev	sev:20|Sev:9|SEV:2	sevenless:31:0.1630	0.1630	31
SEV	SEV:10|sev:6	sevoflurane:16:0.0815	0.0815	16
Se-W	Se-W:5|SeW:4	selenoprotein W:9:0.6794	0.6794	9
SEZ	SEZ:12	subependymal zone:12:0.7571	0.7571	12
SE	SE:16	Clearfil SE Bond:16:0.8165	0.8165	16
SE	SE:51	conventional spin-echo:51:0.0639	0.0639	51
SE	SE:9	energy:9:0.0009	0.0009	9
SE	SE:15	epithelium:15:0.0016	0.0016	15
SE	SE:9	equivalents:9:0.0009	0.0009	9
SE	SE:9	exposure:9:0.0009	0.0009	9
SE	SE:37	extract:37:0.0042	0.0042	37
SE	SE:14	extraction:14:0.0015	0.0015	14
SE	SE:16	mean +/- standard error:16:0.4480	0.4480	16
SE	SE:141|Se:2	Salmonella enteritidis:143:0.7459	0.7459	143
SE	SE:18	secondary electron:18:0.6903	0.6903	18
SE	SE:9	secondary erythrocytosis:9:0.5470	0.5470	9
Se	Se:14|SE:1|se:1	Secretor:16:0.0019	0.0019	16
Se	Se:1045|SE:13|-Se:1	selenium:1059:0.1238	0.1238	1059
SE	SE:24	self-efficacy:24:0.0027	0.0027	24
SE	SE:27	self-esteem:27:0.0030	0.0030	27
Se	Se:64|SE:32|se:2	sensitivity:98:0.0113	0.0113	98
SE	SE:12	serine esterase:12:0.5050	0.5050	12
SE	SE:6	Shannon entropy:6:0.0666	0.0666	6
SE	SE:74	shared epitope:74:0.9596	0.9596	74
SE	SE:44	sheep erythrocytes:44:0.8076	0.8076	44
SE	SE:9	side effects:9:0.4587	0.4587	9
SE	SE:6	silicone elastomer:6:0.1838	0.1838	6
SE	SE:14	sleep efficiency:14:0.3585	0.3585	14
Se	Se:14|SE:3	sodium selenite:17:0.5374	0.5374	17
SE	SE:16	Southeast:16:0.0018	0.0018	16
SE	SE:203	spin echo:203:0.9482	0.9482	203
SE	SE:13	spongiform encephalopathy:13:0.4444	0.4444	13
SE	SE:20	squalene epoxidase:20:0.8525	0.8525	20
SE	SE:8	standard errors:8:0.4102	0.4102	8
SE	SE:117	Staphylococcal enterotoxins:65:0.7998|Staphylococcal enterotoxin:52:0.7938	0.7998	117
SE	SE:14	staphylococcal exotoxins:14:0.7909	0.7909	14
SE	SE:18|Se:4	staphylococcus epidermidis:22:0.6531	0.6531	22
SE	SE:14|S-E:5	Starr-Edwards:19:0.0021	0.0021	19
SE	SE:10	State Entropy:10:0.2643	0.2643	10
SE	SE:502	status epilepticus:502:0.9842	0.9842	502
SE	SE:20	stress echocardiography:20:0.5568	0.5568	20
SE	SE:11	subendothelium:11:0.0012	0.0012	11
SE	SE:29	T1- and T2-weighted spin-echo:29:0.3053	0.3053	29
SE	SE:76	T1-weighted spin-echo:76:0.1047	0.1047	76
SF(6)	SF(6):12	sulfur hexafluoride:12:0.6460	0.6460	12
SF-1293	SF-1293:11	Studies on the biosynthesis of bialaphos:11:0.7357	0.7357	11
SF-20	SF-20:16	Health Survey:16:0.6577	0.6577	16
SF-REA	SF-REA:8	restriction endonuclease analysis:8:0.6411	0.6411	8
SF/HGF	SF/HGF:37	Scatter factor/hepatocyte growth factor:37:0.9197	0.9197	37
SF-12	SF-12:25	12-Item Short-Form Health Survey:15:0.6386|12-item Short Form Health Survey:10:0.5000	0.6386	25
SF-12	SF-12:5	Medical Outcomes Study 12-Item Short Form:5:0.4422	0.4422	5
SF-12	SF-12:39|SF12:2	short form-12:20:0.7766|short form 12:13:0.7753|Short-Form 12:8:0.1196	0.7766	41
Sf21	Sf21:26|Sf-21:7|SF21:4|SF-21:2|sf21:1	Spodoptera frugiperda:40:0.9256	0.9256	40
SF2	SF2:6	superfamily 2:6:0.2243	0.2243	6
SF2	SF2:2	surviving fraction to 2 Gy:2:0.7319	0.7319	2
SF-36	SF-36:9	36-item short-form:9:0.2102	0.2102	9
SF-36	SF-36:10|SF36:1	functioning:11:0.0055	0.0055	11
SF-36	SF-36:27|SF36:2	health status:29:0.6648	0.6648	29
SF-36	SF-36:11	instrument:11:0.0055	0.0055	11
SF-36	SF-36:30	Medical Outcomes Study 36-Item Short Form:30:0.9011	0.9011	30
SF-36	SF-36:83	Medical Outcomes Study 36-Item Short-Form Health Survey:83:0.9640	0.9640	83
SF-36	SF-36:22	Medical Outcomes Study Short Form:22:0.8715	0.8715	22
SF-36	SF-36:115|SF36:1	Medical Outcomes Study Short Form-36:42:0.9291|Medical Outcomes Study Short Form 36:41:0.9274|Medical Outcomes Study Short-Form 36:19:0.8525|Medical Outcome Study Short Form-36:14:0.7909	0.9291	116
SF-36	SF-36:6	Medical Outcomes Study Short Form 36-Item Questionnaire:6:0.5290	0.5290	6
SF-36	SF-36:16	Short-Form-36:16:0.0083	0.0083	16
SF-36	SF-36:11|SF36:2	short form 36 health survey questionnaire:13:0.7753	0.7753	13
SF-36	SF-36:9	Short Form 36-item:9:0.6794	0.6794	9
SF-36	SF-36:11	Short Form 36 questionnaire:11:0.7357	0.7357	11
SF-36	SF-36:7|SF36:2	Short Form Health Survey Questionnaire:9:0.5470	0.5470	9
SF6	SF6:105	sulfur hexafluoride:105:0.7633	0.7633	105
SFAs	SFAs:44	saturated fatty acids:44:0.8941	0.8941	44
sFas	sFas:134|s-Fas:1|sFAS:1	soluble Fas:136:0.7705	0.7705	136
sFas	sFas:8|sFAS:1	soluble Fas antigen:9:0.4587	0.4587	9
SFA	SFA:18|S-FA:1	analysis:19:0.0320	0.0320	19
SFA	SFA:7	feed arteries:7:0.1470	0.1470	7
sfa	sfa:5|Sfa:1	S fimbrial adhesin:6:0.5290	0.5290	6
SFA	SFA:28	saturated:28:0.0480	0.0480	28
SFA	SFA:11	saturated FA:11:0.6182	0.6182	11
SFA	SFA:15	saturated fat:15:0.7096	0.7096	15
SFA	SFA:159|s-FA:1	saturated fatty acids:117:0.9339|Saturated fatty acid:43:0.8590	0.9339	160
SFA	SFA:9	spike frequency adaptation:9:0.6794	0.6794	9
SFA	SFA:119	superficial femoral artery:113:0.9735|superficial femoral arteries:6:0.5290	0.9735	119
SFA	SFA:9	suppressive factor of allergy:9:0.6794	0.6794	9
SFB	SFB:13	Segmented filamentous bacteria:13:0.6701	0.6701	13
SFCM	SFCM:10|SF-CM:2	serum-free conditioned medium:12:0.5664	0.5664	12
SFCs	SFCs:5|sfcs:1	spot-forming cells:6:0.2243	0.2243	6
SFC	SFC:39	spot-forming cells:27:0.3379|spot forming cells:12:0.5934	0.5934	39
SFC	SFC:100	supercritical fluid chromatography:100:0.9100	0.9100	100
SFD	SFD:40	small-for-dates:29:0.1728|small for date:11:0.6182	0.6182	40
SFD	SFD:22	Sorsby's fundus dystrophy:22:0.5863	0.5863	22
SFEMG	SFEMG:26|SF-EMG:1	single-fiber electromyography:27:0.2007	0.2007	27
SFEMG	SFEMG:16	single fiber EMG:16:0.8165	0.8165	16
SFEMG	SFEMG:17	single fibre electromyography:17:0.8270	0.8270	17
SFE	SFE:224	Supercritical fluid extraction:224:0.9715	0.9715	224
SFE	SFE:6|sfe:2	surface free energy:8:0.4102	0.4102	8
SFFQ	SFFQ:9	food frequency questionnaire:9:0.6794	0.6794	9
SFFV	SFFV:106	spleen focus-forming virus:106:0.9718	0.9718	106
SFFVp	SFFVp:11|SFFVP:3	spleen focus-forming virus:14:0.7909	0.7909	14
SFF	SFF:5	solid free-form fabrication:5:0.4422	0.4422	5
SFF	SFF:5	solid freeform fabrication:5:0.4422	0.4422	5
SFF	SFF:23	speaking fundamental frequency:23:0.7500	0.7500	23
SFGH	SFGH:23	San Francisco General Hospital:23:0.8715	0.8715	23
SFGR	SFGR:12	spotted fever group rickettsiae:12:0.7571	0.7571	12
SFGS	SFGS:14	stratum fibrosum et griseum superficiale:14:0.6911	0.6911	14
SFG	SFG:8|SfG:5	Scope for growth:13:0.5934	0.5934	13
SFG	SFG:93	spotted fever group:93:0.9679	0.9679	93
SFG	SFG:22	Sum frequency generation:22:0.8657	0.8657	22
SFG	SFG:10	superior frontal gyrus:10:0.7103	0.7103	10
SFHR	SFHR:9	small fragment homologous replacement:9:0.5470	0.5470	9
SFHS	SFHS:12	stroma-free hemoglobin solution:12:0.6460	0.6460	12
SFHb	SFHb:9|SFHB:1|SF-Hb:1	stroma-free hemoglobin:11:0.4232	0.4232	11
SFH	SFH:33	stroma-free hemoglobin:33:0.6512	0.6512	33
SFH	SFH:8	stroma-free hemoglobin solution:8:0.5006	0.5006	8
SFI	SFI:4	effect of Shenfu injection:4:0.1618	0.1618	4
SFI	SFI:21	sciatic function index:21:0.7291	0.7291	21
SFI	SFI:33	sciatic functional index:33:0.7841	0.7841	33
SFJ	SFJ:57	junction:57:0.9825	0.9825	57
SFK	SFK:19	Src family kinase:14:0.7909|Src family kinases:5:0.5290	0.7909	19
SFKs	SFKs:29	Src family kinases:29:0.9011	0.9011	29
SFL	SFL:11	spray freezing into liquid:11:0.7103	0.7103	11
SFMC	SFMC:21	soluble fibrin monomer complexes:21:0.6812	0.6812	21
SFMC	SFMC:38	synovial fluid mononuclear cells:38:0.9217	0.9217	38
SFME	SFME:20	serum-free mouse embryo:20:0.8525	0.8525	20
SF-MPQ	SF-MPQ:21|SFMPQ:7	short-form McGill pain questionnaire:21:0.3913|Short Form McGill Pain Questionnaire:7:0.8045	0.8045	28
SFM	SFM:25	scanning force microscope:25:0.8816	0.8816	25
SFM	SFM:74	scanning force microscopy:74:0.9159	0.9159	74
SFM	SFM:12	screen-film mammography:12:0.7571	0.7571	12
SFM	SFM:19	serum-free media:19:0.5113	0.5113	19
SFM	SFM:70	serum-free medium:70:0.6685	0.6685	70
SFM	SFM:14|SfM:1	structure-from-motion:15:0.0387	0.0387	15
SFN	SFN:20	Sulforaphane:20:0.3016	0.3016	20
SFO	SFO:17	safflower oil:17:0.2788	0.2788	17
SFO	SFO:401|sfo:1	subfornical organ:402:0.9925	0.9925	402
SFO	SFO:17	sunflower oil:17:0.2788	0.2788	17
SFPC	SFPC:11	State Family Planning Commission:11:0.7357	0.7357	11
SFP	SFP:28|sfp:1	screen filtration pressure:29:0.8978	0.8978	29
SFP	SFP:35	stop-flow pressure:35:0.3384	0.3384	35
SFRP1	SFRP1:4|sFRP1:1	Secreted Frizzled-related protein 1:5:0.4422	0.4422	5
SFR	SFR:6	salivary flow rate:6:0.2243	0.2243	6
SFs	SFs:5	Skin fibroblasts:5:0.0612	0.0612	5
SFS	SFS:12	Social Functioning Scale:12:0.7571	0.7571	12
SFs	SFs:8	stress fibers:8:0.4102	0.4102	8
SFS	SFS:13	synchronous fluorescence spectrophotometry:13:0.7753	0.7753	13
SFS	SFS:10	synchronous fluorescence spectroscopy:10:0.7103	0.7103	10
SFs	SFs:6	Synovial fibroblasts:6:0.1320	0.1320	6
SFs	SFs:10	Synovial fluids:10:0.4363	0.4363	10
SFTs	SFTs:23	solitary fibrous tumors:23:0.8715	0.8715	23
SFT	SFT:6	Sabin-Feldman Test:6:0.0807	0.0807	6
SFT	SFT:25	skinfold thickness:25:0.4315	0.4315	25
SFT	SFT:118	solitary fibrous tumor:89:0.9664|solitary fibrous tumour:17:0.8270|Solitary fibrous tumors:12:0.7571	0.9664	118
SFV-1	SFV-1:16|SFV1:1	simian foamy virus type 1:17:0.8270	0.8270	17
SFV	SFV:482	Semliki Forest Virus:482:0.9867	0.9867	482
SFV	SFV:8	Simian Foamy viruses:8:0.5006	0.5006	8
sFv	sFv:15|SFv:1	single-chain antibody:16:0.4832	0.4832	16
sFv	sFv:36|SFv:1	single-chain Fv:37:0.7758	0.7758	37
SFv	sFv:2|SFv:2	single-chain variable fragment:4:0.0918	0.0918	4
SFV	SFV:24	superficial femoral vein:24:0.8768	0.8768	24
SF	SF:17	fibers:17:0.0053	0.0053	17
Sf	Sf:10	flotation rate:10:0.7103	0.7103	10
SF	SF:12|Sf:1	fractions:13:0.0040	0.0040	13
SF	SF:17	saturated fat:17:0.3366	0.3366	17
SF	SF:7|S-F:2	screen-film:9:0.0026	0.0026	9
sf	sf:26	scurfy:26:0.0083	0.0083	26
SF	SF:6	seizure free:6:0.1543	0.1543	6
SF	SF:130|sF:2|S-f:1	Serum ferritin:133:0.9315	0.9315	133
SF	SF:10|s-F:2	serum folate:12:0.7571	0.7571	12
SF	SF:41|S-F:1|sf:1	serum-free:43:0.0139	0.0139	43
SF	SF:7	sexual function:7:0.1211	0.1211	7
SF	SF:11	sham feeding:11:0.4232	0.4232	11
SF	SF:10	short-term fluctuation:10:0.3470	0.3470	10
SF	SF:53	shortening fraction:53:0.3460	0.3460	53
SF	SF:27	silk fibroin:27:0.7425	0.7425	27
SF	SF:21	skin fibroblasts:21:0.3899	0.3899	21
SF	SF:9	Slaframine:9:0.0026	0.0026	9
SF	SF:21	social functioning:21:0.8594	0.8594	21
SF	SF:21	sodium ferulate:21:0.8594	0.8594	21
SF	SF:6	soluble fiber:6:0.0611	0.0611	6
SF	SF:36|sF:1	soluble fibrin:37:0.9197	0.9197	37
SF	SF:13|sf:1	sorbitol-fermenting:14:0.0043	0.0043	14
SF	SF:8	space flight:8:0.5006	0.5006	8
SF	SF:46|sf:1	spatial frequency:47:0.3957	0.3957	47
Sf	Sf:16|SF:4	Spodoptera frugiperda:20:0.7766	0.7766	20
SF	SF:15	spotted fever:15:0.3110	0.3110	15
SF	SF:101	Steel Factor:101:0.2943	0.2943	101
SF	SF:21	stone formers:21:0.8594	0.8594	21
SF	SF:13|Sf:1	sulforaphane:14:0.0043	0.0043	14
SF	SF:9	superficial:9:0.0026	0.0026	9
SF	SF:12	suppressor factors:12:0.2549	0.2549	12
SF	SF:8|Sf:1	surfactant:9:0.0026	0.0026	9
SF	SF:19	surviving fraction:19:0.0856	0.0856	19
SF	SF:5	sustained field:5:0.0736	0.0736	5
SF	SF:11	sylvian fissure:11:0.7357	0.7357	11
SF	SF:11|S-F:1	symphysis-fundus:12:0.0036	0.0036	12
SF	SF:13	synovial fibroblasts:13:0.1762	0.1762	13
SF	SF:976|Sf:1|sf:1	synovial fluid:887:0.9494|synovial fluids:91:0.8400	0.9494	978
SG-G100	SG-G100:10	salmon gonadotropin:10:0.7103	0.7103	10
SGAP	SGAP:5|S-GAP:4	superior gluteal artery perforator:9:0.6794	0.6794	9
SGAs	SGAs:9	second-generation antipsychotics:9:0.4587	0.4587	9
SGA	SGA:977	small for gestational age:617:0.9590|small-for-gestational-age:231:0.1770|small-for-gestational age:129:0.1379	0.9590	977
SGA	SGA:16	small for gestational age infants:16:0.8165	0.8165	16
SGA	SGA:96	Subjective global assessment:96:0.9500	0.9500	96
SGB	SGB:67	stellate ganglion block:67:0.9554	0.9554	67
SGBS	SGBS:30	Simpson-Golabi-Behmel Syndrome:30:0.7315	0.7315	30
SGCs	SGCs:23	spiral ganglion cells:23:0.8715	0.8715	23
SGC	SGC:9	gland carcinoma:9:0.6794	0.6794	9
SGC	SGC:14	small granule-containing:14:0.7909	0.7909	14
SGC	SGC:5|sgc:1	soft-gel capsule:6:0.1010	0.1010	6
sGC	sGC:221|SGC:5|s-GC:1	soluble guanylate cyclase:227:0.9066	0.9066	227
sGC	sGC:210|SGC:7	soluble guanylyl cyclase:217:0.9392	0.9392	217
SGC	SGC:14	spiral ganglion cell:8:0.5006|spiral ganglion cells:6:0.2243	0.5006	14
SGC	SGC:14|sgc:1	stratum griseum centrale:15:0.7096	0.7096	15
SGD	SGD:11	granule deficiency:11:0.7357	0.7357	11
SGD	SGD:17	Saccharomyces Genome Database:17:0.7539	0.7539	17
SGD	SGD:13	specific growth delay:13:0.7753	0.7753	13
SGF	SGF:29	growth factor:29:0.8369	0.8369	29
SGF	SGF:39	simulated gastric fluid:39:0.7860	0.7860	39
SGF	SGF:6	slow graft function:6:0.2827	0.2827	6
SGGLs	SGGLs:8	sulfoglucuronyl glycolipids:8:0.2327	0.2327	8
SGG	SGG:13	Sulfogalactosylglycerolipid:13:0.1791	0.1791	13
sGH	sGH:8|s-GH:2|S-GH:1	growth hormone:11:0.7357	0.7357	11
SGI1	SGI1:13	Salmonella genomic island 1:13:0.7753	0.7753	13
Sgk1	Sgk1:3|SGK1:2|sgk1:1|SGK-1:1	serum- and glucocorticoid-regulated kinase:7:0.4438	0.4438	7
SGLT	SGLT:20	cotransporter:20:0.5278	0.5278	20
SGLT1	SGLT1:5|SGLT-1:4	cotransporter 1:9:0.2126	0.2126	9
SGLT1	SGLT1:21|SGLT-1:2	glucose transporter:23:0.4486	0.4486	23
SGLT1	SGLT1:5|SGLT-1:2	glucose transporter 1:7:0.2902	0.2902	7
SGLT1	SGLT1:11|SGLT-1:1	Na+/glucose co-transporter:12:0.3058	0.3058	12
SGLT1	SGLT1:47	Na+/glucose cotransporter:47:0.2837	0.2837	47
SGL	SGL:11	Superficial gray layer:11:0.7357	0.7357	11
SGML	SGML:9	Standard Generalized Markup Language:9:0.6794	0.6794	9
SGNs	SGNs:26	spiral ganglion neurons:26:0.8861	0.8861	26
SGOT	SGOT:107|sGOT:3|s-GOT:1|SGO-T:1	serum glutamic oxaloacetic transaminase:112:0.8233	0.8233	112
SGO	SGO:11	Society of Gynecologic Oncologists:11:0.7357	0.7357	11
SGO	SGO:7	splanchnic glucose output:7:0.5926	0.5926	7
SGP-1	SGP-1:16	sulfated glycoprotein-1:16:0.8165	0.8165	16
SGP-2	SGP-2:62|Sgp-2:2|SGP2:1|sgp-2:1	Sulfated glycoprotein-2:50:0.8068|sulfated glycoprotein 2:16:0.7261	0.8068	66
SGPB	SGPB:13	Streptomyces griseus protease B:13:0.6701	0.6701	13
SGPG	SGPG:40	paragloboside:40:0.8667	0.8667	40
SGPT	SGPT:22	alanine aminotransferase:22:0.6934	0.6934	22
SGPT	SGPT:38|S-GPT:2	Serum glutamic-pyruvic transaminase:40:0.6808	0.6808	40
SGP-T	SGP-T:9	Submandibular gland peptide-T:9:0.6794	0.6794	9
SGPs	SGPs:9	sialoglycoproteins:9:0.2667	0.2667	9
SGP	SGP:5	cell surface sialoglycopeptide:5:0.4422	0.4422	5
SGP	SGP:9|sGP:5|S-GP:1	glycoprotein:15:0.0778	0.0778	15
SGP	SGP:15|Sgp:1	sialoglycoprotein:16:0.0833	0.0833	16
SGP	SGP:9	strain gauge plethysmography:9:0.6794	0.6794	9
SGP	SGP:10	stratum griseum profundum:10:0.7103	0.7103	10
SGRQ	SGRQ:112	George's Respiratory Questionnaire:112:0.7368	0.7368	112
SGR	SGR:13	growth rate:13:0.7753	0.7753	13
SGs	SGs:8|SGS:1	salivary glands:9:0.1690	0.1690	9
SGs	SGs:11	secretory granules:11:0.1938	0.1938	11
SGS	SGS:68	stratum griseum superficiale:68:0.8706	0.8706	68
SGs	SGs:14	stress granules:14:0.3039	0.3039	14
SGS	SGS:28	subglottic stenosis:28:0.8941	0.8941	28
SGS	SGS:7	superficial gray layer:7:0.5926	0.5926	7
SGs	SGs:8	sweat glands:8:0.1276	0.1276	8
SGS	SGS:14	syndrome:14:0.0491	0.0491	14
SGTCs	SGTCs:3|sGTCS:2|SGTCS:1	secondarily generalized tonic-clonic seizures:6:0.3728	0.3728	6
SGU	SGU:12	Splanchnic glucose uptake:12:0.7571	0.7571	12
SGV	SGV:8	small granular vesicles:8:0.6411	0.6411	8
SGZ	SGZ:29	subgranular zone:29:0.7970	0.7970	29
SGI	SGI:14	stratum griseum intermediale:14:0.7909	0.7909	14
SG	SG:9|Sg:3	glucose effectiveness at basal insulin:12:0.7571	0.7571	12
SG	SG:13|sg:4|Sg:1	pneumophila serogroup:18:0.5732	0.5732	18
SG	SG:48	salivary gland:28:0.3896|salivary glands:20:0.3614	0.3896	48
SG	SG:9	Santa Gertrudis:9:0.6794	0.6794	9
SG	SG:14	sarcoglycan:14:0.0093	0.0093	14
SG	SG:9	sclareol glycol:9:0.3945	0.3945	9
SG	SG:24|Sg:2	secretory granules:26:0.6455	0.6455	26
SG	SG:5	soybean-derived sterylglucoside:5:0.0902	0.0902	5
SG	SG:66|sg:1	specific gravity:67:0.9554	0.9554	67
SG	SG:27	spiral ganglion:27:0.2299	0.2299	27
sg	sg:12|SG:1	staggerer:13:0.0086	0.0086	13
SG	SG:27	stellate ganglion:27:0.2299	0.2299	27
SG	SG:15	stratum granulosum:15:0.8045	0.8045	15
SG	SG:16|sg:1	study group:17:0.1758	0.1758	17
sg	sg:38|SG:5	subgenomic:43:0.0302	0.0302	43
SG	SG:99	substantia gelatinosa:99:0.9698	0.9698	99
SG	SG:11	subtotal gastrectomy:11:0.3495	0.3495	11
SG	SG:11	superficial gastritis:11:0.6182	0.6182	11
SG	SG:12|Sg:9	suprageniculate nucleus:21:0.8594	0.8594	21
SG	SG:13	sympathetic ganglia:13:0.3331	0.3331	13
SH1	SH1:7	reactive thiol:7:0.3524	0.3524	7
SH3	SH3:342|SH-3:2	Src homology 3:332:0.9807|Src homology-3:12:0.7571	0.9807	344
SHAM	SHAM:5|sham:4	Control rats:9:0.0655	0.0655	9
SHAM	SHAM:46	salicylhydroxamic acid:46:0.7707	0.7707	46
sham	sham:8|SHAM:2	sham-adrenalectomized:10:0.0083	0.0083	10
sham	sham:167|SHAM:107|Sham:7	Sham-operated:238:0.2180|sham operated:43:0.9323	0.9323	281
sham	sham:5|SHAM:4|Sham:2	sham-operated animals:11:0.3495	0.3495	11
sham	sham:9|SHAM:8	sham-operated controls:17:0.2379	0.2379	17
sham	sham:6|SHAM:1	sham-operated group:7:0.0828	0.0828	7
sham	sham:12|SHAM:9	sham-operated rats:21:0.3044	0.3044	21
sham	sham:52|SHAM:32	sham operation:63:0.9253|sham operations:11:0.6182|sham-operation:10:0.0083	0.9253	84
SHAM	SHAM:14|sham:9|Sham:1	sham surgery:24:0.7593	0.7593	24
SHA	SHA:6	humic acid:6:0.0564	0.0564	6
SHA	SHA:8	salicylhydroxamic acid:8:0.1367	0.1367	8
SHA	SHA:13|sHA:11|S-HA:7	saliva-coated hydroxyapatite:31:0.5117	0.5117	31
SHA	SHA:15	sinusoidal harmonic acceleration:15:0.5348	0.5348	15
SHa	SHa:18	Syrian hamster:18:0.8365	0.8365	18
SHBG	SHBG:1488|sHBG:1	sex hormone-binding globulin:772:0.9712|sex hormone binding globulin:708:0.9462|sex-hormone-binding-globulin:9:0.0050	0.9712	1489
SHBG	SHBG:7	sex hormone binding globuline:7:0.3524	0.3524	7
SHCC	SHCC:9|s-HCC:1	hepatocellular carcinoma:10:0.5856	0.5856	10
SHCS	SHCS:20	Swiss HIV Cohort Study:20:0.8525	0.8525	20
SHC	SHC:14	spontaneously hypercholesterolemic:14:0.7909	0.7909	14
SHC	SHC:15|shc:1	Squalene-hopene cyclase:16:0.5564	0.5564	16
Shc	Shc:4	Src homology and collagen:4:0.4422	0.4422	4
SHC	SHC:3|Shc:3	src homology and collagen protein:6:0.5290	0.5290	6
SHD	SHD:9	homology domain:9:0.5470	0.5470	9
SHD	SHD:7	structural heart disease:7:0.5926	0.5926	7
SHEP	SHEP:104	Systolic Hypertension in the Elderly Program:104:0.9715	0.9715	104
SHE	SHE:23	subclinical hepatic encephalopathy:23:0.8038	0.8038	23
SHE	SHE:230	Syrian hamster embryo:230:0.9428	0.9428	230
SHFJV	SHFJV:8	superimposed high-frequency jet ventilation:8:0.5006	0.5006	8
SHFM	SHFM:18	malformation:18:0.7727	0.7727	18
SHFV	SHFV:13	simian hemorrhagic fever virus:13:0.7753	0.7753	13
SHF	SHF:10	schistosomal hepatic fibrosis:10:0.7103	0.7103	10
SHF	SHF:11	simian hemorrhagic fever:11:0.7357	0.7357	11
SHF	SHF:8	systolic heart failure:8:0.4102	0.4102	8
SHG	SHG:112	second-harmonic generation:60:0.4281|second harmonic generation:52:0.9099	0.9099	112
SHG	SHG:20	sonohysterography:20:0.0880	0.0880	20
SHG	SHG:7	static handgrip:7:0.1329	0.1329	7
SHG	SHG:9	Sustained Handgrip:9:0.2500	0.2500	9
SHHF	SHHF:16	spontaneously hypertensive heart failure:16:0.7261	0.7261	16
SHHS	SHHS:12	Sleep Heart Health Study:12:0.4557	0.4557	12
Shh	Shh:516|SHH:110|shh:54|SHh:1	Sonic hedgehog:681:0.9956	0.9956	681
SHH	SHH:6|Shh:2|shh:1	Sonic hedgehog protein:9:0.6794	0.6794	9
SHIP	SHIP:18	inositol 5-phosphatase:18:0.4934	0.4934	18
SHIP	SHIP:37	inositol phosphatase:37:0.5929	0.5929	37
SHIVs	SHIVs:20	immunodeficiency viruses:20:0.4786	0.4786	20
SHIV	SHIV:138	immunodeficiency virus:126:0.8800|immunodeficiency viruses:12:0.6460	0.8800	138
SHI	SHI:15	health insurance:15:0.8045	0.8045	15
SHI	SHI:11	second harmonic imaging:11:0.6182	0.6182	11
SHI	SHI:33	severe head injury:33:0.9100	0.9100	33
shi	shi:25	shiverer:25:0.1714	0.1714	25
SHKS	SHKS:10	Supplemented hypokinetic subjects:10:0.7103	0.7103	10
SHL	SHL:40	hearing loss:40:0.8839	0.8839	40
SHML	SHML:92	sinus histiocytosis with massive lymphadenopathy:92:0.9679	0.9679	92
SHMT	SHMT:92|shmt:1	serine hydroxymethyltransferase:93:0.9675	0.9675	93
SHM	SHM:9	spirohydantoin mustard:9:0.6794	0.6794	9
SHNs	SHNs:7	septo-hippocampal neurons:7:0.2902	0.2902	7
Shn	Shn:6|shn:5	schnurri:11:0.3030	0.3030	11
SHOs	SHOs:69	senior house officers:69:0.9567	0.9567	69
SHP-1	SHP-1:20|SHP1:1	phosphatase 1:21:0.6400	0.6400	21
SHP-1	SHP-1:13	protein tyrosine phosphatase-1:13:0.3134	0.3134	13
SHP-1	SHP-1:9	tyrosine phosphatase:9:0.3069	0.3069	9
SHPT	SHPT:41|sHPT:15	secondary hyperparathyroidism:56:0.9162	0.9162	56
SHP	SHP:18	Schonlein-Henoch purpura:18:0.6903	0.6903	18
SHP	SHP:18|sHP:1	secondary hyperparathyroidism:19:0.8449	0.8449	19
SHP	SHP:19	Short heterodimer partner:19:0.2095	0.2095	19
SHP	SHP:33|Shp:1	small heterodimer partner:34:0.4895	0.4895	34
SHP	SHP:16	summer-type hypersensitivity pneumonitis:16:0.8165	0.8165	16
SHR-R	SHR-R:7	NaCl-resistant SHR:7:0.3524	0.3524	7
SHRP	SHRP:16	stress hyporesponsive period:16:0.8165	0.8165	16
SHRSPs	SHRSPs:27|SHR-SPs:6	stroke-prone spontaneously hypertensive rats:33:0.8644	0.8644	33
SHRSP	SHRSP:6|SHR-sp:1|SHRsp:1	spontaneously hypertensive rats of the stroke-prone strain:4:0.4422|spontaneously hypertensive rats of the stroke prone strain:4:0.3170	0.4422	8
SHRSP	SHRSP:6|SHR-SP:2|SHRsp:1	spontaneously hypertensive stroke-prone:9:0.5934	0.5934	9
SHRSP	SHRSP:26|SHR-SP:10|SHRsp:2	Stroke-prone spontaneously hypertensive:38:0.8098	0.8098	38
SHRSP	SHRSP:669|SHR-SP:54|SHRsp:33|SHR-sp:7	stroke-prone spontaneously hypertensive rats:700:0.9128|stroke-prone spontaneously hypertensive rat:63:0.8283	0.9128	763
SHRSR	SHRSR:13	stroke-resistant spontaneously hypertensive rats:13:0.5934	0.5934	13
SHRV	SHRV:10	snakehead rhabdovirus:10:0.7103	0.7103	10
SHRs	SHRs:595|SHR-S:24|SHRS:2	spontaneously hypertensive rats:621:0.9624	0.9624	621
SHR	SHR:9	heart rate:9:0.1690	0.1690	9
SHR	SHR:11	Okamoto strain:11:0.1547	0.1547	11
SHR	SHR:20	rats with spontaneous hypertension:20:0.4538	0.4538	20
SHR	SHR:9	spontaneous histamine release:9:0.6794	0.6794	9
SHR	SHR:6203|shr:1	spontaneously hypertensive rats:5217:0.9685|Spontaneously Hypertensive Rat:987:0.9678	0.9685	6204
SHR	SHR:3	spontaneously hypertensive rats of the Munster strain:3:0.4422	0.4422	3
SHR	SHR:7	spontaneously hypertensive rate:7:0.4438	0.4438	7
sHSP	sHSP:33|sHsp:20|shsp:7|s-hsp:1	small heat shock protein:29:0.8978|Small heat shock proteins:20:0.8525|small heat-shock protein:12:0.7571	0.8978	61
SH-SY5Y	SH-SY5Y:37|SHSY-5Y:2|SHSY5Y:1	human neuroblastoma:40:0.6808	0.6808	40
SH-SY5Y	SH-SY5Y:24|SH-SY-5Y:1|SHSY5Y:1	human neuroblastoma cells:26:0.5616	0.5616	26
SH-SY5Y	SH-SY5Y:12	human neuroblastoma cell line:12:0.3524	0.3524	12
SHS	SHS:21	secondhand smoke:21:0.3317	0.3317	21
SHS	SHS:17	sliding hip screw:17:0.8270	0.8270	17
SHS	SHS:17	Strong Heart Study:17:0.8270	0.8270	17
SHS	SHS:15	Swollen Head Syndrome:15:0.8045	0.8045	15
SHT	SHT:11	severe head trauma:11:0.7357	0.7357	11
sHT	sHT:8|SHT:3	subclinical hypothyroidism:11:0.7357	0.7357	11
SHV-1	SHV-1:6|SHV1:3	suid herpesvirus 1:9:0.6794	0.6794	9
SH	SH:11	hepatitis:11:0.0048	0.0048	11
SH	SH:8|Sh:1	hypotension:9:0.0039	0.0039	9
SH	SH:10	protein:10:0.0043	0.0043	10
SH	SH:8	sclerosing hemangioma:8:0.3463	0.3463	8
SH	SH:10	secondary hyperparathyroidism:10:0.7103	0.7103	10
SH	SH:9	secondary hypertension:9:0.0836	0.0836	9
SH	SH:9	severe hypoglycaemia:9:0.6794	0.6794	9
SH	SH:19	severe hypoglycemia:19:0.7658	0.7658	19
Sh	Sh:32	Shaker:32:0.0149	0.0149	32
SH	SH:39|Sh:11	Sham-operated:41:0.0193|sham operated:9:0.6794	0.6794	50
SH	SH:7	sham-operated controls:7:0.2902	0.2902	7
SH	SH:14|Sh:3|sh:1	sham operation:18:0.8365	0.8365	18
SH	SH:8	Sima de los Huesos:8:0.5006	0.5006	8
SH	SH:6	simple hyperplasia:6:0.0899	0.0899	6
SH	SH:16	sinus histiocytosis:16:0.7261	0.7261	16
SH	SH:18	sitting height:18:0.4934	0.4934	18
SH	SH:51	small hydrophobic:51:0.9082	0.9082	51
SH	SH:22	sodium hyaluronate:22:0.7955	0.7955	22
SH	SH:8	soybean hulls:8:0.5006	0.5006	8
SH	SH:11	spigelian hernia:11:0.7357	0.7357	11
SH	SH:259	spontaneously hypertensive:259:0.9133	0.9133	259
SH	SH:6	squamous hyperplasia:6:0.0899	0.0899	6
SH	SH:109	src homology:97:0.9352|Src-homology:12:0.0053	0.9352	109
SH	SH:39	standard heparin:39:0.7860	0.7860	39
SH	SH:13|Sh:1	sternohyoid:14:0.0063	0.0063	14
S-H	S-H:6|SH:1	stimulus-to-His bundle:7:0.3524	0.3524	7
SH	SH:33|sH:1	subclinical hypothyroidism:34:0.9126	0.9126	34
SH	SH:10	subcortical hyperintensities:10:0.7103	0.7103	10
SH	SH:5	subtractive hybridization:5:0.0517	0.0517	5
SH	SH:222|-SH:63|--SH:3|S-H:2	sulfhydryl:277:0.1330|sulfhydryls:13:0.0058	0.1330	290
SH	SH:21|-SH:10|--SH:1|S-H:1	sulfhydryl groups:23:0.3697|sulfhydryl group:10:0.1878	0.3697	33
SH	SH:25|-SH:10	sulphydryl:35:0.0164	0.0164	35
-SH	-SH:7|SH:5	sulphydryl groups:12:0.1262	0.1262	12
SH	SH:8	systemic hypertension:8:0.0625	0.0625	8
-SH	-SH:34|SH:31	thiol:55:0.0260|thiols:10:0.0043	0.0260	65
SIADH	SIADH:127	syndrome of inappropriate antidiuretic hormone secretion:127:0.8733	0.8733	127
SIADH	SIADH:19	syndrome of inappropriate secretion of ADH:19:0.6106	0.6106	19
SIADH	SIADH:214	syndrome of inappropriate secretion of antidiuretic hormone:214:0.8277	0.8277	214
SIAD	SIAD:14	syndrome of inappropriate antidiuresis:14:0.7909	0.7909	14
SIAM	SIAM:13	swift increase in alcohol metabolism:13:0.7753	0.7753	13
SIAs	SIAs:11	immunization activities:11:0.7357	0.7357	11
s-IBM	s-IBM:47|sIBM:9|S-IBM:3|SIBM:1	Sporadic inclusion body myositis:42:0.8558|sporadic inclusion-body myositis:18:0.8365	0.8558	60
SIBO	SIBO:29	Small intestinal bacterial overgrowth:29:0.9011	0.9011	29
SIB	SIB:220	self-injurious behavior:197:0.9215|Self-injurious behaviour:23:0.6653	0.9215	220
SIB	SIB:16	Severe Impairment Battery:16:0.8165	0.8165	16
SIB	SIB:11	simultaneous integrated boost:11:0.7357	0.7357	11
SICH	SICH:5|sICH:1	spontaneous intracerebral hemorrhage:6:0.3728	0.3728	6
SICH	SICH:4|sICH:2	symptomatic intracranial hemorrhage:6:0.3728	0.3728	6
SICI	SICI:19	short-interval intracortical inhibition:10:0.1385|short interval intracortical inhibition:9:0.6794	0.6794	19
SICRI	SICRI:12	immunologically cross-reactive with insulin:12:0.5664	0.5664	12
SICU	SICU:17	Surgical ICU:17:0.8270	0.8270	17
SICU	SICU:173|sICU:2	surgical intensive care unit:175:0.9553	0.9553	175
SiC	SiC:33|SIC:1	Silicon carbide:34:0.8644	0.8644	34
SIC	SIC:11	specific inhalation challenge:11:0.7357	0.7357	11
SIC	SIC:10|Sic:8	streptococcal inhibitor of complement:18:0.8365	0.8365	18
SIDD	SIDD:8	duplex destabilization:8:0.5006	0.5006	8
SIDP	SIDP:9	Structured Interview for DSM-III Personality Disorders:9:0.7571	0.7571	9
SIDS	SIDS:30	sudden infant death:30:0.7652	0.7652	30
SIDS	SIDS:1572	Sudden infant death syndrome:1572:0.9871	0.9871	1572
SID	SID:7|sid:1	interaction domain:8:0.1895	0.1895	8
SID	SID:17	strong ion difference:17:0.7407	0.7407	17
SID	SID:62	sudden infant death:62:0.9229	0.9229	62
SID	SID:19	Surface-induced dissociation:19:0.7658	0.7658	19
SIFA	SIFA:10	immunofluorescence assay:10:0.7103	0.7103	10
SIFT-MS	SIFT-MS:24	selected ion flow tube mass spectrometry:24:0.8816	0.8816	24
Sifs	Sifs:10	Salmonella-induced filaments:10:0.7103	0.7103	10
SIF	SIF:8	Serum inhibitory factors:8:0.5006	0.5006	8
SIF	SIF:109	small intensely fluorescent:109:0.9633	0.9633	109
SIGCs	SIGCs:9	spontaneously immortalized granulosa cells:9:0.6794	0.6794	9
SIH	SIH:12	salicylaldehyde isonicotinoyl hydrazone:12:0.5664	0.5664	12
SIH	SIH:55	Spontaneous intracranial hypotension:55:0.9147	0.9147	55
SIH	SIH:20	Stress-induced hyperthermia:20:0.8525	0.8525	20
SIII	SIII:12	type III pneumococcal polysaccharide:12:0.4363	0.4363	12
SII	SII:5	bilateral second sensory cortices:5:0.4422	0.4422	5
SII	SII:12|S-II:1	second somatosensory:13:0.2415	0.2415	13
SII	SII:30|S-II:1	second somatosensory area:31:0.5749	0.5749	31
SII	SII:25	second somatosensory cortex:25:0.1800	0.1800	25
SII	SII:14	secondary somatosensory:14:0.2758	0.2758	14
SII	SII:59|S-II:2	secondary somatosensory cortex:61:0.5905	0.5905	61
SII	SII:9	secondary somatosensory cortices:9:0.4587	0.4587	9
SII	SII:18	Speech Intelligibility Index:18:0.8365	0.8365	18
SIJ	SIJ:36	sacroiliac joint:36:0.8336	0.8336	36
SIK	SIK:11	salt-inducible kinase:11:0.5355	0.5355	11
SILAC	SILAC:3	stable isotope labeling with amino acids in cell culture:3:0.6794	0.6794	3
SILs	SILs:122	squamous intraepithelial lesions:122:0.9482	0.9482	122
SIL	SIL:252	squamous intraepithelial lesions:148:0.9382|squamous intraepithelial lesion:104:0.9538	0.9538	252
SIMA	SIMA:13	small intestinal mucin antigen:13:0.7357	0.7357	13
SIMCA	SIMCA:23	soft independent modeling of class analogy:23:0.8186	0.8186	23
SIMCA	SIMCA:14	soft independent modelling of class analogy:14:0.8045	0.8045	14
SIMS	SIMS:147|SI-MS:5	secondary ion mass spectrometry:152:0.9686	0.9686	152
SIMS	SIMS:17	secondary ion mass spectroscopy:17:0.7407	0.7407	17
SIMV	SIMV:41|sIMV:1	synchronized intermittent mandatory ventilation:42:0.6280	0.6280	42
sim	sim:8|SIM:2	Drosophila single-minded:10:0.1223	0.1223	10
SIM	SIM:11	Sandimmune:11:0.0150	0.0150	11
SIM	SIM:251	selected ion monitoring:251:0.7048	0.7048	251
SIM	SIM:10	selected ion monitoring mode:10:0.3145	0.3145	10
sim	sim:9|SIM:5|Sim:1	simvastatin:15:0.0210	0.0210	15
SIM	SIM:18	specialized intestinal metaplasia:18:0.5940	0.5940	18
SIN-1	SIN-1:7	3-morpholino sydnonimine:7:0.1850	0.1850	7
SIN-1	SIN-1:22|SIN1:1	3-morpholinosydnonimine hydrochloride:23:0.3399	0.3399	23
SIN-1	SIN-1:8	3-morpholinosydnonimine N-ethylcarbamide:8:0.3463	0.3463	8
SIN-1	SIN-1:4	donor 3-morpholinosydnonimine-N-ethylcarbamide:4:0.0736	0.0736	4
SIN-1	SIN-1:21|Sin-1:1	linsidomine:22:0.0376	0.0376	22
SIN-1	SIN-1:10	linsidomine chlorhydrate:10:0.5856	0.5856	10
SIN-1	SIN-1:5	nitric oxide donor 3-morpholinosydnonimine:5:0.7103	0.7103	5
SINEs	SINEs:54	short interspersed elements:54:0.9132	0.9132	54
SINE	SINE:23	short interspersed element:23:0.8715	0.8715	23
SINV	SINV:11	Sindbis virus:11:0.7357	0.7357	11
SIN	SIN:10	salpingitis isthmica nodosa:10:0.7103	0.7103	10
SIN	SIN:29|sin:1|Sin:1	self-inactivating:31:0.1255	0.1255	31
SIN	SIN:25	septation initiation network:25:0.8186	0.8186	25
SIN	SIN:55	Sindbis virus:55:0.9458	0.9458	55
SIOP	SIOP:26	International Society of Paediatric Oncology:26:0.8312	0.8312	26
SIPA	SIPA:30	Shear-induced platelet aggregation:30:0.5162	0.5162	30
SIPK	SIPK:11	Salicylic acid-induced protein kinase:11:0.7357	0.7357	11
SIPP	SIPP:30	Survey of Income and Program Participation:30:0.8472	0.8472	30
SIPS	SIPS:18	stress-induced premature senescence:18:0.8365	0.8365	18
SIPT	SIPT:10	Sensory Integration and Praxis Tests:10:0.7103	0.7103	10
SIP	SIP:45	schedule-induced polydipsia:45:0.8964	0.8964	45
SIP	SIP:12	Selectively infective phage:12:0.6460	0.6460	12
SIP	SIP:344	Sickness Impact Profile:344:0.9861	0.9861	344
SIP	SIP:11	Stable isotope probing:6:0.3728|Stable-isotope probing:5:0.0517	0.3728	11
SIP	SIP:10	steroidogenesis-inducing protein:10:0.1449	0.1449	10
SIP	SIP:8	sympathetically independent pain:8:0.5006	0.5006	8
Sir2	Sir2:10|SIR2:6	silent information regulator 2:16:0.7261	0.7261	16
SIRP	SIRP:7	signal regulatory protein:7:0.5926	0.5926	7
SIRS	SIRS:50	soluble immune response suppressor:50:0.9379	0.9379	50
SIRs	SIRs:37	standardised incidence ratios:37:0.1206	0.1206	37
SIRs	SIRs:163	standardized incidence ratios:163:0.7213	0.7213	163
SIRS	SIRS:10	Structured Interview of Reported Symptoms:10:0.7103	0.7103	10
SIRS	SIRS:13	systemic inflammatory response:13:0.7753	0.7753	13
SIRS	SIRS:549	systemic inflammatory response syndrome:549:0.9779	0.9779	549
SIR	SIR:12	incidence rates:12:0.6460	0.6460	12
SIR	SIR:7|Sir:5	silent information regulator:12:0.7571	0.7571	12
SIR	SIR:14	single isomorphous replacement:14:0.6173	0.6173	14
SIR	SIR:9|Sir:7	sirolimus:16:0.0196	0.0196	16
SIR	SIR:10	speech intelligibility rating:10:0.7103	0.7103	10
SIR	SIR:87	standardised incidence ratio:87:0.2058	0.2058	87
SIR	SIR:6	standardized incidence rate:6:0.2827	0.2827	6
SIR	SIR:335	Standardized Incidence Ratio:242:0.6595|Standardized incidence ratios:93:0.6697	0.6697	335
SiR	SiR:8|SIR:2	sulfite reductase:10:0.5000	0.5000	10
SIR	SIR:11	systemic inflammatory response:11:0.7357	0.7357	11
SISCOM	SISCOM:4	subtraction ictal SPECT coregistered to MRI:4:0.5926	0.5926	4
SISI	SISI:12	Short Increment Sensitivity Index:12:0.7571	0.7571	12
SIS	SIS:8	impingement syndrome:8:0.2619	0.2619	8
SIS	SIS:7	secretory immune system:7:0.1329	0.1329	7
SIs	SIs:9	signal intensities:9:0.4587	0.4587	9
SIS	SIS:9	Skin Immune System:9:0.1895	0.1895	9
SIS	SIS:101	small intestinal submucosa:101:0.9701	0.9701	101
SIS	SIS:27|sis:1	small intestine submucosa:28:0.8941	0.8941	28
SIS	SIS:11	Stroke Impact Scale:11:0.6182	0.6182	11
SIS	SIS:7	Suicidal Intent scale:7:0.1850	0.1850	7
SIS	SIS:6	Suicide Intent Scale:6:0.1148	0.1148	6
SITA	SITA:10	Swedish Interactive Threshold algorithm:10:0.7103	0.7103	10
SITA	SITA:7	Swedish Interactive Thresholding Algorithm:7:0.5926	0.5926	7
SITS	SITS:6	4-acetamido-4'-isothiocyano-2,2'-disulfonic stilbene:6:0.0564	0.0564	6
SITS	SITS:11	4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonate:11:0.0328	0.0328	11
SITS	SITS:65	4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid:65:0.2308	0.2308	65
SITS	SITS:8	acid stilbene:8:0.1367	0.1367	8
SITT	SITT:9	small intestinal transit time:9:0.6794	0.6794	9
SIT	SIT:9	small intestinal transit:9:0.6794	0.6794	9
SIT	SIT:10	small intestinal transplantation:10:0.5856	0.5856	10
SIT	SIT:9	social identity theory:9:0.6794	0.6794	9
SIT	SIT:130|sIT:2|sit:1	specific immunotherapy:133:0.7174	0.7174	133
SIT	SIT:27	Sperm Immobilization Test:27:0.5840	0.5840	27
SIT	SIT:24	sterile insect technique:24:0.8768	0.8768	24
SIT	SIT:6	stress inoculation training:6:0.5290	0.5290	6
SIVagm	SIVagm:7|SIVAGM:3	simian immunodeficiency virus:10:0.7103	0.7103	10
SIVagm	SIVagm:3	simian immunodeficiency virus of African green monkeys:3:0.7571	0.7571	3
SIVD	SIVD:7	subcortical ischemic vascular dementia:7:0.5926	0.5926	7
SIVmac	SIVmac:51|SIVMAC:4|SIV-mac:1	simian immunodeficiency virus:56:0.9467	0.9467	56
SIVmac	SIVmac:20|SIVMAC:1	simian immunodeficiency virus of macaques:21:0.8251	0.8251	21
SIVs	SIVs:38	Simian immunodeficiency viruses:38:0.9217	0.9217	38
SIVsm	SIVsm:18|SIVSM:1	simian immunodeficiency virus:19:0.8449	0.8449	19
SIV	SIV:1232	simian immunodeficiency virus:1196:0.9653|simian immunodeficiency viruses:36:0.9174	0.9653	1232
SIgAD	SIgAD:13|sIgAD:1|SigAD:1	selective IgA deficiency:15:0.5818	0.5818	15
sIgA	sIgA:210|SIgA:112|S-IgA:68|s-IgA:12|SIga:1|SigA:1	secretory IgA:404:0.9294	0.9294	404
SIG	SIG:11	Special Interest Group:11:0.7357	0.7357	11
SIG	SIG:9	strong ion gap:9:0.6794	0.6794	9
sIg	sIg:46|SIg:6|s-Ig:1	surface Ig:53:0.8842	0.8842	53
sIg	sIg:186|SIg:87|S-Ig:8|sig:2|s-Ig:1|SIG:1|Sig:1	surface immunoglobulin:223:0.8604|surface immunoglobulins:63:0.8430	0.8604	286
SI	SI:14	first:14:0.0031	0.0031	14
SI	SI:11	first somatic sensory area:11:0.5355	0.5355	11
SI	SI:8	first somatosensory area:8:0.1591	0.1591	8
SI	SI:9|si:1	infection:10:0.0021	0.0021	10
SI	SI:9	injury:9:0.0019	0.0019	9
SI	SI:147|Si:47	insulin sensitivity:194:0.9596	0.9596	194
SI	SI:9	interval:9:0.0021	0.0021	9
SI	SI:46|S-I:1	primary:47:0.0109	0.0109	47
SI	SI:84|S-I:5	primary somatosensory:89:0.6341	0.6341	89
SI	SI:9	primary somatosensory area:9:0.2102	0.2102	9
SI	SI:234|S-I:17	primary somatosensory cortex:251:0.7057	0.7057	251
SI	SI:90|si:1	sacroiliac:91:0.0213	0.0213	91
SI	SI:14	sacroiliitis:14:0.0031	0.0031	14
SI	SI:83	self-incompatibility:83:0.0194	0.0194	83
SI	SI:13	self-incompatible:13:0.0028	0.0028	13
SI	SI:8	sensory integration:8:0.2987	0.2987	8
SI	SI:9	sequential injection:9:0.1809	0.1809	9
SI	SI:43|Si:1	Serum iron:44:0.8941	0.8941	44
si	si:10	short interfering:10:0.1878	0.1878	10
SI	SI:304	signal intensity:288:0.9031|signal intensities:16:0.7261	0.9031	304
SI	SI:9	silent ischemia:9:0.0638	0.0638	9
SI	SI:10	silent myocardial ischemia:10:0.7103	0.7103	10
Si	Si:14|SI:4	silica:18:0.0040	0.0040	18
Si	Si:91|SI:1	silicon:92:0.0216	0.0216	92
SI	SI:21	Simulated ischemia:21:0.2963	0.2963	21
SI	SI:11	situs inversus:11:0.7357	0.7357	11
si	si:12	small interfering:12:0.2699	0.2699	12
SI	SI:19	small intestinal:19:0.8449	0.8449	19
SI	SI:52|Si:1	small intestine:53:0.9438	0.9438	53
SI	SI:35	social interaction:35:0.9151	0.9151	35
SI	SI:7	social isolation:7:0.0951	0.0951	7
SI	SI:5	somatosensory area I:5:0.1973	0.1973	5
SI	SI:31	special intervention:31:0.6343	0.6343	31
SI	SI:6	specific insulin:6:0.0899	0.0899	6
SI	SI:40	spectroscopic imaging:40:0.8839	0.8839	40
SI	SI:11	spinal cord isolation:11:0.7357	0.7357	11
SI	SI:15	splenic irradiation:15:0.7096	0.7096	15
SI	SI:11	Sputum induction:11:0.5355	0.5355	11
SI	SI:200	stimulation index:190:0.1899|stimulation indexes:10:0.2275	0.2275	200
SI	SI:39	stimulation indices:39:0.5089	0.5089	39
S-I	S-I:54|SI:4	stimulation-induced:49:0.0114|stimulation induced:9:0.3945	0.3945	58
SI	SI:8	stoichiometry of inhibition:8:0.2090	0.2090	8
SI	SI:14	stress incontinence:14:0.6911	0.6911	14
SI	SI:51|Si:1	Structured Interview:52:0.7938	0.7938	52
SI	SI:58	substantia innominata:58:0.8937	0.8937	58
SI	SI:110|S-I:5	sucrase-isomaltase:115:0.0270	0.0270	115
SI	SI:11	suicidal ideation:11:0.6182	0.6182	11
SI	SI:13	syncytia-inducing:13:0.0028	0.0028	13
SI	SI:181	syncytium-inducing:165:0.0389|syncytium inducing:16:0.5564	0.5564	181
SJA	SJA:11	Sophora japonica agglutinin:11:0.6182	0.6182	11
SJC	SJC:10	swollen joint count:10:0.7103	0.7103	10
SJM	SJM:122	Jude Medical:122:0.9755	0.9755	122
SJNNV	SJNNV:10	Striped jack nervous necrosis virus:10:0.7103	0.7103	10
SJS/TEN	SJS/TEN:9	epidermal necrolysis:9:0.6794	0.6794	9
SJW	SJW:44	John's wort:44:0.8941	0.8941	44
SJs	SJs:9	synaptic junctions:9:0.3945	0.3945	9
SJS	SJS:151|SjS:73|Sjs:6|sjs:1	syndrome:231:0.9048	0.9048	231
Sj	Sj:22|SJ:1	schistosoma japonicum:23:0.7046	0.7046	23
SJ	SJ:27	squat jump:21:0.7291|squat jumps:6:0.2243	0.7291	27
SJ	SJ:9	Synaptic junction:9:0.3455	0.3455	9
SK/SD	SK/SD:12	streptokinase/streptodornase:12:0.6111	0.6111	12
SKALP	SKALP:15	skin-derived antileukoproteinase:15:0.8045	0.8045	15
SkA	SkA:7|SKA:2|SK-A:1|skA:1	skeletal alpha-actin:11:0.7357	0.7357	11
SKGFR	SKGFR:9	single kidney glomerular filtration rate:9:0.6794	0.6794	9
SKOV3	SKOV3:4|SK-OV-3:1|SKOV-3:1	ovarian carcinoma cells:6:0.5290	0.5290	6
Skp2	Skp2:13|SKP2:2	S-phase kinase-associated protein 2:15:0.5818	0.5818	15
SKPT	SKPT:10	simultaneous kidney-pancreas transplantation:10:0.7103	0.7103	10
SK-SD	SK-SD:34|SKSD:13	streptokinase-streptodornase:47:0.6970	0.6970	47
SKY	SKY:212	spectral karyotyping:212:0.9858	0.9858	212
SK	SK:5	calcium-activated potassium channels:5:0.1973	0.1973	5
SK	SK:7	K+ channel:7:0.2902	0.2902	7
SK	SK:9	kidney:9:0.0089	0.0089	9
SK	SK:18	seborrheic keratosis:18:0.2956	0.2956	18
SK	SK:9|S-K:7|s-K:4	serum potassium:20:0.2750	0.2750	20
SK	SK:7|S-K:5	Shwachman-Kulczycki:12:0.0123	0.0123	12
SK	SK:10	small:10:0.0100	0.0100	10
SK	SK:11|sK:1	small conductance:12:0.6460	0.6460	12
SK	SK:6	small-conductance Ca(2+)-activated K(+):6:0.3945	0.3945	6
SK	SK:8	small conductance Ca2+-activated K+:8:0.6411	0.6411	8
SK	SK:12	small-conductance calcium-activated potassium:7:0.2500|small conductance calcium-activated potassium:5:0.5926	0.5926	12
SK	SK:9	solar keratoses:9:0.2757	0.2757	9
SK	SK:12	solar keratosis:12:0.1470	0.1470	12
SK	SK:21	sphingosine kinase:21:0.5435	0.5435	21
SK	SK:427|Sk:8	Streptokinase:435:0.4844	0.4844	435
SK	SK:7	stromal keratitis:7:0.3524	0.3524	7
SL1	SL1:9	stem-loop 1:9:0.1945	0.1945	9
SLAC	SLAC:10	Scapholunate advanced collapse:10:0.7103	0.7103	10
SLAM	SLAM:28	signaling lymphocytic activation molecule:28:0.8369	0.8369	28
SLAM	SLAM:47	Systemic Lupus Activity Measure:47:0.9366	0.9366	47
SLAP	SLAP:6|Slap:2	Src-like adaptor protein:8:0.6411	0.6411	8
SLAP	SLAP:6	superior labral anterior posterior:6:0.7357	0.7357	6
SLAP	SLAP:3	superior labrum anterior and posterior:3:0.7357	0.7357	3
SLAP	SLAP:9	superior labrum anterior-posterior:9:0.6794	0.6794	9
SLA	SLA:14	major histocompatibility complex:14:0.6911	0.6911	14
SLA	SLA:1	sand-blasted large-grit acid-etched:1:0.1132	0.1132	1
SLA	SLA:1	sandblasted acid-etched:1:0.3174	0.3174	1
SLA	SLA:15	soluble liver antigen:15:0.4609	0.4609	15
SLA	SLA:30	Specific Leaf Area:30:0.9011	0.9011	30
SLA	SLA:22	spontaneous locomotor activity:22:0.8657	0.8657	22
SLA	SLA:34	swine leukocyte antigen:24:0.7151|Swine leukocyte antigens:10:0.7103	0.7151	34
SLBP	SLBP:25	stem-loop binding protein:25:0.8186	0.8186	25
SLB	SLB:5	surgical lung biopsy:5:0.2818	0.2818	5
SLC6A4	SLC6A4:10	serotonin transporter:10:0.5856	0.5856	10
SLC6A4	SLC6A4:14	serotonin transporter gene:14:0.6911	0.6911	14
SLCs	SLCs:8	lining cells:8:0.2987	0.2987	8
SLC	SLC:10	lung carcinoma:10:0.7103	0.7103	10
SLC	SLC:45	secondary lymphoid tissue chemokine:28:0.8941|secondary lymphoid-tissue chemokine:17:0.8270	0.8941	45
SLC	SLC:9	small luteal cells:9:0.6794	0.6794	9
SLC	SLC:38	sodium-lithium countertransport:38:0.6005	0.6005	38
SLC	SLC:6	sodium-lithium countertransport activity:6:0.3728	0.3728	6
SLC	SLC:6|Slc:1	solute carrier:7:0.3524	0.3524	7
SLC	SLC:9	synovial lining cells:9:0.3069	0.3069	9
SLDF	SLDF:21	scanning laser Doppler flowmetry:21:0.8594	0.8594	21
SLDR	SLDR:10	sublethal damage repair:10:0.7103	0.7103	10
S-LD	S-LD:5|SLD:1	lactate dehydrogenase:6:0.2243	0.2243	6
SLD	SLD:13	sex-linked dwarf:13:0.6701	0.6701	13
SLD	SLD:36	sublethal damage:36:0.7183	0.7183	36
SLEDAI	SLEDAI:9	disease activity:9:0.4587	0.4587	9
SLEDAI	SLEDAI:127|SLE-DAI:1	SLE Disease Activity Index:128:0.6129	0.6129	128
SLEDAI	SLEDAI:52	Systemic Lupus Erythematosus Disease Activity Index:52:0.9427	0.9427	52
SLEs	SLEs:20	seizure-like events:20:0.3171	0.3171	20
SLEs	SLEs:14	Stressful life events:14:0.6173	0.6173	14
SLEV	SLEV:12|SLEv:2	Louis encephalitis virus:14:0.7909	0.7909	14
SLE	SLE:159	Louis encephalitis:159:0.9701	0.9701	159
SLE	SLE:16	Louis encephalitis virus:16:0.8165	0.8165	16
SLE	SLE:16	Slit lamp examination:16:0.8165	0.8165	16
SLE	SLE:8	stressful life events:8:0.4102	0.4102	8
SLE	SLE:22	systemic LE:22:0.8657	0.8657	22
SLE	SLE:14	systemic lupus:14:0.4709	0.4709	14
SLE	SLE:27|sLE:1	systemic lupus erythematodes:28:0.8941	0.8941	28
SLE	SLE:69	systemic lupus erythematosis:69:0.9316	0.9316	69
SLE	SLE:9274|sle:1	systemic lupus erythematosus:9275:0.9932	0.9932	9275
SLE	SLE:28	systemic lupus erythematous:28:0.8941	0.8941	28
SLE	SLE:9	systemic lupus erythmatosus:9:0.6794	0.6794	9
SLF	SLF:95|SlF:1	steel factor:96:0.8813	0.8813	96
SLH	SLH:8	S-layer homology:8:0.2987	0.2987	8
SLIL	SLIL:10	scapholunate interosseous ligament:10:0.7103	0.7103	10
SLI	SLI:173	children with specific language impairment:173:0.5752	0.5752	173
SLI	SLI:9	language impaired:9:0.6794	0.6794	9
SLI	SLI:29	somatostatin:29:0.0383	0.0383	29
SLI	SLI:240	somatostatin-like immunoreactivity:240:0.8047	0.8047	240
SLI	SLI:10	Specific Language Impairments:10:0.5856	0.5856	10
SLI	SLI:10	specifically language-impaired:10:0.5856	0.5856	10
SLK	SLK:18	superior limbic keratoconjunctivitis:18:0.8365	0.8365	18
SLL/CLL	SLL/CLL:9	small lymphocytic lymphoma/chronic lymphocytic leukemia:9:0.6794	0.6794	9
SLL	SLL:42	second-look laparotomy:42:0.7750	0.7750	42
SLL	SLL:47	small lymphocytic lymphoma:47:0.7507	0.7507	47
SLMC	SLMC:11	spontaneous lymphocyte-mediated cytotoxicity:11:0.6182	0.6182	11
SLMV	SLMV:8	synaptic-like microvesicles:8:0.5006	0.5006	8
SLMVs	SLMVs:27	synaptic-like microvesicles:27:0.8312	0.8312	27
SLM	SLM:12	spatial light modulator:12:0.7571	0.7571	12
SLM	SLM:6|SL-M:3|sl-m:1	stratum lacunosum-moleculare:10:0.7103	0.7103	10
SLM	SLM:20	supported liquid membrane:20:0.7766	0.7766	20
SLNB	SLNB:157	Sentinel lymph node biopsy:157:0.9696	0.9696	157
SLND	SLND:34	Sentinel lymph node dissection:34:0.6386	0.6386	34
SLND	SLND:14	sentinel lymphadenectomy:14:0.6911	0.6911	14
SLNs	SLNs:107	sentinel lymph nodes:107:0.9411	0.9411	107
SLNs	SLNs:19	solid lipid nanoparticles:19:0.8365	0.8365	19
SLNs	SLNs:14|SLN-s:1	superior laryngeal nerves:15:0.8045	0.8045	15
SLN	SLN:19	sarcolipin:19:0.0176	0.0176	19
SLN	SLN:596|sLN:1|sln:1	sentinel lymph node:558:0.9832|sentinel lymph nodes:40:0.6808	0.9832	598
SLN	SLN:127	Solid lipid nanoparticles:114:0.9575|solid lipid nanoparticle:13:0.7753	0.9575	127
SLN	SLN:9	solid lipid nanospheres:9:0.6794	0.6794	9
SLN	SLN:10	superior laryngeal:10:0.7103	0.7103	10
SLN	SLN:176	superior laryngeal nerve:166:0.9820|superior laryngeal nerves:10:0.7103	0.9820	176
SLOS	SLOS:106|SLOs:1	Smith-Lemli-Opitz syndrome:107:0.8927	0.8927	107
SLO	SLO:155	scanning laser ophthalmoscope:155:0.9692	0.9692	155
SLO	SLO:25	scanning laser ophthalmoscopy:25:0.8816	0.8816	25
SLO	SLO:28	second-look operation:19:0.4618|second look operation:9:0.6794	0.6794	28
slo	slo:8|SLO:1|Slo:1	slowpoke:10:0.0195	0.0195	10
SLO	SLO:30	Smith-Lemli-Opitz:30:0.0628	0.0628	30
SLO	SLO:10	Smith-Lemli-Opitz syndrome:10:0.4363	0.4363	10
SLO	SLO:11	soybean lipoxygenase:11:0.7357	0.7357	11
SLO	SLO:113|SL-O:8|slo:6|Slo:2	streptolysin O:100:0.9238|streptolysin-O:29:0.0584	0.9238	129
SLP-76	SLP-76:6	domain-containing leukocyte protein of 76 kDa:6:0.3728	0.3728	6
SLP-76	SLP-76:9|Slp-76:1	phosphoprotein of 76 kDa:10:0.2446	0.2446	10
SLPI	SLPI:9	secretory leucocyte proteinase inhibitor:9:0.7103	0.7103	9
SLPI	SLPI:134	Secretory leukocyte protease inhibitor:134:0.9416	0.9416	134
SLPI	SLPI:26	Secretory leukocyte proteinase inhibitor:26:0.8861	0.8861	26
SLPI	SLPI:52	Secretory leukoprotease inhibitor:52:0.9082	0.9082	52
SLPs	SLPs:6	S-layer proteins:6:0.0666	0.0666	6
S-LPS	S-LPS:21|sLPS:4|SLPS:2	smooth lipopolysaccharide:27:0.6745	0.6745	27
SLPs	SLPs:33|S-LPs:1	Speech-language pathologists:34:0.7898	0.7898	34
SLPs	SLPs:10	surface layer proteins:10:0.7103	0.7103	10
SLP	SLP:46	Scanning laser polarimetry:46:0.9353	0.9353	46
Slp	Slp:58|SLP:2|slp:1	sex-limited protein:61:0.6847	0.6847	61
SLP	SLP:7	silkworm larvae plasma:7:0.5926	0.5926	7
SLP	SLP:10	speech-language pathologist:10:0.5000	0.5000	10
SLP	SLP:8	spontaneous lymphocyte proliferation:8:0.6411	0.6411	8
SLRL	SLRL:24	sex-linked recessive lethal:24:0.8115	0.8115	24
SLRPs	SLRPs:21	small leucine-rich proteoglycans:21:0.8594	0.8594	21
SLR	SLR:10	Shinnar-Le Roux:10:0.7103	0.7103	10
SLR	SLR:5	short-latency response:5:0.0612	0.0612	5
SLR	SLR:13	straight leg raise:13:0.7753	0.7753	13
SLR	SLR:20	straight leg raising:20:0.8525	0.8525	20
SLR	SLR:8	subthalamic locomotor region:8:0.6411	0.6411	8
SLSJ	SLSJ:12	Saguenay-Lac-St-Jean:12:0.3929	0.3929	12
SLs	SLs:8|SLS:1	sarcomere lengths:9:0.5470	0.5470	9
SLS	SLS:12	segment-long-spacing:12:0.0144	0.0144	12
SLS	SLS:12	Selective Laser Sintering:12:0.7571	0.7571	12
SLs	SLs:14	sensation levels:14:0.5589	0.5589	14
SLs	SLs:16|Sls:5	sesquiterpene lactones:21:0.7291	0.7291	21
SLS	SLS:59	Sjogren-Larsson syndrome:59:0.5896	0.5896	59
SLS	SLS:227	sodium lauryl sulfate:227:0.9789	0.9789	227
SLS	SLS:145	sodium lauryl sulphate:145:0.9668	0.9668	145
SLs	SLs:10	sphingolipids:10:0.0117	0.0117	10
SLS	SLS:19	Static light scattering:19:0.8449	0.8449	19
SLS	SLS:30	streptolysin S:30:0.7652	0.7652	30
SLT-II	SLT-II:14	Shiga-like toxin II:14:0.7909	0.7909	14
SLT-1	SLT-1:5|SLT1:2	shiga-like toxin 1:7:0.5926	0.5926	7
SLTA	SLTA:7	Standard Language Test of Aphasia:7:0.6794	0.6794	7
SLTEC	SLTEC:8|SLT-EC:2	Shiga-like toxin-producing Escherichia coli:10:0.7103	0.7103	10
SLT-I	SLT-I:24|SLTI:1|Slt-I:1	Shiga-like toxin I:26:0.8861	0.8861	26
SLTs	SLTs:22	Shiga-like toxins:22:0.8657	0.8657	22
SLTs	SLTs:25	speech and language therapists:25:0.8816	0.8816	25
SLTX	SLTX:5|SLTx:2	single lung transplantation:7:0.5926	0.5926	7
SLT	SLT:21	Selective laser trabeculoplasty:21:0.8594	0.8594	21
SLT	SLT:48|slt:2	Shiga-like toxin:39:0.8811|Shiga-like toxins:11:0.7357	0.8811	50
SLT	SLT:7	single lung transplant:7:0.5926	0.5926	7
SLT	SLT:28	Single lung transplantation:28:0.8941	0.8941	28
SLT	SLT:17	smokeless tobacco:17:0.8270	0.8270	17
SLT	SLT:10	specific-locus test:10:0.2275	0.2275	10
SLT	SLT:32	speech and language therapy:32:0.9072	0.9072	32
SLT	SLT:12	split liver transplantation:12:0.5664	0.5664	12
SLVL	SLVL:65	Splenic lymphoma with villous lymphocytes:65:0.8841	0.8841	65
SLX	SLX:7	sialyl SSEA-1 antigen:7:0.5926	0.5926	7
sLe(x)	sLe(x):56|SLe(x):20|sLe(X):7|SLe(X):4	sialyl Lewis X:53:0.8373|sialyl Lewis(x):34:0.7952	0.8373	87
sLex	sLex:34|sLeX:15|SLex:10|SLeX:6|SLEX:4	sialyl Lewis x:69:0.8724	0.8724	69
sLex	sLex:14|SLex:7|sLeX:4|SLEX:3|s-Lex:1|SLeX:1	Sialyl Lewisx:21:0.5435|sialyl-Lewisx:9:0.0494	0.5435	30
SL	SL:13	cardiac sarcolemma:13:0.1025	0.1025	13
SL	SL:19	cardiac sarcolemmal:19:0.1479	0.1479	19
SL	SL:9	db sensation level:9:0.1009	0.1009	9
SL	SL:14	layer:14:0.0074	0.0074	14
SL	SL:11	lymphocytes:11:0.0057	0.0057	11
SL	SL:78|Sl:1	sarcomere length:69:0.3615|sarcomere lengths:10:0.3867	0.3867	79
SL	SL:20	scapholunate:20:0.0108	0.0108	20
SL	SL:137	sea level:122:0.6884|sea-level:15:0.0080	0.6884	137
SL	SL:5	Sentinel lymphadenectomy:5:0.0612	0.0612	5
SL	SL:20	sesquiterpene lactone:10:0.7103|sesquiterpene lactones:10:0.7103	0.7103	20
SL	SL:6	sham laparotomy:6:0.0807	0.0807	6
SL	SL:8	Short latency:8:0.1004	0.1004	8
SL	SL:11	sleep latency:11:0.2040	0.2040	11
SL	SL:16	Smyth line:16:0.5171	0.5171	16
SL	SL:6	sodium lactate:6:0.2243	0.2243	6
SL	SL:10	soleus:10:0.0051	0.0051	10
SL	SL:13	sonoluminescence:13:0.0068	0.0068	13
SL	SL:6	Spin lock:6:0.2243	0.2243	6
SL	SL:13	spiral ligament:13:0.2959	0.2959	13
SL	SL:16	spironolactone:16:0.0085	0.0085	16
SL	SL:104|sl:1	spliced leader:105:0.8918	0.8918	105
sl	sl:9	spotting lethal:9:0.3069	0.3069	9
SL	SL:16	stem-loop:16:0.0085	0.0085	16
SL	SL:9	stereolithographic:9:0.0045	0.0045	9
SL	SL:6	sterically stabilized liposomes:6:0.5926	0.5926	6
SL	SL:24	stride length:24:0.0919	0.0919	24
SL	SL:10	structured lipids:10:0.4363	0.4363	10
SL	SL:26|sl:2	sublingual:28:0.0153	0.0153	28
SL	SL:9	surface Laplacian:9:0.4587	0.4587	9
SL	SL:8	surrogate light:8:0.3463	0.3463	8
SL	SL:11	Suspensory Ligament:11:0.2154	0.2154	11
SM-SOD	SM-SOD:4	SOD derivative:4:0.2987	0.2987	4
SM/SL	SM/SL:8|Sm/Sl:1|sm/sl:1	submandibular/sublingual:10:0.8182	0.8182	10
SM1	SM1:8	primary sensorimotor cortex:8:0.3463	0.3463	8
SMAA	SMAA:8|smaa:1	smooth muscle alpha-actin:9:0.6794	0.6794	9
SMAA	SMAA:10	solid matrix-antibody-antigen:10:0.7103	0.7103	10
SMABF	SMABF:8	superior mesenteric artery blood flow:8:0.6411	0.6411	8
SMAC	SMAC:12|SMac:1	sorbitol MacConkey agar:13:0.7753	0.7753	13
SMAF	SMAF:13	Functional Autonomy Measurement System:13:0.7357	0.7357	13
SMAF	SMAF:9	superior mesenteric artery flow:9:0.6794	0.6794	9
SMANCS	SMANCS:14|Smancs:1|smancs:1	neocarzinostatin:16:0.4286	0.4286	16
SMAO	SMAO:26	superior mesenteric artery occlusion:26:0.8861	0.8861	26
SMARD1	SMARD1:8	spinal muscular atrophy with respiratory distress type 1:8:0.6411	0.6411	8
SMART	SMART:10	Second Manifestations of ARTerial disease:10:0.5856	0.5856	10
SMASH	SMASH:19	SiMultaneous Acquisition of Spatial Harmonics:19:0.8365	0.8365	19
SMAST	SMAST:18|S-MAST:2|sMAST:1	Short Michigan Alcoholism Screening Test:21:0.7865	0.7865	21
SMAS	SMAS:59	superficial musculoaponeurotic system:59:0.8502	0.8502	59
SMAS	SMAS:22	superior mesenteric artery syndrome:22:0.8657	0.8657	22
SMA	SMA:182|sma:2|-SMA:1	muscle actin:185:0.8762	0.8762	185
SMA	SMA:8	shape memory alloy:8:0.6411	0.6411	8
SMA	SMA:9	small mesenteric arteries:9:0.1945	0.1945	9
SMA	SMA:19	smooth muscle:19:0.3721	0.3721	19
SMA	SMA:18	Smooth muscle alpha-actin:18:0.8365	0.8365	18
SMA	SMA:81	smooth muscle antibodies:46:0.6663|smooth muscle antibody:21:0.5435|smooth-muscle antibodies:14:0.0859	0.6663	81
SMA	SMA:17	Snow Mountain agent:17:0.8270	0.8270	17
SMA	SMA:7	sorbitol MacConkey agar:7:0.5926	0.5926	7
SMA	SMA:13	specific methanogenic activity:13:0.7753	0.7753	13
SMA	SMA:599	spinal muscular atrophy:563:0.9885|spinal muscular atrophies:36:0.8336	0.9885	599
SMA	SMA:5	spontaneous mechanical activities:5:0.4422	0.4422	5
SMA	SMA:58	spontaneous motor activity:58:0.9486	0.9486	58
SMA	SMA:22	styrene Maleic anhydride:22:0.8715	0.8715	22
SMA	SMA:21	superior mesenteric:21:0.7865	0.7865	21
SMA	SMA:10	superior mesenteric arterial:10:0.7103	0.7103	10
SMA	SMA:564|sma:1	superior mesenteric artery:555:0.9689|superior mesenteric arteries:10:0.2446	0.9689	565
SMA	SMA:9	supplementary motor:9:0.5470	0.5470	9
SMA	SMA:465	supplementary motor area:455:0.9733|supplementary motor areas:10:0.7103	0.9733	465
SMA	SMA:9	supplementary motor cortex:9:0.6794	0.6794	9
SMBG	SMBG:117	self-monitoring of blood glucose:117:0.7892	0.7892	117
SMBP	SMBP:11	blood pressure:11:0.7357	0.7357	11
SMB	SMB:16	behavior:16:0.0833	0.0833	16
SMB	SMB:39	simulated moving bed:39:0.9237	0.9237	39
SMB	SMB:13|SmB:3	somatomedin B:16:0.4832	0.4832	16
SMB	SMB:17	suckling mouse brain:17:0.7407	0.7407	17
SMB	SMB:10	Syncro-Mate-B:10:0.0500	0.0500	10
SMCD	SMCD:12	Schmid metaphyseal chondrodysplasia:12:0.6460	0.6460	12
SMCD	SMCD:36	Systemic mast cell disease:36:0.9174	0.9174	36
SMCE	SMCE:8	store-mediated Ca(2+) entry:8:0.6411	0.6411	8
SMCP	SMCP:8	sheep mast cell proteinase:8:0.6411	0.6411	8
SMCP	SMCP:10	submucous cleft palate:10:0.7103	0.7103	10
SMCs	SMCs:1273|SMCS:3	smooth muscle cells:1276:0.9977	0.9977	1276
SMCs	SMCs:20	supernumerary marker chromosomes:20:0.7658	0.7658	20
SM-C	SM-C:9|Sm-C:7|SmC:2	plasma somatomedin-C:18:0.0657	0.0657	18
SMC	SMC:64	sensorimotor cortex:64:0.6960	0.6960	64
SMC	SMC:11	Sialomucin complex:11:0.2040	0.2040	11
SMC	SMC:10	sinusoidal modulated currents:10:0.5856	0.5856	10
SMC	SMC:20	smooth muscle:20:0.8525	0.8525	20
SMC	SMC:2167|smc:6	Smooth muscle cells:1320:0.9908|smooth muscle cell:853:0.9873	0.9908	2173
SmC	SmC:33|Sm-C:25|SM-C:14|SMC:7	somatomedin C:79:0.8313	0.8313	79
SMC	SMC:73|smc:1|Smc:1	structural maintenance of chromosomes:63:0.9241|structural maintenance of chromosome:12:0.7571	0.9241	75
SMC	SMC:29	Supernumerary Marker Chromosome:20:0.7173|supernumerary marker chromosomes:9:0.3945	0.7173	29
SMEI	SMEI:28	severe myoclonic epilepsy in infancy:28:0.9274	0.9274	28
SMEs	SMEs:6	small and medium-sized enterprises:6:0.5926	0.5926	6
SME	SME:8	severe myoclonic epilepsy in infancy:8:0.6794	0.6794	8
SME	SME:54|S-ME:10	stalk-median eminence:40:0.4699|stalk median eminence:24:0.8768	0.8768	64
SMFP	SMFP:12	sodium monofluorophosphate:12:0.7571	0.7571	12
SM-FeSV	SM-FeSV:12	McDonough strain of feline sarcoma virus:12:0.7571	0.7571	12
SMF	SMF:44|sMF:1	static magnetic field:26:0.6973|static magnetic fields:19:0.5732	0.6973	45
SmF	SmF:9	submerged fermentation:9:0.6794	0.6794	9
SMGs	SMGs:16	submandibular glands:16:0.6024	0.6024	16
SMg	SMg:3|S-Mg:3|sMg:2|S-mg:1	Serum magnesium:9:0.3945	0.3945	9
S-Mg	S-Mg:8|sMg:1|s-Mg:1	Serum magnesium concentration:10:0.7103	0.7103	10
SMG	SMG:10	Streptococcus milleri group:10:0.5856	0.5856	10
SMG	SMG:20	submandibular ganglion:20:0.4786	0.4786	20
SMG	SMG:210	submandibular gland:179:0.6916|submandibular glands:31:0.4504	0.6916	210
SMG	SMG:11	submandibular salivary glands:11:0.7357	0.7357	11
SMG	SMG:9	superior mesenteric ganglion:9:0.6794	0.6794	9
SMG	SMG:12|SmG:2	supramarginal gyrus:14:0.7909	0.7909	14
SMHC	SMHC:7	Smooth muscle myosin heavy chain:7:0.5926	0.5926	7
SMID	SMID:13	severe motor and intellectual disabilities:13:0.6701	0.6701	13
SMIT	SMIT:39	cotransporter:39:0.5429	0.5429	39
SMIT	SMIT:8	myo-inositol transporter:8:0.2619	0.2619	8
SMLR	SMLR:25|sMLR:1	syngeneic mixed lymphocyte reaction:26:0.8251	0.8251	26
SMMHC	SMMHC:25|SM-MHC:12|smMHC:3|SMM-HC:3|sm-MHC:2|Smmhc:1	smooth muscle myosin heavy chain:46:0.8115	0.8115	46
SMM	SMM:12	S-methylmethionine:12:0.0591	0.0591	12
SMM	SMM:36	scintimammography:36:0.1882	0.1882	36
SMM	SMM:14|S-MM:1	smoldering multiple myeloma:15:0.6386	0.6386	15
SMM	SMM:14	Stepwise Mutation Model:14:0.6911	0.6911	14
SMM	SMM:12|Smm:1	sulfamonomethoxine:13:0.0645	0.0645	13
SMM	SMM:9	sulphamonomethoxine:9:0.0430	0.0430	9
SMN1	SMN1:15	survival motor neuron:15:0.8045	0.8045	15
SMN1	SMN1:9	survival motor neuron 1:9:0.7103	0.7103	9
SMN1	SMN1:19	survival motor neuron gene:19:0.8525	0.8525	19
SMNC	SMNC:14	splenic mononuclear cells:14:0.5111	0.5111	14
SMNs	SMNs:10	motor neurons:10:0.7103	0.7103	10
SMNs	SMNs:24	second malignant neoplasms:24:0.7151	0.7151	24
SMN	SMN:46	second malignant neoplasms:27:0.7425|second malignant neoplasm:19:0.6537	0.7425	46
SMN	SMN:144|Smn:5|smn:2	survival motor neuron:151:0.9619	0.9619	151
SMN	SMN:19|Smn:2|smn:1	survival motor neuron gene:22:0.8978	0.8978	22
SMN	SMN:2|Smn:1	survival motor neuron protein:3:0.4422	0.4422	3
SMN	SMN:38	survival of motor neurons:38:0.8590	0.8590	38
SMOCs	SMOCs:10	spontaneous miniature outward currents:10:0.7103	0.7103	10
SMON	SMON:9	subacute myelo-optic neuropathy:9:0.6794	0.6794	9
SMON	SMON:33	Subacute myelo-optico-neuropathy:33:0.8292	0.8292	33
SMP30	SMP30:33|SMP-30:2	senescence marker protein-30:35:0.9100	0.9100	35
SmpB	SmpB:10	Small protein B:10:0.7103	0.7103	10
SMPS	SMPS:15	scanning mobility particle sizer:15:0.8045	0.8045	15
SMPs	SMPs:13|smps:1	submitochondrial particles:14:0.7909	0.7909	14
SMPTE	SMPTE:7	Society of Motion Picture and Television Engineers:7:0.5926	0.5926	7
SMP	SMP:24|smp:1	Bovine heart submitochondrial particles:25:0.6539	0.6539	25
SMP	SMP:13	Schwann cell myelin protein:13:0.7753	0.7753	13
SMP	SMP:14	skim milk powder:14:0.5589	0.5589	14
SMP	SMP:13	soluble microbial products:13:0.7753	0.7753	13
SMP	SMP:6	submucous plexus:6:0.1543	0.1543	6
SMP	SMP:31	sympathetically maintained pain:31:0.7718	0.7718	31
SMQ	SMQ:14	Questionnaire:14:0.8125	0.8125	14
SMRT	SMRT:19	silencing mediator for retinoid and thyroid hormone receptors:11:0.8045|silencing mediator for retinoid and thyroid hormone receptor:8:0.7103	0.8045	19
SMRV	SMRV:17	Squirrel monkey retrovirus:17:0.8270	0.8270	17
SMRs	SMRs:15	mortality rates:15:0.5818	0.5818	15
SMRs	SMRs:114	standardised mortality ratios:114:0.2464	0.2464	114
SMRs	SMRs:254	standardized mortality ratios:254:0.6097	0.6097	254
SMR	SMR:13	sensorimotor rhythm:13:0.7571	0.7571	13
SMR	SMR:13	severe mental retardation:13:0.5934	0.5934	13
SMR	SMR:56	sleeping metabolic rate:56:0.5360	0.5360	56
SMR	SMR:9	small multidrug resistance:9:0.6794	0.6794	9
SMR	SMR:9	Standard mortality rate:9:0.0969	0.0969	9
SMR	SMR:26	standardized mortality rate:18:0.3548|Standardized mortality rates:8:0.2619	0.3548	26
SMR	SMR:563	standardized mortality ratio:445:0.6684|standardized mortality ratios:118:0.6340	0.6684	563
Smr	Smr:7|SmR:3	streptomycin:10:0.0076	0.0076	10
Smr	SmR:3|Smr:3|SMr:1	streptomycin resistance:7:0.1025	0.1025	7
SMR	SMR:7	Submucous resection:7:0.3524	0.3524	7
SMSAs	SMSAs:20	standard metropolitan statistical areas:20:0.8525	0.8525	20
SMSA	SMSA:26	standard metropolitan statistical area:26:0.8861	0.8861	26
SM-SL	SM-SL:7|SMSL:3	submandibular-sublingual:10:0.5000	0.5000	10
SMSP	SMSP:10	Spectral Maxima Sound Processor:10:0.7103	0.7103	10
SMSV	SMSV:15	San Miguel sea lion virus:15:0.8045	0.8045	15
SMS	SMS:13	Octreotide:13:0.0233	0.0233	13
SMS	SMS:71	Smith-Magenis syndrome:71:0.4325	0.4325	71
SMs	SMs:5|Sms:3|SMS:1	somatomedins:9:0.0155	0.0155	9
SMS	SMS:37|sms:2|Sms:2	somatostatin:41:0.0777	0.0777	41
SMS	SMS:40	space motion sickness:40:0.8491	0.8491	40
SMs	SMs:9	sphingomyelins:9:0.0155	0.0155	9
SMS	SMS:6	Sphingomyelin synthase:6:0.2243	0.2243	6
SMS	SMS:45	Stiff-man syndrome:45:0.2452	0.2452	45
SMTC	SMTC:11|S-MTC:1	S-methyl-L-thiocitrulline:12:0.5500	0.5500	12
SMT	SMT:9	methyl transferase:9:0.5470	0.5470	9
SMT	SMT:28	S-methylisothiourea:28:0.0813	0.0813	28
SMT	SMT:19	S-Methylisothiourea sulfate:19:0.7044	0.7044	19
SMT	SMT:6	second malignant tumors:6:0.5290	0.5290	6
SmT	SmT:7	smooth transparent:7:0.3463	0.3463	7
SMT	SMT:31	spinal manipulative therapy:31:0.9043	0.9043	31
SMT	SMT:6	Stress Management Training:6:0.5290	0.5290	6
SMT	SMT:16	submucosal tumor:9:0.3455|submucosal tumors:7:0.0886	0.3455	16
SMT	SMT:11	sulfamethazine:11:0.0301	0.0301	11
S-MUAPs	S-MUAPs:10|SMUAPs:1	motor unit action potentials:11:0.7357	0.7357	11
SMUs	SMUs:27	single motor units:27:0.8903	0.8903	27
SMU	SMU:20	single motor unit:20:0.8525	0.8525	20
SMVT	SMVT:7	sodium-dependent multivitamin transporter:7:0.3524	0.3524	7
SMVT	SMVT:25	Sustained monomorphic ventricular tachycardia:25:0.8186	0.8186	25
SMVs	SMVs:38	Skeletal muscle ventricles:38:0.9217	0.9217	38
SMV	SMV:17	skeletal muscle ventricle:17:0.8270	0.8270	17
SMV	SMV:20	soybean mosaic virus:20:0.5892	0.5892	20
SMV	SMV:78	superior mesenteric vein:78:0.9617	0.9617	78
SMX-TMP	SMX-TMP:13	sulfamethoxazole-trimethoprim:13:0.7500	0.7500	13
SMX	SMX:78|Smx:2	sulfamethoxazole:80:0.6810	0.6810	80
SMX	SMX:22	sulphamethoxazole:22:0.1810	0.1810	22
SMZL	SMZL:49	splenic marginal zone lymphoma:49:0.9392	0.9392	49
SMZ	SMZ:73	sulfamethazine:73:0.4211	0.4211	73
SMZ	SMZ:10	sulfamethizole:10:0.0526	0.0526	10
SMZ	SMZ:16	sulphamethoxazole:16:0.0877	0.0877	16
SMases	SMases:14	sphingomyelinases:14:0.9286	0.9286	14
SMase	SMase:169|Smase:3	sphingomyelinase:163:0.9000|Sphingomyelinases:9:0.0444	0.9000	172
SN-38G	SN-38G:28	SN-38 glucuronide:28:0.7505	0.7505	28
SN/VTA	SN/VTA:6	substantia nigra/ventral tegmental area:6:0.5290	0.5290	6
SN-38	SN-38:8	active metabolite 7-ethyl-10-hydroxycamptothecin:8:0.6381	0.6381	8
SNAC	SNAC:15	S-nitroso-N-acetylcysteine:15:0.2414	0.2414	15
SNAP-25	SNAP-25:9|SNAP25:1	25-kDa synaptosomal-associated protein:10:0.2873	0.2873	10
SNAP-25	SNAP-25:7	synaptosomal-associated protein-25:7:0.2113	0.2113	7
SNAP-25	SNAP-25:67|SNAP25:4	synaptosomal-associated protein of 25 kDa:55:0.3439|synaptosomal associated protein of 25 kDa:16:0.7291	0.7291	71
SNAP-25	SNAP-25:11|SNAP25:2	synaptosome-associated protein:13:0.1506	0.1506	13
SNAP-25	SNAP-25:37|SNAP25:4|Snap25:1	Synaptosome-associated protein of 25 kDa:42:0.2410	0.2410	42
SNAPs	SNAPs:42	sensory nerve action potentials:42:0.9291	0.9291	42
SNAP	SNAP:12	(+/-)-S-nitroso-N-acetylpenicillamine:12:0.0099	0.0099	12
SNAP	SNAP:5	donor S-nitroso-acetyl-penicillamine:5:0.1470	0.1470	5
SNAP	SNAP:9	donor S-nitroso-N-acetyl-D,L-penicillamine:9:0.1324	0.1324	9
SNAP	SNAP:6	donor S-nitroso-N-acetyl-DL-penicillamine:6:0.1124	0.1124	6
SNAP	SNAP:22	donor S-nitroso-N-acetyl-penicillamine:22:0.2188	0.2188	22
SNAP	SNAP:3	donor S-nitrosoacetylpenicillamine:3:0.1838	0.1838	3
SNAP	SNAP:10	nitric oxide donor S-nitroso-N-acetylpenicillamine:10:0.8525	0.8525	10
SNAP	SNAP:30	S-nitroso-N-acetyl penicillamine:30:0.4881	0.4881	30
SNAP	SNAP:11	S-nitroso-N-penicillamine:11:0.0090	0.0090	11
SNAP	SNAP:10	Schedule for Nonadaptive and Adaptive Personality:10:0.6794	0.6794	10
SNAP	SNAP:33	score for neonatal acute physiology:33:0.9151	0.9151	33
SNAP	SNAP:104	sensory nerve action potential:80:0.9408|sensory nerve action potentials:24:0.8768	0.9408	104
SNAREs	SNAREs:20	soluble N-ethylmaleimide-sensitive factor attachment protein receptors:20:0.6680	0.6680	20
SNAT	SNAT:10	serotonin N-acetyltransferase:10:0.7103	0.7103	10
SNA	SNA:31	Sambucus nigra:31:0.9043	0.9043	31
SNA	SNA:45	Sambucus nigra agglutinin:45:0.8649	0.8649	45
SNA	SNA:9	sinus node artery:9:0.6794	0.6794	9
SNA	SNA:208	Sympathetic nerve activity:208:0.9255	0.9255	208
SNBF	SNBF:6	sciatic nerve blood flow:6:0.5290	0.5290	6
SNB	SNB:102	Sentinel node biopsy:102:0.7830	0.7830	102
SNB	SNB:133	spinal nucleus of the bulbocavernosus:133:0.9654	0.9654	133
SNCV	SNCV:41	sensory nerve conduction velocity:41:0.8867	0.8867	41
SNc	SNc:9|SNC:4	pars compacta of the substantia nigra:13:0.5348	0.5348	13
SNC	SNC:8|S-NC:2	S-nitrosocysteine:10:0.0188	0.0188	10
SNc	SNc:158|SNC:85	substantia nigra pars compacta:243:0.9882	0.9882	243
SND	SND:16	selective neck dissection:16:0.7261	0.7261	16
SND	SND:18	sinus node disease:18:0.6903	0.6903	18
SND	SND:42	sinus node dysfunction:42:0.8893	0.8893	42
SND	SND:66	striatonigral degeneration:66:0.7745	0.7745	66
SND	SND:122	sympathetic nerve discharge:122:0.9612	0.9612	122
SNE	SNE:16	subacute necrotizing encephalomyelopathy:16:0.8165	0.8165	16
SNFF	SNFF:7	Single nephron filtration fraction:7:0.4438	0.4438	7
SNFs	SNFs:78	skilled nursing facilities:78:0.9617	0.9617	78
SNF	SNF:83	Skilled Nursing Facility:74:0.9596|Skilled Nursing Facilities:9:0.6794	0.9596	83
SNHI	SNHI:9	sensorineural hearing impairment:9:0.6794	0.6794	9
SNHL	SNHL:277	sensorineural hearing loss:277:0.9390	0.9390	277
SNI	SNI:14	spared nerve injury:14:0.6911	0.6911	14
SNLG	SNLG:12	Scotland and Newcastle Lymphoma Group:12:0.7571	0.7571	12
SNl	SNl:6|SNL:6	pars lateralis:12:0.6460	0.6460	12
SNL	SNL:46	spinal nerve ligation:46:0.8676	0.8676	46
SNMC	SNMC:10	Stronger Neo-Minophagen C:10:0.7103	0.7103	10
SnMP	SnMP:9	Sn-mesoporphyrin:9:0.1667	0.1667	9
SnMP	SnMP:19|Sn-MP:1	tin-mesoporphyrin:10:0.1875|tin mesoporphyrin:10:0.2643	0.2643	20
SNNS	SNNS:13	Sentinel node navigation surgery:13:0.7753	0.7753	13
SNOC	SNOC:19	S-nitrosocysteine:19:0.8182	0.8182	19
SNOG	SNOG:9	S-nitrosoglutathione:9:0.5000	0.5000	9
SNO-Hb	SNO-Hb:17|SNOHb:4	S-nitrosohemoglobin:21:0.6897	0.6897	21
SNOM	SNOM:18	scanning near-field optical microscope:18:0.8365	0.8365	18
SNOM	SNOM:35	scanning near-field optical microscopy:35:0.8681	0.8681	35
SNOMED	SNOMED:21	Systematized Nomenclature of Medicine:21:0.6306	0.6306	21
SNPF	SNPF:21	plasma flow:21:0.8594	0.8594	21
SnPP	SnPP:28|Sn-PP:3	tin protoporphyrin:22:0.6934|tin-protoporphyrin:9:0.1290	0.6934	31
SnPP	SnPP:5	Tin protoporphyrin IX:5:0.2818	0.2818	5
SNPs	SNPs:2282|snps:1|SNPS:1	single nucleotide polymorphisms:1635:0.9917|single-nucleotide polymorphisms:631:0.2558|single nucleotide polymorphism:18:0.8365	0.9917	2284
SNP	SNP:1088|snp:1	single nucleotide polymorphism:710:0.9868|single-nucleotide polymorphism:203:0.1908|single nucleotide polymorphisms:148:0.9798|single-nucleotide polymorphisms:28:0.0991	0.9868	1089
SNP	SNP:1990|Snp:2|sNP:1|SNp:1	sodium nitroprusside:1994:0.9736	0.9736	1994
SNRPN	SNRPN:7	polypeptide N gene:7:0.3524	0.3524	7
SNRPN	SNRPN:11	Small nuclear ribonucleoprotein polypeptide N:11:0.7357	0.7357	11
SNRT	SNRT:60	SINUS NODE RECOVERY TIME:60:0.9216	0.9216	60
SNRs	SNRs:94	signal-to-noise ratios:94:0.8040	0.8040	94
SNR	SNR:45	signal-to-noise:45:0.0270	0.0270	45
SNR	SNR:993	signal-to-noise ratio:933:0.9080|signal-to-noise ratios:46:0.6663|Signal-to-noise-ratio:14:0.0080	0.9080	993
SNR	SNR:14|SNr:5	substantia nigra:19:0.8365	0.8365	19
SNr	SNr:192|SNR:88|Snr:1	substantia nigra pars reticulata:281:0.9781	0.9781	281
SNR	SNR:9	supernumerary ribs:9:0.5470	0.5470	9
SNTX	SNTX:9	stonustoxin:9:0.5714	0.5714	9
SNT	SNT:15	serum neutralization test:15:0.7096	0.7096	15
SNUC	SNUC:17	sinonasal undifferentiated carcinoma:17:0.8270	0.8270	17
SNV	SNV:52	Sin Nombre virus:52:0.8799	0.8799	52
SNV	SNV:67	spleen necrosis virus:67:0.9548	0.9548	67
SNV	SNV:11	systemic necrotizing vasculitis:11:0.7357	0.7357	11
SNW	SNW:9	slow negative wave:9:0.3945	0.3945	9
SNX1	SNX1:15	sorting nexin 1:15:0.8045	0.8045	15
SNZC	SNZC:6|SN-ZC:1|SNZc:1	substantia nigra zona compacta:8:0.6411	0.6411	8
SNase	SNase:41|Snase:5	staphylococcal nuclease:46:0.8986	0.8986	46
SNIP	SNIP:14	sniff nasal inspiratory pressure:14:0.7909	0.7909	14
SNpc	SNpc:101|SNPC:14|SNPc:1|SN-PC:1	substantia nigra pars compacta:117:0.9749	0.9749	117
SNpr	SNpr:3|SNPR:1	pars reticulata of substantia nigra:4:0.7103	0.7103	4
SNpr	SNpr:39|SNPR:12|SN-PR:3|SNpR:1	substantia nigra pars reticulata:55:0.9241	0.9241	55
SNx	SNx:9|SNX:6|Snx:1	subtotal nephrectomy:16:0.5171	0.5171	16
SNX	SNX:23|SNx:2	subtotally nephrectomized:25:0.6539	0.6539	25
SN	SN:9	nerves:9:0.0033	0.0033	9
SN	SN:12	neurons:12:0.0045	0.0045	12
SN	SN:20	sciatic nerve:20:0.1929	0.1929	20
SN	SN:23	Secretoneurin:23:0.0090	0.0090	23
SN	SN:12	selection negativity:12:0.5050	0.5050	12
SN	SN:9	Semantic Network:9:0.4587	0.4587	9
Sn	Sn:17|SN:15	Sensitivity:32:0.0126	0.0126	32
SN	SN:10	sensory neuron:10:0.5856	0.5856	10
SN	SN:38|sN:7	sentinel lymph node:45:0.8986	0.8986	45
SN	SN:240|sN:2|sn:1	Sentinel node:228:0.6107|Sentinel nodes:15:0.6386	0.6386	243
SN	SN:9|sn:1	seronegative:10:0.0037	0.0037	10
SN	SN:14	serum neutralisation:14:0.6911	0.6911	14
SN	SN:85	serum neutralization:72:0.8948|serum-neutralization:13:0.0049	0.8948	85
SN	SN:25	serum neutralizing:25:0.8186	0.8186	25
Sn	Sn:11|SN:1	sialoadhesin:12:0.0045	0.0045	12
SN	SN:8	silver nitrate:8:0.5006	0.5006	8
SN	SN:16	Sin Nombre:16:0.8165	0.8165	16
SN	SN:15	single nephron:15:0.8045	0.8045	15
SN	SN:65	sinus node:65:0.1445	0.1445	65
sn	sn:27|SN:2	small nuclear:29:0.8422	0.8422	29
SN	SN:16	sodium nitrite:16:0.8165	0.8165	16
SN	SN:17	sodium nitroprusside:17:0.8270	0.8270	17
SN	SN:6	Spitz nevus:6:0.2902	0.2902	6
SN	SN:26	Spontaneous nystagmus:26:0.6645	0.6645	26
SN	SN:11	staphylococcal nuclease:11:0.5355	0.5355	11
SN	SN:17	streptonigrin:17:0.0065	0.0065	17
SN	SN:960|Sn:2|sn:1	substantia nigra:963:0.9859	0.9859	963
SN	SN:85|Sn:3	supernatants:50:0.0199|supernatant:38:0.0151	0.0199	88
SN	SN:18|Sn:2	sural nerve:20:0.1929	0.1929	20
SO(2)	SO(2):5|So(2):1	oxygen saturation:6:0.2243	0.2243	6
SO(2)	SO(2):53	sulfur dioxide:53:0.5868	0.5868	53
SO2	SO2:78|sO2:15|So2:11	oxygen saturation:104:0.6504	0.6504	104
SO2	SO2:265	sulfur dioxide:265:0.6133	0.6133	265
SO2	SO2:134	sulphur dioxide:134:0.2869	0.2869	134
SO4	SO4:13	inorganic sulfate:13:0.3134	0.3134	13
SOAEs	SOAEs:79	spontaneous otoacoustic emissions:79:0.9622	0.9622	79
SOAE	SOAE:35|s-OAE:1	spontaneous otoacoustic emission:19:0.8449|spontaneous otoacoustic emissions:17:0.8270	0.8449	36
SOAS	SOAS:11	Staff Observation Aggression Scale:11:0.7357	0.7357	11
SOAs	SOAs:74	stimulus onset asynchronies:74:0.9596	0.9596	74
SOBP	SOBP:34	spread-out Bragg peak:24:0.5160|spread out Bragg peak:10:0.7103	0.7103	34
sOB-R	sOB-R:14|sOb-R:2|SOB-R:1	soluble leptin receptor:17:0.7407	0.7407	17
SOCE	SOCE:17	store-operated Ca2+ entry:17:0.8270	0.8270	17
SOCE	SOCE:13	store-operated calcium entry:13:0.7753	0.7753	13
SOCS-1	SOCS-1:34|SOCS1:22|Socs1:3	suppressor of cytokine signaling-1:40:0.7653|suppressor of cytokine signaling 1:19:0.6537	0.7653	59
SOCS-2	SOCS-2:5|SOCS2:3|Socs-2:2	suppressor of cytokine signaling-2:10:0.7103	0.7103	10
SOCS-3	SOCS-3:37|SOCS3:34|Socs3:2	suppressor of cytokine signaling 3:38:0.8781|suppressor of cytokine signaling-3:35:0.7952	0.8781	73
SOCS	SOCS:154|Socs:3	cytokine signaling:157:0.9688	0.9688	157
SOCS	SOCS:28	cytokine signalling:28:0.8903	0.8903	28
SOCs	SOCs:11	organic compounds:11:0.6182	0.6182	11
SOCs	SOCs:16	store-operated Ca2+ channels:16:0.8165	0.8165	16
SOCs	SOCs:30	store-operated channels:30:0.3614	0.3614	30
SOC	SOC:13	self-organized criticality:13:0.7753	0.7753	13
SOC	SOC:146|SoC:1	sense of coherence:147:0.9796	0.9796	147
SOC	SOC:15	Sense of Coherence Scale:15:0.7096	0.7096	15
sOC	sOC:9|S-OC:5|s-OC:3|s-Oc:1	Serum osteocalcin:18:0.4672	0.4672	18
SOC	SOC:11	sham-operated control:11:0.4728	0.4728	11
SOC	SOC:20	soil organic carbon:20:0.6259	0.6259	20
SOC	SOC:11	stage of change:11:0.3829	0.3829	11
SOC	SOC:11	Standard of Care:11:0.5355	0.5355	11
SOC	SOC:8	store-operated Ca(2+):8:0.5006	0.5006	8
SOC	SOC:6	store-operated Ca(2+) entry:6:0.5290	0.5290	6
SOC	SOC:9	store-operated Ca2+:9:0.7103	0.7103	9
SOC	SOC:7	store-operated Ca2+ channel:7:0.5926	0.5926	7
SOC	SOC:15	store-operated calcium:15:0.7096	0.7096	15
SOC	SOC:21	store-operated channels:11:0.1938|store-operated channel:10:0.1680	0.1938	21
SOC	SOC:101	superior olivary complex:101:0.9704	0.9704	101
SOD1	SOD1:365|SOD-1:86|Sod1:7|Sod-1:2|sod-1:2|sod1:2	superoxide dismutase:464:0.7937	0.7937	464
SOD1	SOD1:133|SOD-1:31|Sod-1:1|Sod1:1	superoxide dismutase 1:107:0.9156|superoxide dismutase-1:59:0.8710	0.9156	166
SOD1	SOD1:19|SOD-1:4|sod-1:1	superoxide dismutase gene:24:0.7593	0.7593	24
SODD	SODD:9	silencer of death domains:9:0.5470	0.5470	9
S-ODN	S-ODN:7	antisense phosphorothioate oligodeoxynucleotides:7:0.2902	0.2902	7
S-ODN	S-ODN:6|SODN:3|s-ODN:1	oligodeoxynucleotide:10:0.2045	0.2045	10
SODA	SODA:7	sequential occupational dexterity assessment:7:0.5290	0.5290	7
SODA	SODA:7	severity of dyspepsia assessment:7:0.5926	0.5926	7
sodA	sodA:16|SodA:13|SODa:1|SOD-A:1	Superoxide dismutase:31:0.7652	0.7652	31
sodA	sodA:11	superoxide dismutase gene:11:0.4728	0.4728	11
SODs	SODs:109|Sods:1	Superoxide dismutases:110:0.9178	0.9178	110
SOD	SOD:29	septo-optic dysplasia:29:0.7237	0.7237	29
SOD	SOD:43	sphincter of Oddi dysfunction:43:0.9323	0.9323	43
SOD	SOD:6252|Sod:26|sod:9	superoxide dismutase:6198:0.9470|Superoxide dismutases:67:0.8515|superoxide-dismutase:22:0.0031	0.9470	6287
SOD	SOD:32	superoxide dismutase activity:32:0.9072	0.9072	32
SOD	SOD:5	superoxide dismutase enzyme:5:0.4422	0.4422	5
SOFA	SOFA:18	Sepsis-related Organ Failure Assessment:18:0.1281	0.1281	18
SOFA	SOFA:55	Sequential Organ Failure Assessment:55:0.6065	0.6065	55
SOFAS	SOFAS:8	Social and Occupational Functioning Assessment Scale:8:0.6411	0.6411	8
SOGC	SOGC:28	Society of Obstetricians and Gynaecologists of Canada:28:0.8941	0.8941	28
SOGS	SOGS:36	South Oaks Gambling Screen:36:0.9174	0.9174	36
sog	sog:13|Sog:9|SOG:4	short gastrulation:26:0.7760	0.7760	26
SOG	SOG:10	suboesophageal ganglion:10:0.5856	0.5856	10
SOHND	SOHND:12	supraomohyoid neck dissection:12:0.6460	0.6460	12
SOI	SOI:25	surgical orthotopic implantation:25:0.8816	0.8816	25
SOJRA	SOJRA:4|SO-JRA:1|SoJRA:1	systemic onset juvenile rheumatoid arthritis:6:0.5290	0.5290	6
SOLVD	SOLVD:108	Studies of Left Ventricular Dysfunction:108:0.9417	0.9417	108
SOL	SOL:22	sleep onset latency:22:0.8657	0.8657	22
SOL	SOL:30|Sol:10|sol:1	soleus muscle:41:0.8224	0.8224	41
Sol	Sol:4|sol:3|SOL:2	solitary tract:9:0.6794	0.6794	9
SOL	SOL:5	space-occupying lesions:5:0.0902	0.0902	5
SOM-IR	SOM-ir:5|SOM-IR:5	somatostatin-immunoreactive:10:0.5000	0.5000	10
SOM-LI	SOM-LI:5|Som-LI:3|SOMLI:1	somatostatin-like immunoreactivity:9:0.3945	0.3945	9
SOMs	SOMs:27	self-organizing maps:27:0.7834	0.7834	27
SOM	SOM:139	Secretory Otitis Media:139:0.7532	0.7532	139
SOM	SOM:112	self-organizing map:83:0.7597|Self-organizing maps:29:0.7581	0.7597	112
SOM	SOM:59	soil organic matter:59:0.6999	0.6999	59
SOM	SOM:357|Som:22	somatostatin:379:0.4337	0.4337	379
SOM	SOM:21	sphincter of Oddi manometry:21:0.8594	0.8594	21
SOM	SOM:9	Superior oblique myokymia:9:0.6794	0.6794	9
SON	SON:20	superior ovarian nerve:20:0.8525	0.8525	20
sOPCA	sOPCA:10|s-OPCA:1	sporadic olivopontocerebellar atrophy:11:0.5355	0.5355	11
SOPC	SOPC:13	1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine:13:0.2353	0.2353	13
SOPs	SOPs:9	sensory organ precursors:9:0.5470	0.5470	9
SOPs	SOPs:25	standard operating procedures:25:0.8816	0.8816	25
SOP	SOP:21	sensory organ precursor:21:0.6812	0.6812	21
SOP	SOP:30	standard operating procedures:15:0.8045|standard operating procedure:15:0.7096	0.8045	30
SOP	SOP:7	superior oblique palsy:7:0.5926	0.5926	7
SOREMP	SOREMP:7	sleep onset REM period:7:0.5926	0.5926	7
sORF	sORF:5|SORF:2	open reading frame:7:0.4438	0.4438	7
SOR	SOR:16	Superoxide reductase:16:0.6024	0.6024	16
Sosm	Sosm:8|SOsm:2|SOSM:2|sOsm:1	Serum osmolality:13:0.7753	0.7753	13
SOs	SOs:10|SOS:2	significant others:12:0.7753	0.7753	12
Sos	Sos:42|SOS:13|SoS:1	Son of sevenless:40:0.8839|son-of-sevenless:16:0.0242	0.8839	56
SoS	SoS:4|Sos:1	Sotos syndrome:5:0.0902	0.0902	5
SOS	SOS:13	sucrose octasulfate:13:0.7753	0.7753	13
SOS	SOS:36	Swedish obese subjects:36:0.8605	0.8605	36
SOS	SOS:8|SoS:1	velocity:9:0.0129	0.0129	9
SOT	SOT:6	Annual Meeting of the Society of Toxicology:6:0.5290	0.5290	6
SOT	SOT:26	sensory organization test:26:0.8861	0.8861	26
SOT	SOT:26	solid organ transplant:17:0.7407|solid-organ transplant:9:0.1205	0.7407	26
SOT	SOT:10	Squamous odontogenic tumor:10:0.6794	0.6794	10
SOV	SOV:11	sodium orthovanadate:11:0.6182	0.6182	11
SOV	SOV:28	superior ophthalmic vein:28:0.8941	0.8941	28
SOZ	SOZ:13|sOZ:2	serum-opsonized zymosan:15:0.4312	0.4312	15
SOA	SOA:23	Secondary organic aerosol:23:0.8715	0.8715	23
SOA	SOA:145	stimulus onset asynchrony:145:0.9194	0.9194	145
SOA	SOA:18	sucrose octaacetate:18:0.8270	0.8270	18
SOA	SOA:11	superoxide anion:11:0.7357	0.7357	11
SOX	SOX:9	oxidative stress:9:0.5470	0.5470	9
SO	SO:9	output:9:0.0051	0.0051	9
SO	SO:164|S-O:2|So:1	sham-operated:138:0.0873|sham operated:29:0.8978	0.8978	167
SO	SO:35	sham operation:35:0.9151	0.9151	35
SO	SO:11	significant other:11:0.7357	0.7357	11
so	so:37|So:1	sine oculis:38:0.8417	0.8417	38
SO	SO:9	sleep onset:9:0.5470	0.5470	9
SO	SO:11	slow oscillator:11:0.7357	0.7357	11
SO	SO:13	slow-oxidative:13:0.0076	0.0076	13
SO	SO:49	slow-twitch oxidative:37:0.3373|slow-twitch-oxidative:12:0.0070	0.3373	49
So	So:8|SO:1	Socialization:9:0.0051	0.0051	9
SO	SO:29	soleus:29:0.0178	0.0178	29
SO	SO:42	soybean oil:42:0.1570	0.1570	42
SO	SO:204	sphincter of Oddi:204:0.9765	0.9765	204
SO	SO:50	stratum opticum:50:0.8285	0.8285	50
SO	SO:10	stratum oriens:10:0.5000	0.5000	10
SO	SO:51	styrene-7,8-oxide:37:0.0229|styrene 7,8-oxide:14:0.5589	0.5589	51
SO	SO:23	styrene oxide:23:0.8038	0.8038	23
SO	SO:17	sulfite oxidase:17:0.5038	0.5038	17
SO	SO:28	sunflower oil:28:0.0920	0.0920	28
SO	SO:27	superior oblique:27:0.8903	0.8903	27
SO	SO:27	superoxide:27:0.0166	0.0166	27
SO	SO:15	supraoptic nucleus:15:0.5348	0.5348	15
SO	SO:16	sympathetic ophthalmia:16:0.7261	0.7261	16
SP/AP	SP/AP:7	summating potential/action potential:7:0.4438	0.4438	7
Sp17	Sp17:21|SP17:1	Sperm protein 17:22:0.8594	0.8594	22
SP1	SP1:175|SP-1:40|Sp1:1|sp-1:1	Pregnancy-specific beta 1-glycoprotein:128:0.7314|pregnancy specific beta 1-glycoprotein:25:0.8251|Pregnancy-specific beta-1-glycoprotein:23:0.5025|pregnancy specific beta 1 glycoprotein:17:0.8165|pregnancy-specific beta-1 glycoprotein:14:0.3383|pregnancy specific beta-1 glycoprotein:10:0.7103	0.8251	217
SP1	SP1:16|SP-1:1|sp-1:1	pregnancy-specific beta1-glycoprotein:18:0.6748	0.6748	18
SP1	SP1:26|SP-1:2	Schwangerschaftsprotein 1:28:0.1501	0.1501	28
Sp1	Sp1:41|SP-1:4|Sp-1:1|SP1:1	specificity protein 1:37:0.3703|specificity protein-1:10:0.1519	0.3703	47
SP-54	SP-54:6|SP54:5	pentosan polysulfate:11:0.7357	0.7357	11
SP54	SP54:13	pentosan polysulphate:13:0.7753	0.7753	13
SPACE	SPACE:5	single potential analysis of cavernous electrical activity:5:0.4422	0.4422	5
SPAC	SPAC:13|SP-AC:1	cytarabine ocfosfate:14:0.6911	0.6911	14
SPADI	SPADI:15	Shoulder Pain and Disability Index:15:0.8045	0.8045	15
SPAF	SPAF:10	Stroke Prevention in Atrial Fibrillation:10:0.7357	0.7357	10
SPAI	SPAI:10	Social Phobia and Anxiety Inventory:10:0.7357	0.7357	10
SPAMM	SPAMM:22	spatial modulation of magnetization:22:0.8657	0.8657	22
SPAOPD	SPAOPD:7	summer pasture-associated obstructive pulmonary disease:7:0.5926	0.5926	7
S-PAP	S-PAP:2|sPAP:2|SPAP:1	prostatic acid phosphatase:5:0.2818	0.2818	5
SPAP	SPAP:4|sPAP:1	secreted placental alkaline phosphatase:5:0.2818	0.2818	5
SPAP	SPAP:6|sPAP:5|s-PAP:1	systolic pulmonary arterial pressure:12:0.7571	0.7571	12
SPAP	SPAP:17|sPAP:6	systolic pulmonary artery pressure:23:0.8715	0.8715	23
SPAQ	SPAQ:52	Seasonal Pattern Assessment Questionnaire:52:0.9116	0.9116	52
SPARCS	SPARCS:12	Statewide Planning and Research Cooperative System:12:0.7571	0.7571	12
SPARC	SPARC:45	secreted protein acidic and rich in cysteine:45:0.8395	0.8395	45
SpA	SpA:14|SPA:1	patients with spondylarthropathy:9:0.0550|patients with spondylarthropathies:6:0.0522	0.0550	15
SpA	SpA:20|SPA:1	patients with spondyloarthropathy:21:0.1083	0.1083	21
SPA	SPA:9	polysaccharide antigen:9:0.1267	0.1267	9
spa	spa:13|SpA:1	protein A gene:14:0.5589	0.5589	14
SpA	SpA:12	protein A of Staphylococcus aureus:12:0.7340	0.7340	12
SPA	SPA:7	protein antigen:7:0.0655	0.0655	7
SPA	SPA:8|S-PA:1	pulmonary artery:9:0.2500	0.2500	9
SPA	SPA:77	scintillation proximity assay:77:0.9386	0.9386	77
SPA	SPA:19	serum plate agglutination:19:0.7044	0.7044	19
SPA	SPA:1	sheep with pulmonary adenomatosis:1:0.7096	0.7096	1
SPA	SPA:115	single photon absorptiometry:67:0.9074|single-photon absorptiometry:48:0.3053	0.9074	115
SPA	SPA:6	soluble protective antigen:6:0.3728	0.3728	6
SPA	SPA:91	sperm penetration assay:91:0.8083	0.8083	91
SpA	SpA:10	spondyloarthritides:10:0.0070	0.0070	10
SpA	SpA:17	spondyloarthritis:17:0.0124	0.0124	17
SpA	SpA:71|SPA:2	spondyloarthropathies:73:0.0556	0.0556	73
SPA	SPA:17	spontaneous physical activity:17:0.8270	0.8270	17
SPA	SPA:45	Spontaneous Platelet Aggregation:45:0.8676	0.8676	45
SPA	SPA:6	standard peritoneal permeability analysis:6:0.3728	0.3728	6
SPA	SPA:21	stimulation-produced analgesia:21:0.6400	0.6400	21
SPA	SPA:10	Subperiosteal abscess:10:0.5000	0.5000	10
SPA	SPA:7	suprapubic aspiration:7:0.2902	0.2902	7
SP-A	SP-A:8|SPA:1	surfactant apoprotein:9:0.6794	0.6794	9
SP-A	SP-A:13	surfactant protein:13:0.3554	0.3554	13
SP-A	SP-A:62	surfactant protein-A:62:0.6778	0.6778	62
SPBs	SPBs:41	Spindle pole bodies:41:0.8867	0.8867	41
SPB	SPB:18	Solitary plasmacytoma of bone:18:0.8449	0.8449	18
SPB	SPB:153	spindle pole body:153:0.9804	0.9804	153
SP-B	SP-B:168|SPB:7|Sp-B:1	surfactant protein B:158:0.8573|Surfactant Protein-B:18:0.7044	0.8573	176
SPCs	SPCs:16|SpCs:1	spleen cells:17:0.6211	0.6211	17
SPCs	SPCs:10	subtilisin-like proprotein convertases:10:0.5856	0.5856	10
SPC	SPC:8	salivary protein complex:8:0.5926	0.5926	8
SPC	SPC:25	saturated phosphatidylcholine:25:0.5288	0.5288	25
SPC	SPC:4	second primary cancer:4:0.0918	0.0918	4
spc	spc:10	small polydisperse circular:10:0.5856	0.5856	10
SPC	SPC:14	soy protein concentrate:14:0.4071	0.4071	14
SPC	SPC:9|spc:1	spermatocytes:10:0.0117	0.0117	10
SPC	SPC:9	sphingosylphosphocholine:9:0.0104	0.0104	9
SPC	SPC:82	sphingosylphosphorylcholine:82:0.1049	0.1049	82
SPC	SPC:18|SpC:16|SP-C:1	Spleen cells:35:0.5929	0.5929	35
SPC	SPC:15	standard plate count:15:0.7096	0.7096	15
SPC	SPC:35	Statistical process control:35:0.9151	0.9151	35
SPC	SPC:10	subtilisin-like proprotein convertase:10:0.5856	0.5856	10
SPC	SPC:12	Summary of Product Characteristics:12:0.4153	0.4153	12
SP-C	SP-C:123|SPC:9|Sp-C:4|SpC:1	Surfactant protein C:121:0.8196|surfactant protein-C:16:0.8165	0.8196	137
SPDP	SPDP:41	N-succinimidyl 3-(2-pyridyldithio)propionate:24:0.6427|N-succinimidyl-3-(2-pyridyldithio)propionate:17:0.1221	0.6427	41
SPDV	SPDV:11	salmon pancreas disease virus:11:0.7357	0.7357	11
SPD	SPD:12	l-Stepholidine:12:0.0138	0.0138	12
SPD	SPD:83	Schizotypal Personality Disorder:83:0.8643	0.8643	83
SPD	SPD:5|SpD:3|Sp-D:1	Sprague-Dawley:9:0.0100	0.0100	9
SPD	SPD:13	(-)-stepholidine:13:0.0151	0.0151	13
SPD	SPD:32	storage pool deficiency:32:0.8145	0.8145	32
SPD	SPD:8	Storage Pool Disease:8:0.6411	0.6411	8
SPD	SPD:17	subcorneal pustular dermatosis:17:0.8270	0.8270	17
SP-D	SP-D:192	surfactant protein D:169:0.9538|Surfactant protein-D:23:0.8715	0.9538	192
SPD	SPD:15	synpolydactyly:15:0.0176	0.0176	15
SPECT	SPECT:5	Myocardial perfusion scintigraphy:5:0.2818	0.2818	5
SPECT	SPECT:7	myocardial scintigraphy:7:0.0951	0.0951	7
SPECT	SPECT:186	single-photon emission computed tomographic:100:0.4591|Single photon emission computed tomographic:86:0.9653	0.9653	186
SPECT	SPECT:2357|spect:1	single photon emission computed tomography:2358:0.9868	0.9868	2358
SPECT	SPECT:88	single photon emission CT:88:0.9288	0.9288	88
SPECT	SPECT:9	tomographic imaging:9:0.1690	0.1690	9
SPECT	SPECT:11	tomoscintigraphy:11:0.0021	0.0021	11
SPE-C	SPE-C:4|SpeC:3|SPEC:3|speC:1	streptococcal pyrogenic exotoxin C:11:0.7357	0.7357	11
SPEM	SPEM:61	smooth pursuit eye movement:33:0.9100|smooth pursuit eye movements:28:0.8941	0.9100	61
SPEMs	SPEMs:11	smooth pursuit eye movements:11:0.7357	0.7357	11
SPER/NO	SPER/NO:9|Sper/NO:1	spermine NONOate:10:0.7103	0.7103	10
SPET	SPET:62	single-photon emission tomographic:36:0.4386|Single photon emission tomographic:26:0.8861	0.8861	62
SPET	SPET:653	single-photon emission tomography:405:0.5751|single photon emission tomography:248:0.9683	0.9683	653
SPEV	SPEV:9	slow phase eye velocity:9:0.6794	0.6794	9
SPEs	SPEs:9|Spes:1	streptococcal pyrogenic exotoxins:10:0.7103	0.7103	10
SPE	SPE:15	Serum protein electrophoresis:15:0.8045	0.8045	15
SPE	SPE:9	Solar Particle Events:9:0.6794	0.6794	9
SPE	SPE:878	solid-phase extraction:878:0.7464	0.7464	878
SPE	SPE:34|Spe:7|spe:4	streptococcal pyrogenic exotoxin:34:0.8245|streptococcal pyrogenic exotoxins:11:0.6182	0.8245	45
SPE	SPE:7	substance P endopeptidase:7:0.5926	0.5926	7
SPE	SPE:27	sucrose polyester:27:0.8903	0.8903	27
SPFX	SPFX:67|Spfx:1	Sparfloxacin:68:0.9306	0.9306	68
SPFs	SPFs:8	Sun protection factors:8:0.5006	0.5006	8
SPG4	SPG4:10	spastin gene:10:0.7103	0.7103	10
SPGR	SPGR:22	spoiled gradient-echo:22:0.7955	0.7955	22
SPGR	SPGR:2	spoiled gradient recalled acquisition in steady state:2:0.6411	0.6411	2
SPGR	SPGR:14	spoiled GRASS:14:0.6701	0.6701	14
SPG	SPG:57	schizophyllan:57:0.1800	0.1800	57
SPG	SPG:29	Sizofiran:29:0.0933	0.0933	29
SPG	SPG:9	spastic paraplegia:9:0.6794	0.6794	9
SPG	SPG:12	spermatogonia:12:0.0367	0.0367	12
SPG	SPG:17	sphenopalatine ganglion:17:0.8270	0.8270	17
SpG	SpG:5|SPG:4	Streptococcal protein G:9:0.6794	0.6794	9
SPHA	SPHA:5	Solid Phase Haemadsorption Assay:5:0.4422	0.4422	5
SPHK1	SPHK1:4|SphK1:2	sphingosine kinase type 1:6:0.5290	0.5290	6
SPI2	SPI2:6|SPI-2:1	type III secretion system encoded by Salmonella Pathogenicity Island 2:7:0.5926	0.5926	7
SPIA	SPIA:7	sol particle immunoassay:7:0.5926	0.5926	7
SPID	SPID:24	pain intensity difference:24:0.8768	0.8768	24
SPID	SPID:16	sum of pain intensity differences:16:0.6178	0.6178	16
SPIEM	SPIEM:10	Solid phase immune electron microscopy:10:0.7103	0.7103	10
SPIHT	SPIHT:11	set partitioning in hierarchical trees:11:0.7357	0.7357	11
SPINK1	SPINK1:7	serine protease inhibitor Kazal type 1:7:0.8449	0.8449	7
SPIN	SPIN:22	speech perception in noise:22:0.8657	0.8657	22
SPIO	SPIO:97|Spio:1	superparamagnetic iron oxide:98:0.8956	0.8956	98
SPIO	SPIO:10	superparamagnetic iron oxide particles:10:0.7103	0.7103	10
SP-IR	SP-IR:15|SP-ir:3|sP-IR:1|SPir:1	substance P-immunoreactive:20:0.8525	0.8525	20
SP-IR	SP-IR:7|SP-ir:3|SPIR:1	substance P immunoreactivity:11:0.7357	0.7357	11
SP-IR	SP-IR:8|SP-ir:2	Substance P-like immunoreactive:10:0.7103	0.7103	10
SP-IR	SP-IR:7|SPir:1|SPIR:1	substance P-like immunoreactivity:9:0.6794	0.6794	9
SPI	SPI:12	infection:12:0.0244	0.0244	12
SP-I	SP-I:8	secretory protein-I:8:0.5006	0.5006	8
Spi	Spi:13|SPI:4|spi:1	serine protease inhibitor:18:0.8365	0.8365	18
SPI	SPI:7	single-point imaging:7:0.2113	0.2113	7
SPI	SPI:82	soy protein isolate:82:0.6895	0.6895	82
SpI	SpI:11|SPI:2	subnucleus interpolaris:13:0.7753	0.7753	13
SPI	SPI:10	substance P-like immunoreactive:10:0.7103	0.7103	10
SPI	SPI:8|SP-I:1	substance P-like immunoreactivity:9:0.6794	0.6794	9
SPJ	SPJ:14	junction:14:0.9286	0.9286	14
SPKT	SPKT:9|spkt:1	transplantation:10:0.5625	0.5625	10
SPK	SPK:17	simultaneous pancreas and kidney:17:0.7760	0.7760	17
SPK	SPK:14	simultaneous pancreas and kidney transplantation:14:0.8270	0.8270	14
SPK	SPK:63	simultaneous pancreas-kidney:63:0.9018	0.9018	63
SPK	SPK:24	simultaneous pancreas-kidney transplantation:24:0.8115	0.8115	24
SPK	SPK:6	sphingosine kinase:6:0.2243	0.2243	6
SPK	SPK:16	transplant:16:0.0644	0.0644	16
SPLIR	SPLIR:5|SP-LIR:1|SPl-ir:1|SPL-IR:1	substance P-like immunoreactivity:8:0.6411	0.6411	8
SP-LI	SP-LI:27|SPLI:20|SP-li:2|SP-Li:1	SP-like immunoreactivity:50:0.1555	0.1555	50
SP-LI	SP-LI:14	substance P:14:0.7909	0.7909	14
SP-LI	SP-LI:10|SPLI:6	substance P-like immunoreactive:16:0.8165	0.8165	16
SPLI	SPLI:84|SP-LI:82|SP-li:2|SPli:1	substance P-like immunoreactivity:169:0.9823	0.9823	169
SPLP	SPLP:9	synthetic precipitation leaching procedure:9:0.6794	0.6794	9
SPLV	SPLV:6	serum parvovirus-like virus:6:0.5290	0.5290	6
SPLs	SPLs:34	sound pressure levels:34:0.9126	0.9126	34
SpL	SpL:9|SPL:1|Spl:1	lateral spiriform nucleus:11:0.7357	0.7357	11
SPL	SPL:7	phage lysate:7:0.2113	0.2113	7
SPL	SPL:220	sound pressure level:198:0.9849|sound pressure levels:22:0.8657	0.9849	220
SPL	SPL:14	spironolactone:14:0.0218	0.0218	14
SPL	SPL:15|spl:1|Spl:1	splenocytes:17:0.0268	0.0268	17
SPL	SPL:26	superior parietal lobule:26:0.8861	0.8861	26
S-PMA	S-PMA:26|SPMA:3	S-phenylmercapturic acid:29:0.8978	0.8978	29
SPMA	SPMA:11	spinal progressive muscular atrophy:11:0.7357	0.7357	11
SPMDs	SPMDs:67	Semipermeable membrane devices:67:0.7400	0.7400	67
SPME	SPME:41	Solid-phase micro-extraction:18:0.3168|Solid Phase Micro-Extraction:16:0.7261|solid phase micro extraction:7:0.5926	0.7261	41
SPME	SPME:622	Solid-phase microextraction:504:0.7718|Solid phase microextraction:118:0.9465	0.9465	622
SPMR	SPMR:6	Standardized Proportional Mortality Ratio:6:0.5290	0.5290	6
SPMSQ	SPMSQ:42	Short Portable Mental Status Questionnaire:42:0.9291	0.9291	42
SPMS	SPMS:32|SP-MS:6	secondary progressive MS:38:0.9217	0.9217	38
SPMS	SPMS:15|SP-MS:1	secondary progressive multiple sclerosis:16:0.7261	0.7261	16
SPMs	SPMs:20	Statistical Parametric Maps:20:0.8525	0.8525	20
SPMs	SPMs:21	synaptic plasma membranes:21:0.6040	0.6040	21
SPMV	SPMV:10|sPMV:1	satellite panicum mosaic virus:11:0.7357	0.7357	11
SPNs	SPNs:39	solitary pulmonary nodules:39:0.9237	0.9237	39
SPNs	SPNs:88	sympathetic preganglionic neurons:88:0.9660	0.9660	88
SPNs	SPNs:28	sympathetic preganglionic neurones:28:0.8369	0.8369	28
SPN	SPN:39	sacral parasympathetic nucleus:39:0.9237	0.9237	39
SPN	SPN:48	solitary pulmonary nodule:30:0.9011|solitary pulmonary nodules:18:0.8270	0.9011	48
SPN	SPN:18	stimulus-preceding negativity:11:0.3213|stimulus preceding negativity:7:0.5926	0.5926	18
Spn	Spn:7|SPn:5|SPN:5	Streptococcus pneumoniae:17:0.8270	0.8270	17
SPN	SPN:11	superficial peroneal nerve:11:0.7357	0.7357	11
SPN	SPN:31	sympathetic preganglionic neurons:31:0.8519	0.8519	31
SPN	SPN:16	sympathetic preganglionic neurones:16:0.7261	0.7261	16
SpO2	SpO2:209|Spo2:15|SPO2:9|spO2:1	oxygen saturation:234:0.6591	0.6591	234
SpO2	SpO2:14|SPO2:1	oxygen saturation by pulse oximetry:15:0.6400	0.6400	15
SpO2	SpO2:9|Spo2:1	pulse oxymetry:10:0.7103	0.7103	10
SPOMe	SPOMe:9|SPOME:1	substance P methyl ester:10:0.7103	0.7103	10
SPP1	SPP1:7|Spp1:2|Spp-1:1	Osteopontin:10:0.3600	0.3600	10
Spp1	Spp-1:2|spp1:2|Spp1:2|SPP1:1	secreted phosphoprotein 1:7:0.5926	0.5926	7
SPPS	SPPS:32	solid-phase peptide synthesis:32:0.4601	0.4601	32
SPPS	SPPS:9	stable plasma protein solution:9:0.5470	0.5470	9
SPPs	SPPs:9	surface plasmon polaritons:9:0.6794	0.6794	9
SPP	SPP:12	Signal peptide peptidase:12:0.7571	0.7571	12
SPP	SPP:17	skin perfusion pressure:17:0.6748	0.6748	17
SPP	SPP:10	Sodium pentosan polysulphate:10:0.7103	0.7103	10
SPP	SPP:109	sphingosine-1-phosphate:69:0.1960|sphingosine 1-phosphate:40:0.9256	0.9256	109
SPP	SPP:8	stromal processing peptidase:8:0.6411	0.6411	8
SPQ	SPQ:23	6-methoxy-N-(3-sulfopropyl)quinolinium:23:0.2115	0.2115	23
SPQ	SPQ:28	Schizotypal Personality Questionnaire:28:0.8941	0.8941	28
SPRCA	SPRCA:7	solid phase red cell adherence:7:0.5926	0.5926	7
SPRD	SPRD:11	Sprague-Dawley:11:0.5263	0.5263	11
SPRIA	SPRIA:38|SP-RIA:7|S-PRIA:1|spRIA:1	solid-phase radioimmunoassay:47:0.5732	0.5732	47
SPRINT	SPRINT:12	Secondary Prevention Reinfarction Israeli Nifedipine Trial:12:0.7571	0.7571	12
SPRIST	SPRIST:10	solid-phase reverse immunosorbent test:10:0.7103	0.7103	10
SPRMs	SPRMs:11	selective progesterone receptor modulators:11:0.7357	0.7357	11
SPRT	SPRT:14	Sequential Probability Ratio Test:14:0.7909	0.7909	14
SPRs	SPRs:5	Prevalence Ratios:5:0.0736	0.0736	5
SPRs	SPRs:5	Scatter-to-primary ratios:5:0.0736	0.0736	5
SpRs	SpRs:25	specialist registrars:25:0.8186	0.8186	25
SPR	SPR:25	Selective posterior rhizotomy:25:0.7679	0.7679	25
SPR	SPR:10	sepiapterin reductase:10:0.7103	0.7103	10
SPR	SPR:9	skin potential reflex:9:0.6794	0.6794	9
SPR	SPR:10	skin potential response:10:0.7103	0.7103	10
SPR	SPR:14	Slide Positivity Rate:14:0.7909	0.7909	14
SPR	SPR:17|SP-R:1	SP receptor:18:0.1651	0.1651	18
SpR	SpR:13	specialist registrar:13:0.6701	0.6701	13
SPR	SPR:52|SP-R:1	substance P receptor:48:0.9366|substance P receptors:5:0.4422	0.9366	53
SPR	SPR:670	Surface plasmon resonance:670:0.9881	0.9881	670
SPT/AGT	SPT/AGT:10	aminotransferase:10:0.9000	0.9000	10
SPTCL	SPTCL:14	Subcutaneous panniculitis-like T-cell lymphoma:14:0.7909	0.7909	14
s-PTH	s-PTH:6|S-PTH:2|SPTH:2|sPTH:2	serum parathyroid hormone:12:0.4557	0.4557	12
SPTs	SPTs:13	Second primary tumors:13:0.7753	0.7753	13
SPTs	SPTs:74|SPTS:1	Skin prick tests:75:0.9602	0.9602	75
SPTs	SPTs:17	subject-performed tasks:17:0.6748	0.6748	17
SPT	SPT:5	8-(p-sulfophenyl) theophylline:5:0.1132	0.1132	5
SPT	SPT:7	second primary tumor:7:0.3524	0.3524	7
SPT	SPT:47	serine palmitoyltransferase:47:0.9366	0.9366	47
SPT	SPT:9	Single-particle tracking:9:0.3069	0.3069	9
SPT	SPT:391	skin prick test:245:0.9804|skin prick tests:146:0.9795	0.9804	391
SPT	SPT:50	skin prick testing:38:0.9217|skin-prick testing:12:0.1005	0.9217	50
SPT	SPT:6	sleep period time:6:0.5290	0.5290	6
SPT	SPT:32	supportive periodontal therapy:32:0.9072	0.9072	32
SPT	SPT:8	supportive periodontal treatment:8:0.6411	0.6411	8
spv	spv:8|Spv:1	salmonella plasmid virulence:9:0.6794	0.6794	9
SPV	SPV:106|spV:2|SpV:1	selective proximal vagotomy:109:0.9563	0.9563	109
SPV	SPV:44	slow phase velocity:29:0.8978|slow-phase velocity:15:0.1218	0.8978	44
SPV	SPV:8	stratum periventriculare:8:0.5006	0.5006	8
SPV	SPV:11	swinepox virus:11:0.2764	0.2764	11
SPV	SPV:22	systolic pressure variation:22:0.7955	0.7955	22
SPases	SPases:7	type I signal peptidases:7:0.5926	0.5926	7
SPase	SPase:12|SP-ase:1	signal peptidase:13:0.7753	0.7753	13
SPS	SPS:6	protein synthesis:6:0.1010	0.1010	6
SPS	SPS:8	semipermeable surface:8:0.2987	0.2987	8
SPs	SPs:87	Senile plaques:87:0.9656	0.9656	87
SPs	SPs:11	silent periods:11:0.6182	0.6182	11
SPS	SPS:18	simple partial seizures:18:0.8365	0.8365	18
SPS	SPS:9	simulated public speaking:9:0.6794	0.6794	9
SPs	SPs:11	slow potentials:11:0.1330	0.1330	11
SPS	SPS:9	sodium polyanetholesulfonate:9:0.6794	0.6794	9
SPS	SPS:6	sodium polystyrene sulfonate:6:0.5290	0.5290	6
SPs	SPs:64	standardized patients:64:0.6462	0.6462	64
SPS	SPS:25	Stiff-person syndrome:25:0.4451	0.4451	25
SPs	SPs:9|sps:6	stress proteins:15:0.1400	0.1400	15
SPS	SPS:44|Sps:1	sucrose-phosphate synthase:32:0.4711|sucrose phosphate synthase:13:0.6701	0.6701	45
SPS	SPS:10	Suicide Probability Scale:10:0.7103	0.7103	10
SPs	SPS:3|SPs:3	sulfated polysaccharides:6:0.1148	0.1148	6
SQA	SQA:9	Sperm Quality Analyzer:9:0.6794	0.6794	9
SQC	SQC:14|SqC:3	squamous cell carcinoma:17:0.8270	0.8270	17
SQDG	SQDG:12	sulfoquinovosyl diacylglycerol:12:0.5664	0.5664	12
SQDG	SQDG:19	sulfoquinovosyldiacylglycerol:19:0.4091	0.4091	19
SQGs	SQGs:8	sediment quality guidelines:8:0.6411	0.6411	8
SQI	SQI:9	sperm quality index:9:0.4587	0.4587	9
SQOL	SQOL:8	subjective quality of life:8:0.5006	0.5006	8
SQR	SQR:10	oxidoreductase:10:0.3214	0.3214	10
SQS	SQS:22	squalene synthase:22:0.8657	0.8657	22
SQV	SQV:78|sqv:1	Saquinavir:79:0.8864	0.8864	79
SQ	SQ:11	quality:11:0.0310	0.0310	11
SQ	SQ:10	semiquinone:10:0.0279	0.0279	10
SQ	SQ:10	speed quotient:10:0.2446	0.2446	10
SQ	SQ:15|Sq:1	squalene:16:0.0495	0.0495	16
SQ	SQ:14|Sq:5|sq:1	squamous cell carcinoma:11:0.7357|squamous cell carcinomas:9:0.6794	0.7357	20
SQ	SQ:44|sq:4	subcutaneous:48:0.1455	0.1455	48
SQ	SQ:17	subcutaneously:17:0.0495	0.0495	17
SQ	SQ:21	Symptom Questionnaire:21:0.3527	0.3527	21
SR-PGA	SR-PGA:16	self-reinforced polyglycolic acid:16:0.8165	0.8165	16
SR-PGA	SR-PGA:21	self-reinforced polyglycolide:21:0.6040	0.6040	21
SR-PLLA	SR-PLLA:9	self-reinforced poly-L-lactic acid:9:0.4587	0.4587	9
SR-PLLA	SR-PLLA:38	self-reinforced poly-l-lactide:38:0.7860	0.7860	38
SRA	SRA:20	activity:20:0.0779	0.0779	20
SRA	SRA:13	regression analysis:13:0.5934	0.5934	13
SRA	SRA:18	release assay:18:0.5560	0.5560	18
SR-A	SR-A:48|SRA:5	scavenger receptor:42:0.9291|scavenger receptors:11:0.6182	0.9291	53
SRA	SRA:9	serum resistance associated:9:0.6794	0.6794	9
SRA	SRA:12|sra:1	specific radioactivity:13:0.6701	0.6701	13
SRA	SRA:14	steroid receptor RNA activator:14:0.7909	0.7909	14
SR-B1	SR-B1:7|SRB1:1	scavenger receptor B1:8:0.6411	0.6411	8
SRB51	SRB51:14	Brucella abortus strain RB51:14:0.7909	0.7909	14
SRBCs	SRBCs:16|sRBCs:1	sheep erythrocytes:17:0.6748	0.6748	17
SRBCs	SRBCs:65|sRBCs:4	sheep red blood cells:69:0.9316	0.9316	69
SRBC	SRBC:20	anti-sheep erythrocyte:20:0.2611	0.2611	20
SRBC	SRBC:386|sRBC:13|SRbc:1	sheep erythrocytes:376:0.9646|Sheep erythrocyte:24:0.3435	0.9646	400
SRBC	SRBC:114|sRBC:4|Srbc:1	sheep red blood cell:119:0.6193	0.6193	119
SRBD	SRBD:51	sleep-related breathing disorders:30:0.5478|sleep related breathing disorders:12:0.7571|Sleep-related breathing disorder:9:0.6794	0.7571	51
SR-BI	SR-BI:5	class B type I scavenger receptor:5:0.7571	0.7571	5
SR-BI	SR-BI:39|SRBI:1	scavenger receptor BI:40:0.9256	0.9256	40
SR-BI	SR-BI:118|SRB-I:1|SRBI:1	scavenger receptor class B type I:120:0.9830	0.9830	120
SRB	SRB:9	Senegal river basin:9:0.6794	0.6794	9
SRB	SRB:7	sex ratio at birth:7:0.5926	0.5926	7
SRB	SRB:114	sulfate-reducing bacteria:114:0.6210	0.6210	114
SRB	SRB:9	sulfate-reducing bacterium:9:0.3945	0.3945	9
SRB	SRB:47	sulforhodamine B:47:0.6308	0.6308	47
SRC-1	SRC-1:118|SRC1:7	steroid receptor coactivator-1:88:0.8984|steroid receptor coactivator 1:37:0.8292	0.8984	125
SRCA	SRCA:17	Specific Red Cell Adherence:17:0.7407	0.7407	17
SRCA	SRCA:83	subrenal capsule assay:83:0.9422	0.9422	83
SRCC	SRCC:21	cell carcinoma:21:0.7865	0.7865	21
SRCD	SRCD:9	Synchrotron radiation circular dichroism:9:0.6794	0.6794	9
SRCR	SRCR:47	scavenger receptor cysteine-rich:47:0.9379	0.9379	47
SRCs	SRCs:10	steroid receptor coactivators:10:0.7103	0.7103	10
SRC	SRC:5	SCID repopulating cells:5:0.0902	0.0902	5
SRC	SRC:21	Scleroderma renal crisis:21:0.7865	0.7865	21
SRC	SRC:21	sheep erythrocytes:21:0.8594	0.8594	21
SRC	SRC:18	sheep red cells:18:0.8365	0.8365	18
SRC	SRC:18	steroid receptor coactivator:18:0.5940	0.5940	18
SRC	SRC:22	stimulus-response compatibility:22:0.7955	0.7955	22
SRC	SRC:32|src:2	subrenal capsule:34:0.8245	0.8245	34
src	src:9	transforming gene:9:0.2500	0.2500	9
SRD	SRD:5	sarcin/ricin domain:5:0.0736	0.0736	5
SRD	SRD:5	signal response domain:5:0.4422	0.4422	5
SRD	SRD:10	specific reading disability:10:0.7103	0.7103	10
SRD	SRD:24	subnucleus reticularis dorsalis:24:0.8715	0.8715	24
SRD	SRD:5	substance-related disorder:5:0.0736	0.0736	5
SRD	SRD:14	sucrose-rich diet:14:0.4367	0.4367	14
SRE-1	SRE-1:7	sterol regulatory element-1:7:0.5926	0.5926	7
SREBP-1	SREBP-1:53|SREBP1:7|srebp-1:1	sterol regulatory element-binding protein-1:25:0.8816|Sterol regulatory element binding protein-1:24:0.8768|sterol regulatory element-binding protein 1:12:0.7571	0.8816	61
SREBP-2	SREBP-2:23	sterol regulatory element-binding protein-2:11:0.7357|sterol regulatory element binding protein-2:7:0.5926|sterol regulatory element-binding protein 2:5:0.4422	0.7357	23
SREBPs	SREBPs:148	sterol regulatory element-binding proteins:95:0.9682|sterol regulatory element binding proteins:53:0.9438	0.9682	148
SREBP	SREBP:70	sterol regulatory element binding protein:34:0.8605|sterol regulatory element-binding protein:29:0.7834|sterol regulatory element-binding proteins:7:0.5926	0.8605	70
SREHP	SREHP:8	serine rich Entamoeba histolytica protein:8:0.6411	0.6411	8
SREs	SREs:31	serum response elements:31:0.7718	0.7718	31
SREs	SREs:16	skeletal-related events:16:0.6024	0.6024	16
SRE	SRE:258	serum response element:253:0.9335|serum response elements:5:0.2818	0.9335	258
SRE	SRE:9	skeletal-related event:9:0.6794	0.6794	9
SRE	SRE:10|SR-E:2	syringomycin E:12:0.7571	0.7571	12
SRFs	SRFs:4|s-RFs:1|SRFS:1	receptive fields:6:0.2243	0.2243	6
SRFs	SRFs:8	stimulus-response functions:8:0.4102	0.4102	8
SRF	SRF:11	repetitive firing:11:0.7357	0.7357	11
SRF	SRF:375	serum response factor:375:0.9871	0.9871	375
SRF	SRF:11	specific resistance to filtration:11:0.6460	0.6460	11
SRF	SRF:7	split renal function:7:0.2902	0.2902	7
SRF	SRF:43	subretinal fluid:43:0.7795	0.7795	43
SRF	SRF:10	subretrofacial:10:0.0153	0.0153	10
SRF	SRF:12	subretrofacial nucleus:12:0.7571	0.7571	12
SRG	SRG:9	shark rectal gland:9:0.4587	0.4587	9
SRH	SRH:46	self-rated health:46:0.6382	0.6382	46
SRH	SRH:38	single radial haemolysis:38:0.8417	0.8417	38
SRH	SRH:15	single radial hemolysis:15:0.8045	0.8045	15
SRH	SRH:5	Subretinal hemorrhage:5:0.1132	0.1132	5
SRID	SRID:55	single radial immunodiffusion:55:0.8882	0.8882	55
SRIF-LI	SRIF-LI:23	somatostatin-like immunoreactivity:23:0.5719	0.5719	23
SRIF	SRIF:1045|Srif:1	somatostatin:1046:0.9159	0.9159	1046
SRIF	SRIF:17	somatostatin-14:17:0.0140	0.0140	17
SRIF	SRIF:24	somatotropin release-inhibiting factor:17:0.6381|somatotropin release inhibiting factor:7:0.3069	0.6381	24
SRIH	SRIH:182	somatostatin:182:0.9330	0.9330	182
SRII	SRII:12|SR-II:1|sR-II:1	sensory rhodopsin II:14:0.7909	0.7909	14
SRIs	SRIs:79	serotonin reuptake inhibitors:79:0.8580	0.8580	79
SR-I	SR-I:19|SRI:17|sR-I:3	sensory rhodopsin I:39:0.9237	0.9237	39
SRI	SRI:32	serotonin reuptake inhibitor:32:0.7782	0.7782	32
SRI	SRI:21	Strain Rate Imaging:21:0.8594	0.8594	21
SRI	SRI:38	surface regularity index:38:0.9217	0.9217	38
SRK	SRK:8	S locus receptor kinase:8:0.6411	0.6411	8
SRK	SRK:10	S receptor kinase:10:0.1774	0.1774	10
SRK	SRK:13	Shaking rat Kawasaki:13:0.7571	0.7571	13
SRLV	SRLV:11	small ruminant lentiviruses:11:0.7357	0.7357	11
SRMs	SRMs:50	Standard Reference Materials:50:0.9392	0.9392	50
SRM	SRM:62	Standard Reference Material:48:0.9006|standard reference materials:14:0.7909	0.9006	62
SRM	SRM:44	standardized response mean:34:0.6015|standardized response means:10:0.5856	0.6015	44
SRNS	SRNS:67	nephrotic syndrome:67:0.9554	0.9554	67
SRN	SRN:26	subretinal neovascularization:26:0.8251	0.8251	26
SROC	SROC:12|sROC:1	summary receiver operating characteristic:13:0.7753	0.7753	13
SRO	SRO:12	shortest region of overlap:12:0.1299	0.1299	12
SRO	SRO:24	smallest region of overlap:24:0.4060	0.4060	24
SRP54	SRP54:13	signal recognition particle:13:0.7753	0.7753	13
SRPDB	SRPDB:10	signal recognition particle database:10:0.7103	0.7103	10
SRPS	SRPS:16	short rib-polydactyly syndrome:11:0.7357|Short Rib Polydactyly Syndrome:5:0.4422	0.7357	16
SRP	SRP:110	scaling and root planing:110:0.9422	0.9422	110
SRP	SRP:388	signal recognition particle:388:0.9874	0.9874	388
SRP	SRP:7	signal recognition protein:7:0.5926	0.5926	7
SRP	SRP:30	soluble reactive phosphorus:30:0.9011	0.9011	30
SRQ	SRQ:47	Questionnaire:47:0.8519	0.8519	47
SRQ-20	SRQ-20:23	Questionnaire:23:0.8462	0.8462	23
SRRs	SRRs:6	risk ratios:6:0.1010	0.1010	6
SRRS	SRRS:26	Social Readjustment Rating Scale:26:0.8861	0.8861	26
SRR	SRR:8	skin resistance response:8:0.5006	0.5006	8
SRR	SRR:7	steroid-resistant rejection:7:0.2113	0.2113	7
SRSV	SRSV:43	Small round structured virus:27:0.8903|small round structured viruses:16:0.8270	0.8903	43
SRSVs	SRSVs:43	small round structured viruses:28:0.8978|Small round-structured viruses:15:0.8270	0.8978	43
SRSs	SRSs:10	Spontaneous recurrent seizures:10:0.7103	0.7103	10
SRS	SRS:26	Savannah River Site:26:0.8861	0.8861	26
SRs	SRs:16	scavenger receptors:16:0.3317	0.3317	16
SRS	SRS:9	Scoliosis Research Society:9:0.4587	0.4587	9
SRS	SRS:18	sex reassignment surgery:18:0.8365	0.8365	18
SRS	SRS:55	Silver-Russell syndrome:55:0.8622	0.8622	55
SRS	SRS:7	simple random sampling:7:0.3524	0.3524	7
SRS	SRS:57	slow reacting substance:30:0.9011|slow-reacting substance:27:0.3177	0.9011	57
SRS	SRS:94	Somatostatin receptor scintigraphy:94:0.9339	0.9339	94
SRS	SRS:24	spontaneous recurrent seizures:24:0.8768	0.8768	24
SRS	SRS:153	stereotactic radiosurgery:153:0.9397	0.9397	153
SRS	SRS:14	stimulated Raman scattering:14:0.6911	0.6911	14
SRS	SRS:15	subretinal space:15:0.8045	0.8045	15
SRS	SRS:4	Supervision Rating Scale:4:0.0918	0.0918	4
SRs	SRs:15|Srs:1	systemic reactions:16:0.8165	0.8165	16
SRTM	SRTM:8	simplified reference tissue model:8:0.6411	0.6411	8
SRTX	SRTX:9	sarafotoxin:9:0.4211	0.4211	9
SRTs	SRTs:24	saccadic reaction times:24:0.6767	0.6767	24
SRTs	SRTs:22	speech reception thresholds:22:0.7955	0.7955	22
SRT	SRT:16	radiation therapy:16:0.2812	0.2812	16
SRT	SRT:10	reaction time task:10:0.7103	0.7103	10
SRT	SRT:9	Saccadic reaction times:9:0.3069	0.3069	9
SRT	SRT:15	Selective Reminding Test:15:0.8045	0.8045	15
SRT	SRT:65|srt:1	simple reaction time:66:0.4194	0.4194	66
SRT	SRT:33	sludge retention time:33:0.3820	0.3820	33
SRT	SRT:25	solids retention time:25:0.2586	0.2586	25
SRT	SRT:79	speech reception threshold:45:0.9338|speech-reception threshold:26:0.2089|speech reception thresholds:8:0.6411	0.9338	79
SRT	SRT:67	stereotactic radiotherapy:67:0.7400	0.7400	67
SRT	SRT:11	surfactant replacement therapy:11:0.7357	0.7357	11
SRT	SRT:11|S-RT:1|SR-T:1	Sustained-release theophylline:13:0.4444	0.4444	13
SRT	SRT:9	Symptom Rating Test:9:0.5470	0.5470	9
SRUS	SRUS:34	solitary rectal ulcer syndrome:34:0.9126	0.9126	34
SRV-1	SRV-1:9	simian retrovirus type 1:9:0.3945	0.3945	9
SRVG	SRVG:10	silastic ring vertical gastroplasty:10:0.4363	0.4363	10
SRV	SRV:7	sarcoplasmic reticulum vesicles:7:0.5926	0.5926	7
SRV	SRV:15	Simian retrovirus:15:0.2845	0.2845	15
SRV	SRV:6	street rabies virus:6:0.5290	0.5290	6
SRV	SRV:10	type D retrovirus:10:0.7103	0.7103	10
SRW	SRW:9	short ragweed:9:0.6794	0.6794	9
sry	sry:5	Drosophila serendipity:5:0.0517	0.0517	5
SRY	SRY:6|Sry:2	region Y gene:8:0.6794	0.6794	8
SRY	SRY:2	sex determining region of the Y:2:0.8045	0.8045	2
SRY	SRY:18|Sry:2	sex-determining region of the Y chromosome:20:0.5524	0.5524	20
SRY	SRY:20	Sex-determining region Y:20:0.4438	0.4438	20
SRaw	SRaw:66|sRaw:64|SRAW:2|sRAW:2|Sraw:1	specific airway resistance:135:0.9647	0.9647	135
SR	SR:15	Racer:15:0.0022	0.0022	15
SR	SR:14	region:14:0.0019	0.0019	14
SR	SR:10	resection:10:0.0014	0.0014	10
SR	SR:10	Saccharopolyspora rectivirgula:10:0.5000	0.5000	10
SR	SR:11	salt resistant:11:0.1203	0.1203	11
SR	SR:47	sarcoplasmic reticular:47:0.9006	0.9006	47
SR	SR:3283	sarcoplasmic reticulum:3283:0.9845	0.9845	3283
SR	SR:6	sarcoplasmic reticulum membranes:6:0.5290	0.5290	6
SR	SR:9	sarcoplasmic reticulum vesicles:9:0.6794	0.6794	9
SR	SR:14	saturation recovery:14:0.4709	0.4709	14
SR	SR:49	scavenger receptor:32:0.2275|scavenger receptors:17:0.2451	0.2451	49
SR	SR:32	seizure-resistant:18:0.0027|seizure resistant:14:0.1882	0.1882	32
SR	SR:12	self-reinforced:12:0.0017	0.0017	12
SR	SR:8	sensory rhodopsin:8:0.5470	0.5470	8
SR	SR:13	sepiapterin reductase:13:0.4849	0.4849	13
SR	SR:26	serine-arginine:17:0.0025|serine/arginine:9:0.0013	0.0025	26
SR	SR:37	serine/arginine-rich:37:0.0055	0.0055	37
SR	SR:12	sex ratio:12:0.0941	0.0941	12
SR	SR:7	shift reagent:7:0.3524	0.3524	7
SR	SR:20	silicone rubber:20:0.7173	0.7173	20
SR	SR:258	sinus rhythm:258:0.9752	0.9752	258
SR	SR:8	skin resistance:8:0.1061	0.1061	8
SR	SR:97|sr:1|-SR:1|S-R:1	slow-release:68:0.0108|slow release:32:0.1572	0.1572	100
SR	SR:36	spontaneous rate:26:0.0719|spontaneous rates:10:0.0929	0.0929	36
SR	SR:9	Spontaneous Regression:9:0.6794	0.6794	9
SR	SR:6	spontaneous remission:6:0.1838	0.1838	6
SR	SR:7	spontaneous respiration:7:0.2902	0.2902	7
SR	SR:32	standard risk:20:0.7766|standard-risk:12:0.0017	0.7766	32
SR	SR:7	stapedial reflex:7:0.0565	0.0565	7
SR	SR:9	stapedius reflex:9:0.1099	0.1099	9
SR	SR:15	Stereotactic radiosurgery:15:0.8045	0.8045	15
SR	SR:28|Sr:1	steroid-resistant:20:0.0030|steroid resistant:9:0.0783	0.0783	29
S-R	S-R:88|SR:11|S--R:1	stimulus-response:100:0.0157	0.0157	100
SR	SR:48	Stochastic resonance:48:0.9379	0.9379	48
SR	SR:5	storage phosphor radiography:5:0.4422	0.4422	5
SR	SR:33	strain rate:33:0.0993	0.0993	33
SR	SR:27|sr:1	stratum radiatum:28:0.7905	0.7905	28
SR	SR:7	stretch reflex:7:0.0565	0.0565	7
Sr	Sr:80|SR:3	strontium:83:0.0130	0.0130	83
SR	SR:19	superior rectus:19:0.8449	0.8449	19
SR	SR:240|S-R:3|sr:1|s-r:1	sustained-release:148:0.0232|sustained release:97:0.6331	0.6331	245
SR	SR:15	sustained responders:15:0.5818	0.5818	15
SR	SR:43	sustained response:43:0.4524	0.4524	43
SR	SR:29	Sweat rate:29:0.0835	0.0835	29
SR	SR:22	Sweating rate:22:0.0566	0.0566	22
SR	SR:19	synaptic ribbons:19:0.8657	0.8657	19
SR	SR:32	synchrotron radiation:32:0.7166	0.7166	32
SR	SR:13	Systematic review:13:0.7753	0.7753	13
SR	SR:21	systemic reaction:11:0.2040|systemic reactions:10:0.7103	0.7103	21
SS/Jr	SS/Jr:29|SS/jr:1|SS/JR:1	Dahl salt-sensitive:31:0.6343	0.6343	31
SS-14	SS-14:29|SS14:3	Somatostatin:32:0.2562	0.2562	32
SS-14	SS-14:58|SS14:10|S-S-14:2|ss-14:1	somatostatin-14:71:0.5785	0.5785	71
SSADH	SSADH:36|SSA-DH:1	succinic semialdehyde dehydrogenase:37:0.7019	0.7019	37
S-SAD	S-SAD:5|SSAD:1	Subsyndromal SAD:6:0.1838	0.1838	6
SSAO	SSAO:188	semicarbazide-sensitive amine oxidase:177:0.8755|semicarbazide-sensitive amine oxidases:11:0.7357	0.8755	188
SSAP	SSAP:6|S-SAP:4	sequence-specific amplification polymorphism:10:0.5856	0.5856	10
SSAT	SSAT:35	spermidine/spermine N(1)-acetyltransferase:35:0.8681	0.8681	35
SSAT	SSAT:71	spermidine/spermine N1-acetyltransferase:71:0.8436	0.8436	71
SSAV	SSAV:11|SSaV:1	simian sarcoma-associated virus:12:0.7571	0.7571	12
SSA	SSA:18	analysis:18:0.0208	0.0208	18
SSA	SSA:14	senile systemic amyloidosis:14:0.7909	0.7909	14
SSA	SSA:29	single-strand annealing:29:0.7581	0.7581	29
SSA	SSA:8	skin nerve sympathetic activity:8:0.6411	0.6411	8
SSA	SSA:67	Social Security Administration:67:0.9554	0.9554	67
SSA	SSA:13	specific surface area:13:0.5934	0.5934	13
SSA	SSA:41|sSA:2	Sub-Saharan Africa:43:0.8917	0.8917	43
SSA	SSA:14	succinic semialdehyde:14:0.6173	0.6173	14
SSA	SSA:10	sulfosalicylic acid:10:0.1994	0.1994	10
SSA	SSA:8	superoxide scavenging activity:8:0.5006	0.5006	8
SSBE	SSBE:19	short-segment Barrett's esophagus:12:0.2972|Short segment Barrett's esophagus:7:0.5926	0.5926	19
SSBP	SSBP:7	binding protein:7:0.2452	0.2452	7
SSBP	SSBP:12	sitting systolic blood pressure:12:0.4153	0.4153	12
SSBR	SSBR:10	break repair:10:0.5856	0.5856	10
SSBs	SSBs:77|ssbs:4	DNA single-strand breaks:81:0.4902	0.4902	81
SSBs	SSBs:29|ssbs:2	single strand breaks:31:0.8519	0.8519	31
SSBs	SSBs:23	Single-stranded DNA binding proteins:12:0.6460|single-stranded DNA-binding proteins:11:0.7357	0.7357	23
SSB	SSB:77|ssb:23	DNA single-strand breaks:100:0.4067	0.4067	100
SSB	SSB:6|ssb:1	Escherichia coli single-strand binding:7:0.5926	0.5926	7
SSB	SSB:16	Escherichia coli single-stranded DNA binding protein:16:0.4274	0.4274	16
SSB	SSB:10	short spike bursts:10:0.7103	0.7103	10
SSB	SSB:91|ssb:38	single strand breaks:87:0.8573|single-strand break:27:0.4427|single strand break:15:0.8045	0.8573	129
SSB	SSB:4|ssb:1	single strand breakage:5:0.2818	0.2818	5
SSB	SSB:34|ssb:2|Ssb:1	single-stranded DNA-binding:19:0.6106|single-stranded DNA binding:18:0.6903	0.6903	37
SSB	SSB:65|ssb:2|Ssb:1	single-stranded DNA-binding protein:68:0.8075	0.8075	68
SSCA	SSCA:17	single-strand conformation analysis:17:0.2527	0.2527	17
SSCP	SSCP:1290	single-strand conformation polymorphism:840:0.5046|Single Strand Conformation Polymorphism:428:0.8038|single-strand conformation polymorphisms:22:0.4510	0.8038	1290
SSCP	SSCP:39	single-strand conformation polymorphism analysis:39:0.3973	0.3973	39
SSCP	SSCP:219	single-strand conformational polymorphism:214:0.3751|single strand conformational polymorphisms:5:0.2818	0.3751	219
SSCP	SSCP:27	single-strand conformational polymorphism analysis:15:0.1933|single strand conformational polymorphism analysis:12:0.7571	0.7571	27
SSCV	SSCV:6	conformational variant:6:0.2243	0.2243	6
SSCS	SSCS:8	sidestream cigarette smoke:8:0.4102	0.4102	8
SSCs	SSCs:21	spontaneous synaptic currents:21:0.8594	0.8594	21
SSC	SSC:10	light scatter:10:0.0958	0.0958	10
SSc	SSc:10	patients with systemic scleroderma:10:0.1878	0.1878	10
SSC	SSC:11	porcine chromosome:11:0.3495	0.3495	11
SSC	SSC:6	Scientific and Standardization Committee:6:0.5290	0.5290	6
SSC	SSC:6	sodium citrate:6:0.1838	0.1838	6
SSC	SSC:26	stretch-shortening cycle:26:0.5409	0.5409	26
sSC	sSC:11|SSC:7	superior colliculus:18:0.8365	0.8365	18
SSc	SSc:1087|SSC:11|Ssc:3	systemic sclerosis:1101:0.9941	0.9941	1101
SSDI	SSDI:19	Social Security Disability Insurance:19:0.8449	0.8449	19
SSDs	SSDs:7	source-to-surface distances:7:0.3524	0.3524	7
SSD	SSD:18	sexual size dimorphism:18:0.7539	0.7539	18
SSD	SSD:5	sickle cell disease:5:0.4422	0.4422	5
SSD	SSD:17	silver sulfadiazine:17:0.8270	0.8270	17
SSD	SSD:16	source-surface distance:16:0.1263	0.1263	16
SSD	SSD:17	source-to-surface distance:17:0.1393	0.1393	17
SSD	SSD:7	sterol-sensing domain:7:0.2902	0.2902	7
SSD	SSD:23|SSd:1	systemic scleroderma:24:0.8768	0.8768	24
SSEA-1	SSEA-1:12	embryonic antigen:12:0.5050	0.5050	12
SSEA-1	SSEA-1:49|ssea-1:1	stage-specific embryonic antigen-1:31:0.6572|stage-specific embryonic antigen 1:19:0.7044	0.7044	50
SSEH	SSEH:22	spontaneous spinal epidural hematoma:22:0.8657	0.8657	22
SSEP's	SSEP's:12	somatosensory evoked potentials:12:0.7571	0.7571	12
SSEPs	SSEPs:215|S-SEPs:6	somatosensory evoked potentials:221:0.9462	0.9462	221
SSEP	SSEP:15	somatosensory:15:0.0422	0.0422	15
SSEP	SSEP:257|S-SEP:1|sSEP:1	somatosensory evoked potentials:151:0.8992|somatosensory evoked potential:108:0.8727	0.8992	259
SSER	SSER:7	somatosensory evoked response:7:0.5926	0.5926	7
SSEs	SSEs:8	small-scale enterprises:8:0.5006	0.5006	8
SSE	SSE:16	skin self-examination:16:0.8165	0.8165	16
SSE	SSE:4	sodium salicylate extract:4:0.1618	0.1618	4
SSE	SSE:8	stage selector element:8:0.6411	0.6411	8
SSFP	SSFP:122	steady-state free precession:109:0.8640|steady-state free-precession:13:0.7753	0.8640	122
SSFSE	SSFSE:19	single shot fast spin echo:11:0.7357|single-shot fast spin-echo:8:0.4102	0.7357	19
SSF	SSF:48	simultaneous saccharification and fermentation:48:0.9379	0.9379	48
SSF	SSF:9	skinfolds:9:0.0284	0.0284	9
SSF	SSF:49	solid-state fermentation:49:0.2970	0.2970	49
SSF	SSF:12	soluble suppressor factor:12:0.5664	0.5664	12
SSG	SSG:9	salivary gland:9:0.5470	0.5470	9
SSG	SSG:21	sodium stibogluconate:21:0.8594	0.8594	21
SSHL	SSHL:24	sudden sensorineural hearing loss:24:0.8768	0.8768	24
SSH	SSH:29|Ssh:1	snowshoe hare:30:0.8472	0.8472	30
SSH	SSH:205	suppression subtractive hybridization:205:0.8535	0.8535	205
SSIA	SSIA:14	swim stress-induced analgesia:14:0.7909	0.7909	14
SSIs	SSIs:45	surgical site infections:45:0.9338	0.9338	45
SSI	SSI:6	Scale for Suicide Ideation:6:0.5926	0.5926	6
SSI	SSI:8	strength strain index:8:0.2619	0.2619	8
SSI	SSI:71	Streptomyces subtilisin inhibitor:71:0.9579	0.9579	71
SSI	SSI:5	stress strain index:5:0.0517	0.0517	5
SSI	SSI:147	supplemental security income:147:0.9470	0.9470	147
SSI	SSI:125	surgical site infection:61:0.9511|surgical site infections:29:0.8978|surgical-site infection:27:0.1933|surgical-site infections:8:0.0584	0.9511	125
SSI	SSI:18	Synthetic Sentence Identification:18:0.8365	0.8365	18
SSKI	SSKI:15	saturated solution of potassium iodide:15:0.7096	0.7096	15
SSLI	SSLI:17|SS-LI:8	somatostatin-like immunoreactivity:25:0.5496	0.5496	25
SSLP	SSLP:27	simple sequence length polymorphism:27:0.8941	0.8941	27
SSLSE	SSLSE:8	self-sustaining limbic status epilepticus:8:0.4102	0.4102	8
SSL	SSL:10	sterically stabilized liposomes:10:0.7103	0.7103	10
SSM	SSM:7	Scaled Subprofile Model:7:0.5926	0.5926	7
SSM	SSM:19	skin-sparing mastectomy:19:0.6106	0.6106	19
SSM	SSM:6	Slipped-strand mispairing:6:0.1838	0.1838	6
SSM	SSM:10	subsarcolemmal mitochondria:10:0.7103	0.7103	10
SSM	SSM:58	superficial spreading melanoma:46:0.8401|superficial spreading melanomas:12:0.7571	0.8401	58
SSN	SSN:9	Social Security Number:9:0.6794	0.6794	9
SSN	SSN:14	superior salivatory nucleus:14:0.7909	0.7909	14
SSNA	SSNA:31	skin sympathetic nerve activity:31:0.7388	0.7388	31
SSNHL	SSNHL:14|S-SNHL:1	sudden sensorineural hearing loss:15:0.7096	0.7096	15
SSNMR	SSNMR:5|ssNMR:3|SS-NMR:1	solid-state NMR:9:0.3945	0.3945	9
SSNS	SSNS:44	steroid-sensitive nephrotic syndrome:44:0.6404	0.6404	44
SSOP	SSOP:18	sequence-specific oligonucleotide probe:18:0.4226	0.4226	18
SSO	SSO:69	sequence-specific oligonucleotide:59:0.7385|sequence-specific oligonucleotides:10:0.3470	0.7385	69
SSO	SSO:5|sso:2	single-strand origin:7:0.2113	0.2113	7
SSO	SSO:17	sunflower seed oil:17:0.5760	0.5760	17
SSPE	SSPE:626	subacute sclerosing panencephalitis:626:0.9849	0.9849	626
SSPG	SSPG:117	Steady-state plasma glucose:88:0.6590|steady state plasma glucose:29:0.9011	0.9011	117
SSPI	SSPI:17	steady-state plasma insulin:17:0.4480	0.4480	17
SSPS	SSPS:5	Schalling-Sifneos Personality Scale:5:0.1973	0.1973	5
SSP	SSP:5	inhibitor staurosporine:5:0.1111	0.1111	5
SSP	SSP:8	sagittal sinus pressure:8:0.6411	0.6411	8
SSP	SSP:11	secondary spontaneous pneumothorax:11:0.7357	0.7357	11
SSP	SSP:14	sequence-specific primer:14:0.3202	0.3202	14
SSP	SSP:12	slice sensitivity profile:12:0.4557	0.4557	12
SSP	SSP:5|Ssp:1|ssp:1	stringent starvation protein:7:0.5926	0.5926	7
SSQ	SSQ:32	Questionnaire:32:0.5962	0.5962	32
SSRI	SSRI:452	selective serotonin reuptake inhibitor:362:0.9278|selective serotonin reuptake inhibitors:90:0.8083	0.9278	452
SSRI's	SSRI's:7	selective serotonin reuptake inhibitors:7:0.4438	0.4438	7
SSRIs	SSRIs:968	Selective serotonin reuptake inhibitors:968:0.9383	0.9383	968
SSRIs	SSRIs:5	selective serotonin reuptake inhibitor antidepressants:5:0.4422	0.4422	5
SSRO	SSRO:23	sagittal split ramus osteotomy:23:0.8715	0.8715	23
SSRs	SSRs:84	simple sequence repeats:84:0.8167	0.8167	84
SSRs	SSRs:28	Sympathetic skin responses:28:0.7505	0.7505	28
SSR	SSR:9	microsatellite:9:0.0106	0.0106	9
SSR	SSR:5	secretion rate:5:0.0902	0.0902	5
SSR	SSR:8	signal sequence receptor:8:0.6411	0.6411	8
SSR	SSR:195	simple sequence repeat:172:0.9630|Simple sequence repeats:23:0.8715	0.9630	195
SSR	SSR:27	solar-simulated radiation:16:0.2035|solar simulated radiation:11:0.7357	0.7357	27
SS-R	SS-R:18|SSR:12|ss-R:1|ssR:1|ssr:1	Somatostatin receptors:22:0.6531|somatostatin receptor:11:0.2154	0.6531	33
SSR	SSR:19	spinal stretch reflex:19:0.8449	0.8449	19
SSR	SSR:210	sympathetic skin response:187:0.9579|sympathetic skin responses:23:0.8715	0.9579	210
SSSE	SSSE:15	self-sustaining status epilepticus:15:0.4609	0.4609	15
SSS-III	SSS-III:33|SSSIII:1	Type III pneumococcal polysaccharide:34:0.8644	0.8644	34
SSSS	SSSS:62	staphylococcal scalded skin syndrome:62:0.9519	0.9519	62
SSS	SSS:11	salt-sugar solution:11:0.1327	0.1327	11
SSS	SSS:46	Scandinavian Stroke Scale:46:0.8151	0.8151	46
sSS	sSS:7|S-SS:1|SSS:1	secondary SS:9:0.6794	0.6794	9
SSS	SSS:160|sss:1	sick sinus syndrome:161:0.9605	0.9605	161
SSS	SSS:45	Stanford Sleepiness Scale:45:0.8964	0.8964	45
SSS	SSS:16	sugar salt solution:9:0.6794|sugar-salt solution:7:0.0539	0.6794	16
SSS	SSS:16	summed stress score:16:0.5171	0.5171	16
SSS	SSS:103	superior sagittal sinus:103:0.9538	0.9538	103
SSS	SSS:11	synthetic serum substitute:11:0.7103	0.7103	11
SST-14	SST-14:14	somatostatin-14:14:0.5652	0.5652	14
SSTIs	SSTIs:11	skin and soft tissue infections:11:0.7571	0.7571	11
SSTR2	SSTR2:13|SSTr2:2	somatostatin receptor subtype 2:15:0.5818	0.5818	15
SSTRs	SSTRs:40	somatostatin receptors:40:0.5735	0.5735	40
SSTR	SSTR:66|sstr:11|SSTr:1	somatostatin receptor:55:0.5459|somatostatin receptors:23:0.6653	0.6653	78
SSTs	SSTs:8	sea surface temperatures:8:0.6411	0.6411	8
ssts	ssts:6|SSts:1|SSTs:1	somatostatin receptors:8:0.3455	0.3455	8
sst	sst:7|SST:1|Sst:1	receptor subtypes:9:0.6794	0.6794	9
SST	SST:10	sclerosing stromal tumor:10:0.7103	0.7103	10
SST	SST:17	sea surface temperature:17:0.4246	0.4246	17
SST	SST:14	Sho-saiko-to:14:0.0216	0.0216	14
SST	SST:12	Short Synacthen Test:12:0.6460	0.6460	12
SST	SST:10	Simple Shoulder Test:10:0.7103	0.7103	10
SST	SST:17	Social skills training:17:0.7407	0.7407	17
SST	SST:193|sst:4	Somatostatin:197:0.3256	0.3256	197
sst	sst:38|Sst:1	somatostatin receptor:22:0.4883|somatostatin receptors:17:0.4742	0.4883	39
SST	SST:11	sperm storage tubules:11:0.7357	0.7357	11
sst	sst:5	SRIF subtype:5:0.1132	0.1132	5
SST	SST:12	Submacular Surgery Trials:12:0.7357	0.7357	12
SSU	SSU:192|ssu:7|SSu:1	small subunit:144:0.9025|small-subunit:56:0.2174	0.9025	200
SSVEP	SSVEP:6	steady-state visual evoked potential:6:0.2243	0.2243	6
SSVEP	SSVEP:7	Steady-State Visually Evoked Potential:7:0.2452	0.2452	7
SSVs	SSVs:13	small synaptic vesicles:13:0.7753	0.7753	13
SSV	SSV:18	short saphenous vein:18:0.4672	0.4672	18
SSV	SSV:54	simian sarcoma virus:54:0.9448	0.9448	54
SSV	SSV:7|ssv:1	small synaptic vesicles:8:0.4102	0.4102	8
SSW	SSW:17	Staggered Spondaic Word:17:0.8270	0.8270	17
SSZ	SSZ:60	sulfasalazine:60:0.7108	0.7108	60
SSZ	SSZ:21	sulphasalazine:21:0.2410	0.2410	21
SSP2	SSP2:8	Sporozoite surface protein 2:8:0.6411	0.6411	8
ssrRNA	ssrRNA:4|SSrRNA:2	small subunit ribosomal RNA:6:0.5290	0.5290	6
ss	SS:4|ss:4	5' splice site:8:0.3463	0.3463	8
SS	SS:22	Dahl salt-sensitive:22:0.2804	0.2804	22
S-S	S-S:20|SS:9	disulfide:29:0.0048	0.0048	29
SS	SS:5	glands from patients with Sjogren's syndrome:5:0.0740	0.0740	5
SS	SS:17|Ss:1	homozygous:18:0.0029	0.0029	18
SS	SS:122|ss:1	homozygous sickle cell:111:0.7045|homozygous sickle-cell:12:0.7571	0.7571	123
SS	SS:6	salbutamol sulfate:6:0.1543	0.1543	6
SS	SS:14|ss:1	saline:15:0.0024	0.0024	15
SS	SS:12|ss:1	saline solution:13:0.4849	0.4849	13
SS	SS:10	Salmonella-Shigella:10:0.0015	0.0015	10
SS	SS:14	salt sensitive:14:0.1944	0.1944	14
SS	SS:13	scleroderma systematica:13:0.6701	0.6701	13
SS	SS:8	segmental shortening:8:0.0825	0.0825	8
SS	SS:32	Seizure-sensitive:18:0.0029|seizure sensitive:14:0.1944	0.1944	32
SS	SS:77	self-stimulation:77:0.0130	0.0130	77
SS	SS:7|Ss:3	sensitivity:10:0.0015	0.0015	10
SS	SS:18	Septic shock:18:0.6903	0.6903	18
SS	SS:9	serum:9:0.0014	0.0014	9
SS	SS:8	sewage sludge:8:0.5006	0.5006	8
SS	SS:30	shear stress:30:0.6484	0.6484	30
SS	SS:12	short stature:12:0.7571	0.7571	12
SS	SS:13	sickle cell anaemia:13:0.7753	0.7753	13
SS	SS:104|ss:1	sickle cell anemia:105:0.9715	0.9715	105
SS	SS:18	sickle cell disease:18:0.8365	0.8365	18
SS	SS:16	sidestream smoke:16:0.4040	0.4040	16
SS	SS:20	simple spike:20:0.8525	0.8525	20
ss	ss:35|SS:8	single-strand:36:0.0060|single strand:7:0.3524	0.3524	43
ss	ss:433|SS:50|s-s:2|Ss:1	single-stranded:452:0.0772|single stranded:34:0.7048	0.7048	486
SS	SS:10	small:10:0.0015	0.0015	10
SS	SS:14|ss:1	small subunit:15:0.8045	0.8045	15
SS	SS:12	social support:12:0.7571	0.7571	12
SS	SS:27	sodium salicylate:27:0.8903	0.8903	27
SS	SS:19	sodium selenite:19:0.8449	0.8449	19
SS	SS:567|ss:3|S-S:2|Ss:1	somatostatin:573:0.0980	0.0980	573
SS	SS:9	spermatocytic seminoma:9:0.6794	0.6794	9
SS	SS:11	squalene synthase:11:0.1067	0.1067	11
SS	SS:84|ss:2|Ss:1	stainless steel:87:0.9121	0.9121	87
SS	SS:11	starch synthase:11:0.1067	0.1067	11
SS	SS:56|ss:8|S-S:1	steady-state:38:0.0063|steady state:27:0.7425	0.7425	65
SS	SS:11	stenosis:11:0.0017	0.0017	11
SS	SS:14|Ss:2	steroid-sensitive:16:0.0027	0.0027	16
SS	SS:8	straight sinus:8:0.1471	0.1471	8
SS	SS:9	stress-susceptible:9:0.0014	0.0014	9
Ss	Ss:94|SS:8|ss:3	subjects:105:0.0178	0.0178	105
SS	SS:24	subsarcolemmal:24:0.0039	0.0039	24
SS	SS:18	sucrose synthase:18:0.2533	0.2533	18
SS	SS:10	supersaturation:10:0.0015	0.0015	10
SS	SS:11	supraspinatus:11:0.0017	0.0017	11
SS	SS:56	suspended solids:49:0.8254|suspended solid:7:0.3524	0.8254	56
SS	SS:10	sympathetic stimulation:10:0.1680	0.1680	10
SS	SS:13	synchronized sleep:13:0.0801	0.0801	13
SS	SS:69	synovial sarcoma:57:0.9467|synovial sarcomas:12:0.5934	0.9467	69
SS	SS:17|ss:2	system:19:0.0031	0.0031	19
SS	SS:7	systemic scleroderma:7:0.2902	0.2902	7
SS	SS:82	systemic sclerosis:82:0.8628	0.8628	82
SS	SS:5	systolic segment shortening:5:0.1132	0.1132	5
SS	SS:10	Systolic shortening:10:0.1385	0.1385	10
ST-FeSV	ST-FeSV:12	feline sarcoma virus:12:0.7571	0.7571	12
ST3	ST3:51|ST-3:11	stromelysin-3:50:0.5926|stromelysin 3:12:0.7571	0.7571	62
STA-MCA	STA-MCA:30	superficial temporal artery-middle cerebral artery:30:0.9011	0.9011	30
sTAA	sTAA:13	tumor-associated antigens:13:0.7753	0.7753	13
STAIC	STAIC:23|STAIc:1|STAI-C:1	State-Trait Anxiety Inventory for Children:25:0.6873	0.6873	25
STAI-T	STAI-T:9	Anxiety Inventory:9:0.6794	0.6794	9
STAI	STAI:250	State-Trait Anxiety Inventory:250:0.6933	0.6933	250
STAR*D	STAR*D:9	sequenced treatment alternatives to relieve depression:9:0.5470	0.5470	9
STARD	STARD:16	Standards for Reporting of Diagnostic Accuracy:16:0.8165	0.8165	16
STAS	STAS:12	Support Team Assessment Schedule:12:0.7571	0.7571	12
STAT1	STAT1:7|Stat1:2|Stat-1:1|STAT-1:1	signal transducer and activator of transcription:6:0.5290|signal transducers and activators of transcription:5:0.2818	0.5290	11
STAT1	STAT1:84|STAT-1:22|Stat1:17|Stat-1:1	signal transducer and activator of transcription 1:82:0.9247|signal transducer and activator of transcription-1:42:0.9308	0.9308	124
STAT5	STAT5:6|Stat5:3|Stat-5:1|STAT-5:1	signal transducers and activators of transcription:6:0.3728|signal transducer and activator of transcription:5:0.2818	0.3728	11
STAT5	STAT5:64|Stat5:27|Stat-5:1|STAT-5:1	signal transducer and activator of transcription 5:75:0.8349|signal transducer and activator of transcription-5:18:0.7539	0.8349	93
STAT6	STAT6:43|Stat6:16|STAT-6:6	signal transducer and activator of transcription 6:54:0.9147|signal transducer and activator of transcription-6:11:0.7357	0.9147	65
STATs	STATs:163|Stats:23|STATS:1	signal transducers and activators of transcription:187:0.9745	0.9745	187
STAT	STAT:474|Stat:96|stat:1	signal transducer and activator of transcription:337:0.8143|signal transducers and activators of transcription:234:0.7749	0.8143	571
STAT	STAT:7	standard tube agglutination test:7:0.5926	0.5926	7
STAXI	STAXI:24	State-Trait Anger Expression Inventory:24:0.6427	0.6427	24
STA	STA:9	activity:9:0.0154	0.0154	9
STa	STa:43	Escherichia coli heat-stable enterotoxin:43:0.7523	0.7523	43
STa	STa:6	Escherichia coli heat-stable toxin:6:0.5290	0.5290	6
STa	STa:9	Heat-stable enterotoxins:9:0.4587	0.4587	9
STa	STa:10|STA:2	heat-stable enterotoxin of Escherichia coli:12:0.6701	0.6701	12
STA	STA:8	Solanum tuberosum agglutinin:8:0.5006	0.5006	8
STA	STA:15	spike-triggered averaging:15:0.6386	0.6386	15
STA	STA:9	standard tube agglutination:9:0.4587	0.4587	9
STA	STA:80	superficial temporal artery:80:0.9219	0.9219	80
STA	STA:25	systematic toxicological analysis:25:0.8186	0.8186	25
STb	STb:9|STB:1	Escherichia coli heat-stable enterotoxin b:10:0.7103	0.7103	10
STB	STB:11	serum total bilirubin:11:0.7357	0.7357	11
STB	STB:10	Stobadine:10:0.0698	0.0698	10
STC-VM	STC-VM:11	ST change vector magnitude:11:0.6182	0.6182	11
STCs	STCs:11	serum theophylline concentrations:11:0.7357	0.7357	11
STCs	STCs:12	Suppression tuning curves:12:0.4557	0.4557	12
STC	STC:31	serum theophylline concentration:19:0.8449|serum theophylline concentrations:12:0.7571	0.8449	31
STC	STC:5|sTC:2	serum total cholesterol:7:0.4438	0.4438	7
STC	STC:27	slow transit constipation:17:0.8270|slow-transit constipation:10:0.1449	0.8270	27
STC	STC:13	sodium taurocholate:13:0.7753	0.7753	13
STC	STC:75	Stanniocalcin:75:0.2325	0.2325	75
STC	STC:7	Subtotal colectomy:7:0.2902	0.2902	7
STDHF	STDHF:11	sodium tauro-24,25-dihydrofusidate:11:0.7357	0.7357	11
STDHF	STDHF:10	Sodium taurodihydrofusidate:10:0.5856	0.5856	10
STDP	STDP:41	plasticity:41:0.7547	0.7547	41
STDP	STDP:8	short-term dynamic psychotherapy:8:0.5006	0.5006	8
STDs	STDs:1653|STDS:6	sexually transmitted diseases:1648:0.9770|sexually transmitted disease:11:0.6182	0.9770	1659
STDs	STDs:14	Spontaneous transient depolarizations:14:0.7909	0.7909	14
STEC	STEC:219	Shiga toxin-producing Escherichia coli:219:0.9781	0.9781	219
STEL	STEL:11	Short-Term Exposure Limit:11:0.5355	0.5355	11
STEMI	STEMI:20	acute ST-elevation myocardial infarction:14:0.1461|acute ST elevation myocardial infarction:6:0.0611	0.1461	20
STEMI	STEMI:11	patients with ST-elevation myocardial infarction:11:0.1105	0.1105	11
STEMI	STEMI:64	ST-segment elevation myocardial infarction:64:0.5879	0.5879	64
STEP-BD	STEP-BD:13	Systematic Treatment Enhancement Program for Bipolar Disorder:13:0.7753	0.7753	13
ST-EPR	ST-EPR:20|STEPR:1	saturation transfer electron paramagnetic resonance:12:0.7753|saturation-transfer electron paramagnetic resonance:9:0.1585	0.7753	21
ST-EPR	ST-EPR:11	Saturation transfer EPR:11:0.7357	0.7357	11
STE	STE:15	smokeless tobacco extract:15:0.7909	0.7909	15
STE	STE:21|ST-E:1	ST-segment elevation:13:0.2309|ST segment elevation:9:0.5470	0.5470	22
STFM	STFM:10	Society of Teachers of Family Medicine:10:0.7103	0.7103	10
STFT	STFT:27	Fourier transform:27:0.8903	0.8903	27
STF	STF:12	seminiferous tubule fluid:12:0.7571	0.7571	12
STF	STF:7	Serum thymic factor:7:0.1470	0.1470	7
sTF	sTF:11	soluble TF:11:0.4232	0.4232	11
STF	STF:8	soluble thymic factor:8:0.2090	0.2090	8
sTF	sTF:10	soluble tissue factor:10:0.3470	0.3470	10
STF	STF:9	subeschar tissue fluid:9:0.6794	0.6794	9
STGC	STGC:13	syncytiotrophoblastic giant cells:13:0.7753	0.7753	13
STGD	STGD:22	Stargardt disease:22:0.6531	0.6531	22
STH	STH:10	solution:10:0.0315	0.0315	10
STH	STH:44	somatotropic hormone:44:0.3821	0.3821	44
STH	STH:31	somatotropin:31:0.1049	0.1049	31
STH	STH:12|STh:11|Sth:3	subthalamic nucleus:26:0.8861	0.8861	26
STIB	STIB:7	stimulus train-induced bursting:7:0.5926	0.5926	7
STICs	STICs:6	spontaneous transient inward currents:6:0.4438	0.4438	6
STII	STII:8	Escherichia coli heat-stable enterotoxin II:8:0.5006	0.5006	8
STING	STING:13	Teflon injection:13:0.5335	0.5335	13
STIR	STIR:56	short inversion time inversion recovery:34:0.8644|short inversion time inversion-recovery:22:0.8657	0.8657	56
STIR	STIR:82	short tau inversion recovery:82:0.9422	0.9422	82
STIs	STIs:347	sexually transmitted infections:347:0.9771	0.9771	347
STIs	STIs:18	structured treatment interruptions:18:0.8365	0.8365	18
STIs	STIs:35	systolic time intervals:35:0.9151	0.9151	35
STI	STI:232	sexually transmitted infection:134:0.9132|sexually transmitted infections:98:0.9695	0.9695	232
STI	STI:67	soybean trypsin inhibitor:67:0.8173	0.8173	67
STI	STI:16	Speech Transmission Index:16:0.8165	0.8165	16
STI	STI:13	stereotactic irradiation:13:0.6701	0.6701	13
STI	STI:34	structured treatment interruption:22:0.6934|structured treatment interruptions:12:0.5050	0.6934	34
STI	STI:254	systolic time intervals:231:0.9792|systolic time interval:23:0.8715	0.9792	254
STJ	STJ:10	subtalar joint:10:0.7103	0.7103	10
S-TK	S-TK:8|sTK:5|STK:4|s-TK:2	serum thymidine kinase:19:0.6106	0.6106	19
STK	STK:36|Stk:1	Streptokinase:37:0.3789	0.3789	37
STL	STL:8	step-through latency:8:0.3463	0.3463	8
STMS	STMS:12	microsatellite site:12:0.7571	0.7571	12
STMV	STMV:30	satellite tobacco mosaic virus:30:0.9011	0.9011	30
STM	STM:7|STm:1|Stm:1	Salmonella typhimurium:9:0.5006	0.5006	9
STM	STM:7	Salmonella typhimurium mitogen:7:0.4438	0.4438	7
STM	STM:62	scanning tunneling microscope:62:0.9519	0.9519	62
STM	STM:140	scanning tunneling microscopy:140:0.9786	0.9786	140
STM	STM:15	scanning tunnelling microscope:15:0.8045	0.8045	15
STM	STM:36	Scanning tunnelling microscopy:36:0.9174	0.9174	36
STM	STM:15|stm:2	SHOOT MERISTEMLESS:17:0.8270	0.8270	17
STM	STM:9	SHOOTMERISTEMLESS:9:0.0118	0.0118	9
STM	STM:130	short-term memory:130:0.8927	0.8927	130
STM	STM:29	signature-tagged mutagenesis:29:0.6392	0.6392	29
sTM	sTM:44|s-TM:2|STM:1	soluble thrombomodulin:47:0.7366	0.7366	47
STM	STM:7|Stm:2	Streptomycin:9:0.0118	0.0118	9
STM	STM:8	symptothermal method:8:0.5006	0.5006	8
STN-DBS	STN-DBS:10	deep brain stimulation:10:0.7103	0.7103	10
STNS	STNS:24	stomatogastric nervous system:24:0.8768	0.8768	24
STNV	STNV:18	satellite tobacco necrosis virus:18:0.8365	0.8365	18
STNx	STNx:8	subtotal nephrectomy:8:0.5006	0.5006	8
stn	stn:11	enterotoxin gene:11:0.6182	0.6182	11
stn	stn:7|Stn:2	Salmonella enterotoxin:9:0.5470	0.5470	9
STn	STn:9|s-Tn:3|S-Tn:2|STN:1	sialosyl-Tn:15:0.0174	0.0174	15
STn	STn:30|STN:13|sTn:5	sialyl-Tn:31:0.0372|sialyl Tn:17:0.5038	0.5038	48
STN	STN:10|STn:8|sTn:1	sialyl-Tn antigen:11:0.2280|sialyl Tn antigen:8:0.4102	0.4102	19
stn	stn:10|STN:1	stomatogastric nerve:11:0.7357	0.7357	11
STN	STN:582	subthalamic nucleus:582:0.9281	0.9281	582
STOCs	STOCs:60	Spontaneous transient outward currents:60:0.9241	0.9241	60
STPs	STPs:31	sewage treatment plants:31:0.9043	0.9043	31
STP	STP:65	sewage treatment plant:54:0.9448|sewage treatment plants:11:0.6182	0.9448	65
STP	STP:63	short-term potentiation:63:0.8807	0.8807	63
STP	STP:7	soil test phosphorus:7:0.5926	0.5926	7
STP	STP:18|stp:1|Stp:1	staurosporine:20:0.0492	0.0492	20
STP	STP:11	stiripentol:11:0.0259	0.0259	11
STP	STP:12	superior temporal polysensory area:12:0.7571	0.7571	12
STP	STP:9	supratemporal plane:9:0.4587	0.4587	9
STREAM	STREAM:10|stream:1	Stroke Rehabilitation Assessment of Movement:11:0.7103	0.7103	11
STREs	STREs:8	stress response elements:8:0.6411	0.6411	8
STRFs	STRFs:10	receptive fields:10:0.5000	0.5000	10
STRF	STRF:17	receptive field:17:0.6748	0.6748	17
STRPs	STRPs:22	short tandem repeat polymorphisms:22:0.5581	0.5581	22
STRP	STRP:19	short tandem repeat polymorphism:19:0.6106	0.6106	19
STRs	STRs:130	Short tandem repeats:130:0.8235	0.8235	130
STSGs	STSGs:12	split-thickness skin grafts:12:0.7571	0.7571	12
STSP	STSP:6|Stsp:4|stsp:3	staurosporine:13:0.6000	0.6000	13
STSs	STSs:108	sequence-tagged sites:108:0.5245	0.5245	108
STSs	STSs:24	soft tissue sarcomas:24:0.8768	0.8768	24
STSS	STSS:67	streptococcal toxic shock syndrome:67:0.8374	0.8374	67
STs	STs:11	cytosolic sulfotransferases:11:0.1285	0.1285	11
STS	STS:6	Selegiline Transdermal System:6:0.5290	0.5290	6
STS	STS:190	Sequence-tagged site:92:0.4838|Sequence tagged site:53:0.8597|sequence-tagged sites:27:0.3455|Sequence-tagged-site:18:0.0103	0.8597	190
STs	STs:38	sequence types:38:0.8417	0.8417	38
STS	STS:33	sit-to-stand:33:0.0194	0.0194	33
STS	STS:27	Society of Thoracic Surgeons:27:0.8941	0.8941	27
STS	STS:13	sodium tetradecyl sulfate:13:0.7753	0.7753	13
STS	STS:80	sodium thiosulfate:80:0.8738	0.8738	80
STS	STS:6	sodium thiosulphate:6:0.2243	0.2243	6
STS	STS:392|s-t-S:1	soft tissue sarcoma:168:0.9822|Soft tissue sarcomas:153:0.9686|soft-tissue sarcomas:40:0.1419|soft-tissue sarcoma:32:0.1038	0.9822	393
STS	STS:16	solution:16:0.0091	0.0091	16
STS	STS:116|Sts:5	steroid sulfatase:121:0.9606	0.9606	121
Sts	Sts:4|STS:3	steroid sulfatase gene:7:0.5926	0.5926	7
STS	STS:28|Sts:2	steroid sulphatase:30:0.9011	0.9011	30
STS	STS:15	stilbene synthase:15:0.6386	0.6386	15
STS	STS:5	subthreshold stimulation:5:0.0612	0.0612	5
STS	STS:120|STs:3|sts:1	superior temporal sulcus:124:0.9759	0.9759	124
STS	STS:19	tests for syphilis:13:0.4102|Test for Syphilis:6:0.0611	0.4102	19
STT	STT:17	Schirmer tear test:17:0.7407	0.7407	17
STT	STT:6	short-term tests:6:0.2243	0.2243	6
STT	STT:15	soft tissue tumors:15:0.8045	0.8045	15
STT	STT:19	spinothalamic:19:0.0573	0.0573	19
STT	STT:126	spinothalamic tract:126:0.9622	0.9622	126
STUMP	STUMP:4	smooth muscle tumors of uncertain malignant potential:4:0.4422	0.4422	4
ST-VM	ST-VM:16|STVM:1	ST vector magnitude:17:0.6748	0.6748	17
STV	STV:8	short-term variability:8:0.4102	0.4102	8
STWs	STWs:10	sewage treatment works:10:0.7103	0.7103	10
STXc	STXc:10	sarafotoxin S6c:10:0.7103	0.7103	10
Stx	Stx:101|stx:18|STX:4|STx:1	Shiga toxin:98:0.8824|Shiga toxins:26:0.7760	0.8824	124
stx	stx:7	Shiga toxin genes:7:0.5926	0.5926	7
STZ-D	STZ-D:13	streptozocin-induced diabetes:13:0.4849	0.4849	13
STZ-D	STZ-D:28	Streptozocin-induced diabetic:28:0.4950	0.4950	28
STZ	STZ:7	diabetic rats:7:0.3524	0.3524	7
STZ	STZ:63	serum-treated zymosan:52:0.5859|serum treated zymosan:11:0.7357	0.7357	63
STZ	STZ:85	streptozocin:85:0.0697	0.0697	85
STZ	STZ:918|Stz:7|stz:4	Streptozotocin:929:0.7676	0.7676	929
STZ	STZ:24	streptozotocin-induced:24:0.0191	0.0191	24
STZ	STZ:7	streptozotocin-induced diabetic:7:0.2902	0.2902	7
ST	ST:5	endoscopic sclerotherapy:5:0.0902	0.0902	5
ST	ST:32	Escherichia coli heat-stable enterotoxin:32:0.9072	0.9072	32
ST	ST:11	heat stable:11:0.4232	0.4232	11
ST	ST:16	Heat-stable enterotoxins:16:0.6577	0.6577	16
ST	ST:31|st:2	heat-stable toxin:33:0.5600	0.5600	33
ST	ST:2	PKC inhibitor staurosporine:2:0.1838	0.1838	2
ST	ST:24|St:8	Salmonella typhimurium:32:0.5841	0.5841	32
ST	ST:7	saturation transfer:7:0.2902	0.2902	7
ST	ST:19	Scala tympani:19:0.7658	0.7658	19
ST	ST:13	secondary thrombocytosis:13:0.7753	0.7753	13
ST	ST:7	seizure threshold:7:0.1367	0.1367	7
ST	ST:10	self-transcendence:10:0.0030	0.0030	10
ST	ST:14	seminiferous tubules:14:0.6911	0.6911	14
ST	ST:73|St:8	semitendinosus:81:0.0267	0.0267	81
ST	ST:9	Septal Thickness:9:0.1334	0.1334	9
ST	ST:17	sequence type:17:0.5760	0.5760	17
ST	ST:4|st:3|S-T:1	serum testosterone:8:0.1895	0.1895	8
ST	ST:6|St:1	shell thickness:7:0.0692	0.0692	7
ST	ST:8|st:1	short-term:9:0.0027	0.0027	9
ST	ST:36|S-T:3	sialyltransferase:39:0.0127	0.0127	39
ST	ST:9	signal transduction:9:0.6794	0.6794	9
ST	ST:5	silent thyroiditis:5:0.0736	0.0736	5
ST	ST:14	sinus tachycardia:14:0.6911	0.6911	14
ST	ST:19	skin temperature:19:0.4618	0.4618	19
ST	ST:33|st:1	skin test:19:0.1783|Skin tests:15:0.4052	0.4052	34
ST	ST:6	skin testing:6:0.1320	0.1320	6
ST	ST:8|st:7	small T antigen:15:0.8045	0.8045	15
ST	ST:79	smokeless tobacco:79:0.8368	0.8368	79
ST	ST:10	solid tumors:10:0.5000	0.5000	10
ST	ST:16	solitary tract:16:0.8165	0.8165	16
ST	ST:8|St:1	solution:9:0.0027	0.0027	9
ST	ST:25|st:1	somatostatin:26:0.0083	0.0083	26
ST	ST:64|St:1	somatotropin:65:0.0214	0.0214	65
ST	ST:36	spasmodic torticollis:36:0.8716	0.8716	36
ST	ST:3|-ST:2	ST-segment depression:5:0.0902	0.0902	5
ST	ST:5	ST-segment elevation:5:0.1132	0.1132	5
St	St:7|st:4|ST:1	stage:12:0.0037	0.0037	12
ST	ST:25|St:2|st:1	standard:28:0.0090	0.0090	28
ST	ST:7|st:1	standard therapy:8:0.0604	0.0604	8
ST	ST:8	standard treatment:8:0.1471	0.1471	8
ST	ST:11	stanozolol:11:0.0033	0.0033	11
ST	ST:11|St:1	starch:12:0.0037	0.0037	12
ST	ST:45	Sterigmatocystin:45:0.0147	0.0147	45
ST	ST:35	strength training:35:0.6464	0.6464	35
ST	ST:49|st:1	stria terminalis:50:0.9404	0.9404	50
ST	ST:75|St:8|st:1	striatum:84:0.0277	0.0277	84
ST	ST:8|St:6	styrene:14:0.0047	0.0047	14
ST	ST:5	subacute thyroiditis:5:0.0736	0.0736	5
ST	ST:14|S-T:3	sulfamethoxazole-trimethoprim:17:0.0053	0.0053	17
ST	ST:59|St:1	sulfotransferase:60:0.0197	0.0197	60
ST	ST:17	sulphotransferase:17:0.0053	0.0053	17
ST	ST:9	supportive therapy:9:0.0809	0.0809	9
ST	ST:19|st:1	surface tension:20:0.7766	0.7766	20
ST	ST:9	surgical tracheostomy:9:0.5470	0.5470	9
ST	ST:34	survival time:34:0.3980	0.3980	34
ST	ST:9	swine testicular:9:0.3455	0.3455	9
ST	ST:14	swine testis:14:0.6911	0.6911	14
ST	ST:36	syncytiotrophoblast:36:0.0117	0.0117	36
ST	ST:11	synovial tissues:11:0.4728	0.4728	11
SUA	SUA:58|SUa:1|sUA:1	serum uric acid:60:0.9216	0.9216	60
SUA	SUA:34	single umbilical artery:34:0.8644	0.8644	34
SUB	SUB:14|sub:2	subiculum:16:0.1948	0.1948	16
SUDEP	SUDEP:37	Sudden unexpected death in epilepsy:37:0.9274	0.9274	37
SUDEP	SUDEP:12	sudden unexplained death in epilepsy:12:0.5664	0.5664	12
SUDI	SUDI:5	sudden unexpected death in infancy:5:0.4422	0.4422	5
SUDs	SUDs:8	single-use devices:8:0.4102	0.4102	8
SUDs	SUDs:36|SUDS:1	substance use disorders:37:0.7758	0.7758	37
SUDS	SUDS:14	Sudden unexplained death syndrome:14:0.7909	0.7909	14
SUD	SUD:111	substance use disorder:64:0.9534|substance use disorders:47:0.8433	0.9534	111
SUD	SUD:20	sudden unexpected death:20:0.8525	0.8525	20
SUF	SUF:10	sufentanil:10:0.5000	0.5000	10
SUIT-2	SUIT-2:13	human pancreatic cancer cell line:13:0.6701	0.6701	13
SUI	SUI:303|sui:1	stress urinary incontinence:304:0.9740	0.9740	304
SULTs	SULTs:24	sulfotransferases:24:0.8214	0.8214	24
SULT	SULT:65|Sul-T:1	sulfotransferase:56:0.6548|sulfotransferases:10:0.1071	0.6548	66
SULT	SULT:12	sulphotransferase:12:0.1310	0.1310	12
SUMC	SUMC:7	Stanford University Medical Center:7:0.3524	0.3524	7
SUMD	SUMD:12	Scale to Assess Unawareness of Mental Disorder:12:0.7571	0.7571	12
SUMO-1	SUMO-1:18|Sumo-1:1	small ubiquitin-like modifier 1:10:0.7103|small ubiquitin-like modifier-1:9:0.6794	0.7103	19
SUMO-1	SUMO-1:18	small ubiquitin-related modifier-1:18:0.8270	0.8270	18
SuM	SuM:14|SUM:6	supramammillary nucleus:20:0.8525	0.8525	20
SUNCT	SUNCT:13	short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing:13:0.8270	0.8270	13
SUNDS	SUNDS:5	Sudden unexplained nocturnal death syndrome:5:0.4422	0.4422	5
SUN	SUN:44|S-UN:1	serum urea nitrogen:45:0.7091	0.7091	45
SUP	SUP:13|sup:2	SUPERMAN:15:0.1000	0.1000	15
SUP	SUP:6|sup:2|Sup:2	supernatant:10:0.0643	0.0643	10
SUR1	SUR1:33|Sur1:1	sulfonylurea receptor:34:0.5687	0.5687	34
SUR1	SUR1:26	sulfonylurea receptor 1:26:0.7760	0.7760	26
SURs	SURs:13	sulfonylurea receptors:13:0.4849	0.4849	13
SUR	SUR:87|Sur:1	sulfonylurea receptor:79:0.6576|sulfonylurea receptors:9:0.5470	0.6576	88
SUR	SUR:23|Sur:1	sulphonylurea receptor:24:0.1383	0.1383	24
SUR	SUR:12	uptake ratio:12:0.6460	0.6460	12
SUV(max)	SUV(max):7	maximum standardized uptake value:7:0.4438	0.4438	7
SUVmax	SUVmax:8	standardized uptake value:8:0.5006	0.5006	8
SUVs	SUVs:70	small unilamellar vesicles:70:0.8934	0.8934	70
SUVs	SUVs:83	standardized uptake values:83:0.5927	0.5927	83
SUV	SUV:169	small unilamellar vesicles:161:0.9283|small unilamellar vesicle:8:0.5006	0.9283	169
SUV	SUV:222	standardized uptake value:177:0.7024|Standardized uptake values:45:0.6324	0.7024	222
SUZI	SUZI:34	Subzonal insemination:34:0.6666	0.6666	34
SUZI	SUZI:9	subzonal sperm injection:9:0.6794	0.6794	9
SV2	SV2:23	Synaptic vesicle protein 2:23:0.8715	0.8715	23
SV-3T3	SV-3T3:3|SV3T3:2	simian virus 40-transformed 3T3:5:0.4422	0.4422	5
SV40	SV40:48	simian virus:48:0.5497	0.5497	48
SV40	SV40:1830|SV-40:18|sv40:1	simian virus 40:1826:0.9778|simian virus-40:23:0.7500	0.9778	1849
SV41	SV41:10|SV-41:1	simian virus 41:11:0.7357	0.7357	11
SV5	SV5:95|SV-5:3	simian virus 5:98:0.8836	0.8836	98
SVAS	SVAS:53	supravalvular aortic stenosis:53:0.7972	0.7972	53
SVA	SVA:5	simvastatin hydroxy acid:5:0.2818	0.2818	5
SVA	SVA:11	supraventricular arrhythmias:11:0.4728	0.4728	11
SVCO	SVCO:13	superior vena cava obstruction:13:0.7753	0.7753	13
SVCO	SVCO:9	superior vena caval obstruction:9:0.6794	0.6794	9
SVCS	SVCS:73	Superior vena cava syndrome:73:0.9591	0.9591	73
SVCV	SVCV:15	spring viremia of carp virus:15:0.7096	0.7096	15
SVC	SVC:19	slow vital capacity:19:0.7658	0.7658	19
SVC	SVC:10	superior:10:0.0144	0.0144	10
SVC	SVC:466	superior vena cava:466:0.9740	0.9740	466
SVC	SVC:27	superior vena caval:27:0.8312	0.8312	27
SVD	SVD:14	single vessel disease:14:0.2081	0.2081	14
SVD	SVD:151	singular value decomposition:151:0.9684	0.9684	151
SVD	SVD:21	small vessel disease:21:0.4041	0.4041	21
SVD	SVD:35	structural valve deterioration:35:0.9151	0.9151	35
SVD	SVD:9	subcortical vascular dementia:9:0.5470	0.5470	9
SVD	SVD:25	swine vesicular disease:25:0.8186	0.8186	25
SVDV	SVDV:62	swine vesicular disease virus:62:0.9519	0.9519	62
sVEGF	sVEGF:8|S-VEGF:4|s-VEGF:3|SVEGF:1	vascular endothelial growth factor:16:0.8165	0.8165	16
SVE	SVE:14	soil vapor extraction:14:0.7909	0.7909	14
SVE	SVE:10	subcortical vascular encephalopathy:10:0.6794	0.6794	10
SVFs	SVFs:12	synthetic vitreous fibers:12:0.7571	0.7571	12
SVF	SVF:7	seminal vesicle fluid:7:0.5926	0.5926	7
SVF	SVF:6	stroma-vascular fraction:6:0.1148	0.1148	6
SVGs	SVGs:54	saphenous vein grafts:54:0.8862	0.8862	54
SVG	SVG:176	saphenous vein graft:123:0.9612|saphenous vein grafts:53:0.9116	0.9612	176
SVG	SVG:9|Svg:7	sauvagine:16:0.0591	0.0591	16
SVH	SVH:12	subjective visual horizontal:12:0.7571	0.7571	12
SVL	SVL:14	vastus lateralis:14:0.6911	0.6911	14
SVMPs	SVMPs:11|svMPs:1	snake venom metalloproteinases:12:0.7571	0.7571	12
SVMs	SVMs:70	Support vector machines:70:0.9573	0.9573	70
SVM	SVM:169	support vector machine:134:0.9777|support vector machines:35:0.9151	0.9777	169
SVN	SVN:13	superior:13:0.1765	0.1765	13
SVN	SVN:20	Superior vestibular nucleus:20:0.8525	0.8525	20
SvO2	SvO2:103|SVO2:26|Svo2:5|Sv-O2:2	mixed venous oxygen saturation:136:0.8439	0.8439	136
SVP	SVP:9	snake venom phosphodiesterase:9:0.6794	0.6794	9
SVP	SVP:5	venous pressure:5:0.1132	0.1132	5
SVRI	SVRI:15|SVRi:1	systemic vascular resistance:16:0.8165	0.8165	16
SVRI	SVRI:164|SVRi:3	systemic vascular resistance index:167:0.9619	0.9619	167
SVR	SVR:11	surgical ventricular restoration:11:0.7357	0.7357	11
SVR	SVR:36	sustained viral response:36:0.9174	0.9174	36
SVR	SVR:42	sustained virologic response:42:0.9291	0.9291	42
SVR	SVR:89	Sustained virological response:89:0.9664	0.9664	89
SVR	SVR:36	systemic:36:0.0339	0.0339	36
SVR	SVR:697	systemic vascular resistance:674:0.9501|systemic vascular resistances:23:0.8038	0.9501	697
SVTA	SVTA:10	supraventricular tachyarrhythmias:10:0.7103	0.7103	10
SVTs	SVTs:11	supraventricular tachyarrhythmias:11:0.7357	0.7357	11
SVTs	SVTs:13	supraventricular tachycardias:13:0.7753	0.7753	13
SVT	SVT:5	sinus venous thrombosis:5:0.0612	0.0612	5
SVT	SVT:12	superficial vein thrombosis:12:0.2414	0.2414	12
SVT	SVT:7	superficial venous thrombosis:7:0.2113	0.2113	7
SVT	SVT:9	supraventricular:9:0.0130	0.0130	9
SVT	SVT:33|svt:1	supraventricular tachyarrhythmias:23:0.8038|Supraventricular tachyarrhythmia:11:0.5355	0.8038	34
SVT	SVT:403	supraventricular tachycardia:374:0.8308|supraventricular tachycardias:29:0.7970	0.8308	403
SVV	SVV:54	Simian varicella virus:54:0.9448	0.9448	54
SVV	SVV:6	small vessel vasculitis:6:0.5290	0.5290	6
SVV	SVV:37|svv:1	subjective visual vertical:38:0.8417	0.8417	38
SVZa	SVZa:24	subventricular zone:24:0.8768	0.8768	24
SVmR	SVmR:9|SVMR:1	skin vasomotor reflex:10:0.7103	0.7103	10
SVs	SVs:14	seminal vesicles:14:0.1008	0.1008	14
SVS	SVS:10	slit ventricle syndrome:10:0.7103	0.7103	10
SVs	SVs:9	splice variants:9:0.6794	0.6794	9
SVs	SVs:43	synaptic vesicles:43:0.5442	0.5442	43
SVZ	SVZ:249|SVz:1|svz:1	subventricular zone:251:0.9809	0.9809	251
SV	SV:8	median survival:8:0.1367	0.1367	8
SV	SV:137	saphenous vein:126:0.8186|saphenous veins:11:0.7357	0.8186	137
SV	SV:18	scala vestibuli:18:0.7539	0.7539	18
SV	SV:7	selective vagotomy:7:0.3524	0.3524	7
SV	SV:100|sv:1	seminal vesicle:58:0.5608|seminal vesicles:43:0.4194	0.5608	101
SV	SV:82	Sendai virus:82:0.3303	0.3303	82
SV	SV:13	Shell vial:13:0.7753	0.7753	13
SV	SV:42	simian virus:42:0.1456	0.1456	42
SV	SV:22	simple virilizing:22:0.8657	0.8657	22
SV	SV:30	Simvastatin:30:0.0121	0.0121	30
SV	SV:64	Sindbis virus:64:0.2454	0.2454	64
SV	SV:9	Single ventricle:9:0.2500	0.2500	9
SV	SV:10	slow vacuolar:10:0.4363	0.4363	10
SV	SV:25	sodium valproate:25:0.8816	0.8816	25
SV	SV:27	spontaneous ventilation:27:0.7066	0.7066	27
SV	SV:39	stria vascularis:39:0.9237	0.9237	39
SV	SV:1037|sv:1	stroke volume:1013:0.9460|stroke volumes:25:0.8186	0.9460	1038
S-V	S-V:32|SV:9|s-v:3	stromal-vascular:33:0.0133|stromal vascular:11:0.6182	0.6182	44
SV	SV:48|sv:1	synaptic vesicles:25:0.2003|synaptic vesicle:24:0.1720	0.2003	49
SV	SV:23	systemic vasculitis:23:0.8038	0.8038	23
SV	SV:12	value:12:0.0046	0.0046	12
SV	SV:30|Sv:3	velocity:33:0.0133	0.0133	33
SWAA	SWAA:8	Society for Women and AIDS in Africa:8:0.6794	0.6794	8
SWAP	SWAP:8	adult worm antigens:8:0.5006	0.5006	8
SWAP	SWAP:63	short-wavelength automated perimetry:46:0.5889|Short wavelength automated perimetry:17:0.8270	0.8270	63
SWAP	SWAP:8	soluble adult worm antigenic preparation:8:0.5006	0.5006	8
SWAP	SWAP:24	worm antigen preparation:24:0.8115	0.8115	24
SWASV	SWASV:7	square wave anodic stripping voltammetry:7:0.5926	0.5926	7
SWA	SWA:46	slow-wave activity:46:0.4328	0.4328	46
SWB	SWB:44	subjective well-being:44:0.7619	0.7619	44
SWCNTs	SWCNTs:23	carbon nanotubes:23:0.8715	0.8715	23
SWC	SWC:7	sleep-wakefulness cycle:7:0.1850	0.1850	7
SWDs	SWDs:13	spike-and-wave discharges:13:0.1220	0.1220	13
SWDs	SWDs:4	spike wave discharges:4:0.8525	0.8525	4
SWD	SWD:10	discharge:10:0.0811	0.0811	10
SWD	SWD:28	spike-wave discharges:25:0.2789|spike wave discharges:3:0.8657	0.8657	28
SWGDAM	SWGDAM:9	Scientific Working Group on DNA Analysis Methods:9:0.6794	0.6794	9
SWHS	SWHS:10	Women's Health Study:10:0.5856	0.5856	10
SWI	SWI:47	stroke work index:47:0.9027	0.9027	47
SWI	SWI:26	Surgical Wound Infection:16:0.5564|surgical wound infections:10:0.5000	0.5564	26
SWLS	SWLS:30	Satisfaction With Life Scale:30:0.9011	0.9011	30
SWL	SWL:78	extracorporeal shockwave lithotripsy:78:0.6470	0.6470	78
SWL	SWL:64	shock wave lithotripsy:64:0.9253	0.9253	64
SWMA	SWMA:8	Segmental wall motion abnormalities:8:0.5006	0.5006	8
SWMMC	SWMMC:10	Southwest Metropolitan Mexico City:10:0.7103	0.7103	10
SWM	SWM:10	segmental wall motion:10:0.5000	0.5000	10
SWM	SWM:22	spatial working memory:22:0.8657	0.8657	22
SWNT	SWNT:31	carbon nanotube:22:0.6934|carbon nanotubes:9:0.5470	0.6934	31
SWNTs	SWNTs:64	single-walled carbon nanotubes:64:0.5334	0.5334	64
SWS1	SWS1:6|SWS-1:3	light slow wave sleep:9:0.5470	0.5470	9
SWS2	SWS2:7|SWS-2:7	deep slow wave sleep:14:0.6911	0.6911	14
SWs	SWs:13	sex workers:13:0.6701	0.6701	13
SWs	SWs:7	shock waves:7:0.0592	0.0592	7
SWS	SWS:28	short-wavelength-sensitive:17:0.0149|short-wavelength sensitive:6:0.1543|short wavelength sensitive:5:0.4422	0.4422	28
SWs	SWs:18	slow waves:18:0.4226	0.4226	18
SWS	SWS:830|SWs:1	slow wave sleep:467:0.9936|slow-wave sleep:364:0.3975	0.9936	831
SWS	SWS:39	Sturge-Weber syndrome:39:0.6230	0.6230	39
SWS	SWS:9	Stuve-Wiedemann syndrome:9:0.0550	0.0550	9
SWT	SWT:10	shuttle walk test:10:0.7103	0.7103	10
SWT	SWT:10	shuttle walking test:10:0.5000	0.5000	10
SWT	SWT:14|sWT:3	systolic wall thickening:17:0.6211	0.6211	17
SWV	SWV:16	square wave voltammetry:16:0.8165	0.8165	16
SW	SW:5	forced swimming:5:0.0517	0.0517	5
SW	SW:6	generalized spike and wave:6:0.0807	0.0807	6
SW	S-W:3|SW:3	generalized spike-wave:6:0.0522	0.0522	6
SW	SW:20	salt-wasting:20:0.0209	0.0209	20
SW	SW:31	sea water:31:0.5261	0.5261	31
SW	SW:18	shock waves:18:0.4672	0.4672	18
S-W	S-W:11|SW:1	sleep-wakefulness:12:0.0121	0.0121	12
SW	SW:52	slow wave:41:0.4056|slow-wave:11:0.0110	0.4056	52
SW	SW:10|sw:1	spike-and-wave:11:0.0110	0.0110	11
SW	SW:8	stab wounds:8:0.5006	0.5006	8
SW	SW:10	steroid withdrawal:10:0.2873	0.2873	10
SW	SW:73	stroke work:73:0.8474	0.8474	73
SW	SW:31|Sw:4	swainsonine:35:0.0374	0.0374	35
SW	SW:37|S-W:1	Swiss Webster:26:0.8861|Swiss-Webster:12:0.0121	0.8861	38
SW	SW:20	weight:20:0.0209	0.0209	20
SW	SW:12|Sw:1	width:13:0.0132	0.0132	13
SX6c	SX6c:7|SX6C:1|Sx6c:1	sarafotoxin 6C:9:0.6794	0.6794	9
SXA	SXA:10	single energy X-ray absorptiometry:10:0.7103	0.7103	10
SXA	SXA:14	single x-ray absorptiometry:14:0.2326	0.2326	14
SXT	SXT:16	trimethoprim-sulfamethoxazole:16:0.2941	0.2941	16
SYF	SYF:15	small yellow follicles:15:0.8045	0.8045	15
SYNV	SYNV:18	sonchus yellow net virus:18:0.8365	0.8365	18
SYP	SYP:13|Syp:1	synaptophysin:14:0.4194	0.4194	14
SY	SY:9	stretching and yawning:9:0.6794	0.6794	9
SY	SY:27|Sy:1	Synaptophysin:28:0.2727	0.2727	28
SZn	SZn:5|S-Zn:4|sZn:1	serum zinc:10:0.4363	0.4363	10
SZP	SZP:10	superficial zone protein:10:0.6794	0.6794	10
SZ	SZ:73|Sz:1	schizophrenia:74:0.2544	0.2544	74
SZ	SZ:14	stratum zonale:14:0.6173	0.6173	14
SZ	SZ:90|Sz:5	streptozotocin:95:0.3275	0.3275	95
Sa(O(2))	Sa(O(2)):10	saturation:10:0.6923	0.6923	10
Sa,O2	Sa,O2:41|Sa,o2:1	arterial oxygen saturation:42:0.7750	0.7750	42
SA/SO	SA/SO:5|Sa/So:4	sphinganine/sphingosine:9:0.5333	0.5333	9
SaO(2)	SaO(2):37|Sao(2):4	arterial oxygen saturation:41:0.4609	0.4609	41
SaOS-2	SaOS-2:4|Saos-2:2|SAOS-2:2|SaOs-2:1	human osteoblast-like cells:9:0.3455	0.3455	9
SaOS-2	SaOS-2:9|Saos-2:5|SAOS-2:1	human osteosarcoma:15:0.5818	0.5818	15
Saos-2	Saos-2:8|SaOS-2:1|SAOS2:1|SAOS-2:1	human osteosarcoma cells:11:0.4232	0.4232	11
SAC	SAC:5	ion channels:5:0.0612	0.0612	5
SAC	SAC:18	S-allyl cysteine:18:0.8365	0.8365	18
SAC	SAC:24	S-allylcysteine:24:0.0279	0.0279	24
SAC	SAC:27	seasonal allergic conjunctivitis:27:0.8903	0.8903	27
SAC	SAC:6	Segmental antigen challenge:6:0.5290	0.5290	6
Sac	Sac:3|SAC:2	sodium saccharin:5:0.0612	0.0612	5
sAC	sAC:19	soluble adenylyl cyclase:19:0.6537	0.6537	19
SAC	SAC:9	spindle assembly checkpoint:9:0.6794	0.6794	9
SAC	SAC:29	splenic adherent cells:29:0.6392	0.6392	29
SAC	SAC:14	Staphylococcus aureus:14:0.6911	0.6911	14
SAC	SAC:15|Sac:1	Staphylococcus aureus Cowan:16:0.7261	0.7261	16
SAC	SAC:27	Staphylococcus aureus Cowan 1:27:0.8903	0.8903	27
SAC	SAC:117|Sac:2	Staphylococcus aureus Cowan I:119:0.9051	0.9051	119
SAC	SAC:16	Staphylococcus aureus Cowan I strain:16:0.6381	0.6381	16
SAC	SAC:7	Staphylococcus aureus Cowan strain:7:0.5926	0.5926	7
SAC	SAC:14	Staphylococcus aureus Cowan strain 1:14:0.7096	0.7096	14
SAC	SAC:48	Staphylococcus aureus Cowan strain I:48:0.9392	0.9392	48
SAC	SAC:34	systemic arterial compliance:34:0.8644	0.8644	34
S-ALAT	S-ALAT:9	alanine aminotransferase:9:0.5470	0.5470	9
SAN	SAN:23	sino-atrial node:23:0.1328	0.1328	23
SAN	SAN:9	sinoatrial:9:0.0457	0.0457	9
SAN	SAN:74	sinoatrial node:74:0.6192	0.6192	74
SAN	SAN:11	Spinal accessory nerve:11:0.7357	0.7357	11
ScN2a	ScN2a:6	Scrapie-infected mouse neuroblastoma:6:0.3728	0.3728	6
ScO2	ScO2:8|Sco2:3|SCO2:2	oxygen saturation:13:0.4849	0.4849	13
SCAP	SCAP:9	severe community-acquired pneumonia:9:0.5470	0.5470	9
SCAP	SCAP:35	SREBP cleavage-activating protein:35:0.7881	0.7881	35
SCAP	SCAP:13	syringocystadenoma papilliferum:13:0.7753	0.7753	13
SCHAD	SCHAD:20	dehydrogenase:20:0.8636	0.8636	20
SCOP	SCOP:30|Scop:8|scop:3	scopolamine:41:0.4167	0.4167	41
SCPA	SCPA:8|scpA:5|ScpA:1	C5a peptidase:14:0.6911	0.6911	14
SdFFF	SdFFF:31	Sedimentation Field-Flow Fractionation:22:0.8657|sedimentation field flow fractionation:9:0.6794	0.8657	31
SeCys	SeCys:16|Secys:3|Se-Cys:1|secys:1	selenocysteine:21:0.6667	0.6667	21
SeMNPV	SeMNPV:14	Spodoptera exigua multicapsid nucleopolyhedrovirus:14:0.7909	0.7909	14
SeMet	SeMet:61|Se-Met:10|Semet:9|SeMET:3|Se-met:1	selenomethionine:84:0.7477	0.7477	84
SeO2	SeO2:9	selenium dioxide:9:0.6794	0.6794	9
Sendai	Sendai:18	parainfluenza type 1:18:0.5228	0.5228	18
Sep1	Sep1:9|SEP1:1	strand exchange protein 1:10:0.7103	0.7103	10
Ser/Thr	Ser/Thr:28|ser/thr:6	serine/threonine:34:0.6471	0.6471	34
Sey	Sey:22|SEY:1	Small eye:23:0.8594	0.8594	23
Sf9	Sf9:8|SF9:1	expressed in insect:9:0.1052	0.1052	9
Sf9	Sf9:258|Sf-9:35|SF9:21|SF-9:9|sf9:3	Spodoptera frugiperda:326:0.9514	0.9514	326
Sf9	Sf9:12|SF9:2|Sf-9:1	Spodoptera frugiperda cells:15:0.8045	0.8045	15
SGE	SGE:8	generalized epilepsy:8:0.4102	0.4102	8
SGE	SGE:61	salivary gland extract:44:0.9323|salivary gland extracts:17:0.7407	0.9323	61
SGE	SGE:28	spoiled gradient echo:19:0.7658|spoiled gradient-echo:9:0.5470	0.7658	28
SGE	SGE:6	starch gel electrophoresis:6:0.1838	0.1838	6
SgIII	SgIII:10	secretogranin III:10:0.7103	0.7103	10
SgII	SgII:59|SGII:5|SG-II:1	secretogranin II:65:0.8651	0.8651	65
SGCE	SGCE:12|Sgce:1	epsilon-sarcoglycan gene:13:0.7753	0.7753	13
SHOX	SHOX:7	short stature homeobox-containing gene:7:0.5926	0.5926	7
SHO	SHO:27	senior house officer:27:0.8903	0.8903	27
Shiga	Shiga:6|shiga:1|SHIGA:1	Shigella dysenteriae 1:8:0.5926	0.5926	8
ShvO2	ShvO2:10|Shvo2:4|SHVO2:2|ShVO2:1	hepatic venous oxygen saturation:17:0.8270	0.8270	17
SiDBP	SiDBP:16	sitting diastolic blood pressure:16:0.7261	0.7261	16
SiO2	SiO2:11	silicon dioxide:11:0.7357	0.7357	11
SiO	SiO:10	Silicone oil:10:0.7103	0.7103	10
siRNA	siRNA:392|SiRNA:3	small interfering RNA:395:0.7487	0.7487	395
siRNA	siRNA:28|SiRNA:1	small interfering RNAs:29:0.6392	0.6392	29
SIA	SIA:19	activity:19:0.0632	0.0632	19
SIA	SIA:20	sequential injection analysis:20:0.8525	0.8525	20
Sia	Sia:21|SIA:1	sialic acid:22:0.7400	0.7400	22
SIA	SIA:53	Stress-induced analgesia:53:0.7616	0.7616	53
SIA	SIA:9	stress-induced antinociception:9:0.5470	0.5470	9
SIA	SIA:10	Strip Immunoblot Assay:10:0.7103	0.7103	10
SIA	SIA:25	surgically induced astigmatism:25:0.8186	0.8186	25
SimK	SimK:8|Sim-K:1|SIM-K:1	Simulated Keratometry:10:0.7103	0.7103	10
SjO2	SjO2:6|SJO2:2	jugular bulb venous oxygen saturation:8:0.6411	0.6411	8
SjvO2	SjvO2:23|SjVO2:4|Sjvo2:4|SJVO2:4|sjvO2:3	jugular venous oxygen saturation:38:0.8098	0.8098	38
SkBF	SkBF:59|SKBF:6	skin blood flow:65:0.9541	0.9541	65
SKBR3	SKBR3:4|SKBR-3:2|SK-BR3:1	breast cancer cell line:7:0.5926	0.5926	7
SkM	SkM:7|SKM:4|skm:1	skeletal muscle:12:0.7571	0.7571	12
SKs	SKs:13	keratoses:13:0.4286	0.4286	13
Skuse	Skuse:8	Aedes notoscriptus:8:0.1895	0.1895	8
Skuse	Skuse:6	Ochlerotatus notoscriptus:6:0.1329	0.1329	6
sl/sl	sl/sl:12|Sl/Sl:1	homozygous:13:0.4286	0.4286	13
SLG	SLG:21	S-locus glycoprotein:11:0.2422|S locus glycoprotein:10:0.7103	0.7103	21
slg	slg:13|Slg:7	surface immunoglobulin:20:0.7766	0.7766	20
SmIg	SmIg:30|SMIg:5|smIg:4	surface membrane immunoglobulin:26:0.8861|Surface membrane immunoglobulins:13:0.5934	0.8861	39
SMI	SMI:11	effect of Shenmai injection:11:0.3829	0.3829	11
SMI	SMI:6|SmI:2	primary sensorimotor cortex:8:0.4102	0.4102	8
SmI	SmI:5	primary somatosensory:5:0.0517	0.0517	5
SmI	SmI:5	rat somatosensory:5:0.0517	0.0517	5
SMI	SMI:7	Respimat Soft Mist Inhaler:7:0.3524	0.3524	7
SMI	SMI:26	serious mental illness:26:0.2279	0.2279	26
SMI	SMI:9	seriously mentally ill:9:0.1809	0.1809	9
SMI	SMI:54	severe mental illness:47:0.5089|severe mental illnesses:7:0.3524	0.5089	54
SMI	SMI:11	severely mentally ill:11:0.2764	0.2764	11
SMI	SMI:17	silent myocardial ischaemia:17:0.8270	0.8270	17
SMI	SMI:75	silent myocardial ischemia:75:0.9370	0.9370	75
SmI	SmI:21	somatosensory cortex:21:0.3317	0.3317	21
SMI	SMI:20	sperm motility index:20:0.7766	0.7766	20
SMI	SMI:11	structure model index:11:0.6182	0.6182	11
SMD	SMD:39	mean difference:39:0.9237	0.9237	39
SMD	SMD:7	meningococcal disease:7:0.3524	0.3524	7
SMD	SMD:18	senile macular degeneration:18:0.7539	0.7539	18
SMD	SMD:7	spondylometaphyseal dysplasia:7:0.2902	0.2902	7
SMD	SMD:21	Standardized mean differences:21:0.5435	0.5435	21
SMD	SMD:9	Steered molecular dynamics:9:0.6794	0.6794	9
SmD	SmD:7|Smd:3|SMd:1|smd:1|Sm-d:1	streptomycin-dependent:13:0.0471	0.0471	13
SnCl2	SnCl2:35	stannous chloride:35:0.8681	0.8681	35
SnET2	SnET2:13	Tin ethyl etiopurpurin:13:0.7753	0.7753	13
SnF2	SnF2:26	stannous fluoride:26:0.7249	0.7249	26
SnPPIX	SnPPIX:5|SnPP-IX:2	tin protoporphyrin IX:7:0.5926	0.5926	7
S-NO-Cap	S-NO-Cap:4|SNOcap:2|SnoCap:2|SNOCap:2	S-nitrosocaptopril:10:0.7500	0.7500	10
SOHO	SOHO:13	Schizophrenia Outpatient Health Outcomes:13:0.7753	0.7753	13
soman	soman:19|Soman:1|SOMAN:1	pinacolyl methylphosphonofluoridate:21:0.3643	0.3643	21
Sp5C	Sp5C:7	trigeminal nucleus caudalis:7:0.5926	0.5926	7
Sp5O	Sp5O:8	spinal trigeminal nucleus oralis:8:0.5006	0.5006	8
SpNA	SpNA:9	nerve activity:9:0.6794	0.6794	9
SpO(2)	SpO(2):34|Spo(2):3	oxygen saturation:37:0.4832	0.4832	37
SpO(2)	SpO(2):5	oxygen saturation as measured by pulse oximetry:5:0.5926	0.5926	5
SpVi	SpVi:12	subnucleus interpolaris:12:0.4557	0.4557	12
Spain	Spain:6	province of Soria:6:0.1838	0.1838	6
Sph-1-P	Sph-1-P:43|Sph1P:3|sph-1-P:1	sphingosine 1-phosphate:34:0.8644|Sphingosine-1-phosphate:13:0.2500	0.8644	47
SPHK	SPHK:20|SphK:14	sphingosine kinase:34:0.8644	0.8644	34
SPI1	SPI1:35|SPI-1:22	Salmonella pathogenicity island 1:57:0.8920	0.8920	57
Spm	Spm:11	maize Suppressor-mutator:11:0.2972	0.2972	11
SPM	SPM:17	Scanning probe microscopy:17:0.8270	0.8270	17
SPM	SPM:35|SpM:3|Spm:3	sphingomyelin:41:0.0434	0.0434	41
SpM	SpM:11|Spm:3	spleen mononuclear:14:0.7909	0.7909	14
SPM	SPM:14	Spontaneous pneumomediastinum:14:0.7909	0.7909	14
SPM	SPM:196	Statistical parametric mapping:196:0.9756	0.9756	196
SPM	SPM:97	suspended particulate matter:97:0.9073	0.9073	97
SPM	SPM:155	synaptic plasma membranes:91:0.6280|synaptic plasma membrane:64:0.7303	0.7303	155
SP	SP:7	CD4 or CD8 single-positive:7:0.2285	0.2285	7
SP	SP:19	CD4 single-positive:19:0.0979	0.0979	19
SP	SP:7|s-P:2|sp:2	phosphorus:11:0.0011	0.0011	11
SP	SP:9	plate:9:0.0009	0.0009	9
SP	SP:7|Sp:2	power:9:0.0009	0.0009	9
SP	SP:9	process:9:0.0009	0.0009	9
SP	SP:9|S-P:2	pyrimethamine:11:0.0009	0.0009	11
Sp	Sp:22|sp:4|SP:1	Schizosaccharomyces pombe:27:0.8312	0.8312	27
SP	SP:14|sp:1	sclerosing peritonitis:15:0.6386	0.6386	15
SP	SP:7	secondary polycythemia:7:0.2452	0.2452	7
sP	sP:17|sp:2	selectively bred Sardinian alcohol-preferring:19:0.8594	0.8594	19
SP	SP:80|Sp:1	seminal plasma:81:0.9229	0.9229	81
SP	SP:37	senile plaque:37:0.5859	0.5859	37
SP	SP:7|Sp:2	septum:9:0.0009	0.0009	9
SP	SP:24	serine protease:24:0.6427	0.6427	24
SP	SP:10|Sp:1	seropositive:11:0.0011	0.0011	11
S-P	S-P:9	serum phosphate:9:0.2500	0.2500	9
SP	SP:29	short photoperiod:29:0.8978	0.8978	29
SP	SP:79	side population:79:0.8724	0.8724	79
SP	SP:38|sp:9	signal peptide:40:0.4874|signal peptides:7:0.1111	0.4874	47
SP	SP:91	silent period:91:0.8291	0.8291	91
SP	SP:61|sp:1	single positive:62:0.9241	0.9241	62
SP	SP:8	sleep paralysis:8:0.5006	0.5006	8
SP	SP:28	slow pathway:28:0.7905	0.7905	28
SP	SP:17|sp:6|Sp:1	small plaque:13:0.1139|small-plaque:11:0.0011	0.1139	24
SP	SP:26	smooth pursuit:26:0.8312	0.8312	26
SP	SP:61|Sp:1	social phobia:62:0.9241	0.9241	62
SP	SP:10	sodium pentobarbital:10:0.5856	0.5856	10
SP	SP:8|sp:2	solid phase:10:0.1680	0.1680	10
SP	SP:8|Sp:5	Spasmolytic polypeptide:13:0.5934	0.5934	13
Sp	Sp:8|SP:4|sp:1	spectinomycin:13:0.0014	0.0014	13
Sp	Sp:11|SP:2	spectrin:13:0.0014	0.0014	13
Sp	Sp:13|SP:5	Spermine:18:0.0019	0.0019	18
SP	SP:8|Sp:1	Sphingosine:9:0.0009	0.0009	9
Sp	Sp:12	spiroiminodihydantoin:12:0.0013	0.0013	12
SP	SP:20|Sp:2|sp:1	spironolactone:23:0.0025	0.0025	23
SP	SP:25|Sp:7	spleen:32:0.0035	0.0035	32
SP	SP:13|Sp:1	splenius:14:0.0015	0.0015	14
Sp	Sp:35	splotch:35:0.0039	0.0039	35
SP	SP:51|Sp:9	spontaneous pneumothorax:60:0.9216	0.9216	60
SP	SP:9|Sp:2	spore photoproduct:11:0.7357	0.7357	11
SP	SP:62	standardized patient:48:0.7411|standardized-patient:9:0.0009|standardized patients:5:0.0517	0.7411	62
SP	SP:8	storage phosphor:8:0.5006	0.5006	8
SP	SP:16	stratum pyramidale:16:0.7261	0.7261	16
SP	SP:11|S-P:4	streptavidin-peroxidase:15:0.0016	0.0016	15
SP	SP:26|Sp:10	Streptococcus pneumoniae:36:0.8003	0.8003	36
SP	SP:9	subplate:9:0.0009	0.0009	9
SP	SP:4420|Sp:37|sp:8|sP:7|S-P:1	Substance P:4445:0.9825|substance-P:28:0.0031	0.9825	4473
SP	SP:9	sulfadoxine/pyrimethamine:9:0.0009	0.0009	9
SP	SP:44	sulfapyridine:44:0.0049	0.0049	44
SP	SP:14	sulphadoxine/pyrimethamine:14:0.0015	0.0015	14
SP	SP:16	sulphapyridine:16:0.0017	0.0017	16
SP	SP:142|-SP:7	summating potential:132:0.5845|summating potentials:17:0.3232	0.5845	149
SP	SP:17	superficial peroneal:17:0.8270	0.8270	17
SP	SP:7	superficial peroneal nerve:7:0.4438	0.4438	7
SP	SP:7	supine position:7:0.2113	0.2113	7
SP	SP:131	surfactant protein:100:0.5458|Surfactant proteins:31:0.3503	0.5458	131
SP	SP:8	synthetic peptides:8:0.1591	0.1591	8
SP	SP:11	synthetic pyrethroid:11:0.7357	0.7357	11
SP	SP:13	systolic:13:0.0014	0.0014	13
SP	SP:48	systolic pressure:48:0.3744	0.3744	48
Sr2+	Sr2+:15	strontium:15:0.6667	0.6667	15
st.	st.:9	stratum:9:0.3810	0.3810	9
ST2	ST2:6	stromal cell line:6:0.2827	0.2827	6
STD	STD:21	Saturation transfer difference:21:0.8594	0.8594	21
STD	STD:7	seminiferous tubular diameter:7:0.4438	0.4438	7
STD	STD:1796	sexually transmitted disease:1180:0.9700|sexually transmitted diseases:616:0.9679	0.9700	1796
STD	STD:14	short-term depression:14:0.1933	0.1933	14
STD	STD:17|ST-D:2	ST-segment depression:11:0.1098|ST segment depression:8:0.6411	0.6411	19
STD	STD:30|Std:5|StD:1|std:1	standard:37:0.0165	0.0165	37
StMPM	StMPM:6	Syncytiotrophoblast microvillous plasma membrane:6:0.5290	0.5290	6
StO2	StO2:13|Sto2:1|STO2:1	oxygen saturation:15:0.4609	0.4609	15
STAR	STAR:10	Recombinant staphylokinase:10:0.7103	0.7103	10
StAR	StAR:190|Star:1|STAR:1|star:1|stAR:1	steroidogenic acute regulatory:194:0.9025	0.9025	194
StAR	StAR:303|STAR:4|stAR:2|Star:1|star:1	Steroidogenic Acute Regulatory protein:311:0.9571	0.9571	311
STAT3	STAT3:6|Stat3:3|Stat-3:1	signal transducer and activator of transcription:10:0.7103	0.7103	10
STAT3	STAT3:173|Stat3:62|STAT-3:20|stat-3:1|Stat-3:1|stat3:1	Signal Transducer and Activator of Transcription 3:208:0.9376|signal transducer and activator of transcription-3:50:0.9404	0.9404	258
STAT4	STAT4:14|Stat4:5	signal transducer and activator of transcription 4:19:0.8449	0.8449	19
STDR	STDR:5	sight threatening diabetic retinopathy:5:0.4422	0.4422	5
STOP	STOP:14	Stroke Prevention Trial in Sickle Cell Anemia:14:0.7909	0.7909	14
Stx1	Stx1:22|Stx-1:1	Shiga toxin 1:23:0.6653	0.6653	23
Stx2	Stx2:20|stx2:2|Stx-2:1	Shiga toxin 2:23:0.8657	0.8657	23
Stxs	Stxs:20|STXs:1	Shiga toxins:21:0.7291	0.7291	21
Su(H)	Su(H):17	Suppressor of Hairless:17:0.8270	0.8270	17
Su(fu)	Su(fu):11	Suppressor of fused:11:0.7357	0.7357	11
SuCh	SuCh:9	succinylcholine:9:0.7273	0.7273	9
SUMO	SUMO:35|sumo:1	small ubiquitin-like modifier:36:0.9174	0.9174	36
SUMO	SUMO:18	Small ubiquitin-related modifier:18:0.8365	0.8365	18
SuSy	SuSy:16|Susy:1	Sucrose synthase:17:0.6211	0.6211	17
SUVA	SUVA:6	specific ultraviolet absorbance:6:0.5290	0.5290	6
SU	SU:16	stroke unit:16:0.2523	0.2523	16
SU	SU:11|Su:3	sucrose:14:0.0220	0.0220	14
SU	SU:48|Su:5	sulfonylurea:53:0.0898	0.0898	53
SU	SU:13|Su:1	sulphonylurea:14:0.0220	0.0220	14
SU	SU:61|su:1	surface:62:0.1034	0.1034	62
SU	SU:6|Su:1	surface envelope glycoprotein:7:0.2113	0.2113	7
SU	SU:7	surface envelope protein:7:0.3524	0.3524	7
SU	SU:29|Su:1	surface glycoprotein:30:0.4881	0.4881	30
SU	SU:12	surface protein:12:0.3058	0.3058	12
SU	SU:5	surface subunit:5:0.0736	0.0736	5
SU	SU:17	surface unit:17:0.2788	0.2788	17
SU	SU:8|S-U:1	swim-up:9:0.0136	0.0136	9
SU	SU:13|su:1	units:14:0.0220	0.0220	14
SvO(2)	SvO(2):11|Svo(2):1	mixed venous oxygen saturation:12:0.4153	0.4153	12
Sxl	Sxl:87|SXL:13	Sex-lethal:90:0.8165|Sex lethal:10:0.7103	0.8165	100
Sxr	Sxr:10	sex-reversed:10:0.1452	0.1452	10
SXR	SXR:14	steroid and xenobiotic receptor:14:0.6211	0.6211	14
Sy.x	Sy.x:4	standard error of the estimate:4:0.6411	0.6411	4
Syk	Syk:15|SYK:5	spleen tyrosine kinase:20:0.8525	0.8525	20
Syts	Syts:11|syts:3	Synaptotagmins:14:0.8125	0.8125	14
Syt	Syt:29|syt:12|SYT:1	synaptotagmin:42:0.7593	0.7593	42
SzS	SzS:11	Sezary syndrome:11:0.7357	0.7357	11
T&A	T&A:27	tonsillectomy and adenoidectomy:27:0.8369	0.8369	27
T(1)	T(1):14	relaxation time:14:0.6911	0.6911	14
T(1)	T(1):11	spin-lattice relaxation times:11:0.5355	0.5355	11
T(1rho)	T(1rho):9	rotating frame:9:0.6794	0.6794	9
T(2)	T(2):13	relaxation time:13:0.5335	0.5335	13
T(2)	T(2):6	transverse relaxation:6:0.1838	0.1838	6
T(3)	T(3):9	3,3',5-triiodothyronine:9:0.0206	0.0206	9
T(3)	T(3):31	3,5,3'-triiodothyronine:31:0.0773	0.0773	31
T(3)	T(3):41	Thyroid hormone:41:0.8867	0.8867	41
T(3)	T(3):47	tri-iodothyronine:47:0.1186	0.1186	47
T(3)	T(3):174|-T(3):1	Triiodothyronine:175:0.4510	0.4510	175
T(4)	T(4):12	l-thyroxine:12:0.0394	0.0394	12
T(4)	T(4):220	thyroxine:220:0.7849	0.7849	220
T(b)	T(b):84|T(B):7	body temperature:91:0.9015	0.9015	91
T(c)	T(c):38|T(C):2	core temperature:40:0.3722	0.3722	40
T(c)	T(c):6|T(C):3	temperatures:9:0.0630	0.0630	9
T(H)1	T(H)1:9	T helper 1:9:0.5470	0.5470	9
T(H)1	T(H)1:11|T(h)1:1	T helper type 1:12:0.7571	0.7571	12
T(H)2	T(H)2:8	T helper type 2:8:0.6411	0.6411	8
T(H)	T(H):10|T(h):1	T helper:11:0.7357	0.7357	11
T(es)	T(es):20	esophageal temperature:20:0.7173	0.7173	20
T(g)	T(g):80|T(G):1|t(g):1	glass transition temperature:82:0.9422	0.9422	82
T(m)	T(m):70|T(M):3|t(m):1	melting temperature:55:0.4080|melting temperatures:19:0.5404	0.5404	74
T(m)	T(m):13|T(M):1	phase transition temperature:14:0.2238	0.2238	14
T(pot)	T(pot):7|T(Pot):1|t(pot):1	potential doubling time:9:0.5470	0.5470	9
T(re)	T(re):32	rectal temperature:32:0.8145	0.8145	32
T(reg)	T(reg):7|T(Reg):3	regulatory T:10:0.7103	0.7103	10
T(reg)	T(reg):16|T(Reg):1	regulatory T cells:17:0.5760	0.5760	17
T(sk)	T(sk):22|T(SK):1	skin temperature:23:0.8715	0.8715	23
T-588	T-588:19	hydrochloride:19:0.8636	0.8636	19
T-cells	T-cells:12	thymus-derived lymphocytes:12:0.3275	0.3275	12
T-LAK	T-LAK:6	lymphokine-activated T killer:6:0.3728	0.3728	6
T-type	T-type:13	low-voltage-activated:8:0.0708|low voltage-activated:5:0.2243	0.2243	13
T.M.J.	T.M.J.:9	temporomandibular joint:9:0.3945	0.3945	9
T.S.H.	T.S.H.:9	thyroid-stimulating hormone:9:0.3069	0.3069	9
T/2	T/2:8|t/2:2	half-life:10:0.1731	0.1731	10
T/B	T/B:34	ratio:18:0.1828|ratios:16:0.1613	0.1828	34
T/B	T/B:12	tumor-to-background:12:0.1183	0.1183	12
T/C	T/C:14	ratio:14:0.1092	0.1092	14
T/M	T/M:20	ratio:20:0.3393	0.3393	20
T/N	T/N:7	normal tissue:7:0.1329	0.1329	7
T/N	T/N:10	ratio:10:0.1047	0.1047	10
T/N	T/N:12	tumor/normal:12:0.1279	0.1279	12
T/P	T/P:6	trough-to-peak ratio:6:0.1838	0.1838	6
T/T	T/T:10	homozygous:10:0.1216	0.1216	10
T0	T0:12|t0:3	admission:15:0.0192	0.0192	15
T0	T0:50|t0:11	baseline:61:0.0822	0.0822	61
T0	T0:12|t0:2	beginning:14:0.0178	0.0178	14
T0	T0:8|t0:2	operation:10:0.0123	0.0123	10
T0	T0:7|t0:2|T-0:1	study:10:0.0123	0.0123	10
T0	T0:13|t0:2	surgery:15:0.0192	0.0192	15
T0	T0:12|t0:2	therapy:14:0.0178	0.0178	14
T0	T0:37|t0:1	treatment:38:0.0507	0.0507	38
T11TS	T11TS:9	T11 target structure:9:0.4102	0.4102	9
T12	T12:8|t12:1	12 months:9:0.5470	0.5470	9
T1D	T1D:151	type 1 diabetes:151:0.9802	0.9802	151
T1DM	T1DM:39	Type 1 diabetes:39:0.9237	0.9237	39
T1DM	T1DM:134	type 1 diabetes mellitus:134:0.9777	0.9777	134
T1L	T1L:23	type 1 Lang:23:0.7500	0.7500	23
T1WI	T1WI:10	T1-weighted:10:0.0865	0.0865	10
T1WI	T1WI:48|T1-WI:8	T1-weighted images:45:0.6324|T1-weighted image:11:0.4232	0.6324	56
T1WI	T1WI:9	T1-weighted imaging:9:0.3945	0.3945	9
T1W	T1W:38|T1-W:13|T1w:11|T1-w:5	T1-weighted:67:0.7952	0.7952	67
T1rho	T1rho:7	relaxation time in the rotating frame:7:0.5926	0.5926	7
T1	T1:14	1 month:14:0.5111	0.5111	14
T1	T1:9|t1:2|T-1:1	admission:12:0.0042	0.0042	12
T1	T1:44|t1:2|T-1:2	baseline:48:0.0179	0.0179	48
T1	T1:13|t1:2	beginning:15:0.0053	0.0053	15
T1	T1:5	control group:5:0.0902	0.0902	5
T1	T1:10	degrees C:10:0.7103	0.7103	10
T1	T1:15	early:15:0.0053	0.0053	15
T1	T1:24|t-1:1|t1:1	first:26:0.0095	0.0095	26
T1	T1:20	first response:20:0.4037	0.4037	20
T1	T1:8|T-1:1	first thoracic:9:0.4587	0.4587	9
T1	T1:50	first twitch:50:0.8068	0.8068	50
T1	T1:3	first twitch of the TOF:3:0.5926	0.5926	3
T1	T1:7	first twitch of the train-of-four:7:0.6794	0.6794	7
T1	T1:8|t1:1	hours:9:0.0031	0.0031	9
T1	T1:7	induction of anesthesia:7:0.2452	0.2452	7
T1	T1:14|t1:4	later:18:0.0065	0.0065	18
T1	T1:54	longitudinal:54:0.0202	0.0202	54
T1	T1:14	longitudinal relaxation:14:0.2157	0.2157	14
T1	T1:4	lowest excited triplet:4:0.1618	0.1618	4
T1	T1:18|t1:8	months:26:0.0095	0.0095	26
T1	T1:11|t1:2	period:13:0.0046	0.0046	13
t1	t1:5|T1:5	phase:10:0.0034	0.0034	10
T1	T1:115	Spin-lattice:105:0.0401|spin lattice:10:0.7103	0.7103	115
T1	T1:12	Spin-lattice relaxation:12:0.1631	0.1631	12
T1	T1:207	spin-lattice relaxation time:121:0.5111|spin-lattice relaxation times:86:0.5606	0.5606	207
T1	T1:8|t1:1	stage:9:0.0031	0.0031	9
T1	T1:11|t1:1	therapy:12:0.0042	0.0042	12
T1	T1:28	Time 1:28:0.1684	0.1684	28
T1	T1:24	twitch height:24:0.8768	0.8768	24
T1	T1:28	type 1:28:0.1684	0.1684	28
T21	T21:16|t21:1	Trisomy 21:17:0.7407	0.7407	17
T24	T24:14|T-24:1	cell line:15:0.6386	0.6386	15
T24	T24:5	human bladder cancer cells:5:0.2818	0.2818	5
T2D	T2D:47	Type 2 diabetes:47:0.9366	0.9366	47
T2DM	T2DM:53|t2DM:1	Type 2 diabetes:54:0.9132	0.9132	54
T2DM	T2DM:186|T2Dm:1|T2-DM:1	Type 2 diabetes mellitus:188:0.9841	0.9841	188
T2DM	T2DM:11	Type 2 diabetic:11:0.7357	0.7357	11
T2WI	T2WI:62|T2-WI:6	T2-weighted images:54:0.6015|T2-weighted image:14:0.4367	0.6015	68
T2WI	T2WI:15|T2-WI:2	T2-weighted imaging:17:0.5374	0.5374	17
T2W	T2W:49|T2-w:14|T2w:7	T2-weighted:70:0.7188	0.7188	70
T2	T2:7|t2:2	6 months later:9:0.1267	0.1267	9
T2	T2:9	after treatment:9:0.0674	0.0674	9
T2	T2:8	degrees C:8:0.5006	0.5006	8
T2	T2:9	diiodothyronine:9:0.0037	0.0037	9
T2	T2:9|t2:4	discharge:13:0.0055	0.0055	13
T2	T2:19|t2:1	follow-up:20:0.0087	0.0087	20
T2	T2:9|t2:5	hours:14:0.0059	0.0059	14
T2	T2:7|t2:2	minutes:9:0.0037	0.0037	9
T2	T2:17	mitochondrial acetoacetyl-CoA thiolase:17:0.7407	0.7407	17
T2	T2:43|t2:8	months:51:0.0228	0.0228	51
T2	T2:9|t2:2	period:11:0.0046	0.0046	11
T2	T2:9	postoperatively:9:0.0037	0.0037	9
T2	T2:194|T-2:1	relaxation time:132:0.8398|relaxation times:63:0.9253	0.9253	195
T2	T2:7	second target:7:0.1850	0.1850	7
T2	T2:7	second thoracic:7:0.2902	0.2902	7
T2	T2:6	spin-spin relaxation:6:0.0666	0.0666	6
T2	T2:6	stage B:6:0.0732	0.0732	6
T-2	T-2:44|T2:4	T-2 toxin:48:0.8463	0.8463	48
T2	T2:11|t2:1	therapy:12:0.0050	0.0050	12
T2	T2:22|t2:1	Time 2:23:0.1434	0.1434	23
T2	T2:10	transverse relaxation:10:0.2643	0.2643	10
T2	T2:23|T-2:2|t2:1	weeks:26:0.0114	0.0114	26
T2	T2:10|t2:1	years:11:0.0046	0.0046	11
T2	T2:16|t2:1	years later:17:0.1242	0.1242	17
T3RU	T3RU:9|T3-RU:1	T3 resin uptake:10:0.3867	0.3867	10
T3Rs	T3Rs:2	T3 receptors:2:0.1641	0.1641	2
T3R	T3R:22	thyroid hormone receptor:22:0.7955	0.7955	22
T3SS	T3SS:11	type III secretion system:11:0.7357	0.7357	11
T3S	T3S:19|T3-S:1	T3 sulfate:20:0.4786	0.4786	20
T3	T3:11	[125I]triiodothyronine:11:0.0015	0.0015	11
T3	T3:9	3,3',5-tri-iodothyronine:9:0.0012	0.0012	9
T3	T3:11	3,3',5'-triiodothyronine:11:0.0015	0.0015	11
T3	T3:12|t3:1	3 months:13:0.1704	0.1704	13
T3	T3:9	advanced:9:0.0012	0.0012	9
T3	T3:15|t3:3	after:18:0.0026	0.0026	18
T3	T3:10|t3:2	hours:12:0.0017	0.0017	12
T3	T3:11	L-3,3',5-triiodothyronine:11:0.0015	0.0015	11
T3	T3:27	L-3,5,3'-triiodothyronine:27:0.0039	0.0039	27
T3	T3:127	L-triiodothyronine:127:0.0191	0.0191	127
T3	T3:11	later:11:0.0015	0.0015	11
T3	T3:11	period:11:0.0015	0.0015	11
T3	T3:323	Thyroid hormone:323:0.9755	0.9755	323
T3	T3:7	thyroid hormone 3,3',5-triiodo-L-thyronine:7:0.7096	0.7096	7
T3	T3:6	total T3:6:0.1838	0.1838	6
T3	T3:12|t3:1	treatment:13:0.0018	0.0018	13
T3	T3:19	triidothyronine:19:0.0027	0.0027	19
T3	T3:12|t3:1	triiodothyronin:13:0.0018	0.0018	13
T3	T3:14	triiodothyroxine:14:0.0020	0.0020	14
T3	T3:13	triodothyronine:13:0.0018	0.0018	13
T3	T3:11	Type 3:11:0.0762	0.0762	11
T3	T3:10|T-3:1	weeks:11:0.0015	0.0015	11
T3	T3:11	years:11:0.0015	0.0015	11
T47D	T47D:11|T-47D:4	breast cancer cell line:15:0.8045	0.8045	15
T47D	T-47D:3|T47D:3	human breast cancer cells:6:0.5290	0.5290	6
T4L	T4L:10	T4 lysozyme:10:0.7103	0.7103	10
T4MO	T4MO:9	Toluene 4-monooxygenase:9:0.6794	0.6794	9
T4SS	T4SS:23	type IV secretion system:23:0.8715	0.8715	23
T4	T4:16	helper/inducer:16:0.0029	0.0029	16
T4	T4:10	invasion:10:0.0017	0.0017	10
T4	T4:8|t4:1	later:9:0.0015	0.0015	9
T4	T4:15	levothyroxine:15:0.0027	0.0027	15
T4	T4:14	locally advanced:14:0.5111	0.5111	14
T4	T4:10|t4:1	months:11:0.0019	0.0019	11
T4	T4:452|T-4:5	serum thyroxine:457:0.1096	0.1096	457
T4	T4:9	T helper:9:0.1409	0.1409	9
T4	T4:4|T-4:1	T helper cells:5:0.4422	0.4422	5
T4	T4:15	thyroid hormone:15:0.7261	0.7261	15
T4	T4:6	thyroxine level:6:0.2243	0.2243	6
T4	T4:13	tripchlorolide:13:0.0023	0.0023	13
T5	T5:7|T-5:1	fifth thoracic:8:0.5006	0.5006	8
T6	T6:6|t6:2|T-6:1	6 months:9:0.5470	0.5470	9
T84	T84:18|T-84:2	cell line:20:0.8525	0.8525	20
T84	T84:10	epithelial:10:0.1268	0.1268	10
T84	T84:4	intestinal epithelial cells:4:0.0918	0.0918	4
T9	T9:7|T-9:2	thoracic:9:0.1111	0.1111	9
TA-077	TA-077:9	1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea:9:0.8889	0.8889	9
TAAA	TAAA:65	thoracoabdominal aortic aneurysm:56:0.9162|thoracoabdominal aortic aneurysms:9:0.6794	0.9162	65
TAAAs	TAAAs:11|TAAAS:1	thoracoabdominal aortic aneurysms:12:0.7571	0.7571	12
TAAs	TAAs:10	Thoracic aortic aneurysms:10:0.7103	0.7103	10
TAAs	TAAs:80|TAAS:1	tumor-associated antigens:81:0.6289	0.6289	81
TAA	TAA:7	tert-amyl alcohol:7:0.2113	0.2113	7
TAA	TAA:123	thioacetamide:123:0.1298	0.1298	123
TAA	TAA:57	thoracic aortic aneurysm:35:0.5771|thoracic aortic aneurysms:22:0.6178	0.6178	57
TAA	TAA:12|-TAA:1	thoracoabdominal aneurysm:13:0.0915	0.0915	13
TAA	TAA:12	thoracoabdominal aortic aneurysm:12:0.1078	0.1078	12
TAA	TAA:7	Thoracoabdominal asynchrony:7:0.3524	0.3524	7
TAA	TAA:15	total amino acids:10:0.5000|total amino acid:5:0.1973	0.5000	15
TAA	TAA:26	total antioxidant activity:26:0.8861	0.8861	26
TAA	TAA:49	triamcinolone acetonide:49:0.8492	0.8492	49
TAA	TAA:8	tumor-associated Ag:8:0.5006	0.5006	8
TAA	TAA:11	tumor-associated Ags:11:0.7357	0.7357	11
TAA	TAA:272	tumor-associated antigens:151:0.6503|tumor-associated antigen:106:0.6551|tumor associated antigen:15:0.4609	0.6551	272
TABM	TABM:6|T-ABM:4	antigen-binding molecules:10:0.3867	0.3867	10
TABP	TABP:53	Type A behavior pattern:53:0.9116	0.9116	53
TAB	TAB:9	temporal artery biopsy:9:0.6794	0.6794	9
TAB	TAB:13	total androgen blockade:13:0.7753	0.7753	13
TACA	TACA:10	trans-4-aminocrotonic acid:10:0.3470	0.3470	10
TACT	TACT:21	Tuned-aperture computed tomography:21:0.3419	0.3419	21
TA-CVS	TA-CVS:10|TACVS:2	transabdominal chorionic villus sampling:12:0.7571	0.7571	12
TAChR	TAChR:10|tAChR:5|T-AChR:1	acetylcholine receptor:16:0.8165	0.8165	16
TACs	TACs:28	time-activity curves:28:0.5445	0.5445	28
TAC	TAC:17	concentration:17:0.0188	0.0188	17
tac	tac:7	hybrid trp-lac:7:0.2113	0.2113	7
Tac	Tac:9|TAC:3	interleukin 2 receptor:12:0.4557	0.4557	12
Tac	Tac:5	interleukin-2 receptor alpha chain:5:0.1973	0.1973	5
TAC	TAC:93|Tac:54|tac:1	tacrolimus:148:0.1735	0.1735	148
TAC	TAC:14	Teller Acuity Cards:14:0.6911	0.6911	14
TAC	TAC:49	time-activity curve:21:0.4359|time activity curve:12:0.7571|time-activity curves:10:0.3145|time activity curves:6:0.5290	0.7571	49
TAC	TAC:9	total abdominal colectomy:9:0.6794	0.6794	9
TAC	TAC:91	Total antioxidant capacity:91:0.9473	0.9473	91
TAC	TAC:10	transformation-competent artificial chromosome:10:0.5856	0.5856	10
TAC	TAC:25	transverse aortic constriction:25:0.7679	0.7679	25
TAC	TAC:21	triamcinolone acetonide:21:0.8594	0.8594	21
TADs	TADs:9	transactivation domains:9:0.2500	0.2500	9
TAD	TAD:10	diameter:10:0.0375	0.0375	10
TAD	TAD:29	thiazole-4-carboxamide adenine dinucleotide:29:0.7237	0.7237	29
TAD	TAD:40	transactivation domain:40:0.4616	0.4616	40
TAD	TAD:13	transcription activation domain:13:0.2959	0.2959	13
TAD	TAD:11	transcriptional activation domain:11:0.2154	0.2154	11
TAD	TAD:13	transient acantholytic dermatosis:13:0.7753	0.7753	13
TAE	TAE:10	tilt aftereffect:10:0.5856	0.5856	10
TAE	TAE:24	transcatheter arterial chemoembolization:24:0.6122	0.6122	24
TAE	TAE:384	transcatheter arterial embolization:384:0.8942	0.8942	384
TAE	TAE:11	transcatheter arterial embolization therapy:11:0.4232	0.4232	11
TAE	TAE:1	treated by either transarterial embolization:1:0.0801	0.0801	1
TAFE	TAFE:9	transverse alternating field electrophoresis:9:0.5470	0.5470	9
TAFIa	TAFIa:14	activated TAFI:14:0.6173	0.6173	14
TAFIa	TAFIa:9	fibrinolysis inhibitor:9:0.6794	0.6794	9
TAFI	TAFI:146	Thrombin-activatable fibrinolysis inhibitor:75:0.3398|thrombin activatable fibrinolysis inhibitor:71:0.9579	0.9579	146
TAF	TAF:10	aspirate fluid:10:0.5000	0.5000	10
TAF	TAF:10	Studies on the function of concentration maintenance:10:0.4444	0.4444	10
TAF	TAF:14	thought-action fusion:14:0.5589	0.5589	14
TAF	TAF:38	Tumour angiogenesis factor:23:0.4188|Tumor angiogenesis factor:15:0.2119	0.4188	38
TAG-72	TAG-72:35	tumor-associated glycoprotein:35:0.7647	0.7647	35
TAG-72	TAG-72:38|TAG72:1	tumor-associated glycoprotein-72:22:0.5581|tumor-associated glycoprotein 72:17:0.5038	0.5581	39
TA-GVHD	TA-GVHD:48|TAGVHD:3|TA-GvHD:2	Transfusion-associated graft-versus-host disease:53:0.8842	0.8842	53
TAH/BSO	TAH/BSO:3	total abdominal hysterectomy and bilateral salpingo-oophorectomy:3:0.5926	0.5926	3
TAH-BSO	TAH-BSO:8|TAHBSO:4	total abdominal hysterectomy and bilateral salpingo-oophorectomy:12:0.7909	0.7909	12
TAHs	TAHs:13	total artificial hearts:13:0.7753	0.7753	13
TAH	TAH:83	total abdominal hysterectomy:83:0.9640	0.9640	83
TAH	TAH:239	total artificial heart:223:0.9585|total artificial hearts:16:0.8165	0.9585	239
TAI	TAI:8	Anxiety Inventory:8:0.5006	0.5006	8
TAI	TAI:5	thoracoabdominal irradiation:5:0.0736	0.0736	5
TAI	TAI:19	timed artificial insemination:19:0.7044	0.7044	19
TAI	TAI:10	transcatheter arterial infusion:10:0.7103	0.7103	10
TAI	TAI:19	traumatic axonal injury:19:0.7766	0.7766	19
TAK-044	TAK-044:12|TAK044:4	receptor antagonist:16:0.6024	0.6024	16
TAK1	TAK1:11	transforming growth factor-beta-activated kinase 1:11:0.7357	0.7357	11
TALH	TALH:15	thick ascending limb of Henle:15:0.5818	0.5818	15
TALH	TALH:33	thick ascending limb of Henle's loop:33:0.9100	0.9100	33
TALH	TALH:11	thick ascending limb of the loop of Henle:11:0.7357	0.7357	11
TALH	TALH:7	thick ascending loop of Henle:7:0.5926	0.5926	7
T-ALL	T-ALL:18	T-cell acute lymphoblastic leukaemia:18:0.3857	0.3857	18
T-ALL	T-ALL:193	T-cell acute lymphoblastic leukemia:137:0.5817|T cell acute lymphoblastic leukemia:45:0.9338|T cell acute lymphoblastic leukemias:11:0.7357	0.9338	193
TALP	TALP:7	albumin lactate pyruvate:7:0.4587	0.4587	7
TALP	TALP:9|tALP:6|T-ALP:5	total alkaline phosphatase:20:0.7766	0.7766	20
TALs	TALs:9	tumor-associated lymphocytes:9:0.4587	0.4587	9
TAL	TAL:9	taste aversion learning:9:0.6794	0.6794	9
TAL	TAL:5	tendo-Achilles lengthening:5:0.1132	0.1132	5
TAL	TAL:118	thick ascending limb:106:0.9030|thick ascending limbs:12:0.7571	0.9030	118
TAL	TAL:22	thick ascending limb of Henle:22:0.8657	0.8657	22
TAL	TAL:20	thick ascending limb of Henle's loop:20:0.4786	0.4786	20
TAL	TAL:13	thick ascending limb of the loop of Henle:13:0.6911	0.6911	13
TAL	TAL:8	thin agar layer:8:0.6411	0.6411	8
TAL	TAL:9|tal:2	transaldolase:11:0.0297	0.0297	11
TAL	TAL:29	tumor-associated lymphocytes:29:0.5376	0.5376	29
TAMC	TAMC:9	Tripler Army Medical Center:9:0.6794	0.6794	9
TAME	TAME:57|TAMe:7	methyl ester:64:0.8430	0.8430	64
TAMI	TAMI:30	Thrombolysis and Angioplasty in Myocardial Infarction:30:0.9011	0.9011	30
TAMV	TAMV:9	time-averaged maximum velocity:9:0.3945	0.3945	9
TAMs	TAMs:8	thymidine analogue mutations:8:0.6411	0.6411	8
TAMs	TAMs:29	tumor-associated macrophages:29:0.4526	0.4526	29
TAM	TAM:645|Tam:75|tam:7	tamoxifen:727:0.6954	0.6954	727
TAM	TAM:11|Tam:1	tamoxifen citrate:12:0.7571	0.7571	12
TAM	TAM:22	total active motion:22:0.8657	0.8657	22
TAM	TAM:23	transient abnormal myelopoiesis:23:0.8715	0.8715	23
TAM	TAM:65	tumor-associated macrophages:55:0.6163|tumor-associated macrophage:10:0.3867	0.6163	65
TANF	TANF:22	Temporary Assistance for Needy Families:22:0.8644	0.8644	22
TANs	TANs:18	Tonically active neurons:18:0.8365	0.8365	18
TAN	TAN:59	total adenine nucleotide:32:0.8145|total adenine nucleotides:27:0.8312	0.8312	59
TAOC	TAOC:9|T-AOC:2	total antioxidant capacity:11:0.7357	0.7357	11
TAO	TAO:53	Thromboangiitis obliterans:53:0.7149	0.7149	53
TAO	TAO:112	thyroid-associated ophthalmopathy:91:0.7285|thyroid associated ophthalmopathy:21:0.8594	0.8594	112
TAO	TAO:17	thyroid-associated orbitopathy:17:0.5038	0.5038	17
TAO	TAO:41	Triacetyloleandomycin:41:0.1156	0.1156	41
TAO	TAO:44|Tao:1	Troleandomycin:45:0.1272	0.1272	45
TAO	TAO:14	trypanosome alternative oxidase:14:0.6911	0.6911	14
TAP1	TAP1:1	transporter associated with the antigen processing 1:1:0.6182	0.6182	1
TAP2	TAP2:5|Tap-2:1	transporter associated with antigen processing 2:6:0.5290	0.5290	6
TAPVC	TAPVC:80	total anomalous pulmonary venous connection:80:0.9219	0.9219	80
TAPVD	TAPVD:40	total anomalous pulmonary venous drainage:40:0.9274	0.9274	40
TAPVR	TAPVR:37	total anomalous pulmonary venous return:37:0.9197	0.9197	37
TAP	TAP:11	2,4,6-triaminopyrimidine:11:0.0108	0.0108	11
TAP	TAP:9	peptide transporter:9:0.3945	0.3945	9
TAP	TAP:9|Tap:1	proteins:10:0.0097	0.0097	10
TAP	TAP:30	tandem affinity purification:30:0.9011	0.9011	30
TAP	TAP:37	Thiamphenicol:37:0.0388	0.0388	37
TAP	TAP:29	Tick anticoagulant peptide:29:0.8978	0.8978	29
TAP	TAP:26|tAP:1	total alkaline phosphatase:27:0.7425	0.7425	27
TAP	TAP:13|tap:1	tracheal antimicrobial peptide:14:0.7909	0.7909	14
TAP	TAP:27	transesophageal atrial pacing:27:0.6192	0.6192	27
TAP	TAP:8	transmembrane action potential:8:0.4102	0.4102	8
TAP	TAP:38	transporter associated with antigen presentation:38:0.7492	0.7492	38
TAP	TAP:232	transporter associated with antigen processing:232:0.8494	0.8494	232
TAP	TAP:12	Treatment of age-related macular degeneration with photodynamic therapy:12:0.6460	0.6460	12
TAP	TAP:15	tricuspid annuloplasty:15:0.7096	0.7096	15
TAP	TAP:59	trypsinogen activation peptide:38:0.8417|Trypsinogen activation peptides:21:0.8594	0.8594	59
TARC	TARC:67	thymus and activation-regulated chemokine:67:0.7285	0.7285	67
TARP	TARP:7	alternate reading frame protein:7:0.5926	0.5926	7
TART	TART:7	total apexcardiographic relaxation time:7:0.5926	0.5926	7
TAR	TAR:10	Tat protein with the trans-activation responsive region:10:0.7103	0.7103	10
TAR	TAR:8	thoracic aortic rupture:8:0.1367	0.1367	8
TAR	TAR:7	Thrombocytopenia-Absent Radius:7:0.0777	0.0777	7
TAR	TAR:10	thrombocytopenia and absent radii:10:0.7834	0.7834	10
TAR	TAR:2	Thrombocytopenia and absent radius:2:0.8165	0.8165	2
TAR	TAR:19	tissue-air ratio:19:0.4852	0.4852	19
TAR	TAR:17	trans-activation response:17:0.1684	0.1684	17
TAR	TAR:19	trans-activation response element:19:0.1852	0.1852	19
TAR	TAR:8	trans-activation response region:8:0.1730	0.1730	8
TAR	TAR:18	trans-activation responsive:9:0.1809|trans-activation-responsive:9:0.0143	0.1809	18
TAR	TAR:5|tar:3	trans-activation responsive element:8:0.1367	0.1367	8
TAR	TAR:22	transactivation response:22:0.2508	0.2508	22
TAR	TAR:26	transactivation response element:26:0.2951	0.2951	26
TAR	TAR:7	transactivation response region:7:0.1211	0.1211	7
TAR	TAR:21	transformation-associated recombination:21:0.6812	0.6812	21
TAR	TAR:12	traumatic aortic rupture:12:0.3275	0.3275	12
TAS-20	TAS-20:102	Toronto Alexithymia Scale:102:0.9707	0.9707	102
TASC	TASC:11	TransAtlantic Inter-Society Consensus:11:0.6182	0.6182	11
TASH	TASH:10	Transcoronary ablation of septal hypertrophy:10:0.4587	0.4587	10
TASO	TASO:9	AIDS Support Organization:9:0.5470	0.5470	9
TASP	TASP:10	template-assembled synthetic protein:10:0.5000	0.5000	10
tas	tas:10|TAs:6|TAS:2	telomeric associations:18:0.8365	0.8365	18
TAS	TAS:4	termination associated sequence:4:0.1618	0.1618	4
TAS	TAS:76	Toronto Alexithymia Scale:76:0.9607	0.9607	76
TAS	TAS:138	total antioxidant status:138:0.9541	0.9541	138
TAS	TAS:16	transabdominal sonography:16:0.8165	0.8165	16
TAs	TAs:9|tas:1	tubular aggregates:10:0.5856	0.5856	10
TATA	TATA:35	tumor-associated transplantation antigen:19:0.6259|tumor-associated transplantation antigens:16:0.4536	0.6259	35
TATE	TATE:16	tissue eosinophilia:16:0.8165	0.8165	16
TATI	TATI:98	tumor-associated trypsin inhibitor:65:0.5258|Tumour-associated trypsin inhibitor:33:0.2106	0.5258	98
Tat	Tat:3|TAT:1	HIV-1 transactivator:4:0.0828	0.0828	4
TAT	TAT:37	Thematic Apperception Test:37:0.8377	0.8377	37
TAT	TAT:101|T-AT:1	thrombin-antithrombin:102:0.0563	0.0563	102
TAT	TAT:244|T-AT:1	thrombin-antithrombin complex:177:0.3080|thrombin-antithrombin complexes:68:0.3454	0.3454	245
TAT	TAT:101|T-AT:2	thrombin-antithrombin III:103:0.8100	0.8100	103
TAT	TAT:305|T-AT:1	thrombin-antithrombin III complex:242:0.7719|thrombin-antithrombin III complexes:56:0.6570|thrombin-antithrombin III-complex:8:0.5006	0.7719	306
TAT	TAT:7	total adipose tissue:7:0.2902	0.2902	7
Tat	Tat:11|tat:11|TAT:2	trans-activator:24:0.0123	0.0123	24
TAT	TAT:9|Tat:5	transactivator of transcription:14:0.4367	0.4367	14
Tat	Tat:8|tat:5|TAT:2	transactivator protein:15:0.1992	0.1992	15
TAT	TAT:37	tray agglutination test:37:0.5643	0.5643	37
TAT	TAT:32	turnaround time:32:0.4711	0.4711	32
Tat	Tat:48|tat:6|TAT:5	twin-arginine translocation:48:0.6663|twin arginine translocation:11:0.7357	0.7357	59
TAT	TAT:9	tyrosine amino transferase:9:0.6794	0.6794	9
TAT	TAT:283|Tat:3	Tyrosine aminotransferase:286:0.9895	0.9895	286
TauD	TauD:13	dioxygenase:13:0.6316	0.6316	13
TAV	TAV:11	time average velocity:11:0.7357	0.7357	11
TAV	TAV:20	tomato aspermy virus:20:0.7766	0.7766	20
TAZ	TAZ:1|taz:1	beta-lactamase inhibitor tazobactam:2:0.5926	0.5926	2
ta	ta:6|Ta:1	absorption time:7:0.1211	0.1211	7
TA	TA:26	acetate:26:0.0072	0.0072	26
Ta	Ta:14|ta:1|TA:1	air temperatures:16:0.0503	0.0503	16
Ta	Ta:409|TA:9|ta:1	ambient temperature:274:0.8407|ambient temperatures:145:0.8089	0.8407	419
TA	TA:11	analysis:11:0.0029	0.0029	11
TA	TA:12	anterior tibial:12:0.7571	0.7571	12
TA	TA:21|Ta:1	antigen:22:0.0061	0.0061	22
TA	TA:7	patients with Takayasu arteritis:7:0.0902	0.0902	7
TA	TA:5|Ta:3	T cells:8:0.4102	0.4102	8
Ta	Ta:35	tabby:35:0.0095	0.0095	35
TA	TA:87	Takayasu's arteritis:87:0.3251	0.3251	87
TA	TA:61	tannic acid:61:0.1924	0.1924	61
Ta	Ta:14	Tantalum:14:0.0038	0.0038	14
TA	TA:10	technology assessment:10:0.5000	0.5000	10
TA	TA:7	teichoic acids:7:0.3524	0.3524	7
TA	TA:64	telomerase activity:64:0.4834	0.4834	64
TA	TA:5	Temporal artery:5:0.1132	0.1132	5
TA	TA:29	thioacetamide:29:0.0081	0.0081	29
TA	TA:21	thoracic aorta:21:0.7865	0.7865	21
TA	TA:16	thyroarytenoid muscle:16:0.1382	0.1382	16
TA	TA:647|ta:1|Ta:1	tibialis anterior:649:0.9792	0.9792	649
TA	TA:32	tibialis anterior muscle:32:0.9072	0.9072	32
TA	TA:13	Titratable acidity:13:0.4849	0.4849	13
TA	TA:22	tonic accommodation:22:0.7955	0.7955	22
TA	TA:9|Ta:1	total area:10:0.0989	0.0989	10
TA	TA:10	toxic adenoma:10:0.2126	0.2126	10
TA	TA:9	Tracheal agenesis:9:0.6794	0.6794	9
TA	TA:28	tracheal aspirates:15:0.6386|tracheal aspirate:13:0.5335	0.6386	28
TA	TA:48	Tranexamic acid:48:0.1434	0.1434	48
TA	TA:26	transabdominal:26:0.0072	0.0072	26
TA	TA:11	transactivation:11:0.0029	0.0029	11
TA	TA:6	transient absorption:6:0.1838	0.1838	6
TA	TA:5	transit amplifying:5:0.0902	0.0902	5
TA	TA:10	Transplant arteriosclerosis:10:0.7103	0.7103	10
TA	TA:18	transversus abdominis:18:0.6381	0.6381	18
TA	TA:128	triamcinolone acetonide:128:0.7634	0.7634	128
TA	TA:16	triamterene:16:0.0043	0.0043	16
TA	TA:17	tricuspid annulus:17:0.7407	0.7407	17
TA	TA:22	tricuspid atresia:22:0.7955	0.7955	22
TA	TA:17	truncus arteriosus:17:0.8270	0.8270	17
TA	TA:5|Ta:2	tryptamine:7:0.0023	0.0023	7
TA	TA:12|ta:1	tubular adenomas:7:0.2902|tubular adenoma:6:0.0522	0.2902	13
TA	TA:5	tumour antigens:5:0.0736	0.0736	5
TA	TA:17	tunica albuginea:17:0.8270	0.8270	17
TA	TA:14	tyramine:14:0.0038	0.0038	14
TB-RBP	TB-RBP:9	Testis brain RNA-binding protein:9:0.6794	0.6794	9
TBARS	TBARS:30|TBARs:4|TBA-RS:3|tbars:1	lipid peroxidation:38:0.7810	0.7810	38
TBARS	TBARS:10	lipid peroxidation products:10:0.5856	0.5856	10
TBARS	TBARS:11|TBA-RS:1	thiobarbituric acid:12:0.3524	0.3524	12
TBARs	TBARs:9|TBARS:5|TBAR-S:1	thiobarbituric acid reactants:15:0.8045	0.8045	15
TBARS	TBARS:45|TBA-RS:6|TBARs:1	thiobarbituric acid reactive species:35:0.8681|thiobarbituric acid-reactive species:17:0.8270	0.8681	52
TBARS	TBARS:1646|TBA-RS:77|TBARs:36|TBA-rs:5|TBArS:2|TBArs:1	Thiobarbituric acid reactive substances:980:0.9607|thiobarbituric acid-reactive substances:577:0.9440|thiobarbituric acid reactive substance:136:0.9334|thiobarbituric acid-reactive substance:74:0.8975	0.9607	1767
TBAR	TBAR:9	thiobarbituric acid reactants:9:0.6794	0.6794	9
TBAR	TBAR:12	Thiobarbituric acid-reactive material:7:0.5926|thiobarbituric acid reactive material:5:0.4422	0.5926	12
TBAR	TBAR:5	thiobarbituric acid reactive products:5:0.4422	0.4422	5
TBAR	TBAR:6	thiobarbituric acid reactive substances:6:0.5290	0.5290	6
TBAb	TBAb:5|TBAB:1	thyroid blocking antibodies:6:0.2827	0.2827	6
TBAB	TBAB:10	trickle-bed air biofilter:10:0.5856	0.5856	10
TBAs	TBAs:162|TBAS:1	traditional birth attendants:163:0.9612	0.9612	163
TBBM	TBBM:29	total body bone mineral:29:0.8978	0.8978	29
TBBM	TBBM:12	total body bone mineral content:12:0.7571	0.7571	12
TBBMC	TBBMC:23|tb-BMC:1|tbBMC:1	total body bone mineral content:25:0.8186	0.8186	25
TBBMD	TBBMD:9	total body bone mineral density:9:0.6794	0.6794	9
TBBs	TBBs:8	transbronchial biopsies:8:0.4102	0.4102	8
TBB	TBB:15	transbronchial biopsies:15:0.5348	0.5348	15
TBB	TBB:23	Transbronchial lung biopsy:23:0.8715	0.8715	23
TBCa	TBCa:25|TB-Ca:1|TbCa:1	total body calcium:27:0.8903	0.8903	27
TBC	TBC:8|tBC:1	4-tert-butylcatechol:9:0.0258	0.0258	9
TBC	TBC:5	4-tertiary butyl catechol:5:0.1973	0.1973	5
TBC	TBC:13	binding capacity:13:0.4849	0.4849	13
TBC	TBC:19	target-binding cells:12:0.2293|target binding cells:7:0.3524	0.3524	19
TBC	TBC:7	total bacterial count:7:0.5926	0.5926	7
TBC	TBC:35	Total body clearance:35:0.9151	0.9151	35
TBC	TBC:40|tbc:12|Tbc:9	tuberculosis:61:0.1935	0.1935	61
TBDMS	TBDMS:20|tBDMS:6|t-BDMS:5	tert-butyldimethylsilyl:21:0.3636|tert.-butyldimethylsilyl:10:0.1636	0.3636	31
TBD	TBD:16	Trabecular bone density:16:0.6024	0.6024	16
TBEV	TBEV:91|TBEv:4|TBE-V:1	tick-borne encephalitis virus:96:0.8813	0.8813	96
TBE	TBE:542|tbe:1	tick-borne encephalitis:543:0.9173	0.9173	543
TBE	TBE:19	tick-borne encephalitis virus:19:0.8449	0.8449	19
TBE	TBE:12	tracheobronchial epithelial:12:0.7571	0.7571	12
TBE	TBE:17	Tris-borate-EDTA:17:0.0225	0.0225	17
TBE	TBE:15	tumour bed effect:8:0.2090|tumor bed effect:7:0.1470	0.2090	15
TBFVL	TBFVL:8	tidal breathing flow-volume loops:8:0.6411	0.6411	8
TBF	TBF:81|tBF:2	blood flow:83:0.9247	0.9247	83
TBF	TBF:13	terbinafine:13:0.0463	0.0463	13
TBF	TBF:9	tert-butyl formate:9:0.3945	0.3945	9
TBF	TBF:8	thermal biofeedback:8:0.5006	0.5006	8
TBF	TBF:19	tick-borne fever:19:0.7658	0.7658	19
TBF	TBF:59	total body fat:59:0.9203	0.9203	59
TBG	TBG:326	Thyroxine-binding globulin:326:0.4409	0.4409	326
TBG	TBG:11	trophoblastic beta 1-glycoprotein:11:0.7357	0.7357	11
t-BHP	t-BHP:14|TBHP:11|tBHP:10|tbHP:1	t-butyl hydroperoxide:36:0.1755	0.1755	36
t-BHP	t-BHP:10|tBHP:9|TBHP:2	t-butylhydroperoxide:21:0.0962	0.0962	21
TBHP	TBHP:48|t-BHP:29|tBHP:13|t-bHP:1	tert-butyl hydroperoxide:91:0.5574	0.5574	91
t-BHP	t-BHP:15|TBHP:11|tBHP:4	tert-butylhydroperoxide:30:0.1394	0.1394	30
TBHQ	tBHQ:4|TBHQ:4|t-BHQ:2	t-butylhydroquinone:10:0.0588	0.0588	10
TBHQ	TBHQ:4|t-BHQ:3	tert-butyl hydroquinone:7:0.2113	0.2113	7
TBHQ	TBHQ:38|tBHQ:31|t-BHQ:6|t-b-HQ:1	tert-butylhydroquinone:76:0.4902	0.4902	76
TBHQ	TBHQ:9	Tertiary butylhydroquinone:9:0.4587	0.4587	9
TBHT	TBHT:5	extracorporeally induced total-body hyperthermia:5:0.4422	0.4422	5
TBH	TBH:3|tBH:3|tbh:2|t-BH:1	t-butylhydroperoxide:9:0.0442	0.0442	9
tBH	tBH:18|TBH:11|t-BH:4	tert-butyl hydroperoxide:33:0.4300	0.4300	33
tBH	tBH:7|TBH:5|t-BH:2	tert-butylhydroperoxide:14:0.0718	0.0718	14
TBH	TBH:46	tumor-bearing host:31:0.8090|tumor-bearing hosts:15:0.8045	0.8090	46
TBIAb	TBIAb:8|TBI-ab:1	inhibiting antibodies:9:0.3069	0.3069	9
TBIAb	TBIAb:4	TSH binding inhibiting antibody:4:0.1618	0.1618	4
TBII	TBII:8	thyrotrophin binding inhibiting immunoglobulins:8:0.1125	0.1125	8
TBII	TBII:12	thyrotropin binding inhibiting immunoglobulins:12:0.2699	0.2699	12
TBII	TBII:17	thyrotropin binding inhibitor immunoglobulin:17:0.2788	0.2788	17
TBII	TBII:63	TSH-binding inhibitor immunoglobulins:24:0.3721|TSH-binding inhibitor immunoglobulin:16:0.1285|TSH binding inhibitor immunoglobulin:14:0.2264|TSH binding inhibitor immunoglobulins:9:0.3495	0.3721	63
TBII	TBII:41	TSH-binding inhibitory immunoglobulin:17:0.1720|TSH binding inhibitory immunoglobulin:16:0.3844|TSH binding inhibitory immunoglobulins:8:0.2643	0.3844	41
TBIs	TBIs:20	traumatic brain injuries:20:0.8525	0.8525	20
TBI	TBI:24	brain injured:24:0.7593	0.7593	24
TBI	TBI:1217	total body irradiation:1028:0.9818|total-body irradiation:189:0.1309	0.9818	1217
TBI	TBI:12	traumatic brain-injured:12:0.2414	0.2414	12
TBI	TBI:2235	Traumatic brain injury:2190:0.9880|traumatic brain injuries:45:0.9338	0.9880	2235
TBI	TBI:13	traumatically brain-injured:13:0.2802	0.2802	13
TBI	TBI:7	TSH binding inhibition:7:0.3463	0.3463	7
TBK	TBK:141	total body potassium:141:0.9661	0.9661	141
TBLB	TBLB:132	transbronchial lung biopsy:132:0.9029	0.9029	132
TBMD	TBMD:22|T-BMD:1	bone mineral density:23:0.7500	0.7500	23
TBMD	TBMD:27	thin basement membrane disease:27:0.7425	0.7425	27
TBMN	TBMN:18	thin basement membrane nephropathy:18:0.7539	0.7539	18
TBM	TBM:12	total body mass:12:0.7571	0.7571	12
TBM	TBM:7	trabecular bone mass:7:0.2902	0.2902	7
TBM	TBM:13	tracheobronchomalacia:13:0.0227	0.0227	13
TBM	TBM:188|TbM:2|Tbm:1|tbm:1	tuberculous meningitis:192:0.8808	0.8808	192
TBM	TBM:129|Tbm:1	tubular basement membrane:103:0.7039|tubular basement membranes:27:0.8312	0.8312	130
TBM	TBM:17	tumor-bearing mice:17:0.5038	0.5038	17
TBNC	TBNC:10	trigeminal brainstem nuclear complex:10:0.7103	0.7103	10
TBNA	TBNA:84	transbronchial needle aspiration:84:0.9091	0.9091	84
TBOA	TBOA:13	DL-threo-beta-benzyloxyaspartate:13:0.5000	0.5000	13
TBO	TBO:31	toluidine blue O:31:0.9043	0.9043	31
TBPS	TBPS:9	[35S]-t-butylbicyclophosphorothionate:9:0.0471	0.0471	9
TBPS	TBPS:12	binding of [35S]t-butylbicyclophosphorothionate:12:0.1538	0.1538	12
TBPS	TBPS:31	t-butylbicyclophosphorothionate:31:0.1765	0.1765	31
TBPS	TBPS:9	tert-butylbicyclophosphorothionate:9:0.0471	0.0471	9
Tbps	Tbps:6|TBPs:4	transferrin-binding proteins:10:0.2446	0.2446	10
TBPf	TBPf:14|TBPF:1	Trabecular Bone Pattern factor:15:0.8045	0.8045	15
TBP	TBP:10	blood pressure:10:0.7103	0.7103	10
TBP	TBP:10|tbp:1	proteins:11:0.0093	0.0093	11
TBP	TBP:443|tbp:1	TATA-binding protein:444:0.4840	0.4840	444
TBP	TBP:5	TATA box-binding polypeptide:5:0.4422	0.4422	5
TBP	TBP:9	tri-n-butyl phosphate:9:0.0693	0.0693	9
TBP	TBP:29	tributyl phosphate:29:0.5212	0.5212	29
TBRF	TBRF:13	tick-borne relapsing fever:13:0.6701	0.6701	13
TBRV	TBRV:11	Tomato Black Ring Virus:11:0.7357	0.7357	11
Tbr	Tbr:39	brain temperature:39:0.8455	0.8455	39
TBR	TBR:8	tumor-bearing rats:8:0.2987	0.2987	8
TBSA	TBSA:244|tbsa:1	total body surface area:245:0.9739	0.9739	245
TBSA	TBSA:10	tuberculostearic acid:10:0.5856	0.5856	10
TBSV	TBSV:53	tomato bushy stunt virus:53:0.9438	0.9438	53
TBTCl	TBTCl:17|TBT-Cl:1|TBTCL:1	tributyltin chloride:19:0.6537	0.6537	19
TBTC	TBTC:17	tri-n-butyltin chloride:17:0.3366	0.3366	17
TBTC	TBTC:14	Tributyltin chloride:14:0.2421	0.2421	14
TBTO	TBTO:26	bis(tri-n-butyltin)oxide:26:0.3158	0.3158	26
TBT	TBT:5	effects of tri-n-butyltin chloride:5:0.1973	0.1973	5
TBT	TBT:7	template bleeding time:7:0.4438	0.4438	7
TBT	TBT:13	tri-n-butyltin:13:0.0284	0.0284	13
TBT	TBT:296	tributyltin:296:0.6927	0.6927	296
TBT	TBT:15	Tributyltin chloride:15:0.4052	0.4052	15
TBUT	TBUT:13	tear break-up time:13:0.5335	0.5335	13
TBV	TBV:64	total blood volume:64:0.7426	0.7426	64
TBV	TBV:51	trabecular bone volume:51:0.9082	0.9082	51
TBW	TBW:524	Total body water:524:0.9878	0.9878	524
TBW	TBW:53	total body weight:53:0.9438	0.9438	53
TBXA2R	TBXA2R:5	thromboxane A2 receptor:5:0.5290	0.5290	5
TBZ	TBZ:38	tetrabenazine:38:0.2044	0.2044	38
TBZ	TBZ:125|tbz:1	thiabendazole:126:0.6906	0.6906	126
TBil	TBIL:20|TBil:20|T-Bil:11|T-bil:2|t-bil:1|T-BIL:1|TBiL:1	total bilirubin:56:0.8901	0.8901	56
TCAA	TCAA:19	trichloroacetic acid:19:0.7658	0.7658	19
TCAB	TCAB:14	3,3',4,4'-tetrachloroazobenzene:14:0.4333	0.4333	14
TCAI	TCAI:5	tricarboxylic acid cycle intermediates:5:0.4422	0.4422	5
TCAOB	TCAOB:14	3,3',4,4'-tetrachloroazoxybenzene:14:0.5909	0.5909	14
TCAs	TCAs:10	thalamocortical axons:10:0.7103	0.7103	10
TCAs	TCAs:432|TCAS:1	tricyclic antidepressants:433:0.9574	0.9574	433
TCAs	TCAs:10	tricyclic antidepressant drugs:10:0.7103	0.7103	10
TCA	TCA:16	1,1,1-trichloroethane:16:0.0090	0.0090	16
TCA	TCA:10	2,4,6-trichloroanisole:10:0.0054	0.0054	10
TCA	TCA:8	sodium taurocholate:8:0.0648	0.0648	8
TCA	TCA:6	temporal clustering analysis:6:0.5290	0.5290	6
TCa	TCa:10|tCa:3|t-Ca:2|T-Ca:1	total calcium:16:0.5171	0.5171	16
TCA	TCA:8	total circulatory arrest:8:0.5006	0.5006	8
TCA	TCA:25	Total colonic aganglionosis:25:0.8816	0.8816	25
TCA	TCA:35	transluminal coronary angioplasty:35:0.8292	0.8292	35
TCA	TCA:10	triamcinolone acetonide:10:0.7103	0.7103	10
TCA	TCA:321|tca:1	tricarboxylic acid:322:0.3182	0.3182	322
TCA	TCA:19	tricarboxylic acid cycle:19:0.7044	0.7044	19
TCA	TCA:467	trichloroacetic acid:467:0.4746	0.4746	467
TCA	TCA:14	tricyclic:14:0.0078	0.0078	14
TCA	TCA:235	tricyclic antidepressant:147:0.9123|tricyclic antidepressants:88:0.9461	0.9461	235
tCBF	tCBF:3|TCBF:3	Total cerebral blood flow:6:0.3728	0.3728	6
TCBZ	TCBZ:13	triclabendazole:13:0.7500	0.7500	13
TCBS	TCBS:6	citrate bile salts sucrose:6:0.5290	0.5290	6
TCBS	TCBS:8	thiosulfate-citrate-bile salts-sucrose:8:0.2327	0.2327	8
TCBS	TCBS:6	thiosulphate-citrate-bile salts-sucrose:6:0.1010	0.1010	6
TCB	TCB:25|-TCB:1	1,2,4-trichlorobenzene:26:0.0890	0.0890	26
TCB	TCB:59	3,3',4,4'-tetrachlorobiphenyl:59:0.2064	0.2064	59
TCB	TCB:31	3,4,3',4'-tetrachlorobiphenyl:31:0.1068	0.1068	31
TCB	TCB:13	tetrachlorobiphenyl:13:0.0427	0.0427	13
TcB	TcB:18|TCB:1	transcutaneous bilirubin:19:0.7044	0.7044	19
TCC-UUT	TCC-UUT:8	transitional cell carcinoma of the upper urinary tract:8:0.6411	0.6411	8
TCCB	TCCB:1	transitional cell carcinoma of bladder:1:0.8045	0.8045	1
TCCD	TCCD:13	Transcranial color-coded duplex sonography:13:0.7753	0.7753	13
TCCs	TCCs:38	T-cell clones:23:0.3927|T cell clones:15:0.8045	0.8045	38
TCCS	TCCS:22	Transcranial color-coded duplex sonography:22:0.7955	0.7955	22
TCCS	TCCS:20	Transcranial color-coded real-time sonography:20:0.8525	0.8525	20
TCCS	TCCS:22	transcranial color-coded sonography:22:0.8657	0.8657	22
TCCs	TCCs:101	transitional cell carcinomas:101:0.9529	0.9529	101
TCC	TCC:10	bladder cancer:10:0.0829	0.0829	10
TCC	TCC:140|TcC:1|Tcc:1	T cell clones:95:0.9685|T-cell clones:37:0.1861|T cell clone:10:0.7103	0.9685	142
TCC	TCC:18	Tai Chi Chuan:18:0.7539	0.7539	18
TCC	TCC:131	terminal complement complex:111:0.8303|terminal complement complexes:20:0.7173	0.8303	131
TCC	TCC:6	total cell count:6:0.3728	0.3728	6
TCC	TCC:6	total coliform counts:6:0.3728	0.3728	6
TCC	TCC:9	total contact cast:9:0.6794	0.6794	9
TCC	TCC:10	total contact casting:10:0.7103	0.7103	10
TCC	TCC:9	transcervical cell:9:0.3455	0.3455	9
TCC	TCC:30	transitional cell cancer:30:0.9011	0.9011	30
TCC	TCC:959|Tcc:1	transitional cell carcinoma:865:0.9926|transitional cell carcinomas:95:0.9685	0.9926	960
TCC	TCC:23	transitional cell carcinoma of the bladder:23:0.8861	0.8861	23
TCC	TCC:10	transitional cell carcinoma of the urinary bladder:10:0.7103	0.7103	10
TCD50	TCD50:7	control dose 50%:7:0.4438	0.4438	7
TCD50	TCD50:8|TCD-50:1	tumor control dose:9:0.5470	0.5470	9
TcdB	TcdB:7	Clostridium difficile toxin B:7:0.5926	0.5926	7
TCDCA	TCDCA:14	taurochenodeoxycholic acid:14:0.6173	0.6173	14
TCDC	TCDC:34	taurochenodeoxycholate:34:0.6111	0.6111	34
TCDD	TCDD:11	2,3,7,8-[3H]tetrachlorodibenzo-p-dioxin:11:0.0039	0.0039	11
TCDD	TCDD:15	2,3,7,8-tetrachloro-dibenzo-p-dioxin:15:0.0055	0.0055	15
TCDD	TCDD:2205	2,3,7,8-tetrachlorodibenzo-p-dioxin:2180:0.8435|2,3,7,8-tetrachlorodibenzo- p-dioxin:13:0.6701|2,3,7,8 tetrachlorodibenzo-p-dioxin:12:0.1314	0.8435	2205
TCDD	TCDD:13	2,3,7,8-tetrachlorodibenzo-para-dioxin:13:0.0047	0.0047	13
TCDD	TCDD:10	2,3,7,8-tetrachlorodibenzodioxin:10:0.0035	0.0035	10
TCDO	TCDO:17	tetrachlorodecaoxide:17:0.4444	0.4444	17
TCDO	TCDO:5	tetrachlorodecaoxygen anion complex:5:0.2818	0.2818	5
TCD	TCD:76	T cell-depleted:35:0.8292|T-cell-depleted:31:0.0214|T-cell depleted:10:0.5856	0.8292	76
TCD	TCD:59	T-cell depletion:36:0.4560|T cell depletion:23:0.8715	0.8715	59
TCD	TCD:601|TcD:1	transcranial doppler:602:0.9632	0.9632	602
TCD	TCD:239|TcD:1	Transcranial Doppler sonography:240:0.9451	0.9451	240
TCD	TCD:115	transcranial doppler ultrasonography:115:0.9586	0.9586	115
TCD	TCD:101	transcranial Doppler ultrasound:101:0.9108	0.9108	101
TCD	TCD:13	transverse cerebellar diameter:13:0.6701	0.6701	13
TCEC	TCEC:9	Transcatheter electrocoagulation:9:0.6794	0.6794	9
TCEP	TCEP:21	tris(2-carboxyethyl)phosphine:21:0.3448	0.3448	21
TCES	TCES:14	electrical stimulation:14:0.5934	0.5934	14
TCE	TCE:31	1,1,1-Trichloroethane:31:0.0318	0.0318	31
TCE	TCE:9	1,1,2-trichloroethylene:9:0.0085	0.0085	9
TCE	TCE:15	Control Element:15:0.6386	0.6386	15
TCE	TCE:5	metabolites trichloroethanol:5:0.0849	0.0849	5
TCE	TCE:12	tetrachloroethylene:12:0.0117	0.0117	12
TCE	TCE:566|Tce:1	Trichloroethylene:567:0.5985	0.5985	567
TCF-1	TCF-1:5|Tcf-1:1	T cell factor-1:6:0.5290	0.5290	6
TCFs	TCFs:24	ternary complex factors:24:0.8768	0.8768	24
TCF	TCF:29|Tcf:14	T-cell factor:26:0.1129|T cell factor:17:0.3844	0.3844	43
TCF	TCF:9	temperature coefficient of frequency:9:0.6794	0.6794	9
TCF	TCF:17	tissue cage fluid:17:0.8270	0.8270	17
TCF	TCF:8	tissue chamber fluid:8:0.6411	0.6411	8
TCGF	TCGF:133	T cell growth factor:133:0.9641	0.9641	133
T-chol	T-chol:16|T-CHOL:11|TCHOL:8|T-Chol:8|TChol:6|Tchol:4|t-Chol:1|t-chol:1	total cholesterol:55:0.8882	0.8882	55
T-Cho	T-Cho:7|T-CHO:6|TCHO:4|T-cho:3|t-CHO:1|t-Cho:1	total cholesterol:22:0.7955	0.7955	22
TCHQ	TCHQ:24	tetrachlorohydroquinone:24:0.7931	0.7931	24
TCH	TCH:9	Texas Children's Hospital:9:0.3945	0.3945	9
TCh	TCh:16|TCH:14|Tch:8|T-Ch:5|T-ch:2|T-CH:2|t-CH:1	total cholesterol:48:0.8463	0.8463	48
TCID(50)	TCID(50):6	tissue culture infective dose:6:0.5290	0.5290	6
TCID50	TCID50:18	tissue culture infectious doses:18:0.8365	0.8365	18
TCID50	TCID50:39	tissue culture infective doses:20:0.8525|tissue culture infective dose:19:0.8449	0.8525	39
TCII	TCII:46|TC-II:6|TcII:1	transcobalamin II:53:0.8597	0.8597	53
TCIPA	TCIPA:25	platelet aggregation:25:0.8816	0.8816	25
TCI	TCI:11	cerebral ischemia:11:0.7357	0.7357	11
TCI	TCI:99	target-controlled infusion:72:0.6465|target controlled infusion:20:0.8449|Target-Controlled Infusions:7:0.2902	0.8449	99
TCI	TCI:163	Temperament and Character Inventory:163:0.9707	0.9707	163
TCI	TCI:7	Testicular circulatory isolation:7:0.5926	0.5926	7
TCI	TCI:7	transcobalamin I:7:0.3524	0.3524	7
TCI	TCI:17	Transcutaneous immunization:17:0.8270	0.8270	17
TCI	TCI:7	transitory cognitive impairment:7:0.3524	0.3524	7
T-CLL	T-CLL:7|TCLL:1	T-cell chronic lymphocytic leukaemia:8:0.5006	0.5006	8
T-CLL	T-CLL:30	T-cell chronic lymphocytic leukemia:30:0.5478	0.5478	30
TCLP	TCLP:57	Toxicity Characteristic Leaching Procedure:57:0.9477	0.9477	57
TCLs	TCLs:34|TcLs:1|TCLS:1	T cell lines:18:0.7539|T-cell lines:18:0.2956	0.7539	36
TCL	TCL:71	T cell lines:63:0.9253|T cell line:8:0.6411	0.9253	71
TCL	TCL:9	T-cell lymphoma:9:0.3069	0.3069	9
TCL	TCL:7	tachycardia cycle length:7:0.4438	0.4438	7
TCL	TCL:16	transverse carpal ligament:16:0.8165	0.8165	16
TCM-WM	TCM-WM:17	integrated traditional Chinese and Western medicine:17:0.6748	0.6748	17
TCML	TCML:6	thermal cycling and mechanical loading:6:0.5290	0.5290	6
TCMRO	TCMRO:13	muscle receptor organ:13:0.7753	0.7753	13
TCMs	TCMs:22	traditional Chinese medicines:22:0.8657	0.8657	22
Tcm	Tcm:9|TCM:3|tcm:3	tetracenomycin:15:0.0333	0.0333	15
TCM	TCM:16	tissue culture medium:16:0.7261	0.7261	16
TCM	TCM:235	traditional Chinese medicine:223:0.9712|traditional Chinese medicines:12:0.7571	0.9712	235
TCM	TCM:12	trichlormethiazide:12:0.0244	0.0244	12
TCM	TCM:11	Trichloromethane:11:0.0222	0.0222	11
TCNE	TCNE:15	tetracyanoethylene:15:0.6667	0.6667	15
TCNQ	TCNQ:14	7,7,8,8-tetracyanoquinodimethane:14:0.3250	0.3250	14
TCNQ	TCNQ:16	tetracyanoquinodimethane:16:0.3750	0.3750	16
TCNU	TCNU:21	Tauromustine:21:0.6897	0.6897	21
TCN	TCN:14	tetracycline:14:0.1970	0.1970	14
tCO2	tCO2:6|TCO2:5	total carbon dioxide:11:0.5355	0.5355	11
TCOF1	TCOF1:9	Treacher Collins syndrome:9:0.6794	0.6794	9
TCOH	TCOH:12	trichloroethanol:12:0.8462	0.8462	12
TCP-1	TCP-1:10|TCP1:2	t-complex polypeptide 1:12:0.3058	0.3058	12
TCPA	TCPA:9	tetrachlorophthalic anhydride:9:0.6794	0.6794	9
TCPC	TCPC:55	total cavopulmonary connection:55:0.9458	0.9458	55
TCPL	TCPL:9	tricalcium phosphate lysine:9:0.5470	0.5470	9
TCPMe	TCPMe:9	Tris(4-chlorophenyl)methane:9:0.6154	0.6154	9
TC-PTP	TC-PTP:10|TCPTP:7	T-cell protein tyrosine phosphatase:9:0.2285|T cell protein tyrosine phosphatase:8:0.6411	0.6411	17
TCPS	TCPS:64	tissue culture polystyrene:64:0.9534	0.9534	64
TCP	TCP:14	1-[1-(2-thienyl)cyclohexyl]piperidine:14:0.0131	0.0131	14
TCP	TCP:9	2,4,5-trichlorophenol:9:0.0087	0.0087	9
TCP	TCP:29	2,4,6-trichlorophenol:29:0.0305	0.0305	29
TCP	TCP:28	3,5,6-trichloro-2-pyridinol:28:0.0294	0.0294	28
TCP	TCP:35	beta-tricalcium phosphate:35:0.1163	0.1163	35
TCP	TCP:6	inhibitor tranylcypromine:6:0.0502	0.0502	6
TCP	TCP:13	piperidine:13:0.0131	0.0131	13
TCP	TCP:6	tissue culture polystyrene:6:0.5290	0.5290	6
TCP	TCP:10|tcp:2|Tcp:1	toxin co-regulated pilus:13:0.7753	0.7753	13
TCP	TCP:17	toxin-coregulated pili:17:0.6748	0.6748	17
TCP	TCP:58|tcp:3	toxin-coregulated pilus:48:0.4578|toxin coregulated pilus:13:0.7753	0.7753	61
TCP	TCP:8	transcutaneous cardiac pacing:8:0.5006	0.5006	8
TCP	TCP:134	tricalcium phosphate:134:0.5897	0.5897	134
TCP	TCP:9	tricalciumphosphate:9:0.0087	0.0087	9
TCP	TCP:11	tricresylphosphate:11:0.0109	0.0109	11
TCP	TCP:10	tropical calcific pancreatitis:10:0.7103	0.7103	10
TCP	TCP:118|tcp:6	tumor control probability:75:0.5654|Tumour control probability:38:0.2391|tumor control probabilities:11:0.5355	0.5654	124
TCQ	TCQ:11	Questionnaire:11:0.7692	0.7692	11
TCRBCL	TCRBCL:22	T-cell-rich B-cell lymphoma:22:0.5095	0.5095	22
TCRBV	TCRBV:5	receptor beta variable:5:0.1973	0.1973	5
TCRBV	TCRBV:14	variable region:14:0.7909	0.7909	14
TCRB	TCRB:10	2,5,6-Trichloro-1-(beta-D-ribofuranosyl)benzimidazole:10:0.1084	0.1084	10
TCRB	TCRB:10|Tcrb:1	receptor beta chain:11:0.4728	0.4728	11
TCRB	TCRB:14	T cell receptor beta:8:0.6411|T-cell receptor beta:6:0.1470	0.6411	14
TCRE	TCRE:26	transcervical resection of the endometrium:26:0.8605	0.8605	26
TCRT	TCRT:9|Tcrt:4	cortical temperature:13:0.5934	0.5934	13
TCRs	TCRs:115|TcRs:2	T cell receptors:117:0.9744	0.9744	117
TCR	TCR:5	receptor gene:5:0.0736	0.0736	5
Tcr	Tcr:6|TcR:1	resistance to tetracycline:7:0.1367	0.1367	7
TCR	TCR:38|TcR:8|Tcr:1	T-cell antigen receptors:26:0.3698|T cell antigen receptors:21:0.8594	0.8594	47
TCR	TCR:6	T cell antigen receptor complex:6:0.5290	0.5290	6
TCR	TCR:4269|TcR:597|Tcr:48	T cell receptor:2598:0.9445|T-cell receptor:2045:0.3598|T cell receptors:146:0.9467|T-cell receptors:99:0.2660|T-cell-receptor:26:0.0039	0.9467	4914
TCR	TCR:28|TcR:1	T cell receptor for antigen:29:0.8422	0.8422	29
Tcr	Tcr:10	t complex responder:10:0.7103	0.7103	10
Tcr	Tcr:46|TcR:20|TCr:1	tetracycline resistance:54:0.8004|tetracycline-resistance:13:0.0019	0.8004	67
Tcr	Tcr:9|TcR:1	tetracycline-resistant:10:0.0014	0.0014	10
tCr	tCr:21|TCr:17|tCR:1|TCR:1	total creatine:40:0.7419	0.7419	40
TCR	TCR:14	Transcallosal response:7:0.2113|transcallosal responses:7:0.1641	0.2113	14
TCR	TCR:109	Transcription-coupled repair:85:0.6163|transcription coupled repair:24:0.8768	0.8768	109
TCR	TCR:15	transcriptional control region:15:0.5818	0.5818	15
TCSA	TCSA:16	tetrachlorosalicylanilide:16:0.2830	0.2830	16
TCTP	TCTP:34	translationally controlled tumor protein:34:0.8644	0.8644	34
TCT	TCT:24	thyrocalcitonin:24:0.0827	0.0827	24
TCT	TCT:16	tracheal cytotoxin:16:0.8165	0.8165	16
TCT	TCT:28	Transmission computed tomography:28:0.5837	0.5837	28
TCT	TCT:9	transmission CT:9:0.3945	0.3945	9
TCT	TCT:6	tube coagulase test:6:0.5290	0.5290	6
TCU	TCU:5	transitional care unit:5:0.4422	0.4422	5
TCV-116	TCV-116:20|TCV116:1	candesartan cilexetil:21:0.8594	0.8594	21
TCV-116	TCV-116:4|TCV116:1	receptor antagonist:5:0.2243	0.2243	5
TCV	TCV:10	T cell vaccination:10:0.7103	0.7103	10
TCV	TCV:10	tall cell variant:10:0.7103	0.7103	10
TCV	TCV:24	turkey coronavirus:24:0.5848	0.5848	24
TCV	TCV:63	turnip crinkle virus:63:0.9526	0.9526	63
TCS	TCS:10	3,3',4',5-tetrachlorosalicylanilide:10:0.0166	0.0166	10
Tcs	Tcs:5|TCS:2	contrasuppressor T cells:7:0.1641	0.1641	7
TCS	TCS:8	magnetic transcranial stimulation:8:0.2327	0.2327	8
TCS	TCS:26	tethered cord syndrome:26:0.7760	0.7760	26
TCs	TCs:27	Tetracyclines:27:0.0480	0.0480	27
TCs	TCs:11	tetracycline antibiotics:11:0.7357	0.7357	11
TCS	TCS:6	transcranial magnetic stimulation:6:0.3728	0.3728	6
TCS	TCS:17	transcranial sonography:17:0.6577	0.6577	17
TCS	TCS:30	Treacher Collins syndrome:30:0.9011	0.9011	30
TCS	TCS:71	Trichosanthin:71:0.1292	0.1292	71
TCs	TCs:12	tuning curves:12:0.7571	0.7571	12
tcu-PA	tcu-PA:7	active two-chain u-PA:7:0.2987	0.2987	7
tcu-PA	tcu-PA:4|tcuPA:2|Tc-uPA:2|tc-u-PA:1	two-chain urokinase:9:0.2757	0.2757	9
tcu-PA	tcu-PA:8	two-chain urokinase-type plasminogen activator:8:0.3463	0.3463	8
Tc	Tc:13|tc:1|TC:1	cell cycle:15:0.4312	0.4312	15
Tc	Tc:40|TC:7|tc:3	cell cycle time:44:0.7839|cell cycle times:6:0.5290	0.7839	50
TC	TC:9	cellobiose:9:0.0015	0.0015	9
TC	TC:6|Tc:2|tc:1	clearance:9:0.0015	0.0015	9
Tc	Tc:18|TC:3|T-c:1	Colonic:22:0.0041	0.0041	22
Tc	Tc:55	colonic temperature:55:0.1273	0.1273	55
TC	TC:17|Tc:2|tc:2|T-C:1	complex:22:0.0041	0.0041	22
TC	TC:10	concentration:10:0.0019	0.0019	10
TC	TC:23|Tc:1	control:24:0.0046	0.0046	24
Tc	Tc:107|TC:3|tc:1	core temperature:111:0.2976	0.2976	111
Tc	Tc:51|TC:5	cytotoxic T:56:0.8067	0.8067	56
Tc	Tc:64|TC:4|tc:1	cytotoxic T cells:48:0.9027|cytotoxic T cell:11:0.4232|cytotoxic T-cell:10:0.4363	0.9027	69
Tc	Tc:10	cytotoxic T lymphocytes:10:0.5000	0.5000	10
TC	TC:6	human teratocarcinoma:6:0.1148	0.1148	6
Tc	Tc:40|TC:1	phase transition temperature:41:0.3938	0.3938	41
TC	TC:39|Tc:1	sodium taurocholate:40:0.1412	0.1412	40
Tc	Tc:13	T cytotoxic:13:0.3331	0.3331	13
TC	TC:66|Tc:1	target cells:46:0.1983|target cell:21:0.2614	0.2614	67
TC	TC:18	taurocholic acid:18:0.4672	0.4672	18
Tc	Tc:5	taxuyunnanine C:5:0.0902	0.0902	5
Tc	Tc:22|tc:1|TC:1	technetium:24:0.0045	0.0045	24
TC	TC:22	temporal cortex:22:0.8657	0.8657	22
TC	TC:42	terminal cisternae:42:0.9291	0.9291	42
TC	TC:35	Testicular cancer:35:0.4956	0.4956	35
TC	TC:10	testosterone cypionate:10:0.7103	0.7103	10
TC	TC:155|Tc:87|tc:10	tetracycline:252:0.0486	0.0486	252
TC	TC:95|T-C:6	thalamocortical:101:0.0194	0.0194	101
TC	TC:72	therapeutic community:72:0.9585	0.9585	72
TC	TC:8	thoracic circumference:8:0.2987	0.2987	8
TC	TC:16	thyroid cancer:16:0.1650	0.1650	16
TC	TC:12	thyroid carcinoma:12:0.1991	0.1991	12
TC	TC:14|Tc:9|tc:7	time constant:30:0.9011	0.9011	30
TC	TC:9|Tc:1	Tinospora cordifolia:10:0.7103	0.7103	10
TC	TC:31	tissue culture:31:0.7091	0.7091	31
TC	TC:41|T-C:1	total:42:0.0079	0.0079	42
TC	TC:17	total carbon:17:0.7407	0.7407	17
TC	TC:19	total carnitine:19:0.8449	0.8449	19
TC	TC:1705|T-C:20|Tc:11|tC:1|T-c:1	total cholesterol:1728:0.9045|total-cholesterol:10:0.0017	0.9045	1738
TC	TC:33|Tc:1	total coliforms:23:0.8038|Total coliform:11:0.7357	0.8038	34
TC	TC:10	transcarboxylase:10:0.0017	0.0017	10
TC	TC:15	transcervical:15:0.0027	0.0027	15
TC	TC:40	transcobalamin:40:0.0074	0.0074	40
tc	tc:16|TC:7|Tc:4	transcutaneous:27:0.0050	0.0050	27
Tc	Tc:11	transition temperatures:11:0.1683	0.1683	11
TC	TC:11	trauma center:11:0.4728	0.4728	11
TC	TC:6|Tc:3	tubocurarine:9:0.0015	0.0015	9
TC	TC:14	Tumoral calcinosis:14:0.7909	0.7909	14
TC	TC:27	typical carcinoid:19:0.8449|typical carcinoids:8:0.5006	0.8449	27
TD50	TD50:9	carcinogenic potency:9:0.3945	0.3945	9
TD50	TD50:10	median toxic dose:10:0.3867	0.3867	10
TDA	TDA:14	analysis:14:0.0942	0.0942	14
TDA	TDA:11	toluene diamine:11:0.3495	0.3495	11
TDB	TDB:17	tripotassium dicitrato bismuthate:17:0.7407	0.7407	17
TDCA	TDCA:12	taurodeoxycholic acid:12:0.3058	0.3058	12
TDCJ	TDCJ:11	Texas Department of Criminal Justice:11:0.7357	0.7357	11
TDCO	TDCO:13|TdCO:1|TD-CO:1|TDco:1	thermodilution cardiac output:16:0.8165	0.8165	16
TDCRP	TDCRP:10	Treatment of Depression Collaborative Research Program:10:0.7103	0.7103	10
tDCS	tDCS:26|TDCS:2	Transcranial direct current stimulation:28:0.8941	0.8941	28
TDC	TDC:40	taurodeoxycholate:40:0.1931	0.1931	40
TDC	TDC:10	taurodeoxycholic acid:10:0.5856	0.5856	10
TDC	TDC:9	titanocene dichloride:9:0.6794	0.6794	9
TDC	TDC:17|Tdc:5|tdc:1	tryptophan decarboxylase:23:0.5025	0.5025	23
TDD	TDD:6	thiamine deficient diet:6:0.3728	0.3728	6
TDD	TDD:12	Thoracic duct drainage:12:0.7571	0.7571	12
TDDFT	TDDFT:23|TD-DFT:15	time-dependent density functional theory:38:0.7306	0.7306	38
TDDS	TDDS:6	transdermal drug delivery systems:6:0.3728	0.3728	6
TDEE	TDEE:50	total daily energy expenditure:50:0.9404	0.9404	50
TDE	TDE:28	Tissue Doppler echocardiography:28:0.6554	0.6554	28
TDFs	TDFs:13	transcript-derived fragments:13:0.5934	0.5934	13
TDF	TDF:11	tenofovir:11:0.0397	0.0397	11
TDF	TDF:10	tenofovir disoproxil fumarate:10:0.5000	0.5000	10
TDF	TDF:17	testis-determining factor:17:0.1585	0.1585	17
TDF	TDF:1	time dose and fractionation:1:0.7103	0.7103	1
TDF	TDF:55	total dietary fiber:55:0.8882	0.8882	55
TDF	TDF:9	total dietary fibre:9:0.6794	0.6794	9
TDF	TDF:10	transdermal fentanyl:10:0.7103	0.7103	10
TDGS	TDGS:10	two-dimensional gene scanning:10:0.5000	0.5000	10
TDG	TDG:28|Tdg:1	thymine DNA glycosylase:17:0.8270|thymine-DNA glycosylase:12:0.1830	0.8270	29
TDHL	TDHL:10	transdihydrolisuride:10:0.6923	0.6923	10
TDH	TDH:18	Texas Department of Health:18:0.6903	0.6903	18
TDH	TDH:58|tdh:11	thermostable direct hemolysin:69:0.9561	0.9561	69
tdh	tdh:8	thermostable direct hemolysin gene:8:0.6411	0.6411	8
TDH	TDH:4|tdh:2|Tdh:1	threonine dehydrogenase:7:0.2452	0.2452	7
TDI	TDI:15	Thought Disorder Index:15:0.8045	0.8045	15
TDI	TDI:131|TDi:1	tissue Doppler imaging:132:0.9773	0.9773	132
TDI	TDI:68	Tolerable Daily Intake:68:0.9561	0.9561	68
TDI	TDI:14	toluene di-isocyanate:14:0.6173	0.6173	14
TDI	TDI:310	toluene diisocyanate:310:0.8820	0.8820	310
TDI	TDI:8	total dose infusion:8:0.6411	0.6411	8
TDI	TDI:9	transition dyspnea index:9:0.3945	0.3945	9
TDLN	TDLN:28	tumor-draining lymph node:17:0.6748|tumor-draining lymph nodes:11:0.4232	0.6748	28
TDLU	TDLU:6	terminal duct lobular unit:6:0.5290	0.5290	6
TDLUs	TDLUs:6	terminal duct lobular units:6:0.5290	0.5290	6
TDLUs	TDLUs:7	terminal ductal lobular units:7:0.5926	0.5926	7
TDL	TDL:18	thoracic duct lymph:18:0.8365	0.8365	18
TDL	TDL:96	thoracic duct lymphocytes:96:0.9505	0.9505	96
TDMAC	TDMAC:14	tridodecylmethylammonium chloride:14:0.6911	0.6911	14
TDM	TDM:310	Therapeutic drug monitoring:310:0.9793	0.9793	310
TDM	TDM:9	tomodensitometry:9:0.0161	0.0161	9
TDM	TDM:31	trehalose 6,6'-dimycolate:19:0.8449|trehalose-6,6'-dimycolate:12:0.0221	0.8449	31
TDM	TDM:56	trehalose dimycolate:56:0.8667	0.8667	56
TDN	TDN:11	total digestible nutrients:11:0.7357	0.7357	11
TDO	TDO:9	toluene dioxygenase:9:0.3945	0.3945	9
TDO	TDO:8	Tricho-dento-osseous syndrome:8:0.5006	0.5006	8
TDO	TDO:25|TdO:6	tryptophan 2,3-dioxygenase:31:0.9043	0.9043	31
TDPCR	TDPCR:7|TD-PCR:2	terminal transferase-dependent PCR:9:0.6794	0.6794	9
TDP	TDP:13|tdp:1	degradation products:14:0.4709	0.4709	14
TDP	TDP:10	tetradecapeptide:10:0.0227	0.0227	10
TDP	TDP:22	thiamin diphosphate:22:0.2619	0.2619	22
TDP	TDP:26	thiamine diphosphate:26:0.3161	0.3161	26
TDP	TDP:12	time-dependent potentiation:12:0.7753	0.7753	12
TdP	TdP:166|TDP:16|Tdp:9|tdp:2	Torsade de pointes:105:0.4671|torsades de pointes:88:0.3791	0.4671	193
TDZ	TDZ:10	thidiazuron:10:0.3750	0.3750	10
TDS	TDS:10	testicular dysgenesis syndrome:10:0.7103	0.7103	10
TDS	TDS:13	time-dependent sensitization:13:0.6701	0.6701	13
TDS	TDS:21	total defect score:21:0.8594	0.8594	21
TDS	TDS:12	Total Diet Study:12:0.7571	0.7571	12
TDS	TDS:28	total dissolved solids:28:0.8941	0.8941	28
TDS	TDS:17	transdermal delivery system:17:0.5760	0.5760	17
TDS	TDS:8	Trichuris dysentery syndrome:8:0.5006	0.5006	8
Td	Td:14	denaturation temperature:14:0.2238	0.2238	14
TD	TD:20	diameter:20:0.0083	0.0083	20
TD	TD:14	domain:14:0.0057	0.0057	14
Td	Td:27|TD:13|td:6	doubling time:46:0.5569	0.5569	46
TD	TD:34|Td:1	T cell-dependent:26:0.7760|T-cell-dependent:9:0.0035	0.7760	35
TD	TD:27	T-dependent:27:0.0114	0.0114	27
TD	TD:39	Tangier disease:39:0.4101	0.4101	39
TD	TD:561	tardive dyskinesia:561:0.9858	0.9858	561
TD	TD:8	temporal difference:8:0.2327	0.2327	8
Td	Td:8	tetanus and diphtheria toxoids:8:0.6411	0.6411	8
Td	Td:9|TD:1|td:1	tetanus-diphtheria:11:0.0044	0.0044	11
Td	Td:5	tetanus-diphtheria toxoid:5:0.0612	0.0612	5
TD	TD:36	thanatophoric dysplasia:36:0.8336	0.8336	36
TD	TD:72|Td:1	thermodilution:73:0.0315	0.0315	73
TD	TD:29	thiamine deficiency:29:0.6157	0.6157	29
TD	TD:5	thiamine deficient:5:0.1132	0.1132	5
TD	TD:22	thoracic duct:22:0.7400	0.7400	22
td	td:11	thymidylate synthase:11:0.7357	0.7357	11
td	td:10	thymidylate synthase gene:10:0.7103	0.7103	10
TD	TD:89|T-D:1|Td:1	thymus-dependent:78:0.0337|thymus dependent:13:0.2660	0.2660	91
TD	TD:97	tibial dyschondroplasia:97:0.9510	0.9510	97
TD	TD:12|Td:1|td:1	time delay:14:0.2326	0.2326	14
TD	TD:26	tissue Doppler:26:0.7760	0.7760	26
TD	TD:14	total deviation:14:0.6911	0.6911	14
TD	TD:8	total dose:8:0.0672	0.0672	8
TD	TD:24	Tourette's disorder:24:0.3721	0.3721	24
TD	TD:7|td:2	transdermal:9:0.0035	0.0035	9
td	td:18	transformation-defective:18:0.0074	0.0074	18
TD	TD:11	traveler's diarrhea:11:0.2764	0.2764	11
Td	Td:8	Treponema denticola:8:0.4102	0.4102	8
TD	TD:9	triple dose:9:0.0898	0.0898	9
TD	TD:24|tD:3	True digestibility:27:0.4305	0.4305	27
TD	TD:11	true protein digestibility:11:0.5355	0.5355	11
TD	TD:13	tryptophan depletion:13:0.7753	0.7753	13
TD	TD:5	typical development:5:0.0902	0.0902	5
TD	TD:26	typically developing:26:0.8861	0.8861	26
Td	Td:13|TD:1	vaccine:14:0.0057	0.0057	14
TEA+	TEA+:69	tetraethylammonium:69:0.6296	0.6296	69
TEA+	TEA+:28	tetraethylammonium ions:14:0.7909|tetraethylammonium ion:14:0.7909	0.7909	28
TEAA	TEAA:9	triethylammonium acetate:9:0.3455	0.3455	9
TEAC	TEAC:64	Trolox equivalent antioxidant capacity:64:0.9047	0.9047	64
TEAM	TEAM:7	transfemoral endovascular aneurysm management:7:0.4438	0.4438	7
TEAM	TEAM:8	Trauma Evaluation and Management:8:0.6411	0.6411	8
TEAP	TEAP:8	transesophageal atrial pacing:8:0.5006	0.5006	8
TEA	TEA:10	[14C]tetraethylammonium:10:0.0047	0.0047	10
TEA	TEA:7	carotid thromboendarterectomy:7:0.1470	0.1470	7
TEA	TEA:10	endarterectomy:10:0.0047	0.0047	10
TeA	TeA:5|TEA:1	tenuazonic acid:6:0.1148	0.1148	6
TEA	TEA:34	tetraethyl ammonium:19:0.5732|tetraethyl-ammonium:15:0.0073	0.5732	34
TEA	TEA:1085	tetraethylammonium:1085:0.5696	0.5696	1085
TEA	TEA:14	tetraethylammonium bromide:14:0.5111	0.5111	14
TEA	TEA:137	Tetraethylammonium chloride:137:0.8897	0.8897	137
TEA	TEA:46	Tetraethylammonium ion:30:0.8472|tetraethylammonium ions:16:0.5171	0.8472	46
TEA	TEA:16	thoracic epidural anaesthesia:16:0.8165	0.8165	16
TEA	TEA:48	thoracic epidural analgesia:48:0.8221	0.8221	48
TEA	TEA:59	thoracic epidural anesthesia:59:0.9494	0.9494	59
TEA	TEA:8	Total elbow arthroplasty:8:0.6411	0.6411	8
TEA	TEA:5	tranexamic acid:5:0.0517	0.0517	5
TEA	TEA:33|tea:1	triethanolamine:34:0.0173	0.0173	34
TEA	TEA:79	triethylamine:79:0.0409	0.0409	79
TEBs	TEBs:39|TEBS:1	terminal end buds:40:0.9256	0.9256	40
TEB	TEB:12	terminal end bud:12:0.7571	0.7571	12
TEB	TEB:28	thoracic electrical bioimpedance:28:0.6057	0.6057	28
TEB	TEB:11	transient electric birefringence:11:0.7357	0.7357	11
TECK	TECK:11	Thymus-expressed chemokine:11:0.4232	0.4232	11
TECs	TECs:59	epithelial cells:59:0.7824	0.7824	59
TED	TED:23	thromboembolic disease:23:0.2861	0.2861	23
TED	TED:30	Thyroid Eye Disease:30:0.8978	0.8978	30
TEER	TEER:140	transepithelial electrical resistance:140:0.6921	0.6921	140
TEE	TEE:226	total energy expenditure:226:0.8499	0.8499	226
TEE	TEE:25	transesophageal echocardiogram:25:0.7249	0.7249	25
TEE	TEE:60	transesophageal echocardiographic:60:0.8359	0.8359	60
TEE	TEE:1267	transesophageal echocardiography:1267:0.8802	0.8802	1267
TEE	TEE:13	transesophageal echography:13:0.5934	0.5934	13
TEF-1	TEF-1:18	transcription enhancer factor-1:18:0.2956	0.2956	18
TEF-1	TEF-1:19	transcriptional enhancer factor-1:19:0.3221	0.3221	19
TEFRA	TEFRA:9	Tax Equity and Fiscal Responsibility Act:9:0.5470	0.5470	9
TEFRA	TEFRA:9	Tax Equity and Fiscal Responsibility Act of 1982:9:0.6794	0.6794	9
TEFs	TEFs:40|TEfs:1	Toxic equivalency factors:41:0.7311	0.7311	41
TEF	TEF:23	thermic effect of feeding:23:0.8715	0.8715	23
TEF	TEF:58	thermic effect of food:58:0.8710	0.8710	58
TEF	TEF:26	toxic equivalency factor:26:0.8861	0.8861	26
TEF	TEF:7	tracheoesophageal fistulas:7:0.3524	0.3524	7
TEGDMA	TEGDMA:46|TEG-DMA:1	triethylene glycol dimethacrylate:47:0.7960	0.7960	47
TEGDMA	TEGDMA:23	triethyleneglycol dimethacrylate:23:0.1789	0.1789	23
TEGDMA	TEGDMA:9	triethyleneglycoldimethacrylate:9:0.0741	0.0741	9
TEG	TEG:5	tetraethylene glycol:5:0.0902	0.0902	5
TEG	TEG:10	thrombelastogram:10:0.0335	0.0335	10
TEG	TEG:28	thrombelastograph:28:0.1004	0.1004	28
TEG	TEG:63	thrombelastography:63:0.2305	0.2305	63
TEG	TEG:15	thromboelastogram:15:0.0520	0.0520	15
TEG	TEG:18	thromboelastograph:18:0.0632	0.0632	18
TEG	TEG:65	thromboelastography:65:0.2379	0.2379	65
TEG	TEG:5	Triethylene glycol:5:0.0902	0.0902	5
TEI	TEI:10	total energy intake:10:0.7103	0.7103	10
TEL	TEL:9	lysozyme:9:0.0571	0.0571	9
TEL	TEL:8|Tel:2	telencephalon:10:0.0643	0.0643	10
TEL	TEL:13	tetraethyl lead:13:0.3809	0.3809	13
TEMPO	TEMPO:16|Tempo:4|TEM-PO:1	2,2,6,6-Tetramethylpiperidine-1-oxyl:21:0.1709	0.1709	21
TEMPO	TEMPO:7|Tempo:1	2,2,6,6-tetramethylpiperidine-N-oxyl:8:0.0684	0.0684	8
TEMP	TEMP:8|temp:3|Temp:3	temperature:14:0.3333	0.3333	14
TEM	TEM:1	Technical Error Measurement:1:0.5290	0.5290	1
TEM	TEM:25	thermic effect of a meal:25:0.8186	0.8186	25
TEM	TEM:85	Transanal endoscopic microsurgery:85:0.9436	0.9436	85
TEM	TEM:45|tem:1	transendothelial migration:46:0.8401	0.8401	46
TEM	TEM:281	transmission electron microscope:281:0.9772	0.9772	281
TEM	TEM:103	Transmission electron microscopic:103:0.9538	0.9538	103
TEM	TEM:2154	transmission electron microscopy:2154:0.9829	0.9829	2154
TEM	TEM:25	transverse electromagnetic:25:0.7249	0.7249	25
TEM	TEM:66|tem:1	triethylenemelamine:67:0.0196	0.0196	67
TENS	TENS:436	transcutaneous electrical nerve stimulation:436:0.9754	0.9754	436
TEN	TEN:36	total enteral nutrition:36:0.7433	0.7433	36
TEN	TEN:240	toxic epidermal necrolysis:240:0.9672	0.9672	240
TEOAE	TEOAE:97	transient evoked otoacoustic emissions:49:0.3888|Transient evoked otoacoustic emission:48:0.5897	0.5897	97
TEOAE	TEOAE:17	Transiently evoked otoacoustic emission:17:0.1346	0.1346	17
TEOAEs	TEOAEs:89	transient evoked otoacoustic emissions:89:0.5846	0.5846	89
TEOAEs	TEOAEs:43	transiently evoked otoacoustic emissions:43:0.2371	0.2371	43
TEOM	TEOM:23	Tapered Element Oscillating MicroBalance:23:0.8715	0.8715	23
TEP1	TEP1:11|TEP-1:1	telomerase-associated protein:12:0.6460	0.6460	12
TEPC	TEPC:37	tissue-equivalent proportional counter:24:0.4622|tissue equivalent proportional counter:13:0.7753	0.7753	37
TEPD	TEPD:11	potential difference:11:0.7357	0.7357	11
TEP	TEP:11	endoscopic totally extraperitoneal inguinal hernioplasty:11:0.6182	0.6182	11
TEP	TEP:8	evoked potentials:8:0.5006	0.5006	8
TEP	TEP:8	extraperitoneal approach:8:0.5006	0.5006	8
TEP	TEP:6	hernia repair:6:0.1148	0.1148	6
TEP	TEP:17	total extraperitoneal:17:0.1525	0.1525	17
TEP	TEP:43	totally extraperitoneal:43:0.5817	0.5817	43
TEP	TEP:40	tracheoesophageal puncture:40:0.7472	0.7472	40
TEP	TEP:51	transepithelial potential:51:0.6779	0.6779	51
TEQs	TEQs:90|TEqs:4	equivalents:94:0.8532	0.8532	94
TERalb	TERalb:17|TER-alb:1	transcapillary escape rate of albumin:18:0.8365	0.8365	18
TESE	TESE:137|tese:1	testicular sperm extraction:138:0.8818	0.8818	138
TESS	TESS:11	Toxic Exposure Surveillance System:11:0.7357	0.7357	11
TES	TES:90	electrical stimulation:90:0.8274	0.8274	90
Tes	Tes:31	esophageal:31:0.0427	0.0427	31
Tes	Tes:95	Esophageal temperature:95:0.7982	0.7982	95
TES	TES:11|Tes:10	testosterone:21:0.0285	0.0285	21
TEs	TEs:12	thromboembolic events:12:0.5050	0.5050	12
TES	TES:7	total error score:7:0.5926	0.5926	7
TEs	TEs:114|tes:7	transposable elements:121:0.7980	0.7980	121
TES	TES:17	transthoracic endoscopic sympathectomy:17:0.5760	0.5760	17
TES	TES:6	treadmill exercise score:6:0.5290	0.5290	6
TETA	TETA:17	triethylenetetramine:17:0.2424	0.2424	17
TETS	TETS:11	transcutaneous energy transmission system:11:0.7357	0.7357	11
TEV	TEV:29	tobacco etch potyvirus:29:0.8978	0.8978	29
TEV	TEV:86|Tev:1	tobacco etch virus:87:0.9653	0.9653	87
TEW	TEW:24	triple energy window:15:0.8045|triple-energy window:9:0.1409	0.8045	24
TEWL	TEWL:399	transepidermal water loss:399:0.9132	0.9132	399
TE	TE:6|Te:2|te:1	duration of expiration:9:0.0866	0.0866	9
TE	TE:248	echo time:216:0.5023|echo times:32:0.5841	0.5841	248
TE	TE:26	efficiency:26:0.0118	0.0118	26
TE	TE:31|Te:1	extract:32:0.0146	0.0146	32
Te	Te:20|TE:1	tellurium:21:0.0094	0.0094	21
Te	Te:10|TE:5	temperature:15:0.0066	0.0066	15
Te	Te:36|TE:18	testosterone:54:0.0249	0.0249	54
TE	TE:71	testosterone enanthate:71:0.7881	0.7881	71
TE	TE:23|Te:2	thioesterase:25:0.0113	0.0113	25
TE	TE:18	thromboembolic:18:0.0080	0.0080	18
TE	TE:13	thromboembolic events:13:0.7753	0.7753	13
TE	TE:56	Thromboembolism:56:0.0259	0.0259	56
TE	TE:38|T-E:1	thymic epithelial:39:0.5794	0.5794	39
TE	TE:8	thymic epithelium:8:0.2987	0.2987	8
TE	TE:15	tick-borne encephalitis:15:0.0631	0.0631	15
TE	TE:5	time to echo:5:0.1010	0.1010	5
TE	TE:15	Tissue engineering:15:0.7096	0.7096	15
TE	TE:23	tissue-equivalent:13:0.0056|tissue equivalent:10:0.5000	0.5000	23
TE	TE:5	tonic extension:5:0.1132	0.1132	5
TE	TE:5	Total energy:5:0.0736	0.0736	5
TE	TE:10	toxic encephalopathy:10:0.5856	0.5856	10
TE	TE:28	toxoplasma encephalitis:28:0.1618	0.1618	28
TE	TE:62	toxoplasmic encephalitis:62:0.4551	0.4551	62
TE	TE:14	trabeculectomy:14:0.0061	0.0061	14
TE	TE:23	trace elements:13:0.2660|Trace element:10:0.0713	0.2660	23
TE	TE:11	Tracheal epithelial:11:0.0795	0.0795	11
TE	TE:59|T-E:2|t-e:1	tracheoesophageal:62:0.0287	0.0287	62
TE	TE:5	transesophageal echocardiography:5:0.1132	0.1132	5
TE	TE:34	Transposable element:26:0.3586|transposable elements:8:0.0953	0.3586	34
TE	TE:18	tropoelastin:18:0.0080	0.0080	18
TF-1	TF-1:17|TF1:1	cell line:18:0.8365	0.8365	18
TF-1	TF-1:7|TF1:3	theaflavin:10:0.0783	0.0783	10
TF1	TF1:14	thermophilic bacterium PS3:14:0.8165	0.8165	14
TF1	TF1:18	transcription factor 1:18:0.8365	0.8365	18
TF-3	TF-3:7|TF3:4	theaflavin-3,3'-digallate:11:0.4545	0.4545	11
TF5	TF5:37|TF-5:4	thymosin fraction 5:41:0.9274	0.9274	41
TFAA	TFAA:15	trifluoroacetic acid:15:0.6386	0.6386	15
TFA	TFA:6	time-frequency analysis:6:0.0807	0.0807	6
TFA	TFA:4|TFa:3	tissue factor activity:7:0.4438	0.4438	7
TFA	TFA:29|tFA:1|t-FA:1	trans fatty acids:31:0.5162	0.5162	31
TFA	TFA:12	trifluoroacetate:12:0.0236	0.0236	12
TFA	TFA:226	trifluoroacetic acid:226:0.8231	0.8231	226
TFA	TFA:17|Tfa:1	trifluoroacetyl:18:0.0365	0.0365	18
TfBP	TfBP:7	transferrin binding protein:7:0.5926	0.5926	7
TFBSs	TFBSs:16	transcription factor binding sites:16:0.8165	0.8165	16
TFBS	TFBS:10	transcription factor binding sites:10:0.7103	0.7103	10
TFCC	TFCC:98	triangular fibrocartilage complex:98:0.9692	0.9692	98
TFC	TFC:27	thyroid follicular cells:27:0.8903	0.8903	27
TFC	TFC:10	TIMI frame count:10:0.5664	0.5664	10
TFC	TFC:31	triangular fibrocartilage:31:0.9043	0.9043	31
TFEC	TFEC:18	S-(1,1,2,2-tetrafluoroethyl)-L-cysteine:18:0.4857	0.4857	18
TFEQ	TFEQ:42	three-factor eating questionnaire:28:0.4950|Three Factor Eating Questionnaire:14:0.7909	0.7909	42
TFE	TFE:106	2,2,2-Trifluoroethanol:106:0.2658	0.2658	106
TFE	TFE:20	Tetrafluoroethylene:20:0.0481	0.0481	20
TFE	TFE:203	trifluoroethanol:203:0.5114	0.5114	203
TFE	TFE:9	water/trifluoroethanol:9:0.0203	0.0203	9
TFF	TFF:34	trefoil factor family:34:0.9126	0.9126	34
TFF1	TFF1:9|TFF-1:1	trefoil factor 1:10:0.5856	0.5856	10
TFF1	TFF1:8	Trefoil factor family 1:8:0.6411	0.6411	8
TFF3	TFF3:10	trefoil factor 3:10:0.7103	0.7103	10
TFFs	TFFs:10	Trefoil factors:10:0.7103	0.7103	10
TFIIA	TFIIA:25	transcription factor IIA:25:0.8186	0.8186	25
TFIIB	TFIIB:55	transcription factor IIB:55:0.8862	0.8862	55
TFIID	TFIID:43	Transcription factor IID:43:0.8300	0.8300	43
TFIIE	TFIIE:9	transcription factor IIE:9:0.5470	0.5470	9
TFIIF	TFIIF:26	Transcription factor IIF:26:0.8861	0.8861	26
TFIIH	TFIIH:37	transcription factor IIH:37:0.8716	0.8716	37
TFIIIA	TFIIIA:112	transcription factor IIIA:112:0.9079	0.9079	112
TFIIIB	TFIIIB:14	transcription factor IIIB:14:0.5335	0.5335	14
TFIIIC	TFIIIC:24	transcription factor IIIC:24:0.8768	0.8768	24
TFI	TFI:7	treatment-free interval:7:0.3524	0.3524	7
TFI	TFI:15	tubal factor infertility:15:0.8045	0.8045	15
TFLX	TFLX:33	tosufloxacin:33:0.8000	0.8000	33
TFL	TFL:103	tail flick latency:51:0.9416|tail-flick latency:34:0.2788|tail-flick latencies:11:0.3213|tail flick latencies:7:0.5926	0.9416	103
TFL	TFL:15	tensor fascia lata:15:0.8045	0.8045	15
TFL	TFL:9	tensor fasciae latae:9:0.6794	0.6794	9
TFMKs	TFMKs:9	trifluoromethyl ketones:9:0.6794	0.6794	9
TFMPP	TFMPP:21	1-(3-trifluoromethylphenyl)piperazine:21:0.1190	0.1190	21
TFMPP	TFMPP:14	1-(m-trifluoromethylphenyl)piperazine:14:0.0774	0.0774	14
TFMPP	TFMPP:19	m-trifluoromethylphenylpiperazine:19:0.1071	0.1071	19
TFMPP	TFMPP:20	trifluoromethylphenylpiperazine:20:0.1012	0.1012	20
TFNA	TFNA:10	aspiration:10:0.8182	0.8182	10
TFOs	TFOs:53	triplex-forming oligonucleotides:53:0.4249	0.4249	53
TFPI	TFPI:591	tissue factor pathway inhibitor:591:0.9816	0.9816	591
TFPI-2	TFPI-2:37	tissue factor pathway inhibitor-2:37:0.8377	0.8377	37
TFP	TFP:11	mitochondrial trifunctional protein:11:0.3829	0.3829	11
TFP	TFP:405|tfp:1|Tfp:1	trifluoperazine:407:0.7689	0.7689	407
Tfp	Tfp:13|TFP:4|tfp:2	type IV pili:19:0.8449	0.8449	19
TFRs	TFRs:9|TFRS:1	total fertility rates:10:0.7103	0.7103	10
TfRs	TfRs:17|TFRs:1	transferrin receptors:18:0.6903	0.6903	18
TFR	TFR:168	total fertility rate:156:0.9593|Total fertility rates:12:0.7571	0.9593	168
TFR	TFR:4|TfR:2|Tf-R:1|TFr:1|TF-R:1|Tfr:1	transferrin:10:0.0115	0.0115	10
TfR	TfR:434|TFR:50|Tf-R:18|Tfr:6|tfR:5|TF-R:3|TFr:1|TF-r:1|tfr:1	transferrin receptor:460:0.9376|transferrin receptors:59:0.8731	0.9376	519
TFS	TFS:13	testicular feminization syndrome:13:0.7753	0.7753	13
TFs	TFs:99	transcription factors:99:0.8516	0.8516	99
TFS	TFS:7|TfS:2	transferrin saturation:9:0.6794	0.6794	9
TFTs	TFTs:9	thyroid function tests:9:0.6794	0.6794	9
TFTs	TFTs:10	transistors:10:0.3913	0.3913	10
TFT	TFT:7	thin film transistor:7:0.5926	0.5926	7
TFT	TFT:13	Thought Field Therapy:13:0.7753	0.7753	13
TFT	TFT:5	thyroid function test:5:0.4422	0.4422	5
TFT	TFT:57	trifluorothymidine:57:0.3944	0.3944	57
TFX	TFX:22	thymus extract:22:0.6934	0.6934	22
TFX	TFX:11	Thymus Factor X:11:0.4728	0.4728	11
TFD	TFD:11	transcription factor decoy:11:0.7357	0.7357	11
TFd	TFd:17	transfer factor:17:0.8270	0.8270	17
TFO	TFO:53	triplex-forming oligonucleotide:41:0.5450|triplex-forming oligonucleotides:12:0.3058	0.5450	53
TF	TF:20|Tf:2	99mTc-tetrofosmin:22:0.0058	0.0058	22
TF	TF:21|T-f:1|Tf:1	frequency:23:0.0061	0.0061	23
TF	TF:7	inhibition of the nociceptive tail-flick:7:0.0886	0.0886	7
TF	TF:70	tail flick:70:0.9326	0.9326	70
TF	TF:6	tail-flick reflex:6:0.2243	0.2243	6
Tf	Tf:10|TF:1	temperature:11:0.0028	0.0028	11
TF	TF:68	tetralogy of Fallot:68:0.9561	0.9561	68
TF	TF:12|Tf:1	tetrofosmin:13:0.0033	0.0033	13
TF	TF:9	thickening fraction:9:0.2102	0.2102	9
TF	TF:54	Thomsen-Friedenreich:54:0.0147	0.0147	54
TF	TF:10	tibiofemoral:10:0.0025	0.0025	10
TF	TF:12|T-F:2|t-f:2	time-frequency:16:0.0042	0.0042	16
TF	TF:1386	tissue factor:1386:0.7923	0.7923	1386
TF	TF:8	total fat:8:0.4102	0.4102	8
TF	TF:38	transcription factors:38:0.4911	0.4911	38
TF	TF:18	Transfer factors:18:0.1670	0.1670	18
TF	TF:12	transfer function:12:0.3813	0.3813	12
Tf	Tf:576|TF:226|tf:2	transferrin:804:0.2219	0.2219	804
TF	TF:6	transport fraction:6:0.0666	0.0666	6
TF	TF:8	treatment failure:8:0.1276	0.1276	8
TF	TF:9	tubular fluid:9:0.0898	0.0898	9
TF	TF:19	typhoid fever:19:0.7658	0.7658	19
Tg+	Tg+:8|TG+:3|tg+:1	transgenic:12:0.3333	0.3333	12
TGA	TGA:12	thermogravimetry:12:0.0134	0.0134	12
TGA	TGA:11	thioglycolic acid:11:0.4232	0.4232	11
TGA	TGA:4|TgA:4|TGa:1	thyroglobulin:9:0.0098	0.0098	9
TGA	TGA:8	thyroglobulin antibodies:8:0.2987	0.2987	8
TGA	TGA:136	transient global amnesia:136:0.9329	0.9329	136
TGA	TGA:262	transposition of the great arteries:262:0.9183	0.9183	262
TGCTs	TGCTs:55	testicular germ cell tumors:38:0.9217|testicular germ cell tumours:17:0.8270	0.9217	55
TGCTs	TGCTs:6	Testicular germ cell tumours of adolescents and adults:6:0.5290	0.5290	6
TGCT	TGCT:51	testicular germ cell tumors:24:0.8768|testicular germ cell tumours:18:0.8365|testicular germ cell tumor:9:0.6794	0.8768	51
TGCs	TGCs:11	giant cells:11:0.7357	0.7357	11
tgD	tgD:8|t-gD:1	glycoprotein D:9:0.6794	0.6794	9
TGD	TGD:24	tumor growth delay:24:0.5370	0.5370	24
TGEV	TGEV:54	transmissible gastroenteritis coronavirus:54:0.9132	0.9132	54
TGEV	TGEV:249	transmissible gastroenteritis virus:249:0.9806	0.9806	249
TGE	TGE:121|tge:1	transmissible gastroenteritis:122:0.9144	0.9144	122
TGFA	TGFA:21|TGFa:3|Tgfa:2|TGF-a:2	transforming growth factor alpha:28:0.8941	0.8941	28
TGFA	TGFA:13|TG-FA:2	triglyceride fatty acids:15:0.6386	0.6386	15
TGFB1	TGFB1:4|TGF-b1:3	transforming growth factor beta 1:7:0.5926	0.5926	7
TGFBI	TGFBI:10	transforming growth factor beta-induced:10:0.7357	0.7357	10
TGFB	TGFB:5|TGF-B:5|Tgfb:3|TGFb:2|TGF-b:1	transforming growth factor beta:16:0.8165	0.8165	16
TGFs	TGFs:71	transforming growth factors:71:0.8919	0.8919	71
TGF	TGF:422	Transforming growth factor:397:0.9479|transforming growth factors:25:0.8816	0.9479	422
TGF	TGF:247	Tubuloglomerular feedback:247:0.9626	0.9626	247
TGGE	TGGE:145	temperature gradient gel electrophoresis:114:0.8789|Temperature-gradient gel electrophoresis:31:0.1310	0.8789	145
tGH	tGH:14	growth hormone:14:0.7909	0.7909	14
TGH	TGH:10	triacylglycerol hydrolase:10:0.7103	0.7103	10
TGI	TGI:17	growth inhibition:17:0.8270	0.8270	17
TGI	TGI:5	thyroid growth stimulating immunoglobulins:5:0.2818	0.2818	5
TGI	TGI:49	Tracheal gas insufflation:49:0.9404	0.9404	49
TGK	TGK:9|TGk:1	keratinocyte transglutaminase:10:0.5856	0.5856	10
TGMV	TGMV:67	tomato golden mosaic virus:67:0.9554	0.9554	67
TGM	TGM:12	total gaseous mercury:12:0.7571	0.7571	12
TGM	TGM:8|Tgm:3|TgM:1|Tg-m:1	transgenic mice:13:0.6701	0.6701	13
TGM	TGM:3|Tgm:3|TgM:2	transgenic mouse:8:0.5006	0.5006	8
TGNs	TGNs:10	nucleotides:10:0.6923	0.6923	10
TGN	TGN:13	thioguanine nucleotide:7:0.2452|thioguanine nucleotides:6:0.2243	0.2452	13
TGN	TGN:456	trans-Golgi network:456:0.8571	0.8571	456
TGN	TGN:12	trigeminal neuralgia:12:0.7571	0.7571	12
TGP	TGP:18	tobacco glycoprotein:18:0.6903	0.6903	18
tGSH	tGSH:17|TGSH:16|T-GSH:1|t-GSH:1	total glutathione:35:0.6464	0.6464	35
TGSR	TGSR:21|TgSR:2	secretion rate:23:0.8715	0.8715	23
TGS	TGS:17	transcriptional gene silencing:17:0.8270	0.8270	17
TGs	TGs:26	Triacylglycerols:26:0.0880	0.0880	26
TGs	TGs:155|Tgs:1|TGS:1	triglycerides:157:0.5493	0.5493	157
TGT	TGT:7	thrombin generation time:7:0.3524	0.3524	7
TGT	TGT:31|Tgt:4|tgt:1	tRNA-guanine transglycosylase:36:0.7433	0.7433	36
TGT	TGT:6	tumor growth time:6:0.3728	0.3728	6
TGV	TGV:98|Tgv:1	thoracic gas volume:99:0.9231	0.9231	99
TGV	TGV:8	transposition of the great vessels:8:0.5856	0.5856	8
TGZ	TGZ:35|Tgz:3	troglitazone:38:0.9250	0.9250	38
TGases	TGases:35|Tgases:1	transglutaminases:36:0.8974	0.8974	36
TGase	TGase:188|Tgase:4|TGASE:2	Transglutaminase:194:0.9279	0.9279	194
TGr	TGr:13|TGR:1	6-thioguanine resistance:14:0.6173	0.6173	14
TGr	TGr:5|TGR:1	6-thioguanine resistant:6:0.2243	0.2243	6
TGr	TGr:7	frequency of 6-thioguanine-resistant:7:0.0825	0.0825	7
TGR	TGR:4	hypertensive TGR(mREN2)27 rats:4:0.0545	0.0545	4
TGR	TGR:11	TGR(mREN2)27:11:0.0478	0.0478	11
TGR	TGR:17	transgenic rats:10:0.1994|transgenic rat:7:0.2902	0.2902	17
TG	TG:77|tG:1|Tg:1	6-thioguanine:79:0.0098	0.0098	79
Tg	Tg:15|TG:6	anti-thyroglobulin:21:0.0025	0.0025	21
TG	TG:4|Tg:1	Fc receptors for IgG:5:0.1132	0.1132	5
Tg	Tg:4|TG:2|tG:1	generation time:7:0.2113	0.2113	7
Tg	Tg:9	glass transition:9:0.6794	0.6794	9
Tg	Tg:139|TG:3	glass transition temperature:117:0.9344|glass transition temperatures:25:0.8186	0.9344	142
TG	TG:13|Tg:1	glucuronide:14:0.0016	0.0016	14
TG	TG:7	low density lipoprotein (VLDL)-triglyceride:7:0.5926	0.5926	7
TG	TG:27|Tg:1	plasma triacylglycerol:28:0.0513	0.0513	28
TG	TG:254|Tg:1	plasma triglyceride:255:0.1261	0.1261	255
Tg	Tg:221|TG:26|tg:2	Serum thyroglobulin:249:0.1726	0.1726	249
Tg	Tg:12|tg:6|TG:1	TCR-transgenic:19:0.0023	0.0023	19
TG	TG:10	tetragastrin:10:0.0011	0.0011	10
TG	TG:275|Tg:81|tg:1	Thapsigargin:357:0.0448	0.0448	357
TG	TG:12	Thermogravimetric:12:0.0014	0.0014	12
TG	TG:27	thermogravimetry:27:0.0033	0.0033	27
TG	TG:23|Tg:1	thioglycollate:24:0.0029	0.0029	24
TG	TG:18	thioguanine:18:0.0021	0.0021	18
TG	TG:11	thrombin generation:11:0.6182	0.6182	11
Tg	Tg:16|TG:11	thymine glycol:27:0.7066	0.7066	27
TG	TG:23	thyroid gland:23:0.8038	0.8038	23
TG	TG:11|Tg:1	Tissue transglutaminase:12:0.0819	0.0819	12
TG	TG:38	total gastrectomy:38:0.9217	0.9217	38
tg	tg:18	tottering:18:0.0021	0.0021	18
TG	TG:13	training group:13:0.0869	0.0869	13
Tg	Tg:10|tg:7|TG:3	transgene:20:0.0024	0.0024	20
Tg	Tg:560|TG:285|tg:101	transgenic:946:0.1190	0.1190	946
TG	TG:28|Tg:10|tg:1	transgenic mice:39:0.7602	0.7602	39
TG	TG:17	treatment group:17:0.1369	0.1369	17
TG	TG:9	triacylglycerides:9:0.0010	0.0010	9
TG	TG:107|Tg:1	triacylglycerols:108:0.0135	0.0135	108
TG	TG:9	trigeminal:9:0.0010	0.0010	9
TG	TG:84	trigeminal ganglia:84:0.8794	0.8794	84
TG	TG:126	trigeminal ganglion:126:0.9177	0.9177	126
TG	TG:6	triglyceride concentration:6:0.2243	0.2243	6
TG	TG:7	triglyceride levels:7:0.2902	0.2902	7
TG	TG:11	tumour growth:11:0.3829	0.3829	11
TG	TG:12	typhus group:12:0.0749	0.0749	12
TH+	TH+:28	tyrosine hydroxylase-positive:19:0.8449|tyrosine hydroxylase positive:9:0.6794	0.8449	28
THAA	THAA:19	thyroid hormone autoantibodies:19:0.8449	0.8449	19
THAs	THAs:71	total hip arthroplasties:71:0.9579	0.9579	71
THA	THA:15	1,2,3,4-tetrahydro-9-aminoacridine:15:0.0135	0.0135	15
THA	THA:44	9-amino-1,2,3,4-tetrahydroacridine:44:0.0426	0.0426	44
THA	THA:12	tetrahydro-9-aminoacridine:12:0.0106	0.0106	12
THA	THA:106	tetrahydroaminoacridine:106:0.1006	0.1006	106
THA	THA:11	total hip:11:0.4728	0.4728	11
THA	THA:635	total hip arthroplasty:589:0.9891|total hip arthroplasties:46:0.8986	0.9891	635
THBC	THBC:11	tetrahydro-beta-carboline:11:0.4348	0.4348	11
THBF	THBF:20	total hepatic blood flow:20:0.7766	0.7766	20
THBI	THBI:7	thyroid hormone binding inhibitor:7:0.5926	0.5926	7
THB	THB:17	tetrahydroberberine:17:0.1119	0.1119	17
THB	THB:19	Todd-Hewitt broth:19:0.5732	0.5732	19
tHb	tHb:8|THb:3	total haemoglobin:11:0.7357	0.7357	11
tHb	tHb:14|THb:9|T-Hb:2|t-Hb:2|tHB:1	Total hemoglobin:28:0.8941	0.8941	28
THC	THC:9	delta 1-tetrahydrocannabinol:9:0.4587	0.4587	9
THC	THC:586|-THC:1	delta 9-tetrahydrocannabinol:262:0.9269|delta-9-tetrahydrocannabinol:249:0.2221|delta(9)-Tetrahydrocannabinol:76:0.0674	0.9269	587
THC	THC:139	delta9-tetrahydrocannabinol:139:0.1232	0.1232	139
THC	THC:110	tetrahydrocannabinol:110:0.0935	0.0935	110
THC	THC:10	tetrahydrocurcumin:10:0.0081	0.0081	10
THC	THC:18	total haemocyte count:18:0.8365	0.8365	18
THC	THC:9	total hydrocarbon:9:0.6794	0.6794	9
THDOC	THDOC:9	tetrahydrodeoxycorticosterone:9:0.1509	0.1509	9
Thd	Thd:12|THD:3	Thalidomide:15:0.1818	0.1818	15
THD	THD:10	thioridazine:10:0.1169	0.1169	10
THEO	THEO:34|Theo:13|theo:2	theophylline:49:0.8276	0.8276	49
THE	THE:31	tetrahydrocortisone:31:0.2400	0.2400	31
THE	THE:14	tonic hindlimb extension:14:0.7909	0.7909	14
THE	THE:29	transhiatal esophagectomy:29:0.7970	0.7970	29
THF	THF:9	mono-tetrahydrofuran:9:0.0193	0.0193	9
THF	THF:29	tetrahydrofolate:29:0.0676	0.0676	29
THF	THF:12	tetrahydrofolic acid:12:0.6460	0.6460	12
THF	THF:177|thf:2	tetrahydrofuran:179:0.4324	0.4324	179
THF	THF:9	thymic hormone:9:0.5470	0.5470	9
THF	THF:28	thymic humoral factor:28:0.6295	0.6295	28
THGP	THGP:10	Tamm-Horsfall glycoprotein:10:0.4363	0.4363	10
THG	THG:22	Tamm-Horsfall glycoprotein:22:0.7955	0.7955	22
THG	THG:13	Third-harmonic generation:7:0.1641|third harmonic generation:6:0.5290	0.5290	13
THg	THg:26|T-Hg:9|t-Hg:1	Total mercury:36:0.9174	0.9174	36
THIP	THIP:30	4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol:30:0.2339	0.2339	30
TH-IR	TH-IR:22|TH-ir:13|THir:3|THIR:1	TH-immunoreactive:39:0.1659	0.1659	39
TH-IR	TH-IR:6|TH-ir:4	tyrosine hydroxylase:10:0.7103	0.7103	10
TH-IR	TH-IR:46|TH-ir:35|THir:19|THIR:2	tyrosine hydroxylase-immunoreactive:61:0.9511|tyrosine hydroxylase immunoreactive:41:0.9274	0.9511	102
TH-IR	TH-IR:15|TH-ir:4|THir:2|THIR:1	tyrosine hydroxylase immunoreactivity:22:0.7955	0.7955	22
THI	THI:10	2-acetyl-4-tetrahydroxybutylimidazole:10:0.0396	0.0396	10
THI	THI:16	temperature-humidity index:16:0.2362	0.2362	16
THI	THI:17	Tinnitus Handicap Inventory:17:0.8270	0.8270	17
THI	THI:47	tissue harmonic imaging:47:0.9006	0.9006	47
THI	THI:11	traumatic head injury:11:0.7357	0.7357	11
TH-LI	TH-LI:6|TH-li:1	Tyrosine hydroxylase-like immunoreactivity:7:0.5926	0.5926	7
THL	THL:19	tetrahydrolipstatin:19:0.2432	0.2432	19
THL	THL:14	Transvaginal hydrolaparoscopy:14:0.7909	0.7909	14
THL	THL:9	true histiocytic lymphoma:9:0.6794	0.6794	9
THMFP	THMFP:17	trihalomethane formation potential:17:0.5760	0.5760	17
THMs	THMs:100	trihalomethanes:100:0.9167	0.9167	100
THM	THM:53	trihalomethane:34:0.3474|trihalomethanes:19:0.1895	0.3474	53
THM	THM:8	Tsukuba hypertensive mice:8:0.4102	0.4102	8
THOV	THOV:17	Thogoto virus:17:0.8270	0.8270	17
THO	THO:25	tritiated water:25:0.6539	0.6539	25
THP-1	THP-1:7	human monocytes:7:0.2902	0.2902	7
THP-1	THP-1:6	human monocytic:6:0.1148	0.1148	6
THP-1	THP-1:15|THP1:1	monocytic cells:16:0.2288	0.2288	16
THP-1	THP-1:9	monocytic leukemia:9:0.5470	0.5470	9
THPO	THPO:11	4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol:11:0.3846	0.3846	11
THPP	THPP:10	periodic paralysis:10:0.7103	0.7103	10
THP	THP:9	(2"R)-4'-O-tetrahydropyranyladriamycin:9:0.0125	0.0125	9
THP	THP:9	(2''R)-4'-O-Tetrahydropyranyladriamycin:9:0.0125	0.0125	9
THP	THP:9	4'-O-tetrahydropyranyladriamycin:9:0.0125	0.0125	9
THP	THP:77	pirarubicin:77:0.1184	0.1184	77
THP	THP:36|THp:2	Tamm-Horsfall glycoprotein:38:0.7548	0.7548	38
THP	THP:139|THp:1	Tamm-Horsfall protein:140:0.8216	0.8216	140
THP	THP:10	tetrahydropalmatine:10:0.0140	0.0140	10
THP	THP:52	tetrahydropapaveroline:52:0.0779	0.0779	52
THP	THP:20	trihexyphenidyl:20:0.0296	0.0296	20
THR-221	THR-221:13	cefodizime sodium:13:0.7753	0.7753	13
THRP	THRP:6	thyroid hormone responsive protein:6:0.5290	0.5290	6
thr	thr:10|THR:7|Thr:2	thrombin:19:0.0266	0.0266	19
THR	THR:6|thr:1|ThR:1	thyroid hormone receptor:8:0.6411	0.6411	8
THR	THR:7	Total hip:7:0.2902	0.2902	7
THR	THR:338	total hip replacement:298:0.9785|total hip replacements:40:0.9256	0.9785	338
THR	THR:8	transient hyperaemic response:8:0.6411	0.6411	8
THR	THR:6	transient hyperemic response:6:0.5290	0.5290	6
THs	THs:35|THS:1	thyroid hormones:36:0.8716	0.8716	36
THS	THS:29	Tolosa-Hunt syndrome:29:0.5212	0.5212	29
ThT	ThT:16	Thioflavin T:16:0.7261	0.7261	16
THU	THU:23	tetrahydrouridine:23:0.7097	0.7097	23
THX	THX:16|ThX:1|Thx:1	thyroidectomized:18:0.4359	0.4359	18
T-H	T-H:5|TH:4	after trauma-hemorrhage:9:0.2500	0.2500	9
T-H	T-H:6	following trauma-hemorrhage:6:0.0807	0.0807	6
Th	Th:115|TH:15	helper T:130:0.9015	0.9015	130
Th	Th:93|TH:22	helper T cells:62:0.7624|helper T cell:39:0.8455|helper T-cell:14:0.7909	0.8455	115
Th	Th:7|TH:3	helper T lymphocytes:10:0.7103	0.7103	10
TH	TH:12	homogenate:12:0.0018	0.0018	12
Th	Th:4	mean transit time:4:0.0918	0.0918	4
TH	TH:5	nicotinamide nucleotide transhydrogenase:5:0.4422	0.4422	5
Th	Th:870|TH:121|T-h:2|T-H:1	T helper:727:0.9401|T-helper:267:0.0434	0.9401	994
Th	Th:92|TH:18	T helper cell:55:0.8401|T helper cells:39:0.9237|T-helper cell:16:0.0670	0.9237	110
TH	Th:3|TH:3	T helper lymphocytes:6:0.5290	0.5290	6
TH	TH:12|T-H:2	Tamm-Horsfall:14:0.0021	0.0021	14
TH	TH:9	Tamm-Horsfall protein:9:0.4587	0.4587	9
TH	TH:23	target height:23:0.4188	0.4188	23
TH	TH:9	Tec homology:9:0.5470	0.5470	9
TH	TH:18	tension headache:18:0.3548	0.3548	18
TH	TH:13	tension-type headache:13:0.2038	0.2038	13
TH	TH:19|Th:12	thalamus:31:0.0049	0.0049	31
TH	TH:37|Th:16	theophylline:53:0.0085	0.0085	53
Th	Th:9|th:2	thickness:11:0.0016	0.0016	11
Th	Th:14	Thorium:14:0.0021	0.0021	14
TH	TH:8|Th:7	thrombin:15:0.0023	0.0023	15
TH	TH:348|Th:1	thyroid hormone:254:0.9811|thyroid hormones:95:0.9339	0.9811	349
TH	TH:6|Th:1	transition temperature:7:0.2902	0.2902	7
TH	TH:13	triamcinolone hexacetonide:13:0.7909	0.7909	13
TH	TH:9	twitch height:9:0.0783	0.0783	9
TH	TH:3228|Th:2|th:1	tyrosine hydroxylase:3186:0.9757|tyrosine-hydroxylase:45:0.0072	0.9757	3231
TH	TH:10	tyrosine hydroxylase gene:10:0.7103	0.7103	10
TI-mice	TI-mice:10|TI-Mice:2	thermally injured mice:12:0.7571	0.7571	12
TIA's	TIA's:16|Tia's:1	transient ischemic attacks:17:0.8270	0.8270	17
TIA-1	TIA-1:11|TIA1:1|Tia-1:1	intracellular antigen:13:0.5934	0.5934	13
TIA-1	TIA-1:16	T-cell intracellular antigen-1:16:0.6577	0.6577	16
TIAR	TIAR:6	intracellular antigen-related protein:6:0.5290	0.5290	6
TIAs	TIAs:242|TIAS:1	transient ischemic attacks:243:0.9083	0.9083	243
TIA	TIA:15	thin layer immunoassay:15:0.8045	0.8045	15
TIA	TIA:11	Thrombosis-inducing activity:11:0.1009	0.1009	11
TIA	TIA:10	thymidine incorporation assay:10:0.5856	0.5856	10
TIA	TIA:5	trabecular-iris angle:5:0.1132	0.1132	5
TIA	TIA:176	transient ischaemic attack:120:0.8336|Transient Ischaemic Attacks:56:0.8453	0.8453	176
TIA	TIA:588|tia:3	transient ischemic attack:414:0.9036|transient ischemic attacks:177:0.8547	0.9036	591
TIA	TIA:15	trypsin inhibitor activity:15:0.8045	0.8045	15
TIA	TIA:15	turbidimetric immunoassay:15:0.1992	0.1992	15
TIBC	TIBC:7	Serum iron and total iron binding capacity:7:0.5011	0.5011	7
TIBC	TIBC:86	total iron-binding capacity:86:0.9111	0.9111	86
TICT	TICT:10	twisted intramolecular charge transfer:10:0.7103	0.7103	10
TICU	TICU:10	Trauma Intensive Care Unit:10:0.5856	0.5856	10
TIC	TIC:5	intensity curve:5:0.0902	0.0902	5
TIC	TIC:19	theca-interstitial cells:13:0.2211|theca-interstitial cell:6:0.1320	0.2211	19
TIC	TIC:8	thyroid iodine content:8:0.4102	0.4102	8
TIC	TIC:18|Tic:1	ticarcillin:19:0.0659	0.0659	19
TIC	TIC:22	trypsin inhibitory capacity:22:0.8657	0.8657	22
TIDA	TIDA:31	tuberoinfundibular dopamine:31:0.8519	0.8519	31
TIDA	TIDA:122|TI-DA:1	tuberoinfundibular dopaminergic:123:0.9058	0.9058	123
TID	TID:12|tid:9	three times a day:21:0.6812	0.6812	21
TID	TID:17|tid:15	three times daily:32:0.7525	0.7525	32
TIE	TIE:15	inhibitory element:15:0.7096	0.7096	15
TIE	TIE:34	toxicity identification evaluation:34:0.9217	0.9217	34
TIF2	TIF2:18|Tif2:1	intermediary factor 2:19:0.7044	0.7044	19
TIFF	TIFF:13	tagged image file format:13:0.7753	0.7753	13
TIFP	TIFP:12	tumor interstitial fluid pressure:12:0.6460	0.6460	12
TIG1	TIG1:8	Tazarotene-induced gene 1:8:0.5006	0.5006	8
TIGR	TIGR:12	glucocorticoid response protein:12:0.6460	0.6460	12
TIGR	TIGR:7	trabecular meshwork inducible glucocorticoid response:7:0.5926	0.5926	7
TIG	TIG:11	tungsten inert gas:11:0.7357	0.7357	11
TIH	TIH:9	Tumor-induced hypercalcemia:9:0.5470	0.5470	9
TIL's	TIL's:10	lymphocytes:10:0.9000	0.9000	10
TILs	TILs:163	Tumor-infiltrating lymphocytes:163:0.5078	0.5078	163
TIL	TIL:8	tumor-infiltrating leukocytes:8:0.2327	0.2327	8
TIL	TIL:431|TiL:1	Tumor-infiltrating lymphocytes:382:0.5287|tumor-infiltrating lymphocyte:31:0.3638|tumor infiltrating lymphocyte:19:0.6537	0.6537	432
TIMI	TIMI:465	thrombolysis in myocardial infarction:465:0.9408	0.9408	465
TIMI	TIMI:16	Thrombolysis in Myocardial Infarction trial:16:0.7261	0.7261	16
TIMI	TIMI:9	Thrombolysis in Myocardial Ischemia:9:0.5470	0.5470	9
TIMP-1	TIMP-1:7	metalloproteinase inhibitor:7:0.0516	0.0516	7
TIMP-1	TIMP-1:12|Timp1:1	tissue inhibitor:13:0.2121	0.2121	13
TIMP-1	TIMP-1:1	tissue inhibitor metalloprotease-1:1:0.6794	0.6794	1
TIMP-1	TIMP-1:7|TIMP1:1	tissue inhibitor of matrix metalloproteinase:8:0.6411	0.6411	8
TIMP-1	TIMP-1:44|TIMP1:1	tissue inhibitor of matrix metalloproteinase-1:45:0.9353	0.9353	45
TIMP-1	TIMP-1:73|TIMP1:4	tissue inhibitor of metalloproteinases:45:0.9353|tissue inhibitor of metalloproteinase:32:0.9072	0.9353	77
TIMP-1	TIMP-1:495|TIMP1:18|Timp-1:2|timp-1:1	tissue inhibitor of metalloproteinase-1:233:0.9729|tissue inhibitor of metalloproteinases-1:171:0.9634|tissue inhibitor of metalloproteinase 1:57:0.9477|tissue inhibitor of metalloproteinases 1:55:0.9162	0.9729	516
TIMP-1	TIMP-1:8|TIMP1:2	tissue inhibitor of MMP:10:0.7103	0.7103	10
TIMP-1	TIMP-1:10	tissue inhibitor of MMP-1:10:0.7103	0.7103	10
TIMP-1	TIMP-1:6|TIMP1:1	tissue inhibitor of MMPs:7:0.5926	0.5926	7
TIMP-2	TIMP-2:6	tissue inhibitor:6:0.0899	0.0899	6
TIMP-2	TIMP-2:7	tissue inhibitor of metalloproteinases:7:0.5926	0.5926	7
TIMP-2	TIMP-2:192|Timp2:4|TIMP2:4|Timp-2:1	tissue inhibitor of metalloproteinase-2:97:0.9698|Tissue inhibitor of metalloproteinases-2:78:0.9393|tissue inhibitor of metalloproteinase 2:17:0.8270|tissue inhibitor of metalloproteinases 2:9:0.5470	0.9698	201
TIMP-2	TIMP-2:1	tissue inhibitor of the MMP-2:1:0.8045	0.8045	1
TIMP-3	TIMP-3:79|TIMP3:32|Timp-3:2	tissue inhibitor of metalloproteinases-3:59:0.9229|tissue inhibitor of metalloproteinase-3:33:0.9126|tissue inhibitor of metalloproteinase 3:21:0.8594	0.9229	113
TIMPs	TIMPs:7	tissue inhibitors of matrix metalloproteinase:7:0.5926	0.5926	7
TIMPs	TIMPs:12	tissue inhibitors of metalloproteases:12:0.7571	0.7571	12
TIMPs	TIMPs:19	Tissue inhibitors of metalloproteinase:19:0.7658	0.7658	19
TIMP	TIMP:8	metalloproteinase inhibitor:8:0.0726	0.0726	8
TIMP	TIMP:15	tissue inhibitor of metalloproteases:15:0.8045	0.8045	15
TIMP	TIMP:219|Timp:3	tissue inhibitor of metalloproteinases:222:0.9720	0.9720	222
TIMP	TIMP:24	tissue inhibitor of MMP:15:0.8045|tissue inhibitors of MMP:9:0.6794	0.8045	24
TIMP	TIMP:5	tissue inhibitor of MMPs:5:0.4422	0.4422	5
TIMS	TIMS:17	thermal ionization mass spectrometry:17:0.8270	0.8270	17
TIN-ag	TIN-ag:11|TIN-Ag:2	Tubulointerstitial nephritis antigen:13:0.7753	0.7753	13
TINU	TINU:3	tubulointerstitial nephritis with uveitis:3:0.5348	0.5348	3
TIN	TIN:18	testicular intraepithelial neoplasia:18:0.8270	0.8270	18
TiN	TiN:33	Titanium nitride:33:0.9100	0.9100	33
TIN	TIN:70	tubulointerstitial nephritis:70:0.6868	0.6868	70
TIO	TIO:14	tumor-induced osteomalacia:14:0.6173	0.6173	14
TIP39	TIP39:18|Tip39:1	tuberoinfundibular peptide of 39 residues:19:0.8449	0.8449	19
TIPP	TIPP:10	H-Tyr-Tic-Phe-Phe-OH:10:0.3000	0.3000	10
TIPPB	TIPPB:22	transperineal interstitial permanent prostate brachytherapy:22:0.8657	0.8657	22
TIPSS	TIPSS:76	Transjugular intrahepatic portosystemic stent shunt:39:0.9217|transjugular intrahepatic portosystemic stent-shunt:27:0.8903|Transjugular intrahepatic portosystemic stent shunts:10:0.6794	0.9217	76
TIPs	TIPs:7	Tonoplast intrinsic proteins:7:0.5926	0.5926	7
TIPS	TIPS:590	Transjugular intrahepatic portosystemic shunt:481:0.9614|Transjugular intrahepatic portosystemic shunts:109:0.9726	0.9726	590
TIPS	TIPS:24	transjugular intrahepatic portosystemic shunting:24:0.8115	0.8115	24
TIPS	TIPS:22	transjugular intrahepatic portosystemic stent-shunt:22:0.7400	0.7400	22
TIP	TIP:12	tonoplast intrinsic protein:12:0.5664	0.5664	12
TIP	TIP:9	tubularized incised plate:9:0.6182	0.6182	9
TIQs	TIQs:22	tetrahydroisoquinolines:22:0.8750	0.8750	22
TIQ	TIQ:39	1,2,3,4-Tetrahydroisoquinoline:39:0.4810	0.4810	39
TIQ	TIQ:25|Tiq:1	tetrahydroisoquinoline:26:0.3165	0.3165	26
TIRF	TIRF:33	total internal reflection fluorescence:33:0.8605	0.8605	33
TIRFM	TIRFM:36|TIR-FM:9	Total internal reflection fluorescence microscopy:45:0.9338	0.9338	45
TIRs	TIRs:42	terminal inverted repeats:42:0.8893	0.8893	42
TIR	TIR:28	terminal inverted repeat:17:0.8270|terminal inverted repeats:11:0.7357	0.8270	28
TIR	TIR:19	Toll/interleukin-1 receptor:19:0.1032	0.1032	19
TIR	TIR:22	Total internal reflection:22:0.8657	0.8657	22
TIR	TIR:20	translation initiation region:20:0.5568	0.5568	20
Tir	Tir:24|tir:3	translocated intimin receptor:27:0.7834	0.7834	27
TISS-28	TISS-28:10	Therapeutic Intervention Scoring System:10:0.7103	0.7103	10
TISS	TISS:98	Therapeutic Intervention Scoring System:98:0.9510	0.9510	98
Tis	Tis:17|TIS:6	Carcinoma in situ:23:0.5719	0.5719	23
TIS	TIS:9	Information Services:9:0.6794	0.6794	9
TIS	TIS:7	Total irritation score:7:0.5926	0.5926	7
TIS	TIS:21|tis:1	transcription initiation site:22:0.6934	0.6934	22
tITP	tITP:6|TITP:2|t-ITP:1	transient isotachophoresis:9:0.6794	0.6794	9
TIVA	TIVA:76	total intravenous anaesthesia:76:0.9378	0.9378	76
TIVA	TIVA:96	total intravenous anesthesia:96:0.9505	0.9505	96
TIVADs	TIVADs:7	totally implantable venous access devices:7:0.5926	0.5926	7
TIVCC	TIVCC:12	thoracic inferior vena caval constriction:12:0.7571	0.7571	12
TIV	TIV:14	Tipula iridescent virus:14:0.7909	0.7909	14
TIV	TIV:8	total intracranial volume:8:0.6411	0.6411	8
TIV	TIV:4	trivalent inactivated influenza vaccine:4:0.1618	0.1618	4
Ti	Ti:9	commercially pure titanium:9:0.1409	0.1409	9
Ti	Ti:7|TI:5	duration of inspiration:12:0.1573	0.1573	12
TI	TI:8|Ti:2	indices:10:0.0046	0.0046	10
TI	TI:9	injury:9:0.0041	0.0041	9
TI	TI:65|Ti:12|ti:3	inspiratory duration:80:0.8596	0.8596	80
TI	TI:131|Ti:45|ti:12	inspiratory time:183:0.6658|inspiratory times:5:0.0517	0.6658	188
TI	TI:7|ti:2	interval:9:0.0041	0.0041	9
TI	TI:49	inversion time:43:0.1197|inversion times:6:0.1148	0.1197	49
TI	TI:9	ischemia:9:0.0041	0.0041	9
Ti	Ti:5	T cell antigen receptor:5:0.2818	0.2818	5
TI	TI:30|T-I:2	T cell-independent:25:0.8816|T-cell independent:7:0.0732	0.8816	32
Ti	Ti:6	T cell receptor:6:0.2827	0.2827	6
TI	TI:25|T-I:1	T-independent:26:0.0127	0.0127	26
Ti	Ti:7|TI:3	temperature:10:0.0046	0.0046	10
TI	TI:8	thalassaemia intermedia:8:0.0953	0.0953	8
TI	TI:13	thalassemia intermedia:13:0.2660	0.2660	13
TI	TI:10	theca interna:10:0.5856	0.5856	10
T-I	T-I:6|TI:4	theca-interstitial:10:0.0046	0.0046	10
TI	TI:40	therapeutic index:40:0.2076	0.2076	40
TI	TI:9	thermodynamic integration:9:0.2500	0.2500	9
TI	TI:7	thoracic electrical impedance:7:0.5926	0.5926	7
TI	TI:10	thoracic irradiation:10:0.2446	0.2446	10
TI	TI:5	threshold intensity:5:0.0902	0.0902	5
TI	TI:8	thymic irradiation:8:0.1471	0.1471	8
TI	TI:82	thymus-independent:73:0.0367|thymus independent:9:0.1409	0.1409	82
Ti	Ti:1	time in inspiration:1:0.0866	0.0866	1
Ti	Ti:13|TI:1	titanium alloy:14:0.4709	0.4709	14
TI	TI:67	tonic immobility:67:0.9554	0.9554	67
TI	TI:8|Ti:1	transcallosal inhibition:9:0.3945	0.3945	9
TI	TI:14	transient inward current:14:0.7909	0.7909	14
TI	TI:8	treatment interruption:8:0.5006	0.5006	8
TI	TI:9	tricuspid incompetence:9:0.6794	0.6794	9
TI	TI:24	tricuspid insufficiency:24:0.7593	0.7593	24
TI	TI:11	true insulin:11:0.6182	0.6182	11
TI	TI:50	trypsin inhibitor:41:0.7952|trypsin inhibitors:9:0.4587	0.7952	50
TI	TI:13	tuberoinfundibular:13:0.0061	0.0061	13
TI	TI:19|ti:1	tubulointerstitial:20:0.0097	0.0097	20
Ti	Ti:70	tumor-inducing:58:0.0290|tumour-inducing:12:0.0061	0.0290	70
TJ-10	TJ-10:6	herbal medicine Saiko-keishi-to:6:0.5926	0.5926	6
TJ-48	TJ-48:12	Juzen-taiho-to:12:0.4400	0.4400	12
TJ-9	TJ-9:9	herbal medicine sho-saiko-to:9:0.6182	0.6182	9
TJ-41	TJ-41:10|TJ41:1	Hochu-ekki-to:11:0.6250	0.6250	11
TJR	TJR:17	total joint replacement:17:0.8270	0.8270	17
TJs	TJs:138	tight junctions:138:0.9654	0.9654	138
TK+	TK+:16|tk+:1	thymidine kinase-positive:17:0.7407	0.7407	17
TK-	TK-:23|tk-:3	thymidine kinase-deficient:26:0.8251	0.8251	26
TK-	TK-:18|tk-:2|Tk-:1	thymidine kinase-negative:21:0.7865	0.7865	21
TK1	TK1:36|Tk-1:5|Tk1:3|tk-1:3|TK-1:2	thymidine kinase:49:0.9392	0.9392	49
TK1	TK1:31|TK-1:3	thymidine kinase 1:34:0.8644	0.8644	34
TK2	TK2:18|TK-2:5	mitochondrial thymidine kinase:23:0.8038	0.8038	23
TK2	TK2:11	Thymidine kinase 2:11:0.7357	0.7357	11
TK6	TK6:6	human lymphoblastoid cell line:6:0.5926	0.5926	6
TKAs	TKAs:72	total knee arthroplasties:72:0.9585	0.9585	72
TKA	TKA:610	total knee arthroplasty:584:0.9839|total knee arthroplasties:26:0.8861	0.9839	610
TKA	TKA:8	tyrosine kinase activity:8:0.5006	0.5006	8
TKD	TKD:9	tyrosine kinase domain:9:0.5470	0.5470	9
TKIs	TKIs:28	tyrosine kinase inhibitors:28:0.8941	0.8941	28
TKI	TKI:19	tyrosine kinase inhibitors:11:0.6182|tyrosine kinase inhibitor:8:0.4102	0.6182	19
TK-LI	TK-LI:7|TKLI:2	immunoreactivity:9:0.8889	0.8889	9
TKR	TKR:178	total knee replacement:161:0.9349|total knee replacements:17:0.8270	0.9349	178
TKRs	TKRs:12	total knee replacements:12:0.7571	0.7571	12
TKT	TKT:7|tkt:4|Tkt:2	transketolase:13:0.5000	0.5000	13
tkv	tkv:18|Tkv:5	thick veins:23:0.8715	0.8715	23
TKs	TKs:28|Tks:1	tachykinins:29:0.4118	0.4118	29
TKs	TKs:25	tyrosine kinases:25:0.6873	0.6873	25
TK	TK:9	erythrocyte transketolase:9:0.0577	0.0577	9
TK	TK:9	kidney:9:0.0037	0.0037	9
TK	TK:31	tachykinin:20:0.0088|Tachykinins:11:0.0046	0.0088	31
TK	TK:1151|tk:297|Tk:21	thymidine kinase:1461:0.8137|thymidine kinases:8:0.0953	0.8137	1469
tk	tk:41|TK:15	thymidine kinase gene:56:0.8901	0.8901	56
TK	TK:39|tK:3	tissue kallikrein:42:0.9291	0.9291	42
TK	TK:12	toxicokinetic:12:0.0051	0.0051	12
TK	TK:243|tk:7	tyrosine kinase:234:0.1168|tyrosine kinases:16:0.3831	0.3831	250
TL,CO	TL,CO:12	transfer factor of the lung for carbon monoxide:12:0.7571	0.7571	12
TLA	TLA:8	local anesthesia:8:0.5006	0.5006	8
TLA	TLA:5	theta-like activity:5:0.1132	0.1132	5
TLA	TLA:7	total lesion area:7:0.3524	0.3524	7
TLA	TLA:23	Toxoplasma lysate antigen:23:0.8038	0.8038	23
TLC-FID	TLC-FID:9	ionization detection:9:0.4587	0.4587	9
TLCK	TLCK:127	chloromethyl ketone:127:0.8129	0.8129	127
TLCK	TLCK:20	chloromethylketone:20:0.0896	0.0896	20
TLCO	TLCO:36|Tlco:1	carbon monoxide transfer factor:37:0.8749	0.8749	37
TLCO	TLCO:5|TLco:2	diffusion capacity:7:0.2452	0.2452	7
TLCO	TLCO:8	lung transfer factor for CO:8:0.5006	0.5006	8
TLCO	TLCO:27|Tlco:1|TLco:1|TlCO:1	transfer factor for carbon monoxide:30:0.8563	0.8563	30
TLCV	TLCV:10	tomato leaf curl virus:10:0.5856	0.5856	10
TLC	TLC:9	carcinoma:9:0.0035	0.0035	9
TLC	TLC:45	T lymphocyte clones:32:0.9072|T-lymphocyte clones:13:0.1103	0.9072	45
TLC	TLC:19	taurolithocholate:19:0.0079	0.0079	19
TLC	TLC:14	thin-layer:14:0.0057	0.0057	14
TLC	TLC:137	thin-layer chromatographic:93:0.5545|thin layer chromatographic:44:0.9323	0.9323	137
TLC	TLC:744|tlc:2	thin-layer chromatography:746:0.6202	0.6202	746
TLC	TLC:20	total leukocyte count:20:0.7766	0.7766	20
TLC	TLC:595	Total lung capacity:595:0.9609	0.9609	595
TLC	TLC:48	Total lymphocyte count:40:0.8491|total lymphocyte counts:8:0.6411	0.8491	48
TLD's	TLD's:10	thermoluminescent dosimeters:10:0.7103	0.7103	10
TLDs	TLDs:22|TLDS:1	Thermoluminescence dosemeters:23:0.3069	0.3069	23
TLDs	TLDs:15	Thermoluminescent detectors:15:0.4052	0.4052	15
TLDs	TLDs:84|TLDS:1	thermoluminescent dosimeters:85:0.6826	0.6826	85
tld	tld:3|TLD:2|Tld:1	Drosophila tolloid:6:0.0807	0.0807	6
TLD	TLD:14	thermoluminescence dosemeter:8:0.1895|thermoluminescence dosemeters:6:0.0611	0.1895	14
TLD	TLD:30	Thermoluminescence dosimetry:30:0.2265	0.2265	30
TLD	TLD:18	thermoluminescent dosemeters:12:0.3524|thermoluminescent dosemeter:6:0.0807	0.3524	18
TLD	TLD:105	thermoluminescent dosimeters:64:0.6462|thermoluminescent dosimeter:41:0.6524	0.6524	105
TLD	TLD:58	thermoluminescent dosimetry:58:0.5387	0.5387	58
TLESRs	TLESRs:26|tLESRs:1	transient lower esophageal sphincter relaxations:27:0.8903	0.8903	27
TLESR	TLESR:16|tLESR:2	transient lower esophageal sphincter relaxation:13:0.7753|Transient lower esophageal sphincter relaxations:5:0.4422	0.7753	18
TLE	TLE:774	temporal lobe epilepsy:774:0.9938	0.9938	774
TLE	TLE:10	transducin-like enhancer of split:10:0.3470	0.3470	10
TLFB	TLFB:10	Timeline Follow-Back:10:0.5000	0.5000	10
TLFB	TLFB:12	Timeline Followback:12:0.6460	0.6460	12
TLF	TLF:11	trypanosome lytic factor:11:0.7357	0.7357	11
T-LGL	T-LGL:13|TLGL:1	large granular lymphocyte:14:0.6911	0.6911	14
TLH	TLH:32	total laparoscopic hysterectomy:32:0.8563	0.8563	32
TLIF	TLIF:15	transforaminal lumbar interbody fusion:15:0.5111	0.5111	15
TLI	TLI:41|T-LI:4	thymidine labeling index:45:0.6921	0.6921	45
TLI	TLI:21	thymidine labelling index:21:0.4041	0.4041	21
TLI	TLI:247	total lymphoid irradiation:247:0.9803	0.9803	247
TLI	TLI:21	trypsin-like immunoreactivity:21:0.5721	0.5721	21
T-LL	T-LL:6	lymphoblastic lymphoma:6:0.1838	0.1838	6
tll	tll:27	tailless:27:0.3514	0.3514	27
TLN	TLN:9|tln:1	telencephalin:10:0.1765	0.1765	10
TLN	TLN:15	thermolysin:15:0.2745	0.2745	15
TLOSR	TLOSR:8	transient lower oesophageal sphincter relaxation:8:0.6411	0.6411	8
TLOSRs	TLOSRs:10	Transient lower oesophageal sphincter relaxations:10:0.7103	0.7103	10
TLPs	TLPs:7	thaumatin-like proteins:7:0.3524	0.3524	7
TLR2	TLR2:152|TLR-2:18	Toll-like receptor 2:157:0.9503|toll-like receptor-2:13:0.6701	0.9503	170
TLR3	TLR3:29|TLR-3:2	toll-like receptor 3:31:0.9011	0.9011	31
TLR4	TLR4:315|TLR-4:36|Tlr4:22|tlr4:3|tlr-4:1	Toll-like receptor 4:326:0.9472|Toll-like receptor-4:51:0.9416	0.9472	377
TLR5	TLR5:22|TLR-5:1|Tlr5:1	toll-like receptor 5:24:0.8768	0.8768	24
TLR9	TLR9:56|TLR-9:5	toll-like receptor 9:61:0.9229	0.9229	61
TLRs	TLRs:521|Tlrs:1	Toll-like receptors:522:0.9768	0.9768	522
TLR	TLR:90	target lesion revascularization:90:0.9668	0.9668	90
TLR	TLR:486|Tlr:2	Toll-like receptor:368:0.9373|toll-like receptors:120:0.8754	0.9373	488
TLS	TLS:22	translesion DNA synthesis:22:0.8657	0.8657	22
TLS	TLS:45	translesion synthesis:45:0.5219	0.5219	45
TLS	TLS:10	tRNA-like structure:10:0.5000	0.5000	10
TLS	TLS:58	tumor lysis syndrome:58:0.7489	0.7489	58
TLTF	TLTF:7	lymphocyte triggering factor:7:0.5926	0.5926	7
TLT	TLT:12	TransLaryngeal Tracheostomy:12:0.6460	0.6460	12
TLV	TLV:159	threshold limit value:141:0.9788|Threshold Limit Values:18:0.8365	0.9788	159
TLV	TLV:8	Tidal liquid ventilation:8:0.1591	0.1591	8
TLV	TLV:10	total liquid ventilation:10:0.2643	0.2643	10
TLV	TLV:7	total liver volume:7:0.5926	0.5926	7
TLV	TLV:10	total lung volume:10:0.5856	0.5856	10
TLV	TLV:20	two-lung ventilation:20:0.2904	0.2904	20
TLVs	TLVs:49	threshold limit values:49:0.9392	0.9392	49
TLW	TLW:11	total lung water:11:0.7357	0.7357	11
TLX	TLX:7	trophoblast-lymphocyte cross-reactive:7:0.2113	0.2113	7
TLM	TLM:12	Thiolactomycin:12:0.1183	0.1183	12
TLM	TLM:5	triple-layer model:5:0.1132	0.1132	5
TLM	TLM:16	two-layer method:16:0.4536	0.4536	16
tL	tL:4|Tl:2|TL:1	lag time:7:0.2452	0.2452	7
tl	tl:7	mutation toothless:7:0.0726	0.0726	7
TL	TL:11	T lymphocytes:11:0.1486	0.1486	11
TL	TL:14	tail length:14:0.1124	0.1124	14
TL	TL:26	temporal lobe:26:0.8861	0.8861	26
TL	TL:12	temporal lobectomy:12:0.4557	0.4557	12
Tl	Tl:40	thallium:40:0.0329	0.0329	40
Tl	Tl:25|TL:3	thallium-201:28:0.0228	0.0228	28
TL	TL:34	thermolabile:34:0.0278	0.0278	34
TL	TL:102	thermoluminescence:102:0.0852	0.0852	102
TL	TL:51	thermoluminescent:51:0.0422	0.0422	51
TL	TL:11|T-L:3	thoracolumbar:14:0.0110	0.0110	14
TL	TL:63|Tl:1	thymus leukemia:35:0.5687|thymus-leukemia:29:0.0228	0.5687	64
TL	TL:11	thymus leukemia antigen:11:0.5856	0.5856	11
TL	TL:7	thyroid lymphoma:7:0.2113	0.2113	7
TL	TL:9	tomato lectin:9:0.6794	0.6794	9
TL	TL:8	Tonsillar lymphocytes:8:0.0726	0.0726	8
TL	TL:18	total laryngectomy:18:0.8365	0.8365	18
TL	TL:22	total length:22:0.2313	0.2313	22
TL	TL:77	total lipids:51:0.8799|total lipid:26:0.7340	0.8799	77
TL	TL:9	tracheal ligation:9:0.1690	0.1690	9
TL	TL:10	transfer latency:10:0.5000	0.5000	10
TL	TL:11	tubal ligation:11:0.2582	0.2582	11
TM-906	TM-906:13	Effects of trimebutine maleate:13:0.6701	0.6701	13
TM2	TM2:12|tm2:2	second transmembrane domain:14:0.6173	0.6173	14
TM2	TM2:14	second transmembrane segment:14:0.6911	0.6911	14
TM4SF	TM4SF:37	transmembrane 4 superfamily:37:0.9197	0.9197	37
TMA+	TMA+:49	tetramethylammonium:49:0.7500	0.7500	49
TMADH	TMADH:13	trimethylamine dehydrogenase:13:0.7753	0.7753	13
TMA-DPH	TMA-DPH:11	1-[4-(trimethylamino)phenyl]-6-phenylhexa-1,3,5-triene:11:0.0446	0.0446	11
TMA-DPH	TMA-DPH:11|TMADPH:1	1-(4-trimethylaminophenyl)-6-phenyl-1,3,5-hexatriene:12:0.0491	0.0491	12
TMA-DPH	TMA-DPH:12	trimethylamino-diphenylhexatriene:12:0.0491	0.0491	12
TMA-DPH	TMA-DPH:8	trimethylammonium diphenylhexatriene:8:0.5006	0.5006	8
TMAFM	TMAFM:14|TM-AFM:10|TmAFM:1	tapping mode atomic force microscopy:15:0.8045|tapping-mode atomic force microscopy:10:0.1680	0.8045	25
TMAH	TMAH:28	tetramethylammonium hydroxide:28:0.6455	0.6455	28
TMAO	TMAO:149|TMA-O:1	Trimethylamine N-oxide:98:0.8956|trimethylamine-N-oxide:52:0.2065	0.8956	150
TMAO	TMAO:50|TMA-O:1	Trimethylamine oxide:51:0.5245	0.5245	51
TMAO	TMAO:23	trimethylarsine oxide:23:0.1776	0.1776	23
TMAS	TMAS:9|T-MAS:1	Taylor Manifest Anxiety Scale:10:0.7103	0.7103	10
TMAs	TMAs:57	tissue microarrays:57:0.9477	0.9477	57
TMA	TMA:12	4,6,4'-trimethylangelicin:12:0.0126	0.0126	12
TMA	TMA:73	tetramethylammonium:73:0.0828	0.0828	73
TMA	TMA:11	Thermomechanical analysis:11:0.2972	0.2972	11
TMA	TMA:132	thrombotic microangiopathy:123:0.9757|thrombotic microangiopathies:9:0.6794	0.9757	132
TMA	TMA:12	thyroid microsomal antibodies:12:0.6460	0.6460	12
TMA	TMA:92	Tissue microarray:77:0.9386|tissue microarrays:15:0.6386	0.9386	92
TMA	TMA:43	transcription-mediated amplification:34:0.6194|Transcription Mediated Amplification:9:0.6794	0.6794	43
TMA	TMA:143	trimellitic anhydride:143:0.9456	0.9456	143
TMA	TMA:113	trimethylamine:113:0.1276	0.1276	113
TMB-8	TMB-8:18	3,4,5-trimethoxybenzoate hydrochloride:18:0.1426	0.1426	18
TMB-8	TMB-8:14	3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester:14:0.8045	0.8045	14
TMB-8	TMB-8:15|TMB8:1	8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate:10:0.0356|8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate:6:0.0807	0.0807	16
TMB-8	TMB-8:3	intracellular Ca2+ antagonist 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate:3:0.5926	0.5926	3
TMB	TMB:37	3,3',5,5'-tetramethylbenzidine:37:0.1281	0.1281	37
TMB	TMB:31	Tetramethyl benzidine:31:0.7388	0.7388	31
TMB	TMB:89	tetramethylbenzidine:89:0.3132	0.3132	89
tMCAO	tMCAO:13|t-MCAO:2|tMCA-O:1	transient middle cerebral artery occlusion:16:0.4536	0.4536	16
TMC	TMC:9	medullary carcinoma:9:0.3455	0.3455	9
TMC	TMC:17	N-trimethyl chitosan chloride:17:0.5760	0.5760	17
TMC	TMC:8	Tonsillar mononuclear cells:8:0.3463	0.3463	8
TMC	TMC:9	trapeziometacarpal:9:0.0423	0.0423	9
TMC	TMC:9	trimethylene carbonate:9:0.2327	0.2327	9
TMDI	TMDI:8	Theoretical Maximum Daily Intake:8:0.6794	0.6794	8
TMDs	TMDs:55	Temporomandibular disorders:55:0.8645	0.8645	55
t-MDS	t-MDS:13|tMDS:3	therapy-related myelodysplasia:16:0.3044	0.3044	16
t-MDS	t-MDS:21|tMDS:3	Therapy-related myelodysplastic syndrome:24:0.5848	0.5848	24
TMDs	TMDs:64|Tmds:1	transmembrane domains:65:0.9047	0.9047	65
TMDS	TMDS:8|T-MDS:3	trilineage myelodysplasia:11:0.1547	0.1547	11
TMD	TMD:11	distance:11:0.0108	0.0108	11
TMD	TMD:5	membrane disease:5:0.0517	0.0517	5
TMD	TMD:9|tMD:1	Targeted molecular dynamics:10:0.7103	0.7103	10
TMD	TMD:534	temporomandibular disorders:411:0.8930|temporomandibular disorder:123:0.6664	0.8930	534
TMD	TMD:39	temporomandibular dysfunction:39:0.5418	0.5418	39
TMD	TMD:13	temporomandibular joint dysfunction:13:0.7909	0.7909	13
TMD	TMD:10	Tibial muscular dystrophy:10:0.7103	0.7103	10
TMD	TMD:14	total mood disturbance:14:0.7909	0.7909	14
TMD	TMD:30	Transient myeloproliferative disorder:30:0.8032	0.8032	30
TMD	TMD:124	transmembrane domain:102:0.8766|transmembrane domains:22:0.8657	0.8766	124
TMEDA	TMEDA:6|tmeda:3	N,N,N',N'-tetramethylethylenediamine:9:0.5714	0.5714	9
TMEV	TMEV:257	Theiler's murine encephalomyelitis virus:239:0.9602|Theiler's murine encephalomyelitis viruses:18:0.7539	0.9602	257
TME	TME:146	Total mesorectal excision:146:0.9563	0.9563	146
TME	TME:35	transmissible mink encephalopathy:35:0.9151	0.9151	35
TME	TME:10	true metabolisable energy:10:0.7103	0.7103	10
TME	TME:25	true metabolizable energy:25:0.8816	0.8816	25
TMF	TMF:14	transmitral flow:14:0.6911	0.6911	14
TMGMV	TMGMV:8|TM-GMV:1	tobacco mild green mosaic virus:9:0.6794	0.6794	9
TMg	TMg:8|tMg:7	total magnesium:15:0.7096	0.7096	15
TMH	TMH:5	Tata Memorial Hospital:5:0.4422	0.4422	5
t-MH	t-MH:50|tMH:1	tele-methylhistamine:51:0.4348	0.4348	51
TMH	TMH:17	Transmembrane helix:17:0.6748	0.6748	17
TmI	TmI:7	Drosophila tropomyosin I:7:0.3524	0.3524	7
TMI	TMI:18	Three Mile Island:18:0.8365	0.8365	18
TMI	TMI:9	transient myocardial ischemia:9:0.4587	0.4587	9
TMI	TMI:8	transmandibular implant:8:0.5006	0.5006	8
TMI	TMI:8	transmural myocardial infarction:8:0.4102	0.4102	8
TMJD	TMJD:12	temporomandibular joint dysfunction:12:0.7571	0.7571	12
TMJs	TMJs:105|TMJS:1	temporomandibular joints:106:0.9273	0.9273	106
TMJ	TMJ:9	temporomandibular:9:0.0046	0.0046	9
TMJ	TMJ:1674|tmj:1	temporomandibular joint:1596:0.9638|temporomandibular joints:79:0.9401	0.9638	1675
TMK	TMK:6|TM-K:1	Thymidylate kinase:7:0.2902	0.2902	7
TMLR	TMLR:14	Transmyocardial laser revascularisation:14:0.6173	0.6173	14
TMLR	TMLR:93	transmyocardial laser revascularization:93:0.9325	0.9325	93
T-ML	T-ML:5	malignant lymphoma:5:0.0902	0.0902	5
TMN	TMN:14	tuberomammillary nucleus:14:0.3202	0.3202	14
TMO	TMO:47	trimethadione:47:0.5349	0.5349	47
TMP-SMZ	TMP-SMZ:128	trimethoprim-sulfamethoxazole:128:0.8523	0.8523	128
TMP-SMZ	TMP-SMZ:9	trimethoprim-sulphamethoxazole:9:0.0537	0.0537	9
TMP/SMX	TMP/SMX:97	trimethoprim/sulfamethoxazole:69:0.5397|trimethoprim-sulfamethoxazole:28:0.2143	0.5397	97
TMP/SMX	TMP/SMX:9	trimethoprim/sulphamethoxazole:9:0.0635	0.0635	9
TMP/SMZ	TMP/SMZ:19	trimethoprim/sulfamethoxazole:19:0.5455	0.5455	19
TMPA	TMPA:10	trimethylphenylammonium:10:0.4286	0.4286	10
TMPDS	TMPDS:12	temporomandibular pain and dysfunction syndrome:12:0.5664	0.5664	12
TMPD	TMPD:43	N,N,N',N'-tetramethyl-p-phenylenediamine:43:0.3134	0.3134	43
TMPD	TMPD:13	tetramethyl-p-phenylenediamine:13:0.0896	0.0896	13
TMPG	TMPG:15	TIMI myocardial perfusion grade:15:0.7096	0.7096	15
TMPP	TMPP:19	trimethylolpropane phosphate:19:0.5732	0.5732	19
TMP-SMX	TMP-SMX:213|Tmp-Smx:1	trimethoprim-sulfamethoxazole:214:0.7889	0.7889	214
TMP-SMX	TMP-SMX:24	trimethoprim-sulphamethoxazole:24:0.0852	0.0852	24
TMPTA	TMPTA:13	trimethylolpropane triacrylate:13:0.5934	0.5934	13
TMPZ	TMPZ:9|TMPz:2	tetramethylpyrazine:11:0.8333	0.8333	11
TMPase	TMPase:11	thiamine monophosphatase:11:0.7357	0.7357	11
TMPase	TMPase:12|Tm-Pase:1	Trimetaphosphatase:13:0.4615	0.4615	13
TMP	TMP:16	2,2,4-trimethylpentane:16:0.0181	0.0181	16
TMP	TMP:13	Effects of tetramethylpyrazine:13:0.0899	0.0899	13
TMP	TMP:13	thiamine monophosphate:13:0.1506	0.1506	13
TMP	TMP:13	thymidine monophosphate:13:0.1506	0.1506	13
TMP	TMP:9	thymidylate:9:0.0097	0.0097	9
TMP	TMP:7	tocopherol-mediated peroxidation:7:0.2902	0.2902	7
TMP	TMP:41	transmembrane potential:41:0.8525	0.8525	41
TMP	TMP:31	transmembrane pressure:31:0.4504	0.4504	31
TMP	TMP:7	transmembrane protein:7:0.2113	0.2113	7
TMP	TMP:12	transmural pressure:12:0.1005	0.1005	12
TMP	TMP:16	trimetaphan:16:0.0181	0.0181	16
TMP	TMP:235|Tmp:16	trimethoprim:251:0.3016	0.3016	251
TMP	TMP:16	trimethylpsoralen:16:0.0181	0.0181	16
TmP	TmP:6	tubular reabsorption of phosphate:6:0.5290	0.5290	6
TMQ	TMQ:13	trimetoquinol:13:0.1395	0.1395	13
TMQ	TMQ:50	trimetrexate:50:0.5698	0.5698	50
TMRE	TMRE:15	tetramethylrhodamine ethyl ester:15:0.4609	0.4609	15
TMRM	TMRM:17	tetramethylrhodamine methyl ester:17:0.5374	0.5374	17
TMR	TMR:23	tetramethylrhodamine:23:0.0597	0.0597	23
TMR	TMR:27	tissue maximum ratio:13:0.6701|tissue-maximum ratio:9:0.1052|tissue maximum ratios:5:0.4422	0.6701	27
TMR	TMR:10	Topical Magnetic Resonance:10:0.7103	0.7103	10
TMR	TMR:51	total mixed ration:31:0.9043|total mixed rations:20:0.8525	0.9043	51
TMR	TMR:62	Transmyocardial laser revascularization:62:0.9241	0.9241	62
TMR	TMR:36	transmyocardial revascularization:36:0.2574	0.2574	36
TMR	TMR:12	transverse microradiography:12:0.3058	0.3058	12
TMSE	TMSE:10	Mental State Examination:10:0.5856	0.5856	10
TMSe	TMSe:5|TmSe:3	trimethylselenonium ion:8:0.5006	0.5006	8
TMSs	TMSs:16	transmembrane segments:16:0.4832	0.4832	16
TMS	TMS:11	N,N,N-trimethylsphingosine:11:0.0056	0.0056	11
TMS	TMS:6	Topographic Modeling System:6:0.5290	0.5290	6
TMS	TMS:9	transcranial magnetic:9:0.6794	0.6794	9
TMS	TMS:1163	transcranial magnetic stimulation:1163:0.9883	0.9883	1163
TMS	TMS:9	transcranial magnetic stimuli:9:0.6794	0.6794	9
TMs	TMs:28|Tms:1	transmembrane domains:29:0.6928	0.6928	29
TMs	TMs:7	transmembrane helices:7:0.3524	0.3524	7
TMS	TMS:30|TMs:24	transmembrane segments:43:0.7363|transmembrane segment:11:0.5355	0.7363	54
TMS	TMS:10	trimethoprim-sulfamethoxazole:10:0.0050	0.0050	10
TMS	TMS:142|-TMS:1	trimethylsilyl:143:0.0796	0.0796	143
TMs	TMs:13|Tms:3|tms:1	tropomyosins:17:0.0090	0.0090	17
TMTD	TMTD:16	tetramethylthiuram disulfide:16:0.5171	0.5171	16
TMTFs	TMTFs:13|tMTFs:3	temporal modulation transfer functions:16:0.6577	0.6577	16
TMTX	TMTX:58	trimetrexate:58:0.9344	0.9344	58
TMT	TMT:9	tarsometatarsal:9:0.0173	0.0173	9
TMT	TMT:19	thiol methyltransferase:19:0.8449	0.8449	19
TMT	TMT:74	Trail Making Test:74:0.9361	0.9361	74
TMT	TMT:209	trimethyltin:209:0.4471	0.4471	209
TMT	TMT:24	trimethyltin chloride:24:0.8768	0.8768	24
TMU	TMU:11	tetramethylurea:11:0.3226	0.3226	11
TMVP	TMVP:18	tobacco mosaic virus protein:18:0.8365	0.8365	18
TMV	TMV:19	tobacco mosaic tobamovirus:19:0.8449	0.8449	19
TMV	TMV:537	tobacco mosaic virus:537:0.9852	0.9852	537
TMV	TMV:21	tracheal mucus velocity:21:0.8594	0.8594	21
TMX	TMX:63|Tmx:4|tmx:1	tamoxifen:68:0.7053	0.7053	68
TMZ	TMZ:112	temozolomide:112:0.5163	0.5163	112
TMZ	TMZ:83|Tmz:1	trimetazidine:84:0.3860	0.3860	84
TMEP	TMEP:9	telangiectasia macularis eruptiva perstans:9:0.5470	0.5470	9
TMNs	TMNs:8	trigeminal motoneurons:8:0.4102	0.4102	8
TN368	TN368:5|TN-368:5	Trichoplusia ni:10:0.7103	0.7103	10
TNAB	TNAB:8	transthoracic needle aspiration biopsy:8:0.3945	0.3945	8
TNAs	TNAs:18	total nutrient admixtures:18:0.8365	0.8365	18
TNBS	TNBS:11	2,4,6-trinitrobenzene sulfonate:11:0.1612	0.1612	11
TNBS	TNBS:51	2,4,6-Trinitrobenzene sulfonic acid:51:0.2441	0.2441	51
TNBS	TNBS:13	2,4,6-trinitrobenzenesulfonate:13:0.0248	0.0248	13
TNBS	TNBS:19	trinitrobenzene sulfonate:19:0.4211	0.4211	19
TNBS	TNBS:89	trinitrobenzene sulfonic acid:89:0.4813	0.4813	89
TNBS	TNBS:16	trinitrobenzenesulfonate:16:0.0310	0.0310	16
TNBS	TNBS:62	trinitrobenzenesulfonic acid:62:0.1235	0.1235	62
TNBT	TNBT:11	tetrazolium:11:0.6250	0.6250	11
TNB	TNB:25	1,3,5-trinitrobenzene:25:0.1353	0.1353	25
TNB	TNB:21	Transthoracic needle biopsy:21:0.6812	0.6812	21
TNB	TNB:10	trinitrobenzene:10:0.0529	0.0529	10
TNCB	TNCB:20	2,4,6-trinitrochlorobenzene:20:0.2000	0.2000	20
TNCB	TNCB:51	trinitrochlorobenzene:51:0.5263	0.5263	51
TNCs	TNCs:26	Thymic nurse cells:26:0.8861	0.8861	26
TNDM	TNDM:18	Transient neonatal diabetes mellitus:18:0.8365	0.8365	18
TNFR1	TNFR1:7|TNF-R1:3	TNF receptor type 1:10:0.1449	0.1449	10
TNFR1	TNFR1:41|TNF-R1:20|TNFR-1:8|Tnfr1:1	tumor necrosis factor receptor 1:54:0.8036|tumor necrosis factor receptor-1:16:0.6577	0.8036	70
TNFR1	TNFR1:7|TNFR-1:3|TNF-R1:3	tumor necrosis factor receptor type 1:13:0.7753	0.7753	13
TNFR2	TNFR2:24|TNF-R2:2	tumor necrosis factor receptor 2:26:0.6973	0.6973	26
TNFRs	TNFRs:12|TNF-Rs:4	tumor necrosis factor receptors:16:0.7407	0.7407	16
TNFR	TNFR:106|TNF-R:39|TNFr:2	TNF receptor:106:0.2717|TNF receptors:41:0.4322	0.4322	147
TNFR	TNFR:157|TNF-R:31|TNFr:4|Tnfr:2	tumor necrosis factor receptor:181:0.7869|tumor necrosis factor receptors:13:0.4444	0.7869	194
TNF-a	TNF-a:30|TNFa:3	tumor necrosis factor-a:33:0.7238	0.7238	33
TNF-a	TNF-a:21|TNFa:17|TNFA:15|TNF-A:4|Tnfa:2	tumor necrosis factor alpha:36:0.6538|tumor necrosis factor-alpha:23:0.5025	0.6538	59
TNFbp	TNFbp:8|TNF-BP:4|TNF-bp:3	TNF binding protein:15:0.3429	0.3429	15
TNFbp	TNFbp:5|TNF-BP:3|TNF-bp:1	tumor necrosis factor binding protein:9:0.5470	0.5470	9
TNFRII	TNFRII:4|TNF-RII:3	Tumor necrosis factor receptor II:7:0.3524	0.3524	7
TNFRI	TNFRI:8|TNFR-I:2	tumor necrosis factor receptor I:10:0.5000	0.5000	10
TNF	TNF:16	TNF-alpha:16:0.0018	0.0018	16
TNF	TNF:5779|Tnf:2	tumor necrosis factor:5756:0.8051|Tumor necrosis factors:25:0.5496	0.8051	5781
TNF	TNF:1183|Tnf:6	Tumor necrosis factor-alpha:661:0.7922|tumor necrosis factor alpha:316:0.7672|tumour necrosis factor-alpha:140:0.1443|tumour necrosis factor alpha:72:0.1433	0.7922	1189
TNF	TNF:19	tumor necrosis factor/cachectin:19:0.6106	0.6106	19
TNG	TNG:73	nitroglycerin:73:0.6186	0.6186	73
TNG	TNG:12	toxic nodular goiter:12:0.7571	0.7571	12
T-NHL	T-NHL:10	T-cell non-Hodgkin's lymphoma:10:0.3470	0.3470	10
TnI	TnI:6|TNI:3|TN-I:2	inhibitory subunit of troponin:11:0.7357	0.7357	11
TNI	TNI:28	total nodal irradiation:28:0.8941	0.8941	28
TnI	TnI:283|Tn-I:14|TNI:11|TN-I:6|tni:1	troponin I:286:0.9724|troponin-I:29:0.0705	0.9724	315
TNK	TNK:14	Tenecteplase:14:0.5652	0.5652	14
TNM	TNM:2	nodes and metastases:2:0.0899	0.0899	2
TNM	TNM:62	tetranitromethane:62:0.1704	0.1704	62
TNM	TNM:97	tumor-node-metastasis:72:0.1983|Tumor Node Metastasis:25:0.4722	0.4722	97
TNNT2	TNNT2:8	cardiac troponin T:8:0.4102	0.4102	8
TNP-ATP	TNP-ATP:11	trinitrophenyl-ATP:11:0.1205	0.1205	11
TNP-LPS	TNP-LPS:26	trinitrophenyl-lipopolysaccharide:26:0.3378	0.3378	26
TNP-LPS	TNP-LPS:15	trinitrophenylated lipopolysaccharide:15:0.4052	0.4052	15
TNP-PAA	TNP-PAA:10	polyacrylamide beads:10:0.5856	0.5856	10
TNP	TNP:16	anti-2,4,6-trinitrophenyl:16:0.0313	0.0313	16
TNP	TNP:55|Tnp:1	anti-trinitrophenyl:56:0.1148	0.1148	56
TNP	TNP:10	antitrinitrophenyl:10:0.0188	0.0188	10
TNP	TNP:5|Tnp:1	hapten 2,4,6-trinitrophenyl:6:0.0648	0.0648	6
Tnp	Tnp:11	Tn5 transposase:11:0.2040	0.2040	11
TNP	TNP:25	trinitrophenol:25:0.0501	0.0501	25
TNP	TNP:123	trinitrophenyl:123:0.2547	0.2547	123
TNP	TNP:6	trinitrophenyl hapten:6:0.0666	0.0666	6
TNP	TNP:28	trinitrophenylated:28:0.0564	0.0564	28
TNRs	TNRs:14	trinucleotide repeats:14:0.6911	0.6911	14
TN-R	TN-R:9	extracellular matrix glycoprotein tenascin-R:9:0.6794	0.6794	9
TNR	TNR:17	trinucleotide repeat:17:0.8270	0.8270	17
TNSALP	TNSALP:53|TNS-ALP:1	alkaline phosphatase:54:0.9132	0.9132	54
TNS	TNS:2	fluorescent probe 2-p-toluidinylnaphthalene-6-sulfonate:2:0.1973	0.1973	2
TNS	TNS:149	nerve stimulation:149:0.8826	0.8826	149
TNS	TNS:7	transdermal nicotine system:7:0.5926	0.5926	7
TNS	TNS:23	transient neurologic symptoms:23:0.8038	0.8038	23
TNS	TNS:11	tumor necrosis serum:11:0.4232	0.4232	11
TNV	TNV:19	Tobacco necrosis virus:19:0.8449	0.8449	19
TNX	TNX:19|TN-X:11|Tnx:1|Tn-X:1|TnX:1	tenascin-X:33:0.5926	0.5926	33
TNZ	TNZ:10	thermoneutral zone:10:0.4363	0.4363	10
TNZ	TNZ:8|Tnz:1	Tinidazole:9:0.3333	0.3333	9
TNase	TNase:17|TNAse:1	thermonuclease:18:0.5000	0.5000	18
TO2	TO2:11	O2 transport:11:0.4232	0.4232	11
TOAST	TOAST:34	Trial of Org 10172 in Acute Stroke Treatment:34:0.9100	0.9100	34
TOA	TOA:14	tubo-ovarian abscess:14:0.4367	0.4367	14
TOBEC	TOBEC:59	total body electrical conductivity:44:0.9323|Total-body electrical conductivity:15:0.1265	0.9323	59
TOB	TOB:72|tob:1|Tob:1	tobramycin:74:0.8795	0.8795	74
TOCE	TOCE:19	transcatheter oily chemoembolization:19:0.5404	0.5404	19
Toc	Toc:12|TOC:8	alpha-tocopherol:20:0.0432	0.0432	20
TOC	Toc:5|TOC:5	tocopherol:10:0.0205	0.0205	10
TOC	TOC:272	total organic carbon:272:0.9710	0.9710	272
TOC	TOC:7	total organic carbon content:7:0.5926	0.5926	7
TOC	TOC:8	turkey osteomyelitis complex:8:0.5006	0.5006	8
TOC	TOC:4	tylosis oesophageal cancer:4:0.3524	0.3524	4
TOFHLA	TOFHLA:8	Test of Functional Health Literacy in Adults:8:0.6794	0.6794	8
TOFMS	TOFMS:12|TOF-MS:6	time-of-flight mass spectrometer:18:0.7539	0.7539	18
TOF	TOF:223|ToF:15|toF:1	tetralogy of Fallot:239:0.9672	0.9672	239
TOF	TOF:34|ToF:2	time of flight:36:0.7433	0.7433	36
TOF	TOF:370|tof:1	train-of-four:355:0.3242|train of four:16:0.5564	0.5564	371
TOF	TOF:7	train-of-four stimulation:7:0.3524	0.3524	7
TOHP	TOHP:13	Trials of Hypertension Prevention:13:0.7096	0.7096	13
TOH	TOH:10	alpha-tocopherol:10:0.0629	0.0629	10
TOH	TOH:17|ToH:1	Tower of Hanoi:18:0.7539	0.7539	18
TOH	TOH:18	transient osteoporosis of the hip:18:0.8365	0.8365	18
TOH	TOH:9	tritiated water:9:0.6794	0.6794	9
TOH	TOH:46|T-OH:22|Toh:2	tyrosine hydroxylase:70:0.9326	0.9326	70
TOI	TOI:15	tissue oxygenation index:15:0.8045	0.8045	15
TOI	TOI:11	Trial Outcome Index:11:0.7357	0.7357	11
TOJ	TOJ:12	temporal order judgment:12:0.7571	0.7571	12
TOJs	TOJs:10	Temporal order judgments:10:0.7103	0.7103	10
TOL	TOL:9|tol:1	tolbutamide:10:0.0511	0.0511	10
TOL	TOL:29|ToL:6	Tower of London:35:0.8681	0.8681	35
TOL	TOL:37	trial of labor:28:0.7905|trial of labour:9:0.6794	0.7905	37
ToM	ToM:46|TOM:6	theory of mind:52:0.9427	0.9427	52
TOM	TOM:10	toxic oxygen metabolites:10:0.7103	0.7103	10
TOM	TOM:8	translocase of the outer membrane:8:0.2757	0.2757	8
TOM	TOM:7|Tom:2	translocase of the outer mitochondrial membrane:9:0.5470	0.5470	9
top1	top1:46|Top1:22|TOP1:19	topoisomerase I:87:0.9280	0.9280	87
TOPA	TOPA:5|topa:5	2,4,5-Trihydroxyphenylalanine:10:0.2571	0.2571	10
TOPV	TOPV:14	trivalent oral polio vaccine:14:0.7909	0.7909	14
TOPV	TOPV:11	trivalent oral poliovirus vaccine:11:0.7357	0.7357	11
TOP	TOP:13	Tendency-Oriented Perimetry:7:0.1641|Tendency oriented perimetry:6:0.5290	0.5290	13
TOP	TOP:81	termination of pregnancy:81:0.8478	0.8478	81
TOP	TOP:12	thimet oligopeptidase:12:0.6460	0.6460	12
TORP	TORP:14	total ossicular replacement prosthesis:14:0.6911	0.6911	14
TORPs	TORPs:10	total ossicular replacement prostheses:10:0.7103	0.7103	10
TOSC	TOSC:18	Total Oxyradical Scavenging Capacity:18:0.8365	0.8365	18
TOSV	TOSV:7|TOSv:2|ToSv:1	Toscana virus:10:0.7103	0.7103	10
TOS	TOS:154	thoracic outlet syndrome:154:0.9806	0.9806	154
TOS	TOS:76	toxic oil syndrome:76:0.9607	0.9607	76
TOT	TOT:21	tip-of-the-tongue:21:0.1681	0.1681	21
TOVA	TOVA:28	Test of Variables of Attention:28:0.8941	0.8941	28
TO	TO:5|to:3|To:1	baseline:9:0.0155	0.0155	9
To	To:9|TO:1|to:1	temperature:11:0.0194	0.0194	11
TO	TO:36	thiazole orange:36:0.8336	0.8336	36
TO	TO:12	time-out:12:0.0233	0.0233	12
TO	TO:44	tracheal occlusion:44:0.7839	0.7839	44
TO	TO:18	tracheobronchopathia osteochondroplastica:18:0.7539	0.7539	18
TO	TO:30	triolein:30:0.0563	0.0563	30
TO	TO:18	Tryptophan oxygenase:18:0.7539	0.7539	18
TO	TO:18	turbulence onset:18:0.4672	0.4672	18
TP1	TP1:11	telomerase-associated protein:11:0.4232	0.4232	11
TP-1	TP-1:22|TP1:6|Tp1:1|TP--1:1	thymostimulin:30:0.2522	0.2522	30
TP1	TP1:18|Tp-1:1	transition protein 1:19:0.4226	0.4226	19
TP2	TP2:12|TP-2:2	transition protein 2:14:0.7909	0.7909	14
TP-5	TP-5:36|TP5:22	thymopentin:58:0.5327	0.5327	58
TP-5	TP-5:15|TP5:6	thymopoietin pentapeptide:21:0.7291	0.7291	21
TPA	TPA:9	12-O-tetra-decanoyl-phorbol-13-acetate:9:0.0007	0.0007	9
TPA	TPA:18	12-O-Tetra-decanoylphorbol-13-acetate:18:0.0015	0.0015	18
TPA	TPA:16	12-O-tetradecanoyl-13-acetate:16:0.0013	0.0013	16
TPA	TPA:12	12-tetradecanoyl-phorbol-13-acetate:12:0.0009	0.0009	12
TPA	TPA:11	12-tetradecanoylphorbol-13-acetate:11:0.0009	0.0009	11
tPA	tPA:8|t-PA:6|TPA:3	alteplase:17:0.0014	0.0014	17
TPA	TPA:123	phorbol 12-myristate 13-acetate:104:0.8452|phorbol-12-myristate-13-acetate:19:0.0015	0.8452	123
TPA	TPA:7	phorbol diester:7:0.2902	0.2902	7
TPA	TPA:208	phorbol ester:179:0.8955|phorbol esters:29:0.8978	0.8978	208
TPA	TPA:17	phorbol ester 12-0-tetradecanoylphorbol-13-acetate:17:0.8768	0.8768	17
TPA	TPA:109	phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate:49:0.9370|phorbol ester 12-O-tetradecanoyl phorbol-13-acetate:38:0.9353|phorbol ester 12-O-tetradecanoyl phorbol 13-acetate:22:0.9043	0.9370	109
TPA	TPA:341	phorbol ester 12-O-tetradecanoylphorbol-13-acetate:245:0.9860|phorbol ester 12-O-tetradecanoylphorbol 13-acetate:96:0.9770	0.9860	341
t-PA	t-PA:20|tPA:6|TPA:1	plasminogen activators:27:0.7834	0.7834	27
t-PA	t-PA:7|tPA:2|TPA:1	plasminogen activator activity:10:0.7103	0.7103	10
TPA	TPA:15	Terephthalic acid:15:0.3110	0.3110	15
TPA	TPA:126	tetradecanoyl phorbol acetate:126:0.7604	0.7604	126
TPA	TPA:19	tetradecanoylphorbol-13-acetate:19:0.0015	0.0015	19
TPA	TPA:84	tetradecanoylphorbol acetate:84:0.1528	0.1528	84
TPA	TPA:12	texture profile analysis:12:0.7571	0.7571	12
TPA	TPA:14	time-resolved phosphorescence anisotropy:14:0.6911	0.6911	14
t-PA	t-PA:3|tPA:1	tissue activator of plasminogen:4:0.2818	0.2818	4
t-PA	t-PA:1020|tPA:1019|TPA:182|tpa:2|T-PA:2|t-Pa:1|t-pA:1	tissue plasminogen activator:2227:0.5145	0.5145	2227
tPA	tPA:15|t-PA:14|TPA:1	tissue type:30:0.9011	0.9011	30
tPA	tPA:78|t-PA:70|TPA:3	tissue-type PA:127:0.6479|tissue type PA:24:0.8186	0.8186	151
t-PA	t-PA:4|tPA:2	tissue-type plasminogen:6:0.0666	0.0666	6
t-PA	t-PA:1222|tPA:482|TPA:60|tPa:3|T-PA:3|t-pA:2|t-pa:1|tpA:1	tissue-type plasminogen activator:1774:0.4090	0.4090	1774
TPA	TPA:10	tripropylamine:10:0.0008	0.0008	10
TPA	TPA:10	tumor promoter:10:0.3867	0.3867	10
TPA	TPA:17	tumor promoter 12-0-tetradecanoyl-phorbol-13-acetate:13:0.6386|tumor promoter 12-0-tetradecanoyl phorbol-13-acetate:4:0.2827	0.6386	17
TPA	TPA:53	tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate:53:0.8233	0.8233	53
TPA	TPA:251	tumor promoter 12-O-tetradecanoylphorbol-13-acetate:251:0.8379	0.8379	251
TPA	TPA:13	two-photon absorption:13:0.6701	0.6701	13
TPB-	TPB-:20	tetraphenylboron:20:0.5938	0.5938	20
TPB	TPB:13	tetraphenylboron:13:0.0745	0.0745	13
TPB	TPB:78	Theory of Planned Behavior:46:0.8401|theory of planned behaviour:32:0.9072	0.9072	78
TPB	TPB:17	tryptose phosphate broth:17:0.7407	0.7407	17
TPCK	TPCK:120	chloromethyl ketone:120:0.6999	0.6999	120
TPCK	TPCK:7	N-tosyl-L-phenylalanine chloromethylketone:7:0.0951	0.0951	7
TPCs	TPCs:9	triggered propagated contractions:9:0.6794	0.6794	9
TPC	TPC:8|TPc:1	nucleus tegmenti pedunculopontinus pars compacta:9:0.5470	0.5470	9
TPC	TPC:5	protein concentration:5:0.0736	0.0736	5
TPC	TPC:13	total peripheral conductance:13:0.7753	0.7753	13
TPC	TPC:6	total phenolic content:6:0.5290	0.5290	6
TPC	TPC:20	Total plasma cholesterol:20:0.8525	0.8525	20
TPC	TPC:8	total plate count:8:0.6411	0.6411	8
TPDMT-4	TPDMT-4:11	pregnancy-dependent mouse mammary tumor:11:0.7357	0.7357	11
TPEN	TPEN:5	chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine:5:0.1690	0.1690	5
TPE	TPE:17	position effect:17:0.6748	0.6748	17
TPE	TPE:69	therapeutic plasma exchange:69:0.8555	0.8555	69
TPE	TPE:13	total pelvic exenteration:13:0.7753	0.7753	13
TPE	TPE:51	tropical pulmonary eosinophilia:51:0.9427	0.9427	51
TPE	TPE:10	two-photon excitation:10:0.7103	0.7103	10
TPF	TPF:5	Tumor proliferative fraction:5:0.4422	0.4422	5
TPGS	TPGS:12	d-alpha-tocopheryl polyethylene glycol 1000 succinate:12:0.4557	0.4557	12
TPG	TPG:11|tpg:1	total product generated:12:0.7571	0.7571	12
TPG	TPG:13	transpulmonary gradient:13:0.4102	0.4102	13
TPHA	TPHA:10	hemagglutination test:10:0.1596	0.1596	10
TPHA	TPHA:19	Treponema pallidum haemagglutination:19:0.6537	0.6537	19
TPHA	TPHA:36	Treponema Pallidum Haemagglutination Assay:36:0.7183	0.7183	36
TPHA	TPHA:7	Treponema pallidum Haemagglutination Test:7:0.4438	0.4438	7
TPHA	TPHA:25	Treponema pallidum hemagglutination:25:0.7249	0.7249	25
TPHA	TPHA:15	Treponema pallidum hemagglutination assay:15:0.6386	0.6386	15
tpH	tpH:6|t-pH:2|TpH:1	tissue pH:9:0.6794	0.6794	9
TPH	TPH:48	Total petroleum hydrocarbons:26:0.8861|total petroleum hydrocarbon:22:0.8657	0.8861	48
TPH	TPH:270|TpH:8|tph:2|Tph:1	tryptophan hydroxylase:281:0.9669	0.9669	281
TPI	TPI:15	inhibitor:15:0.0348	0.0348	15
TPI	TPI:13	Treatment Priority Index:13:0.7753	0.7753	13
TPI	TPI:16|tpi:6|Tpi:3	triose phosphate isomerase:25:0.8816	0.8816	25
TPI	TPI:102|tpi:6|Tpi:3	triosephosphate isomerase:111:0.6662	0.6662	111
TPI	TPI:16	triphosphoinositide:16:0.0373	0.0373	16
TPI	TPI:12	tumor profile index:12:0.6460	0.6460	12
TPJ	TPJ:16	junction:16:0.9375	0.9375	16
TPKs	TPKs:10	tyrosine protein kinases:10:0.7103	0.7103	10
TPK	TPK:48	tyrosine protein kinase:48:0.6918	0.6918	48
T-PLL	T-PLL:16	T-cell prolymphocytic leukaemia:16:0.4040	0.4040	16
T-PLL	T-PLL:38	T-cell prolymphocytic leukemia:38:0.6678	0.6678	38
T-PLL	T-PLL:14	T-prolymphocytic leukaemia:14:0.1769	0.1769	14
T-PLL	T-PLL:19	T-prolymphocytic leukemia:19:0.1577	0.1577	19
TPLO	TPLO:8	tibial plateau leveling osteotomy:8:0.6411	0.6411	8
TPLSM	TPLSM:8	Two-photon laser scanning microscopy:8:0.4102	0.4102	8
TPL	TPL:7|tpl:1|Tpl:1	thromboplastin:9:0.0533	0.0533	9
TPL	TPL:27	total phospholipid:16:0.7261|total phospholipids:11:0.4728	0.7261	27
TPL	TPL:14|Tpl:1	tyrosine phenol-lyase:15:0.8045	0.8045	15
TPM1	TPM1:11	alpha-Tropomyosin:11:0.4348	0.4348	11
TPMP+	TPMP+:21	triphenylmethylphosphonium:21:0.4545	0.4545	21
TPMT	TPMT:11	thiopurine methyl transferase:11:0.6182	0.6182	11
TPMT	TPMT:172	thiopurine methyltransferase:172:0.9722	0.9722	172
TPMT	TPMT:73	Thiopurine S-methyltransferase:73:0.9353	0.9353	73
TPM	TPM:217	topiramate:217:0.6372	0.6372	217
TPM	TPM:34	total particulate matter:34:0.7587	0.7587	34
TPN	TPN:5	total parenteral:5:0.0736	0.0736	5
TPN	TPN:32	total parenteral nutrient:32:0.9072	0.9072	32
TPN	TPN:1964	total parenteral nutrition:1964:0.9789	0.9789	1964
tPO2	tPO2:4|tpO2:3|TPO2:3|TpO2:2	tissue oxygen tension:12:0.7571	0.7571	12
TPOAb	TPOAb:15|TPO-Ab:3|TPO-ab:1|TPO-AB:1|TPOab:1	thyroid peroxidase:21:0.6400	0.6400	21
TPOAb	TPOAb:24|TPO-Ab:16|TPOab:4|TPO-ab:1	thyroid peroxidase antibodies:25:0.4451|thyroid peroxidase antibody:20:0.6259	0.6259	45
TPOAb	TPOAb:8|TPO-ab:2|TPO-Ab:1	thyroperoxidase:11:0.0758	0.0758	11
TPOH	TPOH:10|TpOH:7	tryptophan hydroxylase:17:0.8270	0.8270	17
TPO	TPO:765|Tpo:95|TpO:4|tpo:1	thrombopoietin:865:0.5690	0.5690	865
TPO	TPO:406	thyroid peroxidase:406:0.8850	0.8850	406
TPP+	TPP+:16	lipophilic cation tetraphenylphosphonium:16:0.6748	0.6748	16
TPPII	TPPII:7	tripeptidyl peptidase II:7:0.5926	0.5926	7
TPPase	TPPase:81|TPP-ase:2	thiamine pyrophosphatase:83:0.9081	0.9081	83
TPP-I	TPP-I:10	Tripeptidyl peptidase I:10:0.5856	0.5856	10
TPP	TPP:7	sodium tripolyphosphate:7:0.0692	0.0692	7
TPP	TPP:11	tegmental pedunculopontine nucleus:11:0.5355	0.5355	11
TPP	TPP:14	tetraphenylphosphonium:14:0.0228	0.0228	14
TPP	TPP:41|Tpp:1	thiamin pyrophosphate:42:0.2282	0.2282	42
TPP	TPP:85	thiamine pyrophosphate:85:0.5479	0.5479	85
TPP	TPP:8	three-phase partitioning:8:0.4102	0.4102	8
TpP	TpP:12	thrombus precursor protein:12:0.6182	0.6182	12
TPP	TPP:7	thrust plate prosthesis:7:0.5926	0.5926	7
TPP	TPP:41	Thyrotoxic periodic paralysis:41:0.8224	0.8224	41
TPP	TPP:15	Tolpa Peat Preparation:15:0.6911	0.6911	15
TPP	TPP:16	total plasma protein:16:0.8165	0.8165	16
TPP	TPP:9	transpulmonary pressure:9:0.1690	0.1690	9
TPP	TPP:11	triphenyl phosphate:11:0.6182	0.6182	11
TPP	TPP:18	triphenyl phosphite:18:0.6903	0.6903	18
TPP	TPP:9	triphenylphosphate:9:0.0140	0.0140	9
TPP	TPP:13	triphenylphosphine:13:0.0210	0.0210	13
TPP	TPP:6	tympanometric peak pressure:6:0.2243	0.2243	6
TPQ	TPQ:18	2,4,5-trihydroxyphenylalanine quinone:18:0.3412	0.3412	18
TPQ	TPQ:11	topaquinone:11:0.0552	0.0552	11
TPQ	TPQ:115	Tridimensional Personality Questionnaire:115:0.8896	0.8896	115
TPrA	TPrA:11	tri-n-propylamine:11:0.3600	0.3600	11
TPRI	TPRI:76	total peripheral resistance index:76:0.9180	0.9180	76
TPRT	TPRT:15	reverse transcription:15:0.8045	0.8045	15
TPR	TPR:13	tetratricopeptide:13:0.0115	0.0115	13
TPR	TPR:145	tetratricopeptide repeat:131:0.8524|tetratricopeptide repeats:14:0.6386	0.8524	145
TPR	TPR:9	total peripheral:9:0.6794	0.6794	9
TPR	TPR:627	total peripheral resistance:616:0.9720|Total peripheral resistances:11:0.6182	0.9720	627
TPS1	TPS1:6|tps1:2	trehalose-6-phosphate synthase:8:0.3463	0.3463	8
tPSA	tPSA:22|t-PSA:5|TPSA:3	total prostate-specific antigen:21:0.7291|total prostate specific antigen:9:0.3455	0.7291	30
TPSs	TPSs:10	treatment planning systems:10:0.7103	0.7103	10
TPST	TPST:27	tyrosylprotein sulfotransferase:27:0.8312	0.8312	27
TPS	TPS:9	specific:9:0.0134	0.0134	9
TPS	TPS:6	theta pulse stimulation:6:0.5290	0.5290	6
TPS	TPS:15	thin-plate spline:15:0.4951	0.4951	15
TPS	TPS:6	time to peak shortening:6:0.5290	0.5290	6
TPS	TPS:123|tps:1	tissue polypeptide specific antigen:79:0.9401|tissue polypeptide-specific antigen:45:0.9338	0.9401	124
TPS	TPS:47	Titanium plasma-sprayed:37:0.7492|titanium plasma sprayed:10:0.5856	0.7492	47
TPS	TPS:4|tPS:3	Total protein S:7:0.3524	0.3524	7
TPS	TPS:67	treatment planning system:53:0.9438|treatment planning systems:14:0.7909	0.9438	67
TPS	TPS:6|tps:2	trehalose-6-phosphate synthase:8:0.1471	0.1471	8
TPs	TPs:9	trigger points:9:0.3455	0.3455	9
TPTA	TPTA:21	triphenyltin acetate:21:0.8525	0.8525	21
TPTX	TPTX:169|T-PTX:3|TPTx:1	thyroparathyroidectomized:173:0.7137	0.7137	173
TPTX	TPTX:50|TPTx:1|T-PTX:1	thyroparathyroidectomy:52:0.2116	0.2116	52
TPT	TPT:7	Tactual Performance Test:7:0.3524	0.3524	7
TPT	TPT:51|tpt:1	time to peak tension:52:0.9099	0.9099	52
TPT	TPT:79|Tpt:2	Topotecan:81:0.2326	0.2326	81
TPT	TPT:5	triose phosphate/phosphate translocator:5:0.4422	0.4422	5
TPT	TPT:9	Triphalangeal thumb:9:0.6794	0.6794	9
TPT	TPT:9	triphenyltin chloride:9:0.5470	0.5470	9
TPVR	TPVR:31	total peripheral vascular resistance:31:0.9043	0.9043	31
TPVR	TPVR:16	total pulmonary vascular resistance:16:0.8165	0.8165	16
TPx	TPx:17|TPX:1|Tpx:1	thioredoxin peroxidase:19:0.4405	0.4405	19
TPZ	TPZ:46	tirapazamine:46:0.7759	0.7759	46
TPase	TPase:9	thymidine phosphorylase:9:0.3945	0.3945	9
TPeA	TPeA:17	tetrapentylammonium:17:0.6818	0.6818	17
TPhT	TPhT:17	triphenyltin:17:0.7619	0.7619	17
TP	TP:14	potential:14:0.0040	0.0040	14
Tp	Tp:9|TP:1	potential doubling time:10:0.3867	0.3867	10
TP	TP:10	pregnancy:10:0.0028	0.0028	10
TP	TP:13	protein concentration:13:0.5934	0.5934	13
TP	TP:8	renal transplantation:8:0.2619	0.2619	8
Tp	Tp:6	resistance to trimethoprim:6:0.0666	0.0666	6
TP	TP:10|t-p:1	Tail Pinch:11:0.7357	0.7357	11
TP	TP:18	tea polyphenols:18:0.7539	0.7539	18
Tp	Tp:17|TP:2	temperature:19:0.0056	0.0056	19
TP	TP:16	tender points:16:0.5564	0.5564	16
TP	TP:8	tensor palatini:8:0.4102	0.4102	8
TP	TP:60	terminal protein:60:0.1462	0.1462	60
TP	TP:629|Tp:8|tp:1	testosterone propionate:638:0.9809	0.9809	638
TP	TP:40|Tp:2	theophylline:42:0.0127	0.0127	42
TP	TP:9	thiamphenicol:9:0.0025	0.0025	9
TP	TP:23	ThinPrep:23:0.0068	0.0068	23
TP	TP:9	ThinPrep Pap Test:9:0.6794	0.6794	9
TP	TP:14	threshold pressure:14:0.1944	0.1944	14
TP	TP:17	thrombocytopenia:17:0.0050	0.0050	17
TP	TP:11	thrombocytopenic purpura:11:0.4728	0.4728	11
TP	TP:7|Tp:2	thromboplastin:9:0.0031	0.0031	9
TP	TP:13	thromboxane:13:0.0037	0.0037	13
TP	TP:14	thromboxane A(2) receptor:14:0.6911	0.6911	14
TP	TP:9	thromboxane A2:9:0.6794	0.6794	9
TP	TP:6	thromboxane A2/prostaglandin endoperoxide:6:0.3728	0.3728	6
TP	TP:12	thromboxane A2/prostaglandin H2:12:0.7753	0.7753	12
TP	TP:12	thromboxane A2 receptor:12:0.7571	0.7571	12
TP	TP:11	thromboxane receptor:11:0.0667	0.0667	11
TP	TP:276	thymidine phosphorylase:276:0.9388	0.9388	276
TP	TP:13|Tp:1	thymopoietin:14:0.0040	0.0040	14
TP	TP:15	tibialis posterior:15:0.7096	0.7096	15
TP	TP:10|Tp:5|tp:5|T-P:2	time to peak:12:0.6173|time-to-peak:10:0.0025	0.6173	22
TP	TP:20	tooth pulp:20:0.8525	0.8525	20
TP	TP:9	Torsades de Pointes:9:0.6794	0.6794	9
TP	TP:22|tP:2	Total P:24:0.6767	0.6767	24
TP	TP:13	total pancreatectomy:13:0.7753	0.7753	13
TP	TP:105|T-P:6	total phosphorus:111:0.9571	0.9571	111
TP	TP:50	total power:50:0.7866	0.7866	50
TP	TP:230|Tp:2|tp:1	Total protein:214:0.6367|total proteins:19:0.5732	0.6367	233
TP	TP:7|Tp:1	transit peptide:8:0.1730	0.1730	8
TP	TP:10	transperitoneal:10:0.0028	0.0028	10
Tp	Tp:10|TP:10	Treponema pallidum:20:0.6259	0.6259	20
TP	TP:44	true positive:26:0.8861|true-positive:18:0.0053	0.8861	44
TP	TP:23	tryptophan:23:0.0068	0.0068	23
TP	TP:8	tryptophan pyrrolase:8:0.5006	0.5006	8
TP	TP:10	tube precipitin:10:0.5856	0.5856	10
TP	TP:11|Tp:1	turning point:12:0.2868	0.2868	12
TP	TP:7|Tp:4	Tyrophagus putrescentiae:11:0.6182	0.6182	11
TQI	TQI:9	total quality improvement:9:0.6794	0.6794	9
TQM	TQM:252	Total Quality Management:252:0.9810	0.9810	252
TQ	TQ:27	thymoquinone:27:0.2600	0.2600	27
TQ	TQ:6	Tinnitus Questionnaire:6:0.1320	0.1320	6
TR/TE	TR/TE:11	repetition time/echo time:11:0.7357	0.7357	11
TRADD	TRADD:5	tumor necrosis factor receptor-associated death domain protein:5:0.4422	0.4422	5
TRAF1	TRAF1:11	receptor-associated factor 1:11:0.3495	0.3495	11
TRAF2	TRAF2:30|TRAF-2:3|Traf2:1	TNF receptor-associated factor 2:28:0.5929|TNF receptor-associated factor-2:6:0.2827	0.5929	34
TRAF6	TRAF6:6|Traf6:2	TNF receptor-associated factor 6:8:0.1890	0.1890	8
TRAF6	TRAF6:19|TRAF-6:1	Tumor necrosis factor receptor-associated factor 6:20:0.7044	0.7044	20
TRAF	TRAF:45	tumor necrosis factor receptor-associated factor:45:0.8649	0.8649	45
TRALI	TRALI:94|Trali:1	transfusion-related acute lung injury:95:0.8670	0.8670	95
TRAM	TRAM:23	Transverse rectus abdominis muscle:23:0.8038	0.8038	23
TRAM	TRAM:147	transverse rectus abdominis musculocutaneous:147:0.9470	0.9470	147
TRAM	TRAM:101	transverse rectus abdominis myocutaneous:101:0.9529	0.9529	101
TRAMP	TRAMP:24	transgenic adenocarcinoma of the mouse prostate:24:0.9503	0.9503	24
TRAMP	TRAMP:5	Tyrosine-rich acidic matrix protein:5:0.4422	0.4422	5
TRANCE	TRANCE:9	TNF-related activation-induced cytokine:9:0.1334	0.1334	9
TRANCE	TRANCE:5|trance:1	tumor necrosis factor-related activation-induced cytokine:6:0.4438	0.4438	6
TRAP+	TRAP+:14	tartrate-resistant acid phosphatase-positive:14:0.8045	0.8045	14
TRAP	TRAP:16	antioxidant capacity:16:0.4274	0.4274	16
TRAP	TRAP:442|TrAP:3|TR-AP:1|TRaP:1	tartrate-resistant acid phosphatase:447:0.7925	0.7925	447
TRAP	TRAP:8	tartrate-resistant acid phosphatase activity:8:0.5006	0.5006	8
TRAP	TRAP:248|Trap:1	telomeric repeat amplification protocol:249:0.7756	0.7756	249
TRAP	TRAP:70	thrombin receptor activating peptide:43:0.8590|thrombin receptor-activating peptide:27:0.8903	0.8903	70
TRAP	TRAP:29	thrombin receptor agonist peptide:29:0.8978	0.8978	29
TRAP	TRAP:16	Thrombospondin-related adhesive protein:16:0.6577	0.6577	16
TRAP	TRAP:32	thrombospondin-related anonymous protein:32:0.5841	0.5841	32
TRAP	TRAP:18	Total Radical-Trapping Antioxidant Parameter:18:0.5228	0.5228	18
TRAP	TRAP:27	Total radical-trapping antioxidant potential:27:0.8312	0.8312	27
TRAP	TRAP:16	total reactive antioxidant potential:16:0.8165	0.8165	16
TRAP	TRAP:39	trp RNA-binding attenuation protein:39:0.9237	0.9237	39
TRAP	TRAP:28	twin reversed arterial perfusion:28:0.7905	0.7905	28
TRAS	TRAS:31	transplant renal artery stenosis:31:0.8090	0.8090	31
TRAb	TRAb:7|TRAB:1|Tr-Ab:1	autoantibodies:9:0.0357	0.0357	9
TRAb	TRAb:32|TRab:1|TR-Ab:1	thyrotropin receptor antibodies:18:0.1552|thyrotropin receptor antibody:16:0.1109	0.1552	34
TRAb	TRAb:7	TSH receptor:7:0.3829	0.3829	7
TRAb	TRAb:60|TRab:4|TRAB:4|TR-ab:1	TSH receptor antibody:38:0.4596|TSH receptor antibodies:31:0.3907	0.4596	69
tra	tra:72|t-RA:46|TRA:7|T-RA:3	all-trans-retinoic acid:71:0.3665|all-trans retinoic acid:57:0.8097	0.8097	128
TRA	TRA:6	repeat array:6:0.1148	0.1148	6
TRA	TRA:32	theory of reasoned action:32:0.8145	0.8145	32
TRA	TRA:5	time-reversing array:5:0.0517	0.0517	5
tra	tra:32	transfer:32:0.0687	0.0687	32
tra	tra:42|Tra:5|TRA:2	transformer:49:0.1064	0.1064	49
tra	tra:15	transversus abdominis:15:0.8045	0.8045	15
TRA	TRA:8	traumatic rupture of the aorta:8:0.6411	0.6411	8
TRA	TRA:8	Traumatic rupture of the thoracic aorta:8:0.6411	0.6411	8
TRBF	TRBF:12	total renal blood flow:12:0.6460	0.6460	12
TRCHII	TRCHII:7	tanned red cell hemagglutination inhibition immunoassay:7:0.5926	0.5926	7
TRCs	TRCs:34	taste receptor cells:34:0.8644	0.8644	34
TRC	TRC:8	total renin concentration:8:0.6411	0.6411	8
TRC	TRC:11	total ridge count:11:0.7357	0.7357	11
TRD	TRD:9	traction retinal detachment:9:0.1809	0.1809	9
TRD	TRD:11	tractional retinal detachment:11:0.2764	0.2764	11
TRD	TRD:12	transcriptional repression domain:12:0.4557	0.4557	12
TRD	TRD:25|trd:1	Transmission ratio distortion:26:0.8861	0.8861	26
TRD	TRD:46	treatment-resistant depression:34:0.5132|treatment resistant depression:12:0.7753	0.7753	46
TRD	TRD:11|TrD:2	Trinidad donkey:13:0.7753	0.7753	13
TREM	TREM:1	triggering receptor expressed by myeloid cells:1:0.4422	0.4422	1
tren	tren:11|TREN:2|Tren:1	tris(2-aminoethyl)amine:14:0.6190	0.6190	14
TREs	TREs:56	thyroid hormone response elements:56:0.9162	0.9162	56
TRFC	TRFC:4|T-RFC:1	total rosette forming cells:5:0.4422	0.4422	5
TRFIA	TRFIA:8|TR-FIA:3	time-resolved fluorescence immunoassay:11:0.6182	0.6182	11
TR-FIA	TR-FIA:93|TRFIA:11|tr-FIA:2|TrFIA:1	time-resolved fluoroimmunoassay:107:0.9039	0.9039	107
T-RFLP	T-RFLP:96|TRFLP:10	terminal restriction fragment length polymorphism:106:0.9551	0.9551	106
TRFs	TRFs:26|T-RFs:10|tRFs:1	terminal restriction fragments:37:0.8051	0.8051	37
TRF	TRF:21	restriction fragments:21:0.8594	0.8594	21
TRF	TRF:56	T cell-replacing factor:29:0.8422|T-cell replacing factor:14:0.2758|T cell replacing factor:13:0.6701	0.8422	56
TRF	TRF:21	terminal renal failure:21:0.8594	0.8594	21
TRF	TRF:55|T-RF:7	terminal restriction fragment:62:0.5718	0.5718	62
TRF	TRF:30	thyrotropin-releasing factor:30:0.1143	0.1143	30
TRF	TRF:11	time-resolved fluorescence:11:0.5355	0.5355	11
TRF	TRF:12	tocotrienol-rich fraction:12:0.5664	0.5664	12
TRF	TRF:39|Trf:34|trf:2	transferrin:75:0.1296	0.1296	75
TRG	TRG:8	receptor gamma:8:0.2327	0.2327	8
TRG	TRG:9	regression grade:9:0.6794	0.6794	9
TRG	TRG:5|TrG:3	trigeminal ganglion:8:0.1591	0.1591	8
TRG	TRG:9	trigeminal root ganglion:9:0.5470	0.5470	9
TRH-LI	TRH-LI:13	TRH-like immunoreactivity:13:0.5335	0.5335	13
TRH-R	TRH-R:5|TRHR:2	TRH receptors:7:0.3524	0.3524	7
TRH-ST	TRH-ST:4|TRHST:3	hormone stimulation test:7:0.3524	0.3524	7
TRH-IR	TRH-IR:6|TRH-ir:2	TRH immunoreactivity:8:0.2987	0.2987	8
TRH	TRH:14	protirelin:14:0.0030	0.0030	14
trh	trh:6|TRH:1	thermostable direct hemolysin-related hemolysin:7:0.5926	0.5926	7
TRH	TRH:116	thyroliberin:116:0.0265	0.0265	116
TRH	TRH:158	thyrotrophin releasing hormone:158:0.1300	0.1300	158
TRH	TRH:3406|trh:3	Thyrotropin-releasing hormone:2589:0.6259|thyrotropin releasing hormone:803:0.7467|thyrotropin-releasing-hormone:17:0.0037	0.7467	3409
trh	trh:8|Trh:1	trachealess:9:0.0018	0.0018	9
TRH	TRH:6|TrH:4	tryptophan hydroxylase:10:0.7103	0.7103	10
TR-IFMA	TR-IFMA:18|TRIFMA:6|trIFMA:2|TrIFMA:1|Tr-IFMA:1	time-resolved immunofluorometric assay:28:0.8369	0.8369	28
TRIF	TRIF:12	inducing IFN-beta:12:0.5050	0.5050	12
TRIG	TRIG:8|Trig:6	triglycerides:14:0.4333	0.4333	14
TRISS	TRISS:38	Trauma and Injury Severity Score:38:0.7995	0.7995	38
TRITC	TRITC:19|Tritc:1	tetramethylrhodamine isothiocyanate:20:0.3492	0.3492	20
TRLFS	TRLFS:8	Time-resolved laser-induced fluorescence spectroscopy:8:0.6411	0.6411	8
TRLs	TRLs:32	lipoproteins:32:0.8611	0.8611	32
TRL	TRL:94	triglyceride-rich lipoproteins:50:0.6348|triglyceride-rich lipoprotein:44:0.4664	0.6348	94
TRM	TRM:147	transplant-related mortality:147:0.5150	0.5150	147
TRM	TRM:57	treatment-related mortality:57:0.1691	0.1691	57
TRNG	TRNG:12	Neisseria gonorrhoeae:12:0.3524	0.3524	12
trNOE	TRNOE:3|trNOE:3|tr-NOE:1	transferred NOE:7:0.3524	0.3524	7
TRNOE	TRNOE:20|trNOE:6|TR-NOE:1|TrNOE:1	Transferred nuclear Overhauser effect:28:0.8941	0.8941	28
TRNOE	TRNOE:8|trNOE:1	Transferred nuclear Overhauser enhancement:9:0.6794	0.6794	9
TRN	TRN:65	thalamic reticular nucleus:65:0.9541	0.9541	65
TROSY	TROSY:10	Transverse relaxation-optimized spectroscopy:10:0.5856	0.5856	10
TRO	TRO:45|Tro:12	Troglitazone:57:0.5895	0.5895	57
TRP-1	TRP-1:53|TRP1:11|Trp-1:1	tyrosinase-related protein-1:43:0.7572|Tyrosinase-related protein 1:22:0.6531	0.7572	65
TRP-2	TRP-2:35|TRP2:20|Trp2:1|Trp-2:1	tyrosinase-related protein 2:30:0.8032|Tyrosinase-related protein-2:27:0.8312	0.8312	57
TRPCs	TRPCs:10	transient receptor potential channels:10:0.7103	0.7103	10
TRPL	TRPL:5|trpl:3|TrpL:1	transient receptor potential-like:9:0.6794	0.6794	9
TRPM-2	TRPM-2:13|TRPM2:1	testosterone-repressed prostate message-2:14:0.5589	0.5589	14
TRPs	TRPs:12	tachykinin-related peptides:12:0.5664	0.5664	12
TRPS	TRPS:8	tricho-rhino-phalangeal syndrome:8:0.2327	0.2327	8
TrPs	TrPs:9	trigger points:9:0.6794	0.6794	9
TRPV1	TRPV1:7	capsaicin receptor:7:0.1591	0.1591	7
TRPV1	TRPV1:22	transient receptor potential vanilloid 1:22:0.8657	0.8657	22
TRPV1	TRPV1:7	transient receptor potential vanilloid receptor 1:7:0.5926	0.5926	7
TRPV1	TRPV1:8|TRPV-1:1	transient receptor potential vanilloid type 1:9:0.6794	0.6794	9
TRPV1	TRPV1:10	vanilloid receptor:10:0.2643	0.2643	10
TRPV1	TRPV1:11	vanilloid receptor-1:11:0.7357	0.7357	11
TRPV4	TRPV4:7	transient receptor potential vanilloid 4:7:0.5926	0.5926	7
TRQ	TRQ:12	tritoqualine:12:0.6875	0.6875	12
TrR	TrR:4|Trr:2|TRR:2|trr:1	Thioredoxin reductase:9:0.4587	0.4587	9
TRS	TRS:11	Rating Scale:11:0.4232	0.4232	11
TRS	TRS:16|TRs:2	repeat sequences:11:0.4232|repeat sequence:7:0.1850	0.4232	18
TRs	TRs:7	tandem repeats:7:0.0732	0.0732	7
TRs	TRs:13|trs:1	terminal repeats:14:0.3383	0.3383	14
trs	trs:11|TRs:4|TRS:3	terminal resolution site:18:0.8365	0.8365	18
TRs	TRs:148	Thyroid hormone receptors:148:0.9798	0.9798	148
TRS	TRS:5	time-resolved spectroscopy:5:0.0902	0.0902	5
TRS	TRS:12	transrectal sonography:12:0.7571	0.7571	12
TRS	TRS:9	treatment-resistant schizophrenia:9:0.5470	0.5470	9
TRS	TRS:24	tubuloreticular structures:24:0.6767	0.6767	24
TRTV	TRTV:13	turkey rhinotracheitis virus:13:0.7753	0.7753	13
TRT	TRT:21	thoracic radiation therapy:21:0.7865	0.7865	21
TRT	TRT:27	thoracic radiotherapy:27:0.8312	0.8312	27
TRT	TRT:18	Tinnitus retraining therapy:18:0.8365	0.8365	18
TRT	TRT:6|Trt:3|trt:1	treatment:10:0.0446	0.0446	10
TRT	TRT:17	turkey rhinotracheitis:17:0.8270	0.8270	17
TRUS	TRUS:294	Transrectal ultrasound:294:0.9193	0.9193	294
TRUS	TRUS:9	transrectal US:9:0.3945	0.3945	9
TRV	TRV:44	tobacco rattle virus:44:0.9323	0.9323	44
Trx2	Trx-2:4|Trx2:4|TRX-2:1	Thioredoxin-2:9:0.3478	0.3478	9
Trx	Trx:217|TRX:193|trx:3|TRx:1|TrX:1	thioredoxin:396:0.7996|thioredoxins:19:0.0364	0.7996	415
trx	trx:22|TRX:11|Trx:4	trithorax:37:0.0729	0.0729	37
TRY	TRY:16|Try:7	tryptophan:23:0.3667	0.3667	23
TRZ	TRZ:12	trazodone:12:0.2245	0.2245	12
TRZ	TRZ:21|Trz:1	triazolam:22:0.4286	0.4286	22
TR-beta	TR-beta:6|TRbeta:4	thyroid hormone receptor:10:0.6182	0.6182	10
TRbeta	TRbeta:36|TR-beta:4	thyroid hormone receptor beta:29:0.8978|thyroid hormone receptor-beta:11:0.7357	0.8978	40
TR	TR:11	human transferrin receptor:11:0.0667	0.0667	11
TR	TR:20	ratio:20:0.0076	0.0076	20
Tr	Tr:31|tr:24|TR:12	rectal temperature:67:0.7431	0.7431	67
TR	TR:9	recurrence:9:0.0032	0.0032	9
tr	tr:11|TR:7|Tr:7	regulatory T:25:0.7679	0.7679	25
TR	TR:14	repetition:14:0.0052	0.0052	14
TR	TR:215	repetition time:187:0.7279|repetition times:28:0.5269	0.7279	215
TR	TR:14|tr:1	resistance:15:0.0056	0.0056	15
TR	TR:7|Tr:1|tr:1	resistant:9:0.0032	0.0032	9
TR	TR:14	response:14:0.0052	0.0052	14
tR	tR:5|tr:3	retention times:8:0.0548	0.0548	8
Tr	Tr:18|tr:6|TR:2	T regulatory:26:0.7760	0.7760	26
TR	TR:16	tandem repeat:10:0.0807|tandem repeats:6:0.0731	0.0807	16
TR	TR:18	taste reactivity:18:0.8365	0.8365	18
tr	tr:8|TR:1	temperature-resistant:9:0.0032	0.0032	9
TR	TR:36|tr:1	terminal repeat:27:0.4305|terminal repeats:10:0.2873	0.4305	37
TR	TR:10	Texas red:10:0.2643	0.2643	10
TR	TR:6	Thiazin red:6:0.0666	0.0666	6
TR	TR:80	Thioredoxin reductase:80:0.5132	0.5132	80
TR	TR:14	thyroid hormone:14:0.7909	0.7909	14
TR	TR:322	thyroid hormone receptor:275:0.9302|Thyroid hormone receptors:47:0.9366	0.9366	322
TR	TR:18	Tiazofurin:18:0.0068	0.0068	18
TR	TR:9	time-resolved:9:0.0032	0.0032	9
tr	tr:6|TR:3	trachea:9:0.0032	0.0032	9
TR	TR:21|tr:7	trained:28:0.0108	0.0108	28
TR	TR:10|tr:5	training:15:0.0056	0.0056	15
tr	tr:9|TR:7	transferrin:16:0.0060	0.0060	16
TR	TR:7	transitional region:7:0.1211	0.1211	7
TR	TR:14|tr:2	transport rate:16:0.2154	0.2154	16
TR	TR:10	trapezius:10:0.0036	0.0036	10
TR	TR:15	treadmill running:15:0.5818	0.5818	15
tr	tr:10|Tr:6	trembler:16:0.0060	0.0060	16
TR	TR:213	tricuspid regurgitation:213:0.8964	0.8964	213
TR	TR:6	trp repressor:6:0.2243	0.2243	6
TR	TR:42	trypanothione reductase:42:0.2301	0.2301	42
TR	TR:5|tr:4	trypsin:9:0.0032	0.0032	9
TR	TR:5|tr:1	Turnover rates:6:0.1838	0.1838	6
TS-DHFR	TS-DHFR:10	thymidylate synthase-dihydrofolate reductase:10:0.7103	0.7103	10
tSAH	tSAH:9|TSAH:6|t-SAH:1	traumatic subarachnoid hemorrhage:16:0.7261	0.7261	16
TSAT	TSAT:37|Tsat:3|TSat:3|tSAT:1	transferrin saturation:44:0.8335	0.8335	44
TSAbs	TSAbs:10	thyroid-stimulating antibodies:10:0.3867	0.3867	10
TSAb	TSAb:5	stimulating autoantibodies:5:0.1132	0.1132	5
TSAb	TSAb:4|TSAB:2	thyroid stimulating:6:0.1543	0.1543	6
TSAb	TSAb:249|TSAB:8|TSab:8|TsAb:3|TS-Ab:2|TS-AB:1|TS-ab:1	thyroid-stimulating antibody:86:0.4586|thyroid stimulating antibody:64:0.9033|thyroid stimulating antibodies:63:0.8283|thyroid-stimulating antibodies:59:0.3417	0.9033	272
TSA	TSA:9	analysis:9:0.0164	0.0164	9
TSA	TSA:6	thyroid-stimulating activity:6:0.0731	0.0731	6
TSA	TSA:12	Total shoulder arthroplasty:12:0.7571	0.7571	12
TSA	TSA:70	total sialic acid:70:0.8573	0.8573	70
TSA	TSA:10	transition state analog:5:0.4422|transition-state analog:5:0.0902	0.4422	10
TSA	TSA:17	transition state analogue:9:0.6794|transition-state analogue:8:0.1730	0.6794	17
TSA	TSA:38	tryptic soy agar:38:0.4384	0.4384	38
TSA	TSA:6|Tsa:1	type-specific antigen:7:0.1329	0.1329	7
TSA	TSA:42	tyramide signal amplification:42:0.8867	0.8867	42
TSBAb	TSBAb:11|TSBab:1|TSBAB:1	blocking antibodies:13:0.2532	0.2532	13
TSBAb	TSBAb:20|TSBAB:1	thyroid stimulation blocking antibody:21:0.8594	0.8594	21
TSB	TSB:33	Total serum bilirubin:33:0.8196	0.8196	33
TSB	TSB:70	tryptic soy broth:70:0.4395	0.4395	70
TSB	TSB:54	Trypticase soy broth:54:0.3188	0.3188	54
TSC2	TSC2:11|Tsc2:9|TSC-2:1	tuberous sclerosis:21:0.7865	0.7865	21
TSC2	TSC2:27|Tsc2:11|Tsc-2:8	tuberous sclerosis 2:37:0.9197|tuberous sclerosis-2:9:0.6794	0.9197	46
Tsc2	Tsc2:6|TSC2:5	tuberous sclerosis gene:11:0.7357	0.7357	11
TSCA	TSCA:24	Toxic Substances Control Act:24:0.8768	0.8768	24
TSCE	TSCE:14	clonal expansion:14:0.7909	0.7909	14
TSCM	TSCM:17	tandem scanning confocal microscopy:17:0.8270	0.8270	17
TSCPC	TSCPC:14	transscleral cyclophotocoagulation:14:0.5589	0.5589	14
TSCS	TSCS:24	Tennessee Self-Concept Scale:24:0.8768	0.8768	24
TSCs	TSCs:7	Terminal Schwann cells:7:0.5926	0.5926	7
TSC	TSC:8	sulfur colloid:8:0.2327	0.2327	8
TSC	TSC:11	thiazide-sensitive Na-Cl cotransporter:11:0.5355	0.5355	11
TSC	TSC:14	thiosemicarbazide:14:0.0207	0.0207	14
TSC	TSC:8	thymic stromal cells:8:0.5006	0.5006	8
TSC	TSC:13	total serum cholesterol:13:0.7753	0.7753	13
TSC	TSC:123|TSc:1	tuberous sclerosis:124:0.9616	0.9616	124
TSC	TSC:234	tuberous sclerosis complex:234:0.9872	0.9872	234
TSD	TSD:76	Tay-Sachs disease:76:0.9000	0.9000	76
TSD	TSD:33	temperature-dependent sex determination:33:0.6976	0.6976	33
TSD	TSD:96	Total sleep deprivation:96:0.9200	0.9200	96
TSEBT	TSEBT:14	total skin electron beam therapy:14:0.7909	0.7909	14
TSEI	TSEI:10	total skin electron irradiation:10:0.7103	0.7103	10
TSEPs	TSEPs:9	somatosensory evoked potentials:9:0.6794	0.6794	9
TSEP	TSEP:5	trigeminal somatosensory evoked potential:5:0.2818	0.2818	5
TSET	TSET:11	Total Skin Electron Therapy:11:0.7357	0.7357	11
TSEs	TSEs:213	transmissible spongiform encephalopathies:213:0.9628	0.9628	213
TsF	TsF:21|TSF:1	suppressor factors:22:0.3913	0.3913	22
TsF	TsF:13|TSF:3	T suppressor factor:16:0.2362	0.2362	16
tsf	tsf:19|TSF:1	Temperature-sensitive folding:20:0.6812	0.6812	20
TSF	TSF:13	Triceps Skin Fold:13:0.5934	0.5934	13
TSF	TSF:36	triceps skinfold:36:0.8336	0.8336	36
TSF	TSF:40	triceps skinfold thickness:40:0.8525	0.8525	40
TSF	TSF:6	Twelve-Step Facilitation:6:0.1320	0.1320	6
TSGs	TSGs:74	tumor suppressor genes:74:0.6489	0.6489	74
TSG	TSG:11	thapsigargin:11:0.0422	0.0422	11
TSG	TSG:111|TSg:1	tumor suppressor gene:76:0.6479|tumor suppressor genes:36:0.7183	0.7183	112
Tsg	Tsg:15|TSG:7|tsg:3	twisted gastrulation:25:0.8816	0.8816	25
TSH-R	TSH-R:12|TSHR:9	TSH-receptor:15:0.0246|TSH receptors:6:0.2113	0.2113	21
TSH	TSH:12	anti-thyrotropin:12:0.0021	0.0021	12
tsh	tsh:7	gene teashirt:7:0.0655	0.0655	7
TSH	TSH:38	serum thyrotrophin:38:0.0839	0.0839	38
tsh	tsh:5|Tsh:4	temperature-sensitive hemagglutinin:9:0.6794	0.6794	9
TSH	TSH:2438|tsh:2|TSh:1	thyroid-stimulating hormone:1454:0.5371|thyroid stimulating hormone:978:0.9617|Thyroid-Stimulating-Hormone:9:0.0015	0.9617	2441
TSH	TSH:11	thyrotropic:11:0.0019	0.0019	11
TSH	TSH:2181	thyrotropin:2181:0.4073	0.4073	2181
TSH	TSH:10	thyrotropine:10:0.0017	0.0017	10
TSIR	TSIR:15|TS-IR:1	inhibition rate:16:0.8165	0.8165	16
TSI	TSI:6	thromboxane synthetase inhibitor:6:0.2827	0.2827	6
TSI	TSI:90	thyroid stimulating immunoglobulins:28:0.8941|thyroid-stimulating immunoglobulins:24:0.2978|thyroid-stimulating immunoglobulin:21:0.3643|thyroid stimulating immunoglobulin:17:0.8270	0.8941	90
TSI	TSI:9	tobramycin solution for inhalation:9:0.6794	0.6794	9
TSI	TSI:13	transferrin saturation index:13:0.5934	0.5934	13
TSLP	TSLP:33	thymic stromal lymphopoietin:33:0.9100	0.9100	33
TSLS	TSLS:29	Toxic shock-like syndrome:29:0.8978	0.8978	29
TSMCs	TSMCs:13	canine cultured tracheal smooth muscle cells:13:0.5934	0.5934	13
TSMCs	TSMCs:8	cultured canine tracheal smooth muscle cells:8:0.4102	0.4102	8
TSM	TSM:10	microscope:10:0.0393	0.0393	10
TSM	TSM:10	Thickness shear mode:10:0.7103	0.7103	10
TSM	TSM:125	tracheal smooth muscle:125:0.9619	0.9619	125
TSNAs	TSNAs:13	tobacco-specific nitrosamines:13:0.6701	0.6701	13
TSNA	TSNA:27	tobacco-specific N-nitrosamines:27:0.8312	0.8312	27
TSNA	TSNA:30	tobacco-specific nitrosamines:30:0.8032	0.8032	30
TSNC	TSNC:16	trigeminal sensory nuclear complex:16:0.8165	0.8165	16
TSO	TSO:30	trans-stilbene oxide:30:0.6736	0.6736	30
TSP/HAM	TSP/HAM:7	tropical spastic paraparesis:7:0.3524	0.3524	7
TSP/HAM	TSP/HAM:8	tropical spastic paraparesis/HTLV-1 associated myelopathy:8:0.6411	0.6411	8
TSP/HAM	TSP/HAM:26	tropical spastic paraparesis/HTLV-I-associated myelopathy:26:0.8251	0.8251	26
TSP1	TSP1:7|TSP-1:6	thrombospondin:13:0.0295	0.0295	13
TSP-1	TSP-1:247|TSP1:104|tsp-1:2|Tsp-1:2	thrombospondin-1:300:0.7346|thrombospondin 1:55:0.6593	0.7346	355
TSP2	TSP2:26|TSP-2:10	thrombospondin-2:20:0.4419|thrombospondin 2:16:0.7261	0.7261	36
TSPs	TSPs:17	thrombospondins:17:0.3265	0.3265	17
Tsp	Tsp:5|tsp:1	tail-specific protease:6:0.2243	0.2243	6
TSP	TSP:11	temperature-sensitive period:11:0.1845	0.1845	11
TSP	TSP:18	thermospray:18:0.0143	0.0143	18
TSP	TSP:323|Tsp:6|tsp:2	thrombospondin:331:0.2767	0.2767	331
TSP	TSP:18	Thrombospondin-1:18:0.0143	0.0143	18
TSP	TSP:21|tsp:1	Total serum protein:22:0.8657	0.8657	22
TSP	TSP:33	total suspended particles:33:0.8605	0.8605	33
TSP	TSP:89	Total suspended particulates:52:0.9427|total suspended particulate:37:0.9197	0.9427	89
TSP	TSP:16	Total suspended particulate matter:16:0.8165	0.8165	16
tsp	tsp:192|TSP:5	Transcription start point:135:0.8160|transcription start points:62:0.6997	0.8160	197
TSP	TSP:12	traveling salesman problem:12:0.4557	0.4557	12
TSP	TSP:29	Trisodium phosphate:29:0.6392	0.6392	29
TSP	TSP:103	tropical spastic paraparesis:103:0.6534	0.6534	103
TSRH	TSRH:13	Texas Scottish Rite Hospital:13:0.6701	0.6701	13
TSRs	TSRs:8	thrombospondin type 1 repeats:8:0.5006	0.5006	8
TSR	TSR:7	thrombospondin type 1 repeat:7:0.4438	0.4438	7
TSR	TSR:16	total systemic resistance:16:0.8165	0.8165	16
TSSA	TSSA:6	surface antigen:6:0.2243	0.2243	6
TSSE	TSSE:7	transmissible subacute spongiform encephalopathies:7:0.5926	0.5926	7
TSST	TSST:12	toxic shock syndrome toxin:12:0.7571	0.7571	12
TSST	TSST:17	Trier Social Stress Test:17:0.8270	0.8270	17
TSST-1	TSST-1:33	toxic shock syndrome toxin:33:0.8563	0.8563	33
TSST-1	TSST-1:347|TSST1:7	Toxic shock syndrome toxin-1:224:0.9646|toxic shock syndrome toxin 1:130:0.9772	0.9772	354
TSSs	TSSs:10	start sites:10:0.5856	0.5856	10
TSS	TSS:73	total suspended solids:73:0.9353	0.9353	73
TSS	TSS:26	total symptom score:26:0.8251	0.8251	26
TSS	TSS:262	toxic shock syndrome:262:0.9756	0.9756	262
TSS	TSS:44|tss:3	transcription start site:33:0.6111|transcription start sites:14:0.4709	0.6111	47
TSS	TSS:26	transsphenoidal surgery:26:0.8251	0.8251	26
TSTA	TSTA:65	tumor-specific transplantation antigen:44:0.6810|tumor-specific transplantation antigens:21:0.5435	0.6810	65
TSTGF	TSTGF:10	thymic stroma-derived T cell growth factor:10:0.6794	0.6794	10
TSTs	TSTs:14	tuberculin skin tests:14:0.7909	0.7909	14
TST	TST:19	tail skin temperature:19:0.7658	0.7658	19
TST	TST:19	Testosterone:19:0.0326	0.0326	19
TST	TST:107	total sleep time:107:0.9555	0.9555	107
tst	tst:4|TST:3	toxic shock syndrome toxin:7:0.5926	0.5926	7
TST	TST:5	transition state theory:5:0.4422	0.4422	5
TST	TST:11	triceps skinfold thickness:11:0.6182	0.6182	11
TST	TST:16	triple stimulation technique:16:0.8165	0.8165	16
TST	TST:161	tuberculin skin test:153:0.9401|Tuberculin skin tests:8:0.6411	0.9401	161
TST	TST:23	tuberculin skin testing:23:0.8715	0.8715	23
TSVR	TSVR:12	total systemic vascular resistance:12:0.7571	0.7571	12
TSWV	TSWV:16	tomato spotted wilt tospovirus:16:0.6911	0.6911	16
TSWV	TSWV:82	Tomato spotted wilt virus:82:0.9631	0.9631	82
TT4	TT4:15|tT4:2	total thyroxin:17:0.7407	0.7407	17
TT4	TT4:93|tT4:9|t-T4:1	Total thyroxine:103:0.8279	0.8279	103
TTAB	TTAB:17	tetradecyltrimethylammonium bromide:17:0.4035	0.4035	17
tTA	tTA:15	tetracycline-controlled transactivator:15:0.1316	0.1316	15
TTA	TTA:42	tetradecylthioacetic acid:42:0.7995	0.7995	42
tTA	tTA:6	transactivator protein:6:0.2243	0.2243	6
TTA	TTA:7	transtibial amputation:7:0.3524	0.3524	7
TTA	TTA:36	transtracheal aspiration:36:0.8336	0.8336	36
TTCA	TTCA:37	2-thiothiazolidine-4-carboxylic acid:37:0.6250	0.6250	37
TTCP	TTCP:21	tetracalcium phosphate:21:0.7291	0.7291	21
TTCs	TTCs:9	transnational tobacco companies:9:0.6794	0.6794	9
TTC	TTC:100	2,3,5-triphenyltetrazolium chloride:100:0.2419	0.2419	100
TTC	TTC:64	triphenyl tetrazolium chloride:64:0.5955	0.5955	64
TTC	TTC:117	triphenyltetrazolium chloride:117:0.2898	0.2898	117
TTDE	TTDE:36	transthoracic Doppler echocardiography:36:0.9174	0.9174	36
TTD	TTD:7	thought translation device:7:0.5926	0.5926	7
TTD	TTD:6	time to detection:6:0.2243	0.2243	6
TTD	TTD:92	Trichothiodystrophy:92:0.4194	0.4194	92
TTE	TTE:60	transthoracic:60:0.1308	0.1308	60
TTE	TTE:18	transthoracic echocardiographic:18:0.6903	0.6903	18
TTE	TTE:260	transthoracic echocardiography:260:0.8710	0.8710	260
TTF-1	TTF-1:231|TTF1:7|Ttf1:2	thyroid transcription factor-1:170:0.9538|thyroid transcription factor 1:70:0.9326	0.9538	240
TTF-2	TTF-2:6|TTF2:1	Thyroid transcription factor-2:7:0.3524	0.3524	7
TTFA	TTFA:19	thenoyltrifluoroacetone:19:0.5143	0.5143	19
TTFCA	TTFCA:9	Total Triterpenic fraction of Centella Asiatica:9:0.6794	0.6794	9
TTFD	TTFD:13	thiamine tetrahydrofurfuryl disulfide:13:0.5335	0.5335	13
TTF	TTF:32	tetrathiafulvalene:32:0.1667	0.1667	32
TTF	TTF:98	time to treatment failure:98:0.9359	0.9359	98
TTGE	TTGE:43	temporal temperature gradient gel electrophoresis:43:0.9308	0.9308	43
tTG	tTG:185|tTg:13|TTG:9|t-TG:1|TTg:1	Tissue transglutaminase:209:0.8527	0.8527	209
TTH	TTH:55|T-TH:1	Tension-type headache:56:0.8254	0.8254	56
Tth	Tth:12	Thermus thermophilus:12:0.6460	0.6460	12
TTH	TTH:26	thyrotropic hormone:26:0.6645	0.6645	26
TTI	TTI:56	tension time index:32:0.8145|tension-time index:24:0.2273	0.8145	56
TTI	TTI:24	transthoracic impedance:24:0.8115	0.8115	24
TTJV	TTJV:7	transtracheal jet ventilation:7:0.3524	0.3524	7
TTKG	TTKG:11	transtubular potassium concentration gradient:11:0.7357	0.7357	11
TTKG	TTKG:8	transtubular potassium gradient:8:0.5006	0.5006	8
TTMS	TTMS:9	3-[2-(2,4,6-trimethylphenyl)thioethyl]-4-methylsydnone:9:0.4444	0.4444	9
TTM	TTM:8	tensor tympani muscle:8:0.6411	0.6411	8
TTM	TTM:36	Tetrathiomolybdate:36:0.1786	0.1786	36
TTM	TTM:12	total tumor mass:12:0.7571	0.7571	12
TTM	TTM:63	Transtheoretical Model:63:0.9253	0.9253	63
TTM	TTM:16	trichotillomania:16:0.0816	0.0816	16
TTN	TTN:10	transient tachypnea of the newborn:10:0.7357	0.7357	10
TTN	TTN:7	transient tachypnoea of the newborn:7:0.6411	0.6411	7
TTN	TTN:10	triakontatetraneuropeptide:10:0.1552	0.1552	10
TTO	TTO:21	Tea tree oil:21:0.8657	0.8657	21
TTO	TTO:9	time to occlusion:9:0.5470	0.5470	9
TTO	TTO:8	Time Trade Off:8:0.6411	0.6411	8
TTO	TTO:18	time tradeoff:18:0.8365	0.8365	18
TTP-HUS	TTP-HUS:23	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:23:0.8657	0.8657	23
TTP/HUS	TTP/HUS:14	thrombotic thrombocytopenic purpura/hemolytic uremic syndrome:14:0.7909	0.7909	14
TTP	TTP:10	protein tristetraprolin:10:0.0704	0.0704	10
TTP	TTP:9	thiamin triphosphate:9:0.0758	0.0758	9
TTP	TTP:13	thiamine triphosphate:13:0.1599	0.1599	13
TTP	TTP:766	thrombotic thrombocytopenic purpura:766:0.9724	0.9724	766
TTP	TTP:12	thymidine triphosphate:12:0.1379	0.1379	12
TTP	TTP:58|ttp:4|TtP:1|T-t-p:1	time to peak:34:0.8644|time-to-peak:30:0.0194	0.8644	64
ttp	ttp:6|TTP:2	time to peak contraction:8:0.5470	0.5470	8
TTP	TTP:15	time to peak tension:15:0.8045	0.8045	15
TTP	TTP:30	time to pregnancy:30:0.8422	0.8422	30
TTP	TTP:219|TtP:1	Time to progression:220:0.6594	0.6594	220
TTP	TTP:53	time to tumor progression:53:0.9147	0.9147	53
TTP	TTP:8	Tolpa Torf Preparation:8:0.5006	0.5006	8
TTQ	TTQ:46	tryptophan tryptophylquinone:46:0.9353	0.9353	46
TTSSs	TTSSs:18	Type III secretion systems:18:0.8365	0.8365	18
TTSs	TTSs:11	temporary threshold shifts:11:0.7357	0.7357	11
TTSS	TTSS:151	type III secretion system:136:0.9780|type III secretion systems:15:0.8045	0.9780	151
TTS	TTS:18	Tarsal tunnel syndrome:18:0.8365	0.8365	18
TTS	TTS:183	Temporary threshold shift:142:0.9357|Temporary threshold shifts:41:0.8867	0.9357	183
TTS	TTS:84	transdermal therapeutic system:67:0.9296|transdermal therapeutic systems:17:0.7407	0.9296	84
TTS	TTS:8	twin-to-twin transfusion syndrome:8:0.1895	0.1895	8
TTS	TTS:36	type III secretion:36:0.8716	0.8716	36
TTTS	TTTS:85	twin-twin transfusion syndrome:85:0.5526	0.5526	85
TTT	TTT:5	tear thinning time:5:0.4422	0.4422	5
TTT	TTT:7	thymol turbidity test:7:0.5926	0.5926	7
TTT	TTT:111	Transpupillary thermotherapy:111:0.9432	0.9432	111
TTV	TTV:5	Total tumor volume:5:0.4422	0.4422	5
TTW	TTW:11	total tissue water:11:0.7357	0.7357	11
TTX-R	TTX-R:21|TTX-r:2|TTXr:2	TTX-resistant:25:0.1875	0.1875	25
TTx	TTx:4|TTX:3|Ttx:2	tetanus toxin:9:0.6794	0.6794	9
TTX	TTX:1867|TTx:8	tetrodotoxin:1875:0.9645	0.9645	1875
TTase	TTase:19	thioltransferase:19:0.9000	0.9000	19
TT	TT:4|Tt:1	breath duration:5:0.1132	0.1132	5
TT	TT:10	cell line:10:0.5856	0.5856	10
T-T	T-T:5|TT:3	cis-syn thymine-thymine:8:0.1004	0.1004	8
TT	TT:10|tt:1	genotype:11:0.0045	0.0045	11
TT	TT:8	homozygous:8:0.0040	0.0040	8
TT	TT:7	talar tilt:7:0.3524	0.3524	7
TT	TT:6	test treatment:6:0.1320	0.1320	6
TT	TT:10	testicular torsion:10:0.4587	0.4587	10
TT	TT:53|tt:4|Tt:2	tetanus toxin:59:0.8731	0.8731	59
TT	TT:565|tt:5	tetanus toxoid:570:0.9229	0.9229	570
TT	TT:12	tetrathionate:12:0.0049	0.0049	12
TT	TT:41	therapeutic touch:41:0.9274	0.9274	41
TT	TT:17	thiotepa:17:0.0072	0.0072	17
TT	TT:14|Tt:1	threshold:15:0.0063	0.0063	15
TT	TT:8	thrombin times:8:0.1591	0.1591	8
TT	TT:38	thrombolytic therapy:38:0.8098	0.8098	38
TT	TT:22	Thrombotest:22:0.0094	0.0094	22
TT	TT:41	time trial:19:0.8449|time-trial:13:0.0054|time trials:9:0.6794	0.8449	41
TT	TT:5|Tt:2	tissue thickness:7:0.3524	0.3524	7
TT	TT:13|tT:3	total:16:0.0067	0.0067	16
TT	TT:67|tT:3|T-T:1	total testosterone:71:0.8146	0.8146	71
TT	TT:29	total thyroidectomy:29:0.7970	0.7970	29
TT	TT:28	tracheal tube:28:0.5104	0.5104	28
TT	TT:42|tt:2	transit time:37:0.1035|transit times:7:0.1111	0.1111	44
Tt	Tt:11|TT:2	transition temperature:13:0.2121	0.2121	13
TT	TT:10	transthoracic:10:0.0040	0.0040	10
TT	TT:28	transverse tubule:20:0.7766|transverse tubules:8:0.4102	0.7766	28
TT	TT:9	tube thoracostomy:9:0.6794	0.6794	9
TT	TT:64	tuberculoid:64:0.0282	0.0282	64
TT	TT:16	tuberculoid leprosy:16:0.8165	0.8165	16
TT	TT:14	twitch tension:14:0.4709	0.4709	14
TUDC	TUDC:49	tauroursodeoxycholate:49:0.6957	0.6957	49
TUDC	TUDC:14	tauroursodeoxycholic acid:14:0.7909	0.7909	14
TUDCA	TUDCA:13|T-UDCA:1	tauroursodeoxycholate:14:0.1605	0.1605	14
TUDCA	TUDCA:53	Tauroursodeoxycholic acid:53:0.8373	0.8373	53
TUG	TUG:14	timed up and go:14:0.7909	0.7909	14
TUG	TUG:5	Timed Up and Go test:5:0.2818	0.2818	5
TUG	TUG:7	Timed Up&Go:7:0.7103	0.7103	7
TUG	TUG:5	Timed Up&Go Test:5:0.5290	0.5290	5
TUIP	TUIP:21|TUI-P:1	transurethral incision of the prostate:22:0.7593	0.7593	22
TULIP	TULIP:9	Transurethral ultrasound-guided laser-induced prostatectomy:9:0.6411	0.6411	9
TUMT	TUMT:142	transurethral microwave thermotherapy:142:0.9789	0.9789	142
TUNEL	TUNEL:14|Tunel:1	dUTP nick-end-labeling:15:0.3821	0.3821	15
TUNEL	TUNEL:5	nick end labeling assay:5:0.2818	0.2818	5
TUNEL	TUNEL:11	nick end labeling method:6:0.2243|nick end-labeling method:5:0.1973	0.2243	11
TUNEL	TUNEL:63	nick end-labelling:63:0.8259	0.8259	63
TUNEL	TUNEL:14	TdT-mediated dUTP-biotin nick end-labeling:14:0.0899	0.0899	14
TUNEL	TUNEL:7|Tunel:1	terminal deoxynucleotidyl transferase:8:0.6411	0.6411	8
TUNEL	TUNEL:117	terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling:63:0.9018|terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling:54:0.8862	0.9018	117
TUNEL	TUNEL:15	terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling:15:0.7096	0.7096	15
TURBT	TURBT:3|TUR-Bt:2	transurethral bladder tumor resection:5:0.4422	0.4422	5
TURBT	TURBT:7|TUR-Bt:2	transurethral resection:9:0.2102	0.2102	9
TURBT	TURBT:20|TUR-Bt:16|TUR-BT:9|TURBt:2|TUR-bt:1	transurethral resection of bladder tumor:48:0.9386	0.9386	48
TURBT	TURBT:1	transurethral resection of the bladder tumour:1:0.8270	0.8270	1
TURB	TURB:7|TUR-B:2	transurethral resection:9:0.3455	0.3455	9
TURB	TURB:19	transurethral resection of the bladder:19:0.8525	0.8525	19
TURP	TURP:17	transurethral prostate resection:17:0.8270	0.8270	17
TURP	TURP:85|TUR-P:10	transurethral prostatectomy:95:0.9339	0.9339	95
TURP	TURP:19|TUR-P:2	transurethral prostatic resection:21:0.8594	0.8594	21
TURP	TURP:35|TUR-P:6	transurethral resection:41:0.3672	0.3672	41
TURP	TURP:616|TUR-P:58	transurethral resection of the prostate:674:0.9509	0.9509	674
TUR	TUR:382	transurethral resection:382:0.9200	0.9200	382
TUR	TUR:1	transurethral resection of prostate:1:0.5926	0.5926	1
TUTase	TUTase:10|tutase:1	terminal uridylyl transferase:11:0.6182	0.6182	11
TUVP	TUVP:18|TUV-P:3	transurethral electrovaporization of the prostate:21:0.8594	0.8594	21
TUVRP	TUVRP:5	Transurethral vaporization resection of the prostate:5:0.4422	0.4422	5
TU	TU:7	5 tuberculin units:7:0.2452	0.2452	7
TU	TU:56	testosterone undecanoate:56:0.8254	0.8254	56
TU	TU:17	thiouracil:17:0.0548	0.0548	17
TU	TU:30|tu:1|Tu:1	thiourea:32:0.1062	0.1062	32
TU	TU:7	toxic unit:7:0.0886	0.0886	7
TVCs	TVCs:9	total viable counts:9:0.6794	0.6794	9
TVDT	TVDT:8	tumor volume doubling time:8:0.5006	0.5006	8
TVE	TVE:15	Total vascular exclusion:15:0.8045	0.8045	15
TVF	TVF:10	Thiry-Vella fistulas:10:0.5856	0.5856	10
TVI	TVI:24	time-velocity integral:13:0.2802|time velocity integral:11:0.7357	0.7357	24
TVI	TVI:9	tissue velocity imaging:9:0.6794	0.6794	9
TVL	TVL:10	tunica vasculosa lentis:10:0.7103	0.7103	10
TVMV	TVMV:37	tobacco vein mottling virus:37:0.9197	0.9197	37
TVOC	TVOC:13	total volatile organic compounds:13:0.6701	0.6701	13
TVOR	TVOR:4|tVOR:3	translational vestibulo-ocular reflex:7:0.4438	0.4438	7
TVOR	TVOR:6|tVOR:1	translational vestibuloocular reflex:7:0.5926	0.5926	7
TVPM	TVPM:15	tensor veli palatini muscle:15:0.8045	0.8045	15
TVP	TVP:18	tensor veli palatini:18:0.8365	0.8365	18
TVP	TVP:7	textured vegetable protein:7:0.2902	0.2902	7
TVP	TVP:13	transurethral electrovaporization of the prostate:13:0.7261	0.7261	13
TVP	TVP:14	truncal vagotomy and pyloroplasty:14:0.8165	0.8165	14
TVR	TVR:77	target vessel revascularization:77:0.9386	0.9386	77
TVR	TVR:39	tonic vibration reflex:39:0.9237	0.9237	39
TVR	TVR:45	tricuspid valve replacement:45:0.8151	0.8151	45
TVS	TVS:9	Transplant vascular sclerosis:9:0.6794	0.6794	9
TVS	TVS:146	transvaginal sonography:146:0.9467	0.9467	146
TVS	TVS:27	transvaginal ultrasonography:27:0.8903	0.8903	27
TVS	TVS:17	transvaginal ultrasound:17:0.8270	0.8270	17
TVS	TVS:11	Tubulovesicular structures:11:0.7103	0.7103	11
TVT	TVT:212	tension-free vaginal tape:212:0.9261	0.9261	212
TVT	TVT:10	tension-free vaginal tape procedure:10:0.5000	0.5000	10
TVT	TVT:21	transmissible venereal tumor:11:0.7357|transmissible venereal tumour:10:0.7103	0.7357	21
TVT	TVT:10	trivittatus:10:0.0300	0.0300	10
TVU	TVU:17	transvaginal ultrasound:17:0.8270	0.8270	17
TVUS	TVUS:17|TV-US:1	transvaginal ultrasonography:18:0.8365	0.8365	18
TVUS	TVUS:15|TV-US:1|tvUS:1	transvaginal ultrasound:17:0.8270	0.8270	17
TWA	TWA:83	T-wave alternans:42:0.3842|T wave alternans:41:0.9274	0.9274	83
TWA	TWA:14	T-wave amplitude:14:0.6173	0.6173	14
TWA	TWA:232	time-weighted average:190:0.7382|time weighted average:42:0.8558	0.8558	232
TWEAK	TWEAK:17	weak inducer of apoptosis:17:0.8270	0.8270	17
TWHF	TWHF:12|TWHf:7|TwHF:2	Tripterygium wilfordii Hook f:21:0.8715	0.8715	21
TWI	TWI:11	Tooth Wear Index:11:0.7357	0.7357	11
TWOC	TWOC:12	trial without catheter:12:0.7571	0.7571	12
TWSTRS	TWSTRS:16	Toronto Western Spasmodic Torticollis Rating Scale:16:0.8165	0.8165	16
TWiST	TWiST:5|TWIST:2	symptoms and toxicity:7:0.4102	0.4102	7
TW	TW:7	tap water:7:0.1111	0.1111	7
TW	TW:15	total work:15:0.7096	0.7096	15
TW	TW:14	Tripterygium wilfordii:14:0.6911	0.6911	14
TW	TW:6	tympanometric width:6:0.1010	0.1010	6
Tw	Tw:3	water at temperatures:3:0.2452	0.2452	3
Tw	Tw:13|TW:1	water temperature:14:0.4312	0.4312	14
TW	TW:25|Tw:1	weight:26:0.0965	0.0965	26
TXA(2)	TXA(2):76|TxA(2):31	thromboxane A(2):107:0.8820	0.8820	107
TXA2	TXA2:922|TxA2:479|TX-A2:1|Tx-A2:1	thromboxane A2:1403:0.9764	0.9764	1403
TXAS	TXAS:7	thromboxane A2 synthase:7:0.5926	0.5926	7
TxB	TxB:12|TXB:5	thromboxane B2:17:0.8270	0.8270	17
TXRF	TXRF:11	X-ray fluorescence:11:0.7357	0.7357	11
TXT	TXT:64	docetaxel:64:0.8077	0.8077	64
TXS	TXS:15|TxS:3|TX-S:1	thromboxane synthase:19:0.5404	0.5404	19
Tx	Tx:8|TX:2	after kidney transplantation:10:0.1385	0.1385	10
Tx	Tx:25|TX:4|tx:1	after renal transplantation:30:0.4203	0.4203	30
Tx	Tx:28|tx:5|TX:1	after transplantation:34:0.1068	0.1068	34
Tx	Tx:8|TX:3	hypothyroid:11:0.0056	0.0056	11
Tx	Tx:6|TX:2|tx:1	kidney transplants:9:0.2285	0.2285	9
Tx	Tx:6	neonatal thymectomy:6:0.0564	0.0564	6
Tx	Tx:9|TX:1	Rats were thyroidectomized:10:0.0605	0.0605	10
Tx	Tx:18|TX:1|tx:1	renal transplant:20:0.2547	0.2547	20
Tx	Tx:26|TX:23|-Tx:1	tamoxifen:50:0.0272	0.0272	50
TX	TX:574|Tx:331	thromboxane:905:0.5011	0.5011	905
Tx	Tx:18|TX:6	thymectomized:24:0.0128	0.0128	24
Tx	Tx:38|TX:25	thyroidectomy:63:0.0344	0.0344	63
tx	tx:9|TX:2	toxic milk:11:0.7357	0.7357	11
Tx	Tx:7|TX:3	transplant recipients:10:0.5856	0.5856	10
Tx	Tx:5|TX:5	transplanted:10:0.0050	0.0050	10
TX	TX:15|Tx:1	Triton X-100:16:0.8165	0.8165	16
TYLCSV	TYLCSV:9	Tomato yellow leaf curl Sardinia virus:9:0.6794	0.6794	9
TYLCV	TYLCV:36	tomato yellow leaf curl virus:36:0.9197	0.9197	36
TYMS	TYMS:11	thymidylate synthase:11:0.7357	0.7357	11
TYMV	TYMV:77	Turnip yellow mosaic virus:77:0.9612	0.9612	77
TYRP1	TYRP1:8|Tyrp1:7|TYRP-1:3|Tyrp-1:1	tyrosinase-related protein 1:11:0.4728|tyrosinase-related protein-1:8:0.3463	0.4728	19
TZD	TZD:119	thiazolidinedione:85:0.6562|Thiazolidinediones:34:0.2578	0.6562	119
TZDs	TZDs:196	thiazolidinediones:196:0.9466	0.9466	196
TZ	TZ:81|tz:1	transition zone:82:0.5839	0.5839	82
TZ	TZ:10|Tz:5	triazolam:15:0.0553	0.0553	15
TA1	TA1:6|TA-1:2|Ta1:1	thymosin alpha 1:9:0.6794	0.6794	9
TaClo	TaClo:17	1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline:17:0.8947	0.8947	17
TACE	TACE:37	TNF-alpha converting enzyme:37:0.3044	0.3044	37
TACE	TACE:6	transarterial chemoembolisation:6:0.2243	0.2243	6
TACE	TACE:9|TAC-E:5	transcatheter arterial chemo-embolization:14:0.5111	0.5111	14
TACE	TACE:193	transcatheter arterial chemoembolization:193:0.8970	0.8970	193
TACE	TACE:36	tumor necrosis factor-alpha converting enzyme:36:0.8716	0.8716	36
T-Ag	T-Ag:4|Tag:2	large tumor Ag:6:0.5290	0.5290	6
Tag	Tag:9|T-ag:5|TAg:5|T-Ag:4|TAG:1	SV40 large T-antigen:24:0.4418	0.4418	24
Tag	Tag:30|TAg:10|T-Ag:2|T-ag:1	SV40 T antigen:32:0.1174|SV40 T-antigen:11:0.0559	0.1174	43
TAG	TAG:8	Threshold Assessment Grid:8:0.5926	0.5926	8
TAG	TAG:10	triacylglycerides:10:0.0084	0.0084	10
TAG	TAG:410	triacylglycerol:305:0.2838|triacylglycerols:105:0.0971	0.2838	410
TAPP	TAPP:12	hernia repair:12:0.2699	0.2699	12
TAPP	TAPP:47	transabdominal preperitoneal:47:0.8703	0.8703	47
TaqMan	TaqMan:5|Taqman:1	7700 Sequence Detection System:6:0.5290	0.5290	6
Taq	Taq:45	Thermus aquaticus:45:0.8649	0.8649	45
Tau-Cl	Tau-Cl:18|TauCl:10	taurine chloramine:28:0.8941	0.8941	28
tax	tax:19|Tax:2	paclitaxel:21:0.3279	0.3279	21
TBS	TBS:20	Bethesda System:20:0.7173	0.7173	20
TBs	TBs:9	taste buds:9:0.6794	0.6794	9
TBS	TBS:18	tensile bond strength:18:0.8365	0.8365	18
TBS	TBS:40	theta burst stimulation:22:0.8657|theta-burst stimulation:18:0.2687	0.8657	40
TBS	TBS:11	total body scan:11:0.6182	0.6182	11
TBS	TBS:18	Townes-Brocks syndrome:18:0.6381	0.6381	18
TBS	TBS:9	tris-buffered saline:9:0.3455	0.3455	9
TB	TB:13	anti-tuberculosis:13:0.0026	0.0026	13
Tb	Tb:332|TB:7|tb:1	body temperature:323:0.8648|Body temperatures:17:0.6748	0.8648	340
Tb	Tb:14	terbium:14:0.0028	0.0028	14
TB	TB:9	testosterone buciclate:9:0.5470	0.5470	9
TB	TB:26|Tb:3	theobromine:29:0.0060	0.0060	29
TB	TB:9	thiabendazole:9:0.0017	0.0017	9
TB	TB:12	thiobenzamide:12:0.0023	0.0023	12
TB	TB:15|Tb:2	Thoroughbred:17:0.0034	0.0034	17
TB	TB:9	tissue basophils:9:0.6794	0.6794	9
TB	TB:11|Tb:1	tolbutamide:12:0.0023	0.0023	12
TB	TB:37	toluidine blue:37:0.1727	0.1727	37
TB	TB:33	total bilirubin:33:0.7525	0.7525	33
TB	TB:47	total body:47:0.5257	0.5257	47
TB	TB:21|T-B:2	tracheobronchial:23:0.0047	0.0047	23
TB	TB:13	trapezoid body:13:0.0788	0.0788	13
TB	TB:9	tributyrin:9:0.0017	0.0017	9
TB	TB:42	triceps brachii:42:0.9308	0.9308	42
TB	TB:10	Tris-borate:10:0.0019	0.0019	10
TB	TB:45|Tb:1	trypan blue:46:0.2284	0.2284	46
Tb	Tb:9	Trypanosoma brucei:9:0.5470	0.5470	9
TB	TB:3219|Tb:31|tb:7	tuberculosis:3257:0.6945	0.6945	3257
TB	TB:35|Tb:1	tuberculous:36:0.0075	0.0075	36
TB	TB:75	tumor-bearing:75:0.0158	0.0158	75
Tc-TF	Tc-TF:16	Technetium-99m tetrofosmin:16:0.5564	0.5564	16
Tc-99m	Tc-99m:14|Tc99m:2|Tc--99m:1	pertechnetate:17:0.0947	0.0947	17
Tc-99m	Tc-99m:101|Tc99m:4|tc-99m:1	Technetium-99m:106:0.6213	0.6213	106
Tc-GSA	Tc-GSA:6|TcGSA:5	human serum albumin:11:0.4232	0.4232	11
TCLA	TCLA:17	T-cell line-adapted:10:0.2873|T cell line-adapted:7:0.5926	0.5926	17
TcO4-	TcO4-:12	pertechnetate:12:0.7333	0.7333	12
tcpCO2	tcpCO2:3|tcPCO2:2|TCPCO2:1|tc-PCO2:1|TcPCO2:1	carbon dioxide pressure:8:0.6411	0.6411	8
tcPCO2	tcPCO2:8|TcPCO2:7|tcpCO2:2|tc-pco2:1|tc-PCO2:1|tc-Pco2:1	carbon dioxide tension:20:0.8525	0.8525	20
tcPCO2	tcPCO2:7|TcPCO2:4|tcpCO2:1	transcutaneous PCO2:12:0.2549	0.2549	12
TcPO(2)	TcPO(2):5|tcPO(2):2|TcpO(2):2|tcpO(2):1|tcPo(2):1	transcutaneous oxygen pressure:11:0.6182	0.6182	11
TcPO(2)	TcPO(2):4|tcPO(2):3|TcpO(2):2|TcPo(2):1|TCPO(2):1	transcutaneous oxygen tension:11:0.6182	0.6182	11
TcPYP	TcPYP:7|Tc-PYP:6|Tc-PyP:2|TcPyp:1	pyrophosphate:16:0.6818	0.6818	16
TCAD	TCAD:18	transplant coronary artery disease:18:0.5038	0.5038	18
Tcol	Tcol:13	colonic temperature:13:0.7753	0.7753	13
TCRA	TCRA:5|Tcra:1	T-cell receptor alpha:6:0.1838	0.1838	6
TCRD	TCRD:9	T-cell receptor delta:9:0.5470	0.5470	9
TCRG	TCRG:12	T cell receptor gamma:12:0.7571	0.7571	12
TdR	TdR:36|Tdr:3|TDR:1|-Tdr:1	[3H]thymidine:41:0.1020	0.1020	41
TDR	TDR:17	Special Program for Research and Training in Tropical Diseases:17:0.8270	0.8270	17
TdR	TdR:120|Tdr:4|TDR:3|tdR:1	thymidine:128:0.3240	0.3240	128
TDR	TDR:11	time domain reflectometry:11:0.7357	0.7357	11
TDR	TDR:37	transmural dispersion of repolarization:37:0.9197	0.9197	37
TdT+	TdT+:11	terminal deoxynucleotidyl transferase-positive:11:0.6182	0.6182	11
TdT	TdT:531|TDT:21|Tdt:16|tdt:1	Terminal deoxynucleotidyl transferase:569:0.9810	0.9810	569
TdT	TdT:44|TDT:1	Terminal deoxynucleotidyltransferase:45:0.8917	0.8917	45
TDT	TDT:7	transmission disequilibrium:7:0.1850	0.1850	7
TDT	TDT:357	transmission disequilibrium test:224:0.9786|transmission/disequilibrium test:120:0.2634|transmission disequilibrium tests:13:0.7753	0.9786	357
TDT	TDT:13	Transmission disequilibrium testing:13:0.7753	0.7753	13
TDT	TDT:5	transmission test for linkage disequilibrium:5:0.4422	0.4422	5
TDT	TDT:12|Tdt:1	Tumor doubling time:13:0.5934	0.5934	13
Tdp1	Tdp1:8|TDP1:2	tyrosyl-DNA phosphodiesterase:10:0.5000	0.5000	10
TeTx	TeTx:44|TeTX:6|Tetx:4	Tetanus toxin:54:0.9448	0.9448	54
TEQ	TEQ:12	toxic equivalence:12:0.5664	0.5664	12
TEQ	TEQ:19	toxic equivalency:19:0.6537	0.6537	19
TEQ	TEQ:54|TEq:2	Toxic equivalents:29:0.5212|toxic equivalent:27:0.5157	0.5212	56
TEQ	TEQ:8	toxic equivalent quantity:8:0.3463	0.3463	8
TESA	TESA:15	testicular sperm aspiration:15:0.8045	0.8045	15
TetC	TetC:5|TETC:1	fragment C of tetanus toxin:6:0.6411	0.6411	6
tetr	TetR:13|tetr:13|tetR:3	Tet repressor:29:0.3446	0.3446	29
tetr	tetr:25|Tetr:1	tetracycline repressor:26:0.2951	0.2951	26
Tetr	Tetr:6|tetr:3|tet-r:1	tetracycline resistance:10:0.7103	0.7103	10
Tfn	Tfn:18|TFN:5	transferrin:23:0.4889	0.4889	23
TfR1	TfR1:13|TfR-1:2	transferrin receptor 1:15:0.7096	0.7096	15
TfR2	TfR2:17|TFR2:4|tfr-2:1	transferrin receptor 2:22:0.7955	0.7955	22
Tfm	Tfm:34|tfm:5|TFM:4	testicular feminization:43:0.9308	0.9308	43
Tfm	Tfm:11|tfm:3	testicular feminization mutation:14:0.7909	0.7909	14
Tfm	Tfm:28|tfm:3	Testicular feminized:31:0.9043	0.9043	31
Tfm	Tfm:3|TFM:2|tfm:2	testicular feminized male:7:0.5926	0.5926	7
TFM	TFM:11	total fat mass:11:0.4728	0.4728	11
TgAb	TgAb:9|TG-Ab:1|Tg-Ab:1	antithyroglobulin:11:0.0602	0.0602	11
TgAb	TgAb:21|Tg-Ab:5|TG-Ab:1|TGAb:1|TG-ab:1|TG-AB:1|Tgab:1	thyroglobulin:31:0.1807	0.1807	31
TgAb	TgAb:22|Tgab:3|Tg-ab:2|TgAB:1|TG-Ab:1|TGAb:1	thyroglobulin antibodies:30:0.4013	0.4013	30
TgAb	TgAb:7|Tg-Ab:2|TGAb:1|tg-ab:1|Tg-ab:1|TGAB:1	thyroglobulin autoantibodies:13:0.4849	0.4849	13
Tgb	Tgb:11|TGB:3|tgb:1	thyroglobulin:15:0.0952	0.0952	15
TGB	TGB:86	Tiagabine:86:0.5782	0.5782	86
TGB	TGB:24	triple gene block:24:0.8768	0.8768	24
Th1/Th2	Th1/Th2:5	T helper 1/T helper 2:5:0.4422	0.4422	5
Th1	Th1:6|Th-1:3	cell-mediated:9:0.0059	0.0059	9
Th1	Th1:13	IFN-gamma:13:0.0104	0.0104	13
Th1	Th1:5|Th-1:3|TH1:2	proinflammatory:10:0.0067	0.0067	10
Th1	Th1:356|TH1:18|Th-1:11|TH-1:5	T helper 1:336:0.9684|T-helper-1:30:0.0215|T helper-1:24:0.8115	0.9684	390
Th1	Th1:270|TH1:21|Th-1:5|TH-1:1	T helper type 1:193:0.9453|T-helper type 1:76:0.1437|T-helper type-1:18:0.3412|T helper type-1:10:0.7103	0.9453	297
Th1	Th1:8|TH1:1	type 1 helper:9:0.6794	0.6794	9
Th1	Th1:13|TH1:1	type 1 helper T:14:0.6173	0.6173	14
Th1	Th1:9|TH1:4	Type 1 helper T cells:7:0.5926|type 1 helper T cell:6:0.5290	0.5926	13
Th1	Th1:22	type 1 T helper:15:0.8045|type 1 T-helper:7:0.5926	0.8045	22
Th1	Th1:5|TH1:1	type 1 T helper cell:6:0.5290	0.5290	6
Th2	Th2:25|Th-2:4|TH2:3|TH-2:1	T-helper-2:19:0.0187|T helper-2:14:0.5111	0.5111	33
Th2	Th2:5	T-helper 2 cell:5:0.2818	0.2818	5
TH2	TH2:3|Th2:3	T helper cells:6:0.2827	0.2827	6
Th2	Th2:44|TH2:3	T helper cell type 2:47:0.9379	0.9379	47
Th2	Th2:157|TH2:16|Th-2:2	T helper type 2:123:0.9255|T-helper type 2:45:0.1124|T helper type-2:7:0.5926	0.9255	175
Th2	Th2:6	type 2 cells:6:0.2243	0.2243	6
Th2	Th2:9|TH2:1	type 2 helper:10:0.7103	0.7103	10
Th2	Th2:16|TH2:1	type 2 helper T:17:0.8270	0.8270	17
Th2	Th2:4|TH2:2	type 2 helper T cells:6:0.5290	0.5290	6
Th2	Th2:25|TH2:2	type 2 T helper:16:0.7261|type 2 T-helper:11:0.7357	0.7357	27
ThDP	ThDP:15	thiamin diphosphate:15:0.3262	0.3262	15
ThDP	ThDP:12	thiamine diphosphate:12:0.2183	0.2183	12
ThTP	ThTP:11	thiamine triphosphate:11:0.6182	0.6182	11
THVE	THVE:12	total hepatic vascular exclusion:12:0.7571	0.7571	12
THAM	THAM:1	Tris hydroxymethyl aminomethane:1:0.5006	0.5006	1
THAM	THAM:17	tromethamine:17:0.1404	0.1404	17
ThrRS	ThrRS:16	threonyl-tRNA synthetase:16:0.8165	0.8165	16
Thy	Thy:11|T-hy:1	Hypothalamic:12:0.0932	0.0932	12
Thy	Thy:28	hypothalamic temperature:28:0.7905	0.7905	28
THz	THz:50	terahertz:50:0.8033	0.8033	50
TiF4	TiF4:12	titanium tetrafluoride:12:0.7571	0.7571	12
TIM	TIM:7|Tim:1	family of T-cell immunoglobulin domain and mucin domain:8:0.5006	0.5006	8
TIM	TIM:20|tim:6	triose phosphate isomerase:26:0.8861	0.8861	26
TIM	TIM:84	triosephosphate isomerase:84:0.6417	0.6417	84
TiO(2)	TiO(2):31	titanium dioxide:31:0.9043	0.9043	31
TiO2	TiO2:114|TIO2:1	titanium dioxide:115:0.9586	0.9586	115
TiO2	TiO2:8	titanium oxide:8:0.3463	0.3463	8
TJA	TJA:21	total joint arthroplasty:21:0.8594	0.8594	21
TJ	TJ:206|tj:2|Tj:2	tight junction:131:0.9636|tight junctions:79:0.9622	0.9636	210
TmP/GFR	TmP/GFR:10|Tmp/GFR:3	glomerular filtration rate:13:0.6701	0.6701	13
Tmax	Tmax:9	maximum temperature:9:0.1585	0.1585	9
Tmax	Tmax:5|tmax:3	peak plasma concentrations:8:0.2619	0.2619	8
Tmax	Tmax:2|tmax:1	time at which Cmax was reached:3:0.1973	0.1973	3
tmax	tmax:18|Tmax:9	time to maximum plasma concentration:27:0.4482	0.4482	27
Tmax	Tmax:7|tmax:7	time to peak plasma concentration:14:0.2887	0.2887	14
tmax	tmax:11|Tmax:4	Time to reach maximum concentration:15:0.5279	0.5279	15
Tmod	Tmod:15|TMOD:1	tropomodulin:16:0.8333	0.8333	16
TMS-1	TMS-1:8	Topographic Modeling System:8:0.4102	0.4102	8
Tn5	Tn5:16	Transposon:16:0.4412	0.4412	16
TNAP	TNAP:9|TN-AP:1	tissue non-specific alkaline phosphatase:10:0.7103	0.7103	10
TNAP	TNAP:8|tnAP:1|TN-AP:1	tissue-nonspecific alkaline phosphatase:10:0.1385	0.1385	10
tna	tna:12	expression of the tryptophanase:12:0.3275	0.3275	12
TNa	TNa:6	sodium reabsorption:6:0.2243	0.2243	6
TNA	TNA:19	total nutrient admixture:19:0.8449	0.8449	19
TNA	TNA:10	transthoracic needle aspiration:10:0.5856	0.5856	10
TN-C	TN-C:97|TNC:20|Tn-C:19|TnC:2	Tenascin-C:138:0.2239	0.2239	138
TNC	TNC:38	Thymic nurse cells:31:0.9043|thymic nurse cell:7:0.5926	0.9043	38
TNC	TNC:4	total neutrophil count:4:0.1618	0.1618	4
TNC	TNC:37|tNC:1	total nucleated cell:20:0.8525|total nucleated cells:18:0.7539	0.8525	38
TNC	TNC:18	trigeminal nucleus caudalis:18:0.8365	0.8365	18
TnC	TnC:264|TN-C:14|TNC:8|Tn-C:3	troponin C:264:0.9501|troponin-C:25:0.0392	0.9501	289
TNT	TNT:251	2,4,6-Trinitrotoluene:251:0.3383	0.3383	251
TNT	TNT:72	trinitrotoluene:72:0.0887	0.0887	72
TnT	TnT:7|TN-T:2	troponin:9:0.0109	0.0109	9
TnT	TnT:275|Tn-T:15|TNT:14|TN-T:7|tn-T:3|tnT:3	troponin T:282:0.9530|Troponin-T:35:0.0464	0.9530	317
TNP2	TNP2:6|Tnp2:5|Tnp-2:1	transition protein 2:12:0.5050	0.5050	12
TN	TN:9	number:9:0.0081	0.0081	9
T-N	T-N:8|TN:1	temporal-to-nasal:9:0.0081	0.0081	9
TN	TN:109|Tn:23	tenascin:132:0.1333	0.1333	132
TN	TN:17|Tn:2	tenascin-C:19:0.0183	0.0183	19
TN	TN:30|tn:1	terminal nerve:31:0.4614	0.4614	31
TN	TN:26	tetranectin:26:0.0254	0.0254	26
TN	TN:13	thermoneutral:13:0.0122	0.0122	13
TN	TN:8	thyroid nodules:8:0.5006	0.5006	8
TN	TN:11	tibial nerve:11:0.0869	0.0869	11
TN	TN:77|T-N:13|tN:1	Total nitrogen:91:0.9311	0.9311	91
TN	TN:20	toxin neutralization:20:0.8525	0.8525	20
Tn	Tn:9	transposon:9:0.0081	0.0081	9
TN	TN:123	trigeminal neuralgia:123:0.9612	0.9612	123
TN	TN:11	triple negative:11:0.1758	0.1758	11
Tn	Tn:78|TN:9	troponin:87:0.0875	0.0875	87
TN	TN:18	true negative:18:0.3548	0.3548	18
TN	TN:8	tumor necrosis:8:0.2619	0.2619	8
ToBI	ToBI:11	toxin binding inhibition:11:0.7357	0.7357	11
TOMM	TOMM:21	Test of Memory Malingering:21:0.8594	0.8594	21
ToMV	ToMV:30	tomato mosaic virus:30:0.9011	0.9011	30
TOD	TOD:32	target organ damage:32:0.9072	0.9072	32
ToMO	ToMO:12|TOMO:1	monooxygenase:13:0.7500	0.7500	13
topos	topos:5|Topos:3	DNA topoisomerases:8:0.5006	0.5006	8
Tor	Tor:10	oral temperature:10:0.5000	0.5000	10
TOR	TOR:67|Tor:5|ToR:1	target of rapamycin:73:0.9585	0.9585	73
TOR	TOR:27|Tor:8	toremifene:35:0.1604	0.1604	35
tPDC	tPDC:4|t-PDC:2	L-trans-pyrrolidine-2,4-dicarboxylic acid:6:0.2243	0.2243	6
TPD	TPD:12|tPD:3|tpd:3	potential difference:18:0.6903	0.6903	18
TPD	TPD:9	temperature-programmed desorption:9:0.2102	0.2102	9
TPD	TPD:22	tidal peritoneal dialysis:22:0.7955	0.7955	22
TPD	TPD:8	Two-point discrimination:8:0.5006	0.5006	8
TRACP	TRACP:44|TRAcP:13|TrACP:5|TR-ACP:5|TracP:2|Tr-ACP:1|Tr-Acp:1|TrAcP:1	Tartrate-resistant acid phosphatase:72:0.6934	0.6934	72
TrJ	TrJ:8|Tr-J:3	trembler-J:11:0.6471	0.6471	11
Tre6P	Tre6P:7|tre-6-P:1|tre-6-p:1	trehalose-6-phosphate:9:0.6667	0.6667	9
TREC	TREC:9	T-cell receptor excision circle:9:0.3069	0.3069	9
Tregs	Tregs:28|T-regs:3	regulatory T cells:31:0.8090	0.8090	31
Treg	Treg:42|TReg:1	regulatory T:43:0.7795	0.7795	43
Treg	Treg:54|T-reg:4	regulatory T cells:58:0.7489	0.7489	58
Treg	Treg:27|T-reg:5|TReg:1	T regulatory:23:0.8715|T-regulatory:10:0.0520	0.8715	33
Tre	Tre:285|tre:1	rectal temperature:261:0.9266|rectal temperatures:25:0.8816	0.9266	286
TRE	TRE:12|tre:1	target registration error:13:0.7753	0.7753	13
TRE	TRE:54|tre:7	thyroid hormone response element:52:0.8821|thyroid hormone response elements:9:0.6794	0.8821	61
Tre	Tre:5|tre:4	trehalose:9:0.0098	0.0098	9
TRF1	TRF1:10	repeat binding factor 1:10:0.5000	0.5000	10
TrfR	TrfR:7|TRFr:2|Trf-R:2|TRF-R:2|Trfr:1|Trf-r:1|TRFR:1	transferrin receptor:16:0.6577	0.6577	16
TRIM	TRIM:15	1-(2-trifluoromethylphenyl) imidazole:15:0.7096	0.7096	15
TRIM	TRIM:16	tripartite motif:16:0.8165	0.8165	16
TRIR	TRIR:14	time-resolved infrared:14:0.7909	0.7909	14
Tris-BP	Tris-BP:8	flame retardant tris(2,3-dibromopropyl)phosphate:8:0.7103	0.7103	8
Tris-BP	Tris-BP:5|tris-bp:1	tris(2,3-dibromopropyl) phosphate:6:0.1838	0.1838	6
Tris	Tris:60|tris:3	tris(hydroxymethyl)aminomethane:63:0.3316	0.3316	63
TrkA	TrkA:11|trkA:10	NGF receptor:21:0.2996	0.2996	21
TrkA	TrkA:7|trkA:2	tyrosine kinase:9:0.4587	0.4587	9
TrkA	TrkA:3|trkA:2	tyrosine kinase receptor:5:0.7571	0.7571	5
TrkC	TrkC:5|trkC:2	tyrosine kinase C:7:0.4438	0.4438	7
Trolox	Trolox:10|trolox:3	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid:13:0.2660	0.2660	13
Trp-P-1	Trp-P-1:102|trp-P-1:1	3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole:103:0.6800	0.6800	103
trpEG	trpEG:6|TrpEG:3	anthranilate synthase:9:0.6794	0.6794	9
TrpRS	TrpRS:29|Trp-RS:1	tryptophanyl-tRNA synthetase:30:0.7652	0.7652	30
Trx-1	Trx-1:11|Trx1:2|TRX1:2|TRX-1:1	thioredoxin-1:16:0.4545	0.4545	16
TrxR	TrxR:63|TRxR:1	Thioredoxin reductase:64:0.8123	0.8123	64
Ts-	Ts-:6|ts-:4|TS-:1	temperature-sensitive:11:0.3571	0.3571	11
Ts/c	Ts/c:6|TS/C:3	T suppressor/cytotoxic:9:0.4587	0.4587	9
Ts1	Ts1:9|Ts-1:1	suppressor T cells:10:0.7103	0.7103	10
Ts2	Ts2:8	suppressor T cells:8:0.5006	0.5006	8
TSE	TSE:31	testicular self-examination:31:0.8519	0.8519	31
TSE	TSE:13	transition state ensemble:13:0.7753	0.7753	13
TSE	TSE:203	transmissible spongiform encephalopathies:106:0.9039|transmissible spongiform encephalopathy:97:0.9510	0.9510	203
TSE	TSE:5	trophoblast-specific element:5:0.0736	0.0736	5
TSE	TSE:134	turbo spin-echo:59:0.9203|turbo spin echo:53:0.9116|turbo-spin-echo:22:0.0390	0.9203	134
TsTX	TsTX:16|TsTx:4	tityustoxin:20:0.7600	0.7600	20
TSAd	TSAd:7	T cell-specific adapter protein:7:0.5926	0.5926	7
TSER	TSER:8	enhancer region:8:0.5006	0.5006	8
TSIF	TSIF:16	tooth surface index of fluorosis:16:0.8165	0.8165	16
Tsk/+	Tsk/+:8|TSK/+:3	tight-skin:11:0.4167	0.4167	11
Tsk	Tsk:22	Skin temperatures:22:0.7955	0.7955	22
TSK	TSK:6	Tampa Scale for Kinesiophobia:6:0.5470	0.5470	6
Tsk	Tsk:32|TSK:29|tsk:2|TSk:1	tight-skin:38:0.0934|Tight skin:26:0.1769	0.1769	64
TSV	TSV:30	Taura syndrome virus:30:0.9011	0.9011	30
TSV	TSV:5|TsV:3	Tityus serrulatus venom:8:0.5470	0.5470	8
TSV	TSV:17	Tobacco streak virus:17:0.8270	0.8270	17
TTFC	TTFC:17	tetanus toxin fragment C:17:0.8270	0.8270	17
TTOT	TTOT:8|Ttot:4	respiratory cycle:12:0.5664	0.5664	12
TTR	TTR:11	thermotolerance ratio:11:0.2040	0.2040	11
TTR	TTR:584|ttr:3	transthyretin:587:0.8284	0.8284	587
Tty	Tty:17	tympanic:17:0.2353	0.2353	17
Tty	Tty:33|TTY:1	tympanic temperature:34:0.6015	0.6015	34
TuJ1	TuJ1:5|TUJ1:3	monoclonal antibody:8:0.5006	0.5006	8
TuMV	TuMV:10	turnip mosaic potyvirus:10:0.7103	0.7103	10
TuMV	TuMV:34	turnip mosaic virus:34:0.9126	0.9126	34
TUL	TUL:18	transurethral ureterolithotripsy:18:0.8365	0.8365	18
TUN	TUN:14	total urinary nitrogen:14:0.7909	0.7909	14
TUS	TUS:12	ultrasonography:12:0.1833	0.1833	12
Tvent	Tvent:18|TVENT:1	ventilatory threshold:19:0.6537	0.6537	19
TV	TV:6	Tacaribe virus:6:0.1148	0.1148	6
TV	TV:65	television:65:0.1121	0.1121	65
T-V	T-V:8|TV:3	Thiry-Vella:11:0.0175	0.0175	11
TV	TV:64	tidal volume:64:0.3936	0.3936	64
TV	TV:13	transvaginal:13:0.0210	0.0210	13
TV	TV:30|Tv:5	Trichomonas vaginalis:35:0.8292	0.8292	35
TV	TV:47	tricuspid valve:47:0.9006	0.9006	47
TV	TV:25	truncal vagotomy:25:0.6539	0.6539	25
TXA	TXA:19	tranexamic acid:19:0.8449	0.8449	19
TXB(2)	TXB(2):38|TxB(2):33	thromboxane B(2):71:0.8934	0.8934	71
TxB2	TxB2:9|TXB2:7	thromboxane-B2:16:0.0093	0.0093	16
TxCAD	TxCAD:28|Tx-CAD:1	transplant coronary artery disease:29:0.5738	0.5738	29
TXL	TXL:68	paclitaxel:68:0.7882	0.7882	68
TXRA	TXRA:6|TxRA:5	receptor antagonist:11:0.7357	0.7357	11
TxSI	TxSI:4|TXSI:2	thromboxane synthase inhibitor:6:0.3728	0.3728	6
Ty-VLPs	Ty-VLPs:10	virus-like particles:10:0.6794	0.6794	10
Tyr(P)	Tyr(P):10	phosphotyrosine:10:0.6429	0.6429	10
TyrRS	TyrRS:35	tyrosyl-tRNA synthetase:35:0.8292	0.8292	35
Tyr-k	Tyr-k:11|Tyr-K:3|TyrK:2|Tyrk:1|tyr-k:1	tyrosine kinase:18:0.8365	0.8365	18
Tyr	Tyr:10|tyr:2	L-tyrosine:12:0.0228	0.0228	12
tyr	tyr:27|Tyr:14	tyramine:41:0.0830	0.0830	41
tyr	tyr:32|Tyr:19	tyrosinase:51:0.1037	0.1037	51
tyr	tyr:9|Tyr:1	tyrosinase gene:10:0.4363	0.4363	10
Tyr	Tyr:13|tyr:1	tyrosinated:14:0.0270	0.0270	14
U(Na)V	U(Na)V:24	sodium excretion:24:0.7151	0.7151	24
U(crit)	U(crit):8	critical swimming speed:8:0.5006	0.5006	8
U(S)	U(S):7	unique short:7:0.3524	0.3524	7
U.C.	U.C.:9	ulcerative colitis:9:0.6794	0.6794	9
U.K.	U.K.:21	United Kingdom:21:0.8594	0.8594	21
U.S.	U.S.:8|u.s.:1	ultrasonography:9:0.0421	0.0421	9
U.S.	U.S.:65	United States:65:0.9541	0.9541	65
U/S	U/S:10	ultrasonography:10:0.2093	0.2093	10
U/S	U/S:19|u/s:1	ultrasound:20:0.4419	0.4419	20
U1	U1:8	infected promonocytic cell line:8:0.6411	0.6411	8
U-266	U-266:4|U266:3	myeloma cell line:7:0.4438	0.4438	7
U2AF	U2AF:7	U2 snRNP auxiliary factor:7:0.4438	0.4438	7
U46619	U46619:7	thromboxane A2 analog:7:0.5926	0.5926	7
U46619	U46619:7|U-46619:6	thromboxane analogue:13:0.1962	0.1962	13
U46619	U46619:5|U-46619:2	thromboxane mimetic:7:0.1211	0.1211	7
U50	U50:3	agonist U50,488H:3:0.3524	0.3524	3
U937	U937:7	human myelomonocytic leukemia cells:7:0.2902	0.2902	7
UAB	UAB:20	University of Alabama at Birmingham:20:0.8657	0.8657	20
UACL	UACL:15	cell lineage:15:0.7909	0.7909	15
UAC	UAC:17	umbilical artery catheter:17:0.8270	0.8270	17
UAC	UAC:13	urinary albumin concentration:13:0.5934	0.5934	13
UADT	UADT:57	Upper aerodigestive tract:57:0.9477	0.9477	57
UAER	UAER:75|uAER:1|U-AER:1	urinary albumin excretion rate:77:0.8848	0.8848	77
UAE	UAE:127	United Arab Emirates:127:0.9766	0.9766	127
UAE	UAE:323|U-AE:1	urinary albumin excretion:324:0.9403	0.9403	324
UAE	UAE:27	urinary albumin excretion rate:27:0.8312	0.8312	27
UAE	UAE:8	urinary excretion of albumin:8:0.6411	0.6411	8
UAE	UAE:94	uterine artery embolization:94:0.9682	0.9682	94
UAF	UAF:6	upstream activating factor:6:0.5290	0.5290	6
UAI	UAI:57	unprotected anal intercourse:57:0.9477	0.9477	57
UAL	UAL:15	Ultrasound-assisted lipoplasty:15:0.6386	0.6386	15
UAMS	UAMS:10	University of Arkansas for Medical Sciences:10:0.7103	0.7103	10
UAO	UAO:48	upper airway obstruction:48:0.9379	0.9379	48
UAPI	UAPI:7	umbilical artery pulsatility index:7:0.3524	0.3524	7
UAP	UAP:23	unlicensed assistive personnel:23:0.8715	0.8715	23
UAP	UAP:12|u-AP:2|uAP:1	unstable angina:15:0.8045	0.8045	15
UAP	UAP:121	unstable angina pectoris:121:0.9753	0.9753	121
UARS	UARS:53	Upper airway resistance syndrome:53:0.9438	0.9438	53
UAR	UAR:15	upper airway resistance:15:0.8045	0.8045	15
UASB	UASB:29	upflow anaerobic sludge bed:29:0.7970	0.7970	29
UASB	UASB:128	upflow anaerobic sludge blanket:128:0.8660	0.8660	128
UASG	UASG:9	upstream activating sequence:9:0.6794	0.6794	9
UAS	UAS:10	ultrasonically activated scalpel:10:0.7103	0.7103	10
UAS	UAS:81	upstream activating sequence:65:0.9275|upstream activating sequences:16:0.8165	0.9275	81
UAS	UAS:55	upstream activation sequence:45:0.8964|upstream activation sequences:10:0.7103	0.8964	55
UAS	UAS:21	upstream activation site:21:0.7865	0.7865	21
UAS	UAS:33	upstream activator sequence:33:0.8605	0.8605	33
UAT	UAT:11	upper aerodigestive tract:11:0.7357	0.7357	11
UAW	UAW:18	upper airway:18:0.8365	0.8365	18
UA	UA:9	activity:9:0.0071	0.0071	9
UA	UA:9	aldosterone:9:0.0071	0.0071	9
UA	UA:20	umbilical arterial:20:0.4574	0.4574	20
UA	UA:155|ua:1|Ua:1	umbilical artery:151:0.7532|umbilical arteries:6:0.0666	0.7532	157
UA	UA:15|uA:2	undifferentiated arthritis:17:0.6211	0.6211	17
UA	UA:242	unstable angina:242:0.9876	0.9876	242
UA	UA:9	unstable angina pectoris:9:0.6794	0.6794	9
UA	UA:100	upper airway:91:0.9672|upper airways:9:0.6794	0.9672	100
UA	UA:15	uranyl acetate:15:0.7096	0.7096	15
UA	UA:244|Ua:2	uric acid:246:0.7960	0.7960	246
UA	UA:15	urinalysis:15:0.0124	0.0124	15
UA	UA:11	urinary amylase:11:0.3829	0.3829	11
UA	UA:9|Ua:1	uterine arteries:10:0.2643	0.2643	10
UBA	UBA:27|uba:1|Uba:1	ubiquitin-associated:29:0.4000	0.4000	29
UBBC	UBBC:10	Unsaturated vitamin B12 binding capacity:10:0.7103	0.7103	10
UBCs	UBCs:6|Ubcs:2	ubiquitin-conjugating enzymes:8:0.2619	0.2619	8
UBCs	UBCs:13	unipolar brush cells:13:0.7753	0.7753	13
UBC	UBC:8|Ubc:6	ubiquitin-conjugating enzyme:14:0.5589	0.5589	14
UBC	UBC:8	unipolar brush cell:8:0.5006	0.5006	8
UBC	UBC:13	University of British Columbia:13:0.6701	0.6701	13
UBC	UBC:9	urinary bladder cancer:9:0.6794	0.6794	9
UBD	UBD:16	urinary bladder distension:16:0.7261	0.7261	16
UBE3A	UBE3A:9	ubiquitin-protein ligase:9:0.5470	0.5470	9
UBF	UBF:55	Upstream binding factor:55:0.8645	0.8645	55
UBF	UBF:75	uterine blood flow:75:0.7548	0.7548	75
UBI	UBI:7|Ubi:4|ubi:1	ubiquitin:12:0.3438	0.3438	12
UBLs	UBLs:4|Ubls:2|ubls:1	ubiquitin-like proteins:7:0.2902	0.2902	7
UbL	UbL:15|UBL:6|ubl:4|Ubl:3	ubiquitin-like:28:0.6429	0.6429	28
UBM	UBM:18	ultrasound biomicroscope:18:0.7539	0.7539	18
UBM	UBM:164	ultrasound biomicroscopy:164:0.9067	0.9067	164
UBP	UBP:5|Ubp:3	ubiquitin-specific protease:8:0.2987	0.2987	8
UBSM	UBSM:19	urinary bladder smooth muscle:19:0.8449	0.8449	19
UBT	UBT:205	breath test:205:0.9617	0.9617	205
Ubx	Ubx:23|UBX:2	homeotic gene Ultrabithorax:25:0.4992	0.4992	25
UCAD	UCAD:13	unstable coronary artery disease:13:0.6701	0.6701	13
UCA	UCA:18	contrast agent:18:0.8365	0.8365	18
UCA	UCA:17	trans-urocanic acid:17:0.1008	0.1008	17
UCA	UCA:10	ultrasound contrast agents:10:0.4363	0.4363	10
uCa	uCa:10|UCa:5|u-Ca:3|U-Ca:1|uCA:1|Uca:1	urinary calcium:21:0.4359	0.4359	21
UCa	UCa:6|Uca:1	Urinary calcium excretion:7:0.5926	0.5926	7
UCA	UCA:50	urocanic acid:50:0.4569	0.4569	50
UCB	UCB:255	umbilical cord blood:255:0.9633	0.9633	255
UCB	UCB:58	unconjugated bilirubin:58:0.9486	0.9486	58
UCBT	UCBT:17	cord blood transplantation:17:0.8270	0.8270	17
UCC	UCC:15	urothelial cell carcinoma:15:0.7096	0.7096	15
UCd	UCd:7|U-Cd:3|UCD:2	urinary cadmium:12:0.5050	0.5050	12
UCG	UCG:18	echocardiography:18:0.3036	0.3036	18
UCH	UCH:6	Ubiquitin C-terminal hydrolase:6:0.3728	0.3728	6
UCH-L1	UCH-L1:4|UCHL1:3|UchL1:1	ubiquitin carboxy-terminal hydrolase L1:8:0.6411	0.6411	8
UCHS	UCHS:5	treatment of uncontrolled hemorrhagic shock:5:0.2818	0.2818	5
UCHs	UCHs:6	ubiquitin C-terminal hydrolases:6:0.3728	0.3728	6
UCLA	UCLA:26	University of California at Los Angeles:26:0.9124	0.9124	26
UCLP	UCLP:118|uCLP:1	unilateral cleft lip and palate:119:0.8686	0.8686	119
UCL	UCL:43	ulnar collateral ligament:43:0.9308	0.9308	43
UCM	UCM:12	uncontrolled manifold:12:0.7571	0.7571	12
UCM	UCM:16	unresolved complex mixture:16:0.8165	0.8165	16
UCN-01	UCN-01:65	7-Hydroxystaurosporine:65:0.8267	0.8267	65
UCNT	UCNT:14	undifferentiated carcinoma of nasopharyngeal type:14:0.8365	0.8365	14
Ucn	Ucn:53|UCN:42	Urocortin:95:0.8103	0.8103	95
UCO	UCO:11	umbilical cord occlusion:11:0.7357	0.7357	11
UCP1	UCP1:28|UCP-1:8|Ucp1:2	uncoupling protein:38:0.8781	0.8781	38
UCP1	UCP1:154|UCP-1:48|ucp-1:3|Ucp1:1	uncoupling protein 1:112:0.9733|uncoupling protein-1:94:0.9495	0.9733	206
UCP2	UCP2:122|UCP-2:33|Ucp2:2	uncoupling protein 2:91:0.9668|uncoupling protein-2:66:0.9548	0.9668	157
UCP3	UCP3:89|UCP-3:17|ucp3:1|Ucp3:1	uncoupling protein 3:63:0.9018|Uncoupling protein-3:45:0.8649	0.9018	108
UCPs	UCPs:110	Uncoupling proteins:110:0.9571	0.9571	110
UCP	UCP:299|Ucp:7|UcP:5|ucp:3	uncoupling protein:278:0.9392|uncoupling proteins:36:0.8716	0.9392	314
UCP	UCP:9	urethral closure pressure:9:0.5470	0.5470	9
UCRP	UCRP:13	ubiquitin cross-reactive protein:13:0.7753	0.7753	13
UCR	UCR:10	unconditioned response:10:0.4363	0.4363	10
UCr	UCr:6|uCr:4|U-Cr:2|Ucr:1|u-Cr:1	urinary creatinine:14:0.2636	0.2636	14
UCSD	UCSD:7	University of California San Diego:7:0.8768	0.8768	7
UCSF	UCSF:14	University of California San Francisco:14:0.9682	0.9682	14
UCS	UCS:114	unconditioned stimulus:114:0.8591	0.8591	114
UCs	UCs:5	urothelial carcinomas:5:0.0736	0.0736	5
UCTD	UCTD:27|uCTD:1	undifferentiated connective tissue disease:28:0.6057	0.6057	28
UCVA	UCVA:11	uncorrected:11:0.0392	0.0392	11
UCVA	UCVA:238	uncorrected visual acuity:238:0.9669	0.9669	238
UCa/Cr	UCa/Cr:3|uCa/Cr:2|Uca/cr:1	urinary calcium/creatinine ratio:6:0.2827	0.2827	6
UC	UC:9	controls:9:0.0033	0.0033	9
UC	UC:12|uc:1	ultracentrifugation:13:0.0049	0.0049	13
UC	UC:34	umbilical cord:34:0.8644	0.8644	34
UC	UC:12	undifferentiated carcinoma:12:0.2083	0.2083	12
UC	UC:42	unesterified cholesterol:42:0.8263	0.8263	42
UC	UC:15	University of California:15:0.8045	0.8045	15
UC	UC:13	urothelial carcinoma:13:0.2415	0.2415	13
UC	UC:88	usual care:88:0.8352	0.8352	88
UC	UC:12	uterine contractions:12:0.7571	0.7571	12
UDA	UDA:6|uDA:3|u-DA:1|U-DA:1	dopamine:11:0.2174	0.2174	11
UDA	UDA:14	Urtica dioica agglutinin:14:0.7909	0.7909	14
UDB	UDB:10	use-dependent block:10:0.5000	0.5000	10
UD-BMT	UD-BMT:5	unrelated donor bone marrow transplantation:5:0.4422	0.4422	5
UDC	UDC:29	ursodeoxycholate:29:0.3457	0.3457	29
UDC	UDC:22	ursodeoxycholic acid:22:0.8715	0.8715	22
UDCA	UDCA:19	ursodeoxycholate:19:0.0263	0.0263	19
UDCA	UDCA:18	ursodeoxycholic:18:0.0248	0.0248	18
UDCA	UDCA:625	ursodeoxycholic acid:625:0.9607	0.9607	625
UDG	UDG:14	DNA repair enzyme uracil DNA glycosylase:14:0.6911	0.6911	14
UDG	UDG:49|Udg:1	uracil-DNA glycosylase:50:0.3245	0.3245	50
UDI	UDI:10	Urogenital Distress Inventory:10:0.5856	0.5856	10
UDMA	UDMA:23	urethane dimethacrylate:23:0.8715	0.8715	23
UDMH	UDMH:27	1,1-dimethylhydrazine:27:0.6190	0.6190	27
UDPGDH	UDPGDH:5|UDP-GDH:3|Udpgdh:1	UDP-glucose dehydrogenase:9:0.4587	0.4587	9
UDPGD	UDPGD:15|UDPG-D:1	uridine diphosphoglucose dehydrogenase:16:0.8165	0.8165	16
UDPGT	UDPGT:8|UDP-GT:3	microsomal UDP-glucuronyltransferase:11:0.0869	0.0869	11
UDPGT	UDPGT:72|UDP-GT:22	UDP-glucuronosyltransferase:88:0.2871|UDP glucuronosyltransferase:6:0.0731	0.2871	94
UDPGT	UDPGT:4|UDP-GT:3|UDPG-T:1	uridine diphosphate glucuronosyltransferase:8:0.5006	0.5006	8
UDPGT	UDPGT:3|UDP-GT:2|UDPG-T:1	uridine diphosphate glucuronyltransferase:6:0.5290	0.5290	6
UDP-Gal	UDP-Gal:6|UDPGal:2|UDPgal:1	uridine diphosphate galactose:9:0.6794	0.6794	9
UDPG	UDPG:9	uridine diphosphate glucose:9:0.6794	0.6794	9
UDPG	UDPG:15|UDPg:1	uridine diphosphoglucose:16:0.8165	0.8165	16
U-DPD	U-DPD:6|uDPD:5|Udpd:2|UDPD:2|udpd:1|u-DPD:1|u-Dpd:1	deoxypyridinoline:18:0.8500	0.8500	18
UDP	UDP:19	uridine 5'-diphosphate:19:0.6903	0.6903	19
UDP	UDP:42	uridine diphosphate:42:0.8558	0.8558	42
udp	udp:10|Udp:1	uridine phosphorylase:11:0.7357	0.7357	11
UDSMR	UDSMR:7|UDSmr:3	Uniform Data System for Medical Rehabilitation:10:0.7103	0.7103	10
UDS	UDS:522	Unscheduled DNA synthesis:522:0.9793	0.9793	522
UDS	UDS:19	Urodynamic study:10:0.7103|urodynamic studies:9:0.4587	0.7103	19
UDT	UDT:21	undescended testes:11:0.7357|undescended testis:10:0.7103	0.7357	21
UD	UD:15	ulcer disease:15:0.6386	0.6386	15
UD	UD:7|ud:3	ultradistal:10:0.0443	0.0443	10
UD	UD:27	unrelated donor:19:0.8449|unrelated donors:8:0.5006	0.8449	27
UEA	UEA:30	Ulex europaeus agglutinin:30:0.9043	0.9043	30
UEA	UEA:9	Ulex europeus agglutinin I:9:0.6794	0.6794	9
UEA-1	UEA-1:10|UEA1:3	Ulex europaeus:13:0.7753	0.7753	13
UEA-1	UEA-1:7|UEA1:2	Ulex europaeus agglutinin:9:0.7103	0.7103	9
UEA-1	UEA-1:32|UEA1:4	Ulex europaeus agglutinin-1:22:0.8657|Ulex europaeus agglutinin 1:14:0.7909	0.8657	36
UEA-1	UEA-1:8|UEA1:6	Ulex europaeus agglutinin I:14:0.7909	0.7909	14
UEA-I	UEA-I:22|UEAI:4	Ulex europaeus:26:0.8861	0.8861	26
UEA-I	UEA-I:13|UEAI:2	Ulex europaeus agglutinin:15:0.8045	0.8045	15
UEA-I	UEA-I:97|UEAI:11	Ulex europaeus agglutinin I:64:0.9526|Ulex Europaeus Agglutinin-I:44:0.9323	0.9526	108
UEA-I	UEA-I:12	Ulex europaeus-I:12:0.7571	0.7571	12
UEBP	UEBP:22	unusual estrogen-binding protein:22:0.7400	0.7400	22
UEBW	UEBW:11	bladder weight:11:0.7357	0.7357	11
UEC	UEC:12	uterine epithelial cells:12:0.5664	0.5664	12
UEDVT	UEDVT:10	deep vein thrombosis:10:0.7103	0.7103	10
UEDVT	UEDVT:11	upper extremity deep venous thrombosis:11:0.7357	0.7357	11
U-EPX	U-EPX:6|uEPX:1|u-EPX:1|UEPX:1	Urinary eosinophil protein X:9:0.4587	0.4587	9
UES	UES:5	Undifferentiated embryonal sarcoma:5:0.7103	0.7103	5
UES	UES:148	upper esophageal sphincter:148:0.9210	0.9210	148
UE	UE:40	upper extremity:40:0.9256	0.9256	40
UFCT	UFCT:22|UF-CT:1	ultrafast computed tomography:23:0.8038	0.8038	23
UFC	UFC:103|U-FC:1	urinary free cortisol:104:0.8030	0.8030	104
UFC	UFC:8	urinary free cortisol excretion:8:0.6411	0.6411	8
UFE	UFE:23	uterine fibroid embolization:23:0.8715	0.8715	23
UFF	UFF:11	Ultrafiltration failure:11:0.6182	0.6182	11
UFFI	UFFI:7	urea formaldehyde foam insulation:7:0.5926	0.5926	7
UFH	UFH:592|UF-H:1	unfractionated heparin:593:0.9401	0.9401	593
UFN	UFN:7	unreamed femoral nail:7:0.4438	0.4438	7
UFOV	UFOV:17	Useful Field of View:17:0.8270	0.8270	17
UFO	UFO:13|ufo:2	UNUSUAL FLORAL ORGANS:15:0.8045	0.8045	15
UFP	UFP:12	ultrafine particles:12:0.6460	0.6460	12
UFR	UFR:15	ultrafiltration rate:15:0.1687	0.1687	15
UFR	UFR:20	urine flow rate:20:0.4379	0.4379	20
UFS	UFS:8	force-moment sensor:8:0.3463	0.3463	8
UFs	UFs:14	uncertainty factors:14:0.7753	0.7753	14
UFT	UFT:33	Tegafur/Uracil:17:0.0693|Tegafur-Uracil:16:0.0649	0.0693	33
UFT	UFT:1	tegafur with uracil:1:0.3026	0.3026	1
UFT	UFT:23	uracil and tegafur:23:0.4652	0.4652	23
UFT	UFT:35	uracil/tegafur:19:0.0779|uracil-tegafur:16:0.0649	0.0779	35
UF	UF:6	flow rate:6:0.1838	0.1838	6
UF	UF:27|uf:2|Uf:2	ultrafiltrate:31:0.0427	0.0427	31
UF	UF:324|uf:3	ultrafiltration:327:0.4644	0.4644	327
UF	UF:34	unfractionated:34:0.0470	0.0470	34
UF	UF:15	urinary flow:15:0.1400	0.1400	15
UF	UF:37	urine flow:37:0.5384	0.5384	37
Uf	Uf:14|UF:12	uteroferrin:26:0.0356	0.0356	26
UGB	UGB:9	upper gastrointestinal bleeding:9:0.6794	0.6794	9
UGCR	UGCR:13	ultrasound-guided compression repair:13:0.5934	0.5934	13
UGDP	UGDP:15	university group diabetes program:15:0.8045	0.8045	15
UGE	UGE:11	upper gastrointestinal endoscopy:11:0.7357	0.7357	11
UGFNAB	UGFNAB:5|UG-FNAB:4|ug-FNAB:1	aspiration biopsy:10:0.7103	0.7103	10
uGH	uGH:10|U-GH:2|u-GH:2	urinary GH:14:0.6911	0.6911	14
uGH	uGH:9|U-GH:6|UGH:5|u-GH:3	urinary growth hormone:23:0.8715	0.8715	23
UGIB	UGIB:51	upper gastrointestinal bleeding:51:0.9416	0.9416	51
UGIE	UGIE:11	upper gastrointestinal endoscopy:11:0.7357	0.7357	11
UGIH	UGIH:10	upper gastrointestinal hemorrhage:10:0.7103	0.7103	10
UGIS	UGIS:9	upper gastrointestinal series:9:0.6794	0.6794	9
UGIT	UGIT:7	upper gastrointestinal tract:7:0.5926	0.5926	7
Ugi	Ugi:7	bacteriophage PBS2 uracil-DNA glycosylase inhibitor:7:0.5926	0.5926	7
UGI	UGI:156|uGI:1	upper gastrointestinal:157:0.9809	0.9809	157
UGI	UGI:14	upper gastrointestinal series:14:0.7909	0.7909	14
UGM	UGM:20	urogenital sinus mesenchyme:20:0.8594	0.8594	20
UGPase	UGPase:15	pyrophosphorylase:15:0.8750	0.8750	15
UGP	UGP:19	Urinary gonadotropin peptide:19:0.8449	0.8449	19
UGS	UGS:31	urogenital sinus:31:0.9043	0.9043	31
UGT	UGT:10	UDP-glucuronosyl transferase:10:0.1680	0.1680	10
UGT	UGT:273	UDP-glucuronosyltransferase:237:0.5514|UDP-glucuronosyltransferases:28:0.0631|UDP glucuronosyltransferase:8:0.0672	0.5514	273
UGT	UGT:16	UDP-glucuronyltransferase:16:0.0350	0.0350	16
UGT	UGT:4	uridine diphosphate glucuronosyl transferase:4:0.3170	0.3170	4
UGT	UGT:21	uridine diphosphate glucuronosyltransferase:21:0.8594	0.8594	21
UGT1A1	UGT1A1:6	bilirubin UDP-glucuronosyltransferase:6:0.0807	0.0807	6
UGT1A1	UGT1A1:5	bilirubin UDP-glucuronosyltransferase gene:5:0.2818	0.2818	5
UGT1A1	UGT1A1:7	phenol UDP-glucuronosyltransferase:7:0.1329	0.1329	7
UGT1A1	UGT1A1:6|UGT-1A1:2	UDP-glucuronosyltransferase 1:8:0.3463	0.3463	8
UGT1A1	UGT1A1:15	UDP-glucuronosyltransferase 1A1:15:0.2344	0.2344	15
UGT1	UGT1:8	UDP-glucuronosyltransferase family 1:8:0.6411	0.6411	8
UGTs	UGTs:125|UGTS:1	UDP-glucuronosyltransferases:126:0.7225	0.7225	126
UGTs	UGTs:6	Uridine diphosphate glucuronosyltransferases:6:0.5290	0.5290	6
UG	UG:17	unleaded gasoline:17:0.8270	0.8270	17
UG	UG:45|Ug:1	uteroglobin:46:0.2885	0.2885	46
UHC	UHC:11	University HealthSystem Consortium:11:0.7357	0.7357	11
UHC	UHC:10	University Hospital Consortium:10:0.7103	0.7103	10
UHDBT	UHDBT:9	5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole:9:0.5714	0.5714	9
UHDRS	UHDRS:16	Unified Huntington's Disease Rating Scale:16:0.8165	0.8165	16
UHF	UHF:10	frequency:10:0.3913	0.3913	10
U-Hg	U-Hg:9	urinary mercury:9:0.5470	0.5470	9
UHMW	UHMW:11	molecular weight:11:0.7357	0.7357	11
UHMWPE	UHMWPE:59|UHMW-PE:6	ultrahigh molecular weight polyethylene:65:0.1867	0.1867	65
UHN	UHN:9	unreamed humeral nail:9:0.6794	0.6794	9
UHS	UHS:8	uncontrolled hemorrhagic shock:8:0.6794	0.6794	8
UHT	UHT:25	temperature:25:0.4444	0.4444	25
UHV	UHV:13	ultrahigh vacuum:13:0.6701	0.6701	13
UHWI	UHWI:46	University Hospital of the West Indies:46:0.9366	0.9366	46
UH	UH:9	unfavorable histology:9:0.3945	0.3945	9
UH	UH:97	unfractionated heparin:97:0.8385	0.8385	97
UH	UH:14	University Hospital:14:0.5589	0.5589	14
UIBC	UIBC:26|uIBC:1	unsaturated iron binding capacity:27:0.6745	0.6745	27
UIC	UIC:9	University of Illinois at Chicago:9:0.6794	0.6794	9
UIC	UIC:11	urinary iodine concentration:11:0.6182	0.6182	11
UICC	UICC:8	Union Internacional Contra la Cancrum:8:0.6411	0.6411	8
UIE	UIE:27	urinary iodine excretion:27:0.8903	0.8903	27
UIHC	UIHC:18	University of Iowa Hospitals and Clinics:18:0.8365	0.8365	18
UII	UII:53|U-II:51	Urotensin II:71:0.8592|Urotensin-II:33:0.2832	0.8592	104
UIP	UIP:14	undegradable intake protein:14:0.5111	0.5111	14
UIP	UIP:141	usual interstitial pneumonia:141:0.8926	0.8926	141
UI	UI:22	ulcer index:22:0.2359	0.2359	22
UI	UI:11	unexplained infertility:11:0.7357	0.7357	11
UI	UI:16	unsaturation index:16:0.1436	0.1436	16
UI	UI:275	Urinary incontinence:275:0.9102	0.9102	275
UI	UI:21	urinary iodine:21:0.6400	0.6400	21
UI	UI:28	Urotensin I:28:0.7581	0.7581	28
UKCC	UKCC:1	United Kingdom Central Council for Nursing Midwifery and Health Visiting:1:0.8657	0.8657	1
UKE	UKE:10	urinary kallikrein excretion:10:0.7103	0.7103	10
UKM	UKM:9	Universiti Kebangsaan Malaysia:9:0.4587	0.4587	9
UKM	UKM:13|UkM:1	urea kinetic model:14:0.7909	0.7909	14
UKM	UKM:30	urea kinetic modeling:30:0.9011	0.9011	30
UKM	UKM:12	urea kinetic modelling:12:0.7571	0.7571	12
UKPDS	UKPDS:63	United Kingdom Prospective Diabetes Study:63:0.9519	0.9519	63
UKR	UKR:9	unicompartmental knee replacement:9:0.6794	0.6794	9
UKU	UKU:13	Udvalg for Kliniske Undersogelser:13:0.5335	0.5335	13
UKV	UKV:14|UkV:1	urinary potassium excretion:15:0.2845	0.2845	15
UK	UK:470	United Kingdom:470:0.9936	0.9936	470
UK	UK:357|Uk:2	Urokinase:359:0.2502	0.2502	359
UL54	UL54:10	DNA polymerase:10:0.5000	0.5000	10
ULD	ULD:13	Unverricht-Lundborg disease:13:0.4444	0.4444	13
ULF	ULF:10	Uterine luminal fluid:10:0.7103	0.7103	10
ULLS	ULLS:7	Unilateral lower limb suspension:7:0.5926	0.5926	7
ULN	ULN:63	upper limit of normal:63:0.9033	0.9033	63
ULO	ULO:30	Unilateral ovariectomy:30:0.9011	0.9011	30
ULO	ULO:15	unilaterally ovariectomized:15:0.8045	0.8045	15
ULV	ULV:26	ultra-low volume:17:0.2379|ultra-low-volume:9:0.0800	0.2379	26
ULV	ULV:11	ultralow volume:11:0.1098	0.1098	11
ULV	ULV:31	upper limit of vulnerability:31:0.9072	0.9072	31
ULvWF	ULvWF:6|ULVWF:6|UlvWF:1	von Willebrand factor:13:0.7753	0.7753	13
UMATI	UMATI:10	Family Planning Association of Tanzania:10:0.7103	0.7103	10
UMC	UMC:6	University Medical Center:6:0.2827	0.2827	6
UME-21	UME-21:21	Undergraduate Medical Education for the 21st Century:21:0.8657	0.8657	21
UML	UML:17	Unified Modeling Language:17:0.7407	0.7407	17
UMLS	UMLS:121	Unified Medical Language System:121:0.9478	0.9478	121
UMMC	UMMC:12	Medical Center:12:0.7571	0.7571	12
UMN	UMN:40	upper motor neuron:40:0.9274	0.9274	40
UMP	UMP:28	uridine 5'-monophosphate:28:0.8941	0.8941	28
UMP	UMP:39	uridine monophosphate:39:0.8142	0.8142	39
UMR-106	UMR-106:7	rat osteosarcoma cells:7:0.2452	0.2452	7
UMS	UMS:7	Ulnar-mammary syndrome:7:0.3524	0.3524	7
UM	UM:22	Utilization management:22:0.8657	0.8657	22
UM	UM:10	uveal melanoma:10:0.7103	0.7103	10
U-NAG	U-NAG:14|UNAG:6|u-NAG:2	N-acetyl-beta-D-glucosaminidase:22:0.6000	0.6000	22
UNAIDS	UNAIDS:5	Joint UN Program on HIV/AIDS:5:0.1464	0.1464	5
UNA	UNA:16	urea nitrogen appearance:16:0.8165	0.8165	16
UNa	UNa:9|UNA:1|U-Na:1	urinary Sodium:11:0.2582	0.2582	11
UNa	UNa:7|UNA:1	urinary sodium excretion:8:0.3463	0.3463	8
unc	unc:9|Unc:1	uncoordinated:10:0.1200	0.1200	10
UNC	UNC:12	University of North Carolina:12:0.7571	0.7571	12
UNDP	UNDP:7	UN development Program:7:0.1850	0.1850	7
UNDP	UNDP:6	United Nations Development Program:6:0.5290	0.5290	6
UNDW	UNDW:46	ultrasonically nebulized distilled water:46:0.9353	0.9353	46
UNE	UNE:19|UN-E:1	ulnar neuropathy at the elbow:20:0.8594	0.8594	20
UNE	UNE:5|UNe:2|U-NE:1	urinary norepinephrine:8:0.2987	0.2987	8
UNFPA	UNFPA:9	UN Fund for Population Activities:9:0.1099	0.1099	9
UNFPA	UNFPA:49	UN Population Fund:49:0.3524	0.3524	49
UNFPA	UNFPA:16	United Nations Fund for Population Activities:16:0.8165	0.8165	16
UNFPA	UNFPA:56	United Nations Population Fund:56:0.9467	0.9467	56
UNHS	UNHS:27	universal newborn hearing screening:27:0.8903	0.8903	27
UNICEF	UNICEF:10	UN International Children's Emergency Fund:10:0.3470	0.3470	10
uNK	uNK:26|unk:1|u-NK:1	uterine natural killer:28:0.8369	0.8369	28
uNK	uNK:10	uterine NK:10:0.5856	0.5856	10
UNM	UNM:11	University of New Mexico:11:0.7357	0.7357	11
UNOS	UNOS:151	United Network for Organ Sharing:151:0.9630	0.9630	151
UNPC	UNPC:8	undifferentiated nasopharyngeal carcinoma:8:0.6411	0.6411	8
UNX	UNX:16	after uninephrectomy:16:0.1928	0.1928	16
UNX	UNX:35|UNx:9|uNX:4|Unx:1	unilateral nephrectomy:49:0.8034	0.8034	49
UNX	UNX:13|UNx:10|Unx:3	uninephrectomized:26:0.1838	0.1838	26
UNaV	UNaV:10	sodium excretion rate:10:0.5000	0.5000	10
UNaV	UNaV:38	urinary excretion of sodium:38:0.7548	0.7548	38
UNaV	UNaV:121|UNAV:1	urinary sodium excretion:122:0.4518	0.4518	122
UN	UN:5	after uninephrectomy:5:0.1132	0.1132	5
UN	UN:12	undernourished:12:0.0431	0.0431	12
un	un:10|Un:1	undulated:11:0.0392	0.0392	11
UN	UN:16	unilateral nephrectomy:16:0.8165	0.8165	16
UN	UN:40	United Nations:40:0.9256	0.9256	40
UN	UN:32	uranyl nitrate:32:0.9043	0.9043	32
UN	UN:47	urea nitrogen:47:0.7960	0.7960	47
UOS	UOS:13	upper oesophageal sphincter:13:0.7096	0.7096	13
UOX	UOX:8|Uox:3	urate oxidase:11:0.7357	0.7357	11
UP1	UP1:9	protein 1:9:0.6794	0.6794	9
u-PA	u-PA:5|uPA:5|UPA:1	plasminogen activators:11:0.5355	0.5355	11
UPA	UPA:12	Underprivileged Area:12:0.6460	0.6460	12
uPA	uPA:197|u-PA:113|UPA:3|uPa:1	urokinase:314:0.1137	0.1137	314
uPA	uPA:12|u-PA:5	urokinase PA:17:0.0555	0.0555	17
uPA	uPA:386|u-PA:72|UPA:9	urokinase plasminogen activator:467:0.2077	0.2077	467
u-PA	u-PA:16|uPA:8|U-PA:1|UPA:1	urokinase type:26:0.6645	0.6645	26
uPA	uPA:70|u-PA:55|UPA:1	urokinase-type PA:107:0.6228|urokinase type PA:19:0.7658	0.7658	126
uPA	uPA:951|u-PA:420|UPA:25|U-PA:2|uPa:2|u-Pa:1	urokinase-type plasminogen activator:1401:0.6617	0.6617	1401
UPDRS	UPDRS:318|UP-DRS:1	Unified Parkinson's Disease Rating Scale:319:0.9544	0.9544	319
UPD	UPD:205|upd:1	uniparental disomy:206:0.9355	0.9355	206
UPEC	UPEC:25	Uropathogenic Escherichia coli:25:0.6873	0.6873	25
UPE	UPE:21	urinary protein excretion:21:0.7865	0.7865	21
UPF	UPF:14	ultraviolet protection factor:14:0.3585	0.3585	14
UPJ	UPJ:189	ureteropelvic junction:189:0.9006	0.9006	189
UPJO	UPJO:40|UPJ-O:2	ureteropelvic junction obstruction:42:0.8558	0.8558	42
UPMC	UPMC:12	University of Pittsburgh Medical Center:12:0.7571	0.7571	12
UPOs	UPOs:8	unstable periodic orbits:8:0.6411	0.6411	8
UPPP	UPPP:210	Uvulopalatopharyngoplasty:210:0.8750	0.8750	210
UPPs	UPPs:7|UPPS:2	Undecaprenyl pyrophosphate synthase:9:0.6794	0.6794	9
UPP	UPP:17	ubiquitin-proteasome pathway:17:0.4035	0.4035	17
UPP	UPP:47	urethral pressure profile:37:0.8377|urethral pressure profiles:10:0.7103	0.8377	47
UPP	UPP:18	urethral pressure profilometry:18:0.8365	0.8365	18
UPRT	UPRT:23	uracil phosphoribosyltransferase:23:0.7500	0.7500	23
UPR	UPR:166	unfolded protein response:166:0.9712	0.9712	166
UPSC	UPSC:72	uterine papillary serous carcinoma:72:0.9124	0.9124	72
UPSIT	UPSIT:71|UP-SIT:1	University of Pennsylvania Smell Identification Test:72:0.9585	0.9585	72
UPS	UPS:11	photoelectron spectroscopy:11:0.5355	0.5355	11
UPS	UPS:40|UP-S:1	ubiquitin-proteasome system:41:0.6072	0.6072	41
UPs	UPs:11	Uroplakins:11:0.0794	0.0794	11
UPTAH	UPTAH:9	undulation pump total artificial heart:9:0.6794	0.6794	9
UPTC	UPTC:13	urease-positive thermophilic Campylobacter:13:0.7753	0.7753	13
UPase	UPase:17	uridine phosphorylase:17:0.8270	0.8270	17
UP	UP:19|uP:1|U-P:1|up:1|Up:1	protein:23:0.0501	0.0501	23
UP	UP:27|up:1	unipolar:28:0.0615	0.0615	28
UP	UP:21	Universal Precautions:21:0.8594	0.8594	21
UP	UP:10|Up:1	upstream:11:0.0228	0.0228	11
UP	UP:7	ureteral pressure:7:0.2113	0.2113	7
UP	UP:13	uridine phosphorylase:13:0.7753	0.7753	13
UP	UP:9|U-P:1	urinary protein excretion:10:0.5000	0.5000	10
UP	UP:12|Up:1	uroporphyrin:13:0.0273	0.0273	13
UP	UP:24	Urticaria pigmentosa:24:0.8768	0.8768	24
UP	UP:14	Uttar Pradesh:14:0.7909	0.7909	14
UQ10	UQ10:6|UQ-10:5	ubiquinone-10:11:0.6667	0.6667	11
UQ	UQ:43	Ubiquinone:43:0.6774	0.6774	43
URE	URE:15	upstream regulatory element:15:0.8045	0.8045	15
URE	URE:9	urethane:9:0.1633	0.1633	9
URF	URF:12	reading frame:12:0.7571	0.7571	12
URFs	URFs:14	reading frames:14:0.8045	0.8045	14
URI	URI:12	upper respiratory illness:12:0.7571	0.7571	12
URI	URI:75	upper respiratory infection:50:0.9404|Upper respiratory infections:25:0.8816	0.9404	75
URI	URI:53	upper respiratory tract infection:42:0.9291|upper respiratory tract infections:11:0.7357	0.9291	53
URIs	URIs:30	upper respiratory infections:30:0.9011	0.9011	30
URIs	URIs:22	upper respiratory tract infections:22:0.8657	0.8657	22
URL	URL:8	upper reference limit:8:0.6411	0.6411	8
URM	URM:17	underrepresented minority:17:0.6748	0.6748	17
UROD	UROD:42|URO-D:36|Uro-D:4|UroD:2	uroporphyrinogen decarboxylase:84:0.9091	0.9091	84
UROgen	urogen:3|UROgen:3|UROGEN:2|Urogen:1	uroporphyrinogen:9:0.8889	0.8889	9
UROS	UROS:8|URO-S:1	uroporphyrinogen III synthase:9:0.6794	0.6794	9
URO	URO:19|Uro:3	urodilatin:22:0.3043	0.3043	22
URO	URO:19|uro:2|Uro:1	uroporphyrin:22:0.3043	0.3043	22
URR	URR:69	upstream regulatory region:69:0.9100	0.9100	69
URR	URR:75	urea reduction ratio:75:0.9370	0.9370	75
URSO	URSO:5|Urso:4|urso:2	Ursodeoxycholic acid:11:0.4728	0.4728	11
URTD	URTD:13	upper respiratory tract disease:13:0.7753	0.7753	13
URTI	URTI:150	upper respiratory tract infection:104:0.9259|upper respiratory tract infections:46:0.9353	0.9353	150
URTIs	URTIs:44|uRTIs:1	upper respiratory tract infections:45:0.9338	0.9338	45
URT	URT:53	upper respiratory tract:53:0.9438	0.9438	53
URs	URs:7	unconditioned responses:7:0.2452	0.2452	7
URS	URS:8	upstream repression sequence:8:0.6411	0.6411	8
URS	URS:19	ureterorenoscopy:19:0.1259	0.1259	19
URS	URS:26	ureteroscopy:26:0.1748	0.1748	26
UR	UR:28	unconditioned response:28:0.6295	0.6295	28
UR	UR:9	uptake ratio:9:0.6794	0.6794	9
UR	UR:9|Ur:1	uridine:10:0.0354	0.0354	10
UR	UR:10	urinary retention:10:0.5856	0.5856	10
UR	UR:36	utilization review:36:0.8716	0.8716	36
USAID	USAID:21	United States Agency for International Development:21:0.8594	0.8594	21
USAID	USAID:69	US Agency for International Development:69:0.6008	0.6008	69
USA	USA:12	United States:12:0.5050	0.5050	12
USA	USA:85	United States of America:85:0.9648	0.9648	85
USC	USC:12	University of Southern California:12:0.7571	0.7571	12
USC	USC:13	Uterine serous carcinoma:13:0.7753	0.7753	13
USDA	USDA:24	US Department of Agriculture:24:0.1102	0.1102	24
USEPA	USEPA:24|US-EPA:2	United States Environmental Protection Agency:26:0.8861	0.8861	26
USE	USE:18	ultrasonic examination:18:0.5560	0.5560	18
USE	USE:14	Upstream Sequence Element:14:0.7909	0.7909	14
USF	USF:97	upstream stimulatory factor:86:0.9449|upstream stimulatory factors:11:0.7357	0.9449	97
USF-1	USF-1:4|USF1:3	Upstream stimulating factor-1:7:0.5926	0.5926	7
USF1	USF1:17|USF-1:10	upstream stimulatory factor 1:18:0.8165|upstream stimulatory factor-1:9:0.6794	0.8165	27
USF2	USF2:10|USF-2:1	upstream stimulatory factor 2:11:0.7357	0.7357	11
USFDA	USFDA:15|US-FDA:2	Food and Drug Administration:17:0.8270	0.8270	17
US-FNAB	US-FNAB:10	ultrasound-guided fine-needle aspiration biopsy:10:0.4363	0.4363	10
USG	USG:11	ultrasonographic:11:0.0592	0.0592	11
USG	USG:97	ultrasonography:97:0.5680	0.5680	97
USG	USG:6|Usg:4|U-SG:1	urine specific gravity:11:0.5664	0.5664	11
USH1	USH1:8|USH-1:1	Usher syndrome type 1:9:0.6794	0.6794	9
USH1	USH1:11	Usher syndrome type I:11:0.7357	0.7357	11
USH2	USH2:10	Usher syndrome type II:10:0.7103	0.7103	10
USI	USI:7	ultrasonic investigation:7:0.1111	0.1111	7
USI	USI:9	ultrasound investigation:9:0.2102	0.2102	9
USI	USI:10	universal salt iodization:10:0.7103	0.7103	10
USI	USI:30	urinary stress incontinence:30:0.5315	0.5315	30
USI	USI:12	urodynamic stress incontinence:12:0.1227	0.1227	12
USMGs	USMGs:18	medical graduates:18:0.6903	0.6903	18
USMLE	USMLE:52	United States Medical Licensing Examination:52:0.9427	0.9427	52
USN	USN:29	unilateral spatial neglect:29:0.8978	0.8978	29
uSpA	uSpA:12|USpA:2	undifferentiated SpA:14:0.7909	0.7909	14
uSpA	uSpA:12|USpA:4|uSpa:1|USpa:1	undifferentiated spondyloarthropathy:18:0.6903	0.6903	18
USPC	USPC:9	uterine serous papillary carcinoma:9:0.6794	0.6794	9
USPHS	USPHS:22	United States Public Health Service:22:0.8657	0.8657	22
USPIO	USPIO:53	ultrasmall superparamagnetic iron oxide:53:0.8572	0.8572	53
USPIO	USPIO:8	ultrasmall superparamagnetic iron oxide particles:8:0.6411	0.6411	8
USPSTF	USPSTF:13	US Preventive Services Task Force:13:0.1114	0.1114	13
USP	USP:7	ultraspiracle protein:7:0.1025	0.1025	7
USP	USP:61	United States Pharmacopeia:61:0.9511	0.9511	61
USP	USP:21	United States Pharmacopoeia:21:0.8594	0.8594	21
USS	USS:17	ultrasound scan:17:0.8270	0.8270	17
USS	USS:7	ultrasound scanning:7:0.2452	0.2452	7
USS	USS:10	Universal Spine System:10:0.7103	0.7103	10
USVI	USVI:10	Virgin Islands:10:0.7103	0.7103	10
USVs	USVs:52	ultrasonic vocalizations:52:0.9427	0.9427	52
USV	USV:61	ultrasonic vocalization:40:0.8839|ultrasonic vocalizations:21:0.6812	0.8839	61
US	US:9	California:9:0.0012	0.0012	9
US	US:8|Us:5	short unique:13:0.6173	0.6173	13
US	US:34	sonographic:34:0.0049	0.0049	34
US	US:102	sonography:102:0.0149	0.0149	102
US	US:38	ultrasonic:38:0.0054	0.0054	38
US	US:310	ultrasonographic:310:0.0454	0.0454	310
US	US:20	ultrasonographically:20:0.0028	0.0028	20
US	US:1950|Us:1	ultrasonography:1951:0.2867	0.2867	1951
US	US:2828|Us:1	ultrasound:2809:0.4129|Ultrasounds:20:0.0028	0.4129	2829
US	US:13	ultrasound examination:13:0.4849	0.4849	13
US	US:8	ultrasound imaging:8:0.5006	0.5006	8
US	US:20	ultrasound scan:20:0.8525	0.8525	20
US	US:11	ultrasound scanning:11:0.3495	0.3495	11
US	US:432|Us:1|us:1	unconditioned stimulus:434:0.8355	0.8355	434
US	US:23|Us:12	unique short:35:0.9151	0.9151	35
US	US:258	United States:258:0.9884	0.9884	258
US	US:9	United States of America:9:0.6794	0.6794	9
US	US:7	Usher syndrome:7:0.2113	0.2113	7
UTC	UTC:14	ultrasonic tissue characterization:14:0.7909	0.7909	14
UTC	UTC:10	undifferentiated thyroid carcinoma:10:0.7103	0.7103	10
UTD	UTD:21	up-to-date:21:0.7143	0.7143	21
UTE	UTE:8|Ute:1	ultrashort TE:9:0.6794	0.6794	9
UTIs	UTIs:452	Urinary tract infections:452:0.9858	0.9858	452
UTI	UTI:12	ulinastatin:12:0.0067	0.0067	12
UTI	UTI:10	urinary tract:10:0.7103	0.7103	10
UTI	UTI:1467|uti:1	urinary tract infection:1046:0.9910|urinary tract infections:422:0.9812	0.9910	1468
UTI	UTI:103|uTi:2	urinary trypsin inhibitor:105:0.9543	0.9543	105
UTJ	UTJ:31	junction:31:0.8571	0.8571	31
UTMB	UTMB:15	University of Texas Medical Branch:15:0.8045	0.8045	15
UTN	UTN:12	unreamed tibial nail:12:0.4153	0.4153	12
UTP	UTP:18	uridine-5'-triphosphate:18:0.0482	0.0482	18
UTR	UTR:301|utr:2	3' untranslated region:303:0.4352	0.4352	303
UTR	UTR:14	5' and 3' untranslated regions:14:0.2524	0.2524	14
UTR	UTR:314|utr:1	5' untranslated region:298:0.4274|5' untranslated regions:17:0.1469	0.4274	315
UTS	UTS:51	Ullrich-Turner syndrome:51:0.8102	0.8102	51
UTS	UTS:46	ultimate tensile strength:46:0.9353	0.9353	46
UTT	UTT:6	urinary tract tumors:6:0.3728	0.3728	6
UT	UT:17	3' untranslated:17:0.4246	0.4246	17
UT	UT:9	ulinastatin:9:0.0183	0.0183	9
UT	UT:92	untrained:92:0.2078	0.2078	92
UT	UT:19	untrained subjects:19:0.7658	0.7658	19
UT	UT:26	untreated:26:0.0571	0.0571	26
UT	UT:9	urinary tract:9:0.6794	0.6794	9
UT	UT:12	utricular:12:0.0251	0.0251	12
UUI	UUI:12	urge urinary incontinence:12:0.6460	0.6460	12
UUI	UUI:5	urinary urge incontinence:5:0.1464	0.1464	5
UUN	UUN:18	Urinary urea nitrogen:18:0.5560	0.5560	18
UUO	UUO:216	unilateral ureteral obstruction:216:0.9568	0.9568	216
UUT	UUT:43	upper urinary tract:33:0.9126|upper urinary tracts:10:0.7103	0.9126	43
UV-Vis	UV-Vis:19|UV-vis:10|UV-VIS:5	ultraviolet-visible:34:0.3750	0.3750	34
UVA1	UVA1:10	ultraviolet A1:10:0.7103	0.7103	10
UVA	UVA:4	320-400 nm:4:0.1273	0.1273	4
UVA	UVA:19|UV-A:2	long-wave ultraviolet:21:0.2677	0.2677	21
UVA	UVA:5|UV-A:4	near-ultraviolet:9:0.0183	0.0183	9
UVA	UVA:42|UV-A:22	ultraviolet-A:64:0.1438	0.1438	64
UVA	UVA:7	ultraviolet irradiation:7:0.1850	0.1850	7
UVA	UVA:55|UV-A:18	ultraviolet light:73:0.7269	0.7269	73
UVA	UVA:34|UV-A:6	ultraviolet radiation:40:0.5578	0.5578	40
UVB	UVB:5|UV-B:1	280-320 nm:6:0.1061	0.1061	6
UVB	UVB:8|UV-B:1	phototherapy:9:0.0083	0.0083	9
UVB	UVB:20|UV-B:5	ultraviolet:25:0.0248	0.0248	25
UVB	UVB:504|UV-B:128|uvB:1|uvb:1	ultraviolet B:471:0.8935|ultraviolet-B:163:0.1677	0.8935	634
UVB	UVB:6	ultraviolet B irradiation:6:0.5290	0.5290	6
UVB	UVB:27|UV-B:5	Ultraviolet B light:22:0.7955|ultraviolet-B light:10:0.0537	0.7955	32
UVB	UVB:34|UV-B:15	Ultraviolet B radiation:28:0.8941|ultraviolet-B radiation:21:0.1511	0.8941	49
UVB	UVB:6	ultraviolet irradiation:6:0.0522	0.0522	6
UVB	UVB:25|UV-B:2	ultraviolet light:27:0.2835	0.2835	27
UVB	UVB:15|UV-B:5	ultraviolet radiation:20:0.1404	0.1404	20
UVCP	UVCP:12	unilateral vocal cord paralysis:12:0.7571	0.7571	12
UVC	UVC:7|UV-C:3	ultraviolet:10:0.0692	0.0692	10
UVC	UVC:22|UV-C:10	ultraviolet C:23:0.5719|ultraviolet-C:9:0.0615	0.5719	32
UVC	UVC:14|UV-C:4	ultraviolet light:18:0.4438	0.4438	18
UVC	UVC:5|UV-C:1	Ultraviolet radiation:6:0.1320	0.1320	6
UVDE	UVDE:8	UV damage endonuclease:8:0.4102	0.4102	8
UVD	UVD:29|uVD:2	unilateral vestibular deafferentation:31:0.9043	0.9043	31
UVFP	UVFP:13	unilateral vocal fold paralysis:13:0.7753	0.7753	13
UVGI	UVGI:10	ultraviolet germicidal irradiation:10:0.4363	0.4363	10
UVI	UVI:12|UV-I:1	ultraviolet irradiation:13:0.5934	0.5934	13
UVJ	UVJ:42	junction:42:0.8039	0.8039	42
UVL	UVL:32	ultraviolet light:32:0.8145	0.8145	32
UVRR	UVRR:47	resonance Raman:47:0.8187	0.8187	47
UVR	UVR:10|uvR:1	ultraviolet irradiation:11:0.4728	0.4728	11
UVR	UVR:417	Ultraviolet radiation:417:0.8373	0.8373	417
UV-DDB	UV-DDB:6|UVdDb:1	DNA binding protein:7:0.5926	0.5926	7
UV	UV:63	ultra-violet:37:0.0094|ultra violet:26:0.8816	0.8816	63
UV	UV:2699|uv:41	Ultraviolet:2740:0.7162	0.7162	2740
UV	UV:6	ultraviolet absorption:6:0.1838	0.1838	6
UV	UV:29	ultraviolet irradiation:29:0.6928	0.6928	29
UV	UV:260|uv:6	ultraviolet light:266:0.9074	0.9074	266
UV	UV:120|uv:1	ultraviolet radiation:121:0.8939	0.8939	121
UV	UV:71|Uv:2|uv:2	umbilical vein:75:0.6938	0.6938	75
UV	UV:6	Urinary flow rate:6:0.1010	0.1010	6
UV	UV:24|Uv:1|uV:1	urinary volume:26:0.1503	0.1503	26
UV	UV:22	Urine flow:22:0.6531	0.6531	22
UV	UV:8	urine flow rate:8:0.2327	0.2327	8
UV	UV:7|Uv:2	urine output:9:0.6794	0.6794	9
UV	UV:73|Uv:1	urine volume:74:0.5859	0.5859	74
UWL	UWL:27	unstirred water layer:27:0.8903	0.8903	27
UW-QoL	UW-QoL:4|UW-QOL:1	University of Washington Quality of Life Questionnaire:5:0.4422	0.4422	5
UWS	UWS:24|UWs:4	University of Wisconsin solution:28:0.8978	0.8978	28
UWW	UWW:30|uww:1	underwater weighing:31:0.8519	0.8519	31
UW	UW:17	University of Washington:17:0.7407	0.7407	17
UW	UW:460	University of Wisconsin:460:0.9896	0.9896	460
UW	UW:104	University of Wisconsin solution:104:0.9710	0.9710	104
UXO	UXO:9	unexploded ordnance:9:0.6794	0.6794	9
UZ	UZ:10	unsaturated zone:10:0.5856	0.5856	10
Ubq	Ubq:9|UBQ:7	ubiquitin:16:0.7143	0.7143	16
Ub	Ub:167|UB:5|ub:2	ubiquitin:174:0.5059	0.5059	174
UB	UB:5	ultimobranchial body:5:0.0612	0.0612	5
UB	UB:6	unconjugated bilirubin:6:0.2243	0.2243	6
UB	UB:5	upper body:5:0.0612	0.0612	5
UB	UB:27	ureteric bud:27:0.8903	0.8903	27
UB	UB:24	urinary bladder:24:0.8768	0.8768	24
U-B	U-B:5	urine minus blood:5:0.4422	0.4422	5
UcAMP	UcAMP:5|u-cAMP:1|U-cAMP:1	Urinary cyclic AMP:7:0.4438	0.4438	7
UGT1A6	UGT1A6:7	UDP-glucuronosyltransferase 1A6:7:0.2902	0.2902	7
UKA	UKA:23	unicompartmental knee arthroplasty:23:0.5719	0.5719	23
UKA	UKA:8	urinary kallikrein activity:8:0.6411	0.6411	8
UL	UL:9	Tolerable Upper Intake Level:9:0.6794	0.6794	9
UL	UL:17	unilateral:17:0.0503	0.0503	17
UL	UL:61	unilateral labyrinthectomy:61:0.8987	0.8987	61
UL	UL:25	unique long:25:0.8186	0.8186	25
UL	UL:8	upper limb:8:0.4102	0.4102	8
Uosm	Uosm:57|UOsm:13|UOSM:7|u-osm:1	osmolality:78:0.8556	0.8556	78
UO	UO:10	ureteral obstruction:10:0.5000	0.5000	10
UO	UO:18	urine output:18:0.6903	0.6903	18
URD	URD:47	unrelated donor:29:0.8978|unrelated donors:18:0.7539	0.8978	47
UvrD	UvrD:13|uvrD:1	helicase II:14:0.6173	0.6173	14
UWB	UWB:9	ultra-wideband:9:0.4706	0.4706	9
V'E	V'E:29	minute ventilation:29:0.7237	0.7237	29
V'O2	V'O2:18|V'o2:1	oxygen consumption:19:0.7658	0.7658	19
V(1/2)	V(1/2):2	voltage of half-maximal activation:2:0.1973	0.1973	2
V(A)/Q	V(A)/Q:11	ventilation-perfusion:11:0.4545	0.4545	11
V(d)	V(d):24|V(D):2	volume of distribution:26:0.8312	0.8312	26
V(H)	V(H):20	heavy chain:20:0.7766	0.7766	20
V(H)	V(H):6	heavy chain variable:6:0.5290	0.5290	6
V(H)	V(H):7|V(h):7	holding potential:14:0.7909	0.7909	14
V(H)	V(H):16	variable heavy:16:0.2709	0.2709	16
V(MCA)	V(MCA):3|V(mca):2	blood flow velocity in the middle cerebral artery:5:0.2818	0.2818	5
V(mca)	V(mca):4|V(MCA):3	flow velocity:7:0.3524	0.3524	7
V(O(2))	V(O(2)):16	oxygen consumption:16:0.7261	0.7261	16
V(o)	V(o):11	unloaded shortening velocity:11:0.5355	0.5355	11
V(O2)	V(O2):10	oxygen consumption:10:0.3145	0.3145	10
V(O2)	V(O2):8	oxygen uptake:8:0.2327	0.2327	8
V(A)	V(A):6|V(a):3	volume:9:0.2500	0.2500	9
V(E)	V(E):43|V(e):1	minute ventilation:44:0.4200	0.4200	44
V(E)	V(E):5|V(e):2	minute volume:7:0.2452	0.2452	7
V(I)	V(I):5|V(i):1	minute ventilation:6:0.1320	0.1320	6
V(j)	V(j):12	transjunctional voltage:12:0.5664	0.5664	12
V(max)	V(max):33|v(max):1	maximal velocity:34:0.2334	0.2334	34
V(ss)	V(ss):14|V(SS):6	volume of distribution at steady state:20:0.7865	0.7865	20
V(T)	V(T):108|V(t):18|v(t):1	tidal volume:112:0.8591|tidal volumes:15:0.4609	0.8591	127
V(te)	V(te):9	transepithelial voltage:9:0.6794	0.6794	9
V-I	V-I:11	voltage-current:11:0.4167	0.4167	11
V/Q	V/Q:190|v/Q:1	ventilation/perfusion:96:0.3909|ventilation-perfusion:83:0.3374|ventilation perfusion:12:0.6767	0.6767	191
V/Q	V/Q:6	ventilation-perfusion ratio:6:0.0899	0.0899	6
V0	V0:20	shortening velocity:20:0.3744	0.3744	20
V0	V0:12	velocity of unloaded shortening:12:0.7753	0.7753	12
V0	V0:17	volume:17:0.0941	0.0941	17
V1aR	V1aR:10|V1AR:1	Vasopressin V1a receptor:11:0.5050	0.5050	11
V1a	V1a:10	vasopressin:10:0.3214	0.3214	10
V1	V1:22	central compartment:22:0.6934	0.6934	22
V1	V1:9	domain:9:0.0095	0.0095	9
V1	V1:10	primary:10:0.0107	0.0107	10
V1	V1:26	primary visual area:26:0.7760	0.7760	26
V1	V1:271|V-1:1	primary visual cortex:272:0.9212	0.9212	272
V1	V1:72	striate cortex:72:0.1599	0.1599	72
V1	V1:18	vascular:18:0.0202	0.0202	18
V1	V1:16	vasopressin:16:0.0178	0.0178	16
V1	V1:16|V-1:1	vasopressor:17:0.0190	0.0190	17
V1	V1:12	volume of distribution:12:0.5050	0.5050	12
V2O5	V2O5:23	vanadium pentoxide:23:0.8715	0.8715	23
V2R	V2R:14|V2-R:1	V2 vasopressin receptor:15:0.4312	0.4312	15
V2R	V2R:15	vasopressin V2 receptor:15:0.4609	0.4609	15
V2	V2:25	antidiuretic:25:0.0706	0.0706	25
V2	V2:24	second visual area:24:0.8115	0.8115	24
V2	V2:7	visual area 2:7:0.5926	0.5926	7
V2	V2:3	volume of the peripheral compartment:3:0.1464	0.1464	3
V3	V3:1	mandibular division of the trigeminal nerve:1:0.3170	0.3170	1
V3	V3:14	third hypervariable region:14:0.7909	0.7909	14
V3	V3:47	third variable:47:0.8433	0.8433	47
V3	V3:26|v3:1	third variable domain:27:0.8312	0.8312	27
V3	V3:31	third variable region:31:0.7388	0.7388	31
V3	V3:10	variable region 3:10:0.3867	0.3867	10
v6	v6:6	variant exon 6:6:0.3728	0.3728	6
V79-4	V79-4:10	Chinese hamster lung fibroblast:10:0.7103	0.7103	10
V79	V79:6|V-79:3	cell line:9:0.4587	0.4587	9
V79	V79:18|V-79:7	Chinese hamster:25:0.8186	0.8186	25
V79	V79:23|V-79:5	Chinese hamster cells:28:0.7505	0.7505	28
V79	V79:9|V-79:2	Chinese hamster fibroblasts:11:0.6182	0.6182	11
V79	V79:16	Chinese hamster lung:16:0.8165	0.8165	16
V79	V79:21|V-79:3	Chinese hamster lung fibroblasts:15:0.7096|Chinese hamster lung fibroblast:9:0.6794	0.7096	24
VA/Q	VA/Q:178|Va/Q:8	ventilation-perfusion:166:0.5340|ventilation/perfusion:20:0.0615	0.5340	186
VA/Q	VA/Q:51|Va/Q:1	ventilation-perfusion ratio:26:0.4719|ventilation-perfusion ratios:26:0.6645	0.6645	52
VA/Q	VA/Q:6	ventilation to perfusion:6:0.7261	0.7261	6
VABS	VABS:25	Vineland Adaptive Behavior Scales:19:0.8449|Vineland Adaptive Behavior Scale:6:0.3728	0.8449	25
VAB	VAB:16	venoarterial bypass:16:0.4274	0.4274	16
VacA	VacA:9	Helicobacter pylori vacuolating toxin:9:0.5470	0.5470	9
vacA	vacA:14	vacuolating cytotoxin gene:14:0.7909	0.7909	14
VACV	VACV:18	vaccinia virus:18:0.8365	0.8365	18
VACV	VACV:10	valaciclovir:10:0.2432	0.2432	10
VAChT	VAChT:152|VAchT:6|VACHT:3|VachT:1	vesicular acetylcholine transporter:162:0.9605	0.9605	162
VAC	VAC:17|Vac:3|vac:1	vaccinia virus:21:0.7865	0.7865	21
VAC	VAC:33	vacuum-assisted closure:25:0.5095|Vacuum Assisted Closure:8:0.6411	0.6411	33
VAC	VAC:4|V-AC:1	ventriculoatrial conduction:5:0.0902	0.0902	5
VADs	VADs:21	venous access devices:21:0.6040	0.6040	21
VADs	VADs:96|VADS:1	ventricular assist devices:97:0.9692	0.9692	97
VAD	VAD:9	vascular atherosclerotic disease:9:0.6794	0.6794	9
VAD	VAD:223	ventricular assist device:184:0.9499|ventricular assist devices:39:0.8811	0.9499	223
VAD	VAD:14	vertebral artery dissection:14:0.7909	0.7909	14
VAD	VAD:19	Vibroacoustic disease:19:0.4405	0.4405	19
VAD	VAD:11	vincristine-Adriamycin-dexamethasone:11:0.0101	0.0101	11
VAD	VAD:63	vitamin A deficiency:63:0.9003	0.9003	63
VAD	VAD:49	vitamin A-deficient:39:0.9237|vitamin A deficient:10:0.5000	0.9237	49
VAERS	VAERS:96	Vaccine Adverse Event Reporting System:73:0.9567|Vaccine Adverse Events Reporting System:23:0.8715	0.9567	96
VAE	VAE:54	venous air embolism:54:0.9448	0.9448	54
VAHS	VAHS:51	virus-associated hemophagocytic syndrome:51:0.7371	0.7371	51
VAH	VAH:10	ventilatory acclimatization to hypoxia:10:0.7103	0.7103	10
VAIN	VAIN:35|VaIN:9	vaginal intraepithelial neoplasia:44:0.9323	0.9323	44
VAMCs	VAMCs:28	Veterans Affairs Medical Centers:28:0.8941	0.8941	28
VAMP	VAMP:58	Vesicle-associated membrane protein:58:0.6959	0.6959	58
VAMP-2	VAMP-2:19|VAMP2:10	Vesicle-associated membrane protein 2:15:0.5818|vesicle-associated membrane protein-2:14:0.5111	0.5818	29
VAM	VAM:7	vesicular-arbuscular mycorrhizal:7:0.3524	0.3524	7
VAN	VAN:17|van:14|Van:1	vancomycin:32:0.4844	0.4844	32
VAO	VAO:7	vanillyl-alcohol oxidase:7:0.2452	0.2452	7
VAP-1	VAP-1:55	vascular adhesion protein-1:44:0.8917|vascular adhesion protein 1:11:0.7357	0.8917	55
VAPS	VAPS:9	visual analog pain scale:9:0.5470	0.5470	9
VAPS	VAPS:7	visual analog pain score:7:0.5926	0.5926	7
VAPS	VAPS:15	visual analogue pain score:8:0.6411|Visual analogue pain scores:7:0.5926	0.6411	15
VAP	VAP:303	ventilator-associated pneumonia:303:0.8845	0.8845	303
VARETA	VARETA:8	Variable Resolution Electromagnetic Tomography:8:0.6411	0.6411	8
VASP	VASP:131	vasodilator-stimulated phosphoprotein:131:0.8406	0.8406	131
VASs	VASs:20	Visual analogue scales:20:0.8525	0.8525	20
VAS	VAS:7	vagal afferent stimulation:7:0.5926	0.5926	7
VAs	VAs:13|VAS:1	ventricular arrhythmias:14:0.7909	0.7909	14
VAS	VAS:15	ventricular assist system:15:0.8045	0.8045	15
VAs	VAs:18	vertebral arteries:18:0.8365	0.8365	18
VAS	VAS:10	vibroacoustic stimulation:10:0.1680	0.1680	10
VAS	VAS:1182	Visual analog scale:1042:0.9858|visual analog scales:140:0.9786	0.9858	1182
VAS	VAS:24	visual analog score:24:0.8768	0.8768	24
VAS	VAS:15	visual analogue:15:0.6386	0.6386	15
VAS	VAS:25	visual analogue pain scores:13:0.6701|visual analogue pain score:12:0.7571	0.7571	25
VAS	VAS:1624	visual analogue scale:1395:0.9903|visual analogue scales:229:0.9792	0.9903	1624
VAS	VAS:5	visual analogue scale of pain:5:0.6794	0.6794	5
VAS	VAS:82	Visual Analogue Score:42:0.9291|visual analogue scores:40:0.9256	0.9291	82
VAs	VAs:8	volatile anesthetics:8:0.4102	0.4102	8
VATs	VATs:24|VATS:2	variable antigen types:26:0.6351	0.6351	26
VATS	VATS:279|Vats:1	Video-assisted thoracic surgery:280:0.9042	0.9042	280
VATS	VATS:15	video-assisted thoracic surgical:15:0.7096	0.7096	15
VATS	VATS:14	video-assisted thoracoscopic:14:0.6173	0.6173	14
VATS	VATS:261	video-assisted thoracoscopic surgery:261:0.8866	0.8866	261
VATS	VATS:8	video-assisted thoracoscopic surgical:8:0.6411	0.6411	8
VATS	VATS:19	video-assisted thoracoscopy:19:0.5732	0.5732	19
VAT	VAT:20	variable antigen type:20:0.7658	0.7658	20
VAT	VAT:5	variant antigenic type:5:0.1973	0.1973	5
VAT	VAT:10	vascular access thrombosis:10:0.7103	0.7103	10
VAT	VAT:35	ventilatory anaerobic threshold:35:0.7952	0.7952	35
VAT	VAT:10	ventricular activation time:10:0.7103	0.7103	10
VAT	VAT:14	vestibular autorotation test:14:0.7909	0.7909	14
VAT	VAT:15	video-assisted thoracoscopic:15:0.7096	0.7096	15
VAT	VAT:31	Video-assisted thoracoscopy:24:0.5848|video assisted thoracoscopy:7:0.5926	0.5926	31
VAT	VAT:25	visceral:25:0.0674	0.0674	25
VAT	VAT:90	visceral adipose tissue:90:0.9668	0.9668	90
VAVD	VAVD:13	venous drainage:13:0.7753	0.7753	13
VAMC	VAMC:42	Veterans Affairs Medical Center:42:0.7995	0.7995	42
VA	VA:8	adenovirus virus-associated:8:0.0863	0.0863	8
VA	VA:65|Va:4	alveolar ventilation:69:0.6650	0.6650	69
VA	VA:55|Va:5	alveolar volume:60:0.6296	0.6296	60
Va	Va:20|VA:2	apical membrane potential:22:0.6178	0.6178	22
VA	VA:5|Va:4	apical membrane voltage:9:0.5470	0.5470	9
VA	VA:435	Department of Veterans Affairs:435:0.6333	0.6333	435
VA	VA:5	patients with vasospastic angina:5:0.0902	0.0902	5
VA	VA:6|V-A:4	retrograde:10:0.0028	0.0028	10
VA	VA:9	vaccenic acid:9:0.0606	0.0606	9
VA	VA:9	vacuum aspiration:9:0.4587	0.4587	9
VA	VA:19	Valproic acid:19:0.2412	0.2412	19
VA	VA:13	variant angina:13:0.2802	0.2802	13
VA	VA:32	vascular access:32:0.9072	0.9072	32
Va	Va:8|VA:5	velocity:13:0.0037	0.0037	13
VA	VA:8|V-A:7|v-a:1	veno-arterial:16:0.0046	0.0046	16
VA	VA:26|V-A:3|v-a:1	venoarterial:30:0.0089	0.0089	30
V-A	V-A:6|v-a:4	venous-arterial:10:0.0028	0.0028	10
VA	VA:21	ventral anterior:21:0.4538	0.4538	21
VA	VA:11	ventral anterior nucleus:11:0.7357	0.7357	11
VA	VA:10	ventralis anterior:10:0.1223	0.1223	10
VA	VA:6	ventricular aneurysm:6:0.2243	0.2243	6
VA	VA:100	ventricular arrhythmias:73:0.9353|Ventricular arrhythmia:27:0.8312	0.9353	100
VA	VA:20|V-A:7|v-a:1	ventriculo-atrial:28:0.0083	0.0083	28
VA	VA:10|V-A:1	ventriculoarterial:11:0.0031	0.0031	11
VA	VA:126|V-A:14	ventriculoatrial:140:0.0428	0.0428	140
VA	VA:27	veratryl alcohol:27:0.7905	0.7905	27
VA	VA:23	verbal autopsy:23:0.8715	0.8715	23
VA	VA:283	vertebral artery:259:0.9539|vertebral arteries:24:0.8115	0.9539	283
VA	VA:23|Va:1	vessel area:24:0.3190	0.3190	24
VA	VA:24	vestibular aqueduct:24:0.8768	0.8768	24
VA	VA:166	Veterans Administration:166:0.6594	0.6594	166
VA	VA:45	Veterans Health Administration:45:0.8964	0.8964	45
VA	VA:15	villous atrophy:15:0.8045	0.8045	15
VA	VA:18	vinyl acetate:18:0.5560	0.5560	18
VA	VA:9	Viscum album:9:0.6794	0.6794	9
VA	VA:552|Va:1	visual acuity:553:0.9884	0.9884	553
VA	VA:11	voluntary activation:11:0.4232	0.4232	11
VB12	VB12:17|vB12:1	Vitamin B12:18:0.8365	0.8365	18
VBAC	VBAC:13	vaginal birth after Caesarean:13:0.7753	0.7753	13
VBAC	VBAC:43	Vaginal birth after cesarean:43:0.9323	0.9323	43
VBAC	VBAC:12	vaginal birth after cesarean delivery:12:0.7571	0.7571	12
VBAC	VBAC:23	vaginal birth after cesarean section:23:0.8715	0.8715	23
VBAP	VBAP:12	prednisone:12:0.7500	0.7500	12
VBDS	VBDS:11	vanishing bile duct syndrome:11:0.7357	0.7357	11
VBD	VBD:8	vertebral bone density:8:0.3463	0.3463	8
VBF	VBF:20	blood flow:20:0.7766	0.7766	20
VBG	VBG:144	Vertical banded gastroplasty:144:0.9792	0.9792	144
VBI	VBI:10	ventral blood island:10:0.7103	0.7103	10
VBI	VBI:40	vertebrobasilar insufficiency:40:0.6003	0.6003	40
Vbl	Vbl:19|VBL:7	basolateral membrane potential:26:0.8251	0.8251	26
Vbl	Vbl:15	basolateral membrane voltage:15:0.8165	0.8165	15
VBL	VBL:165|Vbl:2	vinblastine:167:0.6103	0.6103	167
VBL	VBL:10	vinblastine sulfate:10:0.7103	0.7103	10
VBM	VBM:3|V-B-M:1	bleomycin and methotrexate:4:0.6460	0.6460	4
VBM	VBM:8	vascular basement membrane:8:0.6411	0.6411	8
VBM	VBM:8	visual backward masking:8:0.5006	0.5006	8
VBM	VBM:72	voxel-based morphometry:72:0.8309	0.8309	72
VBNC	VBNC:15	viable but non-culturable:15:0.8270	0.8270	15
VBNC	VBNC:46	viable but nonculturable:46:0.9353	0.9353	46
VBR	VBR:32	ventricular brain ratio:32:0.6512	0.6512	32
VBs	VBs:11	vertebral bodies:11:0.5355	0.5355	11
VBS	VBS:7	vertebrobasilar system:7:0.1111	0.1111	7
VBS	VBS:9	visible burrow system:9:0.6794	0.6794	9
VBT	VBT:25	vascular brachytherapy:25:0.8186	0.8186	25
VCAM	VCAM:52	vascular cell adhesion molecule:52:0.8821	0.8821	52
VCAP	VCAP:9	Vocal cord abductor paralysis:9:0.6794	0.6794	9
VCA	VCA:7	Vero cell assay:7:0.5926	0.5926	7
VCA	VCA:6	viral capsid:6:0.1838	0.1838	6
VCC	VCC:8	Vibrio cholerae cytolysin:8:0.4102	0.4102	8
VCC	VCC:8	Vienna challenge chamber:8:0.6411	0.6411	8
VCD	VCD:13	4-vinylcyclohexene diepoxide:13:0.4102	0.4102	13
VCD	VCD:7	vacuum constriction device:7:0.5926	0.5926	7
VCD	VCD:18	vibrational CD:18:0.7539	0.7539	18
VCD	VCD:93	Vibrational circular dichroism:93:0.9500	0.9500	93
VCD	VCD:10	vitreous chamber depth:10:0.7103	0.7103	10
VCD	VCD:27	Vocal cord dysfunction:27:0.8903	0.8903	27
VCEAC	VCEAC:9	Vitamin C equivalent antioxidant capacity:9:0.6794	0.6794	9
VCFS	VCFS:72	Velo-cardio-facial syndrome:72:0.3976	0.3976	72
VCFs	VCFs:17	Vertebral compression fractures:17:0.8270	0.8270	17
Vcfc	Vcfc:7|VCFc:4|VcFc:2|VCFC:1	velocity of circumferential fiber shortening:14:0.6911	0.6911	14
VCF	VCF:9|Vcf:6|VcF:1	shortening velocity:16:0.8165	0.8165	16
VCGs	VCGs:20|VCGS:1	vectorcardiograms:21:0.6897	0.6897	21
VCG	VCG:25|vcg:1	Vectorcardiograms:26:0.1142	0.1142	26
VCG	VCG:39	vectorcardiography:39:0.1735	0.1735	39
VCH	VCH:16	4-vinylcyclohexene:16:0.4688	0.4688	16
VCI	VCI:28	vascular cognitive impairment:28:0.8369	0.8369	28
VCI	VCI:8|vci:1	vena cava inferior:9:0.6794	0.6794	9
VCL	VCL:82|Vcl:3	curvilinear velocity:85:0.9101	0.9101	85
VCMs	VCMs:44	Vacuous chewing movements:44:0.8300	0.8300	44
VCM	VCM:24	vacuous chewing movements:24:0.8115	0.8115	24
VCM	VCM:119	vancomycin:119:0.4048	0.4048	119
VCM	VCM:17	Vancomycin hydrochloride:17:0.8270	0.8270	17
VCM	VCM:11	vinyl chloride:11:0.7103	0.7103	11
VCM	VCM:63	vinyl chloride monomer:63:0.9526	0.9526	63
VCN	VCN:20	acrylonitrile:20:0.0880	0.0880	20
VCN	VCN:105	ventral cochlear nucleus:105:0.9547	0.9547	105
VCN	VCN:33	Vibrio cholerae neuraminidase:33:0.9100	0.9100	33
VCO(2)	VCO(2):6	carbon dioxide output:6:0.3728	0.3728	6
VCO	VCO:8|Vco:1	endogenous production of carbon monoxide:9:0.6794	0.6794	9
VCP	VCP:31	vaccinia virus complement control protein:31:0.9043	0.9043	31
VCP	VCP:26	valosin-containing protein:26:0.2245	0.2245	26
VCP	VCP:11	ventriculocisternal perfusion:11:0.4728	0.4728	11
VCP	VCP:14	vocal cord paralysis:14:0.7753	0.7753	14
VCRII	VCRII:11	vital capacity rapid inhalation induction:11:0.7357	0.7357	11
VCR	VCR:15	Vestibulocollic reflex:15:0.4609	0.4609	15
VCR	VCR:4	video cassette recorder:4:0.1618	0.1618	4
VCR	VCR:671|Vcr:15|vcr:5|VcR:3	vincristine:694:0.8361	0.8361	694
VCR	VCR:24	vincristine sulfate:24:0.8768	0.8768	24
VCSEL	VCSEL:9	vertical-cavity surface-emitting laser:9:0.6794	0.6794	9
VCS	VCS:5	closure system:5:0.0612	0.0612	5
VCS	VCS:8	vaginal-cervical stimulation:8:0.0953	0.0953	8
VCS	VCS:14	vaginocervical stimulation:14:0.3039	0.3039	14
VCS	VCS:11	Vascular Closure Staple:11:0.7357	0.7357	11
VCS	VCS:13	Visual contrast sensitivity:13:0.7753	0.7753	13
VCT	VCT:17	voluntary counseling and testing:17:0.4246	0.4246	17
VCT	VCT:30	voluntary counselling and testing:30:0.6484	0.6484	30
VCUG	VCUG:13	voiding cysto-urethrography:13:0.7753	0.7753	13
VCUG	VCUG:32	voiding cystourethrogram:32:0.9072	0.9072	32
VCUG	VCUG:105	voiding cystourethrography:105:0.9715	0.9715	105
VCU	VCU:20	voiding cystourethrography:20:0.8525	0.8525	20
VCV	VCV:12	volume-controlled ventilation:12:0.2699	0.2699	12
VCV	VCV:17|V-C-V:2|v-c-v:1	vowel-consonant-vowel:20:0.3393	0.3393	20
VC	VC:7|Vc:1	Ascorbic acid:8:0.3463	0.3463	8
Vc	Vc:7|VC:1	curvilinear velocity:8:0.4102	0.4102	8
Vc	Vc:45|VC:10	pulmonary capillary blood volume:55:0.6065	0.6065	55
Vc	Vc:9	spinal trigeminal nucleus:9:0.6794	0.6794	9
Vc	Vc:23	trigeminal subnucleus caudalis:23:0.4486	0.4486	23
VC	VC:11	Vapnik-Chervonenkis:11:0.0048	0.0048	11
VC	VC:9	variance components:9:0.3455	0.3455	9
VC	VC:13	variation coefficient:13:0.4849	0.4849	13
VC	VC:6	vascular calcification:6:0.1838	0.1838	6
VC	VC:13	vascular conductance:13:0.4849	0.4849	13
VC	VC:6	vehicle control:6:0.0807	0.0807	6
VC	VC:12	veiled cells:12:0.3524	0.3524	12
VC	VC:17|Vc:1	vena cava:18:0.8365	0.8365	18
VC	VC:9	Venous Capacitance:9:0.6794	0.6794	9
VC	VC:32	verrucous carcinoma:32:0.8145	0.8145	32
Vc	Vc:7|VC:3	Vibrio cholerae:10:0.7103	0.7103	10
VC	VC:15|Vc:1	vincristine:16:0.0071	0.0071	16
VC	VC:21	vinyl carbamate:21:0.8594	0.8594	21
VC	VC:194	vinyl chloride:194:0.9846	0.9846	194
VC	VC:17	virtual colonoscopy:17:0.7407	0.7407	17
VC	VC:93	visual cortex:93:0.9325	0.9325	93
VC	VC:634	vital capacity:634:0.9389	0.9389	634
VC	VC:65|Vc:6|V-C:1	vitamin C:72:0.8168	0.8168	72
VC	VC:16|vc:2	vitelline coat:18:0.8365	0.8365	18
Vc	Vc:7|VC:2	voltage:9:0.0038	0.0038	9
Vc	Vc:11|VC:1	volume of distribution:12:0.6460	0.6460	12
Vd/Vt	Vd/Vt:3|VD/VT:2	dead space fraction:5:0.4422	0.4422	5
VD/VT	VD/VT:16|Vd/Vt:2	dead space to tidal volume:18:0.8365	0.8365	18
VD/VT	VD/VT:19|Vd/Vt:4|VD/Vt:1	dead space to tidal volume ratio:24:0.8816	0.8816	24
VD/VT	VD/VT:8|Vd/Vt:1	dead space ventilation:9:0.6794	0.6794	9
VD/VT	VD/VT:4|Vd/Vt:1	ventilation fraction:5:0.0517	0.0517	5
VD4	VD4:11	Visceral Dorsal 4:11:0.7357	0.7357	11
VDAC	VDAC:104	voltage-dependent anion channel:95:0.8925|voltage-dependent anion channels:9:0.6411	0.8925	104
VDAC	VDAC:21	voltage-dependent anion-selective channel:21:0.6934	0.6934	21
VDACs	VDACs:17	voltage-dependent anion channels:17:0.8270	0.8270	17
VDBT	VDBT:9	vascular dementia of the Binswanger type:9:0.7103	0.7103	9
vDB	vDB:4|VDB:3	vertical limb of the diagonal band:7:0.4438	0.4438	7
VDB	VDB:9	vertical limb of the diagonal band of Broca:9:0.6182	0.6182	9
VDCC	VDCC:21	voltage-dependent Ca2+ channels:21:0.5721	0.5721	21
VDCC	VDCC:92	voltage-dependent calcium channel:51:0.8316|voltage-dependent calcium channels:41:0.8224	0.8316	92
VDCCs	VDCCs:38|VD-CCs:1	voltage-dependent Ca2+ channels:39:0.7860	0.7860	39
VDCCs	VDCCs:86|VD-CCs:1	voltage-dependent calcium channels:87:0.8973	0.8973	87
VDC	VDC:21|VdC:1	vinylidene chloride:22:0.8657	0.8657	22
VDE	VDE:11	violaxanthin de-epoxidase:11:0.5355	0.5355	11
VDEPT	VDEPT:9	virus-directed enzyme prodrug therapy:9:0.4587	0.4587	9
VDH	VDH:8|vdh:3|Vdh:1	Valine dehydrogenase:12:0.4557	0.4557	12
VDO	VDO:11	vertical dimension of occlusion:11:0.7357	0.7357	11
VDPs	VDPs:9	vocational dental practitioners:9:0.6794	0.6794	9
VDRE	VDRE:60	vitamin D response element:54:0.9448|vitamin D response elements:6:0.5290	0.9448	60
VDREs	VDREs:30	vitamin D response elements:30:0.9011	0.9011	30
VDRL	VDRL:116	Venereal Disease Research Laboratory:116:0.8715	0.8715	116
VDRL	VDRL:8	Venereal Disease Research Laboratory test:8:0.6411	0.6411	8
VDRR	VDRR:11	vitamin D-resistant rickets:11:0.7357	0.7357	11
VDR	VDR:6	1,25-dihydroxyvitamin D3 receptors:6:0.1320	0.1320	6
VDR	VDR:8	vitamin D:8:0.5006	0.5006	8
VDR	VDR:1093|VD-R:1	vitamin D receptor:1062:0.9745|vitamin D receptors:32:0.7458	0.9745	1094
VDR	VDR:23	vitamin D receptor gene:23:0.8715	0.8715	23
VDR	VDR:7	vitamin D3:7:0.2902	0.2902	7
VDs	VDs:9	variable domains:9:0.6794	0.6794	9
VDS	VDS:6	Ventral Derotation Spondylodesis:6:0.2827	0.2827	6
VDS	VDS:8	verbal descriptor scale:8:0.6411	0.6411	8
VDS	VDS:117	Vindesine:117:0.4813	0.4813	117
VDS	VDS:9	vindesine sulfate:9:0.5470	0.5470	9
VDTs	VDTs:46	video display terminals:46:0.6815	0.6815	46
VDT	VDT:28	display terminals:28:0.7905	0.7905	28
VDT	VDT:62	video display terminal:62:0.4551	0.4551	62
VDT	VDT:49	visual display terminal:49:0.3384	0.3384	49
VDT	VDT:12	volume doubling time:12:0.6460	0.6460	12
VDUP1	VDUP1:9	vitamin D3 up-regulated protein 1:9:0.5470	0.5470	9
VDUs	VDUs:16|VDUS:1	visual display units:17:0.4480	0.4480	17
VDU	VDU:12	display units:12:0.6460	0.6460	12
VDU	VDU:34	visual display unit:34:0.6194	0.6194	34
vdW	vdW:11|VDW:3|vdw:1	van der Waals:15:0.8045	0.8045	15
VE/VCO2	VE/VCO2:7|VE/VCo2:1|VE/Vco2:1	carbon dioxide production:9:0.3069	0.3069	9
VE/VCO2	VE/VCO2:7	ventilatory equivalent for carbon dioxide:7:0.6411	0.6411	7
VE/VO2	VE/VO2:8	ventilatory equivalent:8:0.5006	0.5006	8
VE/VO2	VE/VO2:11	ventilatory equivalent for O2:11:0.6460	0.6460	11
VE/VO2	VE/VO2:16|Ve/VO2:1	ventilatory equivalent for oxygen:17:0.7658	0.7658	17
VEA	VEA:17	ventricular ectopic activity:17:0.8270	0.8270	17
VEB	VEB:29	ventricular ectopic beats:29:0.8978	0.8978	29
VEBs	VEBs:23	ventricular ectopic beats:23:0.8715	0.8715	23
VEC-DIC	VEC-DIC:5	video-enhanced contrast differential interference contrast:5:0.5926	0.5926	5
VECP	VECP:77	cortical potential:44:0.8941|cortical potentials:33:0.8605	0.8941	77
VECPs	VECPs:26	evoked cortical potentials:26:0.7760	0.7760	26
VECs	VECs:11	vaginal epithelial cells:11:0.4728	0.4728	11
VECs	VECs:42|vECs:1	vascular endothelial cells:43:0.8590	0.8590	43
VEDs	VEDs:9	ventricular ectopic depolarizations:9:0.6794	0.6794	9
VED	VED:4|Ved:3	end-diastolic volume:7:0.2452	0.2452	7
VEEV	VEEV:30	Venezuelan equine encephalitis virus:30:0.8472	0.8472	30
VEE	VEE:143	Venezuelan equine encephalitis:143:0.9448	0.9448	143
VEE	VEE:45	Venezuelan equine encephalitis virus:45:0.8964	0.8964	45
VEE	VEE:91	Venezuelan equine encephalomyelitis:91:0.9015	0.9015	91
VEG/PF	VEG/PF:14	Vascular endothelial growth/permeability factor:14:0.7909	0.7909	14
VEGF-A	VEGF-A:28|VEGFA:1	vascular endothelial growth factor:29:0.8978	0.8978	29
VEGF-A	VEGF-A:74|vegf-A:1|Vegf-A:1|Vegfa:1	vascular endothelial growth factor-A:77:0.9612	0.9612	77
VEGF-C	VEGF-C:91|Vegfc:1	Vascular endothelial growth factor-C:47:0.9366|vascular endothelial growth factor C:45:0.9338	0.9366	92
VEGF-D	VEGF-D:12|Vegf-d:1	Vascular endothelial growth factor-D:13:0.6701	0.6701	13
VEGFR-1	VEGFR-1:14|VEGFR1:4	vascular endothelial growth factor receptor-1:11:0.7357|vascular endothelial growth factor receptor 1:7:0.5926	0.7357	18
VEGFR-2	VEGFR-2:41|VEGFR2:19|VEGF-R2:6	vascular endothelial growth factor receptor-2:36:0.8716|vascular endothelial growth factor receptor 2:30:0.8472	0.8716	66
VEGFR-3	VEGFR-3:40|Vegfr-3:1|VEGFR3:1	vascular endothelial growth factor receptor-3:27:0.8903|vascular endothelial growth factor receptor 3:15:0.8045	0.8903	42
VEGFR	VEGFR:24|VEGF-R:5|VEGF-r:1	vascular endothelial growth factor receptor:30:0.8032	0.8032	30
VEGFR	VEGFR:12	VEGF receptors:12:0.4574	0.4574	12
VEGF	VEGF:7593|Vegf:8|vEGF:2|vegf:2|Veg-f:1|VEGf:1	vascular endothelial growth factor:7579:0.9902|vascular endothelial growth factors:28:0.8941	0.9902	7607
VEGF	VEGF:13	Vascular endothelial growth factor-A:13:0.7753	0.7753	13
VEI	VEI:10	efficiency index:10:0.5000	0.5000	10
VEL	VEL:16|Vel:8|vel:1	velocity:25:0.7059	0.7059	25
VEMPs	VEMPs:41	vestibular evoked myogenic potentials:30:0.9011|vestibular-evoked myogenic potentials:11:0.1098	0.9011	41
VEN	VEN:11	Venlafaxine:11:0.3846	0.3846	11
VEP's	VEP's:28	Visual evoked potentials:28:0.7905	0.7905	28
VEPs	VEPs:599|VEPS:5	Visual evoked potentials:604:0.8679	0.8679	604
VEP	VEP:14	virtual electrode polarization:14:0.7909	0.7909	14
VEP	VEP:805	visual evoked potential:443:0.8666|visual evoked potentials:362:0.8368	0.8666	805
VER's	VER's:8|VER'S:1	Visual evoked responses:9:0.3455	0.3455	9
VERP	VERP:67|V-ERP:3	ventricular effective refractory period:70:0.8741	0.8741	70
VERs	VERs:52|VERS:3	Visual evoked responses:55:0.7690	0.7690	55
VER	VER:89|Ver:80|ver:1	verapamil:170:0.3885	0.3885	170
VER	VER:5|Ver:4	veratridine:9:0.0184	0.0184	9
VER	VER:20	viral encephalopathy and retinopathy:20:0.8525	0.8525	20
VER	VER:138	visual evoked response:84:0.6798|visual evoked responses:54:0.7338	0.7338	138
VEST	VEST:9	ventricular function monitor:9:0.6794	0.6794	9
VESV	VESV:12	vesicular exanthema of swine virus:12:0.7571	0.7571	12
VES	VES:31|VEs:4	Ventricular extrasystoles:35:0.7952	0.7952	35
VEs	VEs:24	virtual environments:24:0.8768	0.8768	24
VES	VES:7	visual erotic stimulation:7:0.5926	0.5926	7
VES	VES:36	Vitamin E succinate:36:0.8716	0.8716	36
VETF	VETF:11	vaccinia virus early transcription factor:11:0.7357	0.7357	11
VeT	VeT:5|VET:2	ventilatory threshold:7:0.2113	0.2113	7
VET	VET:10	ventricular ejection time:10:0.4363	0.4363	10
VET	VET:12	Vietnam Era Twin:12:0.7571	0.7571	12
VE	VE:14|vE:1	alpha-tocopherol:15:0.0059	0.0059	15
VE	VE:5|Ve:1	expiratory flow:6:0.1010	0.1010	6
VE	VE:6	flow rate:6:0.1838	0.1838	6
VE	VE:703|Ve:33	minute ventilation:736:0.5456	0.5456	736
VE	VE:63|Ve:8	minute volume:71:0.5216	0.5216	71
Ve	Ve:6	transepithelial voltage:6:0.2243	0.2243	6
VE	VE:19	vaccine effectiveness:19:0.6106	0.6106	19
VE	VE:29	vaccine efficacy:29:0.8422	0.8422	29
VE	VE:10	variable error:10:0.7103	0.7103	10
VE	VE:15	vascular endothelial:15:0.8045	0.8045	15
VE	VE:27	Venezuelan encephalitis:27:0.6745	0.6745	27
VE	VE:22|Ve:1	ventilatory:23:0.0092	0.0092	23
VE	VE:22	ventricular extrasystoles:11:0.7357|ventricular extrasystole:11:0.7357	0.7357	22
VE	VE:30|vE:1	virtual endoscopy:31:0.8090	0.8090	31
VE	VE:39	virtual environment:39:0.9237	0.9237	39
VE	VE:21	visceral endoderm:21:0.8657	0.8657	21
VE	VE:10	vital exhaustion:10:0.5856	0.5856	10
VE	VE:152|vE:1|V-E:1	vitamin E:154:0.9161	0.9161	154
VE	VE:38	vitelline envelope:38:0.8417	0.8417	38
VE	VE:94	volume expansion:94:0.9682	0.9682	94
VF-14	VF-14:17	visual function index:17:0.8270	0.8270	17
VFAs	VFAs:75	volatile fatty acids:75:0.9602	0.9602	75
VFA	VFA:18	visceral fat area:18:0.8365	0.8365	18
VFA	VFA:376	volatile fatty acids:245:0.9804|volatile fatty acid:131:0.9636	0.9804	376
VFC	VFC:20	Vaccines for Children:20:0.7766	0.7766	20
VFCL	VFCL:7	ventricular fibrillation cycle length:7:0.5926	0.5926	7
VFDs	VFDs:9	visual field defects:9:0.6794	0.6794	9
VFD	VFD:12	visual field defects:12:0.7571	0.7571	12
VFG	VFG:10	Videofluorography:10:0.4286	0.4286	10
VFI	VFI:21	venous filling index:21:0.8594	0.8594	21
VFI	VFI:17	voluntary food intake:17:0.8270	0.8270	17
VFP	VFP:18	ventricular fluid pressure:18:0.8365	0.8365	18
VFP	VFP:19	vibrating flow pump:19:0.8449	0.8449	19
VFP	VFP:9	vitreous fluorophotometry:9:0.6794	0.6794	9
VFP	VFP:9	vocal fold paralysis:9:0.6794	0.6794	9
VFR	VFR:8	volume flow rate:8:0.2987	0.2987	8
VFSS	VFSS:10	swallowing study:10:0.5856	0.5856	10
VFs	VFs:10	virulence factors:10:0.7103	0.7103	10
VFs	VFs:11	visual fields:11:0.7357	0.7357	11
VFT	VFT:153	ventricular fibrillation threshold:153:0.9804	0.9804	153
VFT	VFT:8	Verbal Fluency Test:8:0.6411	0.6411	8
Vf	Vf:5|VF:1	formation rate:6:0.1010	0.1010	6
VF	VF:6|Vf:1	fresh gas flow:7:0.5926	0.5926	7
Vf	Vf:8|VF:7	variant frequency:9:0.1596|variant frequencies:6:0.1838	0.1838	15
VF	VF:5|Vf:2	ventilatory frequency:7:0.0655	0.0655	7
VF	VF:9	ventral funiculus:9:0.6794	0.6794	9
VF	VF:6	Ventricular function:6:0.1838	0.1838	6
VF	VF:12	verbal fluency:12:0.7571	0.7571	12
VF	VF:7	vesicular fluid:7:0.0951	0.0951	7
VF	VF:5	virulence factor:5:0.1132	0.1132	5
VF	VF:21	visceral fat:21:0.7291	0.7291	21
VF	VF:80	visual field:80:0.9048	0.9048	80
VF	VF:7	vitreous fluid:7:0.0951	0.0951	7
VF	VF:11	vitreous fluorophotometry:11:0.7357	0.7357	11
VF	VF:6|Vf:1	Volume flow:7:0.0886	0.0886	7
VF	VF:8|Vf:5	volume fraction:13:0.4849	0.4849	13
VGAM	VGAM:6	vein of Galen aneurysmal malformation:6:0.5290	0.5290	6
VGAMs	VGAMs:8	vein of Galen aneurysmal malformations:8:0.6411	0.6411	8
VGAT	VGAT:21	vesicular GABA transporter:21:0.6812	0.6812	21
VGB	VGB:153	vigabatrin:153:0.7795	0.7795	153
vgb	vgb:8	Vitreoscilla hemoglobin gene:8:0.4363	0.4363	8
VGCC	VGCC:15	voltage-gated Ca2+ channels:15:0.7096	0.7096	15
VGCC	VGCC:47	voltage-gated calcium channel:24:0.5848|voltage-gated calcium channels:23:0.7046	0.7046	47
VGCCs	VGCCs:58	voltage-gated calcium channels:58:0.8308	0.8308	58
VGE	VGE:43	venous gas emboli:43:0.9308	0.9308	43
VGF	VGF:7	Vaccinia virus growth factor:7:0.5926	0.5926	7
VGH	VGH:10	General Hospital:10:0.7103	0.7103	10
VGLUT1	VGLUT1:5|VGluT1:4	Vesicular glutamate transporter 1:9:0.6794	0.6794	9
VGLUT2	VGLUT2:10|VGluT2:3	vesicular glutamate transporter 2:13:0.7753	0.7753	13
VGP	VGP:24	vertical growth phase:24:0.8768	0.8768	24
VGSC	VGSC:20	voltage-gated sodium channels:11:0.7357|voltage-gated sodium channel:9:0.6794	0.7357	20
VGSCs	VGSCs:23	voltage-gated sodium channels:23:0.8038	0.8038	23
VGS	VGS:13	viridans group streptococci:13:0.7753	0.7753	13
VGLUT	VGLUT:9|VGluT:4	vesicular glutamate transporter:13:0.6701	0.6701	13
VHA	VHA:118	Veterans Health Administration:118:0.9013	0.9013	118
VHCs	VHCs:11	vestibular hair cells:11:0.7357	0.7357	11
VHC	VHC:9	valved holding chamber:9:0.5470	0.5470	9
VHDL	VHDL:17	high density lipoproteins:9:0.6794|high density lipoprotein:8:0.6411	0.6794	17
VHD	VHD:41	valvular heart disease:41:0.8525	0.8525	41
VHD	VHD:15	viral haemorrhagic disease:15:0.8045	0.8045	15
VHF	VHF:8	high frequency:8:0.5006	0.5006	8
VHF	VHF:13	viral hemorrhagic fever:13:0.4444	0.4444	13
VHF	VHF:18	visual half-field:18:0.8365	0.8365	18
VHI	VHI:39	Voice Handicap Index:39:0.9237	0.9237	39
VHLD	VHLD:17|vHLD:1	von Hippel-Lindau disease:18:0.8365	0.8365	18
VHL	VHL:518|vHL:9|Vhl:1	Von Hippel-Lindau:499:0.9871|von Hippel Lindau:29:0.8978	0.9871	528
VHL	VHL:101|vHL:2	von Hippel-Lindau disease:103:0.9538	0.9538	103
VHL	VHL:6|Vhl:1	von Hippel-Lindau gene:7:0.5926	0.5926	7
VHL	VHL:18|vHL:3	von Hippel-Lindau syndrome:21:0.8594	0.8594	21
VHL	VHL:11|vhl:1	von Hippel-Lindau tumor suppressor gene:12:0.7571	0.7571	12
VHL	VHL:5	von Hippel-Lindau tumor suppressor protein:5:0.4422	0.4422	5
VHPB	VHPB:10	Viral Hepatitis Prevention Board:10:0.7103	0.7103	10
VHPC	VHPC:8|vHPC:1	ventral hippocampus:9:0.6794	0.6794	9
VHP	VHP:10	hydrogen peroxide:10:0.7103	0.7103	10
VHSV	VHSV:66	viral haemorrhagic septicaemia virus:66:0.9286	0.9286	66
VHS	VHS:13	Veterans Health Study:13:0.7753	0.7753	13
VHS	VHS:30	viral haemorrhagic septicaemia:30:0.7970	0.7970	30
VHS	VHS:17	viral hemorrhagic septicemia:17:0.7407	0.7407	17
vhs	vhs:42|Vhs:7|VHS:1	virion host shutoff:50:0.7866	0.7866	50
vhs	vhs:8|Vhs:1	virion host shutoff protein:9:0.5470	0.5470	9
VHVs	VHVs:9	village health volunteers:9:0.6794	0.6794	9
VHV	VHV:14|vHV:1	voluntary hyperventilation:15:0.8045	0.8045	15
VHWs	VHWs:21	Village Health Workers:21:0.7865	0.7865	21
VHW	VHW:11	village health worker:11:0.6182	0.6182	11
VHB	VHB:15|VH-B:1	viral hepatitis B:16:0.4832	0.4832	16
VHb	VHb:39	Vitreoscilla hemoglobin:39:0.6392	0.6392	39
VH	VH:43|vh:1|Vh:1	heavy chain variable:33:0.8605|heavy-chain variable:12:0.0507	0.8605	45
VH	VH:9	heavy chain variable domain:9:0.6794	0.6794	9
VH	VH:142|Vh:4	heavy chain variable region:100:0.9704|heavy-chain variable region:27:0.1085|heavy-chain variable-region:11:0.5355|heavy chain variable regions:8:0.6411	0.9704	146
Vh	Vh:56|VH:46	holding potential:88:0.8352|holding potentials:14:0.6911	0.8352	102
VH	VH:27	vaginal hysterectomy:27:0.8903	0.8903	27
VH	VH:5	variable genes:5:0.0736	0.0736	5
VH	VH:45	variable heavy:45:0.3485	0.3485	45
VH	VH:29	variable heavy chain:29:0.2468	0.2468	29
VH	VH:5	variable region heavy chain:5:0.5564	0.5564	5
VH	VH:20	vehicle:20:0.0182	0.0182	20
VH	VH:9	ventral hippocampal:9:0.6794	0.6794	9
VH	VH:41	ventral hippocampus:41:0.9274	0.9274	41
VH	VH:11	ventral horn:11:0.7357	0.7357	11
VH	VH:42	viral hepatitis:42:0.7750	0.7750	42
VH	VH:13	Visual hallucinations:13:0.7753	0.7753	13
VH	VH:6	vitreous hemorrhage:6:0.2243	0.2243	6
VH	VH:12	vitreous humor:12:0.7571	0.7571	12
VIAAT	VIAAT:8|Viaat:1	Vesicular Inhibitory Amino Acid Transporter:9:0.5470	0.5470	9
VIA	VIA:10	video image analysis:10:0.7103	0.7103	10
VIA	VIA:7	virus infection associated:7:0.5926	0.5926	7
VIA	VIA:2	visual inspection using acetic acid:2:0.8657	0.8657	2
VIBE	VIBE:12	volumetric interpolated breath-hold examination:12:0.5664	0.5664	12
VIC	VIC:41	vasoactive intestinal contractor:41:0.8417	0.8417	41
VIDAS	VIDAS:4|VI-DAS:1	Vitek ImmunoDiagnostic Assay System:5:0.4422	0.4422	5
Vif	Vif:33|vif:8|VIF:1	infectivity factor:42:0.7995	0.7995	42
VIGS	VIGS:37	virus-induced gene silencing:37:0.8051	0.8051	37
VIG	VIG:8	vaccinia immune globulin:8:0.6411	0.6411	8
VIIIC	VIIIC:3|VIIIc:3|VIII-C:1	factor VIII coagulant activity:7:0.5926	0.5926	7
VIIIc	VIIIC:3|VIIIc:3|VIII-C:1	factor VIII procoagulant activity:7:0.5926	0.5926	7
VIIa	VIIa:21	activated factor VII:21:0.6812	0.6812	21
VIIa	VIIa:28	factor VIIa:28:0.7505	0.7505	28
VIIag	VIIag:8|VII-Ag:1	factor VII antigen:9:0.6794	0.6794	9
VIIc	VIIc:28|VIIC:1	factor VII coagulant activity:29:0.8978	0.8978	29
VILI	VILI:34	ventilator-induced lung injury:34:0.7048	0.7048	34
Vim	Vim:9|VIM:3	ventral intermediate:12:0.7571	0.7571	12
Vim	Vim:10|VIM:8	ventral intermediate nucleus:18:0.7539	0.7539	18
Vim	Vim:6|VIM:1	ventral intermediate nucleus of the thalamus:7:0.5926	0.5926	7
Vim	Vim:21|VIM:10	ventralis intermedius:31:0.7718	0.7718	31
VIM	VIM:80|Vim:21|vim:3	vimentin:104:0.3931	0.3931	104
VIN	VIN:6|Vin:4	vincristine:10:0.0474	0.0474	10
VIN	VIN:24	vulval intraepithelial neoplasia:24:0.1073	0.1073	24
VIN	VIN:106	Vulvar Intraepithelial Neoplasia:106:0.7103	0.7103	106
VIP-LI	VIP-LI:8|VIPLI:2	immunoreactive:10:0.1500	0.1500	10
VIP-LI	VIP-LI:15|VIPLI:1	vasoactive intestinal polypeptide-like immunoreactivity:16:0.8165	0.8165	16
VIP-IR	VIP-IR:12|VIP-ir:2|VIP-Ir:1|VIPir:1	immunoreactivity:16:0.3659	0.3659	16
VIP	VIP:3161	vasoactive intestinal peptide:3161:0.9768	0.9768	3161
VIP	VIP:2409|vip:1	vasoactive intestinal polypeptide:2410:0.9793	0.9793	2410
VIP	VIP:26	ventral intraparietal area:26:0.8861	0.8861	26
VIP	VIP:12	visual immunoprecipitate assay:12:0.7571	0.7571	12
VIP	VIP:9	Visual Impairment Project:9:0.6794	0.6794	9
VIQ	VIQ:11	verbal intelligence quotient:11:0.7357	0.7357	11
VIQ	VIQ:44	Verbal IQ:44:0.8941	0.8941	44
VISA	VISA:9	vancomycin-intermediate Staphylococcus aureus:9:0.2102	0.2102	9
VIT	VIT:55	Venom immunotherapy:55:0.9147	0.9147	55
vit	vit:8|VIT:1	vitellogenin:9:0.0748	0.0748	9
VIE	VIE:10	endoscopy:10:0.5294	0.5294	10
VK3	VK3:12	vitamin K3:12:0.6460	0.6460	12
VKA	VKA:13|vKA:1	vitamin K antagonists:14:0.6911	0.6911	14
VKC	VKC:111	vernal keratoconjunctivitis:111:0.9731	0.9731	111
VKDB	VKDB:14	vitamin K deficiency bleeding:14:0.7909	0.7909	14
VKD	VKD:10	vitamin K-dependent:10:0.7103	0.7103	10
VKH	VKH:88|V-K-H:1	Vogt-Koyanagi-Harada:80:0.5852|Vogt-Koyanagi-Harada's:9:0.0593	0.5852	89
VKH	VKH:22	Vogt-Koyanagi-Harada disease:22:0.6178	0.6178	22
VKH	VKH:10|V-K-H:1	Vogt-Koyanagi-Harada syndrome:11:0.5355	0.5355	11
VKOR	VKOR:8	vitamin K 2,3-epoxide reductase:8:0.6411	0.6411	8
VKOR	VKOR:7	vitamin K epoxide reductase:7:0.5926	0.5926	7
VK	VK:17	vitamin K:17:0.8270	0.8270	17
VLA-4	VLA-4:52|VLA4:1	late activation antigen-4:37:0.8377|late activation antigen 4:16:0.8165	0.8377	53
VLA-4	VLA-4:143|VLA4:9	late antigen-4:114:0.6231|late antigen 4:38:0.5510	0.6231	152
VLAP	VLAP:33	visual laser ablation of the prostate:33:0.8681	0.8681	33
VLA	VLA:12	late activation:12:0.7571	0.7571	12
VLA	VLA:5	late activation antigens:5:0.4422	0.4422	5
VLA	VLA:26	late antigen:26:0.5616	0.5616	26
VLBW	VLBW:463	low birth weight:426:0.9930|low-birth-weight:26:0.0285|low birth-weight:11:0.7357	0.9930	463
VLBW	VLBW:14	low birth weight infants:14:0.7909	0.7909	14
VLBW	VLBW:203	low birthweight:186:0.9658|low-birthweight:17:0.0182	0.9658	203
VLBW	VLBW:107	very-low-birth-weight:107:0.1209	0.1209	107
VLBW	VLBW:27	very-low-birthweight:27:0.0296	0.0296	27
VLBWI	VLBWI:15	low birth weight infants:15:0.8045	0.8045	15
VLB	VLB:123	vinblastine:123:0.8299	0.8299	123
VLCD	VLCD:79	low calorie diet:67:0.8670|low calorie diets:12:0.7571	0.8670	79
VLCD	VLCD:55	very-low-calorie diet:55:0.2857	0.2857	55
VLCDs	VLCDs:20	very-low-calorie diets:20:0.5892	0.5892	20
VLCFA	VLCFA:112	long chain fatty acids:55:0.9147|long chain fatty acid:29:0.8978|long-chain fatty acids:28:0.1634	0.9147	112
VLCFA	VLCFA:25	very-long-chain fatty acids:25:0.1394	0.1394	25
VLCS	VLCS:10	acyl-CoA synthetase:10:0.7103	0.7103	10
VLDL-TG	VLDL-TG:7	lipoprotein triglycerides:7:0.2452	0.2452	7
VLDL-TG	VLDL-TG:17|VLDL-Tg:1	low density lipoprotein triglyceride:9:0.6794|low density lipoprotein-triglyceride:9:0.6794	0.6794	18
VLDL-C	VLDL-C:40|VLDLC:7|VLDLc:3|VLDL-c:2	low density lipoprotein cholesterol:43:0.8917|low density lipoprotein-cholesterol:9:0.6794	0.8917	52
VLDL-C	VLDL-C:27|VLDLC:2|vLDLC:1|VLDLc:1|VLDL-c:1	very-low-density lipoprotein cholesterol:32:0.1922	0.1922	32
VLDLR	VLDLR:33|VLDL-R:12|VLDLr:4|Vldlr:2|VLDL-r:1	low density lipoprotein receptor:52:0.8345	0.8345	52
VLDL	VLDL:9	lipoprotein cholesterol:9:0.5856	0.5856	9
VLDL	VLDL:105	low density:92:0.9167|low-density:13:0.0038	0.9167	105
VLDL	VLDL:2105	low density lipoprotein:1164:0.9707|low density lipoproteins:681:0.9822|low-density lipoprotein:260:0.1196	0.9822	2105
VLDL	VLDL:25	very-low-density:25:0.0076	0.0076	25
VLDL	VLDL:167	very-low-density lipoproteins:128:0.1183|very-low-density-lipoprotein:39:0.0124	0.1183	167
VLED	VLED:9	low energy diet:9:0.6794	0.6794	9
VLED	VLED:18	very-low-energy diet:18:0.4033	0.4033	18
VLF	VLF:37	low frequency:37:0.7548	0.7548	37
VLF	VLF:29	ventrolateral funiculus:29:0.7237	0.7237	29
VLF	VLF:9	very-low-frequency:9:0.0611	0.0611	9
VLH	VLH:20	ventrolateral hypothalamus:20:0.7766	0.7766	20
VLM	VLM:8	ventrolateral medulla oblongata:8:0.4102	0.4102	8
VLM	VLM:29	visceral larva migrans:29:0.8422	0.8422	29
vlNTS	vlNTS:2|vl-NTS:1	ventrolateral nucleus of the tractus solitarius:3:0.4438	0.4438	3
VLPA	VLPA:9	ventrolateral medullary pressor area:9:0.6794	0.6794	9
vlPAG	vlPAG:8|VLPAG:1	ventrolateral PAG:9:0.6794	0.6794	9
vlPAG	vlPAG:29|VLPAG:2	ventrolateral periaqueductal gray:31:0.6572	0.6572	31
VLPFC	VLPFC:10	ventrolateral prefrontal cortex:10:0.7103	0.7103	10
VLPO	VLPO:13|vLPO:1	ventrolateral preoptic area:14:0.6911	0.6911	14
VLPO	VLPO:13	ventrolateral preoptic nucleus:13:0.7753	0.7753	13
VLPP	VLPP:24	Valsalva leak point pressure:24:0.8115	0.8115	24
VLPs	VLPs:13	Ventricular late potentials:13:0.7753	0.7753	13
VLPs	VLPs:493	virus-like particles:493:0.8701	0.8701	493
VLP	VLP:30	ventricular late potentials:30:0.8472	0.8472	30
VLP	VLP:186	virus-like particles:134:0.8083|virus-like particle:52:0.8134	0.8134	186
vLT	vLT:5|V-LT:1	velocity at the lactate threshold:6:0.4587	0.4587	6
VLC	VLC:10	long chain:10:0.7103	0.7103	10
VLc	VLc:3	ventralis lateralis pars caudalis:3:0.5290	0.5290	3
VLC	VLC:18	Visible light-cured:18:0.8365	0.8365	18
VLo	VLo:5	ventralis lateralis pars oralis:5:0.5006	0.5006	5
VLO	VLO:21	ventrolateral orbital cortex:21:0.8594	0.8594	21
VLS	VLS:47	vascular leak syndrome:47:0.9366	0.9366	47
VLS	VLS:9	ventrolateral striatum:9:0.4587	0.4587	9
VL	VL:31	light chain:31:0.9043	0.9043	31
VL	VL:7	light chain variable domain:7:0.5926	0.5926	7
VL	VL:11	light chain variable region:11:0.7357	0.7357	11
VL	VL:43|Vl:1	lung volume:44:0.7220	0.7220	44
VL	VL:16|Vl:1	variable:17:0.0105	0.0105	17
VL	VL:205|vl:1	vastus lateralis:206:0.8254	0.8254	206
VL	VL:17	vastus lateralis muscle:17:0.8270	0.8270	17
VL	VL:17	ventral lateral nucleus:17:0.8270	0.8270	17
VL	VL:94|vl:9|Vl:1	ventrolateral:104:0.0673	0.0673	104
VL	VL:24	ventrolateral nucleus:24:0.2792	0.2792	24
VL	VL:3	ventrolateral nucleus of the thalamus:3:0.1464	0.1464	3
VL	VL:11	ventrolateral thalamic nucleus:11:0.5355	0.5355	11
VL	VL:140	viral load:131:0.8534|viral loads:9:0.6794	0.8534	140
VL	VL:18	visceral:18:0.0111	0.0111	18
VL	VL:411	visceral leishmaniasis:411:0.9883	0.9883	411
VM-26	VM-26:162|VM26:47|Vm-26:1|Vm26:1	teniposide:211:0.9013	0.9013	211
VMAT1	VMAT1:5	vesicular monoamine transporter 1:5:0.4422	0.4422	5
VMAT2	VMAT2:62|VMAT-2:4|Vmat2:1|vMAT2:1	vesicular monoamine transporter:68:0.8515	0.8515	68
VMAT2	VMAT2:46|VMAT-2:20|Vmat2:1	vesicular monoamine transporter 2:41:0.8867|vesicular monoamine transporter-2:26:0.8861	0.8867	67
VMATs	VMATs:13	vesicular monoamine transporters:13:0.7753	0.7753	13
VMAT	VMAT:13	vesicular monoamine transporter:13:0.5934	0.5934	13
VMA	VMA:203	vanillylmandelic acid:203:0.4751	0.4751	203
VMD2	VMD2:6	vitelliform macular dystrophy:6:0.2827	0.2827	6
VMD	VMD:7	Vertebral mineral density:7:0.3524	0.3524	7
VMD	VMD:6|VmD:1	volume median diameter:7:0.5926	0.5926	7
Vme	Vme:8	mesencephalic trigeminal nucleus:8:0.6411	0.6411	8
VMH	VMH:12	hypothalamic ventromedial nucleus:12:0.1078	0.1078	12
VMH	VMH:61	ventromedial:61:0.0633	0.0633	61
VMH	VMH:137	ventromedial hypothalamic:137:0.9150	0.9150	137
VMH	VMH:10	ventromedial hypothalamic nuclei:10:0.7103	0.7103	10
VMH	VMH:131|Vmh:1	ventromedial hypothalamic nucleus:132:0.9639	0.9639	132
VMH	VMH:395|VmH:1	ventromedial hypothalamus:396:0.7396	0.7396	396
VMH	VMH:81	ventromedial nucleus of the hypothalamus:81:0.9149	0.9149	81
VMI	VMI:10	Developmental Test of Visual-Motor Integration:10:0.5856	0.5856	10
VMM	VMM:16	ventromedial medulla:16:0.8165	0.8165	16
VMN	VMN:57	ventromedial hypothalamic nucleus:57:0.9477	0.9477	57
VMN	VMN:18	ventromedial nuclei:18:0.5560	0.5560	18
VMN	VMN:138	ventromedial nucleus:138:0.6025	0.6025	138
VMN	VMN:61	ventromedial nucleus of the hypothalamus:61:0.9087	0.9087	61
Vmo	Vmo:15	trigeminal motor nucleus:15:0.8045	0.8045	15
VMO	VMO:10	vaccinia melanoma oncolysate:10:0.5856	0.5856	10
VMO	VMO:20	vastus medialis oblique:20:0.8525	0.8525	20
VMO	VMO:23	vastus medialis obliquus:23:0.8715	0.8715	23
VMR	VMR:22	vasomotor reactivity:22:0.8657	0.8657	22
VMR	VMR:8	vasomotor rhinitis:8:0.5006	0.5006	8
VMTH	VMTH:11	Veterinary Medical Teaching Hospital:11:0.7357	0.7357	11
VMT	VMT:17|vmt:1	ventral mesencephalic tegmentum:18:0.4934	0.4934	18
Vms	Vms:12	potential difference:12:0.7571	0.7571	12
VMs	VMs:9	vascular malformations:9:0.1585	0.1585	9
VMs	VMs:13	venous malformations:13:0.3331	0.3331	13
VMS	VMS:36	ventral medullary surface:36:0.6538	0.6538	36
VMS	VMS:1	ventral surface of medulla:1:0.5006	0.5006	1
VNAB	VNAB:15	ventral noradrenergic bundle:15:0.8045	0.8045	15
VNA	VNA:23	virus neutralizing antibody:10:0.5856|virus neutralizing antibodies:7:0.4438|virus-neutralizing antibodies:6:0.0899	0.5856	23
VNA	VNA:11	Visiting Nurse Association:11:0.7357	0.7357	11
VNB	VNB:43	vinorelbine:43:0.7925	0.7925	43
VNC	VNC:27|vNC:1	ventral nerve cord:28:0.8941	0.8941	28
VNC	VNC:24	vestibular nuclear complex:24:0.8115	0.8115	24
VNC	VNC:19	vestibular nucleus complex:19:0.8449	0.8449	19
VNLL	VNLL:20	ventral nucleus of the lateral lemniscus:20:0.8525	0.8525	20
VNOs	VNOs:9	vomeronasal organs:9:0.6794	0.6794	9
VNO	VNO:208	vomeronasal organ:208:0.9554	0.9554	208
VNPI	VNPI:11	Van Nuys Prognostic Index:11:0.7357	0.7357	11
VNP	VNP:10	vasonatrin peptide:10:0.1994	0.1994	10
VNP	VNP:12	ventricular natriuretic peptide:12:0.7571	0.7571	12
VNS	VNS:176	vagus nerve stimulation:176:0.7335	0.7335	176
VNS	VNS:11	vomeronasal system:11:0.3829	0.3829	11
VNT	VNT:12	virus neutralisation test:12:0.7571	0.7571	12
VNT	VNT:14	virus neutralization test:14:0.7909	0.7909	14
VNTB	VNTB:13	ventral nucleus of the trapezoid body:13:0.7753	0.7753	13
VNTR	VNTR:353	variable number of tandem repeats:205:0.9453|variable number of tandem repeat:148:0.9832	0.9832	353
VNTR	VNTR:7	Variable-number tandem-repeat:7:0.3524	0.3524	7
VN	VN:8	vagus nerve:8:0.1196	0.1196	8
VN	VN:10	vestibular neuritis:10:0.7103	0.7103	10
VN	VN:34|Vn:2	vestibular nuclei:36:0.9174	0.9174	36
VN	VN:16	Vestibular nucleus:16:0.6577	0.6577	16
VN	VN:24	virus neutralisation:24:0.8768	0.8768	24
VN	VN:9	virus neutralising:9:0.6794	0.6794	9
VN	VN:132	virus neutralization:99:0.9091|virus-neutralization:33:0.0377	0.9091	132
VN	VN:94	virus neutralizing:48:0.8463|virus-neutralizing:46:0.0531	0.8463	94
Vn	Vn:14|VN:1	vitellin:15:0.0165	0.0165	15
VN	VN:19|vn:1	vomeronasal:20:0.0224	0.0224	20
VO(2)max	VO(2)max:11|Vo(2)max:5|VO(2)MAX:2	Maximal oxygen uptake:18:0.5940	0.5940	18
VO(2)max	VO(2)max:16|Vo(2)max:3	oxygen consumption:19:0.8449	0.8449	19
VO(2)	VO(2):29|Vo(2):9	O(2) consumption:38:0.1525	0.1525	38
VO(2)	VO(2):107|Vo(2):24	oxygen consumption:131:0.6903	0.6903	131
VO(2)	VO(2):92|Vo(2):19	oxygen uptake:111:0.6662	0.6662	111
VO(2max)	VO(2max):12|VO(2MAX):1	maximal oxygen consumption:13:0.4849	0.4849	13
VO(2max)	VO(2max):36|Vo(2max):4|V-O(2max):1	maximal oxygen uptake:41:0.6524	0.6524	41
VO2,max	VO2,max:9	maximal oxygen uptake:9:0.3455	0.3455	9
VO2AT	VO2AT:16|VO2-AT:5|VO2at:1	anaerobic threshold:22:0.7955	0.7955	22
VO2max	VO2max:57|Vo2max:1	maximal aerobic capacity:58:0.5232	0.5232	58
VO2max	VO2max:82|Vo2max:4	maximal aerobic power:86:0.6315	0.6315	86
VO2max	VO2max:5|Vo2max:1	maximal exercise:6:0.1010	0.1010	6
VO2max	VO2max:85|Vo2max:4	Maximal O2 consumption:89:0.6750	0.6750	89
VO2max	VO2max:240|Vo2max:9|VO2-max:2|VO2MAX:2|VO2Max:2	maximal oxygen consumption:255:0.6014	0.6014	255
VO2max	VO2max:22|Vo2max:1	maximal oxygen intake:23:0.5997	0.5997	23
VO2max	VO2max:509|Vo2max:16|VO2MAX:4	Maximal oxygen uptake:529:0.7529	0.7529	529
VO2max	VO2max:95|Vo2max:3	maximum oxygen consumption:98:0.2044	0.2044	98
VO2max	VO2max:4|Vo2max:1	oxygen consumption rate:5:0.4422	0.4422	5
VO2	VO2:38|Vo2:2	metabolic rate:40:0.4616	0.4616	40
VO2	VO2:9	O2 intake:9:0.1809	0.1809	9
VO2	VO2:250|Vo2:17	O2 uptake:267:0.1998	0.1998	267
VO2	VO2:1501|Vo2:94|vO2:1|V-O2:1	oxygen consumption:1597:0.8162	0.8162	1597
VO2	VO2:15|Vo2:3	oxygen consumption per beat:18:0.7539	0.7539	18
VO2	VO2:21|Vo2:2	oxygen consumption rate:14:0.4951|Oxygen consumption rates:9:0.4587	0.4951	23
VO2	VO2:11	oxygen intake:11:0.2764	0.2764	11
VO2	VO2:877|Vo2:32|vo2:1	oxygen uptake:910:0.7364	0.7364	910
VOCC	VOCC:12	voltage-operated Ca2+ channels:12:0.7571	0.7571	12
VOCCs	VOCCs:21	voltage-operated calcium channels:21:0.5721	0.5721	21
VOCs	VOCs:35	volatile organic chemicals:35:0.9151	0.9151	35
VOCs	VOCs:518	volatile organic compounds:518:0.9819	0.9819	518
VOC	VOC:14	channels:14:0.0459	0.0459	14
VOC	VOC:18	vaso-occlusive crisis:18:0.5560	0.5560	18
VOC	VOC:167	Volatile organic compounds:89:0.9664|volatile organic compound:78:0.9393	0.9664	167
VOC	VOC:10	voltage-operated Ca2+ channel:10:0.7103	0.7103	10
VOD	VOD:258	veno-occlusive disease:258:0.7914	0.7914	258
VOD	VOD:23	veno-occlusive disease of the liver:23:0.5598	0.5598	23
VOG	VOG:11	video-oculography:11:0.5882	0.5882	11
VOIs	VOIs:26	volumes of interest:26:0.8861	0.8861	26
VOI	VOI:82	volume of interest:62:0.5949|Volume-of-interest:20:0.1418	0.5949	82
VOPBA	VOPBA:5	virus overlay protein binding assay:5:0.2818	0.2818	5
Vop	Vop:10|VOP:2|vop:1	posterior:13:0.2500	0.2500	13
VOP	VOP:11	Venous occlusion plethysmography:11:0.7357	0.7357	11
VOR	VOR:9	vestibulo-ocular:9:0.0085	0.0085	9
VOR	VOR:646	vestibulo-ocular reflex:634:0.7253|vestibulo-ocular reflexes:12:0.4153	0.7253	646
VOR	VOR:12	vestibulo-ocular response:12:0.4557	0.4557	12
VOSO4	VOSO4:13	vanadyl sulfate:13:0.6701	0.6701	13
VOT	VOT:8	Hooper Visual Organization Test:8:0.6411	0.6411	8
VOT	VOT:8	venous occlusion test:8:0.6411	0.6411	8
VOT	VOT:132|vot:1	voice onset time:118:0.9596|voice-onset-time:15:0.0761	0.9596	133
Vo	Vo:11	subnucleus oralis:11:0.1203	0.1203	11
Vo	Vo:10	trigeminal nucleus oralis:10:0.3145	0.3145	10
Vo	Vo:19	Unloaded shortening velocity:19:0.3582	0.3582	19
VO	VO:49	vaginal opening:49:0.8753	0.8753	49
Vo	Vo:6	velocity of shortening:6:0.1838	0.1838	6
VO	VO:40|vo:1	Venous occlusion:41:0.7472	0.7472	41
VO	VO:8	venous outflow:8:0.4102	0.4102	8
VO	VO:8|V-O:1	vestibulo-ocular:9:0.0181	0.0181	9
Vo	Vo:16|VO:1	void volume:17:0.4035	0.4035	17
Vo	Vo:5|VO:1	volume intercept:6:0.1010	0.1010	6
VP/SI	VP/SI:8	ventral pallidum/substantia innominata:8:0.6411	0.6411	8
VP1	VP1:17	major capsid protein:17:0.3512	0.3512	17
VP1	VP1:13|Vp1:1	viral protein 1:14:0.4071	0.4071	14
VP2	VP2:7	Viral protein 2:7:0.3524	0.3524	7
VP5	VP5:14	major capsid protein:14:0.5111	0.5111	14
VP6	VP6:10|vp6:1	inner capsid protein:11:0.6182	0.6182	11
VP7	VP7:20	glycoprotein:20:0.2436	0.2436	20
VP7	VP7:6	major outer capsid protein:6:0.3728	0.3728	6
VPA	VPA:160	sodium valproate:160:0.2384	0.2384	160
VPA	VPA:10	vaginal pulse amplitude:10:0.7103	0.7103	10
VPA	VPA:6	valproate sodium:6:0.2243	0.2243	6
VPA	VPA:732	valproic acid:732:0.9664	0.9664	732
VPA	VPA:4|v-PA:4|vPA:1	vascular plasminogen activator:9:0.6794	0.6794	9
VPA	VPA:10	vigorous physical activity:10:0.5856	0.5856	10
VPBs	VPBs:112	Ventricular premature beats:112:0.9733	0.9733	112
VPB	VPB:96	ventricular premature beats:76:0.9180|ventricular premature beat:20:0.8525	0.9180	96
VPCs	VPCs:111	ventricular premature complexes:111:0.9731	0.9731	111
VPCs	VPCs:63	ventricular premature contractions:63:0.9526	0.9526	63
VPCs	VPCs:25	vulval precursor cells:25:0.7249	0.7249	25
VPC	VPC:8	Vector producer cells:8:0.5006	0.5006	8
VPC	VPC:36	ventricular premature complexes:21:0.8594|ventricular premature complex:15:0.8045	0.8594	36
VPC	VPC:41	ventricular premature contraction:28:0.8369|ventricular premature contractions:13:0.7753	0.8369	41
VPDs	VPDs:28	ventricular premature depolarizations:28:0.8941	0.8941	28
VPD	VPD:22	valpromide:22:0.1909	0.1909	22
VPD	VPD:28	vapor pressure deficit:16:0.3472|vapour pressure deficit:12:0.2083	0.3472	28
VPD	VPD:18	ventricular premature depolarizations:9:0.6794|ventricular premature depolarization:9:0.6794	0.6794	18
VPEL	VPEL:18	visually perceived eye level:18:0.7539	0.7539	18
VPE	VPE:12	vacuolar processing enzyme:12:0.7571	0.7571	12
VPLI	VPLI:11|VP-LI:2	vasopressin-like immunoreactive:13:0.7753	0.7753	13
VPLo	VPLo:18	pars oralis:18:0.8365	0.8365	18
VPL	VPL:2	nucleus of thalamus:2:0.1367	0.1367	2
VPL	VPL:25	nucleus ventralis posterolateralis:25:0.6539	0.6539	25
VPL	VPL:22	ventral posterior lateral:22:0.8657	0.8657	22
VPL	VPL:18	ventral posterior lateral nucleus:18:0.8365	0.8365	18
VPL	VPL:16	ventral posterolateral:16:0.7261	0.7261	16
VPL	VPL:17	ventral posterolateral nucleus:17:0.8270	0.8270	17
VPL	VPL:32	ventroposterolateral:32:0.1054	0.1054	32
VPL	VPL:19	ventroposterolateral nucleus:19:0.1247	0.1247	19
VPL	VPL:21	verapamil:21:0.0680	0.0680	21
VPL	VPL:10	vertical partial laryngectomy:10:0.7103	0.7103	10
Vpr	Vpr:52|VPR:1	Viral protein R:53:0.7578	0.7578	53
VPR	VPR:9	volume-pressure response:9:0.5470	0.5470	9
VPTs	VPTs:14	perception thresholds:14:0.7909	0.7909	14
VPT	VPT:18	perception thresholds:18:0.8365	0.8365	18
VPT	VPT:66	vibration perception threshold:66:0.6577	0.6577	66
VPT	VPT:20	vibratory perception threshold:20:0.1282	0.1282	20
VPg	VPg:34	genome-linked protein:34:0.4215	0.4215	34
VPI	VPI:8|VPi:1	inferior:9:0.0415	0.0415	9
VPI	VPI:9|VPi:1	inferior nucleus:10:0.5856	0.5856	10
VPI	VPI:30	velopharyngeal incompetence:30:0.8472	0.8472	30
VPI	VPI:51	velopharyngeal insufficiency:51:0.9416	0.9416	51
VPI	VPI:11	Vibrio pathogenicity island:11:0.5355	0.5355	11
VPI	VPI:18	Visible Plaque Index:18:0.6903	0.6903	18
VPO	VPO:15	vapor pressure osmometry:15:0.7096	0.7096	15
vps	VPS:20|vps:20|Vps:12	vacuolar protein sorting:42:0.8263|vacuolar protein-sorting:10:0.7103	0.8263	52
VPS	VPS:29	ventriculoperitoneal shunt:21:0.5721|ventriculoperitoneal shunts:8:0.3463	0.5721	29
VP	VP:10	Arginine-vasopressin:10:0.0037	0.0037	10
Vp	Vp:5	correction for the residual plasma volume:5:0.1973	0.1973	5
VP	VP:10	etoposide:10:0.0037	0.0037	10
Vp	Vp:17|VP:2|vp:2	flow propagation velocity:21:0.5435	0.5435	21
Vp	Vp:8|VP:3|-Vp:1	potential:12:0.0045	0.0045	12
Vp	Vp:6|VP:1	principal sensory trigeminal nucleus:7:0.5926	0.5926	7
VP	VP:9	proteins:9:0.0033	0.0033	9
VP	VP:52	variegate porphyria:52:0.9099	0.9099	52
VP	VP:27	vascular parkinsonism:27:0.8903	0.8903	27
VP	VP:32	vascular permeability:32:0.8145	0.8145	32
VP	VP:884|Vp:8|vp:1	vasopressin:893:0.3659	0.3659	893
VP	VP:21|V-P:2|v-p:1	velopharyngeal:24:0.0094	0.0094	24
VP	VP:20|Vp:1|vp:1	venous pressure:22:0.2943	0.2943	22
V-P	V-P:35|VP:5	ventilation-perfusion:40:0.0160	0.0160	40
VP	VP:10|Vp:1	ventral:11:0.0041	0.0041	11
VP	VP:69	ventral pallidum:69:0.9100	0.9100	69
VP	VP:6	ventral posterior:6:0.1543	0.1543	6
VP	VP:83	ventral prostate:83:0.9640	0.9640	83
VP	VP:5	ventralis posterior:5:0.0736	0.0736	5
VP	VP:26	ventricular pacing:26:0.8251	0.8251	26
VP	VP:20|V-P:11	ventriculo-peritoneal:31:0.0123	0.0123	31
VP	VP:183|V-P:25	ventriculoperitoneal:208:0.0850	0.0850	208
VP	VP:15	ventroposterior:15:0.0057	0.0057	15
VP	VP:10	ventroposterior nucleus:10:0.0958	0.0958	10
VP	VP:33|Vp:20|vp:2	verapamil:55:0.0222	0.0222	55
vp	vp:6|VP:1	viral particles:7:0.2113	0.2113	7
VP	VP:7	viral protein:7:0.1010	0.1010	7
V-P	V-P:27|VP:6|v-p:1	Volume-pressure:34:0.0136	0.0136	34
VP	VP:10	vulnerable period:10:0.7103	0.7103	10
VQ	VQ:10	vector quantization:10:0.7103	0.7103	10
VQ	VQ:9|V-Q:3	ventilation-perfusion:12:0.2037	0.2037	12
VR1	VR1:12	capsaicin receptor:12:0.1308	0.1308	12
VR1	VR1:10	vanilloid:10:0.0335	0.0335	10
VR1	VR1:44|VR-1:1	vanilloid receptor:38:0.4799|vanilloid receptors:7:0.2452	0.4799	45
VR1	VR1:75|VR-1:10	vanilloid receptor 1:60:0.9190|vanilloid receptor-1:25:0.8816	0.9190	85
VR1	VR1:29	vanilloid receptor subtype 1:29:0.8422	0.8422	29
VR1	VR1:20|VR-1:2	vanilloid receptor type 1:22:0.8715	0.8715	22
VRAC	VRAC:33	volume-regulated anion channel:20:0.7766|volume-regulated anion channels:13:0.5934	0.7766	33
VRACs	VRACs:16	volume-regulated anion channels:16:0.6386	0.6386	16
VRA	VRA:38	Visual reinforcement audiometry:38:0.9217	0.9217	38
VRBC	VRBC:17|Vrbc:4|vRBC:1|vrbc:1	red blood cell velocity:23:0.8715	0.8715	23
Vrbc	Vrbc:4|VRBC:3	red cell velocities:7:0.3524	0.3524	7
VRB	VRB:11|Vrb:1	vinorelbine:12:0.4783	0.4783	12
VRC	VRC:16	Voriconazole:16:0.3261	0.3261	16
VRD	VRD:10	volume regulatory decrease:10:0.7103	0.7103	10
VRD	VRD:11|vRD:1	Von Recklinghausen's Disease:12:0.6460	0.6460	12
VRE	VRE:17	vancomycin-resistant enterococcal:17:0.8270	0.8270	17
VRE	VRE:412	vancomycin-resistant enterococci:412:0.8666	0.8666	412
VRE	VRE:86	vancomycin-resistant enterococcus:86:0.8204	0.8204	86
VRE	VRE:29	vancomycin-resistant Enterococcus faecium:29:0.7970	0.7970	29
VREF	VREF:64	vancomycin-resistant Enterococcus faecium:64:0.8283	0.8283	64
VRG	VRG:96	ventral respiratory group:96:0.9689	0.9689	96
VRI	VRI:5	voluntary response index:5:0.2818	0.2818	5
VRL	VRL:11	vinorelbine:11:0.5263	0.5263	11
VRML	VRML:15	Virtual Reality Modeling Language:15:0.8045	0.8045	15
VRNF	VRNF:9|vRNF:1	von Recklinghausen neurofibromatosis:10:0.7103	0.7103	10
VRP	VRP:12	ventral root potential:12:0.7571	0.7571	12
VRP	VRP:57|Vrp:1	verapamil:58:0.5000	0.5000	58
V-RQOL	V-RQOL:12|VRQOL:1|VR-QOL:1	Voice-Related Quality of Life:14:0.4367	0.4367	14
VRSA	VRSA:13	vancomycin-resistant Staphylococcus aureus:13:0.6701	0.6701	13
VRS	VRS:8	verbal rating score:8:0.6411	0.6411	8
VRS	VRS:11	volume reduction surgery:11:0.7357	0.7357	11
VRT	VRT:12	Virtual Reality Therapy:12:0.7571	0.7571	12
VRT	VRT:9	Visual Reaction Time:9:0.2643	0.2643	9
VRT	VRT:11	volume rendering technique:11:0.7357	0.7357	11
Vrev	Vrev:20|VRev:2	reversal potential:22:0.8657	0.8657	22
Vr	Vr:9|VR:1	reversal potential:10:0.2446	0.2446	10
VR	VR:9	Valsalva ratio:9:0.0550	0.0550	9
VR	VR:28	valve replacement:28:0.7505	0.7505	28
VR	VR:9	vanilloid receptor:9:0.1409	0.1409	9
VR	VR:24	variable ratio:15:0.1495|variable-ratio:9:0.0084	0.1495	24
VR	VR:12	variable region:12:0.5664	0.5664	12
VR	VR:11	vascular reactivity:11:0.5355	0.5355	11
VR	VR:50	vascular resistance:50:0.7866	0.7866	50
VR	VR:16	venous return:16:0.7261	0.7261	16
VR	VR:10	ventilation rate:10:0.1223	0.1223	10
VR	VR:7	ventilatory response:7:0.0732	0.0732	7
VR	VR:18|vr:1	ventral root:19:0.7658	0.7658	19
VR	VR:11	ventricular rate:11:0.1486	0.1486	11
VR	VR:10	verapamil:10:0.0095	0.0095	10
VR	VR:8	vesamicol receptor:8:0.1061	0.1061	8
VR	VR:241	virtual reality:241:0.9800	0.9800	241
VR	VR:9	Visual Reproduction:9:0.6794	0.6794	9
VR	VR:30	vocational rehabilitation:30:0.6252	0.6252	30
Vr	Vr:19|VR:7	volume:26:0.0263	0.0263	26
VR	VR:32	volume rendering:32:0.9072	0.9072	32
VSAs	VSAs:11	variant surface antigens:11:0.6182	0.6182	11
VSA	VSA:18	variant surface antigens:18:0.6903	0.6903	18
VSA	VSA:32	vasospastic angina:32:0.9072	0.9072	32
VSA	VSA:26	ventral septal area:26:0.8861	0.8861	26
VSA	VSA:10	volatile substance abuse:10:0.7103	0.7103	10
VSCCs	VSCCs:19	voltage-sensitive Ca2+ channels:19:0.7658	0.7658	19
VSCCs	VSCCs:34	voltage-sensitive calcium channels:34:0.7048	0.7048	34
VSCC	VSCC:27	voltage-sensitive Ca2+ channels:27:0.6192	0.6192	27
VSCC	VSCC:79	voltage-sensitive calcium channels:40:0.7419|voltage-sensitive calcium channel:39:0.6392	0.7419	79
VSCs	VSCs:20	volatile sulfur compounds:20:0.8525	0.8525	20
VSCs	VSCs:9	volatile sulphur compounds:9:0.6794	0.6794	9
VSCT	VSCT:13	ventral spinocerebellar tract:13:0.7753	0.7753	13
VSC	VSC:31	volatile sulfur compounds:31:0.9043	0.9043	31
VSC	VSC:20	volatile sulphur compounds:20:0.8525	0.8525	20
VSC	VSC:17	voluntary surgical contraception:17:0.8270	0.8270	17
VSDs	VSDs:82	ventricular septal defects:82:0.9636	0.9636	82
VSD	VSD:12	Vaccine Safety Datalink:12:0.7571	0.7571	12
VSD	VSD:16	vascular surface density:16:0.8165	0.8165	16
VSD	VSD:918|-VSD:1|vsd:1	ventricular septal defect:847:0.9856|ventricular septal defects:73:0.9591	0.9856	920
VSD	VSD:17	virtually safe dose:17:0.8270	0.8270	17
VSD	VSD:9	voltage-sensitive dye:9:0.6794	0.6794	9
VSE	VSE:12	venom sac extract:12:0.7571	0.7571	12
VSGs	VSGs:60	variant surface glycoproteins:60:0.6592	0.6592	60
VSG	VSG:268|Vsg:1|vsg:1	variant surface glycoprotein:260:0.7682|variant surface glycoproteins:10:0.5856	0.7682	270
VSMCs	VSMCs:1069|vSMCs:12|vsmcs:2	vascular smooth muscle cells:1083:0.9749	0.9749	1083
VSMC	VSMC:12	vascular smooth muscle:12:0.6460	0.6460	12
VSMC	VSMC:1657|vSMC:15|v-SMC:2|V-SMC:1	vascular smooth muscle cells:1156:0.9646|vascular smooth muscle cell:519:0.9876	0.9876	1675
VSM	VSM:428|vsm:3	Vascular smooth muscle:424:0.9887|vascular smooth muscles:7:0.5926	0.9887	431
VSM	VSM:12	vascular smooth muscle cells:12:0.7571	0.7571	12
VSOR	VSOR:7	Volume-Sensitive Outwardly Rectifying:7:0.5006	0.5006	7
VSPs	VSPs:14	variant-specific surface proteins:14:0.3585	0.3585	14
VSRM	VSRM:10	voltage-sensitive release mechanism:10:0.7103	0.7103	10
VSR	VSR:21	ventricular septal rupture:21:0.7865	0.7865	21
VSR	VSR:15	vestibulospinal reflex:15:0.3614	0.3614	15
VSTM	VSTM:19	visual short-term memory:19:0.6537	0.6537	19
VSV-G	VSV-G:35|VSVG:3	vesicular stomatitis virus:38:0.9217	0.9217	38
VSV-G	VSV-G:12|VSVG:3	vesicular stomatitis virus G:15:0.8045	0.8045	15
VSV-G	VSV-G:21|VSVG:5	vesicular stomatitis virus G protein:26:0.8861	0.8861	26
VSV-G	VSV-G:36|VSVG:7|VSVg:2	vesicular stomatitis virus glycoprotein:45:0.8964	0.8964	45
VSV-NJ	VSV-NJ:6	vesicular stomatitis virus New Jersey:6:0.5290	0.5290	6
VSV-NJ	VSV-NJ:3	vesicular stomatitis virus New Jersey serotype:3:0.6411	0.6411	3
VSV	VSV:17	vesicular stomatitis:17:0.8270	0.8270	17
VSV	VSV:1277|vsv:2	vesicular stomatitis virus:1269:0.9813|vesicular stomatitis viruses:10:0.7103	0.9813	1279
VT/TI	VT/TI:88|VT/Ti:14|VT/tI:3|Vt/Ti:1	mean inspiratory flow:106:0.8705	0.8705	106
VT/TI	VT/TI:17|VT/Ti:4|Vt/Ti:1|VT/tI:1	mean inspiratory flow rate:23:0.5997	0.5997	23
VT/VF	VT/VF:24	ventricular tachycardia/fibrillation:24:0.8768	0.8768	24
VT/VF	VT/VF:13	ventricular tachycardia/ventricular fibrillation:13:0.7753	0.7753	13
VT1	VT1:16|VT-1:1	Verotoxin 1:17:0.3232	0.3232	17
VT2	VT2:14	verotoxin 2:14:0.2415	0.2415	14
VTA-SN	VTA-SN:7	ventral tegmental area-substantia nigra:7:0.5926	0.5926	7
VTA	VTA:8	ventral tegmental:8:0.5006	0.5006	8
VTA	VTA:1133|vta:1	ventral tegmental area:1134:0.9781	0.9781	1134
VTA	VTA:12	ventral tegmental area of Tsai:12:0.7571	0.7571	12
VTCs	VTCs:14	vesicular tubular clusters:14:0.6911	0.6911	14
VTD	VTD:18	venous thromboembolic disease:18:0.7539	0.7539	18
VTD	VTD:15	veratridine:15:0.3111	0.3111	15
VTEC	VTEC:259|vtec:1	Escherichia coli:260:0.7379	0.7379	260
VTEC	VTEC:1	verocytotoxin-producing E coli:1:0.0913	0.0913	1
VTEC	VTEC:1	verotoxin-producing E coli:1:0.1874	0.1874	1
VTED	VTED:14	Venous thromboembolic disease:14:0.7909	0.7909	14
VTEs	VTEs:10	venous thromboembolic events:10:0.7103	0.7103	10
Vte	Vte:11|VTE:5	transepithelial voltage:16:0.6024	0.6024	16
VTE	VTE:21	venous thromboembolic:21:0.8594	0.8594	21
VTE	VTE:19	venous thromboembolic disease:19:0.7658	0.7658	19
VTE	VTE:22	venous thromboembolic events:22:0.8657	0.8657	22
VTE	VTE:792	venous thromboembolism:792:0.9863	0.9863	792
VTh	VTh:10|Vth:2	ventilatory threshold:12:0.5664	0.5664	12
VTR	VTR:10	variable tandem repeat:10:0.7103	0.7103	10
VTs	VTs:10	ventricular tachyarrhythmias:10:0.7103	0.7103	10
VTs	VTs:44	ventricular tachycardias:44:0.9323	0.9323	44
VTs	VTs:17	verotoxins:17:0.1185	0.1185	17
VT	VT:4	exposure to the trichothecene vomitoxin:4:0.0902	0.0902	4
VT	VT:5	insertion of ventilation tubes:5:0.1464	0.1464	5
VT	VT:1216|Vt:129	tidal volume:1259:0.9438|tidal volumes:86:0.8820	0.9438	1345
Vt	VT:11|Vt:11	transepithelial potential:22:0.5327	0.5327	22
Vt	Vt:14|VT:4	transepithelial potential difference:18:0.5228	0.5228	18
VT	VT:37|Vt:36	transepithelial voltage:73:0.7930	0.7930	73
VT	VT:46	vasotocin:46:0.0095	0.0095	46
VT	VT:11	venous thromboembolism:11:0.7357	0.7357	11
VT	VT:37|vT:1	venous thrombosis:38:0.7810	0.7810	38
VT	VT:5	venous tone:5:0.0736	0.0736	5
VT	VT:6	ventilating tubes:6:0.1010	0.1010	6
VT	VT:12	Ventilation tube:12:0.7571	0.7571	12
VT	VT:144|Vt:1	ventilatory threshold:145:0.7703	0.7703	145
VT	VT:8	ventral tegmentum:8:0.5006	0.5006	8
VT	VT:56	ventricular tachyarrhythmias:38:0.8781|ventricular tachyarrhythmia:18:0.8365	0.8781	56
VT	VT:2207	ventricular tachycardia:2157:0.9845|ventricular tachycardias:50:0.9064	0.9845	2207
VT	VT:15	vero cytotoxin:15:0.4951	0.4951	15
VT	VT:25	verocytotoxin:25:0.0051	0.0051	25
VT	VT:75|vt:2	verotoxin:64:0.0134|verotoxins:13:0.0025	0.0134	77
VT	VT:10|Vt:9	vitellin:19:0.0038	0.0038	19
VT	VT:5	vocational training:5:0.1132	0.1132	5
VT	VT:5	volume transmission:5:0.1543	0.1543	5
VUC	VUC:16	voided urine cytology:16:0.8165	0.8165	16
VUE	VUE:7	Villitis of unknown etiology:7:0.5926	0.5926	7
VUJ	VUJ:17	junction:17:0.9412	0.9412	17
VUMC	VUMC:12	Vanderbilt University Medical Center:12:0.6460	0.6460	12
VUV	VUV:20	vacuum ultraviolet:20:0.8525	0.8525	20
VU	VU:5	vertebral unit:5:0.1132	0.1132	5
VVA	VVA:18	Vicia villosa:18:0.8365	0.8365	18
VVA	VVA:33	Vicia villosa agglutinin:33:0.9100	0.9100	33
VVB	VVB:10	veno-venous bypass:10:0.1680	0.1680	10
VVB	VVB:15	venovenous bypass:15:0.3614	0.3614	15
VVF	VVF:11	vesicovaginal fistula:11:0.2764	0.2764	11
VVF	VVF:6	vesicovaginal fistulae:6:0.1838	0.1838	6
VVIQ	VVIQ:9	Vividness of Visual Imagery Questionnaire:9:0.6794	0.6794	9
VVI	VVI:26	ventricular:26:0.1111	0.1111	26
VVI	VVI:19	ventricular demand:19:0.6537	0.6537	19
VVI	VVI:4	ventricular demand pacemaker:4:0.4422	0.4422	4
VVI	VVI:19	ventricular inhibited:19:0.6537	0.6537	19
VVI	VVI:16	ventricular pacing:16:0.2709	0.2709	16
VVND	VVND:10	Newcastle disease:10:0.7103	0.7103	10
VVOR	VVOR:8|V-VOR:2	vestibulo-ocular reflex:10:0.3145	0.3145	10
VVOR	VVOR:7	visually enhanced VOR:7:0.5926	0.5926	7
VVS	VVS:29	vasovagal syncope:29:0.7581	0.7581	29
VVS	VVS:34	Vulvar Vestibulitis Syndrome:34:0.8644	0.8644	34
VVC	VVC:38	Vulvovaginal candidiasis:38:0.9217	0.9217	38
VV	VV:17|vv:2	recombinant vaccinia viruses:19:0.6537	0.6537	19
VV	VV:409|vv:7|Vv:1	vaccinia virus:417:0.9648	0.9648	417
VV	VV:33|vv:1	varicose veins:27:0.8903|varicose vein:7:0.2452	0.8903	34
VV	VV:7|Vv:4	vascular volume:11:0.0557	0.0557	11
V-V	V-V:5|VV:3|v-v:1	veno-venous:9:0.0085	0.0085	9
VV	VV:12	venous volume:12:0.0659	0.0659	12
VV	VV:31|V-V:1	venovenous:32:0.0328	0.0328	32
VV	VV:16|Vv:2	Vicia villosa:18:0.8365	0.8365	18
vv	vv:30	virulent:30:0.0307	0.0307	30
Vv	Vv:63|VV:10	volume density:73:0.8212	0.8212	73
Vv	Vv:27|VV:6	volume fraction:19:0.8449|volume fractions:14:0.6911	0.8449	33
VWFA	VWFA:10	Visual Word Form Area:10:0.7103	0.7103	10
vWF-cp	vWF-cp:4|VWF-cp:3|VWF-CP:3|vWF-CP:2|VWFcp:1|VWFCP:1	von Willebrand factor-cleaving protease:14:0.7909	0.7909	14
VWF	VWF:112	vibration-induced white finger:87:0.5497|vibration induced white finger:25:0.8816	0.8816	112
vWF	vWF:1813|VWF:452|vWf:418|Vwf:1|v-WF:1|VWf:1|vwf:1	von Willebrand factor:2687:0.9631	0.9631	2687
vWF	vWF:12|vWf:8	von Willebrand factor antigen:20:0.7766	0.7766	20
vWF	vWF:5|VWF:3	von Willebrand factor gene:8:0.6411	0.6411	8
VWM	VWM:6|vWM:1	verbal working memory:7:0.3524	0.3524	7
VWM	VWM:11	white matter:11:0.7357	0.7357	11
vW	vW:14	von Willebrand:14:0.6911	0.6911	14
VX	VX:11	methylphosphonothioate:11:0.0926	0.0926	11
VX	VX:15	methylphosphonothiolate:15:0.1296	0.1296	15
VX	VX:13	Verruciform xanthoma:13:0.7753	0.7753	13
VYS	VYS:47	visceral yolk sac:47:0.9366	0.9366	47
VZIG	VZIG:13	immune globulin:13:0.6701	0.6701	13
VZIG	VZIG:13	immunoglobulin:13:0.3871	0.3871	13
VZV	VZV:30	varicella-zoster:18:0.0094|varicella zoster:12:0.4557	0.4557	30
VZV	VZV:1708	varicella-zoster virus:1233:0.6799|varicella zoster virus:475:0.9465	0.9465	1708
VZ	VZ:49|V-Z:32	varicella-zoster:63:0.2583|Varicella zoster:18:0.7539	0.7539	81
VZ	VZ:98|vz:4	ventricular zone:102:0.9108	0.9108	102
ValRS	ValRS:17	valyl-tRNA synthetase:17:0.8270	0.8270	17
VAL	VAL:5	sodium valproate:5:0.0902	0.0902	5
VAL	VAL:6|Val:5|val:2	valinomycin:13:0.0486	0.0486	13
VAPP	VAPP:46	vaccine-associated paralytic poliomyelitis:46:0.7142	0.7142	46
Varea	Varea:12	volume of distribution:12:0.6460	0.6460	12
Vb	Vb:11|VB:3|-Vb:1	basolateral membrane potential:15:0.4052	0.4052	15
VB	VB:13|Vb:8	basolateral membrane voltage:21:0.7865	0.7865	21
VB	VB:9	biopsy:9:0.0124	0.0124	9
Vb	Vb:14|VB:6|vb:1	blood volume:21:0.3767	0.3767	21
Vb	Vb:9	cardiac output:9:0.6794	0.6794	9
VB	VB:10	ventral noradrenergic bundle:10:0.7103	0.7103	10
VB	VB:78|Vb:1	ventrobasal:79:0.1209	0.1209	79
VB	VB:67|Vb:1	ventrobasal complex:68:0.7099	0.7099	68
VB	VB:4	ventrobasal nucleus of the thalamus:4:0.5926	0.5926	4
VB	VB:10	ventrobasal thalamus:10:0.1449	0.1449	10
VB	VB:28	vertebral body:28:0.7154	0.7154	28
VB	VB:15|V-B:2	vertebrobasilar:17:0.0248	0.0248	17
VB	VB:20|Vb:5	vinblastine:25:0.0372	0.0372	25
VB	VB:13	virtual bronchoscopy:13:0.7753	0.7753	13
VCE	VCE:7	video capsule endoscopy:7:0.5926	0.5926	7
VCO2	VCO2:12	carbon dioxide:12:0.7571	0.7571	12
VCO2	VCO2:13|Vco2:1	carbon dioxide excretion:14:0.7909	0.7909	14
VCO2	VCO2:24|Vco2:1	CO2 elimination:25:0.3308	0.3308	25
VCO2	VCO2:12|Vco2:2	CO2 excretion:14:0.2758	0.2758	14
VCZ	VCZ:9	voriconazole:9:0.4444	0.4444	9
Vd(ss)	Vd(ss):11|VD(ss):1	volume of distribution:12:0.6460	0.6460	12
Vd(ss)	Vd(ss):14	volume of distribution at steady state:14:0.6386	0.6386	14
Vd/F	Vd/F:19|Vd/f:7|VD/F:1	apparent volume of distribution:27:0.5951	0.5951	27
Vdss	Vdss:84|VDss:4|VdSS:3	volume of distribution:91:0.9167	0.9167	91
Vdss	Vdss:71|VDSS:1|VDss:1|VdSS:1	volume of distribution at steady state:74:0.9229	0.9229	74
VD	VD:18	1,25-dihydroxyvitamin D3:18:0.2060	0.2060	18
VD	VD:57	dead space:57:0.9477	0.9477	57
VD	VD:7	dead space ventilation:7:0.5926	0.5926	7
VD	VD:11|Vd:1	dead space volume:12:0.7571	0.7571	12
Vd	Vd:46|VD:5	distribution volume:51:0.5245	0.5245	51
VD	VD:18	vaginal delivery:18:0.8365	0.8365	18
VD	VD:20	vas deferens:20:0.8525	0.8525	20
VD	VD:10	vascular density:10:0.1223	0.1223	10
VD	VD:19	Venereal disease:13:0.1114|venereal diseases:6:0.1838	0.1838	19
VD	VD:22	ventricular dilator:22:0.6531	0.6531	22
VD	VD:6	vessel diameter:6:0.1010	0.1010	6
VD	VD:9|vd:1	vessel disease:10:0.0667	0.0667	10
VD	VD:18	vitamin D:18:0.5940	0.5940	18
VD	VD:5	voiding dysfunction:5:0.0902	0.0902	5
VD	VD:11|Vd:2|vd:1	volume density:14:0.2326	0.2326	14
Vd	Vd:392|VD:29	volume of distribution:421:0.9295	0.9295	421
VeCO	VeCO:5|VECO:2|VEco:1	excretion rate of carbon monoxide:8:0.6411	0.6411	8
VEMP	VEMP:60	vestibular evoked myogenic potential:30:0.9011|vestibular evoked myogenic potentials:16:0.8165|vestibular-evoked myogenic potential:14:0.1579	0.9011	60
VEC	VEC:19	vaginal epithelial cells:19:0.5732	0.5732	19
VEC	VEC:77	vascular endothelial cells:58:0.8502|vascular endothelial cell:19:0.6106	0.8502	77
VEC	VEC:9|vec:1|Vec:1	vecuronium:11:0.0521	0.0521	11
VEC	VEC:12	velocity-encoded cine:12:0.5050	0.5050	12
VEC	VEC:6	video-enhanced contrast:6:0.2243	0.2243	6
VEGF-B	VEGF-B:8|VEGFB:1	vascular endothelial growth factor B:9:0.6794	0.6794	9
Vero	Vero:8	African green monkey:8:0.6411	0.6411	8
Vero	Vero:31|VERO:7	African green monkey kidney:38:0.7364	0.7364	38
VG	VG:8|Vg:3	glomerular volume:11:0.3829	0.3829	11
VG	VG:9	graft:9:0.0220	0.0220	9
VG	VG:9	group:9:0.0220	0.0220	9
VG	VG:6	vein grafts:6:0.2243	0.2243	6
VG	VG:9	ventriculography:9:0.0220	0.0220	9
VG	VG:12	vestibular ganglion:12:0.4557	0.4557	12
vg	vg:26|Vg:7|VG:2	vestigial:35:0.0937	0.0937	35
Vg	Vg:125|VG:7	Vitellogenin:132:0.3609	0.3609	132
Vicryl	Vicryl:5	polyglactin 910 mesh:5:0.4422	0.4422	5
vIRF	vIRF:9	viral interferon regulatory factor:9:0.4587	0.4587	9
VisoV	VisoV:13|Visov:1	volume of isoflow:14:0.7909	0.7909	14
Vj	Vj:22	transjunctional voltage:22:0.7400	0.7400	22
VJ	VJ:12	vertical jump:12:0.7571	0.7571	12
Vmax	Vmax:11	concentration:11:0.0041	0.0041	11
Vmax	Vmax:7	expiratory flow rates:7:0.4438	0.4438	7
Vmax	Vmax:25	maximal activity:25:0.1342	0.1342	25
Vmax	Vmax:10	maximal expiratory flow:10:0.1596	0.1596	10
Vmax	Vmax:26	maximal rate:26:0.0894	0.0894	26
Vmax	Vmax:21	maximal rate of depolarization:21:0.1836	0.1836	21
Vmax	Vmax:9	maximal rate of transport:9:0.2500	0.2500	9
Vmax	Vmax:13|vmax:1	maximal transport capacity:14:0.2326	0.2326	14
Vmax	Vmax:24|vmax:1	maximal transport rate:25:0.5722	0.5722	25
Vmax	Vmax:6	maximal uptake rate:6:0.0611	0.0611	6
Vmax	Vmax:245|vmax:2	maximal velocity:234:0.2144|maximal velocities:13:0.1250	0.2144	247
Vmax	Vmax:6	maximal velocity of uptake:6:0.1320	0.1320	6
Vmax	Vmax:15	maximum expiratory flow:15:0.3429	0.3429	15
Vmax	Vmax:45	maximum rate of depolarization:45:0.5470	0.5470	45
Vmax	Vmax:10	maximum rate of metabolism:10:0.4363	0.4363	10
Vmax	Vmax:47	maximum rate of rise:47:0.5232	0.5232	47
Vmax	Vmax:12	maximum rate of rise of action potential:12:0.5113	0.5113	12
Vmax	Vmax:7	maximum rate of rise of the action potential upstroke:7:0.4728	0.4728	7
Vmax	Vmax:6	maximum rate of uptake:6:0.0899	0.0899	6
Vmax	Vmax:9	maximum uptake rate:9:0.1945	0.1945	9
Vmax	Vmax:311|VMax:1|vmax:1|VMAX:1	maximum velocity:300:0.2837|maximum velocities:14:0.1425	0.2837	314
Vmax	Vmax:3	maximum velocity of reaction:3:0.1464	0.1464	3
Vmax	Vmax:29	maximum velocity of shortening:29:0.4913	0.4913	29
Vmax	Vmax:5	maximum velocity of transport:5:0.0902	0.0902	5
Vmax	Vmax:16	phase 0 depolarization:16:0.8165	0.8165	16
Vmax	Vmax:15	upstroke velocity of the action potential:15:0.8525	0.8525	15
VMCA	VMCA:10|Vmca:5|V-MCA:1|vmca:1	blood flow velocity in the middle cerebral artery:17:0.7593	0.7593	17
Vmca	Vmca:15|VMCA:4|vmca:2	middle cerebral artery blood flow velocity:21:0.8594	0.8594	21
Vmca	Vmca:7|vmca:2|VMCA:2	middle cerebral artery flow velocity:11:0.7357	0.7357	11
Vmes	Vmes:7	trigeminal mesencephalic nucleus:7:0.3524	0.3524	7
Vm	Vm:5|vm:3	mean blood flow velocity:8:0.2327	0.2327	8
Vm	Vm:13|VM:1	mean velocity:14:0.0958	0.0958	14
Vm	Vm:8|VM:7|vM:1	membrane:16:0.0115	0.0115	16
Vm	Vm:237|VM:10|V-m:1	membrane potential:223:0.7782|Membrane potentials:25:0.5496	0.7782	248
Vm	Vm:58|VM:1	membrane voltage:48:0.6918|membrane voltages:11:0.6182	0.6918	59
Vm	Vm:5|VM:2	minute volume:7:0.1470	0.1470	7
VM	VM:15	Vacuolar myelopathy:15:0.8045	0.8045	15
VM	VM:44	Valsalva maneuver:44:0.8076	0.8076	44
VM	VM:14	Valsalva manoeuvre:14:0.6173	0.6173	14
VM	VM:39	Ventral mesencephalic:39:0.8811	0.8811	39
VM	VM:57	ventral mesencephalon:57:0.9477	0.9477	57
VM	VM:11	ventricular muscle:11:0.3213	0.3213	11
VM	VM:46|vm:4	ventromedial:50:0.0375	0.0375	50
VM	VM:18	ventromedial nucleus:18:0.2215	0.2215	18
VM	VM:12|Vm:2	ventromedial thalamic nucleus:14:0.5111	0.5111	14
VM	VM:7|Vm:3	vimentin:10:0.0069	0.0069	10
VNR	VNR:55	vinorelbine:55:0.3600	0.3600	55
VNR	VNR:47|VnR:24	vitronectin receptor:71:0.9335	0.9335	71
VO2I	VO2I:6	oxygen consumption:6:0.2243	0.2243	6
Vp-TDH	Vp-TDH:8	thermostable direct hemolysin:8:0.6411	0.6411	8
VPF	VPF:118	vascular permeability factor:118:0.8379	0.8379	118
VPM	VPM:8	medial thalamus:8:0.1367	0.1367	8
VPM	VPM:7|VPm:1	nucleus of the thalamus:8:0.1809	0.1809	8
VPM	VPM:15	nucleus ventralis posteromedialis:15:0.6386	0.6386	15
VPM	VPM:28	ventral posterior medial:28:0.8369	0.8369	28
VPM	VPM:13	ventral posterior medial nucleus:13:0.7753	0.7753	13
VPM	VPM:8	ventral posteromedial thalamic nucleus:8:0.6411	0.6411	8
VPM	VPM:7|VPm:3	ventroposterior medial:10:0.0902	0.0902	10
VPM	VPM:12|Vpm:1	verapamil:13:0.0492	0.0492	13
Vrest	Vrest:5|VREST:3	resting potential:8:0.4102	0.4102	8
VsEPs	VsEPs:11	short latency vestibular evoked potentials:11:0.6182	0.6182	11
VSP	VSP:13|vsp:2	Short Patch:15:0.8045	0.8045	15
Vsp	Vsp:8|VSP:1	spinal trigeminal nucleus:9:0.6794	0.6794	9
VSP	VSP:10	variant-specific surface protein:10:0.2643	0.2643	10
VSP	VSP:7	variant surface protein:7:0.1111	0.1111	7
VSP	VSP:14	vasospasm:14:0.0756	0.0756	14
VSP	VSP:36	ventricular septal perforation:36:0.9174	0.9174	36
Vss	Vss:10|VSS:1	distribution volume:11:0.3829	0.3829	11
VSS	VSS:6	Vancouver Scar Scale:6:0.5290	0.5290	6
VSs	VSs:24	vestibular schwannomas:24:0.8768	0.8768	24
VSS	VSS:10	visual sexual stimulation:10:0.7103	0.7103	10
VSS	VSS:30	volatile suspended solids:30:0.9043	0.9043	30
Vss	Vss:146|VSS:10|vss:1	volume of distribution:157:0.8901	0.8901	157
Vss	Vss:102|VSS:6	volume of distribution at steady state:75:0.9219|volume of distribution at steady-state:33:0.8605	0.9219	108
VS	VS:5	gain of the vestibulospinal:5:0.0516	0.0516	5
Vs	Vs:14|VS:4	stroke volume:18:0.3857	0.3857	18
VS	VS:9	system:9:0.0087	0.0087	9
Vs	Vs:13|VS:1	systolic velocity:14:0.3039	0.3039	14
VS	VS:6	vagal nerve stimulation:6:0.2827	0.2827	6
VS	VS:12|Vs:2	vagal stimulation:14:0.1669	0.1669	14
VS	VS:11	vanadyl sulfate:11:0.4232	0.4232	11
VS	VS:15	vasospasm:15:0.0152	0.0152	15
VS	VS:25	Vegetative State:25:0.8816	0.8816	25
VS	VS:14	ventral striatum:14:0.7909	0.7909	14
VS	VS:19	ventricular septum:19:0.7044	0.7044	19
vs	vs:9	versus:9:0.0087	0.0087	9
VS	VS:34	vesicular stomatitis:34:0.9126	0.9126	34
VS	VS:102	vestibular schwannoma:77:0.9378|vestibular schwannomas:25:0.8186	0.9378	102
VS	VS:7	Vibration syndrome:7:0.1470	0.1470	7
VS	VS:10	Viridans Streptococci:10:0.4363	0.4363	10
VS	VS:9	visual scoring:9:0.6794	0.6794	9
VS	VS:31	volatile solids:31:0.8519	0.8519	31
Vtg	Vtg:23|VTG:3	thoracic gas volume:26:0.7340	0.7340	26
VTG	VTG:198|Vtg:76|vtg:11|VtG:1	vitellogenin:286:0.8074	0.8074	286
VTG	VTG:17|Vtg:1	Volume of trapped gas:18:0.8365	0.8365	18
Vti	Vti:4	pulmonary tissue volume:4:0.1618	0.1618	4
VTI	VTI:5|Vti:1	tidal volume:6:0.1543	0.1543	6
VTI	VTI:53|vti:1|vTI:1	velocity time integral:29:0.8422|velocity-time integral:14:0.1392|velocity time integrals:12:0.7571	0.8422	55
Vus	Vus:10|VUS:1	unloaded shortening velocity:11:0.7357	0.7357	11
VUS	VUS:17	voiding urosonography:17:0.8270	0.8270	17
W-2719	W-2719:9	4-(p-Chlorophenylthio)butanol:9:0.6154	0.6154	9
W.H.O.	W.H.O.:13	World Health Organization:13:0.7753	0.7753	13
W.Th	W.Th:10	wall thickness:10:0.7103	0.7103	10
W/A	W/A:10|w/a:1	weight/age:11:0.2778	0.2778	11
W/A	W/A:10|w/a:1	weight for age:11:0.6182	0.6182	11
W/BF1	W/BF1:16	NZW x BXSB)F1:16:0.8165	0.8165	16
W/D	W/D:22|W/d:1|w/d:1	weight:24:0.1655	0.1655	24
W/D	W/D:70|w/d:1|W/d:1	weight ratio:59:0.7824|weight ratios:13:0.4849	0.7824	72
W/D	W/D:9	wet/dry:9:0.0576	0.0576	9
W/Fu	W/Fu:14	Wistar/Furth:14:0.5652	0.5652	14
W/H	W/H:28|w/h:2	ratio:30:0.3295	0.3295	30
W/H	W/H:17	weight-for-height:10:0.1023|weight for height:7:0.5006	0.5006	17
W/H	W/H:15	weight/height:15:0.1591	0.1591	15
W/L	W/L:10	ratio:10:0.3600	0.3600	10
w/o/w	w/o/w:6|W/O/W:5	emulsion:11:0.0763	0.0763	11
w/o/w	w/o/w:44|W/O/W:32	water-in-oil-in-water:76:0.5725	0.5725	76
W/Wv	W/Wv:10	mast cell-deficient:10:0.7103	0.7103	10
W-5	W-5:14|W5:2	N-(6-aminohexyl)-1-naphthalenesulfonamide:16:0.3846	0.3846	16
W-7	W-7:18|W7:2	calmodulin antagonist:20:0.7766	0.7766	20
W-7	W-7:1	calmodulin antagonist N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide:1:0.5290	0.5290	1
W-7	W-7:15|W7:4	N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide:19:0.3721	0.3721	19
W-7	W-7:4|W7:2	N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide:6:0.1838	0.1838	6
W-7	W-7:16|W7:2	N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride:18:0.3885	0.3885	18
WAB	WAB:16	Western Aphasia Battery:16:0.8165	0.8165	16
Wada	Wada:13	Intracarotid amobarbital:13:0.5934	0.5934	13
WAD	WAD:23	West African dwarf:23:0.8715	0.8715	23
WAD	WAD:68	Whiplash-Associated Disorders:28:0.3698|Whiplash Associated Disorders:22:0.8657|whiplash-associated disorder:10:0.2643|whiplash associated disorder:8:0.6411	0.8657	68
WAF	WAF:20	water accommodated fraction:12:0.7571|water-accommodated fraction:8:0.1276	0.7571	20
WAGR	WAGR:10	retardation:10:0.5625	0.5625	10
WAIS-R	WAIS-R:9	Wechsler Adult Intelligence Scale:9:0.4587	0.4587	9
WAIS-R	WAIS-R:127	Wechsler Adult Intelligence Scale-Revised:119:0.9237|Wechsler Adult Intelligence Scale revised:8:0.6182	0.9237	127
WAIS	WAIS:129	Wechsler Adult Intelligence Scale:129:0.9195	0.9195	129
WAI	WAI:16	work ability index:16:0.6577	0.6577	16
WAI	WAI:7	Working Alliance Inventory:7:0.5926	0.5926	7
WAN	WAN:7	Wide Area Network:7:0.5926	0.5926	7
WAP	WAP:119|Wap:4|wap:1	whey acidic protein:124:0.9616	0.9616	124
WAP	WAP:8	Wireless Application Protocol:8:0.6411	0.6411	8
WARs	WARs:8	Wistar audiogenic rats:8:0.6411	0.6411	8
WASI	WASI:9	Wechsler abbreviated scale of intelligence:9:0.6794	0.6794	9
WASO	WASO:24	after sleep onset:24:0.8768	0.8768	24
WASP	WASP:97|WASp:37	Wiskott-Aldrich syndrome protein:134:0.8563	0.8563	134
WAS	WAS:21	ward atmosphere scale:21:0.8594	0.8594	21
WAS	WAS:15	waste activated sludge:15:0.7096	0.7096	15
WAS	WAS:251	Wiskott-Aldrich syndrome:251:0.9330	0.9330	251
WAT	WAT:309	white adipose tissue:309:0.9793	0.9793	309
WAXS	WAXS:24	wide-angle X-ray scattering:15:0.3821|wide angle x-ray scattering:9:0.6794	0.6794	24
WAnT	WAnT:20|WanT:2	Wingate Anaerobic Test:22:0.8657	0.8657	22
WB-F344	WB-F344:12	rat liver epithelial cells:12:0.7571	0.7571	12
WBA	WBA:7	Western blot analysis:7:0.5926	0.5926	7
WBA	WBA:8	whole blood assay:8:0.6411	0.6411	8
WBA	WBA:12	whole-body autoradiography:12:0.5050	0.5050	12
WBCC	WBCC:16|wbcc:2	white blood cell count:18:0.8365	0.8365	18
WBCT	WBCT:20	whole blood clotting time:20:0.8525	0.8525	20
WBCs	WBCs:24	leukocytes:24:0.0824	0.0824	24
WBCs	WBCs:182|wbcs:1	white blood cells:183:0.9836	0.9836	183
WBCs	WBCs:10	white blood cell counts:10:0.7103	0.7103	10
WBC	WBC:20	leucocyte:10:0.0038|leucocytes:10:0.0038	0.0038	20
WBC	WBC:93|wbc:1	leukocytes:52:0.0217|leukocyte:42:0.0174	0.0217	94
WBC	WBC:1579|wbc:2|WbC:1	white blood cell:1151:0.9838|white blood cells:431:0.9720	0.9838	1582
WBC	WBC:331|wbc:3|Wbc:1	white blood cell count:290:0.9835|white blood cell counts:45:0.9338	0.9835	335
WBC	WBC:70	white blood count:70:0.8919	0.8919	70
WBC	WBC:9	whole-body counter:9:0.3069	0.3069	9
WBE	WBE:12	whole body extract:12:0.7571	0.7571	12
WBGD	WBGD:6	whole body glucose disposal:6:0.5290	0.5290	6
WBGT	WBGT:36	Wet Bulb Globe Temperature:36:0.9217	0.9217	36
WBH	WBH:125	whole body hyperthermia:76:0.9378|whole-body hyperthermia:49:0.2944	0.9378	125
WBI	WBI:51	whole body irradiation:33:0.8605|whole-body irradiation:18:0.1360	0.8605	51
WBI	WBI:16	whole bowel irrigation:16:0.8165	0.8165	16
WBPS	WBPS:5|WbPS:1	whole-body protein synthesis:6:0.2827	0.2827	6
WBPT	WBPT:9	protein turnover:9:0.6794	0.6794	9
WBQ	WBQ:6|W-BQ:2	Well-Being Questionnaire:8:0.5006	0.5006	8
WBRT	WBRT:8	whole brain irradiation:8:0.6411	0.6411	8
WBRT	WBRT:27	whole brain radiation therapy:27:0.8312	0.8312	27
WBRT	WBRT:97	whole brain radiotherapy:58:0.9486|whole-brain radiotherapy:39:0.2829	0.9486	97
WBR	WBR:39	whole body retention:22:0.8657|whole-body retention:17:0.2247	0.8657	39
WBSF	WBSF:20	Warner-Bratzler shear force:20:0.8525	0.8525	20
WBS	WBS:23	Warner-Bratzler shear:23:0.8038	0.8038	23
WBS	WBS:10	Warner-Bratzler shear force:10:0.5856	0.5856	10
WBS	WBS:15	whole blood serum:15:0.8045	0.8045	15
WBS	WBS:54	whole body scan:32:0.8563|whole-body scan:22:0.2456	0.8563	54
WBS	WBS:9	Whole-body scanning:9:0.4587	0.4587	9
WBS	WBS:9|wbs:1	Whole body scintigraphy:10:0.7103	0.7103	10
WBS	WBS:36	Wiedemann-Beckwith syndrome:36:0.2491	0.2491	36
WBS	WBS:61	Williams-Beuren syndrome:61:0.4908	0.4908	61
WBS	WBS:11	wound breaking strength:11:0.7357	0.7357	11
WBV	WBV:54|wbv:1	whole blood viscosity:55:0.9458	0.9458	55
WBV	WBV:45|wbv:2	whole-body vibration:35:0.5771|whole body vibration:12:0.7571	0.7571	47
WB	WB:11	weight-bearing:11:0.0099	0.0099	11
WB	WB:352|Wb:4	western blot:343:0.9691|Western blots:13:0.7753	0.9691	356
WB	WB:13	Western blot analysis:13:0.7753	0.7753	13
WB	WB:98|Wb:1|wb:1	Western blotting:100:0.9525	0.9525	100
WB	WB:10	Western immunoblot:10:0.3145	0.3145	10
WB	WB:11	Western immunoblotting:11:0.6182	0.6182	11
WB	WB:49|Wb:2	wheat bran:51:0.9082	0.9082	51
WB	WB:7	white bread:7:0.5006	0.5006	7
WB	WB:186	whole blood:177:0.9641|whole-blood:9:0.0079	0.9641	186
WB	WB:45|Wb:1	whole body:30:0.9011|whole-body:16:0.0148	0.9011	46
WC-1	WC-1:9|wc-1:5	white collar-1:14:0.7909	0.7909	14
WCB	WCB:14	Compensation Board:14:0.7909	0.7909	14
WCC	WCC:66	white cell count:58:0.7954|white cell counts:8:0.5006	0.7954	66
WCE	WCE:9	white coat effect:9:0.6794	0.6794	9
WCGF	WCGF:14	wet corn gluten feed:14:0.7909	0.7909	14
WCH	WCH:41	White coat hypertension:41:0.9256	0.9256	41
WCH	WCH:6	Women's and Children's Hospital:6:0.3728	0.3728	6
WCI	WCI:9	chymotrypsin inhibitor:9:0.6794	0.6794	9
WCL	WCL:11	Wenckebach cycle length:11:0.7357	0.7357	11
WCST	WCST:17	Wisconsin Card Sorting Task:17:0.8270	0.8270	17
WCST	WCST:332	Wisconsin Card Sorting Test:332:0.9909	0.9909	332
WCS	WCS:14	whole cottonseed:14:0.6911	0.6911	14
WCW	WCW:9	Fourth World Conference on Women:9:0.6794	0.6794	9
WC	WC:13	tungsten carbide:13:0.7753	0.7753	13
WC	WC:8	warm controls:8:0.4102	0.4102	8
WC	WC:15	water content:15:0.8045	0.8045	15
WC	WC:20|W-C:4	Watson-Crick:24:0.0420	0.0420	24
WC	WC:10	weight cycling:10:0.7103	0.7103	10
WC	WC:25	White Carneau:25:0.8816	0.8816	25
WC	WC:11	White Composite:11:0.7357	0.7357	11
WC	WC:45|wc:3|Wc:2	whole cell:18:0.7539|whole-cell:16:0.0274|whole cells:16:0.6577	0.7539	50
WC	WC:29	workers' compensation:29:0.6392	0.6392	29
WC	WC:9	writer's cramp:9:0.6794	0.6794	9
WDLL	WDLL:7	well-differentiated lymphocytic lymphoma:7:0.3524	0.3524	7
WDRC	WDRC:12	wide dynamic range compression:12:0.7571	0.7571	12
WDR	WDR:235	wide dynamic range:180:0.9834|wide-dynamic-range:55:0.2007	0.9834	235
WDSV	WDSV:20	Walleye dermal sarcoma virus:20:0.8525	0.8525	20
WDS	WDS:39	wet dog shakes:39:0.9237	0.9237	39
WDTC	WDTC:11	well-differentiated thyroid cancer:11:0.6182	0.6182	11
WDTC	WDTC:9	well-differentiated thyroid carcinoma:9:0.6794	0.6794	9
WDV	WDV:24	wheat dwarf virus:24:0.8768	0.8768	24
WD	WD:9	Trp-Asp:9:0.0147	0.0147	9
WD	WD:20	Wallerian degeneration:20:0.8525	0.8525	20
WD	WD:14	water deprivation:14:0.7909	0.7909	14
WD	WD:14	well-differentiated:14:0.0239	0.0239	14
WD	WD:5	Western diet:5:0.1320	0.1320	5
WD	WD:238	Wilson's disease:145:0.4268|Wilson disease:93:0.2561	0.4268	238
WD	WD:16	winter dysentery:16:0.8165	0.8165	16
Web	Web:18|web:1	World Wide Web:19:0.8525	0.8525	19
WEC	WEC:21	Whole embryo culture:21:0.7291	0.7291	21
WEE	WEE:59	Western equine encephalitis:59:0.9494	0.9494	59
WEE	WEE:6	Western equine encephalitis virus:6:0.5290	0.5290	6
WEE	WEE:62	western equine encephalomyelitis:62:0.7766	0.7766	62
WERG	WERG:10	wheelchair ergometer:10:0.7103	0.7103	10
WESDR	WESDR:15	Wisconsin Epidemiologic Study of Diabetic Retinopathy:15:0.8045	0.8045	15
WE	WE:50	Wernicke's encephalopathy:36:0.5704|Wernicke encephalopathy:14:0.1359	0.5704	50
WE	WE:8	wide excision:8:0.3463	0.3463	8
WFA	WFA:10	weight-for-age:10:0.1184	0.1184	10
WFA	WFA:9	Wistaria floribunda:9:0.3455	0.3455	9
WFA	WFA:10	Wistaria floribunda agglutinin:10:0.1094	0.1094	10
WFA	WFA:25	Wisteria floribunda agglutinin:25:0.5288	0.5288	25
WFD	WFD:11	Water Framework Directive:11:0.7357	0.7357	11
WFN	WFN:10	World Federation of Neurology:10:0.7103	0.7103	10
WFNS	WFNS:10	World Federation of Neurological Surgeons:10:0.7103	0.7103	10
WFS	WFS:9	Wolfram syndrome:9:0.3069	0.3069	9
WFS	WFS:40	World Fertility Survey:40:0.8839	0.8839	40
WF	WF:9	donor-type:9:0.0190	0.0190	9
WF	WF:18|Wf:1	factor:19:0.0427	0.0427	19
WF	WF:9	Weil-Felix:9:0.0190	0.0190	9
WF	WF:140|W-F:2	Wistar Furth:69:0.9316|Wistar-Furth:61:0.1422|Wistar/Furth:12:0.0261	0.9316	142
WF	WF:52	Working Formulation:52:0.9438	0.9438	52
WF	WF:10	wound fluid:10:0.5856	0.5856	10
WGA-HRP	WGA-HRP:19	horseradish peroxidase conjugated with wheat germ agglutinin:19:0.9308	0.9308	19
WGA-HRP	WGA-HRP:7	wheat germ agglutinin-conjugated HRP:7:0.6411	0.6411	7
WGA-HRP	WGA-HRP:120	Wheat germ agglutinin conjugated to horseradish peroxidase:120:0.9827	0.9827	120
WGA-HRP	WGA-HRP:163	wheat germ agglutinin-horseradish peroxidase:163:0.9816	0.9816	163
WGA-HRP	WGA-HRP:22	Wheat germ agglutinin-horseradish peroxidase conjugate:22:0.8657	0.8657	22
WGA-HRP	WGA-HRP:8	wheat germ agglutinin-HRP:8:0.6411	0.6411	8
WGA	WGA:13	Triticum vulgare:13:0.7753	0.7753	13
WGA	WGA:81	Triticum vulgaris:81:0.8901	0.8901	81
WGA	WGA:26	wheat germ:26:0.8861	0.8861	26
WGA	WGA:1036	wheat germ agglutinin:1036:0.9704	0.9704	1036
WGA	WGA:6	wheat germ lectin:6:0.5290	0.5290	6
WGA	WGA:17	whole genome amplification:17:0.8270	0.8270	17
WGCTA	WGCTA:10	Watson-Glaser Critical Thinking Appraisal:10:0.5856	0.5856	10
WGE	WGE:9	wheat germ extract:9:0.6794	0.6794	9
WGL	WGL:12	wheat germ lectin:12:0.7571	0.7571	12
WGRH	WGRH:7|WG-RH:5	radiation hybrid:12:0.7571	0.7571	12
WGS	WGS:11	whole-genome shotgun:11:0.4232	0.4232	11
WGTT	WGTT:7	whole gut transit time:7:0.5926	0.5926	7
WG	WG:18|wg:10|wG:1	weeks of gestation:29:0.7117	0.7117	29
WG	WG:595|W-G:1	Wegener's granulomatosis:596:0.9177	0.9177	596
WG	WG:19	weight gain:19:0.6537	0.6537	19
WG	WG:11|wg:1	wheat germ:12:0.7571	0.7571	12
WG	WG:10	wheat gluten:10:0.7103	0.7103	10
WG	WG:9	white:9:0.0071	0.0071	9
WG	WG:28	white gastrocnemius:28:0.7905	0.7905	28
wg	wg:123|Wg:116|WG:3	wingless:242:0.2150	0.2150	242
WG	WG:5	Working Group:5:0.1132	0.1132	5
WHA	WHA:10	World Health Assembly:10:0.7103	0.7103	10
WHBP	WHBP:10|WH-BP:1	working heart-brainstem preparation:11:0.7357	0.7357	11
WHC	WHC:44	water-holding capacity:29:0.4777|water holding capacity:15:0.8045	0.8045	44
WHD	WHD:15	Werdnig-Hoffmann disease:15:0.5348	0.5348	15
WHEL	WHEL:9	Women's Healthy Eating and Living:9:0.6794	0.6794	9
WHHL	WHHL:29	Watanabe Heritable Hyperlipidaemic:29:0.8978	0.8978	29
WHHL	WHHL:228	Watanabe heritable hyperlipidemic:228:0.9790	0.9790	228
WHHL	WHHL:21	Watanabe heritable hyperlipidemic rabbits:15:0.8045|Watanabe Heritable Hyperlipidemic rabbit:6:0.3728	0.8045	21
WHIMS	WHIMS:14	Women's Health Initiative Memory Study:14:0.7753	0.7753	14
WHO-ISH	WHO-ISH:5	World Health Organization-International Society of Hypertension:5:0.4422	0.4422	5
WHO-ORS	WHO-ORS:7	oral rehydration solution:7:0.3524	0.3524	7
WHO/ISH	WHO/ISH:9	World Health Organization/International Society of Hypertension:9:0.5470	0.5470	9
WHO/MDT	WHO/MDT:12	multidrug therapy:12:0.5664	0.5664	12
WHOQOL	WHOQOL:6	World Health Organization Quality of Life:6:0.5290	0.5290	6
WHO	WHO:8	grade III:8:0.2987	0.2987	8
WHO	WHO:238	World Health Organisation:238:0.9874	0.9874	238
WHO	WHO:2970	World Health Organization:2873:0.9908|World Health Organization's:97:0.9692	0.9908	2970
WHP	WHP:8	workplace health promotion:8:0.4102	0.4102	8
WHQ	WHQ:14	Women's Health Questionnaire:14:0.6173	0.6173	14
WHR	WHR:5	ratio of waist-to-hip circumference:5:0.2818	0.2818	5
WHR	WHR:6	waist to hip circumference:6:0.2987	0.2987	6
WHR	WHR:10	waist-to-hip ratios:10:0.2446	0.2446	10
WHS	WHS:72	Wolf-Hirschhorn syndrome:72:0.9136	0.9136	72
WHS	WHS:10	Women's Health Study:10:0.7103	0.7103	10
WHtR	WHtR:8|WHTR:1	waist-to-height ratio:9:0.3945	0.3945	9
WHV	WHV:244	Woodchuck hepatitis virus:244:0.9620	0.9620	244
WHVP	WHVP:18	wedged hepatic venous pressure:18:0.6903	0.6903	18
WHYMPI	WHYMPI:9	West Haven-Yale Multidimensional Pain Inventory:9:0.6794	0.6794	9
WHZ	WHZ:7|WHz:1|whz:1	weight for height:9:0.6794	0.6794	9
WHsAg	WHsAg:21	surface antigen:21:0.8594	0.8594	21
Wh	Wh:7	anophthalmic white:7:0.2452	0.2452	7
WH	WH:6|W-H:2	weight for height:8:0.3069	0.3069	8
W-H	W-H:5|WH:4	Werdnig-Hoffmann:9:0.0645	0.0645	9
WI-38	WI-38:6|WI38:1	fibroblast cells:7:0.0886	0.0886	7
WI-38	WI-38:23|WI38:8	human fibroblasts:31:0.2429	0.2429	31
WI38	WI-38:3|WI38:3	lung fibroblast:6:0.0807	0.0807	6
WIF-1	WIF-1:6|Wif1:1	Wnt inhibitory factor-1:7:0.5926	0.5926	7
WIPK	WIPK:17	protein kinase:17:0.8270	0.8270	17
WIPP	WIPP:11	Waste Isolation Pilot Plant:11:0.7357	0.7357	11
WIQ	WIQ:21	Walking Impairment Questionnaire:21:0.8594	0.8594	21
WIR	WIR:13	water immersion restraint:13:0.7753	0.7753	13
WISC	WISC:19	Wechsler Intelligence Scale for Children:19:0.7291	0.7291	19
WISC-R	WISC-R:72	Wechsler Intelligence Scale for Children-Revised:72:0.8948	0.8948	72
WISE	WISE:42	Women's Ischemia Syndrome Evaluation:42:0.9291	0.9291	42
WISH	WISH:11	amnion-derived:11:0.1370	0.1370	11
WIST	WIST:17	Whitaker Index of Schizophrenic Thinking:17:0.6748	0.6748	17
WITS	WITS:17	Women and Infants Transmission Study:17:0.8270	0.8270	17
WIT	WIT:22	warm ischemia time:22:0.8657	0.8657	22
WKHA	WKHA:14|WK-HA:1	hyperactive:15:0.6667	0.6667	15
WKR	WKR:13	Wistar Kyoto rats:13:0.7753	0.7753	13
WKS	WKS:33	Wernicke-Korsakoff syndrome:33:0.7841	0.7841	33
WKYMVm	WKYMVm:11	Trp-Lys-Tyr-Met-Val-D-Met:11:0.4167	0.4167	11
WKYs	WKYs:21	Wistar Kyoto rats:21:0.8594	0.8594	21
WKY	WKY:2	normotensive control the Wistar-Kyoto rat:2:0.4934	0.4934	2
WKY	WKY:4	normotensive rats of the Wistar-Kyoto strain:4:0.2243	0.2243	4
WKY	WKY:5	normotensive Wistar/Kyoto:5:0.0736	0.0736	5
WKY	WKY:8	Wistar-Kyoto control:8:0.0566	0.0566	8
WKY	WKY:40	Wistar Kyoto rat:40:0.8839	0.8839	40
WK	WK:12|W-K:1	normotensive Wistar-Kyoto:13:0.2415	0.2415	13
wk	wk:13	weeks:13:0.1017	0.1017	13
WK	WK:11	Wistar Kyoto:11:0.7357	0.7357	11
WK	WK:8	Wistar-Kyoto rats:8:0.3463	0.3463	8
WLB	WLB:17	Western Ligand Blot:17:0.7407	0.7407	17
WLB	WLB:30	Western ligand blotting:30:0.9011	0.9011	30
WLE	WLE:40	wide local excision:40:0.9256	0.9256	40
WLM	WLM:15	working level months:15:0.7096	0.7096	15
WLS	WLS:10	Weight loss surgery:10:0.7103	0.7103	10
WLS	WLS:27	weighted least squares:16:0.6577|weighted least-squares:11:0.6182	0.6577	27
WL	WL:5	wait-list control:5:0.0902	0.0902	5
WL	WL:7	waiting list:7:0.2113	0.2113	7
WL	WL:27	weight loss:27:0.7834	0.7834	27
WL	WL:42	White Leghorn:42:0.9291	0.9291	42
WL	WL:15	white light:15:0.8045	0.8045	15
WL	WL:12	working length:12:0.3813	0.3813	12
WMAs	WMAs:8	wall motion abnormalities:8:0.6411	0.6411	8
WMA	WMA:42	wall motion abnormalities:28:0.8941|wall motion abnormality:14:0.7909	0.8941	42
WMA	WMA:9	World Medical Association:9:0.6794	0.6794	9
WMC	WMC:15	White matter changes:15:0.8045	0.8045	15
WMC	WMC:8	working memory capacity:8:0.6411	0.6411	8
WMD	WMD:20	weapons of mass destruction:20:0.7173	0.7173	20
WMD	WMD:10	white matter damage:10:0.7103	0.7103	10
WMD	WMD:7	White muscle disease:7:0.5926	0.5926	7
WMFT	WMFT:13	Wolf Motor Function Test:13:0.7753	0.7753	13
WMH	WMH:57	white matter hyperintensities:47:0.9379|white matter hyperintensity:10:0.7103	0.9379	57
WMHs	WMHs:25	white matter hyperintensities:25:0.8816	0.8816	25
WMI	WMI:26	wall motion index:26:0.8861	0.8861	26
WML	WML:53	white matter lesions:53:0.9438	0.9438	53
WMLA	WMLA:9	White matter low attenuation:9:0.6794	0.6794	9
WMLs	WMLs:46	white matter lesions:46:0.9353	0.9353	46
WMS-III	WMS-III:6	Wechsler Memory Scale-Third Edition:6:0.3728	0.3728	6
WMSDs	WMSDs:20	work-related musculoskeletal disorders:20:0.7173	0.7173	20
WMSI	WMSI:100|WMSi:1	wall motion score index:101:0.9704	0.9704	101
WMS-R	WMS-R:74|WMSr:1|WMS-r:1	Wechsler Memory Scale-Revised:76:0.9180	0.9180	76
WMS	WMS:30	wall motion score:30:0.9011	0.9011	30
WMS	WMS:59	Wechsler Memory Scale:59:0.8548	0.8548	59
WMS	WMS:17	Williams syndrome:17:0.3670	0.3670	17
WMS	WMS:8	Wriggle mouse Sagami:8:0.4102	0.4102	8
WMT	WMT:9	Word Memory Test:9:0.4587	0.4587	9
WM	WM:27	Waldenstrom's macroglobulinaemia:27:0.6455	0.6455	27
WM	WM:199|Wm:1	Waldenstrom's macroglobulinemia:168:0.7615|Waldenstrom macroglobulinemia:32:0.0965	0.7615	200
WM	WM:28	wall motion:28:0.8941	0.8941	28
WM	WM:27	water maze:27:0.8903	0.8903	27
WM	WM:17	Western medicine:17:0.8270	0.8270	17
WM	WM:10	wheat middlings:10:0.7103	0.7103	10
WM	WM:11	white men:11:0.7357	0.7357	11
WM	WM:9	whole milk:9:0.4587	0.4587	9
WM	WM:266	working memory:266:0.9760	0.9760	266
WM	WM:19|Wm:2	wortmannin:21:0.0183	0.0183	21
WNDP	WNDP:9	Wilson's disease protein:9:0.6794	0.6794	9
WND	WND:12	Wilson disease:12:0.5050	0.5050	12
WNF	WNF:17	West Nile fever:17:0.8270	0.8270	17
WNL	WNL:11	normal limits:11:0.7357	0.7357	11
WNV	WNV:12	West Nile:12:0.7571	0.7571	12
WNV	WNV:475|WNv:1	West Nile virus:476:0.9864	0.9864	476
WN	WN:10	well-nourished:10:0.0319	0.0319	10
WN	WN:200	West Nile:200:0.9759	0.9759	200
WN	WN:18	West Nile Virus:18:0.8365	0.8365	18
WN	WN:14|wN:1	white noise:15:0.8045	0.8045	15
WOB	WOB:70|WoB:3|Wob:1	work of breathing:74:0.9602	0.9602	74
WOC	WOC:29	water-oxidizing complex:20:0.3614|water oxidizing complex:9:0.5470	0.5470	29
WOMAC	WOMAC:41	Western Ontario and McMaster Universities:41:0.9274	0.9274	41
WOMAC	WOMAC:8	Western Ontario and McMaster Universities Osteoarthritis:8:0.6794	0.6794	8
WOMAC	WOMAC:75	Western Ontario and McMaster Universities Osteoarthritis Index:75:0.9627	0.9627	75
WOMAC	WOMAC:8	Western Ontario McMaster:8:0.6794	0.6794	8
WOR	WOR:10|WoR:1	washout rate:11:0.6182	0.6182	11
WO	WO:9	Wet oxidation:9:0.5470	0.5470	9
WPA	WPA:9	World Psychiatric Association:9:0.5470	0.5470	9
WPBs	WPBs:10|WPbs:1	Weibel-Palade bodies:11:0.6182	0.6182	11
WPB	WPB:15|WPb:3	Weibel-Palade bodies:18:0.6903	0.6903	18
WPHS	WPHS:8	Women Physicians' Health Study:8:0.6411	0.6411	8
wpi	wpi:3|WPI:2	week post-infection:5:0.1132	0.1132	5
WPI	WPI:42	whey protein isolate:42:0.8893	0.8893	42
WPPSI	WPPSI:14	Wechsler Preschool and Primary Scale of Intelligence:14:0.6911	0.6911	14
WPPSI-R	WPPSI-R:9	Wechsler Preschool and Primary Scale of Intelligence-Revised:9:0.5470	0.5470	9
WPR	WPR:13	Western Pacific Region:13:0.7753	0.7753	13
WPSI	WPSI:25	Washington Psychosocial Seizure Inventory:25:0.8768	0.8768	25
WPV	WPV:17	wild poliovirus:17:0.8270	0.8270	17
WPW	WPW:276|W-P-W:5	Wolff-Parkinson-White:281:0.7053	0.7053	281
WPW	WPW:69|W-P-W:2	Wolff-Parkinson-White syndrome:71:0.8146	0.8146	71
WP	WP:1	increase in number of the Weibel-Palade:1:0.0918	0.0918	1
WP	WP:16	pulmonary artery wedge pressure:16:0.8165	0.8165	16
WP	WP:18	pulmonary capillary wedge pressure:18:0.8365	0.8365	18
WP	WP:26	Washed Platelets:26:0.7340	0.7340	26
WP	WP:13	water placebo:13:0.7753	0.7753	13
WP	WP:19	wettable powder:19:0.8449	0.8449	19
WP	WP:7	whey protein:7:0.1470	0.1470	7
WP	WP:6	Wolfgram protein:6:0.0899	0.0899	6
WRAIR	WRAIR:1	Walter Reed Army Institute for Research:1:0.6794	0.6794	1
WRAMC	WRAMC:16	Walter Reed Army Medical Center:16:0.8165	0.8165	16
WRAML	WRAML:9	Wide Range Assessment of Memory and Learning:9:0.6794	0.6794	9
WRAT	WRAT:24	Wide Range Achievement Test:24:0.8768	0.8768	24
WRAT-R	WRAT-R:17	Wide Range Achievement Test-Revised:17:0.8270	0.8270	17
WRA	WRA:8	work-related asthma:8:0.3463	0.3463	8
WRK	WRK:10	reagent K:10:0.7103	0.7103	10
WRN	WRN:8|wrn:1	helicase:9:0.0615	0.0615	9
WRN	WRN:11	Werner protein:11:0.1330	0.1330	11
WRN	WRN:21	Werner syndrome:21:0.5021	0.5021	21
WRN	WRN:7	Werner syndrome gene:7:0.2452	0.2452	7
WRN	WRN:15	Werner syndrome protein:15:0.7096	0.7096	15
WRS	WRS:7	tryptophanyl-tRNA synthetase:7:0.3524	0.3524	7
WRS	WRS:20	water immersion and restraint stress:20:0.8525	0.8525	20
WRUEDs	WRUEDs:10	work-related upper extremity disorders:10:0.4363	0.4363	10
WR	WR:11	Waldeyer's ring:11:0.7357	0.7357	11
WR	WR:23	Walter Reed:23:0.8715	0.8715	23
WR	WR:55|W-R:1	washout rate:51:0.4046|washout rates:5:0.1132	0.4046	56
WR	WR:8	Water absorption response:8:0.6411	0.6411	8
WR	WR:20	Western Reserve:20:0.8525	0.8525	20
WR	WR:11	wheel running:11:0.3495	0.3495	11
WR	WR:6	wild running:6:0.0731	0.0731	6
WR	WR:9|Wr:2	Wistar:11:0.0224	0.0224	11
WR	WR:25	Wistar rats:25:0.7679	0.7679	25
wr	wr:9|WR:5|Wr:1	wobbler:15:0.0336	0.0336	15
WR	WR:41	work rate:41:0.3054	0.3054	41
WS1	WS1:11	Waardenburg syndrome type 1:11:0.7357	0.7357	11
WS2	WS2:13	Waardenburg syndrome type 2:13:0.7753	0.7753	13
WSC	WSC:13	water-soluble carbodiimide:13:0.6701	0.6701	13
WSD	WSD:8	White spot disease:8:0.6411	0.6411	8
WSF	WSF:20|wsf:1	water-soluble fraction:21:0.4733	0.4733	21
WSLH	WSLH:10	Wisconsin State Laboratory of Hygiene:10:0.7103	0.7103	10
WSMV	WSMV:24	wheat streak mosaic virus:24:0.8768	0.8768	24
WSN	WSN:11	white sponge nevus:11:0.7357	0.7357	11
WSOC	WSOC:5	water soluble organic carbon:5:0.4422	0.4422	5
WSP	WSP:7	water-soluble phosphorus:7:0.3524	0.3524	7
WSP	WSP:36	Withdrawal seizure-prone:19:0.7658|Withdrawal Seizure Prone:17:0.8270	0.8270	36
wsp	wsp:7|WSP:7	Wolbachia Surface Protein:14:0.6173	0.6173	14
WSR	WSR:17	wall shear rate:17:0.7407	0.7407	17
WSSG	WSSG:11	wall shear stress gradient:11:0.7357	0.7357	11
WSSV	WSSV:159	white spot syndrome virus:159:0.9809	0.9809	159
WSS	WSS:11	syndrome:11:0.0690	0.0690	11
WSS	WSS:87	wall shear stress:87:0.9280	0.9280	87
WST	WST:6	Wheelchair Skills Test:6:0.5290	0.5290	6
WSU	WSU:10	Wayne State University:10:0.4363	0.4363	10
WSW	WSW:14	women who have sex with women:14:0.6911	0.6911	14
WS	WS:525|Ws:1	syndrome:526:0.5721	0.5721	526
WS	WS:15	wall stress:15:0.6386	0.6386	15
WS	WS:9	warning signal:9:0.6794	0.6794	9
WS	WS:8	warning stimulus:8:0.5006	0.5006	8
WS	WS:15|W-S:4	Warthin-Starry:19:0.0197	0.0197	19
Ws	Ws:6|WS:4	Wassilewskija:10:0.0098	0.0098	10
WS	WS:42|W-S:1|ws:1	water-soluble:34:0.0360|water soluble:10:0.7103	0.7103	44
WS	WS:14	wheat straw:14:0.7909	0.7909	14
WS	WS:6|Ws:3	Withania somnifera:9:0.6794	0.6794	9
WT1	WT1:6|WT-1:1	tumor gene 1:7:0.1329	0.1329	7
WT1	WT1:24|wt-1:1|Wt1:1|WT-1:1	Wilms' tumor:18:0.4226|Wilms tumor:9:0.1150	0.4226	27
WT1	WT1:30|WT-1:2|wt1:1|Wt1:1	Wilms' tumor 1:24:0.5160|Wilms tumor 1:10:0.1134	0.5160	34
WT1	WT1:62|wt1:6|WT-1:5|wt-1:1	Wilms' tumor gene:44:0.4591|Wilms tumor gene:30:0.2742	0.4591	74
WT1	WT1:5|WT-1:2	Wilms' tumor gene product:7:0.3524	0.3524	7
WT1	WT1:7|wt1:2	Wilms' tumor suppressor:9:0.4587	0.4587	9
WT1	WT1:29|WT-1:4|wt1:3|Wt-1:1	Wilms' tumor suppressor gene:37:0.5783	0.5783	37
WTC	WTC:59	World Trade Center:59:0.9494	0.9494	59
WTD	WTD:8	white-tailed deer:8:0.5006	0.5006	8
WTF	WTF:10	fraction:10:0.5000	0.5000	10
WTO	WTO:40	World Trade Organization:40:0.9256	0.9256	40
WTP	WTP:10	treatment plant:10:0.7103	0.7103	10
WTP	WTP:202|wtp:2	willingness to pay:142:0.9452|willingness-to-pay:62:0.2563	0.9452	204
WTR	WTR:21	with-the-rule:21:0.3279	0.3279	21
WTh	WTh:20|Wth:4	wall thickening:24:0.8768	0.8768	24
WTs	WTs:11	Wilms' tumors:11:0.2764	0.2764	11
WUE	WUE:42	Water use efficiency:23:0.3697|water-use efficiency:19:0.2759	0.3697	42
WURS	WURS:19	Wender Utah Rating Scale:19:0.8365	0.8365	19
WUSPI	WUSPI:7	Wheelchair User's Shoulder Pain Index:7:0.5926	0.5926	7
WVP	WVP:8	water vapor permeability:8:0.6411	0.6411	8
WVTR	WVTR:8	transmission rate:8:0.4102	0.4102	8
WWE	WWE:12	women with epilepsy:12:0.7571	0.7571	12
WWII	WWII:23	World War II:23:0.8715	0.8715	23
WWS	WWS:49	Walker-Warburg syndrome:49:0.8492	0.8492	49
WWTPs	WWTPs:59	wastewater treatment plants:59:0.8731	0.8731	59
WWTP	WWTP:82|wwtp:3|WwTP:1	wastewater treatment plant:66:0.7882|wastewater treatment plants:20:0.7766	0.7882	86
WWW	WWW:234|www:8	World Wide Web:242:0.9675	0.9675	242
WW	WW:20	watchful waiting:20:0.8525	0.8525	20
WW	WW:6	weaning weights:6:0.2243	0.2243	6
ww	ww:41|WW:5|Ww:1	wet weight:47:0.5532	0.5532	47
W-W	W-W:9|WW:1	white-on-white:10:0.0425	0.0425	10
Wales	Wales:7	Babesia motasi:7:0.2113	0.2113	7
WA	WA:10	wall area:10:0.3867	0.3867	10
WA	WA:9	warm-acclimated:9:0.0253	0.0253	9
WA	WA:2	weight age:2:0.5470	0.5470	2
WA	WA:11	weight-for-age:11:0.0316	0.0316	11
WA	WA:85|Wa:7	Western Australia:92:0.9675	0.9675	92
WA	WA:9	Western Australian:9:0.5470	0.5470	9
wa	wa:14	white-apricot:14:0.0411	0.0411	14
WeeFIM	WeeFIM:32	Functional Independence Measure for Children:32:0.9043	0.9043	32
WES	WES:12	Work Environment Scale:12:0.7571	0.7571	12
WIN	WIN:9	agonist WIN 55,212-2:9:0.4363	0.4363	9
WI	WI:5	T1- and T2-weighted images:5:0.1464	0.1464	5
WI	WI:13	T1-weighted images:9:0.1334|T1 weighted images:4:0.0545	0.1334	13
WI	WI:24|Wi:1	warm ischemia:25:0.8816	0.8816	25
WI	WI:86	water immersion:86:0.9449	0.9449	86
WI	WI:10	Weight index:10:0.0958	0.0958	10
Wi	Wi:14	Wistar:14:0.0315	0.0315	14
Wmax	Wmax:8	maximal power:8:0.1004	0.1004	8
Wmax	Wmax:13|WMAX:1	maximal workload:14:0.5111	0.5111	14
Wmax	Wmax:8	maximum work capacity:8:0.3463	0.3463	8
Wmax	Wmax:25	power output:25:0.8186	0.8186	25
Wnt	Wnt:9|wnt:3|WNT:1	wingless:13:0.3529	0.3529	13
Ws/Ws	Ws/Ws:15	mast cell-deficient:15:0.8045	0.8045	15
X/XO	X/XO:39|X/Xo:1	xanthine/xanthine oxidase:40:0.5378	0.5378	40
X4	X4:14	CXCR4:14:0.1008	0.1008	14
X4	X4:9	CXCR4-dependent:9:0.0620	0.0620	9
X4	X4:10	CXCR4-using:10:0.0698	0.0698	10
XAC	XAC:27	xanthine amine congener:27:0.7066	0.7066	27
XAFS	XAFS:64	X-ray absorption fine structure:64:0.9264	0.9264	64
X-ALD	X-ALD:11	X-adrenoleukodystrophy:11:0.0787	0.0787	11
X-ALD	X-ALD:103|XALD:4	X-linked adrenoleukodystrophy:107:0.9039	0.9039	107
XANES	XANES:13	X-Ray Absorption Near-Edge Spectroscopy:7:0.5926|X-ray absorption near edge spectroscopy:6:0.5290	0.5926	13
XANES	XANES:107	x-ray absorption near-edge structure:60:0.8971|X-ray absorption near edge structure:47:0.9366	0.9366	107
Xan	Xan:11|XAN:1	xanthine:12:0.3143	0.3143	12
XAP2	XAP2:12	hepatitis B virus X-associated protein 2:12:0.7571	0.7571	12
XAS	XAS:9	X-ray absorption:9:0.6794	0.6794	9
XAS	XAS:9	X-ray absorption spectroscopic:9:0.6794	0.6794	9
XAS	XAS:114	X-ray absorption spectroscopy:114:0.9582	0.9582	114
X-CGD	X-CGD:26|XCGD:2	X-linked chronic granulomatous disease:28:0.5445	0.5445	28
XCI	XCI:64	X-chromosome inactivation:36:0.4224|X chromosome inactivation:28:0.8941	0.8941	64
XCIPs	XCIPs:12	X-chromosome inactivation patterns:12:0.5664	0.5664	12
XCT	XCT:11|X-CT:6	x-ray computed tomography:17:0.8270	0.8270	17
Xcv	Xcv:2	Xanthomonas campestris pv vesicatoria:2:0.7753	0.7753	2
XDH	XDH:123|Xdh:6|XDh:1	xanthine dehydrogenase:130:0.7368	0.7368	130
XDP	XDP:16	fibrin degradation products:16:0.8165	0.8165	16
XD	XD:41	xanthine dehydrogenase:41:0.7703	0.7703	41
XD	XD:9	Xanthoma disseminatum:9:0.7103	0.7103	9
XD	XD:10	xenodiagnosis:10:0.1084	0.1084	10
Xe-CT	Xe-CT:9|XeCT:5|XECT:1	xenon-enhanced computed tomography:15:0.3821	0.3821	15
Xe-CT	Xe-CT:7|XeCT:2	xenon-enhanced computerized tomography:9:0.3945	0.3945	9
XeCT	Xe-CT:3|XeCT:3	Xenon-enhanced CT:6:0.1148	0.1148	6
XES	XES:6	x-ray energy spectroscopy:6:0.5290	0.5290	6
XET	XET:18	xyloglucan endotransglycosylase:18:0.8365	0.8365	18
Xe	Xe:51	xenon:51:0.7143	0.7143	51
XFD	XFD:11	FGF receptor:11:0.7571	0.7571	11
XFS	XFS:22	exfoliation syndrome:22:0.8657	0.8657	22
XGC	XGC:28	xanthogranulomatous cholecystitis:28:0.8903	0.8903	28
XGP	XGP:62	Xanthogranulomatous pyelonephritis:62:0.9003	0.9003	62
XGPRT	XGPRT:11	phosphoribosyltransferase:11:0.6667	0.6667	11
XG	XG:14	Xanthan gum:14:0.7909	0.7909	14
XG	XG:21	xyloglucan:21:0.2667	0.2667	21
XHIM	XHIM:17|X-HIM:2	X-linked hyper-IgM syndrome:19:0.7044	0.7044	19
XH	XH:9	xylazine hydrochloride:9:0.6794	0.6794	9
XIC	XIC:15|Xic:4	X inactivation center:19:0.7658	0.7658	19
Xic	Xic:7|XIC:3	X-inactivation centre:10:0.3470	0.3470	10
XIE	XIE:11	crossed immunoelectrophoresis:11:0.7357	0.7357	11
X-IEP	X-IEP:7|XIEP:2	crossed immunoelectrophoresis:9:0.6794	0.6794	9
XIIa	XIIa:10	activated factor XII:10:0.4363	0.4363	10
Xist	Xist:4|XIST:3	X inactive specific transcript:7:0.6411	0.6411	7
XK	XK:9	xylulokinase:9:0.2759	0.2759	9
XLA	XLA:50|X-LA:2	X-linked agammaglobulinaemia:52:0.7578	0.7578	52
XLA	XLA:182|X-LA:5	X-linked agammaglobulinemia:187:0.8934	0.8934	187
XLHED	XLHED:7	X-Linked hypohidrotic ectodermal dysplasia:7:0.4438	0.4438	7
XLH	XLH:62|X-LH:1	X-linked hypophosphatemia:63:0.9253	0.9253	63
XLH	XLH:27	X-linked hypophosphatemic rickets:27:0.6745	0.6745	27
XLI	XLI:36	X-linked ichthyosis:36:0.7433	0.7433	36
XLMR	XLMR:81	X-linked mental retardation:81:0.7753	0.7753	81
XLMTM	XLMTM:22	myotubular myopathy:22:0.7955	0.7955	22
XLP	XLP:29	X-linked lymphoproliferative:29:0.8978	0.8978	29
XLP	XLP:82	X-linked lymphoproliferative disease:82:0.9422	0.9422	82
XLP	XLP:52	X-linked lymphoproliferative syndrome:52:0.8799	0.8799	52
XLRP	XLRP:58|xlRP:2|XL-RP:1	X-linked retinitis pigmentosa:61:0.7455	0.7455	61
XLRS	XLRS:25|xlRS:2	retinoschisis:27:0.9630	0.9630	27
XLSA	XLSA:15	X-linked sideroblastic anemia:15:0.8045	0.8045	15
Xl	Xl:17|XL:4	Xenopus laevis:21:0.8594	0.8594	21
XMA	XMA:8|X-MA:1	X-ray microanalysis:9:0.6794	0.6794	9
XMCD	XMCD:21|X-MCD:1	X-ray magnetic circular dichroism:22:0.7400	0.7400	22
XML	XML:78	extensible markup language:78:0.8862	0.8862	78
XMP	XMP:9	monophosphate:9:0.2759	0.2759	9
XMP	XMP:10	xanthosine 5'-monophosphate:10:0.7103	0.7103	10
XMT	XMT:10	X-ray microtomography:10:0.7103	0.7103	10
XNA	XNA:28	xenoreactive natural antibodies:28:0.8369	0.8369	28
XN	XN:9	night blindness:9:0.6794	0.6794	9
XN	XN:13|Xn:1	xanthohumol:14:0.3939	0.3939	14
XOD	XOD:88	xanthine oxidase:88:0.7213	0.7213	88
XOR	XOR:59	xanthine oxidoreductase:59:0.9203	0.9203	59
XO	XO:10	males:10:0.0141	0.0141	10
XO	XO:513|Xo:1	xanthine oxidase:514:0.9055	0.9055	514
XPA	XPA:7|XP-A:6	xeroderma pigmentosum:13:0.7753	0.7753	13
XPA	XPA:13	xeroderma pigmentosum group A protein:13:0.7753	0.7753	13
XPC	XPC:13|XP-C:6	xeroderma pigmentosum group C:19:0.8449	0.8449	19
XPD	XPD:6|XP-D:5	xeroderma pigmentosum complementation group D:11:0.7753	0.7753	11
XPD	XPD:13|XP-D:5	xeroderma pigmentosum group D:18:0.8365	0.8365	18
XP-E	XP-E:3|XPE:2	xeroderma pigmentosum complementation group E:5:0.4422	0.4422	5
XP-E	XP-E:6|XPE:2	xeroderma pigmentosum group E:8:0.6411	0.6411	8
XPG	XPG:2|Xpg:1	xeroderma pigmentosum complementation group G:3:0.3170	0.3170	3
XPN	XPN:12	xanthogranulomatous pyelonephritis:12:0.7571	0.7571	12
XPS	XPS:13	X-ray photoelectron spectroscopic:13:0.7753	0.7753	13
XPS	XPS:470	X-ray photoelectron spectroscopy:470:0.9800	0.9800	470
XP-V	XP-V:21|XPV:16	xeroderma pigmentosum variant:37:0.9197	0.9197	37
Xp	Xp:7	short arm of the X chromosome:7:0.6411	0.6411	7
XP	XP:10	Xenopsin:10:0.0101	0.0101	10
XP	XP:698|Xp:1	xeroderma pigmentosum:699:0.9931	0.9931	699
XRA	XRA:10	x-ray angiography:10:0.5856	0.5856	10
XRCC1	XRCC1:21	x-ray repair cross-complementing group 1:15:0.8045|X-ray repair cross complementing group 1:6:0.5290	0.8045	21
XRD	XRD:491|X-RD:1	X-ray diffraction:492:0.8717	0.8717	492
XRD	XRD:18	X-ray powder diffractometry:18:0.8365	0.8365	18
XREs	XREs:17	xenobiotic response elements:17:0.8270	0.8270	17
XRF	XRF:118	x-ray fluorescence:118:0.9344	0.9344	118
XRF	XRF:10	X-ray fluorescence analysis:10:0.7103	0.7103	10
XRII	XRII:12	x-ray image intensifier:12:0.7571	0.7571	12
XRMA	XRMA:26	X-ray microanalysis:26:0.8861	0.8861	26
XRPD	XRPD:60	X-ray powder diffraction:60:0.9503	0.9503	60
XRPD	XRPD:9	X-ray powder diffractometry:9:0.6794	0.6794	9
XRT	XRT:34	irradiation:34:0.1041	0.1041	34
XRT	XRT:44	radiation:44:0.1356	0.1356	44
XRT	XRT:103	radiation therapy:103:0.8568	0.8568	103
XRT	XRT:99|xRT:7	radiotherapy:106:0.3312	0.3312	106
XR	XR:38	venlafaxine extended release:30:0.7388|Venlafaxine extended-release:8:0.1730	0.7388	38
XR	XR:30	xylose reductase:30:0.6736	0.6736	30
XSA	XSA:10|X-SA:2	cross-sectional area:12:0.6460	0.6460	12
XSCID	XSCID:49|X-SCID:16	X-linked severe combined immunodeficiency:65:0.8474	0.8474	65
XTT	XTT:13	hydroxide:13:0.1618	0.1618	13
XTT	XTT:5	tetrazolium salt:5:0.0902	0.0902	5
XXY	XXY:8	Klinefelter's syndrome:8:0.2987	0.2987	8
XX	XX:11	hermaphrodites:11:0.0847	0.0847	11
XYL1	XYL1:5|xyl1:2	xylose reductase gene:7:0.5926	0.5926	7
XYL	XYL:16|Xyl:2	xylazine:18:0.2179	0.2179	18
Xa	Xa:20	activated factor X:20:0.5021	0.5021	20
Xa	Xa:5|XA:4	xanthine:9:0.0615	0.0615	9
XA	XA:19|Xa:6	xanthurenic acid:25:0.7249	0.7249	25
Xcc	Xcc:1	Xanthomonas campestris pv campestris:1:0.4363	0.4363	1
Xdsh	Xdsh:11	dishevelled:11:0.7692	0.7692	11
Xe/CT	Xe/CT:9	xenon-enhanced computed tomography:9:0.4587	0.4587	9
XLT	XLT:26	X-linked thrombocytopenia:26:0.8251	0.8251	26
Xoo	Xoo:1	Xanthomonas oryzae pv oryzae:1:0.8365	0.8365	1
XRE	XRE:23	xenobiotic response element:23:0.6653	0.6653	23
Y.e.	Y.e.:15|Y.E.:1	Yersinia enterocolitica:16:0.7261	0.7261	16
Y-1	Y-1:8|Y1:7	cell line:15:0.6386	0.6386	15
Y-27632	Y-27632:4	dihydrochloride monohydrate:4:0.6794	0.6794	4
Y2H	Y2H:17	Yeast two-hybrid:17:0.8270	0.8270	17
Y2K	Y2K:15	year 2000:15:0.6173	0.6173	15
Y-79	Y-79:7|Y79:6	retinoblastoma:13:0.4286	0.4286	13
Y-79	Y-79:6|Y79:4	retinoblastoma cell line:10:0.5470	0.5470	10
Y8	Y8:5	mouse leukemia L1210 cell line:5:0.4422	0.4422	5
Y-90	Y-90:13|Y90:2	Yttrium-90:15:0.5000	0.5000	15
YACs	YACs:336|YACS:1	yeast artificial chromosomes:337:0.9765	0.9765	337
YAC	YAC:645|Yac:1	yeast artificial chromosome:622:0.9952|yeast artificial chromosomes:24:0.8768	0.9952	646
YADH	YADH:11|Y-ADH:1	yeast alcohol dehydrogenase:12:0.6460	0.6460	12
YAP	YAP:5	Alu polymorphism:5:0.1132	0.1132	5
YAP	YAP:16|Yap:1	Yes-associated protein:17:0.7407	0.7407	17
YASR	YASR:9	Young Adult Self-Report:9:0.6794	0.6794	9
Y-BOCS	Y-BOCS:112|YBOCS:31	Yale-Brown Obsessive Compulsive Scale:76:0.9000|Yale-Brown Obsessive-Compulsive Scale:67:0.8688	0.9000	143
YC-93	YC-93:11	hydrochloride:11:0.5263	0.5263	11
YC-1	YC-1:23	indazole:23:0.4889	0.4889	23
YDV	YDV:9	yeast-derived hepatitis B vaccine:9:0.5470	0.5470	9
YES	YES:22	yeast estrogen screen:22:0.8657	0.8657	22
YES	YES:9	yeast extract sucrose:9:0.7103	0.7103	9
YFP	YFP:99	yellow fluorescent protein:99:0.7946	0.7946	99
YFV	YFV:53	yellow fever virus:53:0.9438	0.9438	53
YF	YF:165	yellow fever:165:0.9819	0.9819	165
YF	YF:17	Yellow Fever virus:17:0.8270	0.8270	17
YGTSS	YGTSS:23	Yale Global Tic Severity Scale:23:0.8715	0.8715	23
YG	YG:13	yield grade:13:0.5934	0.5934	13
YHV	YHV:17	yellow head virus:17:0.8270	0.8270	17
YIGSR	YIGSR:19	Tyr-Ile-Gly-Ser-Arg:19:0.5588	0.5588	19
YJV	YJV:9	Yellow jacket venom:9:0.6794	0.6794	9
YKB	YKB:10	Yayasan Kusuma Buana:10:0.7103	0.7103	10
YLD	YLD:6	years lived with disability:6:0.3524	0.3524	6
YLDs	YLDs:7	years lived with disability:7:0.3524	0.3524	7
YLL	YLL:16	years of life lost:16:0.8165	0.8165	16
YLLs	YLLs:9	years of life lost:9:0.6794	0.6794	9
YM881	YM881:10	zinostatin stimalamer:10:0.6794	0.6794	10
YMDD	YMDD:27	tyrosine-methionine-aspartate-aspartate:27:0.5532	0.5532	27
YMRS	YMRS:88|Y-MRS:5	Young Mania Rating Scale:93:0.9490	0.9490	93
YMSM	YMSM:11	young men who have sex with men:11:0.7357	0.7357	11
YNB	YNB:14	yeast nitrogen base:14:0.7909	0.7909	14
YNK01	YNK01:8	cytarabine ocfosfate:8:0.3524	0.3524	8
YNS	YNS:14	yellow nail syndrome:14:0.7909	0.7909	14
YOLS	YOLS:5	per year of life saved:5:0.4422	0.4422	5
YOPD	YOPD:5	young onset Parkinson's disease:5:0.4422	0.4422	5
YPAS	YPAS:9	Yale Physical Activity Survey:9:0.6794	0.6794	9
YPLL	YPLL:65	years of potential life lost:65:0.9264	0.9264	65
YPM	YPM:11	Yersinia pseudotuberculosis-derived mitogen:11:0.4728	0.4728	11
YSL	YSL:27|ysl:1	yolk syncytial layer:28:0.8941	0.8941	28
YSM	YSM:56|ysm:1	years since menopause:57:0.8478	0.8478	57
YSM	YSM:15	yolk sac membrane:15:0.7096	0.7096	15
YSR	YSR:58	Youth Self-report:37:0.8749|Youth Self Report:21:0.7865	0.8749	58
YST	YST:60	Yolk Sac Tumor:46:0.9353|yolk sac tumors:14:0.7909	0.9353	60
YTX	YTX:28	yessotoxin:28:0.9310	0.9310	28
YW	YW:10	yearling weight:10:0.5856	0.5856	10
YY1	YY1:11|Yy1:1	transcription factor Yin Yang 1:12:0.6173	0.6173	12
YAG	YAG:24	Yttrium-aluminum-garnet:15:0.1522|yttrium aluminum garnet:9:0.2764	0.2764	24
YB-1	YB-1:11|YB1:1	protein 1:12:0.6460	0.6460	12
YB-1	YB-1:7	Y-box binding protein:7:0.5926	0.5926	7
YB-1	YB-1:7	Y-box binding protein-1:7:0.5926	0.5926	7
Ybt	Ybt:20	yersiniabactin:20:0.9500	0.9500	20
Yb	Yb:19	ytterbium:19:0.3051	0.3051	19
YE	YE:21|Ye:2	yeast extract:23:0.7500	0.7500	23
Ye	Ye:29	Yersinia enterocolitica:29:0.8978	0.8978	29
YM	YM:5	Young's modulus:5:0.1132	0.1132	5
YOH	YOH:38|Yoh:12	yohimbine:50:0.8596	0.8596	50
YOPs	YOPs:8|Yops:7	outer membrane proteins:15:0.8045	0.8045	15
Yops	Yops:21|YOPS:1	Yersinia outer proteins:22:0.6934	0.6934	22
YO	YO:10|Yo:3	yohimbine:13:0.3333	0.3333	13
YP	YP:5|Yp:4|yp:4	yolk protein:13:0.6701	0.6701	13
Yqs	Yqs:10	Y chromosome:10:0.7103	0.7103	10
Yq	Yq:5	long arm of the Y chromosome:5:0.6411	0.6411	5
Yq	Yq:10	Y chromosome long arm:10:0.7103	0.7103	10
YS	YS:36	yolk sac:36:0.9174	0.9174	36
YS	YS:10	Yoshida sarcoma:10:0.5000	0.5000	10
Z0	Z0:14	impedance:14:0.5652	0.5652	14
Z1	Z1:5	zymodeme 1:5:0.1838	0.1838	5
ZACE	ZACE:12	zoapatle aqueous crude extract:12:0.7571	0.7571	12
ZAC	ZAC:13	Zinc acexamate:13:0.7753	0.7753	13
ZAP-70	ZAP-70:9|ZAP70:1	zeta-associated protein 70:10:0.7103	0.7103	10
ZAP-70	ZAP-70:7|Zap-70:1	zeta-associated protein of 70 kDa:8:0.4587	0.4587	8
ZAP	ZAP:64	zymosan-activated plasma:64:0.7269	0.7269	64
ZAS	ZAS:93|Zas:1	zymosan-activated serum:72:0.5785|zymosan activated serum:22:0.8657	0.8657	94
ZA	ZA:8	zoledronic acid:8:0.4102	0.4102	8
ZA	ZA:14	zonula adherens:14:0.6911	0.6911	14
ZBI	ZBI:9	Zarit Caregiver Burden Interview:9:0.6794	0.6794	9
ZCL	ZCL:30	zoonotic cutaneous leishmaniasis:30:0.9011	0.9011	30
Zc	Zc:20|ZC:2	characteristic impedance:22:0.5327	0.5327	22
ZDEC	ZDEC:8	zinc diethyldithiocarbamate:8:0.5006	0.5006	8
ZDF	ZDF:134	Zucker diabetic fatty:134:0.9777	0.9777	134
ZDV	ZDV:479|Zdv:3	zidovudine:482:0.9816	0.9816	482
ZD	ZD:12	Zenker's diverticulum:12:0.7571	0.7571	12
ZD	ZD:17	zinc deficiency:17:0.8270	0.8270	17
ZD	ZD:52	zinc-deficient:40:0.2600|zinc deficient:12:0.7571	0.7571	52
ZEA	ZEA:60	zearalenone:60:0.7973	0.7973	60
ZEBRA	ZEBRA:11	replication activator:11:0.5355	0.5355	11
ZEEP	ZEEP:66	zero end-expiratory pressure:66:0.9061	0.9061	66
ZEME	ZEME:7	external zone of the median eminence:7:0.5926	0.5926	7
ZES	ZES:164	Zollinger-Ellison syndrome:164:0.9283	0.9283	164
ZE	ZE:13|Z-E:4	Zollinger-Ellison:17:0.2581	0.2581	17
ZE	ZE:17	Zone electrophoresis:17:0.8270	0.8270	17
ZF/R	ZF/R:11	zona fasciculata-reticularis:11:0.7357	0.7357	11
ZFPs	ZFPs:12	zinc finger proteins:12:0.6460	0.6460	12
ZGA	ZGA:9	Zygotic gene activation:9:0.6794	0.6794	9
ZGs	ZGs:8	zymogen granules:8:0.6794	0.6794	8
ZG	ZG:163|zG:5|zg:2|Z-G:1	zona glomerulosa:171:0.9545	0.9545	171
ZG	ZG:20	zymogen granules:20:0.7766	0.7766	20
ZHX1	ZHX1:8	zinc-fingers and homeoboxes 1:8:0.6411	0.6411	8
ZIA	ZIA:10	zone immunoelectrophoresis assay:10:0.7103	0.7103	10
ZIFT	ZIFT:15	zygote intra-Fallopian transfer:15:0.8045	0.8045	15
ZIFT	ZIFT:25	zygote intrafallopian transfer:25:0.8816	0.8816	25
ZIM	ZIM:11|Zim:1	zimelidine:12:0.6111	0.6111	12
Zin	Zin:16	input impedance:16:0.8165	0.8165	16
ZIO	ZIO:18	zinc-iodide-osmium:18:0.2297	0.2297	18
ZIO	ZIO:19	zinc iodide-osmium tetroxide:19:0.8449	0.8449	19
zip	zip:9|ZIP:4	leucine zipper:13:0.4849	0.4849	13
ZIP	ZIP:9	zero-inflated Poisson:9:0.6794	0.6794	9
ZI	ZI:100	zona incerta:100:0.9701	0.9701	100
ZLI	ZLI:6|zli:3	zona limitans intrathalamica:9:0.6794	0.6794	9
ZMC	ZMC:9	zygomaticomaxillary complex:9:0.3945	0.3945	9
ZNS	ZNS:83	zonisamide:83:0.7523	0.7523	83
ZO-1	ZO-1:78	zonula occludens-1:67:0.7644|zonula occludens 1:11:0.4232	0.7644	78
ZO-1	ZO-1:7	zonula occludens protein-1:7:0.5926	0.5926	7
ZOE	ZOE:31	zinc oxide-eugenol:20:0.8525|zinc oxide eugenol:11:0.8449	0.8525	31
ZOL	ZOL:19|Zol:3	zoledronic acid:22:0.7955	0.7955	22
ZON	ZON:31	zearalenone:31:0.9375	0.9375	31
ZP3	ZP3:7|Zp3:1	zona pellucida 3:8:0.6411	0.6411	8
ZP3	ZP3:8	zona pellucida glycoprotein 3:8:0.6411	0.6411	8
ZPA	ZPA:70	zone of polarizing activity:70:0.9335	0.9335	70
ZPC	ZPC:13	zopiclone:13:0.4138	0.4138	13
ZPG	ZPG:10|zpg:1|Zpg:1	zero population growth:12:0.7571	0.7571	12
ZPI	ZPI:9	Protein Z-dependent protease inhibitor:9:0.6794	0.6794	9
ZPP	ZPP:157|Zpp:2	zinc protoporphyrin:149:0.9799|zinc-protoporphyrin:10:0.0471	0.9799	159
ZPT	ZPT:10|Zpt:2	zinc pyrithione:12:0.7571	0.7571	12
Zp	Zp:12	promoter:12:0.0208	0.0208	12
ZP	ZP:9	zeta potential:9:0.6794	0.6794	9
ZP	ZP:374|zp:5|Zp:1	zona pellucida:380:0.9088	0.9088	380
ZP	ZP:26	zonae pellucidae:17:0.4246|zona pellucidae:9:0.1267	0.4246	26
Zrs	Zrs:34	respiratory impedance:34:0.4301	0.4301	34
Zrs	Zrs:9	respiratory system:9:0.5470	0.5470	9
ZR	ZR:9	zeatin riboside:9:0.3455	0.3455	9
Zr	Zr:11	zirconium:11:0.0877	0.0877	11
ZSDS	ZSDS:21	Zung Self-rating Depression Scale:21:0.6400	0.6400	21
ZSR	ZSR:9	zeta sedimentation ratio:9:0.6794	0.6794	9
ZS	ZS:58	Zellweger syndrome:58:0.8548	0.8548	58
ZVL	ZVL:12	Zoonotic visceral leishmaniasis:12:0.7571	0.7571	12
ZYMV	ZYMV:35	zucchini yellow mosaic virus:35:0.8605	0.8605	35
ZEN	ZEN:58|Zen:1	zearalenone:59:0.4754	0.4754	59
zen	zen:24|Zen:2	zerknullt:26:0.2049	0.2049	26
ZEN	ZEN:20	Zinc-ENriched:20:0.1557	0.1557	20
ZFP	ZFP:9|Zfp:1	zinc finger protein:10:0.7103	0.7103	10
ZF	ZF:25|Zf:8|zf:2	zinc finger:35:0.8292	0.8292	35
ZF	ZF:74|zF:2|zf:1	zona fasciculata:77:0.8848	0.8848	77
ZF	ZF:14	Zucker fatty:14:0.7909	0.7909	14
Zmax	Zmax:20|zmax:1	maximum lod score:21:0.5178	0.5178	21
Zn2+	Zn2+:15	zinc ions:15:0.7096	0.7096	15
ZNF	ZNF:7|ZnF:4|Zn-f:1	zinc finger:12:0.7571	0.7571	12
ZnO	ZnO:39	zinc oxide:39:0.8811	0.8811	39
ZnPP-IX	ZnPP-IX:3|ZnPPIX:3|Zn-PPIX:1	Zinc protoporphyrin IX:7:0.5926	0.5926	7
ZnPP	ZnPP:33|Znpp:1	zinc protoporphyrin:34:0.7587	0.7587	34
ZnPP	ZnPP:11	Zinc protoporphyrin IX:11:0.5355	0.5355	11
ZnPc	ZnPc:13|ZnPC:3	zinc phthalocyanine:16:0.4040	0.4040	16
ZN	ZN:52|Z-N:6	Ziehl-Neelsen:58:0.0473	0.0473	58
Zo	Zo:11	characteristic impedance:11:0.2154	0.2154	11
ZO	ZO:7|Zo:1	zonula occludens:8:0.5006	0.5006	8
Zrp	Zrp:8|ZRP:1	zona radiata proteins:9:0.6794	0.6794	9
ZT	ZT:42|zt:1	zeitgeber time:43:0.8590	0.8590	43
Zy	Zy:9|ZY:1	zymosan:10:0.8182	0.8182	10
ZZ	ZZ:10	IgG-binding domains:10:0.4363	0.4363	10
[(3)H]NE	[(3)H]NE:12	[(3)H]norepinephrine:12:0.7857	0.7857	12
[14C]DG	[14C]DG:9	[14C]deoxyglucose:9:0.2353	0.2353	9
[18F]FDG	[18F]FDG:14	[18F]2-fluoro-2-deoxy-D-glucose:14:0.1300	0.1300	14
[18F]FDG	[18F]FDG:15|[18F]-FDG:1	[18F]fluorodeoxyglucose:16:0.1500	0.1500	16
[18F]FDG	[18F]FDG:14	2-[18F]fluoro-2-deoxy-D-glucose:14:0.1300	0.1300	14
[18F]FDG	[18F]FDG:7	fluorine-18 fluorodeoxyglucose:7:0.3524	0.3524	7
[3H]5-HT	[3H]5-HT:50|[3H]-5-HT:16|[3H]5HT:2	[3H]5-hydroxytryptamine:53:0.4094|[3H]-5-hydroxytryptamine:15:0.1102	0.4094	68
[3H]5-HT	[3H]5-HT:6|[3H]5HT:1	tritiated serotonin:7:0.1470	0.1470	7
[3H]AA	[3H]AA:29	[3H]arachidonic acid:29:0.5376	0.5376	29
[3H]ACh	[3H]ACh:64|[3H]-ACh:3|[3H]Ach:1|[3H]ACH:1	[3H]acetylcholine:69:0.6126	0.6126	69
[3H]ACh	[3H]ACh:10	acetylcholine:10:0.0811	0.0811	10
[3H]-ACh	[3H]-ACh:11|[3H]ACh:2	release of [3H]-acetylcholine:13:0.2660	0.2660	13
[3H]BTX-B	[3H]BTX-B:8|[3H]-BTX-B:2|[3H]BTX-b:1|[3H]BTXB:1	20-alpha-benzoate:12:0.4583	0.4583	12
[3H]CHA	[3H]CHA:16	[3H]cyclohexyladenosine:16:0.3571	0.3571	16
[3H]DA	[3H]DA:82|[3H]-DA:11	[3H]dopamine:82:0.7570|[3H]-dopamine:11:0.0935	0.7570	93
[3H]DHA	[3H]DHA:46|[3H]-DHA:10	[3H]dihydroalprenolol:46:0.5625|[3H]-Dihydroalprenolol:10:0.1125	0.5625	56
[3H]DHE	[3H]DHE:10	[3H]Dihydroergocryptine:10:0.6000	0.6000	10
[3H]DTG	[3H]DTG:10	[3H]1,3-di-o-tolylguanidine:10:0.2812	0.2812	10
[3H]E2	[3H]E2:15	[3H]estradiol:15:0.4242	0.4242	15
[3H]EKC	[3H]EKC:14	[3H]ethylketocyclazocine:14:0.7222	0.7222	14
[3H]FNZ	[3H]FNZ:17|[3h]FNZ:1	[3H]flunitrazepam:18:0.8500	0.8500	18
[3H]FLU	[3H]FLU:7|[3H]Flu:4	[3H]flunitrazepam:11:0.7143	0.7143	11
[3H]HC-3	[3H]HC-3:11	[3H]hemicholinium-3:11:0.8333	0.8333	11
[3H]IP1	[3H]IP1:14	[3H]inositol monophosphate:14:0.4709	0.4709	14
[3H]IP3	[3H]IP3:9	[3H]inositol trisphosphate:9:0.3945	0.3945	9
[3H]IPs	[3H]IPs:12	[3H]inositol phosphates:12:0.4557	0.4557	12
[3H]IP	[3H]IP:11	[3H]inositol phosphate:11:0.5355	0.5355	11
[3H]LSD	[3H]LSD:14|[3H]-LSD:1	acid diethylamide:15:0.8045	0.8045	15
[3H]NA	[3H]NA:85|[3H]-NA:36	[3H]noradrenaline:80:0.5809|[3H]-noradrenaline:41:0.2941	0.5809	121
[3H]NBI	[3H]NBI:13	[3H]nitrobenzylthioinosine:13:0.8571	0.8571	13
[3H]NE	[3H]NE:97|[3H]-NE:7	[3H]norepinephrine:93:0.7023|[3H]-norepinephrine:11:0.0763	0.7023	104
[3H]NE	[3H]NE:9	Tritiated norepinephrine:9:0.2102	0.2102	9
[3H]NMS	[3H]NMS:14|[3H]-NMS:6	[3H]N-methyl scopolamine:12:0.2549|[3H]-N-methyl scopolamine:8:0.1061	0.2549	20
[3H]NMS	[3H]NMS:56|[3H]-NMS:14	[3H]N-methylscopolamine:54:0.3655|[3H]-N-methylscopolamine:16:0.1034	0.3655	70
[3H]NMS	[3H]NMS:13	N-[3H]methylscopolamine:13:0.0828	0.0828	13
[3H]NMS	[3H]NMS:8	[N-methyl-3H]scopolamine:8:0.0552	0.0552	8
[3H]PAC	[3H]PAC:10|[3H]pAC:1	[3H]p-aminoclonidine:11:0.6250	0.6250	11
[3H]PEt	[3H]PEt:13	[3H]phosphatidylethanol:13:0.8571	0.8571	13
[3H]PZ	[3H]PZ:12	[3H]pirenzepine:12:0.7333	0.7333	12
[3H]PDBu	[3H]PDBu:22|[3H]PdBu:3|[3H]-PDBU:2	[3H]phorbol 12,13-dibutyrate:18:0.3857|[3H]phorbol-12,13-dibutyrate:9:0.1176	0.3857	27
[3H]PDBu	[3H]PDBu:10	[3H]phorbol dibutyrate:10:0.7103	0.7103	10
[3H]QNB	[3H]QNB:98|[3H]-QNB:1	[3H]quinuclidinyl benzilate:99:0.4943	0.4943	99
[3H]QNB	[3H]QNB:14	[3H]quinuclidinyl benzylate:14:0.4709	0.4709	14
[3H]QNB	[3H]QNB:15	[3H]quinuclidinylbenzilate:15:0.0576	0.0576	15
[3H]TdR	[3H]TdR:44|[3H]-TdR:16|[3H]Tdr:3|[3H]TDR:2|[3-H]TdR:1	tritiated thymidine:66:0.7252	0.7252	66
[3H]dThd	[3H]dThd:25|[3H]dTHd:1|[3H]-dThd:1	tritiated thymidine:27:0.8312	0.8312	27
[3H]OXO-M	[3H]OXO-M:4|[3H]oxo-M:3|[3H]Oxo-M:2	[3H]oxotremorine-M:9:0.7273	0.7273	9
[ATP]i	[ATP]i:13	intracellular ATP concentration:13:0.7753	0.7753	13
[CO2]	[CO2]:31	CO2 concentration:24:0.5598|CO2 concentrations:7:0.3524	0.5598	31
[Ca(2+)]	[Ca(2+)]:14	Ca(2+) concentration:14:0.5111	0.5111	14
[Ca(2+)](c)	[Ca(2+)](c):3|[Ca(2+)](C):1	cytosolic Ca(2+):4:0.4444	0.4444	4
[Ca(2+)](c)	[Ca(2+)](c):25|[Ca(2+)](C):1	cytosolic Ca(2+) concentration:26:0.4719	0.4719	26
[Ca(2+)](i)	[Ca(2+)](i):29	cytosolic Ca(2+):29:0.1093	0.1093	29
[Ca(2+)](i)	[Ca(2+)](i):35	cytosolic free Ca(2+) concentration:35:0.2508	0.2508	35
[Ca(2+)](i)	[Ca(2+)](i):8|[CA(2+)](i):1	cytosolic free calcium:9:0.0836	0.0836	9
[Ca(2+)](i)	[Ca(2+)](i):120|[Ca(2+)](I):1	intracellular Ca(2+):121:0.5267	0.5267	121
[Ca(2+)](i)	[Ca(2+)](i):374	Intracellular Ca(2+) concentration:351:0.5908|intracellular Ca(2+) concentrations:23:0.5466	0.5908	374
[Ca(2+)](i)	[Ca(2+)](i):113	intracellular calcium:113:0.5638	0.5638	113
[Ca(2+)](i)	[Ca(2+)](i):156	Intracellular calcium concentration:139:0.5279|intracellular calcium concentrations:17:0.5760	0.5760	156
[Ca(2+)](i)	[Ca(2+)](i):12	intracellular calcium levels:12:0.3275	0.3275	12
[Ca(2+)](i)	[Ca(2+)](i):22	intracellular free Ca(2+):22:0.5722	0.5722	22
[Ca(2+)](i)	[Ca(2+)](i):53	intracellular free Ca(2+) concentration:53:0.4298	0.4298	53
[Ca(2+)](i)	[Ca(2+)](i):25	intracellular free calcium:25:0.5095	0.5095	25
[Ca(2+)](m)	[Ca(2+)](m):4	mitochondrial Ca(2+):4:0.2987	0.2987	4
[Ca(2+)](o)	[Ca(2+)](o):7	extracellular Ca(2+):7:0.4849	0.4849	7
[Ca(2+)](o)	[Ca(2+)](o):17	extracellular Ca(2+) concentration:17:0.6211	0.6211	17
[Ca(2+)]i	[Ca(2+)]i:9	intracellular Ca(2+):9:0.3867	0.3867	9
[Ca(2+)]i	[Ca(2+)]i:15	intracellular Ca(2+) concentration:15:0.3614	0.3614	15
[Ca(2+)]i	[Ca(2+)]i:6|[Ca(2+)]I:1	intracellular calcium:7:0.2452	0.2452	7
[Ca(2+)]i	[Ca(2+)]i:13	intracellular calcium concentration:13:0.3554	0.3554	13
[Ca++]i	[Ca++]i:28	Ca++ concentration:28:0.3379	0.3379	28
[Ca++]i	[Ca++]i:11	intracellular Ca++:11:0.2422	0.2422	11
[Ca++]i	[Ca++]i:18	intracellular calcium:18:0.1889	0.1889	18
[Ca++]i	[Ca++]i:13	intracellular calcium concentration:13:0.2802	0.2802	13
[Ca++]i	[Ca++]i:13	intracellular free calcium:13:0.2532	0.2532	13
[Ca2+]	[Ca2+]:85	Ca2+ concentration:69:0.5097|Ca2+ concentrations:16:0.4035	0.5097	85
[Ca2+]	[Ca2+]:42	calcium concentration:33:0.1984|calcium concentrations:9:0.1205	0.1984	42
[Ca2+]	[Ca2+]:7	ionized calcium:7:0.2113	0.2113	7
[Ca2+](i)	[Ca2+](i):5	intracellular Ca2+:5:0.0902	0.0902	5
[Ca2+](i)	[Ca2+](i):12	intracellular Ca2+ concentration:12:0.2549	0.2549	12
[Ca2+](i)	[Ca2+](i):6	intracellular calcium:6:0.1320	0.1320	6
[Ca2+](i)	[Ca2+](i):8	intracellular calcium concentration:8:0.2987	0.2987	8
[Ca2+]0	[Ca2+]0:8	extracellular Ca2+ concentration:8:0.4102	0.4102	8
[Ca2+]cyt	[Ca2+]cyt:11	cytosolic Ca2+ concentration:11:0.1166	0.1166	11
[Ca2+]cyt	[Ca2+]cyt:14	cytosolic free Ca2+ concentration:14:0.4367	0.4367	14
[Ca2+]cyt	[Ca2+]cyt:4	cytosolic free calcium:4:0.1618	0.1618	4
[Ca2+]c	[Ca2+]c:10	cytoplasmic free calcium concentration:10:0.2582	0.2582	10
[Ca2+]c	[Ca2+]c:17	cytosolic Ca2+:17:0.5263	0.5263	17
[Ca2+]c	[Ca2+]c:39	cytosolic Ca2+ concentration:39:0.4310	0.4310	39
[Ca2+]c	[Ca2+]c:7	cytosolic calcium:7:0.0951	0.0951	7
[Ca2+]c	[Ca2+]c:15	cytosolic calcium concentration:15:0.1992	0.1992	15
[Ca2+]c	[Ca2+]c:16	cytosolic free Ca2+ concentration:16:0.5171	0.5171	16
[Ca2+]c	[Ca2+]c:5	Cytosolic free calcium:5:0.2818	0.2818	5
[Ca2+]c	[Ca2+]c:10	cytosolic free calcium concentration:10:0.2126	0.2126	10
[Ca2+]e	[Ca2+]e:22	extracellular Ca2+:22:0.5616	0.5616	22
[Ca2+]e	[Ca2+]e:27	extracellular Ca2+ concentration:22:0.6178|extracellular Ca2+ concentrations:5:0.2818	0.6178	27
[Ca2+]e	[Ca2+]e:17	extracellular calcium:17:0.5038	0.5038	17
[Ca2+]e	[Ca2+]e:18	extracellular calcium concentration:14:0.6911|extracellular calcium concentrations:4:0.0918	0.6911	18
[Ca2+]f	[Ca2+]f:5	cytosolic free calcium concentration:5:0.2818	0.2818	5
[Ca2+]in	[Ca2+]in:7	free Ca2+ concentration:7:0.2902	0.2902	7
[Ca2+]i	[Ca2+]i:76	calcium ions:38:0.7364|calcium ion:38:0.8417	0.8417	76
[Ca2+]i	[Ca2+]i:6	calcium transients:6:0.2243	0.2243	6
[Ca2+]i	[Ca2+]i:1	concentration in cytosol:1:0.1132	0.1132	1
[Ca2+]i	[Ca2+]i:39	cytosolic Ca2+ concentrations:39:0.1264	0.1264	39
[Ca2+]i	[Ca2+]i:34	cytosolic Ca2+ level:34:0.3704	0.3704	34
[Ca2+]i	[Ca2+]i:123	cytosolic free Ca2+:123:0.3227	0.3227	123
[Ca2+]i	[Ca2+]i:31	cytosolic free Ca2+ concentrations:31:0.3103	0.3103	31
[Ca2+]i	[Ca2+]i:22	cytosolic free Ca2+ levels:13:0.1890|cytosolic free Ca2+ level:9:0.1809	0.1890	22
[Ca2+]i	[Ca2+]i:134	cytosolic free calcium:134:0.2760	0.2760	134
[Ca2+]i	[Ca2+]i:210|[Ca2+]I:2	cytosolic free calcium concentration:188:0.3083|cytosolic free calcium concentrations:24:0.2095	0.3083	212
[Ca2+]i	[Ca2+]i:13	cytosolic free calcium levels:13:0.1599	0.1599	13
[Ca2+]i	[Ca2+]i:25	free cytosolic Ca2+:25:0.1267	0.1267	25
[Ca2+]i	[Ca2+]i:21	free cytosolic calcium:21:0.0807	0.0807	21
[Ca2+]i	[Ca2+]i:5	increase cytosolic Ca2+ concentration:5:0.0749	0.0749	5
[Ca2+]i	[Ca2+]i:19	increase in cytosolic Ca2+:19:0.0818	0.0818	19
[Ca2+]i	[Ca2+]i:397	intracellular Ca2+:397:0.3621	0.3621	397
[Ca2+]i	[Ca2+]i:18	intracellular Ca2+ activity:18:0.4226	0.4226	18
[Ca2+]i	[Ca2+]i:1173	intracellular Ca2+ concentration:1080:0.4194|intracellular Ca2+ concentrations:93:0.3534	0.4194	1173
[Ca2+]i	[Ca2+]i:19	intracellular Ca2+ levels:19:0.1678	0.1678	19
[Ca2+]i	[Ca2+]i:450|[CA2+]i:2	intracellular calcium:452:0.3644	0.3644	452
[Ca2+]i	[Ca2+]i:14	intracellular calcium activity:14:0.3202	0.3202	14
[Ca2+]i	[Ca2+]i:638	intracellular calcium concentration:574:0.4034|intracellular calcium concentrations:64:0.2822	0.4034	638
[Ca2+]i	[Ca2+]i:56	intracellular calcium levels:46:0.3505|intracellular calcium level:10:0.1596	0.3505	56
[Ca2+]i	[Ca2+]i:151	intracellular free Ca2+:151:0.3863	0.3863	151
[Ca2+]i	[Ca2+]i:27	intracellular free Ca2+ concentrations:27:0.2694	0.2694	27
[Ca2+]i	[Ca2+]i:26	intracellular free Ca2+ levels:17:0.3285|intracellular free Ca2+ level:9:0.1809	0.3285	26
[Ca2+]i	[Ca2+]i:216	intracellular free calcium:216:0.4714	0.4714	216
[Ca2+]i	[Ca2+]i:328	intracellular free calcium concentration:289:0.4923|intracellular free calcium concentrations:39:0.4242	0.4923	328
[Ca2+]i	[Ca2+]i:23	intracellular free calcium levels:18:0.2771|intracellular free calcium level:5:0.0902	0.2771	23
[Ca2+]m	[Ca2+]m:18	Ca2+ concentration:18:0.4934	0.4934	18
[Ca2+]m	[Ca2+]m:5	mitochondrial Ca2+:5:0.2524	0.2524	5
[Ca2+]o	[Ca2+]o:21	external Ca2+ concentration:21:0.1013	0.1013	21
[Ca2+]o	[Ca2+]o:47	extracellular Ca2+:47:0.6252	0.6252	47
[Ca2+]o	[Ca2+]o:103	extracellular Ca2+ concentration:90:0.6818|extracellular Ca2+ concentrations:13:0.4849	0.6818	103
[Ca2+]o	[Ca2+]o:21	extracellular calcium:21:0.3419	0.3419	21
[Ca2+]o	[Ca2+]o:24	extracellular calcium concentration:24:0.5722	0.5722	24
[Ca]in	[Ca]in:5	cytosolic free calcium concentration:5:0.4422	0.4422	5
[Ca]in	[Ca]in:4	increase in the cytosolic Ca2+ concentration:4:0.1618	0.1618	4
[Ca]i	[Ca]i:6	cytosolic calcium:6:0.0666	0.0666	6
[Ca]i	[Ca]i:1|[CA]i:1	intracellular Ca:2:0.1850	0.1850	2
[Ca]i	[Ca]i:12	intracellular Ca concentration:12:0.3275	0.3275	12
[Ca]i	[Ca]i:12	intracellular Ca2+ concentration:12:0.3058	0.3058	12
[Ca]i	[Ca]i:8	intracellular calcium:8:0.1591	0.1591	8
[Ca]i	[Ca]i:12	intracellular calcium concentration:12:0.2293	0.2293	12
[Ca]o	[Ca]o:10	extracellular Ca concentration:10:0.4363	0.4363	10
[Ca]o	[Ca]o:8	extracellular calcium concentration:8:0.5006	0.5006	8
[Cl(-)](i)	[Cl(-)](i):13	intracellular Cl(-) concentration:13:0.6701	0.6701	13
[Cl-]i	[Cl-]i:8|[Cl]i:2	intracellular chloride concentration:10:0.4363	0.4363	10
[Cl-]i	[Cl-]i:3	intracellular Cl-:3:0.1320	0.1320	3
[Cl-]i	[Cl-]i:32	intracellular Cl- concentration:32:0.8563	0.8563	32
[Cl-]o	[Cl-]o:10	Cl- concentration:10:0.3867	0.3867	10
[H+]i	[H+]i:13|[H+]I:1	concentration:14:0.8667	0.8667	14
[HCO3-]	[HCO3-]:19|[HCO3]:1|[HCO-3]:1	bicarbonate concentration:21:0.5178	0.5178	21
[Hb]	[Hb]:46	concentration:46:0.7377	0.7377	46
[K(+)](e)	[K(+)](e):9	concentration:9:0.6667	0.6667	9
[K(+)](o)	[K(+)](o):15	extracellular K(+) concentration:15:0.5348	0.5348	15
[K+]0	[K+]0:8	extracellular potassium concentration:8:0.3463	0.3463	8
[K+]e	[K+]e:9	extracellular K+:9:0.3829	0.3829	9
[K+]e	[K+]e:14	extracellular K+ concentration:14:0.6911	0.6911	14
[K+]e	[K+]e:9	extracellular potassium:9:0.4587	0.4587	9
[K+]e	[K+]e:11	Extracellular potassium concentration:11:0.5355	0.5355	11
[K+]i	[K+]i:9	intracellular K+ concentration:9:0.5470	0.5470	9
[K+]o	[K+]o:10	activity:10:0.0290	0.0290	10
[K+]o	[K+]o:21	external K+ concentration:21:0.1115	0.1115	21
[K+]o	[K+]o:10	extracellular K+:10:0.4037	0.4037	10
[K+]o	[K+]o:90|[K+]O:1	extracellular K+ concentration:83:0.6845|extracellular K+ concentrations:8:0.3463	0.6845	91
[K+]o	[K+]o:37	extracellular potassium:37:0.5930	0.5930	37
[K+]o	[K+]o:55|[K+]O:1	extracellular potassium concentration:56:0.6755	0.6755	56
[La]	[La]:29|[La-]:9|[LA]:5|[LA-]:2	lactate concentration:45:0.8649	0.8649	45
[Lac-]	[Lac-]:8|[Lac]:2	lactate concentration:10:0.5000	0.5000	10
[Mg(2+)](i)	[Mg(2+)](i):9	intracellular free Mg(2+) concentration:9:0.5470	0.5470	9
[Mg2+]	[Mg2+]:9	concentration:9:0.6154	0.6154	9
[Mg2+]i	[Mg2+]i:6	free Mg2+ concentrations:6:0.2827	0.2827	6
[Mg2+]i	[Mg2+]i:4	Intracellular free magnesium:4:0.0918	0.0918	4
[Mg2+]i	[Mg2+]i:9	intracellular free magnesium concentration:9:0.4587	0.4587	9
[Mg2+]i	[Mg2+]i:13	intracellular free Mg2+:13:0.4367	0.4367	13
[Mg2+]i	[Mg2+]i:17	intracellular free Mg2+ concentration:17:0.4033	0.4033	17
[Mg2+]i	[Mg2+]i:13	intracellular Mg2+ concentration:13:0.1281	0.1281	13
[Mg2+]o	[Mg2+]o:11	extracellular magnesium ions:11:0.5355	0.5355	11
[Mg2+]o	[Mg2+]o:10	extracellular Mg2+ concentration:10:0.7103	0.7103	10
[NO]	[NO]:21	concentration:21:0.8333	0.8333	21
[Na(+)](i)	[Na(+)](i):14	intracellular Na(+) concentration:14:0.4367	0.4367	14
[Na+]	[Na+]:13	concentration:13:0.5455	0.5455	13
[Na+]i	[Na+]i:19	intracellular Na+:19:0.4089	0.4089	19
[Na+]i	[Na+]i:66	intracellular Na+ concentration:66:0.6363	0.6363	66
[Na+]i	[Na+]i:9	intracellular sodium:9:0.1267	0.1267	9
[Na+]i	[Na+]i:23	intracellular sodium concentration:23:0.4188	0.4188	23
[Na+]o	[Na+]o:6	external Na+:6:0.1025	0.1025	6
[Na+]o	[Na+]o:10	extracellular Na+:10:0.3524	0.3524	10
[Na+]o	[Na+]o:23	extracellular Na+ concentration:23:0.5236	0.5236	23
[Na+]o	[Na+]o:9	extracellular sodium concentration:9:0.4587	0.4587	9
[Na]i	[Na]i:15	concentration:15:0.4375	0.4375	15
[Na]	[Na]:7|[NA]:2	concentration:9:0.3810	0.3810	9
[PCr]	[PCr]:6	phosphocreatine:6:0.4706	0.4706	6
[SID]	[SID]:16	strong ion difference:16:0.7407	0.7407	16
[cAMP]i	[cAMP]i:11	intracellular cAMP concentration:11:0.6182	0.6182	11
[eta]	[eta]:9	intrinsic viscosity:9:0.6794	0.6794	9
[la-]b	[la-]b:5|[La]b:4|[La-]b:3|[La-]B:1	blood lactate concentration:13:0.6173	0.6173	13
a(w)	a(w):85|A(w):2|a(W):2	water activity:79:0.8724|water activities:10:0.7103	0.8724	89
a.c.	a.c.:10	alternating current:10:0.7103	0.7103	10
a.h.p.	a.h.p.:19	after-hyperpolarization:19:0.6207	0.6207	19
a.m.	a.m.:7|A.M.:2	morning:9:0.2222	0.2222	9
a.n.	a.n.:6|A.N.:4|A.n.:1	anorexia nervosa:11:0.7357	0.7357	11
a/APO2	a/APO2:9	oxygen tension ratio:9:0.6794	0.6794	9
A/P	A/P:50|a/p:6	anterior/posterior:36:0.3125|anterior-posterior:20:0.1696	0.3125	56
A/P	A/P:22	anteroposterior:22:0.1875	0.1875	22
A2	A2:10	Adenosine:10:0.0163	0.0163	10
A2	A2:5	atrial extrastimulus:5:0.1132	0.1132	5
A2	A2:8	component of the second heart sound:8:0.4587	0.4587	8
aAbs	aAbs:24|AAbs:12|Aabs:8|aabs:1|AABs:1|A-Abs:1	autoantibodies:47:0.7931	0.7931	47
ABGA	ABGA:9	anti-basal ganglia antibodies:9:0.4587	0.4587	9
aCGH	aCGH:8	Array-based comparative genomic hybridization:8:0.2987	0.2987	8
aCML	aCML:8|a-CML:1	atypical chronic myeloid leukemia:9:0.5470	0.5470	9
aCSF	aCSF:197|ACSF:187|a-CSF:3	artificial cerebrospinal fluid:387:0.9834	0.9834	387
aCSF	aCSF:24|ACSF:12	artificial CSF:36:0.9174	0.9174	36
aCli	aCli:9|aCl-i:2	intracellular Cl- activity:11:0.6182	0.6182	11
ACL	ACL:11	adenocarcinoma of the lung:11:0.7357	0.7357	11
ACL	ACL:21	Adjective Check List:21:0.8594	0.8594	21
ACL	ACL:77	American cutaneous leishmaniasis:77:0.7905	0.7905	77
ACL	ACL:11	anterior:11:0.0036	0.0036	11
ACL	ACL:12	anterior cruciate:12:0.7571	0.7571	12
ACL	ACL:1666|acl:3|aCl:1	anterior cruciate ligament:1642:0.9934|anterior cruciate ligaments:28:0.8941	0.9934	1670
aCL	aCL:24|ACL:3	anti-cardiolipin:27:0.0093	0.0093	27
aCL	aCL:17	anti-cardiolipin antibody:17:0.0746	0.0746	17
aCL	aCL:18|a-CL:2|ACL:2|A-CL:1	antibodies to cardiolipin:23:0.3808	0.3808	23
aCL	aCL:171|ACL:27|aCl:2	anticardiolipin:200:0.0711	0.0711	200
aCL	aCL:438|ACL:26|aCl:2|acL:2|a-CL:1	anticardiolipin antibodies:374:0.8740|anticardiolipin antibody:95:0.7453	0.8740	469
ACL	ACL:23	ATP-citrate lyase:12:0.1907|ATP citrate lyase:11:0.7357	0.7357	23
ADNP	ADNP:16	activity-dependent neuroprotective protein:16:0.7261	0.7261	16
A-FABP	A-FABP:5|AFABP:3|aFABP:2	adipocyte fatty acid-binding protein:10:0.5000	0.5000	10
A-FABP	A-FABP:8|AFABP:2|aFABP:1|a-FABP:1	fatty acid binding protein:12:0.6460	0.6460	12
aFGF	aFGF:359|a-FGF:7|AFGF:2	acidic fibroblast growth factor:368:0.9438	0.9438	368
AGAG	AGAG:20|aGAG:1	acidic glycosaminoglycans:21:0.5435	0.5435	21
AKG	AKG:10	alpha-ketoglutarate:10:0.5000	0.5000	10
A-LAK	A-LAK:8|ALAK:2|aLAK:1	adherent LAK:11:0.6182	0.6182	11
A-LAK	A-LAK:17|ALAK:1	adherent lymphokine-activated killer:18:0.6903	0.6903	18
A-LAK	A-LAK:6	adherent lymphokine-activated killer cells:6:0.5290	0.5290	6
aMT6s	aMT6s:28|aMT6S:1	6-sulfatoxymelatonin:29:0.2745	0.2745	29
aMT6s	aMT6s:49|a-MT6s:1|aMT6S:1	6-sulphatoxymelatonin:51:0.4902	0.4902	51
aNai	aNai:15|aNAi:1	intracellular Na+ activity:16:0.7261	0.7261	16
aODNs	aODNs:9|AODNs:3|A-ODNs:2	antisense oligodeoxynucleotides:14:0.7909	0.7909	14
aODN	aODN:5|AODN:3	antisense oligodeoxynucleotide:8:0.5006	0.5006	8
AONs	AONs:13|aONs:2	antisense oligonucleotides:15:0.8045	0.8045	15
AP-2	AP-2:58|AP2:8|Ap-2:1	activator protein-2:36:0.6009|activator protein 2:31:0.5213	0.6009	67
aP2	aP2:9	adipocyte fatty acid-binding protein:9:0.4587	0.4587	9
aP2	aP2:16|AP2:1	adipocyte P2:17:0.5760	0.5760	17
AP2	AP2:14|ap2:1|Ap2:1	APETALA2:16:0.0617	0.0617	16
aP2	aP2:18	fatty acid binding protein:18:0.8365	0.8365	18
aPCCs	aPCCs:6|APCCs:3	activated prothrombin complex concentrates:9:0.5470	0.5470	9
aPKC	aPKC:17	atypical PKC:17:0.8270	0.8270	17
aPKC	aPKC:47|a-PKC:1	atypical protein kinase C:48:0.8221	0.8221	48
aPTTs	aPTTs:17|APTTs:8	activated partial thromboplastin times:25:0.8186	0.8186	25
ARNA	ARNA:33	afferent renal nerve activity:33:0.9100	0.9100	33
aRNA	aRNA:12	antisense RNA:12:0.3813	0.3813	12
aSFP	aSFP:8	acidic seminal fluid protein:8:0.4102	0.4102	8
aaIPI	aaIPI:5|Aa-IPI:2|A-AIPI:1|AA-IPI:1|AaIPI:1	age-adjusted International Prognostic Index:10:0.7103	0.7103	10
AAMphi	AAMphi:5|aaMphi:2|aaMPhi:1|aamphi:1|AAMPhi:1	alternatively activated macrophages:10:0.7103	0.7103	10
AA-NAT	AA-NAT:41|AANAT:32|aaNAT:2|Aanat:2	arylalkylamine N-acetyltransferase:61:0.6847|arylalkylamine-N-acetyltransferase:16:0.1515	0.6847	77
aaRSs	aaRSs:24|AARSs:6	aminoacyl-tRNA synthetases:30:0.8032	0.8032	30
aaRS	aaRS:31|AARS:3|aa-RS:1	aminoacyl-tRNA synthetases:21:0.7865|Aminoacyl-tRNA synthetase:14:0.6911	0.7865	35
AcLDL	AcLDL:33|Ac-LDL:23|acLDL:17|ac-LDL:5	acetylated LDL:78:0.8709	0.8709	78
Ac-LDL	Ac-LDL:33|AcLDL:32|acLDL:19|ac-LDL:9	acetylated low density lipoprotein:44:0.7619|acetylated low-density lipoprotein:39:0.8455|acetylated low density lipoproteins:10:0.5000	0.8455	93
ACA	ACA:20	1'-acetoxychavicol acetate:20:0.6259	0.6259	20
ACA	ACA:17|AcA:6	acetaldehyde:23:0.0191	0.0191	23
ACA	ACA:54	acrodermatitis chronica atrophicans:54:0.9132	0.9132	54
ACA	ACA:15	Active cutaneous anaphylaxis:15:0.8045	0.8045	15
ACA	ACA:4	adaptive conjoint analysis:4:0.1618	0.1618	4
ACA	ACA:20	adenocarcinoma:20:0.0165	0.0165	20
ACA	ACA:6	Adenylate cyclase activity:6:0.1543	0.1543	6
aca	aca:4|ACA:4	adenylyl cyclase:8:0.5006	0.5006	8
ACA	ACA:6|Aca:2	aminocaproic acid:8:0.0532	0.0532	8
ACA	ACA:220|aca:1	anterior cerebral artery:200:0.9608|anterior cerebral arteries:21:0.8594	0.9608	221
ACA	ACA:13	anti-centromere antibody:13:0.0608	0.0608	13
ACA	ACA:14	anticardiolipin:14:0.0113	0.0113	14
ACA	ACA:215|aCA:1	Anticardiolipin antibodies:170:0.5655|Anticardiolipin antibody:46:0.3391	0.5655	216
ACA	ACA:34	Anticentromere antibody:34:0.2284	0.2284	34
ACA	ACA:6	anticentromere autoantibodies:6:0.0666	0.0666	6
ACA	ACA:10|aca:2	anticomplementary activity:12:0.1758	0.1758	12
aca	aca:6|ACA:2	Automatic Clinical Analyzer:8:0.5006	0.5006	8
ACEA	ACEA:6|ACE-A:1	angiotensin converting enzyme activity:7:0.4438	0.4438	7
acto-S1	acto-S1:6|actoS1:2	actomyosin subfragment 1:8:0.6411	0.6411	8
adFNDI	adFNDI:5	autosomal dominant familial neurohypophyseal diabetes insipidus:5:0.4422	0.4422	5
adPEO	adPEO:13|AD-PEO:1	autosomal dominant progressive external ophthalmoplegia:14:0.7909	0.7909	14
ADRP	ADRP:33|adrp:1	adipose differentiation-related protein:23:0.5719|adipose differentiation related protein:11:0.6182	0.6182	34
ADRP	ADRP:77|adRP:49	autosomal dominant retinitis pigmentosa:126:0.9761	0.9761	126
adRP	adRP:6|ADRP:3	autosomal dominant RP:9:0.6794	0.6794	9
ADD	ADD:6	acute diarrheal disease:6:0.5290	0.5290	6
ADD	ADD:14	afterdischarge duration:14:0.5111	0.5111	14
ADD	ADD:9	androsta-1,4-diene-3,17-dione:9:0.0198	0.0198	9
ADD	ADD:11	anterior disc displacement:11:0.7357	0.7357	11
ADD	ADD:174|add:5	Attention Deficit Disorder:179:0.9563	0.9563	179
ADD	ADD:5	surgical induction of anterior disk displacement:5:0.3728	0.3728	5
ADN	ADN:13	associate degree nursing:13:0.7909	0.7909	13
ADN	ADN:11	electrical stimulation of the aortic depressor nerve:11:0.5050	0.5050	11
adr	adr:5	adrenergic receptor:5:0.0902	0.0902	5
adr	adr:12	Adrenodoxin reductase:12:0.4153	0.4153	12
adr	adr:525|ADR:256|Adr:18	adriamycin:799:0.5715	0.5715	799
ADR	ADR:245|adr:1	adverse drug reaction:136:0.9649|adverse drug reactions:110:0.9728	0.9728	246
ADR	ADR:13	alternative dispute resolution:13:0.7753	0.7753	13
AdR	AdR:14	deoxyadenosine:14:0.0093	0.0093	14
ADR	ADR:47|Adr:2|AdR:1	doxorubicin:50:0.0358	0.0358	50
AGEs	AGEs:626|ages:9|AGES:2	advanced glycation end products:498:0.9903|advanced glycation end-products:139:0.9657	0.9903	637
AGEs	AGEs:125	advanced glycation endproducts:125:0.9616	0.9616	125
AGEs	AGEs:88|ages:3	advanced glycosylation end products:91:0.9479	0.9479	91
AGF	AGF:13	growth factor:13:0.5934	0.5934	13
AH	AH:9	abdominal hysterectomy:9:0.6794	0.6794	9
AH	AH:13	abductor hallucis:13:0.7753	0.7753	13
AH	AH:12	absolute humidity:12:0.7753	0.7753	12
AH	AH:21	absorptive hypercalciuria:21:0.8594	0.8594	21
AH	AH:6	Adenoid hypertrophy:6:0.1320	0.1320	6
AH	AH:60	adenomatous hyperplasia:60:0.3967	0.3967	60
AH	AH:10	adult height:10:0.3867	0.3867	10
AH	AH:16	airway hyperresponsiveness:16:0.8165	0.8165	16
AH	AH:43	alcoholic hepatitis:43:0.2598	0.2598	43
AH	AH:5	aluminium hydroxide:5:0.0902	0.0902	5
AH	AH:5	aluminum hydroxide:5:0.0902	0.0902	5
AH	AH:10	Alveolar hemorrhage:10:0.4363	0.4363	10
AH	AH:10	ancestral haplotype:10:0.7103	0.7103	10
AH	AH:5	aniline hydrochloride:5:0.0902	0.0902	5
AH	AH:27	aniline hydroxylase:27:0.7425	0.7425	27
AH	AH:22	anterior:22:0.0109	0.0109	22
AH	AH:7	anterior horn:7:0.2452	0.2452	7
AH	AH:11	anterior hypothalamic:11:0.5355	0.5355	11
AH	AH:65|ah:1	Anterior Hypothalamus:66:0.8858	0.8858	66
AH	AH:77|ah:1	aqueous humor:78:0.9393	0.9393	78
AH	AH:17	aqueous humour:17:0.8270	0.8270	17
Ah	Ah:43|AH:12	aromatic hydrocarbon:55:0.1711	0.1711	55
AH	AH:305|ah:1	arterial hypertension:306:0.9698	0.9698	306
AH	AH:21	artificial heart:21:0.7291	0.7291	21
Ah	Ah:161|AH:19	aryl hydrocarbon:180:0.6896	0.6896	180
AH	AH:16	Assisted hatching:16:0.5564	0.5564	16
AH	AH:10	ataxic hemiparesis:10:0.7103	0.7103	10
AH	AH:14|A-H:6	atrio-His:20:0.0099	0.0099	20
AH	AH:48	atypical hyperplasia:48:0.2998	0.2998	48
AH	AH:9	Autonomic hyperreflexia:9:0.5470	0.5470	9
A-H	A-H:7|AH:6	bundle:13:0.0063	0.0063	13
AH	AH:10	conduction time:10:0.7103	0.7103	10
AH	AH:3	PAF acetylhydrolase:3:0.1132	0.1132	3
AH	AH:19	patients with acute hepatitis:19:0.2007	0.2007	19
AH	AH:6	Rat ascites hepatoma:6:0.2827	0.2827	6
aiCl	aiCl:20|AiCl:3|aicl:1	intracellular Cl- activity:24:0.8115	0.8115	24
aiK	aiK:8|aik:2	Intracellular K+ activity:10:0.7103	0.7103	10
aiNa	aiNa:43	intracellular Na+ activity:43:0.8037	0.8037	43
aiNa	aiNa:24	intracellular sodium activity:24:0.8768	0.8768	24
AIJ	AIJ:16	ampullary-isthmic junction:16:0.5564	0.5564	16
AIR	AIR:9	5-aminoimidazole ribonucleotide:9:0.2102	0.2102	9
AIR	AIR:69	Acute insulin response:61:0.9229|acute insulin responses:8:0.5006	0.9229	69
AIR	AIR:9	aminoimidazole ribonucleotide:9:0.2102	0.2102	9
ai	ai:20|AI:8	active ingredient:28:0.7905	0.7905	28
ai	ai:5|AI:3|Ai:1	activity:9:0.0025	0.0025	9
AI	AI:12	acute ileus:12:0.6460	0.6460	12
AI	AI:15|ai:2	Adequate Intake:17:0.6748	0.6748	17
AI	AI:6|ai:2	adrenal incidentalomas:8:0.5006	0.5006	8
AI	AI:14|ai:3	adrenal insufficiency:17:0.0688	0.0688	17
AI	AI:4|ai:1	after infection:5:0.0736	0.0736	5
ai	ai:6	airway inflammation:6:0.1010	0.1010	6
AI	AI:104|ai:22	allelic imbalance:117:0.9460|allelic imbalances:9:0.6794	0.9460	126
AI	AI:12	aluminum:12:0.0034	0.0034	12
AI	AI:68|ai:6	Amelogenesis imperfecta:74:0.9596	0.9596	74
AI	AI:18|ai:6	American Indian:14:0.6911|American Indians:10:0.7103	0.7103	24
AI	AI:14|ai:4	anchorage-independent:18:0.0053	0.0053	18
AI	AI:44|ai:5	androgen-independent:39:0.0118|androgen independent:10:0.3867	0.3867	49
AI	AI:150|ai:27|A-I:14	angiotensin I:181:0.8422|angiotensin-I:10:0.0028	0.8422	191
AI	AI:9|ai:1	anti-inflammatory:10:0.0028	0.0028	10
AI	AI:13|ai:1	aortic incompetence:14:0.4709	0.4709	14
AI	AI:80|ai:8	aortic insufficiency:88:0.6194	0.6194	88
AI	AI:8|ai:2	Apoptosis:10:0.0028	0.0028	10
AI	AI:7|ai:4	Apoptotic:11:0.0031	0.0031	11
AI	AI:256|ai:48|Ai:2	apoptotic index:306:0.3123	0.3123	306
AI	AI:13|ai:3	apoptotic indices:16:0.2154	0.2154	16
AI	AI:39|ai:3	aromatase inhibitor:26:0.6973|aromatase inhibitors:16:0.7261	0.7261	42
AI	AI:245|ai:90	artificial insemination:323:0.9711|artificial inseminations:12:0.6460	0.9711	335
AI	AI:55|ai:8	Artificial intelligence:63:0.9018	0.9018	63
AI	AI:21|ai:5	artificially inseminated:26:0.7760	0.7760	26
AI	AI:6|ai:3	association-induction:9:0.0025	0.0025	9
AI	AI:4|ai:3	Astragalus Injection:7:0.2452	0.2452	7
AI	AI:47|ai:14	avian influenza:61:0.9511	0.9511	61
ai	ai:9|AI:4	Axonal injury:13:0.4444	0.4444	13
AI	AI:9|ai:3	intensity:12:0.0034	0.0034	12
AI	AI:17|ai:2|A-I:1	primary:20:0.0059	0.0059	20
AI	AI:6|ai:2	primary auditory area:8:0.5006	0.5006	8
AI	AI:172|ai:21|A-I:1	primary auditory cortex:194:0.9253	0.9253	194
AI	AI:12|ai:1	primary auditory field:13:0.7753	0.7753	13
AK	AK:34|A-K:1|ak:1	above-knee:36:0.0440	0.0440	36
AK	AK:12|ak:1	acanthamoeba keratitis:13:0.7753	0.7753	13
AK	AK:29|ak:1	actinic keratoses:30:0.8472	0.8472	30
AK	AK:91	actinic keratosis:91:0.9672	0.9672	91
AK	AK:23	activated killer:23:0.3808	0.3808	23
AK	AK:162|ak:6|Ak:4	adenylate kinase:172:0.4723	0.4723	172
AK	AK:18|Ak:6	amikacin:24:0.0289	0.0289	24
ak	ak:12	aphakia:12:0.0138	0.0138	12
AK	AK:18|ak:2	astigmatic keratotomy:20:0.5568	0.5568	20
aK	aK:4|ak:2	Extracellular potassium activity:6:0.5290	0.5290	6
aK	aK:4|AK:2|ak:2	K+ activity:8:0.1730	0.1730	8
ALPI	ALPI:9	argon laser peripheral iridoplasty:9:0.5470	0.5470	9
A-LAP	A-LAP:9|ALAP:3	adipocyte-derived leucine aminopeptidase:12:0.7571	0.7571	12
AlkA	AlkA:16	glycosylase II:16:0.7261	0.7261	16
ALKP	ALKP:18|AlkP:15|ALK-P:12|Alk-P:5|alkP:2|ALK-p:1|alkp:1	alkaline phosphatase:54:0.9448	0.9448	54
alpha-T	alpha-T:90|alphaT:10	alpha-tocopherol:100:0.7021	0.7021	100
alpha	alpha:7	calcium absorption:7:0.1329	0.1329	7
alpha	alpha:17	catalytic subunit:17:0.2379	0.2379	17
alpha	alpha:26	immediate-early:14:0.0068|immediate early:12:0.4557	0.4557	26
alpha	alpha:8	intrinsic activity:8:0.1591	0.1591	8
alpha	alpha:7	molecular polarizability:7:0.3524	0.3524	7
alpha	alpha:8	separation factors:8:0.2327	0.2327	8
alpha	alpha:18	volume fraction:18:0.4934	0.4934	18
alum	alum:13	aluminium hydroxide:13:0.1384	0.1384	13
alum	alum:10	aluminium hydroxide gel:10:0.1385	0.1385	10
alum	alum:31	aluminum hydroxide:31:0.5414	0.5414	31
alum	alum:19	aluminum hydroxide gel:19:0.4405	0.4405	19
alum	alum:14	aluminum sulfate:14:0.6386	0.6386	14
AMBER	AMBER:12	Advanced multiple beam equalization radiography:12:0.7571	0.7571	12
amu	amu:12|AMU:1	atomic mass units:13:0.7753	0.7753	13
AND	AND:5|and:4	Axillary node dissection:9:0.4587	0.4587	9
anergy	anergy:8	functional inactivation:8:0.4102	0.4102	8
anergy	anergy:20	unresponsiveness:20:0.3455	0.3455	20
anti-HA	anti-HA:7	antibody to hepatitis A antigen:7:0.3524	0.3524	7
anti-HD	anti-HD:5	antibody to hepatitis delta antigen:5:0.1973	0.1973	5
anti-HD	anti-HD:7	hepatitis D virus:7:0.5926	0.5926	7
anti-id	anti-id:51|anti-Id:7|anti-ID:1	anti-idiotypic antibodies:32:0.6024|anti-idiotypic antibody:27:0.6192	0.6192	59
anti-TB	anti-TB:14|antiTB:1	antituberculosis:15:0.6364	0.6364	15
anti-Tg	anti-Tg:14|anti-TG:3	anti-thyroglobulin:17:0.2909	0.2909	17
anti-Tg	anti-Tg:12|anti-TG:1	antithyroglobulin:13:0.2182	0.2182	13
aoHGE	aoHGE:10	agent of human granulocytic ehrlichiosis:10:0.7103	0.7103	10
AP's	AP's:9|ap's:4|Ap's:2	action potentials:15:0.8045	0.8045	15
APEX	APEX:10	arrayed primer extension:10:0.7103	0.7103	10
AP-HP	AP-HP:7	Assistance publique-Hopitaux de Paris:7:0.5926	0.5926	7
APNEA	APNEA:14	N6-2-(4-aminophenyl)ethyladenosine:14:0.1912	0.1912	14
apo(a)	apo(a):94|Apo(a):2	apolipoprotein(a):96:0.9245	0.9245	96
apo-	apo-:21|Apo-:1	Apolipoprotein:22:0.5000	0.5000	22
apoA-II	apoA-II:54|ApoA-II:9|apo-A-II:3|APOA-II:2|apo-AII:1|apoAII:1	apolipoprotein A-II:70:0.8919	0.8919	70
apoAII	apoAII:12|ApoAII:1	apolipoprotein AII:13:0.6701	0.6701	13
apoA-IV	apoA-IV:42|ApoA-IV:3|apo-A-IV:2|apoAIV:1	apolipoprotein A-IV:48:0.8463	0.8463	48
apoA-I	apoA-I:357|ApoA-I:21|apo-A-I:15|apoAI:8|apo-AI:2|ApoAI:2|Apo-AI:1|APOA-I:1	apolipoprotein A-I:407:0.9273	0.9273	407
apoAI	apoAI:68|ApoAI:14|Apo-AI:6|apoA-I:5|apo-AI:3|apo-A-I:1|APOAI:1|ApoA-I:1	apolipoprotein AI:99:0.8732	0.8732	99
apoB-48	apoB-48:14|apoB48:1|apo-B-48:1	Apolipoprotein B-48:16:0.7261	0.7261	16
apoC-II	apoC-II:46|apo-C-II:2|APOC-II:1|ApoC-II:1	Apolipoprotein C-II:50:0.8520	0.8520	50
apoCII	apoCII:17|ApoCII:3|apo-CII:1|APOCII:1	apolipoprotein CII:22:0.8657	0.8657	22
apoE(-/-)	apoE(-/-):8|ApoE(-/-):3|apoe(-/-):1	apoE-deficient:12:0.1170	0.1170	12
apoE(-/-)	apoE(-/-):28|ApoE(-/-):5|Apoe(-/-):1	apolipoprotein E-deficient:34:0.8245	0.8245	34
apoE(-/-)	apoE(-/-):8|ApoE(-/-):1	apolipoprotein E knockout:9:0.6794	0.6794	9
apoE-/-	apoE-/-:10|ApoE-/-:1|apoe-/-:1	apoE-deficient:12:0.1122	0.1122	12
apoE-/-	apoE-/-:27|ApoE-/-:8|Apoe-/-:1	Apolipoprotein E-deficient:36:0.8716	0.8716	36
apoE-/-	apoE-/-:5|ApoE-/-:1	apolipoprotein E-deficient mice:6:0.5290	0.5290	6
apoE-/-	apoE-/-:5|Apoe-/-:1	apolipoprotein E knockout:6:0.5290	0.5290	6
apoE3	apoE3:12	apolipoprotein E3:12:0.6460	0.6460	12
apoE4	apoE4:7|ApoE4:1|APOE-4:1|APOE4:1	apolipoprotein E:10:0.7103	0.7103	10
APOE4	APOE4:2|apoE4:1|ApoE4:1|ApoE-4:1	apolipoprotein E epsilon4:5:0.4422	0.4422	5
apoE4	apoE4:30|ApoE4:17|APOE4:12	apolipoprotein E4:59:0.8731	0.8731	59
ApoER2	ApoER2:9|apoER2:6|Apoer2:1	apolipoprotein E receptor 2:16:0.8165	0.8165	16
APOE	APOE:17|apoE:10|ApoE:5	apolipoprotein:32:0.0144	0.0144	32
apoE	apoE:972|APOE:485|ApoE:409|apo-E:32|Apo-E:19|APO-E:8|Apoe:1	apolipoprotein E:1883:0.9623|apolipoprotein-E:43:0.0195	0.9623	1926
APOE	APOE:8|ApoE:1	apolipoprotein E genotype:9:0.6794	0.6794	9
apoII	apoII:5|apo-II:2	apolipoprotein II:7:0.3524	0.3524	7
apoJ	apoJ:33|ApoJ:7	Apolipoprotein J:40:0.8491	0.8491	40
apoTf	apoTf:8|apoTF:1|apo-Tf:1|Apo-Tf:1	apotransferrin:11:0.4348	0.4348	11
apo[a]	apo[a]:18	apolipoprotein[a]:18:0.4722	0.4722	18
APRE	APRE:6	acute phase response element:6:0.5290	0.5290	6
APTE	APTE:17	acute pulmonary thromboembolism:17:0.8270	0.8270	17
aPT	aPT:11	antiprothrombin:11:0.0353	0.0353	11
APT	APT:26|apt:2	applied potential tomography:28:0.8941	0.8941	28
APT	APT:36	atopy patch test:36:0.8245	0.8245	36
APT	APT:16	pulmonary toxicity:16:0.8165	0.8165	16
ara-AC	ara-AC:4|Ara-AC:4|araAC:1	arabinosyl-5-azacytosine:9:0.4000	0.4000	9
ara-AMP	ara-AMP:8|araAMP:1	9-Beta-D-arabinofuranosyladenine 5'-monophosphate:9:0.1205	0.1205	9
ARA-AMP	ARA-AMP:7|ara-AMP:2	adenine arabinoside 5'-monophosphate:9:0.6794	0.6794	9
ara-AMP	ara-AMP:8|Ara-AMP:3|ARA-AMP:2	adenine arabinoside monophosphate:13:0.7753	0.7753	13
ara-ATP	ara-ATP:5|araATP:2	9-beta-D-arabinofuranosyladenine 5'-triphosphate:7:0.2902	0.2902	7
ara-A	ara-A:49|araA:19|Ara-A:7|ARA-A:5|AraA:3	9-beta-D-arabinofuranosyladenine:83:0.3444	0.3444	83
ara-A	ara-A:34|Ara-A:27|ARA-A:11|araA:4|AraA:3|Ara-a:1	adenine arabinoside:80:0.9210	0.9210	80
ara-A	ara-A:5|Ara-A:2|araA:2	arabinosyladenine:9:0.0332	0.0332	9
ara-A	ara-A:9|Ara-A:3|AraA:1	vidarabine:13:0.0498	0.0498	13
ara-CTP	ara-CTP:19|araCTP:7	1-beta-D-arabinofuranosylcytosine 5'-triphosphate:26:0.4309	0.4309	26
ara-C	ara-C:18|Ara-C:9|araC:6|AraC:3	1-beta-D-Arabinofuranosyl cytosine:22:0.1763|1-beta-D-arabinofuranosyl-cytosine:14:0.0060	0.1763	36
ara-C	ara-C:293|Ara-C:74|araC:50|AraC:9|ARA-C:8	1-beta-D-arabinofuranosylcytosine:426:0.1968|1-beta-D Arabinofuranosylcytosine:8:0.0698	0.1968	434
Ara-C	Ara-C:12|ara-C:8|ARA-C:5|araC:3	arabinosyl cytosine:28:0.2491	0.2491	28
ara-C	ara-C:24|araC:15|Ara-C:12|Ara-c:1|AraC:1	arabinosylcytosine:53:0.0241	0.0241	53
Ara-C	Ara-C:122|ara-C:121|ARA-C:33|AraC:31|araC:14|ara-c:5|ARAC:2	cytarabine:328:0.1517	0.1517	328
AraC	AraC:7|Ara-C:3|ara-C:2|ARA-C:1|araC:1	cytosine arabinofuranoside:14:0.7909	0.7909	14
Ara-C	Ara-C:493|ara-C:303|ARA-C:88|AraC:82|araC:53|ara-c:5|Ara-c:4|ARAC:4|ARAc:2	cytosine arabinoside:972:0.9697|cytosine-arabinoside:62:0.0283	0.9697	1034
Ara-C	AraC:4|Ara-C:4|ARA-C:2|araC:2|ara-C:1	cytosine-beta-D-arabinofuranoside:13:0.0056	0.0056	13
araG	araG:10|ara-G:5|Ara-G:3	9-beta-D-Arabinofuranosylguanine:18:0.5000	0.5000	18
ArgR	ArgR:8|argR:1	arginine repressor:9:0.6794	0.6794	9
ARMS	ARMS:29	alveolar rhabdomyosarcoma:29:0.8422	0.8422	29
ARMS	ARMS:125|arms:1	amplification refractory mutation system:126:0.9490	0.9490	126
aro-	aro-:10	aromatic-dependent:10:0.6000	0.6000	10
AS-ODNs	AS-ODNs:26|ASODNs:6|asODNs:4|AsODNs:3|As-ODNs:1	antisense oligodeoxynucleotides:40:0.8525	0.8525	40
AS-ODNs	AS-ODNs:14|asODNs:3|ASODNs:1	antisense oligonucleotides:18:0.6903	0.6903	18
as-hCG	as-hCG:7|AshCG:1	Desialylated hCG:8:0.5006	0.5006	8
ATPe	ATPe:15	extracellular ATP:15:0.8045	0.8045	15
attB	attB:9	bacterial attachment site:9:0.2285	0.2285	9
autism	autism:7	autistic disorder:7:0.3524	0.3524	7
auto	auto:26	autologous:26:0.3247	0.3247	26
AW	AW:7|Aw:3	Active wakefulness:10:0.2446	0.2446	10
AW	AW:12|Aw:1|aW:1	Active waking:14:0.5589	0.5589	14
aw	aw:11	alcohol withdrawal:11:0.4232	0.4232	11
AW	AW:8	anterior wall:8:0.1471	0.1471	8
AW	AW:5	ash weight:5:0.0517	0.0517	5
aw	aw:117|Aw:13|aW:7|a-w:1	water activity:121:0.9753|water activities:17:0.8270	0.9753	138
azaC	azaC:7|aza-C:6|AzaC:4|Aza-C:2|AZA-C:1	5-azacytidine:20:0.5429	0.5429	20
aza-dC	aza-dC:4|Aza-dC:3|azadC:1|AzadC:1|AZAdC:1	5-aza-2'-deoxycytidine:10:0.5294	0.5294	10
b(5)	b(5):15	Cytochrome b(5):15:0.8165	0.8165	15
b.d.	b.d.:18	twice daily:18:0.8365	0.8365	18
b.i.d.	b.i.d.:40	twice a day:40:0.6808	0.6808	40
b.i.d.	b.i.d.:99|B.I.D.:2	twice daily:90:0.9304|twice-daily:11:0.0472	0.9304	101
b.w.	b.w.:183|B.W.:13	body weight:196:0.9527	0.9527	196
b.wt.	b.wt.:24|B.Wt.:1	body weight:25:0.8816	0.8816	25
b/b	b/b:10	Belgrade:10:0.1233	0.1233	10
b/b	b/b:18	Belgrade laboratory:18:0.8365	0.8365	18
B0	B0:10	magnetic field:10:0.3867	0.3867	10
b5R	b5R:22|B5R:2|b5r:1	b5 reductase:25:0.7679	0.7679	25
bBMP	bBMP:21	bovine bone morphogenetic protein:21:0.8657	0.8657	21
bDNA	bDNA:110|b-DNA:2|BDNA:1	branched DNA:89:0.6590|branched-DNA:24:0.1111	0.6590	113
bDNA	bDNA:7	branched DNA signal amplification:7:0.5926	0.5926	7
bDNA	bDNA:5	Versant HCV RNA 3.0 Assay:5:0.4422	0.4422	5
B-FABP	B-FABP:13|bFABP:2	fatty acid-binding protein:8:0.6411|fatty acid binding protein:7:0.4438	0.6411	15
bFF	bFF:57|BFF:13	bovine follicular fluid:70:0.8741	0.8741	70
bFGF	bFGF:4005|b-FGF:90|BFGF:7|B-FGF:2	basic fibroblast growth factor:4093:0.9795|basic fibroblast growth factors:11:0.6182	0.9795	4104
BGAL	BGAL:4|B-gal:2|Bgal:1|bGAL:1|B-GAL:1|bgal:1	beta-galactosidase:10:0.6923	0.6923	10
bGH	bGH:86	bovine GH:86:0.8700	0.8700	86
bGH	bGH:190|BGH:13|b-GH:2	bovine growth hormone:205:0.8823	0.8823	205
bGRF	bGRF:6	bovine growth hormone-releasing factor:6:0.5290	0.5290	6
bHLH	bHLH:703|b-HLH:10|BHLH:7|B-HLH:3	basic helix-loop-helix:637:0.9653|basic-helix-loop-helix:79:0.0980|basic helix loop helix:7:0.5926	0.9653	723
BI-1	BI-1:9	Bax inhibitor-1:9:0.6794	0.6794	9
BLES	BLES:14|bLES:2	bovine lipid extract surfactant:16:0.8165	0.8165	16
bNED	bNED:10	biochemical no evidence of disease:10:0.6911	0.6911	10
bNED	bNED:8	freedom from biochemical failure:8:0.4102	0.4102	8
bNOS	bNOS:19|BNOS:3	brain nitric oxide synthase:22:0.5095	0.5095	22
bPAG	bPAG:7	bovine pregnancy-associated glycoprotein:7:0.3524	0.3524	7
BPE	BPE:35	benign prostatic enlargement:35:0.8681	0.8681	35
BPE	BPE:34|bPE:1	bovine pituitary extract:35:0.9151	0.9151	35
bPIV3	BPIV3:7|bPIV3:7|BPIV-3:4|bPIV-3:1	bovine parainfluenza virus type 3:19:0.8449	0.8449	19
bPRL	bPRL:16|BPRL:3|bPrl:2|bPrL:1	bovine prolactin:22:0.6934	0.6934	22
bPTH	bPTH:25|BPTH:5|b-PTH:4	bovine parathyroid hormone:34:0.7587	0.7587	34
BRD	BRD:35	bovine respiratory disease:35:0.9151	0.9151	35
bTP-1	bTP-1:16	bovine trophoblast protein-1:16:0.8165	0.8165	16
bTSH	bTSH:7	bovine thyroid-stimulating hormone:7:0.4438	0.4438	7
bTSH	bTSH:15|b-TSH:3	bovine thyrotropin:18:0.6381	0.6381	18
B-WGA	B-WGA:4|b-WGA:3|bWGA:1	germ agglutinin:8:0.6794	0.6794	8
bZIP	bZIP:64|bZip:14|b-Zip:3	basic leucine zipper:81:0.5491	0.5491	81
bZIP	bZIP:46|bZip:8|B-ZIP:3|bzip:2|b-zip:1	basic region-leucine zipper:36:0.9174|basic region leucine zipper:24:0.8251	0.9174	60
bZIP	bZIP:8|b-ZIP:1|B-ZIP:1	leucine-zipper:10:0.0326	0.0326	10
baPWV	baPWV:26|BAPWV:1|ba-PWV:1	brachial-ankle pulse wave velocity:28:0.7505	0.7505	28
baPWV	baPWV:14	brachial-ankle PWV:14:0.6173	0.6173	14
BAD	BAD:16	bipolar affective disorder:16:0.8165	0.8165	16
BAG	BAG:15	bioactive glass:15:0.8045	0.8045	15
BCD	BCD:10	beta-cyclodextrin:10:0.0357	0.0357	10
BCd	BCd:9|B-Cd:3	blood cadmium:12:0.4557	0.4557	12
B-Cd	B-Cd:5	Cadmium in blood:5:0.0736	0.0736	5
BCD	BCD:5	crystalline dystrophy:5:0.1132	0.1132	5
BEACH	BEACH:11	Bettering the Evaluation And Care of Health:11:0.7357	0.7357	11
BEST	BEST:2	Beta-Blocker Evaluation Survival Trial:2:0.7571	0.7571	2
beta(2)m	beta(2)m:58|beta(2)M:25|beta(2)-m:12	beta(2)-microglobulin:95:0.8017	0.8017	95
beta-CF	beta-CF:9	Beta-core fragment:9:0.5470	0.5470	9
beta-EI	beta-EI:23	immunoreactivity:23:0.9565	0.9565	23
beta-GL	beta-GL:5|beta-Gl:4	beta-glucuronidase:9:0.6667	0.6667	9
beta-2-m	beta-2-m:20|beta2m:20|beta2M:18|beta2-m:12|beta-2M:9|beta-2m:8|beta2-M:1	beta-2-microglobulin:59:0.1324|beta-2 microglobulin:20:0.2485|beta(2)-microglobulin:9:0.0183	0.2485	88
beta2m	beta2m:165|beta2M:66|beta2-m:65|beta2-M:3|Beta2-m:1|Beta2M:1	beta2-microglobulin:276:0.6279|beta2 microglobulin:25:0.3470	0.6279	301
betaAP	betaAP:15|beta-AP:11	beta-amyloid peptide:26:0.7340	0.7340	26
beta-AP	beta-AP:11|betaAP:3|beta-Ap:1	beta-Amyloid protein:15:0.4951	0.4951	15
beta-AR	beta-AR:168|betaAR:82	beta-adrenergic receptor:197:0.8888|beta-adrenergic receptors:53:0.8597	0.8888	250
beta-AR	beta-AR:68|betaAR:11|beta-ar:2	beta-adrenoceptor:64:0.1595|beta-adrenoceptors:17:0.0405	0.1595	81
beta-CD	beta-CD:263|betaCD:46|beta-cd:2	beta-cyclodextrin:311:0.8988	0.8988	311
beta-E	beta-E:41|betaE:4	beta-endorphin:45:0.8627	0.8627	45
beta-GP	beta-GP:37|betaGP:4	beta-glycerophosphate:41:0.6557	0.6557	41
beta-G	beta-G:24|betaG:14|beta-g:1	beta-glucuronidase:39:0.8085	0.8085	39
beta-HB	beta-HB:18|betaHB:6|betaHb:1	beta-hydroxybutyrate:25:0.8571	0.8571	25
beta-LG	beta-LG:76|beta-Lg:40|beta-lg:39|betaLG:8|betaLg:3|betalg:3	beta-lactoglobulin:169:0.9282	0.9282	169
beta-ME	beta-ME:31|betaME:2|Beta-ME:2	beta-mercaptoethanol:35:0.8947	0.8947	35
beta-NF	beta-NF:84|betaNF:22	beta-naphthoflavone:106:0.8974	0.8974	106
beta-PL	beta-PL:11|betaPL:2	beta-propiolactone:13:0.9231	0.9231	13
betaPP	betaPP:9	beta-amyloid precursor protein:9:0.5470	0.5470	9
beta-TG	beta-TG:317|betaTG:19|beta-tg:5|beta-Tg:2|Beta-TG:2	beta-thromboglobulin:345:0.9319	0.9319	345
betac	betac:5	common beta subunit:5:0.1973	0.1973	5
beta	beta:12	betamethasone:12:0.0064	0.0064	12
beta	beta:10	buffer capacity:10:0.3867	0.3867	10
beta	beta:14	buffering power:14:0.6173	0.6173	14
beta	beta:20	elimination:20:0.0110	0.0110	20
beta	beta:36	Elimination rate constant:36:0.5303	0.5303	36
beta	beta:7	human fibroblast:7:0.1010	0.1010	7
beta	beta:9	isoproterenol:9:0.0046	0.0046	9
beta	beta:10	propranolol:10:0.0052	0.0052	10
beta	beta:12|Beta:1	regression coefficient:13:0.1962	0.1962	13
beta	beta:6	regulatory subunits:6:0.1838	0.1838	6
beta	beta:18	skeletofusimotor:18:0.0099	0.0099	18
beta	beta:5	spectral exponent:5:0.0736	0.0736	5
beta	beta:7	stiffness index:7:0.2452	0.2452	7
beta	beta:7	stiffness parameter:7:0.1025	0.1025	7
bi-mAb	biMAb:5|bi-mAb:5|BiMAb:4|Bi-MAb:2|Bi-mAb:2|bimAb:2|bi-Mab:1|bi-mab:1	bispecific monoclonal antibody:13:0.6701|bispecific monoclonal antibodies:9:0.6794	0.6794	22
BIB	BIB:16	Bioenterics Intragastric Balloon:16:0.7096	0.7096	16
BID	BID:4	Beta Interaction Domain:4:0.1618	0.1618	4
Bid	Bid:7|BID:2	domain death agonist:9:0.6794	0.6794	9
bid	bid:15|BID:14	twice a day:29:0.6928	0.6928	29
BID	BID:67|bid:58	twice daily:103:0.9395|twice-daily:22:0.0758	0.9395	125
bimAbs	bimAbs:4|Bi-MAbs:3|biMAbs:3|Bi-mAbs:2|bi-mAbs:1	bispecific monoclonal antibodies:13:0.7753	0.7753	13
binase	binase:8|Binase:1|BINASE:1	Bacillus intermedius:10:0.4363	0.4363	10
BioB	BioB:11|bioB:1	Biotin synthase:12:0.7571	0.7571	12
bipy	bipy:14	2,2'-bipyridine:14:0.4062	0.4062	14
blacks	blacks:10|Blacks:1	African Americans:11:0.5355	0.5355	11
blebs	blebs:11	retinal detachments:11:0.6182	0.6182	11
bm/bm	bm/bm:15	brachymorphic:15:0.8750	0.8750	15
BOF	BOF:9	branchio-oculo-facial:9:0.3478	0.3478	9
bpy	bpy:40|BPY:1|Bpy:1	2,2'-bipyridine:42:0.5395	0.5395	42
bpy	bpy:7|BPY:2	4,4'-bipyridine:9:0.1053	0.1053	9
BRA	BRA:9	Bilateral renal agenesis:9:0.6794	0.6794	9
BRA	BRA:9	bone-resorbing activity:9:0.2102	0.2102	9
bryo	bryo:14|Bryo:6	bryostatin 1:20:0.8525	0.8525	20
BsAbs	BsAbs:17|bsAbs:6|Bs-Abs:1	bispecific antibodies:24:0.5160	0.5160	24
bsMAbs	bsMAbs:5|BsMAbs:2|bsmAbs:1	bispecific monoclonal antibodies:8:0.6411	0.6411	8
BSTL	BSTL:10	bed nucleus of the stria terminalis:10:0.7103	0.7103	10
btl	btl:7|BTL:2|Btl:2	breathless:11:0.2041	0.2041	11
BTL	BTL:11	bunitrolol:11:0.2041	0.2041	11
Bu-WSA	Bu-WSA:8|bu-WSA:1	water-soluble adjuvant:9:0.4587	0.4587	9
bud	bud:107|BUD:5|Bud:1	budesonide:113:0.8960	0.8960	113
BUT	BUT:5	biopsy urease test:5:0.4422	0.4422	5
BUT	BUT:14	tear break-up time:14:0.1044	0.1044	14
BUT	BUT:20|but:1	tear film break-up time:21:0.7865	0.7865	21
bxd	bxd:10	bithoraxoid:10:0.3000	0.3000	10
B-Y	B-Y:6|BY:5|by:1|b-y:1	blue-yellow:13:0.2500	0.2500	13
c-Myb	c-Myb:14	c-myb proto-oncogene product:14:0.7909	0.7909	14
c-Fos-IR	c-Fos-IR:4|c-Fos-ir:3|c-fos-IR:2	c-fos immunoreactivity:9:0.3945	0.3945	9
c-fos-li	c-fos-li:7	c-fos-like immunoreactivity:7:0.3524	0.3524	7
c.f.u.	c.f.u.:36|C.F.U.:2	colony forming units:24:0.8768|colony-forming units:14:0.1882	0.8768	38
c.m.c.	c.m.c.:9	critical micelle concentration:9:0.6794	0.6794	9
C.N.S.	C.N.S.:15|c.n.s.:6	central nervous system:21:0.8594	0.8594	21
c.p.	c.p.:15|C.P.:2	commercially pure:17:0.8270	0.8270	17
C.p.	C.p.:9|C.P.:2	Corynebacterium parvum:11:0.7357	0.7357	11
c.s.f.	c.s.f.:25|C.S.F.:24	cerebrospinal fluid:49:0.9046	0.9046	49
c/c	c/c:9	albino:9:0.0678	0.0678	9
c/deg	c/deg:9	cycles/degree:9:0.2353	0.2353	9
c/deg	c/deg:16	cycles per degree:16:0.7261	0.7261	16
c3Ado	c3Ado:19|C3ado:1|c3-Ado:1|c3-ado:1	3-deazaadenosine:22:0.8750	0.8750	22
cADPR	cADPR:20|cADPr:6|cAD-PR:1	cyclic adenosine diphosphate ribose:19:0.7658|cyclic adenosine diphosphate-ribose:8:0.6411	0.7658	27
cADPR	cADPR:18|cADPr:1	Cyclic adenosine diphosphoribose:19:0.8449	0.8449	19
cADPR	cADPR:222|cADPr:13|cADP-R:1	cyclic ADP-ribose:219:0.9641|cyclic ADP ribose:17:0.8270	0.9641	236
cAK	cAK:11	catalytic subunit:11:0.7357	0.7357	11
cALL	cALL:11|c-ALL:5|C-ALL:4	common acute lymphoblastic leukaemia:20:0.6259	0.6259	20
cALL	cALL:22|c-ALL:6|C-ALL:4|CALL:1	common acute lymphoblastic leukemia:33:0.7238	0.7238	33
cAMP-PK	cAMP-PK:44	cAMP-dependent protein kinase:44:0.5652	0.5652	44
cAMP	cAMP:1085|camp:2	adenosine 3',5'-cyclic monophosphate:1087:0.9604	0.9604	1087
cAMP	cAMP:12	adenosine 3',5'-cyclic phosphate:12:0.7571	0.7571	12
cAMP	cAMP:14	adenosine 3'-5'-monophosphate:14:0.7909	0.7909	14
cAMP	cAMP:14	adenosine 3',5'-phosphate:14:0.2157	0.2157	14
cAMP	cAMP:27|CAMP:1	adenosine 3'5'-monophosphate:28:0.8941	0.8941	28
cAMP	cAMP:20	adenosine cyclic 3',5'-phosphate:20:0.8525	0.8525	20
CAMP	CAMP:30	Childhood Asthma Management Program:30:0.8978	0.8978	30
cAMP	cAMP:10	cyclic 3',5'-AMP:10:0.7103	0.7103	10
cAMP	cAMP:434|c-AMP:7	cyclic adenosine 3',5'-monophosphate:312:0.6437|cyclic adenosine 3':5'-monophosphate:82:0.5839|cyclic adenosine-3',5'-monophosphate:46:0.6519|cyclic adenosine 3' 5'-monophosphate:1:0.5682	0.6519	441
cAMP	cAMP:16	cyclic adenosine 5'-monophosphate:16:0.8045	0.8045	16
cAMP	cAMP:1430|c-AMP:17|CAMP:3|C-AMP:1|camp:1	cyclic adenosine monophosphate:1439:0.8588|cyclic adenosine-monophosphate:13:0.6701	0.8588	1452
cAMP	cAMP:7	monophosphoric acid:7:0.1329	0.1329	7
c-ANCA	c-ANCA:19|cANCA:18|C-ANCA:7	antineutrophil cytoplasmic antibodies:22:0.4510|antineutrophil cytoplasmic antibody:22:0.4190	0.4510	44
cANCA	cANCA:9|c-ANCA:6|C-ANCA:4	cytoplasmic ANCA:19:0.7044	0.7044	19
C-ANCA	c-ANCA:2|cANCA:2|C-ANCA:2	cytoplasmic autoantibodies:6:0.2243	0.2243	6
c-ANCA	c-ANCA:5|C-ANCA:3|cANCA:1	cytoplasmic pattern:9:0.1409	0.1409	9
c-ANCA	c-ANCA:4|C-ANCA:4|cANCA:3	cytoplasmic staining pattern:11:0.6460	0.6460	11
cAPK	cAPK:72|cA-PK:10|CAPK:1	cAMP-dependent protein kinase:83:0.5927	0.5927	83
car1	car1:3|cAR1:3|CAR1:2	cAMP receptor 1:8:0.5006	0.5006	8
cAspAT	cAspAT:12	cytosolic aspartate aminotransferase:12:0.5664	0.5664	12
cBSA	cBSA:10|CBSA:4|C-BSA:3	bovine serum albumin:17:0.8270	0.8270	17
cCMP	cCMP:7|c-CMP:2	monophosphate:9:0.2857	0.2857	9
cDCE	cDCE:11|c-DCE:1	cis-1,2-dichloroethene:12:0.1618	0.1618	12
CDCE	CDCE:25	constant denaturant capillary electrophoresis:25:0.8768	0.8768	25
CDGS	CDGS:25	Carbohydrate-deficient glycoprotein syndrome:25:0.6767	0.6767	25
CDGs	CDGs:11	Congenital disorders of glycosylation:11:0.7357	0.7357	11
cDNAs	cDNAs:126	complementary DNAs:126:0.9080	0.9080	126
cDNA	cDNA:19	complementary:19:0.0122	0.0122	19
cDNA	cDNA:90	complementary deoxyribonucleic acid:90:0.8384	0.8384	90
cDNA	cDNA:1189|CDNA:2	complementary DNA:1191:0.9459	0.9459	1191
cDNA	cDNA:13	complementary DNAs:13:0.6701	0.6701	13
cDNA	cDNA:18	DNA complementary to RNA:18:0.8365	0.8365	18
C-FABP	C-FABP:6|cFABP:4	fatty acid-binding protein:10:0.7103	0.7103	10
cFLIP	cFLIP:13|c-FLIP:11|c-Flip:1	cellular FLICE-inhibitory protein:16:0.4832|cellular FLICE inhibitory protein:9:0.3945	0.4832	25
cFLIP	cFLIP:6|c-FLIP:4	cellular FLICE-like inhibitory protein:10:0.5470	0.5470	10
c-FLI	c-FLI:18|cFLI:1	c-Fos-like immunoreactivity:19:0.8449	0.8449	19
cGH	cGH:6	canine GH:6:0.0564	0.0564	6
cGH	cGH:11	chicken GH:11:0.2764	0.2764	11
cGH	cGH:35|c-GH:2	chicken growth hormone:37:0.6009	0.6009	37
CGH	CGH:86	Comparative genomic hybridisation:86:0.9648	0.9648	86
CGH	CGH:1237	comparative genomic hybridization:1237:0.9901	0.9901	1237
cGI-PDE	cGI-PDE:8	cGMP-inhibited cAMP phosphodiesterase:8:0.5006	0.5006	8
cGKI	cGKI:8|cGK-I:1	cGMP-dependent protein kinase I:9:0.3945	0.3945	9
cGKs	cGKs:12	cGMP-dependent protein kinases:12:0.6460	0.6460	12
cGK	cGK:37	cGMP-dependent protein kinase:37:0.5783	0.5783	37
cGPK	cGPK:7|cG-PK:3	protein kinase:10:0.7103	0.7103	10
cGPx	cGPx:13|cGPX:6|CGPx:1|C-GPx:1|CGPX:1	glutathione peroxidase:22:0.8657	0.8657	22
cGVHD	cGVHD:106|CGVHD:12|cGvHD:12|C-GVHD:3|c-GVHD:1	chronic graft-versus-host disease:134:0.9641	0.9641	134
cGTH	cGTH:5|cGtH:2|c-GTH:2	carp gonadotropin:9:0.4587	0.4587	9
cGy	cGy:38	centigray:21:0.3571|centiGrays:17:0.2857	0.3571	38
cHyp	cHyp:9	cis-4-Hydroxy-L-proline:9:0.8000	0.8000	9
cIAP2	c-IAP2:2|cIAP2:2	cellular inhibitor of apoptosis 2:4:0.1618	0.1618	4
c-IAP2	c-IAP2:2|cIAP2:2	inhibitor of apoptosis protein 2:4:0.2818	0.2818	4
cICAM-1	cICAM-1:11	circulating ICAM-1:11:0.3829	0.3829	11
cICAM-1	cICAM-1:29	circulating intercellular adhesion molecule-1:29:0.6648	0.6648	29
CIMP	CIMP:31	CpG island methylator phenotype:31:0.9043	0.9043	31
CitS	CitS:5	citrate carrier of Klebsiella pneumoniae:5:0.5290	0.5290	5
c-kit	c-kit:8|c-KIT:2|c-Kit:1	stem cell factor receptor:11:0.7357	0.7357	11
cLPM	cLPM:17	canalicular:17:0.4000	0.4000	17
cLPM	cLPM:10	canalicular liver plasma membrane:10:0.7103	0.7103	10
cMDH	cMDH:11|c-MDH:1	malate dehydrogenase:12:0.7571	0.7571	12
cMGF	cMGF:19	chicken myelomonocytic growth factor:19:0.8449	0.8449	19
cMOAT	cMOAT:68|cmoat:3|cMoat:2|Cmoat:1	canalicular multispecific organic anion transporter:74:0.8349	0.8349	74
cMRF	cMRF:9|CMRF:1	central mesencephalic reticular formation:10:0.7103	0.7103	10
CMRI	CMRI:16|cMRI:8	magnetic resonance imaging:24:0.7593	0.7593	24
CMUTs	CMUTs:8|cMUTs:5	capacitive micromachined ultrasonic transducers:13:0.7753	0.7753	13
CMVR	CMVR:28|CMV-R:5	cytomegalovirus retinitis:33:0.6111	0.6111	33
CNAPs	CNAPs:11|cNAPs:1|CNAPS:1	nerve action potentials:13:0.6701	0.6701	13
cNOS	cNOS:23	constitutive:23:0.0759	0.0759	23
cNOS	cNOS:88	constitutive nitric oxide synthase:88:0.6888	0.6888	88
cNOS	cNOS:34|c-NOS:1	constitutive NO synthase:35:0.1510	0.1510	35
cNOS	cNOS:50|c-NOS:3	constitutive NOS:53:0.6743	0.6743	53
cP-450	cP-450:3|cP450:2|CP450:2|CP-450:1|C-P450:1	cytochrome P-450:9:0.6794	0.6794	9
CPDR	CPDR:9	Center for Prostate Disease Research:9:0.6794	0.6794	9
CPDase	CPDase:6|cPDase:4	phosphodiesterase:10:0.9000	0.9000	10
cPGES	cPGES:14	cytosolic PGES:14:0.7909	0.7909	14
cPGI2	cPGI2:10|c-PGI2:1	carbaprostacyclin:11:0.6667	0.6667	11
cPKA	cPKA:4|C-PKA:1	catalytic subunit of PKA:5:0.2818	0.2818	5
cPKC	cPKC:23	conventional PKC:23:0.4652	0.4652	23
cPKC	cPKC:22	protein kinase C:22:0.8657	0.8657	22
cPLA(2)	cPLA(2):153	cytosolic phospholipase A(2):153:0.8175	0.8175	153
cPLA(2)	cPLA(2):22	cytosolic PLA(2):22:0.5863	0.5863	22
cPLA2	cPLA2:357	cytosolic phospholipase A2:357:0.8622	0.8622	357
cPLA2	cPLA2:96	cytosolic PLA2:96:0.7823	0.7823	96
cPRP	cPRP:3|C-PRP:2|c-PRP:1	citrated platelet-rich plasma:6:0.2243	0.2243	6
C-PTH	C-PTH:11|cPTH:5|c-PTH:2|CPTH:1	parathyroid hormone:19:0.6106	0.6106	19
CRNAs	CRNAs:31	Certified Registered Nurse Anesthetists:31:0.9043	0.9043	31
CRNA	CRNA:15	Certified Registered Nurse Anesthetist:15:0.7096	0.7096	15
cRNA	cRNA:70	complementary RNA:70:0.7379	0.7379	70
cRT-PCR	cRT-PCR:5	competitive reverse transcription polymerase chain reaction:5:0.5290	0.5290	5
cSHMT	cSHMT:7|CSHMT:1	cytoplasmic serine hydroxymethyltransferase:8:0.5006	0.5006	8
cSLO	cSLO:10|CSLO:4	confocal scanning laser ophthalmoscope:14:0.8045	0.8045	14
CSLO	CSLO:10|cSLO:3	confocal scanning laser ophthalmoscopy:13:0.7753	0.7753	13
cSNPs	cSNPs:10	single nucleotide polymorphisms:10:0.5856	0.5856	10
c-Src	c-Src:10|c-src:9|c-SRC:1	cellular Src:20:0.7766	0.7766	20
cTALH	cTALH:6	cortical thick ascending limb of Henle:6:0.5290	0.5290	6
cTnT	cTnT:8|CTnT:1	cardiac TnT:9:0.6794	0.6794	9
cTnT	cTnT:305|cTNT:27|cTn-T:13|CTnT:1|c-TnT:1	cardiac troponin T:337:0.8698|cardiac troponin-T:10:0.4363	0.8698	347
cTSH	cTSH:8	canine thyroid-stimulating hormone:8:0.5006	0.5006	8
cTnI	cTnI:13	cardiac TnI:13:0.7753	0.7753	13
cTnI	cTnI:406|cTn-I:25|CTnI:10|cTNI:6|c-TnI:1	cardiac troponin I:418:0.8379|cardiac troponin-I:30:0.8472	0.8472	448
cVCAM-1	cVCAM-1:13	vascular cell adhesion molecule-1:13:0.7753	0.7753	13
CAMT	CAMT:16	Congenital amegakaryocytic thrombocytopenia:16:0.8165	0.8165	16
CACT	CACT:10	carnitine-acylcarnitine translocase:10:0.2873	0.2873	10
cagPAI	cagPAI:11|cag-PAI:5	cag pathogenicity island:16:0.7261	0.7261	16
CAPE	CAPE:144|cape:1	caffeic acid phenethyl ester:145:0.9560	0.9560	145
CAPE	CAPE:8	Clifton Assessment Procedures for the Elderly:8:0.6411	0.6411	8
CAP-R	CAPr:4|CAP-R:4|CAPR:1|CAP-r:1	chloramphenicol-resistant:10:0.2000	0.2000	10
CAPS	CAPS:10	activator protein for secretion:10:0.5856	0.5856	10
CAPs	CAPs:7|CAPS:1	air particles:8:0.0532	0.0532	8
CAPS	CAPS:21	Cardiac Arrhythmia Pilot Study:21:0.8594	0.8594	21
CAPs	CAPs:7	cardioacceleratory peptides:7:0.1850	0.1850	7
CAPS	CAPS:19	catastrophic antiphospholipid syndrome:19:0.7658	0.7658	19
CAPs	CAPs:7	clathrin-associated proteins:7:0.0732	0.0732	7
CAPS	CAPS:33	cleaved amplified polymorphic sequence:22:0.7400|cleaved amplified polymorphic sequences:11:0.7357	0.7400	33
CAPS	CAPS:60	Clinician Administered PTSD Scale:32:0.9043|Clinician-Administered PTSD Scale:28:0.3095	0.9043	60
CAPs	CAPs:116|cAPs:5|caps:3	compound action potentials:124:0.9164	0.9164	124
CAPs	CAPs:7	Effects of subchronic exposures to concentrated ambient particles:7:0.5926	0.5926	7
CARDIA	CARDIA:106|cardia:2	Coronary Artery Risk Development in Young Adults:108:0.9731	0.9731	108
CARDIA	CARDIA:5	Coronary Artery Risk Development in Young Adults Study:5:0.5926	0.5926	5
CARDS	CARDS:11	Collaborative AtoRvastatin Diabetes Study:11:0.7357	0.7357	11
CARP	CARP:13|carp:2	Cardiac ankyrin repeat protein:15:0.7096	0.7096	15
CARP	CARP:10	catch-relaxing peptide:10:0.3945	0.3945	10
CART	CART:109	Classification and Regression Tree:66:0.8688|classification and regression trees:43:0.9323	0.9323	109
CART	CART:9	classification and regression tree analysis:9:0.6794	0.6794	9
CART	CART:123	Cocaine- and amphetamine-regulated transcript:123:0.7858	0.7858	123
CART	CART:5	combination antiretroviral therapy:5:0.1973	0.1973	5
CASMC	CASMC:15	coronary artery smooth muscle cells:15:0.8045	0.8045	15
CatS	CatS:9|catS:2	cathepsin S:11:0.7357	0.7357	11
CATS	CATS:6|cats:1	Ticlopidine Study:7:0.1211	0.1211	7
CAT	CAT:8|cat:2	agglutination test:10:0.0626	0.0626	10
CAT	CAT:7|cat:4	carboxyatractylate:11:0.0016	0.0016	11
CAT	CAT:10|cat:6	carboxyatractyloside:16:0.0025	0.0025	16
CAT	CAT:5	carnitine acyltransferase:5:0.0517	0.0517	5
cat	cat:6|CAT:3	Catalase activity:9:0.2285	0.2285	9
cat	cat:10|CAT:1	catecholamine:11:0.0016	0.0016	11
cat	cat:13|Cat:3	cathepsin:16:0.0025	0.0025	16
cat	cat:13|CAT:2	cationic amino acid transporter:15:0.8045	0.8045	15
CAT	CAT:7	Chlamydia antibody testing:7:0.3524	0.3524	7
CAT	CAT:550|cat:91|Cat:2	chloramphenicol acetyl transferase:584:0.8500|chloramphenicol acetyl-transferase:59:0.7670	0.8500	643
CAT	CAT:1757|cat:322|Cat:3	chloramphenicol acetyltransferase:2073:0.7924|chloramphenicol-acetyltransferase:9:0.0013	0.7924	2082
cat	cat:28|CAT:24	chloramphenicol acetyltransferase gene:52:0.8345	0.8345	52
CAT	CAT:8	chloramphenicol acyltransferase:8:0.2619	0.2619	8
CAT	CAT:5|cat:2	cognitive analytic therapy:7:0.5926	0.5926	7
CAT	CAT:5|cat:1	Column Agglutination Technology:6:0.5290	0.5290	6
CAT	CAT:43|cat:5	computed axial tomography:48:0.1798	0.1798	48
CAT	CAT:20	computer assisted tomography:20:0.6259	0.6259	20
CAT	CAT:9|cat:3	computerized adaptive testing:12:0.3524	0.3524	12
CAT	CAT:11|cat:2	computerized axial tomographic:13:0.3809	0.3809	13
CAT	CAT:116|cat:9	computerized axial tomography:125:0.5617	0.5617	125
CAT	CAT:18|cat:11	reporter gene:29:0.1285	0.1285	29
CaT	CaT:13|Cat:3	total calcium:16:0.6024	0.6024	16
CaT	CaT:6|cat:2|CAT:1	transient:9:0.0013	0.0013	9
CAV-1	CAV-1:14	canine adenovirus type 1:14:0.7909	0.7909	14
CAV	CAV:11	canine adenovirus:11:0.7357	0.7357	11
CAV	CAV:116	cardiac allograft vasculopathy:116:0.8905	0.8905	116
CAV	CAV:38	Chicken anaemia virus:38:0.8781	0.8781	38
CAV	CAV:51	chicken anemia virus:51:0.9416	0.9416	51
cbEGF	cbEGF:6	calcium binding epidermal growth factor-like:6:0.5290	0.5290	6
CBT	CBT:7	caffeine breath test:7:0.2902	0.2902	7
CBT	CBT:17	carotid body tumor:10:0.7103|carotid body tumors:7:0.5926	0.7103	17
CBT	CBT:7	childhood brain tumors:7:0.5926	0.5926	7
CBT	CBT:211	cognitive-behavioral therapy:211:0.3204	0.3204	211
CBT	CBT:45	cognitive-behavioral treatment:45:0.5944	0.5944	45
CBT	CBT:12	Computer-based training:12:0.4153	0.4153	12
CBT	CBT:52	cord blood transplantation:52:0.9427	0.9427	52
CBT	CBT:31|cBT:3	core body temperature:34:0.9126	0.9126	34
cccDNA	cccDNA:32|CCC-DNA:1|ccc-DNA:1	covalently closed circular DNA:34:0.9151	0.9151	34
CCC	CCC:5	child care center:5:0.1973	0.1973	5
CCC	CCC:13	Chlorocholine chloride:13:0.2959	0.2959	13
CCC	CCC:11	cholangiocarcinoma:11:0.0158	0.0158	11
CCC	CCC:64	cholangiocellular carcinoma:52:0.5461|cholangiocellular carcinomas:12:0.5664	0.5664	64
CCC	CCC:9	chronic calculous cholecystitis:9:0.6794	0.6794	9
CCC	CCC:5	chronic Chagas' disease cardiomyopathy:5:0.4422	0.4422	5
CCC	CCC:10	chronic chagasic cardiomyopathy:10:0.7103	0.7103	10
CCC	CCC:16	clear cell carcinoma:16:0.6024	0.6024	16
CCC	CCC:13	concordance correlation coefficient:13:0.6701	0.6701	13
CCC	CCC:12	confronting cisternae:12:0.6460	0.6460	12
CCC	CCC:12	continuous circular capsulorhexis:12:0.6460	0.6460	12
CCC	CCC:64	continuous curvilinear capsulorhexis:64:0.9264	0.9264	64
CCC	CCC:6	continuous curvilinear capsulorrhexis:6:0.3728	0.3728	6
CCC	CCC:30	Counter-current chromatography:30:0.5315	0.5315	30
CCC	CCC:13	countercurrent chromatography:13:0.1423	0.1423	13
ccc	CCC:40|ccc:40	covalently closed circular:80:0.9429	0.9429	80
cdb3	cdb3:14|CDB3:6	cytoplasmic domain of band 3:20:0.8594	0.8594	20
cdc2	cdc2:6|CDC2:3|Cdc2:1	cell division cycle 2:10:0.7103	0.7103	10
CDE	CDE:10	chlordiazepoxide:10:0.0335	0.0335	10
CDE	CDE:5	choline-deficient ethionine-supplemented:5:0.8861	0.8861	5
CDE	CDE:15	Colour Doppler Energy:8:0.2090|color Doppler Energy:7:0.1470	0.2090	15
CDE	CDE:6	convection-dispersion equation:6:0.2243	0.2243	6
CDE	CDE:11	Doppler echocardiography:11:0.6182	0.6182	11
CDE	CDE:15	dust extract:15:0.6386	0.6386	15
CDE	CDE:12	ethionine:12:0.0409	0.0409	12
CDHA	CDHA:10	calcium-deficient hydroxyapatite:10:0.3145	0.3145	10
Cdk2	Cdk2:8|cdk2:3|CDK2:2	cyclin-dependent kinase:13:0.5335	0.5335	13
CDK2	CDK2:107|Cdk2:64|cdk2:49|CDK-2:4|cdk-2:2|Cdk-2:1	cyclin-dependent kinase 2:197:0.7444|cyclin-dependent kinase-2:30:0.6736	0.7444	227
cdk4	cdk4:3|CDK4:2|cdk-4:1|Cdk4:1	cyclin-dependent kinase:7:0.2902	0.2902	7
CDK4	CDK4:73|Cdk4:36|cdk4:35|CDK-4:1	cyclin-dependent kinase 4:134:0.7778|cyclin-dependent kinase-4:11:0.5355	0.7778	145
Cdk5	Cdk5:129|cdk5:58|CDK5:29|cdk-5:2|CDK-5:2|Cdk-5:1	cyclin-dependent kinase 5:198:0.8680|cyclin-dependent kinase-5:23:0.6653	0.8680	221
CDK6	CDK6:12|cdk6:6|Cdk6:3	cyclin-dependent kinase 6:21:0.7291	0.7291	21
CDKs	CDKs:409|Cdks:138|cdks:132	cyclin-dependent kinases:679:0.7973	0.7973	679
CE-MRA	CE-MRA:35|CEMRA:5|ce-MRA:1	Contrast-enhanced magnetic resonance angiography:41:0.7057	0.7057	41
CE-MRA	CE-MRA:11|ceMRA:4|CEMRA:3	Contrast-enhanced MR angiography:18:0.5940	0.5940	18
CE-MRA	CE-MRA:8|CEMRA:3|ce-MRA:2	contrast-enhanced MRA:13:0.4444	0.4444	13
CFU/ml	CFU/ml:4|cfu/mL:1|cfu/ml:1	colony forming units/ml:6:0.5290	0.5290	6
CFU/ml	CFU/ml:10|CFU/mL:5|cfu/ml:5|cfu/mL:2	colony-forming units per milliliter:22:0.5863	0.5863	22
CGP	CGP:24	choline glycerophospholipids:15:0.6386|choline glycerophospholipid:9:0.6794	0.6794	24
CHAOS	CHAOS:12	Congenital high airway obstruction syndrome:12:0.7357	0.7357	12
CHART	CHART:31	continuous hyperfractionated accelerated radiotherapy:31:0.9323	0.9323	31
CHART	CHART:32	Craig Handicap Assessment and Reporting Technique:32:0.9100	0.9100	32
chenic	chenic:10	chenodeoxycholic:10:0.8333	0.8333	10
CHEST	CHEST:16	Chick Embryotoxicity Screening Test:16:0.8165	0.8165	16
chiA	chiA:5	chitinase gene:5:0.2243	0.2243	5
ChIPS	ChIPS:11	Children's Interview for Psychiatric Syndromes:11:0.7103	0.7103	11
chi	chi:9|Chi:1	Chitosan:10:0.0094	0.0094	10
CHI	CHI:27|chi:1	closed head injured:12:0.7571|closed-head-injured:9:0.0084|closed-head injured:7:0.1025	0.7571	28
CHI	CHI:179|chi:26	closed head injury:196:0.9600|Closed head injuries:9:0.6794	0.9600	205
CHI	CHI:14	Congenital hyperinsulinism:14:0.7909	0.7909	14
CHI	CHI:11	contrast harmonic imaging:11:0.5355	0.5355	11
CHI	CHI:11	creatinine height index:11:0.7357	0.7357	11
CHI	CHI:28|chi:1	Cycloheximide:29:0.0293	0.0293	29
Chk2	Chk2:14|chk2:1|CHK2:1	checkpoint kinase 2:16:0.8165	0.8165	16
chr.	chr.:6|Chr.:5	chromosome:11:0.6667	0.6667	11
CHR	CHR:4|chr:1	Calgary Health Region:5:0.2818	0.2818	5
Chr	Chr:594|chr:196	Chromosome:765:0.7159|Chromosomes:25:0.0224	0.7159	790
chr	chr:13	chrysene:13:0.0112	0.0112	13
CHR	CHR:7|chr:2	complete hematologic remission:9:0.6794	0.6794	9
CHR	CHR:13|chr:4	complete hematologic response:17:0.8270	0.8270	17
CHR	CHR:6|chr:1	complete hematological remission:7:0.5926	0.5926	7
CHR	CHR:16	contact hypersensitivity reaction:16:0.7261	0.7261	16
CHR	CHR:12	homology region:12:0.3524	0.3524	12
CHr	CHr:24|chr:3	reticulocyte hemoglobin content:27:0.8312	0.8312	27
CIRP	CIRP:5|Cirp:3|cirp:1	cold-inducible RNA-binding protein:9:0.4587	0.4587	9
cis-UCA	cis-UCA:21	cis-urocanic acid:21:0.8594	0.8594	21
cis-DCE	cis-DCE:8|cisDCE:1	cis-1,2-dichloroethene:9:0.2353	0.2353	9
cis-DCE	cis-DCE:9	cis-1,2-dichloroethylene:9:0.2353	0.2353	9
cis-DDP	cis-DDP:30|cisDDP:2	cis-diamminedichloroplatinum:32:0.0948	0.0948	32
cis-DDP	cis-DDP:113|cisDDP:2|CIS-DDP:1	cis-diamminedichloroplatinum(II):104:0.3150|cis-diamminedichloroplatinum II:12:0.4664	0.4664	116
cis-DDP	cis-DDP:16|cisDDP:1|Cis-DDP:1	cis-dichlorodiammineplatinum:18:0.0520	0.0520	18
cis-DDP	cis-DDP:19	cis-dichlorodiammineplatinum(II):19:0.0550	0.0550	19
cis-Pt	cis-Pt:13|cisPt:2	cis-diamminedichloroplatinum(II):14:0.2167|Cis-diamminedichloroplatinum II:1:0.2619	0.2619	15
CLASS	CLASS:6	Celecoxib Long-term Arthritis Safety Study:6:0.5290	0.5290	6
CLOGP	CLOGP:5|ClogP:3|clogP:3	partition coefficient:11:0.6182	0.6182	11
CNX	CNX:22|Cnx:4	Calnexin:26:0.7576	0.7576	26
COBRA	COBRA:11	Consolidated Omnibus Budget Reconciliation Act of 1985:11:0.7357	0.7357	11
CODES	CODES:7	delivery system:7:0.3524	0.3524	7
COL2A1	COL2A1:36|Col2a1:5|col2a1:1	type II collagen gene:42:0.8893	0.8893	42
COL2A1	COL2A1:23|Col2a1:1	type II procollagen:24:0.8715	0.8715	24
COL2A1	COL2A1:22|Col2a1:1	type II procollagen gene:23:0.8038	0.8038	23
COLI	COLI:8|ColI:3|Col-I:2	type I collagen:13:0.6701	0.6701	13
COMA	COMA:8|C-OMA:2	congenital ocular motor apraxia:10:0.7103	0.7103	10
CON	CON:17|con:15|CoN:1	certificate-of-need:17:0.0146|Certificate of Need:16:0.8165	0.8165	33
con	con:11|Con:2	concanavalin:13:0.0109	0.0109	13
con	con:42|Con:2	concentric:44:0.0391	0.0391	44
con	con:142|Con:3	controls:145:0.1310	0.1310	145
con	con:13	control diet:13:0.3331	0.3331	13
con	con:54	control group:54:0.7654	0.7654	54
con	con:12|Con:2	control rats:14:0.6173	0.6173	14
con	con:21|Con:1	control subjects:22:0.6178	0.6178	22
con	con:10	control trial:10:0.5000	0.5000	10
core	core:12	nucleocapsid:12:0.0409	0.0409	12
cowpea	cowpea:9	Vigna unguiculata:9:0.6794	0.6794	9
COX-1	COX-1:38|cox-1:1|COX1:1|Cox-1:1	constitutive:41:0.0821	0.0821	41
COX-1	COX-1:19|Cox-1:3|COX1:1	constitutive cyclooxygenase:23:0.3592	0.3592	23
COX-1	COX-1:13|COX1:1|Cox-1:1	cyclo-oxygenase-1:15:0.0287	0.0287	15
COX-1	COX-1:232|Cox-1:14|COX1:11|cox1:1	cyclooxygenase-1:222:0.4538|cyclooxygenase 1:36:0.4386	0.4538	258
cox1	cox1:4|COX1:1	oxidase subunit I:5:0.2818	0.2818	5
COXII	COXII:6|coxII:4|CoxII:1|COX-II:1	cytochrome c oxidase subunit II:12:0.6460	0.6460	12
coxII	coxII:7|COXII:1	cytochrome oxidase subunit II:8:0.1276	0.1276	8
COXI	COXI:4|coxI:4|COX-I:4|CoxI:1	cytochrome c oxidase subunit I:13:0.7753	0.7753	13
cp/cp	cp/cp:4	homozygous for the cp gene:4:0.1618	0.1618	4
cpDNA	cpDNA:111|cp-DNA:2	chloroplast DNA:113:0.9579	0.9579	113
cpSRP	cpSRP:8	chloroplast signal recognition particle:8:0.4102	0.4102	8
CPs	CPs:7	capsid proteins:7:0.0825	0.0825	7
CPS	CPS:168|CPs:9|cps:7	capsular polysaccharide:146:0.8602|capsular polysaccharides:38:0.8781	0.8781	184
cps	cps:11	capsular polysaccharide synthesis:11:0.7357	0.7357	11
CPS	CPS:39	carbamoyl phosphate synthetase:39:0.5663	0.5663	39
CPS	CPS:14	carbamoylphosphate synthetase:14:0.0721	0.0721	14
CPS	CPS:16	carbamyl phosphate synthetase:16:0.1526	0.1526	16
CPS	CPS:7	cardioplegic solution:7:0.2452	0.2452	7
CPS	CPS:32	cardiopulmonary support:32:0.7458	0.7458	32
CPS	CPS:10	cerebral protein synthesis:10:0.5000	0.5000	10
CPS	CPS:48	child protective services:37:0.8377|child protective service:11:0.7357	0.8377	48
CPs	CPs:18	chlorophenols:18:0.0124	0.0124	18
CPS	CPS:10	chlorpyrifos:10:0.0066	0.0066	10
CPS	CPS:7	clinical pharmacokinetic service:7:0.5926	0.5926	7
CPS	CPS:7	Clinical prediction of survival:7:0.5926	0.5926	7
CPS	CPS:6	coagulase-positive staphylococci:6:0.2243	0.2243	6
CPs	CPs:14	coat proteins:14:0.2636	0.2636	14
CPS	CPS:12	Cognitive Performance Scale:12:0.6460	0.6460	12
CPS	CPS:183	complex partial seizures:165:0.9819|complex partial seizure:18:0.8365	0.9819	183
CPS	CPS:21	contact photosensitivity:21:0.8594	0.8594	21
CPS	CPS:61	Current Population Survey:61:0.9229	0.9229	61
CPs	CPs:17	cysteine proteinases:17:0.8270	0.8270	17
CPS	CPS:6	diphosphate synthase:6:0.0807	0.0807	6
CPS	CPS:5	patients with chest pain syndrome:5:0.3524	0.3524	5
cps	cps:13|CPS:1	per second:14:0.7909	0.7909	14
CPS	CPS:17	synthetase I:17:0.8270	0.8270	17
CRIB	CRIB:10	Cdc42/Rac interactive binding:10:0.3867	0.3867	10
CRIB	CRIB:29	clinical risk index for babies:29:0.7652	0.7652	29
croup	croup:12	laryngotracheitis:12:0.3056	0.3056	12
croup	croup:14	laryngotracheobronchitis:14:0.3611	0.3611	14
CRO	CRO:26|cro:4	ceftriaxone:30:0.4028	0.4028	30
CRP	CRP:4669|C-RP:26|CrP:3|Crp:2|crp:1	C-reactive protein:4683:0.8654|C-reactive proteins:18:0.4033	0.8654	4701
CRP	CRP:12	Canalith Repositioning Procedure:12:0.6460	0.6460	12
CRP	CRP:10	cardiac rehabilitation program:10:0.7103	0.7103	10
CRP	CRP:36	collagen-related peptide:36:0.7433	0.7433	36
CRP	CRP:12	confluent and reticulated papillomatosis:12:0.7571	0.7571	12
CRp	CRp:9	platelet recovery:9:0.6794	0.6794	9
cryo-EM	cryo-EM:43|cryoEM:5|Cryo-EM:1	cryo-electron microscopy:49:0.5849	0.5849	49
cryo-EM	cryo-EM:5|cryoEM:5	electron cryomicroscopy:10:0.7103	0.7103	10
cryo	cryo:12	cryoprecipitate:12:0.3438	0.3438	12
cry	cry:23|CRY:10|Cry:4	cryptochrome:37:0.4932	0.4932	37
ctDNA	ctDNA:18|CT-DNA:15|ct-DNA:9|CTDNA:2	calf thymus DNA:44:0.8941	0.8941	44
CTSL	CTSL:8|Ctsl:2|ctsl:2	Cathepsin L:12:0.5050	0.5050	12
CURE	CURE:17	Clopidogrel in Unstable angina to prevent Recurrent Events:17:0.7407	0.7407	17
CUSUM	CUSUM:36|cusum:13|Cusum:2	cumulative sum:51:0.9099	0.9099	51
CyaA	CyaA:13|cyaA:2	adenylate cyclase:15:0.6386	0.6386	15
CyaA	CyaA:17|cyaA:2	Adenylate cyclase toxin:19:0.8449	0.8449	19
cya	cya:7	adenyl cyclase:7:0.0692	0.0692	7
cya	cya:16|Cya:2	adenylate cyclase:18:0.4934	0.4934	18
cya	cya:10	adenylate cyclase gene:10:0.5000	0.5000	10
CyA	CyA:89|CYA:14|Cya:1|cyA:1	cyclosporin:105:0.2051	0.2051	105
CyA	CyA:31|Cy-A:16|CYA:1	cyclosporin-A:48:0.0927	0.0927	48
CyA	CyA:197|CYA:34|Cya:2|cya:1	cyclosporine:234:0.4596	0.4596	234
CyA	CyA:8|Cy-A:3|CYA:1	cyclosporine-A:12:0.0217	0.0217	12
cybrid	cybrid:17	cytoplasmic hybrid:17:0.8365	0.8365	17
cyclam	cyclam:9|Cyclam:2|CYCLAM:1	1,4,8,11-tetraazacyclotetradecane:12:0.6875	0.6875	12
CysLT	CysLT:21|cys-LT:16|cysLT:13|Cys-LT:6	cysteinyl leukotriene:27:0.8312|cysteinyl leukotrienes:17:0.6211|cysteinyl-leukotriene:12:0.1642	0.8312	56
cyt.c	cyt.c:9|Cyt.c:5	cytochrome c:14:0.7909	0.7909	14
cyt.	cyt.:14|Cyt.:2	cytochrome:16:0.7143	0.7143	16
cytb	cytb:19|Cytb:8|cyt-b:7|CYTB:3|CytB:1|Cyt-b:1|cytB:1	cytochrome b:40:0.6147	0.6147	40
CytoD	CytoD:9|cytoD:2|cyto-D:2|Cyto-D:1	cytochalasin D:14:0.7909	0.7909	14
CYTOX	CYTOX:7|CytOx:4|CytOX:1|Cytox:1|cytox:1|Cyt-Ox:1	cytochrome c oxidase:15:0.8045	0.8045	15
CytOx	CytOx:10|cytox:4|CYTOX:2|CYT-OX:1	cytochrome oxidase:17:0.2695	0.2695	17
d.p.c.	d.p.c.:24	days post coitum:24:0.7151	0.7151	24
d.p.c.	d.p.c.:8	days postcoitum:8:0.2987	0.2987	8
d.p.i.	d.p.i.:17	days post-infection:12:0.5050|days post infection:5:0.1973	0.5050	17
d.p.i.	d.p.i.:13|D.P.I.:1	days post-inoculation:14:0.7909	0.7909	14
d.s.c.	d.s.c.:14|D.S.C.:1	Differential scanning calorimetry:15:0.8045	0.8045	15
d.w.	d.w.:19|D.W.:2	dry weight:21:0.8594	0.8594	21
D4T	D4T:14|d4T:11	2',3'-didehydro-3'-deoxythymidine:25:0.0873	0.0873	25
d4T	d4T:155|D4T:21	stavudine:176:0.6327	0.6327	176
d-AMP	d-AMP:9|d-amp:6|D-AMP:5|DAMP:3	d-amphetamine:23:0.1897	0.1897	23
dATP	dATP:34|d-ATP:1	deoxyadenosine triphosphate:35:0.8292	0.8292	35
dAdo	dAdo:36	2'-deoxyadenosine:36:0.3846	0.3846	36
dAdo	dAdo:42|dADO:2|d-ado:1	deoxyadenosine:45:0.4835	0.4835	45
DAPG	DAPG:13	2,4-Diacetylphloroglucinol:13:0.8571	0.8571	13
DARC	DARC:30	Duffy antigen/receptor for chemokines:17:0.8270|Duffy antigen receptor for chemokines:13:0.7753	0.8270	30
DBSP	DBSP:21	dibromosulfophthalein:21:0.4878	0.4878	21
dCK	dCK:170|DCK:11|dck:4|dCk:3|Dck:1	deoxycytidine kinase:189:0.9180	0.9180	189
dCMP	dCMP:10|DCMP:2	deoxycytidylate:12:0.0948	0.0948	12
DCMP	DCMP:46|dCMP:2|D-CMP:1|d-CMP:1	dilated cardiomyopathy:50:0.6597	0.6597	50
dCTP	dCTP:10	deoxycytidine 5'-triphosphate:10:0.4363	0.4363	10
dCTP	dCTP:31	deoxycytidine triphosphate:31:0.7091	0.7091	31
dCyd	dCyd:29	2'-deoxycytidine:29:0.2772	0.2772	29
dCyd	dCyd:65	deoxycytidine:65:0.6337	0.6337	65
dDNA	dDNA:9|d-DNA:3	denatured DNA:12:0.5050	0.5050	12
dEMG	dEMG:13|DEMG:10|D-EMG:2	electromyogram:25:0.6486	0.6486	25
DFF	DFF:28	DNA Fragmentation Factor:28:0.8369	0.8369	28
dFdU	dFdU:5	metabolite 2',2'-difluorodeoxyuridine:5:0.3455	0.3455	5
dG-C8-AF	dG-C8-AF:17	N-(deoxyguanosin-8-yl)-2-aminofluorene:17:0.6400	0.6400	17
dGMP	dGMP:6	2'-deoxyguanosine 5'-monophosphate:6:0.2243	0.2243	6
dGTP	dGTP:21	deoxyguanosine triphosphate:21:0.7865	0.7865	21
D-gal	D-gal:25|D-Gal:3|d-gal:1|d-Gal:1	D-galactosamine:30:0.5370	0.5370	30
D-gal	D-gal:8|DGal:1	D-galactose:9:0.1481	0.1481	9
dGlc	dGlc:17	2-deoxy-D-glucose:17:0.3265	0.3265	17
dGlc	dGlc:9	2-deoxyglucose:9:0.1633	0.1633	9
dGuo	dGuo:54	2'-deoxyguanosine:54:0.4530	0.4530	54
dGuo	dGuo:51|d-Guo:2	deoxyguanosine:53:0.4359	0.4359	53
dHGF	dHGF:11	deleted form of hepatocyte growth factor:11:0.7357	0.7357	11
dHGF	dHGF:5	deletion variant of hepatocyte growth factor:5:0.0902	0.0902	5
DIF-1	DIF-1:13	differentiation-inducing factor-1:13:0.5934	0.5934	13
dIgA	dIgA:28	dimeric IgA:28:0.8369	0.8369	28
dNTPs	dNTPs:17	5'-triphosphates:17:0.1379	0.1379	17
dNTPs	dNTPs:9	deoxyribonucleotides:9:0.0690	0.0690	9
dNTPs	dNTPs:73	triphosphates:73:0.6207	0.6207	73
dNTP	dNTP:48	deoxynucleoside triphosphate:48:0.2846	0.2846	48
dNTP	dNTP:57	deoxyribonucleoside triphosphate:57:0.3439	0.3439	57
dNTP	dNTP:14	deoxyribonucleotide:14:0.0684	0.0684	14
dNTP	dNTP:14	triphosphates:14:0.0684	0.0684	14
D-phe	D-phe:11|d-Phe:1|dPhe:1|D-Phe:1	d-phenylalanine:14:0.6190	0.6190	14
D-RNAs	D-RNAs:9|dRNAs:7	defective RNAs:16:0.8165	0.8165	16
D-RNA	D-RNA:9|dRNA:1	defective RNA:10:0.5000	0.5000	10
dRTA	dRTA:76|DRTA:15|d-RTA:1	distal renal tubular acidosis:92:0.8903	0.8903	92
dRVVT	dRVVT:24|DRVVT:23|dRVVt:1	dilute Russell's viper venom time:28:0.7154|dilute Russell viper venom time:20:0.6680	0.7154	48
dRib	dRib:19	2-deoxy-D-ribose:19:0.8571	0.8571	19
dRpase	dRpase:9	deoxyribophosphodiesterase:9:0.7273	0.7273	9
dSSc	dSSc:11|DSSc:1	diffuse cutaneous SSc:12:0.7571	0.7571	12
dSSc	dSSc:9	diffuse cutaneous systemic sclerosis:9:0.6794	0.6794	9
dSSc	dSSc:10	diffuse SSc:10:0.1994	0.1994	10
-dT/dt	-dT/dt:6	rate of relaxation:6:0.1543	0.1543	6
dT/dt	dT/dt:16|dT/dT:1	rate of tension development:17:0.6211	0.6211	17
DTF	DTF:15	directed transfer function:15:0.8045	0.8045	15
DTF	DTF:9	dorsal tegmental field:9:0.4587	0.4587	9
dTGR	dTGR:8	human renin and angiotensinogen genes:8:0.6411	0.6411	8
dTK	dTK:9|dTk:4	deoxythymidine kinase:13:0.4849	0.4849	13
dTMP	dTMP:5	deoxythymidine 5'-monophosphate:5:0.0902	0.0902	5
dTMP	dTMP:9	deoxythymidine monophosphate:9:0.2102	0.2102	9
dTMP	dTMP:5	thymidine 5'-monophosphate:5:0.0902	0.0902	5
dTMP	dTMP:8	thymidine monophosphate:8:0.1591	0.1591	8
dTMP	dTMP:28	thymidylate:28:0.3333	0.3333	28
DTR	DTR:7	Diphtheria toxin receptor:7:0.4438	0.4438	7
dTTP	dTTP:32|DTTP:1	deoxythymidine triphosphate:33:0.4694	0.4694	33
dTTP	dTTP:7	thymidine 5'-triphosphate:7:0.1470	0.1470	7
dTTP	dTTP:17	thymidine triphosphate:17:0.1758	0.1758	17
dTC	dTC:54|dTc:50|d-TC:42|d-Tc:16|DTC:12|dtc:7|D-TC:6|D-Tc:3|d-tc:2|dtC:1	d-tubocurarine:193:0.2807	0.2807	193
DTC	DTC:94	differentiated thyroid cancer:94:0.8670	0.8670	94
DTC	DTC:131	differentiated thyroid carcinoma:122:0.9365|differentiated thyroid carcinomas:9:0.6794	0.9365	131
DTC	DTC:37	Direct-to-consumer:37:0.0526	0.0526	37
DTC	DTC:8	disseminated tumor cells:8:0.4102	0.4102	8
DTC	DTC:8|dtc:2	dithiocarbamate:10:0.0117	0.0117	10
DTC	DTC:15	sodium diethyldithiocarbamate:15:0.1495	0.1495	15
dThd	dThd:11	[3H]thymidine:11:0.0568	0.0568	11
dThd	dThd:13	Deoxythymidine:13:0.0682	0.0682	13
dUMP	dUMP:9	2'-deoxyuridine-5'-monophosphate:9:0.1212	0.1212	9
dUMP	dUMP:15	deoxyuridine monophosphate:15:0.6386	0.6386	15
dUMP	dUMP:9	deoxyuridylate:9:0.1212	0.1212	9
dUrd	dUrd:17	2'-deoxyuridine:17:0.4324	0.4324	17
dUrd	dUrd:15	deoxyuridine:15:0.3784	0.3784	15
DACA	DACA:21	N-[2-(dimethylamino)ethyl]acridine-4-carboxamide:21:0.3226	0.3226	21
dACC	dACC:7	Dorsal anterior cingulate cortex:7:0.3524	0.3524	7
Dacron	Dacron:15	polyethylene terephthalate:15:0.6386	0.6386	15
DAIS	DAIS:20	Diabetes Atherosclerosis Intervention Study:20:0.8365	0.8365	20
dansyl	dansyl:15	5-dimethylaminonaphthalene-1-sulfonyl:15:0.3182	0.3182	15
days	days:7	gestational age:7:0.1196	0.1196	7
days	days:9	hospital stay:9:0.1945	0.1945	9
db/db	db/db:21	diabetic mice:21:0.5178	0.5178	21
db/db	db/db:8	diabetic mouse:8:0.5006	0.5006	8
db/db	db/db:59|DB/DB:1	genetically diabetic:60:0.2848	0.2848	60
dbEST	dbEST:14|dBEST:1	database of Expressed Sequence Tags:15:0.4951	0.4951	15
DBT	DBT:10	deep body temperature:10:0.5000	0.5000	10
DBT	DBT:26	Dialectical Behavior Therapy:26:0.8861	0.8861	26
DBT	DBT:78	dibenzothiophene:78:0.2626	0.2626	78
DBT	DBT:6	dibutyltin dichloride:6:0.1838	0.1838	6
dcAMP	dcAMP:13|d-cAMP:3|DcAMP:2|dCAMP:1|DC-AMP:1	dibutyryl cyclic AMP:20:0.7766	0.7766	20
dcAMP	dcAMP:6|D-cAMP:3|DcAMP:2|d-cAMP:1	monophosphate:12:0.2200	0.2200	12
dcSSc	dcSSc:11|dcSSC:1|DCSSc:1|dc-SSc:1	diffuse cutaneous SSc:14:0.7909	0.7909	14
DCW	DCW:10	dry cell weight:10:0.7103	0.7103	10
ddAdo	ddAdo:18	2',3'-Dideoxyadenosine:18:0.7391	0.7391	18
ddCTP	ddCTP:8|DDCTP:1|DDC-TP:1	2',3'-dideoxycytidine 5'-triphosphate:10:0.3867	0.3867	10
ddCyd	ddCyd:24	2',3'-dideoxycytidine:24:0.8214	0.8214	24
ddNs	ddNs:9	2',3'-dideoxynucleosides:9:0.3478	0.3478	9
DD-PCR	DD-PCR:19|ddPCR:10|DDPCR:6	differential display PCR:35:0.9151	0.9151	35
DD-PCR	DD-PCR:16|ddPCR:8|DDPCR:6	differential display polymerase chain reaction:30:0.8472	0.8472	30
ddTTP	ddTTP:8	2',3'-dideoxythymidine 5'-triphosphate:8:0.2987	0.2987	8
ddTTP	ddTTP:6	dideoxythymidine triphosphate:6:0.1543	0.1543	6
DeltaG	deltaG:7|DeltaG:7	free energy change:14:0.6911	0.6911	14
deltaP	deltaP:8|DeltaP:6|delta-p:1	pressure difference:15:0.8045	0.8045	15
DeltaP	DeltaP:7|deltaP:6|Deltap:1	pressure gradient:14:0.6173	0.6173	14
Deltap	Deltap:4|deltap:1	protonmotive force:5:0.0902	0.0902	5
deltaT	deltaT:3|DeltaT:3|deltat:1|delta-T:1	temperature difference:8:0.2987	0.2987	8
delta	delta:15	androstenedione:15:0.0133	0.0133	15
Delta	Delta:8|delta:7	carbon isotope discrimination:15:0.8045	0.8045	15
delta	delta:12	chemical shifts:12:0.7571	0.7571	12
delta	delta:7	electrical distance:7:0.1850	0.1850	7
delta	delta:19|Delta:1	prism diopters:20:0.8525	0.8525	20
DENV	DENV:13	Dengue virus:13:0.6701	0.6701	13
DFR	DFR:25	delayed footpad reaction:25:0.8816	0.8816	25
DFR	DFR:30|dfr:5	dihydroflavonol 4-reductase:21:0.8594|dihydroflavonol-4-reductase:14:0.1066	0.8594	35
DFR	DFR:10	dihydroflavonol reductase:10:0.5000	0.5000	10
DG-hCG	DG-hCG:4|dghCG:2|dg-hCG:2|DGhCG:1	deglycosylated hCG:9:0.5470	0.5470	9
DHAR	DHAR:20	dehydroascorbate reductase:20:0.7766	0.7766	20
DiC8	DiC8:16|diC8:12	1,2-dioctanoyl-sn-glycerol:28:0.1656	0.1656	28
diC8	diC8:13|DiC8:7	1,2-dioctanoylglycerol:20:0.1166	0.1166	20
diC8	DiC8:21|diC8:21|di-C8:1	dioctanoylglycerol:43:0.2515	0.2515	43
diC8	diC8:15|DiC8:8|DiC-8:1|DIC8:1	sn-1,2-dioctanoylglycerol:25:0.1472	0.1472	25
DIGEST	DIGEST:12	Domestic/International Gastroenterology Surveillance Study:12:0.7357	0.7357	12
DIM	DIM:29|dim:4	3,3'-diindolylmethane:33:0.1448	0.1448	33
DIM	DIM:38|dim:2	days in milk:40:0.4046	0.4046	40
DIM	DIM:15|dim:1	diindolylmethane:16:0.0679	0.0679	16
dioxin	dioxin:25	2,3,7,8-tetrachlorodibenzo-p-dioxin:25:0.3611	0.3611	25
DIPs	DIPs:11	defective interfering particles:11:0.7357	0.7357	11
DIVA	DIVA:8|Diva:1	intravenous angiography:9:0.5470	0.5470	9
dlPAG	dlPAG:11|DLPAG:2|DL-PAG:1	dorsolateral periaqueductal gray:14:0.6173	0.6173	14
DLK	DLK:9	Deep lamellar keratoplasty:9:0.6794	0.6794	9
dlk	dlk:8|Dlk:2	delta-like:10:0.0938	0.0938	10
DLK	DLK:54	diffuse lamellar keratitis:54:0.9448	0.9448	54
DLK	DLK:9	Dual leucine zipper-bearing kinase:9:0.6794	0.6794	9
DM1	DM1:28|DM-1:3	Myotonic dystrophy:31:0.8519	0.8519	31
DM1	DM1:72|DM-1:3	Myotonic dystrophy type 1:75:0.9169	0.9169	75
DM1	DM1:9	type 1 diabetes:9:0.6794	0.6794	9
DM1	DM1:40|DM-1:3	Type 1 diabetes mellitus:43:0.9308	0.9308	43
dmPGE2	dmPGE2:14|DMPGE2:3|dm-PGE2:1	16,16-dimethyl PGE2:18:0.4672	0.4672	18
dmPGE2	dmPGE2:38|DMPGE2:13|dm-PGE2:3|DmPGE2:3	16,16-dimethyl prostaglandin E2:57:0.6798	0.6798	57
dmins	dmins:14	double minutes:14:0.7909	0.7909	14
dmins	dmins:6	double minute chromosomes:6:0.5290	0.5290	6
dmin	dmin:40|Dmin:1	double minutes:30:0.9011|Double minute:11:0.7357	0.9011	41
dmin	dmin:24	double minute chromosomes:24:0.8768	0.8768	24
Dmin	Dmin:5	minimum diameter:5:0.1132	0.1132	5
Dmin	Dmin:5	minimum target dose:5:0.4422	0.4422	5
dmnX	dmnX:22|DMNX:11|DmnX:5	dorsal motor nucleus of the vagus:38:0.9217	0.9217	38
dmnX	DMNX:5|dmnX:5|DMNx:1	dorsal motor nucleus of the vagus nerve:11:0.6182	0.6182	11
DNTs	DNTs:11|DNTS:1	dysembryoplastic neuroepithelial tumors:12:0.7571	0.7571	12
DNAs	DNAs:18	deoxyribonucleic acids:18:0.8449	0.8449	18
DNs	DNs:6	descending neurons:6:0.1543	0.1543	6
DNs	DNs:18	district nurses:18:0.7539	0.7539	18
DNS	DNS:14	dysplastic naevus syndrome:14:0.6911	0.6911	14
DNS	DNS:38	dysplastic nevus syndrome:38:0.9217	0.9217	38
DNs	DNs:20	dysplastic nodules:20:0.8525	0.8525	20
DOEs	DOEs:10	diffractive optical elements:10:0.7103	0.7103	10
DOG	DOG:21|dog:3	1,2-dioctanoyl-sn-glycerol:24:0.0659	0.0659	24
DOG	DOG:13	2-Deoxy-D-glucose:13:0.0344	0.0344	13
DOG	DOG:15	2-deoxyglucose:15:0.0401	0.0401	15
DOG	DOG:8|DoG:1	Difference-of-Gaussian:9:0.0229	0.0229	9
DOG	DOG:11	dioctanoylglycerol:11:0.0287	0.0287	11
DOTS	DOTS:18	directly observed treatment short-course:10:0.8749|directly observed treatment short course:8:0.8045	0.8749	18
DOTS	DOTS:8	directly observed treatment strategy:8:0.6411	0.6411	8
doxy	doxy:34|DOXY:2	doxycycline:36:0.8974	0.8974	36
DO	DO:8|do:1	days open:9:0.5470	0.5470	9
DO	DO:24|do:2	denuded oocytes:26:0.8861	0.8861	26
DO	DO:22|do:1	detrusor overactivity:23:0.8715	0.8715	23
DO	DO:212|do:15	dissolved oxygen:227:0.9869	0.9869	227
DO	DO:63|do:4	distraction osteogenesis:67:0.9561	0.9561	67
DO	DO:7|do:2	HLA-DO:9:0.0130	0.0130	9
do	do:9	mean lethal dose:9:0.6794	0.6794	9
dP/dt	dP/dt:5|dP/dT:3|dp/dt:3	cardiac contractility:11:0.1009	0.1009	11
dP/dt	dP/dt:42|dp/dt:4|-dP/dt:1	first derivative of left ventricular pressure:47:0.6967	0.6967	47
dP/dt	dP/dt:7|Dp/Dt:1|DP/Dt:1|dp/dt:1	left ventricular contractility:10:0.7103	0.7103	10
dP/dt	dP/dt:5	pressure with respect to time:5:0.1464	0.1464	5
dP/dt	dP/dt:4|dp/dt:3	rate of left ventricular pressure rise:7:0.3524	0.3524	7
dP/dt	dP/dt:15|dP/dT:1	rate of pressure development:16:0.4035	0.4035	16
-dP/dt	-dP/dt:13|-dP/dT:1|-dp/dt:1	rate of relaxation:15:0.2264	0.2264	15
dP/dt	dP/dt:10|dp/dt:1	rate of rise of left ventricular pressure:11:0.8525	0.8525	11
dP/dt	dP/dt:11	rate of tension development:11:0.6182	0.6182	11
DRA	DRA:11	antibodies:11:0.0575	0.0575	11
DRA	DRA:60|dra:1	dialysis-related amyloidosis:61:0.7592	0.7592	61
DRA	DRA:13|Dra:1	down-regulated in adenoma:14:0.3383	0.3383	14
DRD	DRD:59	Dopa-responsive dystonia:59:0.6656	0.6656	59
DRM	DRM:18	Deese-Roediger-McDermott:18:0.1429	0.1429	18
DRM	DRM:23	detergent-resistant membrane:15:0.6386|detergent-resistant membranes:8:0.3463	0.6386	23
DRM	DRM:9	doramectin:9:0.0672	0.0672	9
dsDNA	dsDNA:10|ds-DNA:1	deoxyribonucleic acid:11:0.4728	0.4728	11
dsDNA	dsDNA:9	double-stranded:9:0.0152	0.0152	9
dsDNA	dsDNA:336|ds-DNA:16|DSDNA:3	double-stranded DNA:355:0.6951	0.6951	355
dsRAD	dsRAD:5|DsRAD:1	double-stranded RNA adenosine deaminase:6:0.5290	0.5290	6
dsRBD	dsRBD:10	double-stranded RNA-binding domain:10:0.7103	0.7103	10
dsRNAs	dsRNAs:57|ds-RNAs:1	double-stranded RNAs:58:0.8308	0.8308	58
dsRNA	dsRNA:7|ds-RNA:2	double-stranded ribonucleic acid:9:0.4587	0.4587	9
dsRNA	dsRNA:629|ds-RNA:7|dsRna:1|DSRNA:1	Double-stranded RNA:638:0.9226	0.9226	638
DsRed	DsRed:21|dsRed:2|DsRED:1	red fluorescent protein:24:0.8768	0.8768	24
dsSIN	dsSIN:11	double subgenomic Sindbis:11:0.7357	0.7357	11
dsrAB	dsrAB:5|DsrAB:2	dissimilatory sulfite reductase:7:0.4438	0.4438	7
dsx	dsx:59|DSX:2|Dsx:1	doublesex:62:0.9104	0.9104	62
ds	ds:10|DS:1	Anti-double stranded:11:0.0548	0.0548	11
DS	DS:187|ds:2	Dahl salt-sensitive:182:0.8052|Dahl Salt Sensitive:7:0.3524	0.8052	189
DS	DS:6	Dahl salt-sensitive hypertensive:6:0.4438	0.4438	6
DS	DS:23	Dahl salt-sensitive rats:23:0.8038	0.8038	23
DS	DS:8|ds:1	dead space:9:0.2500	0.2500	9
ds	DS:5|ds:5	decayed surfaces:10:0.3867	0.3867	10
DS	DS:10	deep sclerectomy:10:0.5856	0.5856	10
DS	DS:68|ds:10	degree of substitution:64:0.6238|degrees of substitution:14:0.0712	0.6238	78
DS	DS:43|ds:4|D-S:2|Ds:1	dehydroepiandrosterone sulfate:50:0.0914	0.0914	50
DS	DS:8	depressive symptoms:8:0.4102	0.4102	8
DS	DS:198|ds:9	dermatan sulfate:207:0.4738	0.4738	207
DS	DS:66|ds:2	dermatan sulphate:68:0.4241	0.4241	68
DS	DS:22	desynchronized sleep:22:0.7400	0.7400	22
DS	DS:78|ds:17	dextran sulfate:95:0.1961	0.1961	95
DS	DS:35|ds:3	dextran sulphate:38:0.2038	0.2038	38
DS	DS:12|ds:1	diagnostic score:13:0.1423	0.1423	13
Ds	Ds:10|DS:2	diameter:12:0.0023	0.0023	12
DS	DS:28|ds:1	diameter stenosis:29:0.7970	0.7970	29
DS	DS:9|ds:1	diazepam-sensitive:10:0.0021	0.0021	10
DS	DS:35|ds:2	diclofenac sodium:37:0.6424	0.6424	37
DS	DS:18	digital subtraction:18:0.8365	0.8365	18
DS	DS:14	direct stenting:14:0.5589	0.5589	14
DS	DS:6	direction selectivity:6:0.1148	0.1148	6
DS	DS:7	directional selectivity:7:0.1850	0.1850	7
DS	DS:29|ds:2	directionally selective:31:0.8519	0.8519	31
DS	DS:79|ds:3	discriminative stimulus:82:0.9238	0.9238	82
Ds	Ds:12	Disorganization:12:0.0023	0.0023	12
DS	DS:12|ds:1	disseminated sclerosis:13:0.5335	0.5335	13
Ds	Ds:49|ds:1	Dissociation:50:0.0104	0.0104	50
DS	DS:6	distribution space:6:0.0807	0.0807	6
DS	DS:30|ds:3	disulfiram:33:0.0068	0.0068	33
DS	DS:10|ds:1	Doppler sonography:11:0.2764	0.2764	11
ds	ds:38|DS:1	double-strand:32:0.0066|double strand:7:0.2452	0.2452	39
ds	ds:686|DS:11|d-s:1	double-stranded:638:0.1352|double stranded:60:0.6766	0.6766	698
DS	DS:1370|ds:46|Ds:1|D-S:1	Down syndrome:861:0.5656|Down's syndrome:557:0.3571	0.5656	1418
DS	DS:15	duodenal switch:15:0.7096	0.7096	15
DS	DS:13|ds:2|D-S:1	duplex scanning:16:0.6577	0.6577	16
DS	DS:9	duplex sonography:9:0.1809	0.1809	9
DS	DS:8|ds:3	dyad symmetry:11:0.7357	0.7357	11
DS	DS:7|D-S:5|Ds:1|ds:1	scale:14:0.0028	0.0028	14
DS	DS:9|ds:1	sensitivity:10:0.0019	0.0019	10
dS	dS:7|ds:6|Ds:1	synonymous:14:0.0028	0.0028	14
DVs	DVs:8	distress vocalizations:8:0.5006	0.5006	8
dyl	dyl:10	dysgenetic lens:10:0.6794	0.6794	10
e.d.l.	e.d.l.:24	extensor digitorum longus:24:0.8768	0.8768	24
e.j.p.	e.j.p.:57	excitatory junction potential:57:0.9477	0.9477	57
e.j.p.s	e.j.p.s:33	excitatory junction potentials:33:0.8605	0.8605	33
e.j.ps	e.j.ps:53	Excitatory junction potentials:53:0.9438	0.9438	53
e.m.g.	e.m.g.:23|E.M.G.:1	electromyogram:24:0.4035	0.4035	24
e.m.g.	e.m.g.:21	Electromyographic:21:0.3509	0.3509	21
e.p.c.s	e.p.c.s:11	end-plate currents:11:0.6182	0.6182	11
e.p.p.s	e.p.p.s:32	End-plate potentials:32:0.6024	0.6024	32
e.p.p.	e.p.p.:23	potential:23:0.7333	0.7333	23
e.p.ps	e.p.ps:28	endplate potentials:28:0.7154	0.7154	28
e.p.r.	e.p.r.:18|E.P.R.:1	electron paramagnetic resonance:19:0.8449	0.8449	19
e.p.s.cs	e.p.s.cs:12	excitatory postsynaptic currents:12:0.7571	0.7571	12
e.p.s.p.	e.p.s.p.:44	excitatory post-synaptic potential:44:0.9323	0.9323	44
e.p.s.p.s	e.p.s.p.s:61	excitatory post-synaptic potentials:61:0.9511	0.9511	61
e.p.s.ps	e.p.s.ps:23	excitatory postsynaptic potentials:23:0.8715	0.8715	23
e.s.r.	e.s.r.:17|E.S.R.:3	electron spin resonance:20:0.8525	0.8525	20
eEF-Tu	eEF-Tu:7|eEF-TU:1	eucaryotic elongation factor Tu:8:0.4102	0.4102	8
eEF1A	eEF1A:15	elongation factor 1A:15:0.8045	0.8045	15
eEF-2K	eEF-2K:7	elongation factor-2 kinase:7:0.5926	0.5926	7
eEPSCs	eEPSCs:11	excitatory postsynaptic currents:11:0.7357	0.7357	11
E-FABP	E-FABP:24	fatty acid-binding protein:14:0.7753|fatty acid binding protein:10:0.7103	0.7753	24
eGPx	eGPx:6|E-GPx:4|EGPx:2|eGPX:2|E-GPX:1	Extracellular glutathione peroxidase:15:0.6386	0.6386	15
EH	EH:37	eclosion hormone:37:0.9197	0.9197	37
EH	EH:20	endolymphatic hydrops:20:0.8525	0.8525	20
EH	EH:19	endometrial hyperplasia:19:0.5892	0.5892	19
Eh	Eh:9|EH:4	Entamoeba histolytica:13:0.5934	0.5934	13
EH	EH:8	environmental heating:8:0.5006	0.5006	8
EH	EH:21	Epidermolytic hyperkeratosis:21:0.6040	0.6040	21
EH	EH:6	episodic hypoxia:6:0.2243	0.2243	6
EH	EH:24	epithelioid hemangioendothelioma:24:0.7151	0.7151	24
EH	EH:8	epoxide hydrase:8:0.5006	0.5006	8
EH	EH:115	epoxide hydrolase:106:0.9718|epoxide hydrolases:9:0.6794	0.9718	115
EH	EH:33	eps15 homology:33:0.7525	0.7525	33
EH	EH:11	essential hyperhidrosis:11:0.6182	0.6182	11
EH	EH:591	Essential hypertension:591:0.9841	0.9841	591
EH	EH:42	essential hypertensives:25:0.6873|essential hypertensive:17:0.6211	0.6873	42
EH	EH:13	essential hypertensive patients:13:0.4849	0.4849	13
EH	EH:9	extramedullary hematopoiesis:9:0.5470	0.5470	9
Eh	Eh:10|eH:1|EH:1	oxidation-reduction potential:12:0.0932	0.0932	12
Eh	Eh:40|eH:1	redox potential:41:0.5236	0.5236	41
eIF-4D	eIF-4D:10	initiation factor 4D:10:0.7103	0.7103	10
eIF2B	eIF2B:23|eIF-2B:8	initiation factor 2B:31:0.9043	0.9043	31
eIF-2	eIF-2:9|eIF2:3	alpha subunit of eukaryotic initiation factor 2:12:0.4951	0.4951	12
eIF-2	eIF-2:5|eIF2:1	eukaryotic initiation factor:6:0.2827	0.2827	6
eIF-2	eIF-2:21|eIF2:7	eukaryotic initiation factor-2:28:0.6057	0.6057	28
eIF3	eIF3:50|eIF-3:10|EIF-3:1	initiation factor 3:61:0.9216	0.9216	61
eIF-4A	eIF-4A:15|eIF4A:15	initiation factor 4A:30:0.8472	0.8472	30
eIF4B	eIF4B:6|eIF-4B:2	initiation factor 4B:8:0.6411	0.6411	8
eIF4F	eIF4F:18|eIF-4F:10	initiation factor 4F:28:0.8941	0.8941	28
eIF4GI	eIF4GI:7	eukaryotic initiation factor 4GI:7:0.1641	0.1641	7
eIF4GI	eIF4GI:7	eukaryotic translation initiation factor 4GI:7:0.5926	0.5926	7
eIF5	eIF5:10|eIF-5:7	Eukaryotic translation initiation factor 5:17:0.5374	0.5374	17
EII	EII:12	enzyme II:12:0.2699	0.2699	12
eIPSCs	eIPSCs:20	inhibitory postsynaptic currents:20:0.6680	0.6680	20
EI	EI:9	early intervention:9:0.2285	0.2285	9
EI	EI:115|ei:1	electron impact:103:0.8778|electron-impact:13:0.0111	0.8778	116
EI	EI:10|Ei:1	electron impact ionization:11:0.5355	0.5355	11
EI	EI:8	electron ionisation:8:0.3463	0.3463	8
EI	EI:73	electron ionization:73:0.6616	0.6616	73
EI	EI:20	emotional intelligence:20:0.8525	0.8525	20
EI	EI:8	endotracheal intubation:8:0.3463	0.3463	8
EI	EI:136	energy intake:136:0.9780	0.9780	136
EI	EI:33	enzyme I:33:0.6305	0.6305	33
EI	EI:10	enzyme-inhibitor complex:10:0.2873	0.2873	10
EI	EI:10	erythema infectiosum:10:0.7103	0.7103	10
EI	EI:115|Ei:3	index:118:0.1082	0.1082	118
eKt/V	eKt/V:15|eKT/V:1	equilibrated Kt/V:16:0.6748	0.6748	16
e-NANC	e-NANC:5|eNANC:3	excitatory nonadrenergic noncholinergic:8:0.7103	0.7103	8
E-NCAM	E-NCAM:6|eN-CAM:2|eNCAM:1	neural cell adhesion molecule:9:0.6794	0.6794	9
ePTFE	ePTFE:21|e-PTFE:7|E-PTFE:1	expanded polytetrafluorethylene:29:0.8422	0.8422	29
ePTFE	ePTFE:429|e-PTFE:79|EPTFE:31|E-PTFE:17|eptfe:1|e-PT-FE:1	expanded polytetrafluoroethylene:558:0.9023	0.9023	558
ePTFE	ePTFE:4|e-PTFE:3	expanded polytetrafluoroethylene membrane:7:0.5926	0.5926	7
eRF1	eRF1:10	Eukaryotic release factor 1:10:0.3470	0.3470	10
eRF3	eRF3:9	release factor 3:9:0.4587	0.4587	9
eSET	eSET:10	elective single embryo transfer:10:0.7103	0.7103	10
eaq-	eaq-:11	hydrated electrons:11:0.7357	0.7357	11
ear	ear:8	allergen-induced early:8:0.0625	0.0625	8
EAR	EAR:11|ear:1	aneurysm repair:12:0.6460	0.6460	12
ear	ear:13	early asthmatic reaction:13:0.7753	0.7753	13
ear	ear:28|EAR:1	early asthmatic response:29:0.8472	0.8472	29
EAR	EAR:26|ear:2	estimated average requirement:28:0.8369	0.8369	28
EAR	EAR:7	Extracellular acidification rate:7:0.3728	0.3728	7
echo	echo:42|ECHO:2	echocardiogram:32:0.0994|Echocardiograms:12:0.0353	0.0994	44
echo	echo:40|ECHO:2|Echo:1	Echocardiographic:43:0.1346	0.1346	43
echo	echo:145|ECHO:10|Echo:3	echocardiography:158:0.5032	0.5032	158
ECoG	ECoG:9|ECOG:1|EcoG:1	electrocochleogram:11:0.0099	0.0099	11
ECoG	ECoG:47|ECOG:7|EcoG:2|Ecog:1|ecog:1	Electrocochleography:58:0.0563	0.0563	58
ECoG	ECoG:44|ECOG:2	electrocortical:46:0.0445	0.0445	46
ECoG	ECoG:20|ECOG:2	electrocortical activity:22:0.4883	0.4883	22
ECoG	ECoG:199|ECOG:6|EcoG:5|ecog:1	electrocorticogram:188:0.1848|electrocorticograms:23:0.0217	0.1848	211
ECoG	ECoG:73	Electrocorticographic:73:0.0711	0.0711	73
ECoG	ECoG:26|ECOG:1	intraoperative electrocorticography:27:0.1651	0.1651	27
EEL	EEL:14	external elastic lamina:14:0.7909	0.7909	14
EGG	EGG:93	electrogastrogram:82:0.2030|Electrogastrograms:11:0.0251	0.2030	93
EGG	EGG:23	Electrogastrographic:23:0.0551	0.0551	23
EGG	EGG:155	Electrogastrography:155:0.3835	0.3835	155
EGG	EGG:9	electroglottograph:9:0.0201	0.0201	9
EGG	EGG:23	electroglottographic:23:0.0551	0.0551	23
EGG	EGG:28	electroglottography:28:0.0677	0.0677	28
EJPs	EJPs:97|ejps:7	Excitatory junction potentials:104:0.9712	0.9712	104
EJPs	EJPs:34|ejps:3	excitatory junctional potentials:37:0.9197	0.9197	37
e-mail	e-mail:46|E-mail:8|email:8|Email:1	electronic mail:63:0.9526	0.9526	63
EMFs	EMFs:150	electromagnetic fields:150:0.8087	0.8087	150
enTNF	enTNF:9|en-TNF:3	endogenous tumor necrosis factor:12:0.6460	0.6460	12
eNO	eNO:95|ENO:34|eno:8	Exhaled nitric oxide:137:0.8897	0.8897	137
ENTs	ENTs:12|ents:2|Ents:1	equilibrative nucleoside transporters:15:0.7096	0.7096	15
env	env:406|Env:6|ENV:1	envelope:413:0.5801	0.5801	413
env	env:23	envelope gene:23:0.6653	0.6653	23
env	env:104|Env:2	envelope glycoprotein:94:0.9045|envelope glycoproteins:12:0.7753	0.9045	106
env	env:8	envelope glycoprotein complex:8:0.6411	0.6411	8
env	env:75|Env:1	envelope protein:63:0.9253|envelope proteins:13:0.6701	0.9253	76
epg	epg:12|EPG:10|EpG:1	egg counts:23:0.6306	0.6306	23
epg	epg:43|EPG:31	eggs per gram:74:0.7833	0.7833	74
epg	epg:19|EPG:13	eggs per gram of faeces:32:0.7995	0.7995	32
epg	epg:13|EPG:12	eggs per gram of feces:25:0.6736	0.6736	25
epg	epg:4|EPG:3	eggs per gram of stool:7:0.5856	0.5856	7
EPG	EPG:10	electropalatographic:10:0.0244	0.0244	10
EPG	EPG:38	electropalatography:38:0.1003	0.1003	38
EPG	EPG:14	ethanolamine phosphoglycerides:14:0.7909	0.7909	14
EpiT	EpiT:4|epiT:3|EPIT:1|epi-T:1	epitestosterone:9:0.4706	0.4706	9
ErbB1	ErbB1:7|erbB1:3|erbb-1:1|ErbB-1:1|erbB-1:1	epidermal growth factor receptor:13:0.7753	0.7753	13
ER-fMRI	ER-fMRI:9|erfMRI:2	Event-related functional magnetic resonance imaging:11:0.7357	0.7357	11
ERO	ERO:14	effective regurgitant orifice:14:0.7909	0.7909	14
ery	ery:43|ERY:2|Ery:1	erythromycin:46:0.6429	0.6429	46
eta'	eta':17	dynamic viscosity:17:0.4438	0.4438	17
eut	eut:8|Eu-T:3|Eut:1	euthyroid:12:0.3056	0.3056	12
eve	eve:88|Eve:11	even-skipped:88:0.6304|even skipped:11:0.7357	0.7357	99
EXIT	EXIT:31	Ex Utero Intrapartum Treatment:31:0.9043	0.9043	31
exons	exons:6	coding regions:6:0.2243	0.2243	6
exo	exo:17|Exo:1	exonuclease:18:0.3864	0.3864	18
Exp	Exp:8|exp:4	Experiment:12:0.0724	0.0724	12
exp	exp:10|Exp:2	experimental:12:0.0724	0.0724	12
exp	exp:6	Two experiments:6:0.1010	0.1010	6
exu	exu:8|Exu:1	exuperantia:9:0.5333	0.5333	9
f(H)	f(H):13	heart rate:13:0.7753	0.7753	13
f(R)	f(R):13|F(R):2|f(r):1	frequency:16:0.5769	0.5769	16
f/VT	f/VT:4|F/Vt:1	ratio of respiratory frequency to tidal volume:5:0.4422	0.4422	5
f/tPSA	f/tPSA:5|f/t-PSA:1	free-to-total PSA ratio:6:0.3728	0.3728	6
FBAT	FBAT:17	family-based association test:17:0.5760	0.5760	17
F-BSA	F-BSA:4|f-BSA:3|FBSA:1|fBSA:1	bovine serum albumin:9:0.5470	0.5470	9
fEPSPs	fEPSPs:65|f-EPSPs:4|fEPSPS:1	field excitatory postsynaptic potentials:70:0.5838	0.5838	70
fEPSP	fEPSP:74|fepsp:2|f-EPSP:2	field excitatory postsynaptic potential:58:0.8308|field excitatory postsynaptic potentials:20:0.6259	0.8308	78
FH	FH:35|fH:22	factor H:57:0.9176	0.9176	57
FH	FH:234	familial hypercholesterolaemia:234:0.9871	0.9871	234
FH	FH:15	familial hypercholesterolaemic:15:0.8045	0.8045	15
FH	FH:760	familial hypercholesterolemia:760:0.9788	0.9788	760
FH	FH:24	familial hypercholesterolemic:24:0.8115	0.8115	24
FH	FH:85|-FH:1	family history:86:0.9272	0.9272	86
FH	FH:25	favorable histology:25:0.6240	0.6240	25
FH	FH:75	Fawn-Hooded:63:0.0328|Fawn Hooded:12:0.7571	0.7571	75
FH	FH:9	fibrous histiocytoma:9:0.6794	0.6794	9
FH	FH:18|F-H:3	Ficoll-Hypaque:21:0.0106	0.0106	21
FH	FH:52	final height:52:0.6826	0.6826	52
FH	FH:10	follicular hyperplasia:10:0.3145	0.3145	10
FH	FH:14	formin homology:14:0.6911	0.6911	14
FH	FH:7	Frankfort horizontal:7:0.2452	0.2452	7
FH	FH:51	fulminant hepatitis:51:0.9064	0.9064	51
FH	FH:18	fumarate hydratase:18:0.7658	0.7658	18
fH	fH:8|FH:1	heart frequency:9:0.2757	0.2757	9
fH	fH:42|fh:13|Fh:1	heart rate:56:0.9467	0.9467	56
FH	FH:8|Fh:2	recovery ratio:10:0.5856	0.5856	10
fMLF	fMLF:9	fMet-Leu-Phe:9:0.1481	0.1481	9
fMRI	fMRI:11|FMRI:1	functional magnetic resonance:12:0.7571	0.7571	12
fMRI	fMRI:25	functional magnetic resonance images:15:0.8045|functional magnetic resonance image:10:0.7103	0.8045	25
fMRI	fMRI:2225|FMRI:54|f-MRI:4|FM-RI:1	functional magnetic resonance imaging:2284:0.9923	0.9923	2284
fMRI	fMRI:463|FMRI:7|f-MRI:2	functional MRI:472:0.9898	0.9898	472
FQRSD	FQRSD:5|FQRSd:2|fQRSd:2|f-QRSd:2|fQRSD:1	Filtered QRS duration:12:0.7571	0.7571	12
f-QRS	f-QRS:7|fQRS:6	filtered QRS:13:0.7753	0.7753	13
fQRS	fQRS:7|f-QRS:2|FQRS:2|F-QRS:1	filtered QRS duration:12:0.7571	0.7571	12
FSpO2	FSpO2:15|fSpO2:1	oxygen saturation:16:0.7261	0.7261	16
FT(4)	FT(4):29|fT(4):6	free thyroxine:35:0.9151	0.9151	35
FVEP	FVEP:20|F-VEP:3|fVEP:2|f-VEP:2	flash visual evoked potentials:17:0.6748|flash visual evoked potential:10:0.7103	0.7103	27
FVIIa	FVIIa:58|fVIIa:1	activated factor VII:59:0.7670	0.7670	59
FVIIa	FVIIa:36	activated FVII:36:0.8336	0.8336	36
FVIIc	FVIIc:23	factor VII coagulant activity:23:0.8715	0.8715	23
FVIIc	FVIIc:12|FVIIC:1	FVII coagulant activity:13:0.1882	0.1882	13
fa/fa	fa/fa:9|Fa/Fa:1|FA/FA:1|FA/fa:1	heterozygous:12:0.0110	0.0110	12
fa/fa	fa/fa:8|Fa/Fa:1|FA/FA:1	homozygous:10:0.0100	0.0100	10
fa/fa	fa/fa:18	obese Zucker rat:18:0.4438	0.4438	18
FabG	FabG:3|fabG:3	carrier protein reductase:6:0.5926	0.5926	6
FabH	FabH:13|fabH:1	beta-ketoacyl-acyl carrier protein synthase III:14:0.5589	0.5589	14
FADD	FADD:72	Fas-associated death domain:72:0.5504	0.5504	72
FADD	FADD:56	Fas-associated death domain protein:56:0.8453	0.8453	56
FADD	FADD:14	Fas-associated protein with death domain:14:0.3383	0.3383	14
FADD	FADD:7	Fas-associating protein with death domain:7:0.1061	0.1061	7
FAIR	FAIR:50	flow-sensitive alternating inversion recovery:50:0.8776	0.8776	50
FaRP	FaRP:19	FMRFamide-related peptide:19:0.8365	0.8365	19
FASI	FASI:9	field-amplified sample injection:9:0.3455	0.3455	9
fast	fast:8|Fast:2	fast agglutination screening test:10:0.7103	0.7103	10
FAST	FAST:29	focused abdominal sonography for trauma:29:0.9011	0.9011	29
FAST	FAST:15	Functional assessment staging:15:0.8045	0.8045	15
FATS	FATS:12	Familial Atherosclerosis Treatment Study:12:0.7571	0.7571	12
FED	FED:10	first electrical discharge:10:0.5856	0.5856	10
FED	FED:20	Fish-eye disease:13:0.3809|Fish eye disease:7:0.5926	0.5926	20
FEMA	FEMA:5	performed by the Expert Panel of the Flavor and Extract Manufacturers Association:5:0.4422	0.4422	5
FiRE	FiRE:9	response element:9:0.2500	0.2500	9
FISH	FISH:387|fish:2	fluorescence in situ hybridisation:389:0.7235	0.7235	389
FISH	FISH:4799|fish:8|Fish:1	fluorescence in situ hybridization:4808:0.8071	0.8071	4808
FISH	FISH:7	fluorescence in situ hybridization technique:7:0.3524	0.3524	7
FISH	FISH:108	fluorescent in situ hybridisation:108:0.1767	0.1767	108
FISH	FISH:10	situ hybridization analysis:10:0.7103	0.7103	10
FIT	FIT:17	Fracture Intervention Trial:17:0.7407	0.7407	17
fkh	fkh:17|FKH:1	fork head:18:0.6381	0.6381	18
FK	FK:20	FK506:20:0.0936	0.0936	20
FK	FK:47|Fk:12|fk:1	forskolin:60:0.2906	0.2906	60
FK	FK:30	tacrolimus:30:0.1429	0.1429	30
FLASH	FLASH:200	fast low-angle shot:144:0.8947|fast low angle shot:56:0.7891	0.8947	200
FLASH	FLASH:6	gradient echo sequence:6:0.5290	0.5290	6
fla	fla:11	flagellar:11:0.0685	0.0685	11
fla	fla:14	flagellin:14:0.0890	0.0890	14
FLA	FLA:8|Fla:3	fluoranthene:11:0.0685	0.0685	11
FLA	FLA:5|Fl-A:1	fluorescein angiography:6:0.2243	0.2243	6
FLA	FLA:9	free-living amoebae:9:0.3455	0.3455	9
flg	flg:8|Flg:1	fibroblast growth factor receptor:9:0.6794	0.6794	9
flo	flo:9	floricaula:9:0.3478	0.3478	9
FML	FML:9	fucose-mannose ligand:9:0.3945	0.3945	9
FOCI	FOCI:7	Fibre optic confocal imaging:7:0.5926	0.5926	7
fp2	fp2:7|FP2:2|Fp2:1	reductase:10:0.4091	0.4091	10
fpMP	fpMP:6	frontal peak of Motor Potential:6:0.7103	0.7103	6
FRD	FRD:13|frd:4|Frd:3	fumarate reductase:20:0.7766	0.7766	20
free	free:9	non-protein-bound:9:0.0207	0.0207	9
free	free:15	unconjugated:15:0.0362	0.0362	15
free	free:13	unesterified:13:0.0310	0.0310	13
frq	frq:26|FRQ:13	frequency:39:0.8636	0.8636	39
fsn	fsn:16	flaky skin:16:0.8165	0.8165	16
FTCD	FTCD:9	formiminotransferase cyclodeaminase:9:0.6794	0.6794	9
fTCD	fTCD:16	Functional transcranial Doppler sonography:16:0.8165	0.8165	16
ftz	ftz:104|Ftz:8|FTZ:4	fushi tarazu:116:0.9742	0.9742	116
fvFTD	fvFTD:7|fv-FTD:3	frontal variant frontotemporal dementia:10:0.7571	0.7571	10
G(j)	G(j):9|g(j):7	junctional conductance:16:0.7261	0.7261	16
G2	G2:15	grade 2:15:0.0801	0.0801	15
G2	G2:47|G-2:5	Group 2:52:0.4682	0.4682	52
G2	G2:12|G-2:2	patients:14:0.0216	0.0216	14
G2	G2:11	second group:11:0.1612	0.1612	11
g32P	g32P:11	Gene 32 protein:11:0.7357	0.7357	11
G5	G5:9	maltopentaose:9:0.0889	0.0889	9
gCBF	gCBF:15|GCBF:1	global cerebral blood flow:16:0.8165	0.8165	16
GCG	GCG:5|GCg:3	(-)-gallocatechin gallate:8:0.2619	0.2619	8
GCG	GCG:6	Genetics Computer Group:6:0.5290	0.5290	6
gDNA	gDNA:27	genomic DNA:27:0.8312	0.8312	27
gEUD	gEUD:7|GEUD:1	generalized equivalent uniform dose:8:0.5006	0.5006	8
gIFN	gIFN:5|G-IFN:3|g-IFN:2|GIFN:1	Gamma-interferon:11:0.4545	0.4545	11
GNA	GNA:22	Galanthus nivalis agglutinin:22:0.8657	0.8657	22
GNa	GNa:7|gNa:7|-gNa:1	Na+ conductance:15:0.1462	0.1462	15
gNa	gNa:15|GNa:4|GNA:1	sodium conductance:20:0.2318	0.2318	20
GA1	GA1:23	asialo-GM1:12:0.1158|asialo GM1:11:0.4232	0.4232	23
GA1	GA1:4|GA-1:2	glutaric aciduria type 1:6:0.5290	0.5290	6
GADA	GADA:7	GAD antibody:7:0.2619	0.2619	7
GADA	GADA:48|GAD-A:1	glutamic acid decarboxylase:49:0.9027	0.9027	49
GADA	GADA:21	glutamic acid decarboxylase antibodies:21:0.8594	0.8594	21
GADA	GADA:5|GAD-A:1	glutamic acid decarboxylase autoantibodies:6:0.5290	0.5290	6
GADD	GADD:5|gadd:5	growth arrest and DNA damage-inducible:10:0.7103	0.7103	10
GAIN	GAIN:9	Glycine Antagonist in Neuroprotection:9:0.6794	0.6794	9
gain	gain:9	sensitivity:9:0.0909	0.0909	9
galE	galE:5	galactose epimerase:5:0.1132	0.1132	5
GALE	GalE:2|GALE:2|galE:1	UDP-galactose 4-epimerase:5:0.1132	0.1132	5
gamma(c)	gamma(c):14	common cytokine receptor gamma chain:14:0.7753	0.7753	14
gamma(c)	gamma(c):24	common gamma chain:15:0.2729|common gamma-chain:9:0.2757	0.2757	24
gamma-T	gamma-T:8|gammaT:8	gamma-tocopherol:16:0.7143	0.7143	16
gammac	gammac:8	common gamma-chain:8:0.4102	0.4102	8
gamma	gamma:7	Correlation coefficient:7:0.1470	0.1470	7
gamma	gamma:34	single-channel conductance:25:0.3470|single channel conductance:9:0.3455	0.3470	34
gamma	gamma:31	surface tension:31:0.7091	0.7091	31
Gas6	Gas6:11|gas6:6|GAS6:1|Gas-6:1	growth arrest-specific gene 6:19:0.8449	0.8449	19
GCAD	GCAD:19	graft coronary artery disease:19:0.8449	0.8449	19
GCR	GCR:14	galactic cosmic radiation:14:0.7909	0.7909	14
GCR	GCR:47	galactic cosmic rays:33:0.8605|galactic cosmic ray:14:0.7909	0.8605	47
GCR	GCR:55|GcR:10|GC-R:4|gcR:1	Glucocorticoid receptor:49:0.5209|glucocorticoid receptors:21:0.5721	0.5721	70
Gd-MRA	Gd-MRA:5|GD-MRA:1|gdMRA:1	magnetic resonance angiography:7:0.5926	0.5926	7
gdhA	gdhA:9|GdhA:1|GDH-A:1	glutamate dehydrogenase:11:0.6182	0.6182	11
genes	genes:6	number of variables:6:0.1320	0.1320	6
GHI	GHI:15	insensitivity:15:0.4375	0.4375	15
ghosts	ghosts:21|Ghosts:1	erythrocyte membranes:22:0.3621	0.3621	22
ghosts	ghosts:4	red cell membranes:4:0.0612	0.0612	4
GJC	GJC:42|gjc:1	gap junctional communication:43:0.9308	0.9308	43
GJ	GJ:92|Gj:5|gj:3	gap junction:56:0.9467|gap junctions:44:0.9323	0.9467	100
GJ	GJ:18	gastrojejunostomy:18:0.0653	0.0653	18
GJ	GJ:9	grapefruit juice:9:0.3945	0.3945	9
gj	gj:46|Gj:19	junctional conductance:65:0.7615	0.7615	65
GKO	GKO:11	IFN-gamma-deficient:11:0.1163	0.1163	11
glaA	glaA:11|GLAA:1	glucoamylase:12:0.3929	0.3929	12
glaA	glaA:10	glucoamylase gene:10:0.3470	0.3470	10
GLB	GLB:8|Glb:3	glibenclamide:11:0.1786	0.1786	11
glnA	glnA:17|GlnA:2	glutamine synthetase:19:0.8449	0.8449	19
glnA	glnA:9	glutamine synthetase gene:9:0.6794	0.6794	9
glnA	glnA:11	structural gene:11:0.2422	0.2422	11
Gln	Gln:226|GLN:113|gln:6	glutamine:345:0.7070	0.7070	345
Gln	Gln:17|GLN:8	L-Glutamine:25:0.0492	0.0492	25
glpD	glpD:5|GlpD:2	glycerol-3-phosphate dehydrogenase:7:0.2902	0.2902	7
GLPD	GLPD:8	granular lymphocyte-proliferative disorders:8:0.6411	0.6411	8
glpF	GlpF:6|glpF:6	facilitator:12:0.6875	0.6875	12
glpK	glpK:7|GlpK:4	glycerol kinase:11:0.7357	0.7357	11
gltA	gltA:28|glta:1|GltA:1	citrate synthase:30:0.9011	0.9011	30
gltA	gltA:16	citrate synthase gene:16:0.8165	0.8165	16
glu	glu:816|Glu:42|GLU:13	glutamate:871:0.5475	0.5475	871
glu	glu:98|Glu:2|-GLU:1|GLU:1	glutamic acid:102:0.5363	0.5363	102
glu	glu:9	glutaraldehyde:9:0.0050	0.0050	9
glu	glu:130|Glu:6|GLU:1	L-glutamate:137:0.0855	0.0855	137
glu	glu:34|Glu:1|GLU:1	L-glutamic acid:36:0.1485	0.1485	36
Glx	Glx:15	glutamate/glutamine:15:0.1892	0.1892	15
Glx	Glx:11|GLX:4|glx:4	glutamine:19:0.2297	0.2297	19
Glx	Glx:9	glutamine and glutamate:9:0.3069	0.3069	9
gly	gly:34|Gly:1	glycerol:35:0.0739	0.0739	35
gly	gly:14|Gly:1	glycogen:15:0.0304	0.0304	15
GL	GL:10|gl:2	gastrocnemius lateralis:12:0.5664	0.5664	12
Gl	Gl:14|GL:2	gastrointestinal:16:0.0198	0.0198	16
GL	GL:8|gl:2	germ-line:10:0.0119	0.0119	10
GL	GL:15|gl:2	germline:17:0.0211	0.0211	17
gl	gl:28	glomerular layer:28:0.5634	0.5634	28
gl	gl:10|GL:1	glossopharyngeal nerve:11:0.7357	0.7357	11
gl	gl:19	glucose:19:0.0237	0.0237	19
gl	gl:10	glycerol:10:0.0119	0.0119	10
gl	gl:11|GL:1	Glycolipid:12:0.0145	0.0145	12
gl	gl:12	glycoprotein L:12:0.4153	0.4153	12
gl	gl:12	glycyrrhizic acid:12:0.5664	0.5664	12
gl	gl:65|GL:18	glycyrrhizin:83:0.1054	0.1054	83
GL	GL:26	granular lymphocytes:26:0.8861	0.8861	26
GL	GL:9|gl:1	human granulosa-luteal:10:0.3867	0.3867	10
G-L	G-L:3|GL:2	human granulosa-lutein:5:0.0736	0.0736	5
GL	GL:9	lateral geniculate nucleus:9:0.6794	0.6794	9
GL	GL:8|gl:1	length:9:0.0105	0.0105	9
GL	GL:14	pulmonary conductance:14:0.3383	0.3383	14
Gmax	Gmax:12|gmax:5	conductance:17:0.4324	0.4324	17
GOAT	GOAT:17	Galveston Orientation and Amnesia Test:17:0.8365	0.8365	17
GOLD	GOLD:33|gold:2	Global Initiative for Chronic Obstructive Lung Disease:35:0.9151	0.9151	35
gp120	gp120:79	envelope glycoprotein:79:0.6033	0.6033	79
gp120	gp120:18	envelope protein:18:0.4934	0.4934	18
gp120	gp120:54	glycoprotein 120:54:0.8862	0.8862	54
gp160	gp160:14	envelope glycoprotein:14:0.3202	0.3202	14
gp160	gp160:6	envelope glycoprotein precursor:6:0.2243	0.2243	6
gp32	gp32:21|GP32:1	Gene 32 protein:22:0.7955	0.7955	22
gp330	gp330:14|Gp330:2	glycoprotein 330:16:0.8165	0.8165	16
gp39	gp39:8	CD40 ligand:8:0.6794	0.6794	8
gp41	gp41:11	glycoprotein 41:11:0.7357	0.7357	11
gp41	gp41:17	transmembrane glycoprotein:17:0.4480	0.4480	17
gp41	gp41:13	transmembrane protein:13:0.3134	0.3134	13
gp43	gp43:14	DNA polymerase:14:0.3809	0.3809	14
gp43	gp43:13|Gp43:2	glycoprotein:15:0.2258	0.2258	15
gp46	gp46:18	glycoprotein:18:0.4048	0.4048	18
gp51	gp51:10|gp-51:1	glycoprotein:11:0.5882	0.5882	11
gp52	gp52:18|Gp52:1	glycoprotein:19:0.3617	0.3617	19
gp55	gp55:11|GP55:1	membrane glycoprotein:12:0.2414	0.2414	12
gp60	gp60:12|GP60:1	glycoprotein:13:0.4286	0.4286	13
gp63	gp63:11|GP63:1|Gp63:1	major surface glycoprotein:13:0.5335	0.5335	13
gp70	gp70:21	envelope glycoprotein:21:0.3221	0.3221	21
gp71	gp71:16	glycoprotein:16:0.6250	0.6250	16
gp80	gp80:8	surface glycoprotein of Mr 80,000:8:0.6794	0.6794	8
gp85	gp85:8|Gp85:1|GP85:1	glycoprotein:10:0.4286	0.4286	10
gp90	gp90:10|GP90:6	glycoprotein:16:0.5357	0.5357	16
GPIV	GPIV:12|gpIV:1	glycoprotein IV:13:0.6701	0.6701	13
GRIP	GRIP:17	glutamate receptor-interacting protein:10:0.5000|Glutamate receptor interacting protein:7:0.4438	0.5000	17
GSA	GSA:11	activity:11:0.0420	0.0420	11
GSA	GSA:15|gsa:2	glutamate 1-semialdehyde:17:0.8270	0.8270	17
GSA	GSA:8|gsa:3|GS-A:1	group-specific antigen:12:0.4557	0.4557	12
GSA	GSA:46	guanidinosuccinic acid:46:0.7921	0.7921	46
GSA	GSA:44	serum albumin:44:0.8620	0.8620	44
gsd/gsd	gsd/gsd:5	phosphorylase b kinase-deficient:5:0.4422	0.4422	5
GUM	GUM:227	genitourinary medicine:227:0.8709	0.8709	227
gusA	gusA:31|GusA:1	beta-glucuronidase:32:0.5167	0.5167	32
gusA	gusA:9	beta-glucuronidase gene:9:0.2102	0.2102	9
gyrA	gyrA:2	gyrase subunit:2:0.3463	0.3463	2
H/I	H/I:9	hypoxia/ischemia:9:0.1778	0.1778	9
H/R	H/R:12	hypoxia and reoxygenation:12:0.3058	0.3058	12
H/R	H/R:82	hypoxia/reoxygenation:67:0.4204|hypoxia-reoxygenation:15:0.0892	0.4204	82
h/r	h/r:10|H/R:1	ratio:11:0.0637	0.0637	11
H4B	H4B:18	tetrahydrobiopterin:18:0.5312	0.5312	18
hAAT	hAAT:11	human alpha 1-antitrypsin:11:0.7357	0.7357	11
hAAT	hAAT:11	human alpha1-antitrypsin:11:0.7357	0.7357	11
hADA	hADA:12|h-ADA:2	human adenosine deaminase:14:0.7909	0.7909	14
hADM	hADM:10	adrenomedullin:10:0.9000	0.9000	10
hANF	hANF:12|h-ANF:2|HANF:1	human atrial natriuretic factor:15:0.5818	0.5818	15
hANP	hANP:103|h-ANP:8|HANP:6	human atrial natriuretic peptide:117:0.7731	0.7731	117
hANP	hANP:15	human atrial natriuretic polypeptide:15:0.5818	0.5818	15
hAPP	hAPP:7	human amyloid precursor protein:7:0.4438	0.4438	7
hARE	hARE:9	human antioxidant response element:9:0.6794	0.6794	9
HARE	HARE:11	receptor for endocytosis:11:0.7357	0.7357	11
HASMC	HASMC:14	human airway smooth muscle cells:14:0.7909	0.7909	14
HASMC	HASMC:25|hASMC:4|haSMC:3	human aortic smooth muscle cells:26:0.8251|human aortic smooth muscle cell:6:0.5290	0.8251	32
haSMC	haSMC:5|hASMC:1	human arterial smooth muscle cell:6:0.5290	0.5290	6
hBD-2	hBD-2:37|HBD-2:26|hBD2:6|HBD2:1|hbd-2:1	human beta-defensin-2:47:0.8703|human beta-defensin 2:24:0.8768	0.8768	71
hBD-3	hBD-3:6|hBD3:3|HBD-3:2	human beta-defensin 3:11:0.7357	0.7357	11
hBMP	hBMP:6|h-BMP:3	human bone morphogenetic protein:9:0.6794	0.6794	9
hBMSCs	hBMSCs:13|HBMSCs:3	human bone marrow stromal cells:16:0.8165	0.8165	16
hBNP	hBNP:17	human brain natriuretic peptide:17:0.8270	0.8270	17
hCG/LH	hCG/LH:6	human chorionic gonadotropin/luteinizing hormone:6:0.5290	0.5290	6
hCGRP	hCGRP:20|HCGRP:1	human calcitonin gene-related peptide:21:0.6040	0.6040	21
HCNP	HCNP:19	hippocampal cholinergic neurostimulating peptide:19:0.6903	0.6903	19
hCRF	hCRF:20|h-CRF:1	human corticotropin-releasing factor:21:0.8594	0.8594	21
hCRH	hCRH:5|h-CRH:3	Human corticotropin releasing hormone:8:0.5006	0.5006	8
hCRP	hCRP:9|H-CRP:1	Human C-reactive protein:10:0.5856	0.5856	10
hCTR	hCTR:10|h-CTR:1	human calcitonin receptor:11:0.7357	0.7357	11
hDAF	hDAF:39|h-DAF:1|HDAF:1	human decay accelerating factor:21:0.6812|human decay-accelerating factor:20:0.7173	0.7173	41
hDHFR	hDHFR:23|hdhfr:2	human dihydrofolate reductase:25:0.7679	0.7679	25
hDNA	hDNA:23	heteroduplex DNA:23:0.5719	0.5719	23
hEGFR	hEGFR:4|hEGF-R:2|HEGFR:1|hEGF-r:1	human epidermal growth factor receptor:8:0.6411	0.6411	8
hEGF	hEGF:158|h-EGF:15	Human epidermal growth factor:173:0.9108	0.9108	173
hENT1	hENT1:12	human equilibrative nucleoside transporter 1:12:0.6460	0.6460	12
hEPO	hEPO:16|hEpo:9|H-EPO:1	human erythropoietin:26:0.8861	0.8861	26
HERG	HERG:150|hERG:18|herg:1	human ether-a-go-go-related gene:132:0.9207|human ether-a-go-go related gene:37:0.8749	0.9207	169
H-FABP	H-FABP:73|hFABP:11|HFABP:4|h-FABP:2|h-fabp:1	fatty acid-binding protein:52:0.9099|fatty acid binding protein:39:0.8811	0.9099	91
hFIX	hFIX:26|hF-IX:1	human factor IX:27:0.4992	0.4992	27
hFSH	hFSH:58|HFSH:4	human follicle-stimulating hormone:42:0.6138|human follicle stimulating hormone:20:0.7173	0.7173	62
hFSH	hFSH:9	human follitropin:9:0.4363	0.4363	9
hFVIII	hFVIII:9	human factor VIII:9:0.3455	0.3455	9
HFL	HFL:9	human fetal lung:9:0.6794	0.6794	9
hG-CSF	hG-CSF:44	Human granulocyte colony-stimulating factor:31:0.9043|Human granulocyte-colony stimulating factor:7:0.4438|human granulocyte colony stimulating factor:6:0.3728	0.9043	44
hGH-N	hGH-N:17	growth hormone:17:0.8270	0.8270	17
hGHRH	hGHRH:10	human GH-releasing hormone:10:0.7103	0.7103	10
hGHRH	hGHRH:8|hGH-RH:3|h-GH-RH:1	human growth hormone-releasing hormone:12:0.7571	0.7571	12
hGH-V	hGH-V:7	growth hormone variant:7:0.5926	0.5926	7
hGM-CSF	hGM-CSF:53	Human granulocyte-macrophage colony-stimulating factor:39:0.8417|human granulocyte-macrophage colony stimulating factor:14:0.7909	0.8417	53
hGRF	hGRF:28	human growth hormone-releasing factor:15:0.7096|human growth hormone releasing factor:13:0.5934	0.7096	28
hGR	hGR:54	human glucocorticoid receptor:54:0.8862	0.8862	54
hGHR	hGHR:11|hGhR:1	human growth hormone receptor:12:0.6460	0.6460	12
hH1	hH1:5	cardiac sodium channels:5:0.2818	0.2818	5
hH1	hH1:14	human heart:14:0.7909	0.7909	14
hH1	hH1:7	Na+ channel:7:0.1111	0.1111	7
hHGF	hHGF:53|h-HGF:5	human hepatocyte growth factor:58:0.9486	0.9486	58
hHTg	hHTg:5|hHTG:3|HHTg:1	hereditary hypertriglyceridemic:9:0.6794	0.6794	9
hIAPP	hIAPP:19	human islet amyloid polypeptide:19:0.6537	0.6537	19
HIBM	HIBM:13|hIBM:2|h-IBM:2|H-IBM:1	hereditary inclusion body myopathy:18:0.6903	0.6903	18
hIGF-I	hIGF-I:26|hIGFI:1	human insulin-like growth factor I:17:0.8270|human insulin-like growth factor-I:10:0.7103	0.8270	27
hIL-1ra	hIL-1ra:6|hIL-1Ra:3	receptor antagonist:9:0.6794	0.6794	9
hIL-2	hIL-2:21|hIL2:1|HIL-2:1	human interleukin-2:23:0.8715	0.8715	23
hIL-3	hIL-3:11|hIL3:2	human interleukin-3:13:0.6701	0.6701	13
hIL-6	hIL-6:36|hIL6:4|h-IL-6:1	human interleukin-6:34:0.8245|human interleukin 6:7:0.4438	0.8245	41
hINV	hINV:18	Human involucrin:18:0.5228	0.5228	18
hIgG	hIgG:14|HIgG:9|h-IgG:1|H-IgG:1	human immunoglobulin G:25:0.7679	0.7679	25
hLDL	hLDL:6|h-LDL:1	Human low density lipoprotein:7:0.5926	0.5926	7
hLHR	hLHR:10	human LH receptor:10:0.5856	0.5856	10
HLH	HLH:36	haemophagocytic lymphohistiocytosis:36:0.1941	0.1941	36
HLH	HLH:236|H-L-H:3|hlh:1|h-l-h:1	helix-loop-helix:241:0.4167	0.4167	241
HLH	HLH:88	hemophagocytic lymphohistiocytosis:88:0.6107	0.6107	88
hLH	hLH:87|HLH:8	human luteinizing hormone:95:0.7012	0.7012	95
hLH	hLH:12	human lutropin:12:0.3813	0.3813	12
HLT	HLT:19|H-LT:1	heart-lung transplant:20:0.6680	0.6680	20
HLT	HLT:31	heart-lung transplantation:31:0.5414	0.5414	31
HLT	HLT:16|hLT:1	heat-labile toxin:17:0.6748	0.6748	17
hM-CSF	hM-CSF:14	human macrophage colony-stimulating factor:14:0.5589	0.5589	14
hMAM	hMAM:11|h-MAM:2	mammaglobin:13:0.8571	0.8571	13
hMBP	hMBP:9|HMBP:3|h-MBP:1	human myelin basic protein:13:0.7753	0.7753	13
hMLH1	hMLH1:8	human mutL homologue 1:8:0.6411	0.6411	8
hMOR	hMOR:9	human mu opioid receptor:9:0.6794	0.6794	9
hMSCs	hMSCs:7	Human bone marrow stromal cells:7:0.5926	0.5926	7
hMSCs	hMSCs:68|HMSCs:1	human mesenchymal stem cells:69:0.7238	0.7238	69
hMSH2	hMSH2:6	human MutS homolog 2:6:0.3728	0.3728	6
hMT-IIA	hMT-IIA:9	human metallothionein-IIA:9:0.5470	0.5470	9
hMYH	hMYH:10	human MutY homolog:10:0.7103	0.7103	10
hNET	hNET:19	human norepinephrine transporter:19:0.6537	0.6537	19
hNGF	hNGF:19	human nerve growth factor:19:0.8449	0.8449	19
hNIS	hNIS:26|h-NIS:1	human sodium iodide symporter:27:0.7425	0.7425	27
HOB	HOB:24|hOB:12|hOb:2	human osteoblasts:27:0.5524|human osteoblast:11:0.7357	0.7357	38
hOB	hOB:29|HOB:9	human osteoblast-like:38:0.8098	0.8098	38
hOB	hOB:11|HOB:8	human osteoblast-like cells:19:0.6106	0.6106	19
hOB	hOB:9|HOB:4	human osteoblastic:13:0.4849	0.4849	13
hOB	HOB:4|hOB:4	human osteoblastic cells:8:0.2987	0.2987	8
hOGG1	hOGG1:3|hOgg1:2	human 8-oxoguanine DNA glycosylase:5:0.1973	0.1973	5
hOGG1	hOGG1:7	human 8-oxoguanine DNA glycosylase 1:7:0.5926	0.5926	7
hPAH	hPAH:12	Human phenylalanine hydroxylase:12:0.7571	0.7571	12
hpAP	hpAP:9|HPAP:2|hPAP:2	human placental alkaline phosphatase:13:0.5335	0.5335	13
hPAP	hPAP:11|HPAP:1	Human prostatic acid phosphatase:12:0.5664	0.5664	12
hPBMC	hPBMC:11|HPBMC:8|H-PBMC:3|HPBMc:1	human peripheral blood mononuclear cells:23:0.8038	0.8038	23
HPg	HPg:13|HPG:4|hPg:2	human plasminogen:19:0.6537	0.6537	19
hpg	hpg:118|HPG:7	hypogonadal:125:0.3272	0.3272	125
HPG	HPG:90|H-P-G:3	hypothalamic-pituitary-gonadal:93:0.2427	0.2427	93
HPG	HPG:25	hypothalamo-pituitary-gonadal:25:0.0633	0.0633	25
HPG	HPG:9	hypothalamus-pituitary-gonadal:9:0.0211	0.0211	9
hPIV1	hPIV1:13|hPIV-1:8|HPIV-1:6|HPIV1:5	human parainfluenza virus type 1:32:0.9072	0.9072	32
hPLAP	hPLAP:10|HPLAP:4	human placental alkaline phosphatase:14:0.7909	0.7909	14
HPLP	HPLP:10	Health Promoting Lifestyle Profile:10:0.7103	0.7103	10
HPL	HPL:8	fatty acid hydroperoxide lyase:8:0.6411	0.6411	8
HPL	HPL:9	Helix pomatia lectin:9:0.6794	0.6794	9
HPL	HPL:25|hPL:3	Human pancreatic lipase:28:0.7905	0.7905	28
HPL	HPL:15	human peripheral lymphocytes:15:0.8045	0.8045	15
hPL	hPL:5|HPL:3	placental lactogen hormone:8:0.6411	0.6411	8
hPRL	hPRL:86|hPrl:7|HPRL:5|h-PRL:2	human prolactin:100:0.5392	0.5392	100
HPRL	HPRL:16|hPRL:1|h-PRL:1	hyperprolactinemia:18:0.0739	0.0739	18
HpSA	HpSA:16	Helicobacter pylori stool antigen:16:0.4274	0.4274	16
HpSA	HpSA:14|HPSA:1	stool antigen test:15:0.8045	0.8045	15
hPSTI	hPSTI:13	human pancreatic secretory trypsin inhibitor:13:0.6460	0.6460	13
hPTHrP	hPTHrP:5|hPTHrp:1	human parathyroid hormone-related peptide:6:0.2827	0.2827	6
hPTH	hPTH:73|h-PTH:5|HPTH:1	human parathyroid hormone:79:0.8875	0.8875	79
HPTH	HPTH:8|H-PTH:1	Primary hyperparathyroidism:9:0.1052	0.1052	9
HPTH	HPTH:10	secondary hyperparathyroidism:10:0.1327	0.1327	10
hPXR	hPXR:16	human pregnane X receptor:16:0.6577	0.6577	16
hRFC	hRFC:17	human reduced folate carrier:17:0.7407	0.7407	17
hREN	hREN:10|hRen:4|HREN:2	human renin:16:0.8165	0.8165	16
hSERT	hSERT:15	human serotonin transporter:15:0.4609	0.4609	15
hSHBG	hSHBG:8	human sex hormone-binding globulin:8:0.6411	0.6411	8
hSOD1	hSOD1:5|hSOD-1:3|h-SOD1:1	superoxide dismutase:9:0.5470	0.5470	9
h-SOD	h-SOD:14|hSOD:9|HSOD:2|H-SOD:1	human superoxide dismutase:26:0.4874	0.4874	26
HSPI	HSPI:7|hSPI:4	human seminal plasma inhibin:11:0.7357	0.7357	11
hTERT	hTERT:17	catalytic subunit of human telomerase:17:0.8270	0.8270	17
hTERT	hTERT:30	catalytic subunit of telomerase:30:0.7652	0.7652	30
hTERT	hTERT:37|hTert:1	human telomerase catalytic subunit:38:0.4015	0.4015	38
hTERT	hTERT:5|hTert:2	human telomerase gene:7:0.4438	0.4438	7
hTERT	hTERT:397|HTERT:2|hTeRT:1	human telomerase reverse transcriptase:400:0.8117	0.8117	400
hTERT	hTERT:11	telomerase reverse transcriptase gene:11:0.7357	0.7357	11
hTNF	hTNF:7|h-TNF:1	human tumor necrosis factor:8:0.6411	0.6411	8
hTPO	hTPO:12	human thrombopoietin:12:0.7571	0.7571	12
hTPO	hTPO:20	human thyroid peroxidase:20:0.6680	0.6680	20
hTRX	hTRX:5|hTrx:3	human thioredoxin:8:0.5006	0.5006	8
hTSHR	hTSHR:15|hTSH-R:3|hTSHr:2	human TSH receptor:20:0.7173	0.7173	20
hTSH	hTSH:26|H-TSH:1|HTSH:1|h-TSH:1	human thyroid-stimulating hormone:16:0.6577|human thyroid stimulating hormone:13:0.5335	0.6577	29
hTSH	hTSH:25|h-TSH:1	human thyrotropin:26:0.5840	0.5840	26
hUBF	hUBF:8	human upstream binding factor:8:0.6411	0.6411	8
hU-II	hU-II:14|hUII:1	human urotensin-II:15:0.7096	0.7096	15
hVDR	hVDR:23	human vitamin D receptor:23:0.8715	0.8715	23
hVEGF	hVEGF:9	human vascular endothelial growth factor:9:0.6794	0.6794	9
HVSMCs	HVSMCs:13|hVSMCs:8	human vascular smooth muscle cells:21:0.7865	0.7865	21
HVSMC	HVSMC:18|hVSMC:14|hvSMC:1	human vascular smooth muscle cells:33:0.8196	0.8196	33
HALO	HALO:29	after light onset:29:0.8978	0.8978	29
halo	halo:11	haloperidol:11:0.1333	0.1333	11
hbFGF	hbFGF:9|HbFGF:1	human basic fibroblast growth factor:10:0.7103	0.7103	10
HDP	HDP:16	high density polyethylene:9:0.6794|high-density polyethylene:7:0.1730	0.6794	16
hDP	hDP:14	human decidua-associated protein:14:0.7909	0.7909	14
HDP	HDP:10	human dental pulp:10:0.7103	0.7103	10
HDP	HDP:7	hypertensive disorders of pregnancy:7:0.6794	0.6794	7
heaves	heaves:24	recurrent airway obstruction:24:0.7249	0.7249	24
heliox	heliox:6|Heliox:2	helium-oxygen mixture:8:0.1471	0.1471	8
HELP	HELP:10	extracorporeal low-density lipoprotein precipitation:10:0.5856	0.5856	10
HELP	HELP:23	heparin-induced extracorporeal LDL precipitation:23:0.6934	0.6934	23
HELP	HELP:7	Hospitalized Elderly Longitudinal Project:7:0.5926	0.5926	7
heme	heme:4	iron protoporphyrin IX:4:0.1618	0.1618	4
HEMO	HEMO:17|hemo:11	hemodialysis:28:0.8182	0.8182	28
heroin	heroin:30|HEROIN:1	diacetylmorphine:31:0.4348	0.4348	31
hER	hER:60|her:17|HER:1	human estrogen receptor:78:0.9617	0.9617	78
HET	HET:3|het:2	Binghamton Heterogeneous:5:0.0517	0.0517	5
het	het:12	heterokaryon incompatibility:12:0.7753	0.7753	12
het	het:17|HET:1	heterozygous:18:0.1214	0.1214	18
HEt	HEt:7|het:1|HET:1	hydroethidine:9:0.0571	0.0571	9
hiNOS	hiNOS:11	human inducible nitric oxide synthase:11:0.7357	0.7357	11
high-T(c)	high-T(c):11	high-transition-temperature:11:0.7143	0.7143	11
HIM	HIM:19	health information management:19:0.8449	0.8449	19
HIM	HIM:9	hyper-IgM:9:0.0842	0.0842	9
HIM	HIM:11	inductive microenvironment:11:0.2972	0.2972	11
HITS	HITS:65	high-intensity transient signals:42:0.4929|High intensity transient signals:23:0.8038	0.8038	65
HLOD	HLOD:12|H-LOD:2|hlod:1	heterogeneity lod:15:0.6386	0.6386	15
HLOD	HLOD:8	heterogeneity LOD score:8:0.4102	0.4102	8
HMCL	HMCL:15	human myeloma cell lines:15:0.6386	0.6386	15
hmUra	hmUra:7|HmUra:6	5-hydroxymethyluracil:13:0.6316	0.6316	13
HMPS	HMPS:53|hmps:1	hexose monophosphate shunt:54:0.9458	0.9458	54
hnRNPs	hnRNPs:55	Heterogeneous nuclear ribonucleoproteins:55:0.8882	0.8882	55
hnRNP	hnRNP:199|HnRNP:1	heterogeneous nuclear ribonucleoprotein:185:0.9362|heterogeneous nuclear ribonucleoproteins:15:0.8045	0.9362	200
hnRNP	hnRNP:5|HnRNP:1	Heterogeneous nuclear ribonucleoprotein particles:6:0.4438	0.4438	6
hnRNP	hnRNP:14	heterogeneous nuclear RNP:14:0.6173	0.6173	14
HOG	HOG:10	glycerol response:10:0.5856	0.5856	10
HOG	HOG:28|hog:1	High Osmolarity Glycerol:20:0.8525|high-osmolarity glycerol:9:0.1099	0.8525	29
HOG	HOG:9	human oligodendroglioma:9:0.5470	0.5470	9
HOSE	HOSE:28|hOSE:3	human ovarian surface epithelial:31:0.9043	0.9043	31
HOSE	HOSE:12	human ovarian surface epithelium:12:0.7571	0.7571	12
HOST	HOST:14	hypo-osmotic swelling test:14:0.1717	0.1717	14
HOST	HOST:27	hypoosmotic swelling test:27:0.4837	0.4837	27
hpGRF	hpGRF:23|hp-GRF:1	human pancreatic growth hormone-releasing factor:14:0.7909|human pancreatic growth hormone releasing factor:10:0.6794	0.7909	24
HPC1	HPC1:8	hereditary prostate cancer 1:8:0.6411	0.6411	8
HRGC-MS	HRGC-MS:7	gas chromatography-mass spectrometry:7:0.5926	0.5926	7
HR-HPV	HR-HPV:14|hrHPV:3|hr-HPV:2	high-risk human papillomavirus:19:0.4852	0.4852	19
hs-CRP	hs-CRP:81|hsCRP:50|HSCRP:4|HS-CRP:2|hsC-rp:1	high-sensitivity C-reactive protein:138:0.5211	0.5211	138
hs-CRP	hs-CRP:16|hsCRP:9	high-sensitivity CRP:25:0.4315	0.4315	25
hsc70	hsc70:4|HSC70:2|Hsc70:2	heat shock cognate:8:0.6411	0.6411	8
hsc70	hsc70:10|HSC70:3|Hsc70:3	heat shock cognate 70:16:0.8165	0.8165	16
Hsc70	Hsc70:16|HSC70:14|hsc70:11	heat shock cognate protein:30:0.9043|heat-shock cognate protein:11:0.1067	0.9043	41
HSC70	HSC70:9|Hsc70:7|hsc70:5	heat shock cognate protein 70:21:0.7865	0.7865	21
HSC70	HSC70:9|Hsc70:2|hsc70:1|hsc-70:1	heat shock protein 70:13:0.7753	0.7753	13
hsp's	hsp's:8|HSP's:7|Hsp's:2|HSP'S:1	heat shock proteins:18:0.8365	0.8365	18
Hsp25	Hsp25:7|HSP25:5|hsp25:3	heat shock protein 25:15:0.8045	0.8045	15
HSP27	HSP27:40|hsp27:19|Hsp27:15|HSP-27:1	heat shock protein:75:0.9602	0.9602	75
HSP27	HSP27:82|Hsp27:30|hsp27:28|hsp-27:5|HSP-27:4|Hsp-27:3	heat shock protein 27:134:0.9644|heat shock protein-27:18:0.8365	0.9644	152
Hsp40	Hsp40:4|HSP40:1|hsp40:1	heat shock protein 40:6:0.5290	0.5290	6
hsp65	hsp65:38|HSP65:15|Hsp65:7|HSP-65:2|hsp-65:2|Hsp-65:1	heat shock protein:65:0.9047	0.9047	65
hsp65	hsp65:10|HSP65:7|HSP-65:3|Hsp65:1	heat shock protein 65:21:0.8594	0.8594	21
hsp68	hsp68:5|HSP68:1|HSP-68:1	heat shock protein:7:0.5926	0.5926	7
Hsp70s	Hsp70s:10|HSP70s:3|hsp70s:2	heat shock proteins:15:0.8045	0.8045	15
HSP70	HSP70:45|hsp70:29|Hsp70:23|HSP-70:1|hsp-70:1	70-kDa heat shock protein:79:0.2185|70-kDa heat-shock protein:20:0.1651	0.2185	99
hsp70	hsp70:3|hsp-70:2|HSP-70:1	heat shock gene:6:0.5290	0.5290	6
HSP70	HSP70:20|hsp70:15|Hsp70:10|HSP-70:3	heat shock proteins:37:0.9197|heat-shock proteins:11:0.0732	0.9197	48
HSP70	HSP70:325|hsp70:174|Hsp70:152|HSP-70:42|hsp-70:5|Hsp-70:2	heat shock protein 70:553:0.9780|heat-shock protein 70:106:0.1280|heat shock protein-70:41:0.9274	0.9780	700
hsp70	hsp70:4|HSP70:1	heat shock protein 70 gene:5:0.4422	0.4422	5
HSP70	HSP70:3|HSP-70:2|Hsp70:2|hsp70:1	heat shock protein 70 kD:8:0.6411	0.6411	8
HSP70	HSP70:4|hsp70:1	heat shock protein family:5:0.4422	0.4422	5
hsp90	hsp90:35|Hsp90:15|HSP90:13|hsp-90:3	90 kDa heat shock protein:39:0.9237|90-kDa heat-shock protein:14:0.2238|90 kDa heat-shock protein:13:0.7571	0.9237	66
HSP90	HSP90:3|Hsp90:2|hsp90:2|HSP-90:1	heat shock proteins:8:0.6411	0.6411	8
Hsp90	Hsp90:125|hsp90:65|HSP90:57|Hsp-90:4|hsp-90:1	heat shock protein 90:245:0.9620|heat shock protein-90:7:0.5926	0.9620	252
HTS	HTS:5	Ca2+ spike:5:0.1132	0.1132	5
HTS	HTS:201|HTs:1	high-throughput screening:145:0.6421|High throughput screening:57:0.8920	0.8920	202
hts	hts:8|Hts:1	hu-li tai shao:9:0.5470	0.5470	9
HTS	HTS:71	Hypertonic saline:71:0.8757	0.8757	71
HTS	HTS:8	Hypertonic saline solution:8:0.6411	0.6411	8
hu-PBL	hu-PBL:8|huPBL:7|HuPBL:1	Human peripheral blood lymphocytes:16:0.8165	0.8165	16
HUT	HUT:170	head-up tilt:170:0.8180	0.8180	170
HUT	HUT:31	head-up tilt test:31:0.8090	0.8090	31
HUT	HUT:12	head-up tilt testing:12:0.5664	0.5664	12
hut	hut:32	histidine utilization:32:0.9072	0.9072	32
HUT	HUT:8	hyperplasia of usual type:8:0.5006	0.5006	8
HUT	HUT:7	tilt table testing:7:0.5926	0.5926	7
HUV	HUV:46|hUV:3	human umbilical vein:49:0.8753	0.8753	49
HXK	HXK:12|hxk:1	hexokinase:13:0.8571	0.8571	13
hypox	hypox:103|HYPOX:19|Hypox:17|Hypo-X:3|hypoX:1	hypophysectomized:143:0.7772	0.7772	143
hypox	hypox:14|HYPOX:10|Hypox:6|HypoX:1	hypophysectomy:31:0.1630	0.1630	31
i.a.	i.a.:10	arterial:10:0.0231	0.0231	10
i.a.	i.a.:22	artery:22:0.0538	0.0538	22
i.a.	i.a.:9	injected intra-arterially:9:0.0836	0.0836	9
i.a.	i.a.:103|I.A.:5	intra-arterial:108:0.2744	0.2744	108
i.a.	i.a.:26	Intra-articular:26:0.0641	0.0641	26
i.a.	i.a.:65	Intraarterial:65:0.1641	0.1641	65
i.a.	i.a.:27	intraarterially:27:0.0667	0.0667	27
i.a.	i.a.:11|I.A.:2	intraarticular:13:0.0308	0.0308	13
i.c.v.	i.c.v.:141|I.C.V.:1	administered intracerebroventricularly:142:0.1922	0.1922	142
i.c.v.	i.c.v.:13|I.C.V.:1	cerebral ventricles:14:0.4312	0.4312	14
i.c.v.	i.c.v.:110|I.C.V.:2	injected intracerebroventricularly:112:0.1429	0.1429	112
i.c.v.	i.c.v.:1862|I.C.V.:38	intracerebroventricular:1900:0.6001	0.6001	1900
i.c.v.	i.c.v.:15	intracerebroventricular injection:15:0.3614	0.3614	15
i.c.v.	i.c.v.:39|I.C.V.:1	intraventricular:40:0.0123	0.0123	40
i.c.v.	i.c.v.:39|I.C.V.:2	lateral cerebral ventricle:41:0.6869	0.6869	41
i.c.v.	i.c.v.:20	lateral ventricle:20:0.1166	0.1166	20
i.c.v.	i.c.v.:12	morphine:12:0.0032	0.0032	12
i.c.v.	i.c.v.:14	Pretreatment:14:0.0041	0.0041	14
i.c.v	i.c.v:20	intracerebroventricular:20:0.5135	0.5135	20
i.c.	i.c.:27	after intracerebral:27:0.1200	0.1200	27
i.c.	i.c.:6	carotid artery:6:0.2243	0.2243	6
i.c.	i.c.:9	cisterna magna:9:0.5470	0.5470	9
i.c.	i.c.:12	injected intracisternally:12:0.1281	0.1281	12
i.c.	i.c.:56|I.C.:3	Intracarotid:59:0.0855	0.0855	59
i.c.	i.c.:108|I.C.:1	intracisternal:109:0.1593	0.1593	109
i.c.	i.c.:55	intracoronary:55:0.0796	0.0796	55
i.c.	i.c.:43	intracranial:43:0.0619	0.0619	43
i.c.	i.c.:15	intracutaneous:15:0.0206	0.0206	15
i.c.	i.c.:6	mice injected intracerebrally:6:0.2243	0.2243	6
i.c.	i.c.:5	mice inoculated intracerebrally:5:0.1850	0.1850	5
i.d.	i.d.:16|I.D.:5	internal diameter:21:0.4945	0.4945	21
i.d.	i.d.:138|I.D.:2	intradermal:140:0.3668	0.3668	140
i.d.	i.d.:57|I.D.:3	intradermally:60:0.1557	0.1557	60
i.d.	i.d.:41|I.D.:3	intraduodenal:44:0.1135	0.1135	44
i.d.	i.d.:9	intraduodenal administration:9:0.6794	0.6794	9
i.d.	i.d.:5	mg/kg intraduodenally:5:0.0732	0.0732	5
i.g.	i.g.:97|I.G.:2	intragastric:99:0.4876	0.4876	99
i.g.	i.g.:46|I.G.:1	intragastrically:47:0.2289	0.2289	47
i.j.p.	i.j.p.:20	inhibitory junction potential:20:0.8525	0.8525	20
i.j.ps	i.j.ps:16	inhibitory junction potentials:16:0.8165	0.8165	16
i.n.	i.n.:252	intranasal:252:0.6452	0.6452	252
i.n.	i.n.:112	intranasally:112:0.2853	0.2853	112
i.o.	i.o.:11	intraocular:11:0.3030	0.3030	11
i.p.s.p.	i.p.s.p.:12	inhibitory post-synaptic potential:12:0.7571	0.7571	12
i.p.s.p.s	i.p.s.p.s:23	inhibitory post-synaptic potentials:23:0.8715	0.8715	23
i.p.	i.p.:169|I.P.:2	administered intraperitoneally:171:0.1282	0.1282	171
i.p.	i.p.:22|I.P.:1	intra-peritoneal:23:0.0045	0.0045	23
i.p.	i.p.:2093|I.P.:25	intraperitoneal:2118:0.4320	0.4320	2118
i.p.	i.p.:56	intraperitoneal injection:56:0.3927	0.3927	56
i.p.	i.p.:10	Mice injected intraperitoneally:10:0.1202	0.1202	10
i.pl.	i.pl.:68	intraplantar:68:0.5826	0.5826	68
i.pl.	i.pl.:18	Intrapleural:18:0.1478	0.1478	18
i.p	i.p:9	intraperitoneal:9:0.1905	0.1905	9
i.r.a.	i.r.a.:8	intrarenal arterial:8:0.5006	0.5006	8
i.r.	i.r.:15	Intrarectal:15:0.1818	0.1818	15
i.t.	i.t.:40	administered intrathecally:40:0.1190	0.1190	40
i.t.	i.t.:43	injected intrathecally:43:0.1343	0.1343	43
i.t.	i.t.:6	injected intratumorally:6:0.1148	0.1148	6
i.t.	i.t.:9	injection:9:0.0058	0.0058	9
i.t.	i.t.:660|I.T.:7	intrathecal:667:0.4791	0.4791	667
i.t.	i.t.:13	intrathoracic:13:0.0086	0.0086	13
i.t.	i.t.:25	intrathymic:25:0.0173	0.0173	25
i.t.	i.t.:106|I.T.:5	Intratracheal:111:0.0791	0.0791	111
i.t.	i.t.:37	intratracheally:37:0.0259	0.0259	37
i.t.	i.t.:56|I.T.:1	intratumoral:57:0.0403	0.0403	57
i.th.	i.th.:54	intrathecal:54:0.7361	0.7361	54
i.th.	i.th.:10	intrathecally:10:0.1250	0.1250	10
i.v.Ig	i.v.Ig:27|i.v.IG:15|i.v.-IG:2	intravenous immunoglobulin:37:0.9197|intravenous immunoglobulins:7:0.3524	0.9197	44
i.v.t.	i.v.t.:15|I.V.T.:1	intracerebroventricular:16:0.1974	0.1974	16
i.v.t.	i.v.t.:30	intraventricular:30:0.3816	0.3816	30
i.v.	i.v.:177|I.V.:3	administered intravenously:180:0.1216	0.1216	180
i.v.	i.v.:12	injections:12:0.0017	0.0017	12
i.v.	i.v.:3751|I.V.:99|I.v.:1	intravenous:3851:0.5925	0.5925	3851
i.v.	i.v.:14	intravenous administration:14:0.1944	0.1944	14
i.v.	i.v.:13	intravenous infusion:13:0.2121	0.2121	13
i.v.	i.v.:26	Intravenous injection:26:0.3586	0.3586	26
i.v.	i.v.:7|I.V.:1	jugular vein:8:0.1061	0.1061	8
i.v.	i.v.:9	systemically:9:0.0012	0.0012	9
i.v	i.v:11	intravenous:11:0.4348	0.4348	11
I/A	I/A:11	irrigation/aspiration:11:0.2857	0.2857	11
I/M	I/M:11	inspection and maintenance:11:0.7357	0.7357	11
I/M	I/M:17	intima/media:17:0.1584	0.1584	17
I/M	I/M:6	intima/media ratio:6:0.1148	0.1148	6
I/M	I/M:11	intima-to-media:11:0.0990	0.0990	11
I/M	I/M:9	intimal/medial:9:0.0792	0.0792	9
I/V	I/V:58|i/V:2|i/v:1	current/voltage:45:0.5057|current-voltage:16:0.1724	0.5057	61
i3vt	i3vt:7	third cerebral ventricle:7:0.4438	0.4438	7
I-ACTH	I-ACTH:5|iACTH:2	immunoreactive ACTH:7:0.3524	0.3524	7
iANF	iANF:7|i-ANF:1	immunoreactive atrial natriuretic factor:8:0.5006	0.5006	8
iANP	iANP:8|i-ANP:1	immunoreactive atrial natriuretic peptide:9:0.6794	0.6794	9
ICGN	ICGN:11	ICR-derived glomerulonephritis:11:0.1243	0.1243	11
ICGN	ICGN:11|IC-GN:3	immune complex glomerulonephritis:14:0.7909	0.7909	14
iCGRP	iCGRP:17|i-CGRP:1	immunoreactive calcitonin gene-related peptide:18:0.6903	0.6903	18
iCGRP	iCGRP:11|i-CGRP:3	immunoreactive CGRP:14:0.7909	0.7909	14
ICT	ICT:17	connective tissue:17:0.8270	0.8270	17
ICT	ICT:47|Ict:1	contraction time:48:0.7411	0.7411	48
ICT	ICT:22	immunochromatographic test:22:0.2508	0.2508	22
iCT	iCT:59|ICT:4|I-CT:1|i-CT:1	immunoreactive calcitonin:65:0.6156	0.6156	65
iCT	iCT:9	immunoreactive CT:9:0.5470	0.5470	9
ICT	ICT:9	impression cytology with transfer:9:0.6794	0.6794	9
ICT	ICT:8	induction chemotherapy:8:0.2987	0.2987	8
ICT	ICT:57	Information and communication technology:41:0.8917|information and communication technologies:16:0.8165	0.8917	57
ICT	ICT:8|iCT:1	initial collecting tubule:9:0.6794	0.6794	9
ICT	ICT:5	intensified conventional therapy:5:0.1973	0.1973	5
ICT	ICT:7	intensified conventional treatment:7:0.5926	0.5926	7
ICT	ICT:5	intra-oral cariogenicity test:5:0.0736	0.0736	5
ICT	ICT:17|IC-T:1	intracoronary thrombolysis:18:0.6903	0.6903	18
ICT	ICT:19	intramolecular charge transfer:19:0.6106	0.6106	19
iCa2+	iCa2+:8|ICa2+:6	ionized calcium:14:0.4367	0.4367	14
iGluR	iGluR:27	ionotropic glutamate receptor:27:0.8903	0.8903	27
iGluRs	iGluRs:47	ionotropic glutamate receptors:47:0.7960	0.7960	47
iIELs	iIELs:12|i-IELs:5	intestinal intraepithelial lymphocytes:17:0.6748	0.6748	17
i-IEL	i-IEL:28|iIEL:24|I-IEL:1	intestinal intraepithelial lymphocytes:53:0.9116	0.9116	53
IK,ATP	IK,ATP:6	ATP-sensitive K+ current:6:0.3728	0.3728	6
IK1	IK1:20|iK1:2	inward rectifier:22:0.8657	0.8657	22
IK1	IK1:23|Ik1:1|iK1:1	inward rectifier K+ current:25:0.7249	0.7249	25
IK1	IK1:12|iK1:2	inwardly rectifying K+ current:14:0.4709	0.4709	14
IK1	IK1:8	K+ channel:8:0.2619	0.2619	8
IK1	IK1:7	K+ currents:7:0.2902	0.2902	7
I-LH	I-LH:11|iLH:5	immunoreactive LH:16:0.4274	0.4274	16
ILH	ILH:10	interstitial laser hyperthermia:10:0.7103	0.7103	10
IMVD	IMVD:30|iMVD:4	intratumoral microvessel density:34:0.7306	0.7306	34
i-NANC	i-NANC:4	inhibitory non-adrenergic non-cholinergic:4:0.5006	0.5006	4
i-NANC	i-NANC:6|iNANC:4|iN-ANC:2	inhibitory nonadrenergic noncholinergic:12:0.7096	0.7096	12
iNKT	iNKT:8	invariant NKT:8:0.4102	0.4102	8
iPGE2	iPGE2:6|i-PGE2:2	immunoreactive prostaglandin E2:8:0.5006	0.5006	8
iPGE	iPGE:6|I-PGE:1|iPgE:1	immunoreactive prostaglandin E:8:0.5006	0.5006	8
iPLA(2)	iPLA(2):8	calcium-independent PLA(2):8:0.1895	0.1895	8
iPLA(2)	iPLA(2):31	phospholipase A(2):31:0.9043	0.9043	31
iPLA2	iPLA2:11	Ca2+-independent PLA2:11:0.2422	0.2422	11
iPLA2	iPLA2:50	phospholipase A2:50:0.9404	0.9404	50
iPTH	iPTH:10|IPTH:2	immunoreactive parathormone:12:0.1105	0.1105	12
iPTH	iPTH:55|i-PTH:2|IPTH:2	immunoreactive PTH:59:0.3336	0.3336	59
iPTH	iPTH:23|I-PTH:1	intact parathormone:24:0.3435	0.3435	24
iPTH	iPTH:395|i-PTH:33|I-PTH:16|IPTH:13	parathyroid hormone:457:0.9652	0.9652	457
IRBs	IRBs:87	Institutional review boards:87:0.9455	0.9455	87
ISDR	ISDR:6	IFN sensitivity-determining region:6:0.1519	0.1519	6
iSDR	iSDR:9	Inducible stable DNA replication:9:0.4587	0.4587	9
ISDR	ISDR:52	interferon sensitivity determining region:36:0.7183|interferon sensitivity-determining region:16:0.3643	0.7183	52
i-TXB2	iTxB2:6|i-TXB2:6|iTXB2:5|i-TxB2:1	immunoreactive thromboxane B2:18:0.5560	0.5560	18
IVTA	IVTA:10	triamcinolone acetonide:10:0.7103	0.7103	10
ICER	ICER:59	incremental cost-effectiveness ratio:59:0.9494	0.9494	59
ICER	ICER:62	inducible cAMP early repressor:62:0.9519	0.9519	62
icv.	icv.:13	intracerebroventricular:13:0.3750	0.3750	13
icv.	icv.:10	intracerebroventricularly:10:0.2812	0.2812	10
icv	icv:1	administered either intracerebroventricularly:1:0.1583	0.1583	1
ICV	ICV:8|icv:3	cerebral ventricles:11:0.3495	0.3495	11
ICV	ICV:18	ileocecal valve:18:0.7539	0.7539	18
icv	icv:35|ICV:35	injected intracerebroventricularly:70:0.1826	0.1826	70
ICV	ICV:5	internal cerebral vein:5:0.4422	0.4422	5
ICV	ICV:761|icv:486	Intracerebroventricular:1247:0.6174	0.6174	1247
icv	icv:7|ICV:6	intracerebroventricular injection:13:0.3134	0.3134	13
ICV	ICV:25	intracranial volume:25:0.3953	0.3953	25
ICV	ICV:11|icv:7	intraventricular:18:0.0084	0.0084	18
icv	icv:9|ICV:4	intraventricularly:13:0.0059	0.0059	13
ICV	ICV:13|icv:7	lateral cerebral ventricle:20:0.3171	0.3171	20
ICV	ICV:11|icv:4	lateral ventricle:15:0.1044	0.1044	15
icv	icv:3|ICV:2	third cerebroventricle:5:0.1132	0.1132	5
IDE	IDE:6|ide:3	erythropoiesis:9:0.0352	0.0352	9
IDE	IDE:8|ide:1	inner dental epithelium:9:0.6794	0.6794	9
IDE	IDE:82|ide:34	insulin-degrading enzyme:90:0.6618|insulin degrading enzyme:26:0.8861	0.8861	116
IDE	IDE:14|ide:4	Investigational Device Exemption:18:0.6903	0.6903	18
ide	ide:9	iodipamide ethyl ester:9:0.5470	0.5470	9
IES	IES:117|ies:8|IEs:1	Impact of Event Scale:95:0.9685|Impact of Events Scale:31:0.9043	0.9685	126
IEs	IEs:5	infected erythrocytes:5:0.0517	0.0517	5
IEs	IEs:4	Plasmodium falciparum-infected erythrocytes:4:0.1618	0.1618	4
ifo	ifo:78|IFO:11|Ifo:2	ifosfamide:91:0.8333	0.8333	91
IIPMF	IIPMF:3|IIP-MF:3|iip-MF:2|iipMF:1	intra- and infrapyramidal mossy fiber:9:0.6794	0.6794	9
IleRS	IleRS:15|Ile-RS:1|ILERS:1|ileRS:1	isoleucyl-tRNA synthetase:18:0.6903	0.6903	18
ileS	ileS:7	isoleucyl-tRNA synthetase:7:0.2902	0.2902	7
ileum	ileum:15	small intestine:15:0.5818	0.5818	15
InAs	InAs:12	Indium arsenide:12:0.7571	0.7571	12
In-As	In-As:6|InAs:3	inorganic arsenic:9:0.6794	0.6794	9
indels	indels:15	insertions and deletions:15:0.7044	0.7044	15
indels	indels:8|INDELs:1|InDels:1	insertions/deletions:10:0.1429	0.1429	10
indels	indels:4|InDels:1	insertion/deletion polymorphisms:5:0.1132	0.1132	5
indel	indel:20|Indel:2|INDEL:2|InDel:1	insertion/deletion:25:0.5714	0.5714	25
ind	ind:12	indapamide:12:0.0226	0.0226	12
ind	ind:7|Ind:2	Indeterminate:9:0.0164	0.0164	9
ind	ind:171|Ind:19	indomethacin:190:0.3881	0.3881	190
IND	IND:8|ind:2	inflammatory neurological diseases:10:0.7103	0.7103	10
IND	IND:47|ind:6	intestinal neuronal dysplasia:53:0.9438	0.9438	53
IND	IND:37|ind:2	investigational new drug:39:0.8811	0.8811	39
IND	IND:19	investigational new drug application:19:0.8449	0.8449	19
inn	inn:10	innervated:10:0.1731	0.1731	10
InsP	InsP:10	inositol monophosphate:10:0.3867	0.3867	10
InsP	InsP:72|Ins-P:3|insP:1	inositol phosphate:53:0.7492|inositol phosphates:23:0.5997	0.7492	76
intein	intein:7	protein splicing element:7:0.5926	0.5926	7
IPAD	IPAD:10	integrated pulsed amperometric detection:10:0.7103	0.7103	10
IPSPs	IPSPs:474|ipsps:3|IPSPS:1	inhibitory postsynaptic potentials:478:0.9804	0.9804	478
IQ	IQ:10	2-amino-3-methyl-3H-imidazo[4,5-f]quinoline:10:0.0093	0.0093	10
IQ	IQ:25	2-amino-3-methyl-imidazo[4,5-f]quinoline:25:0.0249	0.0249	25
IQ	IQ:364|iq:5	2-amino-3-methylimidazo[4,5-f]quinoline:318:0.3278|2-amino-3-methylimidazo [4,5-f]quinoline:11:0.7357|2-amino-3-methylimidazo(4,5-f)quinoline:11:0.0104|2-amino-3-methylimidazo[4,5-f] quinoline:11:0.1430|2-amino-3-methylimidazo[4,5-f]-quinoline:9:0.0083|2-amino-3-methylimidazo-[4,5-f]quinoline:9:0.0083	0.7357	369
IQ	IQ:12	5-f]quinoline:12:0.0104	0.0104	12
IQ	IQ:10	Ilimaquinone:10:0.0093	0.0093	10
IQ	IQ:39|iq:1	intelligence:40:0.0405	0.0405	40
IQ	IQ:270|iq:2	intelligence quotient:251:0.8669|intelligence quotients:21:0.8594	0.8669	272
IQ	IQ:11	interquartile:11:0.0104	0.0104	11
ir-Dyn	ir-Dyn:5|ir-DYN:4|ir-dyn:4|IR-DYN:1	immunoreactive dynorphin:14:0.6173	0.6173	14
ir-TRH	ir-TRH:7|IR-TRH:2	immunoreactive thyrotropin-releasing hormone:9:0.5470	0.5470	9
ir-TRH	ir-TRH:22|IR-TRH:12	immunoreactive TRH:34:0.8644	0.8644	34
IR-ACTH	IR-ACTH:12|ir-ACTH:3|irACTH:2|Ir-ACTH:1	immunoreactive ACTH:18:0.6903	0.6903	18
irACTH	irACTH:4|IR-ACTH:1	immunoreactive adrenocorticotropic hormone:5:0.4422	0.4422	5
IR-ANF	IR-ANF:16|irANF:8|IRANF:1|Ir-ANF:1|ir-ANF:1	immunoreactive ANF:27:0.8903	0.8903	27
IR-ANF	IR-ANF:20|irANF:10|Ir-ANF:2|ir-ANF:1	immunoreactive atrial natriuretic factor:33:0.9100	0.9100	33
IR-ANP	IR-ANP:23|irANP:16|ir-ANP:10|IrANP:1	immunoreactive ANP:50:0.9064	0.9064	50
IR-ANP	IR-ANP:5|irANP:3|ir-ANP:2|IrANP:2	Plasma levels of immunoreactive atrial natriuretic peptide:12:0.5664	0.5664	12
ir-AVP	ir-AVP:5|irAVP:2|IR-AVP:1|Ir-AVP:1	Immunoreactive arginine vasopressin:9:0.3945	0.3945	9
irET-1	irET-1:9	immunoreactive endothelin-1:9:0.6794	0.6794	9
irET-1	irET-1:9|IRET-1:1	immunoreactive ET-1:10:0.5856	0.5856	10
ir-ET	ir-ET:19|irET:9|IR-ET:7	immunoreactive endothelin:35:0.7952	0.7952	35
irET	irET:6|IR-ET:4|ir-ET:3	immunoreactive ET:13:0.7753	0.7753	13
ir-LH-RH	ir-LH-RH:2|IR-LH-RH:2|ir-LHRH:1|IR-LHRH:1	immunoreactive luteinizing hormone-releasing hormone:6:0.5290	0.5290	6
IR-NPY	IR-NPY:3|ir-NPY:2|Ir-NPY:1|irNPY:1	Immunoreactive neuropeptide Y:7:0.6411	0.6411	7
irSP	irSP:6|IR-SP:2|ir-SP:2	immunoreactive substance P:10:0.3867	0.3867	10
IR-SRIF	IR-SRIF:13|irSRIF:1|IRSRIF:1	immunoreactive somatostatin:15:0.6386	0.6386	15
IRIS	IRIS:16	immune reconstitution inflammatory syndrome:16:0.8045	0.8045	16
IRP2	IRP2:14|IRP-2:1	iron regulatory protein 2:15:0.8045	0.8045	15
Ito1	Ito1:10|ItO1:1|ito1:1	transient outward current:12:0.7753	0.7753	12
IVC	IVC:1134	inferior vena cava:1134:0.9857	0.9857	1134
IVC	IVC:13	inferior vena cavae:8:0.6411|inferior venae cavae:5:0.4422	0.6411	13
IVC	IVC:64	inferior vena caval:64:0.9534	0.9534	64
IVC	IVC:27	inspiratory vital capacity:27:0.6455	0.6455	27
IVC	IVC:30	intravenous cholangiography:30:0.8032	0.8032	30
IV-C	IV-C:17	type IV collagen:17:0.6748	0.6748	17
IVT	IVT:24|ivt:9	intracerebroventricular:33:0.1461	0.1461	33
IVT	IVT:36|ivt:13|Ivt:3|IVt:1	Intraventricular:53:0.2420	0.2420	53
IVT	IVT:8|ivt:5	intraventricularly:13:0.0548	0.0548	13
IVT	IVT:8|ivt:1	ventricle:9:0.0365	0.0365	9
IVT	IVT:8	ventricular tachycardia:8:0.3463	0.3463	8
j/j	j/j:9	homozygous:9:0.4444	0.4444	9
JEM	JEM:40	job exposure matrix:28:0.8903|job-exposure matrix:12:0.1338	0.8903	40
JET	JET:19	Junctional ectopic tachycardia:19:0.7044	0.7044	19
jnd's	jnd's:14|JND's:1	differences:15:0.9333	0.9333	15
JNDs	JNDs:18|jnds:1	noticeable differences:19:0.5404	0.5404	19
jsd	jsd:11	juvenile spermatogonial depletion:11:0.7357	0.7357	11
JVS	JVS:35|jvs:14	juvenile visceral steatosis:49:0.9392	0.9392	49
k(1)	k(1):8|k(-1):2	rate constants:10:0.5000	0.5000	10
k(2)	k(2):26	rate constant:18:0.5940|rate constants:8:0.5470	0.5940	26
k(ass)	k(ass):7	association rate constant:7:0.5926	0.5926	7
k(cat)	k(cat):12	catalytic constant:12:0.2414	0.2414	12
k(cat)	k(cat):8	catalytic rate constant:8:0.2987	0.2987	8
k(e)	k(e):5|K(e):2	elimination rate constant:7:0.3524	0.3524	7
K(f)	K(f):10|K(F):2|k(f):1	coefficient:13:0.2143	0.2143	13
k(f)	k(f):6|K(f):4	constant:10:0.1607	0.1607	10
k(obs)	k(obs):33|K(obs):1	rate constant:20:0.6259|rate constants:14:0.6173	0.6259	34
k(obsd)	k(obsd):9	pseudo-first-order rate coefficients:9:0.6794	0.6794	9
k(off)	k(off):24	dissociation rate constant:16:0.6577|dissociation rate constants:8:0.5006	0.6577	24
k(q)	k(q):9|K(q):2|K(Q):2	constant:13:0.5455	0.5455	13
k(tr)	k(tr):7|K(tr):1|k(TR):1	force redevelopment:9:0.3945	0.3945	9
k+1	k+1:11|K+1:1	association:12:0.2115	0.2115	12
k1	k1:14|K1:8	association:22:0.0271	0.0271	22
k-1	k-1:4|K-1:1	dissociation rates:5:0.0736	0.0736	5
K1	K1:22|k1:1	keratin 1:23:0.3310	0.3310	23
K1	K1:11	kringle 1:11:0.0958	0.0958	11
K1	K1:5	ligand transport:5:0.0736	0.0736	5
K1	K1:13	phylloquinone:13:0.0155	0.0155	13
k1	k1:15|K1:10|k-1:8	rate constants:33:0.4679	0.4679	33
k2	k2:6|k-2:3|K2:1	dissociation:10:0.0201	0.0201	10
K2	K2:11|k2:1	fractional removal rate:12:0.7571	0.7571	12
K2	K2:10	kringle 2:10:0.3470	0.3470	10
k2	k2:23|k-2:2|K2:2	rate constants:27:0.7425	0.7425	27
K3	K3:6	keratin 3:6:0.1838	0.1838	6
K4	K4:16	kringle 4:16:0.2812	0.2812	16
kDNA	kDNA:128|k-DNA:8|K-DNA:2	kinetoplast DNA:138:0.8757	0.8757	138
kDa	kDa:9	120-kilodalton:9:0.0076	0.0076	9
kDa	kDa:12	50-kilodalton:12:0.0105	0.0105	12
kDa	kDa:12	60-kilodalton:12:0.0105	0.0105	12
kDa	kDa:549|KDa:2|KDA:1|Kda:1|kDA:1	kilodaltons:404:0.3845|kilodalton:150:0.1422	0.3845	554
KMS	KMS:13	Kabuki make-up syndrome:13:0.7753	0.7753	13
kMTs	kMTs:7|kMts:2|k-MTs:1	kinetochore microtubules:10:0.5856	0.5856	10
kVp	kVp:8	tube potential:8:0.3463	0.3463	8
kV	kV:8	tube voltage:8:0.2619	0.2619	8
KV	KV:9	virus:9:0.0195	0.0195	9
Kv	Kv:26|KV:4	voltage-dependent K+:22:0.1535|voltage-dependent K(+):8:0.0672	0.1535	30
Kv	Kv:18|KV:2	voltage-gated:20:0.0463	0.0463	20
Kv	Kv:56|KV:14	voltage-gated K+:47:0.4331|Voltage-gated K(+):23:0.4831	0.4831	70
Kv	Kv:20|KV:3	voltage-gated K+ channels:11:0.4728|voltage-gated K(+) channels:6:0.1838|voltage-gated K+ channel:6:0.2243	0.4728	23
Kv	Kv:51|KV:3	voltage-gated potassium:54:0.5920	0.5920	54
Kv	Kv:17|KV:2	voltage-gated potassium channels:12:0.5050|voltage-gated potassium channel:7:0.2452	0.5050	19
Kampo	Kampo:6	traditional Chinese herbal:6:0.2243	0.2243	6
kappa	kappa:4|Kappa:1	agreement beyond chance:5:0.2818	0.2818	5
kappa	kappa:17	kappa coefficient:11:0.3213|Kappa coefficients:6:0.1320	0.3213	17
kappa	kappa:31	kappa statistic:22:0.8657|kappa statistics:9:0.5470	0.8657	31
KAPP	KAPP:13	Karolinska Psychodynamic Profile:13:0.7753	0.7753	13
kapp	kapp:14|Kapp:3	rate constant:17:0.2527	0.2527	17
katG	katG:7|KatG:1	catalase-peroxidase gene:8:0.2987	0.2987	8
KatG	KatG:8|katG:1	Mycobacterium tuberculosis catalase-peroxidase:9:0.4587	0.4587	9
KAT	KAT:27	kynurenine aminotransferase:27:0.8312	0.8312	27
KBP	KBP:4	kainate binding protein:4:0.0918	0.0918	4
KBP	KBP:9	kallikrein-binding protein:9:0.1945	0.1945	9
kbp	kbp:162|Kbp:1|kBp:1	kilobase pairs:139:0.9075|kilobase pair:25:0.3161	0.9075	164
kcal	kcal:12	kilocalories:12:0.2000	0.2000	12
kcat	kcat:28|Kcat:4	catalytic constant:26:0.4574|Catalytic constants:6:0.1148	0.4574	32
kcat	kcat:7|Kcat:2	catalytic rate:9:0.1809	0.1809	9
kcat	kcat:15|Kcat:1	catalytic rate constant:12:0.5664|catalytic rate constants:4:0.0918	0.5664	16
kcat	kcat:5|Kcat:1	turnover rate:6:0.0564	0.0564	6
Kel	Kel:29|kel:25	elimination rate constant:54:0.8622	0.8622	54
KG	KG:13|kg:1	alpha-ketoglutarate:14:0.0156	0.0156	14
kg	kg:9	body fat:9:0.2500	0.2500	9
kg	kg:9|Kg:1	bodyweight:10:0.0120	0.0120	10
Kg	Kg:5|KG:4	glucose disappearance:9:0.6794	0.6794	9
Kg	Kg:6|KG:3|kg:1	glucose disappearance constant:10:0.7103	0.7103	10
KG	KG:8|Kg:5|kG:3|kg:1	glucose disappearance rate:17:0.8270	0.8270	17
Kg	KG:4|Kg:4	glucose tolerance:8:0.5006	0.5006	8
kg	kg:5|KG:5	group:10:0.0108	0.0108	10
khat	khat:7|Khat:2	Catha edulis:9:0.6794	0.6794	9
KIE	KIE:49|kie:1	kinetic isotope effect:35:0.9151|kinetic isotope effects:15:0.7096	0.9151	50
KIF	KIF:12	keratin intermediate filaments:12:0.7571	0.7571	12
Kin	Kin:9|kin:3	constant:12:0.1410	0.1410	12
kit	kit:25	c-kit receptor tyrosine kinase:25:0.5288	0.5288	25
Kit	kit:6|Kit:6|KIT:4	receptor:16:0.1327	0.1327	16
kobs	kobs:30|Kobs:1	rate constant:24:0.6427|rate constants:7:0.2113	0.6427	31
koff	koff:20|Koff:1	dissociation rate constant:21:0.6040	0.6040	21
kon	kon:15|Kon:1|kON:1	association:17:0.1818	0.1818	17
kon	kon:20|Kon:5	association rate constant:25:0.6539	0.6539	25
KpOmpA	KpOmpA:5|kpOmpA:4	Klebsiella pneumoniae:9:0.6794	0.6794	9
KTR	KTR:9|KT-R:1	kidney transplant recipients:10:0.7103	0.7103	10
ktr	ktr:7|kTR:1	rate of tension redevelopment:8:0.2987	0.2987	8
l.t.p.	l.t.p.:9|L.T.P.:1	Long-term potentiation:10:0.5856	0.5856	10
LAgP	LAgP:10|LagP:1	localized aggressive periodontitis:11:0.7357	0.7357	11
Lfng	Lfng:16|L-fng:5|l-fng:2|lfng:2|lFng:2|LFNG:1|l-Fng:1	lunatic Fringe:29:0.8978	0.8978	29
LacI	LacI:9|lacI:4	Lac repressor:13:0.3331	0.3331	13
LACI	LACI:23	Lipoprotein-associated coagulation inhibitor:23:0.7046	0.7046	23
lacO	lacO:11|LacO:1	lac operator:12:0.5050	0.5050	12
LacY	LacY:14|lacY:1	lactose permease:15:0.8045	0.8045	15
lacZ	lacZ:10|LacZ:5	bacterial beta-galactosidase gene:15:0.1061	0.1061	15
LAG	LAG:22	lymphangiography:22:0.1628	0.1628	22
LAK	LAK:1845|lak:1	lymphokine-activated killer:1475:0.7470|Lymphokine Activated Killer:354:0.8885|lymphokine-activated killers:12:0.3524|lymphokine activated killers:5:0.2818	0.8885	1846
LAK	LAK:105	lymphokine-activated killer cells:51:0.4881|lymphokine-activated killer cell:30:0.4881|lymphokine activated killer cells:24:0.7593	0.7593	105
LAK	LAK:20	lymphokine-activated killing:12:0.3058|lymphokine activated killing:8:0.6411	0.6411	20
lambda	lambda:5	Escherichia coli:5:0.1132	0.1132	5
lambda	lambda:45	partition coefficient:36:0.7183|partition coefficients:9:0.5470	0.7183	45
lambda	lambda:12	population growth rate:12:0.5664	0.5664	12
lambda	lambda:14	reorganization energy:14:0.3813	0.3813	14
L-AmB	L-AmB:6|L-AMB:2|LAMB:1	liposomal AMB:9:0.5000	0.5000	9
L-AmB	L-AmB:25|LAMB:7|L-AMB:4|l-AmB:2|LamB:1|LAmB:1	liposomal amphotericin B:40:0.7907	0.7907	40
LAMP-2	LAMP-2:7|lamp2:2|LAMP2:1|Lamp-2:1	membrane protein-2:11:0.7357	0.7357	11
LAMPs	LAMPs:20|Lamps:1|LAMPS:1	membrane proteins:22:0.8657	0.8657	22
lasat	lasat:8|Lasat:1	asplenic-athymic:9:0.4211	0.4211	9
LAST	LAST:15	Left anterior small thoracotomy:15:0.7909	0.7909	15
latex	latex:5	natural rubber:5:0.1132	0.1132	5
lcSSc	lcSSc:9|LCSSc:2|lc-SSc:1	limited cutaneous SSc:12:0.7571	0.7571	12
LCK	LCK:9|Lck:1	cell kill:10:0.7103	0.7103	10
LCK	LCK:6|Lck:1	lymphocyte-specific protein tyrosine kinase:7:0.2902	0.2902	7
lck	lck:5	tyrosine kinase p56(lck):5:0.2818	0.2818	5
lck	lck:11	tyrosine kinase p56lck:11:0.4728	0.4728	11
LCNB	LCNB:13	large-core needle biopsy:13:0.5335	0.5335	13
LDL-A	LDL-A:9|LDLA:1|LDL-a:1	Low-density lipoprotein apheresis:11:0.5355	0.5355	11
LEAD	LEAD:20	Lower extremity arterial disease:20:0.8525	0.8525	20
lectin	lectin:7	carbohydrate-binding protein:7:0.1470	0.1470	7
left	left:21	ipsilateral:21:0.0392	0.0392	21
left	left:28	unilateral:28:0.0569	0.0569	28
LESS	LESS:10	Lateral electrical surface stimulation:10:0.7103	0.7103	10
lev	lev:39|Lev:4	Levamisole:43:0.2270	0.2270	43
lev	lev:59|Lev:20	levetiracetam:79:0.4216	0.4216	79
LGG	LGG:8|L-GG:2	Lactobacillus GG:10:0.1243	0.1243	10
LGG	LGG:12	Lactobacillus rhamnosus GG:12:0.7571	0.7571	12
LGG	LGG:7	Lactobacillus rhamnosus strain GG:7:0.5926	0.5926	7
LGG	LGG:25	low-grade glioma:17:0.6748|low-grade gliomas:8:0.5006	0.6748	25
L-HCA	L-HCA:10	L-homocysteic acid:10:0.7103	0.7103	10
L-HPC	L-HPC:9	low-substituted hydroxypropylcellulose:9:0.3455	0.3455	9
Lig4	Lig4:10|LIG4:5	DNA ligase IV:15:0.8045	0.8045	15
Lin(-)	Lin(-):9|lin(-):4|LIN(-):1	lineage-negative:14:0.3611	0.3611	14
LiPA	LiPA:58|LIPA:5	line probe assay:63:0.9253	0.9253	63
lipA	lipA:5|LIPA:1	lipase gene:6:0.1148	0.1148	6
LIPID	LIPID:15	Long-Term Intervention with Pravastatin in Ischaemic Disease:15:0.6386	0.6386	15
LIPID	LIPID:12|lipid:2	Long-term Intervention with Pravastatin in Ischemic Disease:14:0.7909	0.7909	14
LIX	LIX:14	CXC chemokine:14:0.6173	0.6173	14
LLR	LLR:6	long-latency reflexes:6:0.1838	0.1838	6
LLR	LLR:8	lower lip retraction:8:0.6411	0.6411	8
LMW-PTP	LMW-PTP:11	protein tyrosine phosphatase:11:0.6182	0.6182	11
LOAD	LOAD:25	late-onset AD:25:0.5969	0.5969	25
LOAD	LOAD:34	late-onset Alzheimer's disease:34:0.6591	0.6591	34
logP	logP:20|LogP:2	partition coefficient:22:0.8657	0.8657	22
log	log:9	logarithmic:9:0.0755	0.0755	9
LOSs	LOSs:17	lipooligosaccharides:17:0.2462	0.2462	17
LpxC	LpxC:14	deacetylase:14:0.7500	0.7500	14
LSP	LSP:22	Life Skills Profile:22:0.8657	0.8657	22
LSP	LSP:12|lsp:1	liver-specific lipoprotein:13:0.1220	0.1220	13
LSP	LSP:15	liver-specific membrane lipoprotein:15:0.3821	0.3821	15
LSP	LSP:27	liver-specific protein:15:0.2119|liver specific protein:12:0.4728	0.4728	27
LTK	LTK:17	laser thermal keratoplasty:17:0.8270	0.8270	17
LTK	LTK:17	laser thermokeratoplasty:17:0.7407	0.7407	17
LTK	LTK:8|ltk:1	Leukocyte tyrosine kinase:9:0.6794	0.6794	9
lung	lung:7	remote organ:7:0.0886	0.0886	7
lung	lung:6	target organ:6:0.0522	0.0522	6
lux	lux:10	bioluminescence:10:0.1268	0.1268	10
lux	lux:11|LUX:7|Lux:2	luciferase:20:0.2676	0.2676	20
lux	lux:4	Vibrio fischeri luminescence:4:0.0918	0.0918	4
lysoPA	lysoPA:11|lyso-PA:3|Lyso-PA:1	lysophosphatidic acid:15:0.7096	0.7096	15
lyso-PC	lyso-PC:7|lysoPC:1|Lyso-PC:1	lyso-phosphatidylcholine:9:0.0280	0.0280	9
lysoPC	lysoPC:134|lyso-PC:76|lyso-Pc:10|Lyso-PC:8|LysoPC:8|lyso-pc:1|lyso--PC:1	Lysophosphatidylcholine:238:0.8287	0.8287	238
lysoPE	lysoPE:15|lyso-PE:3|LysoPE:1	lysophosphatidylethanolamine:19:0.6429	0.6429	19
lysoPI	lysoPI:9|lyso-PI:2	lysophosphatidylinositol:11:0.6250	0.6250	11
lysoPS	lysoPS:15|lyso-PS:3|LysoPS:2|Lyso-PS:1	lysophosphatidylserine:21:0.8000	0.8000	21
m(b)	m(b):5|M(b):4|M(B):3	body mass:12:0.7571	0.7571	12
m-Nif	m-Nif:12	m-nifedipine:12:0.8462	0.8462	12
m.e.p.c.s	m.e.p.c.s:23	miniature end-plate currents:23:0.8715	0.8715	23
m.e.p.cs	m.e.p.cs:8	miniature endplate currents:8:0.6411	0.6411	8
m.e.p.p.	m.e.p.p.:20	miniature end-plate potential:20:0.8525	0.8525	20
m.e.p.p.	m.e.p.p.:15	miniature endplate potential:15:0.8045	0.8045	15
m.e.p.p.s	m.e.p.p.s:37	miniature end-plate potentials:37:0.8377	0.8377	37
m.e.p.ps	m.e.p.ps:30	miniature endplate potentials:30:0.9011	0.9011	30
m.o.i.	m.o.i.:45|M.O.I.:2	multiplicity of infection:47:0.6717	0.6717	47
m.u.	m.u.:27	map units:27:0.6192	0.6192	27
m/z	m/z:13|M/Z:1	mass/charge:14:0.1327	0.1327	14
m/z	m/z:19	mass-to-charge:19:0.1837	0.1837	19
m/z	m/z:14	mass-to-charge ratio:14:0.5348	0.5348	14
m1A	m1A:9	1-methyladenosine:9:0.3478	0.3478	9
m5C	m5C:32|m5c:1	5-methylcytosine:33:0.5714	0.5714	33
m6A	m6A:16	N6-methyladenosine:16:0.3846	0.3846	16
M6	M6:10	6 months:10:0.3867	0.3867	10
m7Gua	m7Gua:11|m7-Gua:1	7-methylguanine:12:0.6111	0.6111	12
m7G	m7G:20|m-7-G:1	7-methylguanosine:21:0.4878	0.4878	21
mAAT	mAAT:6|m-AAT:3	mitochondrial:9:0.2667	0.2667	9
mAAT	mAAT:12|m-AAT:2	mitochondrial aspartate aminotransferase:14:0.6911	0.6911	14
mACON	mACON:6|m-Acon:2|m-acon:2	mitochondrial aconitase:10:0.7103	0.7103	10
mAChRs	mAChRs:135|mAchRs:4|M-AChRs:1|MAChRs:1|MAchRs:1	muscarinic acetylcholine receptors:142:0.9452	0.9452	142
mAChR	mAChR:322|mAchR:20|mACh-R:7|MAChR:6|m-AChR:5|MACHR:1|mAChr:1|M-AchR:1	muscarinic acetylcholine receptor:248:0.9273|Muscarinic acetylcholine receptors:115:0.9212	0.9273	363
mAChR	mAChR:20|MAChR:8|mAchR:2|mACHR:1|m-AchR:1	muscarinic cholinergic receptors:32:0.9072	0.9072	32
m-AECT	m-AECT:3|mAECT:3|MAECT:2	Centrifugation Technique:8:0.5006	0.5006	8
MAEC	MAEC:6	aortic endothelial cells:6:0.3728	0.3728	6
MAEC	MAEC:6|mAEC:1	monkey amniotic epithelial cells:7:0.5926	0.5926	7
MAHA	MAHA:9	Microangiopathic haemolytic anaemia:9:0.6794	0.6794	9
MAHA	MAHA:35	microangiopathic hemolytic anemia:35:0.8681	0.8681	35
mAHP	mAHP:14	afterhyperpolarization:14:0.4815	0.4815	14
m-AMPH	m-AMPH:11|mAMPH:4|M-AMPH:1	methamphetamine:16:0.9375	0.9375	16
m-AMSA	m-AMSA:71|mAMSA:10	4'-(9-acridinylamino)methanesulfon-m-anisidide:58:0.2533|4'-(9-acridinylamino)-methanesulfon-m-anisidide:14:0.0622|4'-(9-acridinylamino) methanesulfon-m-anisidide:9:0.3945	0.3945	81
mAspAT	mAspAT:6|m-AspAT:3	aspartate aminotransferase:9:0.6794	0.6794	9
mBBr	mBBr:26|MBBR:1	monobromobimane:27:0.6500	0.6500	27
MBBR	MBBR:8	moving bed biofilm reactor:8:0.6411	0.6411	8
mCG	mCG:16|MCG:1	chorionic gonadotropin:17:0.8270	0.8270	17
MCG	MCG:27	magnetocardiogram:27:0.0959	0.0959	27
MCG	MCG:29	magnetocardiographic:29:0.1033	0.1033	29
MCG	MCG:44	magnetocardiography:44:0.1587	0.1587	44
MCG	MCG:8	mast cell granules:8:0.6411	0.6411	8
MCG	MCG:13	Medical College of Georgia:13:0.7753	0.7753	13
MCG	MCG:9	membrane-coating granules:9:0.1690	0.1690	9
MCG	MCG:25	midbrain central gray:25:0.6240	0.6240	25
mCPBG	mCPBG:2|m-CPBG:1	5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide:3:0.5926	0.5926	3
m-CPBG	mCPBG:6|m-CPBG:6	m-chlorophenylbiguanide:12:0.2245	0.2245	12
MCs	MCs:196	mast cells:196:0.3939	0.3939	196
MCS	MCS:20	mechanical circulatory support:20:0.8525	0.8525	20
MCS	MCS:6	Mental Component Scale:6:0.5290	0.5290	6
MCS	MCS:11	mental component score:11:0.4728	0.4728	11
MCS	MCS:7	mesocaval shunt:7:0.3524	0.3524	7
MCs	MCs:24	microcystins:24:0.0181	0.0181	24
MCS	MCS:13	minimally conscious state:13:0.7753	0.7753	13
MCS	MCS:20	motor cortex stimulation:20:0.8525	0.8525	20
MCS	MCS:8	multicellular spheroids:8:0.2327	0.2327	8
MCS	MCS:151	multiple chemical sensitivity:110:0.9563|multiple chemical sensitivities:41:0.9274	0.9563	151
MCS	MCS:12	Multiple chemical sensitivity syndrome:12:0.7357	0.7357	12
MCS	MCS:84	multiple cloning site:68:0.9561|multiple cloning sites:16:0.8165	0.9561	84
MDU	MDU:7	mood disorders unit:7:0.5926	0.5926	7
mE-RABP	mE-RABP:7	retinoic acid-binding protein:7:0.5926	0.5926	7
mEGF	mEGF:51|m-EGF:1	Mouse epidermal growth factor:52:0.6283	0.6283	52
mEPHX	mEPHX:13|mEPHx:1	microsomal epoxide hydrolase:14:0.6911	0.6911	14
mEPSCs	mEPSCs:87|MEPSCs:4|mepscs:2	miniature excitatory postsynaptic currents:93:0.8903	0.8903	93
mEPSC	mEPSC:11	miniature EPSC:11:0.7357	0.7357	11
MF	MF:12	fibres:12:0.0040	0.0040	12
MF	MF:9	fibroblasts:9:0.0029	0.0029	9
MF	MF:9	fluid:9:0.0029	0.0029	9
MF	MF:13	force:13:0.0043	0.0043	13
MF	MF:18|Mf:2	fraction:20:0.0069	0.0069	20
MF	MF:20	idiopathic myelofibrosis:20:0.1298	0.1298	20
MF	MF:4	increase in mutation frequency:4:0.0877	0.0877	4
MF	MF:209	magnetic field:109:0.8363|magnetic fields:100:0.9525	0.9525	209
M-F	M-F:7|MF:3	male-to-female:10:0.0033	0.0033	10
MF	MF:5	marrow fibrosis:5:0.0517	0.0517	5
Mf	Mf:9|MF:3	meclofenoxate:12:0.0040	0.0040	12
MF	MF:84	median frequency:84:0.2383	0.2383	84
MF	MF:9	medium fat:9:0.2102	0.2102	9
MF	MF:24	membrane filter:24:0.6122	0.6122	24
MF	MF:11|mF:1	membrane filtration:12:0.5664	0.5664	12
MF	MF:4|mf:1	membrane fractions:5:0.0612	0.0612	5
MF	MF:31	Methyl farnesoate:31:0.9043	0.9043	31
MF	MF:28	microfilament:28:0.0098	0.0098	28
mf	mf:7|MF:4|Mf:1	microfilaremia:12:0.0040	0.0040	12
mf	mf:70|MF:13|Mf:7|mF:1	microfilaria:91:0.0326	0.0326	91
mf	mf:188|Mf:44|MF:17	microfilariae:249:0.0899	0.0899	249
mf	mf:28|Mf:5|MF:4	Microfilarial:37:0.0130	0.0130	37
MF	MF:38	microfiltration:38:0.0134	0.0134	38
MF	MF:7|Mf:5	Micropolyspora faeni:12:0.6460	0.6460	12
MF	MF:9	mid-frequency:9:0.0029	0.0029	9
MF	MF:7	milk fat:7:0.1111	0.1111	7
MF	MF:32	mitogenic factor:26:0.3766|mitogenic factors:6:0.2243	0.3766	32
MF	MF:9	mitotic figures:9:0.5470	0.5470	9
MF	MF:6	mitral flow:6:0.0807	0.0807	6
MF	MF:44	mometasone furoate:44:0.8941	0.8941	44
MF	MF:14	morphogenetic furrow:14:0.7909	0.7909	14
MF	MF:69|mf:4	Mossy fiber:61:0.7198|mossy fibers:12:0.1299	0.7198	73
MF	MF:9	mossy fibre:9:0.5470	0.5470	9
MF	MF:9	mother-fed:9:0.0029	0.0029	9
MF	MF:11	muscle fibers:11:0.1098	0.1098	11
MF	MF:108|Mf:18|mf:1|mF:1	mutant frequency:109:0.3227|mutant frequencies:19:0.4405	0.4405	128
MF	MF:503|Mf:1	mycosis fungoides:504:0.9905	0.9905	504
MF	MF:9	myelinated fibers:9:0.0713	0.0713	9
MF	MF:13|Mf:3	myofibroblasts:16:0.0054	0.0054	16
MF	MF:6	sequential methotrexate and 5-fluorouracil:6:0.2827	0.2827	6
mGM-CSF	mGM-CSF:19	granulocyte-macrophage colony-stimulating factor:19:0.7658	0.7658	19
mGPD	mGPD:7	mitochondrial glycerol phosphate dehydrogenase:7:0.5926	0.5926	7
mGST	mGST:5|MGST:3	Microsomal glutathione S-transferase:8:0.5006	0.5006	8
mGluR1	mGluR1:14	metabotropic glutamate receptor:14:0.7909	0.7909	14
mGluR1	mGluR1:17	metabotropic glutamate receptor subtype 1:17:0.7407	0.7407	17
mGluR2	mGluR2:5	Metabotropic glutamate receptor 2:5:0.4422	0.4422	5
mGluR5	mGluR5:35	metabotropic glutamate receptor 5:35:0.9151	0.9151	35
mGluR5	mGluR5:33	metabotropic glutamate receptor subtype 5:33:0.9100	0.9100	33
mGluRs	mGluRs:87	group I metabotropic glutamate receptors:87:0.8973	0.8973	87
mGluR	mGluR:453|mGLUR:1|mGlu-R:1	metabotropic glutamate receptor:381:0.9921|metabotropic glutamate receptors:74:0.9159	0.9921	455
mGnRH	mGnRH:23|m-GnRH:1	mammalian GnRH:24:0.7151	0.7151	24
mGnRH	mGnRH:14|MGnRH:1	mammalian gonadotropin-releasing hormone:15:0.6386	0.6386	15
mHags	mHags:23|mHAgs:12	minor histocompatibility antigens:35:0.9151	0.9151	35
mHag	mHag:18|mHAg:7	minor histocompatibility antigens:13:0.7753|minor histocompatibility antigen:12:0.7571	0.7753	25
MII	MII:204|M-II:20|mII:5	metaphase II:220:0.6914|Metaphase-II:9:0.0188	0.6914	229
MII	MII:11	Multichannel intraluminal impedance:11:0.4728	0.4728	11
mIL-3	mIL-3:9	interleukin-3:9:0.5333	0.5333	9
mIL-12	mIL-12:10|mIL12:1	murine interleukin-12:11:0.4232	0.4232	11
mIL-2	mIL-2:8|mIL2:3|MIL-2:2	murine interleukin-2:13:0.5335	0.5335	13
mIL-6	mIL-6:9	Murine interleukin-6:9:0.5470	0.5470	9
mIMCD-3	mIMCD-3:6|mIMCD3:3	collecting duct cells:9:0.6794	0.6794	9
mIMCD3	mIMCD3:14|mIMCD-3:12	inner medullary collecting duct:26:0.7760	0.7760	26
mIPSC	mIPSC:9	miniature IPSC:9:0.6794	0.6794	9
mIPSCs	mIPSCs:106|MIPSCs:1	miniature inhibitory postsynaptic currents:107:0.9156	0.9156	107
mIgA	mIgA:13|m-IgA:7	Monomeric IgA:20:0.7766	0.7766	20
mIgM	mIgM:31	membrane IgM:31:0.5749	0.5749	31
mIgM	mIgM:10	membrane immunoglobulin M:10:0.5000	0.5000	10
MLAP	MLAP:8|mLAP:2	mean left atrial pressure:10:0.7103	0.7103	10
mM-CSF	mM-CSF:5|m-M-CSF:1	macrophage colony-stimulating factor:6:0.5290	0.5290	6
mMDH	mMDH:28|m-MDH:1	Mitochondrial malate dehydrogenase:29:0.8422	0.8422	29
mMT-I	mMT-I:10	mouse metallothionein-I:10:0.7103	0.7103	10
MoDC	MoDC:14|Mo-DC:8|moDC:5|MODC:2|mo-DC:1	monocyte-derived DC:30:0.7652	0.7652	30
MoDC	MoDC:22|Mo-DC:6|moDC:3|MO-DC:2|mo-DC:1	monocyte-derived dendritic cells:34:0.7898	0.7898	34
mPaw	mPaw:4|MPAW:2|Mpaw:1|MPaw:1	mean airway pressure:8:0.6411	0.6411	8
mPFC	mPFC:324|MPFC:72|mPFc:9|mPfc:3|mpFC:2|MpFC:1	medial prefrontal cortex:411:0.9675	0.9675	411
mPGES	mPGES:10	microsomal PGES:10:0.3867	0.3867	10
mPGES	mPGES:10	prostaglandin E synthase:10:0.5856	0.5856	10
mPGES-1	mPGES-1:9|mPGEs1:1	microsomal prostaglandin E synthase-1:10:0.5856	0.5856	10
mPL-II	mPL-II:11	mouse placental lactogen-II:11:0.7357	0.7357	11
M-PLA2	M-PLA2:10|mPLA2:1	phospholipase A2:11:0.7357	0.7357	11
MPOA/AH	MPOA/AH:5|mPOA/AH:3	medial preoptic area/anterior hypothalamus:8:0.6411	0.6411	8
MPOA	MPOA:376|mPOA:104|mpoa:2	medial preoptic area:482:0.9722	0.9722	482
mPSDp	mPSDp:5	major postsynaptic density protein:5:0.4422	0.4422	5
mRNA's	mRNA's:9	messenger RNA's:9:0.6794	0.6794	9
mRNAs	mRNAs:93|MRNAs:1	messenger ribonucleic acids:94:0.9682	0.9682	94
mRNAs	mRNAs:445|m-RNAs:1	messenger RNAs:446:0.9790	0.9790	446
mRNA	mRNA:14	gene expression:14:0.2892	0.2892	14
mRNA	mRNA:889|m-RNA:2|MRNA:1	messenger ribonucleic acid:892:0.9911	0.9911	892
mRNA	mRNA:4671|MRNA:3|m-RNA:2	messenger RNA:4665:0.9808|messenger-RNA:11:0.0017	0.9808	4676
mRNA	mRNA:29	Messenger RNAs:29:0.8978	0.8978	29
mRNP	mRNP:56	Messenger ribonucleoprotein:56:0.8067	0.8067	56
mRNP	mRNP:13	messenger ribonucleoprotein particles:7:0.3524|messenger ribonucleoprotein particle:6:0.3728	0.3728	13
mRNPs	mRNPs:18	Messenger ribonucleoprotein particles:18:0.7539	0.7539	18
mRNPs	mRNPs:7	ribonucleoprotein complexes:7:0.2113	0.2113	7
MROD	MROD:6	7-methoxyresorufin O-demethylation:6:0.1838	0.1838	6
mTALH	mTALH:8	medullary thick ascending limb of Henle's loop:8:0.4102	0.4102	8
mTALH	mTALH:8	thick ascending limb of the loop of Henle:8:0.6411	0.6411	8
mTERF	mTERF:14	mitochondrial transcription termination factor:14:0.6911	0.6911	14
MTHF	MTHF:10	5-methyltetrahydrofolate:10:0.1875	0.1875	10
mTHPC	mTHPC:1	hydroxyphenyl chlorin:1:0.1367	0.1367	1
mTHPC	mTHPC:16|m-THPC:3	meta-tetra(hydroxyphenyl)chlorin:19:0.1250	0.1250	19
mTHPC	mTHPC:16|m-THPC:4	meta-tetrahydroxyphenylchlorin:20:0.1397	0.1397	20
mTOR	mTOR:308|m-TOR:1|mTor:1	mammalian target of rapamycin:310:0.9064	0.9064	310
MT-SP1	MT-SP1:7	serine protease 1:7:0.4438	0.4438	7
mUPD7	mUPD7:5	maternal uniparental disomy of chromosome 7:5:0.5926	0.5926	5
MAP1	MAP-1:2|MAP1:2|map1:1	major antigenic protein:5:0.4422	0.4422	5
MAP-1	MAP-1:7	microtubule-associated protein-1:7:0.3524	0.3524	7
MAFA	MAFA:19	mast cell function-associated antigen:19:0.8449	0.8449	19
Mal-BSA	Mal-BSA:5|mal-BSA:2|MAL-BSA:1	maleylated bovine serum albumin:8:0.6411	0.6411	8
MalE	MalE:21|malE:4	maltose-binding protein:19:0.4618|maltose binding protein:6:0.3728	0.4618	25
MAN	MAN:11|man:1	magnocellular nucleus of the anterior neostriatum:12:0.7571	0.7571	12
man	man:19	mannitol:19:0.0717	0.0717	19
MAN	MAN:8	medial amygdaloid nucleus:8:0.6411	0.6411	8
MAN	MAN:10	medial articular nerve:10:0.7103	0.7103	10
MAN	MAN:7|man:2	Methacrylonitrile:9:0.0319	0.0319	9
MBE	MBE:9|mbe:1	Molecular beam epitaxy:10:0.7103	0.7103	10
mda-7	mda-7:20|MDA-7:1	melanoma differentiation-associated gene-7:11:0.7357|melanoma differentiation associated gene-7:10:0.5856	0.7357	21
mdg	mdg:23|MDG:2	muscular dysgenesis:25:0.8816	0.8816	25
mdx	mdx:100|MDX:2	dystrophic:102:0.4654	0.4654	102
mdx	mdx:9|MDX:1	dystrophic mouse:10:0.4363	0.4363	10
mdx	mdx:26|MDX:1	dystrophin-deficient:27:0.1198	0.1198	27
mdx	mdx:5	dystrophin-deficient mice:5:0.1132	0.1132	5
mdx	mdx:27|MDX:3	muscular dystrophy:30:0.8472	0.8472	30
MeCCNU	MeCCNU:10|Me-CCNU:3	1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea:13:0.1935	0.1935	13
MeCCNU	MeCCNU:8|Me-CCNU:1	1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea:9:0.1290	0.1290	9
M-ECT	M-ECT:7|MECT:2|mECT:1	maintenance electroconvulsive therapy:10:0.5000	0.5000	10
medfly	medfly:11|Medfly:4	Mediterranean fruit fly:15:0.8045	0.8045	15
MelB	MelB:10	melibiose permease:10:0.7103	0.7103	10
MEPP	MEPP:65|mepp:9	miniature end-plate potential:53:0.9438|miniature end-plate potentials:21:0.7865	0.9438	74
MEPP	MEPP:62|mepp:7|mEPP:3|Mepp:1	miniature endplate potential:63:0.9526|miniature endplate potentials:10:0.7103	0.9526	73
MerA	MerA:6|merA:4	mercuric reductase:10:0.3470	0.3470	10
mesDA	mesDA:7|MesDA:1	mesencephalic dopaminergic:8:0.5006	0.5006	8
MesPGN	MesPGN:12|mesPGN:5|mes-PGN:2	mesangial proliferative glomerulonephritis:19:0.8449	0.8449	19
Met-Enk	Met-Enk:66|met-enk:23|Met-enk:16|Met-ENK:11|MET-ENK:5|met-Enk:3|met-ENK:2|MET-enk:1	methionine-enkephalin:104:0.4858|methionine enkephalin:23:0.8038	0.8038	127
mev/mev	mev/mev:12	viable motheaten:12:0.7571	0.7571	12
mfERGs	mfERGs:10|MF-ERGs:1	multifocal electroretinograms:11:0.7357	0.7357	11
mfVEP	mfVEP:11	Multifocal Visual Evoked Potential:11:0.7357	0.7357	11
mfVSG	mfVSG:10|mf-VSG:1	variant surface glycoprotein:11:0.6182	0.6182	11
mg/dl	mg/dl:4|mg/dL:2	total bilirubin:6:0.1838	0.1838	6
mg/kg	mg/kg:11	body weight:11:0.3495	0.3495	11
mg/kg	mg/kg:11	concentrations:11:0.0388	0.0388	11
mg/kg	mg/kg:9	ED50 values:9:0.1585	0.1585	9
mg/L	mg/L:21|mg/l:12	concentrations:33:0.1416	0.1416	33
mhsp70	mHsp70:5|mhsp70:5	mitochondrial hsp70:10:0.5000	0.5000	10
mi/mi	mi/mi:21	microphthalmic:21:0.4255	0.4255	21
mi/mi	mi/mi:13	osteopetrotic:13:0.2553	0.2553	13
MiHA	MiHA:11|miHA:6|MIHA:5	minor histocompatibility antigens:22:0.7955	0.7955	22
Mini	Mini:34|mini:2|MINI:2	Mini International Neuropsychiatric Interview:38:0.9197	0.9197	38
min	min:9	30 minutes:9:0.1009	0.1009	9
min	min:18	duration:18:0.0377	0.0377	18
min	min:33	medial interlaminar nucleus:33:0.9100	0.9100	33
MIN	MIN:54|min:6	microsatellite instability:60:0.9216	0.9216	60
Min	Min:38|min:9|MIN:3	multiple intestinal neoplasia:50:0.9404	0.9404	50
MIP-1	MIP-1:32|MIP1:1	macrophage inflammatory protein-1:23:0.8715|macrophage inflammatory protein 1:10:0.7103	0.8715	33
mitDNA	mitDNA:7|mit-DNA:3	mitochondrial DNA:10:0.7103	0.7103	10
MITEs	MITEs:42|MITES:1	miniature inverted-repeat transposable elements:28:0.8941|miniature inverted repeat transposable elements:15:0.8045	0.8941	43
MKP-1	MKP-1:36	map kinase phosphatase-1:36:0.4256	0.4256	36
MKP-1	MKP-1:35	MAPK phosphatase-1:35:0.2203	0.2203	35
MKP-1	MKP-1:7	mitogen-activated protein kinase phosphatase:7:0.5926	0.5926	7
MKP-1	MKP-1:41|MKP1:1|mkp-1:1	mitogen-activated protein kinase phosphatase-1:31:0.8090|mitogen-activated protein kinase phosphatase 1:12:0.7571	0.8090	43
MLBs	MLBs:7|mlbs:1	multilamellar bodies:8:0.5006	0.5006	8
MLPA	MLPA:36	multiplex ligation-dependent probe amplification:36:0.9151	0.9151	36
MMHg	MMHg:6	monomethyl mercury:6:0.1010	0.1010	6
MMHg	MMHg:9	monomethylmercury:9:0.0229	0.0229	9
MM-LDL	MM-LDL:9|mmLDL:3|mm-LDL:2	minimally modified LDL:14:0.8045	0.8045	14
MM-LDL	MM-LDL:9|mmLDL:3|mm-LDL:2	minimally modified low-density lipoprotein:8:0.5006|Minimally modified low density lipoprotein:6:0.5290	0.5290	14
MM-LDL	MM-LDL:4|mmLDL:1|MmLDL:1|mm-LDL:1	minimally oxidized LDL:7:0.2902	0.2902	7
MOM	MOM:11	metal-on-metal:11:0.0246	0.0246	11
MOM	MOM:10	midecamycin acetate:10:0.5470	0.5470	10
MOM	MOM:15	miocamycin:15:0.0344	0.0344	15
MOM	MOM:13	Miokamycin:13:0.0295	0.0295	13
MOM	MOM:9	mucoid otitis media:9:0.6794	0.6794	9
MoM	MoM:100|MOM:45	multiples of the median:145:0.5490	0.5490	145
MORE	MORE:34	Multiple Outcomes of Raloxifene Evaluation:34:0.9126	0.9126	34
mot	mot:7	percent motility:7:0.0886	0.0886	7
mox-LDL	mox-LDL:7|moxLDL:3|m-ox-LDL:1	mildly oxidized LDL:11:0.5355	0.5355	11
mo	mo:20	ab initio molecular orbital:20:0.8525	0.8525	20
Mo	Mo:7|mo:3	cell line:10:0.5000	0.5000	10
MO	MO:4|mo:1	excitant and inflammatory irritant mustard oil:5:0.1973	0.1973	5
mo	mo:10	Human peripheral blood monocytes:10:0.1680	0.1680	10
mo	mo:15|MO:14|Mo:12	macrophage:41:0.0271	0.0271	41
MO	MO:14|mo:8	medulla oblongata:22:0.8657	0.8657	22
MO	MO:14|mo:3	membrane oxygenator:17:0.8270	0.8270	17
MO	MO:50|mo:13	menhaden oil:63:0.3534	0.3534	63
MO	MO:7|mo:3	methoxamine:10:0.0061	0.0061	10
MO	MO:7|mo:6	methyl orange:13:0.7753	0.7753	13
MO	MO:26|mo:16	migraine without aura:42:0.7523	0.7523	42
mo	mo:93|Mo:7	molybdenum:100:0.0672	0.0672	100
mo	mo:35|Mo:2	monocyte:37:0.0244	0.0244	37
mo	mo:18|Mo:1	monocytes/macrophages:19:0.0122	0.0122	19
mo	mo:9|Mo:1	monoolein:10:0.0061	0.0061	10
mo	mo:12|Mo:1	monooxygenase:13:0.0081	0.0081	13
mo	mo:23	months:23:0.0149	0.0149	23
mo	mo:8|Mo:6	Morbid Obesity:14:0.6911	0.6911	14
mo	mo:11|Mo:1	morbidly obese:12:0.6460	0.6460	12
mo	mo:25|Mo:1	morphine:26:0.0170	0.0170	26
mo	mo:9	mottled:9:0.0054	0.0054	9
mo	mo:24|Mo:1	mouse:25:0.0163	0.0163	25
MO	MO:7|mo:6|Mo:3	peritoneal macrophages:16:0.0683	0.0683	16
mo	mo:5	Sodium molybdate:5:0.0736	0.0736	5
mPL-I	mPL-I:16	mouse placental lactogen-I:16:0.7261	0.7261	16
MRCA	MRCA:20	Magnetic resonance coronary angiography:20:0.7766	0.7766	20
MRCA	MRCA:22	recent common ancestor:22:0.7955	0.7955	22
MS/VDB	MS/VDB:7|ms/vdB:2|MS/vDB:1	medial septum/vertical limb of the diagonal band:10:0.7103	0.7103	10
msDNA	msDNA:22	multicopy single-stranded DNA:22:0.8115	0.8115	22
MSPCR	MS-PCR:4|MSPCR:4	methylation-specific PCR:8:0.1367	0.1367	8
MS-PCR	MS-PCR:8|MSPCR:1	methylation-specific polymerase chain reaction:9:0.1267	0.1267	9
MS-PCR	MS-PCR:9	mutagenically separated PCR:9:0.6794	0.6794	9
MS-PCR	MS-PCR:11	mutagenically separated polymerase chain reaction:11:0.7357	0.7357	11
mt+	mt+:16	mating-type plus:9:0.2285|Mating type plus:7:0.5926	0.5926	16
mt-	mt-:8	mating type minus:8:0.6411	0.6411	8
mtDNAs	mtDNAs:59	mitochondrial DNAs:59:0.8954	0.8954	59
mtDNA	mtDNA:23	mitochondrial:23:0.0066	0.0066	23
mtDNA	mtDNA:3143|mt-DNA:14|Mt-DNA:2|MtDNA:1	mitochondrial DNA:3160:0.9865	0.9865	3160
mtDNA	mtDNA:11	mitochondrial DNAs:11:0.6182	0.6182	11
mtDNA	mtDNA:47	mitochondrial genome:47:0.8433	0.8433	47
mtNOS	mtNOS:15	mitochondrial nitric oxide synthase:15:0.6903	0.6903	15
mtPTP	mtPTP:8	mitochondrial permeability transition pore:8:0.5006	0.5006	8
mtRNA	mtRNA:9	Mitochondrial RNA:9:0.6794	0.6794	9
mtSSB	mtSSB:8	mitochondrial single-stranded DNA-binding protein:8:0.5006	0.5006	8
mtTF1	mtTF1:8	Mitochondrial transcription factor 1:8:0.6411	0.6411	8
mTld	mTld:5|mTLD:4	mammalian tolloid:9:0.6794	0.6794	9
mtrII	mtrII:7	morphological transforming region II:7:0.3524	0.3524	7
mu(max)	mu(max):9	maximum specific growth rate:9:0.5470	0.5470	9
muCT	muCT:14|mu-CT:3	tomography:17:0.8889	0.8889	17
muOR	muOR:22|mu-OR:7|MuOR:2	mu-opioid receptor:22:0.4689|mu opioid receptor:9:0.5470	0.5470	31
MuV	MuV:28|MUV:1	mumps virus:29:0.8978	0.8978	29
MUC1	MUC1:7|MUC-1:2	polymorphic epithelial mucin:9:0.3455	0.3455	9
mucin	mucin:14	mucus glycoprotein:14:0.5589	0.5589	14
mucosa	mucosa:6	rise in myeloperoxidase activity:6:0.5290	0.5290	6
MUG	MUG:16	4-methylumbelliferyl-beta-D-glucuronide:16:0.1974	0.1974	16
Mug	MUG:3|Mug:3	mismatch-specific uracil-DNA glycosylase:6:0.2243	0.2243	6
MUSIC	MUSIC:11	multiple signal classification:11:0.6182	0.6182	11
MuSK	MuSK:27|MUSK:1	muscle-specific kinase:28:0.2881	0.2881	28
MuSK	MuSK:21	muscle-specific receptor tyrosine kinase:21:0.8594	0.8594	21
MU	MU:54|mu:3	3 million units:57:0.2881	0.2881	57
MU	MU:9	4-methylumbelliferone:9:0.0061	0.0061	9
mu	mu:9	attenuation coefficient:9:0.2285	0.2285	9
mu	mu:13	dipole moment:13:0.5335	0.5335	13
mu	mu:17	electrophoretic mobility:17:0.4742	0.4742	17
mu	mu:16	heavy:16:0.0115	0.0115	16
mu	mu:12	heavy chain:12:0.5050	0.5050	12
mu	mu:33	ionic strength:33:0.9100	0.9100	33
MU	MU:7|mu:2	megaunits:9:0.0061	0.0061	9
MU	MU:18|mu:8|Mu:2	monitor unit:28:0.0957	0.0957	28
mu	mu:25	morphine:25:0.0183	0.0183	25
mu	mu:66|MU:63	motor unit:129:0.6356	0.6356	129
mu	mu:26|Mu:1	Murine:27:0.0199	0.0199	27
mu	mu:9	ratio:9:0.0061	0.0061	9
mu	mu:6|Mu:3	Robertson's Mutator:9:0.1052	0.1052	9
mu	mu:5	shear elastic modulus:5:0.4422	0.4422	5
mu	mu:61	specific growth rate:56:0.6417|specific growth rates:5:0.2818	0.6417	61
mu	mu:11	viscosity:11:0.0076	0.0076	11
mwh	mwh:22	multiple wing hairs:22:0.8657	0.8657	22
MX-1	MX-1:6	breast carcinoma:6:0.2243	0.2243	6
MYOC	MYOC:7|Myoc:1	myocilin gene:8:0.4102	0.4102	8
myoFb	myoFb:9|MyoFb:2	myofibroblasts:11:0.9091	0.9091	11
MYSTIC	MYSTIC:23	Meropenem Yearly Susceptibility Test Information Collection:23:0.8715	0.8715	23
n.c.a.	n.c.a.:18	no-carrier-added:18:0.8500	0.8500	18
n.m.r.	n.m.r.:79|N.M.R.:3	nuclear magnetic resonance:82:0.9070	0.9070	82
N2	N2:15	dinitrogen:15:0.0233	0.0233	15
N2	N2:13	lymph nodes:13:0.3331	0.3331	13
N2	N2:7	lymph node metastases:7:0.4438	0.4438	7
N2	N2:9	negative:9:0.0133	0.0133	9
N2	N2:7	negative component:7:0.2902	0.2902	7
N2	N2:82	nitrogen:82:0.1350	0.1350	82
N2	N2:6	nitrogen gas:6:0.0731	0.0731	6
nAChRs	nAChRs:616|nAchRs:16|NAChRs:4	nicotinic acetylcholine receptors:636:0.9809	0.9809	636
nAChR	nAChR:779|nAchR:11|NAChR:5|nACh-R:4|n-AChR:3|nACHR:1|N-AChR:1|n-ACh-r:1|n-AchR:1|nAChr:1	nicotinic acetylcholine receptor:656:0.9591|nicotinic acetylcholine receptors:151:0.9394	0.9591	807
nAPC-SR	nAPC-SR:3|n-APC-SR:1|nAPCsr:1|n-APC-sr:1|nAPC-sr:1	sensitivity ratio:7:0.2902	0.2902	7
nBOR	nBOR:48	nucleus of the basal optic root:48:0.9379	0.9379	48
nBUA	nBUA:10	attenuation:10:0.6000	0.6000	10
nChE	nChE:8|nCHE:1	cholinesterase:9:0.8000	0.8000	9
NDPA	NDPA:13	N-nitrosodipropylamine:13:0.3529	0.3529	13
nGRE	nGRE:12	negative glucocorticoid response element:12:0.7571	0.7571	12
NH	NH:10	amide:10:0.0116	0.0116	10
nH	nH:68|NH:2|nh:1	Hill coefficient:71:0.8757	0.8757	71
NH	NH:11	Neonatal hemochromatosis:11:0.7357	0.7357	11
NH	NH:25	Neonatal hepatitis:25:0.8861	0.8861	25
NH	NH:28|Nh:2	neurohypophysis:30:0.0373	0.0373	30
NH	NH:5	nodular hyperplasia:5:0.1132	0.1132	5
NH	NH:10	norharman:10:0.0116	0.0116	10
NH	NH:38	normal-hearing:27:0.0335|normal hearing:11:0.5355	0.5355	38
NH	NH:18	normal host:18:0.8365	0.8365	18
NH	NH:125	Nursing Home:107:0.9721|nursing homes:18:0.8365	0.9721	125
N-LDL	N-LDL:3|n-LDL:2|nLDL:1	low density lipoprotein:6:0.5290	0.5290	6
n-LDL	n-LDL:3|nLDL:3	native low-density lipoprotein:6:0.2827	0.2827	6
N-MAbs	N-MAbs:18|nMAbs:7|nmAbs:4|NMAbs:2|N-mAbs:1|n-MAbs:1	Neutralizing monoclonal antibodies:33:0.7238	0.7238	33
NMTS	NMTS:6	nuclear matrix targeting signal:6:0.5290	0.5290	6
NMO	NMO:29	neuromyelitis optica:29:0.8978	0.8978	29
nPKC	nPKC:15|NPKC:1	protein kinase C:16:0.8165	0.8165	16
nPNA	nPNA:8	normalized protein equivalent of nitrogen appearance:8:0.5355	0.5355	8
nPNA	nPNA:6|NPNA:1	normalized protein nitrogen appearance:7:0.4102	0.4102	7
NRBCs	NRBCs:10	nucleated erythrocytes:10:0.5856	0.5856	10
NRBCs	NRBCs:41|nRBCs:5	nucleated red blood cells:46:0.9353	0.9353	46
nRNA	nRNA:9|n-RNA:1	nuclear RNA:10:0.5856	0.5856	10
nRNP	nRNP:16	nuclear ribonucleoprotein:16:0.5171	0.5171	16
NRPC	NRPC:11|NRPc:2|nRPC:1	nucleus reticularis pontis caudalis:14:0.7909	0.7909	14
N-SMase	N-SMase:36|nSMase:20|NSMase:4	neutral sphingomyelinase:60:0.8359	0.8359	60
nVDR	nVDR:7	nuclear vitamin D receptor:7:0.4438	0.4438	7
NVI	NVI:7	Neovascularization of the iris:7:0.2902	0.2902	7
nXII	nXII:9	hypoglossal nucleus:9:0.4587	0.4587	9
NAG-1	NAG-1:6	Nonsteroidal anti-inflammatory drug-activated gene:6:0.3728	0.3728	6
nahG	nahG:7|NahG:5	salicylate hydroxylase:12:0.7571	0.7571	12
naive	naive:6	Male rats were implanted with placebo:6:0.5290	0.5290	6
NaSal	NaSal:24|Na-Sal:5|NaSAL:1	sodium salicylate:30:0.9011	0.9011	30
NcAMP	NcAMP:8|ncAMP:2	nephrogenous cAMP:10:0.5000	0.5000	10
NcAMP	NcAMP:9|N-cAMP:1	nephrogenous cyclic adenosine monophosphate:10:0.7103	0.7103	10
NcAMP	NcAMP:15|N-cAMP:1|N-CAMP:1	nephrogenous cyclic AMP:17:0.8270	0.8270	17
Nclk	Nclk:9|nclk:2|NCLK:1	neuronal cdc2-like kinase:12:0.7571	0.7571	12
NEAT	NEAT:17	activity thermogenesis:17:0.8165	0.8165	17
neo(r)	neo(r):6|Neo(r):3	neomycin resistance:9:0.6794	0.6794	9
NET	NET:13|net:1	nerve excitability test:14:0.7909	0.7909	14
NET	NET:47|net:1	neuroendocrine tumors:27:0.8312|neuroendocrine tumours:14:0.6911|Neuroendocrine Tumor:7:0.2902	0.8312	48
NET	NET:164|net:7	norepinephrine transporter:161:0.7187|norepinephrine transporters:10:0.5856	0.7187	171
NET	NET:71|net:6	norethindrone:77:0.1123	0.1123	77
NET	NET:123|net:7	norethisterone:130:0.1969	0.1969	130
NET	NET:8	norethisterone acetate:8:0.5006	0.5006	8
ngn1	ngn1:10|Ngn1:5	neurogenin1:15:0.7000	0.7000	15
ngn3	ngn3:7|Ngn3:3|NGN3:1|Ngn-3:1	neurogenin 3:12:0.6460	0.6460	12
ngn3	ngn3:6|Ngn3:3	neurogenin3:9:0.3636	0.3636	9
niaD	niaD:14	nitrate reductase:14:0.7909	0.7909	14
niaD	niaD:9	nitrate reductase gene:9:0.6794	0.6794	9
nifHDK	nifHDK:5	structural genes for nitrogenase:5:0.5290	0.5290	5
NIF	NIF:24	Neutrophil inhibitory factor:24:0.8768	0.8768	24
nif	nif:136|NIF:7|Nif:5	nifedipine:148:0.4212	0.4212	148
nif	nif:81|NIF:2|Nif:1	nitrogen fixation:84:0.9436	0.9436	84
NINR	NINR:9	National Institute of Nursing Research:9:0.7571	0.7571	9
nit	nit:22|NIT:1|Nit:1	nitrendipine:24:0.1811	0.1811	24
NMJ	NMJ:301|nmj:20	neuromuscular junction:285:0.9832|neuromuscular junctions:36:0.9174	0.9832	321
NOC/oFQ	NOC/oFQ:16|noc/OFQ:4|Noc/OFQ:2|noc/oFQ:2|Noc/oFQ:1	nociceptin/orphanin FQ:25:0.6539	0.6539	25
non-LTR	non-LTR:40|Non-LTR:1	non-long terminal repeat:24:0.8768|non-long-terminal-repeat:17:0.3636	0.8768	41
non-HDL	non-HDL:8|nonHDL:1	non-high-density lipoprotein:9:0.3945	0.3945	9
non-REM	non-REM:41|nonREM:2|Non-REM:2	non-rapid eye movement:45:0.7461	0.7461	45
non-Tg	non-Tg:8|non-TG:4|Non-Tg:2	non-transgenic:14:0.3421	0.3421	14
non-Tg	non-Tg:6|non-TG:3|Non-Tg:2|nonTg:1|non-tg:1|nonTG:1	nontransgenic:14:0.3421	0.3421	14
noncp	noncp:14	noncytopathogenic:14:0.6842	0.6842	14
noni	noni:10|Noni:10	Morinda citrifolia:20:0.8525	0.8525	20
nor-BNI	nor-BNI:3|norBNI:2|NorBNI:1|NOR-BNI:1	antagonist norbinaltorphimine:7:0.2288	0.2288	7
NORM	NORM:14|norm:1	naturally occurring radioactive materials:15:0.8045	0.8045	15
NPRQ	NPRQ:11|npRQ:9|NP-RQ:1	respiratory quotient:21:0.8594	0.8594	21
NPPV	NPPV:19|nPPV:1	non-invasive positive pressure ventilation:20:0.1032	0.1032	20
NPPV	NPPV:104	noninvasive positive pressure ventilation:77:0.6746|noninvasive positive-pressure ventilation:27:0.7066	0.7066	104
NPR-A	NPR-A:11|NPRA:2|Npra:1|NPr-A:1	natriuretic peptide receptor:15:0.8165	0.8165	15
NPR-A	NPR-A:19|NPRA:4	natriuretic peptide receptor-A:23:0.6653	0.6653	23
NPT2	NPT2:7|Npt2:4	cotransporter:11:0.5000	0.5000	11
nrDNA	nrDNA:19	nuclear ribosomal DNA:19:0.8449	0.8449	19
NRP	NRP:5	National Registry of Patients:5:0.4422	0.4422	5
NRP	NRP:15	Neonatal Resuscitation Program:15:0.8045	0.8045	15
NRP	NRP:9	raphe pallidus:9:0.5470	0.5470	9
nsLTP	nsLTP:15|nsL-TP:8|ns-LTP:8|nsltp:1	lipid transfer protein:32:0.9072	0.9072	32
NSPs	NSPs:11	non-starch polysaccharides:11:0.3829	0.3829	11
nsPs	nsPs:5|nsps:5|NSPs:3	nonstructural proteins:13:0.3554	0.3554	13
Nth	Nth:11|nth:4|NTH:2	endonuclease III:17:0.8270	0.8270	17
nu/+	nu/+:9	heterozygote:9:0.0406	0.0406	9
nu/+	nu/+:6|Nu/+:2	heterozygous littermates:8:0.0906	0.0906	8
nu/+	nu/+:9	normal littermates:9:0.1205	0.1205	9
nu/nu	nu/nu:99|Nu/Nu:3	athymic nude:102:0.3522	0.3522	102
nu/nu	nu/nu:39|Nu/Nu:3	congenitally athymic:42:0.1535	0.1535	42
nu/nu	nu/nu:14	homozygous:14:0.0194	0.0194	14
Nubain	Nubain:8	nalbuphine hydrochloride:8:0.5006	0.5006	8
nude	nude:6	congenitally thymus-deficient:6:0.1838	0.1838	6
nude	nude:9	hypothymic:9:0.0146	0.0146	9
nude	nude:10	immunodeficient:10:0.0164	0.0164	10
nu	nu:10|NU:8|nU:1	normalized units:19:0.6106	0.6106	19
nvCJD	nvCJD:8	new variant CJD:8:0.7753	0.7753	8
nvCJD	nvCJD:8|nv-CJD:1	new variant of Creutzfeldt-Jakob disease:9:0.7955	0.7955	9
OATP	OATP:23|oatp:8|Oatp:3	organic anion transporting polypeptide:34:0.9126	0.9126	34
oATP	oATP:20	oxidized ATP:20:0.2352	0.2352	20
OCG	OCG:33	oral cholecystography:33:0.8605	0.8605	33
oCRF	oCRF:44|o-CRF:8	ovine corticotropin-releasing factor:36:0.8716|ovine corticotropin releasing factor:16:0.7261	0.8716	52
oCRH	oCRH:35	Ovine corticotropin-releasing hormone:35:0.8681	0.8681	35
OCSP	OCSP:18	Oxfordshire Community Stroke Project:18:0.6903	0.6903	18
oGH	oGH:33|o-GH:2|OGH:1	ovine growth hormone:36:0.8003	0.8003	36
OGTT	OGTT:18|oGTT:1	oral glucose load:19:0.7044	0.7044	19
OGTT	OGTT:16|oGTT:1	oral glucose tolerance:17:0.6211	0.6211	17
OGTT	OGTT:1466|oGTT:56|O-GTT:9|o-GTT:1	oral glucose tolerance test:1402:0.9823|Oral glucose tolerance tests:130:0.9403	0.9823	1532
OGTT	OGTT:21|oGTT:3	oral glucose tolerance testing:24:0.8768	0.8768	24
oLH	oLH:40|OLH:1	ovine luteinizing hormone:41:0.8867	0.8867	41
oPRL	oPRL:129|oPrl:10|OPRL:2|o-PRL:2	ovine prolactin:143:0.8716	0.8716	143
oTP-1	oTP-1:38|OTP-1:1	ovine trophoblast protein-1:39:0.8455	0.8455	39
OAP	OAP:15	orthogonal arrays of particles:15:0.8045	0.8045	15
OAP	OAP:12	oscillatory afterpotentials:12:0.7571	0.7571	12
oatp2	oatp2:5|Oatp2:3|OATP2:1	organic anion transporting polypeptide 2:9:0.6794	0.6794	9
OAT	OAT:15|O-AT:5	O-acetyltransferase:20:0.0467	0.0467	20
OAT	OAT:10|o-AT:1	o-aminoazotoluene:11:0.0246	0.0246	11
OAT	OAT:28	oligoasthenoteratozoospermia:28:0.0663	0.0663	28
OAT	OAT:48|oat:1	oral anticoagulant therapy:49:0.9392	0.9392	49
OAT	OAT:18	oral anticoagulant treatment:18:0.8365	0.8365	18
OAT	OAT:21|Oat:2|oat:1	organic anion transporter:24:0.8115	0.8115	24
OAT	OAT:88	ornithine aminotransferase:88:0.8700	0.8700	88
OAT	OAT:16	ornithine-delta-aminotransferase:16:0.0369	0.0369	16
ob/ob	ob/ob:219|Ob/Ob:1	genetically obese:220:0.3683	0.3683	220
ob/ob	ob/ob:14	genetically obese mice:14:0.3585	0.3585	14
ob/ob	ob/ob:28	leptin-deficient:28:0.0323	0.0323	28
ob/ob	ob/ob:31	obese diabetic:22:0.6178|obese-diabetic:9:0.0096	0.6178	31
ob/ob	ob/ob:33	obese hyperglycaemic:33:0.9151	0.9151	33
ob/ob	ob/ob:44|OB/OB:1	obese hyperglycemic:24:0.8186|obese-hyperglycemic:21:0.0239	0.8186	45
oc/oc	oc/oc:13	osteosclerotic:13:0.8571	0.8571	13
ODA	ODA:10	octadecylamine:10:0.1268	0.1268	10
OED	OED:13	Oral epithelial dysplasia:13:0.7753	0.7753	13
OGG1	OGG1:10|Ogg1:2	glycosylase 1:12:0.7571	0.7571	12
oh8Gua	oh8Gua:12	8-hydroxyguanine:12:0.8462	0.8462	12
oh8dG	oh8dG:12|OH8dG:6|Oh8dG:1	8-hydroxy-2'-deoxyguanosine:19:0.4500	0.4500	19
oh8dG	oh8dG:11|OH8dG:1	8-hydroxydeoxyguanosine:12:0.2750	0.2750	12
OLD	OLD:19	obstructive lung disease:19:0.7044	0.7044	19
oligos	oligos:11	antisense oligodeoxynucleotides:11:0.1547	0.1547	11
oligos	oligos:18	antisense oligonucleotides:18:0.3019	0.3019	18
oligos	oligos:58	oligodeoxyribonucleotides:58:0.4191	0.4191	58
oligo	oligo:6	antisense oligodeoxynucleotide:6:0.1196	0.1196	6
oligo	oligo:51	oligodeoxyribonucleotide:51:0.4505	0.4505	51
oligo	oligo:13	oligonucleotide:13:0.1171	0.1171	13
OMB	OMB:43	Office of Management and Budget:43:0.9323	0.9323	43
omb	omb:19	optomotor-blind:19:0.2278	0.2278	19
omp1	omp1:5|OMP1:2	major outer membrane protein:7:0.3524	0.3524	7
omp1	omp1:11|omp-1:1	major outer membrane protein gene:12:0.7571	0.7571	12
OmpA	OmpA:17|ompA:4	outer membrane protein:21:0.8594	0.8594	21
OmpF	OmpF:7|ompF:4	outer membrane protein F:11:0.7357	0.7357	11
Onc	Onc:11|onc:6|ONC:1	Onconase:18:0.2615	0.2615	18
one	one:14	bleeding:14:0.0050	0.0050	14
one	one:7	cell carcinoma:7:0.0517	0.0517	7
one	one:25	infection:25:0.0103	0.0103	25
one	one:9	leukemia:9:0.0031	0.0031	9
one	one:19	lymphoma:19:0.0069	0.0069	19
one	one:9	obstruction:9:0.0031	0.0031	9
one	one:9	pancreatitis:9:0.0031	0.0031	9
one	one:11	pneumonia:11:0.0046	0.0046	11
one	one:15	stenosis:15:0.0061	0.0061	15
one	one:22	syndrome:22:0.0088	0.0088	22
one	one:9	tuberculosis:9:0.0031	0.0031	9
onfFN	onfFN:10|onf-FN:1	oncofetal fibronectin:11:0.6182	0.6182	11
op/op	op/op:9	Osteopetrosis:9:0.0611	0.0611	9
op/op	op/op:99|Op/Op:1	osteopetrotic:100:0.7405	0.7405	100
OP-1	OP-1:92	osteogenic protein-1:79:0.9210|Osteogenic protein 1:13:0.6701	0.9210	92
open	open:12	conventional:12:0.0597	0.0597	12
open	open:9	traditional:9:0.0448	0.0448	9
OprI	OprI:10	Outer membrane protein I:10:0.7103	0.7103	10
ORC	ORC:186|orc:4|Orc:1	origin recognition complex:191:0.9665	0.9665	191
ORC	ORC:11	Oxidized regenerated cellulose:11:0.6460	0.6460	11
ORF	ORF:2952|orf:73|Orf:1	open reading frame:2780:0.9946|open reading frames:246:0.9740	0.9946	3026
oriC	oriC:31	origin of replication:31:0.5414	0.5414	31
oriC	oriC:8	origin of the Escherichia coli chromosome:8:0.2987	0.2987	8
oriC	oriC:45|oric:2	replication origin:47:0.6007	0.6007	47
oris	oris:8|oriS:4|ORIs:4|ORIS:2	replication:18:0.3778	0.3778	18
ORIs	ORIs:6	replication origins:6:0.2243	0.2243	6
oriT	oriT:75	origin of transfer:75:0.7315	0.7315	75
oriT	oriT:12	transfer origin:12:0.6460	0.6460	12
oriV	oriV:9|OriV:1	origin of vegetative replication:10:0.7103	0.7103	10
oriV	oriV:9	replication origin:9:0.4587	0.4587	9
ortho-k	ortho-k:12|Ortho-K:1	orthokeratology:13:0.9231	0.9231	13
or	or:6|OR:3	NADPH-cytochrome P450 reductase:9:0.6794	0.6794	9
or	or:38|OR:35	objective response:64:0.3165|objective responses:9:0.2757	0.3165	73
or	or:9	Ocular retardation:9:0.6794	0.6794	9
or	or:6057|OR:1694	odds ratio:6288:0.9866|odds ratios:1447:0.9763|odds-ratio:16:0.0016	0.9866	7751
or	or:12|OR:3	odds ration:15:0.8045	0.8045	15
or	or:32	odorant receptor:32:0.1457	0.1457	32
or	or:24	oestrogen receptor:24:0.0979	0.0979	24
or	or:58	olfactory receptor:58:0.3120	0.3120	58
or	or:12|OR:5	open repair:17:0.6748	0.6748	17
or	or:227|OR:131	operating room:347:0.9653|operating rooms:11:0.7357	0.9653	358
or	or:12|OR:2	operations research:14:0.5111	0.5111	14
or	or:8	Opioid receptors:8:0.0906	0.0906	8
or	or:8|OR:1	optical rotation:9:0.5470	0.5470	9
or	or:6	orienting reaction:6:0.2243	0.2243	6
or	or:14	orienting reflex:14:0.5111	0.5111	14
or	or:53	orienting response:53:0.2568	0.2568	53
or	or:16|OR:3	ouabain-resistant:19:0.0020	0.0020	19
or	or:4|OR:1	outflow resistance:5:0.0736	0.0736	5
or	or:19|OR:6	ovulation rate:25:0.3744	0.3744	25
or	or:9	P450 oxidoreductase:9:0.2500	0.2500	9
or	or:4|OR:2	relative risk:6:0.0611	0.0611	6
OR	OR:11|or:5	response rate:16:0.1879	0.1879	16
or	or:8	right operator:8:0.3463	0.3463	8
ouar	ouar:5|Ouar:4|OuaR:3|ouaR:2|OUAR:1|OUAr:1	ouabain resistance:16:0.8165	0.8165	16
ouar	ouar:8|OuaR:6|Ouar:6|OUAr:1	ouabain-resistant:21:0.4082	0.4082	21
oval	oval:8	liver progenitor:8:0.4102	0.4102	8
OWLS	OWLS:15	optical waveguide lightmode spectroscopy:15:0.8045	0.8045	15
oxLDLs	oxLDLs:13|ox-LDLs:4|Ox-LDLs:4|OxLDLs:3	Oxidized low density lipoproteins:13:0.7753|oxidized low-density lipoproteins:11:0.5355	0.7753	24
OxPAPC	OxPAPC:5|ox-PAPC:4|Ox-PAPC:3|oxPAPC:1|OXPAPC:1	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine:14:0.6911	0.6911	14
P(aw)	P(aw):14|P(AW):2	airway pressure:16:0.8165	0.8165	16
p(un)	p(un):8	pink-eyed unstable:8:0.5006	0.5006	8
p-NTLI	p-NTLI:9	neurotensin-like immunoreactivity:9:0.6794	0.6794	9
p-XSC	p-XSC:33	1,4-phenylenebis(methylene)selenocyanate:33:0.7273	0.7273	33
p.c.	p.c.:10	days postcoitum:10:0.1057	0.1057	10
p.c.	p.c.:126|P.C.:1	post coitum:104:0.9715|post-coitum:23:0.0743	0.9715	127
p.c.	p.c.:28	post conception:19:0.8449|post-conception:9:0.0270	0.8449	28
p.d.	p.d.:53|P.D.:9	potential difference:62:0.9519	0.9519	62
p.i.	p.i.:6	4 weeks postinoculation:6:0.1010	0.1010	6
p.i.	p.i.:100|P.I.:2	days post-infection:102:0.2158	0.2158	102
p.i.	p.i.:44	days post-inoculation:44:0.2346	0.2346	44
p.i.	p.i.:75	days postinfection:75:0.1818	0.1818	75
p.i.	p.i.:7	days postinjection:7:0.0565	0.0565	7
p.i.	p.i.:36	days postinoculation:36:0.2125	0.2125	36
p.i.	p.i.:73|P.I.:1	h post-infection:74:0.1508	0.1508	74
p.i.	p.i.:9	h post-injection:9:0.1267	0.1267	9
p.i.	p.i.:17	h post-inoculation:17:0.0619	0.0619	17
p.i.	p.i.:71	h postinfection:71:0.1732	0.1732	71
p.i.	p.i.:12	h postinjection:12:0.1991	0.1991	12
p.i.	p.i.:19	h postinoculation:19:0.0863	0.0863	19
p.i.	p.i.:35|P.I.:1	post-immunization:22:0.0133|post immunization:14:0.7096	0.7096	36
p.i.	p.i.:241|P.I.:3	post infection:244:0.9083	0.9083	244
p.i.	p.i.:32	post injection:32:0.7166	0.7166	32
p.i.	p.i.:60|P.I.:1	post inoculation:61:0.7455	0.7455	61
p.i.	p.i.:14	postimmunization:14:0.0082	0.0082	14
P.I.	P.I.:7|p.i.:1	pulsatility index:8:0.0756	0.0756	8
p.m.p.	p.m.p.:10	per million population:10:0.7571	0.7571	10
p.o.	p.o.:16	oral administration:16:0.4040	0.4040	16
p.o.	p.o.:14	oral gavage:14:0.5589	0.5589	14
p.o.	p.o.:107|P.O.:1	orally:108:0.1042	0.1042	108
p.o.	p.o.:47|P.O.:1	per os:48:0.9379	0.9379	48
p.o.	p.o.:19	peroral:19:0.0174	0.0174	19
p.o.	p.o.:15	perorally:15:0.0135	0.0135	15
p.o.	p.o.:18|P.O.:2	postoperative:20:0.0183	0.0183	20
p.o.	p.o.:13|P.O.:1	postoperatively:14:0.0125	0.0125	14
p.p.m.	p.p.m.:19	parts per million:19:0.8449	0.8449	19
p.s.p.s	p.s.p.s:12	post-synaptic potentials:12:0.6460	0.6460	12
P10	P10:63	postnatal day 10:63:0.8259	0.8259	63
p110	p110:7	catalytic subunit:7:0.1850	0.1850	7
P12	P12:5	12-(1-pyrene) dodecanoic acid:5:0.1464	0.1464	5
P14	P14:51|p14:1	postnatal day 14:52:0.8572	0.8572	52
p15	p15:9	p15INK4b:9:0.0428	0.0428	9
P15	P15:27|P-15:1	postnatal day 15:28:0.8941	0.8941	28
p16	p16:24	p16(INK4A):24:0.1036	0.1036	24
p16	p16:20	p16INK4A:20:0.0901	0.0901	20
P16	P16:10	postnatal day 16:10:0.5856	0.5856	10
P-170	P-170:13|P170:8|p170:6|p-170:1	glycoprotein:28:0.2261	0.2261	28
P-170	P-170:43|P170:4|p170:2	P-glycoprotein:49:0.4174	0.4174	49
p185	p185:7	gene product:7:0.1641	0.1641	7
P188	P188:9|P-188:6	Poloxamer 188:15:0.8045	0.8045	15
P19	P19:6	embryonal carcinoma cells:6:0.2243	0.2243	6
p24	p24:12	core antigen:12:0.1830	0.1830	12
p24	p24:20|P24:2	core protein:22:0.2001	0.2001	22
p27	p27:6	cyclin-dependent kinase inhibitor p27(Kip1):6:0.4438	0.4438	6
P28	P28:14|P-28:1	postnatal day 28:15:0.6386	0.6386	15
P-32	P-32:7|P32:4	chromic phosphate:11:0.3495	0.3495	11
p38	p38:15|P38:1	p38 MAP kinase:16:0.7261	0.7261	16
p38	p38:29	p38 mitogen-activated protein kinase:29:0.8422	0.8422	29
p38	p38:29|P38:1	synaptophysin:30:0.1408	0.1408	30
p40	p40:10	40-kDa protein:10:0.1177	0.1177	10
p53(+/+)	p53(+/+):12	wild-type:12:0.5500	0.5500	12
p53+/+	p53+/+:19	wild-type:19:0.4000	0.4000	19
p53-/-	p53-/-:12	p53-deficient:12:0.1803	0.1803	12
p53	p53:5|P53:1	p53 protein:6:0.0564	0.0564	6
p53	p53:20|P53:1	tumor suppressor gene:16:0.4832|tumor suppressor genes:5:0.4422	0.4832	21
p55	p55:7	55-kDa protein:7:0.0565	0.0565	7
p56lck	p56lck:6	lymphocyte-specific protein tyrosine kinase:6:0.2827	0.2827	6
P5	P5:76|p5:1	postnatal day 5:77:0.8547	0.8547	77
P5	P5:61	pregnenolone:61:0.2083	0.2083	61
P60	P60:12	postnatal day 60:12:0.7571	0.7571	12
p66	p66:6|P66:1	66-kDa protein:7:0.1641	0.1641	7
p68	p68:7|P68:2	protein kinase:9:0.5470	0.5470	9
p70(S6K)	p70(S6K):9|p70(S6k):4|p70(s6k):1|P70(S6k):1	ribosomal protein S6 kinase:15:0.7096	0.7096	15
p70	p70:6|P70:2	70-kDa protein:8:0.1125	0.1125	8
p75(NTR)	p75(NTR):29	p75 neurotrophin receptor:29:0.6392	0.6392	29
p75NTR	p75NTR:14|P75NTR:1	neurotrophin receptor p75:15:0.7096	0.7096	15
p75NTR	p75NTR:87|P75NTR:2|p75ntr:1	p75 neurotrophin receptor:90:0.6223	0.6223	90
p75	p75:13|P75:1	low-affinity neurotrophin receptor:14:0.2326	0.2326	14
p75	p75:21|P75:1	nerve growth factor receptor:22:0.8657	0.8657	22
p85	p85:5	85-kDa protein:5:0.0736	0.0736	5
p85	p85:6	phosphatidylinositol 3-kinase:6:0.0899	0.0899	6
p85	p85:5	PI 3-kinase:5:0.1470	0.1470	5
P85	P85:8	Pluronic P85:8:0.5006	0.5006	8
p85	p85:20	regulatory subunit:20:0.3492	0.3492	20
P8	P8:27|p8:1	postnatal day 8:28:0.7905	0.7905	28
P8	P8:12|p8:5|P-8:1	protein:18:0.1339	0.1339	18
p90(rsk)	p90(RSK):2|p90(rsk):2|P90(RSK):1|p90(Rsk):1	p90 ribosomal S6 kinase:6:0.3728	0.3728	6
p90RSK	p90RSK:15|p90rsk:11|p90-RSK:1|p90Rsk:1	ribosomal S6 kinase:28:0.6057	0.6057	28
p97	p97:18|P97:2	melanotransferrin:20:0.3000	0.3000	20
P9	P9:17|p-9:1	postnatal day 9:18:0.7539	0.7539	18
PA2	PA2:15|PA-2:1	phospholipase A2:16:0.8165	0.8165	16
PAAm	PAAm:11|pAAm:1	polyacrylamide:12:0.5500	0.5500	12
PADPRP	PADPRP:23|pADPRP:6|pADPRp:3	poly(ADP-ribose) polymerase:32:0.5841	0.5841	32
pAII	pAII:4|PAII:3	plasma angiotensin II:7:0.2902	0.2902	7
PAI-I	PAI-I:7	plasminogen activator inhibitor:7:0.5926	0.5926	7
PAI-I	PAI-I:14	plasminogen activator inhibitor-I:14:0.6173	0.6173	14
pANCAs	pANCAs:4|P-ANCAs:3|p-ANCAs:3	cytoplasmic antibodies:10:0.5856	0.5856	10
pANCA	pANCA:4|P-ANCA:3|p-ANCA:1	cytoplasmic autoantibodies:8:0.5006	0.5006	8
pANCA	pANCA:15|p-ANCA:9|P-ANCA:6	perinuclear ANCA:30:0.7652	0.7652	30
pANCA	pANCA:28|p-ANCA:10|P-ANCA:9	perinuclear antineutrophil cytoplasmic antibodies:34:0.6591|perinuclear antineutrophil cytoplasmic antibody:13:0.6701	0.6701	47
p-ANCA	p-ANCA:10|pANCA:5|P-ANCA:5	perinuclear pattern:20:0.3614	0.3614	20
P-ANCA	pANCA:3|P-ANCA:3	perinuclear staining:6:0.2243	0.2243	6
pANCA	pANCA:5|p-ANCA:2|P-ANCA:2	perinuclear staining pattern:9:0.3945	0.3945	9
PANP	PANP:5|pANP:4|P-ANP:2|p-ANP:2	atrial natriuretic peptide:13:0.7753	0.7753	13
pAVP	pAVP:14|PAVP:12|Pavp:1|p-AVP:1	plasma arginine vasopressin:28:0.6839	0.6839	28
pAVP	PAVP:4|pAVP:4|Pavp:1	plasma arginine vasopressin concentration:9:0.6794	0.6794	9
PAVP	PAVP:9|pAVP:3|P-AVP:1	plasma vasopressin:13:0.1220	0.1220	13
PAVP	PAVP:7|pAVP:3	plasma vasopressin concentration:10:0.2446	0.2446	10
PARG	PARG:43|Parg:2	poly(ADP-ribose) glycohydrolase:45:0.7619	0.7619	45
pBNP	pBNP:18	porcine brain natriuretic peptide:18:0.6903	0.6903	18
p-BPB	p-BPB:15|pBPB:11|PBPB:3	p-bromophenacyl bromide:29:0.5551	0.5551	29
PC-9	PC-9:7|PC9:3	cell line:10:0.7103	0.7103	10
PCBCL	PCBCL:11	primary cutaneous B-cell lymphoma:11:0.7357	0.7357	11
PCET	PCET:18|pcet:1	Proton-coupled electron transfer:19:0.7658	0.7658	19
PCMB	PCMB:70|pCMB:29|p-CMB:10	p-chloromercuribenzoate:109:0.4909	0.4909	109
PCMB	PCMB:30|pCMB:12|p-CMB:5	p-chloromercuribenzoic acid:47:0.6183	0.6183	47
PCMB	PCMB:4|p-CMB:2|pCMB:1	p-chloromercuric benzoate:7:0.1850	0.1850	7
PCPA	PCPA:7|p-CPA:1|pCPA:1	methyl ester:9:0.5470	0.5470	9
PCPA	PCPA:258|pCPA:64|p-CPA:50|PcPA:1	p-chlorophenylalanine:373:0.5575	0.5575	373
PCPA	PCPA:45|pCPA:22|p-CPA:15	para-chlorophenylalanine:82:0.1211	0.1211	82
PCPA	PCPA:91|pCPA:24|p-CPA:5	Parachlorophenylalanine:120:0.1764	0.1764	120
PCPE	PCPE:6	Procollagen C-proteinase enhancer:6:0.5290	0.5290	6
PD-1	PD-1:36	Programmed Death-1:28:0.7905|Programmed death 1:8:0.3463	0.7905	36
PDK1	PDK1:49|PDK-1:12	3-phosphoinositide-dependent protein kinase-1:45:0.6065|3-Phosphoinositide-dependent protein kinase 1:16:0.4832	0.6065	61
PDK1	PDK1:8|PDK-1:1	protein kinase:9:0.3069	0.3069	9
pDNA	pDNA:134|p-DNA:1	plasmid DNA:135:0.8160	0.8160	135
pDXA	pDXA:8	x-ray absorptiometry:8:0.5006	0.5006	8
PEMT	PEMT:8|PeMT:1	Phosphatidylethanolamine methyltransferase:9:0.6794	0.6794	9
PEMT	PEMT:24|PeMT:3	phosphatidylethanolamine N-methyltransferase:27:0.6745	0.6745	27
pEPSP	pEPSP:18	population excitatory postsynaptic potential:18:0.6903	0.6903	18
pERK1/2	pERK1/2:5|p-ERK1/2:4|p-Erk1/2:1|P-Erk1/2:1	phosphorylated ERK1/2:11:0.5355	0.5355	11
pFSH	pFSH:9	follicle stimulating hormone:9:0.5470	0.5470	9
pFSH	pFSH:13	Porcine follicle-stimulating hormone:13:0.3134	0.3134	13
pFSH	pFSH:12	porcine FSH:12:0.4557	0.4557	12
PG-1	PG-1:4	antimicrobial peptide protegrin-1:4:0.5926	0.5926	4
PGC-1	PGC-1:10|Pgc1:1	coactivator 1:11:0.3495	0.3495	11
PGC-1	PGC-1:18|PGC1:2	peroxisome proliferator-activated receptor-gamma coactivator-1:11:0.5355|Peroxisome proliferator-activated receptor gamma coactivator-1:9:0.6794	0.6794	20
PGH	PGH:9	phosphoglycolohydroxamate:9:0.0340	0.0340	9
pGH	pGH:29	porcine GH:29:0.5738	0.5738	29
pGH	pGH:68|PGH:6	porcine growth hormone:74:0.7187	0.7187	74
PGH	PGH:22	prostaglandin endoperoxide:22:0.6934	0.6934	22
PGH	PGH:32	prostaglandin H:32:0.7782	0.7782	32
pGPL-Mc	pGPL-Mc:1	polar glycopeptidolipids from Mycobacterium chelonae:1:0.6411	0.6411	1
PGRP	PGRP:12	peptidoglycan recognition protein:12:0.7357	0.7357	12
pH(e)	pH(e):19	extracellular pH:19:0.6537	0.6537	19
pH(i)	pH(i):295|pH(I):1	intracellular pH:296:0.8365	0.8365	296
pH(o)	pH(o):15|pH(O):2	external pH:17:0.1497	0.1497	17
pH(o)	pH(o):43	extracellular pH:43:0.5699	0.5699	43
pH1	pH1:16	Intracellular pH:16:0.4274	0.4274	16
Ph1	Ph1:119|Ph-1:5|PH1:2	Philadelphia:126:0.2917	0.2917	126
Ph1	Ph1:125|PH1:1	Philadelphia chromosome:126:0.9494	0.9494	126
PH1	PH1:8|PH-1:2	primary hyperoxaluria:10:0.6794	0.6794	10
PH1	PH1:73|PH-1:2	primary hyperoxaluria type 1:75:0.9602	0.9602	75
PH1	PH1:7|PH-1:1	Primary hyperoxaluria type I:8:0.6411	0.6411	8
PH3	PH3:23	phosphine:23:0.5897	0.5897	23
PHMB	PHMB:15|pHMB:8|p-HMB:2	p-hydroxymercuribenzoate:25:0.2202	0.2202	25
PHMB	PHMB:6|p-HMB:1	p-hydroxymercuribenzoic acid:7:0.3524	0.3524	7
PHMB	PHMB:35	polyhexamethylene biguanide:35:0.7952	0.7952	35
PHM	PHM:13	partial hydatidiform mole:13:0.7753	0.7753	13
PHM	PHM:9	peptide histidine-methionine:9:0.6794	0.6794	9
PHM	PHM:35	peptidylglycine alpha-hydroxylating monooxygenase:35:0.8644	0.8644	35
PHPMA	PHPMA:7|pHPMA:3	poly[N-(2-hydroxypropyl)methacrylamide]:10:0.3913	0.3913	10
p-HPPH	p-HPPH:14|pHPPH:2	5-(p-hydroxyphenyl)-5-phenylhydantoin:16:0.4054	0.4054	16
pHVA	pHVA:43|PHVA:1|phVA:1	homovanillic acid:45:0.9338	0.9338	45
PHEX	PHEX:6|Phex:1	gene with homologies to endopeptidases on the X chromosome:7:0.5926	0.5926	7
pHe	pHe:163	extracellular pH:163:0.6853	0.6853	163
phe	phe:36	L-phenylalanine:36:0.0316	0.0316	36
PHE	PHE:10	partial hepatectomy:10:0.7103	0.7103	10
phe	phe:34|PHE:2|Phe:1	phenanthrene:37:0.0325	0.0325	37
phe	phe:13|PHE:1|Phe:1	phentolamine:15:0.0126	0.0126	15
phe	phe:341|Phe:5|PHE:1	Phenylalanine:347:0.3129	0.3129	347
phe	phe:187|Phe:9|PHE:4	phenylephrine:200:0.1794	0.1794	200
pHim	pHim:9	intramucosal pH:9:0.6794	0.6794	9
pHin	pHin:36	intracellular pH:36:0.8003	0.8003	36
phi	phi:10	acrophase:10:0.0025	0.0025	10
phi	phi:5|PH-I:3|Phi:1	fraction:9:0.0022	0.0022	9
pHi	pHi:12	intracellular:12:0.0031	0.0031	12
pHi	pHi:1987|pHI:3|PHi:1	intracellular pH:1991:0.7317	0.7317	1991
PHI	PHI:10	peptide HI:10:0.5470	0.5470	10
PHI	PHI:16	peptide histidine-isoleucine:16:0.8045	0.8045	16
PHI	PHI:2	peptide with N-terminal histidine and C-terminal isoleucine amide:2:0.5006	0.5006	2
phi	phi:15|Phi:1	phase angle:16:0.2527	0.2527	16
PHI	PHI:58|Phi:3	phosphohexose isomerase:61:0.7735	0.7735	61
PHI	PHI:10	phosphohexoseisomerase:10:0.0025	0.0025	10
PHI	PHI:17	primary HIV-1 infection:17:0.6748	0.6748	17
PHI	PHI:27	primary HIV infection:27:0.8312	0.8312	27
PHI	PHI:10	Private Health Insurance:10:0.5856	0.5856	10
phi	phi:24|Phi:8	quantum yield:23:0.7046|quantum yields:9:0.6794	0.7046	32
phi	phi:5	rotational correlation time:5:0.2818	0.2818	5
pHo	pHo:192|pHO:1	extracellular pH:193:0.6810	0.6810	193
pho	pho:12|PHO:4	phosphate:16:0.0374	0.0374	16
PHO	PHO:5|pho:4|Pho:3	pleiohomeotic:12:0.0274	0.0274	12
pHu	pHu:10|pHU:1	ultimate pH:11:0.4728	0.4728	11
PHV	PHV:59	peak height velocity:59:0.9494	0.9494	59
PHV	PHV:11	Peptide histidine valine:11:0.7357	0.7357	11
PHV	PHV:11	prosthetic heart valves:11:0.7357	0.7357	11
pH	pH:15|PH:1	acidity:16:0.0043	0.0043	16
PH	PH:8|-PH:1	history:9:0.0023	0.0023	9
PH	PH:12|Ph:1	hydrochloride:13:0.0034	0.0034	13
pH	pH:16|PH:1	Hydrogen ion concentration:17:0.8270	0.8270	17
PH	PH:18	hyperplasia:18:0.0049	0.0049	18
pH	pH:8	Intracellular pH:8:0.1471	0.1471	8
PH	PH:17	palmar hyperhidrosis:17:0.6211	0.6211	17
PH	PH:9	partially hepatectomized:9:0.3945	0.3945	9
PH	PH:8	peak height:8:0.0953	0.0953	8
PH	PH:9	Periventricular heterotopia:9:0.6794	0.6794	9
PH	PH:12|Ph:8	phenol:20:0.0054	0.0054	20
PH	PH:11|Ph:8	phentolamine:19:0.0052	0.0052	19
PH	PH:10|Ph:3|pH:1	phenylalanine hydroxylase:14:0.1124	0.1124	14
PH	PH:8|Ph:4	phenylephrine:12:0.0031	0.0031	12
PH	PH:8|pH:2|Ph:1|ph:1	phenylhydrazine:12:0.0031	0.0031	12
Ph	Ph:326	Philadelphia:326:0.0930	0.0930	326
Ph	Ph:147|pH:1	Philadelphia chromosome:148:0.9474	0.9474	148
Ph	Ph:6|PH:5	physostigmine:11:0.0029	0.0029	11
PH	PH:509|Ph:6	Pleckstrin homology:515:0.9665	0.9665	515
ph	ph:22|Ph:4|PH:3	polyhomeotic:29:0.0080	0.0080	29
PH	PH:11	posterior:11:0.0029	0.0029	11
PH	PH:10	posterior hypothalamic nucleus:10:0.7103	0.7103	10
PH	PH:54	posterior hypothalamus:54:0.9132	0.9132	54
PH	PH:20	postural hypotension:20:0.7173	0.7173	20
PH	PH:24|Ph:2	prepositus hypoglossi:26:0.7340	0.7340	26
PH	PH:31	primary hyperoxaluria:31:0.9043	0.9043	31
PH	PH:9	primary hyperparathyroidism:9:0.5470	0.5470	9
PH	PH:24	prolyl 4-hydroxylase:24:0.8115	0.8115	24
PH	PH:29	prolyl hydroxylase:29:0.3446	0.3446	29
PH	PH:17	proportional hazards:17:0.8270	0.8270	17
PH	PH:10|Ph:1	pubic hair:11:0.7357	0.7357	11
PH	PH:6|Ph:1	public health:7:0.1329	0.1329	7
PH	PH:21	pulmonary hemorrhage:21:0.6400	0.6400	21
PH	PH:454|Ph:1	pulmonary hypertension:455:0.8193	0.8193	455
PH	PH:24	pulmonary hypoplasia:24:0.8768	0.8768	24
pI's	pI's:9	isoelectric points:9:0.6794	0.6794	9
pIEF	pIEF:6|PIEF:4	preparative isoelectric focusing:10:0.4363	0.4363	10
PIX	PIX:8|Pix:1	exchange factor:9:0.6794	0.6794	9
pIX	pIX:14	protein IX:14:0.4071	0.4071	14
pIgA-R	pIgA-R:6|pIgAR:3	polymeric IgA receptor:9:0.6794	0.6794	9
pIgA	pIgA:53|p-IgA:13|PIgA:2|P-IgA:1	polymeric IgA:69:0.8905	0.8905	69
pIgR	pIgR:36|pIg-R:1	polymeric Ig receptor:37:0.8749	0.8749	37
pIgR	pIgR:94|PIGR:5|PIgR:4|pIg-R:4|pigR:1	polymeric immunoglobulin receptor:108:0.9559	0.9559	108
PIs	PIs:20	phosphoinositides:20:0.0291	0.0291	20
PIs	PIs:343	protease inhibitors:343:0.8800	0.8800	343
PIs	PIs:12	Pulsatility Indices:12:0.1907	0.1907	12
PIS	PIS:12	syndrome:12:0.0169	0.0169	12
PI	PI:44|Pi:27|pi:1	Alpha-1-antitrypsin:41:0.0032|alpha 1-antitrypsin:26:0.8861|Alpha 1 antitrypsin:5:0.4422	0.8861	72
PI	PI:8|Pi:5	alpha1-antitrypsin:13:0.0010	0.0010	13
pi	pi:7	colloid osmotic pressure:7:0.1470	0.1470	7
PI	PI:20|pi:19	days post-infection:39:0.1904	0.1904	39
PI	PI:26|pi:6	days post-inoculation:32:0.1585	0.1585	32
PI	PI:60|pi:11	days postinfection:71:0.2204	0.2204	71
PI	PI:99|pi:5|Pi:1	days postinoculation:105:0.2691	0.2691	105
PI	PI:3|P-I:2	days postirradiation:5:0.0612	0.0612	5
PI	PI:27|pi:7	hr postinoculation:34:0.0682	0.0682	34
PI	PI:6	hydrolysis of [3H]phosphatidylinositol:6:0.1543	0.1543	6
PI	PI:16	hydrolysis of phosphoinositides:16:0.2154	0.2154	16
PI	PI:14|Pi:1	inferior pulvinar:15:0.8045	0.8045	15
PI	PI:15	infusion:15:0.0011	0.0011	15
PI	PI:14	injury:14:0.0011	0.0011	14
Pi	Pi:27	inorganic orthophosphate:27:0.1887	0.1887	27
Pi	Pi:14	inorganic P:14:0.7909	0.7909	14
Pi	Pi:1109|PI:6|pI:1	inorganic phosphate:1106:0.7478|inorganic phosphates:10:0.3867	0.7478	1116
Pi	Pi:68	inorganic phosphorus:68:0.7206	0.7206	68
PI	PI:17	inositol phospholipid:17:0.7407	0.7407	17
Pi	Pi:10	interstitial fluid hydrostatic pressure:10:0.7103	0.7103	10
PI	PI:9	intervals:9:0.0006	0.0006	9
pI	pI:802|PI:8|pi:1	isoelectric point:604:0.9595|isoelectric points:207:0.9427	0.9595	811
PI	PI:13	Padua Inventory:13:0.3809	0.3809	13
PI	PI:18	pain intensity:18:0.3412	0.3412	18
PI	PI:30	pancreatic insufficiency:30:0.4881	0.4881	30
PI	PI:10	pars intercerebralis:10:0.7103	0.7103	10
PI	PI:80|pi:3|Pi:3	pars intermedia:86:0.6781	0.6781	86
PI	PI:9	peak intensity:9:0.0932	0.0932	9
PI	PI:15	performance improvement:15:0.7096	0.7096	15
PI	PI:9	peripheral iridectomy:9:0.6794	0.6794	9
PI	PI:64|pi:2	persistently infected:66:0.9061	0.9061	66
Pi	Pi:15	phosphate ions:9:0.4587|Phosphate ion:6:0.1320	0.4587	15
PI	PI:84	phosphatidyl inositol:68:0.8220|phosphatidyl-inositol:16:0.0012	0.8220	84
PI	PI:11	phosphatidylinositide:11:0.0008	0.0008	11
PI	PI:2027|Pi:32|pI:2	phosphatidylinositol:2049:0.1654|phosphatidylinositols:12:0.0009	0.1654	2061
PI	PI:593|Pi:4	phosphoinositide:597:0.0482	0.0482	597
PI	PI:21	phosphoinositol:21:0.0016	0.0016	21
PI	PI:9	phosphotyrosine interaction:9:0.5470	0.5470	9
PI	PI:24	plaque:24:0.0019	0.0019	24
PI	PI:12	plasma insulin:12:0.1631	0.1631	12
PI	PI:31	pneumatosis intestinalis:31:0.9043	0.9043	31
PI	PI:17	polyphosphoinositide:17:0.0013	0.0013	17
PI	PI:9	porcine insulin:9:0.0898	0.0898	9
PI	PI:5	Positive ion:5:0.0612	0.0612	5
PI	PI:43|pi:26	post infection:69:0.5605	0.5605	69
PI	PI:18|pi:5	post-injection:14:0.0011|post injection:9:0.3069	0.3069	23
PI	PI:46|pi:18|Pi:3	post inoculation:67:0.8515	0.8515	67
PI	PI:17|pi:5	postinjection:22:0.0017	0.0017	22
PI	PI:29|P-I:2	povidone-iodine:22:0.0017|povidone iodine:9:0.3455	0.3455	31
PI	PI:10	Primary isolates:10:0.7103	0.7103	10
PI	PI:16	principal investigator:16:0.6577	0.6577	16
PI	PI:42|Pi:1	proactive interference:43:0.9308	0.9308	43
PI	PI:38|Pi:2	proinsulin:40:0.0032	0.0032	40
PI	PI:13	proliferation indices:13:0.0765	0.0765	13
PI	PI:767|Pi:6|pI:1	Propidium iodide:774:0.9317	0.9317	774
PI	PI:509|Pi:54	protease inhibitor:402:0.7948|protease inhibitors:161:0.8244	0.8244	563
PI	PI:5|pI:4|pi:1	protein:10:0.0007	0.0007	10
PI	PI:13	protein I:13:0.1599	0.1599	13
PI	PI:10	pulmonary insufficiency:10:0.0787	0.0787	10
PI	PI:6	pulsatility indexes:6:0.0666	0.0666	6
PI	PI:35	pulsatility indices:35:0.3436	0.3436	35
PI	PI:34	pulse interval:34:0.4055	0.4055	34
PI	PI:8	putatively immune:8:0.5006	0.5006	8
pi	pi:20	surface pressure:14:0.0641|surface pressures:6:0.1838	0.1838	20
PI	PI:14|pi:3|p-i:1	weeks post-infection:18:0.0643	0.0643	18
PI	PI:12|pi:5	weeks post-inoculation:17:0.0634	0.0634	17
PI	PI:21|pi:2	weeks postinfection:23:0.0515	0.0515	23
PI	PI:5|P-I:1	weeks postirradiation:6:0.1320	0.1320	6
pJP4	pJP4:12	Ralstonia eutropha JMP134:12:0.7571	0.7571	12
PKA	PKA:1084|PK-A:25|Pk-A:3|PKa:2|pkA:1|Pka:1|pKA:1	cAMP-dependent protein kinase:1101:0.6968|cAMP-dependent protein kinases:16:0.5564	0.6968	1117
pKa	pKa:37|pKA:2	dissociation constants:20:0.4037|dissociation constant:19:0.2927	0.4037	39
pKa	pKa:10	ionization constant:10:0.0929	0.0929	10
PKA	PKA:28	prekallikrein activator:28:0.8251	0.8251	28
PKA	PKA:21|PK-A:7	protein kinase-A:28:0.7905	0.7905	28
PKB	PKB:322	protein kinase B:322:0.6916	0.6916	322
PKN	PKN:20	Protein kinase N:20:0.7173	0.7173	20
PLH	PLH:7|p-LH:2	lateral hypothalamus:9:0.4587	0.4587	9
pLH	pLH:10	porcine luteinizing hormone:10:0.5856	0.5856	10
PLMA	PLMA:29	ProSeal laryngeal mask airway:29:0.8472	0.8472	29
pMDIs	pMDIs:39|pMDIS:1	metered dose inhalers:40:0.9256	0.9256	40
pMDIs	pMDIs:14|p-MDIs:1	pressurized metered-dose inhalers:15:0.5818	0.5818	15
pMMO	pMMO:25	particulate methane monooxygenase:25:0.5095	0.5095	25
PMT	PMT:7	pacemaker-mediated tachycardia:7:0.2113	0.2113	7
PMT	PMT:7	parent management training:7:0.4438	0.4438	7
PMT	PMT:39|Pm-T:1	Pasteurella multocida toxin:40:0.7143	0.7143	40
PMT	PMT:9	percutaneous mechanical thrombectomy:9:0.6794	0.6794	9
PMT	PMT:34	photomultiplier tube:34:0.7306	0.7306	34
PMT	PMT:18	premenstrual tension:18:0.8365	0.8365	18
PMT	PMT:7	premotor time:7:0.2902	0.2902	7
PMT	PMT:17	protection motivation theory:17:0.8270	0.8270	17
PMT	PMT:15	putrescine N-methyltransferase:15:0.5818	0.5818	15
pN0	pN0:8	lymph nodes:8:0.3463	0.3463	8
PNBs	PNBs:17	prenucleolar bodies:17:0.8270	0.8270	17
PNPA	PNPA:16|pNPA:7|p-NPA:7	p-nitrophenyl acetate:30:0.8472	0.8472	30
PNPB	PNPB:8|p-NPB:2	p-nitrophenyl butyrate:10:0.7103	0.7103	10
PNPH	PNPH:13|p-NPH:3|pNPH:1	p-nitrophenol hydroxylase:17:0.8270	0.8270	17
pNPP	pNPP:49|PNPP:23|p-NPP:15	p-nitrophenyl phosphate:87:0.7926	0.7926	87
p-NPP	pNPP:20|p-NPP:20|PNPP:9|PNpP:1	p-nitrophenylphosphate:50:0.2722	0.2722	50
PNP	PNP:95|pNP:23|p-NP:16|pnp:1	p-nitrophenol:135:0.1590	0.1590	135
pNP	PNP:11|pNP:11|p-NP:3|pnp:1	p-nitrophenyl:26:0.0294	0.0294	26
PNP	PNP:5|pNP:4	para-nitrophenol:9:0.0094	0.0094	9
PNP	PNP:66	paraneoplastic pemphigus:66:0.9548	0.9548	66
PNP	PNP:14	pediatric nurse practitioner:14:0.7909	0.7909	14
PNP	PNP:8	platelet neutralization procedure:8:0.6411	0.6411	8
PNP	PNP:9	Poisson-Nernst-Planck:9:0.0094	0.0094	9
PNP	PNP:34	polyneuropathy:34:0.0389	0.0389	34
PNP	PNP:14	posterior neuropore:14:0.7909	0.7909	14
PNP	PNP:12	pyridoxine 5'-phosphate:12:0.7571	0.7571	12
PNSP	PNSP:1	penicillin-nonsusceptible S pneumoniae:1:0.1973	0.1973	1
PNSP	PNSP:7	penicillin-nonsusceptible Streptococcus pneumoniae:7:0.2902	0.2902	7
PNM	PNM:36	perinatal mortality:36:0.6666	0.6666	36
POA	POA:33|poa:1	pancreatic oncofetal antigen:34:0.9072	0.9072	34
POA	POA:7|Poa:1	phenoxyacetic acid:8:0.1367	0.1367	8
POA	POA:10	preoptic:10:0.0130	0.0130	10
POA	POA:1	preoptic and anterior hypothalamus:1:0.1320	0.1320	1
POA	POA:501|POa:1	preoptic area:502:0.9275	0.9275	502
POA	POA:7	preoptic area of the hypothalamus:7:0.4438	0.4438	7
POA	POA:10	pyrazinoic acid:10:0.2275	0.2275	10
pPDM	pPDM:11|p-PDM:1	N,N'-p-phenylenedimaleimide:12:0.4231	0.4231	12
pPNETs	pPNETs:8	peripheral primitive neuroectodermal tumors:8:0.6411	0.6411	8
pPVN	pPVN:14	paraventricular nucleus:14:0.6173	0.6173	14
pQCT	pQCT:9	peripheral QCT:9:0.6794	0.6794	9
pQCT	pQCT:251|PQCT:5|pQ-CT:1	peripheral quantitative computed tomography:257:0.9639	0.9639	257
PSAP	PSAP:16	Point Subtraction Aggression Paradigm:16:0.8165	0.8165	16
PSRs	PSRs:14	slowly adapting pulmonary stretch receptors:14:0.7909	0.7909	14
PSX	PSX:12	pseudoexfoliation:12:0.3143	0.3143	12
pSym	pSym:14	symbiotic plasmid:14:0.7909	0.7909	14
pT1	pT1:6	minimally invasive:6:0.1543	0.1543	6
pT3	pT3:4|PT3:1	pathologic stage T3:5:0.1973	0.1973	5
PT4	PT4:10|PT-4:1	phage type 4:11:0.7357	0.7357	11
P-TEFb	P-TEFb:53|p-TEFb:2	positive transcription elongation factor b:55:0.9132	0.9132	55
PTS-1	PTS-1:9	peptide transport system-1:9:0.6794	0.6794	9
PTS1	PTS1:28|PTS-1:2	peroxisomal targeting signal:30:0.7652	0.7652	30
PTS1	PTS1:21|PTS-1:4	peroxisomal targeting signal 1:15:0.5348|peroxisomal targeting signal-1:10:0.5000	0.5348	25
PTS1	PTS1:15|PTS-1:3	signal type 1:18:0.5940	0.5940	18
PVEP	PVEP:4|P-VEP:1|pVEP:1	pattern VEP:6:0.2243	0.2243	6
PVEP	PVEP:40|P-VEP:10	pattern visual evoked potential:30:0.5652|pattern visual evoked potentials:20:0.5021	0.5652	50
pVHL	pVHL:19	gene product:19:0.8449	0.8449	19
pVHL	pVHL:20	VHL protein:20:0.1827	0.1827	20
pVHL	pVHL:16	von Hippel-Lindau protein:16:0.8165	0.8165	16
pVHL	pVHL:13	von Hippel-Lindau tumor suppressor protein:13:0.7753	0.7753	13
pVIII	pVIII:8|PVIII:1	major coat protein:9:0.4587	0.4587	9
PV-ir	PV-ir:6|PV-IR:4|PV-Ir:1|pv-ir:1	parvalbumin-immunoreactive:12:0.3793	0.3793	12
p[NH]ppG	p[NH]ppG:19	guanosine 5'-[beta gamma-imido]triphosphate:19:0.8861	0.8861	19
PACG	PACG:80	primary angle-closure glaucoma:52:0.9099|primary angle closure glaucoma:28:0.8312	0.9099	80
PACE	PACE:9|PA-CE:1	electrophoresis:10:0.0544	0.0544	10
PACE	PACE:38	Program of All-inclusive Care for the Elderly:38:0.7750	0.7750	38
pain	pain:10|PAIN:1	nociceptive:11:0.0840	0.0840	11
Paw	Paw:173|PAW:9|PaW:1	Airway pressure:163:0.8612|airway pressures:20:0.6680	0.8612	183
PAW	PAW:10|Paw:1	pulmonary artery wedge:11:0.6182	0.6182	11
PC-PLC	PC-PLC:115|PC-plc:3|pcPLC:1	phospholipase C:119:0.8170	0.8170	119
pcd/pcd	pcd/pcd:14	Purkinje cell degeneration:14:0.7909	0.7909	14
PCD	PCD:9|pcd:1	detection:10:0.0066	0.0066	10
PCD	PCD:18	papillary collecting duct:18:0.8365	0.8365	18
PCD	PCD:82|pcd:1	Paraneoplastic cerebellar degeneration:83:0.9247	0.9247	83
PCD	PCD:25	Percutaneous catheter drainage:25:0.7679	0.7679	25
PCD	PCD:8|pcd:1	percutaneous drainage:9:0.0836	0.0836	9
PCD	PCD:14	plasma cell dyscrasia:14:0.7909	0.7909	14
PCD	PCD:28	Premature centromere division:28:0.8861	0.8861	28
PCD	PCD:107	primary ciliary dyskinesia:107:0.9723	0.9723	107
PCD	PCD:705|pcd:6	Programmed cell death:711:0.9654	0.9654	711
PCD	PCD:8	Pterin-4a-carbinolamine dehydratase:8:0.2090	0.2090	8
pcd	pcd:53|PCD:13	Purkinje cell degeneration:66:0.9286	0.9286	66
PDP	PDP:11	Pachydermoperiostosis:11:0.0520	0.0520	11
PDP	PDP:16	parallel distributed processing:16:0.8165	0.8165	16
PDP	PDP:2	Population and Development Program:2:0.3728	0.3728	2
PDP	PDP:6	process dissociation procedure:6:0.5290	0.5290	6
PDP	PDP:11	pyruvate dehydrogenase phosphatase:11:0.6182	0.6182	11
PDU	PDU:8	Doppler ultrasound:8:0.5006	0.5006	8
PDU	PDU:7	power Doppler ultrasonography:7:0.3524	0.3524	7
pdu	pdu:12	utilization:12:0.1864	0.1864	12
PDX-1	PDX-1:10|pdx-1:1	pancreatic and duodenal homeobox gene 1:6:0.6794|pancreatic and duodenal homeobox gene-1:5:0.6411	0.6794	11
PDX-1	PDX-1:10|Pdx1:3|Pdx-1:2	Pancreatic duodenal homeobox-1:10:0.7571|pancreatic duodenal homeobox 1:5:0.5290	0.7571	15
PD	PD:10	after pancreaticoduodenectomy:10:0.0597	0.0597	10
PD	PD:14	after pancreatoduodenectomy:14:0.1332	0.1332	14
PD	PD:8	along the proximodistal:8:0.2102	0.2102	8
PD	PD:7	cell membrane potential:7:0.1850	0.1850	7
PD	PD:6	coronary artery:6:0.2243	0.2243	6
PD	PD:6	cyclic nucleotide phosphodiesterase:6:0.5290	0.5290	6
PD	PD:10	depression:10:0.0007	0.0007	10
Pd	Pd:5|PD:2	diastolic pressure:7:0.0565	0.0565	7
Pd	Pd:13|PD:1	diffusional water permeability:14:0.5589	0.5589	14
PD	PD:11	disease of bone:11:0.7357	0.7357	11
PD	PD:10	disease progression:10:0.1680	0.1680	10
PD	PD:8|Pd:1	duration:9:0.0006	0.0006	9
PD	PD:17	paired domain:17:0.5760	0.5760	17
PD	PD:16	Pancreas divisum:16:0.8165	0.8165	16
PD	PD:15	pancreatic duct:15:0.6386	0.6386	15
PD	PD:417|Pd:1	panic disorder:418:0.7231	0.7231	418
PD	PD:5485|pd:3|Pd:1	Parkinson's disease:5480:0.8266|Parkinson's diseases:9:0.1945	0.8266	5489
PD	PD:3	Parkinson's disease with dementia:3:0.6794	0.6794	3
PD	PD:10	parkinsonian:10:0.0007	0.0007	10
PD	PD:9	Parkinsonism:9:0.0006	0.0006	9
PD	PD:64|Pd:1|pd:1	pars distalis:66:0.9548	0.9548	66
PD	PD:17	patients:17:0.0012	0.0012	17
PD	PD:12	percutaneous drainage:12:0.1830	0.1830	12
PD	PD:9	Perfusion defect:9:0.3069	0.3069	9
PD	PD:9	peripheral dose:9:0.1267	0.1267	9
PD	PD:13	peritoneal dialysate:13:0.7753	0.7753	13
PD	PD:1388|pd:1	peritoneal dialysis:1389:0.9932	0.9932	1389
PD	PD:8	peritoneal drainage:8:0.0756	0.0756	8
PD	PD:12	persistent diarrhea:12:0.5050	0.5050	12
PD	PD:12	persistent diarrhoea:12:0.7571	0.7571	12
PD	PD:181|Pd:1	personality disorder:122:0.1816|personality disorders:60:0.6391	0.6391	182
PD	PD:9	pharmacokinetic (PK)-pharmacodynamic:9:0.6794	0.6794	9
Pd	Pd:8|PD:3	Phosducin:11:0.0008	0.0008	11
PD	PD:23	phosphate depletion:23:0.6653	0.6653	23
PD	PD:9	pirfenidone:9:0.0006	0.0006	9
PD	PD:11	plasma desorption:11:0.5355	0.5355	11
PD	PD:12|Pd:7	plasmodesmata:19:0.0014	0.0014	19
PD	PD:6	platelet deposition:6:0.1543	0.1543	6
PD	PD:7	pneumatic dilatation:7:0.2452	0.2452	7
PD	PD:9	pneumatic dilation:9:0.3455	0.3455	9
PD	PD:18|pd:1	poorly differentiated:19:0.8449	0.8449	19
PD	PD:64|pd:4	population doublings:54:0.9448|population doubling:14:0.6911	0.9448	68
PD	PD:225|pd:14|Pd:4	Postnatal Day:180:0.9150|postnatal days:63:0.8430	0.9150	243
PD	PD:11	postural drainage:11:0.1547	0.1547	11
PD	PD:766|pd:14|Pd:5	potential difference:769:0.9619|potential differences:16:0.6024	0.9619	785
PD	PD:9	potential difference across the cell membrane:9:0.6794	0.6794	9
PD	PD:12	power density:12:0.0701	0.0701	12
PD	PD:49	power Doppler:49:0.5377	0.5377	49
PD	PD:15|Pd:1	prednisolone:16:0.0011	0.0011	16
PD	PD:7|Pd:1|pd:1	preferred direction:9:0.6794	0.6794	9
PD	PD:23	Prenatal diagnosis:23:0.7500	0.7500	23
P-D	P-D:10|PD:4	pressure-diameter:14:0.0010	0.0010	14
PD	PD:6	Preterm Delivery:6:0.1320	0.1320	6
PD	PD:61|pd:9	prism diopters:70:0.9573	0.9573	70
PD	PD:8|pd:1	prism dioptres:9:0.6794	0.6794	9
PD	PD:11	Prisoner's Dilemma:11:0.5355	0.5355	11
PD	PD:390|pd:1|P-D:1	probing depth:335:0.7706|probing depths:57:0.8478	0.8478	392
PD	PD:20|Pd:1	probing pocket depth:21:0.1722	0.1722	21
PD	PD:11	progressed:11:0.0008	0.0008	11
PD	PD:8	Prolidase deficiency:8:0.2090	0.2090	8
PD	PD:7|Pd:1|P-D:1	protein:9:0.0006	0.0006	9
PD	PD:13	protein degradation:13:0.3809	0.3809	13
PD	PD:5	protein deposition:5:0.0736	0.0736	5
PD	PD:33	proton density:33:0.3381	0.3381	33
PD	PD:9|P-D:5	proximal-distal:14:0.0010	0.0010	14
PD	PD:10|Pd:4|pd:2	pseudodeficiency:16:0.0011	0.0011	16
Pd	Pd:14|PD:3	Psychopathic deviate:17:0.8270	0.8270	17
PD	PD:22	pulsed Doppler:22:0.1790	0.1790	22
PD	PD:10	pupillary diameter:10:0.0989	0.0989	10
PD	PD:47	pyloric dilator:47:0.9366	0.9366	47
PD	PD:46	pyridostigmine:46:0.0035	0.0035	46
pet.	pet.:14	petrolatum:14:0.8667	0.8667	14
pfDHFR	pfDHFR:5|pfdhfr:3|PfDHFR:2	falciparum dihydrofolate reductase:10:0.5856	0.5856	10
pfcrt	pfcrt:15|Pfcrt:5|PfCRT:4|PFCRT:2	chloroquine resistance transporter:26:0.8251	0.8251	26
PFOR	PFOR:17	pyruvate:ferredoxin oxidoreductase:17:0.4742	0.4742	17
pgRNA	pgRNA:18	pregenomic RNA:18:0.6903	0.6903	18
PGCL	PGCL:10|PGCl:1	nucleus paragigantocellularis lateralis:11:0.5355	0.5355	11
PGIL	PGIL:7	primary gastrointestinal lymphoma:7:0.5926	0.5926	7
phox	phox:6|Phox:1	phagocyte NADPH oxidase:7:0.4438	0.4438	7
phox	phox:12	phagocyte oxidase:12:0.2549	0.2549	12
phaco	phaco:14	phacoemulsification:14:0.9286	0.9286	14
phage	phage:12	bacteriophage:12:0.6471	0.6471	12
phen	phen:76	1,10-phenanthroline:76:0.4032	0.4032	76
phen	phen:16	phenanthrene:16:0.0806	0.0806	16
phen	phen:11	phenanthroline:11:0.0538	0.0538	11
phen	phen:11	phentermine:11:0.0538	0.0538	11
phen	phen:13|PHEN:1|Phen:1	phentolamine:15:0.0753	0.0753	15
phen	phen:9	phenylephrine:9:0.0430	0.0430	9
pheos	pheos:6|PHEOs:2|Pheos:1	pheochromocytomas:9:0.8000	0.8000	9
phyB	phyB:30|PHYB:5|PhyB:4	phytochrome B:39:0.8455	0.8455	39
PIA	PIA:42	adenosine:42:0.0777	0.0777	42
PIA	PIA:10	N6-(L-2-phenylisopropyl)adenosine:10:0.0175	0.0175	10
PIA	PIA:40	N6-phenylisopropyladenosine:40:0.0738	0.0738	40
PIA	PIA:34	phenylisopropyladenosine:34:0.0621	0.0621	34
PIA	PIA:25	polysaccharide intercellular adhesin:25:0.8115	0.8115	25
PIA	PIA:6	pontine inhibitory area:6:0.5290	0.5290	6
PIA	PIA:23	pristane-induced arthritis:23:0.5997	0.5997	23
PIA	PIA:9	processing-independent analysis:9:0.2987	0.2987	9
PIA	PIA:5	receptor agonist (-)-N6-phenylisopropyladenosine:5:0.4422	0.4422	5
pi-A	pi-A:11|Pi-A:1	surface pressure-area:12:0.5050	0.5050	12
PI-G	PI-G:16|PIG:5	phosphatidylinositol-glycan:12:0.0585|phosphatidylinositol glycan:9:0.6794	0.6794	21
PILs	PILs:8	patient information leaflets:8:0.4102	0.4102	8
pilo	pilo:21|PILO:3|Pilo:2	Pilocarpine:26:0.7812	0.7812	26
Pins	Pins:10	Partner of Inscuteable:10:0.7103	0.7103	10
PINX	PINX:13|PIN-X:4|Pinx:3|pinx:3|PINx:2|pin-x:1	pinealectomized:26:0.7812	0.7812	26
PLCA	PLCA:8	primary localized cutaneous amyloidosis:8:0.6411	0.6411	8
Plk	Plk:21|PLK:18	polo-like kinase:39:0.6937	0.6937	39
PLNs	PLNs:22|pLNs:3	lymph nodes:25:0.8816	0.8816	25
PMPM	PMPM:12|pmpm:2	per member per month:14:0.8045	0.8045	14
PODs	PODs:25	PML oncogenic domains:25:0.6656	0.6656	25
PODs	PODs:42	postoperative days:42:0.8558	0.8558	42
polII	polII:8|PolII:6|Pol-II:1|POLII:1	RNA polymerase II:16:0.6577	0.6577	16
polh	polh:13|Polh:2	polyhedrin:15:0.5000	0.5000	15
polh	polh:8	polyhedrin gene:8:0.3463	0.3463	8
polio	polio:10	Poliomyelitis:10:0.5000	0.5000	10
polyP	polyP:59|poly-P:3|polyp:2|Poly-P:1	polyphosphate:65:0.7711	0.7711	65
polyQ	polyQ:93|poly-Q:4	polyglutamine:97:0.8348	0.8348	97
PORTs	PORTs:10	Research Teams:10:0.7103	0.7103	10
POSSUM	POSSUM:21	Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity:21:0.7581	0.7581	21
po	po:7|PO:2	administered:9:0.0037	0.0037	9
PO	PO:7|po:5	day of birth:12:0.3058	0.3058	12
PO	PO:3|po:1	granulosa cells of preovulatory:4:0.2818	0.2818	4
Po	Po:6|po:3	maximum isometric force:9:0.1945	0.1945	9
Po	Po:7|po:3	maximum isometric tension:10:0.1774	0.1774	10
Po	Po:5|po:3	Maximum isometric tetanic force:8:0.3463	0.3463	8
Po	Po:178|po:91|PO:1	open probability:261:0.7743|open probabilities:9:0.4587	0.7743	270
po	po:31|PO:23	orally:54:0.0243	0.0243	54
PO	PO:19|po:6	palm oil:25:0.2683	0.2683	25
PO	PO:9|po:6	paraoxon:15:0.0064	0.0064	15
po	po:6|PO:3	parieto-occipital:9:0.0037	0.0037	9
PO	PO:11	peanut oil:11:0.0691	0.0691	11
po	po:18|PO:6	per os:24:0.8768	0.8768	24
PO	PO:6|po:1	Perceptual Organization:7:0.1641	0.1641	7
po	po:7|PO:4	peroral:11:0.0046	0.0046	11
PO	PO:46|po:14|Po:1	peroxidase:61:0.0275	0.0275	61
PO	PO:6	Personality Organization:6:0.1010	0.1010	6
PO	PO:7|po:4	Phenol oxidase:11:0.2154	0.2154	11
PO	PO:48|po:19	phenoloxidase:67:0.0302	0.0302	67
PO	PO:26|po:15|P-O:1	phosphodiester:42:0.0188	0.0188	42
po	po:9	polyolefin:9:0.0037	0.0037	9
po	po:23	posterior:23:0.0101	0.0101	23
po	po:6	posterior complex:6:0.2243	0.2243	6
po	po:10	Posterior group of thalamic nuclei:10:0.7103	0.7103	10
po	po:12	posterior nuclear group:12:0.5664	0.5664	12
po	po:8	posterior nucleus:8:0.1591	0.1591	8
po	po:23	postoperative:23:0.0101	0.0101	23
po	po:62|PO:4	power output:57:0.9203|power outputs:9:0.6794	0.9203	66
po	po:8|PO:3	preoptic area:11:0.4232	0.4232	11
Po	Po:17|PO:9|po:5	pressure:31:0.0137	0.0137	31
PO	PO:11|po:5	principal olive:16:0.8165	0.8165	16
Po	Po:6|po:1	probability of being open:7:0.0951	0.0951	7
Po	Po:7|po:3	probability of channel opening:10:0.7103	0.7103	10
po	po:5|Po:1	probability of opening:6:0.0611	0.0611	6
Po	Po:3|po:2	probability of the channel being open:5:0.1132	0.1132	5
Po	Po:13|po:3	progesterone:16:0.0064	0.0064	16
PO	PO:5	prostate only:5:0.0902	0.0902	5
PO	PO:8|po:4	protein oxidation:12:0.6701	0.6701	12
PO	PO:9|po:2	Pulse oximetry:11:0.7357	0.7357	11
Po	Po:30|po:13|PO:2	tetanic tension:45:0.4264	0.4264	45
pp-vWF	pp-vWF:11	Propolypeptide of von Willebrand factor:11:0.7357	0.7357	11
PP12	PP12:29	Placental protein 12:29:0.6839	0.6839	29
p-p38	p-p38:8	phosphorylated p38:8:0.2987	0.2987	8
pp65	pp65:5	matrix phosphoprotein:5:0.1132	0.1132	5
pp65	pp65:8	phosphoprotein 65:8:0.3524	0.3524	8
ppET-1	ppET-1:13|PPET-1:12|ppET1:1	preproendothelin-1:26:0.4167	0.4167	26
ppGpp	ppGpp:23	guanosine 3',5'-bispyrophosphate:23:0.8715	0.8715	23
ppGpp	ppGpp:12	guanosine 3'-diphosphate 5'-diphosphate:12:0.7909	0.7909	12
ppGpp	ppGpp:55	guanosine 5'-diphosphate 3'-diphosphate:42:0.8753|guanosine-5'-diphosphate-3'-diphosphate:13:0.0529	0.8753	55
ppGpp	ppGpp:68	guanosine tetraphosphate:68:0.9554	0.9554	68
PPSOM	ppSOM:4|PPSOM:4|ppSom:1|pp-SOM:1	preprosomatostatin:10:0.8182	0.8182	10
ppbv	ppbv:6|ppbV:1	parts per billion by volume:7:0.6794	0.6794	7
PPH	PPH:4|PP-H:3	periportal hepatocytes:7:0.3524	0.3524	7
PPH	PPH:14	phosphatidate phosphohydrolase:14:0.4367	0.4367	14
PPH	PPH:24	postpartum haemorrhage:24:0.5848	0.5848	24
PPH	PPH:26	postpartum hemorrhage:26:0.6645	0.6645	26
PPH	PPH:31	Postprandial hypotension:31:0.9043	0.9043	31
PPH	PPH:417	primary pulmonary hypertension:417:0.8972	0.8972	417
ppmv	ppmv:4|ppmV:1	per million by volume:5:0.6411	0.6411	5
ppm	ppm:19	parts/million:19:0.0232	0.0232	19
ppm	ppm:344|PPM:4	parts per million:348:0.9039	0.9039	348
PPM	PPM:14	polypropylene mesh:14:0.7909	0.7909	14
PPM	PPM:7	professional practice model:7:0.5926	0.5926	7
pppGpp	pppGpp:8	guanosine 5'-triphosphate 3'-diphosphate:8:0.7103	0.7103	8
PPTR	PPTR:7	Pulsed photothermal radiometry:7:0.4438	0.4438	7
prcd	prcd:24|PRCD:4	progressive rod-cone degeneration:28:0.8861	0.8861	28
pre-BCR	pre-BCR:30|preBCR:1	pre-B cell receptor:31:0.8090	0.8090	31
pre-B	pre-B:12|preB:1	precursor B:13:0.6701	0.6701	13
pred	pred:63|Pred:4	prednisolone:67:0.3815	0.3815	67
pred	pred:63|Pred:4	prednisone:67:0.3815	0.3815	67
Pref-1	Pref-1:20|pref-1:5	Preadipocyte factor-1:15:0.7096|Preadipocyte factor 1:10:0.7103	0.7103	25
preop	preop:10	preoperatively:10:0.2903	0.2903	10
PREP	PREP:10|prep:1	education and practice:11:0.7357	0.7357	11
PRESS	PRESS:6	predicted residual sum of squares:6:0.5290	0.5290	6
PRIME	PRIME:12	Prospective Epidemiological Study of Myocardial Infarction:12:0.7357	0.7357	12
pro-uPA	pro-uPA:16|Pro-uPA:1	plasminogen activator:17:0.8270	0.8270	17
proANF	proANF:9|pro-ANF:7|ProANF:1	natriuretic factor:17:0.8270	0.8270	17
proANP	proANP:13|pro-ANP:9|ProANP:2|Pro-ANP:1	natriuretic peptide:25:0.8816	0.8816	25
proBNP	proBNP:9|pro-BNP:3|Pro-BNP:1	pro-brain natriuretic peptide:13:0.5335	0.5335	13
proCCK	proCCK:8|pro-CCK:5	procholecystokinin:13:0.7500	0.7500	13
ProCT	ProCT:16|pro-CT:2|proCT:2	proCalcitonin:20:0.9048	0.9048	20
proMBP	proMBP:23|pro-MBP:3|ProMBP:2	proform of eosinophil major basic protein:28:0.8422	0.8422	28
proPO	proPO:48|pro-PO:5	prophenoloxidase:53:0.7536	0.7536	53
proSS	proSS:5|Pro-SS:3|pro-SS:1	prosomatostatin:9:0.8000	0.8000	9
pro-TRH	pro-TRH:6	thyrotropin-releasing hormone prohormone:6:0.5290	0.5290	6
pro-vWF	pro-vWF:9	Willebrand factor:9:0.6794	0.6794	9
prtF	prtF:2	gene that encodes protein F:2:0.4422	0.4422	2
PrtP	PrtP:7|prtP:2	proteinase:9:0.4706	0.4706	9
PSCA	PSCA:31	Prostate stem cell antigen:31:0.9043	0.9043	31
PSFs	PSFs:15	point spread functions:15:0.8045	0.8045	15
PSI	PSI:10	inhibition:10:0.0094	0.0094	10
PSI	PSI:24	Inventory:24:0.0241	0.0241	24
psi	psi:7	membrane potential:7:0.1025	0.1025	7
psi	psi:8|Psi:1	packaging:9:0.0084	0.0084	9
Psi	Psi:6|psi:5	packaging signal:11:0.4728	0.4728	11
PSI	PSI:24	Parenting Stress Index:24:0.7593	0.7593	24
PSI	PSI:8	Paul Scherrer Institute:8:0.6411	0.6411	8
PSI	PSI:267|psi:9|PS-I:6	photosystem I:282:0.9238	0.9238	282
PSI	PSI:26	Pneumonia Severity Index:26:0.5040	0.5040	26
PSI	PSI:16	Population Services International:16:0.8165	0.8165	16
psi	psi:8|PSI:1	pounds per square inch:9:0.5470	0.5470	9
psi	psi:46|Psi:20|PSI:1	pseudouridine:67:0.0693	0.0693	67
Psi	Psi:5|psi:4	water potential:9:0.1945	0.1945	9
PSRA	PSRA:14	reactive arthritis:14:0.7753	0.7753	14
p-tHcy	p-tHcy:6|P-tHcy:2|ptHcy:1	plasma total homocysteine:9:0.6794	0.6794	9
Ptac	Ptac:6|ptac:2	tac promoter:8:0.2987	0.2987	8
PTA	PTA:24	pancreas transplant alone:16:0.8165|pancreas transplants alone:8:0.6411	0.8165	24
PTA	PTA:12	pancreas transplantation alone:12:0.7571	0.7571	12
PTA	PTA:13	Parallel tubular arrays:13:0.7753	0.7753	13
PTA	PTA:6	patellar tilt angle:6:0.3728	0.3728	6
PTA	PTA:926|pta:2	percutaneous transluminal angioplasty:913:0.9837|percutaneous transluminal angioplasties:15:0.8045	0.9837	928
PTA	PTA:23	peritonsillar abscess:23:0.8038	0.8038	23
PTA	PTA:12|pta:5	persistent truncus arteriosus:17:0.8270	0.8270	17
Pta	Pta:10|PTA:8|pta:8	phosphotransacetylase:26:0.0136	0.0136	26
PTA	PTA:71|pta:2	phosphotungstic acid:73:0.8191	0.8191	73
PTA	PTA:4	pontine taste area:4:0.1618	0.1618	4
PTA	PTA:58	post-traumatic amnesia:58:0.5638	0.5638	58
PTA	PTA:24	posttraumatic amnesia:24:0.1765	0.1765	24
PTA	PTA:20	predicted transmitting abilities:20:0.7766	0.7766	20
PTA	PTA:7	Prothymosin alpha:7:0.2452	0.2452	7
PTA	PTA:35|pta:1	pure tone audiometry:19:0.8449|Pure-tone audiometry:17:0.2788	0.8449	36
PTA	PTA:77	pure-tone average:53:0.5868|pure tone average:19:0.8449|pure-tone averages:5:0.1132	0.8449	77
PTI	PTI:3|pti:2	pancreatic trypsin inhibitor:5:0.2818	0.2818	5
PTI	PTI:9|PtI:1	pressure-time integral:10:0.4363	0.4363	10
pts.	pts.:73|Pts.:2	patients:75:0.9867	0.9867	75
pulA	pulA:5	pullulanase structural gene:5:0.2818	0.2818	5
PUMP	PUMP:8	plant uncoupling mitochondrial protein:8:0.5006	0.5006	8
PUN	PUN:16	plasma urea N:16:0.6024	0.6024	16
PUN	PUN:37	plasma urea nitrogen:37:0.7758	0.7758	37
PUPs	PUPs:16|Pups:1	previously untreated patients:17:0.8270	0.8270	17
PurR	PurR:13	purine repressor:13:0.4849	0.4849	13
PUR	PUR:30|PU-R:1	polyurethane:31:0.3846	0.3846	31
pur	pur:9|Pur:1	puromycin:10:0.1154	0.1154	10
put	put:10|PUT:1|Put:1	proline utilization:12:0.7571	0.7571	12
put	put:104|PUT:5|Put:2	putrescine:111:0.7006	0.7006	111
PUU	PUU:16	Puumala virus:16:0.8165	0.8165	16
PYAR	PYAR:10|pyar:3	person-years at risk:7:0.1641|person years at risk:6:0.5290	0.5290	13
PYC	PYC:13|pyc:1	Pycnogenol:14:0.2653	0.2653	14
PYC	PYC:15|pyc:6	pyruvate carboxylase:21:0.8594	0.8594	21
PYK	PYK:15|pyk:4|PyK:2|Pyk:2	pyruvate kinase:23:0.7046	0.7046	23
q(2)	q(2):10|Q(2):1	cross-validated R(2):11:0.7357	0.7357	11
q.d.	q.d.:12	once daily:12:0.5355	0.5355	12
qBEI	qBEI:9	quantitative backscattered electron imaging:9:0.6794	0.6794	9
QMRI	QMRI:4|qMRI:4	Quantitative magnetic resonance imaging:8:0.4102	0.4102	8
QNP	QNP:13	quinpirole:13:0.7500	0.7500	13
QID	QID:9|qid:4	four times daily:13:0.5934	0.5934	13
qk	qk:24|Qk:5|QK:1	quaking:30:0.8333	0.8333	30
QPM	QPM:12	quality protein maize:12:0.7571	0.7571	12
quartz	quartz:15	crystalline silica:15:0.3614	0.3614	15
quokka	quokka:16|Quokka:2	Setonix brachyurus:18:0.8365	0.8365	18
Q-V	Q-V:10	charge-voltage:10:0.2143	0.2143	10
r.b.e.	r.b.e.:11|R.B.E.:2	relative biological effectiveness:13:0.7753	0.7753	13
r.h.	r.h.:26|R.H.:10	relative humidity:36:0.9197	0.9197	36
r.m.s.	r.m.s.:69	root-mean-square:43:0.5676|root mean square:26:0.8861	0.8861	69
R2	R2:9	component:9:0.0070	0.0070	9
R2	R2:8	late response:8:0.2987	0.2987	8
R2	R2:5|r2:4	regulatory subunit:9:0.2102	0.2102	9
R2	R2:10	resistance:10:0.0079	0.0079	10
R2	R2:9	small subunit:9:0.2102	0.2102	9
R2	R2:29	transverse relaxation rate:18:0.4672|transverse relaxation rates:11:0.4728	0.4728	29
R2	R2:10|r2:1	variability:11:0.0088	0.0088	11
R2	R2:10|r2:3	variation:13:0.0105	0.0105	13
rAAV2	rAAV2:7	Recombinant adeno-associated virus serotype 2:7:0.4438	0.4438	7
rANF	rANF:10|r-ANF:1	rat atrial natriuretic factor:11:0.7357	0.7357	11
rANP	rANP:23	rat atrial natriuretic peptide:23:0.5236	0.5236	23
rASVs	rASVs:6	recovered avian sarcoma viruses:6:0.5290	0.5290	6
rBMD	rBMD:5|RBMD:3	bone mineral density:8:0.5006	0.5006	8
rBNP	rBNP:8	Rat brain natriuretic peptide:8:0.6411	0.6411	8
rBPI21	rBPI21:21	bactericidal/permeability-increasing protein:21:0.5435	0.5435	21
rBPI23	rBPI23:13|rBPI-23:1	bactericidal/permeability-increasing protein:14:0.3585	0.3585	14
rCBF	rCBF:4|r-CBF:2	cerebral perfusion:6:0.2243	0.2243	6
rCBF	rCBF:113|r-CBF:1|RCBF:1	regional CBF:115:0.9212	0.9212	115
rCBF	rCBF:2434|r-CBF:23|RCBF:15|rcbf:2	regional cerebral blood flow:2461:0.9570|Regional cerebral blood flows:13:0.6701	0.9570	2474
rCBF	rCBF:8	regional cerebral bloodflow:8:0.5006	0.5006	8
rCBV	rCBV:88	relative cerebral blood volume:88:0.3100	0.3100	88
rCD4	rCD4:13	recombinant CD4:13:0.2415	0.2415	13
rCD4	rCD4:9	recombinant soluble CD4:9:0.6794	0.6794	9
rCGRP	rCGRP:14	rat calcitonin gene-related peptide:14:0.6911	0.6911	14
RCGU	RCGU:14|rCGU:11	regional cerebral glucose utilization:25:0.8186	0.8186	25
rCMRGl	rCMRGl:4	regional cerebral metabolic rate of glucose:4:0.6911	0.6911	4
rCMRO2	rCMRO2:16	oxygen consumption:16:0.8165	0.8165	16
rCO2	rCO2:7	CO2 production:7:0.3524	0.3524	7
rCRF	rCRF:9	rat corticotropin-releasing factor:9:0.4587	0.4587	9
rCTB	rCTB:21	recombinant cholera toxin B subunit:21:0.6680	0.6680	21
rCVR	rCVR:7	regional cerebrovascular resistance:7:0.5926	0.5926	7
RCL	RCL:19	reactive center loop:19:0.8449	0.8449	19
RCL	RCL:10	reactive centre loop:10:0.7103	0.7103	10
RC	RC:16	capacity:16:0.0098	0.0098	16
RC	RC:21|Rc:1|R-C:1	cells:23:0.0144	0.0144	23
Rc	Rc:6|RC:2	central airway resistance:8:0.6794	0.6794	8
RC	RC:43|rc:4|Rc:2	coefficient:39:0.0248|coefficients:10:0.0059	0.0248	49
RC	RC:22	fetal rat calvaria:22:0.4689	0.4689	22
RC	RC:11	radical cystectomy:11:0.7357	0.7357	11
RC	RC:5	rapid cycling:5:0.1132	0.1132	5
RC	RC:234	reaction center:193:0.9200|reaction centers:41:0.9274	0.9274	234
RC	RC:17	reaction centre:17:0.6748	0.6748	17
Rc	Rc:9	receptor:9:0.0052	0.0052	9
RC	RC:14	recombinant congenic:14:0.7909	0.7909	14
RC	RC:5	rectal cancer:5:0.0736	0.0736	5
RC	RC:8	Referred Care:8:0.1895	0.1895	8
RC	RC:17	regenerated cellulose:17:0.8270	0.8270	17
RC	RC:7	reliable change:7:0.2113	0.2113	7
RC	RC:8	renal cell carcinoma:8:0.5006	0.5006	8
RC	RC:12	replication complex:12:0.2699	0.2699	12
RC	RC:24	respiratory chain:24:0.8768	0.8768	24
RC	RC:29	resting zone:29:0.8978	0.8978	29
RC	RC:49|rc:1	rib cage:50:0.9064	0.9064	50
RC	RC:22	right coronary:22:0.8657	0.8657	22
RC	RC:29	rolling-circle:17:0.0105|rolling circle:12:0.7571	0.7571	29
RC	RC:9	rotator cuff:9:0.6794	0.6794	9
rDAO	rDAO:8	rostral dorsal accessory olive:8:0.5006	0.5006	8
rDNAs	rDNAs:14	ribosomal DNAs:14:0.6911	0.6911	14
rDNA	rDNA:42	16S rRNA gene:42:0.4602	0.4602	42
rDNA	rDNA:4	genes coding for rRNA:4:0.0545	0.0545	4
rDNA	rDNA:710	ribosomal DNA:710:0.9053	0.9053	710
rDNA	rDNA:19	ribosomal RNA:19:0.7658	0.7658	19
rDNA	rDNA:113	ribosomal RNA gene:58:0.8937|Ribosomal RNA genes:55:0.9147	0.9147	113
r-EAE	R-EAE:4|r-EAE:4|REAE:2|rEAE:1	relapsing experimental allergic encephalomyelitis:11:0.4232	0.4232	11
R-EAE	R-EAE:23|REAE:1|rEAE:1	relapsing experimental autoimmune encephalomyelitis:25:0.5969	0.5969	25
rEGF	rEGF:6|r-EGF:3|REGF:1	epidermal growth factor:10:0.5856	0.5856	10
rENaC	rENaC:11	rat epithelial Na+ channel:11:0.6182	0.6182	11
RERs	RERs:33	replication errors:33:0.9100	0.9100	33
rEpo	rEpo:5|rEPO:3|r-epo:2|r-EPO:1	recombinant EPO:11:0.5355	0.5355	11
rEpo	rEpo:25|rEPO:21|r-EPO:15|r-Epo:3|R-EPO:1	recombinant erythropoietin:65:0.5704	0.5704	65
rEPO	rEPO:16|r-EPO:4|rEpo:4|R-EPO:2|r-epo:1	recombinant human erythropoietin:27:0.8903	0.8903	27
rFPV	rFPV:8	recombinant fowlpox virus:8:0.5006	0.5006	8
rFSH	rFSH:15|r-FSH:6	recombinant follicle stimulating hormone:21:0.4733	0.4733	21
rFSH	rFSH:48	recombinant FSH:48:0.6121	0.6121	48
rFVIII	rFVIII:25|r-FVIII:1	Recombinant Factor VIII:26:0.6973	0.6973	26
rFVIII	rFVIII:23|r-FVIII:1	recombinant FVIII:24:0.7151	0.7151	24
rFVIIa	rFVIIa:101	recombinant activated factor VII:101:0.9529	0.9529	101
rFVIIa	rFVIIa:105|rF-VIIa:2|rfVIIa:1|r-FVIIa:1	recombinant factor VIIa:109:0.7722	0.7722	109
rFVIIa	rFVIIa:15	recombinant FVIIa:15:0.6386	0.6386	15
rG-CSF	rG-CSF:11|rGCSF:2	granulocyte colony stimulating factor:13:0.7753	0.7753	13
rG-CSF	rG-CSF:48|rGCSF:1	recombinant granulocyte colony-stimulating factor:49:0.4639	0.4639	49
rG-CSF	rG-CSF:34	recombinant human granulocyte colony-stimulating factor:34:0.9126	0.9126	34
rGH	rGH:83|RGH:2	rat growth hormone:85:0.5880	0.5880	85
rGM-CSF	rGM-CSF:14	granulocyte-macrophage colony stimulating factor:14:0.6173	0.6173	14
rGM-CSF	rGM-CSF:12	recombinant GM-CSF:12:0.5050	0.5050	12
rGM-CSF	rGM-CSF:40	recombinant granulocyte-macrophage colony-stimulating factor:40:0.6077	0.6077	40
rHBsAg	rHBsAg:17|r-HBsAg:3	recombinant hepatitis B surface antigen:20:0.7173	0.7173	20
rHDL	rHDL:38|R-HDL:3|r-HDL:1	high density lipoproteins:23:0.8715|high density lipoprotein:19:0.8449	0.8715	42
rHDL	rHDL:43|R-HDL:2|r-HDL:1	reconstituted HDL:46:0.6519	0.6519	46
rHDL	rHDL:6|R-HDL:1	Reconstituted high-density lipoprotein:7:0.3524	0.3524	7
rHGF	rHGF:11	recombinant HGF:11:0.7357	0.7357	11
rHPC	rHPC:6|rhPC:4	recombinant human Protein C:10:0.5856	0.5856	10
rHSA	rHSA:34	recombinant human serum albumin:34:0.7841	0.7841	34
rHb1.1	rHb1.1:14	recombinant human hemoglobin:14:0.7909	0.7909	14
rHuEPO	rHuEPO:23|rHuEpo:12|r-HuEPO:3|rhuEPO:1|rHu-EPO:1	recombinant human EPO:40:0.9256	0.9256	40
rHuEPO	rHuEPO:548|r-HuEPO:205|rHuEpo:195|rHu-EPO:31|r-HuEpo:19|rhuEPO:13|r-huEPO:10|r-Hu-EPO:9|rHu-Epo:6|rhu-EPO:5|rhuEpo:4|r-hu-Epo:3|rHU-EPO:2|r-hu-EPO:2|RHuEPO:2|r-HuEPo:2|rHu-epo:1|r-Hu-Epo:1|rhu-Epo:1|r-huepo:1|r-HUEPO:1|rHUEPO:1|rHuEPo:1|R-HuEpo:1|r-huEpo:1|R-Hu-EPO:1	recombinant human erythropoietin:1066:0.9886	0.9886	1066
rHuKGF	rHuKGF:7	recombinant human keratinocyte growth factor:7:0.5926	0.5926	7
rHuTNF	rHuTNF:22|rHu-TNF:9|rhuTNF:1	Recombinant human tumor necrosis factor:32:0.9072	0.9072	32
rIFN	rIFN:19|r-IFN:2	recombinant interferon:21:0.5178	0.5178	21
rIGF-II	rIGF-II:7|rIGFII:2	rat insulin-like growth factor II:9:0.5470	0.5470	9
rIL-12	rIL-12:22	recombinant IL-12:22:0.7400	0.7400	22
rIL-12	rIL-12:13	recombinant interleukin-12:13:0.5335	0.5335	13
rIL-1	rIL-1:13	interleukin 1:13:0.7753	0.7753	13
rIL-1	rIL-1:10|rIl-1:1	recombinant IL-1:11:0.3829	0.3829	11
rIL-1	rIL-1:17|RIL-1:1	recombinant interleukin-1:18:0.6381	0.6381	18
rIL-6	rIL-6:19	recombinant IL-6:19:0.4852	0.4852	19
rIL-6	rIL-6:7	recombinant interleukin-6:7:0.2113	0.2113	7
rIL-2	rIL-2:136|r-IL-2:6|RIL-2:4|rIl-2:2	recombinant IL-2:148:0.8424	0.8424	148
rIL2	rIL2:15	recombinant IL2:15:0.7096	0.7096	15
rIL-2	rIL-2:714|rIL2:58|RIL-2:22|r-IL2:11|r-IL-2:4|R-IL2:2|RIL2:1	recombinant interleukin-2:601:0.8521|recombinant interleukin 2:211:0.8323	0.8521	812
rIL-3	rIL-3:9	recombinant IL-3:9:0.4587	0.4587	9
rIL-3	rIL-3:27|rIL3:2|r-IL-3:1|rIl-3:1	recombinant interleukin-3:18:0.3412|recombinant interleukin 3:13:0.4444	0.4444	31
ri	ri:7|Ri:2	Internal longitudinal resistance:9:0.3455	0.3455	9
ri	ri:5|Ri:1	internal radius:6:0.1543	0.1543	6
RI	RI:27	interval:18:0.0062|intervals:9:0.0029	0.0062	27
rI	rI:11|ri:6|Ri:5|RI:2	intraclass correlation coefficient:19:0.8449|intraclass correlation coefficients:5:0.1973	0.8449	24
RI	RI:37	radioisotope:37:0.0132	0.0132	37
RI	RI:6	radionuclide imaging:6:0.2243	0.2243	6
RI	RI:330|ri:1|Ri:1	recombinant inbred:332:0.9855	0.9855	332
RI	RI:8	recurrent inhibition:8:0.0863	0.0863	8
RI	RI:9	regular insulin:9:0.6794	0.6794	9
RI	RI:18	relapse incidence:18:0.5560	0.5560	18
RI	RI:12	renal impairment:12:0.6460	0.6460	12
RI	RI:36|Ri:1	Renal insufficiency:37:0.6250	0.6250	37
RI	RI:7	reperfusion injury:7:0.2113	0.2113	7
RI	RI:24	replicative intermediate:24:0.6767	0.6767	24
RI	RI:8	resistance indexes:8:0.2090	0.2090	8
RI	RI:21	resistance indices:21:0.2291	0.2291	21
RI	RI:13	resistive indices:13:0.1046	0.1046	13
Ri	Ri:12|RI:1	resistivity:13:0.0044	0.0044	13
RI	RI:9	respiratory insufficiency:9:0.0591	0.0591	9
RI	RI:9	retroactive interference:9:0.6794	0.6794	9
RI	RI:18|Ri:9	ribonuclease inhibitor:27:0.4692	0.4692	27
RI	RI:4|Ri:2	ribonuclease inhibitor protein:6:0.5290	0.5290	6
RI	RI:36	type I:36:0.5303	0.5303	36
RI	RI:5|R-I:1	type I cAMP-dependent protein kinase:6:0.5290	0.5290	6
RI	RI:6|R-I:1	type I regulatory:7:0.5926	0.5926	7
RI	RI:14|R-I:1	type I regulatory subunit:15:0.7096	0.7096	15
rK1	rK1:12	Tissue kallikrein:12:0.7571	0.7571	12
RKBP	RKBP:9|rKBP:1	rat kallikrein-binding protein:10:0.7103	0.7103	10
RK	RK:19	rabbit kidney:19:0.2539	0.2539	19
RK	RK:157	Radial Keratotomy:157:0.9333	0.9333	157
RK	RK:18	remnant kidney:18:0.2332	0.2332	18
RK	RK:32|Rk:1	Rhodopsin kinase:33:0.6976	0.6976	33
rLHR	rLHR:7	rat lutropin/choriogonadotropin receptor:7:0.5926	0.5926	7
rLH	rLH:14|RLH:2|r-LH:1	luteinizing hormone:17:0.6748	0.6748	17
RLH	RLH:25	reactive lymphoid hyperplasia:25:0.8816	0.8816	25
rM-CSF	rM-CSF:9	macrophage colony-stimulating factor:9:0.6794	0.6794	9
rMSCs	rMSCs:6	Rat marrow stromal cells:6:0.5290	0.5290	6
rMTT	rMTT:20	mean transit time:20:0.8525	0.8525	20
rMVA	rMVA:6	recombinant modified vaccinia virus Ankara:6:0.3728	0.3728	6
rNAPc2	rNAPc2:10	Recombinant nematode anticoagulant protein c2:10:0.7103	0.7103	10
ROAT	ROAT:22	repeated open application test:22:0.7955	0.7955	22
rOEF	rOEF:48	oxygen extraction fraction:48:0.9379	0.9379	48
ROMP	ROMP:23	Ring-opening metathesis polymerization:23:0.7046	0.7046	23
rPAI-1	rPAI-1:9	recombinant plasminogen activator inhibitor-1:9:0.4587	0.4587	9
rPF4	rPF4:9	recombinant platelet factor 4:9:0.4587	0.4587	9
r-pGH	r-pGH:6|rpGH:5|rPGH:2	Recombinant porcine growth hormone:13:0.6701	0.6701	13
rPL	rPL:13|RPL:1	rat placental lactogen:14:0.6911	0.6911	14
RPL	RPL:62	recurrent pregnancy loss:62:0.9003	0.9003	62
rPRL	rPRL:48|rPrl:3|r-PRL:1	rat prolactin:52:0.6826	0.6826	52
rRNAs	rRNAs:47	ribosomal RNAs:47:0.9006	0.9006	47
rRNA	rRNA:49|r-RNA:1	ribosomal ribonucleic acid:50:0.8776	0.8776	50
rRNA	rRNA:656|r-RNA:4	ribosomal RNA:660:0.9682	0.9682	660
rSCF	rSCF:10	stem cell factor:10:0.7103	0.7103	10
rSO(2)	rSO(2):15|rSo(2):1	oxygen saturation:16:0.8165	0.8165	16
rSO2	rSO2:15|rSo2:1	regional oxygen saturation:16:0.1356	0.1356	16
rT(3)	rT(3):9	reverse T(3):9:0.6794	0.6794	9
rT3	rT3:14	reverse tri-iodothyronine:14:0.7909	0.7909	14
rTAP	rTAP:19|r-TAP:3	Recombinant tick anticoagulant peptide:22:0.7400	0.7400	22
rTFPI	rTFPI:14	recombinant TFPI:14:0.4709	0.4709	14
rTFPI	rTFPI:14|r-TFPI:1	Recombinant tissue factor pathway inhibitor:15:0.5348	0.5348	15
rTMS	rTMS:37|RTMS:1	Repetitive TMS:38:0.8098	0.8098	38
rTMS	rTMS:440|RTMS:5|r-TMS:1	repetitive transcranial magnetic stimulation:446:0.9052	0.9052	446
rTNF	rTNF:8	necrosis factor alpha:8:0.6411	0.6411	8
rTNF	rTNF:18|RTNF:2|r-TNF:1	recombinant human tumor necrosis factor:21:0.8525	0.8525	21
rTNF	rTNF:18	recombinant TNF:18:0.6381	0.6381	18
rTNF	rTNF:53|RTNF:1|r-TNF:1	recombinant tumor necrosis factor:55:0.5459	0.5459	55
rt-PA	rt-PA:22	recombinant t-PA:22:0.6934	0.6934	22
rt-PA	rt-PA:280|rtPA:104|rTPA:38|r-TPA:19|r-tPA:12|rt-Pa:2|rtpa:1|Rt-PA:1	recombinant tissue plasminogen activator:457:0.8655	0.8655	457
rt-PA	rt-PA:292|rTPA:17|rtPA:14|r-tPA:5|r-t-PA:2|r-TPA:1|RTPA:1|rT-PA:1	recombinant tissue-type plasminogen activator:333:0.7642	0.7642	333
RUTI	RUTI:7|rUTI:2	recurrent urinary tract infections:9:0.5470	0.5470	9
rVIIa	rVIIa:11	recombinant factor VIIa:11:0.7357	0.7357	11
rVRG	rVRG:10|r-VRG:1	rostral ventral respiratory group:11:0.5355	0.5355	11
RADS	RADS:41	reactive airways dysfunction syndrome:41:0.9256	0.9256	41
rAds	rAds:6|RAds:2|Rads:1	recombinant adenoviruses:9:0.6794	0.6794	9
RADS	RADS:11	Reynolds Adolescent Depression Scale:11:0.6182	0.6182	11
rad	rad:10	radiation-sensitive:10:0.0310	0.0310	10
RAD	RAD:6|rad:1	reactive airway disease:7:0.5926	0.5926	7
rAd	rAd:21|RAd:3	Recombinant adenovirus:24:0.6122	0.6122	24
RAD	RAD:9	renal tubule assist device:9:0.6794	0.6794	9
rafts	rafts:9	membrane domains:9:0.2764	0.2764	9
raft	raft:22	organotypic:22:0.3000	0.3000	22
RAFT	RAFT:9|raft:1	reversible addition-fragmentation chain transfer:10:0.7103	0.7103	10
RAGE	RAGE:7	AGE receptor:7:0.0809	0.0809	7
RAGE	RAGE:129|rage:1	receptor for advanced glycation end products:109:0.9582|receptor for advanced glycation end-products:15:0.6911|receptor for advanced glycation end product:6:0.3524	0.9582	130
RAGE	RAGE:19	receptor for advanced glycation endproducts:19:0.8525	0.8525	19
RAGE	RAGE:72	receptor for AGE:57:0.8731|receptor for AGEs:15:0.7096	0.8731	72
RALES	RALES:25	Randomized Aldactone Evaluation Study:25:0.8115	0.8115	25
RAMP	RAMP:36	receptor activity-modifying protein:16:0.8165|receptor activity modifying protein:12:0.7571|receptor-activity-modifying proteins:8:0.1850	0.8165	36
RAM	RAM:9|rAM:2|ram:1	alveolar macrophages:12:0.7571	0.7571	12
RAM	RAM:36	radial arm maze:36:0.9174	0.9174	36
RAM	RAM:10|ram:3	random access memory:13:0.7753	0.7753	13
RAM	RAM:21	restricted access material:21:0.8594	0.8594	21
RAM	RAM:10	Restricted Access Media:10:0.7103	0.7103	10
ram	ram:5|Ram:4	Ribosomal ambiguity:9:0.4587	0.4587	9
RANK	RANK:7	receptor activator of NF-kappa B:7:0.4438	0.4438	7
RANK	RANK:41	receptor activator of NF-kappaB:41:0.8525	0.8525	41
RANK	RANK:5	receptor activator of NFkappaB:5:0.6794	0.6794	5
RANK	RANK:8	receptor activator of nuclear factor kappa B:8:0.6411	0.6411	8
RANK	RANK:38	receptor activator of nuclear factor-kappaB:24:0.8115|receptor activator of nuclear factor kappaB:14:0.7909	0.8115	38
RARE	RARE:64	Rapid Acquisition with Relaxation Enhancement:64:0.9335	0.9335	64
RARE	RARE:17	RecA-assisted restriction endonuclease:17:0.8270	0.8270	17
RARE	RARE:67	retinoic acid response element:62:0.9519|retinoic acid response elements:5:0.4422	0.9519	67
rats	rats:7	small laboratory animals:7:0.1850	0.1850	7
rat	rat:1	allogeneic or a xenogeneic:1:0.0731	0.0731	1
rat	rat:8	animal model:8:0.3463	0.3463	8
rat	rat:10	heterologous:10:0.0107	0.0107	10
rat	rat:12	homologous:12:0.0130	0.0130	12
rat	rat:36	mammalian:36:0.0415	0.0415	36
rbFGF	rbFGF:10	basic fibroblast growth factor:10:0.7103	0.7103	10
rbGH	rbGH:10	recombinant bovine GH:10:0.5856	0.5856	10
rbGH	rbGH:9|r-bGH:3	recombinant bovine growth hormone:12:0.4728	0.4728	12
rbST	rbST:33|rBST:6|rbSt:5|RBST:1	recombinant bovine somatotropin:45:0.7461	0.7461	45
rcG-CSF	rcG-CSF:10	Recombinant canine granulocyte colony-stimulating factor:10:0.7103	0.7103	10
rcGH	rcGH:9|r-cGH:1	chicken growth hormone:10:0.5856	0.5856	10
rcd1	rcd1:4|RCD1:1	rod-cone dysplasia type 1:5:0.4422	0.4422	5
rdgB	rdgB:14|RdgB:3	retinal degeneration B:17:0.8270	0.8270	17
re-	re-:16	recombinant:16:0.3947	0.3947	16
re-OLT	re-OLT:8|Re-OLT:1	retransplantation:9:0.5000	0.5000	9
recFSH	recFSH:5|rec-FSH:1	follicle-stimulating hormone:6:0.2243	0.2243	6
redox	redox:54|REDOX:2	oxidation-reduction:45:0.2514|oxidation/reduction:11:0.0571	0.2514	56
redox	redox:79|REDOX:2|red-ox:1|Redox:1	reduction-oxidation:46:0.2514|reduction/oxidation:37:0.2057	0.2514	83
red	red:8	long-wavelength:8:0.0239	0.0239	8
red	red:6	P450 reductase:6:0.1148	0.1148	6
RED	RED:51|red:4	repeat expansion detection:55:0.9458	0.9458	55
Ref-1	Ref-1:33|ref-1:3	redox factor-1:29:0.7581|redox factor 1:7:0.4438	0.7581	36
reg	reg:15|Reg:1	regenerating:16:0.1339	0.1339	16
reg	reg:12	regenerating gene:12:0.5664	0.5664	12
REG	REG:14|reg:3	rheoencephalography:17:0.1429	0.1429	17
relCBF	relCBF:6|rel-CBF:2	cerebral blood flow:8:0.6411	0.6411	8
REL	REL:13	Recommended Exposure Limit:13:0.7753	0.7753	13
rep-PCR	rep-PCR:13|REP-PCR:10|Rep-PCR:2|repPCR:1	polymerase chain reaction:26:0.7679	0.7679	26
rep-PCR	rep-PCR:13|REP-PCR:1|Rep-PCR:1	repetitive element sequence-based PCR:15:0.8045	0.8045	15
rep-PCR	rep-PCR:9|REP-PCR:1	repetitive sequence-based PCR:10:0.1223	0.1223	10
REPs	REPs:9	relative potencies:9:0.6794	0.6794	9
rest	rest:6|REST:5	Restricted environmental stimulation therapy:11:0.4232	0.4232	11
REST	REST:19|rest:6	transcription factor:25:0.7046	0.7046	25
retGC	retGC:10|RetGC:6	guanylyl cyclase:16:0.4832	0.4832	16
RETs	RETs:5	peripheral blood reticulocytes:5:0.4422	0.4422	5
RFM	RFM:7	cows with retained fetal membranes:7:0.3463	0.3463	7
rgp120	rgp120:31	recombinant gp120:31:0.6131	0.6131	31
rgp160	rgp160:21|r-gp160:1	recombinant gp160:22:0.5581	0.5581	22
rhAPC	rhAPC:21|rh-APC:1	recombinant human activated protein C:22:0.8657	0.8657	22
rhBMP-2	rhBMP-2:28	recombinant human BMP-2:28:0.8941	0.8941	28
rhBMP-2	rhBMP-2:16	recombinant human bone morphogenetic protein:16:0.8165	0.8165	16
rhBMP-2	rhBMP-2:226|rhBMP2:6|rh-BMP2:1	recombinant human bone morphogenetic protein-2:198:0.9678|recombinant human bone morphogenetic protein 2:35:0.9151	0.9678	233
rhC5a	rhC5a:7|rHC5a:2	recombinant human C5a:9:0.6794	0.6794	9
RhCMV	RhCMV:15|rhCMV:1	rhesus cytomegalovirus:16:0.8165	0.8165	16
rHCNTF	rHCNTF:5|rhCNTF:4|rh-CNTF:1|rH-CNTF:1	recombinant human ciliary neurotrophic factor:11:0.7357	0.7357	11
rhEGF	rhEGF:21	Recombinant human epidermal growth factor:21:0.8594	0.8594	21
rhEPO	rhEPO:22|rhEpo:10|rh-EPO:3|r-hEPO:1	recombinant human EPO:36:0.9174	0.9174	36
rhEPO	rhEPO:182|rhEpo:59|rh-EPO:23|rh-Epo:13|rH-EPO:7|r-hEPO:3|rHEpo:3|RhEPO:3|rh-epo:1|RHEPO:1|r-HEPO:1|Rh-EPO:1	recombinant human erythropoietin:297:0.9686	0.9686	297
rhFSH	rhFSH:6|r-hFSH:2|r-HFSH:1	recombinant human follicle stimulating hormone:9:0.7103	0.7103	9
rhFSH	rhFSH:34|r-hFSH:17	recombinant human FSH:51:0.9427	0.9427	51
rhG-CSF	rhG-CSF:37|rh-G-CSF:1	recombinant human G-CSF:38:0.9217	0.9217	38
rhG-CSF	rhG-CSF:473|rhGCSF:4|rh-G-CSF:4|RHG-CSF:1|rh-GCSF:1	Recombinant human granulocyte colony-stimulating factor:398:0.9838|recombinant human granulocyte colony stimulating factor:48:0.9027|Recombinant human granulocyte-colony stimulating factor:37:0.9197	0.9838	483
rhGH	rhGH:9|r-hGH:4	recombinant hGH:13:0.6701	0.6701	13
rhGH	rhGH:135|r-hGH:5|rh-GH:1|rHGH:1	recombinant human GH:142:0.9357	0.9357	142
rhGH	rhGH:446|r-hGH:28|rHGH:12|rh-GH:3|R-hGH:1|r-hgh:1|RHGH:1|RH-GH:1	Recombinant human growth hormone:493:0.9306	0.9306	493
rhHGF	rhHGF:10|r-hHGF:3|rh-HGF:2	recombinant human Hepatocyte Growth Factor:15:0.8045	0.8045	15
rhHGF	rhHGF:14|rh-HGF:2	recombinant human HGF:16:0.8165	0.8165	16
rhIGF-1	rhIGF-1:9	Recombinant human IGF-1:9:0.6794	0.6794	9
rhIGF-1	rhIGF-1:8	recombinant human insulin-like growth factor-1:8:0.6411	0.6411	8
rhIGF-I	rhIGF-I:57	Recombinant human IGF-I:57:0.9176	0.9176	57
rhIGF-I	rhIGF-I:87|RhIGF-I:1	recombinant human insulin-like growth factor-I:49:0.9392|recombinant human insulin-like growth factor I:39:0.9237	0.9392	88
rhIL-10	rhIL-10:12	recombinant human IL-10:12:0.7571	0.7571	12
rhIL-12	rhIL-12:13	recombinant human IL-12:13:0.7753	0.7753	13
rhIL-12	rhIL-12:10	recombinant human interleukin-12:10:0.7103	0.7103	10
rhIL-1	rhIL-1:13	recombinant human interleukin-1:13:0.7753	0.7753	13
rhIL-11	rhIL-11:10	recombinant human IL-11:10:0.7103	0.7103	10
rhIL-11	rhIL-11:56|rhIL11:1	recombinant human interleukin-11:46:0.9338|recombinant human interleukin 11:11:0.7357	0.9338	57
rhIL-2	rhIL-2:28	recombinant human IL-2:28:0.8369	0.8369	28
rhIL-2	rhIL-2:75|rHIL-2:5|rhIL2:3|rH-IL-2:2|rH-IL2:1	recombinant human interleukin-2:69:0.9316|Recombinant human interleukin 2:17:0.7407	0.9316	86
rhIL-3	rhIL-3:8	recombinant human IL-3:8:0.6411	0.6411	8
rhIL-3	rhIL-3:71|rh-IL-3:3|rhIL3:2|rhIl-3:1|RhIL-3:1	recombinant human interleukin-3:61:0.8987|recombinant human interleukin 3:17:0.8270	0.8987	78
rhIL-4	rhIL-4:9|rhIL4:1	recombinant human interleukin-4:10:0.5856	0.5856	10
rhIL-5	rhIL-5:10	Recombinant human interleukin-5:10:0.7103	0.7103	10
rhIL-6	rhIL-6:33	Recombinant human IL-6:33:0.8605	0.8605	33
rhIL-6	rhIL-6:50|rhIL6:2	recombinant human interleukin-6:38:0.8098|recombinant human interleukin 6:14:0.7909	0.8098	52
rhLF	rhLF:4|rh-LF:3|rhLf:2|RHLF:1	recombinant human lactoferrin:10:0.7103	0.7103	10
rhLT	rhLT:8	recombinant human lymphotoxin:8:0.6411	0.6411	8
rhM-CSF	rhM-CSF:9	recombinant human M-CSF:9:0.6794	0.6794	9
rhM-CSF	rhM-CSF:33|rhMCSF:1	recombinant human macrophage colony-stimulating factor:34:0.9126	0.9126	34
rhNGF	rhNGF:28	Recombinant human nerve growth factor:28:0.7905	0.7905	28
rhNGF	rhNGF:13	recombinant human NGF:13:0.7753	0.7753	13
rhOP-1	rhOP-1:16	recombinant human osteogenic protein-1:16:0.8165	0.8165	16
rhPRL	rhPRL:4|r-hPRL:2|rhPrl:1	recombinant human prolactin:7:0.4438	0.4438	7
rhRLX	rhRLX:7|rhRlx:3	recombinant human relaxin:10:0.7103	0.7103	10
rhSCF	rhSCF:24|rh-SCF:1	recombinant human stem cell factor:25:0.8816	0.8816	25
rhSOD	rhSOD:3|rh-SOD:2|r-h-SOD:1	recombinant human SOD:6:0.3728	0.3728	6
rhSOD	rhSOD:7|r-hSOD:6|rh-SOD:4|r-h-SOD:3|r-HSOD:3|RH-SOD:2|rH-SOD:1|rHSOD:1	recombinant human superoxide dismutase:27:0.7834	0.7834	27
rhTNF	rhTNF:12|rHTNF:1	Recombinant human TNF:13:0.7753	0.7753	13
rhTNF	rhTNF:30|rH-TNF:22|rHTNF:4|rh-TNF:2	recombinant human tumor necrosis factor:58:0.9190	0.9190	58
rhTPO	rhTPO:20|rhTpo:2	recombinant human thrombopoietin:22:0.7955	0.7955	22
rhTPO	rhTPO:11|rhTpo:2	Recombinant human TPO:13:0.7753	0.7753	13
rhTSH	rhTSH:22	recombinant human thyroid-stimulating hormone:22:0.8525	0.8525	22
rhTSH	rhTSH:26	recombinant human thyrotropin:26:0.8861	0.8861	26
rhTSH	rhTSH:58	recombinant human TSH:58:0.9486	0.9486	58
rhVEGF	rhVEGF:12	recombinant human vascular endothelial growth factor:12:0.7571	0.7571	12
rhbFGF	rhbFGF:15|rh-bFGF:8|Rh-bFGF:2	recombinant human basic fibroblast growth factor:25:0.7679	0.7679	25
rHir	rHir:11|rHIR:2|r-Hir:2|r-hir:1|r-HIR:1	recombinant hirudin:17:0.7407	0.7407	17
rho	rho:9	conductance ratio:9:0.2285	0.2285	9
rho	rho:13|Rho:4	correlation:17:0.0379	0.0379	17
rho	rho:24|Rho:4|RHO:1	correlation coefficient:20:0.6680|correlation coefficients:9:0.3455	0.6680	29
rho	rho:9	resistivity:9:0.0190	0.0190	9
rho	rho:11|Rho:2	rhodamine 123:13:0.7753	0.7753	13
rho	rho:34|Rho:4	rhodopsin:38:0.0877	0.0877	38
rho	rho:30|Rho:8|RHO:1	rhomboid:39:0.0900	0.0900	39
rhs-TM	rhs-TM:9|rhsTM:4|RHS-TM:1	recombinant human soluble thrombomodulin:14:0.7909	0.7909	14
rhuIL-4	rhuIL-4:9	recombinant human interleukin-4:9:0.6794	0.6794	9
riMLF	riMLF:1	rostral interstitial nucleus of MLF:1:0.6411	0.6411	1
riMLF	riMLF:40	rostral interstitial nucleus of the medial longitudinal fasciculus:40:0.8867	0.8867	40
rib	rib:8|Rib:2	ribavirin:10:0.1915	0.1915	10
rice	rice:15	Oryza sativa:15:0.6386	0.6386	15
Rin	Rin:48|rin:15|RIN:3	input resistance:66:0.8670	0.8670	66
RIN	RIN:27|rin:2	rat insulinoma:29:0.8422	0.8422	29
RIN	RIN:4|rin:2	rat insulinoma cell line:6:0.5290	0.5290	6
RIS	RIS:75	Radioimmunoscintigraphy:75:0.1845	0.1845	75
RIS	RIS:71|ris:1	Radiology Information System:60:0.6592|radiology information systems:12:0.4102	0.6592	72
RIS	RIS:6|RIs:1	Recombinant inbred strains:7:0.5926	0.5926	7
RIs	RIs:11	replication intermediates:11:0.2422	0.2422	11
RIs	RIs:11	replicative intermediates:11:0.2422	0.2422	11
RIs	RIs:12|ris:2	Resistance Indices:14:0.3039	0.3039	14
RIs	RIs:8	resistive indexes:8:0.5006	0.5006	8
RIs	RIs:8	resistive indices:8:0.0953	0.0953	8
ris	ris:15|Ris:1	Risedronate:16:0.0374	0.0374	16
ris	ris:16|RIS:3	Risperidone:19:0.0449	0.0449	19
RLX	RLX:15|Rlx:2	raloxifene:17:0.1468	0.1468	17
rmIL-12	rmIL-12:8	recombinant murine IL-12:8:0.6411	0.6411	8
rmIL-3	rmIL-3:5	Recombinant murine interleukin-3:5:0.4422	0.4422	5
rMu	rMu:8|rmu:4	recombinant murine:12:0.6460	0.6460	12
rnu/+	rnu/+:11	heterozygous:11:0.3143	0.3143	11
rod	rod:12	Nemaline:12:0.0556	0.0556	12
ROD	ROD:11|rod:2	Relative Optical Density:13:0.7753	0.7753	13
ROD	ROD:55|rod:1	renal osteodystrophy:56:0.9467	0.9467	56
ROLL	ROLL:8	occult lesion localization:8:0.6411	0.6411	8
ROLL	ROLL:7	Radioguided occult lesion localisation:7:0.3524	0.3524	7
RP-HPLC	RP-HPLC:13|RPHPLC:1	reverse-phase HPLC:14:0.1498	0.1498	14
RP-HPLC	RP-HPLC:44	reversed-phase high-performance liquid chromatographic:36:0.8336|reversed phase high performance liquid chromatographic:8:0.6411	0.8336	44
RP-HPLC	RP-HPLC:264|rpHPLC:6|RPHPLC:3|rp-HPLC:2	reversed-phase high-performance liquid chromatography:261:0.6447|reversed phase-high performance liquid chromatography:14:0.2010	0.6447	275
RP-HPLC	RP-HPLC:22|rpHPLC:2|RPHPLC:2	reversed-phase HPLC:26:0.3966	0.3966	26
rpS6	rpS6:7|RPS6:3|rps6:1	ribosomal protein S6:11:0.7357	0.7357	11
rpST	rpST:22|rpSt:3|rPST:1	recombinant porcine somatotropin:26:0.7760	0.7760	26
rpL32	rpL32:6|RPL32:2|Rpl32:1	ribosomal protein L32:9:0.6794	0.6794	9
RPLA	RPLA:30	reversed passive latex agglutination:30:0.5838	0.5838	30
RPLS	RPLS:28	reversible posterior leukoencephalopathy syndrome:28:0.8941	0.8941	28
rpoB	rpoB:6	beta subunit of RNA polymerase:6:0.5926	0.5926	6
rpoB	rpoB:8	RNA polymerase beta subunit:8:0.6411	0.6411	8
rpoB	rpoB:11	RNA polymerase gene:11:0.7357	0.7357	11
rpoD	rpoD:5|RpoD:3	sigma factor:8:0.4102	0.4102	8
rps12	rps12:6|RPS12:2	ribosomal protein S12:8:0.6411	0.6411	8
RPS19	RPS19:12|rps19:2	ribosomal protein S19:14:0.7571	0.7571	14
rpS3	rpS3:5|rps3:2|RPS3:2	ribosomal protein S3:9:0.6794	0.6794	9
RQ-PCR	RQ-PCR:23	real-time quantitative PCR:23:0.8186	0.8186	23
RQ-PCR	RQ-PCR:23|rqPCR:1	real-time quantitative polymerase chain reaction:24:0.6767	0.6767	24
rrCBV	rrCBV:10	relative regional cerebral blood volume:10:0.7103	0.7103	10
rrSCF	rrSCF:11	recombinant rat stem cell factor:11:0.7357	0.7357	11
rrn	rrn:22	ribosomal RNA:22:0.8657	0.8657	22
rrn	rrn:9	rRNA operons:9:0.3470	0.3470	9
rsCD4	rsCD4:14	Recombinant soluble CD4:14:0.6911	0.6911	14
rscu-PA	rscu-PA:5	recombinant single-chain u-PA:5:0.2818	0.2818	5
rscu-PA	rscu-PA:13|r-scu-PA:4	recombinant single-chain urokinase-type plasminogen activator:17:0.6903	0.6903	17
RSK	RSK:47|Rsk:1|rsk:1	ribosomal S6 kinase:49:0.6820	0.6820	49
rtER	rtER:12	rainbow trout estrogen receptor:12:0.7571	0.7571	12
rtTA	rtTA:11	reverse tetracycline transactivator:11:0.7357	0.7357	11
rvWF	rvWF:7|rVWF:3|r-vWF:2	recombinant vWF:12:0.6460	0.6460	12
RYR1	RYR1:16|RyR1:8	release channel:24:0.7151	0.7151	24
RYR1	RYR1:29|RyR1:2|ryr1:1	ryanodine receptor gene:32:0.9072	0.9072	32
RyR1	RyR1:10|RYR1:4|RyR-1:1	skeletal muscle:15:0.8045	0.8045	15
RyR1	RyR1:20|RYR1:15|ryr1:2	skeletal muscle ryanodine receptor:37:0.9197	0.9197	37
s(4)U	s(4)U:9	4-thiouridine:9:0.8889	0.8889	9
s.c.	s.c.:1208|S.C.:13|S.c.:1	subcutaneous:1222:0.4598	0.4598	1222
s.c.	s.c.:9	subcutaneous injection:9:0.1009	0.1009	9
s.c.	s.c.:727|S.C.:8	subcutaneously:735:0.2763	0.2763	735
s.c.	s.c.:9	systemically:9:0.0030	0.0030	9
s.c	s.c:10	subcutaneous:10:0.3913	0.3913	10
s.e.e.	s.e.e.:3|S.E.E.:2	standard error of the estimate:5:0.6411	0.6411	5
s.e.	s.e.:5|S.E.:4	standard error:9:0.3945	0.3945	9
s.l.	s.l.:18	Borrelia burgdorferi sensu lato:18:0.5940	0.5940	18
s.r.	s.r.:30|S.R.:4	sarcoplasmic reticulum:34:0.9126	0.9126	34
s.s.	s.s.:17	sensu stricto:17:0.7407	0.7407	17
S/V	S/V:13	surface-to-volume ratio:13:0.3809	0.3809	13
sADP	sADP:8	slow afterdepolarization:8:0.4102	0.4102	8
sAHP	sAHP:42|S-AHP:1	slow afterhyperpolarization:43:0.7363	0.7363	43
sALP	sALP:17|S-ALP:13|SALP:4|s-ALP:2|S-Alp:1|s-Alp:1|S-Al-p:1	alkaline phosphatase:39:0.8811	0.8811	39
sAML	sAML:4|s-AML:3	secondary acute myeloid leukemia:7:0.3524	0.3524	7
sAML	sAML:7|SAML:3|s-AML:1	secondary AML:11:0.7357	0.7357	11
SBBR	SBBR:13	Sequencing Batch Biofilm Reactor:13:0.7753	0.7753	13
SBT	SBT:56|S-BT:1	sequence-based typing:51:0.4566|sequence based typing:6:0.0611	0.4566	57
SBT	SBT:12	Sequencing Based Typing:12:0.3524	0.3524	12
SBT	SBT:5	serous borderline tumors:5:0.4422	0.4422	5
SBT	SBT:5	Short Blessed Test:5:0.4422	0.4422	5
SBT	SBT:70	small bowel transplantation:70:0.9573	0.9573	70
SBT	SBT:26	sulbactam:26:0.0772	0.0772	26
sCAMs	sCAMs:14	adhesion molecules:14:0.7909	0.7909	14
sCD40	sCD40:5	soluble form of CD40:5:0.4422	0.4422	5
sCD40L	sCD40L:37	soluble CD40 ligand:37:0.6610	0.6610	37
sCD4	sCD4:128	soluble CD4:128:0.7125	0.7125	128
sCD62L	sCD62L:12	Soluble L-selectin:12:0.4557	0.4557	12
sCD8	sCD8:60|SCD8:1|s-CD8:1	soluble CD8:62:0.6475	0.6475	62
sCD8	sCD8:8	soluble CD8 antigen:8:0.4102	0.4102	8
sCJD	sCJD:18	sporadic CJD:18:0.6903	0.6903	18
sCJD	sCJD:36	sporadic Creutzfeldt-Jakob disease:36:0.8336	0.8336	36
SDNA	SDNA:9	standard deviation of nuclear area:9:0.7753	0.7753	9
SDNA	SDNA:7|SD-NA:1	standard deviation of nucleolar area:8:0.6411	0.6411	8
SDPP	SDPP:13	spray-dried porcine plasma:13:0.7753	0.7753	13
sEGFR	sEGFR:6	epidermal growth factor receptor:6:0.5290	0.5290	6
sEPSCs	sEPSCs:15	spontaneous EPSCs:15:0.6386	0.6386	15
sEPSCs	sEPSCs:51|SEPSCs:2	spontaneous excitatory postsynaptic currents:53:0.9116	0.9116	53
sEPSPs	sEPSPs:10|SEPSPs:1|s-EPSPs:1	excitatory postsynaptic potentials:12:0.7571	0.7571	12
sEpo	sEpo:12|sEPO:6|s-Epo:5|s-EPO:4|S-Epo:4|S-EPO:3	serum erythropoietin:34:0.8644	0.8644	34
SFRPs	SFRPs:6|sFRPs:5|Sfrps:3|sFrps:2	secreted frizzled-related proteins:16:0.7261	0.7261	16
sFRP	sFRP:5|SFRP:2|sFrp:1	secreted frizzled-related protein:8:0.6411	0.6411	8
sFlt1	sFlt1:4|sFlt-1:3	soluble fms-like tyrosine kinase 1:7:0.4438	0.4438	7
sFlt-1	sFlt-1:4|SFlt-1:1	soluble receptor:5:0.0902	0.0902	5
sFlt-1	sFlt-1:5|sFlt1:1	soluble VEGF receptor 1:6:0.5290	0.5290	6
S-GAGs	S-GAGs:5|SGAGs:2|s-GAGs:2|sGAGs:1	sulfated glycosaminoglycans:10:0.4363	0.4363	10
sGAG	sGAG:25|S-GAG:20|SGAG:3|s-GAG:1	sulfated glycosaminoglycans:29:0.6648|sulfated glycosaminoglycan:20:0.7766	0.7766	49
sGDH	sGDH:6|s-GDH:3	glucose dehydrogenase:9:0.6794	0.6794	9
SGaw	SGaw:114|sGaw:90|SGAW:5|sGAW:5	specific airway conductance:214:0.9568	0.9568	214
sGnRH	sGnRH:39|SGnRH:1	salmon gonadotropin-releasing hormone:40:0.7653	0.7653	40
sHLA-I	sHLA-I:8|S-HLA-I:1	class I antigens:9:0.6794	0.6794	9
sHLA-I	sHLA-I:16|S-HLA-I:1|sHLAI:1	soluble HLA Class I:18:0.7044	0.7044	18
sHLA	sHLA:11|SHLA:1	soluble HLA:12:0.6460	0.6460	12
sICAM-1	sICAM-1:5|s-ICAM-1:1	soluble intercellular adhesion molecule:6:0.3728	0.3728	6
sICAM-1	sICAM-1:348|s-ICAM-1:9|S-ICAM-1:1	soluble intercellular adhesion molecule-1:301:0.7470|soluble intercellular adhesion molecule 1:57:0.7567	0.7567	358
sICAM	sICAM:7	soluble intercellular adhesion molecule:7:0.3524	0.3524	7
sIL-1Ra	sIL-1Ra:7|sIL-1ra:6|sIL-1RA:5	receptor antagonist:18:0.6903	0.6903	18
sIL-1R	sIL-1R:8|sIL-1r:2	soluble IL-1 receptor:10:0.5000	0.5000	10
sIL-2R	sIL-2R:6	soluble form of IL-2R:6:0.2827	0.2827	6
sIL-2R	sIL-2R:184|sIL-2r:10|SIL-2R:8|sIL2R:5|sIL2-R:2|sIl-2R:1|s-IL-2-R:1|S-IL-2R:1	soluble IL-2 receptor:170:0.8440|soluble IL-2 receptors:34:0.9126|soluble IL-2-receptor:8:0.5006	0.9126	212
sIL-2R	sIL-2R:135|sIL2R:19|SIL-2R:11|sIL-2r:5|s-IL-2R:3|sIL2-R:2|SIL2-R:2|S-IL2R:1|sIl-2R:1|sIL-2-R:1|sIL2r:1|S-IL-2R:1	soluble interleukin 2 receptor:107:0.9156|Soluble interleukin-2 receptors:75:0.8661	0.9156	182
sIL-2R	sIL-2R:8|SIL-2R:1	soluble interleukin-2 receptor levels:9:0.6794	0.6794	9
sIL-2R	sIL-2R:4	soluble receptors for IL-2:4:0.5290	0.5290	4
sIL-2R	sIL-2R:7	soluble receptors for interleukin-2:5:0.6411|soluble receptor for interleukin-2:2:0.2452	0.6411	7
sIL-2r	sIL-2R:1|sIL-2r:1	soluble receptor of IL-2:2:0.4438	0.4438	2
sIL-4R	sIL-4R:11	soluble IL-4 receptor:11:0.4728	0.4728	11
sIL-6R	sIL-6R:6	soluble form of IL-6R:6:0.6411	0.6411	6
sIL-6R	sIL-6R:118|sIL-6r:4|sIL-6-R:3|sIL6R:1|sIL6-R:1	soluble IL-6 receptor:127:0.7994	0.7994	127
sIL-6R	sIL-6R:39|sIL6R:2|sIL-6-R:1|SIL-6R:1	soluble interleukin-6 receptor:43:0.7795	0.7795	43
sIPSCs	sIPSCs:59	Spontaneous inhibitory postsynaptic currents:59:0.7855	0.7855	59
sIPSCs	sIPSCs:23	spontaneous IPSCs:23:0.5997	0.5997	23
sIg+	sIg+:20|SIg+:5|s-Ig+:1|sig+:1	surface immunoglobulin positive:16:0.8165|surface immunoglobulin-positive:11:0.7357	0.8165	27
sIgD	sIgD:12	surface IgD:12:0.4557	0.4557	12
sIgE	sIgE:4|S-IgE:3|SIgE:1	immunoglobulin E:8:0.4102	0.4102	8
sIgE	sIgE:23|s-IgE:4|SIgE:1	specific IgE:28:0.4302	0.4302	28
sIgM	sIgM:67	surface IgM:67:0.6235	0.6235	67
sIgM	sIgM:11	surface immunoglobulin M:11:0.5355	0.5355	11
SIL-2Rs	SIL-2Rs:5|sIL-2Rs:3	soluble interleukin-2 receptors:8:0.5006	0.5006	8
S-LDH	S-LDH:9|s-LDH:3|SLDH:3|sLDH:1	serum lactate dehydrogenase:16:0.5564	0.5564	16
SLRP	SLRP:17	small leucine-rich proteoglycan:17:0.8270	0.8270	17
s-MDH	s-MDH:13|sMDH:4|SMDH:1	malate dehydrogenase:18:0.8365	0.8365	18
SMDs	SMDs:5	pooled analysis was performed using standardized mean differences:5:0.4422	0.4422	5
sMDS	sMDS:5|s-MDS:1|SMDS:1	secondary myelodysplastic syndrome:7:0.5926	0.5926	7
sMMO	sMMO:55	soluble methane monooxygenase:55:0.8882	0.8882	55
SNCA	SNCA:10	alpha-synuclein gene:10:0.5856	0.5856	10
SNOs	SNOs:11|-SNOs:1	S-Nitrosothiols:12:0.7857	0.7857	12
S-NSE	S-NSE:7|s-NSE:3	serum neuron-specific enolase:10:0.5856	0.5856	10
S-ODNs	S-ODNs:10|sODNs:2|S-ODns:1	phosphorothioate oligodeoxynucleotides:13:0.3809	0.3809	13
S-ODNs	S-ODNs:15|SODNs:1	phosphorothioate oligonucleotides:16:0.7261	0.7261	16
sPDA	sPDA:9|SPDA:1	Symptomatic patent ductus arteriosus:10:0.5000	0.5000	10
S-PGI	S-PGI:5|SPGI:1|sPG-I:1|sPGI:1	Serum pepsinogen I:8:0.3463	0.3463	8
sPLA(2)	sPLA(2):50	secretory phospholipase A(2):50:0.6118	0.6118	50
sPLA(2)	sPLA(2):10	secretory PLA(2):10:0.3145	0.3145	10
sPLA(2)s	sPLA(2)s:13	secreted phospholipases A(2):13:0.5335	0.5335	13
sPLA2s	sPLA2s:16	phospholipases A2:16:0.7261	0.7261	16
sPLA2	sPLA2:118	secretory phospholipase A2:118:0.6384	0.6384	118
sPLA2	sPLA2:35	secretory PLA2:35:0.6096	0.6096	35
sPSCs	sPSCs:15	spontaneous postsynaptic currents:15:0.6386	0.6386	15
sP-sel	sP-sel:6|sPsel:2|sP-Sel:1	soluble P-selectin:9:0.6794	0.6794	9
sTNFR1	sTNFR1:9|sTNF-R1:2|STNFR1:1	soluble TNF receptor 1:12:0.7571	0.7571	12
sTNFR1	sTNF-R1:3|sTNFR1:3	soluble tumor necrosis factor receptor 1:6:0.5290	0.5290	6
sTNF-RI	sTNF-RI:3|sTNFRI:2|sTNFR-I:1|sTNFr-I:1	necrosis factor receptor type I:7:0.5926	0.5926	7
sTNF-RI	sTNF-RI:3|sTNFR-I:2|sTNFRI:2	soluble TNF receptor I:7:0.3524	0.3524	7
sTNFRI	sTNFRI:3|sTNF-RI:2	soluble TNF receptor type I:5:0.1973	0.1973	5
sTNF-RI	sTNF-RI:7|sTNFRI:2|sTNF-rI:1	Soluble tumor necrosis factor receptor I:10:0.7103	0.7103	10
sTNFRs	sTNFRs:11|sTNF-Rs:10	soluble tumor necrosis factor receptors:21:0.7291	0.7291	21
sTNFR	sTNFR:18|sTNF-R:13|sTNFr:1	soluble TNF receptors:32:0.6656	0.6656	32
sTNFR	sTNFR:27|sTNF-R:14|sTNFr:6|sT-NF-R:1|STNFR:1|s-TNFr:1	soluble tumor necrosis factor receptor:34:0.8644|soluble tumor necrosis factor receptors:16:0.7261	0.8644	50
sTfR	sTfR:82|sTfr:5|s-TfR:4|sTFR:2|sTf-r:1|STFR:1|sTf-R:1	Soluble transferrin receptor:96:0.5027	0.5027	96
sTfR	sTfR:8|sTfr:2|STfR:1|S-Tf-R:1|sTFr:1|s-TfR:1	transferrin receptors:14:0.6911	0.6911	14
sVCAM-1	sVCAM-1:29	vascular cell adhesion molecule 1:29:0.8978	0.8978	29
sVCAM	sVCAM:10|s-VCAM:1	soluble vascular cell adhesion molecule:11:0.5355	0.5355	11
sVRP	sVRP:9	slow ventral root potential:9:0.6794	0.6794	9
sWGA	sWGA:4|S-WGA:4|SWGA:3|s-WGA:2	succinylated wheat germ agglutinin:13:0.4709	0.4709	13
SX	SX:13|Sx:1	sympathectomized:14:0.0956	0.0956	14
SX	SX:9|Sx:2	syndrome X:11:0.7357	0.7357	11
sALT	sALT:6|s-ALT:3|S-ALT:1	serum alanine aminotransferase:10:0.4363	0.4363	10
salt	salt:8	sodium chloride:8:0.4102	0.4102	8
SC-CO(2)	SC-CO(2):16|scCO(2):9|SC--CO(2):1|sc-CO(2):1	supercritical carbon dioxide:27:0.7834	0.7834	27
scFv	scFv:96|ScFv:11	single-chain antibody:49:0.3717|single chain antibody:27:0.8312|single-chain antibodies:19:0.2840|single chain antibodies:12:0.7571	0.8312	107
scFv	scFv:70|ScFv:10|SCFV:1	single-chain antibody fragment:42:0.4066|single-chain antibody fragments:20:0.2743|single chain antibody fragment:19:0.8449	0.8449	81
scFv	scFv:29|ScFv:5	single-chain fragment variable:21:0.4344|single chain fragment variable:13:0.7753	0.7753	34
scFv	scFv:254|ScFv:12|scFV:2|Scfv:1	single-chain Fv:186:0.6236|single chain Fv:83:0.9640	0.9640	269
scFv	scFv:18|scFV:1	Single-chain Fv fragments:12:0.3275|Single chain Fv fragments:7:0.5926	0.5926	19
scFv	scFv:119|ScFv:21	single-chain variable fragment:70:0.4715|single chain variable fragment:44:0.9338|single-chain variable fragments:17:0.3512|Single chain variable fragments:9:0.6794	0.9338	140
scFv	scFv:5|ScFv:1	variable domain:6:0.0807	0.0807	6
scFv	scFv:7	variable region:7:0.2902	0.2902	7
scFvs	scFvs:13|ScFvs:1	Single-chain antibodies:14:0.4071	0.4071	14
scFvs	scFvs:11	single-chain antibody fragments:11:0.3495	0.3495	11
scFvs	scFvs:9	single-chain Fv fragments:9:0.3455	0.3455	9
scFvs	scFvs:14	single-chain Fvs:14:0.4367	0.4367	14
scFvs	scFvs:9	Single-chain variable fragments:9:0.3945	0.3945	9
scPTZ	scPTZ:14	subcutaneous pentylenetetrazole:14:0.7909	0.7909	14
scRNA	scRNA:13	small cytoplasmic RNA:13:0.7753	0.7753	13
SCC	SCC:7|scc:6	cholesterol side-chain cleavage:13:0.3809	0.3809	13
SCC	SCC:31	semicircular canal:23:0.7500|semicircular canals:8:0.5006	0.7500	31
SCC	SCC:214|scc:5	short-circuit current:219:0.6630	0.6630	219
SCC	SCC:28	short-course chemotherapy:20:0.5021|short course chemotherapy:8:0.6411	0.6411	28
SCC	SCC:16|Scc:1	side-chain cleavage enzyme:10:0.2873|side chain cleavage enzyme:7:0.5926	0.5926	17
SCC	SCC:8	small cell carcinoma of the lung:8:0.5006	0.5006	8
SCC	SCC:246|scc:2	Somatic Cell Count:179:0.9733|somatic cell counts:69:0.9100	0.9733	248
SCC	SCC:29	spinal cord compression:29:0.8978	0.8978	29
SCC	SCC:17	Squamous carcinoma cell:11:0.6182|squamous carcinoma cells:6:0.3728	0.6182	17
SCC	SCC:48	squamous cell cancer:39:0.7860|squamous cell cancers:9:0.6794	0.7860	48
SCC	SCC:2530|scc:5	squamous cell carcinoma:2134:0.9530|squamous cell carcinomas:401:0.9604	0.9604	2535
SCC	SCC:4	squamous cell carcinoma of the cervix:4:0.1618	0.1618	4
SCC	SCC:7	squamous cell carcinoma of the skin:7:0.5926	0.5926	7
SCC	SCC:16	squamous cell carcinoma-related antigen:16:0.8165	0.8165	16
SCOPE	SCOPE:18	Study on COgnition and Prognosis in the Elderly:18:0.8165	0.8165	18
sct-PA	sct-PA:8|sctPA:2|sc-tPA:1	plasminogen activator:11:0.7357	0.7357	11
scu-PA	scu-PA:14	single-chain u-PA:14:0.3585	0.3585	14
scuPA	scuPA:3|scu-PA:1	single chain uPA:4:0.1618	0.1618	4
scuPA	scuPA:7|scu-PA:4|Sc-uPA:1	single-chain urokinase:12:0.3524	0.3524	12
scu-PA	scu-PA:66|scuPA:7|sc-uPA:2|Sc-uPA:1|SCU-PA:1	single-chain urokinase-type plasminogen activator:77:0.7028	0.7028	77
SDRR	SDRR:4	standard deviation of RR intervals:4:0.4422	0.4422	4
SDHB	SDHB:5|SDHb:1	succinate dehydrogenase subunit b:6:0.5290	0.5290	6
sec	sec:8|SEC:1	secretin:9:0.0076	0.0076	9
sec	sec:21	secretory:21:0.0189	0.0189	21
Sec	Sec:59|SEC:11|SeC:4|sec:1	selenocysteine:75:0.0701	0.0701	75
SEC	SEC:25	series elastic component:25:0.8186	0.8186	25
SEC	SEC:9	serpin-enzyme complex:9:0.3945	0.3945	9
SEC	SEC:97	sinusoidal endothelial cells:64:0.7825|sinusoidal endothelial cell:33:0.5930	0.7825	97
SEC	SEC:6|sec:1	size-exclusion chromatographic:7:0.3524	0.3524	7
SEC	SEC:352|sec:3	size-exclusion chromatography:182:0.4372|size exclusion chromatography:173:0.9248	0.9248	355
SEC	SEC:58|sec:5	spontaneous echo contrast:63:0.9526	0.9526	63
SEC	SEC:15|sec:2	spontaneous echocardiographic contrast:17:0.8270	0.8270	17
SEC	SEC:9	standard error of calibration:9:0.6794	0.6794	9
SEC	SEC:15|sec:1	Staphylococcal enterotoxin C:16:0.5171	0.5171	16
sec	sec:3|SEC:3	superficial esophageal carcinoma:6:0.2827	0.2827	6
SEC	SEC:11	surface epithelial cells:11:0.1683	0.1683	11
SEC	SEC:11	swine endothelial cell:11:0.1009	0.1009	11
SENSE	SENSE:64	Sensitivity encoding:64:0.9526	0.9526	64
SENSOR	SENSOR:15	Sentinel Event Notification System for Occupational Risks:15:0.7909	0.7909	15
SERA	SERA:11	Plasmodium falciparum serine repeat antigen:11:0.7357	0.7357	11
serpin	serpin:137|SERPIN:12|Serpin:3	serine protease inhibitor:146:0.9467|serine protease inhibitors:6:0.5290	0.9467	152
serpin	serpin:89|SERPIN:8	serine proteinase inhibitor:97:0.9365	0.9365	97
SER	SER:9	enhancement ratios:9:0.4587	0.4587	9
SER	SER:8|ser:1	scanning equalization radiography:9:0.5470	0.5470	9
SER	SER:20|ser:1	sebum excretion rate:21:0.8594	0.8594	21
SER	SER:26|ser:3	sensitizer enhancement ratio:29:0.5212	0.5212	29
ser	ser:24	serotonin:24:0.0249	0.0249	24
SER	SER:275|ser:32|sER:16|Ser:7|s-ER:1|S-ER:1	smooth endoplasmic reticulum:332:0.8908	0.8908	332
SER	SER:27	somatosensory evoked response:17:0.4246|somatosensory evoked responses:10:0.7103	0.7103	27
SER	SER:9	spherical equivalent refraction:9:0.7103	0.7103	9
SER	SER:35|ser:1	spontaneously epileptic rats:19:0.8449|spontaneously epileptic rat:17:0.8165	0.8449	36
sgRNA	sgRNA:15	subgenomic RNA:15:0.6386	0.6386	15
SGFS	SGFS:9|sgfs:1	stratum griseum et fibrosum superficiale:10:0.7103	0.7103	10
SH2	SH2:15	src homology:15:0.8045	0.8045	15
SH2	SH2:587|SH-2:4	src homology 2:531:0.9824|src homology-2:48:0.9027|src-homology-2:12:0.0145	0.9824	591
SH2	SH2:6	Src homology 2 domain:6:0.5290	0.5290	6
shRNA	shRNA:53	short hairpin RNA:53:0.7654	0.7654	53
shRNAs	shRNAs:43	Short hairpin RNAs:43:0.7795	0.7795	43
SHIM	SHIM:20	Sexual Health Inventory for Men:20:0.8715	0.8715	20
shock	shock:6	Acute circulatory failure:6:0.2827	0.2827	6
shock	shock:4|SHOCK:3	emergently revascularize Occluded Coronaries for cardiogenic shocK:7:0.7103	0.7103	7
SHP-2	SHP-2:16|SHP2:6|Shp2:1	protein tyrosine phosphatase-2:13:0.4849|protein tyrosine phosphatase 2:10:0.2873	0.4849	23
SHP-2	SHP-2:9|SHP2:2	tyrosine phosphatase:11:0.2764	0.2764	11
sHsps	sHsps:57|sHSPs:48|shsps:5	Small heat shock proteins:90:0.9473|small heat-shock proteins:20:0.7173	0.9473	110
siRNAs	siRNAs:247	small interfering RNAs:247:0.6643	0.6643	247
sialic	sialic:21	N-acetylneuraminic:21:0.5882	0.5882	21
sigma	sigma:6	electrical conductivity:6:0.2243	0.2243	6
sigma	sigma:83	reflection coefficient:62:0.7796|reflection coefficients:21:0.6812	0.7796	83
sigma	sigma:20	standard deviation:20:0.8594	0.8594	20
sigma	sigma:6	surface charge density:6:0.2827	0.2827	6
SIGN	SIGN:25|sign:1	Scottish intercollegiate guidelines network:26:0.8861	0.8861	26
sina	sina:15|Sina:4|SINA:3	seven in absentia:22:0.8657	0.8657	22
skc	skc:8	streptokinase gene:8:0.4102	0.4102	8
SLIT	SLIT:53	sublingual immunotherapy:53:0.6334	0.6334	53
smMLCK	smMLCK:15|SM-MLCK:1	smooth muscle myosin light chain kinase:16:0.8165	0.8165	16
SMCC	SMCC:11	Silicified microcrystalline cellulose:11:0.7357	0.7357	11
SmCC	SmCC:5|SMCC:3	small cell carcinoma:8:0.6411	0.6411	8
sm	sm:11	expression of alpha-smooth muscle:11:0.1009	0.1009	11
SM	SM:8|sm:2	Margin:10:0.0033	0.0033	10
SM	SM:14|sm:1	medium:15:0.0051	0.0051	15
SM	SM:10	memory:10:0.0033	0.0033	10
SM	SM:14|sm:1	method:15:0.0051	0.0051	15
Sm	Sm:29|SM:2|sm:1	nucleus submedius:32:0.8145	0.8145	32
SM	SM:9|Sm:1|sm:1	Salmeterol:11:0.0036	0.0036	11
SM	SM:20|sm:7|Sm:4	Salvia miltiorrhiza:31:0.7718	0.7718	31
SM	SM:9	scala media:9:0.4587	0.4587	9
Sm	Sm:5|SM:3	Schistosoma mansoni:8:0.3463	0.3463	8
sm	sm:12	selective mutism:12:0.7571	0.7571	12
SM	SM:10	self-monitoring:10:0.0033	0.0033	10
SM	SM:45|Sm:1|sm:1	semimembranosus:47:0.0168	0.0168	47
SM	SM:10|Sm:3|sm:1	serum somatomedin:14:0.0899	0.0899	14
SM	SM:49|sm:9	skeletal muscle:58:0.1165	0.1165	58
SM	SM:13|sm:1	skim milk:14:0.3039	0.3039	14
SM	SM:8|Sm:2	slow myosin:10:0.5856	0.5856	10
Sm	Sm:5|sm:1	Smith antigen:6:0.2243	0.2243	6
sm	sm:9	smokers:9:0.0029	0.0029	9
sm	sm:239|SM:5	smooth muscle:237:0.5879|smooth muscles:7:0.2452	0.5879	244
SM	Sm:5|SM:5|sm:3	somatomedins:13:0.0047	0.0047	13
SM	SM:5|Sm:1	soybean meal:6:0.0807	0.0807	6
Sm	Sm:9	sparsomycin:9:0.0029	0.0029	9
SM	SM:12	standard model:12:0.3813	0.3813	12
SM	SM:11	Steatocystoma multiplex:11:0.4728	0.4728	11
SM	SM:10	sternomastoid:10:0.0033	0.0033	10
Sm	Sm:4|SM:4	Streptococcus mutans:8:0.5006	0.5006	8
SM	SM:140|sm:40|Sm:35	streptomycin:215:0.0780	0.0780	215
SM	SM:8|sm:2	streptomycin sulfate:10:0.5856	0.5856	10
SM	SM:6	stress management:6:0.1543	0.1543	6
SM	SM:12	submandibular:12:0.0040	0.0040	12
SM	SM:9|sm:8	submucosal:17:0.0058	0.0058	17
SM	SM:46|sm:1|S-M:1	sulfur mustard:48:0.5317	0.5317	48
SM	SM:23|sm:2	sulphur mustard:25:0.2188	0.2188	25
SM	SM:57|sm:5	synovial membrane:55:0.5538|synovial membranes:7:0.0777	0.5538	62
SM	SM:9	syringomyelia:9:0.0029	0.0029	9
SM	SM:48|sm:7	systemic mastocytosis:55:0.9132	0.9132	55
Sm	Sm:7|SM:2|sm:1	systolic:10:0.0033	0.0033	10
Sm	Sm:6|SM:2	systolic velocity:8:0.2090	0.2090	8
snRNAs	snRNAs:116	small nuclear RNAs:116:0.9742	0.9742	116
snRNA	snRNA:202	small nuclear RNA:202:0.9684	0.9684	202
snRNPs	snRNPs:129	small nuclear ribonucleoproteins:129:0.9768	0.9768	129
snRNPs	snRNPs:72	small nuclear ribonucleoprotein particles:72:0.9585	0.9585	72
snRNPs	snRNPs:12	small nuclear RNPs:12:0.7571	0.7571	12
snRNP	snRNP:146|SnRNP:1|sn-RNP:1	small nuclear ribonucleoprotein:133:0.9036|small nuclear ribonucleoproteins:15:0.7096	0.9036	148
snRNP	snRNP:59	small nuclear ribonucleoprotein particle:51:0.9082|small nuclear ribonucleoprotein particles:8:0.5006	0.9082	59
snRNP	snRNP:15	small nuclear RNP:15:0.8045	0.8045	15
SNARE	SNARE:58	soluble N-ethylmaleimide-sensitive factor attachment protein receptor:58:0.8710	0.8710	58
SNGFR	SNGFR:9|sngfr:1	filtration rates:10:0.7103	0.7103	10
SNGFR	SNGFR:58	single nephron GFR:35:0.7952|single-nephron GFR:23:0.2333	0.7952	58
SNGFR	SNGFR:113|sngfr:1	single nephron glomerular filtration rate:114:0.9322	0.9322	114
snoRNA	snoRNA:66	small nucleolar RNA:66:0.9548	0.9548	66
snoRNP	snoRNP:11	small nucleolar ribonucleoprotein:11:0.7357	0.7357	11
SNs	SNs:6	culture supernatants:6:0.0731	0.0731	6
SNS	SNS:77	nerve stimulation:77:0.9612	0.9612	77
SNs	SNs:29	sensory neurons:29:0.7581	0.7581	29
SNs	SNs:14	sentinel lymph nodes:14:0.7909	0.7909	14
SNs	SNs:30	sentinel nodes:30:0.5017	0.5017	30
SNS	SNS:488	sympathetic nervous system:488:0.9725	0.9725	488
SNS	SNS:10	syndrome:10:0.0111	0.0111	10
snuff	snuff:7	smokeless tobacco:7:0.3524	0.3524	7
SOD2	SOD2:43|Sod2:10|SOD-2:7|sod2:1	superoxide dismutase:61:0.8042	0.8042	61
SOD2	SOD2:8|SOD-2:1	superoxide dismutase 2:9:0.6794	0.6794	9
SOF	SOF:11|sof:1	serum opacity factor:12:0.7571	0.7571	12
SOF	SOF:9	soluble organic fraction:9:0.6794	0.6794	9
SOF	SOF:33	synthetic oviduct fluid:33:0.9100	0.9100	33
SOF	SOF:18	Synthetic Oviductal Fluid:18:0.8365	0.8365	18
sour	sour:11	citric acid:11:0.4102	0.4102	11
SOUR	SOUR:11	specific oxygen uptake rate:11:0.7357	0.7357	11
sowda	sowda:6|Sowda:3	onchocerciasis:9:0.3103	0.3103	9
SOWS	SOWS:11	Opiate Withdrawal Scale:11:0.6182	0.6182	11
SP-SHR	SP-SHR:6|SPSHR:5|spSHR:5|SpSHR:1	stroke-prone spontaneously hypertensive rats:17:0.6903	0.6903	17
spcDNA	spcDNA:14|spc-DNA:1	small polydisperse circular DNA:15:0.8045	0.8045	15
SpeB	SpeB:12|speB:1|SPEB:1	streptococcal pyrogenic exotoxin B:14:0.6173	0.6173	14
SPF	SPF:3	cells in S-phase:3:0.1132	0.1132	3
SPF	SPF:39|SpF:1	DNA ploidy and S-phase fraction:40:0.6555	0.6555	40
SPF	SPF:8	S-phase cells:8:0.5006	0.5006	8
SPF	SPF:14	S-phase fractions:14:0.5589	0.5589	14
spf	spf:32	sparse-fur:32:0.0226	0.0226	32
SPF	SPF:564|spf:9	specific pathogen-free:229:0.8981|Specific-pathogen-free:222:0.1614|specific pathogen free:122:0.8862	0.8981	573
SPF	SPF:4|Spf:3	subparafascicular thalamic nucleus:7:0.5926	0.5926	7
SPF	SPF:102	sun protection factor:89:0.8857|sun protection factors:13:0.7753	0.8857	102
SPF	SPF:14	Supernatant protein factor:14:0.7909	0.7909	14
SPGP	SPGP:4|Spgp:3|spgp:3|sP-gp:1	Sister of P-glycoprotein:11:0.5664	0.5664	11
SPH	SPH:11|sPH:1	secondary pulmonary hypertension:12:0.5664	0.5664	12
sph	sph:70|Sph:1	sphingomyelin:71:0.2555	0.2555	71
sph	sph:56|Sph:4	Sphingosine:60:0.2153	0.2153	60
SPH	SPH:10	superporous hydrogel:10:0.7103	0.7103	10
SPh	SPh:8|Sph:1	synaptophysin:9:0.0292	0.0292	9
spikes	spikes:21	action potentials:21:0.7500	0.7500	21
SPU	SPU:26|spu:1	segmented polyurethane:27:0.7834	0.7834	27
SqCC	SqCC:20|SQCC:10|sqcc:1	squamous cell carcinoma:31:0.9043	0.9043	31
SQUID	SQUID:68	superconducting quantum interference device:68:0.7935	0.7935	68
srRNA	srRNA:11|SrRNA:4	small subunit ribosomal RNA:15:0.8045	0.8045	15
SRFA	SRFA:12	Suwannee River fulvic acid:12:0.7571	0.7571	12
SRL	SRL:76	sirolimus:76:0.3886	0.3886	76
SRL	SRL:11	skin resistance level:11:0.7357	0.7357	11
SRL	SRL:25|sRL:13	specific lung resistance:38:0.9217	0.9217	38
ssDNA	ssDNA:10	single-stranded:10:0.0156	0.0156	10
ssDNA	ssDNA:467|ss-DNA:15|SSDNA:2	Single-stranded DNA:484:0.7716	0.7716	484
ssRNA	ssRNA:50|ss-RNA:2	single-stranded RNA:52:0.9099	0.9099	52
ssTnI	ssTnI:8	slow skeletal TnI:8:0.5006	0.5006	8
sst2	sst2:18|SST2:1	Somatostatin receptor subtype 2:19:0.6537	0.6537	19
SSTR1-5	SSTR1-5:10|sstr1-5:2	receptor subtypes:12:0.5050	0.5050	12
STA2	STA2:7	thromboxane A2 analogue:7:0.5926	0.5926	7
START	START:11	StAR-related lipid transfer:11:0.4232	0.4232	11
statin	statin:62	reductase inhibitor:62:0.9326	0.9326	62
stem	stem:8	progenitor:8:0.0277	0.0277	8
STEM	STEM:1	scanning and transmission electron microscope:1:0.9353	0.9353	1
STEM	STEM:111|stem:5	scanning transmission electron microscopy:116:0.9742	0.9742	116
stent	stent:10	endoprosthesis:10:0.2250	0.2250	10
STEP	STEP:7	striatal enriched phosphatase:7:0.4438	0.4438	7
STEP	STEP:8	tyrosine phosphatase:8:0.1730	0.1730	8
stg	stg:4	mutant mouse stargazer:4:0.4422	0.4422	4
STG	STG:4|sTG:2|S-Tg:1	serum triglycerides:7:0.1641	0.1641	7
STG	STG:100	stomatogastric ganglion:100:0.8976	0.8976	100
STG	STG:96	superior temporal gyrus:96:0.9689	0.9689	96
stroke	stroke:6	cerebral ischemia:6:0.2113	0.2113	6
stroke	stroke:16|STROKE:1	cerebrovascular disease:17:0.7539	0.7539	17
STR	STR:8|str:1	microsatellite:9:0.0065	0.0065	9
STR	STR:32|str:2	scotopic threshold response:34:0.8644	0.8644	34
STR	STR:590|str:106	short tandem repeat:617:0.9439|short tandem repeats:68:0.7673|short-tandem-repeat:11:0.0081	0.9439	696
STR	STR:5	ST-segment resolution:5:0.0736	0.0736	5
str	str:27|Str:3	streptomycin:30:0.0234	0.0234	30
str	str:7|Str:3	Strictosidine synthase:10:0.7103	0.7103	10
str	str:24|Str:4	strychnine:28:0.0218	0.0218	28
STR	STR:16	subtotal resection:16:0.7261	0.7261	16
sTR	sTR:2|STR:1|str:1|s-TR:1	transferrin receptor:5:0.1132	0.1132	5
STW	STW:23	sewage treatment works:23:0.7500	0.7500	23
sub-MIC	sub-MIC:18|subMIC:4|subMic:1	inhibitory concentration:12:0.4557|inhibitory concentrations:11:0.2422	0.4557	23
sul	sul:6|SUL:3	sulforaphane:9:0.1013	0.1013	9
sul	sul:12|Sul:1|SUL:1	sulpiride:14:0.1646	0.1646	14
supF	supF:9	suppressor tRNA:9:0.6794	0.6794	9
sural	sural:6	cutaneous nerve:6:0.2243	0.2243	6
SUs	SUs:6	stroke units:6:0.1838	0.1838	6
Sus	SuS:3|SUS:3|Sus:3	sucrose synthase:9:0.5470	0.5470	9
SUs	SUs:11	sulfonylureas:11:0.0625	0.0625	11
SUS	SUS:22	Unified Health System:22:0.2872	0.2872	22
SWAps	SWAps:7|SWAPs:2	sector-wide approaches:9:0.6794	0.6794	9
SWEET	SWEET:8	Square-Wave Endurance Exercise Test:8:0.4102	0.4102	8
syn	syn:5	activities of glycogen synthase:5:0.2818	0.2818	5
syn	syn:63|SYN:5|Syn:2	synaptophysin:70:0.3503	0.3503	70
syn	syn:18	syncytial:18:0.0863	0.0863	18
t(1/2)	t(1/2):199|T(1/2):21	Half-life:220:0.5973	0.5973	220
t(1/2)	t(1/2):20|T(1/2):5	half-lives:25:0.0649	0.0649	25
T(1/2)	T(1/2):11|t(1/2):10	half-time:21:0.0541	0.0541	21
T(a)	T(a):53|T(A):1	ambient temperature:42:0.6280|ambient temperatures:12:0.5050	0.6280	54
T(I)	T(I):9	inspiratory time:9:0.5470	0.5470	9
t(max)	t(max):3|T(max):1	time to maximum plasma concentration:4:0.1132	0.1132	4
t(max)	t(max):11|T(max):6	time to reach C(max):17:0.7407	0.7407	17
T(R)	T(R):15|T(r):1	regulatory T:16:0.8165	0.8165	16
t-DCTN	t-DCTN:9	trans-Dehydrocrotonin:9:0.8889	0.8889	9
t.i.d.	t.i.d.:15	three times a day:15:0.6577	0.6577	15
t.i.d.	t.i.d.:25	three times daily:25:0.7679	0.7679	25
t.i.w.	t.i.w.:8	three times weekly:8:0.5006	0.5006	8
t1/2e	t1/2E:3|t1/2e:3|T1/2E:1|T1/2e:1	elimination half-life:8:0.5006	0.5006	8
t1/2z	t1/2z:6|t1/2Z:1	terminal elimination half-life:7:0.4102	0.4102	7
t1/2	t1/2:11|T1/2:7	clearance:18:0.0079	0.0079	18
t1/2	t1/2:339|T1/2:44	elimination half-life:383:0.2953	0.2953	383
t1/2	t1/2:28|T1/2:5	elimination half-lives:33:0.1386	0.1386	33
T1/2	T1/2:9|t1/2:2	gastric half-emptying time:11:0.2582	0.2582	11
t1/2	t1/2:68|T1/2:26	half life:94:0.9682	0.9682	94
t1/2	t1/2:8	half-life of elimination:8:0.1125	0.1125	8
t1/2	t1/2:9|T1/2:4	half lives:13:0.7753	0.7753	13
t1/2	t1/2:156|T1/2:80	half-time:142:0.0652|Half time:50:0.2381|half-times:32:0.0148|half times:12:0.2549	0.2549	236
tADA	tADA:4|t-ADA:3	trans-azetidine-2,4-dicarboxylic acid:7:0.2452	0.2452	7
t-AML	t-AML:28|tAML:1	therapy-related acute myeloid leukemia:29:0.4950	0.4950	29
t-AML	t-AML:13|tAML:2	therapy-related AML:15:0.4609	0.4609	15
t-ANLL	t-ANLL:9|tANLL:1	acute nonlymphocytic leukemia:10:0.7103	0.7103	10
TBA	TBA:51|tBA:1	tert-butyl alcohol:52:0.4937	0.4937	52
TBA	TBA:14	tertiary butyl alcohol:14:0.6911	0.6911	14
TBA	TBA:44	tetrabutylammonium:44:0.0531	0.0531	44
TBA	TBA:328	thiobarbituric acid:328:0.7822	0.7822	328
TBA	TBA:20|tBA:1	total bile acids:21:0.7865	0.7865	21
TBA	TBA:45	traditional birth attendant:23:0.8715|traditional birth attendants:22:0.7955	0.8715	45
TBA	TBA:9	transluminal balloon angioplasty:9:0.5470	0.5470	9
TBA	TBA:30|TbA:1	trenbolone acetate:31:0.8090	0.8090	31
tBid	tBid:13|tBID:5|t-Bid:1|tbid:1	truncated BID:20:0.5279	0.5279	20
TBN	TBN:37	total body nitrogen:37:0.9197	0.9197	37
t-BOOH	t-BOOH:30|tBOOH:19|tbOOH:3|TBOOH:2|t-booH:1	tert-butyl hydroperoxide:55:0.5789	0.5789	55
t-BOOH	t-BOOH:10|tB-OOH:8|TBOOH:4|tBOOH:3	tert-butylhydroperoxide:25:0.1905	0.1905	25
tBuBHQ	tBuBHQ:10	2,5-di-(tert-butyl)-1,4-benzohydroquinone:10:0.3103	0.3103	10
t-BuOOH	t-BuOOH:7|tBuOOH:3|t-buOOH:1	t-Butylhydroperoxide:11:0.0833	0.0833	11
t-BuOOH	t-BuOOH:32|t-bu-OOH:8|tBuOOH:5|t-buOOH:1	tert-butyl hydroperoxide:46:0.4650	0.4650	46
t-BuOOH	t-BuOOH:11|t-buOOH:2|tBu-OOH:2|tBuOOH:1	tert-butylhydroperoxide:16:0.1250	0.1250	16
TCFU	TCFU:5|tCFU:1	tumor colony-forming units:6:0.2827	0.2827	6
T-DNA	T-DNA:57	Transferred DNA:57:0.5719	0.5719	57
TERT	TERT:10	catalytic subunit:10:0.3867	0.3867	10
TERT	TERT:14|Tert:1	catalytic subunit of telomerase:15:0.7096	0.7096	15
TERT	TERT:90	Telomerase reverse transcriptase:90:0.8869	0.8869	90
TG2	TG2:17	Tissue transglutaminase:17:0.6106	0.6106	17
TG2	TG2:9	Transglutaminase 2:9:0.2757	0.2757	9
tHcy	tHcy:237|tHCY:3|t-hcy:2|THCy:1|t-Hcy:1	plasma total homocysteine:244:0.4376	0.4376	244
tHcy	tHcy:9	total homocyst(e)ine:9:0.2285	0.2285	9
tHcy	tHcy:9	Total homocysteine concentration:9:0.4587	0.4587	9
tHcy	tHcy:81|tHCY:1|tHCy:1|t-Hcy:1	total plasma homocysteine:84:0.6016	0.6016	84
tPAag	tPAag:6|tPA-Ag:5|t-PA-Ag:4|tPA-ag:4|t-PAag:2	plasminogen activator antigen:21:0.7865	0.7865	21
tRNAs	tRNAs:14	transfer ribonucleic acids:14:0.7909	0.7909	14
tRNA	tRNA:35	transfer ribonucleic acid:35:0.5481	0.5481	35
tRNA	tRNA:157	transfer RNA:157:0.7632	0.7632	157
tTGase	tTGase:17|tTgase:5	Tissue transglutaminase:22:0.6934	0.6934	22
TACI	TACI:4	CAML interactor:4:0.1329	0.1329	4
TACI	TACI:8	cyclophilin ligand interactor:8:0.5006	0.5006	8
TAGs	TAGs:54	triacylglycerols:54:0.5889	0.5889	54
tau(R)	tau(R):4|tau(r):2	rotational correlation time:6:0.3728	0.3728	6
tau(SD)	tau(SD):9|tau(sd):1	strength-duration time constant:10:0.5856	0.5856	10
tau(m)	tau(m):9	correlation time:9:0.6794	0.6794	9
TAUT	TAUT:23|TauT:11|tau-T:3	taurine transporter:37:0.8749	0.8749	37
tau	tau:28|Tau:1	circadian period:29:0.1861	0.1861	29
tau	tau:10	decay rate:10:0.3470	0.3470	10
tau	tau:5	dosing interval:5:0.1132	0.1132	5
tau	tau:14	efficacy:14:0.0103	0.0103	14
tau	tau:32	free-running period:32:0.2128	0.2128	32
tau	tau:42	lifetime:32:0.0245|lifetimes:10:0.0071	0.0245	42
tau	tau:6	microtubule-associated protein tau:6:0.2243	0.2243	6
tau	tau:8	period length:8:0.4102	0.4102	8
tau	tau:22|Tau:4	pressure decay:26:0.3863	0.3863	26
tau	tau:18	shear stress:18:0.7539	0.7539	18
tau	tau:5	tau protein:5:0.0612	0.0612	5
tau	tau:246|Tau:9	time constant:222:0.9195|time constants:33:0.9100	0.9195	255
tau	tau:7	time constant of decay:7:0.7103	0.7103	7
tau	tau:29|Tau:1	time constant of isovolumic relaxation:30:0.9043	0.9043	30
tau	tau:12|Tau:1	time constant of LV relaxation:13:0.7753	0.7753	13
tau	tau:10|TAU:2|Tau:1	time constant of relaxation:13:0.5934	0.5934	13
TAU	TAU:41	treatment as usual:29:0.8422|treatment-as-usual:12:0.0087	0.8422	41
TcPO2	TcPO2:6|TcpO2:4|TCPO2:2|tcPO2:2|tcpO2:1	transcutaneous oximetry:15:0.7096	0.7096	15
TcPO2	TcPO2:16|tcPO2:9|tcpO2:3|TcPo2:2|tcPo2:1|TcpO2:1	transcutaneous oxygen:32:0.4395	0.4395	32
tcPO2	tcPO2:30|TcPO2:29|tcpO2:7|TCPO2:4|TcpO2:2|tcPo2:1|tc-PO2:1	Transcutaneous oxygen pressure:74:0.8329	0.8329	74
TcPO2	TcPO2:4|tcpO2:1|TcPo2:1|TcpO2:1|tcPO2:1	transcutaneous oxygen pressure measurement:4:0.3170|Transcutaneous oxygen pressure measurements:4:0.1618	0.3170	8
TcPO2	TcPO2:56|tcPO2:56|tcPo2:7|tcpO2:7|tc-PO2:7|TcPo2:6|TcpO2:6|TCpO2:4|TCPO2:2|tc-po2:1|Tcpo2:1	transcutaneous oxygen tension:153:0.8595	0.8595	153
TcPO2	TcPO2:6|tcpO2:3|tcPO2:3|TcPo2:1|TCPO2:1	transcutaneous partial pressure of oxygen:14:0.6173	0.6173	14
tcPO2	tcPO2:36|tcpO2:14|TcPO2:11|TCpO2:3|TcpO2:3|tcPo2:2|TcPo2:2|TCPO2:1	transcutaneous PO2:72:0.7782	0.7782	72
tcRNA	tcRNA:6	total cellular RNA:6:0.5290	0.5290	6
Tco	Tco:31|TCO:1	colonic temperature:32:0.4045	0.4045	32
Tco	Tco:21|TCO:2	core temperature:23:0.2422	0.2422	23
TCO	TCO:9	occlusion:9:0.0640	0.0640	9
TEC	TEC:139|tec:6	thymic epithelial cells:121:0.5058|Thymic epithelial cell:24:0.5370	0.5370	145
TEC	TEC:9	Total eosinophil count:9:0.6794	0.6794	9
TEC	TEC:37	transient erythroblastopenia of childhood:37:0.9197	0.9197	37
TEC	TEC:19|tec:1	transluminal extraction catheter:20:0.7766	0.7766	20
TEC	TEC:24	triethyl citrate:24:0.7593	0.7593	24
Tempol	Tempol:7|TEMPOL:4|tempol:2|TEM-POL:1	4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl:14:0.1300	0.1300	14
TEMPOL	TEMPOL:5|Tempol:3|tempol:1	4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl:9:0.0800	0.0800	9
TeNT	TeNT:28	Tetanus neurotoxin:28:0.8941	0.8941	28
TeNT	TeNT:9|tent:1|TeNt:1	Tetanus toxin:11:0.7357	0.7357	11
ter	ter:6|tER:3|t-ER:1|TER:1	endoplasmic reticulum:11:0.6182	0.6182	11
ter	ter:10|Ter:1	terbutaline:11:0.0186	0.0186	11
TER	TER:42|ter:16	thermal enhancement ratio:43:0.9308|Thermal enhancement ratios:15:0.8045	0.9308	58
TER	TER:7|ter:3	transcapillary escape rate:10:0.5856	0.5856	10
TER	TER:85|ter:43	transepithelial electrical resistance:128:0.6626	0.6626	128
TER	TER:44|ter:44	transepithelial resistance:88:0.2418	0.2418	88
test	test:16	testosterone:16:0.0355	0.0355	16
tetrac	tetrac:6|TETRAC:5|Tetrac:3	tetraiodothyroacetic acid:14:0.5589	0.5589	14
tet	tet:13|Tet:1	Tetanus toxoid:14:0.7909	0.7909	14
tet	tet:69|Tet:3	tetracycline:72:0.1384	0.1384	72
tet	tet:17	tetracycline resistance:17:0.8270	0.8270	17
tet	tet:6	tetracycline resistance gene:6:0.5290	0.5290	6
TET	TET:8	transcutaneous energy transfer:8:0.5006	0.5006	8
TET	TET:12	Treadmill exercise test:12:0.7571	0.7571	12
TET	TET:10	triethyl tin:10:0.7103	0.7103	10
TET	TET:72	triethyltin:72:0.1365	0.1365	72
TET	TET:13	triethyltin bromide:13:0.6701	0.6701	13
TET	TET:21	tubal embryo transfer:21:0.7291	0.7291	21
TGC	TGC:6	trophoblast giant cells:6:0.2827	0.2827	6
TGL	TGL:8	triglyceride lipase:8:0.4102	0.4102	8
thal	thal:24	beta-thalassemia:24:0.1729	0.1729	24
thal	thal:9|Thal:1	thalassemia:10:0.0677	0.0677	10
thal	thal:23|Thal:11	thalidomide:34:0.2481	0.2481	34
THAL	THAL:10	thick ascending limb:10:0.7103	0.7103	10
theta	theta:16	conduction velocity:16:0.4832	0.4832	16
theta	theta:5	Contact angles:5:0.0612	0.0612	5
theta	theta:9	hippocampal theta:9:0.0655	0.0655	9
theta	theta:72	recombination fraction:62:0.9253|recombination fractions:10:0.7103	0.9253	72
theta	theta:7	rhythmic slow activity:7:0.4728	0.4728	7
thiram	thiram:9|Thiram:2	Tetramethylthiuram disulfide:11:0.6182	0.6182	11
THRs	THRs:32|THRS:1	total hip replacements:33:0.9100	0.9100	33
TICs	TICs:5	intensity curves:5:0.1132	0.1132	5
TICS	TICS:12	Telephone Interview for Cognitive Status:12:0.8165	0.8165	12
TIF	TIF:22|tif:1|tIF:1	testicular interstitial fluid:24:0.7151	0.7151	24
TIF	TIF:7	transcription initiation factor:7:0.2452	0.2452	7
TIF	TIF:12	tubulointerstitial fibrosis:12:0.5664	0.5664	12
tiw	tiw:7|TIW:2	three times a week:9:0.4587	0.4587	9
TIW	TIW:6|tiw:2	three times weekly:8:0.2987	0.2987	8
TIW	TIW:10|tiw:5	thrice weekly:15:0.2845	0.2845	15
TKN	TKN:35	total Kjeldahl nitrogen:35:0.9151	0.9151	35
Tlim	Tlim:6|tlim:4|TLIM:1	endurance time:11:0.2582	0.2582	11
Tlim	Tlim:6|tlim:4	time to exhaustion:10:0.3867	0.3867	10
Tm	Tm:12|TM:6	alpha-tropomyosin:18:0.0040	0.0040	18
Tm	Tm:10|tm:1	capacity:11:0.0023	0.0023	11
TM	TM:15	Landsat Thematic Mapper:15:0.4951	0.4951	15
Tm	Tm:10	melting point:10:0.5000	0.5000	10
Tm	Tm:188|tm:6|TM:3|T-m:1	melting temperature:150:0.3807|melting temperatures:48:0.4639	0.4639	198
TM	TM:8|Tm:1	method:9:0.0019	0.0019	9
Tm	Tm:6|tm:2|TM:1	midpoint:9:0.0019	0.0019	9
TM	TM:6|Tm:4|tm:1	muscle:11:0.0023	0.0023	11
TM	TM:2	neurons of the tuberomammillary:2:0.0899	0.0899	2
Tm	Tm:7	phase transition:7:0.0951	0.0951	7
Tm	Tm:63|tm:5|TM:1	phase transition temperature:60:0.3618|phase transition temperatures:9:0.1585	0.3618	69
TM	TM:11	seven-transmembrane:11:0.0023	0.0023	11
TM	TM:11|tm:2	tail moment:13:0.6701	0.6701	13
TM	TM:9|tm:2	Tamoxifen:11:0.0023	0.0023	11
TM	TM:47|tm:1|Tm:1	tectorial membrane:49:0.1572	0.1572	49
TM	TM:25|tm:5	temporomandibular:30:0.0068	0.0068	30
TM	TM:27	testicular microlithiasis:27:0.8903	0.8903	27
TM	TM:17|tm:5	tetrathiomolybdate:22:0.0049	0.0049	22
TM	TM:17|tm:1	thalassaemia major:18:0.1381	0.1381	18
TM	TM:31|tm:2	thalassemia major:33:0.3326	0.3326	33
TM	TM:613|Tm:8|tm:4	thrombomodulin:625:0.1464	0.1464	625
TM	TM:20	Thrombotic microangiopathy:20:0.8525	0.8525	20
TM	TM:9|tm:1	timolol maleate:10:0.3867	0.3867	10
TM	TM:7|tm:4	tooth mobility:11:0.7357	0.7357	11
TM	TM:183|tm:3	trabecular meshwork:186:0.9839	0.9839	186
TM	TM:60|tm:3	transcendental Meditation:63:0.9526	0.9526	63
TM	TM:17	transformed migraine:17:0.7539	0.7539	17
TM	TM:11	transgenic mice:11:0.7357	0.7357	11
TM	TM:12	transitional mucosa:12:0.5050	0.5050	12
TM	TM:643|tm:7|Tm:4	transmembrane:654:0.1532	0.1532	654
TM	TM:102|tm:2	transmembrane domain:73:0.8474|transmembrane domains:31:0.9043	0.9043	104
TM	TM:13	transmembrane glycoprotein:13:0.4849	0.4849	13
TM	TM:27	transmembrane protein:27:0.6192	0.6192	27
TM	TM:12	transmembrane region:12:0.6460	0.6460	12
TM	TM:35|tm:3	transmembrane segment:23:0.8715|transmembrane segments:15:0.8045	0.8715	38
TM	TM:9	transmembrane subunit:9:0.5470	0.5470	9
Tm	Tm:30|TM:3|tm:1	transport maximum:34:0.6666	0.6666	34
TM	TM:24	transverse myelitis:24:0.8768	0.8768	24
TM	TM:41|tm:2	treadmill:43:0.0099	0.0099	43
TM	TM:90|Tm:75	tropomyosin:165:0.0385	0.0385	165
TM	TM:11|tm:1	tuberculous meningitis:12:0.7571	0.7571	12
TM	TM:8	tuberomamillary nucleus:8:0.0625	0.0625	8
TM	TM:23	tuberomammillary nucleus:23:0.4486	0.4486	23
TM	TM:9|tm:1	tubular myelin:10:0.7103	0.7103	10
TM	TM:5	tumour markers:5:0.0902	0.0902	5
TM	TM:101|tm:10|Tm:4	Tunicamycin:115:0.0267	0.0267	115
TM	TM:178|tm:4	tympanic membrane:173:0.7008|tympanic membranes:9:0.4587	0.7008	182
tnpA	tnpA:11|TnpA:4	transposase:15:0.4667	0.4667	15
TOE	TOE:77	transoesophageal echocardiography:77:0.8693	0.8693	77
tomato	tomato:29	Lycopersicon esculentum:29:0.7970	0.7970	29
TONE	TONE:7	tilted optimized nonsaturating excitation:7:0.5926	0.5926	7
TONE	TONE:12	Trial of Nonpharmacologic Interventions in the Elderly:12:0.7571	0.7571	12
TON	TON:11	Traumatic optic neuropathy:11:0.7357	0.7357	11
top2	top2:6|TOP2:5|Top2:4	topoisomerase II:15:0.7096	0.7096	15
topo-II	topo-II:10|topoII:9|TopoII:5|Topo-II:4|TOPO-II:3|TOPOII:1	Topoisomerase II:23:0.7500|topoisomerase-II:9:0.1667	0.7500	32
Topo-I	Topo-I:8|topo-I:8|TopoI:3|TOPO-I:2|topoI:2	topoisomerase-I:14:0.5000|topoisomerase I:9:0.5470	0.5470	23
topo	topo:182|Topo:4	Topoisomerase:186:0.7974	0.7974	186
TOPO	TOPO:13	trioctylphosphine oxide:13:0.2802	0.2802	13
TorA	TorA:4|torA:1	TMAO reductase:5:0.1111	0.1111	5
TorA	TorA:8|torA:1	trimethylamine N-oxide reductase:9:0.6794	0.6794	9
total-C	total-C:13|Total-C:4|TOTAL-C:1|total-c:1	total cholesterol:19:0.7044	0.7044	19
TR-FRET	TR-FRET:6|trFRET:1|tr-FRET:1	time-resolved fluorescence resonance energy transfer:8:0.6411	0.6411	8
tra-2	tra-2:19|TRA-2:2|Tra2:2|tra2:1	transformer-2:24:0.6486	0.6486	24
TRACE	TRACE:19	Trandolapril Cardiac Evaluation:19:0.7658	0.7658	19
TRAPS	TRAPS:16	Tumor necrosis factor receptor-associated periodic syndrome:16:0.4951	0.4951	16
TRIO	TRIO:8	tracheal insufflation of oxygen:8:0.5470	0.5470	8
TRI	TRI:9|tri:3	Toxics Release Inventory:12:0.3275	0.3275	12
TRI	TRI:16	transient radicular irritation:16:0.8165	0.8165	16
TRI	TRI:6	transradial coronary intervention:6:0.5290	0.5290	6
tri	tri:13	trichloroethene:13:0.0337	0.0337	13
tri	tri:109|TRI:7|Tri:1	trichloroethylene:117:0.3287	0.3287	117
tri	tri:10	triglycerides:10:0.0253	0.0253	10
TRI	TRI:23	tubuloreticular inclusions:23:0.8715	0.8715	23
TrkB	TrkB:10|trkB:2	receptor tyrosine kinase B:12:0.2660	0.2660	12
TrkB	TrkB:4|trkB:3|Trk-B:1	tyrosine receptor kinase B:8:0.3463	0.3463	8
Trk	Trk:29|trk:16|TRK:1	tyrosine kinase:46:0.5672	0.5672	46
Trk	Trk:7|trk:4|TRK:1	tyrosine kinase receptors:6:0.3728|Tyrosine kinase receptor:6:0.2827	0.3728	12
TRMA	TRMA:13	thiamine-responsive megaloblastic anemia:13:0.5934	0.5934	13
TRPC	TRPC:17	canonical transient receptor potential:17:0.4246	0.4246	17
TRPC	TRPC:11|TrpC:1	transient receptor potential channel:12:0.7571	0.7571	12
Trp	Trp:50|TRP:31|trp:3	L-tryptophan:84:0.0700	0.0700	84
TRP	TRP:184|trp:39|Trp:19	transient receptor potential:242:0.9801	0.9801	242
Trp	Trp:328|TRP:200|trp:70	tryptophan:598:0.5034	0.5034	598
TRP	TRP:11	tubular reabsorption of phosphate:11:0.7357	0.7357	11
TRP	TRP:8	tubular reabsorption of phosphorus:8:0.6411	0.6411	8
TRP	TRP:9	tyrosinase-related protein:9:0.1367	0.1367	9
trxA	trxA:16|TrxA:8	thioredoxin:24:0.6970	0.6970	24
trxG	trxG:24|trx-G:8|TrxG:2|TRX-G:1	trithorax group:35:0.9151	0.9151	35
TSG101	TSG101:4|tsg101:3|Tsg101:2	tumor susceptibility gene 101:9:0.5470	0.5470	9
TSG-6	TSG-6:6	tumor necrosis factor-stimulated gene-6:6:0.5290	0.5290	6
TS	TS:5|ts:2	alpha-tocopheryl hemisuccinate:7:0.2902	0.2902	7
TS	TS:6|ts:1	alpha-tocopheryl succinate:7:0.1025	0.1025	7
Ts	Ts:6|ts:5|TS:3	DNA synthesis:14:0.6911	0.6911	14
ts	Ts:10|ts:10|TS:5	DNA synthesis time:25:0.7679	0.7679	25
Ts	Ts:6|ts:3	duration of S phase:9:0.4052	0.4052	9
TS	TS:45|ts:15	girls with Turner syndrome:43:0.1764|girls with Turner's syndrome:17:0.1076	0.1764	60
ts	ts:12	patients with Turner's syndrome:12:0.0589	0.0589	12
Ts	Ts:10|TS:3	S-phase duration:13:0.3331	0.3331	13
Ts	Ts:17|ts:7|TS:2	skin temperature:26:0.3586	0.3586	26
TS	TS:5|ts:5	solitary tract:10:0.7103	0.7103	10
Ts	Ts:53|ts:19|TS:2	suppressor T:74:0.8349	0.8349	74
Ts	Ts:127|ts:31|TS:7	suppressor T cells:128:0.9093|suppressor T cell:37:0.9197	0.9197	165
Ts	Ts:6|ts:2	suppressor T lymphocytes:8:0.6411	0.6411	8
TS	TS:5|ts:4	surgery:9:0.0014	0.0014	9
TS	TS:6|ts:3	system:9:0.0014	0.0014	9
Ts	Ts:57|ts:32|TS:13	T suppressor:102:0.7520	0.7520	102
Ts	Ts:18|ts:4|TS:2	T suppressor cells:24:0.6122	0.6122	24
Ts	Ts:4|ts:2|T-s:1	T suppressor/cytotoxic:7:0.3524	0.3524	7
Ts	Ts:8|ts:3	tail-short:11:0.0017	0.0017	11
TS	TS:7|T-S:3|ts:1	Takagi-Sugeno:11:0.0017	0.0017	11
Ts	Ts:7|ts:4	temperatures:11:0.0017	0.0017	11
ts	ts:1022|TS:18|Ts:16|t-s:1	temperature-sensitive:924:0.1613|Temperature sensitive:133:0.9036	0.9036	1057
ts	ts:10|TS:1	temperature sensitivity:11:0.4232	0.4232	11
TS	TS:13|Ts:2|ts:2	tensile strength:17:0.5038	0.5038	17
TS	TS:12|ts:2	test stimulus:14:0.4367	0.4367	14
TS	TS:18|ts:9|T-S:2|Ts:1	testosterone:30:0.0051	0.0051	30
TS	TS:6|ts:4	tetanic stimulation:10:0.1273	0.1273	10
TS	TS:5|Ts:3|ts:2	thermal sensation:10:0.5856	0.5856	10
ts	ts:22|Ts:3|TS:3	thermosensitive:28:0.0047	0.0047	28
TS	TS:24|ts:4	thermostable:28:0.0047	0.0047	28
TS	TS:9|ts:1	threshold shift:10:0.7103	0.7103	10
TS	TS:12|ts:6	thrombospondin:18:0.0030	0.0030	18
TS	TS:641|ts:310	thymidylate synthase:951:0.9447	0.9447	951
TS	TS:65|ts:27	thymidylate synthetase:92:0.8892	0.8892	92
ts	ts:14|TS:8	thymostimulin:22:0.0037	0.0037	22
ts	TS:3|ts:3	thyroid scintigraphy:6:0.1838	0.1838	6
TS	TS:17|ts:11	tobacco smoke:28:0.8369	0.8369	28
ts	ts:10|TS:5	Tokishakuyakusan:15:0.0024	0.0024	15
TS	TS:12|ts:7	torus semicircularis:19:0.8449	0.8449	19
TS	TS:8	Total sleep:8:0.1591	0.1591	8
TS	TS:26|ts:7	total solids:33:0.9100	0.9100	33
TS	TS:275|ts:184	Tourette's syndrome:233:0.2763|Tourette syndrome:226:0.2673	0.2763	459
TS	TS:19|ts:5	tractus solitarius:24:0.8768	0.8768	24
TS	TS:9|ts:4	transcribed strand:13:0.7909	0.7909	13
TS	TS:61|ts:24	transferrin saturation:85:0.8807	0.8807	85
TS	TS:32|ts:17	transition state:49:0.8492	0.8492	49
TS	TS:6|ts:4	transmural stimulation:10:0.1273	0.1273	10
TS	TS:4|ts:1	transthoracic sonography:5:0.0902	0.0902	5
TS	TS:35|ts:20	trauma score:55:0.6833	0.6833	55
TS	TS:10|ts:7	triangularis sterni:17:0.8270	0.8270	17
ts	ts:25|TS:24	triceps surae:49:0.9392	0.9392	49
ts	ts:9|Ts:4|TS:1	Trichinella spiralis:14:0.7909	0.7909	14
TS	TS:6|ts:2	tricuspid stenosis:8:0.1895	0.1895	8
TS	TS:17	trophoblast stem:17:0.7407	0.7407	17
TS	TS:4	Trypanosoma cruzi trans-sialidase:4:0.0545	0.0545	4
TS	TS:96|ts:58	tuberous sclerosis:154:0.9690	0.9690	154
TS	TS:5	tumor size:5:0.0736	0.0736	5
ttk	ttk:13|TTK:5|Ttk:4	tramtrack:22:0.6774	0.6774	22
TTX-S	TTX-S:45|TTXs:3|TTX-s:2	tetrodotoxin-sensitive:50:0.5698	0.5698	50
TTX-S	TTX-S:18|TTXs:2|TTX-s:1	TTX-sensitive:21:0.2326	0.2326	21
tuf	tuf:7|Tuf:2	elongation factor Tu:9:0.6794	0.6794	9
TUNA	TUNA:41	transurethral needle ablation:41:0.8781	0.8781	41
TUNA	TUNA:12	Transurethral needle ablation of the prostate:12:0.7357	0.7357	12
TVA	TVA:5	total vascular area:5:0.4422	0.4422	5
TvC	TvC:8|tvc:1	contrast:9:0.0842	0.0842	9
TVC	TVC:32	total viable count:17:0.8270|total viable counts:15:0.8045	0.8270	32
TVC	TVC:9	vascular conductance:9:0.6794	0.6794	9
two	two:15	hemorrhage:15:0.0072	0.0072	15
two	two:22	infection:22:0.0108	0.0108	22
two	two:10	lymphoma:10:0.0046	0.0046	10
two	two:10	resection:10:0.0046	0.0046	10
u.v.	u.v.:36|U.V.:10	ultraviolet:46:0.5422	0.5422	46
u.v.	u.v.:14|U.V.:1	ultraviolet light:15:0.7096	0.7096	15
UFAs	UFAs:25|uFAs:1	unsaturated fatty acids:26:0.8861	0.8861	26
uFSH	uFSH:17|u-FSH:2	urinary FSH:19:0.6537	0.6537	19
uH2A	uH2A:6|UH2A:1|U-H2A:1	ubiquitinated histone H2A:8:0.4102	0.4102	8
uLTE4	uLTE4:6|u-LTE4:4|U-LTE4:3	urinary leukotriene E4:13:0.5934	0.5934	13
uORF	uORF:54	upstream open reading frame:54:0.8427	0.8427	54
uORFs	uORFs:41	upstream open reading frames:41:0.8224	0.8224	41
uPAR	uPAR:7|UPAR:2|uPA-R:1	receptor for uPA:10:0.7103	0.7103	10
uPAR	uPAR:18|u-PAR:5|uPA-R:4	receptor for urokinase-type plasminogen activator:27:0.7012	0.7012	27
ucOC	ucOC:11|uc-OC:1|UcOC:1	undercarboxylated osteocalcin:13:0.5934	0.5934	13
ufCB	ufCB:7|UfCB:1|UFCB:1	Ultrafine carbon black:9:0.5470	0.5470	9
UFA	UFA:51|ufa:2	unsaturated fatty acids:32:0.6024|Unsaturated fatty acid:21:0.5721	0.6024	53
UNG	UNG:23|Ung:13|ung:6	uracil-DNA glycosylase:42:0.5750	0.5750	42
UNG	UNG:11	Uracil N-glycosylase:11:0.4728	0.4728	11
USH	USH:20	Usher syndrome:20:0.8525	0.8525	20
Uu	Uu:33|UU:28	Ureaplasma urealyticum:61:0.9511	0.9511	61
V(m)	V(m):38|V(M):2	membrane potential:40:0.6147	0.6147	40
v-src	v-src:6	viral src gene:6:0.3728	0.3728	6
vBMD	vBMD:26	Volumetric BMD:26:0.8861	0.8861	26
vBMD	vBMD:41	volumetric bone mineral density:41:0.8525	0.8525	41
vCJD	vCJD:35	variant CJD:35:0.7523	0.7523	35
vCJD	vCJD:14|V-CJD:4	variant of Creutzfeldt-Jakob disease:18:0.8861	0.8861	18
vCSF	vCSF:7|VCSF:5|v-CSF:1	ventricular cerebrospinal fluid:13:0.7753	0.7753	13
vFLIP	vFLIP:7|v-FLIP:2	inhibitory protein:9:0.3945	0.3945	9
vGPCR	vGPCR:6|v-GPCR:1	G protein-coupled receptor:7:0.5926	0.5926	7
vIL-10	vIL-10:17	viral interleukin-10:17:0.6748	0.6748	17
vIL-6	vIL-6:14	viral interleukin-6:14:0.3813	0.3813	14
vLGN	vLGN:22|VLGN:3	ventral lateral geniculate nucleus:25:0.8186	0.8186	25
vMIP-II	vMIP-II:7	macrophage inflammatory protein-II:7:0.4438	0.4438	7
vPAG	vPAG:14|VPAG:1	periaqueductal gray:15:0.7096	0.7096	15
vRNPs	vRNPs:11	ribonucleoproteins:11:0.6667	0.6667	11
vSAGs	vSAGs:5|vSAgs:2|vSags:1|v-SAGs:1	superantigens:9:0.8889	0.8889	9
vWD	vWD:417|VWD:184|vWd:89|VWd:1	von Willebrand disease:406:0.9926|von Willebrand's disease:285:0.9674	0.9926	691
VWD	VWD:4|vWD:3	Von Willebrand disorder:7:0.5926	0.5926	7
vWFAg	vWFAg:14|vWF-Ag:10|vWf-Ag:5|vWfAg:4|vWFag:2|VWF-Ag:1	von Willebrand factor antigen:36:0.9174	0.9174	36
VWS	VWS:29|vWS:2	Van der Woude syndrome:31:0.9043	0.9043	31
var	var:6	variola virus:6:0.1543	0.1543	6
VAR	VAR:6	veno-arteriolar reflex:6:0.1320	0.1320	6
VAR	VAR:15	venoarteriolar response:15:0.8045	0.8045	15
vir	vir:66	virulence:66:0.6500	0.6500	66
vmPFC	vmPFC:8|VMPFC:6	ventromedial prefrontal cortex:14:0.5111	0.5111	14
VOO	VOO:16	virgin olive oil:16:0.7261	0.7261	16
VPH	VPH:17	veterinary public health:17:0.8270	0.8270	17
vvIBDV	vvIBDV:12	virulent infectious bursal disease virus:12:0.6460	0.6460	12
w.t.	w.t.:10|W.T.:2	wild-type:12:0.4074	0.4074	12
w.w.	w.w.:16	wet weight:16:0.8270	0.8270	16
w/o	w/o:48|W/O:34	water-in-oil:82:0.7105	0.7105	82
W/W	W/W:11	white-on-white:11:0.0028	0.0028	11
WET	WET:9	waste extraction test:9:0.6794	0.6794	9
WHI	WHI:5	weight-for-height index:5:0.0902	0.0902	5
WHI	WHI:124|whi:13	Women's Health Initiative:137:0.9150	0.9150	137
WPC	WPC:10	weighted pairwise correlation:10:0.7103	0.7103	10
WPC	WPC:28|wpc:1	whey protein concentrate:29:0.8978	0.8978	29
wpm	wpm:8|WPM:3	words per minute:11:0.6182	0.6182	11
WRIST	WRIST:14	Washington Radiation for In-Stent restenosis Trial:14:0.7909	0.7909	14
WT	WT:13|Wt:10|wt:6	body weight:29:0.1944	0.1944	29
WT	WT:6|wt:2|Wt:1	cells:9:0.0013	0.0013	9
WT	WT:4	inhibitor wortmannin:4:0.0906	0.0906	4
WT	WT:9	walking test:9:0.1205	0.1205	9
WT	WT:39	wall thickening:39:0.9237	0.9237	39
WT	WT:38|Wt:1	wall thickness:39:0.9237	0.9237	39
WT	WT:52	wavelet transform:52:0.9427	0.9427	52
WT	WT:3209|wt:1801|Wt:77|W-T:1|w-t:1	wild-type:4101:0.6444|wild type:988:0.9798	0.9798	5089
WT	WT:3|wt:2	wild-type C57BL/6:5:0.0902	0.0902	5
WT	WT:11	wild-type controls:11:0.4728	0.4728	11
WT	WT:11|wt:1	wild-type enzyme:6:0.1148|wild type enzyme:6:0.5290	0.5290	12
WT	WT:13|Wt:2	wild-type littermates:15:0.4609	0.4609	15
WT	WT:35|Wt:2	wild-type mice:37:0.5038	0.5038	37
WT	WT:7|wt:1	wild-type protein:8:0.5006	0.5006	8
WT	WT:68|wt:23	wildtype:91:0.0141	0.0141	91
WT	WT:228|wt:12	Wilms' tumor:118:0.5239|wilms tumor:61:0.2390|Wilms' tumour:37:0.5510|Wilms tumour:9:0.0526|Wilms' tumors:9:0.2285|Wilms tumors:6:0.0731	0.5510	240
wv/wv	wv/wv:9	homozygous:9:0.0964	0.0964	9
wv	wv:34	weaver:34:0.3173	0.3173	34
WY	WY:14|Wy:1	Wy-14,643:15:0.3256	0.3256	15
XT	XT:10	exotropia:10:0.1304	0.1304	10
XBP-1	XBP-1:7|XBP1:4	X-box binding protein 1:11:0.6182	0.6182	11
XIAP	XIAP:19|X-IAP:1|Xiap:1|xiap:1	X-linked IAP:22:0.4883	0.4883	22
XIAP	XIAP:49	X-linked inhibitor of apoptosis:49:0.6546	0.6546	49
XIAP	XIAP:59|Xiap:8|X-IAP:1	X-linked inhibitor of apoptosis protein:68:0.6117	0.6117	68
xid	xid:6|Xid:2	X-linked immune deficiency:8:0.6411	0.6411	8
xid	xid:48|Xid:11|XID:4	X-linked immunodeficiency:63:0.7943	0.7943	63
xid	xid:22|XID:7|Xid:7	x-linked immunodeficient:36:0.7704	0.7704	36
Xis	Xis:17|xis:3	excisionase:20:0.7037	0.7037	20
xnf7	xnf7:9|Xnf7:1|XNF7:1	Xenopus nuclear factor 7:11:0.7357	0.7357	11
xynA	xynA:7	xylanase gene:7:0.2113	0.2113	7
xynB	xynB:6|XynB:3	beta-xylosidase:9:0.3478	0.3478	9
yeast	yeast:29	Saccharomyces cerevisiae:29:0.8978	0.8978	29
ZFR	ZFR:21|zfr:3|Z-F-R:1	zona fasciculata-reticularis:16:0.6577|zona fasciculata/reticularis:9:0.5470	0.6577	25
ZFS	ZFS:26|zfs:12	zero-field splitting:32:0.6429|zero-field splittings:6:0.2243	0.6429	38
ziram	ziram:7|Ziram:3	zinc dimethyldithiocarbamate:10:0.7103	0.7103	10
ZL	ZL:8|Zl:1	input impedance:9:0.1585	0.1585	9
ZL	ZL:14	Zucker lean:14:0.5111	0.5111	14
Zot	Zot:21|zot:16|ZOT:9	zonula occludens toxin:46:0.8649	0.8649	46
zwf	zwf:7|Zwf:1	glucose-6-phosphate dehydrogenase:8:0.5006	0.5006	8
anti-D	anti-D:11	immunoglobulin:11:0.2326	0.2326	11
Azone	Azone:11|azone:1	1-dodecylazacycloheptan-2-one:12:0.3125	0.3125	12
C3H/HeJ	C3H/HeJ:11|C3H/Hej:1	endotoxin-resistant:12:0.0598	0.0598	12
CXCR4	CXCR4:58|CXCR-4:3	CXC chemokine receptor 4:50:0.7015|CXC chemokine receptor-4:11:0.6182	0.7015	61
D-dimer	D-dimer:30|D-Dimer:5|d-dimer:2	Fibrin degradation products:28:0.8369|fibrin degradation product:9:0.6794	0.8369	37
FK506	FK506:10|FK-506:2	tacrolimus hydrate:12:0.7357	0.7357	12
grade	grade:6	necroinflammatory activity:6:0.1148	0.1148	6
mouse	mouse:4	allogeneic or xenogeneic:4:0.1543	0.1543	4
SCORE	SCORE:12	simple calculated osteoporosis risk estimation:12:0.6460	0.6460	12
tissue	tissue:12	surface area of the blood-gas:12:0.7909	0.7909	12
VALUE	VALUE:11	Valsartan Antihypertensive Long-term Use Evaluation:11:0.7357	0.7357	11
weeks	weeks:25	gestational age:25:0.5524	0.5524	25
white	white:6|White:1	non-Hispanic white:7:0.3524	0.3524	7
(123)I-MIBG	(123)I-MIBG:11	(123)I-metaiodobenzylguanidine:11:0.5556	0.5556	11
1,25(OH)(2)D(3)	1,25(OH)(2)D(3):54|1,25-(OH)(2)D(3):22	1,25-dihydroxyvitamin D(3):76:0.6556	0.6556	76
1,25(OH)2D3	1,25(OH)2D3:68|1,25-(OH)2D3:43|1,25-(OH)2-D3:7|1,25(OH)2-D3:1	1,25-dihydroxycholecalciferol:111:0.1155|1,25 dihydroxycholecalciferol:8:0.5006	0.5006	119
1,25(OH)2D3	1,25(OH)2D3:8|1,25-(OH)2D3:5|1,25-(OH)2-D3:1	1,25-Dihydroxyvitamin D:14:0.3383	0.3383	14
1,25(OH)2D3	1,25(OH)2D3:9|1,25-(OH)2D3:7|1,25-(OH)2D-3:1|1,25(OH)2D-3:1	1,25-Dihydroxyvitamin D-3:18:0.5940	0.5940	18
1,25(OH)2D3	1,25(OH)2D3:330|1,25-(OH)2D3:173|1,25-(OH)2-D3:14	1,25-dihydroxyvitamin D3:517:0.6751	0.6751	517
1,25(OH)2D	1,25(OH)2D:7|1,25-(OH)2D:4	1,25-dihydroxycholecalciferol:11:0.0408	0.0408	11
1,25(OH)2D	1,25(OH)2D:104|1,25-(OH)2D:53|1,25-(OH)2-D:3|1,25(OH)2-D:1|1,25--(OH)2D:1	1,25-dihydroxyvitamin D:162:0.7321	0.7321	162
1,25(OH)2D	1,25(OH)2D:9|1,25-(OH)2D:4|1,25(OH)2-D:1	1,25-dihydroxyvitamin D3:14:0.4709	0.4709	14
1,25-DHCC	1,25-DHCC:18	1,25-dihydroxycholecalciferol:18:0.7083	0.7083	18
11beta-HSD1	11beta-HSD1:61|11betaHSD1:15|11beta-HSD-1:12|11betaHSD-1:2	11beta-hydroxysteroid dehydrogenase type 1:90:0.8740	0.8740	90
11beta-HSD2	11beta-HSD2:9|11betaHSD2:3	11beta-hydroxysteroid dehydrogenase:12:0.6460	0.6460	12
11beta-HSD2	11beta-HSD2:52|11betaHSD2:18|11beta-HSD-2:4|11betaHSD-2:2	11Beta-hydroxysteroid dehydrogenase type 2:76:0.8834	0.8834	76
11beta-HSD	11beta-HSD:113|11betaHSD:42	11beta-hydroxysteroid dehydrogenase:145:0.8871|11beta-hydroxysteroid dehydrogenases:10:0.7103	0.8871	155
123I-IMP	123I-IMP:46	N-isopropyl-p-[123I]iodoamphetamine:29:0.2545|N-isopropyl-p-[123I]-iodoamphetamine:11:0.0909|N-isopropyl-p-[123I] iodoamphetamine:6:0.1838	0.2545	46
123I-MIBG	123I-MIBG:22	123I-metaiodobenzylguanidine:22:0.2625	0.2625	22
123I-MIBG	123I-MIBG:9|123I-mIBG:1	iodine-123 metaiodobenzylguanidine:10:0.1680	0.1680	10
125I-EGF	125I-EGF:29	epidermal growth factor:29:0.6928	0.6928	29
125I-LDL	125I-LDL:7	density lipoprotein:7:0.2902	0.2902	7
125I-hCG	125I-hCG:9	human chorionic gonadotropin:9:0.5470	0.5470	9
131I-MIBG	131I-MIBG:9|131I-mIBG:3	131I-meta-iodobenzylguanidine:12:0.1122	0.1122	12
131I-MIBG	131I-MIBG:48	[131I]metaiodobenzylguanidine:26:0.2551|131I-metaiodobenzylguanidine:22:0.2143	0.2551	48
131I-MIBG	131I-MIBG:7|131I-mIBG:1	iodine-131 metaiodobenzylguanidine:8:0.2113	0.2113	8
15d-PGJ(2)	15d-PGJ(2):29|15-d-PGJ(2):2|15dPGJ(2):2	15-deoxy-Delta(12,14)-PGJ(2):33:0.2581	0.2581	33
15d-PGJ(2)	15d-PGJ(2):36|15dPGJ(2):4|15-d-PGJ(2):2	15-deoxy-Delta(12,14)-prostaglandin J(2):42:0.4455	0.4455	42
17,20beta-P	17,20beta-P:13|17,20betaP:3	17,20beta-dihydroxy-4-pregnen-3-one:16:0.5769	0.5769	16
17-OH-Preg	17OHPreg:3|17-OHPreg:3|17-OH-Preg:3|17OH-Preg:1|17-OH-preg:1|17OH-PREG:1	17-hydroxypregnenolone:12:0.6111	0.6111	12
17alpha-OHP	17alpha-OHP:8|17alphaOHP:2|17alphaOH-P:1	17alpha-hydroxyprogesterone:11:0.8333	0.8333	11
17beta-HSD1	17beta-HSD1:1	17beta-hydroxysteroid dehydrogenase of type 1:1:0.4438	0.4438	1
17beta-HSDs	17beta-HSDs:16|17betaHSDs:3	17Beta-hydroxysteroid dehydrogenases:19:0.7658	0.7658	19
17beta-HSD	17beta-HSD:97|17betaHSD:21	17beta-hydroxysteroid dehydrogenase:118:0.8233	0.8233	118
18F-FDG-PET	18F-FDG-PET:13	positron emission tomography:13:0.4849	0.4849	13
18-OH-DOC	18-OH-DOC:36|18-OHDOC:3|18OH-DOC:3|18OHDOC:1	18-hydroxy-11-deoxycorticosterone:43:0.3962	0.3962	43
18-OH-DOC	18-OH-DOC:23|18-OHDOC:9|18OH-DOC:2	18-hydroxydeoxycorticosterone:34:0.3113	0.3113	34
19-nor-DOC	19-nor-DOC:23|19-Nor-DOC:2	19-nor-deoxycorticosterone:25:0.7500	0.7500	25
1-alpha-OHD3	1-alpha-OHD3:5|1-alpha-OH-D3:4|1alpha-OH-D3:2|1alpha-OHD3:1	1-Alpha-hydroxycholecalciferol:12:0.2444	0.2444	12
1alpha-OH-D3	1alpha-OH-D3:6|1alpha-OHD3:3|1alphaOHD3:3	1alpha-hydroxycholecalciferol:12:0.2444	0.2444	12
2,3,7,8-TCDD	2,3,7,8-TCDD:44	2,3,7,8-tetrachlorodibenzo-p-dioxin:44:0.8113	0.8113	44
2-methyl-5-HT	2-methyl-5-HT:9	2-methyl-5-hydroxytryptamine:9:0.4444	0.4444	9
201Tl-SPECT	201Tl-SPECT:10	emission computed tomography:10:0.7103	0.7103	10
20alpha-HSD	20alpha-HSD:30|20alphaHSD:3	20alpha-hydroxysteroid dehydrogenase:33:0.8605	0.8605	33
22q11DS	22q11DS:7	22q11 deletion syndrome:7:0.3524	0.3524	7
24,25(OH)2D3	24,25(OH)2D3:9|24,25-(OH)2D3:6	24,25-dihydroxycholecalciferol:15:0.1750	0.1750	15
24,25(OH)2D	24,25(OH)2D:16|24,25-(OH)2D:7|24,25-(OH)2-D:1	24,25-dihydroxyvitamin D:24:0.6427	0.6427	24
2-MeS-ATP	2-MeS-ATP:8|2MeSATP:7|2-MeSATP:6|2-Me-S-ATP:1|2Me-SATP:1	2-methylthioadenosine 5'-triphosphate:23:0.7500	0.7500	23
2-MeSATP	2MeSATP:9|2-MeSATP:9|2-MeS-ATP:1|2MeS-ATP:1	2-methylthioadenosine triphosphate:20:0.6259	0.6259	20
3-MeO-AAB	3-MeO-AAB:16	3-methoxy-4-aminoazobenzene:16:0.9375	0.9375	16
3-O-MFPase	3-O-MFPase:9	3-O-methylfluorescein phosphatase:9:0.5470	0.5470	9
35S-TBPS	35S-TBPS:9	35S-t-butylbicyclophosphorothionate:9:0.4706	0.4706	9
3DFT-CISS	3DFT-CISS:8	interference in steady state:8:0.6794	0.6794	8
3alpha,5alpha-THP	3alpha,5alpha-THP:5|3alpha,5alphaTHP:1	neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one:6:0.1148	0.1148	6
3alpha-diol	3alpha-diol:12|3alpha-DIOL:1|3alphaDIOL:1	5alpha-androstane-3alpha,17beta-diol:14:0.2549	0.2549	14
3alpha-HSD	3alpha-HSD:28|3alphaHSD:2	3alpha-hydroxysteroid dehydrogenase:30:0.8032	0.8032	30
3beta-HSD	3beta-HSD:124|3betaHSD:41	3beta-hydroxysteroid dehydrogenase:165:0.7747	0.7747	165
3beta-HSD	3beta-HSD:17|3betaHSD:3	3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase:10:0.7103|3Beta-hydroxysteroid dehydrogenase/delta5-delta4-isomerase:10:0.7103	0.7103	20
3beta-HSD	3beta-HSD:11|3betaHSD:1	3beta-hydroxysteroid dehydrogenase/isomerase:12:0.4153	0.4153	12
450191-S	450191-S:9	hydrochloride dihydrate:9:0.7357	0.7357	9
5,6-MeXAA	5,6-MeXAA:8	5,6-dimethylxanthenone-4-acetic acid:8:0.5006	0.5006	8
5-phosphatase	5-phosphatase:9	inositol polyphosphate 5-phosphatase:9:0.6794	0.6794	9
5-CH3-THF	5-CH3-THF:5|5-CH3THF:3|5CH3THF:1	5-methyltetrahydrofolate:9:0.5714	0.5714	9
5-HTTLPR	5-HTTLPR:7	functional polymorphism in the upstream regulatory region of the serotonin transporter gene:7:0.5926	0.5926	7
5-HTTLPR	5-HTTLPR:10	polymorphism in the promoter region of the serotonin transporter gene:10:0.4557	0.4557	10
5-HTTLPR	5-HTTLPR:12|5HTTLPR:1	serotonin transporter:13:0.6701	0.6701	13
5-HTTLPR	5-HTTLPR:7	serotonin transporter promoter polymorphism:7:0.5926	0.5926	7
5-MeODMT	5-MeODMT:8|5MeODMT:1	5-methoxy-N,N-dimethyl-tryptamine:9:0.0556	0.0556	9
5-MeODMT	5-MeODMT:82|5-MeO-DMT:8|5MeODMT:5|5-MEODMT:2|5MEODMT:1	5-methoxy-N,N-dimethyltryptamine:98:0.6736	0.6736	98
5alpha-DHP	5alpha-DHP:11	5alpha-dihydroprogesterone:11:0.5263	0.5263	11
5alpha-DHT	5alpha-DHT:39|5alphaDHT:4|5-alphaDHT:1	5alpha-dihydrotestosterone:44:0.7818	0.7818	44
5-AZA-CdR	5-AZA-CdR:29|5-Aza-CdR:28|5-aza-CdR:18|5-azaCdR:2|5-AzaCDR:1|5azaCdR:1|5-aza-Cdr:1	5-aza-2'-deoxycytidine:80:0.8571	0.8571	80
6H5MI2C	6H5MI2C:5|6H5MI-2-C:3	6-hydroxy-5-methoxyindole-2-carboxylic acid:8:0.4102	0.4102	8
6beta-OHF	6beta-OHF:6|6betaOHF:3	6beta-hydroxycortisol:9:0.6154	0.6154	9
7-OH-DPAT	7-OH-DPAT:7	agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin:7:0.2764	0.2764	7
7-Cl-KYNA	7-Cl-KYNA:7|7-CLKYNA:1|7ClKynA:1	7-chlorokynurenic acid:9:0.3945	0.3945	9
7beta-OH	7beta-OH:8|7betaOH:1	7beta-hydroxycholesterol:9:0.8889	0.8889	9
8-oxodGuo	8-oxodGuo:39	8-oxo-7,8-dihydro-2'-deoxyguanosine:39:0.7170	0.7170	39
8-BrcAMP	8-BrcAMP:41|8-Br-cAMP:23|8Br-cAMP:4|8BrcAMP:2|8-brcAMP:1|8-br-cAMP:1	8-bromoadenosine 3',5'-cyclic monophosphate:72:0.7548	0.7548	72
8-BrcGMP	8-BrcGMP:30|8-Br-cGMP:15|8-br-cGMP:3|8-Brc-GMP:1	8-bromoguanosine 3',5'-cyclic monophosphate:49:0.6680	0.6680	49
8-CPT-cAMP	8-CPT-cAMP:5|8cpt-cAMP:1|8-CPTcAMP:1	3',5'-cyclic monophosphate:7:0.1850	0.1850	7
8-Cl-cAMP	8-Cl-cAMP:8	8-Chloroadenosine 3',5'-monophosphate:8:0.4102	0.4102	8
8-OH-DPAT	8-OH-DPAT:38|8-OHDPAT:1	5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin:31:0.2023|5-HT1A agonist 8-hydroxy-2-(di-N-propylamino) tetralin:8:0.1271	0.2023	39
8-OH-DPAT	8-OH-DPAT:4	5-HT1A receptor agonist:4:0.1973	0.1973	4
8-OH-DPAT	8-OH-DPAT:60|8-OHDPAT:1	5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin:45:0.5719|5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin:9:0.2660|5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin:7:0.4363	0.5719	61
8-OH-DPAT	8-OH-DPAT:11	8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide:11:0.0691	0.0691	11
8-OH-DPAT	8-OH-DPAT:10	8-hydroxy-2-(di-n-propylamino)tetraline:10:0.0082	0.0082	10
8-OH-DPAT	8-OH-DPAT:6	agonist 8-hydroxy-2(di-n-propylamino)tetralin:6:0.1004	0.1004	6
8-OH-DPAT	8-OH-DPAT:5	agonist 8-hydroxy-2-(dipropylamino)tetralin:5:0.2902	0.2902	5
8-OHDPAT	8-OHDPAT:2|8-OH-DPAT:2	agonist 8-hydroxydipropylaminotetralin:4:0.0902	0.0902	4
8-OH-DPAT	8-OH-DPAT:4	receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin:4:0.2113	0.2113	4
8-OH-DPAT	8-OH-DPAT:3	receptor agonist 8-hydroxy-dipropylaminotetralin:3:0.1838	0.1838	3
8-oxoGua	8-oxoGua:19	8-oxo-7,8-dihydroguanine:19:0.5294	0.5294	19
99Tcm-DTPA	99Tcm-DTPA:8	99Tcm-diethylenetriamine pentaacetate:8:0.5006	0.5006	8
99Tcm-MAG3	99Tcm-MAG3:9	99Tcm-mercaptoacetyltriglycine:9:0.5333	0.5333	9
99Tcm-MIBI	99Tcm-MIBI:9	99Tcm-methoxyisobutyl isonitrile:9:0.6794	0.6794	9
99mTc-HMPAO	99mTc-HMPAO:28	technetium-99m hexamethylpropylene amine oxime:28:0.5269	0.5269	28
99mTc-MIBI	99mTc-MIBI:13	technetium-99m methoxyisobutylisonitrile:13:0.4849	0.4849	13
99mTc-PYP	99mTc-PYP:14	technetium-99m stannous pyrophosphate:14:0.5589	0.5589	14
99mTc-DTPA	99mTc-DTPA:10	diethylene triamine penta-acetic acid:10:0.5856	0.5856	10
99mTc-DTPA	99mTc-DTPA:9|99mTcDTPA:1	diethylenetriamine pentaacetate:10:0.3145	0.3145	10
99mTc-DTPA	99mTc-DTPA:13|99mTcDTPA:2|99mTC-DTPA:2	diethylenetriamine pentaacetic acid:17:0.4480	0.4480	17
99mTc-MAG3	99mTc-MAG3:17	99mTC-mercaptoacetyltriglycine:17:0.2857	0.2857	17
99mTc-MAG3	99mTc-MAG3:6	technetium-99m mercaptoacetyltriglycine:6:0.1320	0.1320	6
99mTc-MDP	99mTc-MDP:29|99mTcMDP:4|99mTC-MDP:1|99m-Tc-MDP:1	methylene diphosphonate:35:0.3921	0.3921	35
A-kinase	A-kinase:50|A-Kinase:2	cAMP-dependent protein kinase:52:0.4507	0.4507	52
A-kinase	A-kinase:28	cyclic AMP-dependent protein kinase:28:0.8941	0.8941	28
AACOCF(3)	AACOCF(3):13	arachidonyl trifluoromethyl ketone:13:0.6701	0.6701	13
AACOCF3	AACOCF3:26	arachidonyl trifluoromethyl ketone:26:0.7340	0.7340	26
ACC-NCDR	ACC-NCDR:5	American College of Cardiology-National Cardiovascular Data Registry:5:0.4422	0.4422	5
ADAMTS-13	ADAMTS-13:8|ADAMTS13:7	von Willebrand factor-cleaving protease:15:0.8045	0.8045	15
ADAS-cog	ADAS-cog:25|ADAS-Cog:19|ADAScog:2|ADASCOG:1	Alzheimer's Disease Assessment Scale-cognitive subscale:40:0.7907|Alzheimer's Disease Assessment Scale Cognitive Subscale:7:0.4438	0.7907	47
ADAS-Cog	ADAS-Cog:10|ADAS-cog:6	cognitive subscale of the Alzheimer's Disease Assessment Scale:16:0.8365	0.8365	16
ADAS-Cog	ADAS-Cog:5|ADAS-cog:4|ADAScog:1|ADAS-COG:1	Disease Assessment Scale-cognitive:11:0.7357	0.7357	11
ADPbetaS	ADPbetaS:10|ADP-beta-S:8	adenosine 5'-O-(2-thiodiphosphate):18:0.8365	0.8365	18
AFCAPS/TexCAPS	AFCAPS/TexCAPS:22	Air Force/Texas Coronary Atherosclerosis Prevention Study:22:0.8525	0.8525	22
AIDS-NHL	AIDS-NHL:21	non-Hodgkin's lymphoma:11:0.4728|non-Hodgkin's lymphomas:10:0.2873	0.4728	21
AIDSCAP	AIDSCAP:27	AIDS Control and Prevention:27:0.8903	0.8903	27
ALI/ARDS	ALI/ARDS:6	acute lung injury/acute respiratory distress syndrome:6:0.5290	0.5290	6
AlkPase	AlkPase:10|ALKPASE:2|alkPase:1|ALK-pase:1|alkpase:1|Alkpase:1	alkaline phosphatase:16:0.8165	0.8165	16
AML/TMDS	AML/TMDS:4	acute myeloid leukemia with trilineage myelodysplasia:4:0.3170	0.3170	4
AML/TMDS	AML/TMDS:6	AML with trilineage myelodysplasia:6:0.2327	0.2327	6
ANZDATA	ANZDATA:8	New Zealand Dialysis and Transplant Registry:8:0.6411	0.6411	8
APE/Ref-1	APE/Ref-1:9|APE/ref-1:3|APE/REF-1:1	apurinic/apyrimidinic endonuclease:13:0.5934	0.5934	13
Apobec1	Apobec1:2|APOBEC1:2|apobec-1:1|APOBEC-1:1	apolipoprotein B mRNA editing enzyme:6:0.5290	0.5290	6
APOBEC-1	APOBEC-1:5	mRNA-editing enzyme catalytic polypeptide 1:5:0.5290	0.5290	5
APRTase	APRTase:9	Adenine phosphoribosyltransferase:9:0.6794	0.6794	9
ARE/EpRE	ARE/EpRE:12	antioxidant/electrophile response element:12:0.4557	0.4557	12
ATF/CREB	ATF/CREB:8	element binding protein:8:0.6411	0.6411	8
ATP-MgCl2	ATP-MgCl2:9	adenosine triphosphate-magnesium chloride:9:0.6794	0.6794	9
ATPDase	ATPDase:17	diphosphohydrolase:17:0.6818	0.6818	17
ATPases	ATPases:28	Adenosine Triphosphatases:28:0.7154	0.7154	28
ATPgammaS	ATPgammaS:9	adenosine 5'-O-(thiotriphosphate):9:0.5470	0.5470	9
ATR-FTIR	ATR-FTIR:21	attenuated total reflection Fourier transform infrared:21:0.8594	0.8594	21
AUC0-infinity	AUC0-infinity:15	area under the plasma concentration-time curve:15:0.8045	0.8045	15
AVP-NPII	AVP-NPII:13	vasopressin-neurophysin II:13:0.5335	0.5335	13
AalphaC	AalphaC:15	2-amino-9H-pyrido[2,3-b]indole:15:0.6667	0.6667	15
AbetaPP	AbetaPP:20	amyloid-beta precursor protein:11:0.1612|amyloid beta precursor protein:9:0.6794	0.6794	20
AbetaPP	AbetaPP:10	amyloid beta protein precursor:10:0.7103	0.7103	10
Ac-DEVD-CHO	Ac-DEVD-CHO:9	acetyl-Asp-Glu-Val-Asp-aldehyde:9:0.1698	0.1698	9
acrylodan	acrylodan:6|Acrylodan:3	6-acryloyl-2-dimethylaminonaphthalene:9:0.4444	0.4444	9
Ag-ELISA	Ag-ELISA:7	enzyme-linked immunosorbent assay:7:0.3524	0.3524	7
AmBisome	AmBisome:100|Ambisome:13|ambisome:1	liposomal amphotericin B:114:0.8401	0.8401	114
anammox	anammox:8|ANAMMOX:7|Anammox:4	anaerobic ammonium oxidation:19:0.7291	0.7291	19
anti-LPS	anti-LPS:13	Antilipopolysaccharide:13:0.3750	0.3750	13
anti-AChR	anti-AChR:26|anti-AchR:1|AntiAchR:1	anti-acetylcholine receptor:28:0.5269	0.5269	28
Apo2L/TRAIL	Apo2L/TRAIL:16|APO2L/TRAIL:2	necrosis factor-related apoptosis-inducing ligand:18:0.8365	0.8365	18
apyrase	apyrase:9	ATP-diphosphohydrolase:9:0.3636	0.3636	9
Avitene	Avitene:12	Microfibrillar collagen:12:0.5664	0.5664	12
Avitene	Avitene:15	microfibrillar collagen hemostat:15:0.8045	0.8045	15
BAC1.2F5	BAC1.2F5:8|Bac1.2F5:1	macrophage cell line:9:0.6794	0.6794	9
BAPTA-AM	BAPTA-AM:23|BAPTAAM:1	acid acetoxymethyl ester:24:0.5157	0.5157	24
BASIS-32	BASIS-32:10	Behavior and Symptom Identification Scale:10:0.5856	0.5856	10
BDDrFVIII	BDDrFVIII:6|BDD-rFVIII:2	B-domain deleted recombinant factor VIII:8:0.6411	0.6411	8
BEHAVE-AD	BEHAVE-AD:14|Behave-AD:2	Behavioral Pathology in Alzheimer's Disease Rating Scale:16:0.5171	0.5171	16
BP-7,8-diol	BP-7,8-diol:10	7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene:10:0.2308	0.2308	10
BS-RNase	BS-RNase:32|BSRNase:1	Bovine seminal ribonuclease:33:0.8245	0.8245	33
BS-RNase	BS-RNase:7|BSRNase:1	Bovine seminal RNase:8:0.4102	0.4102	8
baculovirus	baculovirus:9	Autographa californica nuclear polyhedrosis virus:9:0.6794	0.6794	9
Biostator	Biostator:4|BIOSTATOR:1	glucose controlled insulin infusion system:5:0.5290	0.5290	5
Bt2cAMP	Bt2cAMP:12|Bt2-cAMP:2|bt2cAMP:2	3':5'-cyclic monophosphate:8:0.1004|3',5'-cyclic monophosphate:8:0.1004	0.1004	16
Bt2cAMP	Bt2cAMP:9	adenosine 3':5'-monophosphate:9:0.4587	0.4587	9
Bt2cAMP	Bt2cAMP:63|Bt2-cAMP:4	dibutyryl cyclic AMP:67:0.8874	0.8874	67
Buscopan	Buscopan:6	hyoscine butylbromide:6:0.1838	0.1838	6
C/EBPalpha	C/EBPalpha:6	CCAAT/enhancer-binding protein:6:0.1010	0.1010	6
C/EBPalpha	C/EBPalpha:59|C/EBP-alpha:2|c/EBPalpha:1	CCAAT/enhancer binding protein alpha:49:0.6417|CCAAT/enhancer binding protein-alpha:13:0.3809	0.6417	62
C/EBPbeta	C/EBPbeta:20|C/EBP-beta:7	CCAAT/enhancer binding protein-beta:14:0.4367|CCAAT/enhancer-binding protein-beta:13:0.1650	0.4367	27
C/EBPdelta	C/EBPdelta:18|c/EBPdelta:2	CCAAT/enhancer-binding protein delta:12:0.2699|CCAAT/enhancer binding protein delta:8:0.5006	0.5006	20
C/EBPepsilon	C/EBPepsilon:5|C/EBP-epsilon:1	CCAAT/enhancer-binding protein epsilon:6:0.1148	0.1148	6
CADASIL	CADASIL:17	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy:17:0.8165	0.8165	17
CADASIL	CADASIL:170|cadasil:1|CA-DASIL:1	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy:172:0.9826	0.9826	172
CAT/CLAMS	CAT/CLAMS:13	Linguistic and Auditory Milestone Scale:13:0.8270	0.8270	13
CAVEAT-I	CAVEAT-I:9	Coronary Angioplasty Versus Excisional Atherectomy Trial:9:0.6794	0.6794	9
CBFbeta	CBFbeta:14|Cbfbeta:1	core binding factor beta:8:0.4438|core-binding factor beta:7:0.1470	0.4438	15
CDP-choline	CDP-choline:11	cytidine diphosphate choline:11:0.5355	0.5355	11
CEACAM1	CEACAM1:9|CEACAM-1:1	carcinoembryonic antigen-related cell adhesion molecule 1:10:0.7103	0.7103	10
Cerasorb	Cerasorb:7|CERASORB:1	beta-tricalcium phosphate:8:0.5006	0.5006	8
CFU-GEMM	CFU-GEMM:2	erythroid macrophage megakaryocyte:2:0.5856	0.5856	2
CFU-GEMM	CFU-GEMM:8|CFUGEMM:1	pluripotent hemopoietic progenitors:9:0.4587	0.4587	9
CHAMPUS	CHAMPUS:18	Civilian Health and Medical Program of the Uniformed Services:18:0.7261	0.7261	18
CHO/HGPRT	CHO/HGPRT:14	phosphoribosyl transferase:14:0.7909	0.7909	14
CHSE-214	CHSE-214:11	Chinook salmon embryo:11:0.7357	0.7357	11
CHSE-214	CHSE-214:6	Chinook salmon embryo cells:6:0.5290	0.5290	6
CIBIC-Plus	CIBIC-Plus:4|CIBIC-plus:3	Clinician's Interview-Based Impression of Change plus Caregiver Input:7:0.5926	0.5926	7
CIBIC-Plus	CIBIC-Plus:3|CIBIC-plus:2	Interview-Based Impression of Change with Caregiver Input:5:0.2818	0.2818	5
CINC/gro	CINC/gro:7|CINC/Gro:2	cytokine-induced neutrophil chemoattractant:9:0.6794	0.6794	9
CMP-NANA	CMP-NANA:9	cytidine 5'-monophospho-N-acetyl neuraminic acid:9:0.6794	0.6794	9
CM-beta-CD	CM-beta-CD:12	carboxymethyl-beta-cyclodextrin:12:0.4783	0.4783	12
CODH/ACS	CODH/ACS:7	carbon monoxide dehydrogenase/acetyl-CoA synthase:7:0.5290	0.5290	7
COMBINE	COMBINE:17	comparative binding energy:17:0.8270	0.8270	17
CONSORT	CONSORT:16	Consolidated Standards of Reporting Trials:16:0.8715	0.8715	16
COUP-TFII	COUP-TFII:22	chicken ovalbumin upstream promoter transcription factor II:11:0.7357|chicken ovalbumin upstream promoter-transcription factor II:11:0.7103	0.7357	22
COUP-TFs	COUP-TFs:15	Chicken ovalbumin upstream promoter-transcription factors:8:0.6411|chicken ovalbumin upstream promoter transcription factors:7:0.5926	0.6411	15
CPT-cAMP	CPT-cAMP:17|cpt-cAMP:2|CPTcAMP:2	3',5'-cyclic monophosphate:21:0.3527	0.3527	21
CPT-cAMP	CPT-cAMP:16|cpt-cAMP:6|CPTcAMP:1	8-(4-chlorophenylthio)-cAMP:23:0.1930	0.1930	23
CPT-cAMP	CPT-cAMP:7|cpt-cAMP:3|cptcAMP:1|CPTcAMP:1	chlorophenylthio-cAMP:12:0.0965	0.0965	12
CR2/CD21	CR2/CD21:6	complement receptor type 2:6:0.5290	0.5290	6
CRABP-II	CRABP-II:6|CRABPII:2|CrabpII:1	cellular retinoic acid-binding protein II:9:0.6794	0.6794	9
CRABP-II	CRABP-II:5	retinoic acid binding protein-II:5:0.4422	0.4422	5
CRYO-ROP	CRYO-ROP:12	Multicenter Trial of Cryotherapy for Retinopathy of Prematurity:12:0.6460	0.6460	12
CTAP-III	CTAP-III:6	connective tissue activating peptide:6:0.5290	0.5290	6
CTAP-III	CTAP-III:22	connective tissue-activating peptide III:13:0.7753|Connective tissue activating peptide-III:9:0.6794	0.7753	22
CTGF/CCN2	CTGF/CCN2:11	connective tIssue growth factor:11:0.7357	0.7357	11
CTGF/Hcs24	CTGF/Hcs24:8	Connective tissue growth factor/hypertrophic chondrocyte-specific gene product 24:8:0.6411	0.6411	8
CTLA4Ig	CTLA4Ig:5	antigen 4 immunoglobulin:5:0.5290	0.5290	5
CV11974	CV11974:4|CV-11974:3	receptor antagonist:7:0.2113	0.2113	7
CYP11B2	CYP11B2:97	aldosterone synthase:97:0.9346	0.9346	97
CYP11B2	CYP11B2:26|Cyp11b2:1	aldosterone synthase gene:27:0.8903	0.8903	27
CYP27A1	CYP27A1:16	sterol 27-hydroxylase:16:0.6577	0.6577	16
CYP2C11	CYP2C11:11	cytochrome P450 2C11:11:0.7357	0.7357	11
CYP2C19	CYP2C19:17	cytochrome P450 2C19:17:0.7407	0.7407	17
CYP2C19	CYP2C19:21	S-mephenytoin 4'-hydroxylase:21:0.6040	0.6040	21
CYVADIC	CYVADIC:2	Adriamycin and dacarbazine:2:0.2902	0.2902	2
Ca(2+)-ATPase	Ca(2+)-ATPase:7	calcium adenosine triphosphatase:7:0.2113	0.2113	7
Ca2+-ATPase	Ca2+-ATPase:13	adenosine triphosphatase:13:0.4102	0.4102	13
Ca-ATPase	Ca-ATPase:14|CaATPase:3	adenosine triphosphatase:17:0.7407	0.7407	17
CADILLAC	CADILLAC:14	Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications:14:0.7909	0.7909	14
CaPSURE	CaPSURE:12|CapSURE:1	Cancer of the Prostate Strategic Urologic Research Endeavor:13:0.7753	0.7753	13
CLtotal	CLtotal:7|Cltotal:1	total body clearance:8:0.6411	0.6411	8
CpG-ODNs	CpG-ODNs:5	oligodeoxynucleotides containing CpG motifs:5:0.4422	0.4422	5
Cu/Zn-SOD	Cu/Zn-SOD:18|Cu/ZnSOD:16	copper/zinc superoxide dismutase:34:0.3980	0.3980	34
CuZnSOD	CuZnSOD:67|CuZn-SOD:28|Cu-Zn-SOD:3	copper-zinc superoxide dismutase:98:0.3634	0.3634	98
D-values	D-values:21	decimal reduction times:21:0.8594	0.8594	21
DAP-kinase	DAP-kinase:12|DAP-Kinase:1	Death-associated protein kinase:13:0.6701	0.6701	13
DARPP-32	DARPP-32:6|Darpp-32:1	dopamine- and cAMP-regulated phosphoprotein of 32 kDa:7:0.6411	0.6411	7
DAS-ELISA	DAS-ELISA:5	double antibody sandwich enzyme-linked immunosorbent assay:5:0.5290	0.5290	5
DATATOP	DATATOP:6	Deprenyl and tocopherol antioxidative therapy of parkinsonism:6:0.5290	0.5290	6
DBPCFCs	DBPCFCs:5	double-blind placebo-controlled food challenges:5:0.7571	0.7571	5
DDRT-PCR	DDRT-PCR:36|ddRT-PCR:4	differential display reverse transcription-polymerase chain reaction:22:0.8657|differential display reverse transcription polymerase chain reaction:18:0.8449	0.8657	40
DDRT-PCR	DDRT-PCR:8|ddRT-PCR:1	differential display RT-PCR:9:0.6794	0.6794	9
DETC-MeSO	DETC-MeSO:6	S-methyl N,N-diethylthiolcarbamate sulfoxide:6:0.5290	0.5290	6
DHEA-SO4	DHEA-SO4:8	dehydroepiandrosterone sulfate:8:0.5006	0.5006	8
DHODase	DHODase:8	Dihydroorotate dehydrogenase:8:0.5006	0.5006	8
DHbetaE	DHbetaE:33|dHbetaE:1|DH-beta-E:1	dihydro-beta-erythroidine:35:0.8095	0.8095	35
DIG-ELISA	DIG-ELISA:22	diffusion-in-gel enzyme-linked immunosorbent assay:22:0.7291	0.7291	22
DM-beta-CD	DM-beta-CD:13|DMbetaCD:5	dimethyl-beta-cyclodextrin:18:0.4146	0.4146	18
DNA-PKcs	DNA-PKcs:26|DNA-PKCS:1	catalytic subunit of DNA-dependent protein kinase:27:0.9256	0.9256	27
DNA-PKcs	DNA-PKcs:19	catalytic subunit of DNA-PK:19:0.7766	0.7766	19
DNA-PKcs	DNA-PKcs:42|dna-pkcs:1|DNA-PKCS:1	DNA-dependent protein kinase catalytic subunit:44:0.8620	0.8620	44
DNA-PKcs	DNA-PKcs:21	DNA-PK catalytic subunit:21:0.1245	0.1245	21
DNA-PK(CS)	DNA-PK(CS):5|DNA-PK(cs):3|DNAPK(cs):1	catalytic subunit of DNA-dependent protein kinase:9:0.7103	0.7103	9
DOCA-salt	DOCA-salt:13	deoxycorticosterone acetate-salt:13:0.7753	0.7753	13
Delta(9)-THC	Delta(9)-THC:58|delta(9)-THC:9	delta(9)-tetrahydrocannabinol:67:0.8684	0.8684	67
DeltaCp	DeltaCp:6|deltaCp:3	heat capacity change:9:0.6794	0.6794	9
deltaF508	DeltaF508:2|deltaF508:2	deletion of phenylalanine 508:4:0.0918	0.0918	4
DeltaPsim	DeltaPsim:61|Deltapsim:40|deltapsim:18|deltaPsim:2|DeltaPsiM:1	mitochondrial membrane potential:122:0.8209	0.8209	122
DeltaPsim	DeltaPsim:42|Deltapsim:11|deltapsim:10|deltaPsim:1	mitochondrial transmembrane potential:64:0.7553	0.7553	64
Desferal	Desferal:4|desferal:3	desferrioxamine mesylate:7:0.1211	0.1211	7
DiI-Ac-LDL	DiI-Ac-LDL:3|DiI-AcLDL:2|DiIac-LDL:1|DiI-ac-LDL:1|DiI-acLDL:1	acetylated low-density lipoprotein:8:0.5006	0.5006	8
Diapulse	Diapulse:9|DIAPULSE:1	electromagnetic energy:10:0.7103	0.7103	10
dithiocarb	dithiocarb:6|Dithiocarb:3	sodium diethyldithiocarbamate:9:0.4587	0.4587	9
Duovent	Duovent:3	fenoterol with ipratropium bromide:3:0.2827	0.2827	3
E(2)17betaG	E(2)17betaG:9	17beta-estradiol 17-(beta-d-glucuronide):9:0.6794	0.6794	9
E-10-OH-NT	E-10-OH-NT:10	E-10-hydroxynortriptyline:10:0.6923	0.6923	10
E-selectin	E-selectin:12	endothelial leukocyte adhesion molecule-1:12:0.7571	0.7571	12
EF-1alpha	EF-1alpha:7|EF1alpha:2	elongation factor-1 alpha:5:0.4422|elongation factor 1 alpha:4:0.3170	0.4422	9
EF-1alpha	EF-1alpha:49|EF1alpha:14|Ef-1alpha:1	elongation factor 1alpha:33:0.8605|elongation factor-1alpha:31:0.8519	0.8605	64
EGF-like	EGF-like:11|Egf-like:1	epidermal growth factor-like:12:0.7571	0.7571	12
EGFR-TKI	EGFR-TKI:9	epidermal growth factor receptor tyrosine kinase inhibitor:9:0.6794	0.6794	9
EGFRvIII	EGFRvIII:9|EGFR-vIII:1	epidermal growth factor receptor:10:0.7103	0.7103	10
EGFRvIII	EGFRvIII:6	growth factor receptor variant III:6:0.5290	0.5290	6
ELISPOT	ELISPOT:13|ELISpot:2	enzyme-linked immunosorbent spot:15:0.6386	0.6386	15
ELISPOT	ELISPOT:224|ELISpot:22|Elispot:6|elispot:2|ELIspot:2|ELI-spot:1|ELI-Spot:1|ELI-SPOT:1	enzyme-linked immunospot:259:0.9261	0.9261	259
ELISPOT	ELISPOT:38|ELISpot:1|Elispot:1	enzyme-linked immunospot assay:40:0.8839	0.8839	40
Emdogain	Emdogain:11|EMDOGAIN:7	enamel matrix derivative:18:0.8365	0.8365	18
EMMPRIN	EMMPRIN:38	extracellular matrix metalloproteinase inducer:38:0.9217	0.9217	38
ENRICHD	ENRICHD:9	Enhancing Recovery in Coronary Heart Disease:9:0.5470	0.5470	9
ERIC-PCR	ERIC-PCR:7	enterobacterial repetitive intergenic consensus PCR:7:0.5926	0.5926	7
ERK/MAPK	ERK/MAPK:10|Erk/MAPK:1	extracellular signal-regulated kinase/mitogen-activated protein kinase:11:0.7357	0.7357	11
ERK1/ERK2	ERK1/ERK2:7	extracellular signal-regulated kinases:7:0.5926	0.5926	7
ERRalpha	ERRalpha:17|Erralpha:1	estrogen-related receptor alpha:18:0.5560	0.5560	18
ERalpha	ERalpha:491|ER-alpha:122	estrogen receptor alpha:420:0.8997|estrogen receptor-alpha:193:0.8861	0.8997	613
ESI-FTICR	ESI-FTICR:11	transform ion cyclotron resonance:11:0.7357	0.7357	11
ESI-FTICR-MS	ESI-FTICR-MS:8	Electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry:8:0.6411	0.6411	8
ESI-ITMS	ESI-ITMS:7	electrospray ionization ion trap mass spectrometry:7:0.5926	0.5926	7
ESI-TOFMS	ESI-TOFMS:8	time-of-flight mass spectrometry:8:0.5006	0.5006	8
ESSENCE	ESSENCE:20	Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events:20:0.7766	0.7766	20
ET-18-OCH3	ET-18-OCH3:21|Et-18-OCH3:1	1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine:22:0.2386	0.2386	22
EquiTest	EquiTest:10|Equitest:6	Dynamic posturography:16:0.8165	0.8165	16
EuroSCORE	EuroSCORE:14	European System for Cardiac Operative Risk Evaluation:14:0.7909	0.7909	14
Evo-Devo	Evo-Devo:4|evo-devo:3|EvoDevo:1	evolutionary developmental biology:8:0.6794	0.6794	8
FAO/WHO/UNU	FAO/WHO/UNU:10	Food and Agriculture Organization/World Health Organization/United Nations University:10:0.7103	0.7103	10
FAST-ELISA	FAST-ELISA:7	Falcon assay screening test-enzyme-linked immunosorbent assay:7:0.5926	0.5926	7
FAT/CD36	FAT/CD36:28	Fatty acid translocase:28:0.8941	0.8941	28
FEF(25-75)	FEF(25-75):6	forced expiratory flow:6:0.3728	0.3728	6
FEF25-75	FEF25-75:7	forced expiratory flow between 25% and 75% of vital capacity:7:0.7357	0.7357	7
FEF25-75	FEF25-75:2	forced expiratory flow during the middle half of FVC:2:0.5926	0.5926	2
FEF25-75	FEF25-75:9	forced mid-expiratory flow:9:0.3455	0.3455	9
FEV1/FVC	FEV1/FVC:1	ratio of the forced expiratory volume at 1 second to the forced vital capacity:1:0.4422	0.4422	1
FITC-dextran	FITC-dextran:8|FITC-Dextran:2	fluorescein isothiocyanate dextran:10:0.7103	0.7103	10
FITC-PSA	FITC-PSA:10	Pisum sativum agglutinin:10:0.4363	0.4363	10
FITC-WGA	FITC-WGA:10	wheat germ agglutinin:10:0.7103	0.7103	10
FITC-BSA	FITC-BSA:35|FITCBSA:5	bovine serum albumin:40:0.8184	0.8184	40
FLT3/ITD	FLT3/ITD:4|Flt3/ITD:1	internal tandem duplication of the FLT3 gene:5:0.4422	0.4422	5
FMRFamide	FMRFamide:6	neuropeptide Phe-Met-Arg-Phe-amide:6:0.0807	0.0807	6
FPEC-GLC	FPEC-GLC:6	frequency-pulsed electron capture gas-liquid chromatography:6:0.5290	0.5290	6
FRalpha	FRalpha:8|FR-alpha:3	folate receptor alpha:11:0.7357	0.7357	11
FSIVGTT	FSIVGTT:20	frequently sampled intravenous glucose tolerance test:20:0.8525	0.8525	20
FT-Raman	FT-Raman:14	Fourier transform Raman:14:0.7909	0.7909	14
FTICR-MS	FTICR-MS:16|FTICRMS:10|FT-ICR-MS:3	Fourier transform ion cyclotron resonance mass spectrometry:29:0.8422	0.8422	29
FVIII/vWF	FVIII/vWF:26|FVIII/VWF:7|fVIII/vWf:2|FVIII/vWf:2	Factor VIII/von Willebrand factor:37:0.9197	0.9197	37
FVIIIRAg	FVIIIRAg:16|FVIIIRAG:7|FVIII-RAg:6|FVIII-RAG:5|FVIII-rAg:2|FVIIIR-Ag:2|FVIII-Rag:1|FVIIIrAg:1|F-VIII-R-Ag:1	factor VIII-related antigen:30:0.7652|factor VIII related antigen:11:0.6182	0.7652	41
FVIII-vWF	FVIII-vWF:5|FVIII-VWF:3	Factor VIII-von Willebrand Factor:8:0.6411	0.6411	8
FapyGua	FapyGua:15	2,6-diamino-4-hydroxy-5-formamidopyrimidine:15:0.7778	0.7778	15
FoodNet	FoodNet:27|Food-Net:1	Foodborne Diseases Active Surveillance Network:28:0.7834	0.7834	28
Fragmin	Fragmin:29|fragmin:7	low molecular weight heparin:36:0.9237	0.9237	36
Fru-2,6-P2	Fru-2,6-P2:73|fru-2,6-P2:2	fructose 2,6-bisphosphate:57:0.9176|fructose-2,6-bisphosphate:18:0.2208	0.9176	75
Fru-1,6-P2	Fru-1,6-P2:15|Fru1,6P2:2|fru-1,6-P2:1	fructose 1,6-bisphosphate:18:0.8365	0.8365	18
Fungizone	Fungizone:8|fungizone:1	amphotericin B deoxycholate:9:0.6794	0.6794	9
G-proteins	G-proteins:52	guanine nucleotide-binding proteins:52:0.8345	0.8345	52
G-proteins	G-proteins:30	guanine nucleotide-binding regulatory proteins:19:0.8449|guanine nucleotide binding regulatory proteins:11:0.7357	0.8449	30
G-proteins	G-proteins:14	guanine nucleotide regulatory proteins:14:0.6911	0.6911	14
GABAergic	GABAergic:15|GABA-ergic:1	gamma-aminobutyric acid-ergic:16:0.6577	0.6577	16
GABAergic	GABAergic:10	gamma-aminobutyric acid-mediated:10:0.5856	0.5856	10
GABAergic	GABAergic:24|GABA-ergic:1	gamma-aminobutyric acidergic:25:0.7679	0.7679	25
GAD65Ab	GAD65Ab:10|GAD65-Ab:2	glutamic acid decarboxylase:12:0.7571	0.7571	12
GAD65Ab	GAD65Ab:3|GAD65-Ab:1|GAD65ab:1	Glutamic acid decarboxylase antibodies:5:0.4422	0.4422	5
GADD153	GADD153:5|gadd153:1	DNA damage-inducible gene 153:6:0.5290	0.5290	6
GBV-C/HGV	GBV-C/HGV:2	GB virus C and hepatitis G virus:2:0.7103	0.7103	2
GBV-C/HGV	GBV-C/HGV:68	GB virus C/hepatitis G virus:68:0.9561	0.9561	68
GC-C-IRMS	GC-C-IRMS:9	gas chromatography-combustion-isotope ratio mass spectrometry:9:0.6794	0.6794	9
GC/C/IRMS	GC/C/IRMS:25	gas chromatography/combustion/isotope ratio mass spectrometry:25:0.8816	0.8816	25
GCDFP-15	GCDFP-15:21	gross cystic disease fluid protein:21:0.7291	0.7291	21
GCDFP-15	GCDFP-15:41|GCDFP15:1	Gross cystic disease fluid protein-15:36:0.9174|gross cystic disease fluid protein 15:6:0.3728	0.9174	42
GFRalpha-1	GFRalpha-1:5|GFRalpha1:1	GDNF family receptor alpha-1:6:0.5006	0.5006	6
GFRalpha1	GFRalpha1:8	GDNF Family Receptor alpha1:8:0.6411	0.6411	8
GFRalpha	GFRalpha:8	GDNF family receptor alpha:8:0.6411	0.6411	8
GPIIb-IIIa	GPIIb-IIIa:9	glycoprotein IIb-IIIa complex:9:0.6794	0.6794	9
GROalpha	GROalpha:13|GRO-alpha:9|Gro-alpha:5|Groalpha:1	growth-related oncogene alpha:17:0.3512|Growth-related oncogene-alpha:11:0.2582	0.3512	28
GRalpha	GRalpha:8	glucocorticoid receptor alpha:8:0.6411	0.6411	8
GSH/GSSG	GSH/GSSG:8	glutathione/glutathione disulfide:8:0.3463	0.3463	8
GSK-3beta	GSK-3beta:7|GSK3beta:4	glycogen synthase kinase 3 beta:11:0.7357	0.7357	11
GSK-3beta	GSK-3beta:181|GSK3beta:99|Gsk-3beta:2|Gsk3beta:1	glycogen synthase kinase-3beta:166:0.9447|glycogen synthase kinase 3beta:117:0.9339	0.9447	283
GSSG-Red	GSSG-Red:11|GSSGRed:1	glutathione reductase:12:0.5664	0.5664	12
GTP[gamma-S]	GTP[gamma-S]:7|GTP[gammaS]:3	guanosine 5'-[gamma-thio]triphosphate:10:0.7103	0.7103	10
GTPases	GTPases:36|GT-Pases:1	guanosine triphosphatases:37:0.8377	0.8377	37
GTPgammaS	GTPgammaS:28	guanosine 5'-3-O-(thio)triphosphate:28:0.7154	0.7154	28
GTPgammaS	GTPgammaS:85|GTP-gamma-S:51|GTP-gammaS:4	guanosine 5'-O-(3-thiotriphosphate):117:0.8818|guanosine-5'-o-(3-thiotriphosphate):23:0.0688	0.8818	140
GUSTO-III	GUSTO-III:7	Global Use of Strategies to Open Occluded Coronary Arteries:7:0.3524	0.3524	7
GalNAc-T	GalNAc-T:5|GalNAcT:3|Gal-NAc-T:1|Gal-NAcT:1	N-acetylgalactosaminyltransferase:10:0.3000	0.3000	10
GalTase	GalTase:23	beta 1,4-galactosyltransferase:12:0.7571|beta-1,4-galactosyltransferase:11:0.1471	0.7571	23
Gbetagamma	Gbetagamma:6	G protein betagamma subunits:6:0.4438	0.4438	6
Gd-BOPTA	Gd-BOPTA:25	Gadobenate dimeglumine:25:0.8115	0.8115	25
Glc-1,6-P2	Glc-1,6-P2:10	glucose 1,6-bisphosphate:10:0.7103	0.7103	10
GlcNAc-TIII	GlcNAc-TIII:8	N-acetylglucosaminyltransferase III:8:0.5006	0.5006	8
GlyCAM-1	GlyCAM-1:8|GlyCAM1:2|GLYCAM1:1	glycosylation-dependent cell adhesion molecule 1:11:0.5355	0.5355	11
Gore-Tex	Gore-Tex:32|gore-tex:2|Gore-tex:1|GORE-TEX:1	expanded polytetrafluoroethylene:36:0.3220	0.3220	36
G-protein	G-protein:48	guanine nucleotide-binding protein:30:0.7012|guanine nucleotide binding protein:18:0.7539	0.7539	48
G-protein	G-protein:10	guanine nucleotide-binding regulatory protein:10:0.7103	0.7103	10
G-protein	G-protein:14	guanine nucleotide regulatory protein:14:0.6173	0.6173	14
GroPIns	GroPIns:10	glycerophosphoinositol:10:0.9000	0.9000	10
Gsalpha	Gsalpha:6|Gs-alpha:1	stimulatory G protein:7:0.2452	0.2452	7
H(+)-ATPase	H(+)-ATPase:15	H(+)-adenosinetriphosphatase:15:0.2414	0.2414	15
H(+)-ATPase	H(+)-ATPase:7	plasma membrane proton pump:7:0.5926	0.5926	7
H(+)-K(+)-ATPase	H(+)-K(+)-ATPase:16	H(+)-K(+)-adenosinetriphosphatase:16:0.7500	0.7500	16
H-kininogen	H-kininogen:8	high molecular weight kininogen:8:0.6411	0.6411	8
H.pylori	H.pylori:10|H.Pylori:1	Helicobacter pylori:11:0.7357	0.7357	11
HCASMCs	HCASMCs:7|hCASMCs:2|HCA-SMCs:1	human coronary artery smooth muscle cells:10:0.7103	0.7103	10
HCFC-123	HCFC-123:15|HCFC123:1	1,1-dichloro-2,2,2-trifluoroethane:16:0.4839	0.4839	16
HCFC-141b	HCFC-141b:16|HCFC141b:1	1,1-dichloro-1-fluoroethane:17:0.8889	0.8889	17
HCoV-229E	HCoV-229E:9	human coronavirus 229E:9:0.6794	0.6794	9
HDL-chol	HDL-chol:8|HDL-Chol:2|HDL-CHOL:2	high density lipoprotein cholesterol:12:0.7571	0.7571	12
HEK293t	HEK293t:6|HEK293T:3	human embryonic kidney:9:0.6794	0.6794	9
HER1/EGFR	HER1/EGFR:9	epidermal growth factor receptor:9:0.6794	0.6794	9
HGPRTase	HGPRTase:18|HG-PRTase:1	hypoxanthine-guanine phosphoribosyltransferase:19:0.4852	0.4852	19
HGXPRTase	HGXPRTase:11	hypoxanthine-guanine-xanthine phosphoribosyltransferase:11:0.7357	0.7357	11
HID-TCH-SP	HID-TCH-SP:7	high iron diamine-thiocarbohydrazide-silver proteinate:7:0.5926	0.5926	7
HIF-1alpha	HIF-1alpha:12|Hif-1alpha:1	hypoxia-inducible factor-1 alpha:13:0.4444	0.4444	13
HIF-1alpha	HIF-1alpha:257|HIF1alpha:16|hif-1alpha:1|Hif-1alpha:1	hypoxia-inducible factor-1alpha:151:0.6625|hypoxia-inducible factor 1alpha:74:0.7716|hypoxia inducible factor-1alpha:50:0.9416	0.9416	275
HIV/AIDS	HIV/AIDS:32	human immunodeficiency virus/acquired immune deficiency syndrome:32:0.9072	0.9072	32
HIV/AIDS	HIV/AIDS:54|HIV/Aids:1	human immunodeficiency virus/acquired immunodeficiency syndrome:55:0.9458	0.9458	55
HIV/AIDS	HIV/AIDS:8	human immunodeficiency virus and acquired immunodeficiency syndrome:8:0.6794	0.6794	8
HKc/HPV16	HKc/HPV16:6	human papillomavirus type 16 DNA:6:0.5290	0.5290	6
HLTBMCs	HLTBMCs:8|hLTBMCs:1	Human long-term bone marrow cultures:9:0.5470	0.5470	9
HMW-BCGF	HMW-BCGF:5	high molecular weight B cell growth factor:5:0.4422	0.4422	5
HNF-1alpha	HNF1alpha:4|HNF-1alpha:4	Hepatocyte nuclear factor 1 alpha:8:0.5006	0.5006	8
HNF-1alpha	HNF-1alpha:38|HNF1alpha:22	hepatocyte nuclear factor-1alpha:37:0.8051|Hepatocyte nuclear factor 1alpha:23:0.6400	0.8051	60
HNF-1beta	HNF-1beta:13	hepatocyte nuclear factor-1beta:13:0.7753	0.7753	13
HNF-3beta	HNF-3beta:21|HNF3beta:6|Hnf-3beta:1	hepatocyte nuclear factor-3beta:14:0.6911|hepatocyte nuclear factor 3beta:14:0.7096	0.7096	28
HNF-4alpha	HNF-4alpha:28|HNF4alpha:27|Hnf4alpha:1	Hepatocyte nuclear factor 4alpha:39:0.7364|hepatocyte nuclear factor-4alpha:17:0.7407	0.7407	56
HPAE-PAD	HPAE-PAD:8	anion-exchange chromatography with pulsed amperometric detection:8:0.5006	0.5006	8
HPAEC-PAD	HPAEC-PAD:30	anion-exchange chromatography with pulsed amperometric detection:30:0.5841	0.5841	30
HPLC-DAD	HPLC-DAD:9	high-performance liquid chromatography-diode array detection:9:0.5470	0.5470	9
HPLC/ICPMS	HPLC/ICPMS:5|HPLC/ICP-MS:1	High-performance liquid chromatography/inductively coupled plasma mass spectrometry:6:0.3728	0.3728	6
HPLC/MS/MS	HPLC/MS/MS:18	high-performance liquid chromatography/tandem mass spectrometry:18:0.6381	0.6381	18
HPP-CFCs	HPP-CFCs:9	high proliferative potential colony-forming cells:9:0.6794	0.6794	9
HP-beta-CD	HPbetaCD:13|HP-beta-CD:13|hp-beta-CD:1	2-hydroxypropyl-beta-cyclodextrin:27:0.1238	0.1238	27
HP-beta-CD	HP-beta-CD:96|HPbetaCD:27|HP-betaCD:2	hydroxypropyl-beta-cyclodextrin:125:0.5905	0.5905	125
HP-beta-CyD	HP-beta-CyD:20|hp-beta-CyD:2|Hp-beta-CyD:1	2-hydroxypropyl-beta-cyclodextrin:23:0.5238	0.5238	23
HSV1-sr39tk	HSV1-sr39tk:6	mutant herpes simplex virus type 1 thymidine kinase:6:0.5290	0.5290	6
HSV-tk/GCV	HSV-tk/GCV:11|HSV-TK/GCV:4|HSVtk/GCV:3|HSVTK/GCV:1	herpes simplex virus thymidine kinase/ganciclovir:19:0.8449	0.8449	19
HTLV-I/II	HTLV-I/II:8	human T-cell lymphotropic virus types I and II:8:0.6411	0.6411	8
HTLV-I/II	HTLV-I/II:8	human T-lymphotropic virus types I and II:8:0.7103	0.7103	8
HTLV-III/LAV	HTLV-III/LAV:10	human T-cell lymphotropic virus type III/lymphadenopathy-associated virus:10:0.7103	0.7103	10
HTLV-III/LAV	HTLV-III/LAV:25	human T-lymphotropic virus type III/lymphadenopathy-associated virus:25:0.8903	0.8903	25
HTLV-III	HTLV-III:7	human T-lymphotropic retrovirus:7:0.5926	0.5926	7
HTLV-III	HTLV-III:5|HTLVIII:1	human T-lymphotropic virus:6:0.5290	0.5290	6
HTLV-III	HTLV-III:75	Human T-lymphotropic virus type III:75:0.9370	0.9370	75
HYSCORE	HYSCORE:11	hyperfine sublevel correlation:11:0.7357	0.7357	11
HoNOSCA	HoNOSCA:6	Health of the Nation Outcome Scales for children and Adolescents:6:0.3728	0.3728	6
HuIFN-beta	HuIFN-beta:27	human fibroblast interferon:27:0.8903	0.8903	27
Hypaque	Hypaque:8|hypaque:1	diatrizoate meglumine:9:0.4587	0.4587	9
HyperGEN	HyperGEN:26	Hypertension Genetic Epidemiology Network:26:0.8861	0.8861	26
HyperPP	HyperPP:14|hyperPP:2	hyperkalemic periodic paralysis:16:0.8165	0.8165	16
hyperapoB	hyperapoB:14|HyperapoB:5	Hyperapobetalipoproteinemia:19:0.9474	0.9474	19
IFN-alpha	IFN-alpha:29	human leukocyte interferon:29:0.5058	0.5058	29
IFN-beta	IFN-beta:30|IFN--beta:1	human fibroblast interferon:31:0.5414	0.5414	31
IL-2Rbeta	IL-2Rbeta:13	IL-2 receptor beta chain:13:0.4709	0.4709	13
IMPROVE	IMPROVE:9	Interagency Monitoring of Protected Visual Environments:9:0.6794	0.6794	9
IP-RP-HPLC	IP-RP-HPLC:9	ion-pair reversed-phase high-performance liquid chromatography:9:0.5470	0.5470	9
IR-beta-EP	IR-beta-EP:13|ir-beta-EP:9|Ir-beta-EP:2|ir-beta-Ep:1|IR-beta-Ep:1	immunoreactive beta-endorphin:26:0.7760	0.7760	26
IVF/ICSI	IVF/ICSI:4	fertilization or intracytoplasmic sperm injection:4:0.5926	0.5926	4
IalphaI	IalphaI:26|I-alpha-I:1	inter-alpha-inhibitor:27:0.6341	0.6341	27
IalphaI	IalphaI:9|I-alpha-I:2	inter-alpha-trypsin inhibitor:11:0.6182	0.6182	11
Implanon	Implanon:10	contraceptive implant:10:0.3867	0.3867	10
Ins(1,3,4)P3	Ins(1,3,4)P3:10	inositol 1,3,4-trisphosphate:10:0.5856	0.5856	10
Ins(1,3,4,5)P4	Ins(1,3,4,5)P4:18	inositol 1,3,4,5-tetrakisphosphate:18:0.5560	0.5560	18
Ins(1,4,5)P(3)	Ins(1,4,5)P(3):12	inositol 1,4,5-trisphosphate:12:0.6460	0.6460	12
Ins(1,4,5)P3	Ins(1,4,5)P3:9	inositol 1,4,5-triphosphate:9:0.5470	0.5470	9
Ins(1,4,5)P3	Ins(1,4,5)P3:151|ins-(1,4,5)-P3:1|Ins-(1,4,5)P3:1|ins(1,4,5)P3:1	inositol 1,4,5-trisphosphate:130:0.7737|inositol-1,4,5-trisphosphate:11:0.0459|inositol(1,4,5)trisphosphate:10:0.0413|inositol 1,4,5 trisphosphate:3:0.5926	0.7737	154
Ins-1,3,4,5-P4	Ins-1,3,4,5-P4:8|Ins1,3,4,5P4:1	Inositol 1,3,4,5-tetrakisphosphate:9:0.6794	0.6794	9
Ins-1,4,5-P3	Ins-1,4,5-P3:21|Ins1,4,5P3:8|Ins1,4,5-P3:2|Ins-1,4,5P3:1	inositol 1,4,5-trisphosphate:32:0.7587	0.7587	32
Ishikawa	Ishikawa:9|ISHIKAWA:1	endometrial adenocarcinoma cell line:10:0.7103	0.7103	10
JNK/SAPK	JNK/SAPK:44	c-Jun N-terminal kinase/stress-activated protein kinase:44:0.7619	0.7619	44
JAK/STAT	JAK/STAT:37|Jak/STAT:6|Jak/Stat:1	Janus kinase/signal transducer and activator of transcription:30:0.7012|Janus kinase/signal transducers and activators of transcription:14:0.5589	0.7012	44
JAK-STAT	JAK-STAT:12|Jak-STAT:4|Jak-Stat:1	Janus kinase-signal transducer and activator of transcription:17:0.5760	0.5760	17
K-NPPase	K-NPPase:13	p-nitrophenylphosphatase:13:0.6316	0.6316	13
K2Cr2O7	K2Cr2O7:27	potassium dichromate:27:0.8903	0.8903	27
KRN7000	KRN7000:12	alpha-galactosylceramide:12:0.6111	0.6111	12
kala-azar	kala-azar:99|Kala-Azar:8|Kala-azar:8	visceral leishmaniasis:115:0.9442	0.9442	115
Kaletra	Kaletra:9	Lopinavir/ritonavir:9:0.5625	0.5625	9
Kayexalate	Kayexalate:9|kayexalate:2	sodium polystyrene sulfonate:11:0.6182	0.6182	11
L-threo-DOPS	L-threo-DOPS:31|L-threo-dops:1|L-threo-Dops:1	L-threo-3,4-dihydroxyphenylserine:33:0.8000	0.8000	33
L-trans-PDC	L-trans-PDC:9	L-trans-pyrrolidine-2,4-dicarboxylate:9:0.4444	0.4444	9
L-364,718	L-364,718:7|L364,718:3	receptor antagonist:10:0.3867	0.3867	10
LA-ICP-MS	LA-ICP-MS:16	laser ablation inductively coupled plasma mass spectrometry:16:0.8045	0.8045	16
LC/APCI-MS	LC/APCI-MS:6	pressure chemical ionization mass spectrometry:6:0.3728	0.3728	6
LC/ESI/MS	LC/ESI/MS:9	ionization mass spectrometry:9:0.5470	0.5470	9
LCMRglc	LCMRglc:3|lCMRGlc:2|LCMRGlc:2	local cerebral glucose metabolism:7:0.5926	0.5926	7
LCMRglc	LCMRglc:14|LCMRGlc:8|lCMRGlc:7|lCMRglc:6	local cerebral metabolic rates for glucose:21:0.8186|local cerebral metabolic rate for glucose:14:0.8594	0.8594	35
LCMRglu	LCMRglu:8|LCMRGlu:1	local cerebral metabolic rates for glucose:5:0.5290|local cerebral metabolic rate for glucose:4:0.5290	0.5290	9
LCMRglcs	LCMRglcs:9|LCM-Rglcs:1	local cerebral metabolic rates for glucose:10:0.7357	0.7357	10
LCPUFAs	LCPUFAs:25|LC-PUFAs:7|Lc-PUFAs:1	long-chain polyunsaturated fatty acids:33:0.6305	0.6305	33
LDL-chol	LDL-chol:12|LDL-CHOL:3|LDL-Chol:3	low-density lipoprotein cholesterol:10:0.2643|low density lipoprotein cholesterol:8:0.6411	0.6411	18
LMW-BCGF	LMW-BCGF:8	low molecular weight B cell growth factor:8:0.5006	0.5006	8
LRC-CPPT	LRC-CPPT:9	Lipid Research Clinics Coronary Primary Prevention Trial:9:0.6794	0.6794	9
LTbetaR	LTbetaR:37|LT-betaR:7|LTbeta-R:1	lymphotoxin beta receptor:24:0.7593|lymphotoxin-beta receptor:21:0.2038	0.7593	45
LVdP/dtmax	LVdP/dtmax:5|LVdp/dtmax:1	maximum rate of rise of left ventricular pressure:6:0.4438	0.4438	6
LY83583	LY83583:15|LY-83583:2	6-anilino-5,8-quinolinedione:17:0.4211	0.4211	17
lenograstim	lenograstim:6|Lenograstim:1	recombinant human granulocyte colony-stimulating factor:7:0.5926	0.5926	7
Leu-Leu-OMe	Leu-Leu-OMe:16|LeuLeuOMe:2|Leu-leu-OMe:1|leu-leu-OMe:1|Leu-Leu-OME:1	L-leucyl-L-leucine methyl ester:21:0.6400	0.6400	21
lindane	lindane:28|Lindane:3	gamma-hexachlorocyclohexane:31:0.2566	0.2566	31
lisinopril	lisinopril:12|Lisinopril:1	angiotensin converting enzyme inhibitor:7:0.4438|angiotensin-converting enzyme inhibitor:6:0.1010	0.4438	13
LpA-I/A-II	LpA-I/A-II:6	containing apoA-I and apoA-II:6:0.5000	0.5000	6
M6P/IGF2R	M6P/IGF2R:13|M6p/Igf2r:2|M6P/IGF2r:2	mannose 6-phosphate/insulin-like growth factor 2 receptor:17:0.8270	0.8270	17
M6P/IGF-IIR	M6P/IGF-IIR:5|M6P/IGFIIR:4|M6P/IGFIIr:1|M6-P/IGF-IIR:1|M6-P/IGF-IIr:1	mannose 6-phosphate/insulin-like growth factor II receptor:6:0.5290|mannose 6-phosphate/insulin-like growth factor-II receptor:6:0.5290	0.5290	12
MALDI/MS	MALDI/MS:12	matrix-assisted laser desorption/ionization mass spectrometry:12:0.7571	0.7571	12
MALDI/TOF-MS	MALDI/TOF-MS:13|MALDI/TOFMS:1	matrix-assisted laser desorption/ionization time-of-flight mass spectrometry:14:0.7909	0.7909	14
MALDI-MS	MALDI-MS:194|MALDIMS:1	matrix-assisted laser desorption/ionization mass spectrometry:157:0.9176|Matrix-assisted laser desorption ionization mass spectrometry:38:0.6937	0.9176	195
MALDI-TOFMS	MALDI-TOFMS:137|MALDI-TOF-MS:62|MALDI-ToF-MS:2|MALDITOFMS:1|MALDI-Tof-MS:1	matrix-assisted laser desorption/ionization time-of-flight mass spectrometry:203:0.9614	0.9614	203
MALDI-TOF	MALDI-TOF:172|MALDI-ToF:7	matrix-assisted laser desorption/ionization time-of-flight:123:0.9058|Matrix-assisted laser desorption ionization time-of-flight:47:0.8102|matrix-assisted laser desorption/ionization time of flight:9:0.5470	0.9058	179
MALDI-TOF	MALDI-TOF:11	matrix-assisted laser desorption/ionization time-of-flight mass spectrometry:11:0.7357	0.7357	11
MAPK/ERK	MAPK/ERK:17	mitogen-activated protein kinase:17:0.4035	0.4035	17
MAPK/ERK	MAPK/ERK:18	mitogen-activated protein kinase/extracellular signal-regulated kinase:18:0.6903	0.6903	18
MAP-kinase	MAP-kinase:11|MAPkinase:2|MAP-Kinase:1	mitogen-activated protein kinase:14:0.5111	0.5111	14
MAdCAM-1	MAdCAM-1:9	mucosal addressin cell adhesion molecule:9:0.5470	0.5470	9
MAdCAM-1	MAdCAM-1:100|MadCAM-1:1	mucosal addressin cell adhesion molecule-1:86:0.9111|mucosal addressin cell adhesion molecule 1:15:0.6386	0.9111	101
MC3T3-E1	MC3T3-E1:12	mouse osteoblast-like cells:12:0.3213	0.3213	12
MDA-MB-231	MDA-MB-231:13	breast cancer cell line:13:0.7753	0.7753	13
MERIT-HF	MERIT-HF:7	Metoprolol CR/XL Randomized Intervention Trial in chronic Heart Failure:7:0.5926	0.5926	7
MERIT-HF	MERIT-HF:7	Metoprolol CR/XL Randomized Intervention Trial in Heart Failure:7:0.5926	0.5926	7
MGlcDAG	MGlcDAG:11|MGLcDAG:1	monoglucosyldiacylglycerol:12:0.4783	0.4783	12
MHPG-SO4	MHPG-SO4:5	3-methoxy-4-hydroxyphenylethyleneglycol sulphate:5:0.1132	0.1132	5
MIDCABG	MIDCABG:12|MID-CABG:1	minimally invasive direct coronary artery bypass grafting:13:0.7753	0.7753	13
MIP-1alpha	MIP-1alpha:9	macrophage inflammatory protein:9:0.6794	0.6794	9
MIP-1alpha	MIP-1alpha:28	Macrophage inflammatory protein-1 alpha:28:0.8369	0.8369	28
MIP-1alpha	MIP-1alpha:318|MIP1alpha:1	macrophage inflammatory protein-1alpha:248:0.9626|macrophage inflammatory protein 1alpha:71:0.9573	0.9626	319
MIP-1beta	MIP-1beta:52|MIP1beta:3	macrophage inflammatory protein-1beta:34:0.9126|macrophage inflammatory protein 1beta:21:0.8594	0.9126	55
MIP-3alpha	MIP-3alpha:9|Mip-3alpha:2	macrophage inflammatory protein-3alpha:11:0.4728	0.4728	11
MLCKase	MLCKase:10	myosin light chain kinase:10:0.7103	0.7103	10
MMTV-CAT	MMTV-CAT:7	mouse mammary tumor virus-chloramphenicol acetyltransferase:7:0.3524	0.3524	7
MMTV-LTR	MMTV-LTR:20	mouse mammary tumor virus-long terminal repeat:11:0.7357|mouse mammary tumor virus long terminal repeat:9:0.4587	0.7357	20
MPO-ANCA	MPO-ANCA:7	against myeloperoxidase:7:0.1367	0.1367	7
MPO-ANCA	MPO-ANCA:42	cytoplasmic antibody:31:0.6736|cytoplasmic antibodies:11:0.4232	0.6736	42
MALToma	MALToma:10|MALT-oma:2|MALTOMA:1	mucosa-associated lymphoid tissue lymphoma:13:0.4849	0.4849	13
matrigel	matrigel:3|Matrigel:3	Basement membrane components:6:0.5290	0.5290	6
Matrigel	Matrigel:12|matrigel:2	basement membrane extract:14:0.8045	0.8045	14
Matrigel	Matrigel:32|matrigel:2	basement membrane matrix:34:0.9126	0.9126	34
Matrigel	Matrigel:12|matrigel:1	basement membrane proteins:13:0.6701	0.6701	13
Matrigel	Matrigel:118|matrigel:20	reconstituted basement membrane:138:0.7973	0.7973	138
MbetaCD	MbetaCD:47|M-beta-CD:5|M-betaCD:2|mbetaCD:2|mbetacd:1	methyl-beta-cyclodextrin:57:0.8750	0.8750	57
MeAalphaC	MeAalphaC:11	2-amino-3-methyl-9H-pyrido[2,3-b]indole:11:0.6667	0.6667	11
Mg2+-ATPase	Mg2+-ATPase:11|Mg2+ATPase:1	adenosine triphosphatase:12:0.7571	0.7571	12
Mg-ATPase	Mg-ATPase:11	adenosine triphosphatase:11:0.6182	0.6182	11
micro-IF	micro-IF:8|Micro-IF:1	micro-immunofluorescence:9:0.2759	0.2759	9
micro-IF	micro-IF:11|Micro-IF:2|MicroIF:1	microimmunofluorescence:14:0.4483	0.4483	14
MnSOD-PL	MnSOD-PL:11	manganese superoxide dismutase-plasmid/liposome:11:0.7357	0.7357	11
N-AcO-AAF	N-AcO-AAF:11|N-ACO-AAF:1	N-acetoxy-2-acetylaminofluorene:12:0.3143	0.3143	12
N-Aco-AAF	N-Aco-AAF:6|N-AcO-AAF:5	N-acetoxy-N-2-acetylaminofluorene:11:0.2857	0.2857	11
N-OH-2-FAA	N-OH-2-FAA:11	N-hydroxy-N-2-fluorenylacetamide:11:0.6667	0.6667	11
N-OH-AABP	N-OH-AABP:17	N-hydroxy-4-acetylaminobiphenyl:17:0.7619	0.7619	17
N-hydroxy-AAF	N-hydroxy-AAF:10	N-hydroxy-2-acetylaminofluorene:10:0.6429	0.6429	10
N1-Ac-Spd	N1-Ac-Spd:4|N1-AcSPD:3|N1AcSpd:1|N1-AcSpd:1	N1-Acetylspermidine:9:0.8889	0.8889	9
NAALADase	NAALADase:20	N-acetylated alpha-linked acidic dipeptidase:20:0.8594	0.8594	20
NADP-GDH	NADP-GDH:16	glutamate dehydrogenase:16:0.5564	0.5564	16
NADPH-diaphorase	NADPH-diaphorase:10	nicotinamide adenine dinucleotide phosphate diaphorase:10:0.5856	0.5856	10
NADPase	NADPase:16	nicotinamide adenine dinucleotide phosphatase:16:0.8165	0.8165	16
NANSAIDs	NANSAIDs:4|NA-NSAIDs:1	non-aspirin non-steroidal anti-inflammatory drugs:5:0.5926	0.5926	5
NANSAIDs	NANSAIDs:3|NANSAIDS:1	nonaspirin nonsteroidal anti-inflammatory drugs:4:0.0918	0.0918	4
NAP-taurine	NAP-taurine:9|NAP-Taurine:1	N-(4-azido-2-nitrophenyl)-2-aminoethylsulfonate:10:0.5000	0.5000	10
NAPRTCS	NAPRTCS:66	North American Pediatric Renal Transplant Cooperative Study:66:0.9548	0.9548	66
NBCCEDP	NBCCEDP:19	National Breast and Cervical Cancer Early Detection Program:19:0.8449	0.8449	19
NCI-H292	NCI-H292:6	human airway epithelial:6:0.5290	0.5290	6
NCLEX-RN	NCLEX-RN:15	National Council Licensure Examination for Registered Nurses:15:0.8045	0.8045	15
NCS-Chrom	NCS-Chrom:7|NCS-chrom:4	neocarzinostatin chromophore:11:0.7357	0.7357	11
NFkappaB	NFkappaB:7|NF-kappaB:5	nuclear factor kappa beta:12:0.7571	0.7571	12
NG108-15	NG108-15:25	neuroblastoma x glioma:25:0.8816	0.8816	25
NG108-15	NG108-15:17	neuroblastoma x glioma hybrid:17:0.8270	0.8270	17
NHANES-I	NHANES-I:10|NHANESI:2	National Health and Nutrition Examination Survey:12:0.7571	0.7571	12
NIH-CPSI	NIH-CPSI:15	National Institutes of Health Chronic Prostatitis Symptom Index:15:0.8045	0.8045	15
NINDS-AIREN	NINDS-AIREN:10	Internationale pour la Recherche et l'Enseignement en Neurosciences:10:0.7103	0.7103	10
NK-cells	NK-cells:15	natural killer cells:15:0.8045	0.8045	15
NKF-DOQI	NKF-DOQI:16	National Kidney Foundation-Dialysis Outcomes Quality Initiative:16:0.8165	0.8165	16
NO-NSAIDs	NO-NSAIDs:8	anti-inflammatory drugs:8:0.4102	0.4102	8
NOD/SCID	NOD/SCID:25|NOD/scid:2	Nonobese diabetic/severe combined immunodeficiency:27:0.7066	0.7066	27
NOD/SCID	NOD/SCID:47	nonobese diabetic/severe combined immunodeficient:47:0.6717	0.6717	47
Norplant	Norplant:17	levonorgestrel implants:17:0.2527	0.2527	17
NSD-1015	NSD-1015:13	3-hydroxybenzylhydrazine:13:0.3158	0.3158	13
NSTE-ACS	NSTE-ACS:10|NSTEACS:6	acute coronary syndromes:16:0.8165	0.8165	16
NSTEACS	NSTEACS:6|NSTE-ACS:3	elevation acute coronary syndrome:9:0.5006	0.5006	9
NTPDase	NTPDase:11	nucleoside triphosphate diphosphohydrolase:11:0.6182	0.6182	11
NT-proBNP	NT-proBNP:43|NT-pro-BNP:4|Nt-proBNP:3|NTproBNP:1	N-terminal pro-brain natriuretic peptide:43:0.7363|N-terminal pro brain natriuretic peptide:8:0.5006	0.7363	51
Na(+)-K(+)-ATPase	Na(+)-K(+)-ATPase:29	Na(+)-K(+)-adenosinetriphosphatase:29:0.5185	0.5185	29
Na+,K(+)-ATPase	Na+,K(+)-ATPase:10	adenosine triphosphatase:10:0.3145	0.3145	10
Na+,K+-ATPase	Na+,K+-ATPase:13|Na+,K+ATPase:1	adenosine triphosphatase:14:0.4367	0.4367	14
Na+-K+-ATPase	Na+-K+-ATPase:5|Na+--K+-ATPase:2|Na+K+ATPase:1	adenosine triphosphatase:8:0.2987	0.2987	8
Na,K-ATPase	Na,K-ATPase:26	adenosine triphosphatase:26:0.5409	0.5409	26
NaDodSO4	NaDodSO4:31|NaDod-SO4:1|Na-DodSO4:1|NaDoDSO4:1	sodium dodecyl sulfate:34:0.9126	0.9126	34
Na-K-ATPase	Na-K-ATPase:21|NaK-ATPase:10|NaKATPase:1	adenosine triphosphatase:32:0.5841	0.5841	32
Na-K-ATPase	Na-K-ATPase:15	Na-K-adenosinetriphosphatase:15:0.1750	0.1750	15
NalBzoH	NalBzoH:21|NalBzOH:4|nalBzoH:1|nalbzoh:1	Naloxone benzoylhydrazone:27:0.8312	0.8312	27
Namalva	Namalva:12	human lymphoblastoid:12:0.3813	0.3813	12
Namalwa	Namalwa:8	human lymphoblastoid:8:0.4102	0.4102	8
neuro-2A	Neuro-2A:2|Neuro-2a:2|neuro-2A:2|Neuro2A:1	mouse neuroblastoma:7:0.1470	0.1470	7
Neuro-2a	Neuro-2a:6|Neuro-2A:4|neuro-2A:3|neuro-2a:3|Neuro2a:2	neuroblastoma cells:18:0.5228	0.5228	18
Neuro-2a	Neuro-2A:3|Neuro-2a:3|Neuro2a:2|Neuro2A:2|neuro-2a:2|neuro2a:1	neuroblastoma cell line:13:0.4444	0.4444	13
nnAChRs	nnAChRs:7|NnAChRS:1	neuronal nicotinic acetylcholine receptors:8:0.6411	0.6411	8
NovoSeven	NovoSeven:6|Novoseven:1	Recombinant activated factor VII:7:0.5926	0.5926	7
Nt-proANP	Nt-proANP:4|NT-pro-ANP:2|NT-proANP:2|NtproANP:1|Nt-pro-ANP:1	N-terminal pro-atrial natriuretic peptide:10:0.5856	0.5856	10
O-GlcNAc	O-GlcNAc:14	O-linked beta-N-acetylglucosamine:14:0.6911	0.6911	14
O-GlcNAc	O-GlcNAc:52	O-linked N-acetylglucosamine:52:0.6570	0.6570	52
ONO-1101	ONO-1101:8	Toxicity studies of landiolol hydrochloride:8:0.6411	0.6411	8
ONO-5046	ONO-5046:15	Neutrophil elastase inhibitor:15:0.8045	0.8045	15
ONO-5046.Na	ONO-5046.Na:8	neutrophil elastase inhibitor:8:0.5006	0.5006	8
ONTARGET	ONTARGET:11	Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial:11:0.7357	0.7357	11
OPRTase	OPRTase:22|OPRtase:1	orotate phosphoribosyltransferase:23:0.8715	0.8715	23
P450(arom)	P450(arom):7	cytochrome P450 aromatase:7:0.4438	0.4438	7
P450(scc)	P450(scc):6	cytochrome P450 side-chain cleavage:6:0.3728	0.3728	6
P-450AROM	P-450AROM:17|P-450arom:11|P450arom:1	aromatase cytochrome P-450:29:0.8422	0.8422	29
P450arom	P450arom:52|P450AROM:9	aromatase cytochrome P450:61:0.9229	0.9229	61
P450arom	P450arom:57|P450AROM:2|p450arom:2	cytochrome P450 aromatase:61:0.5942	0.5942	61
P450c17	P450c17:21|P-450c17:4	17 alpha-hydroxylase:25:0.8816	0.8816	25
P450c17	P450c17:12|P450C17:1	17 alpha-hydroxylase cytochrome P450:13:0.6701	0.6701	13
P450c17	P450c17:5	cytochrome P450 17alpha-hydroxylase:5:0.4422	0.4422	5
P450c21	P450c21:20|P-450C21:2|P-450c21:1	Steroid 21-hydroxylase:23:0.3179	0.3179	23
P-450scc	P-450scc:14|P-450SCC:2|P450scc:1	cholesterol side-chain cleavage cytochrome P-450:17:0.8270	0.8270	17
P450scc	P450scc:40|P450SCC:3	cholesterol side-chain cleavage cytochrome P450:43:0.8300	0.8300	43
P450scc	P450scc:1	cytochrome P450 for side chain cleavage:1:0.4849	0.4849	1
P450scc	P450scc:38	cytochrome P450 side-chain cleavage:38:0.6322	0.6322	38
P450scc	P450scc:17|p450scc:2|P-450SCC:1	side chain cleavage enzyme:20:0.7766	0.7766	20
PA-TCH-SP	PA-TCH-SP:13	periodate-thiocarbohydrazide-silver proteinate:13:0.1139	0.1139	13
PA-TCH-SP	PA-TCH-SP:30	periodic acid-thiocarbohydrazide-silver proteinate:30:0.9011	0.9011	30
PA-inhibitor	PA-inhibitor:7	plasminogen activator inhibitor:7:0.5926	0.5926	7
PACAP-27	PACAP-27:12|PACAP27:2	pituitary adenylate cyclase-activating polypeptide:14:0.7909	0.7909	14
PACAP38	PACAP38:14|PACAP-38:7	pituitary adenylate cyclase-activating polypeptide:21:0.8594	0.8594	21
PACAP-38	PACAP-38:11|PACAP38:9	pituitary adenylate cyclase-activating polypeptide 38:8:0.5926|pituitary adenylate cyclase activating polypeptide-38:6:0.3728|Pituitary adenylate cyclase-activating polypeptide-38:6:0.5290	0.5926	20
PARAFAC	PARAFAC:17	parallel factor analysis:17:0.8270	0.8270	17
PBD-ZrO2	PBD-ZrO2:8	Polybutadiene-coated zirconia:8:0.5006	0.5006	8
PCDDs/Fs	PCDDs/Fs:5	polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans:5:0.4422	0.4422	5
PCNA/cyclin	PCNA/cyclin:32|PCNA/Cyclin:5	proliferating cell nuclear antigen:37:0.9197	0.9197	37
PCR-CTPP	PCR-CTPP:12	Polymerase chain reaction with confronting two-pair primers:12:0.7571	0.7571	12
PCR/SSCP	PCR/SSCP:6	polymerase chain reaction/single strand conformation polymorphism:6:0.5290	0.5290	6
PCR-RFLP	PCR-RFLP:4	analysis of PCR products:4:0.2818	0.2818	4
PCR-RFLP	PCR-RFLP:21	fragment length polymorphism analysis:21:0.8594	0.8594	21
PD20FEV1	PD20FEV1:4	forced expiratory volume in one second:4:0.3170	0.3170	4
PD-ECGF/TP	PD-ECGF/TP:19|PDECGF/TP:1	Platelet-derived endothelial cell growth factor/thymidine phosphorylase:20:0.7173	0.7173	20
PDGFRalpha	PDGFRalpha:4|PDGFR-alpha:1	growth factor alpha receptor:5:0.4422	0.4422	5
PDGFRalpha	PDGFRalpha:16|PDGFR-alpha:7|PDGF-Ralpha:2|pdgfr-alpha:1	Platelet-derived growth factor receptor alpha:16:0.6577|platelet-derived growth factor receptor-alpha:10:0.7103	0.7103	26
PDGFR-beta	PDGFR-beta:6	platelet-derived growth factor receptor:6:0.5290	0.5290	6
PDGFRbeta	PDGFRbeta:18|PDGFR-beta:17|PDGF-Rbeta:3|PDGFr-beta:1	platelet-derived growth factor receptor-beta:23:0.8715|platelet-derived growth factor receptor beta:16:0.6024	0.8715	39
PDGFalphaR	PDGFalphaR:6|PDGFalpha-R:1	platelet-derived growth factor alpha receptor:7:0.4438	0.4438	7
PDGFbetaR	PDGFbetaR:10|PDGF-betaR:1|PDGF-beta-R:1|PDGFbetar:1	platelet-derived growth factor beta receptor:13:0.6701	0.6701	13
PDGF-beta	PDGF-beta:9|PDGFbeta:2	platelet-derived growth factor-beta:11:0.7357	0.7357	11
PEG-rHuMGDF	PEG-rHuMGDF:47|PEGrHuMGDF:2|PEG-rhuMGDF:1	pegylated recombinant human megakaryocyte growth and development factor:50:0.8520	0.8520	50
PEP/LVET	PEP/LVET:4	ratio of the pre-ejection period to left ventricular ejection time:4:0.6701	0.6701	4
PEP/LVET	PEP/LVET:10	ventricular ejection time ratio:10:0.5000	0.5000	10
PEPCase	PEPCase:18|PEPcase:1|PEP-Case:1	phosphoenolpyruvate carboxylase:20:0.6259	0.6259	20
PFK-2/FBPase-2	PFK-2/FBPase-2:5	bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase:5:0.5926	0.5926	5
PGC-1alpha	PGC-1alpha:23|PGC1alpha:2	peroxisome proliferator-activated receptor gamma coactivator-1alpha:11:0.7357|peroxisome proliferator-activated receptor-gamma coactivator-1alpha:7:0.5926|Peroxisome proliferator-activated receptor gamma coactivator 1alpha:7:0.5926	0.7357	25
PHTVL/PHPV	PHTVL/PHPV:5	persistent hyperplastic tunica vasculosa lentis/persistent hyperplastic primary vitreous:5:0.4422	0.4422	5
PI3Kgamma	PI3Kgamma:14|PI-3Kgamma:1|PI3-Kgamma:1	phosphoinositide 3-kinase gamma:16:0.6024	0.6024	16
PI3-kinase	PI3-kinase:276|PI-3-kinase:24|Pi3-kinase:2|PI3kinase:2	phosphatidylinositol 3-kinase:241:0.7455|phosphatidylinositol-3-kinase:28:0.0696|phosphatidylinositol-3 kinase:13:0.1962|phosphatidylinositol 3 kinase:11:0.5355|phosphatidylinositol 3'-kinase:11:0.4728	0.7455	304
PI3-kinase	PI3-kinase:48|PI3-Kinase:3|PI-3-kinase:1	Phosphoinositide 3-kinase:52:0.1224	0.1224	52
PIVKA-II	PIVKA-II:6|PIVKAII:1	induced by vitamin K absence:7:0.5856	0.5856	7
PIVKA-II	PIVKA-II:29|PIVKAII:1	protein induced by vitamin K absence or antagonist-II:17:0.7044|protein induced by vitamin K absence or antagonist II:13:0.8045	0.8045	30
PKC-beta	PKC-beta:15|PKCbeta:1	protein kinase C-beta:16:0.8165	0.8165	16
PKCdelta	PKCdelta:5	delta isoform of protein kinase C:5:0.4422	0.4422	5
PKCepsilon	PKCepsilon:5|PKC-epsilon:1	epsilon isoform of protein kinase C:6:0.5290	0.5290	6
PKC-zeta	PKC-zeta:28|PKCzeta:17	protein kinase c-zeta:30:0.9011|protein kinase C zeta:15:0.8045	0.9011	45
PKCzeta	PKCzeta:19	protein kinase Czeta:19:0.7658	0.7658	19
PLC/PRF/5	PLC/PRF/5:11	hepatocellular carcinoma cell line:11:0.7357	0.7357	11
PLC/PRF/5	PLC/PRF/5:6	human hepatoma cell line:6:0.2243	0.2243	6
PLC-beta	PLC-beta:33|PLCbeta:2	Phospholipase C-beta:35:0.8292	0.8292	35
PLCbeta	PLCbeta:28	phospholipase Cbeta:28:0.8369	0.8369	28
PM-IRRAS	PM-IRRAS:4|PMIRRAS:4	polarization modulation infrared reflection absorption spectroscopy:8:0.5006	0.5006	8
PML-RARalpha	PML-RARalpha:7	promyelocytic leukemia-retinoic acid receptor alpha:7:0.5926	0.5926	7
PNIPAAm	PNIPAAm:26|PNIPAAM:1|PNiPAAm:1	poly(N-isopropylacrylamide):28:0.6000	0.6000	28
PPARalpha	PPARalpha:17|PPAR-alpha:3	peroxisome proliferator-activated receptor:20:0.8525	0.8525	20
PPARalpha	PPARalpha:306|PPAR-alpha:38|Pparalpha:1	peroxisome proliferator-activated receptor alpha:241:0.9798|peroxisome proliferator-activated receptor-alpha:104:0.9259	0.9798	345
PPARdelta	PPARdelta:16	peroxisome proliferator-activated receptor delta:16:0.8045	0.8045	16
PPARgamma1	PPARgamma1:6|PPAR-gamma1:1	peroxisome proliferator-activated receptor gamma1:7:0.5926	0.5926	7
PPARgamma2	PPARgamma2:22|PPAR-gamma2:12	peroxisome proliferator-activated receptor gamma2:17:0.8270|peroxisome proliferator-activated receptor-gamma2:17:0.8270	0.8270	34
PPARgamma	PPARgamma:16|PPAR-gamma:1	peroxisome proliferator-activated receptor:17:0.8270	0.8270	17
PPARgamma	PPARgamma:732|PPAR-gamma:206|PPargamma:1	Peroxisome proliferator-activated receptor gamma:585:0.9561|peroxisome proliferator-activated receptor-gamma:354:0.9550	0.9561	939
PPIases	PPIases:8	peptidyl prolyl cis/trans isomerases:8:0.6411	0.6411	8
PP-ribose-P	PP-ribose-P:10	phosphoribosylpyrophosphate:10:0.3214	0.3214	10
PREEMPT	PREEMPT:6|Preempt:1	competitive exclusion culture:7:0.5926	0.5926	7
Premarin	Premarin:5|premarin:2	conjugated equine oestrogens:7:0.6794	0.6794	7
PRIME-MD	PRIME-MD:29	Primary Care Evaluation of Mental Disorders:29:0.8978	0.8978	29
PRISM-PLUS	PRISM-PLUS:10	Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms:10:0.7103	0.7103	10
PROSPER	PROSPER:8	prospective study of Pravastatin in the Elderly at Risk:8:0.6411	0.6411	8
PROWESS	PROWESS:7	Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis:7:0.5926	0.5926	7
PRTases	PRTases:9	phosphoribosyltransferases:9:0.8889	0.8889	9
PSA-NCAM	PSA-NCAM:26	highly polysialylated neural cell adhesion molecule:26:0.3846	0.3846	26
PSA-NCAM	PSA-NCAM:6	polysialylated NCAM:6:0.1320	0.1320	6
PTH/PTHrP	PTH/PTHrP:7	parathyroid hormone/parathyroid hormone-related peptide:7:0.5926	0.5926	7
PTH/PTHrP	PTH/PTHrP:6	parathyroid hormone/parathyroid hormone-related protein:6:0.5290	0.5290	6
PTPalpha	PTPalpha:12	protein tyrosine phosphatase alpha:12:0.7357	0.7357	12
PTPases	PTPases:185	protein tyrosine phosphatases:130:0.9299|Protein-tyrosine phosphatases:55:0.1939	0.9299	185
PTPepsilon	PTPepsilon:7	tyrosine phosphatase epsilon:7:0.5926	0.5926	7
Pchlide	Pchlide:36|PChlide:4|pchlide:1	protochlorophyllide:41:0.8696	0.8696	41
Pergonal	Pergonal:6|pergonal:1	human menopausal gonadotropin:7:0.4438	0.4438	7
Pf155/RESA	Pf155/RESA:15	ring-infected erythrocyte surface antigen:15:0.6386	0.6386	15
preproPTH	preproPTH:7|prepro-PTH:4|PreProPTH:1	preproparathyroid hormone:12:0.4557	0.4557	12
Prepidil	Prepidil:3	prostaglandin E2 intracervical gel:3:0.3170	0.3170	3
ProtoVIEW	ProtoVIEW:7	protocol processing system:7:0.5926	0.5926	7
PtdIns(3)P	PtdIns(3)P:11	phosphatidylinositol 3-phosphate:11:0.6182	0.6182	11
PtdIns(3,4)P2	PtdIns(3,4)P2:9	phosphatidylinositol 3,4-bisphosphate:9:0.6794	0.6794	9
PtdIns(3,4,5)P(3)	PtdIns(3,4,5)P(3):17|PtdIns-(3,4,5)P(3):1	phosphatidylinositol 3,4,5-trisphosphate:18:0.8365	0.8365	18
PtdIns(3,4,5)P3	PtdIns(3,4,5)P3:23	phosphatidylinositol 3,4,5-trisphosphate:23:0.8715	0.8715	23
PtdIns(4)P	PtdIns(4)P:15	phosphatidylinositol 4-phosphate:15:0.8045	0.8045	15
PtdIns(4,5)P(2)	PtdIns(4,5)P(2):18	phosphatidylinositol 4,5-bisphosphate:18:0.8365	0.8365	18
PtdIns(4,5)P2	PtdIns(4,5)P2:62|PtdIns-(4,5)P2:1|PtdIns(4,5)-P2:1	phosphatidylinositol 4,5-bisphosphate:53:0.8373|phosphatidylinositol-4,5-bisphosphate:11:0.1087	0.8373	64
PtdIns3P	PtdIns3P:8|PtdIns-3-P:5	Phosphatidylinositol 3-phosphate:13:0.4849	0.4849	13
PtdIns-4,5-P2	PtdIns-4,5-P2:14|PtdIns4,5P2:7|PtdIns4,5-P2:2	phosphatidylinositol 4,5-bisphosphate:14:0.6173|phosphatidylinositol-4,5-bisphosphate:9:0.2105	0.6173	23
PtdIns4P	PtdIns4P:32|PtdIns-4-P:4|PtdIns-4P:1	phosphatidylinositol 4-phosphate:37:0.7019	0.7019	37
PtdInsP2	PtdInsP2:35|PtdIns-P2:3	phosphatidylinositol 4,5-bisphosphate:38:0.7810	0.7810	38
PtdInsP2	PtdInsP2:9|Ptd-InsP2:1	phosphatidylinositol bisphosphate:10:0.7103	0.7103	10
PtdInsP	PtdInsP:10|PtdIns-P:1	phosphatidylinositol 4-phosphate:11:0.4728	0.4728	11
PtdInsP	PtdInsP:7	phosphatidylinositol phosphate:7:0.2902	0.2902	7
PyNPase	PyNPase:50|Py-NPase:2|pyNPase:1	pyrimidine nucleoside phosphorylase:53:0.9427	0.9427	53
RAPD-PCR	RAPD-PCR:11	amplified polymorphic DNA:11:0.4728	0.4728	11
RAPD-PCR	RAPD-PCR:43|RAPDPCR:1	random amplified polymorphic DNA-polymerase chain reaction:23:0.5466|Random amplified polymorphic DNA polymerase chain reaction:21:0.6306	0.6306	44
RARalpha	RARalpha:5|RAR-alpha:3|Raralpha:1	retinoic acid receptor:9:0.3455	0.3455	9
RARalpha	RARalpha:93|RAR-alpha:28|RAralpha:1|Rar-alpha:1	retinoic acid receptor alpha:85:0.8075|retinoic acid receptor-alpha:38:0.8098	0.8098	123
RARbeta2	RARbeta2:16|RAR-beta2:3	retinoic acid receptor beta2:19:0.7658	0.7658	19
RARbeta	RARbeta:55|RAR-beta:37	retinoic acid receptor beta:63:0.9526|retinoic acid receptor-beta:29:0.8978	0.9526	92
RARgamma	RARgamma:11|RAR-gamma:2	Retinoic acid receptor gamma:13:0.7753	0.7753	13
RASSF1A	RASSF1A:10	Ras association domain family 1A:10:0.7103	0.7103	10
RASSF1A	RASSF1A:7	Ras association domain family 1A gene:7:0.5926	0.5926	7
REGRESS	REGRESS:21	Regression Growth Evaluation Statin Study:21:0.8594	0.8594	21
REST/NRSF	REST/NRSF:5	silencing transcription factor/neuron-restrictive silencing factor:5:0.4422	0.4422	5
RHA/Verh	RHA/Verh:10	Roman high-avoidance:10:0.7103	0.7103	10
RM-ANOVA	RMANOVA:3|RM-ANOVA:3	Repeated measures analysis of variance:6:0.5290	0.5290	6
RPTPbeta	RPTPbeta:6	Receptor protein tyrosine phosphatase beta:6:0.3524	0.3524	6
RSV-IGIV	RSV-IGIV:6	respiratory syncytial virus immune globulin intravenous:6:0.5926	0.5926	6
RXRalpha	RXRalpha:79|RXR-alpha:9	retinoid X receptor alpha:70:0.7855|retinoid X receptor-alpha:18:0.6903	0.7855	88
RXRbeta	RXRbeta:9|RXR-beta:1	retinoid X receptor beta:10:0.7103	0.7103	10
RabGGTase	RabGGTase:9	Rab geranylgeranyltransferase:9:0.6794	0.6794	9
Rac1V12	Rac1V12:5	constitutively active Rac1:5:0.4422	0.4422	5
RhoGEFs	RhoGEFs:5|rhoGEFs:1	guanine nucleotide exchange factors:6:0.3728	0.3728	6
rituximab	rituximab:29|Rituximab:12|RITUXIMAB:1	anti-CD20 monoclonal antibody:42:0.6752	0.6752	42
rituximab	rituximab:5|Rituximab:2	monoclonal anti-CD20 antibody:7:0.1211	0.1211	7
Rp-cAMPS	Rp-cAMPS:7	adenosine 3',5'-cyclic monophosphothioate:7:0.1641	0.1641	7
Rp-cAMPS	Rp-cAMPS:9|RpcAMPs:1	adenosine cyclic 3',5'-phosphorothioate:10:0.7103	0.7103	10
Rp-cAMPS	Rp-cAMPS:7	Rp-adenosine 3',5'-cyclic monophosphothioate:7:0.1641	0.1641	7
Rp-cAMPS	Rp-cAMPS:6|Rp-cAMPs:2	Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine:8:0.6411	0.6411	8
Rubisco	Rubisco:19|RubisCO:3|RuBisCo:2|rubisco:1|RuBisCO:1	ribulose-1,5-bisphosphate carboxylase:26:0.3422	0.3422	26
Rubisco	Rubisco:108|RubisCO:46|RuBisCO:41|rubisco:19|RUBISCO:2|RuBisCo:1	ribulose-1,5-bisphosphate carboxylase/oxygenase:135:0.4267|ribulose 1,5-bisphosphate carboxylase/oxygenase:64:0.9534|ribulose 1,5-bisphosphate carboxylase-oxygenase:10:0.5856|ribulose-1,5-bisphosphate carboxylase-oxygenase:8:0.0906	0.9534	217
Rubisco	Rubisco:7|RuBisCO:4|RUBISCO:1	ribulose bisphosphate carboxylase:12:0.7571	0.7571	12
S-antigen	S-antigen:6	retinal soluble antigen:6:0.3728	0.3728	6
SA-beta-gal	SA-beta-gal:18|SA-beta-Gal:11	senescence-associated beta-galactosidase:29:0.6928	0.6928	29
SAPALDIA	SAPALDIA:1	Swiss study of air pollution and lung diseases in adults:1:0.5006	0.5006	1
SAPK/JNK	SAPK/JNK:17	stress-activated protein kinase:17:0.5374	0.5374	17
SAPK/JNK	SAPK/JNK:37	stress-activated protein kinase/c-Jun N-terminal kinase:37:0.8051	0.8051	37
SARS-CoV	SARS-CoV:48|SARSCoV:1	severe acute respiratory syndrome-associated coronavirus:49:0.9046	0.9046	49
SARS-CoV	SARS-CoV:86|SARS-Cov:2|SARSCoV:1	severe acute respiratory syndrome Coronavirus:79:0.9617|severe acute respiratory syndrome-coronavirus:10:0.7103	0.9617	89
SBE-beta-CD	SBE-beta-CD:7|SBEbetaCD:3	sulfobutyl ether beta-cyclodextrin:10:0.7357	0.7357	10
SBT/ABPC	SBT/ABPC:21	sulbactam/ampicillin:21:0.8333	0.8333	21
SCIWORA	SCIWORA:21|SCI-WORA:1	spinal cord injury without radiographic abnormality:22:0.8594	0.8594	22
SDF-1/CXCL12	SDF-1/CXCL12:12|SDF1/CXCL12:1	stromal cell-derived factor-1:13:0.7753	0.7753	13
SDF-1alpha	SDF-1alpha:70|SDF1alpha:1	stromal cell-derived factor-1alpha:41:0.8867|stromal cell-derived factor 1alpha:30:0.8032	0.8867	71
SDS-PAGE	SDS-PAGE:11	polyacrylamide gel electrophoresis in sodium dodecyl sulfate:11:0.7357	0.7357	11
SDS-PAGE	SDS-PAGE:5	polyacrylamide gel electrophoresis in the presence of SDS:5:0.4422	0.4422	5
SDS-PAGE	SDS-PAGE:24	polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate:24:0.8768	0.8768	24
SDS-PAGE	SDS-PAGE:8	sodium dodecyl sulfate-polyacrylamide gels:8:0.6411	0.6411	8
SDS-PAGE	SDS-PAGE:1843|SDS-Page:1	sodium dodecyl sulfate-polyacrylamide gel electrophoresis:1481:0.9899|sodium dodecyl sulfate polyacrylamide gel electrophoresis:363:0.9868	0.9899	1844
SELDI-TOF	SELDI-TOF:11	laser desorption/ionization time-of-flight:11:0.7357	0.7357	11
SERCA1a	SERCA1a:6|Serca1a:1	reticulum Ca(2+)-ATPase:7:0.2113	0.2113	7
SERCA2a	SERCA2a:6	cardiac sarcoplasmic reticulum:6:0.2827	0.2827	6
SERCA2a	SERCA2a:13	reticulum Ca(2+)-ATPase:13:0.2309	0.2309	13
SERCA2a	SERCA2a:7	sarcoplasmic reticulum Ca(2+) ATPase:7:0.4438	0.4438	7
SERCA2a	SERCA2a:15	sarcoplasmic reticulum Ca2+ ATPase:9:0.5470|sarcoplasmic reticulum Ca2+-ATPase:6:0.2827	0.5470	15
SHR-SP/Izm	SHR-SP/Izm:8|SHRSP/Izm:6	stroke-prone spontaneously hypertensive rats:14:0.6911	0.6911	14
SIGH-SAD	SIGH-SAD:9	Affective Disorder Version:9:0.6794	0.6794	9
SIRPalpha	SIRPalpha:7	signal regulatory protein alpha:7:0.3728	0.3728	7
SIVmac251	SIVmac251:17|SIV-mac251:1	simian immunodeficiency virus:18:0.8365	0.8365	18
SLICC/ACR	SLICC/ACR:21	Systemic Lupus International Collaborating Clinics/American College of Rheumatology:21:0.8594	0.8594	21
SOCRATES	SOCRATES:9	Stages of Change Readiness and Treatment Eagerness Scale:9:0.6794	0.6794	9
SOREMPs	SOREMPs:10	sleep onset REM periods:10:0.7103	0.7103	10
SREBP-1a	SREBP-1a:5	sterol regulatory element binding protein-1a:5:0.4422	0.4422	5
SREBP-1c	SREBP-1c:55|SREBP1c:4	Sterol regulatory element binding protein-1c:23:0.7955|sterol regulatory element-binding protein-1c:19:0.8449|sterol regulatory element-binding protein 1c:9:0.5470|sterol regulatory element binding protein 1c:8:0.5006	0.8449	59
SSUrRNA	SSUrRNA:10|SSU-rRNA:3	small subunit ribosomal RNA:13:0.7909	0.7909	13
STLV-III	STLV-III:6	simian T-lymphotropic virus type III:6:0.5290	0.5290	6
SULT1A1	SULT1A1:12	phenol sulfotransferase:12:0.3524	0.3524	12
SULT1A1	SULT1A1:10	Sulfotransferase 1A1:10:0.7103	0.7103	10
SVS/ISCVS	SVS/ISCVS:5	Society for Vascular Surgery/International Society for Cardiovascular Surgery:5:0.5290	0.5290	5
SakSTAR	SakSTAR:10	recombinant staphylokinase:10:0.5000	0.5000	10
Sandostatin	Sandostatin:6|sandostatin:2	long-acting somatostatin analogue:8:0.5000	0.5000	8
Scotland	Scotland:12	Communicable Diseases:12:0.7571	0.7571	12
Se-GSH-Px	Se-GSH-Px:15|SeGSHpx:10|Se-GSHPx:10|SeGSH-Px:8|SeGSHPx:4|Se-GSH-px:2	glutathione peroxidase:49:0.6680	0.6680	49
SeaWiFS	SeaWiFS:12	Sea-viewing Wide Field-of-view Sensor:12:0.7753	0.7753	12
Silastic	Silastic:10	polydimethylsiloxane:10:0.1304	0.1304	10
Sm28GST	Sm28GST:9	glutathione S-transferase:9:0.5470	0.5470	9
Sm28GST	Sm28GST:3	glutathione S-transferase from Schistosoma mansoni:3:0.5926	0.5926	3
sparganum	sparganum:7	Spirometra mansoni plerocercoid:7:0.5926	0.5926	7
SpltMNPV	SpltMNPV:10	Spodoptera litura multicapsid nucleopolyhedrovirus:10:0.7103	0.7103	10
Surgicel	Surgicel:12|surgicel:1	oxidized regenerated cellulose:13:0.5589	0.5589	13
Syst-Eur	Syst-Eur:37|SYST-EUR:4|Syst-EUR:1	systolic hypertension in Europe:42:0.9291	0.9291	42
t(1/2)beta	t(1/2)beta:9|T(1/2)beta:2	elimination half-life:11:0.4728	0.4728	11
T-system	T-system:6|t-system:3	transverse tubular system:9:0.6794	0.6794	9
TAZ/PIPC	TAZ/PIPC:21	tazobactam/piperacillin:21:0.8333	0.8333	21
TCPOBOP	TCPOBOP:23	1,4-bis[2-(3,5-dichloropyridyloxy)]benzene:23:0.5366	0.5366	23
TGF-alpha	TGF-alpha:19|TGFalpha:2	transforming growth factor:21:0.6400	0.6400	21
TGF-beta(1)	TGF-beta(1):148|TGFbeta(1):12	Transforming growth factor-beta(1):112:0.9575|transforming growth factor beta(1):42:0.9291|transforming growth factor beta 1:6:0.5290	0.9575	160
TGF-beta1	TGF-beta1:21|TGFbeta1:3	transforming growth factor:24:0.7593	0.7593	24
TGF-beta1	TGF-beta1:40|TGFbeta1:13|TGFbeta-1:2	transforming growth factor beta:29:0.8941|Transforming growth factor-beta:26:0.8861	0.8941	55
TGF-beta1	TGF-beta1:201|TGFbeta1:39|TGFbeta-1:16|TGF-beta-1:6|TGF-Beta1:2|Tgf-beta1:1	transforming growth factor beta 1:88:0.9660|transforming growth factor-beta 1:86:0.9653|transforming growth factor beta-1:76:0.9378|Transforming growth factor-beta-1:15:0.7096	0.9660	265
TGF-beta1	TGF-beta1:1448|TGFbeta1:254|TGFbeta-1:2|TGF-beta-1:1	transforming growth factor-beta1:1165:0.9797|transforming growth factor beta1:540:0.9911	0.9911	1705
TGF-beta2	TGF-beta2:13|TGFbeta2:7|TGFbeta-2:2|Tgfbeta2:1|Tgf-beta2:1	transforming growth factor beta-2:9:0.6794|transforming growth factor-beta 2:9:0.6794|transforming growth factor beta 2:6:0.5290	0.6794	24
TGF-beta2	TGF-beta2:79|TGFbeta2:21	transforming growth factor-beta2:68:0.9306|transforming growth factor beta2:32:0.9072	0.9306	100
TGF-beta3	TGF-beta3:27|TGFbeta3:11|Tgf-beta3:2	transforming growth factor-beta3:22:0.8657|transforming growth factor beta3:18:0.8365	0.8657	40
TGFbetaRII	TGFbetaRII:7|TGF-betaRII:2|TGFbeta-RII:1	transforming growth factor beta type II receptor:10:0.7103	0.7103	10
TGF-betas	TGF-betas:59|TGFbetas:6	Transforming growth factor-betas:46:0.9353|Transforming growth factor betas:19:0.8449	0.9353	65
TGF-beta	TGF-beta:6|TGFbeta:1	transforming growth factors:7:0.3524	0.3524	7
TGF-beta	TGF-beta:4956|TGFbeta:517|TGF-Beta:2|Tgfbeta:2|TGFBeta:1|Tgf-beta:1	transforming growth factor-beta:3648:0.9827|transforming growth factor beta:1809:0.9778|transforming growth factors-beta:12:0.7571|Transforming growth factor-betas:10:0.7103	0.9827	5479
TGF-beta	TGF-beta:41	transforming growth factor-beta 1:23:0.8715|transforming growth factor beta 1:18:0.8365	0.8715	41
TGF-beta	TGF-beta:25|TGFbeta:8	transforming growth factor-beta1:22:0.8657|transforming growth factor beta1:11:0.7357	0.8657	33
TGF-beta	TGF-beta:33|TGFbeta:2	type beta transforming growth factor:35:0.8292	0.8292	35
THCCOOH	THCCOOH:9|THC-COOH:4	11-nor-9-carboxy-delta 9-tetrahydrocannabinol:13:0.7753	0.7753	13
THC-COOH	THC-COOH:5|THCCOOH:5	11-nor-9-carboxy-delta9-tetrahydrocannabinol:10:0.0957	0.0957	10
TMEV-IDD	TMEV-IDD:13	Theiler's murine encephalomyelitis virus-induced demyelinating disease:13:0.5934	0.5934	13
TNF-Rp55	TNF-Rp55:3|TNFRp55:3	Tumor necrosis factor receptor p55:6:0.3728	0.3728	6
TNF-alpha	TNF-alpha:20|TNFalpha:4|tnf-alpha:1	Tumor Necrosis Factor-a:25:0.5409	0.5409	25
TNF-alpha	TNF-alpha:10|TNFalpha:4	tumor necrosis factor alfa:14:0.5589	0.5589	14
TNF-alpha	TNF-alpha:10187|TNFalpha:1688|TNF-Alpha:3|TNFAlpha:1|TNF-ALPHA:1|tnf-alpha:1|TN-Falpha:1	tumor necrosis factor-alpha:7030:0.7693|Tumor necrosis factor alpha:3893:0.7836|Tumour necrosis factor alpha:942:0.1811|tumor-necrosis-factor-alpha:17:0.0011	0.7836	11882
TNFalpha	TNFalpha:9	tumor necrosis factoralpha:9:0.6794	0.6794	9
TNF-beta	TNF-beta:67|TNFbeta:8	tumor necrosis factor-beta:40:0.5341|tumor necrosis factor beta:23:0.4652|tumour necrosis factor beta:12:0.1573	0.5341	75
TNP-self	TNP-self:5	syngeneic spleen cells:5:0.2818	0.2818	5
TOF-SIMS	TOF-SIMS:45|ToF-SIMS:20|TOFSIMS:1	time-of-flight secondary ion mass spectrometry:66:0.7825	0.7825	66
TOPS-MODE	TOPS-MODE:9	TOPological Sub-Structural MOlecular DEsign:9:0.5470	0.5470	9
TRalpha	TRalpha:12|TR-alpha:1	thyroid hormone receptor alpha:13:0.7753	0.7753	13
TRbeta1	TRbeta1:8	thyroid hormone receptor beta1:8:0.6411	0.6411	8
TXA2/PGH2	TXA2/PGH2:52|TxA2/PGH2:5	thromboxane A2/prostaglandin H2:57:0.9477	0.9477	57
TbetaRII	TbetaRII:13|TbetaR-II:2|Tbeta-RII:1	type II TGF-beta receptor:16:0.8165	0.8165	16
TbetaR-I	TbetaR-I:16|TbetaRI:6	TGF-beta type I receptor:22:0.5997	0.5997	22
TdRPase	TdRPase:6|TdR-Pase:5	thymidine phosphorylase:11:0.7357	0.7357	11
Thy-1+DEC	Thy-1+DEC:8|Thy1+DEC:1	dendritic epidermal cells:9:0.6411	0.6411	9
tilapia	tilapia:10|Tilapia:3	Oreochromis mossambicus:13:0.6460	0.6460	13
Trad-MCN	Trad-MCN:32	Tradescantia-micronucleus:23:0.5238|Tradescantia micronucleus:9:0.5470	0.5470	32
true-FISP	TrueFISP:3|true-FISP:3|True-FISP:2|TrueFisp:1|trueFISP:1	true fast imaging with steady-state precession:10:0.5355	0.5355	10
UNSCEAR	UNSCEAR:6	United Nations Scientific Committee on the Effects of Atomic Radiation:6:0.5290	0.5290	6
UPRTase	UPRTase:15	uracil phosphoribosyltransferase:15:0.8045	0.8045	15
UROIIIS	UROIIIS:11|UROIII-S:1|URO-III-S:1	uroporphyrinogen III synthase:13:0.7753	0.7753	13
V-PYRRO/NO	V-PYRRO/NO:1	donor O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate:1:0.0918	0.0918	1
V-PYRRO/NO	V-PYRRO/NO:6	O(2)-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate:6:0.1320	0.1320	6
VANQWISH	VANQWISH:8	Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital:8:0.6411	0.6411	8
VE-cadherin	VE-cadherin:42	vascular endothelial cadherin:24:0.8115|Vascular endothelial-cadherin:18:0.8365	0.8365	42
VEGF(165)	VEGF(165):10	vascular endothelial growth factor:10:0.7103	0.7103	10
VEGF(165)	VEGF(165):9	vascular endothelial growth factor 165:9:0.6794	0.6794	9
VEGF/VPF	VEGF/VPF:51	vascular endothelial growth factor/vascular permeability factor:51:0.9416	0.9416	51
VEGF165	VEGF165:33|VEGF-165:2	vascular endothelial growth factor:35:0.9126	0.9126	35
VIII/vWF	VIII/vWF:6|VIII/vWf:3|VIII/VWF:1	Factor VIII/von Willebrand factor:10:0.7103	0.7103	10
VIIICAg	VIIICAg:7	factor VIII clotting antigen:7:0.5926	0.5926	7
VIIIRAg	VIIIRAg:12|VIIIRAG:1|VIII-RAg:1|VIIIR-Ag:1	factor VIII related antigen:15:0.8045	0.8045	15
VO(2peak)	VO(2peak):12	peak oxygen consumption:12:0.5934	0.5934	12
VO2peak	VO2peak:43|Vo2peak:2|VO2-peak:1	peak oxygen consumption:46:0.7319	0.7319	46
VPF/VEGF	VPF/VEGF:50	Vascular permeability factor/vascular endothelial growth factor:50:0.9392	0.9392	50
Val-HeFT	Val-HeFT:24|ValHeFT:1	Valsartan Heart Failure Trial:25:0.9043	0.9043	25
Vitrebond	Vitrebond:5	light-cured glass ionomer cement:5:0.2818	0.2818	5
Vitremer	Vitremer:6	resin-modified glass ionomer cement:6:0.5290	0.5290	6
Vitreon	Vitreon:22|vitreon:2	perfluoroperhydrophenanthrene:24:0.7931	0.7931	24
VmaxFRC	VmaxFRC:26	flow at functional residual capacity:26:0.5218	0.5218	26
WAIS-III	WAIS-III:16	Wechsler Adult Intelligence Scale-III:16:0.8165	0.8165	16
WAIS-III	WAIS-III:9	Wechsler Adult Intelligence Scale-Third Edition:9:0.6794	0.6794	9
WHO/ISUP	WHO/ISUP:9	World Health Organization/International Society of Urological Pathology:9:0.6794	0.6794	9
WHR-1142A	WHR-1142A:9	lidamidine hydrochloride:9:0.5470	0.5470	9
WISC-III	WISC-III:11	Wechsler Intelligence Scale for Children-Third Edition:11:0.7357	0.7357	11
WISEWOMAN	WISEWOMAN:11	Well-Integrated Screening and Evaluation for Women Across the Nation:11:0.7357	0.7357	11
YGGFMRF	YGGFMRF:10	Met5-enkephalin-Arg6-Phe7:10:0.4737	0.4737	10
Z-scores	Z-scores:4|z-scores:2	standard deviation scores:6:0.5290	0.5290	6
Z-VAD.FMK	Z-VAD.FMK:9|Z-VAD.fmk:3|z-VAD.fmk:2|zVAD.fmk:1|z-VAD.FMK:1	fluoromethyl ketone:16:0.4832	0.4832	16
Z-VAD-fmk	Z-VAD-fmk:2|zVAD-fmk:2|z-VAD-FMK:1	caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone:5:0.3463	0.3463	5
zVAD-fmk	z-VAD-fmk:1|zVAD-fmk:1	caspase inhibitor N-benzyloxycarbonyl-val-ala-asp-fluoromethylketone:2:0.1618	0.1618	2
ZVAD-fmk	ZVADfmk:1|ZVAD-fmk:1|zVAD-fmk:1|zVAD-FMK:1	caspase inhibitor Z-Val-Ala-Asp-fluoromethylketone:4:0.3728	0.3728	4
Zyplast	Zyplast:6	cross-linked collagen:6:0.1010	0.1010	6
[(35)S]GTPgammaS	[(35)S]GTPgammaS:14	guanosine 5'-O-(3-[(35)S]thio)triphosphate:14:0.7909	0.7909	14
[123I]MIBG	[123I]MIBG:11	metaiodobenzylguanidine:11:0.5000	0.5000	11
[125I]ICYP	[125I]ICYP:12	[125I]iodocyanopindolol:12:0.4583	0.4583	12
[125I]MEL	[125I]MEL:9|[125I]Mel:2	2-[125I]iodomelatonin:11:0.4762	0.4762	11
[125I]TID	[125I]TID:12|[125I]-TID:1	3-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine:13:0.3636	0.3636	13
[35S]GTPgammaS	[35S]GTPgammaS:8|[35S]GTP-gammaS:1	[35S]guanosine-5'-O-(3-thio)triphosphate:9:0.0702	0.0702	9
[35S]GTPgammaS	[35S]GTPgammaS:15	guanosine-5'-O-(3-[35S]thio)triphosphate:15:0.1228	0.1228	15
[35S]TBPS	[35S]TBPS:35	[35S]t-butylbicyclophosphorothionate:35:0.3301	0.3301	35
[35S]TBPS	[35S]TBPS:28|[35S]-TBPS:2	t-[35S]butylbicyclophosphorothionate:30:0.2816	0.2816	30
[3H]8-OH-DPAT	[3H]8-OH-DPAT:19	[3H]8-hydroxy-2-(di-n-propylamino)tetralin:19:0.3051	0.3051	19
[3H]DPCPX	[3H]DPCPX:9|[3H]-DPCPX:1	[3H]8-cyclopentyl-1,3-dipropylxanthine:10:0.2000	0.2000	10
[3H]NBMPR	[3H]NBMPR:12	[3H]nitrobenzylthioinosine:12:0.7059	0.7059	12
acetyl-LDL	acetyl-LDL:30|Acetyl-LDL:1	acetylated low density lipoprotein:21:0.7291|acetylated low-density lipoprotein:10:0.5000	0.7291	31
acyl-ACP	acyl-ACP:12	acyl-acyl carrier protein:12:0.7571	0.7571	12
adducts	adducts:5	chemical addition products:5:0.1464	0.1464	5
alginate	alginate:9	mucoid exopolysaccharide:9:0.4587	0.4587	9
allo-BMT	allo-BMT:8|alloBMT:4	allogeneic bone marrow transplant:12:0.6460	0.6460	12
allo-BMT	allo-BMT:91|alloBMT:44|AlloBMT:10|Allo-BMT:3|ALLOBMT:1|ALLO-BMT:1	allogeneic bone marrow transplantation:150:0.8635	0.8635	150
allo-HSCT	allo-HSCT:21|alloHSCT:5|Allo-HSCT:2	allogeneic hematopoietic stem cell transplantation:28:0.8369	0.8369	28
allo-MLR	allo-MLR:7|alloMLR:2	allogeneic mixed lymphocyte reaction:9:0.5470	0.5470	9
allo-PBSCT	allo-PBSCT:30|alloPBSCT:8|Allo-PBSCT:5	allogeneic peripheral blood stem cell transplantation:43:0.8917	0.8917	43
allo-SCT	allo-SCT:6|alloSCT:3|AlloSCT:1	allogeneic stem cell transplant:10:0.5856	0.5856	10
allo-SCT	allo-SCT:57|alloSCT:27|AlloSCT:3|Allo-SCT:1	allogeneic stem cell transplantation:88:0.7640	0.7640	88
allodynia	allodynia:3	tactile hypersensitivity:3:0.0736	0.0736	3
alpha(1)m	alpha(1)m:4|alpha(1)M:3|alpha(1)-m:2	alpha(1)-microglobulin:9:0.6667	0.6667	9
alpha(1)-PI	alpha(1)-PI:15|alpha(1)PI:4	alpha(1)-proteinase inhibitor:19:0.4852	0.4852	19
alpha(2)-ARs	alpha(2)-ARs:7|alpha(2)ARs:3	alpha(2)-adrenergic receptors:10:0.7103	0.7103	10
alpha(2)-AR	alpha(2)-AR:13|alpha(2)AR:3	alpha(2)-adrenergic receptors:8:0.5006|alpha(2)-adrenergic receptor:8:0.2987	0.5006	16
alpha(2)M	alpha(2)M:41|alpha(2)-M:6	Alpha(2)-Macroglobulin:47:0.8846	0.8846	47
alpha,beta-MeATP	alpha,beta-MeATP:5|alpha,beta-meATP:2	alpha,beta-methylene adenosine 5'-triphosphate:7:0.4438	0.4438	7
alpha-AE	alpha-AE:10	Peptidylglycine alpha-amidating enzyme:10:0.5856	0.5856	10
alpha-DFMO	alpha-DFMO:14	alpha-difluoromethylornithine:14:0.6190	0.6190	14
alpha-HBDH	alpha-HBDH:19	alpha-hydroxybutyrate dehydrogenase:19:0.6537	0.6537	19
alpha-hCG	alpha-hCG:6|alpha-HCG:3	human chorionic gonadotropin:9:0.4587	0.4587	9
alpha-HCH	alpha-HCH:50	alpha-hexachlorocyclohexane:50:0.7903	0.7903	50
alpha-KIC	alpha-KIC:12	alpha-ketoisocaproate:12:0.5238	0.5238	12
alpha-KIC	alpha-KIC:7|alpha-kiC:1	alpha-ketoisocaproic acid:8:0.5006	0.5006	8
alpha-Me-5-HT	alpha-Me-5-HT:10|alpha-me-5-HT:1	alpha-methyl-5-hydroxytryptamine:11:0.4762	0.4762	11
alpha-NAGA	alpha-NAGA:9	alpha-N-acetylgalactosaminidase:9:0.8889	0.8889	9
alpha-TCP	alpha-TCP:44	alpha-tricalcium phosphate:44:0.8076	0.8076	44
alpha-TOS	alpha-TOS:20	Alpha-Tocopheryl succinate:20:0.8525	0.8525	20
alpha-GP	alpha-GP:13|alpha-gP:1	alpha-glycerophosphate:14:0.7222	0.7222	14
alpha-hANP	alpha-hANP:62	alpha-human atrial natriuretic peptide:62:0.6673	0.6673	62
alpha-hANP	alpha-hANP:81|alpha-HANP:1	alpha-human atrial natriuretic polypeptide:82:0.8901	0.8901	82
alpha-MNA	alpha-MNA:5|alpha-mNA:4	alpha-methylnoradrenaline:9:0.8000	0.8000	9
alpha-rANP	alpha-rANP:15	alpha-rat atrial natriuretic peptide:15:0.8045	0.8045	15
alpha1,3GT	alpha1,3GT:7|alpha1,3-GT:2	alpha1,3-galactosyltransferase:9:0.3636	0.3636	9
alpha1-PDX	alpha1-PDX:8	alpha1-antitrypsin Portland:8:0.5006	0.5006	8
alpha1ARs	alpha1ARs:7|alpha1-ARs:4	alpha1-adrenergic receptors:11:0.7357	0.7357	11
alpha1-AR	alpha1-AR:14|alpha1AR:2	alpha1-adrenergic receptor:16:0.8165	0.8165	16
alpha1m	alpha1m:8|alpha1M:7|alpha1-m:5|alpha1-M:4	alpha1-microglobulin:24:0.6053	0.6053	24
alpha2-AR	alpha2-AR:10|alpha2AR:5	alpha2-adrenergic receptor:15:0.5348	0.5348	15
alpha2M*	alpha2M*:13|alpha2-M*:1	alpha2-macroglobulin:14:0.5652	0.5652	14
alpha2MR/LRP	alpha2-M-R/LRP:3|alpha2MR/LRP:3|alpha2Mr/LRP:1|alpha2M-R/LRP:1	lipoprotein receptor-related protein:8:0.6411	0.6411	8
alpha-2-M	alpha-2-M:13|alpha2M:9|alpha-2M:2|alpha2-M:1|Alpha-2-M:1|alpha-2-m:1|alpha2m:1	alpha-2-macroglobulin:22:0.1257|alpha-2 macroglobulin:6:0.1320	0.1320	28
alpha2M	alpha2M:85|alpha2-M:37|alpha2m:1|alpha2-m:1|alpha-2-M:1	alpha2-macroglobulin:119:0.7066|alpha2 macroglobulin:6:0.1320	0.7066	125
alpha2-PAG	alpha2-PAG:9|alpha2PAG:1	pregnancy-associated alpha2-glycoprotein:10:0.5856	0.5856	10
alpha7nAChR	alpha7nAChR:9	alpha7 nicotinic acetylcholine receptor:9:0.3945	0.3945	9
alpha-ANP	alpha-ANP:10	alpha-atrial natriuretic polypeptide:10:0.6794	0.6794	10
alpha-CGRP	alpha-CGRP:13|alphaCGRP:8	alpha-calcitonin gene-related peptide:21:0.4538	0.4538	21
alphaCTD	alphaCTD:8	C-terminal domain of the RNA polymerase alpha subunit:8:0.6411	0.6411	8
alphaCTD	alphaCTD:5	RNA polymerase alpha subunit C-terminal domain:5:0.4422	0.4422	5
alpha-FMH	alpha-FMH:41	alpha-fluoromethylhistidine:41:0.7547	0.7547	41
alpha-GPDH	alpha-GPDH:27|alphaGPDH:1|alpha-Gpdh:1	alpha-glycerophosphate dehydrogenase:29:0.4913	0.4913	29
alpha-GPD	alpha-GPD:34|alphaGPD:2|alpha-GP-D:1|alpha-Gpd:1	alpha-glycerophosphate dehydrogenase:38:0.6874	0.6874	38
alpha-GST	alpha-GST:21|alphaGST:4	alpha-glutathione S-transferase:25:0.6240	0.6240	25
alpha-KG	alpha-KG:58|alphaKG:11|alpha-Kg:1|alphaKg:1	alpha-ketoglutarate:71:0.8434	0.8434	71
alpha-KGDH	alpha-KGDH:20|alphaKGDH:3	alpha-ketoglutarate dehydrogenase:23:0.8038	0.8038	23
alphaLP	alphaLP:11|alpha-LP:1	alpha-Lytic protease:12:0.7571	0.7571	12
alpha-MG	alpha-MG:12|alphaMG:3	alpha-methyl-D-glucopyranoside:15:0.2456	0.2456	15
alpha-MG	alpha-MG:10|alphaMG:1	alpha-methyl-D-glucoside:11:0.1754	0.1754	11
alpha-MHC	alpha-MHC:26|alphaMHC:6|alpha-mhc:1	alpha-myosin heavy chain:33:0.6111	0.6111	33
alpha-MPT	alpha-MPT:51|alpha-MpT:14|alphampt:2|alphaMpT:2|alphaMPT:2	alpha-methyl-p-tyrosine:71:0.6667	0.6667	71
alpha-MSH	alpha-MSH:738|alphaMSH:25|alpha-msh:1	alpha-melanocyte-stimulating hormone:480:0.5208|alpha-melanocyte stimulating hormone:284:0.8947	0.8947	764
alpha-MT	alpha-MT:47|alphaMT:3	alpha-methyl-p-tyrosine:50:0.4414	0.4414	50
alpha-MT	alpha-MT:9|alpha-Mt:1	alpha-methyl-para-tyrosine:10:0.0811	0.0811	10
alpha-MT	alpha-MT:21|alphaMT:2	alpha-methyltyrosine:23:0.1982	0.1982	23
alpha-NF	alpha-NF:36|alphaNF:9	alpha-naphthoflavone:45:0.8462	0.8462	45
alpha-SMA	alpha-SMA:372|alphaSMA:38|alpha-sma:6|alpha-Sma:2|alpha-smA:1	alpha-smooth muscle actin:419:0.8211	0.8211	419
alpha-SMA	alpha-SMA:13|alphaSMA:3|alpha-sma:1	smooth muscle alpha-actin:17:0.8270	0.8270	17
alpha-TA	alpha-TA:11|alphaTA:2	alpha-tocopheryl acetate:13:0.4849	0.4849	13
alphaTS	alphaTS:9	alpha subunit of tryptophan synthase:9:0.6794	0.6794	9
alpha-TTP	alpha-TTP:40|alphaTTP:5	alpha-tocopherol transfer protein:45:0.9338	0.9338	45
alteplase	alteplase:17|Alteplase:1	tissue plasminogen activator:18:0.5940	0.5940	18
anandamide	anandamide:23	N-arachidonoylethanolamine:23:0.2095	0.2095	23
Angptl3	Angptl3:4|ANGPTL3:2|angptl-3:1	angiopoietin-like protein 3:7:0.4438	0.4438	7
anti-CCP	anti-CCP:8	anti-cyclic citrullinated peptide antibodies:8:0.4102	0.4102	8
anti-CCP	anti-CCP:30|Anti-CCP:1	citrullinated peptide:31:0.9043	0.9043	31
anti-ENA	anti-ENA:9|Anti-ENA:1	extractable nuclear antigens:10:0.3867	0.3867	10
anti-HBV	anti-HBV:7	anti-hepatitis B virus:7:0.3524	0.3524	7
anti-HBe	anti-HBe:29	antibody to hepatitis B e antigen:29:0.6484	0.6484	29
anti-HDV	anti-HDV:5	antibody to hepatitis D virus:5:0.1973	0.1973	5
anti-HIV	anti-HIV:18	anti-human immunodeficiency virus:18:0.2608	0.2608	18
anti-HIV-1	anti-HIV-1:13|Anti-HIV-1:1	anti-human immunodeficiency virus type 1:14:0.5589	0.5589	14
anti-ICAM-1	anti-ICAM-1:12	anti-intercellular adhesion molecule-1:12:0.5664	0.5664	12
anti-IgE	anti-IgE:10|Anti-IgE:1	anti-immunoglobulin E:11:0.6182	0.6182	11
anti-MPO	anti-MPO:18|anti-Mpo:1	anti-myeloperoxidase:19:0.3529	0.3529	19
anti-Tac	anti-Tac:12|anti-TAC:2	monoclonal antibody:14:0.3383	0.3383	14
anti-VEGF	anti-VEGF:12	endothelial growth factor:12:0.6460	0.6460	12
anti-dsDNA	anti-dsDNA:9	anti-double-stranded DNA antibodies:9:0.4587	0.4587	9
anti-CD3	anti-CD3:4|antiCD3:2	anti-CD3 monoclonal antibody:6:0.3728	0.3728	6
anti-ChE	anti-ChE:15|antiChE:9|antiCHE:3	anticholinesterase:27:0.8125	0.8125	27
anti-GBM	anti-GBM:57|antiGBM:1	anti-glomerular basement membrane:58:0.5119	0.5119	58
anti-GBM	anti-GBM:28|antiGBM:1	antiglomerular basement membrane:29:0.2059	0.2059	29
anti-HAV	anti-HAV:59	antibody to hepatitis A virus:59:0.4593	0.4593	59
anti-HAV	anti-HAV:6	Hepatitis A antibodies:6:0.1320	0.1320	6
anti-HAV	anti-HAV:8	hepatitis A virus antibody:8:0.3463	0.3463	8
anti-HBc	anti-HBc:36	antibodies to hepatitis B core antigen:36:0.1237	0.1237	36
anti-HBc	anti-HBc:51	hepatitis B core antibody:44:0.8620|hepatitis B core antibodies:7:0.3524	0.8620	51
anti-HBs	anti-HBs:146|antiHBs:3|anti-HBS:2|anti-HB-s:1|anti--HBS:1	antibody to hepatitis B surface antigen:153:0.6590	0.6590	153
anti-HBs	anti-HBs:6|Anti-HBs:1	B surface antibodies:7:0.4438	0.4438	7
anti-HCV	anti-HCV:11|Anti-HCV:1	anti-hepatitis C virus antibody:12:0.1423	0.1423	12
anti-HCV	anti-HCV:28	Hepatitis C antibodies:15:0.8045|hepatitis C antibody:13:0.4444	0.8045	28
anti-HCV	anti-HCV:43|Anti-HCV:1	hepatitis C virus antibody:26:0.5040|hepatitis C virus antibodies:18:0.5940	0.5940	44
anti-Ids	anti-Ids:13|anti-ids:9	anti-idiotypic antibodies:22:0.6531	0.6531	22
anti-TPO	anti-TPO:7|antiTPO:1	peroxidase antibodies:8:0.2987	0.2987	8
anti-beta2-GPI	anti-beta2-GPI:5|anti-beta2GPI:3	anti-beta2-glycoprotein I antibodies:8:0.2987	0.2987	8
apoB-100	apoB-100:62|ApoB-100:3|apoB100:2|apo-B-100:2|Apo-B100:1	apolipoprotein B-100:70:0.8919	0.8919	70
apoB100	apoB100:14|ApoB100:4|apo-B100:1	apolipoprotein B100:19:0.5404	0.5404	19
apoC-III	apoC-III:35|ApoC-III:5|apoCIII:2	apolipoprotein C-III:42:0.7995	0.7995	42
apoCIII	apoCIII:9|ApoCIII:2|ApoC-III:1|Apo-CIII:1	Apolipoprotein CIII:13:0.5934	0.5934	13
apoVLDLII	apoVLDLII:6|apo-VLDL-II:1|apo-VLDLII:1	low density apolipoprotein II:8:0.6411	0.6411	8
aptamers	aptamers:6	nucleic acid binding species:6:0.5290	0.5290	6
array-CGH	array-CGH:9|arrayCGH:2	comparative genomic hybridization:11:0.4728	0.4728	11
aspirin	aspirin:125|Aspirin:12|ASPIRIN:1	acetylsalicylic acid:138:0.7664	0.7664	138
auto-PEEP	auto-PEEP:15|AUTO-PEEP:1	end-expiratory pressure:16:0.5564	0.5564	16
auto-BMT	auto-BMT:10|autoBMT:5|Auto-BMT:1	autologous bone marrow transplantation:16:0.8165	0.8165	16
auto-MLR	auto-MLR:6|autoMLR:3	autologous mixed lymphocyte reaction:9:0.6794	0.6794	9
auto-PBSCT	auto-PBSCT:24|autoPBSCT:3|Auto-PBSCT:1	autologous peripheral blood stem cell transplantation:28:0.8941	0.8941	28
autoSCT	autoSCT:5|auto-SCT:4	autologous stem cell transplantation:9:0.5470	0.5470	9
axolotl	axolotl:19	Ambystoma mexicanum:19:0.8449	0.8449	19
bHLH-Zip	bHLH-Zip:4|bHLH-ZIP:3|bHLHZip:2|bHLHZIP:2|bHLHzip:2|b-HLH-zip:1|bHLH-zip:1	basic helix-loop-helix leucine zipper:15:0.7539	0.7539	15
bHLH-Zip	bHLH-Zip:6	encodes a member of the basic-helix-loop-helix-leucine zipper:6:0.1838	0.1838	6
barnase	barnase:4	ribonuclease of Bacillus amyloliquefaciens:4:0.3463	0.3463	4
baseline	baseline:5|base-line:1	induction of anaesthesia:6:0.1543	0.1543	6
beta(1)AR	beta(1)AR:16|beta(1)-AR:6	beta(1)-adrenergic receptor:22:0.7955	0.7955	22
beta(2)AR	beta(2)AR:46|beta(2)-AR:26	beta(2)-adrenergic receptor:62:0.7113|beta(2)-adrenergic receptors:10:0.4363	0.7113	72
beta(2)-MG	beta(2)-MG:10|beta(2)MG:1|beta(2)-mg:1	beta(2)-microglobulin:12:0.6875	0.6875	12
beta(3)AR	beta(3)AR:7|beta(3)-AR:5	beta(3)-adrenergic receptor:12:0.4557	0.4557	12
beta-1,4-GalT	beta-1,4-GalT:10	beta-1,4-galactosyltransferase:10:0.8182	0.8182	10
beta-CNA	beta-CNA:23	beta-chlornaltrexamine:23:0.8800	0.8800	23
beta-ELI	beta-ELI:13	beta-endorphin-like immunoreactivity:13:0.5934	0.5934	13
beta-ELIR	beta-ELIR:8	Beta-endorphin-like immunoreactivity:8:0.5006	0.5006	8
beta-END-LI	beta-END-LI:25|beta-end-LI:1|beta-End-LI:1	beta-endorphin-like immunoreactivity:27:0.7425	0.7425	27
beta-HBA	beta-HBA:17	beta-hydroxybutyrate:17:0.7273	0.7273	17
beta-HCH	beta-HCH:33	beta-hexachlorocyclohexane:33:0.8205	0.8205	33
beta-MSP	beta-MSP:12	beta-microseminoprotein:12:0.9167	0.9167	12
beta-NAG	beta-NAG:15	beta-N-acetylglucosaminidase:15:0.2500	0.2500	15
beta-NAG	beta-NAG:13	N-acetyl-beta-D-glucosaminidase:13:0.2143	0.2143	13
beta-NAG	beta-NAG:13	N-Acetyl-beta-glucosaminidase:13:0.2143	0.2143	13
beta-PEA	beta-PEA:25	beta-phenylethylamine:25:0.8846	0.8846	25
beta-hex	beta-hex:14	beta-hexosaminidase:14:0.9286	0.9286	14
beta-lyase	beta-lyase:19	cysteine conjugate beta-lyase:19:0.8449	0.8449	19
beta1AR	beta1AR:11|beta1-AR:8	beta1-adrenergic receptor:19:0.5732	0.5732	19
beta2-ARs	beta2-ARs:8|beta2ARs:5	beta2-adrenergic receptors:13:0.6701	0.6701	13
beta2AR	beta2AR:68|beta2-AR:23	beta2-adrenergic receptor:77:0.7370|beta2-adrenergic receptors:14:0.6911	0.7370	91
beta2-MG	beta2-MG:18|beta2MG:11	beta2-microglobulin:29:0.6364	0.6364	29
beta3-AR	beta3-AR:26|beta3AR:9	beta3-adrenergic receptor:35:0.6464	0.6464	35
betaAPP	betaAPP:104|beta-APP:101	beta-amyloid precursor protein:205:0.8039	0.8039	205
beta-APP	beta-APP:9|betaAPP:2	beta-amyloid protein precursor:11:0.4232	0.4232	11
betaARK1	betaARK1:11|beta-ARK1:1	beta-adrenergic receptor kinase:12:0.7571	0.7571	12
betaARK1	betaARK1:5|beta-ARK1:3	beta-adrenergic receptor kinase 1:8:0.4102	0.4102	8
betaARK	betaARK:17|beta-ARK:8	beta-adrenergic receptor kinase:25:0.8186	0.8186	25
beta-ARs	beta-ARs:33|betaARs:14	beta-adrenergic receptors:47:0.7552	0.7552	47
beta-CCE	beta-CCE:11	beta-carboline-3-carboxylic acid ethyl ester:11:0.4728	0.4728	11
beta-CCE	beta-CCE:33|betaCCE:2	ethyl-beta-carboline-3-carboxylate:19:0.2609|ethyl beta-carboline-3-carboxylate:16:0.6577	0.6577	35
beta-CCM	beta-CCM:55	methyl beta-carboline-3-carboxylate:34:0.8245|methyl-beta-carboline-3-carboxylate:21:0.2703	0.8245	55
beta-CCt	beta-CCt:7|beta-CCT:1|betaCCt:1|betaCCT:1	beta-carboline-3-carboxylate-t-butyl ester:10:0.5856	0.5856	10
beta-FNA	beta-FNA:160|betaFNA:3	beta-funaltrexamine:163:0.9529	0.9529	163
beta-GPA	beta-GPA:10	creatine analogue beta-guanidinopropionic acid:10:0.7909	0.7909	10
beta-gal	beta-gal:9|beta-Gal:6	beta-D-galactosidase:15:0.0171	0.0171	15
beta-gal	beta-gal:11	beta-galactosidase gene:11:0.3829	0.3829	11
beta-LPH	beta-LPH:5	beta-lipotropic hormone:5:0.1132	0.1132	5
beta-MHC	beta-MHC:55|betaMHC:4	beta-myosin heavy chain:59:0.6881	0.6881	59
beta-MSH	beta-MSH:18	beta-melanocyte stimulating hormone:18:0.8365	0.8365	18
beta-MyHC	beta-MyHC:8|betaMyHC:5	beta-myosin heavy chain:13:0.6911	0.6911	13
beta-OHB	beta-OHB:45|betaOHB:2|beta-OH-B:1	beta-hydroxybutyrate:48:0.8103	0.8103	48
beta-VLDL	beta-VLDL:118|betaVLDL:4|beta--VLDL:1	low density lipoprotein:65:0.9275|low density lipoproteins:58:0.9486	0.9486	123
beta-APN	beta-APN:6|betaAPN:4|betaapn:1	beta-aminopropionitrile:11:0.4762	0.4762	11
beta-blockers	beta-blockers:5	beta-adrenergic receptor blockers:5:0.2818	0.2818	5
beta-hCG	beta-hCG:44|beta-HCG:21|betahCG:6|betaHCG:2	chorionic gonadotrophin:73:0.8789	0.8789	73
beta-hCG	beta-HCG:5|beta-hCG:5	human chorionic gonadotropin beta-subunit:10:0.6182	0.6182	10
buserelin	buserelin:3|Buserelin:2	luteinizing hormone-releasing hormone analogue:5:0.2818	0.2818	5
cAMPdPK	cAMPdPK:6|cAMP-dPK:4|cAMP-DPK:2	cAMP-dependent protein kinase:12:0.4557	0.4557	12
cDNA-AFLP	cDNA-AFLP:7	cDNA-amplified fragment length polymorphism:7:0.3524	0.3524	7
cDNA-RDA	cDNA-RDA:7	cDNA representational difference analysis:7:0.3524	0.3524	7
cGMP-PDE	cGMP-PDE:10	cGMP-phosphodiesterase:10:0.3000	0.3000	10
cMOAT/MRP2	cMOAT/MRP2:8|CMOAT/MRP2:1|c-MOAT/MRP2:1	canalicular multispecific organic anion transporter:10:0.5856	0.5856	10
calbindin-D28K	calbindin-D28K:4|calbindin-D28k:2	Vitamin D-dependent calcium-binding protein:6:0.5290	0.5290	6
calcein-AM	calcein-AM:6	calcein acetoxymethyl ester:6:0.5290	0.5290	6
calcineurin	calcineurin:11	calmodulin-dependent protein phosphatase:11:0.2764	0.2764	11
calcitriol	calcitriol:17	1,25-dihydroxycholecalciferol:17:0.0635	0.0635	17
calpain	calpain:11	calcium-activated neutral protease:11:0.2040	0.2040	11
calpain	calpain:19	Calcium-activated neutral proteinase:19:0.5404	0.5404	19
captopril	captopril:45|Captopril:3	angiotensin converting enzyme inhibitor:26:0.4074|angiotensin-converting enzyme inhibitor:22:0.1790	0.4074	48
captopril	captopril:5	converting enzyme inhibition:5:0.1973	0.1973	5
carbachol	carbachol:18|Carbachol:2	carbamylcholine chloride:20:0.7766	0.7766	20
carboxy-PTIO	carboxy-PTIO:14	2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide:14:0.2453	0.2453	14
catagen	catagen:14	hair follicle regression:14:0.6173	0.6173	14
caveolae	caveolae:11	plasmalemmal vesicles:11:0.3829	0.3829	11
CD-ELISA	CD-ELISA:5|cdELISA:4	competitive direct enzyme-linked immunosorbent assay:9:0.6794	0.6794	9
chemotaxis	chemotaxis:5	directed to a chemoattractant gradient:5:0.4422	0.4422	5
chickenpox	chickenpox:4	primary varicella infection:4:0.1618	0.1618	4
CI-ELISA	CI-ELISA:7|ciELISA:2	competitive indirect enzyme-linked immunosorbent assay:9:0.6794	0.6794	9
cis-platinum	cis-platinum:16	cis-dichlorodiammineplatinum(II):16:0.2344	0.2344	16
cisplatin	cisplatin:37|cis-platin:1	cis-diamminedichloroplatinum:38:0.1022	0.1022	38
cisplatin	cisplatin:120|cis-platin:5	cis-diamminedichloroplatinum(II):99:0.2680|Cis-Diamminedichloroplatinum II:26:0.6083	0.6083	125
clodronate	clodronate:5|Clodronate:2	dichloromethylene bisphosphonate:7:0.2113	0.2113	7
clodronate	clodronate:8|Clodronate:1	dichloromethylene diphosphonate:9:0.6794	0.6794	9
compomers	compomers:5	polyacid-modified composite resins:5:0.5470	0.5470	5
compomers	compomers:9	polyacid-modified resin composites:9:0.7103	0.7103	9
CONSENSUS	CONSENSUS:12	Cooperative North Scandinavian Enalapril Survival Study:12:0.7571	0.7571	12
controls	controls:11	healthy pregnant women:11:0.2422	0.2422	11
control	control:8	administered at dietary levels of 0:8:0.1591	0.1591	8
control	control:5	artificial cerebrospinal fluid:5:0.4422	0.4422	5
control	control:11	fed diets containing 0:11:0.2421	0.2421	11
control	control:8	induction of anesthesia:8:0.1730	0.1730	8
control	control:4	Six-week-old male Sprague-Dawley rats were fed either normal rat chow:4:0.3170	0.3170	4
cromolyn	cromolyn:17	disodium cromoglycate:17:0.4742	0.4742	17
cruzipain	cruzipain:15	major cysteine proteinase:15:0.6386	0.6386	15
cryo-SEM	cryo-SEM:8|Cryo-SEM:2	electron microscopy:10:0.7103	0.7103	10
cryo-TEM	cryo-TEM:14|cryoTEM:1|Cryo-TEM:1	cryo-transmission electron microscopy:16:0.3643	0.3643	16
cybrids	cybrids:16	cytoplasmic hybrids:16:0.6577	0.6577	16
cystatin	cystatin:11	cysteine proteinase inhibitor:11:0.7357	0.7357	11
cystatins	cystatins:6	cysteine proteinase inhibitors:6:0.5290	0.5290	6
cytosol	cytosol:7	g supernatant fraction:7:0.2113	0.2113	7
dP/dt(max)	dP/dt(max):5|dp/dt(max):2	left ventricular pressure:7:0.5926	0.5926	7
dThdPase	dThdPase:99|dTHdPase:1	Thymidine phosphorylase:100:0.8976	0.8976	100
dUTPase	dUTPase:13	deoxyuridine triphosphatase:13:0.7753	0.7753	13
dUTPase	dUTPase:21	Deoxyuridine triphosphate nucleotidohydrolase:21:0.8594	0.8594	21
dUTPase	dUTPase:9	dUTP pyrophosphatase:9:0.5470	0.5470	9
dalteparin	dalteparin:40|Dalteparin:2	low molecular weight heparin:26:0.8861|Low-molecular-weight heparin:16:0.1744	0.8861	42
delta(psi)m	delta(psi)m:10|Delta(psi)m:5|Delta(Psi)m:5	mitochondrial membrane potential:20:0.7766	0.7766	20
delta-ALA-D	delta-ALA-D:13	delta-aminolevulinate dehydratase:13:0.2802	0.2802	13
delta-ALA-D	delta-ALA-D:11	delta-aminolevulinic acid dehydratase:11:0.6182	0.6182	11
delta13C	delta13C:8	Carbon isotope composition:8:0.6411	0.6411	8
delta8-THC	delta8-THC:9|Delta8-THC:2	delta8-tetrahydrocannabinol:11:0.5882	0.5882	11
delta-9-THC	delta-9-THC:48|delta9-THC:9|Delta-9-THC:7|Delta9-THC:4|delta-9THC:2|delta9THC:1	delta-9-tetrahydrocannabinol:71:0.3084	0.3084	71
delta9-THC	delta9-THC:97|Delta9-THC:30	delta9-tetrahydrocannabinol:127:0.5507	0.5507	127
delta-ALA	delta-ALA:33|delta-ala:1|deltaALA:1	delta-aminolevulinic acid:35:0.5929	0.5929	35
DeltaC(p)	DeltaC(p):10|deltaC(p):1|Deltac(p):1|DeltaC(P):1	heat capacity change:13:0.7753	0.7753	13
DeltaPsi(m)	DeltaPsi(m):71|Deltapsi(m):35|deltapsi(m):20|DeltaPsi(M):6|Deltapsi(M):3|deltaPsi(m):1	mitochondrial membrane potential:136:0.8107	0.8107	136
DeltaPsi(m)	DeltaPsi(m):29|Deltapsi(m):17|deltapsi(m):12|deltaPsi(m):1	mitochondrial transmembrane potential:59:0.7123	0.7123	59
deoxy-Hb	deoxy-Hb:8|deoxyHb:3|DeoxyHb:2|Deoxy-Hb:1	deoxygenated hemoglobin:14:0.6911	0.6911	14
dinoseb	dinoseb:9|Dinoseb:1	2-sec-butyl-4,6-dinitrophenol:10:0.6429	0.6429	10
disulfiram	disulfiram:9	tetraethylthiuram disulfide:9:0.4587	0.4587	9
dopamine	dopamine:64	3,4-dihydroxyphenylethylamine:64:0.3424	0.3424	64
dot-ELISA	dot-ELISA:24|Dot-ELISA:16|DOT-ELISA:1	dot enzyme-linked immunosorbent assay:41:0.8184	0.8184	41
dP/dtmax	dP/dtmax:5|dp/dtmax:2	left ventricular pressure rise:7:0.5926	0.5926	7
dP/dtmax	dP/dtmax:9|dp/dtmax:1	rate of pressure development:10:0.3145	0.3145	10
dP/dtmax	dP/dtmax:1	rate of rise in left ventricular pressure:1:0.6182	0.6182	1
dyslexia	dyslexia:6	specific reading disability:6:0.2827	0.2827	6
eIF2alpha	eIF2alpha:6	alpha-subunit of eukaryotic initiation factor 2:6:0.1004	0.1004	6
eIF2alpha	eIF2alpha:5|eIF-2alpha:5	alpha subunit of eukaryotic translation initiation factor 2:10:0.7103	0.7103	10
eIF-2alpha	eIF-2alpha:5|eIF2alpha:3	eukaryotic initiation factor-2:8:0.5006	0.5006	8
eIF2alpha	eIF2alpha:40|eIF-2alpha:8	eukaryotic initiation factor 2alpha:37:0.6250|eukaryotic initiation factor-2alpha:11:0.5355	0.6250	48
eIF2alpha	eIF2alpha:7|eIF-2alpha:2	Phosphorylation of the alpha subunit of eukaryotic initiation factor 2:9:0.4232	0.4232	9
ecdysone	ecdysone:7	steroid hormone 20-hydroxyecdysone:7:0.5926	0.5926	7
enalapril	enalapril:31|Enalapril:1	angiotensin-converting enzyme inhibitor:18:0.2687|angiotensin converting enzyme inhibitor:14:0.3813	0.3813	32
enoxaparin	enoxaparin:58|Enoxaparin:8	low molecular weight heparin:35:0.9151|Low-molecular-weight heparin:31:0.2744	0.9151	66
epitopes	epitopes:23	antigenic determinants:23:0.7500	0.7500	23
epoetin	epoetin:53|Epoetin:2	recombinant human erythropoietin:55:0.9147	0.9147	55
epsilon	epsilon:20	dielectric constant:20:0.8525	0.8525	20
fMet-Leu-Phe	f-Met-Leu-Phe:2|fMet-Leu-Phe:2|F-Met-Leu-Phe:1|f-met-leu-phe:1	chemotactic peptide formyl-methionyl-leucyl-phenylalanine:6:0.3728	0.3728	6
fMet-Leu-Phe	fMet-Leu-Phe:2	chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine:2:0.5926	0.5926	2
fMet-Leu-Phe	fMet-Leu-Phe:10|fMetLeuPhe:2|f-Met-Leu-Phe:1|f-met-leu-phe:1	formylmethionyl-leucyl-phenylalanine:14:0.0703	0.0703	14
fMet-Leu-Phe	fMet-Leu-Phe:14|f-Met-Leu-Phe:8|f-met-leu-phe:5|F-Met-Leu-Phe:3|F-met-leu-phe:2|fmet-leu-phe:2|fMetLeuPhe:2	N-formyl-methionyl-leucyl-phenylalanine:36:0.1838	0.1838	36
fMet-Leu-Phe	fMet-Leu-Phe:7|f-Met-Leu-Phe:3|fMetLeuPhe:2|f-met-leu-phe:1	N-formylmethionyl-leucyl-phenylalanine:13:0.0649	0.0649	13
fMet-Leu-Phe	fMet-Leu-Phe:14|f-Met-Leu-Phe:3|fmet-leu-phe:2	N-formylmethionylleucylphenylalanine:19:0.0973	0.0973	19
fast-FLAIR	fast-FLAIR:11|FAST-FLAIR:2	fast fluid-attenuated inversion recovery:13:0.7753	0.7753	13
fenugreek	fenugreek:6|Fenugreek:4	Trigonella foenum graecum:10:0.7103	0.7103	10
fibrates	fibrates:15	fibric acid derivatives:15:0.8045	0.8045	15
filgrastim	filgrastim:13|Filgrastim:2	recombinant human granulocyte colony-stimulating factor:15:0.7096	0.7096	15
flip-flop	flip-flop:11	transbilayer movement:11:0.4232	0.4232	11
fluproquazone	fluproquazone:9	4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone:9:0.7273	0.7273	9
furylfuramide	furylfuramide:2	suppressive effect on umu gene expression of SOS response in Salmonella typhimurium TA1535/pSK1002 against the mutagen 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide:2:0.3170	0.3170	2
gamma-MSH	gamma-MSH:19	gamma-melanocyte-stimulating hormone:14:0.3813|gamma-melanocyte stimulating hormone:5:0.1464	0.3813	19
gamma-ECS	gamma-ECS:10|gammaECS:1	gamma-glutamylcysteine synthetase:11:0.7357	0.7357	11
gamma-GCS	gamma-GCS:142|gammaGCS:9	gamma-glutamylcysteine synthetase:151:0.7829	0.7829	151
gamma-GTP	gamma-GTP:150|gammaGTP:6|gamma--GTP:1	gamma-Glutamyl transpeptidase:157:0.9028	0.9028	157
gamma-GTP	gamma-GTP:49	gamma-glutamyltranspeptidase:49:0.2025	0.2025	49
gamma-GT	gamma-GT:60|gammaGT:14|Gamma-GT:1	gamma-glutamyl transferase:63:0.7656|gamma-glutamyl-transferase:12:0.0200	0.7656	75
gamma-GT	gamma-GT:180|gammaGT:8	gamma-glutamyl transpeptidase:188:0.8780	0.8780	188
gamma-GT	gamma-GT:111|gammaGT:9|Gamma-GT:1	gamma-glutamyltransferase:121:0.2186	0.2186	121
gamma-GT	gamma-GT:78|gammaGT:9|gamma-Gt:2	gamma-glutamyltranspeptidase:89:0.1603	0.1603	89
gamma-HCH	gamma-HCH:32	gamma-Hexachlorocyclohexane:32:0.4247	0.4247	32
gammaHV68	gammaHV68:18|gammaHV-68:3	Murine gammaherpesvirus 68:21:0.5721	0.5721	21
gammaTuRC	gammaTuRC:9|gamma-TuRC:4	gamma-tubulin ring complex:13:0.5934	0.5934	13
genipin	genipin:9	naturally occurring crosslinking agent:9:0.6794	0.6794	9
gliomas	gliomas:5	primary brain tumors:5:0.1973	0.1973	5
gludopa	gludopa:12	gamma-L-Glutamyl-L-dopa:12:0.6111	0.6111	12
gp120-gp41	gp120-gp41:2	HIV-1 envelope glycoprotein:2:0.3524	0.3524	2
hCG-beta	hCG-beta:8|HCG-beta:2	human chorionic gonadotropin-beta:10:0.7103	0.7103	10
hCG-beta	hCG-beta:4|hCGbeta:2	human chorionic gonadotropin beta-subunit:6:0.5926	0.5926	6
hERalpha	hERalpha:15	human estrogen receptor alpha:15:0.8165	0.8165	15
hTNF-alpha	hTNF-alpha:15|hTNFalpha:5|h-TNF-alpha:1	human tumor necrosis factor-alpha:13:0.5934|human tumor necrosis factor alpha:8:0.6411	0.6411	21
hepatoma	hepatoma:26	hepatocellular carcinoma:26:0.7340	0.7340	26
holoenzyme	holoenzyme:10	DNA polymerase III holoenzyme:10:0.7103	0.7103	10
hpGRF-44	hpGRF-44:5	Human pancreatic growth hormone-releasing factor:5:0.4422	0.4422	5
hrGM-CSF	hrGM-CSF:6	human recombinant granulocyte-macrophage colony-stimulating factor:6:0.5290	0.5290	6
hrIL-1ra	hrIL-1ra:6|hrIL-1Ra:2|hrIL-1RA:1	receptor antagonist:9:0.6794	0.6794	9
hu-PBL-SCID	hu-PBL-SCID:4|Hu-PBL-SCID:2	human peripheral blood lymphocytes:6:0.5290	0.5290	6
icIL-1ra	icIL-1ra:5|icIL-1Ra:4	receptor antagonist:9:0.5470	0.5470	9
iloprost	iloprost:9|Iloprost:9	prostacyclin analogue:18:0.6903	0.6903	18
immuno-PCR	immuno-PCR:8	immuno-polymerase chain reaction:8:0.5006	0.5006	8
immuno-EM	immuno-EM:9|immunoEM:2|immunoem:1	immunoelectron microscopy:12:0.5664	0.5664	12
Imuthiol	imuthiol:6|Imuthiol:6	sodium diethyldithiocarbamate:12:0.7571	0.7571	12
INSIGHT	INSIGHT:3	International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment:3:0.8045	0.8045	3
insular	insular:15	poorly differentiated:15:0.8251	0.8251	15
introns	introns:20	intervening sequences:20:0.5892	0.5892	20
iohexol	iohexol:4|Iohexol:1	nonionic contrast agent:5:0.1464	0.1464	5
iso-OMPA	iso-OMPA:9|ISO-OMPA:1	tetraisopropylpyrophosphoramide:10:0.3750	0.3750	10
isoniazid	isoniazid:27|Isoniazid:2	isonicotinic acid hydrazide:29:0.8978	0.8978	29
kindling	kindling:6	electrical stimulation:6:0.1320	0.1320	6
lectins	lectins:19	carbohydrate-binding proteins:19:0.3019	0.3019	19
losartan	losartan:9	angiotensin II receptor antagonist:9:0.4587	0.4587	9
lyso-PAF	lyso-PAF:7|lyso-Paf:1	lyso-platelet activating factor:8:0.2987	0.2987	8
mATPase	mATPase:18|M-ATPase:3|m-ATPase:3	adenosine triphosphatase:24:0.8768	0.8768	24
mATPase	mATPase:19|M-ATPase:3|m-ATPase:3	myofibrillar ATPase:25:0.4596	0.4596	25
mGluR1alpha	mGluR1alpha:14	metabotropic glutamate receptor 1alpha:14:0.7909	0.7909	14
matrilysin	matrilysin:9	human matrix metalloproteinase 7:9:0.3945	0.3945	9
Medi-Cal	Medi-Cal:16	California Medicaid:16:0.6381	0.6381	16
menadione	menadione:24	2-methyl-1,4-naphthoquinone:24:0.2911	0.2911	24
microLC	microLC:8|micro-LC:5	liquid chromatography:13:0.7753	0.7753	13
micro-TAS	micro-TAS:4|microTAS:3	micro total analysis system:7:0.4438	0.4438	7
microTBS	microTBS:29|micro-TBS:1|micro-tbs:1	microtensile bond strength:31:0.5576	0.5576	31
mitoK(ATP)	mitoK(ATP):14	mitochondrial ATP-sensitive K(+):14:0.6911	0.6911	14
mitoK(ATP)	mitoK(ATP):11|mito-K(ATP):1	mitochondrial ATP-sensitive potassium:12:0.7571	0.7571	12
mitoK(ATP)	mitoK(ATP):4	mitochondrial ATP-sensitive potassium channels:4:0.3170	0.3170	4
mnm5s2U	mnm5s2U:10|mnm5S2U:1	5-methylaminomethyl-2-thiouridine:11:0.7692	0.7692	11
monoHER	monoHER:8|mono-HER:1|MonoHER:1	7-monohydroxyethylrutoside:10:0.6000	0.6000	10
morphoea	morphoea:11	localized scleroderma:11:0.4232	0.4232	11
mtHsp70	mtHsp70:8|mt-hsp70:1|mt-Hsp70:1|mtHSP70:1	heat shock protein 70:11:0.7357	0.7357	11
mtHSP70	mt-Hsp70:3|mtHSP70:3|mtHsp70:2|mt-hsp70:1	mitochondrial HSP70:9:0.3069	0.3069	9
muricide	muricide:9	mouse-killing behavior:9:0.6794	0.6794	9
nAcChoR	nAcChoR:18	nicotinic acetylcholine receptor:18:0.8365	0.8365	18
naproxen	naproxen:13	D-2-(6'-methoxy-2'-naphthyl)-propionic acid:13:0.2959	0.2959	13
neutrophil	neutrophil:8	polymorphonuclear leukocyte:8:0.2987	0.2987	8
niosomes	niosomes:14	non-ionic surfactant vesicles:14:0.5111	0.5111	14
nitro-PAH	nitro-PAH:9	aromatic hydrocarbons:9:0.6794	0.6794	9
non-HDL-C	non-HDL-C:18	non-high-density lipoprotein cholesterol:18:0.4934	0.4934	18
non-SCLC	non-SCLC:8	non-small cell lung cancer:8:0.6411	0.6411	8
non-NMDA	non-NMDA:115|nonNMDA:1	Non-N-methyl-D-aspartate:116:0.7770	0.7770	116
non-REMS	non-REMS:9|nonREMS:1	non-rapid eye movement sleep:10:0.5000	0.5000	10
oncocytoma	oncocytoma:5	Oxyphilic granular cell adenoma:5:0.3170	0.3170	5
oxysterols	oxysterols:14	Cholesterol oxidation products:14:0.7909	0.7909	14
oxysterols	oxysterols:6	Oxygenated derivatives of cholesterol:6:0.3728	0.3728	6
p125(FAK)	p125(FAK):23|p125(fak):1	focal adhesion kinase:24:0.8768	0.8768	24
p125FAK	p125FAK:53|p125fak:1|P125FAK:1	focal adhesion kinase:55:0.9132	0.9132	55
p38(MAPK)	p38(MAPK):10	p38 mitogen-activated protein kinase:10:0.7103	0.7103	10
p38MAPK	p38MAPK:52|p38-MAPK:10|P38MAPK:1	p38 mitogen-activated protein kinase:63:0.9526	0.9526	63
p42mapk	p42mapk:9|p42MAPK:6	mitogen-activated protein kinase:15:0.5818	0.5818	15
p75LNGFR	p75LNGFR:4|p75LNGFr:2	nerve growth factor receptor:6:0.5290	0.5290	6
p75NGFR	p75NGFR:6|p75-NGFR:3|p75NGFr:2	low affinity nerve growth factor receptor:11:0.7357	0.7357	11
p75NGFR	p75NGFR:9|p75NGF-R:1	low-affinity NGF receptor:10:0.1680	0.1680	10
p-GlcNAc	p-GlcNAc:9|p-GLcNAc:1|P-GlcNAc:1|pGlcNAc:1	poly-N-acetyl glucosamine:12:0.6460	0.6460	12
pNPPase	pNPPase:9|p-NPPase:6|p-NPP-ase:1|PNPPase:1	p-nitrophenyl phosphatase:17:0.4246	0.4246	17
pNPPase	pNPPase:11|p-NPPase:7|PNPPase:3	p-nitrophenylphosphatase:21:0.3125	0.3125	21
parabens	parabens:11	esters of p-hydroxybenzoic acid:11:0.7357	0.7357	11
pargyline	pargyline:6	monoamine oxidase inhibitor:6:0.5290	0.5290	6
perlecan	perlecan:16|Perlecan:1	heparan sulfate proteoglycan:17:0.8270	0.8270	17
photo-CIDNP	photo-CIDNP:11|photoCIDNP:1|Photo-CIDNP:1	Photochemically induced dynamic nuclear polarization:13:0.5335	0.5335	13
pituicytes	pituicytes:8	Neurohypophysial astrocytes:8:0.2987	0.2987	8
preBotC	preBotC:5	neurons in the preBotzinger complex:5:0.1320	0.1320	5
pre-BotC	pre-BotC:33|preBotC:4|Pre-BotC:1|pre-BOTC:1	pre-Botzinger complex:39:0.6230	0.6230	39
pre-mRNA	pre-mRNA:23	precursor messenger RNA:23:0.7593	0.7593	23
PREVENT	PREVENT:11	Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial:11:0.7571	0.7571	11
pristane	pristane:13	2,6,10,14-tetramethylpentadecane:13:0.6000	0.6000	13
proHB-EGF	proHB-EGF:6	heparin-binding EGF-like growth factor:6:0.5290	0.5290	6
proMMP-2	proMMP-2:8|pro-MMP-2:4|proMMP2:1	metalloproteinase-2:13:0.2407	0.2407	13
PROGRESS	PROGRESS:21|progress:1	Perindopril Protection Against Recurrent Stroke Study:22:0.7766	0.7766	22
propachlor	propachlor:9	2-chloro-N-isopropylacetanilide:9:0.7273	0.7273	9
PURSUIT	PURSUIT:2	platelet glycoprotein IIb/IIIa in unstable angina Receptor suppression using integrilin therapy:2:0.8768	0.8768	2
quinone	quinone:17	NAD(P)H dehydrogenase:17:0.5038	0.5038	17
r-metHuG-CSF	r-metHuG-CSF:8	human granulocyte colony-stimulating factor:8:0.5006	0.5006	8
r-metHuLeptin	r-metHuLeptin:8	Recombinant methionyl human leptin:8:0.6411	0.6411	8
rBoIFN-gamma	rBoIFN-gamma:4|rboIFN-gamma:2|rboIfn-gamma:1	recombinant bovine interferon-gamma:7:0.4438	0.4438	7
rCMRGlu	rCMRGlu:11|rCMRglu:6	regional cerebral glucose metabolism:17:0.7407	0.7407	17
rCMRglu	rCMRglu:5|rCMRGlu:4	regional cerebral metabolic rate for glucose:9:0.7096	0.7096	9
rCMRglc	rCMRglc:12|rCMRGlc:3	Regional cerebral glucose metabolism:15:0.8045	0.8045	15
rCMRglc	rCMRglc:7|rCMRGlc:4	regional cerebral glucose utilization:11:0.5355	0.5355	11
rCMRglc	rCMRglc:39|rCMRGlc:4	Regional cerebral metabolic rates for glucose:43:0.8964	0.8964	43
rCMRglc	rCMRglc:20|rCMRGlc:4	regional cerebral metabolic rate of glucose:24:0.8401	0.8401	24
rHuG-CSF	rHuG-CSF:21|rhuG-CSF:2|rHu-G-CSF:1	Recombinant human granulocyte colony-stimulating factor:24:0.7593	0.7593	24
rHuIFN-gamma	rHuIFN-gamma:22|rhuIFN-gamma:4	recombinant human interferon-gamma:18:0.8365|recombinant human interferon gamma:8:0.5006	0.8365	26
rHuIL-10	rHuIL-10:5|rhuIL-10:4	recombinant human IL-10:9:0.6794	0.6794	9
rHuIL-12	rHuIL-12:9	recombinant human interleukin-12:9:0.6794	0.6794	9
rHuMGDF	rHuMGDF:9|r-HuMGDF:1	Recombinant human megakaryocyte growth and development factor:10:0.7103	0.7103	10
rHuTNF-alpha	rHuTNF-alpha:16|rhuTNF-alpha:1	recombinant human tumor necrosis factor-alpha:17:0.8270	0.8270	17
rIFN-alpha	rIFN-alpha:46|r-IFN-alpha:3|rIFNalpha:3	recombinant interferon-alpha:42:0.6927|recombinant interferon alpha:10:0.4363	0.6927	52
rIFN-gamma	rIFN-gamma:39|r-IFN-gamma:7	recombinant gamma interferon:31:0.5933|recombinant gamma-interferon:15:0.4312	0.5933	46
rIFN-gamma	rIFN-gamma:11	recombinant human interferon gamma:11:0.5355	0.5355	11
rIFN-gamma	rIFN-gamma:195|r-IFN-gamma:4|rIFNgamma:2	recombinant interferon-gamma:160:0.6905|recombinant interferon gamma:41:0.6072	0.6905	201
rMETase	rMETase:13	recombinant methioninase:13:0.5934	0.5934	13
rMuIFN-beta	rMuIFN-beta:5	recombinant murine interferon-beta:5:0.4422	0.4422	5
rMuIFN-gamma	rMuIFN-gamma:11	recombinant murine gamma interferon:11:0.6182	0.6182	11
rMuIFN-gamma	rMuIFN-gamma:14|rmuIFN-gamma:2	recombinant murine interferon-gamma:16:0.7261	0.7261	16
rTNF-alpha	rTNF-alpha:12	recombinant human tumor necrosis factor-alpha:12:0.7571	0.7571	12
rTNF-alpha	rTNF-alpha:22	tumor necrosis factor alpha:22:0.6934	0.6934	22
rhDNase	rhDNase:32|rhDNAse:1	Recombinant human deoxyribonuclease:33:0.8644	0.8644	33
rhDNase	rhDNase:15|rh-DNase:1	recombinant human deoxyribonuclease I:16:0.8165	0.8165	16
rhDNase	rhDNase:19	recombinant human DNase:19:0.8449	0.8449	19
rhDNase	rhDNase:11	recombinant human DNase I:11:0.7357	0.7357	11
rhGM-CSF	rhGM-CSF:11	granulocyte-macrophage CSF:11:0.6182	0.6182	11
rhGM-CSF	rhGM-CSF:27	recombinant human GM-CSF:27:0.8312	0.8312	27
rhGM-CSF	rhGM-CSF:203|rh-GMCSF:3|rHGM-CSF:3|RhGM-CSF:2|rh-GM-CSF:2|rhGm-CSF:1|RHGMCSF:1	recombinant human granulocyte-macrophage colony-stimulating factor:173:0.9632|recombinant human granulocyte-macrophage colony stimulating factor:32:0.9072|recombinant human granulocyte macrophage colony stimulating factor:10:0.5856	0.9632	215
rhIFN-gamma	rhIFN-gamma:26|rHIFN-gamma:1	recombinant human interferon-gamma:27:0.8903	0.8903	27
rhTNF-alpha	rhTNF-alpha:26|rh-TNF-alpha:2|rhTNFalpha:1	recombinant human tumor necrosis factor-alpha:22:0.7955|Recombinant human tumour necrosis factor-alpha:7:0.5926	0.7955	29
rHuGM-CSF	rHuGM-CSF:14|rhuGM-CSF:11	recombinant human granulocyte-macrophage colony-stimulating factor:25:0.8816	0.8816	25
ribavirin	ribavirin:15	1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide:15:0.4375	0.4375	15
ribotypes	ribotypes:7	rRNA gene restriction patterns:7:0.4438	0.4438	7
ribotyping	ribotyping:6	restriction fragment length polymorphisms of rRNA genes:6:0.5926	0.5926	6
ribotyping	ribotyping:6	rRNA gene restriction patterns:6:0.4438	0.4438	6
rmGM-CSF	rmGM-CSF:11	recombinant murine granulocyte-macrophage colony-stimulating factor:11:0.7357	0.7357	11
sIL-1RII	sIL-1RII:5	soluble IL-1 receptor II:5:0.4422	0.4422	5
sIL-1RII	sIL-1RII:8	soluble IL-1 receptor type II:8:0.5006	0.5006	8
sTNF-RII	sTNF-RII:4|sTNFRII:2|sTNFrii:1	necrosis factor receptor II:7:0.5926	0.5926	7
semi-IPN	semi-IPN:7	semi-interpenetrating polymer network:7:0.5926	0.5926	7
serpins	serpins:51|SERPINS:1	serine protease inhibitors:52:0.8842	0.8842	52
serpins	serpins:46|Serpins:3|SERPINS:2	serine proteinase inhibitors:51:0.8546	0.8546	51
snoRNAs	snoRNAs:135	small nucleolar RNAs:135:0.9647	0.9647	135
snoRNPs	snoRNPs:13	small nucleolar ribonucleoprotein particles:13:0.7753	0.7753	13
Sorbinil	Sorbinil:7|sorbinil:5	aldose reductase inhibitor:12:0.7753	0.7753	12
spheroids	spheroids:7	spherical multicellular aggregates:7:0.2113	0.2113	7
statins	statins:6	3-hydroxy-3-methylglutaryl coenzyme A reductase:6:0.2243	0.2243	6
statins	statins:88	3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors:88:0.5200	0.5200	88
statins	statins:26|STATINS:1	hydroxymethylglutaryl coenzyme A reductase inhibitors:27:0.1230	0.1230	27
statins	statins:7	inhibitors of HMG-CoA reductase:7:0.3463	0.3463	7
statins	statins:5	lipid-lowering drugs:5:0.0517	0.0517	5
sulfamoxole	sulfamoxole:13	N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide:13:0.7500	0.7500	13
SUPPORT	SUPPORT:39|support:1	study to understand prognoses and preferences for outcomes and risks of treatments:31:0.9043|Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment:9:0.6794	0.9043	40
synprint	synprint:12	synaptic protein interaction:12:0.7909	0.7909	12
t1/2beta	t1/2beta:31|T1/2beta:1	elimination half-life:32:0.5213	0.5213	32
tacrine	tacrine:8|Tacrine:1	9-amino-1,2,3,4-tetrahydroacridine:9:0.2424	0.2424	9
tegafur	tegafur:11|Tegafur:4	1-(2-tetrahydrofuryl)-5-fluorouracil:15:0.5000	0.5000	15
thiotepa	thiotepa:19|thioTEPA:12|thio-TEPA:5|ThioTEPA:3|Thio-TEPA:2|thiotEPA:1	N,N',N"-triethylenethiophosphoramide:25:0.2035|N,N',N''-triethylenethiophosphoramide:17:0.1327	0.2035	42
thio-TEPA	thio-TEPA:8|thiotepa:3|ThioTEPA:3|thioTEPA:3|Thio-TEPA:2|thio-tepa:2|Thio-Tepa:1|Thiotepa:1	triethylenethiophosphoramide:23:0.1947	0.1947	23
tinzaparin	tinzaparin:8	low molecular weight heparin:8:0.6411	0.6411	8
tolerance	tolerance:5	specific unresponsiveness:5:0.0517	0.0517	5
uPAR/CD87	uPAR/CD87:6	urokinase-type plasminogen activator receptor:6:0.3728	0.3728	6
ureaplasmas	ureaplasmas:9	Ureaplasma urealyticum organisms:9:0.5470	0.5470	9
uveitis	uveitis:8	intraocular inflammation:8:0.4102	0.4102	8
V-ATPase	V-ATPase:15	vacuolar proton-translocating ATPase:15:0.4951	0.4951	15
V-ATPase	V-ATPase:27	vacuolar-type H(+)-ATPase:27:0.1454	0.1454	27
vimentin	vimentin:9	intermediate filaments:9:0.6794	0.6794	9
virosomes	virosomes:7	reconstituted influenza virus envelopes:7:0.5926	0.5926	7
wethers	wethers:14	orchidectomized sheep:14:0.4709	0.4709	14
